-DOCSTART- -9514454- O O

Comparative NNP N
dose NN N
efficacy NN o
study NN N
of IN N
atorvastatin JJ i
versus NN N
simvastatin NN i
, , i
pravastatin NN i
, , i
lovastatin NN i
, , i
and CC i
fluvastatin NN i
in IN N
patients NNS p
with IN p
hypercholesterolemia NN p
( ( N
the DT N
CURVES NNP N
study NN N
) ) N
The DT N
objective NN N
of IN N
this DT N
multicenter NN p
, , N
randomized VBN N
, , N
open-label JJ N
, , N
parallel-group JJ N
, , N
8-week JJ N
study NN N
was VBD N
to TO N
evaluate VB N
the DT N
comparative JJ N
dose JJ N
efficacy NN N
of IN N
the DT N
3-hydroxy-3-methylglutaryl JJ i
coenzyme NN i
A NNP i
( ( i
HMG-CoA NNP i
) ) i
reductase NN i
inhibitor NN i
atorvastatin VBD i
10 CD i
, , i
20 CD i
, , i
40 CD i
, , i
and CC i
80 CD i
mg NNS i
compared VBN i
with IN i
simvastatin NN i
10 CD i
, , i
20 CD i
, , i
and CC i
40 CD i
mg NN i
, , i
pravastatin NN i
10 CD i
, , i
20 CD i
, , i
and CC i
40 CD i
mg NN i
, , i
lovastatin VBZ i
20 CD i
, , i
40 CD i
, , i
and CC i
80 CD i
mg NN i
, , i
and CC i
fluvastatin $ i
20 CD i
and CC i
40 CD i
mg. NN i
Investigators NNS N
enrolled VBD N
534 CD p
hypercholesterolemic JJ p
patients NNS p
( ( p
low-density JJ p
lipoprotein NN p
[ NNP p
LDL NNP p
] NNP p
cholesterol NN p
> NN p
or CC p
= $ p
160 CD p
mg/dl NN p
[ VBD p
4.2 CD p
mmol/L NN p
] NN p
and CC p
triglycerides NNS p
< VBP p
or CC p
= VBP p
400 CD p
mg/dl NN p
[ VBD p
4.5 CD p
mmol/L NNS p
] RB p
) ) p
. . p

The DT N
efficacy JJ N
end NN N
points NNS N
were VBD N
mean JJ N
percent NN N
change NN N
in IN N
plasma NN o
LDL NNP o
cholesterol NN o
( ( o
primary JJ o
) ) o
, , o
total JJ o
cholesterol NN o
, , o
triglycerides NNS o
, , o
and CC o
high-density NN o
lipoprotein NN o
cholesterol NN o
concentrations NNS o
from IN N
baseline NN N
to TO N
the DT N
end NN N
of IN N
treatment NN N
( ( N
week NN N
8 CD N
) ) N
. . N

Atorvastatin $ i
10 CD N
, , N
20 CD N
, , N
and CC N
40 CD N
mg NN N
produced VBN N
greater JJR N
( ( N
p JJ N
< NN N
or CC N
= VB N
0.01 CD N
) ) N
reductions NNS N
in IN N
LDL NNP o
cholesterol NN o
, , N
-38 CD N
% NN N
, , N
-46 CD N
% NN N
, , N
and CC N
-51 NNP N
% NN N
, , N
respectively RB N
, , N
than IN N
the DT N
milligram JJ N
equivalent JJ N
doses NNS N
of IN N
simvastatin NN i
, , i
pravastatin NN i
, , i
lovastatin NN i
, , N
and CC N
fluvastatin NN i
. . i

Atorvastatin $ i
10 CD N
mg NN N
produced VBN N
LDL NNP o
cholesterol NN o
reductions NNS N
comparable JJ N
to TO N
or CC N
greater JJR N
than IN N
( ( N
p JJ N
< NN N
or CC N
= VB N
0.02 CD N
) ) N
simvastatin NN i
10 CD N
, , N
20 CD N
, , N
and CC N
40 CD N
mg NN N
, , N
pravastatin NN i
10 CD N
, , N
20 CD N
, , N
and CC N
40 CD N
mg NN N
, , N
lovastatin CC i
20 CD N
and CC N
40 CD N
mg NN N
, , N
and CC N
fluvastatin $ i
20 CD N
and CC N
40 CD N
mg. NN N
Atorvastatin NNP i
10 CD N
, , N
20 CD N
, , N
and CC N
40 CD N
mg NN N
produced VBN N
greater JJR N
( ( N
p JJ N
< NN N
or CC N
= VB N
0.01 CD N
) ) N
reductions NNS N
in IN N
total JJ o
cholesterol NN o
than IN N
the DT N
milligram JJ N
equivalent JJ N
doses NNS N
of IN N
simvastatin NN i
, , i
pravastatin NN i
, , i
lovastatin NN i
, , N
and CC N
fluvastatin NN i
. . i

All DT N
reductase NN N
inhibitors NNS N
studied VBD N
had VBD N
similar JJ N
tolerability NN o
. . o

There EX N
were VBD N
no DT N
incidences NNS N
of IN N
persistent JJ N
elevations NNS N
in IN N
serum NN o
transaminases NNS o
or CC o
myositis NN o
. . o

-DOCSTART- -8473426- O O

A DT N
controlled VBN N
study NN N
comparing VBG N
patients NNS p
with IN p
and CC p
without IN p
polycystic JJ p
ovaries NNS p
undergoing VBG p
in-vitro JJ o
fertilization NN o
. . o

The DT N
outcome NN N
of IN N
in-vitro JJ i
fertilization NN i
and CC i
embryo NN i
transfer NN i
( ( i
IVF-ET NNP i
) ) i
was VBD N
compared VBN N
in IN N
76 CD p
patients NNS p
with IN p
polycystic JJ p
ovaries NNS p
( ( p
PCO NNP p
) ) p
diagnosed VBD p
on IN p
pre-treatment JJ p
ultrasound JJ p
scan NN p
, , p
and CC p
76 CD p
control NN p
patients NNS p
who WP p
had VBD p
normal JJ p
ovaries NNS p
and CC p
were VBD p
matched VBN p
for IN p
age NN p
, , p
cause NN p
of IN p
infertility NN p
and CC p
stimulation NN p
regimen NNS p
. . p

Despite IN N
receiving VBG N
significantly RB N
less JJR N
human JJ i
menopausal NN i
gonadotrophin NN i
( ( i
HMG NNP i
) ) i
, , N
patients NNS p
with IN p
PCO NNP p
, , N
as IN N
compared VBN N
with IN N
controls NNS N
, , N
had VBD N
significantly RB N
higher JJR N
serum NN o
oestradiol NN o
levels NNS o
on IN N
the DT N
day NN N
of IN N
human JJ N
chorionic NN i
gonadotrophin NN i
administration NN N
( ( N
5940 CD N
+/- NN N
255 CD N
versus NN N
4370 CD N
+/- JJ N
240 CD N
pmol/l NN N
, , N
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
developed VBD N
more JJR N
follicles NNS o
( ( N
14.9 CD N
+/- JJ N
0.7 CD N
versus NN N
9.8 CD N
+/- JJ N
0.6 CD N
, , N
P NNP N
< NNP N
0.001 CD N
) ) N
and CC N
produced VBD N
more JJR N
oocytes NNS o
( ( N
9.3 CD N
+/- JJ N
0.6 CD N
versus NN N
6.8 CD N
+/- JJ N
0.5 CD N
, , N
P NNP N
= NNP N
0.003 CD N
) ) N
. . N

However RB N
, , N
fertilization NN o
rates NNS o
were VBD N
reduced VBN N
in IN N
the DT N
PCO NNP N
patients NNS N
( ( N
52.8 CD N
+/- JJ N
3.4 CD N
% NN N
versus NN N
66.1 CD N
+/- JJ N
3.4 CD N
% NN N
, , N
P NNP N
= NNP N
0.007 CD N
) ) N
. . N

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
cleavage NN o
rates NNS o
. . o

The DT N
pregnancy NN o
rate/embryo NN o
transfer NN o
was VBD N
25.4 CD N
% NN N
in IN N
the DT N
PCO NNP p
group NN p
and CC N
23.0 CD N
% NN N
in IN N
the DT N
group NN p
with IN p
normal JJ p
ovaries NNS p
. . p

There EX N
were VBD N
three CD N
high JJ N
order NN N
multiple JJ N
pregnancies NNS N
in IN N
the DT N
PCO NNP N
group NN N
compared VBN N
with IN N
none NN N
in IN N
the DT N
group NN N
with IN N
normal JJ N
ovaries NNS N
. . N

Of IN N
the DT N
PCO NNP N
patients NNS N
, , N
10.5 CD N
% NN N
developed VBD N
moderate/severe RB N
ovarian JJ o
hyperstimulation NN o
syndrome NN o
( ( o
OHSS NNP o
) ) o
compared VBN N
with IN N
none NN N
of IN N
the DT N
controls NNS N
( ( N
P NNP N
= NNP N
0.006 CD N
) ) N
. . N

Patients NNS p
with IN p
and CC p
without IN p
PCO NNP p
undergoing VBG p
IVF NNP p
have VBP N
comparable JJ N
pregnancy NN o
and CC o
livebirth JJ o
rates NNS o
. . o

However RB N
, , N
it PRP N
is VBZ N
important JJ N
to TO N
diagnose VB N
PCO NNP N
before IN N
ovarian JJ N
stimulation NN N
is VBZ N
initiated VBN N
as IN N
these DT N
patients NNS N
are VBP N
more RBR N
likely JJ N
to TO N
develop VB N
moderate JJ N
or CC N
severe JJ N
OHSS NNP N
following VBG N
IVF-ET NNP N
. . N

-DOCSTART- -9399611- O O

Evaluation NN N
of IN N
hypertensive JJ p
patients NNS p
after IN N
care NN N
provided VBN N
by IN N
community NN i
pharmacists NNS i
in IN p
a DT p
rural JJ p
setting NN p
. . p

We PRP N
evaluated VBD N
blood NN o
pressure NN o
control NN o
, , o
quality NN o
of IN o
life NN o
, , o
quality NN o
of IN o
care NN o
, , o
and CC o
satisfaction NN o
of IN o
patients NNS o
who WP p
were VBD p
monitored VBN p
by IN p
specially RB i
trained VBN i
community NN i
pharmacists NNS i
in IN p
a DT p
group NN p
medical JJ p
practice NN p
. . p

After IN N
participating VBG N
in IN N
an DT N
intensive JJ i
skill NN i
development NN i
program NN i
, , N
pharmacists NNS N
performed VBD N
in IN N
an DT N
interdisciplinary JJ N
team NN N
in IN N
a DT N
rural JJ N
clinic NN N
. . N

The DT N
primary JJ N
objective NN N
was VBD N
assessed VBN N
by IN N
evaluating VBG N
outcome JJ N
variables NNS N
at IN N
6 CD N
months NNS N
compared VBN N
with IN N
baseline NN N
in IN N
25 CD p
patients NNS p
randomly RB N
assigned VBN N
to TO N
a DT N
study NN N
group NN N
. . N

A DT N
control NN p
group NN p
of IN p
26 CD p
patients NNS p
was VBD N
also RB N
evaluated VBN N
to TO N
determine VB N
if IN N
outcome JJ N
variables NNS N
remained VBD N
constant JJ N
from IN N
baseline NN N
to TO N
6 CD N
months NNS N
. . N

Systolic NNP o
blood NN o
pressure NN o
was VBD N
reduced VBN N
in IN N
the DT N
study NN N
group NN N
( ( N
151 CD N
mm NN N
Hg NNP N
baseline NN N
, , N
140 CD N
mm NN N
Hg NNP N
at IN N
6 CD N
mo NN N
, , N
p NN N
< NNP N
0.001 CD N
) ) N
and CC N
diastolic JJ o
blood NN o
pressure NN o
was VBD N
significantly RB N
lower JJR N
at IN N
2 CD N
, , N
4 CD N
, , N
and CC N
5 CD N
months NNS N
compared VBN N
with IN N
baseline NN N
. . N

Ratings NNS N
from IN N
a DT N
blinded VBN N
peer NN N
review NN N
panel NN N
indicated VBD N
significant JJ N
improvement NN N
in IN N
the DT N
appropriateness NN N
of IN N
the DT N
blood NN N
pressure NN N
regimen NNS N
, , N
going VBG N
from IN N
8.7 CD N
+/- JJ N
4.7 CD N
to TO N
10.9 CD N
+/- JJ N
4.5 CD N
in IN N
the DT N
study NN N
group NN N
( ( N
p JJ N
< NNP N
0.01 CD N
) ) N
, , N
but CC N
they PRP N
did VBD N
not RB N
change VB N
in IN N
the DT N
control NN N
group NN N
. . N

Several JJ N
quality NN o
of IN o
life NN o
scores NNS o
improved VBN N
significantly RB N
in IN N
the DT N
study NN N
group NN N
after IN N
6 CD N
months NNS N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
. . N

These DT N
included VBD N
physical JJ o
functioning NN o
( ( N
61.6 CD N
vs RB N
70.7 CD N
) ) N
, , N
physical JJ o
role NN o
limitations NNS o
( ( N
56.8 CD N
vs RB N
72.8 CD N
) ) N
, , N
and CC N
bodily RB o
pain NN o
( ( N
60.0 CD N
vs RB N
71.7 CD N
) ) N
at IN N
baseline NN N
and CC N
6 CD N
months NNS N
, , N
respectively RB N
. . N

There EX N
were VBD N
no DT N
significant JJ N
changes NNS N
in IN N
the DT N
control NN N
group NN N
. . N

Patient JJ o
satisfaction NN o
scores NNS o
were VBD N
consistently RB N
higher JJR N
in IN N
the DT N
study NN N
group NN N
at IN N
the DT N
end NN N
of IN N
the DT N
study NN N
. . N

Our PRP$ N
results NNS N
indicate VBP N
that IN N
when WRB N
community NN i
pharmacists VBZ i
in IN N
a DT N
clinic JJ N
setting NN N
are VBP N
trained VBN N
and CC N
included VBN N
as IN N
members NNS N
of IN N
the DT N
primary JJ N
care NN N
team NN N
, , N
significant JJ N
improvements NNS N
in IN N
blood NN o
pressure NN o
control NN o
, , o
quality NN o
of IN o
life NN o
, , o
and CC o
patient JJ o
satisfaction NN o
can MD N
be VB N
achieved VBN N
. . N

-DOCSTART- -12651674- O O

Esmolol NNP i
blunts VBZ N
the DT N
cerebral JJ o
blood NN o
flow NN o
velocity NN o
increase NN o
during IN N
emergence NN N
from IN N
anesthesia NN N
in IN N
neurosurgical JJ p
patients NNS p
. . p

UNLABELLED JJ N
Cerebral NNP o
hyperemia NN o
has VBZ N
been VBN N
demonstrated VBN N
during IN N
emergence NN N
from IN N
anesthesia NN N
in IN N
neurosurgical JJ p
patients NNS p
, , N
but CC N
its PRP$ N
mechanism NN N
is VBZ N
speculative JJ N
. . N

We PRP N
performed VBD N
this DT N
study NN N
to TO N
test VB N
the DT N
hypothesis NN N
that IN N
this DT N
could MD N
be VB N
attributed VBN N
to TO N
sympathetic JJ N
overactivity NN N
. . N

Thirty NNP p
neurosurgical JJ p
patients NNS p
were VBD N
included VBN N
in IN N
a DT N
prospective JJ N
, , N
randomized VBN N
, , N
double-blinded JJ N
study NN N
comparing VBG N
esmolol NN i
, , N
a DT N
short-acting JJ N
beta-blocker NN N
, , N
and CC N
a DT N
placebo NN i
. . i

Esmolol NNP i
( ( N
0.3 CD N
mg. NN N
kg NN N
( ( N
-1 NNP N
) ) N
. . N

min NN N
( ( N
-1 NNP N
) ) N
) ) N
was VBD N
infused VBN N
from IN N
the DT N
end NN N
of IN N
anesthesia NN i
to TO N
15 CD N
min NNS N
after IN N
extubation NN i
. . i

Cerebral JJ o
blood NN o
flow NN o
velocity NN o
( ( o
CBFV NNP o
) ) o
, , o
mean JJ o
arterial JJ o
blood NN o
pressure NN o
, , o
and CC o
heart NN o
rate NN o
were VBD N
recorded VBN N
before IN N
anesthesia NN N
, , N
during IN N
anesthesia NN N
after IN N
surgery NN N
, , N
at IN N
extubation NN N
, , N
and CC N
5-60 JJ N
min NN N
after IN N
extubation NN N
. . N

Cardiac NNP o
output NN o
( ( o
COe NNP o
) ) o
was VBD N
estimated VBN N
by IN N
using VBG N
an DT N
esophageal JJ N
Doppler NN N
from IN N
anesthesia NN N
to TO N
60 CD N
min NNS N
after IN N
extubation NN N
. . N

CBFV NNP o
, , o
COe NNP o
, , o
and CC o
heart NN o
rate NN o
were VBD N
significantly RB N
lower JJR N
in IN N
the DT N
esmolol NN N
group NN N
. . N

Mean NNP o
arterial JJ o
blood NN o
pressure NN o
was VBD N
comparable JJ N
between IN N
the DT N
groups NNS N
. . N

There EX N
was VBD N
no DT N
correlation NN N
between IN N
CBFV NNP o
and CC o
COe NNP o
at IN N
any DT N
time NN N
point NN N
during IN N
the DT N
study NN N
. . N

In IN N
conclusion NN N
, , N
esmolol RB N
blunted VBD N
the DT N
CBFV NNP o
increase NN o
during IN N
emergence NN N
, , N
confirming VBG N
that IN N
sympathetic JJ N
overactivity NN N
contributes NNS N
to TO N
cerebral JJ o
hyperemia NN o
during IN N
neurosurgical JJ N
recovery NN N
. . N

IMPLICATIONS NNP N
Esmolol NNP N
blunted VBD N
the DT N
postoperative JJ N
increase NN N
in IN N
cerebral JJ o
blood NN o
flow NN o
velocity NN o
in IN N
neurosurgical JJ p
patients NNS p
. . p

The DT N
origin NN N
of IN N
sympathetic JJ N
hyperactivity NN N
and CC N
its PRP$ N
potential JJ N
deleterious JJ N
consequences NNS N
require VBP N
further JJ N
study NN N
. . N

-DOCSTART- -17884602- O O

Continuous JJ i
event NN i
recorders NNS i
did VBD N
not RB N
affect VB N
anxiety NN o
or CC N
quality NN o
of IN o
life NN o
in IN N
patients NNS p
with IN p
palpitations NNS p
. . p

OBJECTIVES NNP N
Palpitations NNPS N
can MD N
generate VB N
feelings NNS N
of IN N
anxiety NN o
and CC N
decrease NN N
quality NN o
of IN o
life NN o
( ( o
QoL NNP o
) ) o
due JJ N
to TO N
fear VB N
of IN N
a DT N
cardiac JJ N
abnormality NN N
. . N

Continuous JJ i
event NN i
recorders NNS i
( ( i
CERs NNP i
) ) i
have VBP N
proven VBN N
to TO N
be VB N
successful JJ N
in IN N
diagnosing VBG N
causes NNS N
of IN N
palpitations NNS N
but CC N
may MD N
affect VB N
patient NN N
QoL NNP o
and CC N
anxiety NN o
. . o

The DT N
aim NN N
is VBZ N
to TO N
determine VB N
anxiety NN o
and CC N
health-related JJ o
( ( o
HR NNP o
) ) o
-QoL NN o
and CC N
evaluate VB N
the DT N
burden NN N
of IN N
carrying VBG N
a DT N
CER NNP i
in IN N
general JJ N
practice NN N
populations NNS N
. . N

STUDY NNP N
DESIGN NNP N
AND NNP N
SETTING NNP N
Patients NNP p
( ( p
n=244 JJ p
) ) p
participated VBD N
in IN N
a DT N
randomized JJ N
trial NN N
. . N

One CD N
group NN N
( ( N
n=127 RB N
) ) N
carried VBD N
a DT N
CER NNP i
during IN N
4 CD N
weeks NNS N
. . N

One CD p
hundred CD p
and CC p
seventeen JJ p
patients NNS p
formed VBD N
the DT N
usual JJ i
care NN i
( ( i
UC NNP i
) ) i
group NN N
. . N

State-Trait NNP o
Anxiety NNP o
Inventory NNP o
( ( o
STAI NNP o
) ) o
and CC o
the DT o
Short NNP o
Form-36 NNP o
( ( o
SF-36 NNP o
) ) o
were VBD N
administered VBN N
at IN N
study NN N
inclusion NN N
, , N
after IN N
1 CD N
, , N
6 CD N
months NNS N
. . N

RESULTS NNP N
At IN N
baseline NN N
, , N
patients NNS N
reported VBD N
greater JJR N
anxiety NN o
and CC N
lower JJR o
QoL NNP o
than IN N
healthy JJ N
populations NNS N
. . N

The DT N
CER NNP i
group NN N
had VBD N
three CD N
times NNS N
more RBR N
cardiac JJ o
diagnoses NNS o
than IN N
the DT N
UC NNP i
group NN N
. . N

No DT N
differences NNS N
were VBD N
found VBN N
between IN N
CER NNP i
group NN N
and CC N
UC NNP i
group NN N
at IN N
6 CD N
weeks NNS N
. . N

At IN N
6 CD N
months NNS N
, , N
the DT N
UC NNP i
group NN N
showed VBD N
QoL NNP o
improvement NN o
and CC N
less JJR N
anxiety NN o
compared VBN N
to TO N
the DT N
CER NNP i
group NN N
. . N

Type NN o
of IN o
diagnosis NN o
had VBD N
influence NN N
, , N
but CC N
did VBD N
not RB N
fully RB N
explain VB N
these DT N
differences NNS N
. . N

CONCLUSION VB N
A DT N
CER NNP i
does VBZ N
not RB N
negatively RB N
influence JJ N
anxiety NN o
or CC N
QoL NNP o
. . o

Better NNP N
outcomes VBZ N
in IN N
the DT N
UC NNP i
group NN N
might MD N
be VB N
attributed VBN N
to TO N
less JJR N
cardiac JJ o
diagnosis NN o
and CC N
more JJR N
emphasis NN N
on IN N
psychological JJ o
well-being NN o
. . o

-DOCSTART- -8904679- O O

Impact NN N
of IN N
triiodothyronine NN i
on IN N
the DT N
survival NN o
of IN o
high-risk JJ o
patients NNS o
undergoing VBG p
open JJ i
heart NN i
surgery NN i
. . i

Experimental NNP N
and CC N
clinical JJ N
studies NNS N
have VBP N
shown VBN N
the DT N
beneficial JJ o
effects NNS o
of IN N
triiodothyronine NN i
( ( i
T3 NNP i
) ) i
following VBG N
myocardial JJ N
revascularization NN N
on IN N
cardiopulmonary JJ i
bypass NN i
( ( i
CPB NNP i
) ) i
. . i

In IN N
this DT N
study NN N
, , N
open-label JJ p
T3 NNP i
was VBD p
administered VBN p
to TO p
68 CD p
high-risk JJ p
patients NNS p
undergoing VBG p
open JJ p
heart NN p
surgery NN p
. . p

The DT N
New NNP o
Jersey NNP o
Risk NNP o
Assessment NNP o
was VBD N
used VBN N
to TO N
calculate VB N
the DT N
preoperative NN o
estimated VBD o
surgical JJ o
mortality NN o
. . o

A DT N
loading VBG N
dose NN N
of IN N
T3 NNP i
was VBD N
administered VBN N
: : N
( ( N
a DT N
) ) N
at IN N
release NN N
of IN N
the DT N
aortic JJ N
cross-clamp NN N
, , N
( ( N
b NN N
) ) N
whenever WRB N
the DT N
patient NN N
became VBD N
CPB NNP N
dependent NN N
, , N
( ( N
c NN N
) ) N
if IN N
the DT N
patient NN N
exhibited VBD N
low JJ N
cardiac NN N
output NN N
after IN N
discontinuing VBG N
CPB NNP N
and CC N
( ( N
d NN N
) ) N
as IN N
pretreatment NN N
before IN N
initiating VBG N
CPB NNP N
. . N

All NNP N
therapeutic JJ N
modalities NNS N
were VBD N
followed VBN N
by IN N
a DT N
continuous JJ N
T3 NNP i
infusion NN N
. . N

Following VBG N
T3 NNP i
therapy NN i
, , i
CPB NNP i
was VBD N
discontinued VBN N
in IN N
all DT N
patients NNS N
. . N

Based VBN N
upon IN N
discriminant JJ N
analysis NN N
, , N
a DT N
total NN N
of IN N
26 CD N
deaths NNS o
were VBD N
expected VBN N
from IN N
the DT N
entire JJ N
group NN N
, , N
but CC N
only RB N
7 CD N
patients NNS N
died VBD o
, , N
therefore RB N
, , N
the DT N
observed JJ o
mortality NN o
was VBD N
reduced VBN N
by IN N
72 CD N
% NN N
( ( N
p JJ N
< NNP N
0.007 CD N
) ) N
. . N

The DT N
use NN N
of IN N
T3 NNP i
had VBD N
a DT N
major JJ N
impact NN N
on IN N
reducing VBG o
surgical JJ o
mortality NN o
, , N
and CC N
may MD N
be VB N
advocated VBN N
as IN N
a DT N
new JJ N
therapeutic JJ N
modality NN N
in IN N
patients NNS p
with IN p
high JJ p
estimated VBN o
mortality NN o
undergoing VBG p
open JJ p
heart NN p
surgery NN p
. . p

-DOCSTART- -14685645- O O

Prediction NN N
of IN N
the DT N
response NN N
to TO N
citalopram VB i
and CC i
reboxetine VB i
in IN N
post-stroke NN p
depressed JJ p
patients NNS p
. . p

RATIONALE NNP N
AND NNP N
OBJECTIVE NNP N
Depression NNP N
is VBZ N
a DT N
significant JJ N
complication NN N
of IN N
stroke NN N
. . N

The DT N
effectiveness NN N
of IN N
antidepressant JJ N
drugs NNS N
in IN N
the DT N
management NN N
of IN N
post-stroke JJ N
depression NN N
( ( N
PSD NNP N
) ) N
has VBZ N
been VBN N
widely RB N
investigated VBN N
. . N

However RB N
, , N
the DT N
choice NN N
of IN N
antidepressant JJ N
drug NN N
is VBZ N
critically RB N
influenced VBN N
by IN N
its PRP$ N
safety NN o
and CC N
tolerability NN o
and CC N
by IN N
its PRP$ N
effect NN N
on IN N
concurrent NN N
pathologies NNS N
. . N

Here RB N
we PRP N
investigate VBP N
the DT N
efficacy NN N
and CC N
safety NN N
of IN N
a DT N
selective JJ N
serotonin NN i
reuptake NN i
inhibitor NN i
( ( i
SSRI NNP i
) ) i
, , i
citalopram NN i
, , i
and CC i
a DT i
noradrenaline JJ i
reuptake NN i
inhibitor NN i
( ( i
NARI NNP i
) ) i
, , i
reboxetine NN i
, , N
in IN N
post-stroke JJ p
patients NNS p
affected VBN p
by IN p
anxious JJ p
depression NN p
or CC p
retarded VBN p
depression NN p
. . p

METHODS NNP N
This DT N
was VBD N
a DT N
randomized JJ N
double-blind NN N
study NN N
. . N

Seventy-four JJ p
post-stroke NN p
depressed JJ p
patients NNS p
were VBD N
diagnosed VBN N
as IN N
affected VBN N
by IN N
anxious JJ N
or CC N
retarded VBN N
depression NN N
by IN N
using VBG N
a DT N
synoptic JJ N
table NN N
. . N

Randomisation NN N
was VBD N
planned VBN N
so RB N
that IN N
50 CD N
% NN N
of IN N
the DT N
patients NNS N
in IN N
each DT N
subgroup NN N
were VBD N
assigned VBN N
for IN N
16 CD N
weeks NNS N
to TO N
treatment NN N
with IN N
citalopram NN i
and CC N
the DT N
remaining VBG N
50 CD N
% NN N
were VBD N
assigned VBN N
to TO N
treatment NN N
with IN N
reboxetine NN i
. . i

The DT N
Beck NNP o
Depression NNP o
Inventory NNP o
( ( o
BDI NNP o
) ) o
, , o
the DT o
Hamilton NNP o
Depression NNP o
Rating NNP o
Scale NNP o
( ( o
HDRS NNP o
) ) o
and CC N
a DT N
synoptic JJ N
table NN N
were VBD N
used VBN N
to TO N
score VB N
depressive JJ o
symptoms NNS o
. . o

RESULTS NNP N
Both NNP N
citalopram NN i
and CC N
reboxetine NN i
showed VBD N
good JJ N
safety NN o
and CC o
tolerability NN o
. . o

Citalopram NNP N
exhibited VBD N
greater JJR o
efficacy NN o
in IN N
anxious JJ N
depressed JJ N
patients NNS p
, , N
while IN N
reboxetine NN i
was VBD N
more RBR N
effective JJ o
in IN N
retarded JJ N
depressed JJ N
patients NNS N
. . N

CONCLUSIONS NNP N
Citalopram NNP i
or CC N
other JJ N
SSRIs NNP N
and CC N
reboxetine NN i
may MD N
be VB N
of IN N
first JJ N
choice NN N
treatment NN N
in IN N
PSD NNP N
because IN N
of IN N
their PRP$ N
good JJ N
efficacy NN o
and CC o
lack NN o
of IN o
severe JJ o
side NN o
effects NNS o
. . o

In IN N
addition NN N
, , N
PSD NNP p
patients NNS p
should MD N
be VB N
classified VBN N
according VBG N
to TO N
their PRP$ N
clinical JJ N
profile NN N
( ( N
similarly RB N
to TO N
patients NNS N
affected VBN N
by IN N
primary JJ N
depression NN N
) ) N
for IN N
the DT N
selection NN N
of IN N
SSRIs NNP N
or CC N
reboxetine VB N
as IN N
drugs NNS N
of IN N
choice NN N
in IN N
particular JJ N
subgroups NNS N
of IN N
patients NNS N
. . N

-DOCSTART- -7053590- O O

Laser NNP i
conization NN i
versus NN N
cold JJ i
knife NN i
conization NN i
. . i

This DT N
prospective JJ N
, , N
randomized VBN N
study NN N
compares VBZ N
, , N
for IN N
the DT N
first JJ N
time NN N
, , N
measured VBN N
blood NN N
loss NN N
at IN N
conization NN N
and CC N
within IN N
24 CD N
hours NNS N
after IN N
using VBG N
either CC N
the DT N
cold JJ i
knife NN i
technique NN i
or CC i
the DT i
carbon NN i
dioxide NN i
laser NN i
scalpel NN i
. . i

One CD p
hundred CD p
and CC p
ten VB p
consecutive JJ p
patients NNS p
were VBD p
evaluated VBN p
. . p

The DT N
median JJ o
blood NN o
loss NN o
in IN N
the DT N
laser NN N
group NN N
of IN N
55 CD N
patients NNS N
was VBD N
4.6 CD N
milliliters NNS N
at IN N
, , N
and CC N
within IN N
, , N
24 CD N
hours NNS N
after IN N
operation NN N
compared VBN N
with IN N
30.1 CD N
milliliters NNS N
in IN N
the DT N
cold JJ i
knife NN i
group NN N
of IN N
55 CD N
patients NNS N
. . N

More RBR N
important JJ N
, , N
however RB N
, , N
is VBZ N
that IN N
the DT N
corresponding JJ N
figures NNS N
for IN N
the DT N
range NN o
of IN o
bleeding VBG o
were VBD N
0.4 CD N
to TO N
155.4 CD N
milliliters NNS N
and CC N
5.6 CD N
to TO N
1,570.9 CD N
milliliters NNS N
, , N
respectively RB N
. . N

The DT N
incidence NN o
rate NN o
for IN o
bleeding VBG o
complications NNS o
requiring VBG o
surgical JJ o
intervention NN o
was VBD N
1.8 CD N
per IN N
cet NN N
for IN N
the DT N
laser NN N
group NN N
and CC N
14.6 CD N
per IN N
cent NN N
for IN N
the DT N
cold JJ i
knife NN i
group NN N
. . N

This DT N
difference NN N
was VBD N
statistically RB N
significant JJ N
, , N
p RB N
less JJR N
than IN N
0.015 CD N
-- : N
Fischer NNP N
's POS N
exact JJ N
test NN N
. . N

Conization NN N
for IN N
treatment NN N
of IN N
premalignant JJ p
changes NNS p
of IN p
the DT p
cervix NN p
uteri NN p
will MD N
probably RB N
remain VB N
the DT N
treatment NN N
of IN N
choice NN N
for IN N
some DT N
time NN N
to TO N
come VB N
. . N

It PRP N
is VBZ N
our PRP$ N
opinion NN N
that IN N
, , N
in IN N
the DT N
future NN N
, , N
laser JJR i
conization NN N
will MD N
replace VB N
cold JJ i
knife NN i
conization NN N
. . N

-DOCSTART- -4619431- O O

[ JJ i
Piribedil NNP i
in IN N
arterial JJ o
diseases NNS o
] VBP o
. . N

-DOCSTART- -12881389- O O

Cisplatin NNP i
, , i
epirubicin NN i
, , i
leucovorin NN i
and CC i
5-fluorouracil JJ i
( ( i
PELF NNP i
) ) i
is VBZ N
more RBR N
active JJ N
than IN N
5-fluorouracil JJ i
, , i
doxorubicin JJ i
and CC i
methotrexate NN i
( ( i
FAMTX NNP i
) ) i
in IN N
advanced JJ p
gastric JJ p
carcinoma NN p
. . p

BACKGROUND NNP N
5-Fluorouracil JJ i
( ( i
5-FU JJ i
) ) i
, , i
doxorubicin NN i
and CC i
methotrexate NN i
( ( i
FAMTX NNP i
) ) i
and CC i
cisplatin NN i
, , i
epirubicin NN i
, , i
leucovorin NN i
and CC i
5-FU JJ i
( ( i
PELF NNP i
) ) i
have VBP N
both DT N
been VBN N
reported VBN N
to TO N
be VB N
superior JJ N
to TO N
the DT N
combination NN N
5-FU JJ N
, , N
doxorubicin JJ N
and CC N
mitomycin JJ N
C NNP N
( ( N
FAM NNP N
) ) N
in IN N
advanced JJ p
gastric JJ p
carcinoma NN p
. . N

On IN N
the DT N
basis NN N
of IN N
the DT N
presence NN N
and CC N
dose JJ N
intensity NN N
of IN N
the DT N
included JJ N
agents NNS N
, , N
we PRP N
hypothesised VBD N
that IN N
PELF NNP N
would MD N
be VB N
superior JJ N
to TO N
FAMTX NNP i
. . i

PATIENTS NNP N
AND CC N
METHODS NNP N
Two CD p
hundred VBD p
patients NNS p
with IN p
untreated JJ p
advanced JJ p
gastric JJ p
carcinoma NN p
were VBD N
randomised VBN N
to TO N
receive VB N
PELF NNP i
or CC i
FAMTX NNP i
for IN N
a DT N
maximum NN N
of IN N
six CD N
cycles NNS N
or CC N
until IN N
disease JJ N
progression NN N
. . N

RESULTS VB N
The DT N
complete JJ o
response NN o
( ( o
CR NNP o
) ) o
rates NNS o
to TO N
PELF NNP N
and CC N
FAMTX NNP i
were VBD N
, , N
respectively RB N
, , N
13 CD N
% NN N
[ JJ N
95 CD N
% NN N
confidence NN N
intervals NNS N
( ( N
CI NNP N
) ) N
6 CD N
% NN N
to TO N
20 CD N
% NN N
] NN N
and CC N
2 CD N
% NN N
( ( N
95 CD N
% NN N
CI NNP N
0 CD N
% NN N
to TO N
5 CD N
% NN N
; : N
P NNP N
= NNP N
0.003 CD N
) ) N
, , N
and CC N
the DT N
objective JJ o
response NN o
rates NNS o
[ VBP N
CR NNP N
plus CC N
partial JJ o
response NN o
( ( N
PR NNP N
) ) N
rates NNS N
] VBP N
39 CD N
% NN N
( ( N
95 CD N
% NN N
CI NNP N
29 CD N
% NN N
to TO N
49 CD N
% NN N
) ) N
and CC N
22 CD N
% NN N
( ( N
95 CD N
% NN N
CI NNP N
13 CD N
% NN N
to TO N
30 CD N
% NN N
; : N
P NNP N
= NNP N
0.009 CD N
) ) N
, , N
thus RB N
significantly RB N
favouring VBG N
the DT N
PELF NNP N
combination NN N
. . N

The DT N
survival NN o
rates NNS o
after IN N
12 CD N
months NNS N
( ( N
30.8 CD N
% NN N
versus IN N
22.4 CD N
% NN N
) ) N
and CC N
24 CD N
months NNS N
( ( N
15.7 CD N
% NN N
versus IN N
9.5 CD N
% NN N
) ) N
were VBD N
also RB N
higher JJR N
among IN N
patients NNS N
receiving VBG N
PELF NNP N
, , N
but CC N
these DT N
differences NNS N
were VBD N
not RB N
statistically RB N
significant JJ N
. . N

The DT N
toxicities NNS o
were VBD N
qualitatively RB N
different JJ N
but CC N
quantitatively RB N
similar JJ N
. . N

Both DT N
regimens VBZ N
seem VBP N
to TO N
be VB N
feasible JJ N
provided VBN N
that IN N
careful JJ N
patient JJ N
monitoring NN N
is VBZ N
assured VBN N
. . N

CONCLUSIONS NNP N
PELF NNP i
is VBZ N
significantly RB N
more RBR N
active JJ N
than IN N
FAMTX NNP i
and CC N
deserves VBZ N
further JJ N
research NN N
in IN N
the DT N
adjuvant JJ N
setting NN N
. . N

-DOCSTART- -16079640- O O

Effect NN N
of IN N
mild JJ i
endurance NN i
exercise NN i
training NN i
and CC N
pravastatin NN i
on IN N
peripheral JJ N
vasodilatation NN N
of IN N
forearm NN N
resistance NN N
vessels NNS N
in IN N
patients NNS p
with IN p
coronary JJ p
artery NN p
disease NN p
. . p

BACKGROUND NNP N
Improved NNP N
endothelial JJ N
function NN N
may MD N
contribute VB N
to TO N
the DT N
beneficial JJ N
effects NNS N
of IN N
cholesterol NN N
lowering VBG N
therapy NN N
in IN N
patients NNS p
with IN p
coronary JJ p
artery NN p
disease NN p
( ( p
CAD NNP p
) ) p
, , N
but CC N
results NNS N
of IN N
the DT N
effect NN N
of IN N
statin NN N
therapy NN N
on IN N
endothelial JJ N
function NN N
are VBP N
disparate NN N
in IN N
these DT N
patients NNS N
. . N

Exercise NNP i
training NN i
has VBZ N
been VBN N
reported VBN N
to TO N
improve VB N
endothelial JJ N
function NN N
of IN N
patients NNS N
at IN N
risk NN N
of IN N
or CC N
with IN N
established VBN N
CAD NNP N
. . N

The DT N
goal NN N
of IN N
the DT N
study NN N
was VBD N
to TO N
compare VB N
the DT N
effect NN N
of IN N
mild JJ i
exercise NN i
training NN i
or CC N
statin NN i
therapy NN i
on IN N
forearm JJ N
endothelial JJ N
function NN N
in IN N
CAD NNP p
patients NNS p
with IN p
average JJ p
cholesterol NN p
levels NNS p
. . p

DESIGN NNP N
AND CC N
METHODS NNP N
Twenty-eight NNP p
sedentary JJ p
male NN p
patients NNS p
with IN p
angiographically RB p
documented VBN p
CAD NNP p
and CC p
average JJ p
pretreatment JJ p
total NN p
plasma NN p
cholesterol NN p
levels NNS p
( ( p
5.1+/-0.9 JJ p
mmol/l NN p
) ) p
aged VBD p
42-75 CD p
years NNS p
were VBD p
included VBN p
. . p

They PRP N
were VBD N
randomly RB N
assigned VBN N
in IN N
a DT N
2 CD N
: : N
1 CD N
order NN N
to TO N
either DT N
statin NN i
therapy NN i
( ( i
pravastatin NN i
, , N
40 CD N
mg JJ N
daily RB N
) ) N
or CC N
exercise NN i
training NN i
therapy NN i
( ( i
mild JJ i
endurance NN i
exercise NN i
three CD i
or CC i
more JJR i
times NNS i
a DT i
week NN i
) ) i
. . N

The DT N
effects NNS N
of IN N
10 CD N
weeks NNS N
of IN N
either DT N
treatment NN N
on IN N
endothelium-dependent JJ N
and CC N
independent JJ N
vasodilation NN N
of IN N
forearm NN N
resistance NN N
vessels NNS N
was VBD N
assessed VBN N
by IN N
plethysmography NN N
. . N

Cardiopulmonary NNP i
exercise NN i
testing NN N
was VBD N
performed VBN N
at IN N
baseline NN N
and CC N
after IN N
10 CD N
weeks NNS N
. . N

RESULTS NNP N
Ten NNP N
weeks NNS N
of IN N
pravastatin NN i
therapy NN i
significantly RB N
reduced VBD N
low-density JJ o
lipoprotein NN o
cholesterol NN o
( ( N
from IN N
3.8+/-0.6 CD N
to TO N
3.1+/-0.6 CD N
mmol/l NN N
at IN N
study JJ N
end NN N
, , N
P=0.04 NNP N
) ) N
and CC N
the DT N
ratio NN o
of IN o
total JJ o
to TO o
high-density NN o
lipoprotein NN o
cholesterol NN o
( ( N
from IN N
4.9+/-0.8 CD N
to TO N
3.7+/-0.7 CD N
mmol/l NNS N
, , N
P=0.002 NNP N
) ) N
. . N

Exercise NN i
training NN i
did VBD N
not RB N
significantly RB N
modify VB N
the DT N
lipid JJ o
profile NN o
. . o

Peak NNP o
oxygen NN o
consumption NN o
, , o
maximal JJ o
achieved VBN o
workload NN o
and CC o
exercise NN o
duration NN o
tended VBD N
to TO N
improve VB N
in IN N
the DT N
exercise NN N
training NN N
group NN N
but CC N
remained VBD N
unchanged JJ N
in IN N
the DT N
pravastatin-treated JJ i
group NN N
. . N

Neither CC N
10 CD N
weeks NNS N
of IN N
pravastatin NNS i
nor CC N
mild JJ i
endurance NN i
exercise NN i
training NN i
improved VBD N
endothelium-dependent JJ o
or CC o
independent JJ o
vasomotor NN o
function NN o
in IN o
forearm NN o
resistance NN o
vessels NNS o
. . o

CONCLUSIONS NNP N
In IN N
patients NNS p
with IN p
CAD NNP p
and CC p
average JJ p
cholesterol NN p
levels NNS p
, , N
10 CD N
weeks NNS N
of IN N
treatment NN N
with IN N
mild JJ i
endurance NN i
exercise NN i
training NN i
or CC N
with IN N
pravastatin NN i
failed VBD N
to TO N
improve VB N
endothelium-dependent NN N
or CC N
independent JJ N
vasomotor NN N
function NN N
in IN N
forearm NN N
resistance NN N
vessels NNS N
. . N

-DOCSTART- -22723176- O O

The DT N
in IN N
vitro JJ N
effects NNS N
of IN N
verbascoside NN i
on IN N
human JJ p
platelet NN p
aggregation NN p
. . p

Preliminary NNP N
in IN N
vitro NN N
and CC N
animal NN N
studies NNS N
have VBP N
shown VBN N
that IN N
verbascoside NN i
, , N
a DT N
phenolic JJ N
compound NN N
, , N
may MD N
have VB N
several JJ N
favourable JJ N
biological JJ N
activities NNS N
, , N
including VBG N
an DT N
influence NN N
on IN N
endothelial JJ N
function NN N
and CC N
on IN N
platelet NN N
aggregation NN N
. . N

We PRP N
sought VBD N
to TO N
evaluate VB N
the DT N
effects NNS N
of IN N
verbascoside NN i
, , N
biotechnologically RB N
produced VBN N
from IN N
plant NN N
cell NN N
cultures NNS N
, , N
on IN N
human JJ N
platelet NN N
aggregation NN N
( ( N
PA NNP N
) ) N
. . N

The DT N
blood NN N
from IN N
40 CD p
aspirin-na?ve JJ p
volunteers NNS p
with IN p
at IN p
least JJS p
one CD p
cardiovascular NN p
risk NN p
factor NN p
was VBD N
preincubated VBN N
in IN N
vitro NN N
with IN i
verbascoside NN i
( ( N
1 CD N
and CC N
2 CD N
mg/dL NN N
) ) N
and CC i
aspirin NN i
( ( i
100 CD N
?M NN N
) ) N
. . N

The DT N
blood NN N
from IN N
20 CD p
patients NNS p
with IN p
a DT p
prior JJ p
diagnosis NN p
of IN p
coronary JJ p
heart NN p
disease NN p
who WP p
were VBD p
chronically RB p
assuming VBG i
aspirin NN i
was VBD i
preincubated VBN N
in IN N
vitro NN N
with IN N
verbascoside NN i
( ( i
1 CD i
and CC N
2 CD N
mg/dL NN N
) ) N
. . N

PA NNP N
is VBZ N
measured VBN N
with IN N
a DT N
light JJ N
transmission NN N
aggregometry NN N
and CC N
multiplate NN N
analyzer NN N
. . N

As IN N
compared VBN N
to TO N
reference VB N
, , N
preincubation NN N
with IN N
verbascoside NN N
resulted VBD N
in IN N
a DT N
significant JJ o
inhibition NN o
of IN o
adenosine JJ o
diphosphate NN o
( ( o
ADP NNP o
) ) o
and CC o
arachidonic JJ o
acid NN o
( ( o
AA NNP o
) ) o
-induced VBD o
PA NNP o
( ( o
p VB N
< $ N
0.01 CD N
for IN N
both DT N
) ) N
. . N

Verbascoside $ i
2 CD i
mg/dL NN i
did VBD N
not RB N
show VB N
a DT N
stronger JJR N
effect NN N
as IN N
compared VBN N
to TO N
verbascoside VB N
1 CD N
mg/dL NN N
( ( N
p JJ N
= NNP N
0.4 CD N
) ) N
. . N

As IN N
expected VBN N
, , N
the DT N
in IN N
vitro JJ N
addition NN N
of IN N
aspirin NN N
reduced VBN o
AA NNP o
induced JJ o
PA NNP o
( ( N
p VB N
< RB N
0.01 CD N
) ) N
, , N
but CC N
not RB N
that IN N
induced VBN N
by IN N
ADP NNP N
( ( N
p JJ N
= NNP N
0.5 CD N
) ) N
. . N

The DT N
addition NN N
of IN N
verbascoside NN N
to TO N
the DT N
blood NN N
of IN N
aspirin-treated JJ i
patients NNS N
did VBD N
not RB N
improve VB N
the DT N
values NNS o
of IN o
PA NNP o
after IN o
AA NNP o
stimulus NN o
( ( o
p JJ o
= NNP N
0.8 CD N
) ) N
, , N
whereas IN N
it PRP N
ensured VBD N
a DT N
stronger JJR o
inhibition NN o
after IN o
ADP NNP o
stimulus NN o
( ( N
p JJ N
< NNP N
0.01 CD i
) ) i
. . i

Verbascoside NNP i
in IN i
vitro JJ i
affects NNS N
PA VBN N
by IN N
mildly RB N
inhibiting VBG o
aggregation NN o
, , o
triggered VBD o
both DT N
by IN N
ADP NNP N
and CC N
AA NNP N
. . N

These DT N
preliminary JJ N
data NNS N
, , N
while IN N
intriguing NN N
, , N
require VBP N
confirmation NN N
in IN N
subjects NNS N
receiving VBG N
verbascoside NN i
orally RB i
in IN N
order NN N
to TO N
determine VB N
whether IN N
these DT N
findings NNS N
are VBP N
clinically RB N
relevant JJ N
. . N

-DOCSTART- -17722829- O O

[ JJ N
Effect NNP N
of IN N
acupuncture NN i
on IN N
rehabilitation NN N
training NN N
of IN N
child NN p
's POS p
autism NN p
] NN p
. . N

OBJECTIVE UH N
To TO N
observe VB N
the DT N
effect NN N
of IN N
acupuncture NN i
on IN N
rehabilitation NN N
training NN N
for IN N
children NNS p
's POS p
autism NN p
. . p

METHODS NNP N
Forty NNP p
autistic JJ p
children NNS p
receiving VBG p
rehabilitation NN p
training NN p
were VBD N
divided VBN N
into IN N
a DT N
control NN N
group NN N
and CC N
a DT N
treatment NN N
group NN N
, , N
20 CD N
cases NNS N
in IN N
each DT N
group NN N
. . N

The DT N
control NN N
group NN N
received VBD N
rehabilitation NN i
training NN i
including VBG i
ABA NNP i
training NN i
, , i
the DT i
Conductive NNP i
Education NNP i
Approach NNP i
and CC i
the DT i
training NN i
of IN i
sensory JJ i
integration NN i
, , N
about RB N
90 CD N
sessions NNS N
for IN N
each DT N
training NN N
; : N
the DT N
treatment NN N
group NN N
received VBD N
acupuncture JJ i
treatment NN i
for IN N
60-90 JJ N
sessions NNS N
after IN i
the DT i
rehabilitation NN i
training NN i
. . i

Their PRP$ N
results NNS N
were VBD N
detected VBN N
by IN N
the DT N
revised VBN o
Chinese JJ o
version NN o
of IN o
Psycho-Educational NNP o
Profile NNP o
for IN o
autistic JJ o
and CC o
developmentally RB o
disabled JJ o
children NNS o
( ( o
C-PEP NNP o
) ) o
. . o

RESULTS VB N
The DT N
markedly RB N
effective JJ o
rate NN o
was VBD N
55.0 CD N
% NN N
in IN N
the DT N
treatment NN N
group NN N
and CC N
15.0 CD N
% NN N
in IN N
the DT N
control NN N
group NN N
with IN N
a DT N
very RB N
significant JJ N
difference NN N
between IN N
the DT N
two CD N
groups NNS N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
; : N
the DT N
differences NNS N
before IN N
and CC N
after IN N
training NN N
in IN N
some DT N
projects NNS N
such JJ N
as IN N
the DT N
total JJ o
score NN o
of IN o
development NN o
, , o
imitation NN o
, , o
oral JJ o
cognition NN o
in IN N
the DT N
treatment NN N
group NN N
were VBD N
very RB N
significantly RB N
different JJ N
from IN N
those DT N
in IN N
the DT N
control NN N
group NN N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

CONCLUSION NNP N
Acupuncture NNP i
combined VBN N
with IN N
scientific JJ i
and CC i
effective JJ i
rehabilitation NN i
training NN i
has VBZ N
a DT N
better RBR N
therapeutic JJ o
effect NN o
than IN N
that DT N
of IN N
the DT N
simple JJ i
rehabilitation NN i
training NN i
for IN N
child NN p
's POS p
autism NN p
. . p

-DOCSTART- -25294277- O O

Comparing VBG N
antipsychotic JJ N
treatments NNS N
for IN N
schizophrenia NN p
: : p
a DT N
health NN N
state NN N
approach NN N
. . N

The DT N
overall JJ N
impact NN N
of IN N
first JJ N
and CC N
second JJ N
generation NN N
antipsychotics NNS i
on IN N
quality NN o
of IN o
life NN o
and CC o
symptoms NNS o
of IN N
people NNS p
with IN p
schizophrenia NN o
remains VBZ N
controversial JJ N
. . N

We PRP N
applied VBD N
health NN N
state NN N
modeling NN N
to TO N
data NNS N
from IN N
the DT N
Clinical NNP N
Antipsychotic NNP N
Trials NNP N
of IN N
Intervention NNP N
Effectiveness NNP N
( ( N
CATIE NNP N
) ) N
Schizophrenia NNP N
study NN N
, , N
a DT N
randomized JJ N
trial NN N
of IN N
antipsychotic JJ i
medications NNS i
, , N
and CC N
evaluated VBD N
the DT N
likelihood NN N
of IN N
patients NNS N
moving VBG N
to TO N
more RBR o
favorable JJ o
health NN o
states NNS o
over IN N
time NN N
. . N

We PRP N
applied VBD N
K-means NNP N
clustering VBG N
to TO N
the DT N
data NNS N
to TO N
create VB N
discrete JJ N
groupings NNS N
of IN N
patients NNS N
with IN N
symptom JJ o
and CC o
side JJ o
effect NN o
characteristics NNS o
that WDT N
were VBD N
then RB N
validated VBN N
using VBG N
quality NN o
of IN o
life NN o
measures NNS o
. . o

We PRP N
compared VBN N
cluster NN N
distributions NNS N
across IN N
medications NNS N
at IN N
baseline NN N
and CC N
6 CD N
months NNS N
after IN N
randomization NN N
. . N

1,049 CD p
patients NNS p
were VBD p
included VBN p
in IN p
the DT p
initial JJ p
cluster NN p
analysis NN p
. . p

Five CD N
health NN N
states NNS N
were VBD N
identified VBN N
: : N
( ( N
1 CD N
) ) N
low NN N
symptoms NNS N
and CC N
low JJ N
side NN N
effects NNS N
( ( N
LS NNP N
+ NNP N
LSE NNP N
) ) N
( ( N
2 CD N
) ) N
low NN N
symptoms NNS N
and CC N
obesity NN N
( ( N
LS NNP N
+ NNP N
Ob NNP N
) ) N
( ( N
3 CD N
) ) N
high NN N
symptoms NNS N
and CC N
low JJ N
side NN N
effects NNS N
( ( N
HS NNP N
+ NNP N
LSE NNP N
) ) N
( ( N
4 CD N
) ) N
high NN N
symptoms NNS N
with IN N
depression NN o
and CC o
akathisia NN o
( ( N
HS NNP N
+ NNP N
Dp NNP N
+ NNP N
Ak NNP N
) ) N
and CC N
( ( N
5 CD N
) ) N
moderate NN N
symptoms NNS N
and CC N
high JJ N
side NN N
effects NNS N
( ( N
MS NNP N
+ NNP N
HSE NNP N
) ) N
. . N

Six-month JJ N
outcomes NNS N
among IN N
patients NNS N
randomly RB N
assigned VBN N
to TO N
perphenazine VB i
, , i
olanzapine NN i
, , i
risperidone NN i
and CC N
quetiapine NN i
were VBD N
compared VBN N
. . N

At IN N
baseline NN N
, , N
almost RB N
20 CD N
% NN N
of IN N
patients NNS N
were VBD N
in IN N
the DT N
worst JJS o
health NN o
state NN o
( ( N
HS NNP N
+ NNP N
Dp NNP N
+ NNP N
Ak NNP N
) ) N
, , N
with IN N
greater JJR N
decreases NNS N
at IN N
6 CD N
months NNS N
in IN N
this DT N
health NN N
state NN N
for IN N
perphenazine NN i
( ( N
9.2 CD N
% NN N
decrease NN N
) ) N
and CC N
olanzapine NN i
( ( N
11.1 CD N
% NN N
) ) N
groups NNS N
compared VBN N
to TO N
risperidone VB i
( ( N
4.7 CD N
% NN N
) ) N
and CC N
quetiapine NN N
( ( N
6.7 CD N
% NN N
) ) N
. . N

This DT N
study NN N
demonstrated VBD N
that IN N
health NN N
state NN N
analysis NN N
can MD N
provide VB N
insight RB N
into IN N
the DT N
overall JJ N
clinical JJ N
state NN N
of IN N
patients NNS N
beyond IN N
the DT N
mere JJ N
comparison NN N
of IN N
average JJ N
scores NNS N
and CC N
largely RB N
confirmed VBN N
original JJ N
CATIE NNP N
findings NNS N
. . N

-DOCSTART- -25791707- O O

Magnetic JJ i
resonance NN i
imaging NN i
in IN N
the DT N
evaluation NN N
of IN N
clinical JJ N
treatment NN N
of IN N
otospongiosis NN p
: : p
a DT N
pilot NN N
study NN N
. . N

OBJECTIVES NNP N
To TO N
evaluate VB N
the DT N
applicability NN N
of IN N
magnetic JJ i
resonance NN i
imaging NN i
( ( i
MRI NNP i
) ) i
as IN N
a DT N
method NN N
for IN N
monitoring VBG N
the DT N
activity NN N
of IN N
otospongiotic JJ N
lesions NNS N
before IN N
and CC N
after IN N
clinical JJ N
treatment NN N
. . N

STUDY NNP N
DESIGN NNP N
Prospective NNP N
, , N
randomized VBD N
, , N
controlled VBD N
, , N
double-blind NN N
study NN N
. . N

SETTING CC N
One CD p
single JJ p
tertiary NN p
care NN p
institution NN p
in IN p
a DT p
large JJ p
, , p
cosmopolitan JJ p
city NN p
. . p

METHODS NNP N
Twenty-six JJ p
patients NNS p
( ( p
n JJ p
= $ p
42 CD p
ears NNS p
) ) p
with IN p
clinical JJ p
, , p
audiometric JJ p
, , p
and CC p
tomographic JJ p
diagnosis NN p
of IN p
otosclerosis NN p
were VBD p
enrolled VBN p
. . p

If IN N
computed VBN i
tomography NN i
( ( N
CT NNP N
) ) N
demonstrated VBD N
active JJ N
lesions NNS N
, , N
these DT N
patients NNS N
underwent VBD i
MRI NNP i
to TO N
detect VB N
otospongiotic JJ N
foci NN N
, , N
seen VBN N
as IN N
areas NNS N
of IN N
gadolinium NN N
enhancement NN N
. . N

Patients NNS N
were VBD N
divided VBN N
into IN N
3 CD N
groups NNS N
and CC N
received VBN N
treatment NN N
with IN N
placebo NN i
, , i
sodium NN i
alendronate NN i
, , i
or CC i
sodium NN i
fluoride NN i
for IN N
6 CD N
months NNS N
. . N

After IN N
this DT N
period NN N
, , N
clinical JJ N
and CC N
audiometric JJ N
evaluations NNS N
and CC N
a DT N
second JJ N
MRI NNP i
were VBD N
performed VBN N
. . N

Each DT N
MRI NNP i
was VBD N
evaluated VBN N
by IN N
both DT N
a DT N
neuroradiologist NN N
and CC N
an DT N
otolaryngologist NN N
in IN N
a DT N
subjective JJ N
( ( N
visual JJ N
) ) N
and CC N
objective JJ N
( ( N
using VBG N
specific JJ N
eFilm JJ N
Workstation NNP N
software NN N
) ) N
manner NN N
. . N

RESULTS NNP N
Otospongiosis NNP N
was VBD N
most JJS N
predominantly RB N
identified VBN N
in IN N
the DT N
region NN N
anterior RB N
to TO N
the DT N
oval NN N
window NN N
, , N
and CC N
this DT N
site NN N
was VBD N
reliable JJ N
for IN N
comparing VBG N
pre- JJ N
and CC N
posttreatment JJ N
scans NNS N
. . N

The DT N
patients NNS N
in IN N
the DT N
alendronate NN N
and CC N
sodium NN N
fluoride NN N
groups NNS N
had VBD N
MRI NNP i
findings NNS N
that WDT N
suggested VBD N
a DT N
decrease NN N
in IN N
activity NN N
of IN N
otospongiotic JJ N
lesions NNS N
, , N
more RBR N
relevant JJ N
in IN N
the DT N
alendronate NN N
group NN N
. . N

These DT N
findings NNS N
were VBD N
statistically RB N
significant JJ N
for IN N
both DT N
subjective JJ N
and CC N
objective JJ N
MRI NNP i
evaluations NNS N
. . N

CONCLUSIONS NNP N
MRI NNP N
shows VBZ N
higher JJR N
sensitivity NN N
than IN N
clinical JJ N
or CC N
audiometric JJ N
assessment NN N
for IN N
detecting VBG N
reduction NN N
in IN N
activity NN N
of IN N
otospongiosis NN N
. . N

The DT N
objective JJ N
MRI NNP i
evaluation NN N
based VBN N
on IN N
software NN N
analysis NN N
was VBD N
the DT N
most RBS N
accurate JJ N
method NN N
of IN N
monitoring VBG N
clinical JJ N
treatment NN N
response NN N
in IN N
otospongiosis NN N
. . N

-DOCSTART- -10618526- O O

Early JJ N
immunisation NN N
with IN N
hepatitis NN i
B NNP i
vaccine NN i
: : i
a DT N
five-year JJ N
study NN N
. . N

We PRP N
evaluated VBD N
the DT N
response NN N
to TO N
the DT N
recombinant NN i
Hepatitis NNP i
B NNP i
vaccine NN i
using VBG N
an DT N
accelerated JJ N
schedule NN N
versus IN N
the DT N
traditional JJ N
schedule NN N
by IN N
studying VBG N
the DT N
immunologic JJ N
memory NN N
induced VBN N
in IN N
200 CD p
children NNS p
with IN p
HBs-Ag NNP p
negative JJ p
mothers NNS p
. . p

At IN N
seroconversion NN N
, , N
the DT N
traditional JJ N
schedule NN N
presented VBD N
a DT N
higher JJR N
percentage NN N
of IN N
children NNS p
with IN p
serum JJ p
HBs-Ag JJ p
concentrations NNS p
over IN p
100 CD p
mIU/ml NNS p
than IN p
the DT p
accelerated JJ p
schedule NN p
. . p

After IN N
five CD N
years NNS N
this DT N
difference NN N
was VBD N
no RB N
longer RBR N
statistically RB N
significant JJ N
and CC N
children NNS p
who WP p
presented VBD p
anti-HBsAg JJ o
concentrations NNS o
below IN o
10 CD o
mUI/ml NN o
received VBD N
an DT N
additional JJ N
booster NN N
dose NN N
which WDT N
stimulated VBD N
the DT N
antibody NN o
concentration NN o
to TO o
exceed VB o
100 CD o
mIU/ml NNS o
in IN o
all DT N
cases NNS N
. . N

Recombinant JJ i
HBV NNP i
vaccine NN i
induced VBD N
better JJR N
long JJ N
term NN N
immunologic JJ o
memory NN o
when WRB N
it PRP N
was VBD N
administered VBN N
earlier RBR N
. . N

-DOCSTART- -21983766- O O

[ JJ N
Comparative NNP N
effects NNS N
of IN N
nebivolol NN i
and CC i
valsartan NN i
on IN N
atrial JJ o
electromechanical JJ o
coupling NN o
in IN N
newly RB p
diagnosed VBN p
stage NN p
1 CD p
hypertensive JJ p
patients NNS p
] VBP p
. . N

OBJECTIVES NNP N
Hypertension NNP N
is VBZ N
an DT N
important JJ N
cardiovascular NN N
risk NN N
factor NN N
for IN N
the DT N
development NN N
of IN N
atrial JJ o
fibrillation NN o
( ( o
AF NNP o
) ) o
. . o

Increased VBN N
atrial JJ N
electromechanical JJ N
coupling NN N
time NN N
interval NN N
measured VBN N
by IN N
tissue NN N
Doppler NNP N
is VBZ N
accepted VBN N
as IN N
an DT N
important JJ N
factor NN N
for IN N
prediction NN N
of IN N
AF NNP o
development NN o
in IN N
hypertensive JJ p
patients NNS p
. . p

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
compare VB N
the DT N
effects NNS N
of IN N
valsartan NN i
, , N
an DT N
angiotensin NN N
receptor NN N
blocker NN N
, , N
and CC N
nebivolol RB i
, , N
a DT N
beta-blocker NN N
, , N
on IN N
atrial JJ N
electromechanical JJ N
coupling NN N
in IN N
newly RB p
diagnosed VBN p
stage NN p
1 CD p
hypertensive JJ p
patients NNS p
. . p

STUDY NNP N
DESIGN NNP N
The DT N
study NN N
included VBD N
60 CD p
newly RB p
diagnosed VBN p
stage NN p
1 CD p
hypertensive JJ p
patients NNS p
with IN p
no DT p
other JJ p
systemic JJ p
disease NN p
. . p

The DT N
patients NNS N
were VBD N
randomized VBN N
to TO N
receive VB N
nebivolol JJ i
5 CD i
mg NN i
( ( N
30 CD N
patients NNS N
; : N
21 CD N
women NNS N
, , N
9 CD N
men NNS N
; : N
mean JJ N
age NN N
48.4 CD N
? . N
11.4 CD N
years NNS N
) ) N
and CC i
valsartan $ i
160 CD i
mg NN i
( ( N
30 CD N
patients NNS N
; : N
21 CD N
women NNS N
, , N
9 CD N
men NNS N
; : N
mean JJ N
age NN N
49.8 CD N
? . N
11.3 CD N
years NNS N
) ) N
. . N

All PDT N
the DT N
patients NNS N
underwent JJ N
tissue NN N
Doppler NNP N
echocardiographic JJ N
examination NN N
before IN N
and CC N
three CD N
months NNS N
after IN N
treatment NN N
to TO N
compare VB N
the DT N
effects NNS N
of IN N
the DT N
two CD N
drugs NNS N
on IN N
atrial JJ o
electromechanical JJ o
coupling NN o
. . o

RESULTS NNP o
Baseline NNP o
blood NN o
pressures NNS o
, , o
electrocardiographic JJ o
and CC o
echocardiographic JJ o
findings NNS o
, , o
and CC o
atrial JJ o
electromechanical JJ o
coupling NN o
were VBD o
similar JJ N
in IN N
both DT N
groups NNS N
( ( N
p JJ N
> NNP N
0.05 CD N
) ) N
. . N

Both DT N
drugs NNS N
significantly RB N
reduced VBD o
blood NN o
pressure NN o
after IN o
treatment NN N
, , N
with IN N
similar JJ N
efficacy NN N
( ( N
p JJ N
> NNP o
0.05 CD o
) ) o
. . o

Atrial JJ o
electromechanical JJ o
coupling NN o
time NN o
intervals NNS o
showed VBD o
significant JJ N
decreases NNS N
in IN N
both DT N
groups NNS N
. . N

CONCLUSION NNP o
Prolonged VBD o
interatrial JJ o
electromechanical JJ o
time NN o
intervals NNS o
in IN o
hypertensives NNS N
are VBP N
improved VBN N
with IN N
antihypertensive JJ N
treatment NN N
. . N

-DOCSTART- -22038637- O O

[ JJ i
Prophylactic NNP i
intraaortic JJ i
balloon NN i
pumping VBG i
in IN N
high-risk JJ p
cardiac JJ p
surgery NN p
patients NNS p
] VBP p
. . N

BACKGROUND NNP N
We PRP N
examined VBD N
the DT N
impact NN N
of IN N
prophylactic JJ i
IABP NNP i
insertion NN i
in IN N
EuroSCORE-stratified JJ p
high-risk JJ p
cardiac NN p
surgery NN p
patients NNS p
with IN p
a DT p
score NN p
?8 NN p
. . p

MATERIAL NNP N
AND NNP N
METHODS NNP N
A NNP N
randomized JJ N
trial NN N
with IN p
104 CD p
patients NNS p
either CC i
without IN i
prophylactic JJ i
IABP NNP i
insertion NN i
( ( i
group NN i
A NNP p
, , p
n=52 NN p
) ) p
or CC p
with IN p
IABP NNP i
( ( i
group NN i
B NNP p
, , p
n=52 NN p
) ) p
was VBD p
conducted VBN N
. . N

The DT N
primary JJ N
endpoint NN N
was VBD N
30-day JJ o
mortality NN o
. . o

RESULTS VB o
The DT p
median JJ p
age NN p
of IN p
the DT p
patients NNS p
was VBD p
74 CD p
years NNS p
and CC p
43 CD p
% NN p
of IN p
participants NNS p
were VBD p
females NNS o
. . o

The DT o
30-day JJ o
mortality NN o
did VBD o
not RB o
differ VB N
between IN N
group NN N
A NNP N
( ( N
17.3 CD N
% NN N
) ) N
and CC N
group NN N
B NNP N
( ( N
13.4 CD N
% NN N
; : N
p=0.78 NN N
) ) N
. . N

The DT o
median JJ o
hospital NN o
stay NN o
was VBD o
14 CD N
days NNS N
in IN N
both DT N
groups NNS N
. . N

Intra- NNP N
and CC N
postoperative JJ i
IABP NNP i
support NN i
was VBD N
required VBN N
by IN N
13 CD N
patients NNS N
( ( N
21 CD N
% NN N
) ) N
in IN N
group NN N
A NNP N
. . N

The DT o
median JJ o
ventilation NN o
time NN o
( ( o
14 CD o
hours NNS N
versus VBD N
13 CD N
hours NNS N
) ) N
, , N
median JJ o
catecholamine NN o
dose NN o
, , o
frequency NN o
of IN o
dialysis-dependent JJ o
acute JJ o
renal JJ o
failure NN o
( ( o
28 CD o
% NN N
versus IN N
18 CD N
% NN N
) ) N
, , N
cardiac JJ o
indices NNS o
, , o
and CC o
frequency NN o
of IN o
a DT o
low JJ o
cardiac JJ o
output NN o
syndrome NN o
( ( o
26 CD o
% NN N
versus IN N
25 CD N
% NN N
) ) N
did VBD N
not RB N
significantly RB N
differ VBP N
between IN N
groups NNS N
. . N

CONCLUSION NNP N
Prophylactic NNP i
preoperative JJ i
IABP NNP i
insertion NN i
in IN i
EuroSCORE-stratified JJ p
high-risk JJ p
patients NNS p
is VBZ p
not RB N
associated VBN N
with IN N
decreased JJ N
30-day JJ N
mortality NN N
. . N

-DOCSTART- -25660225- O O

Lung NNP p
cancer NN p
diagnosis NN p
and CC N
staging VBG N
with IN N
endobronchial JJ i
ultrasound-guided JJ i
transbronchial JJ i
needle JJ i
aspiration NN i
compared VBN N
with IN N
conventional JJ N
approaches NNS N
: : N
an DT N
open-label JJ N
, , N
pragmatic JJ N
, , N
randomised VBD N
controlled VBN N
trial NN N
. . N

BACKGROUND VB N
The DT N
diagnosis NN N
and CC N
staging NN N
of IN N
lung NN N
cancer NN N
is VBZ N
an DT N
important JJ N
process NN N
that IN N
identifies VBZ N
treatment NN N
options NNS N
and CC N
guides NNS N
disease JJ N
prognosis NN N
. . N

We PRP N
aimed VBD N
to TO N
assess VB N
endobronchial JJ i
ultrasound-guided JJ i
transbronchial JJ i
needle JJ i
aspiration NN i
as IN N
an DT N
initial JJ N
investigation NN N
technique NN N
for IN N
patients NNS p
with IN p
suspected JJ p
lung NN p
cancer NN p
. . p

METHODS NNP N
In IN N
this DT N
open-label JJ N
, , N
multicentre NN N
, , N
pragmatic JJ N
, , N
randomised VBD N
controlled VBN N
trial NN N
, , N
we PRP N
recruited VBD p
patients NNS p
who WP p
had VBD p
undergone NN p
a DT p
CT NNP p
scan JJ p
and CC p
had VBD p
suspected VBN p
stage NN p
I PRP p
to TO p
IIIA NNP p
lung NN p
cancer NN p
, , p
from IN p
six CD p
UK NNP p
centres NNS p
and CC N
randomly RB N
assigned VBD N
them PRP N
to TO N
either DT N
endobronchial JJ i
ultrasound-guided JJ i
transbronchial JJ i
needle JJ i
aspiration NN i
( ( N
EBUS-TBNA NNP N
) ) N
or CC N
conventional JJ i
diagnosis NN i
and CC i
staging NN i
( ( N
CDS NNP N
) ) N
, , N
for IN N
further JJ N
investigation NN N
and CC N
staging NN N
. . N

If IN N
a DT N
target NN N
node NN N
could MD N
not RB N
be VB N
accessed VBN N
by IN N
EBUS-TBNA NNP N
, , N
then RB N
endoscopic VBZ i
ultrasound-guided JJ i
fine JJ i
needle JJ i
aspiration NN i
( ( N
EUS-FNA NNP N
) ) N
was VBD N
allowed VBN N
as IN N
an DT N
alternative JJ N
procedure NN N
. . N

Randomisation NN N
was VBD N
stratified VBN N
according VBG N
to TO N
the DT N
presence NN N
of IN N
mediastinal JJ N
lymph NN N
nodes NNS N
measuring VBG N
1 CD N
cm NN N
or CC N
more RBR N
in IN N
the DT N
short JJ N
axis NN N
and CC N
by IN N
recruiting VBG N
centre NN N
. . N

We PRP N
used VBD N
a DT N
telephone NN N
randomisation NN N
method NN N
with IN N
permuted JJ N
blocks NNS N
of IN N
four CD N
generated VBN N
by IN N
a DT N
computer NN N
. . N

Because IN N
of IN N
the DT N
nature NN N
of IN N
the DT N
intervention NN N
, , N
masking VBG N
of IN N
participants NNS N
and CC N
consenting VBG N
investigators NNS N
was VBD N
not RB N
possible JJ N
. . N

The DT N
primary JJ N
endpoint NN N
was VBD N
the DT N
time-to-treatment JJ o
decision NN o
after IN N
completion NN N
of IN N
the DT N
diagnostic JJ N
and CC N
staging JJ N
investigations NNS N
and CC N
analysis NN N
was VBD N
by IN N
intention-to-diagnose JJ N
. . N

This DT N
trial NN N
is VBZ N
registered VBN N
with IN N
ClinicalTrials.gov NNP N
, , N
number NN N
NCT00652769 NNP N
. . N

FINDINGS NNP N
Between NNP N
June NNP N
10 CD N
, , N
2008 CD N
, , N
and CC N
July NNP N
4 CD N
, , N
2011 CD N
, , N
we PRP N
randomly RB p
allocated VBD p
133 CD p
patients NNS p
to TO p
treatment NN p
: : p
66 CD p
to TO p
EBUS-TBNA NNP p
and CC p
67 CD p
to TO p
CDS NNP p
( ( N
one CD N
later RB N
withdrew JJ N
consent NN N
) ) N
. . N

Two CD N
patients NNS N
from IN N
the DT N
EBUS-TBNA NNP N
group NN N
underwent JJ N
EUS-FNA NNP N
. . N

The DT N
median JJ o
time NN o
to TO o
treatment NN o
decision NN o
was VBD N
shorter JJR N
with IN N
EBUS-TBNA NNP N
( ( N
14 CD N
days NNS N
; : N
95 CD N
% NN N
CI NNP N
14-15 CD N
) ) N
than IN N
with IN N
CDS NNP N
( ( N
29 CD N
days NNS N
; : N
23-35 JJ N
) ) N
resulting VBG N
in IN N
a DT N
hazard NN N
ratio NN N
of IN N
1?98 CD N
, , N
( ( N
1?39-2?82 JJ N
, , N
p JJ N
< NNP N
0?0001 CD N
) ) N
. . N

One CD N
patient NN N
in IN N
each DT N
group NN N
had VBD N
a DT o
pneumothorax NN o
from IN o
a DT N
CT-guided JJ N
biopsy NN N
sample NN N
; : N
the DT N
patient NN N
from IN N
the DT N
CDS NNP N
group NN o
needed VBD o
intercostal JJ o
drainage NN o
and CC o
was VBD N
admitted VBN N
to TO N
hospital VB N
. . N

INTERPRETATION NNP i
Transbronchial NNP i
needle JJ i
aspiration NN i
guided VBN i
by IN i
endobronchial JJ i
ultrasound NN i
should MD i
be VB N
considered VBN N
as IN N
the DT N
initial JJ N
investigation NN N
for IN N
patients NNS p
with IN p
suspected JJ p
lung NN p
cancer NN p
, , p
because IN p
it PRP N
reduces VBZ N
the DT N
time NN N
to TO N
treatment NN N
decision NN N
compared VBN N
with IN N
conventional JJ N
diagnosis NN N
and CC N
staging VBG N
techniques NNS N
. . N

FUNDING NN N
UK NNP N
Medical NNP N
Research NNP N
Council NNP N
. . N

-DOCSTART- -16503545- O O

[ JJ N
Effect NNP N
of IN N
Selaginella NNP i
combined VBD N
with IN N
radiotherapy NN i
on IN N
nasopharyngeal JJ p
carcinoma NN p
] NNP p
. . N

OBJECTIVE NNP N
To TO N
observe VB N
the DT N
Chinese JJ N
herbal JJ N
medicine NN N
Selaginella-induced NNP N
radiosensitization NN N
of IN N
terminal JJ p
nasopharyngeal JJ p
carcinoma NN p
( ( p
NPC NNP p
) ) p
. . p

METHODS NNP N
Totally RB N
180 CD p
patients NNS p
with IN p
NPC NNP p
were VBD N
divided VBN N
equally RB N
into IN N
3 CD N
groups NNS N
with IN N
the DT N
same JJ N
radiotherapeutic JJ N
protocols NNS N
. . N

The DT N
patients NNS N
in IN N
group NN i
A NNP i
received VBD i
radiotherapy NN i
alone RB i
, , i
those DT i
in IN i
group NN i
B NNP i
were VBD i
given VBN i
daily JJ i
Selaginella NNP i
( ( i
30 CD i
g NN i
) ) i
prepared VBD i
into IN i
50 CD i
ml JJ i
decoction NN i
during IN i
the DT i
entire JJ i
course NN i
of IN i
radiotherapy NN i
, , N
and CC N
those DT N
in IN N
group NN i
C NNP i
had VBD i
Selaginella NNP i
30 CD i
g JJ i
daily RB i
in IN i
the DT i
late JJ i
course NN i
of IN i
radiotherapy NN i
. . i

RESULTS VB N
The DT N
complete JJ o
remission NN o
rate NN o
of IN o
nasopharyngeal JJ o
primary JJ o
lesions NNS o
in IN N
groups NNS N
B NNP N
and CC N
C NNP N
was VBD N
significantly RB N
higher JJR N
than IN N
that DT N
in IN N
group NN N
A NNP N
, , N
with IN N
also RB N
significantly RB N
higher JJR N
complete JJ N
remission NN o
rates NNS o
of IN o
the DT o
cervical JJ o
lymph NN o
nodes NNS o
. . o

The DT N
acute JJ o
toxicity NN o
of IN o
the DT o
skin NN o
and CC o
mucous JJ o
membrane NN o
was VBD N
milder RBR N
in IN N
the DT N
latter JJ N
two CD N
groups NNS N
, , N
but CC N
the DT N
differences NNS N
were VBD N
not RB N
significant JJ N
. . N

CONCLUSION NNP N
Selaginella NNP i
may MD N
induce VB N
radiosensitization NN N
for IN N
terminal JJ p
NPC NNP p
and CC N
does VBZ N
not RB N
increase VB N
the DT N
acute JJ N
toxicity NN N
of IN N
radiotherapy NN N
. . N

-DOCSTART- -11318022- O O

Double NNP N
hearing NN N
protection NN N
and CC N
speech NN N
intelligibility-room NN N
for IN N
improvement NN N
. . N

INTRODUCTION NNP N
Double NNP N
hearing NN N
protection NN N
is VBZ N
used VBN N
in IN N
many JJ N
air NN N
forces NNS N
around IN N
the DT N
world NN N
for IN N
protection NN N
in IN N
noisy NN N
aircraft NN N
environments NNS N
, , N
particularly RB N
in IN N
helicopters NNS N
. . N

The DT N
usual JJ N
combination NN N
is VBZ N
foam JJ N
ear JJ N
plugs NNS N
under IN N
headset NN N
or CC N
helmet JJ N
muffs NNS N
. . N

Much RB N
of IN N
the DT N
research NN N
that WDT N
spurred VBD N
the DT N
introduction NN N
of IN N
foam NN N
earplugs NNS N
indicated VBD N
little JJ N
change NN N
in IN N
speech NN N
intelligibility NN N
in IN N
persons NNS N
with IN N
normal JJ N
hearing NN N
. . N

However RB N
, , N
aircrew VBD N
often RB N
complain VBP N
about IN N
having VBG N
to TO N
maximize VB N
intercom JJ N
volume NN N
for IN N
speech NN N
understanding NN N
, , N
causing VBG N
a DT N
situation NN N
with IN N
no DT N
reserve NN N
volume NN N
and CC N
bad JJ N
sound NN N
quality NN N
. . N

In IN N
recent JJ N
years NNS N
, , N
further JJ N
developments NNS N
have VBP N
included VBN N
so-called JJ N
hi-fi JJ N
plugs NNS N
and CC N
custom NN N
made VBD N
ear NN N
plugs NNS N
which WDT N
are VBP N
claimed VBN N
to TO N
improve VB N
speech NN N
communication NN N
. . N

The DT N
aim NN N
of IN N
the DT N
present JJ N
project NN N
was VBD N
to TO N
investigate VB N
different JJ N
types NNS N
of IN N
ear NN N
plugs NNS N
and CC N
their PRP$ N
effect NN N
on IN N
speech NN N
intelligibility NN N
in IN N
helicopter NN N
noise NN N
. . N

METHODS NNP N
Each DT p
of IN p
nine CD p
normal-hearing JJ p
pilot NN p
subjects NNS p
were VBD p
placed VBN p
in IN N
an DT i
environment NN i
of IN i
recorded VBN i
helicopter NN i
noise NN i
from IN i
a DT i
BO-105 JJ i
helicopter NN i
. . i

Speech NNP i
audiometry NN i
was VBD i
performed VBN i
under IN i
four CD i
different JJ i
conditions NNS i
: : i
headset NN i
only RB i
, , i
and CC i
three CD i
different JJ i
ear NN i
plugs NNS i
worn VBN i
under IN i
the DT i
headset NN i
. . i

Fitting NN i
of IN i
the DT i
ear JJ i
plugs NN i
was VBD i
performed VBN i
by IN i
an DT i
ear NN i
, , i
nose JJ i
and CC i
throat JJ i
specialist NN i
to TO i
ensure VB i
similar JJ i
conditions NNS i
. . i

The DT N
sequence NN N
of IN N
test NN N
conditions NNS N
was VBD N
randomized VBN N
and CC N
double-blind JJ N
. . N

In IN N
addition NN N
, , N
a DT N
subjective JJ o
rating NN o
scale NN o
was VBD N
used VBN N
. . N

RESULTS NNP N
Wearing NNP N
foam JJ N
ear NN N
plugs NNS N
under IN N
the DT N
headset NN N
decreased VBD N
speech JJ o
intelligibility NN o
dramatically RB N
. . N

The DT N
hi-fi JJ N
plug NN N
was VBD N
somewhat RB N
better JJR N
than IN N
foam NN N
plugs NNS N
, , N
and CC N
the DT N
custom NN N
made VBD N
ear JJ N
plug NN N
provided VBD N
a DT N
speech NN o
intelligibility NN o
close RB N
to TO N
the DT N
headset-only JJ N
situation NN N
. . N

Subjective JJ o
rating NN o
scores NNS o
coincided VBD N
with IN N
these DT N
findings NNS N
. . N

DISCUSSION NNP N
In IN N
helicopter NN N
noise NN N
, , N
custom NN N
made VBD N
ear JJ N
plugs NNS N
may MD N
provide VB N
a DT N
much RB N
improved VBN N
speech JJ o
intelligibility NN o
over IN N
conventional JJ N
plugs NNS N
when WRB N
worn VBN N
under IN N
a DT N
headset NN N
, , N
while IN N
maintaining VBG N
improved JJ N
noise NN o
protection NN o
over IN N
the DT N
headset-alone JJ N
situation NN N
. . N

Custom NNP N
made VBD N
ear JJ N
plugs NNS N
might MD N
therefore RB N
be VB N
a DT N
good JJ N
alternative NN N
to TO N
other JJ N
forms NNS N
of IN N
enhanced JJ o
noise NN o
protection NN o
in IN N
helicopters NNS N
. . N

-DOCSTART- -11748974- O O

Fibrin NNP i
application NN i
for IN N
preventing VBG N
lymphocysts NNS N
after IN N
retroperitoneal JJ N
lymphadenectomy NN N
in IN N
patients NNS p
with IN p
gynecologic JJ p
malignancies NNS p
. . p

OBJECTIVE IN N
We PRP N
performed VBD N
a DT N
randomized VBN N
, , N
prospective JJ N
trial NN N
to TO N
assess VB N
the DT N
impact NN N
of IN N
fibrin JJ i
glue NN i
on IN N
the DT N
incidence NN N
of IN N
lymphocysts NNS N
after IN N
systematic JJ N
pelvic NN N
or CC N
pelvic NN N
and CC N
paraaortic JJ N
lymphadenectomy NN N
in IN N
patients NNS p
with IN p
gynecologic JJ p
malignancies NNS p
. . p

METHODS NNP N
Ninety-three JJ p
consecutive JJ p
patients NNS p
with IN p
gynecologic JJ p
pelvic JJ p
malignancies NNS p
who WP p
underwent VBP p
surgery NN p
including VBG p
pelvic NN p
or CC p
pelvic NN p
and CC p
paraaortic JJ p
lymphadenectomy NN p
were VBD N
randomized VBN N
during IN N
surgery NN N
to TO N
be VB N
treated VBN i
with IN i
fibrin JJ i
glue NN i
or CC i
not RB i
. . i

Serial JJ i
computed JJ i
tomography NN i
( ( i
CT NNP i
) ) i
scans NNS i
were VBD N
performed VBN N
during IN N
follow-up JJ N
. . N

CT NNP N
findings NNS N
of IN N
a DT N
smooth JJ N
and CC N
thin-walled JJ N
cavity NN N
filled VBN N
with IN N
a DT N
water-equivalent JJ N
fluid NN N
, , N
sharply RB N
demarcated VBN N
from IN N
its PRP$ N
surroundings NNS N
and CC N
without IN N
signs NNS N
of IN N
infiltration NN N
were VBD N
interpreted VBN N
as IN N
lymphocysts NNS o
. . o

RESULTS NNP N
Forty-seven JJ N
patients NNS N
( ( N
51 CD N
% NN N
) ) N
were VBD N
treated VBN N
with IN N
fibrin JJ i
glue NN i
and CC N
46 CD N
( ( N
49 CD N
% NN N
) ) N
were VBD N
not RB N
. . N

All DT N
93 CD p
patients NNS p
underwent JJ N
pelvic JJ N
lymphadenectomy NN N
; : N
15 CD N
patients NNS N
( ( N
32 CD N
% NN N
) ) N
of IN N
the DT N
fibrin NN N
group NN N
and CC N
12 CD N
( ( N
26 CD N
% NN N
) ) N
of IN N
the DT N
controls NNS N
also RB N
underwent JJ N
paraaortic JJ N
lymphadenectomy NN N
. . N

We PRP N
found VBD N
no DT o
significant JJ o
differences NNS o
between IN N
patients NNS N
who WP N
received VBD N
fibrin JJ o
glue NN o
and CC N
those DT N
who WP N
did VBD N
not RB N
. . N

CONCLUSION NNP N
Intraoperative NNP N
application NN N
of IN N
fibrin JJ N
glue NN N
did VBD o
not RB o
reduce VB o
the DT o
rate NN o
of IN o
postoperative JJ o
lymphocysts NNS o
after IN N
lymphadenectomy NN N
and CC N
had VBD N
no DT o
impact NN o
on IN N
any DT N
follow-up JJ o
parameter NN o
. . o

Its PRP$ N
use NN N
seems VBZ N
not RB N
to TO N
be VB N
indicated VBN N
in IN N
systematic JJ N
gynecologic NN N
pelvic NN N
or CC N
pelvic NN N
and CC N
paraaortic JJ N
lymphadenectomy NN N
. . N

-DOCSTART- -11378833- O O

Dose NNP N
response NN N
effect NN N
of IN N
cyclical JJ i
medroxyprogesterone NN i
on IN N
blood NN o
pressure NN o
in IN N
postmenopausal JJ p
women NNS p
. . p

OBJECTIVE VB N
This DT N
study NN N
was VBD N
designed VBN N
to TO N
compare VB N
with IN N
placebo PDT i
the DT N
dose-response JJ N
effect NN N
of IN N
cyclical JJ N
doses NNS N
of IN N
the DT N
C21 NNP i
progestogen NN i
, , i
medroxyprogesterone NN i
acetate NN i
( ( N
MPA NNP N
) ) N
on IN N
blood NN N
pressure NN N
( ( N
BP NNP N
) ) N
when WRB N
administered VBN N
to TO N
normotensive JJ p
postmenopausal NN p
women NNS p
receiving VBG p
a DT p
fixed JJ p
mid-range JJ p
daily JJ p
dose NN p
of IN p
conjugated JJ i
equine NN i
oestrogen NN i
( ( i
CEE NNP i
) ) i
. . i

MATERIALS NNP N
AND CC N
METHODS NNP N
Twenty NNP p
normotensive JJ p
postmenopausal NN p
women NNS p
( ( p
median JJ p
age NN p
53 CD p
years NNS p
) ) p
participated VBD N
in IN N
the DT N
study NN N
which WDT N
used VBD N
a DT N
double-blind JJ N
crossover NN N
design NN N
. . N

There EX N
were VBD N
four CD i
randomised VBN i
treatment NN i
phases NNS i
, , N
each DT N
of IN N
4 CD N
weeks NNS N
duration NN N
. . N

The DT N
four CD N
blinded VBD N
treatments NNS N
were VBD N
MPA NNP i
2.5 CD i
mg NN i
, , i
MPA NNP i
5 CD i
mg NN i
, , i
MPA NNP i
10 CD i
mg NN i
and CC i
matching VBG i
placebo NN i
, , i
taken VBN i
for IN i
the DT i
last JJ i
14 CD i
days NNS i
of IN i
each DT i
28 CD i
day NN i
treatment NN i
cycle NN i
. . i

CEE NNP N
0.625 CD N
mg NN N
was VBD N
also RB N
administered VBN N
once RB N
daily JJ N
as IN N
open JJ N
labelled VBD N
tablets NNS N
to TO N
all DT N
subjects NNS N
throughout IN N
the DT N
study NN N
. . N

Clinic NNP o
BP NNP o
was VBD N
measured VBN N
weekly RB N
with IN N
the DT N
mean JJ N
values NNS N
of IN N
weeks NNS N
3 CD N
and CC N
4 CD N
of IN N
each DT N
phase NN N
used VBN N
for IN N
analysis NN N
. . N

Ambulatory NNP o
BP NNP o
was VBD N
performed VBN N
in IN N
the DT N
final JJ N
week NN N
of IN N
each DT N
phase NN N
. . N

RESULTS NNP N
Compared VBD N
with IN N
the DT N
placebo NN N
phase NN N
, , N
end NN N
of IN N
phase NN N
clinic JJ o
BP NNP o
was VBD N
unchanged JJ N
by IN N
any DT N
of IN N
the DT N
progestogen NN N
treatments NNS N
. . N

There EX N
was VBD N
a DT N
dose-dependent JJ N
decrease NN o
in IN o
ambulatory JJ o
daytime JJ o
diastolic NN o
and CC o
mean JJ o
arterial JJ o
BP NNP o
with IN N
the DT N
progestogen NN N
treatments NNS N
compared VBN N
with IN N
placebo NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

CONCLUSION NNP N
In IN N
a DT N
regimen NN N
of IN N
postmenopausal NN N
hormone NN N
replacement NN N
therapy NN N
with IN N
a DT N
fixed JJ N
mid-range JJ N
daily JJ N
dose NN N
of IN N
CEE NNP i
combined VBD N
with IN N
a DT N
cyclical JJ N
regimen NN N
of IN N
a DT N
C21 NNP N
progestogen NN N
spanning VBG N
the DT N
current JJ N
clinical JJ N
dose NN N
range NN N
, , N
the DT N
progestogen NN i
has VBZ N
either CC N
no DT N
effect NN N
or CC N
a DT N
small JJ N
dose-dependent JJ N
reduction NN N
in IN N
clinic NN o
and CC o
ambulatory JJ o
BPs NNP o
over IN N
one CD N
treatment NN N
cycle NN N
. . N

-DOCSTART- -16095446- O O

Nitrous JJ N
oxide JJ N
diffusion NN N
into IN N
tracheal JJ N
tube JJ N
cuffs NNS o
-- : o
efficacy NN o
of IN N
a DT N
new JJ N
prototype NN N
cuff NN i
pressure NN i
release NN i
valve NN i
. . i

BACKGROUND IN N
The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
evaluate VB N
the DT N
performance NN o
of IN N
a DT N
new JJ N
cuff NN o
pressure NN o
release NN i
valve NN i
( ( N
CPRV NNP N
) ) N
, , N
in IN N
which WDT N
the DT N
release NN N
pressure NN N
can MD N
be VB N
adjusted VBN N
from IN N
10 CD N
to TO N
25 CD N
cmH2O NNS N
, , N
particularly RB N
intended VBN N
to TO N
control VB N
pressure NN N
in IN N
paediatric JJ p
cuffed NN p
tracheal NN p
tubes NNS p
and CC N
to TO N
avoid VB N
cuff NN N
hyperinflation NN N
caused VBN N
by IN N
N2O NNP N
diffusion NN N
. . N

METHODS NNP N
In IN N
vitro NN N
: : N
the DT N
PRV NNP N
was VBD N
set VBN N
to TO N
10 CD N
, , N
15 CD N
, , N
20 CD N
or CC N
25 CD N
cmH2O JJ N
release NN N
pressure NN N
and CC N
connected VBN N
to TO N
a DT N
cuffed NN N
tube NN N
placed VBD N
into IN N
a DT N
box NN N
flushed VBN N
with IN N
66 CD N
% NN N
N2O NNP N
in IN N
O2 NNP N
. . N

The DT N
cuff NN o
pressure NN o
was VBD N
monitored VBN N
with IN N
and CC N
without IN N
CPRV NNP N
for IN N
60 CD N
min NN N
. . N

Experiments NNS N
were VBD N
performed VBN N
four CD N
times NNS N
using VBG N
two CD N
different JJ N
CPRVs NNP N
. . N

In IN N
vivo NN N
: : N
with IN N
Institutional NNP N
Review NNP N
Board NNP N
approval NN N
, , N
CPRV NNP N
was VBD N
studied VBN N
in IN N
50 CD p
children NNS p
undergoing VBG p
general JJ p
anaesthesia NN p
with IN p
tracheal JJ p
intubation NN p
and CC p
standardized JJ p
anaesthesia NN p
technique NN p
( ( p
including VBG p
66 CD p
% NN p
N2O NNP p
in IN p
O2 NNP p
) ) p
and CC p
ventilator JJ p
settings NNS p
. . p

Patients NNS N
were VBD N
randomized VBN N
into IN N
two CD N
groups NNS N
( ( i
with IN i
and CC i
without IN i
CPRV NNP i
) ) i
. . N

The DT N
cuff JJ o
pressure NN o
baseline NN N
was VBD N
20 CD N
cmH2O NN N
and CC N
CPRV NNP N
was VBD N
set VBN N
to TO N
25 CD N
cmH2O NN N
. . N

If IN N
the DT N
cuff NN o
pressure NN o
exceeded VBD N
25 CD N
cmH2O NN N
, , N
it PRP N
was VBD N
manually RB N
released VBN N
to TO N
20 CD N
cmH2O NN N
. . N

The DT N
numbers NNS N
of IN N
deflations NNS N
in IN N
both DT N
groups NNS N
were VBD N
noted VBN N
and CC N
compared VBN N
by IN N
Mann-Whitney NNP N
U-test NNP N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

RESULTS NNP N
In IN N
vitro NN N
: : N
the DT N
cuff NN o
pressure NN o
exceeded VBD N
50 CD N
cmH2O NN N
after IN N
60 CD N
min NN N
without IN N
CPRV NNP N
, , N
but CC N
did VBD N
not RB N
exceed VB N
the DT N
settings NNS N
with IN N
CPRV NNP N
. . N

In IN N
vivo NN N
: : N
there EX N
was VBD N
no DT N
need NN N
to TO N
manually RB N
deflate VB N
the DT N
cuff NN N
in IN N
the DT N
CPRV NNP N
group NN N
but CC N
, , N
in IN N
every DT N
patient NN N
in IN N
the DT N
control NN N
group NN N
, , N
three CD N
( ( N
two CD N
to TO N
seven CD N
) ) N
deflating VBG N
manoeuvres NNS N
were VBD N
required VBN N
within IN N
the DT N
first JJ N
hour NN N
of IN N
anaesthesia NN N
( ( N
P NNP N
< NNP N
0.0001 CD N
) ) N
. . N

CONCLUSION VB N
The DT N
CPRV NNP N
allows VBZ N
reliable JJ o
cuff NN o
pressure NN o
release NN o
at IN N
various JJ N
pressure NN N
levels NNS N
and CC N
reliably RB N
prevents NNS N
cuff JJ o
pressure NN o
increases NNS N
caused VBN N
by IN N
N2O NNP N
. . N

-DOCSTART- -2959901- O O

Bronchodilator NNP N
effect NN N
of IN N
fenoterol NN i
and CC i
ipratropium NN i
bromide NN i
in IN N
infants NNS p
with IN p
acute JJ p
wheezing NN p
: : p
use NN N
of IN N
MDI NNP N
with IN N
a DT N
spacer NN N
device NN N
. . N

Twenty-eight JJ p
infants NNS p
admitted VBN p
to TO p
Exequiel NNP p
Gonz?lez NNP p
Cortes NNP p
Children NNP p
's POS p
Hospital NNP p
because IN p
of IN p
acute NN p
wheezing NN p
( ( p
AW NNP p
) ) p
were VBD N
randomly RB N
assigned VBN N
to TO N
three CD N
study NN N
groups NNS N
. . N

Fenoterol NNP i
( ( i
FNT NNP i
) ) i
, , i
ipratropium JJ i
bromide NN i
( ( i
IB NNP i
) ) i
, , i
and CC i
placebo NN i
were VBD N
administered VBN N
respectively RB N
to TO N
children NNS N
in IN N
the DT N
different JJ N
groups NNS N
by IN N
means NNS N
of IN N
metered VBN N
dose JJ N
inhalers NNS N
( ( N
MDI NNP N
) ) N
with IN N
spacers NNS N
, , N
using VBG N
doses NNS N
of IN N
3 CD N
puffs NNS N
every DT N
hour NN N
, , N
for IN N
4 CD N
hours NNS N
. . N

The DT N
degree NN N
of IN N
bronchial JJ N
obstruction NN N
was VBD N
assessed VBN N
clinically RB N
and CC N
scored VBN N
with IN N
the DT N
single-blind JJ N
method NN N
every DT N
hour NN N
prior RB N
to TO N
each DT N
treatment NN N
. . N

The DT N
criterion NN N
of IN N
a DT N
bronchodilator NN o
effect NN o
was VBD N
a DT N
significant JJ N
decrease NN N
in IN N
the DT N
degree NN N
of IN N
bronchial JJ N
obstruction NN N
at IN N
subsequent JJ N
scorings NNS N
. . N

The DT o
scores NNS o
of IN o
the DT o
three CD o
groups NNS o
were VBD N
compared VBN N
using VBG N
the DT N
Student NN N
's POS N
t JJ N
test NN N
for IN N
matched JJ N
samples NNS N
. . N

The DT N
same JJ N
test NN N
was VBD N
also RB N
applied VBN N
to TO N
the DT N
independent JJ N
samples NNS N
for IN N
determining VBG N
the DT N
superiority NN N
of IN N
one CD N
treatment NN N
, , N
FNT NNP i
or CC i
IB NNP i
, , i
over IN N
the DT N
other JJ N
. . N

The DT N
results NNS N
indicated VBD N
a DT N
significant JJ N
decrease NN N
in IN N
the DT N
scores NNS N
of IN N
the DT N
groups NNS N
receiving VBG i
FNT NNP i
and CC i
IB NNP i
( ( N
P NNP N
less JJR N
than IN N
0.05 CD N
) ) N
; : N
this DT N
did VBD N
not RB N
occur VB N
in IN N
the DT N
group NN N
in IN N
which WDT i
placebo NN i
was VBD N
used VBN N
. . N

FNT NNP i
produced VBD N
a DT N
more RBR N
rapid JJ N
and CC N
sustained VBD N
effect NN N
than IN i
IB NNP i
( ( N
P NNP N
less JJR N
than IN N
0.05 CD N
) ) N
. . N

Significant JJ N
bronchodilator NN N
effect NN N
was VBD N
obtained VBN N
in IN p
infants NNS p
with IN p
AW NNP p
when WRB N
repeated VBN N
doses NNS N
of IN i
FNT NNP i
or CC i
IB NNP i
were VBD N
administered VBN N
with IN N
MDI NNP N
and CC N
spacers NNS N
. . N

This DT N
effect NN N
was VBD N
significantly RB N
greater JJR N
in IN N
the DT N
group NN N
treated VBD N
with IN i
FNT NNP i
. . i

-DOCSTART- -392623- O O

Controlled VBN N
trial NN N
of IN N
induction NN N
of IN N
labor NN o
by IN N
vaginal JJ N
suppositories NNS i
containing VBG N
prostaglandin NN i
E2 NNP i
. . i

A NNP N
group NN N
of IN N
84 CD p
women NNS p
at IN p
39-43 JJ p
weeks NNS p
of IN p
pregnancy NN p
were VBD N
randomly RB N
allocated VBN N
to TO N
a DT N
blind JJ N
trial NN N
of IN N
induction NN N
of IN N
labor NN o
with IN N
vaginal JJ N
suppositories NNS i
containing VBG N
inert JJ i
material NN i
or CC N
either CC N
0.2 CD N
mg NN N
or CC N
0.4 CD N
mg NN N
of IN N
prostaglandin NN i
E2 NNP i
. . i

The DT N
suppositories NNS N
were VBD N
self-administered JJ N
every DT N
two CD N
hours NNS N
during IN N
waking VBG N
hours NNS N
on IN N
two CD N
successive JJ N
days NNS N
until IN N
labor NN N
started VBD N
or CC N
15 CD N
had VBD N
been VBN N
used VBN N
. . N

Side-effects NNS N
were VBD N
absent JJ N
. . N

Labor NN o
was VBD o
established VBN o
within IN N
48 CD N
hr NN N
of IN N
insertion NN N
of IN N
the DT N
first JJ N
suppository NN N
in IN N
9.3 CD N
% NN N
of IN N
control NN N
patients NNS N
, , N
65.4 CD N
% NN N
of IN N
those DT N
treated VBN N
with IN N
0.2 CD N
mg NNS N
PGE2 NNP i
and CC N
85.7 CD N
% NN N
of IN N
those DT N
treated VBN N
with IN N
0.4 CD N
mg NNS N
PGE2 NNP i
. . i

The DT N
mean JJ o
Apgar NNP o
scores NNS o
in IN N
the DT N
three CD N
groups NNS N
were VBD N
the DT N
same JJ N
. . N

The DT N
mean JJ o
total NN o
dose NN o
of IN o
PGE2 NNP o
were VBD N
2.0 CD N
mg NN N
( ( N
0.2 CD N
mg NNS N
group NN N
) ) N
and CC N
2.3 CD N
mg NN N
( ( N
0.4 CD N
mg NNS N
group NN N
) ) N
. . N

It PRP N
is VBZ N
concluded VBN N
that IN N
vaginal JJ o
PGE2 NNP o
is VBZ N
an DT N
effective JJ N
and CC N
acceptable JJ N
method NN o
of IN o
inducing VBG o
labor NN o
at IN o
term NN o
. . o

-DOCSTART- -3314516- O O

Effects NNS N
of IN N
maternal JJ i
glucose JJ i
infusion NN i
on IN N
fetal JJ N
acid-base JJ N
status NN N
in IN N
human JJ p
pregnancy NN p
. . p

The DT N
maternal JJ N
and CC N
fetal JJ N
metabolic JJ N
effects NNS N
of IN N
three CD N
commonly NNS N
used VBD N
intravenous JJ N
fluids NNS N
administered VBD N
before IN N
regional JJ N
anesthesia NN N
were VBD N
studied VBN N
in IN N
32 CD p
gravid JJ p
women NNS p
undergoing VBG p
elective JJ p
cesarean JJ p
section NN p
at IN p
term NN p
. . p

Patients NNS N
were VBD N
randomized VBN N
into IN N
one CD N
of IN N
three CD N
groups NNS N
to TO N
receive VB N
1 CD N
L NNP N
of IN N
either RB N
5 CD i
% NN i
dextrose NN i
( ( N
50 CD N
gm NN N
of IN N
glucose NN i
) ) i
or CC i
Ringer NNP i
's POS i
lactate NN i
or CC i
isotonic JJ i
saline JJ i
solution NN i
before IN N
epidural JJ i
anesthesia NN i
. . i

Acute NNP o
glucose JJ o
infusion NN o
resulted VBD o
in IN o
maternal JJ o
hyperglycemia NN o
, , o
hyperinsulinemia NN o
, , o
and CC o
an DT o
increase NN o
in IN o
the DT o
blood NN o
lactate NN o
level NN o
. . o

Cord NNP o
blood NN o
glucose NN o
, , o
insulin NN o
, , o
and CC o
lactate NN o
levels NNS o
were VBD o
also RB o
increased VBN o
in IN o
this DT o
group NN o
. . o

The DT o
key JJ o
finding NN o
of IN o
this DT o
study NN o
was VBD o
the DT o
significant JJ o
lowering NN o
of IN o
pH NN o
in IN o
the DT o
umbilical JJ o
cord NN o
vein NN o
( ( o
7.31 CD o
+/- JJ o
0.04 CD o
) ) o
and CC o
artery NN o
( ( o
7.21 CD o
+/- JJ o
0.06 CD o
) ) o
in IN o
the DT o
glucose-infused JJ o
group NN o
when WRB o
compared VBN o
with IN o
the DT o
non-glucose JJ o
infusion NN o
groups NNS o
( ( o
p NN o
less JJR o
than IN o
0.05 CD o
) ) o
. . o

Confounding VBG o
perinatal JJ o
factors NNS o
such JJ o
as IN o
maternal JJ o
position NN o
, , o
maternal JJ o
hypotension NN o
, , o
and CC o
prolonged VBD o
time NN o
of IN o
surgery NN o
did VBD o
not RB o
influence VB o
the DT o
fetal JJ o
acid-base JJ o
status NN o
. . o

Thus RB o
acute JJ o
maternal JJ o
glucose NN o
infusion NN o
in IN o
normal JJ o
patients NNS o
can MD o
cause VB o
fetal JJ o
hyperglycemia NN o
, , o
metabolic JJ o
acidosis NN o
, , o
and CC o
neonatal JJ o
hypoglycemia NN o
. . o

These DT o
findings NNS o
may MD o
be VB o
of IN o
particular JJ o
clinical JJ o
importance NN o
when WRB o
fetal JJ o
distress NN o
or CC o
fetal JJ o
hypoxemia NN o
is VBZ o
due JJ o
to TO o
other JJ o
perinatal JJ o
events NNS o
. . o

Under IN o
these DT o
circumstances NNS o
, , o
acute JJ o
maternal JJ o
glucose JJ o
infusion NN o
may MD o
further RB o
contribute VB o
to TO o
fetal JJ o
metabolic JJ o
acidosis NN o
. . o

-DOCSTART- -20594308- O O

Non-pharmacological JJ N
care NN N
for IN N
patients NNS p
with IN p
generalized JJ o
osteoarthritis NN o
: : o
design NN N
of IN N
a DT N
randomized JJ N
clinical JJ N
trial NN N
. . N

BACKGROUND NNP N
Non-pharmacological JJ i
treatment NN i
( ( i
NPT NNP i
) ) i
is VBZ N
a DT N
useful JJ N
treatment NN N
option NN N
in IN N
the DT N
management NN N
of IN N
hip NN o
or CC o
knee NN o
osteoarthritis NN o
. . o

To TO N
our PRP$ N
knowledge NN N
however RB N
, , N
no DT N
studies NNS N
have VBP N
investigated VBN N
the DT N
effect NN N
of IN N
NPT NNP i
in IN N
patients NNS p
with IN p
generalized JJ p
osteoarthritis NN p
( ( p
GOA NNP p
) ) p
. . p

The DT N
primary JJ N
aim NN N
of IN N
this DT N
study NN N
is VBZ N
to TO N
compare VB N
the DT N
effectiveness NN N
of IN N
two CD N
currently RB N
existing VBG N
health NN N
care NN N
programs NNS N
with IN N
different JJ N
intensity NN N
and CC N
mode NN N
of IN N
delivery NN N
on IN N
daily JJ N
functioning NN N
in IN N
patients NNS p
with IN p
GOA NNP p
. . p

The DT N
secondary JJ N
objective NN N
is VBZ N
to TO N
compare VB N
the DT N
cost-effectiveness NN N
of IN N
both DT N
interventions NNS N
. . N

METHODS/DESIGN NNP N
In IN N
this DT N
randomized VBN N
, , N
single JJ N
blind NN N
, , N
clinical JJ N
trial NN N
with IN N
active JJ N
controls NNS N
, , N
we PRP p
aim VBP p
to TO p
include VB p
170 CD p
patients NNS p
with IN p
GOA NNP p
. . p

The DT N
experimental JJ N
intervention NN N
consist NN N
of IN N
six CD i
self-management JJ i
group NN i
sessions NNS i
provided VBN i
by IN i
a DT i
multi-disciplinary JJ i
team NN i
( ( N
occupational JJ N
therapist NN N
, , N
physiotherapist NN N
, , N
dietician JJ N
and CC N
specialized JJ N
nurse NN N
) ) N
. . N

The DT N
active JJ N
control NN N
group NN N
consists VBZ N
of IN N
two CD i
group NN i
sessions NNS i
and CC i
four CD i
sessions NNS i
by IN i
telephone NN i
, , N
provided VBN N
by IN N
a DT N
specialized JJ N
nurse NN N
and CC N
physiotherapist NN N
. . N

Both DT N
therapies NNS N
last JJ N
six CD N
weeks NNS N
. . N

Main NNP N
study NN N
outcome NN N
is VBZ N
daily JJ o
functioning VBG o
during IN o
the DT o
first JJ o
year NN o
after IN o
the DT o
treatment NN o
, , o
assessed VBN o
on IN o
the DT o
Health NNP o
Assessment NNP o
Questionnaire NNP o
. . o

Secondary JJ N
outcomes NNS N
are VBP N
health NN o
related JJ o
quality NN o
of IN o
life NN o
, , o
specific JJ o
complaints NNS o
, , o
fatigue NN o
, , o
and CC o
costs NNS o
. . o

Illness NNP o
cognitions NNS o
, , o
global JJ o
perceived VBN o
effect NN o
and CC o
self-efficacy NN o
, , N
will MD N
also RB N
be VB N
assessed VBN N
for IN N
a DT N
responder NN N
analysis NN N
. . N

Outcome CC N
assessments NNS N
are VBP N
performed VBN N
directly RB N
after IN N
the DT N
intervention NN N
, , N
after IN N
26 CD N
weeks NNS N
and CC N
after IN N
52 CD N
weeks NNS N
. . N

DISCUSSION NN N
This DT N
article NN N
describes VBZ N
the DT N
design NN N
of IN N
a DT N
randomized VBN N
, , N
single JJ N
blind NN N
, , N
clinical JJ N
trial NN N
with IN N
a DT N
one CD N
year NN N
follow VB N
up IN N
to TO N
compare VB N
the DT N
costs NNS o
and CC o
effectiveness NN o
of IN N
two CD N
non-pharmacological JJ i
interventions NNS i
with IN N
different JJ N
modes NNS N
of IN N
delivery NN N
for IN N
patients NNS p
with IN p
GOA NNP p
. . p

TRIAL NNP N
REGISTRATION NNP N
Dutch NNP N
Trial NNP N
Register NNP N
NTR2137 NNP N
. . N

-DOCSTART- -20356395- O O

Comparison NNP N
of IN N
yoga NNP i
versus NN i
stretching VBG i
for IN N
chronic JJ o
low JJ o
back RB o
pain NN o
: : o
protocol NN N
for IN N
the DT N
Yoga NNP N
Exercise NNP N
Self-care NNP N
( ( N
YES NNP N
) ) N
trial NN N
. . N

BACKGROUND NNP N
Back NNP o
pain NN o
, , N
one CD N
of IN N
the DT N
most RBS N
prevalent JJ N
conditions NNS N
afflicting VBG N
American JJ N
adults NNS N
, , N
is VBZ N
the DT N
leading VBG N
reason NN N
for IN N
using VBG N
complementary JJ i
and CC i
alternative JJ i
medicine NN i
( ( i
CAM NNP i
) ) i
therapies NNS i
. . i

Yoga NNP i
is VBZ N
an DT N
increasingly RB N
popular JJ N
mind-body NN N
CAM NNP N
therapy NN N
often RB N
used VBN N
for IN N
relieving VBG o
back RB o
pain NN o
and CC N
several JJ N
small JJ N
studies NNS N
have VBP N
found VBN N
yoga RB N
effective JJ N
for IN N
this DT N
condition NN N
. . N

This DT N
study NN N
will MD N
assess VB N
whether IN N
yoga NN i
is VBZ N
effective JJ N
for IN N
treating VBG N
chronic JJ o
low JJ o
back RB o
pain NN o
compared VBN N
with IN N
self PRP i
care NN i
and CC i
exercise NN i
and CC N
will MD N
explore VB N
the DT N
mechanisms NNS N
responsible JJ N
for IN N
any DT N
observed JJ N
benefits NNS N
. . N

METHODS/DESIGN NNP N
A NNP p
total NN p
of IN p
210 CD p
participants NNS p
with IN p
low JJ p
back RB p
pain NN p
lasting NN p
at IN p
least JJS p
3 CD p
months NNS p
will MD p
be VB p
recruited VBN p
from IN p
primary JJ p
care NN p
clinics NNS p
of IN p
a DT p
large JJ p
healthcare NN p
system NN p
based VBN p
in IN p
Seattle NNP p
. . p

They PRP N
will MD N
be VB N
randomized VBN N
in IN N
a DT N
2:2:1 CD N
ratio NN N
to TO N
receive VB N
12 CD i
weekly JJ i
yoga NN i
classes NNS i
, , i
12 CD i
weekly JJ i
conventional JJ i
therapeutic JJ i
exercise NN i
classes NNS i
of IN i
comparable JJ i
physical JJ i
exertion NN i
, , i
or CC i
a DT i
self-care JJ i
book NN i
. . i

Interviewers NNS N
masked VBD N
to TO N
participants NNS N
' POS N
treatment NN N
group NN N
will MD N
assess VB N
outcomes NNS N
at IN N
baseline NN N
and CC N
6 CD N
, , N
12 CD N
and CC N
26 CD N
weeks NNS N
after IN N
randomization NN N
. . N

Primary JJ N
outcomes NNS N
will MD N
be VB N
back-related JJ o
dysfunction NN o
and CC o
symptom NN o
bothersomeness NN o
. . o

In IN N
addition NN N
, , N
data NNS N
will MD N
be VB N
collected VBN N
on IN N
physical JJ o
measurements NNS o
( ( o
e.g. NN o
, , N
flexion NN o
) ) o
at IN N
baseline NN N
and CC N
12 CD N
weeks NNS N
and CC N
saliva NN N
samples NNS N
will MD N
be VB N
obtained VBN N
at IN N
baseline NN N
, , N
6 CD N
and CC N
12 CD N
weeks NNS N
. . N

Information NN N
will MD N
be VB N
collected VBN N
on IN N
specific JJ N
physical JJ N
, , N
psychological JJ N
, , N
and CC N
physiological JJ N
factors NNS N
to TO N
allow VB N
exploration NN N
of IN N
possible JJ N
mechanisms NNS N
of IN N
action NN N
through IN N
which WDT N
yoga NN i
could MD N
relieve VB o
back RB o
pain NN o
and CC o
dysfunction NN o
. . o

The DT N
effectiveness NN N
of IN N
yoga NN i
will MD N
be VB N
assessed VBN N
using VBG N
analysis NN N
of IN N
covariance NN N
( ( N
using VBG N
general JJ N
estimating VBG N
equations NNS N
- : N
GEE NNP N
) ) N
within IN N
an DT N
intention-to-treat JJ N
context NN N
. . N

If IN N
yoga NN i
is VBZ N
found VBN N
effective JJ N
, , N
further JJ N
analyses NNS N
will MD N
explore VB N
whether IN N
yoga NN N
's POS N
benefits NNS N
are VBP N
attributable JJ N
to TO N
physical JJ N
, , N
psychological JJ N
and/or NN N
physiological JJ N
factors NNS N
. . N

CONCLUSIONS VB N
This DT N
study NN N
will MD N
provide VB N
the DT N
clearest JJS N
evidence NN N
to TO N
date NN N
about IN N
the DT N
value NN N
of IN N
yoga NN i
as IN N
a DT N
therapeutic JJ N
option NN N
for IN N
treating VBG N
chronic JJ o
back RB o
pain NN o
, , N
and CC N
if IN N
the DT N
results NNS N
are VBP N
positive JJ N
, , N
will MD N
help VB N
focus VB N
future JJ N
, , N
more RBR N
in-depth JJ N
, , N
research NN N
on IN N
the DT N
most RBS N
promising JJ N
potential JJ N
mechanisms NN N
of IN N
action NN N
identified VBN N
by IN N
this DT N
study NN N
. . N

-DOCSTART- -130920- O O

A DT p
controlled JJ p
clinical JJ p
trial NN p
of IN p
a DT p
muscle NN i
relaxant NN i
analgesic JJ i
combination NN i
in IN p
the DT p
treatment NN p
of IN p
acute JJ p
lumbago NN p
. . p

-DOCSTART- -21030056- O O

Gene NNP i
expression NN i
of IN i
endothelin-1 JJ i
and CC i
its PRP$ i
receptors NNS i
in IN N
the DT N
heart NN p
of IN p
broiler NN p
chickens NNS p
with IN p
T NNP p
( ( p
3 CD p
) ) p
-induced VBD p
pulmonary JJ p
hypertension NN p
. . p

To TO N
investigate VB N
the DT N
effect NN N
of IN N
T NNP N
( ( N
3 CD N
) ) N
-induced VBD N
pulmonary JJ N
hypertension NN N
on IN N
endothelin NN N
( ( N
ET NNP N
) ) N
production NN N
and CC N
genes NNS o
expression NN o
of IN o
ET-1 NNP o
, , o
ET NNP o
( ( o
A NNP o
) ) o
and CC o
ET NNP o
( ( o
B NNP o
) ) o
receptors NNS o
( ( o
ET NNP o
( ( o
A NNP o
) ) o
R NNP o
and CC o
ET NNP o
( ( o
B NNP o
) ) o
R NNP o
) ) o
during IN N
rearing NN N
, , N
semiquantitative JJ i
RT-PCR NNP i
and CC i
enzyme VB i
immunometric JJ i
assay NN i
were VBD N
performed VBN N
in IN N
the DT N
heart NN N
ventricles NNS N
and CC N
serum NN N
, , N
respectively RB N
. . N

The DT N
ET-1 JJ o
and CC o
its PRP$ o
receptor NN o
genes NNS o
were VBD N
expressed VBN N
in IN N
the DT N
right NN N
and CC N
left VBD N
ventricles NNS N
of IN N
control NN N
and CC N
T NNP N
( ( N
3 CD N
) ) N
-treated VBD N
broilers NNS N
at IN N
12 CD N
, , N
28 CD N
and CC N
49 CD N
days NNS N
of IN N
age NN N
. . N

There EX N
were VBD N
significant JJ N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
reductions NNS o
of IN o
the DT o
relative JJ o
amounts NNS o
of IN o
ET-1 NNP o
( ( o
in IN o
both DT o
ventricles NNS o
) ) o
and CC o
ET NNP o
( ( o
A NNP o
) ) o
R NNP o
( ( o
in IN o
the DT o
right JJ o
ventricle NN o
) ) o
mRNAs NN o
at IN N
28 CD N
and CC N
49 CD N
days NNS N
of IN N
age NN N
, , N
in IN N
T NNP N
( ( N
3 CD N
) ) N
-treated VBD N
broilers NNS N
compared VBN N
to TO N
controls NNS N
. . N

The DT N
relative JJ o
amounts NNS o
of IN o
ET NNP o
( ( o
B NNP o
) ) o
R NNP o
mRNA NN o
in IN N
the DT N
right NN N
and CC N
left VBD N
ventricles NNS N
did VBD N
not RB N
significantly RB N
differ VBP N
between IN N
control NN N
and CC N
T NNP N
( ( N
3 CD N
) ) N
-treated VBD N
broilers NNS N
at IN N
any DT N
age NN N
. . N

The DT N
serum JJ o
level NN o
of IN o
ET NNP o
was VBD N
significantly RB N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
increased VBN N
in IN N
T NNP N
( ( N
3 CD N
) ) N
-treated VBD N
chickens NNS N
at IN N
28 CD N
and CC N
49 CD N
days NNS N
of IN N
age NN N
when WRB N
compared VBN N
with IN N
that DT N
of IN N
the DT N
control NN N
. . N

It PRP N
is VBZ N
concluded VBN N
that IN N
ET-1 NNP o
, , o
ET NNP o
( ( o
A NNP o
) ) o
R NNP o
and CC o
ET NNP o
( ( o
B NNP o
) ) o
R NNP o
genes NNS o
are VBP N
normally RB N
expressed VBN N
in IN N
the DT N
heart NN N
ventricles NNS N
of IN N
broilers NNS N
. . N

It PRP N
is VBZ N
likely JJ N
that IN N
increased VBD N
serum JJ o
level NN o
of IN o
ET NNP o
and CC o
decreased VBN o
ET-1/ET NNP o
( ( o
A NNP o
) ) o
R NNP o
genes NNS o
expression NN o
in IN N
the DT N
ventricles NNS N
are VBP N
involved VBN N
in IN N
the DT N
heart NN N
dysfunction NN N
of IN N
broiler NN p
chickens NNS p
with IN p
developmental JJ p
pulmonary JJ p
hypertension NN p
. . p

-DOCSTART- -23266440- O O

Reducing VBG N
breast NN o
cancer NN o
recurrence NN o
with IN N
weight JJ N
loss NN N
, , N
a DT N
vanguard JJ N
trial NN N
: : N
the DT N
Exercise NNP N
and CC N
Nutrition NNP N
to TO N
Enhance VB N
Recovery NNP N
and CC N
Good NNP N
Health NNP N
for IN N
You PRP N
( ( N
ENERGY NNP N
) ) N
Trial NNP N
. . N

Breast NNP N
cancer NN N
is VBZ N
the DT N
most RBS N
common JJ N
invasive JJ N
cancer NN N
among IN N
women NNS N
in IN N
developed JJ N
countries NNS N
. . N

Obesity NN N
is VBZ N
a DT N
major JJ N
risk NN N
factor NN N
for IN N
breast NN N
cancer NN N
recurrence NN N
and CC N
mortality NN N
in IN N
both DT N
pre- JJ p
and CC p
postmenopausal JJ p
women NNS p
. . p

Co-morbid NNP N
medical JJ N
conditions NNS N
are VBP N
common JJ N
among IN N
breast JJ N
cancer NN N
survivors NNS N
. . N

The DT N
Exercise NN N
and CC N
Nutrition NN N
to TO N
Enhance VB N
Recovery NNP N
and CC N
Good NNP N
Health NNP N
for IN N
You PRP N
( ( N
ENERGY NNP N
) ) N
study NN N
is VBZ N
a DT N
4-year JJ N
randomized JJ N
clinical JJ N
trial NN N
of IN p
693 CD p
overweight/obese JJ p
women NNS p
aged VBN p
?21years NNS p
diagnosed VBD p
with IN p
any DT p
early JJ p
stage NN p
breast NN p
cancer NN p
( ( p
stages NNS p
I PRP p
[ VBP p
?1cm JJ p
] NNP p
-III NN p
) ) p
within IN p
the DT p
previous JJ p
five CD p
years NNS p
, , p
designed VBN p
to TO N
demonstrate VB N
the DT N
feasibility NN N
of IN N
achieving VBG N
sustained JJ N
weight JJ N
loss NN N
and CC N
to TO N
examine VB N
the DT N
impact NN N
of IN N
weight JJ N
loss NN N
on IN N
quality NN N
of IN N
life NN N
and CC N
co-morbidities NNS N
, , N
and CC N
to TO N
enable VB N
future JJ N
exploration NN N
of IN N
biochemical JJ N
mechanisms NNS N
linking VBG N
obesity NN N
to TO N
lower JJR N
likelihood NN N
of IN N
disease-free JJ N
survival NN N
. . N

This DT N
trial NN N
is VBZ N
strategically RB N
designed VBN N
as IN N
a DT N
vanguard NN N
for IN N
a DT N
fully-powered JJ N
trial NN N
of IN N
women NNS N
who WP N
will MD N
be VB N
evaluated VBN N
for IN N
breast NN o
cancer NN o
recurrence NN o
and CC o
disease-free JJ o
survival NN o
. . o

Participants NNS o
were VBD p
recruited VBN p
between IN p
2010 CD p
and CC p
2012 CD p
at IN p
four CD p
sites NNS p
, , p
had VBD p
completed VBN p
initial JJ p
therapies NNS p
, , p
and CC p
had VBD p
a DT o
body NN o
mass NN o
index NN o
between IN o
25 CD p
and CC p
45kg/m CD p
( ( p
2 CD p
) ) p
. . p

The DT p
intervention NN N
featured VBD i
a DT i
group-based JJ i
cognitive-behavioral JJ i
weight JJ i
loss NN i
program NN i
with IN i
telephone NN i
counseling NN i
and CC i
tailored VBD i
newsletters NNS i
to TO i
support VB i
initial JJ o
weight NN o
loss NN o
and CC o
subsequent JJ o
maintenance NN o
, , o
with IN o
the DT i
goal NN i
of IN i
7 CD i
% NN i
weight JJ i
loss NN i
at IN i
two CD i
years NNS i
. . i

This DT i
study NN N
has VBZ N
high JJ N
potential NN N
to TO N
have VB N
a DT N
major JJ N
impact NN N
on IN N
clinical JJ N
management NN N
and CC N
outcomes NNS N
after IN N
a DT N
breast NN N
cancer NN N
diagnosis NN N
. . N

This DT N
trial NN N
initiates VBZ N
the DT N
effort NN N
to TO N
establish VB N
weight NN N
loss NN N
support NN N
for IN N
overweight NN p
or CC p
obese JJ p
breast NN p
cancer NN p
survivors NNS p
as IN p
a DT N
new JJ N
standard NN N
of IN N
clinical JJ N
care NN N
. . N

-DOCSTART- -15275765- O O

Gabapentin NNP i
for IN N
the DT N
prevention NN N
of IN N
postoperative JJ o
pain NN o
after IN p
vaginal JJ p
hysterectomy NN p
. . p

Gabapentin NNP i
alleviates VBZ N
and/or JJ N
prevents NNS N
acute JJ o
nociceptive JJ o
and CC o
inflammatory JJ o
pain NN o
both DT N
in IN N
animals NNS p
and CC p
volunteers NNS p
, , N
especially RB N
when WRB N
given VBN N
before IN N
trauma NN N
. . N

Gabapentin NNP i
might MD N
also RB N
reduce VB N
postoperative JJ o
pain NN o
. . o

To TO N
test VB N
the DT N
hypothesis NN N
that WDT N
gabapentin NN i
reduces VBZ N
the DT N
postoperative JJ o
need NN o
for IN o
additional JJ o
pain NN o
treatment NN o
( ( N
postoperative JJ N
opioid NN N
sparing VBG N
effect NN N
of IN N
gabapentin NN i
in IN N
humans NNS p
) ) p
, , N
we PRP N
gave VBD N
1200 CD N
mg NN N
of IN N
gabapentin NN i
or CC N
15 CD N
mg NN N
of IN N
oxazepam NN i
( ( i
active JJ i
placebo NN i
) ) i
2.5 CD N
h NN N
prior RB N
to TO N
induction NN N
of IN N
anaesthesia NN N
to TO N
patients NNS p
undergoing VBG p
elective JJ i
vaginal JJ i
hysterectomy NN i
in IN N
an DT N
active JJ N
placebo-controlled JJ N
, , N
double JJ N
blind NN N
, , N
randomised VBD N
study NN N
. . N

Gabapentin NNP i
reduced VBD N
the DT N
need NN N
for IN N
additional JJ N
postoperative JJ o
pain NN o
treatment NN o
( ( N
PCA NNP N
boluses NNS N
of IN N
50 CD N
microg NN N
of IN N
fentanyl NN N
) ) N
by IN N
40 CD N
% NN N
during IN N
the DT N
first JJ N
20 CD N
postoperative JJ N
hours NNS N
. . N

During IN N
the DT N
first JJ N
2 CD N
postoperative JJ N
hours NNS N
pain VBP o
scores NNS o
at IN o
rest NN o
and CC o
worst JJS o
pain NN o
score NN o
( ( N
VAS NNP N
0-100 NNP N
mm NN N
) ) N
were VBD N
significantly RB N
higher JJR N
in IN N
the DT N
active JJ N
placebo NN i
group NN N
compared VBN N
to TO N
the DT N
gabapentin-treated JJ i
patients NNS N
. . N

Additionally RB N
, , N
pretreatment NN N
with IN N
gabapentin NN i
reduced VBD N
the DT N
degree NN o
of IN o
postoperative JJ o
nausea NN o
and CC o
incidence NN o
of IN o
vomiting/retching VBG o
possibly RB N
either RB N
due JJ N
to TO N
the DT N
diminished JJ N
need NN N
for IN N
postoperative JJ o
pain NN o
treatment NN N
with IN N
opioids NNS N
or CC N
because IN N
of IN N
an DT N
anti-emetic JJ N
effect NN N
of IN N
gabapentin NN i
itself PRP N
. . N

No DT N
preoperative JJ N
differences NNS N
between IN N
the DT N
two CD N
groups NNS N
were VBD N
encountered VBN N
with IN N
respect NN N
to TO N
the DT N
side NN N
effects NNS N
of IN N
the DT N
premedication NN N
. . N

However RB N
, , N
15 CD N
mg NN N
oxazepam NN i
was VBD N
more RBR N
effective JJ o
in IN N
relieving VBG N
preoperative JJ o
anxiety NN o
than IN N
1200 CD N
mg NN N
gabapentin NN i
. . i

-DOCSTART- -24451146- O O

Assessment NN N
of IN N
osteopontin NN N
in IN N
early JJ p
breast NN p
cancer NN p
: : p
correlative JJ N
study NN N
in IN N
a DT N
randomised JJ N
clinical JJ N
trial NN N
. . N

INTRODUCTION NNP N
Osteopontin NNP i
( ( N
OPN NNP N
) ) N
is VBZ N
a DT N
malignancy-associated JJ N
glycoprotein NN N
that WDT N
contributes VBZ N
functionally RB N
to TO N
tumor VB N
aggressiveness NN N
. . N

In IN N
metastatic JJ N
breast NN N
cancer NN N
, , N
we PRP N
previously RB N
demonstrated VBD N
that IN N
elevated VBD N
OPN NNP N
in IN N
primary JJ N
tumor NN N
and CC N
blood NN N
was VBD N
associated VBN N
with IN N
poor JJ N
prognosis NN N
. . N

METHODS NNP N
We PRP N
measured VBD N
OPN NNP i
in IN N
plasma NN N
by IN N
ELISA NNP N
, , N
and CC N
in IN N
tumors NNS N
by IN N
immunohistochemistry NN i
, , N
in IN p
624 CD p
( ( p
94 CD p
% NN p
) ) p
and CC p
462 CD p
( ( p
69 CD p
% NN p
) ) p
, , p
respectively RB p
, , p
of IN p
667 CD p
postmenopausal JJ p
women NNS p
with IN p
hormone NN p
responsive VBP p
early JJ p
breast NN p
cancer NN p
treated VBN p
by IN p
surgery NN i
followed VBN p
by IN p
adjuvant JJ p
treatment NN p
with IN p
tamoxifen JJ i
+/- JJ i
octreotide NN i
in IN p
a DT p
randomized JJ p
trial NN p
( ( p
NCIC NNP p
CTG NNP p
MA.14 NNP p
; : p
National NNP p
Cancer NNP p
Institute NNP p
of IN p
Canada NNP p
Clinical NNP p
Trials NNP p
Group NNP p
Mammary.14 NNP p
) ) p
. . p

RESULTS NNP N
Plasma NNP o
OPN NNP o
was VBD N
measured VBN N
in IN N
2,540 CD p
samples NNS p
; : p
688 CD p
at IN p
baseline NN p
and CC p
1,852 CD p
collected VBN p
during IN N
follow-up JJ N
. . N

Mean NNP o
baseline NN o
plasma NN o
OPN NNP o
was VBD N
46 CD N
ng/ml NN N
( ( N
range VB N
22.6 CD N
to TO N
290 CD N
) ) N
which WDT N
did VBD N
not RB N
differ VB N
from IN N
normal JJ N
levels NNS N
. . N

Mean NNP o
percentage NN o
OPN NNP o
tumor NN o
cell NN o
positivity NN o
was VBD N
33.9 CD N
( ( N
95 CD N
% NN N
CI NNP N
: : N
30.2 CD N
to TO N
37.9 CD N
) ) N
. . N

There EX N
was VBD N
no DT N
correlation NN N
between IN o
plasma NN o
and CC o
tumor NN o
OPN NNP o
values NNS o
. . o

In IN N
multivariate JJ N
analysis NN N
, , N
neither DT N
was VBD N
associated VBN N
with IN o
event-free JJ o
survival NN o
( ( o
EFS NNP o
) ) o
, , o
relapse-free JJ o
survival NN o
( ( o
RFS NNP o
) ) o
, , o
overall JJ o
survival NN o
( ( o
OS NNP o
) ) o
, , o
bone JJ o
RFS NNP o
or CC o
non-bone JJ o
RFS NNP o
. . o

An DT N
exploratory JJ N
analysis NN N
in IN N
patients NNS N
with IN N
recurrence NN N
showed VBD N
higher JJR o
mean JJ o
OPN NNP o
plasma NN o
levels NNS o
60.7 CD N
ng/ml NN N
( ( N
23.9 CD N
to TO N
543 CD N
) ) N
in IN N
the DT N
recurrence NN N
period NN N
compared VBN N
with IN N
baseline NN N
levels NNS N
. . N

CONCLUSIONS VB N
The DT N
hypothesis NN N
that WDT o
OPN NNP o
tumor NN o
expression NN o
would MD o
have VB N
independent JJ N
prognostic JJ N
value NN N
in IN N
early JJ N
breast NN N
cancer NN N
was VBD N
not RB N
supported VBN N
by IN N
multivariate JJ N
analysis NN N
of IN N
this DT N
study NN N
population NN o
. . o

Plasma NNP o
OPN NNP o
levels NNS o
in IN o
women NNS p
with IN p
hormone NN p
responsive VBP p
early JJ p
breast NN p
cancer NN p
in IN p
the DT N
MA.14 NNP N
trial NN N
were VBD N
not RB N
elevated VBN N
and CC N
there EX N
was VBD N
no DT N
evidence NN N
for IN N
prognostic JJ N
value NN N
of IN N
plasma JJ N
OPN NNP N
in IN N
this DT N
defined JJ N
group NN N
of IN N
patients NNS N
. . N

However RB N
, , N
our PRP$ N
finding NN N
of IN N
elevated JJ o
mean JJ o
OPN NNP o
plasma NN o
level NN o
around IN o
the DT N
time NN N
of IN N
recurrence NN N
warrants NNS N
further RBR N
study NN N
. . N

TRIAL NNP N
REGISTRATION NNP N
NCT00002864 NNP N
, , N
http NN N
: : N
//clinicaltrials.gov/show/NCT00002864 NN N
. . N

-DOCSTART- -21047588- O O

Detection NN o
rates NNS o
of IN o
cancer NN o
, , o
high JJ o
grade NN o
PIN NNP o
and CC o
atypical JJ o
lesions NNS o
suspicious JJ o
for IN o
cancer NN o
in IN N
the DT N
European NNP p
Randomized NNP p
Study NNP p
of IN p
Screening NNP p
for IN p
Prostate NNP p
Cancer NNP p
. . p

THE NNP N
AIM NNP N
OF IN N
THE NNP N
STUDY NNP N
This DT N
article NN N
presents VBZ N
the DT N
incidence NN N
of IN N
prostate NN N
cancer NN N
, , N
isolated VBN N
high JJ N
grade NN N
prostatic JJ N
intraepithelial JJ N
neoplasia NN N
( ( N
PIN NNP N
) ) N
and CC N
atypical JJ N
lesions NNS N
suspicious JJ N
for IN N
prostate NN N
cancer NN N
( ( N
LSPC NNP N
) ) N
during IN N
subsequent JJ N
screening VBG i
rounds NNS i
in IN N
the DT N
centres NNS N
of IN N
five CD N
of IN N
the DT N
countries NNS N
participating VBG p
in IN p
the DT p
European NNP p
Randomized NNP p
Study NNP p
of IN p
Screening NNP p
for IN p
Prostate NNP p
Cancer NNP p
( ( p
ERSPC NNP p
) ) p
. . p

The DT N
incidence NN N
and CC N
predictive JJ N
value NN N
of IN N
high JJ N
grade NN N
PIN NNP N
and CC N
LSPC NNP N
for IN N
prostate NN N
cancer NN N
in IN N
subsequent JJ N
biopsy NN i
following VBG N
these DT N
diagnoses NNS N
were VBD N
evaluated VBN N
. . N

PATIENTS NNP N
AND CC N
METHODS NNP N
Study NNP N
group NN N
consisted VBD N
of IN N
56,653 CD p
screened JJ i
men NNS p
in IN p
the DT p
ERSPC NNP p
centres NNS p
of IN p
Finland NNP p
, , p
Italy NNP p
, , p
Netherlands NNP p
, , p
Sweden NNP p
and CC p
Switzerland NNP p
, , p
who WP p
underwent VBD p
3-7 JJ p
screening NN i
rounds NNS i
at IN p
2-4 JJ p
year NN p
interval NN p
. . p

Data NNP p
for IN p
prostate NN p
cancer NN p
were VBD p
obtained VBN p
from IN p
the DT p
ERSPC NNP p
central JJ p
database NN p
. . p

Data NNP p
for IN p
high JJ p
grade NN p
PIN NNP p
and CC p
LSPC NNP p
were VBD p
gathered VBN p
from IN p
each DT p
ERSPC NNP p
centre NN p
. . p

Detection NNP o
rates NNS o
of IN N
subsequent JJ o
prostate NN o
cancer NN o
in IN N
the DT N
first JJ N
re-biopsy NN N
after IN N
these DT N
diagnoses NNS N
were VBD N
determined VBN N
. . N

RESULTS VB N
The DT N
average JJ o
cancer NN o
detection NN o
rate NN o
was VBD N
3.5 CD N
% NN N
, , N
3.2 CD N
% NN N
and CC N
3.5 CD N
% NN N
for IN N
the DT N
completed VBN N
rounds NNS N
1 CD N
, , N
2 CD N
and CC N
3 CD N
, , N
respectively RB N
, , N
in IN N
all DT N
five CD N
centres NNS N
. . N

Incidence NN o
of IN o
high JJ o
grade NN o
PIN NNP o
increased VBD N
from IN N
1.5 CD N
% NN N
in IN N
the DT N
first JJ N
round NN N
to TO N
5.0 CD N
% NN N
in IN N
the DT N
third JJ N
round NN N
, , N
varying VBG N
among IN N
centres NNS N
in IN N
the DT N
first JJ N
round NN N
between IN N
0.8 CD N
% NN N
and CC N
7.6 CD N
% NN N
. . N

The DT N
cancer NN o
detection NN o
rate NN o
in IN N
the DT N
first JJ N
re-biopsy NN N
after IN N
the DT N
diagnosis NN N
of IN N
high JJ N
grade NN N
PIN NNP N
was VBD N
12.9 CD N
% NN N
. . N

Incidence NN o
of IN o
LSPC NNP o
was VBD N
2.4 CD N
% NN N
, , N
2.7 CD N
% NN N
, , N
2.2 CD N
% NN N
and CC N
2.6 CD N
% NN N
in IN N
the DT N
first JJ N
, , N
second JJ N
, , N
third JJ N
and CC N
fourth JJ N
round NN N
, , N
respectively RB N
. . N

The DT N
cancer NN o
detection NN o
rate NN o
at IN N
the DT N
first JJ N
re-biopsy NN N
after IN N
the DT N
diagnosis NN N
of IN N
LSPC NNP N
was VBD N
in IN N
average JJ N
33.8 CD N
% NN N
. . N

CONCLUSIONS NNP N
Cancer NNP o
detection NN o
rate NN o
was VBD N
stable JJ N
during IN N
the DT N
three CD N
screening VBG i
rounds NNS N
. . N

The DT N
wide JJ N
variation NN N
in IN N
frequency NN N
in IN N
particular JJ N
of IN N
high JJ N
grade NN N
PIN NNP N
among IN N
the DT N
ERSPC NNP N
centres VBZ N
suggests VBZ N
a DT N
considerable JJ N
inter-observer JJ N
variation NN N
. . N

The DT N
average JJ N
comparatively RB N
low JJ N
detection NN o
rate NN o
of IN N
isolated JJ N
high JJ N
grade NN N
PIN NNP N
in IN N
the DT N
first JJ N
screening NN N
round NN N
may MD N
be VB N
screening-related JJ N
, , N
while IN N
its PRP$ N
consistent JJ N
increase NN N
during IN N
three CD N
screening VBG N
rounds NNS N
could MD N
be VB N
the DT N
consequence NN N
of IN N
a.o NN N
. . N

previous JJ N
screening NN N
and CC N
ageing NN N
of IN N
the DT N
population NN N
. . N

The DT N
observed JJ N
low JJ o
risk NN o
of IN o
prostate NN o
cancer NN o
after IN N
isolated VBN N
high JJ N
grade NN N
PIN NNP N
in IN N
this DT N
screening NN N
setting NN N
is VBZ N
in IN N
line NN N
with IN N
the DT N
current JJ N
recommendation NN N
to TO N
abstain VB N
from IN N
early JJ N
repeat NN N
biopsies NNS N
after IN N
this DT N
diagnosis NN N
. . N

The DT N
association NN N
of IN N
LSPC NNP N
with IN N
high JJ N
incidence NN N
of IN N
prostate NN N
cancer NN N
in IN N
re-biopsies NNS N
confirms NNS N
the DT N
need NN N
for IN N
early JJ N
repeat NN N
biopsies NNS N
and CC N
follow-up NN N
of IN N
these DT N
men NNS p
. . p

The DT N
low JJ N
percentage NN N
of IN N
LSPC NNP N
( ( N
< VB N
3 CD N
% NN N
of IN N
biopsies NNS N
) ) N
throughout IN N
all DT N
rounds NNS N
is VBZ N
reassuring VBG N
as IN N
it PRP N
limits VBZ N
the DT N
biopsy NN N
burden NN N
in IN N
a DT N
screening NN N
setting NN N
. . N

-DOCSTART- -10195003- O O

A DT N
comparison NN N
of IN N
a DT N
non-ionic JJ i
dimer NN i
, , i
iodixanol NN i
with IN N
a DT i
non-ionic JJ i
monomer NN i
, , i
iohexol NN i
in IN N
low JJ p
dose VBP p
intravenous JJ p
urography NN p
. . p

A DT N
prospective JJ N
, , N
double-blind JJ N
study NN N
of IN N
392 CD p
patients NNS p
randomized VBN N
into IN N
four CD N
groups NNS N
was VBD N
performed VBN N
to TO N
establish VB N
whether IN N
diagnostic JJ N
intravenous JJ N
urograms NNS N
could MD N
be VB N
obtained VBN N
with IN N
a DT N
lower JJR N
dose NN N
of IN N
iodine NN N
when WRB N
using VBG N
the DT N
dimeric NN N
, , N
non-ionic JJ i
contrast NN i
medium NN i
iodixanol NN i
compared VBN N
with IN N
the DT N
monomeric NN i
, , i
non-ionic JJ i
iohexol NN i
. . i

Patients NNS N
received VBD N
iodixanol JJ i
or CC i
iohexol JJ i
containing VBG N
either CC N
9 CD N
or CC N
12 CD N
g NN N
of IN N
iodine NN i
( ( N
gI NN N
) ) N
. . N

The DT N
primary JJ N
parameter NN N
was VBD N
the DT N
diagnostic JJ o
quality NN o
of IN N
the DT N
6 CD N
min NN N
film NN N
, , N
assessed VBN N
in IN N
a DT N
blinded JJ N
fashion NN N
, , N
by IN N
consensus NN N
, , N
by IN N
four CD N
radiologists NNS N
. . N

Iodixanol NN i
at IN N
both DT N
doses NNS N
was VBD N
diagnostic JJ o
in IN N
over IN N
90 CD N
% NN N
of IN N
cases NNS N
. . N

Iohexol NNP i
was VBD N
only RB N
diagnostic JJ o
in IN N
74 CD N
% NN N
( ( N
9 CD N
gI NN N
) ) N
and CC N
81.8 CD N
% NN N
( ( N
12 CD N
gI NN N
) ) N
. . N

Pairwise VB N
comparisons NNS N
revealed VBD N
that IN N
iodixanol JJ N
9 CD N
gI NN N
was VBD N
significantly RB N
better JJR N
than IN N
both DT N
iohexol JJ i
9 CD N
gI NN N
( ( N
p JJ N
= NNP N
0.0005 CD N
) ) N
and CC N
12 CD N
gI NN N
( ( N
p JJ N
= NNP N
0.014 CD N
) ) N
. . N

No DT N
significant JJ N
difference NN N
was VBD N
present JJ N
for IN N
different JJ N
doses NNS N
within IN N
the DT N
same JJ N
contrast NN N
medium NN N
group NN N
. . N

Iodixanol NNP i
resulted VBD N
in IN N
poorer NN o
bladder NN o
distension NN o
than IN N
iohexol NN i
. . i

Iodixanol NNP i
caused VBD N
significantly RB o
less JJR o
discomfort NN o
than IN N
iohexol NN i
. . i

-DOCSTART- -7499684- O O

Effect NN N
of IN N
six-hour JJ N
exposure NN N
to TO N
nitrogen VB i
dioxide NN i
on IN N
early-phase JJ N
nasal JJ o
response NN o
to TO N
allergen VB N
challenge NN N
in IN N
patients NNS p
with IN p
a DT p
history NN p
of IN p
seasonal JJ p
allergic JJ p
rhinitis NN p
. . p

BACKGROUND NNP N
Recent NNP N
studies NNS N
have VBP N
suggested VBN N
that IN N
exposure NN N
to TO N
air NN N
pollutants NNS N
may MD N
enhance VB N
the DT N
airway NN N
responsiveness NN N
of IN N
susceptible JJ p
individuals NNS p
to TO N
inhaled VB N
allergen NN N
. . N

METHODS NNP N
To TO N
investigate VB N
the DT N
effect NN N
of IN N
exposure NN N
to TO N
nitrogen VB i
dioxide NN i
( ( i
NO2 NNP i
) ) i
on IN N
nasal NN N
airways NNS N
resistance NN N
( ( N
NAR NNP N
) ) N
and CC N
inflammatory JJ N
mediators NNS N
in IN N
nasal JJ N
lavage NN N
fluid NN N
, , N
eight CD p
subjects NNS p
with IN p
a DT p
history NN p
of IN p
seasonal JJ p
allergic JJ p
rhinitis NN p
, , p
who WP p
were VBD p
tested VBN p
out IN p
of IN p
season NN p
, , N
were VBD N
exposed VBN N
in IN N
a DT N
randomized JJ N
single-blind NN N
, , N
crossover NN N
study NN N
to TO N
either DT N
air NN i
or CC N
400 CD N
ppb NNS N
NO2 NNP i
for IN N
6 CD N
hours NNS N
. . N

The DT N
changes NNS o
in IN o
NAR NNP o
and CC o
eosinophil VB o
cationic JJ o
protein NN o
( ( o
ECP NNP o
) ) o
, , o
mast RB o
cell NN o
tryptase NN o
( ( o
MCT NNP o
) ) o
, , o
neutrophil JJ o
myeloperoxidase NN o
( ( o
MPO NNP o
) ) o
, , o
and CC o
interleukin-8 JJ o
( ( o
IL-8 NNP o
) ) o
in IN o
nasal JJ o
lavage NN o
fluid NN o
before IN N
and CC N
after IN N
exposure NN N
were VBD N
evaluated VBN N
. . N

Another DT p
group NN p
of IN p
eight CD p
subjects NNS p
with IN p
a DT p
history NN p
of IN p
seasonal JJ p
allergic JJ p
rhinitis NN p
were VBD N
also RB N
randomized VBN N
to TO N
exposure VB N
to TO N
air NN N
or CC N
400 CD N
ppb NNS N
NO2 NNP i
for IN N
6 CD N
hours NNS N
and CC N
then RB N
challenged VBD N
with IN N
allergen NN N
, , N
before IN N
evaluation NN N
for IN N
changes NNS o
in IN o
NAR NNP o
and CC o
changes NNS o
in IN o
ECP NNP o
, , o
MCT NNP o
, , o
MPO NNP o
, , o
and CC o
IL-8 NNP o
in IN o
nasal JJ o
lavage NN o
fluid NN o
. . o

RESULTS NNP N
Exposure NNP N
to TO N
air NN N
or CC N
NO2 NNP i
did VBD N
not RB N
alter VB N
either CC N
NAR NNP o
or CC N
the DT N
levels NNS o
of IN o
ECP NNP o
, , o
MCT NNP o
, , o
MPO NNP o
, , o
or CC o
IL-8 NNP o
in IN N
nasal JJ N
lavage NN N
fluid NN N
. . N

Allergen NNP N
challenge NN N
after IN N
exposure NN N
to TO N
both DT N
air NN N
and CC N
NO2 NNP i
significantly RB N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
increased VBD N
levels NNS N
of IN N
MCT NNP o
, , N
but CC N
not RB N
MPO NNP o
and CC o
IL-8 NNP o
in IN N
the DT N
nasal JJ N
lavage NN N
fluid NN N
. . N

In IN N
addition NN N
, , N
allergen NN N
challenge NN N
after IN N
exposure NN N
to TO N
NO2 NNP i
but CC N
not RB N
air NN N
, , N
significantly RB N
increased JJ N
levels NNS N
of IN N
only RB N
ECP NNP o
in IN o
nasal JJ o
lavage NN o
fluid NN N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
. . N

CONCLUSIONS NNP N
These DT N
results NNS N
suggest VBP N
that IN N
acute JJ N
exposure NN N
to TO N
NO2 NNP i
at IN N
concentrations NNS N
found VBN N
at IN N
the DT N
curbside NN N
in IN N
heavy JJ N
traffic NN N
during IN N
episodes NNS N
of IN N
pollution NN N
, , N
may MD N
prime VB N
eosinophils NNS N
for IN N
subsequent JJ N
activation NN N
by IN N
allergen NN N
in IN N
individuals NNS N
with IN N
a DT N
history NN N
of IN N
seasonal JJ N
allergic JJ N
rhinitis NN N
. . N

-DOCSTART- -1342306- O O

Long-term JJ N
anticoagulant NN i
treatment NN i
after IN N
acute JJ N
myocardial JJ N
infarction NN N
. . N

The DT N
Warfarin NNP N
Re-Infarction NNP N
Study NNP N
. . N

High NNP N
levels NNS N
of IN N
fibrinogen NN N
and CC N
clotting VBG N
factor NN N
VII NNP N
are VBP N
associated VBN N
with IN N
an DT N
increased VBN o
risk NN o
for IN N
subsequent JJ o
death NN o
and CC N
cardiovascular JJ o
disease NN o
in IN N
apparently RB p
healthy JJ p
individuals NNS p
. . p

Furthermore RB N
, , N
pathoanatomic JJ N
studies NNS N
and CC N
coronary JJ N
angiography NN N
have VBP N
confirmed VBN N
a DT N
relationship NN o
between IN o
coronary JJ o
thrombus NN o
formation NN o
and CC o
acute JJ o
Q-wave NNP o
infarction NN o
. . o

Effective JJ N
antithrombotic JJ N
agents NNS N
may MD N
prevent VB N
or CC N
limit VB N
thrombus JJ o
formation NN o
and CC N
events NNS o
related VBN o
to TO o
thrombosis NN o
. . o

The DT N
Warfarin NNP N
Re-Infarction NNP N
Study NNP N
( ( N
WARIS NNP N
) ) N
studied VBD N
the DT N
effect NN N
of IN N
warfarin NN i
in IN N
survivors NNS p
of IN p
acute JJ p
myocardial JJ p
infarction NN p
. . p

Patients NNS p
aged VBD p
75 CD p
years NNS p
or CC p
less JJR p
were VBD N
randomized VBN N
in IN N
a DT N
double-blind JJ N
, , N
placebo-controlled JJ i
study NN N
to TO N
test VB N
whether IN N
long-term JJ N
treatment NN N
with IN N
warfarin JJ i
reduces NNS N
the DT N
risk NN o
of IN N
death NN o
, , o
reinfarction NN o
, , N
and CC N
thromboembolic JJ o
morbidity NN o
. . o

A DT p
total NN p
of IN p
1918 CD p
patients NNS p
were VBD p
screened VBN p
for IN p
participation NN p
; : p
1214 CD p
were VBD p
recruited VBN p
. . p

The DT N
mean JJ N
follow-up NN N
was VBD N
37 CD N
months NNS N
. . N

Analyzed VBN N
on IN N
an DT N
intention-to-treat JJ N
basis NN N
, , N
123 CD N
( ( N
20 CD N
% NN N
) ) N
in IN N
the DT N
placebo NN i
group NN N
died VBD o
, , N
versus FW N
94 CD N
( ( N
15 CD N
% NN N
) ) N
in IN N
the DT N
warfarin NN i
group NN N
, , N
a DT N
risk NN o
reduction NN o
of IN N
24 CD N
% NN N
( ( N
P NNP N
= NNP N
0.026 CD N
) ) N
. . N

Considering VBG N
patients NNS N
on IN N
treatment NN N
or CC N
within IN N
28 CD N
days NNS N
after IN N
discontinuing VBG N
the DT N
test NN N
medication NN N
, , N
92 CD N
in IN N
the DT N
placebo NN N
group NN N
died VBD o
, , N
as IN N
compared VBN N
with IN N
60 CD N
of IN N
the DT N
warfarin-treated JJ i
patients NNS N
, , N
a DT N
risk NN o
reduction NN o
of IN N
35 CD N
% NN N
( ( N
P NNP N
= NNP N
0.005 CD N
) ) N
. . N

Relapsing VBG o
myocardial JJ o
infarction NN o
( ( o
fatal JJ o
and CC o
nonfatal JJ o
) ) o
was VBD N
reduced VBN N
by IN N
43 CD N
% NN N
( ( N
P NNP N
= NNP N
0.0001 CD N
) ) N
. . N

The DT N
incidence NN o
of IN o
cerebrovascular JJ o
attacks NNS o
was VBD N
lower RBR N
in IN N
the DT N
warfarin NN i
group NN N
( ( N
16 CD N
patients NNS N
) ) N
than IN N
the DT N
placebo NN i
group NN N
( ( N
41 CD N
patients NNS N
) ) N
, , N
a DT N
highly RB N
significant JJ N
reduction NN N
of IN N
61 CD N
% NN N
( ( N
P NNP N
= NNP N
0.0003 CD N
) ) N
. . N

Serious JJ o
bleeding NN o
occurred VBD N
in IN N
11 CD N
patients NNS N
taking VBG N
warfarin NN i
, , N
an DT N
incidence NN N
of IN N
0.6 CD N
% NN N
per IN N
year NN N
. . N

In IN N
conclusion NN N
, , N
long-term JJ N
anticoagulant JJ i
therapy NN i
may MD N
be VB N
recommended VBN N
after IN N
acute JJ N
myocardial JJ N
infarction NN N
. . N

-DOCSTART- -2928074- O O

Motion NN N
aftereffects NNS N
with IN N
horizontally RB N
moving VBG N
sound NN N
sources NNS N
in IN N
the DT N
free JJ N
field NN N
. . N

A DT N
horizontally RB i
moving VBG i
sound NN i
was VBD N
presented VBN N
to TO N
an DT p
observer NN p
seated VBN p
in IN p
the DT p
center NN p
of IN p
an DT p
anechoic JJ p
chamber NN p
. . p

The DT N
sound NN N
, , N
either CC N
a DT N
500-Hz JJ i
low-pass JJ i
noise NN i
or CC i
a DT i
6300-Hz JJ i
high-pass NN i
noise NN i
, , N
repeatedly RB N
traversed VBD N
a DT N
semicircular JJ N
arc NN N
in IN N
the DT N
observer NN p
's POS p
front JJ p
hemifield NN p
at IN p
ear JJ p
level NN p
( ( N
distance NN N
: : N
1.5 CD N
m NN N
) ) N
. . N

At IN N
10-sec JJ N
intervals NNS N
this DT N
adaptor NN N
was VBD N
interrupted VBN N
, , N
and CC N
a DT N
750-msec JJ N
moving NN i
probe NN i
( ( N
a DT N
500-Hz JJ N
low-pass JJ N
noise NN N
) ) N
was VBD N
presented VBN N
from IN N
a DT N
horizontal JJ N
arc NN N
1.6 CD N
m NN N
in IN N
front NN N
of IN N
the DT N
observer NN N
. . N

During IN N
a DT N
run NN N
, , N
the DT N
adaptor NN N
was VBD N
presented VBN N
at IN N
a DT N
constant JJ N
velocity NN N
( ( N
-200 JJ N
degrees NNS N
to TO N
+200 VB N
degrees/sec NN N
) ) N
, , N
while IN N
probes NNS N
with IN N
velocities NNS N
varying VBG N
from IN N
-10 JJ N
degrees NNS N
to TO N
+10 VB N
degrees/sec NN N
were VBD N
presented VBN N
in IN N
a DT N
random JJ N
order NN N
. . N

Observers NNS p
judged VBD p
the DT p
direction NN p
of IN p
motion NN p
( ( p
left VBD p
or CC p
right JJ p
) ) p
of IN p
each DT p
probe NN p
. . p

As IN N
in IN N
the DT N
case NN N
of IN N
stimuli NNS N
presented VBN N
over IN N
headphones NNS N
( ( N
Grantham NNP N
& CC N
Wightman NNP N
, , N
1979 CD N
) ) N
, , N
an DT N
auditory JJ o
motion NN o
aftereffect NN o
( ( o
MAE NNP o
) ) o
occurred VBD N
: : N
subjects NNS N
responded VBD N
left VBN N
to TO N
probes VB N
more RBR N
often RB N
when WRB N
the DT N
adaptor NN N
moved VBD N
right RB N
than IN N
when WRB N
it PRP N
moved VBD N
left RB N
. . N

When WRB N
the DT N
adaptor NN N
and CC N
probe NN N
were VBD N
spectrally RB N
the DT N
same JJ N
, , N
the DT N
MAE NNP o
was VBD N
greater JJR N
than IN N
when WRB N
they PRP N
were VBD N
from IN N
different JJ N
spectral JJ N
regions NNS N
; : N
the DT N
magnitude NN N
of IN N
this DT N
difference NN N
depended VBD N
on IN N
adaptor NN N
speed NN N
and CC N
was VBD N
subject-dependent NN N
. . N

It PRP N
is VBZ N
proposed VBN N
that IN N
there EX N
are VBP N
two CD N
components NNS N
underlying VBG N
the DT N
auditory JJ N
MAE NNP o
: : o
( ( N
1 CD N
) ) N
a DT N
generalized JJ N
bias NN N
to TO N
respond VB N
that DT N
probes NNS N
move VBP N
in IN N
the DT N
direction NN N
opposite NN N
to TO N
that DT N
of IN N
the DT N
adaptor NN N
, , N
independent JJ N
of IN N
their PRP$ N
spectra NN N
; : N
and CC N
( ( N
2 CD N
) ) N
a DT N
loss NN N
of IN N
sensitivity NN N
to TO N
the DT N
velocity NN N
of IN N
moving VBG N
sounds NNS N
after IN N
prolonged JJ N
exposure NN N
to TO N
moving VBG N
sounds NNS N
having VBG N
the DT N
same JJ N
spectral JJ N
content NN N
. . N

-DOCSTART- -22134468- O O

In IN N
high JJ p
risk NN p
hypertensive JJ p
subjects NNS p
with IN p
incidental JJ p
and CC p
unilateral JJ p
renal JJ p
artery NN p
stenosis NN p
percutaneous JJ p
revascularization NN p
with IN N
stent JJ N
improves NNS N
blood NN o
pressure NN o
control NN o
but CC N
not RB N
glomerular JJ o
filtration NN o
rate NN o
. . o

AIM NNP N
In IN N
high-risk JJ p
hypertensive JJ p
subjects NNS p
( ( p
HTs NNP p
) ) p
with IN p
incidental JJ p
unilateral JJ p
renal JJ p
artery NN p
stenosis NN p
( ( p
RAS NNP p
) ) p
, , N
the DT N
effectiveness NN N
of IN N
percutaneous JJ i
revascularization NN i
with IN i
stent NN i
( ( i
PR-STENT NNP i
) ) i
on IN N
blood NN o
pressure NN o
( ( o
BP NNP o
) ) o
and CC N
glomerular JJ o
filtration NN o
rate NN o
( ( o
GFR NNP o
) ) o
is VBZ N
not RB N
established VBN N
. . N

METHODS NNP N
Eighteen NNP p
HTs NNP p
aged VBD p
65.7 CD p
? . p
9.2 CD p
years NNS p
with IN p
angiographically RB p
diagnosed VBN p
unilateral JJ p
RAS NNP p
( ( p
? . p
60 CD p
% NN p
) ) p
were VBD p
randomized VBN N
to TO N
receive VB N
PR-STENT NNP N
( ( N
N=9 NNP N
) ) N
or CC N
to TO N
NO-STENT NNP i
( ( i
N=9 NNP i
) ) N
. . N

BP NNP N
( ( N
mercury NN N
sphygmomanometer NN N
) ) N
and CC N
GFR NNP N
( ( N
99mTc-DTPA JJ N
clearances NNS N
during IN N
renal JJ N
scintigraphy NN N
) ) N
were VBD N
evaluated VBN N
yearly RB N
for IN N
three CD N
years NNS N
. . N

Echo-Doppler NN N
of IN N
renal JJ N
arteries NNS N
was VBD N
performed VBN N
to TO N
verify VB N
the DT N
anatomic JJ N
patency NN N
and CC N
flow JJ N
velocities NNS N
of IN N
the DT N
reperfused JJ N
artery NN N
. . N

Analysis NN N
of IN N
variance NN N
compared VBN N
BP NNP N
and CC N
GFR NNP N
values NNS N
changes NNS N
from IN N
baseline NN N
to TO N
the DT N
follow-up NN N
; : N
differences NNS N
for IN N
continuous JJ N
variables NNS N
were VBD N
evaluated VBN N
between IN N
groups NNS N
with IN N
the DT N
Tukey NNP N
's POS N
post NN N
hoc NN N
test NN N
after IN N
adjustment NN N
for IN N
age NN N
, , N
change NN N
of IN N
BP NNP N
between IN N
baseline NN N
and CC N
at IN N
the DT N
follow-up NN N
, , N
GFR NNP N
and CC N
body NN N
mass NN N
index NN N
( ( N
BMI NNP N
) ) N
. . N

RESULTS NNP o
Baseline NNP o
systolic JJ o
BP NNP o
and CC o
GFR NNP o
values NNS o
were VBD o
not RB N
different JJ N
between IN N
groups NNS N
. . N

The DT N
significantly RB N
greater JJR o
GFR NNP o
increase NN o
observed VBD o
in IN N
PR-STENT NNP N
than IN N
in IN N
NO-STENT NNP N
at IN N
univariate JJ N
analysis NN N
at IN N
the DT N
end NN N
of IN N
follow-up NN N
( ( N
62.5 CD N
? . N
19.2 CD N
vs. IN N
42.24 CD N
? . N
17.6 CD N
, , N
P NNP N
< NNP N
0.02 CD N
) ) N
disappeared VBD N
after IN N
adjustment NN N
for IN N
confounding VBG N
factors NNS N
. . N

However RB o
, , o
systolic JJ o
BP NNP o
remained VBD o
significantly RB N
lower JJR N
in IN N
PR-STENT NNP N
than IN N
in IN N
NO-STENT NNP N
( ( N
140.1 CD N
? . N
4.6 CD N
vs. IN N
170.0 CD N
? . N
8.3 CD N
, , N
P NNP N
< NNP N
0.0001 CD N
) ) N
also RB N
after IN N
adjustment NN N
for IN N
age NN N
, , N
GFR NNP N
and CC N
BMI NNP N
. . N

CONCLUSION NNP N
PR-STENT NNP N
reduces VBZ N
systolic JJ o
BP NNP o
without IN o
improving VBG o
GFR NNP o
. . o

Due NNP o
to TO N
the DT N
strong JJ N
association NN N
between IN N
high JJ N
BP NNP N
and CC N
renal JJ N
damage NN N
, , N
this DT N
study NN N
raises VBZ N
the DT N
question NN N
on IN N
whether IN N
PR-STENT NNP N
should MD N
be VB N
performed VBN N
in IN N
all DT N
HTs NNP p
with IN p
unilateral JJ p
and CC p
incidental JJ p
RAS NNP p
. . p

-DOCSTART- -1642441- O O

[ JJ N
Comparison NNP N
of IN N
the DT N
efficacy/tolerability NN N
ratio NN N
of IN N
cibenzoline NN i
and CC N
propafenone NN i
in IN N
the DT N
treatment NN N
of IN N
ventricular JJ p
arrhythmia NN p
] NNP p
. . N

Cibenzoline NNP i
( ( i
C NNP i
) ) i
was VBD N
compared VBN N
with IN N
propafenone NN i
( ( i
P NNP i
) ) i
in IN N
18 CD p
adult NN p
patients NNS p
( ( p
7 CD p
women NNS p
and CC p
11 CD p
men NNS p
) ) p
aged VBD p
50 CD p
+/- JJ p
7 CD p
in IN N
double-blind NN N
, , N
placebo-controlled JJ i
crossover NN N
trial NN N
. . N

After IN N
a DT N
therapeutic JJ N
wash-out NN N
period NN N
corresponding VBG N
to TO N
5 CD N
times NNS N
the DT N
half-life NN N
of IN N
previous JJ N
anti-arrhythmic JJ i
drugs NNS i
, , N
patients NNS p
with IN p
more JJR p
than IN p
100 CD p
premature JJ p
ventricular JJ p
contractions NNS p
( ( p
PVC NNP p
) ) p
per IN p
hour NN p
in IN p
two CD p
24 CD p
hour NN p
Holter NNP p
records NNS p
obtained VBN p
at IN p
an DT p
interval NN p
of IN p
7 CD p
days NNS p
were VBD N
treated VBN N
in IN N
succession NN N
and CC N
after IN N
randomised VBN N
by IN N
C NNP i
( ( N
390 CD N
mg/day NN N
in IN N
3 CD N
divided JJ N
doses NNS N
) ) N
and CC N
P NNP i
( ( N
900 CD N
mg/day NN N
in IN N
3 CD N
divided JJ N
doses NNS N
) ) N
for IN N
a DT N
period NN N
of IN N
two CD N
weeks NNS N
, , N
each DT N
active JJ N
sequence NN N
being VBG N
followed VBN N
by IN N
a DT N
two CD N
week NN N
wash-out JJ N
period NN N
. . N

Efficacy NNP N
( ( N
based VBN N
upon IN N
the DT N
decrease NN N
in IN N
PVC/hour NNP N
in IN N
a DT N
24 CD N
hour NN N
Holter NNP N
) ) N
and CC N
tolerability NN N
were VBD N
evaluated VBN N
at IN N
the DT N
end NN N
of IN N
each DT N
sequence NN N
, , N
with IN N
samples NNS N
drawn VBN N
at IN N
the DT N
same JJ N
times NNS N
for IN N
assay NN N
of IN N
the DT N
study NN N
drugs NNS N
. . N

Three CD N
patients NNS N
dropped VBD N
out IN N
of IN N
the DT N
trial NN N
, , N
1 CD N
with IN N
each DT N
active JJ N
drug NN N
( ( N
for IN N
epigastric RB o
pain NN o
) ) o
and CC N
1 CD N
with IN N
dummy NN N
. . N

No DT N
significant JJ N
difference NN N
was VBD N
seen VBN N
between IN N
the DT N
two CD N
drugs NNS N
regarding VBG N
the DT N
decrease NN N
in IN N
the DT N
total JJ o
number NN o
of IN o
PVC/hour NNP o
in IN N
the DT N
15 CD N
patients NNS N
completing VBG N
the DT N
cross-over JJ N
protocol NN N
. . N

A DT o
reduction NN o
in IN o
PVC/hour NNP o
of IN o
more JJR o
than IN o
70 CD o
per IN o
cent NN o
was VBD o
seen VBN o
in IN o
7 CD o
patients NNS o
with IN o
C NNP o
and CC o
in IN o
9 CD o
patients NNS o
with IN o
P. NNP o
C NNP o
was VBD o
better RBR o
tolerated VBN o
than IN o
P NNP o
on IN o
the DT o
basis NN o
of IN o
both DT o
clinical JJ o
and CC o
electrocardiographic JJ o
parameters NNS o
. . o

One CD N
patient NN N
developed VBD N
troublesome JJ N
adverse JJ o
reactions NNS o
with IN N
C NNP i
as IN N
compared VBN N
with IN N
4 CD N
patients NNS N
in IN N
the DT N
case NN N
of IN N
P. NNP N
A NNP o
more JJR o
than IN o
20 CD o
per IN o
cent NN o
increase NN o
in IN o
QRS NNP o
was VBD o
seen VBN o
in IN o
7 CD o
patients NNS o
with IN o
C NNP o
and CC o
in IN o
10 CD o
patients NNS o
with IN o
P NNP o
, , o
the DT o
figures NNS o
for IN o
PR NNP o
being VBG o
2 CD o
and CC o
6 CD o
patients NNS o
respectively RB o
. . o

One CD N
patient NN N
showed VBD N
a DT N
proarrhythmic JJ o
effect NN o
with IN o
P. NNP o
Plasma NNP o
levels NNS o
of IN o
C NNP o
were VBD o
significantly RB o
higher JJR o
in IN o
responders NNS o
( ( o
328 CD o
+/- JJ o
149 CD o
ng/ml NN o
) ) o
than IN o
in IN o
non-responders NNS o
( ( o
137 CD o
+/- JJ o
41 CD o
ng/ml NN o
, , o
p NN o
less JJR o
than IN o
0.05 CD o
) ) o
. . o

No DT o
significant JJ o
difference NN o
was VBD o
found VBN o
concerning VBG o
plasma NN o
levels NNS o
of IN o
P NNP o
( ( o
578 CD o
+/- JJ o
477 CD o
ng/ml NNS o
compared VBN o
with IN o
646 CD o
+/- JJ o
457 CD o
ng/ml NN o
, , o
p NN o
greater JJR o
than IN o
0.05 CD o
) ) o
. . o

In IN N
conclusion NN N
, , N
the DT N
efficacy/tolerability NN o
ratio NN o
in IN N
this DT N
population NN p
with IN p
a DT p
low JJ p
risk NN p
of IN p
serious JJ p
rhythm JJ p
events NNS p
appeared VBD N
to TO N
be VB N
better JJR N
with IN N
C NNP i
than IN N
with IN N
P NNP i
. . i

-DOCSTART- -20124218- O O

Oral JJ i
6-mercaptopurine JJ i
versus NN N
oral JJ i
6-thioguanine JJ i
and CC N
veno-occlusive JJ N
disease NN N
in IN p
children NNS p
with IN p
standard-risk JJ p
acute JJ p
lymphoblastic JJ p
leukemia NN p
: : p
report NN N
of IN N
the DT N
Children NNP N
's POS N
Oncology NNP N
Group NNP N
CCG-1952 NNP N
clinical JJ N
trial NN N
. . N

The DT N
Children NNP p
's POS p
Cancer NNP p
Group NNP p
1952 CD p
( ( p
CCG-1952 NNP p
) ) p
clinical JJ N
trial NN N
studied VBD N
the DT N
substitution NN i
of IN i
oral JJ i
6-thioguanine JJ i
( ( i
TG NNP i
) ) i
for IN i
6-mercaptopurine JJ i
( ( i
MP NNP i
) ) i
and CC i
triple JJ i
intrathecal JJ i
therapy NN i
( ( i
ITT NNP i
) ) i
for IN i
intrathecal JJ i
methotrexate NN i
( ( i
IT-MTX NNP i
) ) i
in IN N
the DT N
treatment NN N
of IN N
standard-risk JJ p
acute JJ p
lymphoblastic JJ p
leukemia NN p
. . p

After IN p
remission NN p
induction NN p
, , p
2027 CD p
patients NNS p
were VBD N
randomized VBN N
to TO N
receive VB N
MP NNP i
( ( N
n JJ N
= NN N
1010 CD N
) ) N
or CC i
TG NNP i
( ( N
n JJ N
= NN N
1017 CD N
) ) N
and CC i
IT-MTX NNP i
( ( N
n CD N
= NNP N
1018 CD N
) ) N
or CC i
ITT NNP i
( ( N
n JJ N
= NN N
1009 CD N
) ) N
. . N

The DT N
results NNS N
of IN N
the DT N
thiopurine NN N
comparison NN N
are VBP N
as IN N
follows VBZ N
. . N

The DT N
estimated JJ N
7-year JJ N
event-free JJ o
survival NN o
( ( o
EFS NNP o
) ) o
for IN N
subjects NNS N
randomized VBN N
to TO N
TG NNP N
was VBD N
84.1 CD N
% NN N
( ( N
+/- JJ N
1.8 CD N
% NN N
) ) N
and CC N
to TO N
MP NNP N
was VBD N
79.0 CD N
% NN N
( ( N
+/- JJ N
2.1 CD N
% NN N
; : N
P NNP N
= NNP N
.004 NNP N
log NNP N
rank NN N
) ) N
, , N
although IN N
overall JJ o
survival NN o
was VBD N
91.9 CD N
% NN N
( ( N
+/- JJ N
1.4 CD N
% NN N
) ) N
and CC N
91.2 CD N
% NN N
( ( N
+/- JJ N
1.5 CD N
% NN N
) ) N
, , N
respectively RB N
( ( N
P NNP N
= NNP N
.6 NNP N
log NNP N
rank NN N
) ) N
. . N

The DT N
TG NNP N
starting VBG N
dose NN N
was VBD N
reduced VBN N
from IN N
60 CD N
to TO N
50 CD N
mg/m NN N
( ( N
2 CD N
) ) N
per IN N
day NN N
after IN N
recognition NN N
of IN N
hepatic JJ o
veno-occlusive JJ o
disease NN o
( ( o
VOD NNP o
) ) o
. . o

A DT N
total NN N
of IN N
257 CD p
patients NNS p
on IN N
TG NNP N
( ( N
25 CD N
% NN N
) ) N
developed VBD N
VOD NNP o
or CC N
disproportionate VB o
thrombocytopenia NN o
and CC N
switched VBD N
to TO N
MP NNP N
. . N

Once NNP N
portal JJ o
hypertension NN o
occurred VBD N
, , N
all DT N
subjects NNS N
on IN N
TG NNP N
were VBD N
changed VBN N
to TO N
MP NNP N
. . N

The DT N
benefit NN N
of IN N
randomization NN N
to TO N
TG NNP N
over IN N
MP NNP N
, , N
as IN N
measured VBN N
by IN N
EFS NNP N
, , N
was VBD N
evident JJ N
primarily RB N
in IN N
boys NNS N
who WP N
began VBD N
TG NNP N
at IN N
60 CD N
mg/m NN N
( ( N
2 CD N
) ) N
( ( N
relative JJ N
hazard NN N
rate NN N
[ NNP N
RHR NNP N
] NNP N
0.65 CD N
, , N
P NNP N
= NNP N
.002 NNP N
) ) N
. . N

The DT N
toxicities NNS N
of IN N
TG NNP N
preclude VBP N
its PRP$ N
protracted JJ N
use NN N
as IN N
given VBN N
in IN N
this DT N
study NN N
. . N

This DT N
study NN N
is VBZ N
registered VBN N
at IN N
http NN N
: : N
//clinicaltrials.gov NN N
as IN N
NCT00002744 NNP N
. . N

-DOCSTART- -25225951- O O

Efficacy NN N
of IN N
rhubarb NN i
combined VBN N
with IN N
early JJ i
enteral JJ i
nutrition NN i
for IN N
the DT N
treatment NN N
of IN N
severe JJ N
acute JJ N
pancreatitis NN N
: : N
a DT N
randomized NN N
controlled VBN N
trial NN N
. . N

OBJECTIVE UH N
To TO N
investigate VB N
the DT N
effect NN N
of IN N
rhubarb NN i
combined VBN i
with IN i
early JJ i
enteral JJ i
nutrition NN i
( ( i
EEN NNP i
) ) i
on IN N
the DT N
gastrointestinal JJ N
function NN N
, , N
disease NN N
severity NN N
and CC N
systemic JJ N
inflammation NN N
in IN N
patients NNS p
with IN p
severe JJ p
acute NN p
pancreatitis NN p
( ( p
SAP NNP p
) ) p
. . p

METHODS CC N
A DT N
total NN N
of IN N
126 CD p
patients NNS p
with IN p
SAP NNP p
were VBD N
randomly RB N
assigned VBN N
into IN N
three CD N
groups NNS N
: : N
parenteral JJ i
nutrition NN i
group NN i
, , i
treated VBN i
with IN i
standard JJ i
solution NN i
first RB i
and CC i
EN NNP i
14 CD i
days NNS i
later RB i
; : i
EEN NNP i
group NN i
, , i
treated VBN i
with IN i
EN NNP i
suspension NN i
; : i
or CC i
EEN NNP i
combined VBN i
with IN i
rhubarb NN i
group NN i
, , i
treated VBN i
with IN i
rhubarb NN i
and CC i
then RB i
EN NNP i
2 CD i
h NN i
later RB i
. . i

The DT N
gastrointestinal JJ o
function NN o
, , o
APACHE NNP o
II NNP o
scores NNS o
, , o
the DT o
levels NNS o
of IN o
plasma NN o
IL-6 NNP o
, , o
IL-11 NNP o
, , o
C-reactive JJ o
proteins NNS o
( ( o
CRP NNP o
) ) o
and CC o
the DT o
liver NN o
and CC o
kidney NN o
functional JJ o
measures NNS o
were VBD N
longitudinally RB N
analyzed VBN N
. . N

RESULTS JJ N
Patients NNPS N
in IN N
the DT N
EEN/rhubarb NNP i
group NN N
had VBD N
the DT N
shortest JJS N
period NN o
of IN o
abdominal JJ o
pain NN o
and CC o
the DT o
fastest JJS o
recovery NN o
from IN o
abnormal JJ o
bowel NN o
movement NN o
and CC o
high JJ o
fever NN o
as RB N
well RB N
as IN N
significantly RB N
shorter JJR N
periods NNS N
of IN N
intensive-care JJ N
unit NN N
and CC N
hospital NN N
stays NNS N
. . N

The DT N
combination NN N
of IN N
EEN NNP i
and CC i
rhubarb VB i
significantly RB N
reduced VBN N
the DT N
values NNS N
of IN N
APACHE NNP o
II NNP o
scores NNS o
. . o

Combination NNP N
therapies VBZ N
significantly RB N
reduced VBN N
abnormally RB N
higher JJR N
white JJ o
blood NN o
cell NN o
( ( o
WBC NNP o
) ) o
counts NNS o
and CC o
levels NNS o
of IN o
plasma NN o
CRP NNP o
and CC o
IL-6 NNP o
, , N
but CC N
increased VBD N
the DT N
levels NNS o
of IN o
plasma JJ o
IL-11 NNP o
. . o

Finally NNP N
, , N
combination NN N
therapies NNS N
improved VBD N
the DT N
SAP-related JJ N
damages NNS N
of IN N
liver NN o
and CC o
kidney NN o
function NN o
by IN N
reducing VBG N
abnormally RB N
higher JJR N
levels NNS o
of IN o
plasma NN o
alanine NN o
aminotransferase NN o
, , o
aspartate JJ o
aminotransferase NN o
, , o
and CC o
creatinine NN o
( ( o
Cr NNP o
) ) o
. . o

CONCLUSION NNP N
Combination NNP N
of IN N
EEN NNP i
and CC i
rhubarb VB i
significantly RB N
improved VBN N
the DT N
gastrointestinal JJ N
function NN N
, , N
inhibited JJ N
systemic JJ N
inflammation NN N
and CC N
disease NN N
severity NN N
and CC N
mitigated VBD N
the DT N
disease-related JJ N
damages NNS N
of IN N
liver NN N
and CC N
kidney NN N
function NN N
in IN N
SAP NNP p
patients NNS p
. . p

-DOCSTART- -9632036- O O

A DT N
double-blind JJ N
, , N
placebo-controlled JJ i
trial NN N
of IN N
nefazodone NN i
in IN N
the DT N
treatment NN N
of IN N
patients NNS p
hospitalized VBN p
for IN p
major JJ p
depression NN p
. . p

BACKGROUND IN N
There EX N
are VBP N
few JJ N
published VBN N
placebo-controlled JJ i
clinical JJ N
trials NNS N
demonstrating VBG N
the DT N
efficacy NN N
of IN N
the DT N
newer NN N
antidepressants NNS N
in IN N
markedly RB p
or CC p
severely RB p
depressed JJ p
hospitalized JJ p
patients NNS p
. . p

This DT N
study NN N
demonstrates VBZ N
the DT N
efficacy NN N
of IN N
nefazodone NN i
compared VBN N
with IN N
placebo NN i
in IN N
the DT N
treatment NN N
of IN N
patients NNS p
hospitalized VBN p
for IN p
major JJ p
depression NN p
. . p

METHOD NNP N
Nefazodone NNP i
and CC i
placebo VB i
treatment NN i
were VBD N
compared VBN N
in IN N
a DT N
6-week JJ N
trial NN N
of IN N
120 CD p
patients NNS p
hospitalized VBN p
for IN p
DSM-III-R NNP p
diagnosed VBD p
major JJ p
depression NN p
( ( p
without IN p
psychosis NN p
) ) p
at IN N
2 CD N
study NN N
centers NNS N
. . N

Efficacy NN N
was VBD N
evaluated VBN N
using VBG N
standard JJ o
psychiatric NN o
rating NN o
scales NNS o
, , N
and CC N
patients NNS N
were VBD N
monitored VBN N
for IN N
safety NN N
. . N

RESULTS NNP N
Nefazodone NNP N
treatment NN N
resulted VBD N
in IN N
a DT N
significant JJ N
reduction NN N
( ( N
p JJ N
< NNP N
.01 NNP N
) ) N
of IN N
the DT N
17-item JJ o
Hamilton NNP o
Rating NNP o
Scale NNP o
for IN o
Depression NNP o
( ( N
HAM-D-17 NNP N
) ) N
total NN N
score NN N
compared VBN N
with IN N
placebo NN i
from IN N
the DT N
end NN N
of IN N
the DT N
first JJ N
treatment NN N
week NN N
through IN N
the DT N
end NN N
of IN N
the DT N
study NN N
( ( N
-12.2 NNP N
nefazodone RB i
vs. FW N
-7.7 NNP N
placebo NN i
) ) i
. . N

At IN N
the DT N
end NN N
of IN N
the DT N
trial NN N
, , N
significantly RB N
more RBR N
nefazodone-treated JJ i
patients NNS N
( ( N
50 CD N
% NN N
) ) N
than IN N
placebo-treated JJ i
patients NNS N
( ( N
29 CD N
% NN N
) ) N
had VBD N
responded VBN N
, , N
as IN N
indicated VBN N
by IN N
their PRP$ N
Clinical JJ o
Global NNP o
Impressions-Improvement NN o
score NN o
( ( N
p JJ N
= NNP N
.021 NNP N
) ) N
or CC N
by IN N
a DT N
> NN N
or CC N
= VB N
50 CD N
% NN N
reduction NN N
in IN N
their PRP$ N
HAM-D-17 JJ o
scores NNS o
( ( N
p VB N
= NNP N
.017 NNP N
) ) N
. . N

Significantly RB N
more RBR N
patients NNS N
treated VBN N
with IN N
nefazodone NN i
( ( N
36 CD N
% NN N
) ) N
than IN N
placebo-treated JJ i
patients NNS N
( ( N
14 CD N
% NN N
) ) N
had VBD N
a DT N
HAM-D-17 NNP o
score NN o
< NN N
or CC N
= VB N
10 CD N
at IN N
the DT N
end NN N
of IN N
treatment NN N
( ( N
p JJ N
= NNP N
.004 NNP N
) ) N
. . N

Significant JJ N
treatment NN N
differences NNS N
( ( N
p JJ N
< NNP N
.01 NNP N
) ) N
in IN N
favor NN N
of IN N
nefazodone NN N
were VBD N
also RB N
seen VBN N
in IN N
the DT N
Montgomery-Asberg NNP o
Depression NNP o
Rating NNP o
Scale NNP o
; : o
the DT o
HAM-D NNP o
retardation NN o
, , o
anxiety NN o
, , o
and CC o
sleep JJ o
disturbance NN o
factors NNS o
; : o
and CC o
HAM-D NNP o
item NN o
1 CD o
( ( N
depressed JJ N
mood NN N
) ) N
. . N

Patients NNS p
with IN p
dysthymia NN o
in IN p
addition NN p
to TO p
major JJ o
depression NN o
also RB N
showed VBD N
significant JJ N
improvement NN N
( ( N
p JJ N
< NNP N
.05 NNP N
) ) N
when WRB N
treated VBN N
with IN N
nefazodone NN N
, , N
with IN N
significant JJ N
differences NNS N
in IN N
response NN N
rates NNS N
seen VBN N
as RB N
early RB N
as IN N
week NN N
2 CD N
and CC N
through IN N
the DT N
end NN N
of IN N
the DT N
trial NN N
. . N

The DT N
mean JJ o
nefazodone NN o
dose NN o
was VBD N
491 CD N
mg/day NN N
at IN N
the DT N
end NN N
of IN N
week NN N
2 CD N
and CC N
503 CD N
mg/day NN N
at IN N
the DT N
end NN N
of IN N
treatment NN N
. . N

Nefazodone NN N
was VBD N
well RB o
tolerated VBN o
, , N
and CC N
the DT N
number NN N
of IN N
patients NNS N
discontinuing VBG N
owing VBG N
to TO N
adverse JJ o
events NNS o
was VBD N
small JJ N
, , N
with IN N
no DT N
significant JJ N
safety NN N
issues NNS N
noted VBN N
in IN N
either DT N
treatment NN N
group NN N
. . N

Fewer JJR N
nefazodone-treated JJ i
than IN N
placebo-treated JJ i
patients NNS N
discontinued VBN N
owing VBG N
to TO N
lack VB N
of IN N
efficacy NN o
. . o

CONCLUSION NNP N
Nefazodone NNP i
was VBD N
superior JJ N
to TO N
placebo VB N
in IN N
the DT N
treatment NN N
of IN N
marked VBN p
to TO p
severe VB p
major JJ p
depression NN p
in IN p
patients NNS p
requiring VBG p
hospitalization NN p
. . p

The DT N
clinical JJ N
benefit NN N
of IN N
nefazodone NN i
was VBD N
evident JJ N
as RB N
early RB N
as IN N
the DT N
first JJ N
week NN N
of IN N
treatment NN N
as IN N
judged VBN N
by IN N
several JJ N
measures NNS N
of IN N
efficacy NN N
, , N
with IN N
significant JJ N
differences NNS N
from IN N
placebo NN N
sustained VBN N
throughout IN N
the DT N
trial NN N
. . N

-DOCSTART- -3963358- O O

[ JJ i
Aortofemoral NNP i
bifurcation NN i
bypass NN i
. . i

Effect NN N
of IN N
the DT N
anesthesia JJ N
procedure NN N
( ( i
NLA NNP i
, , i
thoracic RB i
continuous JJ i
catheter NN i
peridural JJ i
anesthesia NN i
) ) i
on IN N
circulation NN N
, , N
respiration NN N
and CC N
metabolism NN N
. . N

Homeostasis NNP N
and CC N
oxygen NN N
transport NN N
] NNP N
. . N

50 CD p
patients NNS p
were VBD p
investigated VBN p
during IN p
induction NN p
of IN p
anaesthesia NN p
and CC p
infrarenal JJ i
aortic JJ i
bypass NN i
surgery NN i
. . i

26 CD p
were VBD p
operated VBN p
on IN p
under IN p
neuroleptanaesthesia NN i
( ( i
NA NNP i
group NN i
) ) i
and CC p
24 CD p
under IN p
continuous JJ i
epidural JJ i
combined VBN i
with IN i
a DT i
light JJ i
general JJ i
anaesthesia NN i
( ( i
epidural JJ i
group NN i
) ) i
. . i

Blood NN N
losses NNS N
were VBD N
replaced VBN N
with IN N
5 CD N
per IN N
cent NN N
human JJ N
albumin NN N
, , N
red JJ N
cell NN N
concentrates NNS N
, , N
and CC N
fresh JJ N
frozen JJ N
plasma NN N
. . N

Ringer NNP i
lactate JJ i
solution NN i
was VBD N
used VBN N
to TO N
replace VB N
the DT N
functional JJ N
extracellular JJ N
fluid NN N
volume NN N
. . N

During IN N
induction NN N
and CC N
maintenance NN N
of IN N
anaesthesia NN N
body NN N
temperature NN N
fell VBD N
( ( N
NA NNP N
group NN N
from IN N
36.7 CD N
to TO N
35.3 CD N
degrees NNS N
C NNP N
; : N
epidural JJ N
group NN N
from IN N
36.7 CD N
to TO N
34.9 CD N
degrees NNS N
C NNP N
) ) N
but CC N
no DT N
statistically RB N
significant JJ N
difference NN N
could MD N
be VB N
found VBN N
between IN N
the DT N
groups NNS N
, , N
in IN N
spite NN N
of IN N
better JJR N
surface NN o
perfusion NN o
of IN N
the DT N
lower JJR N
part NN N
of IN N
the DT N
body NN N
in IN N
the DT N
epidural JJ N
group NN N
. . N

The DT N
increase NN o
of IN o
plasma JJ o
glucose JJ o
concentration NN o
was VBD N
lower JJR N
in IN N
the DT N
epidural JJ N
group NN N
as IN N
compared VBN N
to TO N
the DT N
NA NNP N
group NN N
. . N

Stress NNP o
mediated VBD o
hypokalaemia NN o
was VBD N
of IN N
the DT N
same JJ N
degree NN N
in IN N
both DT N
groups NNS N
, , N
the DT N
median JJ o
values NNS o
of IN o
the DT o
plasma NN o
potassium NN o
concentrations NNS o
being VBG N
in IN N
the DT N
lower JJR N
reference NN N
range NN N
( ( N
3.5-3.7 JJ N
mmol NN N
X $ N
1 CD N
( ( N
-1 JJ N
] NN N
, , N
although IN N
large JJ N
amounts NNS N
of IN N
red JJ N
cell NN N
concentrates NNS N
were VBD N
given VBN N
. . N

During IN N
clamping NN N
of IN N
the DT N
aorta NN N
a DT N
moderate JJ o
compensated VBN o
acidosis NN o
developed VBN N
in IN N
both DT N
groups NNS N
. . N

Declamping VBG N
caused VBD N
a DT N
more RBR N
marked JJ o
increase NN o
of IN o
paCO2 NN o
and CC N
a DT N
greater JJR o
fall NN o
of IN o
pH NN o
in IN N
the DT N
NA NNP N
group NN N
as IN N
compared VBN N
to TO N
the DT N
epidural JJ N
group NN N
. . N

Induction NN N
of IN N
anaesthesia NN N
was VBD N
followed VBN N
by IN N
a DT N
fall NN o
in IN o
oxygen NN o
uptake NN o
( ( N
NA NNP N
group NN N
from IN N
221 CD N
to TO N
163 CD N
ml NNS N
X JJ N
min-1 JJ N
; : N
epidural JJ N
group NN N
from IN N
230 CD N
to TO N
189 CD N
ml NNS N
X NNP N
min-1 NN N
) ) N
which WDT N
appears VBZ N
to TO N
be VB N
delayed VBN N
in IN N
the DT N
epidural JJ N
group NN N
, , N
with IN N
a DT N
short JJ N
lasting NN N
statistically RB N
significant JJ N
difference NN N
between IN N
the DT N
groups NNS N
after IN N
eventration NN N
of IN N
the DT N
gut NN N
( ( N
NA NNP N
group NN N
: : N
162 CD N
ml NN N
X NNP N
min-1 NN N
less JJR N
than IN N
epidural JJ N
group NN N
184 CD N
ml NN N
X NNP N
min-1 NN N
) ) N
. . N

Later RBR N
on IN N
, , N
oxygen FW o
uptake NN o
was VBD N
equal JJ N
in IN N
both DT N
groups NNS N
, , N
with IN N
no DT N
further JJ N
changes NNS N
due JJ N
to TO N
clamping VBG N
or CC N
declamping NN N
of IN N
the DT N
aorta NN N
. . N

At IN N
the DT N
end NN N
of IN N
the DT N
operation NN N
, , N
when WRB N
nitrous JJ N
oxide NN N
had VBD N
been VBN N
turned VBN N
of IN N
, , N
the DT N
oxygen NN o
uptake NN o
increased VBD N
considerably RB N
in IN N
several JJ N
patients NNS N
, , N
despite IN N
continuing VBG N
artificial JJ N
ventilation NN N
and CC N
intravenous JJ N
hypnotics NNS N
and CC N
analgesics NNS N
having VBG N
been VBN N
given VBN N
. . N

Eventration NN N
and CC N
exterioration NN N
of IN N
the DT N
gut NN N
caused VBD N
the DT N
most RBS N
marked JJ N
changes NNS N
in IN N
haemodynamics NNS N
and CC N
oxygen NN N
transport NN N
with IN N
significant JJ N
differences NNS N
between IN N
the DT N
groups NNS N
. . N

Immediately RB N
after IN N
eventration NN N
there EX N
was VBD N
a DT N
sudden JJ N
fall NN N
in IN N
paO2 NN N
in IN N
both DT N
groups NNS N
( ( N
NA NNP N
group NN N
from IN N
99 CD N
to TO N
83 CD N
mm NNS N
Hg NNP N
; : N
epidural JJ N
group NN N
from IN N
96 CD N
to TO N
84 CD N
mm NNS N
Hg NNP N
) ) N
and CC N
an DT N
increase NN N
of IN N
the DT N
calculated JJ N
intrapulmonary JJ N
right-to-left-shunt NN N
( ( N
NA NNP N
group NN N
from IN N
7 CD N
to TO N
21 CD N
% NN N
; : N
epidural JJ N
group NN N
from IN N
10 CD N
to TO N
19 CD N
% NN N
) ) N
. . N

( ( N
ABSTRACT NNP N
TRUNCATED NNP N
AT NNP N
400 CD N
WORDS NNP N
) ) N
-DOCSTART- -3531514- O O

Trial NN N
of IN N
( ( i
+ NNP i
) ) i
-cyanidanol-3 NN i
in IN N
patients NNS p
with IN p
hepatitis NN p
B NNP p
chronic NN p
liver NN p
disease NN p
. . p

A DT N
double-blind NN N
controlled VBN N
trial NN N
of IN N
12 CD i
months NNS i
' POS i
treatment NN i
with IN i
( ( i
+ NN i
) ) i
-cyanidanol-3 NN i
was VBD i
carried VBN i
out RP N
in IN N
26 CD p
patients NNS p
with IN p
chronic JJ p
hepatitis NN p
B NNP p
liver NN p
disease NN p
. . p

Treatment NN N
did VBD N
not RB N
improve VB N
liver RB o
blood NN o
tests NNS o
nor CC o
histological JJ o
appearances NNS o
of IN o
the DT o
liver NN o
, , N
but CC N
there RB N
was VBD N
a DT N
trend NN N
towards IN N
reduction NN N
of IN N
serum NN o
titres NNS o
of IN o
hepatitis NN o
B NNP o
surface NN o
antigen NN o
. . o

-DOCSTART- -8101194- O O

Comparison NNP N
of IN N
the DT N
effects NNS N
of IN N
terazosin NN i
and CC N
enalapril NN i
on IN N
laboratory NN N
stress NN N
testing VBG N
blood NN N
pressure NN N
in IN N
patients NNS p
with IN p
essential JJ p
hypertension NN p
. . p

It PRP N
is VBZ N
the DT N
current JJ N
opinion NN N
that IN N
an DT N
ideal JJ N
antihypertensive JJ i
drug NN i
should MD N
reduce VB N
blood NN N
pressure NN N
( ( N
BP NNP N
) ) N
not RB N
only RB N
at IN N
rest NN N
but CC N
also RB N
during IN N
stressful JJ N
situations NNS N
. . N

The DT N
current JJ N
study NN N
was VBD N
aimed VBN N
to TO N
compare VB N
the DT N
effects NNS N
of IN N
the DT N
selective JJ i
alpha NN i
1-adrenergic JJ i
blocker NN i
terazosin NN i
( ( N
5 CD N
mg NN N
once RB N
daily JJ N
) ) N
and CC N
of IN N
the DT N
angiotensin-converting JJ i
enzyme NN i
inhibitor NN i
enalapril NN i
( ( N
20 CD N
mg NN N
once RB N
daily RB N
) ) N
on IN N
cardiovascular JJ N
response NN N
to TO N
a DT N
set NN N
of IN N
standardized JJ N
laboratory NN N
stressors NNS N
, , N
such JJ N
as IN N
mental JJ N
arithmetic JJ N
, , N
handgrip JJ N
test NN N
and CC N
cycle NN N
ergometry NN N
, , N
in IN N
a DT N
group NN p
of IN p
16 CD p
essential JJ p
hypertensive JJ p
patients NNS p
. . p

The DT N
study NN N
was VBD N
a DT N
randomized JJ N
, , N
double-blind JJ N
, , N
cross-over JJ N
trial NN N
preceded VBN N
by IN N
a DT N
placebo JJ i
run-in JJ N
period NN N
. . N

Terazosin NNP i
and CC i
enalapril VB i
had VBD N
a DT N
comparable JJ N
effect NN N
on IN N
resting VBG o
BP NNP o
, , o
reducing VBG o
systolic JJ o
( ( o
SBP NNP o
) ) o
and CC o
diastolic JJ o
( ( o
DBP NNP o
) ) o
blood NN o
pressure NN o
from IN N
159.5 CD N
+/- JJ N
13.9/101.6 CD N
+/- JJ N
8.8 CD N
mm NN N
Hg NNP N
during IN N
placebo NN N
by IN N
7.8 CD N
% NN N
/6.7 CC N
% NN N
and CC N
by IN N
11.3 CD N
% NN N
/10.2 CD N
% NN N
, , N
respectively RB N
. . N

The DT N
response NN o
rate NN o
to TO N
the DT N
two CD N
treatments NNS N
was VBD N
approximately RB N
the DT N
same JJ N
, , N
being VBG N
69 CD N
% NN N
and CC N
75 CD N
% NN N
after IN N
terazosin NN i
and CC N
enalapril NN i
, , N
respectively RB N
. . N

During IN N
mental JJ N
arithmetic JJ N
, , N
from IN N
an DT N
average NN N
of IN N
181.6 CD N
+/- JJ N
17.8/118.6 CD N
+/- JJ N
11.5 CD N
mm NN N
Hg NNP N
during IN N
placebo NN i
, , N
BP NNP o
was VBD N
reduced VBN N
by IN N
11.5 CD N
% NN N
/7.9 CD N
% NN N
after IN N
terazosin NN i
and CC N
by IN N
13.6 CD N
% NN N
/8.5 CD N
% NN N
after IN N
enalapril NN i
; : i
during IN N
handgrip NN N
test NN N
, , N
BP NNP o
decreased VBD N
from IN N
207.2 CD N
+/- JJ N
22.2/142.2 CD N
+/- JJ N
13.6 CD N
mm NN N
Hg NNP N
by IN N
7.3 CD N
% NN N
/8.4 CD N
% NN N
after IN N
terazosin NN i
and CC N
by IN N
7.7 CD N
% NN N
/7.1 CD N
% NN N
after IN N
enalapril NN i
; : i
finally RB N
, , N
during IN N
cycle NN N
ergometry NN N
, , N
terazosin NN N
and CC N
enalapril NN N
lowered VBN N
BP NNP o
by IN N
5.4 CD N
% NN N
/6.7 CC N
% NN N
and CC N
7 CD N
% NN N
/3.1 CD N
% NN N
, , N
respectively RB N
, , N
from IN N
a DT N
placebo NN i
value NN N
of IN N
215.5 CD N
+/- JJ N
17.3/127.6 CD N
+/- JJ N
11.2 CD N
. . N

No DT N
significant JJ N
difference NN N
in IN N
antihypertensive JJ N
efficacy NN N
was VBD N
observed VBN N
between IN N
the DT N
two CD N
drugs NNS N
, , N
either RB N
at IN N
rest NN N
and CC N
during IN N
stress JJ N
testing VBG N
. . N

( ( N
ABSTRACT NNP N
TRUNCATED NNP N
AT NNP N
250 CD N
WORDS NNP N
) ) N
-DOCSTART- -19415341- O O

Pilot NNP N
study NN N
of IN N
Panax NNP i
quinquefolius NN i
( ( i
American NNP i
ginseng NN i
) ) i
to TO N
improve VB N
cancer-related JJ p
fatigue NN p
: : p
a DT N
randomized JJ N
, , N
double-blind JJ N
, , N
dose-finding JJ N
evaluation NN N
: : N
NCCTG NNP N
trial NN N
N03CA NNP N
. . N

PURPOSE NNP N
This DT N
pilot NN N
trial NN N
sought VBD N
to TO N
investigate VB N
whether IN N
any DT N
of IN N
three CD N
doses NNS N
of IN N
American JJ i
ginseng NN i
( ( i
Panax NNP i
quinquefolius RB i
) ) i
might MD N
help VB N
cancer-related JJ p
fatigue NN p
. . p

A DT N
secondary JJ N
aim NN N
was VBD N
to TO N
evaluate VB N
toxicity NN N
. . N

METHODS NNP N
Eligible JJ p
adults NNS p
with IN p
cancer NN p
were VBD N
randomized VBN N
in IN N
a DT N
double-blind JJ N
manner NN N
, , N
to TO N
receive VB N
American JJ i
ginseng NN i
in IN N
doses NNS N
of IN N
750 CD N
, , N
1,000 CD N
, , N
or CC N
2,000 CD N
mg/day NN N
or CC N
placebo VB i
given VBN N
in IN N
twice JJ N
daily JJ N
dosing NN N
over IN N
8 CD N
weeks NNS N
. . N

Outcome NNP N
measures NNS N
included VBD N
the DT N
Brief NNP o
Fatigue NNP o
Inventory NNP o
, , o
vitality NN o
subscale NN o
of IN o
the DT o
Medical NNP o
Outcome NNP o
Scale NNP o
Short NNP o
Form-36 NNP o
( ( o
SF-36 NNP o
) ) o
, , o
and CC o
the DT o
Global NNP o
Impression NNP o
of IN o
Benefit NNP o
Scale NNP o
at IN N
4 CD N
and CC N
8 CD N
weeks NNS N
. . N

RESULTS NNP N
Two CD p
hundred VBD p
ninety NN p
patients NNS p
were VBD p
accrued VBN p
to TO p
this DT p
trial NN p
. . p

Nonsignificant JJ N
trends NNS N
for IN N
all DT N
outcomes NNS N
were VBD N
seen VBN N
in IN N
favor NN N
of IN N
the DT N
1,000- JJ N
and CC N
2,000-mg/day JJ N
doses NNS N
of IN N
American JJ i
ginseng NN i
. . i

Area NNP N
under IN N
the DT N
curve NN N
analysis NN N
of IN N
activity NN o
interference NN o
from IN o
the DT o
Brief NNP o
Fatigue NNP o
Inventory NNP o
was VBD N
460-467 JJ N
in IN N
the DT N
placebo NN i
group NN N
and CC N
750 CD N
mg/day NN N
group NN N
versus VBD N
480-551 CD N
in IN N
the DT N
1,000- JJ N
and CC N
2,000-mg/day JJ N
arms NNS N
, , N
respectively RB N
. . N

Change NN N
from IN N
baseline NN N
in IN N
the DT N
vitality NN o
subscale NN o
of IN N
the DT N
SF-36 NNP N
was VBD N
7.3-7.8 JJ N
in IN N
the DT N
placebo NN i
and CC N
the DT N
750-mg/day JJ N
arm NN N
, , N
versus NN N
10.5-14.6 JJ N
in IN N
the DT N
1,000- JJ N
and CC N
2,000-mg/day JJ N
arms NNS N
. . N

Over NNP N
twice RB N
as RB N
many JJ N
patients NNS N
on IN N
ginseng NN i
perceived VBD N
a DT N
benefit NN N
and CC N
were VBD N
satisfied VBN o
with IN N
treatment NN N
over IN N
those DT N
on IN N
placebo NN i
. . i

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
any DT N
measured JJ N
toxicities NNS o
between IN N
any DT N
of IN N
the DT N
arms NNS N
. . N

CONCLUSION NN N
There EX N
appears VBZ N
to TO N
be VB N
some DT N
activity NN N
and CC N
tolerable JJ N
toxicity NN N
at IN N
1,000-2,000 CD N
mg/day JJ N
doses NNS N
of IN N
American JJ i
ginseng NN i
with IN N
regard NN N
to TO N
cancer-related JJ p
fatigue NN p
. . p

Thus NNP N
, , N
further JJ N
study NN N
of IN N
American NNP i
ginseng NN i
is VBZ N
warranted VBN N
. . N

-DOCSTART- -12663340- O O

Dose-response JJ N
characteristics NNS N
during IN N
long-term JJ N
inhalation NN N
of IN N
nitric JJ i
oxide NN i
in IN N
patients NNS p
with IN p
severe JJ p
acute JJ p
respiratory NN p
distress JJ p
syndrome NN p
: : p
a DT N
prospective JJ N
, , N
randomized VBN N
, , N
controlled VBN N
study NN N
. . N

Inhaled VBN N
nitric JJ i
oxide NN i
( ( i
NO NNP i
) ) i
improves VBZ N
systemic JJ N
oxygenation NN N
( ( N
PaO2/FIO2 NNP N
) ) N
in IN N
adult NN p
patients NNS p
with IN p
acute JJ p
respiratory NN p
distress NN p
syndrome NN p
( ( p
ARDS NNP p
) ) p
. . p

However RB N
, , N
individual JJ N
response NN N
varies NNS N
, , N
and CC N
previous JJ N
trials NNS N
demonstrated VBD N
no DT N
outcome NN N
benefit NN N
. . N

This DT N
prospective JJ N
, , N
randomized VBN N
study NN N
in IN N
40 CD p
ARDS NNP p
patients NNS p
analyzed VBD N
dose-response JJ o
( ( o
DR NNP o
) ) o
characteristics NNS o
during IN N
long-term JJ N
inhaled JJ N
NO NNP i
. . i

Patients NNS p
were VBD p
randomized VBN i
for IN i
conventional JJ i
therapy NN i
( ( i
control NN i
) ) i
or CC i
continuous JJ i
treatment NN i
with IN i
10 CD i
parts NNS i
per IN i
million CD i
( ( i
ppm NN i
) ) i
inhaled VBD i
NO NNP i
until IN i
weaning VBG i
was VBD i
initiated VBN i
. . i

We PRP N
measured VBD N
DR NNP o
curves NNS o
of IN o
PaO2/FIO2 NNP o
versus IN o
the DT o
inhaled JJ o
NO NNP o
dose NN o
at IN N
regular JJ N
intervals NNS N
. . N

Before IN N
treatment NN N
( ( N
Day NNP N
0 CD N
) ) N
, , N
peak JJ N
improvement NN N
in IN N
PaO2/FIO2 NNP o
was VBD N
achieved VBN N
at IN N
10 CD N
ppm NN N
for IN N
both DT N
control NN N
and CC N
NO-treated JJ i
patients NNS N
. . N

After IN N
4 CD N
days NNS N
, , N
the DT N
DR NNP o
curve NN o
of IN o
the DT o
NO-treated JJ o
patients NNS o
was VBD N
left VBN N
shifted VBN N
with IN N
a DT N
peak JJ N
response NN N
at IN N
1 CD N
ppm NN N
. . N

At IN N
higher JJR N
doses NNS N
( ( N
10 CD N
and CC N
100 CD N
ppm NN N
) ) N
, , N
oxygenation NN o
deteriorated VBD o
, , N
and CC N
the DT N
response NN N
to TO N
inhaled VB N
NO RB N
disappeared VBN N
in IN N
several JJ N
patients NNS N
. . N

This DT N
effect NN N
was VBD N
not RB N
observed VBN N
in IN N
the DT N
control NN N
group NN N
. . N

There EX N
was VBD N
no DT N
effect NN N
of IN N
inhaled JJ N
NO NNP N
on IN N
duration NN N
of IN N
mechanical JJ o
ventilation NN o
or CC o
stay VB o
at IN o
the DT o
intensive JJ o
care NN o
unit NN o
. . o

In IN N
conclusion NN N
, , N
long-term JJ N
inhaled VBD N
NO NNP N
with IN N
constant JJ N
doses NNS N
of IN N
10 CD N
ppm NNS N
leads VBZ N
to TO N
enhanced VB N
sensitivity NN N
after IN N
several JJ N
days NNS N
and CC N
does VBZ N
do VB N
not RB N
allow VB N
reduction NN N
of IN N
ventilation NN N
parameters NNS N
. . N

Hence NNP N
, , N
previous JJ N
trials NNS N
on IN N
therapy NN N
with IN N
inhaled JJ N
NO NNP N
in IN N
ARDS NNP N
should MD N
be VB N
carefully RB N
interpreted VBN N
, , N
as IN N
they PRP N
used VBD N
constant JJ N
NO NNP N
concentrations NNS N
, , N
which WDT N
may MD N
have VB N
become VBN N
overdoses NNS N
leading VBG N
to TO N
deterioration NN N
of IN N
oxygenation NN o
after IN N
several JJ N
days NNS N
. . N

-DOCSTART- -10758987- O O

American NNP N
College NNP N
of IN N
Cardiology/European NNP N
Society NNP N
of IN N
Cardiology NNP N
International NNP N
Study NNP N
of IN N
Angiographic NNP N
Data NNP N
Compression NNP N
Phase NNP N
I PRP N
: : N
The DT N
effect NN N
of IN N
lossy JJ N
data NNS i
compression NN i
on IN N
recognition NN N
of IN N
diagnostic JJ N
features NNS N
in IN N
digital JJ i
coronary JJ i
angiography NN i
. . i

OBJECTIVES CC N
This DT N
study NN N
intended VBD N
to TO N
determine VB N
the DT N
effect NN N
of IN N
varying VBG N
degrees NNS N
of IN N
lossy JJ i
Joint NNP i
Photographic NNP o
Experts NNP i
Group NNP i
( ( i
JPEG NNP i
) ) i
compression NN i
on IN N
detection NN o
of IN o
coronary JJ o
angiographic JJ o
features NNS o
. . o

BACKGROUND NNP N
Compression NNP N
of IN N
digital JJ N
coronary JJ N
angiograms NNS N
facilitates VBZ N
playback NN N
of IN N
images NNS N
and CC N
decreases VBZ N
cost NN N
. . N

There EX N
are VBP N
little JJ N
data NNS N
on IN N
the DT N
effect NN N
of IN N
compression NN N
on IN N
the DT N
accuracy NN N
of IN N
coronary JJ N
angiography NN N
. . N

METHODS NNP N
At IN p
six CD p
centers NNS p
, , p
71 CD p
angiographers NNS p
each DT p
reviewed VBD p
a DT p
set NN p
of IN p
100 CD p
angiographic JJ p
sequences NNS p
. . p

The DT p
100 CD p
sequences NNS p
were VBD p
divided VBN p
into IN p
four CD p
, , p
25-sequence JJ p
subsets NNS p
. . p

Each DT N
subset NN N
of IN N
25 CD N
was VBD N
displayed VBN N
either CC N
as IN N
original JJ N
images NNS N
or CC N
at IN N
one CD N
of IN N
three CD N
compression NN N
ratios NNS N
( ( N
CRs NNP N
) ) N
( ( N
6:1 CD N
, , N
10:1 CD N
or CC N
16:1 CD N
) ) N
. . N

The DT N
effect NN o
of IN o
lossy JJ o
compression NN o
on IN o
the DT o
sensitivity NN o
and CC o
specificity NN o
for IN o
detection NN o
of IN o
diagnostic JJ o
features NNS o
was VBD N
determined VBN N
. . N

The DT N
effect NN o
of IN o
compression NN o
on IN o
subjective JJ o
measures NNS o
of IN o
image NN o
quality NN o
graded VBN o
by IN o
the DT o
angiographers NNS o
was VBD N
also RB N
examined VBN N
. . N

RESULTS NNP N
Lossy NNP o
compression NN o
at IN N
a DT N
ratio NN N
of IN N
16:1 CD N
decreased VBD N
the DT N
sensitivity NN N
for IN N
the DT N
detection NN N
of IN N
diagnostic JJ N
features NNS N
( ( N
76 CD N
% NN N
vs. FW N
80 CD N
% NN N
p NN N
= NNP N
0.004 CD N
) ) N
. . N

The DT N
largest JJS N
effect NN N
was VBD N
in IN N
the DT N
detection NN o
of IN o
calcification NN o
( ( N
52 CD N
% NN N
vs. FW N
63 CD N
% NN N
at IN N
16:1 CD N
compression NN N
vs. FW N
original JJ N
images NNS N
, , N
p VBP N
< RB N
0.001 CD N
) ) N
. . N

Subjective JJ N
indicators NNS N
of IN N
image NN N
quality NN N
indicated VBD N
a DT N
reduction NN N
in IN N
confidence NN o
in IN o
interpretation NN o
at IN N
CRs NNP N
of IN N
10:1 CD N
and CC N
16:1 CD N
. . N

CONCLUSIONS NN N
With IN N
increased JJ N
ratios NNS N
of IN N
lossy JJ N
compression NN N
, , N
a DT N
degradation NN N
of IN N
digital JJ N
coronary JJ N
angiograms NNS N
occurs VBZ N
that IN N
results NNS N
in IN N
decreased JJ o
diagnostic JJ o
accuracy NN o
. . o

The DT o
sensitivity NN o
for IN o
detection NN o
of IN o
common JJ o
diagnostic JJ o
features NNS o
was VBD N
decreased VBN N
, , N
and CC N
subjective JJ N
assessment NN N
of IN N
image NN N
quality NN N
was VBD N
impaired VBN N
. . N

Caution NN N
is VBZ N
warranted VBN N
in IN N
the DT N
interpretation NN N
of IN N
coronary JJ i
angiograms NNS i
that WDT N
have VBP N
been VBN N
subjected VBN N
to TO N
lossy VB N
JPEG NNP i
compression NN i
beyond IN N
a DT N
ratio NN N
of IN N
6:1 CD N
. . N

-DOCSTART- -3885290- O O

Neuroleptic-related JJ i
dyskinesias NN i
in IN N
autistic JJ p
children NNS p
: : p
a DT N
prospective JJ N
study NN N
. . N

-DOCSTART- -18632218- O O

Which JJ N
socio-demographic JJ i
factors NNS i
are VBP N
associated VBN N
with IN N
participation NN i
in IN i
oral JJ i
cancer NN i
screening NN i
in IN p
the DT p
developing NN p
world NN p
? . N
Results NNS N
from IN N
a DT N
population-based JJ i
screening NN i
project NN p
in IN p
India NNP p
. . p

BACKGROUND NNP N
This DT N
study NN N
examines VBZ N
socio-demographic JJ N
determinants NNS N
of IN N
participation NN N
in IN N
a DT N
population-based JJ N
randomized NN N
controlled VBD N
trial NN N
that IN N
proved VBD N
that IN N
oral JJ i
visual JJ i
inspection NN i
was VBD N
effective JJ N
in IN N
reducing VBG N
oral JJ o
cancer NN o
mortality NN o
in IN p
high-risk JJ p
individuals NNS p
in IN p
India NNP p
. . p

METHODS NNP N
Multivariate NNP N
logistic JJ N
regression NN N
was VBD N
used VBN N
to TO N
establish VB N
socio-demographic JJ N
characteristics NNS N
of IN N
participants NNS N
versus IN N
non-participants NNS N
in IN N
the DT N
intervention NN i
arm NN N
. . N

Compliance NN o
with IN o
referral NN o
was VBD N
analysed VBN N
according VBG N
to TO N
the DT N
socio-demographic JJ N
characteristics NNS N
of IN N
screen-positives NNS N
. . N

RESULTS NNP N
Of IN N
96,517 CD p
eligible JJ p
subjects NNS p
, , p
87,655 CD p
were VBD p
screened VBN i
, , p
8688 CD p
individuals NNS p
never RB p
received VBD p
the DT p
invitation NN p
and CC p
174 CD p
refused VBD p
screening NN i
. . i

Compared VBN N
to TO N
the DT N
non-screened JJ N
, , N
a DT N
higher JJR N
proportion NN N
of IN N
screened JJ o
individuals NNS N
were VBD N
women NNS N
( ( N
OR=4.51 NNP N
; : N
CI NNP N
: : N
4.28-4.75 JJ N
) ) N
, , N
lived VBD N
in IN N
better RBR N
housing NN N
( ( N
OR=1.35 NNP N
; : N
CI NNP N
: : N
1.25-1.41 JJ N
) ) N
, , N
had VBD N
television/radio NN N
( ( N
OR=1.50 NNP N
; : N
CI NNP N
: : N
1.43-1.58 JJ N
) ) N
and CC N
were VBD N
tobacco NN N
and CC N
alcohol NN N
users NNS N
( ( N
OR=2.75 NNP N
; : N
CI NNP N
: : N
2.57-2.95 JJ N
) ) N
. . N

Being VBG N
65 CD N
and CC N
older JJR N
decreased VBD N
the DT N
chances NNS o
of IN o
screening NN o
( ( N
OR=0.39 NNP N
; : N
CI NNP N
: : N
0.37-0.42 NN N
) ) N
, , N
as RB N
well RB N
as IN N
living NN o
in IN o
high-size JJ o
households NNS o
( ( N
OR=0.73 NNP N
; : N
CI NNP N
: : N
0.68-0.78 NN N
) ) N
. . N

Sixty-three JJ N
percent NN N
of IN N
5143 CD p
screen-positives NNS p
complied VBN N
with IN N
referral JJ o
. . o

Controlling VBG N
for IN N
all DT N
other JJ N
factors NNS N
, , N
individuals NNS N
older JJR N
than IN N
44 CD N
, , N
and CC N
those DT N
with IN N
more RBR N
advanced JJ N
lesions NNS N
were VBD N
more RBR N
likely JJ N
to TO N
comply VB N
with IN N
referral JJ o
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
. . N

Individuals NNS N
living VBG N
in IN N
better JJR N
housing NN N
were VBD N
less RBR N
likely JJ N
to TO N
comply VB o
with IN o
referral JJ o
( ( N
OR=0.79 NNP N
; : N
CI NNP N
: : N
0.65-0.95 NN N
) ) N
. . N

CONCLUSIONS NNP N
In IN N
summary JJ N
, , N
adequate JJ N
coverage NN N
can MD N
be VB N
obtained VBN N
in IN N
population-based JJ i
oral JJ i
screening NN i
in IN N
developing VBG N
countries NNS N
. . N

The DT N
study NN N
underscores VBZ N
the DT N
important JJ N
role NN N
of IN N
patient-provider JJ i
communication NN i
in IN N
assuring VBG N
high JJ N
compliance NN N
with IN N
referral JJ N
. . N

-DOCSTART- -7708953- O O

The DT N
influence NN N
of IN N
breast NN N
size NN N
on IN N
late JJ N
radiation NN N
effects NNS N
and CC N
association NN N
with IN N
radiotherapy NN N
dose JJ N
inhomogeneity NN N
. . N

A DT N
prospective JJ N
assessment NN N
of IN N
late JJ N
changes NNS N
in IN N
breast NN N
appearance NN N
in IN N
559 CD p
patients NNS p
after IN p
tumour JJ i
excision NN i
and CC i
radiotherapy NN i
for IN p
early JJ p
breast NN p
cancer NN p
noted VBD N
a DT N
strong JJ N
association NN N
with IN N
breast NN N
size NN N
. . N

Only RB N
3/48 CD N
( ( N
6 CD N
% NN N
) ) N
patients NNS N
with IN N
small JJ N
breasts NNS N
developed VBD N
moderate JJ N
or CC N
severe JJ N
late JJ N
changes NNS N
compared VBN N
with IN N
94/423 CD N
( ( N
22 CD N
% NN N
) ) N
with IN N
medium NN N
sized VBN N
breasts NNS N
and CC N
34/88 CD N
( ( N
39 CD N
% NN N
) ) N
patients NNS N
with IN N
large JJ N
breasts NNS N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
. . N

One CD N
possibility NN N
is VBZ N
that IN N
greater JJR N
radiation NN N
changes NNS N
are VBP N
related VBN N
to TO N
greater JJR N
dose JJ N
inhomogeneity NN N
in IN N
women NNS N
with IN N
large JJ N
breasts NNS N
. . N

To TO N
explore VB N
this DT N
hypothesis NN N
, , N
radiation NN N
dose JJ N
distributions NNS N
were VBD N
assessed VBN N
in IN N
a DT N
separate JJ N
group NN N
of IN N
37 CD N
women NNS N
in IN N
whom WP N
three-level JJ N
transverse NN N
computer NN N
tomographic JJ N
images NNS N
of IN N
the DT N
breast NN N
in IN N
the DT N
treatment NN N
position NN N
were VBD N
available JJ N
. . N

A DT N
significant JJ N
correlation NN N
was VBD N
found VBN N
between IN N
breast NN N
size NN N
and CC N
dose NN N
inhomogeneity NN N
which WDT N
may MD N
account VB N
for IN N
the DT N
marked JJ N
changes NNS N
in IN N
breast NN N
appearance NN N
reported VBD N
in IN N
women NNS N
with IN N
large JJ N
breasts NNS N
. . N

-DOCSTART- -22434360- O O

Pemetrexed NNP i
in IN i
combination NN i
with IN i
cisplatin JJ i
versus NN i
cisplatin NN i
monotherapy NN i
in IN N
patients NNS p
with IN p
recurrent NN p
or CC p
metastatic JJ p
head NN p
and CC p
neck NN p
cancer NN p
: : p
final JJ N
results NNS N
of IN N
a DT N
randomized JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ i
, , N
phase VB N
3 CD N
study NN N
. . N

BACKGROUND NNP N
Recurrent NNP p
or CC p
metastatic JJ p
squamous JJ p
cell NN p
carcinoma NN p
of IN p
the DT p
head NN p
and CC p
neck NN p
( ( p
SCCHN NNP p
) ) p
is VBZ N
associated VBN N
with IN N
poor JJ N
survival NN N
. . N

Platinum-based JJ i
chemotherapy NN i
is VBZ N
often RB N
a DT N
first-line JJ N
treatment NN N
. . N

Pemetrexed NNP i
has VBZ N
shown VBN N
single-agent JJ N
activity NN N
in IN N
SCCHN NNP N
and CC N
in IN N
combination NN N
with IN N
cisplatin NN N
for IN N
other JJ N
tumors NNS N
. . N

This DT N
trial NN N
examined VBD N
the DT N
efficacy NN N
of IN N
pemetrexed-cisplatin NN i
for IN N
SCCHN NNP N
. . N

METHODS NNP N
In IN N
a DT N
double-blind JJ N
phase NN N
3 CD N
trial NN N
, , N
patients NNS p
with IN p
recurrent NN p
or CC p
metastatic JJ p
SCCHN NNP p
and CC p
no DT p
prior JJ p
systemic JJ p
therapy NN p
for IN p
metastatic JJ p
disease NN p
were VBD p
randomized VBN p
to TO p
pemetrexed VB i
( ( p
500 CD p
mg/m NN p
( ( p
2 CD p
) ) p
) ) p
plus CC i
cisplatin NN i
( ( p
75 CD p
mg/m NN p
( ( p
2 CD p
) ) p
; : p
n CC p
= VB p
398 CD p
) ) p
or CC p
placebo JJ i
plus CC i
cisplatin NN i
( ( p
75 CD p
mg/m NN p
( ( p
2 CD p
) ) p
; : p
n CC p
= VB p
397 CD p
) ) p
to TO N
assess VB N
overall JJ o
survival NN o
( ( o
OS NNP o
) ) o
and CC N
secondary JJ N
endpoints NNS N
. . N

RESULTS NNP N
Median JJ o
OS NNP o
was VBD N
7.3 CD N
months NNS N
in IN N
the DT N
pemetrexed-cisplatin JJ i
arm NN N
and CC N
6.3 CD N
months NNS N
in IN N
the DT N
placebo-cisplatin JJ i
arm NN N
( ( N
hazard JJ N
ratio NN N
[ NNP N
HR NNP N
] NNP N
, , N
0.87 CD N
; : N
95 CD N
% NN N
confidence NN N
interval NN N
[ NNP N
CI NNP N
] NNP N
, , N
0.75-1.02 NNP N
; : N
P NNP N
= NNP N
.082 NNP N
) ) N
. . N

Median JJ o
progression-free JJ o
survival NN o
( ( o
PFS NNP o
, , o
months NNS o
) ) o
was VBD N
similar JJ N
in IN N
both DT N
treatment NN N
arms NNS N
( ( i
pemetrexed-cisplatin NN i
, , N
3.6 CD N
; : N
placebo-cisplatin NN i
, , N
2.8 CD N
; : N
HR NNP N
, , N
0.88 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
0.76-1.03 NNP N
; : N
P NNP N
= NNP N
.166 NNP N
) ) N
. . N

Among IN N
patients NNS N
with IN N
performance NN N
status NN N
0 CD N
or CC N
1 CD N
, , N
pemetrexed-cisplatin NN i
( ( N
n JJ N
= NNP N
347 CD N
) ) N
led VBD N
to TO N
longer JJR o
OS NNP o
and CC o
PFS NNP o
than IN N
placebo-cisplatin NN i
( ( N
n JJ N
= VBZ N
343 CD N
; : N
8.4 CD N
vs IN N
6.7 CD N
months NNS N
; : N
HR NNP N
, , N
0.83 CD N
; : N
P NNP N
= NNP N
.026 NNP N
; : N
4.0 CD N
vs IN N
3.0 CD N
months NNS N
; : N
HR NNP N
, , N
0.84 CD N
; : N
P NNP N
= NNP N
.044 NNP N
, , N
respectively RB N
) ) N
. . N

Among IN N
patients NNS p
with IN p
oropharyngeal JJ p
cancers NNS p
, , N
pemetrexed-cisplatin NN i
( ( N
n JJ N
= NNP N
86 CD N
) ) N
resulted VBD N
in IN N
longer JJR N
OS NNP o
and CC o
PFS NNP o
than IN N
placebo-cisplatin NN i
( ( N
n JJ N
= VBZ N
106 CD N
; : N
9.9 CD N
vs IN N
6.1 CD N
months NNS N
; : N
HR NNP N
, , N
0.59 CD N
; : N
P NNP N
= NNP N
.002 NNP N
; : N
4.0 CD N
vs IN N
3.4 CD N
months NNS N
; : N
HR NNP N
, , N
0.73 CD N
; : N
P NNP N
= NNP N
.047 NNP N
, , N
respectively RB N
) ) N
. . N

Pemetrexed-cisplatin JJ o
toxicity NN o
was VBD N
consistent JJ N
with IN N
studies NNS N
in IN N
other JJ N
tumors NNS N
. . N

CONCLUSIONS NNP N
Pemetrexed-cisplatin NNP i
compared VBN N
with IN N
placebo-cisplatin NN N
did VBD N
not RB N
significantly RB N
improve VB N
survival NN o
for IN N
the DT N
intent-to-treat JJ N
population NN N
. . N

However RB N
, , N
in IN N
a DT N
prespecified JJ N
subgroup NN N
analysis NN N
, , N
pemetrexed-cisplatin NN i
showed VBD N
OS NNP o
and CC o
PFS NNP o
advantage NN o
for IN N
patients NNS N
with IN N
performance NN N
status NN N
0 CD N
or CC N
1 CD N
or CC N
oropharyngeal JJ N
cancers NNS N
. . N

-DOCSTART- -17984242- O O

Effects NNS N
of IN N
resistance NN i
versus NN i
endurance NN i
training NN i
on IN N
serum NN o
adiponectin NN o
and CC o
insulin NN o
resistance NN o
index NN o
. . o

PURPOSE VB N
The DT N
purpose NN N
of IN N
the DT N
present JJ N
study NN N
was VBD N
to TO N
investigate VB N
the DT N
effects NNS N
of IN N
resistance NN i
and CC i
endurance NN i
training NN i
on IN N
serum NN o
adiponectin NN o
and CC o
insulin NN o
resistance NN o
index NN o
( ( o
SI NNP o
) ) o
in IN N
healthy JJ p
men NNS p
. . p

METHODS NNP N
Twenty-four CD p
healthy JJ p
males NNS p
( ( p
age NN p
, , p
35-48 CD p
years NNS p
) ) p
participated VBD p
in IN p
the DT p
study NN p
. . p

The DT N
subjects NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
one CD N
of IN N
three CD N
groups NNS N
: : N
endurance NN i
training NN i
group NN i
( ( i
n=8 NN i
) ) i
, , i
resistance NN i
training NN i
group NN i
( ( i
n=8 CC i
) ) i
and CC i
control NN i
group NN i
( ( i
n=8 RB i
) ) i
. . i

Blood NN o
samples NNS o
were VBD i
taken VBN i
in IN i
fasting VBG i
state NN i
from IN i
all DT i
subjects NNS i
. . i

The DT i
experimental JJ i
groups NNS i
performed VBD i
either CC i
endurance NN i
or CC i
resistance NN i
training NN i
3 CD i
days NNS i
a DT i
week NN i
for IN i
12 CD i
weeks NNS i
. . i

The DT i
endurance NN i
training NN i
programme NN i
included VBD i
continuous JJ i
running VBG i
at IN i
an DT i
intensity NN i
corresponding VBG i
to TO i
75-85 CD i
% NN i
of IN i
maximal JJ i
heart NN i
rate NN i
, , i
while IN i
resistance NN i
training NN i
consisted VBD i
of IN i
four CD i
sets NNS i
of IN i
circuit NN i
weight NN i
training NN i
for IN i
11 CD i
stations NNS i
and CC i
at IN i
an DT i
intensity NN i
corresponding VBG i
to TO i
50-60 CD i
% NN i
of IN i
one-repetition JJ i
maximum NN i
. . i

The DT N
maximum JJ N
numbers NNS N
of IN N
repetitions NNS N
in IN N
each DT N
station NN N
was VBD N
12 CD N
. . N

RESULTS VB N
There EX N
were VBD N
significant JJ N
negative JJ N
correlations NNS N
between IN N
serum NN o
adiponectin NN o
and CC o
body NN o
fat JJ o
percentage NN o
, , o
waist-to-hip JJ o
ratio NN o
, , o
body NN o
mass NN o
index NN o
and CC o
the DT o
insulin NN o
resistance NN o
index NN o
at IN o
baseline NN o
, , N
whereas JJ N
changes NNS N
in IN N
response NN N
to TO N
training NN N
were VBD N
not RB N
significantly RB N
correlated VBN N
. . N

Both DT N
endurance NN N
and CC N
resistance NN N
training NN N
resulted VBD N
in IN N
a DT N
significant JJ N
decrease NN N
in IN N
the DT N
SI NNP o
in IN N
comparison NN N
with IN N
the DT N
control NN N
group NN N
. . N

However RB N
, , N
serum JJ o
adiponectin NN o
did VBD N
not RB N
change VB N
significantly RB N
in IN N
response NN N
to TO N
resistance NN N
and CC N
endurance NN N
training NN N
. . N

CONCLUSION NNP N
Endurance NNP N
and CC N
resistance NN N
training NN N
caused VBD N
an DT N
improvement NN N
in IN N
insulin NN N
resistance NN N
in IN N
healthy JJ p
men NNS p
, , N
but CC N
this DT N
improvement NN N
was VBD N
not RB N
accompanied VBN N
by IN N
increased JJ N
adiponectin NN N
levels NNS N
. . N

-DOCSTART- -16704894- O O

A DT N
randomised JJ N
trial NN N
comparing VBG N
holmium NN i
laser NN i
enucleation NN i
versus IN N
transurethral JJ i
resection NN i
in IN N
the DT N
treatment NN p
of IN p
prostates NNS p
larger JJR p
than IN p
40 CD p
grams NNS p
: : p
results NNS N
at IN N
2 CD N
years NNS N
. . N

OBJECTIVE NN N
To TO N
compare VB N
holmium NN i
laser JJR i
enucleation NN i
of IN i
the DT i
prostate NN i
( ( i
HoLEP NNP i
) ) i
with IN N
transurethral JJ i
resection NN i
of IN i
the DT i
prostate NN i
( ( i
TURP NNP i
) ) i
for IN N
treatment NN N
of IN N
men NNS p
with IN p
bladder NN p
outflow JJ p
obstruction NN p
( ( p
BOO NNP p
) ) p
secondary VBP p
to TO p
benign VB p
prostatic JJ p
hyperplasia NN p
with IN p
a DT p
minimum NN p
of IN p
24-month JJ p
follow-up JJ p
. . p

PATIENTS NNPS N
AND CC N
METHODS NNP N
Sixty-one CD p
patients NNS p
were VBD N
randomised VBN N
to TO N
either DT N
HoLEP NNP i
or CC N
TURP NNP i
. . i

All DT p
patients NNS p
had VBD p
BOO NNP p
proven RB p
on IN p
urodynamic JJ p
studies NNS p
pre-operatively RB p
( ( p
prostate JJ p
size NN p
40-200 JJ p
g NN p
) ) p
. . p

One CD N
patient NN N
died VBD N
before IN N
treatment NN N
, , N
which WDT N
left VBD N
30 CD p
patients NNS p
in IN p
each DT p
group NN p
. . p

Perioperative NNP o
data NN o
, , o
as RB o
well RB o
as IN o
symptom NN o
scores NNS o
, , o
Quality NNP o
of IN o
Life NNP o
( ( o
QoL NNP o
) ) o
scores VBZ o
, , o
and CC o
maximum JJ o
urinary JJ o
flow NN o
rates NNS o
( ( o
Qmax NNP o
) ) o
were VBD N
obtained VBN N
at IN N
one CD N
, , N
three CD N
, , N
six,12 NN N
, , N
and CC N
24 CD N
months NNS N
. . N

Post-void JJ o
residual JJ o
volumes NNS o
, , o
transrectal JJ o
ultrasound NN o
( ( o
TRUS NNP o
) ) o
volumes NNS o
, , o
and CC o
pressure NN o
flow NN o
studies NNS o
were VBD N
obtained VBN N
six CD N
months NNS N
post-operatively RB N
. . N

Continence NN o
and CC o
potency NN o
data NNS o
were VBD N
also RB N
recorded VBN N
. . N

RESULTS VB N
There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
between IN N
the DT N
two CD N
surgical JJ N
groups NNS N
pre-operatively RB N
. . N

Mean JJ o
pre-operative JJ o
TRUS NNP o
volume NN o
was VBD N
77.8+/-5.6 JJ N
g NN N
( ( N
42-152 JJ N
) ) N
in IN N
the DT N
HoLEP NNP N
group NN N
and CC N
70.0+/-5.0 JJ N
g NN N
( ( N
46-156 JJ N
) ) N
in IN N
the DT N
TURP NNP i
group NN N
. . N

Patients NNS N
in IN N
the DT N
HoLEP NNP i
group NN N
had VBD N
shorter JJR N
catheter NN o
times NNS o
and CC N
hospital NN o
stays NNS o
. . o

More JJR N
prostate JJ o
tissue NN o
was VBD N
retrieved VBN N
in IN N
the DT N
HoLEP NNP i
group NN N
. . N

At IN N
six CD N
months NNS N
, , N
HoLEP NNP i
was VBD N
urodynamically RB o
superior JJ N
to TO N
TURP NNP i
in IN N
relieving VBG N
BOO NNP N
. . N

At IN N
24 CD N
months NNS N
, , N
there EX N
was VBD N
no DT N
significant JJ N
difference NN N
between IN N
the DT N
two CD N
surgical JJ N
groups NNS N
with IN N
respect NN N
to TO N
American NNP o
Urology NNP o
Association NNP o
scores NNS o
, , o
QoL NNP o
scores VBZ o
, , o
or CC o
Qmax NNP o
values NNS o
; : o
however RB N
, , N
two CD N
patients NNS N
in IN N
the DT N
TURP NNP N
group NN N
required VBD N
re-operation NN N
. . N

CONCLUSIONS NNP N
HoLEP NNP i
has VBZ N
less RBR N
perioperative JJ o
morbidity NN o
and CC N
produces VBZ N
superior JJ N
urodynamic JJ o
outcomes NNS o
than IN N
TURP NNP i
, , N
when WRB N
treating VBG N
prostates NNS N
> VBP N
40 CD N
g. NN N
At IN N
24 CD N
months NNS N
of IN N
follow-up NN N
, , N
HoLEP NNP i
is VBZ N
equivalent JJ N
to TO N
TURP NNP i
. . i

-DOCSTART- -16275518- O O

The DT N
evaluation NN N
of IN N
pulmonary JJ N
hypertension NN N
using VBG N
right JJ i
ventricular JJ i
myocardial JJ i
isovolumic JJ i
relaxation NN i
time NN i
. . i

Right JJ N
ventricular NN N
( ( N
RV NNP N
) ) N
blood VBD N
pool-derived JJ N
isovolumic JJ N
relaxation NN N
time NN N
( ( N
IVRT NNP N
) ) N
correlates VBZ N
well RB N
with IN N
systolic JJ N
pulmonary JJ N
arterial JJ N
pressure NN N
( ( N
PAP NNP N
) ) N
. . N

However RB N
, , N
because IN N
of IN N
complex JJ N
parameter NN N
derivation NN N
, , N
the DT N
method NN N
is VBZ N
rarely RB N
used VBN N
. . N

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
validate VB N
the DT N
measurement NN N
of IN N
myocardial JJ N
velocity NN N
imaging-derived JJ N
RV NNP i
IVRT NNP i
( ( i
IVRT NNP i
' POS i
) ) i
against IN N
invasively RB i
measured VBN i
PAP NNP i
. . i

Transthoracic NNP i
echocardiography NN i
with IN i
myocardial JJ i
velocity NN i
imaging NN i
and CC i
right JJ i
heart NN i
catheterization NN i
were VBD N
performed VBN N
in IN N
33 CD p
patients NNS p
with IN p
pulmonary JJ p
hypertension NN p
. . p

Blood NNP o
pool NN o
IVRT NNP o
and CC o
myocardial JJ o
IVRTs NNP o
for IN o
the DT o
tricuspid JJ o
valve NN o
annulus NN o
ring NN o
, , o
basal NN o
and CC o
apical JJ o
RV NNP o
free JJ o
wall NN o
segments NNS o
were VBD N
measured VBN N
and CC N
compared VBN N
with IN N
data NNS N
from IN N
33 CD p
age- JJ p
and CC p
sex-matched JJ p
control NN p
subjects NNS p
. . p

Measured VBN o
IVRTs NNP o
were VBD N
significantly RB o
longer RBR o
in IN N
patients NNS N
with IN N
pulmonary JJ N
hypertension NN N
than IN N
in IN N
control NN N
subjects NNS N
. . N

The DT N
strongest JJS N
correlation NN N
( ( N
R NNP N
= NNP N
0.74 CD N
, , N
P NNP N
< NNP N
.0001 NNP N
) ) N
was VBD N
found VBN N
between IN N
systolic JJ o
PAP NNP o
and CC o
the DT o
heart NN o
rate-corrected JJ o
IVRT NNP o
' POS o
derived VBN N
from IN N
the DT N
basal NN N
RV NNP N
free JJ N
wall NN N
segment NN N
. . N

The DT N
basal NN o
segment NN o
IVRT NNP o
' POS o
corrected VBN N
for IN N
heart NN o
rate NN o
correlates NNS N
well RB N
with IN N
the DT N
invasive JJ N
PAP NNP N
measurement NN N
and CC N
, , N
therefore RB N
, , N
can MD N
be VB N
used VBN N
to TO N
predict VB N
systolic JJ o
PAP NNP o
. . o

It PRP N
can MD N
even RB N
be VB N
considered VBN N
as IN N
an DT N
alternative NN N
to TO N
tricuspid VB N
regurgitation-derived JJ N
PAP NNP N
systolic NN N
when WRB N
tricuspid JJ N
regurgitation NN N
is VBZ N
nonrecordable JJ N
. . N

A DT N
proposed VBN N
method NN N
to TO N
derive VB N
systolic JJ N
PAP NNP N
should MD N
be VB N
used VBN N
while IN N
screening VBG N
the DT N
patients NNS N
at IN N
risk NN N
for IN N
pulmonary JJ N
hypertension NN N
, , N
monitoring VBG N
the DT N
disease NN N
progression NN N
and CC N
the DT N
effect NN N
of IN N
treatment NN N
. . N

-DOCSTART- -11488317- O O

Comparison NNP N
of IN N
the DT N
acute JJ N
effects NNS o
of IN N
salbutamol NN i
and CC i
terbutaline NN i
on IN N
heart NN o
rate NN o
variability NN o
in IN N
adult JJ p
asthmatic JJ p
patients NNS p
. . p

This DT N
study NN N
investigated VBD N
the DT N
effects NNS N
of IN N
beta2-adrenergic JJ i
agonist JJ N
therapy NN N
on IN N
heart NN o
rate NN o
variability NN o
( ( o
HRV NNP o
) ) o
in IN N
adult NN p
asthmatic JJ p
patients NNS p
by IN N
using VBG N
frequency NN N
domain NN N
measures NNS N
of IN N
HRV NNP N
. . N

A NNP N
randomized JJ N
crossover NN N
design NN N
was VBD N
used VBN N
. . N

Twenty NNP p
adult NN p
patients NNS p
with IN p
asthma NNS p
were VBD p
studied VBN p
. . p

All DT N
patients NNS N
showed VBD N
a DT N
mild-to-moderate JJ N
decrease NN N
in IN N
baseline NN N
forced VBN o
expiratory JJ o
volume NN o
in IN o
one CD o
second NN o
. . o

Any CC N
diseases NNS N
that WDT N
might MD N
have VB N
influenced VBN N
the DT N
autonomic JJ N
function NN N
were VBD N
excluded VBN N
. . N

All DT N
patients NNS N
had VBD N
a DT N
complete JJ N
physical JJ N
examination NN N
and CC N
medical JJ N
history NN N
that WDT N
revealed VBD N
no DT p
cardiovascular JJ p
disease NN p
or CC p
medication NN p
. . p

The DT N
study NN N
used VBD N
200 CD N
microg NN N
inhaled VBN N
salbutamol NN i
and CC N
500 CD N
microg NN N
inhaled VBN i
terbutaline NN i
. . i

HRV NNP N
analysis NN N
was VBD N
performed VBN N
for IN N
each DT N
5-min CD N
segment NN N
, , N
5 CD N
min NN N
before IN N
inhalation NN N
of IN N
the DT N
study NN N
drug NN N
and CC N
5 CD N
, , N
10 CD N
, , N
15 CD N
, , N
20 CD N
, , N
25 CD N
and CC N
30 CD N
min NN N
after IN N
inhalation NN N
. . N

Total JJ o
power NN o
( ( o
TP NNP o
: : o
< NN o
0.40 CD o
Hz NNP o
) ) o
, , o
high-frequency JJ o
power NN o
( ( o
HF NNP o
: : o
0.15-0.40 JJ o
Hz NNP o
) ) o
, , o
low-frequency JJ o
power NN o
( ( o
LF JJ o
: : o
0.04-0.15 JJ o
Hz NNP o
) ) o
and CC N
LF/HF NNP o
ratio NN o
were VBD N
calculated VBN N
. . N

The DT N
LF NNP o
and CC o
LF/HF NNP o
ratio NN o
increased VBD N
and CC N
TP NNP o
decreased VBD N
at IN N
5 CD N
, , N
10 CD N
, , N
15 CD N
and CC N
20 CD N
min NN N
after IN N
the DT N
salbutamol NN i
and CC N
the DT N
terbutaline NN i
inhalation NN N
, , N
HF NNP o
did VBD N
not RB N
change VB N
significantly RB N
after IN N
the DT N
salbutamol NN i
and CC N
terbutaline JJ i
inhalation NN N
. . N

Acute NNP i
salbutamol NN i
and CC i
terbutaline JJ i
inhalation NN i
produce VBP N
similar JJ N
effects NNS N
on IN N
heart NN o
rate NN o
variability NN o
and CC N
increase VB N
sympathetic JJ o
modulation NN o
in IN N
the DT N
cardiac JJ N
autonomic JJ N
activity NN N
. . N

-DOCSTART- -14736356- O O

Single-needle JJ i
acupuncture NN i
alleviates VBZ N
gag JJ N
reflex NN N
during IN p
transesophageal JJ p
echocardiography NN p
: : p
a DT N
blinded VBN N
, , N
randomized VBN N
, , N
controlled VBD N
pilot NN N
trial NN N
. . N

OBJECTIVES UH N
To TO N
study VB N
the DT N
effect NN N
of IN N
single-needle JJ i
acupuncture NN i
in IN N
suppressing VBG N
gag-reflex JJ N
in IN N
transesophageal JJ N
echocardiography NN N
( ( N
TEE NNP N
) ) N
. . N

DESIGN NNP N
Prospective NNP N
, , N
blinded VBD N
trial NN N
. . N

Settings/locations NNS N
: : N
Patients NNS p
with IN p
ischemic JJ p
stroke NN p
or CC p
transient JJ p
ischemic JJ p
attack NN p
undergoing JJ p
TEE NNP p
because IN p
of IN p
presumed JJ p
cardioembolic JJ p
origin NN p
in IN p
a DT p
specialized JJ p
stroke NN p
unit NN p
of IN p
the DT p
Johann NNP p
Wolfgang NNP p
Goethe-University NNP p
, , p
Frankfurt/Main NNP p
, , p
Germany NNP p
. . p

Subjects/Study NNP N
interventions NNS N
: : N
Forty-one CD p
( ( p
41 CD p
) ) p
patients NNS p
were VBD p
studied VBN p
. . p

Patients NNS N
received VBD N
single-needle JJ i
acupuncture NN i
with IN N
a DT N
0.2 CD N
x NN N
13 CD N
mm NN N
disposable JJ N
acupuncture NN N
needle NN N
( ( N
Suzhou NNP N
Medical NNP N
Appliances NNP N
, , N
China NNP N
) ) N
, , N
10-mm JJ N
deep NN N
either NN N
at IN N
Chengjiang NNP N
( ( N
midline NN N
between IN N
lower JJR N
lip NN N
and CC N
chin NN N
) ) N
or CC N
superficially RB N
at IN N
a DT N
sham NN N
point NN N
( ( N
tip NN N
of IN N
the DT N
chin NN N
) ) N
during IN N
TEE NNP N
or CC N
no DT i
acupuncture NN i
for IN N
alleviating VBG N
gag NN N
reflex NN N
. . N

OUTCOME NNP N
MEASURES NNP N
Severity NNP o
of IN o
gagging NN o
was VBD N
rated VBN N
on IN N
a DT N
visual-analogue JJ N
scale NN N
. . N

RESULTS VB N
The DT N
acupuncture NN N
group NN N
experienced VBD N
significantly RB N
less RBR o
gagging VBG o
than IN N
the DT N
sham NN N
group NN N
( ( N
p JJ N
= NNP N
0.037 CD N
) ) N
or CC N
the DT N
nonacupuncture NN N
group NN N
( ( N
p JJ N
= NNP N
0.013 CD N
) ) N
. . N

CONCLUSIONS NNP N
Acupuncture NNP i
of IN i
CV24 NNP i
is VBZ N
an DT N
easy JJ N
to TO N
apply VB N
and CC N
effective JJ N
method NN N
to TO N
reduce VB N
gag NN o
reflex NN o
during IN N
TEE NNP N
. . N

-DOCSTART- -9337835- O O

Exhaled JJ N
NO NNP N
during IN N
graded VBN N
changes NNS N
in IN N
inhaled JJ N
oxygen NN N
in IN N
man NN p
. . p

BACKGROUND NNP N
Nitric NNP i
oxide NN i
( ( N
NO NNP N
) ) N
is VBZ N
present JJ N
in IN N
the DT N
exhaled JJ N
air NN N
of IN N
animals NNS N
and CC N
humans NNS N
. . N

In IN N
isolated JJ N
animal JJ N
lungs NNS N
the DT N
amount NN N
of IN N
exhaled JJ N
NO NNP N
is VBZ N
decreased VBN N
during IN N
hypoxia NN N
. . N

A DT N
study NN N
was VBD N
undertaken VBN N
to TO N
determine VB N
whether IN N
changes NNS N
in IN N
arterial JJ N
oxygen NN N
tension NN N
affect NN N
levels NNS N
of IN N
exhaled JJ N
NO NNP N
in IN N
humans NNS p
. . p

METHODS NNP N
Sixteen NNP p
healthy JJ p
subjects NNS p
were VBD N
randomised VBN N
to TO N
inhale VB i
different JJ i
gas NN i
mixtures NNS i
of IN i
oxygen NN i
and CC i
nitrogen NN i
in IN N
a DT N
double JJ N
blind NN N
crossover NN N
study NN N
. . N

Eight NNP N
gas NN i
mixtures NNS i
of IN i
oxygen NN i
and CC i
nitrogen NN i
( ( N
fractional JJ N
inspired VBN N
oxygen NN N
concentration NN N
( ( N
FiO2 NNP N
) ) N
0.1 CD N
to TO N
1.0 CD N
) ) N
were VBD N
administered VBN N
. . N

Exhaled VBD o
NO DT o
was VBD N
measured VBN N
with IN N
a DT N
chemiluminescence NN N
detector NN N
from IN N
end NN N
expiratory NN N
single JJ N
breath NN N
exhalation NN N
. . N

RESULTS VB N
A DT N
dose-dependent JJ N
change NN N
in IN N
exhaled JJ o
NO NNP o
during IN N
graded VBN o
oxygen NN o
breathing NN o
was VBD N
observed VBN N
( ( N
p JJ N
= NNP N
0.0012 CD N
) ) N
. . N

The DT N
mean NN o
( ( o
SE NNP o
) ) o
exhaled VBD o
NO DT o
concentration NN o
was VBD N
31 CD N
( ( N
3 CD N
) ) N
ppb NN N
at IN N
baseline NN N
, , N
39 CD N
( ( N
4 CD N
) ) N
ppb NN N
at IN N
an DT N
FiO2 NNP N
of IN N
1.0 CD N
, , N
and CC N
26 CD N
( ( N
3 CD N
) ) N
ppb NN N
at IN N
an DT N
FiO2 NNP N
of IN N
0.1 CD N
. . N

CONCLUSIONS VB N
The DT N
NO NNP o
concentration NN o
in IN N
exhaled JJ N
air NN N
in IN N
healthy JJ p
humans NNS p
is VBZ N
dependent JJ N
on IN N
oxygen NN N
tension NN N
. . N

Hyperoxia NNP N
increases VBZ N
the DT N
level NN N
of IN N
exhaled JJ N
NO NNP N
, , N
which WDT N
indicates VBZ N
increased VBD N
NO DT N
production NN N
. . N

The DT N
mechanism NN N
behind IN N
this DT N
phenomenon NN N
remains VBZ N
to TO N
be VB N
elucidated VBN N
. . N

-DOCSTART- -18602522- O O

Cardiopulmonary JJ i
exercise NN i
variables NNS N
in IN N
diastolic JJ p
versus NN p
systolic JJ p
heart NN p
failure NN p
. . p

The DT N
response NN N
to TO N
cardiopulmonary JJ i
exercise NN i
( ( i
CPX NNP i
) ) i
in IN N
patients NNS p
with IN p
heart NN p
failure NN p
( ( p
HF NNP p
) ) p
with IN p
normal JJ p
left JJ p
ventricular NN p
( ( p
LV NNP p
) ) p
ejection NN p
fractions NNS p
( ( p
EFs NNP p
) ) p
is VBZ N
not RB N
well RB N
characterized VBN N
. . N

To TO N
determine VB N
if IN N
CPX NNP i
testing VBG N
could MD N
distinguish VB N
between IN N
patients NNS p
with IN p
HF NNP p
with IN p
normal JJ p
EFs NNP p
( ( p
> VB p
50 CD p
% NN p
; : p
i.e. CC p
, , N
diastolic JJ p
HF NNP p
) ) p
and CC N
those DT N
with IN N
decreased JJ N
EFs NNP N
( ( N
> CD N
or CC N
=50 CD N
% NN N
; : N
i.e. CC N
, , N
systolic JJ N
HF NNP N
) ) N
, , N
CPX NNP i
responses NNS N
were VBD N
compared VBN N
between IN N
185 CD p
patients NNS p
with IN p
systolic JJ p
HF NNP p
( ( p
79 CD p
% NN p
men NNS p
, , p
mean JJ p
age NN p
62.6 CD p
+/- JJ p
10.9 CD p
years NNS p
) ) p
and CC p
43 CD p
with IN p
diastolic JJ p
HF NNP p
( ( p
54 CD p
% NN p
men NNS p
, , p
mean JJ p
age NN p
67.4 CD p
+/- JJ p
9.8 CD p
years NNS p
) ) p
enrolled VBD p
in IN p
a DT p
phase NN p
II NNP p
multicenter NN p
clinical JJ p
trial NN p
. . p

All DT N
patients NNS N
were VBD N
evaluated VBN N
with IN N
echocardiography NN i
and CC N
a DT N
standardized JJ i
CPX NNP i
test NN i
as IN N
part NN N
of IN N
the DT N
trial NN N
. . N

CPX NNP o
variables NNS o
, , N
including VBG N
oxygen NN o
uptake NN o
at IN o
peak NN o
exercise NN o
( ( o
peak JJ o
VO NNP o
( ( o
2 CD o
) ) o
) ) o
and CC o
the DT o
slope NN o
of IN o
the DT o
ventilation/carbon NN o
dioxide NN o
production NN o
ratio NN o
( ( o
VE/VCO NNP o
( ( o
2 CD o
) ) o
) ) o
, , N
were VBD N
determined VBN N
and CC N
analyzed VBN N
by IN N
core NN N
laboratory NN N
personnel NNS N
. . N

Echocardiographic JJ o
measurements NNS o
included VBD N
the DT N
LV NNP o
EF NNP o
, , o
the DT o
E/A NNP o
ratio NN o
, , o
filling VBG o
time NN o
, , o
cavity NN o
volumes NNS o
, , o
right JJ o
ventricular NN o
function NN o
, , o
and CC o
mitral JJ o
regurgitation NN o
. . o

Patients NNS p
in IN p
the DT p
diastolic JJ p
HF NNP p
group NN p
tended VBD p
to TO p
be VB p
older JJR p
( ( p
p JJ p
< NNP p
0.08 CD p
) ) p
, , p
with IN p
more JJR p
women NNS p
( ( p
p JJ p
< NNP p
0.006 CD p
) ) p
and CC p
with IN p
greater JJR p
body NN p
mass NN p
indexes NNS p
( ( p
p JJ p
< NNP N
0.02 CD N
) ) N
, , N
than IN N
those DT N
in IN N
the DT N
systolic JJ N
HF NNP N
group NN N
. . N

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
the DT N
use NN o
of IN o
beta NN o
blockers NNS o
or CC o
the DT o
incidence NN o
of IN o
coronary JJ o
artery NN o
disease NN o
. . o

Patients NNS N
with IN N
diastolic JJ N
HF NNP N
had VBD N
decreased VBN N
E/A NNP o
ratios NNS o
( ( N
0.9 CD N
+/- JJ N
0.4 CD N
vs JJ N
1.4 CD N
+/- JJ N
1.1 CD N
, , N
p NN N
< VBD N
0.02 CD N
, , N
diastolic JJ N
HF NNP N
vs NN N
systolic JJ N
HF NNP N
) ) N
and CC N
increased VBD N
filling VBG o
times NNS o
( ( N
30.4 CD N
+/- JJ N
3.2 CD N
vs JJ N
26.5 CD N
+/- JJ N
4.7 CD N
ms NN N
, , N
p NN N
< VBD N
0.01 CD N
, , N
diastolic JJ N
HF NNP N
vs NN N
systolic JJ N
HF NNP N
) ) N
. . N

No DT N
significant JJ N
differences NNS N
in IN N
peak NN o
VO NNP o
( ( o
2 CD o
) ) o
( ( N
14.4 CD N
+/- JJ N
1.9 CD N
vs JJ N
15.6 CD N
+/- JJ N
3.2 CD N
ml/kg/min NN N
, , N
p NN N
= VBD N
0.06 CD N
, , N
diastolic JJ N
HF NNP N
vs NN N
systolic JJ N
HF NNP N
) ) N
were VBD N
observed VBN N
. . N

The DT N
VE/VCO NNP o
( ( o
2 CD o
) ) o
ratios NNS o
for IN N
the DT N
2 CD N
groups NNS N
were VBD N
abnormal JJ N
and CC N
comparable JJ N
( ( N
32 CD N
2 CD N
+/- JJ N
7.5 CD N
vs JJ N
34.0 CD N
+/- JJ N
8.3 CD N
, , N
p NN N
= VBD N
0.3 CD N
, , N
diastolic JJ N
HF NNP N
vs NN N
systolic JJ N
HF NNP N
) ) N
. . N

In IN N
conclusion NN N
, , N
the DT N
CPX NNP o
response NN o
in IN N
patients NNS N
with IN N
diastolic JJ N
HF NNP N
and CC N
systolic JJ N
HF NNP N
is VBZ N
markedly RB N
abnormal JJ N
and CC N
indistinguishable JJ N
with IN N
regard NN N
to TO N
peak VB o
VO NNP o
( ( o
2 CD o
) ) o
and CC o
ventilation NN o
despite IN N
marked JJ N
differences NNS N
in IN N
the DT N
LV NNP N
EF NNP N
. . N

-DOCSTART- -18070300- O O

Transthoracic NNP i
versus NN i
transesophageal NN i
cardioversion NN i
of IN i
atrial JJ i
fibrillation NN i
under IN i
light JJ i
sedation NN i
: : i
a DT N
prospective JJ N
randomized VBN N
trial NN N
. . N

BACKGROUND NNP N
Electrical JJ p
cardioversion NN p
( ( p
ECV NNP p
) ) p
of IN p
atrial JJ p
fibrillation NN p
( ( p
AF NNP p
) ) p
is VBZ N
limited VBN N
by IN N
a DT N
5-10 JJ N
% NN N
failure NN N
rate NN N
and CC N
by IN N
the DT N
expense NN N
arising VBG N
from IN N
a DT N
perceived JJ N
need NN N
for IN N
general JJ N
anesthesia NN N
. . N

A DT N
transesophageal JJ N
approach NN N
using VBG N
light JJ N
sedation NN N
has VBZ N
been VBN N
proposed VBN N
as IN N
a DT N
means NN N
of IN N
augmenting VBG N
the DT N
success NN N
rate NN N
and CC N
avoiding VBG N
the DT N
need NN N
for IN N
general JJ N
anesthesia NN N
. . N

We PRP N
hypothesized VBD N
that IN N
the DT N
high JJ N
rate NN N
of IN N
success NN N
and CC N
the DT N
lower JJR N
energy NN N
requirement NN N
associated VBN N
with IN N
biphasic JJ N
cardioversion NN N
might MD N
eliminate VB N
any DT N
advantage NN N
of IN N
the DT N
transesophageal JJ N
approach NN N
. . N

METHODS NNP N
We PRP N
randomly VBP N
assigned VBD N
60 CD p
patients NNS p
attending VBG p
for IN p
ECV NNP i
of IN i
persistent JJ i
AF NNP i
to TO i
a DT i
transesophageal NN i
or CC i
a DT i
transthoracic JJ i
approach NN i
. . i

Sedation NN N
of IN N
moderate JJ N
depth NN N
was VBD N
achieved VBN N
with IN N
intravenous JJ i
midazolam NNS i
. . i

The DT N
dose NN N
of IN N
midazolam NN N
was VBD N
titrated VBN N
in IN N
the DT N
same JJ N
manner NN N
in IN N
both DT N
groups NNS N
. . N

RESULTS NNP N
Sinus NNP o
rhythm NN o
was VBD N
restored VBN N
in IN N
29/30 CD N
patients NNS N
( ( N
97 CD N
% NN N
) ) N
in IN N
each DT N
group NN N
using VBG N
a DT N
similar JJ N
number NN N
of IN N
shocks NNS N
for IN N
both DT N
groups NNS N
( ( N
1.3 CD N
+/- JJ N
0.6 CD N
transesophageal NN N
vs NN N
1.4 CD N
+/- JJ N
0.7 CD N
transthoracic NN N
, , N
P NNP N
= NNP N
NS NNP N
) ) N
with IN N
a DT N
similar JJ N
procedure NN N
duration NN N
( ( N
14.1 CD N
+/- JJ N
8.2 CD N
minutes NNS N
vs JJ N
13.8 CD N
+/- JJ N
7.5 CD N
minutes NNS N
, , N
P NNP N
= NNP N
NS NNP N
) ) N
. . N

Both DT N
groups NNS N
received VBD N
similar JJ N
doses NNS N
of IN N
midazolam NN N
( ( N
4.2 CD N
+/- JJ N
2.7 CD N
mg NN N
vs NN N
4.4 CD N
+/- JJ N
2.8 CD N
mg NN N
, , N
P NNP N
= NNP N
NS NNP N
) ) N
and CC N
both DT N
reported VBD N
a DT N
similar JJ N
discomfort NN o
score NN o
in IN N
( ( N
0.9 CD N
+/- JJ N
1.3 CD N
vs JJ N
1.1 CD N
+/- JJ N
1.8 CD N
, , N
P NNP N
= NNP N
NS NNP N
) ) N
. . N

No DT N
complication NN o
occurred VBD N
in IN N
either DT N
group NN N
. . N

CONCLUSION NNP N
AF NNP N
may MD N
be VB N
cardioverted VBN N
safely RB o
and CC o
effectively RB o
by IN N
either CC N
a DT N
transthoracic NN N
or CC N
a DT N
transesophageal JJ N
approach NN N
. . N

The DT N
use NN N
of IN N
sedation NN N
of IN N
moderate JJ N
depth NN N
renders NNS N
cardioversion NN N
by IN N
either DT N
approach NN N
acceptable JJ N
. . N

As IN N
transesophageal NN N
ECV NNP N
shows VBZ N
no DT N
clear JJ N
advantage NN N
, , N
transthoracic JJ N
cardioversion NN N
should MD N
remain VB N
the DT N
approach NN N
of IN N
first JJ N
choice NN N
. . N

-DOCSTART- -7559165- O O

A DT N
two-filter JJ i
model NN i
for IN N
frequency NN o
discrimination NN o
. . o

In IN N
this DT N
paper NN N
, , N
we PRP N
explore VBP N
a DT N
two-filter JJ i
model NN i
, , N
the DT N
simplest JJS N
version NN N
of IN N
multi-channel JJ N
models NNS N
for IN N
frequency NN o
discrimination NN o
of IN N
simple JJ N
tones NNS N
. . N

According VBG N
to TO N
this DT N
model NN N
, , N
frequency NN N
discrimination NN N
is VBZ N
based VBN N
on IN N
a DT N
change NN N
in IN N
the DT N
relative JJ N
output NN N
levels NNS N
of IN N
two CD N
auditory JJ N
filters NNS N
, , N
one CD N
centered VBN N
below IN N
and CC N
the DT N
other JJ N
above IN N
the DT N
frequency NN N
of IN N
the DT N
tone NN N
. . N

This DT N
idea NN N
can MD N
explain VB N
the DT N
experimental JJ N
results NNS N
that IN N
frequency NN N
discrimination NN N
is VBZ N
relatively RB N
unaffected JJ N
by IN N
randomization NN N
of IN N
stimulus JJ N
level NN N
. . N

Moreover RB N
, , N
it PRP N
suggests VBZ N
a DT N
close JJ N
relationship NN N
between IN N
the DT N
ability NN N
of IN N
listeners NNS p
to TO N
perform VB N
frequency NN N
discrimination NN N
of IN N
simple JJ N
tones NNS N
and CC N
spectral-shape JJ N
discrimination NN N
of IN N
two-tone NN N
complexes NNS N
. . N

The DT N
ability NN N
of IN N
three CD p
listeners NNS p
to TO N
perform VB N
these DT N
two CD N
tasks NNS N
was VBD N
measured VBN N
at IN N
six CD i
frequencies NNS i
( ( i
from IN i
0.25 CD i
to TO i
8 CD i
kHz NN i
) ) i
. . N

The DT N
results NNS N
from IN N
the DT N
spectral-shape-discrimination NN N
task NN N
were VBD N
used VBN N
to TO N
predict VB N
frequency-difference NN N
limens NNS N
. . N

There EX N
was VBD N
a DT N
high JJ N
correlation NN N
between IN N
obtained VBN N
and CC N
predicted VBN N
values NNS N
. . N

-DOCSTART- -20881754- O O

Multicenter NNP N
, , N
double-blind NN N
, , N
placebo-controlled JJ N
crossover NN N
study NN N
to TO N
assess VB N
the DT N
acute JJ o
prokinetic JJ o
efficacy NN o
of IN N
nizatidine-controlled JJ i
release NN i
( ( N
150 CD N
and CC N
300 CD N
mg NN N
) ) N
in IN p
patients NNS p
with IN p
gastroesophageal JJ p
reflux JJ p
disease NN p
. . p

INTRODUCTION VBZ N
The DT N
aim NN N
of IN N
the DT N
study NN N
is VBZ N
to TO N
test VB N
whether IN N
nizatidine NN i
delivered VBN N
via IN N
a DT N
unique JJ N
bimodal JJ N
pulsatile-controlled JJ N
release NN N
system NN N
, , N
nizatidine NN i
controlled VBN i
release NN i
( ( i
CR NNP i
) ) i
, , N
accelerates VBZ N
gastric JJ o
emptying VBG o
in IN N
patients NNS p
with IN p
gastroesophageal JJ p
reflux NN p
disease NN p
( ( p
GERD NNP p
) ) p
. . p

METHODS NNP N
Combined NNP N
data NNS N
were VBD N
analyzed VBN N
on IN N
39 CD p
patients NNS p
with IN p
delayed JJ o
gastric NN o
emptying NN o
( ( p
DGE NNP p
) ) p
from IN p
2 CD p
studies NNS p
( ( p
n JJ p
= NNP p
84 CD p
) ) p
assessing VBG N
the DT N
prokinetic JJ N
effect NN N
of IN N
nizatidine JJ i
CR NNP i
. . i

A DT N
single-blind JJ i
placebo NN i
baseline NN i
was VBD i
followed VBN i
by IN i
double-blind JJ i
nizatidine JJ i
CR NNP i
( ( i
150 CD i
and CC i
300 CD i
mg NN i
) ) i
in IN i
randomized VBN i
sequence NN i
, , i
2 CD i
to TO i
5 CD i
days NNS i
apart RB i
. . i

Each DT i
dose NN i
was VBD i
followed VBN i
1 CD i
hour NN i
later RB i
by IN i
an DT i
egg-beater JJ i
meal NN i
, , i
labeled VBN i
with IN i
Tc99m NNP i
. . i

Gamma NNP o
camera NN o
images NNS o
were VBD i
obtained VBN i
at IN i
meal JJ i
completion NN i
, , i
1- JJ i
, , i
2- JJ i
, , i
3- JJ i
and CC i
4-hour JJ i
postmeal NN i
. . i

All PDT p
the DT p
84 CD p
patients NNS p
were VBD p
classified VBN p
at IN p
baseline NN p
with IN p
DGE NNP o
( ( p
gastric JJ p
retention NN p
> VBD p
6.3 CD p
% NN p
at IN p
4 CD p
hours NNS p
) ) p
or CC p
normal JJ o
gastric JJ o
emptying NN o
. . o

RESULTS NNP N
In IN N
the DT N
39 CD N
patients NNS N
identified VBN N
with IN N
DGE NNP N
, , N
change NN N
from IN N
placebo NN i
baseline NN N
( ( o
CFB NNP o
) ) o
for IN N
percent NN o
gastric JJ o
retention NN o
at IN N
4-hour JJ N
postmeal NN N
with IN N
nizatidine JJ i
CR NNP i
( ( N
150 CD N
and CC N
300 CD N
mg NN N
) ) N
was VBD N
each DT N
improved VBN N
and CC N
statistically RB N
significant JJ N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

In IN N
a DT N
subgroup NN p
of IN p
diabetic JJ p
patients NNS p
with IN p
DGE NNP p
( ( p
n JJ p
= NNP p
10 CD p
) ) p
, , N
the DT N
CFB NNP N
with IN N
nizatidine JJ N
CR NNP N
( ( N
300 CD N
mg NN N
) ) N
was VBD N
significant JJ N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
at IN N
3- JJ N
and CC N
4-hour JJ N
postmeal NN N
. . N

CONCLUSIONS NNP N
Nizatidine NNP i
CR NNP i
( ( N
150 CD N
and CC N
300 CD N
mg NN N
) ) N
significantly RB N
enhanced VBN N
gastric JJ o
emptying NN o
of IN N
a DT N
standard JJ N
meal NN N
in IN N
patients NNS p
with IN p
GERD NNP p
with IN p
DGE NNP p
. . p

-DOCSTART- -10649829- O O

The DT N
relationship NN N
between IN N
repetitive JJ o
behaviors NNS o
and CC o
growth NN o
hormone NN o
response NN o
to TO N
sumatriptan VB i
challenge NN N
in IN N
adult NN p
autistic JJ p
disorder NN p
. . p

Autism NNP N
is VBZ N
heterogeneous JJ N
with IN N
respect NN N
to TO N
clinical JJ N
symptoms NNS N
and CC N
etiology NN N
. . N

To TO N
sort VB N
out RP N
this DT N
heterogeneity NN N
in IN N
autism NN N
, , N
we PRP N
investigated VBD N
whether IN N
specific JJ o
neurobiological JJ o
markers NNS o
vary VBP N
in IN N
parallel NN N
to TO N
core VB o
symptomatology NN o
. . o

Specifically RB N
, , N
we PRP N
assessed VBD N
growth NN o
hormone NN o
response NN o
to TO N
the DT N
5-HT JJ i
1d CD i
agonist NN i
, , i
sumatriptan NN i
, , N
and CC N
linked VBD o
this DT o
measure NN o
of IN o
serotonergic JJ o
function NN o
to TO N
the DT o
severity NN o
of IN o
repetitive JJ o
behaviors NNS o
in IN p
adult NN p
autistic JJ p
patients NNS p
. . p

Eleven NNP p
adult NN p
patients NNS p
with IN p
autism NN p
or CC p
Asperger NNP p
's POS p
disorder NN p
were VBD p
randomized VBN p
to TO N
single JJ N
dose JJ N
sumatriptan NN i
( ( N
6 CD N
mg RB N
SQ NNP N
) ) N
and CC N
placebo NN i
challenges NNS N
, , N
separated VBN N
by IN N
a DT N
one-week JJ N
interval NN N
. . N

In IN N
adult JJ N
autistic JJ N
disorders NNS N
, , N
severity NN o
of IN o
repetitive JJ o
behaviors NNS o
at IN o
baseline NN o
, , N
as IN N
measured VBN o
by IN o
YBOCS-compulsion NNP o
score NN o
, , o
significantly RB o
positively RB o
correlated VBN o
with IN N
both DT N
peak JJ o
delta NN o
growth NN o
hormone NN o
response NN o
and CC o
area NN o
under IN o
the DT o
curve NN o
growth NN o
hormone NN o
response NN o
to TO N
sumatriptan VB i
. . i

Thus RB N
, , N
the DT N
severity NN o
of IN o
a DT o
specific JJ o
behavioral JJ o
dimension NN o
in IN N
autism NN N
( ( o
repetitive JJ o
behaviors NNS o
) ) o
parallels VBP o
the DT o
sensitivity NN o
of IN N
the DT N
5-HT JJ i
1d CD i
receptor NN i
, , N
as IN N
manifest NN N
by IN N
sumatriptan NN o
elicited VBN o
GH NNP o
response NN o
. . o

-DOCSTART- -7956629- O O

A DT N
cost-benefit JJ o
comparison NN N
of IN N
intensive JJ i
diabetes NNS i
management NN i
with IN i
implantable JJ i
pumps NNS i
versus IN N
multiple JJ i
subcutaneous JJ i
injections NNS i
in IN N
patients NNS p
with IN p
type NN p
I PRP p
diabetes VBZ p
. . p

OBJECTIVE NNP N
To TO N
investigate VB N
if IN N
intraperitoneal JJ i
( ( i
IP NNP i
) ) i
insulin NN i
infusion NN i
via IN i
programmable JJ i
implantable JJ i
pumps NNS i
is VBZ N
a DT N
potential JJ N
alternative NN N
to TO N
subcutaneous JJ i
( ( i
SC NNP i
) ) i
insulin NN i
via IN i
multiple JJ i
injections NNS i
. . i

RESEARCH NNP N
DESIGN NNP N
AND NNP N
METHODS NNP N
We PRP N
compared VBN N
the DT N
cost-benefits NNS o
of IN N
the DT N
two CD N
methods NNS N
using VBG N
a DT N
randomized VBN N
, , N
prospective JJ N
, , N
6-month JJ N
, , N
crossover JJ N
design NN N
in IN N
10 CD p
adult NN p
type NN p
I PRP p
diabetic JJ p
patients NNS p
. . p

RESULTS NNP N
When WRB N
judged VBN N
on IN N
the DT N
last JJ N
month NN N
of IN N
IP NNP N
versus NN N
SC NNP N
periods NNS N
in IN N
the DT N
nine CD N
patients NNS N
who WP N
completed VBD N
the DT N
study NN N
, , N
metabolic JJ o
data NN o
showed VBD N
better JJR N
glycemic JJ o
control NN o
( ( N
HbA1c NNP N
: : N
7.2 CD N
+/- JJ N
0.2 CD N
IP NNP N
vs. FW N
8.5 CD N
+/- JJ N
0.7 CD N
% NN N
SC NNP N
, , N
mean JJ N
+/- JJ N
SE NNP N
, , N
P NNP N
= NNP N
0.02 CD N
) ) N
, , N
reduced VBN o
glycemic JJ o
fluctuations NNS o
( ( N
SD NNP N
of IN N
capillary JJ N
glucose JJ N
values NNS N
: : N
3.4 CD N
+/- JJ N
0.2 CD N
IP NNP N
vs. FW N
4.6 CD N
+/- JJ N
0.2 CD N
mM NN N
SC NNP N
, , N
P NNP N
< NNP N
0.01 CD N
) ) N
, , N
and CC N
fewer JJR N
mild JJ o
hypoglycemic JJ o
events NNS o
( ( N
5.7 CD N
+/- JJ N
2.0 CD N
IP NNP N
vs. FW N
10.0 CD N
+/- JJ N
3.1 CD N
events/month JJ N
SC NNP N
, , N
P NNP N
= NNP N
0.02 CD N
) ) N
. . N

Quality NN o
of IN o
life NN o
, , o
judged VBN o
by IN o
Diabetes NNP o
Control NNP o
and CC o
Complications NNP o
Trial NNP o
questionnaires NNS o
, , N
was VBD N
unaffected VBN N
by IN N
pump NN i
therapy NN N
. . N

Direct JJ o
costs NNS o
, , o
including VBG o
pump JJ o
acquisition NN o
, , o
implantation NN o
, , o
and CC o
follow-up NN o
, , N
were VBD N
2.6-fold JJ N
higher JJR N
with IN N
IP NNP N
than IN N
with IN N
SC NNP N
delivery NN N
. . N

CONCLUSIONS VB N
The DT N
implantable JJ i
pump NN i
is VBZ N
more RBR o
effective JJ o
in IN N
the DT N
short JJ N
term NN N
, , N
equally RB N
accepted VBN o
, , N
but CC N
more RBR N
costly JJ o
than IN N
multiple JJ i
injections NNS i
and CC N
should MD N
be VB N
limited VBN N
to TO N
patients NNS N
with IN N
unsatisfactory JJ N
glycemic JJ o
control NN o
despite IN N
intensive JJ N
diabetes NNS N
management NN N
with IN N
SC NNP N
insulin NN N
. . N

In IN N
addition NN N
, , N
longer-term JJ N
, , N
larger-scale JJ N
, , N
and CC N
comparative JJ N
evaluation NN N
is VBZ N
required VBN N
. . N

-DOCSTART- -25262168- O O

Feasibility NNP N
study NN N
of IN N
the DT N
effects NNS o
of IN N
art NN N
as IN N
a DT N
creative JJ N
engagement NN N
intervention NN N
during IN N
stroke NN N
rehabilitation NN N
on IN N
improvement NN N
of IN N
psychosocial JJ o
outcomes NNS o
: : o
study NN N
protocol NN N
for IN N
a DT N
single JJ N
blind NN N
randomized VBD N
controlled VBN N
trial NN N
: : N
the DT N
ACES NNP N
study NN N
. . N

BACKGROUND NNP N
Benefits NNP N
of IN N
art NN N
participation NN N
after IN N
stroke NN N
are VBP N
becoming VBG N
increasingly RB N
recognized VBN N
. . N

Qualitative JJ N
studies NNS N
suggest VBP N
that IN N
participation NN N
in IN N
visual JJ N
arts NNS N
creative JJ N
engagement JJ N
interventions NNS N
( ( N
CEIs NNP N
) ) N
during IN N
rehabilitation NN N
after IN N
stroke NN N
may MD N
improve VB N
mood NN o
, , o
self-esteem JJ o
, , o
hope NN o
and CC N
some DT N
aspects NNS N
of IN N
physical JJ N
recovery NN N
. . N

This DT N
study NN N
examines VBZ N
the DT N
feasibility NN N
of IN N
undertaking VBG N
a DT N
randomized VBN N
controlled JJ N
trial NN N
of IN N
a DT N
CEI NNP N
delivered VBN N
by IN N
artists NNS N
within IN N
in-patient JJ N
stroke NN N
rehabilitation NN N
to TO N
test VB N
effectiveness NN N
. . N

METHODS/DESIGN NNP N
This DT N
trial NN N
is VBZ N
a DT N
two CD N
arm NN N
, , N
single-blind NN N
, , N
randomized VBN N
controlled VBN N
feasibility NN N
trial NN N
within IN N
in-patient JJ N
stroke NN N
rehabilitation NN N
. . N

We PRP N
will MD N
recruit VB N
80 CD p
patients NNS p
receiving VBG i
stroke NN i
rehabilitation NN i
in IN i
two CD i
stroke VBD i
units NNS i
in IN i
a DT i
health NN i
board NN i
area NN i
of IN i
Scotland NNP i
( ( i
40 CD i
patients NNS i
in IN i
each DT i
arm NN i
) ) i
. . i

Intervention NNP i
arm NN i
participants NNS i
will MD i
receive VB i
a DT i
visual-arts NNS i
based VBN i
CEI NNP i
facilitated VBN i
by IN i
experienced JJ i
artists NNS i
. . i

Artists NNS i
will MD i
follow VB i
an DT i
intervention NN i
protocol NN i
with IN i
specific JJ i
components NNS i
that WDT i
enable VBP i
participants NNS i
to TO i
set VB i
, , i
achieve VB i
and CC i
review VB i
artistic JJ i
goals NNS i
. . i

Participants NNS i
will MD i
receive VB i
up RP i
to TO i
eight CD i
intervention NN i
sessions NNS i
, , i
four CD i
within IN i
a DT i
group NN i
and CC i
four CD i
one-to-one NN i
with IN i
the DT i
artist NN i
. . i

Control NNP N
group NN N
participants NNS N
will MD N
receive VB N
usual JJ N
care NN N
only.Data JJ N
collection NN N
will MD N
occur VB N
at IN N
baseline NN N
, , N
post-intervention NN N
and CC N
three-month JJ N
follow-up NN N
. . N

Stroke-related JJ o
health NN o
status NN o
is VBZ N
the DT N
primary JJ N
outcome NN N
; : N
mood NN o
, , o
self-esteem JJ o
, , o
self-efficacy JJ o
, , o
perceived JJ o
recovery NN o
control NN o
and CC o
hope NN o
are VBP o
secondary JJ o
outcomes NNS N
. . N

Semi-structured JJ N
interviews NNS N
will MD N
be VB N
conducted VBN N
with IN N
purposively RB N
selected VBN N
patients NNS N
, , N
artists NNS N
and CC N
healthcare JJ N
staff NN N
to TO N
elicit VB o
views NNS o
and CC o
experiences NNS o
of IN N
the DT N
intervention NN N
and CC N
feasibility NN o
and CC o
acceptability NN o
of IN N
trial NN N
processes NNS N
. . N

Recruitment JJ o
rates NNS o
, , o
retention NN o
rates NNS o
and CC o
patient JJ o
preference NN o
for IN o
art JJ o
participation NN o
will MD N
also RB N
be VB N
collected VBN N
. . N

Data NNP N
will MD N
indicate VB N
, , N
with IN N
confidence NN N
intervals NNS N
, , N
the DT N
proportion NN N
of IN N
patients NNS N
choosing VBG N
or CC N
refusing VBG N
participation NN N
in IN N
the DT N
CEI NNP N
and CC N
will MD N
allow VB N
calculation NN N
of IN N
recruitment NN o
rates NNS o
for IN N
a DT N
future JJ N
definitive JJ N
trial NN N
. . N

Summary NNP N
data NNS N
will MD N
indicate VB N
potential JJ N
variability NN N
, , N
magnitude NN N
and CC N
direction NN N
of IN N
difference NN N
between IN N
groups NNS N
. . N

Findings NNS N
will MD N
inform VB N
sample JJ N
size NN N
calculations NNS N
for IN N
a DT N
definitive JJ N
trial NN N
. . N

Thematic JJ N
analysis NN N
of IN N
qualitative JJ N
data NNS N
will MD N
be VB N
managed VBN N
using VBG N
the DT N
Framework NNP N
Approach NNP N
. . N

Framework NNP N
is VBZ N
an DT N
analytical JJ N
approach NN N
for IN N
qualitative JJ N
data NNS N
, , N
commonly RB N
used VBN N
in IN N
policy NN N
and CC N
medical JJ N
research NN N
. . N

DISCUSSION NNP N
If IN N
shown VBN N
to TO N
demonstrate VB N
effects NNS N
, , N
this DT N
intervention NN N
has VBZ N
the DT N
potential JJ N
to TO N
address VB N
aspects NNS N
of IN N
stroke NN N
recovery NN N
previously RB N
. . N

Not RB N
routinely RB N
addressed VBN N
in IN N
rehabilitation NN N
. . N

TRIAL NNP N
REGISTRATION NNP N
Registered NNP N
with IN N
Clinical NNP N
Trials.Gov NNP N
: : N
NCT02085226 NN N
on IN N
6th CD N
March NNP N
2014 CD N
. . N

-DOCSTART- -4004503- O O

Therapist NNP o
success NN o
and CC N
its PRP$ N
determinants NNS N
. . N

This DT N
study NN N
examined VBD N
the DT N
relatively RB N
unexplored JJ N
contribution NN N
of IN N
the DT N
therapist NN o
's POS o
performance NN o
in IN N
determining VBG N
outcomes NNS o
of IN o
treatment NN o
. . o

Nine JJ p
therapists NNS p
were VBD p
studied VBN i
: : i
three CD i
performed VBD i
supportive-expressive JJ i
psychotherapy NN i
; : i
three CD i
, , i
cognitive-behavioral JJ i
psychotherapy NN i
; : i
and CC i
three CD i
, , i
drug NN i
counseling NN i
. . i

Profound NNP N
differences NNS N
were VBD N
discovered VBN N
in IN N
the DT N
therapists NNS N
' POS N
success NN N
with IN N
the DT N
patients NNS N
in IN N
their PRP$ N
case NN N
loads VBZ N
. . N

Four CD N
potential JJ N
determinants NNS N
of IN N
these DT N
differences NNS N
were VBD N
explored VBN N
: : N
patient JJ o
factors NNS o
; : o
therapist JJ o
factors NNS o
; : o
patient-therapist JJ o
relationship NN o
factors NNS o
; : o
and CC N
therapy NN o
factors NNS o
. . o

Results NNS N
showed VBD N
that IN N
patient NN N
characteristics NNS N
within IN N
each DT N
case NN N
load NN N
( ( N
after IN N
random NN N
assignments NNS N
) ) N
were VBD N
similar JJ N
and CC N
disclosed VBD N
no DT N
differences NNS N
that WDT N
would MD N
have VB N
explained VBN N
the DT N
differences NNS N
in IN N
success NN N
; : N
therapist NN o
's POS o
personal JJ o
qualities NNS o
were VBD N
correlated VBN N
with IN N
outcomes NNS N
but CC N
not RB N
significantly RB N
( ( N
mean JJ N
r NN N
= NNP N
.32 NNP N
) ) N
; : N
an DT N
early-in-treatment JJ N
measure NN N
of IN N
the DT N
patient-therapist JJ o
relationship NN o
, , o
the DT o
Helping NNP o
Alliance NNP o
Questionnaire NNP o
, , N
yielded VBD N
significant JJ N
correlations NNS N
with IN N
outcomes NNS N
( ( N
mean JJ N
r NN N
= NNP N
.65 NNP N
) ) N
; : N
among IN N
the DT N
therapy NN N
techniques NNS N
, , N
purity NN o
provided VBD N
significant JJ N
correlations NNS N
with IN N
outcomes NNS N
( ( N
mean JJ N
r NN N
= NNP N
.44 NNP N
) ) N
, , N
both DT N
across IN N
therapists NNS N
and CC N
within IN N
each DT N
therapist NN N
's POS N
case NN N
load NN N
. . N

The DT N
three CD N
therapist-related JJ N
factors NNS N
were VBD N
moderately RB N
associated VBN N
with IN N
each DT N
other JJ N
. . N

-DOCSTART- -9742715- O O

Memory NN o
monitoring NN N
by IN N
animals NNS p
and CC p
humans NNS p
. . p

The DT N
authors NNS N
asked VBD N
whether IN N
animals NNS p
and CC p
humans NNS p
would MD N
use VB N
similarly RB N
an DT N
uncertain JJ N
response NN o
to TO N
escape VB N
indeterminate JJ N
memories NNS N
. . N

Monkeys NNS p
and CC p
humans NNS p
performed VBD p
serial JJ i
probe NN i
recognition NN i
tasks NNS i
that WDT N
produced VBD N
differential JJ N
memory NN N
difficulty NN N
across IN N
serial JJ N
positions NNS N
( ( N
e.g. NN N
, , N
primacy NN N
and CC N
recency NN N
effects NNS N
) ) N
. . N

Participants NNS p
were VBD N
given VBN N
an DT N
escape NN N
option NN N
that WDT N
let VBD N
them PRP N
avoid VB N
any DT N
trials NNS N
they PRP N
wished VBD N
and CC N
receive VB N
a DT N
hint NN N
to TO N
the DT N
trial NN N
's POS N
answer NN N
. . N

Across IN N
species NNS N
, , N
across IN N
tasks NNS N
, , N
and CC N
even RB N
across IN N
conspecifics NNS N
with IN N
sharper NN N
or CC N
duller NN N
memories NNS N
, , N
monkeys NNS p
and CC p
humans NNS p
used VBD o
the DT o
escape NN o
option NN o
selectively RB N
when WRB N
more RBR N
indeterminate JJ N
memory NN N
traces NNS N
were VBD N
probed VBN N
. . N

Their PRP$ N
pattern NN N
of IN N
escaping VBG N
always RB N
mirrored VBN N
the DT N
pattern NN N
of IN N
their PRP$ N
primary JJ N
memory NN N
performance NN N
across IN N
serial JJ N
positions NNS N
. . N

Signal-detection NN o
analyses NNS o
confirm VBP N
the DT N
similarity NN N
of IN N
the DT N
animals NNS N
' POS N
and CC N
humans NNS N
' POS N
performances NNS N
. . N

Optimality NNP o
analyses VBZ o
assess VB N
their PRP$ N
efficiency NN o
. . o

Several JJ N
aspects NNS N
of IN N
monkeys NNS N
' POS N
performance NN N
suggest VBP N
the DT N
cognitive JJ N
sophistication NN N
of IN N
their PRP$ N
decisions NNS N
to TO N
escape VB N
. . N

-DOCSTART- -8387067- O O

Radiation-induced JJ N
brachial JJ N
plexopathy NN N
: : N
neurological JJ N
follow-up NN N
in IN N
161 CD p
recurrence-free JJ p
breast NN p
cancer NN p
patients NNS p
. . p

PURPOSE VB N
The DT N
purpose NN N
was VBD N
to TO N
assess VB o
the DT o
incidence NN o
and CC o
clinical JJ o
manifestations NNS o
of IN N
radiation-induced JJ N
brachial JJ N
plexopathy NN N
in IN N
breast NN p
cancer NN p
patients NNS p
, , p
treated VBD p
according VBG p
to TO p
the DT p
Danish JJ p
Breast NNP p
Cancer NNP p
Cooperative NNP p
Group NNP p
protocols VBZ p
. . p

METHODS NNP N
AND CC N
MATERIALS NNP N
One NNP p
hundred CD p
and CC p
sixty-one JJ p
recurrence-free JJ p
breast NN p
cancer NN p
patients NNS p
were VBD p
examined VBN p
for IN p
radiation-induced JJ p
brachial JJ p
plexopathy NN p
after IN p
a DT p
median JJ p
follow-up JJ p
period NN p
of IN p
50 CD p
months NNS p
( ( p
13-99 JJ p
months NNS p
) ) p
. . p

After IN N
total JJ N
mastectomy NN N
and CC N
axillary JJ N
node NN N
sampling NN N
, , N
high-risk JJ p
patients NNS p
were VBD N
randomized VBN N
to TO N
adjuvant VB i
therapy NN i
. . i

One CD N
hundred VBD N
twenty-eight JJ N
patients NNS N
were VBD N
treated VBN N
with IN N
postoperative JJ i
radiotherapy NN i
with IN i
50 CD i
Gy NNP i
in IN N
25 CD N
daily JJ N
fractions NNS N
over IN N
5 CD N
weeks NNS N
. . N

In IN N
addition NN N
, , N
82 CD N
of IN N
these DT N
patients NNS N
received VBD N
cytotoxic JJ i
therapy NN i
( ( i
cyclophosphamide NN i
, , i
methotrexate NN i
, , i
and CC i
5-fluorouracil JJ i
) ) i
and CC N
46 CD N
received VBD N
tamoxifen NN i
. . i

RESULTS NNP N
Five CD N
percent NN N
and CC N
9 CD N
% NN N
of IN N
the DT N
patients NNS N
receiving VBG N
radiotherapy NN N
had VBD N
disabling NN o
and CC o
mild JJ o
radiation-induced JJ o
brachial NN o
plexopathy NN o
, , N
respectively RB N
. . N

Radiation-induced JJ o
brachial JJ o
plexopathy NN o
was VBD N
more RBR N
frequent JJ N
in IN N
patients NNS N
receiving VBG N
cytotoxic JJ N
therapy NN N
( ( N
p JJ N
= NNP N
0.04 CD N
) ) N
and CC N
in IN N
younger JJR N
patients NNS N
( ( N
p JJ N
= NNP N
0.04 CD N
) ) N
. . N

The DT N
clinical JJ N
manifestations NNS N
were VBD N
paraesthesia JJ o
( ( N
100 CD N
% NN N
) ) N
, , N
hypaesthesia NN o
( ( N
74 CD N
% NN N
) ) N
, , N
weakness NN o
( ( N
58 CD N
% NN N
) ) N
, , N
decreased VBN o
muscle NN o
stretch NN o
reflexes NNS o
( ( N
47 CD N
% NN N
) ) N
, , N
and CC N
pain NN o
( ( N
47 CD N
% NN N
) ) N
. . N

CONCLUSION VB N
The DT N
brachial JJ N
plexus NN N
is VBZ N
more RBR N
vulnerable JJ N
to TO N
large JJ N
fraction NN N
size NN N
. . N

Fractions NNS N
of IN N
2 CD N
Gy NNP N
or CC N
less JJR N
are VBP N
advisable JJ N
. . N

Cytotoxic NNP i
therapy NN i
adds VBZ N
to TO N
the DT N
damaging JJ N
effect NN N
of IN N
radiotherapy NN N
. . N

Peripheral JJ N
nerves NNS N
in IN N
younger JJR p
patients NNS p
seems VBZ N
more RBR N
vulnerable JJ N
. . N

Radiation-induced JJ N
brachial JJ N
plexopathy NN N
occurs VBZ N
mainly RB N
as IN N
diffuse NN N
damage NN N
to TO N
the DT N
brachial JJ N
plexus NN N
. . N

-DOCSTART- -10973645- O O

Randomized VBN N
trial NN N
of IN N
a DT N
stage-of-change NN i
oriented VBN i
smoking VBG i
cessation NN i
intervention NN i
in IN N
infertile NN p
and CC p
pregnant JJ p
women NNS p
. . p

OBJECTIVE NNP N
To TO N
assess VB N
a DT N
stage-of-change NN i
oriented VBN i
smoking VBG i
cessation NN i
intervention NN i
for IN N
infertile NN p
and CC p
pregnant JJ p
women NNS p
, , N
compared VBN N
with IN N
standard NN N
of IN N
care NN N
. . N

DESIGN NNP N
Randomized NNP N
controlled VBD N
trial NN N
. . N

SETTING NNP N
Three CD p
university NN p
teaching VBG p
hospitals NNS p
in IN p
Hamilton NNP p
, , p
Ontario NNP p
, , p
Canada NNP p
. . p

PATIENT NNP N
( ( N
S NNP N
) ) N
Infertile NNP p
women NNS p
at IN p
their PRP$ p
first JJ p
visit NN p
to TO p
a DT p
tertiary JJ p
referral JJ p
infertility NN p
clinic NN p
( ( p
n JJ p
= NNP p
94 CD p
) ) p
and CC p
new JJ p
patients NNS p
seeking VBG p
pre-natal JJ p
care NN p
( ( p
n JJ p
= NNP p
110 CD p
) ) p
who WP p
had VBD p
smoked VBN p
> NNP p
/= $ p
3 CD p
cigarettes NNS p
in IN p
the DT p
past JJ p
six CD p
months NNS p
. . p

INTERVENTION NNP N
( ( N
S NNP N
) ) N
A NNP N
three CD i
to TO i
five CD i
minute NN i
scripted VBN i
intervention NN i
and CC i
booklet NN i
specific NN i
to TO i
the DT i
woman NN i
's POS i
stage-of-change NN i
in IN i
the DT i
smoking NN i
continuum NN i
, , i
versus JJ i
standard NN i
of IN i
care NN i
. . i

Exhaled VBN i
carbon-monoxide NN i
( ( i
CO NNP i
) ) i
monitoring NN i
was VBD N
used VBN N
to TO N
validate VB N
exposure NN N
in IN N
both DT N
groups NNS N
. . N

MAIN NNP N
OUTCOME NNP N
MEASURE NNP N
( ( N
S NNP N
) ) N
Delta NNP o
stage-of-change NN o
and CC o
rate NN o
of IN o
maintained VBN o
cessation NN o
at IN N
12 CD N
months NNS N
post VBN N
follow-up JJ N
. . N

RESULT NNP N
( ( N
S NNP N
) ) N
Intervention NNP N
and CC N
control NN N
were VBD N
similarly RB N
effective JJ N
for IN N
infertile JJ N
women NNS N
: : N
the DT N
rate NN o
of IN o
maintained VBN o
cessation NN o
rose VBD N
significantly RB N
from IN N
4 CD N
% NN N
to TO N
24 CD N
% NN N
over IN N
twelve JJ N
months NNS N
, , N
with IN N
a DT N
mean JJ o
delta NN o
stage-of-change NN o
0.28 CD N
. . N

In IN N
prenatal JJ N
women NNS N
, , N
neither CC N
approach NN N
was VBD N
effective JJ N
. . N

Maintained VBN o
cessation NN o
did VBD N
not RB N
significantly RB N
change VBP N
from IN N
0 CD N
to TO N
12 CD N
months NNS N
( ( N
19 CD N
% NN N
to TO N
18 CD N
% NN N
) ) N
. . N

Mean JJ o
delta JJ o
stage-of-change NN o
declined VBN N
by IN N
-0.62 NNP N
. . N

CONCLUSION NNP N
( ( N
S NNP N
) ) N
For IN N
infertile JJ N
women NNS N
, , N
basic JJ N
information NN N
describing VBG N
the DT N
impact NN N
of IN N
smoking VBG N
on IN N
fertility NN N
, , N
along IN N
with IN N
exhaled JJ N
CO NNP N
monitoring NN N
and CC N
a DT N
more RBR N
intensive JJ N
intervention NN N
were VBD N
both DT N
highly RB N
effective JJ N
. . N

In IN N
pregnant JJ N
women NNS N
neither CC N
approach NN N
was VBD N
beneficial JJ N
, , N
with IN N
some DT N
evidence NN N
of IN N
post-partum JJ N
relapse NN N
. . N

-DOCSTART- -18783414- O O

Cemented VBN i
CeraOne NNP i
and CC i
porcelain NN i
fused VBD i
to TO i
TiAdapt NNP i
abutment JJ i
single-implant JJ i
crown JJ i
restorations NNS i
: : i
a DT N
10-year JJ N
comparative JJ N
follow-up NN N
study NN N
. . N

BACKGROUND NNP N
Long-term NNP N
data NNS N
comparing NN N
cemented VBN i
and CC N
noncemented VBN i
single-implant JJ i
restorations NNS i
has VBZ N
not RB N
been VBN N
reported VBN N
. . N

AIM NNP N
To TO N
compare VB N
clinical JJ o
and CC o
radiographic JJ o
performance NN o
of IN N
single-implant JJ i
crown NN i
restorations NNS i
made VBN N
by IN N
either DT N
directly RB N
baked VBN i
porcelain NN i
to TO i
custom-made JJ i
TiAdapt NNP i
titanium NN i
abutments NNS i
( ( N
Nobel NNP N
Biocare NNP N
AB NNP N
, , N
G?teborg NNP N
, , N
Sweden NNP N
) ) N
( ( N
test NN N
) ) N
or CC i
cement JJ i
crowns NNS i
onto IN i
CeraOne NNP i
( ( i
Nobel NNP i
Biocare NNP i
AB NNP i
) ) i
abutments NNS i
( ( i
control NN i
) ) i
after IN N
10 CD N
years NNS N
in IN N
function NN N
. . N

MATERIALS NNP N
AND CC N
METHODS NNP p
Altogether NNP p
, , p
35 CD p
consecutive JJ p
patients NNS p
were VBD p
provided VBN p
with IN p
41 CD p
turned VBD i
single JJ i
Br?nemark NNP i
System NNP i
implants NNS i
( ( i
Nobel NNP i
Biocare NNP i
AB NNP i
) ) i
in IN i
the DT p
partially RB p
edentulous JJ p
upper JJ p
jaw NN p
. . p

By IN p
random NN p
, , p
15 CD p
and CC p
20 CD p
patients NNS p
were VBD p
provided VBN p
with IN p
18 CD p
test NN i
and CC i
23 CD p
control NN i
implant JJ i
crowns NNS i
, , i
respectively RB p
. . p

Thereafter NNP o
, , o
clinical JJ o
and CC o
radiographic JJ o
data NNS o
were VBD o
collected VBN N
and CC N
compared VBN N
between IN N
the DT N
two CD N
groups NNS N
. . N

RESULTS NNP o
None NN o
of IN o
the DT i
implants NNS i
were VBD o
found VBN o
loose RB o
during IN o
the DT N
follow-up JJ N
period NN N
( ( N
100 CD o
% NN o
) ) o
. . o

Few JJ o
clinical JJ o
problems NNS o
were VBD o
observed VBN N
, , N
and CC N
the DT o
overall JJ o
average JJ o
marginal JJ o
bone NN o
loss NN o
was VBD o
0.26 CD N
mm NN N
( ( N
SD NNP N
0.64 CD N
) ) N
during IN N
10 CD N
years NNS N
in IN N
function NN N
. . N

After IN N
the DT N
final JJ N
tightening NN N
of IN N
the DT N
crowns NNS o
, , o
no DT o
significant JJ o
differences NNS o
were VBD o
observed VBN N
between IN N
the DT i
test NN i
and CC i
control NN i
groups NNS i
( ( N
p JJ N
> NNP N
.05 NNP N
) ) N
. . N

The DT N
head NN N
of IN N
the DT i
implants NNS i
was VBD i
placed VBN N
on IN N
an DT N
average JJ N
6.3 CD N
mm NN N
( ( N
SD NNP N
2.24 CD N
) ) N
below IN N
the DT N
cement/enamel JJ N
junction NN N
of IN N
the DT N
adjacent JJ N
teeth NN N
( ( N
range JJ N
2.5-10.0 JJ N
mm NN N
) ) i
. . i

Implants NNS i
with IN i
reported JJ N
mechanical JJ N
and/or NN N
mucosal NN N
problems NNS N
or CC N
placed VBD N
more JJR N
apically RB N
in IN N
relation NN N
to TO N
the DT N
adjacent JJ N
teeth NN N
did VBD N
not RB N
present VB N
more JJR o
bone JJ o
loss NN o
as IN o
compared VBN N
with IN i
implants NNS i
with IN i
no DT N
problems NNS N
or CC N
placed VBD N
more RBR N
coronally RB N
, , N
respectively RB N
( ( N
p JJ N
> NNP N
.05 NNP N
) ) N
. . N

CONCLUSIONS NNP N
There EX N
seems VBZ N
to TO N
be VB N
no DT N
obvious JJ o
clinical JJ o
or CC o
radiographic JJ o
differences NNS o
between IN o
the DT i
test NN i
and CC i
control VB i
single-implant JJ i
restorations NNS i
during IN i
10 CD N
years NNS N
of IN N
follow-up JJ N
. . N

Occasionally NNP N
, , N
some DT i
restorations NNS i
presented VBD i
loose JJ o
abutment JJ o
screws NNS o
and/or VBP o
fistulas NNS o
during IN o
follow-up JJ N
. . N

This DT N
implies VBZ N
a DT N
certain JJ N
need NN N
for IN N
maintenance NN N
where WRB N
a DT N
one-piece JJ i
single-implant JJ i
protocol NN i
( ( i
test NN i
) ) i
allows VBZ i
both DT N
for IN N
a DT N
simple JJ N
clinical JJ N
procedure NN N
at IN N
placement NN N
without IN N
cementation NN N
problems NNS N
, , N
as RB N
well RB N
as IN N
for IN N
an DT N
easy JJ N
and CC N
simple JJ N
maintenance NN N
of IN N
installed JJ i
single JJ i
implant NN i
crowns NNS i
in IN i
long-term JJ N
function NN N
. . N

-DOCSTART- -7910732- O O

Exposure NN N
reduced VBN N
agoraphobia NNS N
but CC N
not RB N
panic JJ N
, , N
and CC N
cognitive JJ i
therapy NN i
reduced VBD N
panic JJ N
but CC N
not RB N
agoraphobia RB N
. . N

Earlier JJR N
studies NNS N
showed VBD N
that IN N
cognitive JJ i
therapy NN i
has VBZ N
anti-panic JJ N
effects NNS N
and CC N
exposure NN N
has VBZ N
anti-agoraphobic JJ N
effects NNS N
while IN N
other JJ N
studies NNS N
suggest VBP N
that IN N
agoraphobia NN N
is VBZ N
a DT N
secondary JJ N
complication NN N
of IN N
panic JJ N
disorder NN N
. . N

It PRP N
was VBD N
therefore RB N
hypothesized VBN N
that IN N
cognitive JJ i
therapy NN i
not RB N
only RB N
reduces VBZ N
panic NN N
but CC N
also RB N
agoraphobia JJ N
and CC N
that IN N
it PRP N
potentiates VBZ N
the DT N
effects NNS N
of IN N
exposure NN N
in IN N
vivo NN N
. . N

Two CD p
groups NNS p
of IN p
12 CD p
severe JJ p
agoraphobics NNS p
were VBD p
treated VBN p
with IN N
4 CD N
sessions NNS N
of IN N
cognitive JJ i
therapy NN i
followed VBN i
by IN i
8 CD i
sessions NNS i
of IN i
cognitive JJ i
therapy NN i
combined VBN i
with IN i
in IN i
vivo NN i
exposure NN i
. . i

The DT N
other JJ N
12 CD p
received VBD p
4 CD i
sessions NNS i
of IN i
'associative JJ i
therapy NN i
' '' i
, , N
a DT N
presumably RB N
inert JJ N
treatment NN N
that WDT N
controls VBZ N
for IN N
therapist NN N
attention NN N
, , N
followed VBN N
by IN N
8 CD N
sessions NNS N
of IN N
in IN N
vivo NN N
exposure NN N
that WDT N
was VBD N
framed VBN N
in IN N
common JJ N
behavioral JJ N
terms NNS N
. . N

The DT N
initial JJ N
cognitive JJ N
therapy NN N
produced VBD N
a DT N
significant JJ N
reduction NN N
in IN N
panic JJ o
frequency NN o
, , N
while IN N
associative JJ N
therapy NN N
did VBD N
not RB N
affect VB N
panic NN N
. . N

Neither CC N
cognitive JJ i
therapy NN i
alone RB N
, , N
nor CC N
associate JJ i
therapy NN i
alone RB N
significantly RB N
reduced VBN N
depression NN o
, , o
state NN o
or CC o
trait NN o
anxiety NN o
, , o
self-rated JJ o
agoraphobia NN o
or CC o
behavioral JJ o
avoidance NN o
. . o

After IN N
adding VBG N
exposure NN N
however RB N
, , N
these DT N
parameters NNS N
were VBD N
clearly RB N
and CC N
significantly RB N
reduced VBN N
. . N

Cognitive JJ i
therapy NN i
did VBD N
not RB N
potentiate VB N
exposure NN N
effects NNS N
. . N

The DT N
results NNS N
are VBP N
discussed VBN N
. . N

-DOCSTART- -24986270- O O

The DT N
effects NNS N
of IN N
two CD N
Chinese JJ i
herbal JJ i
medicinal JJ i
formulae NN i
vs. FW N
placebo NN i
controls NNS N
for IN N
treatment NN N
of IN N
allergic JJ p
rhinitis NN p
: : p
a DT N
randomised JJ N
controlled VBN N
trial NN N
. . N

BACKGROUND NNP N
Allergic NNP p
rhinitis NN p
is VBZ N
a DT N
chronic JJ N
illness NN N
, , N
affecting VBG N
10 CD N
to TO N
40 CD N
% NN N
of IN N
the DT N
worldwide JJ N
population NN N
. . N

Chinese JJ N
herbal JJ N
medicines NNS N
, , N
the DT N
treatment NN N
of IN N
allergic JJ N
rhinitis NN N
, , N
adopted VBD N
thousands NNS N
of IN N
years NNS N
in IN N
ancient JJ N
China NNP N
, , N
has VBZ N
recently RB N
raised VBN N
much JJ N
attention NN N
among IN N
researchers NNS N
globally RB N
. . N

This DT N
study NN N
evaluates VBZ N
the DT N
effects NNS N
of IN N
two CD N
Chinese JJ i
herbal NNS i
formulae JJ i
[ JJ i
Cure-allergic-rhinitis NNP i
Syrup NNP i
( ( i
CS NNP i
) ) i
and CC i
Yu-ping-feng JJ i
San NNP i
( ( i
YS NNP i
) ) i
] NN i
in IN N
treating VBG N
undergraduate JJ p
nursing NN p
students NNS p
with IN p
allergic JJ p
rhinitis NN p
over IN p
a DT p
3-month JJ p
follow-up NN p
, , N
when WRB N
compared VBN N
to TO N
a DT N
placebo NN N
control NN N
group NN N
. . N

METHODS NNP N
A DT N
double-blind NN N
, , N
randomised VBD N
controlled VBN N
trial NN N
with IN N
repeated-measures NNS N
, , N
three-parallel-groups JJ N
design NN N
was VBD N
conducted VBN N
in IN N
a DT N
random JJ N
sample NN N
of IN N
249 CD p
participants NNS p
recruited VBN p
from IN p
one CD p
university NN p
in IN p
Hong NNP p
Kong NNP p
. . p

After IN N
baseline NN N
measurements NNS N
, , N
participants NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
CS NNP i
, , i
YS NNP i
, , i
or CC i
placebo NN i
groups NNS N
( ( N
n=83 JJ N
per IN N
group NN N
) ) N
. . N

The DT N
main JJ N
outcomes NNS N
, , N
including VBG N
symptom JJ o
severity NN o
, , o
quality NN o
of IN o
life NN o
, , o
and CC o
body NN o
constitution NN o
, , N
were VBD N
measured VBN N
with IN N
self-administered JJ o
questionnaires NNS o
at IN N
baseline NN N
and CC N
immediately RB N
, , N
1 CD N
and CC N
3 CD N
months NNS N
after IN N
the DT N
4-week JJ N
interventions NNS N
. . N

RESULTS $ N
240 CD p
participants NNS p
completed VBD p
the DT p
trial NN p
, , p
with IN p
9 CD p
( ( p
3.6 CD p
% NN p
) ) p
drop-outs NN p
. . p

The DT N
results NNS N
of IN N
Generalised JJ o
Estimating NNP o
Equations NNP o
test NN o
followed VBN N
by IN N
pairwise NN N
contrasts NNS N
tests NNS N
indicated VBD N
that IN N
the DT N
participants NNS N
who WP N
received VBD N
CS NNP i
showed VBD N
significantly RB N
greater JJR N
reduction NN o
of IN o
symptoms NNS o
( ( N
mean JJ N
difference NN N
of IN N
CS NNP N
vs. IN N
placebo=26.13-34.55 NN N
, , N
P NNP N
< NNP N
0.0005 CD N
) ) N
and CC N
improvements NNS o
in IN o
quality NN o
of IN o
life NN o
( ( N
mean JJ N
difference NN N
of IN N
CS NNP N
vs. IN N
placebo=12.81-16.76 NN N
, , N
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
and CC N
body NN o
constitution NN o
in IN o
'Qi-deficiency NN o
' '' o
, , o
'Yang-deficiency NN o
' '' o
, , o
and CC o
'Inherited VBD o
Special NNP o
' POS o
( ( N
mean JJ N
difference NN N
of IN N
CS NNP N
vs. IN N
placebo=7.05-8.12 JJ N
, , N
7.56-8.92 JJ N
, , N
and CC N
4.48-8.10 JJ N
, , N
P=0.01- NNP N
< NNP N
0.0005 CD N
, , N
0.001-0.004 CD N
, , N
and CC N
0.01- JJ N
< NN N
0.0005 CD N
, , N
accordingly RB N
, , N
at IN N
three CD N
post-tests NNS N
) ) N
. . N

The DT N
participants NNS N
who WP N
received VBD N
YS NNP N
also RB N
indicated VBD N
significant JJ N
greater JJR o
improvements NNS o
in IN o
symptom JJ o
severity NN o
, , o
quality NN o
of IN o
life NN o
, , o
and CC o
a DT o
few JJ o
patterns NNS o
of IN o
body NN o
constitution NN o
when WRB o
compared VBN N
to TO N
the DT N
placebo NN N
group NN N
. . N

However RB N
, , N
its PRP$ N
effects NNS N
were VBD N
lesser JJR N
in IN N
strength NN N
( ( N
i.e. FW N
, , N
smaller JJR N
effect NN N
sizes NNS o
) ) o
, , o
varieties NNS o
of IN o
symptoms NNS o
, , o
and CC o
body NN o
constitution NN o
and CC o
sustainability NN o
over IN o
the DT N
3 CD N
months NNS N
. . N

CONCLUSIONS VB N
The DT N
herbal JJ N
formula NN N
CS NNP N
was VBD N
found VBN N
effective JJ N
to TO N
reduce VB o
symptoms NNS o
and CC o
enhance JJ o
quality NN o
of IN o
life NN o
in IN o
young JJ N
adults NNS N
( ( N
nursing VBG N
students NNS N
) ) N
with IN N
allergic JJ N
rhinitis NN N
in IN N
'Yang- JJ N
and/or JJ N
Qi-deficiency NNP N
' POS N
body NN N
constitution NN N
. . N

Further NNP N
controlled VBD N
trials NNS N
of IN N
its PRP$ N
effects NNS N
in IN N
Chinese JJ N
and/or NNS N
Asians NNPS N
with IN N
allergic JJ N
rhinitis NN N
in IN N
terms NNS N
of IN N
socio-demographic JJ N
, , N
ethnic JJ N
and CC N
illness JJ N
characteristics NNS N
and CC N
a DT N
longer-term JJ N
follow-up NN N
are VBP N
recommended VBN N
. . N

TRIAL NNP N
REGISTRATION NNP N
The DT N
trial NN N
has VBZ N
registered VBN N
at IN N
ClinicalTrials.gov NNP N
with IN N
an DT N
ID NN N
: : N
NCT02027194 NNP N
( ( N
3 CD N
January NNP N
2014 CD N
) ) N
. . N

-DOCSTART- -19201326- O O

Effect NN N
of IN N
light-cured JJ N
filled VBN N
sealant NN N
on IN N
shear JJ N
bond NN N
strength NN N
of IN N
metal NN N
and CC N
ceramic JJ N
brackets NNS N
bonded VBN N
with IN N
a DT N
resin-modified JJ N
glass NN N
ionomer NN N
cement NN N
. . N

INTRODUCTION NNP N
Our PRP$ N
objective NN N
was VBD N
to TO N
evaluate VB N
the DT N
effects NNS N
of IN N
a DT N
highly RB N
filled VBN N
light-cured JJ i
sealant NN i
( ( i
HFLCS NNP i
) ) i
on IN N
the DT N
shear JJ N
bond NN N
strength NN N
and CC N
bond NN N
failure NN N
site NN N
of IN N
metal NN N
and CC N
ceramic JJ N
brackets NNS N
bonded VBN N
with IN N
resin-modified JJ N
glass NN N
ionomer NN N
cement NN N
( ( N
RMGIC NNP N
) ) N
. . N

METHODS NNP N
Eighty NNP p
freshly RB p
extracted VBD p
maxillary JJ p
premolars NNS p
were VBD p
randomly RB p
divided VBN p
into IN p
4 CD p
groups NNS p
( ( p
20 CD p
in IN p
each DT p
group NN p
) ) p
. . p

In IN N
all DT N
groups NNS N
, , N
the DT N
teeth NNS p
were VBD N
etched VBN N
with IN N
37 CD i
% NN i
phosphoric JJ i
acid NN i
for IN i
20 CD i
seconds NNS i
, , i
and CC i
RMGIC NNP i
( ( i
Fuji NNP i
Ortho NNP i
LC NNP i
, , i
GC NNP i
Europe NNP i
, , i
Leuven NNP i
, , i
Belgium NNP i
) ) i
was VBD N
used VBN N
for IN N
bracket NN N
bonding NN N
. . N

In IN N
groups NNS N
1 CD N
and CC N
3 CD N
, , N
the DT N
brackets NNS N
were VBD N
bonded VBN N
directly RB N
to TO N
etched VB N
enamel JJ N
surfaces NNS N
; : N
in IN N
groups NNS N
2 CD N
and CC N
4 CD N
, , N
the DT N
etched JJ N
enamel NN N
was VBD N
covered VBN N
with IN N
HFLCS NNP i
( ( i
Pro NNP i
Seal NNP i
, , i
Reliance NNP i
Orthodontic NNP i
Products NNP i
, , i
Itasca NNP i
, , i
Ill NNP i
) ) i
. . i

Groups $ N
1 CD N
and CC N
2 CD N
received VBD N
metal JJ i
brackets NNS i
, , N
and CC N
groups NNS N
3 CD N
and CC N
4 CD N
had VBD N
ceramic JJ i
brackets NNS i
. . i

The DT N
specimens NNS N
were VBD N
stored VBN N
in IN N
distilled JJ N
water NN N
at IN N
room NN N
temperature NN N
for IN N
24 CD N
hours NNS N
and CC N
subsequently RB N
tested VBN N
in IN N
shear JJ N
mode NN N
with IN N
a DT N
universal JJ N
testing NN N
machine NN N
. . N

After IN N
debonding VBG N
, , N
the DT N
teeth NNS N
and CC N
the DT N
brackets NNS N
were VBD N
examined VBN N
under IN N
a DT N
stereomicroscope NN N
( ( N
model JJ N
SMZ-1B NNP N
, , N
Nikon NNP N
, , N
Osaka NNP N
, , N
Japan NNP N
) ) N
at IN N
20-times JJ N
magnification NN N
to TO N
assess VB N
the DT N
residual JJ N
adhesive NN N
on IN N
the DT N
tooth NN N
surfaces NNS N
. . N

RESULTS NNP N
Interaction NNP N
between IN N
HFLCS NNP N
and CC N
bracket NN N
type NN N
was VBD N
not RB N
statistically RB N
significant JJ N
( ( N
P NNP N
= NNP N
0.15 CD N
) ) N
. . N

Pretreatment NN N
with IN N
HFLCS NNP o
did VBD o
not RB o
cause VB o
a DT o
statistically RB o
significant JJ o
change NN o
in IN o
the DT o
shear JJ o
bond NN o
values NNS o
of IN o
either DT o
metal NN o
or CC o
ceramic JJ o
brackets NNS o
( ( N
P NNP N
= NNP N
0.38 CD N
) ) N
. . N

Shear JJ o
bond NN o
values NNS o
of IN o
the DT o
ceramic JJ o
brackets NNS o
were VBD N
higher JJR N
than IN N
those DT N
of IN N
the DT N
metal JJ N
brackets NNS N
independent JJ N
of IN N
HFLCS NNP N
application NN N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

No DT N
significant JJ N
differences NNS N
were VBD N
found VBN N
in IN N
bond NN o
failure NN o
modes VBZ o
in IN N
the DT N
4 CD N
groups NNS N
. . N

CONCLUSIONS NNP N
HFLCS NNP N
application NN N
on IN N
enamel NN N
etched VBN N
with IN N
37 CD N
% NN N
phosphoric JJ N
acid NN N
did VBD N
not RB N
affect VB N
the DT N
bond NN o
strength NN o
values NNS o
and CC N
the DT N
bond NN o
failure NN o
modes NNS o
of IN N
metal NN N
and CC N
ceramic JJ N
brackets NNS N
bonded VBN N
with IN N
RMGIC NNP N
. . N

RESULTS NNP N
Interaction NNP N
between IN N
HFLCS NNP N
and CC N
bracket NN N
type NN N
was VBD N
not RB N
statistically RB N
significant JJ N
( ( N
P NNP N
= NNP N
0.15 CD N
) ) N
. . N

Pretreatment NN N
with IN N
HFLCS NNP N
did VBD N
not RB N
cause VB N
a DT N
statistically RB N
significant JJ N
change NN N
in IN N
the DT N
shear JJ o
bond NN o
values NNS o
of IN o
either DT o
metal NN o
or CC o
ceramic JJ o
brackets NNS o
( ( N
P NNP N
= NNP N
0.38 CD N
) ) N
. . N

Shear JJ o
bond NN o
values NNS o
of IN o
the DT o
ceramic JJ o
brackets NNS o
were VBD N
higher JJR N
than IN N
those DT N
of IN N
the DT N
metal JJ N
brackets NNS N
independent JJ N
of IN N
HFLCS NNP N
application NN N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

No DT N
significant JJ N
differences NNS N
were VBD N
found VBN N
in IN N
bond NN N
failure NN N
modes VBZ N
in IN N
the DT N
4 CD N
groups NNS N
. . N

CONCLUSIONS NNP N
HFLCS NNP N
application NN N
on IN N
enamel NN N
etched VBN N
with IN N
37 CD N
% NN N
phosphoric JJ N
acid NN N
did VBD N
not RB N
affect VB N
the DT N
bond NN N
strength NN N
values NNS N
and CC N
the DT N
bond NN N
failure NN N
modes NNS N
of IN N
metal NN N
and CC N
ceramic JJ N
brackets NNS N
bonded VBN N
with IN N
RMGIC NNP N
. . N

-DOCSTART- -18270751- O O

The DT N
effects NNS N
of IN N
candesartan NN i
on IN N
diabetes NNS o
glomerulopathy NNS o
: : o
a DT N
double-blind NN N
, , N
placebo-controlled JJ i
trial NN N
. . N

Our PRP$ N
objective NN N
was VBD N
to TO N
study VB N
the DT N
effects NNS N
of IN N
candesartan NN i
on IN N
diabetic JJ o
glomerulopathy NN o
in IN N
young JJ p
normoalbuminuric JJ p
and CC p
normotensive JJ p
patients NNS p
with IN p
type JJ p
1 CD p
diabetes NNS p
in IN N
a DT N
double-blind JJ N
, , N
placebo-controlled JJ i
trial NN N
. . N

In IN N
13 CD p
patients NNS p
aged VBN p
24 CD p
years NNS p
at IN p
baseline NN p
, , N
we PRP N
evaluated VBD N
blood NN N
pressure NN N
, , N
kidney NN N
biopsies NNS N
and CC N
kidney NN N
function NN N
tests NNS N
at IN N
baseline NN N
and CC N
after IN N
5 CD N
years NNS N
of IN N
treatment NN N
. . N

Kidney NNP N
biopsies NNS N
were VBD N
examined VBN N
with IN N
light JJ N
and CC N
electron JJ N
microscopy NN N
, , N
glomerular JJ N
filtration NN N
rate NN N
and CC N
effective JJ N
renal JJ N
plasma NN N
flow NN N
determined VBD N
with IN N
inulin NN N
and CC N
para-aminohippuric JJ N
acid NN N
clearances NNS N
. . N

Two CD N
patients NNS N
in IN N
the DT N
placebo NN i
group NN N
needed VBD N
antihypertensive JJ N
treatment NN N
because IN N
they PRP N
developed VBD N
microalbuminuria NNS o
and/or JJ o
hypertension NN o
, , N
but CC N
no DT N
patient NN N
in IN N
the DT N
candesartan NN i
group NN N
did VBD N
. . N

A DT N
significant JJ N
reduction NN N
in IN N
mesangial JJ o
matrix NN o
volume NN o
and CC o
mesangial JJ o
volume NN o
occurred VBD N
in IN N
the DT N
candesartan NN N
group NN N
, , N
although IN N
changes NNS N
in IN N
morphological JJ o
parameters NNS o
were VBD N
similar JJ N
between IN N
groups NNS N
. . N

Office NNP o
blood NN o
pressure NN o
was VBD N
significantly RB N
lower JJR N
in IN N
the DT N
candesartan NN i
group NN N
at IN N
follow-up NN N
than IN N
in IN N
the DT N
placebo NN i
group NN N
. . N

Deterioration NN N
in IN N
morphological JJ o
parameters NNS o
observed VBD N
in IN N
earlier JJR N
studies NNS N
of IN N
our PRP$ N
patients NNS N
did VBD N
not RB N
become VB N
worse JJR N
during IN N
treatment NN N
with IN N
candesartan NN i
or CC N
placebo NN i
. . i

The DT N
effects NNS N
of IN N
candesartan NN i
, , N
with IN N
reduction NN N
in IN N
morphological JJ o
parameters NNS o
and CC o
lowering NN o
of IN o
blood NN o
pressure NN o
, , N
might MD N
influence VB N
future JJ N
treatment NN N
of IN N
glomerulopathy NN N
in IN N
type NN p
1 CD p
diabetes VBZ p
patients NNS p
. . p

-DOCSTART- -18989547- O O

Comparison NNP N
between IN N
intermittent JJ i
mandatory JJ i
ventilation NN i
and CC N
synchronized JJ i
intermittent NN i
mandatory JJ i
ventilation NN i
with IN N
pressure NN i
support NN i
in IN p
children NNS p
. . p

OBJECTIVE NN N
To TO N
compare VB N
intermittent JJ i
mandatory JJ i
ventilation NN i
( ( i
IMV NNP i
) ) i
with IN N
synchronized JJ i
intermittent JJ i
mandatory NN i
ventilation NN i
plus CC i
pressure NN i
support NN i
( ( i
SIMV+PS NNP i
) ) i
in IN N
terms NNS N
of IN N
time NN o
on IN o
mechanical JJ o
ventilation NN o
, , o
duration NN o
of IN o
weaning VBG o
and CC o
length NN o
of IN o
stay NN o
in IN o
a DT o
pediatric JJ o
intensive JJ o
care NN o
unit NN o
( ( p
PICU NNP p
) ) p
. . p

METHODS NNP N
This DT N
was VBD N
a DT N
randomized JJ N
clinical JJ N
trial NN N
that WDT N
enrolled VBD p
children NNS p
aged VBN p
28 CD p
days NNS p
to TO p
4 CD p
years NNS p
who WP p
were VBD p
admitted VBN p
to TO p
a DT p
PICU NNP p
between IN p
October NNP p
of IN p
2005 CD p
and CC p
June NNP p
of IN p
2007 CD p
and CC p
put VB p
on IN p
mechanical JJ i
ventilation NN i
( ( i
MV NNP i
) ) i
for IN p
more JJR p
than IN p
48 CD p
hours NNS p
. . p

These DT N
patients NNS N
were VBD N
allocated VBN N
to TO N
one CD N
of IN N
two CD N
groups NNS N
by IN N
drawing VBG N
lots NNS N
: : N
IMV NNP i
group NN N
( ( i
IMVG NNP i
; : i
n CC N
= VB N
35 CD N
) ) N
and CC N
SIMV+PS NNP i
group NN N
( ( i
SIMVG NNP i
; : i
n CC N
= VB N
35 CD N
) ) N
. . N

Children NNP p
were VBD p
excluded VBN p
if IN p
they PRP p
had VBD p
undergone JJ p
tracheotomy NN p
or CC p
had VBD p
chronic JJ p
respiratory NN p
diseases NNS p
. . p

Data NNS N
on IN N
oxygenation NN o
and CC o
ventilation NN o
were VBD N
recorded VBN N
at IN N
admission NN N
and CC N
at IN N
the DT N
start NN N
of IN N
weaning VBG N
. . N

RESULTS CC N
There EX N
were VBD N
no DT N
statistical JJ N
differences NNS N
between IN N
the DT N
groups NNS N
in IN N
terms NNS N
of IN N
age NN o
, , o
sex NN o
, , o
indication NN o
for IN o
MV NNP o
, , o
PRISM NNP o
score NN o
, , o
Comfort NNP o
scale NN o
, , o
use NN o
of IN o
sedatives NNS o
or CC o
ventilation NN o
and CC o
oxygenation NN o
parameters NNS o
. . o

The DT N
median JJ o
time NN o
on IN o
MV NNP o
was VBD N
5 CD N
days NNS N
for IN N
both DT N
groups NNS N
( ( N
p JJ N
= NNP N
0.120 CD N
) ) N
. . N

There EX N
were VBD N
also RB N
no DT N
statistical JJ N
differences NNS N
between IN N
the DT N
two CD N
groups NNS N
for IN N
duration NN o
of IN o
weaning VBG o
[ JJ i
IMVG NNP i
: : i
1 CD N
day NN N
( ( N
1-6 JJ N
) ) N
vs. FW N
SIMVG NNP i
: : i
1 CD N
day NN N
( ( N
1-6 JJ N
) ) N
; : N
p CC N
= $ N
0.262 CD N
] NN N
or CC N
length NN o
of IN o
hospital NN o
stay NN o
[ JJ i
IMVG NNP i
: : i
8 CD N
days NNS N
( ( N
2-22 JJ N
) ) N
vs. FW N
SIMVG NNP i
: : i
6 CD N
days NNS N
( ( N
3-20 JJ N
) ) N
; : N
p CC N
= $ N
0.113 CD N
] NNP N
. . N

CONCLUSION NNP N
Among IN N
the DT N
children NNS p
studied VBN p
here RB p
, , N
there EX N
was VBD N
no DT N
statistically RB N
significant JJ N
difference NN N
between IN N
IMV NNP i
and CC N
SIMV+PS NNP i
in IN N
terms NNS N
of IN N
time NN N
on IN N
MV NNP o
, , o
duration NN o
of IN o
weaning VBG o
or CC o
time NN o
spent VBN o
in IN o
the DT o
PICU NNP o
. . o

ClinicalTrials.govID NN N
: : N
NCT00549809 NNP N
. . N

-DOCSTART- -6364880- O O

Suppression NN N
of IN N
immediate JJ N
and CC N
late JJ N
anti-IgE-induced JJ o
skin NN o
reactions NNS o
by IN N
topically RB N
applied VBN N
alcohol/onion NN i
extract NN i
. . i

In IN N
a DT N
double JJ N
blind NN N
study NN N
, , N
alcohol/onion NN i
extract NN i
( ( i
5 CD i
% NN i
ethanol NN i
) ) i
was VBD N
injected VBN N
simultaneously RB N
with IN N
20 CD i
IU NNP i
and CC i
200 CD i
IU NNP i
rabbit NN i
anti-human-IgE JJ i
intradermally RB i
in IN N
12 CD p
adult NN p
volunteers NNS p
( ( p
6 CD p
atopics NNS p
, , p
6 CD p
non-atopics NNS p
) ) p
. . p

Diameters NNS N
of IN N
wheals NNS N
and CC N
flares NNS N
were VBD N
measured VBN N
10 CD N
min NN N
after IN N
and CC N
compared VBN N
with IN N
control NN N
sites NNS N
challenged VBD N
with IN N
20 CD N
IU NNP N
and CC N
200 CD N
IU NNP N
anti-IgE NN i
in IN i
a DT i
5 CD i
% NN i
ethanol JJ i
solution NN N
. . N

The DT N
skin NN N
sites NNS N
were VBD N
then RB N
treated VBN N
epidermally RB N
with IN N
45 CD i
% NN i
alcohol/onion NN i
extract NN i
and CC N
45 CD i
% NN i
ethanol NN i
under IN N
occlusion NN N
. . N

Diameters NNS N
of IN N
late JJ N
cutaneous JJ N
reactions NNS N
were VBD N
measured VBN N
hourly RB N
. . N

Oedema NNP N
formation NN N
was VBD N
clinically RB N
estimated VBN N
according VBG N
to TO N
an DT N
arbitrary JJ N
scale NN N
and CC N
skin NN N
thickness NN N
measured VBN N
with IN N
a DT N
calliper NN N
. . N

In IN N
the DT N
onion-treated JJ i
skin NN N
sites VBZ N
the DT N
wheal JJ o
areas NNS o
were VBD N
significantly RB o
reduced VBN o
( ( N
20 CD N
IU NNP N
: : N
control NN N
: : N
108 CD N
+/- JJ N
53 CD N
mm2 NN N
; : N
onion NN N
69 CD N
+/- JJ N
42 CD N
mm2 NN N
, , N
P NNP N
less JJR N
than IN N
0.05 CD N
; : N
200 CD N
IU NNP N
anti-IgE JJ N
: : N
control NN N
: : N
152 CD N
+/- JJ N
25 CD N
mm2 NN N
, , N
onion NN N
: : N
138 CD N
+/- JJ N
26 CD N
mm2 NN N
, , N
P NNP N
less JJR N
than IN N
0.02 CD N
) ) N
. . N

The DT N
oedema JJ o
formation NN o
during IN N
the DT N
late JJ N
phase NN N
skin JJ N
reaction NN N
was VBD N
markedly RB N
depressed JJ N
( ( N
P NNP N
less JJR N
than IN N
0.005 CD N
at IN N
2 CD N
h NN N
, , N
P NNP N
less JJR N
than IN N
0.01 CD N
at IN N
4 CD N
and CC N
6 CD N
h NN N
, , N
P NNP N
less JJR N
than IN N
0.02 CD N
at IN N
8 CD N
h NN N
) ) N
. . N

The DT N
extent NN N
of IN N
late JJ N
skin NN o
reactions NNS o
was VBD N
slightly RB N
, , N
but CC N
not RB N
significantly RB N
reduced VBN N
. . N

Obviously RB N
, , N
onions NNS i
contain VBP N
pharmacologically RB N
active JJ N
substances NNS N
with IN N
anti-inflammatory JJ N
and/or NN N
allergic NN N
properties NNS N
. . N

-DOCSTART- -15093843- O O

Calcium NNP i
chloride NN i
before IN i
i.v NN i
. . i

diltiazem NN i
in IN N
the DT N
management NN o
of IN o
atrial JJ o
fibrillation NN o
. . o

Diltiazem NNP i
is VBZ N
commonly RB N
used VBN N
to TO N
treat VB N
atrial JJ p
fibrillation NN p
or CC p
flutter NN p
( ( p
AFF NNP p
) ) p
with IN N
rapid JJ N
ventricular JJ N
response NN N
( ( N
RVR NNP N
) ) N
. . N

Although IN N
it PRP N
is VBZ N
very RB N
effective JJ N
for IN N
rate NN o
control NN o
, , N
up RB N
to TO N
an DT N
18 CD N
% NN N
prevalence NN N
of IN N
reported VBN N
diltiazem-induced JJ o
hypotension NN o
[ NN o
defined VBN o
by IN o
systolic JJ o
blood NN o
pressure NN o
( ( o
SBP NNP o
) ) o
< VBD o
90 CD o
mm NN o
Hg NNP o
] NNP o
, , N
and CC N
a DT N
mean NN N
of IN N
9.7 CD N
% NN N
hypotension NN o
have VBP N
been VBN N
reported VBN N
from IN N
several JJ N
studies NNS N
totaling VBG N
over IN p
450 CD p
patients NNS p
. . p

This DT N
hypotension NN o
may MD N
complicate VB N
therapy NN N
. . N

Our PRP$ N
objective NN N
was VBD N
to TO N
determine VB N
if IN N
calcium JJ i
chloride NN i
( ( i
CaCl NNP i
( ( i
2 CD i
) ) i
) ) i
pre-treatment NN N
would MD N
blunt VB N
a DT N
SBP NNP o
drop NN o
after IN N
i.v NN N
. . N

diltiazem NN N
, , N
while IN N
allowing VBG N
diltiazem NN i
to TO N
maintain VB N
its PRP$ N
efficacy NN N
. . N

A DT N
prospective JJ N
, , N
randomized VBN N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
study NN N
was VBD N
conducted VBN N
. . N

Seventy-eight JJ p
patients NNS p
with IN p
AFF NNP p
and CC p
a DT p
ventricular JJ p
rate NN p
of IN p
> NNP p
/= NNP p
120 CD p
beats NNS p
per IN p
minute NN p
were VBD p
enrolled VBN p
. . p

Half NNP N
received VBD N
i.v JJ N
. . N

CaCl NNP i
( ( i
2 CD i
) ) i
pre-treatment NN N
; : N
the DT N
other JJ N
half NN N
received VBD N
placebo NN i
. . i

All DT N
patients NNS N
then RB N
received VBD N
i.v NN N
. . N

diltiazem NN i
in IN N
a DT N
standard NN N
, , N
weight-based JJ N
dose NN N
. . N

A DT N
second JJ N
dose NN N
of IN N
CaCl NNP N
( ( N
2 CD N
) ) N
pre-treatment NN N
or CC N
placebo NN i
and CC N
diltiazem NN i
was VBD N
given VBN N
if IN N
clinically RB N
indicated VBN N
for IN N
additional JJ N
rate NN N
control NN N
. . N

Both DT N
CaCl NNP N
( ( N
2 CD N
) ) N
and CC N
placebo JJ i
pre-treatment JJ N
groups NNS N
had VBD N
equal JJ N
lowering NN N
of IN N
heart NN o
rate NN o
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
. . N

There EX N
were VBD N
no DT N
adverse JJ o
events NNS o
in IN N
the DT N
calcium NN N
pre-treatment NN N
study NN N
arm NN N
. . N

One CD p
patient NN p
in IN p
the DT p
placebo NN p
group NN p
became VBD N
paradoxically RB N
more JJR N
tachycardic JJ o
and CC o
apneic NN o
after IN N
the DT N
diltiazem JJ N
infusion NN N
. . N

Although IN N
i.v NN N
. . N

CaCl NNP N
( ( N
2 CD N
) ) N
seems VBZ N
to TO N
be VB N
equally RB N
safe JJ N
compared VBN N
to TO N
placebo VB N
as IN N
a DT N
pre-treatment NN N
in IN N
the DT N
management NN N
of IN N
AFF NNP N
with IN N
RVR NNP N
, , N
we PRP N
were VBD N
unable JJ N
to TO N
find VB N
a DT N
statistically RB N
significant JJ N
blunting NN o
of IN o
SBP NNP o
drop NN o
with IN N
CaCl NNP N
( ( N
2 CD N
) ) N
i.v NN N
. . N

pre-treatment NN N
. . N

Until IN N
further JJ N
research NN N
determines VBZ N
a DT N
benefit NN N
exists VBZ N
, , N
we PRP N
can MD N
not RB N
recommend VB N
i.v NN N
. . N

CaCl NNP i
( ( i
2 CD i
) ) i
pre-treatment NN N
before IN N
diltiazem NN i
in IN N
the DT N
treatment NN N
of IN N
AFF NNP N
with IN N
RVR NNP N
. . N

-DOCSTART- -20796074- O O

Effect NN N
of IN N
thermal JJ N
stress NN N
, , N
restricted VBD i
feeding NN i
and CC N
combined VBN i
stresses NNS i
( ( i
thermal JJ i
stress NN i
and CC i
restricted VBD i
feeding VBG i
) ) i
on IN N
growth NN N
and CC N
plasma VB N
reproductive JJ N
hormone NN N
levels NNS N
of IN N
Malpura NNP p
ewes FW p
under IN p
semi-arid JJ p
tropical JJ p
environment NN p
. . p

A DT N
study NN N
was VBD N
conducted VBN N
to TO N
assess VB N
the DT N
effect NN N
of IN N
thermal NN N
, , N
nutritional JJ N
and CC N
combined JJ N
stresses NNS N
( ( N
thermal JJ N
and CC N
nutritional JJ N
) ) N
on IN N
the DT N
growth NN N
, , N
oestradiol NN N
and CC N
progesterone NN N
levels NNS N
during IN N
oestrus NN N
cycles NNS N
in IN N
Malpura NNP p
ewes NN p
. . p

Twenty-eight JJ p
adult NN p
Malpura NNP p
ewes NN p
were VBD p
used VBN p
in IN N
the DT N
present JJ N
study NN N
. . N

The DT N
ewes NN N
were VBD N
randomly RB N
allocated VBN N
into IN N
four CD N
groups NNS N
, , N
viz. NN N
, , N
GI NNP N
( ( N
n=7 RB N
; : N
control NN i
) ) i
, , N
GII NNP N
( ( N
n=7 RB N
; : N
thermal JJ i
stress NN i
) ) i
, , N
GIII NNP N
( ( N
n=7 RB N
; : N
restricted VBN i
feeding NN i
) ) i
and CC N
GIV NNP N
( ( N
n=7 RB N
; : N
combined VBN i
stress NN i
) ) i
. . N

The DT N
animals NNS p
were VBD p
stall JJ i
fed VBN i
with IN i
a DT i
diet JJ i
consisting NN i
of IN i
60 CD i
% NN i
roughage NN i
and CC i
40 CD i
% NN i
concentrate NN i
. . i

GI NNP N
and CC N
GII NNP N
ewes NN N
were VBD N
provided VBN N
with IN N
ad NN N
libitum NN N
feeding VBG N
while IN N
GIII NNP N
and CC N
GIV NNP N
ewes NN N
were VBD N
provided VBN N
with IN N
restricted JJ N
feed NN N
( ( N
30 CD N
% NN N
intake NN N
of IN N
GI NNP N
and CC N
GII NNP N
ewes NN N
) ) N
to TO N
induce VB N
nutritional JJ N
insufficiency NN N
. . N

GII NNP N
and CC N
GIV NNP N
ewes NN N
were VBD N
kept VBN N
in IN N
climatic JJ N
chamber NN N
at IN N
40?C CD N
and CC N
55 CD N
% NN N
RH NNP N
for IN N
6 CD N
h NNS N
a DT N
day NN N
between IN N
10:00 CD N
and CC N
16:00 CD N
hours NNS N
to TO N
induce VB N
thermal JJ N
stress NN N
for IN N
a DT N
period NN N
of IN N
two CD N
oestrous JJ N
cycles NNS N
. . N

Parameters NNS N
studied VBD N
were VBD o
body JJ o
weight NN o
, , o
oestrus NN o
incidences NNS o
, , o
plasma JJ o
oestradiol IN o
17-? JJ o
, , o
plasma JJ o
progesterone NN o
, , o
conception NN o
rate NN o
, , o
gestation NN o
period NN o
, , o
lambing VBG o
rate NN o
, , o
and CC o
birth NN o
weight NN o
of IN o
lambs NN o
. . o

The DT N
results NNS N
indicate VBP N
that IN N
combined VBD N
stress NN N
significantly RB N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
reduced VBN o
body NN o
weight NN o
, , o
oestrus JJ o
duration NN o
, , o
birth NN o
weight NN o
of IN o
lambs NN o
, , o
and CC o
oestradiol JJ o
17-? JJ o
whereas NNS o
significantly RB o
( ( o
p JJ o
< NNP o
0.05 CD o
) ) o
increased VBD o
oestrus JJ o
cycle NN o
length NN o
and CC o
progesterone NN o
. . o

Furthermore RB o
, , N
the DT N
results NNS N
reveal VBP N
that IN N
on IN N
comparative JJ N
basis NN N
, , N
ewes NN N
were VBD N
able JJ N
to TO N
better VB N
adapt NN N
in IN N
terms NNS o
of IN o
growth NN o
and CC o
reproduction NN o
to TO o
restricted VB N
feeding NN N
than IN N
thermal JJ N
stress NN N
. . N

However RB N
, , N
when WRB N
restricted VBD N
feeding NN N
was VBD N
coupled VBN N
with IN N
thermal JJ N
stress NN N
it PRP N
had VBD N
significant JJ N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
influence NN N
on IN N
body NN o
weight NN o
, , o
average JJ o
daily JJ o
gain NN o
, , o
oestradiol JJ o
17-? JJ o
and CC o
progesterone JJ o
concentrations NNS o
. . o

This DT o
showed VBD N
that IN N
combined JJ N
stress NN N
were VBD N
more JJR N
detrimental JJ N
for IN N
these DT N
reproductive JJ N
hormones NNS N
in IN N
Malpura NNP N
ewes NN N
under IN N
a DT N
hot JJ N
semi-arid JJ N
environment NN N
. . N

-DOCSTART- -21048041- O O

Pharmacogenetic JJ N
interaction NN N
analysis NN N
for IN N
the DT N
efficacy NN N
of IN N
systemic JJ N
treatment NN N
in IN N
metastatic JJ p
colorectal JJ p
cancer NN p
. . p

BACKGROUND NNP N
Pharmacogenetic NNP N
markers NNS N
related VBN N
to TO N
drug NN N
metabolism NN N
and CC N
mechanisms NNS N
of IN N
action NN N
could MD N
help VB N
to TO N
better VB N
select JJ N
patients NNS p
with IN p
metastatic JJ p
colorectal NN p
cancer NN p
( ( p
mCRC NN p
) ) p
for IN N
treatment NN N
. . N

Genetic JJ N
interaction NN N
analysis NN N
is VBZ N
used VBN N
as IN N
a DT N
rational JJ N
tool NN N
to TO N
study VB N
the DT N
contribution NN N
of IN N
polygenic JJ N
variation NN N
in IN N
relation NN N
to TO N
drug NN N
response NN N
. . N

PATIENTS NNP N
AND CC N
METHODS NNP N
A NNP N
selection NN N
of IN N
17 CD p
polymorphisms NNS p
in IN p
genes NNS p
encoding VBG p
drug NN p
targets NNS p
, , p
pathway NN o
molecules NNS o
and CC o
detoxification NN o
enzymes NNS o
was VBD p
analyzed VBN p
in IN p
279 CD p
previously RB p
untreated JJ p
mCRC NN p
patients NNS p
treated VBN p
with IN p
capecitabine NN i
, , i
oxaliplatin NN i
and CC i
bevacizumab NN i
( ( i
CAPOX-B NNP i
) ) i
. . i

Multifactor NNP N
dimensionality NN N
reduction NN N
analysis NN N
was VBD N
used VBN N
to TO N
identify VB N
a DT N
genetic JJ o
interaction NN o
profile NN o
for IN o
progression-free JJ o
survival NN o
( ( o
PFS NNP o
) ) o
. . o

RESULTS NNP N
Median JJ N
PFS NNP o
was VBD N
10.9 CD N
[ JJ N
95 CD N
% NN N
confidence NN N
interval NN N
( ( N
CI NNP N
) ) N
9.4-12.4 CD N
] JJ N
months NNS N
. . N

A NNP N
genetic JJ o
interaction NN o
profile NN o
consisting VBG N
of IN N
the DT N
TYMS NNP N
enhancer NN N
region NN N
and CC N
VEGF NNP N
+405G NNP N
> NNP N
C NNP N
polymorphisms NN N
was VBD N
significantly RB N
associated VBN N
with IN N
PFS NNP N
. . N

Median JJ o
PFS NNP o
was VBD N
13.3 CD N
( ( N
95 CD N
% NN N
CI NNP N
11.4-15.3 CD N
) ) N
and CC N
9.7 CD N
( ( N
95 CD N
% NN N
CI NNP N
7.6-11.8 CD N
) ) N
months NNS N
for IN N
the DT N
beneficial JJ N
and CC N
unfavorable JJ N
genetic JJ o
profiles NNS o
, , N
respectively RB N
, , N
corresponding VBG N
to TO N
a DT N
hazards NNS N
ratio NN N
for IN N
PFS NNP o
of IN N
1.58 CD N
( ( N
95 CD N
% NN N
CI NNP N
1.14-2.19 CD N
) ) N
. . N

None NN N
of IN N
the DT N
studied JJ N
polymorphisms NNS N
were VBD N
individually RB N
associated VBN N
with IN N
PFS NNP N
. . N

CONCLUSIONS NNP N
Our PRP$ N
results NNS N
support VB N
a DT N
genetic JJ o
interaction NN o
between IN N
the DT N
TYMS NNP N
enhancer NN N
region NN N
and CC N
VEGF NNP N
+405G NNP N
> NNP N
C NNP N
polymorphisms NN N
as IN N
a DT N
predictor NN N
of IN N
the DT N
efficacy NN N
of IN N
CAPOX-B NNP N
in IN N
mCRC NN p
patients NNS p
. . p

-DOCSTART- -24215858- O O

Menopausal NNP o
quality NN o
of IN o
life NN o
: : o
RCT NNP i
of IN i
yoga NN i
, , i
exercise NN i
, , i
and CC i
omega-3 JJ i
supplements NNS i
. . i

OBJECTIVE IN N
The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
determine VB N
the DT N
efficacy NN N
of IN N
3 CD i
nonhormonal JJ i
therapies NNS i
for IN N
the DT N
improvement NN N
of IN N
menopause-related JJ o
quality NN o
of IN o
life NN o
in IN N
women NNS p
with IN p
vasomotor NN p
symptoms NNS p
. . p

STUDY NNP N
DESIGN NNP N
We PRP N
conducted VBD N
a DT N
12-week JJ N
3 CD N
? . N
2 CD N
randomized VBD N
, , N
controlled VBD N
, , N
factorial JJ N
design NN N
trial NN N
. . N

Peri- NN p
and CC p
postmenopausal JJ p
women NNS p
, , p
40-62 JJ p
years NNS p
old JJ p
, , p
were VBD N
assigned VBN N
randomly RB N
to TO i
yoga VB i
( ( N
n JJ N
= NNP N
107 CD N
) ) N
, , N
exercise NN i
( ( N
n JJ N
= NNP N
106 CD N
) ) N
, , N
or CC i
usual JJ i
activity NN i
( ( N
n JJ N
= NNP N
142 CD N
) ) N
and CC N
also RB N
assigned VBD N
randomly RB N
to TO N
a DT N
double-blind JJ N
comparison NN N
of IN i
omega-3 JJ i
( ( N
n JJ N
= NNP N
177 CD i
) ) i
or CC i
placebo NN i
( ( N
n JJ N
= NNP N
178 CD N
) ) N
capsules NNS N
. . N

We PRP N
performed VBD N
the DT N
following JJ N
interventions NNS N
: : N
( ( N
1 CD i
) ) i
weekly JJ i
90-minute CD i
yoga NN i
classes NNS i
with IN i
daily JJ i
at-home JJ i
practice NN i
, , i
( ( i
2 CD i
) ) i
individualized VBN i
facility-based JJ i
aerobic JJ i
exercise NN i
training NN i
3 CD i
times/week NN i
, , i
and CC N
( ( N
3 CD N
) ) N
0.615 CD N
g JJ N
omega-3 JJ i
supplement NN i
, , i
3 CD N
times/day NN N
. . N

The DT N
outcomes NNS N
were VBD N
assessed VBN N
with IN N
the DT N
following JJ N
scores NNS o
: : o
Menopausal NNP o
Quality NNP o
of IN o
Life NNP o
Questionnaire NNP o
( ( o
MENQOL NNP o
) ) o
total NN o
and CC o
domain NN o
( ( o
vasomotor NN o
symptoms NNS o
, , o
psychosocial JJ o
, , o
physical JJ o
and CC o
sexual JJ o
) ) o
. . o

RESULTS NNP p
Among IN p
355 CD p
randomly NNS p
assigned VBN p
women NNS p
who WP p
average VBP p
age NN p
was VBD p
54.7 CD p
years NNS p
, , p
338 CD p
women NNS p
( ( p
95 CD p
% NN p
) ) p
completed VBD p
12-week JJ p
assessments NNS p
. . p

Mean NNP o
baseline NN o
vasomotor NN o
symptoms JJ o
frequency NN o
was VBD N
7.6/day CD N
, , N
and CC N
the DT o
mean JJ o
baseline NN o
total JJ o
MENQOL NNP o
score NN o
was VBD N
3.8 CD N
( ( N
range NN N
, , N
1-8 CD N
from IN N
better JJR N
to TO N
worse VB N
) ) N
with IN N
no DT N
between-group JJ N
differences NNS N
. . N

For IN i
yoga NN i
compared VBN N
to TO N
usual JJ N
activity NN N
, , N
baseline NN N
to TO N
12-week JJ N
improvements NNS N
were VBD N
seen VBN N
for IN o
MENQOL NNP o
total JJ N
-0.3 NNP N
( ( N
95 CD N
% NN N
confidence NN N
interval NN N
, , N
-0.6 VBP N
to TO N
0 CD N
; : N
P NNP N
= NNP N
.02 NNP N
) ) N
, , N
vasomotor NN o
symptom NN o
domain NN o
( ( N
P NNP N
= NNP N
.02 NNP N
) ) N
, , N
and CC o
sexuality NN o
domain NN o
( ( N
P NNP N
= NNP N
.03 NNP N
) ) N
scores VBZ N
. . N

For IN N
women NNS N
who WP N
underwent VBP i
exercise NN i
and CC i
omega-3 JJ i
therapy NN i
compared VBN N
with IN N
control NN N
subjects NNS N
, , N
improvements NNS N
in IN N
baseline NN N
to TO N
12-week JJ N
total JJ o
MENQOL NNP o
scores NNS o
were VBD N
not RB N
observed VBN N
. . N

Exercise NN N
showed VBD N
benefit NN N
in IN N
the DT o
MENQOL NNP o
physical JJ o
domain NN o
score NN o
at IN N
12 CD N
weeks NNS N
( ( N
P NNP N
= NNP N
.02 NNP N
) ) N
. . N

CONCLUSION NNP N
All NNP N
women NNS N
become VBP N
menopausal JJ N
, , N
and CC N
many JJ N
of IN N
them PRP N
seek VBP N
medical JJ N
advice NN N
on IN N
ways NNS N
to TO N
improve VB o
quality NN o
of IN o
life NN o
; : o
little JJ N
evidence-based JJ N
information NN N
exists NNS N
. . N

We PRP N
found VBD N
that IN N
, , N
among IN p
healthy JJ p
sedentary JJ p
menopausal NN p
women NNS p
, , p
yoga NN i
appears VBZ N
to TO N
improve VB o
menopausal NN o
quality NN o
of IN o
life NN o
; : o
the DT N
clinical JJ N
significance NN N
of IN N
our PRP$ N
finding NN N
is VBZ N
uncertain JJ N
because IN N
of IN N
the DT N
modest JJ N
effect NN N
. . N

-DOCSTART- -21060033- O O

Denosumab NNP i
compared VBN N
with IN N
zoledronic JJ i
acid NN i
for IN N
the DT N
treatment NN N
of IN N
bone NN N
metastases NNS N
in IN N
patients NNS p
with IN p
advanced JJ p
breast NN p
cancer NN p
: : p
a DT N
randomized JJ N
, , N
double-blind JJ N
study NN N
. . N

PURPOSE VB N
This DT N
randomized VBN N
study NN N
compared VBN N
denosumab NN i
, , N
a DT N
fully RB N
human JJ N
monoclonal JJ N
antibody NN N
against IN N
receptor NN N
activator NN N
of IN N
nuclear JJ N
factor NN N
? . N
B NNP N
( ( N
RANK NNP N
) ) N
ligand NN N
, , N
with IN i
zoledronic JJ i
acid NN i
in IN N
delaying VBG N
or CC N
preventing VBG N
skeletal-related JJ N
events NNS N
( ( N
SREs NNP N
) ) N
in IN p
patients NNS p
with IN p
breast JJ p
cancer NN p
with IN p
bone NN p
metastases NNS p
. . p

PATIENTS NNP N
AND CC N
METHODS NNP N
Patients NNPS N
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB i
either RB i
subcutaneous JJ i
denosumab NN i
120 CD i
mg NN i
and CC i
intravenous JJ i
placebo NN i
( ( p
n JJ p
= NNP p
1,026 CD p
) ) p
or CC i
intravenous JJ i
zoledronic JJ i
acid NN i
4 CD i
mg NN i
adjusted VBN i
for IN i
creatinine JJ i
clearance NN i
and CC i
subcutaneous JJ i
placebo NN i
( ( p
n JJ p
= NNP p
1,020 CD p
) ) p
every DT N
4 CD N
weeks NNS N
. . N

All DT N
patients NNS N
were VBD N
strongly RB N
recommended VBN N
to TO N
take VB N
daily JJ i
calcium NN i
and CC i
vitamin NN i
D NNP i
supplements NNS N
. . N

The DT N
primary JJ N
end NN N
point NN N
was VBD N
time NN N
to TO o
first VB o
on-study JJ o
SRE NNP o
( ( o
defined VBN o
as IN o
pathologic JJ o
fracture NN o
, , o
radiation NN o
or CC o
surgery NN o
to TO o
bone VB o
, , o
or CC o
spinal JJ o
cord NN o
compression NN o
) ) o
. . o

RESULTS NNP i
Denosumab NNP i
was VBD N
superior JJ N
to TO i
zoledronic JJ i
acid NN i
in IN o
delaying VBG o
time NN o
to TO o
first VB o
on-study JJ o
SRE NNP o
( ( N
hazard NN N
ratio NN N
, , N
0.82 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
0.71 CD N
to TO N
0.95 CD N
; : N
P NNP N
= NNP N
.01 NNP N
superiority NN N
) ) N
and CC o
time NN o
to TO o
first RB o
and CC o
subsequent JJ o
( ( o
multiple JJ o
) ) o
on-study NN o
SREs NNP o
( ( N
rate NN N
ratio NN N
, , N
0.77 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
0.66 CD N
to TO N
0.89 CD N
; : N
P NNP N
= NNP N
.001 NNP N
) ) N
. . N

Reduction NN o
in IN o
bone NN o
turnover NN o
markers NNS o
was VBD N
greater JJR N
with IN N
denosumab NN N
. . N

Overall JJ o
survival NN o
, , o
disease NN o
progression NN o
, , o
and CC o
rates NNS o
of IN o
adverse JJ o
events NNS o
( ( o
AEs NNP o
) ) o
and CC o
serious JJ o
AEs NNP o
were VBD N
similar JJ N
between IN N
groups NNS N
. . N

An DT o
excess NN o
of IN o
renal JJ o
AEs NNP o
and CC o
acute-phase JJ o
reactions NNS o
occurred VBD N
with IN N
zoledronic JJ N
acid NN o
; : o
hypocalcemia NN o
occurred VBD N
more RBR N
frequently RB N
with IN i
denosumab NN i
. . i

Osteonecrosis NN o
of IN o
the DT o
jaw NN o
occurred VBD N
infrequently RB N
( ( N
2.0 CD N
% NN N
, , N
denosumab NN i
; : i
1.4 CD N
% NN N
, , N
zoledronic JJ i
acid NN i
; : i
P NNP N
= NNP N
.39 NNP N
) ) N
. . N

CONCLUSION NNP i
Denosumab NNP i
was VBD N
superior JJ N
to TO i
zoledronic JJ i
acid NN i
in IN N
delaying VBG N
or CC N
preventing VBG N
SREs NNP N
in IN p
patients NNS p
with IN p
breast JJ p
cancer NN p
metastatic NN p
to TO p
bone NN p
and CC N
was VBD N
generally RB N
well RB N
tolerated VBN N
. . N

With IN N
the DT N
convenience NN N
of IN N
a DT N
subcutaneous JJ N
injection NN N
and CC N
no DT N
requirement NN N
for IN N
renal JJ N
monitoring NN N
, , N
denosumab JJ i
represents VBZ N
a DT N
potential JJ N
treatment NN N
option NN N
for IN p
patients NNS p
with IN p
bone NN p
metastases NNS p
. . p

-DOCSTART- -24246210- O O

A DT N
randomised JJ N
, , N
double-blind JJ N
, , N
parallel JJ N
design NN N
, , N
multi-institutional JJ N
, , N
non-inferiority JJ N
phase NN N
IV NNP N
trial NN N
of IN N
imidafenacin JJ i
versus NN i
fesoterodine NN i
for IN N
overactive JJ p
bladder NN p
. . p

AIMS NNP N
Our PRP$ N
objective NN N
was VBD N
to TO N
compare VB N
the DT N
efficacy NN o
and CC o
safety NN o
of IN N
imidafenacin NN i
over IN N
fesoterodine NN i
in IN N
patients NNS p
with IN p
overactive JJ p
bladder NN p
( ( p
OAB NNP p
) ) p
. . p

METHODS NNP N
This DT N
study NN N
is VBZ N
a DT N
randomised JJ N
, , N
double-blind JJ N
, , N
parallel-group JJ N
, , N
fesoterodine-controlled JJ i
study NN N
in IN N
patients NNS p
with IN p
continuous JJ p
OAB NNP p
symptoms NNS p
for IN p
? . p
3 CD p
months NNS p
, , p
daily JJ p
mean VBP p
voiding VBG p
frequency NN p
( ( p
DMVF NNP p
) ) p
? . p
8 CD p
, , p
and CC p
daily JJ p
mean JJ p
urgency NN p
or CC p
urgency NN p
incontinence NN p
frequency NN p
? . p
2 CD p
. . p

A DT p
twice-daily JJ i
0.1 CD i
mg NN i
imidafenacin NN i
with IN i
placebo NN i
, , i
or CC i
once-daily RB N
4 CD i
mg NNS i
fesoterodine JJ i
with IN i
placebo NN i
were VBD i
administered VBN N
for IN N
12 CD N
weeks NNS N
. . N

The DT N
primary JJ N
efficacy NN N
end-point NN N
was VBD N
the DT o
difference NN o
in IN o
DMVF NNP o
at IN o
12 CD o
weeks NNS N
. . N

The DT N
secondary JJ N
efficacy NN N
end-points NNS N
were VBD o
differences NNS o
in IN o
daily JJ o
mean NN o
: : o
( ( o
i NN o
) ) o
voiding NN o
frequency NN o
at IN o
4 CD o
and CC o
8 CD o
weeks NNS o
; : o
( ( o
ii NN o
) ) o
urgency NN o
frequency NN o
; : o
( ( o
iii NN o
) ) o
urgency NN o
incontinence NN o
frequency NN o
; : o
( ( o
iv NN o
) ) o
incontinence NN o
frequency NN o
; : o
( ( o
v NN o
) ) o
nocturia NN o
frequency NN o
; : o
and CC o
( ( o
vi NN o
) ) o
quality NN o
of IN o
life NN o
score NN o
. . o

The DT N
variables NNS N
for IN o
safety NN o
analysis NN o
were VBD o
adverse JJ o
events NNS o
, , o
vital JJ o
signs NNS o
, , o
residual JJ o
urine NN o
volume NN o
and CC o
clinical JJ o
laboratory NN o
tests NNS o
. . o

An DT o
efficacy NN o
analysis NN o
was VBD N
conducted VBN N
in IN N
per-protocol JJ N
patients NNS N
and CC N
the DT N
safety NN N
analysis NN N
was VBD N
conducted VBN N
in IN N
all DT N
randomised JJ N
patients NNS N
. . N

RESULTS VB N
The DT N
differences NNS N
in IN N
DMVF NNP o
at IN o
12 CD o
weeks NNS N
were VBD N
-3.38 VBN N
? . N
3.63 CD N
and CC N
-2.45 VB N
? . N
3.73 CD N
in IN N
the DT N
imidafenacin NN N
and CC N
fesoterodine NN N
groups NNS N
, , N
respectively RB N
, , N
and CC N
the DT N
difference NN N
was VBD N
not RB N
significant JJ N
between IN N
the DT N
two CD N
groups NNS N
. . N

Imidafenacin NNP N
was VBD N
non-inferior JJ i
to TO i
fesoterodine VB i
, , i
and CC i
the DT N
lower JJR N
limit NN N
of IN N
95 CD N
% NN N
two-sided JJ N
confidence NN N
intervals NNS N
was VBD N
-0.53 RB N
. . N

The DT N
other JJ N
six CD N
secondary JJ N
end-points NNS N
and CC N
variables NNS N
for IN N
safety NN N
analysis NN N
showed VBD N
no DT N
difference NN N
between IN N
the DT N
two CD N
groups NNS N
. . N

CONCLUSIONS NNP i
Imidafenacin NNP i
was VBD i
non-inferior JJ i
to TO i
fesoterodine VB i
in IN i
terms NNS i
of IN N
efficacy NN N
, , N
and CC N
showed VBD N
no DT N
significant JJ N
difference NN N
in IN N
terms NNS N
of IN N
safety NN N
. . N

-DOCSTART- -15602505- O O

A DT N
placebo NN N
controlled VBN N
crossover RB N
trial NN N
of IN N
liquid JJ i
fluoxetine NN i
on IN N
repetitive JJ o
behaviors NNS o
in IN p
childhood NN p
and CC p
adolescent JJ p
autism NN p
. . p

Repetitive JJ o
behaviors NNS o
are VBP N
a DT N
core NN N
symptom NN N
domain NN N
in IN N
autism NN N
that WDT N
has VBZ N
been VBN N
linked VBN N
to TO N
alterations NNS N
in IN N
the DT N
serotonin NN N
system NN N
. . N

While IN N
the DT N
selective JJ N
serotonin-receptive JJ i
inhibitor NN i
fluvoxamine NN i
has VBZ N
been VBN N
shown VBN N
to TO N
be VB N
effective JJ N
in IN N
adults NNS N
with IN N
autism NN N
, , N
as IN N
yet RB N
no DT N
published VBN N
placebo NN i
controlled VBN N
trials NNS N
with IN N
these DT N
agents NNS N
document NN N
safety NN o
and CC N
efficacy NN o
in IN N
children NNS p
with IN p
autism NN p
. . p

This DT N
study NN N
examines VBZ N
the DT N
selective JJ N
serotonin NN i
reuptake NN i
inhibitor NN i
liquid JJ i
fluoxetine NN i
in IN N
the DT N
treatment NN N
of IN N
repetitive JJ o
behaviors NNS o
in IN p
childhood NN p
and CC p
adolescent JJ p
autism NN p
spectrum NN p
disorders NNS p
( ( p
ASDs NNP p
) ) p
. . p

In IN N
total JJ N
, , N
45 CD p
child NN p
or CC p
adolescent JJ p
patients NNS p
with IN p
ASD NNP p
were VBD p
randomized VBN p
into IN p
two CD p
acute JJ p
8-week JJ p
phases NNS p
in IN p
a DT p
double-blind JJ p
placebo-controlled JJ p
crossover NN p
study NN p
of IN p
liquid JJ i
fluoxetine NN i
. . i

Study NNP N
design NN N
included VBD N
two CD N
randomized VBN N
8-week JJ N
fluoxetine NN i
and CC N
placebo NN i
phases NNS N
separated VBN N
by IN N
a DT N
4-week JJ N
washout NN N
phase NN N
. . N

Outcome NNP N
measures NNS N
included VBD N
measures NNS o
of IN o
repetitive JJ o
behaviors NNS o
and CC o
global JJ o
improvement NN o
. . o

Low-dose JJ N
liquid JJ i
fluoxetine NN i
( ( N
mean JJ N
final JJ N
dose NN N
: : N
9.9+/-4.35 JJ N
mg/day NN N
) ) N
was VBD N
superior JJ N
to TO N
placebo VB i
in IN N
the DT N
treatment NN N
of IN N
repetitive JJ o
behaviors NNS o
by IN N
CY-BOCS NNP o
compulsion NN o
scale NN o
. . o

The DT N
effect NN o
size NN o
was VBD N
in IN N
the DT N
moderate NN N
to TO N
large JJ N
range NN N
, , N
and CC N
the DT N
doses NNS N
used VBN N
were VBD N
low JJ N
. . N

Liquid NNP i
fluoxetine NN i
was VBD N
only RB N
slightly RB N
, , N
and CC N
not RB N
significantly RB N
, , N
superior JJ N
to TO N
placebo VB N
on IN N
CGI NNP o
autism NN o
score NN o
partially RB N
due JJ N
to TO N
a DT N
phase NN o
order NN o
effect NN o
. . o

However RB N
, , N
fluoxetine NN i
was VBD N
marginally RB N
superior JJ N
to TO N
placebo VB i
on IN N
a DT N
composite JJ o
measure NN o
of IN o
global JJ o
effectiveness NN o
. . o

Liquid NNP N
fluoxetine NN N
did VBD N
not RB N
significantly RB N
differ VBP N
from IN N
placebo NN i
on IN N
treatment NN o
emergent JJ o
side NN o
effects NNS o
. . o

Liquid NNP i
fluoxetine NN i
in IN N
low JJ N
doses NNS N
is VBZ N
more RBR N
effective JJ N
than IN N
placebo NN i
in IN N
the DT N
treatment NN N
of IN N
repetitive JJ o
behaviors NNS o
in IN N
childhood NN N
autism NN N
. . N

Limitations NNS N
include VBP N
small JJ N
sample JJ N
size NN N
and CC N
the DT N
crossover NN N
design NN N
of IN N
the DT N
study NN N
. . N

Further NNP N
replication NN N
and CC N
long-term JJ N
maintenance NN N
trials NNS N
are VBP N
needed VBN N
. . N

-DOCSTART- -16911869- O O

Cardiac NNP o
safety NN N
of IN N
formoterol NN i
12 CD N
microg NN N
twice RB N
daily RB N
in IN N
patients NNS p
with IN p
chronic JJ p
obstructive JJ p
pulmonary JJ p
disease NN p
. . p

BACKGROUND CC N
Some DT N
evidence NN N
suggests VBZ N
an DT N
increased VBN N
risk NN N
of IN N
myocardial JJ o
infarction NN o
and CC o
dysrhythmia NN o
events NNS o
associated VBN N
with IN N
beta NN N
( ( N
2 CD N
) ) N
-agonist NN N
use NN N
in IN N
patients NNS p
with IN p
chronic JJ p
obstructive JJ p
pulmonary JJ p
disease NN p
( ( p
COPD NNP p
) ) p
. . p

This DT N
prospective JJ N
, , N
multicenter NN N
, , N
randomized VBN N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
study NN N
compared VBN N
the DT N
cardiac JJ N
safety NN N
of IN N
formoterol NN i
and CC N
placebo NN i
in IN N
patients NNS p
with IN p
COPD NNP p
. . p

METHODS NNP N
After IN N
a DT N
3-14-day JJ N
run-in NN N
, , N
204 CD p
patients NNS p
were VBD N
randomized VBN N
to TO N
receive VB N
formoterol NN i
12 CD i
microg NN i
dry JJ i
powder NN i
inhalation NN i
or CC i
matching VBG i
placebo JJ i
twice RB i
daily RB i
for IN i
8 CD i
weeks NNS i
. . i

Twenty CD i
four-hour JJ i
continuous JJ i
electrocardiography NN i
( ( i
Holter NNP i
monitoring NN i
) ) i
was VBD N
performed VBN N
at IN N
screening NN N
and CC N
after IN N
2 CD N
and CC N
8 CD N
weeks NNS N
of IN N
treatment NN N
. . N

RESULTS NNP N
Only RB N
a DT N
small JJ N
number NN N
of IN N
patients NNS N
met VBD N
the DT N
predefined JJ N
criteria NNS N
for IN N
a DT N
proarrhythmic JJ o
event NN o
( ( N
4 CD N
formoterol NN i
and CC N
2 CD N
placebo NN i
patients NNS N
) ) N
. . N

No UH N
patients NNS N
had VBD N
sustained VBN N
postbaseline JJ o
ventricular JJ o
tachycardia NN o
events NNS o
, , o
postbaseline JJ o
run NN o
of IN o
ventricular JJ o
ectopic NN o
beats NNS o
associated VBN N
with IN N
relevant JJ o
symptoms NNS o
( ( o
e.g NN o
. . o

hypotension NN o
, , o
syncope NN o
) ) o
, , N
or CC N
an DT N
episode NN o
of IN o
ventricular JJ o
flutter NN o
or CC o
fibrillation NN o
. . o

Holter NNP N
monitoring VBG N
data NNS N
were VBD N
variable JJ N
but CC N
showed VBD N
no DT N
clinically RB N
meaningful JJ N
differences NNS N
between IN N
the DT N
formoterol NN N
and CC N
placebo NN N
groups NNS N
, , N
respectively RB N
, , N
for IN N
variables NNS N
such JJ N
as IN N
( ( N
mean+/-SD NN N
at IN N
end NN N
of IN N
treatment NN N
) ) N
: : N
heart NN o
rate NN o
( ( N
80+/-8.6 JJ N
vs. IN N
80+/-10.6 JJ N
bpm NN N
) ) N
, , N
number NN o
and CC o
rate NN o
of IN o
ventricular JJ o
premature NN o
beats NNS o
( ( N
total JJ N
732+/-2685.4 JJ N
vs. IN N
650+/-2090.6 JJ N
; : N
rate NN N
35+/-131.0 JJ N
vs. IN N
30+/-101.3 JJ N
per IN N
h NN N
) ) N
, , N
ventricular JJ o
tachycardia NN o
events NNS o
( ( N
total JJ N
0.4+/-1.70 JJ N
vs. IN N
1.0+/-9.23 JJ N
; : N
rate NN N
0.02+/-0.082 JJ N
vs. IN N
0.05+/-0.479 JJ N
per IN N
h NN N
) ) N
, , N
and CC N
supraventricular JJ o
premature NN o
beats NNS o
( ( N
total JJ N
504+/-1844.1 JJ N
vs. IN N
823+/-2961.8 JJ N
; : N
rate NN N
22+/-80.6 JJ N
vs. IN N
37+/-129.6 JJ N
per IN N
h NN N
) ) N
. . N

Vital JJ o
signs NNS o
and CC o
electrocardiogram NN o
data NNS o
, , o
including VBG o
corrected VBN o
QT NNP o
intervals NNS o
( ( N
Bazett NNP N
and CC N
Fridericia NNP N
) ) N
, , N
were VBD N
similar JJ N
across IN N
treatment NN N
groups NNS N
. . N

The DT N
overall JJ o
adverse JJ o
event NN o
experience NN o
was VBD N
similar JJ N
in IN N
the DT N
formoterol NN N
( ( N
n=26 JJ N
[ RB N
27 CD N
% NN N
] NN N
) ) N
and CC N
placebo NN N
( ( N
n=33 JJ N
[ RB N
31 CD N
% NN N
] NN N
) ) N
groups NNS N
. . N

The DT N
most RBS N
common JJ N
adverse JJ o
events NNS o
, , o
infections NNS o
and CC o
respiratory JJ o
events NNS o
, , N
were VBD N
expected VBN N
for IN N
this DT N
patient JJ N
population NN N
. . N

The DT N
incidence NN N
of IN N
cardiac JJ o
adverse JJ o
events NNS o
was VBD N
low JJ N
( ( N
1 CD N
formoterol NN N
and CC N
4 CD N
placebo NN N
patients NNS N
) ) N
. . N

CONCLUSIONS VB N
The DT N
results NNS N
of IN N
this DT N
study NN N
confirm VBD N
the DT N
good JJ o
cardiovascular JJ o
safety NN o
profile NN N
of IN N
formoterol NN N
in IN N
patients NNS p
with IN p
COPD NNP p
. . p

-DOCSTART- -17035531- O O

Adenosinergic NNP i
mechanisms NNS i
contribute VBP N
to TO N
individual JJ p
differences NNS p
in IN p
sleep JJ p
deprivation-induced JJ p
changes NNS N
in IN N
neurobehavioral JJ N
function NN N
and CC N
brain NN N
rhythmic JJ N
activity NN N
. . N

Large JJ N
individual JJ N
differences NNS N
characterize VBP N
the DT N
changes NNS N
induced VBN N
by IN N
sleep JJ N
deprivation NN N
on IN N
neurobehavioral JJ N
functions NNS N
and CC N
rhythmic JJ N
brain NN N
activity NN N
. . N

To TO N
investigate VB N
adenosinergic JJ i
mechanisms NNS i
in IN N
these DT N
differences NNS N
, , N
we PRP N
studied VBD N
the DT N
effects NNS N
of IN N
prolonged JJ N
waking NN N
and CC N
the DT N
adenosine NN N
receptor NN N
antagonist JJ N
caffeine NN i
on IN N
sustained VBN N
vigilant JJ N
attention NN N
and CC N
regional JJ N
electroencephalogram NN N
( ( N
EEG NNP N
) ) N
power NN N
in IN N
the DT N
ranges NNS N
of IN N
theta NN N
activity NN N
( ( N
6.25-8.25 JJ N
Hz NNP N
) ) N
in IN N
waking VBG N
and CC N
the DT N
slow JJ N
oscillation NN N
( ( N
< JJ N
1 CD N
Hz NNP N
) ) N
in IN N
sleep NN N
. . N

Activity NN N
in IN N
these DT N
frequencies NNS N
is VBZ N
functionally RB N
related VBN N
to TO N
sleep VB N
deprivation NN N
. . N

In IN N
12 CD p
subjectively RB p
caffeine-sensitive JJ p
and CC p
10 CD p
-insensitive JJ p
young JJ p
men NNS p
, , N
psychomotor NN N
vigilance NN N
task NN N
( ( N
PVT NNP N
) ) N
performance NN N
and CC N
EEG NNP N
were VBD N
assessed VBN N
at IN N
3 CD N
h NN N
intervals NNS N
before IN N
, , N
during IN N
, , N
and CC N
after IN N
one CD i
night NN i
without IN i
sleep NN i
. . i

After IN N
11 CD N
and CC N
23 CD N
h NN N
waking NN N
, , N
subjects VBZ N
received VBN N
200 CD N
mg JJ N
caffeine NN i
and CC N
placebo NN i
in IN N
double-blind NN N
, , N
cross-over JJ N
manner NN N
. . N

In IN N
the DT N
placebo NN i
condition NN N
, , N
sleep JJ N
deprivation NN N
impaired VBD N
PVT NNP N
speed VBD N
more RBR N
in IN N
caffeine-sensitive JJ N
than IN N
in IN N
caffeine-insensitive JJ N
men NNS N
. . N

This DT N
difference NN N
was VBD N
counteracted VBN N
by IN N
caffeine NN i
. . i

Theta NNP o
power NN o
in IN o
waking VBG o
increased VBD N
more RBR N
in IN N
a DT N
frontal JJ N
EEG NNP N
derivation NN N
than IN N
in IN N
a DT N
posterior JJ N
derivation NN N
. . N

Caffeine NNP i
attenuated VBD N
this DT N
power NN N
gradient NN N
in IN N
caffeine JJ N
sensitive JJ N
subjects NNS N
. . N

Sleep NNP o
loss NN o
also RB N
differently RB N
affected VBD N
the DT N
power NN N
distribution NN N
< VBD N
1 CD N
Hz NNP N
in IN N
non-rapid JJ o
eye NN o
movement NN o
sleep NN o
between IN N
caffeine NN N
sensitive JJ N
and CC N
insensitive JJ N
subjects NNS N
. . N

Also RB N
, , N
this DT N
difference NN N
was VBD N
mirrored VBN N
by IN N
the DT N
action NN N
of IN N
caffeine NN i
. . i

The DT N
effects NNS N
of IN N
sleep JJ o
deprivation NN o
and CC N
caffeine NN i
on IN N
sustained JJ N
attention NN N
and CC N
regional JJ N
EEG NNP N
power NN N
in IN N
waking NN o
and CC o
sleep NN o
were VBD N
inversely RB N
related VBN N
. . N

These DT N
findings NNS N
suggest VBP N
that IN N
adenosinergic JJ i
mechanisms NNS i
contribute VBP N
to TO N
individual JJ N
differences NNS N
in IN N
waking-induced JJ o
impairment NN o
of IN o
neurobehavioral JJ o
performance NN o
and CC o
functional JJ o
aspects NNS o
of IN o
EEG NNP o
topography NN o
associated VBN o
with IN o
sleep JJ o
deprivation NN o
. . o

-DOCSTART- -7017139- O O

Value NNP N
of IN N
an DT N
anal JJ i
dilator NN i
after IN N
anal JJ N
stretch NN N
for IN N
haemorrhoids NNS o
. . o

A DT N
prospective JJ N
randomized VBN N
trial NN N
compared VBN N
anal JJ i
stretch NN i
with IN i
or CC i
without IN i
continued JJ i
dilatation NN i
for IN N
three CD N
months NNS N
in IN N
89 CD p
consecutive JJ p
patients NNS p
with IN p
haemorrhoids NNS p
. . p

Complications NNS o
of IN o
therapy NN o
occurred VBD N
in IN N
only RB N
4 CD N
patients NNS N
, , N
3 CD N
of IN N
whom WP N
had VBD N
transient JJ N
incontinence NN o
of IN N
flatus NN N
. . N

When WRB N
patients NNS N
were VBD N
reviewed VBN N
four CD N
months NNS N
after IN N
treatment NN N
, , N
only RB N
4 CD N
of IN N
44 CD N
patients NNS N
( ( N
9 CD N
% NN N
) ) N
who WP N
used VBD N
a DT N
dilator NN N
had VBD N
not RB N
been VBN N
improved VBN N
and CC N
required VBN N
additional JJ N
therapy NN N
, , N
compared VBN N
with IN N
15 CD N
of IN N
42 CD N
patients NNS N
( ( N
36 CD N
% NN N
) ) N
who WP N
had VBD N
anal JJ i
stretch NN i
alone RB N
( ( N
P NNP N
less JJR N
than IN N
0.02 CD N
) ) N
. . N

It PRP N
is VBZ N
concluded VBN N
that IN N
the DT N
use NN N
of IN N
an DT N
anal JJ N
dilator NN N
improves VBZ N
the DT N
results NNS N
of IN N
anal JJ o
stretch NN o
. . o

-DOCSTART- -19502023- O O

Transdermal NNP i
scopolamine NN i
patch NN i
in IN N
addition NN N
to TO N
ondansetron VB i
for IN N
postoperative JJ N
nausea NN N
and CC N
vomiting VBG N
prophylaxis NN N
in IN N
patients NNS p
undergoing VBG p
ambulatory JJ p
cosmetic JJ p
surgery NN p
. . p

STUDY NNP N
OBJECTIVE NNP N
To TO N
determine VB N
the DT N
efficacy NN N
of IN N
transdermal JJ i
scopolamine NN i
in IN N
addition NN N
to TO N
ondansetron VB i
in IN N
decreasing VBG N
the DT N
incidence NN N
of IN N
postoperative JJ o
nausea NN o
and CC o
vomiting NN o
( ( p
PONV NNP p
) ) p
. . p

DESIGN NNP N
Randomized NNP N
controlled VBD N
trial NN N
. . N

SETTING NN N
Academic NNP p
hospital NN p
. . p

PATIENTS CC N
126 CD p
ASA NNP p
physical JJ p
status NN p
I PRP p
and CC p
II NNP p
patients NNS p
undergoing VBG p
outpatient JJ p
plastic NN p
surgery NN p
with IN p
three CD p
or CC p
more JJR p
risk NN p
factors NNS p
for IN p
PONV NNP p
. . p

INTERVENTIONS NNP N
Patients NNPS N
were VBD N
randomly RB N
assigned VBN N
to TO N
one CD N
of IN N
two CD N
groups NNS N
to TO N
receive VB N
( ( N
Group NNP N
1 CD N
) ) N
a DT N
transdermal JJ i
scopolamine NN i
( ( i
TDS NNP i
) ) i
patch NN i
or CC N
( ( N
Group NNP N
2 CD N
) ) N
, , N
a DT i
placebo JJ i
patch NN i
two CD N
hours NNS N
before IN N
surgery NN N
. . N

MEASUREMENTS NNP N
Occurrence NNP o
of IN o
vomiting VBG o
, , o
severity NN o
of IN o
nausea NN o
using VBG o
a DT o
visual JJ o
analog NN o
scale NN o
( ( o
VAS NNP o
) ) o
, , o
rescue JJ o
medication NN o
, , o
pain VBP o
intensity NN o
and CC o
pain NN o
medications NNS o
, , o
and CC o
side JJ o
effects NNS o
were VBD N
recorded VBN N
every DT N
hour NN N
until IN N
discharge NN N
from IN N
hospital NN N
, , N
then RB N
every DT N
4 CD N
hours NNS N
thereafter RB N
for IN N
a DT N
total NN N
of IN N
24 CD N
hours NNS N
. . N

MAIN NNP N
RESULTS NNP N
A NNP N
statistically RB N
significant JJ N
reduction NN N
in IN N
postoperative JJ o
nausea NN o
between IN N
8 CD N
and CC N
24 CD N
hours NNS N
in IN N
patients NNS N
receiving VBG N
TDS NNP N
was VBD N
noted VBN N
. . N

CONCLUSIONS NNP N
Transdermal NNP N
scopolamine NN i
in IN N
addition NN N
to TO N
ondansetron VB N
benefits NNS N
patients NNS p
at IN p
high JJ p
risk NN p
for IN p
PONV NNP p
undergoing JJ p
outpatient NN p
plastic NN p
surgery NN p
for IN N
up IN N
to TO N
20 CD N
hours NNS N
after IN N
surgery NN N
. . N

-DOCSTART- -10091821- O O

Independent NNP N
prognostic JJ N
information NN N
provided VBN N
by IN N
sphygmomanometrically RB i
determined VBN i
pulse JJ o
pressure NN o
and CC i
mean JJ i
arterial JJ o
pressure NN o
in IN N
patients NNS p
with IN p
left JJ p
ventricular JJ p
dysfunction NN p
. . p

OBJECTIVES CC N
The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
evaluate VB N
the DT N
relationship NN N
of IN N
baseline NN N
pulse JJ N
pressure NN N
and CC N
mean JJ N
arterial JJ N
pressure NN N
to TO N
mortality NN N
in IN N
patients NNS p
with IN p
left JJ p
ventricular JJ p
dysfunction NN p
. . p

BACKGROUND NNP N
Increased VBD N
conduit NN N
vessel NN N
stiffness NN N
increases VBZ N
pulse JJ N
pressure NN N
and CC N
pulsatile NN N
load NN N
, , N
potentially RB N
contributing VBG N
to TO N
adverse VB N
outcomes NNS N
in IN N
patients NNS p
with IN p
left JJ p
ventricular JJ p
dysfunction NN p
. . p

METHODS NNP N
Pulse NNP N
and CC N
mean VB N
arterial JJ N
pressure NN N
were VBD N
analyzed VBN N
for IN N
their PRP$ N
effect NN N
on IN N
mortality NN o
, , N
adjusting VBG N
for IN N
other JJ N
modifiers NNS N
of IN N
risk NN N
, , N
using VBG N
Cox NNP N
proportional JJ N
hazards NNS N
regression NN N
analysis NN N
of IN N
data NNS N
collected VBN N
from IN N
6,781 CD p
patients NNS p
randomized VBN p
into IN p
the DT p
Studies NNPS p
of IN p
Left NNP p
Ventricular NNP p
Dysfunction NNP p
trials NNS p
. . p

RESULTS NNP N
Pulse NNP o
and CC o
mean VB o
arterial JJ o
pressure NN o
were VBD N
related VBN N
positively RB N
to TO N
each DT N
other JJ N
, , N
age NN N
, , N
ejection NN N
fraction NN N
and CC N
prevalence NN N
of IN N
diabetes NNS N
and CC N
hypertension NN N
and CC N
inversely RB N
to TO N
prior VB N
myocardial JJ N
infarction NN N
and CC N
beta-adrenergic JJ N
blocking NN N
agent NN N
use NN N
. . N

Higher JJR o
pulse JJ o
pressure NN o
was VBD N
associated VBN N
with IN N
increased JJ N
prevalence NN N
of IN N
female JJ N
gender NN N
, , N
greater JJR N
calcium NN i
channel NN i
blocking VBG i
agent NN i
, , i
digoxin NN i
and CC N
diuretic JJ i
use NN N
, , N
lower JJR N
heart NN N
rate NN N
and CC N
a DT N
higher JJR N
rate NN N
of IN N
reported VBN N
smoking NN N
history NN N
. . N

Higher JJR o
mean JJ o
arterial JJ o
pressure NN o
was VBD N
associated VBN N
with IN N
higher JJR N
heart NN N
rate NN N
, , N
lower JJR N
calcium NN i
channel NN i
blocker NN i
and CC N
digoxin NN i
use NN N
and CC N
lower JJR N
New NNP N
York NNP N
Heart NNP N
Association NNP N
functional JJ N
class NN N
. . N

Over IN N
a DT N
61-month JJ N
follow-up JJ N
1,582 CD N
deaths NNS o
( ( N
1,397 CD N
cardiovascular NN N
) ) N
occurred VBD N
. . N

In IN N
a DT N
multivariate NN N
analysis NN N
adjusting VBG N
for IN N
the DT N
above JJ N
covariates NNS N
and CC N
treatment NN N
assignment NN N
, , N
higher JJR N
pulse JJ o
pressure NN o
remained VBD N
an DT N
independent JJ N
predictor NN N
of IN N
total JJ o
and CC o
cardiovascular JJ o
mortality NN o
( ( N
total JJ N
mortality NN N
relative NN N
risk NN N
, , N
1.05 CD N
per IN N
10 CD N
mm NN N
Hg NNP N
increment NN N
; : N
95 CD N
% NN N
confidence NN N
interval NN N
, , N
1.01 CD N
to TO N
1.10 CD N
; : N
p NN N
= VBZ N
0.02 CD N
) ) N
. . N

Mean JJ o
arterial JJ o
pressure NN o
was VBD N
inversely RB N
related VBN N
to TO N
total JJ o
and CC o
cardiovascular JJ o
mortality NN o
( ( N
total JJ N
mortality NN N
relative NN N
risk NN N
, , N
0.89 CD N
; : N
95 CD N
% NN N
confidence NN N
interval NN N
, , N
0.85 CD N
to TO N
0.94 CD N
; : N
p NN N
< VBZ N
0.0001 CD N
) ) N
. . N

CONCLUSIONS NNP N
One CD N
noninvasive JJ i
blood NN i
pressure NN i
measurement NN i
provides VBZ N
two CD N
independent JJ N
prognostic JJ N
factors NNS N
for IN N
survival NN o
. . o

Increased VBD o
conduit NN o
vessel NN o
stiffness NN o
, , N
as IN N
assessed VBN N
by IN N
pulse JJ N
pressure NN N
, , N
may MD N
contribute VB N
to TO N
increased VBN N
mortality NN o
in IN N
patients NNS N
with IN N
left JJ N
ventricular JJ N
dysfunction NN N
, , N
independent JJ N
of IN N
mean JJ N
arterial JJ N
pressure NN N
. . N

-DOCSTART- -4085165- O O

Chronic JJ p
lateral JJ p
humeral JJ p
epicondylitis NN p
-- : p
a DT p
double-blind NN N
controlled JJ N
assessment NN N
of IN N
pulsed JJ i
electromagnetic JJ i
field NN i
therapy NN i
. . i

Pulsed VBN i
electromagnetic JJ i
fields NNS i
( ( i
PEMF NNP i
) ) i
have VBP N
been VBN N
shown VBN N
to TO N
be VB N
beneficial JJ N
in IN N
the DT N
treatment NN N
of IN N
rotator NN N
cuff NN N
tendinitis NN N
. . N

As IN N
lateral JJ p
humeral JJ p
epicondylitis NN p
( ( p
tennis IN p
elbow NN p
) ) p
is VBZ N
a DT N
similar JJ N
chronic NN N
tendon NN N
lesion NN N
, , N
30 CD p
patients NNS p
with IN p
both DT p
clinical JJ p
and CC p
thermographic JJ p
evidence NN p
of IN p
tennis NN p
elbow NN p
were VBD N
randomly RB i
allocated VBN i
to TO i
receive VB i
either RB i
active JJ i
or CC i
inactive JJ i
PEMF NNP i
therapy NN i
. . i

Treatment NN N
was VBD N
continued VBN N
for IN N
a DT N
minimum JJ N
period NN N
of IN N
eight CD N
weeks NNS N
. . N

At IN N
this DT N
time NN N
there EX N
was VBD N
no DT o
statistical JJ o
difference NN o
between IN N
the DT N
two CD N
groups NNS N
. . N

-DOCSTART- -1829841- O O

[ RB p
4 CD p
years NNS p
' POS p
experience NN p
with IN p
a DT p
balloon-expandable JJ i
endoprosthesis NN i
. . i

Experimental JJ p
and CC p
clinical JJ p
application NN p
] NNP p
. . N

During IN N
a DT N
4-year JJ N
period NN N
of IN N
clinical JJ N
application NN N
of IN N
the DT N
balloon-expandable JJ i
Palmaz NNP i
stent NN i
, , N
a DT N
randomized JJ N
trial NN N
comparing VBG N
stent JJ i
implantation NN i
and CC i
traditional JJ i
balloon NN i
angioplasty NN i
of IN N
iliac JJ p
arteries NNS p
in IN p
arterial JJ p
occlusive JJ p
disease NN p
was VBD N
started VBN N
. . N

The DT N
first JJ N
long-term JJ N
results NNS N
, , N
recorded VBD N
after IN N
2 CD N
years NNS N
, , N
indicate VBP N
statistically RB N
significant JJ N
differences NNS N
in IN N
the DT N
complication NN o
rate NN o
( ( N
after IN N
stenting VBG p
2/62 CD p
and CC N
after IN N
angioplasty JJ p
5/69 CD p
) ) p
and CC N
patency NN o
( ( N
greater JJR N
than IN N
or CC N
equal JJ N
to TO N
70 CD N
% NN N
of IN N
original JJ N
lumen NNS N
size NN N
upon IN N
stent JJ i
implantation NN i
or CC i
balloon NN i
inflation NN i
: : i
95 CD N
% NN N
after IN N
stenting VBG N
and CC N
72 CD N
% NN N
after IN N
angioplasty NN N
) ) N
. . N

Clinical JJ o
improvement NN o
after IN o
2 CD o
years NNS o
was VBD N
89 CD N
% NN N
after IN N
stenting VBG N
and CC N
70 CD N
% NN N
after IN N
angioplasty NN N
. . N

Parallel NNP N
to TO N
the DT N
clinical JJ p
trials NNS p
, , N
experimental JJ N
canine NN p
artery NN N
stenting NN N
was VBD N
performed VBN N
to TO N
evaluate VB N
differences NNS N
in IN N
the DT N
long-term JJ N
patency NN N
of IN N
stents NNS N
exposed VBN N
to TO N
restricted VBN N
flow NN N
. . N

Significant JJ N
differences NNS N
in IN N
neointimal JJ o
healing NN o
were VBD N
found VBN N
between IN N
normally RB N
perfused VBN N
stents NNS N
and CC N
stents NNS N
with IN N
artificially RB N
reduced VBN N
flow NN N
: : N
during IN N
the DT N
total JJ N
observation NN N
period NN N
of IN N
6 CD N
months NNS N
the DT N
neointimal JJ o
height NN o
was VBD N
up RB N
to TO N
200 CD N
% NN N
higher JJR N
in IN N
flow-restricted JJ N
stents NNS N
, , N
while IN N
the DT N
histological JJ o
composition NN o
of IN o
the DT o
neointima NN o
was VBD N
the DT N
same JJ N
as IN N
with IN N
normally RB N
perfused VBN N
stents NNS N
. . N

-DOCSTART- -8752181- O O

Prediction NN N
of IN N
the DT N
infarct-related JJ N
artery NN N
in IN N
acute JJ N
myocardial JJ N
infarction NN N
by IN N
a DT N
scoring NN N
system NN N
using VBG N
summary JJ i
ST-segment JJ i
and CC i
T-wave JJ i
changes NNS i
. . i

We PRP N
developed VBD N
a DT N
scoring NN N
system NN N
to TO N
predict VB N
the DT N
artery NN N
responsible JJ N
for IN N
an DT N
acute JJ N
myocardial JJ N
infarction NN N
( ( N
AMI NNP N
) ) N
using VBG N
ST-segment JJ i
and CC i
T-wave JJ i
changes NNS i
on IN i
the DT i
initial JJ i
electrocardiogram NN i
( ( i
ECG NNP i
) ) i
using VBG N
data NNS N
from IN N
228 CD p
patients NNS p
( ( p
development NN p
set VBN p
) ) p
with IN p
symptoms NNS p
compatible JJ p
with IN p
AMI NNP p
and CC p
tested VBN p
in IN p
a DT p
similar JJ p
group NN p
of IN p
223 CD p
patients NNS p
( ( p
test NN p
set VBN p
) ) p
from IN p
the DT p
Thrombolysis NNP p
and CC p
Angioplasty NNP p
in IN p
Myocardial NNP p
Infarction NNP p
( ( p
TAMI-5 NNP p
) ) p
Trial NNP p
. . p

Using VBG N
stepwise JJ N
logistic JJ N
regression NN N
we PRP N
were VBD N
able JJ N
to TO N
accurately RB N
predict VB N
the DT N
left NN N
anterior JJ N
descending NN N
( ( N
LAD NNP N
) ) N
, , N
right JJ N
, , N
or CC N
left VBD N
circumflex NN N
( ( N
LC NNP N
) ) N
coronary JJ N
artery NN N
as IN N
the DT N
infarct-related JJ N
artery NN N
using VBG N
2 CD N
variables NNS N
: : N
( ( N
1 CD N
) ) N
the DT N
summation NN N
of IN N
the DT N
ST-segment JJ N
elevation NN N
in IN N
leads VBZ N
V1 NNP N
to TO N
V4 NNP N
; : N
and CC N
( ( N
2 CD N
) ) N
the DT N
summation NN N
of IN N
the DT N
T-wave NNP N
negativity NN N
in IN N
leads NNS N
I PRP N
, , N
aVL RB N
, , N
and CC N
V5 NNP N
. . N

In IN N
the DT N
development NN N
set NN N
, , N
these DT N
2 CD N
variables NNS N
demonstrated VBD N
respective JJ N
sensitivity NN o
and CC o
specificity NN o
of IN N
98 CD N
% NN N
and CC N
90 CD N
% NN N
for IN N
LAD NNP N
lesions NNS N
, , N
82 CD N
% NN N
and CC N
85 CD N
% NN N
for IN N
right JJ N
narrowings NNS N
, , N
and CC N
82 CD N
% NN N
and CC N
84 CD N
% NN N
for IN N
LC NNP N
narrowings NNS N
. . N

In IN N
the DT N
test NN N
set NN N
, , N
the DT N
sensitivity NN o
and CC o
specificity NN o
were VBD N
97 CD N
% NN N
and CC N
95 CD N
% NN N
for IN N
LAD NNP N
lesions NNS N
, , N
85 CD N
% NN N
and CC N
86 CD N
% NN N
for IN N
right JJ N
lesions NNS N
, , N
and CC N
73 CD N
% NN N
and CC N
60 CD N
% NN N
for IN N
LC NNP o
coronary JJ o
artery NN o
lesions NNS o
. . o

Information NNP N
easily RB N
obtained VBD N
on IN N
the DT N
ECG NNP N
can MD N
accurately RB N
predict VB N
the DT N
likelihood NN N
of IN N
the DT N
LAD NNP N
, , N
right RB N
, , N
or CC N
LC NNP N
artery RB N
as IN N
the DT N
infarct-related JJ N
artery NN N
. . N

This DT N
may MD N
be VB N
useful JJ N
in IN N
the DT N
decision NN N
to TO N
administer VB N
thrombolytic JJ N
treatment NN N
. . N

-DOCSTART- -709549- O O

Comparison NNP N
of IN N
the DT N
therapeutic JJ N
effects NNS N
of IN N
adriamycin NN i
alone RB i
versus NN i
adriamycin JJ i
plus CC i
vincristine JJ i
versus NN i
adriamycin NN i
plus CC i
cyclophosphamide NN i
in IN N
the DT N
treatment NN N
of IN N
advanced JJ p
carcinoma NN p
of IN p
the DT p
cervix NN p
. . p

-DOCSTART- -26208985- O O

A DT N
pilot JJ N
double-blind JJ N
placebo-controlled JJ i
trial NN N
of IN N
pioglitazone NN i
as IN N
adjunctive JJ N
treatment NN N
to TO N
risperidone VB N
: : N
Effects NNS N
on IN N
aberrant JJ N
behavior NN N
in IN N
children NNS p
with IN p
autism NN o
. . o

To TO N
assess VB N
the DT N
safety NN o
and CC o
efficacy NN o
of IN N
pioglitazone NN i
added VBD i
to TO i
risperidone VB i
in IN N
the DT N
treatment NN N
of IN N
irritability NN N
in IN N
autistic JJ p
disorder NN p
( ( p
AD NNP p
) ) p
, , N
we PRP N
conducted VBD N
this DT N
study NN N
. . N

In IN N
a DT N
10-week JJ N
, , N
randomized VBN N
, , N
double-blind JJ N
, , N
parallel-group JJ N
, , N
placebo-controlled JJ i
clinical JJ N
trial NN N
, , N
44 CD p
outpatients NNS p
of IN p
both DT p
genders NNS p
aged VBN p
4-12 CD p
years NNS p
with IN p
a DT p
diagnosis NN p
of IN p
AD NNP p
and CC p
a DT p
score NN p
of IN p
?12 NN p
on IN p
the DT p
Aberrant NNP p
Behavior NNP p
Checklist-Community NNP p
( ( p
ABC-C NNP p
) ) p
irritability NN p
subscale NN p
were VBD p
included VBN o
. . o

Mean NNP o
change NN o
of IN o
ABC-C NNP o
irritability NN o
subscale NN o
score NN o
as IN o
primary JJ N
outcome NN N
, , N
change NN N
in IN N
other JJ N
ABC-C JJ N
subscale NN N
scores NNS N
and CC N
partial JJ N
and CC N
complete JJ N
responses NNS N
were VBD N
compared VBN N
between IN N
two CD N
groups NNS p
. . p

Twenty CD p
patients NNS p
completed VBD p
the DT N
trial NN N
in IN N
each DT N
group NN N
. . N

Level NNP N
of IN N
reduction NN N
and CC N
effect NN N
of IN N
time?treatment JJ N
interaction NN N
in IN N
the DT N
treatment NN N
group NN N
were VBD N
significant JJ N
for IN N
irritability NN o
( ( o
P=0.03 NNP o
) ) o
, , o
lethargy/social JJ o
withdrawal NN o
( ( o
P=0.04 NNP o
) ) N
and CC N
hyperactivity/non-compliance NN o
( ( o
P=0.03 NNP o
) ) N
but CC N
not RB N
for IN N
stereotypic JJ N
behavior NN N
and CC N
inappropriate JJ N
speech NN N
subscales NNS N
compared VBN N
with IN N
the DT N
placebo NN N
group NN o
. . o

Vomiting NNP o
and CC o
headache NN o
were VBD o
the DT N
most RBS N
frequent JJ N
reported VBD N
side-effects NNS N
. . N

Results NNS N
of IN N
this DT N
preliminary JJ N
study NN N
indicate VBP N
positive JJ N
effects NNS N
of IN N
pioglitazone NN N
compared VBN N
with IN N
placebo NN N
in IN N
improving VBG N
the DT N
behavioral JJ o
symptoms NNS o
of IN o
AD NNP o
. . N

-DOCSTART- -19002124- O O

Combined VBN i
delivery NN i
approach NN i
of IN N
bone NN i
marrow NN i
mononuclear JJ i
stem NN i
cells NNS i
early RB i
and CC N
late RB N
after IN N
myocardial JJ p
infarction NN p
: : p
the DT N
MYSTAR NNP N
prospective JJ N
, , N
randomized VBN N
study NN N
. . N

BACKGROUND NNP N
Combined VBD N
intracoronary JJ N
and CC N
intramyocardial JJ N
administration NN N
might MD N
improve VB N
outcomes NNS N
for IN N
bone-marrow-derived JJ i
stem NN i
cell NN i
therapy NN i
for IN N
acute JJ N
myocardial JJ N
infarction NN N
( ( N
AMI NNP N
) ) N
. . N

We PRP N
compared VBN N
the DT N
safety NN o
and CC o
feasibility NN o
of IN N
early JJ N
and CC N
late JJ N
delivery NN N
of IN N
stem NN i
cells NNS i
with IN N
combined JJ N
therapy NN N
approaches NNS N
. . N

METHODS NNP N
Patients NNPS p
with IN p
left JJ p
ventricular JJ p
ejection NN p
fraction NN p
less JJR p
than IN p
45 CD p
% NN p
after IN p
AMI NNP p
were VBD p
randomly RB p
assigned VBN p
stem NN i
cell NN i
delivery NN i
via IN i
intramyocardial JJ i
injection NN i
and CC i
intracoronary JJ i
infusion NN i
3-6 JJ i
weeks NNS i
or CC i
3-4 JJ i
months NNS i
after IN i
AMI NNP i
. . i

Primary JJ N
end NN N
points NNS N
were VBD N
changes NNS o
in IN o
infarct NN o
size NN o
and CC o
left VBD o
ventricular JJ o
ejection NN o
fraction NN o
3 CD o
months NNS o
after IN o
therapy NN o
. . o

RESULTS VB N
A DT p
total NN p
of IN p
60 CD p
patients NNS p
were VBD p
treated VBN p
. . p

The DT N
mean JJ o
changes NNS o
in IN o
infarct JJ o
size NN o
at IN o
3 CD o
months NNS o
were VBD N
-3.5 JJ N
+/- JJ N
5.1 CD N
% NN N
( ( N
95 CD N
% NN N
CI NNP N
-5.5 NNP N
% NN N
to TO N
-1.5 CD N
% NN N
, , N
P NNP N
= NNP N
0.001 CD N
) ) N
in IN N
the DT N
early JJ N
group NN N
and CC N
-3.9 VBZ N
+/- JJ N
5.6 CD N
% NN N
( ( N
95 CD N
% NN N
CI NNP N
-6.1 NNP N
% NN N
to TO N
-1.6 CD N
% NN N
, , N
P NNP N
= NNP N
0.002 CD N
) ) N
in IN N
the DT N
late JJ N
group NN N
, , N
and CC N
changes NNS o
in IN o
ejection NN o
fraction NN o
were VBD N
3.5 CD N
+/- JJ N
5.6 CD N
% NN N
( ( N
95 CD N
% NN N
CI NNP N
1.3-5.6 CD N
% NN N
, , N
P NNP N
= NNP N
0.003 CD N
) ) N
and CC N
3.4 CD N
+/- JJ N
7.0 CD N
% NN N
( ( N
95 CD N
% NN N
CI NNP N
0.7-6.1 CD N
% NN N
, , N
P NNP N
= NNP N
0.017 CD N
) ) N
, , N
respectively RB N
. . N

At IN N
9-12 JJ N
months NNS N
after IN N
AMI NNP N
, , N
ejection NN o
fraction NN o
remained VBD N
significantly RB N
higher JJR N
than IN N
at IN N
baseline NN N
in IN N
both DT N
groups NNS N
. . N

In IN N
the DT N
early JJ N
and CC N
late JJ N
groups NNS N
, , N
a DT N
mean NN N
of IN N
200.3 CD N
+/- JJ N
68.7 CD N
x JJ N
10 CD N
( ( N
6 CD N
) ) N
and CC N
194.8 CD N
+/- JJ N
60.4 CD N
x JJ N
10 CD N
( ( N
6 CD N
) ) N
stem NN o
cells NNS o
, , N
respectively RB N
, , N
were VBD N
delivered VBN N
to TO N
the DT N
myocardium NN N
, , N
and CC N
1.30 CD N
+/- JJ N
0.68 CD N
x JJ N
10 CD N
( ( N
9 CD N
) ) N
and CC N
1.29 CD N
+/- JJ N
0.41 CD N
x JJ N
10 CD N
( ( N
9 CD N
) ) N
cells NNS N
, , N
respectively RB N
, , N
were VBD N
delivered VBN N
into IN N
the DT N
artery NN N
. . N

A DT N
high JJ N
number NN o
of IN o
cells NNS o
was VBD N
required VBN N
for IN N
significant JJ N
improvements NNS N
in IN N
the DT N
primary JJ N
end NN N
points NNS N
. . N

CONCLUSIONS NNP N
Combined VBD N
cardiac JJ i
stem NN i
cell NN i
delivery NN i
induces VBZ N
a DT N
moderate JJ N
but CC N
significant JJ N
improvement NN N
in IN N
myocardial JJ o
infarct NN o
size NN o
and CC o
left VBD o
ventricular JJ o
function NN o
. . o

-DOCSTART- -18235123- O O

Osteosarcoma NN N
: : N
the DT N
addition NN N
of IN N
muramyl NN i
tripeptide NN i
to TO N
chemotherapy VB N
improves NNS N
overall JJ o
survival NN o
-- : o
a DT o
report NN N
from IN N
the DT N
Children NNP p
's POS p
Oncology NNP p
Group NNP p
. . p

PURPOSE NNP N
To TO N
compare VB N
three-drug JJ N
chemotherapy NN N
with IN N
cisplatin NN i
, , i
doxorubicin NN i
, , i
and CC i
methotrexate NN i
with IN N
four-drug JJ i
chemotherapy NN i
with IN i
cisplatin NN i
, , i
doxorubicin NN i
, , i
methotrexate NN i
, , i
and CC i
ifosfamide NN i
for IN N
the DT N
treatment NN N
of IN N
osteosarcoma NN N
. . N

To TO N
determine VB N
whether IN N
the DT N
addition NN N
of IN N
muramyl NN i
tripeptide NN i
( ( i
MTP NNP i
) ) i
to TO N
chemotherapy VB N
enhances NNS N
event-free JJ o
survival NN o
( ( o
EFS NNP o
) ) o
and CC o
overall JJ o
survival NN o
in IN N
newly RB N
diagnosed VBN N
patients NNS N
with IN N
osteosarcoma NN N
. . N

PATIENTS NNP N
AND CC N
METHODS NNP N
Six NNP p
hundred VBD p
sixty-two JJ p
patients NNS p
with IN p
osteosarcoma NN p
without IN p
clinically RB p
detectable JJ p
metastatic JJ p
disease NN p
and CC p
whose WP$ p
disease NN p
was VBD p
considered VBN p
resectable JJ p
received VBD p
one CD p
of IN p
four CD p
prospectively RB p
randomized JJ p
treatments NNS p
. . p

All DT N
patients NNS N
received VBD N
identical JJ N
cumulative JJ N
doses NNS N
of IN N
cisplatin NN i
, , i
doxorubicin NN i
, , i
and CC i
methotrexate NN i
and CC N
underwent JJ N
definitive JJ N
surgical JJ N
resection NN N
of IN N
primary JJ N
tumor NN N
. . N

Patients NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
or CC N
not RB N
to TO N
receive VB i
ifosfamide JJ i
and/or NN i
MTP NNP i
in IN N
a DT N
2 CD N
x NN N
2 CD N
factorial JJ N
design NN N
. . N

The DT N
primary JJ N
end NN N
points NNS N
for IN N
analysis NN N
were VBD N
EFS NNP o
and CC o
overall JJ o
survival NN o
. . o

RESULTS NNP N
In IN N
the DT N
current JJ N
analysis NN N
, , N
there EX N
was VBD N
no DT N
evidence NN N
of IN N
interaction NN N
, , N
and CC N
we PRP N
were VBD N
able JJ N
to TO N
examine VB N
each DT N
intervention NN N
separately RB N
. . N

The DT N
chemotherapy NN N
regimens VBZ N
resulted VBN N
in IN N
similar JJ N
EFS NNP o
and CC o
overall JJ o
survival NN o
. . o

There EX N
was VBD N
a DT N
trend NN N
toward IN N
better JJR N
EFS NN o
with IN N
the DT N
addition NN N
of IN N
MTP NNP N
( ( N
P NNP N
= NNP N
.08 NNP N
) ) N
. . N

The DT N
addition NN N
of IN N
MTP NNP N
to TO N
chemotherapy VB N
improved JJ N
6-year JJ o
overall JJ o
survival NN o
from IN N
70 CD N
% NN N
to TO N
78 CD N
% NN N
( ( N
P NNP N
= NNP N
.03 NNP N
) ) N
. . N

The DT N
hazard NN o
ratio NN o
for IN o
overall JJ o
survival NN o
with IN N
the DT N
addition NN N
of IN N
MTP NNP N
was VBD N
0.71 CD N
( ( N
95 CD N
% NN N
CI NNP N
, , N
0.52 CD N
to TO N
0.96 CD N
) ) N
. . N

CONCLUSION VB N
The DT N
addition NN N
of IN N
ifosfamide NN N
to TO N
cisplatin VB N
, , N
doxorubicin NN N
, , N
and CC N
methotrexate NN N
did VBD N
not RB N
enhance VB N
EFS NNP o
or CC N
overall JJ o
survival NN o
for IN N
patients NNS N
with IN N
osteosarcoma NN N
. . N

The DT N
addition NN N
of IN N
MTP NNP N
to TO N
chemotherapy VB N
resulted VBN N
in IN N
a DT N
statistically RB N
significant JJ N
improvement NN N
in IN N
overall JJ o
survival NN o
and CC N
a DT N
trend NN N
toward IN N
better JJR N
EFS NNP o
. . o

-DOCSTART- -18004169- O O

A DT N
systems NNS N
analysis NN N
of IN N
obstetric JJ N
triage NN N
. . N

OBJECTIVE CC N
The DT N
purpose NN N
of IN N
this DT N
study NN N
is VBZ N
to TO N
examine VB N
some DT N
of IN N
the DT N
variables NNS N
involved VBN N
in IN N
obstetric JJ p
triage NN p
in IN N
an DT N
effort NN N
to TO N
develop VB N
a DT N
more RBR N
efficient JJ N
patient NN N
care NN N
delivery NN N
system NN N
in IN N
a DT N
high-volume JJ N
obstetric JJ N
unit NN N
. . N

An DT N
efficient JJ N
triage NN N
system NN N
is VBZ N
essential JJ N
to TO N
a DT N
busy JJ N
labor NN N
and CC N
delivery NN N
unit NN N
for IN N
the DT N
evaluation NN N
of IN N
unscheduled JJ N
patient NN N
visits NNS N
. . N

In IN N
hospitals NNS N
that WDT N
lack VBP N
an DT N
efficient JJ N
obstetric JJ N
triage NN N
system NN N
, , N
it PRP N
is VBZ N
very RB N
difficult JJ N
to TO N
regulate VB N
patient NN N
flow NN N
and CC N
wait JJ N
times NNS N
. . N

METHOD NNP N
The DT N
study NN N
was VBD N
designed VBN N
to TO N
determine VB N
whether IN N
a DT N
triage NN N
room NN N
and/or NN N
standing VBG N
orders NNS N
decreased VBD N
length NN o
of IN o
stay NN o
as IN N
compared VBN N
to TO N
the DT N
existing VBG N
system NN N
of IN N
evaluating VBG N
women NNS p
in IN p
labor NN p
rooms NNS p
. . p

In IN N
2 CD N
separate JJ N
phases NNS N
, , N
women NNS p
who WP p
met VBD p
triage NN p
criteria NNS p
were VBD N
randomly RB N
assigned VBN N
to TO N
either CC N
the DT N
triage NN i
room NN i
or CC i
the DT i
standard JJ i
care NN i
labor NN i
room NN i
. . i

During IN N
phase NN N
1 CD N
, , N
the DT N
effect NN N
of IN N
room NN N
assignment NN N
was VBD N
evaluated VBN N
. . N

During IN N
phase NN N
2 CD N
, , N
the DT N
effect NN N
of IN N
room NN N
assignment NN N
and CC N
the DT N
intervention NN N
of IN N
standing VBG i
orders NNS i
in IN i
common JJ i
obstetric JJ i
problems NNS i
were VBD N
utilized VBN N
. . N

The DT p
total JJ p
sample NN p
size NN p
was VBD p
398 CD p
patients NNS p
. . p

The DT N
study NN N
took VBD N
place NN N
on IN N
a DT N
midsize JJ N
labor NN N
and CC N
delivery NN N
unit NN N
, , N
in IN N
an DT N
academic JJ N
medical JJ N
center NN N
averaging VBG N
3600 CD N
births NNS N
per IN N
year NN N
. . N

RESULTS NNP N
Results NNP N
showed VBD N
that IN N
using VBG N
a DT N
triage NN N
room NN N
and/or NN N
standing VBG N
orders NNS N
did VBD N
not RB N
significantly RB N
decrease JJ N
length NN o
of IN o
stay NN o
. . o

CONCLUSION VB N
The DT N
results NNS N
of IN N
this DT N
study NN N
suggest VBP N
that IN N
the DT N
triage NN N
process NN N
in IN N
this DT N
setting NN N
is VBZ N
strongly RB N
dependent JJ N
on IN N
the DT N
provider NN N
's POS N
availability NN N
to TO N
assess VB N
, , N
triage NN N
, , N
and CC N
discharge NN N
patients NNS N
. . N

-DOCSTART- -19073386- O O

Moist NN i
Exposed VBD i
Burn NNP i
Ointment NNP i
( ( i
MEBO NNP i
) ) i
in IN N
partial JJ p
thickness NN p
burns NNS p
- : N
a DT N
randomized JJ N
, , N
comparative JJ N
open JJ N
mono-center NN N
study NN N
on IN N
the DT N
efficacy NN N
of IN N
dermaheal NN i
( ( i
MEBO NNP i
) ) i
ointment NN N
on IN N
thermal JJ p
2nd CD p
degree NN p
burns NNS p
compared VBN N
to TO N
conventional JJ N
therapy NN N
. . N

OBJECTIVE NNP N
Wound NNP N
healing NN N
in IN N
burn NN N
wounds NNS N
presents VBZ N
a DT N
challenge NN N
in IN N
healthcare NN N
, , N
and CC N
there EX N
is VBZ N
still RB N
a DT N
lack NN N
of IN N
alternatives NNS N
in IN N
topical JJ N
burn NN N
wound NN N
treatments NNS N
. . N

- : N
The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
evaluate VB N
the DT N
efficacy NN N
of IN N
a DT N
new JJ N
therapeutic JJ N
ointment NN N
( ( i
MEBO NNP i
) ) i
in IN N
the DT N
treatment NN N
of IN N
partial JJ p
thickness NN p
burns NNS p
. . p

METHODS NNP N
40 CD p
patients NNS p
received VBD p
either RB p
topical JJ p
treatment NN p
with IN p
Moist NNP i
Exposed VBD i
Burn NNP i
Ointment NNP i
( ( i
MEBO NNP i
) ) i
or CC i
standard JJ i
Flammazine NNP i
treatment NN i
. . i

All DT p
patients NNS p
suffered VBD p
from IN p
partial-thickness JJ p
burn NN p
injuries NNS p
( ( p
< VB p
20 CD p
% NN p
TBSA NNP p
) ) p
. . p

Wounds NNS N
were VBD N
evaluated VBN N
for IN N
60 CD N
up RB N
to TO N
days NNS N
regarding VBG N
wound NN o
healing NN o
, , o
water NN o
loss NN o
, , o
inflammation NN o
, , o
and CC o
pain NN o
alleviation NN o
. . o

RESULTS NNP N
For IN N
transepidermal JJ o
water NN o
loss NN o
, , N
there EX N
was VBD N
a DT N
difference NN N
of IN N
2.3 CD N
gr/m2/h NN N
between IN N
MEBO NNP i
, , N
and CC N
Flammazine NNP i
, , N
favoring VBG N
MEBO NNP i
. . i

However RB N
, , N
this DT N
difference NN N
was VBD N
not RB N
statistically RB N
significant JJ N
( ( N
p=0.78 NN N
) ) N
. . N

For IN N
all DT N
secondary JJ o
efficacy NN o
parameter NN N
results NNS N
were VBD N
similar JJ N
. . N

- : N
CONCLUSIONS NN N
This DT N
study NN N
showed VBD N
that IN N
MEBO NNP i
ointment NN i
for IN N
topical JJ N
treatment NN N
of IN N
burn NN o
injuries NNS o
presents VBZ N
an DT N
attractive JJ N
alternative NN N
for IN N
the DT N
topical JJ N
treatment NN N
of IN N
limited JJ p
partial JJ p
thickness NN p
thermal JJ p
burns NNS p
. . p

-DOCSTART- -25502833- O O

Intravitreal NNP N
ranibizumab VBZ i
versus FW N
isovolemic JJ i
hemodilution NN i
in IN N
the DT N
treatment NN N
of IN N
macular JJ p
edema NN p
secondary JJ p
to TO p
central JJ p
retinal JJ p
vein NN p
occlusion NN p
: : p
twelve-month JJ N
results NNS N
of IN N
a DT N
prospective JJ N
, , N
randomized VBN N
, , N
multicenter RBR N
trial NN N
. . N

PURPOSE VB N
This DT N
is VBZ N
a DT N
prospective JJ N
, , N
randomized VBN N
, , N
multicenter RBR p
, , N
investigator-initiated JJ N
trial NN N
to TO N
evaluate VB N
the DT N
12-month JJ N
effectiveness NN N
of IN N
isovolemic JJ i
hemodilution NN i
( ( i
IH NNP i
) ) i
with IN N
prompt JJ N
versus NN N
deferred VBD N
intravitreal JJ N
injections NNS N
( ( N
IVI NNP N
) ) N
of IN N
ranibizumab NN i
0.5 CD i
mg NN i
for IN N
the DT N
treatment NN N
of IN N
macular JJ p
edema NN p
secondary JJ p
to TO p
early JJ p
central JJ p
retinal JJ p
vein NN p
occlusion NN p
( ( p
CRVO NNP p
) ) p
. . p

METHODS NNP N
Eyes NNP p
with IN p
macular JJ p
edema NNS p
due JJ p
to TO p
CRVO NNP p
having VBG p
occurred VBD p
not RB p
more JJR p
than IN p
8 CD p
weeks NNS p
previously RB p
received VBD N
either CC N
monthly JJ N
ranibizumab NN i
IVI NNP i
in IN N
combination NN N
with IN N
IH NNP i
( ( N
group NN N
I PRP N
, , N
n RB N
= VBZ N
28 CD N
) ) N
or CC N
IH NNP i
alone RB N
( ( N
group NN N
II NNP N
, , N
n JJ N
= NNP N
30 CD N
) ) N
. . N

From IN N
month NN N
2 CD N
to TO N
12 CD N
, , N
the DT N
patients NNS N
in IN N
both DT N
groups NNS N
could MD N
be VB N
treated VBN N
with IN N
monthly JJ N
intravitreal NN N
ranibizumab NN i
. . i

The DT N
main JJ N
outcome NN N
variables NNS N
were VBD N
gain NN o
of IN o
visual JJ o
acuity NN o
and CC o
the DT o
course NN o
of IN o
central JJ o
retinal JJ o
thickness NN o
as IN N
measured VBN N
with IN N
optical JJ N
coherence NN N
tomography NN N
. . N

RESULTS NNP N
At IN N
12 CD N
months NNS N
, , N
eyes NNS N
in IN N
group NN N
I PRP N
on IN N
average NN N
gained VBN N
+28.1 NNP N
( ( o
?19.3 NNP o
) ) o
letters NNS o
compared VBN N
to TO N
+25.2 VB N
( ( N
?20.9 NN N
) ) N
letters NNS N
in IN N
group NN N
II NNP N
( ( N
p JJ N
= NNP N
0.326 CD N
) ) N
. . N

This DT N
result NN N
was VBD N
achieved VBN N
with IN N
significantly RB N
fewer JJR N
injections NNS N
in IN N
group NN N
II NNP N
. . N

Additionally RB N
, , N
30 CD N
% NN N
of IN N
the DT N
eyes NNS N
in IN N
group NN N
II NNP N
did VBD N
not RB N
need VB i
ranibizumab JJ i
IVI NNP i
during IN N
the DT N
12 CD N
months NNS N
of IN N
the DT N
trial NN N
. . N

CONCLUSION NNP i
Ranibizumab NNP i
IVI NNP i
in IN N
addition NN N
to TO N
IH NNP N
proved VBD N
to TO N
be VB N
highly RB o
effective JJ o
in IN o
increasing VBG o
visual JJ o
acuity NN o
and CC o
reducing VBG o
macular JJ o
edema NN o
secondary JJ o
to TO o
CRVO NNP o
. . o

Initial NNP N
IH NNP N
in IN N
early JJ N
CRVO NNP N
may MD N
be VB N
a DT N
first JJ N
treatment NN N
option NN N
in IN N
patients NNS N
anxious JJ N
about IN N
IVI NNP N
. . N

-DOCSTART- -2696035- O O

Methods NNS N
for IN N
assessing VBG N
treatment NN o
efficacy NN o
in IN N
trials NNS p
for IN p
adjuvant JJ i
therapy NN i
for IN p
breast NN p
cancer NN p
. . p

-DOCSTART- -21083385- O O

Effect NN N
of IN N
VX-770 NNP i
in IN N
persons NNS p
with IN p
cystic JJ p
fibrosis NN p
and CC p
the DT p
G551D-CFTR NNP p
mutation NN p
. . p

BACKGROUND VB N
A DT N
new JJ N
approach NN N
in IN N
the DT N
treatment NN N
of IN N
cystic JJ N
fibrosis NN N
involves VBZ N
improving VBG N
the DT N
function NN N
of IN N
mutant JJ N
cystic JJ N
fibrosis NN N
transmembrane NN N
conductance NN N
regulator NN N
( ( N
CFTR NNP N
) ) N
. . N

VX-770 NNP N
, , N
a DT N
CFTR NNP N
potentiator NN N
, , N
has VBZ N
been VBN N
shown VBN N
to TO N
increase VB N
the DT N
activity NN N
of IN N
wild-type NN N
and CC N
defective JJ N
cell-surface NN N
CFTR NNP N
in IN N
vitro NN N
. . N

METHODS NNP N
We PRP N
randomly VBP N
assigned VBD N
39 CD p
adults NNS p
with IN p
cystic JJ p
fibrosis NN p
and CC p
at IN p
least JJS p
one CD p
G551D-CFTR JJ p
allele NN p
to TO N
receive VB N
oral JJ i
VX-770 NNP i
every DT N
12 CD N
hours NNS N
at IN N
a DT N
dose NN N
of IN N
25 CD N
, , N
75 CD N
, , N
or CC N
150 CD N
mg NN N
or CC N
placebo NN i
for IN N
14 CD N
days NNS N
( ( N
in IN N
part NN N
1 CD N
of IN N
the DT N
study NN N
) ) N
or CC N
VX-770 JJ i
every DT N
12 CD N
hours NNS N
at IN N
a DT N
dose NN N
of IN N
150 CD N
or CC N
250 CD N
mg NN N
or CC N
placebo NN i
for IN N
28 CD N
days NNS N
( ( N
in IN N
part NN N
2 CD N
of IN N
the DT N
study NN N
) ) N
. . N

RESULTS VBN N
At IN N
day NN N
28 CD N
, , N
in IN N
the DT N
group NN N
of IN N
subjects NNS N
who WP N
received VBD N
150 CD N
mg NNS N
of IN N
VX-770 NNP N
, , N
the DT N
median JJ N
change NN N
in IN N
the DT N
nasal JJ o
potential JJ o
difference NN o
( ( N
in IN N
response NN N
to TO N
the DT N
administration NN N
of IN N
a DT N
chloride-free JJ N
isoproterenol JJ N
solution NN N
) ) N
from IN N
baseline NN N
was VBD N
-3.5 JJ N
mV NN N
( ( N
range NN N
, , N
-8.3 NNP N
to TO N
0.5 CD N
; : N
P=0.02 NNP N
for IN N
the DT N
within-subject JJ N
comparison NN N
, , N
P=0.13 NNP N
vs. FW N
placebo NN N
) ) N
, , N
and CC N
the DT N
median JJ N
change NN N
in IN N
the DT N
level NN o
of IN o
sweat NN o
chloride NN o
was VBD N
-59.5 JJ N
mmol NN N
per IN N
liter NN N
( ( N
range NN N
, , N
-66.0 NN N
to TO N
-19.0 VB N
; : N
P=0.008 NNP N
within-subject NN N
, , N
P=0.02 NNP N
vs. FW N
placebo NN N
) ) N
. . N

The DT N
median JJ N
change NN N
from IN N
baseline NN N
in IN N
the DT N
percent NN N
of IN N
predicted VBN N
forced JJ o
expiratory NN o
volume NN o
in IN N
1 CD N
second NN N
was VBD N
8.7 CD N
% NN N
( ( N
range NN N
, , N
2.3 CD N
to TO N
31.3 CD N
; : N
P=0.008 NNP N
for IN N
the DT N
within-subject JJ N
comparison NN N
, , N
P=0.56 NNP N
vs. FW N
placebo NN N
) ) N
. . N

None NN N
of IN N
the DT N
subjects NNS N
withdrew VBD N
from IN N
the DT N
study NN N
. . N

Six NNP N
severe JJ o
adverse JJ o
events NNS o
occurred VBD N
in IN N
two CD N
subjects NNS N
( ( o
diffuse IN o
macular NN o
rash NN o
in IN N
one CD N
subject NN N
and CC N
five CD N
incidents NNS N
of IN N
elevated VBN o
blood NN o
and CC o
urine JJ o
glucose NN o
levels NNS o
in IN N
one CD N
subject NN N
with IN N
diabetes NNS o
) ) o
. . N

All DT N
severe JJ N
adverse JJ N
events NNS N
resolved VBN N
without IN N
the DT N
discontinuation NN N
of IN N
VX-770 NNP N
. . N

CONCLUSIONS NNP N
This DT N
study NN N
to TO N
evaluate VB N
the DT N
safety NN o
and CC o
adverse-event JJ o
profile NN o
of IN N
VX-770 NNP N
showed VBD N
that IN N
VX-770 NNP N
was VBD N
associated VBN N
with IN N
within-subject JJ N
improvements NNS N
in IN N
CFTR NNP o
and CC o
lung NN o
function NN o
. . o

These DT N
findings NNS N
provide VBP N
support NN N
for IN N
further JJ N
studies NNS N
of IN N
pharmacologic JJ N
potentiation NN N
of IN N
CFTR NNP N
as IN N
a DT N
means NN N
to TO N
treat VB p
cystic JJ p
fibrosis NN p
. . p

( ( N
Funded VBN N
by IN N
Vertex NNP N
Pharmaceuticals NNP N
and CC N
others NNS N
; : N
ClinicalTrials.gov NNP N
number NN N
, , N
NCT00457821 NNP N
. . N

) ) N
. . N

-DOCSTART- -17852958- O O

A DT N
randomized VBN N
controlled JJ N
trial NN N
of IN N
a DT N
health-promotion NN i
programme NN i
and CC N
its PRP$ N
effect NN N
on IN N
ADL NNP o
dependence NN N
and CC N
self-reported JJ o
health NN o
problems NNS o
for IN N
the DT p
elderly JJ p
visually RB p
impaired VBN p
. . p

BACKGROUND NNP N
Ageing VBG N
with IN N
visual JJ N
impairment NN N
is VBZ N
associated VBN N
with IN N
a DT N
high JJ N
degree NN N
of IN N
disability NN N
whereby WRB N
age-related JJ N
macular JJ N
degeneration NN N
in IN N
particular JJ N
causes NNS N
dependence NN N
in IN N
activities NNS o
of IN o
daily JJ o
living NN o
( ( o
ADL NNP o
) ) o
even RB N
at IN N
an DT N
early JJ N
stage NN N
. . N

AIMS NNP N
To TO N
compare VB N
an DT N
activity-based JJ N
, , N
health-promotion JJ i
programme NN i
with IN N
an DT N
individual JJ i
programme NN i
, , N
targeting VBG N
the DT p
elderly JJ p
with IN p
age-related JJ p
macular JJ p
degeneration NN p
concerning VBG N
the DT N
effect NN N
on IN N
the DT N
development NN N
of IN N
dependence NN N
in IN N
ADL NNP N
, , N
general JJ N
health NN N
, , N
and CC N
self-reported JJ N
health NN N
problems NNS N
. . N

METHODS VB N
A DT N
randomized NN N
controlled VBN N
study NN N
with IN N
a DT N
28-month JJ N
follow-up NN N
. . N

A DT p
total NN p
of IN p
229 CD p
persons NNS p
were VBD p
randomized VBN p
to TO p
the DT p
study NN p
and CC N
131 CD N
( ( N
57 CD N
% NN N
) ) N
were VBD N
followed VBN N
up RP N
( ( i
individual JJ i
intervention NN i
n=69 NN N
, , N
health-promotion NN i
programme NN i
n=62 NN N
) ) N
at IN N
28-month JJ N
. . N

RESULTS VB N
The DT N
health-promotion NN i
group NN i
maintained VBD N
their PRP$ N
ADL NNP o
level NN o
despite IN N
a DT N
significant JJ N
decrease NN N
in IN N
visual JJ o
acuity NN o
, , N
while IN N
the DT N
individual JJ i
intervention NN i
group NN N
increased VBD N
its PRP$ N
dependence NN N
in IN N
ADL NNP o
. . o

General NNP o
health NN o
systematically RB N
dropped VBD N
to TO N
a DT N
lower JJR N
level NN N
in IN N
both DT N
groups NNS N
, , N
but CC N
participants NNS N
from IN N
the DT N
health-promotion NN i
group NN i
reported VBD N
fewer JJR o
health NN o
problems NNS o
. . o

There EX N
were VBD N
significantly RB N
fewer JJR o
reports NNS o
of IN o
tiredness NN o
and CC o
dizziness NN o
among IN N
the DT N
health-promotion NN i
participants NNS N
. . N

CONCLUSION VB N
The DT N
health-promotion NN i
programme NN i
seems VBZ N
to TO N
have VB N
slowed VBN N
down RP N
the DT N
disablement JJ o
process NN o
among IN N
elderly JJ p
with IN p
decreased JJ p
vision NN p
by IN N
enabling VBG N
them PRP N
to TO N
maintain VB N
their PRP$ N
ADL NNP o
level NN o
and CC N
by IN N
reducing VBG o
self-reported JJ o
health NN o
problems NNS o
for IN N
at IN N
least JJS N
28 CD N
months NNS N
following VBG N
intervention NN N
. . N

-DOCSTART- -21193295- O O

Effect NN N
of IN N
weight JJ N
loss NN N
on IN N
inflammation NN N
in IN N
patients NNS p
with IN p
mild JJ p
obstructive JJ p
sleep NN p
apnea NN p
. . p

BACKGROUND NNP N
AND CC N
AIMS NNP N
Inflammation NNP N
may MD N
be VB N
one CD N
mediating VBG N
mechanism NN N
for IN N
cardiovascular JJ p
diseases NNS p
in IN p
obstructive JJ p
sleep NN p
apnea NN p
( ( p
OSA NNP p
) ) p
. . N

However RB N
, , N
little JJ N
is VBZ N
known VBN N
about IN N
subclinical JJ N
inflammation NN N
or CC N
the DT N
effect NN N
of IN N
lifestyle JJ N
intervention NN N
on IN N
inflammation NN N
in IN N
early JJ N
stages NNS N
of IN N
OSA NNP N
. . N

The DT N
aim NN N
of IN N
this DT N
substudy NN N
of IN N
an DT N
existing VBG N
randomized NN N
controlled VBD N
trial NN N
, , N
with IN N
post NN N
hoc NN N
analyses NNS N
, , N
was VBD N
to TO N
determine VB N
the DT N
impact NN N
of IN N
lifestyle JJ N
changes NNS N
aimed VBN N
at IN N
weight JJ N
reduction NN N
on IN N
inflammatory NN N
biomarkers NNS N
in IN N
overweight JJ p
patients NNS p
with IN p
mild JJ p
OSA NNP p
. . p

METHODS NNP N
AND CC N
RESULTS NNP N
Patients NNPS p
were VBD p
randomized VBN p
to TO p
supervised VBN i
intensive JJ i
lifestyle JJ i
intervention NN i
group NN i
( ( p
N=28 NNP p
) ) p
or CC p
to TO p
control VB i
group NN i
( ( p
N=31 NNP p
) ) p
, , p
which WDT p
received VBD p
routine JJ i
lifestyle JJ i
advices NNS i
. . i

Circulating VBG N
concentrations NNS N
of IN N
pro- JJ N
and CC N
anti-inflammatory JJ N
mediators NNS N
were VBD N
measured VBN N
before IN N
and CC N
after IN N
the DT N
1-year JJ N
intervention NN N
. . N

The DT N
concentrations NNS N
of IN N
two CD N
pro-inflammatory JJ N
mediators NNS N
, , N
high-sensitivity JJ o
C-reactive JJ o
protein NN o
( ( o
hsCRP NN o
) ) o
and CC o
interleukin JJ o
( ( o
IL NNP o
) ) o
-6 NN o
, , o
decreased VBN o
significantly RB N
in IN N
both DT N
groups NNS N
. . N

Although IN N
the DT N
changes NNS N
in IN N
inflammatory JJ o
biomarkers NNS o
favored VBD o
the DT N
supervised JJ N
lifestyle NN i
intervention NN i
, , N
the DT N
only JJ N
significant JJ N
reduction NN N
observed VBD N
between IN N
the DT N
groups NNS N
was VBD N
for IN N
the DT N
anti-inflammatory JJ N
IL-1 NNP N
receptor NN N
antagonist NN N
( ( N
IL-1RA NNP N
) ) N
. . N

The DT N
change NN o
in IN o
hsCRP NN o
was VBD N
associated VBN N
with IN N
apnea-hypopnea JJ o
index NN o
, , N
and CC N
improving VBG o
night-time JJ o
oxygen NN o
saturation NN o
was VBD N
related VBN N
to TO N
tumor VB N
necrosis JJ N
factor NN N
alpha NN N
. . N

IL-1RA JJ N
and CC N
IL-6 NNP N
were VBD N
associated VBN N
with IN N
insulin NN N
metabolism NN N
. . N

CONCLUSION NNP N
Weight NNP o
loss NN o
resulted VBD N
in IN N
reductions NNS N
in IN N
concentrations NNS N
of IN N
some DT N
pro- JJ N
and CC N
anti-inflammatory JJ N
mediators NNS N
in IN N
overweight JJ p
patients NNS p
with IN p
mild JJ p
OSA NNP p
, , N
overall JJ N
favoring VBG N
the DT N
supervised JJ N
lifestyle JJ i
intervention NN i
. . i

These DT N
findings NNS N
suggest VBP N
that IN N
more RBR N
intensive JJ N
treatment NN N
of IN N
obesity NN N
in IN N
OSA NNP p
patients NNS p
might MD N
be VB N
well-justified JJ N
. . N

-DOCSTART- -1707337- O O

Evolution NN N
of IN N
neuropathy JJ N
and CC N
myopathy JJ N
during IN N
intensive JJ N
vincristine/corticosteroid NNS i
chemotherapy NN i
for IN N
non-Hodgkin NN N
's POS N
lymphoma NN N
. . N

Neuropathy NNP N
and CC N
myopathy NN N
are VBP N
common JJ N
sequelae NN N
of IN N
intensive JJ i
chemotherapy NN i
protocols NNS i
that WDT i
contain VBP i
vincristine JJ i
and CC i
corticosteroids NNS i
. . i

The DT N
authors NNS N
prospectively RB N
monitored VBD N
the DT N
evolution NN N
of IN N
neuropathy JJ N
and CC N
myopathy JJ N
during IN N
an DT N
intensive JJ N
12-week JJ N
chemotherapy NN i
program NN N
for IN N
patients NNS p
with IN p
intermediate JJ p
and CC p
high-grade JJ p
non-Hodgkin NN p
's POS p
lymphoma NN p
. . p

In IN N
this DT N
study NN N
, , N
vincristine NN i
was VBD N
administered VBN N
by IN N
bolus NN i
injection NN N
followed VBN N
by IN N
a DT N
3-day JJ N
continuous JJ N
intravenous JJ N
( ( N
IV NNP N
) ) N
infusion NN N
( ( N
total JJ N
dose NN N
of IN N
2.0 CD N
mg/m2 NNS N
every DT N
other JJ N
week NN N
) ) N
; : N
the DT N
maximum JJ N
dose NN N
of IN N
vincristine NN i
was VBD N
not RB N
arbitrarily RB N
limited VBN N
. . N

Cronassial NNP i
, , i
a DT i
mixture NN i
of IN i
four CD i
naturally RB i
occurring VBG i
gangliosides NNS i
, , N
was VBD N
administered VBN N
in IN N
a DT N
randomized JJ N
double-blind JJ N
test NN N
to TO N
evaluate VB N
whether IN N
this DT N
agent NN N
could MD N
prevent VB N
vincristine-induced JJ i
neuropathy NN N
. . N

High JJ N
doses NNS N
of IN N
dexamethasone NN i
( ( N
50 CD N
mg/d NN N
for IN N
3 CD N
days NNS N
weekly RB N
or CC N
every DT N
other JJ N
week NN N
) ) N
were VBD N
also RB N
prescribed VBN N
. . N

Patients NNS N
were VBD N
monitored VBN N
every DT N
4 CD N
weeks NNS N
with IN N
comprehensive JJ N
physical JJ N
and CC N
neurologic JJ N
examinations NNS N
and CC N
electrophysiologic JJ N
studies NNS N
of IN N
peripheral JJ N
nerve NN N
function NN N
. . N

Twenty-seven JJ p
patients NNS p
were VBD p
fully RB p
evaluable JJ p
. . p

Weakness NNP o
was VBD N
a DT N
prominent JJ N
adverse JJ N
reaction NN N
in IN N
this DT N
study NN N
, , N
and CC N
all DT N
patients NNS N
had VBD N
moderate JJ o
to TO o
severe VB o
signs NNS o
and CC o
symptoms NNS o
of IN o
neuropathy JJ o
and CC o
myopathy JJ o
. . o

Cronassial NNP i
( ( N
100 CD N
mg NN N
) ) N
administered VBN N
by IN N
intramuscular NN N
( ( N
IM NNP N
) ) N
injection NN N
daily RB N
provided VBD N
no DT N
protection NN N
against IN N
the DT N
development NN o
of IN o
neuropathic JJ o
symptoms NNS o
. . o

Vincristine NNP i
typically RB N
impaired VBD N
fine-motor JJ o
coordination NN o
initially RB N
, , N
whereas JJ N
corticosteroids NNS i
were VBD N
associated VBN N
with IN N
delayed JJ N
development NN o
of IN o
proximal JJ o
muscle NN o
weakness NN o
. . o

Results NNS N
of IN N
electrodiagnostic JJ N
studies NNS N
did VBD N
not RB N
add VB N
to TO N
the DT N
clinical JJ N
examination NN N
results NNS N
. . N

The DT N
authors NNS N
conclude VBP N
that IN N
symptomatic JJ o
weakness NN o
due JJ N
to TO N
neuropathy JJ N
or CC N
myopathy JJ N
appears VBZ N
in IN N
a DT N
predictable JJ N
manner NN N
during IN N
intensive JJ N
vincristine/corticosteroid-based JJ i
treatment NN i
protocols NNS N
. . N

Simple JJ N
clinical JJ N
tests NNS N
can MD N
be VB N
used VBN N
to TO N
rapidly RB N
distinguish VB N
between IN N
toxic JJ N
effects NNS N
due JJ N
either RB N
to TO N
vincristine VB i
or CC i
corticosteroids NNS i
, , N
and CC N
routine JJ N
implementation NN N
of IN N
these DT N
tests NNS N
can MD N
prevent VB N
inappropriate JJ N
dose JJ N
attenuation NN N
of IN N
these DT N
agents NNS N
. . N

-DOCSTART- -25252600- O O

The DT N
REFLO-STEMI NNP N
trial NN N
comparing VBG N
intracoronary JJ i
adenosine NN i
, , i
sodium NN i
nitroprusside RB i
and CC i
standard JJ i
therapy NN i
for IN N
the DT N
attenuation NN N
of IN N
infarct JJ N
size NN N
and CC N
microvascular JJ N
obstruction NN N
during IN N
primary JJ N
percutaneous JJ N
coronary JJ N
intervention NN N
: : N
study NN N
protocol NN N
for IN N
a DT N
randomised JJ N
controlled VBN N
trial NN N
. . N

BACKGROUND NNP N
Microvascular NNP N
obstruction NN N
( ( N
MVO NNP N
) ) N
secondary JJ N
to TO N
ischaemic-reperfusion JJ N
injury NN N
is VBZ N
an DT N
important JJ N
but CC N
underappreciated JJ N
determinant NN N
of IN N
short- JJ N
and CC N
longer-term JJ N
outcome NN N
following VBG N
percutaneous JJ i
coronary JJ i
intervention NN i
( ( i
PCI NNP i
) ) i
treatment NN N
of IN N
ST-elevation NNP N
myocardial JJ N
infarction NN N
( ( N
STEMI NNP N
) ) N
. . N

Several JJ N
small JJ N
studies NNS N
have VBP N
demonstrated VBN N
a DT N
reduction NN N
in IN N
the DT N
degree NN N
of IN N
MVO NNP o
utilising VBG N
a DT N
variety NN N
of IN N
vasoactive JJ i
agents NNS i
, , i
with IN i
adenosine NN i
and CC i
sodium NN i
nitroprusside NN i
( ( i
SNP NNP i
) ) i
being VBG N
most JJS N
evaluated VBN N
. . N

However RB N
, , N
the DT N
evidence NN N
base NN N
remains VBZ N
weak JJ N
as IN N
the DT N
trials NNS N
have VBP N
had VBN N
variable JJ N
endpoints NNS N
, , N
differing VBG N
drug NN N
doses NNS N
and CC N
delivery NN N
. . N

As IN N
such JJ N
, , N
the DT N
results NNS N
regarding VBG N
benefit NN N
are VBP N
conflicting VBG N
. . N

METHODS NNP N
The DT N
REperfusion NNP N
Facilitated NNP N
by IN N
LOcal NNP i
adjunctive JJ i
therapy NN i
in IN i
STEMI NNP i
( ( i
REFLO-STEMI NNP i
) ) i
trial NN N
is VBZ N
a DT N
multicentre NN N
, , N
prospective JJ N
, , N
randomised VBD N
, , N
controlled VBD N
, , N
open JJ N
label NN N
, , N
study NN N
with IN N
blinded JJ N
endpoint NN N
analysis NN N
: : N
Patients NNS p
presenting VBG p
within IN p
6 CD p
h NN p
of IN p
onset NN p
of IN p
STEMI NNP p
and CC p
undergoing JJ p
planned VBN p
primary JJ p
PCI NNP p
( ( p
P-PCI NNP p
) ) p
with IN p
TIMI NNP p
0/1 CD p
flow NN p
in IN p
the DT p
infarct-related JJ p
artery NN p
( ( p
IRA NNP p
) ) p
and CC p
no DT p
significant JJ p
bystander NN p
coronary JJ p
artery NN p
disease NN p
on IN p
angiography NN i
, , p
are VBP p
randomised VBN p
into IN p
one CD p
of IN p
three CD p
groups NNS p
: : p
PCI NNP p
with IN p
adjunctive JJ p
pharmacotherapy NN p
( ( p
intracoronary JJ p
adenosine NN p
or CC p
SNP NNP p
) ) p
or CC p
control NN p
( ( p
standard JJ p
PCI NNP p
) ) p
. . p

All DT p
receive VBP p
Bivalirudin NNP i
anticoagulation NN i
and CC i
thrombus JJ i
aspiration NN i
. . i

The DT N
primary JJ N
outcome NN N
is VBZ N
infarct JJ o
size NN o
( ( o
IS NNP o
) ) o
( ( N
determined VBN N
as IN N
a DT N
percentage NN N
of IN N
total JJ N
left VBD N
ventricular JJ N
mass NN N
) ) N
measured VBN N
by IN N
cardiac JJ N
magnetic JJ N
resonance NN N
imaging NN N
( ( N
CMRI NNP N
) ) N
undertaken VBP N
at IN N
48 CD N
to TO N
72 CD N
h NNS N
post JJ N
P-PCI NNP N
. . N

Secondary NNP N
outcome NN N
measures NNS N
include VBP N
MVO NNP o
( ( o
hypoenhancement NN o
within IN o
infarct JJ o
core NN o
) ) o
on IN o
CMRI NNP o
, , o
angiographic JJ o
markers NNS o
of IN o
microvascular JJ o
perfusion NN o
and CC o
MACE NNP o
during IN N
1-month JJ N
follow-up NN N
. . N

The DT N
study NN N
aims VBZ N
to TO N
recruit VB N
240 CD p
patients NNS p
( ( p
powered VBN p
at IN p
80 CD p
% NN p
to TO p
detect VB p
a DT p
5 CD p
% NN p
absolute JJ p
reduction NN p
in IN p
IS NNP p
) ) p
. . p

DISCUSSION VB N
The DT N
REFLO-STEMI NNP N
study NN N
has VBZ N
been VBN N
designed VBN N
to TO N
address VB N
the DT N
weaknesses NNS N
of IN N
previous JJ N
trials NNS N
, , N
which WDT N
have VBP N
collectively RB N
failed VBN N
to TO N
demonstrate VB N
whether IN N
adjunctive JJ i
pharmacotherapy NN i
with IN N
adenosine JJ N
and/or NN N
SNP NNP N
can MD N
reduce VB N
measures NNS N
of IN N
myocardial JJ N
injury NN N
( ( N
infarct JJ N
size NN N
and CC N
MVO NNP N
) ) N
and CC N
improve VB N
clinical JJ N
outcome NN N
, , N
despite IN N
good JJ N
basic JJ N
evidence NN N
that IN N
they PRP N
have VBP N
the DT N
potential JJ N
to TO N
attenuate VB N
this DT N
process NN N
. . N

The DT N
REFLO-STEMI NNP N
study NN N
will MD N
be VB N
the DT N
most RBS N
scientifically RB N
robust JJ N
trial NN N
to TO N
date NN N
evaluating VBG N
whether IN N
adjunctive JJ i
therapy NN i
( ( i
intracoronary JJ i
adenosine NN i
or CC i
SNP NNP i
following VBG i
thrombus JJ i
aspiration NN i
) ) i
reduces VBZ N
CMRI NNP o
measured VBN N
IS NNP o
and CC o
MVO NNP o
in IN N
patients NNS N
undergoing VBG N
P-PCI NNP N
within IN N
6 CD N
h NN N
of IN N
onset NN N
of IN N
STEMI NNP N
. . N

TRIAL NNP N
REGISTRATION NNP N
Trial NNP N
registered VBD N
20th CD N
November NNP N
2012 CD N
: : N
ClinicalTrials.gov NNP N
Identifier NNP N
NCT01747174 NNP N
. . N

-DOCSTART- -18802161- O O

Randomized VBN N
controlled JJ N
trial NN N
of IN N
collaborative JJ i
care NN i
management NN i
of IN i
depression NN i
among IN p
low-income JJ p
patients NNS p
with IN p
cancer NN p
. . p

PURPOSE NNP N
To TO N
determine VB N
the DT N
effectiveness NN N
of IN N
the DT N
Alleviating NNP i
Depression NNP i
Among IN i
Patients NNPS i
With IN i
Cancer NNP i
( ( i
ADAPt-C NNP i
) ) i
collaborative NN i
care NN i
management NN i
for IN N
major JJ N
depression NN N
or CC N
dysthymia NN N
. . N

PATIENTS NNP N
AND CC N
METHODS NNP N
Study NNP p
patients NNS p
included VBD p
472 CD p
low-income JJ p
, , p
predominantly RB p
female JJ p
Hispanic JJ p
patients NNS p
with IN p
cancer NN p
age NN p
> VBD p
or= JJ p
18 CD p
years NNS p
with IN p
major JJ o
depression NN o
( ( p
49 CD p
% NN p
) ) p
, , p
dysthymia NN o
( ( p
5 CD p
% NN p
) ) p
, , p
or CC p
both DT p
( ( p
46 CD p
% NN p
) ) p
. . p

Patients NNS p
were VBD p
randomly RB p
assigned VBN p
to TO p
intervention NN i
( ( p
n JJ p
= NNP p
242 CD p
) ) p
or CC p
enhanced VBN i
usual JJ i
care NN i
( ( p
EUC NNP p
; : p
n CC p
= VB p
230 CD p
) ) p
. . p

Intervention NN N
patients NNS N
had VBD N
access NN i
for IN i
up IN i
to TO i
12 CD i
months NNS i
to TO i
a DT i
depression NN i
clinical JJ i
specialist NN i
( ( i
supervised VBN i
by IN i
a DT i
psychiatrist NN i
) ) i
who WP i
offered VBD i
education NN i
, , i
structured VBD i
psychotherapy NN i
, , i
and CC i
maintenance/relapse NN i
prevention NN i
support NN i
. . i

The DT N
psychiatrist NN N
prescribed VBD N
antidepressant JJ i
medications NNS i
for IN N
patients NNS N
preferring VBG N
or CC N
assessed VBN N
to TO N
require VB N
medication NN N
. . N

RESULTS NNP N
At IN N
12 CD N
months NNS N
, , N
63 CD N
% NN N
of IN N
intervention NN N
patients NNS N
had VBD N
a DT N
50 CD N
% NN N
or CC N
greater JJR N
reduction NN N
in IN N
depressive JJ o
symptoms NNS o
from IN N
baseline NN N
as IN N
assessed VBN N
by IN N
the DT N
Patient NNP o
Health NNP o
Questionnaire-9 NNP o
( ( o
PHQ-9 NNP o
) ) o
depression NN o
scale NN o
compared VBN N
with IN N
50 CD N
% NN N
of IN N
EUC NNP N
patients NNS N
( ( N
odds NNS N
ratio VBP N
[ CD N
OR NNP N
] NNP N
= VBZ N
1.98 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
1.16 CD N
to TO N
3.38 CD N
; : N
P NNP N
= NNP N
.01 NNP N
) ) N
. . N

Improvement NN N
was VBD N
also RB N
found VBN N
for IN N
5-point JJ N
decrease NN N
in IN N
PHQ-9 NNP o
score NN o
among IN N
72.2 CD N
% NN N
of IN N
intervention NN N
patients NNS N
compared VBN N
with IN N
59.7 CD N
% NN N
of IN N
EUC NNP N
patients NNS N
( ( N
OR NNP N
= VBZ N
1.99 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
1.14 CD N
to TO N
3.50 CD N
; : N
P NNP N
= NNP N
.02 NNP N
) ) N
. . N

Intervention NN N
patients NNS N
also RB N
experienced VBD N
greater JJR o
rates NNS o
of IN o
depression NN o
treatment NN o
( ( N
72.3 CD N
% NN N
v JJ N
10.4 CD N
% NN N
of IN N
EUC NNP N
patients NNS N
; : N
P NNP N
< NNP N
.0001 NNP N
) ) N
and CC N
significantly RB N
better JJR o
quality-of-life JJ o
outcomes NNS o
, , N
including VBG N
social/family RB N
( ( N
adjusted VBN N
mean NN N
difference NN N
between IN N
groups NNS N
, , N
2.7 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
1.22 CD N
to TO N
4.17 CD N
; : N
P NNP N
< NNP N
.001 NNP N
) ) N
, , N
emotional JJ o
( ( N
adjusted JJ N
mean NN N
difference NN N
, , N
1.29 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
0.26 CD N
to TO N
2.22 CD N
; : N
P NNP N
= NNP N
.01 NNP N
) ) N
, , N
functional JJ o
( ( N
adjusted JJ N
mean NN N
difference NN N
, , N
1.34 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
0.08 CD N
to TO N
2.59 CD N
; : N
P NNP N
= NNP N
.04 NNP N
) ) N
, , N
and CC N
physical JJ o
well-being NN o
( ( N
adjusted VBN N
mean NN N
difference NN N
, , N
2.79 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
0.49 CD N
to TO N
5.1 CD N
; : N
P NNP N
= NNP N
.02 NNP N
) ) N
. . N

CONCLUSION NNP N
ADAPt-C NNP i
collaborative JJ i
care NN i
is VBZ N
feasible JJ N
and CC N
results NNS N
in IN N
significant JJ N
reduction NN N
in IN N
depressive JJ N
symptoms NNS N
, , N
improvement NN N
in IN N
quality NN N
of IN N
life NN N
, , N
and CC N
lower JJR N
pain NN N
levels NNS N
compared VBN N
with IN N
EUC NNP N
for IN N
patients NNS p
with IN p
depressive JJ p
disorders NNS p
in IN p
a DT p
low-income JJ p
, , p
predominantly RB p
Hispanic JJ p
population NN p
in IN p
public JJ p
sector NN p
oncology NN p
clinics NNS p
. . p

-DOCSTART- -18676757- O O

Combination NNP i
chemotherapy NN i
and CC N
ALVAC-CEA/B7.1 NNP i
vaccine NN i
in IN N
patients NNS p
with IN p
metastatic JJ p
colorectal JJ p
cancer NN p
. . p

PURPOSE VB N
The DT N
combination NN N
of IN N
vaccines NNS i
and CC N
chemotherapy NN i
holds VBZ N
promise NN N
for IN N
cancer NN N
therapy NN N
, , N
but CC N
the DT N
effect NN N
of IN N
cytotoxic NN N
chemotherapy NN N
on IN N
vaccine-induced JJ N
antitumor NN N
immunity NN N
is VBZ N
unknown JJ N
. . N

This DT N
study NN N
was VBD N
conducted VBN N
to TO N
assess VB N
the DT N
effects NNS N
of IN N
systemic JJ N
chemotherapy NN N
on IN N
ALVAC-CEA/B7.1-induced NNP N
T-cell NNP N
immunity NN N
in IN N
patients NNS p
with IN p
metastatic JJ p
colorectal JJ p
cancer NN p
. . p

EXPERIMENTAL NNP N
DESIGN NNP N
Patients NNPS p
with IN p
metastatic JJ p
colorectal JJ p
cancer NN p
were VBD N
treated VBN N
with IN N
fluorouracil NN i
, , i
leucovorin NN i
, , i
and CC i
irinotecan JJ i
and CC N
were VBD N
also RB N
given VBN N
ALVAC-CEA/B7.1 NNP i
vaccine NN i
with IN i
or CC i
without IN i
tetanus JJ i
toxoid NN i
adjuvant NN i
. . i

Eligible JJ N
patients NNS N
were VBD N
randomized VBN N
to TO N
ALVAC NNP i
followed VBN i
by IN i
chemotherapy NN i
and CC i
booster NN i
vaccination NN i
( ( i
group NN i
1 CD i
) ) i
, , i
ALVAC NNP i
and CC i
tetanus NN i
toxoid NN i
followed VBN i
by IN i
chemotherapy NN i
( ( i
group NN i
2 CD i
) ) i
, , i
or CC i
chemotherapy VB i
alone RB i
followed VBN i
by IN i
ALVAC NNP i
in IN i
patients NNS i
without IN i
disease JJ i
progression NN i
( ( i
group NN i
3 CD N
) ) N
. . N

Humoral NNP N
immune JJ N
responses NNS N
were VBD N
measured VBN N
by IN N
standard JJ N
ELISA NNP i
assay NN i
, , N
and CC N
carcinoembryonic JJ N
antigen NN N
( ( N
CEA NNP N
) ) N
-specific VBD N
T-cell NNP N
responses NNS N
were VBD N
measured VBN N
by IN N
IFN-gamma NNP i
enzyme-linked JJ i
immunospot NN i
assay NN i
. . i

RESULTS NNP N
One CD p
hundred VBD p
eighteen JJ p
patients NNS p
were VBD N
randomized VBN N
to TO N
receive VB N
either DT N
ALVAC NNP i
before IN N
and CC N
concomitantly RB N
with IN N
chemotherapy NN i
( ( N
n JJ N
= NNP N
39 CD N
) ) N
, , N
ALVAC NNP i
with IN N
tetanus NN i
adjuvant NN i
before IN N
and CC N
concomitantly RB N
with IN N
chemotherapy NN i
( ( N
n JJ N
= NNP N
40 CD N
) ) N
, , N
or CC N
chemotherapy NN i
followed VBN N
by IN N
ALVAC NNP i
( ( N
n JJ N
= NNP N
39 CD N
) ) N
. . N

Serious JJ o
adverse JJ o
events NNS o
were VBD N
largely RB N
gastrointestinal JJ o
( ( N
n JJ N
= NNP N
30 CD N
) ) N
and CC N
hematologic $ o
( ( N
n JJ N
= NNP N
24 CD N
) ) N
. . N

Overall JJ N
, , N
42 CD N
patients NNS N
( ( N
40.4 CD N
% NN N
) ) N
showed VBD N
objective JJ N
clinical JJ N
responses NNS N
. . N

All DT N
patients NNS N
developed VBD N
antibody JJ o
responses NNS o
against IN o
ALVAC NNP o
, , N
but CC N
increased VBD N
anti-CEA JJ o
antibody NN o
titers NNS o
were VBD N
detected VBN N
in IN N
only RB N
three CD N
patients NNS N
. . N

Increases NNS N
in IN N
CEA-specific NNP o
T NNP o
cells NNS o
were VBD N
detected VBN N
in IN N
50 CD N
% NN N
, , N
37 CD N
% NN N
, , N
and CC N
30 CD N
% NN N
of IN N
patients NNS N
in IN N
groups NNS N
1 CD N
, , N
2 CD N
, , N
and CC N
3 CD N
, , N
respectively RB N
. . N

There EX N
were VBD N
no DT N
differences NNS N
in IN N
clinical JJ N
or CC N
immune JJ N
responses NNS N
between IN N
the DT N
treatment NN N
groups NNS N
. . N

CONCLUSION NNP N
The DT N
combination NN N
of IN N
ALVAC-CEA/B7.1 NNP i
vaccine NN i
and CC N
systemic JJ N
chemotherapy NN i
has VBZ N
an DT N
acceptable JJ N
safety NN N
profile NN N
in IN N
patients NNS p
with IN p
metastatic JJ p
colorectal JJ p
cancer NN p
. . p

Systemic NNP N
chemotherapy NN N
did VBD N
not RB N
affect VB N
the DT N
generation NN N
of IN N
CEA-specific NNP o
T-cell NNP o
responses NNS o
following VBG N
vaccination NN N
. . N

-DOCSTART- -19680697- O O

Clinical JJ N
effects NNS N
of IN N
nanocrystalline JJ i
hydroxyapatite JJ i
paste NN i
in IN N
the DT N
treatment NN N
of IN N
intrabony JJ N
periodontal JJ N
defects NNS N
: : N
a DT N
randomized NN N
controlled VBD N
clinical JJ N
study NN N
. . N

The DT N
purpose NN N
of IN N
the DT N
present JJ N
randomized NN N
controlled VBD N
clinical JJ N
study NN N
was VBD N
to TO N
compare VB N
the DT N
clinical JJ N
outcomes NNS N
of IN N
papilla NN N
preservation NN N
flap NN N
surgery NN N
with IN N
or CC N
without IN N
the DT N
application NN N
of IN N
a DT N
novel JJ N
nanocrystalline NN i
hydroxyapatite NN i
( ( i
nano-HA JJ i
) ) i
bone NN i
graft NN i
substitute NN i
. . i

Fourteen JJ p
patients NNS p
with IN p
paired JJ p
intrabony NN p
periodontal JJ p
defects NNS p
of IN p
? . p
4 CD p
mm NN p
participated VBN p
in IN p
this DT N
split-mouth JJ N
design NN N
study NN N
. . N

The DT N
defects NNS N
in IN N
each DT N
subject NN N
were VBD i
randomly RB i
selected VBN i
to TO i
receive VB i
nano-HA JJ i
paste NN i
in IN i
conjunction NN i
with IN i
papilla NN i
preservation NN i
flaps NNS i
or CC i
papilla NN i
preservation NN i
flaps NNS i
alone RB o
. . o

Probing VBG o
bone NN o
levels NNS o
( ( o
PBL NNP o
) ) o
from IN o
a DT i
customized JJ i
acrylic JJ i
stent NN i
and CC o
probing VBG o
pocket NN o
depths NNS o
( ( o
PPD NNP o
) ) o
were VBD o
measured VBN i
at IN i
baseline NN i
and CC i
again RB i
6 CD i
months NNS i
following VBG i
surgery NN i
. . i

No DT N
differences NNS N
in IN N
any DT N
of IN N
the DT N
investigated JJ N
parameters NNS N
were VBD N
observed VBN N
at IN N
baseline NN N
between IN N
the DT N
two CD N
groups NNS o
. . o

Healing NNP o
was VBD o
uneventful JJ N
in IN N
all DT N
patients NNS N
. . N

Both DT N
treatments NNS N
resulted VBD N
in IN N
significant JJ N
improvements NNS N
between IN N
baseline NN N
and CC N
6 CD N
months NNS N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
. . N

At IN N
6 CD N
months NNS N
after IN N
therapy NN N
, , N
the DT N
sites NNS N
treated VBD N
with IN i
nano-HA JJ i
paste NN i
showed VBD i
a DT N
reduction NN N
in IN N
mean JJ o
PPD NNP o
from IN o
8.3 CD N
? . N
1.2 CD N
to TO N
4.0 CD N
? . N
1.1 CD N
mm NN N
and CC N
a DT N
gain NN N
in IN o
PBL NNP o
of IN N
4.3 CD N
? . N
1.4 CD N
mm NN N
, , N
whereas NNS N
in IN N
the DT N
control NN N
group NN N
, , N
the DT N
mean NN N
PPD NNP o
changed VBD N
from IN N
7.9 CD N
? . N
1.2 CD N
mm NN N
to TO N
5.0 CD N
? . N
1.2 CD N
mm NN N
and CC N
PBL NNP o
gain NN o
was VBD N
2.6 CD N
? . N
1.4 CD N
mm NN N
. . N

Results NNP N
demonstrated VBD N
statistically RB N
greater JJR N
PPD NNP o
reduction NN o
and CC o
PBL NNP o
gain NN o
( ( o
p JJ o
< NNP N
0.05 CD N
) ) N
in IN N
the DT N
test NN N
group NN N
as IN N
compared VBN N
with IN N
the DT N
control NN N
group NN N
. . N

In IN N
conclusion NN N
, , N
after IN N
6 CD N
months NNS N
, , N
the DT N
treatment NN N
of IN N
intrabony JJ N
periodontal JJ N
defects NNS N
with IN N
a DT N
nano-HA JJ N
paste NN N
leads VBZ N
to TO N
significantly RB N
improved VBN N
clinical JJ N
outcomes NNS N
when WRB N
compared VBN N
with IN i
papilla NN i
preservation NN i
flap NN i
surgery NN i
alone RB N
. . N

-DOCSTART- -2768768- O O

Cardiovascular JJ N
and CC N
behavioral JJ N
effects NNS N
of IN N
aerobic JJ i
exercise NN i
training NN N
in IN N
healthy JJ p
older JJR p
men NNS p
and CC p
women NNS p
. . p

The DT N
cardiovascular JJ N
and CC N
behavioral JJ N
adaptations NNS N
associated VBN N
with IN N
a DT N
4-month JJ N
program NN N
of IN N
aerobic JJ i
exercise NN i
training NN i
were VBD N
examined VBN N
in IN N
101 CD p
older JJR p
men NNS p
and CC p
women NNS p
( ( p
mean JJ p
age NN p
= VBD p
67 CD p
years NNS p
) ) p
. . p

Subjects NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
an DT N
Aerobic NNP i
Exercise NNP i
group NN i
, , i
a DT i
Yoga NNP i
and CC i
Flexibility NNP i
control NN i
group NN i
, , i
or CC i
a DT i
Waiting JJ i
List NNP i
control NN i
group NN i
. . i

Prior NNP N
to TO N
and CC N
following VBG N
the DT N
4-month JJ N
program NN N
, , N
subjects VBZ N
underwent JJ N
comprehensive JJ N
physiological NN N
and CC N
psychological JJ N
evaluations NNS N
. . N

Physiological JJ o
measures NNS o
included VBD o
measurement NN o
of IN o
blood NN o
pressure NN o
, , o
lipids NNS o
, , o
bone NN o
density NN o
, , o
and CC o
cardiorespiratory JJ o
fitness NN o
including VBG o
direct JJ o
measurements NNS o
of IN o
peak NN o
oxygen NN o
consumption NN o
( ( o
VO2 NNP o
) ) o
and CC o
anaerobic JJ o
threshold NN o
. . o

Psychological JJ o
measures NNS o
included VBD o
measures NNS o
of IN o
mood NN o
, , o
psychiatric JJ o
symptoms NNS o
, , o
and CC o
neuropsychological JJ o
functioning NN o
. . o

This DT N
study NN N
demonstrated VBD N
that IN N
4 CD N
months NNS N
of IN N
aerobic JJ i
exercise NN i
training NN N
produced VBD N
an DT N
overall JJ N
11.6 CD N
% NN N
improvement NN N
in IN N
peak NN N
VO2 NNP N
and CC N
a DT N
13 CD N
% NN N
increase NN N
in IN N
anaerobic JJ N
threshold NN N
. . N

In IN N
contrast NN N
, , N
the DT N
Yoga NNP i
and CC N
Waiting NNP i
List NNP i
control NN N
groups NNS N
experienced VBD N
no DT N
change NN N
in IN N
cardiorespiratory NN N
fitness NN N
. . N

Other JJ N
favorable JJ N
physiological JJ N
changes NNS N
observed VBN N
among IN N
aerobic JJ N
exercise NN N
participants NNS N
included VBD N
lower JJR N
cholesterol NN N
levels NNS N
, , N
diastolic JJ N
blood NN N
pressure NN N
levels NNS N
, , N
and CC N
for IN N
subjects NNS N
at IN N
risk NN N
for IN N
bone NN N
fracture NN N
, , N
a DT N
trend NN N
toward IN N
an DT N
increase NN N
in IN N
bone JJ N
mineral JJ N
content NN N
. . N

Although IN N
few JJ N
significant JJ N
psychological JJ N
changes NNS N
could MD N
be VB N
attributed VBN N
to TO N
aerobic VB i
exercise NN i
training NN N
, , N
participants NNS N
in IN N
the DT N
two CD N
active JJ N
treatment NN N
groups NNS N
perceived VBD N
themselves PRP N
as IN N
improving VBG N
on IN N
a DT N
number NN N
of IN N
psychological JJ N
and CC N
behavioral JJ N
dimensions NNS N
. . N

-DOCSTART- -10052279- O O

Pre-operative JJ i
short-term JJ i
pulmonary JJ i
rehabilitation NN i
for IN i
patients NNS p
of IN p
chronic JJ p
obstructive JJ p
pulmonary JJ p
disease NN p
undergoing VBG p
coronary JJ i
artery NN i
bypass NN i
graft NN i
surgery NN i
. . i

The DT N
role NN N
of IN N
pre-operative JJ i
short-term JJ i
pulmonary JJ i
rehabilitation NN i
in IN N
patients NNS p
with IN p
chronic JJ p
obstructive JJ p
pulmonary JJ p
disease NN p
who WP p
undergo VBP p
coronary JJ p
artery NN p
bypass NN p
graft NN p
surgery NN p
has VBZ N
been VBN N
assessed VBN N
for IN N
the DT N
first JJ N
time NN N
prospectively RB N
. . N

Forty-five JJ p
patients NNS p
posted VBD p
for IN p
coronary JJ i
artery NN i
bypass NN p
graft NN p
surgery NN p
were VBD N
randomised VBN N
to TO N
receive VB N
either DT N
short-term JJ i
pulmonary JJ i
rehabilitation NN i
( ( N
group NN N
I PRP N
) ) N
or CC i
no DT i
such JJ i
programme NN i
( ( N
group NN N
II NNP N
) ) N
. . N

Patients NNS N
of IN N
both DT N
the DT N
groups NNS N
were VBD N
evenly RB N
matched VBN N
with IN N
respect NN N
to TO N
age NN N
, , N
sex NN N
, , N
body NN N
surface JJ N
area NN N
, , N
duration NN N
and CC N
severity NN N
of IN N
chronic JJ N
obstructive JJ N
pulmonary JJ N
disease NN N
and CC N
coronary JJ N
artery NN N
disease NN N
. . N

Normal JJ N
individuals NNS N
who WP N
evenly RB N
matched VBD N
with IN N
the DT N
study NN N
group NN N
were VBD N
assessed VBN N
for IN N
normal JJ N
respiratory JJ N
function NN N
parameters NNS N
. . N

Pre-operative JJ o
and CC o
post-operative JJ o
peak NN o
expiratory NN o
flow NN o
rate NN o
, , o
inspiratory NN o
capacity NN o
, , o
post-operative JJ o
ventilation NN o
time NN o
, , o
post-operative JJ o
pulmonary JJ o
complication NN o
and CC o
hospital NN o
stay NN o
were VBD N
determined VBN N
in IN N
both CC N
the DT N
groups NNS N
. . N

Peak NNP o
expiratory JJ o
flow NN o
rate NN o
( ( N
220.0 CD N
+/- JJ N
12.9 CD N
and CC N
324.3 CD N
+/- JJ N
84.3 CD N
in IN N
group NN N
I PRP N
, , N
218.0 CD N
+/- JJ N
16.4 CD N
and CC N
260.5 CD N
+/- JJ N
35.2 CD N
in IN N
group NN N
II NNP N
) ) N
and CC N
inspiratory JJ o
capacity NN o
( ( N
844.0 CD N
+/- JJ N
147.4 CD N
and CC N
1100.0 CD N
+/- JJ N
158.1 CD N
in IN N
group NN N
I PRP N
, , N
830.0 CD N
+/- JJ N
117.4 CD N
and CC N
1090 CD N
+/- JJ N
137 CD N
in IN N
group NN N
II NNP N
) ) N
were VBD N
significantly RB N
lower JJR N
before IN N
and CC N
after IN N
surgery NN N
respectively RB N
in IN N
both DT N
groups NNS N
compared VBN N
to TO N
normal JJ N
values NNS N
. . N

Even RB N
though IN N
both DT N
groups NNS N
showed VBD N
a DT N
significant JJ N
rise NN o
in IN o
post-operative JJ o
peak JJ o
expiratory NN o
flow NN o
rate NN o
and CC o
inspiratory NN o
capacity NN o
after IN o
surgery NN o
, , o
the DT o
post-operative JJ o
peak NN o
expiratory NN o
flow NN o
rate NN o
and CC o
inspiratory NN o
capacity NN o
in IN N
group NN N
I PRP N
was VBD N
significantly RB N
higher JJR N
than IN N
in IN N
group NN N
II NNP N
. . N

In IN N
group NN N
I PRP N
, , N
the DT N
post-operative JJ o
ventilation NN o
time NN o
( ( N
24.5 CD N
+/- JJ N
6.00 CD N
hours NNS N
) ) N
, , N
post-operative JJ o
complications NNS o
( ( N
n JJ N
= NNP N
4 CD N
) ) N
and CC N
hospital JJ o
stay NN o
( ( N
12.4 CD N
+/- JJ N
3.6 CD N
days NNS N
) ) N
were VBD N
significantly RB N
lower JJR N
than IN N
in IN N
group NN N
II NNP N
( ( N
35.2 CD N
+/- JJ N
22.3 CD N
hours NNS N
, , N
n JJ N
= NN N
11 CD N
, , N
18.8 CD N
+/- JJ N
6.6 CD N
days NNS N
respectively RB N
) ) N
. . N

These DT N
data NNS N
suggest VBP N
that IN N
short-term JJ N
pulmonary JJ N
rehabilitation NN N
is VBZ N
feasible JJ o
and CC N
effective JJ o
in IN N
improving VBG N
pulmonary JJ N
functions NNS N
before IN N
and CC N
after IN N
surgery NN N
and CC N
in IN N
reducing VBG N
surgical JJ o
morbidity NN o
and CC o
cost NN o
of IN o
medical JJ o
care NN o
significantly RB N
. . N

-DOCSTART- -10832773- O O

Comments NNS N
on IN N
Secretin NNP o
and CC N
autism NN o
: : o
a DT N
two-part JJ N
clinical JJ N
investigation NN N
by IN N
M.G NNP N
. . N

Chez NNP N
et CC N
al NN N
. . N

-DOCSTART- -12844138- O O

Effect NN N
of IN N
2 CD N
weeks NNS N
of IN N
theophylline NN N
on IN N
glucose JJ o
counterregulation NN o
in IN N
patients NNS p
with IN p
type JJ p
1 CD p
diabetes NNS p
and CC p
unawareness NN p
of IN p
hypoglycemia NN p
. . p

BACKGROUND NNP N
AND NNP N
OBJECTIVE NNP N
A NNP N
single JJ N
dose NN N
of IN N
theophylline JJ N
improves NNS N
hypoglycemia NN N
unawareness NN N
in IN N
type NN p
1 CD p
diabetic JJ p
patients NNS p
. . p

Prolonged NNP N
theophylline NN N
use NN N
is VBZ N
, , N
however RB N
, , N
associated VBN N
with IN N
emergence NN N
of IN N
tolerance NN N
. . N

This DT N
study NN N
investigated VBD N
whether IN N
prolonged JJ N
use NN N
of IN N
theophylline NN N
retains NNS N
efficacy VBP N
for IN N
counterregulatory NN o
defects NNS o
in IN N
patients NNS p
with IN p
type JJ p
1 CD p
diabetes NNS p
and CC p
hypoglycemia NN p
unawareness NN p
. . p

METHODS JJ N
Experiments NNS N
were VBD N
performed VBN N
with IN N
12 CD p
subjects NNS p
with IN p
type JJ p
1 CD p
diabetes NNS p
and CC p
hypoglycemia NN p
unawareness NN p
. . p

All DT N
subjects NNS p
participated VBN N
in IN N
a DT N
crossover NN N
study NN N
of IN N
2 CD N
randomly NNS N
scheduled VBN N
15-day JJ i
study NN i
periods NNS i
during IN i
which WDT i
250 CD i
mg NN i
theophylline NN i
twice RB i
daily RB i
or CC i
matching VBG i
placebo NN i
was VBD i
used VBN i
. . i

On IN i
the DT i
final JJ i
day NN i
of IN i
each DT i
period NN i
, , i
hyperinsulinemic JJ i
( ( i
360 CD i
pmol NN i
x NNP i
m NN i
( ( i
-2 NNP i
) ) i
x VBP i
min NN i
( ( i
-1 NNP i
) ) i
) ) i
hypoglycemic NN i
( ( i
5.0 CD i
, , i
3.5 CD i
, , i
2.5 CD i
mmol NN i
x NN i
L NNP i
( ( i
-1 NNP i
) ) i
) ) i
glucose VBP i
clamps NNS i
were VBD i
used VBN i
to TO i
assess VB i
counterregulatory NN o
and CC o
cardiovascular JJ o
responses NNS o
. . o

RESULTS NNP N
Under IN N
normoglycemic JJ N
conditions NNS N
, , N
there EX N
were VBD N
no DT N
differences NNS N
between IN N
theophylline NN N
and CC N
placebo NN N
. . N

Under IN N
hypoglycemic JJ N
conditions NNS N
, , N
theophylline NN N
enhanced VBD N
responses NNS N
of IN N
growth NN o
hormone NN o
, , o
symptoms NNS o
, , o
heart NN o
rate NN o
, , o
and CC o
pulse JJ o
pressure NN o
( ( N
all DT N
P NNP N
< NNP N
.05 NNP N
) ) N
, , N
induced VBD o
sweating VBG o
at IN o
higher JJR o
plasma NN o
glucose NN o
levels NNS o
( ( N
P NNP N
=.039 NNP N
) ) N
, , N
and CC N
reduced VBD o
exogenous JJ o
glucose NN o
requirements NNS o
( ( N
P NNP N
=.018 NNP N
) ) N
. . N

Hypoglycemia-induced JJ N
responses NNS N
of IN N
epinephrine NN N
, , N
norepinephrine NN N
, , N
and CC N
cortisol NNS N
were VBD N
not RB N
enhanced VBN N
by IN N
theophylline NN N
. . N

CONCLUSIONS NNP N
Prolonged NNP N
use NN N
of IN N
theophylline NN N
has VBZ N
a DT N
sustained VBN N
effect NN N
on IN N
cardiovascular NN o
, , o
metabolic NN o
, , o
and CC o
symptom JJ o
responses NNS o
to TO N
hypoglycemia VB N
in IN N
patients NNS p
with IN p
type JJ p
1 CD p
diabetes NNS p
and CC p
hypoglycemia NN p
unawareness NN p
. . p

Whether IN N
these DT N
results NNS N
translate VBP N
into IN N
clinical JJ N
benefit NN N
remains VBZ N
to TO N
be VB N
determined VBN N
. . N

-DOCSTART- -23332872- O O

Are NNP N
tyrosine JJ i
kinase NN i
inhibitors NNS i
still RB N
active JJ N
in IN N
patients NNS p
with IN p
metastatic JJ p
renal NN p
cell NN p
carcinoma VBZ p
previously RB p
treated VBN p
with IN p
a DT p
tyrosine JJ i
kinase NN i
inhibitor NN i
and CC p
everolimus VB i
? . N
Experience NNP N
of IN N
36 CD p
patients NNS p
treated VBN p
in IN p
France NNP p
in IN p
the DT p
RECORD-1 JJ p
Trial NNP p
. . p

BACKGROUND NNP N
Because IN N
the DT N
response NN N
to TO N
treatment NN N
is VBZ N
limited JJ N
, , N
patients NNS p
with IN p
metastatic JJ p
renal NN p
cell NN p
carcinoma NN p
( ( p
mRCC NN p
) ) p
typically RB N
receive JJ N
multiple NN N
treatments NNS N
. . N

Guidelines NNS N
recommend VBP N
everolimus NN i
for IN N
patients NNS N
previously RB N
treated VBN N
with IN N
tyrosine JJ i
kinase NN i
inhibitors NNS i
( ( i
TKI NNP i
) ) i
sunitinib NN i
or CC i
sorafenib NN i
. . i

This DT N
study NN N
evaluated VBD N
the DT N
efficacy NN o
of IN N
TKI NNP i
re-treatment NN N
in IN N
patients NNS p
with IN p
disease JJ p
progression NN p
after IN p
a DT p
TKI-everolimus JJ i
sequence NN i
. . i

PATIENTS NNP N
AND CC N
METHODS NNP N
Data NNP N
were VBD N
reviewed VBN N
for IN N
patients NNS p
enrolled VBN p
in IN p
RECORD-1 NNP p
( ( p
Renal NNP p
Cell NNP p
Cancer NNP p
Treatment NNP p
With IN p
Oral NNP p
RAD001 NNP p
Given NNP p
Daily NNP p
) ) p
at IN p
French JJ p
sites NNS p
. . p

Response NNP o
, , o
progression-free JJ o
survival NN o
( ( o
PFS NNP o
) ) o
, , o
and CC o
overall JJ o
survival NN o
were VBD N
evaluated VBN N
in IN N
patients NNS p
treated VBN p
with IN p
a DT p
TKI-everolimus-TKI JJ i
sequence NN i
. . i

RESULTS NNP N
Thirty-six JJ p
patients NNS p
received VBD N
a DT N
TKI NNP i
after IN N
everolimus NN i
: : i
sunitinib NN i
in IN N
17 CD N
patients NNS N
, , N
sorafenib NN i
in IN N
15 CD N
, , N
and CC N
dovitinib NN i
( ( N
TKI258 NNP N
) ) N
in IN N
4 CD N
. . N

The DT N
response NN o
rate NN o
with IN N
TKI NNP i
re-treatment NN N
was VBD N
8 CD N
% NN N
, , N
and CC N
the DT N
disease-control JJ o
rate NN o
( ( o
response NN o
plus CC o
stable JJ o
disease NN o
) ) o
was VBD N
75 CD N
% NN N
. . N

The DT N
median JJ o
PFS NNP o
with IN N
each DT N
component NN N
of IN N
the DT N
TKI-everolimus-TKI NNP i
sequence NN N
was VBD N
10.7 CD N
months NNS N
( ( N
95 CD N
% NN N
CI NNP N
, , N
1.8-28.5 JJ N
months NNS N
) ) N
, , N
8.9 CD N
months NNS N
( ( N
95 CD N
% NN N
CI NNP N
, , N
1.7-34.6 JJ N
months NNS N
) ) N
, , N
and CC N
8.2 CD N
months NNS N
( ( N
95 CD N
% NN N
CI NNP N
, , N
5.2-11.9 JJ N
months NNS N
) ) N
, , N
respectively RB N
. . N

The DT N
median JJ o
overall JJ o
survival NN o
from IN N
the DT N
start NN N
of IN N
everolimus NN i
was VBD N
29.1 CD N
months NNS N
( ( N
95 CD N
% NN N
CI NNP N
21.1 CD N
to TO N
not RB N
reached VB N
months NNS N
) ) N
, , N
which WDT N
suggests VBZ N
a DT N
benefit NN N
in IN N
using VBG N
TKI NNP i
in IN N
this DT N
setting NN N
. . N

CONCLUSIONS NNP N
Administration NNP N
of IN N
a DT N
TKI-everolimus-TKI JJ i
sequence NN i
may MD N
be VB N
associated VBN N
with IN N
clinical JJ o
benefit NN o
and CC N
should MD N
be VB N
prospectively RB N
investigated VBN N
. . N

-DOCSTART- -25304364- O O

Effects NNS N
of IN N
aerobic JJ i
exercise NN i
on IN N
cognition NN N
and CC N
hippocampal JJ N
volume NN N
in IN N
Alzheimer NNP p
's POS p
disease NN p
: : p
study NN N
protocol NN N
of IN N
a DT N
randomized VBN N
controlled VBN N
trial NN N
( ( N
The DT N
FIT-AD NNP N
trial NN N
) ) N
. . N

BACKGROUND NNP N
Alzheimer NNP p
's POS p
disease NN p
, , N
a DT N
global JJ N
public JJ N
health NN N
issue NN N
, , N
accounts NNS N
for IN N
60 CD N
to TO N
80 CD N
% NN N
of IN N
all DT N
dementias NNS N
. . N

Alzheimer NNP N
's POS N
disease NN N
primarily RB N
causes VBZ N
cognitive JJ N
impairment NN N
and CC N
drugs NNS N
have VBP N
only RB N
modest JJ N
short-term JJ N
effects NNS N
, , N
highlighting VBG N
a DT N
pressing VBG N
need NN N
to TO N
develop VB N
effective JJ N
interventions NNS N
. . N

Aerobic NNP i
exercise NN i
holds VBZ N
promise NN N
for IN N
treating VBG N
cognitive JJ N
impairment NN N
in IN N
Alzheimer NNP p
's POS p
disease NN p
through IN N
biologically RB N
sound JJ N
mechanisms NNS N
. . N

Nonetheless RB N
, , N
aerobic JJ i
exercise NN i
studies NNS N
in IN N
Alzheimer NNP N
's POS N
disease NN N
are VBP N
limited VBN N
with IN N
mixed JJ N
findings NNS N
. . N

METHODS/DESIGN NNP N
This DT N
pilot NN N
randomized VBD N
controlled VBN N
trial NN N
will MD N
investigate VB N
the DT N
effects NNS N
of IN N
a DT N
6-month JJ N
, , N
individualized JJ N
, , N
moderate-intensity JJ i
cycling NN i
intervention NN i
( ( N
20 CD N
to TO N
50 CD N
minutes NNS N
per IN N
session NN N
, , N
3 CD N
times NNS N
a DT N
week NN N
) ) N
on IN N
cognition NN N
and CC N
hippocampal JJ N
volume NN N
in IN N
community-dwelling JJ p
older NN p
adults NNS p
with IN p
mild-to-moderate JJ p
Alzheimer NNP p
's POS p
disease NN p
. . p

The DT N
specific JJ N
aims NNS N
are VBP N
to TO N
: : N
1 CD N
) ) N
determine VB N
the DT N
immediate JJ N
effect NN N
of IN N
the DT N
cycling NN N
intervention NN N
on IN N
cognition NN o
in IN N
Alzheimer NNP N
's POS N
disease NN N
; : N
2 CD N
) ) N
examine NN N
if IN N
the DT N
cycling NN N
intervention NN N
slows VBZ N
cognitive JJ o
decline NN o
in IN N
Alzheimer NNP N
's POS N
disease NN N
from IN N
baseline NN N
to TO N
12 CD N
months NNS N
; : N
and CC N
3 CD N
) ) N
assess IN N
the DT N
effect NN N
of IN N
aerobic JJ i
exercise NN i
on IN N
hippocampal JJ N
volume NN N
over IN N
12 CD N
months NNS N
. . N

Ninety NNP p
subjects NNS p
will MD p
be VB p
randomized VBN p
on IN N
a DT N
2:1 CD N
allocation NN N
ratio NN N
to TO N
cycling NN i
or CC N
attention NN N
control NN N
( ( i
low-intensity JJ i
stretching NN i
) ) i
and CC N
followed VBN N
for IN N
another DT N
6 CD N
months NNS N
. . N

Allocations NNS N
will MD N
be VB N
concealed VBN N
to TO N
all DT N
investigators NNS N
and CC N
outcome JJ N
assessors NNS N
will MD N
be VB N
blinded VBN N
to TO N
group NN N
assignments NNS N
and CC N
previous JJ N
data NNS N
. . N

Cognition NN N
will MD N
be VB N
measured VBN N
by IN N
the DT N
Alzheimer NNP o
's POS o
disease NN o
Assessment NNP o
Scale-Cognition NN o
at IN N
baseline NN N
before IN N
randomization NN N
and CC N
at IN N
3 CD N
, , N
6 CD N
, , N
9 CD N
, , N
and CC N
12 CD N
months NNS N
. . N

Hippocampal NNP o
volume NN o
will MD N
be VB N
measured VBN N
by IN N
magnetic JJ N
resonance NN N
imaging NN N
at IN N
baseline NN N
and CC N
6 CD N
and CC N
12 CD N
months NNS N
. . N

The DT N
sample JJ p
size NN p
of IN p
90 CD p
will MD N
give VB N
80 CD N
% NN N
power NN N
to TO N
detect VB N
a DT N
2.5-point JJ N
difference NN N
in IN N
within-group JJ N
changes NNS N
in IN N
the DT N
Alzheimer NNP o
's POS o
disease NN o
Assessment NNP o
Scale-Cognition NN o
at IN N
6 CD N
months NNS N
for IN N
the DT N
cycling NN N
group NN N
. . N

DISCUSSION NNP N
Findings NNS N
from IN N
this DT N
study NN N
will MD N
address VB N
the DT N
critical JJ N
gap NN N
of IN N
exercise NN o
efficacy NN o
in IN N
Alzheimer NNP N
's POS N
disease NN N
and CC N
use NN N
of IN N
magnetic JJ N
resonance NN N
imaging NN N
as IN N
an DT N
outcome NN N
measure NN N
in IN N
clinical JJ N
trials NNS N
. . N

This DT N
study NN N
will MD N
provide VB N
a DT N
potential JJ N
treatment NN N
that WDT N
may MD N
increase VB N
physical JJ o
function NN o
and CC o
quality NN o
of IN o
life NN o
and CC N
curb VB N
the DT N
prohibitive JJ o
costs NNS o
for IN N
the DT N
growing VBG N
dementia JJ N
population NN N
. . N

TRIAL NNP N
REGISTRATION NNP N
Primary NNP N
registration NN N
: : N
( ( N
NCT01954550 NNP N
; : N
date NN N
of IN N
registration NN N
: : N
20 CD N
September NNP N
2013 CD N
) ) N
. . N

Secondary JJ N
registration NN N
: : N
( ( N
NCT01954550 NNP N
; : N
date NN N
of IN N
registration NN N
: : N
1 CD N
October NNP N
2013 CD N
) ) N
. . N

-DOCSTART- -19017582- O O

Comparing VBG N
two CD N
web-based JJ p
smoking VBG o
cessation NN o
programs NNS p
: : p
randomized VBN N
controlled JJ N
trial NN N
. . N

BACKGROUND NNP N
Smoking NNP o
cessation NN o
remains VBZ N
a DT N
significant JJ N
public JJ N
health NN N
problem NN N
. . N

Innovative JJ N
interventions NNS N
that WDT N
use VBP N
the DT N
Internet NNP N
have VBP N
begun VBN N
to TO N
emerge VB N
that DT N
offer NN N
great JJ N
promise NN N
in IN N
reaching VBG N
large JJ N
numbers NNS N
of IN N
participants NNS N
and CC N
encouraging VBG N
widespread JJ N
behavior NN N
change NN N
. . N

To TO N
date NN N
, , N
the DT N
relatively RB N
few JJ N
controlled JJ N
trials NNS N
of IN N
Web-based JJ N
smoking NN o
cessation NN o
programs NNS N
have VBP N
been VBN N
limited VBN N
by IN N
short JJ N
follow-up JJ N
intervals NNS N
. . N

OBJECTIVE IN N
We PRP N
describe VBP N
the DT N
6-month JJ N
follow-up JJ N
results NNS N
of IN N
a DT N
randomized VBN N
controlled VBN N
trial NN N
in IN N
which WDT N
participants NNS p
recruited VBD p
online NN p
were VBD N
randomly RB i
assigned VBN i
to TO i
either VB i
a DT i
Web-based JJ i
smoking NN o
cessation NN o
program NN i
( ( i
Quit NNP i
Smoking NNP i
Network NNP i
; : i
QSN NNP i
) ) i
or CC i
a DT i
Web-based JJ i
exercise NN i
enhancement NN i
program NN i
( ( i
Active NNP i
Lives VBZ i
) ) i
adapted VBD i
somewhat RB i
to TO i
encourage VB i
smoking VBG i
cessation NN i
. . i

METHODS NNP N
The DT N
study NN N
was VBD N
a DT N
two-arm JJ N
randomized NN N
controlled VBD N
trial NN N
that IN N
compared VBN N
two CD i
Web-based JJ i
smoking VBG o
cessation NN o
programs NNS i
: : i
( ( i
1 CD i
) ) i
the DT i
QSN NNP i
intervention NN i
condition NN i
presented VBD i
cognitive-behavioral JJ i
strategies NNS i
, , i
and CC i
( ( i
2 CD i
) ) i
the DT i
Active NNP i
Lives VBZ i
control VB i
condition NN i
provided VBD i
participants NNS i
with IN i
guidance NN i
in IN i
developing VBG i
a DT i
physical JJ i
activity NN i
program NN i
to TO i
assist VB i
them PRP i
with IN i
quitting VBG i
. . i

The DT i
QSN NNP i
condition NN i
provided VBD i
smoking VBG i
cessation NN i
information NN i
and CC i
behavior NN i
change NN i
strategies NNS i
while IN i
the DT i
Active NNP i
Lives VBZ i
condition NN i
provided VBD i
participants NNS i
with IN i
physical JJ i
activity NN i
recommendations NNS i
and CC i
goal NN i
setting NN i
. . i

The DT i
QSN NNP i
condition NN i
was VBD i
designed VBN i
to TO i
be VB i
more JJR i
engaging NN i
( ( i
eg UH i
, , i
it PRP i
included VBD i
multimedia JJ i
components NNS i
) ) i
and CC i
to TO i
present VB i
much RB i
greater JJR i
content NN i
than IN i
is VBZ i
typically RB i
found VBN i
in IN i
smoking VBG i
cessation NN i
programs NNS i
. . i

RESULTS NNP N
Contrary NNP N
to TO N
our PRP$ N
hypotheses NNS N
, , N
no DT N
between-condition NN N
differences NNS N
in IN N
smoking VBG o
abstinence NN o
were VBD N
found VBN N
at IN N
3- JJ N
and CC N
6-month JJ N
follow-up JJ N
assessments NNS N
. . N

While IN N
participants NNS N
in IN N
the DT N
QSN NNP N
intervention NN N
condition NN N
spent VBD N
more JJR N
time NN N
than IN N
controls NNS N
visiting VBG N
the DT N
online JJ N
program NN N
, , N
the DT N
median JJ N
number NN N
of IN N
1.0 CD N
visit NN N
in IN N
each DT N
condition NN N
and CC N
the DT N
substantial JJ N
attrition NN N
( ( N
60.8 CD N
% NN N
at IN N
the DT N
6-month JJ N
follow-up NN N
) ) N
indicate VBP N
that IN N
participants NNS N
were VBD N
not RB N
as RB N
engaged VBN N
as IN N
we PRP N
had VBD N
expected VBN N
. . N

CONCLUSIONS NNP N
Contrary NNP N
to TO N
our PRP$ N
hypothesis NN N
, , N
our PRP$ N
test NN N
of IN N
two CD N
Web-based JJ N
smoking VBG o
cessation NN o
conditions NNS N
, , N
an DT N
intervention NN N
and CC N
an DT N
attention NN N
placebo NN N
control NN N
, , N
failed VBD N
to TO N
show VB N
differences NNS N
at IN N
3- JJ N
and CC N
6-month JJ N
assessments NNS N
. . N

We PRP N
explored VBD N
possible JJ N
reasons NNS N
for IN N
this DT N
finding NN N
, , N
including VBG N
limited JJ N
engagement NN N
of IN N
participants NNS N
and CC N
simplifying VBG N
program NN N
content NN N
and CC N
architecture NN N
. . N

Future JJ N
research NN N
needs VBZ N
to TO N
address VB N
methods NNS N
to TO N
improve VB N
participant JJ N
engagement NN N
in IN N
online JJ N
smoking NN N
cessation NN N
programs NNS N
. . N

Possible JJ N
approaches NNS N
in IN N
this DT N
regard NN N
can MD N
include VB N
new JJ N
informed JJ N
consent NN N
procedures NNS N
that WDT N
better VBP N
explain VB N
the DT N
roles NNS N
and CC N
responsibilities NNS N
of IN N
being VBG N
a DT N
research NN N
participant NN N
, , N
new JJ N
program NN N
designs NNS N
that WDT N
add VBP N
more JJR N
vitality NN N
( ( N
changing VBG N
content NN N
from IN N
visit NN N
to TO N
visit VB N
) ) N
, , N
and CC N
new JJ N
types NNS N
of IN N
reminders NNS N
pushed VBN N
out RP N
to TO N
participants NNS N
to TO N
encourage VB N
return VB N
visits NNS N
. . N

Simplifying VBG N
program NN N
content NN N
through IN N
a DT N
combination NN N
of IN N
enhanced JJ N
tailoring NN N
and CC N
information NN N
architecture NN N
also RB N
merits VBZ N
further JJ N
research NN N
attention NN N
. . N

-DOCSTART- -25865294- O O

Oxytocin NNP i
reduces VBZ N
caloric JJ N
intake NN N
in IN N
men NNS p
. . p

OBJECTIVE NNP N
Preclinical NNP N
studies NNS N
indicate VBP N
that IN N
oxytocin NN i
is VBZ N
anorexigenic JJ N
and CC N
has VBZ N
beneficial JJ N
metabolic JJ N
effects NNS N
. . N

Oxytocin NNP i
effects NNS N
on IN N
nutrition NN N
and CC N
metabolism NN N
in IN N
humans NNS N
are VBP N
not RB N
well RB N
defined VBN N
. . N

It PRP N
was VBD N
hypothesized VBN N
that IN N
oxytocin NN i
would MD N
reduce VB N
caloric JJ N
intake NN N
and CC N
appetite NN N
and CC N
alter NN N
levels NNS N
of IN N
appetite-regulating JJ N
hormones NNS N
. . N

Metabolic JJ N
effects NNS N
of IN N
oxytocin NN N
were VBD N
also RB N
explored VBN N
. . N

METHODS VB N
A DT N
randomized JJ N
, , N
placebo-controlled JJ i
crossover NN N
study NN N
of IN N
single-dose JJ i
intranasal NN i
oxytocin NN i
( ( i
24 CD i
IU NNP i
) ) i
in IN N
25 CD p
fasting VBG p
healthy JJ p
men NNS p
was VBD N
performed VBN N
. . N

After IN N
oxytocin/placebo NN i
, , N
subjects NNS N
selected VBN i
breakfast NN i
from IN i
a DT i
menu NN i
and CC i
were VBD i
given VBN i
double JJ i
portions NNS i
. . i

Caloric NNP i
content NN i
of IN i
food NN i
consumed VBN i
was VBD i
measured VBN i
. . i

Visual JJ i
analog NN i
scales NNS i
were VBD N
used VBN N
to TO N
assess VB N
appetite NN o
, , N
and CC N
blood NN i
was VBD i
drawn VBN i
for IN i
appetite-regulating JJ i
hormones NNS i
, , i
insulin NN i
, , i
and CC i
glucose VB i
before IN i
and CC i
after IN i
oxytocin/placebo NN i
. . i

Indirect JJ i
calorimetry NN i
assessed VBD i
resting VBG i
energy NN i
expenditure NN i
( ( i
REE NNP i
) ) i
and CC i
substrate JJ i
utilization NN i
. . i

RESULTS NNP N
Oxytocin NNP i
reduced VBD o
caloric JJ o
intake NN o
with IN N
a DT N
preferential JJ N
effect NN N
on IN N
fat JJ o
intake NN o
and CC N
increased JJ o
levels NNS o
of IN o
the DT o
anorexigenic JJ o
hormone NN o
cholecystokinin NN o
without IN N
affecting VBG N
appetite NN N
or CC N
other JJ N
appetite-regulating JJ N
hormones NNS N
. . N

There EX N
was VBD N
no DT N
effect NN N
of IN N
oxytocin NN N
on IN N
REE NNP o
. . o

Oxytocin NNP i
resulted VBD N
in IN N
a DT N
shift NN N
from IN N
carbohydrate NN N
to TO N
fat VB N
utilization NN N
and CC N
improved JJ N
insulin NN N
sensitivity NN N
. . N

CONCLUSIONS NNP N
Intranasal NNP N
oxytocin MD i
reduces VB N
caloric JJ N
intake NN N
and CC N
has VBZ N
beneficial JJ N
metabolic JJ N
effects NNS N
in IN N
men NNS p
without IN N
concerning VBG N
side NN N
effects NNS N
. . N

The DT N
efficacy NN N
and CC N
safety NN N
of IN N
sustained JJ N
oxytocin JJ i
administration NN N
in IN N
the DT N
treatment NN N
of IN N
obesity NN N
warrants NNS N
investigation NN N
. . N

-DOCSTART- -1358607- O O

Oral NNP N
ondansetron NN i
in IN N
the DT N
prevention NN o
of IN o
postoperative JJ o
nausea NN o
and CC o
vomiting NN o
. . o

The DT N
effect NN N
of IN N
three CD N
times NNS N
daily JJ N
oral JJ N
ondansetron NN N
in IN N
preventing VBG N
postoperative JJ o
nausea NN o
and CC o
vomiting NN o
was VBD N
investigated VBN N
in IN N
two CD N
randomized JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ i
, , N
multi-centre JJ N
studies NNS N
. . N

The DT N
first JJ N
study NN N
compared VBN N
ondansetron RB i
1 CD i
, , i
8 CD i
and CC i
16 CD i
mg NN i
to TO N
placebo VB i
, , N
and CC N
the DT N
second JJ N
study NN N
compared VBN N
8 CD i
mg JJ i
ondansetron NN i
to TO i
placebo VB i
. . i

Both DT N
studies NNS N
included VBD N
ASA NNP p
Class NNP p
I-III NNP p
female JJ p
patients NNS p
about IN p
to TO p
undergo VB p
major JJ p
abdominal JJ p
gynaecological JJ p
surgery NN p
or CC p
vaginal JJ p
hysterectomy NN p
. . p

In IN N
the DT N
first JJ N
study NN N
, , N
the DT N
8 CD i
and CC i
16 CD i
mg NN i
ondansetron NN i
groups NNS i
had VBD N
a DT N
significantly RB N
lower JJR N
incidence NN o
of IN o
nausea NN o
and CC o
vomiting NN o
in IN N
the DT N
0-24 JJ N
h JJ N
period NN N
following VBG N
recovery NN N
from IN N
anaesthesia NN N
than IN N
the DT N
placebo NN i
group NN N
. . N

Ondansetron NNP i
8 CD N
mg NN N
three CD N
times NNS N
daily RB N
was VBD N
also RB N
significantly RB N
better JJR N
than IN N
placebo NN N
in IN N
the DT N
second JJ N
study NN N
. . N

Side-effects NNS o
mainly RB N
consisted VBD N
of IN N
constipation NN o
, , o
headache NN o
, , o
and CC o
asymptomatic JJ o
elevation NN o
of IN o
liver NN o
enzymes NNS o
. . o

The DT N
incidence NN N
of IN N
side-effects NNS o
was VBD N
similar JJ N
in IN N
ondansetron- JJ N
and CC N
placebo-treated JJ N
patients NNS N
. . N

There EX N
appeared VBD N
to TO N
be VB N
no DT N
clinically RB o
important JJ o
benefit NN o
of IN N
the DT N
16 CD N
mg NN N
three CD N
times NNS N
daily JJ N
ondansetron VBP i
regimen NNS N
over IN N
the DT N
8 CD N
mg NN N
three CD N
times NNS N
daily RB N
dose VBP N
, , N
therefore RB N
8 CD N
mg NN N
three CD N
times NNS N
daily RB N
is VBZ N
recommended VBN N
as IN N
the DT N
optimal JJ o
oral JJ o
dose NN o
in IN N
the DT N
prevention NN N
of IN N
postoperative JJ o
nausea NN o
and CC o
vomiting NN o
. . o

-DOCSTART- -25934164- O O

Three-year JJ N
efficacy NN o
and CC o
safety NN o
of IN N
a DT N
new JJ N
52-mg JJ N
levonorgestrel-releasing JJ i
intrauterine NN N
system NN N
. . N

OBJECTIVE UH N
To TO N
assess VB N
3-year JJ N
data NNS N
on IN N
the DT N
efficacy NN o
and CC o
safety NN o
of IN N
a DT N
new JJ N
52-mg JJ N
levonorgestrel NN i
intrauterine JJ i
contraceptive NN i
( ( i
LNG20 NNP i
) ) i
designed VBN N
for IN N
up IN N
to TO N
7 CD N
years NNS N
use RB N
. . N

STUDY NNP N
DESIGN NNP N
Nulliparous NNP p
and CC p
parous JJ p
women NNS p
aged VBN p
16-45 JJ p
years NNS p
at IN p
enrollment NN p
with IN p
regular JJ p
menstrual JJ p
cycles NNS p
and CC p
requesting VBG p
contraception NN p
were VBD p
enrolled VBN p
in IN p
an DT p
open-label JJ p
, , N
partially RB N
randomized VBN N
trial NN N
to TO N
evaluate VB N
LNG20 NNP i
. . i

The DT N
primary JJ N
outcome NN N
was VBD N
pregnancy NN o
rate NN o
for IN N
women NNS N
aged VBN N
16-35 CD N
years NNS N
calculated VBD N
as IN N
the DT N
Pearl NNP o
Index NNP o
. . o

Women NNP p
aged VBD p
36-45 CD p
years NNS p
received VBD p
LNG20 NNP i
for IN p
safety NN p
evaluation NN p
only RB p
. . p

All DT N
participants NNS N
had VBD N
in-person NN N
or CC N
phone NN N
follow-up JJ N
approximately RB N
every DT N
3 CD N
months NNS N
during IN N
the DT N
study NN N
. . N

RESULTS VB N
A DT N
total NN p
of IN p
1600 CD p
women NNS p
aged VBN p
16-35 CD p
years NNS p
and CC p
151 CD p
women NNS p
aged VBN p
36-45 CD p
years NNS p
agreed VBD p
to TO p
LNG20 NNP o
placement NN o
, , p
including VBG p
1011 CD p
( ( p
57.7 CD p
% NN p
) ) p
nulliparous JJ p
and CC p
438 CD p
( ( p
25.1 CD p
% NN p
) ) p
obese JJ p
women NNS p
. . p

Successful JJ p
placement NN p
occurred VBD p
in IN p
1714 CD p
( ( p
97.9 CD p
% NN p
) ) p
women NNS p
. . p

Six NNP p
pregnancies NNS o
occurred VBD p
, , p
four CD p
of IN p
which WDT p
were VBD p
ectopic NNS o
. . o

The DT o
Pearl NNP o
Index NNP o
for IN o
LNG20 NNP o
was VBD N
0.15 CD N
( ( N
95 CD N
% NN N
CI NNP N
0.02-0.55 NN N
) ) N
through IN N
Year $ N
1 CD N
, , N
0.26 CD N
( ( N
95 CD N
% NN N
CI NNP N
0.10-0.57 NN N
) ) N
through IN N
Year $ N
2 CD N
, , N
and CC N
0.22 CD N
( ( N
95 CD N
% NN N
CI NNP N
0.08-0.49 NN N
) ) N
through IN N
Year $ N
3 CD N
. . N

The DT N
cumulative JJ o
life-table JJ o
pregnancy NN o
rate NN o
was VBD N
0.55 CD N
( ( N
95 CD N
% NN N
CI NNP N
0.24-1.23 NN N
) ) N
through IN N
3 CD N
years NNS N
. . N

Expulsion NN o
was VBD N
reported VBN N
in IN N
62 CD N
( ( N
3.5 CD N
% NN N
) ) N
participants NNS N
, , N
most JJS N
( ( N
50 CD N
[ RB N
80.6 CD N
% NN N
] NN N
) ) N
during IN N
the DT N
first JJ N
year NN N
of IN N
use NN N
. . N

Of IN N
women NNS p
who WP p
discontinued VBD p
LNG20 NNP i
and CC p
desired VBD p
pregnancy NN p
, , N
86.8 CD N
% NN N
conceived VBD o
spontaneously RB o
within IN N
12 CD N
months NNS N
. . N

Pelvic NNP o
infection NN o
was VBD N
diagnosed VBN N
in IN N
10 CD p
( ( p
0.6 CD p
% NN p
) ) p
women NNS p
. . p

Only RB N
26 CD p
( ( p
1.5 CD p
% NN p
) ) p
LNG20 NNP i
users NNS N
discontinued VBD N
due JJ N
to TO N
bleeding VBG o
complaints NNS o
. . o

CONCLUSION VB N
The DT N
LNG20 NNP i
intrauterine NN N
system NN N
is VBZ N
highly RB N
effective JJ o
and CC o
safe JJ o
over IN N
3 CD N
years NNS N
of IN N
use NN N
in IN N
nulliparous JJ p
and CC p
parous JJ p
women NNS p
. . p

IMPLICATIONS NNP N
STATEMENT NNP N
A NNP N
new JJ N
52-mg JJ N
levonorgestrel-releasing JJ i
intrauterine NN i
system NN i
is VBZ N
effective JJ o
and CC o
safe JJ o
for IN N
nulliparous JJ N
and CC N
parous JJ N
women NNS N
for IN N
at IN N
least JJS N
3 CD N
years NNS N
. . N

-DOCSTART- -19901118- O O

Conjugated VBN N
equine JJ N
estrogen NN N
influence NN N
on IN N
mammographic JJ o
density NN o
in IN N
postmenopausal JJ p
women NNS p
in IN p
a DT p
substudy NN p
of IN p
the DT p
women NNS p
's POS p
health NN p
initiative NN p
randomized VBN p
trial NN p
. . p

PURPOSE NNP N
Increased VBD N
mammographic JJ o
density NN o
is VBZ N
associated VBN N
with IN N
increased JJ N
breast NN N
cancer NN N
risk NN N
and CC N
reduced JJ N
sensitivity NN N
of IN N
screening VBG N
mammography NN N
and CC N
is VBZ N
related VBN N
to TO N
hormone VB N
exposure NN N
. . N

However RB N
, , N
the DT N
effects NNS N
of IN N
conjugated JJ i
equine NN i
estrogens NNS i
( ( i
CEEs NNP i
) ) i
alone RB N
on IN N
mammographic JJ o
density NN o
in IN N
diverse JJ p
racial/ethnic JJ p
populations NNS p
are VBP N
not RB N
established VBN N
. . N

We PRP N
examined VBD N
the DT N
effect NN N
of IN N
CEE NNP N
alone RB N
on IN N
mammographic JJ o
density NN o
in IN N
a DT N
subsample NN p
of IN p
the DT p
Women NNP p
's POS p
Health NNP p
Initiative NNP p
( ( p
WHI NNP p
) ) p
clinical JJ p
trial NN p
participants NNS p
. . p

PATIENTS NNS N
AND CC N
METHODS NNP N
In IN N
the DT N
WHI NNP N
trial NN N
, , N
women NNS p
were VBD N
randomly RB N
assigned VBN N
to TO N
daily VB i
CEE NNP i
0.625 CD i
mg NN i
or CC i
placebo NN i
. . i

The DT N
effect NN N
of IN N
CEE NNP N
on IN N
mammographic JJ o
percent NN o
density NN o
was VBD N
determined VBN N
over IN N
1 CD N
and CC N
2 CD N
years NNS N
in IN N
a DT N
stratified JJ N
random JJ p
sample NN p
of IN p
435 CD p
racially RB p
and CC p
ethnically RB p
diverse JJ p
participants NNS p
from IN p
15 CD p
of IN p
40 CD p
WHI NNP p
clinics NNS p
. . p

RESULTS NNP N
Use NNP N
of IN N
CEE NNP N
resulted VBD N
in IN N
mean JJ N
increase NN N
in IN N
mammographic JJ o
percent NN o
density NN o
of IN N
1.6 CD N
percentage NN N
points NNS N
( ( N
95 CD N
% NN N
CI NNP N
, , N
0.8 CD N
to TO N
2.4 CD N
) ) N
at IN N
year NN N
1 CD N
compared VBN N
with IN N
a DT N
mean JJ N
decrease NN N
of IN N
1.0 CD N
percentage NN N
point NN N
( ( N
95 CD N
% NN N
CI NNP N
, , N
-1.7 NNP N
to TO N
-0.4 VB N
) ) N
in IN N
the DT N
placebo NN N
group NN N
( ( N
P NNP N
< NNP N
.001 NNP N
) ) N
. . N

The DT N
effect NN N
persisted VBD N
for IN N
2 CD N
years NNS N
, , N
with IN N
a DT N
mean JJ N
increase NN N
of IN N
1.7 CD N
percentage NN N
points NNS N
( ( N
95 CD N
% NN N
CI NNP N
, , N
0.7 CD N
to TO N
2.7 CD N
) ) N
versus NN N
a DT N
mean JJ N
decrease NN N
of IN N
1.2 CD N
percentage NN N
points NNS N
( ( N
95 CD N
% NN N
CI NNP N
, , N
-1.8 NNP N
to TO N
-0.5 VB N
; : N
P NNP N
< NNP N
.001 NNP N
) ) N
in IN N
the DT N
hormone NN N
and CC N
placebo NN N
groups NNS N
, , N
respectively RB N
. . N

These DT N
effects NNS N
were VBD N
greater JJR N
in IN N
women NNS p
age NN p
60 CD p
to TO p
79 CD p
years NNS p
( ( N
P NNP N
= NNP N
.03 NNP N
for IN N
interaction NN N
across IN N
age NN N
) ) N
. . N

CONCLUSION NNP N
Use NNP N
of IN N
CEE NNP N
results NNS N
in IN N
a DT N
modest JJ N
but CC N
statistically RB N
significant JJ N
increase NN N
in IN N
mammographic JJ o
density NN o
that WDT N
is VBZ N
sustained VBN N
over IN N
at IN N
least JJS N
a DT N
2-year JJ N
period NN N
. . N

The DT N
clinical JJ N
significance NN N
of IN N
the DT N
CEE NNP N
effect NN N
on IN N
mammographic JJ o
density NN o
remains VBZ N
to TO N
be VB N
determined VBN N
. . N

-DOCSTART- -8419816- O O

Effect NN N
of IN N
ranitidine NN i
and CC i
amoxicillin JJ i
plus CC i
metronidazole JJ i
on IN N
the DT N
eradication NN N
of IN N
Helicobacter NNP o
pylori NN o
and CC o
the DT o
recurrence NN o
of IN o
duodenal JJ o
ulcer NN o
. . o

BACKGROUND NNP N
Persistent NNP N
infection NN N
with IN N
Helicobacter NNP N
pylori NN N
is VBZ N
associated VBN N
with IN N
the DT N
recurrence NN N
of IN N
duodenal JJ N
ulcer NN N
. . N

Whether IN N
the DT N
efficacy NN N
of IN N
bismuth NN N
therapy NN N
in IN N
reducing VBG N
the DT N
rate NN N
of IN N
recurrence NN N
of IN N
duodenal JJ N
ulcer NN N
is VBZ N
due JJ N
to TO N
its PRP$ N
antimicrobial JJ N
effects NNS N
on IN N
H. NNP o
pylori NN o
or CC N
to TO N
a DT N
direct JJ N
protective JJ N
action NN N
on IN N
the DT N
mucosa NN N
is VBZ N
still RB N
a DT N
matter NN N
of IN N
debate NN N
. . N

METHODS NNP N
To TO N
study VB N
the DT N
effect NN N
of IN N
the DT N
eradication NN N
of IN N
H. NNP N
pylori NN o
on IN N
the DT N
recurrence NN N
of IN N
duodenal JJ N
ulcer NN N
, , N
we PRP N
treated VBD N
104 CD p
patients NNS p
with IN p
H. NNP p
pylori FW p
infection NN p
and CC p
recurrent JJ p
duodenal JJ p
ulcer NN p
with IN N
either DT N
amoxicillin NN i
( ( N
750 CD N
mg NN N
three CD N
times NNS N
daily RB N
) ) N
plus CC N
metronidazole JJ i
( ( N
500 CD N
mg NN N
three CD N
times NNS N
daily RB N
) ) N
or CC N
identical-appearing JJ i
placebos NN i
, , N
given VBN N
orally RB N
for IN N
12 CD N
days NNS N
. . N

All DT N
patients NNS N
also RB N
received VBD N
ranitidine NN i
( ( N
300 CD N
mg RB N
each DT N
night NN N
) ) N
for IN N
6 CD N
or CC N
10 CD N
weeks NNS N
. . N

Endoscopy NNP N
was VBD N
performed VBN N
before IN N
treatment NN N
and CC N
periodically RB N
during IN N
follow-up NN N
for IN N
up IN N
to TO N
12 CD N
months NNS N
after IN N
healing VBG N
. . N

RESULTS NNP N
Among IN N
the DT N
52 CD p
patients NNS p
given VBN p
antibiotics NNS i
, , N
H. NNP o
pylori NN o
was VBD N
eradicated VBN o
in IN N
46 CD N
, , N
as IN N
compared VBN N
with IN N
1 CD N
of IN N
the DT N
52 CD N
given VBN N
placebo NN i
( ( N
89 CD N
percent NN N
vs. FW N
2 CD N
percent NN N
, , N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

After IN N
six CD N
weeks NNS N
, , N
the DT N
ulcers NNS o
were VBD N
healed VBN o
in IN N
48 CD N
patients NNS N
given VBN N
antibiotics NNS i
and CC N
39 CD N
given VBN N
placebo NN i
( ( N
92 CD N
percent NN N
vs. FW N
75 CD N
percent NN N
, , N
P NNP N
= NNP N
0.011 CD N
) ) N
. . N

Side JJ N
effects NNS N
, , N
mainly RB N
diarrhea NN o
, , N
occurred VBD N
in IN N
15 CD N
percent NN N
of IN N
the DT N
patients NNS N
given VBN N
antibiotics NNS i
. . i

Among IN N
the DT N
patients NNS N
followed VBD N
up RP N
for IN N
12 CD N
months NNS N
, , N
duodenal JJ o
ulcers NNS o
recurred VBD o
in IN N
4 CD N
of IN N
50 CD N
patients NNS N
given VBN N
antibiotics NNS i
and CC N
42 CD N
of IN N
49 CD N
given VBN N
placebo NN i
( ( N
8 CD N
percent NN N
vs. FW N
86 CD N
percent NN N
, , N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

Ulcers NNS o
recurred VBD o
in IN N
1 CD N
of IN N
46 CD N
patients NNS N
in IN N
whom WP N
H. NNP N
pylori NN N
had VBD N
been VBN N
eradicated VBN N
, , N
as IN N
compared VBN N
with IN N
45 CD N
of IN N
53 CD N
in IN N
whom WP N
H. NNP o
pylori NN o
persisted VBD N
( ( N
2 CD N
percent NN N
vs. FW N
85 CD N
percent NN N
, , N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

CONCLUSIONS NNP N
In IN N
patients NNS p
with IN p
recurrent JJ p
duodenal JJ p
ulcer NN p
, , N
eradication NN o
of IN o
H. NNP o
pylori NN o
by IN N
a DT N
regimen NNS N
that WDT N
does VBZ N
not RB N
have VB N
any DT N
direct JJ N
action NN N
on IN N
the DT N
mucosa NN N
is VBZ N
followed VBN N
by IN N
a DT N
marked JJ N
reduction NN N
in IN N
the DT N
rate NN N
of IN N
recurrence NN N
, , N
suggesting VBG N
a DT N
causal JJ N
role NN N
for IN N
H. NNP N
pylori NN N
in IN N
recurrent JJ N
duodenal JJ N
ulcer NN N
. . N

-DOCSTART- -9190129- O O

Low JJ i
intensity NN i
physical JJ i
training NN i
in IN N
older JJR p
subjects NNS p
. . p

BACKGROUND NNP N
This DT N
study NN N
was VBD N
designed VBN N
to TO N
evaluate VB N
the DT N
effects NNS N
of IN N
a DT N
low JJ i
intensity NN i
general JJ i
training NN i
program NN i
( ( N
< JJ N
50 CD N
% NN N
of IN N
heart NN N
rate NN N
reserve NN N
) ) N
on IN N
physical JJ N
fitness NN N
of IN N
healthy JJ p
older JJR p
subjects NNS p
, , N
by IN N
comparing VBG N
maximal JJ N
and CC N
submaximal JJ N
indices NNS N
of IN N
training NN N
response NN N
. . N

METHODS NNP N
Twenty-two JJ p
volunteers NNS p
over IN p
60 CD p
years NNS p
of IN p
age NN p
participated VBN N
in IN N
the DT N
present JJ N
study NN N
. . N

The DT N
sample NN N
was VBD N
randomly RB N
divided VBN N
in IN N
an DT p
experimental JJ p
group NN p
of IN p
13 CD p
older JJR p
subjects NNS p
( ( p
3 CD p
men NNS p
and CC p
10 CD p
women NNS p
, , p
mean JJ p
age NN p
63.5 CD p
+/- JJ p
3 CD p
years NNS p
) ) p
while IN p
the DT p
remaining VBG p
9 CD p
subjects NNS p
( ( p
3 CD p
men NNS p
and CC p
6 CD p
women NNS p
, , p
mean JJ p
age NN p
64.2 CD p
+/- JJ p
4 CD p
years NNS p
) ) p
served VBD p
as IN p
inactive JJ i
control NN i
group NN i
. . i

After IN N
medical JJ N
screening VBG N
all DT N
participants NNS N
were VBD N
evaluated VBN N
before IN N
and CC N
after IN N
12 CD N
weeks NNS N
in IN N
which WDT N
the DT N
experimental JJ N
subjects NNS N
underwent VBD N
a DT N
low JJ i
intensity NN i
training NN i
. . i

Each DT N
subjects-either JJ N
inactive JJ N
or CC N
active-performed JJ N
two CD i
treadmill NN i
tests NNS i
at IN N
two-days JJ N
interval NN N
, , N
to TO N
measure VB N
maximal JJ N
and CC N
submaximal JJ N
responses NNS N
to TO N
exercise VB N
, , N
respectively RB N
. . N

Heart NNP N
rate NN N
( ( N
HR NNP N
) ) N
, , N
oxygen JJ o
uptake NN o
( ( o
VO2 NNP o
) ) o
and CC N
pulmonary JJ o
ventilation NN o
( ( o
VE NNP o
) ) o
were VBD N
measured VBN N
using VBG N
a DT N
telemetric JJ N
apparatus NN N
. . N

RESULTS VB N
The DT N
major JJ N
finding NN N
of IN N
the DT N
study NN N
was VBD N
the DT N
significant JJ N
improvement NN N
in IN N
submaximal JJ o
response NN o
to TO o
exercise NN o
of IN o
experimental JJ o
subjects NNS o
, , N
expressed VBN N
by IN N
the DT N
reduction NN N
in IN N
HR NNP o
, , o
VO2 NNP o
VE NNP o
while IN o
VO2 NNP o
max NN o
did VBD N
not RB N
change NN N
. . N

CONCLUSIONS NNP N
Thus NNP N
, , N
it PRP N
appears VBZ N
that IN N
a DT N
low JJ N
intensity NN N
general JJ N
training NN N
similar JJ N
to TO N
that DT N
followed VBN N
in IN N
the DT N
present JJ N
study NN N
may MD N
represent VB N
a DT N
good JJ N
means NN N
to TO N
improve VB N
physical JJ o
fitness NN o
in IN N
healthy JJ p
elderly JJ p
people NNS p
. . p

Similarly RB N
, , N
this DT N
study NN N
supports VBZ N
the DT N
effectiveness NN N
of IN N
evaluation NN N
tests NNS N
based VBN N
on IN N
submaximal JJ o
responses NNS o
to TO N
exercise VB N
in IN N
this DT N
population NN N
. . N

-DOCSTART- -23605599- O O

Evaluation NN N
of IN N
the DT N
effect NN N
of IN N
low JJ i
level NN i
laser NN i
on IN N
prevention NN o
of IN o
chemotherapy-induced JJ o
mucositis NN o
. . o

Radiotherapy NNP i
in IN N
the DT N
head NN N
and CC N
neck JJ N
region NN N
and CC N
chemotherapy NN i
might MD N
give VB N
rise NN N
to TO N
oral JJ N
mucositis NN N
which WDT N
is VBZ N
a DT N
severe JJ N
and CC N
painful JJ N
inflammation NN N
. . N

There EX N
is VBZ N
no DT N
known JJ N
definite JJ N
cure NN N
for IN N
mucositis NN N
. . N

A DT N
number NN N
of IN N
studies NNS N
have VBP N
attempted VBN N
to TO N
evaluate VB N
the DT N
effect NN N
of IN N
low-power JJR i
laser NN i
on IN i
radiotherapy- JJ o
and CC N
chemotherapy-induced JJ o
mucositis NN o
. . o

The DT N
present JJ N
study NN N
was VBD N
undertaken VBN N
to TO N
evaluate VB N
the DT N
effect NN N
of IN N
low-power JJR i
laser NN i
on IN N
the DT N
prevention NN o
of IN o
mucositis NN o
, , o
xerostomia NN o
and CC o
pain NN o
as IN o
a DT o
result NN o
of IN o
chemotherapy NN o
. . o

The DT N
subjects NNS N
in IN N
this DT N
double-blind JJ N
randomized NN N
controlled VBN N
study NN N
were VBD N
24 CD p
adult NN p
patients NNS p
who WP p
underwent JJ p
chemotherapy NN i
during IN p
2009-2010 JJ p
. . p

The DT N
results NNS N
showed VBD N
that IN N
low-power JJR N
laser NN N
was VBD N
able JJ N
to TO N
decrease VB N
the DT N
effect NN o
of IN o
chemotherapy NN o
on IN o
oral JJ o
mucositis NN o
, , o
xerostomia NN o
and CC o
pain NN o
in IN o
a DT o
variety NN o
of IN o
malignancies NNS o
( ( N
P NNP N
& CC N
lt NN N
; : N
0.05 CD N
) ) N
. . N

It PRP N
can MD N
be VB N
concluded VBN N
that IN N
low-power JJR i
laser NN i
might MD N
decrease VB N
the DT N
intensity NN o
of IN o
mucositis NN o
. . o

-DOCSTART- -9129469- O O

Effects NNS N
of IN N
age NN N
at IN N
introduction NN N
of IN N
complementary JJ i
foods NNS i
to TO N
breast-fed JJ N
infants NNS N
on IN N
duration NN N
of IN N
lactational JJ p
amenorrhea NN p
in IN p
Honduran NNP p
women NNS p
. . p

Lactational JJ o
amenorrhea NN o
( ( N
LA NNP N
) ) N
is VBZ N
associated VBN N
with IN N
postpartum NN p
infertility NN N
and CC N
is VBZ N
known VBN N
to TO N
be VB N
related VBN N
to TO N
breast-feeding JJ N
frequency NN N
and CC N
duration NN N
, , N
but CC N
the DT N
exact JJ N
role NN N
of IN N
complementary JJ i
feeding NN i
of IN N
the DT N
infant NN N
has VBZ N
not RB N
been VBN N
clearly RB N
defined VBN N
. . N

Data NNS N
on IN N
LA NNP N
were VBD N
collected VBN N
during IN N
and CC N
after IN N
a DT N
2-mo JJ N
intervention NN N
trial NN N
in IN N
which WDT N
low-income JJ p
Honduran NNP p
women NNS p
who WP p
had VBD p
breast-fed VBN p
fully RB p
for IN p
4 CD p
mo NNS p
were VBD p
randomly RB p
assigned VBN p
to TO p
one CD p
of IN p
three CD p
groups NNS p
: : p
continued VBN i
full JJ i
breast-feeding NN i
until IN i
6 CD i
mo NNS i
( ( N
FBF NNP N
, , N
n JJ N
= NNP N
50 CD N
) ) N
, , N
introduction NN i
of IN i
complementary JJ i
foods NNS i
at IN i
4 CD i
mo NN i
with IN i
ad NN i
libitum NN i
breast-feeding NN i
from IN i
4 CD i
to TO i
6 CD i
mo NN i
( ( N
SF NNP N
, , N
n JJ N
= NNP N
47 CD N
) ) N
, , N
or CC N
introduction NN i
of IN i
complementary JJ i
foods NNS i
at IN i
4 CD i
mo NN i
with IN i
maintenance NN i
of IN i
baseline JJ i
breast-feeding JJ i
frequency NN i
from IN i
4 CD i
to TO i
6 CD i
mo NNS i
( ( N
SF-M NNP N
, , N
n JJ N
= NNP N
44 CD N
) ) N
. . N

Women NNS N
were VBD N
followed VBN N
up RP N
until IN N
the DT N
infant NN N
was VBD N
12 CD N
mo NN N
of IN N
age NN N
, , N
or CC N
later RB N
if IN N
menses NNS N
had VBD N
not RB N
occurred VBN N
by IN N
then RB N
. . N

All DT N
but CC N
six CD N
of IN N
the DT N
women NNS N
continued VBD N
to TO N
breast-feed VB N
for IN N
> NN N
or CC N
= $ N
12 CD N
mo NN N
. . N

With IN N
the DT N
exclusion NN N
of IN N
those DT N
whose WP$ N
menses NNS N
returned VBD N
before IN N
18 CD N
wk NN N
postpartum NN N
( ( N
which WDT N
could MD N
not RB N
have VB N
been VBN N
due JJ N
to TO N
the DT N
intervention NN N
) ) N
, , N
the DT N
proportion NN o
of IN o
women NNS o
who WP o
were VBD o
amenorrheic VBN o
at IN N
6 CD N
mo NN N
was VBD N
64.5 CD N
% NN N
in IN N
the DT N
SF NNP N
group NN N
, , N
80.0 CD N
% NN N
in IN N
the DT N
FBF NNP N
group NN N
, , N
and CC N
85.7 CD N
% NN N
in IN N
the DT N
SF-M NNP N
group NN N
( ( N
chi-square JJ N
test NN N
= NN N
4.13 CD N
, , N
P NNP N
= NNP N
0.02 CD N
; : N
one-tailed JJ N
test NN N
with IN N
the DT N
latter JJ N
two CD N
groups NNS N
combined VBN N
) ) N
. . N

The DT N
total JJ o
duration NN o
of IN o
LA NNP o
did VBD N
not RB N
differ VB N
significantly RB N
among IN N
groups NNS N
. . N

The DT N
most RBS N
significant JJ N
determinant NN N
of IN N
LA NNP o
was VBD N
time NN o
spent VBN o
breast-feeding NN o
( ( o
min/d NN o
) ) o
, , N
which WDT N
was VBD N
in IN N
turn NN N
negatively RB N
associated VBN N
( ( N
P NNP N
= NNP N
0.06 CD N
) ) N
with IN N
the DT N
infant NN o
's POS o
energy NN o
intake NN o
from IN N
complementary JJ i
foods NNS i
in IN N
regression NN N
analyses NNS N
. . N

These DT N
results NNS N
indicate VBP N
that IN N
there EX N
is VBZ N
a DT N
significant JJ N
effect NN N
of IN N
introducing VBG N
foods NNS N
at IN N
4 CD N
mo NN N
on IN N
the DT N
likelihood NN N
of IN N
amenorrhea NN N
at IN N
6 CD N
mo NN N
postpartum NN N
, , N
but CC N
not RB N
thereafter RB N
, , N
and CC N
that IN N
this DT N
effect NN N
is VBZ N
not RB N
seen VBN N
in IN N
mothers NNS N
who WP N
maintain VBP N
breast-feeding JJ N
frequency NN N
. . N

-DOCSTART- -17201277- O O

[ IN N
The DT N
effects NNS N
of IN N
mexicor NN i
on IN N
thrombocyte JJ o
aggregation NN o
, , o
blood NN o
viscosity NN o
, , o
hemodynamics NNS o
, , N
and CC N
the DT N
clinical JJ N
course NN N
of IN N
coronary JJ p
artery NN p
disease NN p
] NNP p
. . N

The DT N
authors NNS N
analyze VBP N
their PRP$ N
experience NN N
in IN N
the DT N
application NN N
of IN N
mexicor NN i
, , i
a DT i
Russian JJ i
cytoprotector NN i
, , N
in IN N
50patients CD p
with IN p
chronic JJ p
coronary JJ p
artery NN p
disease NN p
( ( p
CAD NNP p
) ) p
and CC p
51 CD p
patients NNS p
with IN p
acute JJ p
coronary JJ p
syndrome NN p
. . p

In IN N
additional JJ N
to TO N
cytoprotective JJ N
action NN N
, , N
the DT N
use NN N
of IN N
mexidor NN i
in IN N
complex JJ N
therapy NN N
of IN N
CAD NNP N
lowers VBZ N
the DT N
functional JJ o
activity NN o
of IN o
thrombocytes NNS o
, , N
eliminates VBZ N
high JJ o
blood NN o
viscosity NN o
syndrome NN o
, , N
and CC N
lowers NNS N
low JJ o
density NN o
lipoprotein NN o
cholesterol NN o
level NN o
. . o

These DT N
favorable JJ N
changes NNS N
in IN N
hemorheological JJ N
parameters NNS N
improves VBZ N
myocardial JJ o
perfusion NN o
, , N
lowers VBZ N
the DT N
strength NN o
and CC o
frequency NN o
of IN o
coronary JJ o
pain NN o
attacks NNS o
, , N
retards NNS N
postinfarction NN o
left VBD o
ventricular JJ o
remodeling NN o
, , N
and CC N
increases VBZ N
the DT N
quality NN o
of IN o
life NN o
of IN o
patients NNS o
with IN p
various JJ p
CAD NNP p
forms NNS p
. . p

-DOCSTART- -18029492- O O

Several JJ N
indicators NNS o
of IN o
oxidative JJ o
stress NN o
, , o
immunity NN o
, , o
and CC o
illness NN o
improved VBN N
in IN N
trained JJ p
men NNS p
consuming VBG N
an DT N
encapsulated JJ i
juice NN i
powder NN i
concentrate NN i
for IN N
28 CD N
weeks NNS N
. . N

Phytonutrients NNS i
from IN i
plant NN i
foods NNS i
provide VBP N
numerous JJ N
antioxidants NNS N
. . N

We PRP N
hypothesized VBD N
that DT N
supplementation NN N
for IN N
28 CD N
wk NN N
with IN N
a DT N
commercially RB i
available JJ i
encapsulated JJ i
juice NN i
powder NN i
concentrate NN i
( ( i
JPC NNP i
) ) i
could MD N
influence VB N
indicators NNS o
of IN o
oxidative JJ o
stress NN o
, , o
immunity NN o
, , o
and CC o
illness NN o
. . o

Trained VBN p
men NNS p
( ( p
n JJ p
= VBZ p
41 CD p
; : p
34 CD p
+/- JJ p
5 CD p
y NN p
; : p
maximum JJ p
oxygen NN p
uptake JJ p
= JJ p
55 CD p
+/- JJ p
7 CD p
mL NN p
x NN p
kg NN p
( ( p
-1 NNP p
) ) p
x VBP p
min NN p
( ( p
-1 NNP p
) ) p
) ) p
from IN p
a DT p
homogenous JJ p
police NN p
Special JJ p
Forces NNS p
unit NN p
were VBD N
randomly RB N
assigned VBN N
in IN N
a DT N
double JJ N
blind NN N
manner NN N
to TO N
either DT N
JPC NNP i
( ( N
n JJ N
= NNP N
21 CD N
) ) N
or CC i
placebo NN i
( ( N
n JJ N
= NNP N
20 CD N
) ) N
. . N

We PRP N
used VBD N
multiple JJ N
7-d JJ o
food NN o
records NNS o
to TO N
assess VB N
dietary JJ N
intake NN N
and CC N
found VBD N
inadequate JJ p
mean JJ p
daily JJ p
fruit NN p
and CC p
vegetable JJ p
consumption NN p
( ( p
3.2 CD p
+/- JJ p
1.2 CD p
servings NNS p
) ) p
. . p

The DT N
group NN N
physician NN N
documented VBD N
all DT N
duty NN N
days NNS N
lost VBD N
due JJ N
to TO N
illness VB o
. . o

We PRP i
collected VBD i
plasma NN i
at IN i
baseline NN i
and CC i
study NN i
wk VBP i
4 CD i
, , i
8 CD i
, , i
16 CD i
, , i
and CC i
28 CD i
for IN i
analysis NN i
of IN i
carbonyl NN o
groups NNS o
on IN o
protein NN o
( ( o
CP NNP o
) ) o
and CC o
TNFalpha NNP o
. . o

Over IN N
the DT N
28-wk JJ N
investigation NN N
, , N
CP NNP o
was VBD N
lower RBR N
in IN N
the DT N
JPC NNP i
group NN N
, , N
with IN N
both DT N
a DT N
treatment NN N
and CC N
a DT N
time NN N
x JJ N
treatment NN N
interaction NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

Concentrations NNS N
of IN N
both DT N
CP NNP o
and CC o
TNFalpha NNP o
at IN N
16 CD N
and CC N
28 CD N
wk NNS N
were VBD N
lower JJR N
in IN N
the DT N
JPC NNP i
than IN N
in IN N
the DT N
placebo NN i
group NN N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

TNFalpha NNP o
increased VBD N
during IN N
the DT N
first JJ N
8 CD N
wk NN N
followed VBN N
by IN N
a DT N
decrease NN N
in IN N
both DT N
groups NNS N
for IN N
the DT N
following JJ N
20 CD N
wk NN N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

Over IN N
the DT N
final JJ N
20 CD N
wk NN N
of IN N
the DT N
study NN N
, , N
the DT N
placebo NN i
group NN N
tended VBD N
to TO N
have VB N
more JJR N
days NNS N
of IN N
illness NN o
than IN N
the DT N
JPC NNP i
group NN N
( ( N
P NNP N
= NNP N
0.068 CD N
) ) N
. . N

These DT N
data NNS N
suggest VBP N
beneficial JJ N
JPC NNP i
effects NNS N
with IN N
regard NN N
to TO N
reduction NN N
of IN N
duty NN N
days NNS N
lost VBD N
due JJ N
to TO N
illness VB o
and CC N
reduction NN N
of IN N
CP NNP o
and CC o
TNFalpha NNP o
concentrations NNS o
in IN N
this DT N
group NN p
of IN p
trained JJ p
men NNS p
over IN p
28 CD p
wk NNS p
. . p

-DOCSTART- -24293165- O O

Short-term JJ i
amiodarone NN i
therapy NN i
after IN N
reversion NN N
of IN N
persistent JJ p
atrial JJ p
fibrillation NN p
reduces NNS N
recurrences NNS o
at IN N
18 CD N
months NNS N
. . N

BACKGROUND NNP N
The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
compare VB N
the DT N
outcome NN o
of IN N
3 CD N
months NNS N
vs. IN N
18 CD N
months NNS N
of IN N
amiodarone NN i
treatment NN N
after IN N
atrial JJ N
fibrillation NN N
( ( N
AF NNP N
) ) N
conversion NN N
in IN N
patients NNS p
who WP N
experienced VBD N
the DT N
first JJ N
episode NN N
of IN N
persistent JJ N
AF NNP N
. . N

METHODS NNP N
We PRP N
included VBD N
51 CD p
patients NNS p
who WP p
experienced VBD p
the DT p
first JJ p
episode NN p
of IN p
persistent JJ p
AF NNP p
receiving VBG p
amiodarone NN i
( ( p
600 CD p
mg NN p
) ) p
daily RB p
for IN p
4-6 JJ p
weeks NNS p
. . p

If IN N
AF NNP N
persisted VBD N
, , N
electrical JJ i
cardioversion NN i
( ( i
ECV NNP i
) ) i
was VBD N
performed VBN N
. . N

All DT N
patients NNS N
received VBD N
amiodarone RB i
( ( N
200 CD N
mg NNS N
daily RB N
) ) N
for IN N
3 CD N
months NNS N
and CC N
then RB N
were VBD N
randomized VBN N
to TO N
amiodarone VB i
( ( N
Group NNP N
I PRP N
) ) N
or CC i
placebo NN i
( ( N
Group NNP N
II NNP N
) ) N
and CC N
followed VBD N
for IN N
15 CD N
months NNS N
. . N

The DT N
control NN p
group NN p
comprised VBD N
9 CD N
untreated JJ N
patients NNS p
undergoing VBG N
ECV NNP i
. . i

Treatment NNP N
effectiveness NN o
was VBD N
evaluated VBN N
using VBG N
a DT N
Bayesian JJ N
model NN N
. . N

RESULTS NNP N
Eighteen NNP N
months NNS N
after IN N
AF NNP N
reversion NN N
, , N
22 CD N
( ( N
81.5 CD N
% NN N
) ) N
patients NNS N
in IN N
Group NNP N
I PRP N
, , N
13 CD N
( ( N
54.2 CD N
% NN N
) ) N
patients NNS N
in IN N
Group NNP N
II NNP N
, , N
and CC N
1 CD N
( ( N
11.1 CD N
% NN N
) ) N
patient NN N
in IN N
the DT N
control NN N
group NN N
remained VBD o
in IN o
sinus NN o
rhythm NN o
. . o

No DT N
differences NNS N
were VBD N
found VBN N
between IN N
Group NNP N
I PRP N
patients NNS N
who WP N
required VBD N
ECV NNP i
and CC N
Group NNP N
II NNP N
patients NNS N
. . N

Sinus NNP o
rhythm NN o
was VBD N
preserved VBN N
in IN N
all DT N
Group NNP N
I PRP N
patients NNS N
when WRB N
it PRP N
was VBD N
achieved VBN N
during IN N
amiodarone JJ N
administration NN N
. . N

Limiting VBG o
adverse JJ o
effects NNS o
occurred VBD N
in IN N
3 CD N
( ( N
11.1 CD N
% NN N
) ) N
patients NNS N
in IN N
Group NNP N
I PRP N
. . N

CONCLUSIONS NNP N
In IN N
patients NNS N
regaining VBG N
sinus NN N
rhythm NN N
after IN N
the DT N
first JJ N
episode NN N
of IN N
persistent JJ N
AF NNP N
, , N
a DT N
3-month JJ N
amiodarone NN i
treatment NN N
after IN N
reversion NN N
is VBZ N
a DT N
reasonable JJ N
option NN N
for IN N
rhythm NN N
control NN N
. . N

-DOCSTART- -19565731- O O

[ JJ N
Clinical NNP N
observation NN N
on IN N
acupuncture NN i
combined VBN N
with IN N
Yizhi NNP i
Jiannao NNP i
granules NNS i
for IN N
treatment NN N
of IN N
Alzheimer NNP N
's POS N
disease NN N
] NNP N
. . N

OBJECTIVE NNP N
To TO N
observe VB N
clinical JJ N
therapeutic JJ o
effect NN o
of IN N
acupuncture NN i
combined VBN N
with IN N
Yizhi NNP i
Jiannao NNP i
Granules NNP i
for IN N
treatment NN N
of IN N
Alzheimer NNP N
's POS N
disease NN N
and CC N
its PRP$ N
effects NNS N
on IN N
intelligence NN o
, , o
daily JJ o
life NN o
and CC o
social JJ o
activity NN o
ability NN o
. . o

METHODS NNP N
Eighty-four JJ p
cases NNS p
were VBD p
randomly RB p
divided VBN p
into IN p
3 CD p
groups NNS p
, , p
28 CD p
cases NNS p
in IN p
each DT p
group NN p
. . p

The DT N
combined JJ N
acupuncture NN i
and CC N
medication NN N
group NN N
was VBD N
treated VBN N
with IN N
acupuncture NN i
at IN N
Baihui NNP N
( ( N
GV NNP N
20 CD N
) ) N
, , N
Sishencong NNP N
( ( N
EX-HN NNP N
1 CD N
) ) N
, , N
Dazhui NNP N
( ( N
GV NNP N
14 CD N
) ) N
, , N
Guanyuan NNP N
( ( N
CV NNP N
4 CD N
) ) N
, , N
etc FW N
. . N

and CC N
oral JJ N
administration NN N
of IN N
Yizhi NNP i
Jiannao NNP i
Granules NNP i
; : i
the DT N
Chinese NNP N
herb NN N
group NN N
was VBD N
treated VBN N
with IN N
Yizhi NNP i
Jiannao NNP i
Granules NNP i
, , N
and CC N
the DT N
western JJ i
medicine NN i
group NN i
with IN N
oral JJ N
administration NN N
of IN N
Aricept NNP i
. . i

The DT N
scores NNS o
for IN o
the DT o
Mini-Mental JJ o
State NNP o
Examination NNP o
( ( o
MMSE NNP o
) ) o
, , o
Ability NNP o
of IN o
Daily NNP o
Life NNP o
( ( o
ADL NNP o
) ) o
and CC o
the DT o
therapeutic JJ o
effects NNS o
were VBD N
assessed VBN N
and CC N
compared VBN N
before IN N
treatment NN N
and CC N
after IN N
treatment NN N
for IN N
12 CD N
weeks NNS N
among IN N
the DT N
groups NNS N
. . N

RESULTS NNP N
After IN N
treatment NN N
, , N
the DT N
scores NNS N
for IN N
MMSE NNP o
and CC o
ADL NNP o
were VBD N
improved VBN N
in IN N
the DT N
combined JJ i
acupuncture NN i
and CC i
medication NN i
group NN N
, , N
the DT N
Chinese JJ i
herb NN i
group NN N
and CC N
the DT N
western JJ i
medicine NN i
group NN N
, , N
which WDT N
were VBD N
better RBR N
in IN N
the DT N
combined JJ N
acupuncture NN i
and CC i
medication NN i
group NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

The DT N
total JJ o
effective JJ o
rate NN o
of IN N
85.7 CD N
% NN N
in IN N
the DT N
combined JJ i
acupuncture NN i
and CC i
medication NN i
group NN N
was VBD N
better JJR N
than IN N
71.4 CD N
% NN N
in IN N
the DT N
Chinese JJ N
herb NN N
group NN N
and CC N
67.9 CD N
% NN N
in IN N
the DT N
western JJ N
medicine NN N
group NN N
. . N

CONCLUSION NNP N
Acupuncture NNP i
combined VBN i
with IN i
Yizhi NNP i
Jiannao NNP i
Granules NNP i
has VBZ N
a DT N
significant JJ N
therapeutic JJ o
effect NN o
on IN N
Alzheimer NNP N
's POS N
disease NN N
, , N
which WDT N
is VBZ N
better JJR N
than IN N
that DT N
of IN N
Yizhi NNP i
Jiannao NNP i
Granules NNP i
or CC N
Aricept NNP i
. . i

-DOCSTART- -3303886- O O

Prognostic JJ o
significance NN o
and CC N
beneficial JJ o
effect NN o
of IN N
diltiazem NN i
on IN N
the DT N
incidence NN N
of IN N
early JJ o
recurrent NN o
ischemia NN o
after IN p
non-Q-wave JJ p
myocardial JJ p
infarction NN p
: : p
results NNS N
from IN N
the DT N
Multicenter NNP N
Diltiazem NNP N
Reinfarction NNP N
Study NNP N
. . N

Of IN N
576 CD p
patients NNS p
with IN p
non-Q-wave JJ p
acute JJ p
myocardial JJ p
infarction NN p
enrolled VBN p
in IN p
the DT p
Diltiazem NNP p
Reinfarction NNP p
Study NNP p
, , p
246 CD p
( ( p
43 CD p
% NN p
) ) p
had VBD p
1 CD p
or CC p
more JJR p
episodes NNS p
of IN p
angina NN p
at IN p
rest NN p
or CC p
with IN p
minimal JJ p
effort NN p
during IN p
10.5 CD p
days NNS p
of IN p
treatment NN p
with IN p
either DT p
diltiazem NN i
( ( p
90 CD p
mg NN p
every DT p
6 CD p
hours NNS p
) ) p
or CC i
placebo NN i
. . i

Reinfarction NNP o
( ( N
12.2 CD N
% NN N
vs JJ N
3.6 CD N
% NN N
, , N
p NN N
less JJR N
than IN N
0.0001 CD N
) ) N
or CC N
death NN o
( ( N
6.1 CD N
% NN N
vs JJ N
1.5 CD N
% NN N
, , N
p NN N
= NNP N
0.003 CD N
) ) N
was VBD N
more RBR N
likely JJ N
to TO N
occur VB N
within IN N
2 CD N
weeks NNS N
of IN N
randomization NN N
in IN N
patients NNS N
with IN N
postinfarction NN N
angina NNS N
than IN N
in IN N
those DT N
without IN N
angina NNS N
. . N

Based VBN N
on IN N
serial JJ N
electrocardiographic JJ N
data NNS N
, , N
115 CD N
of IN N
the DT N
246 CD N
patients NNS N
with IN N
angina NNS N
had VBD N
transient JJ N
ST-T JJ o
changes NNS N
and CC N
131 CD N
did VBD N
not RB N
. . N

Comparison NNP N
of IN N
the DT N
14-day JJ N
event NN N
rates NNS N
in IN N
these DT N
2 CD N
groups NNS N
showed VBD N
that IN N
the DT N
115 CD N
patients NNS N
with IN N
electrocardiographic JJ N
evidence NN N
of IN N
ischemia NN N
had VBD N
a DT N
higher JJR N
frequency NN N
of IN N
reinfarction NN o
( ( N
20 CD N
% NN N
vs JJ N
5.3 CD N
% NN N
, , N
p NN N
less JJR N
than IN N
0.001 CD N
) ) N
, , N
more RBR N
extensive JJ o
damage NN o
as IN N
assessed VBN N
by IN N
peak JJ o
MB-creatine JJ o
kinase NN o
levels NNS o
( ( N
91 CD N
+/- JJ N
76 CD N
vs JJ N
37 CD N
+/- JJ N
19 CD N
IU/liter NNP N
, , N
p NN N
= VBD N
0.059 CD N
[ NNP N
Wilcoxon NNP N
rank NN N
sum NN N
] NN N
) ) N
and CC N
a DT N
higher JJR o
mortality NN o
rate NN o
( ( N
11.3 CD N
% NN N
vs JJ N
1.5 CD N
% NN N
, , N
p NN N
= NNP N
0.001 CD N
) ) N
. . N

Angina NNP o
associated VBD N
with IN N
transient JJ o
ST-T JJ o
changes NNS o
occurred VBD N
in IN N
70 CD N
of IN N
the DT N
289 CD N
patients NNS N
in IN N
the DT N
placebo NN i
group NN N
but CC N
in IN N
only RB N
45 CD N
of IN N
the DT N
287 CD N
patients NNS N
in IN N
the DT N
diltiazem NN N
group NN N
-- : N
a DT N
28 CD N
% NN N
reduction NN N
in IN N
cumulative JJ o
life-table JJ o
incidence NN o
( ( N
p JJ N
= $ N
0.0103 CD N
[ NNP N
2-tail JJ N
, , N
log JJ N
rank NN N
] NN N
; : N
95 CD N
% NN N
confidence NN N
interval NN N
, , N
9.3 CD N
to TO N
53.8 CD N
% NN N
) ) N
. . N

It PRP N
is VBZ N
concluded VBN N
that IN N
patients NNS p
with IN p
early JJ p
postinfarction NN p
angina NN p
are VBP N
at IN N
increased JJ N
risk NN o
of IN o
reinfarction NN o
and CC o
death NN o
, , N
and CC N
angina RB o
associated VBN o
with IN o
transient JJ o
electrocardiographic JJ o
changes NNS o
identified VBD N
a DT N
very RB N
high JJ N
risk NN N
subset NN N
. . N

This DT N
subset NN N
appeared VBD N
to TO N
have VB N
a DT N
larger JJR N
area NN N
of IN N
viable JJ o
but CC N
jeopardized JJ o
myocardium NN o
and CC N
benefited VBD N
from IN N
prophylactic JJ N
therapy NN N
with IN N
diltiazem NN i
. . i

-DOCSTART- -20038728- O O

Acupuncture NNP i
versus NN i
venlafaxine NN i
for IN N
the DT N
management NN N
of IN N
vasomotor NN o
symptoms NNS o
in IN N
patients NNS p
with IN p
hormone JJ p
receptor-positive JJ p
breast NN p
cancer NN p
: : p
a DT N
randomized NN N
controlled VBN N
trial NN N
. . N

PURPOSE NNP N
Vasomotor NNP o
symptoms NNS o
are VBP N
common JJ N
adverse JJ N
effects NNS N
of IN N
antiestrogen NN i
hormone NN i
treatment NN i
in IN N
conventional JJ N
breast NN N
cancer NN N
care NN N
. . N

Hormone CD i
replacement NN i
therapy NN i
is VBZ N
contraindicated VBN N
in IN N
patients NNS p
with IN p
breast JJ p
cancer NN p
. . p

Venlafaxine NNP i
( ( i
Effexor NNP i
) ) i
, , N
the DT N
therapy NN N
of IN N
choice NN N
for IN N
these DT N
symptoms NNS N
, , N
has VBZ N
numerous JJ N
adverse JJ N
effects NNS N
. . N

Recent JJ N
studies NNS N
suggest VBP N
acupuncture NN i
may MD N
be VB N
effective JJ N
in IN N
reducing VBG N
vasomotor NN o
symptoms NNS o
in IN N
menopausal JJ p
women NNS p
. . p

This DT N
randomized VBD N
controlled JJ N
trial NN N
tested VBD N
whether IN N
acupuncture NN i
reduces NNS N
vasomotor NN o
symptoms NNS o
and CC N
produces VBZ N
fewer JJR N
adverse JJ N
effects NNS N
than IN N
venlafaxine NN i
. . i

PATIENTS NNP N
AND CC N
METHODS NNP N
Fifty NNP p
patients NNS p
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
12 CD N
weeks NNS N
of IN N
acupuncture NN i
( ( N
n JJ N
= NNP N
25 CD N
) ) N
or CC N
venlafaxine NN i
( ( N
n JJ N
= NNP N
25 CD N
) ) N
treatment NN N
. . N

Health NNP o
outcomes NNS o
were VBD N
measured VBN N
for IN N
up RB N
to TO N
1 CD N
year NN N
post-treatment NN N
. . N

RESULTS NNP N
Both NNP N
groups NNS N
exhibited VBD N
significant JJ N
decreases NNS N
in IN N
hot JJ o
flashes NNS o
, , o
depressive NN o
symptoms NNS o
, , o
and CC o
other JJ o
quality-of-life NN o
symptoms NNS o
, , N
including VBG N
significant JJ o
improvements NNS o
in IN o
mental JJ o
health NN o
from IN N
pre- JJ N
to TO N
post-treatment JJ N
. . N

These DT N
changes NNS N
were VBD N
similar JJ N
in IN N
both DT N
groups NNS N
, , N
indicating VBG N
that IN N
acupuncture NN i
was VBD N
as RB N
effective JJ N
as IN N
venlafaxine NN i
. . i

By IN N
2 CD N
weeks NNS N
post-treatment JJ N
, , N
the DT N
venlafaxine NN i
group NN N
experienced VBD N
significant JJ N
increases NNS N
in IN N
hot JJ o
flashes NNS o
, , N
whereas NNS N
hot JJ N
flashes NNS N
in IN N
the DT N
acupuncture NN i
group NN N
remained VBD N
at IN N
low JJ N
levels NNS N
. . N

The DT N
venlafaxine NN i
group NN N
experienced VBD N
18 CD N
incidences NNS N
of IN N
adverse JJ N
effects NNS N
( ( N
eg NN N
, , N
nausea NN o
, , o
dry JJ o
mouth NN o
, , o
dizziness NN o
, , o
anxiety NN o
) ) o
, , N
whereas IN N
the DT N
acupuncture NN i
group NN N
experienced VBD N
no DT N
negative JJ N
adverse JJ N
effects NNS N
. . N

Acupuncture NN i
had VBD N
the DT N
additional JJ N
benefit NN N
of IN N
increased JJ N
sex NN o
drive NN o
in IN N
some DT N
women NNS N
, , N
and CC N
most JJS N
reported VBD N
an DT N
improvement NN N
in IN N
their PRP$ N
energy NN o
, , o
clarity NN o
of IN o
thought NN o
, , o
and CC o
sense NN o
of IN o
well-being NN o
. . o

CONCLUSION NNP N
Acupuncture NNP i
appears VBZ N
to TO N
be VB N
equivalent JJ N
to TO N
drug NN N
therapy NN N
in IN N
these DT N
patients NNS N
. . N

It PRP N
is VBZ N
a DT N
safe JJ N
, , N
effective JJ N
and CC N
durable JJ N
treatment NN N
for IN N
vasomotor NN N
symptoms NNS N
secondary JJ N
to TO N
long-term JJ N
antiestrogen NN i
hormone NN i
use NN N
in IN N
patients NNS p
with IN p
breast JJ p
cancer NN p
. . p

-DOCSTART- -24885187- O O

Quantitative JJ N
measurements NNS N
of IN N
HER2 NNP N
and CC N
phospho-HER2 JJ N
expression NN N
: : N
correlation NN N
with IN N
pathologic JJ N
response NN N
to TO N
neoadjuvant JJ i
chemotherapy NN i
and CC i
trastuzumab NN i
. . i

BACKGROUND NNP N
Preoperative NNP i
therapy NN i
with IN i
chemotherapy NN i
and CC N
the DT N
HER2-targeted JJ i
monoclonal JJ i
antibody NN i
trastuzumab NN i
is VBZ N
valuable JJ N
for IN N
patients NNS p
with IN p
large JJ p
or CC p
locally RB p
advanced JJ p
HER2-positive NNP p
( ( p
HER2+ NNP p
) ) p
breast NN p
cancers NNS p
but CC N
traditional JJ N
methods NNS N
of IN N
measuring VBG N
HER2 NNP N
expression NN N
do VBP N
not RB N
accurately RB N
stratify JJ N
patients NNS N
for IN N
likelihood NN N
of IN N
response NN N
. . N

Quantitative JJ N
immunofluorescent NN N
approaches NNS N
have VBP N
the DT N
potential JJ N
to TO N
provide VB N
a DT N
mathematically RB N
continuous JJ N
measure NN N
of IN N
HER2 NNP N
. . N

Here RB N
we PRP N
seek VBP N
to TO N
determine VB N
whether IN N
quantitative JJ N
measurement NN N
of IN N
HER2 NNP N
or CC N
phospho-HER2 JJ N
correlates NNS N
with IN N
likelihood NN N
of IN N
response NN N
to TO N
trastuzumab- JJ N
containing NN N
neoadjuvant JJ N
therapy NN N
. . N

METHODS NNP N
We PRP N
evaluated VBD N
core NN p
biopsy NN p
samples NNS p
from IN p
27 CD p
HER2+ NNP p
breast NN p
cancer NN p
patients NNS p
enrolled VBN p
in IN p
a DT p
preoperative JJ p
clinical JJ p
trial NN p
using VBG p
trastuzumab NN i
, , i
nab-paclitaxel JJ i
and CC i
carboplatin JJ i
combination NN i
therapy NN i
( ( p
BrUOG NNP p
BR-211B NNP p
( ( p
NCT00617942 NNP p
) ) p
) ) p
. . p

Tumor NNP N
core NN N
biopsies NNS N
were VBD N
taken VBN N
before IN N
initiation NN N
of IN N
treatment NN N
and CC N
9-13 CD N
days NNS N
after IN N
patients NNS N
received VBD N
run-in JJ N
doses NNS N
of IN N
either DT N
single JJ N
agent NN N
trastuzumab NN i
or CC N
nab-paclitaxel NN i
. . i

The DT N
AQUA NNP N
method NN N
of IN N
quantitative JJ N
immunofluorescence NN N
was VBD N
used VBN N
for IN N
analysis NN N
of IN N
in IN N
situ NN N
protein NN N
expression NN N
. . N

Patients NNS N
then RB N
received VBD N
18 CD p
weeks NNS p
of IN p
treatment NN p
, , p
followed VBN N
by IN N
surgery NN N
to TO N
assess VB o
pathologic JJ o
response NN o
to TO N
the DT N
neoadjuvant JJ N
regimen NNS N
. . N

RESULTS VB N
A DT N
HER2 NNP N
score NN N
of IN N
2111 CD N
by IN N
AQUA NNP N
analysis NN N
has VBZ N
been VBN N
shown VBN N
to TO N
be VB N
equivalent JJ N
to TO N
HER2 NNP N
3+ CD N
by IN N
immunohistochemical JJ N
staining NN N
in IN N
previous JJ N
studies NNS N
. . N

Of IN N
20 CD N
evaluable JJ N
patients NNS N
, , N
10 CD N
cases NNS N
who WP N
achieved VBD N
a DT N
pathologic JJ o
complete JJ o
response NN o
( ( o
pathCR NN o
) ) o
with IN N
neoadjuvant JJ N
treatment NN N
had VBD N
a DT N
mean JJ N
HER2 NNP N
level NN N
of IN N
10251 CD N
compared VBN N
with IN N
4766 CD N
in IN N
the DT N
patients NNS N
without IN N
pathCR NN N
( ( N
p JJ N
= NNP N
0.0021 CD N
) ) N
. . N

Measurement NN o
of IN o
phospho-HER2 NN o
showed VBD o
no DT N
difference NN N
in IN N
pathCR JJ N
vs JJ N
non-pathCR JJ N
groups NNS N
. . N

In IN N
9 CD N
patients NNS N
who WP N
had VBD N
HER2 NNP N
levels NNS N
repeated VBN N
after IN N
a DT N
single JJ N
treatment NN N
with IN N
trastuzumab NN N
there EX N
was VBD N
no DT N
evidence NN N
of IN N
a DT N
reduction NN N
in IN N
the DT o
HER2 NNP o
or CC o
phospho-HER2 JJ o
levels NNS o
following VBG o
that IN N
exposure NN N
. . N

CONCLUSIONS NNP N
High NNP N
levels NNS o
of IN o
HER2 NNP o
are VBP N
associated VBN N
with IN N
achievement NN N
of IN N
a DT N
pathCR NN N
in IN N
the DT N
preoperative JJ N
setting NN N
, , N
while IN N
levels NNS o
of IN o
Phospho-HER2 NNP o
were VBD o
not RB N
predictive JJ N
of IN N
response NN N
. . N

This DT N
data NN N
suggests VBZ N
that IN N
accurate JJ N
measurement NN N
of IN N
HER2 NNP N
may MD N
help VB N
determine VB N
the DT N
likelihood NN N
of IN N
response NN N
in IN N
the DT N
pre-surgical JJ N
setting NN N
. . N

Further JJ N
validation NN N
in IN N
larger JJR N
cohorts NNS N
is VBZ N
required VBN N
, , N
but CC N
this DT N
pilot NN N
data NN N
shows VBZ N
the DT N
feasibility NN N
of IN N
this DT N
approach NN N
. . N

-DOCSTART- -15749735- O O

Magnesium NN i
sulphate NN i
only RB N
slightly RB N
reduces VBZ N
the DT N
shivering VBG o
threshold NN o
in IN p
humans NNS p
. . p

BACKGROUND NNP N
Hypothermia NNP i
may MD N
be VB N
an DT N
effective JJ N
treatment NN N
for IN N
stroke NN N
or CC N
acute JJ N
myocardial JJ N
infarction NN N
; : N
however RB N
, , N
it PRP N
provokes VBZ N
vigorous JJ N
shivering NN N
, , N
which WDT N
causes VBZ N
potentially RB N
dangerous JJ N
haemodynamic JJ N
responses NNS N
and CC N
prevents NNS N
further RBR N
hypothermia NN N
. . N

Magnesium NNP i
is VBZ N
an DT N
attractive JJ N
anti-shivering NN N
agent NN N
because IN N
it PRP N
is VBZ N
used VBN N
for IN N
treatment NN N
of IN N
postoperative JJ N
shivering NN N
and CC N
provides VBZ N
protection NN N
against IN N
ischaemic JJ N
injury NN N
in IN N
animal JJ N
models NNS N
. . N

We PRP N
tested VBD N
the DT N
hypothesis NN N
that WDT N
magnesium NN i
reduces VBZ N
the DT N
threshold NN N
( ( N
triggering VBG N
core RB N
temperature NN N
) ) N
and CC N
gain NN N
of IN N
shivering VBG o
without IN N
substantial JJ N
sedation NN o
or CC N
muscle NN N
weakness NN N
. . N

METHODS NNP N
We PRP N
studied VBD N
nine CD p
healthy JJ p
male NN p
volunteers NNS p
( ( p
18-40 JJ p
yr NN p
) ) p
on IN p
two CD p
randomly NNS p
assigned VBN p
treatment NN p
days NNS p
: : p
( ( N
1 CD N
) ) N
control NN i
and CC N
( ( N
2 CD N
) ) N
magnesium NN i
( ( N
80 CD N
mg NN N
kg NN N
( ( N
-1 NNP N
) ) N
followed VBN N
by IN N
infusion NN N
at IN N
2 CD N
g NN N
h NN N
( ( N
-1 NNP N
) ) N
) ) N
. . N

Lactated VBN i
Ringer NNP i
's POS i
solution NN i
( ( N
4 CD N
degrees NNS N
C NNP N
) ) N
was VBD N
infused VBN N
via IN N
a DT N
central JJ N
venous JJ N
catheter NN N
over IN N
a DT N
period NN N
of IN N
approximately RB N
2 CD N
h NN N
to TO N
decrease VB N
tympanic JJ o
membrane NN o
temperature NN o
by IN N
approximately RB N
1.5 CD N
degrees NNS N
C NNP N
h NN N
( ( N
-1 NNP N
) ) N
. . N

A DT N
significant JJ N
and CC N
persistent JJ N
increase NN N
in IN N
oxygen JJ o
consumption NN N
identified VBD N
the DT N
threshold NN N
. . N

The DT N
gain NN o
of IN o
shivering NN o
was VBD N
determined VBN N
by IN N
the DT N
slope NN N
of IN N
oxygen NN N
consumption NN N
vs NN N
core NN o
temperature NN o
regression NN N
. . N

Sedation NN o
was VBD N
evaluated VBN N
using VBG N
a DT N
verbal JJ o
rating NN o
score NN o
( ( o
VRS NNP o
) ) o
from IN N
0 CD N
to TO N
10 CD N
and CC N
bispectral JJ o
index NN o
( ( o
BIS NNP o
) ) o
of IN o
the DT o
EEG NNP o
. . o

Peripheral NNP o
muscle NN o
strength NN o
was VBD N
evaluated VBN N
using VBG N
dynamometry NN N
and CC N
spirometry NN N
. . N

Data NNS N
were VBD N
analysed VBN N
using VBG N
repeated JJ N
measures NNS N
anova VBP N
; : N
P NNP N
< VBD N
0.05 CD N
was VBD N
statistically RB N
significant JJ N
. . N

RESULTS NNP N
Magnesium NNP i
reduced VBD N
the DT N
shivering NN o
threshold NN o
( ( N
36.3 CD N
[ NNP N
SD NNP N
0.4 CD N
] NNP N
degrees NNS N
C NNP N
vs VBD N
36.6 CD N
[ JJ N
0.3 CD N
] NN N
degrees NNS N
C NNP N
, , N
P NNP N
= NNP N
0.040 CD N
) ) N
. . N

It PRP N
did VBD N
not RB N
affect VB N
the DT N
gain NN o
of IN o
shivering VBG o
( ( N
control NN N
, , N
437 CD N
[ NN N
289 CD N
] NN N
ml NN N
min NN N
( ( N
-1 NNP N
) ) N
degrees VBZ N
C NNP N
( ( N
-1 NNP N
) ) N
; : N
magnesium NN N
, , N
573 CD N
[ NN N
370 CD N
] NN N
ml NN N
min NN N
( ( N
-1 NNP N
) ) N
degrees VBZ N
C NNP N
( ( N
-1 NNP N
) ) N
; : N
P=0.344 NNP N
) ) N
. . N

The DT N
magnesium NN i
bolus NN N
did VBD N
not RB N
produce VB N
significant JJ N
sedation NN o
or CC N
appreciably RB N
reduce VB N
muscle NN o
strength NN o
. . o

CONCLUSIONS NNP N
Magnesium NNP i
significantly RB N
reduced VBD N
the DT N
shivering NN o
threshold NN o
. . o

However RB N
, , N
in IN N
view NN N
of IN N
the DT N
modest JJ N
absolute NN N
reduction NN N
, , N
this DT N
finding NN N
is VBZ N
considered VBN N
to TO N
be VB N
clinically RB N
unimportant JJ N
for IN N
induction NN N
of IN N
therapeutic JJ N
hypothermia NN N
. . N

-DOCSTART- -7954555- O O

Use NNP o
and CC o
limitations NNS o
of IN N
Holter NNP i
electrocardiography NN i
in IN N
assessing VBG N
drug NN p
therapy NN p
of IN p
myocardial JJ p
ischemia NN p
during IN p
the DT p
peri-PTCA JJ p
period NN p
. . p

Incidence NN N
and CC N
pattern NN N
of IN N
myocardial JJ N
ischemia NN N
during IN N
the DT N
peri-PTCA JJ p
( ( p
percutaneous JJ p
transluminal JJ p
coronary JJ p
angioplasty NN p
) ) p
period NN N
and CC N
the DT N
possible JJ N
role NN N
of IN N
continuous JJ i
intravenous JJ i
isosorbide NN i
dinitrate NN i
in IN N
its PRP$ N
prevention NN N
were VBD N
examined VBN N
prospectively RB N
in IN N
30 CD p
patients NNS p
. . p

Holter NNP o
electrocardiographic JJ o
monitoring NN o
was VBD N
performed VBN N
for IN N
21 CD N
+/- JJ N
3 CD N
h NN N
before IN N
PTCA NNP N
and CC N
continued VBN N
during IN N
and CC N
for IN N
41 CD N
+/- JJ N
8 CD N
h NN N
after IN N
the DT N
procedure NN N
. . N

Before IN N
PTCA NNP N
, , N
19 CD N
ischemic JJ N
episodes NNS N
were VBD N
present JJ N
in IN N
10 CD N
( ( N
33 CD N
% NN N
) ) N
of IN N
30 CD p
patients NNS p
. . p

PTCA NNP N
produced VBD N
an DT N
abrupt JJ N
decrease NN N
in IN N
number NN N
( ( N
p JJ N
= NNP N
0.015 CD N
) ) N
and CC N
duration NN N
( ( N
p JJ N
= NNP N
0.03 CD N
) ) N
of IN N
spontaneous JJ o
ischemic JJ o
episodes NNS o
. . o

The DT N
rarity NN N
of IN N
recurrent JJ o
myocardial JJ o
ischemic JJ o
events NNS o
by IN N
Holter NNP i
monitoring NN i
after IN N
PTCA NNP N
negated VBD N
any DT N
attempt NN N
at IN N
assessing VBG N
the DT N
efficacy NN N
of IN N
intravenous JJ N
isosorbide JJ i
dinitrate NN i
in IN N
their PRP$ N
prevention NN N
. . N

Holter NNP i
monitoring NN i
could MD N
not RB N
be VB N
used VBN N
as IN N
an DT N
early JJ N
predictor NN N
of IN N
late JJ N
coronary JJ N
restenosis NN N
. . N

-DOCSTART- -6586277- O O

Evaluation NN N
of IN N
AMSA NNP i
in IN N
children NNS p
with IN p
acute JJ p
leukemia NN p
. . p

A DT N
Pediatric NNP N
Oncology NNP N
Group NNP N
study NN N
. . N

One CD p
hundred VBD p
four CD p
children NNS p
with IN p
advanced JJ p
leukemia NN p
in IN p
relapse NN p
( ( p
74 CD p
with IN p
acute JJ p
lymphocytic JJ p
leukemia NN p
[ NNP p
ALL NNP p
] NNP p
and CC p
30 CD p
with IN p
acute JJ p
nonlymphocytic JJ p
leukemia NN p
[ NNP p
ANLL NNP p
] NNP p
) ) p
received VBD N
AMSA NNP i
( ( i
4'- JJ i
( ( i
9-Acridinylamino CD i
) ) i
methanesulfon FW i
-m-anisidide NN i
) ) i
at IN N
a DT N
dose NN N
of IN N
120 CD N
mg/m2/day NN N
for IN N
5 CD N
days NNS N
( ( N
Regimen NNP N
I PRP N
) ) N
or CC N
60 CD N
mg/m2/day NN N
for IN N
10 CD N
days NNS N
( ( N
Regimen NNP N
II NNP N
) ) N
. . N

Children NNP p
with IN p
ALL NNP p
were VBD N
randomized VBN N
between IN N
Regimens NNP N
I PRP N
and CC N
II NNP N
( ( N
31 CD N
and CC N
36 CD N
evaluable JJ N
patients NNS N
, , N
respectively RB N
) ) N
. . N

All DT N
29 CD p
evaluable JJ p
patients NNS p
with IN p
ANLL NNP p
were VBD N
treated VBN N
on IN N
Regimen NNP N
I. NNP N
Eighty-eight NNP N
percent NN N
of IN N
evaluable JJ N
patients NNS N
experienced VBD N
severe JJ o
or CC o
life-threatening JJ o
toxicity NN o
, , N
with IN N
no DT N
statistical JJ N
differences NNS N
between IN N
Regimens NNP N
I PRP N
and CC N
II NNP N
. . N

Bacterial NNP o
or CC o
fungal JJ o
infections NNS o
( ( N
considered VBN N
life-threatening NN N
or CC N
fatal NN N
) ) N
occurred VBD N
in IN N
17 CD p
children NNS p
with IN p
ALL DT p
and CC p
in IN p
7 CD p
with IN p
ANLL NNP p
. . p

Fatal NNP o
cardiac JJ o
toxicity NN o
occurred VBD p
in IN p
one CD p
patient NN p
. . p

Complete NNP o
or CC o
partial JJ o
response NN o
occurred VBD N
in IN N
25.0 CD N
% NN N
( ( N
SE NNP N
= RB N
8.8 CD N
% NN N
) ) N
, , N
28.1 CD N
% NN N
( ( N
SE NNP N
= RB N
8.0 CD N
% NN N
) ) N
, , N
and CC N
25.9 CD N
% NN N
( ( N
SE NNP N
= RB N
8.4 CD N
% NN N
) ) N
of IN N
evaluable JJ N
patients NNS N
on IN N
ALL NNP N
Regimen NNP N
I PRP N
, , N
ALL DT N
Regimen NNP N
II NNP N
, , N
and CC N
ANLL NNP N
, , N
respectively RB N
. . N

However RB N
, , N
responses NNS o
were VBD N
of IN N
short JJ N
duration NN N
( ( N
16-91 JJ N
days NNS N
) ) N
. . N

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
the DT N
duration NN o
of IN o
survival NN o
from IN N
treatment NN N
start NN N
for IN N
the DT N
two CD N
ALL DT N
regimens NNS N
( ( N
P NNP N
= NNP N
0.46 CD N
) ) N
. . N

The DT N
median JJ o
duration NN o
of IN o
survival NN o
for IN N
ANLL NNP N
patients NNS N
was VBD N
significantly RB N
longer JJR N
( ( N
P NNP N
= NNP N
0.004 CD N
) ) N
than IN N
that DT N
of IN N
ALL NNP N
patients NNS N
treated VBD N
on IN N
Regimens NNP N
I PRP N
and CC N
II NNP N
combined VBD N
. . N

Eighty-two JJ N
percent NN N
of IN N
the DT N
complete JJ o
or CC o
partial JJ o
responses NNS o
( ( N
18 CD N
of IN N
22 CD N
) ) N
occurred VBD N
after IN N
the DT N
first JJ N
course NN N
of IN N
AMSA NNP i
. . i

At IN N
the DT N
dose JJ N
schedules NNS N
investigated VBN N
, , N
and CC N
in IN N
a DT N
heavily RB p
pretreated VBN p
patient JJ p
population NN p
, , N
AMSA NNP N
had VBD N
activity NN o
in IN o
childhood NN o
leukemia NN o
. . o

However RB N
, , N
the DT N
high JJ N
incidence NN o
of IN o
severe JJ o
, , o
life-threatening JJ o
, , o
or CC o
fatal JJ o
infections NNS o
meant VBP N
that IN N
the DT N
quality NN o
and CC o
quantity NN o
of IN o
responses NNS o
and CC o
survival NN o
was VBD N
not RB N
commensurate JJ N
with IN N
the DT N
toxicity NN o
, , N
and CC N
that IN N
it PRP N
would MD N
be VB N
difficult JJ N
to TO N
incorporate VB N
this DT N
drug NN N
into IN N
combination NN N
chemotherapy NN N
with IN N
other JJ N
myelosuppressive JJ N
agents NNS N
. . N

-DOCSTART- -16311751- O O

Comparison NNP N
of IN N
a DT N
biopsychosocial JJ i
therapy NN i
( ( i
BT NNP i
) ) i
with IN i
a DT i
conventional JJ i
biomedical JJ i
therapy NN i
( ( i
MT NNP i
) ) i
of IN N
subacute NN o
low JJ o
back RB o
pain NN o
in IN N
the DT N
first JJ N
episode NN N
of IN N
sick JJ N
leave NN N
: : N
a DT N
randomized NN N
controlled VBN N
trial NN N
. . N

This DT N
randomized VBD N
controlled JJ N
clinical JJ N
trial NN N
compares VBZ N
the DT N
effectiveness NN N
of IN N
a DT N
biopsychosocial JJ i
treatment NN i
with IN i
a DT i
solely JJ i
conventional JJ i
biomedical JJ i
therapy NN i
in IN N
patients NNS N
with IN N
subacute JJ o
low JJ o
back RB o
pain NN o
using VBG N
parameters NNS N
for IN N
pain NN N
intensity NN N
, , N
functional JJ N
status NN N
, , N
depressive JJ N
dysfunction NN N
and CC N
work NN N
performance NN N
. . N

Sixty-four JJ p
patients NNS p
with IN p
a DT p
first-time JJ p
sick NN p
leave VBP p
between IN p
3 CD p
and CC p
12 CD p
weeks NNS p
due JJ p
to TO p
low VB p
back RB p
pain NN p
were VBD N
randomly RB N
assigned VBN N
to TO N
either VB N
a DT N
conventional JJ i
biomedical JJ i
therapy NN i
( ( N
MT NNP N
; : N
n=33 CC N
) ) N
group NN N
, , N
or CC N
a DT N
biopsychosocial JJ i
therapy NN i
( ( N
BT NNP N
; : N
n=31 CC N
) ) N
group NN N
including VBG N
a DT N
psychotherapeutic JJ N
module NN N
; : N
both DT N
in IN N
accordance NN N
with IN N
a DT N
standardized JJ N
3 CD N
weeks NNS N
inpatient JJ N
treatment NN N
. . N

Pain NNP o
intensity NN o
, , o
functional JJ o
back RB o
capacity NN o
, , o
clinical JJ o
parameters NNS o
and CC o
depressive JJ o
dysfunction NN o
revealed VBD N
significant JJ N
improvement NN N
in IN N
both DT N
treatment NN N
groups NNS N
at IN N
end NN N
of IN N
3 CD N
weeks NNS N
therapy NN N
( ( N
T1 NNP N
) ) N
. . N

However RB N
, , N
at IN N
6 CD N
months NNS N
( ( N
T2 NNP N
) ) N
, , N
analysis NN N
revealed VBD N
significant JJ N
better JJR N
results NNS N
for IN N
nearly RB N
all DT N
parameters NNS N
in IN N
the DT N
BT NNP N
group NN N
that WDT N
showed VBD N
further JJ N
improvement NN N
from IN N
T1 NNP o
to TO o
T2 NNP o
, , N
whereas IN N
the DT N
values NNS N
in IN N
the DT N
MT NNP N
group NN N
deteriorated VBD N
from IN N
T1 NNP N
back RB N
to TO N
the DT N
baseline NN N
values NNS N
. . N

During IN N
the DT N
2-year JJ N
period NN N
after IN N
therapy NN N
, , N
10 CD N
% NN N
in IN N
MT NNP N
and CC N
59 CD N
% NN N
in IN N
BT NNP N
required VBD N
no DT N
further JJ N
sick NN o
leave VBP o
due JJ N
to TO N
low VB o
back RB o
pain NN o
. . o

The DT N
results NNS N
of IN N
the DT N
study NN N
indicate VBP N
that IN N
a DT N
psychotherapeutic JJ N
element NN N
in IN N
the DT N
treatment NN N
of IN N
low JJ o
back RB o
pain NN o
appears VBZ N
to TO N
positively RB N
influence VB N
pain NN o
, , o
functional JJ o
status NN o
and CC o
work NN o
performance NN o
when WRB N
conducted VBN N
at IN N
an DT N
early JJ N
stage NN N
of IN N
chronification NN N
and CC N
helps VBZ N
in IN N
the DT N
achievement NN N
of IN N
a DT N
better JJR N
outcome NN N
. . N

-DOCSTART- -20530957- O O

Comparison NNP N
of IN N
inguinal JJ i
approach NN i
, , i
scrotal JJ i
sclerotherapy NN i
and CC N
subinguinal JJ i
antegrade NN i
sclerotherapy NN i
in IN N
varicocele JJ p
treatment NN N
: : N
a DT N
randomized JJ N
prospective JJ N
study NN N
. . N

We PRP N
compared VBN N
outcome NN N
and CC N
complications NNS N
of IN N
three CD N
simple JJ N
varicocelectomy NN N
techniques NNS N
. . N

Groups NNP p
were VBD p
divided VBN p
according VBG p
to TO p
whether IN p
they PRP p
would MD p
receive VB p
the DT p
Ivanissevich NNP i
technique NN i
( ( p
n JJ p
= NNP p
55 CD p
) ) p
, , p
Tauber NNP i
's POS i
technique NN i
( ( p
n JJ p
= NNP p
51 CD p
) ) p
or CC p
subinguinal JJ i
sclerotherapy NN i
( ( p
n JJ p
= NNP p
49 CD p
) ) p
. . p

Selection NN p
criteria NNS p
were VBD p
: : p
infertility NN p
> VBZ p
1 CD p
year NN p
, , p
subnormal JJ p
semen NNS p
, , p
sonographic JJ p
diameter NN p
of IN p
veins NNS p
> VBP p
3 CD p
mm NN p
and CC p
time NN p
of IN p
regurge NN p
> $ p
2 CD p
s. NN p
Patients NNS p
were VBD N
randomly RB N
assigned VBN N
to TO N
the DT N
groups NNS N
of IN N
treatment NN N
, , N
with IN N
follow-up JJ N
every DT N
3 CD N
months NNS N
for IN N
1 CD N
year NN N
. . N

Improvement NNP N
was VBD N
only RB N
in IN N
sperm JJ o
count NN o
and CC o
total JJ o
motility NN o
for IN N
all DT N
groups NNS N
. . N

Pregnancy NN o
rates NNS o
were VBD N
20 CD N
, , N
13.73 CD N
and CC N
12.24 CD N
% NN N
, , N
respectively RB N
, , N
with IN N
no DT N
significant JJ N
difference NN N
between IN N
groups NNS N
. . N

Hydrocele NNP o
occurred VBD N
only RB N
in IN N
the DT N
group NN N
which WDT N
received VBD N
the DT N
Ivanissevich NNP N
technique NN N
( ( N
5.5 CD N
% NN N
) ) N
. . N

Tauber NNP N
's POS N
technique NN N
is VBZ N
simple JJ N
; : N
however RB N
, , N
it PRP N
has VBZ N
the DT N
disadvantage NN N
of IN N
multiple JJ o
branching NN o
of IN o
small JJ o
veins NNS o
. . o

-DOCSTART- -22324448- O O

Randomised VBN N
clinical JJ N
trial NN N
: : N
efficacy NN o
of IN N
a DT N
new JJ N
synbiotic JJ i
formulation NN i
containing VBG i
Lactobacillus NNP i
paracasei NN i
B21060 NNP i
plus CC i
arabinogalactan JJ i
and CC i
xilooligosaccharides NNS i
in IN N
children NNS p
with IN p
acute JJ p
diarrhoea NN p
. . p

BACKGROUND NNP N
Acute NNP N
diarrhoea NN N
is VBZ N
a DT N
frequent JJ N
problem NN N
in IN N
children NNS p
with IN p
heavy JJ p
economic JJ p
burden NN p
for IN p
families NNS p
and CC p
society NN p
. . p

AIM NNP N
To TO N
test VB N
the DT N
efficacy NN N
of IN N
a DT N
new JJ N
synbiotic JJ i
formulation NN i
containing VBG i
Lactobacillus NNP i
paracasei NN i
B21060 NNP i
, , i
arabinogalactan NN i
and CC i
xilooligosaccharides NNS i
in IN N
children NNS p
with IN p
acute JJ p
diarrhoea NN p
. . p

METHODS NNP N
Double-blind NNP N
, , N
randomised VBD N
, , N
placebo-controlled JJ N
trial NN N
, , N
including VBG N
children NNS p
( ( p
age NN p
3-36 CD p
m NN p
) ) p
with IN p
acute JJ p
diarrhoea NNS p
who WP N
were VBD N
allocated VBN N
to TO N
placebo VB i
or CC i
synbiotic JJ i
group NN i
. . i

Major NNP N
outcome NN N
was VBD N
resolution JJ o
rate NN o
of IN o
diarrhoea NN o
at IN o
72 CD o
h. JJ o
Total NNP N
duration NN o
of IN o
diarrhoea NN o
, , o
daily JJ o
stool NN o
outputs NNS o
, , o
stool NN o
consistency NN o
, , o
working VBG o
days NNS o
lost VBN o
by IN o
parents NNS o
, , o
adjunctive JJ o
medications NNS o
, , o
and CC o
hospitalisation NN o
were VBD N
also RB N
assessed VBN N
. . N

RESULTS NNP N
We PRP N
enrolled VBD N
55 CD p
children NNS p
in IN p
placebo NN i
group NN p
and CC p
52 CD p
in IN p
synbiotic JJ i
group NN p
. . p

The DT p
two CD p
groups NNS p
were VBD p
similar JJ p
for IN p
demographic JJ p
and CC p
clinical JJ p
characteristics NNS p
. . p

Resolution NNP o
rate NN o
of IN o
diarrhoea NN o
at IN N
72 CD N
h NN N
was VBD N
significantly RB N
higher JJR N
in IN N
synbiotic JJ N
group NN N
( ( N
67 CD N
% NN N
) ) N
compared VBN N
to TO N
placebo VB i
group NN N
( ( N
40 CD N
% NN N
, , N
P NNP N
= NNP N
0.005 CD N
) ) N
. . N

Children NNP N
in IN N
synbiotic JJ N
group NN N
showed VBD N
a DT N
significant JJ N
reduction NN N
in IN N
the DT N
duration NN o
of IN o
diarrhoea NN o
( ( N
90.5 CD N
h NN N
, , N
78.1-102.9 JJ N
vs. FW N
109.8 CD N
h NN N
, , N
96.0-123.5 CD N
, , N
P NNP N
= NNP N
0.040 CD N
) ) N
, , N
daily JJ o
stool NN o
outputs NNS o
( ( N
3.3 CD N
, , N
2.8-3.8 JJ N
vs. FW N
2.4 CD N
, , N
1.9-2.8 CD N
, , N
P NNP N
= NNP N
0.005 CD N
) ) N
and CC N
stool JJ o
consistency NN o
( ( N
1.3 CD N
, , N
0.9-1.6 JJ N
vs. FW N
0.6 CD N
, , N
0.4-0.9 CD N
, , N
P NNP N
= NNP N
0.002 CD N
) ) N
compared VBN N
to TO N
placebo VB i
group NN N
( ( N
data NNS N
expressed VBN N
as IN N
mean NN N
, , N
95 CD N
% NN N
CI NNP N
) ) N
. . N

Rate NN o
of IN o
parents NNS o
that WDT o
missed VBD o
at IN o
least JJS o
one CD o
working VBG o
day NN o
( ( N
41.8 CD N
% NN N
vs. FW N
15.4 CD N
% NN N
, , N
P NNP N
= NNP N
0.003 CD N
) ) N
, , N
rate NN o
of IN o
children NNS o
that WDT o
needed VBD o
adjunctive JJ o
medications NNS o
( ( N
25.5 CD N
% NN N
vs. FW N
5.8 CD N
% NN N
, , N
P NNP N
= NNP N
0.005 CD N
) ) N
or CC N
hospitalisation NN o
( ( N
10.9 CD N
% NN N
vs. FW N
0 CD N
% NN N
, , N
P NNP N
= NNP N
0.014 CD N
) ) N
after IN N
the DT N
first JJ N
72 CD N
h NN N
of IN N
treatment NN N
, , N
were VBD N
reduced VBN N
in IN N
synbiotic JJ N
group NN N
. . N

CONCLUSION NNP N
The DT N
synbiotic JJ i
formulation NN i
studied VBN N
is VBZ N
effective JJ N
in IN N
children NNS N
with IN N
acute JJ N
diarrhoea NN N
. . N

Australian JJ N
New NNP N
Zealand NNP N
Clinical NNP N
Trials NNP N
Registry NNP N
( ( N
ACTRN12611000641998 NNP N
) ) N
. . N

-DOCSTART- -11714591- O O

Social JJ o
support NN o
and CC N
abstinence NN o
from IN N
opiates NNS N
and CC N
cocaine NN N
during IN p
opioid JJ i
maintenance NN i
treatment NN i
. . i

Social NNP i
support NN i
may MD N
play VB N
an DT N
important JJ N
role NN N
in IN N
helping VBG N
drug NN p
users NNS p
achieve VBP N
abstinence NN o
; : o
however RB N
these DT N
benefits NNS N
may MD N
depend VB N
on IN N
the DT N
type NN N
of IN N
support NN N
experienced VBN N
. . N

In IN N
this DT N
prospective JJ N
observational NN N
study NN N
, , N
we PRP N
examined VBD N
the DT N
extent NN N
to TO N
which WDT N
general JJ i
and CC i
abstinence-specific JJ i
support NN i
, , i
both DT i
structural JJ i
and CC i
functional JJ i
, , N
predicted JJ N
opiate NN N
and CC N
cocaine NN N
abstinence NN N
in IN N
128 CD p
opioid JJ p
maintenance NN p
patients NNS p
receiving VBG p
either CC p
methadone NN i
or CC i
LAAM NNP i
. . i

A DT N
new JJ N
multidimensional JJ N
self-report NN N
instrument NN N
assessing VBG N
abstinence-specific JJ i
functional JJ N
support NN N
was VBD N
developed VBN N
for IN N
the DT N
study NN N
. . N

Previously RB N
validated VBN N
measures NNS N
were VBD N
used VBN N
to TO N
assess VB N
the DT N
remaining VBG N
types NNS N
of IN N
support NN N
. . N

With IN N
baseline JJ N
abstinence NN N
and CC N
other JJ N
statistically RB N
important JJ N
covariates NNS N
adjusted VBN N
, , N
hierarchical JJ N
logistic JJ N
regression NN N
analyses NNS N
demonstrated VBD N
that IN N
the DT N
associations NNS N
between IN N
social JJ o
support NN o
at IN N
study NN N
baseline NN N
and CC N
biochemically RB N
confirmed VBN N
abstinence NN N
3 CD N
months NNS N
later RB N
varied VBN N
by IN N
type NN N
of IN N
support NN N
and CC N
by IN N
drug NN N
. . N

Greater NNP N
abstinence-specific JJ o
structural JJ o
support NN o
( ( N
operationalized VBN N
as IN N
fewer JJR N
drug NN N
users NNS N
in IN N
the DT N
social JJ N
network NN N
) ) N
and CC N
decreases VBZ N
in IN N
three CD N
types NNS N
of IN N
negative JJ o
abstinence-specific JJ o
functional JJ o
support NN o
( ( o
Complaints NNS o
about IN o
Drug NNP o
Use NNP o
, , o
Drug NNP o
Exposure NNP o
, , o
and CC o
Demoralization NNP o
) ) o
predicted VBD o
cocaine NN o
, , N
but CC N
not RB N
opiate JJ o
abstinence NN o
. . o

There EX N
were VBD N
no DT N
effects NNS N
for IN N
general JJ o
support NN o
, , N
whether IN N
structural JJ N
or CC N
functional JJ N
, , N
on IN N
abstinence NN o
from IN N
either DT N
drug NN N
. . N

Interventions NNS N
that WDT N
focus VBP N
on IN N
modifying VBG N
patients NNS N
' POS N
abstinence-specific JJ i
support NN N
may MD N
be VB N
helpful JJ N
in IN N
reducing VBG N
the DT N
high JJ p
rates NNS o
of IN o
cocaine NN o
use NN o
disorders NNS o
in IN N
this DT N
population NN N
. . N

-DOCSTART- -4479815- O O

Comparative JJ N
trial NN N
of IN N
cephacetrile JJ i
versus NN i
cephaloridine NN i
in IN N
the DT N
treatment NN N
of IN N
secondary JJ o
respiratory NN o
infections NNS o
in IN p
childhood NN p
pertussis NN p
. . p

-DOCSTART- -8374255- O O

Torasemide NNP i
versus NN N
furosemide NN i
in IN N
cirrhosis NN p
: : p
a DT N
long-term JJ N
, , N
double-blind JJ N
, , N
randomized JJ N
clinical JJ N
study NN N
. . N

The DT N
effects NNS N
of IN N
long-term JJ N
therapy NN N
( ( N
70 CD N
days NNS N
) ) N
with IN N
torasemide NN i
( ( N
20 CD N
mg/day NN N
) ) N
, , N
a DT N
new JJ N
loop NN N
diuretic JJ N
, , N
were VBD N
compared VBN N
with IN N
those DT N
of IN N
furosemide NN i
( ( N
50 CD N
mg/day NN N
) ) N
in IN N
a DT N
randomized JJ N
double-blind JJ N
trial NN N
. . N

Both DT N
drugs NNS N
were VBD N
administered VBN N
in IN N
association NN N
with IN N
spironolactone NN i
( ( N
200 CD N
mg/day NN N
) ) N
in IN N
28 CD p
nonazotemic JJ p
cirrhotic JJ p
patients NNS p
with IN p
controlled JJ p
ascites NNS p
. . p

The DT N
treatments NNS N
did VBD N
not RB N
modify VB N
creatinine JJ o
clearance NN o
and CC N
exhibited VBD N
a DT N
similar JJ N
effect NN N
on IN N
body NN o
weight NN o
, , o
urinary JJ o
volume NN o
, , N
and CC N
fractional JJ o
excretion NN o
of IN o
uric JJ o
acid NN o
, , o
sodium NN o
, , o
and CC o
chloride NN o
. . o

The DT N
effect NN N
of IN N
torasemide NN i
on IN N
fractional JJ o
potassium NN o
excretion NN o
was VBD N
lower JJR N
than IN N
that DT N
of IN N
furosemide NN i
. . i

Torasemide VB i
showed VBD N
higher JJR N
sparing VBG o
effect NN o
than IN N
furosemide NN i
on IN N
calcium NN o
, , o
inorganic JJ o
phosphate NN o
, , o
and CC o
magnesium NN o
excretion NN o
and CC N
stronger JJR N
action NN N
on IN N
free JJ o
water NN o
clearance NN o
. . o

No DT N
changes NNS N
in IN N
serum NN o
parameters NNS o
were VBD N
induced VBN N
by IN N
either DT N
treatment NN N
. . N

Two CD N
episodes NNS N
of IN N
hepatic JJ o
encephalopathy NN o
occurred VBD N
in IN N
the DT N
torasemide NN i
group NN N
. . N

In IN N
view NN N
of IN N
its PRP$ N
effects NNS o
on IN o
sodium NN o
and CC o
water NN o
excretion NN o
and CC N
on IN o
other JJ o
urinary JJ o
parameters NNS o
, , N
torasemide NN i
can MD N
represent VB N
an DT N
alternative JJ N
tool NN N
for IN N
the DT N
long-term JJ N
treatment NN N
of IN N
ascites NNS p
. . p

-DOCSTART- -3957541- O O

An DT N
analysis NN N
of IN N
the DT N
mortality NN N
effect NN N
in IN N
a DT N
breast NN i
cancer NN i
screening VBG i
study NN N
. . N

In IN N
order NN N
to TO N
better JJR N
understand VB N
the DT N
effect NN N
of IN N
breast NN p
cancer NN p
screening VBG N
on IN N
mortality NN N
, , N
we PRP N
use VBP N
the DT N
theory NN N
of IN N
competing VBG N
risks NNS N
to TO N
analyse VB N
deaths NNS N
from IN N
the DT N
long-term JJ p
follow-up NN p
of IN p
the DT p
HIP NNP i
breast NN i
cancer NN i
screening VBG i
trial NN i
. . i

We PRP N
conclude VBP N
that IN N
some DT N
, , N
but CC N
not RB N
all DT N
, , N
of IN N
the DT N
breast NN p
cancer NN p
cases NNS p
detected VBD N
early RB N
as IN N
a DT N
result NN N
of IN N
screening VBG i
realized VBN N
a DT N
benefit NN N
in IN N
terms NNS N
of IN N
elimination NN N
of IN N
the DT N
risk NN N
of IN N
breast NN o
cancer NN o
mortality NN o
. . o

Breast NNP i
cancer NN i
screening VBG i
appears VBZ N
not RB N
to TO N
affect VB N
the DT N
rate NN o
of IN o
mortality NN o
from IN N
causes NNS N
of IN N
death NN N
other JJ N
than IN N
breast JJ N
cancer NN N
. . N

Methodologically RB N
, , N
we PRP N
demonstrate VBP N
the DT N
importance NN N
of IN N
analysing VBG N
mortality NN N
separately RB N
for IN N
the DT N
breast NN p
cancer NN p
cases NNS N
as RB N
well RB N
as IN N
for IN N
the DT N
entire JJ p
population NN p
in IN N
a DT N
trial NN N
. . N

-DOCSTART- -7806134- O O

Lipoprotein NNP N
( ( N
a DT N
) ) N
serum NN N
levels NNS N
in IN N
post-menopausal JJ p
women NNS p
treated VBN p
with IN p
oral JJ i
estrogens NNS i
administered VBN p
at IN p
different JJ p
times NNS p
. . p

The DT N
different JJ N
effects NNS o
on IN N
serum NN N
lipoprotein NN N
( ( N
a DT N
) ) N
[ NN N
Lp NNP N
( ( N
a DT N
) ) N
] NN N
levels NNS N
by IN N
administering VBG N
estrogens NNS i
at IN i
different JJ i
times NNS i
of IN i
the DT i
day NN i
( ( N
8 CD N
a.m. RB N
and CC N
8 CD N
p.m. NN N
) ) N
were VBD N
evaluated VBN N
in IN N
twenty-four JJ p
post-menopausal JJ p
women NNS p
. . p

Patients NNS N
were VBD N
assigned VBN N
to TO N
one CD N
of IN N
the DT N
two CD N
treatment NN N
groups NNS N
by IN N
random JJ N
sampling VBG N
numbers NNS N
. . N

Patients NNS N
of IN N
both DT N
groups NNS N
received VBD N
0.625 CD N
mg NNS N
conjugated VBN i
equine JJ i
estrogens NNS i
daily JJ N
per IN N
os NN N
for IN N
21 CD N
days NNS N
. . N

Group NNP N
A NNP N
patients NNS N
( ( N
n JJ N
: : N
9 CD N
) ) N
received VBD N
the DT N
pill NN N
at IN N
8 CD N
a.m. NN N
, , N
and CC N
group NN N
B NNP N
patients NNS N
( ( N
n JJ N
: : N
12 CD N
) ) N
received VBD N
the DT N
pill NN N
at IN N
8 CD N
p.m NN N
. . N

There EX N
were VBD N
no DT N
statistically RB N
significant JJ N
differences NNS N
between IN N
the DT N
two CD N
treatment NN N
groups NNS N
as IN N
regards NNS N
the DT N
anthropometric JJ o
characteristics NNS o
, , o
the DT o
basal NN o
values NNS o
of IN o
the DT o
Lp NNP o
( ( o
a DT o
) ) o
, , o
the DT o
sex NN o
steroid NN o
and CC o
pituitary JJ o
hormone NN o
levels NNS o
. . o

Administration NN N
of IN N
conjugated JJ i
equine NN i
estrogens NNS i
resulted VBD N
in IN N
decreased JJ N
levels NNS o
of IN o
Lp NNP o
( ( o
a DT o
) ) o
only RB N
in IN N
group NN N
B NNP N
after IN N
treatment NN N
. . N

The DT N
different JJ N
Lp NNP N
( ( N
a DT N
) ) N
behaviour NN N
in IN N
the DT N
two CD N
groups NNS N
and CC N
in IN N
the DT N
presence NN N
of IN N
the DT N
same JJ N
serum JJ N
hormonal NN N
levels NNS N
, , N
seems VBZ N
to TO N
be VB N
dependent JJ N
on IN N
the DT N
existence NN N
of IN N
a DT N
circadian JJ N
rhythm NN N
of IN N
the DT N
hepatic JJ N
responsiveness NN N
to TO N
estrogens VB N
, , N
whose WP$ N
expression NN N
is VBZ N
higher JJR N
during IN N
evening NN N
hours NNS N
. . N

-DOCSTART- -799982- O O

Disopyramide NNP i
in IN N
the DT N
treatment NN N
and CC N
prevention NN N
of IN N
arrhythmias NN o
following VBG p
myocardial JJ p
infarction NN p
. . p

-DOCSTART- -11957440- O O

[ JJ N
One-year JJ N
effect NN N
of IN N
health NN i
counseling NN i
on IN N
life NN N
style NN N
and CC N
risk NN N
factors NNS N
of IN N
heart NN N
disease NN N
] NNP N
. . N

INTRODUCTION NNP N
We PRP N
examined VBD N
the DT N
need NN N
for IN N
counselling VBG N
and CC N
the DT N
effect NN N
on IN N
willingness NN N
and CC N
ability NN N
to TO N
change VB N
life-style JJ o
, , o
and CC o
subsequent JJ o
changes NNS o
in IN o
risk NN o
factors NNS o
for IN o
CHD NNP o
. . o

MATERIAL NNP N
AND CC N
METHODS NNP N
All NNP p
152 CD p
male NN p
employees NNS p
in IN p
a DT p
computer NN p
company NN p
, , p
25-45 JJ p
years NNS p
of IN p
age NN p
, , p
were VBD p
invited VBN p
to TO p
participate VB p
in IN N
a DT N
controlled VBN N
intervention NN N
study NN N
over IN N
one CD N
year NN N
. . N

The DT N
subjects NNS N
were VBD N
randomised VBN N
to TO N
an DT N
intervention NN i
group NN i
( ( N
I PRP N
group NN N
) ) N
and CC N
a DT N
control NN i
group NN i
. . i

The DT N
I PRP N
group NN N
was VBD N
divided VBN N
into IN N
subgroups NNS N
based VBN N
on IN N
baseline NN N
behaviour NN N
and CC N
risk NN N
factor NN N
status NN N
. . N

Changes NNS N
were VBD N
evaluated VBN N
after IN N
one CD N
year NN N
. . N

After IN N
an DT N
initial JJ N
health NN N
examination NN N
, , N
participants NNS N
in IN N
the DT N
I PRP N
group NN N
were VBD N
counselled VBN i
at IN N
baseline NN N
and CC N
at IN N
5 CD N
months NNS N
. . N

RESULTS NNP N
Eighty-five JJ p
( ( p
56 CD p
% NN p
) ) p
men NNS p
participated VBD p
. . p

Twenty-nine NN N
were VBD N
assigned VBN N
to TO N
a DT N
control NN N
group NN N
and CC N
56 CD N
to TO N
an DT N
intervention NN N
group NN N
( ( N
I PRP N
group NN N
) ) N
( ( N
dropouts JJ N
= NNP N
8 CD N
) ) N
. . N

An DT N
exercise NN i
group NN i
( ( N
E NNP N
group NN N
) ) N
was VBD N
advised VBN N
to TO N
take VB N
up RP N
aerobics NNS i
exercise VBP i
three CD N
times/week NN N
, , N
a DT N
diet JJ i
group NN i
to TO N
reduce VB i
the DT i
intake NN i
of IN i
saturated JJ i
fat NN i
and CC i
increase VB i
fish JJ i
products NNS i
, , N
and CC N
smokers NNS N
to TO N
stop VB i
smoking NN i
. . i

Forty NNP N
were VBD N
recommended VBN N
one CD i
or CC i
more JJR i
behavioural JJ i
changes NNS i
and CC N
eight CD N
had VBD N
no DT N
need NN N
. . N

Thirty-four CD N
were VBD N
willing JJ N
to TO N
make VB N
behavioural JJ N
changes NNS N
. . N

Compared VBN N
to TO N
the DT N
control NN N
group NN N
, , N
the DT N
fitness JJ o
level NN o
increased VBD N
( ( N
p JJ N
< NNP N
0.01 CD N
) ) N
and CC N
body NN o
weight NN o
decreased VBN N
in IN N
the DT N
I PRP N
group NN N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
. . N

DISCUSSION NNP N
Individual NNP i
counselling VBG i
promotes NNS N
regular JJ N
exercise NN N
with IN N
subsequent JJ N
improvements NNS N
in IN N
CHD NNP o
risk NN o
factors NNS o
. . o

The DT N
diet JJ i
and CC i
smoking VBG i
counselling VBG i
models NNS i
were VBD N
less RBR N
successful JJ N
in IN N
terms NNS N
of IN N
compliance NN N
. . N

-DOCSTART- -12458862- O O

Prospective JJ N
randomized VBN N
trial NN N
of IN N
an DT N
anterior JJ N
surface NN N
modified VBD N
prolate JJ N
intraocular JJ N
lens NNS N
. . N

PURPOSE NNP N
We PRP N
compare VBP N
the DT N
contrast NN o
sensitivity NN o
obtained VBN N
with IN N
an DT N
anterior JJ N
surface NN N
modified VBD N
prolate JJ N
intraocular JJ N
lens NNS N
with IN N
the DT N
contrast NN N
sensitivity NN N
obtained VBN N
with IN N
a DT N
standard JJ N
spherical JJ N
intraocular NN N
lens NNS N
. . N

METHODS NNP N
Patients NNPS p
presenting VBG p
for IN p
cataract NN p
surgery NN p
in IN p
one CD p
eye NN p
were VBD p
randomized VBN p
to TO N
receive VB N
either CC N
the DT N
Tecnis NNP i
Z9000 NNP i
intraocular JJ i
lens NNS i
( ( i
Pharmacia NNP i
) ) i
or CC i
the DT i
AMO NNP i
AR40e NNP i
Opti-Edge NNP i
intraocular JJ i
lens NNS i
( ( N
AMO NNP N
) ) N
. . N

Sine NNP N
wave VBP N
grating VBG N
contrast NN o
sensitivity NN o
testing VBG N
under IN N
mesopic NN N
and CC N
photopic NN N
conditions NNS N
served VBD N
as IN N
the DT N
principal JJ N
outcome JJ N
measure NN N
. . N

RESULTS VB N
The DT N
Tecnis NNP N
Z9000 NNP N
intraocular JJ N
lens NNS N
provided VBD N
statistically RB o
significantly RB o
better RBR o
contrast NN o
sensitivity NN o
at IN N
1.5 CD N
and CC N
3 CD N
cycles NNS N
per IN N
degree NN N
under IN N
mesopic NN N
conditions NNS N
and CC N
at IN N
6 CD N
, , N
12 CD N
and CC N
18 CD N
cycles NNS N
per IN N
degree NN N
under IN N
photopic NN N
conditions NNS N
. . N

CONCLUSION NNP N
The DT N
use NN N
of IN N
a DT N
modified JJ N
prolate NN N
intraocular JJ N
lens NNS N
during IN N
cataract NN N
surgery NN N
has VBZ N
the DT N
potential NN N
to TO N
improve VB N
contrast NN o
sensitivity NN o
under IN N
both DT N
mesopic NN N
and CC N
photopic NN N
conditions NNS N
. . N

-DOCSTART- -8137583- O O

Intraperitoneal NNP o
distribution NN o
imaging VBG i
prior RB N
to TO N
chromic VB N
phosphate NN N
( ( N
P-32 NNP N
) ) N
therapy NN N
in IN N
ovarian JJ p
cancer NN p
patients NNS p
. . p

This DT N
study NN N
addressed VBD N
the DT N
technique NN N
of IN N
intraperitoneal JJ i
distribution NN i
imaging NN i
( ( i
IDI NNP i
) ) i
. . i

A DT N
literature NN N
search NN N
( ( N
MEDLINE NNP N
database NN N
) ) N
revealed VBD N
wide JJ N
variations NNS N
in IN N
IDI NNP i
techniques NNS N
without IN N
a DT N
basis NN N
for IN N
comparison NN N
. . N

From IN N
April NNP N
1990 CD N
to TO N
September NNP N
1992 CD N
, , N
the DT N
authors NNS N
studied VBD N
8 CD p
patients NNS p
( ( p
age NN p
43-65 CD p
years NNS p
) ) p
with IN p
ovarian JJ p
cancer NN p
. . p

A DT N
total NN N
of IN N
1000 CD N
ml NN N
of IN N
normal JJ i
saline NN i
and CC i
1 CD i
mCi NN i
of IN i
Tc-99m NNP i
SC NNP i
was VBD N
infused VBN N
intraperitoneally RB N
for IN N
IDI NNP i
. . i

In IN N
one CD N
patient NN N
loculation NN o
was VBD N
observed VBN N
, , N
but CC N
only RB N
250 CD N
ml NNS N
of IN N
normal JJ i
saline NN i
was VBD N
infused VBN N
with IN N
Tc-99m NNP i
SC NNP i
. . i

A NNP N
repeat NN N
study NN N
using VBG N
our PRP$ N
standard NN N
technique NN N
rendered VBD N
free JJ o
intraperitoneal NN o
distribution NN o
in IN N
this DT N
patient NN N
, , N
as RB N
well RB N
as IN N
in IN N
the DT N
other JJ N
seven CD N
cases NNS N
. . N

Some DT N
investigators NNS N
recommend VBP N
low JJ N
volumes NNS N
, , N
but CC N
in IN N
our PRP$ N
experience NN N
this DT N
produced VBD N
the DT N
finding NN N
of IN N
pseudoloculation NN o
, , N
which WDT N
could MD N
change VB N
treatment NN N
inappropriately RB N
. . N

Although IN N
the DT N
number NN N
of IN N
patients NNS N
studied VBN N
at IN N
our PRP$ N
institution NN N
was VBD N
small JJ N
, , N
administration NN N
of IN N
1 CD N
liter NN N
intraperitoneally RB N
provided VBD N
consistent JJ N
IDI NNP o
results NNS N
. . N

-DOCSTART- -18368792- O O

[ IN N
The DT N
prognostic JJ N
value NN N
of IN N
gastric JJ N
metaplasia NN N
in IN N
the DT N
duodenal JJ N
mucosa NN N
in IN N
patients NNS p
with IN p
Helicobacter NNP p
pylori VBP p
positive JJ p
duodenal JJ p
bulb NN p
ulcer NN p
] NNP p
. . N

The DT N
predictive JJ N
value NN N
of IN N
gastric JJ N
metaplasia NN N
in IN N
the DT N
duodenal JJ N
mucosa NN N
in IN N
patients NNS p
Helicobacter NNP p
pylori-positive JJ p
patients NNS p
with IN p
duodenal JJ p
bulb NN p
ulcer NN p
( ( p
DBU NNP p
) ) p
was VBD N
investigated VBN N
. . N

One CD p
hundred CD p
and CC p
twenty VB p
four CD p
randomly RB p
selected VBN p
patients NNS p
with IN p
DBU NNP p
were VBD N
included VBN N
in IN N
this DT N
prospective JJ N
study NN N
. . N

The DT i
detection NN i
of IN i
Helicobacter NNP i
pylori FW i
( ( i
HP NNP i
) ) i
in IN i
the DT i
stomach NN i
and CC i
duodenum NN i
was VBD i
carried VBN i
out RP i
with IN i
Giemsa NNP i
( ( i
using VBG i
standard JJ i
visual JJ i
analogue NN i
scale NN i
) ) i
, , i
rapid JJ i
urease JJ i
test NN i
( ( i
standard JJ i
Jatrox-HP NNP i
test NN i
, , i
Rohm NNP i
Pharma NNP i
, , i
Germany NNP i
) ) i
, , i
and CC i
polymerase NN i
chain NN i
reaction NN i
( ( i
PCR NNP i
) ) i
to TO i
detect VB i
the DT i
specific JJ i
fragment NN i
of IN i
ureC JJ i
HP NNP i
gene NN i
( ( i
Helicopol NNP i
II NNP i
, , i
Lytech NNP i
, , i
Russia NNP i
) ) i
. . N

Regions NNS N
of IN N
gastric JJ N
metaplasia NN N
of IN N
the DT N
duodenum NN N
were VBD N
confirmed VBN N
by IN N
periodic JJ N
acid-Schiff JJ N
and CC N
alcian JJ N
blue NN N
( ( N
Serva NNP N
) ) N
staining NN N
( ( N
pH JJ N
1.0 CD N
; : N
2.5 CD N
) ) N
Duodenal NNP N
ulcer NN N
( ( N
DU NNP N
) ) N
complications NNS N
were VBD N
registered VBN N
within IN N
8 CD N
to TO N
10 CD N
years NNS N
. . N

Estimation NN N
of IN N
the DT N
predictive JJ N
factor NN N
( ( o
gastric JJ o
metaplasia NN o
in IN o
the DT o
duodenum NN o
) ) o
was VBD N
carried VBN N
out RP N
in IN N
patients NNS N
with IN N
non-complicated JJ N
DU NNP N
( ( N
Group NNP N
1 CD N
; : N
n CC N
= VB N
73 CD N
) ) N
, , N
and CC N
with IN N
such JJ N
complications NNS N
as IN N
bleeding NN N
, , N
perforation NN N
, , N
penetration NN N
, , N
pyloroduodenal JJ N
stenosis NN N
( ( N
Group NNP N
2 CD N
; : N
n CC N
= VB N
51 CD N
) ) N
which WDT N
were VBD N
revealed VBN N
within IN N
the DT N
8 CD N
to TO N
10 CD N
years NNS N
of IN N
observation NN N
. . N

Gastric NNP o
metaplasia NN o
in IN o
the DT o
duodenum NN o
was VBD N
found VBN N
in IN N
64 CD N
or CC N
87.7 CD N
% NN N
of IN N
the DT N
73 CD N
patients NNS N
with IN N
non-complicated JJ N
DU NNP N
and CC N
in IN N
5 CD N
or CC N
9.8 CD N
% NN N
of IN N
the DT N
51 CD N
patients NNS N
with IN N
complicated JJ N
DU NNP N
within IN N
8 CD N
to TO N
10 CD N
years NNS N
of IN N
observation NN N
. . N

The DT N
following JJ N
facts NNS N
about IN N
the DT N
predictive JJ N
factor NN N
for IN N
the DT N
prognosis NN N
of IN N
DU NNP N
complication NN N
were VBD N
found VBN N
: : N
the DT N
sensitivity NN o
of IN N
83.6 CD N
% NN N
, , N
the DT N
specificity NN o
of IN N
92.8 CD N
% NN N
, , N
the DT N
predictive JJ o
accuracy NN o
of IN N
88.7 CD N
% NN N
, , N
the DT N
relative JJ o
risk NN o
of IN o
the DT o
predicted JJ o
outcome NN o
of IN N
7.5 CD N
, , N
the DT N
relative JJ N
risk NN N
of IN N
a DT N
different JJ N
outcome NN N
of IN N
0.11 CD N
, , N
the DT N
odds NNS N
ration NN N
of IN N
65.4 CD N
. . N

The DT N
study NN N
revealed VBD N
a DT N
high JJ N
and CC N
significant JJ N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
predictive JJ N
value NN N
of IN N
gastric JJ o
metaplasia NN o
in IN N
the DT N
duodenum NN N
as IN N
a DT N
marker NN N
of IN N
non-complicated JJ N
clinical JJ N
course NN N
of IN N
DU NNP N
in IN N
HP-positive JJ p
patients NNS p
within IN N
an DT N
8 CD N
to TO N
10-year JJ N
period NN N
. . N

-DOCSTART- -10194485- O O

High-pressure NN i
, , i
rapid-inflation NN i
pneumatic JJ i
compression NN i
improves VBZ N
venous JJ N
hemodynamics NNS N
in IN N
healthy JJ p
volunteers NNS p
and CC p
patients NNS p
who WP p
are VBP p
post-thrombotic JJ p
. . p

PURPOSE NNP N
Deep NNP p
vein NN p
thrombosis NN p
( ( p
DVT NNP p
) ) p
is VBZ N
a DT N
preventable JJ N
cause NN N
of IN N
morbidity NN p
and CC p
mortality NN p
in IN p
patients NNS p
who WP p
are VBP p
hospitalized VBN p
. . p

An DT N
important JJ N
part NN N
of IN N
the DT N
mechanism NN N
of IN N
DVT NNP N
prophylaxis NN N
with IN N
intermittent JJ N
pneumatic JJ N
compression NN N
( ( N
IPC NNP N
) ) N
is VBZ N
reduced VBN N
venous JJ N
stasis NN N
with IN N
increased JJ N
velocity NN N
of IN N
venous JJ N
return NN N
. . N

The DT N
conventional JJ N
methods NNS N
of IN N
IPC NNP N
use NN N
low JJ N
pressure NN N
and CC N
slow JJ N
inflation NN N
of IN N
the DT N
air NN N
bladder NN N
on IN N
the DT N
leg NN N
to TO N
augment VB N
venous JJ N
return NN N
. . N

Recently RB N
, , N
compression NN N
devices NNS N
have VBP N
been VBN N
designed VBN N
that IN N
produce VBP N
high JJ N
pressure NN N
and CC N
rapid JJ N
inflation NN N
of IN N
air NN N
cuffs NNS N
on IN N
the DT N
plantar NN N
plexus NN N
of IN N
the DT N
foot NN N
and CC N
the DT N
calf NN N
. . N

The DT N
purpose NN N
of IN N
this DT N
study NN N
is VBZ N
to TO N
evaluate VB N
the DT N
venous JJ N
velocity NN N
response NN N
to TO N
high-pressure NN N
, , N
rapid-inflation NN N
compression NN N
devices NNS N
versus VBP N
standard JJ N
, , N
low-pressure JJ N
, , N
slow-inflation JJ N
compression NN N
devices NNS N
in IN N
healthy JJ p
volunteers NNS p
and CC p
patients NNS p
with IN p
severe JJ p
post-thrombotic JJ p
venous JJ p
disease NN p
. . p

METHOD NNP N
Twenty-two NNP p
lower JJR p
extremities NNS p
from IN p
healthy JJ p
volunteers NNS p
and CC p
11 CD p
lower JJR p
extremities NNS p
from IN p
patients NNS p
with IN p
class NN p
4 CD p
to TO p
class NN p
6 CD p
post-thrombotic JJ p
chronic JJ p
venous JJ p
insufficiency NN p
were VBD p
studied VBN p
. . p

With IN N
duplex JJ i
ultrasound NN i
scanning NN i
( ( N
ATL-Ultramark NNP N
9 CD N
, , N
Advanced NNP N
Tech NNP N
Laboratory NNP N
, , N
Bothell NNP N
, , N
Wash NNP N
) ) N
, , N
acute JJ N
DVT NNP N
was VBD N
excluded VBN N
before IN N
subject JJ N
evaluation NN N
. . N

Venous JJ N
velocities NNS N
were VBD N
monitored VBN N
after IN N
the DT N
application NN N
of IN N
each DT N
of IN N
five CD N
IPC NNP N
devices NNS N
, , N
with IN N
all PDT N
the DT N
patients NNS N
in IN N
the DT N
supine JJ N
position NN N
. . N

Three CD i
high-pressure NN i
, , i
rapid-compression NN i
devices NNS i
and CC i
two CD i
standard NN i
, , i
low-pressure JJ i
, , i
slow-inflation JJ i
compression NN i
devices NNS i
were VBD N
applied VBN N
in IN N
a DT N
random JJ N
sequence NN N
. . N

Maximal NNP N
venous JJ N
velocities NNS N
were VBD N
obtained VBN N
at IN N
the DT N
common JJ N
femoral JJ N
vein NN N
and CC N
the DT N
popliteal NN N
vein NN N
for IN N
all PDT N
the DT N
devices NNS N
and CC N
were VBD N
recorded VBN N
as IN N
the DT N
mean JJ N
peak JJ N
velocity NN N
of IN N
three CD N
compression NN N
cycles NNS N
and CC N
compared VBN N
with IN N
baseline NN N
velocities NNS N
. . N

RESULTS VB N
The DT N
baseline NN N
venous JJ N
velocities NNS N
were VBD N
higher JJR N
in IN N
the DT N
femoral JJ N
veins NNS N
than IN N
in IN N
the DT N
popliteal NN N
veins NNS N
in IN N
both DT N
the DT N
volunteers NNS N
and CC N
the DT N
post-thrombotic JJ N
subjects NNS N
. . N

Standard NNP o
and CC o
high-pressure NN o
, , o
rapid-inflation NN o
compression NN o
significantly RB N
increased VBD N
the DT N
popliteal NN o
and CC o
femoral JJ o
vein NN o
velocities NNS o
in IN N
healthy JJ N
and CC N
post-thrombotic JJ N
subjects NNS N
. . N

High-pressure NN N
, , N
rapid-inflation NN N
compression NN N
produced VBD N
significantly RB N
higher JJR N
maximal JJ o
venous JJ o
velocities NNS o
in IN o
the DT o
popliteal NN o
and CC o
femoral JJ o
veins NNS o
in IN N
both DT N
healthy JJ N
volunteers NNS N
and CC N
patients NNS N
who WP N
were VBD N
post-thrombotic JJ N
as IN N
compared VBN N
with IN N
standard JJ N
compression NN N
. . N

Compared VBN N
with IN N
the DT N
healthy JJ N
volunteers NNS N
, , N
the DT N
patients NNS N
who WP N
were VBD N
post-thrombotic JJ N
had VBD N
a DT N
significantly RB N
attenuated VBN N
velocity NN o
response NN o
at IN N
both DT N
the DT N
popliteal NN N
and CC N
the DT N
femoral JJ N
vein NN N
levels NNS N
. . N

CONCLUSION NNP N
High-pressure NNP N
, , N
rapid-inflation NN N
pneumatic JJ N
compression NN N
increases NNS N
popliteal NN o
and CC o
femoral JJ o
vein NN o
velocity NN o
as IN N
compared VBN N
with IN N
standard JJ N
, , N
low-pressure JJ N
, , N
slow-inflation JJ N
pneumatic JJ N
compression NN N
. . N

Patients NNS p
with IN p
post-thrombotic JJ p
venous JJ p
disease NN p
have VBP N
a DT N
compromised JJ N
hemodynamic JJ N
response NN N
to TO N
all DT N
IPC NNP N
devices NNS N
. . N

However RB N
, , N
an DT N
increased VBN N
velocity NN N
response NN N
to TO N
the DT N
high-pressure NN N
, , N
rapid-inflation NN N
compression NN N
device NN N
is VBZ N
preserved VBN N
. . N

High-pressure NN N
, , N
rapid-inflation NN N
pneumatic JJ N
compression NN N
may MD N
offer VB N
additional JJ N
protection NN N
from IN N
thrombotic JJ N
complications NNS N
on IN N
the DT N
basis NN N
of IN N
an DT N
improved JJ N
hemodynamic JJ o
response NN o
, , N
both DT N
in IN N
healthy JJ p
volunteers NNS p
and CC p
in IN p
patients NNS p
who WP p
were VBD p
post-thrombotic JJ p
. . p

-DOCSTART- -17434069- O O

Comparison NNP N
of IN N
three CD N
methods NNS N
to TO N
increase VB N
knowledge NN o
about IN N
breast NN N
cancer NN N
and CC N
breast NN N
cancer NN N
screening VBG N
in IN N
screening VBG p
mammography NN p
patients NNS p
. . p

RATIONALE NNP N
AND CC N
OBJECTIVES NNP N
The DT N
specific JJ N
aim NN N
of IN N
the DT N
study NN N
was VBD N
to TO N
determine VB N
which WDT N
of IN N
several JJ N
cost-effective JJ N
interventions NNS N
is VBZ N
best RBS N
able JJ N
to TO N
improve VB N
the DT N
breast NN o
cancer NN o
knowledge NN o
of IN N
women NNS p
who WP p
present VBP p
for IN p
screening VBG p
mammography NN p
. . p

MATERIALS NNP N
AND NNP N
METHODS NNP N
A NNP p
total NN p
of IN p
198 CD p
English-speaking JJ p
women NNS p
, , p
with IN p
no DT p
personal JJ p
or CC p
family NN p
history NN p
of IN p
breast NN p
cancer NN p
, , p
were VBD p
recruited VBN p
and CC p
randomized VBN p
to TO p
four CD p
groups NNS p
when WRB p
they PRP p
presented VBD p
to TO p
the DT p
clinic NN p
for IN p
a DT p
screening NN p
mammogram NN p
. . p

All DT N
women NNS N
filled VBN N
in IN N
a DT N
demographic JJ N
data NN N
form NN N
and CC N
answered VBD N
a DT N
questionnaire NN N
containing VBG N
nine CD N
questions NNS N
about IN N
breast NN N
cancer NN N
, , N
risk NN N
, , N
and CC N
screening VBG N
to TO N
assess VB N
their PRP$ N
knowledge NN N
and CC N
perception NN N
. . N

Three CD N
educational JJ i
interventions NNS i
were VBD N
tested VBN N
in IN N
this DT N
study NN N
. . N

The DT N
first JJ N
consisted VBN N
of IN N
a DT N
brochure NN i
, , i
which WDT i
provided VBD i
answers NNS i
to TO i
the DT i
questionnaire NN i
items NNS i
and CC i
addressed VBD i
the DT i
issues NNS i
in IN i
more JJR i
depth NN i
. . i

The DT N
second JJ N
intervention NN N
was VBD N
an DT N
educational JJ i
conversation NN i
with IN i
a DT i
specially RB i
trained JJ i
mammography NN i
technologist NN i
. . i

She PRP N
reviewed VBD N
the DT N
subject NN N
's POS N
answers NNS N
to TO N
the DT N
questionnaire NN N
items NNS N
correcting VBG N
and/or NN N
clarifying VBG N
them PRP N
. . N

The DT N
third JJ N
intervention NN N
consisted VBD N
of IN N
the DT N
brochure NN i
together RB i
with IN i
the DT i
conversation NN i
with IN i
a DT i
trained JJ i
technologist NN i
. . i

There EX N
was VBD N
also RB N
a DT N
control NN N
group NN N
that WDT N
just RB N
filled VBN N
in IN N
the DT N
study NN N
questionnaire NN N
but CC i
did VBD i
not RB i
receive VB i
an DT i
educational JJ i
intervention NN i
. . i

The DT N
same JJ N
questionnaire NN N
was VBD N
administered VBN N
by IN N
telephone NN N
4 CD N
to TO N
6 CD N
weeks NNS N
after IN N
the DT N
screening NN N
experience NN N
to TO N
all DT N
study NN N
subjects NNS N
. . N

Changes NNS N
in IN N
their PRP$ N
knowledge NN o
and CC o
perceptions NNS o
of IN o
breast NN o
cancer NN o
were VBD N
measured VBN N
and CC N
compared VBN N
. . N

RESULTS VB N
A NNP N
statistically RB N
significant JJ N
increase NN N
in IN N
knowledge NN o
was VBD N
found VBN N
in IN N
all DT N
of IN N
the DT N
three CD N
investigated VBD N
groups NNS N
compared VBN N
to TO N
the DT N
control NN N
group NN N
. . N

There EX N
were VBD N
no DT N
statistically RB N
significant JJ N
differences NNS N
in IN N
the DT N
amount NN N
of IN N
increase NN N
between IN N
women NNS N
who WP N
underwent VBP N
different JJ N
interventions NNS N
. . N

CONCLUSIONS NNP N
All NNP N
three CD N
interventions NNS N
resulted VBD N
in IN N
increased VBN N
knowledge NN o
about IN N
breast NN N
cancer NN N
and CC N
screening NN N
. . N

No DT N
differences NNS N
in IN N
the DT N
amount NN N
of IN N
knowledge NN o
increase NN N
were VBD N
found VBN N
between IN N
three CD N
interventions NNS N
tested VBN N
. . N

The DT N
educational JJ N
brochure NN N
seems VBZ N
to TO N
represent VB N
the DT N
most RBS N
convenient JJ N
and CC N
least JJS N
costly JJ N
method NN N
to TO N
increase VB N
knowledge NN o
about IN N
breast NN N
cancer NN N
and CC N
screening VBG N
among IN N
women NNS N
who WP N
present VBP N
for IN N
screening VBG N
mammography NN N
. . N

-DOCSTART- -8932546- O O

Inhibition NN N
of IN N
histamine-induced JJ i
skin NN N
wheal NN N
and CC N
flare NN N
after IN N
5 CD N
days NNS N
of IN N
mizolastine NN i
. . i

Mizolastine NNP i
is VBZ N
a DT N
new JJ N
, , N
nonsedating JJ N
antihistamine NN N
providing VBG N
satisfactory JJ N
symptomatic JJ N
relief NN o
in IN o
allergic JJ o
rhinitis NN o
and CC o
urticaria NN o
. . o

The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
use VB N
inhibition NN N
of IN N
wheal NN N
and CC N
flare NN N
formation NN N
after IN N
2-mu JJ N
g NN N
intradermal JJ N
histamine NN N
injections NNS N
as IN N
a DT N
measure NN N
of IN N
the DT N
antihistamine JJ N
effect NN N
of IN N
repeated JJ N
doses NNS N
of IN N
mizolastine NN N
. . N

Eight CD p
volunteers NNS p
were VBD p
enrolled VBN p
in IN N
this DT N
four-arm JJ N
, , N
double-blind JJ N
, , N
cross-over JJ N
, , N
randomized VBN N
study NN N
. . N

Three CD N
dose JJ N
levels NNS N
of IN N
once-daily JJ i
mizolastine NN i
( ( N
5 CD N
mg NN N
, , N
10 CD N
mg NN N
, , N
and CC N
15 CD N
mg NN N
) ) N
were VBD N
compared VBN N
with IN N
placebo NN i
during IN N
5-day JJ N
dose JJ N
periods NNS N
. . N

Histamine NN i
tests NNS i
were VBD N
performed VBN N
before IN N
drug NN N
intake NN N
on IN N
days NNS N
1 CD N
and CC N
5 CD N
, , N
and CC N
then RB N
2 CD N
, , N
3 CD N
, , N
4 CD N
, , N
6 CD N
, , N
8 CD N
, , N
10 CD N
, , N
12 CD N
, , N
14 CD N
, , N
and CC N
24 CD N
hours NNS N
after IN N
drug NN N
intake NN N
on IN N
day NN N
5 CD N
. . N

All DT N
3 CD N
doses NNS N
of IN N
mizolastine NN i
were VBD N
more RBR o
effective JJ o
than IN N
placebo NN i
in IN N
suppressing VBG N
wheal NN o
and CC o
flare NN o
reactions NNS o
, , N
and CC N
the DT N
antihistamine NN o
activity NN o
was VBD N
highest JJS N
at IN N
both DT N
the DT N
10- JJ N
and CC N
15-mg JJ N
dose NN N
levels NNS N
. . N

The DT N
effect NN o
on IN o
the DT o
flare JJ o
reaction NN o
appeared VBD N
within IN N
1 CD N
hour NN N
, , N
reached VBD N
a DT N
maximum JJ N
effect NN N
4 CD N
hours NNS N
after IN N
administration NN N
, , N
and CC N
persisted VBD N
for IN N
as RB N
long RB N
as IN N
24 CD N
hours NNS N
. . N

The DT N
relative JJ N
changes NNS o
in IN N
wheal NN N
and CC N
flare JJ N
areas NNS N
were VBD N
correlated VBN N
with IN N
mizolastine NN i
trough IN N
plasma NN N
levels NNS N
on IN N
day NN N
5 CD N
. . N

Safety NN o
was VBD N
satisfactory JJ N
in IN N
all DT N
groups NNS N
. . N

This DT N
study NN N
confirms VBZ N
that IN N
mizolastine NN i
is VBZ N
a DT N
rapid JJ N
and CC N
potent JJ N
antihistamine NN o
; : o
and CC N
its PRP$ N
long-lasting JJ N
effectiveness NN N
indicates VBZ N
that IN N
a DT N
once-daily JJ N
regimen NN N
is VBZ N
acceptable JJ N
for IN N
clinical JJ N
use NN N
. . N

-DOCSTART- -15141043- O O

A DT N
comparison NN N
of IN N
laparoscopically RB i
assisted VBN i
and CC i
open JJ i
colectomy NN i
for IN N
colon NN p
cancer NN p
. . p

BACKGROUND NNP N
Minimally NNP N
invasive JJ N
, , N
laparoscopically RB i
assisted VBN i
surgery NN i
was VBD N
first RB N
considered VBN N
in IN N
1990 CD p
for IN p
patients NNS p
undergoing VBG p
colectomy NN p
for IN p
cancer NN p
. . p

Concern VB N
that IN N
this DT N
approach NN N
would MD N
compromise VB N
survival NN N
by IN N
failing VBG N
to TO N
achieve VB N
a DT N
proper JJ N
oncologic JJ N
resection NN N
or CC N
adequate JJ N
staging NN N
or CC N
by IN N
altering VBG N
patterns NNS N
of IN N
recurrence NN N
( ( N
based VBN N
on IN N
frequent JJ N
reports NNS N
of IN N
tumor NN N
recurrences NNS N
within IN N
surgical JJ N
wounds NNS N
) ) N
prompted VBD N
a DT N
controlled VBN N
trial NN N
evaluation NN N
. . N

METHODS NNP N
We PRP N
conducted VBD N
a DT N
noninferiority NN N
trial NN N
at IN N
48 CD p
institutions NNS p
and CC p
randomly RB p
assigned VBD p
872 CD p
patients NNS p
with IN p
adenocarcinoma NN p
of IN p
the DT p
colon NN p
to TO p
undergo VB p
open JJ i
or CC i
laparoscopically RB i
assisted VBN i
colectomy NN i
performed VBN p
by IN p
credentialed JJ p
surgeons NNS p
. . p

The DT N
median JJ N
follow-up NN N
was VBD N
4.4 CD N
years NNS N
. . N

The DT N
primary JJ N
end NN N
point NN N
was VBD N
the DT N
time NN o
to TO o
tumor VB o
recurrence NN o
. . o

RESULTS NN N
At IN N
three CD N
years NNS N
, , N
the DT N
rates NNS o
of IN o
recurrence NN o
were VBD N
similar JJ N
in IN N
the DT N
two CD N
groups NNS N
-- : N
16 CD N
percent NN N
among IN N
patients NNS N
in IN N
the DT N
group NN N
that WDT N
underwent JJ N
laparoscopically RB N
assisted VBN N
surgery NN N
and CC N
18 CD N
percent NN N
among IN N
patients NNS N
in IN N
the DT N
open-colectomy JJ N
group NN N
( ( N
two-sided JJ N
P=0.32 NNP N
; : N
hazard PRP$ N
ratio NN N
for IN N
recurrence NN N
, , N
0.86 CD N
; : N
95 CD N
percent NN N
confidence NN N
interval NN N
, , N
0.63 CD N
to TO N
1.17 CD N
) ) N
. . N

Recurrence NN o
rates NNS o
in IN o
surgical JJ o
wounds NNS o
were VBD N
less JJR N
than IN N
1 CD N
percent NN N
in IN N
both DT N
groups NNS N
( ( N
P=0.50 NNP N
) ) N
. . N

The DT N
overall JJ o
survival NN o
rate NN o
at IN N
three CD N
years NNS N
was VBD N
also RB N
very RB N
similar JJ N
in IN N
the DT N
two CD N
groups NNS N
( ( N
86 CD N
percent NN N
in IN N
the DT N
laparoscopic-surgery JJ N
group NN N
and CC N
85 CD N
percent NN N
in IN N
the DT N
open-colectomy JJ N
group NN N
; : N
P=0.51 NNP N
; : N
hazard PRP$ o
ratio NN o
for IN o
death NN o
in IN N
the DT N
laparoscopic-surgery JJ N
group NN N
, , N
0.91 CD N
; : N
95 CD N
percent NN N
confidence NN N
interval NN N
, , N
0.68 CD N
to TO N
1.21 CD N
) ) N
, , N
with IN N
no DT N
significant JJ N
difference NN N
between IN N
groups NNS N
in IN N
the DT N
time NN o
to TO o
recurrence VB o
or CC o
overall JJ o
survival NN o
for IN N
patients NNS N
with IN N
any DT N
stage NN N
of IN N
cancer NN N
. . N

Perioperative JJ o
recovery NN o
was VBD N
faster RBR N
in IN N
the DT N
laparoscopic-surgery NN N
group NN N
than IN N
in IN N
the DT N
open-colectomy JJ N
group NN N
, , N
as IN N
reflected VBN N
by IN N
a DT N
shorter NN N
median JJ o
hospital NN o
stay NN o
( ( N
five CD N
days NNS N
vs. FW N
six CD N
days NNS N
, , N
P NNP N
< NNP N
0.001 CD N
) ) N
and CC N
briefer VBP N
use NN N
of IN N
parenteral JJ N
narcotics NNS N
( ( N
three CD N
days NNS N
vs. FW N
four CD N
days NNS N
, , N
P NNP N
< NNP N
0.001 CD N
) ) N
and CC N
oral JJ N
analgesics NNS N
( ( N
one CD N
day NN N
vs. FW N
two CD N
days NNS N
, , N
P=0.02 NNP N
) ) N
. . N

The DT N
rates NNS o
of IN o
intraoperative JJ o
complications NNS o
, , o
30-day JJ o
postoperative JJ o
mortality NN o
, , o
complications NNS o
at IN o
discharge NN o
and CC o
60 CD o
days NNS o
, , o
hospital JJ o
readmission NN o
, , o
and CC o
reoperation NN o
were VBD N
very RB N
similar JJ N
between IN N
groups NNS N
. . N

CONCLUSIONS NNP N
In IN N
this DT N
multi-institutional JJ N
study NN N
, , N
the DT N
rates NNS o
of IN o
recurrent JJ o
cancer NN o
were VBD N
similar JJ N
after IN N
laparoscopically RB i
assisted VBN i
colectomy NN i
and CC N
open JJ i
colectomy NN i
, , N
suggesting VBG N
that IN N
the DT N
laparoscopic NN N
approach NN N
is VBZ N
an DT N
acceptable JJ N
alternative NN N
to TO N
open VB N
surgery NN N
for IN N
colon NN N
cancer NN N
. . N

-DOCSTART- -14660988- O O

Identification NN N
, , N
course NN N
, , N
and CC N
treatment NN N
of IN N
depression NN p
after IN p
admission NN p
for IN p
a DT p
cardiac JJ p
condition NN p
: : p
rationale NN N
and CC N
patient JJ N
characteristics NNS N
for IN N
the DT N
Identifying NNP N
Depression NNP N
As IN N
a DT N
Comorbid NNP N
Condition NNP N
( ( N
IDACC NNP N
) ) N
project NN N
. . N

BACKGROUND NNP N
Given NNP N
the DT N
prevalence NN N
of IN N
cardiovascular JJ N
disease NN N
and CC N
the DT N
high JJ N
rates NNS N
of IN N
depression NN N
among IN N
cardiac JJ p
patients NNS p
, , N
there EX N
is VBZ N
a DT N
need NN N
to TO N
develop VB N
practical JJ N
ways NNS N
to TO N
identify VB N
this DT N
population NN N
and CC N
provide VB N
pragmatic JJ N
general-practitioner-based JJ i
interventions NNS i
for IN N
managing VBG N
depression NN N
as IN N
a DT N
comorbid NN N
condition NN N
. . N

METHOD NNP N
The DT N
Identifying NNP N
Depression NNP N
As IN N
a DT N
Comorbid NNP N
Condition NNP N
( ( N
IDACC NNP N
) ) N
study NN N
employed VBD N
a DT N
hybrid JJ N
design NN N
, , N
incorporating VBG N
a DT N
randomized VBN N
controlled VBN N
trial NN N
nested VBN N
within IN N
a DT N
prospective JJ N
cohort NN N
study NN N
. . N

IDACC NNP N
screened VBD N
for IN N
depression NN p
in IN p
patients NNS p
hospitalized VBN p
in IN p
South NNP p
Australia NNP p
for IN p
a DT p
range NN p
of IN p
cardiac JJ p
conditions NNS p
, , N
with IN N
outcome JJ N
measures NNS N
monitored VBD N
for IN N
12 CD N
months NNS N
after IN N
discharge NN N
. . N

The DT p
subgroup NN p
identified VBD p
as IN p
depressed VBN p
was VBD p
entered VBN p
into IN p
the DT p
nested JJ p
IDACC NNP p
trial NN p
, , N
which WDT N
tests VBZ N
the DT N
hypothesis NN N
that IN N
identifying VBG i
depression NN i
and CC i
offering VBG i
an DT i
evidence-based JJ i
intervention NN i
to TO N
general JJ N
practitioners NNS N
, , N
incorporating VBG N
multidisciplinary JJ i
telephone NN i
case NN i
conferencing NN i
, , N
will MD N
reduce VB N
levels NNS N
of IN N
depression NN o
, , N
improve VB N
quality NN N
of IN N
life NN N
, , N
and CC N
reduce VB N
associated VBN N
economic JJ o
costs NNS o
. . o

RESULTS NNP N
At IN N
baseline NN N
, , N
46.3 CD N
% NN N
of IN N
1455 CD p
participants NNS p
screened VBN p
were VBD p
classified VBN p
as IN p
depression NN o
cases NNS p
on IN N
the DT N
basis NN N
of IN N
their PRP$ N
score NN N
on IN N
the DT N
Center NNP o
for IN o
Epidemiological NNP o
Studies NNPS o
Depression NNP o
Scale NNP o
( ( N
> CD N
or CC N
=16 VB N
) ) N
or CC N
the DT N
Hospital NNP o
Anxiety NNP o
and CC o
Depression NNP o
Scale NNP o
( ( N
> CD N
or CC N
=8 NNP N
) ) N
. . N

Elevated VBN N
scores NNS N
were VBD N
associated VBN N
with IN N
being VBG N
younger JJR N
, , N
female JJ N
, , N
divorced VBD N
or CC N
separated VBN N
, , N
not RB N
employed VBN N
, , N
living VBG N
alone RB N
, , N
having VBG N
a DT N
lower JJR N
level NN N
of IN N
education NN N
, , N
and CC N
having VBG N
poorer JJR N
health NN N
and CC N
quality NN N
of IN N
life NN N
. . N

Nearly RB N
one CD N
fifth NN N
( ( N
19.4 CD N
% NN N
) ) N
of IN N
participants NNS N
had VBD N
Center NNP o
for IN o
Epidemiological NNP o
Studies NNPS o
Depression NNP o
Scale NNP o
scores VBZ o
> JJ o
27 CD o
, , N
which WDT N
is VBZ N
indicative CD N
of IN N
major JJ N
depression NN N
. . N

CONCLUSIONS VB N
This DT N
project NN N
confirms VBZ N
, , N
in IN N
an DT N
Australian JJ p
setting NN p
, , N
the DT N
high JJ N
prevalence NN N
of IN N
depressive JJ o
symptoms NNS o
among IN N
hospitalized JJ p
cardiac JJ p
patients NNS p
. . p

Follow-up NNP N
over IN N
12 CD N
months NNS N
will MD N
enhance VB N
understanding NN N
of IN N
the DT N
natural JJ N
history NN N
of IN N
depression NN p
in IN p
cardiac JJ p
patients NNS p
, , N
while IN N
the DT N
nested JJ N
trial NN N
will MD N
inform VB N
on IN N
effectiveness NN N
of IN N
an DT N
intervention NN N
involving VBG N
tailored VBN N
advice NN N
and CC N
support NN N
to TO N
general JJ N
practitioners NNS N
. . N

-DOCSTART- -22692114- O O

The DT N
acute JJ N
effects NNS N
of IN N
fluid JJ N
intake NN N
on IN N
urine JJ N
specific JJ N
gravity NN N
and CC N
fluid JJ N
retention NN N
in IN N
a DT p
mildly RB p
dehydrated JJ p
state NN p
. . p

Many JJ N
athletes NNS p
arrive VBP N
at IN N
training NN N
sessions NNS N
and CC N
competitions NNS N
in IN N
a DT N
mildly RB p
hypohydrated VBN p
( ( p
HYPO NNP p
) ) p
state NN p
and CC N
are VBP N
instructed VBN N
to TO N
drink VB N
fluids NNS N
before IN N
exercise NN N
to TO N
reach VB N
a DT N
euhydrated JJ N
( ( N
HYD NNP N
) ) N
state NN N
. . N

Ten CD p
recreational JJ p
athletes NNS p
( ( p
6 CD p
women NNS p
, , p
4 CD p
men NNS p
; : p
71.9 CD p
? . p
4.6 CD p
kg NN p
, , p
25.2 CD p
? . p
0.9 CD p
years NNS p
) ) p
participated VBD p
in IN p
the DT N
studies NNS N
to TO N
examine VB N
( ( N
a DT N
) ) N
the DT N
day-to-day JJ N
variability NN N
of IN N
morning NN N
urine NN N
specific JJ N
gravity NN N
( ( N
USG NNP N
) ) N
, , N
( ( N
b NN N
) ) N
the DT N
effects NNS N
of IN N
consuming VBG i
600 CD i
ml NN i
of IN i
water NN i
on IN i
the DT N
hydration NN N
status NN N
of IN N
HYD NNP N
and CC N
HYPO NNP N
( ( N
USG NNP N
> NNP N
1.020 CD N
) ) N
subjects NNS N
, , N
and CC N
( ( N
c NN N
) ) N
the DT N
effects NNS N
of IN N
consuming VBG i
water NN i
( ( i
W NNP i
) ) i
, , i
salt-water JJ i
( ( i
SW NNP N
, , N
40 CD N
mM NN N
Na NNP N
) ) N
, , N
a DT N
carbohydrate-electrolyte JJ i
solution NN i
with IN i
3 CD i
% NN i
or CC i
light JJ i
carbohydrate NN i
( ( i
CES-L NNP N
, , N
20 CD N
mM NN N
Na NNP N
) ) N
or CC N
a DT N
CES NN i
with IN i
6 CD i
% NN i
carbohydrate NN i
( ( i
CES NNP N
, , N
20 CD N
mM NN N
Na NNP N
) ) N
on IN N
the DT N
hydration NN N
status NN N
of IN N
HYPO NNP N
subjects NNS N
. . N

The DT N
hydration NN N
status NN N
was VBD N
assessed VBN N
with IN N
USG NNP N
and CC N
body NN N
mass NN N
measures NNS N
and CC N
urine JJ N
volume NN N
collections NNS N
. . N

The DT N
day-to-day JJ N
variability NN N
in IN N
morning NN N
USG NNP N
( ( N
coefficient NN N
of IN N
variation NN N
= FW N
0.2 CD N
? . N
0.1 CD N
% NN N
) ) N
was VBD N
low JJ N
and CC N
the DT N
responses NNS N
to TO N
600 CD N
ml NN N
of IN N
W NNP N
ingestion NN N
were VBD N
repeatable JJ o
. . o

Pretrial JJ o
USG NNP o
was VBD o
1.022 CD N
? . N
0.001 CD N
in IN N
the DT N
HYPO NNP N
trial NN N
and CC N
decreased VBD N
< NNS N
1.020 CD N
by IN N
45 CD N
minutes NNS N
( ( N
1.013 CD N
? . N
0.003 CD N
) ) N
. . N

In IN N
the DT N
CES NNP N
study NN N
, , N
HYPO NNP N
subjects VBZ N
reached VBN N
HYD NNP N
status NN N
at IN N
45 CD N
minutes NNS N
in IN N
all DT N
conditions NNS N
( ( N
W NNP N
1.013 CD N
? . N
0.003 CD N
, , N
SW NNP N
1.013 CD N
? . N
0.003 CD N
, , N
CES-L NNP N
1.011 CD N
? . N
0.003 CD N
, , N
CES NNP N
1.017 CD N
? . N
0.004 CD N
) ) N
because IN N
salt NN N
or CC N
CES NNP N
ingestion NN N
did VBD N
not RB N
affect VB o
fluid NN o
retention NN o
( ( o
W NNP o
68 CD o
% NN o
, , o
SW NNP N
72 CD N
% NN N
, , N
CES-L JJ N
68 CD N
% NN N
, , N
CES NNP N
76 CD N
% NN N
) ) N
. . N

This DT N
study NN N
demonstrated VBD p
that IN p
mildly RB p
HYPO NNP p
subjects NNS p
could MD N
reach VB N
euhydration NN N
within IN N
45 CD N
minutes NNS N
of IN N
the DT N
ingestion NN N
of IN N
600 CD N
ml NN N
of IN N
W NNP i
or CC N
a DT N
combination NN N
of IN N
salt NN N
and CC N
CES NNP i
solutions NNS N
. . N

Following VBG N
this DT N
practice NN N
will MD N
minimize VB N
the DT N
incidence NN N
of IN N
starting VBG N
a DT N
practice NN N
or CC N
competition NN N
hypohydrated VBN N
. . N

-DOCSTART- -1927197- O O

Prospective JJ N
comparison NN N
of IN N
the DT N
value NN N
of IN N
brushings NNS i
before IN i
and CC i
after IN i
biopsy NN i
in IN N
the DT N
endoscopic JJ N
diagnosis NN N
of IN N
gastroesophageal JJ p
malignancy NN p
. . p

The DT N
hypothesis NN N
that IN N
the DT N
cytodiagnostic JJ N
results NNS N
on IN N
endoscopic JJ i
brushings NNS i
obtained VBN N
before IN N
biopsy NN N
may MD N
be VB N
superior JJ N
to TO N
those DT N
brushings NNS i
obtained VBN N
after IN N
biopsy NN N
, , N
but CC N
with IN N
the DT N
accuracy NN N
of IN N
the DT N
subsequent JJ N
biopsy NN N
reduced VBD N
, , N
was VBD N
examined VBN N
for IN N
300 CD p
consecutive JJ p
patients NNS p
, , p
including VBG p
256 CD p
with IN p
esophageal NN p
or CC p
gastric JJ p
carcinomas NN p
. . p

Following VBG N
stratification NN N
by IN N
site NN N
and CC N
endoscopic JJ N
appearance NN N
of IN N
their PRP$ N
lesions NNS N
, , N
the DT N
patients NNS N
were VBD N
randomized VBN N
to TO N
undergo VB i
brushing VBG i
either CC i
before IN i
or CC i
after IN i
forceps JJ i
biopsy NN i
. . i

The DT o
accuracy NN o
of IN o
brushing VBG o
cytology NN o
in IN o
patients NNS o
with IN o
carcinoma NN o
was VBD o
significantly RB o
higher JJR o
when WRB o
the DT o
brushing NN o
was VBD o
performed VBN o
before IN o
biopsy NN o
than IN o
after IN o
biopsy NN o
( ( N
93.5 CD N
% NN N
versus IN N
82.6 CD N
% NN N
; : N
P NNP N
less JJR N
than IN N
.01 NN N
) ) N
. . N

The DT o
diagnostic JJ o
yield NN o
of IN o
the DT o
biopsy NN o
was VBD o
not RB o
significantly RB o
different JJ o
whether IN N
the DT N
lesions NNS N
were VBD N
brushed VBN N
before IN N
or CC N
after IN N
the DT N
biopsy NN N
( ( N
92.7 CD N
% NN N
versus IN N
93.2 CD N
% NN N
; : N
P NNP N
less JJR N
than IN N
.5 NN N
) ) N
. . N

The DT N
diagnostic JJ o
superiority NN o
of IN o
brushings NNS o
obtained VBN o
before IN o
biopsy NN o
did VBD o
not RB o
relate VB o
to TO o
the DT o
site NN o
or CC o
endoscopic JJ o
appearance NN o
of IN o
the DT o
tumor NN o
. . o

There EX N
were VBD N
no DT o
false-positive JJ o
cytologic NN o
or CC o
histologic JJ o
reports NNS o
. . o

For IN N
all DT N
256 CD N
carcinomas NNS N
, , N
the DT N
cumulative JJ o
accuracy NN o
( ( o
brushing VBG o
cytology NN o
plus CC o
biopsy NN o
) ) o
reached VBD N
98.8 CD N
% NN N
and CC N
was VBD N
significantly RB N
better JJR N
( ( N
P NNP N
less JJR N
than IN N
.001 NN N
) ) N
than IN N
that DT N
of IN N
biopsy NN o
alone RB o
( ( N
93.9 CD N
% NN N
) ) N
or CC N
cytology NN o
alone RB o
( ( N
87.9 CD N
% NN N
) ) N
. . N

Apart RB N
from IN N
reinforcing VBG N
the DT N
belief NN N
that IN N
the DT N
combined JJ o
application NN o
of IN o
brushing NN o
and CC o
biopsy NN o
is VBZ N
mandatory JJ N
for IN N
achieving VBG N
optimal JJ N
results NNS N
, , N
this DT N
study NN N
indicated VBD N
that IN N
the DT N
brushing NN i
should MD N
be VB N
performed VBN N
before IN N
the DT N
biopsy NN N
. . N

-DOCSTART- -9772108- O O

Functional JJ N
modification NN p
of IN p
agonist-antagonist JJ p
electromyographic JJ p
activity NN p
for IN p
rapid JJ p
movement NN p
inhibition NN p
. . p

Subjects NNS p
made VBD p
a DT p
fast JJ p
elbow NN p
extension NN p
movement NN p
to TO p
designated VBN p
target NN p
in IN p
response NN p
to TO p
a DT p
go JJ i
signal NN i
. . i

In IN N
45 CD N
% NN N
of IN N
trials NNS N
a DT N
stop JJ N
signal NN N
was VBD N
presented VBN N
after IN N
the DT N
go JJ N
signal NN N
, , N
to TO N
which WDT N
subjects NNS N
were VBD N
asked VBN N
to TO N
stop VB N
the DT N
movement NN N
as RB N
rapidly RB N
as IN N
possible JJ N
. . N

The DT i
interstimulus JJ i
interval NN i
( ( i
ISI NNP i
) ) i
, , i
or CC i
time NN i
interval NN i
between IN i
the DT i
go NN i
and CC i
stop NN i
signals NNS i
, , N
was VBD N
randomly RB N
varied VBN N
between IN N
0 CD N
and CC N
200 CD N
ms. NN N
Electromyographic NNP o
( ( o
EMG NNP o
) ) o
activity NN o
was VBD i
recorded VBN i
from IN i
biceps NNS i
brachii NNS i
and CC i
triceps NNS i
brachii NN i
. . i

Subjects NNS N
could MD N
sometimes RB N
completely RB N
inhibit JJ N
initiation NN N
of IN N
the DT N
movements NNS N
when WRB N
the DT N
ISI NNP N
was VBD N
0 CD N
ms NN N
, , N
but CC N
could MD N
rarely RB N
do VB N
so RB N
when WRB N
the DT N
ISI NNP N
exceeded VBD N
100 CD N
ms. NN N
For IN N
responses NNS N
that WDT N
were VBD N
initiated VBN N
but CC N
stopped VBN N
on IN N
the DT N
way NN N
, , N
the DT N
amplitude NN o
of IN o
the DT o
movement NN o
decreased VBD N
linearly RB N
as IN N
the DT N
time NN N
interval NN N
( ( N
=modification JJ N
time NN N
) ) N
from IN N
the DT N
stop JJ N
signal NN N
to TO N
EMG NNP N
onset NN N
increased VBD N
. . N

The DT N
peak JJ o
velocity NN o
increased VBD N
linearly RB N
as IN N
the DT N
movement NN N
amplitude NN N
increased VBD N
. . N

This DT N
tendency NN N
was VBD N
similar JJ N
to TO N
those DT N
previously RB N
reported VBN N
in IN N
step-tracking JJ N
movements NNS N
with IN N
various JJ N
amplitudes NNS N
. . N

In IN N
spite NN N
of IN N
the DT N
similarity NN N
in IN N
the DT N
kinematics NNS N
of IN N
the DT N
movement NN N
, , N
the DT N
EMG NNP o
pattern NN o
was VBD N
different JJ N
from IN N
that DT N
of IN N
step-tracking JJ o
movement NN o
. . o

While IN N
the DT N
initial JJ o
agonist NN o
burst NN o
( ( o
AG1 NNP o
) ) o
decreased VBD N
linearly RB N
after IN N
the DT N
modification NN N
time NN N
exceeded VBD N
100 CD N
ms NN N
, , N
the DT N
antagonist NN o
burst NN o
( ( o
ANT NNP o
) ) o
increased VBD N
compared VBN N
with IN N
the DT N
go JJ N
trial NN N
for IN N
the DT N
modification NN N
time NN N
from IN N
0 CD N
to TO N
200 CD N
ms NNS N
and CC N
decreased VBN N
after IN N
the DT N
modification NN N
time NN N
exceeded VBD N
300 CD N
ms NN N
. . N

This DT N
change NN N
of IN N
activation NN N
is VBZ N
analogous JJ N
to TO N
functional JJ N
modification NN N
of IN N
middle-latency NN N
reflex NN N
EMG NNP o
response NN o
to TO N
load VB N
, , N
or CC N
cutaneous JJ N
perturbation NN N
. . N

In IN N
conclusion NN N
, , N
it PRP N
is VBZ N
suggested VBN N
that IN N
adaptive JJ N
mechanisms NNS N
, , N
which WDT N
would MD N
functionally RB N
modify VB N
the DT N
reflex NN N
responses NNS N
, , N
are VBP N
also RB N
continuously RB N
working VBG N
during IN N
voluntary JJ N
movements NNS N
in IN N
response NN N
to TO N
sudden JJ N
changes NNS N
in IN N
environmental JJ N
information NN N
. . N

-DOCSTART- -22821273- O O

Different JJ N
cardiac JJ N
biomarkers NNS N
to TO N
detect VB N
peri-procedural JJ N
myocardial JJ N
infarction NN N
in IN N
contemporary JJ p
coronary JJ p
stent NN p
trials NNS p
: : p
impact NN N
on IN N
outcome NN N
reporting NN N
. . N

OBJECTIVE UH N
To TO N
assess VB N
the DT N
differential JJ N
implications NNS N
of IN N
cardiac JJ N
biomarker NN N
type NN N
on IN N
peri-procedural JJ N
myocardial JJ N
infarction NN N
( ( N
PMI NNP N
) ) N
reporting NN N
. . N

SETTING CC N
The DT p
Resolute NNP p
'All-Comers NNS p
' POS p
stent JJ p
trial NN p
. . p

INTERVENTIONS NNP N
Blood NNP N
samples NNS N
for IN N
creatine NN N
kinase NN N
( ( N
CK NNP N
) ) N
, , N
CK-myoband NNP N
( ( N
CK-MB NNP N
) ) N
mass NN N
or CC N
cardiac JJ N
troponin NN N
( ( N
cTn NN N
) ) N
( ( N
optional JJ N
) ) N
were VBD N
collected VBN N
before RB N
and CC N
at IN N
6 CD N
, , N
12 CD N
and CC N
18 CD N
h NN N
after IN p
the DT p
assigned JJ p
percutaneous JJ i
coronary JJ i
intervention NN i
or CC p
at IN p
discharge NN p
. . p

PMIs NNP N
were VBD N
adjudicated VBN N
using VBG N
either CC N
the DT N
2007 CD N
universal JJ N
definition NN N
of IN N
MI NNP N
( ( N
type-4a JJ N
) ) N
or CC N
the DT N
extended JJ N
historical JJ N
definition NN N
of IN N
MI NNP N
. . N

PATIENTS NNP N
2121/2292 CD p
patients NNS p
( ( p
92.5 CD p
% NN p
) ) p
had VBD p
an DT p
analysable JJ p
dataset NN p
for IN p
either DT p
biomarker NN p
. . p

890/2121 CD p
patients NNS p
( ( N
42 CD N
% NN N
) ) N
presented VBN N
with IN N
an DT N
acute JJ N
coronary JJ N
syndrome NN N
( ( N
ACS NNP N
) ) N
. . N

267/890 CD p
patients NNS p
( ( N
30 CD N
% NN N
) ) N
were VBD N
within IN N
24 CD N
h NN N
of IN N
an DT N
ST-segment JJ N
elevation NN N
MI NNP N
. . N

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
Type-4a NNP o
MI NNP o
was VBD N
diagnosed VBN N
in IN N
208/2121 CD N
patients NNS N
( ( N
9.8 CD N
% NN N
) ) N
when WRB N
cTn NN N
was VBD N
used VBN N
( ( N
CK-MB JJ N
mass NN N
if IN N
cTn NN N
not RB N
available JJ N
) ) N
, , N
and CC N
in IN N
93/2121 CD N
of IN N
patients NNS N
( ( N
4.4 CD N
% NN N
) ) N
when WRB N
CK-MB JJ N
mass NN N
was VBD N
used VBN N
( ( N
cTn JJ N
if IN N
CK-MB NNP N
mass NN N
not RB N
available JJ N
) ) N
. . N

With IN N
the DT N
extended JJ N
historical JJ N
CK-based JJ N
definition NN N
of IN N
MI NNP N
, , N
PMI NNP o
was VBD N
diagnosed VBN N
in IN N
65/2121 CD N
patients NNS N
( ( N
3.1 CD N
% NN N
) ) N
. . N

Adjudication NN N
of IN N
type-4a JJ o
MI NNP o
in IN N
patients NNS N
with IN N
an DT N
ACS NNP N
was VBD N
problematic JJ N
with IN N
< JJ N
10 CD N
% NN N
of IN N
the DT N
potential JJ N
type-4a NN N
MI NNP N
being VBG N
confirmed VBN N
as IN N
an DT N
event NN N
, , N
as IN N
compared VBN N
with IN N
approximately RB N
95 CD N
% NN N
in IN N
stable JJ N
patients NNS N
undergoing VBG N
elective JJ N
PCI NNP N
. . N

Type-4a NNP N
MI NNP N
was VBD N
not RB N
associated VBN N
with IN N
the DT N
subsequent JJ N
hazard NN N
for IN N
cardiac JJ o
mortality NN o
( ( N
p=0.6 NN N
) ) N
. . N

CONCLUSIONS VB N
The DT N
percentage NN N
of IN N
adjudicated JJ N
PMI NNP o
events NNS o
is VBZ N
driven VBN N
by IN N
the DT N
MI-definition NNP N
criteria NNS N
and CC N
biomarker NN N
type NN N
. . N

Type-4a JJ N
MI NNP N
may MD N
not RB N
be VB N
a DT N
reliable JJ N
component NN N
of IN N
the DT N
primary JJ N
composite JJ N
end NN N
point NN N
in IN N
coronary JJ N
stent NN N
investigations NNS N
which WDT N
recruit VBP N
patients NNS N
with IN N
ACS NNP N
. . N

TRIAL NNP N
REGISTRATION NNP N
NUMBER NNP N
http NN N
: : N
//www.ClinicalTrials.gov NN N
; : N
Unique NNP N
identifier NN N
: : N
NCT00617084 NNP N
. . N

-DOCSTART- -10947757- O O

The DT N
effect NN N
of IN N
halothane NN i
and CC N
isoflurane NN i
on IN N
plasma JJ o
cytokine NN o
levels NNS o
. . o

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
investigate VB N
the DT N
effect NN N
of IN N
halothane NN i
vs. FW N
isoflurane NN i
on IN N
cytokine JJ o
production NN o
during IN p
minor JJ p
elective JJ p
surgery NN p
. . p

Forty NNP p
adult NN p
patients NNS p
, , p
ASA NNP p
I-II NNP p
were VBD N
randomly RB N
allocated VBN N
to TO N
receive VB N
halothane NN i
or CC N
isoflurane NN i
. . i

Venous JJ N
samples NNS N
for IN N
interleukin NN N
( ( N
IL NNP N
) ) N
-1beta NN N
, , N
IL-2 NNP N
, , N
IL-6 NNP N
, , N
tumour JJ N
necrosis NN N
factor-alpha NN N
( ( N
TNF-alpha NNP N
) ) N
and CC N
interferon-gamma JJ N
( ( N
IFN-gamma NNP N
) ) N
were VBD N
taken VBN N
before RB N
anaesthesia JJ N
, , N
before IN N
incision NN N
, , N
at IN N
the DT N
end NN N
of IN N
anaesthesia NN N
and CC N
24 CD N
h NN N
postoperatively RB N
. . N

In IN N
both DT N
groups NNS N
, , N
IL-6 NNP o
and CC o
TNF-alpha NNP o
levels NNS o
remained VBD N
low JJ N
throughout IN N
the DT N
study NN N
period NN N
. . N

Before IN N
incision NN N
, , N
in IN N
both DT N
groups NNS N
IL-1beta NNP o
and CC o
IFN-gamma NNP o
showed VBD N
a DT N
decrease NN N
( ( N
p JJ N
< VBP N
0.01 CD N
for IN N
IL-1beta NNP o
in IN N
isoflurane NN N
group NN N
and CC N
p NN N
< VBP N
0.05 CD N
for IN N
the DT N
others NNS N
) ) N
compared VBN N
with IN N
pre-induction NN N
. . N

By IN N
the DT N
end NN N
of IN N
anaesthesia NN N
and CC N
surgery NN N
, , N
IL-1beta NNP o
had VBD N
increased VBN N
significantly RB N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
and CC N
IFN-gamma NNP o
had VBD N
decreased VBN N
significantly RB N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
in IN N
both DT N
groups NNS N
compared VBN N
with IN N
pre-incisional JJ N
levels NNS N
. . N

By IN N
24 CD N
h NNS N
postoperatively RB N
in IN N
both DT N
groups NNS N
, , N
IL-1beta NNP o
had VBD N
decreased VBN N
significantly RB N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
, , N
whereas JJ N
IFN-gamma NNP o
had VBD N
increased VBN N
significantly RB N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
compared VBN N
with IN N
the DT N
end NN N
of IN N
anaesthesia NN N
and CC N
surgery NN N
level NN N
. . N

Pre-incisionally RB N
, , N
IL-2 NNP o
increased VBD N
in IN N
the DT N
halothane NN i
group NN N
( ( N
p JJ N
< NNP N
0.01 CD N
) ) N
, , N
whereas IN N
it PRP N
decreased VBD N
significantly RB N
in IN N
the DT N
isoflurane NN i
group NN N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
compared VBN N
with IN N
the DT N
pre-induction NN N
level NN N
. . N

By IN N
the DT N
end NN N
of IN N
anaesthesia NN N
and CC N
surgery NN N
and CC N
by IN N
24 CD N
h NN N
postoperatively RB N
, , N
IL-2 NNP o
had VBD N
decreased VBN N
significantly RB N
in IN N
the DT N
halothane NN i
group NN N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
, , N
whereas IN N
it PRP N
increased VBD N
significantly RB N
in IN N
the DT N
isoflurane NN i
group NN N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
compared VBN N
with IN N
pre-incision NN N
and CC N
end NN N
of IN N
anaesthesia NN N
and CC N
surgery NN N
levels NNS N
, , N
respectively RB N
. . N

-DOCSTART- -21317341- O O

Effects NNS N
of IN N
diet JJ i
and CC i
Aspergillus NNP i
oryzae VBP i
extract NN i
or CC i
Saccharomyces NNS i
cervisiae VBP i
on IN N
growth NN N
and CC N
carcass NN N
characteristics NNS N
of IN N
lambs NNS p
and CC p
steers NNS p
fed VBP p
to TO p
meet VB p
requirements NNS p
of IN p
natural JJ p
markets NNS p
. . p

Two CD N
studies NNS N
were VBD N
conducted VBN N
to TO N
determine VB N
the DT N
effects NNS N
of IN N
diet JJ i
and CC i
feed JJ i
additive NN i
on IN N
growth NN N
and CC N
carcass NN N
characteristics NNS N
of IN N
lambs NNS p
and CC p
cattle NNS p
destined VBD p
for IN p
all DT p
natural JJ p
markets NNS p
. . p

In IN N
Exp NNP N
. . N

1 CD p
, , p
48 CD p
Dorset NNP p
? . p
Hampshire NNP p
lambs NN p
( ( p
initial JJ p
BW NNP p
29.4 CD p
? . p
0.1 CD p
kg NN p
) ) p
were VBD p
used VBN N
in IN N
a DT N
randomized JJ N
complete JJ N
block NN N
experiment NN N
to TO N
determine VB N
the DT N
effects NNS N
of IN N
Aspergillus NNP i
oryzae NNP i
extract NN i
, , i
Amaferm NNP i
( ( i
AMF NNP i
) ) i
supplementation NN i
( ( i
1 CD N
g/d NN N
) ) N
in IN N
an DT N
85 CD N
% NN i
concentrate NN i
diet NN i
on IN i
growth NN N
and CC N
carcass NN N
characteristics NNS p
. . p

Lambs NNP p
were VBD p
allotted VBN p
to TO p
12 CD p
pens NNS p
( ( p
4 CD p
lambs NNS p
per IN p
pen NN p
) ) p
, , p
and CC p
blocked VBN p
by IN p
sex NN p
and CC p
BW NNP p
. . p

Lambs NNP N
were VBD N
fed VBN N
until IN N
the DT N
average JJ N
BW NNP N
of IN N
each DT N
pen NN N
reached VBD N
a DT N
target NN N
BW NNP N
( ( N
55.4 CD N
kg NN N
for IN N
wethers NNS N
and CC N
50.0 CD N
kg NN N
for IN N
ewes NN N
) ) N
, , N
at IN N
which WDT N
time NN N
the DT N
entire JJ N
pen NN N
of IN N
lambs NN N
was VBD N
slaughtered VBN N
. . N

Amaferm NNP N
resulted VBD N
in IN N
a DT N
greater JJR N
( ( N
P=0.07 NNP o
) ) o
G NNP o
: : o
F. NNP o
In IN N
Exp NNP p
. . p

2 CD p
, , N
168 CD p
crossbred VBD p
steers NNS p
( ( p
initial JJ p
BW NNP p
300 CD p
? . p
0.7 CD p
kg NN p
) ) p
were VBD p
used VBN N
in IN N
a DT N
trial NN N
with IN N
a DT N
3 CD N
? . N
2 CD N
factorial JJ N
arrangement NN N
of IN N
treatments NNS N
to TO N
examine VB N
the DT N
effects NNS N
of IN N
0.5 CD N
g/d NN N
of IN i
Saccaromyces NNP i
cervisiae NN i
boulardii NN i
CNCM NNP i
1079-Levucell CD i
SB NNP i
( ( i
LEV NNP i
) ) i
, , i
or CC i
3 CD N
g/d NN N
of IN i
AMF NNP i
with IN N
2 CD N
corn NN N
sources NNS i
, , i
dry JJ i
whole-shelled JJ i
corn NN i
or CC i
high JJ i
moisture NN i
corn NN i
, , i
on IN i
growth NN N
and CC N
carcass NN N
characteristics NNS o
. . o

Neither CC o
LEV NNP o
nor CC o
AMF NNP o
improved VBD o
( ( o
P NNP o
> NNP o
0.10 CD o
) ) o
carcass NN o
characteristics NNS o
compared VBN o
with IN o
control NN o
or CC o
non-feed-supplemented JJ o
steers NNS o
. . o

Addition NN o
of IN i
LEV NNP i
to TO N
high-concentrate NN N
, , N
corn-based JJ N
diets NNS o
did VBD o
not RB o
improve VB o
( ( o
P NNP o
> NNP o
0.10 CD o
) ) o
growth NN o
performance NN o
of IN o
feedlot NN o
steers NNS o
. . o

However RB o
, , N
addition NN i
of IN i
AMF NNP i
to TO N
a DT N
diet JJ N
composed VBN N
of IN N
dry JJ N
whole-shelled JJ N
corn NN N
resulted VBD N
in IN N
an DT o
improvement NN o
( ( o
P NNP o
< NNP o
0.05 CD o
) ) o
in IN o
G NNP o
: : o
F NNP o
( ( N
0.208 CD N
vs. FW N
0.194 CD N
) ) N
. . N

Results VB N
indicate JJ N
that WDT N
at IN N
the DT N
amounts NNS N
fed VBN N
, , N
AMF NNP i
may MD N
improve VB o
G NNP o
: : o
F NNP o
for IN N
lambs NN p
and CC p
steers NNS p
fed VBP p
dry JJ N
corn-based JJ N
finishing VBG N
diets NNS N
. . N

-DOCSTART- -11815321- O O

Marginal NNP N
biotin NN N
deficiency NN N
during IN N
normal JJ p
pregnancy NN p
. . p

BACKGROUND NNP N
Biotin NNP N
deficiency NN N
is VBZ N
teratogenic JJ N
in IN N
several JJ p
mammalian JJ p
species NNS p
. . p

Approximately RB N
50 CD N
% NN N
of IN N
pregnant JJ p
women NNS p
have VBP N
an DT N
abnormally RB N
increased JJ N
urinary JJ N
excretion NN N
of IN N
3-hydroxyisovaleric JJ o
acid NN o
( ( o
3-HIA JJ o
) ) o
, , N
which WDT N
probably RB N
reflects VBZ N
decreased JJ N
activity NN N
of IN N
the DT N
biotin-dependent JJ N
enzyme JJ N
methylcrotonyl-CoA JJ N
carboxylase NN N
. . N

However RB N
, , N
increased VBD N
3-HIA JJ N
excretion NN N
could MD N
result VB N
from IN N
pregnancy NN N
per IN N
se NN N
( ( N
eg JJ N
, , N
from IN N
an DT N
effect NN N
of IN N
pregnancy NN N
on IN N
renal JJ N
handling NN N
of IN N
organic JJ N
acids NNS N
) ) N
. . N

OBJECTIVE IN N
We PRP N
tested VBD N
the DT N
hypothesis NN N
that WDT N
biotin VBZ N
supplementation NN N
significantly RB N
decreases VBZ N
3-HIA JJ N
excretion NN N
in IN N
pregnant JJ p
women NNS p
with IN p
abnormally RB p
increased VBN p
3-HIA JJ p
excretion NN p
. . p

DESIGN NNP N
Twenty-six NNP p
pregnant JJ p
women NNS p
with IN p
increased JJ p
3-HIA JJ p
excretion NN p
were VBD p
studied VBN p
in IN p
a DT p
randomized JJ p
, , p
placebo-controlled JJ i
trial NN p
; : p
10 CD N
women NNS N
were VBD N
studied VBN N
during IN N
early JJ N
pregnancy NN N
( ( N
6-17 JJ N
wk NN N
gestation NN N
) ) N
and CC N
16 CD N
women NNS N
during IN N
late JJ N
pregnancy NN N
( ( N
21-37 JJ N
wk NN N
gestation NN N
) ) N
. . N

Urine JJ o
samples NNS o
were VBD N
collected VBN N
before IN N
and CC N
after IN N
14 CD N
d NN N
of IN N
supplementation NN N
with IN N
300 CD i
microg NNS i
( ( i
1.2 CD i
micromol NN i
) ) i
biotin/d NN i
or CC i
placebo NN i
. . i

RESULTS NNP N
In IN N
the DT N
early-pregnancy NN N
group NN N
, , N
3-HIA JJ o
excretion NN o
decreased VBN N
( ( N
P NNP N
< NNP N
0.006 CD N
) ) N
by IN N
11.7 CD N
+/- JJ N
3.6 CD N
mmol/mol NN N
creatinine NN N
( ( N
mean JJ N
+/- NNP N
SEM NNP N
) ) N
in IN N
the DT N
5 CD N
women NNS N
who WP N
received VBD N
biotin NN N
supplements NNS N
, , N
whereas IN N
3-HIA JJ o
excretion NN o
increased VBN N
by IN N
1.6 CD N
+/- JJ N
0.6 CD N
mmol/mol JJ N
creatinine NN N
in IN N
the DT N
5 CD N
women NNS N
who WP N
received VBD N
placebo NN N
. . N

In IN N
the DT N
late-pregnancy NN N
group NN N
, , N
3-HIA JJ o
excretion NN o
decreased VBN N
( ( N
P NNP N
< NNP N
0.002 CD N
) ) N
by IN N
7.1 CD N
+/- JJ N
1.2 CD N
mmol/mol JJ N
creatinine NN N
in IN N
the DT N
8 CD N
women NNS N
who WP N
received VBD N
biotin NN N
supplements NNS N
, , N
whereas IN N
3-HIA JJ o
excretion NN o
increased VBN N
by IN N
0.9 CD N
+/- JJ N
1.8 CD N
mmol/mol JJ N
creatinine NN N
in IN N
the DT N
8 CD N
women NNS N
who WP N
received VBD N
placebo NN N
. . N

CONCLUSIONS VB N
This DT N
study NN N
provides VBZ N
evidence NN N
that IN N
the DT N
increased JJ N
excretion NN o
of IN o
3-HIA JJ o
seen VBN N
frequently RB N
in IN N
normal JJ p
pregnancy NN p
reflects VBZ N
reduced VBN N
biotin JJ o
status NN o
. . o

The DT N
conclusion NN N
that IN N
marginal JJ N
biotin NN N
deficiency NN N
occurs VBZ N
frequently RB N
in IN N
the DT N
first JJ N
trimester NN N
further RBR N
raises NNS N
concern NN N
about IN N
potential JJ N
human JJ N
teratogenicity NN N
. . N

-DOCSTART- -10203382- O O

Predictors NNS N
of IN N
survival NN N
and CC N
eradication NN N
of IN N
Mycobacterium NNP N
avium NN N
complex NN N
bacteremia NN N
( ( N
MAC NNP N
) ) N
in IN p
AIDS NNP p
patients NNS p
in IN p
the DT p
Canadian NNP p
randomized VBD p
MAC NNP p
treatment NN p
trial NN p
. . p

Canadian JJ N
HIV NNP N
Trials NNP N
Network NNP N
Protocol NNP N
010 CD N
Study NNP N
Group NNP N
. . N

OBJECTIVE NNP N
To TO N
assess VB N
the DT N
importance NN N
of IN N
baseline NN N
characteristics NNS N
including VBG N
medical JJ o
history NN o
, , o
indicators NNS o
of IN o
current JJ o
disease NN o
status NN o
, , o
therapeutic JJ o
drug NN o
use NN o
, , o
in IN o
vitro JJ o
drug NN o
susceptibility NN o
, , o
immune JJ o
status NN o
and CC o
mycobacterial JJ o
load NN o
on IN o
bacteriologic JJ o
response NN o
and CC N
survival NN o
in IN N
HIV-positive JJ p
patients NNS p
with IN p
Mycobacterium NNP p
avium NN p
complex NN p
( ( p
MAC NNP p
) ) p
bacteremia NN p
. . p

DESIGN NNP N
An DT N
observational JJ N
substudy NN N
of IN N
an DT N
open-label JJ N
randomized NN N
controlled VBD N
trial NN N
of IN N
two CD i
alternative JJ i
therapeutic JJ i
regimens NNS i
for IN i
MAC NNP i
. . i

SETTING NNP N
Twenty-four JJ p
hospital-based JJ p
HIV NNP p
clinics NNS p
in IN p
16 CD p
Canadian JJ p
cities NNS p
. . p

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
The DT N
main JJ N
outcome NN N
measures NNS N
were VBD N
survival JJ o
and CC o
bacteriologic JJ o
response NN o
, , o
defined VBN o
by IN o
consecutive JJ o
negative JJ o
blood NN o
cultures NNS o
for IN o
MAC NNP o
at IN N
least JJS N
2 CD N
weeks NNS N
apart RB N
within IN N
16 CD N
weeks NNS N
of IN N
study NN N
entry NN N
. . N

RESULTS NNP N
Prior NNP N
AIDS NNP N
diagnosis NN N
, , N
low JJ N
Karnofsky NNP N
score NN N
, , N
active JJ N
unstable JJ N
AIDS-related JJ N
conditions NNS N
, , N
absence NN N
of IN N
antiretroviral JJ N
therapy NN N
and CC N
absence NN N
of IN N
Pneumocystis NNP N
carinii NN N
pneumonia NN N
prophylaxis NN N
were VBD N
associated VBN N
with IN N
shorter JJR N
survival NN o
by IN N
univariate JJ N
regression NN N
using VBG N
the DT N
proportional JJ N
hazards NNS N
model NN N
. . N

On IN N
multivariate NN N
analysis NN N
, , N
antiretroviral JJ N
therapy NN N
was VBD N
not RB N
an DT N
independent JJ N
predictor NN N
of IN N
mortality NN o
, , N
and CC N
previous JJ N
rifabutin NN N
prophylaxis NN N
was VBD N
independently RB N
associated VBN N
with IN N
poor JJ N
survival NN N
outcomes NNS N
, , N
a DT N
result NN N
consistent JJ N
across IN N
study NN N
treatment NN N
. . N

Using VBG N
a DT N
logistic JJ N
regression NN N
model NN N
, , N
baseline JJ o
quantitative JJ o
mycobacterial JJ o
load NN o
[ NNP N
relative JJ N
odds NNS N
of IN N
clearing NN N
, , N
1.97 CD N
for IN N
a DT N
decrease NN N
of IN N
1 CD N
log10 JJ N
colony NN N
forming VBG N
count NN N
; : N
95 CD N
% NN N
confidence NN N
interval NN N
( ( N
CI NNP N
) ) N
, , N
1.36-2.87 JJ N
; : N
P NNP N
< VBD N
0.001 CD N
] NN N
and CC N
Karnofsky NNP o
score NN o
were VBD N
the DT N
only JJ N
statistically RB N
significant JJ N
univariate JJ N
predictors NNS N
of IN N
clearance NN N
, , N
although IN N
previous JJ N
prophylaxis NN N
with IN N
rifabutin NN N
was VBD N
also RB N
a DT N
significant JJ N
predictor NN N
in IN N
a DT N
multivariate NN o
model NN o
( ( N
relative JJ N
odds NNS N
of IN N
clearing NN N
, , N
0.39 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
0.17-0.88 NNP N
; : N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

CONCLUSIONS VB N
This DT N
study NN N
indicates VBZ N
that IN N
although IN N
the DT N
level NN N
of IN N
MAC NNP N
bacteremia NN N
is VBZ N
an DT N
important JJ N
predictor NN N
of IN N
clearance NN N
, , N
it PRP N
is VBZ N
not RB N
associated VBN N
with IN N
survival NN N
. . N

-DOCSTART- -15733631- O O

Is VBZ N
successful JJ N
rehabilitation NN N
of IN N
complex JJ p
regional JJ p
pain NN p
syndrome NN p
due JJ N
to TO N
sustained JJ N
attention NN N
to TO N
the DT N
affected JJ N
limb NN N
? . N
A DT N
randomised JJ N
clinical JJ N
trial NN N
. . N

In IN N
complex JJ N
regional JJ N
pain NN N
syndrome NN N
( ( N
CRPS1 NNP N
) ) N
initiated VBN N
by IN N
wrist JJ N
fracture NN N
, , N
a DT N
motor NN i
imagery NN i
program NN i
( ( N
MIP NNP N
) ) N
, , N
consisting VBG N
of IN N
hand NN N
laterality NN N
recognition NN N
followed VBN N
by IN N
imagined JJ i
movements NNS i
and CC N
then RB N
mirror NN i
movements NNS i
, , N
reduces NNS N
pain VBP o
and CC o
disability NN o
, , N
but CC N
the DT N
mechanism NN N
of IN N
effect NN N
is VBZ N
unclear JJ N
. . N

Possibilities NNS N
include VBP N
sustained JJ N
attention NN N
to TO N
the DT N
affected JJ N
limb NN N
, , N
in IN N
which WDT N
case NN N
the DT N
order NN N
of IN N
MIP NNP N
components NNS N
would MD N
not RB N
alter VB N
the DT N
effect NN N
, , N
and CC N
sequential JJ N
activation NN N
of IN N
cortical JJ N
motor NN N
networks NNS N
, , N
in IN N
which WDT N
case NN N
it PRP N
would MD N
. . N

Twenty VB p
subjects NNS p
with IN p
chronic JJ p
CRPS1 NNP p
initiated VBN p
by IN p
wrist JJ p
fracture NN p
and CC p
who WP p
satisfied VBD p
stringent JJ p
inclusion NN p
criteria NNS p
, , N
were VBD N
randomly RB N
allocated VBN N
to TO N
one CD N
of IN N
three CD N
groups NNS N
: : N
hand NN i
laterality NN i
recognition NN i
, , i
imagined VBD i
movements NNS i
, , i
mirror NN i
movements NNS i
( ( i
RecImMir NNP i
, , i
MIP NNP i
) ) i
; : i
imagined VBN i
movements NNS i
, , i
recognition NN i
, , i
imagined VBD i
movements NNS i
( ( i
ImRecIm NNP i
) ) i
; : i
recognition NN i
, , i
mirror NN i
movements NNS i
, , i
recognition NN i
( ( i
RecMirRec NNP i
) ) i
. . i

At IN N
6 CD N
and CC N
18 CD N
weeks NNS N
, , N
reduced VBD N
pain NN o
and CC o
disability NN o
were VBD N
greater JJR N
for IN N
the DT N
RecImMir NNP N
group NN N
than IN N
for IN N
the DT N
other JJ N
groups NNS N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

Hand NNP N
laterality NN N
recognition NN N
imparted VBD N
a DT N
consistent JJ N
reduction NN N
in IN N
pain NN o
and CC o
disability NN o
across IN N
groups NNS N
, , N
however RB N
, , N
this DT N
effect NN N
was VBD N
limited VBN N
in IN N
magnitude NN N
. . N

Imagined VBD N
movements NNS N
imparted VBD N
a DT N
further JJ N
reduction NN N
in IN N
pain NN o
and CC o
disability NN o
, , N
but CC N
only RB N
if IN N
they PRP N
followed VBD N
hand NN N
laterality NN N
recognition NN N
. . N

Mirror NN N
movements NNS N
also RB N
imparted VBD N
a DT N
reduction NN N
in IN N
pain NN o
and CC o
disability NN o
, , N
but CC N
only RB N
when WRB N
they PRP N
followed VBD N
imagined JJ N
movements NNS N
. . N

The DT N
effect NN o
of IN N
the DT N
MIP NNP N
seems VBZ N
to TO N
be VB N
dependent JJ N
on IN N
the DT N
order NN N
of IN N
components NNS N
, , N
which WDT N
suggests VBZ N
that IN N
it PRP N
is VBZ N
not RB N
due JJ N
to TO N
sustained JJ N
attention NN N
to TO N
the DT N
affected JJ N
limb NN N
, , N
but CC N
is VBZ N
consistent JJ N
with IN N
sequential JJ N
activation NN N
of IN N
cortical JJ N
motor NN N
networks NNS N
. . N

-DOCSTART- -17715164- O O

Anti-inflammatory JJ o
effects NNS o
of IN N
inhaled JJ i
carbon NN i
monoxide NN i
in IN N
patients NNS p
with IN p
COPD NNP p
: : p
a DT N
pilot NN N
study NN N
. . N

In IN N
vitro NN N
and CC N
in IN N
vivo JJ N
studies NNS N
have VBP N
shown VBN N
that IN N
carbon NN i
monoxide NN i
( ( N
CO NNP N
) ) N
has VBZ N
both DT N
anti-inflammatory JJ N
and CC N
anti-oxidant JJ N
capacities NNS N
. . N

Since IN N
chronic JJ N
obstructive JJ N
pulmonary JJ N
disease NN N
( ( N
COPD NNP N
) ) N
is VBZ N
characterised VBN N
by IN N
inflammation NN N
and CC N
oxidative JJ N
stress NN N
, , N
low-dose JJ i
CO NNP i
could MD N
be VB N
of IN N
therapeutic JJ N
use NN N
. . N

The DT N
aim NN N
of IN N
the DT N
present JJ N
study NN N
was VBD N
to TO N
investigate VB N
the DT N
feasibility NN o
and CC o
anti-inflammatory JJ o
effects NNS o
of IN N
100-125 JJ N
ppm NN N
CO NNP i
inhalation NN i
in IN N
patients NNS p
with IN p
stable JJ p
COPD NNP p
. . p

In IN N
total JJ N
, , N
20 CD p
ex-smoking JJ p
COPD NNP p
patients NNS p
with IN p
post-bronchodilator NN p
forced JJ p
expiratory NN p
volume NN p
in IN p
one CD p
second NN p
( ( p
FEV NNP p
( ( p
1 CD p
) ) p
) ) p
> $ p
1.20 CD p
L NNP p
and CC p
FEV NNP p
( ( p
1 CD p
) ) p
/forced VBD p
vital JJ p
capacity NN p
< VBP p
70 CD p
% NN p
were VBD N
enrolled VBN N
in IN N
a DT N
randomised JJ N
, , N
placebo-controlled JJ i
, , N
crossover NN N
study NN N
. . N

Effects NNS o
on IN o
inflammation NN o
were VBD N
measured VBN N
in IN N
induced JJ o
sputum NN o
and CC o
blood NN o
. . o

CO NNP o
inhalation NN o
was VBD N
feasible JJ o
and CC N
patients NNS o
' POS o
vital JJ o
signs NNS o
were VBD N
unaffected VBN N
; : N
2 CD N
h.day NN N
( ( N
-1 NNP N
) ) N
inhalation NN N
of IN N
low-dose JJ N
CO NNP N
on IN N
4 CD N
consecutive JJ N
days NNS N
led VBD N
to TO N
a DT N
maximal JJ N
individual JJ N
carboxyhaemoglobin NN o
level NN o
of IN N
4.5 CD N
% NN N
. . N

Two CD N
exacerbations NNS o
occurred VBD N
in IN N
the DT N
CO NNP N
period NN N
. . N

CO NNP N
inhalation NN N
led VBD N
to TO N
trends NNS N
in IN N
reduced JJ o
sputum NN o
eosinophils NNS o
( ( N
median JJ N
reduction NN N
0.25 CD N
% NN N
point NN N
) ) N
and CC N
improved JJ o
responsiveness NN o
to TO o
methacholine VB o
( ( N
median JJ N
provocative NN N
concentration NN N
causing VBG N
a DT N
20 CD N
% NN N
fall NN N
in IN N
FEV NNP N
( ( N
1 CD N
) ) N
0.85 CD N
versus $ N
0.63 CD N
mg.mL NN N
( ( N
-1 NNP N
) ) N
) ) N
. . N

Inhalation NN N
of IN N
100-125 JJ N
ppm NN N
carbon NN i
monoxide NN i
by IN N
patients NNS p
with IN p
chronic JJ p
obstructive JJ p
pulmonary JJ p
disease NN p
in IN p
a DT p
stable JJ p
phase NN p
was VBD N
feasible JJ N
and CC N
led VBD N
to TO N
trends NNS N
in IN N
reduction NN N
of IN N
sputum NN N
eosinophils NNS N
and CC N
improvement NN o
of IN o
responsiveness NN o
to TO o
methacholine VB o
. . o

Further NNP N
studies NNS N
need VBP N
to TO N
confirm VB N
the DT N
safety NN o
and CC o
efficacy NN o
in IN N
inflammatory JJ p
lung NN p
diseases NNS p
. . p

-DOCSTART- -3342655- O O

The DT N
effects NNS N
of IN N
hypoxemia NN p
on IN N
cardiac JJ N
output NN N
. . N

A DT N
dose-response JJ N
curve NN N
. . N

To TO N
establish VB N
a DT N
dose-response JJ N
curve NN N
for IN N
the DT N
effects NNS N
of IN N
isocapnic JJ N
hypoxemia NN N
on IN N
cardiac JJ o
output NN o
( ( o
CO NNP o
) ) o
, , N
we PRP p
studied VBD p
20 CD p
healthy JJ p
men NNS p
, , p
aged VBD p
20 CD p
to TO p
34 CD p
years NNS p
, , p
using VBG p
a DT p
tight-fitting JJ i
face NN i
mask NN i
and CC i
an DT i
isocapnic JJ i
partial NN i
rebreathing NN i
system NN i
( ( p
a DT p
modified VBN p
anesthesia NN p
machine NN p
) ) p
. . N

We PRP N
blended VBD N
oxygen NN i
and CC i
hypoxic NN i
gas NN i
to TO N
achieve VB N
arterial JJ i
oxygen NN i
saturations NNS i
( ( i
SaO2 NNP i
) ) i
of IN N
80 CD N
, , N
85 CD N
, , N
and CC N
90 CD N
percent NN N
; : N
subjects NNS N
also RB N
breathed VBD N
100 CD i
percent NN i
oxygen NN i
and CC N
room NN i
air NN i
( ( N
RA NNP N
) ) N
. . N

Target NNP N
SaO2 NNP N
and CC N
end-tidal JJ N
carbon NN N
dioxide NN N
were VBD N
continuously RB N
monitored VBN N
using VBG N
an DT N
ear JJ N
oximeter NN N
and CC N
CO2 NNP N
gas NN N
analyzer NN N
. . N

Subjects NNS N
experienced VBD N
the DT N
five CD N
SaO2 NNP N
measurements NNS N
in IN N
random JJ N
order NN N
. . N

CO NNP o
was VBD N
measured VBN N
noninvasively RB N
at IN N
approximately RB N
two-minute JJ N
intervals NNS N
, , N
using VBG N
continuous-wave JJ N
Doppler NNP N
echocardiography NN N
. . N

Mean NNP o
cardiac JJ o
output NN o
increased VBD N
with IN N
increasing VBG N
hypoxemia NN o
from IN N
6.84 CD N
L/min NNP N
at IN N
FIo2 NNP N
1.0 CD N
to TO N
8.44 CD N
L/min NNP N
at IN N
SaO2 NNP N
80 CD N
percent NN N
( ( N
p NN N
less JJR N
than IN N
0.0005 CD N
) ) N
; : N
the DT N
increase NN N
was VBD N
entirely RB N
due JJ N
to TO N
increased JJ N
heart NN o
rate NN o
. . o

We PRP N
concluded VBD N
that IN N
cardiac JJ o
output NN o
increases NNS N
significantly RB N
in IN N
a DT N
dose-response JJ N
manner NN N
in IN N
response NN N
to TO N
acute VB N
isocapnic JJ N
hypoxemia NN N
in IN N
normal JJ N
persons NNS N
. . N

-DOCSTART- -14715180- O O

Azimilide NNP i
decreases VBZ N
recurrent JJ o
ventricular JJ o
tachyarrhythmias NN o
in IN N
patients NNS p
with IN p
implantable JJ p
cardioverter NN p
defibrillators NNS p
. . p

OBJECTIVES VB N
This DT N
study NN N
evaluated VBD N
the DT N
effects NNS N
of IN N
azimilide JJ i
dihydrochloride NN i
( ( i
AZ NNP i
) ) i
on IN N
anti-tachycardia JJ o
pacing NN o
( ( o
ATP NNP o
) ) o
and CC N
shock-terminated JJ o
events NNS o
in IN N
patients NNS p
with IN p
implantable JJ p
cardioverter NN p
defibrillators NNS p
( ( p
ICDs NNP p
) ) p
. . p

BACKGROUND NNP N
Animal NNP N
studies NNS N
have VBP N
shown VBN N
the DT N
effectiveness NN N
of IN N
AZ NNP N
for IN N
therapy NN N
of IN N
supraventricular JJ N
and CC N
ventricular JJ N
tachycardia NN N
( ( N
VT NNP N
) ) N
. . N

Azimilide NNP i
dihydrochloride NN i
was VBD N
investigated VBN N
as IN N
adjunctive JJ N
treatment NN N
for IN N
reducing VBG N
the DT N
frequency NN N
of IN N
VT NNP N
and CC N
, , N
thus RB N
, , N
the DT N
need NN N
for IN N
ICD NNP N
therapies NNS N
, , N
including VBG N
ATP NNP N
and CC N
cardioversion/defibrillation NN N
( ( N
ICD NNP N
shocks NNS N
) ) N
in IN N
patients NNS N
with IN N
inducible JJ N
monomorphic JJ N
VT. NNP N
METHODS NNP N
A NNP N
total NN N
of IN N
172 CD p
patients NNS p
were VBD N
randomized VBN N
to TO N
daily VB N
treatment NN N
with IN N
placebo NN i
, , N
35 CD N
mg NN N
, , N
75 CD N
mg NN N
, , N
or CC N
125 CD N
mg NN N
of IN N
oral JJ i
AZ NNP i
in IN N
this DT N
dose-ranging JJ N
pilot NN N
study NN N
of IN N
patients NNS p
with IN p
ICDs NNP p
. . p

The DT p
majority NN p
of IN p
patients NNS p
had VBD p
a DT p
history NN p
of IN p
documented JJ p
remote JJ p
myocardial JJ p
infarction NN p
and CC p
congestive JJ p
heart NN p
failure NN p
New NNP p
York NNP p
Heart NNP p
Association NNP p
class NN p
II NNP p
or CC p
III NNP p
. . p

RESULTS VB N
The DT N
frequency NN o
of IN o
appropriate JJ o
shocks NNS o
and CC o
ATP NNP o
were VBD N
significantly RB N
decreased VBN N
among IN N
AZ-treated JJ N
patients NNS N
compared VBN N
with IN N
placebo NN N
patients NNS N
. . N

The DT N
incidence NN o
of IN o
ICD NNP o
therapies NNS o
per IN o
patient-year NN o
among IN N
the DT N
placebo NN N
group NN N
was VBD N
36 CD N
, , N
and CC N
it PRP N
was VBD N
10 CD N
, , N
12 CD N
, , N
and CC N
9 CD N
among IN N
35 CD N
mg NNS N
, , N
75 CD N
mg NN N
, , N
and CC N
125 CD N
mg NNS N
AZ NNP N
patients NNS N
, , N
respectively RB N
( ( N
hazard JJ N
ratio NN N
= VBD N
0.31 CD N
, , N
p NN N
= NNP N
0.0001 CD N
) ) N
. . N

Azimilide NNP N
dihydrochloride NN N
was VBD N
generally RB N
well RB o
tolerated VBN o
and CC N
did VBD N
not RB N
affect VB o
left VBD o
ventricular JJ o
ejection NN o
fraction NN o
or CC o
minimal JJ o
energy NN o
requirements NNS o
for IN o
defibrillation NN o
or CC o
pacing NN o
. . o

CONCLUSIONS NNP N
Azimilide NNP i
dihydrochloride NN i
may MD N
be VB N
a DT N
safe JJ N
and CC N
effective JJ N
drug NN N
for IN N
reducing VBG N
the DT N
frequency NN o
of IN o
VT NNP o
and CC o
ventricular JJ o
fibrillation NN o
in IN N
patients NNS N
with IN N
implanted JJ N
ICDs NNP N
. . N

-DOCSTART- -4818631- O O

[ JJ o
Folic NNP o
acid NN o
deficiency NN o
in IN N
pregnant JJ p
women NNS p
in IN p
Switzerland NNP p
] NNP p
. . N

-DOCSTART- -15956086- O O

Acute NNP N
pressor NN N
and CC N
hormonal JJ N
effects NNS N
of IN N
beta-endorphin NN i
at IN N
high JJ N
doses NNS N
in IN N
healthy JJ p
and CC p
hypertensive JJ p
subjects NNS p
: : p
role NN N
of IN N
opioid JJ N
receptor NN N
agonism NN N
. . N

CONTEXT VB N
The DT N
opioid NN N
system NN N
is VBZ N
involved VBN N
in IN N
blood NN N
pressure NN N
regulation NN N
in IN N
both DT N
normal JJ p
humans NNS p
and CC p
patients NNS p
with IN p
essential JJ p
hypertension NN p
. . p

OBJECTIVE CC N
The DT N
objective NN N
of IN N
the DT N
study NN N
was VBD N
to TO N
investigate VB N
the DT N
effects NNS N
of IN N
a DT N
high-dose JJ N
infusion NN N
of IN N
beta-endorphin NN i
, , N
an DT N
opioid JJ N
peptide NN N
, , N
on IN N
blood NN N
pressure NN N
and CC N
on IN N
the DT N
hormonal JJ N
profile NN N
in IN N
healthy JJ p
subjects NNS p
and CC p
in IN p
hypertensive JJ p
patients NNS p
and CC N
the DT N
mediation NN N
played VBN N
by IN N
opioid JJ N
receptor NN N
agonism NN N
. . N

DESIGN NNP N
, , N
SETTING NNP N
, , N
AND NNP N
PARTICIPANTS NNP N
According VBG N
to TO N
a DT N
randomized VBN N
double-blind NN N
design NN N
, , N
11 CD p
healthy JJ p
subjects NNS p
( ( p
controls NNS p
) ) p
and CC p
12 CD p
hypertensive JJ p
inpatients NNS p
( ( p
mean JJ p
age NN p
, , p
38.9 CD p
and CC p
40.4 CD p
yr NN p
, , p
respectively RB p
) ) p
received VBD N
1-h JJ i
iv JJ i
infusion NN i
of IN i
beta-endorphin JJ i
( ( i
250 CD i
mug/h NN i
) ) i
and CC i
, , i
on IN i
another DT i
occasion NN i
, , i
the DT i
same JJ i
infusion NN i
protocol NN i
preceded VBN i
by IN i
the DT i
opioid JJ i
antagonist NN i
naloxone NN i
( ( i
8 CD i
mg NN i
) ) i
. . i

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
Hemodynamic NNP o
and CC o
hormonal JJ o
measurements NNS o
were VBD N
performed VBN N
at IN N
established VBN N
times NNS N
during IN N
the DT N
infusion NN N
protocols NNS N
. . N

RESULTS NNP N
At IN N
baseline NN N
, , N
circulating VBG o
beta-endorphin JJ o
, , o
norepinephrine JJ o
, , o
and CC o
endothelin-1 NN o
in IN N
hypertensive JJ N
patients NNS N
were VBD N
significantly RB N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
higher JJR N
than IN N
in IN N
controls NNS N
. . N

In IN N
controls NNS N
, , N
beta-endorphin JJ N
reduced VBD N
blood NN o
pressure NN o
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
and CC N
circulating VBG o
norepinephrine NN o
( ( N
P NNP N
< NNP N
0.02 CD N
) ) N
and CC N
increased VBD N
plasma JJ o
atrial JJ o
natriuretic JJ o
factor NN o
( ( N
P NNP N
< NNP N
0.003 CD N
) ) N
and CC N
GH NNP N
( ( N
P NNP N
< NNP N
0.0001 CD N
) ) N
. . N

In IN N
hypertensive JJ N
patients NNS N
, , N
beta-endorphin JJ i
decreased JJ N
systemic JJ o
vascular NN o
resistance NN o
( ( N
P NNP N
< NNP N
0.0001 CD N
) ) N
, , N
blood NN o
pressure NN o
( ( N
P NNP N
< NNP N
0.0001 CD N
) ) N
, , N
and CC N
plasma JJ o
norepinephrine NN o
( ( N
P NNP N
< NNP N
0.0001 CD N
) ) N
and CC N
endothelin-1 JJ o
( ( N
P NNP N
< NNP N
0.0001 CD N
) ) N
and CC N
raised VBD N
circulating VBG o
atrial JJ o
natriuretic JJ o
factor NN o
( ( N
P NNP N
< NNP N
0.0001 CD N
) ) N
, , N
GH NNP o
( ( N
P NNP N
< NNP N
0.0001 CD N
) ) N
, , N
and CC N
IGF-I NNP o
( ( N
P NNP N
< NNP N
0.0001 CD N
) ) N
. . N

These DT N
hemodynamic JJ o
and CC o
hormonal JJ o
responses NNS o
to TO N
beta-endorphin JJ N
in IN N
hypertensive JJ N
patients NNS N
were VBD N
significantly RB N
( ( N
P NNP N
< NNP N
0.0001 CD N
) ) N
greater JJR N
than IN N
in IN N
controls NNS N
but CC N
were VBD N
annulled VBN N
in IN N
all DT N
individuals NNS N
when WRB N
naloxone NN N
preceded VBD N
beta-endorphin JJ N
infusion NN N
. . N

CONCLUSIONS NNP N
High NNP N
doses NNS N
of IN N
beta-endorphin JJ i
induce NN N
hypotensive NN N
and CC N
beneficial JJ N
hormonal JJ N
effects NNS N
in IN N
humans NNS N
, , N
which WDT N
are VBP N
enhanced VBN N
in IN N
essential JJ N
hypertension NN N
and CC N
are VBP N
mediated VBN N
by IN N
opioid JJ N
receptors NNS N
. . N

-DOCSTART- -22690882- O O

Effectiveness NN N
of IN N
web-based JJ i
tailored JJ i
smoking NN i
cessation NN i
advice NN p
reports NNS p
( ( N
iQuit NN N
) ) N
: : N
a DT N
randomized JJ N
trial NN N
. . N

AIMS NNP N
To TO N
determine VB N
whether IN N
web-based JJ N
tailored JJ N
cessation NN N
advice NN N
, , N
based VBN N
on IN N
social JJ N
cognitive JJ N
theory NN N
and CC N
the DT N
perspectives NNS N
on IN N
change NN N
model NN N
, , N
was VBD N
more RBR N
effective JJ N
in IN N
aiding VBG N
a DT N
quit NN N
attempt NN N
than IN N
broadly RB N
similar JJ N
web-based JJ N
advice NN N
that WDT N
was VBD N
not RB N
tailored VBN N
. . N

DESIGN JJ N
Participants NNS p
were VBD p
allocated VBN p
randomly RB p
to TO p
one CD p
of IN p
two CD p
groups NNS p
, , N
to TO i
receive VB i
either CC i
a DT i
cessation NN i
advice NN i
report NN i
and CC i
progress JJ i
report NN i
that WDT i
were VBD i
tailored VBN i
to TO i
individual-level JJ i
characteristics NNS i
or CC i
a DT i
cessation NN i
advice NN i
report NN i
that WDT i
presented VBD i
standardized JJ i
( ( i
non-tailored JJ i
) ) i
content NN i
. . i

Tailoring NNP N
was VBD N
based VBN N
on IN N
smoking-related JJ N
beliefs NN N
, , N
personal JJ N
characteristics NNS N
and CC N
smoking NN N
patterns NNS N
, , N
self-efficacy NN N
and CC N
outcome JJ N
expectations NNS N
. . N

SETTING NN N
Participant JJ N
enrolment NN N
and CC N
baseline NN i
assessments NNS i
were VBD N
conducted VBN N
remotely RB N
online JJ N
via IN N
the DT N
study NN N
website NN N
, , N
with IN N
the DT N
advice NN N
reports NNS N
presented VBN N
by IN N
the DT N
same JJ N
website NN N
. . N

PARTICIPANTS JJ N
Participants NNS p
( ( p
n IN p
= NNP p
1758 CD p
) ) p
were VBD p
visitors NNS p
to TO p
the DT p
QUIT NNP p
website NN p
who WP p
were VBD p
based VBN p
in IN p
the DT p
United NNP p
Kingdom NNP p
, , p
aged VBD p
18 CD p
years NNS p
or CC p
over RB p
and CC p
who WP p
smoked VBD p
cigarettes NNS p
or CC p
hand-rolled JJ p
tobacco NN p
. . p

MEASUREMENTS NNP p
Follow-up JJ N
assessments NNS N
were VBD N
made VBN N
at IN N
6 CD N
months NNS N
by IN N
telephone NN N
interview NN N
. . N

The DT N
primary JJ N
outcome NN N
measure NN N
was VBD N
self-reported JJ o
3 CD o
months NNS o
prolonged VBN o
abstinence NN o
, , o
and CC o
secondary JJ N
outcomes NNS N
were VBD N
1 CD o
month NN o
prolonged VBD o
abstinence NN o
, , o
7-day JJ o
and CC o
24-hour JJ o
point NN o
prevalence NN o
abstinence NN o
. . o

FINDINGS IN o
The DT N
intervention NN p
group NN p
did VBD p
not RB N
differ VB N
from IN N
the DT N
control NN p
group NN p
on IN p
the DT N
primary JJ o
outcome NN o
( ( o
9.1 CD o
% NN N
versus IN N
9.3 CD N
% NN N
; : N
odds NNS N
ratio VBP N
= $ N
1.02 CD N
95 CD N
% NN N
confidence NN N
interval JJ N
0.73-1.42 NN N
) ) N
or CC N
on IN N
any DT N
of IN N
the DT o
secondary JJ o
outcomes NNS o
. . o

Intervention NN o
participants NNS p
gave VBD p
more RBR p
positive JJ N
evaluations NNS N
of IN N
the DT N
materials NNS p
than IN p
control NN p
participants NNS p
. . p

CONCLUSIONS VB p
A DT N
web-based JJ N
intervention NN N
that WDT N
tailored VBD N
content JJ N
according VBG N
to TO N
smoking-related JJ N
beliefs NN N
, , N
personal JJ N
characteristics NNS N
and CC N
smoking NN N
patterns NNS N
, , N
self-efficacy NN N
and CC N
outcome NN N
expectations NNS N
, , N
was VBD N
not RB N
more RBR N
effective JJ N
than IN N
web-based JJ N
materials NNS N
presenting VBG N
broadly RB N
similar JJ N
non-tailored JJ N
information NN N
. . N

-DOCSTART- -1319876- O O

Effects NNS N
of IN N
temafloxacin NN i
and CC N
ciprofloxacin NN i
on IN N
the DT N
pharmacokinetics NNS N
of IN N
caffeine NN N
. . N

A DT N
number NN N
of IN N
quinolone JJ N
antibacterial JJ N
agents NNS N
, , N
particularly RB N
enoxacin NN N
, , N
pefloxacin NN N
, , N
pipemidic JJ N
acid NN N
and CC N
ciprofloxacin NN i
, , N
are VBP N
known VBN N
to TO N
decrease VB N
the DT N
clearance NN N
of IN N
methylxanthines NNS N
. . N

The DT N
effects NNS N
of IN N
temafloxacin NN i
and CC i
ciprofloxacin NN i
on IN N
the DT N
pharmacokinetics NNS N
of IN N
caffeine NN N
were VBD N
therefore RB N
compared VBN N
in IN N
a DT N
3-way JJ N
crossover NN N
study NN N
in IN N
12 CD p
healthy JJ p
young JJ p
volunteers NNS p
. . p

Each DT N
volunteer NN N
received VBD N
183mg CD i
once-daily JJ i
doses NNS i
of IN i
caffeine NN i
in IN N
conjunction NN N
with IN N
twice-daily JJ N
placebo NN i
, , i
temafloxacin CC i
600mg CD i
and CC i
ciprofloxacin VB i
750mg CD i
in IN N
3 CD N
separate JJ N
phases NNS N
according VBG N
to TO N
a DT N
randomised JJ N
sequence NN N
. . N

A DT N
doubling NN N
of IN N
the DT N
area NN o
under IN o
the DT o
plasma JJ o
concentration-time JJ o
curve NN o
( ( N
77.8 CD N
vs RB N
31.8 CD N
mg/L.h NN N
) ) N
and CC N
terminal-phase JJ o
half-life NN o
( ( N
9.7 CD N
vs RB N
4.5h CD N
) ) N
of IN N
caffeine NN i
were VBD N
observed VBN N
in IN N
the DT N
presence NN N
of IN N
ciprofloxacin NN N
. . N

The DT N
magnitude NN o
of IN o
the DT o
reduction NN o
in IN o
the DT o
intrinsic JJ o
clearance NN o
of IN o
caffeine NN o
produced VBN N
by IN N
ciprofloxacin NN i
was VBD N
greater JJR N
than IN N
that DT N
described VBN N
in IN N
the DT N
literature NN N
for IN N
ciprofloxacin NN i
and CC i
theophylline NN i
. . i

This DT N
may MD N
partly RB N
be VB N
explained VBN N
by IN N
intertrial JJ N
differences NNS N
in IN N
dosage NN N
and CC N
study NN N
design NN N
. . N

Coadministration NN N
of IN N
temafloxacin NN i
did VBD N
not RB N
have VB N
any DT N
effect NN N
on IN N
the DT N
pharmacokinetics NNS o
of IN o
caffeine NN o
, , N
confirming VBG N
results NNS N
of IN N
other JJ N
studies NNS N
suggesting VBG N
that IN N
this DT N
agent NN N
does VBZ N
not RB N
affect VB N
methylxanthine JJ o
clearance NN o
. . o

Accordingly RB N
, , N
it PRP N
appears VBZ N
that IN N
restriction NN N
of IN N
caffeine JJ N
intake NN N
during IN N
temafloxacin JJ i
therapy NN N
is VBZ N
not RB N
necessary JJ N
. . N

-DOCSTART- -15553821- O O

[ NN N
Study NNP N
on IN N
treatment NN N
of IN N
iron-deficiency NN N
anemia NN N
by IN N
shengxuening VBG i
] NNP i
. . N

OBJECTIVE NNP N
To TO N
observe VB N
the DT N
therapeutic JJ N
effect NN N
of IN N
shengxuening VBG i
( ( i
SXN NNP i
) ) i
in IN N
treating VBG N
iron-deficiency NN p
anemia NN p
( ( p
IDA NNP p
) ) p
and CC N
to TO N
explore VB N
its PRP$ N
molecular JJ N
mechanism NN N
on IN N
iron NN N
metabolism NN N
balance NN N
regulation NN N
. . N

METHODS NNP N
Patients NNPS p
with IN p
IDA NNP p
were VBD N
randomly RB N
divided VBN N
into IN N
the DT p
treated VBN p
group NN p
and CC p
the DT p
control NN i
group NN p
, , p
50 CD p
in IN p
each DT p
group NN p
. . p

They PRP N
were VBD N
treated VBN N
with IN N
SXN NNP i
( ( i
0.1 CD i
g NN i
, , i
three CD i
times NNS i
per IN i
day NN i
) ) i
and CC i
ferrous JJ i
gluconate NN i
( ( i
0.1 CD i
g NN i
, , i
three CD i
times NNS i
per IN i
day NN i
) ) i
respectively RB i
, , i
for IN i
30 CD i
days NNS i
. . i

Levels NNS o
of IN o
serum NN o
iron NN o
( ( o
Fe NNP o
) ) o
, , o
total JJ o
iron NN o
binding NN o
capacity NN o
( ( o
TIBC NNP o
) ) o
, , o
transferrin JJ o
saturation NN o
( ( o
TS NNP o
) ) o
, , o
serum JJ o
ferritin NN o
( ( o
SF NNP o
) ) o
, , o
transferrin NN o
( ( o
Tf NNP o
) ) o
, , o
soluble JJ o
transferrin NN o
receptor NN o
( ( o
sTfR NN o
) ) o
and CC o
blood NN o
routine JJ o
test NN o
, , o
as RB o
well RB o
as IN o
scoring NN o
of IN o
TCM NNP o
qi-blood JJ o
deficiency NN o
Syndrome NNP o
were VBD N
conducted VBN N
before IN N
and CC N
after IN N
treatment NN N
. . N

RESULTS VB N
The DT N
total JJ N
effective JJ N
rate NN N
in IN N
the DT N
treated JJ N
group NN N
reached VBD N
92 CD N
% NN N
, , N
it PRP N
was VBD N
shown VBN N
that IN N
SXN NNP N
could MD N
improve VB N
the DT N
iron NN o
metabolism NN o
, , o
increase NN o
levels NNS o
of IN o
Fe NNP o
, , o
TS NNP o
, , o
SF NNP o
and CC o
reduce VB o
levels NNS o
of IN o
TIBC NNP o
, , o
Tf NNP o
, , o
sTfR NN o
, , N
it PRP N
has VBZ N
obvious JJ N
effect NN N
in IN N
promoting VBG N
erythrocyte JJ N
generation NN N
and CC N
could MD N
promote VB N
formation NN N
of IN N
leucocytes NNS N
and CC N
platelets NNS N
. . N

The DT N
total JJ o
effective JJ o
rate NN o
in IN N
the DT N
control NN N
group NN N
was VBD N
32 CD N
% NN N
, , N
which WDT N
was VBD N
significantly RB N
lower JJR N
than IN N
that DT N
in IN N
the DT N
treated JJ N
group NN N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

CONCLUSION VB N
The DT N
effect NN N
of IN N
SXN NNP i
in IN N
treating VBG N
IDA NNP N
and CC N
qi-blood JJ N
deficiency NN N
Syndrome NNP N
is VBZ N
evident JJ N
, , N
it PRP N
could MD N
improve VB N
the DT N
iron NN N
metabolism NN N
, , N
increase NN N
levels NNS N
of IN N
Fe NNP N
, , N
TS NNP N
, , N
SF NNP N
and CC N
lower JJR N
levels NNS N
of IN N
TIBC NNP N
, , N
Tf NNP N
, , N
sTfR NN N
. . N

-DOCSTART- -18855271- O O

The DT N
effect NN N
of IN N
trandolapril NN i
and CC N
its PRP$ N
fixed-dose JJ N
combination NN N
with IN N
verapamil NN i
on IN N
circulating VBG N
adhesion NN N
molecules NNS N
levels NNS N
in IN N
hypertensive JJ p
patients NNS p
with IN p
type JJ p
2 CD p
diabetes NNS p
. . p

BACKGROUND NNP N
AND NNP N
AIM NNP N
Endothelial NNP N
dysfunction NN N
in IN N
hypertensive JJ p
type-2 JJ p
diabetic JJ p
patients NNS p
is VBZ N
associated VBN N
with IN N
increased JJ N
levels NNS N
of IN N
circulating VBG N
soluble JJ o
adhesion NN o
molecules NNS o
( ( o
SAM NNP o
) ) o
. . o

SAM NNP N
participate VB N
in IN N
the DT N
development NN N
of IN N
diabetic JJ N
macroangiopathy NN N
and CC N
microangiopathy NN N
. . N

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
compare VB N
the DT N
effect NN N
of IN N
trandolapril NN i
( ( i
T NNP i
) ) i
and CC N
its PRP$ N
fixed-dose JJ N
combination NN N
with IN N
verapamil NN i
( ( i
FDTV NNP i
) ) i
on IN N
SAM NNP N
levels NNS N
in IN N
hypertensive JJ p
type-2 JJ p
diabetic JJ p
patients NNS p
. . p

METHODS NNP N
Forty NNP p
type-2 JJ p
diabetic JJ p
patients NNS p
with IN p
never-treated JJ p
hypertension NN p
were VBD N
randomly RB N
assigned VBN N
to TO N
two CD N
groups NNS N
. . N

One CD N
group NN N
( ( i
FDTV NNP i
) ) i
received VBD N
2/180 CD N
mg NN N
once RB N
a DT N
day NN N
; : N
the DT N
other JJ N
group NN N
received VBD N
T NNP i
2 CD N
mg NN N
once RB N
a DT N
day NN N
. . N

Study NNP N
drugs NNS N
were VBD N
administered VBN N
for IN N
three CD N
months NNS N
in IN N
both DT N
groups NNS N
. . N

VCAM-1 NNP o
, , o
ICAM NNP o
, , o
and CC o
E-selectin NNP o
were VBD N
measured VBN N
by IN N
ELISA NNP N
at IN N
the DT N
beginning NN N
and CC N
end NN N
of IN N
the DT N
study NN N
. . N

Patients NNS N
were VBD N
evaluated VBN N
monthly RB N
for IN N
blood NN N
pressure NN N
, , N
fasting VBG N
serum NN N
glucose NN N
, , N
and CC N
adverse JJ N
events NNS N
. . N

Statistical JJ N
analysis NN N
was VBD N
performed VBN N
with IN N
ANOVA NNP N
. . N

RESULTS NNP N
Both NNP N
therapeutics NNS N
regimens NNS N
reduced VBD N
significantly RB N
the DT N
levels NNS o
of IN o
the DT o
SAM NNP o
tested VBD o
. . o

When WRB N
both DT N
groups NNS N
were VBD N
compared VBN N
, , N
we PRP N
did VBD N
not RB N
find VB N
a DT N
significant JJ N
difference NN N
in IN N
ICAM NNP o
and CC o
E-selectin NNP o
reduction NN o
. . o

However RB N
, , N
VCAM-1 NNP o
presented VBD N
a DT N
significantly RB N
greater JJR N
reduction NN N
( ( N
p JJ N
= NNP N
0.022 CD N
) ) N
in IN N
the DT N
trandolapril-verapamil JJ i
group NN N
. . N

No DT N
patient NN N
suffered VBD N
adverse JJ o
events NNS o
. . o

CONCLUSION NNP N
Our PRP$ N
results NNS N
show VBP N
that IN N
FDTV NNP N
produces VBZ N
a DT N
greater JJR N
reduction NN N
of IN N
VCAM-1 NNP N
circulating NN N
levels NNS N
than IN N
trandolapril NN N
alone RB N
. . N

This DT N
may MD N
explain VB N
some DT N
of IN N
the DT N
beneficial JJ N
effects NNS N
of IN N
this DT N
fixed VBN N
dosed JJ N
combination NN N
that WDT N
are VBP N
non-related JJ N
to TO N
its PRP$ N
antihypertensive JJ N
effects NNS N
. . N

-DOCSTART- -1595776- O O

Combined VBN N
therapy NN N
for IN N
obese JJ o
type NN o
2 CD o
diabetes NNS o
: : o
suppertime NN i
mixed JJ i
insulin NN i
with IN i
daytime JJ i
sulfonylurea NN i
. . i

Combined VBN i
insulin NN i
and CC i
sulfonylurea JJ i
therapy NN i
for IN N
type NN o
2 CD o
diabetes NNS o
may MD N
improve VB N
the DT N
effectiveness NN o
of IN N
a DT N
single JJ N
injection NN i
of IN i
insulin NN i
, , N
thereby RB N
postponing VBG N
the DT N
need NN N
for IN N
multiple JJ N
injections NNS N
. . N

This DT N
concept NN N
was VBD N
tested VBN N
in IN N
21 CD p
obese JJ p
subjects NNS p
imperfectly RB p
controlled VBN p
by IN p
20 CD i
mg NNS i
of IN i
glyburide JJ i
daily JJ i
in IN i
a DT N
double JJ N
masked VBN N
, , N
placebo-controlled JJ i
, , N
parallel JJ N
design NN N
, , N
16-week JJ N
protocol NN N
. . N

Premixed CC i
70 CD i
% NN i
NPH/30 NNP i
% NN i
Regular NNP i
insulin NN i
was VBD i
taken VBN i
before RB i
supper JJ i
, , i
and CC i
the DT i
dosage NN i
was VBD i
adjusted VBN i
weekly RB i
by IN i
an DT i
algorithm NN i
seeking VBG i
nearly RB i
normal JJ i
fasting VBG i
glycemia NN i
. . i

Eleven JJ p
subjects NNS p
using VBG p
insulin NN i
plus CC i
10 CD p
mg NNS p
glyburide NN i
before IN N
breakfast NN N
had VBD N
lower JJR N
mean NN N
fasting VBG N
glucose NN N
at IN N
10-16 JJ N
weeks NNS N
than IN N
10 CD N
subjects NNS N
using VBG N
insulin NN N
with IN N
placebo NN i
( ( N
mean JJ N
+/- JJ N
SEM NNP N
; : N
5.9 CD N
+/- JJ N
0.3 CD N
versus NN N
7.5 CD N
+/- JJ N
0.7 CD N
mmol/L NN N
; : N
p CC N
less JJR N
than IN N
0.05 CD N
) ) N
, , N
and CC N
had VBD N
a DT N
greater JJR N
decrement NN N
of IN N
glycosylated JJ o
hemoglobin NN o
from IN N
baseline NN N
values NNS N
( ( N
1.3 CD N
+/- JJ N
0.1 CD N
versus NN N
0.8 CD N
+/- JJ N
0.2 CD N
% NN N
A1 NNP N
, , N
p NN N
less JJR N
than IN N
0.05 CD N
) ) N
. . N

After IN N
16 CD N
weeks NNS N
the DT N
combined JJ N
therapy NN N
group NN N
used VBD o
half NN N
as IN N
much JJ N
insulin NN o
as IN N
the DT N
insulin-only JJ N
group NN N
( ( N
50 CD N
+/- JJ N
5 CD N
versus NN N
101 CD N
+/- JJ N
13 CD N
units/d NN N
; : N
p CC N
less JJR N
than IN N
0.01 CD N
) ) N
. . N

Fasting VBG o
serum JJ o
free JJ o
insulin NN o
values NNS o
increased VBD N
58 CD N
% NN N
from IN N
baseline NN N
after IN N
insulin NN N
therapy NN N
in IN N
the DT N
insulin-only JJ N
group NN N
( ( N
p VBZ N
less JJR N
than IN N
0.05 CD N
) ) N
but CC N
did VBD N
not RB N
increase VB N
with IN N
combined JJ N
therapy NN N
. . N

Weight NNP o
gain NN o
was VBD N
similar JJ N
in IN N
the DT N
two CD N
groups NNS N
. . N

These DT N
data NNS N
support NN N
this DT N
form NN N
of IN N
combined JJ N
therapy NN N
as IN N
one CD N
option NN N
for IN N
treating VBG N
obese JJ p
persons NNS p
with IN p
type JJ p
2 CD p
diabetes VBZ p
no RB N
longer RBR N
responsive VB N
to TO N
oral JJ N
therapy NN N
alone RB N
. . N

-DOCSTART- -10470636- O O

Effect NN N
of IN N
spinal JJ i
versus NN i
general JJ i
anesthesia NN i
on IN N
bladder NN o
compliance NN o
and CC o
intraabdominal JJ o
pressure NN o
during IN N
transurethral JJ p
procedures NNS p
. . p

STUDY NNP N
OBJECTIVE NNP N
To TO N
evaluate VB N
the DT N
influence NN N
of IN N
spinal JJ i
versus NN i
general JJ i
anesthesia NN i
on IN N
bladder NN o
compliance NN o
and CC o
intraabdominal JJ o
pressure NN o
in IN N
elderly JJ p
males NNS p
undergoing VBG p
elective JJ i
transurethral JJ i
resection NN i
of IN i
the DT i
prostate NN i
. . i

DESIGN NNP N
Prospective NNP N
, , N
randomized VBD N
, , N
open-label JJ N
study NN N
. . N

SETTING NN N
Teaching NNP p
hospital NN p
. . p

PATIENTS CC N
21 CD p
ASA NNP p
physical JJ p
status NN p
I PRP p
, , p
II NNP p
, , p
and CC p
III NNP p
patients NNS p
at IN p
least JJS p
18 CD p
years NNS p
of IN p
age NN p
, , p
undergoing VBG p
transurethral JJ i
surgery NN i
. . i

INTERVENTIONS NNP N
According VBG N
to TO N
a DT N
computer-generated JJ N
randomization NN N
schedule NN N
, , N
patients NNS N
were VBD N
allocated VBN N
to TO N
one CD N
of IN N
two CD N
groups NNS N
. . N

In IN N
Group NNP N
Spinal NNP N
( ( N
S NNP N
) ) N
, , N
10 CD N
mg NN N
of IN N
hyperbaric JJ i
tetracaine NN i
was VBD N
administered VBN N
intrathecally RB N
. . N

In IN N
Group NNP N
General NNP i
Anesthesia NNP i
( ( i
GA NNP i
) ) i
, , N
patients NNS N
received VBD N
, , N
fentanyl RB i
intravenous JJ i
( ( N
i.v JJ N
. . N

1 CD N
to TO N
2 CD N
micrograms/kg NNS N
and CC N
propofol NN N
i.v NN N
. . N

1.0 CD N
to TO N
2.0 CD N
mg/kg NN N
for IN N
induction NN N
of IN N
anesthesia NN i
. . i

Thereafter NNP N
, , N
a DT N
laryngeal JJ N
mask NN N
airway NN N
was VBD N
inserted VBN N
and CC N
, , N
with IN N
spontaneous JJ N
ventilation NN N
, , N
anesthesia NN i
was VBD N
maintained VBN N
by IN N
administering VBG N
isoflurane NN i
( ( N
end-tidal JJ N
0.7 CD N
% NN N
to TO N
1.2 CD N
% NN N
) ) N
and CC N
70 CD N
% NN N
nitrous JJ i
oxide NN i
( ( i
N2O NNP i
) ) i
in IN i
oxygen NN i
. . i

Intraabdominal JJ o
pressure NN o
and CC o
bladder NN o
compliance NN o
were VBD N
recorded VBN N
prior RB N
to TO N
the DT N
induction NN N
of IN N
anesthesia NN i
and CC N
immediately RB N
before IN N
the DT N
onset NN N
of IN N
the DT N
surgical JJ N
procedure NN N
. . N

MEASUREMENTS NNP N
AND CC N
MAIN NNP N
RESULTS NNP N
The DT N
two CD N
groups NNS N
were VBD N
demographically RB N
comparable JJ N
. . N

In IN N
Group NNP N
S NNP N
, , N
mean JJ N
bladder NN N
compliance NN N
was VBD N
significantly RB N
( ( N
p JJ N
= NNP N
0.003 CD N
) ) N
higher JJR N
and CC N
mean JJ N
intraabdominal JJ o
pressure NN o
significantly RB N
lower JJR N
( ( N
p JJ N
= NNP N
0.007 CD N
) ) N
when WRB N
compared VBN N
to TO N
baseline VB N
preanesthetic JJ N
values NNS N
. . N

In IN N
Group NNP N
GA NNP N
, , N
mean JJ o
intraabdominal JJ o
pressure NN o
significantly RB N
( ( N
p JJ N
= NNP N
0.006 CD N
) ) N
decreased VBD N
when WRB N
compared VBN N
to TO N
baseline VB N
preanesthetic JJ N
recordings NNS N
. . N

Following VBG N
the DT N
induction NN N
of IN N
general JJ N
anesthesia NN N
, , N
a DT N
small JJ N
change NN N
in IN N
bladder NN o
compliance NN o
was VBD N
noted VBN N
. . N

However RB N
, , N
statistical JJ N
significance NN N
was VBD N
not RB N
reached VBN N
. . N

Data NNS N
were VBD N
analyzed VBN N
and CC N
compared VBN N
using VBG N
Student NNP N
's POS N
t-test NN N
( ( N
p JJ N
< NN N
0.05 CD N
was VBD N
considered VBN N
statistically RB N
significant JJ N
) ) N
. . N

CONCLUSION NNP N
Both NNP N
spinal JJ i
and CC i
general JJ i
anesthesia NN i
induced VBD N
a DT N
significant JJ o
decrease NN o
in IN o
intraabdominal JJ o
pressure NN o
. . o

While IN N
both DT N
techniques NNS N
were VBD N
associated VBN N
with IN N
an DT N
increase NN o
in IN o
bladder NN o
compliance NN o
, , N
statistical JJ N
significance NN N
was VBD N
demonstrated VBN N
only RB N
in IN N
the DT N
spinal JJ i
anesthesia NN i
treatment NN N
group NN N
. . N

-DOCSTART- -21261975- O O

Impact NN N
of IN N
early JJ N
parenteral JJ N
nutrition NN N
completing VBG N
enteral JJ N
nutrition NN N
in IN N
adult NN p
critically RB p
ill JJ p
patients NNS p
( ( N
EPaNIC NNP N
trial NN N
) ) N
: : N
a DT N
study NN N
protocol NN N
and CC N
statistical JJ N
analysis NN N
plan NN N
for IN N
a DT N
randomized VBN N
controlled VBN N
trial NN N
. . N

BACKGROUND NNP N
For IN N
critically RB p
ill JJ p
patients NNS p
treated VBN p
in IN p
intensive JJ p
care NN p
units NNS p
( ( p
ICU NNP p
) ) p
, , N
two CD N
feeding NN N
strategies NNS N
are VBP N
currently RB N
being VBG N
advocated VBN N
, , N
one CD N
by IN N
American/Canadian JJ N
and CC N
the DT N
other JJ N
by IN N
European JJ N
expert NN N
guidelines NNS N
. . N

These DT N
guidelines NNS N
differ VBP N
particularly RB N
in IN N
the DT N
timing NN N
of IN N
initiating VBG N
parenteral JJ N
nutrition NN N
( ( N
PN NNP N
) ) N
in IN N
patients NNS p
for IN p
whom WP p
enteral JJ p
nutrition NN p
( ( p
EN NNP p
) ) p
does VBZ p
not RB p
reach VB p
caloric JJ p
targets NNS p
. . p

METHODS/DESIGN NNP N
The DT N
EPaNIC NNP N
trial NN N
is VBZ N
an DT N
investigator-initiated JJ N
, , N
non-commercial JJ N
, , N
multi-center JJ N
, , N
randomized VBN N
, , N
controlled VBN N
, , N
clinical JJ N
trial NN N
with IN N
a DT N
parallel JJ N
group NN N
design NN N
. . N

This DT N
study NN N
compares VBZ N
early JJ N
( ( N
European JJ N
guideline NN N
) ) N
versus NN N
late JJ N
( ( N
American/Canadian JJ N
guideline NN N
) ) N
initiation NN i
of IN i
PN NNP i
when WRB i
EN NNP i
fails VBZ i
to TO N
reach VB N
a DT N
caloric JJ N
target NN N
. . N

In IN i
the DT i
early JJ i
PN NNP i
group NN i
, , i
PN NNP i
is VBZ i
initiated VBN i
within IN i
24-48 JJ i
hours NNS i
after IN i
ICU NNP i
admission NN i
to TO i
complete VB i
early JJ i
enteral JJ i
nutrition NN i
( ( i
EN NNP i
) ) i
up RB i
to TO i
a DT i
calculated JJ i
nutritional JJ i
target NN i
. . i

In IN i
the DT i
late JJ i
PN NNP i
group NN i
, , i
PN NNP i
completing VBG i
EN NNP i
is VBZ i
initiated VBN i
when WRB i
the DT i
target NN i
is VBZ i
not RB i
reached VBN i
on IN i
day NN i
8 CD i
. . i

In IN N
both DT N
groups NNS N
, , N
the DT N
same JJ N
early JJ N
EN NNP i
protocol NN N
is VBZ N
applied VBN N
. . N

The DT N
study NN N
is VBZ N
designed VBN N
to TO N
compare VB N
clinical JJ o
outcome NN o
( ( o
morbidity NN o
and CC o
mortality NN o
) ) o
in IN N
the DT N
2 CD N
study NN N
arms NNS N
as RB N
well RB N
as IN N
to TO N
address VB N
several JJ N
mechanistical JJ N
questions NNS N
. . N

We PRP N
here RB N
describe VBP N
the DT N
EPaNIC NNP N
study NN N
protocol NN N
and CC N
the DT N
statistical JJ N
analysis NN N
plan NN N
for IN N
the DT N
primary JJ N
report NN N
of IN N
the DT N
clinical JJ N
results NNS N
. . N

DISCUSSION NNP N
The DT N
study NN N
has VBZ N
been VBN N
initiated VBN N
as IN N
planned VBN N
on IN N
august NN N
01 CD N
2007 CD N
. . N

One CD N
interim JJ N
analysis NN N
advised VBD N
continuation NN N
of IN N
the DT N
trial NN N
. . N

The DT N
study NN N
will MD N
be VB N
completed VBN N
in IN N
February NNP N
2011 CD N
. . N

TRIAL NNP N
REGISTRATION NNP N
ClinicalTrials NNP N
( ( N
NCT NNP N
) ) N
: : N
NCT00512122 NN N
. . N

-DOCSTART- -23280086- O O

Treatment NN N
of IN N
adults NNS p
with IN p
acute JJ p
lymphoblastic JJ p
leukemia NN p
: : p
do VB N
the DT N
specifics NNS N
of IN N
the DT N
regimen NNS N
matter NN N
? . N
: : N
Results NNS N
from IN N
a DT N
prospective JJ N
randomized VBN N
trial NN N
. . N

BACKGROUND NNP N
Induction NNP N
therapy NN N
for IN N
adults NNS p
with IN p
acute JJ p
lymphoblastic JJ p
leukemia NN p
( ( p
ALL DT p
) ) p
is VBZ N
similar JJ N
across IN N
essentially RB N
all DT N
regimens NNS N
, , N
comprised VBN N
of IN N
vincristine NN i
, , i
corticosteroids NNS i
, , i
and CC i
anthracyclines NNS i
intensified VBN i
with IN i
cyclophosphamide NN i
, , i
asparaginase NN i
, , i
or CC i
both DT i
. . i

Given VBN N
the DT N
lack NN N
of IN N
randomized VBN N
data NNS N
, , N
to TO N
date NN N
, , N
no DT N
regimen NN N
has VBZ N
emerged VBN N
as IN N
standard NN N
. . N

The DT N
authors NNS N
previously RB N
evaluated VBD N
cytarabine JJ i
3 CD N
g/m NN N
( ( N
2 CD N
) ) N
daily RB N
for IN N
5 CD N
days NNS N
with IN N
mitoxantrone NN i
80 CD N
mg/m NN N
( ( N
2 CD N
) ) N
( ( N
the DT N
ALL-2 NNP N
regimen NNS N
) ) N
as IN N
a DT N
novel JJ N
induction NN N
regimen NNS N
. . N

Compared VBN N
with IN N
historic JJ N
controls NNS N
, , N
the DT N
ALL-2 NNP N
regimen NN N
was VBD N
superior JJ N
in IN N
terms NNS N
of IN N
incidence NN N
of IN N
complete JJ N
remission NN N
, , N
failure NN N
with IN N
resistant JJ N
disease NN N
, , N
and CC N
activity NN N
in IN N
patients NNS p
with IN p
Philadelphia NNP p
chromosome NN p
( ( p
Ph NNP p
) ) p
-positive VBP p
ALL NNP p
. . p

METHODS NNP N
The DT N
authors NNS N
conducted VBD N
a DT N
multicenter NN N
, , N
prospective JJ N
, , N
randomized JJ N
trial NN N
of IN N
the DT N
ALL-2 NNP N
regimen NNS N
compared VBN N
with IN N
a DT N
standard JJ N
4-drug JJ i
induction NN i
( ( i
the DT i
L-20 NNP i
regimen NNS i
) ) i
. . i

Patients NNS N
also RB N
received VBD N
consolidation NN i
, , i
maintenance NN i
therapy NN i
, , i
and CC i
central JJ i
nervous JJ i
system NN i
prophylaxis NN i
. . i

The DT N
trial NN N
accrued VBD p
patients NNS p
from IN p
August NNP p
1996 CD p
to TO p
October NNP p
2004 CD p
. . p

RESULTS VB N
The DT N
median JJ o
follow-up NN o
for IN o
survivors NNS o
was VBD N
7 CD N
years NNS N
, , N
and CC N
the DT N
median JJ p
patient NN p
age NN p
was VBD p
43 CD p
years NNS p
. . p

Responses NNS p
were VBD p
evaluated VBN p
in IN p
164 CD p
patients NNS p
. . p

The DT N
treatment NN N
arms NNS N
were VBD N
balanced VBN N
in IN N
terms NNS N
of IN N
pretreatment NN N
characteristics NNS N
. . N

The DT N
frequency NN o
of IN o
complete JJ o
remission NN o
for IN N
the DT N
ALL-2 NNP N
regimen NNS N
versus IN N
the DT N
L-20 JJ N
regimen NN N
was VBD N
83 CD N
% NN N
versus IN N
71 CD N
% NN N
( ( N
P NNP N
= NNP N
.06 NNP N
) ) N
. . N

More JJR N
patients NNS p
on IN N
the DT N
L-20 NNP N
arm NN N
failed VBD N
with IN N
resistant JJ o
disease NN o
( ( N
21 CD N
% NN N
vs JJ N
8 CD N
% NN N
; : N
P NNP N
= NNP N
.02 NNP N
) ) N
. . N

Induction NNP o
deaths NNS o
were VBD N
comparable JJ N
at IN N
9 CD N
% NN N
( ( N
ALL-2 NNP N
) ) N
versus VBD N
7 CD N
% NN N
( ( N
L-20 NNP N
) ) N
. . N

The DT N
median JJ o
survival NN o
was VBD N
similar JJ N
; : N
and CC N
, , N
at IN N
5 CD N
years NNS N
, , N
the DT N
survival NN o
rate NN o
was VBD N
33 CD N
% NN N
alive JJ N
on IN N
the DT N
ALL-2 NNP N
arm NN N
versus NN N
27 CD N
% NN N
on IN N
the DT N
L-20 NNP N
. . N

CONCLUSIONS NNP N
Despite IN N
superior JJ N
results NNS N
of IN N
induction NN N
therapy NN N
with IN N
the DT N
ALL-2 NNP N
regimen NNS N
, , N
this DT N
treatment NN N
did VBD N
not RB N
improve VB N
long-term JJ o
outcomes NNS o
. . o

When WRB N
coupled VBN N
to TO N
the DT N
reported VBN N
experience NN N
of IN N
other JJ N
studies NNS N
in IN N
adults NNS N
with IN N
ALL NNP N
, , N
the DT N
results NNS N
of IN N
this DT N
randomized VBN N
trial NN N
raise NN N
the DT N
possibility NN N
that WDT N
ultimate JJ N
outcomes NNS N
in IN N
adult NN N
ALL NNP N
may MD N
be VB N
independent JJ N
of IN N
the DT N
specific JJ N
regimen NNS N
chosen VBN N
. . N

Cancer NN N
2013 CD N
. . N

? . N
2012 CD N
American JJ N
Cancer NNP N
Society NNP N
. . N

-DOCSTART- -17126434- O O

Effect NN N
of IN N
age NN N
and CC N
radiation NN i
dose NN N
on IN N
local JJ o
control NN o
after IN N
breast NN i
conserving NN i
treatment NN i
: : i
EORTC JJ N
trial NN N
22881-10882 JJ N
. . N

PURPOSE NN N
To TO N
determine VB N
whether IN N
the DT N
effect NN N
of IN N
an DT N
additional JJ N
boost NN i
radiation NN i
after IN N
breast NN i
conservative JJ i
therapy NN i
( ( i
BCT NNP i
) ) i
on IN N
local JJ N
control NN N
depends VBZ N
on IN N
age NN N
and CC N
evaluate VB N
the DT N
impact NN N
of IN N
a DT N
treatment NN N
policy NN N
with IN N
a DT N
threshold NN N
for IN N
age NN N
. . N

PATIENTS NNP N
AND CC N
METHODS NNP N
We PRP p
used VBD p
data NNS p
from IN p
EORTC NNP p
22881-10882 JJ p
trial NN p
, , p
with IN p
median JJ p
follow-up NN p
of IN p
77.4 CD p
months NNS p
. . p

Patients NNS p
receiving VBG p
BCT NNP i
and CC i
50Gy CD i
whole JJ i
breast NN i
irradiation NN i
were VBD p
randomized VBN p
to TO p
no DT i
boost NN i
and CC i
16Gy CD i
boost NN i
( ( N
N=5318 NNP N
) ) N
. . N

RESULTS NNP N
In IN N
univariate JJ N
analysis NN N
, , N
a DT N
boost NN i
reduced VBN N
local JJ o
failure NN o
by IN N
a DT N
factor NN N
of IN N
2 CD N
( ( N
P NNP N
< NNP N
0.0001 CD N
) ) N
. . N

Multivariate NNP N
analysis NN N
showed VBD N
local JJ o
control NN o
increased VBD N
with IN N
age NN N
( ( N
P=0.0003 NNP N
) ) N
. . N

There EX N
was VBD N
no DT N
evidence NN N
that IN N
the DT N
relative JJ N
effect NN N
of IN N
a DT N
boost NN i
on IN N
local JJ o
control NN o
depends VBZ N
on IN N
age NN N
( ( N
P=0.97 NNP N
) ) N
However RB N
in IN N
younger JJR p
patients NNS p
the DT N
5-year JJ N
local JJ o
failure NN o
was VBD N
higher JJR N
, , N
therefore IN N
the DT N
absolute JJ N
reduction NN N
was VBD N
greater JJR N
. . N

If IN N
the DT N
threshold-age NN N
for IN N
boost NN N
treatment NN N
were VBD N
set VBN N
at IN N
40 CD N
years NNS N
, , N
8.4 CD p
% NN p
of IN p
the DT p
study NN p
population NN p
would MD p
receive VB p
a DT N
boost NN i
, , N
resulting VBG N
in IN N
a DT N
5-year JJ N
local JJ o
failure NN o
of IN N
6.1 CD N
% NN N
in IN N
the DT N
study NN N
population NN N
. . N

Changing VBG N
the DT N
threshold-age NN N
to TO N
60 CD N
years NNS N
, , N
67 CD p
% NN p
of IN p
the DT p
study NN p
population NN p
would MD N
receive VB N
a DT N
boost NN i
and CC N
the DT N
5-year JJ N
local JJ o
failure NN o
would MD N
be VB N
reduced VBN N
to TO N
4.4 CD N
% NN N
. . N

CONCLUSIONS NNP N
In IN N
younger JJR p
patients NNS p
a DT N
boost NN N
dose NN N
resulted VBD N
in IN N
a DT N
greater JJR N
absolute JJ N
reduction NN N
of IN N
local JJ o
failure NN o
. . o

The DT N
relative JJ o
risk NN o
reduction NN o
was VBD N
however RB N
similar JJ N
for IN N
all DT N
ages NNS N
. . N

Applying VBG N
a DT N
treatment NN N
policy NN N
with IN N
a DT N
threshold-age NN N
of IN N
60 CD N
would MD N
result VB N
in IN N
0.6 CD N
% NN N
increase NN N
in IN N
local JJ o
failure NN o
in IN N
the DT N
total NN N
study NN N
population NN N
, , N
while IN N
sparing VBG N
the DT N
boost NN N
to TO N
1/3 CD N
of IN N
the DT N
patients NNS N
. . N

-DOCSTART- -18410301- O O

Genital NNP o
responsiveness NN o
in IN N
healthy JJ p
women NNS p
with IN p
and CC p
without IN p
sexual JJ p
arousal NN p
disorder NN p
. . p

INTRODUCTION NNP N
Most NNP N
pharmacological JJ N
treatments NNS N
that WDT N
are VBP N
currently RB N
being VBG N
developed VBN N
for IN N
women NNS p
with IN p
sexual JJ p
arousal NN p
disorder NN p
are VBP N
aimed VBN N
at IN N
remedying VBG N
a DT N
vasculogenic JJ N
deficit NN N
. . N

AIM VB N
This DT N
study NN N
investigated VBD N
whether IN N
pre- NN p
and CC p
postmenopausal JJ p
women NNS p
with IN p
sexual JJ p
arousal NN p
disorder NN p
are VBP N
less RBR N
genitally RB N
responsive JJ N
to TO N
visual JJ N
sexual JJ N
stimuli NN N
than IN N
pre- JJ N
and CC N
postmenopausal JJ N
women NNS N
without IN N
sexual JJ N
problems NNS N
. . N

METHOD NNP N
Twenty-nine NNP p
medically RB p
healthy JJ p
women NNS p
with IN p
sexual JJ p
arousal NN p
disorder NN p
( ( p
15 CD p
premenopausal NN p
and CC p
14 CD p
postmenopausal NN p
) ) p
, , p
diagnosed VBD p
using VBG p
the DT p
Diagnostic NNP p
and CC p
Statistical NNP p
Manual NNP p
of IN p
Mental NNP p
Disorders NNP p
, , p
4th CD p
Edition NNP p
( ( p
DSM-IV NNP p
) ) p
criteria NN p
, , p
and CC p
30 CD p
age-matched JJ p
women NNS p
without IN p
sexual JJ p
problems NNS p
( ( p
16 CD p
premenopausal NN p
and CC p
14 CD p
postmenopausal NN p
) ) p
were VBD N
shown VBN N
sexual JJ i
stimuli NNS i
depicting VBG i
cunnilingus NN i
and CC i
intercourse NN i
. . i

MAIN NNP N
OUTCOME NNP N
MEASURE NNP N
Genital NNP N
arousal NN N
was VBD N
assessed VBN N
as IN N
vaginal JJ o
pulse NN o
amplitude NN o
( ( o
VPA NNP o
) ) o
using VBG N
vaginal JJ o
photoplethysmography NN o
. . o

RESULTS NNP N
Results NNP N
showed VBD N
no DT N
significant JJ N
differences NNS N
between IN N
the DT N
two CD N
groups NNS N
in IN N
mean JJ o
and CC o
maximum JJ o
VPA NNP o
, , N
nor CC N
in IN N
latency NN N
of IN N
VPA NNP o
response NN o
. . o

CONCLUSION NNP N
Women NNP p
with IN p
sexual JJ p
arousal NN p
disorder NN p
diagnosed VBD p
according VBG p
to TO p
DSM-IV NNP p
criteria NNS N
were VBD N
not RB N
less RBR N
genitally RB N
responsive JJ N
to TO N
visual JJ N
sexual JJ N
stimuli NNS N
than IN N
women NNS N
without IN N
such JJ N
problems NNS N
. . N

These DT N
findings NNS N
are VBP N
in IN N
line NN N
with IN N
previous JJ N
studies NNS N
. . N

The DT N
sexual JJ N
problems NNS N
these DT N
women NNS N
report NN N
are VBP N
clearly RB N
not RB N
related VBN N
to TO N
their PRP$ N
potential JJ N
to TO N
become VB N
genitally RB N
aroused JJ N
. . N

We PRP N
argue VBP N
that IN N
the DT N
DSM-IV NNP N
criteria NNS N
for IN N
sexual JJ N
arousal NN N
disorder NN N
are VBP N
in IN N
need NN N
of IN N
revision NN N
. . N

In IN N
medically RB p
healthy JJ p
women NNS p
, , N
impaired JJ N
genital JJ N
responsiveness NN N
is VBZ N
not RB N
a DT N
valid JJ N
diagnostic JJ N
criterion NN N
. . N

-DOCSTART- -9101947- O O

[ JJ N
Laparoscopic NNP N
or CC N
conventional JJ N
inguinal JJ o
hernia NN o
repair NN o
with IN i
or CC i
without IN i
implant JJ i
. . i

A DT N
prospective JJ N
randomized NN N
study NN N
] NNP N
. . N

-DOCSTART- -25546925- O O

The DT N
effect NN N
of IN N
treatment NN N
on IN N
pregnancy NN o
outcomes NNS o
in IN N
women NNS p
with IN p
one CD p
elevated JJ p
oral JJ p
glucose JJ p
tolerance NN p
test NN p
value NN p
. . p

OBJECTIVE CC N
The DT N
aim NN N
of IN N
the DT N
study NN N
was VBD N
to TO N
evaluate VB N
whether IN N
dietary JJ i
intervention NN i
could MD N
reduce VB N
maternal JJ o
and CC o
perinatal JJ o
morbidity NN o
in IN N
pregnancies NNS N
with IN N
one CD N
elevated VBD N
100 CD N
g JJ N
oral JJ N
glucose JJ N
tolerance NN N
test NN N
( ( N
OGTT NNP N
) ) N
value NN N
. . N

MATERIAL NNP N
AND CC N
METHODS NNP N
The DT N
study NN N
was VBD N
conducted VBN N
among IN N
patients NNS p
with IN p
positive JJ p
50 CD p
g NN p
glucose JJ p
challenge NN p
test NN p
( ( p
GCT NNP p
) ) p
and CC p
one CD p
elevated VBD p
100 CD p
g NN p
OGTT NNP p
value NN p
. . p

Plasma NNP N
glucose JJ N
value NN N
of IN N
140 CD N
mg/dL NN N
was VBD N
used VBN N
as IN N
the DT N
threshold NN N
to TO N
define VB N
an DT N
abnormal JJ N
GCT NNP N
result NN N
. . N

Carpenter NNP N
and CC N
Coustan NNP N
criteria NNS N
were VBD N
used VBN N
to TO N
evaluate VB N
the DT N
OGTT NNP N
results NNS N
. . N

Seventy-four JJ p
women NNS p
with IN p
normal JJ p
GCT NNP p
values NNS p
comprised VBD p
group NN p
I. NNP p
Ninety-nine NNP p
women NNS p
with IN p
one CD p
elevated VBD p
100 CD p
g NN p
OGTT NNP p
value NN p
who WP p
were VBD p
given VBN p
a DT p
caloric JJ i
diet NN i
and CC p
102 CD p
women NNS p
with IN p
one CD p
elevated VBD p
OGTT NNP p
value NN p
in IN p
group NN p
III NNP p
who WP p
received VBD p
antenatal JJ i
care NN i
with IN i
no DT i
special JJ i
diet NN i
were VBD p
randomly RB p
assigned VBN p
to TO p
groups NNS p
II NNP p
and CC p
III NNP p
, , p
respectively RB p
. . p

All DT p
women NNS p
were VBD p
followed VBN p
up RP p
until IN p
the DT p
end NN p
of IN p
pregnancy NN p
. . p

Poor NNP N
maternal JJ N
outcome NN N
was VBD N
defined VBN N
as IN N
: : N
cesarean JJ o
delivery NN o
performed VBD o
due JJ o
to TO o
cephalopelvic VB o
disproportion NN o
, , o
failure NN o
to TO o
progress NN o
or CC o
fetal JJ o
distress NN o
, , o
preeclampsia NN o
, , o
and/or JJ o
preterm JJ o
labor NN o
. . o

Poor NNP N
perinatal JJ N
outcome NN N
was VBD N
defined VBN N
as IN N
: : N
small JJ o
for IN o
gestational JJ o
age NN o
, , o
large JJ o
for IN o
gestational JJ o
age NN o
or CC o
admission NN o
to TO o
a DT o
neonatal JJ o
intensive JJ o
care NN o
unit NN o
. . o

The DT N
groups NNS N
were VBD N
compared VBN N
in IN N
terms NNS N
of IN N
maternal NN N
and CC N
perinatal JJ N
outcomes NNS N
. . N

RESULTS VB N
The DT N
rates NNS o
of IN o
macrosomia NN o
and CC o
large JJ o
for IN o
gestational JJ o
age NN o
incidence NN o
were VBD N
significantly RB N
higher JJR N
in IN N
group NN N
III NNP N
as IN N
compared VBN N
to TO N
groups NNS N
I PRP N
and CC N
II NNP N
. . N

When WRB N
we PRP N
examined VBD N
the DT N
multivariate NN N
effects NNS N
of IN N
the DT N
risk NN N
factors NNS N
considered VBN N
to TO N
be VB N
predictive JJ N
of IN N
poor JJ N
maternal JJ N
outcomes NNS N
, , N
group NN N
III NNP N
was VBD N
the DT N
only JJ N
statistically RB N
significant JJ N
risk NN N
factor NN N
( ( N
OR=3.90 NNP N
, , N
95 CD N
% NN N
CI:1.95- JJ N
7.84 CD N
; : N
p= NN N
< VBZ N
0.001 CD N
) ) N
. . N

In IN N
terms NNS N
of IN N
poor JJ N
perinatal JJ N
outcome NN N
, , N
one CD N
elevated VBD N
OGTT NNP o
value NN o
( ( N
group NN N
III NNP N
) ) N
was VBD N
the DT N
only JJ N
significant JJ N
risk NN N
factor NN N
( ( N
OR=2.92 NNP N
, , N
95 CD N
% NN N
CI:1.56-5.46 NNP N
; : N
p= VBZ N
< $ N
0.001 CD N
) ) N
. . N

CONCLUSION NNP N
Women NNP p
with IN p
one CD p
elevated VBD p
OGTT NNP o
value NN o
benefit NN p
from IN p
a DT p
structured JJ p
program NN p
of IN p
diet JJ i
therapy NN i
aimed VBN N
to TO N
reduce VB N
adverse JJ N
maternal NN o
and CC o
perinatal JJ o
outcomes NNS o
. . o

-DOCSTART- -3146231- O O

[ JJ p
Complaints NNS p
in IN p
the DT p
postoperative JJ p
phase NN p
related VBN p
to TO p
anesthetics NNS p
] NNP p
. . N

In IN N
two CD N
prospective JJ N
, , N
randomized JJ N
studies NNS N
the DT N
frequency NN o
of IN o
headache NN o
, , o
nausea NN o
, , o
vomiting NN o
, , o
and CC o
analgesic JJ o
requirement NN o
during IN p
the DT p
first JJ p
postoperative JJ p
24 CD p
h NN p
was VBD N
observed VBN N
in IN N
order NN N
to TO N
study VB N
differences NNS N
between IN N
the DT N
sexes NNS N
and CC N
the DT N
inhalation NN N
anesthetics NNS i
halothane NN i
, , i
enflurane NN i
, , i
isoflurane NN i
, , i
or CC i
balanced VBD i
anesthesia NNS i
with IN i
enflurane/alfentanil NN i
. . i

Nausea NN o
and CC o
vomiting NN o
were VBD N
more RBR N
frequent JJ N
after IN N
enflurane NN i
than IN N
after IN N
halothane NN i
or CC N
isoflurane NN i
. . i

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
between IN N
anesthetics NNS N
and CC N
frequency NN o
of IN o
headache NN o
, , N
but CC N
there EX N
were VBD N
significant JJ N
differences NNS N
in IN N
postoperative JJ o
analgesic NN o
requirements NNS o
which WDT N
were VBD N
highest JJS N
after IN N
halothane NN i
and CC N
lowest JJS N
after IN N
isoflurane NN i
. . i

Postoperative JJ o
complaints NNS o
were VBD N
always RB N
significantly RB N
greater JJR N
among IN N
women NNS p
than IN N
among IN N
men NNS p
. . p

The DT N
second JJ N
study NN N
indicated VBD N
that IN N
balanced VBD N
anesthesia NN N
did VBD N
not RB N
reduce VB N
the DT N
analgesic JJ o
requirement NN o
compared VBN N
to TO N
enflurane VB i
without IN N
alfentanil NN i
, , N
but CC N
lead VBP N
to TO N
a DT N
higher JJR N
incidence NN N
of IN N
vomiting VBG o
. . o

After IN N
premedication NN N
with IN N
flunitrazepam NN N
and CC N
atropine NN N
and CC N
combined VBN N
with IN N
70 CD N
% NN N
N2O/30 NNP N
% NN N
O2 NNP N
, , N
isoflurane NN i
was VBD N
the DT N
most RBS N
favorable JJ N
anesthetic JJ N
agent NN N
with IN N
regard NN N
to TO N
the DT N
parameters NNS N
studied VBN N
. . N

Balanced NNP i
anesthesia NN i
with IN i
enflurane/alfentanil NN i
did VBD N
not RB N
show VB N
any DT N
advantages NNS N
for IN N
patients NNS p
in IN p
the DT p
postoperative JJ p
phase NN p
under IN N
the DT N
given VBN N
conditions NNS N
. . N

-DOCSTART- -16354710- O O

Using VBG N
dietetic JJ i
assistants NNS i
to TO N
improve VB N
the DT N
outcome NN N
of IN N
hip JJ p
fracture NN p
: : p
a DT N
randomised JJ N
controlled JJ N
trial NN N
of IN N
nutritional JJ N
support NN N
in IN N
an DT N
acute NN p
trauma NN p
ward NN p
. . p

OBJECTIVE UH N
To TO N
examine VB N
how WRB N
improved JJ N
attention NN N
to TO N
nutritional JJ o
status NN o
and CC o
dietary JJ o
intake NN o
, , N
achieved VBN N
through IN N
the DT N
employment NN N
of IN N
dietetic JJ i
assistants NNS i
( ( i
DAs NNP i
) ) i
, , N
will MD N
affect VB N
postoperative JJ o
clinical JJ o
outcome NN o
among IN N
elderly JJ p
women NNS p
with IN p
hip JJ p
fracture NN p
. . p

DESIGN NNP N
Open NNP N
prospective NN N
randomised VBD N
controlled VBN N
trial NN N
, , N
comparing VBG N
conventional JJ i
nursing NN i
care NN i
with IN N
the DT N
additional JJ i
nutritional JJ i
support NN i
provided VBN i
by IN i
DA NNP i
. . i

SETTING NNP N
Thirty-eight NNP p
bedded VBD p
acute JJ p
trauma NN p
ward NN p
in IN p
a DT p
teaching JJ p
hospital NN p
. . p

PARTICIPANTS VB N
All DT p
but CC p
11 CD p
of IN p
344 CD p
consecutive JJ p
admissions NNS p
with IN p
acute JJ p
nonpathological JJ p
hip NN p
fracture NN p
were VBD p
approached VBN p
. . p

Three CD p
hundred VBD p
and CC p
eighteen JJ p
( ( p
93 CD p
% NN p
) ) p
agreed VBD p
to TO p
inclusion NN p
. . p

Sixteen NNP p
were VBD p
ineligible JJ p
as IN N
they PRP N
were VBD N
immediately RB N
transferred VBN N
to TO N
another DT N
acute NN N
ward NN N
, , N
were VBD N
managed VBN N
conservatively RB N
or CC N
died VBD N
preoperatively RB N
. . N

PRIMARY NNP N
OUTCOME NNP N
MEASURE NNP N
Postoperative NNP o
mortality NN o
in IN N
the DT N
acute JJ N
trauma NN N
unit NN N
. . N

SECONDARY NNP N
OUTCOME NNP N
MEASURES NNP N
Postoperative NNP o
mortality NN o
at IN o
4 CD o
months NNS o
after IN o
fracture NN o
, , o
length NN o
of IN o
stay NN o
, , o
energy NN o
intake NN o
and CC N
nutritional JJ o
status NN o
. . o

RESULTS NNP N
DA-supported JJ N
participants NNS N
were VBD N
less RBR N
likely JJ o
to TO o
die VB o
in IN N
the DT N
acute JJ N
ward NN N
( ( N
4.1 CD N
versus RB N
10.1 CD N
% NN N
, , N
P NNP N
= NNP N
0.048 CD N
) ) N
. . N

This DT N
effect NN N
was VBD N
still RB N
apparent JJ N
at IN N
4 CD N
month NN N
follow-up NN N
( ( N
13.1 CD N
versus RB N
22.9 CD N
% NN N
, , N
P NNP N
= NNP N
0.036 CD N
) ) N
. . N

DA-supported JJ N
subjects NNS N
had VBD N
significantly RB N
better RBR N
mean JJ o
daily JJ o
energy NN o
intake NN o
( ( N
1,105 CD N
kcal JJ N
versus NN N
756 CD N
kcal/24 NN N
h NN N
, , N
95 CD N
% NN N
CI NNP N
259-440 JJ N
kcal/24 NN N
h NN N
, , N
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
significantly RB N
smaller JJR N
reduction NN N
in IN N
mid-arm JJ N
circumference NN N
during IN N
their PRP$ N
inpatient JJ N
stay NN N
( ( N
0.39 CD N
cm NN N
, , N
P NNP N
= NNP N
0.002 CD N
) ) N
and CC N
nonsignificantly RB N
favourable JJ N
results NNS N
for IN N
other JJ N
anthropometric JJ o
and CC o
laboratory JJ o
measurements NNS o
. . o

CONCLUSION NNP N
Dietetic NNP i
or CC i
nutrition NN i
assistants NNS i
are VBP N
being VBG N
introduced VBN N
in IN N
units NNS N
across IN p
the DT p
UK NNP p
. . p

This DT N
, , N
the DT N
largest JJS N
ever RB N
study NN N
of IN N
nutritional JJ N
support NN N
after IN N
hip NN N
fracture NN N
, , N
shows VBZ N
that IN N
their PRP$ N
employment NN N
significantly RB N
reduced VBD N
patients NNS o
' POS o
risk NN o
of IN o
dying VBG o
in IN N
the DT N
acute JJ N
trauma NN N
unit NN N
; : N
an DT N
effect NN N
that WDT N
persisted VBD N
at IN N
4 CD N
month NN N
follow-up NN N
. . N

-DOCSTART- -11786587- O O

Dronabinol NNP i
versus NN i
megestrol NN i
acetate VBP i
versus NN i
combination NN i
therapy NN i
for IN N
cancer-associated JJ N
anorexia NN N
: : N
a DT N
North JJ N
Central JJ N
Cancer NNP N
Treatment NNP N
Group NNP N
study NN N
. . N

PURPOSE NNP N
To TO N
determine VB N
whether IN N
dronabinol NN i
administered VBN N
alone RB N
or CC N
with IN N
megestrol JJ i
acetate NN i
was VBD N
more RBR N
, , N
less RBR N
, , N
or CC N
equal JJ N
in IN N
efficacy NN N
to TO N
single-agent JJ N
megestrol NN i
acetate NN i
for IN N
palliating VBG N
cancer-associated JJ N
anorexia NN N
. . N

PATIENTS NNP N
AND CC N
METHODS NNP N
Four NNP p
hundred VBD p
sixty-nine JJ p
assessable JJ p
advanced JJ p
cancer NN p
patients NNS p
were VBD p
randomized VBN p
to TO p
( ( p
1 CD p
) ) p
oral JJ p
megestrol NN i
acetate VBP i
800 CD p
mg/d NN p
liquid NN i
suspension NN i
plus CC i
placebo NN i
, , p
( ( p
2 CD p
) ) p
oral JJ p
dronabinol $ i
2.5 CD p
mg NN p
twice RB p
a DT p
day NN p
plus CC p
placebo NN i
, , p
or CC p
( ( p
3 CD p
) ) p
both DT i
agents NNS i
. . i

Eligible JJ p
patients NNS p
acknowledged VBD p
that IN p
loss NN p
of IN p
appetite NN p
or CC p
weight NN p
was VBD p
a DT p
problem NN p
and CC p
reported VBD p
the DT p
loss NN p
of IN p
5 CD p
pounds NNS p
or CC p
more JJR p
during IN p
2 CD p
months NNS p
and/or IN p
a DT p
daily JJ p
intake NN p
of IN p
less JJR p
than IN p
20 CD p
calories/kg NN p
of IN p
body NN p
weight NN p
. . p

RESULTS JJ N
Groups NNP N
were VBD N
comparable JJ N
at IN N
baseline NN N
in IN N
age NN N
, , N
sex NN N
, , N
tumor NN N
type NN N
, , N
weight JJ N
loss NN N
, , N
and CC N
performance NN N
status NN N
. . N

A DT N
greater JJR N
percentage NN N
of IN N
megestrol NN i
acetate-treated JJ i
patients NNS p
reported VBD N
appetite JJ o
improvement NN o
and CC o
weight VBD o
gain NN o
compared VBN N
with IN N
dronabinol-treated JJ i
patients NNS p
: : p
75 CD N
% NN N
versus IN N
49 CD N
% NN N
( ( N
P NNP N
=.0001 NNP N
) ) N
for IN N
appetite NN N
and CC N
11 CD N
% NN N
versus IN N
3 CD N
% NN N
( ( N
P NNP N
=.02 NNP N
) ) N
for IN N
> NN N
or CC N
= VB N
10 CD N
% NN N
baseline NN N
weight NN N
gain NN N
. . N

Combination NNP N
treatment NN N
resulted VBD N
in IN N
no DT N
significant JJ N
differences NNS o
in IN o
appetite NN o
or CC o
weight NN o
compared VBN N
with IN N
megestrol NN i
acetate NN i
alone RB N
. . N

The DT N
Functional NNP N
Assessment NNP N
of IN N
Anorexia/Cachexia NNP N
Therapy NNP N
questionnaire NN N
, , N
which WDT N
emphasizes VBZ N
anorexia-related JJ N
questions NNS N
, , N
demonstrated VBD N
an DT N
improvement NN N
in IN N
quality NN o
of IN o
life NN o
( ( o
QOL NNP o
) ) o
among IN N
megestrol JJ i
acetate-treated JJ i
and CC p
combination-treated JJ p
patients NNS p
. . p

The DT N
single-item JJ N
Uniscale NNP N
, , N
a DT N
global JJ N
QOL NNP o
instrument NN N
, , N
found VBN N
comparable JJ N
scores NNS N
. . N

Toxicity NN o
was VBD N
also RB N
comparable JJ N
, , N
with IN N
the DT N
exception NN N
of IN N
an DT N
increased JJ N
incidence NN N
of IN N
impotence NN o
among IN N
men NNS p
who WP p
received VBD p
megestrol NN i
acetate NN i
. . i

CONCLUSION NNP N
In IN N
the DT N
doses NNS N
and CC N
schedules NNS N
we PRP N
studied VBD N
, , N
megestrol NN i
acetate NN i
provided VBD N
superior JJ N
anorexia JJ N
palliation NN N
among IN N
advanced JJ p
cancer NN p
patients NNS p
compared VBN N
with IN N
dronabinol NN i
alone RB N
. . N

Combination NNP N
therapy NN N
did VBD N
not RB N
appear VB N
to TO N
confer VB N
additional JJ N
benefit NN N
. . N

-DOCSTART- -21063747- O O

West NNP N
vs. FW N
West NNP N
like IN N
East NNP N
vs. FW N
West NNP N
? . N
A NNP N
comparison NN N
between IN N
Italian JJ p
and CC p
US JJ p
American JJ p
context NN p
sensitivity NN p
and CC p
Fear NNP p
of IN p
Isolation NNP p
. . p

Easterners NNS p
tend VBP N
to TO N
process VB N
information NN N
more RBR N
holistically RB N
than IN N
Westerners NNS p
. . p

Kim NNP N
and CC N
Markman NNP N
( ( N
J NNP N
Exp NNP N
Soc NNP N
Psychol NNP N
42 CD N
( ( N
3 CD N
) ) N
:350-364 NN N
, , N
2006 CD N
) ) N
suggest VBP N
that IN N
these DT N
differences NNS N
are VBP N
rooted VBN N
in IN N
higher JJR N
chronic NN o
levels NNS N
of IN N
Fear NNP N
of IN N
Isolation NNP N
( ( N
FOI NNP N
) ) N
for IN N
those DT N
cultures NNS N
that WDT N
process VBP N
information NN N
more RBR N
holistically RB N
. . N

The DT N
goal NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
determine VB N
if IN N
these DT N
differences NNS o
and CC N
their PRP$ N
suggested VBN N
cause NN N
could MD N
be VB N
found VBN N
with IN N
two CD p
different JJ p
Western JJ p
cultures NNS p
. . p

Testing VBG p
Italian JJ p
( ( p
IT NNP p
) ) p
and CC p
US JJ p
American NNP p
( ( p
US NNP p
) ) p
adults NNS p
, , N
we PRP N
found VBD N
that IN N
IT NNP N
participants VBZ N
processed VBN N
information NN o
more RBR o
holistically RB o
and CC o
had VBD o
a DT o
higher JJR o
chronic JJ o
level NN o
of IN o
FOI NNP o
than IN N
US NNP N
participants NNS N
; : N
furthermore RB N
, , N
the DT N
manipulation NN N
of IN N
FOI NNP o
affected VBD o
context JJ o
sensitivity NN o
more RBR N
for IN N
IT NNP N
than IN N
for IN N
US JJ p
participants NNS p
. . p

The DT N
results NNS N
demonstrate VBP N
that IN N
IT NNP N
participants NNS N
were VBD N
more JJR N
similar JJ N
to TO N
previous JJ N
research NN N
with IN N
Eastern NNP p
populations NNS p
than IN N
with IN N
Western JJ N
populations NNS N
( ( N
Kim NNP N
and CC N
Markman NNP N
in IN N
J NNP N
Exp NNP N
Soc NNP N
Psychol NNP N
42 CD N
( ( N
3 CD N
) ) N
:350-364 NN N
, , N
2006 CD N
) ) N
and CC N
indicate VB N
a DT N
within-Western JJ N
culture NN N
difference NN N
for IN N
reasoning VBG N
styles NNS N
and CC N
support VB N
the DT N
hypothesis NN N
that IN N
this DT o
difference NN o
is VBZ o
due JJ o
to TO o
different JJ o
chronic JJ o
levels NNS o
of IN o
FOI NNP o
. . o

-DOCSTART- -25449737- O O

Selective JJ N
attention NN N
effects NNS N
on IN N
early JJ N
integration NN N
of IN N
social JJ N
signals NNS N
: : N
same JJ N
timing NN N
, , N
modulated VBD N
neural JJ N
sources NNS N
. . N

Humans NNPS p
combine JJ p
co-emitted JJ p
social JJ p
signals NNS p
to TO N
predict VB N
other JJ N
's POS N
immediate JJ N
intentions NNS N
and CC N
prepare VB N
an DT N
adapted JJ N
response NN N
. . N

However RB N
, , N
little JJ N
is VBZ N
known VBN N
about IN N
whether IN N
attending VBG N
to TO N
only RB N
one CD N
of IN N
co-emitted JJ N
social JJ N
signals NNS N
impacts NNS N
on IN N
its PRP$ N
combination NN N
with IN N
other JJ N
signals NNS N
. . N

Here RB N
, , N
using VBG N
electroencephalography NN i
, , N
we PRP N
address VBP N
selective JJ o
attention NN o
effects NNS o
on IN N
early JJ N
combination NN N
of IN N
social JJ N
signals NNS N
. . N

We PRP N
manipulated VBD N
three CD N
visual JJ N
cues NNS N
: : N
gaze JJ N
direction NN N
, , N
emotional JJ N
expression NN N
, , N
and CC N
pointing VBG N
gesture NN N
, , N
while IN N
participants NNS p
performed VBD N
either CC N
emotion NN N
or CC N
gaze JJ N
direction NN N
judgments NNS N
. . N

Results NNS N
showed VBD N
that IN N
a DT N
temporal JJ N
marker NN N
of IN N
social JJ N
cues NNS N
integration NN N
emerges VBZ N
170ms CD N
after IN N
the DT N
stimulus NN N
onset NN N
, , N
even RB N
if IN N
the DT N
integration NN N
of IN N
the DT N
three CD N
visual JJ N
cues NNS N
was VBD N
not RB N
required VBN N
to TO N
perform VB N
the DT N
task NN N
, , N
as IN N
only RB N
one CD N
feature NN N
at IN N
a DT N
time NN N
was VBD N
task JJ N
relevant NN N
. . N

Yet CC N
in IN N
addition NN N
to TO N
common JJ N
temporal JJ N
regions NNS N
, , N
the DT N
relative JJ N
contribution NN N
of IN N
specific JJ N
neural JJ N
sources NNS N
of IN N
this DT N
integration NN N
changed VBD N
as IN N
a DT N
function NN N
of IN N
the DT N
attended JJ N
feature NN N
: : N
integration NN N
during IN N
emotion NN N
judgments NNS N
was VBD N
mainly RB N
implemented VBN N
in IN N
classic JJ N
limbic JJ N
areas NNS N
but CC N
in IN N
the DT N
dorsal NN N
pathway NN N
during IN N
gaze JJ N
direction NN N
judgments NNS N
. . N

Together RB N
, , N
these DT N
findings NNS N
demonstrate VBP N
that IN N
co-emitted JJ o
social JJ o
cues NNS o
are VBP o
integrated VBN o
as RB N
long RB N
as IN N
they PRP N
are VBP N
relevant JJ N
to TO N
the DT N
observer NN p
, , N
even RB N
when WRB N
they PRP N
are VBP N
irrelevant JJ N
to TO N
the DT N
ongoing JJ N
task NN N
. . N

-DOCSTART- -12644413- O O

Clonidine NNP i
premedication NN N
improves VBZ N
metabolic JJ o
control NN o
in IN o
type NN o
2 CD o
diabetic JJ o
patients NNS o
during IN p
ophthalmic JJ p
surgery NN p
. . p

BACKGROUND NNP N
In IN N
stressful JJ N
conditions NNS N
, , N
increasing VBG N
blood NN N
glucose NN N
concentrations NNS N
are VBP N
closely RB N
related VBN N
to TO N
an DT N
increase NN N
in IN N
catecholamines NNS N
and CC N
cortisol NN N
release NN N
. . N

Clonidine NNP N
, , N
a DT N
centrally RB N
acting VBG N
alpha NN N
( ( N
2 CD N
) ) N
-adrenoceptor NN N
agonist NN N
, , N
has VBZ N
neuroendocrine JJ N
effects NNS N
, , N
including VBG N
inhibition NN N
of IN N
sympathoadrenal JJ N
activity NN N
. . N

We PRP N
therefore RB N
evaluated VBD N
the DT N
effect NN N
of IN N
clonidine NN i
on IN N
blood NN o
glucose NN o
control NN o
and CC N
insulin NN o
requirements NNS o
during IN N
ophthalmic JJ N
surgery NN N
when WRB N
given VBN N
as IN N
premedication NN N
in IN N
type NN p
2 CD p
diabetic JJ p
patients NNS p
. . p

METHODS NNP N
After IN N
randomization NN N
, , N
patients NNS N
were VBD N
premedicated VBN N
with IN N
clonidine NN i
or CC i
flunitrazepam NN i
( ( N
control NN N
) ) N
. . N

Patients NNPS N
were VBD N
given VBN N
insulin NN i
by IN N
continuous JJ N
i.v NN N
. . N

infusion NN N
to TO N
maintain VB N
blood NN N
glucose NN N
in IN N
the DT N
range NN N
5.5-11.1 JJ N
mmol NN N
litre NN N
( ( N
-1 NNP N
) ) N
. . N

Blood NNP o
glucose JJ o
concentrations NNS o
were VBD N
measured VBN N
every DT N
15 CD N
min NN N
during IN N
surgery NN N
, , N
and CC N
hourly RB N
for IN N
6 CD N
h NN N
after IN N
surgery NN N
. . N

Plasma NNP o
C-peptide JJ o
and CC o
counter-regulatory JJ o
hormones NNS o
were VBD N
also RB N
measured VBN N
. . N

RESULTS NNP N
Glycaemia NNP o
was VBD N
significantly RB N
lower JJR N
in IN N
the DT N
clonidine NN N
group NN N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
and CC N
the DT N
median JJ o
amount NN o
of IN o
insulin NN o
administered VBN o
was VBD N
significantly RB N
reduced VBN N
: : N
clonidine NN N
group NN N
9.0 CD N
( ( N
interquartile JJ N
range NN N
5.1 CD N
) ) N
units NNS N
; : N
control VB N
18.6 CD N
( ( N
10.2 CD N
) ) N
units NNS N
; : N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

Plasma NNP o
catecholamine JJ o
concentrations NNS o
were VBD N
lower JJR N
in IN N
patients NNS N
given VBN N
clonidine NN i
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
but CC N
there EX N
was VBD N
no DT N
difference NN N
in IN N
cortisol JJ o
concentrations NNS o
. . o

CONCLUSION NNP N
Premedication NNP N
of IN N
type NN p
2 CD p
diabetic JJ p
patients NNS p
with IN N
clonidine JJ i
90 CD N
min NN N
before IN N
surgery NN N
improves VBZ N
blood NN o
glucose VB o
control NN o
and CC N
decreases VBZ N
insulin NN o
requirements NNS o
during IN N
ophthalmic JJ N
surgery NN N
. . N

-DOCSTART- -11699803- O O

Multisite NNP N
, , N
double-blind NN N
, , N
placebo-controlled JJ i
trial NN N
of IN N
porcine NN i
secretin NN i
in IN N
autism NN p
. . p

OBJECTIVE UH N
To TO N
examine VB N
the DT N
efficacy NN o
of IN N
intravenous JJ N
porcine NN i
secretin NN i
for IN N
the DT N
treatment NN o
of IN N
autistic JJ o
disorder NN o
. . o

METHOD NNP N
Randomized NNP N
, , N
double-blind NN N
, , N
placebo-controlled JJ i
, , N
crossover JJ N
design NN N
. . N

Fifty-six JJ p
subjects NNS p
with IN p
autistic JJ p
disorder NN p
received VBD N
either CC N
a DT N
secretin NN i
or CC i
placebo NN i
infusion NN i
at IN N
baseline NN N
and CC N
the DT N
other JJ N
substance NN N
at IN N
week NN N
4 CD N
. . N

Subjects NNS N
were VBD N
given VBN N
the DT N
Autism NNP o
Diagnostic NNP o
Observation NNP o
Schedule NNP o
( ( o
ADOS NNP o
) ) o
and CC N
other JJ N
pertinent JJ o
developmental JJ o
measures NNS o
at IN N
baseline NN N
and CC N
at IN N
weeks NNS N
4 CD N
and CC N
8 CD N
to TO N
assess VB N
drug NN N
effects NNS N
. . N

RESULTS NNP N
For IN N
the DT N
primary JJ N
efficacy NN N
analysis NN N
, , N
change NN N
of IN N
ADOS NNP o
social-communication NN o
total JJ o
score NN o
from IN N
week NN N
0 CD N
to TO N
week NN N
4 CD N
, , N
no DT N
statistically RB N
significant JJ N
difference NN N
was VBD N
obtained VBN N
between IN N
placebo NN i
( ( N
-0.8 JJ N
+/- JJ N
2.9 CD N
) ) N
and CC N
secretin JJ i
groups NNS N
( ( N
-0.6 JJ N
+/- JJ N
1.4 CD N
; : N
t54 NN N
= VBZ N
0.346 CD N
, , N
p NN N
< NNP N
.73 NNP N
) ) N
. . N

The DT N
other JJ N
measures NNS N
showed VBD N
no DT N
treatment NN o
effect NN o
for IN N
secretin NN i
compared VBN N
with IN N
placebo NN i
. . i

CONCLUSION NNP N
There EX N
was VBD N
no DT N
evidence NN N
for IN N
efficacy NN o
of IN N
secretin NN N
in IN N
this DT N
randomized JJ N
, , N
placebo-controlled JJ N
, , N
double-blind JJ N
trial NN N
. . N

-DOCSTART- -20386431- O O

Weight-adjusted JJ N
dalteparin NN i
for IN N
prevention NN N
of IN N
vascular JJ o
thromboembolism NN o
in IN N
advanced JJ p
pancreatic JJ p
cancer NN p
patients NNS p
decreases VBZ N
serum JJ o
tissue NN o
factor NN o
and CC o
serum-mediated JJ o
induction NN o
of IN o
cancer NN o
cell NN o
invasion NN o
. . o

The DT N
aim NN N
of IN N
the DT N
present JJ N
study NN N
was VBD N
to TO N
assess VB N
the DT N
role NN N
of IN N
tissue NN N
factor NN N
and CC N
serum-induced JJ N
cell NN N
invasion NN N
in IN N
patients NNS p
with IN p
advanced JJ o
pancreatic JJ o
cancer NN o
( ( p
APC NNP p
) ) p
. . p

A DT N
cohort NN p
of IN p
39 CD p
patients NNS p
with IN p
APC NNP p
, , p
without IN p
thrombosis NN p
, , p
receiving VBG p
chemotherapy NN i
, , N
were VBD N
entered VBN N
in IN N
a DT N
randomized NN N
controlled VBN N
trial NN N
( ( N
ISRCTN NNP N
= NNP N
76464767 CD N
) ) N
of IN N
thromboprevention NN i
with IN i
weight-adjusted JJ i
dalteparin NN i
( ( N
WAD NNP N
) ) N
. . N

A DT N
total NN N
of IN N
19 CD N
patients NNS N
received VBD N
WAD NNP i
, , N
the DT N
remaining VBG N
20 CD N
acting VBG N
as IN N
a DT N
control NN i
group NN i
. . i

Serum NNP N
from IN N
baseline NN N
and CC N
week NN N
8 CD N
was VBD N
analysed VBN N
for IN N
circulating-tissue JJ N
factor NN N
antigen NN N
using VBG N
ELISA NNP N
. . N

Circulating-tissue NNP o
factor NN o
antigen NN o
rose VBD N
from IN N
324 CD N
pg/ml NN N
, , N
[ NNP N
interquartile NN N
range NN N
( ( N
IQR NNP N
) ) N
282-347 CD N
pg/ml NN N
] NN N
to TO N
356 CD N
pg/ml NN N
, , N
( ( N
IQR NNP N
319-431 NNP N
pg/ml NN N
) ) N
in IN N
controls NNS N
( ( N
C NNP N
) ) N
, , N
and CC N
decreased VBN N
in IN N
the DT N
dalteparin-treated JJ N
group NN N
( ( N
D NNP N
) ) N
from IN N
336 CD N
pg/ml NN N
( ( N
IQR NNP N
281-346 CD N
pg/ml NN N
) ) N
to TO N
303 CD N
pg/ml NN N
( ( N
IQR NNP N
274-339 CD N
pg/ml NN N
) ) N
. . N

The DT N
difference NN N
in IN N
median JJ N
percentage NN N
change NN N
between IN N
D NNP N
and CC N
C NNP N
was VBD N
statistically RB N
significant JJ N
[ JJ N
-4.0 NN N
( ( N
D NNP N
) ) N
vs. FW N
4.7 CD N
( ( N
C NNP N
) ) N
; : N
P NNP N
= VBZ N
0.005 CD N
, , N
n RB N
= VBZ N
39 CD N
] NN N
. . N

Serum-induced JJ o
cellular JJ o
invasion NN o
of IN o
MIA-Paca-2 NNP o
cells NNS o
in IN N
response NN N
to TO N
patient VB N
serum NN N
was VBD N
studied VBN N
using VBG N
a DT N
Boyden NNP N
chamber NN N
assay NN N
in IN N
30 CD N
patients NNS N
( ( N
14 CD N
WAD NNP N
and CC N
16 CD N
C NNP N
) ) N
. . N

The DT N
median JJ o
percentage NN o
change NN o
between IN N
C NNP N
and CC N
D NNP N
was VBD N
significant JJ N
[ JJ N
+54.9 NN N
( ( N
C NNP N
) ) N
vs. FW N
-21.9 FW N
( ( N
D NNP N
) ) N
P NNP N
= $ N
0.025 CD N
, , N
n RB N
= VBZ N
30 CD N
] NN N
. . N

There EX N
was VBD N
a DT N
weak JJ N
correlation NN N
between IN N
BB-tissue NNP N
factor NN N
reduction NN N
and CC N
cellular JJ N
invasion NN N
reduction NN N
( ( N
Spearman NNP N
) ) N
[ VBZ N
0.384 CD N
( ( N
P NNP N
= NNP N
0.037 CD N
, , N
n RB N
= VBZ N
30 CD N
) ) N
] NN N
. . N

APC NNP p
patients NNS p
treated VBD p
with IN N
WAD NNP N
have VBP N
lower JJR o
tissue NN o
factor NN o
antigen NN o
levels NNS o
and CC o
attenuated JJ o
induction NN o
of IN o
cellular JJ o
invasion NN o
in IN o
their PRP$ o
blood NN o
. . o

These DT N
assays NNS N
may MD N
provide VB N
useful JJ N
markers NNS N
to TO N
guide VB N
appropriate JJ N
dalteparin NN N
( ( N
and CC N
other JJ N
low-molecular JJ N
weight NN N
heparin NN N
) ) N
dosing VBG N
schedules NNS N
to TO N
optimize VB N
anticancer JJ o
effects NNS o
of IN N
dalteparin NN N
in IN N
APC NNP N
. . N

-DOCSTART- -22999292- O O

Memantine NNP i
as IN N
adjunctive JJ N
treatment NN N
to TO N
risperidone VB i
in IN N
children NNS p
with IN p
autistic JJ p
disorder NN p
: : p
a DT N
randomized JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ i
trial NN N
. . N

Autism NNP N
is VBZ N
a DT N
neurodevelopmental JJ N
disorder NN N
that WDT N
causes VBZ N
significant JJ N
impairment NN N
in IN N
socialization NN N
and CC N
communication NN N
. . N

It PRP N
is VBZ N
also RB N
associated VBN N
with IN N
ritualistic JJ N
and CC N
stereotypical JJ N
behaviour NN N
. . N

Recent JJ N
studies NNS N
propose VBP N
both DT N
hyper-and JJ N
hypoglutamatergic NN N
ideologies NNS N
for IN N
autism NN N
. . N

The DT N
objective NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
assess VB N
the DT N
effects NNS N
of IN N
memantine NN i
plus CC i
risperidone NN i
in IN N
the DT N
treatment NN N
of IN N
children NNS p
with IN p
autism NN p
. . p

Children NNP p
with IN p
autism NN p
were VBD N
randomly RB N
allocated VBN N
to TO N
risperidone VB i
plus JJ i
memantine NN i
or CC N
placebo NN i
plus CC i
risperidone NN i
for IN N
a DT N
10-wk JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
study NN N
. . N

The DT N
dose NN N
of IN N
risperidone NN i
was VBD N
titrated VBN N
up RB N
to TO N
3 CD N
mg/d NNS N
and CC i
memantine NN i
was VBD N
titrated VBN N
to TO N
20 CD N
mg/d NN N
. . N

Children NNP N
were VBD N
assessed VBN N
at IN N
baseline NN N
and CC N
after IN N
2 CD N
, , N
4 CD N
, , N
6 CD N
, , N
8 CD N
and CC N
10 CD N
wk NN N
of IN N
starting VBG N
medication NN N
protocol NN N
. . N

The DT N
primary JJ N
outcome NN N
measure NN N
was VBD N
the DT o
irritability NN o
subscale NN o
of IN o
Aberrant NNP o
Behavior NNP o
Checklist-Community NNP o
( ( o
ABC-C NNP o
) ) o
. . o

Difference NN N
between IN N
the DT N
two CD N
treatment NN N
arms NNS N
was VBD N
significant JJ N
as IN N
the DT N
group NN N
that WDT N
received VBD i
memantine NN i
had VBD i
greater JJR N
reduction NN N
in IN N
ABC-C NNP o
subscale NN o
scores NNS o
for IN o
irritability NN o
, , o
stereotypic VB o
behaviour NN o
and CC o
hyperactivity NN o
. . o

Eight CD o
side-effects NNS o
were VBD o
observed VBN N
over IN N
the DT N
trial NN N
, , N
out IN N
of IN N
the DT N
25 CD N
side-effects NNS N
that IN N
the DT N
checklist NN N
included VBD N
. . N

The DT N
difference NN N
between IN N
the DT N
two CD N
groups NNS N
in IN N
the DT N
frequency NN N
of IN N
side-effects NNS N
was VBD N
not RB N
significant JJ N
. . N

The DT N
present JJ N
study NN N
suggests VBZ N
that IN i
memantine NN i
may MD i
be VB N
a DT N
potential JJ N
adjunctive JJ N
treatment NN N
strategy NN N
for IN N
autism NN N
and CC N
it PRP N
was VBD N
generally RB N
well RB N
tolerated VBN N
. . N

This DT N
trial NN N
is VBZ N
registered VBN N
with IN N
the DT N
Iranian JJ N
Clinical NNP N
Trials NNP N
Registry NNP N
( ( N
IRCT1138901151556N10 NNP N
; : N
www.irct.ir NN N
) ) N
. . N

-DOCSTART- -1999025- O O

Ten-year JJ N
incidence NN N
of IN N
myocardial JJ N
infarction NN N
and CC N
prognosis NN N
after IN N
infarction NN N
. . N

Department NNP N
of IN N
Veterans NNP N
Affairs NNP N
Cooperative NNP N
Study NNP N
of IN N
Coronary NNP N
Artery NNP N
Bypass NNP N
Surgery NNP N
. . N

BACKGROUND NNP N
The DT N
10-year JJ N
incidence NN N
of IN N
myocardial JJ N
infarction NN N
( ( N
fatal JJ N
and CC N
nonfatal JJ N
) ) N
and CC N
the DT N
prognosis NN N
after IN N
infarction NN N
were VBD N
evaluated VBN N
in IN N
686 CD p
patients NNS p
with IN p
stable JJ p
angina NNS p
who WP N
were VBD N
randomly RB N
assigned VBN N
to TO N
medical JJ i
or CC i
surgical JJ i
treatment NN i
in IN N
the DT N
Veterans NNPS N
Administration NNP N
Cooperative NNP N
Study NNP N
of IN N
Coronary NNP N
Artery NNP N
Bypass NNP N
Surgery NNP N
. . N

METHODS NNP N
AND CC N
RESULTS NNP N
Myocardial NNP N
infarction NN N
was VBD N
defined VBN N
by IN N
either DT N
new JJ N
Q NNP N
wave VBP N
findings NNS N
or CC N
clinical JJ N
symptoms NNS N
compatible JJ N
with IN N
myocardial JJ p
infarction NN p
accompanied VBN p
by IN p
serum NN p
enzyme NN p
elevations NNS p
with IN p
or CC p
without IN p
electrocardiographic JJ p
findings NNS N
. . N

Treatment JJ N
comparisons NNS N
were VBD N
made VBN N
according VBG N
to TO N
original JJ N
treatment NN N
assignment NN N
; : N
35 CD N
% NN N
of IN N
the DT N
medical JJ N
cohort NN N
had VBD N
bypass NN i
surgery NN i
during IN N
the DT N
10-year JJ N
follow-up JJ N
period NN N
. . N

The DT N
overall JJ o
cumulative JJ o
infarction NN o
rate NN o
was VBD N
somewhat RB N
higher JJR N
in IN N
patients NNS N
assigned VBN N
to TO N
surgery VB i
( ( N
36 CD N
% NN N
) ) N
than IN N
in IN N
medical JJ N
patients NNS N
( ( N
31 CD N
% NN N
) ) N
( ( N
p JJ N
= NNP N
0.13 CD N
) ) N
due JJ N
to TO N
perioperative JJ N
infarctions NNS N
( ( N
13 CD N
% NN N
) ) N
and CC N
an DT N
accelerated JJ o
infarction NN o
rate NN o
after IN N
the DT N
fifth JJ N
year NN N
of IN N
follow-up NN N
( ( N
average JJ N
, , N
2.4 CD N
% NN N
/yr NN N
in IN N
the DT N
surgical JJ N
group NN N
versus VBD N
1.4 CD N
% NN N
/yr NN N
in IN N
the DT N
medical JJ N
group NN N
) ) N
. . N

The DT N
10-year JJ o
cumulative JJ o
incidence NN o
of IN o
death NN o
or CC o
myocardial JJ o
infarction NN o
was VBD N
also RB N
higher JJR N
in IN N
surgical JJ N
( ( N
54 CD N
% NN N
) ) N
than IN N
in IN N
medical JJ N
( ( N
49 CD N
% NN N
) ) N
patients NNS N
( ( N
p JJ N
= NNP N
0.20 CD N
) ) N
. . N

According VBG N
to TO N
the DT N
Cox NNP N
model NN N
, , N
the DT N
estimated VBN o
risk NN o
of IN o
death NN o
after IN o
infarction NN o
was VBD N
59 CD N
% NN N
lower JJR N
in IN N
surgical JJ N
than IN N
in IN N
medical JJ N
patients NNS N
( ( N
p NN N
less JJR N
than IN N
0.0001 CD N
) ) N
. . N

The DT N
reduction NN o
in IN N
postinfarction NN o
mortality NN o
with IN N
surgery NN N
was VBD N
most RBS N
striking JJ N
in IN N
the DT N
first JJ N
month NN N
after IN N
the DT N
event NN N
: : N
99 CD N
% NN N
in IN N
the DT N
first JJ N
month NN N
( ( N
p NN N
less JJR N
than IN N
0.0001 CD N
) ) N
and CC N
49 CD N
% NN N
subsequently RB N
( ( N
p NN N
less JJR N
than IN N
0.0001 CD N
) ) N
. . N

The DT N
estimated VBN N
risk NN o
of IN o
death NN o
in IN o
the DT o
absence NN o
of IN o
infarction NN o
was VBD N
nearly RB N
identical JJ N
regardless NN N
of IN N
treatment NN N
( ( N
p JJ N
= NNP N
0.75 CD N
) ) N
. . N

Exclusion NN N
of IN N
perioperative JJ N
infarctions NNS N
did VBD N
not RB N
alter VB N
the DT N
findings NNS N
. . N

CONCLUSIONS NNP N
Although IN N
surgery NN N
does VBZ N
not RB N
reduce VB N
the DT N
incidence NN N
of IN N
myocardial JJ o
infarction NN o
overall RB N
, , N
it PRP N
does VBZ N
reduce VB N
the DT N
risk NN N
of IN N
mortality NN o
after IN N
infarction NN N
, , N
particularly RB N
in IN N
the DT N
first JJ N
30 CD N
days NNS N
after IN N
the DT N
event NN N
( ( N
fatal JJ N
infarctions NNS N
) ) N
. . N

-DOCSTART- -22582764- O O

Teacher-implemented JJ i
joint JJ i
attention NN i
intervention NN i
: : i
pilot NN N
randomized VBD N
controlled VBN N
study NN N
for IN N
preschoolers NNS p
with IN p
autism NN p
. . p

OBJECTIVE CC N
The DT N
vast JJ N
majority NN N
of IN N
children NNS p
with IN p
an DT p
autism NN p
spectrum NN p
disorder NN p
( ( p
ASD NNP p
) ) p
attend VBP p
public JJ p
preschools NNS p
at IN N
some DT N
point NN N
in IN N
their PRP$ N
childhood NN N
. . N

Community NNP N
preschool NN N
practices NNS N
often RB N
are VBP N
not RB N
evidence NN N
based VBN N
, , N
and CC N
almost RB N
none NN N
target NN N
the DT N
prelinguistic JJ N
core NN N
deficits NNS N
of IN N
ASD NNP N
. . N

This DT N
study NN N
investigated VBD N
the DT N
effectiveness NN N
of IN N
public JJ p
preschool NN p
teachers NNS p
implementing VBG N
a DT N
validated VBN N
intervention NN N
( ( i
the DT i
Joint NNP i
Attention NNP i
and CC i
Symbolic NNP i
Play/Engagement NNP i
and CC i
Regulation NNP i
intervention NN i
; : i
JASP/ER NNP i
) ) i
on IN N
a DT N
core NN N
deficit NN N
of IN N
autism NN N
, , N
initiating VBG N
joint JJ N
attention NN N
. . N

METHOD NNP N
Sixteen NNP p
dyads NNS p
( ( p
preschoolers NNS p
with IN p
ASD NNP p
and CC p
the DT p
public JJ p
school NN p
teachers NNS p
who WP p
worked VBD p
in IN p
the DT p
child NN p
's POS p
classroom NN p
) ) p
were VBD N
randomly RB N
assigned VBN N
to TO N
the DT N
6-week JJ N
JASP/ER NNP i
intervention NN i
or CC N
a DT N
control NN i
group NN i
. . i

RESULTS NNP N
At IN N
the DT N
end NN N
of IN N
the DT N
intervention NN N
, , N
JASP/ER NNP i
teachers NNS N
used VBD N
more RBR N
JASP/ER NNP i
strategies NNS N
than IN N
the DT N
control NN N
teachers NNS N
, , N
and CC N
JASP/ER NNP i
preschoolers NNS N
used VBD N
more RBR N
joint JJ o
attention NN o
in IN N
their PRP$ N
classroom NN N
than IN N
control NN N
children NNS N
. . N

Additionally RB N
, , N
JASP/ER NNP i
children NNS N
spent VBD o
more JJR o
time NN o
in IN o
supported JJ o
engagement NN o
and CC o
less JJR o
time NN o
in IN o
object JJ o
engagement NN o
than IN N
control NN N
preschoolers NNS N
on IN N
a DT N
taped VBN i
play NN i
interaction NN i
. . i

CONCLUSIONS NNP N
Findings NNP N
suggest VBP N
that IN N
teachers NNS p
were VBD N
able JJ N
to TO N
improve VB N
a DT N
core NN o
deficit NN o
of IN o
children NNS o
with IN o
ASD NNP o
in IN p
a DT p
public JJ p
preschool NN p
context NN N
. . N

-DOCSTART- -9040453- O O

Determining VBG N
the DT N
trough-to-peak JJ o
ratio NN o
in IN N
parallel-group JJ N
trials NNS N
. . N

Systolic JJ N
Hypertension NNP N
in IN N
Europe NNP N
( ( N
SYST-EUR NNP N
) ) N
Trial NNP N
Investigators NNP N
. . N

We PRP N
explored VBD N
how WRB N
in IN N
parallel-group JJ N
trials NNS N
interindividual JJ N
variability NN N
, , N
correction NN N
for IN N
placebo NN N
effects NNS N
, , N
and CC N
smoothing NN N
of IN N
blood NN N
pressure NN N
profiles NNS N
can MD N
be VB N
handled VBN N
in IN N
measuring VBG N
the DT N
trough-to-peak JJ o
ratio NN o
in IN N
244 CD p
individuals NNS p
with IN p
isolated JJ p
systolic JJ p
hypertension NN p
( ( p
> CD p
or CC p
= $ p
60 CD p
years NNS p
) ) p
enrolled VBD p
in IN p
the DT p
placebo-controlled JJ p
Systolic NNP p
Hypertension NNP p
in IN p
europe JJ p
Trial NNP p
. . p

Net JJ N
treatment NN N
effects NNS N
were VBD N
computed VBN N
by IN N
subtracting VBG N
the DT N
mean JJ N
changes NNS N
from IN N
baseline NN N
during IN N
placebo NN N
( ( N
n JJ N
= NNP N
133 CD N
) ) N
from IN N
those DT N
during IN N
active JJ N
treatment NN N
( ( N
n JJ N
= NNP N
111 CD N
) ) N
. . N

At IN p
entry NN p
, , p
systolic/diastolic JJ o
pressures NNS o
averaged VBD p
176/86 CD p
mm NN p
Hg NNP p
in IN p
the DT p
clinic NN p
and CC p
149/80 CD p
mm NN p
Hg NNP p
on IN p
24-hour JJ p
ambulatory JJ p
monitoring NN p
. . p

With IN N
corrections NNS N
applied VBN N
for IN N
baseline NN N
and CC N
placebo NN N
, , N
nitrendipine NN i
( ( i
10 CD i
to TO i
40 CD i
mg/d NN i
) ) i
, , i
with IN i
the DT i
possible JJ i
addition NN i
of IN i
enalapril NN i
( ( i
5 CD i
to TO i
20 CD i
mg/d NN i
) ) i
and/or NN i
hydrochlorothiazide NN i
( ( i
12.5 CD i
to TO i
25 CD i
mg/d NN i
) ) i
, , i
reduced VBN i
( ( i
P NNP i
< NNP i
.001 NNP i
) ) i
these DT i
blood NN o
pressure NN o
values NNS o
by IN i
16.6/7.3 CD i
and CC i
9.8/4.7 CD i
mm NN i
Hg NNP i
, , i
respectively RB i
. . i

The DT N
net JJ o
trough-to-peak JJ o
ratios NNS o
were VBD N
first RB N
determined VBN N
from IN N
blood NN o
pressure NN o
profiles NNS o
( ( i
12 CD i
hours NNS i
) ) i
with IN i
1-hour JJ i
precision NN i
, , i
synchronized VBN i
by IN i
the DT i
morning NN i
and CC i
evening NN i
doses NNS i
of IN i
the DT i
double-blind JJ i
medication NN i
. . i

According VBG N
to TO N
the DT N
usual JJ N
approach NN N
, , N
disregarding VBG N
interindividual JJ N
variability NN N
, , N
the DT N
systolic/diastolic JJ o
net JJ o
trough-to-peak JJ o
ratios NNS o
were VBD N
0.46/0.40 CD N
in IN N
the DT N
morning NN N
and CC N
0.77/0.99 CD N
in IN N
the DT N
evening NN N
. . N

In IN N
individual JJ N
subjects NNS N
, , N
the DT N
baseline-adjusted JJ o
trough-to-peak JJ o
ratios NNS o
were VBD N
nonnormally RB N
distributed VBN N
. . N

We PRP N
therefore VBP N
used VBD N
a DT N
nonparametric JJ N
technique NN N
to TO N
calculate VB N
the DT N
net JJ o
trough-to-peak JJ o
ratios NNS o
from IN N
the DT N
results NNS N
in IN N
individual JJ N
subjects NNS N
. . N

In IN N
the DT N
morning NN N
, , N
these DT N
ratios NNS N
averaged VBD N
0.25 CD N
systolic NN N
( ( N
95 CD N
% NN N
confidence NN N
interval NN N
, , N
0.09 CD N
to TO N
0.41 CD N
) ) N
and CC N
0.15 CD N
diastolic NN N
( ( N
95 CD N
% NN N
confidence NN N
interval NN N
, , N
0.00 CD N
to TO N
0.31 CD N
) ) N
and CC N
in IN N
the DT N
evening NN N
, , N
0.19 CD N
and CC N
0.36 CD N
( ( N
95 CD N
% NN N
confidence NN N
intervals NNS N
, , N
0.00 CD N
to TO N
0.38 CD N
and CC N
0.14 CD N
to TO N
0.56 CD N
) ) N
, , N
respectively RB N
. . N

When WRB N
the DT N
blood NN o
pressure NN o
profiles NNS o
were VBD N
smoothed VBN N
by IN N
substituting VBG N
the DT N
1-hour JJ N
averages NNS N
by IN N
moving VBG N
or CC N
fixed VBN N
2-hour JJ N
averages NNS N
or CC N
by IN N
Fourier NNP N
modeling NN N
, , N
the DT N
trough-to-peak JJ o
ratios NNS o
remained VBD N
unchanged JJ N
after IN N
the DT N
morning NN N
dose NN N
( ( N
0.20/0.13 CD N
, , N
0.20/0.14 CD N
, , N
and CC N
0.16/0.21 CD N
, , N
respectively RB N
) ) N
but CC N
tended VBD N
to TO N
increase VB N
in IN N
the DT N
evening NN N
( ( N
0.32/0.38 CD N
, , N
0.28/0.40 CD N
, , N
and CC N
0.48/0.49 CD N
) ) N
. . N

In IN N
conclusion NN N
, , N
the DT N
parallel-group JJ N
analysis NN N
proposed VBN N
makes VBZ N
it PRP N
possible JJ N
for IN N
one CD N
to TO N
correct VB N
the DT N
trough-to-peak JJ o
ratio NN o
for IN N
baseline NN N
as RB N
well RB N
as IN N
placebo NN N
, , N
to TO N
account VB N
for IN N
interindividual JJ N
variability NN N
, , N
and CC N
to TO N
calculate VB N
a DT N
confidence NN N
interval NN N
for IN N
the DT N
net JJ N
trough-to-peak JJ o
ratio NN o
. . o

Accounting NN N
for IN N
interindividual JJ N
variability NN N
reduces VBZ N
the DT N
trough-to-peak JJ o
ratio NN o
. . o

Smoothing VBG N
affects VBZ N
the DT N
individualized JJ N
net JJ N
trough-to-peak JJ o
ratios NNS o
in IN N
an DT N
unpredictable JJ N
way NN N
and CC N
should MD N
therefore RB N
be VB N
avoided VBN N
. . N

-DOCSTART- -25279666- O O

Dental NNP i
prophylaxis NN i
decreases VBZ p
the DT p
risk NN p
of IN p
esophageal JJ o
cancer NN o
in IN p
males NNS p
; : p
a DT p
nationwide JJ p
population-based JJ p
study NN p
in IN p
Taiwan NNP p
. . p

BACKGROUND NNP N
Periodontal NNP N
disease NN N
( ( N
PD NNP N
) ) N
is VBZ N
one CD N
of IN N
the DT N
most RBS N
common JJ N
chronic JJ N
inflammatory NN N
diseases NNS N
. . N

Esophageal NN o
cancer NN o
( ( o
EC NNP o
) ) o
is VBZ p
also RB p
a DT p
common JJ p
cause NN p
of IN p
death NN p
due JJ p
to TO p
cancer NN p
among IN p
males NNS p
. . p

Systemic NNP N
inflammatory NN N
processes NNS N
have VBP N
been VBN N
shown VBN N
to TO N
increase VB N
the DT N
risk NN N
of IN N
cancer NN o
. . o

We PRP N
conducted VBD N
a DT N
retrospective JJ N
cohort NN N
study NN N
to TO N
investigate VB N
the DT N
association NN N
between IN N
PD NNP o
and CC o
EC NNP o
. . o

METHODS NNP N
A NNP N
total NN N
of IN N
718,409 CD p
subjects NNS p
were VBD p
recruited VBN p
from IN p
the DT p
Taiwan NNP p
National NNP p
Health NNP p
Insurance NNP p
Research NNP p
Database NNP p
( ( p
NHIRD NNP p
) ) p
and CC N
followed VBN N
from IN N
January NNP N
1 CD N
, , N
2000 CD N
to TO N
December NNP N
31 CD N
, , N
2010 CD N
. . N

Of IN N
these DT N
, , N
519,831 CD p
subjects NNS p
were VBD p
diagnosed VBN p
with IN p
PD NNP p
and CC N
were VBD N
grouped VBN N
according VBG N
to TO N
the DT N
most RBS N
advanced JJ N
treatment NN N
they PRP N
received VBD N
: : N
dental JJ i
prophylaxis NN i
, , i
intensive JJ i
treatment NN i
, , i
or CC i
no DT i
treatment NN i
. . i

The DT N
IRs NNP o
of IN o
EC NNP o
were VBD N
compared VBN N
among IN N
groups NNS N
. . N

RESULTS VB N
A DT N
total NN N
of IN N
682 CD p
patients NNS p
developed VBD p
EC NNP o
, , N
resulting VBG N
in IN N
an DT N
overall JJ o
IR NNP o
of IN N
0.11 CD N
case-number JJ N
per IN N
1000 CD N
person-years NNS N
( ( p
?/y NN p
) ) p
. . p

The DT p
dental JJ p
prophylaxis NN p
group NN p
had VBD p
a DT N
significantly RB N
lower JJR o
IR NNP o
of IN o
EC NNP o
( ( o
0.06?/y CD N
) ) N
than IN N
other JJ N
groups NNS N
( ( N
p JJ N
< NNP N
0.001 CD o
) ) o
. . o

Multivariable JJ o
Cox NNP o
regression NN o
analysis NN o
further RBR o
revealed VBD N
that IN N
male JJ p
subjects NNS p
[ JJ p
hazard NN p
ratio NN N
( ( N
HR NNP N
) ) N
= VBD N
10.04 CD N
, , N
95 CD N
% NN N
confidence NN N
interval NN N
( ( N
CI NNP N
) ) N
= VBD N
7.58-13.30 JJ N
] NN N
, , N
as RB N
well RB N
as IN N
a DT N
history NN N
of IN N
esophageal JJ N
ulcers NNS N
( ( N
HR NNP N
= NNP N
7.10 CD N
, , N
95 CD N
% NN N
CI NNP N
= NNP N
5.03-10.01 JJ N
) ) N
, , N
alcohol NN N
abuse NN N
( ( N
HR NNP N
= NNP N
5.46 CD N
, , N
95 CD N
% NN N
CI NNP N
= NNP N
2.26-13.18 JJ N
) ) N
, , N
or CC N
esophageal VB N
reflux NN N
( ( N
HR NNP N
= NNP N
1.86 CD N
, , N
95 CD N
% NN N
CI NNP N
= NNP N
1.02-3.52 JJ N
) ) N
, , N
were VBD N
factors NNS N
associated VBN N
with IN N
a DT N
higher JJR N
risk NN N
of IN N
EC NNP N
. . N

And CC p
the DT p
dental JJ p
prophylaxis NN p
group NN p
showed VBD N
a DT N
significantly RB N
lower JJR N
risk NN N
for IN o
EC NNP o
( ( o
HR NNP N
= NNP N
0.53 CD N
, , N
95 CD N
% NN N
CI NNP N
= NNP N
0.44-0.65 NN N
) ) N
. . N

Further NNP N
subgroup NN N
analysis NN p
showed VBD p
that IN p
the DT p
dental JJ p
prophylaxis NN p
group NN p
among IN p
males NNS p
had VBD p
a DT p
significant JJ p
lower JJR p
risk NN p
( ( p
HR NNP p
= NNP N
0.54 CD N
, , N
95 CD N
% NN N
CI NNP N
= NNP N
0.44-0.66 NN N
) ) N
for IN o
EC NNP o
, , N
while IN N
that DT N
of IN N
the DT N
females NNS N
did VBD N
not RB N
has VBZ N
statistically RB N
significant JJ N
difference NN N
. . N

CONCLUSION NN N
For IN N
this DT N
cohort NN N
, , N
subjects VBZ N
received VBN N
dental JJ N
prophylaxis NN N
reduced VBD N
the DT o
risk NN o
of IN o
EC NNP o
compared VBN N
to TO N
all DT N
PD NNP N
and CC N
no DT N
PD NNP N
groups NNS N
among IN N
males NNS N
. . N

-DOCSTART- -19897177- O O

Intranasal NNP N
oxytocin PRP i
improves VBZ N
emotion NN o
recognition NN o
for IN N
youth NN p
with IN p
autism NN p
spectrum NN p
disorders NNS p
. . p

BACKGROUND VB N
A NNP N
diagnostic JJ N
hallmark NN N
of IN N
autism NN N
spectrum NN N
disorders NNS N
is VBZ N
a DT N
qualitative JJ N
impairment NN N
in IN N
social JJ N
communication NN N
and CC N
interaction NN N
. . N

Deficits NNS N
in IN N
the DT N
ability NN N
to TO N
recognize VB N
the DT N
emotions NNS N
of IN N
others NNS N
are VBP N
believed VBN N
to TO N
contribute VB N
to TO N
this DT N
. . N

There EX N
is VBZ N
currently RB N
no DT N
effective JJ N
treatment NN N
for IN N
these DT N
problems NNS N
. . N

METHODS NNP N
In IN N
a DT N
double-blind NN N
, , N
randomized VBN N
, , N
placebo-controlled JJ N
, , N
crossover JJ N
design NN N
, , N
we PRP N
administered VBD N
oxytocin RP i
nasal JJ i
spray NN i
( ( N
18 CD N
or CC N
24 CD N
IU NNPS N
) ) N
or CC N
a DT N
placebo NN i
to TO N
16 CD p
male NN p
youth NN p
aged VBD p
12 CD p
to TO p
19 CD p
who WP p
were VBD p
diagnosed VBN p
with IN p
Autistic NNP p
or CC p
Asperger NNP p
's POS p
Disorder NNP p
. . p

Participants NNS p
then RB N
completed VBD N
the DT N
Reading VBG o
the DT o
Mind NNP o
in IN o
the DT o
Eyes NNP o
Task NNP o
, , N
a DT N
widely RB N
used VBN N
and CC N
reliable JJ N
test NN N
of IN N
emotion NN o
recognition NN o
. . o

RESULTS NNP N
In IN N
comparison NN N
with IN N
placebo NN i
, , i
oxytocin JJ i
administration NN N
improved VBD N
performance NN o
on IN o
the DT o
Reading VBG o
the DT o
Mind NNP o
in IN o
the DT o
Eyes NNP o
Task NNP o
. . o

This DT N
effect NN N
was VBD N
also RB N
shown VBN N
when WRB N
analysis NN N
was VBD N
restricted VBN N
to TO N
the DT N
younger JJR p
participants NNS p
aged VBD p
12 CD p
to TO p
15 CD p
who WP N
received VBD N
the DT N
lower JJR N
dose NN N
. . N

CONCLUSIONS VB N
This DT N
study NN N
provides VBZ N
the DT N
first JJ N
evidence NN N
that IN N
oxytocin JJ N
nasal NN N
spray NN N
improves VBZ N
emotion NN o
recognition NN o
in IN N
young JJ p
people NNS p
diagnosed VBN p
with IN p
autism NN p
spectrum NN p
disorders NNS p
. . p

Findings NNS N
suggest VBP N
the DT N
potential NN N
of IN N
earlier JJR N
intervention NN N
and CC N
further JJ N
evaluation NN N
of IN N
oxytocin JJ i
nasal JJ N
spray NN N
as IN N
a DT N
treatment NN N
to TO N
improve VB N
social JJ N
communication NN N
and CC N
interaction NN N
in IN N
young JJ p
people NNS p
with IN p
autism NN p
spectrum NN p
disorders NNS p
. . p

-DOCSTART- -10593347- O O

Cholesterol-lowering JJ N
effect NN N
of IN N
stanol NN i
ester NN i
in IN N
a DT N
US NNP p
population NN p
of IN p
mildly RB p
hypercholesterolemic JJ p
men NNS p
and CC p
women NNS p
: : p
a DT N
randomized NN N
controlled VBN N
trial NN N
. . N

OBJECTIVE NN N
To TO N
determine VB N
the DT N
efficacy NN N
of IN N
stanol NN i
esters NNS i
in IN N
lowering VBG N
cholesterol NN N
in IN N
a DT N
US NNP p
population NN p
. . p

SUBJECTS NNP N
AND NNP N
METHODS NNP N
After IN N
a DT N
run-in JJ N
phase NN N
, , N
318 CD p
subjects NNS p
were VBD N
randomized VBN N
to TO N
receive VB N
one CD N
of IN N
the DT N
following JJ N
margarine-like JJ N
spreads NNS N
containing VBG N
stanol JJ i
ester NN i
or CC i
placebo NN i
for IN N
8 CD N
weeks NNS N
: : N
EU NNP N
3 CD N
G NNP N
: : N
1 CD N
g NN N
of IN N
stanol NN i
( ( i
ester JJ i
form NN i
) ) i
per IN N
8-g JJ N
serving NN N
of IN N
a DT N
European JJ N
formula NN N
3 CD N
times NNS N
a DT N
day NN N
; : N
US PRP N
3 CD N
G NNP N
: : N
1 CD N
g NN N
of IN N
stanol NN i
( ( i
ester JJ i
form NN i
) ) i
per IN N
8-g JJ N
serving NN N
of IN N
a DT N
US NNP N
reformulation NN N
3 CD N
times NNS N
a DT N
day NN N
; : N
US PRP N
2 CD N
G NNP N
: : N
0.67 CD N
g NN N
of IN N
stanol NN i
( ( N
ester JJ N
form NN N
) ) N
per IN N
8-g JJ N
serving NN N
of IN N
a DT N
US NNP N
reformulation NN N
3 CD N
times NNS N
a DT N
day NN N
; : N
or CC N
placebo VB i
spread NN N
. . N

RESULTS JJ N
Mean JJ o
+/- JJ o
SD NNP o
baseline NN o
total NN o
cholesterol NN o
( ( o
TC NNP o
) ) o
and CC o
low-density JJ o
lipoprotein NN o
cholesterol NN o
( ( o
LDL-C NNP o
) ) o
levels NNS o
were VBD N
233+/-20 JJ N
and CC N
153+21 CD N
mg+/-dL NN N
, , N
respectively RB N
. . N

In IN N
the DT N
US NNP N
3 CD N
G NNP N
group NN N
, , N
3 CD N
g JJ N
daily NN N
of IN N
stanol JJ i
esters NNS i
lowered VBD N
TC NNP o
and CC o
LDL-C NNP o
levels NNS o
by IN N
6.4 CD N
% NN N
and CC N
10.1 CD N
% NN N
, , N
respectively RB N
. . N

There EX N
was VBD N
a DT N
dose-dependent JJ N
response NN N
compared VBN N
with IN N
2 CD N
g NNS N
daily RB N
( ( N
US PRP N
2 CD N
G NNP N
) ) N
. . N

Triglyceride NNP o
and CC o
high-density NN o
lipoprotein NNS o
cholesterol NN o
levels NNS o
were VBD N
unchanged JJ N
. . N

The DT N
incidence NN N
of IN N
adverse JJ o
effects NNS o
was VBD N
not RB N
different JJ N
from IN N
placebo NN i
. . i

Serum NNP o
vitamin VBD o
A DT o
and CC o
25-hydroxyvitamin JJ o
D NNP o
levels NNS o
were VBD N
not RB N
affected VBN N
. . N

CONCLUSIONS NNP N
Stanol NNP i
esters NNS i
lowered VBD N
TC NNP o
and CC o
LDL-C NNP o
levels NNS o
in IN N
a DT N
mildly RB p
hypercholesterolemic JJ p
US NNP p
population NN p
without IN N
evidence NN N
of IN N
adverse JJ N
effects NNS N
. . N

It PRP N
may MD N
be VB N
a DT N
useful JJ N
dietary JJ N
adjunct NN N
to TO N
lower VB N
cholesterol NN N
. . N

-DOCSTART- -9697788- O O

Comparison NNP N
of IN N
prostate-specific JJ i
antigen NN i
corrected VBN i
for IN i
total JJ i
prostate NN i
volume NN i
and CC i
transition NN i
zone NN i
volume NN i
in IN N
a DT N
population-based JJ p
screening NN p
study NN p
. . p

OBJECTIVES NNP N
To TO N
compare VB N
the DT N
discriminatory JJ N
potential NN N
between IN N
prostate NN p
cancer NN p
and CC p
benign JJ p
conditions NNS p
of IN p
the DT p
prostate NN p
in IN N
a DT N
population-based JJ N
screening NN i
study NN i
, , i
of IN i
serum JJ i
prostate-specific JJ i
antigen NN i
levels NNS i
( ( i
PSA NNP i
) ) i
and CC i
PSA NNP i
corrected VBD i
for IN i
both DT i
the DT i
total JJ i
prostate NN i
volume NN i
( ( i
PSA-D NNP i
) ) i
and CC i
the DT i
transition NN i
zone NN i
volume NN i
( ( i
PSA-T NNP i
) ) i
. . i

METHODS NNP N
In IN N
a DT N
randomized JJ N
population-based JJ N
screening NN N
study NN N
( ( p
Rotterdam NNP p
section NN p
of IN p
the DT p
European NNP p
Randomized NNP p
Study NNP p
of IN p
Screening NNP p
for IN p
Prostate NNP p
Cancer NNP p
) ) p
, , N
in IN N
which WDT N
10,865 CD p
men NNS p
have VBP p
been VBN p
screened VBN p
, , N
the DT N
biopsy NN i
results NNS i
of IN p
1202 CD p
men NNS p
with IN p
PSA NNP p
levels NNS p
of IN p
4 CD p
ng/mL NNS p
or CC p
more JJR p
were VBD N
evaluated VBN N
. . N

Planimetric NNP i
and CC i
prolate VB i
ellipsoid JJ i
volumes NNS i
of IN i
the DT i
total JJ i
prostate NN i
as RB i
well RB i
as IN i
of IN i
the DT i
transition NN i
zone NN i
were VBD i
measured VBN i
. . i

The DT N
measured JJ N
volumes NNS N
were VBD N
compared VBN N
with IN N
the DT N
volumes NNS i
of IN i
57 CD i
radical JJ i
prostatectomy NN i
specimens NNS i
through IN N
Spearman NNP N
's POS N
rank NN N
correlation NN N
coefficient NN N
and CC N
agreement NN N
tests NNS N
. . N

A DT N
receiver NN N
operating VBG N
characteristic JJ N
( ( N
ROC NNP N
) ) N
curve VBP N
analysis NN N
was VBD N
done VBN N
of IN N
sensitivity NN N
and CC N
specificity NN N
of IN N
biopsy NN N
indications NNS N
through IN N
PSA NNP i
and CC i
PSA NNP i
corrected VBD i
for IN i
the DT i
volumes NNS i
measured VBN i
with IN N
transrectal JJ N
ultrasound NN N
. . N

RESULTS NNP N
In IN N
the DT N
1202 CD p
men NNS p
studied VBD p
, , p
361 CD p
cases NNS p
of IN p
prostate NN p
cancer NN p
were VBD N
diagnosed VBN N
. . N

Both DT N
PSA-D NNP N
and CC N
PSA-T NNP N
showed VBD N
a DT N
significantly RB N
higher JJR N
area NN o
under IN o
the DT o
ROC NNP o
curve NN o
( ( N
0.77 CD N
and CC N
0.79 CD N
, , N
respectively RB N
) ) N
than IN N
PSA NNP N
alone RB N
( ( N
area NN N
0.65 CD N
) ) N
. . N

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
between IN N
PSA-D NNP N
and CC N
PSA-T NNP N
. . N

The DT N
use NN N
of IN N
a DT N
PSA-D NNP N
threshold JJ N
value NN N
of IN N
0 CD N
. . N

10 CD N
ng/mL/cc NN N
would MD N
have VB N
avoided VBN N
28 CD N
% NN N
of IN N
biopsies NNS N
at IN N
the DT N
cost NN N
of IN N
10 CD N
% NN N
of IN N
detectable JJ N
cancers NNS N
. . N

A DT N
PSA-D JJ N
threshold NN N
of IN N
0.15 CD N
ng/mL/cc NNS N
would MD N
have VB N
avoided VBN N
73.8 CD N
% NN N
of IN N
biopsies NNS N
at IN N
the DT N
cost NN N
of IN N
not RB N
diagnosing VBG N
43.8 CD N
% NN N
of IN N
detectable JJ N
cancers NNS N
. . N

CONCLUSIONS VB N
The DT N
planimetrically RB N
obtained JJ N
prostate NN N
volume NN N
showed VBD N
a DT N
more RBR N
favorable JJ N
agreement NN N
with IN N
the DT N
radical JJ N
prostatectomy NN N
volume NN N
than IN N
the DT N
prolate JJ N
ellipsoid NN N
volume NN N
. . N

The DT N
discriminatory JJ N
potential NN N
of IN N
the DT N
corrected VBN N
PSA NNP o
value NN o
is VBZ N
better JJR N
at IN N
predicting VBG N
the DT N
results NNS N
of IN N
needle JJ N
biopsy NN N
of IN N
the DT N
prostate NN N
when WRB N
compared VBN N
with IN N
PSA NNP N
alone RB N
. . N

The DT N
use NN N
of IN N
the DT N
transition NN i
zone NN i
volume NN i
for IN N
this DT N
correction NN N
results NNS N
in IN N
a DT N
higher JJR N
discriminatory JJ N
potential NN N
when WRB N
compared VBN N
to TO N
the DT N
use NN N
of IN N
the DT N
total JJ i
prostate NN i
volume NN i
; : i
however RB N
, , N
the DT N
observed JJ N
difference NN N
was VBD N
not RB N
statistically RB N
significant JJ N
. . N

-DOCSTART- -8823584- O O

One CD i
quadrant JJ i
sub-Tenon NN i
's POS i
capsule NN i
anesthesia NN i
in IN N
anterior JJ p
segment NN p
surgery NN p
. . p

Reports NNS N
of IN N
complications NNS N
associated VBN N
with IN N
local JJ p
anesthesia NN p
in IN p
ophthalmic JJ p
surgery NN p
have VBP N
increased VBN N
conspicuously RB N
in IN N
recent JJ N
years NNS N
. . N

Sub-Tenon NNP i
's POS i
capsule NN i
anesthesia NN i
for IN N
anterior JJ N
segment NN N
surgery NN N
avoids IN N
the DT N
risks NNS N
of IN N
retrobulbar NN i
and CC N
peribulbar NN N
injections NNS N
. . N

This DT N
study NN N
compared VBN N
sub-Tenon NN i
's POS i
and CC N
retrobulbar NN i
anesthesia NN i
. . i

Patients NNS p
undergoing VBG p
various JJ p
anterior JJ p
segment NN p
surgery NN p
were VBD N
randomly RB N
assigned VBN N
to TO N
sub-Tenon NN i
's POS i
or CC i
retrobulbar NN i
anesthesia NN i
; : i
300 CD p
were VBD p
operated VBN p
with IN p
1-quadrant JJ i
sub-Tenon NN i
's POS i
anesthesia NN i
( ( i
1-QST JJ i
) ) i
and CC p
the DT p
results NNS p
were VBD p
compared VBN p
with IN p
270 CD p
patients NNS p
operated VBN p
with IN p
retrobulbar NN i
anesthesia NN i
. . i

Retrobulbar NNP i
anesthesia NN i
consisted VBD N
of IN N
a DT N
2.5 CD N
ml NN N
injection NN N
of IN N
a DT N
1:1 CD N
mixture NN N
of IN N
2 CD N
% NN N
lidocaine NN i
without IN i
epinephrine NN i
and CC i
0.5 CD i
% NN i
bupivacaine NN i
. . i

Sub-Tenon NNP i
's POS i
anesthesia NN i
involved VBN N
direct JJ N
transconjunctival JJ N
infiltration NN N
of IN N
the DT N
same JJ N
local JJ N
anesthetic JJ N
directly RB N
into IN N
the DT N
sub-Tenon NN N
's POS N
space NN N
, , N
in IN N
the DT N
inferior-nasal JJ N
quadrant NN N
, , N
using VBG N
a DT N
blunt NN N
23-gauge JJ N
cannula NN N
. . N

Patients NNS p
undergoing VBG p
various JJ p
anterior JJ p
segment NN p
surgery NN p
procedures NNS p
were VBD N
randomly RB N
assigned VBN N
to TO N
1-QST CD i
or CC N
retrobulbar VB i
anesthesia NN i
; : i
300 CD N
patients NNS N
were VBD N
operated VBN N
with IN N
1-QST JJ N
and CC N
the DT N
results NNS N
were VBD N
compared VBN N
with IN N
270 CD N
patients NNS N
operated VBN N
with IN N
retrobulbar NN N
anesthesia NN N
. . N

Preinjection NN o
mean NN o
( ( o
+/- JJ o
SD NNP o
) ) o
IOP NNP o
wer $ N
12.9 CD N
+/- JJ N
3.7 CD N
mmHg NN N
in IN N
the DT N
retrobulbar NN i
and CC N
13.4 CD N
+/- JJ N
3.2 CD N
mmHg NN N
in IN N
the DT N
1-QST JJ i
patients NNS N
. . N

Preoperative JJ o
intraocular JJ o
pressures NNS o
were VBD N
8.7 CD N
+/- JJ N
3.0 CD N
mmHg NN N
in IN N
the DT N
retrobulbar NN i
and CC N
9.2 CD N
+/- JJ N
3.2 CD N
mmHg NN N
in IN N
1-QST JJ i
patients NNS N
. . N

Pre- NNP o
and CC o
postinjection NN o
IOP NNP o
for IN N
retrobulbar NN i
and CC N
1-QST JJ i
patients NNS N
were VBD N
similar JJ N
. . N

Pain NN o
scores NNS o
for IN o
delivery NN o
of IN o
the DT o
anesthetic JJ o
, , N
using VBG N
a DT N
numerical JJ o
rating NN o
scale NN o
, , N
produced VBD N
a DT N
median JJ N
score NN N
of IN N
1 CD N
for IN N
1-QST JJ N
and CC N
2 CD N
for IN N
the DT N
retrobulbar NN i
technique NN N
. . N

For IN N
the DT N
subsequent JJ N
operative JJ N
procedure NN N
, , N
the DT N
median JJ N
score NN N
was VBD N
1 CD N
for IN N
1-QST JJ i
and CC N
2 CD N
for IN N
the DT N
retrobulbar NN N
patients NNS N
. . N

Complete JJ o
akinesia NN o
was VBD N
achieved VBN N
in IN N
41 CD N
% NN N
with IN N
1-QST JJ i
and CC N
in IN N
69 CD N
% NN N
of IN N
retrobulbar NN N
patients NNS N
. . N

1-QST JJ i
patients NNS N
with IN N
incomplete JJ o
akinesia NN o
most RBS N
often RB N
had VBD N
lateral JJ o
muscle NN o
function NN o
which WDT N
did VBD N
not RB N
interfere VB N
with IN N
the DT N
operation NN N
. . N

We PRP N
found VBD N
the DT N
use NN N
of IN N
a DT N
blunt NN N
cannula NN N
to TO N
deliver VB N
anesthetic JJ N
into IN N
the DT N
sub-Tenon NN N
's POS N
space NN N
as IN N
a DT N
simple NN N
, , N
safe JJ N
and CC N
effective JJ N
alternative JJ N
approach NN N
to TO N
traditional JJ N
retrobulbar NN i
anesthesia NN i
in IN N
anterior JJ N
segment NN N
surgery NN N
. . N

-DOCSTART- -16957425- O O

Effects NNS N
of IN N
monotherapy NN i
and CC i
combination NN i
therapy NN i
on IN N
blood NN N
pressure NN N
control NN N
and CC N
target NN N
organ JJ N
damage NN N
: : N
a DT N
randomized JJ N
prospective JJ N
intervention NN N
study NN N
in IN N
a DT N
large JJ p
population NN p
of IN p
hypertensive JJ p
patients NNS p
. . p

This DT N
prospective JJ N
, , N
randomized JJ N
trial NN N
evaluated VBD N
the DT N
effect NN N
of IN N
monotherapy NN i
and CC i
different JJ i
combination NN i
therapies NNS i
on IN N
cardiovascular JJ p
target NN p
organ JJ p
damage NN p
and CC p
metabolic JJ p
profile NN p
in IN p
520 CD p
hypertensive JJ p
patients NNS p
. . p

Patients NNS N
were VBD N
allocated VBN N
to TO N
a DT N
single JJ N
agent NN N
: : N
carvedilol NN i
25 CD i
mg NN i
, , i
amlodipine VBP i
10 CD i
mg NN i
, , i
enalapril VBZ i
20 CD i
mg NN i
, , i
or CC i
losartan VBZ i
50 CD i
mg NN i
( ( N
groups NNS N
C NNP N
, , N
A NNP N
, , N
E NNP N
, , N
and CC N
L NNP N
, , N
respectively RB N
) ) N
. . N

After IN N
2 CD N
months NNS N
( ( N
level JJ N
2 CD N
) ) N
, , N
nonresponders NNS N
received VBD N
a DT N
low-dose JJ i
thiazide NN i
diuretic NN i
, , N
and CC N
after IN N
4 CD N
months NNS N
( ( N
level JJ N
3 CD N
) ) N
, , N
amlodipine JJ i
( ( N
groups NNS N
E NNP N
, , N
C NNP N
, , N
and CC N
L NNP N
) ) N
and CC N
carvedilol NN i
( ( N
group NN N
A DT N
) ) N
. . N

Twenty-four-hour JJ o
blood NN o
pressure NN o
was VBD N
significantly RB N
lowered VBN N
in IN N
all DT N
treatment NN N
groups NNS N
. . N

Blood NNP o
pressure NN o
control NN o
was VBD N
more RBR N
pronounced JJ N
in IN N
patients NNS p
receiving VBG N
two CD N
or CC N
three CD N
drugs NNS N
. . N

At IN N
the DT N
end NN N
of IN N
the DT N
study NN N
, , N
the DT N
carotid JJ o
intima-media JJ o
thickness NN o
decreased VBN N
in IN N
group NN N
L NNP N
( ( N
P NNP N
< NNP N
.01 NNP N
) ) N
, , N
left VBD o
ventricular JJ o
mass NN o
index NN o
in IN N
groups NNS N
E NNP N
and CC N
L NNP N
( ( N
P NNP N
< NNP N
.05 NNP N
and CC N
P NNP N
< NNP N
.001 NNP N
, , N
respectively RB N
) ) N
, , N
with IN N
a DT N
concomitant JJ N
reduction NN N
in IN N
cholesterol NN o
in IN N
group NN N
L NNP N
( ( N
P NNP N
< NNP N
.03 NNP N
) ) N
. . N

Diastolic NNP o
function NN o
improved VBD N
significantly RB N
in IN N
group NN N
L NNP N
( ( N
P NNP N
< NNP N
.05 NNP N
) ) N
. . N

This DT N
study NN N
describes VBZ N
the DT N
need NN N
to TO N
control VB N
blood NN o
pressure NN o
with IN N
two CD N
or CC N
more JJR N
drugs NNS N
in IN N
most JJS N
hypertensive JJ p
patients NNS p
and CC N
illustrates NNS N
good JJ N
clinical JJ N
outcomes NNS N
, , N
independent JJ N
of IN N
blood NN N
pressure NN N
lowering NN N
, , N
using VBG N
combination NN N
therapy NN N
with IN N
losartan JJ i
, , i
low-dose JJ i
thiazide NN i
, , i
and CC i
amlodipine NN i
. . i

-DOCSTART- -6122555- O O

Comparison NNP N
of IN N
the DT N
antihypertensive JJ o
effect NN o
of IN N
metipranolol NN i
, , i
butizide NN i
and CC i
torrat NN i
in IN N
Kenyan NNP p
Africans NNPS p
. . p

-DOCSTART- -10837440- O O

Comparison NNP N
of IN N
a DT N
5 CD N
day NN N
regimen NNS N
of IN N
cefdinir NN i
with IN N
a DT N
10 CD N
day NN N
regimen NNS N
of IN N
cefprozil NN i
for IN N
treatment NN N
of IN N
acute JJ o
exacerbations NNS o
of IN o
chronic JJ o
bronchitis NN o
. . o

Patients NNS p
with IN p
acute JJ p
exacerbations NNS p
of IN p
chronic JJ p
bronchitis NN p
were VBD N
treated VBN N
with IN N
cefdinir NN i
300 CD N
mg NN N
bd NN N
for IN N
5 CD N
days NNS N
or CC N
cefprozil JJ i
500 CD N
mg NN N
bd NN N
for IN N
10 CD N
days NNS N
in IN N
a DT N
prospective JJ N
, , N
randomized VBN N
, , N
double-blind JJ N
, , N
multicentre JJ N
study NN N
. . N

Of IN N
the DT N
548 CD p
patients NNS p
enrolled VBD p
, , p
281 CD p
( ( p
51 CD p
% NN p
) ) p
were VBD p
evaluable JJ p
. . p

The DT N
clinical JJ o
cure NN o
rates NNS o
at IN N
the DT N
test-of-cure JJ N
visit NN N
were VBD N
80 CD N
% NN N
( ( N
114/142 CD N
) ) N
and CC N
72 CD N
% NN N
( ( N
100/139 CD N
) ) N
for IN N
the DT N
evaluable JJ p
patients NNS p
treated VBN p
with IN p
cefdinir NN i
and CC i
cefprozil NN i
, , N
respectively RB N
. . N

Respiratory NNP o
tract JJ o
pathogens NNS o
were VBD N
isolated VBN N
from IN N
409 CD N
( ( N
75 CD N
% NN N
) ) N
of IN N
548 CD N
admission NN N
sputum NN N
specimens NNS N
, , N
with IN N
the DT N
predominant NN N
pathogens VBZ N
being VBG N
Haemophilus NNP N
parainfluenzae NN N
, , N
Haemophilus NNP N
influenzae NN N
, , N
Staphylococcus NNP N
aureus NN N
and CC N
Moraxella NNP N
catarrhalis NN N
. . N

The DT N
microbiological JJ o
eradication NN o
rates NNS o
at IN N
the DT N
test-of-cure JJ N
visit NN N
were VBD N
81 CD N
% NN N
( ( N
157 CD N
of IN N
193 CD N
pathogens NNS N
) ) N
and CC N
84 CD N
% NN N
( ( N
166 CD N
of IN N
198 CD N
pathogens NNS N
) ) N
for IN N
the DT N
evaluable JJ N
patients NNS N
treated VBN N
with IN N
cefdinir NN i
and CC N
cefprozil NN i
, , N
respectively RB N
. . N

Adverse JJ o
event NN o
rates NNS o
while IN N
on IN N
treatment NN N
were VBD N
equivalent JJ N
between IN N
the DT N
two CD N
treatment NN N
groups NNS N
. . N

The DT N
incidence NN o
of IN o
diarrhoea NN o
during IN N
therapy NN N
was VBD N
higher JJR N
for IN N
patients NNS p
treated VBN p
with IN p
cefdinir NN i
( ( p
17 CD p
% NN p
) ) p
than IN p
for IN p
patients NNS p
treated VBN p
with IN p
cefprozil NN i
( ( p
6 CD p
% NN p
) ) p
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
, , N
but CC N
most JJS N
cases NNS N
were VBD N
mild JJ N
and CC N
did VBD N
not RB N
lead VB N
to TO N
discontinuation NN N
of IN N
treatment NN N
. . N

These DT N
results NNS N
indicate VBP N
that IN N
a DT N
5 CD N
day NN N
regimen NNS N
of IN N
cefdinir NN i
is VBZ N
as IN N
effective JJ o
and CC o
safe JJ o
in IN N
the DT N
treatment NN N
of IN N
patients NNS p
with IN N
acute JJ o
exacerbations NNS o
of IN o
chronic JJ o
bronchitis NN o
as IN N
a DT N
10 CD N
day NN N
regimen NNS N
of IN N
cefprozil NN i
. . i

-DOCSTART- -16411994- O O

Does VBZ N
a DT N
first JJ N
trimester NN N
dating VBG N
scan JJ N
using VBG N
crown JJ N
rump NN N
length NN N
measurement NN N
reduce VB N
the DT N
rate NN o
of IN o
induction NN o
of IN o
labour NN o
for IN N
prolonged JJ o
pregnancy NN o
? . N
An DT N
uncompleted JJ N
randomised VBD N
controlled JJ N
trial NN N
of IN N
463 CD p
women NNS p
. . p

OBJECTIVE NNP N
To TO N
evaluate VB N
the DT N
effect NN N
of IN N
a DT N
first JJ N
trimester NN N
ultrasound IN i
dating VBG i
scan JJ i
on IN N
the DT N
rate NN o
of IN o
induction NN o
of IN o
labour NN o
for IN N
prolonged JJ o
pregnancy NN o
. . o

DESIGN NNP N
Randomised VBD N
controlled VBN N
trial NN N
to TO N
include VB N
400 CD p
women NNS p
in IN p
each DT p
arm NN p
of IN p
the DT p
trial NN p
. . p

SETTING NN N
Participating VBG p
general JJ p
practices NNS p
and CC p
a DT p
district NN p
general JJ p
teaching NN p
hospital NN p
. . p

POPULATION NNP N
Women NNP p
attending VBG p
their PRP$ p
general JJ p
practitioner NN p
in IN p
the DT p
first JJ p
trimester NN p
to TO p
confirm VB p
pregnancy NN p
, , p
in IN p
whom WP p
a DT p
first JJ p
trimester NN p
ultrasound JJ i
scan NN i
was VBD p
not RB p
indicated VBN p
. . p

METHODS NNP N
Women NNP N
randomised VBD N
to TO N
the DT N
study NN N
group NN N
( ( N
scan JJ N
group NN N
) ) N
underwent VBD N
an DT N
ultrasound JJ i
dating NN i
scan NN i
between IN i
8 CD i
and CC i
12 CD i
weeks NNS i
, , i
measuring VBG i
crown-rump JJ i
length NN i
. . i

The DT N
estimated JJ N
date NN N
of IN N
delivery NN N
( ( N
EDD NNP N
) ) N
was VBD N
changed VBN N
if IN N
there EX N
was VBD N
a DT N
discrepancy NN N
of IN N
more JJR N
than IN N
5 CD N
days NNS N
from IN N
the DT N
gestation NN N
, , N
calculated VBN N
from IN N
the DT N
last JJ N
menstrual JJ N
period NN N
( ( N
LMP NNP N
) ) N
. . N

For IN N
the DT N
remaining VBG N
women NNS N
( ( N
no-scan JJ N
group NN N
) ) N
, , N
gestation NN N
was VBD N
determined VBN N
using VBG N
the DT N
LMP NNP N
. . N

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
The DT o
rate NN o
of IN o
induction NN o
of IN o
labour NN o
for IN o
prolonged JJ o
pregnancy NN o
. . o

RESULTS NNP N
Due NNP N
to TO N
circumstances NNS N
beyond IN N
the DT N
researchers NNS N
' POS N
control NN N
, , N
recruitment NN N
was VBD N
abandoned VBN N
when WRB N
463 CD p
women NNS p
had VBD p
been VBN p
enrolled VBN p
. . p

The DT N
EDD NNP N
was VBD N
adjusted VBN N
in IN N
13 CD N
( ( N
5.7 CD N
% NN N
) ) N
women NNS N
in IN N
the DT N
scan JJ N
group NN N
and CC N
in IN N
2 CD N
( ( N
0.9 CD N
% NN N
) ) N
in IN N
the DT N
no-scan JJ N
group NN N
. . N

There EX N
was VBD N
no DT N
difference NN N
in IN N
the DT N
rate NN o
of IN o
induction NN o
for IN N
prolonged JJ o
pregnancy NN o
between IN N
the DT N
scan JJ N
( ( N
19 CD N
[ RB N
8.2 CD N
% NN N
] NN N
) ) N
and CC N
the DT N
no-scan JJ N
( ( N
17 CD N
[ RB N
7.4 CD N
% NN N
] NN N
) ) N
groups NNS N
( ( N
relative JJ N
risk NN N
1.10 CD N
; : N
95 CD N
% NN N
CI NNP N
0.59-2.07 NN N
) ) N
. . N

CONCLUSIONS NNP N
Acknowledging VBG N
the DT N
reduced JJ N
numbers NNS N
recruited VBN N
for IN N
study NN N
, , N
it PRP N
is VBZ N
concluded VBN N
that IN N
there EX N
is VBZ N
no DT N
evidence NN N
that IN N
a DT N
first JJ N
trimester NN N
ultrasound IN i
dating VBG i
scan JJ i
reduces NNS N
the DT N
rate NN o
of IN o
induction NN o
of IN o
labour NN o
for IN N
prolonged JJ o
pregnancy NN o
and CC N
may MD N
result VB N
in IN N
a DT N
more RBR N
expensive JJ N
healthcare NN N
strategy NN N
. . N

-DOCSTART- -10352330- O O

Effect NN N
of IN N
granulocyte/colony-stimulating JJ i
factor NN i
on IN N
the DT N
onset NN N
of IN N
the DT N
adult NN p
respiratory NN p
distress JJ p
syndrome NN p
. . p

To TO N
evaluate VB N
the DT N
effect NN N
of IN N
granulocyte/colony-stimulating JJ i
factor NN i
( ( i
G-CSF NNP i
) ) i
on IN N
the DT N
onset NN N
of IN N
the DT N
adult NN N
respiratory NN N
distress NN N
syndrome NN N
( ( N
ARDS NNP N
) ) N
, , N
we PRP N
investigated VBD N
whether IN N
the DT N
incidence NN N
of IN N
ARDS NNP N
due JJ N
to TO N
pulmonary JJ N
infection NN N
differed VBD N
between IN N
the DT N
G-CSF NNP p
group NN p
which WDT p
received VBD p
chemotherapy NN i
with IN i
G-CSF NNP i
and CC p
historical JJ i
controls NNS i
without IN i
G-CSF NNP i
. . i

We PRP N
evaluated VBD N
132 CD p
patients NNS p
with IN p
hematological JJ p
malignancy NN p
in IN p
complete JJ p
remission NN p
without IN p
any DT p
main JJ p
organ JJ p
dysfunction NN p
who WP p
had VBD p
been VBN p
treated VBN p
between IN p
April NNP p
1983 CD p
and CC p
December NNP p
1997 CD p
. . p

We PRP N
compared VBN N
the DT N
incidence NN N
of IN N
ARDS NNP N
due JJ N
to TO N
pulmonary JJ N
infection NN N
between IN N
those DT N
who WP p
received VBD p
G-CSF NNP i
and CC N
those DT N
who WP N
did VBD N
not RB N
. . N

There EX p
was VBD p
no DT p
remarkable JJ p
difference NN p
in IN p
the DT p
number NN p
of IN p
patients NNS p
, , p
gender NN p
, , p
age NN p
, , p
or CC p
distribution NN p
of IN p
primary JJ p
diseases NNS p
between IN p
the DT p
two CD p
groups NNS p
. . p

The DT N
intensity NN o
of IN o
chemotherapy NN o
was VBD N
not RB N
considered VBN N
to TO N
significantly RB N
differ VB N
between IN N
the DT N
two CD N
groups NNS N
, , N
though IN N
the DT N
chemotherapy NN N
regimens VBZ N
administered VBN N
differed VBD N
slightly RB N
. . N

In IN N
the DT N
G-CSF NNP i
group NN N
, , N
the DT N
duration NN o
of IN o
neutropenia NN o
was VBD N
significantly RB N
shorter JJR N
and CC N
the DT N
frequency NN N
of IN N
documented JJ N
infection NN N
was VBD N
significantly RB N
decreased VBN N
. . N

We PRP N
could MD N
not RB N
find VB N
any DT N
relationship NN N
between IN N
ARDS NNP N
due JJ N
to TO N
pulmonary JJ o
infection NN o
and CC N
any DT N
anticancer JJ N
agent NN N
or CC N
antibiotics NNS N
. . N

There EX N
was VBD N
no DT N
relationship NN N
between IN N
the DT N
kind NN N
of IN N
G-CSF NNP i
and CC N
the DT N
incidence NN N
of IN N
ARDS NNP N
due JJ N
to TO N
pulmonary JJ o
infection NN o
( ( N
per IN N
chemotherapy NN N
session NN N
; : N
p CC N
> $ N
0.10 CD N
, , N
per IN N
case NN N
; : N
p CC N
> $ N
0.30 CD N
, , N
chi2 JJ N
test NN N
) ) N
. . N

The DT N
incidence NN o
of IN o
ARDS NNP o
due JJ o
to TO o
pulmonary JJ o
infection NN o
per IN o
chemotherapy NN o
session NN o
was VBD N
4.21 CD N
% NN N
, , N
and CC N
showed VBD N
a DT N
higher JJR N
tendency NN N
in IN N
the DT N
G-CSF NNP i
group NN N
( ( N
p JJ N
< NN N
0.100 CD N
, , N
chi2 JJ N
test NN N
) ) N
. . N

The DT N
incidence NN o
of IN o
ARDS NNP o
due JJ o
to TO o
pulmonary JJ o
infection NN o
per IN o
case NN o
was VBD N
25.4 CD N
% NN N
and CC N
was VBD N
significantly RB N
higher JJR N
in IN N
the DT N
G-CSF NNP i
group NN N
( ( N
p JJ N
< NN N
0.025 CD N
, , N
chi2 JJ N
test NN N
) ) N
. . N

The DT N
incidence NN o
of IN o
ARDS NNP o
due JJ o
to TO o
pulmonary JJ o
infection NN o
was VBD o
higher RBR o
in IN o
the DT o
G-CSF NNP o
group NN o
than IN N
in IN N
the DT N
controls NNS N
, , N
suggesting VBG N
that IN N
G-CSF NNP i
promotes VBZ N
the DT N
development NN N
of IN N
ARDS NNP N
due JJ N
to TO N
pulmonary JJ N
infection NN N
. . N

-DOCSTART- -10155556- O O

Treatment NN N
of IN N
polyarteritis NN p
nodosa NN p
and CC p
Churg-Strauss JJ p
syndrome NN p
: : p
indications NNS N
of IN N
plasma NN N
exchanges NNS N
. . N

To TO N
define VB N
the DT N
most RBS N
effective JJ N
treatment NN N
for IN N
polyarteritis NN p
nodosa NN p
( ( p
PAN NNP p
) ) p
and CC p
Churg-Strauss JJ p
syndrome NN p
( ( p
CSS NNP p
) ) p
, , N
we PRP N
undertook VBD N
4 CD N
consecutive JJ N
prospective JJ N
therapeutic JJ N
trials NNS N
including VBG N
236 CD p
patients NNS p
and CC N
tried VBD N
to TO N
answer VB N
several JJ N
important JJ N
questions NNS N
: : N
Should MD N
cyclophosphamide VB i
( ( N
CYC NNP N
) ) N
be VB N
given VBN N
as IN N
the DT N
first-line JJ N
treatment NN N
? . N
What WP N
is VBZ N
the DT N
place NN N
of IN N
plasma NN i
exchanges NNS i
( ( N
PE NNP N
) ) N
in IN N
the DT N
treatment NN N
of IN N
systemic JJ N
vasculitis NN N
? . N
and CC N
does VBZ N
hepatitis NN N
B NNP N
virus NN N
( ( N
HBV NNP N
) ) N
related VBD N
PAN NNP N
require VBP N
treatment NN N
? . N
Our PRP$ N
first JJ N
randomized VBN N
trial NN N
in IN N
71 CD p
patients NNS p
( ( p
1981-1983 JJ p
) ) p
compared VBN p
the DT p
association NN p
of IN p
CYC NNP p
with IN p
corticosteroids NNS p
( ( p
CS NNP p
) ) p
and CC p
PE NNP i
to TO p
CS NNP p
and CC p
PE NNP i
, , p
in IN p
order NN p
to TO p
evaluate VB p
the DT p
efficacy NN o
of IN p
CYC NNP p
given VBN p
as IN p
the DT p
first-line JJ p
treatment NN p
to TO p
control VB p
disease NN p
activity NN p
and CC p
subsequent JJ o
survival NN o
of IN p
PAN NNP p
and CC p
CSS NNP p
patients NNS p
. . p

Between NNP N
December NNP p
1983 CD p
and CC p
December NNP p
1988 CD p
, , N
we PRP N
conducted VBD N
two CD N
trials NNS N
simultaneously RB N
: : N
one CD N
aimed VBN N
at IN p
patients NNS p
without IN p
HBV NNP p
markers NNS p
and CC p
the DT p
second JJ p
at IN p
patients NNS p
with IN p
HBV NNP p
markers NNS p
. . p

In IN N
78 CD p
patients NNS p
without IN p
HBV NNP p
markers NNS p
, , N
we PRP N
compared VBN N
prednisone NN i
and CC i
PE NNP i
to TO N
prednisone VB i
alone RB N
as IN N
the DT N
initial JJ N
therapeutic JJ N
regimen NNS N
. . N

In IN N
33 CD p
patients NNS p
with IN p
PAN NNP p
related VBD p
to TO p
HBV NNP p
, , N
a DT N
new JJ N
therapeutic JJ N
strategy NN N
was VBD N
applied VBN N
as IN N
an DT N
alternative JJ N
to TO N
long-term JJ N
steroid NN i
and CC i
immunosuppressive JJ i
therapy NN i
: : i
short-term JJ i
steroid NN i
therapy NN i
and CC i
PE NNP i
were VBD N
used VBN N
to TO N
control VB N
the DT N
evolution NN o
of IN o
PAN NNP o
and CC N
anti-viral JJ i
therapy NN i
was VBD N
administered VBN N
to TO N
suppress VB N
the DT N
etiological JJ o
agent NN o
of IN o
the DT o
vasculitis NN o
. . o

In IN N
the DT N
last JJ N
protocol NN N
including VBG N
56 CD p
patients NNS p
and CC p
addressed VBD p
to TO p
severe VB p
PAN NNP p
without IN p
HBV NNP p
markers NNS p
or CC p
CSS NNP p
we PRP N
have VBP N
shown VBN N
that IN N
PE NNP N
did VBD N
not RB N
improve VB N
the DT N
prognosis NN o
and CC N
control NN o
of IN o
the DT o
disease NN o
. . o

Twelve CD N
years NNS N
after IN N
the DT N
beginning NN N
of IN N
the DT N
trials NNS N
on IN N
PAN NNP N
and CC N
CSS NNP N
patients NNS N
, , N
we PRP N
think VBP N
that IN N
the DT N
therapeutic JJ N
strategy NN N
should MD N
be VB N
as IN N
follows VBZ N
: : N
In IN N
PAN NNP N
without IN N
HBV NNP N
and CC N
CSS NNP N
: : N
prednisone NN i
in IN i
association NN i
with IN i
CYC NNP i
improves VBZ N
the DT N
control NN o
of IN o
the DT o
disease NN o
despite IN N
infectious JJ o
side NN o
effects NNS o
which WDT N
may MD N
be VB N
reduced VBN N
by IN N
better JJR N
CYC NNP N
dose JJ N
adaptation NN N
. . N

In IN N
PAN NNP N
related VBD N
to TO N
HBV NNP N
: : N
The DT N
first-line JJ N
treatment NN N
should MD N
be VB N
the DT N
association NN N
of IN N
anti-viral JJ i
agents NNS i
and CC i
PE NNP i
. . i

This DT N
treatment NN N
was VBD N
effective JJ o
and CC N
cured VBD o
a DT N
majority NN N
of IN N
patients NNS N
within IN N
2 CD N
to TO N
3 CD N
months NNS N
; : N
half NN N
of IN N
them PRP N
seroconverted VBD N
. . N

The DT N
length NN o
of IN o
HBV NNP o
infection NN o
before IN N
its PRP$ N
diagnosis NN N
, , N
delay NN N
before IN N
initiation NN N
of IN N
treatment NN N
and CC N
previous JJ N
immunosuppressive JJ N
therapy NN N
led VBD N
to TO N
a DT N
poor JJ N
seroconversion NN o
rate NN o
. . o

The DT N
role NN N
of IN N
PE NNP i
in IN N
the DT N
treatment NN N
of IN N
systemic JJ N
necrotizing JJ N
vasculitis NN N
: : N
PE NN i
are VBP N
obviously RB N
useful JJ N
in IN N
PAN NNP p
related VBD p
to TO p
HBV NNP p
where WRB N
immune NN N
complex JJ N
deposition NN N
has VBZ N
been VBN N
demonstrated VBN N
. . N

When WRB N
PAN NNP N
is VBZ N
not RB N
related VBN N
to TO N
HBV NNP N
and CC N
in IN N
CSS NNP N
, , N
even RB N
in IN N
severe JJ N
cases NNS N
, , N
there EX N
is VBZ N
presently RB N
no DT N
argument NN N
supporting VBG N
systematic JJ N
administration NN N
of IN N
PE NNP i
at IN N
the DT N
time NN N
of IN N
diagnosis NN N
. . N

-DOCSTART- -6980168- O O

Whole JJ N
pelvic JJ N
irradiation NN i
in IN N
stage NN p
I PRP p
endometrial JJ p
carcinoma NN p
: : p
changes NNS o
in IN o
numbers NNS o
and CC o
reactivities NNS o
of IN o
some DT o
blood NN o
lymphocyte JJ o
subpopulations NNS o
. . o

-DOCSTART- -23483320- O O

Effect NN N
of IN N
perioperative JJ N
parecoxib NN i
on IN N
postoperative JJ o
pain NN o
and CC o
local JJ o
inflammation NN o
factors NNS N
PGE2 NNP N
and CC N
IL-6 NNP N
for IN N
total JJ N
knee NN N
arthroplasty NN N
: : N
a DT N
randomized JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ i
study NN N
. . N

To TO N
assess VB N
the DT N
efficacy NN o
of IN N
postoperative JJ N
pain NN N
management NN N
and CC N
the DT N
concentration NN N
change NN N
of IN N
PGE-2 NNP N
and CC N
IL-6 NNP N
of IN N
joint JJ N
fluid NN N
with IN N
parecoxib NN i
after IN N
postoperative JJ N
total JJ N
knee NN N
arthroplasty NN N
. . N

In IN N
the DT N
study NN N
, , N
100 CD p
patients NNS p
experiencing VBG p
primary JJ p
TKA NNP p
were VBD N
randomly RB N
divided VBN N
into IN N
study NN N
group NN N
, , N
receiving VBG N
parecoxib NN i
sodium NN i
( ( N
40 CD N
mg NN N
) ) N
intravenously RB N
( ( N
IV NNP N
) ) N
at IN N
the DT N
completion NN N
of IN N
surgery NN N
and CC N
once RB N
every DT N
12 CD N
h NN N
for IN N
totally RB N
6 CD N
times NNS N
postoperatively RB N
, , N
and CC i
placebo NN i
group NN i
, , N
receiving VBG i
normal JJ i
saline JJ i
2 CD i
mL NN N
IV NNP N
at IN N
the DT N
same JJ N
time NN N
points NNS o
. . o

Efficacy NN o
was VBD o
assessed VBN N
by IN N
total JJ o
amount NN o
of IN o
morphine NN o
consumed VBN o
, , o
pain VBP o
intensity NN o
, , o
range NN o
of IN o
motion NN o
( ( o
ROM NNP o
) ) o
, , o
the DT o
concentration NN o
change NN o
of IN o
PGE-2 NNP o
and CC o
IL-6 NNP o
of IN o
joint JJ o
fluid NN o
, , o
and CC o
postoperative JJ o
nausea NN o
and CC o
vomiting NN o
( ( o
PONV NNP o
) ) o
postoperatively RB o
. . N

Patients NNS N
in IN N
study NN N
group NN N
consumed VBD N
significantly RB N
less JJR o
morphine NN o
, , o
experienced VBD o
significant JJ N
less JJR o
pain NN o
scores NNS o
, , o
and CC o
obtained VBD N
significantly RB N
more RBR o
ROM NNP o
( ( o
P NNP o
< NNP N
0.01 CD N
) ) N
compared VBN N
with IN N
that DT N
in IN N
placebo NN N
group NN N
during IN N
3 CD N
days NNS N
postoperatively RB o
. . o

The DT o
concentration NN o
of IN o
PGE-2 NNP o
and CC o
IL-6 NNP o
of IN o
joint JJ o
fluid NN o
in IN N
study NN N
group NN N
are VBP N
significantly RB N
lower JJR N
than IN N
that DT N
in IN i
placebo NN i
group NN i
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
during IN N
24 CD N
h NNS N
postoperatively RB o
. . o

The DT o
overall JJ o
incidence NN o
of IN o
PONV NNP o
was VBD N
low JJ N
and CC N
was VBD N
not RB N
significantly RB N
different JJ N
between IN N
the DT N
two CD N
groups NNS N
. . N

The DT N
present JJ N
study NN N
demonstrated VBD N
that IN N
the DT N
perioperative JJ N
administration NN i
of IN i
parecoxib NN i
after IN i
primary JJ i
TKA NNP N
resulted VBD N
in IN N
significantly RB N
improved VBN N
postoperative JJ o
analgesic JJ o
management NN o
as IN o
defined VBN o
by IN N
reduction NN N
in IN N
opioid JJ N
requirement NN o
, , o
lower JJR o
pain NN o
scores NNS o
and CC o
ROM NNP o
, , o
and CC N
significantly RB o
lowered VBD o
local JJ o
inflammation NN o
factors NNS o
PGE2 NNP o
and CC o
IL-6 NNP o
. . N

-DOCSTART- -3890395- O O

Interference NN N
on IN N
metabolism NN N
induced VBN N
by IN N
muzolimine NN i
and CC N
chlorthalidone NN i
in IN N
type NN p
II NNP p
hypertensive NN p
diabetics NNS p
. . p

There EX N
is VBZ N
a DT N
very RB N
high JJ N
prevalence NN N
of IN N
hypertension NN p
in IN p
diabetic JJ p
subjects NNS p
, , N
which WDT N
makes VBZ N
it PRP N
necessary JJ N
to TO N
use VB N
an DT N
antihypertensive JJ i
drug NN i
with IN N
the DT N
least JJS N
possible JJ N
metabolic JJ N
interference NN N
. . N

For IN N
example NN N
, , N
in IN N
the DT N
early JJ N
phase NN N
of IN N
hypertension NN N
, , N
diuretics NNS N
usually RB N
worsen VBP N
the DT N
metabolic JJ o
equilibrium NN o
. . o

According VBG N
to TO N
recent JJ N
reports NNS N
, , N
a DT N
new JJ N
diuretic JJ N
, , N
muzolimine NN i
( ( i
MZ NNP i
) ) i
, , N
which WDT N
acts VBZ N
on IN N
the DT N
loop NN N
of IN N
Henle NNP N
, , N
seems VBZ N
to TO N
present VB N
a DT N
minor JJ N
effect NN N
on IN N
carbohydrate NN N
metabolic JJ N
balance NN N
. . N

In IN N
order NN N
to TO N
determine VB N
whether IN N
this DT N
assumption NN N
was VBD N
correct JJ N
or CC N
not RB N
, , N
we PRP N
carried VBD N
out RP N
a DT N
clinical JJ N
trial NN N
on IN N
26 CD p
type NN p
II NNP p
( ( p
non-insulin-dependent JJ p
) ) p
diabetics NNS p
, , p
in IN p
fairly RB p
good JJ p
metabolic NN p
control NN p
and CC p
with IN p
moderate JJ p
hypertension NN p
( ( p
orthostatic JJ p
diastolic NN p
pressure NN p
from IN p
100 CD p
to TO p
115 CD p
mmHg NN p
) ) p
, , N
comparing VBG N
the DT N
effect NN N
of IN N
MZ NNP i
with IN N
those DT N
of IN N
chlorthalidone NN i
( ( i
CL NNP i
) ) i
. . i

According VBG N
to TO N
a DT N
randomized VBN N
, , N
single-blind JJ N
cross-over NN N
design NN N
, , N
the DT N
patients NNS N
were VBD N
treated VBN N
with IN N
MZ NNP i
( ( N
20 CD N
mg/day NN N
) ) N
or CC N
CL NNP i
( ( N
50 CD N
mg/day NN N
) ) N
for IN N
the DT N
duration NN N
of IN N
4 CD N
weeks NNS N
. . N

After IN N
the DT N
treatment NN N
period NN N
with IN N
the DT N
first JJ N
drug NN N
, , N
there EX N
was VBD N
a DT N
2 CD N
week NN N
wash-out JJ N
period NN N
on IN N
placebo NN i
( ( N
PL NNP N
) ) N
before IN N
the DT N
second JJ N
drug NN N
was VBD N
given VBN N
. . N

During IN N
the DT N
study NN N
, , N
a DT N
set NN N
of IN N
metabolic JJ o
and CC o
non-metabolic JJ o
parameters NNS o
was VBD N
monitored VBN N
, , N
as IN N
were VBD N
the DT N
clinostatic JJ o
and CC o
orthostatic JJ o
blood NN o
pressure NN o
values NNS o
. . o

The DT N
results NNS N
show VBP N
that IN N
the DT N
antihypertensive JJ o
effect NN o
of IN N
the DT N
two CD N
drugs NNS N
was VBD N
the DT N
same JJ N
( ( N
both DT N
caused VBD N
a DT N
more RBR N
than IN N
10 CD N
% NN N
decrease NN N
in IN N
systolic JJ o
and CC o
diastolic JJ o
blood NN o
pressure NN o
) ) o
. . N

No DT N
significant JJ N
changes NNS N
in IN N
plasma NN o
electrolyte NN o
levels NNS o
occurred VBD N
. . N

There EX N
was VBD N
a DT N
significant JJ N
( ( N
p NN N
less JJR N
than IN N
0.05 CD N
) ) N
increase NN N
in IN N
urinary JJ o
aldosterone NN o
excretion NN o
after IN N
CL NNP N
( ( N
20.7 CD N
+/- JJ N
11 CD N
micrograms/24 NN N
hours NNS N
vs. IN N
13.3 CD N
+/- JJ N
8.5 CD N
after IN N
PL NNP N
, , N
and CC N
14.5 CD N
+/- JJ N
7.2 CD N
after IN N
MZ NNP N
) ) N
( ( N
mean JJ N
values NNS N
+/- JJ N
standard JJ N
deviations NNS N
) ) N
. . N

( ( N
ABSTRACT NNP N
TRUNCATED NNP N
AT NNP N
250 CD N
WORDS NNP N
) ) N
-DOCSTART- -22219012- O O

Pre-bent JJ i
instruments NNS i
used VBN N
in IN N
single-port JJ i
laparoscopic NN i
surgery NN i
versus IN i
conventional JJ i
laparoscopic NN i
surgery NN i
: : i
comparative JJ N
study NN N
of IN N
performance NN N
in IN N
a DT N
dry JJ N
lab NN N
. . N

BACKGROUND NNP N
Different NNP N
types NNS N
of IN N
single-incision NN i
laparoscopic NN i
surgery NN i
( ( i
SILS NNP i
) ) i
have VBP N
become VBN N
increasingly RB N
popular JJ N
. . N

Although IN N
SILS NNP N
is VBZ N
technically RB N
even RB N
more RBR N
challenging JJ N
than IN N
conventional JJ N
laparoscopy NN N
, , N
published VBN N
data NNS N
of IN N
first JJ N
clinical JJ N
series NN N
seem VBP N
to TO N
demonstrate VB N
the DT N
feasibility NN N
of IN N
these DT N
approaches NNS N
. . N

Various JJ N
attempts NNS N
have VBP N
been VBN N
made VBN N
to TO N
overcome VB N
restrictions NNS N
due JJ N
to TO N
loss NN N
of IN N
triangulation NN N
in IN N
SILS NNP N
by IN N
specially RB N
designed VBN N
SILS-specific JJ N
instruments NNS N
. . N

This DT N
study NN N
involving VBG N
novices NNS N
in IN N
a DT N
dry JJ N
lab NN N
compared VBN N
task NN o
performances NNS o
between IN N
conventional JJ i
laparoscopic NN i
surgery NN i
( ( i
CLS NNP i
) ) i
and CC N
single-port JJ i
laparoscopic NN i
surgery NN i
( ( N
SPLS NNP N
) ) N
using VBG N
newly RB N
designed VBN N
pre-bent JJ N
instruments NNS N
. . N

METHODS NNP N
In IN N
this DT N
study NN N
, , N
90 CD p
medical JJ p
students NNS p
without IN p
previous JJ p
experience NN p
in IN p
laparoscopic NN p
techniques NNS p
were VBD p
randomly RB p
assigned VBN p
to TO p
undergo VB p
one CD p
of IN p
three CD p
procedures NNS p
: : p
CLS NNP p
, , p
SPLS NNP p
using VBG p
two CD p
pre-bent JJ p
instruments NNS p
( ( p
SPLS-pp NNP p
) ) p
, , p
or CC p
SPLS NNP i
using VBG p
one CD p
pre-bent NN p
and CC p
one CD p
straight NN p
laparoscopic NN p
instrument NN p
( ( p
SPLS-ps NNP p
) ) p
. . p

In IN N
the DT N
dry JJ N
lab NN N
, , N
the DT N
participants NNS N
performed VBD N
four CD N
typical JJ N
laparoscopic NN N
tasks NNS N
of IN N
increasing VBG N
difficulty NN N
. . N

Evaluation NNP N
included VBD N
performance NN o
times NNS o
or CC o
number NN o
of IN o
completed VBN o
tasks NNS o
within IN o
a DT o
given VBN o
time NN o
frame NN o
. . o

All DT N
performances NNS o
were VBD N
videotaped VBN N
and CC N
evaluated VBN N
for IN N
unsuccessful JJ o
attempts NNS o
and CC o
unwanted JJ o
interactions NNS o
of IN o
instruments NNS o
. . o

Using VBG N
subjective JJ o
questionnaires NNS o
, , N
the DT N
participants NNS N
rated VBN o
difficulties NNS o
with IN o
two-dimensional JJ o
vision NN o
and CC o
coordination NN o
of IN o
instruments NNS o
. . o

RESULTS NNP N
Task NNP o
performances NNS o
were VBD N
significantly RB N
better RBR N
in IN N
the DT N
CLS NNP N
group NN N
than IN N
in IN N
either DT N
SPLS NNP N
group NN N
. . N

The DT N
SPLS-ps NNP N
group NN N
showed VBD N
a DT N
tendency NN N
toward IN N
better JJR N
performances NNS o
than IN N
the DT N
SPLS-pp NNP N
group NN N
, , N
but CC N
the DT N
difference NN N
was VBD N
not RB N
significant JJ N
. . N

Video NNP N
sequences NNS N
and CC N
participants` NN N
questionnaires NNS N
showed VBD N
instrument JJ o
interaction NN o
as IN N
the DT N
major JJ o
problem NN o
in IN N
the DT N
single-incision NN N
surgery NN N
groups NNS N
. . N

CONCLUSIONS NNP N
Although IN N
SILS NNP N
is VBZ N
feasible JJ N
, , N
as IN N
shown VBN N
in IN N
clinical JJ N
series NN N
published VBN N
by IN N
laparoscopically RB N
experienced JJ N
experts NNS N
, , N
SILS NNP N
techniques NNS N
are VBP N
demanding VBG N
due JJ N
to TO N
restrictions NNS N
that IN N
come VBP N
with IN N
the DT N
loss NN N
of IN N
triangulation NN N
. . N

These DT N
can MD N
be VB N
compensated VBN N
only RB N
partially RB N
by IN N
currently RB N
available JJ N
SILS-designed JJ N
instruments NNS N
. . N

The DT N
future NN N
of IN N
SILS NNP N
depends VBZ N
on IN N
further JJ N
improvements NNS N
in IN N
the DT N
available JJ N
equipment NN N
or CC N
the DT N
development NN N
of IN N
new JJ N
approaches NNS N
such JJ N
as IN N
needlescopically RB N
assisted VBN N
or CC N
robotically RB N
assisted JJ N
procedures NNS N
. . N

-DOCSTART- -25349264- O O

Intratunnel NNP i
versus NN i
extratunnel RB i
autologous JJ i
hamstring VBG i
double-bundle JJ i
graft NN i
for IN N
anterior JJ p
cruciate NN p
ligament JJ p
reconstruction NN p
: : p
a DT N
comparison NN N
of IN N
2 CD N
femoral JJ N
fixation NN N
procedures NNS N
. . N

BACKGROUND NNP N
Anatomic NNP N
double-bundle JJ N
anterior JJ p
cruciate NN p
ligament NN p
( ( p
ACL NNP p
) ) p
reconstruction NN N
provides VBZ N
excellent JJ N
results NNS N
for IN N
restoring VBG o
normal JJ o
kinematics NNS o
to TO o
the DT o
knee NN o
. . o

Nevertheless RB N
, , N
strong JJ N
evidence NN N
supporting VBG N
an DT N
ideal NN N
method NN N
for IN N
fixation NN N
of IN N
the DT N
ACL NNP N
graft NN N
is VBZ N
lacking VBG N
. . N

HYPOTHESIS NNP N
Intratunnel NNP i
femoral JJ i
fixation NN i
of IN i
the DT i
ACL NNP i
graft NN i
via IN i
a DT i
cross-pin JJ i
fixation NN i
technique NN i
would MD N
provide VB N
better JJR N
clinical JJ N
and CC N
objective JJ N
results NNS N
than IN N
the DT N
extratunnel JJ i
femoral JJ i
fixation NN i
with IN i
cortical JJ i
buttons NNS i
. . i

STUDY NNP N
DESIGN NNP N
Randomized NNP N
clinical JJ N
trial NN N
; : N
Level NNP N
of IN N
evidence NN N
, , N
2 CD N
. . N

METHODS NNP N
Seventy NNP p
patients NNS p
with IN p
a DT p
unilateral JJ p
ACL-deficient JJ p
knee NN p
were VBD N
randomly RB N
assigned VBN N
to TO N
1 CD N
of IN N
2 CD N
femoral JJ N
fixation NN N
groups NNS N
. . N

Group NNP N
A NNP N
( ( N
35 CD N
patients NNS N
) ) N
was VBD N
fixed VBN i
with IN i
2 CD i
bioabsorbable JJ i
Rigidfix NNP i
pins NNS i
, , i
1 CD i
cross-pin NN i
per IN i
bundle NN i
, , i
while IN i
group NN i
B NNP i
( ( i
35 CD i
patients NNS i
) ) i
was VBD i
secured VBN i
with IN i
1 CD i
EndoButton NNP i
cortical JJ i
button NN i
per IN i
bundle NN i
. . i

All DT N
femoral JJ N
tunnels NNS N
were VBD N
created VBN N
via IN N
an DT N
anteromedial JJ N
portal NN N
, , N
and CC N
a DT N
bioabsorbable JJ N
Biointrafix NNP N
interference NN N
screw NN N
was VBD N
used VBN N
for IN N
tibial JJ N
fixation NN N
for IN N
both DT N
groups NNS N
. . N

The DT N
evaluation NN N
of IN N
the DT N
patients NNS N
was VBD N
performed VBN N
by IN N
history NN N
details NNS N
, , N
clinical JJ N
examination NN N
findings NNS N
, , N
measurement NN N
of IN N
the DT N
joint JJ N
laxity NN N
by IN N
KT-1000 NNP i
arthrometer NN i
, , N
and CC N
use NN N
of IN N
validated JJ N
patient JJ N
outcome NN N
questionnaires NNS N
. . N

Statistical JJ N
analysis NN N
was VBD N
carried VBN N
out RP N
with IN N
Fisher NNP N
exact JJ N
and CC N
Mann-Whitney NNP N
U NNP N
tests NNS N
, , N
with IN N
P NNP N
< NNP N
.05 NNP N
considered VBD N
the DT N
cutoff NN N
level NN N
of IN N
significance NN N
. . N

RESULTS NNP N
At IN N
a DT N
mean JJ N
follow-up NN N
of IN N
30 CD N
months NNS N
, , N
34 CD p
and CC p
32 CD p
patients NNS p
of IN N
group NN N
A NNP N
and CC N
B NNP N
, , N
respectively RB N
, , N
were VBD N
available JJ N
for IN N
evaluation NN N
. . N

There EX N
were VBD N
no DT N
statistically RB N
significant JJ N
differences NNS N
between IN N
the DT N
treatment NN N
groups NNS N
regarding VBG N
the DT N
subjective NN N
and CC N
objective JJ N
outcomes NNS N
, , N
except IN N
for IN N
KT-1000 NNP N
arthrometer NN N
values NNS N
. . N

The DT N
median JJ o
KT-1000 NNP o
value NN o
of IN N
patients NNS N
in IN N
the DT N
cross-pin JJ N
fixation NN N
group NN N
was VBD N
1.30 CD N
mm NNS N
, , N
while IN N
the DT N
median JJ N
value NN N
in IN N
the DT N
cortical JJ i
button NN i
fixation NN i
group NN N
was VBD N
1.95 CD N
mm NN N
( ( N
P NNP N
< NNP N
.001 NNP N
) ) N
. . N

Four CD N
patients NNS N
with IN N
ACL NNP N
grafts NNS N
that WDT N
were VBD N
fixed VBN N
with IN N
cortical JJ i
buttons NNS i
demonstrated VBD N
failure NN N
of IN N
stability NN o
via IN o
the DT o
instrumented JJ o
knee NN o
laxity NN o
testing NN o
, , N
while IN N
patients NNS N
from IN N
the DT N
other JJ N
group NN N
had VBD N
no DT N
failures NNS N
. . N

CONCLUSION NNP N
Intratunnel NNP i
femoral JJ i
fixation NN i
of IN i
the DT i
double-bundle JJ i
ACL NNP i
graft NN i
from IN N
the DT N
cross-pin JJ N
fixation NN N
technique NN N
provided VBD N
better RBR N
instrumented JJ N
knee NN o
laxity NN o
results NNS N
than IN N
did VBD N
the DT N
extratunnel NN i
femoral JJ i
fixation NN i
with IN i
cortical JJ i
buttons NNS i
. . i

Future NNP N
larger JJR N
studies NNS N
comparing VBG N
these DT N
2 CD N
techniques NNS N
should MD N
be VB N
conducted VBN N
to TO N
ensure VB N
the DT N
availability NN N
of IN N
stronger JJR N
evidence NN N
supporting VBG N
the DT N
findings NNS N
of IN N
this DT N
study NN N
. . N

-DOCSTART- -23392460- O O

A DT N
randomized JJ N
double-blind JJ N
comparison NN N
of IN N
coformulated JJ p
elvitegravir/cobicistat/emtricitabine/tenofovir NN i
disoproxil NN i
fumarate NN i
versus NN p
efavirenz/emtricitabine/tenofovir NN i
disoproxil NN i
fumarate NN i
for IN p
initial JJ p
treatment NN p
of IN p
HIV-1 NNP p
infection NN p
: : p
analysis NN N
of IN N
week NN N
96 CD N
results NNS N
. . N

We PRP N
report VBP N
week NN N
96 CD N
results NNS N
from IN N
a DT N
phase NN N
3 CD N
trial NN N
of IN N
elvitegravir/cobicistat/emtricitabine/tenofovir NN i
disoproxil NN i
fumarate NN i
( ( i
EVG/COBI/FTC/TDF NNP i
, , p
n JJ p
= NNP p
348 CD p
) ) p
vs NN N
efavirenz/emtricitabine/tenofovir JJ i
disoproxil NN i
fumarate NN i
( ( p
EFV/FTC/TDF NNP p
, , p
n JJ p
= NNP p
352 CD p
) ) p
. . N

At IN N
week NN N
48 CD N
, , N
EVG/COBI/FTC/TDF NNP i
was VBD N
noninferior JJ N
to TO N
EFV/FTC/TDF NNP i
( ( N
88 CD N
% NN N
vs JJ N
84 CD N
% NN N
, , N
difference NN N
+3.6 CD N
% NN N
, , N
95 CD N
% NN N
confidence NN N
interval NN N
: : N
-1.6 CD N
% NN N
to TO N
8.8 CD N
% NN N
) ) N
. . N

Virologic NNP o
success NN o
( ( N
HIV-1 NNP N
RNA NNP N
< NNP N
50 CD N
copies/mL NN N
) ) N
was VBD N
maintained VBN N
at IN N
week NN N
96 CD N
( ( N
84 CD N
% NN N
vs JJ N
82 CD N
% NN N
, , N
difference NN N
+2.7 CD N
% NN N
, , N
95 CD N
% NN N
CI NNP N
: : N
-2.9 CD N
% NN N
to TO N
8.3 CD N
% NN N
) ) N
. . N

Discontinuation NN o
due JJ o
to TO o
adverse JJ o
events NNS o
was VBD N
low JJ N
( ( N
5 CD N
% NN N
vs JJ N
7 CD N
% NN N
) ) N
. . N

Median JJ o
changes NNS o
in IN o
serum NN o
creatinine NN o
( ( N
mg/dL NN N
) ) N
at IN N
week NN N
96 CD N
were VBD N
similar JJ N
to TO N
week NN N
48 CD N
. . N

These DT N
results NNS N
support VBP N
the DT N
durable JJ o
efficacy NN o
and CC N
long-term JJ o
safety NN o
of IN N
EVG/COBI/FTC/TDF NNP i
. . i

-DOCSTART- -17433718- O O

Temporal JJ i
judgements NNS i
of IN N
internal JJ N
and CC N
external JJ N
events NNS N
in IN N
persons NNS p
with IN p
and CC p
without IN p
autism NN p
. . p

When WRB N
participants NNS N
make VBP N
judgments NNS i
about IN N
the DT N
onset NN N
of IN N
self-initiated JJ N
movements NNS N
they PRP N
typically RB N
report VBP N
the DT N
movement NN N
occurred VBD N
earlier JJR N
than IN N
it PRP N
had VBD N
[ NNP N
Obhi NNP N
, , N
S. NNP N
S. NNP N
, , N
& CC N
Haggard NNP N
, , N
P. NNP N
( ( N
2004 CD N
) ) N
. . N

Free NNP N
will MD N
and CC N
free JJ N
wo MD N
n't RB N
. . N

American JJ N
Scientific NNP N
, , N
92 CD N
, , N
358-365. JJ N
] NN N
. . N

One CD N
interpretation NN N
is VBZ N
that IN N
feed-forward JJ N
processes NNS N
lead VBP N
to TO N
awareness NN N
of IN N
the DT N
movement NN N
prior RB N
to TO N
execution NN N
. . N

Because IN N
individuals NNS p
with IN p
autism NN p
experience NN N
reduced VBD N
preparatory JJ N
activity NN N
prior RB N
to TO N
a DT N
voluntary JJ N
movement NN N
, , N
the DT N
present JJ N
study NN N
sought VBD N
to TO N
determine VB N
whether IN N
these DT N
anticipatory JJ N
biases NNS N
are VBP N
exhibited VBN N
by IN N
persons NNS p
with IN p
autism NN p
. . p

Participants NNS i
watched VBD i
a DT i
dot JJ i
move NN i
in IN i
a DT i
circle NN i
and CC i
pressed VBD i
the DT i
spacebar NN i
any DT i
time NN i
after IN i
one CD i
revolution NN i
. . i

A DT N
tone NN N
either CC N
followed VBD N
the DT N
participants NNS N
' POS N
voluntary JJ N
movement NN N
or CC N
was VBD N
computer NN N
generated VBN N
. . N

Participants NNS N
in IN N
both DT N
groups NNS N
made VBD N
anticipatory JJ N
judgements NNS o
regarding VBG N
movement NN o
initiation NN o
( ( N
approximately RB N
100 CD N
ms NN N
) ) N
. . N

When WRB N
the DT N
movement NN N
and CC N
tone NN N
occurred VBD N
together RB N
this DT N
anticipatory NN N
bias NN N
was VBD N
also RB N
present JJ N
, , N
regardless RB N
of IN N
which WDT N
event NN N
participants NNS N
focused VBD N
on IN N
. . N

Individuals NNS p
with IN p
autism NN p
appear VBP N
to TO N
have VB N
access NN N
to TO N
a DT N
similar JJ N
representation NN N
of IN N
voluntary JJ o
movements NNS o
, , N
however RB N
this DT N
representation NN N
may MD N
be VB N
more RBR N
variable JJ N
. . N

-DOCSTART- -17114905- O O

A DT N
randomized VBN N
controlled VBN N
trial NN N
to TO N
evaluate VB N
the DT N
efficacy NN o
of IN N
ultrasound-guided JJ i
laser NN i
photocoagulation NN i
for IN N
treatment NN N
of IN N
benign JJ p
thyroid JJ o
nodules NNS o
. . o

This DT N
randomized VBD N
controlled VBN N
study NN N
was VBD N
designed VBN N
to TO N
test VB N
the DT N
efficacy NN o
and CC o
safety NN o
of IN N
percutaneous JJ i
ultrasound NN i
( ( i
US NNP i
) ) i
-guided VBD i
laser NN i
photocoagulation NN i
( ( i
PLP NNP i
) ) i
for IN N
treatment NN N
of IN N
subjects NNS p
with IN p
compressive JJ p
symptoms NNS p
due JJ p
to TO p
benign VB o
thyroid JJ o
nodules NNS o
and/or VBP p
at IN p
high JJ p
surgical JJ p
risk NN p
. . p

Twenty NNP p
six CD p
subjects NNS p
were VBD p
randomized VBN p
to TO p
the DT p
intervention NN i
( ( p
no DT p
. . p

13 CD p
, , p
age NN p
68+/-3 JJ p
yr NN p
, , p
mean+/-SEM NN p
) ) p
or CC i
observation NN i
( ( p
no DT p
. . p

13 CD p
, , p
age NN p
71+/-2 JJ p
yr NN p
) ) p
groups NNS p
. . p

In IN N
the DT N
control NN N
group NN N
, , N
the DT N
volume NN o
of IN o
nodules NNS o
did VBD N
not RB N
significantly RB N
change VBP N
over IN N
the DT N
30 CD N
week NN N
period NN N
of IN N
observation NN N
. . N

In IN N
the DT N
intervention NN N
group NN N
, , N
median JJ o
nodule NN o
volume NN o
at IN N
baseline NN N
was VBD N
8.2 CD N
ml NN N
( ( N
range VB N
2.8-26.9 JJ N
) ) N
and CC N
was VBD N
not RB N
significantly RB N
different JJ N
from IN N
that DT N
of IN N
the DT N
control NN N
group NN N
. . N

Nodules NNS o
decreased VBN N
significantly RB N
( ( N
p JJ N
< NNP N
0.0001 CD N
) ) N
by IN N
22 CD N
% NN N
after IN N
2 CD N
weeks NNS N
( ( N
6.5 CD N
ml NN N
; : N
range VB N
2.4-16.7 JJ N
) ) N
and CC N
by IN N
44 CD N
% NN N
after IN N
30 CD N
weeks NNS N
( ( N
4.6 CD N
ml NN N
; : N
range VB N
0.69-14.2 NN N
) ) N
. . N

Energy NNP N
given VBN N
was VBD N
correlated VBN N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
with IN N
the DT N
reduction NN N
of IN N
thyroid JJ o
nodule NN o
volume NN o
. . o

All DT N
patients NNS N
tolerated VBD N
the DT N
treatment NN o
well RB N
and CC N
reported VBD N
relief NN o
from IN N
compressive JJ o
and CC o
cosmetic JJ o
complaints NNS o
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
. . N

At IN N
the DT N
time NN N
of IN N
enrolment JJ N
7/13 CD N
( ( N
54 CD N
% NN N
) ) N
and CC N
6/13 CD N
( ( N
46 CD N
% NN N
) ) N
of IN N
patients NNS N
in IN N
the DT N
intervention NN N
and CC N
control NN N
groups NNS N
, , N
respectively RB N
, , N
had VBD N
sub VBN o
clinical JJ o
hyperthyroidism NN o
. . o

PLP NNP o
normalized JJ o
thyroid NN o
function NN o
at IN N
6 CD N
and CC N
30 CD N
weeks NNS N
after IN N
treatment NN N
. . N

In IN N
conclusion NN N
, , N
PLP NNP N
is VBZ N
a DT N
promising JJ N
safe JJ o
and CC o
effective JJ o
procedure NN N
for IN N
treatment NN N
of IN N
benign JJ p
thyroid JJ p
nodules NNS p
in IN p
patients NNS p
at IN p
high JJ p
surgical JJ p
risk NN p
. . p

-DOCSTART- -6116246- O O

A DT N
double-blind JJ N
comparison NN N
of IN N
bromperidol NN i
and CC i
haloperidol NN i
in IN N
newly RB p
admitted VBN p
schizophrenic JJ p
patients NNS p
. . p

-DOCSTART- -25346345- O O

A DT N
randomized VBN N
controlled JJ N
trial NN N
of IN N
Pivotal NNP i
Response NNP i
Treatment NNP i
Group NNP i
for IN N
parents NNS p
of IN p
children NNS p
with IN p
autism NN p
. . p

BACKGROUND NNP N
With IN N
rates NNS N
of IN N
autism NN N
diagnosis NN N
continuing VBG N
to TO N
rise VB N
, , N
there EX N
is VBZ N
an DT N
urgent JJ N
need NN N
for IN N
effective JJ N
and CC N
efficient JJ N
service NN N
delivery NN N
models NNS N
. . N

Pivotal JJ i
Response NNP i
Treatment NNP i
( ( i
PRT NNP i
) ) i
is VBZ N
considered VBN N
an DT N
established VBN N
treatment NN N
for IN N
autism NN N
spectrum NN N
disorder NN N
( ( N
ASD NNP N
) ) N
; : N
however RB N
, , N
there EX N
have VBP N
been VBN N
few JJ N
well-controlled JJ N
studies NNS N
with IN N
adequate JJ N
sample NN N
size NN N
. . N

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
conduct VB N
a DT N
randomized NN N
controlled VBN N
trial NN N
to TO N
evaluate VB N
PRT NNP i
parent NN i
training VBG i
group NN i
( ( i
PRTG NNP i
) ) i
for IN N
targeting VBG N
language NN N
deficits NNS N
in IN N
young JJ p
children NNS p
with IN p
ASD NNP p
. . p

METHODS NNP N
Fifty-three JJ p
children NNS p
with IN p
autism NN p
and CC p
significant JJ p
language NN p
delay NN p
between IN p
2 CD p
and CC p
6 CD p
years NNS p
old JJ p
were VBD p
randomized VBN p
to TO i
PRTG NNP i
( ( i
N NNP i
= NNP i
27 CD i
) ) i
or CC i
psychoeducation NN i
group NN i
( ( i
PEG NNP i
; : p
N NNP p
= NNP p
26 CD p
) ) p
for IN p
12 CD p
weeks NNS p
. . p

The DT p
PRTG NNP N
taught VBD N
parents NNS N
behavioral JJ N
techniques NNS N
to TO N
facilitate VB N
language NN N
development NN N
. . N

The DT N
PEG NNP N
taught VBD N
general JJ N
information NN N
about IN N
ASD NNP N
( ( N
clinical JJ N
trial NN N
NCT01881750 NNP N
; : N
http NN N
: : N
//www.clinicaltrials.gov NN N
) ) N
. . N

RESULTS JJ N
Analysis NN o
of IN o
child JJ o
utterances NNS o
during IN o
the DT o
structured JJ o
laboratory NN o
observation NN o
( ( o
primary JJ o
outcome NN N
) ) N
indicated VBD N
that IN N
, , N
compared VBN N
with IN N
children NNS N
in IN N
the DT N
PEG NNP N
, , N
children NNS N
in IN N
the DT N
PRTG NNP N
demonstrated VBD o
greater JJR o
improvement NN o
in IN o
frequency NN o
of IN o
utterances NNS o
( ( o
F NNP o
( ( o
2 CD o
, , o
43 CD N
) ) N
= NN N
3.53 CD N
, , N
p NN N
= NNP N
.038 NNP N
, , N
d NN N
= NNP N
0.42 CD N
) ) N
. . N

Results NNS N
indicated VBD N
that IN N
parents NNS N
were VBD N
able JJ N
to TO N
learn VB i
PRT NNP i
in IN i
a DT N
group NN N
format NN N
, , N
as IN N
the DT N
majority NN N
of IN N
parents NNS N
in IN N
the DT N
PRTG NNP N
( ( N
84 CD N
% NN N
) ) N
met VBD N
fidelity NN N
of IN N
implementation NN N
criteria NNS N
after IN N
12 CD N
weeks NNS N
. . N

Children NNP N
also RB N
demonstrated VBD N
greater JJR o
improvement NN o
in IN o
adaptive JJ o
communication NN o
skills NNS o
( ( o
Vineland-II NNP o
) ) o
following VBG o
PRTG NNP o
and CC N
baseline VB N
Mullen NNP N
visual JJ N
reception NN N
scores NNS N
predicted VBD N
treatment NN N
response NN N
to TO N
PRTG NNP N
. . N

CONCLUSIONS NNP N
This DT N
is VBZ N
the DT N
first JJ N
randomized VBN N
controlled JJ N
trial NN N
of IN N
group-delivered JJ N
PRT NNP N
and CC N
one CD N
of IN N
the DT N
largest JJS N
experimental JJ N
investigations NNS N
of IN N
the DT N
PRT NNP N
model NN N
to TO N
date NN N
. . N

The DT N
findings NNS N
suggest VBP N
that IN N
specific JJ N
instruction NN N
in IN i
PRT NNP i
results NNS i
in IN o
greater JJR o
skill NN o
acquisition NN o
for IN o
both DT o
parents NNS o
and CC o
children NNS o
, , N
especially RB N
in IN N
functional JJ o
and CC o
adaptive JJ o
communication NN o
skills NNS o
. . o

Further NNP o
research NN i
in IN i
PRT NNP i
is VBZ i
warranted VBN i
to TO N
replicate VB N
the DT N
observed JJ N
results NNS N
and CC N
address JJ N
other JJ N
core NN N
ASD NNP N
symptoms NNS N
. . N

-DOCSTART- -12591004- O O

Bioavailability NN o
of IN N
omega-3 JJ i
essential JJ i
fatty JJ i
acids NNS i
from IN p
perilla NN i
seed NN i
oil NN i
. . i

Increased VBD N
dietary JJ N
intake NN N
of IN N
fish JJ i
oil NN i
omega-3 JJ i
fatty NN i
acids NNS i
, , N
eicosapentanoic JJ N
acid NN N
and CC N
docosohexanoic NN N
acid NN N
, , N
and CC N
their PRP$ N
precursor NN N
, , N
alpha-linolenic JJ i
acid NN i
( ( N
ALA NNP N
) ) N
, , N
is VBZ N
associated VBN N
with IN N
various JJ N
health NN N
benefits NNS N
. . N

Enteric-coating NNP N
( ( N
Entrox NNP N
) ) N
, , N
which WDT N
improves VBZ N
stability NN N
of IN N
omega-3 JJ N
capsules NNS N
, , N
has VBZ N
been VBN N
shown VBN N
to TO N
facilitate VB N
fish JJ N
oil NN N
absorption NN N
after IN N
chronic JJ N
treatment NN N
. . N

To TO N
assess VB N
the DT N
effect NN N
of IN N
Entrox NNP N
coating VBG N
on IN N
the DT N
short-term JJ N
bioavailability NN N
of IN N
ALA NNP i
administered VBD N
in IN N
the DT N
form NN N
of IN N
ALA-rich NNP N
Perilla NNP N
seed NN N
oil NN N
, , N
12 CD p
healthy JJ p
subjects NNS p
( ( p
6 CD p
males NNS p
and CC p
6 CD p
females NNS p
) ) p
received VBN N
in IN N
a DT N
random JJ N
order NN N
Entrox-coated JJ i
and CC i
non-coated JJ i
ALA NNP i
formulations NNS i
, , N
each DT N
as IN N
a DT N
single JJ N
6g CD N
dose NN N
separated VBN N
by IN N
a DT N
3-week JJ N
washout NN N
period NN N
. . N

Measurements NNS N
of IN N
plasma NN o
ALA NNP o
concentrations NNS o
from IN N
0 CD N
to TO N
24h CD N
showed VBD N
no DT N
difference NN N
in IN N
ALA NNP N
pharmacokinetics NNS N
between IN N
the DT N
two CD N
formulations NNS N
. . N

However RB N
, , N
significantly RB N
greater JJR N
increases NNS N
in IN N
plasma JJ o
ALA NNP o
levels NNS o
from IN N
baseline NN N
to TO N
24h CD N
were VBD N
observed VBN N
after IN N
ingestion NN N
of IN N
Entrox NNP N
vs. IN N
non-coated JJ N
product NN N
, , N
suggesting VBG N
a DT N
possible JJ N
benefit NN N
of IN N
Entrox NNP N
with IN N
long-term JJ N
treatment NN N
. . N

-DOCSTART- -21034619- O O

Effect NN N
of IN N
medical JJ i
ozone NN i
therapy NN i
on IN N
renal JJ o
blood NN o
flow NN o
and CC o
renal JJ o
function NN o
of IN N
patients NNS p
with IN p
chronic JJ p
severe JJ p
hepatitis NN p
. . p

BACKGROUND NNP N
Medical NNP i
ozone NN i
therapy NN i
system NN i
was VBD N
reported VBN N
to TO N
have VB N
certain JJ N
effects NNS o
on IN o
the DT o
treatment NN o
of IN o
severe JJ o
hepatitis NN o
, , N
but CC N
its PRP$ N
mechanism NN N
is VBZ N
not RB N
very RB N
clear JJ N
. . N

One CD N
of IN N
the DT N
causes NNS N
of IN N
death NN N
of IN N
severe JJ N
hepatitis NN N
is VBZ N
complication NN o
of IN o
renal JJ o
damage NN o
or CC N
hepatorenal JJ o
syndrome NN o
. . o

The DT N
present JJ N
study NN N
aimed VBN N
to TO N
observe VB N
effects NNS N
of IN N
medical JJ i
ozone NN i
therapy NN i
system NN i
on IN N
plasma JJ o
renin NN o
activity NN o
( ( o
PRA NNP o
) ) o
, , o
angiotensin JJ o
II NNP o
( ( o
AII NNP o
) ) o
, , o
aldosterone NN o
( ( o
ALD NNP o
) ) o
, , o
renal JJ o
blood NN o
flow NN o
and CC o
renal JJ o
function NN o
of IN N
patients NNS p
with IN p
chronic JJ p
severe JJ p
hepatitis NN p
and CC N
explore VB N
mechanisms NNS N
of IN N
medical JJ i
ozone NN i
therapy NN i
in IN N
the DT N
treatment NN N
of IN N
severe JJ N
hepatitis NN N
. . N

METHODS NNP N
Eighty-five JJ p
cases NNS p
with IN p
chronic JJ p
severe JJ p
hepatitis NN p
were VBD N
randomly RB N
divided VBN N
into IN N
ozone NN i
therapy NN i
group NN i
( ( N
43 CD N
cases NNS N
) ) N
and CC N
control NN i
group NN i
( ( N
42 CD N
cases NNS N
) ) N
. . N

The DT N
patients NNS N
in IN N
the DT N
ozone NN i
therapy NN i
group NN N
were VBD N
treated VBN N
with IN N
basic JJ i
treatments NNS i
plus CC i
ozone NN i
therapy NN i
system NN i
. . i

Basic JJ o
autohemotherapy NN o
was VBD N
used VBN N
. . N

One CD N
hundred VBD N
milliliter RBR N
venous JJ N
blood NN N
was VBD N
drawn VBN N
from IN N
each DT N
patient NN N
, , N
and CC N
was VBD N
mixed JJ N
with IN N
100 CD N
ml NNS N
( ( N
35 CD N
?g/ml NN i
) ) i
medical JJ i
ozone NN i
and CC N
then RB N
was VBD N
returned VBN N
the DT N
blood NN N
to TO N
the DT N
patient NN N
intravenously RB N
, , N
once RB N
every DT N
other JJ N
day NN N
for IN N
20 CD N
days NNS N
. . N

Only RB N
the DT i
basic JJ i
treatments NNS i
were VBD N
given VBN N
to TO N
the DT i
control NN i
group NN i
. . i

PRA NNP o
, , o
AII NNP o
, , o
ALD NNP o
, , o
renal JJ o
blood NN o
flow NN o
and CC o
damage NN o
to TO o
renal JJ o
function NN o
of IN N
the DT N
two CD N
groups NNS N
before IN N
treatment NN N
and CC N
20 CD N
days NNS N
after IN N
treatment NN N
were VBD N
compared VBN N
. . N

Survival JJ o
rates NNS o
were VBD N
also RB N
compared VBN N
. . N

RESULTS NNP N
Twenty NNP N
days NNS N
after IN N
the DT N
treatment NN N
, , N
in IN i
ozone NN i
therapy NN i
group NN N
, , N
PRA NNP o
was VBD N
( ( N
1.31 CD N
? . N
0.12 CD N
) ) N
ng?ml???h?? NN o
, , o
AII NNP o
( ( o
111.25 CD o
? . N
17.35 CD N
) ) N
pg/ml NN o
, , o
ALD NNP o
( ( N
251.31 CD N
? . N
22.60 CD N
) ) N
pg/ml NN N
, , N
which WDT N
decreased VBD N
significantly RB N
compared VBN N
with IN N
those DT N
before IN N
treatment NN o
( ( o
PRA NNP o
( ( o
2.23 CD o
? . N
0.13 CD N
) ) N
ng?ml???h?? NN N
, , N
AII NNP o
( ( o
155.18 CD o
? . o
19.13 CD o
) ) N
pg/ml NN o
, , o
ALD NNP o
( ( N
405.31 CD N
? . N
29.88 CD N
) ) N
pg/ml NN N
, , N
t EX N
= $ N
4.67 CD N
- : N
14.23 CD N
, , N
P NNP N
< NNP N
0.01 CD N
) ) N
, , N
also RB N
lower JJR N
than IN N
those DT N
of IN N
control NN N
group NN N
20 CD N
days NNS N
after IN N
the DT N
treatment NN o
( ( o
PRA NNP o
( ( o
2.02 CD o
? . N
0.11 CD N
) ) N
ng?ml???h?? NN o
, , o
AII NNP o
( ( N
162.21 CD N
? . o
15.32 CD o
) ) o
pg/ml NN o
, , o
ALD NNP o
( ( N
401.20 CD N
? . N
35.02 CD N
) ) N
pg/ml NN N
, , N
t EX N
= $ N
4.97 CD N
- : N
15.61 CD N
, , N
P NNP N
< NNP N
0.01 CD N
) ) N
; : o
renal JJ o
blood NN o
flow NN o
was VBD o
( ( N
175.15 CD N
? . N
28.20 CD N
) ) N
ml/min NN N
, , N
which WDT N
increased VBD N
compared VBN N
with IN N
that DT N
before IN N
the DT N
treatment NN N
( ( N
( ( N
125.68 CD N
? . N
21.25 CD N
) ) N
ml/min NN N
) ) N
and CC N
was VBD N
higher JJR N
than IN N
that DT N
of IN N
control NN N
group NN N
20 CD N
days NNS N
after IN N
the DT N
treatment NN N
( ( N
( ( N
128.59 CD N
? . N
23.15 CD N
) ) N
ml/min NN N
, , N
t EX N
= JJ N
4.78 CD N
, , N
4.61 CD N
, , N
P NNP N
< NNP N
0.01 CD o
) ) o
. . o

Renal JJ o
damage NN o
occurred VBD N
in IN N
2 CD N
cases NNS N
( ( N
5 CD N
% NN N
) ) N
in IN N
ozone NN N
therapy NN N
group NN N
, , N
less JJR N
than IN N
that DT N
in IN N
control NN N
group NN N
( ( N
9 CD N
cases NNS N
, , N
21 CD N
% NN N
) ) N
( ( N
?? JJ N
= NN N
5.295 CD N
, , N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

Thirty-three JJ N
cases NNS N
( ( N
77 CD N
% NN N
) ) N
in IN N
ozone NN i
therapy NN i
group NN i
vs. FW i
16 CD N
cases NNS N
( ( N
38 CD N
% NN N
) ) N
in IN i
control NN i
group NN o
survived VBD o
( ( N
?? JJ N
= NN N
12.993 CD N
, , N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

CONCLUSIONS NNP i
Basic NNP i
treatment NN i
plus CC N
medical JJ i
ozone NN i
therapy NN i
for IN i
patients NNS p
with IN p
chronic JJ p
severe JJ p
hepatitis NN p
could MD p
decrease VB o
PRA NNP o
, , o
AII NNP o
and CC o
ALD NNP o
levels NNS o
significantly RB o
increase VBP o
renal JJ o
blood NN o
flow NN o
, , o
prevent JJ o
renal JJ o
damage NN o
to TO o
certain JJ N
extent NN N
and CC N
improve VB o
survival NN o
rate NN o
of IN N
the DT N
patients NNS N
. . N

-DOCSTART- -11034934- O O

VLDL NNP o
, , o
apolipoproteins VBZ o
B NNP o
, , o
CIII NNP o
, , o
and CC o
E NNP o
, , N
and CC N
risk NN N
of IN N
recurrent JJ o
coronary JJ o
events NNS o
in IN N
the DT N
Cholesterol NNP N
and CC N
Recurrent NNP N
Events NNP N
( ( N
CARE NNP N
) ) N
trial NN N
. . N

BACKGROUND NNP N
Plasma NNP N
triglyceride NN N
concentration NN N
has VBZ N
been VBN N
an DT N
inconsistent JJ N
independent JJ N
risk NN N
factor NN N
for IN N
coronary JJ N
heart NN N
disease NN N
, , N
perhaps RB N
because IN N
of IN N
the DT N
metabolic JJ N
heterogeneity NN N
among IN N
VLDL NNP N
particles NNS N
, , N
the DT N
main JJ N
carriers NNS N
of IN N
triglycerides NNS N
in IN N
plasma NN N
. . N

METHODS NNP N
AND CC N
RESULTS NNP N
We PRP N
conducted VBD N
a DT N
prospective JJ N
, , N
nested JJ N
case-control NN N
study NN N
in IN N
the DT N
Cholesterol NNP N
and CC N
Recurrent NNP N
Events NNP N
( ( N
CARE NNP N
) ) N
trial NN N
, , N
a DT N
randomized JJ N
placebo-controlled JJ i
trial NN N
of IN N
pravastatin NN i
in IN N
4159 CD p
patients NNS p
with IN p
myocardial JJ p
infarction NN p
and CC p
average JJ p
LDL NNP p
concentrations NNS p
at IN p
baseline NN p
( ( p
115 CD p
to TO p
174 CD p
mg/dL NNS p
, , p
mean VBP p
139 CD p
mg/dL NN p
) ) p
. . p

Baseline NNP N
concentrations NNS N
of IN N
VLDL-apolipoprotein NNP o
( ( N
apo NN N
) ) N
B NNP o
( ( o
the DT o
VLDL NNP o
particle NN o
concentration NN o
) ) o
, , o
VLDL NNP o
lipids NNS o
, , N
and CC N
apoCIII NN o
and CC o
apoE NN o
in IN o
VLDL+LDL NNP o
and CC o
in IN o
HDL NNP o
were VBD N
compared VBN N
in IN N
patients NNS p
who WP p
had VBD p
either CC p
a DT p
myocardial JJ p
infarction NN p
or CC p
coronary JJ p
death NN p
( ( p
cases NNS p
, , p
n=418 NN p
) ) p
with IN N
those DT N
in IN N
patients NNS p
who WP p
did VBD p
not RB p
have VB p
a DT p
cardiovascular JJ p
event NN p
( ( p
control NN p
subjects VBZ p
, , p
n=370 NN p
) ) p
in IN N
5 CD N
years NNS N
of IN N
follow-up JJ N
. . N

VLDL-cholesterol NN o
, , o
VLDL-triglyceride NNP o
, , o
VLDL-apoB NNP o
, , o
apoCIII NN o
and CC o
apoE NN o
in IN o
VLDL+LDL NNP o
and CC o
apoE NN o
in IN o
HDL NNP o
were VBD N
all DT N
interrelated VBN N
, , N
and CC N
each DT N
was VBD N
a DT N
univariate JJ N
predictor NN N
of IN N
subsequent JJ N
coronary JJ N
events NNS N
. . N

The DT N
significant JJ N
independent JJ N
predictors NNS N
were VBD N
VLDL-apoB NNP o
( ( N
relative JJ N
risk NN N
[ NNP N
RR NNP N
] VBZ N
3.2 CD N
for IN N
highest JJS N
to TO N
lowest JJS N
quintiles NNS N
, , N
P NNP N
: : N
=0.04 NN N
) ) N
, , N
apoCIII RB o
in IN o
VLDL+LDL NNP o
( ( N
RR NNP N
2.3 CD N
, , N
P NNP N
: : N
=0.04 NN N
) ) N
, , N
and CC N
apoE NN o
in IN o
HDL NNP o
( ( N
RR NNP N
1.8 CD N
, , N
P NNP N
: : N
=0.02 NN N
) ) N
. . N

Plasma NNP o
triglycerides NNS o
, , N
a DT N
univariate JJ N
predictor NN N
of IN N
coronary JJ o
events NNS o
( ( N
RR NNP N
1.6 CD N
, , N
P NNP N
: : N
=0.03 NN N
) ) N
, , N
was VBD N
not RB N
related VBN N
to TO N
coronary JJ o
events NNS o
( ( N
RR NNP N
1.3 CD N
, , N
P NNP N
: : N
=0.6 NN N
) ) N
when WRB N
apoCIII NN o
in IN o
VLDL+LDL NNP o
was VBD N
included VBN N
in IN N
the DT N
model NN N
, , N
whereas JJ N
apoCIII NN o
remained VBD N
significant JJ N
. . N

Adjustment NN N
for IN N
LDL- NNP o
and CC o
HDL-cholesterol NNP o
did VBD N
not RB N
affect VB N
these DT N
results NNS N
. . N

CONCLUSIONS NNP N
The DT N
plasma JJ N
concentrations NNS N
of IN N
VLDL NNP o
particles NNS o
and CC o
apoCIII NN o
in IN o
VLDL NNP o
and CC o
LDL NNP o
are VBP N
more RBR N
specific JJ N
measures NNS N
of IN N
coronary JJ N
heart NN N
disease NN N
risk NN N
than IN N
plasma JJ N
triglycerides NNS N
perhaps RB N
because IN N
their PRP$ N
known VBN N
metabolic NN N
properties NNS N
link VBP N
them PRP N
more RBR N
closely RB N
to TO N
atherosclerosis NN N
. . N

-DOCSTART- -26209587- O O

Fixed-dose JJ N
combination NN N
of IN N
AR-13324 NNP i
and CC i
latanoprost NN i
: : i
a DT N
double-masked JJ N
, , N
28-day JJ N
, , N
randomised VBN N
, , N
controlled VBN N
study NN N
in IN N
patients NNS p
with IN p
open-angle JJ p
glaucoma NN p
or CC p
ocular JJ p
hypertension NN p
. . p

BACKGROUND/AIMS NNP N
To TO N
evaluate VB N
the DT N
ocular JJ N
hypotensive JJ N
efficacy NN o
of IN N
fixed-dose JJ N
combinations NNS N
of IN N
the DT N
Rho NNP i
kinase NN i
inhibitor NN i
and CC i
norepinephrine JJ i
transport NN i
inhibitor NN i
AR-13324 NNP i
( ( N
0.01 CD N
% NN N
and CC N
0.02 CD N
% NN N
) ) N
and CC N
latanoprost $ i
( ( N
PG324 NNP N
Ophthalmic NNP N
Solution NNP N
) ) N
relative VBP N
to TO N
the DT N
active JJ N
components NNS N
AR-13324 JJ i
0.02 CD N
% NN N
and CC N
latanoprost $ N
0.005 CD N
% NN N
, , N
used VBN N
bilaterally RB N
at IN N
night NN N
. . N

METHODS NNP N
This DT N
was VBD N
a DT N
double-masked JJ N
, , N
randomised VBN N
, , N
parallel JJ N
comparison NN N
study NN N
in IN N
patients NNS p
with IN p
open-angle JJ p
glaucoma NN p
or CC p
ocular JJ p
hypertension NN p
. . p

After IN N
washout NN N
, , N
patients NNS N
were VBD N
randomised VBN N
to TO N
one CD N
of IN N
four CD N
treatment NN N
arms NNS N
and CC N
treated VBD N
for IN N
28 CD N
days NNS N
. . N

The DT N
primary JJ N
efficacy NN N
variable NN N
was VBD o
mean JJ o
diurnal JJ o
intraocular JJ o
pressure NN o
( ( o
IOP NNP o
) ) o
at IN o
day NN N
29 CD N
. . N

RESULTS NN N
We PRP N
randomised VBD p
298 CD p
patients NNS p
, , p
of IN p
whom WP p
292 CD p
( ( p
98 CD p
% NN p
) ) p
completed VBD p
the DT p
study NN p
. . p

Mean NNP o
unmedicated VBD o
diurnal JJ o
IOPs NNP o
( ( o
study VB N
eye NN N
) ) N
was VBD N
25.1 CD N
, , N
25.1 CD N
, , N
26.0 CD N
and CC N
25.4 CD N
in IN N
the DT N
PG324 NNP N
0.01 CD N
% NN N
, , N
PG324 NNP N
0.02 CD N
% NN N
, , N
latanoprost NN N
and CC N
AR-13324 JJ N
0.02 CD N
% NN N
groups NNS N
, , N
respectively RB N
. . N

On IN N
day NN N
29 CD N
, , N
mean JJ o
diurnal JJ o
IOP NNP o
decreased VBD o
to TO N
17.3 CD N
, , N
16.5 CD N
, , N
18.4 CD N
and CC N
19.1 CD N
mm NN N
Hg NNP N
, , N
respectively RB N
. . N

For IN N
the DT N
primary JJ o
efficacy NN o
variable NN o
of IN N
mean JJ o
diurnal JJ o
IOP NNP o
at IN o
day NN N
29 CD N
, , N
PG324 NNP N
0.02 CD N
% NN N
met VBD N
the DT N
criterion NN N
for IN N
statistical JJ N
superiority NN N
relative NN N
to TO N
both DT N
latanoprost FW N
and CC N
AR-13324 NNP N
0.02 CD N
% NN N
( ( N
p JJ N
< NNP N
0.0001 CD N
) ) N
, , N
providing VBG N
additional JJ N
IOP NNP N
lowering NN N
of IN N
1.9 CD N
and CC N
2.6 CD N
mm NN N
Hg NNP N
, , N
respectively RB N
. . N

PG324 VB N
0.01 CD N
% NN N
also RB N
met VBD N
the DT N
criterion NN N
for IN N
superiority NN N
. . N

The DT N
most RBS N
frequently RB N
reported VBD N
adverse JJ N
event NN N
was VBD N
conjunctival JJ o
hyperaemia NN o
with IN o
an DT o
incidence NN o
of IN N
41 CD N
% NN N
( ( N
30/73 CD N
) ) N
, , N
40 CD N
% NN N
( ( N
29/73 CD N
) ) N
, , N
14 CD N
% NN N
( ( N
10/73 CD N
) ) N
and CC N
40 CD N
% NN N
( ( N
31/78 CD N
) ) N
in IN N
the DT N
PG324 NNP N
0.01 CD N
% NN N
, , N
PG324 NNP N
0.02 CD N
% NN N
, , N
latanoprost NN i
and CC i
AR-13324 JJ i
0.02 CD N
% NN N
groups NNS N
, , N
respectively RB N
. . N

CONCLUSIONS NNP N
In IN N
this DT N
short-term JJ N
study NN N
, , N
the DT N
fixed-dose JJ N
combination NN i
of IN i
AR-13324 NNP i
0.02 CD N
% NN N
and CC N
latanoprost $ N
0.005 CD N
% NN N
in IN N
PG324 NNP N
Ophthalmic NNP N
Solution NNP N
provides VBZ N
clinically RB N
and CC N
statistically RB o
superior JJ o
ocular JJ o
hypotensive JJ o
efficacy NN o
relative JJ N
to TO N
its PRP$ N
individual JJ N
active JJ N
components NNS N
at IN N
the DT N
same JJ N
concentrations NNS N
. . N

The DT N
only JJ N
safety NN o
finding NN o
of IN N
note NN N
was VBD N
transient JJ N
asymptomatic JJ N
conjunctival NN N
hyperaemia NN N
which WDT N
was VBD N
typically RB N
of IN N
mild JJ N
severity NN N
. . N

TRIAL NNP N
REGISTRATION NNP N
NUMBER NNP N
NCT02207491 NNP N
. . N

-DOCSTART- -7640140- O O

Comparison NNP N
of IN N
non-invasive JJ i
methods NNS i
for IN N
the DT N
assessment NN N
of IN N
haemodynamic JJ i
drug NN N
effects NNS N
in IN N
healthy JJ p
male NN p
and CC p
female JJ p
volunteers NNS p
: : p
sex NN N
differences NNS N
in IN N
cardiovascular JJ N
responsiveness NN N
. . N

1 CD N
. . N

The DT N
study NN N
was VBD N
performed VBN N
to TO N
determine VB N
the DT N
sensitivity NN N
and CC N
short-term JJ N
and CC N
day-to-day JJ N
variability NN N
of IN N
a DT N
novel NN N
technique NN N
based VBN N
on IN N
laser NN i
interferometry NN i
of IN i
ocular JJ i
fundus NN i
pulsations NNS i
and CC i
of IN i
non-invasive JJ i
methods NNS i
for IN N
the DT N
quantification NN N
of IN N
haemodynamic JJ N
drug NN N
effects NNS N
. . N

An DT N
additional JJ N
aim NN N
was VBD N
to TO N
assess VB N
sex NN N
differences NNS N
in IN N
haemodynamic JJ N
responsiveness NN N
to TO N
cardiovascular VB N
drugs NNS N
in IN N
male NN p
and CC p
female JJ p
healthy JJ p
volunteers NNS p
. . p

2 CD N
. . N

Ten CD p
males NNS p
and CC p
nine CD p
females NNS p
( ( p
age NN p
range NN p
20-33 CD p
years NNS p
) ) p
were VBD N
studied VBN N
in IN N
a DT N
double-blind NN N
, , N
randomized VBN N
, , N
cross-over JJ N
trial NN N
. . N

Simultaneous JJ o
measurements NNS o
from IN o
systemic JJ o
haemodynamics NNS o
, , o
laser JJR o
interferometry NN o
of IN o
ocular JJ o
fundus NN o
pulsations NNS o
, , o
systolic JJ o
time NN o
intervals NNS o
from IN o
mechanocardiography NN o
, , o
a/b VBP o
ratio NN o
from IN o
oxymetric JJ o
fingerplethysmography NN o
and CC o
Doppler NNP o
sonography NN o
of IN o
the DT o
radial JJ o
artery NN o
were VBD N
used VBN N
to TO N
describe VB N
the DT N
haemodynamic JJ N
effects NNS N
of IN N
cumulative JJ N
, , N
stepwise VB N
increasing VBG N
intravenous JJ i
doses NNS i
of IN i
phenylephrine NN i
, , i
isoprenaline NN i
, , i
sodium NN i
nitroprusside NN i
and CC i
of IN i
placebo NN i
. . i

3 CD N
. . N

Laser NNP N
interferometry NN N
detected VBD N
the DT N
isoprenaline-effects NNS N
at IN N
the DT N
lowest JJS N
dose JJ N
level NN N
of IN N
0.1 CD N
micrograms NNS N
min-1 JJ N
with IN N
a DT N
high JJ N
signal-to-noise NN N
ratio NN N
. . N

The DT N
reproducibility NN N
of IN N
measurements NNS N
under IN N
baseline NN N
was VBD N
high JJ N
, , N
no DT N
changes NNS N
were VBD N
observed VBN N
after IN N
systemically RB N
effective JJ N
doses NNS N
of IN N
phenylephrine NN N
or CC N
sodium NN N
nitroprusside RB N
. . N

Systolic JJ N
time NN N
intervals NNS N
were VBD N
sensitive JJ N
and CC N
specific JJ N
for IN N
isoprenaline-induced JJ N
effects NNS N
, , N
PEP NNP N
and CC N
QS2c-measurements NNS N
had VBD N
high JJ N
reproducibility NN N
. . N

Fingerplethysmography NNP N
proved VBD N
a DT N
sensitive JJ N
measurement NN N
for IN N
the DT N
detection NN N
of IN N
the DT N
vasodilating VBG N
effects NNS N
of IN N
sodium NN N
nitroprusside NN N
, , N
but CC N
was VBD N
not RB N
specific JJ N
, , N
and CC N
showed VBD N
low JJ N
reproducibility NN N
. . N

Measurements NNS N
from IN N
Doppler NNP N
sonography NN N
had VBD N
lower JJR N
reproducibility NN o
and CC o
sensitivity NN o
compared VBN N
with IN N
the DT N
other JJ N
applied JJ N
methods NNS N
. . N

4 CD N
. . N

There EX N
was VBD N
a DT N
significant JJ N
sex NN N
difference NN N
for IN N
several JJ N
of IN N
the DT N
haemodynamic JJ N
parameters NNS N
under IN N
baseline NN N
conditions NNS N
; : N
however RB N
, , N
the DT N
responsiveness NN N
to TO N
the DT N
drugs NNS N
under IN N
study NN N
was VBD N
not RB N
different JJ N
, , N
when WRB N
drug NN N
effects NNS N
were VBD N
expressed VBN N
as IN N
% NN N
-change NN N
from IN N
the DT N
baseline NN N
. . N

5 CD N
. . N

Laser NNP i
interferometry NN i
is VBZ N
a DT N
valuable JJ N
non-invasive JJ N
, , N
highly RB N
sensitive JJ N
and CC N
specific JJ N
approach NN N
for IN N
the DT N
detection NN N
of IN N
pulse JJ N
pressure NN N
changes NNS N
. . N

A DT N
battery NN N
of IN N
non-invasive JJ N
tests NNS N
appears VBZ N
useful JJ N
for IN N
the DT N
characterization NN N
of IN N
cardiovascular JJ N
drugs NNS N
. . N

Gender NNP N
differences NNS N
may MD N
not RB N
pose VB N
a DT N
relevant JJ N
problem NN N
for IN N
the DT N
study NN N
of IN N
acute JJ N
haemodynamic JJ N
effects NNS N
of IN N
cardiovascular JJ N
drugs NNS N
. . N

-DOCSTART- -9572900- O O

Scintigraphic JJ N
evaluation NN N
of IN N
a DT N
new JJ i
capsule-type JJ i
colon NN i
specific JJ i
drug NN i
delivery NN i
system NN i
in IN N
healthy JJ p
volunteers NNS p
. . p

Colonic JJ i
drug NN i
delivery NN i
is VBZ N
intended VBN N
for IN N
local JJ N
or CC N
systemic JJ N
therapies NNS N
. . N

The DT N
lack NN N
of IN N
predictive NN N
in IN N
vitro NN N
or CC N
animal JJ N
model NN N
leads VBZ N
to TO N
considerable JJ N
time NN N
delays NNS N
in IN N
colonic JJ N
product NN N
development NN N
. . N

The DT N
objective NN N
of IN N
this DT N
scintigraphic JJ N
study NN N
was VBD N
to TO N
provide VB N
proof NN N
of IN N
concept NN N
for IN N
a DT N
novel JJ i
capsule-type JJ i
colonic NN i
delivery NN i
system NN i
( ( i
Colon-Targeted JJ i
Delivery NNP i
Capsule NNP i
) ) i
in IN N
healthy JJ p
volunteers NNS p
. . p

The DT N
human JJ N
data NN N
validates VBZ N
the DT N
design NN N
concept NN N
behind IN N
the DT N
release NN N
mechanism NN N
, , N
in IN N
that DT N
capsule NN N
disintegration NN N
, , N
and CC N
hence RB N
drug NN o
release NN o
, , N
did VBD N
not RB N
start VB N
until IN N
5 CD N
h NNS N
after IN N
gastric JJ N
emptying NN N
, , N
irrespective NN N
of IN N
whether IN N
the DT N
product NN N
was VBD N
administered VBN N
to TO N
fasted VBN N
or CC N
fed VBN N
subjects NNS N
. . N

However RB N
, , N
the DT N
potential NN N
for IN N
prolonged JJ N
gastric JJ N
residence NN N
for IN N
large JJ N
enteric JJ N
coated VBN N
products NNS N
intended VBN N
for IN N
intestinal JJ N
targeting NN N
was VBD N
also RB N
observed VBN N
; : N
overall JJ N
, , N
the DT N
study NN N
provides VBZ N
a DT N
focus NN N
for IN N
subsequent JJ N
product NN N
development NN N
and CC N
highlights NNS N
the DT N
role NN N
of IN N
scintigraphy NN N
in IN N
dynamically RB N
visualizing VBG N
the DT N
drug NN N
delivery NN N
process NN N
. . N

-DOCSTART- -21978765- O O

Phase NNP N
III NNP N
trial NN N
of IN N
induction NN i
gemcitabine NN i
or CC i
paclitaxel NN i
plus CC i
carboplatin NN i
followed VBN i
by IN i
paclitaxel JJ i
consolidation NN i
in IN N
ovarian JJ p
cancer NN p
. . p

OBJECTIVE CC N
The DT N
safety NN N
and CC N
efficacy NN N
of IN N
gemcitabine JJ i
plus CC i
carboplatin NN i
( ( i
GC NNP i
) ) i
or CC i
paclitaxel JJ i
plus CC i
carboplatin NN i
( ( i
TC NNP i
) ) i
induction NN i
regimens VBZ i
with IN i
or CC i
without IN i
paclitaxel JJ i
consolidation NN N
therapy NN N
were VBD N
assessed VBN N
in IN N
ovarian JJ p
cancer NN p
( ( p
OC NNP p
) ) p
. . p

METHODS JJ N
Patients NNPS p
with IN p
stage JJ p
IC-IV JJ p
OC NNP p
were VBD N
randomized VBN N
to TO N
either DT N
GC NNP i
( ( i
gemcitabine JJ i
1,000 CD N
mg/m NN N
( ( N
2 CD N
) ) N
, , N
days NNS N
1 CD N
and CC N
8 CD N
, , N
plus CC i
carboplatin JJ i
area NN N
under IN N
the DT N
curve NN N
[ NNP N
AUC NNP N
] NNP N
5 CD N
, , N
day NN N
1 CD N
) ) N
or CC N
TC NNP i
( ( i
paclitaxel JJ i
175 CD N
mg/m NN N
( ( N
2 CD N
) ) N
plus CC i
carboplatin JJ i
AUC NNP i
6 CD i
, , N
day NN N
1 CD N
) ) N
every DT N
21 CD N
days NNS N
for IN N
up IN N
to TO N
six CD N
cycles NNS N
. . N

Patients NNS p
with IN p
complete JJ o
response NN o
( ( o
CR NNP o
) ) o
were VBD N
allowed VBN N
optional JJ N
consolidation NN N
with IN N
paclitaxel JJ i
135 CD N
mg/m NN N
( ( N
2 CD N
) ) N
every DT N
28 CD N
days NNS N
for IN N
? . N
12 CD N
months NNS N
. . N

Patients NNS N
without IN N
CR NNP N
received VBD N
single-agent JJ N
crossover NN N
therapy NN N
at IN N
induction NN N
doses/schedules NNS N
until IN N
CR NNP N
, , o
disease NN o
progression NN o
( ( o
PD NNP o
) ) o
, , o
or CC o
unacceptable JJ o
toxicity NN o
. . o

PD NNP o
or CC o
death NN o
in IN o
636 CD p
patients NNS p
was VBD p
required VBN N
to TO N
compare VB N
induction NN N
arms NNS N
with IN N
80 CD N
% NN N
statistical JJ N
power NN N
for IN o
progression-free JJ o
survival NN o
( ( o
PFS NNP o
) ) o
, , o
the DT N
primary JJ N
endpoint NN N
. . N

RESULTS NNP N
Randomized NNP N
induction NN N
therapy NN N
was VBD N
received VBN N
by IN N
820 CD p
of IN p
919 CD p
patients NNS p
enrolled VBD p
; : p
352 CD p
patients NNS p
with IN p
CR NNP p
received VBD p
paclitaxel JJ N
consolidation NN N
whereas NNS p
155 CD p
patients NNS p
without IN p
CR NNP p
received VBD p
single-agent JJ N
crossover NN N
therapy NN o
. . o

PFS NNP o
was VBD o
similar JJ N
for IN i
GC NNP i
and CC i
TC NNP i
( ( i
median JJ N
, , N
20.0 CD N
and CC N
22.2 CD N
months NNS N
, , N
respectively RB N
; : N
P=.199 NNP N
) ) N
. . N

Despite IN N
high JJ N
censoring NN N
rates NNS N
( ( N
> VB N
52 CD o
% NN o
) ) o
, , o
overall JJ o
survival NN o
was VBD o
longer JJR N
for IN N
TC NNP N
( ( N
median JJ N
, , N
57.3 CD N
versus NN N
43.8 CD N
months NNS N
for IN N
GC NNP N
; : N
P=.013 NNP N
) ) N
. . N

Controlling VBG N
for IN N
patient JJ N
characteristics NNS N
including VBG N
performance NN N
status NN N
, , N
residual JJ N
tumor NN N
size NN N
, , N
and CC N
tumor NN N
stage NN N
, , N
there EX N
was VBD N
no DT N
statistical JJ N
difference NN N
in IN N
a DT N
multivariate NN N
analysis NN N
( ( N
HR=1.22 NNP N
; : N
95 CD N
% NN N
CI=0.99-1.52 NNP N
; : N
P=.067 NNP N
) ) N
. . N

CONCLUSIONS NNP i
GC NNP i
does VBZ i
not RB N
improve VB o
PFS NNP o
over RB o
TC NNP i
as IN i
first-line JJ N
induction NN N
chemotherapy NN N
in IN N
OC NNP N
. . N

Although IN N
favoring VBG N
TC NNP N
, , o
overall JJ o
survival NN o
analyses NNS o
were VBD N
limited VBN N
by IN N
the DT N
study NN N
design NN N
and CC N
high JJ N
censoring NN N
rates NNS N
. . N

-DOCSTART- -22395144- O O

Utility NN N
of IN N
the DT N
bladder NN i
flap NN i
at IN N
cesarean JJ i
delivery NN i
: : i
a DT N
randomized NN N
controlled VBN N
trial NN N
. . N

OBJECTIVE UH N
To TO N
test VB N
the DT N
hypothesis NN N
that IN N
omission NN N
of IN N
the DT N
bladder NN i
flap NN i
in IN N
primary JJ p
and CC p
repeat JJ p
cesarean JJ i
deliveries NNS i
shortens VBZ N
operating VBG N
time NN N
without IN N
increasing VBG N
intraoperative JJ N
and CC N
postoperative JJ N
complications NNS N
. . N

METHODS NNP N
We PRP N
randomized VBD N
258 CD p
women NNS p
undergoing VBG p
primary JJ i
and CC i
repeat JJ i
cesarean JJ i
deliveries NNS i
at IN p
32 CD p
weeks NNS p
of IN p
gestation NN p
or CC p
more JJR p
to TO p
creation NN i
( ( p
n=131 JJ p
) ) p
or CC p
omission NN i
( ( p
n=127 JJ p
) ) p
of IN p
the DT p
bladder NN p
flap NN p
. . p

Emergency NNP N
cesarean JJ N
deliveries NNS N
, , N
planned VBD N
vertical JJ N
uterine NN N
incisions NNS N
, , N
and CC N
previous JJ N
abdominal JJ i
surgeries NNS i
besides IN N
cesarean JJ i
deliveries NNS i
were VBD N
excluded VBN N
. . N

The DT N
primary JJ N
outcome NN N
measure NN N
was VBD N
total JJ o
operating NN o
time NN o
. . o

Secondary JJ N
outcomes NNS N
were VBD N
bladder JJ o
injury NN o
, , o
incision-to-delivery JJ o
time NN o
, , o
incision-to-fascial JJ o
closure NN o
time NN o
, , o
estimated VBN o
blood NN o
loss NN o
, , o
postoperative JJ o
microhematuria NN o
, , o
postoperative JJ o
pain NN o
, , o
hospital NN o
days NNS o
, , o
endometritis NN o
, , o
and CC o
urinary JJ o
tract NN o
infection NN o
. . o

Analysis NN N
followed VBD N
the DT N
intention-to-treat JJ N
principle NN N
. . N

RESULTS VB N
The DT N
median JJ o
skin NN o
incision NN o
to TO o
delivery NN o
interval NN o
was VBD N
shorter JJR N
with IN N
omission NN i
of IN i
the DT i
bladder NN i
flap NN i
( ( N
9 CD N
[ NN N
range NN N
1-43 JJ N
] NNS N
compared VBN N
with IN N
10 CD N
[ JJ N
range NN N
2-70 JJ N
] NNP N
minutes NNS N
; : N
P=.04 NNP N
) ) N
, , N
but CC N
there EX N
was VBD N
no DT N
difference NN N
in IN N
total JJ o
operating NN o
time NN o
( ( N
51 CD N
[ NN N
range NN N
18-124 JJ N
] NNP N
minutes NNS N
compared VBN N
with IN N
51 CD N
[ JJ N
range NN N
16-178 JJ N
] NN N
; : N
P=.10 NNP N
) ) N
. . N

No DT N
bladder NN o
injuries NNS o
occurred VBD N
in IN N
either DT N
group NN N
and CC N
there EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
estimated VBN o
blood NN o
loss NN o
, , o
change NN o
in IN o
hemoglobin JJ o
level NN o
, , o
postoperative JJ o
microhematuria NN o
, , o
postoperative JJ o
pain NN o
, , o
hospital NN o
days NNS o
, , o
endometritis NN o
, , o
or CC o
urinary JJ o
tract NN o
infection NN o
. . o

CONCLUSION NNP N
Omission NNP N
of IN N
the DT N
bladder NN N
flap NN N
at IN N
primary JJ N
and CC N
repeat JJ N
cesarean JJ N
deliveries NNS N
does VBZ N
not RB N
increase VB N
intraoperative JJ N
or CC N
postoperative JJ N
complications NNS N
. . N

Incision-to-delivery JJ N
time NN N
is VBZ N
shortened VBN N
but CC N
total JJ N
operating NN N
time NN N
appears VBZ N
unchanged JJ N
. . N

CLINICAL JJ N
TRIAL NNP N
REGISTRATION NNP N
ClinicalTrials.gov NNP N
, , N
www.ClinicalTrials.gov NN N
, , N
NCT00918996 NNP N
. . N

LEVEL NNP N
OF IN N
EVIDENCE NNP N
I PRP N
. . N

-DOCSTART- -20633669- O O

Efficacy NN o
of IN N
patient JJ i
education NN i
and CC i
supervised VBD i
exercise NN i
vs NN N
patient JJ i
education NN i
alone RB i
in IN N
patients NNS p
with IN p
hip JJ p
osteoarthritis NN p
: : p
a DT N
single JJ N
blind NN N
randomized VBD N
clinical JJ N
trial NN N
. . N

OBJECTIVE UH N
To TO N
compare VB N
the DT N
efficacy NN N
of IN N
patient JJ i
education NN i
and CC i
supervised VBD i
exercise NN i
with IN N
that DT N
of IN N
patient JJ i
education NN i
alone RB i
for IN N
the DT N
management NN o
of IN o
pain NN o
in IN N
patients NNS p
with IN p
hip NN p
osteoarthritis NN p
( ( p
OA NNP p
) ) p
. . p

DESIGN NNP N
Single NNP N
blind IN N
randomized JJ N
clinical JJ N
trial NN N
. . N

SETTING NNP N
Recruitment NNP N
of IN N
patients NNS p
from IN p
hospitals NNS p
, , p
primary JJ p
health NN p
care NN p
and CC p
advertisement NN p
, , p
Oslo NNP p
, , p
Norway NNP p
. . p

PARTICIPANTS NNP N
109 CD p
patients NNS p
with IN p
radiographic JJ p
and CC p
symptomatic JJ p
hip NN p
OA NNP p
with IN p
mild NN p
to TO p
moderate VB p
symptoms NNS p
. . p

INTERVENTIONS NNP N
Patient NNP i
education NN i
( ( i
PE NNP i
) ) i
. . i

Patient JJ i
education NN i
and CC i
supervised VBN i
exercise NN i
( ( i
PE+SE NNP i
) ) i
. . i

PRIMARY NNP N
OUTCOME NNP N
MEASURE NNP N
The DT N
pain NN o
subscale NN o
of IN o
the DT o
Western NNP o
Ontario NNP o
and CC o
McMaster NNP o
Universities NNP o
Osteoarthritis NNP o
Index NNP o
( ( o
WOMAC NNP o
pain NN o
) ) o
. . o

RESULTS NNP N
No NNP N
significant JJ N
between IN N
group NN N
differences NNS N
were VBD N
found VBN N
for IN N
WOMAC NNP o
pain NN o
over IN N
the DT N
16-month JJ N
follow-up NN N
. . N

Significant JJ N
improvements NNS N
were VBD N
found VBN N
for IN N
the DT N
secondary JJ N
outcome NN N
WOMAC NNP o
physical JJ o
function NN o
( ( N
P=0.011 NNP N
) ) N
in IN N
the DT N
group NN N
receiving VBG N
PE+SE NNP i
compared VBN N
to TO N
the DT N
group NN N
receiving VBG N
PE NNP i
only RB N
. . N

No DT N
significant JJ N
differences NNS N
were VBD N
found VBN N
for IN N
WOMAC NNP o
stiffness NN o
, , N
the DT N
SF-36 JJ N
subscales NNS N
or CC N
the DT N
activity NN N
scale NN N
. . N

The DT N
effect NN N
sizes VBZ N
( ( N
95 CD N
% NN N
confidence NN N
interval NN N
) ) N
for IN N
WOMAC NNP o
pain NN o
were VBD N
-0.26 NNP N
( ( N
0.11 CD N
, , N
-0.64 NN N
) ) N
, , N
-0.35 NNP N
( ( N
0.07 CD N
, , N
-0.77 NN N
) ) N
, , N
and CC N
-0.30 NNP N
( ( N
0.15 CD N
, , N
-0.75 NN N
) ) N
, , N
and CC N
for IN N
WOMAC NNP o
physical JJ o
function NN o
-0.29 NNP N
( ( N
0.09 CD N
, , N
-0.67 NN N
) ) N
, , N
-0.48 NNP N
( ( N
-0.06 NNP N
, , N
-0.91 NNP N
) ) N
, , N
and CC N
-0.47 NNP N
( ( N
-0.02 NNP N
, , N
-0.93 NNP N
) ) N
at IN N
4 CD N
, , N
10 CD N
and CC N
16 CD N
months NNS N
, , N
respectively RB N
, , N
in IN N
favor NN N
of IN N
the DT N
group NN N
receiving VBG N
both DT N
PE NNP i
and CC i
SE NNP i
. . i

All DT N
patients NNS N
attended VBD N
the DT N
three-session JJ N
PE NNP i
program NN i
, , N
and CC N
75 CD N
% NN N
performed VBN N
?16 JJ N
sessions NNS N
of IN N
the DT N
12-week JJ i
SE NNP i
program NN i
. . N

CONCLUSION NNP N
The DT N
study NN N
could MD N
not RB N
demonstrate VB N
a DT N
significant JJ N
difference NN N
in IN N
pain NN o
reduction NN o
over IN o
time NN N
between IN i
PE+SE NNP i
vs NNP i
PE NNP i
alone RB i
. . i

Adding VBG i
SE NNP i
to TO i
PE NNP i
may MD i
improve VB o
physical JJ o
function NN o
, , o
but CC N
the DT N
magnitude NN N
of IN N
possible JJ N
benefit NN N
is VBZ N
unknown JJ N
as IN N
the DT N
95 CD N
% NN N
confidence NN N
intervals NNS N
around IN N
the DT N
mean JJ N
difference NN N
were VBD N
wide JJ N
. . N

TRIAL NNP N
REGISTRATION NNP N
Clinical NNP N
Trials NNP N
NCT00319423 NNP N
. . N

-DOCSTART- -15272537- O O

Human JJ N
achaete-scute JJ N
homologue NN N
( ( N
hASH1 NN N
) ) N
mRNA NN N
level NN N
as IN N
a DT N
diagnostic JJ N
marker NN N
to TO N
distinguish VB N
esthesioneuroblastoma NN p
from IN N
poorly RB p
differentiated VBN p
tumors NNS p
arising VBG p
in IN p
the DT p
sinonasal NN p
tract NN p
. . p

Distinction NN N
of IN N
high-grade JJ p
esthesioneuroblastomas NN p
from IN N
other JJ p
poorly RB p
differentiated VBN p
tumors NNS p
arising VBG p
in IN p
the DT p
nasal JJ p
cavity NN p
is VBZ N
an DT N
important JJ N
diagnostic JJ N
challenge NN N
because IN N
it PRP N
determines VBZ N
patient JJ N
management NN N
and CC N
prognosis NN N
. . N

The DT N
human JJ N
achaete-scute JJ N
homologue NN N
( ( N
hASH1 NN N
) ) N
gene NN N
is VBZ N
critical JJ N
in IN N
olfactory JJ N
neuronal JJ N
differentiation NN N
and CC N
is VBZ N
expressed VBN N
in IN N
immature NN N
olfactory NN N
cells NNS N
; : N
therefore RB N
, , N
it PRP N
could MD N
have VB N
potential JJ N
use NN N
as IN N
a DT N
diagnostic JJ N
marker NN N
The DT N
aim NN N
of IN N
the DT N
present JJ N
study NN N
was VBD N
to TO N
determine VB N
the DT N
value NN N
of IN N
hASH1 JJ N
messenger NN N
RNA NNP N
( ( N
mRNA NN N
) ) N
levels NNS N
in IN N
differentiating VBG N
esthesioneuroblastoma NN N
from IN N
other JJ N
poorly RB N
differentiated VBN N
tumors NNS N
. . N

A DT N
real-time JJ i
polymerase NN i
chain NN i
reaction NN i
assay NN i
was VBD N
developed VBN N
, , N
permitting VBG N
the DT N
comparative JJ N
determination NN N
of IN N
hASH1 NN o
mRNA NN o
levels NNS o
in IN N
triplicate NN N
in IN N
a DT N
double-blind JJ N
pilot NN N
study NN N
including VBG N
24 CD p
frozen JJ p
cases NNS p
of IN p
esthesioneuroblastoma NN p
and CC p
poorly RB p
differentiated VBN p
tumors NNS p
. . p

All DT N
4 CD N
positive JJ N
cases NNS N
were VBD N
esthesioneuroblastomas JJ o
, , N
and CC N
all DT N
19 CD N
poorly RB N
differentiated VBN N
tumors NNS N
were VBD N
negative JJ N
. . N

In IN N
addition NN N
, , N
there EX N
was VBD N
an DT N
inverse JJ N
association NN N
between IN N
the DT N
grade NN o
of IN o
esthesioneuroblastomas NN o
and CC N
hASH1 NN N
mRNA NN N
levels NNS N
. . N

The DT N
hASH1 NN N
mRNA FW N
level NN N
might MD N
represent VB N
a DT N
useful JJ N
tool NN N
for IN N
distinguishing VBG N
esthesioneuroblastoma NN N
from IN N
poorly RB p
differentiated VBN p
tumors NNS p
of IN p
the DT p
sinonasal JJ p
region NN p
. . p

-DOCSTART- -1541306- O O

Absorption NN o
of IN o
intramuscular JJ o
phenobarbitone NN o
in IN N
children NNS p
with IN p
severe JJ p
falciparum NN p
malaria NN p
. . p

The DT N
absorption NN o
of IN o
intramuscular JJ o
phenobarbitone NN o
7 CD i
mg.kg-1 NN i
was VBD N
studied VBN N
in IN N
11 CD p
Karen NNP p
children NNS p
aged VBD p
between IN p
1.7 CD p
and CC p
11 CD p
y NN p
with IN p
severe JJ p
falciparum NN p
malaria NN p
. . p

Eight CD p
of IN p
the DT p
children NNS p
were VBD p
comatose JJ p
. . p

Clinical JJ N
findings NNS N
were VBD N
compared VBN N
with IN N
those DT N
in IN N
9 CD p
further JJ p
children NNS p
with IN p
severe JJ p
malaria NNS p
of IN p
similar JJ p
age NN p
range NN p
( ( p
four CD p
of IN p
whom WP p
were VBD p
unconscious JJ p
) ) p
, , N
who WP N
received VBD N
an DT N
identical JJ i
placebo NN i
. . i

One CD N
child NN N
, , N
who WP N
had VBD N
received VBN N
placebo NN N
, , N
had VBD N
repeated VBN o
convulsions NNS o
and CC N
died VBD N
1 CD N
h NN N
after IN N
admission NN N
to TO N
hospital NN N
. . N

The DT N
remainder NN N
made VBD N
an DT N
uncomplicated JJ o
recovery NN o
. . o

There EX N
were VBD N
no DT N
convulsions NNS o
subsequent VBP N
to TO N
treatment NN N
, , N
although IN N
the DT N
study NN N
was VBD N
too RB N
small JJ N
to TO N
assess VB N
anticonvulsant JJ N
efficacy NN N
. . N

There EX N
was VBD N
no DT N
observable JJ N
toxicity NN o
, , N
but CC N
phenobarbitone NN N
recipients NNS N
had VBD N
a DT N
significant JJ N
tendency NN N
to TO N
deepen VB N
in IN N
their PRP$ N
level NN o
of IN o
coma NN o
or CC N
to TO N
become VB o
sleepy NN o
within IN N
the DT N
4 CD N
h NN N
after IN N
drug NN N
administration NN N
. . N

Phenobarbitone NNP N
was VBD N
rapidly RB N
absorbed VBN N
, , N
reaching VBG N
a DT N
mean NN N
( ( N
range NN N
) ) N
peak NN N
concentration NN N
of IN N
34.2 CD N
[ JJ N
29.3-42.6 JJ N
] JJ N
mumol.l-1 NN N
in IN N
a DT N
median NN N
( ( N
range NN N
) ) N
of IN N
4 CD N
( ( N
2.5-12 CD N
) ) N
h. NN N
These DT N
values NNS N
are VBP N
comparable JJ N
to TO N
those DT N
previously RB N
reported VBN N
in IN N
healthy JJ N
children NNS N
and CC N
in IN N
children NNS N
with IN N
febrile JJ o
convulsions NNS o
. . o

Intramuscular NNP N
phenobarbitone NN N
is VBZ N
well RB N
absorbed VBN N
in IN N
children NNS p
with IN p
severe JJ p
malaria NNS p
; : p
the DT N
optimum JJ N
prophylactic JJ N
anticonvulsant NN N
dose NN N
remains VBZ N
to TO N
be VB N
determined VBN N
. . N

-DOCSTART- -9809934- O O

Accuracy NN N
and CC N
feasibility NN N
of IN N
contrast NN i
echocardiography NN i
for IN N
detection NN N
of IN N
perfusion NN N
defects NNS N
in IN N
routine JJ N
practice NN N
: : N
comparison NN N
with IN N
wall JJ i
motion NN i
and CC i
technetium-99m JJ i
sestamibi NN i
single-photon JJ i
emission NN i
computed VBD i
tomography NN i
. . i

The DT N
Nycomed NNP N
NC100100 NNP N
Investigators NNP N
. . N

OBJECTIVES NNP N
We PRP N
sought VBD N
to TO N
assess VB N
the DT N
feasibility NN N
and CC N
accuracy NN N
of IN N
myocardial JJ i
contrast NN i
echocardiography NN i
( ( i
MCE NNP i
) ) i
using VBG N
standard JJ N
imaging NN N
approaches NNS N
for IN N
the DT N
detection NN N
of IN N
perfusion NN N
defects NNS N
in IN N
patients NNS p
who WP p
had VBD p
a DT p
myocardial JJ p
infarction NN p
( ( p
MI NNP p
) ) p
. . p

BACKGROUND NNP N
Myocardial NNP i
contrast NN i
echocardiography NN i
may MD N
be VB N
more JJR N
versatile JJ N
than IN N
perfusion NN i
scintigraphy NN i
for IN N
identifying VBG N
the DT N
presence NN N
and CC N
extent NN N
of IN N
perfusion NN N
defects NNS N
after IN N
MI NNP N
. . N

However RB N
, , N
its PRP$ N
reliability NN N
in IN N
routine JJ N
practice NN N
is VBZ N
unclear JJ N
. . N

METHODS NNP N
Fundamental NNP N
or CC N
harmonic JJ N
MCE NNP N
was VBD N
performed VBN N
with IN N
continuous JJ N
or CC N
triggered JJ N
imaging NN N
in IN N
203 CD p
patients NNS p
with IN p
a DT p
previous JJ p
MI NNP p
using VBG N
bolus JJ N
doses NNS N
of IN N
a DT N
perfluorocarbon-filled JJ i
contrast NN i
agent NN i
( ( i
NC100100 NNP i
) ) i
. . i

All DT N
patients NNS N
underwent JJ N
single-photon JJ i
emission NN i
computed VBN i
tomography NN i
( ( i
SPECT NNP i
) ) i
after IN i
the DT i
injection NN i
of IN i
technetium-99m JJ i
( ( i
Tc-99m NNP i
) ) i
sestamibi NN i
at IN i
rest NN i
. . i

Quantitative NNP i
and CC i
semiquantitative JJ i
SPECT NNP i
, , N
wall NN N
motion NN N
and CC N
digitized JJ N
echocardiographic JJ N
data NNS N
were VBD N
interpreted VBN N
independently RB N
. . N

The DT N
accuracy NN N
of IN N
MCE NNP i
was VBD N
assessed VBN N
for IN N
detection NN N
of IN N
segments NNS N
and CC N
patients NNS N
with IN N
moderate JJ N
and CC N
severe JJ N
sestamibi-SPECT JJ N
defects NNS N
, , N
as RB N
well RB N
as IN N
for IN N
detection NN N
of IN N
patients NNS N
with IN N
extensive JJ N
perfusion NN N
defects NNS N
( ( N
> VB N
12 CD N
% NN N
of IN N
left JJ N
ventricle NN N
) ) N
. . N

RESULTS NNP N
In IN N
segments NNS N
with IN N
diagnostic JJ N
MCE NNP N
, , N
the DT N
segmental JJ o
sensitivity NN o
ranged VBD N
from IN N
14 CD N
% NN N
to TO N
65 CD N
% NN N
, , N
and CC N
the DT N
specificity NN o
varied VBD N
from IN N
78 CD N
% NN N
to TO N
95 CD N
% NN N
, , N
depending VBG N
on IN N
the DT N
dose NN N
of IN N
contrast NN N
agent NN N
. . N

Using VBG N
both DT N
segment- JJ N
and CC N
patient-based JJ N
analysis NN N
, , N
the DT N
greatest JJS N
accuracy NN N
and CC N
proportion NN N
of IN N
interpretable JJ N
images NNS N
were VBD N
obtained VBN N
using VBG N
harmonic JJ N
imaging NN N
in IN N
the DT N
triggered JJ N
mode NN N
. . N

For IN N
the DT N
detection NN N
of IN N
extensive JJ N
defects NNS N
, , N
the DT N
sensitivity NN o
varied VBD N
from IN N
13 CD N
% NN N
to TO N
48 CD N
% NN N
, , N
with IN N
specificity NN N
from IN N
63 CD N
% NN N
to TO N
100 CD N
% NN N
. . N

Harmonic NNP N
imaging NN N
remained VBD N
the DT N
most RBS N
accurate JJ N
approach NN N
. . N

Time NNP o
since IN o
MI NNP o
and CC o
SPECT NNP o
defect VBP o
location NN o
and CC o
intensity NN o
were VBD N
all DT N
determinants NNS N
of IN N
the DT N
MCE NNP N
response NN N
. . N

The DT N
extent NN o
of IN o
defects NNS o
on IN o
MCE NNP o
was VBD N
less JJR N
than IN N
the DT N
extent NN N
of IN N
either DT N
abnormal JJ N
wall NN N
motion NN N
or CC N
SPECT NNP N
abnormalities NNS N
. . N

The DT N
combination NN N
of IN N
wall JJ N
motion NN N
and CC N
MCE NNP N
assessment NN N
gave VBD N
the DT N
best JJS N
balance NN N
of IN N
sensitivity NN N
( ( N
46 CD N
% NN N
to TO N
55 CD N
% NN N
) ) N
and CC N
specificity NN N
( ( N
82 CD N
% NN N
to TO N
83 CD N
% NN N
) ) N
. . N

CONCLUSIONS NNP N
Although IN N
MCE NNP N
is VBZ N
specific JJ N
, , N
it PRP N
has VBZ N
limited VBN N
sensitivity NN N
for IN N
detection NN N
of IN N
moderate JJ o
or CC o
severe JJ o
perfusion NN o
defects NNS o
, , N
and CC N
it PRP N
underestimates VBZ N
the DT N
extent NN N
of IN N
SPECT NNP o
defects NNS o
. . N

The DT N
best JJS N
results NNS N
are VBP N
obtained VBN N
by IN N
integration NN N
with IN N
wall DT N
motion NN N
. . N

More RBR N
sophisticated JJ N
methods NNS N
of IN N
acquisition NN N
and CC N
interpretation NN N
are VBP N
needed VBN N
to TO N
enhance VB N
the DT N
feasibility NN N
of IN N
this DT N
technique NN N
in IN N
routine JJ N
practice NN N
. . N

-DOCSTART- -11319711- O O

Physiologic NNP N
modeling NN N
of IN N
the DT N
intravenous JJ o
glucose JJ o
tolerance NN o
test NN o
in IN N
type NN p
2 CD p
diabetes NNS p
: : p
a DT N
new JJ N
approach NN N
to TO N
the DT N
insulin NN N
compartment NN N
. . N

The DT N
minimal JJ N
model NN N
of IN N
Bergman NNP N
et FW N
al NN N
has VBZ N
been VBN N
used VBN N
to TO N
yield VB N
estimates NNS N
of IN N
insulin NN o
sensitivity NN o
( ( o
Si NNP o
) ) o
and CC o
glucose JJ o
effectiveness NN o
( ( o
Sg NNP o
) ) o
in IN N
type NN N
2 CD N
diabetes NNS N
by IN N
incorporating VBG N
exogenous JJ i
insulin NN i
protocols NNS i
into IN N
the DT N
regular JJ N
intravenous JJ N
glucose NN N
tolerance NN N
test NN N
( ( N
IVGTT NNP N
) ) N
. . N

These DT N
estimates NNS N
, , N
however RB N
, , N
are VBP N
influenced VBN N
by IN N
the DT N
degree NN N
to TO N
which WDT N
the DT N
dose NN N
of IN N
exogenous JJ i
insulin NN i
is VBZ N
greater JJR N
than IN N
the DT N
physiologic JJ N
response NN N
to TO N
a DT N
glucose JJ N
load NN N
. . N

Moreover RB N
, , N
most JJS N
studies NNS N
have VBP N
related VBN N
to TO N
type VB p
2 CD p
diabetes NNS p
subjects NNS p
whose WP$ N
diabetes NNS N
was VBD N
relatively RB N
mild JJ N
in IN N
terms NNS N
of IN N
therapeutic JJ N
requirements NNS N
. . N

To TO N
develop VB N
a DT N
minimal JJ N
disturbance NN N
approach NN N
in IN N
estimating VBG N
Si NNP o
and CC o
Sg NNP o
in IN N
type NN N
2 CD N
diabetes NNS N
, , N
we PRP N
have VBP N
used VBN N
a DT N
reduced JJ i
glucose JJ i
load NN i
( ( N
200 CD N
mg/kg NN N
) ) N
and CC i
a DT i
physiologic JJ i
insulin NN i
infusion NN i
throughout IN N
the DT N
IVGTT NNP N
in IN N
a DT N
series NN N
of IN N
8 CD p
patients NNS p
, , p
5 CD p
of IN p
whom WP p
were VBD p
insulin-requiring JJ p
. . p

Data NNS N
from IN N
this DT N
approach NN N
were VBD N
analyzed VBN N
using VBG N
the DT N
modelling VBG N
program NN N
CONSAM NNP N
to TO N
apply VB N
the DT N
Bergman NNP N
model NN N
, , N
either RB N
unmodified JJ N
( ( N
BMM NNP N
) ) N
, , N
or CC N
incorporating VBG N
an DT N
additional JJ N
delay NN N
element NN N
between IN N
the DT N
plasma NN N
and CC N
remote JJ N
insulin NN N
compartments NNS N
( ( N
MMD NNP N
) ) N
. . N

Application NN N
of IN N
the DT N
MMD NNP N
and CC N
extension NN N
of IN N
the DT N
IVGTT NNP N
from IN N
3 CD N
to TO N
5 CD N
hours NNS N
improved VBN N
successful JJ N
resolution NN o
of IN o
Si NNP o
and CC o
Sg NNP o
from IN N
37.5 CD N
% NN N
( ( N
BMM NNP N
, , N
3-hour JJ N
IVGTT NNP N
) ) N
to TO N
100 CD N
% NN N
( ( N
MMD NNP N
, , N
5-hour JJ N
IVGTT NNP N
) ) N
. . N

Si NNP o
was VBD N
reduced VBN N
in IN N
these DT N
type NN N
2 CD N
diabetes VBZ N
patients NNS N
compared VBN N
with IN N
normal JJ N
subjects NNS N
( ( N
1.86 CD N
+/- JJ N
0.60 CD N
v. JJ N
8.65 CD N
+/- JJ N
2.27 CD N
min NN N
( ( N
-1 NNP N
) ) N
x VBP N
microU NN N
( ( N
-1 NNP N
) ) N
x VBP N
mL JJ N
x $ N
10 CD N
( ( N
4 CD N
) ) N
P NNP N
< NNP N
.01 NNP N
) ) N
. . N

The DT N
results NNS N
were VBD N
validated VBN N
in IN N
the DT N
type NN p
2 CD p
diabetes NNS p
group NN p
using VBG N
a DT N
2-stage JJ N
euglycemic JJ N
clamp NN N
( ( N
( ( N
Si NNP N
) ) N
CLAMP NNP N
= $ N
2.02 CD N
+/- JJ N
0.42 CD N
min NN N
( ( N
-1 NNP N
) ) N
x VBP N
microU NN N
( ( N
-1 NNP N
) ) N
x VBP N
mL JJ N
x $ N
10 CD N
( ( N
4 CD N
) ) N
P NNP N
> NNP N
.4 NNP N
) ) N
. . N

Sg NNP o
was VBD N
not RB N
significantly RB N
reduced VBN N
( ( N
2.00 CD N
+/- JJ N
0.25 CD N
type NN N
2 CD N
diabetes NNS N
v. JJ N
1.55 CD N
+/- JJ N
0.26 CD N
normal JJ N
min NN N
( ( N
-1 NNP N
) ) N
x VBZ N
10 CD N
( ( N
2 CD N
) ) N
) ) N
. . N

Data NNS N
from IN N
a DT N
group NN N
of IN N
normal JJ p
nondiabetic JJ p
subjects NNS p
was VBD N
then RB N
analyzed VBN N
using VBG N
the DT N
MMD NNP N
, , N
but CC N
this DT N
approach NN N
did VBD N
not RB N
enhance VB N
the DT N
fit NN N
of IN N
the DT N
model NN N
compared VBN N
with IN N
the DT N
BMM NNP N
. . N

This DT N
result NN N
indicates VBZ N
that IN N
the DT N
delay NN N
in IN N
insulin JJ N
action NN N
in IN N
type NN N
2 CD N
diabetes VBZ N
represents VBZ N
an DT N
abnormality NN N
whereby WRB N
the DT N
onset NN N
of IN N
insulin JJ N
action NN N
can MD N
not RB N
be VB N
described VBN N
as IN N
a DT N
single JJ N
phase NN N
in IN N
the DT N
transfer NN N
of IN N
insulin NN N
from IN N
plasma NN N
to TO N
the DT N
remote JJ N
compartment NN N
. . N

It PRP N
is VBZ N
postulated VBN N
that IN N
the DT N
physiologic JJ N
basis NN N
for IN N
this DT N
delayed JJ N
action NN N
may MD N
relate VB N
to TO N
transcapillary JJ N
endothelial JJ N
transfer NN N
of IN N
insulin NN N
, , N
this DT N
process NN N
limiting VBG N
the DT N
rate NN N
of IN N
onset NN N
of IN N
insulin JJ N
action NN N
. . N

-DOCSTART- -23562009- O O

Daclizumab NNP i
high-yield JJ N
process NN N
in IN N
relapsing-remitting JJ o
multiple JJ o
sclerosis NN o
( ( p
SELECT NNP p
) ) p
: : p
a DT N
randomised JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ i
trial NN N
. . N

BACKGROUND NNP N
Daclizumab NNP i
, , N
a DT N
humanised JJ N
monoclonal NN N
antibody NN N
, , N
modulates VBZ N
interleukin-2 JJ N
signalling NN N
by IN N
blocking VBG N
the DT N
? . N
subunit NN N
( ( N
CD25 NNP N
) ) N
of IN N
the DT N
interleukin-2 JJ N
receptor NN N
. . N

We PRP N
assessed VBD N
whether IN i
daclizumab JJ i
high-yield JJ N
process NN N
( ( N
HYP NNP N
) ) N
would MD N
be VB N
effective JJ N
when WRB N
given VBN N
as IN N
monotherapy NN N
for IN N
a DT N
1 CD N
year NN N
treatment NN N
period NN N
in IN p
patients NNS p
with IN p
relapsing-remitting JJ p
multiple JJ p
sclerosis NN p
. . p

METHODS NNP N
We PRP N
did VBD N
a DT N
randomised VBN N
, , N
double-blind JJ N
, , N
placebo-controlled JJ i
trial NN N
at IN p
76 CD p
centres NNS p
in IN p
the DT p
Czech NNP p
Republic NNP p
, , p
Germany NNP p
, , p
Hungary NNP p
, , p
India NNP p
, , p
Poland NNP p
, , p
Russia NNP p
, , p
Ukraine NNP p
, , p
Turkey NNP p
, , p
and CC p
the DT p
UK NNP p
between IN p
Feb NNP p
15 CD p
, , p
2008 CD p
, , p
and CC p
May NNP p
14 CD p
, , p
2010 CD p
. . p

Patients NNS p
aged VBN p
18-55 JJ p
years NNS p
with IN p
relapsing-remitting JJ p
multiple JJ p
sclerosis NN p
were VBD N
randomly RB N
assigned VBN N
( ( N
1:1:1 CD N
) ) N
, , N
via IN N
a DT N
central JJ N
interactive JJ N
voice NN N
response NN N
system NN N
, , N
to TO N
subcutaneous JJ N
injections NNS N
of IN i
daclizumab NN i
HYP NNP i
150 CD i
mg NN i
or CC i
300 CD i
mg NN i
, , i
or CC i
placebo NN i
, , i
every DT N
4 CD N
weeks NNS N
for IN N
52 CD N
weeks NNS N
. . N

Patients NNS N
and CC N
study NN N
personnel NNS N
were VBD N
masked VBN N
to TO N
treatment NN N
assignment NN N
, , N
except IN N
for IN N
the DT N
site NN N
pharmacist NN N
who WP N
prepared VBD N
the DT N
study NN N
drug NN N
for IN N
injection NN N
, , N
but CC N
had VBD N
no DT N
interaction NN N
with IN N
the DT N
patient NN N
. . N

The DT N
primary JJ N
endpoint NN N
was VBD o
annualised VBN o
relapse NN o
rate NN o
. . o

Analysis NN N
was VBD N
by IN N
intention NN N
to TO N
treat VB N
. . N

The DT N
trial NN N
is VBZ N
registered VBN N
with IN N
ClinicalTrials.gov NNP N
, , N
number NN N
NCT00390221 NNP N
. . N

FINDINGS NNP p
204 CD p
patients NNS p
were VBD p
assigned VBN p
to TO p
receive VB i
placebo NN i
, , i
208 CD p
to TO i
daclizumab VB i
HYP NNP i
150 CD p
mg NN p
, , p
and CC p
209 CD p
to TO i
daclizumab VB i
HYP NNP i
300 CD N
mg NN N
, , N
of IN N
whom WP N
188 CD N
( ( N
92 CD N
% NN N
) ) N
, , N
192 CD N
( ( N
92 CD N
% NN N
) ) N
, , N
and CC N
197 CD N
( ( N
94 CD N
% NN N
) ) N
, , N
respectively RB N
, , N
completed VBD N
follow-up NN N
to TO N
week NN N
52 CD N
. . N

The DT o
annualised JJ o
relapse NN o
rate NN o
was VBD N
lower JJR N
for IN N
patients NNS N
given VBN i
daclizumab JJ i
HYP NNP N
150 CD N
mg NN N
( ( N
0?21 CD N
, , N
95 CD N
% NN N
CI NNP N
0?16-0?29 NN N
; : N
54 CD N
% NN N
reduction NN N
, , N
95 CD N
% NN N
CI NNP N
33-68 CD N
% NN N
; : N
p CC N
< VB N
0?0001 CD N
) ) N
or CC N
300 CD N
mg NN N
( ( N
0?23 CD N
, , N
0?17-0?31 CD N
, , N
50 CD N
% NN N
reduction NN N
, , N
28-65 JJ N
% NN N
; : N
p=0?00015 NN N
) ) N
than IN N
for IN N
those DT N
given VBN i
placebo NNS i
( ( N
0?46 CD N
, , N
0?37-0?57 NN N
) ) N
. . N

More JJR N
patients NNS N
were VBD o
relapse JJ o
free JJ o
in IN o
the DT o
daclizumab NN i
HYP NNP i
150 CD i
mg NN i
( ( N
81 CD N
% NN N
) ) N
and CC N
300 CD N
mg NN N
( ( N
80 CD N
% NN N
) ) N
groups NNS N
than IN N
in IN N
the DT N
placebo NN i
group NN N
( ( N
64 CD N
% NN N
; : N
p CC N
< $ N
0?0001 CD N
in IN N
the DT N
150 CD N
mg NN N
group NN N
and CC N
p=0?0003 NN N
in IN N
the DT N
300 CD N
mg NNS N
group NN N
) ) N
. . N

12 CD N
( ( N
6 CD N
% NN N
) ) N
patients NNS N
in IN N
the DT i
placebo NN i
group NN i
, , N
15 CD N
( ( N
7 CD N
% NN N
) ) N
of IN N
those DT N
in IN N
the DT N
daclizumab NN N
150 CD N
mg NN N
group NN N
, , N
and CC N
19 CD N
( ( N
9 CD N
% NN N
) ) N
in IN N
the DT N
300 CD N
mg NN N
group NN N
had VBD N
serious JJ o
adverse JJ o
events NNS o
excluding VBG o
multiple JJ o
sclerosis NN o
relapse NN o
. . o

One CD o
patient NN N
given VBN N
daclizumab JJ i
HYP NNP i
150 CD i
mg NN i
who WP i
was VBD N
recovering VBG N
from IN N
a DT N
serious JJ N
rash NN N
died VBD o
because IN o
of IN N
local JJ N
complication NN N
of IN N
a DT N
psoas NN N
abscess NN N
. . N

INTERPRETATION NNP N
Subcutaneous NNP i
daclizumab NN i
HYP NNP i
administered VBD i
every DT N
4 CD N
weeks NNS N
led VBD N
to TO N
clinically RB N
important JJ N
effects NNS N
on IN N
multiple JJ N
sclerosis NN N
disease NN N
activity NN N
during IN N
1 CD N
year NN N
of IN N
treatment NN N
. . N

Our PRP$ N
findings NNS N
support VB N
the DT N
potential NN N
for IN N
daclizumab NN i
HYP NNP i
to TO i
offer VB i
an DT N
additional JJ N
treatment NN N
option NN o
for IN o
relapsing-remitting JJ o
disease NN o
. . o

FUNDING NN o
Biogen NNP N
Idec NNP N
and CC N
AbbVie NNP N
Biotherapeutics NNP N
Inc NNP N
. . N

-DOCSTART- -24234676- O O

Effect NN N
of IN N
augmented JJ i
sensorimotor NN i
input NN i
on IN N
learning VBG o
verbal JJ o
and CC o
nonverbal JJ o
tasks NNS o
among IN N
children NNS p
with IN p
autism NN p
spectrum NN p
disorders NNS p
. . p

Thirty-four JJ p
children NNS p
, , p
with IN p
autism NN p
spectrum NN p
disorders NNS p
, , p
ages VBZ p
4-14 CD p
years NNS p
, , N
were VBD N
matched VBN N
and CC N
randomly RB N
assigned VBN N
to TO N
one CD N
of IN N
two CD N
conditions NNS N
for IN N
learning VBG o
a DT o
novel JJ o
juice-making NN o
task NN o
and CC N
producing VBG o
two CD o
novel JJ o
words NNS o
about IN o
the DT o
event NN o
. . o

Seventeen NNP N
sighted VBD N
children NNS N
were VBD N
manually RB i
guided VBN i
to TO N
perform VB N
the DT N
task NN N
and CC N
tactually RB N
prompted VBD N
during IN N
imitated JJ N
productions NNS N
of IN N
novel JJ N
words NNS N
for IN N
the DT N
event NN N
. . N

Their PRP$ N
matched JJ N
controls NNS N
heard VBD N
the DT N
novel JJ o
words NNS o
and CC N
watched VBD N
the DT N
juice-making NN o
task NN o
being VBG N
performed VBN N
. . N

Performances NNS N
on IN N
four CD o
verbal NNS o
and CC o
two CD o
nonverbal JJ o
measures NNS o
right RB N
after IN N
instruction NN N
and CC N
at IN N
24-48 JJ N
h NN N
post-instruction NN N
, , N
revealed VBD N
higher JJR N
scores NNS N
for IN N
the DT N
??hands-on?? JJ N
, , N
participation NN N
than IN N
observation NN N
group NN N
on IN N
both DT N
verbal JJ N
and CC N
nonverbal JJ N
tasks NNS N
. . N

This DT N
study NN N
offers VBZ N
a DT N
paradigm NN N
for IN N
exploring VBG N
the DT N
instructional JJ N
advantage NN o
of IN o
enhanced JJ o
participatory JJ o
experience NN o
. . o

-DOCSTART- -2199180- O O

[ JJ N
Treatment NNP N
of IN N
primary JJ N
osteoporosis NN N
with IN N
calcium NN i
and CC i
salmon JJ i
calcitonin NN i
] NN i
. . N

Fifty-nine JJ p
consecutive JJ p
patients NNS p
( ( p
19 CD p
men NNS p
, , p
40 CD p
women NNS p
, , p
mean JJ p
age NN p
60.8 CD p
[ JJ p
27-80 JJ p
] NNP p
years NNS p
) ) p
with IN p
primary JJ p
osteoporosis NN p
were VBD N
studied VBN N
to TO N
see VB N
if IN N
there EX N
was VBD N
any DT N
significant JJ N
gain NN N
in IN N
bone NN N
mass NN N
after IN N
treatment NN N
with IN N
salmon JJ i
calcitonin NN i
. . i

All PDT N
the DT N
patients NNS N
were VBD N
given VBN N
1 CD N
g JJ N
calcium NN i
by IN N
mouth NN N
every DT N
morning NN N
. . N

Group NNP N
1 CD N
( ( N
n JJ N
= NNP N
20 CD N
) ) N
received VBN N
no DT N
other JJ N
specific JJ N
medication NN N
while IN N
group NN N
2 CD N
( ( N
n JJ N
= NNP N
19 CD N
) ) N
were VBD N
given VBN N
100 CD i
I.U NNP i
. . i

calcitonin NN i
subcutaneously RB i
every DT i
second JJ i
evening NN i
and CC i
group NN i
3 CD i
( ( i
n JJ i
= NNP i
20 CD i
) ) i
received VBD i
the DT i
same JJ i
dose NN i
every DT i
evening NN i
. . i

The DT N
pain NN o
reported VBN N
by IN N
the DT N
patients NNS N
was VBD N
subdivided VBN N
into IN N
four CD N
severity NN N
grades NNS N
, , N
and CC N
analgesic JJ o
consumption NN o
was VBD N
recorded VBN N
. . N

In IN N
group NN N
1 CD N
there EX N
was VBD N
a DT N
nonsignificant JJ N
decrease NN N
in IN N
pain NN o
, , N
but CC N
in IN N
groups NNS N
2 CD N
and CC N
3 CD N
there EX N
was VBD N
a DT N
highly RB N
significant JJ N
diminution NN N
in IN N
pain NN o
( ( N
P NNP N
less JJR N
than IN N
0.005 CD N
) ) N
and CC N
in IN N
analgesic JJ o
intake NN o
( ( N
P NNP N
less JJR N
than IN N
0.01 CD N
) ) N
. . N

Measurements NNS N
of IN N
bone NN o
density NN o
carried VBD N
out RP N
by IN N
photon NN N
absorption NN N
at IN N
the DT N
end NN N
of IN N
12 CD N
months NNS N
showed VBD N
a DT N
5.5 CD N
% NN N
increase NN N
in IN N
the DT N
distal JJ o
radius NN o
in IN N
group NN N
2 CD N
( ( N
P NNP N
= NNP N
0.0001 CD N
) ) N
and CC N
a DT N
7.1 CD N
% NN N
increase NN N
in IN N
group NN N
3 CD N
( ( N
P NNP N
= NNP N
0.0001 CD N
) ) N
, , N
while IN N
in IN N
group NN N
1 CD N
mineral NN N
content NN N
had VBD N
decreased VBN N
by IN N
4.3 CD N
% NN N
( ( N
nonsignificant JJ N
) ) N
. . N

These DT N
results NNS N
show VBP N
that IN N
a DT N
significant JJ N
gain NN N
in IN N
bone NN o
mass NN o
can MD N
be VB N
achieved VBN N
by IN N
administration NN N
of IN N
calcitonin NN N
, , N
either CC N
daily RB N
or CC N
on IN N
alternate JJ N
days NNS N
. . N

The DT N
incidence NN N
of IN N
extravertebral JJ N
fractures NNS N
and CC N
of IN N
new JJ N
or CC N
progressive JJ N
vertebral JJ N
deformity NN N
tended VBD N
to TO N
be VB N
lower JJR N
in IN N
groups NNS N
2 CD N
and CC N
3 CD N
than IN N
in IN N
group NN N
1 CD N
. . N

-DOCSTART- -16109116- O O

Topiramate NNP i
improves VBZ N
health-related JJ o
quality NN o
of IN o
life NN o
when WRB N
used VBN N
to TO N
prevent VB N
migraine NN p
. . p

OBJECTIVE UH N
To TO N
assess VB N
changes NNS N
in IN N
health-related JJ o
quality NN o
of IN o
life NN o
( ( o
HRQoL NNP o
) ) o
measures VBZ o
among IN N
patients NNS p
receiving VBG p
topiramate NN i
( ( i
TPM NNP i
) ) i
100 CD p
mg/d NN p
in IN p
two CD p
divided JJ p
doses NNS p
for IN p
migraine JJ p
prevention NN p
in IN N
three CD N
randomized NNS N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
, , N
26-week JJ N
trials NNS N
with IN N
similar JJ p
protocols NNS p
and CC p
study NN p
populations NNS p
. . p

BACKGROUND NNP N
Migraine NNP N
substantially RB N
impairs VBZ N
HRQoL NNP o
and CC N
work NN o
productivity NN o
before IN N
, , N
during IN N
, , N
and CC N
after IN N
attacks NNS N
. . N

Approximately RB N
50 CD N
% NN N
of IN N
patients NNS N
with IN N
migraine NN N
could MD N
be VB N
recommended VBN N
for IN N
preventive JJ N
therapies NNS N
, , N
yet RB N
only RB N
3 CD N
% NN N
to TO N
5 CD N
% NN N
of IN N
patients NNS N
receive VBP N
them PRP N
. . N

TPM NNP i
is VBZ N
an DT N
effective JJ o
and CC o
generally RB o
well-tolerated JJ o
migraine NN N
prophylactic NN N
( ( N
preventive JJ N
) ) N
therapy NN N
for IN N
adults NNS N
, , N
as IN N
demonstrated VBN N
in IN N
several JJ N
randomized VBN N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
trials NNS N
. . N

The DT N
most RBS N
common JJ N
adverse JJ N
events NNS N
in IN N
double-blind NN N
, , N
placebo-controlled JJ N
studies NNS N
of IN N
TPM NNP i
in IN N
migraine JJ N
prevention NN N
are VBP N
paresthesia NN o
, , o
fatigue NN o
, , o
anorexia NN o
, , o
nausea NN o
, , o
taste NN o
alteration NN o
, , o
and CC o
diarrhea NN o
. . o

DESIGN NNP N
AND CC N
METHODS NNP N
The DT N
Migraine-Specific NNP o
Questionnaire NNP o
( ( o
MSQ NNP o
, , N
version NN N
2.1 CD N
) ) N
was VBD N
used VBN N
to TO N
assess VB N
the DT N
effect NN N
of IN N
TPM NNP i
100 CD N
mg/d NN N
on IN N
the DT N
functionality NN N
and CC N
HRQoL NNP N
of IN N
randomized VBN N
intent-to-treat NN p
( ( p
ITT NNP p
) ) p
and CC p
study-completer JJ p
populations NNS p
pooled VBD N
from IN N
three CD N
randomized VBN N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
trials NNS N
. . N

MSQ NNP o
scores NNS o
( ( N
0 CD N
to TO N
100 CD N
, , N
higher JJR N
score NN N
indicates VBZ N
better RBR N
functioning VBG N
) ) N
were VBD N
assessed VBN N
for IN N
the DT N
following JJ N
three CD N
domains NNS N
: : N
role NN N
restriction NN N
( ( N
examines VBZ N
the DT N
degree NN N
to TO N
which WDT N
performance NN N
of IN N
daily JJ N
activities NNS N
is VBZ N
limited VBN N
by IN N
migraine NN N
) ) N
, , N
role NN N
prevention NN N
( ( N
examines VBZ N
the DT N
degree NN N
to TO N
which WDT N
performance NN N
of IN N
daily JJ N
activities NNS N
is VBZ N
interrupted VBN N
by IN N
migraine NN N
) ) N
, , N
and CC N
emotional JJ o
function NN o
( ( N
examines JJ N
feelings NNS N
of IN N
frustration NN N
and CC N
helplessness NN N
due JJ N
to TO N
migraine VB N
) ) N
. . N

Between-group JJ N
differences NNS N
from IN N
baseline NN N
in IN N
mean JJ o
MSQ NNP o
domain NN o
scores NNS o
for IN N
TPM NNP i
100 CD N
mg/d NN N
and CC N
placebo NN i
were VBD N
compared VBN N
using VBG N
a DT N
mixed-effects NNS N
model NN N
with IN N
piecewise NN N
linear JJ N
regression NN N
. . N

Effect JJ N
sizes NNS N
were VBD N
calculated VBN N
to TO N
estimate VB N
the DT N
magnitude NN N
of IN N
change NN N
in IN N
HRQoL NNP N
that WDT N
can MD N
be VB N
associated VBN N
with IN N
TPM NNP i
therapy NN i
. . i

RESULTS NNP N
TPM NNP i
100 CD N
mg/d NN N
significantly RB N
improved VBN N
all DT o
three CD o
MSQ NNP o
domains NNS o
compared VBN N
with IN N
placebo NN i
for IN N
both DT N
the DT N
ITT NNP N
( ( i
TPM NNP i
, , N
n JJ N
= VBP N
372 CD N
; : N
placebo NN i
, , N
n JJ N
= NNP N
362 CD N
) ) N
and CC N
study-completer NN N
( ( N
TPM NNP N
, , N
n JJ N
= VBP N
220 CD N
; : N
placebo NN N
, , N
n JJ N
= NNP N
216 CD N
) ) N
populations NNS N
( ( N
P NNP N
< NNP N
.001 NNP N
for IN N
all DT N
three CD N
domains NNS N
, , N
both DT N
populations NNS N
) ) N
. . N

Effect JJ N
sizes NN N
for IN N
TPM NNP i
100 CD N
mg/d NN N
varied VBD N
from IN N
0.40 CD N
to TO N
0.78 CD N
, , N
indicating VBG N
that IN N
the DT N
changes NNS N
in IN N
MSQ NNP o
scores NNS o
for IN N
TPM NNP i
100 CD N
mg/d NN N
were VBD N
moderate JJ N
and CC N
may MD N
be VB N
clinically RB N
significant JJ N
. . N

CONCLUSION NNP N
TPM NNP i
100 CD N
mg/d NN N
has VBZ N
been VBN N
shown VBN N
to TO N
be VB N
effective JJ N
in IN N
the DT N
prevention NN N
of IN N
migraine NN o
headache NN o
in IN p
adults NNS p
. . p

As IN N
the DT N
MSQ NNP N
results NNS N
from IN N
the DT N
three CD N
randomized VBN N
, , N
placebo-controlled JJ N
trials NNS N
indicate VBP N
, , N
HRQoL NNP o
is VBZ N
significantly RB N
improved VBN N
for IN N
up RB N
to TO N
6 CD N
months NNS N
following VBG N
initiation NN N
of IN N
treatment NN N
. . N

-DOCSTART- -7803065- O O

Health NNP N
promotion NN N
and CC N
disease NN N
prevention NN N
for IN N
older JJR p
adults NNS p
: : p
opportunity NN N
for IN N
change NN N
or CC N
preaching NN N
to TO N
the DT N
converted VBN N
? . N
Health NNP N
promotion NN N
and CC N
disease NN N
prevention NN N
for IN N
the DT p
elderly JJ p
offer NN N
the DT N
potential NN N
for IN N
improving VBG N
the DT N
quality NN N
of IN N
life NN N
for IN N
the DT N
growing VBG N
population NN N
of IN N
older JJR p
adults NNS p
, , N
while IN N
reducing VBG N
the DT N
economic JJ N
burden NN N
on IN N
the DT N
health NN N
system NN N
. . N

Whether CC N
this DT N
potential JJ N
can MD N
be VB N
realized VBN N
depends NNS N
, , N
in IN N
part NN N
, , N
on IN N
whether IN N
those DT N
older JJR p
adults NNS p
whose WP$ p
health NN p
behaviors NNS p
put VBD p
them PRP p
at IN p
risk NN p
actually RB N
use VBP N
preventive JJ i
services NNS i
when WRB N
offered VBD N
the DT N
opportunity NN N
. . N

In IN N
1988 CD p
the DT p
Health NNP p
Care NNP p
Financing NNP p
Administration NNP p
began VBD N
a DT N
series NN N
of IN N
health NN i
promotion NN i
demonstrations NNS i
to TO N
address VB N
health NN N
issues NNS N
related VBN N
to TO N
older JJR p
adults NNS p
. . p

This DT N
article NN N
reports VBZ N
on IN N
program NN N
participation NN N
at IN N
one CD p
of IN p
the DT p
five CD p
demonstration NN p
sites NNS p
. . p

Over IN p
1,900 CD p
community-dwelling JJ p
Medicare NNP p
beneficiaries NNS p
who WP p
receive VBP p
their PRP$ p
health NN p
care NN p
through IN p
fee-for-service JJ p
providers NNS p
were VBD p
enrolled VBN p
in IN p
the DT p
demonstration NN p
. . p

These DT N
enrollees NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
control VB i
and CC N
experimental JJ N
groups NNS N
, , N
with IN N
the DT N
latter JJ N
offered VBN N
health NN i
screening NN i
and CC i
promotion NN i
services NNS i
. . i

Nine NNP p
hundred-seventy-three NN p
of IN p
the DT p
experimental JJ p
subjects NNS p
and CC p
938 CD p
of IN p
the DT p
control NN p
subjects VBZ p
completed VBN p
a DT p
lengthy JJ p
telephone NN p
interview NN p
, , p
which WDT p
determined VBD p
each DT p
person NN p
's POS p
use NN p
of IN p
preventive JJ p
services NNS p
and CC p
practices NNS p
. . p

Although IN p
all DT p
973 CD p
experimental JJ p
subjects NNS p
were VBD p
invited VBN p
by IN p
letter NN p
and CC p
follow-up JJ p
telephone NN p
calls VBZ p
to TO p
attend VB p
these DT p
free-of-charge JJ p
, , p
Medicare-provided JJ p
sessions NNS p
, , p
not RB p
everyone NN p
attended VBD p
. . N

We PRP N
analyzed VBD N
17 CD N
health NN N
behaviors NNS N
of IN N
those DT N
who WP N
attended VBD N
the DT N
first JJ N
session NN N
and CC N
those DT N
who WP N
did VBD N
not RB N
. . N

Those DT N
engaging VBG N
in IN N
these DT N
preventive JJ N
behaviors NNS N
were VBD N
neither RB N
more JJR N
nor CC N
less RBR N
likely JJ N
to TO N
attend VB N
the DT N
screening NN N
services NNS N
. . N

Thus RB N
, , N
we PRP N
found VBD N
neither CC N
favorable JJ N
nor CC N
unfavorable JJ N
selection NN N
bias NN N
in IN N
the DT N
use NN N
of IN N
these DT N
preventive JJ N
services NNS N
. . N

-DOCSTART- -24630545- O O

A DT N
blinded VBN N
, , N
randomized VBN N
, , N
controlled VBN N
trial NN N
assessing VBG N
conservative JJ N
management NN N
strategies NNS N
for IN N
frozen JJ p
shoulder NN p
. . p

BACKGROUND NNP N
There EX N
is VBZ N
little JJ N
evidence NN N
for IN N
the DT N
optimal JJ N
form NN N
of IN N
nonoperative JJ N
treatment NN N
in IN N
the DT N
management NN N
of IN N
frozen JJ p
shoulder NN p
. . p

This DT N
study NN N
assesses VBZ N
the DT N
efficacy NN N
of IN N
current JJ N
physiotherapy NN N
strategies NNS N
. . N

METHODS NNP N
All DT p
primary JJ p
care NN p
referrals NNS p
of IN p
frozen JJ p
shoulder NN p
to TO p
our PRP$ p
physiotherapy NN p
department NN p
were VBD p
included VBN p
during IN p
a DT p
12-month JJ p
period NN p
. . p

Of IN p
these DT p
referrals NNS p
, , p
17 CD p
% NN p
met VBD p
the DT p
inclusion NN p
criteria NNS p
for IN p
primary JJ p
idiopathic JJ p
frozen JJ p
shoulder NN p
. . p

The DT N
75 CD p
patients NNS p
were VBD N
randomly RB N
assigned VBN N
to TO N
1 CD N
of IN N
3 CD N
groups NNS N
: : N
group NN i
exercise NN i
class NN i
, , i
individual JJ i
physiotherapy NN i
, , i
and CC i
home NN i
exercises NNS i
alone RB i
. . i

A DT N
single JJ N
independent JJ N
physiotherapist NN N
, , N
who WP N
was VBD N
blinded VBN N
to TO N
the DT N
treatment NN N
groups NNS N
, , N
made VBD N
all DT N
assessments NNS N
. . N

Range NNP o
of IN o
motion NN o
, , o
Constant NNP o
score NN o
, , o
Oxford NNP o
Shoulder NNP o
Score NNP o
, , o
Short NNP o
Form NNP o
36 CD o
, , o
and CC o
Hospital NNP o
Anxiety NNP o
and CC o
Disability NNP o
Scale NNP o
( ( o
HADS NNP o
) ) o
outcome NN N
measures NNS N
were VBD N
performed VBN N
at IN N
baseline NN N
, , N
6 CD N
weeks NNS N
, , N
6 CD N
months NNS N
, , N
and CC N
1 CD N
year NN N
. . N

RESULTS VB N
The DT N
exercise NN N
class NN N
group NN N
improved VBD N
from IN N
a DT N
mean JJ o
Constant NNP o
score NN o
of IN N
39.8 CD N
at IN N
baseline NN N
to TO N
71.4 CD N
at IN N
6 CD N
weeks NNS N
and CC N
88.1 CD N
at IN N
1 CD N
year NN N
. . N

There EX N
was VBD N
a DT N
significant JJ N
improvement NN N
in IN N
shoulder NN o
symptoms NNS o
on IN o
Oxford NNP o
and CC o
Constant NNP o
scores NNS o
( ( N
P NNP N
< NNP N
.001 NNP N
) ) N
. . N

This DT N
improvement NN N
was VBD N
greater JJR N
than IN N
with IN N
individual JJ o
physiotherapy NN o
or CC o
home NN o
exercises NNS o
alone RB o
( ( N
P NNP N
< NNP N
.001 NNP N
) ) N
. . N

The DT N
improvement NN N
in IN N
range NN N
of IN N
motion NN N
was VBD N
significantly RB N
greater JJR N
in IN N
both DT N
physiotherapy NN o
groups NNS o
over IN o
home NN o
exercises NNS o
( ( N
P NNP N
< NNP N
.001 NNP N
) ) N
. . N

HADS NNP o
scores VBZ o
significantly RB N
improved VBN N
during IN N
the DT N
course NN N
of IN N
treatment NN N
( ( N
P NNP N
< NNP N
.001 NNP N
) ) N
. . N

The DT N
improvement NN N
in IN N
HADS NNP o
anxiety NN o
score NN o
was VBD N
significantly RB N
greater JJR N
in IN N
both DT N
physiotherapy JJ N
intervention NN N
groups NNS N
than IN N
in IN N
home NN N
exercises NNS N
alone RB N
. . N

CONCLUSIONS VB N
A DT N
hospital-based JJ i
exercise NN i
class NN i
can MD N
produce VB N
a DT N
rapid JJ N
recovery NN N
from IN N
a DT N
frozen JJ p
shoulder NN p
with IN N
a DT N
minimum JJ N
number NN N
of IN N
visits NNS N
to TO N
the DT N
hospital NN N
and CC N
is VBZ N
more RBR N
effective JJ N
than IN N
individual JJ N
physiotherapy NN N
or CC N
a DT N
home NN N
exercise NN N
program NN N
. . N

-DOCSTART- -10685722- O O

Efficacy NN o
and CC N
safety NN o
of IN N
a DT N
fixed JJ N
low-dose JJ N
perindopril/indapamide NN i
combination NN i
in IN N
essential JJ p
hypertension NN p
. . p

A DT N
randomised JJ N
controlled VBN N
study NN N
. . N

This DT N
multicenter NN N
, , N
double-blind JJ N
, , N
parallel-group JJ N
study NN N
was VBD N
designed VBN N
to TO N
assess VB N
the DT N
efficacy NN o
and CC N
the DT N
safety NN o
of IN N
fixed JJ N
low JJ i
dose NN i
combination NN i
perindopril VBD i
2 CD i
mg/indapamide RB i
0.625 CD N
mg NN N
( ( N
Per/Ind NNP N
) ) N
versus NN N
atenolol $ i
50 CD N
mg NN N
( ( N
Ate NNP N
) ) N
. . N

After IN N
a DT N
4-week JJ N
placebo NN N
run-in NN N
, , N
446 CD p
hypertensive JJ p
patients NNS p
( ( p
mean JJ p
age NN p
: : p
55.8 CD p
+/- JJ p
11.0 CD p
years NNS p
) ) p
were VBD N
randomised VBN N
to TO N
receive VB N
Per/Ind NNP i
or CC i
Ate NNP i
for IN N
12 CD N
weeks NNS N
. . N

The DT N
primary JJ N
outcome NN N
measures NNS N
were VBD N
the DT N
changes NNS o
in IN o
trough JJ o
supine NN o
systolic NN o
and CC o
diastolic JJ o
blood NN o
pressure NN o
( ( o
sSBP NN o
, , o
sDBP NN o
) ) o
between IN N
baseline NN N
and CC N
the DT N
last JJ N
observation NN N
. . N

Equivalence NN o
was VBD N
assessed VBN o
in IN N
an DT N
intention-to-treat JJ N
analysis NN N
using VBG N
a DT N
two CD N
one-sided JJ N
tests NNS N
procedure NN N
. . N

Per/Ind NNP N
and CC N
Ate NNP N
decreased VBD o
sSBP NN o
by IN N
-20.5 NNP N
mmHg NN N
and CC N
-20.1 NNP N
mmHg NN N
, , N
respectively RB N
; : N
the DT N
90 CD N
% NN N
confidence NN o
interval NN o
[ NNP N
-2.3 NNP N
; : N
1.5 CD N
] NN N
of IN N
the DT N
intertreatment NN N
difference NN N
( ( N
-0.4 JJ N
mmHg NN N
) ) N
fell VBD N
within IN N
the DT N
predefined JJ o
equivalence NN o
interval NN o
[ NNP N
-8 NNP N
; : N
+8 NNP N
mmHg FW N
] NNP N
. . N

Similarly RB N
, , N
the DT N
sDBP NN o
decreased VBN o
by IN N
-15.1 NNP N
mmHg NN N
( ( N
Per/Ind NNP N
) ) N
and CC N
-16.2 $ N
mmHg NN N
( ( N
Ate NNP N
) ) N
with IN N
an DT N
intertreatment JJ N
difference NN N
of IN N
1.1 CD N
mmHg NNS N
whose WP$ N
90 CD N
% NN N
confidence NN o
interval NN o
[ NNP N
-0.1 NNP N
; : N
2.2 CD N
mmHg NN N
] NN N
fell VBD N
within IN N
the DT N
predefined JJ N
equivalence NN o
interval NN o
[ NNP N
-4 NNP N
; : N
+4 NNP N
mmHg VBZ N
] NNP N
; : N
thus RB N
antihypertensive JJ o
efficacy NN o
of IN N
Per/Ind NNP N
and CC N
Ate NNP N
were VBD N
equivalent JJ o
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

In IN N
patients NNS N
older JJR N
than IN N
65 CD N
, , N
Per/Ind NNP N
induces VBZ N
a DT N
statistically RB N
greater JJR N
decrease NN N
in IN N
sSBP NN o
than IN N
Ate NNP N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

Per/Ind NNP N
was VBD N
well RB N
tolerated VBN o
. . o

Further RBR N
controlled JJ N
studies NNS N
are VBP N
needed VBN N
to TO N
confirm VB N
these DT N
results NNS N
on IN N
a DT N
long-term JJ N
period NN N
. . N

-DOCSTART- -12579266- O O

S-phase JJ i
kinase-associated JJ i
protein NN i
2 CD N
expression NN N
in IN N
laryngeal JJ p
squamous JJ p
cell NN p
carcinomas NN p
and CC N
its PRP$ N
prognostic JJ N
implications NNS N
. . N

The DT N
F-box JJ N
protein JJ N
S-phase JJ i
kinase-associated JJ i
protein NN i
2 CD N
( ( i
Skp2 NNP i
) ) i
positively RB N
regulates VBZ N
the DT N
G1-S JJ N
transition NN N
by IN N
controlling VBG N
the DT N
stability NN N
of IN N
several JJ N
G1 NNP N
regulators NNS N
, , N
such JJ N
as IN N
the DT N
cell NN N
cycle NN N
inhibitor NN N
p27kip1 NN N
. . N

However RB N
, , N
the DT N
clinical JJ N
significance NN N
of IN N
Skp2 NNP i
in IN N
patients NNS p
with IN p
laryngeal JJ p
squamous JJ p
cell NN p
carcinoma NN p
( ( p
LSCC NNP p
) ) p
remains VBZ N
unknown JJ N
. . N

In IN N
this DT N
study NN N
, , N
a DT N
potential JJ N
distribution NN N
of IN N
Skp2 NNP i
in IN N
LSCC NNP N
and CC N
its PRP$ N
clinical JJ N
implications NNS N
was VBD N
investigated VBN N
by IN N
an DT N
immunohistochemical JJ i
study NN i
. . i

Overall NNP N
, , N
Skp2 NNP o
overexpression NN o
was VBD N
observed VBN N
in IN N
36.7 CD p
% NN p
( ( p
37 CD p
of IN p
102 CD p
) ) p
patients NNS p
and CC N
was VBD N
significantly RB N
associated VBN N
with IN N
lymph JJ N
node JJ N
metastasis NN N
( ( N
p=0.002 NN N
) ) N
and CC N
was VBD N
inversely RB N
associated VBN N
with IN N
p27kip1 JJ N
expression NN N
( ( N
p=0.026 NN N
) ) N
. . N

Survival JJ o
analysis NN o
using VBG N
the DT N
Kaplan-Meier NNP N
method NN N
showed VBD N
that IN N
Skp2 NNP i
overexpression NN N
was VBD N
significantly RB N
associated VBN N
with IN N
shorter JJR N
disease-free NN o
and CC o
overall JJ o
survival NN o
( ( N
p=0.0051 NN N
and CC N
p=0.0002 NN N
, , N
respectively RB N
) ) N
. . N

When WRB N
Skp2 NNP o
expression NN o
and CC o
p27kip1 JJ o
expression NN o
were VBD N
combined VBN N
, , N
patients NNS N
with IN N
both DT N
Skp2 NNP i
overexpression NN N
and CC N
reduced JJ N
expression NN o
of IN o
p27kip1 NN o
revealed VBN N
poorest JJS o
disease-free JJ o
and CC N
overall JJ o
survival NN o
as IN N
compared VBN N
to TO N
the DT N
other JJ N
cases NNS N
( ( N
p=0.0017 NN N
and CC N
p NN N
< NN N
0.0001 CD N
, , N
respectively RB N
) ) N
. . N

Additionally RB N
, , N
in IN N
early JJ N
stage NN N
( ( N
I PRP N
, , N
II NNP N
) ) N
cases NNS N
, , N
Skp2 NNP i
expression NN N
was VBD N
also RB N
revealed VBN N
to TO N
possess VB N
a DT N
significant JJ N
prognostic JJ N
factor NN N
in IN N
overall JJ o
survival NN o
( ( o
p=0.0234 NN o
) ) o
, , N
but CC N
not RB N
in IN N
disease-free JJ o
survival NN o
( ( N
p=0.2055 NN N
) ) N
. . N

By IN N
multivariate NN N
analysis NN N
using VBG N
the DT N
Cox NNP o
proportional JJ o
hazards NNS o
model NN o
, , o
tumor NN o
grade NN o
, , o
tumor NN o
size NN o
, , o
clinical JJ o
stage NN o
and CC o
Skp2 NNP o
expression NN o
were VBD N
independent JJ N
prognostic JJ N
factors NNS N
both DT N
in IN N
disease-free JJ o
and CC o
overall JJ o
survival NN o
. . o

These DT N
findings NNS N
indicated VBD N
that IN N
Skp2 NNP o
expression NN o
was VBD N
closely RB N
associated VBN N
with IN N
tumor NN N
progression NN N
and CC N
represented VBD N
an DT N
independent JJ N
marker NN N
for IN N
prognosis NN N
of IN N
LSCC NNP N
. . N

-DOCSTART- -16540291- O O

The DT N
misattribution NN N
of IN N
salience NN N
in IN N
delusional JJ p
patients NNS p
with IN p
schizophrenia NN p
. . p

INTRODUCTION NNP N
Delusions NNP N
may MD N
arise VB N
from IN N
abnormalities NNS N
in IN N
emotional JJ N
perception NN N
. . N

In IN N
this DT N
study NN N
, , N
we PRP N
tested VBD N
the DT N
hypothesis NN N
that WDT N
delusional JJ p
schizophrenia NN p
patients NNS p
are VBP N
more RBR N
likely JJ N
than IN N
non-delusional JJ N
schizophrenia NN N
patients NNS N
and CC N
healthy JJ N
participants NNS N
to TO N
assign VB N
affective JJ N
meanings NNS N
to TO N
neutral JJ N
stimuli NNS N
. . N

METHODS NNP N
Unpleasant NNP i
, , i
pleasant NN i
, , i
and CC i
neutral JJ i
words NNS i
were VBD i
randomly RB i
presented VBN i
to TO i
three CD i
subject JJ i
groups NNS i
-- : i
patients NNS i
with IN p
schizophrenia NN p
with IN p
prominent JJ p
delusions NNS p
, , p
patients NNS p
with IN p
schizophrenia NN p
without IN p
delusions NNS p
, , p
and CC p
healthy JJ p
participants NNS p
. . p

Participants NNS N
performed VBD N
three CD N
tasks NNS N
: : N
one CD i
in IN i
which WDT i
they PRP i
decided VBD i
whether IN i
a DT i
letter NN i
string NN i
was VBD i
a DT i
word NN i
or CC i
a DT i
non-word JJ i
( ( i
lexical JJ i
decision NN i
) ) i
and CC i
two CD i
affective JJ i
classification NN i
tasks NNS i
in IN N
which WDT N
they PRP N
judged VBD N
whether IN N
words NNS N
were VBD N
1 CD N
) ) N
neutral NN i
or CC i
unpleasant JJ i
, , N
or CC N
2 CD N
) ) N
neutral NN i
or CC i
pleasant NN i
. . i

RESULTS NNP N
While IN N
there EX N
were VBD N
no DT N
significant JJ N
between-group JJ N
differences NNS N
in IN N
lexical JJ o
decision NN o
performance NN o
, , N
patients NNS N
with IN N
delusions NNS N
showed VBD N
selective JJ o
performance NN o
deficits NNS o
in IN N
both DT N
affective JJ N
classification NN N
tasks NNS N
. . N

First NNP N
, , N
delusional JJ N
patients NNS N
were VBD N
significantly RB N
more RBR N
likely JJ N
than IN N
non-delusional JJ N
patients NNS N
and CC N
healthy JJ N
participants NNS N
to TO N
classify VB o
words NNS o
as IN o
unpleasant JJ o
. . o

Second JJ N
, , N
delusional JJ N
patients NNS N
took VBD N
significantly RB N
longer JJR N
than IN N
both DT N
other JJ N
groups NNS N
to TO N
correctly VB o
classify VB o
neutral JJ o
words NNS o
in IN N
both DT N
affective JJ N
classification NN N
tasks NNS N
. . N

CONCLUSIONS NNP N
Taken NNP N
together RB N
, , N
these DT N
findings NNS N
suggest VBP N
that IN N
delusions NNS N
are VBP N
associated VBN N
with IN N
the DT N
explicit JJ o
misattribution NN o
of IN o
salience NN o
to TO o
neutral JJ o
stimuli NNS o
. . o

-DOCSTART- -25778317- O O

Assessment NN N
of IN N
radiotherapy NN i
combined VBN i
with IN i
adjuvant JJ i
chemotherapy NN i
in IN N
the DT N
treatment NN N
of IN N
patients NNS p
with IN p
advanced JJ p
nasopharyngeal JJ p
carcinoma NN p
: : p
a DT N
prospective JJ N
study NN N
. . N

PURPOSE NNP N
To TO N
explore VB N
the DT N
clinical JJ N
efficacy NN o
of IN N
radiotherapy NN i
combined VBN i
with IN i
concurrent JJ i
combination NN i
chemotherapy NN i
in IN N
the DT N
treatment NN N
of IN N
patients NNS p
with IN p
advanced JJ p
nasopharyngeal JJ p
carcinoma NN p
( ( p
NPC NNP p
) ) p
. . p

METHODS NNP N
Two CD p
hundred VBD p
patients NNS p
with IN p
stage NN p
III/IV NNP p
NPC NNP p
were VBD p
randomly RB p
allocated VBN p
into IN N
the DT N
treatment NN p
group NN p
( ( p
N=100 NNP p
) ) p
and CC p
the DT p
control NN p
group NN p
( ( p
N=100 NNP p
) ) p
. . p

Patients NNS N
in IN N
the DT N
control NN N
group NN N
received VBD N
conventional JJ i
fractionated JJ i
radiotherapy NN i
, , N
while IN N
patients NNS N
in IN N
the DT N
treatment NN N
group NN N
received VBD N
conventional JJ i
fractionated JJ i
radiotherapy NN i
combined VBN i
with IN i
concurrent JJ i
combination NN i
chemotherapy NN i
with IN i
cisplatin NN i
and CC i
5-fluorouracil JJ i
( ( i
5-FU JJ i
) ) i
. . i

Short-term JJ o
efficacy NN o
, , o
radiotherapy NN o
toxicity NN o
, , o
shortand VB o
long-term JJ o
survival NN o
were VBD N
compared VBN N
. . N

RESULTS VB N
The DT N
short-term JJ o
response NN o
rate NN o
of IN N
the DT N
treatment NN N
group NN N
was VBD N
96 CD N
% NN N
, , N
which WDT N
was VBD N
significantly RB N
higher JJR N
than IN N
that DT N
of IN N
the DT N
control NN N
group NN N
( ( N
87 CD N
% NN N
, , N
p NN N
< NNP N
0.05 CD N
) ) N
. . N

The DT N
local JJ o
radiation NN o
toxicity NN o
of IN N
the DT N
treatment NN N
group NN N
was VBD N
similar JJ N
to TO N
that DT N
of IN N
the DT N
control NN N
group NN N
p VBD N
> NNP N
0.05 CD N
) ) N
, , N
but CC N
the DT N
hematological JJ o
and CC o
gastrointestinal JJ o
toxicities NNS o
were VBD N
significantly RB N
higher JJR N
in IN N
the DT N
treatment NN N
group NN N
p VBD N
< NNP N
0.05 CD N
) ) N
. . N

The DT N
1- JJ N
, , N
3- JJ N
and CC N
5-year JJ N
overall JJ o
survival NN o
rates NNS o
were VBD N
87 CD N
, , N
80 CD N
, , N
and CC N
76 CD N
% NN N
, , N
respectively RB N
, , N
in IN N
the DT N
treatment NN N
group NN N
and CC N
74 CD N
, , N
64 CD N
, , N
and CC N
51 CD N
% NN N
, , N
respectively RB N
, , N
in IN N
the DT N
control NN N
group NN N
, , N
significantly RB N
favoring VBG N
the DT N
treatment NN N
group NN N
p VBD N
< NNP N
0.05 CD N
) ) N
. . N

CONCLUSION NNP N
Radiotherapy NNP i
with IN i
concurrent JJ i
combination NN i
chemotherapy NN i
can MD N
improve VB N
the DT N
prognosis NN o
of IN N
patients NNS p
with IN p
advanced JJ p
NPC NNP p
but CC N
at IN N
the DT N
cost NN N
of IN N
significant JJ N
toxicity NN o
. . o

-DOCSTART- -23547660- O O

The DT N
Tiotropium NNP i
Safety NNP o
and CC o
Performance NNP o
in IN N
Respimat NNP N
Trial NNP N
( ( N
TIOSPIR NNP N
) ) N
, , N
a DT N
large JJ N
scale NN N
, , N
randomized VBN N
, , N
controlled VBN N
, , N
parallel-group JJ N
trial-design NN N
and CC N
rationale NN N
. . N

BACKGROUND NNP N
Tiotropium NNP i
bromide NN i
is VBZ N
an DT N
effective JJ N
therapy NN N
for IN N
COPD NNP p
patients NNS p
. . p

Comparing VBG N
across IN N
programs NNS N
tiotropium VBP i
Respimat NNP i
Soft NNP i
Mist NNP i
inhaler NN i
was VBD N
at IN N
least JJS N
as RB N
efficacious JJ N
as IN N
tiotropium NN i
HandiHaler NNP i
, , N
however RB N
, , N
concerns NNS N
have VBP N
been VBN N
raised VBN N
about IN N
tiotropium NN i
's POS i
safety NN N
when WRB N
given VBN N
via IN N
Respimat NNP N
. . N

METHODS NNP N
The DT N
TIOSPIR NNP N
trial NN N
( ( N
NCT01126437 NNP N
) ) N
compares VBZ N
the DT N
safety NN o
and CC o
efficacy NN o
of IN N
tiotropium NN i
Respimat NNP i
5 CD i
?g NNP i
once RB N
daily RB N
( ( N
marketed VBN N
) ) N
and CC N
2.5 CD N
?g NNS N
once RB N
daily JJ N
( ( N
investigational JJ N
) ) N
with IN i
tiotropium NN i
HandiHaler NNP i
18 CD i
? . i
once RB i
daily JJ i
( ( i
marketed VBN i
) ) N
. . N

The DT N
hypotheses NNS N
to TO N
be VB N
tested VBN N
are VBP N
1 CD N
) ) N
. . N

that IN i
tiotropium NN i
Respimat NNP i
5 CD i
?g NNP N
once RB N
daily RB N
and CC N
Respimat NNP i
2.5 CD i
?g NNP N
once RB N
daily RB N
are VBP N
non-inferior JJ i
to TO i
HandiHaler NNP i
in IN i
terms NNS i
of IN N
all-cause NN N
mortality NN N
, , N
and CC N
2 CD N
) ) N
. . N

that IN N
tiotropium NN i
Respimat NNP i
5 CD i
?g NNP i
once RB N
daily RB N
is VBZ N
superior JJ i
to TO i
HandiHaler NNP i
in IN i
terms NNS i
of IN N
time NN N
to TO N
first JJ N
exacerbation NN N
. . N

A DT N
spirometry NN N
substudy NN N
evaluates VBZ o
the DT o
bronchodilator NN o
efficacy NN o
. . o

The DT o
trial NN N
is VBZ N
a DT N
randomized JJ N
, , N
double-blind JJ N
, , N
double JJ N
dummy NN N
, , N
event-driven JJ N
, , N
parallel JJ N
group NN N
study NN N
. . N

Participants NNS p
can MD p
use VB p
any DT p
background NN p
treatment NN p
for IN p
COPD NNP p
except IN p
inhaled JJ p
anticholinergic JJ p
agents NNS p
. . p

The DT p
study NN p
encompasses VBZ p
a DT p
wide JJ p
range NN p
of IN p
COPD NNP p
patients NNS p
, , p
e.g FW p
. . p

patients NNS p
with IN p
stable JJ p
cardiac JJ p
diseases NNS p
including VBG p
arrhythmia NN p
can MD p
be VB p
included VBN p
. . p

Clinical JJ p
sites NNS p
are VBP p
international JJ p
and CC p
include VBP p
both DT p
primary JJ p
care NN p
as RB p
well RB p
as IN p
specialists NNS p
. . p

RESULTS NNP p
To TO p
date NN p
, , p
over IN p
17,000 CD p
participants NNS p
have VBP p
been VBN p
randomized VBN p
from IN p
over IN p
1200 CD p
sites NNS p
in IN p
50 CD p
countries NNS p
with IN p
an DT N
anticipated JJ N
treatment NN N
duration NN N
of IN N
2-3 JJ N
years NNS N
. . N

CONCLUSION NNP N
TIOSPIR NNP N
will MD N
provide VB N
precise JJ N
estimates NNS N
of IN N
the DT N
relative JJ o
safety NN o
and CC o
efficacy NN o
of IN o
the DT o
Respimat NNP i
and CC i
HandiHaler NNP i
formulations NNS i
of IN i
tiotropium NN i
, , i
assess JJ i
potential JJ o
dose-dependence NN o
of IN o
important JJ o
outcomes NNS o
and CC o
provide VB o
information NN o
on IN o
the DT o
clinical JJ o
epidemiology NN o
of IN o
COPD NNP o
in IN o
a DT o
large JJ o
international JJ o
patient NN o
cohort NN o
. . o

-DOCSTART- -26323772- O O

Effects NNS N
of IN N
bench JJ i
step NN i
exercise NN i
intervention NN i
on IN N
work NN o
ability NN o
in IN N
terms NNS N
of IN N
cardiovascular JJ o
risk NN N
factors NNS N
and CC N
oxidative JJ N
stress NN N
: : N
a DT N
randomized NN N
controlled VBN N
study NN N
. . N

Work NNP o
ability NN o
is VBZ N
partly RB N
determined VBN N
by IN N
physical JJ N
and CC N
mental JJ N
fitness NN N
. . N

Bench JJ i
step NN i
exercise NN i
can MD N
be VB N
practiced VBN N
anywhere RB N
at IN N
any DT N
time NN N
. . N

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
determine VB N
the DT N
effects NNS N
of IN N
a DT N
bench JJ i
step NN i
exercise NN i
on IN N
work NN o
ability NN o
by IN N
examining VBG N
cardiovascular JJ N
risk NN N
factors NNS N
and CC N
oxidative JJ N
stress NN N
. . N

Thirteen NNP p
volunteers NNS p
working VBG p
in IN p
a DT p
warehousing NN p
industry NN p
comprised VBD p
the DT p
bench JJ i
step NN i
exercise NN i
group NN p
( ( p
n=7 CC p
) ) p
and CC p
the DT p
control NN p
group NN p
( ( p
n=6 RB p
) ) p
. . p

The DT N
participants NNS N
in IN N
the DT N
step NN i
exercise NN i
group NN N
were VBD N
encouraged VBN N
to TO N
practice NN N
the DT N
step NN i
exercise NN i
at IN N
home NN N
for IN N
16 CD N
weeks NNS N
. . N

The DT N
step NN i
exercise NN i
improved VBD N
glucose JJ o
metabolism NN o
and CC o
antioxidative JJ o
capacity NN o
and CC N
increased VBD N
work NN o
ability NN o
by IN o
reducing VBG o
absences NNS o
from IN o
work NN o
and CC o
improving VBG o
the DT o
prognosis NN o
of IN o
work NN o
ability NN o
. . o

The DT N
improvement NN N
in IN N
work NN o
ability NN o
was VBD N
related VBN N
to TO N
a DT N
reduction NN N
in IN N
oxidative JJ o
stress NN o
. . o

These DT N
results NNS N
suggest VBP N
that IN N
a DT N
bench JJ i
step NN i
exercise NN i
may MD N
improve VB N
work NN o
ability NN o
by IN N
reducing VBG N
cardiovascular JJ N
risk NN N
factors NNS N
and CC N
oxidative JJ N
stress NN N
. . N

-DOCSTART- -20854436- O O

Tomato NNP i
paste NN i
rich JJ i
in IN i
lycopene JJ i
protects NNS N
against IN N
cutaneous JJ o
photodamage NN o
in IN N
humans NNS p
in IN p
vivo NN p
: : p
a DT N
randomized NN N
controlled VBN N
trial NN N
. . N

BACKGROUND NNP N
Previous NNP N
epidemiological JJ N
, , N
animal JJ N
and CC N
human JJ N
data NNS N
report NN N
that IN N
lycopene NN N
has VBZ N
a DT N
protective JJ N
effect NN N
against IN N
ultraviolet NN o
radiation NN o
( ( o
UVR NNP o
) ) o
-induced VBD o
erythema NN o
. . o

OBJECTIVES IN N
We PRP N
examined VBD N
whether IN N
tomato NN i
paste NN i
-- : i
rich JJ i
in IN i
lycopene NN i
, , N
a DT N
powerful JJ N
antioxidant NN N
-- : N
can MD N
protect VB N
human JJ N
skin NN N
against IN N
UVR-induced JJ N
effects NNS N
partially RB N
mediated VBN N
by IN N
oxidative JJ N
stress NN N
, , N
i.e NN N
. . N

erythema NN N
, , N
matrix NN N
changes NNS N
and CC N
mitochondrial JJ N
DNA NNP N
( ( N
mtDNA NN N
) ) N
damage NN N
. . N

METHODS NNP N
In IN N
a DT N
randomized NN N
controlled VBN N
study NN N
, , N
20 CD p
healthy JJ p
women NNS p
( ( p
median JJ p
age NN p
33 CD p
years NNS p
, , p
range VBP p
21-47 JJ p
; : p
phototype JJ p
I/II NNP p
) ) p
ingested VBD N
55 CD i
g NN i
tomato NN i
paste NN i
( ( i
16 CD i
mg RB i
lycopene NN i
) ) i
in IN i
olive JJ i
oil NN i
, , i
or CC i
olive JJ i
oil NN i
alone RB i
, , i
daily JJ i
for IN i
12 CD i
weeks NNS i
. . i

Pre- NNP N
and CC N
postsupplementation NN N
, , N
UVR NNP N
erythemal JJ o
sensitivity NN o
was VBD N
assessed VBN N
visually RB N
as IN N
the DT N
minimal JJ N
erythema NN N
dose NN N
( ( N
MED NNP N
) ) N
and CC N
quantified VBN N
with IN N
a DT N
reflectance NN N
instrument NN N
. . N

Biopsies NNS N
were VBD N
taken VBN N
from IN N
unexposed JJ N
and CC N
UVR-exposed JJ N
( ( N
3 CD N
? . N
MED NNP N
24 CD N
h NN N
earlier RBR N
) ) N
buttock NN N
skin JJ N
pre- NN N
and CC N
postsupplementation NN N
, , N
and CC N
analysed VBD N
immunohistochemically RB N
for IN N
procollagen NN N
( ( N
pC NN N
) ) N
I PRP N
, , N
fibrillin-1 JJ N
and CC N
matrix JJ N
metalloproteinase NN N
( ( N
MMP NNP N
) ) N
-1 NN N
, , N
and CC N
by IN N
quantitative JJ N
polymerase NN N
chain NN N
reaction NN N
for IN N
mtDNA JJ N
3895-bp JJ N
deletion NN N
. . N

RESULTS VB o
Mean NNP o
? . o
SD NNP o
erythemal JJ o
D NNP o
( ( o
30 CD o
) ) o
was VBD o
significantly RB N
higher JJR N
following VBG N
tomato JJ N
paste NN N
vs. FW N
control NN N
( ( N
baseline NN N
, , N
26?5 CD N
? . N
7?5 CD N
mJ NN N
cm NN N
( ( N
-2 NNP N
) ) N
; : N
control NN N
, , N
23 CD N
? . N
6?6 CD N
mJ NN N
cm NN N
( ( N
-2 NNP N
) ) N
; : N
tomato CC N
paste NN N
, , N
36?6 CD N
? . N
14?7 CD N
mJ NN N
cm NN N
( ( N
-2 NNP N
) ) N
; : N
P NNP N
= NNP N
0?03 CD N
) ) N
, , N
while IN N
the DT N
MED NNP N
was VBD N
not RB N
significantly RB N
different JJ N
between IN N
groups NNS N
( ( N
baseline NN N
, , N
35?1 CD N
? . N
9?9 CD N
mJ NN N
cm NN N
( ( N
-2 NNP N
) ) N
; : N
control NN N
, , N
32?6 CD N
? . N
9?6 CD N
mJ NN N
cm NN N
( ( N
-2 NNP N
) ) N
; : N
tomato CC N
paste NN N
, , N
42?2 CD N
? . N
11?3 CD N
mJ NN N
cm NN N
( ( N
-2 NNP N
) ) N
) ) N
. . N

Presupplementation NN N
, , N
UVR NNP N
induced VBD N
an DT N
increase NN N
in IN o
MMP-1 NNP o
( ( o
P NNP N
= NNP N
0?01 CD N
) ) N
and CC N
a DT N
reduction NN o
in IN o
fibrillin-1 NN o
( ( o
P NNP o
= NNP o
0?03 CD N
) ) N
. . N

Postsupplementation NN N
, , N
UVR-induced JJ o
MMP-1 NNP o
was VBD o
reduced VBN N
in IN N
the DT N
tomato NN N
paste NN N
vs. FW N
control NN N
group NN N
( ( N
P NNP N
= NNP N
0?04 CD N
) ) N
, , N
while IN N
the DT N
UVR-induced JJ N
reduction NN N
in IN o
fibrillin-1 NN o
was VBD o
similarly RB o
abrogated VBN N
in IN N
both DT N
groups NNS N
, , N
and CC N
an DT N
increase NN N
in IN N
pCI JJ N
deposition NN N
was VBD N
seen VBN N
following VBG N
tomato JJ N
paste NN N
( ( N
P NNP N
= NNP N
0?05 CD N
) ) N
. . o

mtDNA JJ o
3895-bp JJ o
deletion NN N
following VBG N
3 CD N
? . N
MED NNP N
UVR NNP N
was VBD N
significantly RB N
reduced VBN N
postsupplementation NN N
with IN N
tomato JJ i
paste NN i
( ( i
P NNP i
= NNP i
0?01 CD i
) ) N
. . N

CONCLUSIONS NNP i
Tomato NNP i
paste NN i
containing VBG N
lycopene NNP N
provides VBZ o
protection NN o
against IN o
acute NN o
and CC o
potentially RB o
longer-term JJ o
aspects NNS o
of IN o
photodamage NN o
. . o

-DOCSTART- -18702687- O O

Long RB i
pediatric JJ i
colonoscope NN i
versus NN N
intermediate JJ i
length NN i
adult NN i
colonoscope NN i
for IN N
colonoscopy NN N
. . N

BACKGROUND NNP N
Controversy NNP N
exists VBZ N
on IN N
how WRB N
the DT N
length NN N
and CC N
diameter NN N
of IN N
colonoscopes NNS N
affect VBP N
the DT N
quality NN o
of IN o
colonoscopy NN o
. . o

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
compare VB N
a DT N
long JJ i
pediatric JJ i
colonoscope NN i
with IN N
an DT N
intermediate JJ i
length NN i
adult NN i
colonoscope NN i
with IN N
regards NNS N
to TO N
completion NN o
rate NN o
and CC o
cecal JJ o
intubation NN o
time NN o
. . o

Whether CC N
either DT N
scope NN N
may MD N
be VB N
more RBR N
efficient JJ o
in IN N
any DT N
subgroups NN N
was VBD N
also RB N
investigated VBN N
. . N

METHODS NNP N
Asymptomatic JJ p
patients NNS p
admitted VBN p
to TO p
the DT p
physical JJ p
check-up JJ p
department NN p
of IN p
Buddhist NNP p
Dalin NNP p
Tzu NNP p
Chi NNP p
General NNP p
Hospital NNP p
were VBD N
included VBN N
. . N

A DT N
single JJ N
endoscopist NN N
performed VBD N
all DT N
of IN N
the DT N
colonoscopic NN i
examinations NNS i
under IN N
sedation NN N
. . N

Consecutive JJ N
patients NNS N
were VBD N
randomized VBN N
to TO N
undergo VB N
colonoscopy NN i
with IN i
either DT i
intermediate JJ i
length NN i
adult NN i
colonoscope NN i
( ( i
CF-240I NNP i
) ) i
or CC i
long JJ i
pediatric JJ i
colonoscope NN i
( ( i
PCF-240L NNP i
) ) i
. . i

The DT N
success NN o
rate NN o
and CC o
time NN o
required VBN o
to TO o
reach VB o
cecum NN o
were VBD N
compared VBN N
between IN N
the DT N
two CD N
groups NNS N
. . N

RESULTS NNP N
Between NNP p
April NNP p
2005 CD p
and CC p
February NNP p
2006 CD p
, , p
a DT p
total NN p
of IN p
918 CD p
patients NNS p
were VBD p
enrolled VBN p
. . p

Incomplete NNP o
colonoscopy NN o
occurred VBD N
in IN N
21 CD N
( ( N
2.3 CD N
% NN N
) ) N
cases NNS N
( ( N
14 CD N
in IN N
the DT N
CF-240I NNP N
group NN N
and CC N
seven CD N
in IN N
the DT N
PCF-240L NNP N
group NN N
, , N
P NNP N
> NNP N
0.1 CD N
) ) N
. . N

The DT N
overall JJ o
cecal JJ o
mean NN o
insertion NN o
time NN o
was VBD N
6.00 CD N
+/- JJ N
3.66 CD N
min NN N
. . N

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
between IN N
the DT N
CF-240I NNP i
and CC N
PCF NNP i
240L CD i
groups NNS N
with IN N
regard NN o
to TO o
the DT o
cecal JJ o
intubation NN o
rate NN o
( ( N
96.9 CD N
% NN N
vs JJ N
98.5 CD N
% NN N
, , N
P NNP N
= NNP N
0.18 CD N
) ) N
, , N
the DT N
need NN o
for IN o
abdominal JJ o
pressure NN o
( ( N
71.7 CD N
% NN N
vs JJ N
73.4 CD N
% NN N
, , N
P NNP N
= NNP N
0.55 CD N
) ) N
and CC N
change NN o
of IN o
position NN o
( ( N
13.5 CD N
% NN N
vs JJ N
11.5 CD N
% NN N
, , N
P NNP N
= NNP N
0.37 CD N
) ) N
. . N

However RB N
, , N
the DT N
cecal JJ o
intubation NN o
time NN o
was VBD N
shorter RBR N
in IN N
the DT N
CF-240I NNP N
group NN N
( ( N
5.75 CD N
+/- JJ N
3.18 CD N
vs JJ N
6.26 CD N
+/- JJ N
3.30 CD N
min NN N
, , N
P NNP N
= NNP N
0.02 CD N
) ) N
. . N

Subgroup NNP N
analysis NN N
by IN N
sex NN N
, , N
age NN N
, , N
and CC N
body NN N
mass NN N
index NN N
showed VBD N
comparable JJ o
outcomes NNS o
between IN N
the DT N
two CD N
groups NNS N
except IN N
that IN N
the DT N
cecal JJ o
intubation NN o
times NNS o
were VBD N
significantly RB N
shorter JJR N
in IN N
the DT N
CF-240I NNP N
group NN N
when WRB N
only RB N
men NNS N
( ( N
4.78 CD N
+/- JJ N
2.57 CD N
vs JJ N
5.50 CD N
+/- JJ N
2.93 CD N
min NN N
, , N
P NNP N
< NNP N
0.01 CD N
) ) N
or CC N
those DT N
younger JJR N
than IN N
50 CD N
years NNS N
( ( N
5.50 CD N
+/- JJ N
2.90 CD N
vs JJ N
6.25 CD N
+/- JJ N
3.68 CD N
min NN N
, , N
P NNP N
= NNP N
0.02 CD N
) ) N
were VBD N
considered VBN N
. . N

CONCLUSION NNP N
Cecal NNP o
intubation NN o
time NN o
is VBZ N
shorter RBR N
in IN N
patients NNS N
examined VBN N
with IN N
an DT N
intermediate JJ i
length NN i
adult NN i
colonoscope NN i
, , N
mainly RB N
in IN N
the DT N
subgroups NNS N
of IN N
men NNS N
and CC N
those DT N
younger JJR N
than IN N
50 CD N
years NNS N
of IN N
age NN N
. . N

-DOCSTART- -22946606- O O

Working VBG N
well RB N
with IN N
a DT N
disability NN p
: : p
health NN i
promotion NN i
as IN N
a DT N
means NN N
to TO N
employment NN N
. . N

PURPOSE/OBJECTIVE VB N
The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
test VB N
the DT N
utility NN N
of IN N
the DT N
Working NNP i
Well NNP i
with IN i
a DT i
Disability NNP i
health-promotion NN i
program NN i
with IN N
vocational JJ i
rehabilitation NN i
( ( p
VR NNP p
) ) p
clients NNS p
. . p

Health-promotion NN i
interventions NNS i
have VBP N
been VBN N
shown VBN N
to TO N
reduce VB N
limitation NN N
from IN N
secondary JJ N
conditions NNS N
, , N
which WDT N
can MD N
be VB N
a DT N
significant JJ N
barrier NN N
to TO N
labor NN N
force NN N
participation NN N
among IN N
people NNS p
with IN p
disabilities NNS p
. . p

The DT N
state NN N
and CC N
federal JJ N
VR NNP N
system NN N
represents VBZ N
a DT N
potential JJ N
access NN N
point NN N
for IN N
delivery NN N
of IN N
health-promotion NN N
activities NNS N
. . N

RESEARCH NNP N
METHOD/DESIGN NNP N
A NNP p
total NN p
of IN p
297 CD p
VR NNP p
clients NNS p
participated VBD p
in IN p
a DT p
randomized JJ p
trial NN p
of IN N
the DT N
Working NNP i
Well NNP i
health NN i
promotion NN i
program NN i
. . i

Control NNP N
and CC N
intervention NN N
participants NNS N
provided VBD N
baseline NN N
and CC N
four CD N
waves NNS N
of IN N
quarterly JJ N
follow-up JJ N
data NNS N
. . N

Data NNS N
were VBD N
analyzed VBN N
with IN N
repeated-measures NNS N
ANOVA NNP N
. . N

RESULTS NNP N
Intervention-group JJ i
participants NNS N
who WP N
attended VBD N
over IN N
half NN N
of IN N
the DT N
Working NNP i
Well NNP i
sessions NNS N
reported VBD N
significantly RB N
lower JJR N
rates NNS o
of IN o
limitation NN o
from IN o
secondary JJ o
conditions NNS o
over IN N
the DT N
1-year JJ N
study NN N
span NN N
, , N
F NNP N
( ( N
1 CD N
, , N
124 CD N
) ) N
= NN N
4.11 CD N
, , N
p NN N
= NNP N
.004 NNP N
. . N

Control-group NN i
participants NNS N
also RB N
experienced VBD N
significantly RB N
lower JJR o
rates NNS o
of IN o
limitation NN o
, , N
but CC N
pre- JJ o
to TO o
postdifferences NNS o
were VBD N
less RBR N
dramatic JJ N
, , N
F NNP N
( ( N
1 CD N
, , N
308 CD N
) ) N
= NN N
4.19 CD N
, , N
p NN N
= NNP N
.006 NNP N
. . N

CONCLUSIONS/IMPLICATIONS NNP N
Overall NNP N
, , N
health NN N
data NNS N
indicated VBD N
that IN N
the DT N
Working NNP i
Well NNP i
program NN i
may MD N
be VB N
particularly RB N
helpful JJ o
to TO N
VR NNP p
clients NNS p
with IN p
higher JJR p
rates NNS p
of IN p
secondary JJ p
health NN p
conditions NNS p
and CC N
may MD N
represent VB N
one CD N
strategy NN N
for IN N
overcoming VBG o
barriers NNS o
to TO o
employment NN o
. . o

-DOCSTART- -14656280- O O

Intraperitoneal NNP i
cisplatin NN i
versus NN N
no DT N
further JJ N
treatment NN N
: : N
8-year JJ N
results NNS N
of IN N
EORTC NNP N
55875 CD N
, , N
a DT N
randomized JJ N
phase NN N
III NNP N
study NN N
in IN N
ovarian JJ p
cancer NN p
patients NNS p
with IN p
a DT p
pathologically RB p
complete JJ p
remission NN p
after IN p
platinum-based JJ i
intravenous JJ i
chemotherapy NN i
. . i

First-line NNP i
intravenous JJ i
chemotherapy NN i
( ( N
CT NNP N
) ) N
following VBG N
debulking VBG N
surgery NN N
is VBZ N
associated VBN N
with IN N
prolonged JJ o
survival NN o
, , N
in IN N
particular JJ N
in IN N
patients NNS p
who WP p
achieve VBP p
a DT p
pathological JJ p
complete JJ p
remission NN p
( ( p
pCR NN p
) ) p
at IN p
second-look NN p
surgery NN p
but CC p
in IN p
whom WP p
a DT p
high JJ p
rate NN p
of IN p
relapses NNS p
still RB p
occurs VBZ p
. . p

Between JJ p
1988 CD p
and CC p
1997 CD p
, , p
153 CD p
patients NNS p
in IN p
pCR JJ p
following VBG p
platinum-based JJ i
intravenous JJ i
CT NNP i
were VBD N
randomized VBN N
between IN N
four CD i
courses NNS i
of IN i
intraperitoneal NN i
cisplatin NN i
( ( i
P NNP i
) ) i
( ( i
90 CD i
mg/m2 NN i
every DT i
3 CD i
weeks NNS i
) ) i
or CC i
observation NN i
. . i

Overall JJ o
survival NN o
( ( o
OS NNP o
) ) o
was VBD N
the DT N
primary JJ N
endpoint NN N
, , N
while IN N
progression-free JJ N
survival NN N
( ( N
PFS NNP N
) ) N
was VBD N
a DT N
secondary JJ N
endpoint NN N
. . N

This DT N
intent-to-treat JJ N
analysis NN N
includes VBZ p
16 CD p
patients NNS p
who WP p
were VBD p
not RB p
eligible JJ p
and CC p
17 CD p
patients NNS p
who WP p
had VBD p
protocol NN p
violations NNS p
. . p

The DT N
two CD p
groups NNS p
were VBD p
well RB p
balanced VBN p
in IN p
terms NNS p
of IN p
age NN p
( ( p
median JJ p
= VBZ p
55 CD p
years NNS p
) ) p
, , p
performance NN p
status NN p
( ( p
78 CD p
% NN p
P.S NNP p
. . p

O NNP p
) ) p
, , p
FIGO NNP p
stage NN p
( ( p
96 CD p
% NN p
stage NN p
III NNP p
) ) p
, , p
histology NN p
( ( p
serous JJ p
in IN p
66 CD p
% NN p
) ) p
, , p
grade VBD p
( ( p
2 CD p
or CC p
3 CD p
in IN p
80 CD p
% NN p
) ) p
, , p
and CC p
residuum NN p
before RB p
intravenous JJ p
CT NNP p
( ( p
> $ p
1 CD p
cm NN p
in IN p
40 CD p
% NN p
) ) p
. . p

Intraperitoneal NNP i
CT NNP i
was VBD N
delivered VBN N
mainly RB N
through IN N
intraperitoneal JJ N
catheters NNS N
( ( N
Port-a-Cath JJ N
61 CD N
% NN N
and CC N
Tenckhoff NNP N
25 CD N
% NN N
) ) N
. . N

Side JJ N
effects NNS N
of IN N
intraperitoneal NN i
cisplatin NN i
included VBD N
vomiting VBG o
[ NNP N
> NNP N
or CC N
=grade VB N
2 CD N
( ( N
82 CD N
% NN N
) ) N
] NN N
, , N
rise NN o
in IN o
serum JJ o
creatinine NN o
[ NNP N
> NNP N
or CC N
=grade VB N
2 CD N
( ( N
14 CD N
% NN N
) ) N
] NN N
, , N
abdominal JJ o
pain NN o
[ JJ N
grade NN N
1-2 JJ N
( ( N
38 CD N
% NN N
) ) N
] NN N
, , N
and CC N
neurotoxicity NN o
[ NNP N
grade VBD N
2-3 CD N
( ( N
15 CD N
% NN N
) ) N
] NN N
. . N

After IN N
a DT N
median JJ N
follow-up NN N
of IN N
8 CD N
years NNS N
, , N
80 CD N
patients NNS N
( ( N
52 CD N
% NN N
) ) N
have VBP N
progressed VBN N
with IN N
no DT N
difference NN N
in IN N
the DT N
pattern NN o
of IN o
relapse NN o
between IN N
the DT N
two CD N
groups NNS N
and CC N
75 CD N
patients NNS N
( ( N
49 CD N
% NN N
) ) N
have VBP N
died VBN o
; : o
the DT N
respective JJ N
hazard NN N
ratios NNS N
for IN N
PFS NNP N
and CC N
OS NNP N
with IN N
95 CD N
% NN N
CI NNP N
are VBP N
0.89 CD N
( ( N
0.59-1.33 NN N
) ) N
and CC N
0.82 CD N
( ( N
0.52-1.29 NN N
) ) N
. . N

These DT N
results NNS N
are VBP N
suggestive JJ N
of IN N
a DT N
treatment NN N
benefit NN N
but CC N
do VBP N
not RB N
support VB N
a DT N
change NN N
in IN N
clinical JJ N
practice NN N
. . N

Other JJ N
randomized JJ N
clinical JJ N
trials NNS N
of IN N
intraperitoneal JJ i
CT NNP i
are VBP N
reviewed VBN N
and CC N
briefly NN N
discussed VBN N
. . N

-DOCSTART- -6410450- O O

Absence NN N
of IN N
central JJ o
effects NNS o
in IN p
man NN p
of IN N
the DT N
benzodiazepine JJ i
antagonist NN N
Ro NNP i
15-1788 JJ i
. . i

The DT N
benzodiazepines NNS N
are VBP N
typified VBN N
by IN N
a DT N
profile NN N
of IN N
side NN N
effects NNS N
which WDT N
includes VBZ N
drowsiness NN o
, , o
ataxia NN o
and CC o
incoordination NN o
. . o

Ro NNP i
15-1788 JJ i
, , N
an DT N
imidazodiazepine JJ N
derivative NN N
, , N
exhibits VBZ N
marked JJ N
antagonism NN N
of IN N
the DT N
behavioural JJ N
and CC N
biochemical JJ N
effects NNS N
of IN N
the DT N
benzodiazepines NNS N
in IN N
animals NNS p
and CC p
man NN p
. . p

It PRP N
is VBZ N
devoid JJ N
of IN N
any DT N
behavioural JJ N
activity NN N
in IN N
animals NNS p
, , N
except IN N
at IN N
very RB N
high JJ N
doses NNS N
. . N

In IN N
the DT N
present JJ N
study NN N
the DT N
effects NNS N
of IN N
single JJ N
rising VBG N
oral JJ N
doses NNS N
of IN N
Ro NNP i
15-1788 JJ i
on IN N
cognitive NN o
, , o
psychomotor NN o
and CC o
subjective JJ o
function NN o
in IN p
man NN p
have VBP N
been VBN N
assessed VBN N
using VBG N
a DT N
battery NN N
of IN N
psychometric JJ o
tests NNS o
designed VBN N
to TO N
identify VB N
the DT N
sedative JJ o
action NN o
of IN N
the DT N
benzodiazepines NNS N
. . N

At IN N
all DT N
doses VBZ N
up RP N
to TO N
600 CD N
mg NNS N
, , N
Ro NNP N
15-1788 CD N
demonstrated VBD N
none NN N
of IN N
the DT N
classical JJ N
behavioural JJ o
effects NNS o
of IN N
the DT N
benzodiazepines NNS N
. . N

-DOCSTART- -21120480- O O

A DT N
two-part JJ N
phase NN N
II NNP N
study NN N
of IN N
cediranib NN i
in IN N
patients NNS p
with IN p
advanced JJ p
solid JJ p
tumours NN p
: : p
the DT N
effect NN N
of IN N
food NN N
on IN N
single-dose JJ N
pharmacokinetics NNS N
and CC N
an DT N
evaluation NN N
of IN N
safety NN o
, , o
efficacy NN o
and CC o
imaging VBG o
pharmacodynamics NNS o
. . o

BACKGROUND NNP N
Cediranib NNP i
( ( i
RECENTIN? NNP i
) ) i
is VBZ i
an DT N
oral JJ N
, , N
highly RB N
potent JJ i
VEGF NNP i
inhibitor NN i
. . i

This DT N
study NN N
evaluated VBD N
the DT N
effect NN N
of IN N
food NN N
on IN N
the DT N
pharmacokinetics NNS N
of IN N
cediranib NN i
and CC i
compared VBN N
the DT N
administration NN N
of IN N
continual JJ i
cediranib NN i
via IN i
two CD N
dosing VBG N
strategies NNS N
using VBG N
this DT N
as IN N
a DT N
platform NN N
to TO N
investigate VB N
pharmacodynamic JJ N
imaging NN N
biomarkers NNS N
. . N

METHODS NNP p
Sixty NNP p
patients NNS p
were VBD p
randomised VBN N
to TO N
receive VB N
two CD N
single JJ N
doses NNS N
of IN N
cediranib NN i
in IN i
either CC i
fed/fasted VBD i
or CC i
fasted/fed JJ i
state NN i
( ( i
Part NNP N
A NNP N
) ) N
. . N

In IN N
continual JJ N
dosage NN N
phase NN N
( ( N
Part NNP N
B NNP N
) ) N
, , N
patients NNS N
were VBD N
randomised VBN N
to TO N
a DT N
fixed-dose JJ N
or CC N
dose-escalation JJ N
arm NN o
. . o

Exploratory JJ o
pharmacodynamic JJ o
assessments NNS o
were VBD o
performed VBN N
using VBG i
DCE-MRI NNP i
and CC i
CT NNP i
enhancing VBG i
fraction NN i
( ( i
EnF NNP N
) ) N
. . N

RESULTS VBN N
In IN N
part NN N
A NNP N
, , N
plasma NN o
AUC NNP o
and CC o
C NNP o
( ( o
max NN o
) ) o
of IN o
cediranib NN o
were VBD o
lower JJR N
in IN N
the DT N
presence NN N
of IN N
food NN N
by IN N
a DT N
mean NN N
of IN N
24 CD N
and CC N
33 CD N
% NN N
, , N
respectively RB N
( ( N
94 CD N
% NN N
CI NNP N
: : N
AUC NNP N
, , N
12-34 CD N
% NN N
and CC N
C NNP N
( ( N
max NN N
) ) N
, , N
20-43 JJ N
% NN N
) ) N
, , N
indicating VBG N
food NN N
reduces NNS o
cediranib VBP o
plasma JJ o
exposure NN o
. . o

In IN N
part NN N
B NNP N
, , N
cediranib VBZ i
30 CD i
mg/day NN N
appeared VBD N
to TO N
be VB N
the DT N
most RBS N
sustainable JJ N
for IN N
chronic JJ N
dosing NN i
. . i

Continuous JJ i
cediranib NN i
therapy NN i
was VBD i
associated VBN N
with IN o
sustained JJ o
antivascular JJ o
effects NNS o
up RB o
to TO N
16 CD N
weeks NNS N
, , N
with IN N
significant JJ N
reductions NNS o
in IN o
DCE-MRI NNP o
parameters NNS o
and CC o
CT NNP o
EnF NNP o
. . N

CONCLUSIONS VB N
It PRP N
is VBZ N
recommended VBN N
that IN N
cediranib NN i
be VB i
administered VBN N
at IN N
least JJS N
1 CD N
h NN N
before IN N
or CC N
2 CD N
h NN N
after IN N
food NN N
. . N

Evidence NN o
of IN o
antitumour JJ o
activity NN o
was VBD o
observed VBN o
, , N
with IN N
significant JJ N
sustained JJ N
effects NNS o
upon IN o
imaging VBG o
vascular JJ o
parameters NNS o
. . o

-DOCSTART- -26467901- O O

Assessment NN N
of IN N
bone NN i
marrow-derived JJ i
Cellular NNP i
Therapy NNP i
in IN N
progressive JJ p
Multiple JJ p
Sclerosis NNP p
( ( N
ACTiMuS NNP N
) ) N
: : N
study NN N
protocol NN N
for IN N
a DT N
randomised JJ N
controlled VBN N
trial NN N
. . N

BACKGROUND IN N
We PRP N
have VBP N
recently RB N
completed VBN N
an DT N
evaluation NN N
of IN N
the DT N
safety NN o
and CC N
feasibility NN o
of IN N
intravenous JJ N
delivery NN i
of IN i
autologous JJ i
bone NN i
marrow NN i
in IN N
patients NNS p
with IN p
progressive JJ p
multiple JJ p
sclerosis NN p
( ( p
MS NNP p
) ) p
. . p

The DT N
possibility NN N
of IN N
repair NN N
was VBD N
suggested VBN N
by IN N
improvement NN N
in IN N
the DT N
neurophysiological JJ N
secondary JJ N
outcome NN N
measure NN N
seen VBN N
in IN N
all DT N
participants NNS N
. . N

The DT N
current JJ N
study NN N
will MD N
examine VB N
the DT N
efficacy NN o
of IN N
intravenous JJ i
delivery NN i
of IN i
autologous JJ i
marrow NN i
in IN N
progressive JJ N
MS NNP N
. . N

Laboratory NNP N
studies NNS N
performed VBN N
in IN N
parallel NN N
with IN N
the DT N
clinical JJ N
trial NN N
will MD N
further RBR N
investigate VB N
the DT N
biology NN N
of IN N
bone NN i
marrow-derived JJ i
stem NN i
cell NN i
infusion NN i
in IN N
MS NNP N
, , N
including VBG N
mechanisms NNS N
underlying VBG N
repair NN N
. . N

METHODS/DESIGN CC N
A DT N
prospective JJ N
, , N
randomised JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ i
, , N
stepped VBD N
wedge NN N
design NN N
will MD N
be VB N
employed VBN N
at IN N
a DT p
single JJ p
centre NN p
( ( p
Bristol NNP p
, , p
UK NNP p
) ) p
. . p

Eighty JJ p
patients NNS p
with IN p
progressive JJ p
MS NNP p
will MD p
be VB p
recruited VBN p
; : p
60 CD p
will MD p
have VB p
secondary JJ p
progressive JJ p
disease NN p
( ( p
SPMS NNP p
) ) p
but CC p
a DT p
subset NN p
( ( p
n JJ p
= NNP p
20 CD p
) ) p
will MD p
have VB p
primary JJ p
progressive JJ p
disease NN p
( ( p
PPMS NNP p
) ) p
. . p

Participants NNS N
will MD N
be VB N
randomised VBN N
to TO N
either DT N
early JJ N
or CC N
late JJ N
( ( N
1 CD N
year NN N
) ) N
intravenous JJ i
infusion NN i
of IN i
autologous JJ i
, , i
unfractionated JJ i
bone NN i
marrow NN i
. . i

The DT N
placebo NN i
intervention NN i
is VBZ N
infusion NN i
of IN i
autologous JJ i
blood NN i
. . i

The DT N
primary JJ N
outcome JJ N
measure NN N
is VBZ N
global JJ o
evoked JJ o
potential JJ o
derived VBN o
from IN o
multimodal NN o
evoked VBN o
potentials NNS o
. . o

Secondary JJ N
outcome NN N
measures NNS N
include VBP N
adverse JJ o
event NN o
reporting NN o
, , o
clinical JJ o
( ( o
EDSS NNP o
and CC o
MSFC NNP o
) ) o
and CC o
self-assessment JJ o
( ( o
MSIS-29 NNP o
) ) o
rating NN o
scales NNS o
, , o
optical JJ o
coherence NN o
tomography NN o
( ( o
OCT NNP o
) ) o
as RB o
well RB o
as IN o
brain NN o
and CC o
spine JJ o
MRI NNP o
. . o

Participants NNS N
will MD N
be VB N
followed VBN N
up RP N
for IN N
a DT N
further JJ N
year NN N
following VBG N
the DT N
final JJ N
intervention NN N
. . N

Outcomes CC N
will MD N
be VB N
analysed VBN N
on IN N
an DT N
intention-to-treat JJ N
basis NN N
. . N

DISCUSSION NNP N
Assessment NNP N
of IN N
bone NN i
marrow-derived JJ i
Cellular NNP i
Therapy NNP i
in IN N
progressive JJ N
Multiple JJ N
Sclerosis NNP N
( ( N
ACTiMuS NNP N
) ) N
is VBZ N
the DT N
first JJ N
randomised VBN N
, , N
placebo-controlled JJ N
trial NN N
of IN N
non-myeloablative JJ i
autologous JJ i
bone NN i
marrow-derived JJ i
stem NN i
cell NN i
therapy NN i
in IN N
MS NNP N
. . N

It PRP N
will MD N
determine VB N
whether IN N
bone NN i
marrow NN i
cell NN i
therapy NN i
can MD N
, , N
as IN N
was VBD N
suggested VBN N
by IN N
the DT N
phase NN N
I PRP N
safety NN N
study NN N
, , N
improve VB N
conduction NN N
in IN N
multiple JJ N
central JJ N
nervous JJ N
system NN N
pathways NNS N
affected VBN N
in IN N
progressive JJ p
MS NNP p
. . p

Furthermore NNP N
, , N
laboratory NN N
studies NNS N
performed VBN N
in IN N
parallel NN N
with IN N
the DT N
clinical JJ N
trial NN N
will MD N
inform VB N
our PRP$ N
understanding NN N
of IN N
the DT N
cellular JJ N
pharmacodynamics NNS N
of IN N
bone NN N
marrow NN N
infusion NN N
in IN N
MS NNP p
patients NNS p
and CC N
the DT N
mechanisms NNS N
underlying VBG N
cell NN i
therapy NN i
. . i

TRIAL NNP N
REGISTRATION NNP N
ISRCTN27232902 NNP N
Registration NNP N
date NN N
11/09/2012 CD N
. . N

NCT01815632 NNP N
Registration NNP N
date NN N
19/03/2013 CD N
. . N

-DOCSTART- -22527308- O O

Successful JJ N
treatment NN N
of IN N
blepharitis NN p
with IN N
bibrocathol NN i
( ( i
Posiformin? NNP i
2 CD i
% NN i
) ) i
. . i

BACKGROUND NNP i
Bibrocathol NNP i
is VBZ N
a DT N
well-established JJ i
antiseptic JJ i
drug NN i
for IN N
the DT N
treatment NN N
of IN p
acute NN p
eyelid JJ p
diseases NNS p
like IN p
blepharitis NN p
. . p

Despite IN N
its PRP$ N
frequent JJ N
use NN N
in IN N
clinical JJ N
practice NN N
, , N
no DT N
controlled JJ N
clinical JJ N
trial NN N
on IN N
the DT o
efficacy NN o
of IN i
bibrocathol $ i
2 CD i
% NN i
eye NN N
ointment NN N
has VBZ N
been VBN N
performed VBN N
until IN N
now RB N
. . N

The DT N
aim NN N
of IN N
the DT N
study NN N
was VBD N
to TO N
investigate VB o
efficacy NN o
, , o
safety NN o
and CC o
tolerability NN o
of IN i
bibrocathol NN i
( ( i
Posiformin? NNP i
2 CD i
% NN N
) ) N
eye NN N
ointment NN N
in IN N
patients NNS p
diagnosed VBN p
with IN p
blepharitis NN p
. . p

METHODS NNP p
In IN N
this DT p
multi-center NN p
, , p
randomized VBN p
, , N
double-masked JJ i
, , i
placebo-controlled JJ i
parallel-group NN i
comparison NN N
, , N
the DT N
change NN N
of IN N
signs NNS N
and CC N
symptoms NNS N
( ( N
sum VB N
score NN N
) ) N
of IN N
blepharitis NN N
in IN N
197 CD p
patients NNS p
( ( p
ITT NNP p
( ( p
intention-to-treat-group JJ p
) ) p
; : p
mean JJ p
age NN p
56 CD p
? . p
18 CD p
years NNS p
, , p
56 CD p
% NN p
female NN p
, , p
active JJ p
drug NN p
: : p
vehicle NN p
= IN p
97:100 CD p
) ) p
over IN p
2 CD p
weeks NNS p
treatment NN N
with IN N
bibrocathol JJ i
2 CD i
% NN i
eye NN i
ointment NN i
was VBD i
evaluated VBN N
. . N

RESULTS JJ N
Patients NNPS N
receiving VBG i
bibrocathol RB i
2 CD i
% NN i
showed VBD o
greater JJR o
improvement NN o
in IN o
the DT o
sum NN o
score NN o
than IN N
the DT i
placebo NN i
patients NNS N
( ( N
p JJ N
< NN N
0.0001 CD N
, , N
Cohen NNP N
's POS N
effect NN N
size NN N
d NN N
= NNP N
0.73 CD N
) ) N
. . N

Also RB N
, , N
the DT N
results NNS N
from IN N
further JJ N
efficacy NN o
assessments NNS o
improvement NN N
of IN o
single JJ o
symptoms NNS o
and CC o
ocular JJ o
discomfort NN o
measured VBN o
by IN N
a DT N
VAS NNP o
( ( o
visual JJ o
analogue NN o
scale NN o
) ) o
supported VBD N
treatment NN N
with IN N
bibrocathol NN i
. . i

Patients NNS i
and CC N
investigators NNS N
provided VBD o
favorable JJ o
tolerability NN o
ratings NNS o
preferring VBG o
bibrocathol NN i
over IN i
placebo NN i
. . N

No DT o
safety NN o
issues NNS o
were VBD o
observed VBN o
with IN N
regard NN N
to TO o
intraocular JJ o
pressure NN o
, , o
visual JJ o
acuity NN o
, , o
or CC o
occurrence NN o
of IN o
adverse JJ o
events NNS o
. . o

CONCLUSIONS NNP o
Blepharitis NNP N
therapy NN N
with IN N
the DT i
antiseptic JJ i
bibrocathol NN i
2 CD i
% NN i
in IN i
this DT i
trial NN N
was VBD N
highly RB N
efficacious JJ N
and CC N
safe JJ N
. . N

-DOCSTART- -1788685- O O

[ JJ N
Effects NNS N
of IN N
hetero-thermal JJ i
water NN i
administration NN i
on IN N
leg JJ o
vein NN o
hemodynamics NNS o
, , o
skin JJ o
microcirculation NN o
and CC o
O2 NNP o
tension NN o
in IN N
chronic JJ p
venous JJ p
insufficiency NN p
] NNP p
. . N

-DOCSTART- -1486965- O O

Salmeterol NNP i
versus VBZ N
slow-release JJ N
theophylline NN i
combined VBN N
with IN N
ketotifen NN i
in IN N
nocturnal JJ p
asthma NN p
: : p
a DT N
multicentre JJ p
trial NN N
. . N

French JJ p
Multicentre NNP p
Study NNP p
Group NNP p
. . p

We PRP N
wished VBD N
to TO N
assess VB N
the DT N
efficacy NN o
of IN N
inhaled JJ N
salmeterol NN i
( ( N
SML NNP N
; : N
50 CD N
micrograms NNS N
b.i.d RB N
. . N

) ) N
compared VBN N
to TO N
a DT N
combination NN N
of IN N
slow-release JJ N
theophylline NN i
and CC i
ketotifen NN i
p.o NN N
. . N

( ( N
TK NNP N
; : N
T NNP N
300 CD N
mg+K NN N
1 CD N
mg NN N
b.i.d NN N
. . N

) ) N
for IN N
the DT N
treatment NN N
of IN N
nocturnal JJ N
asthma NN N
. . N

Ninety NNP p
six CD p
patients NNS p
with IN p
nocturnal JJ p
asthma NN p
, , p
( ( p
forced JJ p
expiratory NN p
volume NN p
in IN p
one CD p
second NN p
( ( p
FEV1 NNP p
) ) p
60-90 CD p
% NN p
of IN p
predicted JJ p
value NN p
, , p
reversibility NN p
> NN p
or CC p
= VB p
15 CD p
% NN p
, , p
at IN p
least JJS p
two CD p
nocturnal JJ p
awakenings NNS p
per IN p
week NN p
) ) p
were VBD N
eligible JJ N
for IN N
a DT N
multicentre NN p
, , N
double-blind JJ N
, , N
double-dummy JJ N
cross-over NN N
study NN N
( ( N
14-day JJ N
run-in NN N
, , N
two CD N
successive JJ N
28-day JJ N
treatment NN N
periods NNS N
) ) N
. . N

Efficacy NN o
was VBD o
assessed VBN o
as IN o
success/failure NN o
, , o
success NN o
being VBG N
defined VBN N
as IN N
the DT N
complete JJ N
disappearance NN N
of IN N
nocturnal JJ N
symptoms/awakening NN N
during IN N
the DT N
last JJ N
week NN N
of IN N
each DT N
treatment NN N
period NN N
. . N

There EX N
was VBD N
a DT N
statistically RB o
significant JJ o
difference NN o
between IN N
SML NNP N
and CC N
TK NNP N
for IN N
this DT N
criterion NN N
: : N
46 CD N
% NN N
and CC N
39 CD N
% NN N
success NN N
with IN N
SML NNP N
during IN N
periods NNS N
I PRP N
( ( N
first JJ N
28-day JJ N
period NN N
) ) N
and CC N
II NNP N
( ( N
following VBG N
the DT N
cross-over NN N
) ) N
, , N
compared VBN N
to TO N
only RB N
15 CD N
% NN N
and CC N
26 CD N
% NN N
with IN N
TK NNP N
, , N
respectively RB N
( ( N
p JJ N
< NNP N
0.01 CD N
) ) N
. . N

SML NNP N
was VBD N
also RB N
significantly RB N
better RBR N
for IN N
the DT N
other JJ o
criteria NNS o
( ( o
lung NN o
function NN o
, , o
rescue NN o
salbutamol NNS o
intake VBP o
during IN o
day NN o
and CC o
night NN o
) ) o
. . o

Side-effects NNS o
were VBD N
five CD N
times NNS N
less RBR N
frequent JJ N
in IN N
SML-treated JJ N
patients NNS N
( ( N
p JJ N
< NNP N
0.004 CD N
) ) N
. . N

Efficacy NN o
and CC o
tolerance NN o
of IN N
SML NNP N
were VBD N
obviously RB N
far RB N
better JJR N
than IN N
those DT N
of IN N
TK NNP N
in IN N
patients NNS p
with IN p
nocturnal JJ p
asthma NN p
. . p

-DOCSTART- -8600885- O O

Around-the-clock NNP N
intraocular JJ o
pressure NN o
reduction NN o
with IN N
once-daily JJ N
application NN N
of IN N
latanoprost NN i
by IN N
itself PRP N
or CC N
in IN N
combination NN i
with IN i
timolol NN i
. . i

OBJECTIVE UH N
To TO N
determine VB N
whether IN N
once-daily RB N
, , N
in IN N
the DT N
morning NN N
, , N
topical JJ N
application NN N
of IN N
the DT N
new JJ N
ocular JJ N
hypotensive JJ N
prostaglandin NN N
analogue NN N
, , N
latanoprost NN i
, , N
yields NNS N
nocturnal JJ o
intraocular JJ o
pressure NN o
( ( o
IOP NNP o
) ) o
reduction NN o
similar JJ N
to TO N
its PRP$ N
diurnal JJ N
IOP NNP N
reducing VBG N
efficacy NN N
. . N

STUDY NNP N
DESIGN NNP N
AND NNP N
PATIENTS NNP N
Placebo- NNP N
controlled VBD N
, , N
randomized VBN N
, , N
and CC N
double-masked JJ N
study NN N
on IN N
hospitalized JJ p
patients NNS p
with IN p
ocular JJ p
hypertension NN p
or CC p
glaucoma NN p
. . p

Patients NNS p
in IN p
group NN p
1 CD p
( ( p
n=9 NN p
) ) p
were VBD N
maintained VBN N
on IN N
twice-daily JJ N
applications NNS N
of IN N
0.5 CD i
% NN i
timolol JJ i
maleate NN i
. . i

Patients NNS p
in IN p
group NN p
2 CD p
( ( p
n=10 NN p
) ) p
terminated VBD N
their PRP$ N
timolol NN i
treatment NN i
3 CD i
weeks NNS i
before IN i
the DT i
beginning NN i
of IN i
the DT i
study NN i
. . i

In IN N
both DT N
groups NNS N
the DT N
test NN N
drug NN N
( ( N
0.005 CD N
% NN N
latanoprost NN i
) ) i
and CC N
its PRP$ N
vehicle NN N
( ( i
placebo NN i
) ) i
was VBD N
applied VBN N
by IN N
hospital JJ N
staff NN N
every DT N
morning NN N
for IN N
9 CD N
days NNS N
. . N

MEASUREMENTS NNS N
After IN N
4 CD N
days NNS N
of IN N
ambulatory JJ N
treatment NN N
, , N
patients NNS N
were VBD N
hospitalized VBN N
, , N
and CC N
IOP NNP o
values NNS o
were VBD N
obtained VBN N
in IN N
the DT N
supine NN N
and CC N
sitting VBG N
positions NNS N
with IN N
a DT N
handheld NN N
electronic JJ N
tonometer NN N
( ( N
Tono-Pen NNP N
XL NNP N
, , N
Bio-Rad NNP N
, , N
Glendale NNP N
, , N
Calif NNP N
) ) N
and CC N
a DT N
Goldmann NNP N
's POS N
applanation NN N
tonometer NN N
, , N
covering VBG N
every DT N
2-hour CD N
interval NN N
, , N
around IN N
the DT N
clock NN N
, , N
but CC N
not RB N
more JJR N
than IN N
at IN N
four CD N
time NN N
points NNS N
per IN N
day NN N
during IN N
a DT N
5-day JJ N
period NN N
. . N

RESULTS VB N
The DT N
mean JJ o
nocturnal JJ o
IOPs NNP o
( ( o
Goldmann NNP o
's POS o
applanation NN o
tonometer NN o
) ) o
collected VBD N
for IN N
5 CD N
days NNS N
were VBD N
mean JJ N
+/-SEM JJ N
17.9+/-0.6 JJ N
vs NN N
20.2+/-0.6 JJ N
mm NN N
Hg NNP N
and CC N
16.8+/-0.3 JJ N
vs NN N
20.6+/-0.5 JJ N
mm NN N
Hg NNP N
for IN N
the DT N
study NN N
vs IN N
the DT N
control NN N
eyes NNS N
in IN N
group NN N
1 CD N
and CC N
group NN N
2 CD N
, , N
respectively RB N
. . N

These DT N
nocturnal JJ o
IOP NNP o
reductions NNS o
were VBD N
statistically RB N
significant JJ N
( ( N
P NNP N
< NNP N
.001 NNP N
, , N
two-tailed JJ N
paired VBD N
Student NNP N
's POS N
t JJ N
test NN N
) ) N
. . N

The DT N
differences NNS N
between IN N
diurnal JJ o
and CC o
nocturnal JJ o
IOP NNP o
reductions NNS o
( ( N
handheld JJ N
electronic JJ N
or CC N
Goldmann NNP N
's POS N
applanation NN N
tonometer NN N
) ) N
were VBD N
minimal JJ N
( ( N
> JJ N
0.3 CD N
mm NN N
Hg NNP N
) ) N
and CC N
statistically RB N
not RB N
significant JJ N
( ( N
P NNP N
> NNP N
.31 NNP N
, , N
two-tailed JJ N
paired VBD N
Student NNP N
's POS N
t JJ N
test NN N
) ) N
. . N

CONCLUSION NNP N
Once-daily JJ N
latanoprost NN i
treatment NN N
provides VBZ N
uniform JJ N
circadian JJ N
( ( N
around-the-clock NN N
) ) N
IOP NNP o
reduction NN o
by IN N
itself PRP N
, , N
or CC N
in IN N
combination NN N
with IN N
timolol NN i
. . i

-DOCSTART- -11876712- O O

Effectiveness NN N
of IN N
two CD N
quadruple NNS N
, , N
tetracycline- JJ i
or CC N
clarithromycin-containing JJ i
, , N
second-line JJ N
, , N
Helicobacter NNP o
pylori VBP o
eradication NN o
therapies NNS o
. . o

BACKGROUND IN N
There EX N
are VBP N
no DT N
guidelines NNS N
on IN N
second-line JJ N
therapies NNS N
for IN N
Helicobacter NNP N
pylori FW N
eradication NN N
failures NNS N
of IN N
omeprazole-clarithromycin-amoxicillin JJ N
triple JJ N
therapy NN N
. . N

AIM NNP N
To TO N
compare VB N
the DT N
efficacy NN N
of IN N
two CD N
second-line JJ N
therapies NNS N
for IN N
persistent JJ N
H. NNP N
pylori NN N
infection NN N
. . N

METHODS NNP N
Over IN N
a DT N
6-year JJ p
period NN p
, , p
patients NNS p
with IN p
persistent JJ p
H. NNP p
pylori FW p
infection NN p
following VBG p
omeprazole-clarithromycin-amoxicillin JJ i
eradication NN p
therapy NN p
were VBD N
randomized VBN N
to TO N
receive VB N
omeprazole NN i
, , i
20 CD i
mg NN i
twice RB i
daily RB i
, , i
bismuth NN i
, , i
120 CD i
mg NN i
four CD i
times NNS i
daily RB i
, , i
metronidazole NN i
, , i
500 CD i
mg NN i
twice RB i
daily RB i
, , i
and CC i
either DT i
tetracycline NN i
, , i
500 CD i
mg NN i
four CD i
times NNS i
daily RB i
, , i
or CC i
clarithromycin NN i
, , i
500 CD i
mg NN i
twice RB i
daily RB i
, , N
given VBN N
for IN N
7 CD N
days NNS N
. . N

Before IN N
therapy NN N
, , N
patients NNS N
underwent JJ N
endoscopy NN N
with IN N
biopsies NNS N
for IN N
histology NN N
, , N
culture NN N
and CC N
antibiotic JJ N
susceptibility NN N
tests NNS N
. . N

H. NNP N
pylori JJ N
infection NN N
was VBD N
confirmed VBN N
by IN N
histology NN N
. . N

RESULTS NNP N
Of IN N
the DT N
95 CD p
randomized JJ p
patients NNS p
, , p
88 CD p
( ( p
93 CD p
% NN p
) ) p
completed VBD p
the DT p
study NN p
. . p

Age NNP N
, , N
sex NN N
, , N
smoking NN N
, , N
ulcer/non-ulcer JJ N
dyspepsia NN N
ratio NN N
and CC N
antibiotic JJ N
resistance NN N
were VBD N
not RB N
significantly RB N
different JJ N
between IN N
the DT N
treatment NN N
groups NNS N
. . N

On IN N
intention-to-treat JJ N
analysis NN N
, , N
eradication NN o
was VBD N
achieved VBN N
in IN N
41 CD N
of IN N
the DT N
49 CD N
patients NNS N
( ( N
84 CD N
% NN N
; : N
95 CD N
% NN N
confidence NN N
interval NN N
, , N
70.4-92.7 CD N
% NN N
) ) N
and CC N
27 CD N
of IN N
the DT N
46 CD N
patients NNS N
( ( N
59 CD N
% NN N
; : N
95 CD N
% NN N
confidence NN N
interval NN N
, , N
43.3-73.0 CD N
% NN N
) ) N
of IN N
the DT N
tetracycline- JJ N
and CC N
clarithromycin-containing JJ N
groups NNS N
, , N
respectively RB N
( ( N
P=0.007 NNP N
) ) N
. . N

On IN N
multivariate JJ N
regression NN N
analysis NN N
, , N
the DT N
sensitivity NN o
of IN o
H. NNP o
pylori FW o
to TO o
metronidazole VB o
had VBD N
a DT N
likelihood NN N
ratio NN N
of IN N
5.2 CD N
( ( N
P=0.022 NNP N
) ) N
, , N
followed VBN N
by IN N
the DT N
type NN N
of IN N
quadruple JJ N
therapy NN N
( ( N
likelihood JJ N
ratio NN N
, , N
4.4 CD N
; : N
P=0.036 NNP N
) ) N
. . N

CONCLUSIONS NNP N
Tetracycline-containing JJ o
quadruple NN o
rescue NN o
therapy NN o
is VBZ N
highly RB N
effective JJ N
in IN N
treating VBG N
H. NNP N
pylori JJ N
eradication NN N
failures NNS N
of IN N
the DT N
omeprazole-amoxicillin-clarithromycin JJ N
regimen NNS N
. . N

-DOCSTART- -8655422- O O

Feedlot NNP N
performance NN N
and CC N
carcass NN N
characteristics NNS N
of IN N
Holstein NNP p
steers NNS p
as IN N
affected VBN N
by IN N
source NN N
of IN N
dietary JJ N
protein NN N
and CC N
level NN N
of IN N
ruminally RB N
protected VBN N
lysine NN N
and CC N
methionine NN N
. . N

The DT N
objective NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
determine VB N
the DT N
effects NNS o
of IN N
source NN N
of IN N
dietary JJ N
CP NNP N
and CC N
level NN N
of IN N
ruminally RB N
protected VBN N
lysine NN N
and CC N
methionine NN N
( ( N
RPLM NNP N
) ) N
on IN N
feedlot NN o
performance NN o
and CC o
carcass NN o
characteristics NNS o
of IN N
Holstein NNP p
steers NNS p
during IN N
a DT N
growing-finishing JJ N
trial NN N
( ( N
266 CD N
d NN N
) ) N
. . N

A DT N
total NN N
of IN N
168 CD p
Holstein NNP p
steers NNS p
( ( p
182.7 CD p
+/- JJ p
27.5 CD p
kg NN p
) ) p
were VBD N
used VBN N
in IN N
a DT N
completely RB N
randomized JJ N
design NN N
experiment NN N
( ( N
eight CD N
treatments NNS N
; : N
three CD N
pens NNS N
of IN N
seven CD N
steers/treatment NN N
) ) N
. . N

Steers NNPS N
were VBD N
given VBN N
ad NN i
libitum NN i
access NN i
to TO i
high-concentrate JJ i
diets NNS i
( ( i
13 CD i
% NN i
CP NNP i
) ) i
containing VBG i
71 CD i
% NN i
whole JJ i
shelled VBN i
corn NN i
, , i
10 CD i
% NN i
corn NN i
silage NN i
, , i
4 CD i
% NN i
condensed JJ i
distillers NNS i
solubles NNS i
, , i
and CC i
15 CD i
% NN i
protein NN i
supplements NNS i
( ( i
DM NNP i
basis NN i
) ) i
. . i

Treatments NNS N
were VBD N
arranged VBN N
as IN N
a DT N
2 CD N
x NN N
4 CD N
factorial JJ N
. . N

The DT N
main JJ N
factors NNS N
were VBD N
two CD N
sources NNS N
of IN N
dietary JJ N
CP NNP N
and CC N
four CD N
levels NNS N
of IN N
RPLM NNP N
. . N

The DT N
sources NNS N
of IN N
dietary JJ o
CP NNP o
were VBD N
soybean JJ N
meal NN N
( ( N
SBM NNP N
) ) N
or CC N
SBM NNP N
and CC N
urea JJ N
( ( N
SBM-U NNP N
) ) N
. . N

Urea-N NNP o
replaced VBD N
50 CD N
% NN N
of IN N
SBM-N NNP N
in IN N
the DT N
SBM-U NNP N
diet NN N
. . N

The DT N
levels NNS N
of IN N
RPLM NNP N
were VBD N
0 CD N
, , N
5 CD N
, , N
10 CD N
, , N
and CC N
15 CD N
g NN N
per IN N
steer NN N
daily RB N
. . N

No UH N
interactions NNS N
( ( N
P NNP N
> NNP N
.10 NNP N
) ) N
between IN N
source NN N
of IN N
dietary JJ o
CP NNP o
and CC o
level NN o
of IN o
RPLM NNP o
were VBD N
observed VBN N
for IN N
feedlot NN N
performance NN N
or CC N
carcass NN o
characteristics NNS o
. . o

Feedlot NNP o
performance NN o
showed VBD N
an DT N
advantage NN N
( ( N
P NNP N
< NNP N
.10 NNP N
) ) N
to TO N
feeding VBG N
SMB NNP N
during IN N
the DT N
first JJ N
84 CD N
d NN N
of IN N
the DT N
trial NN N
and CC N
an DT N
advantage NN N
to TO N
feeding VBG N
SBM-U NNP N
during IN N
the DT N
last JJ N
98 CD N
d NN N
of IN N
the DT N
trial NN N
. . N

However RB N
, , N
feedlot JJ o
performance NN o
for IN N
the DT N
whole JJ N
trial NN N
and CC N
carcass NN N
characteristics NNS N
( ( N
except IN N
for IN N
fat JJ o
thickness NN o
) ) o
were VBD N
not RB N
affected VBN N
( ( N
P NNP N
> NNP N
.10 NNP N
) ) N
by IN N
the DT N
source NN N
of IN N
dietary JJ N
CP NNP N
. . N

Steers NNP N
fed VBD N
diets NNS N
containing VBG N
SBM-U NNP N
had VBD N
12 CD N
% NN N
less JJR N
( ( N
P NNP N
< NNP N
.10 NNP N
) ) N
fat VBZ o
thickness JJ o
than IN N
those DT N
fed JJ N
diets NNS N
containing VBG N
SBM NNP N
. . N

Supplementation NN N
of IN N
diets NNS N
with IN N
increasing VBG N
levels NNS N
of IN N
RPLM NNP o
did VBD N
not RB N
affect VB N
( ( N
P NNP N
> NNP N
.10 NNP N
) ) N
ADG NNP N
or CC N
carcass NN N
characteristics NNS N
. . N

However RB N
, , N
DMI NNP N
and CC N
gain NN N
: : N
feed NN N
showed VBD N
cubic JJ o
( ( o
P NNP o
< NNP o
.10 NNP o
) ) o
responses VBZ o
to TO N
increasing VBG N
dietary JJ N
level NN N
of IN N
RPLM NNP N
. . N

Supplementation NN N
of IN N
RPLM NNP N
at IN N
the DT N
10 CD N
g/d NNS N
level NN N
improved VBD N
gain NN o
: : o
feed VBN o
by IN N
12 CD N
% NN N
during IN N
the DT N
last JJ N
98 CD N
d NN N
of IN N
the DT N
trial NN N
, , N
and CC N
this DT N
was VBD N
a DT N
direct JJ N
response NN N
to TO N
the DT N
cubic JJ N
effects NNS N
of IN N
RPLM NNP N
on IN N
DMI NNP N
. . N

Results NNP N
suggest VBP N
a DT N
cost NN N
advantage NN N
for IN N
replacing VBG N
50 CD N
% NN N
of IN N
SBM-N NNP N
with IN N
that DT N
from IN N
urea JJ N
in IN N
high-corn JJ N
diets NNS N
without IN N
negative JJ N
effects NNS N
on IN N
feedlot NN N
performance NN N
or CC N
carcass NN N
characteristics NNS N
of IN N
growing-finishing JJ p
Holstein NNP p
steers NNS p
with IN p
extended JJ p
feeding NN p
periods NNS p
( ( p
266 CD p
d NN p
) ) p
. . p

These DT N
types NNS N
of IN N
diets NNS N
seem VBP N
to TO N
meet VB N
the DT N
amino NN N
acid NN N
requirements NNS N
and CC N
are VBP N
not RB N
limiting VBG N
in IN N
lysine NN N
and CC N
methionine NN N
. . N

-DOCSTART- -3299950- O O

[ NN i
Domperidone NNP i
in IN N
the DT N
treatment NN N
of IN N
irritable JJ o
colon NN o
. . p

A DT N
placebo-controlled JJ i
double-blind NN N
study NN N
] NNP N
. . N

-DOCSTART- -19858761- O O

Medication NN N
and CC N
parent NN N
training NN N
in IN N
children NNS p
with IN p
pervasive JJ p
developmental NN p
disorders NNS p
and CC p
serious JJ p
behavior NN p
problems NNS p
: : p
results NNS N
from IN N
a DT N
randomized JJ N
clinical JJ N
trial NN N
. . N

OBJECTIVE NNP N
Many JJ N
children NNS p
with IN p
pervasive JJ p
developmental NN p
disorders NNS p
( ( p
PDDs NNP p
) ) p
have VBP p
serious JJ o
, , o
functionally RB o
impairing VBG o
behavioral JJ o
problems NNS o
. . o

We PRP N
tested VBD N
whether IN N
combined VBN i
treatment NN i
( ( i
COMB NNP i
) ) i
with IN i
risperidone NN i
and CC i
parent NN i
training NN i
( ( i
PT NNP i
) ) i
in IN N
behavior JJ N
management NN N
is VBZ N
superior JJ N
to TO N
medication VB N
alone RB N
( ( N
MED NNP N
) ) N
in IN N
improving VBG N
severe JJ o
behavioral JJ o
problems NNS o
in IN N
children NNS p
with IN p
PDDs NNP p
. . p

METHOD NNP N
This DT N
24-week JJ N
, , N
three-site JJ N
, , N
randomized VBN N
, , N
parallel-groups JJ N
clinical JJ N
trial NN N
enrolled VBD N
124 CD p
children NNS p
, , p
aged VBD p
4 CD p
through IN p
13 CD p
years NNS p
, , p
with IN p
PDDs NNP p
, , p
accompanied VBN p
by IN p
frequent JJ p
tantrums NNS p
, , p
self-injury NN p
, , p
and CC p
aggression NN p
. . p

The DT N
children NNS N
were VBD N
randomized VBN N
3:2 CD N
to TO N
COMB NNP N
( ( N
n JJ N
= NNP N
75 CD N
) ) N
or CC N
MED NNP N
( ( N
n JJ N
= NNP N
49 CD N
) ) N
. . N

The DT N
participants NNS N
received VBD N
risperidone JJ i
monotherapy NN i
from IN N
0.5 CD N
to TO N
3.5 CD N
mg/day NN N
( ( N
with IN N
switch NN N
to TO N
aripiprazole VB i
if IN N
risperidone NN i
was VBD N
ineffective JJ N
) ) N
. . N

Parents NNS N
in IN N
the DT N
COMB NNP N
group NN N
( ( N
n JJ N
= VBZ N
75 CD N
; : N
60.5 CD N
% NN N
) ) N
received VBD N
a DT N
mean NN N
of IN N
10.9 CD N
PT NNP N
sessions NNS N
. . N

The DT N
primary JJ N
measure NN N
of IN N
compliance NN N
was VBD N
the DT N
Home NNP o
Situations NNP o
Questionnaire NNP o
( ( o
HSQ NNP o
) ) o
score NN o
. . o

RESULTS NNP N
Primary JJ N
: : N
intent-to-treat JJ N
random NN N
effects NNS N
regression NN N
showed VBD N
that IN N
COMB NNP i
was VBD N
superior JJ N
to TO N
MED NNP N
on IN N
HSQ NNP o
( ( N
p JJ N
= NNP N
.006 NNP N
) ) N
[ VBP N
effect NN N
size NN N
at IN N
week NN N
24 CD N
( ( N
d NN N
) ) N
= VBZ N
0.34 CD N
] NN N
. . N

The DT N
HSQ NNP o
score NN o
declined VBD N
from IN N
4.31 CD N
( ( N
? . N
1.67 CD N
) ) N
to TO N
1.23 CD N
( ( N
? . N
1.36 CD N
) ) N
for IN N
COMB NNP N
compared VBN N
with IN N
4.16 CD N
( ( N
? . N
1.47 CD N
) ) N
to TO N
1.68 CD N
( ( N
? . N
1.36 CD N
) ) N
for IN N
MED NNP N
. . N

Secondary JJ N
: : N
groups NNS N
did VBD N
not RB N
differ VB o
on IN o
Clinical JJ o
Global NNP o
Impressions-Improvement NN o
scores NNS o
at IN o
endpoint NN N
; : N
compared VBN N
with IN N
MED NNP N
, , N
COMB NNP N
showed VBD N
significant JJ N
reductions NNS o
on IN o
Aberrant NNP o
Behavior NNP o
Checklist NNP o
Irritability NNP o
( ( o
d JJ o
= VBZ N
0.48 CD N
; : N
p NN N
= NNP N
.01 NNP N
) ) N
, , o
Stereotypic NNP o
Behavior NNP o
( ( o
d JJ o
= VBZ N
0.23 CD N
; : N
p NN N
= NNP N
.04 NNP N
) ) N
, , N
and CC N
Hyperactivity/Noncompliance NNP o
subscales NNS o
( ( o
d VB o
= RB N
0.55 CD N
; : N
p NN N
= NNP N
.04 NNP N
) ) N
. . N

Final NNP i
risperidone NN o
mean NN o
dose NN o
for IN o
MED NNP N
was VBD N
2.26 CD N
mg/day NN N
( ( N
0.071 CD N
mg/kg NN N
) ) N
, , N
compared VBN N
with IN N
1.98 CD N
mg/day NN N
for IN N
COMB NNP N
( ( N
0.066 CD N
mg/kg NN N
) ) N
( ( N
p JJ N
= NNP N
.04 NNP N
) ) N
. . N

CONCLUSIONS NNP i
Medication NNP i
plus CC i
PT NNP i
resulted VBD N
in IN N
greater JJR o
reduction NN o
of IN o
serious JJ o
maladaptive JJ o
behavior NN o
than IN o
MED NNP N
in IN p
children NNS p
with IN p
PDDs NNP p
, , p
with IN p
a DT N
lower JJR N
risperidone NN N
dose NN N
. . N

-DOCSTART- -24070810- O O

Effectiveness NN N
of IN N
nonpharmacologic JJ i
treatments NNS i
for IN N
acute JJ p
seasonal JJ p
allergic JJ p
conjunctivitis NN p
. . p

OBJECTIVE UH N
To TO N
investigate VB N
whether IN N
artificial JJ N
tears NNS N
and CC N
cold JJ N
compress NN N
alone RB N
or CC N
in IN N
combination NN N
provide VBP N
a DT N
treatment NN N
benefit NN N
and CC N
whether IN N
they PRP N
were VBD N
as RB N
effective JJ N
as IN N
or CC N
could MD N
enhance VB N
topical JJ i
antiallergic JJ i
medication NN i
. . i

DESIGN NNP N
Randomized NNP N
, , N
masked VBD N
clinical JJ N
trial NN N
. . N

PARTICIPANTS NNP N
Eighteen JJ p
subjects NNS p
( ( p
mean JJ p
age NN p
, , p
29.5?11.0 CD p
years NNS p
) ) p
allergic VBP p
to TO p
grass VB p
pollen NN p
. . p

INTERVENTION NNP i
Controlled VBD i
exposure NN i
to TO i
grass VB i
pollen NN i
using VBG i
an DT i
environmental JJ i
chamber NN i
to TO i
stimulate VB i
an DT i
ocular JJ i
allergic NN i
reaction NN i
followed VBN i
by IN i
application NN i
of IN i
artificial JJ i
tears NNS i
( ( i
ATs NNP i
) ) i
, , i
5 CD i
minutes NNS i
of IN i
cold JJ i
compress NN i
( ( i
CC NNP i
) ) i
, , i
ATs NNP i
combined VBD i
with IN i
CC NNP i
, , i
or CC i
no DT i
treatment NN i
applied VBN i
at IN i
each DT i
separate JJ i
visit NN i
in IN i
random JJ i
order NN i
. . i

A DT N
subset NN N
of IN N
11 CD N
subjects NNS N
also RB N
had VBD i
epinastine JJ i
hydrochloride NN i
( ( i
EH NNP i
) ) i
applied VBD i
alone RB i
and CC i
combined VBN i
with IN i
CC NNP i
in IN i
random JJ i
order NN i
or CC i
instillation NN i
of IN i
a DT i
volume-matched JJ i
saline NN i
control NN i
. . i

MAIN NNP N
OUTCOME NNP N
MEASURES NNP o
Bulbar NNP o
conjunctival NN o
hyperemia NN o
, , o
ocular JJ o
surface NN o
temperature NN o
, , o
and CC o
ocular JJ o
symptoms NNS o
repeated VBN N
before RB N
and CC N
every DT N
10 CD N
minutes NNS N
after IN N
treatment NN N
for IN N
1 CD N
hour NN N
. . N

RESULTS NNP o
Bulbar NNP o
conjunctival NN o
hyperemia NN o
and CC o
ocular JJ o
symptoms NNS o
decreased VBN N
and CC N
temperature NN N
recovered VBN N
to TO N
baseline VB N
faster RBR N
with IN i
nonpharmaceutical JJ i
treatments NNS i
compared VBN N
with IN i
no DT i
treatment NN i
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

Artificial JJ N
tears NNS N
combined VBN N
with IN i
CC NNP i
reduced VBD o
hyperemia NN o
more JJR o
than IN N
other JJ N
treatments NNS N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

The DT N
treatment NN N
effect NN i
of IN i
EH NNP i
was VBD i
enhanced VBN N
by IN N
combining VBG N
it PRP N
with IN N
a DT N
CC NNP N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

Cold NNP N
compress NN N
combined VBN i
with IN i
ATs NNP i
or CC i
EH NNP i
lowered VBD N
the DT o
antigen-raised JJ o
ocular JJ o
surface NN o
temperature NN o
to TO o
less JJR o
than IN N
the DT N
pre-exposure JJ N
baseline NN N
. . N

Artificial JJ N
tear JJ N
instillation NN N
alone RB N
or CC i
CC NNP i
combined VBN N
with IN N
ATs NNP N
or CC N
EH NNP N
significantly RB N
reduced VBD N
the DT o
temperature NN o
( ( o
P NNP o
< NNP o
0.05 CD o
) ) N
. . N

Cold NNP N
compress NN N
combined VBN N
with IN i
ATs NNP i
or CC i
EH NNP i
had VBD i
a DT N
similar JJ N
cooling NN o
effect NN o
( ( o
P NNP N
> NNP N
0.05 CD N
) ) N
. . N

At IN N
all DT N
measurement NN N
intervals NNS N
, , N
symptoms NNS N
were VBD N
reduced VBN N
for IN N
both DT N
EH NNP N
and CC N
EH NNP N
combined VBD N
with IN N
CC NNP N
than IN N
CC NNP N
or CC N
ATs NNP N
alone RB N
or CC N
in IN N
combination NN N
( ( N
P NNP N
< NNP N
0.014 CD N
) ) N
. . N

CONCLUSIONS NNP N
After IN N
controlled VBN N
exposure NN N
to TO N
grass VB N
pollen NN N
, , N
CC NNP N
and CC N
AT NNP N
treatment NN N
showed VBD N
a DT N
therapeutic JJ N
effect NN N
on IN N
the DT N
signs NNS N
and CC N
symptoms NNS N
of IN p
allergic JJ p
conjunctivitis NN p
. . p

A DT p
CC NNP p
enhanced VBD p
the DT N
use NN N
of IN N
EH NNP N
alone RB N
and CC N
was VBD N
the DT N
only JJ N
treatment NN N
to TO N
reduce VB N
symptoms NNS N
to TO N
baseline VB N
within IN N
1 CD N
hour NN N
of IN N
antigenic JJ N
challenge NN N
. . N

Signs NNP o
of IN o
allergic JJ o
conjunctivitis NN o
generally RB o
were VBD o
reduced VBN N
most RBS N
by IN N
a DT N
combination NN N
of IN i
a DT i
CC NNP i
in IN i
combination NN i
with IN i
ATs NNP i
or CC i
EH NNP i
. . i

-DOCSTART- -872859- O O

Pharmacokinetics NNS o
of IN N
adriamycin NN i
and CC N
adriamycin NN i
-- : i
DNA NN i
complex NN i
in IN N
L1210 NNP p
mice NN p
and CC p
men NNS p
. . p

-DOCSTART- -25350539- O O

Matching VBG N
doses NNS N
of IN N
distraction NN N
with IN N
child NN p
risk NN p
for IN p
distress NN p
during IN N
a DT N
medical JJ N
procedure NN N
: : N
a DT N
randomized JJ N
clinical JJ N
trial NN N
. . N

BACKGROUND NNP N
Parents NNPS N
often RB N
want VBP N
to TO N
provide VB N
support NN N
to TO N
their PRP$ N
children NNS N
during IN N
medical JJ N
procedures NNS N
, , N
but CC N
not RB N
all DT N
parents NNS N
are VBP N
effective JJ N
in IN N
providing VBG N
distraction NN N
after IN N
brief JJ N
training NN N
. . N

OBJECTIVE CC N
The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
investigate VB N
the DT N
effects NNS N
of IN N
three CD N
doses NNS i
of IN i
distraction NN i
intervention NN i
for IN N
children NNS p
at IN p
high JJ p
and CC p
medium NN p
risk NN p
for IN p
procedure-related JJ p
distress NN p
. . p

METHODS NNP N
Children NNP p
undergoing VBG p
scheduled VBN p
intravenous JJ p
insertions NNS p
for IN p
diagnostic JJ p
or CC p
treatment NN p
purposes NNS p
and CC p
their PRP$ p
parents NNS p
participated VBN p
. . p

A DT N
computerized JJ N
application NN N
, , N
Children NNP N
, , N
Parents NNP N
and CC N
Distraction NNP N
, , N
was VBD N
used VBN N
to TO N
predict VB N
distress NN N
risk NN N
. . N

Doses NNS i
of IN i
intervention NN i
were VBD N
basic JJ N
( ( i
parents NNS i
trained VBN i
on IN i
providing VBG i
distraction NN i
) ) i
, , N
enhanced VBN N
( ( i
basic JJ i
training NN i
plus CC i
tailored JJ i
instructions NNS i
, , i
environmental JJ i
modifications NNS i
, , i
and CC i
support NN i
and CC i
guidance NN i
from IN i
the DT i
research NN i
assistant NN i
) ) i
, , N
and CC N
professional JJ N
( ( i
a DT i
trained VBN i
research NN i
assistant NN i
provided VBD i
distraction NN i
) ) i
. . N

Outcome JJ N
measures NNS N
were VBD N
Observational NNP o
Scale NNP o
of IN o
Behavioral NNP o
Distress-Revised JJ o
for IN o
behavioral JJ o
distress NN o
, , o
Oucher NNP o
for IN o
self-reported JJ o
pain NN o
, , o
parent JJ o
report NN o
of IN o
child JJ o
distress NN o
, , o
and CC o
salivary JJ o
cortisol NN o
for IN o
physiological JJ o
distress NN o
. . o

RESULTS VB N
A DT p
total NN p
of IN p
574 CD p
children NNS p
, , p
ages VBZ p
4-10 JJ p
, , p
and CC p
their PRP$ p
parents NNS p
participated VBN p
. . p

The DT N
Children NNP N
, , N
Parents NNP N
and CC N
Distraction NNP N
predicted VBD N
that IN N
the DT N
risk NN o
for IN o
distress NN o
was VBD N
high JJ N
for IN N
156 CD N
children NNS N
, , N
medium NN N
for IN N
372 CD N
, , N
and CC N
low JJ N
for IN N
46 CD N
. . N

Children NNP N
predicted VBD N
to TO N
have VB N
higher JJR N
risk NN N
for IN N
distress NN N
displayed VBD N
more RBR N
behavioral JJ o
distress NN o
( ( N
p JJ N
< NNP N
.01 NNP N
) ) N
. . N

Children NNP N
in IN N
the DT N
medium-risk JJ N
group NN N
who WP N
had VBD N
the DT N
professional JJ N
intervention NN N
displayed VBD N
significantly RB N
less RBR N
behavioral JJ o
distress NN o
( ( N
p JJ N
< NNP N
.001 NNP N
) ) N
. . N

Children NNP N
in IN N
the DT N
high-risk JJ N
group NN N
tended VBD N
to TO N
have VB N
less JJR N
behavioral JJ N
distress NN N
when WRB N
receiving VBG N
the DT N
professional JJ N
intervention NN N
( ( N
p JJ N
= NNP N
.07 NNP N
) ) N
. . N

There EX N
were VBD N
no DT N
significant JJ N
group NN N
differences NNS N
for IN N
self-report NN o
of IN o
pain NN o
, , o
parent JJ o
report NN o
of IN o
distress NN o
, , o
or CC o
cortisol NN o
levels NNS o
. . o

DISCUSSION NNP N
Some DT N
parents NNS N
may MD N
need VB N
additional JJ N
training NN N
in IN N
providing VBG N
distraction NN N
to TO N
their PRP$ N
children NNS N
during IN N
procedures NNS N
, , N
and CC N
some DT N
children NNS p
at IN p
medium NN p
and CC p
high JJ p
risk NN p
for IN p
distress NN p
may MD N
need VB N
professional JJ N
support NN N
. . N

Parents NNS N
should MD N
be VB N
asked VBN N
about IN N
their PRP$ N
preferences NNS N
in IN N
acting VBG N
as IN N
the DT N
distraction NN N
coach NN N
and CC N
, , N
if IN N
willing JJ N
, , N
be VB N
provided VBN N
as IN N
much JJ N
training NN N
and CC N
support NN N
as IN N
possible JJ N
in IN N
the DT N
clinical JJ N
situation NN N
. . N

-DOCSTART- -22066973- O O

Comparison NNP N
of IN N
epidural JJ i
tramadol-ropivacaine JJ i
and CC i
fentanyl-ropivacaine JJ i
for IN N
labor NN p
analgesia NN p
: : p
a DT N
prospective JJ N
randomized NN N
study NN N
. . N

BACKGROUND NNP N
To TO N
test VB N
the DT N
hypothesis NN N
that IN N
5 CD N
mg/mL NN N
tramadol NN i
is VBZ N
superior JJ N
to TO N
3 CD N
? . N
g/mL NN N
fentanyl NN i
when WRB N
combined VBN N
with IN N
0.125 CD N
% NN N
ropivacaine NN i
in IN N
parturients NNS p
undergoing VBG p
labor NN p
during IN p
epidural JJ p
analgesia NN p
. . p

METHODS NNP N
Sixty-one JJ p
parturients NNS p
undergoing VBG p
labor NN p
selected VBN p
for IN p
delivery NN p
with IN p
epidural JJ p
analgesia NNS p
were VBD N
randomized VBN N
into IN N
two CD N
groups NNS N
: : N
Group NNP N
tramadol VBD i
( ( i
0.125 CD i
% NN i
ropivacaine NN i
plus CC i
tramadol JJ i
5 CD i
mg/mL NN i
) ) i
and CC N
Group NNP N
fentanyl NNP i
( ( i
0.125 CD i
% NN i
ropivacaine NN i
plus CC i
fentanyl JJ i
3 CD i
ug/mL NN i
) ) i
. . N

Hemodynamics NNS o
, , o
rate NN o
of IN o
cesarean JJ o
delivery NN o
, , o
sensory JJ o
block NN o
level NN o
, , o
Bromage NNP o
motor NN o
scale NN o
scores NNS o
, , o
instrument-assisted JJ o
delivery NN o
, , o
oxytocin NN o
use NN o
, , o
visual JJ o
analog NN o
scale NN o
( ( o
VAS NNP o
) ) o
scores VBZ o
, , o
Apgar NNP o
scores VBZ o
, , o
umbilical JJ o
cord NN o
artery NN o
gas NN N
analysis NN o
, , o
and CC o
maternal JJ o
side-effects NNS o
including VBG o
nausea NN o
, , o
vomiting VBG o
, , o
pruritus NN o
, , o
urinary JJ o
retention NN o
, , o
shivering VBG o
, , o
hypotension NN o
, , o
and CC o
respiratory JJ o
depression NN o
were VBD N
recorded VBN N
. . N

RESULTS VB N
The DT N
two CD N
groups NNS N
had VBD N
no DT N
significant JJ N
differences NNS N
with IN N
respect NN N
to TO N
maternal JJ o
hemodynamics NNS o
, , o
neonatal JJ o
heart NN o
rate NN o
, , o
VAS NNP o
scores VBZ o
, , o
rate NN o
of IN o
cesarean JJ o
delivery NN o
, , o
sensory JJ o
block NN o
level NN o
, , o
Bromage NNP o
motor NN o
scale NN o
scores NNS o
, , o
instrument-assisted JJ o
delivery NN o
, , o
oxytocin NN o
use NN o
, , o
hypotension NN o
, , o
nausea NN o
, , o
vomiting NN o
, , o
and CC o
respiratory JJ o
depression NN o
( ( N
p JJ N
> NNP N
0.05 CD N
) ) N
. . N

The DT N
incidence NN N
of IN N
pruritus NN o
, , o
shivering NN o
, , o
and CC o
urinary JJ o
retention NN o
were VBD N
more JJR N
commonly RB N
observed VBN N
in IN N
Group NNP N
fentanyl VBD N
despite IN N
there EX N
was VBD N
no DT N
significant JJ N
difference NN N
between IN N
the DT N
two CD N
groups NNS N
. . N

Umbilical JJ o
artery NN o
pH NN o
was VBD N
significantly RB N
lower JJR N
while IN N
PCO NNP N
( ( N
2 CD N
) ) N
was VBD N
higher RBR N
in IN N
Group NNP N
fentanyl VBD i
than IN N
Group NNP N
tramadol NN i
( ( N
p JJ N
= NN N
0.003 CD N
and CC N
p VB N
= JJ N
0.026 CD N
, , N
respectively RB N
) ) N
. . N

Birth-weight NNP o
, , o
umbilical JJ o
artery NN o
PO NNP o
( ( o
2 CD o
) ) o
and CC o
base NN o
deficit NN o
, , o
and CC o
Apgar NNP o
scores NNS o
at IN N
1 CD N
and CC N
5 CD N
min NNS N
were VBD N
comparable JJ N
between IN N
the DT N
two CD N
groups NNS N
( ( N
p JJ N
> NNP N
0.05 CD N
) ) N
. . N

CONCLUSIONS VB N
Our PRP$ N
observations NNS N
suggest VBP N
that IN N
tramadol NN i
seems VBZ N
to TO N
be VB N
a DT N
safe JJ N
alternative NN N
to TO N
fentanyl VB i
for IN N
labor NN N
analgesia NNS N
due JJ N
to TO N
its PRP$ N
similar JJ N
analgesic JJ N
efficacy NN N
. . N

-DOCSTART- -6428372- O O

Cognitive JJ N
effects NNS N
of IN N
lithium NN i
carbonate NN i
and CC i
haloperidol NN i
in IN N
treatment-resistant JJ p
aggressive JJ p
children NNS p
. . p

The DT N
effects NNS N
of IN N
lithium NN i
carbonate NN i
and CC i
haloperidol NN i
on IN N
cognition NN N
were VBD N
examined VBN N
in IN N
a DT N
placebo-controlled JJ i
, , N
double-blind JJ N
study NN N
of IN N
61 CD p
treatment-resistant JJ p
, , p
hospitalized VBN p
school-aged JJ p
children NNS p
. . p

They PRP N
all DT N
had VBD N
a DT N
DSM-III JJ N
diagnosis NN N
of IN N
conduct NN N
disorder NN N
-- : N
undersocialized JJ p
, , p
aggressive JJ p
, , p
with IN p
a DT p
profile NN p
of IN p
highly RB p
explosive JJ p
and CC p
aggressive JJ p
behavior NN p
. . p

Children NNP p
were VBD p
assessed VBN p
at IN p
the DT p
end NN p
of IN p
a DT p
two-week JJ p
placebo-baseline JJ i
period NN p
and CC p
again RB p
after IN p
four CD p
weeks NNS p
of IN p
treatment NN p
. . p

Drug NNP N
effects NNS N
on IN N
cognition NN N
were VBD N
mild JJ N
. . N

Haloperidol NNP i
( ( N
mean JJ N
dose NN N
, , N
2.95 CD N
mg/day NN N
) ) N
caused VBD N
significant JJ N
decreases NNS N
in IN N
Porteus NNP o
Maze NNP o
test NN o
quotient NN o
scores NNS o
and CC N
a DT N
slowing NN o
of IN o
reaction NN o
time NN o
( ( o
RT NNP o
) ) o
on IN N
a DT N
simple JJ N
RT NNP N
task NN N
. . N

Lithium JJ i
carbonate NN i
( ( N
mean JJ N
dose NN N
, , N
1,166 CD N
mg/day NN N
) ) N
adversely RB N
affected JJ N
qualitative JJ o
scores NNS o
on IN o
the DT o
Porteus NNP o
Maze NNP o
test NN o
. . o

No DT N
significant JJ N
treatment NN N
effects NNS N
were VBD N
found VBN N
for IN N
the DT N
Matching NNP o
Familiar NNP o
Figures NNP o
Test NNP o
, , o
short-term JJ o
recognition NN o
memory NN o
and CC o
concept NN o
attainment NN o
tasks NNS o
, , o
or CC o
the DT o
Stroop NNP o
Test NNP o
. . o

-DOCSTART- -3602307- O O

The DT N
efficacy NN o
and CC o
safety NN o
of IN N
fenfluramine NN i
in IN N
autistic JJ p
children NNS p
: : p
preliminary JJ N
analysis NN N
of IN N
a DT N
double-blind JJ N
study NN N
. . N

-DOCSTART- -25798729- O O

Initial JJ o
abstinence NN o
status NN o
and CC o
contingency NN o
management NN o
treatment NN o
outcomes NNS N
: : N
does VBZ N
race NN N
matter NN N
? . N
OBJECTIVE NNP N
Limited NNP N
research NN N
has VBZ N
evaluated VBN N
African JJ p
American JJ p
substance NN p
users NNS p
' POS p
response NN N
to TO N
evidence-based JJ N
treatments NNS N
. . N

This DT N
study NN N
examined VBD N
the DT N
efficacy NN N
of IN N
contingency NN o
management NN o
( ( o
CM NNP o
) ) o
in IN N
African JJ p
American NNP p
and CC p
White NNP p
cocaine NN p
users NNS p
. . p

METHOD VB N
A DT N
secondary JJ N
analysis NN N
evaluated VBD N
effects NNS N
of IN N
race NN N
, , N
treatment NN N
condition NN N
, , N
and CC N
baseline NN N
cocaine NN N
urine JJ N
sample NN N
results NNS N
on IN N
treatment NN N
outcomes NNS N
of IN N
African JJ p
American NNP p
( ( p
n JJ p
= NNP p
444 CD p
) ) p
and CC p
White NNP p
( ( p
n JJ p
= NNP p
403 CD p
) ) p
cocaine NN p
abusers NNS p
participating VBG p
in IN p
one CD p
of IN p
six CD p
randomized JJ p
clinical JJ p
trials NNS p
comparing VBG p
CM NNP i
to TO p
standard VB i
care NN i
. . i

RESULTS JJ N
African JJ p
American JJ p
and CC p
White NNP p
patients NNS p
who WP p
initiated VBD p
treatment NN p
with IN p
a DT p
cocaine-negative JJ p
urine JJ p
sample NN p
remained VBD N
in IN N
treatment NN N
for IN N
similar JJ N
durations NNS N
and CC N
submitted VBD N
a DT N
comparable JJ N
proportion NN N
of IN N
negative JJ N
samples NNS N
during IN N
treatment NN N
regardless NN N
of IN N
treatment NN N
type NN N
; : N
CM NNP i
was VBD N
efficacious JJ N
in IN N
both DT N
races NNS N
in IN N
terms NNS N
of IN N
engendering VBG N
longer JJR N
durations NNS N
of IN N
abstinence NN N
in IN N
patients NNS N
who WP N
began VBD N
treatment NN N
abstinent NN N
. . N

Whites NNS p
who WP p
began VBD p
treatment NN p
with IN p
a DT p
cocaine NN p
positive JJ p
sample NN p
remained VBD N
in IN N
treatment NN N
longer NN N
and CC N
submitted VBD N
a DT N
higher JJR N
proportion NN N
of IN N
negative JJ N
samples NNS N
when WRB N
assigned VBN N
to TO N
CM NNP i
than IN N
standard JJ i
care NN i
. . i

African JJ p
Americans NNPS p
who WP p
initiated VBD p
treatment NN p
with IN p
a DT p
cocaine NN p
positive JJ p
sample NN p
, , N
however RB N
, , N
did VBD N
not RB N
remain VB N
in IN N
treatment NN N
longer NN N
with IN N
CM NNP i
compared VBN N
with IN N
standard JJ i
care NN i
, , N
and CC N
gains NNS o
in IN o
terms NNS o
of IN o
drug NN o
use NN o
outcomes NNS o
were VBD N
muted VBN N
in IN N
nature NN N
relative NN N
to TO N
Whites NNP N
. . N

This DT N
interaction NN N
effect NN N
persisted VBN N
through IN N
the DT N
9-month JJ N
follow-up JJ N
period NN N
. . N

CONCLUSIONS NNP N
CM NNP i
is VBZ N
not RB N
equally RB N
effective JJ N
in IN N
reducing VBG N
drug NN N
use NN N
among IN N
all DT N
subgroups NNS N
, , N
specifically RB N
African JJ p
American JJ p
patients NNS p
who WP p
are VBP p
using VBG p
cocaine JJ p
upon IN p
treatment NN p
entry NN p
. . p

Future NNP N
research NN N
on IN N
improving VBG N
treatment NN N
outcomes NNS N
in IN N
this DT N
population NN N
is VBZ N
needed VBN N
. . N

-DOCSTART- -2859779- O O

Effect NN N
of IN N
acebutolol NN i
on IN N
left JJ N
ventricular JJ N
performance NN N
. . N

The DT N
effect NN N
of IN N
acebutolol NN i
on IN N
left JJ N
ventricular JJ N
performance NN N
was VBD N
examined VBN N
by IN N
various JJ N
noninvasive JJ N
means NNS N
in IN N
three CD N
studies NNS N
. . N

M-mode NNP N
echocardiographic JJ N
measurements NNS N
were VBD N
made VBN N
in IN N
21 CD p
patients NNS p
with IN p
coronary JJ p
artery NN p
disease NN p
who WP p
were VBD p
receiving VBG p
placebo NN i
, , i
acebutolol NN i
, , p
and CC p
propranolol NN i
in IN p
a DT p
double-blind NN p
, , N
randomized VBN N
, , N
crossover NN N
study NN N
. . N

In IN N
these DT N
patients NNS N
with IN N
normal JJ N
or CC N
near-normal JJ N
resting NN N
left VBD N
ventricular JJ N
function NN N
, , N
neither CC N
drug NN N
induced JJ N
depression NN N
of IN N
left JJ N
ventricular JJ N
function NN N
. . N

In IN N
26 CD p
patients NNS p
with IN p
chronic JJ p
angina NNS p
pectoris VBP p
receiving VBG N
acebutolol NN i
under IN N
double-blind NN N
, , N
placebo-controlled JJ i
conditions NNS N
, , N
gated VBN N
( ( N
equilibrium NN N
) ) N
myocardial NN N
blood NN N
pool NN N
imaging VBG N
using VBG N
red JJ N
blood NN N
cells NNS N
labeled VBN N
with IN N
technetium NN N
99m CD N
showed VBD N
acebutolol NN i
to TO N
have VB N
no DT N
clinically RB N
significant JJ N
negative JJ N
effect NN N
on IN N
left JJ N
ventricular JJ N
performance NN N
at IN N
rest NN N
or CC N
during IN N
supine JJ N
bicycle NN N
exercise NN N
. . N

Acebutolol NNP i
at IN N
effective JJ N
antianginal JJ N
doses NNS N
modestly RB N
improved VBN N
resting NN o
global JJ o
and CC o
regional JJ o
myocardial JJ o
function NN o
. . o

In IN N
13 CD p
patients NNS p
with IN p
stable JJ p
angina NNS p
pectoris VBP p
, , N
single-pass JJ N
studies NNS N
of IN N
left JJ N
ventricular JJ N
function NN N
with IN N
indium NN N
113 CD N
under IN N
double-blind NN N
, , N
placebo-controlled JJ N
conditions NNS N
similarly RB N
showed VBD N
acebutolol NN i
to TO N
have VB N
no DT N
clinically RB N
significant JJ N
negative JJ N
inotropic NN N
effects NNS N
. . N

In IN N
conclusion NN N
, , N
acebutolol NN i
is VBZ N
safe JJ N
for IN N
use NN N
in IN N
patients NNS p
with IN p
coronary JJ p
disease NN p
and CC p
a DT p
wide JJ p
range NN p
of IN p
ejection NN p
fractions NNS p
but CC N
, , N
as IN N
with IN N
all DT N
beta NN N
blockers NNS N
, , N
should MD N
be VB N
used VBN N
cautiously RB N
in IN N
patients NNS N
with IN N
markedly RB N
reduced VBN p
resting NN p
left VBD p
ventricular JJ p
function NN p
. . p

-DOCSTART- -6143667- O O

Effect NN N
of IN N
beta-blocking NN N
drugs NNS N
on IN N
beta-cell NN N
function NN N
and CC N
insulin NN N
sensitivity NN N
in IN N
hypertensive JJ p
non-diabetic JJ p
patients NNS p
. . p

The DT N
effects NNS N
of IN N
two CD N
beta-blocking JJ N
drugs NNS N
on IN N
endogenous JJ N
insulin NN N
secretion NN N
and CC N
insulin NN N
sensitivity NN N
were VBD N
investigated VBN N
in IN N
a DT N
double-blind JJ N
cross-over NN N
study NN N
in IN N
13 CD p
hypertensive JJ p
patients NNS p
. . p

The DT N
patients NNS N
were VBD N
randomly RB N
allocated VBN N
to TO N
each DT N
of IN N
three CD N
2-week JJ N
treatment NN N
periods NNS N
with IN N
propranolol JJ i
80 CD i
mg NN i
b.i.d. NN i
, , N
atenolol RB i
50 CD i
mg NN i
b.i.d NN i
. . i

and CC i
placebo JJ i
b.i.d NN i
. . i

Endogenous JJ N
insulin NN N
secretion NN N
was VBD N
assessed VBN N
by IN N
measuring VBG N
serum JJ N
insulin NN N
and CC N
C-peptide NNP N
before IN N
and CC N
6 CD N
min NN N
after IN N
iv JJ N
administration NN N
of IN N
glucagon NN N
; : N
insulin JJ N
sensitivity NN N
was VBD N
determined VBN N
by IN N
measuring VBG N
insulin NN N
binding VBG N
to TO N
erythrocytes NNS N
, , N
and CC N
as IN N
the DT N
glucose JJ N
disappearance NN N
rate NN N
( ( N
KITT NNP N
) ) N
after IN N
i.v NN N
. . N

insulin NN N
. . N

Fasting VBG N
concentrations NNS N
of IN N
serum JJ N
free JJ N
fatty NN N
acids NNS N
( ( N
S-FFA NNP N
) ) N
and CC N
plasma JJ N
gastric JJ N
inhibitory NN N
polypeptide NN N
( ( N
P-GIP NNP N
) ) N
were VBD N
also RB N
recorded VBN N
during IN N
the DT N
three CD N
study NN N
periods NNS N
. . N

Both DT N
propranolol NN i
and CC N
atenolol NN i
reduced VBD N
blood NN o
pressure NN o
, , o
heart NN o
rate NN o
and CC o
S-FFA NNP o
concentrations NNS o
compared VBN N
to TO N
placebo VB i
, , N
and CC N
all DT N
patients NNS N
showed VBD N
measurable JJ N
plasma JJ N
concentrations NNS N
of IN N
propranolol NN N
and CC N
atenolol NN N
. . N

The DT N
results NNS N
can MD N
be VB N
considered VBN N
representative JJ N
, , N
therefore RB N
, , N
of IN N
clinical JJ o
beta-blockade NN o
. . o

The DT N
two CD N
drugs NNS N
did VBD N
not RB N
significantly RB N
influence VB N
the DT N
fasting NN o
blood NN o
glucose JJ o
level NN o
. . o

There EX N
was VBD N
an DT N
increase NN N
in IN N
fasting VBG o
and CC o
glucagon-stimulated JJ o
serum NN o
C-peptide NNP o
concentration NN o
during IN N
propranolol JJ N
therapy NN N
compared VBN N
with IN N
placebo NN N
( ( N
p JJ N
= NN N
0.037 CD N
and CC N
p VB N
= JJ N
0.030 CD N
, , N
respectively RB N
) ) N
, , N
although IN N
this DT N
was VBD N
not RB N
reflected VBN N
by IN N
a DT N
significant JJ N
change NN N
in IN N
serum JJ o
insulin NN o
. . o

Propranolol NNP i
and CC N
atenolol RB N
did VBD N
not RB N
significantly RB N
influence JJ N
insulin NN o
binding NN o
to TO o
erythrocytes NNS o
, , N
but CC N
they PRP N
clearly RB N
reduced VBD N
the DT N
glucose JJ o
disappearance NN o
rate NN o
KITT NNP o
was VBD N
compared VBN N
to TO N
placebo VB N
( ( N
p JJ N
= NN N
0.0036 CD N
and CC N
p VB N
= NNP N
0.0003 CD N
) ) N
, , N
respectively RB N
) ) N
. . N

The DT N
findings NNS N
support VBP N
the DT N
view NN N
that IN N
beta-blocking JJ N
drugs NNS N
can MD N
influence VB N
glucose JJ o
metabolism NN o
by IN N
mechanisms NNS N
other JJ N
than IN N
inhibition NN N
of IN N
endogenous JJ o
insulin NN o
secretion NN o
. . o

-DOCSTART- -11021553- O O

Beta NNP i
radiation NN i
as IN N
an DT N
adjunct JJ N
to TO N
low-risk JJ p
trabeculectomy NN p
. . p

PURPOSE NNP N
To TO N
assess VB N
a DT N
single JJ N
dose NN N
of IN N
intraoperative JJ i
beta NN i
radiation NN i
used VBN N
to TO N
enhance VB N
the DT N
success NN N
rate NN N
of IN N
trabeculectomy NN N
in IN N
a DT N
population NN p
of IN p
low-risk JJ p
glaucoma NN p
patients NNS p
in IN p
whom WP p
antimetabolites NNS p
might MD p
not RB p
be VB p
indicated VBN p
. . p

METHODS VB N
A DT N
prospective JJ N
randomized VBN N
trial NN N
of IN N
65 CD p
eyes NNS p
was VBD p
designed VBN p
, , p
with IN p
31 CD p
eyes NNS p
receiving VBG p
750 CD i
rads NNS i
of IN i
intraoperative JJ i
beta NN i
radiation NN i
( ( p
group NN p
1 CD p
) ) p
, , p
and CC p
34 CD p
eyes NNS p
receiving VBG i
no DT i
supplementation NN i
( ( p
group NN p
2 CD p
) ) p
. . p

RESULTS JJ N
Mean JJ N
follow-up JJ N
time NN N
was VBD N
24 CD N
months NNS N
. . N

Mean NNP o
postoperative JJ o
intraocular JJ o
pressure NN o
was VBD N
12.2 CD N
mmHg NN N
in IN N
group NN N
1 CD N
, , N
and CC N
13.7 CD N
mmHg NN N
in IN N
group NN N
2 CD N
( ( N
P NNP N
= NNP N
0.16 CD N
) ) N
. . N

Mean JJ N
decrease NN N
in IN N
intraocular JJ o
pressure NN o
was VBD N
10.3 CD N
mmHg NN N
in IN N
group NN N
1 CD N
, , N
and CC N
9.3 CD N
mmHg NN N
in IN N
group NN N
2 CD N
( ( N
P NNP N
= NNP N
0.49 CD N
) ) N
. . N

The DT N
two CD N
groups NNS N
were VBD N
not RB N
significantly RB N
different JJ N
in IN N
terms NNS N
of IN N
surgical JJ o
complications NNS o
. . o

CONCLUSION NN N
For IN N
this DT N
population NN N
of IN N
low-risk JJ p
patients NNS p
, , N
there EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
outcome NN N
after IN N
applications NNS N
of IN N
a DT N
single JJ N
intraoperative JJ N
dose NN N
of IN N
beta NN i
radiation NN i
. . i

-DOCSTART- -10817768- O O

Does NNS N
waiting VBG N
matter NN N
? . N
A DT N
randomized NN N
controlled VBN N
trial NN N
of IN N
new JJ p
non-urgent JJ p
rheumatology NN p
out-patient JJ p
referrals NNS p
. . p

OBJECTIVE NNP N
To TO N
examine VB N
the DT N
effect NN N
of IN N
waiting VBG N
times NNS N
on IN N
the DT N
health NN N
status NN N
of IN N
patients NNS p
referred VBN p
for IN p
a DT p
non-urgent JJ p
rheumatology NN p
opinion NN p
. . p

METHODS NNP N
The DT N
study NN N
was VBD N
a DT N
randomized VBN N
controlled VBN N
clinical JJ N
study NN N
evaluating VBG i
a DT i
'fast JJ i
track NN i
' POS i
appointment NN i
with IN i
a DT i
6-week JJ i
target NN i
waiting VBG i
time NN i
against IN i
an DT i
'ordinary JJ i
' POS i
appointment NN i
in IN p
the DT p
main JJ p
city NN p
out-patient JJ p
clinic NN p
of IN p
the DT p
rheumatology NN p
service NN p
for IN p
the DT p
Lothian JJ p
and CC p
Borders NNPS p
region NN p
( ( p
population NN p
approximately RB p
1 CD p
million CD p
) ) p
. . p

Health NNP o
status NN o
was VBD o
measured VBN o
using VBG o
the DT o
SF12 NNP o
physical JJ o
and CC o
mental JJ o
summary JJ o
component NN o
T-scores NNS o
and CC o
pain NN o
was VBD o
measured VBN o
with IN o
a DT o
100 CD o
mm NN o
visual JJ o
analogue NN o
pain NN o
scale NN o
. . o

Secondary JJ N
outcomes NNS N
were VBD N
health NN o
utility NN o
and CC o
perceived VBD o
health NN o
both DT o
measured VBN o
with IN o
the DT o
EuroQol NNP o
instrument NN o
, , o
mental JJ o
health NN o
measured VBN o
with IN o
the DT o
Hospital NNP o
Anxiety NNP o
and CC o
Depression NNP o
scale NN o
, , o
disability NN o
with IN o
the DT o
modified JJ o
Health NNP o
Assessment NNP o
Questionnaire NNP o
and CC o
economic JJ o
costs NNS o
measured VBN o
from IN o
a DT o
societal JJ o
perspective NN o
. . o

RESULTS JJ N
Mean NNP o
waiting VBG o
times NNS o
were VBD N
43 CD N
days NNS N
( ( N
sigma JJ N
= NNP N
+/-16 NN N
) ) N
and CC N
105 CD N
days NNS N
( ( N
sigma JJ N
= NNP N
+/-51 NN N
) ) N
for IN N
'fast $ N
track NN N
' '' N
and CC N
'ordinary NNP N
' POS N
appointments NNS N
, , N
respectively RB N
. . N

Both DT N
groups NNS N
showed VBD N
significant JJ N
improvements NNS N
in IN N
mean JJ o
[ JJ o
95 CD o
% NN o
confidence NN o
interval NN o
( ( o
CI NNP o
) ) o
] NN o
scores NNS o
for IN o
pain NN o
: : o
11 CD N
( ( N
7 CD N
, , N
16 CD N
) ) N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
; : N
physical JJ o
health NN o
status NN o
: : o
4 CD N
( ( N
2 CD N
, , N
5 CD N
) ) N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
; : N
mental JJ o
health NN o
status NN o
: : o
2 CD N
( ( N
0.1 CD N
, , N
4 CD N
) ) N
( ( N
P NNP N
< NNP N
0.02 CD N
) ) N
; : N
and CC N
health NN o
utility NN o
: : o
0.11 CD N
( ( N
0.07 CD N
, , N
0.16 CD N
) ) N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
by IN N
the DT N
end NN N
of IN N
the DT N
15-month JJ N
period NN N
of IN N
the DT N
study NN N
, , N
but CC N
there EX N
was VBD N
no DT N
significant JJ N
difference NN N
between IN N
either DT N
arm NN N
of IN N
the DT N
study NN N
. . N

CONCLUSIONS NNP N
Rationing NNP N
by IN N
delay NN N
was VBD N
not RB N
detrimental JJ N
to TO N
either DT N
mental JJ N
or CC N
physical JJ N
health NN N
and CC N
patients NNS N
in IN N
both DT N
arms NNS N
of IN N
the DT N
study NN N
showed VBD N
significant JJ N
and CC N
similar JJ N
improvement NN N
in IN N
health NN N
by IN N
15 CD N
months NNS N
. . N

Expenditure NN N
of IN N
resources NNS N
on IN N
waiting VBG N
times NNS N
without IN N
regard NN N
to TO N
clinical JJ N
outcomes NNS N
is VBZ N
likely JJ N
to TO N
be VB N
wasteful JJ N
and CC N
additional JJ N
resources NNS N
should MD N
be VB N
directed VBN N
at IN N
achieving VBG N
the DT N
greatest JJS N
clinical JJ N
benefit NN N
. . N

More JJR N
research NN N
into IN N
effective JJ N
methods NNS N
of IN N
controlling VBG N
demand NN N
and CC N
better JJR N
identification NN N
of IN N
those DT N
who WP N
would MD N
benefit VB N
from IN N
access NN N
to TO N
specialist VB N
care NN N
is VBZ N
needed VBN N
. . N

-DOCSTART- -8590792- O O

Hypertension NN p
and CC p
non-insulin-dependent JJ p
diabetes NNS p
. . p

A DT N
comparison NN N
between IN N
an DT N
angiotensin-converting JJ i
enzyme NN i
inhibitor NN i
and CC N
a DT N
calcium NN i
antagonist NN i
. . i

The DT N
effects NNS N
of IN N
the DT N
angiotensin-converting JJ i
enzyme NN i
lisinopril NN i
were VBD N
compared VBN N
with IN N
those DT N
of IN N
the DT N
calcium NN i
antagonist NN i
nifedipine NN i
in IN N
162 CD p
non-insulin-dependent JJ p
diabetic JJ p
hypertensive NN p
patients NNS p
for IN N
a DT N
24-week JJ N
period NN N
. . N

In IN N
83 CD N
and CC N
79 CD N
patients NNS N
, , N
respectively RB N
, , N
lisinopril JJ i
and CC i
slow-release JJ i
nifedipine NN i
produced VBD N
similar JJ N
reductions NNS o
in IN o
blood NN o
pressure NN o
( ( N
systolic/diastolic JJ N
: : N
-16/-13 NN N
mmHg NN N
supine NN N
and CC N
-14/-11 NN N
mmHg NN N
standing NN N
after IN N
lisinopril NN N
; : N
-15/-12 CC N
mmHg VB N
supine NN N
and CC N
-14/-11 NN N
mmHg NN N
standing VBG N
nifedipine NN N
) ) N
. . N

Fasting VBG o
and CC o
post-prandial JJ o
plasma NN o
glucose NN o
, , o
glycosylated VBN o
haemoglobin NN o
and CC o
plasma JJ o
lipids NNS o
appeared VBD N
to TO N
be VB N
unaffected VBN N
by IN N
either DT N
agent NN N
. . N

Also RB N
, , N
28 CD N
% NN N
of IN N
the DT N
patients NNS N
on IN N
lisinopril NN i
and CC N
30 CD N
% NN N
of IN N
those DT N
on IN N
nifedipine JJ i
presented VBN N
microalbuminuria NN N
. . N

Both DT N
drugs NNS N
induced VBD N
a DT N
reduction NN N
in IN N
the DT N
albumin JJ o
excretion NN o
rate NN o
( ( o
AER NNP o
) ) o
. . o

The DT N
geometric JJ N
mean NN N
x NN N
: : N
tolerance NN N
factor NN N
of IN N
the DT N
reduction NN o
in IN o
AER NNP o
among IN N
the DT N
23 CD N
microalbuminuric JJ N
patients NNS N
on IN N
lisinopril NN i
( ( N
-10.0 JJ N
x:1.3 NNP N
micrograms/min NN N
) ) N
was VBD N
greater JJR N
, , N
though IN N
not RB N
significantly RB N
so RB N
, , N
than IN N
that DT N
observed VBD N
in IN N
the DT N
26 CD N
on IN N
nifedipine NN i
( ( N
-0.9 JJ N
x $ N
1.2 CD N
micrograms/min NN N
) ) N
. . N

Moreover RB N
, , N
lisinopril RB i
appeared VBD N
to TO N
be VB N
better RB N
tolerated VBN o
than IN N
nifedipine NN i
in IN N
our PRP$ N
study NN N
population NN N
. . N

Microalbuminuria NNP N
is VBZ N
an DT N
important JJ N
risk NN N
factor NN N
for IN N
cardiovascular JJ N
mortality NN N
in IN N
non-insulin-dependent JJ p
diabetic JJ p
patients NNS p
as RB N
well RB N
as IN N
in IN N
the DT N
general JJ N
population NN N
. . N

To TO N
what WP N
extent VB N
a DT N
reduction NN N
in IN N
the DT N
AER NNP o
could MD N
ameliorate VB N
diabetic JJ N
patients NNS N
is VBZ N
, , N
at IN N
present JJ N
, , N
unknown JJ N
. . N

Finally RB N
, , N
both DT N
lisinopril FW i
and CC N
nifedipine NN i
showed VBD N
a DT N
similar JJ N
antihypertensive JJ o
effect NN o
in IN N
these DT N
patients NNS N
which WDT N
was VBD N
not RB N
associated VBN N
with IN N
significant JJ N
differences NNS N
in IN N
plasma NN N
glucose NN N
, , N
insulin NN N
or CC N
lipid JJ N
concentrations NNS N
. . N

The DT N
clinical JJ N
consequences NNS N
of IN N
the DT N
insignificant JJ N
differences NNS N
in IN N
AER NNP o
remain VBP N
unclear JJ N
. . N

-DOCSTART- -10997806- O O

Paclitaxel NNP i
( ( N
175 CD N
mg/m2 NN N
) ) N
plus CC i
carboplatin NN i
( ( N
6 CD N
AUC NNP N
) ) N
versus NN i
paclitaxel NN i
( ( N
225 CD N
mg/m2 NN N
) ) N
plus CC i
carboplatin NN i
( ( N
6 CD N
AUC NNP N
) ) N
in IN N
advanced JJ p
non-small-cell JJ p
lung NN p
cancer NN p
( ( p
NSCLC NNP p
) ) p
: : p
a DT N
multicenter NN N
randomized VBN N
trial NN N
. . N

Hellenic NNP N
Cooperative NNP N
Oncology NNP N
Group NNP N
( ( N
HeCOG NNP N
) ) N
. . N

PURPOSE VB N
The DT N
combination NN N
of IN N
paclitaxel NN i
and CC i
carboplatin NN i
has VBZ N
become VBN N
a DT N
widely RB N
used VBN N
regimen NNS N
in IN N
NSCLC NNP N
due JJ N
to TO N
phase VB N
II NNP N
reports NNS N
of IN N
moderate JJ N
toxicity NN N
, , N
reasonable JJ N
activity NN N
and CC N
easy JJ N
outpatient JJ N
administration NN N
. . N

Purpose NNP N
of IN N
our PRP$ N
present JJ N
prospective JJ N
study NN N
was VBD N
to TO N
evaluate VB N
the DT N
dose JJ o
response NN o
relationship NN N
of IN N
paclitaxel NN N
. . N

PATIENTS NNP N
AND CC N
METHODS NNP N
Since IN p
July NNP p
1996 CD p
, , p
198 CD p
patients NNS p
with IN p
non-operable JJ p
NSCLC NNP p
and CC p
measurable JJ p
disease NN p
without IN p
previous JJ p
chemotherapy NN i
entered VBD p
the DT p
trial NN p
. . p

Ninety NNP p
nine CD p
patients NNS p
( ( p
group NN p
A DT p
) ) p
were VBD N
randomized VBN N
to TO N
receive VB N
paclitaxel NN i
175 CD N
mg/m2 NN N
in IN N
three-hour JJ N
infusion NN N
plus CC i
carboplatin NN i
dosed VBD N
to TO N
an DT N
area NN N
under IN N
the DT N
concentration-time JJ N
curve NN N
of IN N
6 CD N
every DT N
3 CD N
weeks NNS N
and CC N
99 CD N
( ( N
group NN N
B NNP N
) ) N
to TO N
receive VB N
the DT N
same JJ N
regimen NN N
with IN N
paclitaxel NN i
increased VBN N
to TO N
225 CD N
mg/m2 NN N
. . N

Eligibility NNP N
criteria NNS N
included VBD N
WHO NNP N
performance NN N
status NN N
0-2 CD N
, , N
documented VBN N
inoperable JJ N
stage NN N
IIIA NNP N
and CC N
IIIB NNP N
, , N
IV NNP N
, , N
no DT N
brain NN N
metastasis NN N
, , N
no DT N
prior JJ N
chemotherapy NN i
and CC N
adequate JJ N
renal NN N
and CC N
hepatic JJ N
function NN N
. . N

Patients NNS N
in IN N
both DT N
groups NNS N
were VBD N
well-matched JJ N
with IN N
baseline JJ N
disease NN N
characteristics NNS N
. . N

RESULTS NNP N
In IN N
group NN N
A NNP N
with IN N
90 CD N
evaluable JJ N
patients NNS N
, , N
the DT N
response NN o
rate NN o
was VBD N
25.6 CD N
% NN N
( ( N
6 CD N
CR NNP N
, , N
17 CD N
PR NNP N
) ) N
whereas VBP N
in IN N
group NN N
B NNP N
with IN N
88 CD N
evaluable JJ N
patients NNS N
, , N
the DT N
response NN o
rate NN o
was VBD N
31.8 CD N
% NN N
( ( N
3 CD N
CR NNP N
, , N
25 CD N
PR NNP N
) ) N
, , N
P NNP N
= VBZ N
0.733 CD N
. . N

Median JJ o
time NN o
to TO o
progression NN o
favored VBD N
the DT N
high-dose JJ N
paclitaxel NN N
( ( N
4.3 CD N
vs. FW N
6.4 CD N
months NNS N
, , N
P NNP N
= NNP N
0.044 CD N
) ) N
. . N

The DT N
median JJ o
survival NN o
was VBD N
9.5 CD N
months NNS N
for IN N
group NN N
A NNP N
versus NN N
11.4 CD N
months NNS N
for IN N
group NN N
B NNP N
( ( N
P NNP N
= NNP N
0.16 CD N
) ) N
. . N

The DT N
one-year JJ o
survival NN o
was VBD N
37 CD N
% NN N
for IN N
group NN N
A NNP N
and CC N
44 CD N
% NN N
for IN N
group NN N
B NNP N
( ( N
P NNP N
= NNP N
0.35 CD N
) ) N
. . N

The DT N
best JJS N
prognostic JJ N
factor NN N
for IN N
one-year JJ o
survival NN o
was VBD N
the DT N
response NN o
rate NN o
( ( N
P NNP N
< NNP N
0.0001 CD N
) ) N
. . N

With IN N
a DT N
relative JJ N
dose JJ N
intensity NN N
of IN N
paclitaxel NN i
0.94 CD N
in IN N
both DT N
groups NNS N
, , N
neurotoxicity NN o
( ( N
P NNP N
= NNP N
0.025 CD N
) ) N
and CC N
leucopenia $ o
( ( N
P NNP N
= NNP N
0.038 CD N
) ) N
were VBD N
more RBR N
pronounced JJ N
in IN N
group NN N
B NNP N
patients NNS N
. . N

No DT N
toxic JJ o
death NN o
was VBD N
observed VBN N
. . N

CONCLUSIONS NNP N
Higher NNP N
dose VBD N
paclitaxel JJ i
prolongs NNS N
the DT N
median JJ N
time NN N
to TO N
progression NN N
but CC N
causes VBZ N
more JJR N
neurotoxicity NN N
and CC N
leucopenia NN N
. . N

The DT N
better JJR N
response NN N
rate NN N
, , N
the DT N
longer JJR N
overall JJ N
and CC N
better JJR N
one-year JJ N
survival NN N
seen VBN N
with IN N
the DT N
higher JJR N
dose NN N
of IN N
paclitaxel NNS i
are VBP N
not RB N
statistically RB N
significant JJ N
. . N

-DOCSTART- -25992523- O O

The DT N
effects NNS N
of IN N
bromazepam NN i
over IN p
the DT p
central JJ p
and CC p
frontal JJ p
areas NNS p
during IN p
a DT p
motor NN p
task NN p
: : p
an DT N
EEG NNP N
study NN N
. . N

The DT N
present JJ N
study NN N
investigates VBZ N
the DT N
influence NN N
of IN N
bromazepam NN i
while IN p
executing VBG p
a DT p
motor NN p
task NN p
. . p

Specifically RB N
, , N
we PRP N
intend VBP N
to TO N
analyze VB N
the DT N
changes NNS N
in IN N
alpha NN o
absolute JJ o
power NN o
under IN N
two CD N
experimental JJ N
conditions NNS N
, , N
bromazepam NN i
and CC i
placebo NN i
. . i

We PRP N
also RB N
included VBD N
analyses NNS N
of IN N
theta NN N
and CC N
beta NN N
frequencies NNS N
. . N

We PRP p
collected VBD p
electroencephalographic JJ i
data NNS i
before IN i
, , i
during IN i
, , i
and CC i
after IN i
motor NN i
task NN i
execution NN i
. . i

We PRP N
used VBD N
a DT N
Two CD i
Way NNP i
ANOVA NNP i
to TO i
investigate VB i
the DT i
condition NN i
( ( i
PL NNP i
? . i
Br6 NNP i
mg NN i
) ) i
and CC i
moment NN i
( ( i
pre NN i
and CC i
post NN i
) ) i
variables NNS i
for IN i
the DT i
following JJ i
electrodes NNS i
: : i
Fp1 NNP i
, , i
Fp2 NNP i
, , i
F7 NNP i
, , i
F3 NNP i
, , i
Fz NNP i
, , i
F4 NNP i
, , i
F8 NNP i
, , i
C3 NNP i
, , i
CZ NNP i
and CC i
C4 NNP i
. . i

We PRP N
found VBD N
a DT N
main JJ N
effect NN N
for IN N
condition NN N
on IN N
the DT N
electrodes NNS N
FP1 NNP N
, , N
F7 NNP N
, , N
F3 NNP N
, , N
Fz NNP N
, , N
F4 NNP N
, , N
C3 NNP N
and CC N
CZ NNP N
, , N
for IN N
alpha NN N
and CC N
beta NN N
bands NNS N
. . N

For IN N
beta NN N
band NN N
we PRP N
also RB N
found VBD N
a DT N
main JJ N
effect NN N
for IN N
condition NN N
on IN N
the DT N
electrodes NNS N
Fp2 NNP N
, , N
F8 NNP N
and CC N
C4 NNP N
; : N
for IN N
theta NN N
band NN N
we PRP N
identified VBD N
a DT N
main JJ N
effect NN N
for IN N
condition NN N
on IN N
C3 NNP N
, , N
Cz NNP N
and CC N
C4 NNP N
electrodes NNS N
. . N

This DT N
finding NN N
suggests VBZ N
that IN N
the DT N
motor NN N
task NN N
did VBD N
not RB N
have VB N
any DT N
influence NN N
on IN N
the DT o
electrocortical JJ o
activity NN o
in IN N
alpha NN N
, , N
and CC N
that IN N
the DT N
existing VBG N
modifications NNS N
were VBD N
a DT N
consequence NN N
due JJ N
merely RB N
to TO N
the DT N
drug NN N
use NN N
. . N

Despite IN N
its PRP$ N
anxiolytic JJ N
and CC N
sedative JJ N
action NN N
, , N
bromazepam NN i
did VBD N
not RB N
show VB N
any DT N
significant JJ N
changes NNS N
when WRB p
the DT p
individuals NNS p
executed VBD p
a DT p
finger NN p
extension NN p
motor NN p
task NN p
. . p

-DOCSTART- -7692028- O O

Early JJ i
educational JJ i
intervention NN i
for IN N
very RB p
low JJ p
birth NN p
weight NN p
infants NNS p
: : p
results NNS N
from IN N
the DT N
Infant NNP i
Health NNP i
and CC i
Development NNP i
Program NNP i
. . i

OBJECTIVE NNP N
To TO N
examine VB N
the DT N
effect NN N
of IN N
early JJ i
educational JJ i
intervention NN i
after IN N
discharge NN N
from IN N
the DT N
hospital NN N
on IN N
the DT N
health NN N
and CC N
developmental JJ N
status NN N
of IN N
very RB p
low JJ p
birth NN p
weight NN p
( ( p
< CD p
or CC p
= VB p
1500 CD p
gm NN p
) ) p
infants NNS p
. . p

DESIGN NNP N
Randomized NNP N
, , N
controlled VBD N
trial NN N
, , N
with IN N
post NN N
hoc NN N
analysis NN N
. . N

SETTING NN N
Eight NNP p
sites NNS p
, , p
heterogeneous JJ p
for IN p
sociodemographic JJ p
and CC p
health NN p
care NN p
use NN p
. . p

PARTICIPANTS NN N
Infants NNS p
( ( p
N NNP p
= NNP p
280 CD p
) ) p
born VBN p
weighing VBG p
< NN p
or CC p
= NN p
1500 CD p
gm NN p
and CC p
selected VBN p
for IN p
the DT p
Infant NNP p
Health NNP p
and CC p
Development NNP p
Program NNP p
. . p

Eligibility NNP N
was VBD N
limited VBN N
primarily RB N
by IN N
geographic JJ p
distance NN p
from IN p
the DT p
day NN p
care NN p
center NN p
. . p

One CD N
third WDT N
were VBD N
randomly RB N
assigned VBN N
to TO N
the DT N
intervention NN N
( ( N
INT NNP N
) ) N
group NN N
and CC N
two CD N
thirds NNS N
to TO N
follow-up JJ i
only RB i
. . i

INTERVENTIONS NNP N
All NNP N
children NNS N
received VBD N
intensive JJ i
pediatric NNS i
and CC i
developmental JJ i
surveillance NN i
. . i

The DT N
INT NNP N
group NN N
received VBD i
home NN i
visits NNS i
and CC i
center-based JJ i
educational JJ i
interventions NNS i
until IN N
36 CD p
months NNS p
of IN p
age NN p
( ( p
corrected VBN p
for IN p
gestational JJ p
age NN p
when WRB p
final JJ p
assessments NNS p
were VBD p
completed VBN p
) ) p
. . p

OUTCOMES NNP N
Cognitive NNP o
development NN o
( ( o
Stanford-Binet JJ o
Intelligence NNP o
Scale NNP o
) ) o
, , o
behavioral JJ o
competence NN o
( ( o
Achebach NNP o
Child NNP o
Behavior NNP o
Checklist NNP o
) ) o
, , o
and CC o
health NN o
status NN o
( ( o
indexes NNS o
summarizing VBG o
reported VBD o
morbidity NN o
, , o
the DT o
Functional NNP o
Status NNP o
II NNP o
( ( o
R NNP o
) ) o
Scale NNP o
, , o
and CC o
General NNP o
Health NNP o
Ratings NNP o
Index NNP o
) ) o
. . N

RESULTS NNP N
Cognitive NNP o
development NN o
scores NNS o
were VBD N
7.2 CD N
points NNS N
higher JJR N
( ( N
p JJ N
= NNP N
0.002 CD N
) ) N
in IN N
the DT N
INT NNP N
group NN N
, , N
after IN N
adjustment NN N
for IN N
baseline NN N
differences NNS N
in IN N
site NN N
, , N
sociodemographic JJ N
characteristics NNS N
, , N
and CC N
neonatal JJ o
morbidity NN o
, , N
and CC N
were VBD N
9.4 CD N
points NNS N
higher JJR N
( ( N
p JJ N
< NNP N
0.0003 CD N
) ) N
when WRB N
the DT N
29 CD N
children NNS N
with IN N
significant JJ N
cerebral JJ N
palsy NN N
were VBD N
removed VBN N
. . N

No DT N
differences NNS N
in IN N
behavior NN o
, , o
serious JJ o
morbidity NN o
, , o
functional JJ o
status NN o
, , o
or CC o
health NN o
rating NN o
were VBD N
found VBN N
overall RB N
. . N

The DT N
infants NNS N
in IN N
the DT N
INT NNP N
group NN N
who WP N
weighted VBD N
< NNP N
or CC N
= VB N
1000 CD N
gm NN N
at IN N
birth NN N
had VBD N
significantly RB N
lower JJR o
behavior NN o
problem NN o
scores NNS o
but CC N
no DT N
differences NNS N
on IN N
other JJ N
outcomes NNS N
. . N

All DT N
children NNS N
in IN N
the DT N
INT NNP N
group NN N
had VBD N
slightly RB N
higher JJR N
rates NNS o
of IN o
less JJR o
serious JJ o
morbidity NN o
. . o

CONCLUSION VB N
The DT N
advantage NN N
conferred VBN N
by IN N
being VBG N
in IN N
the DT N
INT NNP N
group NN N
, , N
as IN N
previously RB N
reported VBN N
for IN N
heavier JJR N
infants NNS N
, , N
extends VBZ N
to TO N
very RB p
low JJ p
birth NN p
weight NN p
children NNS p
, , N
supporting VBG N
the DT N
use NN N
of IN N
early JJ N
intervention NN N
in IN N
this DT N
group NN N
. . N

-DOCSTART- -11284463- O O

Oral JJ N
rizatriptan NN N
versus IN N
oral JJ N
sumatriptan NN N
: : N
a DT N
direct JJ N
comparative NN N
study NN N
in IN N
the DT N
acute JJ p
treatment NN p
of IN p
migraine NN p
. . p

Rizatriptan NNP N
030 CD N
Study NNP N
Group NNP N
. . N

Rizatriptan NNP N
is VBZ N
a DT N
potent NN N
, , N
oral JJ N
, , N
5-HT1B/1D JJ N
agonist NN N
with IN N
more RBR N
rapid JJ N
absorption NN N
and CC N
higher JJR N
bioavailability NN N
than IN N
oral JJ N
sumatriptan NN N
. . N

It PRP N
was VBD N
postulated VBN N
that IN N
this DT N
would MD N
result VB N
in IN N
more RBR N
rapid JJ N
onset NN N
of IN N
effect NN N
. . N

This DT N
randomized JJ N
, , N
double-blind JJ N
, , N
triple-dummy JJ N
, , N
parallel-groups JJ N
study NN N
compared VBN N
rizatriptan VBZ i
5 CD i
mg NN i
, , i
rizatriptan VBZ i
10 CD i
mg NN i
, , i
sumatriptan JJ i
100 CD i
mg NN i
, , i
and CC i
placebo NN i
in IN N
1268 CD p
outpatients NNS p
treating VBG p
a DT p
single JJ p
migraine NN p
attack NN p
. . p

Headache NNP o
relief NN o
rates NNS o
after IN N
rizatriptan JJ N
10 CD N
mg NNS N
were VBD N
consistently RB N
higher JJR N
than IN N
sumatriptan JJR N
at IN N
all DT N
time NN N
points VBZ N
up IN N
to TO N
2 CD N
hours NNS N
, , N
with IN N
significance NN N
at IN N
1 CD N
hour NN N
( ( N
37 CD N
% NN N
versus IN N
28 CD N
% NN N
, , N
P NNP N
= NNP N
0.010 CD N
) ) N
. . N

All DT N
active JJ N
agents NNS N
were VBD N
significantly RB N
superior JJ N
to TO N
placebo VB N
with IN N
regard NN N
to TO N
headache VB o
relief NN o
and CC o
pain NN o
freedom NN o
at IN N
2 CD N
hours NNS N
( ( N
P NNP N
< NNP N
or CC N
= VB N
0.001 CD N
) ) N
. . N

The DT N
primary JJ N
efficacy NN N
endpoint NN N
of IN N
time NN o
to TO o
pain VB o
relief NN o
through IN o
2 CD o
hours NNS N
demonstrated VBD N
that IN N
, , N
after IN N
adjustment NN N
for IN N
age NN N
imbalance NN N
, , N
rizatriptan VBZ N
10 CD N
mg NN N
had VBD N
earlier RBR N
onset VBN N
than IN N
sumatriptan JJ N
100 CD N
mg NN N
( ( N
P NNP N
= NNP N
0.032 CD N
; : N
hazard NN N
ratio VBZ N
1.21 CD N
) ) N
. . N

Rizatriptan $ N
10 CD N
mg NN N
was VBD N
also RB N
superior JJ N
to TO N
sumatriptan VB N
on IN N
pain-free JJ o
response NN o
( ( N
P NNP N
= NNP N
0.032 CD N
) ) N
, , N
reduction NN o
in IN o
functional JJ o
disability NN o
( ( N
P NNP N
= NNP N
0.015 CD N
) ) N
, , N
and CC N
relief NN o
of IN o
nausea NN o
at IN N
2 CD N
hours NNS N
( ( N
P NNP N
= NNP N
0.010 CD N
) ) N
. . N

Significantly RB N
fewer JJR N
drug-related JJ o
clinical JJ o
adverse JJ o
events NNS o
were VBD N
reported VBN N
after IN N
rizatriptan NN N
10 CD N
mg NN N
( ( N
33 CD N
% NN N
, , N
P NNP N
= NNP N
0.014 CD N
) ) N
compared VBN N
with IN N
sumatriptan JJ N
100 CD N
mg NN N
( ( N
41 CD N
% NN N
) ) N
. . N

We PRP N
conclude VBP N
that IN N
rizatriptan VBZ N
10 CD N
mg NN N
has VBZ N
a DT N
rapid JJ N
onset NN N
of IN N
action NN N
and CC N
relieves VBZ N
headache NN N
and CC N
associated VBN N
symptoms NNS N
more RBR N
effectively RB N
than IN N
sumatriptan JJ N
100 CD N
mg NN N
. . N

-DOCSTART- -23065684- O O

Potential JJ N
effect NN N
of IN N
the DT N
risk NN N
of IN N
ovarian JJ i
cancer NN i
algorithm NN i
( ( i
ROCA NNP i
) ) i
on IN N
the DT N
mortality NN o
outcome NN o
of IN N
the DT N
Prostate NNP N
, , N
Lung NNP N
, , N
Colorectal NNP N
and CC N
Ovarian NNP N
( ( N
PLCO NNP N
) ) N
trial NN N
. . N

Recently RB N
, , N
the DT N
Prostate NNP p
, , p
Lung NNP p
, , p
Colorectal NNP p
and CC p
Ovarian NNP p
( ( p
PLCO NNP p
) ) p
Trial NNP p
reported VBD N
no DT N
mortality NN N
benefit NN N
for IN N
annual JJ N
screening NN i
with IN i
CA-125 NNP i
and CC i
transvaginal JJ i
ultrasound NN i
( ( i
TVU NNP i
) ) i
. . i

Currently NNP N
ongoing VBG N
is VBZ N
the DT N
UK NNP N
Collaborative NNP N
Trial NNP N
of IN N
Ovarian JJ N
Cancer NNP N
Screening NNP N
( ( N
UKCTOCS NNP N
) ) N
, , N
which WDT N
utilizes VBZ N
the DT N
risk NN N
of IN N
ovarian JJ i
cancer NN i
algorithm NN i
( ( i
ROCA NNP i
) ) i
, , N
a DT N
statistical JJ N
tool NN N
that IN N
considers NNS N
current JJ N
and CC N
past JJ N
CA125 NNP N
values NNS N
to TO N
determine VB N
ovarian JJ N
cancer NN N
risk NN N
. . N

In IN N
contrast NN N
, , N
PLCO NNP N
used VBD N
a DT N
single JJ N
cutoff NN N
for IN N
CA125 NNP N
, , N
based VBN N
on IN N
current JJ N
levels NNS N
alone RB N
. . N

We PRP N
investigated VBD N
whether IN N
having VBG N
had VBD N
used VBN N
ROCA NNP i
in IN i
PLCO NNP i
could MD N
have VB N
, , N
under IN N
optimal JJ N
assumptions NNS N
, , N
resulted VBD N
in IN N
a DT N
significant JJ o
mortality NN o
benefit NN o
by IN N
applying VBG N
ROCA NNP N
to TO N
PLCO NNP N
CA125 NNP N
screening VBG N
values NNS N
. . N

A DT N
best-case JJ N
scenario NN N
assumed VBD N
that IN N
all DT p
cancers NNS p
showing VBG p
a DT p
positive JJ p
screen NN p
result NN p
earlier RBR p
with IN p
ROCA NNP p
than IN p
under IN p
the DT p
PLCO NNP p
protocol NN N
would MD N
have VB N
avoided VBN N
mortality NN o
; : o
under IN N
a DT N
stage-shift JJ N
scenario NN N
, , N
such JJ p
women NNS p
were VBD N
assigned VBN N
survival JJ N
equivalent NN N
to TO N
Stage VB N
I/II NNP N
screen-detected JJ N
cases NNS N
. . N

Updated VBN N
PLCO NNP N
data NNS N
show VBP N
132 CD p
intervention NN p
arm NN p
ovarian JJ p
cancer NN p
deaths NNS p
versus VBP p
119 CD p
in IN p
usual JJ p
care NN p
( ( N
relative JJ N
risk NN N
, , N
RR NNP N
= NNP N
1.11 CD N
) ) N
. . N

Forty-three JJ N
ovarian JJ N
cancer NN N
cases NNS N
, , N
25 CD N
fatal NN N
, , N
would MD N
have VB N
been VBN N
detected VBN N
earlier RBR N
with IN N
ROCA NNP i
, , N
with IN N
a DT N
median JJ N
( ( N
minimum JJ N
) ) N
advance NN N
time NN N
for IN N
fatal JJ o
cases NNS o
of IN N
344 CD N
( ( N
147 CD N
) ) N
days NNS N
. . N

Best-case JJ N
and CC N
stage-shift JJ N
scenarios NNS N
gave VBD N
25 CD N
and CC N
19 CD N
deaths NNS o
prevented VBN N
with IN N
ROCA NNP i
, , N
for IN N
RRs NNP N
of IN N
0.90 CD N
( ( N
95 CD N
% NN N
CI NNP N
: : N
0.69-1.17 NN N
) ) N
and CC N
0.95 CD N
( ( N
95 CD N
% NN N
CI NNP N
: : N
0.74-1.23 NN N
) ) N
, , N
respectively RB N
. . N

Having VBG N
utilized JJ N
ROCA NNP i
in IN N
PLCO NNP N
would MD N
not RB N
have VB N
led VBN N
to TO N
a DT N
significant JJ N
mortality NN o
benefit NN o
of IN N
screening VBG N
. . N

However RB N
, , N
ROCA NNP i
could MD N
still RB N
show VB N
a DT N
significant JJ N
effect NN N
in IN N
other JJ N
screening NN N
trials NNS N
, , N
including VBG N
UKCTOCS NNP N
. . N

-DOCSTART- -25865762- O O

A DT N
Regulated JJ N
Trial NNP N
of IN N
Bicuspid NNP N
Aortic NNP N
Valve NNP N
Repair NNP N
Supported NNP N
by IN N
Geometric NNP i
Ring NNP i
Annuloplasty NNP i
. . i

BACKGROUND NNP N
Annular NNP N
stabilization NN N
is VBZ N
important JJ N
during IN N
bicuspid JJ N
aortic JJ N
valve NN N
( ( N
BAV NNP N
) ) N
repair NN N
to TO N
obtain VB N
the DT N
best JJS N
long-term JJ N
results NNS N
. . N

This DT N
report NN N
describes VBZ N
the DT N
early JJ N
outcomes NNS N
of IN N
a DT N
novel JJ N
bicuspid JJ N
annuloplasty NN N
ring NN N
for IN N
this DT N
purpose NN N
. . N

METHODS NNP N
Under IN N
regulatory JJ N
supervision NN N
( ( N
NCT02071849 NNP N
) ) N
, , N
a DT N
geometric JJ i
bicuspid NN i
annuloplasty JJ i
ring NN i
was VBD N
used VBN N
during IN p
valve JJ p
repair NN p
in IN p
16 CD p
patients NNS p
. . p

Three CD p
patients NNS p
had VBD p
Sievers NNP p
type JJ p
0 CD p
valves NNS p
, , p
11 CD p
had VBD p
Sievers NNP p
type JJ p
1 CD p
, , p
and CC p
2 CD p
had VBD p
Sievers NNP p
type JJ p
2 CD p
. . p

Thirteen JJ p
patients NNS p
had VBD p
left-/right-coronary JJ p
cusp NN p
fusion NN p
, , p
1 CD p
had VBD p
right-/noncoronary JJ p
cusp NN p
fusion NN p
, , p
and CC p
2 CD p
had VBD p
both DT p
. . p

Moderate NNP p
to TO p
severe VB p
aortic JJ p
insufficiency NN p
( ( p
AI NNP p
) ) p
was VBD p
present JJ p
in IN p
13 CD p
of IN p
16 CD p
patients NNS p
, , p
and CC p
3 CD p
had VBD p
mild VBN p
AI NNP p
with IN p
aortic JJ p
aneurysms NNS p
. . p

Ascending NNP N
aortic JJ N
aneurysms NNS N
, , N
root NN N
aneurysms NNS N
, , N
or CC N
both DT N
were VBD N
replaced VBN N
in IN N
7 CD N
of IN N
16 CD N
patients NNS N
. . N

The DT N
Dacron-covered JJ i
titanium NN i
ring NN i
had VBD N
circular JJ N
base NN N
geometry NN N
and CC N
two CD N
outwardly RB N
flaring JJ N
subcommissural JJ N
posts NNS N
positioned VBD N
opposite RB N
on IN N
the DT N
circumference NN N
. . N

The DT N
ring NN N
was VBD N
implanted VBN N
into IN N
the DT N
annulus JJ N
beneath NN N
the DT N
valve NN N
, , N
and CC N
then RB N
leaflet VB N
repair NN N
was VBD N
performed VBN N
. . N

RESULTS NNP N
Immediate NNP o
postrepair NN o
echocardiograms NN o
showed VBD o
grade JJ o
0 CD o
residual JJ o
AI NNP N
in IN N
all DT N
patients NNS N
, , N
with IN N
good JJ N
cusp NN o
mobility NN o
and CC o
effective JJ o
height NN o
, , o
and CC o
satisfactory JJ o
gradients NNS o
. . o

There EX N
were VBD N
no DT o
in-hospital JJ o
or CC o
late JJ o
mortalities NNS o
. . o

Two CD N
patients NNS N
experienced VBD o
leaflet JJ o
tears NNS o
from IN N
long JJ N
annular JJ N
suture NN N
tails NNS N
, , N
requiring VBG o
late JJ o
valve NN o
replacement NN o
. . o

After IN N
implementation NN N
of IN N
a DT N
lateral JJ N
suture NN N
fixation NN N
technique NN N
, , N
no DT N
more JJR o
failures NNS o
occurred VBD N
. . N

At IN N
a DT N
mean JJ N
follow-up JJ N
time NN N
of IN N
9 CD N
months NNS N
, , N
the DT N
remaining VBG N
14 CD N
patients NNS N
were VBD N
in IN o
New NNP o
York NNP o
Heart NNP o
Association NNP o
class NN o
I PRP N
, , N
with IN N
predominant JJ o
grade NN o
0 CD o
AI NNP o
. . o

CONCLUSIONS NNP N
As IN N
a DT N
technique NN N
for IN N
BAV NNP N
repair NN N
, , N
internal JJ N
ring NN N
annuloplasty NN N
produces VBZ N
major JJ o
annular JJ o
remodeling NN o
and CC o
stabilization NN o
. . o

Annular JJ N
reduction NN N
and CC N
reshaping VBG N
to TO N
a DT N
50/50 CD N
% NN N
symmetric JJ N
circular JJ N
geometry NN N
facilitates NNS o
leaflet VBP o
repair NN o
and CC N
enhances NNS o
cusp JJ o
coaptation NN o
. . o

Geometric NNP N
ring VBG N
annuloplasty NN N
could MD N
have VB N
useful JJ N
applications NNS N
in IN N
BAV NNP N
repair NN N
. . N

-DOCSTART- -3903063- O O

Hodgkin NNP p
's POS p
disease NN p
in IN p
childhood NN p
and CC p
adolescence NN p
: : p
results NNS N
of IN N
chemotherapy-radiotherapy NN N
in IN N
clinical JJ N
stages NNS N
IA-IIB NNP N
. . N

From IN N
April NNP N
1972 CD N
to TO N
May NNP N
1980 CD N
, , N
72 CD p
children NNS p
and CC p
adolescents NNS p
( ( p
aged VBN p
5 CD p
to TO p
19 CD p
years NNS p
old JJ p
, , p
median JJ p
16 CD p
) ) p
with IN p
Hodgkin NNP p
's POS p
disease NN p
, , p
clinical JJ p
stages NNS p
IA-IIB NNP p
( ( p
IA NNP p
, , p
18 CD p
; : p
II2A NNP p
, , p
two CD p
areas NNS p
involved VBN p
on IN p
the DT p
same JJ p
side NN p
of IN p
the DT p
diaphragm NN p
, , p
23 CD p
; : p
II3+A NNP p
, , p
three CD p
areas NNS p
or CC p
more JJR p
, , p
16 CD p
; : p
IIB NNP p
, , p
15 CD p
) ) p
were VBD N
prospectively RB N
treated VBN N
in IN N
two CD N
successive JJ N
clinical JJ N
trials NNS N
( ( N
H NNP N
72 CD N
and CC N
H NNP N
77 CD N
) ) N
. . N

Clinical JJ N
stages NNS N
IA NNP N
and CC N
II2A NNP N
received VBD N
three CD N
courses NNS N
of IN N
mechlorethamine NN i
, , i
Oncovin NNP i
, , i
procarbazine NN i
, , i
and CC i
prednisone NN i
( ( i
MOPP NNP i
) ) i
and CC i
supradiaphragmatic JJ i
radiotherapy NN i
( ( i
40 CD i
Gy NNP i
) ) i
, , i
and CC i
no DT i
laparotomy NN i
was VBD N
performed VBN N
. . N

Clinical JJ N
stages NNS N
II3+A NNP N
and CC N
IIB NNP N
received VBD N
either DT N
six CD N
cycles NNS N
of IN N
MOPP NNP i
( ( N
H NNP N
72 CD N
) ) N
, , N
three CD N
cycles NNS N
of IN N
MOPP NNP N
, , N
or CC N
three CD N
cycles NNS N
of IN N
CCNU NNP i
, , i
vinblastine NN i
, , i
procarbazine NN i
, , N
and CC N
prednisone NN i
( ( N
CVPP NNP N
) ) N
( ( N
H $ N
77 CD N
) ) N
and CC N
subsequently RB N
had VBD N
a DT N
laparotomy NN i
followed VBN N
by IN N
supradiaphragmatic JJ i
radiotherapy NN i
and CC N
a DT N
lumboaortic JJ N
field NN N
if IN N
results NNS N
of IN N
laparotomy NN N
were VBD N
positive JJ N
. . N

Patients NNS p
without IN p
evidence NN p
of IN p
mediastinal JJ p
involvement NN p
did VBD N
not RB N
have VB N
mediastinal JJ N
radiotherapy NN N
. . N

At IN N
the DT N
completion NN N
of IN N
therapy NN N
, , N
the DT N
disease NN N
in IN N
70 CD N
of IN N
72 CD N
patients NNS N
was VBD N
in IN N
complete JJ N
remission NN N
( ( N
one CD N
failure NN o
, , N
one CD N
death NN o
during IN N
treatment NN N
) ) N
. . N

Eight CD N
patients NNS N
relapsed VBN o
( ( N
in IN N
situ NN N
, , N
1 CD N
; : N
marginal JJ N
, , N
1 CD N
; : N
nonirradiated VBN N
subdiaphragmatic JJ N
area NN N
, , N
6 CD N
) ) N
after IN N
three CD N
to TO N
57 CD N
months NNS N
of IN N
complete JJ N
remission NN N
( ( N
median JJ N
20 CD N
months NNS N
) ) N
; : N
one CD N
patient NN N
died VBD N
after IN N
relapse NN N
. . N

There EX N
were VBD N
three CD N
deaths NNS o
after IN N
complete JJ N
remission NN N
of IN N
the DT N
disease NN N
( ( N
infection NN N
, , N
two CD N
; : N
acute CC N
nonlymphocytic JJ o
leukemia NN o
[ NNP N
ANLL NNP N
] NNP N
, , N
one CD N
) ) N
. . N

As IN N
of IN N
June NNP N
1984 CD N
the DT N
median JJ N
follow-up NN N
was VBD N
82 CD N
months NNS N
( ( N
range NN N
, , N
49 CD N
to TO N
145 CD N
months NNS N
) ) N
, , N
the DT o
actuarial JJ o
probabilities NNS o
for IN o
survival NN o
and CC o
freedom NN o
from IN o
relapse NN o
for IN N
all DT N
patients NNS N
being VBG N
91.6 CD N
% NN N
and CC N
87.6 CD N
% NN N
, , N
respectively RB N
. . N

There EX N
was VBD N
no DT N
statistical JJ N
difference NN N
according VBG N
to TO N
clinical JJ N
stage NN N
, , N
age NN N
( ( N
greater JJR N
than IN N
15 CD N
or CC N
less JJR N
than IN N
15 CD N
years NNS N
) ) N
, , N
sex NN N
, , N
or CC N
number NN o
of IN o
cycles NNS o
of IN o
chemotherapy NN o
( ( N
six CD N
or CC N
three CD N
) ) N
. . N

Bone NNP o
growth NN o
defects NNS o
related VBN o
to TO o
radiotherapy VB o
were VBD N
reduced VBN N
particularly RB N
in IN N
the DT N
29 CD N
patients NNS N
who WP N
did VBD N
not RB N
receive VB N
mediastinal JJ N
radiotherapy NN N
. . N

None NN N
of IN N
these DT N
patients NNS N
had VBD N
a DT N
mediastinal JJ o
relapse NN o
. . o

Azoospermia NNP o
was VBD N
the DT N
rule NN N
for IN N
the DT N
male NN N
patients NNS N
studied VBN N
, , N
but CC N
young JJ N
girls NNS N
and CC N
young JJ N
women NNS N
retained VBD N
reproductive JJ N
integrity NN N
. . N

-DOCSTART- -2642730- O O

A DT N
controlled JJ N
trial NN N
of IN N
extended JJ i
radical JJ i
versus NN N
radical JJ i
mastectomy NN i
. . i

Ten-year JJ N
results NNS N
. . N

In IN N
view NN N
of IN N
increasing VBG N
debate NN N
over IN N
possible JJ N
benefit NN N
of IN N
more JJR N
complete JJ N
surgery NN N
compared VBN N
to TO N
conservative JJ N
procedures NNS N
, , N
a DT N
randomized VBN N
controlled VBN N
trial NN N
contrasting VBG N
the DT N
then RB N
standard NN i
Halsted NNP i
radical NN i
( ( i
RDL NNP i
) ) i
operation NN i
with IN N
the DT N
more RBR N
complete JJ i
extended JJ i
radical NN i
( ( i
EXT NNP i
) ) i
mastectomy NN i
was VBD N
initiated VBN N
in IN N
1973 CD N
. . N

Between IN p
November NNP p
1973 CD p
and CC p
July NNP p
1982 CD p
, , p
123 CD p
women NNS p
younger JJR p
than IN p
70 CD p
years NNS p
of IN p
age NN p
and CC p
at IN p
clinical JJ p
Stages NNP p
I PRP p
and CC p
II NNP p
were VBD p
enrolled VBN p
. . p

Of IN N
the DT N
total JJ N
series NN N
, , N
112 CD p
were VBD p
treated VBN p
by IN p
the DT p
same JJ p
surgeon NN p
and CC p
confirmed VBD p
pathologically RB p
as IN p
having VBG p
invasive JJ p
mammary JJ p
carcinoma NN p
. . p

In IN N
this DT N
more RBR N
homogeneous JJ N
subgroup NN N
, , N
the DT N
10-year JJ o
survival NN o
rates NNS o
( ( N
and CC N
standard JJ N
errors NNS N
) ) N
were VBD N
for IN N
RDL NNP N
, , N
60 CD N
% NN N
( ( N
+/- JJ N
7 CD N
% NN N
) ) N
and CC N
for IN N
EXT NNP N
, , N
74 CD N
% NN N
( ( N
+/- JJ N
6 CD N
% NN N
) ) N
( ( N
P NNP N
value NN N
for IN N
comparison NN N
of IN N
survival JJ N
curves NNS N
= VBP N
0.13 CD N
) ) N
. . N

In IN N
patients NNS N
from IN N
this DT N
subgroup NN N
with IN N
central-medial JJ N
tumors NNS N
, , N
comprising VBG N
62 CD N
% NN N
of IN N
the DT N
total NN N
, , N
survival NN o
after IN N
RDL NNP N
at IN N
10 CD N
years NNS N
was VBD N
60 CD N
% NN N
( ( N
+/- JJ N
8 CD N
% NN N
) ) N
, , N
and CC N
after IN N
EXT NNP N
86 CD N
% NN N
( ( N
+/- JJ N
6 CD N
% NN N
) ) N
( ( N
P NNP N
= NNP N
0.025 CD N
) ) N
. . N

In IN N
the DT N
remaining VBG N
patients NNS p
with IN p
lateral JJ p
tumors NNS p
, , N
survival JJ o
rates NNS o
were VBD N
unaffected VBN N
by IN N
treatment NN N
: : N
58 CD N
% NN N
( ( N
+/- JJ N
13 CD N
% NN N
) ) N
and CC N
56 CD N
% NN N
( ( N
+/- JJ N
11 CD N
% NN N
) ) N
, , N
respectively RB N
( ( N
P NNP N
= NNP N
0.62 CD N
) ) N
. . N

Comparison NNP N
of IN N
a DT N
nonrandomized JJ N
series NN N
of IN N
266 CD N
RDL NNP N
and CC N
124 CD N
EXT NNP N
patients NNS p
treated VBD p
between IN p
1960 CD p
and CC p
1978 CD p
found VBD N
differences NNS N
consistent JJ N
with IN N
those DT N
of IN N
the DT N
randomized VBN N
study NN N
, , N
although IN N
not RB N
statistically RB N
significant JJ N
. . N

-DOCSTART- -2225700- O O

Mefloquine NNP i
kinetics NNS i
in IN p
cured JJ p
and CC p
recrudescent JJ p
patients NNS p
with IN p
acute JJ p
falciparum NN p
malaria NN p
and CC p
in IN p
healthy JJ p
volunteers NNS p
. . p

Mefloquine NNP i
pharmacokinetics NNS N
were VBD N
compared VBN N
in IN N
a DT N
randomized JJ N
clinical JJ p
trial NN p
in IN p
Thailand NNP p
among IN p
patients NNS p
with IN p
malaria NNS p
and CC p
healthy JJ p
volunteers NNS p
. . p

A DT N
single JJ N
oral JJ N
dose NN N
of IN N
1500 CD N
mg NN N
mefloquine NN i
hydrochloride NN i
was VBD N
administered VBN p
to TO p
11 CD p
patients NNS p
and CC p
5 CD p
volunteers NNS p
and CC p
750 CD p
mg NN p
was VBD p
given VBN p
to TO p
16 CD p
patients NNS p
and CC p
5 CD p
volunteers NNS p
. . p

Efficacy NNP o
was VBD N
82 CD N
% NN N
for IN N
1500 CD N
mg NN N
and CC N
63 CD N
% NN N
for IN N
750 CD N
mg NN N
. . N

In IN N
cured JJ p
patients NNS p
taking VBG p
750 CD p
mg JJ p
mefloquine NN i
, , p
peak JJ o
plasma JJ o
drug NN o
concentration NN o
( ( o
Cmax NNP o
) ) o
and CC o
area NN o
under IN o
the DT o
plasma JJ o
concentration-time JJ o
curve NN o
( ( o
AUC NNP o
) ) o
were VBD N
significantly RB N
greater JJR N
than IN N
in IN N
the DT N
patients NNS N
for IN N
whom WP N
treatment NN N
failed VBD N
( ( N
p NN N
less JJR N
than IN N
0.0005 CD N
and CC N
p RB N
less JJR N
than IN N
0.01 CD N
, , N
respectively RB N
) ) N
, , N
and CC N
plasma JJ o
mefloquine NN o
levels NNS o
were VBD N
significantly RB N
higher JJR N
from IN N
8 CD N
hours NNS N
to TO N
18 CD N
days NNS N
after IN N
treatment NN N
. . N

Mefloquine NNP o
AUC NNP o
was VBD N
reduced VBN N
and CC N
variable JJ N
in IN N
the DT N
presence NN N
of IN N
diarrhea NN N
. . N

Compared VBN N
with IN N
noninfected JJ N
volunteers NNS N
, , N
clinically RB N
ill JJ N
patients NNS N
displayed VBD N
a DT N
delayed JJ N
time NN o
to TO o
reach VB o
peak JJ o
concentration NN o
( ( N
p NN N
less JJR N
than IN N
0.01 CD N
) ) N
and CC N
significantly RB N
higher JJR N
mefloquine NN o
plasma NN o
levels NNS o
in IN N
the DT N
first JJ N
2 CD N
days NNS N
after IN N
administration NN N
of IN N
either CC N
the DT N
750 CD N
mg NN N
or CC N
the DT N
1500 CD N
mg NN N
dose NN N
. . N

Mefloquine NNP o
AUC NNP o
was VBD N
similar JJ N
in IN N
patients NNS p
with IN p
malaria NNS p
and CC p
healthy JJ p
volunteers NNS p
. . N

Because IN N
plasma JJ N
levels NNS N
increased VBN N
in IN N
temporal JJ N
relationship NN N
with IN N
clinical JJ N
illness NN N
, , N
mefloquine JJ N
volume NN N
of IN N
distribution NN N
or CC N
clearance NN N
( ( N
or CC N
both DT N
) ) N
was VBD N
reduced VBN N
during IN N
the DT N
acute JJ N
phase NN N
of IN N
illness NN N
. . N

-DOCSTART- -16567604- O O

Prolonged JJ N
effects NNS N
of IN N
a DT N
home-based JJ i
intervention NN i
in IN N
patients NNS p
with IN p
chronic JJ p
illness NN p
. . p

BACKGROUND NNP N
Data NNP N
on IN N
the DT N
long-term JJ N
benefits NNS N
of IN N
nonspecific JJ N
disease NN N
management NN N
programs NNS N
are VBP N
limited JJ N
. . N

We PRP N
performed VBD N
a DT N
long-term JJ N
follow-up NN N
of IN N
a DT N
previously RB N
published VBN N
randomized VBN N
trial NN N
. . N

METHODS NNP N
We PRP N
compared VBN N
all-cause JJ o
mortality NN o
and CC o
recurrent JJ o
hospitalization NN o
during IN N
median JJ N
follow-up NN N
of IN N
7.5 CD N
years NNS N
in IN N
a DT N
heterogeneous JJ p
cohort NN p
of IN p
patients NNS p
with IN p
chronic JJ p
illness NN p
initially RB p
exposed VBD p
to TO p
a DT p
multidisciplinary JJ i
, , i
home-based JJ i
intervention NN i
( ( i
HBI NNP i
) ) i
( ( p
n JJ p
= NNP p
260 CD p
) ) p
or CC p
to TO p
usual JJ i
postdischarge NN i
care NN i
( ( p
n JJ p
= NNP p
268 CD p
) ) p
. . p

RESULTS NNP N
During IN N
follow-up JJ N
, , N
HBI NNP i
had VBD N
no DT N
impact NN N
on IN N
all-cause JJ o
mortality NN o
( ( N
relative JJ N
risk NN N
, , N
1.04 CD N
; : N
95 CD N
% NN N
confidence NN N
interval NN N
, , N
0.80-1.35 JJ N
) ) N
or CC N
event-free JJ o
survival NN o
from IN o
death NN o
or CC o
unplanned JJ o
hospitalization NN o
( ( N
relative JJ N
risk NN N
, , N
1.03 CD N
; : N
95 CD N
% NN N
confidence NN N
interval NN N
, , N
0.86-1.24 JJ N
) ) N
. . N

Initial JJ N
analysis NN N
suggested VBD N
that IN N
HBI NNP i
had VBD N
only RB N
a DT N
marginal JJ N
impact NN N
in IN N
reducing VBG N
unplanned JJ o
hospitalization NN o
, , N
with IN N
677 CD N
readmissions NNS N
vs VBP N
824 CD N
for IN N
the DT N
usual JJ N
care NN N
group NN N
( ( N
mean JJ N
+/- JJ N
SD NNP N
rate NN N
, , N
0.72 CD N
+/- JJ N
0.96 CD N
vs JJ N
0.84 CD N
+/- JJ N
1.20 CD N
readmissions/patient NN N
per IN N
year NN N
; : N
P NNP N
= NNP N
.08 NNP N
) ) N
. . N

When WRB N
accounting VBG N
for IN N
increased JJ N
hospital NN o
activity NN o
in IN N
HBI NNP N
patients NNS p
with IN p
chronic JJ p
obstructive JJ p
pulmonary JJ p
disease NN p
during IN N
follow-up NN N
for IN N
2 CD N
years NNS N
, , N
post NN N
hoc NN N
analyses VBZ N
showed VBD N
that IN N
HBI NNP i
reduced VBD N
readmissions NNS o
by IN N
14 CD N
% NN N
within IN N
2 CD N
years NNS N
in IN N
patients NNS N
without IN N
this DT N
condition NN N
( ( N
mean JJ N
+/- JJ N
SD NNP N
rate NN N
, , N
0.54 CD N
+/- JJ N
0.72 CD N
vs JJ N
0.63 CD N
+/- JJ N
0.88 CD N
readmission/patient NN N
per IN N
year NN N
; : N
P NNP N
= NNP N
.04 NNP N
) ) N
and CC N
by IN N
21 CD N
% NN N
in IN N
all DT N
surviving VBG N
patients NNS N
within IN N
3 CD N
to TO N
8 CD N
years NNS N
( ( N
mean JJ N
+/- JJ N
SD NNP N
rate NN N
, , N
0.64 CD N
+/- JJ N
1.26 CD N
vs JJ N
0.81 CD N
+/- JJ N
1.61 CD N
readmissions/patient NN N
per IN N
year NN N
; : N
P NNP N
= NNP N
.03 NNP N
) ) N
. . N

Overall JJ N
, , N
recurrent JJ o
hospital NN o
costs NNS o
were VBD N
significantly RB N
lower JJR N
( ( N
14 CD N
% NN N
) ) N
in IN N
the DT N
HBI NNP i
group NN N
( ( N
mean JJ N
+/- JJ N
SD NNP N
, , N
823 CD N
dollars NNS N
+/- JJ N
1642 CD N
dollars NNS N
vs JJ N
960 CD N
dollars NNS N
+/- JJ N
1376 CD N
dollars NNS N
per IN N
patient NN N
per IN N
year NN N
; : N
P NNP N
= NNP N
.045 NNP N
) ) N
. . N

CONCLUSION VB N
This DT N
unique JJ N
study NN N
suggests VBZ N
that IN N
a DT N
nonspecific JJ N
HBI NNP i
provides VBZ N
long-term JJ N
cost NN N
benefits NNS N
in IN N
a DT N
range NN N
of IN N
chronic JJ N
illnesses NNS N
, , N
except IN N
for IN N
chronic JJ N
obstructive JJ N
pulmonary JJ N
disease NN N
. . N

-DOCSTART- -25432505- O O

Effectiveness NN N
of IN N
a DT N
fundamental JJ i
motor NN i
skill NN i
intervention NN i
for IN N
4-year-old JJ p
children NNS p
with IN p
autism NN p
spectrum NN p
disorder NN p
: : p
A DT N
pilot NN N
study NN N
. . N

A DT N
wait-list JJ i
control NN i
experimental JJ N
design NN N
was VBD N
employed VBN N
to TO N
investigate VB N
the DT N
effectiveness NN N
of IN N
a DT N
fundamental JJ i
motor NN i
skill NN i
intervention NN i
at IN N
improving VBG N
the DT N
motor NN o
skills NNS o
, , o
adaptive JJ o
behavior NN o
, , o
and CC o
social JJ o
skills NNS o
of IN N
4-year-old JJ p
children NNS p
with IN p
autism NN p
spectrum NN p
disorder NN p
( ( p
experimental JJ p
n NN p
= VBD p
5 CD p
, , p
control NN p
n JJ p
= NNP p
4 CD p
) ) p
; : p
the DT p
impact NN p
of IN N
intervention NN N
intensity NN N
was VBD N
also RB N
explored VBN N
. . N

The DT N
experimental JJ N
group NN N
significantly RB N
improved VBN N
their PRP$ o
object JJ o
manipulation NN o
and CC o
overall JJ o
motor NN o
scores NNS o
from IN N
pre- JJ N
to TO N
post-intervention NN i
. . i

The DT i
wait-list JJ i
control NN N
design NN N
revealed VBD N
no DT N
group-by-time JJ N
interactions NNS N
; : N
however RB N
, , N
with IN N
the DT N
groups NNS N
combined VBD N
time NN N
was VBD N
a DT N
significant JJ N
factor NN N
for IN N
all DT N
motor NN o
variables NNS o
. . o

There EX o
were VBD N
no DT N
significant JJ N
changes NNS N
in IN o
adaptive JJ o
behavior NN o
and CC o
social JJ o
skills NNS o
. . o

These DT N
preliminary JJ N
findings NNS N
suggest VBP N
that IN N
a DT N
fundamental JJ N
motor NN N
skill NN N
intervention NN N
may MD N
benefit VB N
young JJ p
children NNS p
with IN p
autism NN p
spectrum NN p
disorder NN p
. . p

Future JJ p
research NN N
with IN N
larger JJR N
samples NNS N
is VBZ N
warranted VBN N
. . N

-DOCSTART- -10402369- O O

Adjuvant JJ N
L-arginine NNP i
treatment NN N
for IN N
in-vitro JJ N
fertilization NN N
in IN N
poor JJ p
responder NN p
patients NNS p
. . p

The DT N
objective NN N
of IN N
the DT N
present JJ N
study NN N
was VBD N
prospectively RB N
and CC N
randomly RB N
to TO N
evaluate VB N
the DT N
role NN N
of IN N
L-arginine NNP i
in IN N
improving VBG N
uterine JJ o
and CC o
follicular JJ o
Doppler NNP o
flow NN o
and CC N
in IN N
improving VBG N
ovarian JJ o
response NN o
to TO o
gonadotrophin VB o
in IN N
poor JJ p
responder NN p
women NNS p
. . p

A DT N
total NN N
of IN N
34 CD p
patients NNS p
undergoing JJ p
assisted JJ p
reproduction NN p
was VBD N
divided VBN N
in IN N
two CD i
groups NNS i
according VBG i
to TO i
different JJ i
ovarian JJ i
stimulation NN i
protocols NNS i
: : i
( ( i
i NN i
) ) i
flare-up JJ i
gonadotrophin-releasing JJ i
hormone NN i
analogue NN i
( ( i
GnRHa NNP i
) ) i
plus CC i
elevated JJ i
pure NN i
follicle NN i
stimulating VBG i
hormone NN i
( ( i
pFSH NN i
) ) i
( ( i
n JJ i
= NNP i
17 CD i
) ) i
; : i
and CC i
( ( i
ii NN i
) ) i
flare-up NN i
GnRHa NNP i
plus CC i
elevated VBN i
pFSH JJ i
plus CC i
oral JJ i
L-arginine NNP i
( ( i
n JJ i
= NNP i
17 CD i
) ) i
. . i

During IN N
the DT N
ovarian JJ N
stimulation NN N
regimen NNS N
, , N
the DT i
patients NNS i
were VBD i
submitted VBN i
to TO i
hormonal VB i
( ( i
oestradiol NN i
and CC i
growth NN i
hormone NN i
) ) i
, , i
ultrasonographic JJ i
( ( i
follicular JJ i
number NN i
and CC i
diameter NN i
, , i
endometrial JJ i
thickness NN i
) ) i
and CC i
Doppler NNP i
( ( i
uterine JJ i
and CC i
perifollicular JJ i
arteries NNS i
) ) i
evaluations NNS i
. . i

Furthermore RB N
, , N
the DT N
plasma NN N
and CC N
follicular JJ N
fluid NN N
concentrations NNS N
of IN N
arginine NN N
, , N
citrulline NN N
, , N
nitrite/nitrate NN N
( ( N
NO2-/NO3- NNP N
) ) N
, , N
and CC N
insulin-like JJ N
growth NN N
factor-1 JJ N
( ( N
IGF-1 NNP N
) ) N
were VBD N
assayed VBN N
. . N

All DT N
34 CD p
patients NNS p
completed VBD N
the DT N
study NN N
. . N

In IN N
the DT N
L-arginine NNP i
treated VBD N
group NN N
a DT N
lower JJR o
cancellation NN o
rate NN o
, , o
an DT o
increased JJ o
number NN o
of IN o
oocytes NNS o
collected VBN o
, , o
and CC o
embryos RB o
transferred VBN o
were VBD N
observed VBN N
. . N

In IN N
the DT N
same JJ N
group NN N
, , N
increased VBD o
plasma NN o
and CC o
follicular JJ o
fluid NN o
concentrations NNS o
of IN o
arginine NN o
, , o
citrulline NN o
, , o
NO2-/NO3- NNP o
, , o
and CC o
IGF-1 NNP o
was VBD N
observed VBN N
. . N

Significant JJ o
Doppler NNP o
flow NN o
improvement NN o
was VBD N
obtained VBN N
in IN N
the DT N
L-arginine NNP i
supplemented VBD N
group NN N
. . N

Three CD N
pregnancies NNS o
were VBD N
registered VBN N
in IN N
these DT N
patients NNS N
. . N

No DT N
pregnancies NNS o
were VBD N
observed VBN N
in IN N
the DT N
other JJ N
group NN N
. . N

It PRP N
was VBD N
concluded VBN N
that IN N
oral JJ N
L-arginine JJ i
supplementation NN N
in IN N
poor JJ p
responder NN p
patients NNS p
may MD N
improve VB N
ovarian JJ o
response NN o
, , o
endometrial JJ o
receptivity NN o
and CC o
pregnancy NN o
rate NN o
. . o

-DOCSTART- -17014731- O O

Nordic NNP i
walking NN i
and CC N
chronic JJ N
low JJ N
back RB N
pain NN N
: : N
design NN N
of IN N
a DT N
randomized JJ N
clinical JJ N
trial NN N
. . N

BACKGROUND NNP N
Low NNP N
Back NNP N
Pain NNP N
is VBZ N
a DT N
major JJ N
public JJ N
health NN N
problem NN N
all DT N
over IN N
the DT N
western JJ N
world NN N
. . N

Active JJ N
approaches NNS N
including VBG N
exercise NN N
in IN N
the DT N
treatment NN N
of IN N
low JJ N
back RB N
pain NN N
results NNS N
in IN N
better JJR N
outcomes NNS N
for IN N
patients NNS N
, , N
but CC N
it PRP N
is VBZ N
not RB N
known VBN N
exactly RB N
which WDT N
types NNS N
of IN N
back NN N
exercises NNS N
are VBP N
most RBS N
beneficial JJ N
or CC N
whether IN N
general JJ N
physical JJ N
activity NN N
provide VBP N
similar JJ N
benefits NNS N
. . N

Nordic NNP i
Walking NNP i
is VBZ N
a DT N
popular JJ N
and CC N
fast JJ N
growing VBG N
type NN N
of IN N
exercise NN N
in IN N
Northern NNP N
Europe NNP N
. . N

Initial NNP N
studies NNS N
have VBP N
demonstrated VBN N
that IN N
persons NNS N
performing VBG N
Nordic NNP i
Walking NNP i
are VBP N
able JJ N
to TO N
exercise VB N
longer JJR N
and CC N
harder RBR N
compared VBN N
to TO N
normal JJ N
walking VBG N
thereby RB N
increasing VBG N
their PRP$ N
cardiovascular JJ N
metabolism NN N
. . N

Until IN N
now RB N
no DT N
studies NNS N
have VBP N
been VBN N
performed VBN N
to TO N
investigate VB N
whether IN N
Nordic NNP i
Walking NNP i
has VBZ N
beneficial JJ N
effects NNS o
in IN N
relation NN N
to TO N
low VB N
back RB N
pain NN N
. . N

The DT N
primary JJ N
aim NN N
of IN N
this DT N
study NN N
is VBZ N
to TO N
investigate VB N
whether IN N
supervised JJ i
Nordic NNP i
Walking NNP i
can MD N
reduce VB o
pain NN o
and CC N
improve VB o
function NN o
in IN p
a DT p
population NN p
of IN p
chronic JJ p
low JJ p
back RB p
pain NN p
patients NNS p
when WRB N
compared VBN N
to TO N
unsupervised JJ i
Nordic NNP i
Walking NNP i
and CC i
advice NN i
to TO i
stay VB i
active JJ i
. . i

In IN N
addition NN N
we PRP N
investigate VBP N
whether IN N
there EX N
is VBZ N
an DT N
increase NN N
in IN N
the DT N
cardiovascular JJ N
metabolism NN N
in IN N
persons NNS p
performing VBG p
supervised VBD i
Nordic NNP i
Walking NNP i
compared VBN N
to TO N
persons NNS p
who WP p
are VBP p
advised VBN i
to TO i
stay VB i
active JJ i
. . i

Finally RB N
, , N
we PRP N
investigate VBP N
whether IN N
there EX N
is VBZ N
a DT N
difference NN N
in IN N
compliance NN o
between IN N
persons NNS p
receiving VBG p
supervised VBD i
Nordic NNP i
Walking NNP i
and CC N
persons NNS p
doing VBG p
unsupervised JJ i
Nordic NNP i
Walking NNP i
. . i

METHODS NNP N
One CD p
hundred CD p
and CC p
fifty JJ p
patients NNS p
with IN p
low JJ p
back RB p
pain NN p
for IN p
at IN p
least JJS p
eight CD p
weeks NNS p
and CC p
referred VBD p
to TO p
a DT p
specialized JJ p
secondary JJ p
sector NN p
outpatient NN p
back RB p
pain NN p
clinic NN p
are VBP p
included VBN p
in IN p
the DT p
study NN p
. . p

After IN N
completion NN N
of IN N
the DT N
standard NN i
back RB i
centre JJ i
treatment NN i
patients NNS N
are VBP N
randomized VBN N
into IN N
one CD N
of IN N
three CD p
groups NNS p
: : p
A DT p
) ) p
Nordic NNP i
Walking NNP i
twice RB i
a DT i
week NN i
for IN i
eight CD i
weeks NNS i
under IN i
supervision NN i
of IN i
a DT i
specially RB i
trained JJ i
instructor NN i
; : i
B NNP p
) ) p
Unsupervised VBD i
Nordic NNP i
Walking NNP i
for IN i
eight CD i
weeks NNS i
after IN i
one CD i
training NN i
session NN i
with IN i
an DT i
instructor NN i
; : i
C NNP p
) ) p
A DT i
one CD i
hour NN i
motivational JJ i
talk NN i
including VBG i
advice NN i
to TO i
stay VB i
active JJ i
. . i

Outcome NN N
measures NNS N
are VBP N
pain NN o
, , o
function NN o
, , o
overall JJ o
health NN o
, , o
cardiovascular JJ o
ability NN o
and CC o
activity NN o
level NN o
. . o

RESULTS NNP N
No NNP N
results NNS N
available JJ N
at IN N
this DT N
point NN N
. . N

DISCUSSION NNP N
This DT N
study NN N
will MD N
investigate VB N
the DT N
effect NN N
of IN N
Nordic NNP i
Walking VBG i
on IN N
pain NN N
and CC N
function NN N
in IN N
a DT N
population NN p
of IN p
people NNS p
with IN p
chronic JJ p
LBP NNP p
. . p

-DOCSTART- -8215273- O O

Cefprozil NNP i
versus NN i
penicillin NN i
V NNP i
in IN N
treatment NN N
of IN N
streptococcal JJ p
tonsillopharyngitis NN p
. . p

In IN N
a DT N
randomized JJ N
multicenter NN N
study NN N
, , N
the DT N
efficacy NN o
and CC o
safety NN o
of IN N
cefprozil NN i
were VBD N
compared VBN N
with IN N
those DT N
of IN N
penicillin NN i
in IN N
the DT N
treatment NN N
of IN N
group NN p
A NNP p
streptococcal JJ p
tonsillopharyngitis NN p
in IN p
children NNS p
. . p

Of IN p
the DT p
409 CD p
patients NNS p
enrolled VBD p
, , p
323 CD p
were VBD p
evaluable JJ p
for IN p
their PRP$ p
clinical JJ p
and CC p
bacteriological JJ p
responses NNS p
; : p
of IN N
these DT N
323 CD p
children NNS p
, , N
172 CD N
received VBD N
cefprozil NN i
and CC N
151 CD N
received VBD N
penicillin NN i
V. NNP i
The DT N
clinical JJ o
responses NNS o
in IN N
patients NNS N
treated VBN N
with IN N
cefprozil NNS i
were VBD N
significantly RB N
better JJR N
than IN N
those DT N
in IN N
patients NNS N
who WP N
received VBD N
penicillin NN i
( ( N
95.3 CD N
versus RB N
88.1 CD N
% NN N
; : N
P NNP N
= NNP N
0.023 CD N
) ) N
. . N

Eradication NN o
of IN o
the DT o
original JJ o
serotype NN o
of IN o
group NN o
A NNP o
streptococci NN o
was VBD N
achieved VBN N
in IN N
91.3 CD N
% NN N
of IN N
patients NNS N
treated VBN N
with IN N
cefprozil NN i
and CC N
87.4 CD N
% NN N
of IN N
patients NNS N
treated VBN N
with IN N
penicillin NN i
, , N
the DT N
difference NN N
not RB N
being VBG N
statistically RB N
significant JJ N
( ( N
P NNP N
= NNP N
0.125 CD N
) ) N
. . N

However RB N
, , N
there EX N
were VBD N
significantly RB N
more RBR N
symptomatic JJ o
patients NNS N
among IN N
the DT N
bacteriological JJ N
failures NNS N
in IN N
the DT N
penicillin NN i
group NN N
( ( N
68.4 CD N
% NN N
) ) N
than IN N
in IN N
the DT N
cefprozil NN i
group NN N
( ( N
26.7 CD N
% NN N
) ) N
. . N

beta-Lactamase-producing JJ N
Staphylococcus NNP o
aureus NN o
was VBD o
more RBR N
frequently RB N
isolated VBN o
from IN o
the DT o
throat NN o
flora NN o
during IN N
penicillin NN i
therapy NN i
than IN N
during IN N
cefprozil JJ i
treatment NN N
. . N

No DT N
difference NN N
in IN N
the DT N
incidence NN o
of IN o
adverse JJ o
events NNS o
probably RB N
related VBD N
or CC N
of IN N
unknown JJ N
relationship NN N
to TO N
the DT N
study NN N
drugs NNS N
was VBD N
observed VBN N
in IN N
the DT N
two CD N
treatment NN N
groups NNS N
( ( N
5.2 CD N
% NN N
of IN N
those DT N
treated VBN N
with IN N
cefprozil NN i
and CC N
6.0 CD N
% NN N
of IN N
those DT N
treated VBN N
with IN N
penicillin NN i
) ) i
. . N

Cefprozil NNP i
can MD N
be VB N
considered VBN N
a DT N
safe JJ N
and CC N
reliable JJ N
drug NN N
for IN N
the DT N
treatment NN N
of IN N
streptococcal JJ p
pharyngitis NN p
in IN p
children NNS p
. . p

-DOCSTART- -19926166- O O

Routine NNP i
antibiotic JJ i
use NN i
in IN N
preterm JJ p
neonates NNS p
: : p
a DT N
randomised JJ N
controlled VBN N
trial NN N
. . N

The DT N
immature NN N
immune JJ N
system NN N
of IN N
preterm NN p
neonates NNS p
puts VBZ N
them PRP N
at IN N
higher JJR N
risk NN N
of IN N
neonatal JJ N
sepsis NN N
. . N

We PRP N
conducted VBD N
a DT N
part-blinded JJ N
randomised VBN N
controlled VBN N
trial NN N
to TO N
compare VB N
the DT N
effect NN N
of IN N
routine JJ i
antibiotic JJ i
treatment NN i
on IN N
the DT N
incidence NN N
of IN N
clinical JJ N
sepsis NN N
in IN N
preterm JJ p
neonates NNS p
. . p

Preterm NNP p
neonates NNS p
without IN p
other JJ p
risk NN p
factors NNS p
for IN p
infection NN p
admitted VBN p
in IN p
the DT p
first JJ p
12h CD p
of IN p
life NN p
were VBD N
randomised VBN N
to TO N
receive VB N
routine JJ i
antibiotics NNS i
or CC N
to TO N
a DT N
control NN i
group NN i
( ( i
no DT i
antibiotics NNS i
unless IN i
clinically RB i
indicated VBN i
) ) i
. . i

The DT N
primary JJ N
outcome NN N
variable NN N
was VBD N
the DT N
incidence NN o
of IN o
clinical JJ o
sepsis NN o
. . o

Secondary JJ N
outcomes NNS N
were VBD N
the DT N
incidence NN o
of IN o
positive JJ o
blood NN o
cultures NNS o
, , o
necrotising VBG o
enterocolitis NN o
( ( o
NEC NNP o
) ) o
stage NN o
II NNP o
or CC o
III NNP o
, , o
or CC o
death NN o
, , o
and CC o
the DT o
duration NN o
of IN o
hospital NN o
stay NN o
. . o

The DT N
incidence NN o
of IN o
clinical JJ o
sepsis NN o
was VBD N
comparable JJ N
in IN N
both DT N
groups NNS N
( ( N
intervention NN N
31.9 CD N
% NN N
, , N
control VB N
25.4 CD N
% NN N
; : N
P=0.392 NNP N
) ) N
. . N

Mortality NNP o
was VBD N
equivalent JJ N
in IN N
both DT N
groups NNS N
. . N

The DT N
control NN N
group NN N
had VBD N
significantly RB N
more RBR N
positive JJ N
blood NN o
cultures NNS o
( ( N
P=0.002 NNP N
) ) N
. . N

The DT N
incidence NN o
of IN o
NEC NNP o
and CC o
the DT o
duration NN o
of IN o
hospital NN o
stay NN o
were VBD N
comparable JJ N
in IN N
both DT N
groups NNS N
. . N

In IN N
low JJ p
risk NN p
preterm NN p
neonates VBZ p
we PRP N
found VBD N
no DT N
evidence NN N
that IN N
routine JJ N
antibiotic JJ i
use NN N
has VBZ N
a DT N
protective JJ N
effect NN N
. . N

-DOCSTART- -23021898- O O

Insular JJ N
and CC N
anterior JJ N
cingulate NN N
circuits NNS N
in IN N
smokers NNS p
with IN p
schizophrenia NN p
. . p

Schizophrenia NNP p
( ( p
SZ NNP p
) ) p
is VBZ N
associated VBN N
with IN N
high JJ N
rates NNS N
of IN N
smoking NN N
. . N

We PRP N
previously RB N
found VBD N
that IN N
resting VBG N
state NN N
functional JJ N
connectivity NN N
( ( N
rsFC NN N
) ) N
between IN N
the DT N
dorsal NN N
anterior JJ N
cingulate NN N
( ( N
dACC NN N
) ) N
and CC N
striatum NN N
is VBZ N
independently RB N
associated VBN N
with IN N
nicotine JJ N
addiction NN N
and CC N
psychiatric JJ N
illness NN N
. . N

Since IN N
the DT N
insula NN N
is VBZ N
implicated VBN N
in IN N
nicotine JJ N
dependence NN N
, , N
we PRP N
hypothesized VBD N
that IN N
SZ NNP N
smokers NNS N
will MD N
have VB N
greater JJR N
dysfunction NN N
in IN N
smoking-related JJ N
insular NN N
and CC N
dACC NN N
circuits NNS N
than IN N
normal JJ p
control NN p
smokers NNS p
( ( p
NC NNP p
) ) p
independent JJ N
of IN N
smoking VBG N
severity NN N
, , N
consistent NN N
with IN N
an DT N
inherent JJ N
disease-related JJ N
weakening NN N
of IN N
smoking-related JJ N
circuits NNS N
. . N

Nicotine NNP N
challenge NN N
was VBD N
used VBN N
to TO N
demonstrate VB N
that DT N
decreased VBD N
rsFC NN N
in IN N
identified JJ N
circuits NNS N
reflects VBZ N
addiction JJ N
trait NN N
and CC N
is VBZ N
not RB N
affected VBN N
by IN N
pharmacological JJ N
state NN N
. . N

Twenty-four CD p
NC NNP p
smokers NNS p
and CC p
20 CD p
smokers NNS p
with IN p
SZ NNP p
matched VBD p
on IN p
nicotine JJ p
addiction NN p
severity NN p
participated VBN N
in IN N
a DT N
resting NN i
state NN i
fMRI NN i
study NN i
and CC i
were VBD i
scanned VBN i
during IN i
two CD i
separate JJ i
sessions NNS i
while IN i
receiving VBG i
a DT i
placebo NN i
or CC i
nicotine JJ i
patch NN i
, , i
in IN i
a DT i
randomized JJ i
, , i
cross-over JJ i
design NN i
. . i

Using VBG N
individualized JJ N
, , N
anatomically RB N
defined VBN N
anterior JJ N
and CC N
posterior JJ N
insula NN N
and CC N
dACC NN N
as IN N
regions NNS N
of IN N
interest NN N
( ( N
ROI NNP N
) ) N
, , N
whole JJ N
brain NN N
rsFC NN N
was VBD N
performed VBN N
using VBG N
each DT N
ROI NNP N
as IN N
a DT N
seed NN N
. . N

Significant NNP N
negative JJ N
correlations NNS N
between IN N
smoking VBG o
severity NN o
and CC o
rsFC NN o
between IN o
insula NN o
, , N
dACC NN N
and CC N
striatum NN N
were VBD N
found VBN N
for IN N
both DT N
groups NNS N
. . N

Furthermore RB N
, , N
smokers NNS p
with IN p
SZ NNP p
demonstrated VBD N
additive JJ N
reductions NNS N
in IN N
circuit NN N
strength NN N
between IN N
the DT N
dACC NN N
and CC N
insula NN N
compared VBN N
to TO N
NC NNP p
smokers NNS p
independent JJ N
of IN N
smoking VBG N
severity NN N
. . N

Nicotine NNP o
challenge NN o
did VBD N
not RB N
significantly RB N
alter VB o
rsFC NN o
in IN o
insula-dACC-striatal JJ o
circuits NNS o
. . o

Reduced VBN N
rsFC JJ o
strength NN o
between IN N
the DT N
insula NN N
, , N
dACC NN N
and CC N
striatum NN N
is VBZ N
associated VBN N
with IN N
nicotine JJ N
addiction NN N
severity NN N
in IN N
both DT N
non-psychiatrically RB N
ill NN N
and CC N
in IN N
SZ NNP N
smokers NNS N
. . N

Decreased VBN N
insula-dACC JJ N
rsFC NN N
may MD N
index NN N
overlapping VBG N
circuitry NN N
associated VBN N
with IN N
smoking NN N
and CC N
SZ NNP N
. . N

-DOCSTART- -16097539- O O

Migration NN p
of IN p
the DT p
acetabular JJ p
component NN p
: : p
effect NN o
of IN o
cement NN o
pressurization NN o
and CC o
significance NN o
of IN o
early JJ o
radiolucency NN o
: : o
a DT N
randomized JJ N
5-year JJ N
study NN N
using VBG N
radiostereometry NN i
. . i

BACKGROUND NNP N
Cementing NNP N
technique NN N
is VBZ N
a DT N
crucial JJ N
factor NN N
in IN N
prosthesis NN p
fixation NN p
. . p

No DT N
randomized JJ N
studies NNS N
have VBP N
been VBN N
published VBN N
, , N
however RB N
, , N
comparing VBG N
the DT N
outcome NN N
of IN N
conventional JJ N
fingerpacking NN N
with IN N
the DT N
outcome NN N
of IN N
pressurization NN N
of IN N
the DT N
cement NN N
prior RB N
to TO N
cup VB N
insertion NN N
. . N

PATIENTS NNP N
AND CC N
METHODS NNP N
We PRP N
randomized VBD N
50 CD p
THAs NNP i
to TO i
either VB i
fingerpacking NN i
or CC i
sequential JJ i
pressurization NN i
( ( i
including VBG i
individual JJ i
pressurization NN i
of IN i
each DT i
anchorage NN i
hole NN i
) ) i
and CC p
followed VBD p
the DT p
patients NNS p
with IN p
RSA NNP i
for IN p
5 CD p
years NNS p
. . p

The DT N
penetration NN N
of IN N
cement NN N
into IN N
the DT N
anchorage NN N
holes NNS N
was VBD N
measured VBN N
on IN N
digital JJ N
radiographs NN N
. . N

Postoperative JJ N
radiolucent NN o
lines NNS o
around IN o
the DT o
cup NN o
were VBD o
correlated VBN o
to TO o
later RBR o
RSA NNP o
results NNS o
. . o

For IN N
clinical JJ N
evaluation NN N
, , N
we PRP N
used VBD N
SF-36 NNP N
and CC N
HHS NNP N
. . N

RESULTS VB N
The DT N
pressurized JJ N
group NN N
of IN N
THAs NNP N
was VBD N
more RBR N
stable JJ N
regarding VBG N
changes NNS N
in IN N
inclination NN N
. . N

We PRP N
found VBD N
no DT N
other JJ N
difference NN N
in IN N
the DT N
migratory NN N
behavior NN N
. . N

The DT N
cement NN N
penetration NN N
into IN N
the DT N
anchorage NN N
holes NNS N
was VBD N
deeper RBR N
with IN N
the DT N
pressurization NN N
technique NN N
than IN N
with IN N
fingerpacking NN N
. . N

For IN N
the DT N
whole JJ N
group NN N
taken VBN N
together RB N
, , N
there EX N
was VBD N
a DT N
strong JJ N
relation NN N
between IN N
the DT N
presence NN N
of IN N
radiolucent NN N
lines NNS N
as IN N
measured VBN N
on IN N
the DT N
postoperative JJ N
radiograph NN N
and CC N
later JJ N
migration NN N
observed VBN N
by IN N
RSA NNP N
at IN N
2 CD N
and CC N
5 CD N
years NNS N
. . N

INTERPRETATION NNP N
Pressurization NNP N
of IN N
the DT N
cement NN N
produced VBD N
better JJR N
cement NN N
penetration NN N
and CC N
increased VBD N
the DT N
cup NN N
stability NN N
in IN N
terms NNS N
of IN N
changes NNS N
in IN N
inclination NN N
. . N

Early JJ N
findings NNS N
of IN N
radiolucent NN N
lines NNS N
can MD N
predict VB N
later RB N
unfavorable JJ N
cup NN N
migration NN N
. . N

-DOCSTART- -339662- O O

Levamisole NNP i
versus NN i
placebo NN i
as IN N
an DT N
adjunct NN N
to TO N
primary JJ N
therapy NN N
of IN N
laryngopharyngeal JJ p
epidermoid JJ p
carcinoma NN p
. . p

Evaluation NN N
of IN N
the DT N
immune JJ N
status NN N
. . N

Twenty-four CD p
patients NNS p
, , p
with IN p
a DT p
biopsy-proven JJ p
laryngeal NN p
or CC p
hypopharyngeal NN p
carcinoma NN p
, , N
received VBD N
as IN N
an DT N
adjunct NN N
to TO N
their PRP$ N
primary JJ N
treatment NN N
( ( N
surgery JJ N
and/or RB N
radiotherapy NN N
) ) N
, , N
levamisole JJ i
( ( i
150 CD i
mg NNS i
daily RB i
during IN i
three CD i
consecutive JJ i
days NNS i
, , i
every DT i
fortnight NN i
) ) i
or CC i
placebo NN i
, , N
following VBG N
a DT N
single-blind JJ N
, , N
but CC N
randomized VBD N
method NN N
. . N

At IN N
the DT N
end NN N
of IN N
the DT N
follow-up NN N
, , N
an DT N
investigation NN N
of IN N
the DT N
immune NN o
status NN N
was VBD N
done VBN N
, , N
and CC N
compared VBN N
with IN N
that DT N
of IN N
a DT N
healthy JJ p
control-group NN p
. . p

It PRP N
is VBZ N
concluded VBN N
that IN N
the DT N
immunity NN o
is VBZ N
disturbed VBN N
in IN N
patients NNS p
with IN p
laryngo-pharyngeal JJ p
cancer NN p
, , N
but CC N
that IN N
this DT N
disturbance NN N
does VBZ N
not RB N
clearly RB N
correlate NN N
with IN N
the DT N
clinical JJ N
state NN N
of IN N
the DT N
disease NN N
. . N

Also RB N
, , N
the DT N
immunological JJ N
measures NNS N
did VBD N
not RB N
appear VB N
relevant JJ N
to TO N
the DT N
significantly RB N
favourable JJ N
effect NN N
of IN N
levamisole NN N
on IN N
the DT N
prognosis NN N
. . N

-DOCSTART- -19594501- O O

Verapamil NNP i
augmentation NN N
of IN N
lithium NN i
treatment NN i
improves VBZ N
outcome VBN N
in IN N
mania NN N
unresponsive JJ N
to TO N
lithium VB i
alone RB N
: : N
preliminary JJ N
findings NNS N
and CC N
a DT N
discussion NN N
of IN N
therapeutic JJ N
mechanisms NNS N
. . N

OBJECTIVES NNP N
Attenuation NNP N
of IN N
protein NN N
kinase NN N
C NNP N
( ( N
PKC NNP N
) ) N
is VBZ N
a DT N
mechanism NN N
common JJ N
to TO N
both DT N
established VBN N
( ( i
lithium NN i
, , i
valproate NN i
) ) i
and CC i
some DT i
novel NN i
( ( i
tamoxifen NN i
) ) i
antimanic JJ i
agents NNS i
. . i

Verapamil NNP i
, , N
although IN N
primarily RB N
known VBN N
as IN N
a DT N
calcium NN N
channel NN N
blocker NN N
, , N
also RB N
has VBZ N
PKC NNP N
inhibitory NN N
activity NN N
. . N

Verapamil NNP i
has VBZ N
shown VBN N
antimanic JJ N
activity NN N
in IN N
some DT N
but CC N
not RB N
all DT N
studies NNS N
. . N

Therefore RB N
, , N
we PRP N
investigated VBD N
verapamil NN i
, , i
used VBD i
alone RB i
or CC i
as IN i
an DT i
adjunctive JJ i
treatment NN i
, , N
in IN N
manic JJ p
patients NNS p
who WP p
did VBD p
not RB p
respond VB p
to TO p
an DT p
initial JJ p
adequate JJ p
trial NN p
of IN p
lithium NN i
. . i

METHODS NNP N
Each DT N
study NN N
phase NN N
lasted VBD N
three CD N
weeks NNS N
. . N

Subjects NNS N
were VBD N
treated VBN N
openly RB N
with IN N
lithium NN i
in IN N
Phase NNP N
1 CD N
( ( p
n JJ p
= NNP p
45 CD p
) ) p
. . N

Those DT N
who WP N
failed VBD N
to TO N
respond VB N
were VBD N
randomly RB N
assigned VBN N
to TO N
double-blind VB N
treatment NN N
in IN N
Phase NNP N
2 CD N
with IN N
either DT N
verapamil NN i
( ( N
n JJ N
= NNP N
10 CD N
) ) N
or CC N
continued-lithium NN i
( ( N
n JJ N
= NNP N
8 CD N
) ) N
. . N

Phase $ N
2 CD N
nonresponders NNS N
( ( N
n JJ N
= NNP N
10 CD N
) ) N
were VBD N
assigned VBN N
to TO N
combined VB i
verapamil/lithium NN i
in IN N
Phase NNP N
3 CD N
. . N

RESULTS NNP N
Response NNP N
in IN N
Phase NNP N
2 CD N
did VBD N
not RB N
differ VB N
significantly RB N
between IN N
verapamil NNS i
and CC N
continued-lithium NN i
. . i

During IN N
Phase NNP N
3 CD N
, , N
response NN N
to TO N
combined VBN N
treatment NN N
was VBD N
significantly RB N
better JJR N
than IN N
overall JJ N
response NN N
to TO N
monotherapy VB N
in IN N
Phase NNP N
2 CD N
( ( o
Fisher NNP o
's POS o
Exact NNP o
test NN o
, , N
p NN N
= NNP N
0.043 CD N
) ) N
. . N

Mania NNP o
ratings NNS o
improved VBN N
during IN N
combined JJ N
treatment NN N
in IN N
Phase NNP N
3 CD N
by IN N
88.2 CD N
% NN N
( ( N
linear JJ N
mixed JJ N
model NN N
analysis NN N
, , N
F NNP N
= NNP N
4.34 CD N
, , N
p NN N
= NNP N
0.013 CD N
) ) N
, , N
compared VBN N
with IN N
10.5 CD N
% NN N
improvement NN N
during IN N
Phase NNP N
2 CD N
. . N

CONCLUSIONS NN N
In IN N
this DT N
preliminary JJ N
investigation NN N
, , N
verapamil JJ i
monotherapy NN N
did VBD N
not RB N
demonstrate VB N
antimanic JJ N
efficacy NN N
. . N

By IN N
contrast NN N
, , N
the DT N
combination NN N
of IN N
verapamil JJ i
plus CC i
lithium NN i
was VBD N
highly RB N
efficacious JJ N
. . N

Our PRP$ N
findings NNS N
thus RB N
suggest VBP N
that IN N
verapamil NN i
may MD N
have VB N
potential JJ N
utility NN N
as IN N
an DT N
adjunct NN N
to TO N
lithium NN i
. . i

This DT N
effect NN N
may MD N
be VB N
mediated VBN N
by IN N
additive JJ N
actions NNS N
on IN N
PKC NNP N
inhibition NN N
, , N
which WDT N
may MD N
be VB N
an DT N
important JJ N
mechanism NN N
for IN N
antimanic JJ N
agents NNS N
in IN N
general JJ N
. . N

-DOCSTART- -4025245- O O

Mass NNP N
inoculation NN N
in IN N
a DT N
community NN N
: : N
the DT N
effect NN N
of IN N
primary JJ N
prevention NN N
of IN N
stress JJ o
reactions NNS o
. . o

This DT N
study NN N
assessed VBD N
the DT N
effectiveness NN N
of IN N
a DT N
brief JJ N
, , N
situation-specific JJ N
, , N
group-administered JJ N
preparatory NN N
intervention NN N
in IN N
a DT N
nonclient JJ p
school NN p
population NN p
undergoing VBG p
mass NN i
inoculation NN i
against IN i
rubella NN i
. . i

Fifty-one CD p
girls NNS p
were VBD N
randomly RB N
assigned VBN N
to TO N
practice NN i
, , i
no-practice JJ i
, , i
or CC i
control NN i
groups NNS i
. . i

Both CC N
the DT N
practice NN N
and CC N
the DT N
no-practice JJ N
groups NNS N
received VBD N
information NN N
that IN N
described VBD N
the DT N
inoculation NN N
procedure NN N
and CC N
how WRB N
to TO N
cope VB N
with IN N
it PRP N
by IN N
using VBG N
cognitive-behavioral JJ N
coping NN N
skills NNS N
. . N

The DT N
practice NN N
group NN N
was VBD N
encouraged VBN N
to TO N
perform VB N
coping VBG N
techniques NNS N
of IN N
this DT N
type NN N
, , N
whereas IN N
the DT N
no-practice JJ N
group NN N
was VBD N
told VBN N
only RB N
that IN N
the DT N
intervention NN N
would MD N
help VB N
them PRP N
during IN N
the DT N
inoculation NN N
. . N

Subjects NNS N
in IN N
both DT N
practice NN N
and CC N
no-practice JJ N
groups NNS N
reported VBD N
less JJR N
anxiety NN o
and CC o
exhibited VBD o
more RBR o
cooperative JJ o
behavior NN o
during IN N
inoculation NN N
than IN N
subjects NNS N
in IN N
the DT N
control NN N
group NN N
, , N
and CC N
those DT N
who WP N
were VBD N
guided VBN N
and CC N
prompted VBN N
to TO N
actively RB N
practice NN N
derived VBD N
greater JJR N
benefit NN o
. . o

-DOCSTART- -20673857- O O

Clinical JJ i
massage NN i
and CC i
modified VBD i
Proprioceptive NNP i
Neuromuscular NNP i
Facilitation NNP i
stretching VBG i
in IN N
males NNS p
with IN p
latent JJ p
myofascial JJ p
trigger NN p
points NNS p
. . p

OBJECTIVES NNP N
To TO N
determine VB N
the DT N
immediate JJ N
effects NNS N
of IN N
modified JJ i
Proprioceptive NNP i
Neuromuscular NNP i
Facilitation NNP i
( ( i
PNF NNP i
) ) i
stretching NN i
( ( N
group NN N
I PRP N
) ) N
versus VBP N
Myofascial JJ i
Trigger NNP i
Point NNP i
( ( i
MTrP NNP i
) ) i
therapy NN i
plus CC i
modified JJ i
PNF NNP i
stretching NN i
( ( N
group NN N
II NNP N
) ) N
in IN N
comparison NN N
to TO N
a DT N
control NN N
group NN N
receiving VBG N
no DT i
treatment NN i
. . i

DESIGN NNP N
Randomized NNP N
, , N
assessor-blind NN N
, , N
( ( N
3 CD N
x RB N
4 CD N
) ) N
mixed-model NN N
repeated VBN N
measures NNS N
. . N

SETTING NNP N
University NNP N
laboratory NN N
. . N

PARTICIPANTS NNP N
Thirty NNP p
physically RB p
active JJ p
males NNS p
with IN p
tight JJ p
hamstrings NNS p
and CC p
at IN p
least JJS p
one CD p
latent NN p
MTrP NNP p
on IN p
muscles NNS p
innervated VBN p
by IN p
the DT p
lumbosacral JJ p
, , p
sciatic JJ p
, , p
tibial JJ p
and CC p
common JJ p
peroneal JJ p
nerves NNS p
. . p

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
Knee NNP o
range NN o
of IN o
motion NN o
( ( o
ROM NNP o
) ) o
, , o
stretch JJ o
perception NN o
, , o
pressure NN o
pain NN o
threshold NN o
( ( o
PPT NNP o
) ) o
and CC o
subjective JJ o
pain NN o
intensity NN o
. . o

Outcomes CC N
were VBD N
evaluated VBN N
at IN N
baseline NN N
, , N
immediately RB N
after IN N
treatment NN N
, , N
at IN N
10 CD N
and CC N
30 CD N
min NN N
. . N

RESULTS NNP N
Significant NNP N
changes VBZ N
over IN N
time NN N
occurred VBD N
for IN N
group NN N
II NNP N
in IN N
all DT N
outcomes NNS N
( ( N
p JJ N
< NN N
or CC N
= VB N
0.001 CD N
) ) N
. . N

Group NNP N
II NNP N
also RB N
showed VBD N
lower JJR o
pain NN o
intensity NN o
scores NNS o
than IN N
group NN N
I PRP N
immediately RB N
post-treatment NN N
( ( N
p JJ N
= NNP N
0.045 CD N
) ) N
and CC N
a DT N
strong JJ N
clinical JJ o
effect NN o
over IN N
group NN N
I PRP N
in IN N
ROM NNP o
at IN N
all DT N
follow-ups NNS N
( ( N
effect NN N
sizes VBZ N
= JJ N
0.9-1.0 JJ N
, , N
p JJ N
< NN N
or CC N
= VB N
0.05 CD N
) ) N
. . N

Other JJ N
differences NNS N
were VBD N
found VBN N
between IN N
both DT N
stretching VBG N
groups NNS N
as IN N
compared VBN N
to TO N
the DT N
control NN N
group NN N
( ( N
p JJ N
< NN N
or CC N
= VB N
0.05 CD N
) ) N
. . N

CONCLUSION VB N
The DT N
results NNS N
indicate VBP N
immediate JJ N
pre- JJ N
to TO N
post-treatment JJ N
benefits NNS N
from IN N
MTrP NNP i
therapy NN i
combined VBN N
with IN N
modified JJ i
PNF NNP i
stretching NN i
in IN N
young JJ p
and CC p
physically RB p
active JJ p
males NNS p
with IN N
latent JJ N
MTrPs NNP N
. . N

-DOCSTART- -9935021- O O

Morphological JJ N
onset NN N
and CC N
early JJ N
diagnosis NN N
in IN N
apical JJ p
hypertrophic JJ p
cardiomyopathy NN p
: : p
a DT N
long JJ N
term NN N
analysis NN N
with IN N
nuclear JJ i
magnetic JJ i
resonance NN i
imaging NN i
. . i

OBJECTIVES VB N
A DT N
long-term JJ N
follow-up NN N
study NN N
with IN N
nuclear JJ i
magnetic JJ i
resonance NN i
( ( i
NMR NNP i
) ) i
imaging NN i
was VBD N
undertaken VBN N
to TO N
detect VB N
the DT N
morphological JJ N
onset NN N
and CC N
to TO N
establish VB N
the DT N
early JJ N
diagnosis NN N
in IN N
apical JJ N
hypertrophic JJ N
cardiomyopathy NN N
( ( N
HCM NNP N
) ) N
. . N

BACKGROUND VB N
A DT N
spadelike JJ N
configuration NN N
on IN N
left JJ o
ventriculogram NN o
( ( o
LVG NNP o
) ) o
is VBZ N
regarded VBN N
as IN N
a DT N
diagnostic JJ N
criterion NN N
for IN N
the DT N
classical JJ N
apical JJ N
HCM NNP N
. . N

There EX N
also RB N
exists VBZ N
a DT N
segmented JJ o
hypertrophy NN o
at IN o
the DT o
apical JJ o
level NN o
without IN N
indicating VBG N
the DT N
spadelike NN N
features NNS N
( ( N
a DT N
nonspade NN N
configuration NN N
) ) N
. . N

To TO N
detect VB N
the DT N
hypertrophied JJ N
myocardium NN N
of IN N
the DT N
nonspade JJ N
configuration NN N
, , N
circumferential JJ N
scrutiny NN N
of IN N
the DT N
apex NN N
is VBZ N
required VBN N
. . N

Although IN N
both DT N
configurations NNS N
can MD N
be VB N
underlying JJ N
causes NNS N
of IN N
giant JJ N
negative JJ N
T NNP N
waves NNS N
, , N
etiological JJ N
relationship NN N
between IN N
the DT N
two CD N
is VBZ N
not RB N
clarified VBN N
. . N

METHODS NNP N
The DT N
criteria NN N
for IN N
the DT N
spadelike NN N
configuration NN N
defined VBN N
on IN N
left JJ N
ventricular JJ N
short-axis JJ N
NMR NNP i
images NNS i
were VBD N
as IN N
follows VBZ N
: : N
( ( N
apical JJ N
maximal NN N
thickness NN N
> NN N
or CC N
= $ N
15 CD N
mm NN N
) ) N
, , N
( ( N
apical JJ N
anterior NN N
thickness NN N
over IN N
basal JJ N
anterior JJ N
thickness NN N
> NN N
or CC N
= VB N
1.3 CD N
) ) N
and CC N
( ( N
apical JJ N
posterior NN N
thickness NN N
over IN N
basal JJ N
posterior JJ N
thickness NN N
> NN N
or CC N
=1.3 NN N
) ) N
. . N

Thirteen JJ p
patients NNS p
who WP p
had VBD p
predominant JJ p
hypertrophy NN p
( ( p
> CD p
or CC p
= VB p
15 CD p
mm NN p
) ) p
at IN p
the DT p
apical JJ p
level NN p
without IN p
the DT p
spadelike NN p
configuration NN p
underwent JJ p
NMR NNP i
imaging VBG i
twice RB i
before RB i
and CC i
after IN i
54+/-10 JJ i
months NNS i
' POS i
follow-up NN i
. . i

RESULTS NNP N
Apical NNP o
hypertrophy NN o
that WDT N
had VBD N
been VBN N
confined VBN N
to TO N
the DT N
lateral JJ N
wall NN N
in IN N
four CD N
, , N
the DT N
anterior-lateral JJ N
wall NN N
in IN N
two CD N
, , N
and CC N
the DT N
septal-anterior JJ N
wall NN N
in IN N
one CD N
developed NN N
to TO N
become VB N
circumferential JJ o
hypertrophy NN o
that WDT N
fulfilled VBD N
the DT N
criteria NNS N
for IN N
the DT N
spadelike NN N
configuration NN N
after IN N
the DT N
follow-up JJ N
period NN N
. . N

CONCLUSIONS VB N
The DT N
spadelike NN N
configuration NN N
can MD N
begin VB N
with IN N
the DT N
nonspade JJ N
configuration NN N
and CC N
therefore NN N
, , N
both DT N
can MD N
constitute VB N
a DT N
single JJ N
disease NN N
entity NN N
of IN N
apical JJ N
HCM NNP N
. . N

The DT N
early JJ N
diagnosis NN N
of IN N
apical JJ o
HCM NNP o
can MD N
be VB N
achieved VBN N
by IN N
identifying VBG N
the DT N
hypertrophy NN o
frequently RB N
confined VBN N
to TO N
the DT N
lateral JJ N
wall NN N
at IN N
the DT N
apical JJ N
level NN N
. . N

-DOCSTART- -16099893- O O

Effect NN N
of IN N
exercise NN i
, , i
training NN i
, , N
and CC N
glycogen NN i
availability NN i
on IN N
IL-6 NNP N
receptor NN N
expression NN N
in IN N
human JJ p
skeletal JJ p
muscle NN p
. . p

The DT N
cytokine JJ N
interleukin-6 JJ N
( ( N
IL-6 NNP N
) ) N
exerts VBZ N
it PRP N
actions NNS N
via IN N
the DT N
IL-6 NNP N
receptor NN N
( ( N
IL-6R NNP N
) ) N
in IN N
conjunction NN N
with IN N
the DT N
ubiquitously RB N
expressed VBN N
gp130 NN N
receptor NN N
. . N

IL-6 NNP N
is VBZ N
tightly RB N
regulated VBN N
in IN N
response NN N
to TO N
exercise NN i
, , N
being VBG N
affected VBN N
by IN N
factors NNS N
such JJ N
as IN N
exercise NN N
intensity NN N
and CC N
duration NN N
, , N
as RB N
well RB N
as IN N
energy NN N
availability NN N
. . N

Although IN N
the DT N
IL-6 NNP N
response NN N
to TO N
exercise NN N
has VBZ N
been VBN N
extensively RB N
studied VBN N
, , N
little JJ N
is VBZ N
known VBN N
about IN N
the DT N
regulation NN N
of IN N
the DT N
IL-6R NNP N
response NN N
. . N

In IN N
the DT N
present JJ N
study NN N
, , N
we PRP N
aimed VBD N
to TO N
investigate VB N
the DT N
effect NN N
of IN N
exercise NN i
, , i
training NN i
, , i
and CC i
glycogen NN i
availability NN i
, , N
factors NNS N
known VBN N
to TO N
affect VB N
IL-6 NNP N
, , N
on IN N
the DT N
regulation NN N
of IN N
gene NN N
expression NN N
of IN N
the DT N
IL-6R NNP N
in IN N
human JJ N
skeletal JJ N
muscle NN N
. . N

Human NNP p
subjects VBZ p
performed VBD N
either CC N
10 CD i
wk NN i
of IN i
training VBG i
with IN i
an DT i
acute JJ i
exercise NN i
bout NN i
before IN i
and CC i
after IN i
the DT i
training NN i
period NN i
, , i
or CC i
a DT i
low-glycogen JJ i
vs. NN i
normal-glycogen JJ i
acute NN i
exercise NN i
trial NN i
. . i

The DT N
IL-6R JJ o
mRNA NN o
response NN o
was VBD N
evaluated VBN N
in IN N
both DT N
trials NNS N
. . N

In IN N
response NN N
to TO N
acute VB N
exercise NN N
, , N
an DT N
increase NN N
in IN N
IL-6R NNP o
mRNA NN o
levels NNS o
was VBD N
observed VBN N
. . N

Neither CC N
training VBG N
nor CC N
intramuscular JJ N
glycogen NN N
levels NNS N
had VBD N
an DT N
effect NN N
on IN N
the DT N
IL-6R NNP o
mRNA NN o
response NN o
to TO N
exercise NN N
. . N

However RB N
, , N
after IN N
10 CD N
wk NN N
of IN N
training NN N
, , N
the DT N
skeletal JJ N
muscle NN N
expressed VBD N
a DT N
higher JJR N
mRNA JJ o
level NN o
of IN o
IL-6R NNP o
compared VBN N
with IN N
before RB N
training VBG N
. . N

The DT N
present JJ N
study NN N
demonstrated VBD N
that IN N
the DT N
IL-6R NNP o
gene NN o
expression NN o
levels NNS o
in IN N
skeletal JJ N
muscle NN N
are VBP N
increased VBN N
in IN N
response NN N
to TO N
acute VB N
exercise NN N
, , N
a DT N
response NN N
that WDT N
is VBZ N
very RB N
well RB N
conserved VBN N
, , N
being VBG N
affected VBN N
by IN N
neither DT N
training NN o
status NN o
nor CC N
intramuscular JJ o
glycogen NN o
levels NNS o
, , N
as IN N
opposed VBN N
to TO N
IL-6 NNP N
. . N

However RB N
, , N
after IN N
the DT N
training NN N
period NN N
, , N
IL-6R JJ o
mRNA NN o
production NN o
was VBD N
increased VBN N
in IN N
skeletal JJ N
muscle NN N
, , N
suggesting VBG N
a DT N
sensitization NN N
of IN N
skeletal JJ N
muscle NN N
to TO N
IL-6 NNP N
at IN N
rest NN N
. . N

-DOCSTART- -15572491- O O

Buccal JJ i
misoprostol NN i
to TO N
decrease VB N
blood NN o
loss NN o
after IN p
vaginal JJ p
delivery NN p
: : p
a DT N
randomized JJ N
trial NN N
. . N

OBJECTIVE UH N
To TO N
assess VB N
the DT N
efficacy NN N
of IN N
buccal JJ i
misoprostol NN i
to TO N
decrease VB N
bleeding NN o
after IN p
vaginal JJ p
delivery NN p
. . p

METHODS NNP N
This DT N
was VBD N
a DT N
randomized JJ N
study NN N
of IN N
patients NNS p
between IN p
22 CD p
weeks NNS p
and CC p
42 CD p
weeks NNS p
of IN p
gestation NN p
with IN p
anticipated JJ p
vaginal JJ p
delivery NN p
. . p

Patients NNS N
were VBD N
given VBN N
either CC N
a DT N
200-mug JJ i
misoprostol NN i
tablet NN i
or CC i
placebo NN i
in IN N
the DT N
buccal JJ N
space NN N
at IN N
the DT N
time NN N
of IN N
cord NN N
clamping NN N
. . N

A DT N
continuous JJ N
dilute NN N
intravenous JJ N
oxytocin JJ i
infusion NN N
was VBD N
given VBN N
to TO N
all DT N
patients NNS N
at IN N
delivery NN N
of IN N
the DT N
placenta NN N
. . N

Postpartum NNP o
hemorrhage NN o
was VBD N
defined VBN N
as IN N
blood NN o
loss NN o
exceeding VBG N
500 CD N
mL NN N
. . N

Sample NNP N
size NN N
calculations NNS N
based VBN N
on IN N
previous JJ N
studies NNS N
assumed VBD N
a DT N
13 CD N
% NN N
incidence NN N
of IN N
postpartum NN N
hemorrhage NN N
in IN N
the DT N
control NN N
group NN N
. . N

To TO N
show VB N
a DT N
statistically RB N
significant JJ N
reduction NN N
of IN N
postpartum NN N
hemorrhage NN N
a DT p
total NN p
of IN p
1,604 CD p
patients NNS p
would MD p
be VB p
required VBN p
in IN p
each DT p
group NN p
. . p

RESULTS VB N
A DT p
total NN p
of IN p
848 CD p
patients NNS p
were VBD p
enrolled VBN p
and CC p
756 CD p
randomly RB p
assigned VBN p
, , p
377 CD p
in IN p
the DT p
misoprostol NN i
group NN p
and CC p
379 CD p
in IN p
the DT p
placebo NN i
group NN p
. . p

Demographic NNP p
, , p
antepartum NN p
, , p
and CC p
intrapartum NN p
characteristics NNS p
were VBD p
similar JJ p
between IN p
the DT p
groups NNS p
. . p

The DT N
incidence NN o
of IN o
postpartum NN o
hemorrhage NN o
, , N
3 CD N
% NN N
compared VBN N
with IN N
5 CD N
% NN N
, , N
( ( N
relative JJ N
risk NN N
0.65 CD N
, , N
95 CD N
% NN N
confidence NN N
interval JJ N
0.33-1.29 JJ N
, , N
P NNP N
= NNP N
.22 NNP N
) ) N
, , N
mean JJ o
estimated VBN o
blood NN o
loss NN o
, , N
322 CD N
compared VBN N
with IN N
329 CD N
mL NNS N
, , N
( ( N
P NNP N
= NNP N
.45 NNP N
) ) N
, , N
and CC N
mean JJ o
minutes NNS o
of IN o
the DT o
third JJ o
stage NN o
of IN o
labor NN o
, , N
6.7 CD N
compared VBN N
with IN N
6.9 CD N
( ( N
P NNP N
= NNP N
.52 NNP N
) ) N
were VBD N
similar JJ N
between IN N
the DT N
groups NNS N
, , N
misoprostol NN i
and CC N
placebo NN i
, , N
respectively RB N
. . N

Hemoglobin NNP o
difference NN o
before IN o
and CC o
after IN o
delivery NN o
, , o
need NN o
for IN o
second JJ o
or CC o
third JJ o
uterotonic JJ o
agent NN o
, , o
and CC o
all DT o
measured VBN o
neonatal JJ o
variables NNS o
including VBG o
birth NN o
weights NNS o
, , o
and CC o
umbilical JJ o
cord NN o
pH NN o
were VBD N
similar JJ N
between IN N
the DT N
groups NNS N
. . N

CONCLUSION NNP N
Buccal NNP i
misoprostol NN i
at IN N
cord NN N
clamping NN N
is VBZ N
no DT N
more RBR N
effective JJ N
than IN N
placebo NN i
in IN N
reducing VBG N
postpartum JJ o
hemorrhage NN o
. . o

-DOCSTART- -8881340- O O

Using VBG N
a DT N
choice NN i
assessment NN i
to TO N
predict VB N
reinforcer NN N
effectiveness NN N
. . N

A DT i
choice NN i
assessment NN i
has VBZ N
been VBN N
found VBN N
to TO N
be VB N
a DT N
more RBR N
accurate JJ N
method NN N
of IN N
identifying VBG N
preferences NNS N
than IN N
is VBZ N
single-item JJ N
presentation NN N
. . N

However RB N
, , N
it PRP N
is VBZ N
not RB N
clear JJ N
whether IN N
the DT N
effectiveness NN N
of IN N
reinforcement NN N
varies NNS N
positively RB N
with IN N
the DT N
degree NN N
of IN N
preference NN N
( ( N
i.e. FW N
, , N
whether IN N
the DT N
relative JJ N
preference NN N
based VBN N
on IN N
the DT N
results NNS N
of IN N
a DT N
choice NN N
assessment NN N
predicts VBZ N
relative JJ N
reinforcer NN N
effectiveness NN N
) ) N
. . N

In IN N
the DT N
current JJ N
study NN N
, , N
we PRP N
attempted VBD N
to TO N
address VB N
this DT N
question NN N
by IN N
categorizing VBG N
stimuli NNS N
as RB N
high JJ N
, , N
middle JJ N
, , N
and CC N
low JJ N
preference NN N
based VBN N
on IN N
the DT N
results NNS N
of IN N
a DT N
choice NN i
assessment NN i
, , N
and CC N
then RB N
comparing VBG N
the DT N
reinforcing VBG N
effectiveness NN N
of IN N
these DT N
stimuli NNS N
using VBG N
a DT N
concurrent NN i
operants VBZ i
paradigm JJ i
. . i

High-preference NN N
stimuli NNS N
consistently RB N
functioned VBN N
as IN N
reinforcers NNS N
for IN N
all DT N
4 CD p
clients NNS p
. . p

Middle-preference NN N
stimuli NN N
functioned VBD N
as IN N
reinforcers NNS N
for IN N
2 CD p
clients NNS p
, , N
but CC N
only RB N
when WRB N
compared VBN N
with IN N
low-preference NN N
stimuli NNS N
. . N

Low-preference NNP N
stimuli NN N
did VBD N
not RB N
function NN N
as IN N
reinforcers NNS N
when WRB N
compared VBN N
to TO N
high- JJ N
and CC N
middle-preference JJ N
stimuli NNS N
. . N

These DT N
results NNS N
suggest VBP N
that IN N
a DT N
choice NN i
assessment NN i
can MD N
be VB N
used VBN N
to TO N
predict VB N
the DT N
relative JJ N
reinforcing VBG N
value NN N
of IN N
various JJ N
stimuli NNS o
, , N
which WDT N
, , N
in IN N
turn NN N
, , N
may MD N
help VB N
to TO N
improve VB N
programs NNS N
for IN N
clients NNS p
with IN p
severe JJ p
to TO p
profound VB p
disabilities NNS p
. . p

-DOCSTART- -20229169- O O

PSK NNP i
may MD N
suppress VB N
CD57 NNP N
( ( N
+ NNP N
) ) N
T NNP N
cells NNS N
to TO N
improve VB N
survival NN N
of IN N
advanced JJ p
gastric JJ p
cancer NN p
patients NNS p
. . p

BACKGROUND NNP N
A NNP N
recent JJ N
report NN N
showed VBD N
that IN N
oral JJ i
adjuvant JJ i
immunochemotherapy NN i
with IN i
protein-bound JJ i
polysaccharide NN i
K NNP i
( ( i
PSK NNP i
) ) i
and CC i
tegafur/uracil NN i
( ( i
UFT NNP i
) ) i
for IN N
stage NN N
II NNP N
and CC N
III NNP N
colorectal JJ N
cancer NN N
improves VBZ N
overall JJ N
survival NN N
compared VBN N
with IN N
UFT NNP i
alone RB i
. . i

PSK NNP i
has VBZ N
been VBN N
supposed VBN N
to TO N
improve VB N
survival NN N
through IN N
immunological JJ N
mechanisms NNS N
such JJ N
as IN N
induction NN N
of IN N
cytokines NNS N
, , N
regulation NN N
of IN N
Th1/Th2 NNP N
balance NN N
, , N
and CC N
inhibition NN N
of IN N
immunosuppressive JJ N
molecules NNS N
. . N

METHODS NNP N
We PRP N
investigated VBD N
the DT N
mechanisms NNS N
by IN N
which WDT N
PSK NNP i
influences VBZ N
immunological JJ o
parameters NNS o
such JJ N
as IN N
Th1 NNP o
cells NNS o
( ( o
IFN-gamma-positive JJ o
CD4 NNP o
( ( o
+ NNP o
) ) o
T NNP o
cells NNS o
) ) o
, , o
Th2 NNP o
cells NNS o
( ( o
IL-4-positive JJ o
CD4 NNP o
( ( o
+ NNP o
) ) o
T NNP o
cells NNS o
) ) o
, , o
Th1/Th2 NNP o
ratio NN o
, , o
NKT NNP o
cells NNS o
( ( o
CD56 NNP o
( ( o
+ NNP o
) ) o
T NNP o
cells NNS o
and CC o
CD57 NNP o
( ( o
+ NNP o
) ) o
T NNP o
cells NNS o
) ) o
, , o
NK NNP o
cells NNS o
, , o
and CC o
CD25 NNP o
( ( o
+ NNP o
) ) o
CD4 NNP o
( ( o
+ NNP o
) ) o
T NNP o
cells NNS o
in IN N
stage NN p
III NNP p
gastric JJ p
cancer NN p
patients NNS p
. . p

Patients NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
either RB N
3 CD N
g NN N
PSK NNP i
plus CC i
300 CD i
mg NN i
UFT NNP i
( ( i
PSK NNP i
group NN i
) ) i
or CC N
300 CD N
mg JJ N
UFT NNP i
alone RB i
( ( N
control NN N
) ) N
orally RB N
each DT N
day NN N
for IN N
at IN N
least JJS N
1 CD N
year NN N
following VBG N
their PRP$ N
operation NN N
. . N

RESULTS NNP N
Twenty-one CD p
registered VBD p
patients NNS p
with IN p
stage NN p
III NNP p
gastric JJ p
cancer NN p
were VBD N
analyzed VBN N
. . N

The DT N
3-year JJ o
overall JJ o
survival NN o
was VBD N
62.2 CD N
% NN N
in IN N
the DT N
PSK NNP i
group NN N
( ( N
n JJ N
= NNP N
10 CD N
) ) N
and CC N
12.5 CD N
% NN N
in IN N
the DT N
control NN i
group NN i
( ( N
n JJ N
= NNP N
11 CD N
) ) N
( ( N
P NNP N
= NNP N
0.038 CD N
) ) N
. . N

Before IN N
operation NN N
, , N
there EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
the DT N
proportions NNS N
of IN N
Th1 NNP o
cells NNS o
, , o
Th2 NNP o
cells NNS o
, , o
Th1/Th2 NNP o
ratio NN o
, , o
CD56 NNP o
( ( o
+ NNP o
) ) o
T NNP o
cells NNS o
, , o
CD57 NNP o
( ( o
+ NNP o
) ) o
T NNP o
cells NNS o
, , o
NK NNP o
cells NNS o
, , o
and CC o
CD4 NNP o
( ( o
+ NNP o
) ) o
CD25 NNP o
( ( o
+ NNP o
) ) o
T NNP o
cells NNS o
between IN N
PSK NNP N
and CC N
control NN N
groups NNS N
. . N

However RB N
, , N
after IN N
operation NN N
, , N
CD57 NNP o
( ( o
+ NNP o
) ) o
T NNP o
cells NNS o
decreased VBD N
significantly RB N
in IN N
the DT N
PSK NNP i
group NN N
compared VBN N
to TO N
the DT N
control NN N
( ( N
P NNP N
= NNP N
0.0486 CD N
) ) N
. . N

When WRB N
all DT N
patients NNS N
were VBD N
analyzed VBN N
, , N
patients NNS N
with IN N
increased JJ N
proportion NN N
( ( N
> JJ N
18 CD N
% NN N
) ) N
of IN N
CD57 NNP N
( ( N
+ NNP N
) ) N
T NNP N
cells NNS N
showed VBD N
worse JJR N
survival NN N
than IN N
those DT N
with IN N
lower JJR N
( ( N
< CD N
or CC N
= VB N
18 CD N
% NN N
) ) N
CD57 NNP N
( ( N
+ NNP N
) ) N
T NNP N
cells NNS N
( ( N
3-year JJ N
survival NN N
, , N
25.0 CD N
and CC N
45.7 CD N
% NN N
, , N
respectively RB N
; : N
P NNP N
= NNP N
0.046 CD N
) ) N
, , N
consistent JJ N
with IN N
our PRP$ N
previous JJ N
report NN N
that WDT N
high JJ N
CD57 NNP N
( ( N
+ NNP N
) ) N
is VBZ N
an DT N
indicator NN N
of IN N
poor JJ N
prognosis NN N
in IN N
patients NNS N
with IN N
advanced JJ N
gastric JJ N
cancer NN N
. . N

However RB N
, , N
in IN N
the DT N
group NN N
treated VBD N
with IN N
PSK NNP i
+ NNP i
UFT NNP i
, , N
3-year JJ o
survival NN o
of IN N
CD57-high JJ N
patients NNS N
was VBD N
as RB N
great JJ N
as IN N
that DT N
of IN N
CD57-low JJ N
patients NNS N
( ( N
66.7 CD N
and CC N
51.4 CD N
% NN N
, , N
respectively RB N
; : N
P NNP N
= NNP N
0.67 CD N
) ) N
. . N

CONCLUSION VB N
The DT N
present JJ N
findings NNS N
suggest VBP N
that IN N
PSK NNP i
improves VBZ N
overall JJ N
survival NN N
of IN N
stage NN p
III NNP p
gastric JJ p
cancer NN p
patients NNS p
partly RB N
by IN N
inhibiting VBG N
CD57 NNP N
( ( N
+ NNP N
) ) N
T NNP N
cells NNS N
, , N
a DT N
proven JJ N
poor JJ N
prognostic JJ N
factor NN N
in IN N
advanced JJ N
gastric JJ N
cancer NN N
. . N

-DOCSTART- -22151477- O O

Effect NN N
of IN N
a DT N
vitamin/mineral JJ i
supplement NN i
on IN N
children NNS p
and CC p
adults NNS p
with IN p
autism NN p
. . p

BACKGROUND NNP N
Vitamin/mineral NNP i
supplements NNS i
are VBP N
among IN N
the DT N
most RBS N
commonly RB N
used JJ N
treatments NNS N
for IN N
autism NN N
, , N
but CC N
the DT N
research NN N
on IN N
their PRP$ N
use NN N
for IN N
treating VBG N
autism NN N
has VBZ N
been VBN N
limited VBN N
. . N

METHOD NNP N
This DT N
study NN N
is VBZ N
a DT N
randomized JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ i
three CD N
month NN N
vitamin/mineral JJ i
treatment NN i
study NN i
. . i

The DT N
study NN N
involved VBD N
141 CD p
children NNS p
and CC p
adults NNS p
with IN p
autism NN p
, , p
and CC p
pre NN p
and CC p
post NN p
symptoms NNS p
of IN p
autism NN p
were VBD N
assessed VBN N
. . N

None NN p
of IN p
the DT p
participants NNS p
had VBD p
taken VBN p
a DT p
vitamin/mineral JJ i
supplement NN i
in IN p
the DT p
two CD p
months NNS p
prior RB p
to TO p
the DT p
start NN p
of IN p
the DT p
study NN p
. . p

For IN p
a DT p
subset NN p
of IN p
the DT p
participants NNS p
( ( p
53 CD p
children NNS p
ages VBZ p
5-16 JJ p
) ) p
pre NN N
and CC N
post NN N
measurements NNS N
of IN N
nutritional JJ N
and CC N
metabolic JJ N
status NN N
were VBD N
also RB N
conducted VBN N
. . N

RESULTS VB N
The DT N
vitamin/mineral JJ i
supplement NN i
was VBD N
generally RB N
well-tolerated JJ o
, , N
and CC N
individually RB N
titrated VBN N
to TO N
optimum JJ N
benefit NN N
. . N

Levels NNP o
of IN o
many JJ o
vitamins NNS o
, , o
minerals NNS o
, , o
and CC o
biomarkers NNS o
improved/increased VBD N
showing VBG N
good JJ N
compliance NN o
and CC o
absorption NN o
. . o

Statistically NNP N
significant JJ N
improvements NNS N
in IN N
metabolic JJ N
status NN N
were VBD N
many JJ N
including VBG N
: : N
total JJ o
sulfate NN o
( ( N
+17 CD N
% NN N
, , N
p NN N
= NNP N
0.001 CD N
) ) N
, , N
S-adenosylmethionine NNP o
( ( N
SAM NNP N
; : N
+6 CD N
% NN N
, , N
p NN N
= NNP N
0.003 CD N
) ) N
, , N
reduced VBD N
glutathione NN o
( ( N
+17 CD N
% NN N
, , N
p NN N
= NNP N
0.0008 CD N
) ) N
, , N
ratio NN o
of IN o
oxidized JJ o
glutathione NN o
to TO o
reduced VB o
glutathione NN o
( ( N
GSSG NNP N
: : N
GSH NNP N
; : N
-27 CD N
% NN N
, , N
p NN N
= NNP N
0.002 CD N
) ) N
, , N
nitrotyrosine JJ o
( ( N
-29 CD N
% NN N
, , N
p NN N
= NNP N
0.004 CD N
) ) N
, , N
ATP NNP o
( ( N
+25 CD N
% NN N
, , N
p NN N
= NNP N
0.000001 CD N
) ) N
, , N
NADH NNP o
( ( N
+28 CD N
% NN N
, , N
p NN N
= NNP N
0.0002 CD N
) ) N
, , N
and CC N
NADPH NNP o
( ( N
+30 CD N
% NN N
, , N
p NN N
= NNP N
0.001 CD N
) ) N
. . N

Most JJS N
of IN N
these DT N
metabolic JJ N
biomarkers NNS N
improved VBN N
to TO N
normal JJ N
or CC N
near-normal JJ N
levels.The JJ N
supplement NN i
group NN N
had VBD N
significantly RB N
greater JJR N
improvements NNS N
than IN N
the DT N
placebo NN i
group NN N
on IN N
the DT N
Parental NNP o
Global NNP o
Impressions-Revised JJ o
( ( N
PGI-R NNP N
, , N
Average NNP N
Change NNP N
, , N
p NN N
= NNP N
0.008 CD N
) ) N
, , N
and CC N
on IN N
the DT N
subscores NNS N
for IN N
Hyperactivity NNP o
( ( N
p JJ N
= NNP N
0.003 CD N
) ) N
, , N
Tantrumming NNP o
( ( N
p JJ N
= NNP N
0.009 CD N
) ) N
, , N
Overall NNP o
( ( N
p NN N
= RB N
0.02 CD N
) ) N
, , N
and CC N
Receptive JJ o
Language NNP o
( ( N
p JJ N
= NNP N
0.03 CD N
) ) N
. . N

For IN N
the DT N
other JJ N
three CD N
assessment NN N
tools VBZ N
the DT N
difference NN N
between IN N
treatment NN N
group NN N
and CC N
placebo NN N
group NN N
was VBD N
not RB N
statistically RB N
significant.Regression JJ N
analysis NN N
revealed VBD N
that IN N
the DT N
degree NN N
of IN N
improvement NN N
on IN N
the DT N
Average JJ o
Change NN o
of IN o
the DT o
PGI-R NNP o
was VBD N
strongly RB N
associated VBN N
with IN N
several JJ N
biomarkers NNS N
( ( N
adj NN N
. . N

R2 NNP N
= VBD N
0.61 CD N
, , N
p NN N
< NNP N
0.0005 CD N
) ) N
with IN N
the DT N
initial JJ N
levels NNS N
of IN N
biotin NN N
and CC N
vitamin NN N
K NNP N
being VBG N
the DT N
most RBS N
significant JJ N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
; : N
both DT N
biotin NN N
and CC N
vitamin NN N
K NNP N
are VBP N
made VBN N
by IN N
beneficial JJ N
intestinal JJ N
flora NN N
. . N

CONCLUSIONS NNP N
Oral NNP N
vitamin/mineral JJ i
supplementation NN i
is VBZ N
beneficial JJ N
in IN N
improving VBG N
the DT N
nutritional JJ N
and CC N
metabolic JJ N
status NN N
of IN N
children NNS p
with IN p
autism NN p
, , N
including VBG N
improvements NNS N
in IN N
methylation NN N
, , N
glutathione NN N
, , N
oxidative JJ N
stress NN N
, , N
sulfation NN N
, , N
ATP NNP N
, , N
NADH NNP N
, , N
and CC N
NADPH NNP N
. . N

The DT N
supplement NN i
group NN N
had VBD N
significantly RB N
greater JJR N
improvements NNS N
than IN N
did VBD N
the DT N
placebo NN i
group NN N
on IN N
the DT N
PGI-R JJ N
Average JJ N
Change NN N
. . N

This DT N
suggests VBZ N
that IN N
a DT N
vitamin/mineral JJ i
supplement NN i
is VBZ N
a DT N
reasonable JJ N
adjunct JJ N
therapy NN N
to TO N
consider VB N
for IN N
most JJS p
children NNS p
and CC p
adults NNS p
with IN p
autism NN p
. . p

TRIAL NNP N
REGISTRATION NNP N
CLINICAL NNP N
TRIAL NNP N
REGISTRATION NNP N
NUMBER NNP N
NCT01225198 NNP N
. . N

-DOCSTART- -8673938- O O

Effects NNS N
of IN N
a DT N
chlorhexidine JJ i
varnish NN i
on IN N
the DT N
gingival NN o
status NN o
of IN p
adolescents NNS p
. . p

The DT N
purpose NN N
of IN N
this DT N
blind NN N
study NN N
was VBD N
to TO N
determine VB N
the DT N
effect NN N
of IN N
a DT N
two-stage JJ N
chlorhexidine NN i
varnish NN i
, , N
after IN N
three CD N
months NNS N
, , N
on IN N
the DT N
gingival NN p
status NN p
of IN p
11- JJ p
to TO p
15-year-old JJ p
children NNS p
attending VBG p
a DT p
school NN p
in IN p
Rio NNP p
de IN p
Janeiro NNP p
, , p
Brazil NNP p
. . p

Subjects NNS N
participating VBG N
in IN N
the DT N
study NN N
were VBD N
randomly RB N
allocated VBN N
to TO N
control VB p
( ( p
C NNP p
) ) p
and CC p
treatment NN p
( ( p
T NNP p
) ) p
groups NNS p
, , p
n JJ p
= NN p
53 CD p
and CC p
n JJ p
= NN p
57 CD p
, , N
respectively RB N
. . N

All DT N
subjects NNS p
were VBD N
matched VBN p
at IN p
baseline NN p
on IN p
age NN p
, , p
salivary JJ p
levels NNS p
of IN p
mutans NNS p
streptococci VBP p
, , p
and CC p
caries NNS p
scores NNS p
. . p

After IN N
elimination NN N
of IN N
carious JJ N
lesions NNS N
, , N
a DT N
prophylaxis NN i
was VBD N
given VBN N
to TO N
both DT N
groups NNS N
. . N

The DT N
chlorhexidine NN i
varnish NN i
was VBD N
then RB N
painted VBN N
on IN N
the DT N
entire JJ N
dentition NN N
of IN N
Group NNP N
T NNP N
subjects VBZ N
only RB N
. . N

Prior NNP N
to TO N
caries NNS N
elimination NN N
, , N
and CC N
again RB N
after IN N
three CD N
months NNS N
, , N
the DT N
gingival NN N
index NN N
was VBD N
used VBN N
to TO N
assess VB N
the DT N
gingival NN o
status NN o
of IN N
study NN N
subjects NNS N
. . N

An DT N
average NN N
of IN N
106.6 CD N
+/- JJ N
8.9 CD N
and CC N
107.7 CD N
+/- JJ N
6.2 CD N
gingival NN N
sites NNS N
per IN N
subject NN N
( ( N
four CD N
sites NNS N
per IN N
tooth NN N
) ) N
in IN N
Groups NNP N
C NNP N
and CC N
T NNP N
, , N
respectively RB N
, , N
were VBD N
examined VBN N
by IN N
the DT N
same JJ N
calibrated JJ N
examiner NN N
on IN N
two CD N
occasions NNS N
. . N

For IN N
statistical JJ N
purposes NNS N
, , N
data NNS N
were VBD N
dichotomized VBN N
[ NNP N
( ( N
0,1 CD N
) ) N
( ( N
2,3 CD N
) ) N
] NN N
for IN N
the DT N
gingival JJ N
index NN N
. . N

Independent NNP N
t-tests NNS N
and CC N
paired VBN N
t-tests NNS N
were VBD N
used VBN N
to TO N
analyze VB N
the DT N
data NN N
. . N

The DT N
percentage NN o
of IN o
sites NNS o
per IN o
subject NN o
with IN o
scores NNS o
of IN o
two CD o
or CC o
three CD o
at IN N
the DT N
baseline NN N
were VBD N
balanced VBN N
between IN N
study NN N
groups NNS N
( ( N
3.7 CD N
+/- JJ N
7.1 CD N
for IN N
T NNP N
; : N
1.8 CD N
+/- JJ N
3.2 CD N
for IN N
C NNP N
; : N
p VBZ N
= $ N
0.08 CD N
) ) N
. . N

After IN N
three CD N
months NNS N
, , N
a DT N
statistically RB N
significant JJ N
decrease NN N
in IN N
the DT N
average JJ N
percentage NN o
of IN o
sites NNS o
with IN o
scores NNS o
of IN o
two CD o
or CC o
three CD o
was VBD N
demonstrated VBN N
in IN N
the DT N
T NNP N
group NN N
( ( N
0.7 CD N
+/- JJ N
2.4 CD N
, , N
T NNP N
, , N
p NN N
< VBD N
0.0001 CD N
; : N
1.3 CD N
+/- JJ N
3.0 CD N
, , N
C NNP N
, , N
p NN N
< NNP N
0.25 CD N
) ) N
. . N

The DT N
authors NNS N
concluded VBD N
that IN N
the DT N
application NN N
of IN N
a DT N
chlorhexidine NN i
varnish NN i
significantly RB N
improved VBD N
the DT N
gingival JJ o
health NN o
of IN N
T NNP N
subjects NNS N
for IN N
up IN N
to TO N
three CD N
months NNS N
. . N

A DT N
significant JJ N
improvement NN N
in IN N
the DT N
gingival NN o
health NN o
could MD N
not RB N
be VB N
demonstrated VBN N
in IN N
the DT N
C NNP N
group NN N
. . N

-DOCSTART- -1440804- O O

The DT N
relationship NN N
between IN N
the DT N
response NN N
of IN N
Plasmodium NNP p
falciparum NN p
malaria NN p
to TO p
mefloquine VB i
in IN p
African JJ p
children NNS p
and CC N
its PRP$ N
sensitivity NN N
in IN N
vitro NN N
. . N

The DT N
clinical JJ N
efficacy NN N
of IN N
two CD N
doses NNS N
of IN N
mefloquine NN i
( ( N
15 CD N
and CC N
25 CD N
mg/kg NN N
body NN N
weight VBD N
) ) N
was VBD N
evaluated VBN N
in IN N
85 CD p
children NNS p
suffering VBG p
from IN p
acute JJ p
symptomatic JJ p
falciparum NN p
malaria NN p
. . p

The DT N
cure NN o
rate NN o
on IN N
day NN N
28 CD N
was VBD N
100 CD N
% NN N
in IN N
both DT N
groups NNS N
. . N

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
( ( N
P NNP N
> NNP N
0.05 CD N
) ) N
in IN N
the DT N
mean JJ o
parasite NN o
and CC o
fever NN o
clearance NN o
times NNS o
in IN N
both DT N
groups NNS N
( ( N
48.5 CD N
+/- JJ N
14.6 CD N
and CC N
32.0 CD N
+/- JJ N
12.7 CD N
h NN N
respectively RB N
for IN N
the DT N
25 CD N
mg/kg NN N
group NN N
and CC N
49.0 CD N
+/- JJ N
15.1 CD N
and CC N
30.0 CD N
+/- JJ N
13.3 CD N
h NN N
respectively RB N
for IN N
the DT N
15 CD N
mg/kg NNS N
group NN N
) ) N
. . N

There EX N
was VBD N
also RB N
no DT N
significant JJ N
difference NN N
( ( N
P NNP N
> NNP N
0.05 CD N
) ) N
in IN N
these DT N
values NNS N
between IN N
children NNS p
with IN p
hyperparasitaemia NN p
( ( N
53.6 CD N
+/- JJ N
11.1 CD N
and CC N
36.0 CD N
+/- JJ N
17.0 CD N
h NN N
respectively RB N
) ) N
and CC N
those DT p
without IN p
hyperparasitaemia NN p
( ( N
49.1 CD N
+/- JJ N
13.6 CD N
and CC N
31.8 CD N
+/- JJ N
14.6 CD N
h NN N
respectively RB N
) ) N
. . N

Recurrence NN o
of IN o
parasitaemia NN o
was VBD N
observed VBN N
after IN N
day NN N
30 CD N
in IN N
2 CD N
patients NNS N
in IN N
the DT N
15 CD N
mg/kg NN N
group NN N
and CC N
in IN N
1 CD N
patient NN N
in IN N
the DT N
25 CD N
mg/kg NN N
group NN N
. . N

In IN N
vitro NN N
, , N
3 CD N
of IN N
21 CD N
isolates NNS N
showed VBD N
reduced JJ N
susceptibility NN o
to TO o
mefloquine VB o
, , N
with IN N
minimum JJ N
inhibitory JJ o
concentrations NNS o
( ( N
MIC NNP N
) ) N
> VBD N
67 CD N
nM/litre NN N
. . N

The DT N
MIC NNP N
and CC N
50 CD N
% NN N
, , N
90 CD N
% NN N
and CC N
99 CD N
% NN N
inhibitory JJ o
concentrations NNS o
were VBD N
200.8 CD N
, , N
6.27 CD N
, , N
31.7 CD N
and CC N
119.6 CD N
nM/litre NNS N
respectively RB N
. . N

Four CD N
of IN N
22 CD N
isolates NNS N
were VBD N
resistant JJ o
to TO N
chloroquine VB i
( ( N
MIC NNP N
> NNP N
108 CD N
nM/litre NN N
) ) N
. . N

Isolates VBZ N
that IN N
showed VBD N
low JJ N
sensitivity NN o
to TO N
mefloquine VB i
in IN N
vitro NN N
were VBD N
sensitive JJ o
to TO N
chloroquine VB N
in IN N
vitro NN N
, , N
and CC N
the DT N
4 CD N
that WDT N
were VBD N
resistant JJ o
to TO N
chloroquine VB N
were VBD N
sensitive JJ o
to TO N
mefloquine VB N
. . N

Irrespective NNP N
of IN N
MIC NNP N
and CC N
dose NN N
of IN N
mefloquine NN N
, , N
parasitaemia NN N
cleared VBN N
in IN N
all DT N
subjects NNS N
in IN N
96 CD N
h NN N
or CC N
less JJR N
. . N

( ( N
ABSTRACT NNP N
TRUNCATED NNP N
AT NNP N
250 CD N
WORDS NNP N
) ) N
-DOCSTART- -19081412- O O

Three-year JJ N
clinical JJ N
outcome NN N
after IN N
primary JJ p
stenting NN p
of IN p
totally RB p
occluded JJ p
native JJ p
coronary JJ p
arteries NNS p
: : p
a DT N
randomized JJ N
comparison NN N
of IN N
bare-metal JJ i
stent JJ i
implantation NN i
with IN i
sirolimus-eluting JJ i
stent NN i
implantation NN i
for IN N
the DT N
treatment NN N
of IN N
total JJ p
coronary JJ p
occlusions NNS p
( ( N
Primary JJ N
Stenting NNP N
of IN N
Totally NNP N
Occluded NNP N
Native NNP N
Coronary NNP N
Arteries NNP N
[ NNP N
PRISON NNP N
] NNP N
II NNP N
study NN N
) ) N
. . N

BACKGROUND IN N
The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
examine VB N
the DT N
3-year JJ N
clinical JJ N
outcome NN N
in IN N
patients NNS p
enrolled VBN p
in IN p
the DT p
Primary NNP p
Stenting NNP p
of IN p
Totally NNP p
Occluded NNP p
Native NNP p
Coronary NNP p
Arteries NNP p
II NNP p
study NN p
. . p

METHODS NNP N
Patients NNPS p
with IN p
totally RB p
occluded JJ p
coronary JJ p
arteries NNS p
randomized VBN N
to TO N
either DT N
sirolimus-eluting JJ i
Cypher NNP i
stents NNS i
( ( i
SESs NNP i
) ) i
( ( N
Cordis NNP N
, , N
a DT N
Johnson NNP N
& CC N
Joshson NNP N
Company NNP N
, , N
Miami NNP N
Lakes NNP N
, , N
FL NNP N
) ) N
( ( p
100 CD p
patients NNS p
) ) p
or CC N
bare-metal JJ i
BxVelocity NNP i
stents NNS i
( ( i
BMSs NNP i
) ) i
( ( p
Cordis NNP p
) ) p
( ( p
100 CD p
patients NNS p
) ) p
were VBD N
followed VBN N
clinically RB N
for IN N
3 CD N
years NNS N
. . N

RESULTS NNP N
Between NNP N
1 CD N
and CC N
3 CD N
years NNS N
, , N
there EX N
were VBD N
infrequent JJ N
additional JJ N
clinical JJ N
events NNS N
that WDT N
were VBD N
equally RB N
distributed VBN N
between IN N
the DT N
SES NNP N
and CC N
the DT N
BMS NNP N
group NN N
. . N

After IN N
3 CD N
years NNS N
, , N
target NN o
lesion NN o
revascularization NN o
was VBD N
7 CD N
% NN N
in IN N
the DT N
SES NNP N
group NN N
versus VBD N
27 CD N
% NN N
in IN N
the DT N
BMS NNP N
group NN N
( ( N
P NNP N
< NNP N
.001 NNP N
) ) N
; : N
and CC N
target VB N
vessel JJ o
revascularization NN o
was VBD N
seen VBN N
in IN N
11 CD N
% NN N
in IN N
the DT N
SES NNP N
group NN N
versus VBD N
30 CD N
% NN N
in IN N
the DT N
BMS NNP N
group NN N
( ( N
P NNP N
= NNP N
.002 NNP N
) ) N
. . N

Major JJ o
adverse JJ o
cardiac NN o
events NNS o
were VBD N
noted VBN N
in IN N
10 CD N
% NN N
of IN N
the DT N
SES NNP N
group NN N
versus VBD N
34 CD N
% NN N
in IN N
the DT N
BMS NNP N
group NN N
( ( N
P NNP N
< NNP N
.001 NNP N
) ) N
. . N

There EX N
were VBD N
no DT N
statistically RB N
significant JJ N
differences NNS N
in IN N
death NN o
, , o
myocardial JJ o
infarction NN o
, , o
and CC o
stent JJ o
thrombosis NN o
according VBG N
to TO N
the DT N
Academic NNP N
Research NNP N
Consortium NNP N
criteria NNS N
between IN N
the DT N
2 CD N
groups NNS N
. . N

CONCLUSIONS NNP N
Clinical NNP N
outcome VBD N
up RB N
to TO N
3 CD N
years NNS N
after IN N
implantation NN N
of IN N
SESs NNP i
for IN N
total JJ N
coronary JJ N
occlusions NNS N
continues VBZ N
to TO N
demonstrate VB N
a DT N
significant JJ N
reduction NN N
in IN N
adverse JJ N
clinical JJ N
events NNS N
compared VBN N
with IN N
BMSs NNP i
without IN N
the DT N
evidence NN N
for IN N
either DT N
disproportionate NN N
late JJ N
restenosis NN N
or CC N
late JJ N
stent JJ N
thrombosis NN N
. . N

-DOCSTART- -25561389- O O

Does VBZ N
watching VBG N
a DT N
video NN N
on IN N
third JJ i
molar JJ i
surgery NN i
increase NN N
patients NNS p
' POS p
anxiety NN p
level NN p
? . N
OBJECTIVE UH N
To TO N
identify VB N
the DT N
effects NNS N
of IN N
watching VBG i
live JJ i
taping NN i
of IN i
third JJ i
molar JJ i
removal NN i
on IN N
patients NNS p
' POS p
anxiety NN p
levels NNS p
before IN N
and CC N
after IN N
extraction NN N
. . N

STUDY NNP N
DESIGN NNP N
This DT N
study NN N
was VBD N
based VBN N
on IN N
a DT N
prospective JJ N
, , N
cross-sectional JJ N
, , N
observational JJ N
investigation NN N
of IN N
the DT N
different JJ N
patient JJ N
education NN N
techniques NNS N
about IN N
the DT N
effect NN N
of IN N
third JJ N
molar JJ N
removal NN N
on IN N
patients NNS p
' POS p
anxiety NN p
level NN p
. . p

A DT N
total NN N
of IN N
333 CD p
patients NNS p
were VBD N
randomized VBN N
into IN N
three CD N
groups NNS N
: : N
two CD N
study NN N
groups NNS N
( ( N
for IN N
group NN N
1 CD N
, , N
basic JJ i
information NN i
was VBD i
given VBN i
verbally RB i
; : i
for IN N
group NN N
2 CD N
, , N
which WDT N
was VBD N
the DT N
study NN N
group NN N
, , N
basic JJ i
information NN i
was VBD i
given VBN i
verbally RB i
and CC i
through IN i
a DT i
movie NN i
on IN i
third JJ i
molar JJ i
extraction NN i
) ) i
; : i
and CC N
a DT N
control NN i
group NN i
( ( i
basic JJ i
information NN i
was VBD i
given VBN i
verbally RB i
; : i
it PRP i
did VBD i
not RB i
include VB i
information NN i
on IN i
operative JJ i
procedures NNS i
and CC i
recovery NN i
) ) i
. . N

Anxiety NN o
levels NNS o
were VBD N
assessed VBN N
by IN N
using VBG N
the DT N
Dental NNP o
Anxiety NNP o
Scale NNP o
( ( o
DAS NNP o
) ) o
and CC N
the DT N
Spielberger NNP o
State-Trait NNP o
Anxiety NNP o
Inventory NNP o
( ( o
STAI NNP o
) ) o
. . o

Pain NN o
was VBD N
assessed VBN N
with IN N
a DT N
visual JJ o
analog NN o
scale NN o
. . o

Statistical JJ N
analysis NN N
was VBD N
performed VBN N
with IN N
SPSS NNP o
16.0 CD o
. . o

RESULTS NNP N
Group NNP N
2 CD N
patients NNS N
were VBD N
significantly RB N
more RBR N
anxious JJ o
before IN N
the DT N
surgical JJ N
procedure NN N
, , N
and CC N
the DT N
most RBS N
significant JJ N
decreases NNS N
in IN N
DAS NNP o
and CC o
STAI NNP o
scores NNS o
were VBD N
observed VBN N
in IN N
that DT N
group NN N
. . N

The DT N
age NN o
, , o
surgery NN o
time NN o
, , N
and CC N
education NN o
level NN o
were VBD N
not RB N
correlated VBN N
with IN N
anxiety NN o
or CC o
pain NN o
levels NNS o
; : o
however RB N
, , N
female JJ N
patients NNS N
had VBD N
high JJ o
levels NNS o
of IN o
anxiety NN o
( ( N
P NNP N
< NNP N
.05 NNP N
) ) N
. . N

CONCLUSION NNP N
Preoperative NNP i
multimedia NN i
information NN i
increases VBZ N
the DT N
anxiety NN N
of IN N
patients NNS p
undergoing VBG p
third JJ p
molar JJ p
surgery NN p
. . p

-DOCSTART- -20946966- O O

Clofarabine NNP i
? . i
fludarabine NN i
with IN N
once RB N
daily JJ N
i.v NN N
. . N

busulfan NN i
as IN N
pretransplant JJ N
conditioning NN N
therapy NN N
for IN p
advanced JJ p
myeloid NN p
leukemia NN p
and CC p
MDS NNP p
. . p

Although IN N
a DT N
combination NN N
of IN i
i.v NN i
. . i

busulfan NN i
( ( i
Bu NNP i
) ) i
and CC i
fludarabine NN i
( ( i
Flu NNP i
) ) i
is VBZ N
a DT N
safe JJ N
, , N
reduced-toxicity JJ N
conditioning NN N
program NN N
for IN N
acute JJ N
myelogenous JJ N
leukemia/myelodysplastic JJ N
syndromes NNS N
( ( N
AML/MDS NNP N
) ) N
, , N
recurrent JJ N
leukemia NN N
posttransplantation NN N
remains VBZ N
a DT N
problem NN N
. . N

To TO N
enhance VB N
the DT N
conditioning NN N
regimen NN N
's POS N
antileukemic JJ N
effect NN N
, , N
we PRP N
decided VBD N
to TO N
supplant VB i
Flu NNP i
with IN i
clofarabine NN i
( ( i
Clo NNP i
) ) i
, , i
and CC N
assayed VBD N
the DT N
interactions NNS N
of IN N
these DT N
nucleoside JJ N
analogs NNS N
alone RB N
and CC N
in IN N
combination NN N
with IN N
Bu NNP N
in IN N
Bu-resistant NNP N
human NN N
cell NN N
lines NNS N
in IN N
vitro NN N
. . N

We PRP N
found VBD N
pronounced VBD N
synergy NN N
between IN N
each DT N
nucleoside NN N
and CC N
the DT N
alkylator NN N
but CC N
even RB N
more RBR N
enhanced JJ N
cytotoxic NN N
synergy NN N
when WRB N
the DT N
nucleoside JJ N
analogs NNS N
were VBD N
combined VBN N
prior RB N
to TO N
exposing VBG N
the DT N
cells NNS N
to TO N
Bu NNP N
. . N

We PRP N
then RB N
designed VBD N
a DT N
4-arm JJ N
clinical JJ N
trial NN N
in IN p
patients NNS p
with IN p
myeloid JJ p
leukemia NN p
undergoing VBG p
allogeneic JJ p
stem NN p
cell NN p
transplantation NN p
( ( p
allo-SCT JJ p
) ) p
. . p

Patients NNS N
were VBD N
adaptively RB N
randomized VBN N
as IN N
follows VBZ N
: : N
Arm JJ N
I-Clo NN i
: : i
Flu CD i
10:30 CD N
mg/m NN N
( ( N
2 CD N
) ) N
, , N
Arm NNP N
II-20:20 NNP N
mg/m NN N
( ( N
2 CD N
) ) N
, , N
Arm NNP N
III-30:10 NNP N
mg/m NN N
( ( N
2 CD N
) ) N
, , N
and CC N
Arm NNP N
IV-single-agent NNP i
Clo NNP i
at IN N
40 CD N
mg/m NN N
( ( N
2 CD N
) ) N
. . N

The DT N
nucleoside JJ N
analog NN N
( ( N
s PRP N
) ) N
were/was NN N
infused VBN N
over IN N
1 CD N
hour NN N
once RB N
daily JJ N
for IN N
4 CD N
days NNS N
, , N
followed VBD N
on IN N
each DT N
day NN N
by IN N
Bu NNP N
, , N
infused VBD N
over IN N
3 CD N
hours NNS N
to TO N
a DT N
pharmacokinetically RB N
targeted VBN N
daily JJ N
area NN N
under IN N
the DT N
curve NN N
( ( N
AUC NNP N
) ) N
of IN N
6000 CD N
?Mol-min NN N
? . N
10 CD N
% NN N
. . p

Fifty-one CD p
patients NNS p
have VBP p
been VBN p
enrolled VBN p
with IN p
a DT N
minimum JJ N
follow-up JJ N
exceeding VBG N
100 CD N
days NNS p
. . p

There EX p
were VBD p
32 CD p
males NNS p
and CC p
19 CD p
females NNS p
, , p
with IN p
a DT p
median JJ p
age NN p
of IN p
45 CD p
years NNS p
( ( p
range NN p
: : p
6-59 JJ p
) ) p
. . p

Nine JJ p
patients NNS p
had VBD p
chronic JJ p
myeloid NN p
leukemia NN p
( ( p
CML NNP p
) ) p
( ( p
BC NNP p
: : p
2 CD p
, , p
second JJ p
AP NNP p
: : p
3 CD p
, , p
and CC p
tyrosine-kinase JJ p
inhibitor NN p
refractory NN p
first RB p
chronic JJ p
phase NN p
[ NNP p
CP NNP p
] NN p
: : p
4 CD p
) ) p
. . p

Forty-two JJ p
patients NNS p
had VBD p
AML NNP p
: : p
14 CD p
were VBD p
induction NN p
failures NNS p
, , p
8 CD p
in IN p
first JJ p
chemotherapy-refractory JJ p
relapse NN p
, , p
7 CD p
in IN p
untreated JJ p
relapse NN p
, , p
3 CD p
in IN p
second JJ p
or CC p
subsequent JJ p
relapse NN p
, , p
4 CD p
were VBD p
in IN p
second JJ p
complete JJ p
remission NN p
( ( p
CR NNP p
) ) p
, , p
and CC p
3 CD p
in IN p
second JJ p
CR NNP p
without IN p
platelet NN p
recovery NN p
( ( p
CRp NNP p
) ) p
, , p
2 CD p
were VBD p
in IN p
high-risk JJ p
CR1 NNP p
. . p

Finally NNP p
, , p
1 CD p
patient NN p
was VBD p
in IN p
first JJ p
CRp NNP p
. . p

Graft-versus-host NNP p
disease NN N
( ( N
GVHD NNP N
) ) N
prophylaxis NN N
was VBD N
tacrolimus JJ N
and CC N
mini-methorexate JJ N
( ( N
MTX NNP N
) ) N
, , N
and CC N
those DT N
who WP N
had VBD N
an DT N
unrelated JJ N
or CC N
1 CD N
antigen-mismatched JJ N
donor NN N
received VBD N
low-dose JJ N
rabbit-ATG NN N
( ( N
Thymoglobulin? NNP N
) ) N
. . N

All DT N
patients NNS N
engrafted VBN p
. . p

Forty-one CD p
patients NNS p
had VBD p
active JJ p
leukemia NN p
at IN p
the DT p
time NN p
of IN p
transplant NN p
, , p
and CC p
35 CD p
achieved VBN p
CR NNP p
( ( p
85 CD N
% NN N
) ) N
. . p

Twenty CD p
of IN N
the DT N
42 CD N
AML NNP N
patients NNS N
and CC N
5 CD N
of IN N
9 CD N
CML NNP N
patients NNS N
are VBP N
alive JJ N
with IN N
a DT o
projected JJ o
median JJ o
overall JJ o
survival NN o
( ( o
OS NNP o
) ) o
of IN N
23 CD N
months NNS o
. . o

Marrow NNP o
and CC o
blood NN o
( ( o
T NNP o
cell NN o
) ) o
chimerism NN o
studies NNS N
at IN N
day NN N
+100 NNP N
revealed VBD N
that IN N
both DT N
in IN N
the DT N
lower-dose JJ N
Clo NNP N
groups NNS N
( ( N
groups NNS N
1+2 CD N
) ) N
and CC N
the DT N
higher-dose JJ N
Clo NNP N
groups NNS N
( ( N
groups NNS N
3+4 CD N
) ) N
, , N
the DT N
patients NNS N
had VBD N
a DT N
median NN o
of IN o
100 CD o
% NN o
donor NN o
( ( o
T NNP o
cell NN o
) ) o
-derived VBD o
DNA NNP o
. . o

There EX N
has VBZ o
been VBN o
no DT o
secondary JJ o
graft NN o
failure NN o
. . o

In IN o
the DT N
first JJ N
100 CD N
days NNS N
, , N
1 CD N
patient NN o
died VBD o
of IN o
pneumonia NN o
, , o
and CC o
1 CD N
of IN N
liver NN o
GVHD NNP o
. . N

We PRP N
conclude VBP N
that IN N
( ( N
1 CD N
) ) N
Clo NNP N
? . N
Flu NNP N
with IN N
i.v NN N
. . N

Bu NNP N
as IN N
pretransplant JJ o
conditioning NN o
is VBZ o
safe JJ o
in IN o
high-risk JJ o
myeloid JJ o
leukemia NN o
patients NNS o
; : o
( ( o
2 CD o
) ) o
clofarabine NN o
is VBZ o
sufficiently RB o
immunosuppressive JJ o
to TO o
support VB o
allo-SCT NN N
in IN N
myeloid JJ N
leukemia NN N
; : N
and CC N
( ( N
3 CD N
) ) N
the DT N
median JJ N
OS NNP N
of IN N
23 CD N
months NNS N
in IN N
this DT N
high-risk JJ N
patient NN N
population NN N
is VBZ N
encouraging VBG N
. . N

Additional JJ N
studies NNS N
to TO N
evaluate VB o
the DT o
antileukemic JJ o
efficacy NN o
of IN o
Clo NNP o
? . i
Flu NNP i
with IN i
i.v NN i
. . i

Bu NNP i
as IN i
pretransplant JJ o
conditioning NN o
therapy NN o
are VBP o
warranted VBN o
. . o

-DOCSTART- -11028492- O O

Short- JJ N
and CC N
long-term JJ N
results NNS N
after IN N
thrombolytic JJ i
treatment NN i
of IN N
deep JJ N
venous JJ N
thrombosis NN N
. . N

OBJECTIVES CC N
The DT N
goal NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
assess VB N
the DT N
short- JJ N
and CC N
long-term JJ N
efficacy NN N
of IN N
different JJ N
thrombolytic JJ i
therapy NN i
regimens NNS N
in IN N
patients NNS p
with IN p
leg NN p
or CC p
pelvic JJ p
deep JJ p
venous JJ p
thrombosis NN p
( ( p
DVT NNP p
) ) p
. . p

BACKGROUND VB N
It PRP N
is VBZ N
unclear JJ N
whether IN N
locoregional JJ N
or CC N
systemic JJ N
thrombolysis NN N
is VBZ N
superior JJ N
in IN N
treating VBG N
acute JJ N
leg NN N
DVT NNP N
or CC N
even RB N
whether IN N
lysis NN N
is VBZ N
more RBR N
effective JJ N
than IN N
anticoagulation NN N
therapy NN N
in IN N
preventing VBG N
postthrombotic JJ N
syndrome NN N
. . N

METHODS NNP N
A NNP N
total NN N
of IN N
250 CD p
patients NNS p
averaging VBG p
40 CD p
years NNS p
of IN p
age NN p
with IN p
acute JJ p
DVT NNP p
were VBD N
randomized VBN N
into IN N
five CD N
groups NNS N
to TO N
receive VB N
full JJ i
heparinization NN i
( ( i
1,000 CD i
IU/h NNP i
) ) i
and CC i
compression NN i
treatment NN i
, , i
with IN i
four CD i
groups NNS i
also RB i
administered VBD i
locoregional JJ i
tissue NN i
plasminogen NN i
activator NN i
( ( i
20 CD i
mg/day NN i
) ) i
or CC i
urokinase JJ i
( ( i
100,000 CD i
IU/day NNP i
) ) i
or CC i
systemic JJ i
streptokinase NN i
( ( i
3,000,000 CD i
IU NNP i
daily RB i
) ) i
or CC i
urokinase JJ i
( ( i
5,000,000 CD i
IU NNP i
daily RB i
) ) i
. . N

All DT N
groups NNS N
then RB N
received VBD N
anticoagulation NN i
and CC i
compression NN i
treatment NN i
for IN i
one CD i
year NN i
. . i

Primary NNP N
efficacy NN N
criteria NNS N
included VBD N
the DT N
change NN N
after IN N
one CD N
year NN N
in IN N
the DT N
number NN N
of IN N
closed JJ o
vein NN o
segments NNS o
and CC N
the DT N
occurrence NN N
of IN N
postthrombotic JJ N
syndrome NN N
. . N

RESULTS NNP N
Systemic NNP i
thrombolytic JJ i
therapy NN i
significantly RB N
reduced VBD N
the DT N
number NN N
of IN N
closed JJ o
vein NN o
segments NNS o
after IN N
12 CD N
months NNS N
in IN N
patients NNS p
with IN p
acute JJ p
DVT NNP p
compared VBN N
with IN N
conventional JJ N
treatment NN N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
. . N

Postthrombotic JJ o
syndrome NN o
also RB N
occurred VBD N
with IN N
less JJR N
frequency NN N
in IN N
systemically RB N
treated JJ N
patients NNS N
versus NN N
controls NNS N
( ( N
p VB N
< RB N
0.001 CD N
) ) N
. . N

High-dose JJ N
thrombolysis NN N
led VBD N
to TO N
better RBR N
rates NNS N
of IN N
complete JJ o
recanalization NN o
after IN N
seven CD N
days NNS N
( ( N
p JJ N
< NNP N
0.01 CD N
) ) N
than IN N
locoregional JJ N
lysis NN N
. . N

However RB N
, , N
12 CD p
patients NNS p
receiving VBG p
thrombolysis NN p
( ( N
9 CD N
systemic NN N
, , N
3 CD N
local JJ N
) ) N
suffered VBD N
major JJ o
bleeding NN o
complications NNS o
; : o
9 CD p
patients NNS p
on IN p
systemic JJ p
treatment NN p
developed VBD N
pulmonary JJ o
emboli NN o
. . o

CONCLUSIONS NNP N
Systemic NNP i
thrombolytic JJ i
treatment NN i
for IN N
acute JJ N
DVT NNP N
achieved VBD N
a DT N
significantly RB N
better JJR N
short- NN N
and CC N
long-term JJ N
clinical JJ N
outcome NN N
than IN N
conventional JJ N
heparin/anticoagulation NN N
therapy NN N
but CC N
at IN N
the DT N
expense NN N
of IN N
a DT N
serious JJ N
increase NN N
in IN N
major JJ N
bleeding NN N
and CC N
pulmonary JJ N
emboli NN N
. . N

Given VBN N
the DT N
inherent JJ N
risks NNS N
for IN N
such JJ N
serious JJ N
complications NNS N
, , N
systemic JJ N
thrombolysis NN N
, , N
although IN N
effective JJ N
, , N
should MD N
be VB N
used VBN N
selectively RB N
in IN N
limb-threatening JJ N
thrombotic JJ N
situations NNS N
. . N

-DOCSTART- -14657766- O O

Nonnucleoside NNP i
reverse JJ i
transcriptase NN i
inhibitor-containing JJ i
regimens NNS i
are VBP N
associated VBN p
with IN p
increased JJ p
satisfaction NN o
with IN o
sexual JJ o
life NN o
. . o

-DOCSTART- -15080019- O O

Efficacy NN N
of IN N
prophylactic JJ N
ondansetron NN N
in IN N
a DT N
patient-controlled JJ p
analgesia NN p
environment NN p
. . p

We PRP N
conducted VBD N
a DT N
prospective JJ N
, , N
randomized VBN N
, , N
double-blind JJ N
, , N
placebo-controlled JJ i
trial NN N
to TO N
examine VB N
the DT N
efficacy NN N
of IN N
prophylactic JJ i
ondansetron NN i
on IN N
post-operative JJ o
nausea NN o
and CC o
vomiting NN o
( ( o
PONV NNP o
) ) o
during IN N
opioid JJ N
patient-controlled JJ N
analgesia NN N
( ( N
PCA NNP N
) ) N
. . N

In IN N
total JJ N
, , N
374 CD p
patients NNS p
using VBG p
opioid JJ p
PCA NNP p
, , p
but CC p
otherwise RB p
considered VBN p
to TO p
be VB p
low JJ p
risk NN p
for IN p
PONV NNP p
, , N
were VBD N
randomly RB N
allocated VBN N
to TO N
ondansetron VB i
( ( N
4 CD N
mg NN N
given VBN N
intravenously RB N
and CC N
16 CD N
mg NN N
added VBD N
into IN N
the DT N
PCA NNP N
pump NN N
) ) N
or CC N
saline JJ i
( ( N
control VB N
group NN N
) ) N
. . N

PONV NNP o
was VBD N
evaluated VBN N
in IN N
terms NNS N
of IN N
nausea NN o
graded VBN o
on IN o
a DT o
visual JJ o
analogue NN o
scale NN o
, , N
and CC N
the DT N
number NN o
of IN o
patients NNS o
who WP o
experienced VBD o
emetic JJ o
episodes NNS o
or CC o
needed VBN o
rescue NN o
anti-emetics NNS o
in IN N
the DT N
48-h JJ N
post-operative JJ N
period NN N
. . N

Patient JJ o
satisfaction NN o
for IN N
PCA NNP N
was VBD N
scored VBN N
at IN N
the DT N
end NN N
of IN N
the DT N
evaluation NN N
period NN N
. . N

The DT N
only JJ N
difference NN N
between IN N
the DT N
two CD N
groups NNS N
was VBD N
the DT N
higher JJR o
number NN o
of IN o
headaches NNS o
in IN N
the DT N
ondansetron NN N
group NN N
. . N

In IN N
patients NNS N
using VBG N
opioid JJ N
PCA NNP N
, , N
but CC N
with IN N
no DT N
other JJ N
high JJ N
risk NN N
factors NNS N
for IN N
PONV NNP o
, , N
prophylactic JJ N
ondansetron NN N
does VBZ N
not RB N
have VB N
any DT N
clinical JJ N
benefit NN N
. . N

-DOCSTART- -23993773- O O

Behavioral JJ i
parent NN i
training NN i
to TO N
address VB N
sleep JJ o
disturbances NNS o
in IN N
young JJ p
children NNS p
with IN p
autism NN p
spectrum NN p
disorder NN p
: : p
a DT N
pilot NN N
trial NN N
. . N

OBJECTIVES CC N
A DT N
large JJ N
percentage NN N
of IN N
children NNS N
with IN N
autism NN N
spectrum NN p
disorders NNS p
( ( p
ASD NNP p
) ) p
have VBP N
bedtime VBN o
and CC N
sleep JJ o
disturbances NNS o
. . o

However RB N
, , N
the DT N
treatment NN N
of IN N
these DT N
disturbances NNS o
has VBZ N
been VBN N
understudied VBN N
. . N

The DT N
purpose NN N
of IN N
our PRP$ N
study NN N
was VBD N
to TO N
develop VB N
a DT N
manualized JJ i
behavioral JJ i
parent NN i
training NN i
( ( N
BPT NNP N
) ) N
program NN N
for IN N
parents NNS p
of IN p
young JJ p
children NNS p
with IN p
ASD NNP p
and CC N
sleep JJ o
disturbances NNS o
and CC N
to TO N
test VB N
the DT N
feasibility NN o
, , o
fidelity NN o
, , o
and CC o
initial JJ o
efficacy NN o
of IN N
the DT N
treatment NN N
in IN N
a DT N
small JJ N
randomized NN N
controlled VBN N
trial NN N
( ( N
RCT NNP N
) ) N
. . N

PARTICIPANTS NNP N
AND CC N
METHODS NNP N
Parents NNP p
of IN p
a DT p
sample NN p
of IN p
40 CD p
young JJ p
children NNS p
diagnosed VBN p
with IN p
ASD NNP p
with IN p
an DT p
average JJ p
age NN p
of IN p
3.5years CD p
were VBD p
enrolled VBN p
in IN p
our PRP$ p
study NN p
. . p

Participants NNS N
were VBD N
randomized VBN N
to TO N
either CC N
the DT N
BPT NNP i
program NN i
group NN i
or CC i
a DT i
comparison NN i
group NN i
who WP i
were VBD i
given VBN i
nonsleep-related JJ i
parent NN i
education NN i
. . i

Each DT N
participant NN N
was VBD N
individually RB N
administered VBN N
a DT N
5-session JJ N
program NN N
delivered VBN N
over IN N
the DT N
8-week JJ N
study NN N
. . N

Outcome NNP N
measures NNS N
of IN N
feasibility NN o
, , o
fidelity NN o
, , o
and CC o
efficacy NN o
were VBD o
collected VBN N
at IN N
weeks NNS N
4 CD N
and CC N
8 CD N
after IN N
the DT N
baseline NN N
time NN N
point NN N
. . N

Children NNP N
's POS N
sleep NN o
was VBD N
assessed VBN N
by IN N
parent NN N
report NN N
and CC N
objectively RB N
by IN N
actigraphy NN N
. . N

RESULTS NNP N
Of IN N
the DT N
20 CD p
participants NNS p
in IN p
each DT p
group NN p
, , p
data NNS p
were VBD p
available JJ p
for IN p
15 CD p
participants NNS p
randomized VBN p
to TO p
BPT NNP p
and CC p
18 CD p
participants NNS p
randomized VBN p
to TO p
the DT p
comparison NN p
condition NN p
. . p

Results NNP N
supported VBD N
the DT N
feasibility NN o
of IN N
the DT N
manualized JJ N
parent NN N
training NN N
program NN N
and CC N
the DT N
comparison NN N
program NN N
. . N

Treatment NNP N
fidelity NN o
was VBD N
high JJ N
for IN N
both DT N
groups NNS N
. . N

The DT N
BPT NNP N
program NN N
group NN N
significantly RB N
improved VBD N
more JJR N
than IN N
the DT N
comparison NN N
group NN N
based VBN N
on IN N
the DT N
primary JJ o
sleep JJ o
outcome NN o
of IN N
parent NN N
report NN N
. . N

There EX N
were VBD N
no DT N
objective JJ N
changes NNS o
in IN o
sleep NN o
detected VBN N
by IN N
actigraphy NN N
. . N

CONCLUSIONS NNP N
Our PRP$ N
study NN N
is VBZ N
one CD N
of IN N
few JJ N
RCTs NNP N
of IN N
a DT N
BPT NNP N
program NN N
to TO N
specifically RB N
target VB N
sleep JJ o
disturbances NNS o
in IN N
a DT N
well-characterized JJ N
sample NN N
of IN N
young JJ N
children NNS N
with IN N
ASD NNP N
and CC N
to TO N
demonstrate VB N
the DT N
feasibility NN o
of IN N
the DT N
approach NN N
. . N

Initial JJ o
efficacy NN o
favored VBD N
the DT N
BPT NNP N
program NN N
over IN N
the DT N
comparison NN N
group NN N
and CC N
suggested VBD N
that IN N
this DT N
manualized JJ N
parent NN N
training NN N
approach NN N
is VBZ N
worthy JJ N
of IN N
further JJ N
examination NN N
of IN N
the DT N
efficacy NN N
within IN N
a DT N
larger JJR N
RCT NNP N
. . N

-DOCSTART- -22311204- O O

Prefrontal JJ N
neuromodulation NN N
using VBG N
rTMS JJ i
improves NNS N
error VBP N
monitoring NN N
and CC N
correction NN N
function NN N
in IN N
autism NN N
. . N

One CD N
important JJ N
executive NN N
function NN N
known VBN N
to TO N
be VB N
compromised VBN N
in IN N
autism NN p
spectrum NN p
disorder NN p
( ( N
ASD NNP N
) ) N
is VBZ N
related VBN N
to TO N
response NN o
error NN o
monitoring NN o
and CC o
post-error JJ o
response NN o
correction NN o
. . o

Several JJ N
reports NNS N
indicate VBP N
that IN N
children NNS p
with IN p
ASD NNP p
show NN N
reduced VBD N
error NN o
processing NN o
and CC N
deficient JJ N
behavioral JJ o
correction NN o
after IN N
an DT N
error NN N
is VBZ N
committed VBN N
. . N

Error NNP N
sensitivity NN N
can MD N
be VB N
readily RB N
examined VBN N
by IN N
measuring VBG N
event-related JJ o
potentials NNS o
( ( o
ERP NNP o
) ) o
associated VBN N
with IN N
responses NNS N
to TO N
errors NNS N
, , N
the DT N
fronto-central JJ o
error-related JJ o
negativity NN o
( ( o
ERN NNP o
) ) o
, , o
and CC o
the DT o
error-related JJ o
positivity NN o
( ( o
Pe NNP o
) ) o
. . o

The DT N
goal NN N
of IN N
our PRP$ N
study NN N
was VBD N
to TO N
investigate VB N
whether IN N
reaction NN o
time NN o
( ( o
RT NNP o
) ) o
, , o
error NN o
rate NN o
, , o
post-error JJ o
RT NNP o
change NN o
, , o
ERN NNP o
, , o
and CC o
Pe NNP o
will MD N
show VB N
positive JJ N
changes NNS N
following VBG N
12-week JJ N
long JJ N
slow JJ N
frequency NN N
repetitive JJ N
TMS NNP N
( ( i
rTMS NN i
) ) i
over IN N
dorsolateral JJ N
prefrontal JJ N
cortex NN N
( ( N
DLPFC NNP N
) ) N
in IN N
high JJ p
functioning NN p
children NNS p
with IN p
ASD NNP p
. . p

We PRP N
hypothesized VBD N
that IN N
12 CD N
sessions NNS N
of IN N
1 CD N
Hz NNP N
rTMS NN i
bilaterally RB N
applied VBN N
over IN N
the DT N
DLPFC NNP N
will MD N
result VB N
in IN N
improvements NNS N
reflected VBN N
in IN N
both DT N
behavioral JJ o
and CC o
ERP NNP o
measures NNS o
. . o

Participants NNS N
were VBD N
randomly RB i
assigned VBN i
to TO i
either DT i
active JJ i
rTMS NN i
treatment NN i
or CC i
wait-list NN i
( ( i
WTL NNP i
) ) i
groups NNS i
. . i

Baseline NNP o
and CC o
post-TMS/or JJ o
WTL NNP o
EEG NNP o
was VBD i
collected VBN i
using VBG i
128 CD i
channel NNS i
EEG NNP i
system NN i
. . i

The DT N
task NN N
involved VBD N
the DT N
recognition NN N
of IN N
a DT N
specific JJ N
illusory NN N
shape NN N
, , N
in IN N
this DT N
case NN N
a DT N
square NN N
or CC N
triangle NN N
, , N
created VBN N
by IN N
three CD N
or CC N
four CD N
inducer NN N
disks NNS N
. . N

ERN NNP o
in IN N
TMS NNP N
treatment NN N
group NN N
became VBD N
significantly RB N
more RBR N
negative JJ N
. . N

The DT N
number NN N
of IN N
omission JJ o
errors NNS o
decreased VBD N
post-TMS NN N
. . N

The DT N
RT NNPS o
did VBD N
not RB N
change NN N
, , N
but CC N
post-error JJ o
RT NNP o
became VBD N
slower JJR N
. . N

There EX N
were VBD N
no DT N
changes NNS N
in IN N
RT NNP o
, , o
error NN o
rate NN o
, , o
post-error NN o
RT NNP o
slowing NN o
, , o
nor CC o
in IN o
ERN/Pe NNP o
measures NNS o
in IN N
the DT N
wait-list JJ N
group NN N
. . N

Our PRP$ N
results NNS N
show VBP N
significant JJ N
post-TMS JJ N
differences NNS N
in IN N
the DT N
response-locked JJ o
ERP NNP o
such JJ N
as IN N
ERN NNP o
, , N
as RB N
well RB N
as IN N
behavioral JJ N
response NN N
monitoring NN N
measures NNS N
indicative JJ N
of IN N
improved JJ N
error NN N
monitoring NN N
and CC N
correction NN N
function NN N
. . N

The DT N
ERN NNP o
and CC o
Pe NNP o
, , N
along IN N
with IN N
behavioral JJ N
performance NN N
measures NNS N
, , N
can MD N
be VB N
used VBN N
as IN N
functional JJ N
outcome NN N
measures NNS N
to TO N
assess VB N
the DT N
effectiveness NN N
of IN N
neuromodulation NN N
( ( N
e.g. JJ N
, , N
rTMS NN N
) ) N
in IN N
children NNS p
with IN p
autism NN p
and CC N
thus RB N
may MD N
have VB N
important JJ N
practical JJ N
implications NNS N
. . N

-DOCSTART- -10517426- O O

Use NNP N
of IN N
the DT N
oral JJ N
neuraminidase NN i
inhibitor NN i
oseltamivir NN i
in IN N
experimental JJ p
human JJ p
influenza NN p
: : p
randomized VBN N
controlled JJ N
trials NNS N
for IN N
prevention NN N
and CC N
treatment NN N
. . N

CONTEXT NNP N
Influenza NNP N
virus NN N
neuraminidase NN N
is VBZ N
thought VBN N
to TO N
be VB N
essential JJ N
for IN N
virus JJ N
replication NN N
in IN N
humans NNS N
; : N
however RB N
, , N
to TO N
date NN N
, , N
available JJ N
neuraminidase NN N
inhibitors NNS N
are VBP N
limited VBN N
to TO N
zanamivir CD N
, , N
which WDT N
is VBZ N
topically RB N
administered VBN N
. . N

OBJECTIVE NN N
To TO N
determine VB N
the DT N
safety NN o
, , o
tolerability NN o
, , o
and CC o
antiviral JJ o
activity NN o
of IN N
oral JJ N
neuraminidase NN N
inhibitor NN N
oseltamivir NN N
( ( N
GS4104/Ro64-0796 NNP N
) ) N
for IN N
prevention NN N
and CC N
the DT N
early JJ N
treatment NN p
of IN p
influenza NN p
in IN p
experimentally RB p
infected JJ p
humans NNS p
. . p

DESIGN NNP N
Two CD N
randomized VBD N
, , N
double-blind JJ N
, , N
placebo-controlled JJ i
trials NNS N
conducted VBN N
between IN N
June NNP N
and CC N
July NNP N
1997 CD N
. . N

SETTING VBG N
Individual JJ N
hotel NN N
rooms NNS N
; : N
2 CD p
large JJ p
US NNP p
university NN p
medical JJ p
schools NNS p
. . p

PARTICIPANTS VB N
A DT p
total NN p
of IN p
117 CD p
healthy JJ p
adult NN p
volunteers NNS p
( ( p
aged VBN p
18-40 CD p
years NNS p
; : p
median JJ p
age NN p
, , p
21 CD p
years NNS p
) ) p
who WP p
were VBD p
susceptible JJ p
( ( p
hemagglutination-inhibition NN p
antibody NN p
titer NN p
< NN p
or CC p
=1:8 NN p
) ) p
. . p

INTERVENTIONS NNP N
All DT N
subjects NNS N
were VBD N
inoculated VBN i
intranasally RB i
with IN i
influenza JJ i
A/Texas/36/91 NNP i
( ( i
H1N1 NNP i
) ) i
virus NN i
. . i

For IN N
the DT N
prophylaxis NN N
study NN N
, , N
oral JJ i
oseltamivir NN i
( ( N
100 CD N
mg NN N
once RB N
daily JJ N
[ NNP N
n NN N
= VBD N
12 CD N
] NNP N
, , N
100 CD N
mg NN N
twice RB N
daily RB N
[ JJ N
n JJ N
= NN N
12 CD N
] NN N
, , N
or CC N
matching VBG i
placebo JJ i
[ JJ N
n NN N
= VBD N
13 CD N
] NN N
, , N
starting VBG N
26 CD N
hours NNS N
before IN N
virus JJ N
inoculation NN N
) ) N
was VBD N
administered VBN N
. . N

For IN N
the DT N
treatment NN N
study NN N
, , N
the DT N
same JJ N
drug NN N
was VBD N
given VBN N
( ( N
20 CD N
mg NN N
, , N
100 CD N
mg NN N
, , N
or CC N
200 CD N
mg JJ N
twice RB N
daily RB N
, , N
200 CD N
mg NN N
once RB N
daily JJ N
, , N
or CC N
matching VBG N
placebo JJ i
[ JJ N
n NN N
= VBD N
16 CD N
] NN N
, , N
in IN N
each DT N
group NN N
starting VBG N
28 CD N
hours NNS N
after IN N
inoculation NN N
) ) N
. . N

All DT N
regimens NNS N
were VBD N
continued VBN N
for IN N
5 CD N
days NNS N
. . N

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
Comparing NNP N
placebo NN N
groups NNS N
with IN N
pooled JJ N
treatment NN N
groups NNS N
, , N
for IN N
prophylaxis NN N
, , N
outcomes RB N
included JJ N
frequency NN o
of IN o
infection NN o
and CC o
viral JJ o
shedding NN o
; : o
for IN N
treatment NN N
, , N
viral JJ N
shedding VBG N
in IN N
titers NNS N
. . N

RESULTS NNP N
In IN N
the DT N
prophylaxis NN N
study NN N
, , N
8 CD N
( ( N
67 CD N
% NN N
) ) N
of IN N
12 CD N
placebo NN N
and CC N
8 CD N
( ( N
38 CD N
% NN N
) ) N
of IN N
21 CD N
oseltamivir JJ N
recipients NNS N
became VBD N
infected JJ o
( ( N
P NNP N
= NNP N
.16 NNP N
; : N
efficacy NN N
, , N
61 CD N
% NN N
) ) N
; : N
6 CD N
( ( N
50 CD N
% NN N
) ) N
placebo NN N
compared VBN N
with IN N
0 CD N
oseltamivir NN N
recipients NNS N
shed VBN N
virus NN N
( ( N
P NNP N
< NNP N
.001 NNP N
; : N
efficacy NN N
, , N
100 CD N
% NN N
) ) N
, , N
and CC N
33 CD N
% NN N
of IN N
placebo NN N
but CC N
no DT N
oseltamivir JJ N
recipient NN N
had VBD N
infection-related JJ N
respiratory NN N
illness NN N
( ( N
P NNP N
< NNP N
.01 NNP N
) ) N
. . N

Among IN N
infected JJ N
subjects NNS N
in IN N
the DT N
treatment NN N
study NN N
( ( N
n JJ N
= NNP N
69 CD N
) ) N
, , N
the DT N
viral JJ o
titer NN o
area NN o
under IN o
the DT o
curve NN o
of IN N
the DT N
combined JJ N
oseltamivir NN N
groups NNS N
( ( N
n JJ N
= NNP N
56 CD N
) ) N
was VBD N
lower JJR N
( ( N
median JJ N
[ NN N
interquartile NN N
range NN N
[ NNP N
IQR NNP N
] NNP N
] NNP N
, , N
80 CD N
[ JJ N
23-151 JJ N
] NN N
vs NN N
273 CD N
[ JJ N
79-306 JJ N
] NN N
log10 JJ N
tissue NN N
culture-infective JJ N
doses50 NN N
per IN N
milliliter NN N
x FW N
hour NN N
; : N
P NNP N
= NNP N
.02 NNP N
) ) N
than IN N
the DT N
placebo NN N
group NN N
( ( N
n JJ N
= NNP N
13 CD N
) ) N
, , N
and CC N
the DT N
median NN o
( ( o
IQR NNP o
) ) o
duration NN o
of IN o
viral JJ o
shedding VBG o
with IN N
therapy NN N
was VBD N
reduced VBN N
from IN N
107 CD N
( ( N
83-131 CD N
) ) N
to TO N
58 CD N
( ( N
35-59 CD N
) ) N
hours NNS N
( ( N
P NNP N
= NNP N
.003 NNP N
) ) N
. . N

Oseltamivir NNP N
treatment NN N
also RB N
reduced VBD N
symptom JJ o
scores NNS o
( ( N
median JJ N
[ NNP N
IQR NNP N
] NNP N
score-hours NN N
, , N
225 CD N
[ JJ N
97-349 CD N
] NNP N
vs FW N
400 CD N
[ JJ N
189-645 JJ N
] NN N
; : N
P NNP N
= NNP N
.05 NNP N
) ) N
, , N
and CC N
nasal JJ o
proinflammatory JJ o
cytokine NN o
levels NNS o
. . o

Transient NNP N
mild NN o
to TO o
moderate VB o
nausea NN o
after IN N
dosing VBG N
was VBD N
observed VBN N
in IN N
15 CD N
( ( N
17 CD N
% NN N
) ) N
of IN N
88 CD N
oseltamivir NNS N
and CC N
2 CD N
( ( N
7 CD N
% NN N
) ) N
of IN N
29 CD N
placebo NN N
recipients NNS N
( ( N
95 CD N
% NN N
confidence NN N
interval NN N
for IN N
difference NN N
, , N
-11 CD N
% NN N
to TO N
68 CD N
% NN N
) ) N
, , N
which WDT N
was VBD N
largely RB N
prevented VBN N
by IN N
ingestion NN N
with IN N
food NN N
. . N

CONCLUSIONS NNP N
In IN N
these DT N
trials NNS N
, , N
prophylaxis NN N
and CC N
early JJ N
treatment NN N
with IN N
oral JJ N
oseltamivir NNS N
were VBD N
both DT N
associated VBN N
with IN N
significant JJ N
antiviral JJ N
and CC N
clinical JJ N
effects NNS N
in IN N
experimental JJ p
human JJ p
influenza NN p
. . N

-DOCSTART- -11751780- O O

Once-daily JJ N
versus NN N
twice-daily RB N
intravenous JJ N
administration NN N
of IN N
vancomycin NN i
for IN N
infections NNS p
in IN p
hospitalized JJ p
patients NNS p
. . p

The DT N
efficacy NN N
and CC N
toxicity NN N
of IN N
once-daily JJ N
( ( N
od MD N
) ) N
versus VB N
twice-daily JJ N
( ( N
bd NN N
) ) N
dosing NN N
of IN N
vancomycin NN i
was VBD N
compared VBN N
in IN N
121 CD p
hospitalized JJ p
patients NNS p
. . p

Eighteen JJ p
patients NNS p
were VBD p
then RB p
withdrawn VBN p
from IN p
the DT p
study NN p
. . p

Clinical NNP N
and CC N
bacteriological JJ N
responses NNS N
were VBD N
evaluated VBN N
in IN N
all DT N
patients NNS p
( ( p
n JJ p
= NNP p
103 CD p
) ) p
. . N

Nephrotoxicity NNP o
was VBD N
assessed VBN N
in IN N
patients NNS N
who WP N
did VBD N
not RB N
receive VB N
nephrotoxic JJ N
agents NNS N
( ( N
n JJ N
= NNP N
76 CD N
) ) N
. . N

Ototoxicity NN o
was VBD N
assessed VBN N
in IN N
patients NNS N
who WP N
completed VBD N
two CD N
audiograms NNS N
and CC N
were VBD N
not RB N
receiving VBG N
ototoxic JJ N
agents NNS N
( ( N
n JJ N
= NNP N
63 CD N
) ) N
. . N

No DT o
significant JJ o
difference NN o
was VBD o
found VBN o
between IN o
the DT o
two CD o
groups NNS o
for IN o
favourable JJ o
clinical JJ o
response NN o
: : o
47/51 CD N
( ( N
92.1 CD N
% NN N
) ) N
and CC N
49/52 CD N
( ( N
94.2 CD N
% NN N
) ) N
in IN N
the DT N
od NN N
and CC N
bd NN N
groups NNS N
, , N
respectively RB N
. . N

In IN N
34 CD N
patients NNS N
vancomycin NN i
was VBD N
the DT N
only JJ o
effective JJ o
antibiotic JJ o
. . o

Fifteen NNP N
of IN N
18 CD N
( ( N
83.3 CD N
% NN N
) ) N
evaluated VBD N
episodes NNS N
in IN N
the DT N
od NN N
and CC N
12/16 CD N
( ( N
75.0 CD N
% NN N
) ) N
evaluated VBD N
episodes NNS N
in IN N
the DT N
bd NN N
group NN N
showed VBD N
a DT N
favourable JJ o
bacteriological JJ o
response NN o
. . o

There EX N
were VBD N
no DT o
significant JJ o
differences NNS o
between IN N
the DT N
od NN N
and CC N
bd NN N
groups NNS N
for IN N
all DT o
adverse JJ o
events NNS o
. . o

Nephrotoxicity NNP o
developed VBD o
in IN N
4/37 CD N
( ( N
10.8 CD N
% NN N
) ) N
and CC N
3/39 CD N
( ( N
7.7 CD N
% NN N
) ) N
patients NNS N
, , N
respectively RB N
. . N

Hearing NNP o
loss NN o
developed VBD N
in IN N
1/31 CD N
( ( N
3.2 CD N
% NN N
) ) N
and CC N
5/32 CD N
( ( N
15.6 CD N
% NN N
) ) N
. . N

Phlebitis NN o
occurred VBD N
in IN N
7/51 CD N
( ( N
13.7 CD N
% NN N
) ) N
and CC N
12/52 CD N
( ( N
23.0 CD N
% NN N
) ) N
. . N

Red JJ o
man NN o
syndrome NN o
occurred VBD N
in IN N
7/51 CD N
( ( N
13.7 CD N
% NN N
) ) N
and CC N
5/52 CD N
( ( N
9.6 CD N
% NN N
) ) N
in IN N
od NN N
and CC N
bd NN N
groups NNS N
, , N
respectively RB N
. . N

The DT N
efficacy NN o
and CC o
safety NN o
profile NN o
of IN o
od JJ N
administration NN N
of IN N
vancomycin NN i
is VBZ N
similar JJ o
to TO N
that DT N
of IN N
the DT N
customary JJ N
, , N
but CC N
less RBR N
convenient JJ N
, , N
bd JJ N
administration NN N
. . N

-DOCSTART- -17974096- O O

Sivelestat NNP i
sodium NN i
hydrate NN i
improves VBZ N
septic JJ p
acute NN p
lung NN p
injury NN p
by IN N
reducing VBG N
alveolar JJ N
dysfunction NN N
. . N

Sivelestat NNP i
sodium NN i
hydrate NN i
( ( i
sivelestat NN i
) ) i
is VBZ N
a DT N
selective JJ N
inhibitor NN N
of IN N
polymorphonuclear JJ N
leukocyte JJ N
elastase NN N
( ( N
PMN-E NNP N
) ) N
. . N

We PRP N
administered VBD N
sivelestat NNS i
to TO N
patients NNS p
with IN p
septic JJ p
acute NN p
lung NN p
injury NN p
( ( p
ALI NNP p
) ) p
to TO N
examine VB N
its PRP$ N
usefulness NN N
. . N

The DT N
primary JJ N
endpoints NNS N
in IN N
the DT N
study NN N
were VBD N
the DT N
duration NN o
of IN o
artificial JJ o
ventilation NN o
and CC o
pulmonary JJ o
oxygenation NN o
ability NN o
, , N
and CC N
the DT N
secondary JJ N
endpoints NNS N
were VBD N
mortality NN o
and CC o
the DT o
concentrations NNS o
of IN o
PMN-E NNP o
, , o
SP-D NNP o
, , o
TNF-alpha NNP o
and CC o
IL-8 NNP o
in IN o
blood NN o
. . o

In IN N
the DT N
sivelestat NN i
group NN N
, , N
the DT N
duration NN o
of IN o
artificial JJ o
ventilation NN o
, , o
pulmonary JJ o
oxygenation NN o
ability NN o
, , o
and CC o
the DT o
blood NN o
PMN-E NNP o
, , o
SP-D NNP o
, , o
TNF-alpha NNP o
and CC o
IL-8 NNP o
concentrations NNS o
decreased VBD N
significantly RB N
. . N

Administration NNP N
of IN N
sivelestat NN i
was VBD N
found VBN N
to TO N
reduce VB N
alveolar JJ o
dysfunction NN o
and CC N
improve VB N
respiratory NN o
function NN o
, , N
and CC N
it PRP N
was VBD N
suggested VBN N
that IN N
early JJ N
administration NN N
might MD N
be VB N
useful JJ N
. . N

-DOCSTART- -25342205- O O

Dexmedetomidine NNP i
pretreatment NN N
alleviates VBZ N
propofol JJ p
injection NN p
pain NN p
. . p

OBJECTIVE CC N
The DT N
incidence NN N
of IN N
propofol JJ i
injection NN N
pain NN N
during IN N
induction NN N
of IN N
general JJ N
anesthesia NN N
varies NNS N
from IN N
28 CD N
% NN N
to TO N
90 CD N
% NN N
. . N

This DT N
prospective JJ N
, , N
randomized VBN N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
study NN N
evaluated VBD N
the DT N
effect NN N
of IN N
dexmedetomidine NN i
( ( i
DEX NNP i
) ) i
for IN N
reducing VBG N
the DT N
incidence NN N
and CC N
severity NN N
of IN N
propofol JJ N
injection NN N
pain NN N
. . N

METHODS NNP N
Patients NNPS p
undergoing VBG p
elective JJ p
surgical JJ p
procedures NNS p
were VBD p
randomly RB p
allocated VBN p
into IN p
seven CD p
groups NNS p
of IN p
30 CD p
patients NNS p
each DT p
. . p

Experimental JJ N
treatments NNS N
were VBD N
intravenously RB N
administered VBN N
over IN N
10 CD N
min NNS N
( ( N
total JJ N
volume NN N
10 CD N
mL NN N
) ) N
prior RB N
to TO N
intravenous JJ N
propofol NN i
injection NN N
, , N
as IN N
follows VBZ N
: : N
group NN N
I PRP N
, , N
the DT N
control NN N
group NN N
, , N
was VBD N
given VBN N
isotonic JJ i
saline NN i
. . i

Patients NNS N
in IN N
groups NNS N
II NNP N
, , N
III NNP N
, , N
and CC N
IV NNP N
received VBD N
DEX NNP i
0.25 CD i
?g/kg NNP i
, , i
0.5 CD i
?g/kg NN i
, , i
or CC i
1.0 CD i
?g/kg NNS i
, , i
respectively RB i
, , i
mixed JJ i
with IN i
isotonic JJ i
saline NN i
immediately RB i
before IN i
propofol JJ i
injection NN i
. . i

Patients NNS i
in IN N
groups NNS N
V NNP N
, , N
VI NNP N
, , N
and CC N
VII NNP N
received VBD i
DEX NNP i
as IN i
above NN i
, , i
but CC i
5 CD i
minutes NNS i
before IN i
propofol JJ i
injection NN i
. . i

Propofol NNP i
consisted VBD i
of IN i
1 CD i
% NN i
long-chain JJ i
triglyceride NN i
propofol NN i
( ( i
2.5 CD i
mg/kg NN i
) ) i
injected VBD i
at IN i
1 CD i
mL/s NNS i
. . i

RESULTS NNP i
Median JJ N
propofol NN o
injection NN o
pain NN o
score NN o
was VBD o
0.00 CD N
( ( N
IQR NNP N
0.00-3.00 NN N
) ) N
in IN N
patients NNS N
who WP N
received VBD N
1.0 CD N
?g/kg NNP N
DEX NNP N
5 CD N
min NN N
before IN N
the DT N
propofol NN N
injection NN N
( ( N
group NN N
VII NNP N
) ) N
, , N
and CC N
only RB N
1 CD N
patient NN N
( ( N
of IN N
30 CD N
) ) N
in IN N
this DT N
group NN N
received VBD N
a DT N
pain NN N
score NN N
> VBD N
2 CD N
. . N

The DT N
median JJ o
pain NN o
score NN o
and CC o
number NN o
of IN o
patients NNS o
with IN o
pain NN o
scores NNS o
> VBP o
2 CD o
in IN N
group NN N
VII NNP N
were VBD N
both DT N
significantly RB N
less JJR N
than IN N
in IN N
the DT N
control NN N
( ( N
group NN N
I PRP N
; : N
p CC N
= $ N
0.000 CD N
, , N
both DT N
) ) N
. . N

There EX N
were VBD N
no DT N
differences NNS N
in IN N
either DT o
mean JJ o
arterial JJ o
pressure NN o
or CC o
heart NN o
rate NN o
at IN o
any DT N
time NN N
point NN N
after IN i
DEX NNP i
injection NN N
among IN N
the DT N
groups NNS N
. . N

CONCLUSIONS NNP N
Pretreatment NNP N
with IN N
intravenous JJ i
DEX NNP i
1 CD N
?g/kg VBD N
5 CD N
min NN N
prior RB N
to TO N
injection NN N
of IN N
long-chain JJ N
triglyceride NN N
propofol NN N
is VBZ N
effective JJ N
and CC N
safe JJ N
in IN N
reducing VBG N
the DT N
incidence NN N
and CC N
severity NN N
of IN N
pain NN N
due JJ N
to TO N
propofol VB N
injection NN N
. . N

-DOCSTART- -10968308- O O

The DT N
effect NN N
of IN N
case NN i
management NN i
on IN N
the DT N
costs NNS o
of IN o
health NN o
care NN o
for IN N
enrollees NNS N
in IN N
Medicare NNP N
Plus NNP N
Choice NNP N
plans VBZ N
: : N
a DT N
randomized JJ N
trial NN N
. . N

OBJECTIVE UH N
To TO N
measure VB N
the DT N
effects NNS N
of IN N
case NN N
management NN N
on IN N
an DT N
older JJR p
population NN p
's POS p
costs NNS o
of IN o
health NN o
care NN o
. . o

DESIGN VB N
A DT N
1-year JJ N
randomized NN N
controlled VBD N
trial NN N
. . N

SETTING NN N
Multiple NNP p
sites NNS p
of IN p
care NN p
in IN p
San NNP p
Francisco NNP p
, , p
California NNP p
. . p

PARTICIPANTS NN N
Patients NNPS p
aged VBD p
65 CD p
or CC p
older JJR p
of IN p
primary JJ p
care NN p
physicians NNS p
in IN p
a DT p
large JJ p
provider NN p
organization NN p
bearing VBG p
financial JJ p
risk NN p
for IN p
their PRP$ p
care NN p
( ( p
n JJ p
= NN p
6409 CD p
) ) p
. . p

INTERVENTION NNP N
Screening VBG i
for IN i
high JJ i
risk NN i
and CC i
provision NN i
of IN i
social JJ i
work-based JJ i
case NN i
management NN i
. . i

OUTCOME NNP N
MEASURES NNP N
Volume NN o
and CC o
cost NN o
of IN o
hospital NN o
, , o
physician NN o
, , o
case NN o
management NN o
, , o
and CC o
other JJ o
health-related JJ o
services NNS o
. . o

RESULTS VB N
The DT N
experimental JJ N
group NN N
used VBD N
more JJR N
case NN o
management NN o
services NNS o
than IN N
the DT N
control NN N
group NN N
( ( N
0.09 CD N
vs. FW N
0.02 CD N
months NNS N
per IN N
person NN N
, , N
P NNP N
< NNP N
.001 NNP N
) ) N
. . N

The DT N
experimental JJ N
group NN N
's POS N
average JJ N
total JJ o
payments NNS o
for IN o
health NN o
care NN o
were VBD N
slightly RB N
lower JJR N
( ( N
$ $ N
3148 CD N
vs IN N
$ $ N
3277 CD N
, , N
P NNP N
= NNP N
.40 NNP N
) ) N
. . N

CONCLUSIONS VB N
This DT N
study NN N
provides VBZ N
no DT N
statistically RB N
significant JJ N
evidence NN N
that IN N
social JJ N
work-oriented JJ N
case NN N
management NN N
reduces VBZ N
the DT N
use NN N
or CC N
the DT N
cost NN o
of IN o
health NN o
care NN o
for IN N
high-risk JJ N
older JJR N
people NNS N
. . N

Other JJ N
potentially RB N
favorable JJ N
effects NNS N
of IN N
this DT N
type NN N
of IN N
case NN N
management NN N
need NN N
to TO N
be VB N
evaluated VBN N
, , N
as IN N
do VBP N
the DT N
effects NNS N
of IN N
other JJ N
types NNS N
of IN N
case NN N
management NN N
. . N

-DOCSTART- -18062520- O O

Comparison NNP N
of IN N
two CD N
sedation NN i
techniques NNS i
in IN N
patients NNS p
undergoing VBG p
surgical JJ p
procedures NNS p
under IN p
regional JJ p
anaesthesia NN p
. . p

OBJECTIVE NNP N
Intraoperative NNP N
comfort NN N
and CC N
patient JJ o
satisfaction NN o
during IN N
surgical JJ N
procedures NNS N
under IN N
regional JJ N
anaesthesia NN N
can MD N
be VB N
improved VBN N
with IN N
the DT N
use NN N
of IN N
supplemental JJ N
intravenous JJ N
sedation NN N
. . N

The DT N
authors NNS N
conducted VBD N
a DT N
study NN N
to TO N
compare VB N
two CD N
sedation NN N
techniques NNS N
for IN N
surgical JJ N
procedures NNS N
performed VBN N
under IN N
regional JJ N
anaesthesia NN N
, , N
i.e. FW N
, , N
midazolam NN i
and CC i
pethidine NN i
combination NN i
compared VBN N
with IN N
midazolam NN i
and CC i
tramadol JJ i
combination NN i
. . i

METHODS NNP N
Forty NNP p
adult JJ p
American JJ p
Society NNP p
of IN p
Anaesthesiologists NNP p
( ( p
ASA NNP p
) ) p
grade VBD p
1-111 JJ p
patients NNS p
, , p
aged VBN p
between IN p
40-65 JJ p
years NNS p
undergoing VBG p
surgery NN p
under IN p
regional JJ p
anaesthesia NN p
( ( p
sub-arachnoid JJ p
block NN p
) ) p
were VBD p
included VBN p
. . p

The DT N
patients NNS N
were VBD N
randomly RB N
divided VBN N
into IN N
two CD N
groups NNS N
. . N

All DT N
patients NNS N
received VBD N
standardized JJ N
premedication NN N
, , N
intraoperative JJ N
monitoring NN N
and CC N
oxygen NN N
therapy NN N
. . N

Group NNP N
A NNP N
patients NNS N
received VBD N
midazolam JJ i
0.03 CD i
mg/kg NN i
followed VBN i
by IN i
pethidine NN i
20 CD i
mg NN i
intravenously RB i
, , N
and CC N
group NN N
B NNP N
patients NNS N
received VBD N
midazolam JJ i
0.03 CD i
mg/kg NN i
followed VBN i
by IN i
tramadol NN i
20 CD i
mg NN i
intravenously RB N
after IN N
the DT N
institution NN N
of IN N
regional JJ N
anaesthesia NN N
. . N

Monitoring NNP N
included VBD N
ECG NNP o
, , o
blood NN o
pressure NN o
, , o
respiratory NN o
rate NN o
, , o
oxygen NN o
saturation NN o
and CC o
sedation NN o
score NN o
. . o

Complications NNS N
, , N
if IN N
any DT N
, , N
were VBD N
recorded VBN N
. . N

Monitoring NN N
was VBD N
continued VBN N
during IN N
the DT N
recovery NN N
room NN N
stay NN N
. . N

All DT N
patients NNS N
were VBD N
interviewed VBN N
in IN N
the DT N
evening NN N
and CC N
time NN N
of IN N
ambulation NN N
and CC N
rating NN N
of IN N
OR NNP N
experience NN N
was VBD N
noted VBN N
. . N

RESULTS NNP N
Data NNP N
analysis NN N
showed VBD N
no DT N
significant JJ N
difference NN N
between IN N
pethidine NN i
and CC N
tramadol NN i
for IN N
all PDT N
the DT N
haemodynamic JJ o
variables NNS o
( ( N
p JJ N
= NNP N
> NNP N
0.05 CD N
) ) N
. . N

There EX N
was VBD N
also RB N
no DT N
significant JJ N
difference NN N
in IN N
patient NN N
's POS N
and CC N
surgeon NN N
's POS N
assessment NN N
of IN N
their PRP$ N
experience NN N
. . N

Complications NNS o
and CC o
recovery NN o
characteristics NNS o
also RB N
did VBD N
not RB N
show VB N
any DT N
significant JJ N
difference NN N
. . N

CONCLUSION NNP N
Midazolam-tramadol NNP i
combination NN i
may MD N
be VB N
used VBN N
as IN N
an DT N
alternative JJ N
to TO N
midazolam-pethidine JJ i
combination NN i
for IN N
sedation NN N
during IN N
surgical JJ N
procedures NNS N
performed VBN N
under IN N
regional JJ N
anaesthesia NN N
. . N

-DOCSTART- -1578953- O O

DNA NN N
as IN N
a DT N
carrier NN N
for IN N
anthracyclines NNS i
in IN N
the DT N
treatment NN p
of IN p
acute JJ o
myelocytic JJ o
leukemia NN o
( ( o
AML NNP o
) ) o
. . o

-DOCSTART- -15492353- O O

Risperidone NN i
in IN N
the DT N
treatment NN N
of IN N
disruptive JJ N
behavioral NN N
symptoms NNS N
in IN N
children NNS p
with IN p
autistic JJ p
and CC p
other JJ p
pervasive JJ p
developmental NN p
disorders NNS p
. . p

OBJECTIVE NNP N
To TO N
investigate VB N
the DT N
efficacy NN N
and CC N
safety NN N
of IN N
risperidone NN i
for IN N
the DT N
treatment NN N
of IN N
disruptive JJ N
behavioral NN N
symptoms NNS N
in IN N
children NNS p
with IN p
autism NN p
and CC p
other JJ p
pervasive JJ p
developmental NN p
disorders NNS p
( ( p
PDD NNP p
) ) p
. . p

METHODS NNP N
In IN N
this DT N
8-week JJ N
, , N
randomized VBN N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
trial NN N
, , N
risperidone/placebo JJ i
solution NN i
( ( N
0.01-0.06 JJ N
mg/kg/day NN N
) ) N
was VBD N
administered VBN N
to TO N
79 CD p
children NNS p
who WP p
were VBD p
aged VBN p
5 CD p
to TO p
12 CD p
years NNS p
and CC p
had VBD p
PDD NNP p
. . p

Behavioral NNP N
symptoms NNS N
were VBD N
assessed VBN N
using VBG N
the DT N
Aberrant NNP o
Behavior NNP o
Checklist NNP o
( ( o
ABC NNP o
) ) o
, , N
Nisonger NNP N
Child NNP N
Behavior NNP N
Rating NNP N
Form NNP N
, , N
and CC N
Clinical JJ N
Global NNP N
Impression-Change NNP N
. . N

Safety NNP N
assessments NNS N
included VBD N
vital JJ N
signs NNS N
, , N
electrocardiogram NN N
, , N
extrapyramidal NN N
symptoms NNS N
, , N
adverse JJ N
events NNS N
, , N
and CC N
laboratory NN N
tests NNS N
. . N

RESULTS NNP N
Subjects NNPS N
who WP N
were VBD N
taking VBG N
risperidone NN i
( ( N
mean JJ N
dosage NN N
: : N
0.04 CD N
mg/kg/day NN N
; : N
1.17 CD N
mg/day NN N
) ) N
experienced VBD N
a DT N
significantly RB N
greater JJR N
mean JJ o
decrease NN o
on IN o
the DT o
irritability NN o
subscale NN o
of IN o
the DT o
ABC NNP o
( ( N
primary JJ N
endpoint NN N
) ) N
compared VBN N
with IN N
those DT N
who WP N
were VBD N
taking VBG N
placebo NN N
. . N

By IN N
study NN N
endpoint NN N
, , N
risperidone-treated JJ i
subjects NNS N
exhibited VBD N
a DT N
64 CD N
% NN N
improvement NN N
over IN N
baseline NN N
in IN N
the DT N
irritability NN o
score NN o
almost RB N
double JJ N
that IN N
of IN N
placebo-treated JJ i
subjects NNS N
( ( N
31 CD N
% NN N
) ) N
. . N

Risperidone-treated JJ i
subjects NNS N
also RB N
exhibited VBD N
significantly RB N
greater JJR N
decreases NNS N
on IN N
the DT N
other JJ N
4 CD o
subscales NNS o
of IN o
the DT o
ABC NNP o
; : o
on IN N
the DT N
conduct NN o
problem NN o
, , o
insecure/anxious JJ o
, , o
hyperactive JJ o
, , o
and CC o
overly RB o
sensitive JJ o
subscales NNS o
of IN o
the DT o
Nisonger NNP o
Child NNP o
Behavior NNP o
Rating NNP o
Form NNP o
( ( o
parent JJ o
version NN o
) ) o
; : o
and CC o
on IN o
the DT o
Visual NNP o
Analog NNP o
Scale NNP o
of IN N
the DT N
most RBS N
troublesome JJ N
symptom NN N
. . N

More JJR N
risperidone-treated JJ i
subjects NNS N
( ( N
87 CD N
% NN N
) ) N
showed VBD N
global JJ N
improvement NN N
in IN N
their PRP$ N
condition NN N
compared VBN N
with IN N
the DT N
placebo NN i
group NN N
( ( N
40 CD N
% NN N
) ) N
. . N

Somnolence NN o
, , N
the DT N
most RBS N
frequently RB N
reported VBD N
adverse JJ N
event NN N
, , N
was VBD N
noted VBN N
in IN N
72.5 CD N
% NN N
versus IN N
7.7 CD N
% NN N
of IN N
subjects NNS N
( ( i
risperidone NN i
vs NN i
placebo NN i
) ) i
and CC N
seemed VBD N
manageable JJ N
with IN N
dose/dose-schedule JJ N
modification NN N
. . N

Risperidone-treated JJ i
subjects NNS N
experienced VBD N
statistically RB N
significantly RB N
greater JJR N
increases NNS N
in IN N
weight NN o
( ( N
2.7 CD N
vs RB N
1.0 CD N
kg NN N
) ) N
, , N
pulse JJ o
rate NN o
, , o
and CC o
systolic JJ o
blood NN o
pressure NN o
. . o

Extrapyramidal NNP N
symptoms JJ N
scores NNS N
were VBD N
comparable JJ N
between IN N
groups NNS N
. . N

CONCLUSIONS NNP N
Risperidone NNP i
was VBD N
well RB N
tolerated VBN N
and CC N
efficacious JJ N
in IN N
treating VBG N
behavioral JJ N
symptoms NNS N
associated VBN N
with IN N
PDD NNP p
in IN p
children NNS p
. . p

-DOCSTART- -16904524- O O

Effectiveness NN N
of IN N
a DT N
clinical JJ i
intervention NN i
in IN N
improving VBG N
pain NN N
control NN N
in IN N
outpatients NNS p
with IN p
cancer NN p
treated VBN p
by IN p
radiation NN i
therapy NN i
. . i

PURPOSE NNP N
To TO N
determine VB N
the DT N
effectiveness NN N
of IN N
a DT N
multicomponent JJ i
clinical JJ i
intervention NN i
to TO N
reduce VB N
pain NN N
in IN N
outpatients NNS p
with IN p
cancer NN p
. . p

METHODS NNP N
AND CC N
MATERIALS NNP N
Sixty-four JJ p
patients NNS p
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
either CC N
a DT N
clinical JJ i
intervention NN i
including VBG N
an DT N
information NN i
session NN i
, , N
the DT N
use NN N
of IN N
a DT N
pain NN i
diary JJ i
, , N
and CC N
the DT N
possibility NN N
to TO N
contact VB i
a DT i
physician NN i
to TO N
adjust VB N
the DT N
pain NN N
medication NN N
, , N
or CC i
the DT i
usual JJ i
treatment NN i
of IN i
pain NN i
by IN i
the DT i
staff NN i
radiation NN i
oncologist NN i
. . i

All DT N
patients NNS N
reported VBD N
their PRP$ N
average NN N
and CC N
worst JJS N
pain NN o
levels NNS o
at IN N
baseline NN N
and CC N
2 CD N
and CC N
3 CD N
weeks NNS N
after IN N
the DT N
start NN N
of IN N
the DT N
intervention NN N
. . N

RESULTS VB N
The DT N
study NN N
groups NNS N
were VBD N
similar JJ N
with IN N
respect NN N
to TO N
their PRP$ N
baseline NN N
characteristics NNS N
and CC N
pain NN N
levels NNS N
at IN N
randomization NN N
. . N

After IN N
3 CD N
weeks NNS N
, , N
the DT N
average NN N
and CC N
worst JJS N
pain NN N
experienced VBN N
by IN N
patients NNS N
randomized VBN N
to TO N
the DT N
clinical JJ i
intervention NN i
group NN i
was VBD N
significantly RB N
inferior JJ N
to TO N
the DT N
average NN N
pain NN N
experienced VBN N
by IN N
patients NNS N
in IN N
the DT N
control NN i
group NN N
( ( N
2.9/10 CD N
vs. FW N
4.4/10 CD N
and CC N
4.2/10 CD N
vs. FW N
5.5/10 CD N
, , N
respectively RB N
) ) N
. . N

Results CC N
showed VBD N
that IN N
the DT N
experimental JJ N
group NN N
patients NNS N
decreased VBD N
their PRP$ N
pain NN N
levels NNS N
more RBR N
than IN N
the DT N
control NN N
group NN N
patients NNS N
did VBD N
over IN N
time NN N
. . N

CONCLUSION NNP N
An DT o
intervention NN o
including VBG o
patient JJ o
education NN o
, , o
a DT o
pain NN o
diary JJ o
, , o
and CC o
defining VBG o
a DT o
procedure NN o
for IN o
therapeutic JJ o
adjustments NNS o
can MD o
be VB o
effective JJ o
to TO o
improve VB o
pain NN o
relief NN o
in IN o
outpatients NNS o
with IN o
cancer NN o
. . o

-DOCSTART- -15691793- O O

Prospective JJ N
randomized VBN N
controlled VBN N
trial NN N
comparing VBG N
plasmakinetic JJ i
vaporesection NN i
and CC N
conventional JJ i
transurethral JJ i
resection NN i
of IN N
the DT N
prostate NN N
. . N

OBJECTIVE NNP N
Plasmakinetic NNP i
vaporesection NN i
of IN i
the DT i
prostate NN i
( ( i
PKVP NNP i
) ) i
using VBG N
normal JJ N
saline JJ N
irrigation NN N
has VBZ N
the DT N
theoretical JJ N
advantage NN N
of IN N
avoiding VBG N
transurethral JJ N
resection NN N
syndrome NN N
and CC N
minimizing VBG N
blood NN N
loss NN N
. . N

It PRP N
may MD N
also RB N
shorten VB N
the DT N
operative JJ N
time NN N
since IN N
tissue NN N
is VBZ N
resected VBN N
instead RB N
of IN N
just RB N
vaporized VBN N
. . N

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
evaluate VB N
the DT N
efficiency NN o
, , o
safety NN o
and CC o
advantages NNS o
of IN N
PKVP NNP N
compared VBN N
with IN N
standard JJ i
transurethral JJ i
resection NN i
of IN i
the DT i
prostate NN i
( ( i
TURP NNP i
) ) i
at IN N
a DT N
regional JJ p
acute NN p
hospital NN p
. . p

METHODS CC N
A DT p
total NN p
of IN p
60 CD p
consecutive JJ p
men NNS p
admitted VBN p
from IN p
a DT p
waiting VBG p
list NN p
for IN p
surgery NN p
for IN p
benign JJ p
prostatic JJ p
hyperplasia NN p
( ( p
BPH NNP p
) ) p
were VBD N
prospectively RB N
randomized VBN N
to TO N
either DT N
PKVP NNP i
or CC N
TURP NNP i
. . i

Peri- NNP N
and CC N
postoperative JJ N
outcome NN N
data NNS N
at IN N
3 CD N
months NNS N
were VBD N
obtained VBN N
. . N

RESULTS VB N
The DT N
PKVP NNP N
loop NN N
achieved VBD N
a DT N
fast JJ N
and CC N
sharp JJ N
cutting VBG N
action NN N
similar JJ N
to TO N
that DT N
with IN N
the DT N
traditional JJ N
TURP NNP N
loop NN N
. . N

Data NNP p
analysis NN p
was VBD p
based VBN p
on IN p
51 CD p
patients NNS p
. . p

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
between IN N
the DT N
methods NNS N
in IN N
resection NN o
time NN o
, , o
postoperative JJ o
catheterization NN o
time NN o
and CC o
hospital NN o
stay NN o
. . o

The DT N
mean JJ o
reductions NNS o
in IN o
serum NN o
sodium NN o
2 CD N
hours NNS N
after IN N
PKVP NNP N
and CC N
on IN N
postoperative JJ N
day NN N
1 CD N
were VBD N
0.52 CD N
mmol/L NNS N
and CC N
3.35 CD N
mmol/L NN N
, , N
respectively RB N
, , N
while IN N
mean JJ N
reductions NNS N
in IN N
haemoglobin NN N
were VBD N
0.36 CD N
g/dL NN N
and CC N
0.24 CD N
g/dL NN N
, , N
respectively RB N
. . N

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
haemoglobin JJ o
reductions NNS o
between IN N
PKVP NNP N
and CC N
TURP NNP N
( ( N
p JJ N
= RB N
0.326 CD N
at IN N
2 CD N
hours NNS N
; : N
p VB N
= $ N
0.192 CD N
on IN N
day NN N
1 CD N
) ) N
and CC N
serum JJ N
sodium NN N
( ( N
p JJ N
= RB N
0.757 CD N
at IN N
2 CD N
hours NNS N
; : N
p VB N
= $ N
0.888 CD N
on IN N
day NN N
1 CD N
) ) N
. . N

Both DT N
groups NNS N
achieved VBD N
comparable JJ N
improvement NN N
in IN N
International NNP o
Prostate NNP o
Symptom NNP o
Score NNP o
( ( N
p JJ N
= NNP N
0.862 CD N
) ) N
, , N
quality-of-life JJ N
score NN N
( ( N
p JJ N
= NNP N
0.169 CD N
) ) N
and CC N
peak JJ N
flow NN N
rate NN N
( ( N
p JJ N
= NNP N
0.96 CD N
) ) N
at IN N
3-month JJ N
follow-up NN N
. . N

CONCLUSION NNP N
PKVP NNP i
achieved VBD N
comparable JJ N
results NNS N
to TO N
traditional JJ N
TURP NNP i
and CC N
was VBD N
an DT N
effective JJ o
and CC o
safe JJ o
procedure NN N
. . N

However RB N
, , N
it PRP N
did VBD N
not RB N
demonstrate VB N
obvious JJ N
advantages NNS N
over IN N
TURP NNP N
in IN N
this DT N
acute JJ N
regional JJ N
hospital NN N
regular JJ N
TURP NNP N
list NN N
setting NN N
. . N

-DOCSTART- -19621686- O O

A DT N
prospective JJ N
comparison NN N
of IN N
transthoracic NN i
and CC i
transhiatal JJ i
resection NN i
for IN N
esophageal JJ p
carcinoma NN p
in IN p
Asians NNPS p
. . p

BACKGROUND/AIMS NNP N
Transthoracic NNP i
and CC i
transhiatal JJ i
esophagectomy NN i
are VBP N
two CD N
common JJ N
procedures NNS N
for IN N
esophageal JJ N
cancer NN N
resection NN N
. . N

Prospective JJ N
studies NNS N
comparing VBG N
the DT N
two CD N
methods NNS N
in IN p
Asian JJ p
people NNS p
are VBP N
few JJ N
. . N

In IN N
addition NN N
, , N
the DT N
data NNS N
comparing VBG N
their PRP$ N
effects NNS N
on IN N
the DT N
quality NN o
of IN o
life NN o
are VBP N
lacking VBG N
. . N

METHODOLOGY NNP N
A NNP N
prospective JJ N
randomized NN N
study NN N
was VBD N
conducted VBN N
from IN N
January NNP N
2003 CD N
. . N

Patients NNS p
of IN p
resectable JJ p
esophageal JJ p
cancer NN p
of IN p
comparable JJ p
stage NN p
were VBD N
allocated VBN N
to TO N
undergo VB N
the DT N
transthoracic NN i
or CC i
transhiatal JJ i
procedure NN i
in IN N
turn NN N
. . N

They PRP i
were VBD i
all DT i
reconstructed VBN i
with IN i
stomach NN i
interposition NN i
through IN i
the DT i
retrosternal JJ i
route NN i
. . i

Discharged VBN i
patients NNS i
were VBD i
followed-up JJ i
in IN i
the DT i
outpatient NN i
clinic NN i
. . i

They PRP i
were VBD i
questioned VBN i
on IN i
the DT i
topics NNS i
of IN i
( ( o
i NN o
) ) o
severity NN o
of IN o
pain NN o
, , o
( ( o
ii NN o
) ) o
ease NN o
of IN o
swallowing NN o
, , o
( ( o
iii NN o
) ) o
satisfaction NN o
of IN o
daily JJ o
activities NNS o
, , o
( ( o
iv NN o
) ) o
dependence NN o
on IN o
medications NNS o
, , o
( ( o
v NN o
) ) o
working VBG o
ability NN o
, , o
( ( o
vi NN o
) ) o
fatigue NN o
, , o
( ( o
vii NN o
) ) o
appetite NN o
, , o
( ( o
viii NN o
) ) o
sociality NN o
, , o
( ( o
ix NN o
) ) o
happiness NN o
and CC o
( ( o
x NNP o
) ) o
self NN o
respect NN o
, , i
in IN i
the DT i
third JJ i
, , i
sixth JJ i
and CC i
twelfth JJ i
month NN i
. . i

Also RB N
the DT N
demographic JJ o
data NNS o
, , o
operative JJ o
results NNS o
and CC o
survival NN o
were VBD N
recorded VBN N
. . N

RESULTS VB N
Up IN p
to TO p
December NNP p
2006 CD p
, , p
eighty-seven JJ p
patients NNS p
of IN p
stage NN p
II NNP p
and CC p
III NNP p
, , p
including VBG p
71 CD p
patients NNS p
of IN p
middle JJ p
third JJ p
lesions NNS p
and CC p
16 CD p
lower JJR p
third JJ p
lesions NNS p
were VBD p
enrolled VBN p
. . p

The DT N
operation NN o
time NN o
was VBD N
significantly RB N
longer JJR N
, , N
and CC N
the DT N
leakage NN o
rate NN o
was VBD N
higher RBR N
in IN N
the DT N
transthoracic NN N
group NN N
( ( N
Student NNP N
's POS N
t-test NN N
and CC N
Fischer NNP N
's POS N
exact JJ N
test NN N
, , N
respectively RB N
) ) N
. . N

However RB N
, , N
intraoperative JJ o
blood NN o
loss NN o
and CC o
postoperative JJ o
hospital NN o
stay NN o
were VBD N
not RB N
significantly RB N
different JJ N
( ( N
Student NNP N
t-test NN N
) ) N
. . N

Also RB N
, , N
the DT N
Kaplan-Meier NNP o
survival NN o
curves NNS o
of IN N
these DT N
two CD N
groups NNS N
were VBD N
not RB N
significantly RB N
different JJ N
by IN N
log-rank JJ N
test NN N
( ( N
p=0.286 NN N
) ) N
. . N

The DT N
score NN N
on IN N
the DT N
quality NN o
of IN o
life NN o
of IN N
transhiatal JJ N
patients NNS N
was VBD N
significantly RB N
higher JJR N
than IN N
that DT N
of IN N
transthoracic NN N
patients NNS N
in IN N
the DT N
third JJ N
, , N
sixth JJ N
and CC N
twelfth JJ N
month NN N
. . N

CONCLUSIONS NNP N
Transhiatal NNP i
esophagectomy NN i
is VBZ N
a DT N
safe JJ N
and CC N
fast JJ N
procedure NN N
. . N

The DT N
survival NN N
was VBD N
similar JJ N
to TO N
that DT N
of IN N
transthoracic JJ N
approach NN N
. . N

Its PRP$ N
leakage NN o
rate NN o
was VBD N
lower JJR N
and CC N
quality NN N
of IN N
life NN N
was VBD N
better RBR N
. . N

-DOCSTART- -18946011- O O

Direct JJ N
and CC N
indirect JJ N
effects NNS N
of IN N
interdental JJ i
hygiene NN i
in IN N
a DT N
clinical JJ N
trial NN N
. . N

Many JJ N
randomized VBD N
controlled JJ N
trials NNS N
( ( N
RCTs NNP N
) ) N
in IN N
dental JJ N
research NN N
test NN N
the DT N
efficacy NN N
of IN N
interventions NNS N
on IN N
more JJR N
than IN N
one CD N
outcome NN N
variable NN N
. . N

Univariate NNP N
methods NNS N
, , N
such JJ N
as IN N
the DT N
t JJ N
test NN N
or CC N
analysis NN N
of IN N
covariance NN N
, , N
can MD N
not RB N
evaluate VB N
the DT N
efficacy NN N
of IN N
interventions NNS N
on IN N
multiple JJ N
outcomes NNS N
simultaneously RB N
. . N

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
use VB N
structural JJ i
equation NN i
modeling NN i
( ( N
SEM NNP N
) ) N
to TO N
re-analyze VB N
a DT N
RCT NNP N
, , N
comparing VBG N
the DT N
effects NNS N
of IN N
pre-curved JJ i
interdental JJ i
brushes NNS i
and CC i
flossing VBG i
on IN N
probing VBG N
pocket NN N
depth NN N
( ( N
PPD NNP N
) ) N
, , N
plaque JJ N
indices NNS N
, , N
and CC N
bleeding VBG N
on IN N
probing VBG N
( ( N
BOP NNP N
) ) N
measured VBD N
at IN N
baseline NN N
, , N
intermediate NN N
, , N
and CC N
final JJ N
examinations NNS N
. . N

Results NNS N
of IN N
SEM NNP N
showed VBD N
that IN N
the DT N
observed JJ N
greater JJR o
reduction NN o
in IN o
PPD NNP o
and CC o
BOP NNP o
in IN N
persons NNS p
using VBG p
interdental JJ p
brushing NN p
than IN p
in IN p
those DT p
flossing NN p
is VBZ N
due JJ N
mainly RB N
to TO N
the DT N
greater JJR N
efficiency NN o
in IN o
plaque NN o
removal NN o
with IN N
the DT N
interdental JJ N
brushes NNS N
( ( N
indirect JJ N
effect NN N
) ) N
rather RB N
than IN N
to TO N
the DT N
compression NN N
of IN N
the DT N
interdental JJ N
papillae NN N
( ( N
direct JJ N
effect NN N
) ) N
. . N

In IN N
contrast NN N
, , N
smokers NNS p
showed VBD N
less JJR N
BOP NNP o
at IN N
baseline NN N
but CC N
also RB N
less RBR N
improvement NN N
in IN N
BOP NNP o
through IN N
direct JJ N
effects NNS N
. . N

-DOCSTART- -20924261- O O

Anatomical JJ N
benefit NN N
from IN N
ranibizumab JJ i
treatment NN N
of IN N
predominantly RB p
classic JJ p
neovascular JJ p
age-related JJ p
macular JJ p
degeneration NN p
in IN N
the DT N
2-year JJ N
anchor NN N
study NN N
. . N

PURPOSE NNP N
To TO N
compare VB N
lesion JJ N
anatomical JJ N
responses NNS N
to TO N
ranibizumab VB i
versus NN N
verteporfin NN i
photodynamic JJ i
therapy NN i
( ( i
PDT NNP i
) ) i
in IN N
the DT N
ANCHOR NNP N
( ( N
Anti-VEGF NNP N
Antibody NNP N
for IN N
the DT N
Treatment NNP N
of IN N
Predominantly NNP p
Classic NNP p
Choroidal NNP p
Neovascularization NNP p
[ NNP p
CNV NNP p
] NNP p
in IN p
Age-Related NNP p
Macular NNP p
Degeneration NNP p
) ) p
study NN N
. . N

METHODS NNP N
In IN N
this DT N
2-year JJ N
, , N
Phase NNP N
III NNP N
, , N
randomized VBD N
, , N
multicenter NN N
, , N
double-masked JJ N
trial NN N
, , N
423 CD p
patients NNS p
received VBN p
ranibizumab NNS i
( ( p
0.3 CD p
or CC p
0.5 CD p
mg NN p
) ) p
monthly RB p
+ NNP p
sham NN i
PDT NNP i
or CC i
PDT NNP i
+ NNP i
monthly JJ p
sham NN i
injection NN i
. . i

Photodynamic NNP i
therapy NN i
( ( i
or CC i
sham VB i
PDT NNP i
) ) i
was VBD N
administered VBN N
at IN N
Day NNP N
0 CD N
and CC N
then RB N
quarterly RB N
as IN N
needed VBN N
. . N

A DT N
central JJ N
reading NN N
center NN N
assessed VBD N
fundus JJ N
photography NN N
and CC N
fluorescein NN N
angiography NN N
images NNS N
. . N

A DT N
subset NN N
( ( N
n JJ N
= NNP N
61 CD N
) ) N
had VBD N
optical JJ N
coherence NN N
tomography NN N
assessments NNS N
. . N

Main NNP N
outcome NN N
measures NNS N
included VBD N
mean JJ N
change NN N
from IN N
baseline NN N
at IN N
Months NNP N
12 CD N
and CC N
24 CD N
for IN N
area NN N
of IN N
classic JJ N
CNV NNP N
and CC N
total JJ N
area NN N
of IN N
leakage NN N
from IN N
CNV NNP N
. . N

RESULTS NNP N
At IN N
Months NNP N
12 CD N
and CC N
24 CD N
, , N
ranibizumab NN i
was VBD N
superior JJ N
to TO N
PDT NNP i
( ( N
P NNP N
< NNP N
0.0001 CD N
) ) N
for IN N
mean JJ N
changes NNS N
from IN N
baseline NN N
in IN N
total JJ o
area NN o
of IN o
lesion NN o
, , o
CNV NNP o
area NN o
, , o
and CC o
total JJ o
area NN o
CNV NNP o
leakage NN o
. . o

Month NNP N
12 CD N
optical JJ N
coherence NN N
tomographies NNS N
showed VBD N
greater JJR N
center NN o
point NN o
thickness JJ o
decrease NN N
from IN N
baseline NN N
with IN N
ranibizumab NN i
than IN N
with IN N
PDT NNP i
( ( N
P NNP N
= NNP N
0.0003 CD N
) ) N
. . N

Ranibizumab NNP i
benefits NNS N
over IN N
PDT NNP i
were VBD N
evident JJ N
by IN N
3 CD N
months NNS N
( ( N
fluorescein JJ N
angiography NN N
) ) N
and CC N
7 CD N
days NNS N
( ( N
optical JJ N
coherence NN N
tomography NN N
) ) N
. . N

CONCLUSION NNP N
Differences NNPS N
between IN N
the DT N
PDT NNP i
and CC N
the DT N
ranibizumab NN i
groups NNS N
in IN N
lesion NN N
anatomical JJ N
outcomes NNS N
were VBD N
early JJ N
, , N
sustained VBN N
, , N
and CC N
favored VBD N
ranibizumab NN i
. . i

-DOCSTART- -21802739- O O

MRI NNP o
signal JJ o
hyperintensities NNS o
and CC o
failure NN o
to TO o
remit VB o
following VBG N
antidepressant JJ i
treatment NN i
. . i

BACKGROUND NNP N
MRI NNP N
signal JJ N
hyperintensities NNS N
predict VBP N
poor JJ N
remission NN o
to TO N
antidepressant VB i
treatment NN i
. . i

Previous JJ N
studies NNS N
using VBG N
volumetrics NNS N
in IN N
outpatient NN N
samples NNS N
have VBP N
relied VBN N
on IN N
total JJ o
lesion NN o
volume NN o
. . o

The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
test VB N
whether IN N
remission NN N
from IN N
geriatric JJ p
depression NN p
depends VBZ N
on IN N
lesion NN o
volume NN o
by IN o
region NN o
of IN o
interest NN o
( ( o
ROI NNP o
) ) o
. . o

METHOD NNP N
Thirty-eight JJ p
patients NNS p
received VBD N
baseline JJ i
MRIs NNP i
as IN N
part NN N
of IN N
a DT N
larger JJR N
12-week JJ N
, , N
randomized JJ N
clinical JJ N
trial NN N
comparing VBG N
sertraline NN i
and CC i
nortriptyline NN i
in IN i
the DT i
treatment NN i
of IN i
late-life JJ i
depression NN i
. . i

MRIcro NNP N
was VBD N
used VBN N
to TO N
quantify VB N
MRI-hyperintensity NNP N
volume NN N
into IN N
total JJ N
hyperintensity NN N
, , N
deep JJ N
white JJ N
matter NN N
hyperintensity NN N
( ( N
DWMH NNP N
) ) N
, , N
and CC N
periventricular JJ N
hyperintensity NN N
( ( N
PVH NNP N
) ) N
volumes NNS N
. . N

High NNP N
versus NN N
low JJ N
total NN N
, , N
DWMH NNP o
, , o
and CC o
PVH NNP o
volumes NNS o
were VBD N
defined VBN N
based VBN N
on IN N
the DT N
highest JJS N
quartile NN N
of IN N
their PRP$ N
respective JJ N
distributions NNS N
. . N

Remission NN o
from IN o
depression NN o
was VBD N
defined VBN N
as IN N
a DT N
24-item JJ N
Hamilton NNP o
Rating NNP o
Scale NNP o
for IN o
Depression NNP o
score NN o
? . N
7 CD N
for IN N
two CD N
consecutive JJ N
weeks NNS N
. . N

RESULTS JJ N
Patients NNS N
classified VBD N
as IN N
having VBG N
high JJ N
DWMH NNP N
were VBD N
7.14 CD N
times NNS N
more RBR N
likely JJ N
not RB N
to TO N
remit VB o
following VBG o
antidepressant JJ i
treatment NN i
compared VBN i
to TO N
patients NNS N
classified VBN N
as IN N
having VBG N
low JJ N
DWMH NNP N
( ( N
p=0.02 NN N
) ) N
. . N

Similar JJ N
odds NNS N
ratios NNS N
were VBD N
obtained VBN N
for IN N
PVH NNP N
( ( N
OR=4.17 NNP N
, , N
p=0.16 NN N
) ) N
and CC N
total JJ N
volumes NNS N
( ( N
OR=5.00 NNP N
, , N
p=0.05 NN N
) ) N
. . N

Importantly RB N
, , N
adjusting VBG N
for IN N
age NN N
did VBD N
not RB N
change VB N
the DT N
magnitude NN N
of IN N
these DT N
effects NNS N
. . N

LIMITATIONS VB N
A NNP N
small JJ p
and CC p
predominantly RB p
White NNP p
sample NN p
. . p

CONCLUSIONS VB N
This DT N
is VBZ N
the DT N
first JJ N
study NN N
to TO N
test VB N
whether IN o
remission NN o
from IN o
geriatric JJ o
depression NN o
depends VBZ o
on IN N
lesion NN o
volume NN o
by IN o
ROI NNP o
in IN o
an DT N
outpatient JJ N
sample NN N
. . N

The DT N
pattern NN N
of IN N
remission NN N
rates NNS N
and CC N
odds JJ N
ratios NNS N
was VBD N
similar JJ N
when WRB N
patients NNS N
were VBD N
classified VBN N
as IN N
having VBG N
high JJ N
DWMH NNP N
, , N
PVH NNP N
or CC N
total JJ N
volume NN N
suggesting VBG N
that IN o
lesion NN o
location NN o
may MD o
not RB N
be VB N
critical JJ N
. . N

-DOCSTART- -8045623- O O

The DT N
biological JJ N
factors NNS N
in IN N
the DT N
etiopathogenesis NN N
and CC N
management NN N
of IN N
cervical JJ p
spondylosis NN p
. . p

Two CD p
hundred JJ p
cases NNS p
of IN p
cervical JJ p
spondylosis NN p
were VBD p
studied VBN p
for IN N
1 CD N
to TO N
4 CD N
average NN N
( ( N
2 CD N
1/2 CD N
) ) N
years NNS N
. . N

No DT N
co-relation NN N
could MD N
be VB N
established VBN N
between IN N
the DT N
clinical JJ N
features NNS N
and CC N
the DT N
radiological JJ N
findings NNS N
in IN N
these DT N
cases NNS N
. . N

It PRP N
was VBD N
found VBN N
that IN N
parasites VBZ o
play VBP o
an DT o
important JJ o
role NN o
in IN o
the DT o
multifactorial JJ o
etiology NN o
of IN o
this DT o
condition NN o
and CC o
their PRP$ o
eradication NN o
by IN o
deworming VBG o
drugs NNS o
gives VBZ o
better JJR o
results NNS o
than IN o
the DT o
traditional JJ o
therapies NNS o
. . o

Many JJ N
new JJ N
hypotheses NNS N
are VBP N
proposed VBN N
to TO N
explain VB N
the DT N
same JJ N
. . N

-DOCSTART- -9438269- O O

Electrical JJ N
sources NNS N
of IN N
P300 NNP N
event-related JJ N
brain NN N
potentials NNS N
revealed VBN N
by IN N
low JJ N
resolution NN N
electromagnetic JJ N
tomography NN N
. . N

2 CD N
. . N

Effects NNS N
of IN N
nootropic JJ i
therapy NN i
in IN N
age-associated JJ p
memory NN p
impairment NN p
. . p

In IN N
a DT N
double-blind JJ N
, , N
placebo-controlled JJ N
study NN N
the DT N
effects NNS N
of IN N
Actovegin NNP i
on IN N
frontal JJ N
and CC N
parietal JJ N
electrical JJ N
P300 NNP N
sources NNS N
revealed VBN N
by IN N
low JJ N
resolution NN N
electromagnetic JJ N
tomography NN N
( ( N
LORETA NNP N
) ) N
were VBD N
studied VBN N
in IN N
age-associated JJ p
memory NN p
impairment NN p
( ( p
AAMI NNP p
) ) p
patients NNS p
. . p

Actovegin NNP N
is VBZ N
a DT N
protein-free JJ N
metabolically RB N
active JJ N
hemoderivative JJ N
improving NN N
oxygen NN N
and CC N
glucose JJ N
utilization NN N
. . N

Each DT N
patient NN N
had VBD N
, , N
in IN N
randomized JJ N
order NN N
, , N
a DT N
treatment NN N
of IN N
2 CD i
weeks NNS i
with IN i
250 CD i
ml NNS i
20 CD i
% NN i
Actovegin NNP i
and CC i
250 CD i
ml NNS i
placebo JJ i
daily RB i
. . i

Auditory NNP i
ERPs NNP i
were VBD N
recorded VBN N
before RB N
and CC N
5 CD N
h NN N
after IN N
drug NN N
administration NN N
on IN N
day NN N
1 CD N
( ( N
acute JJ N
effect NN N
) ) N
and CC N
on IN N
day NN N
15 CD N
( ( N
subacute NN N
and CC N
superimposed JJ N
effect NN N
) ) N
. . N

Compared VBN N
to TO N
age- JJ N
and CC N
sex-matched JJ N
normal JJ N
controls NNS N
, , N
AAMI NNP p
patients NNS p
showed VBD N
a DT N
trend NN N
towards VBZ N
P300 NNP o
latency NN o
prolongation NN o
and CC N
a DT N
significantly RB N
reduced VBN N
P300 NNP o
global JJ o
field NN o
power NN o
( ( N
GFP NNP N
) ) N
. . N

Maximal NNP o
LORETA NNP o
source NN o
strength NN o
did VBD N
not RB N
differ VB N
from IN N
controls NNS N
. . N

After IN N
Actovegin NNP o
parietal JJ o
P300 NNP o
scalp NN o
amplitudes NNS o
increased VBD N
, , N
while IN N
frontal JJ o
and CC o
temporal JJ o
amplitudes NNS o
decreased VBD N
as IN N
compared VBN N
to TO N
placebo VB i
. . i

This DT N
increase NN N
in IN N
hilliness NN o
, , N
measured VBN N
by IN N
the DT N
GFP NNP N
, , N
was VBD N
significant JJ N
. . N

Moreover RB N
, , N
the DT N
parietal JJ o
P300 NNP o
source NN o
strength NN o
increased VBD N
after IN N
acute NN N
, , N
subacute NN N
and CC N
superimposed JJ N
infusion NN N
of IN N
Actovegin NNP N
as IN N
compared VBN N
to TO N
placebo VB i
. . i

This DT N
may MD N
reflect VB N
improved JJ N
availability NN N
of IN N
cognitive JJ N
processing NN N
resources NNS N
in IN N
the DT N
parietal JJ N
cortex NN N
, , N
an DT N
area NN N
that WDT N
on IN N
the DT N
one CD N
hand NN N
plays VBZ N
an DT N
important JJ N
role NN N
in IN N
fundamental JJ N
aspects NNS N
of IN N
attention NN N
and CC N
on IN N
the DT N
other JJ N
hand NN N
has VBZ N
been VBN N
found VBN N
to TO N
be VB N
functionally RB N
impaired VBN N
in IN N
dementia NN N
. . N

-DOCSTART- -27532829- O O

A DT N
Placebo-Controlled JJ N
Trial NNP N
of IN N
Obeticholic NNP i
Acid NNP i
in IN N
Primary NNP p
Biliary NNP p
Cholangitis NNP p
. . p

BACKGROUND NNP N
Primary NNP p
biliary JJ p
cholangitis NN p
( ( p
formerly RB p
called VBN p
primary JJ p
biliary JJ p
cirrhosis NN p
) ) p
can MD N
progress VB N
to TO N
cirrhosis VB N
and CC N
death NN N
despite IN N
ursodiol JJ N
therapy NN N
. . N

Alkaline NNP N
phosphatase NN N
and CC N
bilirubin NN N
levels NNS N
correlate VBP N
with IN N
the DT N
risk NN N
of IN N
liver JJ N
transplantation NN N
or CC N
death NN N
. . N

Obeticholic NNP N
acid NN N
, , N
a DT N
farnesoid JJ N
X NNP N
receptor NN N
agonist NN N
, , N
has VBZ N
shown VBN N
potential JJ N
benefit NN N
in IN N
patients NNS N
with IN N
this DT N
disease NN N
. . N

METHODS NNP N
In IN N
this DT N
12-month JJ p
, , p
double-blind JJ p
, , p
placebo-controlled JJ p
, , p
phase VB p
3 CD p
trial NN p
, , p
we PRP p
randomly VBP p
assigned VBD p
217 CD p
patients NNS p
who WP p
had VBD p
an DT p
inadequate JJ p
response NN p
to TO p
ursodiol VB p
or CC p
who WP p
found VBD p
the DT p
side NN p
effects NNS p
of IN p
ursodiol JJ i
unacceptable JJ p
to TO N
receive VB i
obeticholic JJ i
acid NN i
at IN i
a DT i
dose NN i
of IN i
10 CD i
mg NN i
( ( i
the DT i
10-mg JJ i
group NN i
) ) i
, , i
obeticholic JJ i
acid NN i
at IN i
a DT i
dose NN i
of IN i
5 CD i
mg NN i
with IN i
adjustment NN i
to TO i
10 CD i
mg NNS i
if IN i
applicable JJ i
( ( i
the DT i
5-10-mg NNP i
group NN i
) ) i
, , i
or CC i
placebo NN i
. . i

The DT N
primary JJ N
end NN N
point NN N
was VBD N
an DT N
alkaline JJ o
phosphatase NN o
level NN o
of IN N
less JJR N
than IN N
1.67 CD N
times NNS N
the DT N
upper JJ N
limit NN N
of IN N
the DT N
normal JJ N
range NN N
, , N
with IN N
a DT N
reduction NN N
of IN N
at IN N
least JJS N
15 CD N
% NN N
from IN N
baseline NN N
, , N
and CC N
a DT N
normal JJ N
total JJ N
bilirubin NN o
level NN o
. . o

RESULTS NNP N
Of IN N
216 CD p
patients NNS p
who WP p
underwent JJ p
randomization NN p
and CC p
received VBN p
at IN p
least JJS p
one CD p
dose NN p
of IN p
obeticholic JJ i
acid NN i
or CC p
placebo NN i
, , N
93 CD N
% NN N
received VBD N
ursodiol JJ i
as IN N
background NN N
therapy NN N
. . N

The DT N
primary JJ N
end NN N
point NN N
occurred VBD N
in IN N
more RBR N
patients NNS N
in IN N
the DT N
5-10-mg JJ N
group NN N
( ( N
46 CD N
% NN N
) ) N
and CC N
the DT N
10-mg JJ N
group NN N
( ( N
47 CD N
% NN N
) ) N
than IN N
in IN N
the DT N
placebo NN N
group NN N
( ( N
10 CD N
% NN N
; : N
P NNP N
< VBZ N
0.001 CD N
for IN N
both DT N
comparisons NNS N
) ) N
. . N

Patients NNS N
in IN N
the DT N
5-10-mg JJ N
group NN N
and CC N
those DT N
in IN N
the DT N
10-mg JJ N
group NN N
had VBD N
greater JJR N
decreases NNS N
than IN N
those DT N
in IN N
the DT N
placebo NN N
group NN N
in IN N
the DT N
alkaline JJ o
phosphatase NN o
level NN o
( ( N
least-squares JJ N
mean NN N
, , N
-113 NNP N
and CC N
-130 NNP N
U NNP N
per IN N
liter NN N
, , N
respectively RB N
, , N
vs. FW N
-14 FW N
U NNP N
per IN N
liter NN N
; : N
P NNP N
< VBZ N
0.001 CD N
for IN N
both DT N
comparisons NNS N
) ) N
and CC N
total JJ o
bilirubin NN o
level NN o
( ( N
-0.02 JJ N
and CC N
-0.05 JJ N
mg NN N
per IN N
deciliter NN N
[ NN N
-0.3 NNP N
and CC N
-0.9 NNP N
?mol NNP N
per IN N
liter NN N
] NN N
, , N
respectively RB N
, , N
vs. FW N
0.12 CD N
mg NN N
per IN N
deciliter NN N
[ NN N
2.0 CD N
?mol NN N
per IN N
liter NN N
] NN N
; : N
P NNP N
< VBZ N
0.001 CD N
for IN N
both DT N
comparisons NNS N
) ) N
. . N

Changes NNS N
in IN N
noninvasive JJ o
measures NNS o
of IN o
liver NN o
fibrosis NN o
did VBD o
not RB N
differ VB N
significantly RB N
between IN N
either CC N
treatment NN N
group NN N
and CC N
the DT N
placebo NN N
group NN N
at IN N
12 CD N
months NNS o
. . o

Pruritus NNP o
was VBD o
more RBR N
common JJ N
with IN N
obeticholic JJ N
acid NNS N
than IN N
with IN N
placebo NN N
( ( N
56 CD N
% NN N
of IN N
patients NNS N
in IN N
the DT N
5-10-mg JJ N
group NN N
and CC N
68 CD N
% NN N
of IN N
those DT N
in IN N
the DT N
10-mg JJ N
group NN N
vs. FW N
38 CD N
% NN N
in IN N
the DT N
placebo NN N
group NN N
) ) N
. . N

The DT N
rate NN N
of IN N
serious JJ o
adverse JJ o
events NNS o
was VBD o
16 CD N
% NN N
in IN N
the DT N
5-10-mg JJ N
group NN N
, , N
11 CD N
% NN N
in IN N
the DT N
10-mg JJ N
group NN N
, , N
and CC N
4 CD N
% NN N
in IN N
the DT N
placebo NN N
group NN N
. . N

CONCLUSIONS NNP N
Obeticholic NNP N
acid NN N
administered VBD N
with IN i
ursodiol JJ i
or CC i
as IN N
monotherapy NN N
for IN N
12 CD N
months NNS N
in IN N
patients NNS p
with IN p
primary JJ p
biliary JJ p
cholangitis NN p
resulted VBD p
in IN N
decreases NNS N
from IN N
baseline NN N
in IN N
alkaline JJ o
phosphatase NN o
and CC o
total JJ o
bilirubin NN o
levels NNS o
that WDT o
differed VBD N
significantly RB N
from IN N
the DT N
changes NNS N
observed VBN N
with IN i
placebo NN i
. . i

There EX N
were VBD N
more RBR N
serious JJ N
adverse JJ N
events NNS N
with IN i
obeticholic JJ i
acid NN i
. . i

( ( N
Funded VBN N
by IN N
Intercept NNP N
Pharmaceuticals NNP N
; : N
POISE NNP N
ClinicalTrials.gov NNP N
number NN N
, , N
NCT01473524 NNP N
; : N
Current NNP N
Controlled VBD N
Trials NNP N
number NN N
, , N
ISRCTN89514817 NNP N
. . N

) ) N
. . N

-DOCSTART- -12804020- O O

Safety NN N
of IN N
an DT N
astaxanthin-rich JJ i
Haematococcus NNP i
pluvialis NN i
algal JJ i
extract NN i
: : i
a DT N
randomized JJ N
clinical JJ N
trial NN N
. . N

A DT N
growing VBG N
body NN N
of IN N
scientific JJ N
literature NN N
indicates VBZ N
that IN N
astaxanthin NN i
is VBZ N
a DT N
more RBR N
powerful JJ N
antioxidant JJ N
than IN N
other JJ N
carotenoids NNS N
and CC N
vitamin NN N
E NNP N
and CC N
may MD N
confer VB N
numerous JJ N
health NN N
benefits NNS N
. . N

The DT N
purpose NN N
of IN N
this DT N
investigation NN N
was VBD N
to TO N
conduct VB N
a DT N
human JJ N
safety NN N
study NN N
with IN N
a DT N
Haematococcus NNP i
pluvialis NN i
algal JJ i
extract NN i
with IN i
high JJ i
levels NNS i
of IN i
astaxanthin NN i
. . i

Thirty-five JJ p
healthy JJ p
adults NNS p
age NN p
35-69 CD p
years NNS p
were VBD p
enrolled VBN p
in IN p
a DT p
randomized JJ p
, , p
double-blind JJ p
, , p
placebo-controlled JJ i
trial NN p
of IN p
8 CD p
weeks NNS p
' POS p
duration NN p
. . p

All DT p
participants NNS p
took VBD N
three CD N
gelcaps NNS N
per IN N
day NN N
, , N
one CD N
at IN N
each DT N
meal NN N
. . N

Nineteen JJ p
participants NNS p
received VBD p
gelcaps NNS i
with IN i
an DT i
algal JJ i
extract NN i
in IN i
safflower JJR i
oil NN i
, , N
containing VBG N
2 CD N
mg NN N
of IN N
astaxanthin JJ i
each DT N
( ( N
treatment NN N
) ) N
; : N
16 CD p
participants NNS p
received VBD p
gelcaps NNS i
containing VBG i
safflower NN i
oil NN i
only RB i
( ( i
placebo NN i
) ) i
. . i

Blood NNP N
pressure NN N
and CC N
blood NN N
chemistry NN N
tests NNS N
, , N
including VBG N
a DT N
comprehensive JJ N
metabolic JJ N
panel NN N
and CC N
cell NN N
blood NN N
count NN N
, , N
were VBD N
conducted VBN N
at IN N
the DT N
beginning NN N
of IN N
the DT N
trial NN N
and CC N
after IN N
4 CD N
and CC N
8 CD N
weeks NNS N
of IN N
supplementation NN N
. . N

No DT N
significant JJ o
differences NNS o
were VBD N
detected VBN N
between IN N
the DT N
treatment NN N
and CC N
the DT N
placebo NN i
groups NNS N
after IN N
8 CD N
weeks NNS N
of IN N
supplementation NN N
with IN N
the DT N
algal JJ i
extract NN i
in IN N
the DT N
parameters NNS N
analyzed VBD N
, , N
except IN N
for IN N
serum NN o
calcium NN o
, , o
total JJ o
protein NN o
, , o
and CC o
eosinophils NNS o
( ( N
P NNP N
< NNP N
.01 NNP N
) ) N
. . N

Although IN N
the DT N
differences NNS N
in IN N
these DT N
three CD N
parameters NNS N
were VBD N
statistically RB N
significant JJ N
, , N
they PRP N
were VBD N
very RB N
small JJ N
and CC N
are VBP N
of IN N
no DT N
clinical JJ N
importance NN N
. . N

These DT N
results NNS N
reveal VBP N
that IN N
6 CD N
mg NN N
of IN N
astaxanthin JJ i
per IN N
day NN N
from IN N
a DT N
H. NNP i
pluvialis NN i
algal JJ i
extract NN i
can MD N
be VB N
safely RB o
consumed VBN N
by IN N
healthy JJ N
adults NNS N
. . N

-DOCSTART- -3296982- O O

Need NN N
for IN N
insulin NN i
therapy NN i
in IN N
type NN p
II NNP p
diabetes VBZ p
mellitus NN p
. . p

A DT N
randomized JJ N
trial NN N
. . N

To TO p
identify VB p
patients NNS p
with IN p
type JJ p
II NNP p
diabetes VBZ p
mellitus NN p
for IN p
whom WP p
insulin NN i
therapy NN i
is VBZ p
most RBS p
beneficial JJ p
, , p
we PRP p
conducted VBD p
a DT p
randomized VBN p
controlled VBN p
trial NN p
in IN p
the DT p
general JJ p
medicine NN p
clinic NN p
of IN p
a DT p
university NN p
hospital NN p
. . p

Asymptomatic NNP p
, , p
obese JJ p
, , p
insulin-treated JJ p
patients NNS p
were VBD N
given VBN N
diet JJ i
and CC i
diabetes VBZ i
education NN i
and CC N
, , N
in IN N
half NN N
of IN N
these DT N
patients NNS N
, , N
insulin JJ i
therapy NN i
was VBD i
withdrawn VBN i
. . i

Over IN N
six CD N
months NNS N
, , N
patients NNS N
developing VBG N
hyperglycemic JJ o
symptoms NNS o
or CC o
acetonemia NN o
were VBD N
counted VBN N
as IN N
study NN N
failures NNS N
. . N

Failure NN o
criteria NNS o
developed VBD N
in IN N
13 CD N
of IN N
25 CD p
insulin-withdrawal JJ p
patients NNS p
, , N
at IN N
a DT N
median NN N
of IN N
four CD N
weeks NNS N
after IN N
withdrawal NN N
, , N
compared VBN N
with IN N
two CD N
of IN N
24 CD p
control NN p
subjects NNS p
. . p

Elevated VBN o
stimulated VBD o
glucose JJ o
levels NNS o
predicted VBD N
the DT N
need NN N
for IN N
insulin JJ N
therapy NN N
. . N

Hyperglycemia NNP o
worsened VBD N
in IN N
insulin-withdrawal JJ N
patients NNS N
who WP N
did VBD N
not RB N
meet VB N
study JJ N
failure NN N
criteria NNS N
, , N
but CC N
it PRP N
improved VBD N
in IN N
control NN N
patients NNS N
. . N

Study NNP N
patients NNS N
were VBD N
insulin JJ N
deficient NN N
as IN N
shown VBN N
by IN N
low JJ N
baseline NN o
C NNP o
peptide NN o
values NNS o
( ( o
0.43 CD o
+/- JJ N
0.05 CD N
nmol/L NN N
) ) N
. . N

The DT N
prompt JJ N
metabolic JJ N
decompensation NN N
precipitated VBN N
by IN N
insulin NN N
withdrawal NN N
suggests VBZ N
that IN N
insulin-deficient JJ N
patients NNS N
may MD N
benefit VB N
from IN N
insulin NN N
therapy NN N
and CC N
may MD N
need VB N
it PRP N
to TO N
prevent VB N
symptomatic JJ o
hyperglycemia NN o
. . o

-DOCSTART- -43164- O O

A DT p
double-blind JJ p
crossover NN p
comparison NN p
of IN p
pindolol NN i
, , i
metoprolol NN i
, , i
atenolol NN i
and CC p
labetalol NN i
in IN p
mild NN p
to TO p
moderate VB p
hypertension NN p
. . p

1 CD N
This DT N
study NN N
was VBD N
designed VBN N
to TO N
compare VB N
in IN N
a DT N
double-blind JJ N
randomized JJ N
crossover NN N
trial NN N
, , N
atenolol NN i
, , i
labetalol NN i
, , i
metoprolol NN i
and CC i
pindolol NN i
. . i

Considerable JJ N
differences NNS N
in IN N
dose NN o
( ( i
atenolol JJ i
138 CD N
+/- JJ N
13 CD N
mg JJ N
daily RB N
; : N
labetalol VBZ i
308 CD N
+/- JJ N
34 CD N
mg JJ N
daily RB N
; : N
metoprolol PRP i
234 CD N
+/- JJ N
22 CD N
mg JJ N
daily RB N
; : N
and CC N
pindolol VB i
24 CD N
+/-2 JJ N
mg NNS N
daily JJ N
were VBD N
required VBN N
to TO N
produce VB N
similar JJ N
antihypertensive JJ o
effects NNS o
. . o

3 CD N
The DT o
overall JJ o
incidence NN o
of IN o
side-effects NNS o
was VBD o
similar JJ o
with IN o
atenolol NN o
, , o
metoprolol NN o
and CC o
pindolol NN o
but CC o
was VBD o
slightly RB o
less JJR o
with IN o
labetalol NN o
. . i

Sleep JJ o
disturbances NNS o
and CC o
abnormal JJ o
dreaming NN o
patterns NNS o
were VBD o
most RBS o
frequent JJ o
with IN o
pindolol NN o
. . i

4 CD N
There EX o
was VBD o
a DT o
significantly RB o
greater JJR o
fall NN o
in IN o
pulse JJ o
rate NN o
during IN o
atenolol NN o
and CC o
metoprolol NN o
treatment NN o
periods NNS o
. . N

-DOCSTART- -10720081- O O

Growth NNP o
hormone NN o
( ( o
GH NNP o
) ) o
responses VBZ o
to TO N
GH-releasing NNP i
hormone NN i
alone RB i
or CC N
combined VBN i
with IN i
arginine NN i
in IN N
patients NNS p
with IN p
adrenal JJ p
incidentaloma NN p
: : p
evidence NN N
for IN N
enhanced JJ N
somatostatinergic JJ N
tone NN N
. . N

Spontaneous JJ N
and CC N
stimulated VBD N
GH NNP N
secretion NN N
is VBZ N
blunted VBN N
in IN N
hypercortisolemic JJ N
states NNS N
due JJ N
to TO N
increased VBN N
hypothalamic JJ N
somatostatinergic NN N
tone NN N
. . N

However RB N
, , N
no DT N
data NNS N
are VBP N
available JJ N
on IN N
the DT N
characteristics NNS N
of IN N
GH NNP N
secretion NN N
in IN N
patients NNS p
with IN p
incidentally RB p
discovered VBN p
adrenal JJ p
adenomas NN p
. . p

They PRP N
represent VBP N
an DT N
interesting JJ N
model NN N
for IN N
studying VBG N
GH NNP N
secretion NN N
, , N
as IN N
a DT N
slight JJ N
degree NN N
of IN N
cortisol NN N
excess NN N
may MD N
frequently RB N
be VB N
observed VBN N
in IN N
such JJ N
patients NNS p
who WP p
do VBP p
not RB p
present VB p
with IN p
any DT p
clear JJ p
Cushingoid NNP p
sign NN p
. . p

In IN N
the DT N
present JJ N
study NN N
, , N
10 CD p
patients NNS p
( ( p
3 CD p
men NNS p
and CC p
7 CD p
women NNS p
, , p
aged VBD p
48-63 JJ p
yr NN p
) ) p
with IN p
an DT p
adrenal JJ p
mass NN p
discovered VBD p
serendipitously RB p
underwent JJ N
, , N
on IN N
separate JJ N
occasions NNS N
, , N
a DT N
GHRH NNP i
injection NN i
alone RB i
or CC N
combined VBN i
with IN i
an DT i
infusion NN i
of IN i
the DT i
functional JJ i
somatostatin NN i
antagonist NN i
, , i
arginine NN i
. . i

Thirteen JJ p
age-matched JJ p
healthy JJ p
volunteers NNS p
served VBD p
as IN p
controls NNS i
. . i

Briefly NNP N
, , N
arginine NN i
( ( i
30 CD i
g NN i
) ) i
was VBD i
infused VBN i
from IN i
-30 NN i
to TO i
0 CD i
min NN i
, , i
and CC i
GHRH NNP i
( ( i
100 CD i
microg NN i
) ) i
was VBD i
injected VBN i
as IN i
a DT i
bolus NN i
at IN i
0 CD i
min NNS i
, , N
with IN N
measurement NN N
of IN N
serum NN i
GH NNP i
[ NNP i
immunoradiometric JJ i
assay NN i
( ( i
IRMA NNP i
) ) i
] VBP i
every DT N
15 CD N
min NN N
for IN N
150 CD N
min NN N
. . N

Plasma NNP i
IGF-I NNP i
( ( i
RIA NNP i
after IN i
acid-ethanol JJ i
extraction NN i
) ) i
was VBD N
measured VBN N
in IN N
a DT N
morning NN N
sample NN N
. . N

The DT N
diagnosis NN N
of IN N
cortical JJ N
adenoma NN N
was VBD N
based VBN N
on IN N
computed JJ N
tomography NN N
features NNS N
and CC N
pattern NN N
of IN N
uptake NN N
on IN N
adrenal JJ N
scintigraphy NN N
. . N

Patients NNS p
with IN p
obesity NN p
and/or NN p
diabetes NNS p
were VBD p
excluded VBN p
. . p

The DT N
study NN N
design NN N
included VBD N
also RB N
an DT N
endocrine JJ N
work-up NN N
aimed VBN N
to TO N
study VB N
the DT N
hypothalamic-pituitary-adrenal JJ o
axis NN o
[ NNP o
urinary JJ o
free JJ o
cortisol NN o
( ( o
UFC NNP o
) ) o
excretion NN o
, , o
serum NN o
cortisol NN o
at IN o
0800 CD o
h NN o
, , o
plasma JJ o
ACTH NNP o
at IN o
0800 CD o
h NN o
, , o
morning NN o
cortisol NN o
after IN o
overnight JJ o
1 CD o
mg NN o
dexamethasone NN o
] NN o
. . o

Five CD N
of IN N
10 CD N
patients NNS N
showed VBD N
abnormalities NNS o
of IN o
the DT o
hypothalamic-pituitary-adrenal JJ o
axis NN o
, , N
including VBG N
borderline NN o
or CC o
increased VBN o
UFC JJ o
excretion NN o
in IN N
4 CD N
of IN N
them PRP N
accompanied VBN N
by IN N
blunted JJ N
ACTH NNP N
in IN N
2 CD N
cases NNS N
and CC N
failure NN N
of IN N
cortisol NN N
to TO N
suppress VB N
after IN N
dexamethasone NN N
in IN N
1 CD N
; : N
the DT N
fifth JJ N
patient NN N
displayed VBD N
low JJ N
ACTH NNP N
and CC N
resistance NN N
to TO N
dexamethasone VB N
suppression NN N
. . N

However RB N
, , N
all DT N
patients NNS N
had VBD N
a DT N
unilateral JJ N
uptake NN N
of IN N
the DT N
tracer NN N
on IN N
the DT N
side NN N
of IN N
the DT N
mass NN N
with IN N
suppression NN N
of IN N
the DT N
contralateral JJ N
normal JJ N
adrenal JJ N
gland NN N
. . N

As IN N
a DT N
group NN N
, , N
the DT N
patients NNS N
displayed VBD N
greater JJR N
UFC NNP o
excretion NN o
and CC o
lower JJR o
ACTH NNP o
concentrations NNS o
than IN N
the DT N
controls NNS N
. . N

GH NNP o
release NN o
after IN o
GHRH NNP o
treatment NN o
was VBD N
blunted VBN N
in IN N
patients NNS p
bearing VBG p
adrenal JJ p
incidentaloma NNS p
compared VBN N
with IN N
controls NNS N
( ( N
GH NNP N
peak NN N
, , N
5.7 CD N
+/- JJ N
5.2 CD N
vs. FW N
18.0 CD N
+/- JJ N
7.0 CD N
microg/L NN N
; : N
P NNP N
< NNP N
0.0001 CD N
) ) N
, , N
whereas JJ N
GHRH NNP i
plus CC i
arginine NN i
was VBD N
able JJ N
to TO N
elicit VB N
a DT N
comparable JJ N
response NN N
in IN N
the DT N
2 CD N
groups NNS N
( ( N
GH NNP N
peak NN N
, , N
33.5 CD N
+/- JJ N
20.3 CD N
vs. FW N
33.7 CD N
+/- JJ N
17.5 CD N
microg/L NN N
; : N
P NNP N
= NNP N
NS NNP N
) ) N
. . N

The DT N
ratio NN N
between IN N
GH NNP o
peaks NNS o
after IN o
GHRH NNP o
plus CC o
arginine NN o
and CC o
after IN o
GHRH NNP o
plus CC o
saline NN o
was VBD N
significantly RB N
greater JJR N
in IN N
patients NNS N
than IN N
in IN N
controls NNS N
( ( N
751 CD N
+/- JJ N
531 CD N
% NN N
vs. FW N
81 CD N
+/- JJ N
45 CD N
% NN N
; : N
P NNP N
= NNP N
0.0001 CD N
) ) N
. . N

Similar JJ N
data NNS N
were VBD N
obtained VBN N
when WRB N
comparing VBG N
GH NNP N
area NN N
under IN N
the DT N
curve NN N
after IN N
GHRH NNP N
plus CC N
saline NN N
or CC N
GHRH NNP N
plus CC N
arginine NN N
between IN N
the DT N
2 CD N
groups NNS N
. . N

In IN N
summary JJ N
, , N
the DT N
present JJ N
data NNS N
suggest VBP N
that IN N
in IN N
patients NNS p
with IN p
incidental JJ p
adrenal JJ p
adenomas IN p
the DT N
GH NNP o
response NN o
to TO N
GHRH NNP N
is VBZ N
blunted VBN N
due JJ N
to TO N
increased VBN N
somatostatinergic NN o
tone NN o
, , N
as IN N
it PRP N
can MD N
be VB N
restored VBN N
to TO N
normal JJ N
by IN N
pretreatment NN N
with IN N
the DT N
functional JJ N
somatostatin NN N
antagonist JJ N
arginine NN N
. . N

The DT N
blunted JJ N
GH NNP N
release NN N
to TO N
GHRH NNP N
may MD N
be VB N
an DT N
early JJ N
and CC N
long JJ N
lasting JJ N
sign NN N
of IN N
autonomous JJ N
cortisol NNS N
secretion NN N
by IN N
the DT N
adrenal JJ N
adenoma NN N
. . N

-DOCSTART- -19330795- O O

The DT N
SNRI NNP i
venlafaxine NN i
improves VBZ N
emotional JJ o
unawareness NN o
in IN N
patients NNS p
with IN p
post-stroke JJ p
depression NN p
. . p

OBJECTIVE CC N
Patients NNPS p
with IN p
stroke NNS p
have VBP N
a DT N
high JJ N
prevalence NN N
of IN N
depression NN N
and CC N
unawareness NN N
of IN N
emotions NNS N
or CC N
alexithymia NN o
. . o

Here RB N
we PRP N
investigated VBD N
the DT N
effects NNS N
of IN N
the DT N
serotoninergic NN i
and CC i
noradrenergic JJ i
reuptake NN i
inhibitor NN i
( ( i
SNRI NNP i
) ) i
venlafaxine NN i
in IN N
comparison NN N
with IN N
the DT N
SSRI NNP i
fluoxetine NN i
on IN N
alexithymia NN o
severity NN N
in IN N
patients NNS p
with IN p
DSM-IV NNP p
post-stroke JJ p
major JJ p
depressive-like JJ p
episode NN p
( ( p
PSD NNP p
) ) p
. . p

METHODS NNP N
Fifty NNP p
inpatients NNS p
with IN p
first-ever JJ p
stroke NN p
and CC p
PSD NNP p
were VBD p
consecutively RB p
enrolled VBN p
in IN N
this DT N
randomized JJ N
open-label NN N
study NN N
. . N

Twenty-five JJ N
were VBD N
treated VBN N
with IN N
the DT N
SNRI NNP i
venlafaxine NN i
SR NNP N
( ( N
75-150 JJ N
mg/die NN N
) ) N
, , N
and CC N
25 CD N
with IN N
the DT N
SSRI NNP i
fluoxetine NN i
( ( N
20-40 JJ N
mg/die NN N
) ) N
. . N

All DT N
patients NNS N
were VBD N
assessed VBN N
at IN N
day NN N
0 CD N
, , N
and CC N
after IN N
1 CD N
, , N
2 CD N
, , N
4 CD N
, , N
6 CD N
, , N
and CC N
8 CD N
weeks NNS N
, , N
using VBG N
the DT N
Mini-Mental JJ o
State NNP o
Examination NNP o
, , o
the DT o
Hamilton NNP o
Depression NNP o
Rating NNP o
Scale NNP o
, , o
and CC o
the DT o
Toronto NNP o
Alexithymia NNP o
Scale NNP o
( ( N
TAS-20 NNP N
) ) N
. . N

RESULTS JJ N
Patients NNS N
treated VBN N
with IN N
fluoxetine NN N
and CC N
those DT N
treated VBN N
with IN N
venlafaxine NN N
showed VBD N
similar JJ N
improvement NN N
in IN N
depressive JJ o
symptoms NNS o
. . o

However RB N
, , N
patients NNS N
treated VBD N
with IN N
venlafaxine NN N
had VBD N
a DT N
greater JJR N
improvement NN N
on IN N
alexithymia NN o
severity NN o
than IN N
those DT N
treated VBN N
with IN N
fluoxetine NN N
. . N

The DT N
effect NN N
of IN N
venlafaxine NN N
on IN N
unawareness NN o
of IN o
emotions NNS o
was VBD N
evident JJ N
in IN N
patients NNS N
with IN N
alexithymia NN N
( ( N
TAS-20 NNP N
> NNP N
or= IN N
61 CD N
) ) N
at IN N
the DT N
baseline NN N
and CC N
in IN N
those DT N
without IN N
alexithymia NN N
( ( N
TAS-20 NNP N
< NNP N
61 CD N
) ) N
. . N

CONCLUSIONS JJ N
Antidepressants NNPS N
acting VBG N
on IN N
both CC N
the DT N
serotoninergic NN N
and CC N
noradrenergic JJ N
systems NNS N
might MD N
represent VB N
a DT N
valid JJ N
resource NN N
not RB N
only RB N
for IN N
the DT N
treatment NN N
of IN N
depression NN N
but CC N
also RB N
for IN N
improving VBG N
emotional JJ o
unawareness NN o
in IN N
stroke NN p
patients NNS p
. . p

-DOCSTART- -404962- O O

Comparative JJ N
trial NN N
of IN N
carbenicillin NN i
and CC N
ampicillin NN i
therapy NN N
for IN N
purulent NN p
meningitis NN p
. . p

A DT N
randomized JJ N
therapeutic JJ N
trial NN N
of IN N
carbenicillin NN i
( ( i
CB NNP i
) ) i
or CC i
ampicillin NN i
( ( i
AMP NNP i
) ) i
in IN N
purulent NN N
meningitis NN N
was VBD N
performed VBN N
in IN N
86 CD p
pediatric JJ p
and CC p
adult NN p
patients NNS p
( ( p
41 CD p
Haemophilus NNP p
influenzae NN p
, , p
22 CD p
Streptococcus NNP p
pneumoniae NN p
, , p
13 CD p
Neisseria NNP p
meningitidis NN p
, , p
and CC p
10 CD p
of IN p
unknown JJ p
etiology NN p
) ) p
. . p

All DT N
isolates NNS N
, , N
incuding VBG N
H. NNP N
influenzae NN N
, , N
were VBD N
susceptible JJ N
to TO N
CB NNP N
and CC N
AMP NNP N
. . N

Median JJ N
cerebrospinal JJ o
fluid NN o
( ( o
CSF NNP o
) ) o
antibiotic JJ o
concentrations NNS o
were VBD N
0.85 CD N
and CC N
1.60 CD N
mug/ml NN N
for IN N
CB NNP N
and CC N
AMP NNP N
, , N
respectively RB N
, , N
during IN N
administration NN N
of IN N
daily JJ N
doses NNS N
of IN N
400 CD N
mg/kg NNS N
and CC N
0.65 CD N
and CC N
0.45 CD N
mug/ml NN N
, , N
respectively RB N
, , N
on IN N
daily JJ N
doses NNS N
of IN N
200 CD N
mg/kg NN N
. . N

Higher JJR o
CSF NNP o
concentrations NNS o
, , N
up RB N
to TO N
a DT N
median JJ N
concentration NN N
of IN N
4.5 CD N
mug/ml NNS N
, , N
were VBD N
observed VBN N
in IN N
patients NNS N
with IN N
CSF NNP N
protein NN N
concentrations NNS N
> VBP N
/=75 JJ N
mg/100 NN N
ml NN N
. . N

Clinical JJ o
responses NNS o
were VBD N
equivalent JJ N
on IN N
either CC N
antibiotic JJ N
regimen NNS N
. . N

Among IN N
AMP JJ i
patients NNS N
( ( N
45 CD N
) ) N
, , N
8 CD N
had VBD o
significant JJ o
residua NN o
and CC N
3 CD N
died VBD o
; : o
among IN N
CB NNP i
patients NNS N
( ( N
41 CD N
) ) N
, , N
5 CD N
had VBD o
residua NN o
and CC N
none NN o
died VBD o
. . o

However RB N
, , N
38 CD N
% NN N
of IN N
H. NNP p
influenzae NN p
patients NNS p
treated VBN N
with IN N
CB NNP i
had VBD N
positive JJ o
CSF NNP o
cultures NNS o
on IN N
day NN N
1 CD N
follow-up JJ N
lumbar NN N
punctures NNS N
, , N
compared VBN N
with IN N
only RB N
5.8 CD N
% NN N
of IN N
AMP NNP N
patients NNS p
with IN p
H. NNP p
influenzae NN p
. . p

The DT N
significance NN N
of IN N
a DT N
delay NN o
of IN o
CSF NNP o
sterilization NN o
among IN N
CB-treated JJ N
patients NNS N
is VBZ N
unknown JJ N
, , N
since IN N
there EX N
was VBD N
no DT N
correlation NN N
between IN N
persistence NN N
of IN N
hemophilus JJ N
organisms NNS N
and CC N
the DT N
frequency NN N
of IN N
adverse JJ N
outcome NN N
. . N

AMP NNP i
and CC N
CB NNP i
are VBP N
equivalent JJ N
for IN N
the DT N
treatment NN N
of IN N
bacterial JJ N
meningitis NN N
due JJ N
to TO N
susceptible JJ N
organisms NNS N
. . N

-DOCSTART- -17482439- O O

Fine NNP i
needle JJ i
aspiration NN i
coupled VBN i
with IN i
real-time JJ i
PCR NNP i
: : i
a DT N
painless JJ N
methodology NN N
to TO N
study VB N
adaptive JJ N
functional JJ N
changes NNS N
in IN N
skeletal JJ N
muscle NN N
. . N

BACKGROUND NNP N
AND NNP N
AIM NNP N
In IN N
this DT N
study NN N
we PRP N
developed VBD N
a DT N
new JJ N
methodology NN i
for IN N
obtaining VBG N
human JJ N
skeletal JJ N
muscle NN N
samples NNS N
to TO N
evaluate VB N
gene NN N
expression NN N
. . N

This DT N
approach NN N
is VBZ N
based VBN N
on IN N
a DT N
fine JJ i
needle JJ i
aspiration NN i
technique NN i
, , N
which WDT N
allows VBZ N
us PRP N
to TO N
extract VB N
a DT N
small JJ N
tissue NN N
sample NN N
in IN N
a DT N
significantly RB N
less RBR N
invasive JJ N
manner NN N
than IN N
with IN N
classic JJ N
biopsy NN N
. . N

METHODS NNP N
AND CC N
RESULTS NNP N
Multiplex NNP i
tandem VBD i
RT-PCR NNP i
was VBD N
used VBN N
to TO N
determine VB N
the DT N
mRNA NN N
levels NNS N
of IN N
genes NNS N
involved VBN N
in IN N
ATP NNP N
production NN N
and CC N
mitochondrial JJ N
biogenesis NN N
in IN N
muscle NN N
tissue NN N
. . N

Samples NNS o
of IN o
vastus NN o
lateralis NNS o
muscle NN o
were VBD N
obtained VBN N
from IN N
21 CD p
healthy JJ p
subjects NNS p
with IN p
different JJ p
fitness NN p
levels NNS p
. . p

The DT N
principal JJ N
findings NNS N
in IN N
our PRP$ N
study NN N
show VB N
a DT N
strong JJ N
correlation NN N
between IN N
PGC-1alpha NNP o
and CC o
COX5B NNP o
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
and CC N
between IN N
PGC-1alpha NNP o
and CC o
MT-CO2 NNP o
( ( N
p=0.017 NN N
) ) N
expression NN N
. . N

Furthermore NNP N
, , N
a DT N
significant JJ N
positive JJ N
correlation NN N
between IN N
mtDNA NN N
content NN N
and CC N
the DT N
percentage NN N
of IN N
MHCI NNP N
present NN N
in IN N
the DT N
aspired JJ N
samples NNS N
were VBD N
found VBN N
( ( N
p=0.028 NN N
) ) N
. . N

These DT N
data NNS N
are VBP N
in IN N
agreement NN N
with IN N
current JJ N
knowledge NN N
on IN N
skeletal JJ N
muscle NN N
physiology NN N
and CC N
show VB N
the DT N
reliability NN N
of IN N
the DT N
proposed VBN N
method NN N
. . N

CONCLUSION VB N
This DT N
painless JJ i
methodology NN i
can MD N
be VB N
used VBN N
to TO N
investigate VB N
, , N
in IN N
vivo NN N
, , N
human JJ N
muscle NN N
RNA NNP N
and CC N
DNA NNP N
adaptations NNS N
in IN N
response NN N
to TO N
either DT N
physiological JJ N
and/or NN N
pharmacological JJ N
stimuli NN N
. . N

This DT N
method NN N
has VBZ N
major JJ N
clinical JJ N
relevance NN N
, , N
such JJ N
as IN N
its PRP$ N
application NN N
in IN N
clarifying VBG N
the DT N
mechanisms NN N
underling VBG N
metabolic JJ N
and CC N
systemic JJ N
disorders NNS N
. . N

-DOCSTART- -18382824- O O

Determinants NNS N
of IN N
improvement NN N
in IN N
walking VBG o
capacity NN o
among IN N
individuals NNS p
with IN p
chronic JJ p
stroke NN p
following VBG N
a DT N
multi-dimensional JJ i
exercise NN i
program NN i
. . i

OBJECTIVE NNP N
To TO N
identify VB N
the DT N
determinants NNS N
of IN N
improvement NN N
in IN N
walking VBG o
capacity NN o
following VBG N
therapeutic JJ i
exercise NN i
in IN N
chronic JJ p
stroke NN p
survivors NNS p
. . p

DESIGN VB N
A DT N
secondary JJ N
analysis NN N
of IN N
data NNS N
obtained VBN N
from IN N
a DT N
prospective JJ N
, , N
single-blind JJ N
, , N
randomized VBN N
controlled VBN N
intervention NN N
trial NN N
. . N

SUBJECTS JJ N
Sixty-three JJ p
community-dwelling JJ p
individuals NNS p
( ( p
mean JJ p
age NN p
= VBD p
65 CD p
years NNS p
, , p
age NN p
range NN p
= NNP p
50-87 CD p
years NNS p
) ) p
with IN p
a DT p
chronic JJ p
stroke NN p
( ( p
post-stroke JJ p
duration NN p
: : p
mean JJ p
= VBP p
5.5 CD p
years NNS p
, , p
range NN p
= NNP p
1-28 CD p
years NNS p
) ) p
. . p

METHODS JJ N
Subjects NNPS N
were VBD N
randomized VBN N
into IN N
a DT N
leg JJ i
exercise NN i
group NN N
( ( N
n JJ N
= NNP N
32 CD N
) ) N
or CC N
an DT N
arm JJ i
exercise NN i
group NN N
( ( N
n JJ N
= NNP N
31 CD N
) ) N
. . N

Subjects NNS N
in IN N
each DT N
group NN N
underwent VBD N
3 CD N
1-hour JJ N
exercise NN i
sessions NNS i
per IN N
week NN N
for IN N
19 CD N
weeks NNS N
. . N

Walking VBG o
capacity NN o
, , o
cardiorespiratory NN o
fitness NN o
, , o
isometric JJ o
knee NN o
extensor NN o
muscle NN o
strength NN o
, , o
balance NN o
ability NN o
, , o
and CC o
balance NN o
confidence NN o
were VBD N
evaluated VBN N
before IN N
and CC N
after IN N
the DT N
interventions NNS N
. . N

Multiple JJ N
regression NN N
analysis NN N
was VBD N
performed VBN N
to TO N
identify VB N
the DT N
determinants NNS N
of IN N
improvement NN N
in IN N
walking VBG N
capacity NN N
. . N

RESULTS VB N
After IN N
controlling VBG N
for IN N
age NN N
, , N
gender NN N
, , N
post-stroke JJ N
duration NN N
, , N
and CC N
baseline NN N
walking NN o
capacity NN o
, , o
gain NN o
in IN o
paretic JJ o
leg NN o
muscle NN o
strength NN o
and CC o
peak NN o
oxygen NN o
consumption NN o
remained VBD o
independently RB o
associated VBN N
with IN N
gain NN o
in IN o
walking VBG o
capacity NN o
( ( N
R2 NNP N
= NNP N
0.229 CD N
) ) N
. . N

CONCLUSION NNP N
Enhancement NNP N
of IN N
cardiorespiratory NN N
fitness NN N
and CC N
paretic JJ N
leg NN N
muscle NN N
strength NN N
are VBP N
both DT N
significant JJ N
determinants NNS N
in IN N
improving VBG N
walking JJ N
capacity NN N
among IN N
chronic JJ N
stroke NN N
survivors NNS N
. . N

However RB N
, , N
the DT N
rather RB N
weak JJ N
relationship NN N
( ( N
R2 NNP N
= NNP N
0.229 CD N
) ) N
indicates VBZ N
that IN N
other JJ N
factors NNS N
not RB N
measured VBN N
in IN N
this DT N
study NN N
may MD N
also RB N
contribute VB N
to TO N
the DT N
improvement NN N
in IN N
walking VBG N
capacity NN N
. . N

-DOCSTART- -15894964- O O

Cigarette NNP N
smoking NN N
is VBZ N
associated VBN N
with IN N
increased JJ N
circulating VBG N
proinflammatory NN N
and CC N
procoagulant JJ N
markers NNS N
in IN N
patients NNS p
with IN p
chronic JJ p
coronary JJ p
artery NN p
disease NN p
: : p
effects NNS N
of IN N
aspirin JJ i
treatment NN N
. . N

BACKGROUND NNP N
Smoking NNP N
is VBZ N
associated VBN N
with IN N
endothelial JJ N
dysfunction NN N
. . N

Cytokines NNS N
released VBN N
by IN N
injured JJ N
endothelium NN N
promote NN N
vascular JJ N
interactions NNS N
with IN N
leukocytes NNS N
and CC N
platelets NNS N
. . N

We PRP N
investigated VBD N
whether IN N
( ( N
a DT N
) ) N
cigarette NN N
smoking NN N
is VBZ N
linked VBN N
to TO N
increased VBN N
cytokine NN N
production NN N
, , N
which WDT N
may MD N
mediate VB N
platelet NN N
activation NN N
and CC N
thrombin JJ N
generation NN N
in IN N
chronic JJ N
coronary JJ N
artery NN N
disease NN N
( ( N
CAD NNP N
) ) N
, , N
and CC N
( ( N
b NN N
) ) N
aspirin NN N
treatment NN N
inhibits VBZ N
smoking-related JJ N
changes NNS N
on IN N
cytokines NNS N
, , N
platelets NNS N
, , N
and CC N
thrombin NN N
. . N

METHODS NNP N
AND CC N
RESULTS NNP N
Plasma NNP N
macrophage-colony-stimulating JJ N
factor NN N
( ( N
M-CSF NNP N
) ) N
and CC N
C-reactive JJ N
protein NN N
( ( N
CRP NNP N
) ) N
were VBD N
measured VBN N
in IN N
100 CD p
patients NNS p
with IN p
chronic JJ p
CAD NNP p
, , p
60 CD p
of IN p
whom WP p
were VBD p
chronic JJ p
smokers NNS p
. . p

Prothrombin NNP N
fragments VBZ N
1+2 CD N
and CC N
urinary JJ N
11-dehydro-thromboxane JJ N
B2 NNP N
( ( N
TXB2 NNP N
) ) N
were VBD N
additionally RB N
measured VBN N
in IN N
60 CD p
of IN p
100 CD p
patients NNS p
( ( p
30 CD p
of IN p
whom WP p
were VBD p
smokers NNS p
) ) p
and CC p
in IN p
24 CD p
healthy JJ p
controls NNS p
. . p

Smokers NNS p
( ( p
n JJ p
= NNP p
20 CD p
) ) p
matched VBN p
for IN p
age NN p
, , p
myocardial JJ p
ischemia NN p
, , p
and CC p
other JJ p
risk NN p
factors NNS p
with IN p
20 CD p
nonsmokers NNS p
entered VBD N
a DT N
double-blind JJ N
crossover NN N
trial NN N
of IN N
aspirin NN i
( ( N
300 CD N
mg/d NN N
for IN N
3 CD N
weeks NNS N
) ) N
versus VBP N
placebo NN i
. . i

Blood NNP N
and CC N
urine JJ N
measurements NNS N
were VBD N
repeated VBN N
after IN N
each DT N
treatment NN N
. . N

Compared VBN N
with IN N
nonsmokers NNS N
, , N
smokers NNS N
had VBD N
3-fold JJ o
median JJ o
M-CSF NNP o
( ( N
1499 CD N
vs NN N
476 CD N
pg/mL NN N
) ) N
, , N
2-fold JJ o
CRP NNP o
( ( N
1.5 CD N
vs RB N
0.8 CD N
mg/L NN N
) ) N
, , N
and CC N
higher JJR N
11-dehydro-TXB JJ o
2 CD N
( ( N
3.6 CD N
vs RB N
2.1 CD N
ng/mg JJ N
creatinine NN N
, , N
P NNP N
< NNP N
.01 NNP N
for IN N
all DT N
comparisons NNS N
) ) N
. . N

After IN N
aspirin JJ N
treatment NN N
, , N
M-CSF NNP o
, , o
CRP NNP o
, , o
11-dehydro-TXB JJ o
2 CD o
, , o
and CC o
prothrombin NN o
fragments NNS o
1+2 CD o
remained VBD o
higher JJR o
in IN N
smokers NNS N
compared VBN N
with IN N
nonsmokers NNS N
despite IN N
a DT N
significant JJ N
reduction NN N
of IN N
these DT N
markers NNS N
by IN N
aspirin NN N
( ( N
P NNP N
< NNP N
.05 NNP N
) ) N
. . N

M-CSF NNP N
remained VBD N
related JJ N
to TO N
11-dehydro-TXB JJ N
2 CD N
excretion NN N
during IN N
both DT N
treatment NN N
phases NNS N
( ( N
P NNP N
< NNP N
.01 NNP N
) ) N
suggesting VBG N
that IN N
cytokine-mediated JJ N
thromboxane NN N
A DT N
2 CD N
production NN N
was VBD N
not RB N
altered VBN N
by IN N
aspirin NN N
. . N

CONCLUSIONS NNP N
Smoking NNP N
is VBZ N
associated VBN N
with IN N
increased JJ N
M-CSF NNP N
, , N
CRP NNP N
, , N
and CC N
platelet NN N
activity NN N
. . N

Although IN N
aspirin JJ i
treatment NN N
reduces VBZ N
the DT N
proinflammatory NN N
and CC N
procoagulant JJ N
markers NNS N
in IN N
smokers NNS N
, , N
it PRP N
does VBZ N
not RB N
abolish VB N
the DT N
proinflammatory NN N
effects NNS N
of IN N
smoking NN N
in IN N
patients NNS p
with IN p
chronic JJ p
CAD NNP p
. . p

-DOCSTART- -15968406- O O

Anti-Xa JJ N
effect NN o
of IN N
a DT N
low JJ N
molecular JJ N
weight NN N
heparin NN i
( ( i
dalteparin NN i
) ) i
does VBZ N
not RB N
accumulate VB N
in IN N
extended JJ N
duration NN N
therapy NN N
for IN N
venous JJ p
thromboembolism NN p
in IN p
cancer NN p
patients NNS p
. . p

Many JJ N
patients NNS p
with IN p
venous JJ p
thromboembolism NN p
are VBP N
being VBG N
treated VBN N
with IN N
low JJ N
molecular JJ N
weight NN N
heparin NN N
for IN N
extended JJ N
periods NNS N
of IN N
time NN N
. . N

It PRP N
is VBZ N
not RB N
certain JJ N
if IN N
it PRP N
is VBZ N
necessary JJ N
to TO N
assess VB N
anti-Xa JJ o
levels NNS o
for IN N
extended VBN N
treatment NN N
periods NNS N
. . N

This DT N
study NN N
is VBZ N
a DT N
prospective JJ N
assessment NN N
of IN N
anti-Xa JJ o
levels NNS o
in IN N
patients NNS p
on IN p
long-term JJ p
therapy NN p
for IN p
acute JJ p
venous JJ p
thromboembolism NN p
who WP p
have VBP p
active JJ p
cancer NN p
. . p

Consecutive JJ p
consenting VBG p
patients NNS p
from IN p
one CD p
center NN p
in IN p
a DT p
multicenter NN p
trial NN p
that WDT N
compared VBN N
6 CD N
months NNS N
of IN N
low JJ N
molecular JJ N
weight NN N
heparin NN N
with IN N
oral JJ i
anticoagulant JJ i
therapy NN i
were VBD N
treated VBN N
with IN N
therapeutic JJ N
doses NNS N
of IN N
dalteparin NN N
( ( N
200 CD N
IU NNP N
per IN N
kilogram NN N
) ) N
subcutaneously RB N
daily JJ N
. . N

Anti-Xa JJ o
levels NNS o
were VBD N
assessed VBN N
at IN N
the DT N
end NN N
of IN N
weeks NNS N
1 CD N
and CC N
4,4-6 JJ N
hours NNS N
after IN N
injection NN N
of IN N
dalteparin NN N
. . N

Patients NNS N
were VBD N
followed VBN N
for IN N
bleeding NN o
and CC o
recurrent NN o
venous JJ o
thromboembolism NN o
. . o

There EX N
were VBD N
24 CD p
patients NNS p
who WP p
had VBD p
anti-Xa JJ o
levels NNS o
measured VBN N
at IN N
weeks NNS N
1 CD N
and CC N
4 CD N
. . N

Two CD N
other JJ N
patients NNS N
had VBD N
week NN N
1 CD N
measurements NNS N
performed VBN N
but CC N
died VBD o
before IN N
the DT N
week NN N
4 CD N
sample NN N
was VBD N
collected VBN N
due JJ N
to TO N
their PRP$ N
underlying JJ N
cancer NN N
. . N

The DT N
mean JJ o
anti-Xa JJ o
levels NNS o
at IN N
weeks NNS N
1 CD N
and CC N
4 CD N
were VBD N
1.11 CD N
and CC N
1.03 CD N
anti-Xa JJ N
units/ml NN N
respectively RB N
( ( N
P=0.13 NNP N
) ) N
. . N

These DT N
results NNS N
suggest VBP N
that IN N
for IN N
patients NNS p
with IN p
active JJ i
cancer NN i
receiving VBG i
extended VBN i
duration NN i
therapy NN i
with IN N
low JJ N
molecular JJ N
weight NN N
heparin NN i
( ( i
dalteparin NN i
) ) i
there EX N
is VBZ N
no DT N
accumulation NN o
of IN o
anti-Xa JJ o
effect NN o
over IN N
the DT N
first JJ N
month NN N
of IN N
therapy NN N
. . N

Monitoring NN N
of IN N
anti-Xa JJ o
levels NNS o
in IN N
this DT N
situation NN N
is VBZ N
usually RB N
not RB N
required VBN N
. . N

-DOCSTART- -21576129- O O

Impact NN N
of IN N
dronedarone NN i
on IN N
hospitalization NN o
burden NN o
in IN N
patients NNS p
with IN p
atrial JJ p
fibrillation NN p
: : p
results NNS N
from IN N
the DT N
ATHENA NNP N
study NN N
. . N

AIMS NNP N
Cardiovascular NNP N
( ( N
CV NNP N
) ) N
hospitalization NN N
is VBZ N
a DT N
predictor NN N
of IN N
CV NNP o
mortality NN o
and CC N
has VBZ N
a DT N
negative JJ N
impact NN N
on IN N
patients NNS N
' POS N
quality NN o
of IN o
life NN o
. . o

The DT N
primary JJ N
endpoint NN N
of IN N
A NNP N
placebo-controlled JJ N
, , N
double-blind JJ N
, , N
parallel-arm JJ N
Trial NNP N
to TO N
assess VB N
the DT N
efficacy NN o
of IN N
dronedarone NN i
400 CD N
mg NN N
bid NN N
for IN N
the DT N
prevention NN N
of IN N
cardiovascular JJ o
Hospitalization NNP o
or CC o
death NN o
from IN N
any DT N
cause NN N
in IN N
patiENTs NN p
with IN p
Atrial NNP p
fibrillation/atrial JJ p
flutter NN p
( ( p
ATHENA NNP p
) ) p
, , N
a DT N
composite NN N
of IN N
first JJ N
CV NNP N
hospitalization NN N
or CC N
death NN N
from IN N
any DT N
cause NN N
, , N
was VBD N
significantly RB N
reduced VBN N
by IN N
dronedarone NN i
. . i

This DT N
post NN N
hoc NN N
analysis NN N
evaluated VBD N
the DT N
secondary JJ N
endpoint NN N
of IN N
CV NNP o
hospitalization NN o
and CC N
the DT N
clinical JJ o
benefit NN o
of IN N
dronedarone NN i
on IN N
the DT N
number NN o
and CC o
duration NN o
of IN o
CV NNP o
hospitalizations NNS o
in IN N
patients NNS p
with IN p
atrial JJ p
fibrillation NN p
( ( p
AF NNP p
) ) p
. . p

METHODS NNP N
AND CC N
RESULTS NNP N
ATHENA NNP N
was VBD N
a DT N
double-blind NN N
, , N
parallel JJ N
group NN N
study NN N
in IN N
4628 CD p
patients NNS p
with IN p
a DT p
history NN p
of IN p
paroxysmal/persistent NN p
AF NNP p
and CC p
additional JJ p
risk NN p
factors NNS p
, , N
treated VBN N
with IN N
placebo NN i
or CC i
dronedarone NN i
. . i

Dronedarone NNP i
treatment NN N
significantly RB N
reduced VBD o
the DT o
risk NN o
of IN o
first JJ o
CV NNP o
hospitalization NN o
( ( N
P NNP N
< VBZ N
0.0001 CD N
vs. FW N
placebo NN i
) ) i
, , N
while IN N
the DT N
risk NN N
of IN N
first JJ N
non-CV JJ o
hospitalization NN o
was VBD N
similar JJ N
in IN N
both DT N
groups NNS N
( ( N
P NNP N
= NNP N
0.77 CD N
) ) N
. . N

About IN N
half NN N
of IN N
the DT N
CV NNP o
hospitalizations NNS o
were VBD N
AF-related JJ o
, , N
with IN N
a DT N
median JJ N
duration NN N
of IN N
hospital JJ o
stay NN o
of IN N
four CD N
nights NNS N
. . N

The DT N
risk NN N
of IN N
any DT N
hospitalization NN N
for IN N
AF NNP N
[ NNP N
hazard NN N
ratio NN N
( ( N
95 CD N
% NN N
confidence NN N
interval NN N
) ) N
0.626 CD N
( ( N
0.546-0.719 NN N
) ) N
] NN N
and CC N
duration NN N
of IN N
hospital NN o
stay NN o
were VBD N
significantly RB N
reduced VBN N
by IN N
dronedarone NN i
( ( N
P NNP N
< VBZ N
0.0001 CD N
vs. FW N
placebo NN i
) ) i
. . N

Dronedarone NNP i
treatment NN N
reduced VBD o
total JJ o
hospitalizations NNS o
for IN N
acute JJ N
coronary JJ N
syndrome NN N
( ( N
P NNP N
= NNP N
0.0105 CD N
) ) N
and CC N
the DT N
time NN N
between IN N
the DT N
first JJ o
AF/atrial NNP o
flutter NN o
recurrence NN o
and CC o
CV NNP o
hospitalization/death NN o
( ( N
P NNP N
= NNP N
0.0048 CD N
) ) N
. . N

Hospitalization NNP o
burden NN o
was VBD N
significantly RB N
reduced VBN N
across IN N
all DT N
levels NNS N
of IN N
care NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

Cumulative JJ N
incidence NN N
data NNS N
indicated VBD N
that IN N
the DT N
effects NNS N
of IN N
dronedarone NN i
persisted VBN N
for IN N
at IN N
least JJS N
24 CD N
months NNS N
. . N

CONCLUSION NNP N
Dronedarone NNP i
reduced VBD N
the DT N
risk NN N
for IN N
CV NNP o
hospitalization NN o
and CC N
the DT N
total JJ N
hospitalization NN o
burden NN o
in IN N
this DT N
patient NN N
group NN N
. . N

The DT N
trial NN N
is VBZ N
registered VBN N
under IN N
ClinicalTrials.gov NNP N
# # N
NCT NNP N
00174785 CD N
. . N

-DOCSTART- -23609382- O O

Memantine NNP i
add-on JJ i
to TO i
risperidone VB i
for IN N
treatment NN N
of IN N
negative JJ N
symptoms NNS N
in IN N
patients NNS p
with IN p
stable JJ p
schizophrenia NN p
: : p
randomized VBN N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
study NN N
. . N

We PRP N
aimed VBD N
to TO N
evaluate VB N
the DT N
efficacy NN N
of IN N
memantine JJ i
add-on JJ N
in IN N
the DT N
treatment NN N
of IN N
primary JJ N
negative JJ N
symptoms NNS N
of IN N
patients NNS p
with IN p
stable JJ p
schizophrenia NN p
. . p

In IN N
a DT N
double-blind JJ N
placebo-controlled JJ N
clinical JJ N
trial NN N
, , N
40 CD p
patients NNS p
with IN p
schizophrenia NN p
( ( p
Diagnostic NNP p
and CC p
Statistical NNP p
Manual NNP p
of IN p
Mental NNP p
Disorders NNP p
, , p
Fourth NNP p
Edition NNP p
) ) p
who WP p
were VBD p
stabilized VBN p
on IN p
risperidone NN i
for IN p
a DT p
minimum NN p
of IN p
8 CD p
weeks NNS p
were VBD p
randomized VBN p
to TO p
either DT p
memantine NN i
( ( p
20 CD p
mg NN p
) ) p
or CC p
placebo NN i
in IN p
addition NN p
to TO p
risperidone VB i
, , p
6 CD p
mg/d NN p
, , p
for IN p
eight CD p
weeks NNS p
. . p

Assessment NNP N
was VBD N
done VBN N
using VBG N
the DT N
Positive NNP o
and CC o
Negative NNP o
Syndrome NNP o
Scale NNP o
at IN N
baseline NN N
, , N
week NN N
4 CD N
, , N
and CC N
week NN N
8 CD N
. . N

The DT N
Hamilton NNP o
Depression NNP o
Rating NNP o
Scale NNP o
and CC o
the DT o
Extrapyramidal NNP o
Symptom NNP o
Rating NNP o
Scale NNP o
at IN N
baseline NN N
and CC N
week NN N
8 CD N
were VBD N
used VBN N
to TO N
assess VB N
depression NN N
and CC N
extrapyramidal NN N
symptoms NNS N
, , N
respectively RB N
. . N

All DT p
40 CD p
patients NNS p
had VBD p
at IN p
least JJS p
one CD p
postbaseline NN p
measurement NN p
, , p
and CC p
38 CD p
patients NNS p
completed VBD p
the DT p
trial NN p
. . p

Patients NNS N
in IN N
the DT N
memantine NN N
group NN N
showed VBD N
a DT N
significantly RB o
greater JJR o
improvement NN o
on IN o
negative JJ o
subscale NN o
than IN N
the DT N
placebo NN i
group NN N
at IN N
end NN N
point NN N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

The DT N
same JJ o
effect NN o
was VBD N
observed VBN N
for IN N
the DT N
total JJ o
score NN o
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
and CC N
the DT N
general JJ o
psychopathology NN o
subscale NN o
score NN o
( ( N
P NNP N
= NNP N
0.002 CD N
) ) N
. . N

There EX N
was VBD N
no DT o
significant JJ o
difference NN o
in IN N
reduction NN o
of IN o
positive JJ o
symptoms NNS o
score VBP o
between IN N
the DT N
2 CD N
groups NNS N
( ( N
P NNP N
= NNP N
0.757 CD N
) ) N
. . N

Changes NNS N
in IN N
the DT N
Hamilton NNP o
Depression NNP o
Rating NNP o
Scale NNP o
and CC o
the DT o
Extrapyramidal NNP o
Symptom NNP o
Rating NNP o
Scale NNP o
scores NNS o
and CC o
frequency NN o
of IN o
adverse JJ o
effects NNS o
did VBD o
not RB o
differ VB o
between IN N
the DT N
2 CD N
groups NNS N
. . N

Our PRP$ N
study NN N
showed VBD N
that IN N
memantine NN N
is VBZ N
a DT N
tolerable JJ N
and CC N
efficacious JJ N
add-on JJ N
treatment NN N
for IN N
primary JJ N
negative JJ N
symptoms NNS N
of IN N
schizophrenia NN N
. . N

-DOCSTART- -21822764- O O

Using VBG N
the DT N
transporters NNS i
DVD NNP i
as IN N
a DT N
learning NN i
tool NN i
for IN N
children NNS p
with IN p
Autism NNP p
Spectrum NNP p
Disorders NNP p
( ( p
ASD NNP p
) ) p
. . p

Data NNS N
from IN N
two CD p
groups NNS p
of IN p
children NNS p
who WP N
were VBD N
randomly RB N
allocated VBN N
to TO N
those DT N
groups NNS N
showed VBD N
that IN N
the DT N
ability NN N
of IN N
children NNS p
with IN p
ASD NNP p
to TO N
identify VB o
and CC o
label VB o
basic JJ o
and CC o
complex JJ o
facial JJ o
expressions NNS o
following VBG N
a DT N
3-week JJ N
home NN i
based VBN i
DVD NNP i
intervention NN i
significantly RB N
improved VBN N
when WRB N
viewing VBG N
The DT i
Transporters NNPS i
DVD NNP i
. . i

Improvements NNS N
in IN N
emotion NN o
recognition NN o
appear RB N
related VBN N
to TO N
the DT N
content NN N
of IN N
the DT N
DVD NNP i
as IN N
participants NNS N
in IN N
a DT N
control NN N
group NN N
who WP N
observed VBD N
an DT N
alternate NN i
DVD NNP i
showed VBD N
no DT N
such JJ N
improvement NN N
. . N

Although IN N
social JJ o
behaviour NN o
improved VBD N
significantly RB N
as IN N
a DT N
result NN N
of IN N
watching VBG N
The DT N
Transporters NNPS N
, , N
a DT N
significant JJ N
improvement NN N
in IN N
social JJ o
behaviour NN o
was VBD N
however RB N
, , N
also RB N
observed VBN N
in IN N
the DT N
Thomas NNP N
the DT N
Tank NNP N
Engine NNP N
condition NN N
suggesting VBG N
the DT N
unique JJ N
content NN N
of IN N
The DT N
Transporters NNP i
DVD NNP i
was VBD N
not RB N
pivotal JJ N
to TO N
the DT N
improvement NN N
of IN N
social JJ o
behaviour NN o
in IN N
general JJ N
. . N

-DOCSTART- -23812665- O O

Measuring VBG N
the DT N
plasticity NN N
of IN N
social JJ N
approach NN N
: : N
a DT N
randomized NN N
controlled VBN N
trial NN N
of IN N
the DT N
effects NNS N
of IN N
the DT N
PEERS NNP i
intervention NN i
on IN N
EEG NNP i
asymmetry NN i
in IN N
adolescents NNS p
with IN p
autism NN p
spectrum NN p
disorders NNS p
. . p

This DT N
study NN N
examined VBD N
whether IN N
the DT N
Program NNP i
for IN i
the DT i
Education NNP i
and CC i
Enrichment NNP i
of IN i
Relational NNP i
Skills NNP i
( ( i
PEERS NNS i
: : i
Social NNP N
skills NNS N
for IN N
teenagers NNS p
with IN p
developmental JJ p
and CC p
autism NN p
spectrum NN p
disorders NNS p
: : p
The DT N
PEERS NNP i
treatment NN N
manual NN N
, , N
Routledge NNP N
, , N
New NNP N
York NNP N
, , N
2010a CD N
) ) N
affected VBD N
neural JJ o
function NN o
, , o
via IN o
EEG NNP o
asymmetry NN o
, , N
in IN N
a DT N
randomized NN N
controlled VBN N
trial NN N
of IN N
adolescents NNS p
with IN p
Autism NNP p
spectrum NN p
disorders NNS p
( ( p
ASD NNP p
) ) p
and CC p
a DT p
group NN p
of IN p
typically RB p
developing VBG p
adolescents NNS p
. . p

Adolescents NNS p
with IN p
ASD NNP p
in IN p
PEERS NNP i
shifted VBD N
from IN N
right-hemisphere JJ o
gamma-band NN o
EEG NNP o
asymmetry NN o
before IN N
PEERS NNS N
to TO N
left-hemisphere JJ o
EEG NNP o
asymmetry NN o
after IN N
PEERS NNP N
, , N
versus VBZ N
a DT N
waitlist JJ N
ASD NNP N
group NN N
. . N

Left-hemisphere JJ N
EEG NNP o
asymmetry NN o
was VBD N
associated VBN N
with IN N
more RBR N
social JJ o
contacts NNS o
and CC o
knowledge NN o
, , N
and CC N
fewer JJR N
symptoms NNS o
of IN o
autism NN o
. . o

Adolescents NNS p
with IN p
ASD NNP p
in IN p
PEERS NNP i
no RB N
longer RB N
differed VBN N
from IN N
typically RB N
developing VBG N
adolescents NNS N
in IN N
left-dominant JJ o
EEG NNP o
asymmetry NN o
at IN N
post-test NN N
. . N

These DT N
findings NNS N
are VBP N
discussed VBN N
via IN N
the DT N
Modifier NNP N
Model NNP N
of IN N
Autism NNP N
( ( N
Mundy NNP N
et RB N
al RB N
. . N

in IN N
Res NNP N
Pract NNP N
Persons NNP N
Severe NNP N
Disabl NNP N
32 CD N
( ( N
2 CD N
) ) N
:124 NN N
, , N
2007 CD N
) ) N
, , N
with IN N
emphasis NN N
on IN N
remediating VBG N
isolation/withdrawal NN N
in IN N
ASD NNP N
. . N

-DOCSTART- -18633049- O O

The DT N
effect NN N
of IN N
acupressure NN i
at IN N
the DT N
extra JJ N
1 CD N
point NN N
on IN N
subjective JJ N
and CC N
autonomic JJ o
responses NNS o
to TO N
needle VB N
insertion NN N
. . N

BACKGROUND NNP N
Premedication NNP i
with IN i
sedatives NNS i
can MD N
decrease VB N
the DT N
discomfort NN o
associated VBN N
with IN N
invasive JJ N
anesthetic JJ N
procedures NNS N
. . N

Some DT N
researchers NNS N
have VBP N
shown VBN N
that IN N
acupressure NN N
on IN N
the DT N
acupuncture NN N
extra JJ N
1 CD N
point NN N
is VBZ N
effective JJ N
for IN N
sedation NN N
. . N

We PRP N
investigated VBD N
whether IN N
acupressure NN N
on IN N
the DT N
extra JJ N
1 CD N
point NN N
could MD N
alleviate VB N
the DT N
pain NN o
of IN N
needle JJ N
insertion NN N
. . N

METHODS NNP N
We PRP N
investigated VBD N
the DT N
effect NN N
of IN N
acupressure NN i
at IN N
the DT N
extra JJ N
1 CD N
point NN N
or CC N
a DT N
sham JJ N
point NN N
on IN N
needle JJ N
insertion NN N
using VBG N
verbal JJ o
rating NN o
scale NN o
( ( o
VRS NNP o
) ) o
pain NN o
scores NNS o
and CC N
heart NN o
rate NN o
variability NN o
( ( o
HRV NNP o
) ) o
. . o

Twenty-two NNP p
healthy JJ p
female NN p
volunteers NNS p
were VBD N
randomly RB N
allocated VBN N
to TO N
two CD N
groups NNS N
: : N
the DT N
extra JJ i
1 CD i
group NN i
received VBD N
acupressure NN i
at IN i
the DT i
extra JJ i
1 CD i
point NN i
, , N
and CC N
the DT N
sham NN i
group NN i
received VBD N
acupressure NN i
at IN i
a DT i
sham JJ i
point NN i
. . i

After IN N
starting VBG N
the DT N
electrocardiogram NN i
record NN N
, , N
a DT N
27-gauge JJ N
needle NN N
was VBD N
inserted VBN N
into IN N
the DT N
skin NN N
of IN N
a DT N
forearm NN N
. . N

Thereafter NNP N
, , N
another DT N
needle NN N
was VBD N
inserted VBN N
into IN N
the DT N
skin NN N
of IN N
the DT N
other JJ N
forearm NN N
during IN N
acupressure NN N
. . N

RESULTS JJ N
Acupressure NN i
at IN N
the DT N
extra JJ N
1 CD N
point NN N
significantly RB N
reduced VBD N
the DT N
VRS NNP o
, , N
but CC N
acupressure NN i
at IN N
the DT N
sham NN N
increased VBD N
the DT N
VRS NNP o
. . o

Acupressure NN i
at IN N
the DT N
extra JJ N
1 CD N
significantly RB N
reduced VBD N
the DT N
low JJ o
frequency/high JJ o
frequency NN o
ratio NN o
of IN o
HRV NNP o
responding VBG o
to TO o
needle DT o
insertion NN o
. . o

CONCLUSIONS JJ N
Acupressure NN i
at IN N
the DT N
extra JJ N
1 CD N
point NN N
significantly RB N
reduced VBD N
needle JJ o
insertion NN o
pain NN o
compared VBN N
with IN N
acupressure NN i
at IN N
the DT N
sham NN N
point NN N
. . N

Also RB N
, , N
acupressure NN i
at IN N
the DT N
extra JJ N
1 CD N
point NN N
significantly RB N
reduced VBD N
the DT N
low JJ o
frequency/high JJ o
frequency NN o
ratio NN o
of IN o
HRV NNP o
responding VBG N
to TO N
needle VB N
insertion NN N
, , N
which WDT N
implies VBZ N
a DT N
reduction NN o
in IN N
sympathetic JJ o
nervous JJ o
system NN o
activity NN o
. . o

-DOCSTART- -15689804- O O

Primary JJ i
vitrectomy NN i
for IN N
combined VBN p
rhegmatogenous JJ p
retinal JJ p
detachment NN p
and CC p
choroidal JJ p
detachment NN p
with IN i
or CC i
without IN i
oral JJ i
corticosteroids NNS i
: : i
a DT N
pilot NN N
study NN N
. . N

PURPOSE VB N
The DT N
occurrence NN N
of IN N
choroidal JJ p
detachment NN p
( ( p
CD NN p
) ) p
in IN p
eyes NNS p
with IN p
primary JJ p
rhegmatogenous JJ p
retinal JJ p
detachment NN p
( ( p
RRD NNP p
) ) p
is VBZ N
relatively RB N
uncommon JJ N
( ( N
2 CD N
% NN N
-4.5 NNP N
% NN N
) ) N
. . N

Recent JJ N
reports NNS N
suggest VBP N
that IN N
primary JJ N
vitrectomy NN N
yields NNS N
better RBR N
anatomic JJ N
success NN N
than IN N
scleral JJ N
buckling NN N
. . N

However RB N
, , N
for IN N
these DT N
inflamed JJ p
eyes NNS p
with IN p
low JJ p
intraocular JJ p
pressure NN p
, , N
the DT N
influence NN N
of IN N
preoperative JJ N
oral JJ N
steroids NNS N
on IN N
reattachment NN N
rates NNS N
has VBZ N
not RB N
been VBN N
elucidated VBN N
yet RB N
. . N

METHODS NNP N
Twenty NNP p
eyes NNS p
with IN p
combined JJ p
RRD NNP p
and CC p
CD NNP p
that WDT p
underwent JJ i
primary JJ i
vitrectomy NN i
were VBD N
randomized VBN N
to TO N
receive VB i
oral JJ i
steroids NNS i
( ( i
for IN i
1 CD i
week NN i
) ) i
or CC i
no DT i
oral JJ i
steroids NNS i
before IN i
surgery NN i
. . i

RESULTS NNP N
Preoperative NNP N
clinical JJ N
data NNS N
such JJ N
as IN N
mean JJ N
age NN N
, , N
lens VBZ N
status NN N
, , N
Snellen NNP N
visual JJ N
acuity NN N
, , N
duration NN N
of IN N
macular JJ N
detachment NN N
, , N
CD NNP N
( ( N
size NN N
and CC N
extent NN N
) ) N
, , N
and CC N
retinal JJ N
detachment NN N
characteristics NNS N
( ( N
e.g. NN N
, , N
extent NN N
, , N
number NN N
of IN N
retinal JJ N
breaks NNS N
, , N
atrophic JJ N
or CC N
tractional JJ N
retinal JJ N
break NN N
, , N
size NN N
of IN N
retinal JJ N
break NN N
, , N
and CC N
location NN N
of IN N
retinal JJ N
break NN N
) ) N
were VBD N
similarly RB N
distributed VBN N
in IN N
both DT N
groups NNS N
. . N

Single-operation NNP o
anatomic JJ o
success NN o
was VBD N
81.8 CD N
% NN N
( ( N
9/11 CD N
) ) N
among IN N
those DT N
patients NNS N
who WP N
received VBD N
preoperative JJ N
oral JJ N
steroids NNS i
and CC N
was VBD N
66.7 CD N
% NN N
( ( N
6/9 CD N
) ) N
among IN N
those DT N
who WP N
did VBD N
not RB N
receive VB N
preoperative JJ N
oral JJ N
steroids NNS i
. . i

After IN N
reoperation NN N
, , N
anatomic JJ o
success NN o
was VBD N
100 CD N
% NN N
in IN N
both DT N
groups NNS N
. . N

The DT N
mean JJ N
follow-up NN N
was VBD N
20.1 CD N
months NNS N
. . N

CONCLUSION NNP N
The DT N
results NNS N
suggest VBP N
that IN N
administration NN N
of IN N
oral JJ N
steroids NNS i
before IN N
primary JJ N
vitrectomy NN N
in IN N
eyes NNS N
with IN N
combined JJ p
RRD NNP p
and CC p
CD NNP p
improves VBZ p
reattachment JJ N
rates NNS N
. . N

-DOCSTART- -1359258- O O

Effect NN N
of IN N
enalapril NN i
on IN N
myocardial JJ N
infarction NN N
and CC N
unstable JJ N
angina NN N
in IN N
patients NNS p
with IN p
low JJ p
ejection NN p
fractions NNS p
. . p

An DT N
association NN N
between IN N
raised VBN N
renin NN N
levels NNS N
and CC N
myocardial JJ N
infarction NN N
has VBZ N
been VBN N
reported VBN N
. . N

We PRP N
studied VBD N
the DT N
effects NNS N
of IN N
enalapril NN i
, , N
an DT N
angiotensin-converting JJ N
enzyme NN N
( ( N
ACE NNP N
) ) N
inhibitor NN N
, , N
on IN N
the DT N
development NN N
of IN N
myocardial JJ N
infarction NN N
and CC N
unstable JJ N
angina NN N
in IN N
6797 CD p
patients NNS p
with IN p
ejection NN p
fractions NNS p
< VBP p
or CC p
= VBP p
0.35 CD p
enrolled VBN p
into IN p
the DT p
two CD p
Studies NNS p
of IN p
Left NNP p
Ventricular NNP p
Dysfunction NNP p
( ( p
SOLVD NNP p
) ) p
trials NNS p
. . p

Patients NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
placebo VB i
( ( N
n JJ N
= NN N
3401 CD N
) ) N
or CC N
enalapril $ i
( ( N
n JJ N
= NN N
3396 CD N
) ) N
at IN N
doses NNS N
of IN N
2.5-20 JJ N
mg NNS N
per IN N
day NN N
in IN N
two CD N
concurrent JJ N
double-blind JJ N
trials NNS N
with IN N
the DT N
same JJ N
protocol NN N
. . N

Patients NNS p
with IN p
heart NN p
failure NN p
entered VBD p
the DT p
treatment NN p
trial NN p
( ( p
n JJ p
= NN p
2569 CD p
) ) p
and CC p
those DT p
without IN p
heart NN p
failure NN p
entered VBD p
the DT p
prevention NN p
trial NN p
( ( p
n JJ p
= NN p
4228 CD p
) ) p
. . p

Follow-up NNP N
averaged VBD N
40 CD N
months NNS N
. . N

In IN N
each DT N
trial NN N
there EX N
were VBD N
significant JJ N
reductions NNS N
in IN N
the DT N
number NN N
of IN N
patients NNS N
developing VBG N
myocardial JJ N
infarction NN N
( ( N
treatment NN N
trial NN N
: : N
158 CD N
placebo NN i
vs NN N
127 CD N
enalapril NN i
, , N
p NN N
< VBD N
0.02 CD N
; : N
prevention NN N
trial NN N
: : N
204 CD N
vs NN N
161 CD N
p NN N
< NNP N
0.01 CD N
) ) N
or CC N
unstable JJ N
angina NN N
( ( N
240 CD N
vs RB N
187 CD N
p NN N
< NN N
0.001 CD N
; : N
355 CD N
vs NN N
312 CD N
, , N
p NN N
< NNP N
0.05 CD N
) ) N
. . N

Combined VBN N
, , N
there EX N
were VBD N
362 CD p
placebo NNS i
group NN p
patients NNS N
with IN N
myocardial JJ N
infarction NN N
compared VBN N
with IN N
288 CD N
in IN N
the DT N
enalapril NN i
group NN N
( ( N
risk NN N
reduction NN N
23 CD N
% NN N
, , N
95 CD N
% NN N
CI NNP N
11-34 CD N
% NN N
; : N
p CC N
< VB N
0.001 CD N
) ) N
. . N

595 CD p
placebo NN i
group NN p
patients NNS N
developed VBD N
unstable JJ o
angina NNS o
compared VBN N
with IN N
499 CD N
in IN N
the DT N
enalapril NN i
group NN N
( ( N
risk NN N
reduction NN N
20 CD N
% NN N
, , N
95 CD N
% NN N
CI NNP N
9-29 CD N
% NN N
, , N
p NN N
< NNP N
0.001 CD N
) ) N
. . N

There EX N
was VBD N
also RB N
a DT N
reduction NN o
in IN o
cardiac JJ o
deaths NNS o
( ( N
711 CD N
placebo NN i
, , N
615 CD N
enalapril NN i
; : i
p CC N
< VB N
0.003 CD N
) ) N
, , N
so RB N
that IN N
the DT N
reduction NN N
in IN N
the DT N
combined JJ o
endpoint NN o
of IN o
deaths NNS o
, , o
myocardial JJ o
infarction NN o
, , o
and CC o
unstable JJ o
angina NN o
was VBD N
highly RB N
significant JJ N
( ( N
20 CD N
% NN N
risk NN N
reduction NN N
, , N
95 CD N
% NN N
CI NNP N
14-26 CD N
% NN N
; : N
p CC N
< VB N
0.0001 CD N
) ) N
. . N

Enalapril NNP i
treatment NN N
significantly RB N
reduced VBN N
myocardial JJ o
infarction NN o
, , o
unstable JJ o
angina NN o
, , o
and CC o
cardiac JJ o
mortality NN o
in IN N
patients NNS p
with IN p
low JJ p
ejection NN p
fractions NNS p
. . p

-DOCSTART- -24225126- O O

Etomidate NN i
with IN i
or CC i
without IN i
flumazenil JJ i
anesthesia NN i
for IN N
stem NN N
cell NN N
transplantation NN N
in IN N
autistic JJ p
children NNS p
. . p

BACKGROUND IN N
The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
investigate VB N
etomidate JJ i
administration NN i
with IN i
or CC i
without IN i
flumazenil NNS i
in IN N
autistic JJ p
children NNS p
who WP p
underwent VBP p
intrathecal JJ p
transplantation NN p
of IN p
stem NN p
cells NNS p
by IN p
lumbar NN p
puncture NN p
. . p

METHODS NNP N
Forty NNP p
autistic JJ p
children NNS p
aged VBN p
2-12 CD p
, , p
who WP p
were VBD p
scheduled VBN p
for IN p
stem NN p
cell NN p
transplantation NN p
via IN p
lumbar NN p
puncture NN p
under IN p
anesthesia NN p
, , N
were VBD N
randomized VBN N
for IN N
a DT N
double-blind JJ N
study NN N
. . N

The DT N
children NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
two CD N
groups NNS N
: : N
the DT i
flumazenil NN i
group NN i
( ( N
group NN N
F NNP N
, , N
n=20 NN N
) ) N
and CC N
the DT i
etomidate NN i
group NN i
( ( N
group NN N
E NNP N
, , N
n=20 NN N
) ) N
. . N

All DT N
children NNS N
received VBD N
0.2 CD N
mg/kg NN N
of IN N
etomidate NN i
. . i

In IN N
the DT N
case NN N
of IN N
inadequate JJ N
anesthesia NN N
, , N
patients NNS N
received VBD N
repeated JJ N
doses NNS N
of IN N
0.1 CD N
mg/kg NN N
of IN N
etomidate NN i
until IN N
reaching VBG N
deep JJ N
sedation NN N
. . N

After IN N
operation NN N
, , N
children NNS N
in IN N
group NN N
F NNP N
were VBD N
given VBN N
flumazenil NNS i
( ( N
0.01 CD N
mg/kg NN N
) ) N
and CC N
children NNS N
in IN N
group NN N
E NNP N
received VBD N
placebo NN i
. . i

Heart NNP o
rate NN o
( ( o
HR NNP o
) ) o
, , o
mean JJ o
arterial JJ o
pressure NN o
, , o
oxygen NN o
saturation NN o
, , o
respiratory NN o
rate NN o
, , o
the DT o
Ramsay NNP o
sedation NN o
score NN o
( ( o
RSS NNP o
) ) o
, , o
and CC o
recovery NN o
time NN o
of IN N
all DT N
children NNS N
were VBD N
continuously RB N
monitored VBN N
and CC N
recorded VBN N
during IN N
the DT N
entire JJ N
procedure NN N
. . N

RESULTS NNP N
After IN N
anesthesia NN N
, , N
blood NN o
pressure NN o
and CC o
HR NNP o
measurements NNS o
were VBD N
not RB N
significantly RB N
changed VBN N
in IN N
both DT N
groups NNS N
compared VBN N
with IN N
the DT N
baseline NN N
. . N

There EX N
were VBD N
no DT N
respiratory JJ o
depression NN o
, , o
bradycardia NN o
, , o
hypotension NN o
, , o
nausea NN o
, , o
and CC o
vomiting VBG o
. . o

Five CD N
patients NNS N
complained VBN N
of IN N
pain NN o
on IN o
the DT o
site NN o
of IN o
injection NN o
. . o

Myoclonus NNP o
occurred VBD N
in IN N
seven CD N
patients NNS N
. . N

Recovery JJ o
time NN o
in IN N
group NN N
F NNP N
was VBD N
significantly RB N
shorter JJR N
than IN N
in IN N
group NN N
E NNP N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
, , N
and CC N
after IN N
the DT N
injection NN N
of IN N
flumazenil NN i
, , N
RSS NNP o
in IN N
group NN N
F NNP N
significantly RB N
decreased VBD N
than IN N
in IN N
group NN N
E. NNP N
There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
operation NN o
time NN o
. . o

Physician JJ o
satisfaction NN o
in IN N
both DT N
groups NNS N
was VBD N
similar JJ N
. . N

CONCLUSIONS NNP N
Etomidate NNP i
resulted VBD N
in IN N
stable JJ N
hemodynamic JJ o
responses NNS o
and CC N
relatively RB N
less JJ N
adverse JJ o
effects NNS o
, , N
and CC N
flumazenil RB i
antagonized VBD N
the DT N
anesthetic JJ o
effect NN o
of IN N
etomidate NN N
; : N
thus RB N
, , N
etomidate NN N
with IN N
flumazenil NN N
is VBZ N
suitable JJ N
for IN N
performing VBG N
stem NN N
cell NN N
transplantation NN N
in IN N
autistic JJ p
children NNS p
. . p

-DOCSTART- -25424398- O O

A DT N
randomized VBN N
controlled JJ N
trial NN N
of IN N
cognitive-behavioral JJ i
therapy NN i
versus NN i
treatment NN i
as IN i
usual JJ i
for IN N
adolescents NNS p
with IN p
autism NN o
spectrum NN o
disorders NNS o
and CC o
comorbid NN o
anxiety NN o
. . o

OBJECTIVE NNP N
Examine NNP N
the DT N
efficacy NN o
of IN N
a DT N
personalized JJ i
, , i
modular JJ i
cognitive-behavioral JJ i
therapy NN i
( ( i
CBT NNP i
) ) i
protocol NN i
among IN N
early JJ p
adolescents NNS p
with IN p
high-functioning JJ p
autism NN p
spectrum NN p
disorders NNS p
( ( p
ASDs NNP p
) ) p
and CC p
co-occurring JJ p
anxiety NN p
relative NN N
to TO N
treatment NN i
as IN i
usual JJ i
( ( i
TAU NNP i
) ) i
. . i

METHOD NNP N
Thirty-one CD p
children NNS p
( ( p
11-16 CD p
years NNS p
) ) p
with IN p
ASD NNP p
and CC p
clinically RB p
significant JJ p
anxiety NN p
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
16 CD N
weekly JJ N
CBT NNP i
sessions NNS i
or CC i
an DT i
equivalent JJ i
duration NN i
of IN i
TAU NNP i
. . i

Participants NNS N
were VBD N
assessed VBN N
by IN N
blinded JJ N
raters NNS N
at IN N
screening NN N
, , N
posttreatment NN N
, , N
and CC N
1-month JJ N
follow-up NN N
. . N

RESULTS NNP N
Youth NNP N
randomized VBD N
to TO N
CBT NNP i
demonstrated VBD N
superior JJ o
improvement NN o
across IN N
primary JJ o
outcomes NNS o
relative VBP N
to TO N
those DT N
receiving VBG N
TAU NNP i
. . i

Eleven NNP N
of IN N
16 CD N
adolescents NNS N
randomized VBN N
to TO N
CBT NNP i
were VBD N
treatment NN N
responders NNS N
, , N
versus VBP N
4 CD N
of IN N
15 CD N
in IN N
the DT N
TAU NNP i
condition NN N
. . N

Gains NNS o
were VBD N
maintained VBN N
at IN N
1-month JJ N
follow-up NN N
for IN N
CBT NNP N
responders NNS N
. . N

CONCLUSIONS NNP N
These DT N
data NNS N
extend VBP N
findings NNS N
of IN N
the DT N
promising JJ o
effects NNS o
of IN N
CBT NNP i
in IN N
anxious JJ p
youth NN p
with IN p
ASD NNP p
to TO p
early JJ p
adolescents NNS p
. . p

-DOCSTART- -8882257- O O

Injection NN o
pain NN o
with IN N
propofol NN i
. . i

Reduction NN N
with IN N
aspiration NN N
of IN N
blood NN N
. . N

A DT N
randomised JJ N
, , N
controlled VBN N
, , N
single-blind NN N
study NN N
was VBD N
performed VBN N
on IN N
100 CD p
patients NNS p
to TO N
investigate VB N
a DT N
new JJ N
method NN N
of IN N
reducing VBG N
pain NN o
on IN N
propofol NN i
injection NN N
. . N

Aspiration NNP N
of IN N
2 CD N
ml NN N
of IN N
the DT N
patient NN N
's POS N
blood NN N
into IN N
a DT N
syringe NN N
of IN N
propofol NN i
immediately RB N
before IN N
injection NN N
was VBD N
compared VBN N
with IN N
the DT N
addition NN N
of IN N
lignocaine NN i
20 CD i
mg NN i
or CC i
normal JJ i
saline JJ i
2 CD i
ml NN i
to TO i
the DT i
propofol NN i
before IN i
injection NN i
. . i

The DT N
addition NN N
of IN N
blood NN N
was VBD N
significantly RB N
more RBR N
effective JJ N
in IN N
reducing VBG o
pain NN o
on IN o
injection NN o
than IN N
the DT N
addition NN N
of IN N
saline NN N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
, , N
but CC N
was VBD N
not RB N
significantly RB N
more RBR N
effective JJ o
than IN N
the DT N
addition NN N
of IN N
lignocaine NN N
. . N

-DOCSTART- -8435259- O O

Neostigmine NNP i
and CC N
edrophonium JJ i
antagonism NN N
of IN N
moderate JJ N
neuromuscular JJ N
block NN N
induced VBN N
by IN N
pancuronium NN N
or CC N
tubocurarine NN N
. . N

Edrophonium NN i
and CC i
neostigmine NN i
are VBP N
anticholinesterase JJ N
drugs NNS N
used VBN N
commonly RB N
to TO N
antagonize VB N
competitive JJ N
neuromuscular JJ o
block NN o
. . o

Although IN N
it PRP N
has VBZ N
a DT N
faster RBR N
onset NN N
of IN N
action NN N
than IN N
neostigmine NN i
, , i
edrophonium NN i
is VBZ N
unreliable JJ N
when WRB N
used VBN N
to TO N
antagonize VB N
deep JJ N
neuromuscular JJ o
block NN o
. . o

We PRP N
have VBP N
compared VBN N
the DT N
antagonist NN o
characteristics NNS o
of IN N
these DT N
two CD N
drugs NNS N
when WRB N
used VBN N
to TO N
antagonize VB N
a DT N
moderate JJ N
degree NN N
of IN N
pancuronium- NN N
or CC N
tubocurarine-induced JJ N
neuromuscular JJ N
block NN N
. . N

Forty NNP p
ASA NNP p
I PRP p
or CC p
II NNP p
patients NNS p
undergoing VBG p
surgical JJ p
procedures NNS p
were VBD N
allocated VBN i
randomly RB i
to TO i
receive VB i
either DT i
pancuronium NN i
70 CD i
micrograms JJ i
kg-1 NN i
or CC i
tubocurarine VB i
0.5 CD i
mg JJ i
kg-1 NN i
, , i
and CC i
to TO i
receive VB i
either DT i
edrophonium NN i
0.5 CD i
mg JJ i
kg-1 NN i
or CC i
neostigmine JJ i
0.05 CD i
mg JJ i
kg-1 NN i
. . i

Antagonism NNP N
was VBD N
attempted VBN N
when WRB N
the DT N
first JJ N
response NN N
to TO N
train-of-four NN N
( ( N
TOF NNP N
) ) N
stimulation NN N
recovered VBD N
spontaneously RB N
to TO N
25 CD N
% NN N
of IN N
the DT N
control NN N
height NN N
. . N

Neuromuscular JJ o
function NN o
was VBD N
monitored VBN N
using VBG N
the DT N
evoked VBN o
integrated JJ o
electromyogram NN o
of IN N
the DT N
first JJ N
dorsal NN N
interosseous JJ N
muscle NN N
of IN N
the DT N
hand NN N
. . N

Adequate JJ N
recovery NN N
was VBD N
defined VBN N
as IN N
the DT N
achievement NN N
of IN N
a DT N
TOF NNP N
ratio NN N
of IN N
0.70 CD N
or CC N
greater JJR N
. . N

Only RB N
seven CD N
of IN N
20 CD p
patients NNS p
who WP p
received VBD p
edrophonium NN p
demonstrated VBD N
adequate JJ N
recovery NN N
30 CD N
min NN N
after IN N
antagonism NN N
. . N

Under IN N
the DT N
conditions NNS N
described VBN N
in IN N
this DT N
study NN N
, , N
edrophonium NN N
0.5 CD N
mg NN N
kg-1 NN N
was VBD N
less RBR N
effective JJ N
as IN N
an DT N
antagonist NN N
than IN N
neostigmine JJ N
0.05 CD N
mg JJ N
kg-1 NN N
. . N

-DOCSTART- -20434046- O O

Beneficial JJ N
effect NN N
of IN N
etidronate NN i
therapy NN i
in IN N
chronically RB p
hospitalized VBN p
, , p
disabled JJ p
patients NNS p
with IN p
stroke NN p
. . p

Incidence NN N
of IN N
hip NN N
fractures NNS N
is VBZ N
high JJ N
in IN N
chronically RB p
hospitalized VBN p
, , p
disabled VBD p
, , p
elderly JJ p
patients NNS p
after IN p
stroke NN p
. . p

Duration NN p
of IN p
hospitalization NN p
was VBD p
more JJR p
than IN p
1 CD p
year NN p
because IN p
of IN p
insufficiency NN p
of IN p
nursing NN p
homes NNS p
. . p

Our PRP$ N
study NN N
showed VBD N
that IN N
immobilization-induced JJ N
hypercalcemia NN N
and CC N
25-hydroxyvitamin JJ N
D NNP N
deficiency NN N
contribute NN N
to TO N
reduced VB N
bone JJ N
mineral JJ N
density NN N
( ( N
BMD NNP N
) ) N
. . N

This DT N
study NN N
was VBD N
designed VBN N
to TO N
address VB N
the DT N
possibility NN N
that WDT N
treatment NN N
with IN N
etidronate NN i
may MD N
reduce VB N
the DT N
bone NN N
resorption NN N
and CC N
lower JJR N
the DT N
incidence NN N
of IN N
fractures NNS N
in IN N
elderly JJ p
patients NNS p
who WP p
are VBP p
chronically RB p
hospitalized VBN p
and CC p
disabled VBN p
as IN p
a DT p
result NN p
of IN p
hemiparesis NN p
after IN p
stroke NN p
. . p

Patients NNS p
with IN p
stroke NN p
were VBD N
randomly RB N
assigned VBN N
to TO N
daily VB N
treatment NN N
with IN N
400 CD N
mg NNS N
of IN N
etidronate NN i
( ( N
n JJ N
= NNP N
40 CD N
) ) N
or CC N
a DT N
placebo NN i
( ( N
n JJ N
= NNP N
40 CD N
) ) N
, , N
and CC N
followed VBD N
up RB N
for IN N
2 CD N
years NNS N
. . N

At IN N
baseline NN N
, , N
both DT N
groups NNS N
had VBD N
low JJ N
BMD NNP o
with IN N
high JJ o
levels NNS o
of IN o
serum NN o
ionized VBN o
calcium NN o
and CC o
urinary JJ o
deoxypyridinoline NN o
. . o

In IN N
the DT N
etidronate NN i
group NN N
, , N
serum NN o
calcium NN o
and CC o
urinary JJ o
deoxypyridinoline NN o
levels NNS o
decreased VBN N
significantly RB N
during IN N
the DT N
study NN N
period NN N
, , N
whereas IN N
the DT N
levels NNS N
in IN N
the DT N
placebo NN i
group NN N
were VBD N
increased VBN N
. . N

BMD NNP o
on IN o
the DT o
hemiplegic JJ o
side NN o
increased VBN N
by IN N
1.4 CD N
% NN N
in IN N
the DT N
etidronate NN N
group NN N
and CC N
decreased VBN N
by IN N
2.2 CD N
% NN N
in IN N
the DT N
placebo NN N
group NN N
( ( N
P NNP N
< NNP N
.001 NNP N
) ) N
. . N

Two CD N
patients NNS N
sustained VBD N
hip JJ o
fractures NNS o
in IN N
the DT N
placebo NN i
group NN N
, , N
and CC N
no DT N
hip NN o
fracture NN o
occurred VBD N
in IN N
the DT N
etidronate NN i
group NN N
. . N

Treatment NN N
with IN N
etidronate NN i
increases NNS N
BMD NNP o
in IN N
chronically RB p
hospitalized VBN p
patients NNS p
poststroke VBD p
, , N
and CC N
may MD N
prevent VB N
hip NN N
fracture NN N
. . N

-DOCSTART- -1941391- O O

Randomized VBN N
, , N
double-blind JJ N
, , N
multicenter NN N
, , N
controlled VBD N
trial NN N
of IN N
ibuprofen JJ i
versus NN i
acetaminophen NN i
( ( i
paracetamol NN i
) ) i
and CC i
placebo NN i
for IN N
treatment NN p
of IN p
symptoms NNS o
of IN o
tonsillitis NN o
and CC o
pharyngitis NN o
in IN p
children NNS p
. . p

-DOCSTART- -1302807- O O

Shorter NNP N
treatment NN N
for IN N
vaginal JJ p
candidosis NN p
: : p
comparison NN N
between IN N
single-dose JJ N
oral JJ N
fluconazole NN i
and CC N
three-day JJ N
treatment NN N
with IN N
local JJ N
miconazole NN i
. . i

Fluconazole NNP i
is VBZ N
an DT N
effective JJ N
, , N
simple JJ N
and CC N
safe JJ N
, , N
although IN N
slightly RB N
expensive JJ N
, , N
agent NN N
for IN N
the DT N
treatment NN N
of IN N
vaginal JJ p
candidosis NN p
. . p

Single-dose JJ i
fluconazole NN i
( ( i
150 CD i
mg NN i
) ) i
administered VBD i
orally RB i
in IN i
capsule NN i
form NN i
was VBD i
compared VBN i
with IN i
three-day JJ i
local JJ i
treatment NN i
with IN i
miconazole JJ i
pessaries NNS i
in IN i
the DT i
treatment NN i
of IN i
vaginal JJ i
candidosis NN i
in IN i
a DT i
randomized JJ i
study NN i
in IN i
Finland NNP i
. . i

Cure NN o
rates NNS o
were VBD N
good JJ N
( ( N
> JJ N
80 CD N
% NN N
) ) N
in IN N
randomized VBN N
patient NN N
groups NNS N
assessed VBD N
both DT N
clinically RB N
and CC N
by IN N
the DT N
results NNS N
of IN N
yeast JJ N
cultures NNS N
. . N

Oral JJ N
administration NN N
was VBD N
preferred VBN N
to TO N
local JJ N
therapy NN N
by IN N
patients NNS N
in IN N
both DT N
the DT N
miconazole NN i
and CC N
fluconazole JJ i
groups NNS N
. . N

For IN N
the DT N
time NN N
being VBG N
, , N
fluconazole NN i
is VBZ N
not RB N
recommended VBN N
for IN N
use NN N
during IN N
pregnancy NN N
or CC N
lactation NN N
. . N

-DOCSTART- -16199793- O O

Family RB i
education NN i
for IN N
people NNS p
with IN p
schizophrenia NN p
in IN p
Beijing NNP p
, , p
China NNP p
: : p
randomised VBD N
controlled JJ N
trial NN N
. . N

BACKGROUND NNP N
Much NNP N
of IN N
China NNP N
lacks VBZ N
well-developed JJ N
services NNS N
for IN N
people NNS p
with IN p
schizophrenia NN p
and CC p
their PRP$ p
families NNS p
, , N
and CC N
most JJS N
of IN N
the DT N
existing VBG N
services NNS N
focus NN N
on IN N
hospitals NNS N
. . N

There EX N
is VBZ N
a DT N
need NN N
for IN N
culturally RB N
sensitive JJ N
family NN i
treatments NNS i
offered VBN N
by IN N
nurses NNS N
. . N

AIMS NNP N
To TO N
conduct VB N
a DT N
longitudinal JJ N
experimental NN N
study NN N
examining VBG N
the DT N
effect NN N
of IN N
patient NN i
and CC i
family NN i
education NN i
in IN N
a DT N
sample NN p
of IN p
Chinese JJ p
people NNS p
with IN p
schizophrenia NN p
. . p

METHOD NNP N
A NNP N
randomised VBD N
controlled VBN N
trial NN N
was VBD N
conducted VBN N
in IN N
a DT N
large JJ N
hospital NN N
with IN N
a DT N
was VBD N
conducted VBN N
in IN N
a DT N
large JJ p
hospital NN p
with IN p
a DT p
sample NN p
of IN p
101 CD p
patients NNS p
with IN p
schizophrenia NN p
and CC p
their PRP$ p
families NNS p
. . p

Data NNS N
were VBD N
collected VBN N
at IN N
admission NN N
and CC N
at IN N
discharge NN N
, , N
and CC N
then RB N
at IN N
3 CD N
and CC N
9 CD N
months NNS N
after IN N
discharge NN N
. . N

The DT N
intervention NN N
group NN N
received VBD N
family NN i
education NN i
, , N
and CC N
data NNS N
on IN N
their PRP$ N
knowledge NN o
about IN o
schizophrenia NN o
, , o
symptoms NNS o
, , o
functioning VBG o
, , o
psychosocial JJ o
behaviour NN o
, , o
relapse NN o
and CC o
medication NN o
adherence NN o
were VBD N
collected VBN N
and CC N
compared VBN N
with IN N
the DT N
control NN i
group NN i
. . i

RESULTS NNP N
There EX N
was VBD N
a DT N
significant JJ o
improvement NN o
in IN o
knowledge NN o
about IN o
schizophrenia NN o
in IN N
the DT N
experimental JJ N
group NN N
and CC N
a DT N
significant JJ o
difference NN o
in IN o
symptom JJ o
scores NNS o
and CC o
functioning VBG o
at IN N
9 CD N
months NNS N
after IN N
discharge NN N
. . N

Patients NNS N
who WP N
were VBD N
nonadherent JJ N
to TO N
medication NN N
regimens NNS N
were VBD N
more RBR N
likely JJ N
to TO N
relapse VB o
. . o

CONCLUSIONS NNP N
Family NNP i
education NN i
on IN N
schizophrenia NN N
by IN N
nurses NNS N
in IN N
China NNP N
was VBD N
effective JJ N
in IN N
improving VBG N
knowledge NN N
and CC N
promoting VBG N
improvement NN N
in IN N
patients NNS N
' POS N
symptoms NNS N
. . N

-DOCSTART- -1884668- O O

Levels NNS N
of IN N
opioid JJ p
physical JJ p
dependence NN p
in IN p
heroin NN p
addicts NNS p
. . p

The DT N
levels NNS N
of IN N
opioid JJ N
physical JJ N
dependence NN N
in IN N
a DT N
group NN N
of IN N
long-term JJ p
heroin NN p
addicts NNS p
were VBD N
ascertained VBN N
by IN N
measuring VBG N
the DT N
severity NN N
of IN N
the DT N
opioid JJ o
withdrawal NN o
syndrome NN o
before IN N
and CC N
after IN N
pharmacological JJ N
challenge NN N
with IN N
either DT N
0.4 CD N
mg NN N
naloxone NN i
or CC N
placebo NN i
. . i

Prior NNP N
to TO N
challenge VB N
, , N
patients NNS N
manifested VBD N
some DT N
subjective JJ o
symptoms NNS o
but CC N
few JJ N
objective JJ N
signs NNS N
of IN N
opioid JJ N
withdrawal NN N
. . N

Patients NNS p
who WP p
received VBD p
placebo NN i
( ( p
n JJ p
= NNP p
18 CD p
) ) p
showed VBD N
a DT N
significant JJ N
increase NN N
in IN N
the DT N
mean NN N
score NN N
on IN N
one CD N
of IN N
three CD N
rating NN N
scales NNS N
used VBN N
to TO N
assess VB N
opioid JJ N
withdrawal NN N
. . N

Patients NNS p
who WP p
received VBD p
naloxone NN i
( ( p
n JJ p
= NNP p
58 CD p
) ) p
showed VBD N
significant JJ N
increases NNS N
in IN N
mean JJ N
scores NNS N
on IN N
all DT N
three CD N
rating NN N
scales NNS N
, , N
but CC N
this DT N
was VBD N
due JJ N
primarily RB N
to TO N
increases NNS N
observed VBN N
in IN N
a DT N
minority NN N
of IN N
patients NNS N
. . N

Sixty-one CD N
percent NN N
of IN N
patients NNS N
failed VBD N
to TO N
manifest VB N
clinically RB N
significant JJ N
changes NNS N
in IN N
subjective NN o
symptoms NNS o
, , N
and CC N
74 CD N
% NN N
of IN N
patients NNS N
failed VBD N
to TO N
manifest VB N
clinically RB N
significant JJ N
changes NNS N
in IN N
objective JJ o
signs NNS o
of IN o
opioid JJ o
withdrawal NN o
following VBG N
naloxone JJ i
administration NN N
. . N

The DT N
results NNS N
suggest VBP N
that IN N
a DT N
substantial JJ N
subgroup NN N
of IN N
heroin NN N
addicts NNS N
are VBP N
able JJ N
to TO N
use VB N
opioids NNS N
regularly RB N
while IN N
maintaining VBG N
relatively RB N
low JJ N
levels NNS N
of IN N
physical JJ N
dependence NN N
. . N

-DOCSTART- -7896655- O O

Naltrexone NN i
in IN N
young JJ p
autistic JJ p
children NNS p
: : p
a DT N
double-blind NN N
, , N
placebo-controlled JJ i
crossover NN N
study NN N
. . N

OBJECTIVE NNP N
This DT N
study NN N
evaluated VBD N
the DT N
efficacy NN o
and CC o
safety NN o
of IN N
naltrexone NN i
, , N
an DT N
opiate NN N
blocker NN N
, , N
in IN N
the DT N
treatment NN N
of IN N
autism NN p
. . p

METHOD NNP N
Thirteen NNP p
children NNS p
with IN p
autistic JJ p
disorder NN p
, , p
aged VBD p
3.4 CD p
to TO p
8.3 CD p
years NNS p
( ( p
mean VB p
5.4 CD p
) ) p
, , p
were VBD p
studied VBN p
in IN p
home NN p
, , p
school NN p
, , p
and CC p
outpatient JJ p
laboratory NN p
. . p

Naltrexone NNP i
, , i
1.0 CD i
mg/kg NN i
, , i
was VBD i
given VBN i
daily RB i
in IN i
a DT i
randomized JJ i
, , i
double-blind JJ i
, , i
placebo-controlled JJ i
crossover NN i
design NN i
. . i

Dependent JJ i
measures NNS i
included VBD i
parent NN i
and CC i
teacher RB i
Clinical JJ o
Global NNP o
Impressions NNP o
( ( o
CGI NNP o
) ) o
, , o
Conners NNPS o
Rating NNP o
Scales NNP o
, , o
and CC o
Naltrexone NNP o
Side-Effects NNP o
( ( o
SE NNP o
) ) o
Rating NNP o
Scale NNP o
; : o
laboratory NN o
CGI NNP o
, , o
movement NN o
actometer NN o
readings NNS o
, , o
and CC o
a DT o
10-second JJ o
interval NN o
recording VBG o
system NN o
analysis NN o
of IN o
on-task NN o
, , o
communication NN o
initiations NNS o
, , o
disruptive JJ o
behavior NN o
, , o
and CC o
self-stimulation NN o
. . o

RESULTS NNP N
Eight NNP N
of IN N
13 CD N
subjects NNS N
improved VBN N
in IN N
two CD N
or CC N
more JJR N
settings NNS N
. . N

Changes NNS N
in IN N
parent NN o
measures NNS o
( ( o
CGI NNP o
, , o
Conners NNP o
Impulsivity-Hyperactivity NNP o
Factor NNP o
, , o
and CC o
SE-Restlessness NNP o
) ) o
and CC o
Teacher NNP o
CGI NNP o
achieved VBD N
statistical JJ N
significance NN N
. . N

Teacher CC o
SE-Restlessness JJ o
and CC o
initiation NN o
of IN o
communication NN o
in IN N
the DT N
clinic NN N
showed VBD N
a DT N
trend NN N
toward IN N
improvement NN N
. . N

Actometer NNP o
readings NNS o
improved VBN N
in IN N
two CD N
children NNS N
who WP N
were VBD N
very RB N
active JJ N
at IN N
baseline NN N
. . N

Adverse JJ o
side NN o
effects NNS o
were VBD N
behavioral JJ N
, , N
mild JJ N
, , N
and CC N
transient NN N
. . N

Administering VBG N
the DT N
bitter JJ N
tablet NN N
was VBD N
a DT N
challenge NN N
. . N

CONCLUSIONS NNP N
Naltrexone NNP i
offers VBZ N
promise RB N
as IN N
an DT N
agent NN N
for IN N
modest JJ N
improvement NN N
of IN N
behavior NN o
and CC N
social JJ o
communication NN o
in IN N
young JJ p
children NNS p
with IN p
autism NN p
. . p

Parent NN N
and CC N
teacher NN N
measures NNS N
can MD N
be VB N
useful JJ N
in IN N
outpatient JJ N
trials NNS N
to TO N
evaluate VB N
change NN N
. . N

-DOCSTART- -16794504- O O

POG JJ N
8625 CD N
: : N
a DT N
randomized JJ N
trial NN N
comparing VBG N
chemotherapy NN i
with IN N
chemoradiotherapy NN i
for IN p
children NNS p
and CC p
adolescents NNS p
with IN p
Stages NNP p
I PRP p
, , p
IIA NNP p
, , p
IIIA1 NNP p
Hodgkin NNP p
Disease NNP p
: : p
a DT N
report NN N
from IN N
the DT N
Children NNP N
's POS N
Oncology NNP N
Group NNP N
. . N

To TO N
determine VB N
if IN N
6 CD N
courses NNS N
of IN N
chemotherapy NN i
alone RB N
could MD N
achieve VB N
the DT N
same JJ N
or CC N
better JJR N
outcome NN N
than IN N
4 CD N
courses NNS N
of IN N
chemotherapy NN i
followed VBN i
by IN i
radiation NN i
therapy NN i
( ( i
chemoradiotherapy NN i
) ) i
in IN N
pediatric JJ p
and CC p
adolescent JJ p
patients NNS p
with IN p
Hodgkin NNP p
disease NN p
. . p

Children NNP p
< VBD p
or CC p
=21 CD p
years NNS p
old JJ p
with IN p
biopsy-proven JJ p
, , p
pathologically RB p
staged VBD p
I PRP p
, , p
IIA NNP p
, , p
or CC p
IIIA1 NNP p
Hodgkin NNP p
disease NN p
were VBD N
randomly RB N
assigned VBN N
6 CD N
courses NNS N
of IN N
alternating VBG i
nitrogen JJ i
mustard NN i
, , i
oncovin NN i
, , i
prednisone NN i
, , i
and CC i
procarbazine/doxorubicin NN i
, , i
bleomycin NN i
, , i
vinblastine NN i
, , i
and CC i
dacarbazine NN i
( ( i
treatment NN i
1 CD i
) ) i
or CC N
4 CD i
courses NNS i
of IN i
alternating VBG i
nitrogen JJ i
mustard NN i
, , i
oncovin NN i
, , i
prednisone NN i
, , i
and CC i
procarbazine/doxorubicin NN i
, , i
bleomycin NN i
, , i
vinblastine NN i
, , i
and CC i
dacarbazine VB i
+2550 JJ i
cGy JJ i
involved-field JJ i
radiotherapy NN i
( ( i
treatment NN i
2 CD i
) ) i
. . i

The DT N
complete JJ N
response NN N
rate NN N
was VBD N
89 CD N
% NN N
, , N
with IN N
a DT N
complete JJ N
response NN N
and CC N
partial JJ N
response NN N
rate NN N
of IN N
99.4 CD N
% NN N
. . N

There EX N
was VBD N
no DT N
statistically RB N
significant JJ N
difference NN N
in IN N
event-free JJ o
survival NN o
( ( o
EFS NNP o
) ) o
or CC o
overall JJ o
survival NN o
between IN N
arms NNS N
. . N

The DT N
EFS NNP o
for IN N
those DT N
who WP N
achieved VBD N
an DT N
early JJ N
complete JJ o
response NN o
was VBD N
significantly RB N
higher JJR N
than IN N
for IN N
those DT N
who WP N
did VBD N
not RB N
. . N

For IN N
pediatric JJ p
patients NNS p
with IN p
asymptomatic JJ p
low-stage NN p
and CC p
intermediate-stage NN p
Hodgkin NNP p
disease NN p
, , N
chemotherapy NN i
and CC N
chemoradiotherapy VB i
both DT N
resulted VBN N
in IN N
3-year JJ o
EFS NNP o
of IN N
approximately RB N
90 CD N
% NN N
and CC N
statistically RB N
indistinguishable JJ N
8-year JJ o
EFS NNP o
and CC N
overall JJ o
survival NN o
, , N
without IN N
significant JJ N
long-term JJ o
toxicity NN o
. . o

Early JJ N
response NN o
to TO o
therapy NN o
was VBD N
associated VBN N
with IN N
higher JJR N
EFS NNP o
, , N
a DT N
concept NN N
that WDT N
has VBZ N
led VBN N
to TO N
the DT N
Children NNP N
's POS N
Oncology NNP N
Group NNP N
paradigm NN N
of IN N
response-based JJ N
risk-adapted JJ N
therapy NN N
for IN N
pediatric JJ N
Hodgkin NNP N
disease NN N
. . N

-DOCSTART- -10337657- O O

Effect NN N
of IN N
total JJ i
androgen NN i
ablation NN i
on IN N
pathologic JJ o
stage NN o
and CC o
resection NN o
limit NN o
status NN o
of IN o
prostate NN o
cancer NN o
. . o

Initial JJ N
results NNS N
of IN N
the DT N
Italian JJ p
PROSIT NNP p
study NN p
. . p

The DT N
likelihood NN N
of IN N
finding VBG N
organ-confined JJ N
untreated JJ N
prostate NN N
cancer NN N
( ( N
PCa NNP N
) ) N
by IN N
pathological JJ N
examination NN N
at IN N
the DT N
time NN N
of IN N
radical JJ i
prostatectomy NN i
( ( i
RP NNP i
) ) i
is VBZ N
only RB N
50 CD N
% NN N
in IN N
patients NNS N
with IN N
clinically RB N
organ-confined JJ N
disease NN N
. . N

In IN N
addition NN N
, , N
tumour NN N
is VBZ N
present JJ N
at IN N
the DT N
resection NN N
margin NN N
in IN N
approximately RB N
30 CD N
% NN N
of IN N
clinical JJ N
T2 NNP N
( ( N
clinical JJ N
stage NN N
B NNP N
) ) N
cases NNS N
. . N

The DT N
issue NN N
of IN N
clinical JJ N
understaging NN N
and CC N
of IN N
resection NN N
limit NN N
positivity NN N
have VBP N
led VBN N
to TO N
the DT N
development NN N
of IN N
novel JJ N
management NN N
practices NNS N
, , N
including VBG N
neoadjuvant JJ i
hormonal JJ i
therapy NN i
( ( i
NHT NNP i
) ) i
. . i

The DT N
optimal JJ N
duration NN N
of IN N
NHT NNP N
is VBZ N
unknown JJ N
. . N

We PRP N
undertook VBD N
the DT N
present JJ N
analysis NN N
to TO N
evaluate VB N
the DT N
effect NN o
of IN o
NHT NNP o
on IN o
pathologic JJ o
stage NN o
of IN o
PCa NNP o
and CC o
resection NN o
limit NN o
status NN o
in IN N
patients NNS p
with IN p
prostate JJ p
cancer NN p
and CC p
treated VBN p
with IN p
total JJ i
androgen NN i
ablation NN i
either DT p
for IN p
three CD p
or CC p
six CD p
months NNS p
before IN p
RP NNP p
. . p

Between NNP p
January NNP p
1996 CD p
and CC p
February NNP p
1998 CD p
, , p
259 CD p
men NNS p
with IN p
prostate NN p
cancer NN p
underwent JJ p
radical JJ i
retropubic NN i
prostatectomy NN i
and CC i
bilateral JJ i
pelvic JJ i
node NN i
dissection NN i
in IN p
the DT p
26 CD p
centres NNS p
participating VBG p
in IN p
the DT p
Italian JJ p
randomised VBD p
prospective JJ p
PROSIT NNP p
study NN p
. . p

Whole NNP N
mount NN N
sectioning NN N
of IN N
the DT N
complete JJ N
RP NNP N
specimens NNS N
was VBD N
adopted VBN N
in IN N
each DT N
centre NN N
for IN N
accurately RB N
evaluating VBG N
the DT N
pathologic JJ o
stage NN o
and CC o
resection NN o
limit NN o
status NN o
. . o

By IN N
February NNP N
1998 CD N
, , N
haematoxylin NN N
and CC N
eosin NN N
stained VBD N
sections NNS N
from IN N
155 CD N
RP NNP N
specimens NNS N
had VBD N
been VBN N
received VBN N
and CC N
evaluated VBN N
by IN N
the DT N
reviewing VBG N
pathologist NN N
( ( N
RM NNP N
) ) N
. . N

64 CD N
cases NNS N
had VBD N
not RB N
been VBN N
treated VBN N
with IN N
total JJ i
androgen NN i
ablation NN i
( ( N
e.g JJ N
. . N

NHT NNP i
) ) i
before IN N
RP NNP N
was VBD N
performed VBN N
, , N
whereas JJ N
58 CD N
and CC N
33 CD N
had VBD N
been VBN N
treated VBN N
for IN N
three CD N
and CC N
six CD N
months NNS N
, , N
respectively RB N
. . N

114 CD p
patients NNS p
were VBD N
clinical JJ N
stage NN N
B NNP N
whereas IN N
41 CD N
were VBD N
clinical JJ N
stage NN N
C. NNP N
After IN N
three CD N
months NNS N
of IN N
total JJ i
androgen NN i
ablation NN i
, , N
pathological JJ o
stage NN o
B NNP o
was VBD N
more RBR N
prevalent JJ N
among IN N
patients NNS N
with IN N
clinical JJ N
B NNP N
tumours NN N
, , N
compared VBN N
with IN N
untreated JJ N
patients NNS N
( ( N
57 CD N
% NN N
in IN N
treated JJ N
patients NNS N
vs. FW N
36 CD N
% NN N
in IN N
untreated JJ N
) ) N
. . N

The DT N
percentage NN o
of IN o
cancers NNS o
with IN o
negative JJ o
margins NNS o
was VBD N
statistically RB N
significantly RB N
greater JJR N
in IN N
patients NNS N
treated VBN N
with IN N
neoadjuvant JJ i
therapy NN i
than IN N
those DT N
treated VBN N
with IN N
immediate JJ i
surgery NN i
alone RB i
( ( N
69 CD N
% NN N
vs. FW N
42 CD N
% NN N
, , N
respectively RB N
) ) N
. . N

After IN N
six CD N
months NNS N
of IN N
NHT NNP N
therapy VBP N
the DT N
proportion NN o
of IN o
patients NNS o
with IN o
pathological JJ o
stage NN o
B NNP o
( ( N
67 CD N
% NN N
vs. FW N
36 CD N
% NN N
, , N
respectively RB N
) ) N
and CC N
negative JJ o
margins NNS o
was VBD N
greater JJR N
than IN N
after IN N
3 CD N
months NNS N
( ( N
92 CD N
% NN N
vs. FW N
42 CD N
% NN N
, , N
respectively RB N
) ) N
. . N

For IN N
clinical JJ N
C NNP N
tumours NN N
, , N
the DT N
prevalence NN N
of IN N
pathological JJ o
stage NN o
B NNP o
and CC o
negative JJ o
margins NNS o
in IN N
the DT N
patients NNS N
treated VBD N
for IN N
either DT N
3 CD N
or CC N
6 CD N
months NNS N
was VBD N
not RB N
as RB N
high JJ N
as IN N
in IN N
the DT N
clinical JJ N
B NNP N
tumours NN N
, , N
when WRB N
compared VBN N
with IN N
the DT N
untreated JJ N
group NN N
( ( N
pathological JJ N
stage NN N
B NNP N
: : N
31 CD N
% NN N
and CC N
33 CD N
% NN N
vs. FW N
6 CD N
% NN N
in IN N
the DT N
clinical JJ N
C NNP N
cases NNS N
, , N
respectively RB N
. . N

Negative JJ N
margins NNS N
: : N
56 CD N
% NN N
and CC N
67 CD N
% NN N
vs. FW N
31 CD N
% NN N
, , N
respectively RB N
) ) N
. . N

The DT N
initial JJ N
results NNS N
of IN N
this DT N
study NN N
suggest VBP N
that IN N
total JJ i
androgen NN i
ablation NN i
before IN i
RP NNP i
is VBZ N
beneficial JJ N
in IN N
men NNS N
with IN N
clinical JJ N
stage NN N
B NNP N
because IN N
of IN N
the DT N
significant JJ N
pathological JJ o
downstaging NN o
and CC N
decrease NN N
in IN N
the DT N
number NN N
of IN N
positive JJ o
margins NNS o
in IN o
the DT o
RP NNP o
specimens NNS o
. . o

These DT N
two CD N
effects NNS N
are VBP N
more RBR N
pronounced JJ N
after IN N
six CD N
months NNS N
of IN N
NHT NNP i
than IN N
after IN N
three CD N
months NNS N
of IN N
therapy NN N
. . N

The DT N
same JJ N
degree NN N
of IN N
beneficial JJ o
effects NNS o
are VBP N
not RB N
observed VBN N
in IN N
clinical JJ N
C NNP N
tumours NN N
. . N

-DOCSTART- -1350581- O O

Amisulpride NNP i
versus NN N
bromocriptine NN i
in IN N
infantile JJ p
autism NN p
: : p
a DT N
controlled VBN N
crossover NN N
comparative NN N
study NN N
of IN N
two CD N
drugs NNS N
with IN N
opposite JJ N
effects NNS N
on IN N
dopaminergic JJ N
function NN N
. . N

An DT N
alteration NN N
of IN N
dopaminergic NN o
( ( o
DA NNP o
) ) o
function NN o
much RB N
more RBR N
complex JJ N
than IN N
simple JJ N
hyperactivity NN N
has VBZ N
been VBN N
evoked VBN N
in IN N
infantile JJ p
autism NN p
. . p

We PRP N
therefore RB N
compared VBN N
the DT N
clinical JJ o
efficacy NN o
of IN N
a DT N
DA NNP i
antagonist NN i
( ( i
amisulpride IN i
) ) i
and CC N
a DT N
DA NNP i
agonist NN i
( ( i
bromocriptine NN i
) ) i
in IN N
a DT N
randomized JJ N
, , N
double-blind JJ N
, , N
crossover JJ N
trial NN N
in IN N
9 CD p
children NNS p
with IN p
autism NN p
, , p
likely RB p
severely RB p
mentally RB p
retarded JJ p
. . p

Amisulpride NNP i
acts VBZ N
preferentially RB N
on IN N
specific JJ N
autistic JJ N
symptoms NNS N
whereas VBP N
bromocriptine JJ i
acts NNS N
more RBR N
on IN N
motor NN o
hyperactivity NN o
and CC o
attention NN o
symptoms NNS o
. . o

These DT N
findings NNS N
raise VBP N
the DT N
specificity NN N
of IN N
these DT N
two CD N
drugs NNS N
which WDT N
appear VBP N
to TO N
act VB N
preferentially RB N
on IN N
some DT N
target NN N
symptoms NNS N
and CC N
are VBP N
consistent JJ N
with IN N
some DT N
clinical JJ N
and CC N
pharmacological JJ N
observations NNS N
showing VBG N
a DT N
sedative JJ o
effect NN o
with IN N
low JJ N
doses NNS N
of IN N
DA NNP i
agonists NNS i
and CC N
a DT N
stimulant JJ o
effect NN o
with IN N
low JJ N
doses NNS N
of IN N
DA NNP i
antagonists NNS i
such JJ N
as IN N
the DT N
benzamides NNS i
. . i

-DOCSTART- -17341994- O O

Comparison NNP N
of IN N
increasing VBG N
doses NNS N
of IN N
olmesartan JJ N
medoxomil NN N
, , N
losartan JJ N
potassium NN N
, , N
and CC N
valsartan NN N
in IN N
patients NNS p
with IN p
essential JJ p
hypertension NN p
. . p

This DT N
12-week JJ N
, , N
randomized VBN N
, , N
double-blind JJ N
, , N
forced-titration NN N
study NN N
compared VBN N
the DT N
efficacy NN N
of IN N
3 CD N
angiotensin NNS N
receptor NN N
blockers NNS N
. . N

Patients NNS i
received VBD i
olmesartan JJ i
medoxomil NN i
20 CD i
mg NN i
, , i
losartan JJ i
potassium NN i
50 CD i
mg NN i
, , i
valsartan JJ i
80 CD i
mg NN i
, , i
or CC i
placebo NN i
once RB i
daily JJ i
. . i

At IN i
week NN i
4 CD i
, , i
doses NNS i
were VBD i
titrated VBN i
to TO i
40 CD i
, , i
100 CD i
, , i
and CC i
160 CD i
mg NN i
once RB i
daily JJ i
for IN i
olmesartan NN i
, , i
losartan NN i
, , i
and CC i
valsartan NN i
, , i
respectively RB i
. . i

At IN i
week NN i
8 CD i
, , i
losartan NN i
was VBD i
increased VBN i
to TO i
50 CD i
mg NNS i
twice RB i
daily RB i
and CC i
valsartan NNS i
increased VBD i
to TO i
320 CD i
mg NNS i
once RB i
daily JJ i
( ( i
olmesartan JJ i
remained VBN i
at IN i
40 CD i
mg NNS i
once RB i
daily RB i
) ) i
. . N

The DT N
primary JJ N
end NN N
point NN N
was VBD N
mean JJ N
change NN N
from IN N
baseline NN N
in IN N
seated VBN o
diastolic JJ o
blood NN o
pressure NN o
( ( o
SeDBP NNP o
) ) o
at IN N
week NN N
8 CD N
. . N

All DT N
3 CD N
medications NNS N
significantly RB N
reduced VBN N
mean JJ o
SeDBP NNP o
from IN N
baseline NN N
compared VBN N
with IN N
placebo NN i
at IN N
weeks NNS N
4 CD N
, , N
8 CD N
, , N
and CC N
12 CD N
( ( N
P NNP N
< NNP N
.001 NNP N
) ) N
. . N

At IN N
week NN N
8 CD N
, , N
olmesartan RB N
reduced VBN N
mean JJ N
SeDBP NNP o
more JJR N
than IN N
losartan NN N
( ( N
P NNP N
< NNP N
.001 NNP N
) ) N
; : N
more JJR N
patients NNS N
in IN N
the DT N
olmesartan JJ N
medoxomil NN N
group NN N
achieved VBD N
a DT N
blood NN o
pressure NN o
goal NN N
of IN N
< $ N
140/90 CD N
mm NN N
Hg NNP N
( ( N
P NNP N
< NNP N
.001 NNP N
) ) N
. . N

Olmesartan NNP N
did VBD N
not RB N
reduce VB N
mean NN o
SeDBP NNP o
significantly RB N
compared VBN N
with IN N
valsartan NN N
, , N
although IN N
more JJR N
patients NNS N
attained VBD N
blood JJ o
pressure NN o
goal NN N
with IN N
olmesartan NN N
( ( N
P=.031 NNP N
) ) N
. . N

At IN N
week NN N
12 CD N
, , N
all DT N
agents NNS N
lowered VBD N
blood NN o
pressure NN o
equivalently RB N
. . N

-DOCSTART- -17516492- O O

Bright NNP i
light JJ i
therapy NN i
in IN N
Parkinson NNP p
's POS p
disease NN p
: : p
a DT N
pilot NN N
study NN N
. . N

Several JJ N
observations NNS N
suggest VBP N
a DT N
beneficial JJ N
effect NN N
of IN N
melatonin NN i
antagonism NN i
for IN N
Parkinson NNP p
's POS p
disease NN p
( ( p
PD NNP p
) ) p
. . p

Although IN N
bright JJ i
light JJ i
therapy NN i
( ( i
BLT NNP i
) ) i
suppresses VBZ N
melatonin JJ N
release NN N
and CC N
is VBZ N
an DT N
established JJ N
treatment NN N
for IN N
depression NN N
and CC N
sleep JJ N
disturbances NNS N
, , N
it PRP N
has VBZ N
not RB N
been VBN N
evaluated VBN N
in IN N
PD NNP N
. . N

We PRP N
examined VBD N
effects NNS N
of IN N
BLT NNP i
on IN N
motor NN o
symptoms NNS o
, , o
depression NN o
, , N
and CC N
sleep NN o
in IN N
PD NNP N
in IN N
a DT N
randomized JJ N
placebo-controlled JJ i
double-blind NN N
study NN N
in IN N
36 CD p
PD NNP p
patients NNS p
, , p
using VBG p
Parkinson NNP o
's POS o
Disease NNP o
Rating NNP o
Scale NNP o
( ( o
UPDRS NNP o
) ) o
I-IV NNP o
, , o
Beck NNP o
's POS o
Depression NNP o
Inventory NNP o
, , p
and CC p
Epworth NNP o
Sleepiness NNP o
Scale NNP o
. . o

All DT N
patients NNS N
received VBD N
BLT NNP i
for IN N
15 CD N
days NNS N
in IN N
the DT N
morning NN N
, , N
30 CD N
min JJ N
daily RB N
. . N

Illuminance NNP o
was VBD N
7.500 CD N
lux NN N
in IN N
the DT N
active JJ N
treatment NN N
group NN N
and CC N
950 CD N
lux NN N
in IN N
the DT N
placebo NN i
group NN N
. . N

Although IN N
group NN N
differences NNS N
were VBD N
small JJ N
, , N
BLT NNP i
led VBD N
to TO N
significant JJ N
improvement NN o
of IN o
tremor NN o
, , o
UPDRS NNP o
I PRP o
, , o
II NNP o
, , o
and CC o
IV NNP o
, , o
and CC o
depression NN o
in IN N
the DT N
active JJ N
treatment NN N
group NN N
but CC N
not RB N
in IN N
the DT N
placebo NN i
group NN N
. . N

It PRP N
was VBD N
very RB N
well RB N
tolerated VBN o
. . o

Follow VB N
up RP N
studies NNS N
in IN N
more RBR N
advanced JJ N
patient JJ N
populations NNS N
employing VBG N
longer RBR N
treatment NN N
durations NNS N
are VBP N
warranted VBN N
. . N

-DOCSTART- -16113620- O O

Atomoxetine NNP i
alone RB N
or CC N
combined VBN N
with IN N
fluoxetine NN i
for IN N
treating VBG N
ADHD NNP p
with IN p
comorbid JJ p
depressive NN p
or CC p
anxiety NN p
symptoms NNS p
. . p

OBJECTIVE NNP N
Symptoms NNP N
of IN N
depression NN N
and CC N
anxiety NN N
are VBP N
commonly RB N
comorbid JJ N
with IN N
attention-deficit/hyperactivity JJ N
disorder NN N
( ( N
ADHD NNP N
) ) N
. . N

The DT N
authors NNS N
assessed VBD N
the DT N
safety NN o
and CC N
effectiveness NN o
of IN N
atomoxetine NN i
monotherapy NN N
compared VBN N
with IN N
combined JJ N
atomoxetine/fluoxetine NN i
therapy NN i
in IN N
a DT N
population NN p
of IN p
children NNS p
and CC p
adolescents NNS p
with IN p
ADHD NNP p
and CC p
concurrent NN p
symptoms NNS p
of IN p
depression NN p
or CC p
anxiety NN p
. . p

METHOD JJ N
Patients NNPS p
were VBD p
randomized VBN p
to TO p
treatment NN p
with IN p
fluoxetine NN i
( ( i
n JJ i
= NNP i
127 CD i
) ) i
or CC i
placebo NN i
( ( p
n JJ p
= NNP p
46 CD p
) ) p
under IN N
double-blind JJ N
conditions NNS N
for IN N
8 CD N
weeks NNS N
, , N
with IN N
concomitant JJ i
atomoxetine NN i
use IN i
the DT i
last JJ i
5 CD i
weeks NNS i
. . i

RESULTS NNP N
At IN N
end JJ N
point NN N
, , N
reductions NNS o
in IN o
ADHD NNP o
, , o
depressive NN o
, , o
and CC o
anxiety NN o
symptoms NNS o
were VBD N
marked VBN N
for IN N
both DT N
treatment NN N
groups NNS N
( ( N
p JJ N
< NNP N
.001 NN N
for IN N
the DT N
relevant JJ N
scale NN N
in IN N
each DT N
symptom NN N
cluster NN N
) ) N
. . N

Some DT N
differences NNS o
between IN N
treatment NN N
groups NNS N
for IN N
depressive JJ o
symptoms NNS o
were VBD N
significant JJ o
, , N
but CC N
the DT N
magnitudes NNS o
of IN N
the DT N
differences NNS N
were VBD N
small JJ o
and CC N
likely JJ N
of IN N
limited JJ N
clinical JJ N
importance NN N
. . N

Completion NN o
rates NNS o
for IN N
the DT N
two CD N
groups NNS N
were VBD N
similar JJ N
, , N
as IN N
were VBD N
discontinuation NN o
rates NNS o
for IN N
adverse JJ o
events NNS o
. . o

The DT N
combination NN N
group NN N
had VBD N
greater JJR o
increases NNS o
in IN o
blood NN o
pressure NN o
and CC o
pulse NN o
than IN N
did VBD N
the DT N
monotherapy NN N
group NN N
. . N

CONCLUSIONS NNP N
In IN N
pediatric JJ p
patients NNS p
with IN p
ADHD NNP p
and CC p
comorbid NN p
symptoms NNS p
of IN p
depression NN p
or CC p
anxiety NN p
, , N
atomoxetine JJ i
monotherapy NN i
appears VBZ N
to TO N
be VB N
effective JJ N
for IN N
treating VBG N
ADHD NNP N
. . N

Anxiety NNP o
and CC o
depressive JJ o
symptoms NNS o
also RB N
improved VBN N
, , N
but CC N
the DT N
absence NN N
of IN N
a DT N
placebo-only JJ N
arm NN N
does VBZ N
not RB N
allow VB N
us PRP N
to TO N
conclude VB N
that IN N
these DT N
effects NNS N
are VBP N
specifically RB N
the DT N
result NN N
of IN N
treatment NN N
with IN N
atomoxetine NN i
. . i

Combined VBN i
atomoxetine/fluoxetine JJ i
therapy NN N
was VBD N
well RB N
tolerated VBN N
. . N

-DOCSTART- -2185458- O O

The DT N
placebo NN i
effect NN o
. . o

Drug NNP N
trial NN N
considerations NNS N
. . N

-DOCSTART- -10861653- O O

Response NN N
of IN N
pre-core NN p
mutant NN p
chronic JJ p
hepatitis NN p
B NNP p
infection NN p
to TO N
lamivudine VB i
. . i

The DT N
proportion NN N
of IN N
chronic JJ N
liver NN N
disease NN N
associated VBN N
with IN N
the DT N
pre-core JJ p
mutant NN p
of IN p
hepatitis NN p
B NNP p
virus NN p
( ( p
HBV NNP p
) ) p
infection NN p
is VBZ N
increasing VBG N
, , N
particularly RB N
in IN N
Mediterranean NNP p
Europe NNP p
and CC p
in IN p
Asia NNP p
. . p

The DT N
pre-core JJ p
mutant NN p
HBV NNP p
is VBZ N
unable JJ N
to TO N
produce VB N
hepatitis NN N
B NNP N
e NN N
antigen NN N
( ( N
HBeAg NNP N
) ) N
, , N
so RB N
that IN N
patients NNS p
with IN p
this DT p
variant NN p
do VBP N
not RB N
present VB N
with IN N
HBV NNP N
characterised VBN N
by IN N
HBeAg NNP o
in IN o
the DT o
serum NN o
. . o

Pre-core NN N
mutant JJ N
chronic JJ N
hepatitis NN N
B NNP N
infection NN N
usually RB N
proceeds VBZ N
to TO N
serious JJ N
liver JJ N
disease NN N
. . N

Wild-type JJ N
HBV NNP N
infection NN N
may MD N
be VB N
mild JJ N
and CC N
respond NN N
relatively RB N
well RB N
to TO N
interferon VB N
( ( N
IFN NNP N
) ) N
alpha NN N
therapy NN N
, , N
but CC N
IFN NNP N
alpha NN N
is VBZ N
not RB N
an DT N
effective JJ N
therapeutic JJ N
option NN N
in IN N
pre-core NN N
mutant NN N
hepatitis NN N
B NNP N
infection NN N
and CC N
new JJ N
therapeutic JJ N
options NNS N
are VBP N
needed VBN N
. . N

Clinical JJ N
data NNS N
show VBP N
that IN N
lamivudine NN i
is VBZ N
an DT N
effective JJ o
treatment NN N
for IN N
patients NNS p
with IN p
pre-core JJ p
mutant NN p
hepatitis NN p
B NNP p
. . p

There EX N
is VBZ N
profound JJ N
suppression NN N
of IN N
HBV NNP o
replication NN o
and CC N
improvement NN N
in IN N
indicators NNS o
of IN o
liver JJ o
disease NN o
in IN N
most JJS N
patients NNS N
. . N

In IN N
conclusion NN N
, , N
lamivudine NN i
is VBZ N
suitable JJ N
for IN N
treatment NN N
of IN N
a DT N
wide JJ N
range NN N
of IN N
patients NNS p
with IN p
chronic JJ p
hepatitis NN p
B NNP p
, , p
including VBG p
those DT p
with IN p
pre-core JJ p
mutant JJ p
HBV NNP p
infection NN p
. . p

-DOCSTART- -10926339- O O

Comparison NNP N
of IN N
high JJ N
and CC N
low JJ N
dose NN N
of IN N
the DT N
inhaled JJ i
steroid NN i
, , i
budesonide RB i
, , N
as IN N
an DT N
initial JJ N
treatment NN N
in IN N
newly RB p
detected VBN p
asthma NN p
. . p

The DT N
importance NN N
of IN N
early JJ N
initiation NN N
of IN N
inhaled JJ i
steroids NNS i
even RB N
in IN N
mild JJ N
asthma NN N
has VBZ N
been VBN N
documented VBN N
in IN N
several JJ N
studies NNS N
. . N

It PRP N
is VBZ N
not RB N
, , N
however RB N
, , N
clear JJ N
whether IN N
the DT N
treatment NN N
should MD N
be VB N
started VBN N
with IN N
a DT N
high JJ N
or CC N
a DT N
low JJ N
dose NN N
of IN N
the DT N
inhaled JJ N
steroid NN N
. . N

We PRP N
have VBP N
compared VBN N
the DT N
effects NNS N
of IN N
high JJ i
and CC i
low JJ i
dose NN i
inhaled VBN i
steroid NN i
, , i
budesonide NN i
, , N
in IN N
patients NNS p
with IN p
newly RB p
detected VBN p
asthma NN p
. . p

We PRP N
studied VBD N
101 CD p
adult NN p
patients NNS p
with IN p
newly RB p
detected VBN p
bronchial JJ p
asthma NN p
who WP p
were VBD p
without IN p
inhaled VBN p
steroid NN p
or CC p
any DT p
regular JJ p
pharmacological JJ p
treatment NN p
for IN p
their PRP$ p
asthma NN p
. . p

The DT N
patients NNS N
were VBD N
randomly RB N
allocated VBN N
to TO N
two CD N
treatment NN N
groups NNS N
: : N
one CD N
to TO N
receive VB N
800 CD i
microg NN i
inhaled VBD i
budesonide JJ i
per IN N
day NN N
and CC N
the DT N
other JJ N
to TO N
receive VB N
200 CD i
microg NN i
inhaled VBD i
budesonide JJ i
per IN N
day NN N
. . N

The DT N
drugs NNS N
were VBD N
given VBN N
with IN N
a DT N
Turbuhaler NNP i
dry JJ i
powder NN i
inhaler NN i
. . i

During IN N
the DT N
3-month JJ N
treatment NN N
period NN N
, , N
no DT N
significant JJ N
differences NNS N
between IN N
the DT N
treatment NN N
groups NNS N
were VBD N
noted VBN N
in IN N
morning NN o
or CC o
evening NN o
PEF NNP o
values VBZ o
, , N
in IN N
spirometric JJ N
parameters NNS N
, , N
in IN N
asthmatic JJ N
symptoms NNS N
or CC N
in IN N
the DT N
use NN N
of IN N
rescue NN N
beta2-agonists NNS N
. . N

The DT N
decrease NN o
in IN o
bronchial JJ o
hyperresponsiveness NN o
was VBD N
, , N
however RB N
, , N
more JJR o
marked VBN o
in IN N
the DT N
high JJ N
dose JJ N
budesonide NN i
group NN N
, , N
reaching VBG N
a DT N
borderline NN N
significance NN N
( ( N
P=0.10 NNP N
high RB N
vs. FW N
low JJ N
dose JJ N
budesonide NN N
) ) N
. . N

In IN N
addition NN N
, , N
in IN N
serum JJ o
markers NNS o
of IN o
asthmatic JJ o
inflammation NN o
significant JJ N
differences NNS N
were VBD N
shown VBN N
between IN N
the DT N
treatment NN N
groups NNS N
. . N

The DT N
decrease NN o
in IN o
the DT o
number NN o
of IN o
blood NN o
eosinophils NNS o
during IN N
the DT N
treatment NN N
was VBD N
more RBR o
marked JJ o
in IN N
the DT N
high JJ N
dose JJ N
budesonide NN i
group NN N
( ( N
P=0.02 NNP N
; : N
high JJ N
vs. FW N
low JJ N
dose JJ N
budesonide NN N
) ) N
. . N

In IN N
serum JJ o
ECP NNP o
no DT N
change NN N
was VBD N
observed VBN N
in IN N
the DT N
low JJ N
dose JJ N
budesonide NN N
group NN N
, , N
but CC N
a DT N
marked JJ N
decrease NN N
in IN N
the DT N
high-dose JJ N
budesonide NN N
group NN N
( ( N
P=0.008 NNP N
; : N
high JJ N
vs. FW N
low JJ N
dose JJ N
budesonide NN N
) ) N
. . N

The DT N
change NN N
was VBD N
even RB N
more JJR N
marked JJ o
with IN N
regard NN o
to TO o
serum VB o
EPX NNP o
( ( N
P=0.005 NNP N
; : N
high JJ N
vs. FW N
low JJ N
dose JJ N
budesonide NN N
) ) N
. . N

Our PRP$ N
results NNS N
support VB N
the DT N
view NN N
that IN N
the DT N
treatment NN N
of IN N
newly RB N
detected VBN N
asthma NN N
should MD N
be VB N
started VBN N
with IN N
a DT N
high JJ N
dose NN N
of IN N
inhaled JJ N
steroid NN N
. . N

The DT N
low JJ N
dose NN N
may MD N
not RB N
be VB N
enough RB N
to TO N
suppress VB N
asthmatic JJ N
inflammation NN N
despite IN N
good JJ o
clinical JJ o
primary JJ o
response NN o
. . o

-DOCSTART- -7974179- O O

A DT N
prospective JJ N
randomized NN N
study NN N
concerning VBG N
the DT N
point NN N
A NNP N
dose NN N
in IN N
high-dose JJ i
rate NN i
intracavitary JJ i
therapy NN i
for IN N
carcinoma NN p
of IN p
the DT p
uterine JJ p
cervix NN p
. . p

The DT N
final JJ N
results NNS N
. . N

PURPOSE NNP N
High-dose JJ i
rate NN i
( ( i
HDR NNP i
) ) i
remote VBP i
afterloading VBG i
intracavitary JJ i
therapy NN i
has VBZ N
been VBN N
recognized VBN N
as IN N
an DT N
effective JJ N
and CC N
safe JJ N
treatment NN N
modality NN N
for IN N
carcinoma NN p
of IN p
the DT p
uterine JJ p
cervix NN p
. . p

Since IN N
1983 CD N
, , N
a DT N
prospective JJ N
randomized NN N
study NN N
was VBD N
started VBN N
in IN N
order NN N
to TO N
investigate VB N
the DT N
more RBR N
advantageous JJ N
treatment NN N
schedule NN N
with IN N
keeping VBG N
the DT N
local JJ N
control NN N
rate NN N
. . N

This DT N
paper NN N
reports VBZ N
the DT N
final JJ N
results NNS N
in IN N
terms NNS N
of IN N
survival NN N
, , N
local JJ N
control NN N
and CC N
complications NNS N
. . N

PATIENTS NNP N
AND CC N
METHODS NNP N
Between NNP p
January NNP p
1983 CD p
and CC p
February NNP p
1989 CD p
, , p
a DT p
total NN p
of IN p
165 CD p
patients NNS p
with IN p
carcinoma NN p
of IN p
the DT p
uterine JJ p
cervix NN p
was VBD p
entered VBN p
in IN p
a DT p
prospective JJ p
randomized NN p
study NN p
concerning VBG p
the DT p
point NN p
A NNP p
dose NN i
of IN i
HDR NNP i
therapy NN i
( ( i
6 CD i
Gy/fraction NNP i
vs FW i
7.5 CD i
Gy/fraction NNP i
) ) i
and CC i
external JJ i
irradiation NN i
dose NN i
at IN i
Department NNP i
of IN i
Radiation NNP i
Therapy NNP i
, , p
The DT p
Center NNP p
for IN p
Adult NNP p
Diseases NNP p
, , p
Osaka NNP p
. . p

UICC NNP p
[ VBD p
20 CD p
] JJ p
stage NN p
distribution NN p
of IN p
patients NNS p
was VBD p
as IN p
follows VBZ p
: : p
stage NN p
IA NNP p
= NNP p
4 CD p
, , p
stage NN p
IB NNP p
= NNP p
33 CD p
, , p
stage NN p
IIA NNP p
= NNP p
18 CD p
, , p
stage NN p
IIB NNP p
= NNP p
38 CD p
, , p
stage NN p
III NNP p
= NNP p
57 CD p
, , p
stage NN p
IV NNP p
= VBZ p
15 CD p
. . p

RESULTS VB N
Overall JJ N
5-year JJ o
cause NN o
specific JJ o
survivals NNS o
were VBD N
as IN N
follows VBZ N
: : N
stage NN N
IA NNP N
= VBZ N
100 CD N
% NN N
, , N
stage NN N
IB NNP N
= VBZ N
96 CD N
% NN N
, , N
stage NN N
IIA NNP N
= VBZ N
92 CD N
% NN N
, , N
stage NN N
IIB NNP N
= VBZ N
79 CD N
% NN N
, , N
stage NN N
III NNP N
= VBZ N
57 CD N
% NN N
, , N
stage NN N
IV NNP N
= VBZ N
27 CD N
% NN N
. . N

In IN N
each DT N
stage NN N
, , N
5-year JJ o
survival NN o
rates NNS o
in IN N
groups NNS N
A NNP N
and CC N
B NNP N
were VBD N
100 CD N
% NN N
, , N
93 CD N
% NN N
in IN N
stage NN N
I PRP N
, , N
82 CD N
% NN N
and CC N
85 CD N
% NN N
in IN N
stage NN N
II NNP N
, , N
62 CD N
% NN N
and CC N
52 CD N
% NN N
in IN N
stage NN N
II NNP N
and CC N
22 CD N
% NN N
and CC N
31 CD N
% NN N
in IN N
stage NN N
IV NNP N
, , N
respectively RB N
. . N

There EX N
were VBD N
no DT N
statistically RB N
significant JJ N
differences NNS N
among IN N
these DT N
survival JJ N
curves NNS N
in IN N
each DT N
stage NN N
. . N

Five-year JJ o
local JJ o
failure NN o
rates NNS o
were VBD N
16 CD N
% NN N
in IN N
group NN N
A NNP N
and CC N
16 CD N
% NN N
in IN N
group NN N
B NNP N
( ( N
p JJ N
= NNP N
0.9096 CD N
) ) N
, , N
and CC N
corresponding VBG N
distant JJ N
failure NN N
rates NNS N
were VBD N
23 CD N
% NN N
in IN N
group NN N
A NNP N
and CC N
19 CD N
% NN N
in IN N
group NN N
B NNP N
( ( N
p JJ N
= NNP N
0.2955 CD N
) ) N
. . N

Moderate-to-severe JJ o
complications NNS o
requiring VBG N
treatment NN N
( ( N
Kottmeier NNP N
's POS N
grade NN N
2 CD N
or CC N
more JJR N
) ) N
were VBD N
noted VBN N
in IN N
6 CD N
patients NNS N
( ( N
7 CD N
% NN N
) ) N
in IN N
group NN N
A NNP N
and CC N
6 CD N
patients NNS N
( ( N
7 CD N
% NN N
) ) N
in IN N
group NN N
B NNP N
. . N

All DT N
of IN N
the DT N
bladder NN o
and CC o
rectal JJ o
complications NNS o
needed VBD N
medical JJ N
treatment NN N
( ( N
Kottmeier NNP N
's POS N
grade NN N
2 CD N
) ) N
. . N

Severe JJ o
complications NNS o
receiving VBG N
surgery NN N
were VBD N
noted VBN N
in IN N
4 CD N
patients NNS N
( ( N
A DT N
: : N
1 CD N
; : N
B NNP N
: : N
3 CD N
) ) N
, , N
i.e. FW N
, , N
small JJ N
intestine NN N
3 CD N
and CC N
sigmoid JJ N
colon NN N
1 CD N
patient NN N
. . N

Another DT N
1 CD N
patient NN N
( ( N
A DT N
) ) N
was VBD N
dead JJ o
of IN N
ileus NN N
. . N

CONCLUSIONS NNP N
There EX N
were VBD N
no DT N
statistically RB o
significant JJ o
differences NNS o
between IN o
2 CD o
treatment NN o
schedules NNS o
in IN o
survival NN o
rates NNS o
, , o
failure NN o
patterns NNS o
and CC o
complications NNS o
rates NNS o
. . o

This DT N
fact NN N
suggests VBZ N
that IN N
small JJ N
number NN N
of IN N
fractions NNS N
( ( N
7.5 CD N
Gy/fraction NNP N
) ) N
may MD N
be VB N
advantageous JJ N
because IN N
of IN N
short JJ N
duration NN N
and CC N
a DT N
low JJ N
load NN N
of IN N
treatment NN N
. . N

-DOCSTART- -23690414- O O

Methylphenidate NNP i
and/or VBZ N
a DT N
nursing NN i
telephone NN i
intervention NN i
for IN N
fatigue NN o
in IN N
patients NNS p
with IN p
advanced JJ p
cancer NN p
: : p
a DT N
randomized JJ N
, , N
placebo-controlled JJ i
, , N
phase JJ N
II NNP N
trial NN N
. . N

PURPOSE VB N
Cancer-related-fatigue NNP o
( ( o
CRF NNP o
) ) o
is VBZ N
common JJ N
in IN N
advanced JJ p
cancer NN p
. . p

The DT N
primary JJ N
objective NN N
of IN N
the DT N
study NN N
was VBD N
to TO N
compare VB N
the DT N
effects NNS N
of IN N
methylphenidate NN i
( ( i
MP NNP i
) ) i
with IN N
those DT N
of IN N
placebo NN i
( ( N
PL NNP N
) ) N
on IN N
CRF NNP N
as IN N
measured VBN N
using VBG N
the DT N
Functional NNP o
Assessment NNP o
of IN o
Chronic NNP o
Illness NNP o
Therapy-Fatigue NNP o
( ( o
FACIT-F NNP o
) ) o
fatigue NN N
subscale NN N
. . N

The DT N
effect NN N
of IN N
a DT N
combined JJ N
intervention NN N
including VBG N
MP NNP N
plus CC N
a DT N
nursing NN i
telephone NN i
intervention NN i
( ( i
NTI NNP i
) ) i
was VBD N
also RB N
assessed VBN N
. . N

PATIENTS NNP N
AND CC N
METHODS NNP N
Patients NNP p
with IN p
advanced JJ p
cancer NN p
with IN p
a DT p
fatigue NN p
score NN p
of IN p
? . p
4 CD p
out IN p
of IN p
10 CD p
on IN p
the DT p
Edmonton NNP p
Symptom NNP p
Assessment NNP p
Scale NNP p
( ( p
ESAS NNP p
) ) p
were VBD p
randomly RB N
assigned VBN N
to TO N
one CD N
of IN N
the DT N
following JJ N
four CD N
groups NNS N
: : N
MP+NTI NNP N
, , N
PL+NTI NNP N
, , N
MP NNP N
+ NNP N
control NN i
telephone NN i
intervention NN i
( ( i
CTI NNP N
) ) N
, , N
and CC N
PL+CTI NNP i
. . i

Methylphenidate NNP i
dose NN i
was VBD N
5 CD N
mg NN N
every DT N
2 CD N
hours NNS N
as IN N
needed VBN N
up IN N
to TO N
20 CD N
mg NNS N
per IN N
day NN N
. . N

The DT N
primary JJ N
end NN N
point NN N
was VBD N
the DT o
median JJ o
difference NN o
in IN o
FACIT-F NNP o
fatigue NN o
at IN o
day NN N
15 CD N
. . N

Secondary JJ N
outcomes NNS N
included VBD o
anxiety NN o
, , o
depression NN o
, , o
and CC o
sleep RB o
. . o

RESULTS VB p
One CD p
hundred JJ p
forty-one JJ p
patients NNS p
were VBD p
evaluable JJ o
. . o

Median JJ o
FACIT-F NNP o
fatigue NN o
scores NNS o
improved VBN o
from IN N
baseline NN N
to TO N
day NN N
15 CD N
in IN N
all DT N
groups NNS N
: : N
MP+NTI NNP N
( ( N
median JJ N
score NN N
, , N
4.5 CD N
; : N
P NNP N
= NNP N
.005 NNP N
) ) N
, , N
PL+NTI NNP N
( ( N
median JJ N
score NN N
, , N
8.0 CD N
; : N
P NNP N
< NNP N
.001 NNP N
) ) N
, , N
MP+CTI NNP N
( ( N
median JJ N
score NN N
, , N
7.0 CD N
; : N
P NNP N
= NNP N
.004 NNP N
) ) N
, , N
and CC N
PL+CTI NNP N
( ( N
median JJ N
score NN N
, , N
5.0 CD N
; : N
P NNP N
= NNP N
.03 NNP N
) ) N
. . N

However RB N
, , N
there EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
the DT N
median JJ N
improvement NN N
in IN N
FACIT-F NNP o
fatigue NN o
between IN o
the DT N
MP NNP N
and CC N
PL NNP N
groups NNS N
( ( N
5.5 CD N
v NN N
6.0 CD N
, , N
respectively RB N
; : N
P NNP N
= NNP N
.69 NNP N
) ) N
and CC N
among IN N
all DT N
four CD N
groups NNS N
( ( N
P NNP N
= NNP N
.16 NNP o
) ) o
. . o

Fatigue NNP o
( ( o
P NNP N
< NNP N
.001 NNP o
) ) o
, , o
nausea NN o
( ( o
P NNP N
= NNP N
.01 NNP o
) ) o
, , o
depression NN o
( ( o
P NNP N
= NNP N
.02 NNP o
) ) o
, , o
anxiety NN o
( ( o
P NNP N
= NNP N
.01 NNP o
) ) o
, , o
drowsiness NN o
( ( o
P NNP N
< NNP N
.001 NNP o
) ) o
, , o
appetite RB o
( ( o
P NNP N
= NNP N
.009 NNP o
) ) o
, , o
sleep JJ o
( ( o
P NNP N
< NNP N
.001 NNP N
) ) N
, , N
and CC o
feeling NN o
of IN o
well-being NN o
( ( o
P NNP N
< NNP N
.001 NNP N
) ) N
, , N
as IN N
measured VBN N
by IN N
the DT N
ESAS NNP N
, , N
significantly RB N
improved VBN N
in IN N
patients NNS N
who WP N
received VBD N
NTI NNP o
. . o

Grade NNP o
? . o
3 CD o
adverse JJ o
events NNS o
did VBD o
not RB N
differ VB N
between IN N
MP NNP N
and CC N
PL NNP N
( ( N
40 CD N
of IN N
93 CD N
patients NNS N
v JJ N
29 CD N
of IN N
97 CD N
patients NNS N
, , N
respectively RB N
; : N
P NNP N
= NNP N
.06 NNP N
) ) N
. . N

CONCLUSION NNP N
MP NNP N
and CC N
NTI NNP N
alone RB N
or CC N
combined VBN N
were VBD N
not RB N
superior JJ i
to TO i
placebo VB i
in IN i
improving VBG o
CRF NNP o
. . N

-DOCSTART- -7676782- O O

Comparison NNP N
of IN N
eltanolone NN i
and CC N
thiopental NN i
in IN N
anaesthesia NN o
for IN N
termination NN p
of IN p
pregnancy NN p
. . p

Eltanolone NNP i
, , N
a DT N
new JJ N
steroid JJ N
hypnotic NN N
, , N
was VBD N
compared VBN N
to TO N
thiopental VB N
in IN N
short JJ N
anaesthesia NN N
. . N

Sixty NNP p
unpremedicated VBD p
, , p
Asa NNP p
1-2 JJ p
women NNS p
were VBD N
randomized VBN N
to TO N
receive VB N
eltanolone NN i
0.6 CD i
( ( N
group NN N
E1 NNP N
) ) N
or CC N
0.8 CD N
mg.kg-1 JJ N
( ( N
group NN N
E2 NNP N
) ) N
or CC N
thiopental JJ i
4 CD N
mg.kg-1 NN N
( ( N
group NN N
T NNP N
) ) N
for IN N
induction NN N
of IN N
anaesthesia NN N
. . N

One CD N
minute NN N
before IN N
induction NN N
glycopyrrolate NN i
0.2 CD i
mg NN i
and CC i
alfentanil JJ i
15 CD i
micrograms.kg-1 JJ i
i.v NN N
. . N

were VBD N
administered VBN N
. . N

If IN N
induction NN N
failed VBD N
, , N
additional JJ N
boluses NNS N
of IN N
the DT N
test NN N
drug NN N
were VBD N
given VBN N
. . N

Anaesthesia NNP N
was VBD N
maintained VBN N
with IN N
67 CD N
% NN N
nitrous JJ i
oxide NN i
in IN i
oxygen NN i
, , N
and CC N
additional JJ N
bolus NN N
doses NNS N
of IN N
the DT N
test NN N
drug NN N
were VBD N
given VBN N
in IN N
a DT N
standardized JJ N
fashion NN N
, , N
if IN N
needed VBN N
. . N

Recovery NN o
was VBD N
assessed VBN N
by IN N
a DT N
research NN N
nurse NN N
blinded VBD N
to TO N
the DT N
agent NN N
used VBN N
. . N

Mean JJ o
+/- JJ o
s.d NN o
. . o

induction NN o
doss NN o
were VBD N
0.7 CD N
+/- JJ N
0.1 CD N
mg.kg-1 NN N
( ( N
group NN N
E1 NNP N
) ) N
, , N
0.8 CD N
+/- JJ N
0.1 CD N
mg.kg-1 NN N
( ( N
group NN N
E2 NNP N
) ) N
and CC N
4.0 CD N
+/- JJ N
0.0 CD N
mg.kg-1 NN N
( ( N
group NN N
T NNP N
) ) N
. . N

Induction NN o
time NN o
was VBD N
prolonged VBN N
in IN N
the DT N
group NN N
E1 NNP N
compared VBN N
to TO N
the DT N
other JJ N
two CD N
groups NNS N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

Side JJ o
effects NNS o
were VBD N
few JJ N
in IN N
all DT N
groups NNS N
, , N
but CC N
involuntary JJ o
muscle NN o
movements NNS o
or CC o
hypertonus NN o
occurred VBD N
in IN N
23 CD N
% NN N
of IN N
the DT N
patients NNS N
in IN N
the DT N
eltanolone NN N
and CC N
in IN N
3 CD N
% NN N
in IN N
the DT N
thiopental JJ N
groups NNS N
( ( N
n.s NN N
) ) N
. . N

Early JJ o
recovery NN o
( ( o
eye NN o
opening NN o
, , o
orientation NN o
and CC o
sitting VBG o
) ) o
was VBD N
slower VBN N
in IN N
both DT N
eltanolone NN N
groups NNS N
compared VBN N
to TO N
the DT N
thiopental JJ N
group NN N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

No UH N
differences NNS N
between IN N
the DT N
groups NNS N
were VBD N
found VBN N
in IN N
toleration NN N
of IN N
oral JJ N
fluids NNS N
, , N
walking VBG N
, , N
voiding VBG N
, , N
postoperative JJ N
analgesic JJ N
requirements NNS N
or CC N
postoperative JJ N
nausea NN N
and CC N
vomiting NN N
. . N

( ( N
ABSTRACT NNP N
TRUNCATED NNP N
AT NNP N
250 CD N
WORDS NNP N
) ) N
-DOCSTART- -11890175- O O

Supervisor NNP p
tolerance-responsiveness NN p
to TO N
substance VB N
abuse NN N
and CC N
workplace NN N
prevention NN N
training NN N
: : N
use NN N
of IN N
a DT N
cognitive JJ N
mapping NN N
tool NN N
. . N

Supervisor NNP i
tolerance-responsiveness JJ i
, , N
referring VBG N
to TO N
the DT N
attitudes NNS N
and CC N
behaviors NNS N
associated VBN N
with IN N
either DT N
ignoring VBG N
or CC N
taking VBG N
proactive JJ N
steps NNS N
with IN N
troubled JJ p
employees NNS p
, , N
was VBD N
investigated VBN N
in IN N
two CD N
studies NNS N
. . N

The DT N
studies NNS N
were VBD N
conducted VBN N
to TO N
help VB N
examine VB N
, , N
understand NN N
and CC N
improve VB N
supervisor NN p
responsiveness NN p
to TO p
employee NN p
substance NN p
abuse NN p
. . p

Study NNP N
1 CD N
examined VBD N
supervisor NN p
response NN p
to TO p
and CC p
tolerance NN p
of IN p
coworker NN p
substance NN p
use NN p
and CC N
ways NNS N
of IN N
interfacing VBG N
with IN N
the DT N
Employee NNP i
Assistance NNP i
Program NNP i
( ( i
EAP NNP i
) ) i
in IN p
two CD p
workplaces NNS p
( ( p
n JJ p
= NN p
244 CD p
and CC p
107 CD p
) ) p
. . p

These DT N
surveys NNS N
suggested VBD N
that IN N
engaging VBG N
supervisors NNS N
in IN N
a DT N
dialogue NN N
about IN N
tolerance NN N
might MD N
improve VB o
their PRP$ o
willingness NN o
to TO o
use VB o
the DT o
EAP NNP o
. . o

Study NNP N
2 CD N
was VBD N
a DT N
randomized JJ N
control NN N
field NN N
experiment NN N
that WDT N
assessed VBD N
a DT N
team-oriented JJ N
training NN N
. . N

This DT N
training NN N
adopted VBD N
a DT N
cognitive JJ N
mapping NN N
technique NN N
to TO N
help VB N
improve VB N
supervisor NN N
responsiveness NN N
. . N

Supervisors NNS p
receiving VBG p
this DT p
training NN p
( ( p
n JJ p
= NNP p
29 CD p
) ) p
were VBD N
more RBR N
likely JJ N
to TO N
improve VB N
on IN N
several JJ o
dimensions NNS o
of IN o
responsiveness NN o
( ( N
e.g NN N
. . N

likely JJ N
to TO N
contact VB N
the DT N
EAP NNP N
) ) N
than IN N
were VBD N
supervisors NNS p
who WP p
received VBD p
a DT p
more RBR p
didactic JJ p
, , p
informational JJ p
training NN p
( ( p
n JJ p
= NNP p
23 CD p
) ) p
or CC p
a DT p
no-training JJ i
control NN i
group NN i
( ( p
n JJ p
= NNP p
17 CD p
) ) p
. . p

Trained VBN p
supervisors NNS p
also RB N
showed VBD N
increases NNS N
in IN N
their PRP$ N
own JJ o
help-seeking JJ o
behavior NN o
. . o

Procedures NNS N
and CC N
maps NNS N
from IN N
the DT N
mapping NN N
activity NN N
( ( N
two-stage JJ N
conversational NN N
mapping NN N
) ) N
are VBP N
described VBN N
. . N

Overall JJ N
, , N
results NNS N
indicate VBP N
that IN N
while IN N
supervisor JJ N
tolerance NN N
of IN N
coworker NN N
substance NN N
use NN N
inhibits VBZ N
EAP NNP N
utilization NN N
, , N
it PRP N
may MD N
be VB N
possible JJ N
to TO N
address VB N
this DT N
tolerance NN N
using VBG N
team-oriented JJ N
prevention NN N
training NN N
in IN N
the DT N
work-site JJ N
. . N

-DOCSTART- -17959958- O O

Low-dose JJ N
intravenous JJ N
midazolam NN i
reduces NNS N
etomidate-induced JJ N
myoclonus NN N
: : N
a DT N
prospective JJ N
, , N
randomized VBN N
study NN N
in IN N
patients NNS p
undergoing VBG p
elective JJ p
cardioversion NN p
. . p

BACKGROUND NNP N
Myoclonic NNP N
movements NNS N
are VBP N
a DT N
common JJ N
problem NN N
in IN N
unpremedicated JJ N
patients NNS p
during IN p
induction NN p
of IN p
anesthesia NN p
with IN p
etomidate NN p
. . p

METHODS NNP N
In IN N
a DT N
double-blind JJ N
fashion NN N
, , N
40 CD p
patients NNS p
( ( p
ASA NNP p
physical JJ p
status NN p
III-IV NNP p
) ) p
scheduled VBD p
for IN p
elective JJ p
cardioversion NN p
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
either RB N
0.015 CD N
mg/kg NNS N
midazolam NN i
or CC i
placebo NN i
90 CD N
s NN N
before IN N
the DT N
injection NN N
of IN N
0.3 CD N
mg/kg JJ N
etomidate NN i
. . i

Myoclonic JJ o
movements NNS o
and CC o
sedation NN o
were VBD N
recorded VBN N
on IN N
a DT N
scale NN N
between IN N
0 CD N
and CC N
3 CD N
. . N

Pulse NNP o
oximetry NN o
, , o
noninvasive JJ o
arterial JJ o
blood NN o
pressure NN o
, , o
and CC o
heart NN o
rate NN o
were VBD N
recorded VBN N
during IN N
the DT N
study NN N
period NN N
. . N

RESULTS NNP N
Two CD N
patients NNS N
( ( N
10 CD N
% NN N
) ) N
in IN N
the DT N
midazolam NN i
group NN N
had VBD N
myoclonic JJ o
movements NNS o
after IN N
the DT N
administration NN N
of IN N
etomidate NN i
, , N
whereas IN N
10 CD N
of IN N
the DT N
20 CD N
patients NNS N
( ( N
50 CD N
% NN N
) ) N
receiving VBG N
placebo NN i
experienced VBD N
such JJ N
movements NNS N
( ( N
P NNP N
= NNP N
0.006 CD N
) ) N
. . N

No UH N
other JJ N
differences NNS N
were VBD N
found VBN N
between IN N
the DT N
groups NNS N
; : N
in IN N
particular JJ N
, , N
there EX N
was VBD N
no DT N
difference NN N
in IN N
recovery NN N
5 CD N
min NN N
after IN N
the DT N
administration NN N
of IN N
etomidate NN N
. . N

CONCLUSIONS NNP N
IV NNP N
midazolam VBD i
0.015 CD N
mg/kg NN N
administered VBD N
90 CD N
s NN N
before IN N
induction NN N
of IN N
anesthesia NN N
with IN N
etomidate NN N
is VBZ N
effective JJ N
in IN N
reducing VBG N
myoclonic JJ N
movements NNS N
and CC N
does VBZ N
not RB N
prolong JJ N
recovery NN N
in IN N
unpremedicated JJ N
patients NNS N
after IN N
short JJ N
procedures NNS N
. . N

-DOCSTART- -15453848- O O

Position NN N
of IN N
anterior JJ N
capsulorhexis NN N
and CC N
posterior JJ N
capsule NN N
opacification NN N
. . N

PURPOSE NNP N
To TO N
evaluate VB N
whether IN N
the DT N
position NN N
of IN N
the DT N
anterior JJ N
continuous JJ N
curvilinear NN N
capsulorhexis NN N
influences VBZ N
the DT N
rate NN o
of IN o
posterior JJ o
capsule NN o
opacification NN o
( ( o
PCO NNP o
) ) o
. . o

METHODS CC N
A DT p
total NN p
of IN p
119 CD p
patients NNS p
, , p
aged VBN p
61-86 CD p
years NNS p
, , p
underwent JJ p
cataract NN p
surgery NN p
with IN p
phacoemulsification NN p
performed VBN p
by IN p
a DT p
single JJ p
surgeon NN p
. . p

The DT N
patients NNS N
were VBD N
randomized VBN N
to TO N
implantation NN N
with IN N
either CC N
a DT N
silicone NN i
intraocular NN i
lens NNS i
( ( i
IOL NNP i
) ) i
( ( i
SI40NB NNP i
, , i
Allergan NNP i
) ) i
or CC i
an DT i
AcrySof NNP i
IOL NNP i
( ( N
MA60BM NNP N
, , N
Alcon NNP N
) ) N
. . N

Three CD N
years NNS N
after IN N
surgery NN N
, , N
the DT N
rate NN o
of IN o
PCO NNP o
was VBD N
analysed VBN N
using VBG N
the DT N
evaluation NN N
of IN N
posterior JJ N
capsule NN N
opacification NN N
computer NN N
software NN N
( ( N
EPCO NNP N
) ) N
. . N

The DT N
results NNS N
were VBD N
related VBN N
to TO N
the DT N
capsulorhexis NN N
position NN N
, , N
which WDT N
was VBD N
assessed VBN N
with IN N
a DT N
retroillumination NN N
photograph NN N
. . N

RESULTS VB N
If IN N
the DT N
capsulorhexis NN o
was VBD N
located VBN N
partially RB N
or CC N
completely RB N
off IN N
the DT N
optics NNS o
of IN o
the DT o
IOL NNP o
, , N
compared VBN N
to TO N
totally RB o
on IN o
the DT o
IOL NNP o
, , N
significantly RB N
more JJR N
PCO NNP o
was VBD N
found VBN N
( ( N
p JJ N
= NNP N
0.0014 CD N
) ) N
. . N

When WRB N
comparing VBG N
within IN N
each DT N
IOL NNP N
type NN N
, , N
patients NNS N
with IN N
AcrySof NNP N
IOLs NNP N
were VBD N
found VBN N
to TO N
have VB N
significantly RB N
less JJR N
PCO NNP o
when WRB N
the DT N
capsulorhexis NN N
was VBD N
totally RB N
on IN N
the DT N
optic JJ N
( ( N
p JJ N
= NNP N
0.0048 CD N
) ) N
. . N

This DT N
difference NN N
was VBD N
also RB N
significant JJ N
in IN N
the DT N
silicone NN N
group NN N
( ( N
p JJ N
= NNP N
0.041 CD N
) ) N
. . N

CONCLUSION VB N
A NNP N
relatively RB N
small JJ N
and CC N
central JJ N
capsulorhexis NN N
allowing VBG N
for IN N
the DT N
complete JJ N
covering NN N
of IN N
the DT N
IOL NNP i
optics NNS i
by IN N
the DT N
rhexis NN N
edges VBZ N
seems VBZ N
to TO N
protect VB N
against IN N
PCO NNP o
in IN N
cataract NN N
surgery NN N
, , N
with IN N
both DT N
round-edged JJ N
silicone NN N
IOLs NNP N
and CC N
sharp-edged JJ N
hydrophobic JJ N
acrylic JJ i
IOLs NNP i
. . i

-DOCSTART- -387204- O O

5 CD N
FU NNP N
infusion NN N
with IN N
mitomycin-C JJ i
vs. FW i
5 CD i
FU NNP i
infusion NN i
with IN i
methyl-CCNU NN i
in IN N
the DT N
treatment NN N
of IN N
advanced JJ p
upper JJ p
gastrointestinal JJ p
cancer NN p
: : p
a DT N
Southwest NNP N
Oncology NNP N
Group NNP N
Study NNP N
. . N

A NNP N
randomized JJ N
trial NN N
was VBD N
conducted VBN N
by IN N
the DT N
Southwest NNP N
Oncology NNP N
Group NNP N
( ( N
SWOG NNP N
) ) N
in IN N
advanced JJ p
carcinoma NN p
of IN p
the DT p
stomach NN p
and CC p
pancreas NNS p
. . p

Patients NNS N
were VBD N
assigned VBN N
to TO N
receive VB N
monthly JJ N
5-fluorouracil JJ i
96-hour CD i
continuous JJ i
infusions NNS i
with IN N
either DT N
bolus JJ i
mitomycin-C NN i
or CC i
oral JJ i
methyl-CCNU JJ i
. . i

Mitomycin-C JJ i
and CC i
methyl-CCNU JJ i
were VBD N
administered VBN N
every DT N
eight CD N
weeks NNS N
. . N

The DT N
5 CD i
FU-mitomycin JJ i
combination NN i
produced VBD N
a DT N
14 CD N
% NN N
and CC N
22 CD N
% NN N
response NN o
rate NN o
in IN N
disseminated VBN N
stomach NN N
and CC N
pancreatic JJ N
carcinoma NN N
, , N
respectively RB N
. . N

The DT N
combination NN i
of IN i
infusion NN i
5 CD i
FU NNP i
and CC i
methyl-CCNU JJ i
achieved JJ N
responses NNS o
in IN N
9 CD N
% NN N
and CC N
5 CD N
% NN N
of IN N
stomach NN N
and CC N
pancreatic JJ N
tumors NNS N
, , N
respectively RB N
. . N

There EX N
was VBD N
no DT N
significant JJ N
difference NN o
in IN o
survival NN o
between IN N
limbs NNS N
for IN N
either DT N
tumor NN N
. . N

Median JJ o
survival NN o
in IN N
gastric JJ N
carcinoma NN N
on IN N
the DT N
5 CD i
FU-mitomycin JJ i
regimen NNS N
was VBD N
25 CD N
weeks NNS N
vs. RB N
18 CD N
weeks NNS N
on IN N
the DT N
5 CD i
FU-METHYL-CCNU JJ i
arm NN N
. . N

In IN N
pancreatic JJ o
carcinoma NN o
median JJ o
survival NN o
on IN N
the DT N
mitomycin NN N
limb NN N
was VBD N
19 CD N
weeks NNS N
as RB N
compared VBN N
to TO N
17 CD N
weeks NNS N
on IN N
the DT N
methyl-CCNU JJ i
program NN N
. . N

Leukopenia NNP o
was VBD N
greater JJR N
for IN N
the DT N
first JJ N
course NN N
on IN N
the DT N
mitomycin NN i
limb NN N
. . N

Regression NNP N
analysis NN N
demonstrated VBD N
that IN N
performance NN o
status NN o
was VBD N
the DT N
most RBS N
important JJ N
pretreatment NN N
characteristic NN N
for IN N
predicting VBG N
survival NN o
in IN N
both DT N
tumors NNS N
. . N

Neither CC N
5 CD i
FU NNP i
infusion NN i
combination NN N
appears VBZ N
to TO N
significantly RB N
alter VB o
the DT o
dismal JJ o
prognosis NN o
of IN N
advanced JJ N
upper JJ N
gastrointestinal JJ N
neoplasms NNS N
. . N

-DOCSTART- -22001391- O O

Multi-institutional JJ N
phase NN N
2 CD N
clinical JJ N
and CC N
pharmacogenomic JJ N
trial NN N
of IN N
tipifarnib JJ i
plus CC i
etoposide JJ i
for IN N
elderly JJ p
adults NNS p
with IN p
newly RB p
diagnosed VBN p
acute RB p
myelogenous JJ p
leukemia NN p
. . p

Tipifarnib NNP N
( ( N
T NNP N
) ) N
exhibits VBZ N
modest JJ N
activity NN N
in IN N
elderly JJ p
adults NNS p
with IN p
newly RB p
diagnosed VBN p
acute RB p
myelogenous JJ p
leukemia NN p
( ( p
AML NNP p
) ) p
. . p

Based VBN N
on IN N
preclinical JJ N
synergy NN N
, , N
a DT N
phase NN N
1 CD N
trial NN N
of IN N
T NNP N
plus CC N
etoposide NN N
( ( N
E NNP N
) ) N
yielded VBD N
25 CD N
% NN N
complete JJ N
remission NN N
( ( N
CR NNP N
) ) N
. . N

We PRP N
selected VBD N
2 CD N
comparable JJ N
dose NN N
levels NNS N
for IN N
a DT N
randomized JJ N
phase NN N
2 CD N
trial NN N
in IN N
84 CD p
adults NNS p
( ( p
age NN p
range NN p
, , p
70-90 JJ p
years NNS p
; : p
median JJ p
, , p
76 CD p
years NNS p
) ) p
who WP p
were VBD p
not RB p
candidates NNS p
for IN p
conventional JJ p
chemotherapy NN p
. . p

Arm VB N
A NNP N
( ( N
T NNP N
600 CD N
mg NN N
twice RB N
a DT N
day NN N
? . N
14 CD N
days NNS N
, , N
E NNP N
100 CD N
mg NN N
days NNS N
1-3 CD N
and CC N
8-10 JJ N
) ) N
and CC N
arm NN N
B NNP N
( ( N
T NNP N
400 CD N
mg NN N
twice RB N
a DT N
day NN N
? . N
14 CD N
days NNS N
, , N
E NNP N
200 CD N
mg NN N
days NNS N
1-3 CD N
and CC N
8-10 CD N
) ) N
yielded VBD N
similar JJ N
CR NNP N
, , N
but CC N
arm NN N
B NNP N
had VBD N
greater JJR N
toxicity NN o
. . o

Total JJ o
CR NNP o
was VBD o
25 CD N
% NN N
, , N
day NN N
30 CD N
death NN N
rate NN N
7 CD N
% NN N
. . N

A DT N
2-gene JJ N
signature NN N
of IN N
high JJ N
RASGRP1 NNP N
and CC N
low JJ N
aprataxin NN N
( ( N
APTX NNP N
) ) N
expression NN N
previously RB N
predicted VBN N
for IN N
T NNP N
response NN o
. . o

Assays NNS N
using VBG N
blasts NNS N
from IN N
a DT N
subset NN N
of IN N
40 CD p
patients NNS p
treated VBN p
with IN N
T NNP N
plus CC N
E NNP N
on IN N
this DT N
study NN N
showed VBD N
that IN o
AMLs NNP o
with IN o
a DT o
RASGRP1/APTX NNP o
ratio NN o
of IN o
more JJR N
than IN N
5.2 CD N
had VBD N
a DT N
78 CD N
% NN N
CR NNP N
rate NN N
and CC N
negative JJ N
predictive JJ N
value NN N
87 CD N
% NN N
. . N

This DT N
ratio NN N
did VBD N
not RB N
correlate VB N
with IN N
outcome NN N
in IN N
41 CD N
patients NNS N
treated VBN N
with IN N
conventional JJ N
chemotherapies NNS N
. . N

The DT N
next JJ N
T-based JJ N
clinical JJ N
trials NNS N
will MD N
test VB N
the DT N
ability NN N
of IN N
the DT N
2-gene JJ N
signature NN N
to TO N
enrich VB N
for IN N
T NNP N
responders NNS N
prospectively RB N
. . N

This DT N
study NN N
is VBZ N
registered VBN N
at IN N
www.clinicaltrials.gov NN N
as IN N
# # N
NCT00602771 NNP N
. . N

-DOCSTART- -16797292- O O

The DT N
impact NN N
of IN N
daily JJ N
sodium NN i
intake NN N
on IN N
posttransplant JJ o
hypertension NN o
in IN p
kidney NN p
allograft NN p
recipients NNS p
. . p

INTRODUCTION NNP N
Posttransplant NNP o
hypertension NN o
is VBZ N
a DT N
well-known JJ N
risk NN N
factor NN N
for IN N
long-term JJ N
allograft NN N
failure NN N
and CC N
mortality NN N
in IN N
kidney NN p
recipients NNS p
. . p

Although IN N
dietary JJ N
sodium NN N
restriction NN N
is VBZ N
a DT N
widely RB N
recommended JJ N
nonpharmacological JJ N
measure NN N
for IN N
control NN N
of IN N
blood NN o
pressure NN o
( ( o
BP NNP o
) ) o
, , N
no DT N
detailed JJ N
investigation NN N
has VBZ N
been VBN N
conducted VBN N
regarding VBG N
the DT N
impact NN N
of IN N
dietary JJ N
sodium NN N
restriction NN N
on IN N
this DT N
condition NN N
. . N

METHODS NNP N
Thirty-two JJ p
patients NNS p
on IN p
antihypertensive JJ p
treatment NN p
completed VBD p
the DT p
study NN p
. . p

They PRP N
were VBD N
randomly RB N
divided VBN N
into IN N
two CD N
groups NNS N
: : N
controls NNS i
( ( N
group NN N
1 CD N
) ) N
versus NN i
strict JJ i
sodium NN i
diet NN i
( ( N
group NN N
2 CD N
; : N
80 CD N
to TO N
100 CD N
mmol NNS N
sodium JJ i
daily RB N
) ) N
. . N

After IN N
randomization NN N
, , N
24-hour JJ o
urine NN o
for IN o
sodium NN o
measurement NN o
, , o
BP NNP o
, , o
and CC o
allograft NN o
functions NNS o
were VBD N
recorded VBN N
at IN N
baseline NN N
and CC N
after IN N
3 CD N
months NNS N
. . N

BP NNP N
treatment NN N
was VBD N
reevaluated VBN N
at IN N
each DT N
visit NN N
throughout IN N
the DT N
study NN N
. . N

RESULTS NNP N
At IN N
baseline NN N
, , N
there EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
age NN N
, , N
sex NN o
, , o
serum JJ o
creatinine NN o
, , o
systolic JJ o
and CC o
diastolic JJ o
BP NNP o
, , o
antihypertensive JJ o
drugs NNS o
, , o
or CC o
24-hour JJ o
urinary JJ o
sodium NN o
levels NNS o
between IN N
the DT N
groups NNS N
. . N

After IN N
3 CD N
months NNS N
, , N
daily JJ o
urinary JJ o
sodium NN o
excretion NN o
( ( N
from IN N
190+/-75 CD N
to TO N
106+/-48 JJ N
mEq/d NN N
, , N
P NNP N
< NNP N
.0001 NNP N
) ) N
, , N
systolic JJ o
BP NNP o
( ( N
from IN N
146+/-21 CD N
to TO N
116+/-11 CD N
mm NNS N
Hg NNP N
) ) N
, , N
and CC N
diastolic JJ o
BP NNP o
( ( N
from IN N
89+/-8 CD N
to TO N
72+/-10 CD N
mm NNS N
Hg NNP N
) ) N
had VBD N
significantly RB N
decreased VBN N
in IN N
group NN N
2 CD N
, , N
while IN N
no DT N
significant JJ N
changes NNS N
were VBD N
observed VBN N
in IN N
group NN N
1 CD N
. . N

CONCLUSION NNP N
Low NNP N
sodium NN N
intake NN N
in IN N
combination NN N
with IN N
antihypertensive JJ N
treatment NN N
appears VBZ N
to TO N
efficiently VB N
control NN o
BP NNP o
in IN N
kidney NN p
allograft NN p
recipients NNS p
with IN N
hypertension NN N
. . N

Twenty-four-hour JJ N
urinary JJ N
sodium NN N
excretion NN N
should MD N
be VB N
checked VBN N
regularly RB N
in IN N
these DT N
patients NNS N
as IN N
a DT N
useful JJ N
marker NN N
to TO N
indicate VB N
whether IN N
the DT N
patient NN N
complies NNS N
with IN N
low JJ N
sodium NN N
intake NN N
. . N

-DOCSTART- -9648960- O O

Bronchodilator NNP N
response NN N
to TO N
salbutamol VB i
after IN N
spontaneous JJ N
recovery NN N
from IN N
nonspecific JJ N
bronchial JJ N
provocation NN N
tests NNS N
in IN N
asthma NN p
. . p

Assessment NN N
of IN N
airway NN N
responsiveness NN N
by IN N
bronchoprovocation NN N
and CC N
bronchodilatation NN N
tests NNS N
is VBZ N
important JJ N
in IN N
the DT N
diagnostic JJ N
work-up JJ N
protocol NN N
of IN N
bronchial JJ p
asthma NN p
and CC N
it PRP N
would MD N
be VB N
convenient JJ N
to TO N
undertake VB N
both DT N
tests NNS N
on IN N
the DT N
same JJ N
occasion NN N
. . N

However RB N
, , N
it PRP N
is VBZ N
not RB N
known VBN N
whether IN N
this DT N
can MD N
be VB N
done VBN N
accurately RB N
. . N

Therefore RB N
, , N
this DT N
study NN N
evaluated VBD N
the DT N
effect NN N
of IN N
a DT N
prior JJ N
bronchial JJ N
provocation NN N
test NN N
on IN N
the DT N
bronchodilator NN N
response NN N
to TO N
salbutamol VB i
after IN N
spontaneous JJ N
recovery NN N
of IN N
the DT N
forced JJ N
expiratory NN N
volume NN N
in IN N
one CD N
second NN N
( ( o
FEV1 NNP o
) ) o
in IN N
a DT p
group NN p
of IN p
asthmatic JJ p
subjects NNS p
. . p

On IN N
two CD N
separate JJ N
occasions NNS N
at IN N
the DT N
same JJ N
time NN N
of IN N
day NN N
, , N
concentration-response JJ N
studies NNS N
with IN N
inhaled JJ N
histamine NN i
or CC i
methacholine NN i
, , i
or CC i
a DT i
sham JJ i
challenge NN i
with IN i
normal JJ i
saline NN i
were VBD N
carried VBN N
out RP N
in IN N
a DT N
blinded JJ N
, , N
randomized JJ N
manner NN N
. . N

Changes NNS N
in IN N
airway NN N
calibre NN N
were VBD N
followed VBN N
as IN N
FEV1 NNP o
and CC N
agonist JJ N
responsiveness NN N
expressed VBN N
as IN N
the DT N
provocative JJ N
concentration NN N
causing VBG N
a DT N
20 CD N
% NN N
fall NN N
in IN N
FEV1 NNP o
( ( N
PC20 NNP N
) ) N
. . N

After IN N
either DT N
spontaneous JJ N
recovery NN N
or CC N
a DT N
fixed-duration JJ N
wait NN N
of IN N
45 CD N
min NNS N
( ( N
when WRB N
appropriate NN N
) ) N
, , N
the DT N
subjects NNS N
received VBD N
2x100 CD N
microg NN N
of IN N
salbutamol NN i
from IN N
a DT N
metered VBN N
dose NN N
inhaler NN N
with IN N
a DT N
spacer NN N
. . N

The DT N
bronchodilator NN N
response NN N
to TO N
salbutamol VB N
was VBD N
expressed VBN N
as IN N
a DT N
percentage NN N
of IN N
initial JJ o
FEV1 NNP o
( ( N
deltaFEV1 CD N
% NN N
init NN N
) ) N
. . N

Bronchial JJ N
challenge NN N
with IN N
both DT N
agonists NNS N
failed VBD N
to TO N
alter VB N
significantly RB N
the DT N
airway NN o
response NN o
to TO N
salbutamol VB N
, , N
with IN N
the DT N
deltaFEV1 NN o
% NN o
init JJ o
mean JJ o
value NN o
( ( N
range NN N
) ) N
being VBG N
16.9 CD N
% NN N
( ( N
9.0-31.9 CD N
) ) N
and CC N
17.5 CD N
% NN N
( ( N
11.6-31.2 JJ N
) ) N
on IN N
the DT N
sham NN N
and CC N
histamine/methacholine JJ N
challenge NN N
day NN N
respectively RB N
. . N

It PRP N
was VBD N
shown VBN N
that IN N
the DT N
degree NN N
of IN N
bronchodilatation NN N
achieved VBN N
after IN N
salbutamol JJ N
200 CD N
microg NN N
is VBZ N
not RB N
affected VBN N
by IN N
prior JJ N
bronchoprovocation NN N
testing VBG N
when WRB N
enough JJ N
time NN N
is VBZ N
allowed VBN N
for IN N
the DT N
airways NNS N
to TO N
recover VB N
spontaneously RB N
to TO N
baseline VB N
forced JJ N
expiratory NN N
volume NN N
in IN N
one CD N
second NN N
. . N

Thus NNP N
evaluation NN N
of IN N
airway NN N
responsiveness NN N
by IN N
both DT N
bronchial JJ N
provocation NN N
tests NNS N
and CC N
bronchodilator NN N
testing NN N
can MD N
be VB N
assessed VBN N
reliably RB N
within IN N
a DT N
few JJ N
hours NNS N
in IN N
asthmatic JJ p
patients NNS p
. . p

-DOCSTART- -9403746- O O

Lower JJR o
extremity NN o
deep JJ o
vein NN o
thrombosis NN o
: : o
a DT N
prospective JJ N
, , N
randomized VBN N
, , N
controlled VBN N
trial NN N
in IN N
comatose NN p
or CC p
sedated VBN p
patients NNS p
undergoing JJ p
femoral JJ i
vein NN i
catheterization NN i
. . i

OBJECTIVES UH N
To TO N
determine VB N
the DT N
rate NN o
of IN o
lower JJR o
extremity NN o
deep JJ o
vein NN o
thrombosis NN o
after IN N
the DT N
use NN N
of IN N
femoral JJ i
catheters NNS i
in IN N
intensive JJ N
care NN N
unit NN N
( ( N
ICU NNP N
) ) N
comatose VBD p
or CC p
sedated VBN p
adults NNS p
. . p

Results NNS N
were VBD N
then RB N
compared VBN N
with IN N
results NNS N
of IN N
patients NNS p
undergoing VBG p
superior JJ i
vena NNS i
cava JJ i
catheterization NN i
. . i

DESIGN NNP N
Prospective NNP N
, , N
randomized VBD N
, , N
controlled VBD N
, , N
unblinded VBD N
study NN N
. . N

SETTING VB N
A DT N
mixed JJ N
medical/surgical JJ N
ICU NNP N
in IN N
a DT N
university NN N
hospital NN N
. . N

PATIENTS VB N
Sixty-one JJ p
comatose NN p
or CC p
sedated VBN p
patients NNS p
admitted VBN p
to TO p
the DT p
ICU NNP p
who WP p
underwent JJ p
central JJ i
venous JJ i
catheterization NN i
. . i

INTERVENTIONS JJ N
Patients NNPS N
were VBD N
monitored VBN N
for IN N
signs NNS N
of IN N
thrombotic JJ o
complications NNS o
. . o

On IN N
catheter NN N
removal NN N
, , N
a DT N
lower-extremity JJ N
bilateral JJ N
phlebographic JJ N
examination NN N
was VBD N
performed VBN N
in IN N
each DT N
patient NN N
. . N

MEASUREMENTS NNP N
AND CC N
MAIN NNP N
RESULTS NNP N
After IN N
randomization NN N
, , N
31 CD p
patients NNS p
underwent JJ p
femoral JJ i
vein NN i
catheterization NN i
and CC p
30 CD p
patients NNS p
underwent JJ p
superior JJ i
vena NN i
cava NN i
catheterization NN i
, , p
either RB p
by IN p
axillary JJ p
( ( p
21 CD p
patients NNS p
) ) p
or CC p
internal JJ p
jugular NN p
vein NN p
( ( p
10 CD p
patients NNS p
) ) p
cannulation NN p
. . p

Single NNP i
lumen NNS i
polyurethane NN i
catheters NNS i
were VBD N
inserted VBN N
for IN N
a DT N
mean JJ N
duration NN N
of IN N
7.1 CD N
+/- JJ N
4.6 CD N
( ( N
SD NNP N
) ) N
days NNS N
in IN N
the DT N
femoral JJ i
vein NN i
group NN i
and CC N
9.9 CD N
+/- JJ N
5.5 CD N
days NNS N
in IN N
the DT N
superior JJ i
vena NN i
cava NN i
group NN i
( ( N
p JJ N
= NNP N
NS NNP N
) ) N
. . N

No DT N
patient NN N
had VBD N
clinical JJ o
signs NNS o
of IN o
leg NN o
venous JJ o
thrombosis NN o
or CC o
pulmonary JJ o
embolism NN o
during IN N
the DT N
study NN N
period NN N
. . N

In IN N
each DT N
patient NN N
, , N
lower JJR o
extremity NN o
bilateral JJ o
phlebography NN o
was VBD N
performed VBN N
at IN N
the DT N
time NN N
of IN N
catheter NN N
removal NN N
. . N

Leg JJ o
phlebographies NNS o
were VBD N
normal JJ N
in IN N
18 CD N
( ( N
60 CD N
% NN N
) ) N
patients NNS N
in IN N
the DT N
femoral JJ N
vein NN N
group NN N
and CC N
26 CD N
( ( N
84 CD N
% NN N
) ) N
patients NNS N
in IN N
the DT N
superior JJ N
vena NN N
cava NN N
group NN N
. . N

Fibrin NNP o
sleeves VBZ o
which WDT N
developed VBD N
around IN N
the DT N
femoral JJ N
catheters NNS N
were VBD N
seen VBN N
in IN N
seven CD N
( ( N
23.3 CD N
% NN N
) ) N
patients NNS N
in IN N
the DT N
femoral JJ i
vein NN i
group NN i
and CC N
in IN N
no DT N
patients NNS N
in IN N
the DT N
superior JJ i
vena NN i
cava NN i
cannulation NN i
group NN i
. . i

Three CD N
patients NNS N
had VBD N
femoral JJ o
vein NN o
thrombosis NN o
, , N
two CD N
( ( N
6.6 CD N
% NN N
) ) N
patients NNS N
in IN N
the DT N
femoral JJ i
vein NN i
group NN i
( ( N
two CD N
nonobstructive JJ N
thromboses NNS N
, , N
adherent NN N
to TO N
the DT N
common JJ N
femoral JJ N
vein NN N
wall NN N
) ) N
and CC N
one CD N
( ( N
3.0 CD N
% NN N
) ) N
patient NN N
in IN N
the DT N
superior JJ i
vena NN i
cava NN i
group NN i
( ( N
nonobstructive JJ N
thrombosis NN N
which WDT N
developed VBD N
in IN N
the DT N
superficial JJ N
femoral JJ N
vein NN N
) ) N
( ( N
p JJ N
= NNP N
NS NNP N
) ) N
. . N

Lower JJR o
deep JJ o
extremities NNS o
thrombosis NN o
developed VBD N
in IN N
five CD N
( ( N
16.7 CD N
% NN N
) ) N
patients NNS N
in IN N
the DT N
femoral JJ N
vein NN N
group NN N
and CC N
in IN N
five CD N
( ( N
16 CD N
% NN N
) ) N
patients NNS N
in IN N
the DT N
superior JJ N
vena NN N
cava NN N
group NN N
( ( N
p JJ N
= NNP N
NS NNP N
) ) N
. . N

CONCLUSIONS NNP N
Femoral NNP i
vein POS i
catheterization NN i
with IN N
a DT N
polyurethane NN N
catheter NN i
is VBZ N
associated VBN N
with IN N
a DT N
lower JJR N
rate NN o
of IN o
extremity NN o
deep JJ o
vein NN o
thrombosis NN o
which WDT N
is VBZ N
similar JJ N
to TO N
the DT N
rate NN N
observed VBD N
after IN N
superior JJ N
vena JJ N
cannulation NN N
in IN N
comatose NN p
or CC p
sedated VBN p
patients NNS p
. . p

Femoral NNP o
vein JJ o
thrombosis NN o
was VBD N
observed VBN N
at IN N
a DT N
rate NN N
of IN N
6.6 CD N
% NN N
after IN N
femoral JJ i
vein NN i
cannulation NN i
and CC N
a DT N
rate NN N
of IN N
3 CD N
% NN N
after IN N
superior JJ i
vena NN i
cava NN i
cannulation NN i
. . i

Given VBN N
the DT N
acceptable JJ N
rate NN N
of IN N
this DT N
clinically NN N
important JJ N
complication NN N
, , N
femoral JJ i
vein NN i
cannulation NN i
offers VBZ N
an DT N
attractive JJ N
alternative NN N
to TO N
insertion NN N
via IN N
the DT N
vena NN i
cava NN i
in IN N
the DT N
critically NN N
ill NN N
. . N

-DOCSTART- -23379240- O O

[ JJ i
Afala NNP i
in IN N
the DT N
treatment NN N
of IN N
patients NNS p
with IN p
BPH NNP p
: : p
efficacy NN N
and CC N
safety NN N
] NN N
. . N

The DT N
double-blind JJ N
, , N
placebo-controlled JJ i
, , N
randomized JJ N
clinical JJ N
trial NN N
involving VBG N
94 CD p
patients NNS p
has VBZ N
evaluated VBN N
the DT N
efficacy NN N
and CC N
safety NN N
of IN N
domestic JJ N
preparation NN N
afala NN i
in IN N
patients NNS p
with IN p
symptoms NNS p
of IN p
I-II NNP p
stages NNS p
benign VBP p
prostatic JJ p
hyperplasia NN p
( ( p
BPH NNP p
) ) p
. . p

It PRP N
was VBD N
shown VBN N
that IN N
a DT N
6-month JJ N
course NN N
of IN N
treatment NN N
with IN N
afala NN i
at IN i
a DT i
dose NN i
of IN i
2 CD i
tablets NNS i
4 CD i
times NNS i
a DT i
day NN i
resulted VBD N
in IN N
a DT N
significant JJ N
reduction NN N
in IN N
the DT N
severity NN N
of IN N
urinary JJ N
disorders NNS N
, , N
estimated VBN N
by IN N
total JJ N
IPSS NNP N
score NN N
, , N
relative JJ N
to TO N
baseline VB N
values NNS N
and CC N
compared VBN N
to TO N
placebo VB i
therapy NN N
. . N

The DT N
most RBS N
pronounced JJ N
therapeutic JJ N
effects NNS N
of IN N
the DT N
drug NN N
were VBD N
registered VBN N
in IN N
respect NN N
of IN N
irritative JJ N
symptoms NNS N
of IN N
BPH NNP N
. . N

According VBG N
uroflowmetry NN N
, , N
peak JJ o
flow NN o
rate NN o
after IN o
6 CD N
months NNS N
of IN N
treatment NN N
was VBD N
increased VBN N
by IN N
more JJR N
than IN N
50 CD N
% NN N
. . N

Significant JJ N
clinical JJ N
benefit NN N
persisted VBD N
not RB N
only RB N
within IN N
the DT N
6-month JJ N
course NN N
of IN N
therapy NN N
, , N
but CC N
3 CD N
months NNS N
after IN N
. . N

Long-term JJ N
therapy NN N
had VBD N
no DT N
effect NN N
on IN N
the DT N
concentration NN o
of IN o
total JJ o
, , o
free JJ o
and CC o
complex JJ o
PSA NNP o
, , o
testosterone NN o
( ( o
total JJ o
and CC o
free JJ o
) ) o
, , o
dihydrotestosterone NN o
, , o
and CC o
prolactin NN o
in IN o
the DT o
blood NN o
. . o

Absence NN o
of IN o
adverse JJ o
effects NNS o
, , o
biochemical JJ o
abnormalities NNS o
, , o
changes NNS o
in IN o
clinical JJ o
blood NN o
and CC o
urine NN o
confirmed VBD N
the DT N
safety NN N
of IN N
6-month JJ N
therapy NN N
. . N

-DOCSTART- -21575074- O O

Literacy NNP N
skills NNS N
in IN N
primary JJ p
school-aged JJ p
children NNS p
with IN p
pragmatic JJ p
language NN p
impairment NN p
: : p
a DT N
comparison NN N
with IN N
children NNS p
with IN p
specific JJ p
language NN p
impairment NN p
. . p

BACKGROUND NNP N
Children NNP p
with IN p
pragmatic JJ p
language NN p
impairment NN p
( ( p
CwPLI NNP p
) ) p
are VBP N
characterized VBN N
by IN N
difficulties NNS N
with IN N
the DT N
interpersonal JJ N
use NN N
of IN N
language NN N
in IN N
social JJ N
contexts NN N
and CC N
they PRP N
possess VBP N
a DT N
range NN N
of IN N
language NN N
difficulties NNS N
that WDT N
affect VBP N
their PRP$ N
educational JJ N
attainment NN N
. . N

Since IN N
literacy NN N
skills NNS N
are VBP N
central JJ N
to TO N
this DT N
attainment NN N
, , N
one CD N
way NN N
of IN N
identifying VBG N
appropriate JJ N
support NN N
needs NNS N
for IN N
CwPLI NNP p
would MD N
be VB N
to TO N
profile VB N
their PRP$ N
reading NN N
and CC N
writing VBG N
skills NNS N
as IN N
a DT N
group NN N
. . N

AIMS NNP N
To TO N
investigate VB N
the DT N
word NN o
reading NN o
, , o
non-word JJ o
reading NN o
, , o
reading VBG o
comprehension NN o
, , o
and CC o
written VBN o
expression NN o
skills NNS o
of IN N
CwPLI NNP N
and CC N
a DT N
comparison NN N
group NN N
of IN N
children NNS p
with IN p
specific JJ p
language NN p
impairment NN p
( ( p
CwSLI NNP p
) ) p
. . p

CwSLI NNP N
were VBD N
recruited VBN N
in IN N
order NN N
to TO N
examine VB N
any DT N
overlaps NNS N
in IN N
literacy NN N
impairments NNS N
for IN N
the DT N
two CD N
groups NNS N
. . N

METHODS NNP N
& CC N
PROCEDURES NNP N
Primary NNP p
school-aged JJ p
CwPLI NNP p
( ( p
n= JJ p
59 CD p
) ) p
and CC p
CwSLI NNP p
( ( p
n= JJ p
12 CD p
) ) p
were VBD p
recruited VBN p
from IN p
speech NN p
and CC p
language NN p
therapists NNS p
. . p

Children NNP N
completed VBD N
standardized JJ i
assessments NNS i
of IN N
literacy NN N
skills NNS N
. . N

The DT N
level NN N
of IN N
impairment NN N
for IN N
each DT N
component NN N
literacy NN N
skill NN N
was VBD N
examined VBN N
for IN N
CwPLI NNP N
and CC N
CwSLI NNP N
. . N

OUTCOMES NNP N
& CC N
RESULTS NNP N
For IN N
the DT N
CwPLI NNP N
, , N
group NN N
mean JJ N
scores NNS N
on IN N
each DT N
of IN N
the DT N
literacy NN o
skills NNS o
were VBD N
at IN N
the DT N
lower JJR N
end NN N
of IN N
the DT N
normal JJ N
range NN N
compared VBN N
with IN N
population NN N
norms NNS N
. . N

The DT N
range NN N
of IN N
individual JJ o
scores NNS o
was VBD N
large JJ N
, , N
with IN N
some DT N
children NNS N
scoring VBG N
near IN N
floor NN N
level NN N
and CC N
others NNS N
scoring VBG N
up RB N
to TO N
2 CD N
SDs NNP N
( ( N
standard JJ N
deviations NNS N
) ) N
above IN N
the DT N
mean NN N
, , N
illustrating VBG N
the DT N
heterogeneity NN N
of IN N
literacy NN N
skills NNS N
within IN N
the DT N
group NN N
. . N

For IN N
the DT N
CwSLI NNP N
, , N
group NN N
mean JJ o
scores NNS o
on IN o
each DT o
of IN o
the DT o
literacy NN o
skills NNS o
were VBD N
between IN N
1 CD N
SD NNP N
and CC N
2 CD N
SDs NNP N
below IN N
the DT N
population NN N
mean NN N
. . N

CwSLI NNP N
were VBD N
significantly RB N
more JJR N
impaired JJ N
on IN N
all DT N
of IN N
the DT N
literacy NN o
measures NNS o
compared VBN N
with IN N
CwPLI NNP N
. . N

This DT N
difference NN N
remained VBD N
even RB N
when WRB N
receptive JJ N
language NN o
ability NN o
and CC N
non-verbal JJ o
intelligence NN o
were VBD N
controlled VBN N
for IN N
. . N

CONCLUSIONS NNP N
& CC N
IMPLICATIONS NNP N
The DT N
results NNS N
demonstrate VBP N
that IN N
there EX N
is VBZ N
a DT N
high JJ N
level NN o
of IN o
literacy NN o
impairment NN o
within IN N
CwPLI NNP p
and CC p
CwSLI NNP p
, , N
providing VBG N
evidence NN N
that IN N
individualized JJ N
literacy NN N
skill NN N
intervention NN N
is VBZ N
important JJ N
for IN N
the DT N
long-term JJ N
academic JJ N
outcome NN N
of IN N
these DT N
children NNS N
. . N

-DOCSTART- -19803237- O O

[ JJ N
Observation NNP N
on IN N
therapeutic JJ N
effect NN N
of IN N
electroacupuncture NN i
plus CC i
blood-letting JJ i
puncture NN i
and CC i
cupping NN i
combined VBN i
with IN i
diet JJ i
intervention NN i
for IN N
treatment NN N
of IN N
acute JJ p
gouty NN p
arthritis NN p
] NNP p
. . N

OBJECTIVE NNP N
To TO N
explore VB N
a DT N
more RBR N
effective JJ N
therapy NN N
for IN N
acute JJ p
gouty NN p
arthritis NN p
. . p

METHODS NNP N
Sixty NNP p
cases NNS p
were VBD N
randomly RB N
divided VBN N
into IN N
an DT N
observation NN N
group NN N
and CC N
a DT N
control NN N
group NN N
, , N
30 CD N
cases NNS N
in IN N
eachgroup NN N
. . N

On IN N
the DT N
basis NN N
of IN N
diet JJ i
intervention NN i
, , N
the DT N
observation NN N
group NN N
was VBD N
treated VBN N
with IN N
electroacupuncture NN i
at IN i
local JJ i
points NNS i
combined VBN i
with IN i
blood-letting JJ i
puncture NN i
and CC i
cupping NN i
, , N
and CC N
the DT N
control NN N
group NN N
with IN N
oral JJ N
administration NN N
of IN N
Probenecid NNP i
. . i

Their PRP$ N
therapeutic JJ N
effects NNS N
were VBD N
ob JJ N
served VBN N
. . N

RESULTS VB N
The DT N
effective JJ N
rate NN N
was VBD N
96.7 CD N
% NN N
in IN N
the DT N
observation NN N
group NN N
which WDT N
was VBD N
better JJR N
than IN N
86.7 CD N
% NN N
in IN N
the DT N
control NN N
group NN N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

After IN N
treatment NN N
, , N
blood NN o
uric JJ o
acid NN o
decreased VBN N
significantly RB N
in IN N
the DT N
two CD N
groups NNS N
( ( N
both DT N
P NNP N
< NNP N
0.01 CD N
) ) N
, , N
the DT N
observed JJ N
group NN N
being VBG N
lower JJR N
than IN N
the DT N
control NN N
group NN N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

CONCLUSION NN N
On IN N
the DT N
basis NN N
of IN N
diet JJ i
intervention NN i
, , i
electroacupuncture JJ i
plus CC i
blood-letting JJ i
puncture NN i
and CC i
cupping NN i
is VBZ N
a DT N
better JJR N
therapy NN N
for IN N
acute JJ N
gouty NN N
arthritis NN N
. . N

-DOCSTART- -17196275- O O

Xuezhikang NN i
, , N
an DT N
extract NN N
of IN N
cholestin NN N
, , N
decreases VBZ N
plasma JJ N
inflammatory JJ N
markers NNS N
and CC N
endothelin-1 NN N
, , N
improve VB N
exercise-induced JJ N
ischemia NN N
and CC N
subjective JJ N
feelings NNS N
in IN N
patients NNS p
with IN p
cardiac JJ p
syndrome NN p
X NNP p
. . p

Previous JJ N
studies NNS N
have VBP N
demonstrated VBN N
that IN N
Xuezhikang NNP i
, , N
an DT N
extract NN N
of IN N
cholestin NN N
, , N
available JJ N
from IN N
Chinese JJ N
red JJ N
yeast NN N
rice NN N
, , N
could MD N
effectively RB N
modify VB N
lipid JJ N
profile NN N
. . N

The DT N
present JJ N
study NN N
was VBD N
undertaken VBN N
to TO N
investigate VB N
whether IN N
Xuezhikang NN i
could MD N
modify VB N
endothelin-1 JJ N
( ( N
ET-1 NNP N
) ) N
, , N
interleukin-6 JJ N
( ( N
IL-6 NNP N
) ) N
, , N
high-sensitivity JJ N
C-reactive JJ N
protein NN N
( ( N
CRP NNP N
) ) N
and CC N
exercise-induced JJ N
ischemia NN N
in IN N
patients NNS p
with IN p
cardiac JJ p
syndrome NN p
X NNP p
( ( p
CSX NNP p
) ) p
. . p

Thirty-six JJ p
patients NNS p
with IN p
CSX NNP p
were VBD N
randomly RB N
assigned VBN N
to TO N
1200 CD N
mg/d NN N
of IN N
Xuezhikang NNP i
or CC N
placebo VBN i
group NN N
( ( N
n=18 RB N
respectively RB N
) ) N
. . N

Blood NN N
samples NNS N
were VBD N
drawn VBN N
at IN N
day NN N
0 CD N
and CC N
day NN N
90 CD N
for IN N
measuring VBG N
above IN N
parameters NNS N
. . N

The DT N
treadmill NN N
exercise NN N
tests NNS N
and CC N
subjective JJ N
feelings NNS N
were VBD N
also RB N
assessed VBN N
at IN N
day NN N
0 CD N
and CC N
day NN N
90 CD N
. . N

The DT N
data NN N
showed VBD N
that IN N
Xuezhikang NNP i
therapy NN N
resulted VBD N
in IN N
significant JJ N
reductions NNS N
in IN N
total JJ o
cholesterol NN o
( ( o
TC NNP o
, , o
19 CD o
% NN o
) ) o
, , o
low-density JJ o
lipoprotein NN o
cholesterol NN o
( ( o
LDL-C NNP o
) ) o
( ( o
26 CD o
% NN o
) ) o
, , o
and CC o
triglycerides NNS o
( ( o
TG NNP o
) ) o
compared VBN N
with IN N
baseline NN N
( ( N
16 CD N
% NN N
, , N
p NN N
< VBD N
0.01 CD N
respectively RB N
) ) N
. . N

The DT N
data NN N
also RB N
showed VBD N
that IN N
Xuezhikang NNP i
led VBD N
significantly RB N
to TO N
reductions NNS o
in IN o
median JJ o
and CC o
log-CRP JJ o
levels NNS o
( ( o
38 CD o
% NN o
and CC o
44 CD o
% NN o
, , o
p NN o
< VBD o
0.01 CD o
respectively RB o
) ) o
, , o
IL-6 NNP o
( ( o
20 CD o
% NN o
, , o
p NN o
< NNP o
0.01 CD o
) ) o
, , o
and CC o
ET-1 NNP o
( ( o
47 CD o
% NN o
, , o
p NN o
< NNP o
0.01 CD o
) ) o
compared VBN N
with IN N
baseline NN N
. . N

The DT N
exercise NN N
duration NN N
, , N
and CC N
time NN o
to TO o
1 CD o
mm NNS o
ST-segment JJ o
depression NN o
was VBD N
significantly RB N
prolonged VBN N
after IN N
Xuezhikang NNP i
therapy NN N
( ( N
9 CD N
% NN N
and CC N
6 CD N
% NN N
, , N
p NN N
< VBD N
0.05 CD N
respectively RB N
) ) N
accompanied VBN N
by IN N
improvement NN o
of IN o
subjective JJ o
feelings NNS o
. . o

Data NNP N
suggested VBD N
that IN N
the DT N
benefit NN N
of IN N
Xuezhikang NNP i
resulted VBD N
in IN N
significant JJ N
modification NN N
vascular JJ o
function NN o
by IN N
reduction NN N
of IN N
ET-1 NNP o
, , o
inflammatory JJ o
markers NNS o
and CC o
LDL NNP o
cholesterol NN o
, , N
which WDT N
may MD N
be VB N
clinically RB N
important JJ N
for IN N
patients NNS p
with IN p
CSX NNP p
. . p

-DOCSTART- -23746205- O O

A DT N
randomized JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ i
trial NN N
of IN N
the DT N
effect NN N
of IN N
dried JJ i
purple JJ i
carrot NN i
on IN N
body NN N
mass NN N
, , N
lipids NNS N
, , N
blood NN N
pressure NN N
, , N
body NN N
composition NN N
, , N
and CC N
inflammatory JJ N
markers NNS N
in IN N
overweight NN p
and CC p
obese JJ p
adults NNS p
: : p
the DT N
QUENCH NNP N
trial NN N
. . N

Obesity NNP N
is VBZ N
a DT N
significant JJ N
health NN N
issue NN N
worldwide NN N
and CC N
is VBZ N
associated VBN N
with IN N
chronic JJ N
, , N
low-grade JJ N
inflammation NN N
predisposing VBG N
the DT N
individual NN N
to TO N
cardiovascular VB N
disease NN N
and CC N
impaired JJ N
blood NN N
glucose JJ N
homeostasis NN N
. . N

Anthocyanins NNS i
and CC i
phenolic JJ i
acids NNS i
from IN i
purple JJ i
carrots NNS i
are VBP N
effective JJ N
at IN N
reversing VBG N
inflammation NN N
and CC N
metabolic JJ N
alterations NNS N
in IN N
animal NN N
models NNS N
, , N
potentially RB N
through IN N
inhibition NN N
of IN N
inflammatory JJ N
pathways NNS N
. . N

The DT N
effects NNS N
of IN N
dried JJ i
purple JJ i
carrot NN i
on IN N
body NN o
mass NN o
, , o
body NN o
composition NN o
, , o
blood NN o
pressure NN o
, , o
lipids NNS o
, , o
inflammatory JJ o
markers NNS o
, , o
liver JJ o
function NN o
tests NNS o
, , o
and CC o
appetite RB o
were VBD N
investigated VBN N
in IN N
16 CD p
males NNS p
( ( p
aged VBN p
53.1 CD p
? . p
7.6 CD p
years NNS p
and CC p
with IN p
a DT p
mean JJ p
BMI NNP p
of IN p
32.8 CD p
? . p
4.6 CD p
kg/m NN p
( ( p
2 CD p
) ) p
) ) p
with IN p
normal JJ p
lipid JJ p
and CC p
inflammatory JJ p
markers NNS p
. . p

There EX N
was VBD N
no DT N
evidence NN N
that IN N
118.5 CD N
mg/day NN N
of IN N
anthocyanins NNS i
and CC i
259.2 CD N
mg/day NN N
of IN N
phenolic JJ i
acids NNS i
for IN i
4 CD N
weeks NNS N
resulted VBD N
in IN N
statistically RB N
significant JJ N
changes NNS N
in IN N
body NN o
mass NN o
, , o
body NN o
composition NN o
, , o
appetite RB o
, , o
dietary JJ o
intake NN o
, , o
low JJ o
density NN o
lipoprotein NN o
, , o
total JJ o
cholesterol NN o
, , o
blood NN o
pressure NN o
, , o
or CC o
C-reactive JJ o
protein NN o
in IN o
these DT N
obese JJ N
participants NNS N
at IN N
the DT N
dose NN N
and CC N
length NN N
of IN N
intervention NN N
used VBN N
in IN N
this DT N
trial NN o
. . o

High JJ o
density NN o
lipoprotein VBP o
cholesterol NN o
was VBD o
lower JJR N
in IN N
the DT N
intervention NN N
group NN N
( ( N
p JJ N
< NNP N
0.05 CD o
) ) o
. . o

Aspartate NNP o
amino NN o
transferase NN o
and CC o
alanine NN o
amino NN o
transferase NN o
did VBD o
not RB N
change NN N
, , N
indicating VBG N
that IN N
the DT N
intervention NN N
was VBD N
safe JJ N
. . N

More JJR N
studies NNS N
are VBP N
required VBN N
to TO N
establish VB N
the DT o
bioavailability NN o
and CC o
pharmacokinetic JJ o
effects NNS o
of IN o
purple JJ i
carrot NN i
anthocyanins NNS i
and CC i
phenolic JJ i
acids NNS i
prior RB i
to TO N
further JJ N
trials NNS N
of IN N
efficacy NN N
with IN N
respect NN N
to TO N
treating VBG o
inflammation NN o
and CC o
metabolic JJ o
alterations NNS o
. . o

-DOCSTART- -15781531- O O

A DT N
comparison NN N
of IN N
the DT N
efficacy NN N
of IN N
heparinized VBN i
and CC i
nonheparinized JJ i
solutions NNS i
for IN N
maintenance NN o
of IN o
perioperative JJ o
radial JJ o
arterial JJ o
catheter NN o
patency NN o
and CC o
subsequent JJ o
occlusion NN o
. . o

In IN N
a DT N
randomized JJ N
, , N
double-blind JJ N
, , N
controlled VBD N
study NN N
, , N
we PRP N
compared VBN N
heparinized VBN i
and CC i
nonheparinized VBN i
infusions NNS i
for IN N
the DT N
maintenance NN o
of IN o
perioperative JJ o
arterial JJ o
catheter NN o
patency NN o
and CC o
the DT o
incidence NN o
of IN o
subsequent JJ o
radial JJ o
arterial JJ o
occlusion NN o
. . o

Two-hundred JJ p
patients NNS p
were VBD N
randomized VBN N
into IN N
2 CD i
groups NNS i
to TO i
receive VB i
heparinized VBN i
( ( i
group NN i
H NNP i
, , i
n JJ i
= NNP i
100 CD i
) ) i
or CC i
nonheparinized VBN i
( ( i
group NN i
S NNP i
, , i
n JJ i
= NNP i
100 CD i
) ) i
flush NN i
solutions NNS i
. . i

Radial NNP o
and CC o
ulnar JJ o
blood NN o
flows NNS o
were VBD i
assessed VBN i
using VBG i
Doppler NNP o
probe NN o
and CC o
pulse JJ o
oximetry NN o
before IN i
, , i
just RB i
after IN i
, , i
and CC i
24 CD i
h NN i
after IN i
decannulation NN o
by IN i
the DT i
same JJ i
investigator NN i
. . i

The DT o
cannulation NN o
site NN o
was VBD N
examined VBN N
for IN N
complications NNS o
such JJ o
as IN o
hematoma NN o
, , o
nerve JJ o
injury NN o
, , o
and CC o
infection NN o
. . o

The DT N
mean JJ N
duration NN N
of IN N
cannulations NNS o
was VBD N
378 CD N
+/- JJ N
159.0 CD N
min NN N
in IN N
group NN N
H NNP N
and CC N
332 CD N
+/- JJ N
154.6 CD N
min NN N
in IN N
group NN N
S. NNP N
The DT N
mean JJ N
number NN N
of IN N
corrective JJ N
interventions NNS N
caused VBN N
by IN N
dampening VBG N
of IN N
the DT N
pressure NN N
wave NN N
( ( N
mean JJ N
number NN N
of IN N
positional JJ N
changes NNS N
[ VBP N
group NN N
S NNP N
, , N
1.5 CD N
+/- JJ N
2.0 CD N
; : N
group NN N
H NNP N
, , N
1.4 CD N
+/- JJ N
3.8 CD N
] NN N
and CC N
mean JJ N
number NN N
of IN N
manual JJ o
flushes NNS o
[ VBP N
group NN N
S NNP N
, , N
1.3 CD N
+/- JJ N
1.7 CD N
; : N
group NN N
H NNP N
, , N
1.2 CD N
+/- JJ N
1.2 CD N
] NN N
) ) N
was VBD N
not RB N
significantly RB N
different JJ N
in IN N
both DT N
groups NNS N
. . N

After IN N
decannulation NN N
, , N
partial JJ o
or CC o
total JJ o
occlusion NN o
developed VBD N
in IN N
20 CD N
group NN N
H NNP N
patients NNS N
and CC N
16 CD N
group NN N
S NNP N
patients NNS N
( ( N
not RB N
significant JJ N
) ) N
. . N

The DT N
incidence NN N
of IN N
occlusion NN o
was VBD N
correlated VBN N
to TO N
the DT N
presence NN p
of IN p
hematoma NN o
at IN p
the DT p
puncture NN p
site NN p
after IN p
decannulation NN p
( ( N
P NNP N
= NNP N
0.013 CD N
) ) N
, , N
long JJ o
duration NN o
of IN o
cannulation NN o
( ( N
P NNP N
= NNP N
0.04 CD N
) ) N
, , N
and CC N
age NN p
< VBP p
65 CD p
yr NN p
( ( N
P NNP N
= NNP N
0.009 CD N
) ) N
. . N

In IN N
conclusion NN N
, , N
there EX N
is VBZ N
no DT N
significant JJ N
difference NN N
between IN N
heparinized VBN i
and CC i
nonheparinized VBN i
flush JJ i
solutions NNS i
for IN N
the DT N
maintenance NN o
of IN o
perioperative JJ o
radial JJ o
artery NN o
catheter NN o
patency NN o
. . o

-DOCSTART- -1712835- O O

Effect NN N
of IN N
daily JJ N
etidronate NN i
on IN N
the DT N
osteolysis NN N
of IN N
multiple JJ N
myeloma NN N
. . N

Progressive NNP N
bone NN N
disease NN N
in IN N
multiple JJ N
myeloma NN N
frequently RB N
leads VBZ N
to TO N
osteolysis VB N
, , N
bone NN N
resorption NN N
, , N
pathologic JJ N
fractures NNS N
, , N
vertebral JJ N
compression NN N
, , N
and CC N
hypercalcemia NN N
. . N

We PRP N
conducted VBD N
a DT N
double-blind NN N
study NN N
in IN N
173 CD p
newly RB p
diagnosed VBN p
multiple JJ p
myeloma NN p
patients NNS p
of IN p
etidronate JJ p
disodium NN p
( ( p
EHDP NNP p
) ) p
, , p
a DT p
diphosphonate NN p
compound NN p
that WDT p
reduces VBZ p
bone NN p
resorption NN p
by IN p
inhibiting VBG p
osteoclastic JJ p
activity NN p
. . p

The DT N
patients NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
oral JJ i
EHDP NNP i
5 CD i
mg/kg/d NN i
or CC i
placebo NN i
until IN N
death NN N
or CC N
discontinuation NN N
due JJ N
to TO N
intolerance VB N
or CC N
refusal VB N
. . N

The DT N
extent NN N
of IN N
vertebral JJ N
deformity NN N
was VBD N
measured VBN N
by IN N
a DT N
vertebral JJ N
index NN N
as RB N
well RB N
as IN N
height NN N
. . N

The DT N
frequency NN o
of IN o
pathologic JJ o
fractures NNS o
, , o
hypercalcemia NN o
, , o
and CC o
bone NN o
pain NN o
was VBD N
regularly RB N
assessed VBN N
, , N
as RB N
well RB N
as IN N
size NN N
and CC N
number NN N
of IN N
osteolytic JJ N
lesions NNS N
. . N

All DT N
patients NNS N
received VBD N
melphalan JJ i
and CC N
prednisone JJ i
daily JJ N
for IN N
4 CD N
days NNS N
every DT N
4 CD N
weeks NNS N
as IN N
the DT N
primary JJ N
chemotherapy NN N
for IN N
their PRP$ N
disease NN N
. . N

Although IN N
the DT N
repeated JJ N
measures NNS N
analysis NN N
showed VBD N
a DT N
significant JJ N
height JJ o
loss NN o
, , N
there EX N
was VBD N
no DT N
difference NN N
between IN N
treatment NN N
arms NNS N
( ( N
P NNP N
= NNP N
.98 NNP N
) ) N
. . N

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
bone NN o
pain NN o
, , o
episodes NNS o
of IN o
hypercalcemia NN o
, , o
or CC o
development NN o
of IN o
pathologic JJ o
fractures NNS o
. . o

Patients NNS p
on IN p
EHDP NNP i
showed VBD N
less JJR N
deterioration NN o
in IN o
their PRP$ o
vertebral JJ o
index NN o
, , N
but CC N
this DT N
difference NN N
only RB N
approached VBD N
statistical JJ N
significance NN N
( ( N
P NNP N
= NNP N
.07 NNP N
) ) N
. . N

We PRP N
conclude VBP N
that IN N
EHDP NNP i
therapy NN N
used VBN N
in IN N
this DT N
dosage NN N
schedule NN N
does VBZ N
not RB N
have VB N
a DT N
clinically RB N
significant JJ N
impact NN N
in IN N
multiple JJ N
myeloma NN N
. . N

-DOCSTART- -17901881- O O

The DT N
logMAR NN i
Kay NNP i
picture NN i
test NN i
and CC N
the DT N
logMAR JJ i
acuity NN i
test NN i
: : i
a DT N
comparative JJ N
study NN N
. . N

PURPOSE NNP N
To TO N
compare VB N
the DT N
level NN N
of IN N
visual JJ o
acuity NN o
with IN N
crowded JJ i
and CC i
uncrowded JJ i
versions NNS i
of IN N
the DT N
logMAR JJ i
acuity NN i
test NN i
and CC N
the DT N
Kay NNP i
picture NN i
test NN i
in IN N
amblyopia NN p
. . p

METHODS NNP N
A NNP N
prospective JJ N
study NN N
was VBD N
carried VBN N
out RP N
on IN N
51 CD p
participants NNS p
with IN p
amblyopia NN p
( ( p
strabismic JJ p
n=17 NN p
; : p
anisometropic CC p
n=10 VBP p
; : p
combined VBN p
n=24 NN p
) ) p
, , p
mean JJ p
age NN p
10 CD p
years NNS p
8 CD p
months NNS p
. . p

The DT p
amblyopia NN p
was VBD p
defined VBN p
as IN p
severe/moderate NN p
( ( p
< JJ p
0.250 CD p
logMAR NN p
) ) p
, , p
n=41 RB p
or CC p
mild VB p
( ( p
> CD p
or CC p
= VB p
0.250 CD p
logMAR NN p
) ) p
, , p
n=10 RB p
. . p

Visual JJ o
acuity NN o
was VBD o
assessed VBN o
uniocularly RB N
using VBG N
the DT N
crowded VBN o
and CC o
uncrowded JJ o
logMAR NN o
acuity NN o
tests NNS o
and CC o
the DT o
logMAR NN o
crowded VBD o
and CC o
uncrowded JJ o
Kay NNP o
picture NN o
tests NNS o
in IN N
random JJ N
orders NNS N
. . N

RESULTS VB N
The DT N
mean JJ o
visual JJ o
acuity NN o
outcome NN o
using VBG N
the DT N
logMAR NN i
crowded VBD i
Kay NNP i
picture NN i
test NN i
( ( N
0.343+/-0.150 JJ N
) ) N
was VBD N
comparable JJ N
( ( N
P=0.084 NNP N
) ) N
with IN N
the DT N
mean JJ N
outcome NN N
using VBG N
the DT N
crowded VBN i
logMAR NN i
acuity NN i
test NN i
( ( N
0.402+/-0.188 JJ N
) ) N
. . N

However RB N
, , N
the DT N
mean JJ o
acuity NN o
difference NN o
between IN N
these DT N
two CD N
tests NNS N
in IN N
the DT N
subgroup NN p
with IN p
severe/moderate NN p
amblyopia NN p
( ( p
0.074+/-0.036 JJ p
) ) p
was VBD N
statistically RB N
significant JJ N
( ( N
P=0.0382 NNP N
) ) N
. . N

The DT N
uncrowded JJ i
logMAR NN o
acuity NN o
test NN i
significantly RB N
overestimated VBD N
visual JJ o
acuity NN o
when WRB N
compared VBN N
with IN N
the DT N
logMAR NN o
crowded VBD o
Kay NNP o
picture NN o
test NN i
( ( N
P NNP N
< NNP N
0.005 CD N
) ) N
by IN N
a DT N
mean NN N
of IN N
0.088+/-0.008 NNP N
. . N

CONCLUSION NNP N
The DT i
logMAR NN i
crowded VBD i
Kay NNP i
picture NN i
test NN i
is VBZ N
a DT N
useful JJ N
tool NN N
in IN N
clinical JJ N
practice NN N
. . N

The DT N
test NN N
design NN N
takes VBZ N
the DT N
crowding NN N
phenomenon NN N
into IN N
account NN N
. . N

It PRP N
provides VBZ N
visual JJ o
acuity NN o
measures NNS N
more RBR N
comparable JJ N
with IN N
the DT N
gold JJ N
standard NN N
crowded VBD i
logMAR JJ i
acuity NN i
test NN i
than IN N
the DT N
uncrowded JJ N
logMAR NN N
acuity NN N
test NN N
. . N

However RB N
, , N
the DT N
outcomes NNS N
in IN N
poorer NN N
acuities NNS N
should MD N
still RB N
be VB N
viewed VBN N
with IN N
caution NN N
. . N

-DOCSTART- -19127003- O O

Measuring VBG N
social JJ o
cognition NN o
in IN N
adolescents NNS p
: : p
implications NNS N
for IN N
students NNS p
with IN p
TBI NNP p
returning VBG p
to TO p
school NN p
. . p

In IN N
everyday JJ N
adolescent JJ i
communication NN i
, , N
the DT N
ability NN N
to TO N
empathise VB i
with IN i
the DT i
mental JJ i
state NN i
of IN i
others NNS i
, , N
recognise NN N
or CC N
infer NN i
intentions NNS i
, , N
or CC N
make VB i
judgements NNS i
about IN i
emotional JJ i
state NN i
, , N
is VBZ N
a DT N
non-conscious JJ N
but CC N
vital JJ N
prerequisite NN N
of IN N
relating VBG N
. . N

Execution NN N
of IN N
these DT N
skills NNS N
in IN N
social JJ N
interactions NNS N
supports VBZ N
both CC N
the DT N
exchange NN N
of IN N
social JJ N
knowledge NN N
and CC N
also RB N
the DT N
development NN N
and CC N
maintenance NN N
of IN N
personal JJ N
relationships NNS N
. . N

Thus RB N
, , N
adolescents NNS p
with IN N
impairments NNS N
in IN N
these DT N
skills NNS N
are VBP N
at IN N
risk NN N
for IN N
a DT N
variety NN N
of IN N
negative JJ N
outcomes NNS N
. . N

In IN N
this DT N
paper NN N
, , N
we PRP N
present VBP N
data NNS N
to TO N
illustrate VB N
that IN N
adolescents NNS p
with IN p
traumatic JJ p
brain NN p
injury NN p
( ( p
TBI NNP p
) ) p
are VBP N
likely JJ N
to TO N
have VB N
impairments NNS o
in IN o
processes NNS o
such JJ o
as IN o
emotion NN o
recognition NN o
and CC o
mental JJ o
state NN o
attribution NN o
, , N
and CC N
that IN N
these DT N
might MD N
not RB N
be VB N
identified VBN N
on IN N
standardised JJ N
tests NNS N
. . N

This DT N
is VBZ N
considered VBN N
from IN N
the DT N
perspective NN N
of IN N
clinical JJ N
assessment NN N
and CC N
intervention NN N
in IN N
school NN N
contexts NN N
. . N

-DOCSTART- -18184678- O O

Impact NN N
of IN N
a DT N
controlled VBN i
heated VBN i
breathing VBG i
tube NN i
humidifier NN i
on IN N
sleep JJ o
quality NN o
during IN N
CPAP NNP i
therapy NN i
in IN p
a DT p
cool JJ p
sleeping NN p
environment NN p
. . p

There EX N
are VBP N
conflicting VBG N
data NNS N
on IN N
the DT N
effect NN N
of IN N
adding VBG N
a DT N
heated VBN i
humidifier NN i
to TO N
nasal RB N
continuous JJ i
positive JJ i
airway NN i
pressure NN i
( ( i
CPAP NNP i
) ) i
therapy NN i
for IN N
patients NNS p
with IN p
obstructive JJ p
sleep JJ p
apnoea NN p
syndrome NN p
( ( p
OSAS NNP p
) ) p
. . p

The DT N
effects NNS N
of IN N
heated JJ N
humidification NN N
on IN N
sleep JJ o
quality NN o
and CC o
treatment NN o
side-effects NNS o
for IN N
patients NNS N
who WP N
prefer VBP N
a DT N
cold JJ N
bedroom NN N
environment NN N
have VBP N
not RB N
been VBN N
studied VBN N
. . N

A DT N
randomised JJ N
, , N
controlled VBD N
crossover RB N
trial NN N
involving VBG N
19 CD p
patients NNS p
with IN p
a DT p
first-ever JJ p
diagnosis NN p
of IN p
OSAS NNP p
measured VBD N
the DT N
effect NN N
of IN N
conventional JJ i
heated JJ i
humidification NN i
added VBD i
to TO i
CPAP NNP i
compared VBN N
with IN N
a DT N
controlled VBN i
heated VBN i
breathing VBG i
tube NN i
humidifier NN i
( ( i
ThermoSmart NNP i
( ( i
R NNP i
) ) i
; : i
Fisher NNP N
and CC N
Paykel NNP N
Healthcare NNP N
, , N
Auckland NNP N
, , N
New NNP N
Zealand NNP N
) ) N
on IN N
sleep JJ o
quality NN o
. . o

During IN N
the DT N
night NN N
in IN N
the DT N
sleep JJ N
laboratory NN N
at IN N
a DT N
mean JJ N
room NN N
temperature NN N
of IN N
14 CD N
degrees NNS N
C NNP N
, , N
less JJR N
condensation NN o
formed VBN N
with IN N
the DT N
controlled VBN i
heated VBD i
breathing VBG i
tube NN i
humidifier NN i
( ( N
1.9 CD N
mL NN N
versus NN N
35.3 CD N
mL NN N
) ) N
in IN N
the DT N
delivery NN N
system NN N
. . N

In IN N
addition NN N
, , N
the DT N
total JJ o
sleep JJ o
time NN o
, , o
time NN o
spent VBN o
in IN o
sleep JJ o
stages NNS o
3 CD o
and CC o
4 CD o
, , o
and CC o
rapid JJ o
eye NN o
movement NN o
sleep JJ o
phases NNS o
were VBD N
significantly RB N
longer RBR N
and CC N
the DT N
overall JJ o
side-effect JJ o
score NN o
was VBD N
lower JJR N
than IN N
with IN N
conventional JJ N
heated JJ N
humidification NN N
. . N

Patients NNS N
on IN N
nasal JJ N
continuous JJ N
positive JJ N
airway NN N
pressure NN N
desiring VBG N
a DT N
cool JJ N
bedroom NN N
temperature NN N
could MD N
benefit VB N
from IN N
controlled VBN i
heated VBN i
breathing VBG i
tube JJ i
humidification NN i
technology NN i
( ( N
with IN N
inputs NNS N
from IN N
ambient JJ N
temperature NN N
, , N
set VBN N
pressure NN N
and CC N
flow NN N
) ) N
. . N

-DOCSTART- -3818024- O O

Beta-adrenoceptor NNP N
blockade NN N
and CC N
cardiovascular JJ o
response NN o
to TO N
the DT N
cold JJ N
pressor NN N
test NN N
. . N

Seven NNP p
healthy JJ p
subjects NNS p
immersed VBD N
a DT N
hand NN N
in IN N
random NN N
order NN N
in IN N
either CC N
warm JJ N
water NN N
or CC N
in IN N
cold JJ N
water NN N
at IN N
5 CD N
degrees NNS N
C NNP N
for IN N
2 CD N
min NNS N
, , N
after IN N
taking VBG N
orally RB N
a DT N
single JJ N
dose NN N
of IN N
120 CD N
mg NN N
of IN N
propranolol NN i
or CC i
a DT i
placebo NN i
in IN N
a DT N
double JJ N
blind NN N
fashion NN N
. . N

The DT N
cold JJ N
stress NN N
resulted VBD N
in IN N
a DT N
significant JJ N
increase NN N
in IN N
blood NN o
pressure NN o
and CC N
the DT N
rate NN o
pressure NN o
product NN o
without IN N
a DT N
change NN N
in IN N
heart NN o
rate NN o
. . o

Beta-adrenoceptor NNP N
blockade NN N
did VBD N
not RB N
affect VB N
the DT N
pressor NN o
response NN o
the DT o
cold NN o
. . o

The DT N
changes NNS N
induced VBN N
by IN N
the DT N
cold JJ N
stress NN N
in IN N
the DT N
cardiovascular JJ o
variables NNS o
in IN N
the DT N
placebo NN N
and CC N
propranolol NN N
experiments NNS N
were VBD N
not RB N
statistically RB N
different JJ N
. . N

The DT N
highest JJS N
rate NN o
pressure NN o
product NN o
during IN N
the DT N
cold JJ N
pressor NN N
test NN N
was VBD N
about IN N
109 CD N
units NNS N
. . N

This DT N
was VBD N
well RB N
below IN N
the DT N
pain NN o
threshold JJ o
value NN N
of IN N
about IN N
200 CD N
found NN N
during IN N
exercise NN N
in IN N
patients NNS p
with IN p
ischaemic JJ p
heart NN p
disease NN p
. . p

In IN N
the DT N
recovery NN N
phase NN N
, , N
the DT N
cardiovascular JJ o
variables NNS o
reverted VBN N
to TO N
pre-immersion NN N
values NNS N
within IN N
1 CD N
min JJ N
inspite NN N
of IN N
continued JJ N
low JJ N
hand NN N
skin NN N
temperature NN N
. . N

-DOCSTART- -21142736- O O

Effects NNS N
of IN N
the DT N
810-nm JJ i
diode NN i
laser NN i
on IN N
hair NN N
and CC N
on IN N
the DT N
biophysical JJ N
properties NNS N
of IN N
skin NN N
. . N

INTRODUCTION NNP N
Laser NNP i
therapy NN i
is VBZ N
clinically RB N
effective JJ N
in IN N
hair NN N
removal NN N
; : N
however RB N
, , N
despite IN N
the DT N
development NN N
of IN N
various JJ N
strategies NNS N
, , N
laser NN N
procedures NNS N
still RB N
present VBP N
a DT N
risk NN N
of IN N
adverse JJ N
effects NNS N
due JJ N
to TO N
the DT N
overheating NN N
of IN N
the DT N
skin NN N
. . N

OBJECTIVE UH N
To TO N
investigate VB N
the DT N
effects NNS N
of IN N
810-nm JJ i
diode NN i
laser RBR i
treatment NN i
on IN N
hair NN N
and CC N
on IN N
the DT N
biophysical JJ N
properties NNS N
of IN N
skin NN N
by IN N
using VBG N
various JJ N
non-invasive JJ i
techniques NNS i
on IN N
various JJ N
parameters NNS N
, , N
including VBG N
hair NN N
analysis NN N
, , N
surface NN N
color NN N
changes NNS N
, , N
integrity NN N
of IN N
skin NN N
barrier NN N
, , N
sebum JJ N
production NN N
rate NN N
and CC N
pH NN N
level NN N
. . N

METHODS NNP N
In IN N
this DT N
randomized JJ N
, , N
right-left JJ N
comparison NN N
study NN N
, , N
35 CD p
women NNS p
with IN p
axillary JJ p
hair NN p
received VBD N
single-session JJ i
diode NN i
laser NN i
therapy NN i
. . i

Hair NNP N
analysis NN N
and CC N
biophysical JJ N
properties NNS N
of IN N
the DT N
skin NN N
were VBD N
assessed VBN N
before IN N
treatment NN N
and CC N
at IN N
weeks NNS N
2 CD N
, , N
4 CD N
and CC N
6 CD N
after IN N
the DT N
therapy NN N
. . N

RESULTS NNP N
Hair NNP o
density NN o
and CC o
thicknesses NNS o
statistically RB o
significantly RB o
decreased VBN o
after IN N
the DT N
first JJ N
post-treatment JJ N
evaluation NN N
. . N

Regarding VBG N
comparison NN N
of IN N
the DT N
biophysical JJ N
properties NNS N
of IN N
the DT N
skin NN N
, , N
there EX N
was VBD N
no DT N
statistically RB N
significant JJ N
difference NN N
in IN N
the DT N
assessments NNS N
, , N
except IN N
for IN N
the DT N
increase NN N
determined VBD N
during IN N
the DT N
second JJ N
week NN N
in IN N
the DT N
erythema NN o
index NN o
in IN N
the DT N
laser-treated JJ N
areas NNS N
. . N

CONCLUSION VB N
The DT N
findings NNS N
of IN N
this DT N
study NN N
showed VBD N
that IN N
the DT N
diode NN i
laser NN i
can MD i
perform VB N
a DT N
significant JJ N
reduction NN N
in IN N
the DT N
hair NN o
amount NN o
without IN N
significant JJ N
epidermal JJ N
damage NN N
, , N
at IN N
least JJS N
for IN N
a DT N
short JJ N
period NN N
. . N

-DOCSTART- -10073522- O O

Fertility NNP N
outcome NN N
after IN N
systemic JJ i
methotrexate NN i
and CC i
laparoscopic NN i
salpingostomy NN i
for IN N
tubal JJ p
pregnancy NN p
. . p

-DOCSTART- -25186034- O O

Tofacitinib NN i
with IN i
methotrexate NN i
in IN N
third-line JJ N
treatment NN N
of IN N
patients NNS p
with IN p
active JJ p
rheumatoid NN p
arthritis NN p
: : p
patient-reported JJ N
outcomes NNS N
from IN N
a DT N
phase NN N
III NNP N
trial NN N
. . N

OBJECTIVE UH N
To TO N
assess VB N
patient-reported JJ N
outcomes NNS N
( ( N
PROs NNP N
) ) N
for IN N
tofacitinib NN N
, , N
an DT N
oral JJ N
JAK NNP N
inhibitor NN N
for IN N
the DT N
treatment NN N
of IN N
rheumatoid NN N
arthritis NN N
( ( N
RA NNP N
) ) N
, , N
in IN N
a DT N
6-month JJ N
, , N
phase JJ N
III NNP N
, , N
randomized VBD N
controlled VBN N
trial NN N
. . N

METHODS NNP N
Patients NNPS p
ages VBZ p
?18 CD p
years NNS p
with IN p
active JJ p
RA NNP p
with IN p
an DT p
inadequate JJ p
response NN p
to TO p
?1 VB p
tumor NN p
necrosis NN p
factor NN p
inhibitor NN p
( ( p
TNFi NNP p
) ) p
and CC p
receiving VBG p
stable JJ p
background NN p
methotrexate NN p
were VBD p
randomized VBN p
2:2:1:1 CD i
to TO i
tofacitinib VB i
5 CD i
mg NN i
or CC i
10 CD i
mg JJ i
twice RB i
daily RB i
, , i
or CC i
placebo NN i
advanced VBD i
to TO i
tofacitinib VB i
5 CD i
mg NN i
or CC i
10 CD i
mg JJ i
twice RB i
daily RB i
at IN i
month NN i
3 CD i
. . i

PROs NNS N
measured VBD N
at IN N
month NN N
3 CD N
included VBD o
patient NN o
global JJ o
assessment NN o
of IN o
disease NN o
activity NN o
( ( o
PtGA NNP o
) ) o
, , o
pain VBP o
, , o
Health NNP o
Assessment NNP o
Questionnaire NNP o
( ( o
HAQ NNP o
) ) o
disability NN o
index NN o
( ( o
DI NNP o
) ) o
, , o
Medical NNP o
Outcomes NNP o
Study NNP o
( ( o
MOS NNP o
) ) o
Short NNP o
Form NNP o
36 CD o
Health NNP o
Survey NNP o
version NN o
2 CD o
( ( o
SF-36v2 NNP o
; : o
acute NN o
) ) o
, , o
Functional NNP o
Assessment NNP o
of IN o
Chronic NNP o
Illness NNP o
Therapy-Fatigue NNP o
( ( o
FACIT-F NNP o
) ) o
, , o
and CC o
MOS NNP o
Sleep NNP o
Scale NNP o
. . o

RESULTS NNP o
Patients NNPS N
received VBD N
tofacitinib JJ N
5 CD N
mg NN N
( ( N
n JJ N
= NNP N
133 CD N
) ) N
or CC N
10 CD N
mg NN N
( ( N
n JJ N
= NNP N
134 CD N
) ) N
or CC N
placebo NN N
advanced VBD N
to TO N
tofacitinib VB N
5 CD N
mg NN N
( ( N
n JJ N
= NNP N
66 CD N
) ) N
or CC N
10 CD N
mg NN N
( ( N
n JJ N
= NNP N
66 CD N
) ) N
. . N

HAQ NNP o
DI NNP o
( ( o
reported VBD o
previously RB o
) ) o
, , o
PtGA NNP o
( ( o
P NNP o
< NNP o
0.0001 CD o
) ) o
, , o
and CC o
SF-36v2 NNP o
physical JJ o
and CC o
mental JJ o
component NN o
summary NN o
( ( o
P NNP o
< NNP o
0.05 CD o
) ) o
scores NNS o
were VBD o
improved VBN o
for IN o
both DT N
tofacitinib JJ N
doses NNS N
versus VBP N
placebo NN N
. . N

Furthermore NNP N
, , N
improvements NNS N
greater JJR N
than IN N
or CC N
equal JJ N
to TO N
the DT N
minimum NN N
clinically RB N
important JJ N
difference NN N
were VBD N
more RBR N
frequently RB N
reported VBN N
by IN N
tofacitinib-treated JJ N
patients NNS N
versus VBP N
placebo NN N
for IN N
PtGA NNP o
( ( o
P NNP o
< NNP N
0.05 CD N
) ) o
, , o
pain NN o
( ( o
P NNP o
< NNP N
0.0001 CD o
) ) o
, , o
HAQ NNP o
DI NNP o
( ( N
P NNP N
< NNP N
0.05 CD N
) ) o
, , o
SF-36v2 NNP o
physical JJ o
and CC o
mental JJ o
component NN o
summary JJ o
scores NNS o
( ( o
P NNP o
< NNP N
0.05 CD N
) ) N
, , N
and CC N
FACIT-F NNP o
( ( o
P NNP o
< VBZ N
0.001 CD N
for IN N
5 CD N
mg JJ N
twice RB N
daily RB o
) ) o
. . o

No DT o
statistical JJ o
differences NNS o
were VBD o
observed VBN N
in IN N
the DT N
MOS NNP o
Sleep NNP o
Scale NNP o
. . o

CONCLUSION NNP o
Tofacitinib NNP N
treatment NN N
resulted VBD N
in IN N
significant JJ N
, , N
clinically RB N
meaningful JJ N
improvements NNS N
in IN N
multiple JJ N
PROs NNP N
versus NN N
placebo NN N
over IN N
3 CD N
months NNS N
of IN N
treatment NN p
in IN p
patients NNS p
with IN p
active JJ p
RA NNP p
and CC p
a DT p
previous JJ p
inadequate JJ p
response NN p
to TO p
TNFi NNP p
. . p

-DOCSTART- -18355797- O O

Resource NNP o
utilization NN o
and CC N
economic JJ o
costs NNS o
of IN N
care NN N
based VBN N
on IN N
a DT N
randomized JJ N
trial NN N
of IN N
vacuum-assisted JJ i
closure NN i
therapy NN i
in IN N
the DT N
treatment NN N
of IN N
diabetic JJ p
foot NN p
wounds NNS p
. . p

BACKGROUND NNP N
To TO N
evaluate VB N
resource NN o
utilization NN o
and CC N
direct JJ o
economic JJ o
costs NNS o
of IN N
care NN N
for IN N
patients NNS p
treated VBN p
with IN p
negative-pressure JJ i
wound NN i
therapy NN i
( ( i
NPWT NNP i
) ) i
, , N
using VBG N
the DT i
Vacuum-Assisted JJ i
Closure NNP i
( ( i
V.A.C NNP i
. . i

) ) i
system NN i
, , N
compared VBN N
to TO N
standard VB i
moist NN i
wound IN i
therapy NN i
( ( i
MWT NNP i
) ) i
. . i

METHODS CC N
A DT N
total NN N
of IN N
162 CD p
diabetic JJ p
patients NNS p
with IN p
post-amputation JJ p
wounds NNS p
( ( p
up IN p
to TO p
the DT p
trans-metatarsal JJ p
level NN p
) ) p
entered VBD N
a DT N
16-week JJ N
, , N
randomized JJ N
clinical JJ N
trial NN N
. . N

Patients NNS p
randomized VBD p
to TO p
V.A.C NNP i
. . i

( ( p
n JJ p
= NNP p
77 CD p
) ) p
received VBD p
therapy NN i
with IN i
dressing NN i
changes NNS i
every DT N
48 CD N
hours NNS N
. . N

Control NN p
patients NNS p
( ( p
n JJ p
= NNP p
85 CD p
) ) p
received VBN p
standard JJ p
MWT NNP i
. . i

Resource NNP o
utilization NN o
, , o
procedures NNS o
, , o
and CC o
direct JJ o
costs NNS o
were VBD N
calculated VBN N
and CC N
analyzed VBN N
in IN N
this DT N
post NN N
hoc NN N
retrospective NN N
study NN N
. . N

RESULTS NNP N
There EX N
was VBD N
no DT N
difference NN N
between IN N
groups NNS p
for IN N
in-patient JJ o
hospital NN o
stay NN o
( ( o
number NN o
of IN o
admissions NNS o
or CC o
length NN o
of IN o
stay NN o
) ) o
. . N

More RBR N
surgical JJ N
procedures NNS N
( ( N
including VBG N
debridement NN N
) ) N
were VBD N
required VBN N
in IN N
the DT N
MWT NNP i
group NN N
( ( N
120 CD N
vs RB N
43 CD N
NPWT NNP i
, , N
P NNP N
< NNP N
.001 NNP N
) ) N
. . N

The DT N
average JJ o
number NN o
of IN o
dressing VBG o
changes NNS o
performed VBN o
per IN o
patient NN o
was VBD N
118.0 CD N
( ( N
range VB N
12-226 NNS N
) ) N
for IN N
MWT NNP i
versus NN N
41 CD N
( ( N
6-140 JJ N
) ) N
for IN N
NPWT NNP i
( ( N
P NNP N
= NNP N
.0001 NNP N
) ) N
. . N

The DT N
MWT NNP i
group NN N
had VBD N
11 CD N
( ( N
range VB N
0-106 NN N
) ) N
outpatient NN o
treatment NN o
visits NNS o
during IN N
the DT N
study NN N
versus NN N
4 CD N
( ( N
range VB N
0-47 NN N
) ) N
in IN N
the DT N
NPWT NNP i
group NN N
( ( N
P NNP N
< NNP N
.05 NNP N
) ) N
. . N

The DT N
average JJ o
direct JJ o
cost NN o
per IN o
patient NN o
treated VBN N
for IN N
8 CD N
weeks NNS N
or CC N
longer JJR N
( ( N
independent JJ N
of IN N
clinical JJ N
outcome NN N
) ) N
was VBD N
$ $ N
27,270 CD N
and CC N
$ $ N
36,096 CD N
in IN N
the DT N
NPWT NNP N
and CC N
MWT NNP N
groups NNS N
, , N
respectively RB N
. . N

The DT N
average JJ o
total JJ o
cost NN o
to TO o
achieve VB o
healing NN o
was VBD N
$ $ N
25,954 CD N
for IN N
patients NNS N
treated VBN N
with IN N
NPWT NNP i
( ( N
n JJ N
= NNP N
43 CD N
) ) N
compared VBN N
with IN N
$ $ N
38,806 CD N
for IN N
the DT N
MWT NNP i
group NN N
( ( N
n JJ N
= NNP N
33 CD N
) ) N
. . N

CONCLUSION NNP N
Treatment NNP N
of IN N
diabetic JJ p
patients NNS p
with IN p
post NN p
amputation NN p
wounds VBZ p
using VBG N
NPWT NNP i
resulted VBD N
in IN N
lower JJR N
resource NN o
utilization NN o
and CC N
a DT N
greater JJR N
proportion NN o
of IN o
patients NNS o
obtaining VBG N
wound IN N
healing VBG N
at IN N
a DT N
lower JJR o
overall JJ o
cost NN o
of IN o
care NN o
when WRB N
compared VBN N
to TO N
MWT NNP i
. . i

-DOCSTART- -10808042- O O

Increased VBN o
growth NN o
hormone NN o
response NN N
to TO N
sumatriptan VB i
challenge NN N
in IN N
adult NN p
autistic JJ p
disorders NNS p
. . p

Serotonergic NNP N
( ( N
5-HT JJ N
) ) N
abnormalities NNS N
have VBP N
been VBN N
documented VBN N
in IN N
autism NN N
. . N

To TO N
assess JJ N
sensitivity NN N
of IN N
the DT N
5-HT1d JJ N
receptor NN N
, , N
growth NN o
hormone NN o
response NN o
to TO N
the DT N
5-HT1d JJ i
receptor NN i
agonist NN i
sumatriptan NN i
was VBD N
studied VBN N
in IN N
adult NN p
autistic JJ p
patients NNS p
and CC p
matched VBD p
normal JJ p
controls NNS p
. . p

In IN N
this DT N
study NN N
, , N
11 CD p
adult NN p
patients NNS p
with IN p
autism NN p
or CC p
Asperger NNP p
's POS p
disorder NN p
were VBD p
compared VBN p
with IN p
nine CD p
matched JJ p
controls NNS p
. . p

All DT N
subjects NNS N
were VBD N
randomized VBN N
to TO N
single JJ i
dose JJ i
sumatriptan NN i
( ( i
6 CD i
mg RB i
SQ NNP i
) ) i
and CC i
placebo NN i
challenges NNS i
, , i
separated VBN i
by IN i
a DT i
1-week JJ i
interval NN i
, , i
and CC i
growth NN o
hormone NN o
was VBD i
measured VBN i
before IN i
and CC i
during IN i
the DT i
challenges NNS i
. . i

The DT N
results NNS N
showed VBD N
a DT N
highly RB N
significant JJ N
diagnosisxdrugxtime JJ o
interaction NN o
on IN N
repeated JJ N
measure NN N
analysis NN N
covaried VBD N
for IN N
baseline NN N
. . N

This DT N
suggests VBZ N
that IN N
autistic JJ p
patients NNS p
had VBD N
significantly RB N
greater JJR N
growth NN o
hormone NN o
response NN o
to TO N
sumatriptan VB i
than IN N
normal JJ N
controls NNS N
, , N
independent JJ N
of IN N
placebo JJ N
effects NNS N
. . N

Therefore RB N
, , N
abnormalities NNS N
in IN N
5-HT JJ N
regulation NN N
in IN N
autism NN N
may MD N
be VB N
related VBN N
to TO N
increased VBN N
sensitivity NN N
of IN N
the DT N
5-HT1d JJ N
inhibitory NN N
receptor NN N
in IN N
autism NN N
. . N

-DOCSTART- -11536065- O O

[ JJ N
Comparison NNP N
between IN N
anterior JJ i
rhinomanometry NN i
and CC N
impulse-oscillometric JJ i
rhinometry NN i
found VBD N
within IN N
nasal JJ o
allergen JJ o
provocation NN o
] NNP o
. . N

UNLABELLED NNP N
Besides IN N
the DT N
standard JJ N
method NN N
of IN N
anterior JJ i
rhinomanometry NN i
( ( i
aR NN i
) ) i
, , i
the DT i
impulse-oscillometric JJ i
rhinometry NN i
( ( i
IOS NNP i
) ) i
is VBZ N
available JJ N
for IN N
measurements NNS N
of IN N
the DT N
nasal JJ o
resistance NN o
. . o

The DT N
aR NN N
is VBZ N
a DT N
procedure NN N
dependent NN N
on IN N
the DT N
cooperation NN N
of IN N
the DT N
patient NN N
, , N
whereas JJ N
IOS NNP N
is VBZ N
measured VBN N
regardless RB N
from IN N
the DT N
breathing NN N
activities NNS N
of IN N
the DT N
patient NN N
. . N

We PRP N
examined VBD N
weather RP N
the DT N
resistance-measurement NN N
by IN N
means NNS N
of IN N
IOS NNP N
in IN N
comparison NN N
to TO N
the DT N
aR NN N
is VBZ N
a DT N
more RBR N
suitable JJ N
method NN N
for IN N
nasal JJ o
allergic JJ o
provocation NN o
. . o

METHOD NNP N
17 CD p
patients NNS p
with IN p
anamnestic JJ p
known VBN p
rhinokonjunktivitis NN p
( ( p
6 CD p
f NN p
, , p
11 CD p
m NN p
) ) p
had VBD p
a DT p
pricktest NN i
and CC p
then RB p
a DT p
nasal JJ i
provocation NN i
testing VBG i
with IN p
an DT p
allergen NN p
which WDT p
provoked VBD p
a DT p
reaction NN p
on IN p
the DT p
skin NN p
. . p

The DT N
complete JJ N
resistance NN o
of IN N
the DT N
nose NN N
was VBD N
measured VBN N
in IN N
a DT N
randomized JJ N
order NN N
by IN N
means NNS N
of IN N
aR NN i
and CC i
IOS NNP i
. . i

RESULTS VB N
The DT N
complete JJ o
resistance NN o
showed VBD N
neither CC N
in IN N
the DT N
basic JJ N
measurement NN N
( ( N
aR JJ N
0,38 CD N
+/- JJ N
0,14 CD N
kPa/l/s NN N
; : N
IOS NNP N
0,38 CD N
+/- JJ N
0,11 CD N
kPa/l/s NN N
) ) N
nor CC N
in IN N
the DT N
control NN N
solution NN N
( ( N
aR JJ N
0,38 CD N
+/- JJ N
0,14 CD N
; : N
IOS NNP N
0,39 CD N
+/- JJ N
0,14 CD N
) ) N
nor CC N
after IN N
application NN N
of IN N
the DT N
allergenic JJ N
solution NN N
( ( N
15 CD N
min NN N
: : N
aR JJ N
0,69 CD N
+/- JJ N
0,27 CD N
; : N
IOS NNP N
0,77 CD N
+/- JJ N
0,42 CD N
; : N
30 CD N
min NN N
: : N
aR JJ N
0,65 CD N
+/- JJ N
0,29 CD N
; : N
IOS NNP N
0,6 CD N
+/- JJ N
0,38 CD N
) ) N
a DT N
significant JJ N
difference NN N
between IN N
the DT N
two CD N
methods NNS N
. . N

The DT N
results NNS N
of IN N
the DT N
measurement NN o
of IN o
aR NN o
and CC o
IOS NNP o
after IN N
the DT N
allergenic JJ N
solution NN N
showed VBD N
a DT N
positive JJ N
correlation NN o
( ( N
15 CD N
min NN N
: : N
r NN N
= VBZ N
0,63 CD N
, , N
p NN N
< VBD N
0,01 CD N
; : N
30 CD N
min NN N
: : N
r NN N
= VBZ N
0,67 CD N
, , N
p NN N
< NNP N
0,01 CD N
) ) N
. . N

We PRP N
found VBD N
by IN N
means NNS N
of IN N
clinic NN N
and CC N
measurement NN N
methods NNS N
in IN N
the DT N
aR NN N
of IN N
7 CD p
patients NNS p
a DT p
positive JJ p
reaction NN o
, , p
within IN p
7 CD p
patient NN p
a DT p
negative JJ p
reaction NN o
, , p
3 CD p
patients NNS p
had VBD p
a DT p
unspecific JJ o
nasal NN o
hyperreactivity NN o
. . o

There EX N
was VBD N
a DT N
correspondence NN N
in IN N
6 CD p
of IN p
the DT p
7 CD p
patients NNS p
with IN p
positive JJ p
reaction NN o
in IN p
aR NN p
between IN N
both DT N
methods NNS N
. . N

4 CD N
of IN p
the DT p
7 CD p
results NNS p
with IN p
negative JJ p
reaction NN o
in IN N
the DT N
aR NN N
would MD N
have VB N
been VBN N
positive JJ N
then RB N
underlying VBG N
the DT N
same JJ N
criteria NNS N
in IN N
the DT N
IOS NNP N
without IN N
announcing VBG N
the DT N
symptomscore NN o
a DT N
relevant JJ N
clinical JJ N
symptomatic NN N
while IN N
testing VBG N
. . N

CONCLUSION NNP N
IOS NNP i
is VBZ N
a DT N
suitable JJ N
procedure NN N
for IN N
nasal JJ N
provocation NN N
testing VBG N
and CC N
provides VBZ N
results NNS N
similar JJ N
to TO N
the DT N
aR NN N
. . N

In IN N
comparison NN N
to TO N
aR VB N
IOS NNP N
is VBZ N
not RB N
dependent JJ N
on IN N
the DT N
patients NNS N
cooperation NN N
. . N

Due NNP N
to TO N
its PRP$ N
higher JJR N
sensitivity NN N
the DT N
valid JJ N
limits NNS N
of IN N
the DT N
aR NN N
at IN N
provocation NN N
testings NNS N
can MD N
not RB N
be VB N
transferred VBN N
to TO N
IOS NNP N
to TO N
avoid VB N
a DT N
false JJ o
positive JJ o
reaction NN o
. . o

-DOCSTART- -20920086- O O

The DT N
effect NN N
of IN N
educational JJ i
intervention NN i
on IN N
pain NN o
beliefs NNS o
and CC o
postoperative JJ o
pain NN o
relief NN o
among IN N
Chinese JJ p
patients NNS p
with IN p
fractured JJ p
limbs NNS p
. . p

-DOCSTART- -14617595- O O

Remifentanil NNP N
with IN N
morphine JJ N
transitional JJ N
analgesia NN N
shortens VBZ N
neurological JJ o
recovery NN o
compared VBN N
to TO N
fentanyl VB N
for IN N
supratentorial JJ N
craniotomy NN N
. . N

PURPOSE NNP N
To TO N
compare VB N
the DT N
recovery NN o
profiles NNS o
, , o
efficacy NN o
and CC o
safety NN o
of IN N
remifentanil NN N
and CC N
morphine NN N
for IN N
transitional JJ N
analgesia NN N
with IN N
fentanyl NN N
in IN N
patients NNS p
undergoing VBG p
elective JJ p
craniotomy NN p
for IN p
supratentorial JJ p
mass NN p
lesions NNS p
. . p

METHODS NNP N
Ninety-one JJ p
patients NNS p
were VBD N
enrolled VBN N
in IN N
this DT N
prospective JJ N
, , N
randomized VBN N
, , N
multicentre FW N
study NN N
. . N

Anesthesia NNP i
was VBD i
induced VBN i
with IN i
thiopental JJ i
and CC i
remifentanil NN i
( ( i
1.0 CD i
micro NN i
g NN i
x NNP i
kg NN i
( ( i
-1 NNP i
) ) i
bolus NN i
and CC i
a DT i
1 CD i
micro NN i
g NN i
x NNP i
kg NN i
( ( i
-1 NNP i
) ) i
x VBP i
min NN i
( ( i
-1 NNP i
) ) i
infusion NN i
) ) i
or CC i
fentanyl NN i
( ( i
1 CD i
micro NN i
g NN i
x NNP i
kg NN i
( ( i
-1 NNP i
) ) i
bolus NN i
and CC i
a DT i
1.0 CD i
micro NN i
g NN i
x NNP i
kg NN i
( ( i
-1 NNP i
) ) i
x VBP i
min NN i
( ( i
-1 NNP i
) ) i
infusion NN i
) ) i
. . i

The DT i
opioid JJ i
infusion NN i
continued VBD i
until IN i
the DT i
level NN i
of IN i
anesthesia NN i
was VBD i
deemed VBN i
appropriate JJ i
for IN i
intubation NN i
. . i

Anesthesia NNP i
was VBD i
maintained VBN i
with IN i
N NNP i
( ( i
2 CD i
) ) i
O/O NNP i
( ( i
2 CD i
) ) i
, , i
isoflurane $ i
0.5 CD i
MAC NNP i
and CC i
remifentanil VB i
0.2 CD i
micro NN i
g NN i
x NNP i
kg NN i
( ( i
-1 NNP i
) ) i
x VBP i
min NN i
( ( i
-1 JJ i
) ) i
or CC i
fentanyl $ i
0.04 CD i
micro NN i
g NN i
x NNP i
kg NN i
( ( i
-1 NNP i
) ) i
x VBP i
min NN i
( ( i
-1 NNP i
) ) i
. . i

At IN i
bone NN i
flap NN i
replacement NN i
, , i
either DT i
morphine NN i
0.08 CD i
mg NN i
x NN i
kg NN i
( ( i
-1 NN i
) ) i
( ( i
remifentanil JJ i
group NN i
) ) i
or CC i
saline NN i
( ( i
fentanyl JJ i
group NN i
) ) i
was VBD i
given VBN i
. . i

RESULTS NNP N
Systolic NNP o
blood NN o
pressure NN o
was VBD N
greater JJR N
in IN N
those DT N
receiving VBG N
fentanyl NN N
during IN N
induction NN N
( ( N
145.6 CD N
+/-17.5 JJ N
mmHg NN N
vs NN N
128.8 CD N
+/-18.3 JJ N
mmHg NN N
; : N
P NNP N
= NNP N
0.006 CD N
) ) N
and CC N
intubation NN N
( ( N
126.9 CD N
+/-17.1 JJ N
vs NN N
110.9 CD N
+/-16.5 JJ N
mmHg NN N
; : N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

Median JJ o
time NN o
to TO o
tracheal VB o
extubation NN o
was VBD N
similar JJ N
but CC N
less RBR N
variable JJ N
in IN N
the DT N
remifentanil NN N
group NN N
( ( N
remifentanil JJ N
= $ N
8 CD N
min NN N
: : N
range NN N
= VBZ N
2-44 JJ N
min NN N
; : N
fentanyl CC N
= $ N
8 CD N
min NN N
: : N
range NN N
= VBZ N
1-732 JJ N
min NN N
) ) N
. . N

The DT N
fentanyl JJ N
patients NNS N
required VBD N
a DT N
longer JJR N
time NN o
to TO o
achieve VB o
the DT o
first JJ o
normal JJ o
neurological JJ o
score NN o
( ( N
fentanyl JJ N
= $ N
38.0 CD N
min NN N
; : N
remifentanil CC N
= $ N
26.0 CD N
min NN N
; : N
P NNP N
= NNP N
0.035 CD N
) ) N
. . N

Both CC N
the DT N
anesthesiologists NNS N
and CC N
the DT N
recovery NN N
room NN N
nurses NNS N
rated VBD N
remifentanil JJ N
better RBR N
with IN N
respect NN N
to TO N
level NN o
of IN o
consciousness NN o
. . o

Analgesics NNS o
were VBD N
required VBN N
earlier RBR N
in IN N
patients NNS N
receiving VBG N
remifentanil NN N
; : N
median JJ N
time NN N
0.5 CD N
vs NN N
1.08 CD N
hr NN N
, , N
P NNP N
< VBZ N
0.001 CD N
. . N

CONCLUSIONS NNP N
Remifentanil NNP N
is VBZ N
a DT N
suitable JJ N
alternative NN N
to TO N
fentanyl VB N
in IN N
supratentorial JJ N
craniotomy NN N
. . N

Time NN o
to TO o
preoperative VB o
neurological JJ o
recovery NN o
is VBZ N
faster RBR N
and CC N
morphine VB N
provides VBZ N
some DT N
transitional JJ o
analgesia NN o
without IN N
compromising VBG N
the DT N
quality NN o
of IN o
recovery NN o
. . o

-DOCSTART- -11500608- O O

Does VBZ N
short-term JJ N
treatment NN N
with IN N
proton NN i
pump NN i
inhibitors NNS i
cause VBP N
rebound JJ N
aggravation NN N
of IN N
symptoms NNS N
? . N
BACKGROUND NNP N
Rebound NNP N
acid VBZ N
hypersecretion NN N
might MD N
occur VB N
after IN N
treatment NN N
with IN N
proton NN i
pump NN i
inhibitors NNS i
. . i

This DT N
study NN N
looks VBZ N
for IN N
a DT N
rebound JJ N
aggravation NN N
of IN N
symptoms NNS N
after IN N
short-term JJ N
treatment NN N
with IN N
lansoprazole NN i
. . i

STUDY NNP N
Sixty-two JJ p
patients NNS p
( ( p
19 CD p
men NNS p
and CC p
43 CD p
women NNS p
; : p
mean JJ p
age NN p
, , p
54 CD p
years NNS p
; : p
range NN p
, , p
32-77 CD p
years NNS p
) ) p
with IN p
heartburn NN p
and CC p
regurgitation NN p
and CC p
normal JJ p
upper JJ p
endoscopy NN p
findings NNS p
were VBD N
studied VBN N
in IN N
a DT N
randomized JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ i
trial NN N
with IN N
a DT N
crossover NN N
design NN N
. . N

There EX N
were VBD N
two CD N
5-day JJ N
treatment NN N
periods NNS N
with IN N
lansoprazole JJ i
60 CD i
mg NN i
once RB i
daily JJ i
or CC i
placebo NN i
in IN N
random JJ N
order NN N
, , N
separated VBN N
by IN N
a DT N
9-day JJ N
washout NN N
period NN N
. . N

Reflux NNP o
, , o
total JJ o
, , o
and CC o
antacid JJ o
scores NNS o
were VBD N
calculated VBN N
for IN N
each DT N
of IN N
the DT N
treatment NN N
periods NNS N
. . N

Higher JJR N
scores NNS N
during IN N
the DT N
placebo JJ i
period NN N
in IN N
the DT N
group NN N
given VBN N
lansoprazole VBZ i
first RB N
than IN N
in IN N
the DT N
group NN N
given VBN N
placebo VBP N
first RB N
indicated VBN N
a DT N
rebound NN N
aggravation NN N
of IN N
symptoms NNS N
. . N

RESULTS VB N
The DT N
mean JJ N
symptom NN o
scores NNS o
during IN N
the DT N
placebo JJ i
period NN N
in IN N
the DT N
groups NNS N
given VBN N
lansoprazole VBP N
first JJ N
and CC N
placebo NN N
first RB N
were VBD N
as IN N
follows VBZ N
: : N
reflux NN o
score NN o
, , N
21.5 CD N
and CC N
17.6 CD N
, , N
respectively RB N
( ( N
not RB N
significant JJ N
) ) N
; : N
total JJ o
score NN o
, , N
11.2 CD N
and CC N
10.3 CD N
, , N
respectively RB N
( ( N
not RB N
significant JJ N
) ) N
; : N
and CC N
antacid VB o
score NN o
, , N
8.2 CD N
and CC N
7.2 CD N
, , N
respectively RB N
( ( N
not RB N
significant JJ N
) ) N
. . N

CONCLUSIONS NNP N
There EX N
is VBZ N
no DT N
indication NN N
of IN N
a DT N
rebound JJ N
aggravation NN N
of IN N
symptoms NNS N
12 CD N
to TO N
14 CD N
days NNS N
after IN N
a DT N
5-day JJ N
treatment NN N
with IN N
lansoprazole JJ i
60 CD N
mg NN N
once RB N
daily JJ N
in IN N
patients NNS p
with IN p
reflux NN p
symptoms NNS p
. . p

-DOCSTART- -20362507- O O

Effect NN N
of IN N
zoledronic JJ i
acid NN i
on IN N
disseminated JJ N
tumour NN N
cells NNS N
in IN N
women NNS p
with IN p
locally RB p
advanced JJ p
breast NN p
cancer NN p
: : p
an DT N
open JJ N
label NN N
, , N
randomised VBN N
, , N
phase VB N
2 CD N
trial NN N
. . N

BACKGROUND NNP N
Treatment NNP N
with IN N
bisphosphonates NNS i
decreases NNS N
bone VBP N
loss NN N
and CC N
can MD N
increase VB N
disease-free JJ N
survival NN N
in IN N
patients NNS p
with IN p
breast JJ p
cancer NN p
. . p

The DT N
aim NN N
of IN N
our PRP$ N
study NN N
was VBD N
to TO N
assess VB N
the DT N
effect NN N
of IN N
zoledronic JJ i
acid NN i
on IN N
clearance NN N
of IN N
disseminated JJ o
tumour NN o
cells NNS o
( ( o
DTCs NNP o
) ) o
from IN N
the DT N
bone NN N
marrow NN N
in IN N
women NNS p
undergoing VBG p
neoadjuvant JJ p
chemotherapy NN p
for IN p
breast NN p
cancer NN p
. . p

METHODS NNP N
Patients NNPS N
were VBD N
recruited VBN N
for IN N
this DT N
open-label JJ p
, , p
phase VB p
2 CD p
randomised JJ p
trial NN p
between IN p
March NNP p
17 CD p
, , p
2003 CD p
, , p
and CC p
May NNP p
19 CD p
, , p
2006 CD p
, , p
at IN p
a DT p
single JJ p
centre NN p
. . p

Eligible JJ p
patients NNS p
had VBD p
clinical JJ p
stage NN p
II-III NNP p
( ( p
> CD p
or CC p
= VB p
T2 NNP p
and/or JJ p
> NN p
or CC p
= VB p
N1 NNP p
) ) p
newly RB p
diagnosed VBN p
breast NN p
cancer NN p
, , p
Eastern NNP p
Cooperative NNP p
Oncology NNP p
Group NNP p
performance NN p
status NN p
of IN p
0 CD p
or CC p
1 CD p
, , p
and CC p
normal JJ p
cardiac NN p
, , p
renal JJ p
, , p
and CC p
liver JJ p
function NN p
. . p

120 CD p
women NNS p
were VBD p
randomly RB p
assigned VBN p
, , N
using VBG N
allocation NN N
concealment NN N
, , N
to TO N
receive VB N
4 CD i
mg NN i
zoledronic JJ i
acid NN i
intravenously RB i
every DT i
3 CD N
weeks NNS N
( ( N
n=60 NN N
) ) N
, , N
or CC N
no DT i
zoledronic JJ i
acid NN i
( ( N
n=60 JJ N
) ) N
, , N
for IN N
1 CD N
year NN N
concomitant NN N
with IN N
four CD i
cycles NNS i
of IN i
neoadjuvant JJ i
epirubicin NN i
( ( N
75 CD N
mg/m NN N
( ( N
2 CD N
) ) N
) ) N
plus CC i
docetaxel JJ i
( ( N
75 CD N
mg/m NN N
( ( N
2 CD N
) ) N
) ) N
and CC i
two CD i
cycles NNS i
of IN i
adjuvant JJ i
epirubicin JJ i
plus CC i
docetaxel JJ i
. . i

The DT N
primary JJ N
endpoint NN N
was VBD N
the DT N
number NN N
of IN N
patients NNS N
with IN N
detectable JJ o
DTCs NNP o
at IN N
3 CD N
months NNS N
. . N

Final NNP N
analysis NN N
was VBD N
done VBN N
1 CD N
year NN N
after IN N
the DT N
last JJ N
patient NN N
was VBD N
enrolled VBN N
. . N

Analyses NNS N
were VBD N
done VBN N
for IN N
all DT N
patients NNS N
with IN N
available JJ N
data NNS N
at IN N
3 CD N
months NNS N
. . N

This DT N
study NN N
is VBZ N
registered VBN N
with IN N
ClinicalTrials.gov NNP N
, , N
number NN N
NCT00242203 NNP N
. . N

FINDINGS NNP N
Of IN N
the DT N
120 CD p
patients NNS p
initially RB p
enrolled VBD p
, , p
one CD p
withdrew NN p
after IN p
signing VBG p
consent NN p
and CC p
one CD p
patient NN p
's POS p
baseline NN p
bone NN p
marrow NN p
was VBD p
not RB p
available JJ p
. . p

Both DT N
of IN N
these DT N
patients NNS N
were VBD N
in IN N
the DT N
control NN N
group NN N
. . N

At IN N
3 CD N
months NNS N
, , N
109 CD p
bone-marrow NN p
samples NNS p
were VBD p
available JJ p
for IN N
analysis NN N
. . N

In IN N
the DT N
zoledronic JJ N
acid NN N
group NN N
, , N
bone NN N
marrow NN N
was VBD N
not RB N
collected VBN N
from IN N
one CD N
patient NN N
because IN N
of IN N
disease NN N
progression NN N
, , N
one CD N
patient NN N
was VBD N
taken VBN N
off RP N
study NN N
because IN N
of IN N
severe JJ N
diarrhoea NN N
, , N
and CC N
two CD N
patients NNS N
had VBD N
not RB N
consented VBN N
at IN N
the DT N
time NN N
of IN N
surgery NN N
. . N

In IN N
the DT N
control NN N
group NN N
, , N
bone NN N
marrow NN N
was VBD N
not RB N
collected VBN N
from IN N
two CD N
patients NNS N
because IN N
of IN N
disease NN N
progression NN N
, , N
one CD N
patient NN N
withdrew VBD N
consent NN N
, , N
and CC N
three CD N
patients NNS N
were VBD N
not RB N
consented VBN N
at IN N
the DT N
time NN N
of IN N
surgery NN N
. . N

At IN N
baseline NN N
, , N
DTCs NNP N
were VBD N
detected VBN N
in IN N
26 CD N
of IN N
60 CD N
patients NNS N
in IN N
the DT N
zoledronic JJ i
acid NN i
group NN N
and CC N
28 CD N
of IN N
58 CD N
patients NNS N
in IN N
the DT N
control NN N
group NN N
. . N

At IN N
3 CD N
months NNS N
, , N
17 CD N
of IN N
56 CD N
patients NNS N
receiving VBG N
zoledronic JJ N
acid NN N
versus IN N
25 CD N
of IN N
53 CD N
patients NNS N
who WP N
did VBD N
not RB N
receive VB N
zoledronic JJ N
acid NN N
had VBD N
detectable JJ N
DTCs NNP N
( ( N
p=0.054 NN N
) ) N
. . N

The DT N
most RBS N
common JJ N
grade NN N
3-4 JJ N
toxicities NNS N
were VBD N
infection NN N
( ( N
five CD N
of IN N
60 CD N
patients NNS N
in IN N
the DT N
zoledronic JJ N
acid NN N
group NN N
and CC N
six CD N
of IN N
59 CD N
in IN N
the DT N
control NN N
group NN N
) ) N
and CC N
thrombosis NN N
( ( N
five CD N
of IN N
60 CD N
in IN N
the DT N
zoledronic JJ N
acid NN N
and CC N
two CD N
of IN N
59 CD N
in IN N
the DT N
control NN N
group NN N
) ) N
. . N

There EX N
was VBD N
one CD N
documented JJ N
case NN N
of IN N
osteonecrosis NN o
in IN N
the DT N
zoledronic JJ N
acid NN N
group NN N
. . N

INTERPRETATION NNP N
Zoledronic NNP i
acid NN i
administered VBD N
with IN N
chemotherapy NN N
resulted VBN N
in IN N
a DT N
decreased JJ N
proportion NN N
of IN N
patients NNS N
with IN N
DTCs NNP N
detected VBD N
in IN N
the DT N
bone NN N
marrow NN N
at IN N
the DT N
time NN N
of IN N
surgery NN N
. . N

Our PRP$ N
study NN N
supports VBZ N
the DT N
hypothesis NN N
that IN N
the DT N
antimetastatic JJ N
effects NNS N
of IN N
zoledronic JJ i
acid NN i
may MD N
be VB N
through IN N
effects NNS N
on IN N
DTCs NNP N
. . N

FUNDING NN N
Novartis NN N
Pharmaceuticals NNP N
and CC N
Pfizer NNP N
Inc NNP N
. . N

-DOCSTART- -3278798- O O

Comparison NNP N
of IN N
intermittent NN i
or CC i
continuous JJ i
methotrexate JJ i
plus CC i
6-mercaptopurine JJ i
in IN N
regimens NNS N
for IN N
standard-risk JJ p
acute JJ p
lymphoblastic JJ p
leukemia NN p
in IN p
childhood NN p
( ( p
JCCLSG-S811 NNP p
) ) p
. . p

The DT N
Japanese JJ p
Children NNP p
's POS p
Cancer NNP p
and CC p
Leukemia NNP p
Study NNP p
Group NNP p
. . p

From IN N
1981 CD p
to TO p
1983 CD p
, , p
131 CD p
previously RB p
untreated JJ p
patients NNS p
with IN p
acute JJ p
lymphoblastic JJ p
leukemia NN p
( ( p
ALL DT p
) ) p
standard-risk JJ p
group NN p
were VBD N
entered VBN N
to TO N
the DT N
protocol NN N
JCCLSG-S811 NNP N
. . N

Of IN N
119 CD p
eligible JJ p
patients NNS p
, , N
115 CD N
( ( N
96.6 CD N
% NN N
) ) N
attained VBD N
complete JJ N
remission NN N
by IN N
treatment NN N
with IN N
prednisone NN i
( ( i
PRD NNP i
) ) i
plus CC i
vincristine JJ i
( ( i
VCR NNP i
) ) i
or CC i
vindesine NN i
( ( i
VDS NNP i
) ) i
. . i

After IN N
preventive JJ N
central JJ N
nervous JJ N
system NN N
( ( N
CNS NNP N
) ) N
therapy NN N
including VBG N
18 CD i
Gy NNP i
cranial JJ i
irradiation NN i
and CC N
three CD N
doses NNS N
of IN N
intrathecal JJ i
methotrexate NN i
( ( i
MTX NNP i
) ) i
, , N
the DT N
patients NNS N
were VBD N
assigned VBN N
randomly RB N
to TO N
the DT N
two CD N
maintenance NN N
chemotherapies NNS N
, , N
Regimen NNP N
A NNP N
and CC N
Regimen NNP N
B NNP N
. . N

Regimen VB N
A NNP N
( ( N
intermittent JJ N
regimen NNS N
) ) N
consisted VBD N
of IN N
PRD NNP i
( ( N
120 CD N
mg/m2/day NN N
by IN N
mouth NN N
for IN N
5 CD N
days NNS N
) ) N
plus CC i
6-mercaptopurine JJ i
( ( i
6MP CD i
) ) i
( ( N
175 CD N
mg/m2/day NN N
by IN N
mouth NN N
for IN N
5 CD N
days NNS N
) ) N
plus CC i
VCR NNP i
( ( i
2.0 CD i
mg/m2 RB N
intravenously RB N
) ) N
alternating VBG i
biweekly NN i
with IN i
MTX NNP i
( ( N
225 CD N
mg/m2 RB N
intravenously RB N
) ) N
. . N

Regimen NNP N
B NNP N
( ( N
continuous JJ N
regimen NNS N
) ) N
consisted VBD N
of IN N
6MP CD i
( ( N
50 CD N
mg/m2/day NN N
by IN N
mouth NN N
) ) N
plus CC i
MTX NNP i
( ( N
20 CD N
mg/m2/week NN N
by IN N
mouth NN N
) ) N
combined VBN i
with IN i
pulses NNS o
of IN o
PRD NNP o
and CC o
VCR NNP o
( ( N
the DT N
same JJ N
dosages NNS N
as IN N
Regimen NNP N
A NNP N
) ) N
every DT N
4 CD N
weeks NNS N
. . N

As IN N
the DT N
late JJ N
intensification NN N
therapy NN N
( ( N
LIT NNP N
) ) N
, , N
five CD N
courses NNS N
of IN N
high-dose JJ N
MTX NNP i
( ( N
2000 CD N
mg/m2 NN N
per IN N
dose NN N
per IN N
week NN N
intravenously RB N
for IN N
three CD N
doses NNS N
every DT N
12 CD N
weeks NNS N
) ) N
with IN N
leucovorin NN N
rescue NN N
were VBD N
administered VBN N
to TO N
all DT N
patients NNS N
who WP N
were VBD N
in IN N
continuous JJ N
complete JJ N
remission NN N
( ( N
CCR NNP N
) ) N
for IN N
more JJR N
than IN N
2 CD N
years NNS N
. . N

Sixty NNP N
and CC N
55 CD N
patients NNS N
, , N
respectively RB N
, , N
were VBD N
registered VBN N
in IN N
Regimen NNP N
A NNP N
and CC N
B NNP N
. . N

The DT N
CCR NNP o
rates NNS o
in IN N
Regimen NNP N
A NNP N
and CC N
B NNP N
were VBD N
75.1 CD N
% NN N
+/- JJ N
5.8 CD N
% NN N
( ( N
mean JJ N
+/- JJ N
1 CD N
SE NNP N
) ) N
and CC N
49.7 CD N
% NN N
+/- JJ N
7.3 CD N
% NN N
( ( N
P NNP N
less JJR N
than IN N
0.01 CD N
) ) N
at IN N
4 CD N
years NNS N
, , N
and CC N
72.1 CD N
% NN N
+/- JJ N
6.3 CD N
% NN N
and CC N
49.7 CD N
% NN N
+/- JJ N
7.3 CD N
% NN N
( ( N
P NNP N
less JJR N
than IN N
0.05 CD N
) ) N
at IN N
5 CD N
years NNS N
, , N
respectively RB N
. . N

In IN N
Regimen NNP N
B NNP N
, , N
CNS NNP o
and CC o
testicular JJ o
relapses NNS o
increased VBD N
after IN N
3 CD N
years NNS N
of IN N
CCR NNP N
. . N

In IN N
addition NN N
, , N
the DT N
patients NNS N
in IN N
Regimen NNP N
B NNP N
had VBD N
a DT N
much RB N
higher JJR N
incidence NN o
of IN o
infections NNS o
than IN N
Regimen NNP N
A NNP N
. . N

The DT N
LIT NNP N
did VBD N
not RB N
seem VB N
to TO N
have VB N
important JJ N
effects NNS N
on IN N
the DT N
duration NN o
of IN o
CCR NNP o
. . o

From IN N
these DT N
data NNS N
we PRP N
conclude VBP N
that IN N
the DT N
intermittent JJ N
cyclic JJ N
regimen NNS N
of IN N
6MP CD N
and CC N
MTX NNP i
may MD N
be VB N
more RBR N
effective JJ N
as IN N
compared VBN N
to TO N
the DT N
continuous JJ N
administration NN N
of IN N
these DT N
drugs NNS N
in IN N
the DT N
maintenance NN N
chemotherapy NN N
. . N

-DOCSTART- -8403910- O O

Pharmacokinetic NNP N
study NN N
of IN N
RU NNP i
486 CD i
and CC N
its PRP$ N
metabolites NNS N
after IN N
oral JJ N
administration NN N
of IN N
single JJ N
doses NNS N
to TO N
pregnant VB p
and CC p
non-pregnant JJ p
women NNS p
. . p

RU NNP i
486 CD i
and CC i
three CD i
of IN i
its PRP$ i
metabolites NNS i
( ( i
RU NNP i
42633-monodemethyl CD i
, , i
RU NNP i
42848-didemethyl CD i
, , i
and CC i
RU NNP i
42698-hydroxymetabolite JJ i
) ) i
were VBD N
determined VBN N
by IN N
HPLC NNP N
in IN N
plasma NN N
from IN N
nine CD p
non-pregnant JJ p
and CC p
36 CD p
pregnant JJ p
women NNS p
. . p

Each DT N
non-pregnant JJ N
subject NN N
took VBD N
an DT N
oral JJ N
dose NN N
of IN N
RU NNP i
486 CD i
( ( N
25 CD N
, , N
100 CD N
, , N
400 CD N
and CC N
600 CD N
mg NNS N
consecutively RB N
) ) N
once RB N
per IN N
menstrual JJ N
cycle NN N
. . N

Six CD N
of IN N
the DT N
nine CD N
women NNS N
also RB N
received VBD N
a DT N
dose NN i
of IN N
200 CD N
mg NN N
. . N

The DT N
36 CD p
pregnant JJ p
women NNS p
were VBD N
randomized VBN N
into IN N
four CD N
groups NNS N
which WDT N
were VBD N
given VBN N
a DT N
single JJ N
dose NN N
of IN N
25 CD N
, , N
100 CD N
, , N
400 CD N
or CC N
600 CD N
mg NNS N
RU NNP N
486 CD N
. . N

Blood NN o
samples NNS o
were VBD N
taken VBN N
up RB N
to TO N
120 CD N
h NN N
after IN N
dosing VBG N
. . N

Peak NNP o
concentrations NNS o
of IN o
RU NNP o
486 CD o
occurred VBD N
on IN N
most JJS N
occasions NNS N
within IN N
2 CD N
h. NN N
Plasma NNP o
concentrations NNS o
at IN N
1 CD N
h NN N
and CC N
at IN N
24 CD N
h NN N
increased VBN N
in IN N
proportion NN N
to TO N
log VB N
dose RB N
. . N

There EX N
was VBD N
a DT N
wide JJ N
variability NN N
( ( N
up IN N
to TO N
ten-fold JJ N
) ) N
in IN N
the DT N
pharmacokinetic JJ N
parameters NNS N
within IN N
each DT N
dose NN N
group NN N
. . N

Plasma NNP o
concentrations NNS o
of IN o
RU NNP o
42633 CD o
were VBD N
similar JJ N
to TO N
those DT N
of IN N
RU NNP N
486 CD N
but CC N
concentrations NNS N
of IN N
RU NNP N
42848 CD N
and CC N
RU NNP N
42698 CD N
were VBD N
much JJ N
lower JJR N
. . N

As IN N
with IN N
RU NNP N
486 CD N
, , N
the DT N
plasma JJ o
concentrations NNS o
of IN o
the DT o
metabolites NNS o
were VBD N
maintained VBN N
at IN N
high JJ N
levels NNS N
for IN N
up IN N
to TO N
48-72 JJ N
h NN N
after IN N
dosing VBG N
. . N

The DT N
findings NNS N
were VBD N
consistent JJ N
with IN N
a DT N
rapid JJ N
metabolism NN N
of IN N
RU NNP o
486 CD o
to TO o
RU NNP o
42633 CD o
; : o
removal NN N
of IN N
the DT N
second JJ N
methyl NN N
group NN N
leading VBG N
to TO N
RU NNP N
42698 CD N
occurred VBD N
much RB N
more RBR N
slowly RB N
and CC N
to TO N
a DT N
much RB N
less RBR N
extent JJ N
than IN N
removal NN N
of IN N
the DT N
first JJ N
. . N

There EX N
appeared VBD N
to TO N
be VB N
no DT N
significant JJ N
differences NNS N
between IN N
the DT N
non-pregnant JJ p
and CC p
pregnant JJ p
women NNS p
in IN N
either CC N
the DT N
plasma JJ N
concentrations NNS N
or CC N
pharmacokinetic JJ N
parameters NNS N
of IN N
RU NNP i
486 CD i
and CC N
its PRP$ N
metabolites NNS N
. . N

-DOCSTART- -9758264- O O

Epileptogenic JJ N
activity NN N
of IN N
folic JJ N
acid NN N
after IN N
drug NN N
induces NNS N
SLE NNP N
( ( N
folic JJ N
acid NN N
and CC N
epilepsy NN N
) ) N
OBJECTIVE NN N
To TO N
study VB N
the DT N
effect NN N
of IN N
folic JJ i
acid-containing JJ i
multivitamin NN i
supplementation NN i
in IN N
epileptic JJ p
women NNS p
before IN p
and CC p
during IN p
pregnancy NN p
in IN N
order NN N
to TO N
determine VB N
the DT N
rate NN N
of IN N
structural JJ N
birth NN N
defects NNS N
and CC N
epilepsy-related JJ N
side NN N
effects NNS N
. . N

STUDY NNP N
DESIGN NNP N
First NNP N
a DT N
randomised JJ N
trial NN N
, , N
later RB N
periconception NN N
care NN N
including VBG N
in IN N
total JJ N
12225 CD p
females NNS p
. . p

RESULTS NNP N
Of IN N
60 CD p
epileptic JJ p
women NNS p
with IN p
periconceptional JJ i
folic JJ i
acid NN i
( ( N
0.8 CD N
mg NN i
) ) i
-containing VBG i
multivitamin JJ i
supplementation NN i
, , N
no DT N
one NN N
developed VBD N
epilepsy-related JJ N
side NN N
effects NNS N
during IN N
the DT N
periconception NN N
period NN N
. . N

One CD N
epileptic JJ N
woman NN N
delivered VBD N
a DT N
newborn JJ N
with IN N
cleft NN N
lip NN N
and CC N
palate NN N
. . N

Another DT N
patient NN N
exhibited VBN N
with IN N
a DT N
cluster NN o
of IN o
seizures NNS o
after IN N
the DT N
periconception NN N
period NN N
using VBG N
another DT N
multivitamin NN N
. . N

This DT N
22-year-old JJ N
epileptic JJ N
woman NN N
was VBD N
treated VBN N
continuously RB N
by IN N
carbamazepine NN i
and CC i
a DT i
folic JJ i
acid NN i
( ( N
1 CD N
mg NN i
) ) i
-containing VBG i
multivitamin NN i
from IN N
the DT N
20th JJ N
week NN N
of IN N
gestation NN N
. . N

She PRP N
developed VBD N
status NN o
epilepticus NN o
and CC N
later RB N
symptoms NNS o
of IN o
systemic JJ o
lupus NN o
erythematodes NNS o
. . o

Her PRP$ N
pregnancy NN N
ended VBN N
with IN N
stillbirth NN o
. . o

CONCLUSIONS VB N
The DT N
epileptic JJ N
pregnant JJ N
patient NN N
's POS N
autoimmune JJ N
disease NN N
( ( N
probably RB N
drug-induced JJ N
lupus NN N
) ) N
could MD N
damage VB N
the DT N
blood-brain JJ o
barrier NN o
, , N
therefore IN N
the DT N
therapeutic JJ N
dose NN N
( ( N
> CD N
or CC N
=1 VB N
mg NN N
) ) N
of IN N
folic JJ N
acid NN N
triggered VBD N
a DT N
cluster NN o
of IN o
seizures NNS o
. . o

Physiological NNP N
dose NN N
( ( N
< JJ N
1 CD N
mg NN N
) ) N
of IN N
folic JJ N
acid NNS N
both DT N
in IN N
healthy JJ N
and CC N
60 CD N
epileptic JJ N
women NNS N
, , N
all DT N
without IN N
any DT N
autoimmune JJ N
disease NN N
, , N
did VBD N
not RB N
increase VB N
the DT N
risk NN o
for IN o
epileptic JJ o
seizures NNS o
. . o

-DOCSTART- -18217284- O O

[ JJ o
Optimization NNP o
of IN N
the DT N
postoperative JJ N
period NN N
in IN N
children NNS p
after IN p
adenotonsillectomy JJ i
] NN i
. . N

-DOCSTART- -24682707- O O

Interview NNP N
skills NNS N
for IN N
adults NNS p
with IN p
autism NN p
spectrum NN p
disorder NN p
: : p
a DT N
pilot NN N
randomized VBN N
controlled VBN N
trial NN N
. . N

The DT N
purpose NN N
of IN N
this DT N
pilot NN N
study NN N
was VBD N
to TO N
evaluate VB N
the DT N
efficacy NN N
of IN N
the DT N
interview NN i
skills NNS i
curriculum NN i
( ( i
ISC NNP i
) ) i
, , N
a DT N
manualized JJ N
12-week JJ N
group-delivered JJ N
intervention NN N
for IN N
young JJ p
adults NNS p
with IN p
autism NN p
spectrum NN p
disorder NN p
( ( p
ASD NNP p
) ) p
. . p

This DT N
intervention NN N
aims VBZ N
to TO N
increase VB N
social-pragmatic JJ N
skills NNS N
essential JJ N
to TO N
a DT N
successful JJ N
job NN N
interview NN N
. . N

Twenty-eight JJ p
adults NNS p
( ( p
18-36 CD p
years NNS p
) ) p
were VBD N
randomly RB N
assigned VBN N
to TO N
one CD N
of IN N
two CD N
groups NNS N
: : N
ISC NNP i
or CC N
waitlist VB i
control NN i
. . i

Results NNP N
revealed VBD N
that IN N
the DT N
experimental JJ N
group NN N
showed VBD N
larger JJR N
gains NNS N
in IN N
social-pragmatic JJ o
skills NNS o
observed VBD N
during IN N
a DT N
mock NN N
job NN N
interview NN N
than IN N
the DT N
control NN N
group NN N
. . N

Treatment NNP N
effects NNS N
on IN N
distal JJ N
outcomes NNS N
, , N
including VBG N
social JJ o
adaptive JJ o
behaviors NNS o
and CC o
depressive JJ o
symptoms NNS o
were VBD N
not RB N
significant JJ N
, , N
although IN N
the DT N
respective JJ N
effect NN N
sizes NNS N
were VBD N
medium/large NN N
. . N

Results VB N
indicate JJ N
that IN N
a DT N
brief JJ N
, , N
low-intensity JJ N
treatment NN N
can MD N
improve VB N
the DT N
job-interview JJ o
performance NN o
of IN N
young JJ p
adults NNS p
with IN p
ASD NNP p
. . p

-DOCSTART- -25617202- O O

Effect NN N
of IN N
self-collection NN i
of IN i
HPV NNP i
DNA NNP i
offered VBN N
by IN N
community NN p
health NN p
workers NNS p
at IN N
home NN N
visits NNS N
on IN N
uptake NN o
of IN o
screening VBG o
for IN o
cervical JJ o
cancer NN o
( ( N
the DT N
EMA NNP N
study NN N
) ) N
: : N
a DT N
population-based JJ N
cluster-randomised JJ N
trial NN N
. . N

BACKGROUND NNP N
Control NNP N
of IN N
cervical JJ N
cancer NN N
in IN N
developing VBG N
countries NNS N
has VBZ N
been VBN N
hampered VBN N
by IN N
a DT N
failure NN N
to TO N
achieve VB N
high JJ N
screening VBG o
uptake NN o
. . o

HPV NNP i
DNA NNP i
self-collection NN i
could MD N
increase VB N
screening VBG o
coverage NN o
, , N
but CC N
implementation NN N
of IN N
this DT N
technology NN N
is VBZ N
difficult JJ N
in IN N
countries NNS p
of IN p
middle JJ p
and CC p
low JJ p
income NN p
. . p

We PRP N
investigated VBD N
whether IN N
offering VBG N
HPV NNP i
DNA NNP i
self-collection NN i
during IN N
routine JJ N
home NN N
visits NNS N
by IN N
community NN N
health NN N
workers NNS N
could MD N
increase VB N
cervical JJ o
screening NN o
. . o

METHODS NNP N
We PRP N
did VBD N
a DT N
population-based JJ N
cluster-randomised JJ N
trial NN N
in IN N
the DT N
province NN p
of IN p
Jujuy NNP p
, , p
Argentina NNP p
, , p
between IN p
July NNP p
1 CD p
, , p
2012 CD p
, , p
and CC p
Dec NNP p
31 CD p
, , p
2012 CD p
. . p

Community NNP p
health NN p
workers NNS p
were VBD p
eligible JJ p
for IN p
the DT p
study NN p
if IN p
they PRP p
scored VBD p
highly RB p
on IN p
a DT p
performance NN p
score NN p
, , p
and CC p
women NNS p
aged VBN p
30 CD p
years NNS p
or CC p
older JJR p
were VBD p
eligible JJ p
for IN p
enrolment NN p
by IN p
the DT p
community NN p
health NN p
worker NN p
. . p

200 CD p
community NN p
health NN p
workers NNS p
were VBD p
randomly RB p
allocated VBN p
in IN p
a DT p
1:1 CD p
ratio NN p
to TO p
either CC p
the DT p
intervention NN i
group NN i
( ( i
offered VBN i
women NNS i
the DT i
chance NN i
to TO i
self-collect VB i
a DT i
sample NN i
for IN i
cervical JJ i
screening NN i
during IN i
a DT i
home NN i
visit NN i
) ) i
or CC N
the DT N
control NN i
group NN i
( ( i
advised JJ i
women NNS i
to TO i
attend VB i
a DT i
health NN i
clinic NN i
for IN i
cervical JJ i
screening NN i
) ) i
. . N

The DT N
primary JJ N
outcome NN N
was VBD N
screening VBG o
uptake NN o
, , N
measured VBN N
as IN N
the DT N
proportion NN N
of IN N
women NNS N
having VBG N
any DT N
HPV NNP o
screening NN o
test NN o
within IN N
6 CD N
months NNS N
of IN N
the DT N
community NN N
health NN N
worker NN N
visit NN N
. . N

Analysis NN N
was VBD N
by IN N
intention NN N
to TO N
treat VB N
. . N

This DT N
trial NN N
is VBZ N
registered VBN N
with IN N
ClinicalTrials.gov NNP N
, , N
number NN N
NCT02095561 NNP N
. . N

FINDINGS NNP N
100 CD N
community NN N
health NN N
workers NNS N
were VBD N
randomly RB N
allocated VBN N
to TO N
the DT N
intervention NN N
group NN N
and CC N
100 CD N
were VBD N
assigned VBN N
to TO N
the DT N
control NN N
group NN N
; : N
nine CD N
did VBD N
not RB N
take VB N
part NN N
. . N

191 CD p
participating VBG p
community NN p
health NN p
workers NNS p
( ( p
94 CD p
in IN p
the DT p
intervention NN p
group NN p
and CC p
97 CD p
in IN p
the DT p
control NN p
group NN p
) ) p
initially RB p
contacted JJ p
7650 CD p
women NNS p
; : p
of IN p
3632 CD p
women NNS p
contacted VBN p
by IN p
community NN p
health NN p
workers NNS p
in IN p
the DT p
intervention NN p
group NN p
, , p
3049 CD p
agreed VBD p
to TO p
participate VB p
; : p
of IN p
4018 CD p
women NNS p
contacted VBN p
by IN p
community NN p
health NN p
workers NNS p
in IN p
the DT p
control NN p
group NN p
, , p
2964 CD p
agreed VBD p
to TO p
participate VB p
. . p

2618 CD N
( ( N
86 CD N
% NN N
) ) N
of IN N
3049 CD N
women NNS N
in IN N
the DT N
intervention NN N
group NN N
had VBD N
any DT N
HPV NNP o
test NN o
within IN N
6 CD N
months NNS N
of IN N
the DT N
community NN N
health NN N
worker NN N
visit NN N
, , N
compared VBN N
with IN N
599 CD N
( ( N
20 CD N
% NN N
) ) N
of IN N
2964 CD N
in IN N
the DT N
control NN N
group NN N
( ( N
risk NN N
ratio NN N
4?02 CD N
, , N
95 CD N
% NN N
CI NNP N
3?44-4?71 CD N
) ) N
. . N

INTERPRETATION JJ N
Offering VBG N
self-collection NN N
of IN N
samples NNS N
for IN N
HPV NNP i
testing VBG i
by IN i
community NN N
health NN N
workers NNS N
during IN N
home NN N
visits NNS N
resulted VBD N
in IN N
a DT o
four-fold JJ o
increase NN o
in IN o
screening VBG o
uptake NN o
, , o
showing VBG o
that IN N
this DT N
strategy NN N
is VBZ N
effective JJ o
to TO o
improve VB o
cervical JJ o
screening NN o
coverage NN o
. . o

This DT o
intervention NN N
reduces VBZ o
women NNS o
's POS o
barriers NNS o
to TO o
screening VBG o
and CC o
results NNS N
in IN N
a DT N
substantial JJ N
and CC N
rapid JJ o
increase NN o
in IN o
coverage NN o
. . o

Our PRP$ o
findings NNS N
suggest VBP N
that IN N
HPV NNP N
testing VBG N
could MD N
be VB N
extended VBN N
throughout IN N
Argentina NNP N
and CC N
in IN N
other JJ N
countries NNS N
to TO N
increase VB o
cervical JJ o
screening NN o
coverage NN o
. . o

FUNDING NN o
Instituto NNP N
Nacional NNP N
del FW N
C?ncer NNP N
( ( N
Argentina NNP N
) ) N
. . N

-DOCSTART- -20439105- O O

Small NN N
but CC N
important JJ N
errors NNS N
in IN N
cardiovascular JJ N
risk NN N
calculation NN N
by IN N
practice NN p
nurses NNS p
: : p
a DT N
cross-sectional JJ N
study NN N
in IN N
randomised JJ N
trial NN N
setting NN N
. . N

BACKGROUND NNP N
Practice NNP p
nurses NNS p
play VBP N
an DT N
increasingly RB N
important JJ N
role NN N
in IN N
the DT N
prevention NN N
of IN N
cardiovascular JJ N
diseases NNS N
but CC N
we PRP N
do VBP N
not RB N
have VB N
evidence NN N
about IN N
the DT N
accuracy NN o
of IN N
their PRP$ N
cardiovascular JJ N
risk NN N
assessments NNS N
during IN N
real JJ N
practice NN N
consultations NNS N
. . N

OBJECTIVES NNP N
To TO N
examine VB N
how WRB N
nurses NNS p
perform VBP N
with IN N
regard NN N
to TO N
absolute VB N
10-year JJ N
cardiovascular JJ o
risk NN o
assessment NN o
in IN N
actual JJ N
practice NN N
. . N

DESIGN NNP N
Cross-sectional JJ N
study NN N
. . N

SETTING NN N
This DT p
study NN p
was VBD p
nested VBN p
in IN p
the DT p
IMPALA NNP p
study NN p
, , p
a DT p
clustered VBN p
randomised VBN p
controlled VBN p
trial NN p
involving VBG p
24 CD p
general JJ p
practices NNS p
in IN p
The DT p
Netherlands NNP p
. . p

PARTICIPANTS VB N
24 CD p
practice NN p
nurses NNS p
, , p
trained VBN p
in IN p
10-year JJ p
cardiovascular JJ p
risk NN p
assessment NN p
, , N
calculated VBD N
the DT N
risk NN N
of IN N
a DT N
total NN N
of IN N
421 CD p
patients NNS p
without IN p
established VBN p
cardiovascular JJ p
diseases NNS p
but CC p
eligible JJ p
for IN p
cardiovascular JJ o
risk NN o
assessment NN o
. . o

METHODS NNP N
The DT N
main JJ N
outcome NN N
measure NN N
was VBD N
the DT N
accuracy NN o
of IN o
risk NN o
assessments NNS o
, , N
defined VBN N
as IN N
( ( N
1 CD N
) ) N
the DT N
difference NN o
between IN o
the DT o
10-year JJ o
cardiovascular JJ o
risk NN o
percentage NN o
calculated VBN o
by IN o
nurses NNS o
and CC o
an DT o
independent JJ o
assessor NN o
, , N
and CC N
( ( N
2 CD N
) ) N
the DT o
agreement NN o
between IN o
the DT o
treatment NN o
categories NNS o
assigned VBN o
by IN o
the DT o
nurses NNS o
( ( o
low JJ o
, , o
moderate JJ o
or CC o
high JJ o
risk NN o
) ) o
and CC o
those DT o
assigned VBN o
by IN o
the DT o
independent JJ o
assessor NN o
. . o

RESULTS VB N
Thirty-one NNP N
( ( N
7.4 CD N
% NN N
) ) N
of IN N
the DT N
calculated JJ N
risk NN N
percentages NNS N
differed VBN N
by IN N
more JJR N
than IN N
our PRP$ N
preset NN N
limits NNS N
, , N
25 CD N
( ( N
81 CD N
% NN N
) ) N
being VBG N
underestimations NNS N
. . N

Elderly JJ p
patients NNS p
( ( N
OR NNP N
1.1 CD N
, , N
95 CD N
% NN N
CI NNP N
1.0-1.1 CD N
) ) N
, , N
male JJ p
patients NNS p
( ( p
vs. FW p
female NN p
OR NNP N
3.1 CD N
, , N
95 CD N
% NN N
CI NNP N
1.2-7.3 CD N
) ) N
, , N
and CC N
smoking NN p
patients NNS p
( ( p
vs. IN p
non-smoking NN p
OR NNP N
3.8 CD N
, , N
95 CD N
% NN N
CI NNP N
1.7-8.9 CD N
) ) N
were VBD N
more RBR N
likely JJ N
to TO N
have VB N
their PRP$ N
cardiovascular JJ o
risk NN o
miscalculated VBD o
. . o

Ten NNP p
( ( p
28 CD p
% NN p
) ) p
of IN p
the DT p
36 CD p
patients NNS p
who WP p
should MD p
be VB p
assigned VBN p
to TO p
the DT p
high-risk JJ p
treatment NN p
category NN p
according VBG N
to TO N
the DT N
independent JJ N
calculation NN N
, , N
were VBD N
missed VBN N
as IN N
high-risk JJ N
patients NNS N
by IN N
the DT N
practice NN N
nurses NNS N
. . N

CONCLUSIONS VB N
The DT N
overall JJ N
standard NN N
of IN N
accuracy NN N
of IN N
cardiovascular JJ i
risk NN i
assessment NN i
by IN N
trained JJ p
practice NN p
nurses NNS p
in IN p
actual JJ p
practice NN p
is VBZ N
high JJ N
. . N

However RB N
, , N
a DT N
significant JJ N
number NN N
of IN N
high-risk JJ N
patients NNS N
were VBD N
misclassified VBN N
, , N
with IN N
the DT N
probability NN N
that IN N
it PRP N
led VBD N
to TO N
missed VBN N
opportunities NNS N
for IN N
risk-reducing JJ N
interventions NNS N
. . N

As IN N
cardiovascular JJ N
risk NN N
assessments NNS N
are VBP N
frequently RB N
done VBN N
by IN N
nurses NNS p
in IN p
general JJ p
practice NN p
, , N
further JJ N
specific JJ N
training NN N
should MD N
be VB N
considered VBN N
to TO N
prevent VB N
undertreatment NN N
. . N

-DOCSTART- -16283087- O O

A DT N
training NN N
study NN N
of IN N
theory NN N
of IN N
mind NN N
and CC N
executive NN N
function NN N
in IN N
children NNS p
with IN p
autistic JJ p
spectrum NN p
disorders NNS p
. . p

This DT N
study NN N
investigated VBD N
the DT N
relationship NN N
between IN N
theory NN N
of IN N
mind NN N
and CC N
executive NN N
functioning NN N
in IN N
children NNS p
with IN p
autistic JJ p
spectrum NN p
disorders NNS p
through IN N
a DT N
training NN N
study NN N
. . N

Ten CD p
children NNS p
were VBD p
trained VBN p
on IN p
theory NN i
of IN i
mind NN i
, , p
whilst WP p
ten EX p
were VBD p
trained VBN i
in IN i
executive JJ i
function NN i
. . i

Seven JJ p
children NNS p
were VBD p
assigned VBN p
to TO p
a DT p
control NN p
group NN p
, , p
receiving VBG p
no DT i
intervention NN i
. . i

Training VBG N
programmes NNS N
were VBD N
administered VBN N
individually RB N
, , N
lasting VBG N
for IN N
25 CD N
minutes NNS N
per IN N
day NN N
for IN N
5-10 JJ N
days NNS N
. . N

Children NNP N
were VBD N
tested VBN N
before IN N
training NN N
, , N
after IN N
training NN N
and CC N
at IN N
a DT N
two-month JJ N
follow-up NN N
. . N

Significant JJ N
improvements NNS N
were VBD N
seen VBN N
in IN N
performance NN o
on IN o
theory NN o
of IN o
mind NN o
tasks NNS o
in IN N
both DT N
trained JJ N
groups NNS N
, , N
whilst IN N
the DT N
control NN N
group NN N
showed VBD N
no DT o
improvement NN o
. . o

No DT N
improvement NN N
on IN N
the DT N
executive NN o
function NN o
tasks NNS o
was VBD N
seen VBN N
in IN N
any DT N
of IN N
the DT N
groups NNS N
. . N

The DT N
implications NNS N
of IN N
these DT N
findings NNS N
are VBP N
discussed VBN N
. . N

-DOCSTART- -7643653- O O

In IN N
vivo JJ N
assessment NN o
of IN p
catheter-tip JJ i
PO2 NNP i
sensor NN i
: : i
sampling JJ N
lumen NNS N
fabrication NN N
. . N

Fabrication NN N
of IN N
the DT N
sampling VBG N
lumen NNS N
of IN N
an DT N
intra-arterial JJ i
PO2 NNP i
sensor NN i
is VBZ N
performed VBN N
in IN N
standard JJ p
catheters NNS p
mechanically RB N
or CC N
by IN N
laser NN N
. . N

Clinical JJ o
evaluation NN o
is VBZ N
performed VBN N
with IN N
respect NN N
to TO N
catheter VB o
insertion NN o
, , o
complications NNS o
, , o
accuracy NN o
of IN o
oxygen NN o
sensor NN o
data NNS o
and CC o
fibrin JJ o
deposition NN o
on IN o
the DT o
catheter NN o
surface NN o
. . o

The DT N
success NN o
rate NN o
for IN o
catheter NN o
insertion NN o
is VBZ p
57 CD p
% NN p
for IN p
138 CD p
standard NN p
and CC p
50 CD p
% NN p
for IN p
74 CD p
laser-cut JJ p
catheters NNS p
studied VBN p
. . p

The DT N
proportion NN N
of IN N
catheter NN o
failures NNS o
( ( o
blocked VBD o
or CC o
non-reading JJ o
) ) o
is VBZ N
14 CD N
% NN N
in IN N
laser-cut JJ N
compared VBN N
with IN N
30 CD N
% NN N
in IN N
standard NN N
. . N

These DT N
differences NNS N
are VBP N
not RB N
statistically RB N
significant JJ N
at IN N
the DT N
5 CD N
% NN N
level NN N
. . N

There EX N
is VBZ N
no DT N
clinically RB N
significant JJ N
difference NN N
in IN N
sensor NN o
accuracy NN o
, , N
with IN N
37.5 CD N
% NN N
of IN N
results NNS N
within IN N
+/- JJ N
0.05 CD N
kPa NN N
and CC N
80 CD N
% NN N
within IN N
+/- JJ N
2.0 CD N
kPa NN N
of IN N
simultaneous JJ N
blood NN N
gas NN N
values NNS N
. . N

Drift NN o
is VBZ N
within IN N
+/- JJ N
0.3 CD N
kPa JJ N
h-1 NN N
for IN N
78 CD N
% NN N
of IN N
monitoring NN N
time NN N
. . N

Significant JJ o
errors NNS o
of IN o
recalibration NN o
occur NN N
in IN N
6 CD N
% NN N
of IN N
calibrations NNS N
. . N

Scanning VBG N
electron NN N
micrographs NN N
demonstrate VB N
a DT N
much RB N
smaller JJR N
sampling VBG o
lumen NNS o
in IN N
the DT N
laser-cut JJ N
group NN N
, , N
but CC N
no DT N
reduction NN N
in IN N
fibrin JJ o
deposition NN o
at IN N
the DT N
site NN N
of IN N
the DT N
sampling NN N
hole NN N
. . N

The DT N
low JJ N
success NN o
rate NN o
for IN o
catheter NN o
insertion NN o
is VBZ N
a DT N
problem NN N
because IN N
of IN N
cost NN N
implications NNS N
. . N

The DT N
accuracy NN o
of IN N
the DT N
system NN N
is VBZ N
usually RB N
sufficient JJ N
for IN N
clinical JJ N
purposes NNS N
, , N
provided VBD N
the DT N
calibration NN N
is VBZ N
checked VBN N
every DT N
4 CD N
h NN N
. . N

-DOCSTART- -18261537- O O

Effects NNS N
of IN N
losartan NN i
and CC i
enalapril NN i
on IN N
high-sensitivity NN N
C-reactive JJ N
protein NN N
and CC N
total JJ N
antioxidant NN N
in IN N
renal JJ p
transplant NN p
recipients NNS p
with IN p
Renin-Angiotensin NNP p
system NN p
polymorphisms NN p
. . p

BACKGROUND NNP N
As IN N
renin-angiotensin NN N
system NN N
( ( N
RAS NNP N
) ) N
activity NN N
may MD N
affect VB N
the DT N
severity NN N
of IN N
oxidative JJ N
stress NN N
and CC N
inflammatory NN N
markers NNS N
, , N
we PRP N
assessed VBD N
the DT N
effects NNS N
of IN N
enalapril NN i
( ( i
E NNP i
) ) i
and/or NN i
losartan NN i
( ( N
L NNP N
) ) N
on IN N
these DT N
markers NNS N
in IN N
renal JJ p
transplant NN p
recipients NNS p
with IN p
RAS NNP p
polymorphisms NNS p
. . p

PATIENTS NNP N
AND CC N
METHODS NNP N
After IN N
determination NN N
by IN N
PCR NNP N
of IN N
RAS NNP N
genotypes NNS N
, , N
consisting VBG N
of IN N
the DT N
angiotensin-converting JJ N
enzymes NNS N
( ( N
ACE NNP N
I/D NNP N
) ) N
, , N
angiotensinogens VBZ N
( ( N
AGT NNP N
M235T NNP N
) ) N
and CC N
angiotensin $ N
II NNP N
type NN N
1 CD N
receptors NNS N
( ( N
ATR1 NNP N
A1166C NNP N
) ) N
, , N
76 CD p
recipients NNS p
were VBD p
recruited VBN p
randomly RB p
and CC N
assigned VBD N
4 CD N
groups NNS N
. . N

The DT N
first JJ N
( ( N
n JJ N
= NNP N
17 CD N
) ) N
and CC N
second JJ N
( ( N
n JJ N
= NNP N
24 CD N
) ) N
groups NNS N
were VBD N
treated VBN N
with IN N
E NNP i
( ( N
E NNP N
( ( N
+ NNP N
) ) N
: : N
10 CD N
mg/d NN N
) ) N
and CC N
L NNP i
( ( N
L NNP N
( ( N
+ NNP N
) ) N
: : N
50 CD N
mg/d NN N
) ) N
alone RB N
, , N
respectively RB N
. . N

The DT N
third JJ N
positive JJ N
control NN N
group NN N
( ( N
n JJ N
= NNP N
17 CD N
) ) N
received VBD N
E NNP i
+ NNP i
L NNP i
( ( N
E NNP N
( ( N
+ NNP N
) ) N
L NNP N
( ( N
+ NNP N
) ) N
: : N
10 CD N
mg/d NN N
+ VBD N
50 CD N
mg/d NN N
) ) N
and CC N
the DT N
fourth JJ N
negative JJ N
control NN N
group NN N
( ( N
n JJ N
= NNP N
18 CD N
) ) N
received VBD N
no DT N
medication NN N
( ( N
E NNP N
( ( N
- : N
) ) N
: : N
L NNP N
( ( N
- : N
) ) N
) ) N
. . N

High-sensitivity JJ N
C-reactive JJ N
protein NN N
( ( N
hs-CRP JJ N
) ) N
and CC N
total JJ N
antioxidant NN N
( ( N
TA NNP N
) ) N
inflammatory NN N
and CC N
antioxidative JJ N
markers NNS N
were VBD N
measured VBN N
after IN N
2 CD N
months NNS N
. . N

After IN N
a DT N
2-week JJ N
washout NN N
period NN N
, , N
the DT N
E NNP N
( ( N
+ NNP N
) ) N
group NN N
was VBD N
changed VBN N
to TO N
L NNP N
( ( N
+ NNP N
) ) N
and CC N
vice NN N
versa NN N
in IN N
a DT N
crossover NN N
design NN N
. . N

They PRP N
were VBD N
followed VBN N
for IN N
another DT N
8 CD N
weeks NNS N
before IN N
retesting VBG N
hs-CRP NN N
and CC N
TA NNP N
. . N

A NNP N
value NN N
of IN N
P NNP N
< NNP N
or CC N
= NNP N
.05 NNP N
was VBD N
considered VBN N
significant JJ N
. . N

RESULTS NNP N
After IN N
2 CD N
and CC N
4 CD N
months NNS N
of IN N
treatment NN N
with IN N
the DT N
drug NN N
regimen NNS N
, , N
hs-CRP JJ o
and CC o
TA NNP o
levels NNS o
were VBD N
significantly RB N
decreased VBN N
and CC N
consequently RB N
increased VBN N
among IN N
the DT N
E NNP i
( ( i
+ NNP i
) ) i
L NNP i
( ( i
+ NNP i
) ) i
, , i
L NNP i
( ( i
+ NNP i
) ) i
and CC N
E NNP i
( ( i
+ NNP i
) ) i
groups NNS N
( ( N
P NNP N
< NNP N
.05 NNP N
) ) N
. . N

On IN N
analyzing VBG N
the DT N
relationship NN N
between IN N
RAS NNP N
polymorphisms NNS N
and CC N
baseline VB N
hs-CRP NN N
or CC N
TA NNP N
levels NNS N
, , N
CC NNP N
genotype NN N
of IN N
ATR1 NNP N
showed VBD N
lower JJR N
hs-CRP NN o
levels NNS o
( ( N
P NNP N
= NNP N
.04 NNP N
) ) N
. . N

However RB N
, , N
none NN N
of IN N
the DT N
RAS NNP N
polymorphisms NN N
predicted VBD N
the DT N
antioxidant JJ o
and CC o
anti-inflammatory JJ o
response NN o
rates NNS o
to TO o
the DT o
drugs NNS o
( ( N
P NNP N
> NNP N
.05 NNP N
) ) N
. . N

CONCLUSION NNP N
Although IN N
hs-CRP NN o
was VBD N
lower JJR N
in IN N
the DT N
CC NNP N
genotype NN N
patients NNS N
of IN N
ATR1 NNP N
polymorphisms FW N
E NNP N
and/or NN N
L NNP N
reduced VBD N
hs-CRP JJ N
and CC N
increased JJ N
TA NNP N
regardless NN N
of IN N
the DT N
RAS NNP N
genotype NN N
. . N

-DOCSTART- -3306431- O O

Alpha NNP i
interferon NN i
clinical JJ N
trial NN N
for IN N
multiple JJ p
sclerosis NN p
: : p
design NN N
considerations NNS N
. . N

The DT N
design NN N
and CC N
course NN N
of IN N
a DT N
placebo-controlled JJ i
alpha-2 JJ i
interferon NN i
trial NN N
in IN N
MS NNP p
patients NNS p
are VBP N
described VBN N
. . N

No DT o
beneficial JJ o
effect NN o
of IN N
the DT N
interferon NN o
on IN N
the DT N
course NN N
of IN N
MS NNP N
could MD N
be VB N
shown VBN N
. . N

-DOCSTART- -3112261- O O

Postoperative JJ o
pain NN o
control NN o
for IN N
outpatient JJ p
oral JJ p
surgery NN p
. . p

16 CD p
healthy JJ p
patients NNS p
requiring VBG p
removal NN p
of IN p
bilateral JJ p
symmetrically-impacted JJ p
mandibular JJ p
third JJ p
molars NNS p
participated VBD N
in IN N
a DT N
double-blind NN N
randomised VBN N
crossover RB N
trial NN N
to TO N
test VB N
the DT N
effectiveness NN o
of IN o
postoperative JJ o
pain NN o
control NN o
using VBG N
a DT N
long-acting JJ N
anti-inflammatory JJ N
agent NN N
( ( i
diflunisal NN i
) ) i
in IN N
combination NN N
with IN N
a DT N
long-acting JJ N
local JJ N
anaesthetic JJ N
agent NN N
( ( i
bupivacaine NN i
) ) i
. . N

Results NNS N
were VBD N
compared VBN N
to TO N
the DT N
more RBR N
traditional JJ N
method NN N
of IN N
using VBG N
an DT N
oral JJ N
analgesic NN N
with IN N
shorter JJR N
duration NN N
of IN N
action NN N
( ( i
paracetamol NN i
with IN i
codeine NN i
) ) i
with IN N
lignocaine NN i
as IN N
the DT N
local JJ N
anaesthetic NN N
. . N

Using VBG N
a DT N
visual JJ o
analogue NN o
pain NN o
scale NN o
, , N
patients NNS N
reported VBD N
that IN N
significantly RB N
reduced VBN N
pain NN o
was VBD N
experienced VBN N
over IN N
the DT N
first JJ N
4 CD N
days NNS N
postoperatively RB N
with IN N
the DT N
diflunisal/bupivacaine NN i
treatment NN i
and CC N
patient JJ o
preference NN o
for IN N
this DT N
treatment NN N
was VBD N
highly RB N
significant JJ N
. . N

This DT N
report NN N
represents VBZ N
the DT N
first JJ N
such JJ N
study NN N
of IN N
diflunisal NN i
used VBN N
for IN N
an DT N
extended JJ N
course NN N
in IN N
oral JJ N
surgery NN N
with IN N
pain NN o
assessment NN N
over IN N
the DT N
same JJ N
period NN N
. . N

No DT N
significant JJ N
side-effects NNS o
or CC o
adverse JJ o
reactions NNS o
were VBD N
encountered VBN N
. . N

-DOCSTART- -21660428- O O

Effects NNS N
of IN N
cognitive-behavioral JJ i
therapy NN i
on IN N
anxiety NN o
in IN N
children NNS p
with IN p
autism NN p
spectrum NN p
disorders NNS p
: : p
a DT N
randomized NN N
controlled VBN N
trial NN N
. . N

We PRP N
compared VBN N
the DT N
effects NNS N
of IN N
a DT N
16-week JJ N
Cognitive-Behavioral JJ i
Therapy NNP i
( ( i
CBT NNP i
) ) i
program NN i
and CC i
a DT i
Social NNP i
Recreational NNP i
( ( i
SR NNP i
) ) i
program NN i
on IN N
anxiety NN N
in IN N
children NNS p
with IN p
Autism NNP p
Spectrum NNP p
Disorders NNP p
( ( p
ASD NNP p
) ) p
. . p

Seventy JJ p
children NNS p
( ( p
9-16 CD p
years NNS p
old JJ p
) ) p
were VBD N
randomly RB N
assigned VBN N
to TO N
either DT N
of IN N
the DT N
programs NNS N
( ( N
n FW N
( ( i
CBT NNP i
) ) i
= VBZ N
36 CD N
; : N
n NNS N
( ( N
SR NNP N
) ) N
= VBP N
34 CD N
) ) N
. . N

Measures NNS N
on IN N
child NN N
's POS N
anxiety NN N
using VBG N
the DT N
Spence NNP o
Child NNP o
Anxiety NNP o
Scale NNP o
-- : o
Child NNP o
( ( o
SCAS-C NNP o
) ) o
and CC N
the DT N
Clinical JJ o
Global NNP o
Impression-Severity NNP o
scale NN o
( ( o
CGI NNP o
-- : o
S NNP o
) ) o
were VBD N
administered VBN N
at IN N
pre- JJ N
, , N
post-treatment JJ N
, , N
and CC N
follow-ups NNS N
( ( N
3- CD N
and CC N
6-month JJ N
) ) N
. . N

Children NNP N
in IN N
both DT N
programs NNS N
showed VBD N
significantly RB N
lower JJR N
levels NNS N
of IN N
generalized VBN o
anxiety NN o
and CC o
total JJ o
anxiety NN o
symptoms NNS o
at IN N
6-month JJ N
follow-up NN N
on IN N
SCAS-C. NNP N
Clinician NNP N
ratings NNS N
on IN N
the DT N
CGI-S NNP o
demonstrated VBD N
an DT N
increase NN N
in IN N
the DT N
percentage NN N
of IN N
participants NNS N
rated VBN N
as IN N
Normal NNP N
and CC N
Borderline NNP N
for IN N
both DT N
programs NNS N
. . N

Findings NNS N
from IN N
the DT N
present JJ N
study NN N
suggest JJS N
factors NNS N
such JJ N
as IN N
regular JJ i
sessions NNS i
in IN i
a DT i
structured JJ i
setting NN i
, , i
consistent JJ i
therapists NNS i
, , i
social JJ i
exposure NN i
and CC N
the DT N
use NN N
of IN N
autism-friendly JJ i
strategies NNS i
are VBP N
important JJ N
components NNS N
of IN N
an DT N
effective JJ N
framework NN N
in IN N
the DT N
management NN N
of IN N
anxiety NN N
in IN N
children NNS p
and CC p
adolescents NNS p
with IN p
ASD NNP p
. . p

-DOCSTART- -21321333- O O

Intermittent JJ i
theta-burst JJ i
transcranial JJ i
magnetic JJ i
stimulation NN i
for IN N
treatment NN N
of IN N
Parkinson NNP o
disease NN o
. . o

OBJECTIVE UH N
To TO N
investigate VB N
the DT N
safety NN o
and CC o
efficacy NN o
of IN N
intermittent JJ i
theta-burst JJ i
stimulation NN i
( ( i
iTBS NN i
) ) i
in IN N
the DT N
treatment NN N
of IN N
motor NN o
symptoms NNS o
in IN o
Parkinson NNP o
disease NN o
( ( o
PD NNP o
) ) o
. . N

BACKGROUND NNP N
Progression NNP N
of IN N
PD NNP N
is VBZ N
characterized VBN N
by IN N
the DT N
emergence NN N
of IN N
motor NN N
deficits NNS N
, , N
which WDT N
eventually RB N
respond VBZ N
less JJR N
to TO N
dopaminergic VB N
therapy NN N
and CC N
pose VB N
a DT N
therapeutic JJ N
challenge NN N
. . N

Repetitive JJ i
transcranial JJ i
magnetic JJ i
stimulation NN i
( ( i
rTMS NN i
) ) i
has VBZ N
shown VBN N
promising JJ N
results NNS N
in IN N
improving VBG o
gait NN o
, , N
a DT N
major JJ N
cause NN N
of IN N
disability NN o
, , N
and CC N
may MD N
provide VB N
a DT N
therapeutic JJ N
alternative NN N
. . N

iTBS NN i
is VBZ N
a DT N
novel JJ N
type NN N
of IN N
rTMS NN i
that WDT N
may MD N
be VB N
more RBR N
efficacious JJ N
than IN N
conventional JJ N
rTMS NN i
. . i

METHODS NNP N
In IN N
this DT N
randomized JJ N
, , N
double-blind JJ N
, , N
sham-controlled JJ N
study NN N
, , N
we PRP N
investigated VBD N
safety NN N
and CC N
efficacy NN N
of IN N
iTBS NN i
of IN N
the DT N
motor NN N
and CC N
dorsolateral JJ N
prefrontal NN N
cortices NNS N
in IN N
8 CD N
sessions NNS N
over IN N
2 CD N
weeks NNS N
( ( N
evidence NN N
Class NNP N
I PRP N
) ) N
. . N

Assessment NN N
of IN N
safety NN o
and CC o
clinical JJ o
efficacy NN o
over IN N
a DT N
1-month JJ N
period NN N
included VBD N
timed JJ N
tests NNS N
of IN N
gait NN o
and CC o
bradykinesia NN o
, , o
Unified NNP o
Parkinson NNP o
's POS o
Disease NNP o
Rating NNP o
Scale NNP o
( ( o
UPDRS NNP o
) ) o
, , o
and CC o
additional JJ o
clinical NN o
, , o
neuropsychological JJ o
, , o
and CC o
neurophysiologic JJ o
measures NNS o
. . o

RESULTS NNP N
We PRP N
investigated VBD N
26 CD p
patients NNS p
with IN p
mild JJ p
to TO p
moderate VB p
PD NNP p
: : p
13 CD N
received VBD N
iTBS NN i
and CC N
13 CD N
sham JJ i
stimulation NN i
. . i

We PRP N
found VBD N
beneficial JJ N
effects NNS N
of IN N
iTBS NN i
on IN N
mood NN o
, , N
but CC N
no DT N
improvement NN N
of IN N
gait NN o
, , o
bradykinesia NN o
, , o
UPDRS NNP o
, , o
and CC o
other JJ o
measures NNS o
. . o

EEG/EMG NNP o
monitoring NN N
recorded VBD N
no DT N
pathologic JJ N
increase NN o
of IN o
cortical JJ o
excitability NN o
or CC o
epileptic JJ o
activity NN o
. . o

Few JJ N
reported VBD N
discomfort NN o
or CC o
pain NN o
and CC N
one CD N
experienced JJ N
tinnitus NN o
during IN N
real JJ N
stimulation NN N
. . N

CONCLUSION NNP N
iTBS NN i
of IN N
the DT N
motor NN N
and CC N
prefrontal JJ N
cortices NNS N
appears VBZ N
safe JJ o
and CC o
improves VBZ o
mood NN o
, , N
but CC N
failed VBD N
to TO N
improve VB N
motor NN o
performance NN o
and CC o
functional JJ o
status NN o
in IN N
PD NNP N
. . N

CLASSIFICATION NNP N
OF IN N
EVIDENCE NNP N
This DT N
study NN N
provides VBZ N
Class NNP N
I PRP N
evidence NN N
that IN N
iTBS NN i
was VBD o
not RB o
effective JJ o
for IN N
gait NN o
, , o
upper JJ o
extremity NN o
bradykinesia NN o
, , o
or CC o
other JJ o
motor NN o
symptoms NNS o
in IN o
PD NNP o
. . o

-DOCSTART- -20068494- O O

Monitoring VBG N
acute JJ N
effects NNS N
on IN N
athletic JJ N
performance NN N
with IN N
mixed JJ N
linear JJ N
modeling NN N
. . N

UNLABELLED IN N
There EX N
is VBZ N
a DT N
need NN N
for IN N
a DT N
sophisticated JJ N
approach NN N
to TO N
track VB N
athletic JJ N
performance NN N
and CC N
to TO N
quantify VB N
factors NNS N
affecting VBG N
it PRP N
in IN N
practical JJ N
settings NNS N
. . N

PURPOSE NNP N
To TO N
demonstrate VB N
the DT N
application NN N
of IN N
mixed JJ N
linear JJ N
modeling VBG N
for IN N
monitoring VBG N
athletic JJ N
performance NN N
. . N

METHODS NNP N
Elite NNP p
sprint NN p
and CC p
middle-distance NN p
swimmers NNS p
( ( p
three CD p
females NNS p
and CC p
six CD p
males NNS p
; : p
aged VBN p
21-26 JJ p
yr NN p
) ) p
performed VBD p
6-13 JJ p
time NN p
trials NNS p
in IN p
training NN p
and CC p
competition NN p
in IN p
the DT p
9 CD p
wk NN p
before IN p
and CC p
including VBG p
Olympic-qualifying JJ p
trials NNS p
, , p
all DT p
in IN p
their PRP$ p
specialty NN p
event NN p
. . p

We PRP N
included VBD N
a DT N
double-blind NN N
, , N
randomized VBN N
, , N
diet-controlled JJ i
crossover NN i
intervention NN i
, , N
in IN N
which WDT N
the DT N
swimmers NNS N
consumed VBN N
caffeine NN i
( ( N
5 CD N
mg NN N
x NN N
kg NN N
( ( N
-1 NNP N
) ) N
body NN N
mass NN N
) ) N
or CC N
placebo NN i
. . i

The DT N
swimmers NNS N
also RB N
knowingly RB N
consumed VBD N
varying VBG N
doses NNS N
of IN N
caffeine NN i
in IN N
some DT N
time NN N
trials NNS N
. . N

We PRP N
used VBD N
mixed JJ N
linear JJ N
modeling NN N
of IN N
log-transformed JJ N
swim JJ N
time NN N
to TO N
quantify VB N
effects NNS o
on IN o
performance NN o
in IN N
training VBG N
versus NN N
competition NN N
, , N
in IN N
morning NN N
versus NN N
evening NN N
swims NNS N
, , N
and CC N
with IN N
use NN N
of IN N
caffeine NN N
. . N

Predictor NN N
variables NNS N
were VBD N
coded VBN N
as IN N
0 CD N
or CC N
1 CD N
to TO N
represent VB N
absence NN N
or CC N
presence NN N
, , N
respectively RB N
, , N
of IN N
each DT N
condition NN N
and CC N
were VBD N
included VBN N
as IN N
fixed JJ N
effects NNS N
. . N

The DT N
date NN N
of IN N
each DT N
performance NN N
test NN N
was VBD N
included VBN N
as IN N
a DT N
continuous JJ N
linear JJ N
fixed VBN N
effect NN N
and CC N
interacted VBN N
with IN N
the DT N
random NN N
effect NN N
for IN N
the DT N
athlete NN N
to TO N
represent VB N
individual JJ N
differences NNS N
in IN N
linear JJ N
trends NNS N
in IN N
performance NN N
. . N

RESULTS NNP N
Most JJS N
effects NNS o
were VBD N
clear JJ N
, , N
owing VBG N
to TO N
the DT N
high JJ N
reliability NN N
of IN N
performance NN o
times NNS o
in IN o
training NN o
and CC o
competition NN o
( ( N
typical JJ N
errors NNS N
of IN N
0.9 CD N
% NN N
and CC N
0.8 CD N
% NN N
, , N
respectively RB N
) ) N
. . N

Performance NN o
time NN o
improved VBN N
linearly RB N
by IN N
0.8 CD N
% NN N
per IN N
4 CD N
wk NN N
. . N

The DT N
swimmers NNS N
performed VBD o
substantially RB o
better RBR o
in IN N
evenings NNS N
versus JJ N
mornings NNS N
and CC N
in IN N
competition NN N
versus IN N
training NN N
. . N

A DT N
100-mg JJ N
dose NN N
of IN N
caffeine NN N
enhanced VBN N
performance NN o
in IN o
training NN o
and CC o
competition NN o
by IN N
approximately RB N
1.3 CD N
% NN N
. . N

There EX N
were VBD N
substantial JJ N
but CC N
unclear JJ N
individual JJ N
responses NNS N
to TO N
training NN N
and CC N
caffeine NN N
( ( N
SD NNP N
of IN N
0.3 CD N
% NN N
and CC N
0.8 CD N
% NN N
, , N
respectively RB N
) ) N
. . N

CONCLUSIONS NNP N
Mixed NNP N
linear IN N
modeling VBG N
can MD N
be VB N
applied VBN N
successfully RB N
to TO N
monitor VB N
factors NNS N
affecting VBG N
performance NN N
in IN N
a DT N
squad NN N
of IN N
elite JJ p
athletes NNS p
. . p

-DOCSTART- -17074147- O O

[ IN N
The DT N
effects NNS N
of IN N
antidepressant JJ i
treatment NN i
on IN N
efficacy NN o
of IN N
antihypertensive JJ N
therapy NN N
in IN N
elderly JJ p
hypertension NN p
] NNP p
. . N

OBJECTIVE NNP N
To TO N
explore VB N
the DT N
effect NN N
of IN N
antidepressant JJ N
treatment NN N
on IN N
antihypertensive JJ N
therapy NN N
of IN N
senile JJ p
hypertension NN o
. . o

METHODS NNP N
138 CD p
cases NNS p
of IN p
senile JJ p
hypertension NN p
complicating VBG p
with IN p
depression NN p
were VBD p
studied VBN p
. . p

103 CD p
senile JJ p
hypertensive JJ p
patients NNS p
without IN p
depression NN p
in IN p
the DT p
same JJ p
period NN p
served VBD p
as IN p
controls NNS p
. . p

The DT N
patients NNS N
were VBD N
randomly RB N
divided VBN N
into IN N
3 CD N
groups NNS N
as IN N
A NNP N
, , N
B NNP N
and CC N
C NNP N
for IN N
study NN N
. . N

12.5 CD N
mg/d JJ N
hydrochlorothiazide NN i
and CC N
30 CD N
mg/d JJ N
release-controlling JJ i
tablets NNS i
of IN i
nifedipine NN i
were VBD N
orally RB N
administrated VBN N
as IN N
basic JJ N
antihypertensive JJ N
medication NN N
each DT N
group NN N
. . N

Besides NNP N
, , N
20 CD N
mg/d NN N
fluoxetine NN i
was VBD N
additionally RB N
given VBN N
to TO N
groups NNS N
A NNP N
and CC N
one CD N
tablet NN N
of IN N
almitrine JJ i
l/d NN i
and CC N
20 CD N
mg NN N
oryzanol NN i
3/d CD i
were VBD N
given VBN N
to TO N
group NN N
B NNP N
. . N

The DT N
treatment NN N
lasted VBD N
12 CD N
weeks NNS N
. . N

RESULTS NNP N
In IN N
comparison NN N
with IN N
pre-treatment NN N
, , N
the DT N
blood NN o
pressure NN o
at IN N
base NN N
line NN N
in IN N
sitting VBG N
position NN N
and CC N
the DT N
average JJ o
circadian JJ o
SBP NNP o
and CC o
DBP NNP o
monitored VBD o
with IN o
24-hour JJ o
ambulatory NN o
blood NN o
pressure NN o
monitoring NN o
( ( o
ABPM NNP o
) ) o
was VBD N
remarkably RB N
decreased VBN N
in IN N
group NN N
A NNP N
with IN N
statistical JJ N
significance NN N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

These DT N
blood NN o
pressure NN o
parameters NNS o
in IN N
group NN N
B NNP N
were VBD N
also RB N
decreased VBN N
as IN N
compared VBN N
ith IN N
the DT N
pretreatment JJ N
level NN N
brt NN N
with IN N
less JJR N
statistical JJ N
significance NN N
( ( N
P NNP N
> NNP N
0.05 CD N
) ) N
. . N

It PRP N
was VBD N
also RB N
noted VBN N
tha NN N
with IN N
the DT N
addition NN N
of IN N
antidepressant JJ N
fluoxetine NN N
, , N
the DT N
manifestations NNS N
of IN N
depression NN o
ere RB N
alleviated VBN N
as IN N
shown VBN N
by IN N
Hamilton NNP o
depression NN o
( ( o
HAMD NNP o
) ) o
scale NN o
. . o

untoward JJ N
reactions NNS N
such JJ N
as IN N
nausea NN o
, , o
perspiration NN o
and CC o
skin NN o
rash NN o
were VBD N
noted VBN N
in IN N
a DT N
few JJ N
patients NNS N
, , N
but CC N
none NN N
withdrew NN N
from IN N
the DT N
study NN N
. . N

CONCLUSIONS NNP N
Antidepressant NNP i
and CC i
antianxiety NN i
treatment NN i
is VBZ N
of IN N
benefit NN N
to TO N
the DT N
antihypertensive JJ N
therapy NN N
in IN N
senile JJ N
hypertensive JJ N
patients NNS N
with IN N
complications NNS N
of IN N
depression NN N
and/or NN N
anxiety NN N
neurosis NN N
. . N

Based VBN N
on IN N
the DT N
results NNS N
of IN N
this DT N
study NN N
, , N
it PRP N
is VBZ N
suggested VBN N
that IN N
routine JJ N
administration NN N
of IN N
antidepressants NNS o
and CC o
antianxiety NN o
drugs NNS N
should MD N
be VB N
carried VBN N
out RP N
in IN N
senile JJ p
hypertensive JJ p
patients NNS p
complicating VBG N
with IN N
depression NN N
or CC N
anxiety NN N
. . N

-DOCSTART- -23104956- O O

Effect NN N
of IN N
unfractionated JJ i
and CC i
low-molecular-weight JJ i
heparin NN i
on IN N
OPG NNP o
, , o
sRANKL NN o
, , o
and CC o
von JJ o
Willebrand NNP o
factor NN o
concentrations NNS o
during IN N
hemodialysis NN p
. . p

BACKGROUND NNP N
Endothelial NNP N
dysfunction NN N
marker NN N
, , N
von FW o
Willebrand NNP o
factor NN o
( ( o
vWF NN o
) ) o
, , N
is VBZ N
physically RB N
connected VBN N
with IN N
osteoprotegerin NN N
( ( N
OPG NNP N
) ) N
in IN N
the DT N
Weibel-Palade JJ N
bodies NNS N
. . N

We PRP N
aimed VBD N
to TO N
compare VB N
the DT N
effect NN N
of IN N
unfractionated JJ i
( ( i
UFH NNP i
) ) i
and CC i
low-molecular-weight JJ i
( ( i
LMWH NNP i
enoxaparin RB i
) ) i
heparin NN i
used VBN N
as IN N
anticoagulants NNS N
during IN N
hemodialysis NN p
( ( p
HD NNP p
) ) p
on IN N
plasma NN N
levels NNS N
and CC N
relationships NNS N
of IN N
OPG NNP N
, , N
soluble JJ N
receptor NN N
activator NN N
of IN N
nuclear JJ N
factor NN N
?B NN N
Ligand NNP N
( ( N
sRANKL NN N
) ) N
, , N
and CC N
vWF NN N
. . N

METHODS NNP N
Totally RB p
21 CD p
clinically RB p
stable JJ p
chronic JJ p
HD NNP p
patients NNS p
were VBD N
randomly RB N
assigned VBN N
to TO i
either DT i
enoxaparin NN i
( ( i
n JJ i
= NNP i
10 CD i
) ) i
or CC i
UFH NNP i
( ( i
n JJ i
= NNP i
11 CD i
) ) i
anticoagulation NN i
and CC i
followed VBD i
prospectively RB i
for IN i
12 CD i
weeks NNS i
before IN i
crossing VBG i
over IN i
to TO i
the DT i
alternate NN i
therapy NN i
for IN i
further JJ i
12 CD i
weeks NNS i
. . i

The DT o
OPG NNP o
, , o
RANKL NNP o
, , o
and CC o
vWF NN o
levels NNS o
were VBD i
measured VBN i
at IN i
T0 NNP i
, , i
T10 NNP i
, , i
and CC i
T180 NNP i
of IN i
HD NNP i
session NN i
after IN i
each DT i
period NN i
of IN i
evaluation NN i
. . i

RESULTS VB N
The DT o
baseline NN o
sRANKL NN o
level NN o
was VBD N
higher JJR N
under IN i
UFH NNP i
treatment NN N
. . N

Its PRP$ o
over-HD JJ o
level NN o
does VBZ N
not RB N
behave VB N
significantly RB N
different JJ N
under IN N
enoxaparin NN N
and CC N
UFH NNP N
treatment NN N
. . N

Plasma NNP o
OPG NNP o
levels NNS o
expressly RB N
changed VBN N
during IN N
both DT i
enoxaparin FW i
( ( N
? . N
( ( N
2 CD N
) ) N
analysis NN N
of IN N
variance NN N
[ NNP N
ANOVA NNP N
] NNP N
= NNP N
31.13 CD N
, , N
P NNP N
< NNP N
.016 NNP N
) ) N
and CC N
UFH NNP N
( ( N
? . N
( ( N
2 CD N
) ) N
ANOVA NNP N
= $ N
8.26 CD N
, , N
P NNP N
= NNP N
.016 NNP N
) ) N
anticoagulation NN N
, , N
and CC N
its PRP$ N
increment NN N
at IN N
T10 NNP N
and CC N
T180 NNP N
was VBD N
significantly RB N
different JJ N
between IN N
both DT N
the DT N
heparins NNS N
. . N

The DT N
main JJ N
negative JJ N
predictor NN N
of IN N
OPG NNP o
concentration NN o
was VBD o
the DT N
total JJ o
cholesterol NN o
level NN o
( ( o
? . o
= NN N
-.51 NN N
, , N
P NNP N
= NNP N
.025 NNP N
) ) o
. . o

von JJ o
Willebrand NNP o
factor NN o
concentration NN o
remained VBD o
stable JJ N
during IN i
UFH NNP i
anticoagulation NN N
, , N
whereas JJ N
constant NN N
, , N
no DT N
significant JJ N
increments NNS N
were VBD N
noticed VBN N
, , N
under IN i
enoxaparin JJ i
treatment NN i
. . N

After IN N
10 CD N
minutes NNS N
of IN N
HD NNP N
, , N
especially RB N
under IN i
enoxaparin NN i
use NN i
, , N
a DT N
positive JJ N
correlation NN N
between IN N
OPG NNP N
and CC N
vWF JJ N
increase NN N
was VBD N
noticed VBN N
( ( N
P NNP N
= NNP N
.03 NNP N
, , N
R NNP N
= NNP N
.45 NNP N
) ) N
. . N

CONCLUSIONS NNP N
Impact NNP i
of IN i
heparin NN i
on IN i
endothelial JJ N
cells NNS N
and CC N
simultaneously RB N
on IN N
OPG/RANK/RANKL NNP N
axis NN N
reinforces VBZ N
the DT N
presumption NN N
of IN N
the DT N
pathophysiological JJ N
linkage NN N
between IN N
bone NN N
mineralization NN N
and CC N
endothelial JJ N
dysfunction NN p
in IN p
end-stage JJ p
renal JJ p
disease NN p
. . p

-DOCSTART- -2405223- O O

[ NN N
It PRP N
is VBZ N
difficult JJ N
to TO N
predict VB N
the DT N
effect NN N
of IN N
minoxidil NN i
liniment NN i
on IN N
hair NN o
loss NN o
in IN p
men NNS p
] VBP p
. . N

-DOCSTART- -26225700- O O

Total JJ o
and CC o
Partial JJ o
Prevalence NNP o
of IN o
Cancer NNP o
Across NNP p
Kerman NNP p
Province NNP p
, , p
Iran NNP p
, , p
in IN p
2014 CD p
, , N
Using VBG N
an DT N
Adapted NNP N
Generalized NNP N
Network NNP N
Scale-Up NNP N
Method NNP N
. . N

Due NNP N
to TO N
the DT N
lack NN N
of IN N
nationwide JJ N
population-based JJ N
cancer NN N
registration NN N
, , N
the DT N
total JJ N
cancer NN o
prevalence NN o
in IN N
Iran NNP p
is VBZ N
unknown JJ N
. . N

Our PRP$ N
previous JJ N
work NN N
in IN N
which WDT N
we PRP N
used VBD N
a DT N
basic JJ N
network NN N
scale-up NN N
( ( N
NSU NNP N
) ) N
method NN N
, , N
failed VBD N
to TO N
provide VB N
plausible JJ N
estimates NNS N
of IN N
total JJ p
cancer NN p
prevalence NN p
in IN p
Kerman NNP p
. . p

The DT N
aim NN N
of IN N
the DT N
present JJ N
study NN N
was VBD N
to TO N
estimate VB N
total JJ N
and CC N
partial JJ N
prevalence NN o
of IN o
cancer NN o
in IN N
southeastern JJ N
Iran NNP N
using VBG N
an DT N
adapted JJ N
version NN N
of IN N
the DT N
generalized JJ N
network NN N
scale-up JJ N
method NN N
. . N

A DT N
survey NN N
was VBD N
conducted VBN N
in IN N
2014 CD p
using VBG N
multi-stage JJ N
cluster NN N
sampling VBG N
. . N

A DT N
total NN p
of IN p
1995 CD p
face-to-face JJ p
gender-matched JJ p
interviews NNS p
were VBD N
performed VBN N
based VBN N
on IN N
an DT N
adapted JJ N
version NN N
of IN N
the DT N
NSU NNP i
questionnaire NN i
. . i

Interviewees NNS N
were VBD N
asked VBN N
about IN N
their PRP$ N
family NN N
cancer NN N
history NN N
. . N

Total JJ o
and CC o
partial JJ o
prevalence NN o
were VBD N
estimated VBN N
using VBG N
a DT N
generalized JJ N
NSU NNP N
estimator NN N
. . N

The DT N
Monte NNP N
Carlo NNP N
method NN N
was VBD N
adopted VBN N
for IN N
the DT N
estimation NN N
of IN N
upper/lower JJ N
bounds NNS N
of IN N
the DT N
uncertainty NN N
range NN N
of IN N
point NN N
estimates NNS N
. . N

One-yr JJ o
, , o
2-3 JJ o
yr NN o
, , o
and CC o
4-5 JJ o
yr NN o
prevalence NN o
( ( N
per IN N
100,000 CD N
people NNS N
) ) N
was VBD N
respectively RB N
estimated VBN N
at IN N
78 CD N
( ( N
95 CD N
% NN N
CI NNP N
, , N
66 CD N
, , N
90 CD N
) ) N
, , N
128 CD N
( ( N
95 CD N
% NN N
CI NNP N
, , N
118 CD N
, , N
147 CD N
) ) N
, , N
and CC N
59 CD N
( ( N
95 CD N
% NN N
CI NNP N
, , N
49 CD N
, , N
70 CD N
) ) N
for IN N
women NNS N
, , N
and CC N
48 CD N
( ( N
95 CD N
% NN N
CI NNP N
, , N
38 CD N
, , N
58 CD N
) ) N
, , N
78 CD N
( ( N
95 CD N
% NN N
CI NNP N
, , N
66 CD N
, , N
91 CD N
) ) N
, , N
and CC N
42 CD N
( ( N
95 CD N
% NN N
CI NNP N
, , N
32 CD N
, , N
52 CD N
) ) N
for IN N
men NNS N
. . N

The DT N
5-yr JJ o
prevalence NN o
of IN o
all DT o
cancers NNS o
was VBD N
estimated VBN N
at IN N
0.18 CD N
percent NN N
for IN N
men NNS N
, , N
and CC N
0.27 CD N
percent NN N
for IN N
women NNS N
. . N

This DT N
study NN N
showed VBD N
that IN N
the DT N
generalized VBN N
familial JJ N
network NN N
scale-up JJ N
method NN N
is VBZ N
capable JJ N
of IN N
estimating VBG N
cancer NN o
prevalence NN o
, , N
with IN N
acceptable JJ N
precision NN N
. . N

-DOCSTART- -19054718- O O

Timing VBG N
for IN N
delivering VBG N
individualized JJ i
patient JJ i
education NN i
intervention NN i
to TO N
Coronary NNP p
Artery NNP p
Bypass NNP p
Graft NNP p
patients NNS p
: : p
An DT N
RCT NNP N
. . N

BACKGROUND NNP N
The DT N
primary JJ N
focus NN N
of IN N
this DT N
study NN N
is VBZ N
on IN N
the DT N
timing NN N
of IN N
the DT N
delivery NN N
of IN N
education NN N
to TO N
patients NNS p
who WP p
had VBD p
CABG NNP i
surgery NN i
. . i

AIM NNP N
To TO N
determine VB N
the DT N
efficacy NN N
of IN N
an DT N
individualized JJ i
telephone NN i
patient JJ i
education NN i
intervention NN i
, , N
delivered VBN N
at IN N
two CD N
different JJ N
points NNS N
in IN N
time NN N
( ( N
1-2 JJ N
days NNS N
pre-discharge JJ N
versus JJ N
1-2 JJ N
days NNS N
post-discharge NN N
) ) N
in IN N
enhancing VBG N
the DT N
CABG NNP p
patient NN p
's POS p
knowledge NN N
of IN N
self-care JJ N
behaviours NNS N
, , N
performance NN N
of IN N
self-care JJ N
behaviours NNS N
, , N
and CC N
symptom JJ N
frequency NN N
. . N

METHOD NNP N
A NNP N
randomized VBD N
clinical JJ N
trial NN N
that WDT N
included VBD N
a DT N
convenience NN p
sample NN p
of IN p
first JJ p
time NN p
CABG NNP p
patients NNS p
. . p

Individuals NNS N
who WP N
received VBD N
education NN i
pre-discharge NN i
were VBD N
compared VBN N
to TO N
individuals NNS p
who WP p
received VBD p
education NN p
post-discharge NN p
on IN p
the DT p
outcomes NNS p
. . p

RESULTS NNP N
Results NNP N
indicated VBD N
no DT N
statistically RB N
significant JJ N
difference NN N
in IN N
outcomes NNS o
between IN o
the DT o
two CD o
time NN o
points NNS o
. . o

As NNP N
well RB N
, , N
anxiety NN o
levels NNS o
were VBD N
found VBN N
to TO N
be VB N
significantly RB N
higher JJR N
in IN N
the DT N
pre-discharge NN N
group NN N
than IN N
the DT N
post-discharge JJ N
group NN N
. . N

CONCLUSIONS VB N
The DT N
individualized JJ N
nature NN N
of IN N
the DT N
educational JJ i
intervention NN i
may MD N
have VB N
accounted VBN N
for IN N
non-significant JJ N
findings NNS N
reported VBN N
in IN N
outcomes NNS N
between IN N
the DT N
two CD N
time NN N
points NNS N
. . N

PRACTICE NNP N
IMPLICATIONS NNP N
Nurses NNP N
may MD N
consider VB N
assessing VBG N
anxiety NN o
levels NNS o
prior RB N
to TO N
delivery NN N
of IN N
educational JJ N
interventions NNS N
, , N
implement JJ N
interventions NNS N
aimed VBN N
at IN N
reducing VBG N
anxiety NN N
levels NNS N
, , N
and CC N
provide VB N
individualized JJ N
teaching NN N
. . N

-DOCSTART- -24658964- O O

Older JJR p
patients NNS p
with IN p
chronic JJ p
myeloid NN p
leukemia NN p
( ( p
?65 CD p
years NNS p
) ) p
profit NN p
more RBR N
from IN N
higher JJR i
imatinib NN i
doses NNS i
than IN p
younger JJR p
patients NNS p
: : p
a DT p
subanalysis NN N
of IN N
the DT N
randomized JJ N
CML-Study NNP N
IV NNP N
. . N

The DT N
impact NN N
of IN N
imatinib NN i
dose NN i
on IN N
response NN N
rates NNS N
and CC N
survival NN N
in IN N
older JJR p
patients NNS p
with IN p
chronic JJ p
myeloid NN p
leukemia NN p
in IN p
chronic JJ p
phase NN p
has VBZ p
not RB N
been VBN N
studied VBN N
well RB N
. . N

We PRP N
analyzed VBD N
data NNS N
from IN N
the DT N
German JJ N
CML-Study NNP N
IV NNP N
, , N
a DT N
randomized JJ p
five-arm JJ p
treatment NN p
optimization NN p
study NN p
in IN p
newly RB p
diagnosed VBN p
BCR-ABL-positive JJ p
chronic JJ p
myeloid NN p
leukemia NN p
in IN p
chronic JJ p
phase NN p
. . p

Patients NNS p
randomized VBD p
to TO p
imatinib VB i
400 CD i
mg/day NN p
( ( p
IM400 NNP p
) ) p
or CC p
imatinib $ i
800 CD i
mg/day NN p
( ( p
IM800 NNP p
) ) p
and CC p
stratified VBD p
according VBG p
to TO p
age NN p
( ( p
?65 CD p
years NNS p
vs. FW p
< RB p
65 CD p
years NNS p
) ) p
were VBD p
compared VBN N
regarding VBG N
dose RB N
, , N
response NN N
, , N
adverse JJ N
events NNS N
, , N
rates NNS N
of IN N
progression NN N
, , N
and CC N
survival NN N
. . N

The DT N
full JJ N
800 CD N
mg NN N
dose NN N
was VBD N
given VBN N
after IN N
a DT N
6-week JJ N
run-in JJ N
period NN N
with IN N
imatinib JJ i
400 CD i
mg/day NN N
. . N

The DT N
dose NN N
could MD N
then RB N
be VB N
reduced VBN N
according VBG N
to TO N
tolerability NN p
. . p

A DT p
total NN p
of IN p
828 CD p
patients NNS p
were VBD p
randomized VBN p
to TO p
IM400 NNP N
or CC N
IM800 NNP p
. . p

Seven NNP p
hundred VBD p
eighty-four JJ p
patients NNS p
were VBD p
evaluable JJ p
( ( p
IM400 NNP p
, , p
382 CD p
; : p
IM800 NNP p
, , p
402 CD p
) ) p
. . p

One CD p
hundred VBD p
ten JJ p
patients NNS p
( ( p
29 CD p
% NN p
) ) p
on IN p
IM400 NNP p
and CC p
83 CD p
( ( p
21 CD p
% NN p
) ) p
on IN p
IM800 NNP p
were VBD p
?65 JJ p
years NNS p
. . N

The DT o
median JJ o
dose JJ o
per IN o
day NN o
was VBD o
lower JJR N
for IN N
patients NNS N
?65 CD N
years NNS N
on IN N
IM800 NNP N
, , N
with IN N
the DT N
highest JJS N
median JJ N
dose NN N
in IN N
the DT N
first JJ N
year NN N
( ( N
466 CD N
mg/day NN N
for IN N
patients NNS N
?65 CD N
years NNS N
vs. FW N
630 CD N
mg/day NN N
for IN N
patients NNS N
< JJ N
65 CD N
years NNS N
) ) N
. . N

Older JJR N
patients NNS N
on IN N
IM800 NNP N
achieved VBD o
major JJ o
molecular JJ o
remission NN o
and CC o
deep JJ o
molecular JJ o
remission NN o
as IN N
fast NN N
as IN N
younger JJR N
patients NNS N
, , N
in IN N
contrast NN N
to TO N
standard VB N
dose JJ N
imatinib NN N
with IN N
which WDT N
older JJR p
patients NNS p
achieved VBD o
remissions NNS o
much RB o
later RBR o
than IN o
younger JJR o
patients NNS o
. . o

Grades NNP o
3 CD o
and CC o
4 CD o
adverse JJ o
events NNS o
were VBD o
similar JJ N
in IN N
both DT N
age NN N
groups NNS N
. . o

Five-year JJ o
relative JJ o
survival NN o
for IN N
older JJR N
patients NNS N
was VBD N
comparable JJ N
to TO N
that DT N
of IN N
younger JJR N
patients NNS N
. . N

We PRP N
suggest VBP N
that IN N
the DT N
optimal JJ N
dose NN N
for IN N
older JJR N
patients NNS N
is VBZ N
higher JJR N
than IN N
400 CD N
mg/day NN N
. . N

ClinicalTrials.gov NNP N
identifier NN N
: : N
NCT00055874 NN N
-DOCSTART- -17719303- O O

Sodium NN i
bicarbonate NN i
, , i
N-acetylcysteine NNP i
, , i
and CC i
saline NN i
for IN N
prevention NN N
of IN N
radiocontrast-induced JJ o
nephropathy NN o
. . o

A DT N
comparison NN N
of IN N
3 CD N
regimens NNS N
for IN N
protecting VBG N
contrast-induced JJ N
nephropathy JJ N
in IN N
patients NNS p
undergoing VBG p
coronary JJ i
procedures NNS i
. . i

A DT N
single-center JJ p
prospective NN N
controlled VBN N
trial NN N
. . N

BACKGROUND NNP N
Several NNP N
protective JJ N
therapies NNS N
have VBP N
been VBN N
developed VBN N
to TO N
prevent VB N
contrast-induced JJ o
nephropathy JJ o
( ( o
CIN NNP o
) ) o
. . o

We PRP N
aimed VBD N
to TO N
investigate VB N
the DT N
efficacy NN N
of IN N
sodium NN i
bicarbonate NN i
by IN N
comparing VBG N
2 CD N
other JJ N
regimens NNS N
, , N
including VBG N
combination NN i
of IN i
N-acetylcysteine NNP i
( ( i
NAC NNP i
) ) i
plus CC i
sodium JJ i
chloride NN i
and CC i
sodium NN i
chloride NN i
alone RB i
, , N
to TO N
prevent VB N
CIN NNP N
in IN N
patients NNS p
undergoing VBG p
cardiovascular JJ p
procedures NNS p
. . p

METHODS NNP N
We PRP p
prospectively RB p
enrolled VBD p
264 CD p
patients NNS p
who WP p
were VBD p
scheduled VBN p
for IN p
cardiovascular JJ p
procedures NNS p
and CC p
had VBD p
a DT p
baseline JJ p
creatinine NN p
level NN p
> VBD p
1.2 CD p
mg/dL NN p
. . p

The DT N
patients NNS N
were VBD N
assigned VBN N
1 CD N
of IN N
3 CD N
prophylactic JJ N
regimens NNS N
: : N
infusion NN i
of IN i
sodium NN i
bicarbonate NN i
, , i
sodium NN i
chloride NN i
, , i
sodium NN i
chloride NN i
plus CC i
oral JJ i
NAC NNP i
( ( N
600 CD N
mg RB N
bid NN N
) ) N
. . N

Contrast-induced JJ o
nephropathy NN o
was VBD N
defined VBN N
as IN N
an DT N
increase NN o
in IN o
serum JJ o
creatinine NN o
level NN o
> VBD o
25 CD o
% NN o
or CC N
0.5 CD N
mg/dL NNS N
after IN N
48 CD N
hours NNS N
. . N

RESULTS VB N
There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
among IN N
groups NNS N
regarding VBG N
baseline NN N
demographic JJ o
properties NNS o
and CC N
nephropathy JJ o
risk NN o
factors NNS o
. . o

The DT N
change NN o
in IN o
creatinine JJ o
clearance NN o
was VBD N
significantly RB N
better RBR N
in IN N
the DT N
sodium NN i
bicarbonate NN i
group NN N
than IN N
other JJ N
2 CD N
groups NNS N
( ( N
P NNP N
= NNP N
.007 NNP N
) ) N
. . N

The DT N
incidence NN o
of IN o
CIN NNP o
was VBD N
significantly RB N
lower JJR N
in IN N
the DT N
sodium NN i
bicarbonate NN i
group NN N
( ( N
4.5 CD N
% NN N
) ) N
compared VBN N
with IN N
sodium JJ i
chloride NN i
alone RB i
( ( N
13.6 CD N
% NN N
, , N
P NNP N
= NNP N
.036 NNP N
) ) N
and CC N
tended VBD N
to TO N
be VB N
lower JJR N
than IN N
in IN N
the DT N
combination NN i
group NN N
( ( N
12.5 CD N
% NN N
, , N
P NNP N
= NNP N
.059 NNP N
) ) N
. . N

After IN N
adjusting VBG N
the DT N
Mehran NNP o
nephropathy NN o
risk NN o
score NN o
, , N
the DT N
risk NN o
of IN o
CIN NNP o
significantly RB N
reduced VBD N
with IN N
sodium NN i
bicarbonate NN i
compared VBN N
with IN N
sodium JJ i
chloride NN i
alone RB N
( ( N
adjusted VBN N
risk NN N
ratio NN N
0.29 CD N
, , N
P NNP N
= NNP N
.043 NNP N
) ) N
. . N

CONCLUSIONS NNP N
Hydration NNP N
with IN N
sodium JJ i
bicarbonate NN i
provides VBZ N
better JJR N
protection NN o
against IN N
CIN NNP o
than IN N
the DT N
sodium NN i
chloride JJ i
infusion NN i
does VBZ N
alone RB N
. . N

Combination NNP i
therapy NN i
of IN i
NAC NNP i
plus CC i
sodium JJ i
chloride NN i
did VBD N
not RB N
offer VB N
additional JJ N
benefit NN N
over IN N
hydration NN N
with IN N
sodium JJ i
chloride NN i
alone RB i
. . i

-DOCSTART- -4949377- O O

Miotics NNS i
in IN p
cataract NN p
surgery NN p
. . p

-DOCSTART- -16160627- O O

Tetrahydrobiopterin NN i
in IN N
the DT N
treatment NN N
of IN N
children NNS p
with IN p
autistic JJ p
disorder NN p
: : p
a DT N
double-blind JJ N
placebo-controlled JJ i
crossover NN N
study NN N
. . N

Twelve NNP p
children NNS p
, , p
all DT p
boys NNS p
, , p
aged VBD p
4 CD p
to TO p
7 CD p
years NNS p
, , p
with IN p
a DT p
diagnosis NN p
of IN p
autistic JJ p
disorder NN p
and CC p
low JJ p
concentrations NNS p
of IN p
spinal JJ p
6R-l-erythro-5,6,7,8-tetrahydrobiopterin JJ p
( ( p
tetrahydrobiopterin NN p
) ) p
were VBD N
selected VBN N
to TO N
participate VB N
in IN N
a DT N
double-blind NN N
, , N
randomized VBN N
, , N
placebo-controlled JJ i
, , N
crossover NN N
study NN N
. . N

The DT N
children NNS N
received VBD N
a DT N
daily JJ N
dose NN N
of IN N
3 CD N
mg NNS N
tetrahydrobiopterin JJ i
per IN N
kilogram NN N
during IN N
6 CD N
months NNS N
alternating VBG N
with IN N
placebo NN i
. . i

Treatment-induced JJ o
effects NNS o
were VBD N
assessed VBN N
with IN N
the DT N
Childhood NNP o
Autism NNP o
Rating NNP o
Scale NNP o
every DT N
third JJ N
month NN N
. . N

The DT N
results NNS N
showed VBD N
small JJ N
nonsignificant JJ N
changes NNS N
in IN N
the DT N
total JJ o
scores NNS o
of IN o
Childhood NNP o
Autism NNP o
Rating NNP o
Scale NNP o
after IN N
3- JJ N
and CC N
6-month JJ N
treatment NN N
. . N

Post NNP N
hoc NN N
analysis NN N
looking VBG N
at IN N
the DT N
3 CD N
core NN N
symptoms NNS N
of IN N
autism NN N
, , N
that WDT N
is VBZ N
, , N
social JJ o
interaction NN o
, , o
communication NN o
, , o
and CC o
stereotyped VBD o
behaviors NNS o
, , N
revealed VBD N
a DT N
significant JJ N
improvement NN N
of IN N
the DT N
social JJ o
interaction NN o
score NN o
after IN N
6 CD N
months NNS N
of IN N
active JJ N
treatment NN N
. . N

In IN N
addition NN N
, , N
a DT N
high JJ N
positive JJ N
correlation NN N
was VBD N
found VBN N
between IN N
response NN o
of IN o
the DT o
social JJ o
interaction NN o
score NN o
and CC o
IQ NNP o
. . o

The DT N
results NNS N
indicate VBP N
a DT N
possible JJ N
effect NN N
of IN N
tetrahydrobiopterin NN i
treatment NN N
. . N

-DOCSTART- -6377221- O O

Effect NN N
of IN N
oral JJ N
diuretics NNS i
on IN N
pulmonary JJ N
mechanics NNS N
in IN N
infants NNS p
with IN p
chronic JJ p
bronchopulmonary JJ p
dysplasia NN p
: : p
results NNS N
of IN N
a DT N
double-blind JJ p
crossover NN p
sequential JJ p
trial NN p
. . p

In IN N
a DT N
randomized JJ N
double-blind NN N
crossover NN N
trial NN N
with IN N
sequential JJ N
analysis NN N
, , N
the DT N
effects NNS N
of IN N
oral JJ N
diuretics NNS i
were VBD N
compared VBN N
with IN N
the DT N
effects NNS N
of IN N
placebo NN i
on IN N
pulmonary JJ N
mechanics NNS N
in IN N
ten JJ p
infants NNS p
with IN p
bronchopulmonary JJ p
dysplasia NN p
( ( p
BPD NNP p
) ) p
. . p

Pulmonary JJ N
mechanics NNS N
were VBD N
measured VBN N
before RB N
and CC N
at IN N
the DT N
end NN N
of IN N
a DT N
week NN N
of IN N
treatment NN N
with IN N
oral JJ i
diuretics NNS i
( ( i
chlorothiazide NN i
, , i
20 CD i
mg/kg/dose NN i
and CC i
spironolactone NN i
, , i
1.5 CD i
mg/kg/dose NN i
) ) i
given VBN i
twice RB i
daily RB i
, , i
or CC i
placebo NN i
. . i

Mean NNP o
airway RB o
resistance NN o
decreased VBD N
35.3 CD N
cm NN N
H2O/L/s NNP N
, , N
mean NN N
specific JJ o
airway RB o
conductance NN o
increased VBD N
0.095 CD N
1/L/s/cm CD N
H2O NNP N
, , N
and CC N
mean JJ o
dynamic JJ o
pulmonary JJ o
compliance NN o
increased VBD N
1.74 CD N
mL/cm NN N
H2O NNP N
during IN N
treatment NN N
with IN N
diuretics NNS N
( ( N
all DT N
P NNP N
less JJR N
than IN N
.001 NN N
) ) N
, , N
but CC N
not RB N
during IN N
treatment NN N
with IN N
placebo NN N
. . N

The DT N
infants NNS p
' POS p
rate NN p
of IN p
weight NN o
gain NN o
decreased VBD N
on IN N
the DT N
first JJ N
three CD N
days NNS N
of IN N
diuretic JJ N
treatment NN N
, , N
but CC N
was VBD N
thereafter RB N
comparable JJ N
with IN N
weight JJ o
gain NN o
during IN N
treatment NN N
with IN N
placebo NN i
. . i

Fluid NNP o
intake NN o
was VBD N
similar JJ N
in IN N
infants NNS p
receiving VBG N
diuretics NNS N
and CC N
placebo NN i
. . i

But CC N
, , N
infants NNS p
receiving VBG N
diuretics NNS N
not RB N
only RB N
had VBD N
significantly RB N
increased VBN N
urine JJ o
output NN o
, , o
osmolal JJ o
clearance NN o
, , o
and CC o
potassium NN o
and CC o
phosphorus NN o
excretion NN o
, , N
but CC N
these DT N
infants NNS N
also RB N
retained VBD o
less JJR o
fluid NN o
, , N
and CC N
, , N
in IN N
addition NN N
, , N
excreted VBD o
less JJR o
calcium NN o
than IN N
infants NNS N
receiving VBG N
placebo NN N
. . N

It PRP N
is VBZ N
concluded VBN N
that IN N
oral JJ N
diuretics NNS i
improve VBP N
lung NN o
function NN o
in IN N
infants NNS p
with IN N
chronic JJ N
bronchopulmonary JJ N
dysplasia NN N
; : N
however RB N
, , N
potassium NN N
and CC N
phosphorus NN N
depletion NN N
are VBP N
potential JJ N
complications NNS N
of IN N
treatment NN N
. . N

-DOCSTART- -19919399- O O

Effect NN N
of IN N
device-guided JJ i
breathing NN i
exercises NNS i
on IN N
blood NN o
pressure NN o
in IN N
patients NNS p
with IN p
hypertension NN p
: : p
a DT N
randomized NN N
controlled VBN N
trial NN N
. . N

OBJECTIVE NNP N
Hypertension NNP N
is VBZ N
a DT N
chronic JJ N
disorder NN N
with IN N
a DT N
high JJ N
prevalence NN N
worldwide NN N
. . N

Despite IN N
considerable JJ N
efforts NNS N
, , N
it PRP N
is VBZ N
sometimes RB N
hard JJ N
to TO N
reach VB N
treatment NN N
goals NNS N
for IN N
blood NN o
pressure NN o
( ( o
BP NNP o
) ) o
with IN N
classical JJ N
treatment NN N
options NNS N
. . N

Reducing VBG N
breathing VBG N
frequency NN N
has VBZ N
been VBN N
advocated VBN N
as IN N
a DT N
method NN N
to TO N
reduce VB N
BP NNP o
. . o

METHODS NNP N
A NNP N
randomized JJ N
, , N
single-blind JJ N
, , N
controlled VBD N
trial NN N
was VBD N
conducted VBN N
in IN N
30 CD p
non-diabetic JJ p
patients NNS p
with IN p
hypertension NN p
over IN N
a DT N
period NN N
of IN N
9 CD N
weeks NNS N
to TO N
evaluate VB N
the DT N
effect NN N
of IN N
a DT N
device NN i
that WDT i
helps VBZ i
to TO i
slow VB o
breathing NN o
( ( i
Resperate NNP i
) ) i
on IN N
BP NNP o
and CC o
quality NN o
of IN o
life NN o
( ( o
QoL NNP o
) ) o
. . o

The DT N
control NN N
group NN N
listened VBD i
to TO i
music NN i
and CC i
used VBN i
no DT i
other JJ i
therapeutic JJ i
device NN i
. . i

RESULTS NNP N
There EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
change NN N
in IN N
BP NNP o
between IN N
intervention NN N
and CC N
control NN N
; : N
BP NNP o
-4.2 NNP N
mmHg NN N
( ( N
95 CD N
% NN N
CI NNP N
-12.4 NNP N
to TO N
3.9 CD N
) ) N
/-2.6 NN N
mmHg NN N
( ( N
95 CD N
% NN N
CI NNP N
-8.4 NNP N
to TO N
3.3 CD N
) ) N
. . N

This DT N
result NN N
did VBD N
not RB N
alter VB N
in IN N
post NN N
hoc NN N
analyses NNS N
, , N
when WRB N
patients NNS N
not RB N
achieving VBG N
target NN o
breathing NN o
frequency NN o
( ( N
< JJ N
10 CD N
breaths/min NN N
) ) N
or CC N
non-compliant JJ N
patients NNS N
were VBD N
excluded VBN N
. . N

QoL NNP o
did VBD N
not RB N
change VB N
over IN N
time NN N
. . N

CONCLUSIONS NNP N
We PRP N
found VBD N
no DT N
effect NN N
of IN N
the DT N
Resperate NNP N
on IN N
BP NNP o
or CC N
QoL NNP o
compared VBN N
with IN N
the DT N
control NN N
group NN N
. . N

We PRP N
conclude VBP N
that IN N
, , N
at IN N
this DT N
moment NN N
, , N
this DT N
device NN N
has VBZ N
no DT N
added VBN N
value NN N
in IN N
the DT N
treatment NN N
of IN N
hypertension NN N
. . N

-DOCSTART- -10361382- O O

Effects NNS N
of IN N
pyridostigmine NN i
and CC N
naloxone NN i
on IN N
the DT N
abnormal JJ o
TSH NNP o
response NN o
to TO o
TRH NNP o
during IN o
starvation NN o
in IN p
humans NNS p
. . p

BACKGROUND NNP N
Starvation NNP N
is VBZ N
associated VBN N
with IN N
a DT N
blunted JJ o
TSH NNP o
response NN o
to TO N
thyrotropin-releasing JJ o
hormone NN o
( ( o
TRH NNP o
) ) o
( ( N
peak JJ N
minus NN N
baseline NN N
< $ N
5 CD N
mIU/L NN N
) ) N
, , N
despite IN N
basal JJ N
TSH NNP N
and CC N
thyroid VB N
hormone NN N
levels NNS N
within IN N
the DT N
normal JJ N
range NN N
. . N

In IN N
light NN N
of IN N
the DT N
inhibitory JJ N
effect NN N
of IN N
somatostatin NN N
on IN N
TSH NNP N
secretion NN N
, , N
we PRP N
examined VBD N
whether IN N
this DT N
condition NN N
is VBZ N
caused VBN N
by IN N
an DT N
increased VBN N
hypothalamic NN o
somatostatinergic NN o
tone NN o
in IN N
starving VBG p
subjects NNS p
. . p

The DT N
possible JJ N
involvement NN o
of IN o
endogenous JJ o
opioids NNS o
in IN o
the DT o
mechanism NN o
underlying VBG o
the DT o
abnormal JJ o
TSH NNP o
response NN o
to TO o
TRH NNP o
was VBD N
also RB N
evaluated VBN N
. . N

METHODS NNP N
The DT N
TSH NNP o
response NN o
to TO o
TRH NNP o
( ( o
25 CD o
micrograms NNS o
in IN o
an DT o
intravenous JJ o
bolus NN o
) ) o
, , o
serum JJ o
total NN o
and CC o
free JJ o
T4 NNP o
and CC o
T3 NNP o
levels NNS o
, , o
and CC o
24-hour JJ o
urinary-free JJ o
cortisol NN o
levels NNS o
were VBD N
measured VBN N
in IN N
28 CD p
normal JJ p
men NNS p
( ( p
age NN p
27-35 CD p
years NNS p
) ) p
within IN p
10 CD p
% NN p
of IN p
their PRP$ p
ideal NN p
body NN p
weight NN p
. . p

They PRP p
were VBD p
randomly RB p
divided VBN p
into IN p
4 CD p
groups NNS p
of IN p
7 CD p
. . p

In IN N
21 CD N
subjects NNS N
( ( N
groups NNS N
1 CD N
, , N
2 CD N
, , N
and CC N
3 CD N
) ) N
, , N
TRH NNP i
tests NNS i
were VBD i
performed VBN i
after IN i
an DT i
overnight NN i
( ( i
8 CD i
hours NNS i
) ) i
fast RB i
, , i
placebo JJ i
administrations NNS i
( ( i
control VB i
test NN i
) ) i
, , i
and CC i
after IN i
prolonged VBN i
( ( i
56 CD i
hours NNS i
) ) i
starvation NN i
. . i

TRH NNP o
tests NNS o
after IN o
prolonged JJ o
starvation NN o
were VBD i
performed VBN i
either RB i
after IN i
placebos NN i
( ( i
in IN i
all DT i
subjects NNS i
) ) i
or CC i
the DT i
administration NN i
of IN i
pyridostigmine NN i
( ( i
180 CD i
mg NNS i
orally RB i
) ) i
( ( i
in IN i
7 CD i
subjects NNS i
, , i
group NN i
1 CD i
) ) i
; : i
naloxone NN i
( ( i
0.8 CD i
mg NN i
in IN i
an DT i
i.v NN i
. . i

bolus CC i
injection NN i
) ) i
( ( i
in IN i
7 CD i
subjects NNS i
, , i
group NN i
2 CD i
) ) i
; : i
or CC i
the DT i
combination NN i
of IN i
pyridostigmine NN i
and CC i
naloxone NN i
( ( i
in IN i
7 CD i
subjects NNS i
, , i
group NN i
3 CD i
) ) i
. . i

The DT N
remaining VBG N
7 CD N
subjects NNS N
( ( N
group NN N
4 CD N
) ) N
were VBD N
tested VBN N
at IN N
weekly JJ N
intervals NNS N
with IN N
TRH NNP i
plus CC i
placebo NN i
, , i
TRH NNP i
plus CC i
naloxone NN i
, , i
TRH NNP i
plus CC i
pyridostigmine NN i
, , i
and CC i
TRH NNP i
plus CC i
naloxone JJ i
plus CC i
pyridostigmine NN i
after IN N
a DT N
fasting JJ N
period NN N
of IN N
8 CD N
hours NNS N
. . N

RESULTS NNP N
In IN N
all DT N
subjects NNS N
of IN N
groups NNS N
1 CD N
, , N
2 CD N
, , N
and CC N
3 CD N
, , N
TRH-induced NNP o
TSH NNP o
rise NN o
was VBD N
significantly RB N
lower JJR N
after IN N
prolonged JJ N
starvation NN N
than IN N
after IN N
overnight JJ N
fast NN N
. . N

Neither CC N
pyridostigmine JJ i
nor CC N
naloxone JJ i
, , N
given VBN N
alone RB N
, , N
changed VBD N
the DT N
basal NN o
levels NNS o
of IN o
TSH NNP o
and CC N
the DT N
TSH NNP o
response NN o
to TO o
TRH NNP o
after IN o
prolonged JJ o
starvation NN o
. . o

In IN N
contrast NN N
, , N
the DT N
concomitant JJ N
administration NN N
of IN N
naloxone NN N
and CC N
pyridostigmine NN N
significantly RB N
enhanced VBD N
the DT N
TRH-induced NNP N
TSH NNP N
rise NN N
. . N

After IN N
overnight JJ N
fasting NN N
, , N
naloxone JJ N
administration NN N
in IN N
group NN N
4 CD N
subjects NNS N
did VBD N
not RB N
change VB N
the DT N
TSH NNP N
response NN N
to TO N
TRH NNP N
, , N
whereas JJ N
pyridostigmine VBP N
significantly RB N
enhanced VBN N
the DT N
TSH NNP N
response NN N
to TO N
TRH NNP N
. . N

When WRB N
naloxone NN N
was VBD N
given VBN N
together RB N
with IN N
pyridostigmine NN i
and CC N
TRH NNP i
the DT N
TSH NNP N
response NN N
was VBD N
similar JJ N
to TO N
that DT N
observed VBN N
in IN N
the DT N
TRH NNP N
plus CC N
pyridostigmine JJ N
test NN N
. . N

CONCLUSIONS NNP N
These DT N
data NNS N
indicate VBP N
that IN N
naloxone-sensitive JJ N
endogenous JJ N
opioids NNS N
exert VBP N
an DT N
inhibitory JJ N
effect NN N
on IN N
the DT N
cholinergic JJ o
stimulatory NN o
control NN o
of IN o
TSH NNP o
secretion NN o
during IN N
prolonged JJ N
starvation NN N
. . N

This DT N
suggests VBZ N
that IN N
an DT N
enhanced JJ N
hypothalamic JJ N
somatostatinergic NN N
activity NN N
is VBZ N
involved VBN N
in IN N
the DT N
mechanism NN N
underlying VBG N
the DT N
reduced VBN N
TSH NNP N
response NN N
to TO N
TRH NNP N
. . N

-DOCSTART- -3541602- O O

Prazosin NNP i
versus NN i
captopril NN i
as IN N
initial JJ N
therapy NN N
. . N

Effect VB N
on IN N
hypertension NN o
and CC o
lipid JJ o
levels NNS o
. . o

A DT N
randomized JJ N
, , N
parallel JJ N
group NN N
study NN N
evaluated VBD N
the DT N
safety NN o
, , o
efficacy NN o
, , o
and CC o
effect NN o
of IN N
the DT N
alpha NN N
blocking VBG N
agent JJ N
prazosin NN i
and CC N
the DT N
angiotensin NN N
converting VBG N
enzyme JJ N
inhibitor NN N
captopril NN i
on IN N
serum NN N
lipid JJ N
levels NNS N
in IN N
patients NNS p
with IN p
mild JJ p
to TO p
moderate VB p
hypertension NN p
. . p

Baseline JJ N
evaluations NNS N
were VBD N
performed VBN N
on IN N
31 CD p
patients NNS p
after IN p
a DT p
four-week JJ p
placebo NN p
washout IN p
period NN p
. . p

Patients NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
either DT N
prazosin NN i
( ( N
n JJ N
= NNP N
15 CD N
) ) N
or CC N
captopril NN i
( ( N
n JJ N
= NNP N
16 CD N
) ) N
. . N

Daily JJ N
doses NNS N
were VBD N
titrated VBN N
as IN N
follows VBZ N
: : N
for IN N
prazosin NN i
, , N
1 CD N
mg NN N
two CD N
times NNS N
daily RB N
to TO N
maximum VB N
of IN N
20 CD N
mg NNS N
per IN N
day NN N
; : N
for IN N
captopril NN i
, , N
25 CD N
mg NN N
three CD N
times NNS N
daily RB N
to TO N
a DT N
maximum NN N
of IN N
450 CD N
mg NNS N
per IN N
day NN N
. . N

If IN N
diastolic JJ o
blood NN o
pressure NN o
was VBD N
not RB N
adequately RB N
controlled VBN N
( ( N
less JJR N
than IN N
85 CD N
mm JJ N
Hg NNP N
) ) N
after IN N
four CD N
weeks NNS N
of IN N
monotherapy NN N
, , N
1 CD N
mg NN N
of IN N
polythiazide NN i
was VBD N
added VBN N
to TO N
the DT N
daily JJ N
regimen NNS N
. . N

There EX N
were VBD N
no DT N
statistically RB N
significant JJ N
differences NNS N
between IN N
the DT N
drug NN N
groups NNS N
for IN N
the DT N
measured JJ N
variables NNS N
in IN N
either CC N
the DT N
parallel NN N
or CC N
crossover JJ N
phase NN N
of IN N
the DT N
study NN N
. . N

Five CD N
of IN N
15 CD N
prazosin-treated JJ i
patients NNS N
and CC N
six CD N
of IN N
16 CD N
captopril-treated JJ N
patients NNS N
required VBD N
the DT N
addition NN N
of IN N
thiazide NN i
to TO N
achieve VB N
blood NN o
pressure NN o
control NN o
. . o

-DOCSTART- -15317925- O O

Risk NN i
factors NNS i
for IN i
fracture NN i
in IN p
a DT p
UK JJ p
population NN p
: : p
a DT N
prospective JJ N
cohort NN i
study NN i
. . i

BACKGROUND NNP N
Common NNP N
clinical JJ N
risk NN i
factors NNS i
for IN i
fracture NN i
in IN p
older JJR p
women NNS p
have VBP N
been VBN N
identified VBN N
. . N

To TO N
date NN N
, , N
most JJS N
of IN N
these DT N
risk NN N
factors NNS N
have VBP N
not RB N
been VBN N
confirmed VBN N
in IN N
a DT N
UK NNP p
population NN p
. . p

AIM NNP N
To TO N
confirm VB N
the DT N
important JJ N
risk NN i
factors NNS i
for IN i
fracture NN i
in IN p
older JJR p
women NNS p
. . p

DESIGN NNP N
Comprehensive NNP i
cohort NN i
study NN i
( ( i
CCS NNP i
) ) i
with IN N
a DT N
nested JJ N
randomized NN N
controlled VBD i
trial NN i
. . i

METHODS NNP N
The DT N
CCS NNP i
included VBD p
4292 CD p
women NNS p
aged VBD p
> JJ p
70 CD p
years NNS p
. . p

We PRP N
assessed VBD N
potential JJ N
risk NN i
factors NNS i
for IN i
fracture NN i
, , N
and CC N
followed-up JJ N
participants NNS N
for IN N
24 CD N
months NNS N
for IN N
incidence NN N
of IN N
non-vertebral JJ N
fractures NNS N
. . N

RESULTS NNP N
Odds NNP N
ratios NNS N
( ( N
ORs NNP N
) ) N
for IN N
predicting VBG N
any DT N
non-vertebral JJ N
fracture NN N
were VBD N
: : N
previous JJ o
fracture NN o
, , N
2.67 CD N
( ( N
95 CD N
% NN N
CI NNP N
2.10-3.40 CD N
) ) N
; : N
a DT o
fall NN o
in IN o
the DT o
last JJ o
12 CD o
months NNS o
, , N
2.06 CD N
( ( N
95 CD N
% NN N
CI NNP N
1.63-2.59 CD N
) ) N
; : N
and CC N
age NN o
( ( N
per IN N
year NN N
increase NN N
) ) N
, , N
1.03 CD N
( ( N
95 CD N
% NN N
CI NNP N
1.01-1.05 CD N
) ) N
. . N

ORs NNP N
for IN N
predicting VBG N
hip JJ N
fracture NN N
were VBD N
: : N
previous JJ o
fracture NN o
, , N
2.31 CD N
( ( N
95 CD N
% NN N
CI NNP N
1.31-4.08 CD N
) ) N
; : N
low JJ o
body NN o
weight NN o
( ( N
< JJ N
58 CD N
kg NN N
) ) N
, , N
2.20 CD N
( ( N
95 CD N
% NN N
CI NNP N
1.28-3.77 CD N
) ) N
; : N
maternal JJ o
history NN o
of IN o
hip NN o
fracture NN o
, , N
1.68 CD N
( ( N
95 CD N
% NN N
CI NNP N
0.85-3.31 NN N
) ) N
; : N
a DT o
fall NN o
in IN o
the DT o
last JJ o
12 CD o
months NNS o
, , N
2.92 CD N
( ( N
95 CD N
% NN N
CI NNP N
1.70-5.01 CD N
) ) N
; : N
and CC N
age NN o
( ( N
per IN N
year NN N
increase NN N
) ) N
, , N
1.09 CD N
( ( N
95 CD N
% NN N
CI NNP N
1.04-1.13 CD N
) ) N
. . N

ORs NNP N
for IN N
predicting VBG N
wrist JJ N
fracture NN N
were VBD N
: : N
previous JJ o
fracture NN o
, , N
2.29 CD N
( ( N
95 CD N
% NN N
CI NNP N
1.56-3.34 CD N
) ) N
; : N
and CC N
a DT o
fall NN o
in IN o
the DT o
last JJ o
12 CD o
months NNS o
, , N
1.60 CD N
( ( N
95 CD N
% NN N
CI NNP N
1.10-2.31 CD N
) ) N
. . N

Being VBG N
a DT N
current JJ o
smoker NN o
was VBD N
not RB N
associated VBN N
with IN N
an DT N
increase NN N
in IN N
risk NN N
, , N
and CC N
was VBD N
consistent JJ N
across IN N
all DT N
fracture NN N
types NNS N
. . N

DISCUSSION NNP N
Older NNP N
women NNS N
with IN N
the DT N
clinical JJ N
risk NN N
factors NNS N
identified VBN N
in IN N
this DT N
study NN N
should MD N
be VB N
investigated VBN N
for IN N
osteoporosis NN N
or CC N
offered VBN N
preventive JJ N
treatment NN N
. . N

-DOCSTART- -19692186- O O

Aspirin-associated JJ p
iron NN p
loss NN p
as IN p
an DT p
anticancer NN p
mechanism NN p
. . p

A DT N
consensus NN N
view NN N
has VBZ N
emerged VBN N
favoring VBG N
an DT N
anticancer JJ N
effect NN N
of IN N
long-term JJ N
aspirin NN N
use NN N
. . N

Aspirin-induced JJ i
loss NN N
of IN N
stored VBN N
iron NN N
from IN N
chronic JJ N
gastrointestinal JJ N
bleeding NN N
is VBZ N
proposed VBN N
as IN N
a DT N
mechanism NN N
underlying VBG N
this DT N
beneficial JJ N
effect NN N
. . N

In IN N
iron NN N
depletion NN N
, , N
less JJR N
iron NN N
may MD N
be VB N
available JJ N
for IN N
carcinogenesis NN N
through IN N
free-radical JJ N
mediated VBN N
mechanisms NNS N
and CC N
for IN N
promotion NN N
of IN N
tumor NN N
growth NN N
. . N

Low-dose JJ i
aspirin NN i
increases NNS N
gastrointestinal JJ o
losses NNS o
of IN N
transfused VBN o
radiolabeled VBN o
autologous JJ o
red JJ o
cells NNS o
. . o

Observational JJ N
studies NNS N
report VBP N
lower JJR N
serum NN N
ferritin NN N
values NNS N
with IN N
regular JJ N
aspirin NN N
use NN N
. . N

A DT N
protective JJ N
effect NN N
of IN N
induced JJ N
iron NN N
reduction NN N
against IN N
cancer NN N
mortality NN N
has VBZ N
been VBN N
confirmed VBN N
in IN N
a DT N
recent JJ N
trial NN N
( ( N
FeAST NNP N
) ) N
with IN N
subjects NNS p
randomized VBN p
to TO p
iron VB p
reduction NN p
or CC p
observation NN p
. . p

Serum NNP o
ferritin JJ o
reductions NNS o
in IN N
the DT N
FeAST NNP N
trial NN N
were VBD N
within IN N
conventionally RB N
normal JJ N
reference NN N
ranges NNS N
and CC N
were VBD N
quantitatively RB N
similar JJ N
to TO N
ferritin VB N
reductions NNS N
in IN N
observational JJ N
studies NNS N
in IN N
regular JJ p
aspirin NN p
users NNS p
. . p

Delayed NNP N
anticancer NN N
effects NNS N
of IN N
aspirin NN N
are VBP N
compatible JJ N
with IN N
the DT N
proposed VBN N
mechanism NN N
, , N
as IN N
continual JJ N
microbleeding NN o
has VBZ N
a DT N
gradual JJ N
cumulative JJ N
effect NN N
on IN N
stored VBN N
iron NN N
. . N

-DOCSTART- -26139208- O O

Disclosure NN N
of IN N
HSV-2 NNP N
serological JJ N
test NN N
results NNS N
in IN N
the DT N
context NN N
of IN N
an DT N
adolescent JJ p
HIV NNP p
prevention NN p
trial NN p
in IN p
Kenya NNP p
. . p

OBJECTIVES NNP N
Herpes NNP N
simplex JJ N
virus NN N
type NN N
2 CD N
( ( N
HSV-2 NNP N
) ) N
biomarkers NNS N
are VBP N
often RB N
used VBN N
in IN N
adolescent JJ p
sub-Saharan JJ p
HIV NNP p
prevention NN p
studies NNS N
, , N
but CC N
evaluations NNS N
of IN N
test NN N
performance NN N
and CC N
disclosure NN N
outcomes NNS N
are VBP N
rare JJ N
in IN N
the DT N
published JJ N
literature NN N
. . N

Therefore RB N
, , N
we PRP N
investigated VBD N
the DT N
proportion NN N
of IN N
ELISA-positive JJ N
and CC N
indeterminate JJ N
samples NNS N
confirmed VBN N
by IN N
western JJ i
blot NN i
( ( N
WB NNP N
) ) N
, , N
the DT N
psychosocial JJ N
response NN N
to TO N
disclosure NN N
and CC N
whether IN N
reports NNS N
of IN N
sexual JJ N
behaviour NN N
and CC N
HSV-2 NNP N
symptoms NNS N
are VBP N
consistent JJ N
with IN N
WB NNP N
confirmatory JJ N
results NNS N
among IN N
adolescent JJ p
orphans NNS p
in IN p
Kenya NNP p
. . p

METHODS NNP N
In IN N
2011 CD N
, , N
837 CD p
Kenyan NNP p
orphan MD p
youth VB p
in IN p
grades NNS p
7 CD p
and CC p
8 CD p
enrolled VBN p
in IN p
an DT p
HIV NNP p
prevention NN p
clinical JJ p
trial NN p
with IN p
HSV-2 NNP p
biomarker NN p
outcomes NNS p
. . p

We PRP N
used VBD N
a DT N
modified JJ N
algorithm NN N
for IN N
the DT N
Kalon NNP N
HSV-2 NNP N
ELISA NNP N
to TO N
improve VB N
specificity NN N
; : N
positive JJ N
and CC N
indeterminate JJ N
results NNS N
were VBD N
WB NNP N
tested VBN N
. . N

We PRP N
developed VBD N
culturally RB N
sensitive JJ N
protocols NNS N
for IN N
disclosing VBG N
positive JJ N
results NNS N
, , N
and CC N
documented VBD N
psychosocial JJ N
responses NNS N
, , N
reports NNS N
of IN N
sexual JJ N
contact NN N
and CC N
HSV-2 NNP N
symptoms NNS N
. . N

RESULTS $ N
28 CD p
adolescents NNS p
( ( p
3.3 CD p
% NN p
) ) p
were VBD N
identified VBN N
as IN N
HSV-2 NNP N
seropositive NN N
, , N
six CD N
as IN N
indeterminate NN N
. . N

Of IN N
these DT N
, , N
22 CD p
positive JJ p
and CC p
all DT p
indeterminates NNS p
were VBD p
WB NNP p
tested VBD p
; : p
20 CD p
and CC p
5 CD p
, , p
respectively RB p
, , N
were VBD N
confirmed VBN N
positive JJ N
. . N

Most JJS N
youth RB N
reported JJ N
moderate JJ o
brief NN o
stress NN o
after IN o
disclosure NN o
; : o
22 CD N
% NN N
reported VBN N
longer JJR o
and CC o
more RBR o
severe JJ o
distress NN o
. . o

Boys NNP N
were VBD N
more RBR N
likely JJ N
to TO N
be VB N
in IN N
the DT N
latter JJ N
category NN N
. . N

Self-reported JJ o
virginity NN o
was VBD N
highly RB N
inconsistent JJ N
with IN N
WB-confirmed JJ o
positives NNS o
. . o

CONCLUSIONS VB N
The DT N
higher JJR N
than IN N
manufacturer NN N
's POS N
cut-off NN N
for IN N
Kalon NNP N
ELISA NNP N
modestly RB N
reduced VBD N
the DT N
rate NN N
of IN N
false-positive JJ o
test NN o
results NNS o
, , N
but CC N
also RB N
increased VBD N
false JJ o
negatives NNS o
. . o

Investigators NNS N
should MD N
consider VB N
the DT N
risk NN N
: : N
benefit NN N
ratio NN N
in IN N
deciding VBG N
whether IN N
or CC N
not RB N
to TO N
disclose VB N
HSV-2 NNP N
results NNS N
to TO N
adolescent JJ p
participants NNS p
under IN N
specific JJ N
field NN N
conditions NNS N
. . N

TRIAL NNP N
REGISTRATION NNP N
NUMBER NNP N
NCT01501864 NNP N
. . N

-DOCSTART- -21548512- O O

Pulsed VBN i
azithromycin JJ i
treatment NN i
is VBZ N
as IN N
effective JJ N
and CC N
safe JJ N
as IN N
2-week-longer JJ i
daily JJ i
doxycycline NN i
treatment NN i
of IN N
acne JJ p
vulgaris NN p
: : p
a DT N
randomized JJ N
, , N
double-blind JJ N
, , N
noninferiority NN N
study NN N
. . N

Efficacy NNP N
and CC N
safety NN N
of IN N
azithromycin NN i
and CC i
doxycycline NN i
for IN N
the DT N
treatment NN N
of IN N
moderate JJ p
acne NNS p
vulgaris NNS p
were VBD N
evaluated VBN N
( ( p
240 CD p
patients NNS p
) ) p
in IN p
both DT p
intention-to-treat JJ p
and CC p
per-protocol JJ p
populations NNS p
. . p

The DT N
evaluation NN N
of IN N
clinical JJ N
efficacy NN N
was VBD N
based VBN N
on IN N
the DT N
change NN N
in IN N
the DT N
number NN o
of IN o
facial JJ o
inflammatory JJ o
lesions NNS o
from IN N
baseline NN N
to TO N
the DT N
end NN N
of IN N
treatment NN N
, , N
and CC N
noninferiority NN N
was VBD N
defined VBN N
by IN N
the DT N
upper JJ N
95 CD N
% NN N
confidence NN N
limit NN N
of IN N
the DT N
difference NN N
between IN N
two CD N
treatments NNS N
being VBG N
less JJR N
than IN N
9 CD N
. . N

Reduction NN N
in IN N
the DT N
number NN o
of IN o
lesions NNS o
was VBD N
similar JJ N
with IN N
both DT N
azithromycin NNS i
and CC i
doxycycline NN i
treatments NNS i
( ( N
27 CD N
+/- JJ N
12 CD N
and CC N
30 CD N
+/- JJ N
12 CD N
, , N
respectively RB N
) ) N
in IN N
both DT N
groups NNS N
. . N

Also RB N
, , N
the DT N
upper JJ N
95 CD N
% NN N
confidence NN N
limit NN N
of IN N
5 CD N
inflammatory JJ N
lesions NNS N
has VBZ N
satisfied VBN N
the DT N
noninferiority NN N
criterion NN N
. . N

The DT N
incidence NN N
of IN N
adverse JJ N
events NNS N
did VBD N
not RB N
differ VB N
between IN N
the DT N
two CD N
treatment NN N
groups NNS N
. . N

The DT N
shorter NN N
and CC N
simpler NN N
treatment NN N
schedule NN N
of IN N
azithromycin NN i
had VBD N
similar JJ N
efficacy NN o
and CC o
safety NN o
as IN N
doxycycline NN i
in IN N
the DT N
treatment NN N
of IN N
moderate JJ p
acne NN p
vulgaris NN p
, , N
confirming VBG N
noninferiority NN N
of IN N
azithromycin NN i
as IN N
compared VBN N
with IN N
doxycycline NN i
. . i

-DOCSTART- -17356056- O O

Pathological JJ N
features NNS N
and CC N
inhaled JJ N
corticosteroid NN N
response NN N
of IN N
eosinophilic JJ p
and CC p
non-eosinophilic JJ p
asthma NN p
. . p

BACKGROUND NNP N
Non-eosinophilic JJ N
asthma NN N
is VBZ N
a DT N
potentially RB N
important JJ N
clinicopathological JJ N
phenotype NN N
since IN N
there EX N
is VBZ N
evidence NN N
that IN N
it PRP N
responds VBZ N
poorly RB N
to TO N
inhaled VB N
corticosteroid JJ N
therapy NN N
. . N

However RB N
, , N
little JJ N
is VBZ N
known VBN N
about IN N
the DT N
underlying JJ N
airway NN N
immunopathology NN N
and CC N
there EX N
are VBP N
no DT N
data NNS N
from IN N
placebo-controlled JJ N
studies NNS N
examining VBG N
the DT N
effect NN N
of IN N
inhaled JJ N
corticosteroids NNS N
. . N

METHODS NNP N
Airway NNP N
immunopathology NN N
was VBD N
investigated VBN N
using VBG N
induced JJ o
sputum NN o
, , o
bronchial JJ o
biopsies NNS o
, , o
bronchial JJ o
wash NN o
and CC N
bronchoalveolar JJ o
lavage NN o
in IN N
12 CD p
patients NNS p
with IN p
symptomatic JJ p
eosinophilic JJ p
asthma NN p
, , p
11 CD p
patients NNS p
with IN p
non-eosinophilic JJ p
asthma NN p
and CC p
10 CD p
healthy JJ p
controls NNS p
. . p

The DT N
patients NNS p
with IN p
non-eosinophilic JJ p
asthma NN p
and CC p
6 CD p
different JJ p
patients NNS p
with IN p
eosinophilic JJ p
asthma NN p
entered VBD N
a DT N
randomised JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ i
crossover NN N
study NN N
in IN N
which WDT N
the DT N
effects NNS N
of IN N
inhaled JJ i
mometasone NN i
400 CD i
microg NN i
once RB N
daily JJ N
for IN N
8 CD N
weeks NNS N
on IN N
airway NN o
responsiveness NN o
and CC N
asthma JJ o
quality NN o
of IN o
life NN o
were VBD N
investigated VBN N
. . N

RESULTS JJ N
Patients NNS p
with IN p
non-eosinophilic JJ p
asthma NN p
had VBD N
absence NN o
of IN o
eosinophils NNS o
in IN o
the DT o
mucosa NN o
( ( N
median JJ N
4.4 CD N
cells/mm NN N
( ( N
2 CD N
) ) N
vs NN N
23 CD N
cells/mm NN N
( ( N
2 CD N
) ) N
in IN N
eosinophilic JJ N
asthma NN N
and CC N
0 CD N
cells/mm NN N
( ( N
2 CD N
) ) N
in IN N
normal JJ N
controls NNS N
; : N
p VB N
= $ N
0.03 CD N
) ) N
and CC N
normal JJ N
subepithelial JJ o
layer NN o
thickness NN o
( ( N
5.8 CD N
microm NN N
vs NN N
10.3 CD N
microm NN N
in IN N
eosinophilic JJ N
asthma NN N
and CC N
5.1 CD N
microm NN N
in IN N
controls NNS N
, , N
p VBP N
= RB N
0.002 CD N
) ) N
. . N

Non-eosinophilic JJ p
and CC p
eosinophilic JJ p
asthma NN p
groups NNS p
had VBD N
increased VBN N
mast RB o
cell NN o
numbers NNS o
in IN N
the DT N
airway NN N
smooth JJ N
muscle NN N
compared VBN N
with IN N
normal JJ N
controls NNS N
( ( N
9 CD N
vs RB N
8 CD N
vs NNS N
0 CD N
cells/mm NN N
( ( N
2 CD N
) ) N
, , N
p JJ N
= NNP N
0.016 CD N
) ) N
. . N

Compared VBN N
with IN N
placebo NN N
, , N
8 CD N
weeks NNS N
of IN N
treatment NN N
with IN N
inhaled JJ N
mometasone NN N
led VBD N
to TO N
less RBR N
improvement NN o
in IN N
methacholine JJ o
PC NN o
( ( o
20 CD o
) ) o
( ( N
0.5 CD N
vs RB N
5.5 CD N
doubling VBG N
concentrations NNS N
, , N
95 CD N
% NN N
CI NNP N
of IN N
difference NN N
1.1 CD N
to TO N
9.1 CD N
; : N
p NN N
= VBZ N
0.018 CD N
) ) N
and CC N
asthma JJ o
quality NN o
of IN o
life NN o
( ( N
0.2 CD N
vs RB N
1.0 CD N
points NNS N
, , N
95 CD N
% NN N
CI NNP N
of IN N
difference NN N
0.27 CD N
to TO N
1.43 CD N
; : N
p NN N
= VBZ N
0.008 CD N
) ) N
. . N

CONCLUSIONS NNP N
Non-eosinophilic JJ N
asthma NN N
represents VBZ N
a DT N
pathologically RB N
distinct JJ N
disease NN N
phenotype NN N
which WDT N
is VBZ N
characterised VBN N
by IN N
the DT N
absence NN N
of IN N
airway NN o
eosinophilia NNS o
, , N
normal JJ N
subepithelial JJ o
layer NN o
thickness NN o
and CC N
a DT N
poor JJ N
short-term JJ o
response NN o
to TO o
treatment NN o
with IN N
inhaled JJ N
corticosteroids NNS N
. . N

-DOCSTART- -9495616- O O

A DT N
plaque NN i
index NN i
for IN i
occlusal NN i
surfaces NNS i
and CC i
fissures NNS i
. . i

Measurement NN N
of IN N
repeatability NN N
and CC N
plaque NN N
removal NN N
. . N

Plaque NNP N
indices NNS N
have VBP N
largely RB N
been VBN N
developed VBN N
for IN N
buccal JJ N
and CC N
lingual JJ N
tooth NN N
surfaces NNS N
. . N

There EX N
has VBZ N
been VBN N
minimal JJ N
interest NN N
in IN N
plaque JJ N
accumulation NN N
on IN N
occlusal NN N
surfaces NNS N
despite IN N
the DT N
predilection NN N
for IN N
caries NNS N
at IN N
these DT N
sites NNS N
. . N

A DT N
numerical JJ N
plaque NN N
index NN N
( ( N
0-5 JJ N
) ) N
is VBZ N
described VBN N
based VBN N
on IN N
the DT N
presence NN N
and CC N
distribution NN N
of IN N
plaque NN N
in IN N
the DT N
fissures NNS N
and CC N
over IN N
the DT N
occlusal JJ N
surfaces NNS N
of IN N
permanent JJ N
molar NN N
and CC N
premolar JJ N
teeth NNS N
. . N

The DT N
repeatability NN N
of IN N
a DT N
single JJ N
examiner NN N
in IN N
scoring VBG N
the DT N
index NN N
was VBD N
performed VBN N
using VBG N
4 CD p
groups NNS p
of IN p
10 CD p
subjects NNS p
. . p

Each DT N
group NN N
of IN N
volunteers NNS p
suspended VBN i
tooth RB i
cleaning VBG i
for IN N
48 CD N
h NN N
and CC N
the DT N
index NN N
scored VBD N
after IN N
disclosing VBG N
plaque NN N
deposits NNS N
. . N

The DT N
index NN N
was VBD N
rescored VBN N
60-90 JJ N
min NN N
later RB N
. . N

Plaque NNP N
area NN N
was VBD N
also RB N
determined VBN N
by IN N
drawing VBG N
the DT N
outline NN N
of IN N
plaque NN N
onto IN N
grids NNS N
. . N

Except IN N
for IN N
one CD N
condition NN N
of IN N
repeatability NN N
for IN N
one CD N
group NN N
, , N
the DT N
4 CD N
conditions NNS N
of IN N
repeatability NN N
in IN N
scoring VBG N
the DT N
index NN N
were VBD N
met VBN N
for IN N
all DT N
4 CD N
groups NNS N
of IN N
subjects NNS N
. . N

The DT N
sensitivity NN o
of IN o
the DT o
index NN o
and CC o
area NN o
recordings NNS o
to TO N
detect VB N
plaque NN N
removed VBN N
by IN N
brushing VBG N
was VBD N
then RB N
evaluated VBN N
. . N

A DT p
group NN p
of IN p
10 CD p
subjects NNS p
had VBD p
plaque VBN i
scored VBN i
by IN i
index NN i
and CC N
area NN N
after IN N
suspending VBG N
toothcleaning VBG N
for IN N
48 CD N
h. JJ N
Subjects NNS N
were VBD N
then RB N
randomly RB N
allocated VBN N
to TO N
brush VB N
or CC N
not RB N
brush VB N
their PRP$ N
teeth NNS N
and CC N
plaque NN N
rescored VBN N
. . N

The DT N
experiment NN N
was VBD N
then RB N
repeated VBN N
and CC N
brushing VBG i
or CC N
not RB i
brushing VBG i
crossed VBN N
over IN N
. . N

Highly NNP N
significant JJ N
differences NNS N
between IN N
brushing VBG N
and CC N
no DT N
brushing NN N
plaque NN o
indices NNS o
and CC N
areas NNS N
were VBD N
determined VBN N
. . N

In IN N
conclusion NN N
, , N
the DT N
occlusal JJ o
fissure NN o
plaque NN o
index NN o
was VBD N
easy JJ N
to TO N
apply VB N
, , N
repeatable JJ N
and CC N
sufficiently RB N
sensitive JJ N
to TO N
detect VB N
plaque NN N
removed VBN N
by IN N
brushing VBG N
. . N

The DT N
index NN N
could MD N
find VB N
use NN N
as IN N
an DT N
additional JJ N
measure NN N
of IN N
oral JJ N
hygiene NN N
, , N
in IN N
clinical JJ N
trials NNS N
on IN N
plaque NN N
control NN N
and CC N
possibly RB N
epidemiological JJ N
studies NNS N
relating VBG N
to TO N
caries NNS N
. . N

-DOCSTART- -26121801- O O

[ JJ N
Effect NNP N
of IN N
Preoperative NNP i
Oral NNP i
Rehydration NNP o
on IN N
Onset NNP N
Time NNP N
and CC N
Recovery NNP N
Time NNP N
of IN N
Rocuronium NNP N
] NNP N
. . N

BACKGROUND NNP N
Preoperative NNP N
oral JJ i
rehydration NN o
solution NN i
( ( i
ORS NNP i
) ) i
prevents VBZ N
hypovolemia NN o
. . o

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
compare VB N
the DT N
effect NN N
of IN N
intubating VBG N
dose NN N
of IN N
rocuronium NN i
in IN N
patients NNS p
taking VBG p
and CC p
those DT p
not RB p
taking VBG p
preoperative JJ o
ORS NNP o
. . o

METHODS NNP N
Twenty NNP p
patients NNS p
, , p
ASA NNP p
I PRP p
aged VBD p
20-50 CD p
years NNS p
scheduled VBN p
for IN p
elective JJ p
surgery NN p
, , N
were VBD N
investigated VBN N
and CC N
randomly RB N
assigned VBN N
to TO N
two CD N
groups NNS N
: : N
drinking NN N
1,500 CD N
ml NN N
ORS NNP i
6 CD N
to TO N
2 CD N
hours NNS N
before IN N
anesthesia NN N
( ( i
ORS NNP i
group NN i
) ) i
and CC N
nothing NN i
by IN i
mouth NN i
from IN N
6 CD N
hours NNS N
before IN N
anesthesia NN N
( ( i
control VB i
group NN i
) ) i
. . N

Anesthesia NNP N
was VBD N
maintained VBN N
with IN N
propofol NN i
and CC N
remifentanil NN o
, , N
and CC N
rocuronium NN i
0.6 CD N
mg NN N
x NN N
kg NN N
( ( N
-1 NNP N
) ) N
was VBD N
administrated VBN N
. . N

To TO N
evaluate VB N
the DT N
effect NN N
of IN N
rocuronium NN N
, , N
acceleromyography NN o
at IN N
the DT N
adductor NN N
pollicis NN N
was VBD N
performed VBN N
using VBG N
0.1 CD N
Hz NNP N
stimulation NN N
. . N

Cardiac NNP o
index NN o
( ( o
CI NNP o
) ) o
and CC o
stroke VBD o
volume NN o
variation NN o
( ( o
SVV NNP o
) ) o
from IN N
FloTra/Vigileo NNP N
, , N
times NNS N
to TO N
95 CD N
% NN N
twitch NN N
depression NN o
as IN N
onset JJ o
time NN o
( ( o
OT NNP o
) ) o
, , N
and CC N
times NNS N
to TO N
first JJ N
twitch VB o
re-detection NN o
( ( o
TR NNP o
) ) o
were VBD N
recorded VBN N
. . N

RESULTS NNP N
SVV NNP N
was VBD N
significantly RB N
lower JJR N
in IN N
ORS NNP o
group NN N
( ( N
P NNP N
= NNP N
0.03 CD N
) ) N
, , N
and CC N
CI NNP N
showed VBD N
no DT N
difference NN N
. . N

In IN N
ORS NNP i
group NN N
, , N
TR NNP N
was VBD N
significantly RB N
shorter JJR N
than IN N
that DT N
of IN N
control NN N
group NN N
( ( N
P=0.002 NNP N
) ) N
, , N
and CC N
OT NNP N
tended VBD N
to TO N
be VB N
prolonged VBN N
( ( N
99.0 CD N
? . N
36.3 CD N
s NN N
vs. FW N
84.0 CD N
? . N
37.5 CD N
s NN N
) ) N
, , N
but CC N
not RB N
significantly RB N
. . N

CONCLUSIONS NNP N
Preoperative NNP N
oral JJ N
rehydration NN N
possibly RB N
increases VBZ N
circulating VBG N
blood NN N
volume NN N
, , N
and CC N
shortens VBZ N
the DT N
duration NN N
of IN N
rocuronium NN o
effect NN o
. . o

-DOCSTART- -20394631- O O

The DT N
pulsed-dye JJ i
laser NN i
as IN N
an DT N
adjuvant JJ N
treatment NN N
modality NN N
in IN N
acne JJ p
vulgaris NN p
: : p
a DT N
randomized JJ N
controlled VBN N
single-blinded JJ N
trial NN N
. . N

BACKGROUND NNP N
Acne NNP N
vulgaris NN N
is VBZ N
the DT N
most RBS N
common JJ N
skin NN N
disease NN N
and CC N
can MD N
pose VB N
a DT N
substantial JJ N
therapeutic JJ N
challenge NN N
. . N

Recently RB N
, , N
several JJ N
phototherapeutic JJ N
modalities NNS N
, , N
most JJS N
notably RB N
pulsed-dye JJ i
laser NN i
( ( i
PDL NNP i
) ) i
treatment NN N
, , N
have VBP N
been VBN N
introduced VBN N
, , N
but CC N
the DT N
published VBN N
results NNS N
- : N
albeit IN N
promising VBG N
- : N
are VBP N
controversial JJ N
. . N

OBJECTIVES NNP N
To TO N
assess VB N
the DT N
efficacy NN o
of IN N
an DT N
adjuvant JJ N
PDL NNP i
treatment NN N
when WRB N
combined VBN N
with IN N
a DT N
proven JJ N
topical JJ N
treatment NN N
[ JJ N
fixed-combination NN N
clindamycin NN N
1 CD N
% NN N
-benzoyl NNP N
peroxide RB N
5 CD N
% NN N
hydrating VBG N
gel NN N
( ( N
C/BPO NNP N
) ) N
] NN N
. . N

METHODS NNP N
Eighty NNP p
patients NNS p
( ( p
38 CD p
males NNS p
and CC p
42 CD p
females NNS p
, , p
mean JJ p
+/- JJ p
SD NNP p
age NN p
19.7 CD p
+/- JJ p
5.9 CD p
years NNS p
) ) p
were VBD N
randomized VBN N
in IN N
a DT N
1 CD N
: : N
2 CD N
ratio NN N
to TO N
receive VB N
C/BPO NNP i
alone RB i
or CC i
in IN i
combination NN i
with IN i
PDL NNP i
treatment NN i
( ( N
wavelength JJ N
585 CD N
nm NN N
, , N
energy NN N
fluence NN N
3 CD N
J NNP N
cm NN N
( ( N
-2 NNP N
) ) N
, , N
pulse JJ N
duration NN N
0.35 CD N
ms NN N
, , N
spot NN N
size NN N
7 CD N
mm NN N
) ) N
. . N

Patients NNS N
were VBD N
evaluated VBN N
at IN N
baseline NN N
and CC N
at IN N
2 CD N
and CC N
4 CD N
weeks NNS N
after IN N
initial JJ N
treatment NN N
. . N

The DT N
primary JJ N
end NN N
points NNS N
were VBD N
the DT N
Investigator NNP o
's POS o
Static JJ o
Global NNP o
Assessment NNP o
( ( o
ISGA NNP o
) ) o
score NN o
and CC N
lesion NN o
count NN o
; : o
the DT N
secondary JJ N
end NN N
point NN N
was VBD N
the DT N
Dermatology NNP o
Life NNP o
Quality NNP o
Index NNP o
( ( o
DLQI NNP o
) ) o
. . o

RESULTS NNP N
Both NNP N
groups NNS N
showed VBD N
a DT N
significant JJ N
improvement NN N
during IN N
observation NN o
[ NNP N
ISGA NNP N
27.1 CD N
% NN N
( ( i
C/BPO NNP i
) ) i
and CC N
24.6 CD N
% NN N
( ( i
C/BPO NNP i
+ NNP i
laser NN i
) ) i
, , N
total JJ o
lesion NN o
count NN o
9.2 CD N
% NN N
and CC N
9.0 CD N
% NN N
, , N
inflammatory JJ o
lesion NN o
count NN o
36.3 CD N
% NN N
and CC N
36.9 CD N
% NN N
, , N
DLQI NNP N
54.5 CD N
% NN N
and CC N
42.5 CD N
% NN N
] NN N
, , N
but CC N
there EX N
was VBD N
no DT N
significant JJ N
or CC N
otherwise RB N
appreciable JJ N
difference NN N
between IN N
treatment NN N
modalities NNS N
as RB N
far RB N
as IN N
the DT N
extent NN N
of IN N
improvement NN N
was VBD N
concerned VBN N
. . N

Patients NNS N
with IN N
more RBR N
severe JJ N
findings NNS N
at IN N
baseline NN N
had VBD N
a DT N
greater JJR N
benefit NN N
from IN N
either CC N
therapy JJ N
regimen NNS N
. . N

CONCLUSIONS NNP N
Our PRP$ N
findings NNS N
do VBP N
not RB N
support VB N
the DT N
concept NN N
of IN N
a DT N
substantial JJ N
benefit NN N
of IN N
PDL NNP i
treatment NN N
in IN N
acne JJ N
vulgaris NN N
. . N

-DOCSTART- -8411891- O O

[ JJ N
Comparison NNP N
of IN N
complications NNS o
after IN N
intra- JJ i
and CC i
extracapsular JJ i
cataract NN i
extraction NN i
with IN i
lens JJ i
implantation NN i
. . i

Results NNS N
of IN N
a DT N
prospective JJ N
, , N
randomized VBN N
, , N
clinical JJ N
study NN N
] NNP N
. . N

BACKGROUND NNP N
The DT N
postoperative JJ o
complications NNS o
of IN N
ICCE NNP i
with IN i
ACL NNP i
implantation NN i
are VBP N
compared VBN N
with IN N
those DT N
of IN N
ECCE NNP i
and CC i
PCL NNP i
. . i

Our PRP$ N
clinical JJ N
experience NN N
with IN N
ICCE NNP i
and CC i
ACL NNP i
implantation NN i
can MD N
not RB N
confirm VB N
the DT N
widespread JJ N
rejection NN N
of IN N
this DT N
method NN N
. . N

PATIENTS NNP N
AND CC N
METHOD NNP N
A NNP N
prospective JJ N
, , N
randomized VBN N
, , N
clinical JJ N
study NN N
with IN N
participation NN p
of IN p
medical JJ p
statisticians NNS p
was VBD N
performed VBN N
. . N

A DT p
total NN p
of IN p
190 CD p
patients NNS p
with IN p
ICCE NNP i
and CC i
ACL NNP i
and CC p
170 CD p
patients NNS p
with IN p
ECCE NNP i
and CC i
PCL NNP i
were VBD p
followed VBN p
up RP p
for IN p
2 CD p
years NNS p
. . p

The DT N
follow-up JJ N
examinations NNS N
were VBD N
performed VBN N
upon IN N
dismission NN N
from IN N
the DT N
hospital NN N
, , N
after IN N
6 CD N
, , N
12 CD N
and CC N
24 CD N
months NNS N
. . N

The DT N
data NNS N
were VBD N
compiled VBN N
in IN N
a DT N
computer NN N
program NN N
designed VBN N
for IN N
this DT N
study NN N
and CC N
evaluated VBN N
by IN N
the DT N
statisticians NNS N
. . N

The DT N
surgical JJ N
procedures NNS N
and CC N
the DT N
surgeons NNS N
were VBD N
defined VBN N
prior RB N
to TO N
the DT N
beginning NN N
of IN N
patient JJ N
recruitment NN N
. . N

RESULTS NNP N
ICCE NNP i
with IN i
ACL NNP i
shows NNS N
much RB N
less RBR N
postoperative JJ o
complications NNS o
as IN N
usually RB N
emphasized VBN N
. . N

There EX N
were VBD N
only RB N
2 CD N
( ( N
1.2 CD N
% NN N
) ) N
of IN N
retinal JJ o
detachment NN o
and CC N
no DT N
case NN N
of IN N
corneal NN o
decompensation NN o
. . o

Cystoid NNP o
macular JJ o
edema NN o
8 CD N
( ( N
4.7 CD N
% NN N
) ) N
, , N
postoperative JJ o
vitreous JJ o
prolaps NNS o
into IN o
the DT o
anterior JJ o
chamber NN o
4 CD N
( ( N
2.3 CD N
% NN N
) ) N
and CC N
spontaneous JJ o
complaints NNS o
of IN o
pain NN o
16 CD N
( ( N
9.4 CD N
% NN N
) ) N
occurred VBD N
in IN N
a DT N
low JJ N
percentage NN N
after IN N
ICCE NNP i
with IN i
ACL NNP i
. . i

These DT N
complications NNS N
did VBD N
not RB N
occur VB N
after IN N
ECCE NNP i
with IN i
PCL NNP i
. . i

The DT N
patients NNS N
with IN N
ECCE NNP i
and CC i
PCL NNP i
showed VBD N
capsular JJ o
fibrosis NN o
in IN N
48 CD N
( ( N
28 CD N
% NN N
) ) N
making VBG N
it PRP N
the DT N
most RBS N
frequent JJ N
complication NN N
of IN N
the DT N
whole JJ N
study NN N
. . N

33 CD N
% NN N
of IN N
these DT N
patients NNS N
required VBD N
YAG-laser NNP i
capsulotomy NN i
. . i

Since IN N
retinal JJ N
detachment NN N
occurs VBZ N
in IN N
2.5 CD N
% NN N
after IN N
YAG-laser NNP i
capsulotomy NN i
we PRP N
can MD N
not RB N
regard VB N
capsular JJ N
fibrosis NN N
as IN N
a DT N
totally RB N
harmless JJ N
complication NN N
. . N

It PRP N
is VBZ N
noteworthy JJ N
that IN N
visual JJ o
acuity NN o
is VBZ N
almost RB N
identical JJ N
1 CD N
year NN N
after IN N
surgery NN N
in IN N
both DT N
methods NNS N
. . N

CONCLUSIONS VB N
The DT N
results NNS N
of IN N
this DT N
study NN N
show NN N
that IN N
the DT N
evaluation NN N
of IN N
ICCE NNP i
with IN i
ACL NNP i
is VBZ N
too RB N
negative JJ N
. . N

The DT N
elimination NN N
of IN N
postoperative JJ N
complications NNS N
in IN N
this DT N
method NN N
is VBZ N
more RBR N
difficult JJ N
. . N

ECCE VB i
with IN i
PCL NNP i
is VBZ N
burdened VBN N
by IN N
frequent JJ o
capsular JJ o
fibrosis NN o
. . o

Visual JJ N
acuity NN N
is VBZ N
almost RB N
the DT N
same JJ N
in IN N
both DT N
methods NNS N
1 CD N
years NNS N
after IN N
the DT N
operation NN N
. . N

ACL-implantation NN i
remains VBZ N
our PRP$ N
method NN N
of IN N
choice NN N
for IN N
secondary JJ N
implantation NN N
in IN N
patients NNS p
with IN p
an DT p
intact JJ p
iris JJ p
diaphragm NN p
. . p

-DOCSTART- -16108781- O O

Economic JJ o
evaluation NN o
of IN p
a DT p
nursing-led JJ i
inpatient JJ i
unit NN i
: : i
the DT N
impact NN N
of IN N
findings NNS N
on IN N
management NN N
decisions NNS N
of IN N
service NN N
utility NN N
and CC N
sustainability NN N
. . N

AIMS IN N
The DT N
nursing-led JJ i
inpatient NN i
unit NN i
is VBZ N
designed VBN N
to TO N
substitute VB N
for IN N
a DT N
period NN N
of IN N
care NN N
in IN N
acute JJ N
hospital NN N
wards NNS N
and CC N
to TO N
improve VB N
patient NN N
outcome NN N
prior RB N
to TO N
discharge VB N
to TO N
the DT N
community NN N
. . N

This DT N
paper NN N
aims VBZ N
to TO N
evaluate VB o
the DT o
cost NN o
, , N
from IN N
the DT N
UK NNP N
National NNP N
Health NNP N
Service NNP N
perspective NN N
, , N
of IN N
transfer NN p
to TO p
a DT p
nursing-led JJ p
inpatient NN p
unit NN p
for IN p
intermediate JJ p
care NN p
and CC N
to TO N
discuss VB N
the DT N
impact NN N
of IN N
these DT N
findings NNS N
to TO N
the DT N
future NN N
development NN o
and CC o
sustainability NN o
of IN N
the DT N
nursing-led JJ N
inpatient NN N
unit NN N
. . N

BACKGROUND NNP N
Recent NNP N
economic JJ N
analyses NNS N
have VBP N
showed VBN N
that IN N
nursing-led JJ p
inpatient JJ p
units NNS p
are VBP N
associated VBN N
with IN N
increased JJ N
costs NNS N
of IN N
care NN N
with IN N
length NN N
of IN N
stay NN N
as IN N
the DT N
main JJ N
driver NN N
of IN N
inpatient NN N
costs NNS N
. . N

METHOD VB N
The DT N
cost-effectiveness JJ o
analysis NN o
was VBD N
part NN N
of IN N
a DT N
randomized-controlled JJ N
trial NN N
with IN N
a DT N
sample JJ p
size NN p
of IN p
175 CD p
, , p
of IN p
which WDT p
89 CD p
were VBD p
in IN p
the DT p
nursing-led JJ i
inpatient NN i
unit NN i
arm NN i
and CC i
86 CD p
in IN p
the DT i
control NN i
arm NN i
. . i

Resource NNP o
use NN o
data NNS o
included VBD N
length NN o
of IN o
stay NN o
, , o
investigations NNS o
performed VBD o
, , o
multiprofessional JJ o
input NN o
and CC N
nursing NN o
input NN o
. . o

Clinical JJ o
outcome NN o
was VBD N
measured VBN N
using VBG N
Barthel NNP o
Index NNP o
, , N
a DT N
functional JJ N
status NN N
measure NN N
. . N

RESULTS NNP N
Cost NNP o
per IN o
day NN o
was VBD N
lower JJR N
on IN N
the DT N
nursing-led JJ N
inpatient NN N
unit NN N
although IN N
cost NN o
per IN o
hospital NN o
stay NN o
was VBD N
higher JJR N
due JJ N
to TO N
significantly RB N
increased JJ N
length NN N
of IN N
stay NN N
. . N

Postdischarge NNP o
community NN o
care NN o
costs NNS o
were VBD N
lower JJR N
. . N

The DT N
incremental JJ o
cost-effectiveness JJ o
ratio NN o
of IN N
the DT N
treatment NN N
was VBD N
1044 CD N
pounds NNS N
sterling JJ N
per IN N
point NN N
improvement NN N
of IN N
the DT N
Barthel NNP N
Index NNP N
. . N

CONCLUSIONS VB N
The DT i
nursing-led JJ i
inpatient NN i
unit NN i
was VBD N
associated VBN N
with IN N
higher JJR N
costs NNS N
however RB N
, , N
the DT N
question NN N
of IN N
whether IN N
the DT N
nursing-led JJ N
inpatient NN N
unit NN N
is VBZ N
cost-effective JJ N
has VBZ N
not RB N
been VBN N
clearly RB N
answered VBN N
because IN N
of IN N
the DT N
limited JJ N
follow-up JJ N
period NN N
of IN N
the DT N
study NN N
. . N

The DT N
increased JJ N
cost NN N
of IN N
care NN N
on IN N
the DT N
nursing-led JJ i
inpatient NN i
unit NN i
was VBD N
not RB N
a DT N
major JJ N
factor NN N
in IN N
local JJ N
management NN N
decisions NNS N
about IN N
the DT N
future NN N
of IN N
the DT N
unit NN N
. . N

The DT N
changes NNS N
in IN N
the DT N
context NN N
of IN N
service NN N
provision NN N
within IN N
which WDT N
the DT N
nursing-led JJ i
inpatient NN i
unit NN i
operated VBD N
as IN N
a DT N
result NN N
of IN N
substantial JJ N
investment NN N
in IN N
intermediate JJ N
care NN N
did VBD N
have VB N
a DT N
major JJ N
impact NN N
. . N

-DOCSTART- -2508567- O O

[ RB N
Cooperative NNP N
study NN N
of IN N
surgical JJ i
adjuvant JJ i
chemotherapy NN i
of IN N
colorectal JJ p
carcinoma NN p
( ( p
second JJ p
study NN p
) ) p
: : p
3-year JJ N
survival NN N
after IN N
surgery NN N
of IN N
non-curatively RB p
resected JJ p
patients NNS p
. . p

Cooperative NNP N
Study NNP N
Group NNP N
of IN N
Surgical NNP N
Adjuvant NNP N
Chemotherapy NNP N
of IN N
Colorectal NNP N
Cancer NNP N
in IN N
Japan NNP p
] NNP p
. . N

A NNP N
prospective JJ N
randomized NN N
study NN N
was VBD N
carried VBN N
out IN N
to TO N
evaluate VB N
the DT N
efficacy NN N
of IN N
surgical JJ i
adjuvant NN i
chemotherapy NN i
for IN N
non-curatively RB p
resected VBN p
colorectal JJ p
carcinoma NN p
patients NNS p
as IN p
a DT p
collaborative JJ p
study NN p
at IN p
428 CD p
institutes NNS p
in IN p
Japan NNP p
from IN p
Jan. NNP p
, , N
1984 CD p
to TO p
Dec. NNP p
, , N
1985 CD p
. . p

A DT N
total NN N
of IN N
1,138 CD p
patients NNS p
were VBD p
entered VBN p
in IN p
this DT p
study NN p
. . N

All DT N
patients NNS N
were VBD N
divided VBN N
according VBG N
to TO N
disease NN N
location NN N
( ( N
colon NN N
or CC N
rectum NN N
) ) N
and CC N
received VBD N
one CD N
of IN N
two CD N
chemotherapeutic JJ i
regimens NNS i
after IN N
surgery NN N
( ( i
Regimen NNP i
C NNP i
: : i
MMC NNP i
12 CD N
mg/m2 NN N
i.v NN N
. . N

at IN N
operation NN N
day NN N
and CC N
6 CD N
mg/m2 NN N
in IN N
every DT N
2 CD N
months NNS N
+UFT RB i
600 CD N
mg/day JJ N
p.o. NN N
, , N
D NNP i
: : i
the DT i
same JJ i
dose NN i
of IN i
MMC NNP i
+ NNP i
UFT NNP i
400 CD i
mg/day NN i
p.o NN i
. . i

) ) i
randomly RB i
. . i

556 CD p
cases NNS p
( ( p
colon NN p
carcinoma NN p
regimen NNS p
C NNP p
: : p
148 CD p
, , p
D NNP p
: : p
185 CD p
cases NNS p
, , p
rectal JJ p
carcinoma NN p
regimen NNS p
C NNP p
: : p
94 CD p
, , p
D NNP p
: : p
129 CD p
cases NNS p
) ) p
were VBD N
evaluable JJ N
at IN N
this DT N
presentation NN N
. . N

Three-year-survival JJ o
rate NN o
of IN N
histologically RB N
confirmed VBN N
non-curatively RB N
resected VBN N
colon NN N
carcinoma NN N
patients NNS N
was VBD N
higher RBR N
in IN N
the DT N
group NN N
receiving VBG N
regimen NNS i
C NNP i
than IN N
in IN N
regimen JJ i
D. NNP i
But CC N
no DT N
significant JJ N
difference NN N
was VBD N
found VBN N
among IN N
the DT N
other JJ N
groups NNS N
. . N

-DOCSTART- -9564194- O O

The DT N
problem NN N
of IN N
measurement NN N
error NN N
in IN N
multisite JJ p
clinical JJ p
trials NNS p
. . p

The DT N
implementation NN N
of IN N
a DT N
multisite NN p
, , N
randomized VBN N
, , N
clinical JJ N
psychopharmacologic JJ N
trial NN N
involves VBZ N
a DT N
substantial JJ N
investment NN N
of IN N
time NN N
and CC N
effort NN N
on IN N
the DT N
part NN N
of IN N
all DT N
participants NNS N
. . N

Because IN N
of IN N
their PRP$ N
complexity NN N
, , N
such JJ N
clinical JJ N
trials NNS N
present JJ N
unique JJ N
methodological JJ N
and CC N
design NN N
challenges NNS N
. . N

Indeed RB N
, , N
it PRP N
is VBZ N
not RB N
uncommon JJ N
for IN N
such JJ N
studies NNS N
to TO N
conclude VB N
with IN N
uninterpretable JJ N
results NNS N
, , N
due JJ N
in IN N
part NN N
to TO N
such JJ N
methodological JJ N
pitfalls NNS N
. . N

It PRP N
has VBZ N
been VBN N
suggested VBN N
that IN N
clarification NN N
of IN N
such JJ N
methodologic JJ N
dilemmas NN N
is VBZ N
one CD N
of IN N
the DT N
most RBS N
important JJ N
challenges NNS N
facing VBG N
the DT N
future NN N
of IN N
industry-sponsored JJ N
psychopharmacologic JJ N
drug NN N
development NN N
. . N

Among IN N
the DT N
many JJ N
factors NNS N
that WDT N
may MD N
contribute VB N
to TO N
problematic JJ N
clinical JJ p
trial NN p
results NNS p
, , N
error NN N
in IN N
measuring VBG N
the DT N
phenomena NN N
being VBG N
studied VBN N
is VBZ N
of IN N
particular JJ N
concern NN N
. . N

In IN N
this DT N
article NN N
, , N
we PRP N
describe VBP N
the DT N
outcome NN N
of IN N
an DT N
intensive JJ i
series NN i
of IN i
interrater JJ i
reliability NN i
training NN i
sessions NNS i
for IN N
the DT N
17-item JJ i
Hamilton NNP o
Depression NNP o
Rating NNP o
Scale NNP o
conducted VBD N
at IN N
the DT N
start NN N
of IN N
a DT N
Phase NNP p
II NNP p
multisite RB p
clinical JJ p
drug NN p
trial NN p
. . p

The DT N
data NN N
underscore IN N
the DT N
magnitude NN o
of IN o
error NN o
present NN o
in IN N
such JJ N
a DT N
test NN N
setting NN N
and CC N
provide VB N
preliminary JJ N
evidence NN N
for IN N
the DT N
potential JJ N
effect NN N
of IN N
this DT N
problem NN N
on IN N
the DT N
detection NN N
of IN N
clinical JJ N
change NN N
. . N

-DOCSTART- -10663363- O O

Randomized VBN N
trial NN N
of IN N
the DT N
effects NNS N
of IN N
risedronate NN i
on IN N
vertebral JJ o
fractures NNS o
in IN N
women NNS p
with IN p
established VBN p
postmenopausal NN p
osteoporosis NN p
. . p

Vertebral JJ N
Efficacy NN N
with IN N
Risedronate NNP N
Therapy NNP N
( ( N
VERT NNP N
) ) N
Study NNP N
Group NNP N
. . N

The DT N
purpose NN N
of IN N
this DT N
randomized VBN N
, , N
double-masked JJ N
, , N
placebo-controlled JJ N
study NN N
was VBD N
to TO N
determine VB N
the DT N
efficacy NN o
and CC o
safety NN o
of IN o
risedronate NN o
in IN N
the DT N
prevention NN N
of IN N
vertebral JJ N
fractures NNS N
in IN N
postmenopausal JJ p
women NNS p
with IN p
established VBN p
osteoporosis NN p
. . p

The DT N
study NN N
was VBD N
conducted VBN N
at IN N
80 CD p
study NN p
centers NNS p
in IN p
Europe NNP p
and CC p
Australia NNP p
. . p

Postmenopausal NNP p
women NNS p
( ( p
n JJ p
= NN p
1226 CD p
) ) p
with IN p
two CD p
or CC p
more JJR p
prevalent JJ p
vertebral JJ o
fractures NNS o
received VBD i
risedronate JJ i
2.5 CD i
or CC i
5 CD i
mg/day NN i
or CC i
placebo NN i
; : i
all DT i
subjects NNS i
also RB i
received VBD i
elemental JJ i
calcium NN i
1000 CD i
mg/day NN i
, , i
and CC i
up RB i
to TO i
500 CD i
IU/day NNP i
vitamin FW i
D NNP i
if IN i
baseline NN i
levels NNS i
were VBD i
low JJ i
. . i

The DT N
study NN N
duration NN N
was VBD N
3 CD N
years NNS N
; : N
however RB N
, , N
the DT i
2.5 CD i
mg NN i
group NN i
was VBD i
discontinued VBN i
by IN i
protocol NN i
amendment NN i
after IN i
2 CD i
years NNS i
. . i

Lateral JJ N
spinal JJ N
radiographs NN N
were VBD N
taken VBN N
annually RB N
for IN N
assessment NN N
of IN N
vertebral JJ o
fractures NNS o
, , o
and CC o
bone RB o
mineral JJ o
density NN o
was VBD N
measured VBN N
by IN N
dual-energy JJ N
X-ray JJ N
absorptiometry NN N
at IN N
6-month JJ N
intervals NNS N
. . N

Risedronate VB N
5 CD N
mg NN N
reduced VBD N
the DT N
risk NN N
of IN N
new JJ o
vertebral JJ o
fractures NNS o
by IN N
49 CD N
% NN N
over IN N
3 CD N
years NNS N
compared VBN N
with IN N
control NN N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
. . N

A DT N
significant JJ N
reduction NN N
of IN N
61 CD N
% NN N
was VBD N
seen VBN N
within IN N
the DT N
first JJ N
year NN N
( ( N
p JJ N
= NNP N
0.001 CD N
) ) N
. . N

The DT N
fracture NN o
reduction NN o
with IN N
risedronate NN N
2.5 CD N
mg NN N
was VBD N
similar JJ N
to TO N
that DT N
in IN N
the DT N
5 CD N
mg NN N
group NN N
over IN N
2 CD N
years NNS N
. . N

The DT N
risk NN N
of IN N
nonvertebral JJ o
fractures NNS o
was VBD N
reduced VBN N
by IN N
33 CD N
% NN N
compared VBN N
with IN N
control NN N
over IN N
3 CD N
years NNS N
( ( N
p JJ N
= NNP N
0.06 CD N
) ) N
. . N

Risedronate NNP N
significantly RB N
increased VBD N
bone JJ o
mineral JJ o
density NN o
at IN N
the DT N
spine NN N
and CC N
hip NN N
within IN N
6 CD N
months NNS N
. . N

The DT N
adverse-event JJ N
profile NN N
of IN N
risedronate NN N
, , N
including VBG N
gastrointestinal JJ o
adverse JJ o
events NNS o
, , N
was VBD N
similar JJ N
to TO N
that DT N
of IN N
control NN N
. . N

Risedronate NNP N
5 CD N
mg NN N
provides VBZ N
effective JJ N
and CC N
well-tolerated JJ N
therapy NN N
for IN N
severe JJ p
postmenopausal NN p
osteoporosis NN p
, , N
reducing VBG N
the DT N
incidence NN N
of IN N
vertebral JJ N
fractures NNS N
and CC N
improving VBG N
bone NN N
density NN N
in IN N
women NNS p
with IN p
established VBN p
disease NN p
. . p

-DOCSTART- -10807619- O O

Randomised VBN N
, , N
double JJ N
blind NN N
, , N
placebo NN i
controlled VBD N
study NN N
of IN N
fluticasone NN i
propionate NN i
in IN N
patients NNS p
with IN p
moderate JJ p
to TO p
severe VB p
chronic JJ p
obstructive JJ p
pulmonary JJ p
disease NN p
: : p
the DT N
ISOLDE NNP N
trial NN N
. . N

OBJECTIVES UH N
To TO N
determine VB N
the DT N
effect NN N
of IN N
long JJ N
term NN N
inhaled VBN N
corticosteroids NNS i
on IN N
lung NN o
function NN o
, , o
exacerbations NNS o
, , o
and CC o
health NN o
status NN o
in IN N
patients NNS p
with IN p
moderate JJ p
to TO p
severe VB p
chronic JJ p
obstructive JJ p
pulmonary JJ p
disease NN p
. . p

DESIGN NNP N
Double NNP N
blind NN N
, , N
placebo NN i
controlled VBD N
study NN N
. . N

SETTING NNP N
Eighteen NNP p
UK NNP p
hospitals NNS p
. . p

PARTICIPANTS VB N
751 CD p
men NNS p
and CC p
women NNS p
aged VBD p
between IN p
40 CD p
and CC p
75 CD p
years NNS p
with IN p
mean NN p
forced JJ p
expiratory NN p
volume NN p
in IN p
one CD p
second NN p
( ( p
FEV NNP p
( ( p
1 CD p
) ) p
) ) p
50 CD p
% NN p
of IN p
predicted VBN p
normal JJ p
. . p

INTERVENTIONS NNP N
Inhaled VBD N
fluticasone NN i
propionate NN i
500 CD i
microgram NN i
twice RB i
daily RB i
from IN i
a DT i
metered VBN i
dose JJ i
inhaler NN i
or CC i
identical JJ i
placebo NN i
. . i

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
Efficacy NNP o
measures NNS N
: : N
rate NN o
of IN o
decline NN o
in IN o
FEV NNP o
( ( o
1 CD o
) ) o
after IN o
the DT o
bronchodilator NN o
and CC o
in IN o
health NN o
status NN o
, , o
frequency NN o
of IN o
exacerbations NNS o
, , o
respiratory JJ o
withdrawals NNS o
. . o

Safety NN N
measures NNS N
: : N
morning NN o
serum NN o
cortisol NN o
concentration NN o
, , o
incidence NN o
of IN o
adverse JJ o
events NNS o
. . o

RESULTS NNP N
There EX N
was VBD N
no DT o
significant JJ o
difference NN o
in IN N
the DT N
annual JJ o
rate NN o
of IN o
decline NN o
in IN o
FEV NNP o
( ( o
1 CD o
) ) o
( ( o
P=0.16 NNP o
) ) o
. . N

Mean JJ o
FEV NNP o
( ( o
1 CD o
) ) o
after IN N
bronchodilator NN N
remained VBD N
significantly RB o
higher JJR o
throughout IN N
the DT N
study NN N
with IN N
fluticasone NN i
propionate NN i
compared VBN N
with IN N
placebo NN i
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

Median JJ o
exacerbation NN o
rate NN o
was VBD N
reduced VBN o
by IN N
25 CD N
% NN N
from IN N
1.32 CD N
a DT N
year NN N
on IN N
placebo NN i
to TO N
0.99 CD N
a DT N
year NN N
on IN N
with IN N
fluticasone NN i
propionate NN i
( ( N
P=0.026 NNP N
) ) N
. . N

Health NNP o
status NN o
deteriorated VBN o
by IN N
3.2 CD N
units NNS N
a DT N
year NN N
on IN N
placebo NN i
and CC N
2.0 CD N
units NNS N
a DT N
year NN N
on IN N
fluticasone NN i
propionate NN i
( ( N
P=0.0043 NNP N
) ) N
. . N

Withdrawals NNS o
because IN N
of IN N
respiratory NN N
disease NN N
not RB N
related VBN N
to TO N
malignancy NN N
were VBD N
higher JJR N
in IN N
the DT N
placebo NN i
group NN N
( ( N
25 CD N
% NN N
v JJ N
19 CD N
% NN N
, , N
P=0.034 NNP N
) ) N
. . N

CONCLUSIONS NNP N
Fluticasone NNP i
propionate NN i
500 CD N
microgram NN N
twice RB N
daily RB N
did VBD N
not RB N
affect VB N
the DT N
rate NN o
of IN o
decline NN o
in IN o
FEV NNP o
( ( o
1 CD o
) ) o
but CC N
did VBD N
produce VB o
a DT o
small JJ o
increase NN o
in IN o
FEV NNP o
( ( o
1 CD o
) ) o
. . o

Patients NNS N
on IN N
fluticasone NN i
propionate NN i
had VBD N
fewer JJR N
exacerbations NNS o
and CC N
a DT N
slower JJR o
decline NN o
in IN o
health NN o
status NN o
. . o

These DT N
improvements NNS N
in IN N
clinical JJ N
outcomes NNS N
support VBP N
the DT N
use NN N
of IN N
this DT N
treatment NN N
in IN N
patients NNS p
with IN p
moderate JJ p
to TO p
severe VB p
chronic JJ p
obstructive JJ p
pulmonary JJ p
disease NN p
. . p

-DOCSTART- -19188136- O O

A DT N
randomized VBN N
, , N
phase VB N
II NNP N
trial NN N
of IN N
two CD N
dose JJ N
schedules NNS N
of IN N
carboplatin/paclitaxel/cetuximab NN i
in IN N
stage NN p
IIIB/IV NNP p
non-small-cell JJ p
lung NN p
cancer NN p
( ( p
NSCLC NNP p
) ) p
. . p

BACKGROUND NNP N
This DT N
trial NN N
investigated VBD N
the DT N
efficacy NN o
and CC o
safety NN o
of IN N
weekly JJ N
cetuximab NN i
combined VBN i
with IN i
two CD i
different JJ i
schedules NNS i
of IN i
paclitaxel/carboplatin NN i
for IN N
stage NN p
IIIB/IV NNP p
non-small-cell JJ p
lung NN p
cancer NN p
( ( p
NSCLC NNP p
) ) p
. . p

METHODS CC N
A DT p
total NN p
of IN p
168 CD p
patients NNS p
with IN p
previously RB p
untreated VBN p
stage NN p
IIIB/IV NNP p
NSCLC NNP p
were VBD p
randomized VBN N
to TO N
arm VB N
A NNP N
, , N
cetuximab NN i
( ( N
400 CD N
mg/m NN N
( ( N
2 CD N
) ) N
day NN N
1 CD N
followed VBN N
by IN N
weekly JJ N
250 CD N
mg/m NN N
( ( N
2 CD N
) ) N
) ) N
+ FW i
paclitaxel NN i
( ( i
Taxol NNP i
) ) i
( ( N
225 CD N
mg/m NN i
( ( i
2 CD i
) ) i
) ) i
/carboplatin NN i
( ( i
AUC6 NNP i
) ) i
day NN N
1 CD N
every DT N
3 CD N
weeks NNS N
or CC N
arm NN N
B NNP N
, , N
same JJ N
cetuximab NN i
regimen NNS i
plus CC i
paclitaxel NN i
( ( N
100 CD N
mg/m NN N
( ( N
2 CD N
) ) N
) ) N
days NNS N
1 CD N
, , N
8 CD N
, , N
and CC N
15 CD N
every DT N
3 CD N
weeks NNS N
and CC i
carboplatin NN i
( ( N
AUC6 NNP N
) ) N
day NN N
1 CD N
every DT N
4 CD N
weeks NNS N
. . N

Treatment NNP N
continued VBD N
for IN N
a DT N
four-cycle JJ N
maximum NN N
. . N

Patients NNS N
with IN N
a DT N
complete JJ N
response NN N
, , N
partial JJ N
response NN N
, , N
or CC N
stable JJ N
disease NN N
after IN N
four CD N
cycles NNS N
could MD N
receive VB N
cetuximab NN i
250 CD N
mg/m NN N
( ( N
2 CD N
) ) N
/week NN N
until IN N
disease JJ o
progression NN o
or CC o
unacceptable JJ o
toxicity NN o
. . o

The DT N
primary JJ N
end NN N
point NN N
was VBD N
to TO N
evaluate VB N
progression-free JJ o
survival NN o
( ( o
PFS NNP o
) ) o
. . o

RESULTS NNP N
Median JJ N
PFS NNP o
was VBD N
4.7 CD N
and CC N
4.3 CD N
months NNS N
for IN N
arms NNS N
A NNP N
and CC N
B NNP N
, , N
respectively RB N
( ( N
6-month JJ N
PFS NNP N
, , N
27.3 CD N
% NN N
versus IN N
30.9 CD N
% NN N
) ) N
. . N

Median JJ o
overall JJ o
survival NN o
was VBD N
11.4 CD N
versus NN N
9.8 CD N
months NNS N
for IN N
arms NNS N
A NNP N
and CC N
B NNP N
, , N
respectively RB N
; : N
estimated VBN N
1-year JJ N
survival NN N
, , N
47.7 CD N
% NN N
versus IN N
39.3 CD N
% NN N
; : N
and CC N
objective JJ N
response NN N
rate NN N
, , N
29.6 CD N
% NN N
versus IN N
25 CD N
% NN N
. . N

The DT N
regimen NN N
was VBD N
well RB N
tolerated VBN o
with IN N
rash NN o
and CC o
hematologic JJ o
toxicity NN o
being VBG N
most RBS N
common JJ N
. . N

CONCLUSIONS VB N
This DT N
study NN N
did VBD N
not RB N
meet VB N
the DT N
prespecified JJ N
benchmark NN N
of IN N
35 CD N
% NN N
6-month JJ N
PFS NNP N
rate NN N
; : N
both DT N
combination NN N
schedules NNS N
of IN N
cetuximab NN i
plus CC i
paclitaxel/carboplatin NN i
were VBD N
feasible JJ N
and CC N
equivalent JJ N
for IN N
treating VBG N
advanced JJ p
NSCLC NNP p
. . p

-DOCSTART- -6403413- O O

A DT N
prospective JJ N
randomized VBN N
clinical JJ N
trial NN N
of IN N
melphalan NN i
and CC i
cis-platinum JJ i
versus NN N
hexamethylmelamine NN i
, , i
adriamycin NN i
, , i
and CC i
cyclophosphamide NN i
in IN N
advanced JJ p
ovarian JJ p
cancer NN p
. . p

From CD N
May NNP p
1978 CD p
until IN p
November NNP p
1980 CD p
, , p
169 CD p
previously RB p
untreated JJ p
patients NNS p
with IN p
advanced JJ p
epithelial JJ p
ovarian JJ p
cancer NN p
were VBD N
entered VBN N
into IN N
a DT N
prospective JJ N
randomized VBN N
clinical JJ N
trial NN N
comparing VBG N
the DT N
combination NN N
of IN N
hexamethylmelamine NN i
, , i
Adriamycin NNP i
, , i
and CC i
cyclophosphamide NN i
( ( i
HAC NNP i
) ) i
to TO i
a DT i
combination NN i
of IN i
melphalan NN i
and CC i
cis-platinum NN i
. . i

Eleven JJ p
patients NNS p
were VBD N
excluded VBN N
from IN N
analysis NN N
and CC N
another DT N
5 CD N
patients NNS N
were VBD N
excluded VBN N
from IN N
response NN N
analysis NN N
. . N

Of IN N
153 CD p
patients NNS p
evaluable JJ p
for IN p
response NN p
, , p
there EX p
were VBD p
47 CD p
, , p
or CC p
30.7 CD p
% NN p
, , p
complete JJ o
responders NNS o
( ( o
all DT o
determined VBN o
surgically RB o
) ) o
, , N
6 CD N
partial JJ N
responders NNS N
, , N
and CC N
100 CD N
nonresponders NNS N
. . N

The DT N
response NN o
rate NN o
for IN N
the DT N
HAC NNP i
group NN N
was VBD N
31 CD N
% NN N
and CC N
for IN N
the DT N
melphalan-platinum JJ i
group NN N
was VBD N
37.8 CD N
% NN N
. . N

The DT N
overall JJ N
response NN N
rate NN N
was VBD N
34.6 CD N
% NN N
. . N

Residual JJ N
tumor NN N
diameter NN N
( ( N
less JJR N
than IN N
or CC N
greater JJR N
than IN N
2 CD N
cm NN N
) ) N
exerted VBD N
a DT N
statistically RB N
significant JJ N
effect NN N
on IN N
response NN N
-- : N
47.8 CD N
vs JJ N
24.4 CD N
% NN N
. . N

Of IN N
the DT N
47 CD N
complete JJ N
responders NNS N
, , N
7 CD N
, , N
or CC N
14.9 CD N
% NN N
, , N
have VBP N
relapsed VBN N
, , N
with IN N
the DT N
median JJ N
duration NN N
of IN N
remission NN N
of IN N
44+ CD N
months NNS N
. . N

Of IN N
the DT N
158 CD p
patients NNS p
evaluable JJ N
for IN N
survival NN o
, , N
90 CD N
patients NNS N
have VBP N
died VBN N
, , N
with IN N
a DT N
median JJ o
survival NN o
time NN o
of IN N
27.9 CD N
months NNS N
( ( i
HAC NNP i
= VBZ N
26.4 CD N
months NNS N
, , N
melphalan-platinum JJ i
= NN N
29.6 CD N
months NNS N
) ) N
. . N

Age NNP N
, , N
FIGO NNP N
stage NN N
, , N
histologic JJ N
grade NN N
, , N
and CC N
residual JJ N
disease NN N
all DT N
exerted VBD N
a DT N
significant JJ N
effect NN N
on IN N
survival JJ N
time NN N
. . N

Second-line JJ N
therapy NN N
in IN N
the DT N
treatment NN N
failures NNS N
was VBD N
of IN N
no DT N
benefit NN N
. . N

Hematologic NNP o
toxicity NN o
was VBD N
greater JJR N
in IN N
the DT N
melphalan-platinum JJ i
group NN N
. . N

Gastrointestinal NNP o
toxicity NN o
was VBD N
severe JJ N
in IN N
both DT N
groups NNS N
. . N

Other JJ o
toxicities NNS o
were VBD N
minor JJ N
and CC N
infrequent NN N
. . N

-DOCSTART- -11708589- O O

Evaluation NN N
of IN N
a DT N
new JJ i
computer NN i
intervention NN i
to TO N
teach VB N
people NNS p
with IN p
autism NN p
or CC p
Asperger NNP p
syndrome VBP p
to TO N
recognize VB N
and CC N
predict VB N
emotions NNS N
in IN N
others NNS N
. . N

This DT N
randomized VBD N
controlled JJ N
trial NN N
looked VBD N
at IN N
the DT N
effect NN N
of IN N
a DT N
new JJ i
computer NN i
program NN i
designed VBN N
to TO N
teach VB N
people NNS p
with IN p
autistic JJ p
spectrum NN p
disorders NNS p
to TO N
better JJR N
recognize VB N
and CC N
predict VBP N
emotional JJ N
responses NNS N
in IN N
others NNS N
. . N

Two CD p
groups NNS p
of IN p
11 CD p
children NNS p
( ( p
age NN p
12-18 CD p
) ) p
with IN p
autism NN p
or CC p
Asperger NNP p
syndrome VBP p
at IN p
two CD p
special JJ p
schools NNS p
participated VBD p
: : p
one CD i
group NN i
used VBD i
the DT i
computer NN i
program NN i
for IN i
10 CD i
half-hour JJ i
sessions NNS i
over IN i
2 CD i
weeks NNS i
. . i

Within-program NNP N
data NN N
showed VBD N
a DT N
significant JJ N
reduction NN N
in IN N
errors NNS N
made VBN N
from IN N
first JJ N
to TO N
last JJ N
use NN N
. . N

Students NNS N
were VBD N
assessed VBN N
pre- JJ N
and CC N
post-intervention NN N
using VBG N
facial JJ o
expression NN o
photographs NN o
, , o
cartoons NNS o
depicting VBG o
emotion-laden JJ o
situations NNS o
, , o
and CC o
non-literal JJ o
stories NNS o
. . o

Scores NNS N
were VBD N
not RB N
related VBN N
to TO N
age NN N
or CC N
verbal JJ N
ability NN N
. . N

The DT N
experimental JJ N
group NN N
made VBD N
gains NNS N
relative JJ N
to TO N
the DT N
control NN N
group NN N
on IN N
all DT N
three CD N
measures NNS N
. . N

Gains NNP N
correlated VBD N
significantly RB N
with IN N
the DT N
number NN N
of IN N
times NNS N
the DT N
computer NN i
program NN i
was VBD N
used VBN N
and CC N
results NNS N
suggest VBP N
positive JJ N
effects NNS N
. . N

Further NNP N
research NN N
could MD N
assess VB N
whether IN N
these DT N
gains NNS N
generalized VBD N
into IN N
real JJ N
life NN N
or CC N
improved VBN N
performance NN N
on IN N
theory NN N
of IN N
mind NN N
measures NNS N
. . N

-DOCSTART- -9034258- O O

Effects NNS N
of IN N
preoperative JJ p
intentional JJ i
hemodilution NN i
on IN N
the DT N
extravasation NN o
rate NN o
of IN o
albumin NN o
and CC o
fluid NN o
. . o

OBJECTIVE UH N
To TO N
evaluate VB N
the DT N
effects NNS N
of IN N
preoperative JJ N
intentional JJ N
hemodilution NN N
with IN N
4 CD N
% NN N
albumin JJ i
solution NN N
on IN N
the DT N
extravasation NN N
rate NN N
of IN N
intravascular JJ N
albumin NN N
and CC N
fluid NN N
in IN N
surgical JJ p
patients NNS p
. . p

DESIGN VB N
A DT N
prospective JJ N
, , N
randomized VBN N
, , N
clinical JJ N
study NN N
. . N

SETTING NNP N
University NNP p
teaching VBG p
hospital NN p
. . p

PATIENTS CC N
Two CD p
groups NNS p
( ( p
control NN p
group NN p
[ NNP p
group NN p
1 CD p
] NN p
and CC p
hemodiluted VBN p
group NN p
[ NNP p
group NN p
2 CD p
] NN p
) ) p
of IN p
13 CD p
healthy JJ p
patients NNS p
were VBD N
studied VBN N
during IN N
a DT N
long-term JJ N
( ( N
> JJ N
4 CD N
hrs NN N
) ) N
surgical JJ N
procedure NN N
. . N

INTERVENTIONS NNP N
Autologous JJ i
technetium-99m NN i
( ( i
99mTc CD i
) ) i
-labeled VBD i
red JJ i
blood NN i
cells NNS i
and CC i
indium-oxine NN i
( ( i
( ( i
111 CD i
) ) i
In IN i
) ) i
-labeled VBD i
human JJ i
serum NN i
albumin NN i
were VBD i
injected VBN i
intravenously RB i
during IN N
anesthesia NN N
at IN N
T NNP N
= NNP N
0 CD N
min NN N
in IN N
the DT N
two CD N
groups NNS N
for IN N
the DT N
determination NN N
of IN N
total JJ N
blood NN N
volume NN N
and CC N
albumin JJ N
diffusion NN N
space NN N
, , N
respectively RB N
. . N

In IN N
addition NN N
, , N
body NN N
tetrapolar JJ N
electrical JJ N
impedance NN N
was VBD N
used VBN N
to TO N
assess VB N
extracellular JJ N
fluid NN N
volume NN N
. . N

In IN N
the DT N
hemodiluted VBN p
group NN p
( ( p
group NN p
2 CD p
) ) p
, , N
15 CD N
mL/kg NN N
of IN N
blood NN N
was VBD N
withdrawn VBN N
over IN N
30 CD N
mins NNS N
( ( N
T NNP N
= VBZ N
20 CD N
mins NNS N
to TO N
T NNP N
= NNP N
50 CD N
mins NNS N
) ) N
and CC N
simultaneously RB N
replaced VBN N
by IN N
an DT N
equal JJ N
volume NN N
of IN N
4 CD N
% NN N
albumin JJ N
solution NN N
( ( N
0.6 CD N
g/kg NN N
) ) N
. . N

MEASUREMENTS NNP N
AND CC N
MAIN NNP N
RESULTS NNP N
The DT N
albumin JJ o
diffusion NN o
space NN o
, , o
the DT o
colloid JJ o
oncotic JJ o
pressure NN o
, , o
the DT o
plasma NN o
albumin NN o
concentration NN o
and CC o
the DT o
electrical JJ o
impedance NN o
were VBD N
measured VBN N
before IN N
( ( N
T NNP N
= VBZ N
10 CD N
mins NNS N
) ) N
and CC N
after IN N
( ( N
T NNP N
= NNP N
60 CD N
, , N
120 CD N
, , N
and CC N
240 CD N
mins NNS N
) ) N
hemodilution NN N
. . N

Urine NN o
was VBD N
collected VBN N
from IN N
T NNP N
= NNP N
10 CD N
mins NNS N
to TO N
T NNP N
= NNP N
240 CD N
mins NNS N
. . N

The DT N
total JJ o
blood NN o
volume NN o
was VBD N
calculated VBN N
at IN N
T NNP N
= NNP N
10 CD N
mins NNS N
. . N

No DT N
differences NNS N
in IN N
the DT N
initial JJ N
values NNS N
were VBD N
found VBN N
between IN N
the DT N
two CD N
groups NNS N
. . N

In IN N
group NN N
2 CD N
, , N
hemodilution NN N
( ( N
hematocrit JJ N
30 CD N
+/- JJ N
3 CD N
% NN N
) ) N
resulted VBD N
in IN N
a DT N
steeper JJ N
increase NN N
in IN N
the DT N
albumin NN o
diffusion NN o
space NN o
( ( N
p JJ N
< NNP N
.05 NNP N
) ) N
and CC N
a DT N
progressive JJ N
decrease NN N
in IN N
the DT N
body NN o
electrical JJ o
impedance NN o
( ( N
p JJ N
< NNP N
.05 NNP N
) ) N
. . N

The DT N
extravasation NN o
rate NN o
of IN o
albumin NN o
was VBD N
0.052 CD N
+/- JJ N
0.007 CD N
mL/kg/min NN N
in IN N
group NN N
2 CD N
vs. IN N
0.038 CD N
+/- JJ N
0.020 CD N
mL/kg/min NN N
in IN N
group NN N
1 CD N
( ( N
p JJ N
< NNP N
.05 NNP N
) ) N
. . N

The DT N
value NN o
of IN o
calculated JJ o
plasma NN o
volume NN o
at IN N
T NNP N
= NNP N
0 CD N
min NN N
did VBD N
not RB N
shown VBN N
any DT N
difference NN N
between IN N
the DT N
two CD N
groups NNS N
. . N

This DT N
value NN N
was VBD N
then RB N
lower JJR N
than IN N
expected VBN N
in IN N
group NN N
2 CD N
, , N
corresponding VBG N
to TO N
a DT N
loss NN o
of IN o
plasma JJ o
volume NN o
of IN N
> $ N
3 CD N
mL/kg NN N
. . N

Urine NNP o
output NN o
was VBD N
significantly RB N
lower JJR N
in IN N
group NN N
2 CD N
than IN N
in IN N
group NN p
1 CD p
( ( p
0.7 CD p
+/- JJ p
0.4 CD p
vs. FW p
1.4 CD p
+/- JJ p
1.0 CD p
mL/min NN p
, , p
respectively RB p
; : p
p CC p
< NNP p
.05 NNP p
) ) p
. . p

A DT N
comparable JJ N
decrease NN N
in IN N
colloid JJ o
oncotic JJ o
pressure NN o
and CC o
in IN o
plasma JJ o
albumin JJ o
concentration NN o
was VBD N
observed VBN N
in IN N
both DT N
groups NNS N
. . N

CONCLUSIONS NNP N
These DT N
results NNS N
suggest VBP N
that IN N
preoperative JJ N
hemodilution NN N
using VBG N
4 CD N
% NN N
albumin NN N
on IN N
a DT N
1:1 CD N
volume NN N
basis NN N
for IN N
blood NN N
substitution NN N
during IN N
a DT N
prolonged JJ N
surgical JJ N
procedure NN N
with IN N
reduced JJ N
blood NN N
losses NNS N
enhances VBZ N
the DT N
extravasation NN N
rate NN N
of IN N
albumin NN N
and CC N
fluid NN N
to TO N
the DT N
interstitial JJ N
tissues NNS N
, , N
impeding VBG N
the DT N
maintenance NN N
of IN N
isovolemia NN N
. . N

These DT N
findings NNS N
support VBP N
the DT N
use NN N
of IN N
a DT N
volume NN N
of IN N
infused JJ N
colloid JJ N
solution NN N
higher JJR N
than IN N
that DT N
of IN N
withdrawn NN N
blood NN N
during IN N
preoperative JJ p
hemodilution NN p
. . p

-DOCSTART- -17149529- O O

Further JJ N
validation NN N
of IN N
the DT N
alcohol NN N
dependence NN N
scale NN N
as IN N
an DT N
index NN N
of IN N
severity NN N
. . N

OBJECTIVE CC N
The DT N
Alcohol NNP i
Dependence NNP i
Scale NNP i
( ( N
ADS NNP N
) ) N
yields VBZ N
continuous JJ N
scores NNS N
purported VBN N
to TO N
reflect VB N
the DT N
severity NN N
of IN N
the DT N
dependence NN N
syndrome NN N
. . N

We PRP N
evaluated VBD N
the DT N
concurrent JJ o
validity NN o
of IN o
the DT o
ADS NNP o
as IN o
a DT o
general JJ o
measure NN o
of IN o
severity NN o
and CC o
the DT o
screening VBG o
accuracy NN o
of IN N
the DT N
total JJ N
score NN N
and CC N
subscales NNS N
to TO N
detect VB N
Diagnostic NNP N
and CC N
Statistical NNP N
Manual NNP N
of IN N
Mental NNP N
Disorders NNP N
, , N
Fourth NNP N
Edition NNP N
( ( N
DSM-IV NNP N
) ) N
, , N
physiological JJ N
dependence NN N
. . N

METHOD NNP N
Treatment-seeking JJ p
, , p
alcohol-dependent JJ p
individuals NNS p
entering VBG p
the DT p
Combining NNP p
Pharmacotherapies NNPS p
and CC p
Behavioral NNP p
Interventions NNP p
for IN p
Alcohol NNP p
Dependence NNP p
( ( p
COMBINE NNP p
) ) p
Study NNP p
( ( p
N NNP p
= NNP p
1,372 CD p
; : p
69 CD p
% NN p
men NNS p
) ) p
completed VBD N
the DT N
ADS NNP N
, , N
diagnostic JJ N
interviews NNS N
, , N
and CC N
other JJ N
measures NNS N
before IN N
randomization NN N
. . N

Analyses NNS o
of IN o
variance NN o
tested VBN o
differences NNS o
between IN o
ADS NNP o
quartiles NNS o
on IN o
alcohol- JJ o
related JJ o
measures NNS o
. . o

Areas NNP N
under IN N
the DT N
receiver NN N
operating VBG N
characteristic JJ N
( ( N
AUROC NNP N
) ) N
curve NN N
assessed VBD N
screening VBG N
accuracy NN N
for IN N
DSM-IV NNP N
physiological JJ N
dependence NN N
( ( N
tolerance NN N
or CC N
withdrawal NN N
) ) N
or CC N
withdrawal VB N
alone RB N
. . N

RESULTS NNP N
ADS NNP N
quartiles VBZ N
differed VBN N
on IN N
age NN N
, , N
other JJ N
demographics NNS N
, , N
and CC N
prior RB N
treatment NN N
episodes NNS N
. . N

Linear JJ N
correlation NN N
showed VBD N
moderate JJ N
to TO N
large JJ N
magnitude NN N
associations NNS N
with IN N
alcohol-related JJ N
self-report JJ N
measures NNS N
and CC N
most JJS N
indices NNS N
of IN N
consumption NN N
. . N

ADS NNP N
quartiles NNS N
differed VBD N
significantly RB N
on IN N
proportion NN o
with IN o
DSM-IV NNP o
physiological JJ o
dependence NN o
, , N
but CC N
AUROC NNP N
curves NNS N
indicated VBD N
that IN N
the DT N
ADS NNP N
had VBD N
limited VBN N
accuracy NN o
as IN N
a DT N
continuous JJ N
measure NN N
to TO N
detect VB N
DSMIV NNP o
physiological JJ o
dependence NN o
( ( N
AUROC NNP N
= NNP N
.75 NNP N
[ VBD N
95 CD N
% NN N
confidence NN N
interval NN N
{ ( N
CI NNP N
} ) N
: : N
.70-.79 JJ N
] NN N
and CC N
.67 NNP N
[ VBP N
95 CD N
% NN N
CI NNP N
: : N
.60-.74 JJ N
] NN N
for IN N
men NNS N
and CC N
women NNS N
, , N
respectively RB N
; : N
p CC N
= NNP N
.08 NNP N
) ) N
or CC N
withdrawal VB N
alone RB N
( ( N
AUROC NNP N
= NNP N
.77 NNP N
[ VBD N
95 CD N
% NN N
CI NNP N
: : N
.74-.80 JJ N
] NN N
and CC N
.74 NNP N
[ VBP N
95 CD N
% NN N
CI NNP N
: : N
.69-.79 JJ N
] NN N
for IN N
men NNS N
and CC N
women NNS N
, , N
respectively RB N
; : N
p CC N
= NNP N
.30 NNP N
) ) N
. . N

Screening VBG o
accuracy NN o
was VBD N
comparably RB N
limited VBN N
based VBN N
on IN N
ADS NNP N
subscales NNS N
reflecting VBG N
psychoperceptual JJ N
or CC N
psychophysical JJ N
withdrawal NN N
. . N

CONCLUSIONS VB N
The DT N
ADS NNP N
reflected VBD N
variation NN N
in IN N
symptom JJ N
severity NN N
but CC N
did VBD N
not RB N
adequately RB N
identify VB N
physiological JJ N
dependence NN N
or CC N
withdrawal NN N
in IN N
treatment-seeking JJ p
individuals NNS p
with IN p
DSM-IV NNP p
alcohol NN p
dependence NN p
. . p

-DOCSTART- -9532967- O O

Interfering VBG N
with IN N
the DT N
central JJ N
executive NN N
by IN N
means NNS N
of IN N
a DT N
random NN i
interval JJ i
repetition NN i
task NN i
. . i

Four CD N
dual-task JJ N
experiments NNS N
are VBP N
reported VBN N
in IN N
which WDT N
a DT N
short-term JJ i
memory NN i
task NN i
is VBZ N
performed VBN N
concurrently RB N
with IN N
a DT N
random NN i
interval JJ i
repetition NN i
task NN i
, , N
which WDT N
was VBD N
designed VBN N
to TO N
interfere VB N
with IN N
functions NNS N
normally RB N
attributed VBD N
to TO N
the DT N
central JJ p
executive NN p
in IN N
the DT N
working JJ N
memory NN N
model NN N
of IN N
Baddeley NNP N
and CC N
Hitch NNP N
( ( N
1974 CD N
) ) N
. . N

The DT N
task NN i
was VBD N
found VBN N
to TO N
interfere VB N
with IN N
supra-span JJ N
serial JJ N
recall NN N
and CC N
with IN N
backward JJ o
memory NN o
span NN o
, , N
but CC N
did VBD N
not RB N
disrupt VB N
performance NN N
on IN N
a DT N
forward-memory-span JJ o
task NN i
. . i

The DT N
effects NNS N
were VBD N
observed VBN N
in IN N
dissociation NN N
with IN N
effects NNS N
of IN N
articulatory JJ N
suppression NN N
and CC N
matrix NN N
tapping NN N
, , N
so IN N
that IN N
the DT N
locus NN N
of IN N
the DT N
effects NNS N
of IN N
the DT N
new JJ N
task NN N
is VBZ N
not RB N
due JJ N
to TO N
the DT N
slave JJ N
systems NNS N
. . N

In IN N
addition NN N
, , N
single-task JJ i
random-interval JJ i
repetition NN N
performance NN N
was VBD N
sampled VBN N
and CC N
compared VBN N
to TO N
performance NN N
in IN N
the DT N
dual-task JJ i
conditions NNS N
of IN N
all DT N
four CD N
experiments NNS N
. . N

Although IN N
quality NN N
of IN N
tapping VBG o
performance NN o
differed VBD N
between IN N
the DT N
single-task NN i
and CC N
the DT N
dual-task JJ i
conditions NNS N
, , N
it PRP N
was VBD N
not RB N
related VBN N
to TO N
recall VB o
performance NN o
. . o

All PDT N
the DT N
results NNS N
are VBP N
discussed VBN N
with IN N
reference NN N
to TO N
the DT N
working VBG N
memory NN N
model NN N
. . N

-DOCSTART- -21233425- O O

The DT N
effect NN N
of IN N
an DT N
early JJ i
education NN i
program NN i
on IN N
adult NN p
health NN p
: : p
the DT N
Carolina NNP N
Abecedarian NNP N
Project NNP N
randomized VBD N
controlled VBN N
trial NN N
. . N

OBJECTIVES IN N
We PRP N
explored VBD N
whether IN N
a DT N
successful JJ N
randomized NN N
controlled VBD N
trial NN N
of IN N
early JJ i
education NN i
, , N
the DT N
Carolina NNP N
Abecedarian NNP N
Project NNP N
( ( N
ABC NNP N
) ) N
, , N
which WDT N
enrolled VBD p
infants NNS p
from IN p
1972 CD p
to TO p
1977 CD p
at IN p
the DT p
Frank NNP p
Porter NNP p
Graham NNP p
Child NNP p
Development NNP p
Institute NNP p
in IN p
Chapel NNP p
Hill NNP p
, , p
North NNP p
Carolina NNP p
, , N
improved VBD N
health NN N
outcomes NNS N
and CC N
behaviors NNS N
by IN N
21 CD N
years NNS N
of IN N
age NN N
. . N

METHODS NNP N
ABC NNP N
randomized VBD p
111 CD p
infants NNS p
to TO p
receive VB p
an DT p
intensive JJ i
early JJ i
education NN i
program NN i
or CC i
nutritional JJ i
supplements NNS i
and CC i
parental JJ i
counseling NN i
alone RB i
; : i
participants NNS p
have VBP p
been VBN p
followed VBN p
to TO p
the DT p
present JJ p
day NN p
. . p

We PRP N
examined VBD N
the DT N
effect NN N
of IN N
ABC NNP N
on IN N
health NN N
outcomes NNS N
and CC N
behavioral JJ N
risk NN N
factors NNS N
when WRB p
participants NNS p
were VBD p
aged VBN p
21 CD p
years NNS p
, , N
and CC N
then RB N
explored VBD N
the DT N
mediators NNS N
of IN N
this DT N
relationship NN N
. . N

RESULTS NNP N
Relative NNP N
to TO N
the DT N
control NN i
group NN i
, , N
the DT N
ABC NNP i
treatment NN i
group NN N
was VBD N
previously RB N
found VBN N
to TO N
have VB N
improved VBN o
cognition NN o
and CC o
educational JJ o
attainment NN o
. . o

We PRP N
found VBD N
that IN N
the DT N
intervention NN N
also RB N
improved VBN o
heath NN o
( ( N
P NNP N
= NNP N
.05 NNP N
) ) N
and CC N
health NN o
behaviors NNS o
( ( N
P NNP N
= NNP N
.03 NNP N
) ) N
when WRB N
participants NNS N
were VBD N
aged VBN N
21 CD N
years NNS N
. . N

These DT N
improvements NNS N
in IN N
behaviors NNS N
were VBD N
not RB N
mediated VBN N
by IN N
IQ NNP o
, , o
math NN o
and CC o
reading NN o
scores NNS o
at IN N
15 CD N
years NNS N
of IN N
age NN N
, , N
educational JJ o
attainment NN o
, , o
or CC o
health NN o
insurance NN o
. . o

CONCLUSIONS NNP N
Effective NNP i
early JJ i
education NN i
programs NNS i
may MD N
improve VB N
health NN o
and CC o
reduce VB o
risky JJ o
health NN o
behaviors NNS o
in IN N
adulthood NN N
. . N

-DOCSTART- -12810472- O O

Treatment NN N
of IN N
recurrent NN p
chronic JJ p
hyperplastic JJ p
sinusitis NN p
with IN p
nasal JJ p
polyposis NN p
. . p

OBJECTIVE UH N
To TO N
demonstrate VB N
the DT N
long-term JJ N
efficacy NN N
of IN N
intranasal JJ N
furosemide NN i
, , N
an DT N
inhibitor NN N
of IN N
the DT N
sodium NN N
chloride NN N
cotransporter NN N
channel NN N
at IN N
the DT N
basolateral JJ N
surface NN N
of IN N
the DT N
respiratory JJ N
epithelial JJ N
cell NN N
, , N
vs VBZ N
no DT i
therapeutic JJ i
intervention NN i
vs NN N
intranasal NN N
mometasone NN i
furoate NN i
, , i
a DT i
corticosteroid NN i
, , N
in IN N
preventing VBG N
relapses NNS N
of IN N
chronic JJ N
hyperplastic JJ N
sinusitis NN N
with IN N
nasal JJ N
polyposis NN N
. . N

DESIGN NNP N
Randomized NNP N
prospective NN N
controlled VBD N
study NN N
. . N

Patients NNS N
were VBD N
examined VBN N
every DT N
6 CD N
months NNS N
during IN N
follow-up NN N
( ( N
range NN N
, , N
1-9 JJ N
years NNS N
) ) N
. . N

PATIENTS VB N
One CD p
hundred JJ p
seventy NN p
patients NNS p
with IN p
bilateral JJ p
obstructive CD p
or CC p
minimally RB p
obstructive JJ p
chronic JJ p
hyperplastic JJ p
sinusitis NN p
with IN p
nasal JJ p
polyposis NN p
. . p

INTERVENTION NNP N
All DT p
patients NNS p
were VBD p
surgically RB p
treated VBN p
in IN p
the DT p
ENT NNP p
Department NNP p
, , p
University NNP p
of IN p
Siena NNP p
Medical NNP p
School NNP p
. . p

One CD p
month NN p
after IN p
surgery NN p
, , N
group NN N
1 CD p
patients NNS p
( ( N
n JJ N
= NNP N
97 CD N
) ) N
started VBD N
treatment NN i
with IN i
intranasal JJ i
furosemide NN i
, , N
group NN N
2 CD N
( ( N
n JJ N
= NNP N
40 CD N
) ) N
received VBD i
no DT i
therapeutic JJ i
treatment NN i
, , N
and CC N
group NN N
3 CD N
( ( N
n JJ N
= NNP N
33 CD N
) ) N
were VBD N
treated VBN i
with IN i
mometasone NN i
. . i

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
Clinical NNP o
and CC o
instrumental JJ o
evaluation NN o
of IN o
postoperative JJ o
outcomes NNS o
. . o

RESULTS NNP N
Seventeen NNP N
( ( N
17.5 CD N
% NN N
) ) N
of IN N
97 CD N
patients NNS N
in IN N
group NN N
1 CD N
, , N
12 CD N
( ( N
30.0 CD N
% NN N
) ) N
of IN N
40 CD N
patients NNS N
in IN N
group NN N
2 CD N
, , N
and CC N
8 CD N
( ( N
24.2 CD N
% NN N
) ) N
of IN N
33 CD N
patients NNS N
in IN N
group NN N
3 CD N
experienced VBD N
nasal JJ o
polyposis NN o
relapses NNS o
. . o

We PRP N
noted VBD N
a DT N
prevalence NN N
of IN N
early-stage JJ o
relapse NN o
in IN N
patients NNS p
treated VBN p
with IN p
furosemide NN i
or CC p
mometasone NN i
, , N
whereas JJ N
patients NNS p
who WP p
did VBD p
not RB p
receive VB p
any DT p
treatment NN p
experienced VBD N
more JJR N
severe JJ N
grades NNS o
of IN o
chronic JJ o
hyperplastic JJ o
sinusitis NN o
with IN o
nasal JJ o
polyposis NN o
( ( N
P NNP N
< NNP N
.005 NNP N
) ) N
. . N

CONCLUSION NNP N
Use NNP N
of IN N
intranasal NN N
furosemide JJ i
represents VBZ N
a DT N
valid JJ N
therapeutic JJ N
treatment NN N
in IN N
the DT N
prevention NN N
of IN N
chronic JJ p
hyperplastic JJ p
sinusitis NN p
with IN p
nasal JJ p
polyposis NN p
. . p

-DOCSTART- -9007148- O O

The DT N
management NN N
of IN N
dermoid JJ p
cysts NNS p
-- : p
a DT p
comparative JJ N
study NN N
of IN N
laparoscopy NN i
and CC N
laparotomy NN i
. . i

The DT N
aim NN N
of IN N
our PRP$ N
study NN N
was VBD N
to TO N
compare VB N
laparoscopy NN i
with IN N
laparotomy NN i
for IN N
the DT N
removal NN N
of IN N
ovarian JJ p
dermoid NN p
cysts NNS p
. . p

Thirty-eight JJ p
women NNS p
with IN p
benign JJ p
ovarian JJ p
dermoid NN p
cyst NN p
were VBD N
allocated VBN N
for IN N
either DT N
laparoscopy NN i
( ( N
18 CD N
patients NNS N
) ) N
or CC N
laparotomy NN i
( ( N
20 CD N
patients NNS N
) ) N
. . N

The DT N
two CD N
groups NNS N
were VBD N
compared VBN N
for IN N
operative JJ N
and CC N
hospitalization NN N
times NNS N
and CC N
postoperative JJ N
course NN N
. . N

Operating NN o
time NN o
was VBD N
longer RB N
( ( N
93.6 CD N
+/- JJ N
23.8 CD N
min NN N
) ) N
and CC N
hospitalization NN o
time NN o
significantly RB N
shorter JJR N
( ( N
22.4 CD N
+/- JJ N
6.6 CD N
h NN N
) ) N
in IN N
the DT N
laparoscopy NN N
group NN N
. . N

No DT N
complications NNS o
were VBD N
reported VBN N
in IN N
either DT N
group NN N
. . N

We PRP N
conclude VBP N
that IN N
operative JJ i
laparoscopy NN i
is VBZ N
a DT N
safe JJ o
procedure NN N
for IN N
the DT N
removal NN N
of IN N
dermoid JJ p
ovarian JJ p
cysts NNS p
and CC N
is VBZ N
as RB N
effective JJ o
as IN N
laparotomy NN i
. . i

-DOCSTART- -23988781- O O

Outcomes NNS N
and CC N
biochemical JJ N
parameters NNS N
following VBG N
cardiac JJ i
surgery NN i
: : i
effects NNS N
of IN N
transfusion NN i
of IN i
residual JJ i
blood NN i
using VBG N
centrifugation NN i
and CC i
multiple-pass NN i
hemoconcentration NN i
. . i

OBJECTIVES UH N
To TO N
determine VB N
whether IN N
or CC N
not RB N
there EX N
was VBD N
a DT N
significant JJ N
difference NN N
between IN N
the DT N
methods NNS i
of IN i
centrifugation NN i
( ( i
CF NNP i
) ) i
and CC i
multiple-pass JJ i
hemoconcentration NN i
( ( i
MPH NNP i
) ) i
of IN N
the DT N
residual JJ N
cardiopulmonary-bypass NN N
volume NN N
in IN N
relation NN N
to TO N
biochemical JJ N
measurements NNS N
and CC N
patient JJ N
outcomes NNS N
. . N

DESIGN NNP N
Prospective NNP N
, , N
randomized VBN N
, , N
and CC N
controlled VBD N
. . N

SETTING NN N
Conducted VBN N
at IN N
a DT p
western JJ p
Canadian JJ p
tertiary NN p
care NN p
hospital NN p
. . p

PARTICIPANTS NNP N
Consisted NNP p
of IN p
61 CD p
consecutive JJ p
male NN p
and CC p
female JJ p
patients NNS p
from IN p
ages NNS p
40 CD p
to TO p
80 CD p
who WP p
were VBD p
scheduled VBN p
for IN p
cardiac JJ i
surgery NN i
with IN p
cardiopulmonary JJ i
bypass NN i
. . i

INTERVENTIONS NNP N
Either CC N
the DT N
centrifugation NN i
or CC i
multiple-pass NN i
hemoconcentration NN i
method NN i
was VBD N
used VBN N
to TO N
process VB N
the DT N
residual JJ N
blood NN N
from IN N
the DT N
cardiopulmonary JJ N
bypass NN N
circuit NN N
. . N

RESULTS VB N
The DT N
12-hour JJ o
postoperative JJ o
levels NNS o
of IN o
serum NN o
hemoglobin NNS o
were VBD N
not RB N
significantly RB N
different JJ N
in IN N
the DT N
centrifugation NN i
group NN N
as IN N
compared VBN N
to TO N
the DT N
multiple-pass JJ i
hemoconcentration NN i
group NN N
. . N

However RB N
, , N
the DT N
serum NN o
levels NNS o
of IN o
total JJ o
protein NN o
and CC o
albumin NN o
were VBD N
significantly RB N
higher JJR N
in IN N
the DT N
multiple-pass JJ i
hemoconcentration NN i
group NN N
as IN N
compared VBN N
to TO N
the DT N
centrifugation NN i
group NN N
. . N

Additionally RB N
, , N
after IN N
12-hours JJ N
postoperatively RB N
, , N
the DT N
serum NN o
fibrinogen NN o
and CC o
platelet NN o
counts NNS o
were VBD N
significantly RB N
higher JJR N
in IN N
the DT N
multiple-pass JJ i
hemoconcentration NN i
group NN N
as IN N
compared VBN N
to TO N
those DT N
of IN N
the DT N
centrifugation NN i
group NN N
. . N

The DT N
allogeneic JJ o
product NN o
transfusion NN o
index NN o
and CC o
the DT o
chest-tube JJ o
blood NN o
drainage NN o
indices NNS o
were VBD N
lower JJR o
in IN N
the DT N
multiple-pass JJ i
hemoconcentration NN i
group NN N
as IN N
compared VBN N
to TO N
the DT N
centrifugation NN i
group NN N
. . N

CONCLUSION NNP N
Although IN N
the DT N
CF NNP i
method NN i
provided VBD N
a DT N
product NN N
in IN N
a DT N
shorter JJR N
turnaround NN N
time NN N
, , N
with IN N
consistent JJ N
clearance NN N
of IN N
heparin NN i
, , N
the DT N
MPH NNP i
method NN i
trended VBD N
towards NNS N
enhanced VBN o
biochemical JJ o
and CC o
clinical JJ o
patient NN o
outcomes VBZ o
over IN N
the DT N
12-hour JJ N
postoperative JJ N
period NN N
. . N

-DOCSTART- -16712638- O O

Joint JJ N
attention NN N
and CC N
symbolic JJ N
play NN N
in IN N
young JJ p
children NNS p
with IN p
autism NN p
: : p
a DT N
randomized VBN N
controlled VBN N
intervention NN N
study NN N
. . N

BACKGROUND NNP N
Delays NNPS N
and CC N
deficits NNS N
in IN N
joint JJ N
attention NN N
and CC N
symbolic JJ N
play NN N
constitute NN N
two CD N
important JJ N
developmental NN N
problems NNS N
in IN N
young JJ p
children NNS p
with IN p
autism NN p
. . p

These DT N
areas NNS N
of IN N
deficit NN N
have VBP N
been VBN N
well RB N
studied VBN N
in IN N
autism NN N
but CC N
have VBP N
rarely RB N
been VBN N
the DT N
focus NN N
of IN N
treatment NN N
efforts NNS N
( ( N
see VB N
Kasari NNP N
, , N
Freeman NNP N
, , N
& CC N
Paparella NNP N
, , N
2001 CD N
) ) N
. . N

In IN N
this DT N
study NN N
, , N
we PRP N
examine VBP N
the DT N
efficacy NN N
of IN N
targeted JJ N
interventions NNS N
of IN N
joint JJ i
attention NN i
and CC i
symbolic JJ i
play NN i
. . i

METHODS NNP N
Participants NNPS p
were VBD p
58 CD p
children NNS p
with IN p
autism NN p
aged VBN p
3 CD p
and CC p
4 CD p
years NNS p
( ( p
46 CD p
boys NNS p
) ) p
. . p

Children NNP N
were VBD N
randomized VBN N
to TO N
a DT N
joint JJ i
attention NN i
intervention NN i
, , i
a DT i
symbolic JJ i
play NN i
intervention NN i
, , i
or CC i
control NN i
group NN i
. . i

Interventions NNS N
were VBD N
conducted VBN N
30 CD N
minutes NNS N
daily RB N
for IN N
5-6 JJ N
weeks NNS N
. . N

Both DT N
structured JJ N
assessments NNS N
of IN N
joint JJ N
attention NN N
and CC N
play NN N
skills NNS N
and CC N
mother-child JJ N
interactions NNS N
were VBD N
collected VBN N
pre NN N
and CC N
post NN N
intervention NN N
by IN N
independent JJ N
assessors NNS N
. . N

RESULTS NNP N
Results NNP N
indicate VBP N
that IN N
both DT N
intervention NN N
groups NNS N
improved VBN N
significantly RB N
over IN N
the DT N
control NN N
group NN N
on IN N
certain JJ N
behaviors NNS N
. . N

Children NNP N
in IN N
the DT N
joint JJ N
attention NN N
intervention NN N
initiated VBN N
significantly RB N
more RBR N
showing JJ o
and CC N
responsiveness NN o
to TO o
joint JJ o
attention NN o
on IN N
the DT N
structured VBN o
joint JJ o
attention NN o
assessment NN o
and CC N
more JJR N
child-initiated JJ o
joint NN o
attention NN o
in IN N
the DT N
mother-child JJ o
interaction NN o
. . o

The DT N
children NNS N
in IN N
the DT N
play NN N
group NN N
showed VBD N
more JJR N
diverse JJ N
types NNS o
of IN o
symbolic JJ o
play NN o
in IN N
interaction NN N
with IN N
their PRP$ N
mothers NNS N
and CC N
higher JJR N
play NN o
levels NNS o
on IN N
both DT N
the DT N
play NN o
assessment NN o
and CC N
in IN N
interaction NN o
with IN o
their PRP$ o
mothers NNS o
. . o

CONCLUSIONS VB N
This DT N
randomized VBN N
controlled JJ N
trial NN N
provides VBZ N
promising JJ N
data NNS N
on IN N
the DT N
specificity NN o
and CC o
generalizability NN o
of IN o
joint JJ o
attention NN o
and CC o
play NN o
interventions NNS o
for IN N
young JJ p
children NNS p
with IN p
autism NN p
. . p

Future JJ N
studies NNS N
need VBP N
to TO N
examine VB N
the DT N
long-term JJ N
effects NNS N
of IN N
these DT N
early JJ N
interventions NNS N
on IN N
children NNS N
's POS N
development NN N
. . N

-DOCSTART- -8132701- O O

Treatment NN N
with IN N
coumarin NN i
to TO N
prevent VB N
or CC N
delay VB N
recurrence NN N
of IN N
malignant JJ p
melanoma NN p
. . p

Both DT N
coumarin NN i
( ( i
1,2-benzopyrone CD i
) ) i
and CC i
warfarin $ i
( ( i
4-hydroxycoumarin JJ i
) ) i
have VBP N
been VBN N
shown VBN N
to TO N
prevent VB N
the DT N
recurrence NN N
of IN N
malignant JJ p
melanoma NN p
. . p

Their PRP$ N
action NN N
is VBZ N
macrophage-dependent JJ N
and CC N
the DT N
dosage NN N
is VBZ N
critical JJ N
. . N

In IN N
1984 CD N
a DT N
multicentre NN N
, , N
prospective JJ N
, , N
randomised JJ N
, , N
double-blind JJ N
trial NN N
of IN N
coumarin NN i
, , N
given VBN N
as IN N
a DT N
daily JJ N
50-mg JJ N
dose NN N
for IN N
2 CD N
years NNS N
after IN N
surgery NN N
in IN N
patients NNS p
with IN p
high-risk JJ p
melanoma NN p
, , N
was VBD N
started VBN N
. . N

the DT p
patients NNS p
had VBD p
lesions NNS p
greater JJR p
than IN p
1.70 CD p
mm JJ p
thick NN p
and CC p
TNM NNP p
stage NN p
IB NNP p
or CC p
stage NN p
II NNP p
disease NN p
. . p

To TO N
date NN N
there EX N
are VBP N
4 CD N
recurrences NNS o
in IN N
the DT N
coumarin-treated JJ p
group NN p
of IN p
13 CD p
patients NNS p
, , p
and CC p
10 CD p
recurrences NNS o
in IN p
the DT p
placebo-treated JJ p
group NN p
of IN p
14 CD p
patients NNS p
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

There EX N
were VBD N
no DT N
toxic JJ o
effects NNS o
. . o

-DOCSTART- -7388581- O O

Vaginal NNP o
pH NN o
and CC o
microflora NN o
related VBN N
to TO N
yeast VB p
infections NNS p
and CC p
treatment NN p
. . p

The DT N
relationship NN N
between IN N
vaginal JJ o
pH NN o
, , o
microflora NN o
, , N
and CC N
yeast JJS p
infection NN p
was VBD p
investigated VBN p
in IN p
93 CD p
women NNS p
randomly RB p
treated VBN p
with IN p
either DT p
nystatin NN i
or CC i
miconazole JJ i
pessaries NNS i
and CC i
cream NN i
for IN p
two CD p
weeks NNS p
. . p

The DT N
vaginal JJ o
pH NN o
was VBD N
measured VBN N
in IN N
a DT N
control NN p
group NN p
of IN p
48 CD p
women NNS p
. . p

In IN N
the DT N
study NN N
group NN N
, , N
37 CD N
patients NNS N
defaulted VBD N
, , N
39 CD N
were VBD N
cured VBN N
, , N
and CC N
17 CD N
required JJ N
treatment NN N
during IN N
the DT N
six-month JJ N
follow-up JJ N
period NN N
. . N

In IN N
both DT N
study NN N
and CC N
control NN N
groups NNS N
before IN N
and CC N
after IN N
treatment NN N
the DT N
mean JJ o
vaginal JJ o
pH NN o
was VBD N
in IN N
the DT N
range NN N
of IN N
4.3-4.6 JJ N
. . N

Lactobacilli NNP o
were VBD N
plentiful JJ N
in IN N
78 CD N
( ( N
91 CD N
% NN N
) ) N
out IN N
of IN N
86 CD N
patients NNS N
and CC N
shows VBZ N
that IN N
lactobacilli NN N
and CC N
yeasts NNS N
commonly RB N
coexist VBP N
. . N

The DT N
influence NN N
of IN N
other JJ N
organisms NNS N
appeared VBD N
to TO N
be VB N
negligible JJ N
. . N

The DT N
trial NN N
showed VBD N
that IN N
nystatin NN N
and CC N
micromazole NN N
were VBD N
equallly RB N
effective JJ o
in IN N
the DT N
treatment NN N
of IN N
vaginal JJ p
yeast NN p
infection NN p
and CC N
that IN N
the DT N
broad-spectrum JJ N
activity NN N
of IN N
micronazole NN i
offered VBN N
no DT N
advantage NN N
in IN N
this DT N
condition NN N
. . N

-DOCSTART- -18714238- O O

Concurrent JJ N
training NN i
enhances NNS N
athletes VBZ N
' POS N
cardiovascular JJ p
and CC p
cardiorespiratory JJ p
measures NNS N
. . N

We PRP N
evaluated VBD N
the DT N
effects NNS N
of IN N
concurrent JJ N
strength NN i
and CC N
aerobic JJ i
endurance NN N
training NN N
on IN N
cardiovascular NN p
and CC p
cardiorespiratory NN p
adaptations NNS p
in IN p
college NN p
athletes NNS p
and CC p
compared VBN p
two CD p
concurrent JJ i
exercise NN i
( ( i
CE NNP i
) ) i
protocols NNS p
. . p

Separate JJ N
experiments NNS N
were VBD N
performed VBN p
on IN p
30 CD p
women NNS p
( ( p
mean JJ p
age NN p
19.6 CD p
years NNS p
) ) p
and CC p
20 CD p
men NNS p
( ( p
20.4 CD p
years NNS p
) ) p
. . p

In IN N
both DT N
experiments NNS N
, , N
subjects NNS N
were VBD N
divided VBN N
into IN N
two CD N
groups NNS N
( ( i
serial JJ i
CE NNP i
and CC N
integrated VBN i
CE NNP i
) ) i
matched VBD N
for IN N
initial JJ N
physical JJ N
condition NN N
and CC N
trained VBN N
in IN N
a DT N
vigorous JJ N
3-day JJ N
per IN N
week NN N
CE NNP i
program NN i
of IN N
9 CD N
( ( N
men NNS N
) ) N
to TO N
11 CD N
( ( N
women NNS N
) ) N
weeks NNS N
. . N

The DT N
two CD N
CE NNP i
training NN i
protocols NNS N
were VBD N
equilibrated VBN N
for IN N
exercise NN N
mode NN N
, , N
intensity NN N
, , N
and CC N
volume NN N
, , N
differing VBG N
only RB N
in IN N
the DT N
timing NN N
and CC N
sequence NN N
of IN N
exercises NNS N
. . N

During IN N
training NN N
, , N
serial JJ N
CE NNP N
discernibly NN N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
increased VBD N
cardiovascular JJ N
adaptation NN N
in IN N
women NNS N
, , N
indicated VBN N
by IN N
reduction NN N
( ( N
-5.7 CD N
% NN N
) ) N
in IN N
active JJ o
heart NN o
rate NN o
( ( N
HR NNP N
) ) N
( ( N
HR/aerobic NNP N
exercise VBP N
intensity NN N
) ) N
, , N
whereas RB N
integrated JJ N
CE NNP N
discernibly RB N
reduced VBD N
active JJ o
HR NNP o
in IN o
women NNS o
( ( N
-10.7 CD N
% NN N
) ) N
and CC N
men NNS o
( ( N
-9.1 CD N
% NN N
) ) N
. . N

Before IN N
and CC N
after IN N
comparisons NNS N
in IN N
the DT N
larger JJR N
sample NN N
of IN N
women NNS N
showed VBD N
that IN N
serial JJ N
CE NNP N
discernibly RB N
reduced VBD N
systolic JJ o
and CC o
diastolic JJ o
blood NN o
pressure NN o
( ( N
BP NNP N
) ) N
( ( N
-8.7 CD N
% NN N
and CC N
-14.0 CD N
% NN N
, , N
respectively RB N
) ) N
, , N
increased VBD N
estimated VBN N
[ NNP N
latin JJ N
capital NN N
V NNP N
with IN N
dot NN N
above IN o
] NNP o
o2max NN o
( ( N
18.9 CD N
% NN N
) ) N
, , N
and CC N
produced VBD N
a DT N
trend NN N
( ( N
0.10 CD N
> NNP N
p NN N
> NNP N
0.05 CD N
) ) N
toward IN N
reduced VBN N
resting VBG o
HR NNP o
( ( N
-4.9 NNP N
% NN N
) ) N
. . N

Integrated VBN i
CE NNP i
in IN N
women NNS N
discernibly RB N
reduced VBD N
systolic JJ o
and CC o
diastolic JJ o
BP NNP o
( ( N
-13.2 CD N
% NN N
and CC N
-12.6 CD N
% NN N
, , N
respectively RB N
) ) N
, , N
increased VBD N
estimated VBN N
[ NNP N
latin JJ N
capital NN N
V NNP N
with IN N
dot NN N
above IN o
] NNP o
o2max NN o
( ( N
22.9 CD N
% NN N
) ) N
, , N
and CC N
produced VBD N
a DT N
trend NN N
toward IN N
reduced VBN N
resting VBG o
HR NNP o
( ( N
-2.4 NNP N
% NN N
) ) N
. . N

Integrated VBN i
CE NNP i
produced VBD N
discernibly RB N
larger JJR N
gains NNS N
than IN N
serial JJ N
CE NNP N
or CC N
a DT N
trend NN N
for IN N
four CD N
of IN N
six CD N
training NN N
adaptations NNS N
. . N

Effect JJ N
sizes NNS N
were VBD N
generally RB N
large JJ N
( ( N
60.0 CD N
% NN N
of IN N
discernible JJ N
differences NNS N
) ) N
. . N

We PRP N
conclude VBP N
that DT N
, , N
for IN N
cardiovascular JJ N
and CC N
cardiorespiratory JJ N
adaptations NNS N
in IN N
athletes NNS N
, , N
strength NN N
and CC N
endurance NN N
training NN N
are VBP N
compatible JJ N
and CC N
that DT N
exercise NN N
timing NN N
and CC N
sequence NN N
significantly RB N
influence JJ N
training NN N
adaptations NNS N
, , N
complimenting VBG N
our PRP$ N
previous JJ N
similar JJ N
conclusions NNS N
for IN N
strength NN o
, , o
muscle NN o
endurance NN o
, , o
body NN o
composition NN o
, , o
and CC o
flexibility NN o
. . o

-DOCSTART- -6307704- O O

Bronchoscopic NNP o
findings NNS N
in IN N
patients NNS p
with IN p
a DT p
complete JJ p
radiographic JJ p
regression NN p
of IN p
small JJ o
cell NN o
bronchogenic JJ o
carcinoma NN o
. . o

Fibre-optic JJ i
bronchoscopy NN i
was VBD N
performed VBN N
in IN N
21 CD p
patients NNS p
with IN p
small JJ o
cell NN o
bronchogenic JJ o
carcinoma NN o
who WP p
demonstrated VBD p
a DT p
complete JJ p
radiographic JJ p
regression NN p
of IN p
their PRP$ p
chest JJS p
lesions NNS p
after IN p
3-4 JJ i
months NNS i
of IN i
combination NN i
chemotherapy NN i
. . i

Fifteen JJ N
patients NNS N
showed VBD N
abnormalities NNS o
at IN N
the DT N
site NN o
of IN N
the DT N
original JJ N
tumour NN o
consisting NN N
of IN N
nodular JJ o
elevations NNS o
, , o
narrowing VBG o
of IN o
bronchi NN o
and/or VBP o
fibrous JJ o
strands NNS o
or CC o
membranes NNS o
. . o

Microscopic NNP N
evidence NN N
of IN N
residual JJ N
cancer NN N
was VBD N
obtained VBN N
in IN N
3 CD N
cases NNS N
. . N

In IN N
3 CD N
out IN N
of IN N
8 CD N
patients NNS N
who WP N
underwent VBP N
a DT N
further JJ N
bronchoscopy NN o
after IN N
18 CD N
months NNS N
of IN N
treatment NN N
, , N
disappearance NN N
of IN N
nodules NNS o
was VBD N
noted VBN N
at IN N
the DT N
later JJ N
examination NN N
. . N

Persistent JJ o
bronchial JJ o
narrowing NN o
was VBD N
observed VBN N
in IN N
patients NNS N
who WP N
became VBD N
disease-free JJ N
2-yr JJ N
survivors NNS N
. . N

It PRP N
is VBZ N
concluded VBN N
that IN N
tumour JJ N
regression NN N
may MD N
be VB N
accompanied VBN N
by IN N
scar NN o
formation NN o
, , N
which WDT N
complicate VBP N
the DT N
interpretation NN N
of IN N
post-treatment JJ o
abnormalities NNS o
, , N
and CC N
that IN N
further JJ N
regression NN N
of IN N
intrabronchial JJ N
lesions NNS N
may MD N
occur VB N
beyond IN N
3-4 JJ N
months NNS N
. . N

-DOCSTART- -24352377- O O

Mitigation NN N
of IN N
sociocommunicational JJ N
deficits NNS N
of IN N
autism NN p
through IN N
oxytocin-induced JJ i
recovery NN N
of IN N
medial JJ N
prefrontal JJ N
activity NN N
: : N
a DT N
randomized JJ N
trial NN N
. . N

IMPORTANCE NNP N
Sociocommunicational NNP N
deficits NNS N
make VBP N
it PRP N
difficult JJ N
for IN N
individuals NNS p
with IN p
autism NN p
spectrum NN p
disorders NNS p
( ( p
ASD NNP p
) ) p
to TO N
understand VB N
communication NN N
content NN N
with IN N
conflicting VBG N
verbal JJ N
and CC N
nonverbal JJ N
information NN N
. . N

Despite IN N
growing VBG N
prospects NNS N
for IN N
oxytocin NN i
as IN N
a DT N
therapeutic JJ N
agent NN N
for IN N
ASD NNP N
, , N
no DT N
direct JJ N
neurobiological JJ N
evidence NN N
exists NNS N
for IN N
oxytocin NN i
's POS i
beneficial JJ N
effects NNS N
on IN N
this DT N
core NN N
symptom NN N
of IN N
ASD NNP N
. . N

This DT N
is VBZ N
slowing VBG N
clinical JJ N
application NN N
of IN N
the DT N
neuropeptide NN N
. . N

OBJECTIVE UH N
To TO N
directly RB N
examine VB N
whether IN N
oxytocin NN i
has VBZ N
beneficial JJ N
effects NNS N
on IN N
the DT N
sociocommunicational JJ N
deficits NNS N
of IN N
ASD NNP N
using VBG N
both DT N
behavioral JJ N
and CC N
neural JJ N
measures NNS N
. . N

DESIGN NNP N
, , N
SETTING NNP N
, , N
AND NNP N
PARTICIPANTS NNP N
At IN N
the DT N
University NNP p
of IN p
Tokyo NNP p
Hospital NNP p
, , N
we PRP N
conducted VBD N
a DT N
randomized VBN N
, , N
double-blind JJ N
, , N
placebo-controlled JJ i
, , N
within-subject-crossover JJ N
, , N
single-site JJ N
experimental JJ N
trial NN N
in IN N
which WDT N
intranasal NN N
oxytocin NN i
and CC N
placebo NN i
were VBD N
administered VBN N
. . N

A DT N
total NN p
of IN p
40 CD p
highly RB p
functioning VBG p
men NNS p
with IN p
ASD NNP p
participated VBD N
and CC N
were VBD N
randomized VBN N
in IN N
the DT N
trial NN N
. . N

INTERVENTIONS NNP N
Single-dose JJ N
intranasal JJ N
administration NN N
of IN N
oxytocin NN i
( ( i
24 CD i
IU NNP i
) ) i
and CC N
placebo NN i
. . i

MAIN NNP N
OUTCOMES NNP N
AND NNP N
MEASURES NNP N
Using NNP N
functional JJ N
magnetic JJ N
resonance NN N
imaging NN N
, , N
we PRP N
examined VBD N
effects NNS o
of IN o
oxytocin NN o
on IN N
behavioral JJ o
neural JJ o
responses NNS o
of IN N
the DT N
participants NNS N
to TO N
a DT N
social JJ N
psychological JJ N
task NN N
. . N

In IN N
our PRP$ N
previous JJ N
case-control NN N
study NN N
using VBG N
the DT N
same JJ N
psychological JJ N
task NN N
, , N
when WRB N
making VBG N
decisions NNS N
about IN N
social JJ N
information NN N
with IN N
conflicting VBG N
verbal JJ N
and CC N
nonverbal JJ N
contents NNS N
, , N
participants NNS N
with IN N
ASD NNP N
made VBD N
judgments NNS N
based VBN N
on IN N
nonverbal JJ N
contents NNS N
less RBR N
frequently RB N
with IN N
longer JJR N
time NN N
and CC N
could MD N
not RB N
induce VB N
enough JJ N
activation NN N
in IN N
the DT N
medial JJ N
prefrontal JJ N
cortex NN N
. . N

Therefore RB N
, , N
our PRP$ N
main JJ N
outcomes NNS N
and CC N
measures NNS N
were VBD N
the DT N
frequency NN o
of IN o
the DT o
nonverbal JJ o
information-based JJ o
judgments NNS o
( ( o
NVJs NNP o
) ) o
, , o
the DT o
response NN o
time NN o
for IN o
NVJs NNP o
, , o
and CC o
brain NN o
activity NN o
of IN o
the DT o
medial JJ o
prefrontal JJ o
cortex NN o
during IN o
NVJs NNP o
. . o

RESULTS NNP N
Intranasal NNP N
oxytocin VBZ i
enabled VBD N
the DT N
participants NNS N
to TO N
make VB N
NVJs NNP o
more RBR N
frequently RB N
( ( N
P NNP N
= NNP N
.03 NNP N
) ) N
with IN N
shorter JJR o
response NN o
time NN o
( ( o
P NNP N
= NNP N
.02 NNP N
) ) N
. . N

During IN N
the DT N
mitigated JJ N
behavior NN i
, , i
oxytocin NN i
increased VBD i
the DT N
originally RB o
diminished VBN o
brain NN o
activity NN o
in IN o
the DT N
medial JJ N
prefrontal NN N
cortex NN N
( ( N
P NNP N
< NNP N
.001 NNP N
) ) N
. . N

Moreover RB i
, , i
oxytocin PRP i
enhanced VBD o
functional JJ o
coordination NN o
in IN o
the DT o
area NN N
( ( N
P NNP N
< NNP N
.001 NNP N
) ) N
, , N
and CC N
the DT N
magnitude NN N
of IN N
these DT N
neural JJ N
effects NNS N
was VBD N
predictive JJ N
of IN N
the DT N
behavioral JJ N
effects NNS N
( ( N
P NNP N
? . N
.01 NN N
) ) N
. . N

CONCLUSIONS NNP N
AND CC N
RELEVANCE NNP N
These DT N
findings NNS N
provide VBP N
the DT N
first JJ N
neurobiological JJ N
evidence NN N
for IN i
oxytocin NN i
's POS i
beneficial JJ N
effects NNS N
on IN N
sociocommunicational JJ N
deficits NNS N
of IN N
ASD NNP N
and CC N
give VB N
us PRP N
the DT N
initial JJ N
account NN N
for IN N
neurobiological JJ N
mechanisms NNS N
underlying VBG N
any DT N
beneficial JJ N
effects NNS N
of IN N
the DT N
neuropeptide NN N
. . N

TRIAL NNP N
REGISTRATION NNP N
umin.ac.jp/ctr JJ N
Identifier NNP N
: : N
UMIN000002241 NN N
and CC N
UMIN000004393 NNP N
. . N

-DOCSTART- -22965298- O O

Preschool NNP N
based VBN N
JASPER NNP i
intervention NN i
in IN N
minimally RB p
verbal JJ p
children NNS p
with IN p
autism NN p
: : p
pilot NN N
RCT NNP N
. . N

In IN N
this DT N
pilot NN N
study NN N
, , N
we PRP N
tested VBD N
the DT N
effects NNS N
of IN N
a DT N
novel JJ N
intervention NN N
( ( i
JASPER NNP i
, , i
Joint NNP i
Attention NNP i
Symbolic NNP i
Play NNP i
Engagement NNP i
and CC i
Regulation NNP i
) ) i
on IN N
3 CD p
to TO p
5 CD p
year NN p
old JJ p
, , p
minimally RB p
verbal JJ p
children NNS p
with IN p
autism NN p
who WP p
were VBD p
attending VBG p
a DT p
non-public JJ p
preschool NN p
. . p

Participants NNS N
were VBD i
randomized VBN i
to TO i
a DT i
control NN i
group NN i
( ( i
treatment NN i
as IN i
usual JJ i
, , i
30 CD i
h NN i
of IN i
ABA-based JJ i
therapy NN i
per IN i
week NN i
) ) i
or CC i
a DT i
treatment NN i
group NN i
( ( i
substitution NN i
of IN i
30 CD i
min NN i
of IN i
JASPER NNP i
treatment NN i
, , i
twice RB i
weekly RB i
during IN i
their PRP$ i
regular JJ i
program NN i
) ) i
. . i

A DT i
baseline NN N
of IN N
12 CD N
weeks NNS N
in IN N
which WDT N
no DT N
changes NNS N
were VBD N
noted VBN N
in IN N
core NN o
deficits NNS o
was VBD o
followed VBN N
by IN N
12 CD N
weeks NNS N
of IN N
intervention NN N
for IN N
children NNS N
randomized VBN N
to TO N
the DT N
JASPER NNP i
treatment NN i
. . N

Participants NNS N
in IN N
the DT N
treatment NN N
group NN N
demonstrated VBD N
greater JJR o
play NN o
diversity NN o
on IN o
a DT o
standardized JJ o
assessment NN o
. . o

Effects NNS o
also RB N
generalized VBD N
to TO N
the DT N
classroom NN N
, , N
where WRB N
participants NNS N
in IN N
the DT N
treatment NN N
group NN N
initiated VBD N
more JJR N
gestures NNS o
and CC o
spent VB o
less JJR o
time NN o
unengaged JJ o
. . o

These DT o
results NNS N
provide VBP N
further JJ N
support NN N
that WDT N
even RB N
brief VBP N
, , N
targeted JJ N
interventions NNS N
on IN N
joint JJ N
attention NN N
and CC N
play NN N
can MD N
improve VB o
core NN o
deficits NNS o
in IN o
minimally RB p
verbal JJ p
children NNS p
with IN p
ASD NNP p
. . N

-DOCSTART- -20680681- O O

Anti-angiogenic JJ N
effect NN N
of IN N
tamoxifen NN i
combined VBN i
with IN i
epirubicin NN i
in IN N
breast NN p
cancer NN p
patients NNS p
. . p

Vascular JJ N
endothelial JJ N
growth NN N
factor NN N
A NNP N
( ( N
VEGF-A NNP N
) ) N
and CC N
vascular JJ N
endothelial JJ N
growth NN N
factor NN N
receptor NN N
2 CD N
( ( N
VEGFR2 NNP N
) ) N
are VBP N
the DT N
key JJ N
factors NNS N
mediating VBG N
neo-vascularization NN N
. . N

They PRP N
are VBP N
often RB N
coexpressed VBN N
in IN N
breast NN N
cancer NN N
. . N

Sex NNP N
steroids NNS N
may MD N
stimulate VB N
angiogenesis NN N
via IN N
the DT N
estrogen NN N
receptor NN N
( ( N
ER NNP N
) ) N
pathway RB N
. . N

We PRP N
investigated VBD N
to TO N
compare VB N
the DT N
effects NNS N
of IN N
the DT N
addition NN N
of IN N
tamoxifen NN i
to TO i
epirubicin VB i
versus NN i
epirubicin FW i
alone RB i
on IN N
VEGF NNP N
and CC N
VEGFR2 NNP N
expression NN N
in IN N
breast NN N
cancer NN N
patients NNS N
. . N

The DT N
expression NN N
of IN N
VEGF NNP o
and CC o
VEGFR2 NNP o
was VBD N
assessed VBN N
on IN N
tissue NN N
microarray NN N
by IN N
immunohistochemistry NN N
at IN N
baseline JJ N
conditions NNS N
and CC N
after IN N
treatments NNS N
in IN N
the DT N
case NN N
of IN N
191 CD p
patients NNS p
with IN p
T2-4 NNP p
N0-1 NNP p
breast NN p
cancer NN p
enrolled VBN p
in IN p
a DT p
randomized JJ p
trial NN p
comparing VBG N
four CD N
cycles NNS N
of IN N
single JJ N
agent NN N
epirubicin NN N
versus NN N
epirubicin NN N
plus CC N
tamoxifen NN N
as IN N
primary JJ N
systemic JJ N
treatment NN N
. . N

Epirubicin NNP N
alone RB N
failed VBD N
to TO N
induce VB N
changes NNS o
in IN o
VEGF NNP o
expression NN o
( ( N
P NNP N
= NNP N
0.54 CD N
) ) N
, , N
while IN N
the DT N
addition NN N
of IN N
tamoxifen NN i
to TO i
epirubicin VB i
resulted VBN N
in IN N
a DT N
significant JJ N
reduction NN N
in IN N
VEGF NNP o
expression NN o
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

As IN N
a DT N
consequence NN N
, , N
baseline NN o
VEGF NNP o
had VBD N
a DT N
negative JJ N
prognostic JJ N
role NN N
in IN N
patients NNS N
who WP N
received VBD N
epirubicin JJ N
alone RB N
but CC N
not RB N
in IN N
patients NNS N
receiving VBG N
epirubicin JJ i
plus CC i
tamoxifen JJ i
( ( N
interaction JJ N
test NN N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

VEGFR2 NNP o
expression NN o
increased VBD N
at IN N
residual JJ N
tumor NN N
histology NN N
in IN N
both DT N
treatment NN N
arms NNS N
, , N
with IN N
a DT N
lesser JJR N
extent NN N
in IN N
patients NNS N
receiving VBG N
tamoxifen JJ i
plus CC i
epirubicin JJ i
. . i

Decrease NNP N
in IN N
VEGFR2 NNP o
expression NN o
was VBD N
significantly RB N
associated VBN N
with IN N
response NN o
rate NN o
( ( N
P NNP N
= NNP N
0.02 CD N
) ) N
. . N

The DT N
addition NN i
of IN i
tamoxifen NN i
to TO i
epirubicin VB i
resulted VBN N
in IN N
a DT N
suppression NN o
of IN o
a DT o
key JJ o
angiogenic JJ o
pathway NN o
. . o

These DT N
data NNS N
suggest VBP N
a DT N
potential JJ N
synergism NN N
of IN N
these DT N
two CD N
drugs NNS N
. . N

-DOCSTART- -7488285- O O

Corticosteroids NNP i
plus CC i
pulse JJ i
cyclophosphamide NN i
and CC i
plasma NN i
exchanges NNS i
versus VBP N
corticosteroids NNS i
plus CC i
pulse JJ i
cyclophosphamide NN i
alone RB i
in IN N
the DT N
treatment NN N
of IN N
polyarteritis NN p
nodosa NN p
and CC p
Churg-Strauss NNP p
syndrome NN p
patients NNS p
with IN p
factors NNS p
predicting VBG p
poor JJ p
prognosis NN p
. . p

A DT N
prospective JJ N
, , N
randomized JJ N
trial NN N
in IN N
sixty-two JJ p
patients NNS p
. . p

OBJECTIVE NNP N
To TO N
define VB N
the DT N
most RBS N
effective JJ N
treatment NN N
for IN N
severe JJ p
polyarteritis NN p
nodosa NN p
( ( p
PAN NNP p
) ) p
and CC p
Churg-Strauss JJ p
syndrome NN p
( ( p
CSS NNP p
) ) p
and CC N
to TO N
investigate VB N
the DT N
indication NN N
for IN N
plasma JJ N
exchange NN N
treatment NN N
. . N

METHODS NNP N
We PRP N
conducted VBD N
a DT N
prospective JJ N
, , N
randomized VBN N
, , N
multicenter RBR N
trial NN N
in IN N
which WDT N
62 CD p
patients NNS p
were VBD p
randomly RB p
assigned VBN p
to TO p
receive VB p
either DT p
prednisone NN i
plus CC i
cyclophosphamide NN i
( ( i
intravenous JJ i
bolus NN i
) ) i
( ( i
group NN i
A NNP i
; : i
n JJ i
= NNP i
28 CD i
) ) i
or CC i
prednisone JJ i
plus CC i
cyclophosphamide JJ i
( ( i
intravenous JJ i
bolus NN i
) ) i
plus CC i
plasma JJ i
exchanges NNS i
( ( p
group NN p
B NNP p
; : p
n CC p
= VB p
34 CD p
) ) p
as IN p
first-line JJ p
treatment NN p
for IN p
severe JJ p
PAN NNP p
or CC p
CSS NNP p
. . p

Factors NNS N
predicting VBG N
poor JJ N
prognosis NN N
were VBD N
renal JJ N
symptoms NNS N
, , N
gastrointestinal JJ N
tract NN N
involvement NN N
, , N
cardiomyopathy NN N
, , N
central JJ N
nervous JJ N
system NN N
involvement NN N
, , N
weight JJ N
loss NN N
> VBZ N
10 CD N
% NN N
of IN N
body NN N
weight NN N
, , N
and CC N
age NN N
> VBP N
50 CD N
years NNS N
old JJ N
. . N

Patients NNS N
with IN N
hepatitis NN N
B NNP N
virus-related JJ N
PAN NNP N
were VBD N
not RB N
included VBN N
in IN N
this DT N
study NN N
. . N

The DT N
end NN N
point NN N
of IN N
the DT N
study NN N
was VBD N
control NN N
of IN N
the DT N
disease NN N
( ( N
recovery NN N
or CC N
remission NN N
) ) N
or CC N
death NN N
. . N

RESULTS NNP N
Clinical NNP N
symptoms NNS N
and CC N
laboratory JJ N
findings NNS N
did VBD N
not RB N
differ VB N
significantly RB N
in IN N
the DT N
2 CD N
groups NNS N
. . N

Initial NNP N
control NN N
of IN N
the DT N
disease NN N
was VBD N
similar JJ N
in IN N
both DT N
groups NNS N
. . N

Relapse NNP o
after IN N
initial JJ N
control NN N
of IN N
the DT N
disease NN N
was VBD N
observed VBN N
in IN N
7 CD N
patients NNS N
( ( N
4 CD N
in IN N
group NN N
A NNP N
and CC N
3 CD N
in IN N
group NN N
B NNP N
) ) N
. . N

The DT N
mean JJ o
+/- JJ o
SD NNP o
followup NN o
period NN N
was VBD N
31.1 CD N
+/- JJ N
20 CD N
months NNS N
for IN N
group NN N
A NNP N
and CC N
35.9 CD N
+/- JJ N
16.8 CD N
months NNS N
for IN N
group NN N
B NNP N
. . N

At IN N
5 CD N
years NNS N
of IN N
followup NN N
, , N
38 CD N
patients NNS N
( ( N
61.3 CD N
% NN N
) ) N
were VBD N
cured VBN o
( ( N
16 CD N
in IN N
group NN N
A NNP N
and CC N
22 CD N
in IN N
group NN N
B NNP N
) ) N
, , N
and CC N
5 CD N
( ( N
8.1 CD N
% NN N
) ) N
were VBD N
in IN N
remission NN N
without IN N
treatment NN N
but CC N
had VBD N
not RB N
yet RB N
completed VBN N
the DT N
cure-defining JJ N
period NN N
of IN N
18 CD N
months NNS N
( ( N
3 CD N
in IN N
group NN N
A NNP N
and CC N
2 CD N
in IN N
group NN N
B NNP N
) ) N
. . N

Eight NNP N
( ( N
12.9 CD N
% NN N
) ) N
( ( N
2 CD N
in IN N
group NN N
A NNP N
and CC N
2 CD N
in IN N
group NN N
B NNP N
) ) N
were VBD N
considered VBN N
to TO N
be VB N
in IN N
clinical JJ o
remission NN o
and CC N
required VBD N
a DT N
maintenance NN o
regimen NN o
of IN o
low-dose JJ o
corticosteroids NNS o
. . o

Eleven JJ N
patients NNS N
died VBD o
during IN N
the DT N
study NN N
period NN N
( ( N
7 CD N
in IN N
group NN N
A NNP N
[ RB N
25 CD N
% NN N
] NN N
, , N
4 CD N
in IN N
group NN N
B NNP N
[ VBZ N
11.8 CD N
% NN N
] NN N
) ) N
. . N

Uncontrolled VBN N
vasculitis NN N
was VBD N
responsible JJ N
for IN N
4 CD N
deaths NNS o
( ( N
2 CD N
in IN N
each DT N
group NN N
) ) N
, , N
and CC N
treatment NN o
side NN o
effects NNS o
caused VBD N
the DT N
death NN o
of IN N
1 CD N
patient NN N
in IN N
group NN N
A NNP N
. . N

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
between IN N
the DT N
5-year JJ o
cumulative JJ o
survival NN o
rates NNS o
of IN N
the DT N
2 CD N
groups NNS N
( ( N
75 CD N
% NN N
and CC N
88 CD N
% NN N
, , N
respectively RB N
) ) N
. . N

CONCLUSION NNP N
Based VBD N
on IN N
our PRP$ N
data NNS N
, , N
combined VBN N
treatment NN N
with IN N
prednisone NN i
, , i
cyclophosphamide NN i
, , N
and CC N
plasma NN i
exchanges NNS i
is VBZ N
not RB N
superior JJ N
to TO N
treatment NN N
with IN N
prednisone NN i
and CC N
cyclophosphamide VB i
alone RB N
, , N
and CC N
plasma JJ N
exchanges NNS N
should MD N
not RB N
be VB N
systematically RB N
proposed VBN N
for IN N
initial JJ N
treatment NN N
of IN N
severe JJ N
PAN NNP N
or CC N
CSS NNP N
. . N

-DOCSTART- -19062727- O O

[ JJ N
Safety NNP N
of IN N
adjuvant JJ i
dose-dense JJ i
chemotherapy NN i
with IN i
paclitaxel NN i
and CC i
epirubicin NN i
for IN N
high-risk JJ p
breast NN p
cancer NN p
] NNP p
. . N

OBJECTIVE NNP N
To TO N
investigate VB N
the DT N
safety NN o
and CC o
tolerance NN o
of IN N
adjuvant JJ i
dose-dense JJ i
chemotherapy NN i
with IN i
paclitaxel NN i
and CC i
epirubicin NN i
for IN N
high-risk JJ p
breast NN p
cancer NN p
. . p

METHODS NNP N
From IN N
January NNP N
2004 CD N
to TO N
December NNP N
2006 CD N
, , N
101 CD p
patients NNS p
with IN p
high-risk JJ p
breast NN p
cancer NN p
after IN p
surgical JJ p
resection NN p
were VBD N
enrolled VBN N
into IN N
this DT N
study NN N
. . N

The DT N
patients NNS N
were VBD N
divided VBN N
into IN N
two CD N
groups NNS N
: : N
dose-dense NN N
and CC N
regular JJ N
groups NNS N
. . N

Each DT N
patient NN N
received VBD N
6 CD i
cycles NNS i
of IN i
chemotherapy NN i
with IN i
intravenous JJ i
administration NN i
of IN i
paclitaxel NN i
( ( i
175 CD i
mg/m2 NN i
, , i
on IN i
D3 NNP i
) ) i
and CC i
epirubicin $ i
( ( i
60 CD i
mg/m2 NN i
, , i
on IN i
Dl NNP i
and CC i
D2 NNP i
) ) i
. . i

The DT N
dose-dense JJ i
group NN i
had VBD i
repeated VBN i
treatment NN i
every DT i
two CD i
weeks NNS i
, , N
while IN N
the DT N
regular JJ i
group NN i
repeated VBD i
it PRP i
every DT i
three CD i
weeks NNS i
. . i

G-CSF NNP i
was VBD i
used VBN i
in IN i
a DT i
dose NN i
of IN i
3 CD i
microg/kg NNS i
on IN i
D5-D9 NNP i
during IN N
each DT N
cycle NN N
in IN N
the DT N
dose-dense JJ N
group NN N
. . N

While IN N
in IN N
the DT N
regular JJ N
group NN N
, , N
it PRP N
was VBD N
used VBN N
only RB N
under IN N
the DT N
condition NN N
that IN N
grade VBD N
II NNP N
neutropenia NN N
occurred VBD N
. . N

RESULTS VB N
The DT N
toxicity NN o
could MD N
be VB N
evaluated VBN N
in IN N
101 CD p
patients NNS p
. . p

Major JJ o
grade JJ o
II-IV NNP o
toxicities NNS o
included VBD o
: : o
neutropenia NN o
, , o
nausea NN o
, , o
vomiting VBG o
and CC o
alopecia NN o
. . o

The DT N
incidence NN N
of IN N
grade JJ o
III-IV NNP o
neutropenia NN o
was VBD N
16.0 CD N
% NN N
in IN N
the DT N
dose-dense JJ N
group NN N
versus VBD N
54.9 CD N
% NN N
in IN N
the DT N
regular JJ N
group NN N
( ( N
P NNP N
= NNP N
0.000 CD N
) ) N
; : N
postponing VBG N
of IN N
chemotherapy NN N
was VBD N
2.4 CD N
% NN N
versus IN N
6.0 CD N
% NN N
( ( N
P NNP N
= NNP N
0.027 CD N
) ) N
. . N

Ninety-eight JJ p
patients NNS p
completed VBD p
the DT p
chemotherapy NN p
as IN p
planed VBN p
. . p

After IN N
a DT N
median JJ N
follow-up NN N
of IN N
24 CD N
months NNS N
, , N
the DT N
median JJ o
DFS NNP o
and CC o
OS NNP o
were VBD N
not RB N
reached VBN N
. . N

The DT N
relapse-free JJ o
rate NN o
and CC o
survival NN o
rate NN o
were VBD N
89.8 CD N
% NN N
and CC N
100 CD N
% NN N
in IN N
the DT N
dose-dense JJ N
group NN N
, , N
which WDT N
were VBD N
87.8 CD N
% NN N
and CC N
93.9 CD N
% NN N
in IN N
the DT N
regular JJ N
group NN N
. . N

The DT N
relapse-free JJ o
rate NN o
of IN o
the DT o
high-risk JJ o
patients NNS o
in IN N
the DT N
dose-dense JJ N
group NN N
was VBD N
86.8 CD N
% NN N
versus IN N
81.3 CD N
% NN N
in IN N
the DT N
regular JJ N
group NN N
, , N
and CC N
the DT N
corresponding JJ N
survival NN N
rate NN N
was VBD N
100 CD N
% NN N
versus IN N
90.6 CD N
% NN N
. . N

CONCLUSION NNP N
Adjuvant NNP i
dose-dense JJ i
chemotherapy NN i
with IN i
paclitaxel NN i
and CC i
epirubicin NN i
is VBZ N
safe JJ N
, , N
tolerable JJ N
and CC N
promising VBG N
for IN N
high-risk JJ p
breast NN p
cancer NN p
. . p

-DOCSTART- -14998846- O O

Reduced VBN N
cardiotoxicity NN N
and CC N
comparable JJ N
efficacy NN N
in IN N
a DT N
phase NN N
III NNP N
trial NN N
of IN N
pegylated VBN i
liposomal JJ i
doxorubicin NN i
HCl NNP i
( ( i
CAELYX/Doxil NNP i
) ) i
versus VBP N
conventional JJ i
doxorubicin NN i
for IN N
first-line JJ N
treatment NN N
of IN N
metastatic JJ p
breast NN p
cancer NN p
. . p

BACKGROUND NNP N
This DT N
study NN N
was VBD N
designed VBN N
to TO N
demonstrate VB N
that IN N
efficacy NN N
[ JJ o
progression-free JJ o
survival NN o
( ( o
PFS NNP o
) ) o
] NN o
of IN N
CAELYX NNP i
[ NNP i
pegylated VBD i
liposomal JJ i
doxorubicin NN i
HCl NNP i
( ( i
PLD NNP i
) ) i
] NN i
is VBZ N
non-inferior JJ N
to TO N
doxorubicin VB i
with IN N
significantly RB N
less JJR N
cardiotoxicity NN N
in IN N
first-line JJ p
treatment NN p
of IN p
women NNS p
with IN p
metastatic JJ p
breast NN p
cancer NN p
( ( p
MBC NNP p
) ) p
. . p

PATIENTS NNP N
AND CC N
METHODS NNP N
Women NNP p
( ( p
n=509 JJ p
) ) p
with IN p
MBC NNP p
and CC p
normal JJ p
cardiac JJ p
function NN p
were VBD p
randomized VBN p
to TO N
receive VB N
either DT N
PLD NNP i
50 CD N
mg/m2 NN N
( ( N
every DT N
4 CD N
weeks NNS N
) ) N
or CC N
doxorubicin $ i
60 CD i
mg/m2 NN i
( ( N
every DT N
3 CD N
weeks NNS N
) ) N
. . N

Cardiac JJ o
event NN o
rates NNS o
were VBD N
based VBN N
on IN N
reductions NNS N
in IN N
left JJ N
ventricular JJ N
ejection NN N
fraction NN N
as IN N
a DT N
function NN N
of IN N
cumulative JJ N
anthracycline NN i
dose NN N
. . N

RESULTS NNP N
PLD NNP i
and CC N
doxorubicin NNS i
were VBD N
comparable JJ N
with IN N
respect NN N
to TO N
PFS NNP o
[ NNP N
6.9 CD N
versus NN N
7.8 CD N
months NNS N
, , N
respectively RB N
; : N
hazard NN N
ratio NN N
( ( N
HR NNP N
) ) N
=1.00 VBP N
; : N
95 CD N
% NN N
confidence NN o
interval NN o
( ( o
CI NNP o
) ) o
0.82-1.22 CD N
] NN N
. . N

Subgroup NNP N
results NNS N
were VBD N
consistent JJ N
. . N

Overall JJ o
risk NN o
of IN o
cardiotoxicity NN o
was VBD N
significantly RB N
higher JJR N
with IN N
doxorubicin NN i
than IN N
PLD NNP i
( ( N
HR=3.16 NNP N
; : N
95 CD N
% NN N
CI NNP N
1.58-6.31 CD N
; : N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

Overall JJ o
survival NN o
was VBD N
similar JJ N
( ( N
21 CD N
and CC N
22 CD N
months NNS N
for IN N
PLD NNP i
and CC N
doxorubicin NN i
, , N
respectively RB N
; : N
HR=0.94 NNP N
; : N
95 CD N
% NN N
CI NNP N
0.74-1.19 NN N
) ) N
. . N

Alopecia NNP o
( ( N
overall JJ N
, , N
66 CD N
% NN N
versus IN N
20 CD N
% NN N
; : N
pronounced VBN N
, , N
54 CD N
% NN N
versus IN N
7 CD N
% NN N
) ) N
, , N
nausea NN o
( ( N
53 CD N
% NN N
versus IN N
37 CD N
% NN N
) ) N
, , N
vomiting VBG o
( ( N
31 CD N
% NN N
versus IN N
19 CD N
% NN N
) ) N
and CC N
neutropenia $ o
( ( N
10 CD N
% NN N
versus IN N
4 CD N
% NN N
) ) N
were VBD N
more RBR N
often RB N
associated VBN N
with IN N
doxorubicin NN i
than IN N
PLD NNP i
. . i

Palmar-plantar NNP o
erythrodysesthesia NN o
( ( N
48 CD N
% NN N
versus IN N
2 CD N
% NN N
) ) N
, , N
stomatitis NN o
( ( N
22 CD N
% NN N
versus IN N
15 CD N
% NN N
) ) N
and CC N
mucositis NN o
( ( N
23 CD N
% NN N
versus IN N
13 CD N
% NN N
) ) N
were VBD N
more RBR N
often RB N
associated VBN N
with IN N
PLD NNP i
than IN N
doxorubicin NN i
. . i

CONCLUSIONS NNP N
In IN N
first-line JJ N
therapy NN N
for IN N
MBC NNP N
, , N
PLD NNP i
provides VBZ N
comparable JJ N
efficacy NN N
to TO N
doxorubicin VB i
, , N
with IN N
significantly RB N
reduced VBN N
cardiotoxicity NN o
, , o
myelosuppression NN o
, , o
vomiting VBG o
and CC o
alopecia NN o
. . o

-DOCSTART- -14661011- O O

Early JJ N
reperfusion NN i
and CC N
late JJ N
clinical JJ N
outcomes NNS N
in IN N
patients NNS p
presenting VBG p
with IN p
acute JJ p
myocardial JJ p
infarction NN p
randomly RB N
assigned VBN N
to TO N
primary VB i
percutaneous JJ i
coronary JJ i
intervention NN i
or CC N
streptokinase NN i
. . i

BACKGROUND NNP N
Primary NNP i
percutaneous JJ i
coronary JJ i
intervention NN i
( ( i
PCI NNP i
) ) i
has VBZ N
become VBN N
an DT N
alternative JJ N
to TO N
thrombolytic JJ i
therapy NN i
as IN N
a DT N
reperfusion NN N
strategy NN N
for IN N
ST-elevation NNP p
acute JJ p
myocardial JJ p
infarction NN p
( ( p
AMI NNP p
) ) p
. . p

METHODS PDT N
The DT N
main JJ N
goal NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
determine VB N
whether IN N
PCI NNP i
and CC N
thrombolytic JJ i
therapy NN i
achieve VBP N
comparable JJ N
reperfusion NN N
rates NNS N
, , N
as IN N
evidenced VBN N
by IN N
ST-segment JJ N
resolution NN N
. . N

Secondary JJ N
end NN N
points NNS N
included VBD N
infarct JJ o
vessel NN o
patency NN o
rates NNS o
before IN N
hospital JJ N
discharge NN N
and CC N
short- JJ o
and CC o
long-term JJ o
outcomes NNS o
. . o

Patients NNS p
with IN p
ischemic JJ p
chest NN p
pain NN p
with IN p
duration NN p
< NN p
or CC p
=12 NN p
hours NNS p
and CC p
no DT p
contraindication NN p
for IN p
thrombolytic JJ p
therapy NN p
were VBD p
included VBN p
. . p

RESULTS NNP N
Between NNP p
October NNP p
1993 CD p
and CC p
August NNP p
1995 CD p
, , p
58 CD p
patients NNS p
were VBD p
randomly RB p
assigned VBN p
to TO p
streptokinase VB i
( ( i
SK NNP i
) ) i
and CC p
54 CD p
patients NNS p
to TO p
primary JJ i
PCI NNP i
. . i

Baseline NNP N
clinical JJ N
characteristics NNS N
and CC N
infarct JJ N
location NN N
were VBD N
well RB N
balanced VBN N
in IN N
both DT N
groups NNS N
. . N

Median JJ p
age NN p
( ( p
interquartile JJ p
range NN p
) ) p
was VBD p
68 CD p
( ( p
58 CD p
, , p
75 CD p
) ) p
years NNS p
, , p
29 CD p
% NN p
were VBD p
women NNS p
, , p
and CC p
78 CD p
% NN p
of IN p
the DT p
patients NNS p
met VBD p
at IN p
least JJS p
one CD p
criterion NN p
for IN p
not RB p
low JJ p
risk NN p
AMI NNP p
( ( p
anterior JJ p
location NN p
, , p
age NN p
> VBD p
70 CD p
years NNS p
old JJ p
, , p
previous JJ p
MI NNP p
, , p
systolic JJ p
blood NN o
pressure NN o
< VBZ p
100 CD p
mm NN p
Hg NNP p
, , p
and/or JJ p
heart NN p
rate NN p
> VBD p
100 CD p
bpm NN p
) ) p
. . p

The DT N
median JJ o
time NN o
from IN o
symptom JJ o
onset VBN o
to TO N
random VB N
assignment NN N
was VBD N
217 CD N
( ( N
139 CD N
, , N
335 CD N
) ) N
minutes NNS N
in IN N
the DT N
PCI NNP i
group NN N
and CC N
210 CD N
( ( N
145 CD N
, , N
334 CD N
) ) N
minutes NNS N
in IN N
the DT N
SK NNP i
group NN N
. . N

Median JJ N
random JJ N
assignment NN N
to TO N
balloon VB o
time NN o
was VBD N
82 CD N
( ( N
55 CD N
, , N
100 CD N
) ) N
minutes NNS N
, , N
and CC N
median JJ N
random NN N
assignment NN N
to TO N
needle JJ o
time NN o
was VBD N
15 CD N
( ( N
10 CD N
, , N
26 CD N
) ) N
minutes NNS N
( ( N
P NNP N
< NNP N
.0001 NNP N
) ) N
. . N

TIMI NNP o
grade VBD o
3 CD o
flow NN o
after IN N
primary JJ N
PCI NNP N
was VBD N
obtained VBN N
in IN N
85 CD N
% NN N
of IN N
patients NNS N
. . N

The DT N
proportion NN N
of IN N
patients NNS N
with IN N
ST-segment JJ o
resolution NN o
> NN N
or CC N
=50 VB N
% NN N
at IN N
120 CD N
minutes NNS N
was VBD N
80 CD N
% NN N
in IN N
the DT N
PCI NNP N
group NN N
and CC N
50 CD N
% NN N
in IN N
the DT N
SK NNP N
group NN N
( ( N
P NNP N
=.001 NNP N
) ) N
. . N

The DT N
predischarge NN N
angiogram NN N
showed VBD N
the DT N
presence NN o
of IN o
TIMI NNP o
3 CD o
flow NN o
in IN N
96 CD N
% NN N
of IN N
patients NNS N
who WP N
received VBD N
PCI NNP N
and CC N
65 CD N
% NN N
of IN N
patients NNS N
who WP N
received VBD N
SK NNP N
( ( N
P NNP N
< NNP N
.001 NNP N
) ) N
. . N

A DT N
composite JJ N
of IN N
in-hospital JJ o
death NN o
, , o
reinfarction NN o
, , o
severe JJ o
heart NN o
failure NN o
, , o
stroke NN o
, , o
and CC o
major JJ o
bleeding NN o
occurred VBD N
in IN N
15 CD N
% NN N
of IN N
patients NNS N
who WP N
received VBD N
PCI NNP N
and CC N
21 CD N
% NN N
of IN N
patients NNS N
who WP N
received VBD N
SK NNP N
( ( N
P NNP N
=.4 NNP N
) ) N
. . N

At IN N
3 CD N
years NNS N
, , N
freedom NN N
from IN N
the DT N
composite JJ o
end NN o
point NN o
of IN o
AMI NNP o
, , o
postdischarge NN o
revascularization NN o
, , o
and CC o
death NN o
was VBD N
61 CD N
% NN N
in IN N
the DT N
PCI NNP N
group NN N
and CC N
40 CD N
% NN N
in IN N
the DT N
SK NNP N
group NN N
( ( N
P NNP N
=.025 NNP N
) ) N
. . N

CONCLUSIONS NNP N
Our PRP$ N
study NN N
shows VBZ N
that IN N
primary JJ N
PCI NNP N
, , N
as IN N
compared VBN N
with IN N
SK NNP N
, , N
is VBZ N
associated VBN N
with IN N
more RBR N
effective JJ N
ST-segment JJ o
resolution NN o
, , N
higher JJR N
patency NN o
rates NNS o
in IN N
the DT N
infarct JJ N
vessel NN N
at IN N
7 CD N
days NNS N
, , N
and CC N
more RBR N
favorable JJ N
clinical JJ N
outcomes NNS N
at IN N
3 CD N
years NNS N
of IN N
follow-up NN N
. . N

-DOCSTART- -15463829- O O

Creon NNP i
10,000 CD i
Minimicrospheres NNP i
vs. FW i
Creon NNP i
8,000 CD i
microspheres NNS i
-- : i
an DT i
open JJ N
randomised VBN N
crossover NN N
preference NN N
study NN N
. . N

Creon NNP i
10,000 CD i
Minimicrospherestrade NNP i
mark NN i
( ( i
Creon NNP i
) ) i
10,000 CD i
MMS NNP i
) ) i
is VBZ N
a DT N
pancreatic JJ N
enzyme NN N
formulation NN N
that IN N
contains VBZ N
smaller JJR N
spheres NNS N
of IN N
pancreatin NN N
in IN N
a DT N
50 CD N
% NN N
smaller JJR N
capsule NN N
than IN N
conventional JJ N
microspheres NNS i
( ( i
Creon NNP i
) ) i
8,000 CD i
) ) i
. . i

This DT N
three-centre JJ p
study NN p
investigated VBD p
the DT p
preference NN o
of IN p
cystic JJ p
fibrosis NN p
( ( p
CF NNP p
) ) p
patients NNS p
for IN N
these DT N
products NNS N
. . N

In IN N
one CD N
centre NN N
, , N
72 CD N
h NN N
stool NN o
fat JJ o
excretion NN o
and CC o
coefficient NN o
of IN o
fat JJ o
absorption NN o
( ( o
CFA NNP o
) ) o
were VBD N
also RB N
compared VBN N
. . N

Fifty-nine JJ p
patients NNS p
with IN p
a DT p
mean JJ p
age NN p
10 CD p
years NNS p
( ( p
range VB p
3-17 NNP p
) ) p
took VBD N
Creon NNP N
8,000 CD N
ms NN N
for IN N
14 CD N
days NNS N
and CC N
were VBD N
then RB N
randomised VBN N
to TO N
28 CD i
days NNS i
of IN i
Creon NNP i
8,000 CD i
ms NN i
followed VBN i
by IN i
28 CD i
days NNS i
of IN i
Creon NNP i
10,000 CD i
MMS NNP i
, , i
or CC i
vice NN i
versa NN i
. . i

Dosing NNP N
was VBD N
lipase NN N
for IN N
lipase NN N
according VBG N
to TO N
the DT N
labelled VBN N
declaration NN N
. . N

At IN N
the DT N
end NN N
of IN N
the DT N
second JJ N
treatment NN N
period NN N
, , N
51 CD p
of IN p
54 CD p
patients NNS p
who WP p
completed VBD p
the DT p
study NN p
expressed VBD N
a DT N
preference NN N
, , N
with IN N
a DT N
statistically RB o
significant JJ o
preference NN o
in IN N
favour NN N
of IN N
Creon NNP N
10,000 CD N
MMS NNP N
( ( N
47/51 CD N
; : N
87 CD N
% NN N
) ) N
vs. FW N
Creon NNP N
8,000 CD N
ms NN N
( ( N
4/51 CD N
; : N
7.4 CD N
% NN N
; : N
P NNP N
< NNP N
0.0001 CD N
) ) N
. . N

Stool NNP o
fat NN o
( ( o
g/day NN o
) ) o
and CC o
CFA NNP o
( ( o
% NN o
) ) o
were VBD N
measured VBN N
in IN N
24 CD N
patients NNS N
at IN N
the DT N
end NN N
of IN N
each DT N
treatment NN N
period NN N
: : N
the DT N
products NNS N
were VBD N
therapeutically RB N
equivalent JJ N
( ( i
Creon JJ i
10,000 CD N
: : N
8.4 CD N
g/day NN N
, , N
91.3 CD N
% NN N
CFA NNP N
; : N
Creon NNP N
8,000 CD N
: : N
6.7 CD N
g/day NN N
, , N
93.5 CD N
% NN N
CFA NNP N
) ) N
. . N

Both DT N
products NNS N
were VBD N
well RB N
tolerated VBN N
. . N

In IN N
conclusion NN N
, , N
in IN N
CF NNP p
children NNS p
we PRP N
found VBD N
a DT N
clear JJ N
preference NN N
for IN N
Creon NNP N
10,000 CD N
MMS NNP N
compared VBN N
with IN N
Creon NNP N
8,000 CD N
ms NN N
with IN N
no DT N
difference NN N
in IN N
fat JJ o
absorption NN o
between IN N
the DT N
two CD N
products NNS N
. . N

Creon NNP i
10,000s CD N
smaller JJR N
capsules NNS N
are VBP N
easier JJR N
to TO N
take VB N
and CC N
should MD N
aid VB N
patient NN N
compliance NN N
. . N

-DOCSTART- -22082303- O O

Alkalinized NNP i
lidocaine NN i
and CC i
heparin NN i
provide VBP N
immediate JJ N
relief NN N
of IN N
pain NN o
and CC N
urgency NN N
in IN N
patients NNS p
with IN p
interstitial JJ p
cystitis NN p
. . p

INTRODUCTION NN N
It PRP N
has VBZ N
been VBN N
reported VBN N
in IN N
an DT N
open-label JJ N
study NN N
that IN N
the DT N
combination NN N
of IN N
alkalinized JJ i
lidocaine NN i
and CC i
heparin NN i
can MD N
immediately RB N
relieve VB N
the DT N
symptoms NNS N
of IN N
urinary JJ o
urgency NN o
, , o
frequency NN o
, , o
and CC o
pain NN o
associated VBN N
with IN N
interstitial JJ N
cystitis NN N
( ( N
IC NNP N
) ) N
. . N

This DT N
combination NN N
has VBZ N
also RB N
been VBN N
reported VBN N
to TO N
relieve VB N
pain NN p
associated VBN p
with IN p
sex NN p
in IN p
patients NNS p
with IN p
IC NNP p
. . p

AIM NNP N
The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
corroborate VB N
these DT N
findings NNS N
in IN N
a DT N
multicenter NN N
setting VBG N
. . N

METHODS NNP N
The DT N
study NN N
design NN N
was VBD N
a DT N
multicenter NN N
prospective JJ N
, , N
double-blind JJ N
, , N
crossover NN N
, , N
placebo-controlled JJ i
trial NN N
. . N

Each DT p
participant NN p
met VBD p
all DT p
of IN p
the DT p
clinical JJ p
National NNP p
Institute NNP p
of IN p
Diabetes NNP p
and CC p
Digestive NNP p
and CC p
Kidney NNP p
Diseases NNP p
criteria NNS p
( ( p
excluding VBG p
cystoscopy NN p
) ) p
for IN p
IC NNP p
. . p

Each DT N
patient NN N
received VBN N
drug NN N
and CC N
control NN N
, , N
in IN N
random JJ N
order NN N
, , N
within IN N
48 CD N
hours NNS N
of IN N
enrolling VBG N
in IN N
the DT N
study NN N
. . N

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
The DT N
primary JJ N
outcome NN N
measure NN N
was VBD N
percent JJ o
change NN o
in IN o
pain NN o
score NN o
( ( o
11-point JJ o
analog NN o
pain VB o
scale NN o
) ) o
12 CD N
hours NNS N
after IN N
receiving VBG N
the DT N
drug NN N
or CC N
control NN N
. . N

Secondary JJ N
measures NNS N
were VBD N
the DT N
global JJ N
assessment NN N
response NN N
( ( N
GAR NNP N
) ) N
of IN N
symptoms NNS o
and CC N
12-hour JJ o
average JJ o
urgency NN o
reduction NN o
determined VBD N
from IN N
11-point JJ N
urgency NN N
scales NNS N
. . N

RESULTS NNP N
Eighteen NNP p
( ( p
18 CD p
) ) p
patients NNS p
completed VBD p
the DT p
trial NN p
. . p

The DT N
average JJ N
reduction NN N
of IN N
pain NN N
over IN N
12 CD N
hours NNS N
was VBD N
21 CD N
% NN N
for IN N
control NN N
and CC N
42 CD N
% NN N
for IN N
active JJ N
drug NN N
( ( N
P NNP N
= NNP N
0.0363 CD N
) ) N
. . N

GAR NNP N
was VBD N
13 CD N
% NN N
for IN N
control NN N
and CC N
50 CD N
% NN N
for IN N
drug NN N
( ( N
P NNP N
= NNP N
0.0137 CD N
) ) N
. . N

Average JJ N
urgency JJ N
reduction NN N
was VBD N
13 CD N
% NN N
for IN N
control NN N
and CC N
35 CD N
% NN N
for IN N
drug NN N
( ( N
P NNP N
= NNP N
0.0328 CD N
) ) N
. . N

CONCLUSIONS VB N
The DT N
combination NN N
of IN N
alkalinized JJ N
lidocaine NN N
and CC N
heparin NN N
provides VBZ N
up IN N
to TO N
12 CD N
hours NNS N
of IN N
relief NN N
from IN N
urgency NN o
and CC o
pain NN o
associated VBN N
with IN N
IC NNP N
. . N

This DT N
combination NN N
provides VBZ N
significant JJ N
immediate JJ N
relief NN N
of IN N
symptoms NNS N
for IN N
patients NNS p
with IN p
IC NNP p
. . p

-DOCSTART- -17259154- O O

[ JJ N
Effect NNP N
of IN N
ulinastatin NN i
on IN N
inflammatory JJ o
responses NNS o
induced VBN p
by IN p
oesophagectomy JJ p
] NNP p
. . N

OBJECTIVE NNP N
To TO N
examine VB N
the DT N
effect NN N
of IN N
ulinastatin NN i
( ( N
UTI NNP N
) ) N
on IN N
the DT N
inflammatory JJ o
responses NNS o
induced VBN p
by IN p
oesophagectomy NN p
. . p

METHODS NNP N
Forty NNP p
patients NNS p
with IN p
esophageal JJ p
cancer NN p
( ( p
without IN p
serious JJ p
hypertension NN p
, , p
heart NN p
disease NN p
, , p
or CC p
respiratory JJ p
function NN p
impairment NN p
, , p
including VBG p
34 CD p
men NNS p
and CC p
6 CD p
women NNS p
aged VBD p
46 CD p
to TO p
70 CD p
years NNS p
) ) p
scheduled VBD p
for IN p
oesophagectomy JJ i
via IN i
left JJ i
thoracotomy NN i
were VBD p
randomly RB p
divided VBN p
into IN p
control NN p
group NN p
( ( p
n=20 CC p
) ) p
and CC p
UTI NNP p
group NN p
( ( p
n=20 RB p
) ) p
. . p

Anesthesia NNP i
induction NN i
and CC N
perioperative JJ N
management NN N
followed VBD N
the DT N
same JJ N
protocols NNS N
in IN N
the DT N
two CD N
groups NNS N
, , N
and CC N
in IN N
UTI NNP N
group NN N
, , N
patients NNS N
received VBD i
5000 CD i
U/kg NNP i
UTI NNP i
while IN N
those DT N
in IN N
the DT N
control NN N
group NN N
were VBD N
given VBN N
the DT N
same JJ N
volume NN N
of IN N
saline NN N
. . N

Before IN N
operation NN N
( ( N
T NNP N
( ( N
1 CD N
) ) N
) ) N
, , N
10 CD N
min NN N
after IN N
recovery NN N
of IN N
two-lung JJ N
ventilation NN N
( ( N
T NNP N
( ( N
2 CD N
) ) N
) ) N
, , N
and CC N
24 CD N
h NN N
( ( N
T NNP N
( ( N
3 CD N
) ) N
) ) N
and CC N
48 CD N
h NN N
( ( N
T NNP N
( ( N
4 CD N
) ) N
) ) N
after IN N
operation NN N
, , N
the DT N
venous JJ o
blood NN o
sample NN o
was VBD N
taken VBN N
from IN N
the DT N
internal JJ N
jugular NN N
vein NN N
and CC N
the DT N
plasma NN N
was VBD N
separated VBN N
and CC N
stored VBN N
at IN N
-70 NNP N
degrees NNS N
C NNP N
for IN N
later JJR N
analysis NN N
of IN N
IL-6 NNP N
and CC N
IL-8 NNP N
with IN N
enzyme-linked JJ N
immunosorbent NN N
assay NN N
( ( N
ELISA NNP N
) ) N
. . N

The DT N
bronchoalveoar NN o
lavage NN o
fluid NN o
( ( o
BAFL NNP o
) ) o
was VBD N
also RB N
collected VBN N
at IN N
T NNP N
( ( N
1 CD N
) ) N
and CC N
T NNP N
( ( N
2 CD N
) ) N
for IN N
IL-6 NNP N
and CC N
IL-8 NNP N
detection NN N
. . N

RESULTS NNP N
IL-6 JJ o
, , o
IL-8 JJ o
levels NNS o
in IN o
the DT o
plasma NN o
and CC o
BALF NNP o
collected VBD N
at IN N
T NNP N
( ( N
2 CD N
) ) N
-T NN N
( ( N
4 CD N
) ) N
increased VBD o
significantly RB o
as IN N
compared VBN N
with IN N
those DT N
in IN N
samples NNS N
collected VBN N
at IN N
T NNP N
( ( N
1 CD N
) ) N
, , N
and CC N
their PRP$ N
peak JJ o
concentration NN o
inplasma NN o
and CC o
BALF NNP o
samples NNS N
were VBD N
similar JJ N
. . N

IL-6 JJ o
and CC o
IL-8 JJ o
levels NNS o
in IN N
the DT N
UTI NNP N
group NN N
were VBD N
significantly RB o
lower JJR o
than IN N
those DT N
in IN N
the DT N
control NN N
group NN N
during IN N
the DT N
time NN N
points NNS N
of IN N
T NNP N
( ( N
2 CD N
) ) N
-T NN N
( ( N
4 CD N
) ) N
. . N

CONCLUSION NNP N
Inflammatory NNP N
responses VBZ N
occur VBP N
during IN N
and CC N
after IN N
oesophagectomy NN N
, , N
which WDT N
can MD N
be VB N
inhibited VBN N
with IN N
UTI NNP N
. . N

-DOCSTART- -18409186- O O

The DT N
interobserver JJ N
variability NN N
of IN N
digital JJ i
rectal JJ i
examination NN i
in IN N
a DT N
large JJ N
randomized JJ N
trial NN N
for IN N
the DT N
screening NN N
of IN N
prostate NN N
cancer NN N
. . N

BACKGROUND NNP N
To TO N
analyze VB N
to TO N
what WP N
extent VB N
the DT N
percentage NN N
of IN N
suspicious JJ N
digital JJ i
rectal JJ i
examination NN i
( ( i
DRE NNP i
) ) i
findings NNS N
vary VBP N
between IN N
examiners NNS N
and CC N
to TO p
what WP p
extent VB p
the DT p
percentage NN p
of IN p
prostate NN p
cancers NNS p
( ( p
PCs NNS p
) ) p
detected VBN p
in IN p
men NNS p
with IN p
these DT p
suspicious JJ p
findings NNS p
varies NNS p
between IN p
examiners NNS p
. . p

METHODS NNP N
In IN N
the DT N
first JJ N
screening NN N
round NN N
of IN N
the DT N
European NNP N
Randomized NNP N
study NN N
of IN N
Screening VBG N
for IN N
PC NN N
( ( N
ERSPC NNP N
) ) N
Rotterdam NNP N
, , N
7,280 CD p
men NNS p
underwent VBD p
a DT p
PSA-determination NN i
and CC i
DRE NNP i
of IN i
whom WP i
2,102 CD i
underwent JJ i
prostate NN i
biopsy NN i
( ( p
biopsy JJ p
indication NN p
PSA NNP p
> NNP p
or CC p
= $ p
4.0 CD p
ng/ml JJ p
and/or RB p
suspicious JJ p
DRE NNP p
and/or NN p
TRUS NNP p
) ) p
. . p

Descriptive JJ o
statistics NNS o
of IN o
DRE-outcome NNP o
per IN o
PSA-range NNP o
were VBD N
used VBN N
to TO N
determine VB N
the DT N
observer JJ N
variability NN N
of IN N
six CD N
examiners NNS N
. . N

Because IN N
this DT N
analysis NN N
did VBD N
not RB N
correct VB N
properly RB N
for IN N
other JJ N
predictors NNS N
of IN N
a DT N
suspicious JJ o
DRE NNP o
( ( o
PSA-level NNP o
, , o
biopsy NN o
indication NN o
, , o
TRUS-outcome NNP o
, , o
prostate NN o
volume NN o
and CC o
age NN o
) ) o
, , N
a DT N
logistic JJ N
regression NN N
analysis NN N
controlling VBG N
for IN N
these DT N
explanatory JJ N
variables NNS N
was VBD N
performed VBN N
as RB N
well RB N
. . N

RESULTS NNP N
In IN N
2,102 CD p
men NNS p
biopsied VBD p
, , p
443 CD p
PCs NNS p
were VBD p
detected VBN p
( ( p
PPV NNP p
= RB p
21 CD p
% NN p
) ) p
. . N

For IN N
all DT N
PSA NNP o
levels NNS o
the DT N
percentage NN o
suspicious JJ o
DRE NNP o
varied VBD N
between IN N
examiners NNS N
from IN N
4 CD N
% NN N
to TO N
28 CD N
% NN N
and CC N
percentage NN o
PC NN o
detected VBN N
in IN N
men NNS p
with IN p
a DT p
suspicious JJ p
DRE NNP p
varied VBD N
from IN N
18 CD N
% NN N
to TO N
36 CD N
% NN N
. . N

Logistic JJ N
regression NN N
analysis NN N
showed VBD N
that IN N
three CD N
of IN N
six CD N
examiners NNS N
considered VBN N
DRE NNP o
significantly RB N
more RBR N
often RB N
abnormal JJ N
than IN N
others NNS N
( ( N
ORs NNP N
3.48 CD N
, , N
2.80 CD N
, , N
2.47 CD N
, , N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

For IN N
all DT N
examiners NNS N
the DT N
odds NNS N
to TO N
have VB N
PC NN o
was VBD N
statistically RB N
significantly RB N
higher JJR N
in IN N
case NN N
of IN N
a DT N
suspicious JJ o
DRE NNP o
( ( N
ORs NNP N
2.21-5.96 CD N
, , N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

This DT N
increased VBD N
chance NN N
to TO N
find VB N
PC NN o
was VBD N
not RB N
significantly RB N
observer-dependent JJ N
. . N

CONCLUSIONS NNP N
Three CD N
of IN N
six CD N
examiners NNS N
considered VBN N
DRE NNP o
significantly RB N
more RBR N
often RB N
suspicious JJ N
than IN N
the DT N
others NNS N
. . N

However RB N
, , N
under IN N
equal JJ N
circumstances NNS N
a DT N
suspicious JJ N
DRE NNP o
executed VBN N
by IN N
each DT N
examiner NN N
increased VBD N
the DT N
chance NN N
of IN N
the DT N
presence NN N
of IN N
PC NNP o
similarly RB N
. . N

-DOCSTART- -2168532- O O

Alternating VBG i
chemotherapy NN i
in IN N
small JJ p
cell NN p
lung NN p
cancer NN p
. . p

Based VBN N
on IN N
the DT N
hypothesis NN N
of IN N
Goldie NNP N
and CC N
Coldman NNP N
, , N
rapid JJ i
cyclic JJ i
alternating VBG i
chemotherapy NN i
has VBZ N
been VBN N
supposed VBN N
to TO N
be VB N
a DT N
favorable JJ N
treatment NN N
modality NN N
in IN N
small JJ p
cell NN p
lung NN p
cancer NN p
. . p

This DT N
approach NN N
has VBZ N
been VBN N
tested VBN N
in IN N
a DT N
large JJ N
series NN N
of IN N
trials NNS N
since IN N
the DT N
late JJ N
70 CD N
's POS N
. . N

A NNP N
few JJ N
trials NNS N
performed VBD N
randomization NN N
between IN N
alternating VBG N
and CC N
continuous JJ N
treatment NN N
after IN N
a DT N
period NN N
of IN N
initial JJ i
common JJ i
continuous JJ i
therapy NN i
. . i

The DT N
results NNS N
of IN N
these DT N
studies NNS N
are VBP N
controversial JJ N
and CC N
their PRP$ N
interpretation NN N
is VBZ N
complicated VBN N
by IN N
the DT N
effects NNS N
of IN N
the DT N
continuous JJ N
pretreatment NN N
. . N

Recently RB N
, , N
most JJS N
trials NNS N
were VBD N
designed VBN N
as IN N
2-arm JJ N
approaches NNS N
with IN N
a DT N
comparison NN N
of IN N
continuous JJ i
standard NN i
therapy NN i
based VBN i
on IN i
the DT i
CAV- NNP i
or CC i
CMC-protocol NNP i
with IN i
an DT i
alternating VBG i
schedule NN i
often RB i
consisting VBG i
of IN i
the DT i
CAV- NNP i
or CC i
CMC-derived JJ i
combinations NNS i
and CC i
a DT i
second JJ i
regimen NN i
including VBG i
cisplatinum NN i
and/or NN i
etoposide NN i
. . i

In IN N
these DT N
trials NNS N
the DT N
addition NN N
of IN N
the DT N
second JJ N
regimen NNS N
in IN N
the DT N
alternating NN N
treatment NN N
arms NNS N
has VBZ N
improved VBN N
the DT N
treatment NN N
results NNS N
. . N

However RB N
, , N
these DT N
trials NNS N
could MD N
not RB N
clarify VB N
whether IN N
this DT N
advantage NN N
was VBD N
due JJ N
to TO N
the DT N
concept NN N
of IN N
alternating VBG N
treatment NN N
or CC N
to TO N
the DT N
high JJ N
activity NN N
of IN N
new JJ N
drugs NNS N
given VBN N
early RB N
in IN N
the DT N
course NN N
of IN N
therapy NN N
in IN N
the DT N
alternating NN N
treatment NN N
arms NNS N
. . N

To TO N
ameliorate VB N
this DT N
weakness NN N
, , N
3 CD N
studies NNS N
were VBD N
designed VBN N
as IN N
3-arms JJ N
approaches NNS N
using VBG N
both DT N
alternating VBG N
protocols NNS N
as IN N
continuous JJ N
control NN N
arms NNS N
. . N

Whereas IN N
one CD N
investigation NN N
noticed VBD N
an DT N
advantage NN N
of IN N
the DT N
alternating NN N
schedule NN N
, , N
the DT N
two CD N
others NNS N
observed VBD N
no DT N
difference NN N
. . N

These DT N
studies NNS N
did VBD N
not RB N
report VB N
their PRP$ N
criteria NNS N
for IN N
shifting VBG N
non-responding JJ N
patients NNS N
from IN N
continuous JJ N
treatment NN N
to TO N
second JJ N
line NN N
therapy NN N
. . N

The DT N
longer JJR N
these DT N
patients NNS N
stayed VBD N
on IN N
the DT N
continuous JJ N
protocol NN N
the DT N
more JJR N
the DT N
study NN N
design NN N
favoured VBD N
the DT N
alternating VBG N
therapy NN N
. . N

( ( N
ABSTRACT NNP N
TRUNCATED NNP N
AT NNP N
250 CD N
WORDS NNP N
) ) N
-DOCSTART- -20367417- O O

Teriparatide NNP N
improves VBZ N
early JJ o
callus NN o
formation NN o
in IN N
distal JJ p
radial JJ p
fractures NNS p
. . p

BACKGROUND NNP N
Teriparatide NNP N
( ( N
parathyreoid JJ N
hormone NN N
; : N
PTH NNP N
1-34 CD N
) ) N
increases VBZ N
skeletal JJ N
mass NN N
in IN N
humans NNS N
and CC N
improves VBZ N
fracture NN N
healing VBG N
in IN N
animals NNS N
. . N

A DT N
recent JJ N
randomized JJ N
multicenter NN N
trial NN N
of IN N
nonoperated JJ p
distal JJ p
radial NN p
fractures NNS p
showed VBD N
a DT N
moderate JJ N
shortening NN N
of IN N
the DT N
time NN N
to TO N
restoration NN N
of IN N
cortical JJ N
continuity NN N
by IN N
treatment NN N
with IN N
20 CD i
microg NNS i
( ( i
low-dose JJ i
) ) i
teriparatide NN i
per IN i
day NN i
, , i
but CC i
not RB i
with IN i
40 CD i
microg NNS i
( ( i
high-dose JJ i
) ) i
. . N

As IN N
radiographic JJ N
cortical JJ N
continuity NN N
appears VBZ N
late RB N
in IN N
the DT N
healing NN N
process NN N
, , N
perhaps RB N
too RB N
late JJ N
for IN N
clinical JJ N
relevance NN N
, , N
we PRP N
studied VBD N
the DT N
qualitative JJ N
appearance NN N
of IN N
the DT N
callus JJ N
5 CD N
weeks NNS N
after IN N
fracture NN N
. . N

METHODS NNP N
One CD p
third NN p
of IN p
the DT p
patients NNS p
of IN p
the DT p
international JJ p
trial NN p
were VBD p
treated VBN p
at IN p
Link?ping NNP p
University NNP p
Hospital NNP p
. . p

The DT N
multicenter NN N
trial NN N
did VBD N
not RB N
evaluate VB N
early JJ N
callus NN N
formation NN N
. . N

We PRP N
therefore RB N
made VBD N
a DT N
blinded JJ N
qualitative JJ N
scoring NN N
of IN N
the DT N
callus NN N
at IN N
5 CD N
weeks NNS N
in IN N
our PRP$ p
27 CD p
patients NNS p
. . p

Callus NNP N
formation NN N
was VBD N
arbitrarily RB N
classified VBN N
as IN N
rich JJ N
, , N
intermediate JJ N
, , N
or CC N
poor JJ N
. . N

RESULTS NNP N
9 CD N
patients NNS N
were VBD N
classified VBN N
as IN o
rich JJ o
( ( N
none NN N
had VBD N
received VBN N
placebo RB N
, , N
3 CD N
low-dose JJ N
teriparatide NN N
, , N
and CC N
6 CD N
high-dose JJ N
teriparatide NN N
) ) N
. . N

9 CD N
patients NNS N
were VBD N
classified VBN N
as IN o
intermediate NN o
( ( N
1 CD N
had VBD N
received VBN N
placebo RB N
, , N
5 CD N
low-dose JJ N
, , N
and CC N
3 CD N
high-dose JJ N
) ) N
. . N

9 CD N
patients NNS N
were VBD N
classified VBN N
as IN o
poor JJ o
( ( N
7 CD N
had VBD N
received VBN N
placebo RB N
, , N
1 CD N
low-dose JJ N
, , N
and CC N
1 CD N
high-dose NN N
) ) N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
. . N

INTERPRETATION NN N
This DT N
is VBZ N
a DT N
post NN N
hoc NN N
subgroup NN N
analysis NN N
of IN N
an DT N
outcome NN N
variable NN N
, , N
which WDT N
was VBD N
not RB N
in IN N
the DT N
official JJ N
protocol NN N
. . N

The DT N
results NNS N
must MD N
therefore RB N
be VB N
interpreted VBN N
with IN N
caution NN N
. . N

However RB N
, , N
in IN N
combination NN N
with IN N
the DT N
results NNS N
of IN N
the DT N
larger JJR N
trial NN N
, , N
the DT N
data NN N
suggest NN N
that IN N
radiographic JJ N
quality NN N
at IN N
an DT N
early JJ N
time NN N
point NN N
might MD N
be VB N
a DT N
sensitive JJ N
variable NN N
, , N
perhaps RB N
better JJR N
than IN N
time NN N
to TO N
cortical JJ N
continuity NN N
. . N

Moreover RB N
, , N
teriparatide RB i
appeared VBD N
to TO N
improve VB o
early JJ o
callus NN o
formation NN o
in IN p
distal JJ p
radial JJ p
fractures NNS p
. . p

-DOCSTART- -17113685- O O

B-vitamins NNS i
reduce VB N
plasma NN o
levels NNS o
of IN N
beta NN N
amyloid NN N
. . N

Elevated VBN N
plasma JJ N
homocysteine NN N
( ( N
tHcy NN N
) ) N
is VBZ N
a DT N
risk NN N
factor NN N
for IN N
Alzheimer NNP N
's POS N
disease NN N
( ( N
AD NNP N
) ) N
, , N
and CC N
thus RB N
B NNP i
vitamins NNS i
may MD N
have VB N
a DT N
role NN N
in IN N
the DT N
prevention NN N
of IN N
AD NNP N
. . N

The DT N
objective NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
determine VB N
if IN N
tHcy JJ N
lowering NN N
vitamins NNS N
decrease VBP N
the DT N
circulating NN o
levels NNS o
of IN o
A-beta NNP o
protein NN o
1-40 JJ o
( ( o
A NNP o
beta RB o
40 CD o
) ) o
. . o

We PRP N
randomized VBD N
299 CD p
older JJR p
men NNS p
to TO N
treatment NN N
with IN N
2mg CD i
of IN i
folate NN i
, , i
plus CC i
25mg CD i
of IN i
B6 NNP i
and CC i
400 CD i
microg NN i
of IN i
B12 NNP i
, , i
or CC i
placebo NN i
. . i

After IN N
2 CD N
years NNS N
of IN N
treatment NN N
the DT N
mean NN o
( ( o
S.E NNP o
. . o

) ) o
increase NN o
of IN o
A NNP o
beta NN o
40 CD o
was VBD N
7.0 CD N
pg/ml NN N
( ( N
8.4 CD N
) ) N
in IN N
the DT N
vitamin NN N
group NN N
( ( N
4.9 CD N
% NN N
) ) N
, , N
and CC N
26.8 CD N
pg/ml NN N
( ( N
7.7 CD N
) ) N
( ( N
18.5 CD N
% NN N
) ) N
in IN N
the DT N
placebo NN N
group NN N
. . N

We PRP N
conclude VBP N
that IN N
B NNP N
vitamins NNS N
may MD N
decrease VB N
the DT o
plasma JJ o
level NN o
of IN o
A NNP o
beta NN o
40 CD o
and CC N
have VBP N
a DT N
role NN N
in IN N
the DT N
prevention NN N
of IN N
AD NNP N
. . N

-DOCSTART- -24652860- O O

Aerobic NNP i
versus NN i
resistance NN i
training NN i
effects NNS N
on IN N
health-related JJ o
quality NN o
of IN o
life NN o
, , o
body NN o
composition NN o
, , o
and CC o
function NN o
of IN o
older JJR o
adults NNS o
. . o

This DT N
study NN N
aimed VBD N
to TO N
investigate VB N
the DT N
effects NNS N
of IN N
training VBG N
on IN N
health-related JJ o
quality NN o
of IN o
life NN o
( ( o
HRQoL NNP o
) ) o
, , o
body NN o
composition NN o
, , o
and CC o
function NN o
in IN p
older JJR p
adults NNS p
. . p

Fifty JJ p
participants NNS p
were VBD p
randomized VBN p
into IN N
aerobic JJ i
training NN i
( ( N
AT NNP N
-- : N
70 CD N
% NN N
-80 CD N
% NN N
HR NNP N
reserve NN N
) ) N
, , N
resistance NN i
training NN i
( ( N
RT NNP N
-- : N
80 CD N
% NN N
1RM CD N
) ) N
, , N
or CC N
controls NNS i
. . i

They PRP N
had VBD N
HRQoL NNP o
, , o
body NN o
composition NN o
, , o
and CC o
function NN o
assessed VBN N
before IN N
and CC N
after IN N
8 CD N
months NNS N
. . N

Training VBG N
groups NNS N
reduced VBD o
body NN o
fat JJ o
, , o
increased JJ o
performance NN o
in IN o
the DT o
stair NN o
ascent NN o
, , o
8-ft JJ o
up-and-go JJ o
and CC o
sit-to-stand JJ o
five-times JJ o
tests NNS o
, , N
and CC N
improved VBD o
their PRP$ o
physical JJ o
component NN o
score NN o
( ( N
PCS NNP N
; : N
p NN N
? . N
.03 NN N
) ) N
. . N

AT NNP N
increased VBD o
performance NN o
in IN o
the DT N
6MWT CD N
test NN N
, , N
and CC o
improved VBN o
general JJ o
and CC o
mental JJ o
health NN o
( ( o
MH NNP o
) ) o
domains VBZ o
when WRB N
compared VBN N
to TO N
controls NNS N
( ( N
p JJ N
< NNP N
.01 NNP N
) ) N
. . N

Finally RB N
, , N
changes NNS N
in IN N
stair NN N
ascent NN N
were VBD N
associated VBN N
with IN o
changes NNS o
in IN o
bodily RB o
pain NN o
, , o
MH NNP o
, , o
and CC o
mental JJ o
component NN o
score NN o
( ( o
p VB N
? . N
.04 NN N
) ) N
, , N
while IN N
changes NNS o
in IN o
handgrip NN o
strength NN o
were VBD o
associated VBN N
with IN N
changes NNS o
in IN o
physical JJ o
role NN o
and CC o
MH NNP o
( ( N
p JJ N
= NNP N
.03 NNP N
) ) N
. . i

AT NNP i
and CC N
RT NNP i
were VBD N
effective JJ N
interventions NNS N
for IN N
decreasing VBG o
body NN o
fat JJ o
and CC N
improving VBG o
functionality NN o
and CC o
the DT N
PCS NNP o
in IN o
older JJR o
adults NNS o
. . o

-DOCSTART- -20530107- O O

Ventilator-delivered JJ i
mask NN i
ventilation NN i
compared VBN i
with IN i
three CD i
standard JJ i
methods NNS i
of IN i
mask NN i
ventilation NN i
in IN N
a DT N
manikin JJ p
model NN p
. . p

BACKGROUND NNP N
Little NNP N
is VBZ N
known VBN N
regarding VBG N
the DT N
variations NNS N
in IN N
effective JJ o
ventilation NN o
during IN N
bag NN i
and CC i
mask NN i
resuscitation NN i
with IN N
standard JJ N
methods NNS N
compared VBN N
with IN N
that DT N
delivered VBN N
by IN N
ventilator-delivered JJ i
mask NN i
ventilation NN i
( ( i
VDMV NNP i
) ) i
. . i

AIM UH N
To TO N
measure VB N
the DT N
variations NNS o
in IN o
delivered JJ o
airway NN o
pressure NN o
, , o
tidal JJ o
volume NN o
( ( o
TV NN o
) ) o
, , o
minute JJ o
ventilation NN o
( ( o
MV NNP o
) ) o
and CC o
inspiratory JJ o
time NN o
during IN N
a DT N
3-min JJ N
period NN N
of IN N
mask NN N
ventilation NN N
comparing VBG N
VDMV NNP i
with IN N
three CD N
commonly NNS N
used VBD N
hand-delivered JJ i
methods NNS i
of IN i
bag NN i
and CC i
mask NN i
ventilation NN i
: : i
Laerdal JJ i
self-inflating JJ i
bag NN i
( ( i
SIB NNP i
) ) i
; : i
anaesthetic JJ i
bag NN i
and CC i
T-piece NNP i
Neopuff NNP i
. . i

METHODS NNP N
A NNP N
modified JJ p
resuscitation NN p
manikin NN p
was VBD N
used VBN N
to TO N
measure VB N
variation NN o
in IN o
mechanical JJ o
ventilation NN o
during IN N
3-min JJ N
periods NNS N
of IN N
mask NN i
ventilation NN i
. . i

Thirty-six NNP p
experienced VBD p
practitioners NNS p
gave VBD N
positive JJ N
pressure NN N
mask NN i
ventilation NN i
targeting VBG N
acceptable JJ N
chest NN N
wall NN N
movement NN N
with IN N
a DT N
rate NN N
of IN N
60 CD N
inflations/min NNS N
and CC N
when WRB N
pressures NNS N
could MD N
be VB N
targeted VBN N
or CC N
set VBN N
, , N
a DT N
peak JJ o
inspiratory NN o
pressure NN o
( ( o
PIP NNP o
) ) o
of IN N
18 CD N
cm JJ N
water NN N
, , N
positive JJ o
end-expiratory JJ o
pressure NN o
( ( o
PEEP NNP o
) ) o
of IN N
5 CD N
cm JJ N
water NN N
, , N
for IN N
3 CD N
min NNS N
with IN N
each DT N
of IN N
the DT N
four CD N
mask NN i
ventilation NN i
methods NNS N
. . N

Each DT N
mode NN N
was VBD N
randomly RB N
sequenced VBN N
. . N

RESULTS VB N
A DT N
total NN N
of IN N
21 CD N
136 CD N
inflations NNS N
were VBD N
recorded VBN N
and CC N
analysed VBN N
. . N

VDMV NNP i
achieved VBD N
PIP NNP o
and CC N
PEEP NNP o
closest VBP N
to TO N
that DT N
targeted VBN N
and CC N
significantly RB N
lower JJR N
variation NN N
in IN N
all DT N
measured VBN N
parameters NNS N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
other JJ N
than IN N
with IN N
PIP NNP N
. . N

SIB NNP N
delivered VBD N
TV NN o
and CC N
MV NNP o
over IN N
twice RB N
that DT N
delivered VBN N
by IN N
VDMV NNP i
and CC N
Neopuff NNP i
. . i

CONCLUSION NNP N
During IN N
3-min JJ N
periods NNS N
of IN N
mask NN N
ventilation NN N
on IN N
a DT N
manikin NN N
, , N
VDMV NNP i
produced VBD N
the DT N
least JJS N
variation NN N
in IN N
delivered JJ o
ventilation NN o
. . o

SIB NNP N
produced VBD N
wide JJ N
variation NN N
and CC N
unacceptably RB N
high JJ N
TV NN o
and CC N
MV NNP o
in IN N
experienced JJ N
hands NNS N
. . N

-DOCSTART- -10075386- O O

Effects NNS N
of IN N
insufficient JJ i
sleep NN i
on IN N
blood NN o
pressure NN o
in IN N
hypertensive JJ p
patients NNS p
: : p
a DT N
24-h JJ N
study NN N
. . N

The DT N
influence NN N
of IN N
acute JJ N
sleep JJ N
deprivation NN N
during IN N
the DT N
first JJ N
part NN N
of IN N
the DT N
night NN N
on IN N
24-h JJ i
blood NN o
pressure NN o
monitoring NN i
( ( N
ABPM NNP N
) ) N
was VBD N
studied VBN N
in IN N
36 CD p
never-treated JJ p
mild NN p
to TO p
moderate VB p
hypertensive JJ p
patients NNS p
. . p

According VBG N
to TO N
a DT N
crossover NN N
design NN N
, , N
they PRP N
were VBD N
randomized VBN N
to TO N
have VB N
either DT N
sleep JJ i
deprivation NN i
or CC N
a DT N
full JJ i
night NN i
's POS i
sleep NN i
1 CD N
week NN N
apart RB N
, , N
during IN N
which WDT N
they PRP N
were VBD N
monitored VBN N
with IN N
ABPM NNP N
. . N

Urine NNP N
samples NNS N
for IN N
analysis NN N
of IN N
nocturnal JJ N
urinary JJ N
excretion NN o
of IN o
norepinephrine NN o
were VBD N
collected VBN N
. . N

During IN N
the DT N
sleep-deprivation JJ i
day NN N
, , N
both DT N
mean JJ N
24-h JJ N
blood NN o
pressure NN o
and CC N
mean JJ N
24-h JJ N
heart NN o
rate NN N
were VBD N
higher JJR N
in IN N
comparison NN N
with IN N
those DT N
recorded VBN N
during IN N
the DT N
routine JJ N
workday NN N
, , N
the DT N
difference NN N
being VBG N
more RBR N
pronounced JJ N
during IN N
the DT N
nighttime NN N
( ( N
P NNP N
< NNP N
.01 NNP N
) ) N
. . N

Urinary JJ o
excretion NN o
of IN o
norepinephrine NN o
showed VBD N
a DT N
significant JJ N
increase NN N
at IN N
night NN N
during IN N
sleep JJ i
deprivation NN i
( ( N
P NNP N
< NNP N
.05 NNP N
) ) N
. . N

Blood NNP o
pressure NN o
and CC o
heart NN o
rate NN o
significantly RB N
increased VBN N
in IN N
the DT N
morning NN N
after IN N
a DT N
sleep-insufficient JJ i
night NN N
( ( N
P NNP N
< NNP N
.05 NNP N
) ) N
. . N

These DT N
data NNS N
suggest VBP N
that IN N
lack NN N
of IN N
sleep NN N
in IN N
hypertensive JJ N
patients NNS N
may MD N
increase VB N
sympathetic JJ o
nervous JJ o
activity NN o
during IN N
the DT N
night NN N
and CC N
the DT N
following JJ N
morning NN N
, , N
leading VBG N
to TO N
increased VBN N
blood NN o
pressure NN o
and CC o
heart NN o
rate NN o
. . o

This DT N
situation NN N
might MD N
represent VB N
an DT N
increased VBN N
risk NN o
for IN o
both DT o
target NN o
organ JJ o
damage NN o
and CC o
acute JJ o
cardiovascular JJ o
diseases NNS o
. . o

-DOCSTART- -19523697- O O

Loss NNP N
of IN N
autonomy NN N
among IN N
elderly JJ p
patients NNS p
after IN p
a DT p
stay NN p
in IN p
a DT p
medical JJ p
intensive JJ p
care NN p
unit NN p
( ( p
ICU NNP p
) ) p
: : p
a DT N
randomized JJ N
study NN N
of IN N
the DT N
benefit NN N
of IN N
transfer NN N
to TO N
a DT N
geriatric JJ i
ward NN i
. . i

In IN N
order NN N
to TO N
evaluate VB N
changes NNS N
in IN N
the DT N
functional JJ N
autonomy NN N
of IN N
elderly JJ p
patients NNS p
after IN p
a DT p
stay NN p
in IN p
a DT p
medical JJ p
intensive JJ p
care NN p
unit NN p
( ( p
ICU NNP p
) ) p
, , N
and CC N
the DT N
impact NN N
of IN N
post-ICU JJ i
management NN i
in IN N
geriatric JJ i
ward NN i
, , N
we PRP N
included VBD N
in IN N
a DT N
randomized NN N
controlled VBN N
trial NN N
45 CD p
patients NNS p
aged VBN p
> JJ p
or=75 CD p
years NNS p
. . p

They PRP N
were VBD N
assessed VBN N
for IN N
functional JJ N
autonomy NN N
before IN N
ICU NNP N
stay NN N
, , N
just RB N
after IN N
ICU NNP N
discharge NN N
, , N
just RB N
after IN N
hospital JJ N
discharge NN N
, , N
and CC N
6 CD N
months NNS N
later RB N
. . N

The DT N
patients NNS p
were VBD N
randomly RB N
divided VBN N
into IN N
two CD N
post-ICU JJ i
management NN i
groups NNS N
: : N
geriatric JJ i
ward NN i
and CC N
standard JJ i
care NN i
. . N

Autonomy NNP N
was VBD N
usually RB N
recovered VBN N
rapidly RB N
, , N
but CC N
the DT N
degree NN N
of IN N
recovery NN N
depended VBN N
on IN N
the DT N
patient NN N
's POS N
previous JJ N
autonomy NN N
( ( N
p JJ N
< NNP N
0.0001 CD N
) ) N
. . N

At IN N
the DT N
last JJ N
assessment NN N
, , N
41 CD N
% NN N
of IN N
the DT N
patients NNS N
had VBD N
recovered VBN N
their PRP$ N
previous JJ N
autonomy NN N
. . N

The DT N
mean JJ N
Barthel NNP N
indexes NNS N
were VBD N
81.5+/-30.4 JJ N
in IN N
the DT N
geriatric JJ N
management NN N
arm NN N
and CC N
70.5+/-33.4 JJ N
in IN N
the DT N
standard JJ N
management NN N
arm NN N
( ( N
p=0.4 NN N
) ) N
. . N

The DT N
study NN N
was VBD N
prematurely RB N
ended VBN N
due JJ N
to TO N
insufficient JJ N
recruitment NN N
flow NN N
. . N

These DT N
results NNS N
underline VBP N
the DT N
rapid JJ o
loss NN o
of IN o
autonomy NN o
after IN o
a DT o
stay NN o
in IN o
a DT o
medical JJ o
ICU NNP o
. . o

Early NNP o
specific JJ o
intervention NN o
to TO o
improve VB o
the DT o
autonomy NN o
of IN o
elderly JJ o
patients NNS o
seems VBZ o
an DT o
attractive JJ o
solution NN o
that WDT N
could MD N
be VB N
assessed VBN N
by IN N
randomized VBN N
controlled JJ N
trial NN N
. . N

Above IN N
all DT N
, , N
our PRP$ N
results NNS N
should MD N
also RB N
serve VB N
as IN N
a DT N
basis NN N
for IN N
further RB N
controlled VBN N
randomized JJ N
studies NNS N
in IN N
this DT N
setting NN N
. . N

-DOCSTART- -3277760- O O

Randomized VBN N
study NN N
of IN N
six CD p
umbilical JJ i
cord NN i
care NN i
regimens VBZ i
. . i

Comparing VBG N
length NN N
of IN N
attachment NN N
, , N
microbial JJ N
control NN N
, , N
and CC N
satisfaction NN N
. . N

Two CD p
hundred VBD p
and CC p
seventy VB p
one CD p
infants NNS p
were VBD p
enrolled VBN p
in IN p
a DT p
study NN p
to TO p
compare VB p
six CD p
different JJ p
methods NNS p
of IN p
treating VBG p
the DT p
umbilical JJ p
cord NN p
. . p

Antimicrobial NNP N
control NN N
was VBD N
equal JJ N
for IN N
all DT N
methods NNS N
. . N

Repeated VBN N
triple JJ i
dye NN i
application NN i
was VBD N
considered VBN N
least JJS o
acceptable JJ o
by IN N
staff NN N
and CC N
parents NNS N
and CC N
had VBD N
the DT N
longest JJS o
attachment JJ o
time NN o
. . o

Povidone-iodine NN i
was VBD N
associated VBN N
with IN N
the DT N
shortest JJS N
attachment JJ o
time NN o
and CC N
was VBD N
most RBS N
liked JJ N
. . N

If IN N
there EX N
is VBZ N
no DT N
special JJ N
need NN N
to TO N
treat VB N
a DT N
specific JJ o
nosocomial JJ o
outbreak NN o
, , o
duration NN o
of IN o
cord NN o
attachment NN o
and CC o
satisfaction NN o
of IN o
staff NN o
and CC o
parents NNS o
can MD N
help VB N
clinicians NNS N
decide VB N
on IN N
a DT N
cord NN N
care NN N
regimen NNS N
. . N

-DOCSTART- -11013280- O O

Phase NNP N
III NNP N
comparative JJ N
study NN N
of IN N
high-dose JJ i
cisplatin NN i
versus IN N
a DT N
combination NN N
of IN N
paclitaxel NN i
and CC i
cisplatin NN i
in IN N
patients NNS p
with IN p
advanced JJ p
non-small-cell JJ p
lung NN p
cancer NN p
. . p

PURPOSE NNP N
New NNP N
effective JJ N
chemotherapy NN N
is VBZ N
needed VBN N
to TO N
improve VB N
the DT N
outcome NN N
of IN N
patients NNS p
with IN p
advanced JJ p
non-small-cell JJ p
lung NN p
cancer NN p
( ( p
NSCLC NNP p
) ) p
. . p

Paclitaxel NNP i
administered VBD N
as IN N
a DT N
single JJ N
agent NN N
or CC N
in IN N
combination NN N
with IN N
cisplatin NN i
has VBZ N
been VBN N
shown VBN N
to TO N
be VB N
a DT N
potentially RB N
new JJ N
useful JJ N
agent NN N
for IN N
the DT N
treatment NN N
of IN N
NSCLC NNP N
. . N

PATIENTS NNP N
AND CC N
METHODS NNP N
Between NNP p
January NNP p
1995 CD p
and CC p
April NNP p
1996 CD p
, , p
414 CD p
patients NNS p
with IN p
stage NN p
IIIB NNP p
or CC p
IV NNP p
NSCLC NNP p
were VBD p
randomized VBN p
to TO p
received VB p
either RB p
a DT p
control NN p
arm NN p
of IN p
high-dose JJ i
cisplatin NN i
( ( p
100 CD p
mg/m NN p
( ( p
2 CD p
) ) p
) ) p
or CC p
a DT p
combination NN i
of IN i
paclitaxel NN i
( ( i
175 CD i
mg/m NN i
( ( i
2 CD i
) ) i
, , i
3-hour JJ i
infusion NN i
) ) i
and CC i
cisplatin NN i
( ( p
80 CD p
mg/m NN p
( ( p
2 CD p
) ) p
) ) p
every DT p
21 CD p
days NNS p
. . p

RESULTS NNP N
Compared VBD N
with IN N
the DT N
cisplatin-only JJ N
arm NN N
, , N
there EX N
was VBD N
a DT N
9 CD N
% NN N
improvement NN N
( ( N
95 CD N
% NN N
confidence NN N
interval NN N
, , N
0 CD N
% NN N
to TO N
19 CD N
% NN N
) ) N
in IN N
overall JJ o
response NN o
rate NN o
for IN N
the DT N
paclitaxel/cisplatin NN i
arm NN N
( ( N
17 CD N
% NN N
v JJ N
26 CD N
% NN N
, , N
respectively RB N
; : N
P=.028 NNP N
) ) N
. . N

Median JJ o
time NN o
to TO o
progression NN o
was VBD N
2.7 CD N
and CC N
4.1 CD N
months NNS N
in IN N
the DT N
control NN N
and CC N
paclitaxel/cisplatin NN i
arm NN N
, , N
respectively RB N
( ( N
P=.026 NNP N
) ) N
. . N

The DT N
study NN N
, , N
however RB N
, , N
failed VBD N
to TO N
show VB N
a DT N
significant JJ N
improvement NN N
in IN N
median JJ o
survival NN o
for IN N
the DT N
paclitaxel/cisplatin NN i
arm NN N
( ( N
8.6 CD N
months NNS N
in IN N
the DT N
control NN N
arm NN N
v NN N
8.1 CD N
months NNS N
in IN N
the DT N
paclitaxel/cisplatin NN N
arm NN N
, , N
P=.862 NNP N
) ) N
. . N

There EX N
was VBD N
more JJR N
hematotoxicity NN o
, , o
peripheral JJ o
neuropathy NN o
, , o
and CC o
arthralgia/myalgia NN o
on IN N
the DT N
paclitaxel/cisplatin NN i
arm NN N
, , N
whereas IN N
the DT N
high-dose JJ N
cisplatin NN i
arm NN N
produced VBD N
more JJR N
ototoxicity NN o
, , o
nausea NN o
, , o
vomiting NN o
, , o
and CC o
nephrotoxicity NN o
. . o

Quality NN o
of IN o
life NN o
( ( o
QOL NNP o
) ) o
was VBD N
similar JJ N
overall JJ N
between IN N
the DT N
two CD N
arms NNS N
. . N

CONCLUSION NN N
This DT N
large JJ N
randomized JJ N
phase NN N
III NNP N
trial NN N
failed VBD N
to TO N
show VB N
a DT N
significant JJ N
improvement NN N
in IN N
survival NN N
for IN N
the DT N
paclitaxel/cisplatin NN i
combination NN N
compared VBN N
with IN N
high-dose JJ N
cisplatin NN i
in IN N
patients NNS N
with IN N
advanced JJ N
NSCLC NNP N
. . N

However RB N
, , N
the DT N
paclitaxel/cisplatin NN i
combination NN N
did VBD N
produce VB N
a DT N
better JJR N
clinical JJ N
response NN N
, , N
resulting VBG N
in IN N
an DT N
increased JJ N
time NN N
to TO N
progression NN N
while IN N
providing VBG N
a DT N
similar JJ N
QOL NNP N
. . N

-DOCSTART- -25029834- O O

[ JJ N
Case-controll NNP N
study NN N
on IN N
the DT N
synergistic JJ o
effects NNS o
of IN N
electroacupuncture NN i
on IN N
knee NN N
osteoarthritis NN N
after IN N
arthroscopic JJ i
debridement NN i
] NN i
. . N

OBJECTIVE UH N
To TO N
study VB N
the DT N
synergistic JJ o
effects NNS o
of IN N
electroacupuncture NN i
on IN N
the DT N
treatment NN N
of IN N
knee NN N
osteoarthritis NN N
after IN N
arthroscopic JJ i
debridement NN i
. . i

METHODS NNP N
From NNP N
May NNP p
2008 CD p
to TO p
July NNP p
2010 CD p
, , p
78 CD p
patients NNS p
with IN p
knee JJ p
osteoarthritis NN p
were VBD N
randomly RB N
divided VBN N
into IN N
two CD N
groups NNS N
. . N

There EX N
were VBD N
42 CD p
patients NNS p
in IN p
the DT p
experimental JJ p
group NN p
, , p
including VBG p
16 CD p
males NNS p
and CC p
26 CD p
females NNS p
, , p
ranging VBG p
in IN p
age NN p
from IN p
41 CD p
to TO p
63 CD p
years NNS p
, , p
with IN p
an DT p
average NN p
of IN p
( ( p
53.62 CD p
+/- JJ p
6.53 CD p
) ) p
years NNS p
; : p
the DT p
disease NN p
course NN p
ranged VBD p
from IN p
8 CD p
to TO p
24 CD p
months NNS p
, , p
with IN p
an DT p
average NN p
of IN p
( ( p
10.35 CD p
+/- JJ p
6.42 CD p
) ) p
months NNS p
. . p

The DT N
patients NNS N
were VBD N
treated VBN N
with IN N
arthroscopic JJ i
debridement NN i
combined VBN i
with IN i
electroacupuncture NN i
after IN i
operation NN i
. . i

There EX N
were VBD N
36 CD p
patients NNS p
in IN p
the DT p
control NN p
group NN p
, , p
including VBG p
14 CD p
males NNS p
and CC p
22 CD p
females NNS p
, , p
ranging VBG p
in IN p
age NN p
from IN p
40 CD p
to TO p
62 CD p
years NNS p
, , p
with IN p
an DT p
average NN p
of IN p
( ( p
54.34 CD p
+/- JJ p
7.67 CD p
) ) p
years NNS p
; : p
the DT p
disease NN o
course NN o
ranged VBD p
from IN p
6 CD p
to TO p
25 CD p
months NNS p
, , p
with IN p
an DT p
average NN p
of IN p
( ( p
11.94 CD p
+/- JJ p
5.13 CD p
) ) p
months NNS p
. . p

Those DT N
patients NNS N
were VBD N
treated VBN N
only RB N
with IN N
arthroscopic JJ i
debridment NN i
. . i

All PDT N
the DT N
patients NNS N
performed VBD N
isometric JJ i
quadriceps NNS i
femoris JJ i
contraction NN i
exercise NN i
and CC i
knee NN i
flexion NN i
and CC i
extension NN i
activities NNS i
after IN i
operation NN i
. . i

The DT N
visual JJ o
analog NN o
scale NN o
( ( o
VAS NNP o
) ) o
score NN o
and CC o
Lysholm NNP o
knee VBD o
score NN o
were VBD N
used VBN N
to TO N
evaluate VB N
the DT N
therapeutic JJ N
effects NNS N
. . N

RESULTS NNP N
All PDT N
the DT N
patients NNS N
were VBD N
followed VBN N
up RP N
, , N
and CC N
the DT N
duration NN N
ranged VBD N
from IN N
12 CD N
to TO N
30 CD N
months NNS N
, , N
with IN N
an DT N
average NN N
of IN N
15.6 CD N
months NNS N
. . N

At IN N
the DT N
final JJ N
follow-up NN N
, , N
VAS NNP o
score NN o
was VBD N
significantly RB N
decreased VBN N
, , N
and CC N
the DT N
Lysholm NNP o
score NN o
, , N
except IN N
for IN N
the DT N
item NN N
demanding VBG N
for IN N
support NN N
, , N
significantly RB N
increased VBN N
, , N
compared VBN N
with IN N
those DT N
before IN N
surgery NN N
respectively RB N
in IN N
both DT N
groups NNS N
. . N

There EX N
was VBD N
significant JJ N
difference NN N
in IN N
VAS NNP o
score NN o
between IN N
two CD N
groups NNS N
after IN N
treatment NN N
. . N

As IN N
to TO N
Lysholm NNP o
score NN o
, , N
there EX N
were VBD N
significant JJ N
differences NNS N
in IN N
limp NN o
, , o
pain NN o
, , o
swelling VBG o
, , o
stair NN o
activity NN o
and CC o
squat NN o
, , N
but CC N
there EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
items NNS N
of IN N
interlocking VBG o
and CC o
instability NN o
between IN N
two CD N
groups NNS N
after IN N
treatment NN N
. . N

CONCLUSION NNP N
Electroacupuncture NNP N
can MD N
effectively RB N
improve VB N
the DT N
clinical JJ o
symptoms NNS o
and CC N
knee VB N
joint NN N
's POS N
motor NN o
function NN o
of IN o
knee NN o
joints NNS o
in IN N
patients NNS N
with IN p
knee JJ p
osteoarthritis NN p
, , N
as RB N
well RB N
as IN N
the DT N
synergistic JJ N
effects NNS N
on IN N
the DT N
treatment NN N
of IN N
knee NN N
osteoarthritis NN N
after IN N
arthroscopic JJ N
debridement NN N
, , N
leading VBG N
to TO N
a DT N
much RB N
better JJR N
long-term JJ N
therapeutic JJ N
effect NN N
with IN N
respect NN N
of IN N
improving VBG N
the DT N
function NN N
of IN N
knee NN N
joint NN N
. . N

This DT N
therapy NN N
, , N
combined VBN N
with IN N
traditional JJ N
Chinese JJ N
medicine NN N
and CC N
Western JJ N
Medicine NNP N
, , N
is VBZ N
worth IN N
of IN N
clinical JJ N
application NN N
in IN N
the DT N
treatment NN N
of IN N
knee NN N
osteoarthritis NN N
. . N

-DOCSTART- -19622708- O O

A DT N
psychological JJ i
intervention NN i
reduces NNS N
inflammatory JJ o
markers NNS o
by IN N
alleviating VBG N
depressive JJ o
symptoms NNS o
: : o
secondary JJ N
analysis NN N
of IN N
a DT N
randomized VBN N
controlled VBN N
trial NN N
. . N

OBJECTIVES UH N
To TO N
test VB N
experimentally RB N
whether IN N
a DT N
psychological JJ i
intervention NN i
reduces NNS N
depression-related JJ N
symptoms NNS N
and CC N
markers NNS N
of IN N
inflammation NN N
among IN N
cancer NN p
patients NNS p
and CC N
to TO N
test VB N
one CD N
mechanism NN N
for IN N
the DT N
intervention NN N
effects NNS N
. . N

Depression NNP N
and CC N
inflammation NN N
are VBP N
common JJ N
among IN N
cancer NN p
patients NNS p
. . p

Data NNP N
suggest NN N
that IN N
inflammation NN N
can MD N
contribute VB N
to TO N
depressive VB o
symptoms NNS o
, , N
although IN N
the DT N
converse NN N
remains VBZ N
untested JJ N
. . N

METHODS NNP N
As IN N
part NN N
of IN N
a DT N
randomized JJ N
clinical JJ N
trial NN N
, , N
newly RB p
diagnosed VBN p
breast NN p
cancer NN p
patients NNS p
( ( p
n JJ p
= NNP p
45 CD p
) ) p
with IN p
clinically RB p
significant JJ p
depressive JJ p
symptoms NNS p
were VBD N
evaluated VBN N
and CC N
randomized VBN N
to TO N
psychological JJ i
intervention NN i
with IN i
assessment NN i
or CC i
assessment NN i
only RB i
study VBD i
arms NNS N
. . N

The DT N
intervention NN N
spanned VBD N
12 CD N
months NNS N
, , N
with IN N
assessments NNS N
at IN N
baseline NN N
, , N
4 CD N
, , N
8 CD N
, , N
and CC N
12 CD N
months NNS N
. . N

Mixed-effects NNS N
modeling VBG N
tested VBD N
the DT N
hypothesis NN N
that IN N
the DT N
intervention NN N
reduced VBD N
self-reported JJ o
depressive NN o
symptoms NNS o
( ( N
Center NNP N
for IN N
Epidemiological NNP N
Studies NNPS N
Depression NNP N
scale NN N
, , N
Profile NNP N
of IN N
Mood NNP N
States NNPS N
Depression NNP N
and CC N
Fatigue NNP N
subscales NNS N
, , N
and CC N
Medical NNP N
Outcomes NNP N
Study-Short NNP N
Form NNP N
36 CD N
Bodily NNP N
Pain NNP N
subscale NN N
) ) N
and CC N
immune JJ o
cell NN o
numbers NNS o
that WDT N
are VBP N
elevated VBN N
in IN N
the DT N
presence NN N
of IN N
inflammation NN N
( ( N
white JJ N
blood NN N
cell NN N
count NN N
, , N
neutrophil JJ N
count NN N
, , N
and CC N
helper/suppressor VB N
ratio NN N
) ) N
. . N

Mediation NN N
analyses NNS N
tested VBD N
whether IN N
change NN o
in IN o
depressive JJ o
symptoms NNS o
, , o
pain NN o
, , o
or CC o
fatigue NN o
predicted VBN o
change NN o
in IN o
white JJ o
blood NN o
cell NN o
count NN o
, , o
neutrophil JJ o
count NN o
, , o
or CC o
the DT o
helper/suppressor NN o
ratio NN o
. . o

RESULTS VB N
The DT N
intervention NN N
reduced VBD N
significantly RB N
depressive JJ o
symptoms NNS o
, , o
pain NN o
, , o
fatigue NN o
, , o
and CC o
inflammation NN o
markers NNS o
. . o

Moreover RB N
, , N
the DT N
intervention NN N
effect NN N
on IN N
inflammation NN o
was VBD N
mediated VBN N
by IN N
its PRP$ N
effect NN N
on IN N
depressive NN N
symptoms NNS N
. . N

CONCLUSIONS VB N
This DT N
is VBZ N
the DT N
first JJ N
experiment NN N
to TO N
test VB N
whether IN N
psychological JJ N
treatment NN N
effective JJ N
in IN N
reducing VBG N
depressive JJ o
symptoms NNS o
would MD N
also RB N
reduce VB N
indicators NNS N
of IN N
inflammation NN N
. . N

Data NNP N
show NN N
that IN N
the DT N
intervention NN N
reduced VBD N
directly RB N
depressive JJ o
symptoms NNS o
and CC N
reduced VBN N
indirectly RB N
inflammation NN o
. . o

Psychological JJ N
treatment NN N
may MD N
treat VB N
effectively RB N
depressive JJ o
symptoms NNS o
, , o
pain NN o
, , o
and CC o
fatigue NN o
among IN N
cancer NN p
patients NNS p
. . p

-DOCSTART- -22586827- O O

The DT N
effect NN N
of IN N
the DT N
PostureJac NNP i
on IN N
deep JJ o
cervical JJ o
flexor NN o
endurance NN o
: : o
implications NNS N
in IN N
the DT N
management NN N
of IN N
cervicogenic JJ o
headache NN o
and CC N
mechanical JJ o
neck NN o
pain NN o
. . o

The DT N
convergence NN N
of IN N
cervical JJ N
and CC N
trigeminal JJ N
afferents NNS N
on IN N
second-order JJ N
neurons NNS N
in IN N
the DT N
trigeminocervical JJ N
nucleus NN N
may MD N
refer VB N
pain NN N
from IN N
the DT N
upper JJ N
cervical JJ N
spine NN N
into IN N
the DT N
head NN N
and CC N
face NN N
. . N

Furthermore RB N
, , N
bi-directional JJ N
interactions NNS N
between IN N
trigeminal JJ N
and CC N
upper JJ N
cervical JJ N
afferents NNS N
may MD N
also RB N
explain VB N
neck NN N
symptoms NNS N
of IN N
trigeminal JJ N
origin NN N
( ( N
e.g. JJ N
, , N
migraine NN N
) ) N
. . N

It PRP N
is VBZ N
known VBN N
that IN N
cervicogenic JJ N
headache NN N
sufferers NNS N
present JJ N
with IN N
several JJ N
musculoskeletal JJ N
changes NNS N
including VBG N
poor JJ N
endurance NN N
of IN N
the DT N
deep JJ N
cervical JJ N
flexor NN N
muscles NNS N
. . N

These DT N
intrinsic JJ N
muscles NNS N
of IN N
the DT N
neck NN N
contribute NN N
to TO N
stabilization NN N
and CC N
protection NN N
of IN N
the DT N
cervical JJ N
spine NN N
and CC N
are VBP N
critical JJ N
for IN N
the DT N
control NN N
of IN N
both DT N
intervertebral JJ N
motion NN N
and CC N
the DT N
cervical JJ N
lordosis NN N
. . N

The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
determine VB N
whether IN N
the DT N
use NN N
of IN N
the DT N
PostureJac NNP i
( ( N
SomatoCentric NNP N
Systems NNP N
, , N
Inc. NNP N
, , N
Toronto NNP N
, , N
Ontario NNP N
, , N
Canada NNP N
) ) N
, , N
a DT N
posture NN N
support NN N
and CC N
exercise NN N
jacket NN N
, , N
was VBD N
effective JJ N
in IN N
enhancing VBG N
deep JJ o
cervical JJ o
muscle NN o
endurance NN o
. . o

Forty-five JJ p
( ( p
45 CD p
) ) p
female NN p
subjects NNS p
, , p
between IN p
the DT p
ages NNS p
of IN p
18 CD p
and CC p
40 CD p
years NNS p
, , N
were VBD N
randomly RB N
assigned VBN N
to TO N
three CD N
groups NNS N
consisting VBG N
of IN N
the DT N
no-treatment JJ i
control NN i
, , p
the DT p
treatment-control NN i
( ( i
table JJ i
stabilization NN i
) ) i
, , i
and CC i
the DT i
experimental JJ i
( ( i
PostureJac NNP i
) ) i
group NN i
. . i

The DT N
outcome JJ N
measure NN N
of IN N
deep JJ o
cervical JJ o
flexor NN o
muscle NN o
endurance NN o
was VBD N
based VBN N
on IN N
the DT N
Flexor NNP o
Endurance NNP o
Test NNP o
and CC N
was VBD N
recorded VBN N
in IN N
seconds NNS N
. . N

The DT N
results NNS N
indicated VBD N
that IN N
the DT N
PostureJac NNP i
group NN p
was VBD N
superior JJ N
to TO N
the DT N
no-treatment JJ p
control NN p
( ( p
p=.001 NN p
) ) p
and CC p
the DT p
treatment-control NN p
( ( p
p=.004 NN p
) ) p
groups NNS p
in IN N
terms NNS N
of IN N
increasing VBG N
endurance NN o
of IN o
the DT o
deep JJ o
cervical JJ o
flexors NNS o
. . o

Consequently RB N
, , N
the DT N
PostureJac NNP i
may MD N
be VB N
a DT N
useful JJ N
therapeutic JJ N
tool NN N
in IN N
the DT N
management NN N
of IN N
cervicogenic JJ o
headache NN o
and CC o
mechanical JJ o
neck NN o
pain NN o
. . o

-DOCSTART- -22136317- O O

Outcomes NNS N
of IN N
Japanese JJ p
breast NN p
cancer NN p
patients NNS p
treated VBN N
with IN N
pre-operative JJ i
and CC i
post-operative JJ i
anastrozole NN i
or CC i
tamoxifen NN i
. . i

The DT N
present JJ N
study NN N
examined VBD N
long-term JJ N
efficacy NN o
outcomes NNS o
in IN N
a DT N
subgroup NN p
of IN p
postmenopausal NN p
, , p
estrogen VBP p
receptor-positive JJ p
Japanese JJ p
breast NN p
cancer NN p
patients NNS p
from IN p
the DT p
Pre-Operative JJ i
Arimidex NNP i
Compared NNP p
with IN p
Tamoxifen NNP i
trial NN p
, , N
following VBG i
pre-operative JJ i
( ( i
3 CD i
months NNS i
) ) i
and CC i
post-operative JJ i
( ( i
5 CD i
years NNS i
) ) i
adjuvant VBP i
treatment NN i
with IN i
either DT i
anastrozole NN i
or CC i
tamoxifen NN i
. . i

Patients NNS p
with IN p
large JJ p
, , p
potentially RB p
operable JJ p
, , p
locally-advanced JJ p
breast NN p
cancer NN p
were VBD N
randomized VBN N
to TO N
receive VB i
anastrozole NN i
( ( i
1 CD i
mg/day NN i
) ) i
plus CC i
tamoxifen JJ i
placebo NN i
or CC i
tamoxifen NN i
( ( i
20 CD i
mg/day NN i
) ) i
plus CC i
anastrozole JJ i
placebo NN i
pre-operatively RB i
. . i

After IN N
surgery NN N
at IN N
3 CD N
months NNS N
, , N
patients NNS i
continued VBD i
on IN i
the DT i
same JJ i
study NN i
medication NN i
as IN i
adjuvant JJ i
therapy NN i
for IN i
up IN i
to TO i
5 CD i
years NNS i
or CC i
until IN i
recurrence NN i
, , i
intolerable JJ i
toxicity NN i
or CC i
withdrawal NN i
of IN i
patient JJ i
consent NN i
. . i

Recurrence-free JJ o
survival NN o
and CC o
overall JJ o
survival NN o
were VBD N
measured VBN N
from IN N
the DT N
date NN N
of IN N
randomization NN N
to TO N
the DT N
date NN N
of IN N
recurrence NN N
or CC N
death NN N
, , N
whichever WDT N
occurred VBD N
first RB N
. . N

Patients NNS N
were VBD N
monitored VBN N
for IN N
adverse JJ o
events NNS o
throughout IN N
the DT N
study NN N
period NN N
and CC N
up RB N
to TO N
30 CD N
days NNS N
following VBG N
administration NN N
of IN N
the DT N
last JJ N
study NN N
medication NN N
. . N

During IN N
post-operative JJ N
adjuvant JJ N
therapy NN N
, , N
4/48 CD N
( ( N
8 CD N
% NN N
) ) N
anastrozole NN i
and CC N
25/49 CD N
( ( N
51 CD N
% NN N
) ) N
tamoxifen NN i
patients NNS N
experienced VBD N
recurrence NN o
. . o

There EX N
was VBD N
a DT N
significant JJ N
difference NN N
in IN N
recurrence-free JJ o
survival NN o
between IN N
the DT N
two CD N
groups NNS N
( ( N
hazard JJ N
ratio NN N
0.14 CD N
; : N
95 CD N
% NN N
confidence NN N
interval JJ N
0.05-0.41 NN N
; : N
P NNP N
= NNP N
0.0003 CD N
) ) N
. . N

There EX N
was VBD N
a DT N
significant JJ N
increase NN N
in IN N
overall JJ o
survival NN o
with IN N
anastrozole NN i
( ( N
0.21 CD N
; : N
0.05-0.96 CD N
; : N
P NNP N
= NNP N
0.0436 CD N
) ) N
and CC N
there EX N
were VBD N
2/48 CD N
( ( N
4 CD N
% NN N
) ) N
and CC N
10/49 CD N
( ( N
20 CD N
% NN N
) ) N
deaths NNS o
with IN N
anastrozole JJ i
and CC i
tamoxifen NN i
, , N
respectively RB N
. . N

Most JJS N
patients NNS N
responding VBG N
to TO N
pre-operative JJ N
therapy NN N
remained VBD N
recurrence-free JJ o
. . o

Sequential JJ N
pre-operative/post-operative JJ N
treatment NN N
with IN N
anastrozole JJ i
resulted VBN N
in IN N
lower JJR N
recurrence NN o
and CC N
death NN o
rates NNS o
, , N
compared VBN N
with IN N
tamoxifen NN i
. . i

-DOCSTART- -9703286- O O

Therapy NNP o
effect NN o
of IN N
either CC N
paclitaxel NN i
or CC i
cyclophosphamide JJ i
combination NN i
treatment NN i
in IN N
patients NNS p
with IN p
epithelial JJ p
ovarian JJ p
cancer NN p
and CC p
relation NN p
to TO p
TP53 NNP p
gene NN p
status NN p
. . p

Cell NNP N
death NN N
after IN N
treatment NN N
with IN N
chemotherapy NN i
is VBZ N
exerted VBN N
by IN N
activation NN N
of IN N
apoptosis NN N
, , N
and CC N
the DT N
p53 NN N
protein NN N
has VBZ N
been VBN N
shown VBN N
to TO N
actively RB N
participate VB N
in IN N
this DT N
process NN N
. . N

This DT N
recent JJ N
focus NN N
on IN N
TP53 NNP o
status NN o
as IN N
a DT N
possible JJ N
determinant NN N
of IN N
cancer NN N
therapy NN N
response NN N
has VBZ N
raised VBN N
the DT N
question NN N
of IN N
whether IN N
or CC N
not RB N
mutations NNS N
in IN N
the DT N
TP53 NNP N
gene NN N
have VBP N
an DT N
influence NN N
on IN N
paclitaxel NN i
therapy NN i
. . i

The DT N
TP53 NNP o
status NN o
has VBZ N
been VBN N
analysed VBN N
at IN N
the DT N
DNA NNP N
level NN N
in IN N
tumours NNS N
from IN N
45 CD p
ovarian JJ p
cancer NN p
patients NNS p
randomized VBN p
to TO p
treatment NN p
with IN N
paclitaxel NN i
and CC i
cisplatin NN i
or CC i
cyclophosphamide NN i
and CC i
cisplatin NN i
. . i

Therapy NNP o
response NN o
was VBD N
obtained VBN N
for IN N
38 CD p
patients NNS p
with IN p
clinically RB p
evaluable JJ p
disease NN p
after IN p
initial JJ p
surgery NN p
. . p

The DT N
positive JJ o
response NN o
rate NN o
to TO N
the DT N
paclitaxel/cisplatin NN i
therapy NN i
was VBD N
85 CD N
% NN N
vs JJ N
61 CD N
% NN N
for IN N
the DT N
patients NNS N
who WP N
received VBD N
the DT N
cyclophosphamide/cisplatin JJ i
regimen NNS N
. . N

A DT N
significant JJ N
difference NN N
in IN N
relapse-free JJ o
survival NN o
in IN N
favour NN N
of IN N
paclitaxel/cisplatin NN i
chemotherapy NN i
was VBD N
found VBN N
( ( N
P NNP N
= NNP N
0.001 CD N
) ) N
. . N

A DT N
total NN N
of IN N
33 CD N
tumour NN N
samples NNS N
( ( N
73 CD N
% NN N
) ) N
had VBD N
detectable JJ N
sequence NN o
alterations NNS o
in IN o
the DT o
TP53 NNP o
gene NN o
. . o

When WRB N
relapse-free JJ o
survival NN o
was VBD N
estimated VBN N
for IN N
all DT N
patients NNS N
with IN N
TP53 NNP o
alterations NNS o
in IN N
their PRP$ N
tumours NNS N
, , N
a DT N
significant JJ N
better RBR N
outcome NN N
for IN N
the DT N
paclitaxel/cisplatin NN i
group NN N
was VBD N
found VBN N
compared VBN N
with IN N
the DT N
patient NN N
group NN N
receiving VBG N
cyclophosphamide NN i
and CC N
cisplatin NN i
therapy NN i
( ( N
P NNP N
= NNP N
0.002 CD N
) ) N
. . N

We PRP N
did VBD N
not RB N
observe VB N
an DT N
association NN N
between IN N
TP53 NNP o
tumour NN o
status NN o
and CC N
prognosis NN o
for IN N
patients NNS N
who WP N
received VBD N
paclitaxel/cisplatin JJ i
combination NN N
treatment NN N
, , N
indicating VBG N
that IN N
the DT N
effect NN N
of IN N
this DT N
therapy NN N
is VBZ N
not RB N
influenced VBN N
by IN N
this DT N
parameter NN N
. . N

-DOCSTART- -19853700- O O

Patterns NNS N
of IN N
management NN p
of IN p
atrial JJ p
fibrillation NN p
complicating VBG p
coronary JJ p
artery NN p
bypass NN p
grafting NN p
: : p
Results NNS N
from IN N
the DT N
PRoject NN N
of IN N
Ex-vivo NNP N
Vein NNP N
graft NN N
ENgineering NNP N
via IN N
Transfection NNP N
IV NNP N
( ( N
PREVENT-IV NNP N
) ) N
Trial NNP N
. . N

BACKGROUND NNP N
Current NNP N
practice NN N
related VBD N
to TO N
the DT N
management NN p
of IN p
atrial JJ o
fibrillation NN o
( ( o
AF NNP o
) ) o
complicating VBG p
coronary JJ p
artery NN p
bypass NN p
grafting NN p
( ( p
CABG NNP p
) ) p
is VBZ N
uncertain JJ N
. . N

METHODS NNP N
We PRP N
examined VBD N
management NN N
of IN N
post-CABG JJ p
AF NNP p
in IN p
the DT p
PREVENT-IV NNP p
trial NN p
, , N
and CC N
we PRP N
explored VBD N
patterns NNS N
of IN N
use NN N
of IN N
postoperative JJ i
rhythm NNS i
versus JJ i
rate NN i
control NN i
and CC i
anticoagulation NN i
for IN i
AF NNP o
by IN i
geographic JJ i
region NN i
and CC i
type NN i
of IN i
site NN i
. . i

We PRP N
also RB N
compared VBN N
outcomes NNS N
of IN N
patients NNS p
who WP p
developed VBD p
post-CABG JJ p
AF NNP p
( ( p
663 CD p
) ) p
with IN p
those DT p
who WP p
did VBD p
not RB p
( ( p
2,131 CD p
) ) p
. . p

RESULTS VB N
The DT N
incidence NN N
of IN N
AF NNP o
was VBD N
24 CD N
% NN N
. . N

Post-CABG JJ o
AF NNP o
was VBD N
treated VBN N
with IN N
a DT N
rhythm NN N
control NN N
strategy NN N
in IN N
81 CD N
% NN N
of IN N
patients NNS N
and CC N
with IN N
warfarin NN i
in IN N
23 CD N
% NN N
of IN N
patients NNS N
. . N

Although IN N
there EX N
were VBD N
significant JJ N
variations NNS N
across IN N
sites NNS N
in IN N
the DT N
management NN N
of IN N
post-CABG JJ o
AF NNP o
, , N
patterns NNS N
of IN N
use NN N
of IN N
postoperative JJ N
rhythm NNS N
versus JJ N
rate NN N
control NN N
and CC N
anticoagulation NN N
did VBD N
not RB N
differ VB N
by IN N
geographic JJ N
region NN N
or CC N
by IN N
whether IN N
or CC N
not RB N
the DT N
enrolling VBG N
site NN N
was VBD N
an DT N
academic JJ N
institution NN N
. . N

Mortality NNP o
was VBD N
higher RBR N
in IN N
patients NNS p
with IN p
post-CABG JJ p
AF NNP N
than IN N
patients NNS p
without IN p
AF NNP p
at IN N
30 CD N
days NNS N
( ( N
1.5 CD N
% NN N
vs JJ N
0.7 CD N
% NN N
, , N
P NNP N
= NNP N
.01 NNP N
) ) N
but CC N
not RB N
at IN N
3 CD N
years NNS N
( ( N
6.9 CD N
% NN N
vs JJ N
4.9 CD N
% NN N
, , N
P NNP N
= NNP N
.41 NNP N
) ) N
. . N

There EX N
was VBD N
a DT N
trend NN N
toward IN N
a DT N
higher JJR N
risk NN o
of IN N
mortality NN o
or CC o
stroke NN o
at IN N
30 CD N
days NNS N
in IN N
patients NNS p
with IN p
AF NNP p
( ( N
2.4 CD N
% NN N
vs JJ N
1.9 CD N
% NN N
, , N
P NNP N
= NNP N
.08 NNP N
) ) N
. . N

CONCLUSION NNP N
Although IN N
a DT N
rhythm NN N
control NN N
strategy NN N
was VBD N
used VBN N
in IN N
most JJS N
of IN N
the DT N
patients NNS N
in IN N
this DT N
trial NN N
and CC N
the DT N
overall JJ N
rate NN N
of IN N
use NN N
of IN N
warfarin NN N
was VBD N
low JJ N
, , N
the DT N
significance NN N
of IN N
these DT N
findings NNS N
is VBZ N
uncertain JJ N
because IN N
of IN N
the DT N
lack NN N
of IN N
data NNS N
from IN N
randomized JJ N
clinical JJ N
trials NNS N
. . N

The DT N
substantial JJ N
variations NNS N
in IN N
the DT N
management NN N
of IN N
post-CABG JJ N
AF NNP N
across IN N
sites NNS N
are VBP N
likely JJ N
because IN N
of IN N
definitive JJ N
data NNS N
on IN N
the DT N
most RBS N
effective JJ N
therapies NNS N
, , N
highlighting VBG N
the DT N
need NN N
for IN N
clinical JJ N
trials NNS N
on IN N
rate NN N
versus IN N
rhythm NN N
control NN N
and CC N
on IN N
anticoagulation NN N
for IN N
AF NNP N
in IN N
this DT N
setting NN N
. . N

-DOCSTART- -21131142- O O

Human NNP N
psychopharmacology NN N
and CC N
dose-effects NNS N
of IN N
salvinorin NN i
A NNP i
, , N
a DT N
kappa NN N
opioid JJ N
agonist NN N
hallucinogen NN N
present NN N
in IN N
the DT N
plant NN N
Salvia NNP N
divinorum NN N
. . N

Salvinorin VB i
A DT i
is VBZ N
a DT N
potent NN N
, , N
selective JJ N
nonnitrogenous JJ N
kappa NN N
opioid JJ N
agonist NN N
and CC N
the DT N
known VBN N
psychoactive JJ N
constituent NN N
of IN N
Salvia NNP N
divinorum NN N
, , N
a DT N
member NN N
of IN N
the DT N
mint NN N
family NN N
that WDT N
has VBZ N
been VBN N
used VBN N
for IN N
centuries NNS N
by IN N
Mazatec NNP N
shamans NNS N
of IN N
Mexico NNP N
for IN N
divination NN N
and CC N
spiritual JJ N
healing NN N
. . N

S. NNP N
divinorum NN N
has VBZ N
over RP N
the DT N
last JJ N
several JJ N
years NNS N
gained VBD N
increased JJ N
popularity NN N
as IN N
a DT N
recreational JJ N
drug NN N
. . N

This DT N
is VBZ N
a DT N
double-blind JJ N
, , N
placebo NN i
controlled VBD N
study NN N
of IN N
salvinorin NN i
A NNP i
in IN N
4 CD p
psychologically RB p
and CC p
physically RB p
healthy JJ p
hallucinogen-using NN p
adults NNS p
. . p

Across IN N
sessions NNS N
, , N
participants NNS N
inhaled VBD N
16 CD N
ascending VBG N
doses NNS N
of IN N
salvinorin NN i
A NNP i
and CC i
4 CD i
intermixed JJ i
placebo NN i
doses NNS N
under IN N
comfortable JJ N
and CC N
supportive JJ N
conditions NNS N
. . N

Doses NNS N
ranged VBD N
from IN N
0.375 CD N
?g/kg NNS N
to TO N
21 CD N
?g/kg NNS o
. . o

Subject-rated JJ o
drug NN o
strength NN o
was VBD o
assessed VBN N
every DT N
2 CD N
min NN N
for IN N
60 CD N
min NN N
after IN N
inhalation NN o
. . o

Orderly JJ o
time- JJ o
and CC o
dose-related JJ o
effects NNS o
were VBD o
observed VBN o
. . o

Drug NNP o
strength NN o
ratings NNS o
peaked VBD o
at IN N
2 CD N
min NN N
( ( N
first JJ N
time NN N
point NN N
) ) N
and CC N
definite JJ N
subjective JJ N
effects NNS N
were VBD N
no RB N
longer RBR N
present JJ N
at IN N
approximately RB N
20 CD N
min NNS N
after IN N
inhalation NN N
. . N

Dose-related JJ N
increases NNS N
were VBD N
observed VBN N
on IN N
questionnaire NN o
measures NNS o
of IN o
mystical-type JJ o
experience NN o
( ( o
Mysticism NNP o
Scale NNP o
) ) o
and CC o
subjective JJ o
effects NNS o
associated VBN o
with IN o
classic JJ o
serotonergic NN o
( ( o
5-HT2 JJ o
( ( o
A NNP o
) ) o
) ) o
hallucinogens VBZ o
( ( o
Hallucinogen NNP o
Rating NNP o
Scale NNP o
) ) o
. . o

Salvinorin CC i
A DT i
did VBD N
not RB N
significantly RB N
increase VB o
heart NN o
rate NN o
or CC o
blood NN o
pressure NN o
. . o

Participant NNP p
narratives VBZ p
indicated VBN N
intense JJ N
experiences NNS N
characterized VBN N
by IN N
disruptions NNS N
in IN N
vestibular JJ N
and CC N
interoceptive JJ N
signals NNS N
( ( N
e.g. NN N
, , N
change NN o
in IN o
spatial JJ o
orientation NN o
, , o
pressure NN o
on IN o
the DT o
body NN o
) ) o
and CC o
unusual JJ N
and CC N
sometimes RB N
recurring VBG N
themes NNS N
across IN N
sessions NNS N
such JJ N
as IN N
revisiting VBG N
childhood NN N
memories NNS N
, , N
cartoon-like JJ N
imagery NN N
, , N
and CC N
contact NN N
with IN N
entities NNS N
. . N

Under IN N
these DT N
prepared JJ N
and CC N
supportive JJ N
conditions NNS i
, , i
salvinorin VBP i
A DT i
occasioned VBD N
a DT N
unique JJ N
profile NN N
of IN N
subjective JJ N
effects NNS N
having VBG N
similarities NNS N
to TO N
classic VB N
hallucinogens NNS N
, , N
including VBG N
mystical-type JJ N
effects NNS N
. . N

-DOCSTART- -18672629- O O

Less NNP N
tachycardia NN o
in IN N
adults NNS p
when WRB N
using VBG N
atropine VBP i
0.9 CD N
mg NNS N
compared VBN N
with IN N
1.2 CD N
mg NNS N
plus CC N
neostigmine JJ i
2.5 CD N
mg NN N
. . N

OBJECTIVE CC N
Compare NNP N
the DT N
increase NN N
in IN N
heart NN o
rate NN o
in IN p
adults NNS p
after IN N
0.9 CD N
vs. FW N
1.2 CD N
mg NN N
of IN N
atropine JJ i
plus CC i
neostigmine JJ i
2.5 CD N
mg NN N
as IN N
the DT N
non-depolarizing JJ N
muscle NN N
relaxant NN N
reversal NN N
agent NN N
. . N

MATERIAL NNP N
AND NNP N
METHOD NNP N
A NNP N
randomized NN N
, , N
double JJ N
blind NN N
, , N
controlled VBN N
trial NN N
on IN N
46 CD p
adults NNS p
ASA NNP p
I-II NNP p
, , p
undergoing VBG p
elective JJ p
gynecological NN p
or CC p
general JJ p
surgery NN p
with IN p
balanced JJ p
general JJ p
anesthesia NN p
was VBD N
performed VBN N
. . N

The DT N
subjects NNS N
were VBD N
randomized VBN N
into IN N
two CD N
groups NNS N
, , N
After IN N
surgery NN N
, , N
the DT N
study NN N
group NN N
received VBD N
0.9 CD i
mg NN i
of IN i
atropine NN i
, , N
while IN N
the DT N
control NN i
group NN N
received VBD N
1.2 CD i
mg NN i
of IN i
atropine NN i
. . i

Both DT N
groups NNS N
received VBD N
2.5 CD i
mg NN i
of IN i
neostigmine JJ i
simultaneously RB i
. . i

RESULTS VB N
The DT N
heart NN o
rate NN o
and CC o
blood NN o
pressure NN o
were VBD N
taken VBN N
at IN N
0 CD N
, , N
1 CD N
, , N
2 CD N
, , N
3 CD N
, , N
4 CD N
, , N
5 CD N
, , N
6 CD N
, , N
7 CD N
, , N
8 CD N
, , N
9 CD N
, , N
10 CD N
, , N
15 CD N
, , N
20 CD N
, , N
25 CD N
, , N
and CC N
30 CD N
min NN N
after IN N
the DT N
injection NN N
. . N

The DT N
increase NN o
in IN o
heart NN o
rate NN o
and CC o
blood NN o
pressure NN o
between IN N
the DT N
two CD N
groups NNS N
were VBD N
compared VBN N
. . N

The DT N
heart NN o
rate NN o
( ( N
at IN N
3 CD N
, , N
4 CD N
, , N
5 CD N
, , N
and CC N
6 CD N
min NN N
) ) N
of IN N
patients NNS N
in IN N
the DT N
study NN N
group NN N
increased VBD N
significantly RB N
less JJR N
than IN N
that DT N
of IN N
patients NNS N
in IN N
the DT N
control NN N
group NN N
. . N

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
blood NN o
pressure NN o
between IN N
groups NNS N
and CC N
no DT N
side NN N
effects NNS N
occurred VBD N
. . N

CONCLUSION VB N
The DT N
authors NNS N
conclude VBP N
that IN N
0.9 CD N
mg NN N
of IN N
atropine NN i
with IN N
2.5 CD N
mg NNS N
neostigmine JJ i
can MD N
be VB N
safely RB N
used VBN N
as IN N
the DT N
reversal NN N
agent NN N
for IN N
a DT N
non-depolarizing JJ N
muscle NN N
relaxant NN N
, , N
particularly RB N
in IN N
patients NNS N
for IN N
whom WP N
any DT N
increase NN N
in IN N
heart NN o
rate NN o
would MD N
be VB N
harmful JJ N
. . N

-DOCSTART- -16326121- O O

Minimal JJ N
tolerance NN N
to TO N
the DT N
bronchoprotective JJ o
effect NN o
of IN N
inhaled JJ N
salmeterol/fluticasone NN i
combination NN N
on IN N
allergene JJ N
challenge NN N
. . N

In IN N
order NN N
to TO N
assess VB N
whether IN N
the DT N
administration NN N
of IN i
salmeterol/fluticasone JJ i
propionate NN i
combination NN N
( ( N
50/250 CD N
mcg NN N
by IN N
Diskus NNP N
) ) N
for IN N
1 CD N
week NN N
induces NNS N
tolerance NN o
to TO N
the DT N
bronchoprotective JJ o
effect NN N
of IN N
salmeterol NN i
on IN N
allergen NN N
challenge NN N
, , N
a DT N
single-blind JJ N
, , N
cross-over JJ N
study NN N
was VBD N
carried VBN N
out RP N
. . N

We PRP N
studied VBD N
nine CD p
subjects NNS p
( ( p
eight CD p
men NNS p
and CC p
one CD p
woman NN p
; : p
mean JJ p
age+/-SD NN p
: : p
31.3+/-11.0 JJ p
yr NN p
) ) p
with IN p
mild JJ p
intermittent JJ p
allergic NN p
asthma NN p
, , p
never RB p
treated VBN p
with IN p
regular JJ p
beta2-agonists NNS p
or CC p
inhaled JJ p
corticosteroids NNS p
. . p

In IN N
a DT N
previous JJ N
allergen NN N
challenge NN N
all DT p
subjects NNS p
had VBD p
shown VBN p
a DT p
positive JJ p
early JJ o
airway NN o
response NN o
( ( o
EAR NNP o
) ) o
to TO p
allergen VB p
. . p

They PRP N
underwent JJ N
allergen NN N
challenge NN N
after IN N
1-week JJ N
treatment NN N
with IN N
placebo NN i
and CC N
a DT N
single JJ N
dose NN N
of IN N
placebo NN i
immediately RB N
before IN N
allergen NN i
challenge NN i
( ( i
T1 NNP i
) ) i
, , N
or CC N
1-week JJ N
treatment NN N
with IN N
placebo NN i
and CC i
a DT i
single JJ i
dose NN i
of IN i
salmeterol/fluticasone NN i
immediately RB N
before IN N
allergen NN i
challenge NN i
( ( i
T2 NNP i
) ) i
, , N
or CC N
1-week JJ i
treatment NN i
with IN i
salmeterol/fluticasone JJ i
combination NN i
bid NN N
and CC N
a DT N
single JJ N
dose NN N
of IN N
salmeterol/fluticasone NN i
immediately RB N
before IN N
allergen NN i
challenge NN i
( ( i
T3 NNP i
) ) i
. . i

EAR NN o
was VBD N
evaluated VBN N
both DT N
as IN N
maximum NN N
decrease NN N
in IN N
FEV1 NNP o
( ( N
MaxDeltaFEV1 NNP N
% NN N
) ) N
after IN N
allergen NN N
challenge NN N
and CC N
as IN N
area NN o
under IN o
FEV1 NNP o
-time NNP o
curve NN o
. . o

MaxDeltaFEV1 NNP o
% NN o
during IN o
allergen NN o
challenge NN o
protected VBN N
by IN N
placebo NN N
( ( N
T1 NNP N
) ) N
was VBD N
significantly RB o
greater JJR o
than IN N
MaxDeltaFEV1 NNP o
% NN o
during IN N
allergen NN N
challenges NNS N
protected VBN N
by IN N
single JJ N
dose NN N
of IN N
salmeterol/fluticasone NN N
( ( N
T2 NNP N
) ) N
and CC N
by IN N
salmeterol/fluticasone JJ N
1-week JJ N
treatment NN N
( ( N
T3 NNP N
) ) N
. . N

No DT o
difference NN o
was VBD N
found VBN N
in IN N
MaxDeltaFEV1 NNP o
% NN o
between IN N
T2 NNP N
and CC N
T3 NNP N
. . N

The DT N
same JJ N
results NNS N
were VBD N
observed VBN N
also RB N
after IN N
computing VBG N
the DT N
area NN o
under IN o
the DT o
curve NN o
for IN N
each DT N
challenge NN N
. . N

When WRB N
individually RB N
considered VBN N
, , N
all DT N
subjects NNS N
were VBD N
protected VBN o
against IN o
EAR NNP o
( ( N
protection NN N
index NN N
> VBD N
or CC N
= VB N
80 CD N
% NN N
) ) N
at IN N
T2 NNP N
, , N
while IN N
at IN N
3 CD N
seven CD N
out IN N
of IN N
nine CD N
subjects NNS N
were VBD N
still RB N
protected VBN o
against IN o
EAR NNP o
. . o

In IN N
conclusion NN N
, , N
the DT N
simultaneous JJ N
administration NN N
of IN N
salmeterol NN N
and CC N
fluticasone NN N
in IN N
the DT N
same JJ N
device NN N
prevents NNS N
in IN N
almost RB N
80 CD N
% NN N
of IN N
examined JJ N
subjects NNS N
the DT N
development NN N
of IN N
tolerance NN o
to TO o
the DT o
protective JJ o
effect NN o
of IN N
salmeterol NN N
on IN N
allergen NN N
challenge NN N
. . N

This DT N
observation NN N
may MD N
contribute VB N
to TO N
explain VB N
the DT N
positive JJ N
interaction NN N
between IN N
inhaled VBN N
beta2-agonists NNS N
and CC N
corticosteroids NNS N
in IN N
the DT N
long-term JJ o
treatment NN N
of IN N
asthma NN N
. . N

-DOCSTART- -20379614- O O

Personalized VBN N
smoking NN N
cessation NN N
: : N
interactions NNS N
between IN N
nicotine NN N
dose NN N
, , N
dependence NN N
and CC N
quit-success JJ N
genotype NN N
score NN N
. . N

Improving NNP N
and CC N
targeting VBG N
nicotine JJ i
replacement NN i
therapy NN i
( ( i
NRT NNP i
) ) i
are VBP N
cost-effective JJ N
strategies NNS N
for IN N
reducing VBG N
adverse JJ N
health NN N
consequences NNS N
for IN N
smokers NNS p
. . p

Treatment NNP N
studies NNS N
document VBP N
the DT N
efficacy NN N
of IN N
precessation NN N
NRT NNP i
and CC N
support NN N
important JJ N
roles NNS N
for IN N
level NN N
of IN N
nicotine JJ N
dependence NN N
and CC N
precessation NN N
smoking NN N
reduction NN N
in IN N
successful JJ N
quitting NN N
. . N

However RB N
, , N
prior JJ N
work NN N
has VBZ N
not RB N
identified VBN N
the DT N
optimal JJ N
precessation NN N
dose NN N
or CC N
means NNS N
for IN N
personalizing VBG N
NRT NNP i
. . i

Genome-wide NNP N
association NN N
has VBZ N
identified VBN N
groups NNS N
of IN N
genomic JJ N
markers NNS N
associated VBN N
with IN N
successful JJ N
quitting NN N
, , N
allowing VBG N
us PRP N
to TO N
develop VB N
a DT N
v1.0 JJ N
quit-success JJ N
genotype NN N
score NN N
. . N

We PRP N
now RB N
report VBP N
influences NNS N
of IN N
v1.0 JJ o
quit-success JJ o
genotype NN o
score NN o
, , o
level NN o
of IN o
dependence NN o
and CC o
precessation NN o
smoking NN o
reduction NN o
in IN N
a DT N
smoking NN N
cessation NN N
trial NN N
that WDT N
examined VBD N
effects NNS N
of IN N
21 CD N
versus NN N
42 CD N
mg/24 NN N
h NN N
precessation NN N
NRT NNP i
. . i

Four CD p
hundred VBD p
seventy-nine JJ p
smokers NNS p
were VBD N
randomized VBN N
to TO N
21 CD N
or CC N
42 CD N
mg NN N
NRT NNP i
, , N
initiated VBD N
2 CD N
wks NN N
prior RB N
to TO N
target VB N
quit NN N
dates NNS N
. . N

We PRP N
monitored VBD N
self-reported JJ o
abstinence NN o
and CC o
end-expired JJ o
air NN o
carbon NN o
monoxide NN o
( ( o
CO NNP o
) ) o
. . o

Genotyping VBG p
used VBN p
Affymetrix NNP o
arrays NNS o
( ( p
Santa NNP p
Clara NNP p
, , p
CA NNP p
, , p
USA NNP p
) ) p
. . p

The DT N
primary JJ N
outcome NN N
was VBD N
10-wk JJ o
continuous JJ o
smoking NN o
abstinence NN o
. . o

NRT NNP o
dose NN o
, , o
level NN o
of IN o
nicotine JJ o
dependence NN o
and CC o
genotype NN o
scores NNS o
displayed VBD N
significant JJ o
interactive JJ o
effects NNS o
on IN N
successful JJ N
quitting NN N
. . N

Successful JJ o
abstinence NN o
also RB N
was VBD N
predicted VBN N
by IN N
CO NNP o
reductions NNS o
during IN N
precessation NN N
NRT NNP i
. . i

These DT N
results NNS N
document VBP N
ways NNS N
in IN N
which WDT N
smoking VBG N
cessation NN N
strategies NNS N
can MD N
be VB N
personalized VBN N
based VBN N
on IN N
levels NNS o
of IN o
nicotine JJ o
dependence NN o
, , o
genotype NN o
scores NNS o
and CC o
CO NNP o
monitoring NN o
. . o

These DT N
assessments NNS N
, , N
taken VBN N
together RB N
, , N
can MD N
help VB N
match VB N
most JJS N
smokers NNS p
with IN N
optimal JJ N
NRT NNP i
doses NNS N
and CC N
help VB N
rapidly RB N
identify VB N
some DT N
who WP N
may MD N
be VB N
better RB N
treated VBN N
using VBG N
other JJ N
methods NNS N
. . N

-DOCSTART- -24785600- O O

Hysteroscopic NNP i
morcellation NN i
compared VBN N
with IN N
electrical JJ i
resection NN i
of IN N
endometrial JJ N
polyps NNS N
: : N
a DT N
randomized NN N
controlled VBN N
trial NN N
. . N

OBJECTIVE UH N
To TO N
evaluate VB N
whether IN N
hysteroscopic JJ i
morcellation NN i
or CC N
bipolar JJ i
electrosurgical JJ i
resection NN i
is VBZ N
more RBR N
favorable JJ N
for IN N
removing VBG N
endometrial JJ o
polyps NNS o
in IN N
an DT N
office NN N
setting NN N
in IN N
terms NNS N
of IN N
feasibility NN o
, , o
speed NN o
, , o
pain NN o
, , o
and CC o
acceptability NN o
. . o

METHODS NNP N
A NNP N
multicenter NN N
, , N
single-blind NN N
, , N
randomized VBN N
, , N
controlled VBD N
trial NN N
of IN N
office NN i
hysteroscopic NN i
morcellation NN i
compared VBN N
with IN N
electrosurgical JJ i
resection NN i
was VBD N
conducted VBN N
. . N

A DT N
total NN N
of IN N
121 CD p
women NNS p
were VBD p
randomly RB p
allocated VBN p
to TO p
polyp VB p
removal NN p
by IN N
one CD N
of IN N
the DT N
two CD N
methods NNS N
in IN N
an DT N
office NN N
setting NN N
. . N

The DT N
outcomes NNS N
assessed VBN N
were VBD N
time NN o
taken VBN o
to TO o
complete VB o
the DT o
endometrial JJ o
polypectomy NN o
, , N
defined VBD N
as IN N
the DT N
time NN N
from IN N
insertion NN N
to TO N
removal NN N
of IN N
vaginal JJ N
instrumentation NN N
, , N
completeness NN o
of IN o
polyp NN o
removal NN o
, , o
acceptability NN o
, , o
and CC o
pain NN o
measured VBN o
on IN N
a DT N
100-mm JJ N
visual JJ N
analog NN N
scale NN N
. . N

RESULTS VB N
The DT N
median JJ o
time NN o
taken VBN o
to TO o
complete VB o
the DT o
procedure NN o
was VBD N
5 CD N
minutes NNS N
and CC N
28 CD N
seconds NNS N
for IN N
morcellation NN N
compared VBN N
with IN N
10 CD N
minutes NNS N
and CC N
12 CD N
seconds NNS N
for IN N
electrosurgical JJ N
resection NN N
( ( N
P NNP N
< NNP N
.001 NNP N
) ) N
. . N

The DT N
polyps NNS o
were VBD o
completely RB o
removed VBN o
in IN N
61 CD N
out IN N
of IN N
62 CD N
( ( N
98 CD N
% NN N
) ) N
women NNS N
assigned VBN N
to TO N
morcellation VB i
compared VBN N
with IN N
49 CD N
out IN N
of IN N
59 CD N
( ( N
83 CD N
% NN N
) ) N
women NNS N
treated VBN N
with IN N
electrosurgical JJ i
resection NN i
( ( N
odds NNS N
ratio VBP N
12.5 CD N
; : N
95 CD N
% NN N
confidence NN N
interval NN N
[ NNP N
CI NNP N
] NNP N
1.5-100.6 CD N
; : N
P=.02 NNP N
) ) N
. . N

The DT N
mean JJ o
pain NN o
scores NNS o
during IN N
the DT N
procedure NN N
favored VBN N
morcellation NN i
by IN N
16.1 CD N
points NNS N
on IN N
average NN N
( ( N
35.9 CD N
compared VBN N
with IN N
52.0 CD N
; : N
95 CD N
% NN N
CI NNP N
for IN N
difference NN N
, , N
-24.7 NN N
to TO N
-7.6 VB N
; : N
P NNP N
< NNP N
.001 NNP N
) ) N
. . N

Overall JJ N
, , N
99 CD N
% NN N
of IN N
women NNS N
found VBN N
office NN N
polypectomy NN N
to TO N
be VB N
acceptable JJ o
, , N
with IN N
only RB N
one CD N
woman NN N
in IN N
the DT N
electrosurgical JJ i
resection NN i
group NN N
considering VBG N
the DT N
procedure NN N
unacceptable JJ o
. . o

CONCLUSION NNP N
In IN N
comparison NN N
to TO N
electrosurgical JJ i
resection NN i
during IN N
hysteroscopic NN N
polypectomy NN N
, , N
morcellation NN i
was VBD N
significantly RB N
quicker JJR o
, , N
less RBR N
painful JJ o
, , N
more RBR N
acceptable JJ o
to TO N
women NNS N
, , N
and CC N
more RBR N
likely JJ N
to TO N
completely RB o
remove VB o
endometrial JJ o
polyps NNS o
compared VBN N
with IN N
electrosurgical JJ i
resection NN i
. . i

CLINICAL NNP N
TRIAL NNP N
REGISTRATION NNP N
ClinicalTrials.gov NNP N
, , N
www.clinicaltrials.gov NN N
, , N
NCT01509313 NNP N
. . N

-DOCSTART- -26205311- O O

Multiorgan NNP N
protection NN N
of IN N
remote JJ i
ischemic JJ i
perconditioning NN i
in IN N
valve JJ p
replacement NN p
surgery NN p
. . p

BACKGROUND NNP N
Remote NNP i
ischemic JJ i
perconditioning NN i
( ( i
RIPerc NNP i
) ) i
is VBZ N
a DT N
new JJ N
alternative NN N
of IN N
remote JJ N
ischemic JJ N
conditioning NN N
and CC N
has VBZ N
not RB N
been VBN N
well RB N
studied VBN N
. . N

RIPerc NNP N
attenuates VBZ N
myocardial JJ N
injury NN N
when WRB N
applied VBN N
during IN N
cardiac JJ N
surgery NN N
. . N

However RB N
, , N
its PRP$ N
protective JJ N
effects NNS N
on IN N
other JJ N
organs NNS N
remain VBP N
unknown JJ N
. . N

MATERIALS NNP N
AND CC N
METHODS NNP N
Patients NNPS p
with IN p
rheumatic JJ p
heart NN p
disease NN p
undergoing VBG p
valve JJ p
replacement NN p
surgery NN p
were VBD N
randomized VBN N
into IN N
the DT N
RIPerc NNP i
group NN N
( ( N
n JJ N
= NNP N
101 CD N
) ) N
or CC N
the DT i
control NN i
group NN i
( ( i
n JJ i
= NNP i
100 CD i
) ) i
. . i

RIPerc NNP i
was VBD i
achieved VBN N
by IN N
three CD N
cycles NNS N
of IN N
5-min JJ N
ischemia-5-min JJ N
reperfusion NN N
in IN N
the DT N
right JJ N
thigh NN N
during IN N
surgery NN o
. . o

Clinical NNP o
data NNS o
and CC o
the DT N
levels NNS o
of IN o
injury NN o
biomarkers NNS o
for IN o
the DT o
heart NN o
, , o
lungs NNS o
, , o
liver NN o
, , o
and CC o
kidneys NNS o
within IN o
48 CD N
h NN N
after IN N
surgery NN N
were VBD N
compared VBN N
using VBG N
one-way JJ N
or CC N
repeated VBN N
measurement JJ N
analysis NN N
of IN N
variance NN N
. . N

RESULTS NNP N
In IN N
the DT i
RIPerc NNP i
group NN i
, , N
the DT N
release NN o
of IN o
serum JJ o
cardiac JJ o
troponin NN o
I PRP o
( ( o
128.68 CD o
? . N
102.56 CD N
versus NN N
172.33 CD N
? . N
184.38 CD N
, , N
P NNP N
= NNP N
0.04 CD N
) ) N
and CC o
the DT o
inotropic NN o
score NN o
( ( o
96.4 CD o
? . N
73.8 CD N
versus NN N
121.5 CD N
? . N
89.6 CD N
, , N
P NNP N
= NNP N
0.032 CD N
) ) N
decreased VBN N
compared VBN N
with IN N
that DT N
of IN N
the DT N
control NN N
; : N
postoperative JJ o
drainage NN o
( ( o
458.2 CD o
? . o
264.2 CD o
versus NN N
545.1 CD N
? . N
349.0 CD N
ml NN N
, , N
P NNP N
= NNP N
0.048 CD o
) ) o
and CC o
the DT o
incidence NN o
of IN o
acute JJ o
lung NN o
injury NN o
was VBD o
reduced VBN o
( ( N
36.6 CD N
% NN N
versus IN N
51 CD N
% NN N
, , N
P NNP N
= NNP N
0.04 CD N
) ) N
, , N
and CC N
the DT N
extent NN N
of IN N
hyperbilirubinemia NN o
was VBD o
also RB N
attenuated VBN N
. . N

No DT N
significant JJ N
difference NN N
was VBD N
observed VBN N
in IN N
the DT N
levels NNS o
of IN o
biomarkers NNS o
for IN o
renal JJ o
injury NN o
and CC o
systemic JJ o
inflammation NN o
response NN o
. . N

CONCLUSIONS NNP i
RIPerc NNP i
applied VBD i
during IN N
the DT N
valve JJ N
replacement NN N
surgery NN N
induced VBD o
multiple JJ o
beneficial JJ o
effects NNS o
postoperatively RB o
including VBG o
reduced VBN o
drainage NN o
and CC o
myocardial JJ o
damage NN o
, , o
lower JJR o
incidence NN o
of IN o
acute JJ o
lung NN o
injury NN o
, , o
and CC o
attenuated VBD o
hyperbilirubinemia NN o
. . o

-DOCSTART- -9231814- O O

Safety NN o
of IN N
nifedipine NN i
in IN N
patients NNS p
with IN p
hypertension NN p
: : p
a DT N
meta-analysis NN N
. . N

Our PRP$ N
objective NN N
was VBD N
to TO N
compare VB N
cardiovascular JJ o
event NN o
rates NNS o
in IN N
patients NNS p
with IN p
mild JJ p
or CC p
moderate JJ p
hypertension NN p
who WP p
received VBD p
nifedipine JJ i
with IN p
active JJ i
drug NN i
controls NNS i
. . i

We PRP N
performed VBD N
a DT N
MEDLARS NNP p
search NN p
using VBG p
the DT p
MeSH NNP p
heading NN p
hypertension NN p
and CC p
the DT p
text NN p
word NN p
nifedipine NN i
to TO p
identify VB p
all DT p
articles NNS p
that WDT p
were VBD p
published VBN p
between IN p
1966 CD p
and CC p
August NNP p
1995 CD p
in IN p
English NNP p
, , p
French NNP p
, , p
German NNP p
, , p
Italian NNP p
, , p
and CC p
Spanish JJ p
languages NNS p
and CC p
that DT p
involved VBD p
human JJ p
subjects NNS p
. . p

The DT N
computerized JJ N
search NN N
was VBD N
supplemented VBN N
by IN N
a DT N
manual JJ N
search NN N
of IN N
article NN N
bibliographies NNS N
. . N

Review NNP p
of IN p
1880 CD p
citations NNS p
revealed VBD p
98 CD p
randomized VBN p
controlled VBD p
clinical JJ p
trials NNS p
that WDT p
met VBD p
protocol NN p
criteria NNS p
. . p

Articles NNS p
were VBD p
extracted VBN p
independently RB p
by IN p
two CD p
doctors NNS p
who WP p
were VBD p
blinded VBN p
for IN p
author NN p
, , p
institution NN p
, , p
and CC p
treatment NN p
regimen NNS p
, , p
using VBG p
a DT p
structured VBN p
, , p
pretested VBN p
extraction NN p
form NN p
. . p

Differences NNS N
of IN N
opinion NN N
were VBD N
resolved VBN N
by IN N
consensus NN N
. . N

Fourteen JJ N
events NNS N
occurred VBD N
in IN N
5198 CD N
exposures NNS N
( ( N
0.27 CD N
% NN N
) ) N
to TO N
nifedipine VB i
and CC N
24 CD N
events NNS N
in IN N
5402 CD N
exposures NNS N
( ( N
0.44 CD N
% NN N
) ) N
to TO N
other JJ N
active JJ N
drug NN N
controls NNS N
. . N

Unadjusted VBN o
odds JJ o
ratios NNS o
for IN N
nifedipine JJ N
versus NN N
controls NNS N
were VBD N
0.49 CD N
( ( N
95 CD N
% NN N
confidence NN N
interval NN N
[ NNP N
CI NNP N
] NNP N
, , N
0.22-1.09 NNP N
) ) N
for IN N
definitive JJ o
events NNS o
( ( o
death NN o
, , o
nonfatal JJ o
myocardial JJ o
infarction NN o
or CC o
stroke NN o
, , o
revascularization NN o
procedure NN o
) ) o
and CC N
0.61 CD N
( ( N
95 CD N
% NN N
CI NNP N
, , N
0.31-1.17 NNP N
) ) N
for IN N
all DT o
events NNS o
( ( o
definitive JJ o
plus NN o
increased VBD o
angina RB o
) ) o
. . o

The DT N
odds NNS o
ratio NN o
for IN o
nifedipine JJ o
monotherapy NN o
( ( N
sustained- JJ N
or CC N
extended-release NN N
in IN N
91 CD N
% NN N
of IN N
exposures NNS N
) ) N
was VBD N
nonsignificantly RB N
higher JJR N
for IN N
definitive JJ N
and CC N
all DT N
events NNS N
( ( N
odds NNS N
ratio NN N
, , N
1.40 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
0.49-4.03 JJ N
and CC N
odds NNS N
ratio NN N
, , N
1.39 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
0.59-3.32 NNP N
, , N
respectively RB N
) ) N
. . N

The DT N
odds NNS o
ratio NN o
for IN o
nifedipine NN o
in IN o
combination NN o
with IN o
another DT o
drug NN o
was VBD N
significantly RB N
lower JJR N
for IN N
definitive JJ N
and CC N
all DT N
events NNS N
( ( N
odds NNS N
ratio NN N
, , N
0.09 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
0.01-0.66 JJ N
and CC N
odds NNS N
ratio NN N
, , N
0.15 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
0.03-0.65 NNP N
, , N
respectively RB N
) ) N
. . N

Differences NNS o
in IN o
odds NNS o
ratio NN o
for IN o
nifedipine JJ o
monotherapy NN o
and CC o
combined VBN o
therapy NN o
were VBD N
statistically RB N
significant JJ N
( ( N
P=.02 NNP N
for IN N
definitive JJ N
events NNS N
and CC N
P=.001 NNP N
for IN N
all DT N
events NNS N
) ) N
. . N

Results JJ N
support NN N
the DT N
safety NN o
of IN o
sustained- JJ o
and CC o
extended-release JJ o
nifedipine NN o
in IN N
the DT N
treatment NN N
of IN N
mild NN N
or CC N
moderate JJ N
hypertension NN N
when WRB N
it PRP N
is VBZ N
used VBN N
in IN N
combination NN N
with IN N
other JJ N
drugs NNS N
. . N

-DOCSTART- -9088586- O O

Effects NNS N
of IN N
frusemide NN i
and CC N
hypoxia NN N
on IN N
the DT N
pulmonary JJ p
vascular NN p
bed NN p
in IN p
man NN p
. . p

AIMS NNP N
Diuretic NNP i
therapy NN N
is VBZ N
conventionally RB N
used VBN N
to TO N
treat VB N
oedema NNS p
in IN p
patients NNS p
with IN p
hypoxic JJ p
cor NN p
pulmonale NN p
. . p

This DT N
condition NN N
is VBZ N
associated VBN N
with IN N
activation NN N
of IN N
the DT N
renin NN N
angiotensin NN N
system NN N
( ( N
RAS NNP N
) ) N
with IN N
elevated JJ N
levels NNS N
of IN N
angiotensin NN N
II NNP N
( ( N
ANG NNP N
II NNP N
) ) N
, , N
a DT N
potent JJ N
pulmonary JJ N
pressor NN N
agent NN N
. . N

We PRP N
explored VBD N
the DT N
hypothesis NN N
that WDT N
RAS NNP N
activation NN N
by IN N
diuretic JJ N
therapy NN N
might MD N
therefore VB N
worsen JJ N
hypoxic NN N
pulmonary JJ N
vasoconstriction NN N
via IN N
the DT N
effects NNS N
of IN N
ANG NNP N
II NNP N
on IN N
the DT N
pulmonary JJ N
vascular NN N
bed NN N
. . N

METHODS NNP N
Eight NNP p
normal JJ p
volunteers NNS p
were VBD p
studied VBN p
on IN N
2 CD N
separate JJ N
days NNS N
. . N

They PRP N
either DT N
received VBD N
40 CD i
mg NNS i
frusemide JJ i
daily RB i
or CC i
placebo VB i
for IN N
4 CD N
days NNS N
and CC N
were VBD N
then RB N
rendered VBN N
hypoxaemic NN N
, , N
by IN N
breathing VBG N
an DT N
N2/O2 NNP N
mixture NN N
for IN N
20 CD N
min NN N
to TO N
achieve VB N
an DT N
SaO2 NNP N
of IN N
85-90 CD N
% NN N
adjusted VBN N
for IN N
a DT N
further JJ N
20 CD N
min NN N
to TO N
achieve VB N
an DT N
SaO2 NNP N
of IN N
75-80 CD N
% NN N
. . N

Pulsed VBN N
wave VBP N
doppler NN N
echocardiography NN N
was VBD N
used VBN N
to TO N
measure VB N
mean JJ o
pulmonary JJ o
artery NN o
pressure NN o
, , o
cardiac JJ o
output NN o
and CC N
hence RB N
pulmonary JJ o
vascular JJ o
resistance NN o
( ( o
PVR NNP o
) ) o
. . o

RESULTS NNP N
Plasma NNP o
renin NN o
activity NN o
( ( o
PRA NNP o
) ) o
was VBD N
significantly RB N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
increased VBN N
after IN N
prior JJ N
treatment NN N
with IN N
frusemide JJ i
compared VBN N
with IN N
placebo NN i
at IN N
all DT N
time NN N
points NNS N
. . N

Prior NNP N
treatment NN N
with IN N
frusemide NN i
significantly RB N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
increased VBD N
PVR NNP o
compared VBN N
with IN N
placebo NN i
at IN N
baseline NN N
: : N
185 CD N
+/- JJ N
17 CD N
vs JJ N
132 CD N
+/- JJ N
10 CD N
dyn JJ N
s JJ N
cm-5 NN N
at IN N
an DT N
SaO2 NNP N
of IN N
85-90 JJ N
% NN N
: : N
291 CD N
+/- JJ N
18 CD N
vs JJ N
229 CD N
+/- JJ N
16 CD N
dyn JJ N
s JJ N
cm-5 NN N
and CC N
at IN N
SaO2 NNP N
of IN N
75-80 CD N
% NN N
: : N
356 CD N
+/- JJ N
12 CD N
vs JJ N
296 CD N
+/- JJ N
17 CD N
dyn JJ N
s JJ N
cm-5 NN N
respectively RB N
. . N

However RB N
, , N
the DT N
delta-PVR JJ o
response NN o
to TO o
hypoxaemia NN o
was VBD N
not RB N
significantly RB N
altered VBN N
by IN N
frusemide NN i
compared VBN N
with IN N
placebo NN i
. . i

In IN N
contrast NN N
to TO N
its PRP$ N
effect NN N
on IN N
the DT N
pulmonary JJ N
vasculature NN N
prior JJ N
treatment NN N
with IN N
frusemide NN i
did VBD N
not RB N
significantly RB N
alter VB N
systemic JJ o
haemodynamic JJ o
parameters NNS o
either CC N
at IN N
baseline NN N
or CC N
during IN N
hypoxia NN N
. . N

CONCLUSIONS NNP N
Thus NNP N
, , N
prior JJ N
treatment NN N
with IN N
frusemide NN i
increased VBD N
baseline JJ N
pulmonary JJ o
vascular NN o
resistance NN o
and CC N
significantly RB N
augmented VBD N
the DT N
hypoxaemic JJ o
pulmonary JJ o
vascular NN o
response NN o
in IN N
additive JJ N
fashion NN N
. . N

It PRP N
is VBZ N
hypothesised VBN N
that IN N
this DT N
effect NN N
of IN N
frusemide NN i
may MD N
be VB N
due JJ N
to TO N
RAS NNP N
activation NN N
with IN N
ANG NNP N
II NNP N
mediated VBD N
pulmonary JJ N
vasoconstriction NN N
. . N

-DOCSTART- -1448121- O O

A DT N
controlled JJ N
trial NN N
of IN N
trimethoprim-sulfamethoxazole JJ i
or CC i
aerosolized JJ i
pentamidine NN i
for IN N
secondary JJ N
prophylaxis NN N
of IN N
Pneumocystis NNP N
carinii NN N
pneumonia NN N
in IN N
patients NNS p
with IN p
the DT p
acquired JJ p
immunodeficiency NN p
syndrome NN p
. . p

AIDS NNP N
Clinical JJ N
Trials NNP N
Group NNP N
Protocol NNP N
021 CD N
. . N

BACKGROUND NNP N
Pneumocystis NNP N
carinii NN N
pneumonia NN N
( ( N
PCP NNP N
) ) N
continues VBZ N
to TO N
be VB N
the DT N
most RBS N
common JJ N
index NN N
diagnosis NN N
in IN N
the DT N
acquired JJ N
immunodeficiency NN N
syndrome NN N
( ( N
AIDS NNP N
) ) N
, , N
but CC N
it PRP N
is VBZ N
not RB N
clear JJ N
which WDT N
of IN N
several JJ N
available JJ N
agents NNS N
is VBZ N
the DT N
most RBS N
effective JJ N
in IN N
preventing VBG o
a DT o
recurrence NN o
of IN o
PCP NNP o
. . o

METHODS NNP N
We PRP N
conducted VBD N
a DT N
comparative JJ N
, , N
open-label JJ N
trial NN N
in IN N
310 CD p
adults NNS p
with IN p
AIDS NNP p
who WP p
had VBD p
recently RB p
recovered VBN p
from IN p
an DT p
initial JJ p
episode NN p
of IN p
PCP NNP p
and CC p
had VBD p
no DT p
treatment-limiting JJ p
toxic NN p
effects NNS p
of IN p
trimethoprim-sulfamethoxazole JJ i
or CC i
pentamidine NN i
. . i

All PDT N
the DT N
patients NNS N
were VBD N
treated VBN i
with IN i
zidovudine NN i
and CC N
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB i
either RB i
800 CD i
mg NN i
of IN i
sulfamethoxazole NN i
and CC i
160 CD i
mg NN i
of IN i
trimethoprim JJ i
once JJ i
daily JJ i
or CC i
300 CD i
mg NN i
of IN i
aerosolized JJ i
pentamidine NN i
administered VBN i
every DT i
four CD i
weeks NNS i
by IN i
jet NN i
nebulizer NN i
. . i

The DT N
participants NNS N
were VBD N
followed VBN N
for IN N
a DT N
median NN N
of IN N
17.4 CD N
months NNS N
. . N

RESULTS NNP N
In IN N
the DT N
trimethoprim-sulfamethoxazole JJ i
group NN N
( ( N
n JJ N
= NNP N
154 CD N
) ) N
there EX N
were VBD N
14 CD N
recurrences NNS o
of IN o
PCP NNP o
, , N
as IN N
compared VBN N
with IN N
36 CD N
recurrences NNS N
( ( N
including VBG N
1 CD N
extrapulmonary JJ N
recurrence NN N
) ) N
in IN N
the DT N
aerosolized-pentamidine JJ N
group NN N
( ( N
n JJ N
= NNP N
156 CD N
) ) N
. . N

The DT N
estimated JJ N
recurrence NN o
rates NNS o
at IN N
18 CD N
months NNS N
were VBD N
11.4 CD N
percent NN N
with IN N
trimethoprim-sulfamethoxazole JJ i
and CC N
27.6 CD N
percent NN N
with IN N
pentamidine NN i
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

The DT N
risk NN N
of IN N
a DT N
recurrence NN o
( ( N
adjusted VBN N
for IN N
initial JJ N
CD4 NNP N
cell NN N
count NN N
) ) N
was VBD N
3.25 CD N
times NNS N
higher RBR N
in IN N
the DT N
pentamidine NN i
group NN N
( ( N
P NNP N
< NNP N
0.001 CD N
, , N
95 CD N
percent NN N
confidence NN N
interval NN N
, , N
1.72 CD N
to TO N
6.16 CD N
) ) N
. . N

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
between IN N
the DT N
groups NNS N
in IN N
survival NN o
or CC o
in IN o
hematologic JJ o
or CC o
hepatic JJ o
toxicity NN o
. . o

Crossovers NNS N
from IN N
trimethoprim-sulfamethoxazole JJ i
to TO N
aerosolized JJ N
pentamidine NN i
were VBD N
more JJR N
common JJ N
than IN N
the DT N
reverse NN N
( ( N
27 CD N
vs. FW N
4 CD N
percent NN N
) ) N
, , N
partly RB N
because IN N
of IN N
the DT N
study NN N
protocols NNS N
for IN N
the DT N
management NN N
of IN N
leukopenia NN N
. . N

There EX N
were VBD N
19 CD N
serious JJ N
bacterial JJ o
infections NNS o
in IN N
the DT N
trimethoprim-sulfamethoxazole JJ N
group NN N
and CC N
38 CD N
in IN N
the DT N
pentamidine NN N
group NN N
. . N

The DT N
time NN o
to TO o
a DT o
first JJ o
bacterial JJ o
infection NN o
was VBD N
significantly RB N
greater JJR N
for IN N
those DT N
assigned VBN N
to TO N
trimethoprim-sulfamethoxazole JJ N
( ( N
P NNP N
= NNP N
0.017 CD N
) ) N
. . N

CONCLUSIONS NNP N
In IN N
patients NNS p
with IN p
AIDS NNP p
who WP p
are VBP p
receiving VBG p
zidovudine NN i
, , i
trimethoprim-sulfamethoxazole JJ i
is VBZ N
more RBR N
effective JJ N
than IN N
aerosolized JJ i
pentamidine NN i
in IN N
conventional JJ N
doses NNS N
for IN N
the DT N
prevention NN o
of IN o
recurrent NN o
pneumocystis NN o
infection NN o
. . o

-DOCSTART- -9931911- O O

[ JJ i
Intra-arterial JJ i
( ( i
5-FU/FA JJ i
and CC i
FUDR NNP i
) ) i
versus VBP i
systemic JJ i
chemotherapy NN i
( ( i
5-FU/FA JJ i
) ) i
of IN N
non-resectable JJ o
colorectal JJ o
liver NN o
metastases NNS o
] VBP o
. . N

The DT N
relative JJ o
efficacy NN o
of IN N
HAI NNP i
FUDR NNP i
, , i
HAI NNP i
5-FU/FA CD i
, , i
and CC i
i.v NN i
. . i

5-FU/FA JJ i
chemotherapy NN i
for IN N
the DT N
treatment NN N
of IN N
unresectable JJ p
colorectal JJ p
liver NN p
metastases NNS p
was VBD N
compared VBN N
in IN N
a DT N
prospective JJ N
randomized VBN N
clinical JJ N
trial NN N
. . N

The DT N
response NN o
rate NN o
after IN N
HAI NNP i
treatment NN N
was VBD N
significantly RB N
higher JJR N
as IN N
compared VBN N
to TO N
i.v VB N
. . N

treatment NN N
with IN N
no DT N
statistical JJ N
benefit NN N
regarding VBG N
survival NN o
and CC o
time NN o
to TO o
progression NN o
. . o

HAI NNP i
FUDR NNP i
treatment NN N
was VBD N
inferior JJ o
as IN N
compared VBN N
to TO N
HAI NNP i
or CC N
i.v NN N
. . N

5-FU/FA JJ i
. . i

i.v NN N
. . N

5-FU/FA-therapy NN i
is VBZ N
therefore IN N
the DT N
method NN N
of IN N
choice NN N
outside IN N
clinical JJ N
trials NNS N
. . N

-DOCSTART- -18251162- O O

Effect NN N
of IN N
vitamin NN i
K2 NNP i
on IN N
the DT N
recurrence NN o
in IN N
patients NNS p
with IN p
hepatocellular JJ p
carcinoma NN p
. . p

BACKGROUND/AIMS NNP N
Vitamin NNP i
K2 NNP i
( ( i
VK2 NNP i
) ) i
appears VBZ N
to TO N
have VB N
a DT N
potent JJ N
inhibitory NN N
activity NN N
for IN N
cell NN N
growth NN N
including VBG N
HCC NNP N
cells NNS N
. . N

We PRP N
investigated VBD N
whether IN N
VK2 NNP i
could MD N
reduce VB N
incidence NN N
of IN N
tumor NN N
recurrence NN N
after IN N
treatment NN N
of IN N
HCC NNP N
. . N

Forty-five JJ p
patients NNS p
with IN p
cured JJ p
or CC p
possibly RB p
cured VBN p
HCC NNP p
were VBD N
randomly RB N
selected VBN N
, , N
assigning VBG N
patients NNS N
to TO N
treatment NN N
( ( N
n=21 JJ N
) ) N
or CC N
control VB i
group NN N
( ( N
n=24 CC N
) ) N
with IN N
randomization NN N
list NN N
. . N

METHODOLOGY NNP N
For IN N
the DT N
treatment NN N
group NN N
, , N
forty-five JJ N
mg NN N
of IN N
Glakay NNP i
was VBD N
given VBN N
orally RB N
every DT N
day NN N
after IN N
therapy NN N
for IN N
HCC NNP N
. . N

No CC N
patients NNS N
complained VBD N
of IN N
adverse JJ o
effects NNS o
. . o

Abdominal NNP N
ultrasonography NN N
and CC N
dynamic JJ i
CT NNP i
were VBD N
performed VBN N
at IN N
3-month JJ N
intervals NNS N
. . N

Recurrence NNP o
was VBD N
confirmed VBN N
by IN N
abdominal JJ i
angiography NN i
. . i

RESULTS NNP N
Recurrence NNP o
of IN o
HCC NNP o
occurred VBD N
in IN N
7 CD N
cases NNS N
( ( N
33.3 CD N
% NN N
) ) N
for IN N
the DT N
treatment NN N
group NN N
and CC N
12 CD N
cases NNS N
( ( N
50.0 CD N
% NN N
) ) N
for IN N
the DT N
control NN N
group NN N
during IN N
mean JJ N
observation NN N
periods NNS N
of IN N
19.5 CD N
and CC N
16.5 CD N
months NNS N
, , N
respectively RB N
. . N

Administration NNP N
of IN N
VK2 NNP N
was VBD N
not RB N
an DT N
independent JJ N
variable NN N
for IN N
the DT N
recurrence NN o
on IN N
univariate JJ N
analysis NN N
. . N

Cumulative JJ o
incidence NN o
of IN o
HCC NNP o
recurrence NN o
did VBD N
not RB N
differ VB N
between IN N
the DT N
two CD N
groups NNS N
, , N
and CC N
the DT N
cumulative JJ o
survival NN o
rate NN o
tended VBD N
to TO N
be VB N
high JJ N
in IN N
treatment NN N
group NN N
( ( N
p IN N
=0.054 NN N
) ) N
. . N

Cox NNP N
regression NN N
analysis NN N
revealed VBD N
that IN N
serum NN o
albumin JJ o
concentration NN o
alone RB N
was VBD N
an DT N
independent JJ N
factor NN N
affecting VBG N
the DT N
recurrence NN N
. . N

CONCLUSIONS NNP N
These DT N
findings NNS N
suggest VBP N
that IN N
VK2 NNP N
does VBZ N
not RB N
appear VB N
to TO N
prevent VB N
recurrence NN o
of IN o
HCC NNP o
after IN N
curative JJ N
treatment NN N
. . N

Our PRP$ N
study NN N
is VBZ N
preliminary JJ N
and CC N
large-scale JJ N
trials NNS N
are VBP N
needed VBN N
to TO N
determine VB N
whether IN N
VK2 NNP N
is VBZ N
of IN N
benefit NN N
to TO N
decrease VB N
the DT N
recurrence NN o
of IN o
HCC NNP o
. . o

-DOCSTART- -22014222- O O

Midlife NNP p
women NNS p
online NN N
: : N
evaluation NN N
of IN N
an DT N
internet-based JJ N
program NN N
to TO N
prevent VB N
unintended JJ N
pregnancy NN N
& CC N
STIs NNP N
. . N

BACKGROUND NNP N
Midlife NNP p
women NNS p
are VBP N
an DT N
underserved JJ N
population NN N
in IN N
the DT N
areas NNS N
of IN N
unintended JJ p
pregnancy NN p
and CC p
STI NNP p
prevention NN N
yet RB N
remain VBP N
at IN N
risk NN N
for IN N
both DT N
health NN N
conditions NNS N
. . N

METHODS NNP N
A NNP N
randomized VBD N
controlled JJ N
trial NN N
of IN N
an DT N
Internet-based JJ i
multimedia NN i
program NN i
to TO N
reduce VB N
risk NN N
of IN N
unintended JJ N
pregnancy NN N
and CC N
STIs NNP N
among IN N
midlife JJ p
women NNS p
was VBD p
conducted VBN p
with IN p
164 CD p
women NNS p
ages VBZ p
40-55 CD p
years NNS p
of IN p
age NN p
. . p

RESULTS NNP N
Women NNP N
in IN N
the DT N
treatment NN N
condition NN N
compared VBN N
to TO N
the DT N
control NN N
condition NN N
reported VBD N
significant JJ N
gains NNS N
in IN N
attitudes NNS o
, , o
self-efficacy NN o
, , o
and CC o
behavioral JJ o
intentions NNS o
at IN N
posttest JJS N
. . N

CONCLUSION NNP N
Interventions NNP N
specifically RB N
targeted VBD N
to TO N
midlife VB p
women NNS p
can MD N
impact VB N
constructs NNS N
known VBN N
to TO N
reduce VB N
risk NN N
. . N

Implications NNS N
for IN N
future JJ N
research NN N
and CC N
intervention NN N
development NN N
are VBP N
presented VBN N
. . N

-DOCSTART- -24974254- O O

Visual JJ i
feedback NN i
and CC i
target NN i
size NN i
effects NNS i
on IN i
reach-to-grasp JJ i
tasks NNS i
in IN p
children NNS p
with IN p
autism NN p
. . p

This DT N
study NN N
explores VBZ N
the DT N
effects NNS N
of IN N
visual JJ N
condition NN N
and CC N
target NN N
size NN N
during IN N
four CD N
reach-to-grasp JJ o
tasks NNS o
between IN N
autistic JJ p
children NNS p
and CC p
healthy JJ p
controls NNS p
. . p

Twenty NNP p
children NNS p
with IN p
autism NN p
and CC p
20 CD p
healthy JJ p
controls NNS p
participated VBN p
in IN p
the DT p
study NN p
. . p

Qualisys NNP o
motion NN o
capture NN o
system NN o
and CC o
kinematic JJ o
measures NNS o
were VBD i
used VBN i
to TO i
record VB i
movement NN i
. . i

Autistic NNP p
group NN N
showed VBD N
significantly RB N
longer RBR o
movement NN o
time NN o
, , o
larger JJR o
normalized VBN o
jerk NN o
score NN o
, , o
more RBR o
movement NN o
unit NN N
than IN N
controls NNS N
, , N
especially RB N
in IN N
non-visual JJ N
feedback NN N
and CC N
small JJ N
target NN N
blocks NNS N
. . N

Autistic NNP p
group NN N
also RB N
showed VBD N
significantly RB N
larger JJR o
maximal JJ o
grip NN o
aperture NN o
and CC N
normalized JJ o
maximal JJ o
grip NN o
aperture NN o
in IN N
visual JJ N
feedback NN N
condition NN N
than IN N
controls NNS N
. . N

Autistic JJ p
children NNS p
demonstrate VBP N
motor NN o
coordination NN o
problems NNS o
and CC N
also RB N
depend VBP N
on IN N
more JJR N
visual JJ o
cuing NN o
in IN N
high JJ N
accuracy NN N
tasks NNS N
. . N

Autistic JJ p
children NNS p
develop VB N
other JJ N
compensatory NN o
skills NNS o
while IN N
performing VBG N
tasks NNS N
. . N

-DOCSTART- -8750409- O O

Measuring VBG p
the DT p
impact NN p
of IN p
patient JJ i
counseling NN i
in IN p
the DT p
outpatient JJ p
pharmacy NN p
setting NN p
: : p
the DT p
research NN p
design NN p
of IN p
the DT p
Kaiser NNP p
Permanente/USC NNP p
patient NN p
consultation NN p
study NN p
. . p

This DT N
article NN N
describes VBZ N
the DT N
research NN N
method NN N
used VBN N
to TO N
measure VB N
the DT N
impact NN N
of IN N
three CD N
alternative JJ N
models NNS N
of IN N
patient JJ i
counseling NN i
in IN N
the DT N
outpatient JJ p
pharmacy NN p
setting VBG p
. . p

The DT p
study NN p
was VBD p
conducted VBN p
in IN p
pharmacies NNS p
operated VBN p
by IN p
the DT p
Southern NNP p
California NNP p
region NN p
Kaiser NNP p
Permanente NNP p
Medical NNP p
Care NNP p
Program NNP p
. . p

Both DT N
random JJ N
assignment NN N
and CC N
large-scale JJ N
geographic JJ N
area NN N
research NN N
designs NNS N
were VBD N
used VBN N
. . N

The DT N
presentation NN N
of IN N
the DT N
research NN N
design NN N
includes VBZ N
discussions NNS N
of IN N
data NNS N
collection NN N
and CC N
patient JJ N
sampling VBG N
methods NNS N
; : N
the DT N
measurement NN N
of IN N
patient JJ o
outcomes NNS o
, , N
including VBG N
measures NNS o
of IN o
health NN o
care NN o
costs NNS o
and CC o
utilization NN o
, , o
patient JJ o
functional JJ o
status NN o
, , o
and CC o
quality NN o
of IN o
life NN o
. . o

Demographic NNP N
data NNS N
are VBP N
presented VBN N
for IN N
the DT N
study NN N
population NN N
, , N
including VBG N
an DT N
analysis NN N
of IN N
potential JJ N
biased JJ N
selection NN N
of IN N
patients NNS N
electing VBG N
to TO N
participate VB N
in IN N
random JJ N
assignment NN N
. . N

Data NNS N
are VBP N
also RB N
presented VBN N
documenting VBG N
potential JJ N
selection NN N
bias NN N
across IN N
geographically RB N
determined VBN N
treatment NN N
groups NNS N
in IN N
the DT N
geographic JJ N
area NN N
design NN N
arm NN N
. . N

Finally RB N
, , N
the DT N
article NN N
presents VBZ N
the DT N
analysis NN N
plan NN N
for IN N
the DT N
study NN N
and CC N
discusses NNS N
study VBP N
limitations NNS N
. . N

-DOCSTART- -22198983- O O

Granulocyte-colony JJ i
stimulating NN i
factor NN i
for IN N
mobilizing VBG N
bone NN N
marrow NN N
stem NN N
cells NNS N
in IN N
subacute JJ N
stroke NN N
: : N
the DT N
stem NN i
cell VBP i
trial NN N
of IN N
recovery NN p
enhancement NN p
after IN p
stroke VBD p
2 CD p
randomized VBN N
controlled VBN N
trial NN N
. . N

BACKGROUND NNP N
AND CC N
PURPOSE NNP N
Granulocyte-colony NNP i
stimulating VBG i
factor NN i
( ( i
G-CSF NNP i
) ) i
is VBZ N
neuroprotective JJ N
in IN N
experimental JJ N
stroke NN N
and CC N
mobilizes VBZ N
CD34 NNP N
( ( N
+ NNP N
) ) N
peripheral JJ N
blood NN N
stem NN N
cells NNS N
into IN N
the DT N
circulation NN N
. . N

We PRP N
assessed VBD N
the DT N
safety NN N
of IN N
G-CSF NNP i
in IN N
recent JJ N
stroke NN N
in IN N
a DT N
phase NN N
IIb NNP N
single-center NN N
randomized NN N
, , N
controlled VBN N
trial NN N
. . N

METHODS NNP N
G-CSF NNP i
( ( i
10 CD i
?g/kg NN i
) ) i
or CC i
placebo NN i
( ( N
ratio VB N
2:1 CD N
) ) N
was VBD N
given VBN i
SC NNP i
for IN N
5 CD N
days NNS N
to TO p
60 CD p
patients NNS p
3 CD p
to TO p
30 CD p
days NNS p
after IN p
ischemic JJ p
or CC p
hemorrhagic JJ p
stroke NN p
. . p

The DT N
primary JJ N
outcome NN N
was VBD N
the DT o
frequency NN o
of IN o
serious JJ o
adverse JJ o
events NNS o
. . o

Peripheral NNP o
blood NN o
counts NNS o
, , o
CD34 NNP o
( ( o
+ NNP o
) ) o
count NN o
, , o
and CC o
functional JJ o
outcome NN o
were VBD N
measured VBN N
. . N

MRI NNP N
assessed VBD o
lesion NN o
volume NN o
, , o
atrophy NN o
, , o
and CC o
the DT o
presence NN o
of IN o
iron-labeled JJ o
CD34 NNP o
( ( o
+ NNP o
) ) o
cells NNS o
reinjected VBN N
on IN N
day NN N
6 CD N
. . N

RESULTS NNP p
Sixty NNP p
patients NNS p
were VBD p
recruited VBN p
at IN o
mean NN o
of IN o
8 CD o
days NNS o
( ( p
SD NNP p
? . p
5 CD p
) ) p
post NN p
ictus NN p
, , p
with IN p
mean JJ p
age NN p
71 CD p
years NNS p
( ( p
? . p
12 CD p
years NNS p
) ) p
and CC p
53 CD p
% NN p
men NNS p
. . p

The DT p
groups NNS N
were VBD N
well RB N
matched VBN N
for IN N
baseline JJ N
minimization/prognostic JJ N
factors NNS N
. . N

There EX N
were VBD p
no DT p
significant JJ p
differences NNS p
between IN p
groups NNS p
in IN p
the DT N
number NN N
of IN N
participants NNS N
with IN o
serious JJ o
adverse JJ o
events NNS o
: : o
G-CSF JJ o
15 CD o
( ( N
37.5 CD N
% NN N
) ) N
of IN N
40 CD N
versus NN i
placebo NN i
7 CD i
( ( N
35 CD N
% NN N
) ) N
of IN N
20 CD N
, , N
death NN o
or CC o
dependency NN o
( ( o
modified JJ o
Rankin NNP N
Score NN N
: : N
G-CSF JJ N
3.3 CD N
? . N
1.3 CD N
, , N
placebo NN i
3.0 CD i
? . N
1.3 CD N
) ) N
at IN N
90 CD N
days NNS N
, , N
or CC N
the DT o
number NN o
of IN o
injections NNS o
received VBN o
. . o

G-CSF NNP o
increased VBD o
CD34 NNP o
( ( o
+ NNP o
) ) o
and CC o
total JJ o
white JJ o
cell NN o
counts NNS o
of IN o
9.5- CD o
and CC N
4.2-fold JJ N
, , N
respectively RB N
. . N

There EX N
was VBD N
a DT N
trend NN N
toward IN N
reduction NN o
in IN o
MRI NNP o
ischemic JJ o
lesion NN o
volume NN o
with IN o
respect NN N
to TO N
change VB N
from IN N
baseline NN i
in IN i
G-CSF-treated JJ i
patients NNS i
( ( p
P=0.06 NNP p
) ) N
. . N

In IN N
1 CD N
participant NN N
, , N
there EX N
was VBD N
suggestion NN N
that IN N
labeled VBD o
CD34 NNP o
( ( o
+ NNP o
) ) o
cells NNS o
had VBD o
migrated VBN N
to TO N
the DT N
ischemic JJ N
lesion NN N
. . N

CONCLUSIONS VB N
This DT N
randomized VBN N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
trial NN N
suggests VBZ N
that IN N
G-CSF NNP i
is VBZ i
safe JJ i
when WRB N
administered VBN N
subacutely RB N
. . N

It PRP N
is VBZ N
feasible JJ N
to TO N
label VB N
and CC N
readminister VB N
iron-labeled JJ N
CD34 NNP N
( ( N
+ NNP N
) ) N
cells NNS N
in IN p
patients NNS p
with IN p
ischemic JJ p
stroke NN p
. . p

CLINICAL NNP p
TRIAL NNP N
REGISTRATION NNP N
URL NNP N
: : N
www.controlled-trials.com NN N
. . N

Unique NNP N
identifier NN N
: : N
ISRCTN63336619 NNP N
. . N

-DOCSTART- -20104460- O O

Effect NN N
of IN N
milrinone NN i
on IN N
short-term JJ N
outcome NN N
of IN N
patients NNS p
with IN p
myocardial JJ p
dysfunction NN p
undergoing VBG p
coronary JJ p
artery NN p
bypass NN p
graft NN p
: : p
A DT N
randomized NN N
controlled VBN N
trial NN N
. . N

BACKGROUND NNP N
Myocardial NNP N
dysfunction NN N
needing VBG N
inotropic JJ N
support NN N
is VBZ N
a DT N
typical JJ N
complication NN N
after IN N
on-pump JJ N
cardiac JJ N
surgery NN N
. . N

In IN N
this DT N
study NN N
, , N
we PRP N
evaluate VBP N
the DT N
effect NN N
of IN N
milrinone NN i
on IN N
patients NNS p
with IN p
ventricular JJ p
dysfunction NN p
undergoing VBG p
coronary JJ i
artery NN i
bypass NN i
graft NN i
( ( i
CABG NNP i
) ) i
. . i

METHODS NNP N
Seventy NNP p
patients NNS p
with IN p
impaired JJ p
left VBD p
ventricular JJ p
function NN p
[ NN p
left VBD p
ventricular JJ p
ejection NN p
fraction NN p
( ( p
LVEF NNP p
) ) p
< VBD p
35 CD p
% NN p
] JJ p
undergoing JJ p
on-pump JJ p
CABG NNP p
were VBD p
enrolled VBN p
. . p

Patients NNS N
were VBD N
randomized VBN N
to TO N
receive VB N
either DT N
an DT N
intraoperative JJ i
bolus NN i
of IN i
milrinone NN i
( ( i
50 CD i
microg/kg NN i
) ) i
or CC i
saline NN i
as IN i
placebo NN i
followed VBN N
by IN N
a DT N
24-hour JJ N
infusion NN N
of IN N
each DT N
agent NN N
( ( N
0.5 CD N
microg/kg/min NN N
) ) N
. . N

Hemodynamic JJ o
parameters NNS o
and CC o
transthoracic JJ o
echocardiographic JJ o
measurement NN o
of IN o
systolic JJ o
and CC o
diastolic JJ o
functions NNS o
were VBD N
the DT N
variables NNS N
evaluated VBN N
. . N

RESULTS NNP N
Serum NNP o
levels NNS o
of IN o
creatine NN o
phosphokinase NN o
( ( o
CPK NNP o
) ) o
, , o
the DT o
MB NNP o
isoenzyme NN o
of IN o
creatine NN o
kinase NN o
( ( o
CK-MB NNP o
) ) o
, , o
occurrence NN o
of IN o
myocardial JJ o
ischemia NN o
or CC o
infarction NN o
, , o
and CC o
mean JJ o
duration NN o
of IN o
using VBG o
inotropic JJ o
agents NNS o
were VBD N
significantly RB N
lower JJR N
in IN N
the DT N
milrinone NN N
group NN N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
. . N

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
between IN N
the DT N
two CD N
groups NNS N
regarding VBG N
the DT N
development NN o
of IN o
ventricular JJ o
arrhythmia NN o
, , o
duration NN o
of IN o
cardiopulmonary JJ o
bypass NN o
, , o
intra-aortic JJ o
balloon NN o
pump NN o
and CC o
inotropic JJ o
support NN o
requirement NN o
, , o
duration NN o
of IN o
mechanical JJ o
ventilation NN o
, , o
duration NN o
of IN o
intensive JJ o
care NN o
unit NN o
stay NN o
and CC o
mortality NN o
rate NN o
. . o

Although IN N
mean JJ N
pre-operative JJ N
LVEF NNP N
was VBD N
significantly RB N
lower JJR N
in IN N
the DT N
milrinone NN i
group NN N
, , N
there EX N
was VBD N
no DT N
significant JJ N
difference NN N
between IN N
post-operative JJ N
LVEFs NNP N
. . N

CONCLUSIONS NNP N
We PRP N
suggest VBP N
that IN N
perioperative JJ N
administration NN N
of IN N
milrinone NN i
in IN N
patients NNS p
undergoing VBG p
on-pump JJ p
CABG NNP p
, , N
especially RB N
those DT N
with IN N
low JJ N
LVEF NNP N
, , N
is VBZ N
beneficial JJ N
. . N

-DOCSTART- -14662278- O O

Determination NN N
of IN N
vital JJ N
status NN N
at IN N
the DT N
end NN N
of IN N
the DT N
DIG NNP N
trial NN N
. . N

The DT N
Digitalis NNP N
Investigation NNP N
Group NNP N
( ( N
DIG NNP N
) ) N
trial NN N
was VBD N
a DT N
randomized JJ N
, , N
double-blind JJ N
placebo-controlled JJ i
trial NN N
whose WP$ N
primary JJ N
objective NN N
was VBD N
to TO N
determine VB N
whether IN N
digoxin NN i
had VBD N
beneficial JJ N
, , N
harmful JJ N
, , N
or CC N
no DT N
effect NN N
on IN N
total JJ N
mortality NN N
in IN N
patients NNS p
with IN p
heart NN p
failure NN p
who WP p
were VBD p
in IN p
sinus NN p
rhythm NN p
and CC p
whose WP$ p
ejection NN p
fraction NN p
was VBD p
< JJ p
/=0.45 NNP p
. . p

The DT N
study NN N
was VBD N
designed VBN N
as IN N
a DT N
large JJ N
simple JJ N
trial NN N
with IN N
a DT p
large JJ p
number NN p
of IN p
centers NNS p
( ( p
302 CD p
) ) p
in IN p
the DT p
United NNP p
States NNPS p
and CC p
Canada NNP p
, , p
many JJ p
of IN p
which WDT p
were VBD p
inexperienced VBN p
in IN p
research NN p
. . p

To TO N
ensure VB N
that IN N
the DT N
results NNS N
of IN N
the DT N
trial NN N
would MD N
be VB N
reported VBN N
accurately RB N
without IN N
possible JJ N
bias NN N
due JJ N
to TO N
missing VBG N
data NNS N
, , N
the DT N
study NN N
leadership NN N
decided VBD N
that IN N
no DT N
outcome NN N
results NNS N
would MD N
be VB N
reported VBN N
until IN N
the DT N
vital JJ N
status NN N
at IN N
the DT N
end NN N
of IN N
the DT N
study NN N
was VBD N
known VBN N
for IN N
at IN N
least JJS N
97 CD N
% NN N
of IN N
the DT N
study NN N
participants NNS N
. . N

Planning VBG N
for IN N
closeout NN N
of IN N
the DT N
study NN N
began VBD N
a DT N
year NN N
prior RB N
to TO N
the DT N
common JJ N
end NN N
date NN N
of IN N
December NNP N
31 CD N
, , N
1995 CD N
and CC N
included VBD N
plans NNS N
for IN N
obtaining VBG N
vital JJ N
status NN N
on IN N
December NNP N
31 CD N
, , N
1995 CD N
. . N

Participants NNS N
were VBD N
given VBN i
postcards NNS i
at IN i
their PRP$ i
final JJ i
study NN i
visit NN i
to TO i
be VB i
completed VBN i
and CC i
mailed VBN i
on IN i
or CC i
after IN i
January NNP i
1 CD i
, , i
1996 CD i
. . i

Of IN p
5602 CD p
postcards NNS p
distributed VBN p
, , p
5070 CD p
( ( p
90.5 CD p
% NN p
) ) p
were VBD p
completed VBN p
and CC p
returned VBN p
. . p

A DT N
contract NN N
search NN N
agency NN N
was VBD N
hired VBN N
to TO N
locate VB N
the DT N
remaining VBG N
participants NNS N
. . N

Of IN p
the DT p
total JJ p
7788 CD p
participants NNS p
entered VBD p
into IN p
the DT p
DIG NNP p
trial NN p
, , p
only RB p
97 CD p
participants NNS p
( ( p
1.2 CD p
% NN p
) ) p
could MD p
not RB p
have VB p
their PRP$ p
vital JJ o
status NN o
as IN p
of IN p
December NNP p
31 CD p
, , p
1995 CD p
determined VBD p
. . p

It PRP N
is VBZ N
recommended VBN N
that IN N
investigators NNS N
having VBG N
an DT N
outcome NN N
measure NN N
with IN N
a DT N
common JJ N
end NN N
date NN N
include VBP N
plans NNS N
in IN N
their PRP$ N
protocols NNS N
for IN N
obtaining VBG N
their PRP$ N
measures NNS N
and CC N
activate VBP N
those DT N
plans NNS N
as RB N
early RB N
as IN N
possible JJ N
during IN N
the DT N
course NN N
of IN N
the DT N
study NN N
. . N

-DOCSTART- -21599896- O O

Study NNP N
protocol NN N
: : N
Phase NNP N
III NNP N
single-blinded JJ N
fast-track JJ N
pragmatic NN N
randomised VBD N
controlled JJ N
trial NN N
of IN N
a DT N
complex JJ N
intervention NN N
for IN N
breathlessness NN o
in IN o
advanced JJ o
disease NN o
. . o

BACKGROUND NNP N
Breathlessness NNP N
in IN N
advanced JJ N
disease NN N
causes VBZ N
significant JJ N
distress NN o
to TO o
patients NNS o
and CC N
carers NNS N
and CC N
presents NNS N
management NN o
challenges VBZ o
to TO o
health NN o
care NN o
professionals NNS o
. . o

The DT N
Breathlessness NNP i
Intervention NNP i
Service NNP i
( ( i
BIS NNP i
) ) i
seeks VBZ N
to TO N
improve VB N
the DT N
care NN o
of IN o
breathless NN o
patients NNS o
with IN p
advanced JJ p
disease NN p
( ( p
regardless NN p
of IN p
cause NN p
) ) p
through IN N
the DT N
use NN N
of IN N
evidence-based JJ N
practice NN N
and CC N
working VBG N
with IN N
other JJ N
healthcare NN N
providers NNS N
. . N

BIS NNP i
delivers VBZ N
a DT i
complex JJ i
intervention NN i
( ( i
of IN i
non-pharmacological JJ i
and CC i
pharmacological JJ i
treatments NNS i
) ) i
via IN N
a DT N
multi-professional JJ N
team NN N
. . N

BIS NNP i
is VBZ N
being VBG N
continuously RB N
developed VBN N
and CC N
its PRP$ N
impact NN N
evaluated VBN N
using VBG N
the DT N
MRC NNP N
's POS N
framework NN N
for IN N
complex JJ N
interventions NNS N
( ( N
PreClinical NNP N
, , N
Phase NNP N
I PRP N
and CC N
Phase NNP N
II NNP N
completed VBD N
) ) N
. . N

This DT N
paper NN N
presents VBZ N
the DT N
protocol NN N
for IN N
Phase NNP N
III NNP N
. . N

METHODS/DESIGN NNP N
Phase NNP N
III NNP N
comprises VBZ N
a DT N
pragmatic JJ N
, , N
fast-track JJ N
, , N
single-blind JJ N
randomised VBD N
controlled JJ N
trial NN N
of IN N
BIS NNP i
versus FW N
standard NN i
care NN i
. . i

Due NNP N
to TO N
differing VBG N
disease NN N
trajectories NNS N
, , N
the DT N
service NN N
uses VBZ N
two CD i
broad JJ i
service NN i
models NNS i
: : i
one CD N
for IN N
patients NNS p
with IN p
malignant JJ p
disease NN p
( ( p
intervention NN p
delivered VBN p
over IN p
two CD p
weeks NNS p
) ) p
and CC p
one CD p
for IN p
patients NNS p
with IN p
non-malignant JJ p
disease NN p
( ( p
intervention NN p
delivered VBN p
over IN p
four CD p
weeks NNS p
) ) p
. . p

The DT N
Phase NNP N
III NNP N
trial NN N
therefore NN N
consists VBZ N
of IN N
two CD N
sub-protocols NNS N
: : N
one CD N
for IN N
patients NNS p
with IN p
malignant JJ p
conditions NNS p
( ( p
four CD p
week NN p
protocol NN p
) ) p
and CC p
one CD p
for IN p
patients NNS p
with IN p
non-malignant JJ p
conditions NNS p
( ( N
eight CD N
week NN N
protocol NN N
) ) N
. . N

Mixed JJ i
method NN i
interviews NNS i
are VBP N
conducted VBN N
with IN N
patients NNS N
and CC N
their PRP$ N
lay NN N
carers NNS N
at IN N
three CD N
to TO N
five CD N
measurement NN N
points NNS N
depending VBG N
on IN N
randomisation NN N
and CC N
sub-protocol NN N
. . N

Qualitative JJ N
interviews NNS N
are VBP N
conducted VBN N
with IN N
referring VBG N
and CC N
non-referring JJ N
health NN N
care NN N
professionals NNS N
( ( N
malignant JJ N
disease NN N
protocol NN N
only RB N
) ) N
. . N

The DT N
primary JJ N
outcome JJ N
measure NN N
is VBZ N
'patient JJ o
distress NN o
due JJ o
to TO o
breathlessness VB o
' '' o
measured VBN o
on IN o
a DT o
numerical JJ o
rating NN o
scale NN o
( ( o
0-10 JJ o
) ) o
. . o

The DT N
trial NN N
includes VBZ N
economic JJ o
evaluation NN o
. . o

Analysis NN N
will MD N
be VB N
on IN N
an DT N
intention NN N
to TO N
treat VB N
basis NN N
. . N

DISCUSSION NNP N
This DT N
is VBZ N
the DT N
first JJ N
evaluation NN N
of IN N
a DT N
breathlessness NN N
intervention NN N
for IN N
advanced JJ N
disease NN N
to TO N
have VB N
followed VBN N
the DT N
MRC NNP N
framework NN N
and CC N
one CD N
of IN N
the DT N
first JJ N
palliative JJ N
care NN N
trials NNS N
to TO N
use VB N
fast JJ N
track NN N
methodology NN N
and CC N
single-blinding NN N
. . N

The DT N
results NNS N
will MD N
provide VB N
evidence NN N
of IN N
the DT N
clinical JJ o
and CC o
cost-effectiveness NN o
of IN o
the DT o
service NN o
, , N
informing VBG N
its PRP$ N
longer JJR N
term NN N
development NN N
and CC N
implementation NN N
of IN N
the DT N
model NN N
in IN N
other JJ N
centres NNS N
nationally RB N
and CC N
internationally RB N
. . N

It PRP N
adds VBZ N
to TO N
methodological JJ N
developments NNS N
in IN N
palliative JJ i
care NN i
research NN N
where WRB N
complex JJ N
interventions NNS N
are VBP N
common JJ N
but CC N
evidence NN N
sparse NN N
. . N

TRIAL NNP N
REGISTRATION NNP N
ClinicalTrials.gov NNP N
: : N
NCT00678405ISRCTN NN N
: : N
ISRCTN04119516 NNP N
. . N

-DOCSTART- -22277402- O O

[ JJ p
Branch NNP p
atheromatous JJ p
disease NN p
: : p
prognosis NN N
and CC N
management NN N
. . N

The DT N
SPS3 NNP i
experience NN N
] NN N
. . N

-DOCSTART- -20051135- O O

Improved VBN N
adherence NN o
with IN N
once-daily JJ N
versus NN N
twice-daily RB N
dosing NN N
of IN N
mometasone NN i
furoate NN i
administered VBD N
via IN N
a DT N
dry JJ N
powder NN N
inhaler NN N
: : N
a DT N
randomized JJ N
open-label NN N
study NN N
. . N

BACKGROUND NNP N
Poor NNP N
adherence NN N
with IN N
prescribed JJ N
asthma JJ N
medication NN N
is VBZ N
a DT N
major JJ N
barrier NN N
to TO N
positive JJ N
treatment NN N
outcomes RB N
. . N

This DT N
study NN N
was VBD N
designed VBN N
to TO N
determine VB N
the DT N
effect NN N
of IN N
a DT N
once-daily JJ N
administration NN N
of IN N
mometasone NN i
furoate NN i
administered VBD N
via IN N
a DT N
dry JJ N
powder NN N
inhaler NN N
( ( N
MF-DPI NNP N
) ) N
on IN N
treatment NN N
adherence NN N
compared VBN N
with IN N
a DT N
twice-daily JJ N
administration NN N
. . N

METHODS NNP N
This DT N
was VBD N
a DT N
12-week JJ N
open-label NN N
study NN N
designed VBN N
to TO N
mimic VB N
an DT N
actual JJ N
clinical JJ N
setting NN N
in IN p
patients NNS p
> JJ p
or=12 CD p
years NNS p
old JJ p
with IN p
mild-to-moderate JJ p
persistent JJ p
asthma NN p
. . p

Patients NNS N
were VBD N
randomized VBN N
to TO N
receive VB N
MF-DPI NNP i
400 CD i
microg NN i
once-daily RB i
in IN i
the DT i
evening NN i
or CC i
MF-DPI JJ i
200 CD i
microg JJ i
twice-daily RB i
. . i

Adherence NNP o
was VBD N
assessed VBN N
primarily RB N
using VBG N
the DT N
number NN N
of IN N
actual JJ o
administered VBN o
doses NNS o
reported VBN N
from IN N
the DT N
device NN N
counter NN N
divided VBN N
by IN N
the DT N
number NN N
of IN N
scheduled JJ N
doses NNS N
. . N

Self-reports NNS N
were VBD N
also RB N
used VBN N
to TO N
determine VB N
adherence NN N
. . N

Health-related JJ o
quality NN o
of IN o
life NN o
, , o
healthcare JJ o
resource NN o
utilization NN o
, , o
and CC o
days NNS o
missed VBN o
from IN o
work NN o
or CC o
school NN o
were VBD N
also RB N
reported VBN N
. . N

RESULTS JJ N
1233 CD p
patients NNS p
were VBD p
randomized VBN p
. . p

The DT N
mean JJ o
adherence NN o
rates NNS o
, , N
as IN N
measured VBN N
by IN N
the DT N
automatic JJ N
dose NN N
counter NN N
, , N
were VBD N
significantly RB N
better JJR N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
with IN N
MF-DPI NNP N
400 CD N
microg NN N
once-daily RB N
in IN N
the DT N
evening NN N
( ( N
93.3 CD N
% NN N
) ) N
than IN N
with IN N
MF-DPI NNP N
200 CD N
microg NN N
twice-daily RB N
( ( N
89.5 CD N
% NN N
) ) N
. . N

Mean JJ o
adherence NN o
rates NNS o
based VBN N
on IN N
self-reports NNS N
were VBD N
also RB N
significantly RB N
better RBR N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
with IN N
MF-DPI NNP N
400 CD N
microg NN N
QD NNP N
PM NNP N
( ( N
97.2 CD N
% NN N
) ) N
than IN N
with IN N
MF-DPI NNP N
200 CD N
microg NN N
twice-daily RB N
( ( N
95.3 CD N
% NN N
) ) N
. . N

Adherence NN o
rates NNS o
were VBD N
lower JJR N
in IN N
adolescents NNS N
( ( N
12-17 CD N
years NNS N
old JJ N
) ) N
. . N

Health-related JJ o
quality NN o
of IN o
life NN o
improved VBN N
by IN N
20 CD N
% NN N
in IN N
patients NNS N
using VBG N
MF-DPI JJ N
once-daily RB N
in IN N
the DT N
evening NN N
and CC N
by IN N
14 CD N
% NN N
in IN N
patients NNS N
using VBG N
MF-DPI JJ N
twice-daily JJ N
. . N

Very RB N
few JJ N
( ( N
< JJ N
8 CD N
% NN N
) ) N
patients NNS N
missed JJ o
work/school NN o
. . o

CONCLUSION NNP N
Mean NNP N
adherence NN o
rates NNS o
were VBD N
greater JJR N
with IN N
a DT N
once-daily JJ N
dosing VBG N
regimen NNS N
of IN N
MF-DPI NNP i
than IN N
with IN N
a DT N
twice-daily JJ N
dosing NN N
regimen.This NN N
trial NN N
was VBD N
completed VBN N
prior RB N
to TO N
the DT N
ISMJE NNP N
requirements NNS N
for IN N
trial NN N
registration NN N
. . N

-DOCSTART- -21929716- O O

Comparison NNP N
of IN N
two CD N
artificial JJ i
tear JJ i
formulations NNS i
for IN N
dry JJ N
eye NN N
through IN N
high-resolution JJ N
optical JJ N
coherence NN N
tomography NN N
. . N

PURPOSE VB N
The DT N
aim NN N
was VBD N
to TO N
determine VB N
the DT N
efficacy NN N
of IN N
two CD i
artificial JJ i
eye-drop JJ i
formulations NNS i
by IN N
analysing VBG N
the DT N
lower JJR N
tear NN N
film NN N
meniscus NN N
volume NN N
through IN N
a DT N
commercial JJ N
high-resolution NN N
spectral-domain JJ N
optical JJ N
coherence NN N
tomographer NN N
. . N

METHODS NNP N
Twenty NNP p
dry JJ p
eye NN p
patients NNS p
( ( p
12 CD p
men NNS p
, , p
eight CD p
women NNS p
, , p
aged VBD p
57.5 CD p
? . p
8.4 CD p
years NNS p
) ) p
with IN p
refractive JJ p
errors NNS p
from IN p
-2.50 NN p
to TO p
+0.75 VB p
D NNP p
( ( p
mean JJ p
-1.34 NNP p
? . p
1.02 CD p
D NNP p
) ) p
and CC p
cylinders NNS p
lower JJR p
than IN p
1.00 CD p
D NNP p
were VBD p
examined VBN o
. . o

Tear JJ o
meniscus NN o
volume NN o
was VBD o
measured VBN N
before IN N
, , N
immediately RB N
after IN N
and CC N
10 CD N
, , N
30 CD N
and CC N
60 CD N
minutes NNS N
after IN N
instillation NN N
using VBG N
the DT N
Copernicus NNP N
high-resolution NN N
spectral-domain JJ N
optical JJ N
coherence NN N
tomographer NN N
( ( N
Optopol NNP N
Tech NNP N
SA NNP N
, , N
Zawiercie NNP N
, , N
Poland NNP N
) ) N
. . N

Volume NN N
was VBD N
calculated VBN N
from IN N
the DT N
local JJ N
area NN N
obtained VBN N
from IN N
tomograms NNS N
considering VBG N
a DT N
regular JJ N
distribution NN N
of IN N
the DT N
tear JJ N
meniscus NN N
across IN N
the DT N
eyelid NN N
. . N

Ten CD N
subjects NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
first VB N
receive VB N
either DT i
polyethylene NN i
glycol NN i
( ( i
Blink NNP i
Intensive NNP i
, , i
Abbot NNP i
Medical NNP i
Optics NNP i
Inc NNP i
, , i
CA NNP i
, , i
USA NNP i
) ) i
or CC i
hypromellose JJ i
( ( i
Artific NNP i
, , i
Farma-Lepori NNP i
SA NNP i
, , i
Barcelona NNP i
, , i
Spain NNP i
) ) i
three CD i
times NNS i
daily RB i
in IN i
both DT i
eyes NNS i
for IN i
one CD i
month NN i
. . i

Measures NNS N
were VBD N
then RB N
repeated VBN N
and CC N
after IN N
a DT N
one-week JJ N
wash-out JJ N
period NN N
they PRP N
were VBD N
switched VBN N
to TO N
the DT N
other JJ N
eye-drop NN N
for IN N
another DT N
month NN N
. . N

RESULTS NNP o
Mean NNP o
baseline NN o
volume NN o
was VBD o
0.38 CD N
? . N
0.10 CD N
?L NN N
, , N
while IN N
mean JJ N
baseline NN N
volume NN N
after IN N
the DT N
wash-out JJ N
period NN N
was VBD N
slightly RB N
higher JJR N
, , N
0.39 CD N
? . N
0.10 CD N
?L NN N
( ( N
p JJ N
= NNP N
0.638 CD N
) ) N
. . N

Analysis NN N
of IN N
variance NN N
showed VBD N
significant JJ N
differences NNS N
in IN N
meniscus NN N
volume NN N
with IN N
time NN N
after IN N
instillation NN N
with IN N
both DT N
formulations NNS N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
, , o
mean JJ o
volume NN o
decreasing VBG o
with IN o
time NN o
. . o

At IN N
30 CD N
and CC N
60 CD N
minutes NNS N
following VBG N
instillation NN N
, , N
values NNS N
decreased VBD N
to TO N
almost RB N
baseline VB N
( ( N
average JJ N
difference NN N
0.02 CD N
? . N
0.03 CD N
?L NN N
at IN N
t NN N
( ( N
30 CD N
) ) N
, , N
p JJ N
= NN N
0.016 CD N
and CC N
0.01 CD N
? . N
0.01 CD N
?L NN N
at IN N
t NN N
( ( N
60 CD N
) ) N
, , N
p JJ N
= NNP N
0.098 CD N
) ) N
. . N

CONCLUSION NNP N
An DT N
increase NN N
in IN N
tear JJ N
film NN N
meniscus NN N
volume NN N
in IN N
dry JJ N
eyes NNS N
from IN N
the DT N
use NN N
of IN N
eye-drops NNS N
has VBZ N
been VBN N
shown VBN N
. . N

High JJ N
resolution NN N
imaging NN N
of IN N
lower JJR N
tear NN N
film NN N
meniscus NN N
with IN N
clinical JJ N
optical JJ N
coherence NN N
tomography NN N
systems NNS N
provides VBZ N
useful JJ N
measures NNS N
of IN o
tear JJ o
volume NN o
. . o

Both DT o
formulations NNS N
assessed VBN N
in IN N
the DT N
present JJ N
study NN N
are VBP N
efficient JJ N
in IN N
increasing VBG N
tear JJ o
meniscus NN o
volume NN o
and CC o
reducing VBG o
dry JJ o
eye NN o
signs NNS o
and CC o
symptoms NNS o
, , o
although IN N
results NNS N
in IN N
terms NNS N
of IN N
increase NN N
in IN o
meniscus JJ o
volume NN o
were VBD o
higher JJR N
with IN i
the DT i
polyethylene NN i
glycol NN i
formulation NN i
. . i

-DOCSTART- -18971406- O O

Consumer-directed JJ N
care NN N
for IN N
beneficiaries NNS p
with IN p
mental JJ p
illness NN p
: : p
lessons NNS N
from IN N
New NNP N
Jersey NNP N
's POS N
Cash NNP N
and CC N
Counseling NNP N
program NN N
. . N

OBJECTIVE NNP N
Previous NNP N
research NN N
from IN N
the DT N
Cash NNP p
and CC p
Counseling NNP p
Demonstration NNP p
and CC p
Evaluation NNP p
( ( p
CCDE NNP p
) ) p
programs NNS p
in IN p
New NNP p
Jersey NNP p
, , p
Arkansas NNP p
, , p
and CC p
Florida NNP p
suggests VBZ N
that IN N
consumers NNS N
' POS N
control NN N
over IN N
personal JJ N
care NN N
greatly RB N
improves VBZ N
their PRP$ N
satisfaction NN N
with IN N
care NN o
arrangements NNS o
and CC N
their PRP$ N
outlook NN o
on IN o
life NN o
. . o

Still RB N
, , N
some DT N
argue VBP N
that IN N
consumer-directed JJ N
care NN N
may MD N
not RB N
be VB N
appropriate JJ N
for IN N
consumers NNS N
with IN N
a DT N
diagnosis NN N
of IN N
mental JJ N
illness NN N
. . N

This DT N
study NN N
examined VBD N
the DT N
effectiveness NN o
of IN o
the DT o
CCDE NNP o
program NN o
for IN N
those DT p
with IN p
a DT p
diagnosis NN p
of IN p
mental JJ p
illness NN p
. . p

METHODS NNP N
This DT N
study NN N
examined VBD N
nonelderly RB p
Medicaid NNP p
beneficiaries NNS p
in IN p
New NNP p
Jersey NNP p
with IN p
a DT p
diagnosis NN p
of IN p
mental JJ p
illness NN p
and CC p
compared VBN i
and CC i
contrasted VBN i
the DT i
experiences NNS i
of IN i
those DT i
in IN i
New NNP i
Jersey NNP i
's POS i
CCDE NNP i
program NN i
( ( i
N=109 NNP i
) ) i
and CC i
those DT i
who WP i
received VBD i
services NNS i
provided VBN i
by IN i
an DT i
agency NN i
( ( i
N=119 NNP i
) ) i
. . p

Logistic JJ o
regression NN o
analyses NNS o
were VBD i
performed VBN i
on IN i
baseline NN i
and CC i
nine-month JJ i
follow-up JJ i
data NNS i
. . i

RESULTS VBN N
By IN N
examining VBG N
outcome JJ N
measures NNS N
-- : N
including VBG N
satisfaction NN o
with IN o
care NN o
arrangements NNS o
, , o
consumers NNS o
' POS o
perceptions NNS o
of IN o
paid JJ o
caregivers NNS o
' POS o
attitudes NNS o
, , o
unmet JJ o
needs NNS o
, , o
adverse JJ o
events NNS o
, , o
and CC o
satisfaction NN o
with IN o
life NN o
-- : o
this DT o
study NN N
offers VBZ N
evidence NN N
that IN N
, , N
from IN N
the DT N
perspective NN N
of IN N
consumers NNS N
, , N
the DT N
CCDE NNP N
program NN N
is VBZ N
appropriate JJ N
for IN N
participants NNS N
with IN N
a DT N
mental JJ N
illness NN N
diagnosis NN N
. . N

For IN N
most JJS N
outcome JJ N
measures NNS N
the DT N
CCDE NNP N
program NN N
demonstrated VBD N
a DT N
positive JJ o
effect NN o
after IN N
baseline NN N
characteristics NNS N
were VBD N
controlled VBN N
for IN N
. . N

The DT N
analysis NN N
of IN N
measures NNS N
of IN N
adverse JJ o
events NNS o
, , o
health NN o
problems NNS o
, , o
and CC o
general JJ o
health NN o
status NN o
did VBD N
not RB N
yield VB N
statistically RB N
significant JJ N
differences NNS N
between IN N
the DT N
control NN N
group NN N
and CC N
the DT N
treatment NN N
group NN N
, , N
indicating VBG N
that IN N
CCDE NNP N
care NN N
was VBD N
at IN N
least JJS N
as RB N
safe JJ N
as IN N
agency-directed JJ N
care NN N
. . N

CONCLUSIONS NNP N
Considering VBG N
the DT N
growing VBG N
need NN N
for IN N
long-term JJ N
care NN N
services NNS N
and CC N
the DT N
limited JJ N
resources NNS N
available JJ N
, , N
a DT N
consumer-directed JJ N
option NN N
can MD N
be VB N
a DT N
valuable JJ N
alternative NN N
for IN N
persons NNS p
with IN p
a DT p
diagnosis NN p
of IN p
mental JJ p
illness NN p
. . p

-DOCSTART- -21295919- O O

Using VBG N
personalized VBN i
feedback NN i
to TO N
reduce VB N
alcohol NN N
use NN N
among IN N
hazardous JJ p
drinking VBG p
college NN p
students NNS p
: : p
the DT N
moderating VBG N
effect NN N
of IN N
alcohol-related JJ N
negative JJ N
consequences NNS N
. . N

UNLABELLED JJ N
Web-based JJ i
screening NN i
and CC i
brief JJ i
interventions NNS i
that WDT N
include VBP N
personalized VBN N
feedback NN N
about IN N
their PRP$ N
alcohol NN N
use NN N
have VBP N
proven VBN N
to TO N
be VB N
particularly RB N
promising VBG N
for IN N
reducing VBG N
hazardous JJ p
drinking NN p
among IN p
university JJ p
students NNS p
. . p

Despite IN N
the DT N
increasing VBG N
use NN N
of IN N
these DT N
approaches NNS N
, , N
there EX N
is VBZ N
still RB N
relatively RB N
little JJ N
known VBN N
about IN N
how WRB N
the DT N
content NN N
of IN N
these DT N
interventions NNS N
may MD N
influence VB N
outcomes NNS N
and CC N
who WP N
may MD N
benefit VB N
most JJS N
from IN N
these DT N
approaches NNS N
. . N

The DT N
current JJ N
study NN N
sought VBD N
to TO N
address VB N
these DT N
issues NNS N
by IN N
examining VBG N
how WRB N
individual JJ N
differences NNS N
in IN N
alcohol NN N
consequences NNS N
influence NN N
outcomes NNS N
of IN N
a DT N
laboratory-based JJ i
computerized JJ i
intervention NN i
. . i

METHODS NNP N
One-hundred JJ p
and CC p
nineteen JJ p
introductory NN p
psychology NN p
students NNS p
who WP p
either DT p
had VBD p
two CD p
episodes NNS p
of IN p
heavy JJ p
episodic JJ p
drinking NN p
in IN p
the DT p
past JJ p
month NN p
or CC p
scored VBN p
?8 NNS p
on IN p
the DT p
AUDIT NNP p
participated VBD p
in IN p
this DT p
randomized VBN p
controlled VBD p
trial NN p
for IN p
course NN p
credit NN p
. . p

Participants NNS N
were VBD N
assigned VBN N
to TO N
1 CD N
of IN N
4 CD N
conditions NNS N
in IN N
this DT N
2 CD N
Intervention NNP i
( ( i
Alcohol NNP i
Feedback NNP i
vs. IN i
Control NNP i
) ) i
?2 FW i
Assessment NNP i
( ( i
Motivational NNP i
Assessment NNP i
vs. IN i
No NNP i
Motivational NNP i
Assessment NNP i
) ) i
between-subjects NNS i
design NN o
. . o

Quantity NN o
of IN o
alcohol NN o
consumed VBN o
per IN o
week NN o
and CC o
heavy JJ o
episodic JJ o
drinking VBG o
one CD o
month NN o
later RBR o
were VBD o
the DT N
primary JJ N
dependent JJ N
variables NNS N
. . N

RESULTS NNP N
Controlling VBG N
for IN N
corresponding VBG N
baseline NN o
alcohol NN o
measures NNS o
, , o
hierarchical JJ o
linear JJ N
regression NN N
analyses NNS N
showed VBD N
a DT N
significant JJ N
interaction NN N
between IN N
intervention NN N
condition NN N
and CC N
baseline VB N
alcohol-related JJ N
consequences NNS N
. . N

For IN N
those DT N
who WP N
reported VBD N
more JJR N
alcohol NN N
consequences NNS N
at IN N
baseline NN N
, , N
the DT N
alcohol NN N
intervention NN N
resulted VBD N
in IN N
significantly RB N
less JJR o
alcohol NN o
use NN o
and CC o
fewer JJR o
heavy JJ o
drinking NN o
episodes NNS o
at IN o
follow-up JJ N
, , N
while IN N
no DT N
difference NN N
was VBD N
observed VBN N
between IN N
intervention NN N
conditions NNS N
for IN N
those DT N
with IN N
few JJ N
baseline NN N
consequences NNS N
. . N

Assessment NN N
did VBD N
not RB N
moderate VB N
intervention NN N
effects NNS N
. . N

DISCUSSION NNP N
These DT N
findings NNS N
suggest VBP N
that IN i
a DT i
feedback-based JJ i
computerized JJ i
intervention NN i
that WDT i
includes VBZ N
normative JJ N
information NN N
about IN o
alcohol NN o
use NN o
and CC o
consequences NNS N
may MD N
be VB N
more RBR N
effective JJ N
for IN N
hazardous JJ p
drinking NN p
students NNS p
who WP p
are VBP p
experiencing VBG p
higher JJR p
levels NNS p
of IN p
alcohol-related JJ p
consequences NNS p
. . p

-DOCSTART- -20940688- O O

Patients NNS N
appreciation NN N
for IN N
information NN N
on IN N
anesthesia NN i
and CC N
anxiolysis NN i
in IN N
dentistry NN N
. . N

AIM NNP N
The DT N
research NN N
regards VBZ N
information NN N
on IN N
anesthesia NN i
to TO N
patients NNS p
undergoing VBG p
oral JJ p
surgery NN p
. . p

Every DT N
patient NN N
evaluated VBD N
the DT N
information NN N
received VBD N
at IN N
the DT N
end NN N
of IN N
the DT N
preoperative JJ N
visit NN N
and CC N
in IN N
the DT N
postoperative JJ N
period NN N
. . N

METHODS NNP N
One CD p
hundred-fifty JJ p
dental JJ p
patients NNS p
were VBD N
asked VBN N
about IN N
the DT N
most RBS N
appreciated JJ N
information NN N
received VBN N
in IN N
the DT N
preoperative JJ N
visit NN N
on IN N
the DT N
anxiolytic JJ i
technique NN i
, , N
local JJ N
anesthesia NN N
and CC N
treatment NN N
of IN N
the DT N
perioperative JJ N
pain NN N
. . N

Afterwards IN N
the DT N
patients NNS N
had VBD N
to TO N
report VB N
on IN N
their PRP$ N
reaction NN N
to TO N
the DT N
content NN N
of IN N
the DT N
preoperative JJ N
visit NN N
and CC N
information NN N
quality NN N
. . N

On IN N
a DT N
phone NN N
interview NN N
they PRP N
had VBD N
to TO N
evaluate VB N
their PRP$ N
appreciation NN N
of IN N
the DT N
anxiolytic JJ N
technique NN N
, , N
their PRP$ N
perception NN N
during IN N
loco-regional JJ i
anesthesia NN i
and CC N
incidence NN N
of IN N
pain NN N
and CC N
edema NN N
. . N

RESULTS VB N
The DT N
most RBS N
appreciated JJ N
details NNS N
were VBD N
those DT N
on IN N
the DT N
intervention NN N
, , N
pharmacologic JJ N
treatment NN N
, , N
postoperative JJ N
complicances NNS N
, , N
postoperative JJ N
pain NN N
and CC N
operative JJ N
competence NN N
; : N
less CC N
appreciated JJ N
were VBD N
those DT N
on IN N
loco-regional JJ N
anesthesia NN N
, , N
duration NN N
of IN N
the DT N
intervention NN N
, , N
anxiolytic JJ N
techniques NNS N
, , N
hospital JJ N
reception NN N
and CC N
permanence NN N
in IN N
the DT N
hospital NN N
. . N

Ninety-eight JJ N
percent NN N
of IN N
the DT N
patients NNS N
considered VBN N
to TO N
have VB N
been VBN N
adequately RB N
informed VBN N
on IN N
a DT N
context NN N
judged VBN N
to TO N
be VB N
extraordinary JJ N
( ( N
99.3 CD N
% NN N
) ) N
, , N
96.6 CD N
% NN N
indicated VBD N
the DT N
information NN N
as IN N
necessary JJ N
, , N
98.6 CD N
% NN N
appreciated VBD N
the DT N
treatment NN o
of IN N
the DT N
intraoperative JJ N
and CC N
postoperative JJ N
( ( N
99.3 CD N
% NN N
) ) N
pain NN N
and CC N
99.3 CD N
% NN N
the DT N
anxiolytic JJ N
treatment NN N
. . N

On IN N
the DT N
telephone NN N
interview NN N
, , N
100 CD N
% NN N
of IN N
patients NNS N
expressed VBN N
satisfaction NN N
for IN N
the DT N
experienced JJ N
intraoperative JJ o
tranquillity NN o
, , N
91.3 CD N
% NN N
complained VBD N
for IN N
not RB N
having VBG N
received VBN N
in IN N
the DT N
past NN N
a DT N
similar JJ N
preoperative JJ N
visit NN N
, , N
99.3 CD N
% NN N
wished VBD N
a DT N
diffused JJ o
application NN o
of IN N
the DT N
information NN N
. . N

The DT N
loco-regional JJ N
anesthesia NN N
was VBD N
associated VBN N
to TO N
psychological JJ N
detachment NN N
in IN N
84 CD N
% NN N
of IN N
the DT N
cases NNS N
and CC N
the DT N
incidence NN N
of IN N
postoperative JJ o
pain NN o
was VBD N
of IN N
36 CD N
% NN N
. . N

CONCLUSION NNP N
The DT N
information NN N
on IN N
the DT N
anxiolytic JJ i
techniques NNS i
, , i
loco-regional JJ i
anesthesia NN i
, , i
treatment NN i
of IN i
perioperative JJ i
pain NN i
and CC N
postoperative JJ N
distress NN N
was VBD N
enthusiastically RB N
accepted VBN N
and CC N
albeit VBN N
initially RB N
induced JJ N
feelings NNS N
of IN N
astonishment NN N
resulted VBD N
to TO N
be VB N
appreciated VBN o
and CC N
preferred VBN o
in IN N
the DT N
whole NN N
of IN N
the DT N
patients NNS N
. . N

-DOCSTART- -22989372- O O

Airway NNP o
responses NNS o
and CC o
inflammation NN o
in IN N
subjects NNS p
with IN p
asthma NN p
after IN N
four CD N
days NNS N
of IN N
repeated JJ i
high-single-dose JJ i
allergen NN i
challenge NN i
. . i

BACKGROUND NNP N
Both NNP N
standard JJ N
and CC N
low-dose JJ N
allergen NN N
provocations NNS N
are VBP N
an DT N
established JJ N
tool NN N
in IN N
asthma JJ N
research NN N
to TO N
improve VB N
our PRP$ N
understanding NN N
of IN N
the DT N
pathophysiological JJ N
mechanism NN N
of IN N
allergic JJ p
asthma NN p
. . p

However RB N
, , N
clinical JJ N
symptoms NNS N
are VBP N
less RBR N
likely JJ N
to TO N
be VB N
induced VBN N
. . N

Therefore RB N
, , N
we PRP N
designed VBD N
a DT N
protocol NN N
for IN N
repetitive JJ N
high-dose JJ N
bronchial JJ N
allergen NN N
challenges NNS N
to TO N
generate VB N
clinical JJ N
symptoms NNS N
and CC N
airway JJ N
inflammation NN N
. . N

METHODS NNP N
A NNP N
total NN N
of IN N
27 CD p
patients NNS p
aged VBD p
18 CD p
to TO p
40 CD p
years NNS p
with IN p
positive JJ p
skin-prick JJ p
tests NNS p
and CC p
mild JJ p
asthma JJ p
underwent JJ N
repetitive JJ i
high-dose JJ i
allergen NN i
challenges NNS i
with IN i
household NN i
dust NN i
mites NNS i
for IN i
four CD i
consecutive JJ i
days NNS i
. . i

Pulmonary JJ o
function NN o
and CC o
exhaled VBD o
NO NNP o
were VBD N
measured VBN N
at IN N
every DT N
visit NN N
. . N

Induced NNP o
sputum NN o
was VBD N
analysed VBN N
before IN N
and CC N
after IN N
the DT N
allergen NN N
challenges VBZ N
for IN N
cell NN N
counts NNS N
, , N
ECP NNP N
, , N
IL-5 NNP N
, , N
INF-? NNP N
, , N
IL-8 NNP N
, , N
and CC N
the DT N
transcription NN N
factor NN N
Foxp3 NNP N
. . N

RESULTS NNP N
We PRP N
found VBD N
a DT N
significant JJ N
decrease NN N
in IN o
pulmonary JJ o
function NN o
, , o
an DT N
increased VBN N
use NN N
of IN N
salbutamol NN N
and CC N
the DT o
development NN o
of IN o
a DT o
late JJ o
asthmatic JJ o
response NN o
and CC o
bronchial JJ o
hyperresponsiveness NN o
, , o
as RB N
well RB N
as IN N
a DT N
significant JJ o
induction NN o
of IN o
eNO NN o
, , o
eosinophils NNS o
, , o
and CC o
Th-2 NNP o
cytokines NNS o
. . o

Repeated VBN o
provocation NN o
was VBD N
feasible JJ N
in IN N
the DT N
majority NN N
of IN N
patients NNS N
. . N

Two CD N
subjects NNS N
had VBD o
severe JJ o
adverse JJ o
events NNS o
requiring VBG i
prednisolone NN i
to TO N
cope VB N
with IN N
nocturnal JJ N
asthma NN N
symptoms NNS N
. . N

CONCLUSIONS NNP N
Repeated VBD N
high-dose JJ N
bronchial JJ N
allergen NN N
challenges NNS N
resulted VBD N
in IN N
severe JJ N
asthma NN N
symptoms NNS N
and CC N
marked VBD o
Th-2-mediated NNP o
allergic JJ o
airway NN o
inflammation NN o
. . o

The DT N
high-dose JJ N
challenge NN N
model NN N
is VBZ N
suitable JJ N
only RB N
in IN N
an DT N
attenuated JJ N
form NN N
in IN p
diseased JJ p
volunteers NNS p
for IN N
proof-of-concept JJ N
studies NNS N
and CC N
in IN N
clinical JJ N
settings NNS N
to TO N
reduce VB N
the DT N
risk NN N
of IN N
severe JJ N
asthma JJ N
exacerbations NNS N
. . N

TRIAL NNP N
REGISTRATION NNP N
ClinicalTrials.govNCT00677209 NNP N
. . N

-DOCSTART- -9772038- O O

Involvement NN N
of IN N
cholecystokininA NN N
receptors NNS N
in IN N
transient NN N
lower JJR N
esophageal NN N
sphincter NN N
relaxations NNS N
triggered VBN N
by IN N
gastric JJ N
distension NN N
. . N

OBJECTIVE CC N
Transient NNP o
lower JJR o
esophageal NN o
sphincter NN o
relaxations NNS o
( ( o
TLESRs NNP o
) ) o
are VBP N
the DT N
main JJ N
mechanism NN N
underlying VBG N
gastroesophageal JJ N
reflux NN N
. . N

In IN N
the DT N
present JJ N
study NN N
we PRP N
evaluated VBD N
the DT N
effect NN N
of IN N
loxiglumide NN N
, , N
a DT N
specific JJ N
cholecystokininA NN N
( ( N
CCKA NNP N
) ) N
-receptor NN N
antagonist NN N
, , N
on IN N
the DT N
occurrence NN N
of IN N
TLESRs NNP N
evoked VBN N
by IN N
gastric JJ N
distension NN N
. . N

METHODS NNP N
Eight NNP p
healthy JJ p
subjects NNS p
underwent JJ p
esophageal JJ p
manometry NN p
using VBG p
a DT p
10-lumen JJ i
sleeve NN i
assembly NN i
during IN i
placebo NN i
or CC i
loxiglumide NN i
( ( p
10 CD p
mg/kg/h NN p
) ) p
in IN p
a DT N
randomized JJ N
double-blind JJ N
order NN N
. . N

Gastric NNP N
distension NN N
was VBD N
induced VBN N
by IN N
inflation NN i
of IN i
400 CD i
ml NN i
of IN i
air NN i
. . i

RESULTS VB N
Basal NNP o
lower JJR o
esophageal NN o
pressure NN o
( ( o
LESP NNP o
) ) o
and CC o
swallow-induced JJ o
relaxation NN o
were VBD N
not RB N
affected VBN N
by IN N
loxiglumide NN N
. . N

Loxiglumide NNP N
significantly RB N
reduced VBD N
the DT N
number NN N
of IN N
TLESRs NNP o
, , N
from IN N
11.5 CD N
( ( N
5.8-18.3 JJ N
) ) N
to TO N
6.0 CD N
( ( N
3.3-14.3 JJ N
) ) N
during IN N
the DT N
total JJ N
recording JJ N
period NN N
of IN N
1 CD N
h NN N
, , N
and CC N
from IN N
5.5 CD N
( ( N
4.25-7.5 JJ N
) ) N
to TO N
2.0 CD N
( ( N
0.5-6.8 JJ N
) ) N
during IN N
the DT N
first JJ N
15 CD N
min NN N
. . N

The DT N
number NN o
of IN o
common JJ o
cavities NNS o
was VBD N
significantly RB N
decreased VBN N
by IN N
loxiglumide NN N
, , N
from IN N
8.0 CD N
( ( N
4.0-20.0 JJ N
) ) N
to TO N
5.0 CD N
( ( N
2.0-7.8 JJ N
) ) N
. . N

TLESRs NNP o
represented VBD N
the DT N
main JJ N
mechanism NN N
( ( N
60 CD N
% NN N
during IN N
placebo NN N
, , N
74 CD N
% NN N
during IN N
loxiglumide NN N
) ) N
underlying VBG N
common JJ N
cavities NNS N
, , N
followed VBN N
by IN N
swallow-induced JJ N
relaxation NN N
. . N

CONCLUSIONS NNP N
Loxiglumide NNP N
significantly RB N
reduces VBZ N
the DT N
number NN N
of IN N
TLESRs NNP o
triggered VBN N
by IN N
gastric JJ N
distension NN N
without IN N
interfering VBG N
with IN N
swallow-related JJ N
relaxation NN N
of IN N
the DT N
lower JJR N
esophageal NN N
sphincter NN N
, , N
suggesting VBG N
the DT N
involvement NN N
of IN N
CCKA NNP N
receptors NNS N
in IN N
the DT N
reflex JJ N
pathway NN N
mediating VBG N
TLESRs NNP N
. . N

-DOCSTART- -17490976- O O

Supplementation NN i
with IN i
iron NN i
and CC i
riboflavin NN i
enhances NNS N
dark JJ N
adaptation NN N
response NN N
to TO N
vitamin VB i
A-fortified NNP i
rice NN i
in IN N
iron-deficient JJ p
, , p
pregnant JJ p
, , p
nightblind JJ p
Nepali NNP p
women NNS p
. . p

BACKGROUND NNP N
Nightblindness NNP N
affects VBZ N
16-52 CD N
% NN N
of IN N
pregnant JJ N
women NNS N
in IN N
areas NNS N
of IN N
Nepal NNP N
and CC N
in IN N
some DT N
cases NNS N
persists NNS N
after IN N
vitamin VBG i
A DT i
treatment NN N
. . N

Iron NNP i
and CC i
riboflavin VB i
affect JJ N
vitamin NN N
A DT N
utilization NN N
and CC N
photoreceptor NN N
function NN N
, , N
respectively RB N
, , N
and CC N
pilot NN N
data NNS N
in IN N
the DT N
study NN N
population NN N
showed VBD N
a DT N
high JJ N
prevalence NN N
of IN N
iron NN N
and CC N
riboflavin NN N
deficiencies NNS N
. . N

OBJECTIVE IN N
The DT N
objective NN N
was VBD N
to TO N
assess VB N
the DT N
effect NN N
of IN N
supplemental JJ i
iron NN i
and CC i
riboflavin NN i
on IN N
pupillary JJ N
threshold NN N
( ( N
PT NNP N
) ) N
and CC N
plasma JJ N
retinol NN N
in IN N
nightblind NN N
, , N
pregnant JJ p
Nepali NNP p
women NNS p
given VBN p
vitamin JJ p
A-fortified JJ p
rice NN p
. . p

DESIGN NNP N
Nightblind NNP p
pregnant JJ p
women NNS p
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
, , N
6 CD N
d/wk NN N
under IN N
supervision NN N
for IN N
6 CD N
wk NN N
, , N
a DT N
vitamin JJ i
A-fortified JJ i
rice NN i
curry NN i
dish JJ i
providing VBG N
850 CD N
microg JJ N
retinal JJ N
activity NN N
equivalents/d NN N
with IN N
either DT N
a DT N
30-mg JJ i
Fe NNP i
and CC i
6-mg JJ i
riboflavin NN i
( ( N
FeR NNP N
+ NNP N
VA NNP N
) ) N
capsule NN N
or CC N
a DT N
placebo NN i
control NN i
( ( N
VA NNP N
only RB N
) ) N
capsule NN N
. . N

Hemoglobin NNP o
, , o
erythrocyte NN o
riboflavin NN o
, , o
and CC o
plasma NN o
ferritin NN o
and CC o
retinol NN o
were VBD N
measured VBN N
before IN N
and CC N
after IN N
the DT N
intervention NN N
. . N

Dark NNP N
adaptation NN N
was VBD N
assessed VBN N
by IN N
PT NNP N
score NN N
. . N

RESULTS NNP N
Women NNP N
who WP N
were VBD N
iron JJ N
deficient NN N
at IN N
baseline NN N
( ( N
n=38 JJ N
) ) N
had VBD N
significantly RB N
greater JJR N
improvement NN N
in IN N
PT NNP o
score NN o
with IN o
iron NN o
and CC o
riboflavin NN o
supplementation NN o
than IN N
without IN N
( ( N
P=0.05 NNP N
) ) N
. . N

Iron NNP N
and CC N
riboflavin JJ N
supplements NNS N
significantly RB N
reduced VBD N
the DT N
prevalences NNS N
of IN N
riboflavin JJ o
deficiency NN o
( ( N
from IN N
60 CD N
% NN N
to TO N
6 CD N
% NN N
; : N
P NNP N
< NNP N
0.0001 CD N
) ) N
, , N
iron JJ o
deficiency NN o
anemia NN o
( ( N
from IN N
35 CD N
% NN N
to TO N
15 CD N
% NN N
; : N
P NNP N
< NNP N
0.007 CD N
) ) N
, , N
and CC N
abnormal JJ o
PT NNP o
( ( N
from IN N
87 CD N
% NN N
to TO N
30 CD N
% NN N
; : N
P NNP N
< NNP N
0.05 CD N
) ) N
from IN N
baseline NN N
. . N

Mean JJ N
increases NNS N
in IN N
erythrocyte JJ o
riboflavin NN o
( ( N
P NNP N
< NNP N
0.0001 CD N
) ) N
and CC N
plasma JJ o
ferritin NN o
( ( N
P=0.01 NNP N
) ) N
were VBD N
greater JJR N
in IN N
the DT N
FeR NNP N
+ NNP N
VA NNP N
group NN N
than IN N
in IN N
the DT N
VA NNP N
only RB N
group NN N
. . N

CONCLUSIONS NNP N
Iron NNP N
deficiency NN N
may MD N
limit VB N
the DT N
efficacy NN N
of IN N
vitamin NN i
A DT i
to TO N
normalize VB N
dark JJ N
adaptation NN N
in IN N
pregnant JJ p
Nepali NNP p
women NNS p
. . p

Further JJ N
studies NNS N
are VBP N
needed VBN N
to TO N
assess VB N
the DT N
effect NN N
of IN N
simultaneous JJ N
delivery NN N
of IN N
iron NN N
and CC N
vitamin VB N
A NNP N
for IN N
the DT N
treatment NN N
of IN N
nightblindness NN N
. . N

-DOCSTART- -14605954- O O

Micronized JJ i
flavonoids NNS i
in IN N
pain NN o
control NN o
after IN p
hemorrhoidectomy NN p
: : p
a DT N
prospective JJ N
randomized NN N
controlled VBD N
study NN N
. . N

PURPOSE NNP N
We PRP N
conducted VBD N
a DT N
prospective JJ N
randomized NN N
controlled VBD N
study NN N
to TO N
evaluate VB N
the DT N
effect NN N
of IN N
micronized VBN i
flavonoid JJ i
fractions NNS i
( ( i
MFF NNP i
) ) i
on IN N
pain NN o
after IN p
hemorrhoidectomy NN p
. . p

METHODS NNP N
The DT N
subjects NNS N
were VBD N
112 CD p
consecutive JJ p
patients NNS p
randomly RB N
assigned VBD N
either CC N
to TO N
receive VB i
MFF NNP i
( ( i
group NN i
1 CD i
) ) i
for IN i
1 CD i
week NN i
or CC i
not RB i
to TO i
receive VB i
MFF NNP i
, , i
as IN i
a DT i
control NN i
( ( i
group NN i
2 CD i
) ) i
, , i
after IN i
hemorrhoidectomy NN i
, , i
The DT i
severity NN o
of IN o
pain NN o
and CC o
the DT o
number NN o
of IN o
intramuscular JJ o
analgesic JJ o
injections NNS o
required VBN i
were VBD i
recorded VBN i
for IN i
the DT i
first JJ i
3 CD i
days NNS i
, , i
then RB i
1 CD i
week NN i
after IN i
hemorrhoidectomy NN i
. . i

The DT N
number NN o
of IN o
days NNS o
that WDT o
intramuscular VBP o
analgesic JJ o
injections NNS o
were VBD o
required VBN o
, , o
hospital JJ o
stay NN o
, , o
and CC o
patient JJ o
satisfaction NN o
were VBD N
also RB N
assessed VBN N
. . N

RESULTS VB N
On IN N
postoperative JJ N
day NN N
( ( N
POD NNP N
) ) N
1 CD N
, , N
there EX N
were VBD N
no DT N
significant JJ N
differences NNS N
between IN N
the DT N
parameters NNS N
of IN N
the DT N
two CD N
groups NNS N
, , N
but CC N
on IN N
PODs NNP N
2 CD N
and CC N
3 CD N
, , N
both PDT N
the DT N
pain NN o
score NN o
( ( N
P NNP N
= NNP N
0.033 CD N
and CC N
P NNP N
= NNP N
0.011 CD N
, , N
respectively RB N
) ) N
and CC N
the DT N
number NN N
of IN N
patients NNS N
who WP N
required VBD N
intramuscular JJ o
analgesic JJ o
injections NNS o
were VBD N
significantly RB N
less RBR N
in IN N
group NN N
1 CD N
( ( N
P NNP N
= NNP N
0.022 CD N
and CC N
P NNP N
= NNP N
0.007 CD N
, , N
respectively RB N
) ) N
. . N

Moreover RB N
, , N
the DT N
hospital NN o
stay NN o
was VBD N
shorter JJR N
and CC N
patient JJ o
satisfaction NN o
was VBD N
superior JJ N
in IN N
group NN N
1 CD N
( ( N
P NNP N
= NNP N
0.001 CD N
and CC N
P NNP N
= NNP N
0.001 CD N
, , N
respectively RB N
) ) N
. . N

After IN N
1 CD N
week NN N
, , N
the DT N
pain NN o
score NN o
and CC o
number NN o
of IN o
intramuscular JJ o
analgesic JJ o
injections NNS o
given VBN N
were VBD N
significantly RB N
less RBR N
in IN N
group NN N
1 CD N
( ( N
P NNP N
= NNP N
0.001 CD N
and CC N
P NNP N
= NNP N
0.021 CD N
) ) N
. . N

CONCLUSION NNP N
Using NNP N
MFF NNP i
after IN p
hemorrhoidectomy NN p
reduced VBD N
the DT N
severity NN o
of IN o
pain NN o
and CC o
intramuscular JJ o
analgesic JJ o
requirement NN o
. . o

-DOCSTART- -17691581- O O

[ JJ N
Effect NNP N
of IN N
electroacununcture NN i
on IN N
sex NN N
hormone NN N
levels NNS N
in IN N
patients NNS p
with IN p
Sj?gren NNP p
's POS p
syndrome JJ p
] NN p
. . p

OBJECTIVE UH N
To TO N
observe VB N
the DT N
effect NN N
of IN i
electroacupuncture NN i
( ( i
EA NNP i
) ) i
on IN o
serum NN o
testosterone NN o
( ( o
T NNP o
) ) o
, , o
estradiol FW o
( ( o
F2 NNP o
) ) o
, , o
luteotropic VBZ o
hormone NN o
( ( o
LH NNP o
) ) o
, , o
follicle-stimulating JJ o
hormone NN o
( ( o
FSH NNP o
) ) o
, , o
progesterone NN o
( ( o
P NNP o
) ) o
, , o
and CC o
prolactin NN o
( ( o
PRL NNP o
) ) o
in IN p
patients NNS p
with IN p
Sj?gren NNP p
's POS p
Syndrome NNP p
( ( p
SS NNP p
) ) p
in IN p
order NN N
to TO N
analyze VB N
the DT N
correlation NN N
between IN N
the DT N
adjustment NN N
effect NN N
of IN N
EA NNP i
and CC i
changes NNS N
of IN N
hormone NN N
levels NNS N
. . N

METHODS NNP p
Fifty-seven JJ p
middle-aged JJ p
and CC p
old JJ p
women NNS p
with IN p
SS NNP p
were VBD p
divided VBN N
into IN i
medication NN i
group NN i
( ( N
n=27 CC N
) ) N
and CC i
acupuncture NN i
group NN i
( ( N
n=30 RB N
) ) N
. . N

Patients NNS N
in IN N
acupuncture NN i
group NN i
were VBD i
treated VBN i
with IN i
EA NNP i
( ( i
80 CD i
Hz NNP i
, , i
2.5 CD i
mA NN i
) ) i
of IN i
Shenshu NNP i
( ( i
BL NNP i
23 CD i
) ) i
, , i
Taixi NNP i
( ( i
KI NNP i
3 CD i
) ) i
, , i
Hegu NNP i
( ( i
LI NNP i
4 CD i
) ) i
, , i
etc FW i
. . i

for IN i
30 CD i
min NN i
, , i
once RB i
every DT i
other JJ i
day NN i
, , i
and CC i
those DT i
of IN i
medication NN i
group NN i
were VBD i
treated VBN i
with IN i
oral JJ i
administration NN i
of IN i
hydroxyl-chloroquine JJ i
( ( i
6 CD i
mg/kg NNS i
per IN i
day NN i
) ) i
, , i
oral JJ i
transfer NN i
agent NN i
liquid NN i
, , i
Vit NNP i
B1 NNP i
, , i
Vit NNP i
B2 NNP i
, , i
Vit NNP i
C NNP i
, , i
fish-liver JJ i
oil NN i
, , i
one CD i
tablet/time NN i
, , i
t.i.d. NN i
, , i
and CC i
pilocarpine NN i
( ( i
20 CD i
mg/d NN i
) ) i
, , i
continuously RB i
for IN i
2 CD i
months NNS i
. . i

Venous JJ N
blood NN N
samples NNS N
were VBD N
collected VBN N
before IN N
and CC N
after IN N
the DT N
treatment NN N
to TO N
examine VB N
contents NNS N
of IN N
the DT N
abovementioned JJ N
sex NN N
hormones NNS N
by IN N
using VBG i
electro-chemiluminescent JJ i
immunoassay NN i
( ( i
CLIA NNP i
) ) i
. . i

RESULTS NNP N
( ( N
1 CD N
) ) N
Before IN N
the DT N
treatment NN N
, , N
no DT N
significant JJ N
differences NNS N
were VBD N
found VBN N
between IN N
two CD N
groups NNS N
in IN N
the DT o
levels NNS o
of IN o
serum NN o
T NNP o
, , o
E2 NNP o
, , o
LH NNP o
, , o
FSH NNP o
, , o
P NNP o
and CC o
PRL NNP o
( ( o
P NNP N
> NNP N
0.05 CD N
) ) N
. . N

After IN N
the DT N
treatment NN N
, , N
self-comparison NN N
of IN N
each DT N
group NN N
showed VBD N
that IN o
serum NN o
EF NNP o
and CC o
T NNP o
contents NNS o
in IN o
acupuncture NN N
group NN N
increased VBD N
significantly RB N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
and CC o
serum JJ o
LH NNP o
content NN o
decreased VBN o
significantly RB N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
; : N
while IN N
in IN N
medication NN N
group NN N
, , N
only RB o
serum JJ o
LH NNP o
decreased VBD o
markedly RB N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
in IN N
comparison NN N
with IN N
its PRP$ N
basic JJ N
value NN N
of IN N
pretreatment NN N
. . N

No DT N
significant JJ N
changes NNS N
were VBD N
found VBN N
in IN N
serum NN o
P NNP o
, , o
FSH NNP o
and CC o
PRL NNP o
levels NNS o
in IN o
both DT N
groups NNS N
after IN N
the DT N
treatment NN N
( ( N
P NNP N
> NNP N
0.05 CD N
) ) N
. . N

The DT N
results NNS N
suggested VBD N
that IN N
the DT N
therapeutic JJ N
effect NN N
of IN N
acupuncture NN N
group NN N
was VBD N
better JJR N
than IN N
that DT N
of IN N
medication NN N
group NN N
in IN N
regulating VBG o
multiple JJ o
sex NN o
hormones NNS o
. . o

CONCLUSION NNP i
EA NNP i
can MD i
effectively RB N
adjust VB N
E2 NNP N
, , N
T NNP N
and CC N
LH NNP N
levels NNS N
in IN N
Sj?gren NNP p
's POS p
Syndrome NNP p
patients NNS p
and CC p
improve VB N
most JJS N
patients NNS N
' POS N
clinical JJ N
symptoms NNS N
, , N
and CC N
the DT N
therapeutic JJ N
effect NN N
of IN N
EA NNP i
is VBZ N
better JJR N
than IN N
that DT N
of IN N
medication NN i
. . i

-DOCSTART- -20470677- O O

FloSeal NNP i
hemostatic JJ i
matrix NN i
in IN N
persistent JJ p
epistaxis NN p
: : p
prospective JJ N
clinical JJ N
trial NN N
. . N

OBJECTIVE CC N
Although IN N
most JJS N
cases NNS N
of IN N
epistaxis NN N
are VBP N
managed VBN N
conservatively RB N
, , N
occasionally RB N
they PRP N
can MD N
progress VB N
to TO N
significant JJ N
hemorrhage NN N
requiring VBG N
more JJR N
involved JJ N
management NN N
or CC N
surgery NN N
. . N

Endoscopic NNP N
ligation NN N
surgery NN N
is VBZ N
the DT N
current JJ N
institutional JJ N
standard NN N
of IN N
care NN N
for IN N
patients NNS N
who WP N
fail VBP N
conservative JJ N
management NN N
. . N

However RB N
, , N
surgical JJ N
ligation NN N
requires VBZ N
availability NN N
of IN N
surgical JJ N
resources NNS N
and CC N
patients NNS N
who WP N
are VBP N
able JJ N
to TO N
withstand VB N
an DT N
anesthetic JJ N
. . N

This DT N
study NN N
's POS N
objective NN N
was VBD N
to TO N
determine VB N
the DT N
efficacy NN N
of IN N
FloSeal NNP i
hemostatic JJ i
matrix NN i
( ( N
Baxter NNP N
Healthcare NNP N
Corporation NNP N
, , N
Hayward NNP N
, , N
CA NNP N
) ) N
in IN N
epistaxis JJ N
refractory NN N
to TO N
nasal VB N
packing VBG N
. . N

METHODS NNP N
A NNP N
prospective JJ N
clinical JJ N
trial NN N
was VBD N
conducted VBN N
on IN N
epistaxis NN p
patients NNS p
whose WP$ p
nasal JJ p
hemorrhage NN p
persisted VBD p
despite IN p
adequate JJ p
nasal NNS p
packing VBG p
by IN p
the DT p
otolaryngology-head JJ p
and CC p
neck NN p
surgery NN p
team NN p
. . p

Once RB N
enrolled JJ N
, , N
patients NNS p
are VBP N
given VBN N
a DT N
trial NN N
of IN N
intranasal JJ N
FloSeal NNP i
hemostatic JJ i
matrix NN i
to TO N
abort VB N
the DT N
epistaxis NN N
. . N

Should MD N
this DT N
fail NN N
, , N
patients NNS N
then RB N
proceed VBP N
with IN N
surgical JJ N
clipping NN N
. . N

RESULTS VB N
Our PRP$ N
prospective JJ N
cohort NN N
demonstrated VBD N
significant JJ N
success NN N
in IN N
80 CD p
% NN p
of IN p
patients NNS p
with IN p
persistent JJ p
epistaxis NN p
, , N
who WP N
would MD N
have VB N
otherwise RB N
been VBN N
taken VBN N
to TO N
the DT N
operating NN N
theatre NN N
, , N
avoiding VBG N
the DT N
need NN N
for IN N
further JJ N
surgical JJ o
intervention NN o
. . o

The DT N
majority NN N
of IN N
enrolled JJ N
patients NNS p
with IN p
persistent JJ p
nasal JJ p
hemorrhage NN p
were VBD N
adequately RB N
managed VBN N
with IN N
the DT N
hemostatic JJ N
matrix NN N
alone RB N
and CC N
were VBD N
discharged VBN o
from IN o
hospital NN o
in IN N
a DT N
timeframe NN N
comparable JJ N
to TO N
that DT N
of IN N
surgical JJ N
managment NN N
. . N

CONCLUSIONS VB N
This DT N
study NN N
revealed VBD N
a DT N
highly RB N
effective JJ N
tool NN N
in IN N
the DT N
otolaryngologist NN N
's POS N
management NN N
of IN N
persistent JJ p
epistaxis NN p
. . p

Given VBN N
the DT N
ease NN N
of IN N
use NN N
, , N
decreased VBN N
morbidity NN N
to TO N
the DT N
patient NN N
, , N
and CC N
cost-effectiveness NN N
, , N
FloSeal NNP i
hemostatic JJ i
matrix NN i
could MD N
change VB N
clinical JJ N
practice NN N
in IN N
managing VBG N
this DT N
common JJ N
condition NN N
. . N

-DOCSTART- -21800228- O O

Preliminary JJ N
examination NN N
of IN N
a DT N
cartoon-based JJ i
hostile JJ o
attributional NN o
bias NN o
measure NN o
for IN N
urban JJ p
African JJ p
American JJ p
boys NNS p
. . p

The DT N
current JJ N
study NN N
illustrates VBZ N
how WRB N
researchers NNS N
developed VBD N
and CC N
validated VBD N
a DT N
cartoon-based JJ i
adaptation NN i
of IN N
a DT N
written VBN N
hostile JJ o
attributional JJ o
bias NN o
measure NN o
for IN N
a DT N
sample NN p
of IN p
urban JJ p
, , p
low-income JJ p
, , p
African JJ p
American NNP p
boys NN p
. . p

A DT N
series NN N
of IN N
studies NNS N
were VBD N
conducted VBN N
to TO N
develop VB N
cartoon NN N
illustrations NNS N
to TO N
accompany VB N
a DT N
standard JJ o
written VBN o
hostile JJ o
attributional JJ o
bias NN o
vignette NN o
measure NN o
( ( N
Study NNP N
1 CD N
) ) N
, , N
to TO N
determine VB N
initial JJ N
psychometric JJ o
properties NNS o
( ( N
Study NNP N
2 CD N
) ) N
and CC N
acceptability NN o
( ( N
Study NNP N
3 CD N
) ) N
, , N
and CC N
to TO N
conduct VB N
a DT N
test-retest JJ o
reliability NN o
trial NN N
of IN N
the DT N
adapted JJ N
measure NN N
in IN N
a DT N
separate JJ N
sample NN N
( ( N
Study NNP N
4 CD N
) ) N
. . N

These DT N
studies NNS N
utilize VBP N
a DT N
participatory JJ N
action NN N
research NN N
approach NN N
to TO N
measurement VB N
design NN N
and CC N
adaptation NN N
, , N
and CC N
suggest VBP N
that IN N
collaborations NNS N
between IN N
researchers NNS N
and CC N
key JJ N
school NN N
stakeholders NNS N
can MD N
lead VB N
to TO N
measures NNS N
that WDT N
are VBP N
psychometrically RB N
strong JJ N
, , N
developmentally RB N
appropriate JJ N
, , N
and CC N
culturally RB N
sensitive JJ N
. . N

In IN N
addition NN N
, , N
the DT N
cartoon-based JJ i
hostile JJ o
attributional NN o
bias NN o
measure NN o
appears VBZ N
to TO N
have VB N
promise NN N
as IN N
an DT N
assessment NN N
and/or NN N
outcome NN N
measure NN N
for IN N
aggression NN N
and CC N
bullying VBG N
prevention NN N
programs NNS N
conducted VBN N
with IN N
urban JJ p
African JJ p
American JJ p
boys NNS p
. . p

-DOCSTART- -24679061- O O

Clonidine NNP i
in IN N
patients NNS p
undergoing JJ p
noncardiac JJ p
surgery NN p
. . p

BACKGROUND NNP N
Marked NNP N
activation NN N
of IN N
the DT N
sympathetic JJ N
nervous JJ N
system NN N
occurs VBZ N
during IN N
and CC N
after IN N
noncardiac JJ p
surgery NN p
. . p

Low-dose JJ N
clonidine NN i
, , N
which WDT N
blunts VBZ N
central JJ N
sympathetic JJ N
outflow NN N
, , N
may MD N
prevent VB N
perioperative JJ o
myocardial JJ o
infarction NN o
and CC o
death NN o
without IN N
inducing VBG N
hemodynamic JJ N
instability NN N
. . N

METHODS NNP N
We PRP N
performed VBD N
a DT N
blinded VBN N
, , N
randomized VBN N
trial NN N
with IN N
a DT N
2-by-2 JJ N
factorial JJ N
design NN N
to TO N
allow VB N
separate JJ N
evaluation NN N
of IN N
low-dose JJ i
clonidine NN i
versus NN i
placebo NN i
and CC i
low-dose JJ i
aspirin NN i
versus NN i
placebo NN i
in IN N
patients NNS p
with IN p
, , p
or CC p
at IN p
risk NN p
for IN p
, , p
atherosclerotic JJ p
disease NN p
who WP p
were VBD p
undergoing VBG p
noncardiac JJ p
surgery NN p
. . p

A DT N
total NN N
of IN N
10,010 CD p
patients NNS p
at IN p
135 CD p
centers NNS p
in IN p
23 CD p
countries NNS p
were VBD p
enrolled VBN p
. . p

For IN N
the DT N
comparison NN N
of IN N
clonidine NN i
with IN i
placebo NN i
, , N
patients NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
clonidine NN i
( ( N
0.2 CD N
mg NNS N
per IN N
day NN N
) ) N
or CC i
placebo VB i
just RB N
before RB N
surgery NN N
, , N
with IN N
the DT N
study NN N
drug NN N
continued VBD N
until IN N
72 CD N
hours NNS N
after IN N
surgery NN N
. . N

The DT N
primary JJ N
outcome NN N
was VBD N
a DT N
composite JJ N
of IN N
death NN o
or CC o
nonfatal JJ o
myocardial JJ o
infarction NN o
at IN N
30 CD N
days NNS N
. . N

RESULTS NNP N
Clonidine NNP N
, , N
as IN N
compared VBN N
with IN N
placebo NN N
, , N
did VBD N
not RB N
reduce VB N
the DT N
number NN N
of IN N
primary-outcome JJ o
events NNS o
( ( N
367 CD N
and CC N
339 CD N
, , N
respectively RB N
; : N
hazard PRP$ N
ratio NN N
with IN N
clonidine NN N
, , N
1.08 CD N
; : N
95 CD N
% NN N
confidence NN N
interval NN N
[ NNP N
CI NNP N
] NNP N
, , N
0.93 CD N
to TO N
1.26 CD N
; : N
P=0.29 NNP N
) ) N
. . N

Myocardial JJ o
infarction NN o
occurred VBD N
in IN N
329 CD p
patients NNS p
( ( N
6.6 CD N
% NN N
) ) N
assigned VBD N
to TO N
clonidine VB N
and CC N
in IN N
295 CD N
patients NNS N
( ( N
5.9 CD N
% NN N
) ) N
assigned VBD N
to TO N
placebo VB N
( ( N
hazard NN N
ratio NN N
, , N
1.11 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
0.95 CD N
to TO N
1.30 CD N
; : N
P=0.18 NNP N
) ) N
. . N

Significantly RB N
more JJR N
patients NNS N
in IN N
the DT N
clonidine NN N
group NN N
than IN N
in IN N
the DT N
placebo NN N
group NN N
had VBD N
clinically RB N
important JJ N
hypotension NN o
( ( N
2385 CD N
patients NNS N
[ JJ N
47.6 CD N
% NN N
] NN N
vs. FW N
1854 CD N
patients NNS N
[ JJ N
37.1 CD N
% NN N
] NN N
; : N
hazard CC N
ratio VB N
1.32 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
1.24 CD N
to TO N
1.40 CD N
; : N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

Clonidine NNP N
, , N
as IN N
compared VBN N
with IN N
placebo NN N
, , N
was VBD N
associated VBN N
with IN N
an DT N
increased JJ N
rate NN N
of IN N
nonfatal JJ o
cardiac JJ o
arrest NN o
( ( N
0.3 CD N
% NN N
[ JJ N
16 CD N
patients NNS N
] JJ N
vs. FW N
0.1 CD N
% NN N
[ JJ N
5 CD N
patients NNS N
] VBP N
; : N
hazard NN N
ratio NN N
, , N
3.20 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
1.17 CD N
to TO N
8.73 CD N
; : N
P=0.02 NNP N
) ) N
. . N

CONCLUSIONS NNP N
Administration NNP N
of IN N
low-dose JJ N
clonidine NN N
in IN N
patients NNS p
undergoing JJ p
noncardiac JJ p
surgery NN p
did VBD N
not RB N
reduce VB N
the DT N
rate NN N
of IN N
the DT N
composite JJ N
outcome NN N
of IN N
death NN o
or CC N
nonfatal JJ o
myocardial JJ o
infarction NN o
; : o
it PRP N
did VBD N
, , N
however RB N
, , N
increase VB N
the DT N
risk NN N
of IN N
clinically RB o
important JJ o
hypotension NN o
and CC o
nonfatal JJ o
cardiac JJ o
arrest NN o
. . o

( ( N
Funded VBN N
by IN N
the DT N
Canadian NNP N
Institutes NNPS N
of IN N
Health NNP N
Research NNP N
and CC N
others NNS N
; : N
POISE-2 NNP N
ClinicalTrials.gov NNP N
number NN N
, , N
NCT01082874 NNP N
. . N

) ) N
. . N

-DOCSTART- -18845806- O O

Allopurinol NNP i
use NN N
yields NNS N
potentially RB N
beneficial JJ N
effects NNS N
on IN N
inflammatory JJ N
indices NNS N
in IN N
those DT p
with IN p
recent JJ p
ischemic JJ p
stroke NN p
: : p
a DT N
randomized JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
trial NN N
. . N

BACKGROUND NNP N
AND CC N
PURPOSE NNP N
Elevated NNP N
serum NN N
uric JJ N
acid NN N
level NN N
is VBZ N
associated VBN N
with IN N
poor JJ N
outcome NN N
and CC N
increased VBD N
risk NN N
of IN N
recurrent NN N
events NNS N
after IN N
stroke NN N
. . N

The DT N
xanthine JJ N
oxidase NN N
inhibitor NN N
allopurinol NN i
lowers NNS N
uric JJ N
acid NN N
but CC N
also RB N
attenuates VBZ N
expression NN N
of IN N
inflammatory JJ N
adhesion NN N
molecules NNS N
in IN N
murine NN N
models NNS N
, , N
reduces NNS N
oxidative VBP N
stress NN N
in IN N
the DT N
vasculature NN N
, , N
and CC N
improves VBZ N
endothelial JJ N
function NN N
. . N

We PRP N
sought VBD N
to TO N
investigate VB N
whether IN N
allopurinol JJ i
alters NNS N
expression NN N
of IN N
inflammatory NN N
markers NNS N
after IN N
acute JJ N
ischemic JJ N
stroke NN N
. . N

METHODS NNP N
We PRP N
performed VBD N
a DT N
randomized VBN N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
trial NN N
to TO N
investigate VB N
the DT N
safety NN N
, , N
tolerability NN N
, , N
and CC N
effect NN N
of IN N
6 CD i
weeks NNS i
' POS i
treatment NN i
with IN i
high- NN i
( ( i
300 CD i
mg NN i
once RB i
a DT i
day NN i
) ) i
or CC i
low- JJ i
( ( i
100 CD i
mg NN i
once RB i
a DT i
day NN i
) ) i
dose NN i
allopurinol NN i
on IN N
levels NNS N
of IN N
uric JJ N
acid NN N
and CC N
circulating VBG N
inflammatory JJ N
markers NNS N
after IN N
ischemic JJ N
stroke NN N
. . N

RESULTS NNP N
We PRP N
enrolled VBD N
50 CD p
patients NNS p
with IN p
acute JJ p
ischemic JJ p
stroke NN p
( ( p
17 CD p
, , p
17 CD p
, , p
and CC p
16 CD p
in IN p
the DT p
high JJ p
, , p
low JJ p
, , p
and CC p
placebo NN i
groups NNS p
, , p
respectively RB p
) ) p
. . N

Mean NNP p
( ( p
+/-SD NNP p
) ) p
age NN p
was VBD p
70 CD p
( ( p
+/-13 JJ p
) ) p
years NNS p
. . p

Groups NNP N
had VBD N
similar JJ N
characteristics NNS N
at IN N
baseline NN N
. . N

There EX N
were VBD N
no DT N
serious JJ N
adverse JJ N
events NNS N
. . N

Uric NNP o
acid NN o
levels NNS o
were VBD N
significantly RB N
reduced VBN N
at IN N
both DT N
7 CD N
days NNS N
and CC N
6 CD N
weeks NNS N
in IN N
the DT N
high-dose JJ N
group NN N
( ( N
by IN N
0.14 CD N
mmol/L NNS N
at IN N
6 CD N
weeks NNS N
, , N
P=0.002 NNP N
) ) N
. . N

Intercellular JJ o
adhesion NN o
molecule-1 JJ o
concentration NN o
( ( N
ng/mL JJ N
) ) N
rose VBD N
by IN N
51.2 CD N
in IN N
the DT N
placebo NN N
group NN N
, , N
rose VBD N
slightly RB N
( ( N
by IN N
10.6 CD N
) ) N
in IN N
the DT N
low-dose JJ N
allopurinol NN i
group NN N
, , N
but CC N
fell VBD N
in IN N
the DT N
high-dose JJ N
group NN N
( ( N
by IN N
2.6 CD N
; : N
difference NN N
between IN N
groups NNS N
P=0.012 NNP N
, , N
Kruskal-Wallis NNP N
test NN N
) ) N
. . N

CONCLUSIONS NNP N
Allopurinol NNP i
treatment NN N
is VBZ N
well RB N
tolerated VBN N
and CC N
attenuates VBZ N
the DT N
rise NN N
in IN N
intercellular JJ N
adhesion NN N
molecule-1 NN N
levels NNS N
seen VBN N
after IN N
stroke NN N
. . N

Uric JJ N
acid NN N
levels NNS N
were VBD N
lowered VBN N
with IN N
high JJ N
doses NNS N
. . N

These DT N
findings NNS N
support NN N
further JJ N
evaluation NN N
of IN N
allopurinol NN i
as IN N
a DT N
preventive JJ N
measure NN N
after IN N
stroke NN N
. . N

-DOCSTART- -22690994- O O

Pilot NNP N
randomized VBD N
controlled VBN N
dosing VBG N
study NN N
of IN N
cranberry NN i
capsules NNS i
for IN N
reduction NN N
of IN N
bacteriuria NN o
plus CC o
pyuria NN o
in IN N
female JJ p
nursing NN p
home NN p
residents NNS p
. . p

-DOCSTART- -25659440- O O

Reducing VBG N
blood NN o
loss NN o
in IN N
simultaneous JJ p
bilateral JJ p
total NN p
knee NN p
arthroplasty NN p
: : p
combined VBN N
intravenous-intra-articular JJ N
tranexamic JJ i
acid NN i
administration NN N
. . N

A DT N
prospective JJ N
randomized NN N
controlled VBD N
trial NN N
. . N

BACKGROUND NNP N
We PRP N
asked VBD N
whether IN N
tranexamic JJ i
acid NN i
( ( i
TXA NNP i
) ) i
administration NN N
could MD N
reduce VB N
blood NN o
loss NN o
and CC o
blood NN o
transfusion NN o
requirements NNS o
after IN p
simultaneous JJ p
bilateral JJ p
total NN p
knee NN p
arthroplasty NN p
( ( p
TKA NNP p
) ) p
. . p

This DT N
study NN N
examined VBD N
the DT N
role NN N
of IN N
a DT N
novel JJ N
method NN N
of IN N
TXA NNP N
administration NN N
in IN N
TKA NNP N
. . N

METHODS NNP N
TXA NNP i
was VBD i
administered VBN i
as IN i
a DT i
bolus NN i
dose NN i
of IN i
15 CD i
mg/kg NNS i
10 CD i
min NN i
before IN i
the DT i
inflation NN i
of IN i
the DT i
tourniquet NN i
on IN i
the DT i
first JJ i
side NN i
. . i

This DT i
was VBD i
followed VBN i
by IN i
intra-articular JJ i
administration NN i
of IN i
3 CD i
grams NNS i
at IN i
10 CD i
min NN i
before IN i
the DT i
deflation NN i
of IN i
the DT i
tourniquet NN i
. . i

IV NNP i
infusion NN i
of IN i
10 CD i
mg/kg/h NN i
was VBD i
continued VBN i
for IN i
3h CD i
following VBG i
completion NN i
on IN i
the DT i
second JJ i
side NN i
. . i

We PRP N
measured VBD N
volume NN o
of IN o
drained JJ o
blood NN o
48 CD o
h NN o
postoperatively RB o
, , o
decrease NN o
in IN o
hemoglobin NN o
levels NNS o
12h CD o
postoperatively RB o
, , o
amount NN o
of IN o
blood NN o
transfused VBN o
( ( o
BT NNP o
) ) o
, , N
and CC N
number NN o
of IN o
patients NNS o
requiring VBG o
allogenic JJ o
BT NNP o
. . o

RESULTS NNP N
Median JJ N
postoperative JJ N
volume NN o
of IN o
drained JJ o
blood NN o
was VBD N
lower JJR N
in IN N
the DT N
group NN N
receiving VBG N
TXA NNP i
( ( N
500.00 CD N
mL NN N
) ) N
than IN N
in IN N
control NN N
subjects NNS N
( ( N
900.00 CD N
mL NN N
) ) N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
[ VBD N
95 CD N
% NN N
CI NNP N
( ( N
-525.00 NNP N
) ) N
to TO N
( ( N
-300.00 NNP N
) ) N
] NN N
. . N

The DT N
median JJ o
hemoglobin NN o
decrease NN o
12 CD o
h NN o
postoperatively RB o
was VBD N
lower JJR N
in IN N
patients NNS p
receiving VBG N
TXA NNP N
( ( N
2.10 CD N
g/dL NN N
) ) N
than IN N
in IN N
control NN N
subjects NNS N
( ( N
3.10 CD N
g/dL NN N
) ) N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
[ VBD N
95 CD N
% NN N
CI NNP N
( ( N
-1.60 NNP N
) ) N
to TO N
( ( N
-0.60 NNP N
) ) N
] NN N
. . N

The DT N
amount NN o
of IN o
BT NNP o
and CC o
number NN o
of IN o
patients NNS o
requiring VBG o
BT NNP o
were VBD N
lower JJR N
in IN N
patients NNS N
receiving VBG N
TXA NNP N
than IN N
in IN N
control NN N
subjects NNS N
. . N

Nevertheless RB N
, , N
the DT N
number NN N
of IN N
allogeneic JJ N
units NNS N
of IN N
packed JJ o
red JJ o
blood NN o
cells NNS o
transfused VBN o
in IN N
the DT N
postoperative JJ N
period NN N
was VBD N
not RB N
significantly RB N
higher RBR N
in IN N
the DT N
control NN N
group NN N
than IN N
in IN N
the DT N
TXA NNP N
group NN N
( ( N
p=0.109 NN N
) ) N
[ VBZ N
95 CD N
% NN N
CI NNP N
( ( N
0.101 CD N
) ) N
to TO N
( ( N
0.117 CD N
) ) N
] NN N
. . N

CONCLUSIONS VB N
This DT N
prospective JJ N
randomized NN N
study NN N
showed VBD N
that IN N
during IN N
simultaneous JJ N
bilateral JJ N
TKA NNP N
, , N
TXA NNP i
reduced VBD N
blood NN o
loss NN o
with IN N
negligible JJ N
side NN o
effects NNS o
. . o

-DOCSTART- -6758263- O O

[ IN N
The DT N
analgetic JJ o
effect NN o
of IN N
intramuscular JJ N
pethidine NN i
compared VBN N
with IN N
epidural JJ i
morphine NN i
in IN N
upper JJ p
abdominal JJ p
laparotomies NNS p
] VBP p
. . N

-DOCSTART- -6425480- O O

Short-term JJ N
pulmonary JJ N
effects NNS N
of IN N
total JJ i
parenteral JJ i
nutrition NN i
in IN N
children NNS p
with IN p
cystic JJ p
fibrosis NN p
. . p

Indices NNS N
of IN N
respiratory JJ N
muscle NN N
strength NN N
, , N
pulmonary JJ N
function NN N
, , N
and CC N
pulmonary JJ N
diffusing NN N
capacity NN N
were VBD N
measured VBN N
in IN N
11 CD p
malnourished JJ p
children NNS p
( ( p
age NN p
10 CD p
to TO p
17 CD p
years NNS p
) ) p
with IN p
cystic JJ p
fibrosis NN p
, , p
before IN p
and CC p
after IN p
improvement NN p
of IN p
nutritional JJ p
status NN p
with IN p
supplemental JJ i
parenteral JJ i
nutrients NNS i
for IN p
1 CD p
month NN p
. . p

During IN N
this DT N
time NN N
, , N
the DT N
children NNS N
received VBD N
120 CD N
% NN N
of IN N
estimated VBN N
energy NN N
requirements NNS N
( ( N
either CC N
3.75 CD N
% NN N
or CC N
22.5 CD N
% NN N
as IN N
lipid NN i
) ) i
and CC N
amino JJ i
acids NNS i
2.5 CD N
gm/120 JJ N
kcal JJ N
by IN N
central JJ N
venous JJ N
catheter NN N
, , N
plus CC N
as IN N
much JJ N
of IN N
their PRP$ N
usual JJ N
diet NN N
as IN N
desired VBN N
. . N

With IN N
nutritional JJ o
supplementation NN o
, , o
body NN o
weight NN o
, , o
triceps NNS o
skinfold VBD o
thickness NN o
, , o
and CC o
mid-arm JJ o
muscle NN o
circumference NN o
increased VBD N
( ( N
mean JJ N
15 CD N
% NN N
, , N
62 CD N
% NN N
, , N
and CC N
95 CD N
% NN N
, , N
respectively RB N
) ) N
. . N

Maximum JJ o
inspiratory JJ o
airway NN o
pressure NN o
also RB N
increased VBD N
( ( N
mean JJ N
29 CD N
% NN N
; : N
P NNP N
less JJR N
than IN N
0.01 CD N
) ) N
, , N
suggesting VBG N
improvement NN N
in IN N
respiratory JJ o
muscle NN o
strength NN o
. . o

However RB N
, , N
none NN N
of IN N
the DT N
indices NNS o
of IN o
pulmonary JJ o
function NN o
improved VBN N
. . N

Pulmonary JJ o
diffusing VBG o
capacity NN o
did VBD N
not RB N
change VB N
during IN N
parenteral JJ N
nutrition NN N
regardless NN N
of IN N
the DT N
amount NN N
of IN N
parenteral JJ o
energy NN o
intake NN o
supplied VBN N
by IN N
lipid JJ N
, , N
but CC N
arterial JJ o
oxygen NN o
saturation NN o
decreased VBN N
( ( N
mean NN N
of IN N
93.5 CD N
% NN N
to TO N
91.5 CD N
% NN N
; : N
P NNP N
less JJR N
than IN N
0.005 CD N
) ) N
. . N

During IN N
the DT N
month NN N
following VBG N
parenteral JJ N
nutrition NN N
, , N
weight NN N
, , N
skinfold JJ N
thickness NN N
, , N
and CC N
mid-arm JJ N
muscle NN N
circumference NN N
, , N
but CC N
not RB N
MIP NNP N
, , N
decreased VBD N
and CC N
arterial JJ N
oxygen NN N
saturation NN N
returned VBD N
to TO N
the DT N
initial JJ N
value NN N
( ( N
P NNP N
less JJR N
than IN N
0.01 CD N
) ) N
. . N

-DOCSTART- -5431057- O O

Para-anaesthetic JJ i
headache NN i
in IN p
female JJ p
patients NNS p
. . p

-DOCSTART- -10685169- O O

Effect NN N
of IN N
topical JJ N
rh-TGF-beta JJ i
1 CD i
on IN N
second JJ o
intention NN o
wound IN o
healing VBG o
in IN p
horses NNS p
. . p

OBJECTIVE NNP N
To TO N
investigate VB N
the DT N
effects NNS N
on IN N
wound IN N
healing NN N
of IN N
transforming VBG N
growth NN i
factor-beta JJ i
1 CD i
as IN N
a DT N
topical JJ N
treatment NN N
to TO N
full-thickness NN N
, , N
excisional JJ N
wounds NNS N
of IN N
the DT N
distal JJ N
limb NN N
of IN N
horses NNS p
. . p

DESIGN VB N
A DT N
randomised JJ N
block NN N
study NN N
using VBG N
four CD p
horses NNS p
, , p
each DT p
with IN p
wounds NNS p
assigned VBN N
to TO N
four CD N
treatment NN N
groups NNS N
. . N

ANIMALS NNP N
Four CD p
adult NN p
Standardbred NNP p
geldings NNS p
. . p

PROCEDURE NNP N
Four NNP N
, , N
4 CD N
cm2 NN N
, , N
full-thickness JJ N
wounds NNS N
were VBD N
created VBN N
on IN N
the DT N
dorsomedial JJ N
and CC N
dorsolateral JJ N
aspect NN N
of IN N
the DT N
metacarpus NN N
or CC N
metatarsus NN N
of IN N
each DT N
limb NN N
of IN N
four CD p
horses NNS p
, , p
giving VBG p
a DT p
total NN p
of IN p
64 CD p
wounds NNS p
. . p

For IN N
each DT N
limb NN N
, , N
wounds NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
four CD N
treatment NN N
groups NNS N
: : N
no DT i
treatment NN i
( ( i
control NN i
) ) i
, , i
carrier NN i
( ( i
Methyl NNP i
Cellulose NNP i
gel NN i
) ) i
, , i
50 CD i
ng/wound IN i
rhTGF-beta JJ i
1 CD i
in IN i
carrier NN i
, , i
and CC i
500 CD i
ng/wound JJ i
rhTGF-beta JJ i
1 CD i
in IN i
carrier NN i
. . i

Wounds NNS N
were VBD N
treated VBN N
on IN N
day NN N
0 CD N
and CC N
day NN N
8 CD N
. . N

Effects NNS N
of IN N
treatment NN N
were VBD N
evaluated VBN N
on IN N
the DT N
basis NN N
of IN N
the DT N
presence NN o
of IN o
exuberant JJ o
granulation NN o
tissue NN o
requiring VBG o
excision NN o
, , o
number NN o
of IN o
times NNS o
excision NN o
was VBD o
required VBN o
, , o
total JJ o
wound JJ o
area NN o
, , o
area NN o
of IN o
epithelialisation NN o
, , o
area NN o
of IN o
granulation NN o
, , o
and CC o
histological JJ o
evaluation NN o
of IN o
biopsy NN o
samples NNS o
of IN o
wounds NNS o
on IN N
day NN N
8 CD N
and CC N
excised VBD N
wounds NNS N
on IN N
day NN N
21 CD N
. . N

RESULTS NNP N
Topical JJ N
application NN N
of IN N
TGF-beta NNP N
1 CD N
at IN N
the DT N
two CD N
concentrations NNS N
studied VBN N
had VBD N
no DT N
significant JJ N
effect NN N
on IN N
the DT N
total JJ o
area NN o
of IN o
wounds NNS o
( ( N
P NNP N
= NNP N
0.7 CD N
) ) N
, , N
the DT o
area NN o
of IN o
granulation NN o
tissue NN o
( ( N
P NNP N
= NNP N
0.78 CD N
) ) N
, , N
the DT o
area NN o
of IN o
epithelialisation NN o
( ( N
P NNP N
= NNP N
0.92 CD N
) ) N
, , N
histological JJ N
assessment NN N
or CC N
subjective JJ o
clinical JJ o
assessment NN o
of IN o
wounds NNS o
. . o

CONCLUSION NNP N
TGF-beta NNP i
1 CD i
had VBD N
no DT N
beneficial JJ N
effects NNS N
on IN N
wound NN o
healing NN o
. . o

Additional JJ N
trials NNS N
are VBP N
needed VBN N
to TO N
test VB N
if IN N
it PRP N
has VBZ N
value NN N
for IN N
wound NN N
treatment NN N
in IN N
horses NNS p
. . p

-DOCSTART- -23801256- O O

A DT N
head-to-head JJ N
comparison NN N
of IN N
aripiprazole NN i
and CC i
risperidone NN i
for IN N
safety NN N
and CC N
treating VBG N
autistic JJ p
disorders NNS p
, , N
a DT N
randomized VBN N
double JJ N
blind RB N
clinical JJ N
trial NN N
. . N

Aripiprazole NNP i
and CC i
risperidone NN i
are VBP N
the DT N
only JJ N
FDA NNP N
approved VBD N
medications NNS N
for IN N
treating VBG N
irritability NN N
in IN N
autistic JJ N
disorder NN N
, , N
however RB N
there EX N
are VBP N
no DT N
head-to-head JJ N
data NNS N
comparing VBG N
these DT N
agents NNS N
. . N

This DT N
is VBZ N
the DT N
first JJ N
prospective JJ N
randomized VBN N
clinical JJ N
trial NN N
comparing VBG N
the DT N
safety NN N
and CC N
efficacy NN N
of IN N
these DT N
two CD N
medications NNS N
in IN N
patients NNS p
with IN p
autism NN p
spectrum NN p
disorders NNS p
. . p

Fifty NNP p
nine CD p
children NNS p
and CC p
adolescents NNS p
with IN p
autism NN p
spectrum NN p
disorders NNS p
were VBD N
randomized VBN N
to TO N
receive VB N
either DT N
aripiprazole NN i
or CC i
risperidone NN i
for IN N
2 CD N
months NNS N
. . N

The DT N
primary JJ N
outcome NN N
measure NN N
was VBD o
change NN o
in IN o
Aberrant NNP o
Behavior NNP o
Checklist NNP o
( ( o
ABC NNP o
) ) o
scores VBZ o
. . o

Adverse JJ N
events NNS N
were VBD N
assessed VBN N
. . N

Aripiprazole NNP i
as RB N
well RB N
as IN N
risperidone NN N
lowered VBD o
ABC NNP o
scores NNS o
during IN N
2 CD N
months NNS N
. . N

The DT o
rates NNS o
of IN o
adverse JJ o
effects NNS o
were VBD o
not RB N
significantly RB N
different JJ N
between IN N
the DT N
two CD N
groups NNS N
. . N

The DT o
safety NN o
and CC o
efficacy NN o
of IN o
aripiprazole NN N
( ( N
mean JJ N
dose VBP N
5.5 CD N
mg/day NN N
) ) N
and CC N
risperidone NN N
( ( N
mean JJ N
dose VBP N
1.12 CD N
mg/day NN N
) ) N
were VBD N
comparable JJ N
. . N

The DT N
choice NN N
between IN N
these DT N
two CD N
medications NNS N
should MD N
be VB N
on IN N
the DT N
basis NN N
of IN N
clinical JJ N
equipoise NN N
considering VBG N
the DT N
patient NN N
's POS N
preference NN N
and CC N
clinical JJ N
profile NN N
. . N

-DOCSTART- -20519346- O O

Recombinant JJ i
human JJ i
thyrotropin-stimulated JJ i
radioiodine NN i
therapy NN i
of IN N
nodular JJ N
goiter NN N
allows VBZ N
major JJ N
reduction NN N
of IN N
the DT N
radiation NN o
burden NN o
with IN N
retained JJ N
efficacy NN o
. . o

CONTEXT NNP N
AND NNP N
OBJECTIVE NNP N
Stimulation NNP N
with IN N
recombinant JJ i
human JJ i
TSH NNP i
( ( i
rhTSH NN i
) ) i
before IN N
radioiodine NN i
( ( i
131I CD i
) ) i
therapy NN i
augments NNS N
goiter NN o
volume NN o
reduction NN o
( ( o
GVR NNP o
) ) o
. . o

Observations NNS N
indicate VBP N
that IN N
rhTSH NN i
has VBZ N
a DT N
preconditioning NN N
effect NN N
beyond IN N
increasing VBG N
thyroid NN N
( ( N
131 CD N
) ) N
I PRP N
uptake VBP N
. . N

We PRP N
test VBP N
the DT N
hypothesis NN N
that IN N
an DT N
equivalent JJ N
GVR NNP N
might MD N
be VB N
obtained VBN N
by IN N
an DT N
absorbed JJ N
thyroid NN N
dose NN N
well RB N
below IN N
what WP N
has VBZ N
been VBN N
used VBN N
previously RB N
. . N

PATIENTS NNP N
AND CC N
DESIGN NNP N
In IN N
a DT N
double-blinded JJ N
setup NN N
, , N
90 CD p
patients NNS p
( ( p
78 CD p
women NNS p
; : p
median JJ p
age NN p
, , p
52 CD p
yr NN p
; : p
range NN p
, , p
22-83 JJ p
) ) p
with IN p
a DT p
nontoxic JJ p
nodular JJ p
goiter NN p
( ( p
median JJ p
size NN p
, , p
63 CD p
ml NN p
; : p
range NN p
, , p
25-379 JJ p
ml NN p
) ) p
were VBD p
randomized VBN p
to TO N
either DT N
0.1 CD i
mg NN i
rhTSH NN i
( ( N
n=60 NN N
) ) N
followed VBN N
by IN N
a DT N
thyroid JJ i
dose NN i
of IN i
50 CD i
Gy NNP i
or CC i
placebo NN i
followed VBN N
by IN N
100 CD N
Gy NNP N
( ( N
n=30 NN N
) ) N
. . N

RESULTS NNP N
At IN N
12 CD N
months NNS N
, , N
the DT N
mean JJ N
relative JJ o
GVR NNP o
in IN N
the DT N
placebo NN i
and CC N
the DT N
rhTSH NN i
group NN N
was VBD N
identical JJ N
( ( N
35+/-3 JJ N
% NN N
; : N
P=0.81 NNP N
) ) N
. . N

The DT N
median JJ N
administered VBD N
131I-activity NN o
was VBD N
170 CD N
MBq NNP N
( ( N
45-1269 JJ N
) ) N
in IN N
the DT N
rhTSH NN i
group NN N
and CC N
559 CD N
MBq NNP N
( ( N
245-3530 JJ N
) ) N
in IN N
the DT N
placebo NN i
group NN N
( ( N
70 CD N
% NN N
reduction NN N
, , N
P NNP N
< NNP N
0.0001 CD N
) ) N
. . N

According VBG N
to TO N
the DT N
official JJ N
radiation NN N
regulation NN N
, , N
hospitalization NN o
was VBD N
required VBN N
in IN N
14 CD N
patients NNS N
in IN N
the DT N
placebo NN i
group NN N
vs. FW N
one CD N
patient NN N
in IN N
the DT N
rhTSH NN i
group NN N
( ( N
P NNP N
< NNP N
0.0001 CD N
) ) N
. . N

In IN N
both DT N
groups NNS N
, , N
goiter-related JJ o
symptoms NNS o
were VBD N
effectively RB N
relieved VBN N
in IN N
the DT N
majority NN N
of IN N
patients NNS N
. . N

The DT N
prevalence NN N
of IN N
myxedema NN o
( ( N
10 CD N
% NN N
) ) N
did VBD N
not RB N
differ VB N
among IN N
groups NNS N
. . N

CONCLUSIONS NNP N
This DT N
is VBZ N
the DT N
first JJ N
study NN N
to TO N
demonstrate VB N
that DT N
rhTSH NN i
not RB N
only RB N
increases VBZ N
the DT N
thyroid JJ o
131I CD o
uptake NN o
, , N
but CC N
per IN N
se NN N
potentiates VBZ N
the DT N
effect NN N
of IN N
131I-therapy JJ i
, , N
allowing VBG N
a DT N
major JJ N
reduction NN N
of IN N
the DT N
131I-activity NN o
without IN N
compromising VBG N
efficacy NN o
. . o

This DT N
approach NN N
is VBZ N
attractive JJ N
in IN N
terms NNS N
of IN N
minimizing VBG N
posttherapeutic JJ o
restrictions NNS o
and CC N
in IN N
reducing VBG N
the DT N
potential JJ N
risk NN N
of IN N
radiation-induced JJ o
malignancy NN o
. . N

-DOCSTART- -25524655- O O

Most JJS N
functional JJ N
outcomes NNS N
are VBP N
similar JJ N
for IN N
men NNS p
and CC p
women NNS p
after IN p
hip JJ p
fracture NN p
: : p
a DT N
secondary JJ N
analysis NN N
of IN N
the DT N
enhancing VBG N
mobility NN N
after IN N
hip NN N
fracture NN N
trial NN N
. . N

BACKGROUND VB N
The DT N
impact NN N
of IN N
gender NN N
on IN N
functional JJ N
outcomes NNS N
after IN N
hip NN N
fracture NN N
is VBZ N
not RB N
known VBN N
. . N

We PRP N
aimed VBD N
to TO N
determine VB N
the DT N
extent NN N
to TO N
which WDT N
gender NN N
influenced VBD N
functional JJ o
outcome NN o
and CC o
response NN o
to TO o
exercise VB o
in IN N
older JJR p
people NNS p
after IN p
hip JJ p
fracture NN p
, , N
and CC N
to TO N
determine VB N
if IN N
any DT N
differences NNS N
persisted VBN N
after IN N
adjusting VBG N
for IN N
cognition NN N
, , N
weight NN N
and CC N
age NN N
. . N

METHOD NNP N
Secondary JJ p
analysis NN i
of IN i
data NNS i
from IN i
the DT i
Enhancing NNP i
Mobility NNP i
After IN i
Hip NNP i
Fracture NNP i
trial NN i
in IN p
which WDT p
older JJR p
people NNS p
after IN p
hip JJ p
fracture NN p
received VBD N
either CC N
a DT N
lower JJR i
or CC i
higher JJR i
intensity NN i
exercise NN i
program NN i
. . i

Functional NNP o
outcomes NNS o
included VBD N
physical JJ o
performance NN o
and CC o
self-reported JJ o
measures NNS o
. . o

Regression NNP N
models NNS N
were VBD N
used VBN N
to TO N
compare VB N
genders NNS N
at IN N
baseline NN N
, , N
week NN N
4 CD N
and CC N
week NN N
16 CD N
, , N
with IN N
adjustment NN N
for IN N
baseline NN N
values NNS N
, , N
cognition NN N
, , N
weight NN N
and CC N
age NN N
. . N

Interaction NN N
terms NNS N
were VBD N
used VBN N
to TO N
assess VB N
a DT N
differential JJ N
impact NN N
of IN N
the DT N
intervention NN N
by IN N
gender NN N
. . N

RESULTS NNP N
Outcome NNP N
data NNS N
were VBD N
available JJ N
for IN N
160 CD p
participants NNS p
, , p
30 CD p
men NNS p
( ( p
19 CD p
% NN p
) ) p
and CC p
130 CD p
women NNS p
( ( p
81 CD p
% NN p
) ) p
at IN N
baseline NN N
, , N
with IN N
the DT N
withdrawal NN N
of IN N
4 CD N
men NNS N
( ( N
13 CD N
% NN N
) ) N
and CC N
6 CD N
women NNS N
( ( N
5 CD N
% NN N
) ) N
at IN N
week NN N
16 CD N
. . N

There EX N
were VBD N
no DT o
gender NN o
differences NNS o
for IN N
any DT N
baseline JJ o
measures NNS o
or CC N
for IN N
most JJS N
of IN N
the DT N
19 CD N
functional JJ o
outcome NN o
measures NNS o
at IN N
weeks NNS N
4 CD N
and CC N
16 CD N
. . N

At IN N
week NN N
4 CD N
men NNS N
performed VBD N
better RBR N
in IN N
knee NN o
extensor NN o
strength NN o
( ( N
2.1 CD N
kg NN N
, , N
95 CD N
% NN N
CI NNP N
0.6 CD N
to TO N
3.7 CD N
, , N
p NN N
< NNP N
0.01 CD N
) ) N
. . N

This DT N
difference NN o
did VBD o
not RB o
persist VB o
after IN N
adjustment NN N
for IN N
body NN o
weight NN o
, , N
however RB N
persisted VBN N
after IN N
adjusting VBG N
for IN N
baseline NN o
, , o
cognition NN o
, , o
and CC o
age NN o
( ( N
p JJ N
= NNP N
0.038 CD N
) ) N
. . N

At IN N
week NN N
4 CD N
, , N
men NNS N
performed VBD N
better RBR N
in IN N
coordinated JJ o
stability NN o
( ( N
-10.0 JJ N
error NN N
score NN N
, , N
95 CD N
% NN N
CI NNP N
-17.6 NNP N
to TO N
-2.4 VB N
, , N
p=0.010 NN N
) ) N
and CC N
this DT N
persisted VBN o
after IN N
adjusting VBG N
for IN N
baseline NN o
values NNS o
only RB N
but CC N
not RB N
for IN N
cognition NN o
and CC o
age NN o
( ( N
p JJ N
= NNP N
0.073 CD N
) ) N
. . N

At IN N
week NN N
16 CD N
, , N
men NNS N
performed VBD N
better RBR N
in IN N
coordinated JJ o
stability NN o
( ( N
-10.2 JJ N
error NN N
score NN N
, , N
95 CD N
% NN N
CI NNP N
-18.4 NNP N
to TO N
-1.9 VB N
, , N
p=0.016 NN N
) ) N
and CC N
this DT N
persisted VBN o
after IN N
adjusting VBG N
only RB N
for IN N
cognitive JJ o
impairment NN o
( ( N
p JJ N
= NNP N
0.029 CD N
) ) N
but CC N
not RB N
for IN N
age NN o
and CC o
baseline NN o
( ( N
p JJ N
= NNP N
0.135 CD N
) ) N
. . N

There EX N
was VBD N
no DT N
indication NN N
of IN N
a DT N
differential JJ o
impact NN o
of IN o
intervention NN o
type NN o
on IN N
the DT N
basis NN N
of IN N
gender NN N
. . N

CONCLUSIONS VB N
A DT N
few JJ N
between IN N
gender NN N
differences NNS N
were VBD N
observed VBN N
in IN N
strength NN o
and CC o
balance NN o
, , N
however RB N
these DT N
appeared VBD N
to TO N
be VB N
confounded VBN N
by IN N
body NN o
weight NN o
, , o
age NN o
and/or JJ o
cognition NN o
. . o

-DOCSTART- -22275153- O O

The DT N
effect NN N
of IN N
rectal JJ i
distension NN i
on IN N
bladder NN N
function NN N
in IN N
patients NNS p
with IN p
overactive JJ p
bladder NN p
. . p

AIMS NNP N
To TO N
investigate VB N
the DT N
effect NN N
of IN N
rectal JJ i
distension NN i
on IN N
bladder NN o
sensation NN o
volumes NNS o
and CC o
the DT o
number NN o
of IN o
detrusor NN o
contractions NNS o
in IN N
patients NNS p
with IN p
overactive JJ p
bladder NN p
( ( p
OAB NNP p
) ) p
symptoms NNS p
. . p

METHODS NNP N
A NNP N
prospective JJ N
randomized VBN N
study NN N
included VBD N
patients NNS p
with IN p
OAB NNP p
symptoms NNS p
. . p

Multichannel NNP N
urodynamic JJ N
studies NNS N
were VBD N
completed VBN N
with IN i
and CC i
without IN i
rectal JJ i
balloon NN i
distension NN i
. . i

Bladder NNP N
sensation NN N
volumes NNS N
and CC N
detrusor NN N
contractions NNS N
were VBD N
compared VBN N
. . N

RESULTS NNP N
Twenty-six JJ p
patients NNS p
were VBD N
included VBN N
in IN N
the DT N
study NN N
. . N

The DT p
mean JJ p
age NN p
was VBD p
67 CD p
years NNS p
and CC p
mean JJ p
BMI NNP p
was VBD p
28.3 CD p
kg/m NN p
( ( p
2 CD p
) ) p
. . p

Bladder NNP o
sensation NN o
volumes NNS o
were VBD o
lower JJR N
with IN i
rectal JJ i
distention NN i
as IN i
follows VBZ N
: : N
normal JJ N
desire NN N
to TO N
void VB N
( ( N
139 CD N
ml NN N
SD NNP N
, , N
?114 NNP N
vs. FW N
197 CD N
ml NN N
SD NNP N
?150 NNP N
, , N
P NNP N
= NNP N
0.01 CD N
) ) N
, , N
strong JJ N
desire NN N
to TO N
void VB N
( ( N
260 CD N
ml NN N
SD NNP N
?171 NNP N
vs. IN N
330 CD N
ml NNS N
SD NNP N
?172 NNP N
, , N
P NNP N
= NNP N
0.01 CD N
) ) N
, , N
and CC N
maximum JJ N
cystometric JJ N
capacity NN N
( ( N
326 CD N
ml NN N
SD NNP N
?183 NNP N
vs. IN N
403 CD N
ml NNS N
SD NNP N
?180 NNP N
, , N
P NNP N
= NNP N
0.0001 CD N
) ) N
. . N

There EX N
was VBD N
no DT N
difference NN N
in IN N
the DT N
number NN o
of IN o
detrusor JJ o
contractions NNS o
or CC o
the DT o
bladder NN o
volume NN o
at IN o
which WDT o
the DT o
first JJ o
detrusor NN o
contraction NN o
had VBD o
occurred VBN o
with IN o
and CC o
without IN N
rectal JJ N
distension NN N
. . N

CONCLUSION NNP i
Rectal NNP i
distention NN i
in IN i
patients NNS p
with IN p
OAB NNP p
symptoms NNS N
significantly RB N
lowered VBD o
bladder JJR o
sensation NN o
volumes NNS o
( ( o
normal JJ o
desire NN N
, , N
strong JJ N
desire NN N
, , N
and CC N
maximal JJ N
capacity NN N
) ) N
. . N

-DOCSTART- -16095766- O O

Safety NN N
and CC N
immunogenicity NN N
of IN N
an DT N
oral JJ i
, , i
inactivated JJ i
, , i
whole-cell JJ i
vaccine NN i
for IN i
Shigella NNP i
sonnei NN i
: : i
preclinical JJ N
studies NNS N
and CC N
a DT N
Phase NNP N
I PRP N
trial NN N
. . N

Orally RB N
delivered VBN N
, , N
inactivated VBN N
whole-cell NN N
vaccines NNS i
are VBP N
safe JJ N
methods NNS N
of IN N
inducing VBG N
local JJ N
and CC N
systemic JJ N
immunity NN N
. . N

To TO N
increase VB N
surface NN o
proteins NNS o
associated VBN N
with IN N
adherence NN N
and CC N
invasion NN N
, , N
Shigella NNP N
sonnei NN N
were VBD N
grown VBN N
in IN N
BHI NNP N
broth CC N
containing VBG N
deoxycholate NN N
. . N

A DT N
whole-cell JJ i
vaccine NN i
( ( i
SsWC NNP i
) ) i
was VBD N
then RB N
produced VBN N
by IN N
formalin JJ N
inactivation NN N
. . N

In IN N
pre-clinical JJ N
studies NNS N
, , N
the DT N
SsWC NNP i
vaccine NN i
was VBD N
immunogenic JJ N
and CC N
protected VBN N
against IN N
S. NNP N
sonnei-induced JJ N
keratoconjunctivitis NN N
in IN N
the DT N
guinea NN p
pig NN p
model NN p
. . p

In IN N
a DT N
randomized JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ i
, , N
Phase NNP p
I PRP p
study VBP p
, , p
10 CD p
evaluable JJ p
subjects NNS p
received VBD N
either DT N
three CD N
doses NNS N
of IN N
SsWC NNP i
on IN N
Days NNP N
0 CD N
, , N
14 CD N
, , N
and CC N
28 CD N
( ( N
N NNP N
= NNP N
3 CD N
) ) N
; : N
five CD N
doses NNS N
of IN N
SsWC NNP i
on IN N
Days NNP N
0 CD N
, , N
2 CD N
, , N
4 CD N
, , N
6 CD N
, , N
and CC N
28 CD N
( ( N
N NNP N
= NNP N
4 CD N
) ) N
; : N
or CC i
placebo VB i
( ( N
N NNP N
= NNP N
3 CD N
) ) N
. . N

Each DT N
dose NN N
contained VBD N
2.0 CD N
x JJ N
10 CD N
( ( N
10 CD N
) ) N
inactivated VBN N
cells NNS N
. . N

Serum NNP o
and CC o
fecal JJ o
antibodies NNS o
against IN o
SsWC NNP o
, , o
LPS NNP o
, , o
and CC o
IpaC NNP o
were VBD N
measured VBN N
by IN N
ELISA NNP N
. . N

A NNP N
> NN N
or CC N
= VB N
4-fold JJ N
increase NN N
in IN N
titer NN N
was VBD N
considered VBN N
significant JJ N
. . N

Both DT N
SsWC NNP i
dosing NN N
regimens NNS N
were VBD N
well RB N
tolerated VBN o
. . o

No DT N
fever NN o
or CC o
severe JJ o
gastrointestinal JJ o
symptoms NNS o
were VBD N
noted VBN N
by IN N
any DT N
of IN N
the DT N
vaccinated JJ N
subjects NNS N
. . N

Antibody NN o
responses NNS o
were VBD N
similar JJ N
in IN N
the DT N
two CD N
dosing VBG N
groups NNS N
. . N

Serum NNP o
IgG NNP o
or CC o
IgA NNP o
responses NNS o
to TO N
SsWC NNP i
were VBD N
seen VBN N
in IN N
six CD N
of IN N
seven CD N
vaccinees NNS N
( ( N
86 CD N
% NN N
) ) N
, , N
to TO N
LPS NNP N
in IN N
four CD N
of IN N
seven CD N
( ( N
57 CD N
% NN N
) ) N
, , N
and CC N
to TO N
IpaC NNP N
in IN N
five CD N
of IN N
seven CD N
( ( N
61 CD N
% NN N
) ) N
. . N

Fecal JJ o
IgA NNP o
responses NNS o
to TO N
these DT N
three CD N
antigens NNS N
developed VBN N
in IN N
five CD N
of IN N
five CD N
, , N
three CD N
of IN N
five CD N
, , N
and CC N
three CD N
of IN N
five CD N
subjects NNS N
, , N
respectively RB N
. . N

Among IN N
the DT N
seven CD N
vaccinees NNS N
, , N
geometric JJ N
mean NN N
rises NNS N
in IN N
serum JJ o
IgA NNP o
levels NNS o
to TO N
all DT N
three CD N
immunogens NNS N
were VBD N
significant JJ N
; : N
IgG NNP o
increases VBZ o
trended VBD N
toward IN N
significance NN N
( ( N
paired JJ N
one-tailed JJ N
t-test NN N
) ) N
. . N

We PRP N
conclude VBP N
that IN N
SsWC NNP i
was VBD N
immunogenic JJ o
and CC N
protective JJ o
in IN N
animal JJ N
studies NNS N
and CC N
well RB N
tolerated VBN o
and CC N
immunogenic JJ o
in IN N
a DT N
Phase NNP N
I PRP N
trial NN N
. . N

-DOCSTART- -12241713- O O

Therapeutic JJ o
angiogenesis NN o
for IN N
patients NNS p
with IN p
limb JJ p
ischaemia NN p
by IN N
autologous JJ i
transplantation NN i
of IN i
bone-marrow JJ i
cells NNS i
: : i
a DT N
pilot NN N
study NN N
and CC N
a DT N
randomised VBN N
controlled VBN N
trial NN N
. . N

BACKGROUND NNP N
Preclinical NNP N
studies NNS N
have VBP N
established VBN N
that IN N
implantation NN N
of IN N
bone NN N
marrow-mononuclear JJ N
cells NNS N
, , N
including VBG N
endothelial JJ N
progenitor NN N
cells NNS N
, , N
into IN N
ischaemic JJ N
limbs NN N
increases VBZ N
collateral JJ o
vessel NN o
formation NN o
. . o

We PRP N
investigated VBD N
efficacy NN o
and CC o
safety NN o
of IN N
autologous JJ i
implantation NN i
of IN i
bone NN i
marrow-mononuclear JJ i
cells NNS i
in IN i
patients NNS p
with IN p
ischaemic JJ p
limbs NNS p
because IN p
of IN p
peripheral JJ p
arterial JJ p
disease NN p
. . p

METHODS NNP N
We PRP N
first RB N
did VBD N
a DT N
pilot NN N
study NN N
, , N
in IN N
which WDT N
25 CD p
patients NNS p
( ( p
group NN p
A DT p
) ) p
with IN p
unilateral JJ p
ischaemia NN p
of IN p
the DT p
leg NN p
were VBD N
injected VBN i
with IN i
bone NN i
marrow-mononuclear JJ i
cells NNS i
into IN i
the DT i
gastrocnemius NN i
of IN i
the DT i
ischaemic JJ i
limb NN i
and CC i
with IN i
saline NN i
into IN i
the DT i
less JJR i
ischaemic JJ i
limb NN i
. . i

We PRP N
then RB N
recruited VBD N
22 CD p
patients NNS p
( ( p
group NN p
B NNP p
) ) p
with IN p
bilateral JJ p
leg NN p
ischaemia NN p
, , N
who WP N
were VBD N
randomly RB N
injected VBN i
with IN i
bone NN i
marrow-mononuclear JJ i
cells NNS i
in IN i
one CD i
leg NN i
and CC i
peripheral JJ i
blood-mononuclear JJ i
cells NNS i
in IN i
the DT i
other JJ i
as IN i
a DT i
control NN i
. . i

Primary JJ N
outcomes NNS N
were VBD N
safety NN o
and CC o
feasibility NN o
of IN o
treatment NN o
, , N
based VBN N
on IN N
ankle-brachial JJ o
index NN o
( ( o
ABI NNP o
) ) o
and CC N
rest NN o
pain NN o
, , N
and CC N
analysis NN N
was VBD N
per IN N
protocol NN N
. . N

FINDINGS NNP N
Two CD p
patients NNS p
were VBD p
excluded VBN p
from IN p
group NN p
B NNP p
after IN p
randomisation NN p
. . p

At IN N
4 CD N
weeks NNS N
in IN N
group NN p
B NNP p
patients NNS p
, , N
ABI NNP o
was VBD N
significantly RB N
improved VBN N
in IN N
legs NNS N
injected VBN N
with IN N
bone NN i
marrow-mononuclear JJ i
cells NNS i
compared VBN N
with IN N
those DT N
injected VBN N
with IN N
peripheral JJ i
blood-mononuclear JJ i
cells NNS i
( ( N
difference NN N
0.09 CD N
[ JJ N
95 CD N
% NN N
CI NNP N
0.06-0.11 CD N
] NNP N
; : N
p VBZ N
< $ N
0.0001 CD N
) ) N
. . N

Similar JJ N
improvements NNS N
were VBD N
seen VBN N
for IN N
transcutaneous JJ o
oxygen NN o
pressure NN o
( ( N
13 CD N
[ RB N
9-17 CD N
] NNS N
; : N
p VB N
< $ N
0.0001 CD N
) ) N
, , N
rest VBP o
pain NN o
( ( N
-0.85 JJ N
[ NNP N
-1.6 NN N
to TO N
-0.12 VB N
] NNP N
; : N
p=0.025 NN N
) ) N
, , N
and CC N
pain-free JJ o
walking NN o
time NN o
( ( N
1.2 CD N
[ RB N
0.7-1.7 JJ N
] NN N
; : N
p=0.0001 NN N
) ) N
. . N

These DT N
improvements NNS o
were VBD N
sustained VBN N
at IN N
24 CD N
weeks NNS N
. . N

Similar JJ N
improvements NNS o
were VBD N
seen VBN N
in IN N
group NN p
A DT p
patients NNS p
. . p

Two CD p
patients NNS p
in IN N
group NN N
A NNP N
died VBD o
after IN o
myocardial JJ o
infarction NN o
unrelated VBD N
to TO N
treatment NN N
. . N

INTERPRETATION NNP N
Autologous NNP i
implantation NN i
of IN i
bone NN i
marrow-mononuclear JJ i
cells NNS i
could MD N
be VB N
safe JJ o
and CC o
effective JJ o
for IN N
achievement NN N
of IN N
therapeutic JJ o
angiogenesis NN o
, , N
because IN N
of IN N
the DT N
natural JJ N
ability NN N
of IN N
marrow NN N
cells NNS N
to TO N
supply VB N
endothelial JJ N
progenitor NN N
cells NNS N
and CC N
to TO N
secrete VB N
various JJ N
angiogenic JJ N
factors NNS N
or CC N
cytokines NNS N
. . N

-DOCSTART- -11140546- O O

Do NNP N
heavier JJR p
women NNS p
benefit VBP N
from IN N
a DT N
higher JJR N
dose NN N
of IN N
leuprolide JJ i
acetate NN i
for IN N
suppression NN N
of IN N
serum NN N
estradiol NN N
? . N
OBJECTIVE UH N
To TO N
determine VB N
if IN N
heavier JJR p
women NNS p
benefit VBP N
from IN N
a DT N
higher JJR N
dose NN N
of IN N
the DT N
gonadotropin-releasing JJ i
hormone NN i
analogue NN i
leuprolide NN i
acetate NN i
( ( i
LA NNP i
) ) i
depot NN N
in IN N
terms NNS N
of IN N
suppression NN N
of IN N
serum NN N
estradiol NN N
. . N

METHODS NNP N
This DT N
was VBD N
a DT N
retrospective JJ N
analysis NN N
of IN N
the DT N
effect NN N
of IN N
LA NNP i
depot FW i
3.75 CD N
mg NN N
and CC N
7.5 CD N
mg NN N
on IN N
serum NN i
estradiol NN i
from IN N
a DT N
multicenter NN N
, , N
double-blind JJ N
, , N
parallel-group JJ N
, , N
12-week JJ N
study NN N
of IN N
women NNS p
with IN p
anemia NN p
due JJ p
to TO p
bleeding VBG p
from IN p
uterine JJ p
leiomyomata NN p
. . p

Serum NNP o
estradiol NN o
levels NNS o
were VBD N
obtained VBN N
at IN N
baseline NN N
and CC N
at IN N
week NN N
12 CD N
. . N

Patients NNS p
were VBD p
divided VBN p
into IN p
weight NN p
quartiles NNS p
according VBG p
to TO p
their PRP$ p
baseline NN p
weight NN p
in IN p
kilograms NNS p
: : p
46- JJ p
< NN p
64 CD p
, , p
64- JJ p
< NN p
72 CD p
, , p
72- JJ p
< NN p
89 CD p
, , p
89-159 JJ p
( ( p
pounds-102- JJ p
< NN p
140 CD p
, , p
140- JJ p
< NN p
159 CD p
, , p
159- JJ p
< NN p
196 CD p
, , p
196-350 JJ p
) ) p
. . p

RESULTS VBN N
At IN N
baseline NN N
there EX N
was VBD N
no DT o
statistically RB o
significant JJ o
difference NN o
in IN N
estradiol JJ o
level NN o
between IN N
groups NNS N
as IN N
a DT N
whole NN N
or CC N
within IN N
weight JJ N
quartiles NNS N
. . N

Within IN N
each DT N
group NN N
there EX N
was VBD N
no DT N
relationship NN N
between IN N
weight NN N
and CC N
baseline NN N
estradiol NN N
. . N

At IN N
week NN N
12 CD N
, , N
whereas NNS N
estradiol VBP o
levels NNS o
were VBD N
significantly RB o
greater JJR o
in IN N
the DT N
heavier JJR N
patients NNS N
in IN N
each DT N
of IN N
the DT N
groups NNS N
( ( N
LA NNP N
3.75 CD N
mg NN N
, , N
p NN N
= VBD N
0.044 CD N
; : N
LA NNP N
7.5 CD N
mg NN N
, , N
p NN N
= NNP N
0.002 CD N
) ) N
, , N
there EX N
was VBD N
no DT o
significant JJ o
difference NN o
in IN o
estradiol NN o
between IN N
groups NNS N
as IN N
a DT N
whole NN N
or CC N
within IN N
any DT N
of IN N
the DT N
weight NN N
quartiles NNS N
. . N

Moreover RB N
, , N
at IN N
week NN N
12 CD N
there EX N
was VBD N
no DT o
significant JJ o
difference NN o
between IN N
groups NNS N
in IN N
the DT N
percentage NN o
of IN o
patients NNS o
with IN o
estradiol NNS o
suppressed VBN o
to TO o
the DT o
menopausal NN o
range NN o
. . o

CONCLUSION NNP N
Heavier NNP p
women NNS p
do VBP N
not RB N
benefit VB N
from IN N
a DT N
higher JJR N
dose NN N
of IN N
LA NNP i
depot NNP N
( ( N
7.5 CD N
vs. FW N
3.75 CD N
mg NN N
) ) N
for IN N
suppression NN N
of IN N
serum NN N
levels NNS N
of IN N
estradiol NN N
. . N

-DOCSTART- -23233021- O O

A DT N
randomised VBN N
controlled VBN N
trial NN N
of IN N
bumetanide NN i
in IN N
the DT N
treatment NN N
of IN N
autism NN p
in IN p
children NNS p
. . p

Gamma NNP N
aminobutyric JJ N
acid NN N
( ( N
GABA NNP N
) ) N
-mediated VBD N
synapses NNS N
and CC N
the DT N
oscillations NNS N
they PRP N
orchestrate VBP N
are VBP N
altered VBN N
in IN N
autism NN N
. . N

GABA-acting JJ N
benzodiazepines NNS i
exert NN N
in IN N
some DT N
patients NNS N
with IN N
autism NN N
paradoxical JJ N
effects NNS o
, , N
raising VBG N
the DT N
possibility NN N
that IN N
like IN N
in IN N
epilepsies NNS N
, , N
GABA NNP N
excites VBZ N
neurons NNS N
because IN N
of IN N
elevated JJ N
intracellular JJ N
concentrations NNS N
of IN N
chloride NN N
. . N

Following VBG N
a DT N
successful JJ N
pilot NN N
study NN N
, , N
( ( N
1 CD N
) ) N
we PRP N
have VBP N
now RB N
performed VBN N
a DT N
double-blind JJ N
clinical JJ N
trial NN N
using VBG N
the DT N
diuretic JJ N
, , N
chloride-importer JJ N
antagonist NN N
bumetanide IN i
that DT N
reduces VBZ N
intracellular JJ N
chloride NN N
reinforcing VBG N
GABAergic NNP N
inhibition NN N
. . N

Sixty NNP p
children NNS p
with IN p
autism NN p
or CC p
Asperger NNP p
syndrome VBP p
( ( p
3-11 CD p
years NNS p
old JJ p
) ) p
received VBD N
for IN N
3 CD N
months NNS N
placebo NN i
or CC N
bumetanide NN i
( ( N
1 CD N
mg NNS N
daily RB N
) ) N
, , N
followed VBN N
by IN N
1-month JJ N
wash NN N
out IN N
. . N

Determination NN N
of IN N
the DT N
severity NN N
of IN N
autism NN N
was VBD N
made VBN N
with IN N
video JJ N
films NNS N
at IN N
day NN N
0 CD N
( ( N
D0 NNP N
) ) N
and CC N
D90 NNP N
by IN N
blind NN N
, , N
independent JJ N
evaluators NNS N
. . N

Bumetanide NNP i
reduced VBD N
significantly RB N
the DT N
Childhood NNP o
Autism NNP o
Rating NNP o
Scale NNP o
( ( o
CARS NNP o
) ) o
( ( N
D90-D0 NNP N
; : N
P NNP N
< VBD N
0.004 CD N
treated JJ N
vs NN N
placebo NN i
) ) i
, , N
Clinical JJ o
Global NNP o
Impressions NNP o
( ( N
P NNP N
< VBZ N
0.017 CD N
treated JJ N
vs NN N
placebo NN i
) ) i
and CC N
Autism NNP o
Diagnostic NNP o
Observation NNP o
Schedule NNP o
values NNS o
when WRB N
the DT N
most RBS N
severe JJ N
cases NNS N
( ( N
CARS NNPS N
values NNS N
above IN N
the DT N
mean NN N
? . N
s.d NN N
. . N

; : N
n=9 CC N
) ) N
were VBD N
removed VBN N
( ( N
Wilcoxon JJ N
test NN N
: : N
P-value=0.031 NN N
; : N
Student NNP N
's POS N
t-test NN N
: : N
P-value=0.017 NN N
) ) N
. . N

Side JJ o
effects NNS o
were VBD N
restricted VBN N
to TO N
an DT N
occasional JJ o
mild NN o
hypokalaemia NN o
( ( N
3.0-3.5 JJ N
mM NN N
l NN N
( ( N
-1 NNP N
) ) N
K NNP N
( ( N
+ NNP N
) ) N
) ) N
that WDT N
was VBD N
treated VBN N
with IN N
supplemental JJ N
potassium NN N
. . N

In IN N
a DT N
companion NN N
study NN N
, , N
chronic JJ N
bumetanide NN N
treatment NN N
significantly RB N
improved VBN o
accuracy NN o
in IN o
facial JJ o
emotional JJ o
labelling NN o
, , o
and CC o
increased VBD o
brain NN o
activation NN o
in IN o
areas NNS o
involved VBN o
in IN o
social JJ o
and CC o
emotional JJ o
perception NN o
( ( o
Hadjikhani NNP o
et RB N
al. RB N
, , N
submitted VBN N
) ) N
. . N

Therefore RB i
, , i
bumetanide NN i
is VBZ i
a DT N
promising JJ N
novel NN N
therapeutic JJ N
agent NN N
to TO N
treat VB N
autism NN N
. . N

Larger JJR N
trials NNS N
are VBP N
warranted VBN N
to TO N
better RBR N
determine VB N
the DT N
population NN N
best RB N
suited VBN N
for IN N
this DT N
treatment NN N
. . N

-DOCSTART- -17383295- O O

Exercise NN o
capacity NN o
in IN N
atrial JJ p
fibrillation NN p
: : p
a DT N
substudy NN N
of IN N
the DT N
Sotalol-Amiodarone NNP N
Atrial NNP N
Fibrillation NNP N
Efficacy NNP N
Trial NNP N
( ( N
SAFE-T NNP N
) ) N
. . N

BACKGROUND NNP N
Therapy NNP N
for IN N
chronic JJ p
atrial JJ p
fibrillation NN p
( ( p
AF NNP p
) ) p
focuses VBZ N
on IN N
rate NN N
versus IN N
rhythm NN N
control NN N
, , N
but CC N
little JJ N
is VBZ N
known VBN N
about IN N
the DT N
effects NNS N
of IN N
common JJ N
therapeutic JJ N
interventions NNS N
on IN N
exercise NN N
tolerance NN N
in IN N
AF NNP N
. . N

METHODS NNP N
Six NNP p
hundred VBD p
fifty-five JJ p
patients NNS p
with IN p
chronic JJ p
AF NNP p
underwent NN p
maximal JJ i
exercise NN i
testing VBG i
at IN N
baseline NN N
and CC N
8 CD N
weeks NNS N
, , N
6 CD N
months NNS N
, , N
and CC N
1 CD N
year NN N
after IN N
randomization NN N
to TO N
sotalol VB i
, , i
amiodarone NN i
, , i
or CC i
placebo NN i
therapy NN N
and CC N
attempted VBD i
direct JJ i
current JJ i
cardioversion NN i
. . i

Analyses NNS N
of IN N
baseline JJ N
determinants NNS N
of IN N
exercise NN N
capacity NN N
, , N
predictors NNS N
of IN N
change NN N
in IN N
exercise NN N
capacity NN N
at IN N
6 CD N
months NNS N
and CC N
1 CD N
year NN N
, , N
and CC N
the DT N
short- JJ N
and CC N
long-term JJ N
effects NNS N
of IN N
cardioversion NN N
on IN N
exercise NN N
capacity NN N
were VBD N
made VBN N
. . N

RESULTS NNP N
Age NNP N
, , N
obesity NN N
, , N
and CC N
presence NN N
of IN N
symptoms NNS N
accompanying VBG N
AF NNP N
were VBD N
inversely RB N
associated VBN N
with IN N
baseline NN N
exercise NN N
capacity NN N
, , N
but CC N
these DT N
factors NNS N
accounted VBD N
for IN N
only RB N
10 CD N
% NN N
of IN N
the DT N
variance NN N
in IN N
exercise NN N
capacity NN N
. . N

Patients VBZ N
most RBS N
likely JJ N
to TO N
benefit VB N
from IN N
cardioversion NN N
were VBD N
those DT N
most RBS N
limited JJ N
initially RB N
, , N
younger JJR N
, , N
not RB N
obese JJ N
or CC N
hypertensive JJ N
, , N
and CC N
with IN N
an DT N
uncontrolled JJ N
ventricular NN N
rate NN N
at IN N
baseline NN N
. . N

Conversion NN N
to TO N
sinus VB N
rhythm NN N
( ( N
SR NNP N
) ) N
resulted VBD N
in IN N
significant JJ N
reductions NNS N
in IN N
resting VBG o
( ( N
approximately RB N
25 CD N
beat/min NN N
) ) N
and CC N
peak JJ o
exercise NN o
( ( N
approximately RB N
40 CD N
beat/min NN N
) ) N
heart NN o
rates NNS o
at IN N
6 CD N
months NNS N
and CC N
1 CD N
year NN N
( ( N
P NNP N
< NNP N
.001 NNP N
) ) N
. . N

Successful JJ N
cardioversion NN i
improved VBD N
exercise NN o
capacity NN o
by IN N
15 CD N
% NN N
at IN N
8 CD N
weeks NNS N
, , N
and CC N
these DT N
improvements NNS N
were VBD N
maintained VBN N
throughout IN N
the DT N
year NN N
. . N

This DT N
improvement NN N
was VBD N
observed VBN N
both DT N
among IN N
those DT N
who WP N
maintained VBD N
SR NNP N
and CC N
those DT N
with IN N
intermittent JJ N
AF NNP N
. . N

CONCLUSION NNP N
Cardioversion NNP i
resulted VBD N
in IN N
a DT N
sustained JJ N
improvement NN N
in IN N
exercise NN N
capacity NN N
over IN N
the DT N
course NN N
of IN N
1 CD N
year NN N
, , N
and CC N
this DT N
improvement NN N
was VBD N
similar JJ N
between IN N
those DT N
in IN N
SR NNP N
and CC N
those DT N
with IN N
SR NNP N
and CC N
recurrent JJ N
AF NNP N
. . N

Patients VBZ N
most RBS N
likely JJ N
to TO N
improve VB N
with IN N
treatment NN N
tended VBN N
to TO N
be VB N
younger JJR N
and CC N
nonobese JJ N
and CC N
have VBP N
the DT N
greatest JJS N
limitations NNS N
initially RB N
. . N

-DOCSTART- -11210885- O O

Alternative JJ N
voice NN N
after IN N
laryngectomy NN i
using VBG N
a DT N
sound-producing JJ i
voice NN i
prosthesis NN i
. . i

OBJECTIVE UH N
To TO N
improve VB o
the DT o
voice NN o
quality NN o
of IN N
female JJ p
laryngectomees NNS p
and/or VBP p
laryngectomees NNS p
with IN p
a DT p
hypotonic JJ p
pharyngoesophageal NN p
( ( p
PE NNP p
) ) p
segment NN p
by IN N
means NNS N
of IN N
a DT N
pneumatic JJ o
artificial JJ o
source NN o
of IN o
voice NN o
incorporated VBN o
in IN o
a DT o
regular JJ o
tracheoesophageal NN o
( ( o
TE NNP o
) ) o
shunt NN o
valve NN o
. . o

STUDY NNP N
DESIGN NNP N
Experimental NNP N
, , N
randomized VBD N
, , N
crossover JJ N
trial NN N
. . N

METHODS NNP N
The DT N
new JJ N
sound NN N
source NN N
consists VBZ N
of IN N
a DT N
single JJ N
silicone NN N
lip NN N
, , N
which WDT N
performs VBZ N
an DT N
oscillatory JJ N
movement NN N
driven VBN N
by IN N
expired JJ N
pulmonary JJ N
air NN N
flowing VBG N
along IN N
the DT N
outward-striking JJ N
lip NN N
through IN N
the DT N
TE NNP N
shunt NN N
valve NN N
. . N

A DT N
prototype NN N
of IN N
this DT N
pneumatic JJ i
sound NN i
source NN i
is VBZ N
evaluated VBN N
in IN N
vitro NN N
and CC N
in IN N
six CD p
laryngectomees NNS p
. . p

In IN N
vivo JJ N
evaluation NN N
includes VBZ N
speech JJ o
rate NN o
, , o
maximal JJ o
phonation NN o
time NN o
, , o
perceptual JJ o
voice NN o
evaluation NN o
of IN o
read-aloud JJ o
prose NN o
by IN o
an DT o
expert NN o
listener NN o
, , o
speech JJ o
intelligibility NN o
measurements NNS o
with IN o
12 CD o
listeners NNS o
, , o
and CC o
self-assessment JJ o
by IN o
the DT o
patients NNS o
. . o

Moreover RB N
, , N
extensive JJ o
acoustical JJ o
and CC o
aerodynamic JJ o
in IN o
vivo JJ o
registrations NNS o
are VBP N
performed VBN N
using VBG N
a DT N
newly RB o
developed VBN o
data NNS o
acquisition NN o
system NN o
. . o

RESULTS VB N
The DT N
current JJ N
prototype NN N
seems VBZ N
beneficial JJ N
in IN N
female JJ p
laryngectomees NNS p
with IN p
a DT p
hypotonic JJ p
PE NNP p
segment NN p
only RB N
. . N

For IN N
them PRP N
the DT N
sound-producing JJ i
voice NN i
prosthesis NN i
improves VBZ o
voice JJ o
quality NN o
and CC o
increases VBZ o
the DT o
average JJ o
pitch NN o
of IN o
voice NN o
, , o
without IN o
decreasing VBG o
intelligibility NN o
or CC o
necessitating VBG o
other JJ o
pressure NN o
and CC o
airflow NN o
rates NNS o
than IN o
regular JJ o
TE NNP o
shunt NN o
speech NN o
. . o

Pitch NNP o
regulation NN o
of IN N
this DT N
prosthetic JJ N
voice NN N
is VBZ N
possible JJ N
, , N
yet RB N
limited VBN N
. . N

CONCLUSIONS VB N
The DT N
mechanism NN N
is VBZ N
feasible JJ o
and CC N
does VBZ N
not RB N
result VB N
in IN N
unacceptable JJ N
airflow JJ N
resistance NN N
. . N

For IN N
this DT N
new JJ N
mechanism NN N
of IN N
alaryngeal JJ N
voice NN N
to TO N
become VB N
an DT N
established JJ N
technique NN N
for IN N
postlaryngectomy JJ N
voice NN N
restoration NN N
, , N
a DT N
voice NN N
suitably RB N
pitched VBN N
for IN N
male NN p
laryngectomees NNS p
has VBZ N
to TO N
be VB N
generated VBN N
and CC N
a DT N
large JJ N
part NN N
of IN N
the DT N
melodic NN N
and CC N
dynamic JJ N
range NN N
of IN N
the DT N
sound NN N
source NN N
has VBZ N
to TO N
be VB N
attainable JJ N
within IN N
physiological JJ N
airflow JJ N
rates NNS N
. . N

-DOCSTART- -7743697- O O

Plasma NNP N
norepinephrine NN N
and CC N
mortality NN N
. . N

Plasma NNP N
norepinephrine NN N
levels NNS N
, , N
which WDT N
reflect VBP N
sympathetic JJ N
nervous JJ N
system NN N
activity NN N
, , N
are VBP N
almost RB N
universally RB N
elevated VBN N
in IN N
patients NNS p
with IN p
left JJ p
ventricular JJ p
dysfunction NN p
. . p

This DT N
elevation NN N
occurs VBZ N
in IN N
patients NNS p
with IN p
overt JJ p
, , p
symptomatic JJ p
heart NN p
failure NN p
( ( p
HF NNP p
) ) p
and CC p
in IN p
patients NNS p
with IN p
asymptomatic JJ p
left VBD p
ventricular JJ p
dysfunction NN p
. . p

Evidence NN N
suggests VBZ N
that IN N
the DT N
elevation NN N
in IN N
plasma JJ N
norepinephrine NN N
levels NNS N
can MD N
be VB N
at IN N
least JJS N
partly RB N
attributed VBN N
to TO N
an DT N
increase NN N
in IN N
sympathetic JJ N
nervous JJ N
system NN N
activity NN N
. . N

It PRP N
has VBZ N
become VBN N
evident JJ N
that IN N
elevated VBD N
plasma JJ N
norepinephrine NN N
levels NNS N
are VBP N
directly RB N
related VBN N
to TO N
prognosis NN N
; : N
patients NNS N
with IN N
levels NNS N
> VBP N
900 CD N
pg/ml NNS N
have VBP N
a DT N
poor JJ N
prognosis NN N
and CC N
shortened VBD N
life NN N
expectancy NN N
. . N

However RB N
, , N
plasma JJ o
norepinephrine NN o
levels NNS o
bear VBP N
little JJ N
relationship NN N
to TO N
physiologic VB N
and CC N
clinical JJ N
variables NNS N
observed VBN N
in IN N
HF NNP N
, , N
including VBG N
ejection NN o
fraction NN o
and CC o
exercise NN o
capacity NN o
. . o

Data NNS p
from IN p
the DT p
V-HeFT NNP p
II NNP p
show NN p
that WDT p
at IN p
2-year JJ p
follow-up NN p
, , N
a DT N
progressive JJ N
rise NN o
of IN o
plasma NN o
norepinephrine NN o
was VBD N
observed VBN N
in IN N
both DT N
treatment NN N
arms NNS N
, , N
suggesting VBG N
that IN N
disease NN N
progresses VBZ N
despite IN N
treatment NN N
with IN N
either DT N
an DT N
angiotensin-converting JJ i
enzyme NN i
inhibitor NN i
, , i
enalapril NN i
, , i
or CC i
vasodilator NN i
therapy NN i
with IN i
hydralazine/isosorbide JJ i
dinitrate NN i
. . i

It PRP N
is VBZ N
possible JJ N
that IN N
interventions NNS N
aimed VBN N
at IN N
the DT N
progressive JJ N
neurohormonal JJ N
activation NN N
that WDT N
occurs VBZ N
in IN N
HF NNP N
may MD N
improve VB N
the DT N
course NN N
of IN N
illness NN N
. . N

Further NNP N
study NN N
is VBZ N
needed VBN N
to TO N
test VB N
this DT N
hypothesis NN N
. . N

-DOCSTART- -2709180- O O

Effects NNS N
of IN N
heat NN i
and CC i
cold NN i
on IN N
the DT N
perineum NN N
after IN N
episiotomy/laceration NN p
. . p

The DT N
Redness NNP o
Edema NNP o
Ecchymosis NNP o
Discharge NNP o
Approximation NNP o
( ( o
REEDA NNP o
) ) o
tool NN o
, , N
devised VBN N
to TO N
evaluate VB N
postpartum NN N
healing NN N
of IN N
the DT N
perineum NN N
following VBG N
an DT N
episiotomy/laceration NN i
, , N
was VBD N
used VBN N
to TO N
evaluate VB N
the DT N
effects NNS N
of IN N
heat NN i
and CC i
cold NN i
on IN N
the DT N
perineum NN N
during IN N
the DT N
first JJ N
24 CD N
hours NNS N
after IN N
delivery NN N
. . N

Ninety NN p
patients NNS p
were VBD p
randomly RB p
assigned VBN p
to TO p
one CD p
of IN p
three CD p
treatment NN p
groups NNS p
. . p

Treatment NNP N
consisted VBD N
of IN N
30 CD p
subjects NNS p
applying VBG p
a DT p
warm JJ i
perineal NN i
pack NN i
, , p
30 CD p
applying VBG p
a DT p
cold JJ i
perineal NN i
pack NN i
, , p
and CC p
30 CD p
taking VBG p
a DT p
warm JJ i
sitz NN i
bath NN i
. . i

Analysis NN N
of IN N
variance NN N
indicated VBD N
no DT N
difference NN N
in IN N
the DT N
REEDA NNP o
score NN o
before IN N
or CC N
two CD N
hours NNS N
after IN N
treatment NN N
. . N

A DT N
Pearson NNP N
r NN N
correlation NN N
indicated VBD N
the DT N
REEDA NNP N
score NN N
was VBD N
associated VBN N
with IN N
a DT N
laceration NN o
and CC o
not RB o
with IN o
infant JJ o
weight NN o
. . o

Although IN N
these DT N
findings NNS N
do VBP N
not RB N
support VB N
assumptions NNS N
from IN N
the DT N
literature NN N
, , N
this DT N
study NN N
provides VBZ N
baseline JJ N
data NNS N
and CC N
trends NNS N
for IN N
future JJ N
study NN N
. . N

-DOCSTART- -1683365- O O

The DT N
efficacy NN N
of IN N
early RB N
continuous JJ N
positive JJ N
airway NN N
pressure NN N
therapy NN N
in IN N
patients NNS p
with IN p
acute JJ p
cardiogenic JJ p
pulmonary JJ p
edema NN p
. . p

Although IN N
continuous JJ N
positive JJ N
airway NN N
pressure NN N
( ( N
CPAP NNP N
) ) N
therapy NN N
using VBG N
a DT N
face NN N
mask NN N
is VBZ N
known VBN N
to TO N
improve VB N
oxygenation NN N
, , N
the DT N
intrapulmonary JJ N
shunt NN N
reduction NN N
remains VBZ N
unsettled JJ N
. . N

Our PRP$ N
study NN N
was VBD N
designed VBN N
to TO N
explore VB N
this DT N
issue NN N
. . N

From IN p
1985 CD p
to TO p
1987 CD p
80 CD p
patients NNS p
with IN p
acute JJ p
cardiogenic JJ p
pulmonary JJ p
edema NN p
were VBD N
randomly RB N
chosen VBN N
to TO N
receive VB N
either DT N
serial JJ i
CPAP NNP i
therapy NN i
or CC i
high-flow JJ i
face NN i
mask NN i
oxygen NN i
therapy NN i
without IN i
CPAP NNP i
( ( i
control NN i
) ) i
for IN N
the DT N
purpose NN N
of IN N
evaluating VBG N
the DT N
efficacy NN N
of IN N
CPAP NNP N
therapy NN N
. . N

After IN N
screening VBG N
for IN N
exclusion NN N
, , N
only RB p
55 CD p
patients NNS p
were VBD p
included VBN p
in IN N
the DT N
first JJ N
3-hour JJ N
investigation NN N
period NN N
. . N

PaO2 NNP o
in IN N
the DT N
CPAP NNP N
group NN N
showed VBD N
a DT N
significant JJ N
increase NN N
by IN N
the DT N
end NN N
of IN N
the DT N
initial JJ N
study NN N
; : N
whereas CC N
intrapulmonary JJ o
shunt NN o
and CC N
alveolar-arterial JJ o
oxygen NN o
tension NN o
gradient NN o
AaDO2 NNP o
revealed VBD N
simultaneously RB N
a DT N
significant JJ N
reduction NN N
. . N

Conversely RB N
, , N
neither DT N
PaO2 NNP o
nor CC o
intrapulmonary JJ o
shunt NN o
( ( o
or CC o
AaDO2 NNP o
) ) o
in IN N
the DT N
control NN N
group NN N
demonstrated VBD N
any DT N
significant JJ N
beneficial JJ N
changes NNS N
. . N

As IN N
for IN N
cardiovascular JJ N
function NN N
, , N
only RB N
the DT N
CPAP NNP N
therapy NN N
achieved VBD N
a DT N
significant JJ N
reduction NN N
in IN N
rate NN o
pressure NN o
product NN o
in IN N
contrast NN N
to TO N
the DT N
control NN N
( ( N
face NN N
mask NN N
) ) N
therapy NN N
alone RB N
. . N

In IN N
terms NNS N
of IN N
therapeutic JJ o
failure NN o
, , N
10 CD N
patients NNS N
in IN N
the DT N
control NN N
group NN N
failed VBD N
. . N

However RB N
, , N
in IN N
the DT N
CPAP NNP N
group NN N
only RB N
5 CD N
patients NNS N
had VBD N
failed VBN N
at IN N
the DT N
end NN N
of IN N
the DT N
first JJ N
3-hour JJ N
study NN N
period NN N
. . N

Overall JJ N
, , N
the DT N
cumulative JJ o
therapeutic JJ o
failure NN o
rate NN o
was VBD N
28 CD N
% NN N
in IN N
the DT N
CPAP NNP N
group NN N
and CC N
60 CD N
% NN N
in IN N
the DT N
control NN N
group NN N
during IN N
a DT N
6-hour JJ N
observation NN N
study NN N
. . N

However RB N
, , N
there EX N
was VBD N
no DT N
significant JJ N
difference NN N
between IN N
the DT N
two CD N
groups NNS N
in IN N
24-hour JJ N
hospital NN N
mortality NN N
. . N

( ( N
ABSTRACT NNP N
TRUNCATED NNP N
AT NNP N
250 CD N
WORDS NNP N
) ) N
-DOCSTART- -25180722- O O

Impact NN o
of IN N
early JJ i
mobilization NN i
on IN N
glycemic JJ o
control NN o
and CC N
ICU-acquired NNP o
weakness NN o
in IN N
critically RB p
ill JJ p
patients NNS p
who WP p
are VBP p
mechanically RB p
ventilated VBN p
. . p

BACKGROUND NNP N
ICU-acquired JJ o
weakness NN o
( ( o
ICU-AW NNP o
) ) o
has VBZ N
immediate JJ N
and CC N
long-term JJ N
consequences NNS N
for IN N
critically RB p
ill JJ p
patients NNS p
. . p

Strategies NNS N
for IN N
the DT N
prevention NN N
of IN N
weakness NN N
include VBP N
modification NN N
of IN N
known VBN N
risk NN N
factors NNS N
, , N
such JJ N
as IN N
hyperglycemia NN N
and CC N
immobility NN N
. . N

Intensive JJ i
insulin NN i
therapy NN i
( ( N
IIT NNP N
) ) N
has VBZ N
been VBN N
proposed VBN N
to TO N
prevent VB N
critical JJ N
illness NN N
polyneuropathy NN N
. . N

However RB N
, , N
the DT N
effect NN N
of IN N
insulin NN N
and CC N
early JJ N
mobilization NN N
on IN N
clinically RB N
apparent JJ N
weakness NN N
is VBZ N
not RB N
well RB N
known VBN N
. . N

METHODS NNP N
This DT N
is VBZ N
a DT N
secondary JJ N
analysis NN N
of IN N
all DT p
patients NNS p
with IN p
mechanical JJ p
ventilation NN p
( ( p
N NNP p
= NNP p
104 CD p
) ) p
previously RB p
enrolled VBN p
in IN p
a DT p
randomized NN p
controlled VBN p
trial NN p
of IN p
early JJ p
occupational JJ p
and CC p
physical JJ p
therapy NN p
vs JJ p
conventional JJ p
therapy NN p
, , p
which WDT p
evaluated VBD p
the DT p
end NN p
point NN p
of IN p
functional JJ o
independence NN o
. . o

Every NNP p
patient NN p
had VBD p
IIT NNP p
and CC p
blinded VBD p
muscle NN p
strength NN p
testing VBG p
on IN p
hospital NN p
discharge NN p
to TO N
determine VB N
the DT N
incidence NN N
of IN N
clinically RB o
apparent JJ o
weakness NN o
. . o

The DT N
effects NNS o
of IN o
insulin NN o
dose NN o
and CC N
early JJ o
mobilization NN o
on IN N
the DT N
incidence NN o
of IN o
ICU-AW NNP o
were VBD N
assessed VBN N
. . N

RESULTS VB N
On IN N
logistic JJ N
regression NN N
analyses NNS N
, , N
early JJ N
mobilization NN N
and CC N
increasing VBG N
insulin NN N
dose NN N
prevented VBD N
the DT N
incidence NN o
of IN o
ICU-AW NNP o
( ( N
OR NNP N
, , N
0.18 CD N
, , N
P NNP N
= NNP N
.001 NNP N
; : N
OR NNP N
, , N
0.001 CD N
, , N
P NNP N
= NNP N
.011 NNP N
; : N
respectively RB N
) ) N
independent JJ N
of IN N
known VBN N
risk NN N
factors NNS N
for IN N
weakness NN N
. . N

Early JJ N
mobilization NN N
also RB N
significantly RB N
reduced VBN N
insulin NN o
requirements NNS o
to TO N
achieve VB o
similar JJ o
glycemic JJ o
goals NNS o
as IN N
compared VBN N
with IN N
control NN N
patients NNS N
( ( N
0.07 CD N
units/kg/d RB N
vs JJ N
0.2 CD N
units/kg/d NN N
, , N
P NNP N
< NNP N
.001 NNP N
) ) N
. . N

CONCLUSIONS VB N
The DT N
duel NN N
effect NN N
of IN N
early JJ N
mobilization NN N
in IN N
reducing VBG N
clinically RB o
relevant JJ o
ICU-AW NNP o
and CC N
promoting VBG o
euglycemia JJ o
suggests VBZ N
its PRP$ N
potential JJ N
usefulness NN N
as IN N
an DT N
alternative NN N
to TO N
IIT NNP N
. . N

-DOCSTART- -7859140- O O

Safety NN o
and CC o
efficacy NN o
of IN o
thymopentin NN o
in IN N
zidovudine NN p
( ( p
AZT NNP p
) ) p
-treated VBD p
asymptomatic JJ p
HIV-infected JJ p
subjects NNS p
with IN p
200-500 JJ p
CD4 NNP p
cells/mm3 NN p
: : p
a DT N
double-blind JJ N
placebo-controlled JJ N
trial NN N
. . N

Thymopentin NNP i
, , N
50 CD N
mg NN N
subcutaneously RB N
( ( N
s.c. NN N
) ) N
3 CD N
times NNS N
per IN N
week NN N
, , N
was VBD N
evaluated VBN N
in IN N
a DT N
double-blind NN N
, , N
randomized VBN N
, , N
placebo-controlled JJ i
trial NN N
of IN N
zidovudine NN i
( ( i
AZT NNP i
) ) i
-treated VBD i
asymptomatic JJ i
human JJ i
immunodeficiency NN i
virus NN i
( ( i
HIV NNP i
) ) i
-infected VBD i
subjects NNS i
with IN i
200-500 JJ i
CD4 NNP i
cells/mm3 NN i
at IN i
entry NN i
. . i

The DT N
352 CD p
subjects NNS p
were VBD p
prestratified VBN i
by IN i
prior JJ i
AZT NNP i
use NN i
into IN i
stratum NN i
I PRP i
( ( i
235 CD i
subjects NNS i
, , i
> VBZ i
6 CD i
months NNS i
AZT NNP i
at IN i
entry NN i
) ) i
and CC i
stratum JJ i
II NNP i
( ( i
117 CD i
subjects NNS i
, , i
< '' i
or CC i
= VB i
6 CD i
months NNS i
AZT NNP i
at IN i
entry NN i
) ) i
. . i

Clinical JJ i
end NN i
points NNS i
, , i
CD4 NNP o
cell NN o
counts NNS o
, , o
serum NN o
p24 NN o
, , o
serum JJ o
immune NN o
complex NN o
dissociated VBD o
( ( o
ICD NNP o
) ) o
p24 NN o
, , o
and CC o
safety NN o
variables NNS o
were VBD i
evaluated VBN i
through IN i
48 CD i
weeks NNS i
, , i
using VBG i
an DT i
intent-to-treat JJ i
analysis NN i
. . i

The DT N
two CD N
strata NNS N
were VBD N
analyzed VBN N
individually RB N
because IN N
they PRP N
yielded VBD N
different JJ N
clinical JJ N
outcomes NNS N
, , N
with IN N
a DT N
statistically RB N
significant JJ N
treatment-by-stratum JJ N
interaction NN N
. . N

In IN N
stratum NN N
I PRP N
( ( N
mean VB N
, , N
16 CD N
months NNS N
AZT NNP N
at IN N
entry NN N
) ) N
two CD N
AIDS NNP o
or CC o
death NN o
events NNS o
occurred VBD N
in IN N
thymopentin NN N
and CC N
10 CD N
in IN N
placebo NN N
recipients NNS N
( ( N
p JJ N
= VBZ N
0.024 CD N
; : N
relative JJ N
risk NN N
( ( N
RR NNP N
) ) N
estimate NN N
, , N
4.9 CD N
[ JJ N
95 CD N
% NN N
confidence NN N
limit NN N
( ( N
CI NNP N
) ) N
, , N
1.1 CD N
to TO N
22.2 CD N
] NN N
) ) N
. . N

There EX N
were VBD N
three CD N
AIDS-related JJ o
complex NN o
( ( o
ARC NNP o
) ) o
, , o
AIDS NNP o
, , o
or CC o
death NN o
events NNS o
in IN N
thymopentin NN N
and CC N
18 CD N
in IN N
placebo NN i
recipients NNS N
[ VBP N
p JJ N
= NNP N
0.001 CD N
; : N
RR NNP N
estimate NN N
, , N
5.9 CD N
( ( N
95 CD N
% NN N
CI NNP N
, , N
1.7 CD N
to TO N
20.0 CD N
) ) N
] NN N
. . N

In IN N
stratum NN N
II NNP N
( ( N
mean NN N
, , N
3 CD N
months NNS N
AZT NNP N
at IN N
entry NN N
) ) N
, , N
four CD N
AIDS NNP o
or CC o
death NN o
events NNS o
occurred VBD N
in IN N
thymopentin NN N
and CC N
none NN N
in IN N
placebo NN N
recipients NNS N
( ( N
p JJ N
= NNP N
0.11 CD N
) ) N
, , N
and CC N
four CD N
ARC NNP o
, , o
AIDS NNP o
, , o
or CC o
death NN o
events NNS o
occurred VBD N
in IN N
thymopentin NN N
and CC N
two CD N
in IN N
placebo NN N
recipients NNS N
( ( N
p JJ N
= NNP N
0.79 CD N
) ) N
. . N

The DT N
treatment NN N
groups NNS N
did VBD N
not RB N
differ VB N
significantly RB N
with IN N
respect NN N
to TO N
changes NNS N
in IN N
CD4 NNP o
counts NNS o
or CC o
p24 VB o
antigen NN o
levels NNS o
or CC N
with IN N
respect NN N
to TO N
clinical JJ o
adverse JJ o
experiences NNS o
or CC N
laboratory NN o
abnormalities NNS o
. . o

Thus RB N
, , N
AZT-experienced JJ N
placebo-treated JJ N
subjects NNS N
had VBD N
relatively RB N
high JJ N
progression NN N
rates NNS N
to TO N
AIDS NNP o
or CC o
death NN o
and CC o
to TO o
ARC NNP o
, , o
AIDS NNP o
, , o
or CC o
death NN o
, , N
and CC N
these DT N
rates NNS N
were VBD N
reduced VBN N
by IN N
thymopentin NN N
treatment NN N
. . N

In IN N
contrast NN N
, , N
placebo-treated JJ N
subjects NNS N
with IN N
little JJ N
prior JJ N
AZT NNP N
experience NN N
had VBD N
low JJ N
progression NN N
rates NNS N
; : N
these DT N
were VBD N
not RB N
significantly RB N
changed VBN N
by IN N
thymopentin NN N
treatment NN N
. . N

There EX N
was VBD N
no DT N
increase NN N
in IN N
the DT N
incidence NN N
of IN N
adverse JJ o
reactions NNS o
with IN N
thymopentin NN N
. . N

-DOCSTART- -1799151- O O

Intra-operative JJ N
antibiotic JJ i
prophylaxis NN N
in IN N
neurosurgery NN p
. . p

A DT N
prospective JJ N
, , N
randomized VBN N
, , N
controlled VBN N
study NN N
on IN N
cefotiam NN i
. . i

In IN N
this DT N
prospective JJ N
, , N
randomized VBN N
and CC N
controlled VBN N
study VB N
the DT N
effect NN N
of IN N
cefotiam NN i
for IN N
the DT N
prevention NN N
of IN N
wound JJ N
infections NNS N
following VBG N
trepanations NNS p
was VBD N
investigated VBN N
. . N

The DT N
main JJ N
interest NN N
was VBD N
centered VBN N
on IN N
the DT N
rate NN N
of IN N
post-operative JJ N
bone NN N
flap NN N
infections NNS N
requiring VBG N
operative JJ N
revision NN N
. . N

Administration NNP N
of IN N
cefotiam NN i
was VBD N
randomized VBN N
for IN N
patients NNS p
undergoing VBG p
major JJ p
craniotomies NNS p
. . p

The DT N
antibiotic NN i
was VBD N
administered VBN N
intravenously RB N
in IN N
a DT N
single JJ N
dose NN N
of IN N
2 CD N
g NN N
with IN N
induction NN N
of IN N
anaesthesia NN i
. . i

Only JJ p
clean JJ p
or CC p
clean JJ p
contaminated VBN p
cases NNS p
were VBD p
included VBN p
. . p

Excluded VBN p
were VBD p
contaminated VBN p
cases NNS p
, , p
operations NNS p
with IN p
a DT p
transnasal-transsphenoidal JJ p
approach NN p
, , p
shunt-operations NNS p
and CC p
patients NNS p
with IN p
any DT p
other JJ p
preoperative JJ p
infection NN p
or CC p
antibiotic JJ i
therapy NN i
. . i

Outpatients NNS p
were VBD p
excluded VBN p
due JJ p
to TO p
difficulties NNS p
in IN p
obtaining VBG p
sufficient JJ p
clinical JJ p
information NN p
. . p

From NNP p
originally RB p
918 CD p
consecutive JJ p
patients NNS p
operated VBN p
on IN p
711 CD p
fulfilled VBD p
the DT p
entry NN p
criteria NNS p
. . p

With IN p
regard NN p
to TO p
age NN p
, , p
sex NN p
, , p
diagnosis NN p
and CC p
the DT p
site NN p
of IN p
te JJ p
trepanation NN p
, , p
control NN i
patients NNS i
( ( p
n JJ p
= NNP p
355 CD p
) ) p
and CC p
cefotiam $ p
treated VBN p
patients NNS p
( ( p
n JJ p
= NNP p
356 CD p
) ) p
were VBD p
shown VBN p
to TO p
be VB p
comparable JJ p
. . p

In IN N
the DT N
various JJ N
subgroups NNS N
formed VBN N
for IN N
different JJ p
primary JJ p
diagnoses NNS p
, , p
concomitant JJ i
steroidal NN i
therapy NN i
and CC N
concomitant NN p
severe JJ p
internal JJ p
medical JJ p
diseases NNS p
cefotiam VBP N
treated VBN N
patients NNS N
and CC N
controls NNS N
were VBD N
comparable JJ N
as RB N
well RB N
. . N

A DT N
highly RB N
significant JJ N
difference NN N
for IN N
bone NN o
flap NN o
infection NN o
could MD N
be VB N
shown VBN N
with IN N
0.3 CD N
% NN N
in IN N
the DT N
cefotiam NN N
group NN N
versus VBD N
5.1 CD N
% NN N
in IN N
the DT N
control NN N
group NN N
( ( N
p VBZ N
less JJR N
than IN N
0.001 CD N
) ) N
. . N

The DT N
overall JJ o
rate NN o
of IN o
post-operative JJ o
deep JJ o
wound NN o
infections NNS o
including VBG o
meningitis NN o
and CC o
abscesses NNS o
was VBD N
also RB N
significantly RB N
( ( N
p NN N
less JJR N
than IN N
0.005 CD N
) ) N
different JJ o
with IN N
3.1 CD N
% NN N
in IN N
the DT N
cefotiam NN i
versus IN N
9.0 CD N
% NN N
in IN N
the DT N
control NN N
group NN N
. . N

Thus VB N
it PRP N
was VBD N
concluded VBN N
that IN N
a DT N
single JJ N
dose NN N
of IN N
cefotiam NN N
significantly RB N
reduces VBZ N
post-operative JJ o
deep JJ o
wound NN o
infection NN o
. . o

-DOCSTART- -20851499- O O

Early JJ N
treatment NN N
of IN N
cold JJ N
sores NNS N
with IN N
topical JJ N
ME-609 NNP i
decreases VBZ N
the DT N
frequency NN o
of IN o
ulcerative JJ o
lesions NNS o
: : o
a DT N
randomized JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
, , N
patient-initiated JJ N
clinical JJ N
trial NN N
. . N

BACKGROUND NNP N
Prior NNP N
pilot NN N
studies NNS N
support VBP N
the DT N
use NN N
of IN N
antiviral JJ N
medications NNS N
with IN N
topical JJ N
corticosteroids NNS N
for IN N
herpes NNS p
simplex JJ p
labialis NN p
( ( p
HSL NNP p
) ) p
. . p

ME-609 NNP i
( ( i
Xerese JJ i
, , i
Xerclear NNP i
) ) i
is VBZ N
a DT N
combination NN N
of IN N
5 CD N
% NN N
acyclovir NN i
and CC N
1 CD N
% NN N
hydrocortisone NN i
developed VBD N
for IN N
the DT N
topical JJ N
treatment NN N
of IN N
HSL NNP N
. . N

OBJECTIVES NNP N
The DT N
primary NN N
study VBD N
end JJ N
point NN N
was VBD N
the DT N
prevention NN N
of IN N
ulcerative JJ o
HSL NNP o
lesions NNS o
. . o

METHODS NNP N
In IN N
all DT N
, , N
2437 CD p
patients NNS p
with IN p
a DT p
history NN p
of IN p
HSL NNP p
were VBD N
randomized VBN i
to TO i
self-initiate JJ i
treatment NN i
with IN i
ME-609 NNP i
, , i
5 CD i
% NN i
acyclovir NN i
in IN i
ME-609 NNP i
vehicle NN i
, , i
or CC i
ME-609 JJ i
vehicle NN i
( ( i
placebo NN i
) ) i
at IN i
the DT i
earliest JJS i
sign NN i
of IN i
a DT i
cold JJ i
sore NN i
recurrence NN i
. . i

Cream NNP i
was VBD i
applied VBN i
5 CD i
times/d NN i
for IN i
5 CD i
days NNS i
. . i

A DT N
total NN N
of IN N
1443 CD p
patients NNS p
experienced VBD p
a DT o
recurrence NN o
and CC N
initiated JJ N
treatment NN N
with IN N
ME-609 NNP i
( ( N
n JJ N
= NNP N
601 CD N
) ) N
, , N
acyclovir FW i
( ( N
n JJ N
= NNP N
610 CD N
) ) N
, , N
or CC N
placebo NN i
( ( N
n JJ N
= NNP N
232 CD N
) ) N
. . N

RESULTS NNP N
Of IN N
patients NNS N
receiving VBG N
ME-609 NNP N
, , N
42 CD N
% NN N
did VBD N
not RB N
develop VB N
an DT N
ulcerative JJ o
lesion NN o
compared VBN N
with IN N
35 CD p
% NN p
of IN p
patients NNS p
receiving VBG N
acyclovir NN i
in IN i
ME-609 NNP i
vehicle NN i
( ( N
P NNP N
= NNP N
.014 NNP N
) ) N
and CC N
26 CD N
% NN N
of IN N
patients NNS N
receiving VBG N
placebo NN N
( ( N
P NNP N
< NNP N
.0001 NNP N
) ) N
. . N

In IN N
patients NNS N
with IN N
ulcerative JJ N
lesions NNS N
, , N
healing VBG o
times NNS o
were VBD N
reduced VBN N
in IN N
the DT N
ME-609 NNP N
and CC N
acyclovir NN N
groups NNS N
compared VBN N
with IN N
placebo NN N
( ( N
P NNP N
< NNP N
.01 NNP N
for IN N
both DT N
) ) N
. . N

The DT N
cumulative JJ o
lesion NN o
area NN o
for IN N
all DT N
lesions NNS N
was VBD N
reduced VBN N
50 CD N
% NN N
in IN N
patients NNS N
receiving VBG N
ME-609 NNP N
compared VBN N
with IN N
the DT N
placebo NN N
group NN N
( ( N
P NNP N
< NNP N
.0001 NNP N
) ) N
. . N

There EX N
were VBD N
no DT N
differences NNS N
among IN N
groups NNS N
in IN N
the DT N
number NN N
of IN N
patients NNS N
with IN N
positive JJ N
herpes NNS N
simplex JJ N
virus NN N
cultures NNS N
. . N

The DT N
side-effect JJ o
profile NN o
was VBD N
similar JJ N
among IN N
treatments NNS N
. . N

LIMITATIONS VB N
The DT N
study NN N
did VBD N
not RB N
contain VB N
a DT N
group NN N
treated VBD N
with IN N
a DT N
topical JJ N
corticosteroid NN N
alone RB N
. . N

CONCLUSIONS NNP N
ME-609 NNP N
prevented VBD N
progression NN N
of IN o
cold JJ o
sores NNS o
to TO o
ulcerative JJ o
lesions NNS o
and CC N
significantly RB N
reduced VBD N
the DT N
cumulative JJ o
lesion NN o
area NN o
compared VBN N
with IN N
acyclovir NN N
and CC N
placebo NN N
. . N

ME-609 NNP N
treatment NN N
offers NNS N
additional JJ N
therapeutic JJ N
benefit NN N
compared VBN N
with IN N
therapy NN N
with IN N
topical JJ N
acyclovir NN N
alone RB N
. . N

-DOCSTART- -11348533- O O

Clinical JJ N
description NN N
of IN N
encephalopathic JJ N
syndromes NNS N
and CC N
risk NN N
factors NNS N
for IN N
their PRP$ N
occurrence NN N
and CC N
outcome NN N
during IN N
melarsoprol NN i
treatment NN N
of IN N
human JJ p
African JJ p
trypanosomiasis NN p
. . p

Encephalopathies NNS N
are VBP N
the DT N
most RBS N
feared JJ N
complications NNS N
of IN N
sleeping VBG N
sickness JJ N
treatment NN N
with IN N
melarsoprol NN i
. . i

To TO N
investigate VB N
the DT N
existence NN N
of IN N
risk NN N
factors NNS N
, , N
the DT N
incidence NN N
of IN N
encephalopathic JJ N
syndromes NNS N
and CC N
the DT N
relationship NN N
between IN N
the DT N
development NN N
of IN N
different JJ N
types NNS N
of IN N
encephalopathies NNS N
and CC N
the DT N
clinical JJ N
outcome NN N
was VBD N
studied VBN N
in IN N
a DT N
clinical JJ N
trial NN N
with IN N
588 CD p
patients NNS p
under IN p
treatment NN p
with IN p
melarsoprol NN i
. . i

The DT N
38 CD p
encephalopathy JJ p
cases NNS p
were VBD N
classified VBN N
into IN N
three CD N
types NNS N
according VBG N
to TO N
the DT N
leading VBG N
clinical JJ N
picture NN N
: : N
coma NN N
type NN N
, , N
convulsion NN N
type NN N
and CC N
psychotic JJ N
reactions NNS N
. . N

Nine JJ p
patients NNS p
were VBD p
attributed VBN p
to TO p
the DT p
convulsion NN p
type NN p
, , N
defined VBD N
as IN N
a DT N
transient JJ N
event NN N
of IN N
short JJ N
duration NN N
with IN N
convulsions NNS N
followed VBN N
by IN N
a DT N
post-ictal JJ N
phase NN N
, , N
without IN N
signs NNS N
of IN N
a DT N
generalized JJ N
disease NN N
. . N

None NN N
of IN N
these DT N
patients NNS N
died VBD N
from IN N
the DT N
reaction NN N
. . N

Febrile JJ o
reactions NNS o
in IN N
the DT N
48 CD N
h NN N
preceding VBG N
the DT N
reaction NN N
were VBD N
generally RB N
not RB N
observed VBN N
in IN N
this DT N
group NN N
. . N

Twenty-five JJ N
patients NNS N
were VBD N
attributed VBN N
to TO N
the DT N
coma NN N
type NN N
, , N
which WDT N
is VBZ N
a DT N
progredient JJ N
coma NN N
lasting VBG N
several JJ N
days NNS N
. . N

Those DT N
patients NNS N
often RB N
had VBD N
signs NNS N
of IN N
a DT N
generalized JJ N
disease NN N
such JJ N
as IN N
fever NN o
( ( N
84 CD N
% NN N
) ) N
, , N
headache NN o
( ( N
72 CD N
% NN N
) ) N
or CC N
bullous JJ o
skin NN o
( ( N
8 CD N
% NN N
) ) N
reactions NNS N
. . N

The DT N
risk NN o
of IN o
mortality NN o
was VBD N
high JJ N
in IN N
this DT N
group NN N
( ( N
52 CD N
% NN N
) ) N
. . N

About IN N
14/16 CD N
patients NNS N
with IN N
encephalopathic JJ N
syndrome NN N
of IN N
the DT N
coma NN N
type NN N
were VBD N
infected VBN N
with IN N
malaria NNS N
. . N

Patients NNS N
with IN N
psychotic JJ N
reactions NNS N
or CC N
abnormal JJ N
psychiatric JJ N
behaviour NN N
( ( N
3/38 CD N
) ) N
and CC N
one CD N
patient NN N
who WP N
died VBD o
after IN N
alcohol NN N
intake NN N
were VBD N
excluded VBN N
from IN N
the DT N
analysis NN N
. . N

The DT N
overall JJ o
rate NN o
of IN o
encephalopathic JJ o
syndromes NNS o
in IN N
the DT N
cases NNS N
analysed VBD N
( ( N
n=34 NN N
) ) N
was VBD N
5.8 CD N
% NN N
, , N
of IN N
which WDT N
38.2 CD N
% NN N
died VBD N
. . N

We PRP N
did VBD N
not RB N
find VB N
any DT N
parameters NNS N
of IN N
predictive JJ N
value NN N
for IN N
the DT N
risk NN o
of IN o
developing VBG o
an DT o
encephalopathic JJ o
syndrome NN o
based VBN N
on IN N
the DT N
symptoms NNS N
and CC N
signs NNS N
before IN N
treatment NN N
initiation NN N
. . N

The DT N
appearance NN N
during IN N
treatment NN N
of IN N
febrile JJ o
reactions NNS o
( ( N
RR NNP N
11.5 CD N
) ) N
, , N
headache NN o
( ( N
RR NNP N
2.5 CD N
) ) N
, , N
bullous JJ o
eruptions NNS o
( ( N
RR NNP N
4.5 CD N
) ) N
and CC N
systolic JJ o
hypotension NN o
( ( N
RR NNP N
2.6 CD N
) ) N
were VBD N
associated VBN N
with IN N
an DT N
increased VBN N
risk NN N
for IN N
the DT N
occurrence NN N
of IN N
encephalopathic JJ N
syndromes NNS N
especially RB N
of IN N
the DT N
coma NN N
type NN N
. . N

-DOCSTART- -6261782- O O

Metabolic NNP N
and CC N
circulatory JJ N
effects NNS N
of IN N
oral JJ N
salbutamol NN i
in IN N
the DT p
third JJ p
trimester NN p
of IN p
pregnancy NN p
in IN p
diabetic JJ p
and CC p
non-diabetic JJ p
women NNS p
. . p

Metabolic NNP o
and CC o
cardiovascular JJ o
effects NNS o
of IN N
4 CD i
mg JJ i
oral JJ i
salbutamol NN i
were VBD N
studied VBN N
in IN N
ten JJ p
non-diabetic JJ p
, , p
ten JJ p
chemical JJ p
diabetic NN p
and CC p
five CD p
juvenile NN p
diabetic JJ p
women NNS p
in IN p
late JJ p
pregnancy NN p
. . p

None NN p
of IN p
the DT p
women NNS p
had VBD p
been VBN p
treated VBN p
with IN p
beta-sympathomimetic JJ i
drugs NNS i
earlier RBR p
in IN p
their PRP$ p
pregnancy NN p
. . p

Heart NNP o
rate NN o
and CC o
blood NN o
pressure NN o
were VBD N
recorded VBN N
and CC N
blood NN o
samples NNS o
for IN o
measurement NN o
of IN o
plasma JJ o
cyclic JJ o
AMP NNP o
, , o
insulin NN o
, , o
C-peptide NNP o
, , o
glucose NN o
, , o
lactate NN o
, , o
glycerol NN o
, , o
non-esterified JJ o
fatty JJ o
acids NNS o
( ( o
NEFA NNP o
) ) o
and CC o
3-hydroxybutyrate JJ o
( ( o
3-HB JJ o
) ) o
were VBD N
collected VBN N
every DT N
30 CD N
minutes NNS N
for IN N
120 CD N
minutes NNS N
after IN N
salbutamol NN i
. . i

All DT N
women NNS N
underwent VBD i
the DT i
same JJ i
procedure NN i
at IN i
random NN i
without IN i
salbutamol NN i
. . i

There EX N
were VBD N
significant JJ N
cardiovascular JJ o
effects NNS o
of IN N
salbutamol NN i
in IN N
all PDT N
the DT N
groups NNS N
but CC N
no DT N
differences NNS N
in IN N
these DT N
effects NNS N
between IN N
the DT N
groups NNS N
. . N

Salbutamol NNP i
caused VBD N
significant JJ N
increases NNS o
of IN o
glycogenolysis NN o
and CC o
lipolysis NN o
in IN N
all PDT N
the DT N
groups NNS N
, , N
significantly RB N
larger JJR N
in IN N
the DT N
juvenile NN p
diabetic NN p
than IN N
the DT N
non-diabetic JJ p
and CC N
chemical JJ p
diabetic JJ p
women NNS p
. . p

This DT N
observation NN N
could MD N
be VB N
explained VBN N
by IN N
the DT N
inability NN N
of IN N
the DT N
juvenile NN N
diabetics NNS N
to TO N
secrete VB N
insulin NN N
, , N
shown VBN N
by IN N
their PRP$ N
non-measureable JJ N
plasma JJ N
C-peptide JJ N
levels NNS N
. . N

The DT N
metabolic JJ o
responses NNS o
following VBG N
salbutamol NN i
in IN N
the DT N
chemical NN N
diabetics NNS N
were VBD N
intermediate JJ N
between IN N
the DT N
non-diabetic JJ N
and CC N
juvenile JJ N
diabetic JJ N
groups NNS N
. . N

The DT N
results NNS N
show VBP N
that IN N
diabetes VBZ N
does VBZ N
not RB N
alter VB N
the DT N
sensitivity NN N
of IN N
beta-receptors NNS N
involved VBN N
in IN N
cardiovascular JJ N
regulation NN N
, , N
while IN N
the DT N
metabolic JJ N
responses NNS N
to TO N
oral JJ N
salbutamol NN i
are VBP N
enhanced VBN N
, , N
especially RB N
in IN N
juvenile JJ N
diabetics NNS N
. . N

We PRP N
suggest VBP N
that IN N
during IN N
treatment NN N
with IN N
beta-sympathomimetic JJ i
drugs NNS i
, , N
blood NN N
glucose NN N
should MD N
be VB N
monitored VBN N
in IN N
all DT N
patients NNS p
showing VBG p
criteria NNS p
of IN p
potential JJ p
diabetes NNS p
. . p

-DOCSTART- -22550938- O O

B-type JJ i
natriuretic JJ i
peptide NN i
in IN N
the DT N
evaluation NN N
and CC N
management NN N
of IN N
dyspnoea NN p
in IN p
primary JJ p
care NN p
. . p

OBJECTIVES IN N
The DT N
rapid JJ N
and CC N
accurate JJ N
diagnosis NN N
of IN N
heart NN p
failure NN p
in IN p
primary JJ p
care NN p
is VBZ N
a DT N
major JJ N
unmet JJ N
clinical JJ N
need NN N
. . N

We PRP N
evaluated VBD N
the DT N
additional JJ N
use NN N
of IN N
B-type NNP o
natriuretic JJ o
peptide NN o
( ( o
BNP NNP o
) ) o
levels NNS o
. . o

DESIGN VB N
A DT N
randomized NN N
controlled VBN N
trial NN N
. . N

SETTING CC N
Twenty-nine JJ p
primary JJ p
care NN p
physicians NNS p
in IN p
Switzerland NNP p
and CC p
Germany NNP p
coordinated VBN p
by IN p
the DT p
University NNP p
Hospital NNP p
Basel NNP p
, , p
Switzerland NNP p
. . p

SUBJECTS NNP N
A NNP N
total NN p
of IN p
323 CD p
consecutive JJ p
patients NNS p
presenting VBG p
with IN p
dyspnoea NN p
. . p

INTERVENTIONS NNP N
Assignment NNP N
in IN N
a DT N
1 CD N
: : N
1 CD N
ratio NN N
to TO N
a DT N
diagnostic JJ i
strategy NN i
including VBG i
point-of-care JJ i
measurement NN i
of IN i
BNP NNP i
( ( N
n JJ N
= NNP N
163 CD N
) ) N
or CC N
standard JJ i
assessment NN i
without IN i
BNP NNP i
( ( N
n JJ N
= NNP N
160 CD N
) ) N
. . N

The DT N
total JJ o
medical JJ o
cost NN o
at IN o
3 CD o
months NNS o
was VBD N
the DT N
primary JJ N
end-point NN N
. . N

Secondary JJ N
end-points NNS N
were VBD N
diagnostic JJ o
certainty NN o
, , o
time NN o
to TO o
appropriate VB o
therapy NN o
, , o
functional JJ o
capacity NN o
, , o
hospitalization NN o
and CC o
mortality NN o
. . o

The DT N
final JJ N
diagnosis NN N
was VBD N
adjudicated VBN N
by IN N
a DT N
physician NN N
blinded VBN N
to TO N
the DT N
BNP NNP N
levels NNS N
. . N

RESULTS NNP N
Heart NNP o
failure NN o
was VBD N
the DT N
final JJ N
diagnosis NN N
in IN N
34 CD N
% NN N
of IN N
patients NNS N
. . N

The DT N
number NN o
of IN o
hospitalizations NNS o
, , o
functional JJ o
status NN o
and CC o
total JJ o
medical JJ o
cost NN o
at IN o
3 CD o
months NNS o
[ JJ N
median JJ N
$ $ N
1655 CD N
, , N
interquartile JJ N
range NN N
( ( N
IQR NNP N
) ) N
, , N
850-3331 JJ N
vs. IN N
$ $ N
1541 CD N
, , N
IQR NNP N
859-2827 CD N
; : N
P NNP N
= VBD N
0.68 CD N
] NNS N
were VBD N
similar JJ N
in IN N
both DT N
groups NNS N
. . N

BNP NNP o
increased VBD N
diagnostic JJ o
certainty NN o
as IN N
defined VBN N
by IN N
the DT N
need NN N
for IN N
further JJ N
diagnostic JJ N
work-up NN N
( ( N
33 CD N
% NN N
vs. FW N
45 CD N
% NN N
; : N
P NNP N
= NNP N
0.02 CD N
) ) N
and CC N
accelerated VBD N
the DT N
initiation NN N
of IN N
the DT N
appropriate JJ N
treatment NN N
( ( N
13 CD N
days NNS N
vs. FW N
25 CD N
days NNS N
; : N
P NNP N
= NNP N
0.01 CD N
) ) N
. . N

The DT N
area NN N
under IN N
the DT N
receiver-operating JJ N
characteristics NNS N
curve NN N
for IN N
BNP NNP N
to TO N
identify VB N
heart NN N
failure NN N
was VBD N
0.87 CD N
( ( N
95 CD N
% NN N
confidence NN N
interval NN N
, , N
0.81-0.93 JJ N
) ) N
. . N

CONCLUSIONS VB N
The DT N
use NN N
of IN N
BNP NNP i
levels NNS i
in IN N
primary JJ N
care NN N
did VBD N
not RB N
reduce VB N
total JJ N
medical JJ N
cost NN N
, , N
but CC N
improved VBD N
some DT N
of IN N
the DT N
secondary JJ N
end-points NNS N
including VBG N
diagnostic JJ N
certainty NN N
and CC N
time NN N
to TO N
initiation NN N
of IN N
appropriate JJ N
treatment NN N
. . N

-DOCSTART- -14999992- O O

A DT N
randomised VBN N
controlled VBN N
trial NN N
comparing VBG N
Drawtex NNP i
with IN i
standard JJ i
dressings NNS i
for IN N
exuding VBG p
wounds NNS p
. . p

OBJECTIVE VB N
This DT N
randomised VBN N
controlled VBD N
clinical JJ N
trial NN N
compared VBN N
a DT N
capillary JJ i
dressing NN i
( ( i
Drawtex NNP i
, , i
now RB i
rebranded VBN i
as IN i
Vibriant NNP i
RCD NNP i
[ NNP i
Vibriant NNP i
Technology NNP i
Services NNP i
] NNP i
) ) i
with IN i
routine JJ i
practice NN i
for IN i
exuding VBG i
wounds NNS i
greater JJR p
than IN p
2.5 CD p
x JJ p
2.5 CD p
cm NN p
. . p

METHOD NNP N
The DT N
target NN p
population NN p
was VBD p
300 CD p
control NN p
and CC p
300 CD p
test NN p
subjects NNS p
across IN p
three CD p
sites NNS p
in IN p
the DT p
UK NNP p
, , p
but CC p
recruitment JJ p
difficulties NNS p
resulted VBD p
in IN p
only RB p
125 CD p
patients NNS p
being VBG p
evaluable JJ p
. . p

Wound NNP o
progress NN o
was VBD N
recorded VBN N
by IN N
nurses NNS N
' POS N
perception NN N
of IN N
the DT N
progress NN N
of IN N
wound NN N
healing NN N
and CC N
by IN N
objective JJ N
digital JJ N
imaging NN N
. . N

In IN N
the DT N
final JJ N
analysis NN N
digital JJ N
images NNS N
were VBD N
randomised VBN N
( ( N
in IN N
time NN N
order NN N
) ) N
and CC N
a DT N
panel NN N
of IN N
nurses NNS N
who WP N
were VBD N
not RB N
otherwise RB N
involved VBN N
in IN N
the DT N
research NN N
project NN N
graded VBD N
the DT N
wound NN N
's POS N
progress NN N
. . N

RESULTS NN N
After IN N
deconvolution NN N
of IN N
the DT N
data NNS N
, , N
the DT N
subjective NN N
( ( N
nurse JJ N
perception NN N
) ) N
method NN N
of IN N
evaluation NN N
determined VBD N
that IN N
the DT N
new JJ N
dressing NN N
resulted VBD N
in IN N
wound NN o
improvement NN o
in IN N
12.7 CD N
% NN N
more JJR N
patients NNS N
than IN N
did VBD N
routine JJ N
practice NN N
, , N
but CC N
the DT N
blinded JJ N
assessment NN N
method NN N
( ( N
based VBN N
on IN N
the DT N
digital JJ N
images NNS N
) ) N
showed VBD N
that IN N
routine JJ N
practice NN N
was VBD N
better JJR N
by IN N
6.6 CD N
% NN N
. . N

CONCLUSION NNP N
Evaluation NNP N
of IN N
wound NN o
progress NN o
is VBZ N
clearly RB N
difficult JJ N
. . N

Human JJ N
nature NN N
makes VBZ N
us PRP N
favour VB N
novelty NN N
if IN N
we PRP N
believe VBP N
it PRP N
is VBZ N
going VBG N
to TO N
be VB N
better JJR N
. . N

Making VBG N
interpretation NN N
more RBR N
objective JJ N
removed VBD N
that IN N
bias NN N
and CC N
did VBD N
not RB N
demonstrate VB N
a DT N
significant JJ N
advantage NN N
for IN N
the DT N
test NN N
dressing NN N
. . N

The DT N
findings NNS N
suggest VBP N
that IN N
unblinded JJ N
assessment NN N
by IN N
trial NN N
nurses NNS N
is VBZ N
unacceptable JJ N
on IN N
its PRP$ N
own JJ N
. . N

Blinded VBN N
assessments NNS N
may MD N
miss VB N
finer JJR N
nuances NNS N
of IN N
wound NN o
progression NN o
, , N
but CC N
are VBP N
likely JJ N
to TO N
be VB N
more JJR N
accurate NN N
. . N

The DT N
authors NNS N
suggest VBP N
that IN N
the DT N
true JJ N
result NN N
lies VBZ N
somewhere RB N
in IN N
the DT N
middle NN N
, , N
with IN N
the DT N
trial NN N
dressing VBG N
likely JJ N
to TO N
be VB N
as RB N
effective JJ N
as IN N
, , N
but CC N
not RB N
more RBR N
effective JJ N
than IN N
, , N
a DT N
standard JJ N
dressing NN N
. . N

-DOCSTART- -20069077- O O

PROCLAIM NN N
: : N
pilot NN N
study NN N
to TO N
examine VB N
the DT N
effects NNS N
of IN N
clopidogrel NN i
on IN N
inflammatory JJ N
markers NNS N
in IN N
patients NNS p
with IN p
metabolic JJ p
syndrome JJ p
receiving VBG p
low-dose JJ p
aspirin NN i
. . i

Metabolic NNP N
syndrome NN N
is VBZ N
associated VBN N
with IN N
intravascular JJ N
inflammation NN N
, , N
as IN N
determined VBN N
by IN N
increased JJ N
levels NNS N
of IN N
inflammatory NN N
biomarkers NNS N
and CC N
an DT N
increased VBN N
risk NN N
of IN N
ischemic JJ N
atherothrombotic JJ N
events NNS N
. . N

Evidence NN N
suggests VBZ N
that IN N
atherothrombosis NN N
and CC N
intravascular JJ N
inflammation NN N
share NN N
predictive JJ N
biomarkers NNS N
, , N
including VBG N
high-sensitivity JJ N
C-reactive JJ N
protein NN N
, , N
CD40 NNP N
ligand NN N
, , N
P-selectin NNP N
, , N
and CC N
N-terminal JJ N
pro-brain JJ N
natriuretic JJ N
peptide NN N
. . N

Patients NNS p
who WP p
had VBD p
metabolic JJ p
syndrome NN p
were VBD N
randomized VBN N
to TO N
receive VB N
clopidogrel NN i
75 CD i
mg/day JJ i
plus CC i
aspirin JJ i
81 CD i
mg/day NN i
( ( i
n JJ i
= NNP i
89 CD i
) ) i
or CC i
placebo JJ i
plus CC i
aspirin JJ i
81 CD i
mg/day NN i
( ( i
n JJ i
= NNP i
92 CD i
) ) i
for IN i
9 CD i
weeks NNS i
to TO N
assess VB N
the DT N
efficacy NN N
of IN N
each DT N
treatment NN N
in IN N
suppression NN N
of IN N
inflammatory JJ N
markers NNS N
. . N

Change NN N
from IN N
baseline NN N
in IN N
the DT N
levels NNS N
of IN N
high-sensitivity NN o
C-reactive JJ o
protein NN o
, , o
CD40 NNP o
ligand NN o
, , o
P-selectin NNP o
, , o
and CC o
N-terminal JJ o
pro-brain JJ o
natriuretic JJ o
peptide NN o
at IN N
6 CD N
weeks NNS N
was VBD N
assessed VBN N
to TO N
evaluate VB N
each DT N
treatment NN N
. . N

There EX N
was VBD N
a DT N
significant JJ N
difference NN N
at IN N
Week JJ N
6 CD N
in IN N
model-adjusted JJ o
CD40-ligand NNP o
levels NNS o
in IN N
favor NN N
of IN N
clopidogrel NN i
plus CC i
aspirin JJ i
compared VBN N
with IN N
placebo NN i
plus CC i
aspirin NN i
in IN N
both DT N
the DT N
intent-to-treat JJ N
population NN N
( ( N
difference NN N
between IN N
least-squares NNS N
means NNS N
= VBP N
-186.5 NNP N
; : N
95 CD N
% NN N
confidence NN N
interval NN N
, , N
-342.3 NN N
to TO N
-30.8 VB N
; : N
P NNP N
= NNP N
0.02 CD N
) ) N
and CC N
the DT N
per-protocol JJ N
population NN N
( ( N
P NNP N
= NNP N
0.05 CD N
) ) N
. . N

No DT N
significant JJ N
differences NNS N
were VBD N
observed VBN N
between IN N
the DT N
treatment NN N
arms NNS N
for IN N
high-sensitivity JJ o
C-reactive JJ o
protein NN o
, , o
P-selectin NNP o
, , o
and CC o
N-terminal JJ o
pro-brain JJ o
natriuretic JJ o
peptide NN o
. . o

There EX N
were VBD N
no DT N
deaths NNS o
or CC o
serious JJ o
adverse JJ o
events NNS o
in IN N
either DT N
treatment NN N
arm NN N
. . N

Data NNS N
from IN N
this DT N
study NN N
suggest VBP N
that IN N
clopidogrel NN i
can MD N
decrease VB N
the DT N
expression NN o
of IN o
the DT o
CD40-ligand NNP o
biomarker NN o
. . o

-DOCSTART- -19904268- O O

Chemoradiotherapy NN N
with IN N
concurrent JJ i
gemcitabine NN i
and CC i
cisplatin NN i
with IN i
or CC i
without IN i
sequential JJ i
chemotherapy NN i
with IN i
gemcitabine/cisplatin JJ i
vs NNS N
chemoradiotherapy NN i
with IN i
concurrent JJ i
5-fluorouracil JJ i
in IN N
patients NNS p
with IN p
locally RB p
advanced JJ p
pancreatic JJ p
cancer NN p
-- : p
a DT p
multi-centre JJ p
randomised JJ N
phase NN N
II NNP N
study NN N
. . N

BACKGROUND NNP N
No NNP N
standard NN N
treatment NN N
for IN N
locally RB p
advanced JJ p
pancreatic JJ p
cancer NN p
( ( p
LAPC NNP p
) ) p
is VBZ N
defined VBN N
. . N

PATIENTS NNP N
AND CC N
METHODS NNP N
Within NNP N
a DT N
multi-centre JJ N
, , N
randomised JJ N
phase NN N
II NNP N
trial NN N
, , N
95 CD p
patients NNS p
with IN p
LAPC NNP p
were VBD N
assigned VBN N
to TO N
three CD N
different JJ N
chemoradiotherapy NN N
( ( N
CRT NNP N
) ) N
regimens VBZ N
: : N
patients NNS N
received VBD N
conventionally RB N
fractionated VBN N
radiotherapy NN i
of IN N
50 CD N
Gy NNP N
and CC N
were VBD N
randomised VBN N
to TO N
concurrent VB N
5-fluorouracil NNP i
( ( N
350 CD N
mg NN N
m NN N
( ( N
-2 NNP N
) ) N
per IN N
day NN N
on IN N
each DT N
day NN N
of IN N
radiotherapy NN i
, , N
RT-5-FU NNP N
arm NN N
) ) N
, , N
concurrent JJ i
gemcitabine NN i
( ( N
300 CD N
mg NN N
m NN N
( ( N
-2 NNP N
) ) N
) ) N
, , N
and CC N
cisplatin NN i
( ( N
30 CD N
mg NN N
m NN N
( ( N
-2 NNP N
) ) N
) ) N
on IN N
days NNS N
1 CD N
, , N
8 CD N
, , N
22 CD N
, , N
and CC N
29 CD N
( ( N
RT-GC NNP N
arm NN N
) ) N
, , N
or CC N
the DT N
same JJ i
concurrent NN i
treatment NN i
followed VBN i
by IN i
sequential JJ i
full-dose JJ i
gemcitabine NN i
( ( N
1000 CD N
mg NN N
m NN N
( ( N
-2 NNP N
) ) N
) ) N
and CC N
cisplatin NN i
( ( N
50 CD N
mg NN N
m NN N
( ( N
-2 NNP N
) ) N
) ) N
every DT N
2 CD N
weeks NNS N
( ( N
RT-GC+GC NNP N
arm NN N
) ) N
. . N

Primary JJ N
end NN N
point NN N
was VBD N
the DT N
overall JJ o
survival NN o
( ( o
OS NNP o
) ) o
rate NN o
after IN o
9 CD o
months NNS o
. . o

RESULTS VB N
The DT N
9-month JJ o
OS NNP o
rate NN o
was VBD N
58 CD N
% NN N
in IN N
the DT N
RT-5-FU NNP N
arm NN N
, , N
52 CD N
% NN N
in IN N
the DT N
RT-GC NNP N
arm NN N
, , N
and CC N
45 CD N
% NN N
in IN N
the DT N
RT-GC+GC JJ N
arm NN N
. . N

Corresponding VBG N
median JJ o
survival NN o
times NNS o
were VBD N
9.6 CD N
, , N
9.3 CD N
, , N
and CC N
7.3 CD N
months NNS N
( ( N
P=0.61 NNP N
) ) N
respectively RB N
. . N

The DT N
intent-to-treat JJ o
response NN o
rate NN o
was VBD N
19 CD N
, , N
22 CD N
, , N
and CC N
13 CD N
% NN N
respectively RB N
. . N

Median JJ o
progression-free JJ o
survival NN o
was VBD N
estimated VBN N
with IN N
4.0 CD N
, , N
5.6 CD N
, , N
and CC N
6.0 CD N
months NNS N
( ( N
P=0.21 NNP N
) ) N
. . N

Grade $ o
3/4 CD o
haematological JJ o
toxicities NNS o
were VBD N
more RBR N
frequent JJ N
in IN N
the DT N
two CD N
GC-containing JJ N
arms NNS N
, , N
no DT N
grade NN o
3/4 CD o
febrile NN o
neutropaenia NN o
was VBD N
observed VBN N
. . N

CONCLUSION NNP N
None NN N
of IN N
the DT N
three CD N
CRT NNP N
regimens NNS N
tested VBD N
met VBD N
the DT N
investigators NNS N
' POS N
definition NN N
for IN N
efficacy NN N
; : N
the DT N
median JJ N
OS NNP N
was VBD N
similar JJ N
to TO N
those DT N
previously RB N
reported VBN N
with IN N
gemcitabine NN N
alone RB N
in IN N
LAPC NNP N
. . N

-DOCSTART- -9951491- O O

A DT N
randomized JJ N
, , N
double-masked JJ N
, , N
placebo-controlled JJ N
parallel NN N
study NN N
of IN N
loteprednol JJ i
etabonate JJ i
0.2 CD N
% NN N
in IN N
patients NNS p
with IN p
seasonal JJ p
allergic JJ p
conjunctivitis NN p
. . p

OBJECTIVE UH N
To TO N
evaluate VB N
the DT N
effects NNS N
of IN N
loteprednol JJ i
etabonate NN i
( ( i
LE NNP i
) ) i
0.2 CD N
% NN N
in IN N
reducing VBG N
the DT N
signs NNS N
and CC N
symptoms NNS N
of IN N
seasonal JJ o
allergic JJ o
conjunctivitis NN o
. . o

DESIGN NNP N
Randomized NNP N
, , N
double-masked JJ N
, , N
placebo-controlled JJ i
, , N
parallel JJ N
group NN N
multicenter RBR N
study NN N
of IN N
6 CD N
weeks NNS N
duration NN N
. . N

PARTICIPANTS VB N
A DT p
total NN p
of IN p
135 CD p
patients NNS p
with IN p
signs NNS p
and CC p
symptoms NNS p
of IN p
seasonal JJ p
allergic JJ p
conjunctivitis NN p
participated VBD p
. . p

INTERVENTION NNP N
All NNP N
patients NNS N
received VBD N
either RB N
LE NNP i
0.2 CD i
% NN i
or CC i
placebo NN i
( ( N
vehicle NN N
) ) N
four CD N
times NNS N
a DT N
day NN N
in IN N
both DT N
eyes NNS N
for IN N
42 CD N
days NNS N
. . N

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
Bulbar NNP o
conjunctival NN o
injection NN o
( ( o
primary JJ o
sign NN o
) ) o
and CC o
itching VBG o
( ( o
primary JJ o
symptom NN o
) ) o
over IN N
the DT N
first JJ N
2 CD N
weeks NNS N
of IN N
treatment NN N
was VBD N
measured VBN N
. . N

RESULTS VB N
A DT N
reduction NN o
in IN o
severity NN o
was VBD N
seen VBN N
in IN N
both DT N
LE NNP N
and CC N
placebo NN N
groups NNS N
for IN N
bulbar NN o
conjunctival NN o
injection NN o
( ( N
1.5 CD N
vs. FW N
1.0 CD N
units NNS N
on IN N
a DT N
0-3 JJ N
scale NN N
) ) N
and CC N
itching VBG N
( ( N
3.4 CD N
vs. FW N
3.0 CD N
units NNS N
on IN N
a DT N
0-4 JJ N
scale NN N
) ) N
over IN N
the DT N
first JJ N
2 CD N
weeks NNS N
. . N

The DT N
treatment NN N
effect NN N
by IN N
these DT N
measures NNS N
was VBD N
-0.5 NNP N
and CC N
-0.4 NNP N
units NNS N
in IN N
favor NN N
of IN N
LE NNP N
( ( N
P NNP N
< NNP N
or CC N
= VB N
0.008 CD N
) ) N
. . N

Resolution NNP N
( ( N
i.e. NN N
, , N
the DT N
proportion NN o
of IN o
patients NNS o
with IN o
signs NNS o
or CC o
symptoms VBZ o
no DT o
longer RBR o
present JJ o
) ) o
at IN N
day NN N
14 CD N
strongly RB N
favored VBN N
LE-treated JJ N
patients NNS N
( ( N
36 CD N
% NN N
and CC N
15 CD N
% NN N
; : N
58 CD N
% NN N
and CC N
38 CD N
% NN N
, , N
for IN N
injection NN N
and CC N
itching NN N
, , N
respectively RB N
) ) N
. . N

Both DT N
treatments NNS N
were VBD N
well RB N
tolerated VBN o
. . o

One CD N
patient NN N
in IN N
each DT N
treatment NN N
group NN N
( ( N
1 CD N
of IN N
67 CD N
and CC N
1 CD N
of IN N
68 CD N
, , N
respectively RB N
) ) N
had VBD N
an DT N
elevation NN o
of IN o
intraocular JJ o
pressure NN o
of IN N
10 CD N
mmHg NN N
or CC N
greater JJR N
during IN N
the DT N
6 CD N
weeks NNS N
of IN N
treatment NN N
. . N

CONCLUSIONS NNP N
Loteprednol NNP N
etabonate VB N
0.2 CD N
% NN N
was VBD N
more RBR N
effective JJ N
than IN N
placebo NN N
in IN N
the DT N
treatment NN N
of IN N
seasonal JJ N
allergic JJ N
conjunctivitis NN N
. . N

Loteprednol NNP N
etabonate VBP N
0.2 CD N
% NN N
had VBD N
a DT N
safety NN N
profile NN N
comparable JJ N
to TO N
placebo VB N
. . N

-DOCSTART- -24661050- O O

Left NNP o
ventricular JJ o
vortices NNS o
as IN N
observed VBN N
by IN N
vector NN i
flow NN i
mapping NN i
: : i
main JJ N
determinants NNS N
and CC N
their PRP$ N
relation NN N
to TO N
left VB N
ventricular JJ N
filling NN N
. . N

BACKGROUND NNP N
Swirling NNP N
flow NN N
, , N
organized VBN N
in IN N
vortices NNS N
, , N
contributes NNS N
to TO N
adequate VB N
left JJ N
ventricular JJ N
function NN N
. . N

In IN N
this DT N
study NN N
, , N
we PRP N
apply VBP N
a DT N
novel JJ i
echocardiographic JJ i
flow-mapping NN i
technique NN i
, , i
vector NN i
flow NN i
mapping NN i
( ( i
VFM NNP i
) ) i
, , N
to TO N
evaluate VB N
the DT N
main JJ N
characteristics NNS N
of IN N
left JJ o
ventricular JJ o
vortices NNS o
and CC N
its PRP$ N
relation NN N
to TO N
filling VBG N
parameters NNS N
. . N

METHODS NNP N
Forty-eight JJ p
subjects NNS p
underwent JJ p
conventional JJ i
transthoracic NN i
echocardiographic JJ i
examination NN i
with IN p
additional JJ p
intracardiac NN i
flow NN i
assessment NN i
with IN i
VFM NNP i
using VBG i
a DT i
Aloka NNP i
Alpha-10 NNP i
system NN i
and CC i
experimental JJ i
VFM NNP i
analysis NN i
software NN i
. . i

To TO N
analyze VB N
vortex JJ o
behavior NN o
, , N
its PRP$ N
rotation NN N
direction NN N
, , N
duration NN N
, , N
location NN N
inside IN N
the DT N
left JJ N
ventricle NN N
, , N
size NN N
, , N
and CC N
intensity NN N
were VBD N
assessed VBN N
in IN N
apical JJ N
long-axis JJ N
view NN N
. . N

Its PRP$ N
relation NN N
to TO N
conventional JJ N
left JJ N
ventricular NN N
filling VBG N
parameters NNS N
was VBD N
then RB N
analyzed VBN N
. . N

RESULTS NNP N
Two CD N
vortex JJ o
components NNS o
were VBD N
consistently RB N
identified VBN N
following VBG N
each DT N
transmitral JJ N
filling NN N
wave NN N
. . N

The DT N
anterior JJ o
component NN o
of IN o
these DT o
visualized JJ o
vortices NNS o
was VBD N
analyzed VBN N
, , N
due JJ N
to TO N
its PRP$ N
higher JJR N
significance NN N
in IN N
the DT N
cardiac JJ N
cycle NN N
, , N
following VBG N
early JJ N
filling NN N
( ( N
V1 NNP N
) ) N
and CC N
atrial JJ N
contraction NN N
( ( N
V2 NNP N
) ) N
. . N

Differences NNS N
were VBD N
observed VBN N
in IN N
several JJ N
aspects NNS N
of IN N
vortex JJ o
behavior NN o
between IN N
V1 NNP N
and CC N
V2 NNP N
, , N
particularly RB N
in IN N
patients NNS N
with IN N
normal JJ N
left VBD N
ventricular JJ N
filling NN N
parameters NNS N
. . N

These DT N
differences NNS N
may MD N
be VB N
related VBN N
to TO N
varying VBG N
roles NNS N
of IN N
vortices NNS o
in IN N
different JJ N
periods NNS N
of IN N
the DT N
cardiac JJ N
cycle NN N
. . N

CONCLUSIONS NNP N
Vector NNP i
flow NN i
mapping NN i
allowed VBN N
visualization NN N
and CC N
measurement NN N
of IN N
several JJ N
parameters NNS N
defining VBG N
vortex NN o
behavior NN o
inside IN N
the DT N
cardiac JJ N
cycle NN N
. . N

The DT N
differences NNS N
observed VBD N
in IN N
these DT N
parameters NNS N
between IN N
vortices NNS N
in IN N
different JJ N
phases NNS N
of IN N
the DT N
cardiac JJ N
cycle NN N
may MD N
be VB N
related VBN N
to TO N
their PRP$ N
role NN N
in IN N
optimizing VBG N
cardiac JJ N
function NN N
. . N

-DOCSTART- -10848655- O O

The DT N
effectiveness NN N
of IN N
omeprazole NN i
, , i
clarithromycin NN i
and CC N
tinidazole NN i
in IN N
eradicating VBG o
Helicobacter NNP o
pylori NN o
in IN N
a DT N
community NN N
screen NN N
and CC N
treat NN N
programme NN N
. . N

Leeds NNP N
Help NNP N
Study NNP N
Group NNP N
. . N

INTRODUCTION NNP N
Helicobacter NNP N
pylori NN N
screening NN N
and CC N
treatment NN N
has VBZ N
been VBN N
proposed VBN N
as IN N
a DT N
cost-effective JJ N
method NN N
of IN N
preventing VBG N
gastric JJ N
cancer NN N
. . N

AIM NNP N
To TO N
assess VB N
, , N
in IN N
a DT N
randomized NN N
controlled VBN N
trial NN N
, , N
the DT N
efficacy NN N
of IN N
therapy NN N
in IN N
eradicating VBG N
H. NNP N
pylori NN N
as IN N
part NN N
of IN N
a DT N
screening NN N
programme NN N
, , N
and CC N
to TO N
report VB N
the DT N
adverse JJ N
events NNS N
associated VBN N
with IN N
this DT N
strategy NN N
. . N

METHODS NNP N
Subjects NNPS p
between IN p
the DT p
ages NNS p
of IN p
40-49 JJ p
years NNS p
were VBD p
randomly RB p
selected VBN p
from IN p
the DT p
lists NNS p
of IN p
36 CD p
primary JJ p
care NN p
centres NNS p
. . p

Participants NNS N
attended VBD N
their PRP$ N
local JJ N
practice NN N
and CC N
H. NNP N
pylori VBP N
status NN N
was VBD N
determined VBN N
by IN N
13C-urea JJ N
breath NN N
test NN N
. . N

Infected VBN N
subjects NNS N
were VBD N
randomized VBN N
to TO N
receive VB N
omeprazole JJ i
20 CD i
mg NN i
b.d. NN i
, , N
clarithromycin VBP i
250 CD i
mg NN i
b.d NN i
. . i

and CC i
tinidazole JJ i
500 CD i
mg NN i
b.d NN i
. . i

for IN N
7 CD N
days NNS N
( ( N
OCT NNP N
) ) N
or CC N
identical JJ N
placebos NN i
. . i

Eradication NN o
was VBD N
determined VBN N
by IN N
a DT N
13C-urea JJ N
breath NN N
test NN N
6 CD N
months NNS N
and CC N
2 CD N
years NNS N
after IN N
the DT N
first JJ N
visit NN N
. . N

Successful JJ o
eradication NN o
was VBD N
defined VBN N
as IN N
two CD N
negative JJ o
13C-urea JJ o
breath NN o
tests NNS o
or CC o
one CD o
negative JJ o
and CC o
one CD o
missing VBG o
test NN o
. . o

Adverse JJ o
events NNS o
and CC o
compliance NN o
were VBD N
assessed VBN N
at IN N
the DT N
6-month JJ N
visit NN N
. . N

RESULTS VB N
A DT p
total NN p
of IN p
32 CD p
929 CD p
subjects NNS p
were VBD p
invited VBN p
to TO p
attend VB p
, , p
8407 CD p
were VBD p
evaluable JJ p
, , p
and CC p
2329 CD p
( ( p
28 CD p
% NN p
) ) p
of IN p
these DT p
were VBD p
H. NNP o
pylori-positive JJ o
. . o

A DT p
total NN p
of IN p
1161 CD p
subjects NNS p
were VBD N
randomized VBN N
to TO N
OCT NNP N
and CC N
1163 CD N
to TO N
placebo VB N
; : N
over IN N
80 CD N
% NN N
returned VBN N
for IN N
a DT N
repeat NN N
13C-urea JJ N
breath NN N
test NN N
on IN N
at IN N
least JJS N
one CD N
occasion NN N
. . N

The DT N
eradication NN o
rates NNS o
in IN N
those DT N
allocated VBN N
to TO N
OCT NNP N
were VBD N
as IN N
follows VBZ N
: : N
intention-to-treat NN N
, , N
710 CD N
out IN N
of IN N
1161 CD N
( ( N
61 CD N
% NN N
; : N
95 CD N
% NN N
confidence NN N
interval NN N
: : N
58-64 JJ N
% NN N
) ) N
; : N
evaluable JJ N
710 CD N
out IN N
of IN N
967 CD N
( ( N
73 CD N
% NN N
; : N
95 CD N
% NN N
CI NNP N
: : N
71-76 CD N
% NN N
) ) N
; : N
took VBD N
all DT N
medication NN N
645 CD N
out IN N
of IN N
769 CD N
( ( N
84 CD N
% NN N
; : N
95 CD N
% NN N
CI NNP N
: : N
81-87 CD N
% NN N
) ) N
. . N

Adverse JJ o
events NNS o
occurred VBD N
in IN N
45 CD N
% NN N
of IN N
the DT N
treatment NN N
group NN N
and CC N
in IN N
18 CD N
% NN N
of IN N
the DT N
placebo NN N
group NN N
( ( N
relative JJ N
risk NN N
2.5 CD N
; : N
95 CD N
% NN N
CI NNP N
: : N
2.1-2.9 JJ N
) ) N
. . N

Compliance NN N
, , N
male JJ N
gender NN N
, , N
no DT N
antibiotic JJ N
prescription NN N
in IN N
the DT N
subsequent JJ N
2 CD N
years NNS N
and CC N
experiencing VBG o
a DT o
bitter JJ o
taste NN o
with IN N
the DT N
medication NN N
were VBD N
independently RB N
associated VBN N
with IN N
treatment NN N
success NN N
. . N

CONCLUSIONS VB N
The DT N
OCT NNP N
regimen NN N
has VBZ N
an DT N
eradication NN o
rate NN o
of IN N
61 CD N
% NN N
in IN N
intention-to-treat JJ N
analysis NN N
and CC N
is VBZ N
therefore RB N
less RBR N
successful JJ N
in IN N
treating VBG N
H. NNP N
pylori NN N
as IN N
part NN N
of IN N
a DT N
screening NN N
programme NN N
compared VBN N
with IN N
hospital JJ N
studies NNS N
in IN N
dyspeptic JJ p
patients NNS p
. . p

-DOCSTART- -1536276- O O

Differential JJ N
response NN N
of IN N
seven CD p
subjects NNS p
with IN p
autistic JJ p
disorder NN p
to TO N
clomipramine VB i
and CC N
desipramine VB i
. . i

OBJECTIVE NNP N
Clomipramine NNP N
, , N
a DT N
serotonin JJ N
reuptake NN N
blocker NN N
that WDT N
has VBZ N
unique JJ N
antiobsessional JJ N
properties NNS N
, , N
was VBD N
hypothesized VBN N
to TO N
have VB N
a DT N
different JJ N
effect NN N
from IN N
that DT N
of IN N
desipramine NN N
, , N
a DT N
tricyclic JJ N
antidepressant NN N
with IN N
selective JJ N
adrenergic JJ N
effects NNS N
, , N
for IN N
the DT N
stereotyped NN N
, , N
repetitive JJ N
behaviors NNS N
in IN N
autism NN N
. . N

METHOD NNP N
Seven NNP p
subjects NNS p
, , p
ages VBZ p
6-18 CD p
years NNS p
, , p
with IN p
autistic JJ p
disorder NN p
completed VBD N
a DT N
10-week JJ N
double-blind NN N
, , N
crossover JJ N
trial NN N
of IN N
clomipramine NN i
and CC i
desipramine NN i
following VBG N
a DT N
2-week JJ N
single-blind NN N
, , N
placebo JJ i
phase NN N
. . N

RESULTS NNP N
Clomipramine NNP N
was VBD N
superior JJ N
to TO N
desipramine VB N
and CC N
placebo VB N
, , N
as IN N
indicated VBN N
by IN N
standardized JJ N
ratings NNS o
of IN o
autism NN o
and CC o
anger NN o
as RB N
well RB N
as IN N
ratings NNS o
of IN o
repetitive JJ o
and CC o
compulsive JJ o
behaviors NNS o
. . o

Clomipramine NNP N
and CC N
desipramine NN N
were VBD N
equally RB N
superior JJ N
to TO N
placebo VB N
for IN N
ratings NNS o
of IN o
hyperactivity NN o
. . o

Parents NNS N
of IN N
all DT N
seven CD p
subjects NNS p
elected VBN N
to TO N
have VB N
their PRP$ N
children NNS N
continue VBP N
to TO N
take VB N
clomipramine NN N
after IN N
the DT N
study NN N
. . N

CONCLUSIONS NNP N
Clomipramine NNP N
and CC N
desipramine NN N
are VBP N
differentially RB N
effective JJ N
in IN N
treating VBG N
the DT N
obsessive-compulsive JJ o
and CC o
core NN o
symptoms NNS o
in IN N
autistic JJ N
disorder NN N
. . N

Biological JJ N
links NNS N
between IN N
compulsions NNS N
and CC N
stereotyped VBD N
, , N
repetitive JJ N
behaviors NNS N
in IN N
autistic JJ N
disorder NN N
should MD N
be VB N
explored VBN N
. . N

-DOCSTART- -12148711- O O

Effect NN N
of IN N
clinical JJ i
pharmacy NN i
services NNS i
on IN N
the DT N
blood NN o
pressure NN o
of IN N
African-American JJ p
renal JJ p
transplant NN p
patients NNS p
. . p

OBJECTIVE IN N
The DT N
objective NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
determine VB N
if IN N
African-American JJ p
renal JJ p
transplant NN p
patients NNS p
who WP N
received VBD N
direct JJ N
patient NN N
care NN N
from IN N
a DT N
clinical JJ i
pharmacist NN i
had VBD N
better RBR N
blood NN o
pressure NN o
control NN o
compared VBN N
to TO N
African-American JJ p
renal JJ p
transplant NN p
patients NNS p
who WP p
did VBD p
not RB p
have VB p
clinical JJ p
pharmacy NN p
services NNS p
. . p

METHODS NNP N
Renal NNP p
transplant NN p
patients NNS p
were VBD N
prospectively RB N
randomized VBN N
into IN N
an DT N
intervention NN N
group NN N
or CC N
a DT N
control NN N
group NN N
. . N

Patients NNS N
in IN N
the DT N
intervention NN N
group NN N
received VBD i
clinical JJ i
pharmacy NN i
services NNS i
that WDT i
included VBD i
a DT i
clinical JJ i
pharmacist NN i
performing VBG i
patient JJ i
medication NN i
reviews NNS i
, , i
with IN i
emphasis NN i
on IN i
preventing VBG i
or CC i
resolving VBG i
medication-related JJ i
problems NNS i
and CC i
providing VBG i
medication NN i
recommendations NNS i
. . i

Patients NNS N
in IN N
the DT N
control NN N
group NN N
received VBD i
routine JJ i
clinic NN i
services NNS i
, , i
but CC i
had VBD i
no DT i
clinical JJ i
pharmacist NN i
interaction NN i
. . i

Analysis NN N
was VBD N
performed VBN N
to TO N
detect VB N
differences NNS N
between IN N
the DT N
intervention NN N
and CC N
control NN N
groups NNS N
in IN N
baseline NN o
and CC o
quarterly JJ o
systolic JJ o
blood NN o
pressure NN o
( ( o
SBP NNP o
) ) o
and CC o
diastolic JJ o
blood NN o
pressure NN o
( ( o
DBP NNP o
) ) o
for IN N
one CD N
year NN N
post-study NN N
enrollment NN N
. . N

RESULTS CC N
There EX N
were VBD N
no DT N
differences NNS N
between IN N
the DT N
intervention NN N
( ( p
N NNP p
= NNP p
13 CD p
) ) p
and CC N
control NN N
( ( p
N NNP p
= NNP p
10 CD p
) ) p
groups NNS N
in IN N
baseline NN N
blood NN o
pressures NNS o
or CC N
in IN N
the DT N
percentage NN N
of IN N
hypertensive JJ N
patients NNS N
. . N

Significant JJ N
differences NNS N
in IN N
the DT N
change NN N
in IN N
SBP NNP o
and CC o
DBP NNP o
from IN N
baseline NN N
between IN N
the DT N
intervention NN N
and CC N
control NN N
groups NNS N
were VBD N
observed VBN N
at IN N
the DT N
second JJ N
, , N
third JJ N
, , N
and CC N
fourth JJ N
quarters NNS N
of IN N
the DT N
study NN N
, , N
favoring VBG N
the DT N
intervention NN N
group NN N
( ( N
P NNP N
< NNP N
.01 NNP N
) ) N
. . N

Mean NNP o
SBP NNP o
was VBD N
significantly RB N
lower JJR N
in IN N
the DT N
intervention NN N
group NN N
at IN N
the DT N
second JJ N
( ( N
137.8 CD N
+/- JJ N
15.0 CD N
vs JJ N
168.9 CD N
+/- JJ N
15.3 CD N
) ) N
, , N
third JJ N
( ( N
135.9 CD N
+/- JJ N
11.7 CD N
vs JJ N
164.6 CD N
+/- JJ N
20.1 CD N
) ) N
, , N
and CC N
fourth JJ N
( ( N
145.3 CD N
+/- JJ N
16.8 CD N
vs JJ N
175.8 CD N
+/- JJ N
33.9 CD N
) ) N
quarters NNS N
of IN N
the DT N
study NN N
( ( N
P NNP N
< NNP N
.05 NNP N
) ) N
. . N

Mean NNP o
DBP NNP o
was VBD N
significantly RB N
lower JJR N
in IN N
the DT N
intervention NN N
group NN N
at IN N
the DT N
second JJ N
( ( N
76.0 CD N
+/- JJ N
11.8 CD N
vs JJ N
84.9 CD N
+/- JJ N
6.1 CD N
) ) N
and CC N
fourth JJ N
( ( N
77.0 CD N
+/- JJ N
10.2 CD N
vs JJ N
91.8 CD N
+/- JJ N
12.0 CD N
) ) N
quarters NNS N
( ( N
P NNP N
< NNP N
.05 NNP N
) ) N
. . N

CONCLUSION NNP N
Direct NNP N
patient NN N
care NN N
services NNS N
provided VBN N
by IN N
a DT N
clinical JJ N
pharmacist NN N
, , N
in IN N
addition NN N
to TO N
routine VB N
clinical JJ N
services NNS N
, , N
have VBP N
a DT N
positive JJ N
effect NN N
on IN N
the DT N
blood NN o
pressure NN o
of IN N
African-American JJ p
renal JJ p
transplant NN p
patients NNS p
. . p

A DT N
multidisciplinary JJ N
team NN N
that WDT N
includes VBZ N
a DT N
clinical JJ N
pharmacist NN N
is VBZ N
beneficial JJ N
to TO N
patient VB N
care NN N
. . N

-DOCSTART- -22752489- O O

Effectiveness NN N
and CC N
safety NN N
of IN N
donepezil NN i
in IN N
boys NNS p
with IN p
fragile JJ p
x JJ p
syndrome NN p
: : p
a DT N
double-blind NN N
, , N
randomized VBN N
, , N
controlled VBN N
pilot NN N
study NN N
. . N

The DT N
present JJ N
study NN N
was VBD N
designed VBN N
as IN N
a DT N
12-week JJ N
, , N
randomized VBN N
, , N
double-blind JJ N
, , N
placebo-controlled JJ i
pilot NN N
study NN N
to TO N
evaluate VB N
the DT N
effectiveness NN o
and CC o
safety NN o
of IN N
donepezil NN i
in IN N
boys NNS p
with IN p
fragile JJ p
X NNP p
syndrome NN p
. . p

Twenty NNP p
boys VBZ p
with IN p
fragile JJ p
X NNP p
syndrome NN p
were VBD N
randomized VBN N
to TO N
receive VB N
12 CD N
weeks NNS N
of IN N
treatment NN N
with IN N
either DT N
placebo NN i
or CC i
donepezil NN i
( ( N
2.5 CD N
mg NNS N
daily RB N
for IN N
initial JJ N
4 CD N
weeks NNS N
followed VBN N
by IN N
5 CD N
mg NNS N
daily RB N
for IN N
next JJ N
8 CD N
weeks NNS N
) ) N
. . N

The DT N
outcome NN N
measures NNS N
included VBD N
change NN o
in IN o
intelligence NN o
quotient NN o
scores NNS o
on IN o
Stanford-Binet NNP o
Intelligence NNP o
Scale NNP o
( ( o
Hindi NNP o
adaptation NN o
by IN o
Kulshrestha NNP o
) ) o
, , o
change NN o
in IN o
behavioral JJ o
scores NNS o
by IN o
Conners NNS o
3 CD o
Parent NN o
Rating VBG o
Scale NNP o
( ( o
Short NNP o
) ) o
and CC o
Childhood NNP o
Autism NNP o
Rating NNP o
Scale NNP o
, , o
safety NN o
, , o
and CC o
tolerability NN o
of IN o
donepezil NN o
. . o

The DT N
study NN N
failed VBD N
to TO N
show VB N
significant JJ N
difference NN N
in IN N
intelligence NN o
quotient NN o
and CC N
behavioral JJ o
scales NNS o
with IN N
donepezil JJ i
therapy NN N
over IN N
12 CD N
weeks NNS N
. . N

However RB N
, , N
donepezil RB i
appeared VBD N
to TO N
be VB N
safe JJ N
and CC N
well RB N
tolerated VBN N
. . N

-DOCSTART- -16879331- O O

Effect NN N
of IN N
enamel JJ i
preparation NN i
method NN i
on IN N
in IN N
vitro JJ N
marginal JJ o
microleakage NN o
of IN N
a DT N
flowable JJ N
composite NN N
used VBN N
as IN N
pit NN N
and CC N
fissure NN N
sealant NN N
. . N

OBJECTIVES CC N
The DT N
aim NN N
of IN N
this DT N
in IN N
vitro NN N
study NN N
was VBD N
to TO N
evaluate VB N
the DT N
microleakage NN o
in IN o
occlusal JJ o
surfaces NNS o
, , N
after IN N
preparation NN N
with IN N
Er NNP i
: : i
YAG NNP i
laser NN i
and CC N
compared VBN N
to TO N
the DT N
diamond-bur JJ i
conventional JJ i
technique NN i
. . i

METHODS NNP N
Thirty NNP p
premolars NNS p
were VBD N
divided VBN N
into IN N
three CD N
groups NNS N
: : N
I PRP N
- : N
high-speed JJ i
handpiece NN i
+ VBD i
37 CD i
% NN i
phosphoric JJ i
acid NN i
; : i
II NNP N
- : N
Er NN i
: : i
YAG NNP i
laser NN i
( ( i
350 CD i
mJ NN i
, , i
4 CD i
Hz NNP i
and CC i
112 CD i
J/cm NNP i
( ( i
2 CD i
) ) i
) ) i
+ $ i
37 CD i
% NN i
phosphoric JJ i
acid NN i
; : i
and CC N
III NNP N
- : N
Er NN i
: : i
YAG NNP i
laser NN i
( ( i
350 CD i
mJ NN i
, , i
4 CD i
Hz NNP i
and CC i
112 CD i
J/cm NNP i
( ( i
2 CD i
) ) i
) ) i
+ FW i
Er NNP i
: : i
YAG NNP i
laser NN i
( ( i
80 CD i
mJ NN i
, , i
4 CD i
Hz NNP i
, , i
and CC i
25 CD i
mJ/cm NN i
( ( i
2 CD i
) ) i
) ) i
. . N

All DT N
cavities NNS p
received VBD N
the DT N
same JJ N
adhesive JJ N
system NN N
and CC N
were VBD N
restored VBN N
with IN N
flowable JJ N
composite JJ N
according VBG N
to TO N
manufacturer NN N
's POS N
instructions NNS N
. . N

Teeth NNP N
were VBD N
submitted VBN N
to TO N
thermal VB i
cycling NN i
and CC N
immersed VBN N
in IN N
50 CD N
% NN N
silver NN i
nitrate JJ i
solutions NNS i
for IN N
8 CD N
h NN N
in IN N
total JJ N
darkness NN N
. . N

Specimens NNS N
were VBD N
sectioned VBN N
longitudinally RB N
in IN N
the DT N
bucco-lingual JJ N
direction NN N
, , N
in IN N
slices NNS N
of IN N
1 CD N
mm NNS N
thick JJ N
. . N

Each DT N
slice NN N
was VBD N
immersed VBN N
into IN N
photo NN N
developing VBG N
solution NN N
and CC N
was VBD N
photographed VBN N
, , N
and CC N
microleakage NN o
was VBD o
scored VBN o
from IN o
0 CD o
to TO o
7 CD o
, , N
by IN N
three CD N
calibrated JJ N
examiners NNS N
. . N

RESULTS VB N
A NNP N
statistically RB N
significant JJ N
difference NN N
( ( N
P NNP N
< NNP N
0.0001 CD N
) ) N
was VBD N
observed VBN N
between IN N
Er NNP N
: : N
YAG NNP N
laser NN N
prepared VBD N
and CC N
etched VBD N
specimens NNS N
and CC N
those DT N
in IN N
the DT N
other JJ N
groups NNS N
. . N

CONCLUSIONS VB N
It PRP N
can MD N
be VB N
concluded VBN N
that IN N
no DT N
significant JJ N
difference NN N
was VBD N
noted VBN N
between IN N
the DT N
two CD N
types NNS N
of IN N
enamel NN i
preparation NN i
when WRB N
etching NN N
was VBD N
performed VBN N
. . N

Preparing VBG N
and CC N
treating VBG N
the DT N
enamel JJ N
surface NN N
exclusively RB N
by IN N
Er NNP i
: : i
YAG NNP i
laser NN i
resulted VBD N
in IN N
the DT N
highest JJS N
degree NN o
of IN o
leakage NN o
. . o

-DOCSTART- -17972048- O O

Robotic JJ i
therapy NN i
: : i
a DT N
novel JJ N
approach NN N
in IN N
upper-limb JJ o
neurorehabilitation NN o
after IN N
stroke NN p
. . p

-DOCSTART- -6552999- O O

[ JJ N
Tocolysis NN N
with IN N
hexoprenalin NN i
and CC N
salbutamol NN i
in IN N
a DT N
clinical JJ N
comparison NN N
] NNP N
. . N

140 CD p
patients NNS p
with IN p
a DT p
threatening JJ p
premature NN p
birth NN p
at IN p
the DT p
greater JJR p
than IN p
or CC p
equal JJ p
to TO p
24-less JJ p
than IN p
37 CD p
week NN p
of IN p
gestation NN p
were VBD N
in IN N
this DT N
study NN N
randomly RB N
treated VBN N
with IN N
hexoprenalin NN i
or CC i
salbutamol NN i
. . i

In IN N
77 CD p
% NN p
in IN p
the DT p
hexoprenalin NN i
and CC p
in IN p
74 CD p
% NN p
in IN p
the DT p
salbutamol NN i
group NN p
the DT N
weight NN o
of IN o
the DT o
newborn NN o
was VBD p
greater JJR p
than IN p
or CC p
equal JJ p
to TO p
2500 CD p
g. NN p
In IN N
66 CD p
% NN p
in IN p
both DT p
study NN p
groups NNS p
the DT N
birth NN N
occurred VBD N
after IN N
the DT N
completed VBN N
37 CD N
weeks NNS o
of IN o
gestation NN o
. . o

During IN N
infusion NN N
of IN N
hexoprenalin JJ i
tachycardia NN o
in IN N
mothers NNS N
occurred VBD N
statistically RB N
highly RB N
significantly RB N
less JJR N
than IN N
during IN N
salbutamol NN i
. . i

11 CD p
% NN p
of IN p
the DT p
mothers NNS p
in IN p
the DT p
hexoprenalin NN i
group NN p
had VBD p
side-effects NNS o
during IN o
infusion NN o
compared VBN p
to TO p
30 CD p
% NN p
in IN p
the DT p
salbutamol NN i
group NN p
. . p

The DT N
correlation NN N
between IN N
the DT N
tocolysis-index NN o
( ( o
Baumgarten NNP o
) ) o
and CC N
the DT N
prolongation-index NN o
( ( o
Richter NNP o
) ) o
given VBN N
by IN N
the DT N
regression NN N
lines NNS N
facilitates NNS N
in IN N
some DT N
measure NN N
the DT N
comparison NN N
of IN N
different JJ N
tocolytic JJ N
drugs NNS N
concerning VBG N
its PRP$ N
tocolytic JJ N
effect NN N
. . N

-DOCSTART- -24007198- O O

Network NNP N
coordination NN N
following VBG N
discharge NN N
from IN N
psychiatric JJ i
inpatient JJ i
treatment NN i
: : i
a DT N
study NN N
protocol NN N
. . N

BACKGROUND NNP N
Inadequate NNP N
discharge NN N
planning VBG N
following VBG N
inpatient NN N
stays NNS N
is VBZ N
a DT N
major JJ N
issue NN N
in IN N
the DT N
provision NN N
of IN N
a DT N
high JJ o
standard NN o
of IN o
care NN o
for IN N
patients NNS p
who WP p
receive VBP p
psychiatric JJ i
treatment NN i
. . i

Studies NNS N
have VBP N
shown VBN N
that IN N
half NN N
of IN N
patients NNS p
who WP p
had VBD p
no DT p
pre-discharge JJ p
contact NN p
with IN p
outpatient NN p
services NNS p
do VBP N
not RB N
keep VB N
their PRP$ N
first JJ N
outpatient JJ N
appointment NN N
. . N

Additionally RB N
, , N
discharged VBD p
patients NNS p
who WP p
are VBP p
not RB p
well RB p
linked VBN p
to TO p
their PRP$ p
outpatient NN p
care NN p
networks NNS p
are VBP N
at IN N
twice RB N
the DT N
risk NN N
of IN N
re-hospitalization NN N
. . N

The DT N
aim NN N
of IN N
this DT N
study NN N
is VBZ N
to TO N
investigate VB N
if IN N
the DT N
Post-Discharge NNP o
Network NNP o
Coordination NNP o
Program NNP o
at IN N
ipw NN N
has VBZ N
a DT N
demonstrably RB N
significant JJ N
impact NN N
on IN N
the DT N
frequency NN o
and CC o
duration NN o
of IN o
patient JJ o
re-hospitalization NN o
. . o

Subjects NNS N
are VBP N
randomly RB N
assigned VBN N
to TO N
either CC N
the DT N
treatment NN N
group NN N
or CC N
to TO N
the DT N
control NN N
group NN N
. . N

The DT N
treatment NN N
group NN N
participates VBZ N
in IN N
the DT N
Post-Discharge NNP o
Network NNP o
Coordination NNP o
Program NNP o
. . o

The DT N
control NN N
group NN N
receives VBZ N
treatment NN i
as IN i
usual JJ i
with IN N
no DT N
additional JJ N
social JJ N
support NN N
. . N

Further CC N
outcome JJ N
variables NNS N
include VBP N
: : N
social JJ o
support NN o
, , o
change NN o
in IN o
psychiatric JJ o
symptoms NNS o
, , o
quality NN o
of IN o
life NN o
, , o
and CC o
independence NN o
in IN o
daily JJ o
functioning NN o
. . o

METHODS/DESIGN NNP N
The DT N
study NN N
is VBZ N
conducted VBN N
as IN N
a DT N
randomized NN N
controlled VBN N
trial NN N
. . N

Subjects NNS N
are VBP N
randomly RB N
assigned VBN N
to TO N
either VB N
the DT N
control NN i
group NN N
or CC N
to TO N
the DT N
treatment NN i
group NN N
. . N

Computer NNP i
generated VBD i
block NN i
randomization NN i
is VBZ N
used VBN N
to TO N
assure VB N
both DT N
groups NNS N
have VBP N
the DT N
same JJ N
number NN N
of IN N
subjects NNS N
. . N

Stratified NNP i
block NN i
randomization NN i
is VBZ N
used VBN N
for IN N
the DT N
psychiatric JJ N
diagnosis NN N
of IN N
ICD-10 NNP N
, , N
F1 NNP N
. . N

Approximately RB p
160 CD p
patients NNS p
are VBP p
recruited VBN p
in IN p
two CD p
care NN p
units NNS p
at IN p
Psychiatrie-Zentrum NNP p
Hard NNP p
Embrach NNP p
and CC p
two CD p
care NN p
units NNS p
at IN p
Klinik NNP p
Schlosstal NNP p
Winterthur NNP p
. . p

DISCUSSION NNP N
The DT N
proposed VBN N
post-discharge NN o
network NN o
coordination NN o
program NN o
intervenes NNS N
during IN N
the DT N
critical JJ N
post-discharge NN N
period NN N
. . N

It PRP N
focuses VBZ N
primarily RB N
on IN N
promoting VBG N
the DT N
integration NN o
of IN o
the DT o
patients NNS o
into IN o
their PRP$ o
social JJ o
networks NNS o
, , N
and CC N
additionally RB N
to TO N
coordinating VBG o
outpatient JJ o
care NN o
and CC N
addressing VBG o
concerns NNS o
of IN o
daily JJ o
life NN o
. . o

TRIAL NNP N
REGISTRATION NNP N
ISRCTN NNP N
ISRCTN58280620 NNP N
. . N

-DOCSTART- -184069- O O

Effect NN N
of IN N
radiotherapy NN i
on IN N
blood NN o
lymphocyte JJ o
population NN o
in IN p
mammary JJ p
carcinoma NN p
. . p

-DOCSTART- -16850327- O O

Effects NNS N
of IN N
single JJ N
doses NNS N
of IN N
rabeprazole JJ i
20 CD N
mg NN N
and CC N
esomeprazole JJ i
40 CD N
mg NN N
on IN N
24-h JJ o
intragastric JJ o
pH NN o
in IN p
healthy JJ p
subjects NNS p
. . p

OBJECTIVE NNP N
To TO N
compare VB N
antisecretory JJ N
effects NNS N
of IN N
single JJ N
doses NNS N
of IN N
rabeprazole NN i
and CC N
esomeprazole NN i
. . i

METHODS NNP N
Open NNP N
, , N
randomised VBD N
, , N
2-way JJ N
crossover NN N
, , N
clinical JJ N
pharmacology NN N
study NN N
. . N

24 CD p
healthy JJ p
subjects NNS p
( ( p
10 CD p
men NNS p
; : p
mean JJ p
age NN p
26.2 CD p
y NN p
) ) p
received VBD N
a DT N
single JJ N
dose NN N
of IN N
rabeprazole JJ i
20 CD i
mg NN i
or CC i
esomeprazole JJ i
40 CD i
mg NN i
, , N
with IN N
a DT N
14-day JJ N
'washout NN N
' POS N
. . N

Intragastric NNP o
pH NN o
was VBD N
recorded VBN N
continuously RB N
from IN N
24 CD N
h NN N
before IN N
to TO N
24 CD N
h NN N
after IN N
dosing VBG N
. . N

RESULTS JJ N
Mean NNP o
intragastric JJ o
pH NN o
was VBD N
higher JJR N
after IN N
esomeprazole JJR i
than IN N
rabeprazole NN i
during IN N
0-5 JJ N
h NN N
after IN N
dosing VBG N
( ( N
P=0.0001 NNP N
) ) N
; : N
the DT N
reverse NN N
was VBD N
true JJ N
from IN N
14-24 JJ N
h NN N
( ( N
P=0.0002 NNP N
) ) N
. . N

Mean VB o
% NN o
time NN o
pH JJ o
> $ o
3 CD o
and CC o
> $ o
4 CD o
was VBD N
greater JJR N
after IN N
esomeprazole JJR i
than IN N
rabeprazole NN i
during IN N
0-14 JJ N
h NN N
( ( N
P=0.041 NNP N
and CC N
0.044 CD N
) ) N
, , N
but CC N
the DT N
reverse NN N
was VBD N
true JJ N
during IN N
14-24 JJ N
h NN N
( ( N
P=0.0005 NNP N
and CC N
0.001 CD N
) ) N
. . N

In IN N
the DT N
0-24 JJ N
h NN N
interval NN N
as IN N
a DT N
whole NN N
, , N
there EX N
was VBD N
no DT N
difference NN N
between IN N
treatments NNS N
in IN N
mean JJ o
pH NN o
or CC o
% NN o
time NN o
pH JJ o
> JJ o
3 CD o
or CC o
> $ o
4 CD o
. . o

CONCLUSION NNP N
Single-dose JJ N
rabeprazole NN i
20 CD N
mg NN N
was VBD N
as RB N
effective JJ N
as IN N
esomeprazole JJ i
40 CD N
mg NN N
in IN N
increasing VBG N
intragastric JJ o
pH NN o
and CC N
maintaining VBG N
pH NN o
> $ o
3 CD o
and CC o
> $ o
4 CD o
, , N
despite IN N
the DT N
2-fold JJ N
difference NN N
in IN N
dose NN N
. . N

-DOCSTART- -16923411- O O

Rationale NNP N
and CC N
design NN N
of IN N
the DT N
Folic NNP i
Acid NNP i
for IN N
Vascular NNP o
Outcome NNP o
Reduction NNP N
In IN N
Transplantation NNP N
( ( N
FAVORIT NNP N
) ) N
trial NN N
. . N

BACKGROUND NNP N
Patients NNPS p
with IN p
chronic JJ p
kidney NN p
disease NN p
, , p
including VBG p
kidney NN p
transplant NN p
recipients NNS p
, , N
are VBP N
at IN N
high JJ N
risk NN N
for IN N
cardiovascular JJ o
disease NN o
( ( o
CVD NNP o
) ) o
. . o

In IN N
addition NN N
to TO N
the DT N
constellation NN N
of IN N
traditional JJ N
CVD NNP N
risk NN N
factors NNS N
in IN N
chronic JJ N
kidney NN N
disease NN N
, , N
elevated VBD N
total JJ o
homocysteine NN o
( ( o
tHcy NN o
) ) o
is VBZ N
notably RB N
more RBR N
prevalent JJ N
among IN N
the DT N
general JJ N
population NN N
. . N

The DT i
Folic NNP i
Acid NNP i
for IN N
Vascular NNP N
Outcome NNP N
Reduction NNP N
In IN N
Transplantation NNP N
( ( N
FAVORIT NNP N
) ) N
trial NN N
is VBZ N
designed VBN N
to TO N
evaluate VB N
whether IN N
lowering VBG N
tHcy NN o
using VBG N
vitamin JJ i
supplementation NN i
reduces NNS N
CVD NNP o
events NNS o
in IN N
renal JJ p
transplant NN p
recipients NNS p
. . p

METHODS NNP N
FAVORIT NNP N
is VBZ N
a DT N
multicenter JJ N
double-blind NN N
randomized VBD N
controlled JJ N
clinical JJ N
trial NN N
. . N

Participants NNS p
are VBP p
clinically RB p
stable JJ p
renal JJ p
transplant NN p
recipients NNS p
who WP p
are VBP p
6 CD p
months NNS p
or CC p
longer JJR p
posttransplant NN p
with IN p
elevated JJ p
tHcy NN p
. . p

Patients NNS N
are VBP N
randomized VBN N
to TO N
a DT N
multivitamin NN i
that WDT i
includes VBZ i
either CC i
a DT i
high-dose JJ i
or CC i
low-dose JJ i
of IN i
folic JJ i
acid NN i
( ( N
5 CD N
or CC N
0 CD N
mg NN N
) ) N
, , N
vitamin FW i
B6 NNP i
( ( N
50 CD N
or CC N
1.4 CD N
mg NN N
) ) N
, , N
and CC i
vitamin NN i
B12 NNP i
( ( N
1000 CD N
or CC N
2 CD N
microg NN N
) ) N
. . N

The DT N
primary JJ N
end NN N
point NN N
is VBZ N
a DT N
composite NN o
of IN o
incident NN o
or CC o
recurrent NN o
CVD NNP o
outcomes RB o
, , o
that DT o
is VBZ o
, , o
coronary JJ o
heart NN o
, , o
cerebrovascular JJ o
, , o
or CC o
abdominal JJ o
aortic/lower NN o
extremity NN o
arterial JJ o
events NNS o
. . o

A DT N
sample JJ N
size NN N
of IN N
4000 CD N
is VBZ N
estimated VBN N
to TO N
provide VB N
87 CD N
% NN N
power NN N
to TO N
detect VB N
a DT N
20 CD N
% NN N
treatment NN N
effect NN N
. . N

Recruitment NN p
is VBZ p
expected VBN p
to TO p
continue VB p
until IN p
July NNP p
2006 CD p
, , N
with IN N
follow-up JJ N
through IN N
June NNP N
2010 CD N
. . N

RESULTS VB N
From IN p
August NNP p
2002 CD p
through IN p
December NNP p
2004 CD p
, , p
2234 CD p
of IN p
the DT p
target NN p
4000 CD p
patients NNS p
were VBD p
enrolled VBN p
. . p

In IN N
accordance NN N
with IN N
trial NN N
design NN N
, , N
mean NN o
( ( o
SD NNP o
) ) o
screening VBG o
tHcy NN o
was VBD N
elevated VBN N
( ( N
17.4 CD N
+/- JJ N
6.2 CD N
micromol/L NN N
) ) N
, , N
and CC N
mean NN o
( ( o
SD NNP o
) ) o
estimated VBD o
creatinine JJ o
clearance NN o
was VBD N
consistent JJ N
with IN N
stable JJ N
renal JJ N
function NN N
( ( N
58.0 CD N
+/- JJ N
18.6 CD N
mL/min NN N
) ) N
. . N

Evaluating VBG N
baseline JJ N
results NNS N
to TO N
date NN N
, , N
42 CD N
% NN N
of IN N
the DT N
randomized JJ N
participants NNS N
had VBD N
a DT N
history NN o
of IN o
diabetes NNS o
mellitus NNS o
, , N
and CC N
21 CD N
% NN N
had VBD N
prevalent JJ N
CVD NNP N
. . N

CONCLUSIONS NNP N
The DT N
FAVORIT NNP N
trial NN N
is VBZ N
designed VBN N
with IN N
sufficient JJ N
power NN N
and CC N
follow-up JJ N
time NN N
to TO N
detect VB N
a DT N
clinically RB N
relevant JJ N
change NN N
in IN N
CVD NNP N
risk NN N
between IN N
renal JJ p
transplant NN p
recipients NNS p
receiving VBG N
a DT N
high JJ N
or CC N
low JJ N
tHcy-lowering JJ N
folic JJ i
acid NN i
multivitamin NN i
. . i

Preliminary JJ N
screening NN N
and CC N
baseline NN N
data NNS N
support NN N
the DT N
trial NN N
's POS N
objectives NNS N
. . N

-DOCSTART- -15279417- O O

[ JJ N
Structural NNP N
and CC N
immunohistochemical JJ N
changes NNS N
of IN N
conjunctiva NN N
induced VBN N
by IN N
topical JJ N
glaucoma NN N
medication NN N
] NNP N
. . N

PURPOSE VB N
The DT N
topical JJ i
medication NN i
represents VBZ N
the DT N
first JJ N
line NN N
therapy NN N
for IN N
the DT N
primary JJ N
open JJ N
angle NN N
glaucoma NN N
. . N

The DT N
study NN N
is VBZ N
aimed VBN N
at IN N
assessing VBG N
the DT N
structural JJ N
and CC N
immunohistochemical JJ N
changes NNS N
of IN N
conjunctiva NN N
induced VBN N
by IN N
topical JJ i
glaucoma NN i
medication NN i
. . i

METHODS NNP N
For IN N
this DT N
purpose NN N
, , N
we PRP N
carried VBD N
out RP N
a DT N
40 CD N
weeks NNS N
, , N
prospective JJ N
, , N
experimental JJ N
, , N
epidemiological-operational JJ N
and CC N
randomized JJ N
study NN N
enrolling VBG N
18 CD p
patients NNS p
( ( p
36 CD p
eyes NNS p
) ) p
with IN p
recently RB p
primary JJ p
open JJ p
angle NN p
glaucoma NN p
. . p

The DT N
eyes NNS N
were VBD N
divided VBN N
into IN N
treatment NN N
( ( i
non-selective JJ i
beta NN i
blockers NNS i
or CC i
selective JJ i
, , i
prostaglandin JJ i
analogues NNS i
, , i
topical JJ i
carbonic JJ i
anhydrase NN i
inhibitors NNS i
) ) i
in IN N
four CD N
groups NNS N
. . N

The DT N
assessment NN N
was VBD N
performed VBN N
by IN N
comparison NN N
with IN N
control NN i
group NN p
( ( p
4 CD p
patients NNS p
) ) p
who WP p
was VBD p
instilled VBN p
with IN p
natural JJ i
tears NNS i
( ( p
with IN p
different JJ p
preservative NN p
) ) p
. . p

Both CC N
the DT N
cytology NN N
and CC N
the DT N
conjunctival NN N
biopsy NN N
specimens NNS N
were VBD N
investigated VBN N
by IN N
histological JJ N
exams NNS N
and CC N
immunohistochemistry NN N
using VBG N
different JJ N
monoclonal JJ N
antibodies NNS N
. . N

The DT N
study NN N
was VBD N
performed VBN N
by IN N
collaboration NN N
with IN N
The DT N
National NNP N
Institute NNP N
of IN N
Research NNP N
and CC N
Development NNP N
in IN N
Pathology NNP N
and CC N
Biomedical NNP N
Sciences- NNP N
V. NNP N
Babes NNP N
-Bucharest NNP N
. . N

RESULTS VB N
The DT N
morphometric JJ N
analysis NN N
of IN N
histological JJ N
sections NNS N
of IN N
conjunctiva NN N
showed VBD N
the DT N
following JJ N
changes NNS N
: : N
squamous JJ o
metaplasia NN o
( ( N
significant JJ N
increases NNS N
in IN N
the DT N
thickness NN o
and CC o
number NN o
of IN o
epithelial JJ o
cell NN o
layers NNS o
) ) o
, , o
inflammation NN o
( ( N
increase VB N
the DT N
number NN o
of IN o
lymphocytes NNS o
, , o
macrophages NNS o
and CC o
fibroblasts NNS o
) ) o
and CC o
subconjunctival JJ o
fibrosis NN o
. . o

According VBG N
to TO N
the DT N
type NN N
of IN N
medication NN N
, , N
we PRP N
observed VBD N
the DT N
significant JJ N
increase NN N
of IN N
subepithelial JJ o
collagen NN o
density NN o
and CC o
degenerative JJ o
changes NNS o
of IN o
fibrocytes NNS o
, , o
the DT o
reduction NN o
of IN o
extracellular JJ o
matrix NN o
and CC o
also RB o
the DT o
up-regulation NN o
of IN o
antibodies NNS o
against IN o
matrix JJ o
metalloproteinase NN o
and CC o
allergic JJ o
changes NNS o
. . o

According VBG N
to TO N
structural JJ N
changes NNS N
, , N
the DT N
immunohistochemistry NN N
confirmed VBD N
the DT N
tendency NN N
of IN N
chronic JJ o
inflammation NN o
. . o

CONCLUSIONS VB N
This DT N
study NN N
revealed VBD N
important JJ N
structural JJ N
and CC N
immunohistochemical JJ N
changes NNS N
of IN N
conjunctiva NN o
after IN N
topical JJ i
glaucoma NN i
medication NN i
. . i

The DT N
category NN N
and CC N
the DT N
intensity NN N
of IN N
these DT N
changes NNS N
are VBP N
dependent JJ N
on IN N
the DT N
sort NN N
of IN N
therapy NN N
and CC N
the DT N
topical JJ N
treatment NN N
period NN N
. . N

The DT N
findings NNS N
showed VBD N
that IN N
benzalkonium NN i
chloride NN i
( ( i
the DT i
most RBS i
common JJ i
preservative NN i
of IN i
antiglaucoma NN i
drugs NNS i
) ) i
is VBZ N
a DT N
major JJ N
factor NN N
for IN N
conjunctival NN N
metaplasia NN N
. . N

-DOCSTART- -26037484- O O

The DT N
Beyond NNP N
Ageing NNP N
Project NNP N
Phase NNP N
2 CD N
-- : N
a DT N
double-blind JJ N
, , N
selective JJ N
prevention NN N
, , N
randomised VBN N
, , N
placebo-controlled JJ N
trial NN N
of IN N
omega-3 JJ i
fatty JJ i
acids NNS i
and CC i
sertraline NN i
in IN N
an DT p
older JJR p
age NN p
cohort NN p
at IN p
risk NN p
for IN p
depression NN p
: : p
study NN N
protocol NN N
for IN N
a DT N
randomized VBN N
controlled VBN N
trial NN N
. . N

BACKGROUND NNP N
Late-life JJ p
depression NN p
is VBZ N
associated VBN N
with IN N
high JJ o
rates NNS o
of IN o
morbidity NN o
, , o
premature NN o
mortality NN o
, , o
disability NN o
, , o
functional JJ o
decline NN o
, , o
caregiver NN o
burden NN o
and CC o
increased VBD o
health NN o
care NN o
costs NNS o
. . o

While IN N
clinical JJ N
and CC N
public JJ N
health NN N
approaches NNS N
are VBP N
focused VBN N
on IN N
prevention NN N
or CC N
early JJ N
intervention NN N
strategies NNS N
, , N
the DT N
ideal JJ N
method NN N
of IN N
intervention NN N
remains VBZ N
unclear JJ N
. . N

No DT N
study NN N
has VBZ N
set VBN N
out RP N
to TO N
evaluate VB N
the DT N
role NN N
of IN N
neurobiological JJ N
agents NNS N
in IN N
preventing VBG N
depressive JJ N
symptoms NNS N
in IN N
older JJR N
populations NNS N
at IN N
risk NN N
of IN N
depression NN N
. . N

METHODS/DESIGN NNP N
Subjects VBZ p
with IN p
previously RB p
reported VBN p
sub-threshold JJ p
depressive NN p
symptoms NNS p
, , p
aged VBD p
60 CD p
to TO p
74 CD p
years NNS p
, , N
will MD N
be VB N
screened VBN N
to TO N
participate VB N
in IN N
a DT N
single-centre JJ N
, , N
double-blind JJ N
, , N
randomised VBD N
controlled VBN N
trial NN N
with IN i
three CD i
parallel JJ i
groups NNS i
involving VBG i
omega-3 JJ i
fatty JJ i
acid JJ i
supplementation NN i
or CC i
sertraline NN i
hydrochloride NN i
, , i
compared VBN i
with IN i
matching VBG i
placebo NN i
. . i

Subjects NNS p
will MD p
be VB p
excluded VBN p
if IN p
they PRP p
have VBP p
current JJ p
depression NN p
or CC p
suicide JJ p
ideation NN p
; : p
are VBP p
taking VBG p
antidepressants NNS p
or CC p
any DT p
supplement JJ p
containing VBG p
omega-3 JJ p
fatty JJ p
acid NN p
; : p
or CC p
have VBP p
a DT p
prior JJ p
history NN p
of IN p
stroke NN p
or CC p
other JJ p
serious JJ p
cerebrovascular NN p
or CC p
cardiovascular JJ p
disease NN p
, , p
neurological JJ p
disease NN p
, , p
significant JJ p
psychiatric JJ p
disease NN p
( ( p
other JJ p
than IN p
depression NN p
) ) p
or CC p
neurodegenerative JJ p
disease NN p
. . p

The DT N
trial NN N
will MD N
consist VB N
of IN N
a DT N
12 CD N
month NN N
treatment NN N
phase NN N
with IN N
follow-up NN N
at IN N
three CD N
months NNS N
and CC N
12 CD N
months NNS N
to TO N
assess VB N
outcome JJ N
events NNS N
. . N

At IN i
three CD i
months NNS i
, , i
subjects NNS i
will MD i
undergo VB i
structural JJ o
neuroimaging VBG o
to TO i
assess VB i
whether IN i
treatment NN i
effects NNS i
on IN i
depressive JJ i
symptoms NNS i
correlate VBP i
with IN i
brain NN i
changes NNS i
. . i

Additionally RB N
, , N
proton NN o
spectroscopy NN o
techniques NNS N
will MD N
be VB N
used VBN N
to TO N
capture VB N
brain-imaging JJ o
markers NNS o
of IN N
the DT N
biological JJ N
effects NNS N
of IN N
the DT N
interventions NNS N
. . N

The DT N
trial NN N
will MD N
be VB N
conducted VBN N
in IN N
urban JJ p
New NNP p
South NNP p
Wales NNP p
, , p
Australia NNP p
, , N
and CC N
will MD N
recruit VB N
a DT N
community-based JJ p
sample NN p
of IN p
450 CD p
adults NNS p
. . p

Using VBG N
intention-to-treat JJ N
methods NNS N
, , N
the DT N
primary JJ N
endpoint NN N
is VBZ N
an DT N
absence NN N
of IN N
clinically RB N
relevant JJ N
depression NN N
scores NNS N
at IN N
12 CD N
months NNS N
between IN N
the DT N
omega-3 JJ N
fatty JJ N
acid NN N
and CC N
sertraline JJ N
interventions NNS N
and CC N
the DT N
placebo NN N
condition NN N
. . N

DISCUSSION VB N
The DT N
current JJ N
health NN o
, , o
social JJ o
and CC o
economic JJ o
costs NNS o
of IN N
late-life JJ N
depression NN N
make VBP N
prevention NN N
imperative NN N
from IN N
a DT N
public JJ N
health NN N
perspective NN N
. . N

This DT N
innovative JJ N
trial NN N
aims NNS N
to TO N
address VB N
the DT N
long-neglected JJ N
area NN N
of IN N
prevention NN N
of IN N
depression NN N
in IN N
older JJR N
adults NNS N
. . N

The DT N
interventions NNS N
are VBP N
targeted VBN N
to TO N
the DT N
pathophysiology NN N
of IN N
disease NN N
, , N
and CC N
regardless RB N
of IN N
the DT N
effect NN N
size NN N
of IN N
treatment NN N
, , N
the DT N
outcomes NNS N
will MD N
offer VB N
major JJ N
scientific JJ N
advances NNS N
regarding VBG N
the DT N
neurobiological JJ N
action NN N
of IN N
these DT N
agents NNS N
. . N

The DT N
main JJ N
results NNS N
are VBP N
expected VBN N
to TO N
be VB N
available JJ N
in IN N
2017 CD N
. . N

TRIAL NNP N
REGISTRATION NNP N
Australian NNP N
and CC N
New NNP N
Zealand NNP N
Clinical NNP N
Trials NNP N
Registry NNP N
ACTRN12610000032055 NNP N
( ( N
12 CD N
January NNP N
2010 CD N
) ) N
. . N

-DOCSTART- -19701647- O O

Effects NNS N
of IN N
digoxin NN i
on IN N
muscle NN N
reflexes NNS N
in IN N
normal JJ p
humans NNS p
. . p

Blockade NNP N
of IN N
the DT N
skeletal JJ N
muscle NN N
Na NNP N
( ( N
+ NNP N
) ) N
-K NN N
( ( N
+ NNP N
) ) N
-ATPase NN N
pump NN N
by IN N
digoxin NN i
could MD N
result VB N
in IN N
a DT N
more RBR N
marked JJ N
hyperkaliema NN N
during IN N
a DT N
forearm JJ N
exercise NN N
, , N
which WDT N
in IN N
turn NN N
could MD N
stimulate VB N
the DT N
mechano- NN N
and CC N
metaboreceptors NNS N
. . N

In IN N
a DT N
randomized JJ N
, , N
double-blinded JJ N
, , N
placebo-controlled JJ N
, , N
and CC N
cross-over-design NN N
study NN N
, , N
we PRP N
measured VBD N
mean JJ o
blood NN o
pressure NN o
( ( o
MBP NNP o
) ) o
, , o
heart NN o
rate NN o
( ( o
HR NNP o
) ) o
, , o
ventilation NN o
( ( o
V NNP o
( ( o
E NNP o
) ) o
) ) o
, , o
oxygen JJ o
saturation NN o
( ( o
SpO NNP o
( ( o
2 CD o
) ) o
) ) o
, , o
muscle FW o
sympathetic JJ o
nerve NN o
activity NN o
( ( o
MSNA NNP o
) ) o
, , o
venous JJ o
plasma NN o
potassium NN o
and CC o
lactic JJ o
acid NN o
during IN o
dynamic JJ o
handgrip NN o
exercises NNS o
, , o
and CC o
local JJ o
circulatory NN o
arrest NN o
in IN N
11 CD p
healthy JJ p
subjects NNS p
. . p

Digoxin NNP i
enhanced VBD N
MBP NNP o
during IN N
exercise NN N
but CC N
not RB N
during IN N
the DT N
post-handgrip JJ N
ischemia NN N
and CC N
had VBD N
no DT N
effect NN N
on IN N
HR NNP o
, , o
V NNP o
( ( o
E NNP o
) ) o
, , o
SpO NNP o
( ( o
2 CD o
) ) o
, , o
and CC o
MSNA NNP o
. . o

Venous NNP o
plasma JJ o
potassium NN o
and CC o
lactic JJ o
acid NN o
were VBD N
also RB N
not RB N
affected VBN N
by IN N
digoxin-induced JJ i
skeletal JJ N
muscle NN N
Na NNP N
( ( N
+ NNP N
) ) N
-K NN N
( ( N
+ NNP N
) ) N
-ATPase NN N
blockade NN N
. . N

We PRP N
conclude VBP N
that IN N
digoxin NN i
increased VBD N
MBP NNP N
during IN N
dynamic JJ N
exercise NN N
in IN N
healthy JJ p
humans NNS p
, , N
independently RB N
of IN N
changes NNS N
in IN N
potassium NN N
and CC N
lactic JJ N
acid NN N
. . N

A DT N
modest JJ N
direct JJ N
sensitization NN N
of IN N
the DT N
muscle NN N
mechanoreceptors NNS N
is VBZ N
unlikely JJ N
and CC N
other JJ N
mechanisms NNS N
, , N
independent JJ N
of IN N
muscle NN N
reflexes NNS N
and CC N
related VBN N
to TO N
the DT N
inotropic JJ N
effects NNS N
of IN N
digoxin NN i
, , N
might MD N
be VB N
implicated VBN N
. . N

-DOCSTART- -21354925- O O

[ JJ N
Effects NNS N
of IN N
parecoxib NN i
on IN N
morphine JJ i
dosage NN N
in IN N
postoperative JJ p
patient-controlled JJ i
analgesia NN i
following VBG N
thoracoscope-assisted JJ i
thoracotomy JJ i
] NN i
. . N

OBJECTIVE UH N
To TO N
observe VB N
the DT N
effect NN N
of IN N
parecoxib NN i
on IN N
morphine JJ N
dosage NN N
in IN N
patient-controlled JJ i
analgesia NN i
( ( i
PCA NNP i
) ) i
following VBG N
thoracoscope-assisted JJ i
thoracotomy NN i
. . i

METHODS NNP N
A NNP p
consecutive JJ p
series NN p
of IN p
100 CD p
patients NNS p
undergoing JJ p
thoracoscope-assisted JJ i
thoracotomy NN i
were VBD N
randomized VBN N
into IN N
5 CD N
groups NNS N
and CC N
received VBD N
PCA NNP i
with IN i
morphine NN i
doses NNS N
at IN N
0 CD N
, , N
5 CD N
, , N
10 CD N
, , N
15 CD N
, , N
and CC N
20 CD N
mg NN N
given VBN N
in IN N
200 CD N
ml NNS N
saline NN i
( ( N
groups NNS N
P NNP N
( ( N
1 CD N
) ) N
, , N
P NNP N
( ( N
2 CD N
) ) N
, , N
P NNP N
( ( N
3 CD N
) ) N
, , N
P NNP N
( ( N
4 CD N
) ) N
, , N
and CC N
P NNP N
( ( N
5 CD N
) ) N
, , N
respectively RB N
) ) N
. . N

Parecoxib NNP i
( ( N
40 CD N
mg NN N
) ) N
was VBD N
given VBN N
in IN N
all PDT N
the DT N
patients NNS N
immediately RB N
before IN N
the DT N
operation NN N
, , N
and CC N
the DT N
mixture NN N
( ( i
4-5 JJ i
ml NN i
) ) i
of IN i
lidocaine NN i
and CC i
ropivacaine NN i
was VBD N
administered VBN N
into IN N
the DT N
3 CD N
intercostal JJ N
spaces NNS N
upper JJ N
and CC N
lower JJR N
to TO N
the DT N
incision NN N
before IN N
chest JJ N
closure NN N
. . N

PCA NNP i
was VBD N
administered VBN N
for IN N
each DT N
patient NN N
. . N

The DT N
visual JJ o
analogue NN o
scale NN o
( ( o
VAS NNP o
) ) o
at IN o
rest NN o
and CC N
coughing NN o
and CC o
the DT o
respiratory JJ o
functional JJ o
parameters NNS o
were VBD N
recorded VBN N
at IN N
1 CD N
, , N
2 CD N
, , N
4 CD N
, , N
8 CD N
, , N
12 CD N
, , N
24 CD N
, , N
36 CD N
, , N
and CC N
48 CD N
h NN N
after IN N
the DT N
start NN N
of IN N
PCA NNP i
, , N
and CC N
the DT N
actual JJ N
and CC N
effective JJ N
button-pressing NN N
times NNS N
( ( N
D NNP N
( ( N
1 CD N
) ) N
/D NN N
( ( N
2 CD N
) ) N
) ) N
in IN N
PCA NNP i
were VBD N
also RB N
recorded VBN N
. . N

RESULTS NNP N
No NNP N
patients NNS N
showed VBD N
signs NNS o
of IN o
respiratory NN o
inhibition NN o
within IN N
24 CD N
h NN N
after IN N
the DT N
operation NN N
, , N
and CC N
the DT N
resting VBG o
VAS NNP o
was VBD N
comparable JJ N
between IN N
the DT N
groups NNS N
within IN N
the DT N
initial JJ N
6 CD N
postoperative JJ N
hours NNS N
. . N

At IN N
8 CD N
to TO N
24 CD N
h NN N
postoperatively RB N
, , N
the DT N
VAS NNP o
scores NNS o
at IN N
rest NN N
and CC N
coughing VBG N
were VBD N
significantly RB N
higher JJR N
in IN N
P NNP N
( ( N
1 CD N
) ) N
group NN N
than IN N
in IN N
the DT N
other JJ N
groups NNS N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
, , N
and CC N
no DT N
significant JJ N
differences NNS N
were VBD N
found VBN N
between IN N
the DT N
groups NNS N
at IN N
36 CD N
to TO N
48 CD N
h. NN N
D NNP N
( ( N
1 CD N
) ) N
/D NN N
( ( N
2 CD N
) ) N
in IN N
groups NNS N
P NNP N
( ( N
1 CD N
) ) N
and CC N
P NNP N
( ( N
2 CD N
) ) N
were VBD N
significantly RB N
different JJ N
from IN N
those DT N
in IN N
the DT N
other JJ N
3 CD N
groups NNS N
at IN N
4-24 JJ N
h NN N
, , N
but CC N
no DT N
such JJ N
difference NN N
was VBD N
found VBN N
between IN N
groups NNS N
P NNP N
( ( N
3 CD N
) ) N
, , N
P NNP N
( ( N
4 CD N
) ) N
, , N
and CC N
P NNP N
( ( N
5 CD N
) ) N
. . N

CONCLUSION VB N
The DT N
application NN N
of IN N
parecoxib NN i
may MD N
reduce VB N
the DT N
dosage NN N
of IN N
morphine NN i
in IN N
PCA NNP i
following VBG N
thoracoscope-assisted JJ N
thoracotomy NNS N
and CC N
results NNS N
in IN N
good JJ N
analgesic JJ N
effect NN N
without IN N
affecting VBG N
the DT N
patients NNS N
respiratory JJ N
function NN N
and CC N
sputum JJ N
elimination NN N
. . N

-DOCSTART- -24032193- O O

[ JJ N
Treatment NNP N
of IN N
autism NN p
children NNS p
: : p
observation NN N
on IN N
efficacy NN o
of IN N
behavior JJ o
training NN o
with IN N
retention NN i
of IN i
needles NNS i
on IN i
head NN i
] NN i
. . N

OBJECTIVE UH N
To TO N
observe VB N
the DT N
effect NN N
difference NN N
of IN N
behavior JJ i
training NN i
with IN i
head NN i
needling VBG i
retention NN i
and CC i
behavior NN i
training NN i
after IN i
acupuncture NN i
for IN N
autism NN p
children NNS p
. . p

METHODS NNP N
Sixty NNP p
qualified VBD p
autism NN p
children NNS p
were VBD N
divided VBN N
randomly RB N
into IN N
simultaneous JJ N
head NN i
needling VBG i
retention NN i
and CC i
behavior JJ i
training NN i
group NN i
( ( N
trial NN N
group NN N
) ) N
and CC N
behavior JJ i
training NN i
after IN i
acupuncture NN i
treatment NN i
group NN i
( ( N
control VB N
group NN N
) ) N
with IN N
30 CD N
case NN N
in IN N
each DT N
group NN N
. . N

Retention NNP i
needles NNS i
on IN N
the DT N
head NN N
with IN N
simultaneous JJ N
behavior NN N
training NN N
was VBD N
applied VBN N
for IN N
the DT N
trial NN N
group NN N
. . N

The DT N
main JJ N
acupoints NNS N
included VBD N
Sishen NNP N
Xue NNP N
, , N
Dingshen NNP N
Sanxue NNP N
( ( N
3 CD N
points NNS N
for IN N
mental JJ N
tranquilization NN N
) ) N
, , N
Nao NNP N
Sanxue NNP N
( ( N
3 CD N
points NNS N
for IN N
the DT N
function NN N
of IN N
brain NN N
) ) N
, , N
Shou NNP N
Zhisanxue NNP N
( ( N
3 CD N
points NNS N
for IN N
mental JJ N
activities NNS N
on IN N
hand NN N
) ) N
and CC N
Zozhi NNP N
Sonxue NNP N
( ( N
3 CD N
points NNS N
for IN N
mental JJ N
activities NNS N
on IN N
foot NN N
) ) N
. . N

Other JJ N
points NNS N
were VBD N
combined VBN N
according VBG N
to TO N
conditions NNS N
of IN N
patients NNS N
. . N

Needles NNS N
on IN N
the DT N
4 CD N
extremities NNS N
were VBD N
withdrawn VBN N
first RB N
after IN N
30 CD N
minutes NNS N
, , N
needles NNS N
on IN N
head NN N
were VBD N
remained VBN N
during IN N
behavior JJ i
training NN i
. . i

While IN N
behavior JJ i
training NN i
was VBD N
applied VBN N
to TO N
the DT N
control NN N
group NN N
when WRB N
acupuncture NN N
treatment NN N
was VBD N
completely RB N
accomplished VBN N
. . N

Treatments NNS N
were VBD N
applied VBN N
once RB N
a DT N
day NN N
to TO N
both DT N
groups NNS N
. . N

And CC N
3 CD N
months NNS N
was VBD N
taken VBN N
as IN N
one CD N
observation NN N
cycle NN N
. . N

Estimation NN N
was VBD N
made VBN N
on IN N
therapeutic JJ o
effect NN o
and CC N
developing VBG o
level NN o
of IN o
autism NN o
children NNS o
with IN o
CARS NNP o
and CC o
PEP NNP o
. . o

RESULTS VB N
The DT N
total JJ o
effective JJ o
rate NN o
of IN N
the DT N
trial NN N
group NN N
was VBD N
83.3 CD N
% NN N
( ( N
25/30 CD N
) ) N
, , N
better JJR N
than IN N
66.7 CD N
% NN N
( ( N
20/30 CD N
) ) N
of IN N
the DT N
control NN N
group NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

The DT N
CARS NNPS o
scores NNS o
of IN N
both DT N
groups NNS N
declined VBD N
after IN N
the DT N
treatment NN N
. . N

And CC N
the DT N
score NN N
of IN N
trail NN N
group NN N
was VBD N
lower JJR N
than IN N
the DT N
control NN N
group NN N
( ( N
all DT N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

While IN N
the DT N
PEP NNP o
scores NNS o
of IN N
both DT N
groups NNS N
increased VBD N
, , N
and CC N
the DT N
score NN N
of IN N
trail NN N
group NN N
was VBD N
higher JJR N
than IN N
the DT N
control NN N
group NN N
( ( N
all DT N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

The DT N
increasing VBG N
level NN N
of IN N
scores NNS o
of IN o
cognitive JJ o
understanding NN o
and CC o
cognitive JJ o
expression NN o
were VBD N
all DT N
better JJR N
than IN N
the DT N
control NN N
group NN N
( ( N
all DT N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

CONCLUSION VB N
The DT N
effect NN N
of IN N
behavior JJ i
training NN i
with IN N
head NN N
needle JJ N
retention NN N
on IN N
autism NN p
children NNS p
is VBZ N
better JJR N
than IN N
behavior JJ i
training NN i
after IN i
acupuncture NN i
treatment NN N
, , N
especially RB N
in IN N
enhancing VBG o
cognition NN o
understanding NN o
and CC o
cognition NN o
expression NN o
. . o

-DOCSTART- -2074057- O O

[ JJ o
Therapy NNP o
with IN N
alpha-interferon NN i
in IN N
non-Hodgkin NN p
's POS p
lymphoma NN p
with IN p
a DT p
low JJ p
grade NN p
of IN p
malignancy NN p
( ( N
correct JJ N
title NN N
supplied VBD N
from IN N
Table NNP N
of IN N
Contents NNP N
) ) N
] NN N
. . N

-DOCSTART- -9862848- O O

The DT N
economic JJ N
impact NN N
of IN N
esophageal JJ p
variceal JJ p
hemorrhage NN p
: : p
cost-effectiveness JJ N
implications NNS N
of IN N
endoscopic NN N
therapy NN N
. . N

Esophageal NNP p
variceal JJ p
hemorrhage NN p
( ( p
EVH NNP p
) ) p
is VBZ N
a DT N
serious JJ N
and CC N
expensive JJ N
sequela NN N
of IN N
chronic JJ N
liver NN N
disease NN N
, , N
leading VBG N
to TO N
increased VBN N
utilization NN N
of IN N
resources NNS N
. . N

Today NN N
, , N
endoscopic NN i
sclerotherapy NN i
( ( i
ES NNP i
) ) i
and CC i
endoscopic JJ i
ligation NN i
( ( N
EL NNP N
) ) N
are VBP N
the DT N
accepted JJ N
, , N
community NN N
standards NNS N
of IN N
endoscopic JJ N
treatment NN N
of IN N
patients NNS p
with IN p
EVH NNP p
. . p

However RB N
, , N
there EX N
are VBP N
no DT N
published JJ N
studies NNS N
comparing VBG N
the DT N
economic JJ N
costs NNS N
of IN N
treating VBG N
EVH NNP N
using VBG N
these DT N
interventions NNS N
. . N

As IN N
part NN N
of IN N
a DT N
prospective JJ N
, , N
randomized JJ N
trial NN N
comparing VBG N
ES NNP N
and CC N
EL NNP N
for IN N
the DT N
treatment NN N
of IN N
EVH NNP N
, , N
we PRP N
estimated VBD N
the DT N
direct JJ o
costs NNS o
of IN o
health NN o
care NN o
utilization NN o
and CC o
cost-effectiveness NN o
for IN N
the DT N
prevention NN N
of IN N
variceal NN N
rebleeding NN N
and CC N
patient JJ N
survival NN N
at IN N
1-year JJ N
follow-up JJ N
. . N

Treatment NN N
groups NNS N
were VBD N
similar JJ N
in IN N
incidence NN p
of IN p
variceal NN o
rebleeding NN o
( ( p
41.9 CD p
% NN p
vs. FW p
42.9 CD p
% NN p
) ) p
, , p
variceal JJ o
obliteration NN o
( ( p
41.9 CD p
% NN p
vs. FW p
40.0 CD p
% NN p
) ) p
, , p
hospital JJ o
days NNS o
, , o
blood NN o
transfusions NNS o
, , o
shunt NN o
requirements NNS o
, , p
and CC p
survival NN o
( ( p
71.0 CD p
% NN p
vs. FW p
60.0 CD p
% NN p
) ) p
. . N

There EX N
were VBD N
significantly RB N
more RBR N
treatment NN o
failures NNS o
for IN N
active JJ o
bleeding NN o
using VBG N
EL NNP N
( ( N
42 CD N
% NN N
vs. FW N
0 CD N
% NN N
; : N
P NNP N
=.027 NNP N
) ) N
and CC N
esophageal JJ o
stricture NN o
formation NN o
in IN N
the DT N
ES-treated JJ N
patients NNS N
( ( N
19.4 CD N
% NN N
vs. FW N
2.9 CD N
% NN N
; : N
P NNP N
= NNP N
0.03 CD N
) ) N
. . N

Median JJ o
total JJ o
direct JJ o
cost NN o
outcomes NNS o
were VBD N
similar JJ N
between IN N
groups NNS N
( ( N
EL NNP N
= NNP N
$ $ N
9,696 CD N
and CC N
ES NNP N
= NNP N
$ $ N
13,197 CD N
; : N
P NNP N
=.46 NNP N
) ) N
. . N

EL NNP N
and CC N
ES NNP N
had VBD N
similar JJ N
cost/variceal NN o
rebleeding NN o
prevented VBD N
( ( N
$ $ N
28,678 CD N
vs. IN N
$ $ N
29,093 CD N
) ) N
and CC N
cost/survival NN o
( ( N
$ $ N
27,313 CD N
vs. IN N
$ $ N
23,804 CD N
) ) N
. . N

In IN N
the DT N
subgroup NN N
of IN N
active JJ N
bleeders NNS N
, , N
ES NNP N
had VBD N
a DT N
substantially RB N
lower JJR N
cost/survival NN o
( ( N
$ $ N
28,523 CD N
vs. IN N
$ $ N
51,696 CD N
) ) N
. . N

We PRP N
conclude VBP N
that DT N
resource NN N
utilization NN N
was VBD N
similar JJ N
between IN N
treatment NN N
groups NNS N
and CC N
that IN N
the DT N
choice NN N
of IN N
endoscopic NN N
therapy NN N
for IN N
EVH NNP N
must MD N
still RB N
rely VB N
on IN N
clinical JJ N
grounds NNS N
. . N

Further JJ N
studies NNS N
comparing VBG N
costs NNS N
and CC N
resource VB N
utilization NN N
in IN N
this DT N
patient JJ N
population NN N
are VBP N
needed VBN N
. . N

-DOCSTART- -21869698- O O

Symptomatic JJ N
and CC N
functional JJ N
improvement NN N
in IN N
employed NNS p
depressed JJ p
patients NNS p
: : p
a DT N
double-blind JJ N
clinical JJ N
trial NN N
of IN N
desvenlafaxine NN i
versus NN i
placebo NN i
. . i

OBJECTIVE VB N
This DT N
is VBZ N
the DT N
first JJ N
study NN N
to TO N
assess VB N
the DT N
efficacy NN N
of IN N
desvenlafaxine NN i
( ( N
administered VBN N
as IN N
desvenlafaxine JJ i
succinate NN i
) ) i
for IN N
improving VBG N
depressive JJ o
symptoms NNS o
and CC o
functioning VBG o
exclusively RB N
in IN N
employed JJ p
patients NNS p
with IN p
major JJ p
depressive JJ p
disorder NN p
( ( p
MDD NNP p
) ) p
. . p

METHODS NNP N
Gainfully NNP p
employed VBD p
( ( p
?20 NNP p
h/wk NN p
) ) p
male NN p
and CC p
female JJ p
outpatients NNS p
with IN p
MDD NNP p
were VBD p
randomly RB p
assigned VBN p
( ( p
2:1 CD p
ratio NN p
) ) p
to TO p
12 CD p
weeks NNS p
of IN p
double-blind JJ p
treatment NN p
with IN i
desvenlafaxine JJ i
50 CD i
mg/d NN p
or CC p
placebo NN i
. . i

Analysis NN N
of IN N
covariance NN N
was VBD N
used VBN N
to TO N
compare VB N
differences NNS N
in IN N
week NN N
12 CD N
adjusted VBN N
mean JJ N
changes NNS N
from IN N
baseline NN N
on IN N
the DT N
17-item JJ N
Hamilton NNP N
Depression NNP N
Rating NNP N
Scale NNP N
( ( N
HAM-D?? NNP N
) ) N
( ( N
primary JJ N
outcome NN N
) ) N
and CC N
Sheehan NNP N
Disability NNP N
Scale NNP N
( ( N
SDS NNP N
) ) N
( ( N
key JJ N
secondary JJ N
outcome NN N
) ) N
in IN N
the DT N
intent-to-treat NN N
( ( N
ITT NNP N
) ) N
population NN p
. . p

A DT p
predefined JJ p
, , p
modified VBD p
ITT NNP p
population NN p
( ( p
ie JJ p
, , p
those DT p
in IN p
the DT p
ITT NNP p
population NN p
with IN p
baseline JJ p
HAM-D?? NNP p
?20 NN p
) ) p
was VBD p
also RB N
analyzed VBN N
. . N

Tolerability NNP N
was VBD N
assessed VBN N
by IN N
recording VBG N
adverse JJ N
events NNS N
and CC N
change NN N
on IN N
the DT N
Arizona NNP N
Sexual NNP N
Experience NNP N
Scale NNP N
. . N

RESULTS NNP o
Baseline NNP o
HAM-D?? NNP o
scores NNS o
for IN o
desvenlafaxine NN o
( ( i
n JJ i
= NNP i
285 CD i
) ) i
and CC i
placebo NN i
( ( i
n JJ i
= NNP N
142 CD N
) ) N
were VBD N
22.0 CD N
and CC N
21.8 CD N
, , N
whereas NNS N
baseline VBP N
SDS NNP N
scores NNS N
were VBD N
19.8 CD N
and CC N
20.4 CD o
. . o

Adjusted VBN o
mean JJ o
differences NNS o
between IN o
desvenlafaxine NN i
and CC i
placebo NN i
were VBD i
2.1 CD N
( ( N
95 CD N
% NN N
confidence NN N
interval NN N
[ NNP N
CI NNP N
] NNP N
, , N
0.78-3.46 NNP N
; : N
P NNP N
= NNP N
0.002 CD N
) ) N
on IN N
the DT N
HAM-D?? NNP N
and CC N
1.3 CD N
( ( N
95 CD N
% NN N
CI NNP N
, , N
-0.09 NNP N
to TO N
2.76 CD N
; : N
P NNP N
= NNP N
0.067 CD N
) ) N
on IN N
the DT N
SDS NNP N
. . N

For IN N
the DT N
modified JJ N
ITT NNP N
sample NN N
, , N
desvenlafaxine NN i
( ( i
n JJ i
= NNP i
208 CD i
) ) i
and CC i
placebo NN i
( ( N
n JJ N
= NNP N
102 CD N
) ) N
, , N
baseline JJ N
HAM-D?? JJ o
scores NNS o
were VBD o
23.8 CD N
and CC N
23.9 CD N
; : N
the DT N
SDS NNP o
baseline NN o
scores NNS o
were VBD N
20.1 CD N
and CC N
20.8 CD N
. . N

Mean JJ N
differences NNS N
were VBD N
2.6 CD N
( ( N
95 CD N
% NN N
CI NNP N
, , N
0.93-4.22 NNP N
; : N
P NNP N
= NNP N
0.002 CD N
) ) N
on IN N
the DT o
HAM-D?? NNP o
and CC N
2.1 CD N
( ( N
95 CD N
% NN N
CI NNP N
, , N
0.36-3.76 NNP N
; : N
P NNP N
= NNP N
0.017 CD N
) ) N
on IN N
the DT N
SDS NNP o
. . o

Adverse JJ o
events NNS o
and CC o
Arizona NNP o
Sexual NNP o
Experience NNP o
Scale NNP o
scores NNS o
were VBD o
comparable JJ N
between IN N
groups NNS N
. . N

CONCLUSIONS NNP N
Desvenlafaxine NNP i
50 CD N
mg/d NN N
was VBD N
efficacious JJ N
for IN N
treating VBG N
MDD NNP p
in IN p
gainfully RB p
employed VBN p
adults NNS p
. . p

Between-group NNP N
differences NNS N
on IN N
the DT N
SDS NNP N
narrowly RB N
missed VBD N
statistical JJ N
significance NN N
in IN N
the DT N
ITT NNP N
population NN N
alone RB N
, , N
but CC N
the DT N
totality NN N
of IN N
data NNS N
suggests NNS N
functional JJ N
improvements NNS N
with IN N
active JJ N
treatment NN N
. . N

-DOCSTART- -22884754- O O

Effect NN N
of IN N
antipsychotic JJ i
drugs NNS i
on IN N
cortical JJ o
thickness NN o
. . o

A DT N
randomized JJ N
controlled VBN N
one-year JJ N
follow-up NN N
study NN N
of IN N
haloperidol NN i
, , i
risperidone NN i
and CC i
olanzapine NN i
. . i

BACKGROUND NNP N
Imaging NNP N
evidence NN N
indicates VBZ N
that IN N
brain NN N
alterations NNS N
are VBP N
primary JJ N
to TO N
the DT N
full-blown JJ N
onset NN N
of IN N
schizophrenia NN N
and CC N
seem VBP N
to TO N
progress VB N
across IN N
time NN N
. . N

The DT N
potential JJ N
effects NNS o
of IN o
antipsychotic JJ o
medication NN o
on IN N
brain NN N
structure NN N
represent VBP N
a DT N
key JJ N
factor NN N
in IN N
understanding VBG N
brain NN N
changes NNS N
in IN N
psychosis NN N
. . N

We PRP N
aimed VBD N
to TO N
investigate VB N
the DT N
effects NNS N
of IN N
low JJ N
doses NNS N
of IN N
haloperidol NN i
, , i
risperidone NN i
and CC i
olanzapine NN i
on IN N
cortical JJ o
thickness NN o
. . o

METHOD NNP N
We PRP N
investigated VBD N
the DT N
effects NNS N
of IN N
risperidone NN i
( ( p
N=16 NNP p
) ) p
, , p
olanzapine JJ i
( ( p
N=18 NNP p
) ) p
and CC p
low JJ p
doses NNS p
of IN p
haloperidol NN i
( ( p
N=18 NNP p
) ) p
in IN N
cortical JJ o
thickness NN o
changes NNS N
during IN N
1-year JJ N
follow-up JJ N
period NN N
in IN N
a DT N
large JJ p
and CC p
heterogeneous JJ p
sample NN p
of IN p
schizophrenia NN p
spectrum NN p
patients NNS p
. . p

The DT N
relationship NN N
between IN N
cortical JJ o
thickness NN o
changes NNS o
and CC N
clinical JJ o
and CC o
cognitive JJ o
outcome NN o
was VBD N
also RB N
assessed VBN N
. . N

A DT N
group NN p
of IN p
45 CD p
healthy JJ p
volunteers NNS p
was VBD p
also RB p
longitudinally RB p
evaluated VBN p
. . p

Magnetic JJ N
resonance NN N
imaging VBG N
brain NN N
scans NNS N
( ( N
1.5T CD N
) ) N
were VBD N
obtained VBN N
and CC N
images NNS N
were VBD N
analyzed VBN N
by IN N
using VBG N
BRAINS2 NNP N
. . N

RESULTS NNP N
There EX N
were VBD N
no DT N
significant JJ N
effects NNS N
of IN N
time NN N
( ( N
F NNP N
( ( N
1,47 CD N
) ) N
< NN N
1.66 CD N
; : N
P NNP N
> NNP N
0.204 CD N
) ) N
, , N
treatment NN N
group NN N
( ( N
F NNP N
( ( N
2,47 CD N
) ) N
< NN N
1.47 CD N
; : N
P NNP N
> NNP N
0.242 CD N
) ) N
or CC N
group-by-time JJ N
interaction NN N
( ( N
F NNP N
( ( N
2,47 CD N
) ) N
< NN N
1.82 CD N
; : N
P NNP N
> NNP N
0.174 CD N
) ) N
for IN N
any DT N
of IN N
the DT N
cortical JJ o
thickness NN o
variables NNS o
. . o

When WRB N
the DT N
group NN N
of IN N
healthy JJ N
controls NNS N
was VBD N
included VBN N
in IN N
the DT N
analyses NNS N
, , N
it PRP N
is VBZ N
of IN N
note NN N
that IN N
group-by-time JJ N
interaction NN N
showed VBD N
a DT N
significant JJ N
result NN N
for IN N
the DT N
frontal JJ N
lobe NN N
at IN N
trend NN N
level NN N
( ( N
F NNP N
( ( N
3,81 CD N
) ) N
=2.686 NN N
; : N
P=0.052 NNP N
) ) N
. . N

After IN N
the DT N
Bonferroni NNP N
adjustment NN N
for IN N
multiple JJ N
comparisons NNS N
, , N
there EX N
were VBD N
no DT N
significant JJ N
associations NNS N
between IN N
changes NNS o
in IN o
cortical JJ o
thickness NN o
and CC N
clinical JJ o
and CC o
cognitive JJ o
outcome NN o
. . o

CONCLUSIONS NNP N
Low NNP N
doses NNS N
of IN N
haloperidol NN i
, , i
risperidone NN i
, , i
and CC i
olanzapine NN i
seem VBP N
to TO N
equally RB N
affect VB N
gray JJ o
matter NN o
cortical JJ o
thickness NN o
, , o
overall JJ o
and CC o
lobes JJ o
, , N
at IN N
the DT N
medium-term NN N
( ( N
1 CD N
year NN N
) ) N
. . N

The DT N
clinical JJ N
effectiveness NN N
of IN N
treatments NNS N
was VBD N
not RB N
significantly RB N
related VBN N
to TO N
changes NNS N
in IN N
cortical JJ o
thickness NN o
. . o

-DOCSTART- -9164427- O O

Clinical JJ N
effects NNS N
of IN N
buspirone NN i
in IN N
social JJ N
phobia NN N
: : N
a DT N
double-blind JJ N
placebo-controlled JJ N
study NN N
. . N

BACKGROUND NNP N
The DT N
results NNS N
of IN N
open JJ N
pilot NN N
studies NNS N
suggest VBP N
that IN N
the DT N
serotonin-1A JJ i
( ( i
5-HT1A JJ i
) ) i
receptor NN i
agonist VBP i
buspirone NN i
might MD N
be VB N
effective JJ N
in IN N
social JJ N
phobia NN N
. . N

METHOD NNP N
In IN N
the DT N
present JJ N
study NN N
, , N
the DT N
efficacy NN o
of IN N
buspirone NN i
was VBD N
investigated VBN N
in IN N
patients NNS p
with IN p
social JJ p
phobia NN p
using VBG N
a DT N
12-week JJ N
double-blind JJ N
placebo-controlled JJ i
design NN N
. . N

Thirty NNP p
social JJ p
phobic NN p
patients NNS p
( ( p
DSM-IV NNP p
) ) p
were VBD N
treated VBN N
with IN N
either DT N
buspirone NN i
30 CD i
mg JJ i
daily JJ i
or CC i
placebo NN i
. . i

Efficacy NN N
of IN N
treatment NN N
was VBD N
measured VBN N
using VBG N
the DT N
Social NNP o
Phobia NNP o
Scale NNP o
( ( o
subscores NNS o
anxiety NN o
and CC o
avoidance NN o
) ) o
and CC N
the DT N
Hamilton NNP o
Rating NNP o
Scale NNP o
for IN o
Anxiety NNP o
. . o

RESULTS NNP N
Taking VBG N
a DT N
reduction NN o
of IN N
50 CD N
% NN N
or CC N
more JJR N
on IN N
the DT N
Social NNP o
Phobia NNP o
Scale NNP o
as IN N
a DT N
criterion NN N
for IN N
clinically RB N
relevant JJ N
improvement NN N
, , N
only RB N
1 CD N
patient NN N
on IN N
buspirone NN N
and CC N
1 CD N
on IN N
placebo NN N
were VBD N
classified VBN N
as IN N
responder NN o
to TO N
treatment NN N
. . N

A DT N
subjective JJ N
and CC N
clinically RB N
relevant JJ o
improvement NN o
was VBD N
reported VBN N
by IN N
4 CD N
patients NNS N
( ( N
27 CD N
% NN N
) ) N
on IN N
buspirone NN N
and CC N
2 CD N
patients NNS N
( ( N
13 CD N
% NN N
) ) N
on IN N
placebo NN i
. . i

There EX N
were VBD N
no DT N
statistically RB N
significant JJ N
differences NNS N
between IN N
buspirone NN i
and CC i
placebo NN i
on IN N
any DT N
of IN N
the DT N
outcome NN N
measures NNS N
. . N

Generally NNP N
speaking NN N
, , N
buspirone NN N
was VBD N
well RB o
tolerated VBN o
. . o

CONCLUSION VB N
The DT N
results NNS N
of IN N
the DT N
study NN N
do VBP N
not RB N
support VB N
the DT N
results NNS N
of IN N
open JJ N
studies NNS N
, , N
in IN N
which WDT N
a DT N
reduction NN N
of IN N
social JJ o
anxiety NN o
and CC o
social JJ o
avoidance NN o
was VBD N
reported VBN N
in IN N
patients NNS p
with IN p
social JJ p
phobia NNS p
treated VBN p
with IN p
buspirone NN i
. . i

-DOCSTART- -21998264- O O

Changes NNS N
in IN N
H NNP N
reflex NN N
and CC N
V NNP N
wave VBP N
following VBG N
short-term JJ i
endurance NN i
and CC i
strength NN i
training NN i
. . i

This DT N
study NN N
examined VBD N
the DT N
effects NNS N
of IN N
3 CD N
wk NN N
of IN N
either DT N
endurance NN i
or CC i
strength NN i
training NN i
on IN N
plasticity NN N
of IN N
the DT N
neural JJ N
mechanisms NNS N
involved VBN N
in IN N
the DT N
soleus NN N
H NNP N
reflex NN N
and CC N
V NNP N
wave VBP N
. . N

Twenty-five JJ p
sedentary JJ p
healthy JJ p
subjects NNS p
were VBD N
randomized VBN N
into IN N
an DT N
endurance NN i
group NN i
( ( N
n JJ N
= NNP N
13 CD N
) ) N
or CC N
strength NN i
group NN i
( ( N
n JJ N
= NNP N
12 CD N
) ) N
. . N

Evoked VBN N
V-wave JJ N
, , N
H-reflex NNP N
, , N
and CC N
M-wave NNP N
recruitment NN N
curves NNS N
, , N
maximal JJ N
voluntary JJ N
contraction NN N
( ( N
MVC NNP N
) ) N
, , N
and CC N
time-to-task-failure NN N
( ( N
isometric JJ N
contraction NN N
at IN N
40 CD N
% NN N
MVC NNP N
) ) N
of IN N
the DT N
plantar NN N
flexors NNS N
were VBD N
recorded VBN N
before IN N
and CC N
after IN N
training VBG N
. . N

Following VBG N
strength NN i
training NN i
, , N
MVC NNP o
of IN o
the DT o
plantar NN o
flexors NNS o
increased VBN N
by IN N
14.4 CD N
? . N
5.2 CD N
% NN N
in IN N
the DT N
strength NN N
group NN N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
whereas JJ N
time-to-task-failure NN N
was VBD N
prolonged VBN N
in IN N
the DT N
endurance NN N
group NN N
( ( N
22.7 CD N
? . N
17.1 CD N
% NN N
; : N
P NNP N
< NNP N
0.05 CD o
) ) o
. . o

The DT o
V NNP o
wave-to-maximal JJ o
M NNP o
wave NN o
( ( o
V/M NNP o
( ( o
max NN o
) ) o
) ) o
ratio NN o
increased VBN o
significantly RB N
( ( N
55.1 CD N
? . N
28.3 CD N
% NN N
; : N
P NNP N
< NNP N
0.001 CD N
) ) N
following VBG N
strength NN N
training NN N
, , N
but CC N
the DT N
maximal JJ o
H NNP o
wave-to-maximal JJ o
M NNP o
wave NN o
( ( o
H NNP o
( ( o
max NN o
) ) o
/M NN o
( ( o
max NN o
) ) o
) ) o
ratio NN o
remained VBD o
unchanged JJ N
. . N

Conversely RB N
, , N
in IN N
the DT N
endurance NN N
group NN N
the DT N
V/M NNP o
( ( o
max NN o
) ) o
ratio NN o
was VBD o
not RB N
altered VBN N
, , N
whereas IN N
the DT N
H NNP o
( ( o
max NN o
) ) o
/M NN o
( ( o
max NN o
) ) o
ratio NN o
increased VBN o
by IN N
30.8 CD N
? . N
21.7 CD N
% NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

The DT N
endurance NN i
training NN i
group NN i
also RB N
displayed VBD N
a DT N
reduction NN N
in IN N
the DT N
H-reflex NNP o
excitability NN o
threshold NN o
while IN o
the DT N
H-reflex NNP N
amplitude NN N
on IN N
the DT N
ascending VBG N
limb NN N
of IN N
the DT N
recruitment NN N
curve NN N
increased VBD N
. . N

Strength NNP N
training VBG N
only RB N
elicited VBD N
a DT N
significant JJ N
decrease NN o
in IN o
H-reflex NNP o
excitability NN o
threshold NN o
, , o
while IN o
H-reflex NNP o
amplitudes NNS o
over IN o
the DT N
ascending VBG o
limb NN o
remained VBD o
unchanged JJ N
. . N

These DT N
observations NNS N
indicate VBP N
that IN N
the DT N
H-reflex NNP N
pathway NN N
is VBZ N
strongly RB N
involved VBN N
in IN N
the DT N
enhanced JJ o
endurance NN o
resistance NN o
that WDT o
occurs VBZ N
following VBG i
endurance NN i
training NN i
. . i

On IN i
the DT N
contrary JJ N
, , N
the DT N
improvements NNS o
in IN o
MVC NNP o
following VBG N
strength NN N
training NN N
are VBP N
likely JJ N
attributed VBN N
to TO N
increased VBN N
descending VBG N
drive NN N
and/or NN N
modulation NN N
in IN N
afferents NNS N
other JJ N
than IN N
Ia JJ N
afferents NNS N
. . N

-DOCSTART- -6418295- O O

Blood NNP N
pressure NN N
control NN N
during IN N
weight JJ N
reduction NN N
in IN N
obese JJ p
hypertensive JJ p
men NNS p
: : p
separate JJ N
effects NNS N
of IN N
sodium NN N
and CC N
energy NN N
restriction NN N
. . N

The DT N
separate JJ N
and CC N
combined JJ N
effects NNS N
of IN N
dietary JJ N
energy NN N
and CC N
sodium JJ i
restriction NN i
on IN N
regulation NN N
of IN N
blood NN o
pressure NN o
were VBD N
investigated VBN N
in IN N
30 CD p
middle NNS p
aged VBN p
obese JJ p
men NNS p
with IN p
essential JJ p
hypertension NN p
attending VBG p
the DT p
outpatient JJ p
department NN p
. . p

In IN N
group NN p
1 CD p
( ( N
n JJ N
= NNP N
15 CD N
) ) N
a DT N
basal JJ N
period NN N
with IN N
no DT i
dietary JJ i
restriction NN i
was VBD N
followed VBN N
by IN N
a DT N
period NN N
taking VBG N
an DT i
energy NN i
reduced VBN i
diet JJ i
( ( N
5.1 CD N
MJ NNP N
; : N
1230 CD N
kcal NN N
) ) N
, , N
the DT N
sodium NN i
intake NN i
being VBG i
supplemented VBN i
and CC i
hence RB i
unchanged JJ i
( ( N
1 CD N
: : N
ErSn NN N
) ) N
. . N

In IN N
group NN p
2 CD p
( ( N
n JJ N
= NNP N
15 CD N
) ) N
the DT N
basal JJ N
period NN N
preceded VBD N
a DT N
control NN N
period NN N
with IN N
no DT i
intervention NN i
, , i
which WDT i
was VBD i
followed VBN i
by IN i
taking VBG i
a DT i
diet JJ i
restricted VBN i
in IN i
energy NN i
( ( N
5.1 CD N
MJ NNP N
; : N
1220 CD N
kcal NN N
) ) N
and CC N
sodium NN i
( ( N
2 CD N
: : N
ErSr NN N
) ) N
. . N

During IN N
period NN N
1 CD N
: : N
ErSn NN N
there EX N
were VBD N
reductions NNS N
in IN N
heart NN o
rate NN o
and CC o
urinary JJ o
noradrenaline NN o
output NN o
but CC N
not RB N
in IN N
systolic JJ o
or CC o
diastolic JJ o
blood NN o
pressure NN o
. . o

Body NNP o
weight VBD o
decreased VBN N
by IN N
4.9-11.7 JJ N
kg NN N
and CC N
urinary JJ o
sodium NN o
excretion NN o
did VBD N
not RB N
change NN N
. . N

In IN N
period NN N
2 CD N
: : N
ErSr NNP N
urinary JJ o
sodium NN o
output NN o
was VBD N
reduced VBN N
by IN N
81.4 CD N
( ( N
SEM NNP N
17.8 CD N
) ) N
mmol NN N
( ( N
mEq NN N
) ) N
/24 NN N
h NN N
and CC N
there EX N
was VBD N
a DT N
weight JJ o
loss NN o
of IN N
8.2 CD N
( ( N
SEM NNP N
0.7 CD N
) ) N
kg NN N
. . N

Systolic NNP o
and CC o
diastolic JJ o
blood NN o
pressures NNS o
fell VBD N
significantly RB N
, , N
as IN N
did VBD N
the DT N
heart NN o
rate NN o
and CC N
urinary JJ o
noradrenaline NN o
excretion NN o
. . o

These DT N
results NNS N
show VBP N
that IN N
in IN N
hypertensive JJ p
obese JJ p
men NNS p
a DT N
moderate JJ N
weight NN N
reducing VBG N
diet JJ N
decreases NNS N
indices NNS N
of IN N
sympathetic JJ o
nervous JJ o
system NN o
activity NN o
. . o

Reduction NN N
of IN N
blood NN o
pressure NN o
to TO N
the DT N
normotensive JJ N
range NN N
was VBD N
observed VBN N
only RB N
when WRB N
there EX N
was VBD N
a DT N
concomitant JJ N
restriction NN N
of IN N
sodium NN N
intake NN N
. . N

-DOCSTART- -3556337- O O

Effects NNS N
of IN N
nifedipine NN i
on IN N
gastric JJ o
acid JJ o
secretion NN o
and CC p
gastrin NN o
release NN o
in IN p
man NN p
. . p

As IN N
calcium NN N
is VBZ N
important JJ N
in IN N
the DT N
regulation NN N
of IN N
gastric JJ N
acid JJ N
secretion NN N
and CC N
gastrin NN N
release NN N
, , N
we PRP N
have VBP N
examined VBN N
the DT N
effect NN N
of IN N
the DT N
calcium NN N
antagonist NN N
nifedipine NN i
on IN N
these DT N
processes NNS N
in IN N
man NN p
. . p

Nifedipine CC i
30 CD N
mg NNS N
orally RB N
inhibited VBN N
basal NN N
acid NN N
output NN N
by IN N
37 CD N
% NN N
( ( N
p NN N
less JJR N
than IN N
0.025 CD N
) ) N
and CC N
that IN N
stimulated VBN N
by IN N
low JJ N
infusion NN N
rates NNS N
of IN N
pentagastrin NN i
-- : i
that WDT i
is VBZ N
, , N
0.031 CD N
and CC N
0.062 CD N
microgram/kg/h NN N
by IN N
44 CD N
% NN N
( ( N
p JJ N
= NNP N
0.05 CD N
) ) N
and CC N
39 CD N
% NN N
( ( N
p NN N
less JJR N
than IN N
0.02 CD N
) ) N
respectively RB N
. . N

On IN N
increasing VBG N
the DT N
pentagastrin JJ i
infusion NN N
rate NN N
the DT N
inhibition NN N
was VBD N
surmounted VBN N
suggesting VBG N
it PRP N
was VBD N
competitive JJ N
in IN N
type NN N
. . N

Nifedipine NNP i
did VBD N
not RB N
affect VB N
basal NN o
or CC o
Oxo NNP o
meal NN o
stimulated VBD o
gastrin JJ o
concentrations NNS o
in IN N
normal JJ p
volunteers NNS p
nor CC N
did VBD N
it PRP N
affect VB N
resting VBG o
serum JJ o
gastrin NN o
or CC o
calcium NN o
stimulated JJ o
increase NN o
in IN o
gastrin NN o
in IN N
a DT N
single JJ p
patient NN p
with IN p
Zollinger-Ellison NNP p
syndrome NN p
. . p

These DT N
findings NNS N
are VBP N
consistent JJ N
with IN N
the DT N
transmembrane NN N
flux NN N
of IN N
calcium NN N
ions NNS N
being VBG N
involved VBN N
in IN N
basal NN N
and CC N
pentagastrin NN p
stimulated VBD p
acid JJ p
secretion NN p
in IN p
man NN p
. . p

-DOCSTART- -22244705- O O

The DT N
relationship NN N
of IN N
alexithymia NN N
to TO N
emotional JJ N
dysregulation NN N
within IN N
an DT N
alcohol NN p
dependent JJ p
treatment NN p
sample NN p
. . p

Difficulties NNS N
regulating VBG N
emotions NNS N
have VBP N
implications NNS N
for IN N
the DT N
development NN N
, , N
maintenance NN N
, , N
and CC N
recovery NN N
from IN N
alcohol NN p
problems NNS p
. . p

One CD N
construct NN N
thought NN N
to TO N
impede VB N
the DT N
regulation NN N
of IN N
emotion NN N
is VBZ N
alexithymia JJ N
. . N

Alexithymia NNP N
is VBZ N
characterized VBN N
by IN N
difficulties NNS N
identifying VBG N
, , N
differentiating VBG N
and CC N
expressing VBG N
feelings NNS N
, , N
a DT N
limited JJ N
imagination NN N
and CC N
fantasy JJ N
life NN N
, , N
and CC N
an DT N
externally-oriented JJ N
thinking NN N
style NN N
( ( N
e.g. UH N
, , N
prefer VBP N
talking VBG N
about IN N
daily JJ N
activities NNS N
rather RB N
than IN N
feelings NNS N
) ) N
. . N

Given VBN N
that IN N
poor JJ N
emotion NN N
regulation NN N
skills NNS N
have VBP N
been VBN N
found VBN N
to TO N
predict VB N
posttreatment NN p
levels NNS p
of IN p
alcohol NN p
use NN p
, , N
and CC N
that IN N
several JJ N
defining VBG N
characteristics NNS N
of IN N
alexithymia JJ N
bear JJ N
similarity NN N
to TO N
deficits NNS N
in IN N
emotion NN N
regulation NN N
skills NNS N
, , N
it PRP N
is VBZ N
possible JJ N
that IN N
alexithymia NN N
may MD N
predict VB N
poorer JJR N
alcohol NN N
treatment NN N
outcomes NNS N
. . N

Thus RB N
, , N
the DT N
present JJ N
study NN N
first RB N
examined VBD N
the DT N
relationship NN N
of IN N
alexithymia NN i
to TO N
several JJ N
other JJ N
emotion NN o
regulation NN o
measures NNS o
and CC N
then RB N
investigated VBD N
the DT N
impact NN N
of IN N
alexithymia NN i
on IN N
attrition NN N
and CC N
alcohol NN N
treatment NN N
outcomes NNS N
in IN N
men NNS p
and CC p
women NNS p
( ( p
N=77 NNP p
) ) p
enrolled VBD p
in IN p
a DT p
12-week JJ i
cognitive-behavioral JJ i
intervention NN i
for IN i
alcohol NN i
dependence NN i
. . i

At IN N
baseline NN N
, , N
higher JJR N
scores NNS N
on IN N
alexithymia NN N
were VBD N
associated VBN N
poorer JJR o
emotion NN o
regulation NN o
skills NNS o
, , o
fewer JJR o
percent NN o
days NNS o
abstinent NN o
, , o
greater JJR o
alcohol NN o
dependence NN o
severity NN o
, , o
and CC o
several JJ o
high-risk JJ o
drinking NN o
situations NNS o
. . o

Alexithymia NNP N
was VBD N
unrelated JJ N
to TO N
attrition NN N
and CC N
to TO N
level NN N
of IN N
alcohol NN N
consumption NN N
at IN N
posttreatment NN N
. . N

Overall UH N
, , N
the DT N
construct NN N
of IN N
alexithymia NN N
is VBZ N
shown VBN N
to TO N
be VB N
related VBN N
to TO N
several JJ N
theoretically-related JJ N
constructs NNS N
( ( N
e.g. NN N
, , N
emotion NN N
regulation NN N
, , N
mindfulness NN N
) ) N
but CC N
demonstrated VBD N
a DT N
limited JJ N
relationship NN N
to TO N
drinking VBG N
outcomes NNS N
in IN N
those DT p
seeking VBG p
treatment NN p
for IN p
alcohol NN p
dependence NN p
. . p

-DOCSTART- -16452103- O O

Sham NNP N
device NN N
v NN N
inert NN N
pill NN N
: : N
randomised VBN N
controlled VBD N
trial NN N
of IN N
two CD N
placebo NN N
treatments NNS N
. . N

OBJECTIVE NNP N
To TO N
investigate VB N
whether IN N
a DT N
sham JJ N
device NN N
( ( N
a DT N
validated VBN N
sham NN N
acupuncture NN N
needle NN N
) ) N
has VBZ N
a DT N
greater JJR N
placebo NN N
effect NN N
than IN N
an DT N
inert NN N
pill NN N
in IN N
patients NNS p
with IN p
persistent JJ p
arm NN p
pain NN p
. . p

DESIGN VB N
A DT N
single JJ N
blind NN N
randomised VBD N
controlled VBN N
trial NN N
created VBD N
from IN N
the DT N
two CD N
week NN N
placebo IN N
run-in JJ N
periods NNS N
for IN N
two CD N
nested JJ N
trials NNS N
that WDT N
compared VBN N
acupuncture NN N
and CC N
amitriptyline NN N
with IN N
their PRP$ N
respective JJ N
placebo NN p
controls NNS p
. . p

Comparison NNP N
of IN N
participants NNS N
who WP N
remained VBD N
on IN N
placebo NN N
continued VBN N
beyond IN N
the DT N
run-in JJ N
period NN N
to TO N
the DT N
end NN N
of IN N
the DT N
study NN N
. . N

SETTING NNP N
Academic NNP N
medical JJ N
centre NN N
. . N

PARTICIPANTS CC N
270 CD p
adults NNS p
with IN p
arm NN p
pain NN p
due JJ p
to TO p
repetitive VB p
use NN p
that WDT p
had VBD p
lasted VBN p
at IN p
least JJS p
three CD p
months NNS p
despite IN p
treatment NN p
and CC p
who WP p
scored VBD p
> NNP p
or CC p
=3 VBN p
on IN p
a DT p
10 CD p
point NN p
pain NN p
scale NN p
. . p

INTERVENTIONS NNP N
Acupuncture NNP i
with IN i
sham JJ i
device NN i
twice RB i
a DT i
week NN i
for IN i
six CD i
weeks NNS i
or CC i
placebo NN i
pill NN i
once RB i
a DT i
day NN i
for IN i
eight CD i
weeks NNS i
. . i

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
Arm NNP o
pain NN o
measured VBD N
on IN N
a DT N
10 CD o
point NN o
pain NN o
scale NN o
. . o

Secondary JJ o
outcomes NNS o
were VBD o
symptoms NNS o
measured VBN o
by IN o
the DT o
Levine NNP o
symptom NN o
severity NN o
scale NN o
, , o
function NN o
measured VBN o
by IN o
Pransky NNP o
's POS o
upper JJ o
extremity NN o
function NN o
scale NN o
, , o
and CC o
grip JJ o
strength NN o
. . o

RESULTS NNP N
Pain NNP o
decreased VBD N
during IN N
the DT N
two CD N
week NN N
placebo JJ N
run-in JJ N
period NN N
in IN N
both CC N
the DT N
sham NN N
device NN N
and CC N
placebo NN N
pill NN N
groups NNS N
, , N
but CC N
changes NNS N
were VBD N
not RB N
different JJ N
between IN N
the DT N
groups NNS N
( ( N
-0.14 NNP N
, , N
95 CD N
% NN N
confidence NN N
interval NN N
-0.52 NN N
to TO N
0.25 CD N
, , N
P NNP N
= NNP N
0.49 CD N
) ) N
. . N

Changes NNS N
in IN N
severity NN o
scores NNS o
for IN o
arm NN o
symptoms NNS o
and CC o
grip JJ o
strength NN o
were VBD N
similar JJ N
between IN N
groups NNS N
, , N
but CC N
arm JJ N
function NN N
improved VBD N
more RBR N
in IN N
the DT N
placebo NN N
pill NN N
group NN N
( ( N
2.0 CD N
, , N
0.06 CD N
to TO N
3.92 CD N
, , N
P NNP N
= NNP N
0.04 CD N
) ) N
. . N

Longitudinal JJ N
regression NN N
analyses VBZ N
that IN N
followed VBD N
participants NNS N
throughout IN N
the DT N
treatment NN N
period NN N
showed VBD N
significantly RB N
greater JJR N
downward JJ N
slopes NNS N
per IN N
week NN N
on IN N
the DT N
10 CD o
point NN o
arm NN o
pain NN o
scale NN o
in IN N
the DT N
sham JJ N
device NN N
group NN N
than IN N
in IN N
the DT N
placebo NN N
pill NN N
group NN N
( ( N
-0.33 NNP N
( ( N
-0.40 UH N
to TO N
-0.26 VB N
) ) N
v FW N
-0.15 FW N
( ( N
-0.21 UH N
to TO N
-0.09 VB N
) ) N
, , N
P NNP N
= NNP N
0.0001 CD N
) ) N
and CC N
on IN N
the DT N
symptom JJ N
severity NN N
scale NN N
( ( N
-0.07 NNP N
( ( N
-0.09 UH N
to TO N
-0.05 VB N
) ) N
v FW N
-0.05 FW N
( ( N
-0.06 UH N
to TO N
-0.03 VB N
) ) N
, , N
P NNP N
= NNP N
0.02 CD N
) ) N
. . N

Differences NNS N
were VBD N
not RB N
significant JJ N
, , N
however RB N
, , N
on IN N
the DT N
function NN N
scale NN N
or CC N
for IN N
grip JJ N
strength NN N
. . N

Reported VBN N
adverse JJ N
effects NNS N
were VBD N
different JJ N
in IN N
the DT N
two CD N
groups NNS N
. . N

CONCLUSIONS VB N
The DT N
sham NN N
device NN N
had VBD N
greater JJR N
effects NNS N
than IN N
the DT N
placebo NN N
pill NN N
on IN N
self NN N
reported VBN N
pain NN N
and CC N
severity NN N
of IN N
symptoms NNS N
over IN N
the DT N
entire JJ N
course NN N
of IN N
treatment NN N
but CC N
not RB N
during IN N
the DT N
two CD N
week NN N
placebo NNS N
run VBP N
in IN N
. . N

Placebo NNP N
effects NNS N
seem VBP N
to TO N
be VB N
malleable JJ N
and CC N
depend VB N
on IN N
the DT N
behaviours NN N
embedded VBD N
in IN N
medical JJ N
rituals NNS N
. . N

-DOCSTART- -10379020- O O

Vitamin NNP i
A DT i
supplementation NN i
for IN N
extremely-low-birth-weight JJ p
infants NNS p
. . p

National NNP N
Institute NNP N
of IN N
Child NNP N
Health NNP N
and CC N
Human NNP N
Development NNP N
Neonatal NNP N
Research NNP N
Network NNP N
. . N

BACKGROUND NNP N
Vitamin NNP i
A NNP i
supplementation NN i
may MD N
reduce VB N
the DT N
risk NN N
of IN N
chronic JJ N
lung NN N
disease NN N
and CC N
sepsis NN N
in IN N
extremely-low-birth-weight JJ p
infants NNS p
. . p

The DT N
results NNS N
of IN N
our PRP$ N
pilot NN N
study NN N
suggested VBD N
that IN N
a DT N
dose NN N
of IN N
5000 CD N
IU NNP N
administered VBD N
intramuscularly RB N
three CD N
times NNS N
per IN N
week NN N
for IN N
four CD N
weeks NNS N
was VBD N
more RBR N
effective JJ N
than IN N
the DT N
lower JJR N
doses NNS N
given VBN N
in IN N
past JJ N
trials NNS N
. . N

METHODS NNP N
We PRP N
performed VBD N
a DT N
multicenter NN p
, , N
blinded VBD N
, , N
randomized VBN N
trial NN N
to TO N
assess VB N
the DT N
effectiveness NN o
and CC o
safety NN o
of IN N
this DT N
regimen NN N
as IN N
compared VBN N
with IN N
sham JJ i
treatment NN i
in IN N
807 CD p
infants NNS p
in IN p
need NN p
of IN p
respiratory JJ p
support NN p
24 CD p
hours NNS p
after IN p
birth NN p
. . p

The DT p
mean JJ p
birth NN o
weight NN o
was VBD p
770 CD p
g NN p
in IN p
the DT p
vitamin NN i
A NNP i
group NN p
and CC p
769 CD p
g NN p
in IN p
the DT p
control NN i
group NN i
, , p
and CC p
the DT p
respective JJ p
gestational JJ p
ages NNS p
were VBD p
26.8 CD p
and CC p
26.7 CD p
weeks NNS p
. . p

RESULTS VBN N
By IN N
36 CD N
weeks NNS N
' POS N
postmenstrual JJ N
age NN N
, , N
59 CD N
of IN N
the DT N
405 CD N
infants NNS N
( ( N
15 CD N
percent NN N
) ) N
in IN N
the DT N
vitamin NN N
A NNP N
group NN N
and CC N
55 CD N
of IN N
the DT N
402 CD N
infants NNS N
( ( N
14 CD N
percent NN N
) ) N
in IN N
the DT N
control NN N
group NN N
had VBD N
died VBN N
. . N

The DT N
primary JJ N
outcome NN N
- : N
death NN o
or CC o
chronic JJ o
lung NN o
disease NN o
at IN N
36 CD N
weeks NNS N
' POS N
postmenstrual JJ N
age NN N
- : N
occurred VBD N
in IN N
significantly RB N
fewer JJR N
infants NNS N
in IN N
the DT N
vitamin NN N
A NNP N
group NN N
than IN N
in IN N
the DT N
control NN N
group NN N
( ( N
55 CD N
percent NN N
vs. FW N
62 CD N
percent NN N
; : N
relative JJ N
risk NN N
, , N
0.89 CD N
; : N
95 CD N
percent NN N
confidence NN N
interval NN N
, , N
0.80 CD N
to TO N
0.99 CD N
) ) N
. . N

Overall JJ N
, , N
1 CD N
additional JJ N
infant NN N
survived VBD o
without IN o
chronic JJ o
lung NN o
disease NN o
for IN N
every DT N
14 CD N
to TO N
15 CD N
infants NNS N
who WP N
received VBD N
vitamin VBP N
A DT N
supplements NNS N
. . N

The DT N
proportions NNS N
of IN N
infants NNS N
in IN N
the DT N
vitamin NN N
A NNP N
group NN N
and CC N
the DT N
control NN N
group NN N
who WP N
had VBD N
signs NNS N
of IN N
potential JJ o
vitamin NN o
A DT o
toxicity NN o
were VBD N
similar JJ N
. . N

The DT N
proportion NN o
of IN o
infants NNS o
with IN o
serum JJ o
retinol NN o
values NNS o
below IN N
20 CD N
microg NNS N
per IN N
deciliter NN N
( ( N
0.70 CD N
micromol NN N
per IN N
liter NN N
) ) N
was VBD N
lower JJR N
in IN N
the DT N
vitamin NN N
A NNP N
group NN N
than IN N
in IN N
the DT N
control NN N
group NN N
( ( N
25 CD N
percent NN N
vs. FW N
54 CD N
percent NN N
, , N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

CONCLUSIONS NNP N
Intramuscular NNP N
administration NN N
of IN N
5000 CD N
IU NNP N
of IN N
vitamin NN N
A NNP N
three CD N
times NNS N
per IN N
week NN N
for IN N
four CD N
weeks NNS N
reduced VBD N
biochemical JJ N
evidence NN N
of IN N
vitamin NN N
A NNP N
deficiency NN N
and CC N
slightly RB N
decreased VBD N
the DT N
risk NN N
of IN N
chronic JJ o
lung NN o
disease NN o
in IN N
extremely-low-birth-weight JJ p
infants NNS p
. . p

-DOCSTART- -24684867- O O

A DT N
prospective JJ N
, , N
randomized VBD N
controlled VBN N
trial NN N
of IN N
single-incision NN i
laparoscopic NN i
vs JJ i
conventional JJ i
3-port JJ i
laparoscopic NN i
appendectomy NN i
for IN N
treatment NN N
of IN N
acute JJ N
appendicitis NN N
. . N

BACKGROUND NNP N
Proponents NNPS N
of IN N
single-incision NN i
laparoscopic NN i
surgery NN i
( ( i
SILS NNP i
) ) i
claim NN N
patients NNS N
have VBP N
less JJR N
pain NN N
, , N
faster JJR N
recovery NN N
, , N
and CC N
better JJR N
long-term JJ N
cosmetic JJ N
results NNS N
than IN N
patients NNS N
who WP N
undergo VBP N
multiport NN i
laparoscopy NN i
. . i

However RB N
, , N
randomized JJ N
comparisons NNS N
are VBP N
lacking VBG N
. . N

This DT N
study NN N
presents VBZ N
the DT N
results NNS N
of IN N
a DT N
prospective JJ N
randomized VBN N
trial NN N
of IN N
SILS NNP i
or CC N
3-port JJ i
laparoscopic NN i
appendectomy NN i
. . i

STUDY NNP N
DESIGN NNP N
Adults NNP p
with IN p
uncomplicated JJ p
acute NN p
appendicitis NN p
were VBD N
randomized VBN N
1:1 CD N
to TO N
either DT N
SILS NNP i
or CC i
3-port JJ i
laparoscopic NN i
appendectomy NN i
. . i

The DT N
primary JJ N
end NN N
point NN N
was VBD N
early JJ o
postoperative JJ o
pain NN o
( ( N
measured VBN N
by IN N
opiate JJ N
usage NN N
and CC N
pain NN N
score NN N
in IN N
the DT N
first JJ N
12 CD N
hours NNS N
) ) N
. . N

Secondary JJ N
end NN N
points NNS N
were VBD N
operative JJ o
time NN o
, , o
complication NN o
rate NN o
( ( o
including VBG o
conversions NNS o
) ) o
, , o
and CC o
recovery NN o
time NN o
( ( o
days NNS o
of IN o
oral JJ o
opiate JJ o
usage NN o
and CC o
return NN o
to TO o
work VB o
) ) o
. . N

After IN N
6 CD N
months NNS N
, , N
body NN o
image NN o
and CC N
cosmetic JJ o
appearance NN o
were VBD N
assessed VBN N
using VBG N
a DT N
validated JJ N
survey NN N
. . N

RESULTS VB N
The DT p
trial NN p
was VBD p
planned VBN p
for IN p
150 CD p
patients NNS p
, , p
but CC p
was VBD p
halted VBN p
after IN p
75 CD p
patients NNS p
when WRB p
planned VBN p
interim NN p
analysis NN p
showed VBD p
that IN p
SILS NNP i
patients NNS p
had VBD p
more RBR p
postoperative JJ o
pain NN o
( ( N
pain NN N
score NN N
: : N
4.4 CD N
? . N
1.6 CD N
vs NN N
3.5 CD N
? . N
1.5 CD N
; : N
p NN N
= VBZ N
0.01 CD N
) ) N
and CC N
higher JJR o
inpatient NN o
opiate NN o
usage NN o
( ( o
hydromorphone NN N
use NN N
: : N
3.9 CD N
? . N
1.9 CD N
mg NN N
vs NN N
2.8 CD N
? . N
1.7 CD N
mg NN N
; : N
p CC N
= VB N
0.01 CD N
) ) N
than IN N
3-port JJ N
laparoscopy NN o
. . o

Operative JJ o
time NN o
for IN o
SILS NNP i
averaged VBD i
40 CD N
% NN N
longer JJR N
( ( N
54 CD N
? . N
17 CD N
minutes NNS N
vs RB N
38 CD N
? . N
11 CD N
minutes NNS N
; : N
p VB N
< $ N
0.01 CD N
) ) N
. . N

Only RB N
1 CD N
SILS NNP o
case NN o
was VBD N
converted VBN i
to TO i
3-port JJ i
. . i

There EX i
were VBD N
no DT N
significant JJ N
differences NNS o
in IN o
length NN o
of IN o
stay NN o
, , o
complications NNS o
, , o
oral JJ o
pain NN o
medication NN o
usage NN o
after IN o
discharge NN o
, , o
or CC o
return VB o
to TO o
work VB o
. . o

After IN N
6 CD N
months NNS N
, , N
body NN N
image NN N
and CC N
cosmetic JJ N
appearance NN N
were VBD N
excellent JJ N
for IN N
both DT N
groups NNS N
and CC N
indistinguishable JJ N
by IN N
most JJS N
measures NNS N
. . N

However RB i
, , i
3-port JJ i
patients NNS i
reported VBD N
better RBR N
physical JJ o
attractiveness NN o
( ( o
4.0 CD o
? . N
0.4 CD N
vs NN N
3.8 CD N
? . N
0.4 CD N
; : N
p NN N
= VBZ N
0.04 CD N
) ) N
and CC i
SILS NNP i
patients NNS i
reported VBD N
better JJR o
scars NNS o
( ( o
score VB N
18.4 CD N
? . N
2.7 CD N
vs NN N
16.4 CD N
? . N
3.0 CD N
; : N
p NN N
< VBZ N
0.01 CD N
) ) N
. . N

Results NNS N
are VBP N
reported VBN N
as IN N
mean NN N
? . N
SD NNP N
. . N

CONCLUSIONS NNP N
Single-incision NNP i
laparoscopic NN i
surgery NN i
appendectomy NN i
resulted VBD i
in IN i
more RBR o
pain NN o
and CC N
longer RB N
operative JJ o
times NNS o
without IN o
improving VBG N
short-term JJ N
recovery NN N
or CC N
complications NNS N
. . N

Long-term JJ N
body NN N
image NN N
and CC N
cosmetic JJ N
appearance NN N
were VBD N
excellent JJ N
in IN N
both DT N
groups NNS N
. . N

-DOCSTART- -17985004- O O

Cost-effectiveness NN N
of IN N
clopidogrel NN i
in IN N
acute JJ p
coronary JJ p
syndromes NNS p
in IN p
Canada NNP p
: : p
a DT N
long-term JJ N
analysis NN N
based VBN N
on IN N
the DT N
CURE NNP N
trial NN N
. . N

BACKGROUND NNP N
Cardiovascular NNP N
diseases VBZ N
account NN N
for IN N
nearly RB N
20 CD N
% NN N
of IN N
all DT N
hospitalizations NNS N
in IN N
Canada NNP N
and CC N
consume VB N
12 CD N
% NN N
of IN N
the DT N
total JJ N
cost NN N
of IN N
all DT N
illnesses NNS N
. . N

With IN N
increasing VBG N
trends NNS N
of IN N
cardiovascular JJ N
disease NN N
and CC N
increasing VBG N
costs NNS N
of IN N
care NN N
, , N
development NN N
of IN N
cost-effective JJ N
strategies NNS N
is VBZ N
vital JJ N
. . N

The DT N
Clopidogrel NNP i
in IN N
Unstable NNP N
angina NN N
to TO N
prevent VB N
Recurrent JJ N
Events NNS N
( ( N
CURE NNP N
) ) N
trial NN N
demonstrated VBD N
the DT N
effectiveness NN N
of IN N
clopidogrel NN i
plus CC i
acetylsalicylic JJ i
acid NN i
( ( i
ASA NNP i
) ) i
compared VBN N
with IN N
ASA NNP i
alone RB i
in IN N
reducing VBG N
cardiovascular JJ N
events NNS N
in IN N
patients NNS p
with IN p
acute JJ p
coronary JJ p
syndromes NNS p
and CC p
, , p
in IN p
addition NN p
, , p
patients NNS p
undergoing VBG p
percutaneous JJ p
coronary JJ p
intervention NN p
in IN p
the DT p
Percutaneous NNP p
Coronary NNP p
Intervention NNP p
in IN p
CURE NNP p
( ( p
PCI-CURE NNP p
) ) p
trial NN p
. . p

OBJECTIVE UH N
To TO N
assess VB N
the DT N
cost-effectiveness NN N
of IN N
clopidogrel NN i
in IN N
the DT N
Canadian NNP p
health NN p
care NN p
system NN p
. . p

METHODS NNP N
Estimates NNS N
of IN N
hospitalization NN N
costs NNS N
were VBD N
based VBN N
on IN N
the DT N
2003 CD N
cost NN N
schedules NNS N
released VBN N
by IN N
the DT N
Health NNP N
Funding NNP N
and CC N
Costing NNP N
Branch NNP N
of IN N
the DT N
Alberta NNP N
Health NNP N
and CC N
Wellness NNP N
, , N
as RB N
well RB N
as IN N
on IN N
the DT N
Case NNP N
Mix NNP N
Group NNP N
classification NN N
system NN N
. . N

Life NNP N
expectancy NN N
beyond IN N
the DT N
trial NN N
was VBD N
estimated VBN N
from IN N
the DT N
Saskatchewan NNP N
Health NNP N
Database NNP N
. . N

Cost-effectiveness NNP N
was VBD N
expressed VBN N
as IN N
the DT N
incremental JJ N
cost-effectiveness NN N
ratio NN N
, , N
and CC N
bootstrap NN N
methods NNS N
were VBD N
used VBN N
to TO N
estimate VB N
the DT N
joint JJ N
distribution NN N
of IN N
costs NNS N
and CC N
effectiveness NN N
. . N

RESULTS NNP N
Clopidogrel NNP i
was VBD N
shown VBN N
to TO N
be VB N
cost-effective JJ o
, , N
with IN N
incremental JJ N
cost-effectiveness JJ o
ratios NNS o
less JJR N
than IN N
$ $ N
10,000 CD N
per IN N
event NN N
prevented VBN o
and CC N
less JJR N
than IN N
$ $ N
4,000 CD N
per IN N
life-year NN N
gained VBN o
. . o

The DT N
probability NN N
of IN N
clopidogrel NN i
resulting VBG N
in IN N
cost NN o
per IN o
life-year JJ o
gained VBN o
of IN N
less JJR N
than IN N
$ $ N
20,000 CD N
was VBD N
0.975 CD N
for IN N
CURE NNP p
patients NNS p
and CC N
0.904 CD N
for IN N
PCI-CURE JJ p
patients NNS p
. . p

CONCLUSIONS NNP N
The DT N
economic JJ N
analysis NN N
demonstrated VBD N
that IN N
clopidogrel NN i
combination NN i
therapy NN i
is VBZ N
not RB N
only RB N
cost-effective JJ N
as IN N
antiplatelet NN N
therapy NN N
compared VBN N
with IN N
ASA NNP i
alone RB N
, , N
but CC N
it PRP N
is VBZ N
also RB N
cost-effective JJ N
compared VBN N
with IN N
other JJ N
commonly RB N
used VBN N
and CC N
openly RB N
reimbursed VBD N
cardiovascular JJ N
therapies NNS N
in IN N
the DT N
Canadian NNP N
health NN N
care NN N
system NN N
. . N

-DOCSTART- -20584070- O O

Effects NNS o
of IN N
telmisartan NN i
and CC i
enalapril NN i
on IN N
renoprotection NN N
in IN N
patients NNS p
with IN p
mild JJ p
to TO p
moderate VB p
chronic JJ p
kidney NN p
disease NN p
. . p

BACKGROUND NNP N
Blocking VBG N
the DT N
renin-angiotensin NN N
system NN N
( ( N
RAS NNP N
) ) N
with IN N
angiotensin NN N
receptor NN N
blockers NNS N
or CC N
angiotensin-converting JJ N
enzyme NN N
inhibitors NNS N
protects VBZ N
against IN N
renal JJ N
injury NN N
in IN N
patients NNS p
with IN p
chronic JJ p
kidney NN p
disease NN p
( ( p
CKD NNP p
) ) p
. . p

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
compare VB N
the DT N
chronic JJ N
effects NNS N
of IN N
telmisartan NN i
and CC N
enalapril NN i
on IN N
proteinuria NN N
, , N
urinary JJ o
liver-type JJ o
fatty JJ o
acid-binding JJ o
protein NN o
( ( o
L-FABP NNP o
) ) o
and CC N
endothelin $ o
( ( o
ET NNP o
) ) o
-1 NN o
levels NNS o
in IN N
patients NNS p
with IN p
mild JJ p
CKD NNP p
. . p

MATERIALS NNP N
AND CC N
METHODS NNP N
Thirty NNP p
CKD NNP p
patients NNS p
with IN p
mild JJ p
to TO p
moderate VB p
renal JJ p
insufficiency NN p
( ( p
20 CD p
men NNS p
and CC p
10 CD p
women NNS p
; : p
mean JJ p
age NN p
, , p
37 CD p
years NNS p
; : p
estimated VBN o
glomerular JJ o
filtration NN o
rate NN o
( ( o
eGFR NN o
) ) o
> VBZ p
60 CD p
mL NN p
min NN p
( ( p
-1 NNP p
) ) p
and CC p
blood NN p
pressure NN p
> VBZ p
130/85 CD p
mmHg NN p
) ) p
were VBD p
included VBN p
in IN p
the DT p
study NN p
. . p

Patients NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
telmisartan NN i
at IN i
80 CD i
mg NNS i
day NN i
( ( i
-1 NN i
) ) i
( ( N
n JJ N
= NNP N
15 CD N
) ) N
or CC N
enalapril VBN i
at IN i
10 CD i
mg NNS i
day NN i
( ( i
-1 NN i
) ) i
( ( N
n JJ N
= NNP N
15 CD N
) ) N
. . N

We PRP N
measured VBD N
blood NN o
pressure NN o
, , o
serum JJ o
creatinine NN o
, , o
eGFR NN o
, , o
urinary JJ o
protein NN o
, , o
L-FABP NNP o
and CC o
ET-1 NNP o
before IN N
the DT N
start NN N
of IN N
treatment NN N
and CC N
6 CD N
and CC N
12 CD N
months NNS N
after IN N
the DT N
start NN N
of IN N
treatment NN N
. . N

RESULTS VB N
The DT N
blood NN o
pressure NN o
reduction NN o
rate NN o
was VBD N
similar JJ N
between IN N
the DT N
two CD N
groups NNS N
. . N

Urinary JJ o
protein NN o
, , o
L-FABP NNP o
and CC o
ET-1 NNP o
levels NNS o
were VBD N
significantly RB N
reduced VBN N
in IN N
both DT N
groups NNS N
6 CD N
and CC N
12 CD N
months NNS N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
after IN N
treatment NN N
, , N
but CC N
the DT N
reduction NN o
rates NNS o
were VBD N
more RBR N
pronounced JJ N
in IN N
patients NNS N
receiving VBG N
telmisartan NN i
than IN N
in IN N
those DT N
receiving VBG N
enalapril NN i
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

Estimated VBN N
glomerular JJ o
filtration NN o
rate NN o
was VBD N
increased VBN N
similarly RB N
in IN N
both DT N
groups NNS N
at IN N
12 CD N
months NNS N
. . N

CONCLUSIONS NNP N
The DT N
study NN N
results NNS N
suggest VBP N
that IN N
telmisartan JJ i
results NNS N
in IN N
a DT N
greater JJR N
reduction NN N
of IN N
urinary JJ o
markers NNS o
than IN N
does VBZ N
enalapril VB i
and CC N
that IN N
this DT N
effect NN N
occurs VBZ N
by IN N
a DT N
mechanism NN N
independent JJ N
of IN N
blood NN N
pressure NN N
reduction NN N
. . N

It PRP N
would MD N
be VB N
needed VBN N
to TO N
investigate VB N
whether IN N
the DT N
differences NNS N
may MD N
be VB N
distinct JJ N
or CC N
not RB N
the DT N
same JJ N
when WRB N
other JJ N
dosages NNS N
are VBP N
used VBN N
. . N

-DOCSTART- -15745138- O O

Online NNP i
conductivity NN i
monitoring NN i
: : i
validation NN N
and CC N
usefulness NN N
in IN N
a DT N
clinical JJ N
trial NN N
of IN N
reduced JJ i
dialysate NN i
conductivity NN i
. . i

Relatively RB i
low JJ i
dialysate NN i
conductivity NN i
( ( i
Cndi NNP i
) ) i
may MD N
improve VB N
outcomes NNS N
by IN N
reducing VBG N
the DT N
overall JJ N
sodium NN o
burden NN o
in IN N
dialysis NN p
patients NNS p
. . p

Excess NNP N
sodium NN N
removal NN N
, , N
however RB N
, , N
could MD N
lead VB N
to TO N
hemodynamic JJ N
instability NN N
. . N

We PRP N
performed VBD N
a DT N
randomized VBN N
controlled JJ i
trial NN N
of IN N
reduction NN i
of IN i
Cndi NNP i
. . i

For IN N
the DT N
study NN N
, , N
28 CD p
patients NNS p
were VBD p
randomized VBN p
to TO p
maintenance NN i
of IN i
Cndi NNP i
at IN i
13.6 CD i
mS/cm NNS i
( ( i
equivalent JJ i
to TO i
135 CD i
mmol/L NN i
of IN i
Na+ NNP i
) ) i
or CC i
serial JJ i
reduction NN i
of IN i
Cndi NNP i
in IN i
steps NNS i
of IN i
0.2 CD i
mS/cm NNS i
, , p
guided VBN p
by IN p
symptoms NNS p
and CC p
blood NN p
pressure NN p
. . p

Sodium NNP N
removal NN N
estimated VBN N
from IN N
pre- NN N
and CC N
postplasma JJ N
concentrations NNS N
correlated VBN N
well RB N
with IN N
removal NN N
measured VBN N
by IN N
conductivity NN N
monitoring NN N
as IN N
ionic JJ o
mass NN o
balance NN o
( ( N
R2 NNP N
0.66 CD N
, , N
p NN N
< NNP N
0.0001 CD N
) ) N
. . N

Of IN N
the DT N
16 CD N
patients NNS N
randomized VBN N
to TO N
reduction NN i
of IN i
Cndi NNP i
, , N
6 CD N
achieved VBD N
Cndi NNP N
13.4 CD N
mS/cm NN N
, , N
6 CD N
achieved VBD N
13.2 CD N
mS/cm NN N
, , N
and CC N
4 CD N
achieved VBD N
13.0 CD N
mS/cm NN N
. . N

No DT N
episodes NNS N
of IN N
disequilibrium NN N
occurred VBD N
. . N

Interdialytic JJ o
weight NN o
gain NN o
was VBD N
reduced VBN N
from IN N
2.34 CD N
+/- JJ N
0.10 CD N
kg NN N
to TO N
1.57 CD N
+/- JJ N
0.11 CD N
kg NN N
( ( N
p JJ N
< NNP N
0.0001 CD N
) ) N
. . N

Predialysis NNP o
systolic JJ o
blood NN o
pressure NN o
fell VBD N
from IN N
144 CD N
+/- JJ N
3 CD N
mm NN N
Hg NNP N
to TO N
137 CD N
+/- JJ N
4 CD N
mm NN N
Hg NNP N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
. . N

The DT N
reduction NN o
in IN o
convective JJ o
sodium NN o
removal NN o
was VBD N
balanced VBN N
by IN N
an DT N
increase NN N
in IN N
diffusive JJ o
sodium NN o
removal NN o
( ( N
95 CD N
+/- JJ N
9 CD N
mmol NN N
cf NN N
. . N

175 CD N
+/- JJ N
14 CD N
mmol NN N
, , N
p NN N
< NNP N
0.0001 CD N
) ) N
. . N

Reduction NN i
in IN i
Cndi NNP i
monitored VBN N
by IN N
IMB NNP N
is VBZ N
safe JJ N
and CC N
practical JJ N
and CC N
leads VBZ N
to TO N
improved VBN N
interdialytic JJ N
weight NN N
gains NNS N
and CC N
blood NN N
pressure NN N
control NN N
, , N
while IN N
avoiding VBG N
excessive JJ N
sodium NN N
removal NN N
. . N

-DOCSTART- -9078197- O O

Randomised VBN N
trial NN N
of IN N
effect NN N
of IN N
amiodarone NN i
on IN N
mortality NN o
in IN N
patients NNS p
with IN p
left-ventricular JJ p
dysfunction NN p
after IN p
recent JJ p
myocardial JJ p
infarction NN p
: : p
EMIAT NNP p
. . p

European JJ N
Myocardial NNP N
Infarct NNP N
Amiodarone NNP N
Trial NNP N
Investigators NNP N
. . N

BACKGROUND NNP N
Ventricular NNP N
arrhythmias NNS N
are VBP N
a DT N
major JJ N
cause NN N
of IN N
death NN N
after IN N
myocardial JJ N
infarction NN N
, , N
especially RB N
in IN N
patients NNS p
with IN p
poor JJ p
left-ventricular JJ p
function NN p
. . p

Previous JJ N
attempts NNS N
to TO N
identify VB N
and CC N
suppress VB N
arrhythmias NN N
with IN N
various JJ N
antiarrhythmic JJ N
drugs NNS N
failed VBD N
to TO N
reduce VB N
or CC N
actually RB N
increase JJ N
mortality NN N
. . N

Amiodarone NNP i
is VBZ N
a DT N
powerful JJ N
antiarrhythmic JJ N
drug NN N
with IN N
several JJ N
potentially RB N
beneficial JJ N
actions NNS N
, , N
and CC N
has VBZ N
shown VBN N
benefit NN N
in IN N
several JJ N
small-scale JJ N
studies NNS N
. . N

We PRP N
postulated VBD N
that IN N
this DT N
drug NN N
might MD N
reduce VB N
mortality NN N
in IN N
patients NNS p
at IN p
high JJ p
risk NN p
of IN p
death NN p
after IN N
myocardial JJ N
infarction NN N
because IN N
of IN N
impaired JJ N
ventricular JJ N
function NN N
, , N
irrespective NN N
of IN N
whether IN N
they PRP N
had VBD N
ventricular JJ N
arrhythmias NNS N
. . N

METHODS NNP N
The DT N
European NNP N
Myocardial NNP N
Infarct NNP N
Amiodarone NNP N
Trial NNP N
( ( N
EMIAT NNP N
) ) N
was VBD N
a DT N
randomised JJ N
double-blind JJ N
placebo-controlled JJ i
trial NN N
to TO N
assess VB N
whether IN N
amiodarone NN i
reduced VBD N
all-cause JJ o
mortality NN o
( ( N
primary JJ N
endpoint NN N
) ) N
and CC N
cardiac JJ o
mortality NN o
and CC o
arrhythmic JJ o
death NN o
( ( N
secondary JJ N
endpoints NNS N
) ) N
in IN N
survivors NNS N
of IN N
myocardial JJ N
infarction NN N
with IN N
a DT N
left-ventricular JJ N
ejection NN N
fraction NN N
( ( N
LVEF NNP N
) ) N
of IN N
40 CD N
% NN N
or CC N
less JJR N
. . N

Intention-to-treat NN N
and CC N
on-treatment JJ N
analyses NNS N
were VBD N
done VBN N
. . N

FINDINGS NNP N
EMIAT NNP p
enrolled VBD p
1486 CD p
patients NNS p
( ( p
743 CD p
in IN p
the DT p
amiodarone NN p
group NN p
, , p
743 CD p
in IN p
the DT p
placebo NN p
group NN p
) ) p
. . p

Median JJ N
follow-up NN N
was VBD N
21 CD N
months NNS N
. . N

All-cause NNP o
mortality NN o
( ( p
103 CD p
deaths NNS p
in IN p
the DT p
amiodarone NN i
group NN p
, , p
102 CD p
in IN p
the DT p
placebo NN i
group NN p
) ) p
and CC p
cardiac JJ o
mortality NN o
did VBD N
not RB N
differ VB N
between IN N
the DT N
two CD N
groups NNS N
. . N

However RB N
, , N
in IN N
the DT N
amiodarone NN i
group NN N
, , N
there EX N
was VBD N
a DT N
35 CD N
% NN N
risk NN o
reduction NN o
( ( N
95 CD N
% NN N
CI NNP N
0-58 CD N
, , N
p VBZ N
= NNP N
0.05 CD N
) ) N
in IN N
arrhythmic JJ o
deaths NNS o
. . o

INTERPRETATION NNP N
Our PRP$ N
findings NNS N
do VBP N
not RB N
support VB N
the DT N
systematic JJ N
prophylactic JJ N
use NN N
of IN N
amiodarone NN i
in IN N
all DT N
patients NNS N
with IN N
depressed JJ N
left-ventricular JJ N
function NN N
after IN N
myocardial JJ N
infarction NN N
. . N

However RB N
, , N
the DT N
lack NN N
of IN N
proarrhythmia NN N
and CC N
the DT N
reduction NN N
in IN N
arrhythmic JJ o
death NN o
support NN N
the DT N
use NN N
of IN N
amiodarone NN i
in IN N
patients NNS N
for IN N
whom WP N
antiarrhythmic JJ N
therapy NN N
is VBZ N
indicated VBN N
. . N

-DOCSTART- -21724047- O O

Nepafenac NNP i
for IN N
epiretinal JJ p
membrane NN p
surgery NN p
. . p

-DOCSTART- -1255322- O O

Variance NN N
in IN N
albumin NN i
loading NN N
in IN N
exchange NN p
transfusions NNS p
. . p

To TO N
assess VB N
the DT N
rationale NN N
of IN N
albumin NN N
priming VBG N
prior RB N
to TO N
exchange NN N
transfusions NNS N
, , N
42 CD p
hyperbilirubinemic JJ p
infants NNS p
who WP p
required VBD p
exchange NN p
transfusions NNS p
were VBD N
randomly RB N
assigned VBN N
to TO N
one CD N
of IN N
two CD N
groups NNS N
. . N

Group NNP N
I PRP N
consisted VBD N
of IN N
15 CD p
infants NNS p
who WP N
were VBD N
given VBN N
intravenously RB i
1 CD i
gm/kg NN i
of IN i
salt-poor JJ i
human JJ i
serum NN i
albumin IN i
one CD N
hour NN N
before IN N
the DT N
exchanges NNS N
. . N

Group NNP N
II NNP N
, , N
which WDT N
consisted VBD N
of IN N
27 CD N
infants NNS N
, , N
received VBD N
simple JJ N
exchanges NNS N
. . N

No DT N
statistical JJ N
differences NNS N
were VBD N
found VBN N
in IN N
variations NNS o
in IN o
reserve NN o
albumin-binding JJ o
capacity NN o
, , o
bilirubin NN o
, , o
albumin NN o
, , o
or CC o
red JJ o
cell NN o
bilirubin NN o
at IN o
pre NN o
and CC o
one-hour JJ o
post NN o
albumin NN o
infusion NN o
in IN N
the DT N
primed JJ N
infants NNS N
. . N

The DT N
amount NN o
of IN o
bilirubin NN o
removed VBN o
per IN o
kilogram NN o
is VBZ N
directly RB N
correlated VBN N
to TO N
plasma VB o
bilirubin JJ o
concentration NN o
( ( N
r=0.87 NN N
) ) N
. . N

No DT N
significant JJ N
difference NN N
in IN N
efficiency NN o
on IN o
bilirubin NN o
removal NN o
was VBD N
seen VBN N
between IN N
the DT N
two CD N
groups NNS N
. . N

Beneficial JJ N
effects NNS N
of IN N
albumin JJ N
therapy NN N
was VBD N
apparent JJ N
only RB N
in IN N
those DT N
infants NNS p
with IN p
low JJ p
RABC NNP p
as IN N
determined VBN N
by IN N
the DT N
sephadex NN N
gel JJ N
filtration NN N
technique NN N
. . N

-DOCSTART- -26100611- O O

The DT N
effects NNS N
of IN N
parental JJ i
components NNS i
in IN N
a DT N
trauma-focused JJ i
cognitive JJ i
behavioral NN i
based VBN i
therapy NN i
for IN N
children NNS p
exposed VBN p
to TO p
interparental JJ p
violence NN p
: : p
study NN N
protocol NN N
for IN N
a DT N
randomized VBN N
controlled VBN N
trial NN N
. . N

BACKGROUND NNP N
Interparental NNP N
violence NN N
is VBZ N
both DT N
common JJ N
and CC N
harmful JJ N
and CC N
impacts VBZ N
children NNS N
's POS N
lives NNS N
directly RB N
and CC N
indirectly RB N
. . N

Direct JJ N
effects NNS N
refer VBP N
to TO N
affective VB N
, , N
behavioral JJ N
, , N
and CC N
cognitive JJ N
responses NNS N
to TO N
interparental JJ N
violence NN N
and CC N
psychosocial JJ N
adjustment NN N
. . N

Indirect JJ N
effects NNS N
refer VBP N
to TO N
deteriorated VBN N
parental JJ N
availability NN N
and CC N
parent-child JJ N
interaction NN N
. . N

Standard NNP N
Trauma NNP i
Focused VBD i
Cognitive NNP i
Behavioral NNP i
Therapy NNP i
may MD N
be VB N
insufficient NN N
for IN N
children NNS N
traumatized VBN N
by IN N
exposure NN N
to TO N
interparental JJ N
violence NN N
, , N
given VBN N
the DT N
pervasive JJ N
impact NN N
of IN N
interparental JJ N
violence NN N
on IN N
the DT N
family NN N
system NN N
. . N

HORIZON NNP N
is VBZ N
a DT N
trauma NN i
focused VBD i
cognitive JJ i
behavioral JJ i
therapy NN i
based VBN N
group NN N
program NN N
with IN N
the DT N
added JJ N
component NN N
of IN N
a DT N
preparatory JJ i
parenting NN i
program NN i
aimed VBN N
at IN N
improving VBG N
parental JJ N
availability NN N
; : N
and CC N
the DT N
added JJ N
component NN N
of IN N
parent-child JJ N
sessions NNS N
to TO N
improve VB N
parent-child JJ N
interaction NN N
. . N

METHODS/DESIGN NNP N
This DT N
is VBZ N
a DT N
multicenter NN N
, , N
multi-informant JJ N
and CC N
multi-method JJ N
randomized JJ N
clinical JJ N
trial NN N
study NN N
with IN N
a DT N
2 CD N
by IN N
2 CD N
factorial JJ N
experimental JJ N
design NN N
. . N

Participants NNS p
( ( p
N NNP p
= NNP p
100 CD p
) ) p
are VBP p
children NNS p
( ( p
4-12 CD p
years NNS p
) ) p
, , p
and CC p
their PRP$ p
parents NNS p
, , p
who WP p
have VBP p
been VBN p
exposed VBN p
to TO p
interparental JJ p
violence NN p
. . p

The DT p
main JJ N
aim NN N
of IN N
the DT N
study NN N
is VBZ N
to TO N
test VB N
the DT N
effects NNS p
of IN p
two CD p
parental JJ p
components NNS p
as IN p
an DT N
addition NN N
to TO N
a DT N
trauma NN i
focused VBD i
cognitive JJ i
behavioral NN i
based VBN i
group NN i
therapy NN i
for IN i
reducing VBG N
children NNS N
's POS N
symptoms NNS N
. . N

Primary JJ N
outcome NN N
measures NNS N
are VBP N
posttraumatic JJ o
stress NN o
symptoms NNS o
, , o
and CC o
internalizing VBG o
and CC o
externalizing VBG o
problems NNS o
in IN o
children NNS o
. . o

The DT o
secondary JJ N
aim NN N
of IN N
the DT N
study NN N
is VBZ N
to TO N
test VB N
the DT N
effect NN N
of IN N
the DT N
two CD N
added VBD N
components NNS o
on IN o
adjustment NN o
problems NNS o
in IN o
children NNS o
and CC o
to TO N
test VB N
whether IN N
enhanced JJ N
effects NNS N
can MD N
be VB N
explained VBN o
by IN o
changes NNS o
in IN o
children NNS o
's POS o
responses NNS o
towards NNS o
experienced VBD N
violence NN N
, , N
in IN N
parental JJ o
availability NN o
, , o
and CC o
in IN o
quality NN o
of IN o
parent-child JJ o
interaction NN o
. . o

To TO o
address VB N
this DT N
secondary JJ N
aim NN N
, , N
the DT N
main JJ N
parameters NNS N
are VBP N
observational JJ N
and CC N
questionnaire JJ N
measures NNS o
of IN o
parental JJ o
availability NN o
, , o
parent-child JJ o
relationship NN o
variables NNS o
, , o
children NNS o
's POS o
adjustment NN o
problems NNS o
and CC o
children NNS o
's POS o
responses NNS o
to TO o
interparental JJ N
violence NN N
. . N

Data NNS N
are VBP N
collected VBN N
three CD N
times NNS N
: : N
before IN N
and CC N
after IN N
the DT N
program NN N
and CC N
six CD N
months NNS N
later RB N
. . N

Both DT N
intention-to-treat JJ N
and CC N
completer NN N
analyses NNS N
will MD N
be VB N
done VBN N
. . N

DISCUSSION VB N
The DT N
current JJ N
study NN N
will MD N
enhance VB N
our PRP$ N
understanding NN N
of IN N
the DT N
efficacy NN i
interparental JJ i
violence-related JJ i
parental JJ i
components NNS i
added VBD i
to TO i
trauma VB i
focused JJ i
cognitive JJ i
behavioral JJ i
group NN i
program NN i
for IN i
children NNS N
who WP N
have VBP N
been VBN N
exposed VBN N
to TO N
IPV NNP N
. . N

It PRP N
will MD N
illuminate VB N
mechanisms NNS N
underlying VBG N
change NN N
by IN N
considering VBG N
multiple JJ N
dimensions NNS N
of IN N
child NN N
responses NNS N
, , N
parenting VBG N
variables NNS N
and CC N
identify VB N
selection NN N
criteria NNS N
for IN N
participation NN N
in IN N
treatment NN N
. . N

TRIAL NNP N
REGISTRATION NNP N
Netherlands NNP N
Trial NNP N
Register NNP N
NTR4015 NNP N
. . N

Registered VBD N
4th CD N
of IN N
June NNP N
, , N
2013 CD N
. . N

-DOCSTART- -9182738- O O

Clinical JJ N
evaluation NN N
of IN N
the DT N
speed NN o
and CC o
effectiveness NN o
of IN o
subgingival JJ o
calculus NN o
removal NN o
on IN N
single-rooted JJ N
teeth NNS N
with IN N
diamond-coated JJ i
ultrasonic JJ i
tips NNS i
. . i

Several JJ N
studies NNS N
have VBP N
found VBN N
incomplete JJ N
calculus NN o
removal NN o
during IN N
periodontal JJ N
treatment NN N
with IN N
traditional JJ N
hand NN N
curets NNS N
, , N
sonic JJ N
, , N
and CC N
ultrasonic JJ N
instruments NNS N
. . N

This DT N
study NN N
evaluated VBD N
the DT N
speed NN o
and CC o
effectiveness NN o
of IN o
subgingival JJ o
calculus NN o
removal NN o
with IN N
new JJ i
diamond-coated JJ i
ultrasonic JJ i
tips NNS i
on IN N
single-rooted JJ N
teeth NNS N
. . N

Single NNP N
session NN N
subgingival NN N
scaling NN N
and CC N
root NN N
planing NN N
was VBD N
performed VBN N
on IN N
80 CD p
teeth NNS p
with IN p
5 CD p
to TO p
12 CD p
mm NNS p
probing VBG p
depths NNS p
in IN p
15 CD p
patients NNS p
. . p

Each DT N
patient NN N
provided VBD N
groups NNS p
of IN p
4 CD p
teeth NNS p
that WDT N
were VBD N
randomly RB N
treated VBN N
with IN N
either DT N
hand NN i
curets NNS i
( ( i
HAND NNP i
) ) i
; : i
standard JJ i
smooth CC i
ultrasonic JJ i
tip NN i
( ( i
US NNP i
) ) i
; : i
or CC i
fine VB i
grit NN i
( ( i
FINDIAM NNP i
) ) i
or CC i
medium NN i
grit NN i
( ( i
MEDDIAM NNP i
) ) i
diamond-coated VBD i
ultrasonic JJ i
tips NNS i
. . i

The DT N
time NN o
taken VBN o
to TO o
reach VB o
the DT o
therapeutic JJ o
endpoint NN o
of IN o
a DT o
clean JJ o
, , o
smooth JJ o
root NN o
surface NN o
in IN o
a DT o
defined JJ o
region NN o
on IN o
each DT o
tooth NN o
with IN N
each DT N
instrument NN N
by IN N
the DT N
3 CD N
therapists NNS N
with IN N
differing VBG N
experience NN N
levels NNS N
was VBD N
recorded VBN N
. . N

The DT N
teeth NNS N
were VBD N
then RB N
atraumatically RB N
extracted VBN N
, , N
stored VBN N
in IN N
a DT N
surfactant NN N
, , N
photographed VBN N
at IN N
10X CD N
, , N
and CC N
the DT N
percent NN N
of IN N
calculus JJ N
present NN N
in IN N
the DT N
area NN N
of IN N
the DT N
pocket NN N
or CC N
on IN N
a DT N
comparable JJ N
control NN N
surface NN N
calculated VBN N
by IN N
histometric JJ N
point NN N
counting NN N
. . N

ANOVA NNP N
and CC N
paired VBD N
t NN N
tests NNS N
showed VBD N
that IN N
mean JJ o
percent NN o
remaining VBG o
calculus NN o
on IN N
treated JJ N
versus NN N
control NN N
surfaces NNS N
was VBD N
HAND $ N
4.6 CD N
+/- JJ N
5.3 CD N
versus NN N
57.5 CD N
+/- JJ N
28.2 CD N
, , N
US PRP N
4.7 CD N
+/- JJ N
6.4 CD N
versus NN N
54.4 CD N
+/- JJ N
25.9 CD N
, , N
FINDIAM NNP N
4.3 CD N
+/- JJ N
5.2 CD N
versus NN N
37.5 CD N
+/- JJ N
22.1 CD N
, , N
and CC N
MEDDIAM NNP N
3.4 CD N
+/- JJ N
4.2 CD N
versus NN N
50.7 CD N
+/- JJ N
20.1 CD N
, , N
respectively RB N
( ( N
all DT N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

The DT N
mean JJ o
time NN o
in IN o
seconds NNS o
to TO o
reach VB o
the DT o
clinical JJ o
endpoint NN o
ranged VBD N
from IN N
HAND NNP N
289 CD N
+/- JJ N
193 CD N
, , N
US PRP N
194 CD N
+/- JJ N
67 CD N
, , N
FINDIAM NNP N
167 CD N
+/- JJ N
71 CD N
, , N
to TO N
MEDDIAM NNP N
147 CD N
+/- JJ N
92 CD N
. . N

All DT N
powered JJ N
instruments NNS N
were VBD N
significantly RB N
faster JJR N
than IN N
HAND NNP N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
, , N
but CC N
did VBD N
not RB N
differ VB N
from IN N
each DT N
other JJ N
. . N

On IN N
a DT N
0 CD N
= NN N
smooth NN N
to TO N
3 CD N
= NNS N
rough JJ N
scale NN N
, , N
most RBS N
often RB N
HAND NNP N
resulted VBD N
in IN N
smooth JJ o
surfaces NNS o
( ( N
10/20 CD N
) ) N
, , N
the DT N
powered JJ N
tips NNS N
of IN N
all DT N
types NNS N
slight VBD o
surface NN o
roughness NN o
( ( N
10/20 CD N
each DT N
) ) N
, , N
and CC N
US PRP N
the DT N
most RBS N
moderate JJ o
roughness NN o
( ( N
7/20 CD N
) ) N
. . N

There EX N
were VBD N
no DT N
differences NNS N
in IN N
percent JJ o
calculus NN o
remaining VBG o
, , o
surface NN o
roughness NN o
, , o
or CC o
time NN o
spent VBN o
among IN o
the DT o
3 CD o
treating NN o
clinicians NNS o
despite IN N
their PRP$ N
varying JJ N
experience NN N
levels NNS N
. . N

The DT N
results NNS N
of IN N
this DT N
study NN N
showed VBD N
that IN N
percent NN o
calculus NN o
remaining VBG o
was VBD N
< JJ N
5 CD N
% NN N
with IN N
all PDT N
the DT N
instruments NNS N
given VBN N
time NN N
ad NN N
libitum NN N
on IN N
a DT N
given VBN N
root NN N
surface NN N
. . N

Root NNP o
roughness NN o
was VBD N
generally RB N
slightly RB N
greater JJR N
with IN N
all DT N
3 CD N
powered VBN N
tips NNS N
. . N

All DT N
of IN N
the DT N
powered JJ N
instruments NNS N
took VBD N
significantly RB N
less JJR N
time NN o
than IN N
the DT N
HAND NNP N
. . N

Both DT N
DIAM NNP N
tips NNS N
took VBD N
less JJR N
time NN o
than IN N
US NNP i
. . i

Diamond-coated NNP i
ultrasonic JJ i
tips NNS i
appeared VBD N
to TO N
be VB N
much RB N
more RBR N
efficient JJ N
than IN N
HAND NNP N
or CC N
US NNP N
in IN N
removing VBG N
calculus NN N
in IN N
moderate-deep JJ N
probing VBG N
depths NNS N
on IN N
single-rooted JJ N
teeth NNS N
in IN N
vivo NN N
. . N

-DOCSTART- -16093405- O O

Effect NN N
of IN N
soy NN i
protein NN i
containing VBG i
isoflavones NNS i
on IN N
blood NN o
lipids NNS o
in IN N
moderately RB p
hypercholesterolemic JJ p
adults NNS p
: : p
a DT N
randomized NN N
controlled VBN N
trial NN N
. . N

BACKGROUND NNP N
Dietary NNP i
intake NN i
of IN i
soy JJ i
protein NN i
with IN i
isoflavones NNS i
may MD N
be VB N
associated VBN N
with IN N
reductions NNS N
in IN N
serum NN N
cholesterol NN N
. . N

OBJECTIVES NNP N
To TO N
compare VB N
the DT N
effects NNS N
of IN N
a DT N
water-washed JJ i
soy NN i
protein NN i
concentrate NN i
with IN N
a DT N
milk-protein JJ i
based VBN i
control NN i
on IN N
blood NN N
lipid JJ N
levels NNS N
in IN N
hyperlipidemic JJ p
men NNS p
and CC p
women NNS p
. . p

METHODS VB N
A DT N
randomized JJ N
, , N
double-blind JJ N
, , N
controlled VBD N
clinical JJ N
trial NN N
including VBG N
159 CD p
subjects NNS p
. . p

After IN N
a DT N
3-week JJ N
run-in JJ N
period NN N
during IN N
which WDT N
all DT N
subjects NNS N
consumed VBD N
a DT N
milk NN i
protein-based JJ i
supplement NN i
, , N
participants NNS N
were VBD N
randomized VBN N
into IN N
one CD N
of IN N
two CD N
groups NNS N
: : N
a DT N
control NN N
group NN N
( ( i
continued VBN i
milk NN i
protein NN i
) ) i
and CC N
an DT N
intervention NN N
group NN N
( ( i
soy JJ i
protein NN i
) ) i
for IN N
a DT N
five-week JJ N
period NN N
. . N

Fasting VBG N
venous JJ N
blood NN N
draws NN N
for IN N
lipid JJ N
measurement NN N
were VBD N
obtained VBN N
at IN N
baseline NN N
, , N
towards IN N
the DT N
end NN N
of IN N
the DT N
run-in JJ N
period NN N
and CC N
at IN N
the DT N
end NN N
of IN N
the DT N
intervention NN N
. . N

Blood NNP o
isoflavone NN o
concentrations NNS o
were VBD N
measured VBN N
at IN N
the DT N
end NN N
of IN N
the DT N
study NN N
. . N

RESULTS NNP N
Blood NNP o
lipid JJ o
levels NNS o
were VBD N
not RB N
significantly RB N
different JJ N
between IN N
groups NNS N
at IN N
any DT N
point NN N
in IN N
time NN N
; : N
and CC N
there EX N
were VBD N
no DT N
significant JJ N
associations NNS N
between IN N
blood NN o
isoflavones NNS o
and CC o
lipid JJ o
levels NNS o
. . o

Significant JJ N
decreases NNS o
in IN N
total JJ o
cholesterol NN o
( ( N
19 CD N
mg/dL NN N
) ) N
, , N
and CC N
LDL-cholesterol NNP o
( ( N
11 CD N
mg/dL NN N
) ) N
, , N
were VBD N
observed VBN N
during IN N
the DT N
run-in JJ N
period NN N
, , N
with IN N
no DT N
further JJ N
decreases NNS N
in IN N
lipids NNS N
during IN N
the DT N
intervention NN N
period NN N
in IN N
either DT N
group NN N
. . N

CONCLUSIONS NNP N
These DT N
results NNS N
do VBP N
not RB N
support VB N
the DT N
hypothesis NN N
that IN N
water-washed JJ N
soy NN i
protein NN i
has VBZ N
an DT N
effect NN N
on IN N
blood NN o
lipids NNS o
. . o

Several JJ N
hypotheses NNS N
are VBP N
discussed VBN N
, , N
highlighting VBG N
the DT N
selective JJ N
nature NN N
of IN N
the DT N
effect NN N
of IN N
soy NN N
consumption NN N
in IN N
the DT N
population NN N
. . N

The DT N
cholesterol-lowering JJ N
effect NN N
during IN N
the DT N
run-in JJ N
period NN N
may MD N
be VB N
explained VBN N
by IN N
the DT N
regression NN N
to TO N
the DT N
mean JJ N
effect NN N
and CC N
by IN N
other JJ N
factors NNS N
related VBN N
to TO N
study VB N
participation NN N
, , N
mainly RB N
nutrient JJ N
displacement NN N
induced VBN N
by IN N
the DT N
protein NN i
supplement NN i
. . i

-DOCSTART- -25439417- O O

Absence NN N
of IN N
analgesic JJ N
effect NN N
of IN N
intravenous JJ N
melatonin JJ i
administration NN N
during IN N
daytime NN N
after IN N
laparoscopic JJ N
cholecystectomy NN N
: : N
a DT N
randomized JJ N
trial NN N
. . N

STUDY NNP N
OBJECTIVE NNP N
To TO N
investigate VB N
whether IN N
melatonin NN i
administered VBN N
intraoperatively RB N
reduced VBN N
pain NN o
following VBG p
laparoscopic JJ p
cholecystectomy NN p
. . p

DESIGN NNP N
Randomized NNP N
, , N
placebo-controlled JJ N
, , N
double-blinded JJ N
study NN N
. . N

SETTING CD N
Two CD p
surgical JJ p
departments NNS p
in IN p
Copenhagen NNP p
. . p

PATIENTS NNP N
44 CD p
women NNS p
between IN p
18 CD p
and CC p
70 CD p
years NNS p
of IN p
age NN p
, , p
who WP p
were VBD p
surgical JJ p
candidates NNS p
for IN p
laparoscopic JJ p
cholecystectomy NN p
. . p

INTERVENTIONS JJ N
Patients NNPS N
were VBD N
anesthetized VBN i
by IN i
a DT i
standard JJ i
protocol NN i
and CC i
received VBD i
a DT i
standard JJ i
multimodal NN i
postoperative JJ i
analgesic JJ i
regimen NNS i
. . i

Patients NNS p
undergoing VBG p
surgery NN p
were VBD p
admitted VBN p
on IN p
the DT p
day NN p
of IN p
surgery NN p
and CC p
were VBD p
discharged VBN p
the DT p
day NN p
after IN p
surgery NN p
. . p

Ten CD i
mg NN i
of IN i
intravenous JJ i
( ( i
IV NNP i
) ) i
melatonin NN i
or CC i
placebo NN i
were VBD N
administered VBN N
at IN N
the DT N
time NN N
of IN N
surgical JJ N
incision NN N
. . N

MEASUREMENTS NNP N
Pain NNP o
was VBD N
assessed VBN N
by IN N
a DT N
set NN N
of IN N
questionnaires NNS N
documenting VBG N
pain NN N
at IN N
rest NN N
using VBG N
a DT N
visual JJ o
analog NN o
scale NN o
( ( o
VAS NNP o
) ) o
. . N

The DT N
use NN N
of IN N
rescue NN N
medication NN N
was VBD N
recorded VBN N
. . N

Sleep JJ o
quality NN o
and CC o
general JJ o
well-being NN o
were VBD N
measured VBN N
on IN N
separate JJ N
VAS NNP o
scales NNS o
. . o

Sleepiness NNP o
was VBD N
assessed VBN N
by IN N
the DT N
Karolinska NNP N
Sleepiness NNP N
Scale NNP N
. . N

MAIN NNP N
RESULTS NNP N
Forty-four JJ p
patients NNS p
were VBD p
included VBN p
and CC p
randomized VBN p
to TO p
the DT p
study NN p
. . p

Three CD p
patients NNS p
did VBD p
not RB p
complete VB p
the DT p
study NN p
. . p

No DT N
differences NNS N
in IN N
VAS NNP o
pain NN o
scores NNS o
, , o
sleep VBP o
quality NN o
, , o
general JJ o
well-being NN o
, , o
or CC o
sleepiness NN o
were VBD N
found VBN N
between IN N
the DT N
two CD N
groups NNS N
in IN N
the DT N
postoperative JJ N
period NN N
. . N

The DT N
use NN N
of IN N
postoperative JJ N
rescue NN N
medication NN N
did VBD N
not RB N
differ VB N
between IN N
the DT N
groups NNS N
. . N

CONCLUSIONS VB N
The DT N
use NN N
of IN N
10mg CD N
of IN N
IV NNP N
melatonin NN i
administered VBD N
during IN N
laparoscopic JJ N
cholecystectomy NN N
did VBD N
not RB N
affect VB N
postoperative JJ o
pain NN o
or CC o
use NN o
of IN o
analgesic JJ o
medication NN o
. . o

-DOCSTART- -26122982- O O

Expanding VBG N
care NN N
for IN N
perinatal JJ p
women NNS p
with IN p
depression NN o
( ( p
EXPONATE NNP p
) ) p
: : p
study NN N
protocol NN N
for IN N
a DT N
randomized VBN N
controlled JJ N
trial NN N
of IN N
an DT N
intervention NN N
package NN N
for IN N
perinatal JJ o
depression NN o
in IN N
primary JJ N
care NN N
. . N

BACKGROUND NNP N
Depression NNP o
is VBZ N
common JJ N
among IN N
women NNS N
during IN N
perinatal JJ N
period NN N
and CC N
is VBZ N
associated VBN N
with IN N
long-term JJ N
adverse JJ N
consequences NNS N
for IN N
the DT N
mother NN N
and CC N
infant NN N
. . N

In IN N
Nigeria NNP p
, , N
as IN N
in IN N
many JJ N
other JJ N
low- JJ N
and-middle-income JJ N
countries NNS N
( ( N
LMIC NNP N
) ) N
, , N
perinatal JJ o
depression NN o
usually RB N
goes VBZ N
unrecognized JJ N
and CC N
untreated JJ N
. . N

The DT N
aim NN N
of IN N
EXPONATE NNP N
is VBZ N
to TO N
test VB N
the DT N
effectiveness NN N
and CC N
cost-effectiveness NN N
of IN N
an DT N
intervention NN i
package NN i
for IN i
perinatal JJ o
depression NN o
delivered VBN N
by IN N
community NN N
midwives NNS N
in IN N
primary JJ N
maternal JJ N
care NN N
in IN N
which WDT N
physician JJ N
support NN N
and CC N
enhanced VBD N
patient JJ N
compliance NN N
are VBP N
implemented VBN N
using VBG N
mobile JJ N
phones NNS N
. . N

METHODS/STUDY NNP N
DESIGN NNP N
A NNP N
pragmatic JJ N
two-arm NN N
parallel JJ N
cluster NN N
randomized VBD N
controlled JJ N
trial NN N
was VBD N
designed VBN N
. . N

The DT N
units NNS N
of IN N
allocation NN N
are VBP N
the DT N
primary JJ N
maternal JJ N
care NN N
clinics NNS N
. . N

Thirty NNP p
eligible JJ p
and CC p
consenting VBG p
clinics NNS p
were VBD p
randomized VBN p
but CC p
, , p
due JJ p
to TO p
problems NNS p
with IN p
logistics NNS p
, , p
29 CD p
eventually RB p
participated VBN p
. . p

Consenting VBG p
pregnant JJ p
women NNS p
with IN p
a DT p
gestational JJ p
age NN p
between IN p
16 CD p
and CC p
28 CD p
weeks NNS p
who WP p
screened VBD p
positive JJ p
on IN p
the DT p
Edinburgh NNP o
Postnatal NNP o
Depression NNP o
Scale NNP o
( ( p
EPDS NNP p
score RB p
?12 NNP p
) ) p
, , p
absent JJ o
psychosis NN o
or CC o
bipolar JJ o
disorder NN o
, , o
and CC p
not RB p
actively RB o
suicidal JJ o
were VBD o
recruited VBN p
into IN p
the DT p
trial NN p
( ( p
N NNP p
= NNP p
686 CD i
) ) i
. . i

Midwives NNS i
in IN i
the DT i
intervention NN i
arm NN i
were VBD i
trained VBN i
to TO i
deliver VB i
psychoeducation NN i
, , i
problem NN i
solving VBG i
treatment NN i
, , i
and CC i
parenting VBG i
skills NNS i
. . i

Eight NNP N
weekly JJ N
sessions NNS N
were VBD N
delivered VBN N
following VBG N
entry NN N
into IN N
the DT N
study NN N
. . N

Further JJ N
sessions NNS N
during IN N
pregnancy NN N
and CC N
6 CD N
weeks NNS N
following VBG N
childbirth NN N
were VBD N
determined VBN N
by IN N
level NN N
of IN N
depressive JJ o
symptoms NNS o
. . o

Clinical JJ N
support NN N
and CC N
supervision NN N
, , N
delivered VBN N
mainly RB N
by IN N
mobile JJ N
phone NN N
, , N
were VBD N
provided VBN N
by IN N
general JJ N
physicians NNS N
and CC N
psychiatrists NNS N
. . N

Automated NNP N
text NN N
and CC N
voice NN N
messages NNS N
, , N
also RB N
delivered VBN N
by IN N
mobile JJ N
phones NNS N
, , N
were VBD N
used VBN N
to TO N
facilitate VB N
patient JJ N
compliance NN N
with IN N
clinic JJ N
appointments NNS N
and CC N
'homework NNP N
' POS N
tasks NNS i
. . i

Patients NNS i
in IN i
the DT i
control NN i
arm NN i
received VBD i
care NN i
as IN i
usual JJ i
enhanced VBN i
by IN i
further JJ i
training NN i
of IN i
the DT i
providers NNS i
in IN i
that DT i
arm NN i
in IN i
the DT i
recognition NN i
and CC i
standard JJ i
treatment NN i
of IN i
depression NN i
. . i

Assessments NNS N
are VBP N
undertaken VBN N
at IN N
baseline NN N
, , N
2 CD N
months NNS N
following VBG N
recruitment NN N
into IN N
the DT N
study NN N
and CC N
3 CD N
, , N
6 CD N
, , N
9 CD N
and CC N
12 CD N
months NNS N
after IN N
childbirth NN N
. . N

The DT N
primary JJ N
outcome NN N
is VBZ N
recovery NN o
from IN o
depression NN o
( ( o
EPDS NNP N
< NNP N
6 CD N
) ) N
at IN N
6 CD N
months NNS N
. . N

Secondary JJ N
outcomes NNS N
include VBP o
measures NNS o
of IN o
disability NN o
, , o
parenting VBG o
skills NNS o
, , o
maternal JJ o
attitudes NNS o
, , o
health NN o
care NN o
utilization NN o
as RB o
well RB o
as IN o
infant JJ o
physical JJ o
and CC o
cognitive JJ o
development NN o
comprehensively RB o
assessed VBD N
using VBG N
the DT o
Bayley NNP o
's POS o
Scales NNP o
. . o

DISCUSSION NNP N
To TO N
the DT N
best JJS N
of IN N
our PRP$ N
knowledge NN N
, , N
this DT N
is VBZ N
the DT N
largest JJS N
randomized NN N
controlled VBD N
trial NN N
of IN N
an DT N
intervention NN N
package NN N
delivered VBN N
by IN N
community NN N
midwives NNS N
in IN N
sub-Saharan JJ N
Africa NNP N
. . N

TRIAL NNP N
REGISTRATION NNP N
Trial NNP N
is VBZ N
registered VBN N
with IN N
the DT N
ISRTCN NNP N
registry NN N
at IN N
isrtcn.com NN N
; : N
Trial NNP N
number NN N
ISRCTN60041127 NNP N
. . N

Date NNP N
of IN N
registration NN N
is VBZ N
15/05/2013 CD N
. . N

-DOCSTART- -12424783- O O

Effects NNS N
of IN N
two CD N
types NNS N
of IN N
social JJ i
support NN i
and CC i
education NN i
on IN N
adaptation NN N
to TO N
early-stage JJ p
breast NN p
cancer NN p
. . p

A DT i
Roy NNP i
adaptation NN i
model-based JJ i
support NN i
and CC i
education NN i
intervention NN i
for IN N
women NNS p
with IN p
early-stage JJ p
breast NN p
cancer NN p
was VBD p
tested VBN p
in IN N
a DT p
three-group JJ p
, , p
three-phase JJ p
randomized JJ p
clinical JJ p
trial NN p
of IN p
a DT p
sample NN p
of IN p
125 CD p
women NNS p
. . p

The DT N
experimental JJ N
group NN N
received VBD N
13 CD N
months NNS N
of IN N
combined JJ i
individual JJ i
telephone NN i
and CC i
in-person NN i
group NN i
support NN i
and CC i
education NN i
, , N
Control NNP N
Group NNP N
1 CD N
received VBD N
13 CD N
months NNS N
of IN N
telephone-only JJ i
individual JJ i
support NN i
and CC i
education NN i
, , N
and CC N
Control NNP N
Group NNP N
2 CD N
received VBD N
one-time RB i
mailed JJ i
educational JJ i
information NN i
. . i

The DT N
experimental JJ N
group NN N
and CC N
Control NNP N
Group NNP N
1 CD N
reported VBD N
less JJR N
mood NN o
disturbance NN o
at IN N
the DT N
end NN N
of IN N
all DT N
three CD N
phases NNS N
, , N
less JJR o
loneliness NN o
at IN N
the DT N
end NN N
of IN N
Phases NNP N
II NNP N
and CC N
III NNP N
, , N
and CC N
a DT N
higher-quality NN o
relationship NN o
with IN o
a DT o
significant JJ o
other JJ o
at IN N
the DT N
end NN N
of IN N
Phase NNP N
II NNP N
than IN N
did VBD N
Control NNP N
Group NNP N
2 CD N
. . N

No DT N
group NN N
differences NNS N
were VBD N
found VBN N
for IN N
cancer-related JJ o
worry NN o
or CC o
well-being NN o
. . o

The DT N
findings NNS N
suggest VBP N
that IN N
individual JJ N
telephone NN N
support NN N
may MD N
provide VB N
an DT N
effective JJ N
alternative NN N
to TO N
in-person JJ N
support NN N
groups NNS N
. . N

Further NNP N
study NN N
of IN N
telephone NN N
interventions NNS N
is VBZ N
recommended VBN N
using VBG N
ethnically RB N
and CC N
economically RB N
heterogeneous JJ N
samples NNS N
. . N

-DOCSTART- -1100179- O O

Analysis NN o
of IN o
treatment NN o
in IN N
childhood NN p
leukaemia NN p
. . p

I. NNP N
Predisposition NNP N
to TO N
methotrexate-induced JJ N
neutropenia NN N
after IN p
craniospinal JJ p
irradiation NN p
. . p

Report NNP N
to TO N
the DT N
Medical NNP N
Research NNP N
Council NNP N
of IN N
the DT N
Working NNP N
Party NNP N
on IN N
Leukaemia NNP p
in IN p
Childhood NNP p
. . p

The DT N
degree NN N
of IN N
drug-induced JJ N
neutropenia NNS o
resulting VBG N
from IN N
a DT N
controlled VBN N
trial NN N
( ( N
UKALL NNP N
I PRP N
) ) N
of IN N
treatment NN N
in IN N
acute JJ p
lymphoblastic JJ p
leukaemia NN p
was VBD N
analysed VBN N
. . N

The DT N
main JJ N
agent NN N
associated VBN N
with IN N
severe JJ o
neutropenia NN o
was VBD N
methotrexate NN i
, , N
and CC N
methotrexate-induced JJ o
neutropenia NN o
was VBD N
significantly RB N
greater JJR N
in IN N
patients NNS p
who WP p
had VBD p
received VBN p
craniospinal JJ p
irradiation NN p
. . p

The DT N
synergistic JJ o
toxic NN o
effect NN o
of IN o
irradiation NN o
followed VBN N
by IN N
methotrexate NN N
treatment NN N
seems VBZ N
to TO N
have VB N
contributed VBN N
to TO N
three CD N
of IN N
the DT N
five CD N
deaths NNS o
which WDT N
occurred VBD N
in IN N
complete JJ N
remission NN o
in IN N
this DT N
trial NN N
; : N
all DT N
deaths NNS N
in IN N
remission NN N
occurred VBD N
in IN N
patients NNS N
who WP N
had VBD N
received VBN N
central JJ N
nervous JJ N
system NN N
prophylaxis NN N
. . N

Analysis NN N
of IN N
patients NNS N
who WP N
subsequently RB N
relapsed VBD N
compared VBN N
with IN N
those DT N
still RB N
in IN N
remission NN N
after IN N
18 CD N
months NNS N
of IN N
treatment NN N
indicated VBD N
that IN N
the DT N
former JJ N
, , N
on IN N
average NN N
, , N
had VBD N
slightly RB N
lower JJR N
neutrophil NN o
counts NNS o
. . o

This DT N
suggests VBZ N
that IN N
the DT N
children NNS p
who WP N
relapsed VBD N
did VBD N
not RB N
receive VB N
any DT N
less RBR N
aggressive JJ N
treatment NN N
than IN N
those DT N
who WP N
remained VBD N
in IN N
remission NN N
. . N

-DOCSTART- -25612845- O O

Pharmacokinetic JJ N
study NN N
between IN N
a DT N
bilayer NN i
matrix NN i
fentalyl NN i
patch NN i
and CC i
a DT i
monolayer NN i
matrix NN i
fentanyl JJ i
patch NN i
: : i
single JJ N
dose JJ N
administration NN N
in IN N
healthy JJ p
volunteers NNS p
. . p

AIMS NNP N
Transdermal NNP i
fentanyl NN i
is VBZ N
a DT N
well RB N
established VBN N
treatment NN N
for IN N
cancer NN N
pain NN N
. . N

The DT N
aim NN N
of IN N
the DT N
present JJ N
study NN N
is VBZ N
to TO N
assess VB N
the DT N
relative JJ N
bioavailability NN N
of IN N
fentanyl NN i
from IN N
two CD N
different JJ N
transdermal JJ N
systems NNS N
by IN N
evaluating VBG N
plasma JJ N
drug NN N
concentrations NNS N
after IN N
single JJ N
administration NN N
of IN N
Fentalgon? NNP i
( ( i
test NN i
) ) i
, , i
a DT i
novel JJ i
bilayer NN i
matrix NN i
type NN i
patch NN i
, , i
and CC i
Durogesic NNP i
SMAT NNP i
( ( i
reference NN i
) ) i
, , i
a DT i
monolayer NN i
matrix NN i
type NN i
patch NN i
. . i

In IN N
the DT i
Fentalgon NNP i
patch VB i
the DT N
upper JJ N
6 CD N
% NN N
fentanyl JJ N
reservoir NN N
layer NN N
maintains VBZ N
a DT N
stable JJ N
concentration NN N
gradient NN N
between IN N
the DT N
lower JJR N
4 CD N
% NN N
donor NN N
layer NN N
and CC N
the DT N
skin NN N
. . N

The DT N
system NN N
provides VBZ N
a DT N
constant JJ N
drug NN N
delivery NN N
over IN N
72 CD N
h. JJ N
METHODS NNP N
This DT N
was VBD N
an DT N
open JJ N
label NN N
, , N
single JJ N
centre NN N
, , N
randomized VBN N
, , N
single JJ N
dose NN N
, , N
two CD N
period NN N
crossover VBD N
clinical JJ N
trial NN N
, , N
that WDT N
included VBD p
36 CD p
healthy JJ p
male NN p
volunteers NNS p
. . p

The DT N
patches NNS N
were VBD N
applied VBN N
to TO N
non-irritated JJ N
and CC N
non-irradiated JJ N
skin NN N
on IN N
the DT N
intraclavicular JJ N
pectoral JJ N
area NN N
. . N

Blood NN N
samples NNS N
were VBD N
collected VBN N
at IN N
different JJ N
time NN N
points NNS N
( ( N
from IN N
baseline NN N
to TO N
120 CD N
h JJ N
post-removal NN N
of IN N
the DT N
devices NNS N
) ) N
and CC N
fentanyl JJ N
concentrations NNS N
were VBD N
determined VBN N
using VBG N
a DT N
validated JJ N
LC/MS/MS NNP N
method NN N
. . N

Bioequivalence NNP N
was VBD N
to TO N
be VB N
claimed VBN N
if IN N
the DT N
90 CD N
% NN N
confidence NN N
interval NN N
of IN N
AUC NNP N
( ( N
0 CD N
, , N
t NN N
) ) N
and CC N
C NNP N
( ( N
max NN N
) ) N
ratios NNS N
( ( N
test NN N
: : N
reference NN N
) ) N
were VBD N
within IN N
the DT N
acceptance NN N
range NN N
of IN N
80-125 CD N
% NN N
and CC N
75-133 CD N
% NN N
, , N
respectively RB N
. . N

RESULTS VB N
The DT N
90 CD N
% NN N
confidence NN N
intervals NNS N
of IN N
the DT o
AUC NNP o
( ( o
0 CD o
, , o
t NN o
) ) o
ratio NN o
( ( N
116.3 CD N
% NN N
[ JJ N
109.6 CD N
, , N
123.4 CD N
% NN N
] NN N
) ) N
and CC N
C NNP N
( ( N
max NN N
) ) N
ratio NN N
( ( N
114.4 CD N
% NN N
[ JJ N
105.8 CD N
, , N
123.8 CD N
% NN N
] NN N
were VBD N
well RB N
included VBN N
in IN N
the DT o
acceptance NN o
range NN o
and CC N
the DT o
C NNP o
( ( o
max NN o
) ) o
ratio NN o
also RB N
met VBD N
the DT N
narrower JJR N
bounds NNS N
of IN N
80-125 CD N
% NN N
. . N

There EX N
was VBD N
no DT N
relevant JJ N
difference NN N
in IN N
overall JJ N
safety NN N
profiles NNS N
of IN N
the DT N
two CD N
preparations NNS N
investigated VBD N
, , N
which WDT N
were VBD N
adequately RB o
tolerated VBN o
, , o
as IN N
expected VBN N
for IN N
opioid-na?ve JJ N
subjects NNS N
. . N

CONCLUSIONS VB N
The DT N
new JJ N
bilayer NN N
matrix NN N
type NN N
patch NN i
, , i
Fentalgon? NNP i
, , i
is VBZ i
bioequivalent JJ N
to TO N
the DT N
monolayer NN N
matrix NN N
type NN i
Durogesic NNP i
SMAT NNP i
fentanyl VBD i
patch NN N
with IN N
respect NN N
to TO N
the DT N
rate NN N
and CC N
extent NN N
of IN N
exposure NN N
of IN N
fentanyl NN N
( ( N
Eudra/CT NNP N
no DT N
. . N

2005-000046-36 JJ N
) ) N
. . N

-DOCSTART- -18448859- O O

Omega-3/omega-6 NNP i
fatty JJ i
acids NNS i
for IN N
attention NN o
deficit NN o
hyperactivity NN o
disorder NN o
: : o
a DT N
randomized JJ N
placebo-controlled JJ N
trial NN N
in IN N
children NNS p
and CC p
adolescents NNS p
. . p

OBJECTIVE IN N
The DT N
aim NN N
of IN N
the DT N
study NN N
was VBD N
to TO N
assess VB N
omega JJ i
3/6 CD i
fatty JJ i
acids NNS i
( ( N
eye NN N
q NN N
) ) N
in IN N
attention NN o
deficit NN o
hyperactivity NN o
disorder NN o
( ( o
ADHD NNP o
) ) o
. . o

METHOD PDT N
The DT N
study NN N
included VBD N
a DT N
randomized VBN N
, , N
3-month JJ N
, , N
omega JJ i
3/6 CD i
placebo-controlled JJ i
, , N
one-way JJ N
crossover NN N
trial NN N
with IN N
75 CD p
children NNS p
and CC p
adolescents NNS p
( ( p
8-18 CD p
years NNS p
) ) p
, , N
followed VBN i
by IN i
3 CD i
months NNS i
with IN i
omega JJ i
3/6 CD i
for IN i
all DT i
. . i

Investigator-rated JJ o
ADHD NNP o
Rating NNP o
Scale-IV NNP o
and CC o
Clinical NNP o
Global NNP o
Impression NNP o
( ( o
CGI NNP o
) ) o
scale NN o
were VBD N
outcome JJ N
measures NNS N
. . N

RESULTS VB N
A DT N
majority NN N
did VBD N
not RB N
respond VB N
to TO N
omega VB N
3/6 CD N
treatment NN N
. . N

However RB N
, , N
a DT N
subgroup NN N
of IN N
26 CD N
% NN N
responded VBD N
with IN N
more JJR N
than IN N
25 CD N
% NN N
reduction NN o
of IN o
ADHD NNP o
symptoms NNS o
and CC N
a DT N
drop NN o
of IN o
CGI NNP o
scores NNS o
to TO N
the DT N
near-normal JJ N
range NN N
. . N

After IN N
6 CD N
months NNS N
, , N
47 CD N
% NN N
of IN N
all DT N
showed VBD N
such JJ N
improvement NN N
. . N

Responders NNS p
tended VBD p
to TO p
have VB p
ADHD NNP o
inattentive JJ p
subtype NN p
and CC p
comorbid NN p
neurodevelopmental JJ p
disorders NNS p
. . p

CONCLUSION VB N
A DT p
subgroup NN p
of IN p
children NNS p
and CC p
adolescents NNS p
with IN p
ADHD NNP o
, , N
characterized VBN N
by IN N
inattention NN N
and CC N
associated VBN N
neurodevelopmental JJ N
disorders NNS N
, , N
treated VBN N
with IN N
omega JJ i
3/6 CD i
fatty JJ i
acids NNS i
for IN N
6 CD N
months NNS N
responded VBN N
with IN N
meaningful JJ N
reduction NN o
of IN o
ADHD NNP o
symptoms NNS o
. . o

-DOCSTART- -2895910- O O

Multicenter NNP N
trial NN N
of IN N
cryotherapy NN i
for IN N
retinopathy NN p
of IN p
prematurity NN p
: : p
preliminary JJ N
results NNS N
. . N

Cryotherapy NNP i
for IN N
Retinopathy NNP N
of IN N
Prematurity NNP N
Cooperative NNP N
Group NNP N
. . N

We PRP N
report VBP N
the DT N
preliminary JJ N
3-month JJ N
outcome NN N
of IN N
a DT N
multicenter NN N
randomized VBN N
trial NN N
of IN N
cryotherapy NN i
for IN i
treatment NN i
of IN i
retinopathy NN i
of IN i
prematurity NN i
( ( N
ROP NNP N
) ) N
. . N

Transscleral JJ i
cryotherapy NN i
to TO N
the DT N
avascular JJ N
retina NN N
was VBD N
applied VBN N
to TO N
one CD p
randomly NN p
selected VBN p
eye NN p
when WRB N
there EX N
was VBD N
threshold JJ N
disease NN N
( ( N
defined VBN N
as IN N
five CD N
or CC N
more JJR N
contiguous JJ N
or CC N
eight CD N
cumulative JJ N
30 CD N
degree JJ N
sectors NNS N
[ VBP N
clock NN N
hours NNS N
] CD N
of IN N
stage NN N
3 CD N
ROP NNP N
in IN N
zone CD N
1 CD N
or CC N
2 CD N
in IN N
the DT N
presence NN N
of IN N
plus JJ N
disease NN N
) ) N
. . N

An DT N
unfavorable JJ N
outcome NN N
was VBD N
defined VBN N
as IN N
posterior JJ o
retinal JJ o
detachment NN o
, , o
retinal JJ o
fold NN o
involving VBG o
the DT o
macula NN o
, , o
or CC o
retrolental JJ o
tissue NN o
. . o

At IN N
this DT N
writing NN N
, , N
172 CD p
infants NNS p
had VBD p
been VBN p
examined VBN p
3 CD p
months NNS p
after IN p
randomization NN p
. . p

An DT N
unfavorable JJ o
outcome NN o
was VBD N
significantly RB N
less JJR N
frequent JJ N
in IN N
the DT N
eyes NNS N
undergoing VBG N
cryotherapy NN i
( ( N
21.8 CD N
% NN N
) ) N
compared VBN N
with IN N
the DT N
untreated JJ N
eyes NNS N
( ( N
43 CD N
% NN N
) ) N
. . N

While IN N
the DT N
surgery NN N
was VBD N
stressful JJ N
, , N
no DT N
unexpected JJ o
complications NNS o
occurred VBD N
during IN N
or CC N
following VBG N
treatment NN N
. . N

These DT N
data NNS N
support NN N
the DT N
efficacy NN o
of IN N
cryotherapy NN i
in IN N
reducing VBG N
by IN N
approximately RB N
one CD N
half PDT N
the DT N
risk NN N
of IN N
unfavorable JJ N
retinal JJ N
outcome NN N
from IN N
threshold JJ N
ROP NNP N
. . N

-DOCSTART- -25542821- O O

Efficacy NN o
and CC N
safety NN o
of IN N
repeated VBN N
use NN N
of IN N
ulipristal JJ i
acetate NN i
in IN N
uterine JJ p
fibroids NNS p
. . p

OBJECTIVE NNP N
To TO N
investigate VB N
the DT N
efficacy NN o
and CC N
safety NN o
of IN N
repeated VBN N
12-week JJ N
courses NNS N
of IN N
5 CD N
or CC N
10 CD N
mg JJ N
daily NN N
of IN N
ulipristal JJ i
acetate NN i
for IN N
intermittent JJ N
treatment NN N
of IN N
symptomatic JJ p
uterine JJ p
fibroids NNS p
. . p

DESIGN NNP N
Double-blind NNP N
, , N
randomized JJ N
administration NN N
of IN N
two CD N
12-week JJ N
courses NNS N
of IN N
ulipristal JJ i
acetate NN i
. . i

SETTING NNP N
Gynecology NNP p
centers NNS p
. . p

PATIENT NNP N
( ( N
S NNP N
) ) N
A NNP N
total NN p
of IN p
451 CD p
patients NNS p
with IN p
symptomatic JJ p
uterine JJ p
fibroid NN p
( ( p
s NN p
) ) p
and CC p
heavy JJ p
bleeding NN p
. . p

INTERVENTION NNP N
( ( N
S NNP N
) ) N
Two CD N
repeated VBD N
12-week JJ N
treatment NN N
courses NNS N
of IN N
daily JJ N
5 CD i
or CC i
10 CD i
mg NN i
of IN i
ulipristal JJ i
acetate NN i
. . i

MAIN NNP N
OUTCOME NNP N
MEASURE NNP N
( ( N
S NNP N
) ) N
Amenorrhea NNP o
, , o
controlled VBD o
bleeding NN o
, , o
fibroid JJ o
volume NN o
, , o
quality NN o
of IN o
life NN o
( ( o
QoL NNP o
) ) o
, , o
pain NN o
. . o

RESULT NNP N
( ( N
S NNP N
) ) N
In IN N
the DT N
5- JJ N
and CC N
10-mg JJ N
treatment NN N
groups NNS N
( ( N
62 CD N
% NN N
and CC N
73 CD N
% NN N
of IN N
patients NNS N
, , N
respectively RB N
) ) N
achieved VBD N
amenorrhea NN o
during IN N
both DT N
treatment NN N
courses NNS N
. . N

Proportions NNS N
of IN N
patients NNS N
achieving VBG N
controlled VBD o
bleeding VBG o
during IN N
two CD N
treatment NN N
courses NNS N
were VBD N
> JJ N
80 CD N
% NN N
. . N

Menstruation NN o
resumed VBD o
after IN N
each DT N
treatment NN N
course NN N
and CC N
was VBD N
diminished VBN N
compared VBN N
with IN N
baseline NN N
. . N

After IN N
the DT N
second JJ N
treatment NN N
course NN N
, , N
median JJ o
reductions NNS o
from IN o
baseline NN o
in IN o
fibroid JJ o
volume NN o
were VBD N
54 CD N
% NN N
and CC N
58 CD N
% NN N
for IN N
the DT N
patients NNS N
receiving VBG N
5 CD N
and CC N
10 CD N
mg NN N
of IN N
ulipristal JJ N
acetate NN N
, , N
respectively RB N
. . N

Pain NN o
and CC o
QoL NNP o
improved VBN N
in IN N
both DT N
groups NNS N
. . N

Ulipristal JJ N
acetate NN N
was VBD N
well RB N
tolerated VBN o
with IN N
less JJR N
than IN N
5 CD N
% NN N
of IN N
patients NNS N
discontinuing VBG N
treatment NN N
due JJ N
to TO N
adverse JJ o
events NNS o
. . o

CONCLUSION NNP N
( ( N
S NNP N
) ) N
Repeated VBD N
12-week JJ N
courses NNS N
of IN N
daily JJ N
oral JJ N
ulipristal JJ N
acetate NN N
( ( N
5 CD N
and CC N
10 CD N
mg NN N
) ) N
effectively RB N
control VBP N
bleeding VBG o
and CC o
pain NN o
, , N
reduce VB N
fibroid JJ o
volume NN o
, , N
and CC N
restore VB N
QoL NNP o
in IN N
patients NNS N
with IN N
symptomatic JJ N
fibroids NNS N
. . N

CLINICAL NNP N
TRIAL NNP N
REGISTRATION NNP N
NUMBER NNP N
NCT01629563 NNP N
( ( N
PEARL NNP N
IV NNP N
) ) N
. . N

-DOCSTART- -16505756- O O

Longitudinal JJ N
quality NN o
of IN o
life NN o
study NN N
in IN N
patients NNS p
with IN p
metastatic JJ p
gastric JJ p
cancer NN p
. . p

Analysis NNP N
modalities NNS N
and CC N
clinical JJ N
applicability NN N
of IN N
QoL NNP o
in IN N
randomized JJ N
phase NN N
II NNP N
trial NN N
in IN N
a DT N
digestive JJ N
oncology NN N
. . N

OBJECTIVES CC N
The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
compare VB N
the DT N
longitudinal JJ o
quality NN o
of IN o
life NN o
( ( o
QoL NNP o
) ) o
between IN N
LV5FU2-irinotecan JJ i
and CC i
LV5FU2 NNP i
alone RB i
or CC i
LV5FU2-cisplatin NNP i
in IN N
a DT N
randomized JJ N
Phase NNP N
II NNP N
trial NN N
in IN N
patients NNS p
with IN p
metastatic JJ p
gastric JJ p
adenocarcinoma NN p
. . p

METHODS NNP N
Among IN N
134 CD p
eligible JJ p
patients NNS p
, , N
QLQ-C30 JJ o
scores NNS o
were VBD N
collected VBN N
and CC N
described VBN N
at IN N
each DT N
2 CD N
monthly JJ N
follow-up JJ N
visit NN N
during IN N
6 CD N
months NNS N
. . N

The DT N
frequencies NNS o
of IN o
QLQ-C30 NNP o
score NN o
improvement NN o
were VBD N
calculated VBN N
and CC N
mixed JJ N
models NNS N
for IN N
repeated JJ N
measurements NNS N
were VBD N
applied VBN N
with IN N
or CC N
without IN N
extreme JJ N
poorest JJS N
imputation NN N
for IN N
missing VBG N
scores NNS N
. . N

The DT N
survival NN o
until IN o
definitive JJ o
global JJ o
health NN o
score NN o
( ( o
GHS NNP o
) ) o
deterioration NN o
was VBD N
estimated VBN N
. . N

RESULTS NNP N
At IN N
the DT N
3rd CD N
follow-up NN N
, , N
patients NNS N
with IN N
a DT N
stable JJ N
or CC N
improved VBN N
global JJ o
health NN o
ranged VBD N
from IN N
11 CD N
% NN N
in IN N
the DT N
LV5FU2-cisplatin JJ i
arm NN N
to TO N
18 CD N
% NN N
in IN N
the DT N
LV5FU2-irinotecan JJ i
arm NN N
. . N

The DT N
irinotecan-based-therapy JJ N
presented VBD N
14 CD N
to TO N
15 CD N
scores NNS N
with IN N
a DT N
better JJR N
QoL NNP o
. . o

The DT N
time NN o
until IN o
definitive JJ o
GHS NNP o
deterioration NN o
was VBD N
globally RB N
similar JJ N
between IN N
treatment NN N
arms NNS N
. . N

CONCLUSION NN N
This DT N
study NN N
highlights VBZ N
a DT N
better JJR N
impact NN N
of IN N
LV5FU2-irinotecan JJ i
and CC N
the DT N
interest NN N
of IN N
QoL NNP o
assessment NN o
in IN N
phase NN N
II NNP N
trials NNS N
to TO N
complement VB N
the DT N
risk-benefit JJ N
judgement NN N
. . N

-DOCSTART- -25017958- O O

Comparison NNP N
of IN N
postoperative JJ N
short-term JJ N
complications NNS N
after IN N
laparoscopic JJ i
transabdominal JJ i
preperitoneal NN i
( ( i
TAPP NNP i
) ) i
versus NN i
Lichtenstein NNP i
tension NN i
free JJ i
inguinal JJ i
hernia NN i
repair NN i
: : i
a DT N
randomized JJ N
trial NN N
study NN N
. . N

AIM NNP N
The DT N
aim NN N
of IN N
this DT N
randomized JJ N
trial NN N
was VBD N
to TO N
compare VB N
short-term JJ N
postoperative JJ N
complications NNS p
of IN p
laparoscopic JJ i
transabdominal JJ i
preperitoneal NN i
( ( i
TAPP NNP i
) ) i
and CC i
Lichtenstein NNP i
tension NN i
free JJ i
hernia NN i
repair NN i
. . i

METHODS NNP N
A NNP p
total NN p
of IN p
120 CD p
patients NNS p
who WP p
went VBD p
inguinal JJ i
hernia NN i
repair NN i
at IN p
Shahid NNP p
Sadoughi NNP p
university NN p
training VBG p
hospital NN p
from IN p
April NNP p
2011 CD p
to TO p
August NNP p
2013 CD p
were VBD N
randomized VBN N
into IN N
two CD N
TAPP NNP i
( ( N
N.=60 NNP N
) ) N
and CC N
Lichtenstein NNP i
( ( N
N.=60 NNP N
) ) N
repair NN N
group NN N
. . N

Follow-up CD N
occurred VBD N
within IN N
6 CD N
weeks NNS N
. . N

The DT N
postoperative JJ N
assessments NNS N
included VBD N
pain NN o
score NN o
( ( o
VAS NNP o
) ) o
, , o
hematoma/seroma UH o
, , o
urinary JJ o
retention NN o
, , o
wound JJ o
infection NN o
incidence NN o
, , o
and CC o
duration NN o
of IN o
hospital NN o
stay NN o
. . o

RESULTS NNP N
Pain NNP o
was VBD N
the DT N
most RBS N
common JJ N
symptoms NNS N
in IN N
both DT N
groups NNS N
. . N

The DT N
TAPP NNP N
group NN N
patients NNS N
significantly RB N
had VBD N
experienced VBN N
less RBR N
postoperative JJ o
pain NN o
than IN N
the DT N
Lichtenstein NNP i
group NN N
in IN N
all DT N
moments NNS N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

TAPP NNP N
group NN N
had VBD N
lower JJR N
incidence NN N
of IN N
hematoma NN o
( ( N
TAPP NNP N
, , N
6.6 CD N
% NN N
vs. FW N
Lichtenstein NNP i
13.3 CD N
% NN N
; : N
P=0.67 NNP N
) ) N
, , N
seroma FW o
( ( N
TAPP NNP N
10 CD N
% NN N
vs. FW N
Lichtenstein NNP i
13.3 CD N
% NN N
; : N
P=1.00 NNP N
) ) N
, , N
and CC N
infection NN o
( ( N
TAPP NNP N
0 CD N
vs. NN N
Lichtenstein NNP i
1.6 CD N
% NN N
; : N
P=0.67 NNP N
) ) N
. . N

However RB N
, , N
no DT N
differences NNS N
between IN N
the DT N
2 CD N
groups NNS N
were VBD N
found VBN N
in IN N
terms NNS N
of IN N
postoperative JJ o
complications NNS o
. . o

In IN N
TAPP NNP N
group NN N
mean NN o
of IN o
hospital NN o
stay NN o
significantly RB N
was VBD N
less JJR N
than IN N
Lichtenstein NNP i
group NN N
( ( N
TAPP NNP N
, , N
8.13?2.19 CD N
vs. NN N
Lichtenstein NNP N
, , N
13.15?1.5 CD N
days NNS N
; : N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

CONCLUSION VB N
The DT N
laparoscopic NN N
TAPP NNP N
repair NN N
is VBZ N
safer JJR N
and CC N
less RBR N
complicated JJ N
approach NN N
to TO N
inguinal JJ N
hernia NN N
repair NN N
. . N

The DT N
two CD N
main JJ N
short-term JJ N
advantages NNS N
of IN N
the DT N
laparoscopic NN i
TAPP NNP i
repair NN i
with IN N
the DT N
tension NN N
free JJ i
Lichtenstein NNP i
repair NN i
were VBD N
less RBR N
postoperative JJ N
pain NN N
and CC N
earlier RB N
return VB N
to TO N
the DT N
normal JJ N
life NN N
activities NNS o
. . o

No DT N
difference NN N
was VBD N
seen VBN N
in IN N
overall JJ N
complications NNS N
. . N

-DOCSTART- -22182296- O O

Dopamine NNP i
transporter NN i
gene NN i
moderates VBZ N
response NN N
to TO N
behavioral JJ p
parent NN p
training NN p
in IN p
children NNS p
with IN p
ADHD NNP p
: : p
a DT N
pilot NN N
study NN N
. . N

There EX N
is VBZ N
great JJ N
variability NN N
in IN N
the DT N
degree NN N
to TO N
which WDT N
children NNS p
with IN p
attention NN p
deficit/hyperactivity NN p
disorder NN p
( ( p
ADHD NNP p
) ) p
improve VBP N
through IN N
behavioral JJ N
treatments NNS N
. . N

This DT N
study NN N
investigates VBZ N
the DT N
influence NN N
of IN N
the DT N
dopamine NN i
transporter NN i
gene NN i
( ( i
SCL6A3/DAT1 NNP i
) ) i
on IN N
outcome NN N
of IN N
behavioral JJ i
parent NN i
training NN i
( ( i
BPT NNP i
) ) i
. . i

Study NNP p
subjects NNS p
were VBD p
a DT p
subsample NN p
( ( p
n JJ p
= NN p
50 CD p
, , p
for IN p
whom WP p
DAT1 NNP p
genotypes NNS p
were VBD p
available JJ p
) ) p
of IN p
a DT p
randomized VBN p
controlled VBN p
BPT NNP p
effectiveness NN p
study NN p
( ( p
N NNP p
= NNP p
94 CD p
) ) p
comparing VBG p
BPT NNP i
plus CC i
ongoing JJ i
routine JJ i
clinical JJ i
care NN i
( ( i
RCC NNP i
) ) i
versus NN i
RCC NNP i
alone RB i
in IN i
referred JJ p
children NNS p
( ( p
4-12 CD p
years NNS p
old JJ p
) ) p
with IN p
ADHD NNP p
. . p

Treatment NNP N
outcome NN N
was VBD N
based VBN N
on IN N
parent-reported JJ N
ADHD NNP N
symptoms NNS N
and CC N
behavioral JJ N
problems NNS N
. . N

Presence NNP N
of IN N
2 CD N
versus NN N
no DT N
or CC N
1 CD N
DAT1 NNP N
10-repeat JJ N
allele NN N
served VBD N
as IN N
moderator NN N
variable NN N
. . N

Time NNP N
? . N
Treatment NNP N
? . N
Genotype NNP N
effect NN N
was VBD N
analyzed VBN N
with IN N
repeated-measures JJ N
analysis NN N
of IN N
variance NN N
, , N
controlling VBG N
for IN N
baseline JJ N
medication NN N
status NN N
. . N

Results VB N
indicate JJ N
that IN o
DAT1 NNP o
moderated VBD o
treatment NN o
response NN o
( ( o
p JJ N
= NNP N
.009 NNP o
) ) o
. . o

In IN o
children NNS o
with IN o
no DT o
or CC o
1 CD o
DAT1 NNP o
10-repeat JJ o
allele NN o
, , o
superior JJ o
treatment NN o
effects NNS o
of IN o
BPT NNP o
+ NNP o
RCC NNP o
compared VBN o
with IN o
RCC NNP o
alone RB o
were VBD o
present JJ o
( ( o
p JJ o
= NNP o
.005 NNP o
) ) o
, , o
which WDT o
was VBD o
not RB o
the DT o
case NN o
in IN o
children NNS o
with IN o
2 CD o
DAT1 NNP o
10-repeat JJ o
alleles NNS o
( ( o
p JJ o
= NNP o
.57 NNP o
) ) o
. . o

Our PRP$ N
findings NNS N
suggest VBP N
that IN N
genetic JJ N
differences NNS N
in IN N
DAT1 NNP o
in IN o
children NNS N
with IN N
ADHD NNP N
influence VBP N
their PRP$ N
susceptibility NN N
to TO N
a DT N
behavioral JJ o
intervention NN o
directed VBD o
at IN N
shaping VBG N
their PRP$ N
environment NN N
through IN N
their PRP$ N
parents NNS N
. . N

The DT N
role NN N
of IN N
the DT i
dopamine NN i
system NN i
in IN i
motivation NN N
and CC N
learning NN N
and CC N
in IN N
the DT N
aberrant JJ N
sensitivity NN N
to TO N
reinforcement VB N
in IN N
children NNS N
with IN N
ADHD NNP N
may MD N
explain VB N
this DT N
moderating NN N
effect NN N
, , N
given VBN N
that IN N
the DT N
management NN N
of IN N
contingencies NNS N
is VBZ N
typically RB N
addressed VBN N
in IN N
BPT NNP i
. . i

-DOCSTART- -16887481- O O

Left NNP i
thoracoabdominal JJ i
approach NN i
versus IN N
abdominal-transhiatal JJ i
approach NN i
for IN N
gastric JJ p
cancer NN p
of IN p
the DT p
cardia NN p
or CC p
subcardia NN p
: : p
a DT N
randomised JJ N
controlled VBN N
trial NN N
. . N

BACKGROUND NNP N
Because IN N
of IN N
the DT N
inaccessibility NN N
of IN N
mediastinal JJ N
nodal JJ N
metastases NNS N
, , N
the DT N
left JJ i
thoracoabdominal JJ i
approach NN i
( ( i
LTA NNP i
) ) i
has VBZ N
often RB N
been VBN N
used VBN N
to TO N
treat VB N
gastric JJ p
cancer NN p
of IN p
the DT p
cardia NN p
or CC p
subcardia NN p
. . p

In IN N
a DT N
randomised JJ N
phase NN N
III NNP N
study NN N
, , N
we PRP N
aimed VBD N
to TO N
compare VB o
LTA NNP i
with IN i
the DT i
abdominal-transhiatal JJ i
approach NN i
( ( i
TH NNP i
) ) i
in IN i
the DT i
treatment NN i
of IN N
these DT N
tumours NNS N
. . N

METHODS NNP N
Between NNP p
July NNP p
, , p
1995 CD p
, , p
and CC p
December NNP p
, , p
2003 CD p
, , p
167 CD p
patients NNS p
were VBD p
enrolled VBN p
from IN p
27 CD p
Japanese JJ p
hospitals NNS p
and CC N
randomly RB N
assigned VBN N
to TO N
TH NNP N
( ( N
n=82 NN N
) ) N
or CC N
LTA NNP N
( ( N
n=85 NN N
) ) N
. . N

The DT N
primary JJ N
endpoint NN N
was VBD N
overall JJ o
survival NN o
, , N
and CC N
secondary JJ N
endpoints NNS N
were VBD N
disease-free JJ o
survival NN o
, , o
postoperative JJ o
morbidity NN o
and CC o
hospital NN o
mortality NN o
, , o
and CC o
postoperative JJ o
symptoms NNS o
and CC o
change NN o
of IN o
respiratory NN o
function NN o
. . o

The DT p
projected JJ p
sample NN p
size NN p
was VBD p
302 CD p
. . p

After IN p
the DT p
first JJ p
interim JJ p
analysis NN p
, , p
the DT p
predicted JJ p
probability NN p
of IN p
LTA NNP p
having VBG p
a DT p
significantly RB p
better RBR p
overall JJ p
survival NN p
than IN p
TH NNP p
at IN p
the DT p
final JJ p
analysis NN p
was VBD p
only RB p
3.65 CD p
% NN p
, , p
and CC p
the DT p
trial NN p
was VBD p
closed VBN p
immediately RB p
. . p

Analysis NN N
was VBD N
by IN N
intention NN N
to TO N
treat VB N
. . N

This DT N
study NN N
is VBZ N
registered VBN N
with IN N
, , N
number NN N
NCT00149266 NNP N
. . N

FINDINGS NNP N
5-year JJ o
overall JJ o
survival NN o
was VBD N
52.3 CD N
% NN N
( ( N
95 CD N
% NN N
CI NNP N
40.4-64.1 CD N
) ) N
in IN N
the DT N
TH NNP N
group NN N
and CC N
37.9 CD N
% NN N
( ( N
26.1-49.6 JJ N
) ) N
in IN N
the DT N
LTA NNP N
group NN N
. . N

The DT N
hazard NN o
ratio NN o
of IN o
death NN o
for IN o
LTA NNP o
compared VBN N
with IN N
TH NNP N
was VBD N
1.36 CD N
( ( N
0.89-2.08 CD N
, , N
p=0.92 NN N
) ) N
. . N

Three CD N
patients NNS N
died VBD o
in IN N
hospital NN N
after IN N
LTA NNP N
but CC N
none NN N
after IN N
TH NNP N
. . N

Morbidity NNP o
was VBD N
worse JJR N
after IN N
LTA NNP N
than IN N
after IN N
TH NNP N
. . N

INTERPRETATION NNP N
Because IN N
LTA NNP N
does VBZ N
not RB N
improve VB N
survival NN N
after IN N
TH NNP N
and CC N
leads VBZ N
to TO N
increased VBN N
morbidity NN N
in IN N
patients NNS p
with IN p
cancer NN p
of IN p
the DT p
cardia NN p
or CC p
subcardia NN p
, , N
LTA NNP N
can MD N
not RB N
be VB N
justified VBN N
to TO N
treat VB N
these DT N
tumours NNS N
. . N

-DOCSTART- -1516345- O O

Double JJ N
blind IN N
comparison NN N
of IN N
Iomeprol NNP i
350 CD i
and CC i
Iopamidol NNP i
340 CD i
in IN N
intravenous JJ i
digital JJ i
subtraction NN i
angiography NN i
for IN p
peripheral JJ p
vascular JJ p
disease NN p
. . p

A DT N
randomized JJ N
double JJ N
blind NN N
study NN N
was VBD N
undertaken VBN N
to TO N
compare VB N
the DT N
diagnostic JJ o
efficacy NN o
and CC o
side JJ o
effects NNS o
of IN N
a DT N
new JJ N
non-ionic JJ i
contrast NN i
medium NN i
Iomeprol NNP i
with IN N
a DT N
commonly RB i
used VBN i
one CD i
-- : i
Iopamidol NNP i
. . i

Visual NNP N
and CC N
densitometric JJ N
comparison NN N
was VBD N
made VBN N
of IN N
intravenous JJ N
digital JJ N
subtraction NN N
angiograms NNS N
performed VBD N
for IN N
peripheral JJ N
vascular JJ N
disease NN N
. . N

The DT N
results NNS N
show VBP N
the DT N
two CD N
media NNS N
to TO N
be VB N
similar JJ N
both DT N
in IN N
imaging VBG o
quality NN o
and CC o
in IN o
the DT o
incidence NN o
of IN o
associated JJ o
side NN o
effects NNS o
. . o

Ninety-eight JJ N
per IN N
cent NN N
of IN N
the DT N
intravenous JJ i
digital JJ i
subtraction NN i
angiograms NNS i
were VBD N
assessed VBN N
as IN N
adequate NN N
for IN N
clinical JJ N
management NN N
by IN N
the DT N
vascular JJ N
surgeon NN N
. . N

-DOCSTART- -1617528- O O

Drug NNP N
therapy NN N
of IN N
ventricular JJ p
tachycardia NN p
: : p
a DT N
cost NN N
comparison NN N
of IN N
randomized JJ N
noninvasive JJ i
and CC i
invasive JJ i
approaches NNS i
. . i

OBJECTIVE NNP N
Economic NNP o
evaluation NN o
of IN N
noninvasive JJ i
( ( i
suppression NN i
of IN i
ventricular JJ i
arrhythmias NNS i
detected VBN i
by IN i
ambulatory JJ i
monitoring NN i
) ) i
and CC N
invasive JJ i
( ( i
suppression NN i
of IN i
arrhythmias NNS i
induced VBN i
by IN i
programmed JJ i
stimulation NN i
) ) i
approaches VBZ N
to TO N
antiarrhythmic VB N
drug NN N
selection NN N
for IN N
ventricular JJ N
tachyarrhythmias NN N
. . N

DESIGN/SETTING NNP N
Randomized NNP N
clinical JJ N
trial/tertiary-care JJ N
hospital NN N
. . N

PATIENTS NNP N
Of IN N
124 CD p
consecutive JJ p
patients NNS p
referred VBD p
for IN p
treatment NN p
of IN p
symptomatic JJ p
ventricular NN p
tachyarrhythmias NN p
, , p
57 CD p
consenting NN p
patients NNS p
were VBD p
eligible JJ p
to TO p
have VB p
drug NN p
therapy NN p
selected VBN p
by IN p
either DT p
noninvasive JJ i
or CC i
invasive JJ i
approaches NNS i
. . i

MEASUREMENTS NNP N
Costs NNPS o
of IN o
initial JJ o
and CC o
follow-up JJ o
( ( N
26 CD N
+/- JJ N
15 CD N
months NNS N
) ) N
admissions NNS N
for IN N
the DT N
two CD N
groups NNS N
were VBD N
compared VBN N
. . N

This DT N
economic JJ o
evaluation NN o
also RB N
considered VBN N
relative JJ N
efficacies NNS o
of IN N
the DT N
approaches NNS N
using VBG N
the DT N
primary JJ o
outcome NN o
variable NN o
of IN N
symptomatic JJ o
, , o
sustained VBD o
ventricular JJ o
tachyarrhythmia NN o
recurrence NN o
( ( o
including VBG o
sudden JJ o
death NN o
) ) o
. . o

RESULTS NNP N
Initial JJ o
hospitalization NN o
for IN N
therapy NN N
selection NN N
was VBD N
less RBR N
costly JJ o
by IN N
the DT N
noninvasive JJ N
approach NN N
( ( N
$ $ N
6,869 CD N
+/- JJ N
4,019 CD N
) ) N
than IN N
by IN N
the DT N
invasive JJ i
approach NN i
( ( N
$ $ N
13,164 CD N
+/- JJ N
6,740 CD N
) ) N
( ( N
P NNP N
less JJR N
than IN N
0.001 CD N
) ) N
. . N

However RB N
, , N
the DT N
noninvasive JJ i
approach NN i
generated VBD N
higher JJR N
follow-up JJ o
hospital NN o
costs NNS o
( ( N
$ $ N
9,204 CD N
+/- JJ N
9,217 CD N
) ) N
than IN N
the DT N
invasive JJ N
approach NN N
( ( N
$ $ N
3,784 CD N
+/- JJ N
4,944 CD N
) ) N
( ( N
P NNP N
= NNP N
0.01 CD N
) ) N
. . N

Thus RB N
, , N
total JJ o
hospital NN o
costs NNS o
of IN N
the DT N
noninvasive JJ N
( ( N
$ $ N
16,073 CD N
+/- JJ N
9,423 CD N
) ) N
and CC N
invasive JJ N
approaches NNS N
( ( N
$ $ N
16,949 CD N
+/- JJ N
7,174 CD N
) ) N
were VBD N
equivalent JJ N
. . N

The DT N
two-year JJ o
actuarial JJ o
probability NN o
of IN o
a DT o
recurrent NN o
, , o
sustained VBN o
, , o
symptomatic JJ o
ventricular NN o
tachyarrhythmia NN o
was VBD N
greater JJR N
in IN N
noninvasive JJ i
( ( N
0.50 CD N
+/- JJ N
0.10 CD N
) ) N
than IN N
in IN N
invasive JJ i
( ( N
0.20 CD N
+/- JJ N
0.08 CD N
) ) N
approach NN N
patients NNS N
( ( N
P NNP N
= NNP N
0.02 CD N
) ) N
. . N

CONCLUSIONS VB N
The DT N
lower JJR N
initial JJ o
hospital NN o
costs NNS o
of IN N
the DT N
noninvasive JJ N
approach NN N
are VBP N
offset VBN N
by IN N
greater JJR N
follow-up NN o
costs NNS o
. . o

Within IN N
two CD N
years NNS N
the DT N
costs NNS o
of IN N
the DT N
two CD N
approaches NNS N
are VBP N
equivalent JJ N
. . N

Thus RB N
, , N
greater JJR N
antiarrhythmic JJ o
efficacy NN o
can MD N
be VB N
achieved VBN N
by IN N
the DT N
invasive JJ i
approach NN i
to TO N
drug NN N
selection NN N
without IN N
increasing VBG N
total JJ o
hospital NN o
costs NNS o
. . o

-DOCSTART- -23525780- O O

Process NNP N
evaluation NN N
of IN N
Healthy NNP i
Bodies NNP i
, , i
Healthy NNP i
Souls NNP i
: : i
a DT i
church-based JJ i
health NN i
intervention NN i
program NN i
in IN p
Baltimore NNP p
City NNP p
. . p

Soaring VBG N
obesity NN N
rates NNS N
in IN N
the DT N
United NNP N
States NNPS N
demand VBP N
comprehensive JJ N
health NN N
intervention NN N
strategies NNS N
that WDT N
simultaneously RB N
address VBP N
dietary JJ N
patterns NNS N
, , N
physical JJ N
activity NN N
, , N
psychosocial JJ N
factors NNS N
and CC N
the DT N
food NN N
environment NN N
. . N

Healthy NNP i
Bodies NNPS i
, , i
Healthy NNP i
Souls NNP i
( ( i
HBHS NNP i
) ) i
is VBZ N
a DT N
church-based JJ p
, , p
community-participatory JJ p
, , p
cluster-randomized JJ p
health NN N
intervention NN N
trial NN N
conducted VBN N
in IN N
Baltimore NNP N
City NNP N
to TO N
reduce VB N
diabetes NNS N
risk VBP N
among IN p
urban JJ p
African JJ p
Americans NNPS p
by IN N
promoting VBG N
healthy JJ N
dietary JJ N
intake NN N
, , N
increased VBD N
physical JJ N
activity NN N
and CC N
improvement NN N
to TO N
the DT N
church NN N
food NN N
environment NN N
. . N

HBHS NNP i
was VBD N
organized VBN N
into IN N
five CD N
3-8-week JJ N
phases NNS N
: : N
Healthy NNP i
Beverages NNP i
, , i
Healthy NNP i
Desserts NNP i
, , i
Healthy NNP i
Cooking NNP i
, , i
Healthy NNP i
Snacking NNP i
and CC i
Eating NNP i
Out NNP i
and CC i
Physical NNP i
Activity NNP i
. . i

A DT N
three-part JJ N
process NN N
evaluation NN N
was VBD N
adopted VBN N
to TO N
evaluate VB o
implementation NN N
success NN o
: : o
an DT N
in-church JJ o
instrument NN o
to TO o
assess VB o
the DT o
reach NN o
, , o
dose VB o
delivered VBN o
and CC N
fidelity NN o
of IN N
interactive JJ N
sessions NNS N
; : N
a DT N
post-intervention NN N
exposure NN o
survey NN o
to TO N
assess VB N
individual-level JJ o
dose NN o
received VBN o
in IN N
a DT N
sample NN N
of IN N
congregants NNS N
and CC N
an DT N
evaluation NN o
form NN o
to TO N
assess VB N
the DT N
church NN o
food NN o
environment NN o
. . o

Print NN N
materials NNS N
were VBD N
implemented VBN N
with IN N
moderate JJ N
to TO N
high JJ N
fidelity NN N
and CC N
high JJ N
dose NN N
. . N

Program NNP N
reach NN N
was VBD N
low JJ N
, , N
which WDT N
may MD N
reflect VB N
inaccuracies NNS N
in IN N
church NN N
attendance NN N
rather RB N
than IN N
study VB N
implementation JJ N
issues NNS N
. . N

Intervention NN N
components NNS N
with IN N
the DT N
greatest JJS N
dose NN N
received VBN N
were VBD N
giveaways NNS o
( ( N
42.0-61.7 CD N
% NN N
) ) N
, , N
followed VBN N
by IN N
taste NN o
tests NNS o
( ( N
48.7-53.7 CD N
% NN N
) ) N
and CC N
posters NNS o
( ( N
34.3-65.0 CD N
% NN N
) ) N
. . N

The DT N
dose JJ N
received NN N
of IN N
general JJ N
program NN N
information NN N
was VBD N
moderate JJ N
to TO N
high JJ N
. . N

The DT N
results NNS N
indicate VBP N
successful JJ o
implementation NN o
of IN N
the DT N
HBHS NNP i
program NN i
. . i

-DOCSTART- -11362629- O O

Confirmatory JJ p
trials NNS p
: : p
symptom NN o
reduction NN o
as IN p
efficacy NN o
measure NN p
. . p

-DOCSTART- -7080985- O O

[ RB N
Comparative NNP N
study NN N
of IN N
cinoxacin NN i
( ( i
Cinobac NNP i
) ) i
, , i
nitrofurantoin FW i
( ( i
Furadantine NNP i
MC NNP i
) ) i
and CC i
oxolinic JJ i
acid NN i
( ( i
Uritrate NNP i
) ) i
in IN N
urinary JJ N
tract NN N
infections NNS N
. . N

Results NNS N
of IN N
a DT N
random NN N
study NN N
of IN N
three CD p
groups NNS p
of IN p
30 CD p
patients NNS p
with IN p
uncomplicated JJ p
urinary JJ p
infections NNS p
] VBP p
. . p

-DOCSTART- -25056444- O O

Prior JJ p
experience NN p
with IN p
a DT p
pain NN p
stimulus NN p
as IN N
a DT N
predictor NN N
of IN N
placebo NN N
analgesia NN o
. . o

Placebo NNP i
effects NNS N
are VBP N
important JJ N
in IN N
pain NN o
reduction NN o
, , N
but CC N
the DT N
effects NNS N
are VBP N
inconsistent JJ N
. . N

Prior JJ N
experience NN N
with IN N
a DT N
pain NN N
stimulus NN N
may MD N
moderate VB N
placebo NN N
analgesia NN o
. . o

The DT N
current JJ N
study NN N
tests VBZ N
the DT N
effect NN N
of IN N
prior JJ N
experience NN N
with IN N
a DT N
pain NN N
stimulus NN N
on IN N
placebo NN o
analgesia NN o
during IN N
a DT N
laboratory NN N
pain NN N
task NN N
. . N

Healthy NNP p
normotensive JJ p
undergraduates NNS p
( ( p
66 CD p
women NNS p
, , p
68 CD p
men NNS p
) ) p
who WP p
either DT p
did VBD p
or CC p
did VBD p
not RB p
report VB p
prior JJ p
experience NN p
with IN p
pain NN o
from IN p
submerging VBG p
a DT p
limb NN p
in IN p
cold JJ p
water NN p
were VBD p
enrolled VBN p
. . p

In IN N
the DT N
laboratory NN N
, , N
an DT N
experimenter NN N
applied VBD N
an DT N
inert NN N
, , N
medicinal-smelling JJ i
cream NN i
to TO N
participants NNS N
' POS N
non-dominant JJ N
hand NN N
. . N

Participants NNS N
randomized VBD N
to TO N
the DT N
no-expectation JJ N
group NN N
were VBD N
told VBN N
that IN N
the DT N
cream NN i
was VBD i
a DT i
hand NN i
cleanser NN i
. . i

Participants NNS N
randomized VBD N
to TO N
the DT N
placebo NN i
expectation NN N
group NN N
were VBD N
told VBN N
that IN N
the DT N
cream NN i
would MD N
reduce VB N
the DT N
pain NN o
associated VBN N
with IN N
the DT N
cold JJ i
pressor NN i
task NN i
. . i

Participants NNS N
then RB N
completed VBD N
the DT N
cold JJ i
pressor NN i
task NN i
and CC N
reported VBD N
their PRP$ N
pain NN o
on IN N
the DT N
short JJ N
form NN N
of IN N
the DT N
McGill NNP o
Pain NNP o
Questionnaire NNP o
. . o

Analysis NN N
of IN N
variance NN N
revealed VBD N
a DT N
main JJ N
effect NN N
of IN N
expectation NN N
( ( N
p JJ N
< NNP N
.05 NNP N
) ) N
, , N
such JJ N
that IN N
participants NNS N
in IN N
the DT N
placebo NN N
expectation NN N
group NN N
reported VBD N
less JJR o
pain NN o
. . o

An DT N
interaction NN N
was VBD N
also RB N
found VBN N
between IN N
expectation NN N
and CC N
prior JJ N
experience NN N
( ( N
p JJ N
< NNP N
.05 NNP N
) ) N
, , N
such JJ N
that IN N
participants NNS N
with IN N
prior JJ N
experience NN N
with IN N
pain NN o
from IN o
cold JJ N
water NN N
immersion NN N
showed VBD N
no DT N
difference NN o
in IN o
pain NN o
reports NNS o
between IN o
expectation NN N
groups NNS N
. . N

In IN N
a DT N
pain NN N
context NN p
, , p
prior JJ p
experience NN p
with IN p
the DT p
pain NN p
stimulus NN p
may MD p
prevent VB i
a DT i
placebo JJ i
expectation NN i
from IN N
reducing VBG N
the DT N
experience NN o
of IN o
pain NN o
. . o

-DOCSTART- -18341602- O O

A DT N
double-blind JJ N
randomized JJ N
clinical JJ N
evaluation NN N
of IN N
enamel JJ i
matrix NNS i
derivative JJ i
proteins NNS i
for IN N
the DT N
treatment NN N
of IN N
proximal JJ N
class-II JJ N
furcation NN N
involvements NNS N
. . N

OBJECTIVE IN N
The DT N
aim NN N
of IN N
the DT N
present JJ N
randomized VBN N
, , N
double-blind JJ N
study NN N
was VBD N
to TO N
evaluate VB N
the DT N
clinical JJ o
response NN o
of IN N
proximal JJ N
furcations NNS N
treated VBN N
with IN N
enamel JJ i
matrix NNS i
derivative JJ i
proteins NNS i
( ( i
EMD NNP i
) ) i
. . i

MATERIAL NNP N
AND NNP N
METHODS NNP N
Fifteen NNP p
patients NNS p
, , p
each DT p
with IN p
a DT p
pair NN p
of IN p
contralateral JJ p
class-II JJ p
proximal JJ p
furcation NN p
involvements NNS p
, , p
presenting VBG p
probing VBG p
depths NNS p
( ( p
PDs NNP p
) ) p
> VBP p
/=5 JJ p
mm NN p
and CC p
bleeding NN p
on IN p
probing VBG p
( ( p
BOP NNP p
) ) p
were VBD p
selected VBN p
. . p

The DT N
patients NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
: : N
control NN i
group NN i
( ( N
n=15 NN N
) ) N
- : N
open JJ i
flap NN i
debridement NN i
( ( i
OFD NNP i
) ) i
+24 CD i
% NN i
ethylenediaminetetraacetic JJ i
acid NN i
( ( i
EDTA NNP i
) ) i
conditioning NN i
; : i
test CC N
group NN N
( ( N
n=15 NN N
) ) N
- : N
OFD+24 CD i
% NN i
EDTA NNP i
conditioning+EMD NN i
application NN i
. . i

Plaque NNP o
index NN o
( ( o
PI NNP o
) ) o
, , o
BOP NNP o
, , o
PD NNP o
, , o
gingival NN o
margin NN o
position NN o
( ( o
GMP NNP o
) ) o
, , o
relative JJ o
vertical NN o
and CC o
horizontal JJ o
clinical JJ o
attachment NN o
level NN o
( ( o
RVCAL NNP o
and CC o
RHCAL NNP o
) ) o
, , o
vertical JJ o
and CC o
horizontal JJ o
bone NN o
level NN o
( ( o
VBL NNP o
and CC o
HBL NNP o
) ) o
and CC o
furcation JJ o
closure NN o
were VBD N
evaluated VBN N
immediately RB N
before IN N
and CC N
2 CD N
, , N
4 CD N
and CC N
6 CD N
months NNS N
after IN N
the DT N
surgeries NNS N
. . N

RESULTS NNP N
At IN N
6 CD N
months NNS N
, , N
the DT N
RVCAL NNP o
gains NNS o
of IN N
the DT N
control NN N
and CC N
test NN N
group NN N
were VBD N
0.39 CD N
+/- JJ N
1.00 CD N
and CC N
0.54 CD N
+/- JJ N
0.95 CD N
mm NN N
, , N
while IN N
the DT N
RHCAL NNP o
gains NNS N
were VBD N
1.21 CD N
+/- JJ N
2.28 CD N
and CC N
1.36 CD N
+/- JJ N
1.26 CD N
mm NN N
( ( N
p JJ N
> NNP N
0.05 CD N
) ) N
. . N

The DT N
VBL NNP o
and CC o
HBL NNP o
gains NNS o
of IN N
the DT N
control NN N
group NN N
were VBD N
1.04 CD N
+/- JJ N
1.12 CD N
and CC N
1.00 CD N
+/- JJ N
1.79 CD N
mm NN N
, , N
and CC N
0.82 CD N
+/- JJ N
1.82 CD N
and CC N
1.17 CD N
+/- JJ N
1.38 CD N
mm NN N
for IN N
the DT N
test NN N
group NN N
( ( N
p JJ N
> NNP N
0.05 CD N
) ) N
. . N

In IN N
addition NN N
, , N
a DT N
statistical JJ N
difference NN N
was VBD N
observed VBN N
in IN N
the DT N
number NN o
of IN o
the DT o
remaining VBG o
class-II JJ o
furcations NNS o
between IN N
the DT N
test NN N
and CC N
control NN N
groups NNS N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
in IN N
this DT N
period NN N
. . N

CONCLUSION VB N
It PRP N
may MD N
be VB N
concluded VBN N
that IN N
the DT N
use NN N
of IN N
EMD NNP i
in IN N
proximal JJ N
furcations NNS N
did VBD N
not RB N
promote VB N
a DT N
superior JJ N
reduction NN N
in IN N
PD NNP o
or CC N
a DT N
gain NN N
in IN N
clinical JJ o
and CC o
osseous JJ o
attachment NN o
levels NNS o
, , N
but CC N
resulted VBD N
in IN N
a DT N
higher JJR N
rate NN N
of IN N
class-II NN o
to TO o
class-I JJ o
furcation NN o
conversion NN o
. . o

-DOCSTART- -22926008- O O

Computer-delivered JJ i
tailored VBN i
intervention NN i
improves VBZ N
colon NN o
cancer NN o
screening VBG o
knowledge NN o
and CC N
health NN N
beliefs NNS N
of IN N
African-Americans NNPS p
. . p

We PRP N
conducted VBD N
a DT N
randomized VBN N
controlled VBN N
trial NN N
among IN N
African-American JJ p
patients NNS p
attending VBG p
a DT p
primary-care JJ p
provider NN p
visit NN p
to TO p
compare VB p
efficacy NN p
of IN p
a DT p
computer-delivered JJ i
tailored JJ i
intervention NN i
to TO p
increase VB p
colorectal JJ o
cancer NN o
( ( o
CRC NNP o
) ) o
screening NN o
( ( p
n JJ p
= NNP p
273 CD p
) ) p
with IN p
non-tailored JJ i
print NN i
material-an JJ i
American JJ p
Cancer NNP p
Society NNP p
brochure NN p
on IN p
CRC NNP p
screening NN p
( ( p
n JJ p
= NNP p
283 CD p
) ) p
. . p

Health NNP N
Belief NNP N
Model NNP N
constructs NNS N
were VBD N
used VBN N
to TO N
develop VB N
tailored JJ N
messages NNS N
and CC N
examined VBD N
as IN N
outcomes NNS N
. . N

Analysis NN N
of IN N
covariance NN N
models NNS N
were VBD N
used VBN N
to TO N
compare VB N
changes NNS N
between IN N
CRC NNP o
knowledge NNP o
and CC o
health NN o
belief NN o
scores NNS o
at IN N
baseline NN N
and CC N
1 CD N
week NN N
post-intervention NN N
. . N

At IN N
1 CD N
week NN N
, , N
patients NNS N
who WP N
received VBD N
the DT N
computer-delivered JJ i
tailored JJ i
intervention NN i
had VBD N
greater JJR N
changes NNS N
in IN N
CRC NNP o
knowledge NN o
scores NNS o
( ( o
P NNP o
< NNP o
0.001 CD o
) ) o
, , o
perceived VBD o
CRC NNP o
risk NN o
scores NNS o
( ( o
P NNP o
= NNP o
0.005 CD o
) ) o
, , o
FOBT NNP o
barriers NNS o
scores NNS o
( ( o
P NNP o
= NNP o
0.034 CD o
) ) o
and CC o
colonoscopy JJ o
benefit NN o
scores NNS o
( ( o
P NNP o
< NNP o
0.001 CD o
) ) o
. . o

Findings NNS N
show VBP N
that IN N
computer-delivered JJ N
tailored JJ N
interventions NNS N
are VBP N
an DT N
effective JJ N
adjunct NN N
to TO N
the DT N
clinical JJ N
encounter NN N
that WDT N
can MD N
improve VB N
knowledge NN o
and CC o
health NN o
beliefs NNS o
about IN o
CRC NNP o
screening NN o
, , N
necessary JJ N
precursors NNS N
to TO N
behavior VB N
change NN N
. . N

-DOCSTART- -16480401- O O

CDP571 NNP i
, , N
a DT N
humanized JJ N
monoclonal JJ N
antibody NN N
to TO N
tumour VB N
necrosis NN N
factor-alpha NN N
, , N
for IN N
steroid-dependent JJ N
Crohn NNP N
's POS N
disease NN N
: : N
a DT N
randomized JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ i
trial NN N
. . N

BACKGROUND NNP N
More JJR p
than IN p
50 CD p
% NN p
of IN p
patients NNS p
with IN p
Crohn NNP p
's POS p
disease NN p
become NN N
either CC N
steroid JJ N
resistant NN N
or CC N
dependent NN N
. . N

Accordingly RB N
, , N
development NN N
of IN N
new JJ N
treatments NNS N
for IN N
steroid-dependent JJ N
Crohn NNP N
's POS N
disease NN N
is VBZ N
a DT N
research NN N
priority NN N
. . N

AIM NNP N
To TO N
evaluate VB N
CDP571 NNP i
, , N
a DT N
humanized VBN N
antibody NN N
to TO N
tumour VB N
necrosis NN N
factor-alpha NN N
, , N
for IN N
the DT N
treatment NN N
of IN N
steroid-dependent JJ N
Crohn NNP N
's POS N
disease NN N
. . N

METHODS NNP N
Patients NNPS p
with IN p
steroid-dependent JJ p
Crohn NNP p
's POS p
disease NN p
( ( p
n JJ p
= NNP p
271 CD p
) ) p
were VBD p
enrolled VBN p
in IN N
a DT N
36-week JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ i
trial NN N
. . N

Steroid JJ p
dependence NN p
was VBD p
defined VBN p
as IN p
use NN p
of IN p
prednisolone NN p
or CC p
prednisone NN i
( ( p
15-40 JJ p
mg/day NN p
) ) p
or CC p
budesonide NN p
( ( p
9 CD p
mg/day NN p
) ) p
for IN p
> NN p
or CC p
=8 JJ p
weeks NNS p
, , p
a DT p
previous JJ p
failed JJ p
attempt NN p
to TO p
decrease VB p
or CC p
discontinue VB p
steroids NNS p
within IN p
8 CD p
weeks NNS p
of IN p
screening NN p
, , p
and CC p
a DT p
Crohn NNP p
's POS p
Disease NNP p
Activity NNP p
Index NNP p
score NN p
of IN p
< NN p
or CC p
=150 JJ p
points NNS p
. . p

Patients NNS N
were VBD N
randomized VBN N
to TO N
receive VB N
intravenous JJ i
CDP571 NNP i
10 CD i
mg/kg NN i
or CC i
placebo NN i
8-weekly RB N
through IN N
to TO N
week NN N
32 CD N
. . N

Steroids NNS N
were VBD N
then RB N
tapered VBN N
using VBG N
a DT N
defined JJ N
schedule NN N
. . N

The DT N
primary JJ N
efficacy NN N
endpoint NN N
was VBD N
the DT N
percentage NN o
of IN o
patients NNS o
with IN o
steroid JJ o
sparing NN o
, , o
defined VBD o
as IN o
discontinuation NN o
of IN o
steroid JJ o
therapy NN o
without IN o
a DT o
disease NN o
flare NN o
( ( o
Crohn NNP o
's POS o
Disease NNP o
Activity NNP o
Index NNP o
score VBD o
> NNP o
or CC o
=220 NNP o
points NNS o
) ) o
at IN N
week NN N
36 CD N
. . N

RESULTS NNP N
Steroid NNP o
sparing VBG o
occurred VBD N
in IN N
53 CD N
of IN N
181 CD N
( ( N
29.3 CD N
% NN N
) ) N
CDP571 NNP i
patients NNS N
and CC N
33 CD N
of IN N
90 CD N
( ( N
36.7 CD N
% NN N
) ) N
placebo NN i
patients NNS N
( ( N
P NNP N
= NNP N
0.24 CD N
) ) N
. . N

Adverse JJ o
events NNS o
occurred VBD N
at IN N
similar JJ N
frequencies NNS N
in IN N
both DT N
treatment NN N
groups NNS N
. . N

CONCLUSIONS NNP N
CDP571 NNP i
was VBD N
ineffective JJ N
for IN N
sparing VBG o
steroids NNS o
in IN N
patients NNS p
with IN p
steroid-dependent JJ p
Crohn NNP p
's POS p
disease NN p
. . p

CDP571 NNP i
was VBD N
well RB N
tolerated VBN N
. . N

-DOCSTART- -16264956- O O

Chemotherapy NNP i
for IN p
metastatic JJ p
NSCLC NNP p
: : p
current JJ N
status NN N
and CC N
future JJ N
direction NN N
. . N

-DOCSTART- -15189800- O O

Chronic NNP N
fatigue NN N
syndrome NN N
versus NN N
neuroendocrineimmune JJ N
dysfunction NN N
syndrome NN i
: : i
differential JJ i
attributions NNS i
. . i

Since IN N
1988 CD N
, , N
when WRB N
the DT N
term NN N
chronic JJ N
fatigue NN N
syndrome NN N
( ( N
CFS NNP N
) ) N
was VBD N
coined VBN N
, , N
considerable JJ N
discussion NN N
has VBZ N
occurred VBN N
about IN N
stigma NN N
associated VBN N
with IN N
this DT N
diagnostic JJ N
term NN N
. . N

In IN N
particular JJ N
, , N
patients NNS p
with IN p
CFS NNP p
have VBP N
felt VBN N
that IN N
this DT N
term NN N
trivializes VBZ N
the DT N
serious JJ N
nature NN N
of IN N
this DT N
disorder NN N
. . N

A DT N
Name NN N
Change NNP N
Work NNP N
group NN N
, , N
appointed VBN N
by IN N
the DT N
CFS NNP N
Coordinating NNP N
Committee NNP N
, , N
developed VBD N
an DT N
umbrella JJ N
term NN N
: : N
chronic JJ N
neuroendocrineimmune JJ N
dysfunction NN N
syndrome NN N
( ( N
CNDS NNP N
) ) N
, , N
and CC N
proposed VBD N
that IN N
there EX N
would MD N
be VB N
sub-types JJ N
under IN N
this DT N
term NN N
, , N
one CD N
being VBG N
CFS NNP N
. . N

The DT N
present JJ N
study NN N
examined VBD N
attributions NNS o
of IN N
this DT N
new JJ N
umbrella JJ N
term NN N
when WRB N
compared VBN N
with IN N
CFS NNP N
. . N

Nurses NNS i
and CC i
physician JJ i
assistants NNS i
( ( i
PAs NNP i
) ) i
were VBD i
presented VBN i
a DT i
case NN i
study NN i
of IN i
a DT i
patient NN i
with IN i
symptoms NNS i
of IN i
CFS NNP i
. . i

They PRP N
were VBD N
told VBN N
that IN N
the DT N
patient NN p
had VBD p
either CC p
chronic JJ p
fatigue NN p
syndrome NN p
, , p
chronic JJ p
neuroendocrineimmune JJ p
dysfunction NN p
syndrome NN p
, , p
or CC p
chronic JJ p
neuroendocrineimmune JJ p
dysfunction NN p
syndrome NN p
, , N
which WDT N
had VBD N
formerly RB N
been VBN N
called VBN N
chronic JJ N
fatigue NN N
syndrome NN N
. . N

The DT N
different JJ N
terms NNS N
led VBD N
to TO N
different JJ N
attributions NNS N
, , N
with IN N
PA NNP N
respondents NNS N
rating NN N
the DT N
CNDS NNP N
label NN N
as IN N
more RBR N
severe JJ N
. . N

Results VB N
suggest VBP N
that IN N
a DT N
more RBR N
medical JJ o
sounding VBG o
term NN o
( ( i
CNDS NNP i
) ) i
may MD N
lead VB N
to TO N
attributions NNS o
that IN N
this DT N
syndrome NN N
is VBZ N
a DT N
more RBR o
serious JJ o
, , o
disabling VBG o
illness NN o
. . o

The DT N
policy NN N
implications NNS N
of IN N
these DT N
findings NNS N
are VBP N
discussed VBN N
. . N

-DOCSTART- -789390- O O

Aspirin NNP i
in IN N
coronary JJ o
heart NN o
disease NN o
. . o

The DT N
Coronary JJ N
Drug NNP N
Project NNP N
Research NNP N
Group NNP N
. . N

-DOCSTART- -23463854- O O

Developing VBG N
the DT N
Ho'ouna NNP i
Pono NNP i
substance NN i
use NN i
prevention NN i
curriculum NN i
: : i
collaborating NN N
with IN N
Hawaiian JJ p
youth NN p
and CC p
communities NNS p
. . p

This DT N
article NN N
briefly NN N
outlines VBZ N
a DT N
collaboration NN N
among IN N
communities NNS p
on IN p
Hawai'i NNP p
Island NNP p
and CC N
a DT N
university-based JJ p
research NN p
team NN p
to TO N
develop VB o
, , o
implement NN o
, , o
and CC o
evaluate VB o
a DT o
school-based JJ o
substance NN o
use NN o
prevention NN o
curriculum NN o
called VBN i
Ho'ouna NNP i
Pono NNP i
. . i

In IN N
addition NN N
to TO N
providing VBG N
a DT N
rationale NN N
for IN N
the DT N
project NN N
, , N
the DT N
goal NN N
of IN N
this DT N
paper NN N
is VBZ N
fourfold JJ N
. . N

First NNP N
, , N
an DT N
overview NN N
of IN N
the DT N
Ho'ouna NNP i
Pono NNP i
research NN N
results NNS N
to TO N
date NN N
( ( N
2007-2013 JJ N
) ) N
is VBZ N
provided VBN N
. . N

Second JJ N
, , N
within IN N
this DT N
overview NN N
, , N
the DT N
ways NNS N
in IN N
which WDT N
selected VBD N
results NNS N
informed JJ N
program NN N
development NN N
are VBP N
highlighted VBN N
. . N

Third NNP N
, , N
the DT N
curriculum NN N
is VBZ N
briefly JJ N
described VBN N
, , N
and CC N
finally RB N
, , N
the DT N
role NN N
of IN N
the DT N
students NNS p
and CC p
community NN p
in IN N
the DT N
video NN N
production NN N
is VBZ N
described VBN N
. . N

-DOCSTART- -17241298- O O

Comparison NNP N
of IN N
7-day JJ i
and CC i
14-day JJ i
proton NN i
pump IN i
inhibitor-containing JJ i
triple JJ i
therapy NN i
for IN N
Helicobacter NNP o
pylori JJ o
eradication NN o
: : o
neither CC N
treatment NN N
duration NN N
provides VBZ N
acceptable JJ N
eradication NN N
rate NN N
in IN N
Korea NNP p
. . p

BACKGROUND NNP N
AND CC N
AIMS NNP N
Although IN N
triple JJ i
combination NN i
therapy NN i
containing VBG N
a DT i
proton NN i
pump NN i
inhibitor NN i
( ( i
PPI NNP i
) ) i
and CC N
two CD i
antibiotics NNS i
is VBZ N
considered VBN N
as IN N
a DT N
standard JJ N
regimen NN N
for IN N
the DT N
first-line JJ N
anti-Helicobacter JJ N
pylori NN N
treatment NN N
, , N
there EX N
are VBP N
still RB N
debates NNS N
on IN N
the DT N
ideal JJ N
duration NN N
of IN N
treatment NN N
. . N

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
compare VB N
the DT N
efficacies NNS o
of IN N
7-day JJ i
and CC i
14-day JJ i
PPI-containing JJ i
triple NN i
therapy NN i
. . i

MATERIALS NNP N
AND CC N
METHODS NNP N
This DT N
study NN N
was VBD N
performed VBN N
in IN N
a DT N
randomized JJ N
, , N
multicenter NN N
, , N
prospective JJ N
manner NN N
. . N

After IN p
upper JJ i
gastrointestinal JJ i
endoscopy NN i
, , p
H. NNP p
pylori-infected JJ p
patients NNS p
with IN p
a DT p
gastric JJ p
ulcer NN p
and/or VBZ p
a DT p
duodenal JJ p
ulcer NN p
were VBD N
randomly RB N
assigned VBN N
to TO N
a DT N
PAC7 NNP i
group NN N
( ( i
omeprazole JJ i
20 CD i
mg NN i
or CC i
equivalent JJ i
dose NN i
of IN i
other JJ i
PPIs NNP i
, , i
amoxicillin NN i
1000 CD i
mg NN i
, , i
and CC i
clarithromycin VBZ i
500 CD i
mg NN i
twice RB i
daily RB i
for IN i
7 CD i
days NNS i
) ) i
or CC N
to TO N
a DT N
PAC14 NNP i
group NN N
( ( i
the DT i
same JJ i
regimen NN i
as IN i
the DT i
PAC7 NNP i
group NN i
but CC i
for IN i
14 CD i
days NNS i
) ) i
. . N

H. NNP N
pylori NN N
status NN N
was VBD N
evaluated VBN N
by IN N
( ( o
13 CD o
) ) o
C NNP o
urea JJ o
breath NN o
test NN N
5 CD N
weeks NNS N
after IN N
anti-ulcer JJ N
treatment NN N
completion NN N
. . N

RESULTS VB N
A DT N
total NN p
of IN p
598 CD p
patients NNS p
were VBD p
enrolled VBN p
; : p
337 CD N
were VBD N
randomized VBN N
to TO N
the DT N
PAC7 NNP i
group NN N
and CC N
261 CD N
to TO N
the DT N
PAC14 NNP i
group NN N
. . N

The DT N
two CD N
groups NNS N
were VBD N
comparable JJ N
in IN N
terms NNS N
of IN N
baseline NN N
characteristics NNS N
. . N

The DT N
eradication NN N
rates NNS N
of IN N
the DT N
PAC7 NNP i
group NN N
were VBD N
not RB N
inferior JJ N
to TO N
those DT N
of IN N
the DT N
PAC14 NNP i
group NN N
in IN N
both DT N
intention-to-treat JJ N
analysis NN N
( ( N
71.2 CD N
% NN N
vs. FW N
75.5 CD N
% NN N
) ) N
and CC N
per-protocol JJ N
analysis NN N
( ( N
83.6 CD N
% NN N
vs. FW N
86.6 CD N
% NN N
) ) N
. . N

Incidences NNS N
of IN N
adverse JJ o
events NNS o
were VBD N
comparable JJ N
. . N

CONCLUSIONS NNP N
Although IN N
the DT N
7-day JJ i
PPI-containing JJ i
triple JJ i
anti-H. JJ i
pylori NN i
therapy NN i
is VBZ N
not RB N
inferior JJ N
to TO N
the DT N
14-day JJ i
therapy NN N
, , N
neither CC N
treatment NN N
duration NN N
provides VBZ N
acceptable JJ N
eradication NN o
rate NN o
reaching VBG N
90 CD N
% NN N
in IN N
per-protocol JJ N
analysis NN N
. . N

New NNP N
combination NN N
regimen NNS N
with IN N
higher JJR N
efficacy NN N
should MD N
be VB N
developed VBN N
as IN N
a DT N
first-line JJ N
eradication NN N
therapy NN N
for IN N
H. NNP p
pylori NN p
in IN p
Korea NNP p
. . p

-DOCSTART- -19433686- O O

Adjuvant JJ N
therapy NN N
with IN N
pegylated JJ N
interferon NN N
alfa-2b JJ N
versus NN N
observation NN N
in IN N
resected JJ N
stage NN N
III NNP N
melanoma NN N
: : N
a DT N
phase NN N
III NNP N
randomized VBD N
controlled VBN N
trial NN N
of IN N
health-related JJ N
quality NN N
of IN N
life NN N
and CC N
symptoms NNS N
by IN N
the DT N
European JJ N
Organisation NNP N
for IN N
Research NNP N
and CC N
Treatment NNP N
of IN N
Cancer NNP N
Melanoma NNP N
Group NNP N
. . N

PURPOSE NNP N
Interferon NNP N
( ( N
IFN NNP N
) ) N
-based VBD N
adjuvant JJ N
therapy NN N
in IN N
melanoma NN N
is VBZ N
associated VBN N
with IN N
significant JJ N
side NN N
effects NNS N
, , N
which WDT N
necessitates VBZ N
evaluation NN N
of IN N
health-related JJ o
quality NN o
of IN o
life NN o
( ( N
HRQOL NNP N
) ) N
. . N

Our PRP$ N
trial NN N
examined VBD N
the DT N
HRQOL NNP N
effects NNS N
of IN N
adjuvant JJ N
pegylated VBN N
IFN-alpha-2b NNP N
( ( N
PEG-IFN-alpha-2b NNP N
) ) N
versus NN N
observation NN N
in IN N
patients NNS p
with IN p
stage NN p
III NNP p
melanoma NN p
. . p

METHODS NNP N
A NNP N
total NN N
of IN N
1,256 CD p
patients NNS p
with IN p
stage NN p
III NNP p
melanoma NN p
were VBD p
randomly RB p
assigned VBN p
after IN i
full JJ i
lymphadenectomy NN i
to TO i
receive VB i
either DT i
observation NN i
( ( i
n JJ i
= NNP i
629 CD i
) ) i
or CC i
PEG-IFN-alpha-2b NNP i
( ( i
n JJ i
= NNP i
627 CD i
) ) i
: : i
induction NN i
6 CD i
micrograms/kg/wk NN i
[ NNP i
DOSAGE NNP i
ERROR NNP i
CORRECTED NNP i
] NNP i
for IN i
8 CD i
weeks NNS i
then RB i
maintenance RB i
3 CD i
micrograms/kg/wk NNS i
[ JJ i
DOSAGE NNP i
ERROR NNP i
CORRECTED NNP i
] NNP i
for IN i
an DT i
intended JJ i
total JJ i
duration NN i
of IN i
5 CD i
years NNS i
. . i

The DT N
European JJ o
Organisation NNP o
for IN o
Research NNP o
and CC o
Treatment NNP o
of IN o
Cancer NNP o
Quality NNP o
of IN o
Life NNP o
Questionnaire NNP o
C30 NNP o
was VBD N
used VBN N
to TO N
assess VB N
HRQOL NNP N
. . N

RESULTS NNP N
At IN N
3.8 CD N
years NNS N
of IN N
median JJ N
follow-up NN N
, , N
for IN N
the DT N
primary JJ N
end NN N
point NN N
, , N
recurrence-free JJ o
survival NN o
( ( o
RFS NNP o
) ) o
, , N
risk NN N
was VBD N
reduced VBN N
by IN N
18 CD N
% NN N
( ( N
hazard JJ N
rate NN N
= NNS N
0.82 CD N
; : N
P NNP N
= NNP N
.01 NNP N
) ) N
in IN N
the DT N
PEG-IFN-alpha-2b NNP N
arm NN N
compared VBN N
with IN N
observation NN N
. . N

Significant NNP N
and CC N
clinically RB N
meaningful JJ N
differences NNS N
occurred VBD N
with IN N
the DT N
PEG-IFN-alpha-2b NNP N
treatment NN N
arm NN N
compared VBN N
with IN N
the DT N
observation NN N
group NN N
, , N
showing VBG N
decreased VBN N
global JJ N
HRQOL NNP o
at IN N
month NN N
3 CD N
( ( N
-11.6 JJ N
points NNS N
; : N
99 CD N
% NN N
CI NNP N
, , N
-8.2 NNP N
to TO N
-15.0 VB N
) ) N
and CC N
year NN N
2 CD N
( ( N
-10.5 JJ N
points NNS N
; : N
99 CD N
% NN N
CI NNP N
, , N
-6.6 NNP N
to TO N
-14.4 VB N
) ) N
. . N

Many JJ N
of IN N
the DT N
other JJ N
scales NNS N
showed VBD N
statistically RB N
significant JJ N
differences NNS N
between IN N
scores NNS N
when WRB N
comparing VBG N
the DT N
two CD N
arms NNS N
. . N

From IN N
a DT N
clinical JJ N
point NN N
of IN N
view NN N
, , N
important JJ N
differences NNS N
were VBD N
found VBN N
for IN N
five CD N
scales NNS N
: : N
two CD N
functioning NN N
scales NNS N
( ( o
social JJ o
and CC o
role NN o
functioning NN o
) ) o
and CC N
three CD N
symptom NN N
scales NNS N
( ( o
appetite JJ o
loss NN o
, , o
fatigue NN o
, , o
and CC o
dyspnea NN o
) ) o
, , N
with IN N
the DT N
PEG-IFN-alpha-2b NNP N
arm NN N
being VBG N
most JJS N
impaired JJ N
. . N

CONCLUSION NNP N
PEG-IFN-alpha-2b NNP N
leads VBZ N
to TO N
a DT N
significant JJ N
and CC N
sustained JJ N
improvement NN N
in IN N
RFS NNP N
. . N

There EX N
is VBZ N
an DT N
expected JJ N
negative JJ N
effect NN N
on IN N
global JJ o
HRQOL NNP o
and CC N
selected VBN N
symptoms NNS N
when WRB N
patients NNS N
undergo VBP N
PEG-IFN-alpha-2b NNP N
treatment NN N
. . N

-DOCSTART- -25403582- O O

Zoledronic JJ i
acid NN i
combined VBN i
with IN i
adjuvant JJ i
endocrine JJ i
therapy NN i
of IN i
tamoxifen JJ i
versus NN N
anastrozol NN i
plus CC i
ovarian JJ i
function NN i
suppression NN i
in IN N
premenopausal NN p
early JJ p
breast NN p
cancer NN p
: : p
final JJ N
analysis NN N
of IN N
the DT N
Austrian JJ p
Breast NNP p
and CC p
Colorectal NNP p
Cancer NNP p
Study NNP p
Group NNP p
Trial NNP p
12 CD p
. . p

BACKGROUND NNP N
Zoledronic NNP i
acid NN i
( ( i
ZOL NNP i
) ) i
plus CC i
adjuvant JJ i
endocrine NN i
therapy NN i
significantly RB N
improved VBN N
disease-free JJ o
survival NN o
( ( N
DFS NNP N
) ) N
at IN N
48- JJ N
and CC N
62-month JJ N
follow-up NN N
in IN N
the DT N
ABCSG-12 NNP N
trial NN N
. . N

We PRP N
present JJ N
efficacy JJ N
results NNS N
of IN N
a DT N
final JJ N
additional JJ N
analysis NN N
after IN N
94.4 CD N
months NNS N
. . N

PATIENTS NNP N
AND CC N
METHODS NNP N
Patients NNPS p
were VBD p
premenopausal JJ p
women NNS p
who WP p
had VBD p
undergone JJ p
primary JJ p
surgery NN p
for IN p
stage NN p
I/II NNP p
estrogen-receptor-positive JJ p
and/or NN p
progesterone-receptor-positive JJ p
breast NN p
cancer NN p
with IN p
< $ p
10 CD p
positive JJ p
lymph NN p
nodes NNS p
, , p
and CC p
were VBD p
scheduled VBN p
for IN p
standard JJ p
goserelin NN p
therapy NN p
. . p

All DT N
1803 CD p
patients NNS p
received VBN p
goserelin NNS i
( ( i
3.6 CD i
mg NN i
every DT i
28 CD i
days NNS i
) ) i
and CC i
were VBD i
randomized VBN i
to TO i
tamoxifen VB i
( ( i
20 CD i
mg/days NNS i
) ) i
or CC i
anastrozole JJ i
( ( i
1 CD i
mg/days NNS i
) ) i
, , i
both DT i
with IN i
or CC i
without IN i
ZOL NNP i
( ( i
4 CD i
mg NN i
every DT i
6 CD i
months NNS i
) ) i
for IN i
3 CD i
years NNS i
. . i

The DT N
primary JJ N
end NN N
point NN N
was VBD N
DFS NNP o
; : o
recurrence-free JJ o
survival NN o
and CC o
overall JJ o
survival NN o
( ( o
OS NNP o
) ) o
were VBD N
secondary JJ N
end NN N
points NNS N
. . N

RESULTS NNP N
After IN N
94.4-month JJ N
median JJ N
follow-up NN N
( ( N
range NN N
, , N
0-114 JJ N
months NNS N
) ) N
, , N
relative JJ o
risks NNS o
of IN o
disease NN o
progression NN o
[ NNP o
hazard NN o
ratio NN o
( ( o
HR NNP o
) ) o
= VBZ N
0.77 CD N
; : N
95 CD N
% NN N
confidence NN o
interval NN o
( ( N
CI NNP N
) ) N
0.60-0.99 NN N
; : N
P NNP N
= VBD N
0.042 CD N
] NNP N
and CC N
of IN N
death NN o
( ( N
HR NNP N
= NNP N
0.66 CD N
; : N
95 CD N
% NN N
CI NNP N
0.43-1.02 CD N
; : N
P NNP N
= NNP N
0.064 CD N
) ) N
are VBP N
still RB N
reduced VBN N
by IN N
ZOL NNP N
although IN N
no RB N
longer RBR N
significant JJ N
at IN N
the DT N
predefined JJ N
significance NN N
level NN N
. . N

Overall JJ N
, , N
251 CD N
DFS NNP o
events NNS o
and CC N
86 CD N
deaths NNS o
were VBD N
reported VBN N
. . N

Absolute NNP o
risk NN o
reductions NNS o
with IN N
ZOL NNP N
were VBD N
3.4 CD N
% NN N
for IN N
DFS NNP N
and CC N
2.2 CD N
% NN N
for IN N
OS NNP N
. . N

There EX N
was VBD N
no DT N
DFS NNP o
difference NN o
between IN N
tamoxifen NN N
alone RB N
versus JJ N
anastrozole JJ N
alone RB N
, , N
but CC N
there RB N
was VBD N
a DT N
pronounced JJ N
higher JJR o
risk NN o
of IN o
death NN o
for IN N
anastrozole-treated JJ N
patients NNS N
( ( N
HR NNP N
= NNP N
1.63 CD N
; : N
95 CD N
% NN N
CI NNP N
1.05-1.45 CD N
; : N
P NNP N
= NNP N
0.030 CD N
) ) N
. . N

Treatments NNS N
were VBD N
generally RB N
well RB N
tolerated VBN o
, , N
with IN N
no DT o
reports NNS o
of IN o
renal JJ o
failure NN o
or CC o
osteonecrosis NN o
of IN o
the DT o
jaw NN o
. . o

CONCLUSION NNP N
These DT N
final JJ N
results NNS N
from IN N
ABCSG NNP N
12 CD N
suggest NN N
that IN N
twice-yearly JJ N
ZOL NNP i
enhances VBZ N
the DT N
efficacy NN N
of IN N
adjuvant JJ N
endocrine NN N
treatment NN N
, , N
and CC N
this DT N
benefit NN N
is VBZ N
maintained VBN N
long-term JJ N
. . N

CLINICALTRIALSGOV NNP N
NCT00295646 NNP N
( ( N
http NN N
: : N
//www.clinicaltrials.gov/ct2/results NNS N
? . N
term=00295646 NN N
) ) N
. . N

-DOCSTART- -25885180- O O

Effect NN N
of IN N
cool NN i
vs. FW i
warm JJ i
dialysate NN i
on IN N
toxin NN p
removal NN p
: : p
rationale NN N
and CC N
study NN N
design NN N
. . N

BACKGROUND NNP N
Cool NNP i
dialysate NN i
is VBZ N
often RB N
recommended VBN N
for IN N
prevention NN N
of IN N
intra-dialytic JJ N
hypotensive JJ N
episodes NNS N
in IN N
maintenance NN p
hemodialysis NN p
( ( p
HD NNP p
) ) p
patients NNS p
. . p

However RB N
, , N
its PRP$ N
effect NN N
on IN N
toxin NN N
removal NN N
is VBZ N
not RB N
studied VBN N
. . N

It PRP N
is VBZ N
known VBN N
that IN N
inter-compartmental JJ N
resistance NN N
is VBZ N
the DT N
main JJ N
barrier NN N
for IN N
toxin NN N
removal NN N
. . N

Cool JJ i
dialysate NN i
can MD N
potentially RB N
increase VB N
this DT N
resistance NN N
by IN N
vasoconstriction NN N
and CC N
thus RB N
impair VB N
the DT N
toxin NN N
removal NN N
. . N

The DT N
aim NN N
of IN N
this DT N
trial NN N
is VBZ N
to TO N
compare VB N
the DT N
toxin NN N
removal NN N
outcome NN N
associated VBN N
with IN N
cool NN i
vs. FW i
warm JJ i
dialysate NN i
. . i

METHOD/DESIGN NNP N
This DT N
study NN N
is VBZ N
based VBN N
on IN N
the DT N
hypothesis NN N
that WDT N
dialysate JJ N
temperature NN N
, , N
a DT N
potential JJ N
maneuver NN N
to TO N
maintain VB N
hemodynamic JJ N
stability NN N
during IN N
HD NNP N
, , N
may MD N
influence VB N
inter-compartmental JJ N
resistance NN N
and CC N
hence NN N
, , N
toxin NN N
removal NN N
. . N

Only RB p
stable JJ p
HD NNP p
patients NNS p
will MD p
be VB p
recruited VBN p
for IN N
this DT N
study NN N
. . N

The DT N
quantum NN N
of IN N
removed VBN N
toxins NNS N
will MD N
be VB N
assessed VBN N
by IN N
the DT N
total JJ N
spent NN N
dialysate NN N
, , N
which WDT N
is VBZ N
a DT N
gold JJ N
standard NN N
to TO N
quantify VB N
the DT N
efficacy NN N
of IN N
a DT N
single JJ N
dialysis NN N
session NN N
. . N

Collected VBN N
samples NNS N
will MD N
be VB N
analyzed VBN N
for IN N
urea JJ N
, , N
creatinine NN N
, , N
phosphate NN N
, , N
?2-microglobulin JJ N
, , N
and CC N
uric JJ N
acid NN N
. . N

The DT N
study NN N
is VBZ N
a DT N
single JJ N
center NN N
, , N
self-controlled JJ N
, , N
randomized JJ N
prospective JJ N
clinical JJ N
research NN N
where WRB p
20 CD p
study NN p
subjects NNS p
will MD N
undergo VB N
2 CD N
dialysis NN N
sessions NNS N
: : N
( ( N
a DT i
) ) i
cool JJ i
dialysis NN i
with IN i
dialysate NN i
at IN N
35.5?C CD N
, , N
and CC N
( ( N
b NN N
) ) i
warm JJ i
dialysis NN i
with IN i
dialysate NN i
at IN i
37?C CD N
. . N

Pre- JJ N
and CC N
post-dialysis JJ N
blood NN N
samples NNS N
will MD N
be VB N
collected VBN N
to TO N
quantify VB N
the DT N
dialysis NN o
adequacy NN o
and CC o
toxin NN o
reduction NN o
ratio NN o
. . o

DISCUSSION NNP o
This DT N
is VBZ N
the DT N
first JJ N
clinical JJ N
research NN N
to TO N
investigate VB N
the DT N
effect NN N
of IN N
dialysate NN N
temperature NN N
on IN N
removal NN N
of IN N
both DT N
small JJ N
and CC N
large-sized JJ N
toxins NNS N
. . N

Successful JJ N
completion NN N
of IN N
this DT N
research NN N
will MD N
provide VB N
important JJ N
knowledge NN N
pertaining VBG N
to TO N
dialysate VB N
temperature NN N
prescription NN N
. . N

Results NNS N
can MD N
also RB N
lead VB N
to TO N
the DT N
hypothesis NN N
that WDT N
cool JJ N
dialysate NN N
may MD N
help VB N
in IN N
by IN N
preventing VBG N
intra-dialytic JJ N
hypotensive JJ N
episodes NNS N
, , N
but CC N
prolonged JJ N
prescription NN N
of IN N
cool JJ N
dialysate NN N
may MD N
lead VB N
to TO N
comorbidities NNS N
associated VBN N
with IN N
excess JJ N
toxin NN N
accumulation NN N
. . N

The DT N
new JJ N
knowledge NN N
will MD N
encourage VB N
for IN N
personalized JJ N
dialysate NN N
temperature NN N
profiling VBG N
. . N

TRIAL NNP N
REGISTRATION NNP N
Clinicaltrials.gov NNP N
Identifier NNP N
-- : N
NCT02064153 NNP N
. . N

-DOCSTART- -9105062- O O

The DT N
effect NN N
of IN N
inhaled JJ N
leukotriene NN i
D4 NNP i
and CC N
methacholine VB i
on IN N
sputum NN o
cell NN o
differentials NNS o
in IN N
asthma NN p
. . p

The DT N
cysteinyl JJ i
leukotriene NN i
LTE4 NNP i
has VBZ N
been VBN N
shown VBN N
to TO N
induce VB N
airway RP o
eosinophilia NNS o
in IN N
asthmatics NNS N
in IN N
vivo NN N
. . N

This DT N
phenomenon NN N
has VBZ N
not RB N
yet RB N
been VBN N
reported VBN N
for IN N
LTD4 NNP N
. . N

Hence NNP N
, , N
we PRP N
examined VBD N
the DT N
effect NN N
of IN N
inhaled JJ N
LTD4 NNP i
and CC N
a DT N
control NN N
bronchoconstrictor NN N
agent NN N
, , N
methacholine NN N
, , N
on IN N
cell NN o
differentials NNS o
in IN N
hypertonic JJ N
saline-induced JJ N
whole JJ N
sputum NN N
samples NNS N
of IN N
12 CD p
nonsmoking VBG p
atopic NN p
asthmatic JJ p
subjects NNS p
( ( p
three CD p
women NNS p
, , p
nine CD p
men NNS p
; : p
21 CD p
to TO p
29 CD p
yr NN p
of IN p
age NN p
; : p
FEV1 NNP p
, , p
74 CD p
to TO p
120 CD p
% NN p
pred VBD p
; : p
PC20FEV1 NNP p
methacholine VBP p
< $ p
9.6 CD p
mg/ml NN p
) ) p
. . N

The DT N
study NN N
had VBD N
a DT N
cross-over JJ N
, , N
placebo-controlled JJ N
design NN N
consisting NN N
of IN N
4 CD N
d NN N
separated VBN N
by IN N
> NN N
or CC N
= $ N
1 CD N
wk NN N
. . N

On IN N
each DT N
randomized VBN N
study NN N
day NN N
, , N
the DT N
subjects NNS N
inhaled VBD N
five CD N
serial JJ N
doses NNS N
of IN N
either DT N
LTD4 NNP i
( ( N
mean JJ N
cumulative JJ N
concentration NN N
: : N
95.7 CD N
microM NN N
) ) N
or CC N
methacholine NN i
( ( N
mean JJ N
cumulative JJ N
concentration NN N
: : N
542 CD N
mM NN N
) ) N
or CC N
five CD N
doses NNS N
of IN N
their PRP$ N
respective JJ N
diluents NNS N
( ( i
PBS/ethanol NNP i
or CC N
PBS NNP N
) ) N
. . N

The DT N
airway JJ o
response NN o
was VBD N
measured VBN N
by IN N
FEV1 NNP N
, , N
followed VBN N
by IN N
sputum JJ N
induction NN N
with IN N
4.5 CD N
% NN N
NaCl NNP N
, , N
4 CD N
h NN N
postchallenge NN N
. . N

Inflammatory NNP N
cells NNS N
( ( N
> CD N
or CC N
= VB N
250 CD N
) ) N
were VBD N
counted VBN N
twice RB N
on IN N
coded JJ N
cytospins NNS N
and CC N
expressed VBD N
as IN N
percentages NNS N
of IN N
nonsquamous JJ N
cells NNS N
. . N

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
the DT N
maximal JJ o
percent NN o
fall NN o
in IN o
FEV1 NNP o
from IN o
baseline NN o
between IN N
LTD4 NNP N
( ( N
mean JJ N
+/- JJ N
SEM NNP N
, , N
49.5 CD N
+/- JJ N
4.4 CD N
% NN N
fall NN N
) ) N
and CC N
methacholine NN N
( ( N
mean JJ N
+/- JJ N
SEM NNP N
, , N
55.9 CD N
+/- JJ N
3.4 CD N
% NN N
fall NN N
) ) N
( ( N
p JJ N
= NNP N
0.11 CD N
) ) N
. . N

LTD4 NNP N
induced VBD N
a DT N
significant JJ N
increase NN N
in IN N
the DT N
percentage NN o
of IN o
sputum NN o
eosinophils NNS o
as IN N
compared VBN N
with IN N
its PRP$ N
diluent NN N
( ( N
mean JJ N
+/- JJ N
SD NNP N
, , N
26.6 CD N
+/- JJ N
21.3 CD N
% NN N
and CC N
10.2 CD N
+/- JJ N
8.8 CD N
% NN N
, , N
respectively RB N
; : N
p VB N
= $ N
0.025 CD N
) ) N
, , N
whereas VBZ N
a DT N
similar JJ N
trend NN N
for IN N
methacholine NN N
failed VBD N
to TO N
reach VB N
significance NN N
( ( N
mean JJ N
+/- JJ N
SD NNP N
, , N
19.1 CD N
+/- JJ N
22.9 CD N
% NN N
and CC N
7.8 CD N
+/- JJ N
5.8 CD N
% NN N
, , N
respectively RB N
; : N
p VB N
= $ N
0.11 CD N
) ) N
. . N

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
the DT N
changes NNS N
in IN N
the DT N
percentage NN o
of IN o
sputum NN o
eosinophils NNS o
between IN o
LTD4 NNP o
and CC o
methacholine NN o
( ( N
mean JJ N
difference NN N
+/- JJ N
SD NNP N
, , N
7.5 CD N
+/- JJ N
12.5 CD N
% NN N
eosinophils NNS N
; : N
p VB N
= $ N
0.09 CD N
) ) N
. . N

We PRP N
conclude VBP N
that IN N
LTD4 NNP N
induces NNS N
eosinophilia VBP o
in IN o
sputum NN o
of IN N
asthmatic JJ N
subjects NNS N
4 CD N
h NN N
after IN N
inhalation NN N
. . N

Our PRP$ N
data NNS N
suggest VBP N
that IN N
LTD4 NNP N
recruits VBZ N
eosinophils NNS o
into IN N
the DT N
airways NNS N
of IN N
asthmatics NNS N
in IN N
vivo NN N
, , N
possibly RB N
by IN N
virtue NN N
of IN N
direct JJ N
or CC N
indirect JJ N
chemotactic JJ N
properties NNS N
, , N
whereas IN N
an DT N
additional JJ N
effect NN N
of IN N
vigourous JJ o
airway NN o
narrowing VBG o
per IN N
se NN N
can MD N
not RB N
be VB N
excluded VBN N
. . N

-DOCSTART- -19941058- O O

Low-frequency NNP i
repetitive JJ i
transcranial JJ i
magnetic JJ i
stimulation NN i
( ( i
rTMS NN i
) ) i
affects VBZ N
event-related JJ N
potential JJ N
measures NNS N
of IN N
novelty NN N
processing NN N
in IN N
autism NN p
. . p

In IN N
our PRP$ N
previous JJ N
study NN N
on IN N
individuals NNS p
with IN p
autism NN p
spectrum NN p
disorder NN p
( ( p
ASD NNP p
) ) p
( ( N
Sokhadze NNP N
et RB N
al. RB N
, , N
Appl NNP N
Psychophysiol NNP N
Biofeedback NNP N
34:37-51 JJ N
, , N
2009a CD N
) ) N
we PRP N
reported VBD N
abnormalities NNS N
in IN N
the DT N
attention-orienting JJ N
frontal JJ N
event-related JJ N
potentials NNS N
( ( N
ERP NNP N
) ) N
and CC N
the DT N
sustained-attention JJ N
centro-parietal JJ N
ERPs NNP N
in IN N
a DT N
visual JJ N
oddball NN N
experiment NN N
. . N

These DT N
results NNS N
suggest VBP N
that IN N
individuals NNS p
with IN p
autism NN p
over-process JJ N
information NN N
needed VBN N
for IN N
the DT N
successful JJ N
differentiation NN N
of IN N
target NN N
and CC N
novel JJ N
stimuli NNS N
. . N

In IN N
the DT N
present JJ N
study NN N
we PRP N
examine VBP N
the DT N
effects NNS N
of IN N
low-frequency NN i
, , i
repetitive JJ i
Transcranial NNP i
Magnetic NNP i
Stimulation NNP i
( ( i
rTMS NN i
) ) i
on IN N
novelty NN N
processing NN N
as RB N
well RB N
as IN N
behavior NN N
and CC N
social JJ N
functioning NN N
in IN N
13 CD p
individuals NNS p
with IN p
ASD NNP p
. . p

Our PRP$ N
hypothesis NN N
was VBD N
that IN N
low-frequency NN i
rTMS NN i
application NN N
to TO N
dorsolateral JJ N
prefrontal JJ N
cortex NN N
( ( N
DLFPC NNP N
) ) N
would MD N
result VB N
in IN N
an DT N
alteration NN N
of IN N
the DT N
cortical JJ N
excitatory/inhibitory NN N
balance NN N
through IN N
the DT N
activation NN N
of IN N
inhibitory JJ N
GABAergic NNP N
double JJ N
bouquet NN N
interneurons NNS N
. . N

We PRP N
expected VBD N
to TO N
find VB N
post-TMS JJ N
differences NNS N
in IN N
amplitude NN N
and CC N
latency NN N
of IN N
early JJ N
and CC N
late JJ N
ERP NNP N
components NNS N
. . N

The DT N
results NNS N
of IN N
our PRP$ N
current JJ N
study NN N
validate VBP N
the DT N
use NN N
of IN N
low-frequency NN N
rTMS NN N
as IN N
a DT N
modulatory NN N
tool NN N
that WDT N
altered VBD N
the DT N
disrupted VBN N
ratio NN N
of IN N
cortical JJ N
excitation NN N
to TO N
inhibition NN N
in IN N
autism NN N
. . N

After IN N
rTMS VBG N
the DT N
parieto-occipital JJ o
P50 NNP o
amplitude NN o
decreased VBD o
to TO o
novel JJ o
distracters NNS o
but CC o
not RB o
to TO o
targets NNS o
; : o
also RB N
the DT N
amplitude NN o
and CC o
latency NN o
to TO o
targets NNS o
increased VBN o
for IN o
the DT o
frontal JJ o
P50 NNP o
while IN o
decreasing VBG o
to TO o
non-target JJ o
stimuli NNS o
. . o

Low-frequency NNP N
rTMS NN N
minimized VBD o
early JJ o
cortical JJ o
responses NNS o
to TO o
irrelevant VB o
stimuli JJ o
and CC N
increased JJ o
responses NNS o
to TO o
relevant VB o
stimuli NN o
. . o

Improved VBN N
selectivity NN N
in IN N
early JJ N
cortical JJ N
responses NNS N
lead VBP N
to TO N
better JJR o
stimulus JJ o
differentiation NN o
at IN o
later-stage JJ o
responses NNS o
as IN N
was VBD N
made VBN N
evident JJ N
by IN N
our PRP$ N
P3b NNP N
and CC N
P3a NNP N
component NN N
findings NNS N
. . N

These DT N
results NNS N
indicate VBP N
a DT N
significant JJ o
change NN o
in IN o
early JJ o
, , o
middle-latency JJ o
and CC o
late JJ o
ERP NNP o
components NNS o
at IN o
the DT o
frontal JJ o
, , o
centro-parietal JJ o
, , o
and CC o
parieto-occipital JJ o
regions NNS o
of IN o
interest NN o
in IN o
response NN o
to TO o
target VB o
and CC o
distracter VB o
stimuli NNS o
as IN N
a DT N
result NN N
of IN N
rTMS NN N
treatment NN N
. . N

Overall JJ N
, , N
our PRP$ N
preliminary JJ N
results NNS N
show VBP N
that IN N
rTMS NN N
may MD N
prove VB N
to TO N
be VB N
an DT N
important JJ N
research NN N
tool NN N
or CC N
treatment NN N
modality NN N
in IN N
addressing VBG N
the DT N
stimulus JJ N
hypersensitivity NN N
characteristic NN N
of IN N
autism NN N
spectrum NN N
disorders NNS N
. . N

-DOCSTART- -22006695- O O

Effects NNS N
of IN N
body NN i
orientation NN i
on IN N
maximum JJ N
voluntary JJ N
arm NN N
torques NNS N
. . N

INTRODUCTION NNP N
Increased VBD N
reliance NN N
on IN N
bulbospinal JJ i
motor NN i
systems NNS i
has VBZ N
been VBN N
implicated VBN N
in IN N
individuals NNS p
with IN p
chronic JJ p
stroke NN p
during IN N
maximum JJ N
voluntary JJ N
arm NN N
joint NN N
torque NN N
generation NN N
. . N

METHODS NNP N
Maximum NNP N
isometric JJ o
single-joint NN o
and CC o
multi-joint NN o
arm NN o
strength NN o
was VBD N
observed VBN N
in IN N
two CD i
body NN i
orientations NNS i
( ( i
sitting VBG i
and CC i
supine NN i
) ) i
while IN N
maintaining VBG N
identical JJ N
head/neck/trunk/extremity NN i
joint JJ i
configurations NNS i
in IN N
order NN N
to TO N
identify VB N
bulbospinal JJ p
contributions NNS p
to TO p
maximum VB p
joint JJ p
torque NN p
generation NN p
in IN p
11 CD p
individuals NNS p
with IN p
stroke NN p
and CC p
10 CD p
individuals NNS p
without IN p
stroke NN p
. . p

RESULTS NNP N
During IN N
sitting VBG i
, , N
shoulder JJR o
flexion NN o
was VBD N
greater JJR N
for IN N
both DT N
groups NNS N
, , N
whereas NNS N
shoulder VBP o
extension NN o
and CC o
elbow JJ o
flexion NN o
, , N
part NN N
of IN N
the DT N
flexion NN N
synergy NN N
, , N
were VBD N
greater JJR N
only RB N
in IN N
individuals NNS N
with IN N
stroke NN N
. . N

CONCLUSIONS NNP N
Body NNP i
orientation NN i
influenced VBD N
isometric JJ o
arm NN o
strength NN o
, , N
notably RB N
the DT N
constituents NNS N
of IN N
flexion NN o
synergy NN o
in IN N
individuals NNS N
with IN N
stroke NN N
, , N
suggesting VBG N
bulbospinal JJ N
motor NN N
pathway NN N
involvement NN N
. . N

From IN N
a DT N
practical JJ N
perspective NN N
, , N
clinical JJ N
evaluation NN N
of IN N
single JJ o
joint JJ o
strength NN o
in IN N
the DT N
supine JJ i
position NN i
may MD N
underestimate VB N
strength NN N
available JJ N
during IN N
activities NNS N
of IN N
daily JJ N
living NN N
that WDT N
are VBP N
performed VBN N
in IN N
an DT N
upright JJ i
orientation NN i
. . i

-DOCSTART- -3886510- O O

[ JJ N
Clinical JJ N
trials NNS N
with IN N
pirprofen NN i
and CC i
naproxen NN i
in IN N
patients NNS p
with IN p
gonarthrosis NN o
and CC o
coxarthrosis NN o
] NN o
. . N

-DOCSTART- -15274666- O O

Helicobacter NNP o
pylori JJ o
eradication NN o
in IN p
children NNS p
and CC p
adolescents NNS p
by IN N
a DT N
once RB N
daily JJ N
6-day JJ N
treatment NN i
with IN i
or CC i
without IN i
a DT i
proton NN i
pump NN i
inhibitor NN i
in IN N
a DT N
double-blind JJ N
randomized JJ N
trial NN N
. . N

AIM NNP N
To TO N
evaluate VB N
two CD N
simplified JJ N
Helicobacter NNP o
pylori NN o
eradication NN o
treatment NN N
alternatives NNS N
for IN N
children NNS p
and CC p
adolescents NNS p
. . p

METHODS NNP N
Study NNP N
subjects NNS N
were VBD N
identified VBN N
by IN N
enzyme-linked JJ N
immunosorbent NN o
assay NN o
and CC o
immunoblot NN o
in IN N
a DT N
family NN N
screening VBG N
project NN N
. . N

Helicobacter NNP p
pylori NN p
infected VBD p
10-21 JJ p
year NN p
olds NNS p
were VBD p
offered VBN p
treatment NN p
, , p
individuals NNS p
with IN p
abdominal JJ p
pain NN p
underwent JJ p
upper JJ p
endoscopy NN p
and CC p
those DT p
with IN p
peptic JJ p
ulcers NNS p
were VBD p
excluded VBN p
. . p

Participants NNS N
were VBD N
randomized VBN N
to TO N
either DT N
azithromycin JJ i
500 CD i
mg JJ i
daily JJ i
and CC i
tinidazole JJ i
500 CD i
mg NN i
two CD i
tablets NNS i
daily RB i
in IN i
combination NN i
with IN i
lansoprasole JJ i
30 CD i
mg JJ i
daily RB i
for IN i
6 CD i
days NNS i
( ( i
ATL-group NNP i
) ) i
or CC i
with IN i
placebo NN i
( ( i
ATP-group NNP i
) ) i
. . i

Urea JJ o
Breath NNP o
Test NNP o
was VBD i
performed VBN i
at IN i
inclusion NN i
and CC i
after IN i
a DT i
minimum NN i
of IN i
6 CD i
weeks NNS i
after IN i
end NN i
of IN i
therapy NN i
. . i

RESULTS NNP N
In IN N
total JJ N
, , N
131 CD p
individuals NNS p
were VBD p
randomized VBN p
, , p
of IN p
whom WP p
31 CD p
( ( p
24 CD p
% NN p
) ) p
had VBD p
undergone JJ p
upper JJ p
endoscopy NN p
. . p

Full NNP o
compliance NN o
was VBD p
achieved VBN p
in IN p
93 CD p
% NN p
( ( p
122 CD p
of IN p
131 CD p
) ) p
. . p

The DT N
intention-to-treat JJ o
eradication NN o
rate NN o
was VBD N
67 CD N
% NN N
( ( N
44 CD N
of IN N
66 CD N
) ) N
and CC N
58 CD N
% NN N
( ( N
38 CD N
of IN N
65 CD N
) ) N
for IN N
the DT N
ATL- NNP N
and CC N
the DT N
ATP-group NNP N
, , N
respectively RB N
. . N

CONCLUSION VB N
The DT N
double-blind JJ N
randomized JJ N
clinical JJ N
trial NN N
did VBD N
not RB N
identify VB N
a DT N
simplified VBN N
, , N
successful JJ N
once RB N
daily JJ N
H. NNP N
pylori NN N
treatment NN N
for IN N
children NNS p
and CC p
adolescents NNS p
. . p

Thus RB N
, , N
twice RB N
daily JJ N
proton NN N
pump NN N
inhibitor NN N
( ( N
PPI NNP N
) ) N
-based VBD N
triple JJ N
therapies NNS N
for IN N
7 CD N
days NNS N
remain VBP N
as IN N
the DT N
choice NN N
of IN N
treatment NN N
in IN N
children NNS p
. . p

Further NNP N
, , N
powerful JJ N
and CC N
controlled JJ N
studies NNS N
are VBP N
needed VBN N
to TO N
elucidate VB N
the DT N
best JJS N
treatment NN N
strategies NNS N
for IN N
H. NNP N
pylori JJ N
eradication NN N
in IN N
this DT N
age NN N
group NN N
. . N

-DOCSTART- -1334639- O O

Role NNP N
of IN N
memory NN N
B-cell NNP N
responses NNS N
in IN N
serum NN N
and CC N
mucosal JJ N
fluids NNS N
of IN N
swine NN N
for IN N
protective JJ N
immunity NN N
against IN N
pseudorabies NNS N
virus VBP N
. . N

We PRP N
examined VBD N
primary JJ N
and CC N
memory JJ N
isotype-specific JJ N
antibody NN N
responses NNS N
directed VBN N
against IN N
pseudorabies NNS N
virus VBP N
in IN N
serum NN N
and CC N
mucosal JJ N
fluids NNS N
of IN N
pigs NNS p
with IN p
and CC p
without IN p
passively RB p
acquired VBN p
maternal JJ p
antibody NN p
, , N
and CC N
we PRP N
studied VBD N
the DT N
relationship NN N
between IN N
these DT N
responses NNS N
and CC N
protection NN N
against IN N
virus NN N
challenge NN N
. . N

Pigs NNS p
were VBD N
inoculated VBN N
intranasally RB N
with IN N
the DT N
virulent JJ i
NIA-3 NNP i
strain NN i
or CC i
the DT i
avirulent JJ i
Bartha NNP i
strain NN i
, , i
or CC i
they PRP i
were VBD i
inoculated VBN i
IM NNP i
with IN i
an DT i
inactivated JJ i
vaccine NN i
containing VBG i
the DT i
Phylaxia NNP i
strain NN i
. . i

Ten CD N
weeks NNS N
later RB N
, , N
all DT N
pigs NNS N
were VBD N
challenge-exposed JJ i
intranasally RB i
with IN i
strain JJ i
NIA-3 NNP i
. . i

Only RB N
pigs VBZ N
that IN N
were VBD N
without IN N
passively RB N
acquired VBN N
antibody NN N
at IN N
the DT N
time NN N
they PRP N
were VBD N
inoculated VBN N
with IN N
virulent JJ N
virus NN N
appeared VBD N
to TO N
have VB N
complete JJ o
protective JJ o
immunity NN o
against IN N
challenge NN N
exposure NN N
, , N
as IN N
evidenced VBN N
by IN N
lack NN N
of IN N
clinical JJ o
signs NNS o
of IN o
pseudorabies NNS o
and CC N
lack NN N
of IN N
virus NN o
excretion NN o
. . o

In IN N
contrast NN N
, , N
pigs NNS p
inoculated VBD p
with IN p
strain NN p
Bartha NNP p
or CC p
with IN p
the DT p
inactivated JJ p
vaccine NN p
developed VBD N
fever NN o
, , N
had VBD N
a DT N
period NN o
of IN o
growth NN o
arrest NN o
, , N
and CC N
excreted VBD o
virus NN o
after IN N
challenge NN N
exposure NN N
. . N

In IN N
pigs NNS N
without IN N
passively RB N
acquired VBN N
antibody NN N
, , N
intranasal JJ N
inoculation NN N
with IN N
strains NNS N
NIA-3 NNP N
or CC N
Bartha NNP N
was VBD N
followed VBN N
by IN N
primary JJ N
IgM NNP o
and CC o
IgA NNP o
responses NNS o
in IN N
serum NN o
and CC N
in IN N
oropharyngeal JJ o
fluid NN o
as RB N
well RB N
as IN N
primary JJ N
IgG1 NNP N
and CC N
IgG2 NNP N
responses NNS N
in IN N
serum NN N
. . N

Intramuscular JJ N
inoculation NN N
with IN N
the DT N
inactivated JJ N
vaccine NN N
induced VBD N
primary JJ o
serum NN o
IgM NNP o
, , o
IgG1 NNP o
, , o
and CC o
IgG2 NNP o
responses NNS o
, , N
but CC N
no DT N
mucosal NN o
responses VBZ o
. . o

Challenge NNP N
exposure NN N
of IN N
pigs NNS N
that WDT N
had VBD N
been VBN N
inoculated VBN N
with IN N
the DT N
Bartha NNP N
strain NN N
or CC N
the DT N
inactivated JJ N
vaccine NN N
was VBD N
followed VBN N
by IN N
clear JJ N
memory NN o
responses NNS o
in IN o
serum NN o
and CC o
in IN o
oropharyngeal JJ o
fluid NN o
. . o

In IN N
contrast NN N
, , N
challenge VBP N
exposure NN N
of IN N
pigs NNS N
that WDT N
had VBD N
been VBN N
inoculated VBN N
by IN N
the DT N
virulent JJ N
NIA-3 NNP N
strain NN N
was VBD N
not RB N
followed VBN N
by IN N
memory NN N
responses NNS N
. . N

( ( N
ABSTRACT NNP N
TRUNCATED NNP N
AT NNP N
250 CD N
WORDS NNP N
) ) N
-DOCSTART- -1911498- O O

Intravenous JJ N
lidocaine NN i
does VBZ N
not RB N
cause VB N
shivering-like JJ o
tremor NN o
or CC N
alter NN o
thermoregulation NN o
. . o

We PRP N
tested VBD N
the DT N
hypotheses NNS N
that WDT N
systemic JJ N
absorption NN N
of IN N
epidural JJ N
lidocaine NN i
: : i
( ( N
1 CD N
) ) N
contributes NNS N
to TO N
the DT N
shivering-like JJ o
tremor NN o
seen VBN o
during IN o
epidural JJ o
anesthesia NNS o
by IN N
causing VBG N
central JJ N
nervous JJ N
system NN N
disinhibition NN N
of IN N
spinal JJ N
reflexes NNS N
, , N
or CC N
( ( N
2 CD N
) ) N
activates NNS o
or CC o
alters NNS o
thermoregulatory JJ o
mechanisms NNS o
. . o

In IN N
a DT N
double-blind NN N
, , N
placebo NN i
, , N
cross-over NN N
study NN N
, , N
nine CD p
healthy JJ p
volunteers NNS p
were VBD N
given VBN N
intravenous JJ i
lidocaine NN i
( ( i
or CC i
saline NN i
) ) i
to TO N
approximate VB N
the DT N
plasma NN N
levels NNS N
of IN N
lidocaine NN i
achieved VBN N
during IN N
epidural JJ N
anesthesia NN N
for IN N
major JJ p
abdominal JJ p
surgery NN p
. . p

Five CD N
volunteers NNS N
were VBD N
studied VBN N
in IN N
a DT N
warm JJ N
room NN N
( ( N
to TO N
test VB N
for IN N
nonthermoregulatory JJ o
tremor NN o
) ) o
, , N
and CC N
four CD N
volunteers NNS N
were VBD N
studied VBN N
in IN N
a DT N
cold JJ N
room NN N
( ( N
to TO N
test VB N
the DT N
effects NNS N
of IN N
lidocaine NN i
on IN N
normal JJ o
thermoregulation NN o
) ) o
. . N

Central JJ o
temperatures NNS o
, , o
peripheral JJ o
vasoconstriction NN o
, , o
tremor NN o
and CC o
clonus NN o
were VBD N
unaffected VBN N
by IN N
intravenous JJ N
lidocaine NN N
. . N

We PRP N
conclude VBP N
that IN N
the DT N
systemic JJ N
absorption NN N
of IN N
epidural JJ N
lidocaine NN i
does VBZ N
not RB N
contribute VB N
to TO N
tremor VB o
or CC o
shivering VBG o
by IN N
these DT N
mechanisms NNS N
. . N

-DOCSTART- -20661580- O O

A DT N
comparison NN N
of IN N
the DT N
effect NN N
of IN N
short-term JJ N
aromatase NN i
inhibitor NN i
( ( i
letrozole JJ i
) ) i
and CC i
GnRH NNP i
agonist NN i
( ( i
triptorelin NN i
) ) i
versus NN N
case NN N
control NN N
on IN N
pregnancy NN o
rate NN o
and CC o
symptom NN o
and CC o
sign NN o
recurrence NN o
after IN N
laparoscopic JJ N
treatment NN N
of IN N
endometriosis NN N
. . N

PURPOSE NNP N
To TO N
compare VB N
the DT N
role NN N
of IN N
an DT N
aromatase NN i
inhibitor NN i
( ( i
letrozole JJ i
) ) i
with IN N
a DT N
GnRH NNP i
agonist NN i
( ( i
triptorelin NN i
) ) i
versus NN N
case NN N
control NN N
on IN N
the DT N
pregnancy NN o
rate NN o
and CC o
recurrence NN o
of IN o
symptoms NNS o
and CC o
signs NNS o
in IN N
patients NNS p
with IN p
endometriosis NN p
. . p

METHODS NNP N
In IN N
a DT N
prospective JJ N
randomized VBN N
clinical JJ N
trial NN N
, , N
after IN p
treatment NN p
of IN p
144 CD p
infertile JJ p
women NNS p
in IN p
their PRP$ p
reproductive JJ p
age NN p
by IN p
laparoscopy NN i
( ( p
whose WP$ p
endometriosis NN i
was VBD p
confirmed VBN p
by IN p
prior JJ p
laparoscopy NN i
) ) i
, , N
they PRP N
were VBD N
divided VBN N
into IN N
3 CD N
groups NNS N
: : N
group NN N
1 CD N
( ( p
47 CD p
cases NNS p
) ) p
who WP p
received VBD p
letrozole NN i
for IN p
2 CD p
months NNS p
, , p
group NN p
2 CD p
( ( p
40 CD p
patients NNS p
) ) p
who WP p
were VBD p
prescribed VBN p
triptorelin NN i
for IN p
2 CD p
months NNS p
and CC p
group NN p
3 CD p
who WP p
were VBD p
57 CD p
patients NNS p
in IN p
the DT p
control NN i
group NN p
and CC p
did VBD i
not RB i
receive VB i
any DT i
medication NN i
. . i

We PRP N
followed VBD N
up RP N
each DT N
group NN N
at IN N
least JJS N
for IN N
12 CD N
months NNS N
after IN N
their PRP$ N
restoration NN N
of IN N
regular JJ N
cycle NN N
. . N

RESULTS JJ N
Pregnancy NNP o
rate NN o
was VBD N
23.4 CD N
% NN N
in IN N
group NN N
1 CD N
, , N
27.5 CD N
% NN N
in IN N
group NN N
2 CD N
, , N
and CC N
28.1 CD N
% NN N
in IN N
group NN N
3 CD N
. . N

The DT N
results NNS N
did VBD o
not RB o
show VB o
significant JJ o
differences NNS o
among IN N
the DT N
3 CD N
groups NNS N
. . N

Recurrence NNP o
rate NN o
of IN o
endometriosis NN o
was VBD N
6.4 CD N
% NN N
in IN N
group NN N
1 CD N
, , N
5 CD N
% NN N
group NN N
2 CD N
and CC N
5.3 CD N
% NN N
in IN N
group NN N
3 CD N
, , N
which WDT N
was VBD N
not RB o
statistically RB o
significantly RB o
different JJ o
as RB N
well RB N
. . N

CONCLUSION NNP N
Pregnancy NNP o
rate NN o
and CC o
endometriosis NN o
recurrence NN o
rate NN o
are VBP N
comparable JJ N
among IN N
the DT N
3 CD N
groups NNS N
. . N

-DOCSTART- -17721955- O O

A DT N
1.5-year JJ N
follow-up NN N
of IN N
an DT N
Internet-based JJ i
intervention NN i
for IN N
complicated JJ N
grief NN N
. . N

Only RB N
recently RB N
have VBP N
psychotherapeutic JJ i
interventions NNS i
for IN N
complicated JJ N
grief NN N
been VBN N
developed VBN N
and CC N
evaluated VBN N
in IN N
randomized VBN N
controlled JJ N
trials NNS N
. . N

These DT N
trials NNS N
have VBP N
reported VBN N
significant JJ N
reductions NNS N
in IN N
complicated JJ N
grief NN N
and CC N
related JJ N
symptoms NNS N
in IN N
response NN N
to TO N
treatment NN N
relative JJ N
to TO N
control VB i
groups NNS i
. . i

However RB N
, , N
little JJ N
is VBZ N
known VBN N
about IN N
the DT N
long-term JJ N
outcomes NNS N
of IN N
these DT N
treatments NNS N
. . N

The DT N
authors NNS N
present VBP N
an DT N
evaluation NN N
of IN N
a DT N
1.5-year JJ N
follow-up NN N
of IN N
an DT N
Internet-based JJ i
cognitive-behavioral JJ i
intervention NN i
for IN p
complicated JJ p
grief NN p
. . p

Treatment NNP p
group NN p
patients NNS p
( ( p
n JJ p
= NNP p
22 CD p
) ) p
were VBD p
administered VBN p
various JJ p
assessments NNS p
of IN p
complicated JJ p
grief NN p
indicators NNS p
, , N
including VBG N
the DT N
Impact NN o
of IN o
Event NNP o
Scale NNP o
, , N
the DT N
anxiety NN o
and CC o
depression NN o
subscales NNS o
of IN o
the DT o
Brief NNP o
Symptom NNP o
Inventory NNP o
, , o
and CC o
the DT o
SF-12 NNP o
. . o

Results NNP N
indicate VBP N
that IN N
the DT N
reduction NN N
in IN N
symptoms NNS o
of IN o
complicated JJ o
grief NN o
observed VBN N
at IN N
posttreatment NN N
was VBD N
maintained VBN N
at IN N
1.5-year JJ N
follow-up NN N
. . N

-DOCSTART- -19280799- O O

Neuromuscular JJ N
excitability NN N
changes NNS N
in IN N
the DT N
vastus NN N
medialis NN N
following VBG N
anterior JJ i
cruciate JJ i
ligament NN i
reconstruction NN i
. . i

PURPOSE NNP N
Quadriceps NNP N
weakness NN N
following VBG N
anterior JJ p
cruciate JJ i
ligament NN i
reconstruction NN i
( ( i
ACLR NNP i
) ) i
is VBZ N
prevalent JJ N
despite IN N
intensive JJ N
rehabilitation NN N
. . N

Diminished NNP N
neuromuscular JJ N
excitability NN N
is VBZ N
one CD N
potential JJ N
factor NN N
that WDT N
may MD N
limit VB N
muscular JJ N
recovery NN N
following VBG N
injury NN N
or CC N
surgery NN N
. . N

The DT N
H-reflex NNP o
provides VBZ N
a DT N
measure NN N
of IN N
alpha NN N
motorneuron NN N
( ( N
neuromuscular JJ N
) ) N
excitability NN N
in IN N
the DT N
sensory-motor JJ N
pathway NN N
of IN N
the DT N
respective JJ N
muscle NN N
and CC N
nerve NN N
. . N

To TO N
date NN N
the DT N
vastus NN N
medialis NN N
( ( N
VM NNP N
) ) N
and CC N
soleus NN N
( ( N
SOL NNP N
) ) N
H-reflexes NNP N
have VBP N
been VBN N
examined VBN N
primarily RB N
in IN N
control NN N
subjects NNS p
with IN p
induced JJ p
knee NNS p
joint JJ p
effusion NN p
. . p

This DT N
prospective JJ N
, , N
randomized JJ N
clinical JJ N
trial NN N
evaluated VBD N
the DT N
affect NN N
of IN N
ACLR NNP i
, , N
utilizing VBG N
hamsting NN o
( ( o
HS NNP o
) ) o
or CC o
bone-patellar JJ o
tendon-bone NN o
( ( o
BTB NNP o
) ) o
autograft NN o
, , o
on IN o
VM NNP o
and CC o
SOL NNP o
H-reflex NNP o
latency NN o
and CC o
amplitude NN o
in IN N
twenty JJ p
subjects NNS p
. . p

METHODS NNP N
Preoperatively RB N
bilateral JJ N
VM NNP N
and CC N
SOL NNP N
H-reflex NNP N
tests NNS N
were VBD N
conducted VBN N
. . N

VM NNP o
and CC o
SOL NNP o
H-reflexes NNP o
were VBD N
subsequently RB N
conducted VBN N
on IN N
the DT N
involved VBN N
lower JJR N
extremity NN N
at IN N
1 CD N
and CC N
3 CD N
months NNS N
post VBN N
surgery NN N
. . N

At IN N
each DT N
test NN N
session NN N
subjects NNS p
completed VBN N
visual JJ o
analog NN o
scales NNS o
and CC o
knee VB o
girth NN o
was VBD N
measured VBN N
. . N

RESULTS VB N
The DT N
VM NNP o
H-reflex NNP o
amplitude NN o
increased VBD N
in IN N
the DT N
HS NNP N
group NN N
at IN N
3 CD N
months NNS N
compared VBN N
to TO N
1-month JJ N
post NN N
surgery NN N
( ( N
p JJ N
< NNP N
.05 NNP N
) ) N
. . N

Significant JJ N
changes NNS N
over IN N
time NN N
were VBD N
also RB N
noted VBN N
in IN N
the DT N
visual JJ o
analog NN o
pain NN o
and CC o
functional JJ o
scales NNS o
and CC o
the DT o
mid-patella JJ o
girth NN o
. . o

CONCLUSIONS VB N
The DT N
increased JJ N
VM NNP o
H-reflex NNP o
amplitude NN o
at IN N
3 CD N
months NNS N
following VBG N
HS NNP N
autograft NN N
ACLR NNP i
demonstrates VBZ N
an DT N
increase NN N
in IN N
VM NNP o
neuromuscular JJ o
excitability NN o
. . o

Increased VBN N
VM NNP o
neuromuscular JJ o
excitability NN o
was VBD N
not RB N
evident JJ N
in IN N
patients NNS N
following VBG N
BTB NNP N
reconstruction NN N
. . N

The DT N
increased JJ N
neuromuscular JJ o
excitability NN o
, , N
observed VBD N
only RB N
in IN N
the DT N
HS NNP N
group NN N
, , N
warrants NNS N
consideration NN N
when WRB N
selecting VBG N
graft NN N
type NN N
for IN N
patients NNS p
with IN p
extensive JJ p
preoperative JJ p
quadriceps NNS p
dysfunction NN p
. . p

-DOCSTART- -15356657- O O

Low-dose JJ i
oral JJ i
etoposide-based JJ i
induction NN N
regimen NNS N
for IN N
children NNS p
with IN p
acute JJ p
lymphoblastic JJ p
leukemia NN p
in IN p
first JJ p
bone NN p
marrow NN p
relapse NN p
. . p

We PRP N
evaluated VBD N
the DT N
clinical JJ o
response NN o
to TO N
low-dose JJ i
etoposide NN i
in IN N
relapsed JJ p
acute NN p
lymphoblastic JJ p
leukemia NN p
( ( p
ALL DT p
) ) p
. . p

Of IN N
the DT N
45 CD p
patients NNS p
with IN p
ALL NNP p
in IN p
first JJ p
bone NN p
marrow NN p
relapse NN p
enrolled VBD p
on IN N
the DT N
ALL NNP N
R15 NNP N
protocol NN N
, , N
44 CD N
had VBD N
received VBN N
epipodophyllotoxins NNS i
during IN i
frontline JJ i
therapy NN i
. . i

In IN N
the DT N
first JJ N
week NN N
of IN N
remission NN N
induction NN N
therapy NN N
, , N
patients NNS i
received VBD i
etoposide RB i
( ( i
50 CD i
mg/m NN i
( ( i
2 CD i
) ) i
per IN i
day NN i
) ) i
administered VBD i
orally RB i
as IN i
a DT i
single JJ i
agent NN i
once RB i
or CC i
twice RB i
daily RB i
. . i

On IN N
Day NNP N
8 CD N
, , N
patients NNS N
started VBD N
to TO N
receive VB N
dexamethasone NN i
, , i
vincristine NN i
, , i
and CC i
L-asparaginase NNP i
. . i

Etoposide NNP i
was VBD i
administered VBN i
until IN i
Day NNP i
22 CD i
. . i

Two CD i
courses NNS i
of IN i
consolidation NN i
therapy NN i
were VBD i
followed VBN i
by IN i
continuation NN i
therapy NN i
or CC i
hematopoietic JJ i
stem NN i
cell NN i
transplantation NN i
. . i

After IN N
7 CD N
days NNS N
of IN N
single-agent JJ N
etoposide NN N
treatment NN N
, , N
peripheral JJ o
blast NN o
cell NN o
counts NNS o
( ( N
P=0.013 NNP N
) ) N
and CC N
percentages NNS o
of IN o
bone NN o
marrow NN o
blasts NNS o
( ( N
P=0.016 NNP N
) ) N
were VBD N
significantly RB N
reduced VBN N
. . N

In IN N
all DT N
, , N
38 CD N
( ( N
84.4 CD N
% NN N
) ) N
attained VBD N
second JJ o
remission NN o
. . o

Only RB N
time NN o
to TO o
relapse VB o
was VBD N
significantly RB N
associated VBN N
with IN N
outcome NN N
( ( N
P=0.025 NNP N
) ) N
: : N
the DT N
5-year JJ o
event-free JJ o
survival NN o
estimates NNS N
( ( N
+/-se JJ N
) ) N
were VBD N
52.0+/-9.6 JJ N
% NN N
for IN N
those DT N
with IN N
late JJ N
relapse NN N
and CC N
20.0+/-8.0 JJ N
% NN N
for IN N
those DT N
with IN N
early JJ N
relapse NN N
. . N

We PRP N
conclude VBP N
that IN N
low-dose JJ i
etoposide NN i
administered VBN N
orally RB N
has VBZ N
a DT N
cytoreductive JJ N
effect NN N
in IN N
relapsed VBN N
ALL NNP N
. . N

-DOCSTART- -20705223- O O

Modest JJS N
visceral JJ N
fat NN i
gain NN i
causes VBZ N
endothelial JJ p
dysfunction NN p
in IN p
healthy JJ p
humans NNS p
. . p

OBJECTIVES IN N
The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
determine VB N
the DT N
impact NN N
of IN N
fat JJ N
gain NN N
and CC N
its PRP$ N
distribution NN N
on IN N
endothelial JJ o
function NN o
in IN p
lean JJ p
healthy JJ p
humans NNS p
. . p

BACKGROUND NNP N
Endothelial NNP o
dysfunction NN o
has VBZ N
been VBN N
identified VBN N
as IN N
an DT N
independent JJ N
predictor NN N
of IN N
cardiovascular JJ N
events NNS N
. . N

Whether NNP N
fat JJ i
gain NN i
impairs NNS N
endothelial JJ o
function NN o
is VBZ N
unknown JJ N
. . N

METHODS VB N
A DT N
randomized NN N
controlled VBD N
study NN N
was VBD N
conducted VBN N
to TO N
assess VB N
the DT N
effects NNS N
of IN N
fat JJ i
gain NN i
on IN N
endothelial JJ N
function NN N
. . N

Forty-three JJ p
normal-weight JJ p
healthy JJ p
volunteers NNS p
were VBD p
recruited VBN p
( ( p
mean JJ p
age NN p
29 CD p
years NNS p
; : p
18 CD p
women NNS p
) ) p
. . p

Subjects NNS p
were VBD N
assigned VBN N
to TO N
gain VB i
weight NN i
( ( N
approximately RB N
4 CD N
kg NNS N
) ) N
( ( N
n=35 JJ N
) ) N
or CC N
to TO N
maintain VB i
weight NN i
( ( N
n=8 JJ N
) ) N
. . N

Endothelial JJ o
function NN o
( ( o
brachial JJ o
artery NN o
flow-mediated JJ o
dilation NN o
[ NNP o
FMD NNP o
] NNP o
) ) o
was VBD N
measured VBN N
at IN N
baseline NN N
, , N
after IN N
fat JJ N
gain NN N
( ( N
8 CD N
weeks NNS N
) ) N
, , N
and CC N
after IN N
weight JJ N
loss NN N
( ( N
16 CD N
weeks NNS N
) ) N
for IN N
fat JJ N
gainers NNS N
and CC N
at IN N
baseline NN N
and CC N
follow-up NN N
( ( N
8 CD N
weeks NNS N
) ) N
for IN N
weight NN N
maintainers NNS N
. . N

Body NNP N
composition NN N
was VBD N
measured VBN N
by IN N
dual-energy JJ N
X-ray JJ N
absorptiometry NN N
and CC N
abdominal JJ N
computed JJ N
tomographic JJ N
scans NNS N
. . N

RESULTS NNP N
After IN N
an DT N
average JJ N
weight JJ N
gain NN N
of IN N
4.1 CD N
kg NN N
, , N
fat JJ N
gainers NNS N
significantly RB N
increased VBD N
their PRP$ N
total JJ o
, , o
visceral JJ o
, , o
and CC o
subcutaneous JJ o
fat NN o
. . o

Blood NNP o
pressure NN o
and CC o
overnight JJ o
polysomnography NN o
did VBD N
not RB N
change NN N
after IN N
fat JJ N
gain NN N
or CC N
loss NN N
. . N

FMD NNP o
remained VBD N
unchanged JJ N
in IN N
weight JJ N
maintainers NNS N
. . N

FMD NNP o
decreased VBD N
in IN N
fat JJ N
gainers NNS N
( ( N
9.1+/-3 CD N
% NN N
vs. FW N
7.8+/-3.2 CD N
% NN N
, , N
p=0.003 NN N
) ) N
but CC N
recovered VBD N
to TO N
baseline VB N
when WRB N
subjects NNS N
shed VBD N
the DT N
gained JJ N
weight NN N
. . N

There EX N
was VBD N
a DT N
significant JJ N
correlation NN N
between IN N
the DT N
decrease NN N
in IN N
FMD NNP o
and CC N
the DT N
increase NN N
in IN N
visceral JJ o
fat JJ o
gain NN o
( ( N
rho=-0.42 JJ N
, , N
p=0.004 NN N
) ) N
, , N
but CC N
not RB N
with IN N
subcutaneous JJ o
fat JJ o
gain NN o
( ( N
rho=-0.22 JJ N
, , N
p=0.15 NN N
) ) N
. . N

CONCLUSIONS NNP N
In IN N
normal-weight JJ p
healthy JJ p
young JJ p
subjects NNS p
, , N
modest JJ N
fat JJ i
gain NN i
results NNS N
in IN N
impaired JJ N
endothelial JJ o
function NN o
, , N
even RB N
in IN N
the DT N
absence NN N
of IN N
changes NNS N
in IN N
blood NN o
pressure NN o
. . o

Endothelial JJ o
function NN o
recovers NNS N
after IN N
weight JJ N
loss NN N
. . N

Increased VBN N
visceral JJ o
rather RB o
than IN o
subcutaneous JJ o
fat JJ o
predicts NNS N
endothelial JJ o
dysfunction NN o
. . o

( ( N
Fat JJ N
Gain NNP N
and CC N
Cardiovascular NNP N
Disease NNP N
Mechanisms NNP N
; : N
NCT00589498 NNP N
) ) N
. . N

-DOCSTART- -19708471- O O

Qigong JJ i
massage NN i
treatment NN i
for IN N
sensory JJ o
and CC o
self-regulation JJ o
problems NNS o
in IN p
young JJ p
children NNS p
with IN p
autism NN p
: : p
a DT N
randomized NN N
controlled VBN N
trial NN N
. . N

Autism NN N
is VBZ N
commonly RB N
associated VBN N
with IN N
sensory JJ o
and CC o
self-regulatory JJ o
disturbances NNS o
. . o

This DT N
article NN N
presents VBZ N
a DT N
randomized VBN N
controlled VBN N
study NN N
evaluating VBG N
the DT N
effect NN N
of IN N
a DT N
5-month JJ N
intervention NN N
directed VBD N
toward IN N
improving VBG N
sensory JJ o
impairment NN o
, , o
digestion NN o
, , o
and CC o
sleep NN o
in IN N
46 CD p
children NNS p
with IN p
autism NN p
< NNP p
age NN p
6 CD p
. . p

The DT N
intervention NN N
, , N
Qigong NNP i
Sensory NNP i
Training NNP i
( ( i
QST NNP i
) ) i
, , N
is VBZ N
a DT N
qigong JJ i
massage NN i
intervention NN i
based VBN N
in IN N
Chinese JJ N
medicine NN N
. . N

It PRP N
is VBZ N
two-pronged JJ N
: : N
Trainers NNS N
work VBP N
with IN N
children NNS N
directly RB N
20 CD N
times NNS N
over IN N
5 CD N
months NNS N
, , N
and CC N
parents NNS N
give VBP N
the DT N
massage NN N
daily RB N
to TO N
their PRP$ N
children NNS N
. . N

Improvement NN N
was VBD N
evaluated VBN N
in IN N
two CD N
settings NNS N
-- : N
preschool NN N
and CC N
home NN N
-- : N
by IN N
teachers NNS N
( ( N
blind IN N
to TO N
group NN N
) ) N
and CC N
parents NNS N
. . N

Teacher CC N
evaluations NNS N
showed VBD N
that IN N
treated JJ N
children NNS N
had VBD N
significant JJ N
classroom NN N
improvement NN N
of IN N
social JJ o
and CC o
language NN o
skills NNS o
and CC N
reduction NN o
in IN o
autistic JJ o
behavior NN o
compared VBN N
with IN N
wait-list JJ N
control NN N
participants NNS N
. . N

These DT N
findings NNS N
were VBD N
confirmed VBN N
by IN N
parent NN N
data NNS N
, , N
indicating VBG N
that IN N
the DT N
gains NNS o
had VBD N
generalized VBN N
across IN N
contexts NN N
. . N

A DT N
model NN N
and CC N
supporting VBG N
data NNS N
for IN N
understanding NN N
and CC N
treating VBG N
sensory JJ o
and CC o
self-regulation JJ o
problems NNS o
in IN N
autism NN N
is VBZ N
presented VBN N
. . N

-DOCSTART- -19243606- O O

Randomised VBN N
Phase NNP N
I/II NNP N
trial NN N
assessing VBG N
the DT N
safety NN o
and CC N
efficacy NN o
of IN N
radiolabelled JJ i
anti-carcinoembryonic JJ i
antigen NN i
I PRP i
( ( i
131 CD i
) ) i
KAb201 NNP i
antibodies NNS N
given VBN N
intra-arterially RB N
or CC N
intravenously RB N
in IN N
patients NNS p
with IN p
unresectable JJ p
pancreatic JJ p
adenocarcinoma NN p
. . p

BACKGROUND NNP N
Advanced NNP p
pancreatic JJ p
cancer NN p
has VBZ N
a DT N
poor JJ N
prognosis NN N
, , N
and CC N
the DT N
current JJ N
standard NN N
of IN N
care NN N
( ( i
gemcitabine NN i
based VBN i
chemotherapy NN i
) ) i
provides VBZ N
a DT N
small JJ N
survival NN N
advantage NN N
. . N

However RB N
the DT N
drawback NN N
is VBZ N
the DT N
accompanying VBG N
systemic JJ N
toxicity NN N
, , N
which WDT N
targeted VBD N
treatments NNS N
may MD N
overcome VB N
. . N

This DT N
study NN N
aimed VBD N
to TO N
evaluate VB N
the DT N
safety NN o
and CC N
tolerability NN o
of IN N
KAb201 NNP i
, , N
an DT N
anti-carcinoembryonic JJ N
antigen NN N
monoclonal JJ N
antibody NN N
, , N
labelled VBD N
with IN N
I PRP N
( ( N
131 CD N
) ) N
in IN N
pancreatic JJ N
cancer NN N
( ( N
ISRCTN NNP N
16857581 CD N
) ) N
. . N

METHODS JJ N
Patients NNS p
with IN p
histological/cytological JJ p
proven NN p
inoperable JJ p
adenocarcinoma NN p
of IN p
the DT p
head NN p
of IN p
pancreas NNS p
were VBD p
randomised VBN p
to TO p
receive VB p
KAb NNP i
201 CD i
via IN N
either CC N
the DT N
intra-arterial JJ N
or CC N
intravenous JJ N
delivery NN N
route NN N
. . N

The DT N
dose JJ o
limiting NN o
toxicities NNS o
within IN N
each DT N
group NN N
were VBD N
determined VBN N
. . N

Patients NNS N
were VBD N
assessed VBN N
for IN N
safety NN o
and CC o
efficacy NN o
and CC N
followed VBD N
up RP N
until IN N
death NN N
. . N

RESULTS NNP N
Between NNP p
February NNP p
2003 CD p
and CC p
July NNP p
2005 CD p
, , p
25 CD p
patients NNS p
were VBD p
enrolled VBN p
. . p

Nineteen JJ p
patients NNS p
were VBD p
randomised VBN p
, , p
9 CD p
to TO p
the DT p
intravenous JJ p
and CC p
10 CD p
to TO p
the DT p
intra-arterial JJ p
arms NNS p
. . p

In IN N
the DT N
intra-arterial JJ N
arm NN N
, , N
dose VB N
limiting VBG N
toxicity NN o
was VBD N
seen VBN N
in IN N
2/6 CD N
( ( N
33 CD N
% NN N
) ) N
patients NNS N
at IN N
50 CD N
mCi NNS N
whereas RB N
in IN N
the DT N
intravenous JJ N
arm NN N
, , N
dose VB N
limiting VBG N
toxicity NN o
was VBD N
noted VBN N
in IN N
1/6 CD N
patients NNS N
at IN N
50 CD N
mCi NN N
, , N
but CC N
did VBD N
not RB N
occur VB N
at IN N
75 CD N
mCi NN N
( ( N
0/3 CD N
) ) N
.The CD N
overall JJ N
response NN o
rate NN o
was VBD N
6 CD N
% NN N
( ( N
1/18 CD N
) ) N
. . N

Median JJ o
overall JJ o
survival NN o
was VBD N
5.2 CD N
months NNS N
( ( N
95 CD N
% NN N
confidence NN N
interval NN N
= VBD N
3.3 CD N
to TO N
9 CD N
months NNS N
) ) N
, , N
with IN N
no DT N
significant JJ N
difference NN N
between IN N
the DT N
intravenous JJ N
and CC N
intra-arterial JJ N
arms NNS N
( ( N
log JJ N
rank NN N
test NN N
p NN N
= NNP N
0.79 CD N
) ) N
. . N

One CD N
patient NN N
was VBD N
still RB N
alive JJ N
at IN N
the DT N
time NN N
of IN N
this DT N
analysis NN N
. . N

CONCLUSION NNP N
Dose NNP o
limiting VBG o
toxicity NN o
for IN N
KAb201 NNP i
with IN N
I PRP N
( ( N
131 CD N
) ) N
by IN N
the DT N
intra-arterial JJ N
route NN N
was VBD N
50 CD N
mCi NNS N
, , N
while IN N
dose JJ o
limiting VBG o
toxicity NN o
was VBD N
not RB N
reached VBN N
in IN N
the DT N
intravenous JJ N
arm NN N
. . N

-DOCSTART- -550796- O O

Propranolol NNP i
vs NN i
acetazolamide NN i
. . i

A DT p
long-term JJ p
double-masked JJ p
study NN p
of IN p
the DT p
effect NN p
on IN p
intraocular JJ o
pressure NN o
and CC o
blood NN o
pressure NN o
. . o

-DOCSTART- -21329577- O O

Quitting VBG N
a DT N
weight JJ i
loss NN i
program NN i
is VBZ N
associated VBN N
with IN N
anhedonia NN p
: : p
preliminary JJ p
findings NNS p
of IN p
the DT p
Lifestyle NNP p
Intervention NNP p
Treatment NNP p
Evaluation NNP p
Study NNP p
in IN p
northern JJ p
Finland NNP p
. . p

OBJECTIVES NNP N
To TO N
examine VB N
whether IN N
a DT N
diagnosis NN N
for IN N
major JJ p
depression NN p
, , p
chronic JJ p
depression NN p
or CC p
specific JJ p
symptoms NNS p
of IN p
depression NN p
is VBZ N
associated VBN N
with IN N
the DT N
risk NN N
of IN N
quitting VBG N
a DT N
weight JJ i
loss NN i
program NN i
. . i

STUDY NNP N
DESIGN NNP N
The DT N
study NN N
involved VBD N
82 CD p
overweight JJ p
adults NNS p
participating VBG p
in IN p
the DT p
Lifestyle NNP i
Intervention NNP i
Treatment NNP i
Evaluation NNP i
( ( p
LITE NNP p
) ) p
follow-up NN p
study NN p
at IN p
Oulu NNP p
University NNP p
Hospital NNP p
in IN p
northern JJ p
Finland NNP p
. . p

METHODS NNP N
Psychiatric NNP o
diagnostic JJ o
assessments NNS o
were VBD N
based VBN N
on IN N
the DT N
Structured NNP N
Clinical NNP N
Interview NNP N
for IN N
DSMIV NNP o
disorders NNS N
( ( N
SCID-I NNP N
) ) N
conducted VBN N
by IN N
a DT N
clinical JJ N
psychiatrist NN N
. . N

Anhedonia NNP o
( ( o
lack NN o
of IN o
pleasure NN o
) ) o
was VBD N
assessed VBN N
as IN N
one CD N
of IN N
the DT N
core NN N
symptoms NNS N
of IN N
major JJ N
depression NN N
and CC N
chronic JJ o
depression NN N
( ( N
dysthymia NN N
) ) N
. . N

Anhedonia NNP o
was VBD N
defined VBN N
to TO N
be VB N
present JJ N
if IN N
the DT N
participants NNS N
reported VBD N
having VBG N
suffered VBD N
a DT N
major JJ N
loss NN N
of IN N
interest NN N
during IN N
the DT N
previous JJ N
month NN N
. . N

RESULTS NNP N
Twenty NNP N
participants NNS N
( ( N
24.4 CD N
% NN N
) ) N
quit NN N
during IN N
the DT N
6-month JJ N
intervention NN N
period NN N
. . N

Anhedonia NNP o
put VBD N
individuals NNS N
at IN N
risk NN N
of IN N
quitting VBG N
the DT N
weight JJ N
loss NN N
program NN N
( ( N
bivariate JJ N
analysis NN N
OR NNP N
3.1 CD N
, , N
95 CD N
% NN N
CI NNP N
0.8-11.6 CD N
, , N
p=0.091 NN N
, , N
multivariate JJ N
analysis NN N
OR NNP N
6.5 CD N
, , N
95 CD N
% NN N
CI NNP N
1.1-38.2 CD N
, , N
p=0.038 NN N
) ) N
. . N

However RB N
, , N
a DT N
diagnosis NN N
for IN N
major JJ o
depression NN o
or CC o
chronic JJ o
depression NN o
did VBD N
not RB N
predict JJ N
quitting VBG N
. . N

CONCLUSIONS NNP N
Individual NNP N
assessments NNS N
of IN N
obesity NN N
and CC N
overweight NN N
should MD N
also RB N
include VB N
an DT N
assessment NN N
for IN N
subthreshold JJ N
depression NN N
, , N
mainly RB N
anhedonia NN N
. . N

-DOCSTART- -16316486- O O

Divalproex NNP i
sodium NN i
vs. FW i
placebo NN i
in IN N
the DT N
treatment NN N
of IN N
repetitive JJ o
behaviours NNS o
in IN N
autism NN p
spectrum NN p
disorder NN p
. . p

Autism NNP N
is VBZ N
a DT N
neurodevelopmental JJ N
disorder NN N
characterized VBN N
by IN N
impairment NN N
in IN N
three CD N
core NN N
symptom NN N
domains NNS N
: : N
socialization NN N
, , N
communication NN N
, , N
and CC N
repetitive/stereotyped VBD N
behaviours NNS N
. . N

Other JJ N
associated JJ N
symptom NN N
domains NNS N
are VBP N
also RB N
affected JJ N
including VBG N
impulsivity/aggression NN N
, , N
self-injury NN N
, , N
anxiety NN N
, , N
and CC N
mood NN N
lability NN N
. . N

Divalproex NNP i
has VBZ N
been VBN N
shown VBN N
to TO N
have VB N
efficacy NN N
in IN N
treating VBG N
epilepsy NN N
, , N
bipolar JJ N
disorder NN N
, , N
mood NN N
lability NN N
, , N
and CC N
impulsive JJ N
aggression NN N
. . N

The DT N
present JJ N
study NN N
evaluated VBD N
the DT N
use NN N
of IN N
divalproex NN i
in IN N
the DT N
treatment NN N
of IN N
repetitive JJ o
, , o
compulsive-like JJ o
symptoms NNS o
of IN o
autism NN o
spectrum NN o
disorder NN o
( ( o
ASD NNP o
) ) o
. . o

Thirteen JJ p
individuals NNS p
with IN p
ASD NNP p
participated VBD N
in IN N
an DT N
8-wk JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ i
trial NN N
of IN N
divalproex NN i
sodium NN i
vs. FW i
placebo NN i
. . i

There EX N
was VBD N
a DT N
significant JJ N
group NN N
difference NN N
on IN N
improvement NN N
in IN N
repetitive JJ o
behaviours NNS o
as IN N
measured VBN N
by IN N
the DT N
Children NNP o
's POS o
Yale-Brown JJ o
Obsessive NNP o
Compulsive NNP o
Scale NNP o
( ( o
C-YBOCS NNP o
) ) o
( ( N
p=0.037 NN N
) ) N
and CC N
a DT N
large JJ N
effect NN N
size NN N
( ( N
d=1.616 NN N
) ) N
. . N

This DT N
study NN N
provides VBZ N
preliminary JJ N
support NN N
for IN N
the DT N
use NN N
of IN N
divalproex NN i
in IN N
treating VBG N
repetitive JJ o
behaviours NNS o
in IN N
ASD NNP p
. . p

Further NNP N
research NN N
is VBZ N
needed VBN N
to TO N
evaluate VB N
the DT N
specificity NN N
and CC N
mechanism NN N
of IN N
action NN N
of IN N
these DT N
findings NNS N
. . N

-DOCSTART- -8595286- O O

A DT N
randomised VBN N
controlled VBN N
trial NN N
comparing VBG N
two CD N
schedules NNS i
of IN i
antenatal JJ i
visits NNS i
: : i
the DT N
antenatal JJ i
care NN i
project NN N
. . N

OBJECTIVE UH N
To TO N
compare VB N
the DT N
clinical JJ N
and CC N
psychological JJ N
effectiveness NN N
of IN N
the DT N
traditional JJ i
British JJ i
antenatal JJ i
visit NN i
schedule NN i
( ( i
traditional JJ i
care NN i
) ) i
with IN i
a DT i
reduced JJ i
schedule NN i
of IN i
visits NNS i
( ( i
new JJ i
style NN i
care NN i
) ) i
for IN N
low JJ p
risk NN p
women NNS p
, , N
together RB N
with IN N
maternal JJ N
and CC N
professional JJ N
satisfaction NN N
with IN N
care NN N
. . N

DESIGN NNP N
Randomised VBD N
controlled VBN N
trial NN N
. . N

SETTING NN N
Places NNS N
in IN N
south JJ N
east JJ N
London NNP N
providing NN N
antenatal JJ i
care NN i
for IN N
women NNS p
receiving VBG p
shared VBN p
care NN p
and CC N
planning NN N
to TO N
deliver VB N
in IN N
one CD N
of IN N
three CD N
hospitals NNS N
or CC N
at IN N
home NN N
. . N

SUBJECT JJ N
2794 CD p
women NNS p
at IN p
low JJ p
risk NN p
fulfilling VBG p
the DT p
trial NN p
's POS p
inclusion NN p
criteria NNS p
between IN p
June NNP p
1993 CD p
and CC p
July NNP p
1994 CD p
. . p

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
Measures NNP o
of IN o
fetal NN o
and CC o
maternal JJ o
morbidity NN o
, , o
health NN o
service NN o
use NN o
, , o
psychosocial JJ o
outcomes NNS o
, , o
and CC o
maternal JJ o
and CC o
professional JJ o
satisfaction NN o
. . o

RESULTS NNP N
Pregnant JJ p
women NNS p
allocated VBD p
to TO p
new JJ i
style NN i
care NN i
had VBD N
fewer JJR N
day NN o
admissions NNS o
( ( N
0.8 CD N
v RB N
1.0 CD N
; : N
P=0.002 NNP N
) ) N
and CC N
ultrasound JJ o
scans NNS o
( ( N
1.6 CD N
v RB N
1.7 CD N
; : N
P=0.003 NNP N
) ) N
and CC N
were VBD N
less RBR N
often RB N
suspected VBN o
of IN o
carrying VBG o
fetuses NNS o
that WDT o
were VBD o
small JJ o
for IN o
gestational JJ o
age NN o
( ( N
odds NNS N
ratio VBP N
0.73 CD N
; : N
95 CD N
% NN N
confidence NN N
interval NN N
0.54 CD N
to TO N
0.99 CD N
) ) N
. . N

They PRP N
also RB N
had VBD N
some DT N
poorer JJ o
psychosocial JJ o
outcomes NNS o
; : o
for IN N
example NN N
, , N
they PRP N
were VBD N
more RBR N
worried JJ N
about IN N
fetal JJ o
wellbeing NN o
antenatally RB o
and CC N
coping VBG o
with IN o
the DT o
baby NN o
postnatally RB o
, , N
and CC N
they PRP N
had VBD N
more RBR N
negative JJ N
attitudes NNS o
to TO N
their PRP$ N
babies NNS N
, , N
both DT N
in IN N
pregnancy NN N
and CC N
postnatally RB N
. . N

These DT N
women NNS N
were VBD N
also RB N
more RBR N
dissatisfied JJ o
with IN o
the DT o
number NN o
of IN o
visits NNS o
they PRP N
received VBD N
( ( N
odds NNS N
ratio VBP N
2.50 CD N
; : N
2.00 CD N
to TO N
3.11 CD N
) ) N
. . N

CONCLUSIONS NNP N
Patterns NNP N
of IN N
antenatal JJ i
care NN i
involving VBG N
fewer JJR N
routine JJ N
visits NNS i
for IN N
women NNS N
at IN N
low JJ N
risk NN N
may MD N
lead VB N
to TO N
reduced VB N
psychosocial JJ o
effectiveness NN o
and CC N
dissatisfaction NN o
with IN N
frequency NN N
of IN N
visits NNS N
. . N

The DT N
number NN N
of IN N
antenatal JJ o
day NN o
admissions NNS o
and CC N
ultrasound JJ o
scans NNS o
performed VBN o
may MD N
also RB N
be VB N
reduced VBN N
. . N

For IN N
the DT N
variables NNS N
reported VBN N
, , N
the DT N
visit NN N
schedules NNS N
studied VBN N
are VBP N
similar JJ N
in IN N
their PRP$ N
clinical JJ N
effectiveness NN N
. . N

Uncertainty NN N
remains VBZ N
as IN N
to TO N
the DT N
clinical JJ N
effectiveness NN N
of IN N
reduced JJ i
visit NN i
schedules NNS i
for IN N
rare JJ N
pregnancy NN N
problems NNS N
. . N

-DOCSTART- -20496000- O O

Chumnguh NNP N
thleum NN N
: : N
understanding JJ N
liver NN p
illness NN p
and CC p
hepatitis NN p
B NNP p
among IN p
Cambodian JJ p
immigrants NNS p
. . p

Cambodian JJ p
immigrants NNS p
are VBP N
over IN N
25 CD N
times NNS N
more RBR N
likely JJ N
to TO N
have VB N
evidence NN N
of IN N
chronic JJ N
hepatitis NN N
B NNP N
infection NN N
than IN N
the DT N
general JJ N
US NNP N
population NN N
. . N

Carriers NNS N
of IN N
HBV NNP N
are VBP N
over IN N
100 CD N
times NNS N
more RBR N
likely JJ N
to TO N
develop VB N
liver RB N
cancer NN N
than IN N
non-carriers NNS N
. . N

Liver NNP N
cancer NN N
incidence NN N
is VBZ N
the DT N
second JJ N
leading JJ N
cancer NN N
for IN N
Cambodian JJ p
men NNS p
and CC p
the DT p
sixth JJ p
for IN p
Cambodian JJ p
women NNS p
. . p

Despite IN N
this DT N
, , N
this DT N
underserved JJ p
population NN p
has VBZ N
received VBN N
very RB N
little JJ N
attention NN N
from IN N
health NN N
disparities NNS N
researchers NNS N
. . N

Culturally NNP N
and CC N
linguistically RB N
appropriate JJ N
interventions NNS N
are VBP N
necessary JJ N
to TO N
increase VB N
hepatitis NN o
B NNP o
knowledge NN o
, , o
serologic JJ o
testing NN o
, , N
and CC N
vaccination NN o
among IN N
Cambodian JJ N
Americans NNPS N
. . N

Eight NNP i
group NN i
interviews NNS i
were VBD N
held VBN N
with IN N
Cambodian JJ p
American JJ p
men NNS p
( ( p
48 CD p
) ) p
and CC p
women NNS p
( ( p
49 CD p
) ) p
. . p

Focus NNP N
group NN N
discussion NN N
revealed VBD N
unanticipated JJ N
information NN N
about IN N
sociocultural JJ o
influences NNS o
on IN N
participants NNS o
' POS o
understanding VBG o
about IN o
hepatitis NN o
B NNP o
transmission NN o
, , o
disease NN o
course NN o
, , o
and CC o
prevention NN o
and CC o
treatment NN o
informed VBN N
by IN N
humoral JJ N
theories NNS N
underlying VBG N
Khmer NNP N
medicine NN N
, , N
by IN N
biomedicine NN N
, , N
and CC N
by IN N
migration NN N
experiences NNS N
. . N

Our PRP$ N
findings NNS N
reveal VBP N
the DT N
value NN N
of IN N
qualitative JJ N
exploration NN N
to TO N
providing VBG N
cultural JJ N
context NN N
to TO N
biomedical JJ N
information NN N
-- : N
a DT N
formula NN N
for IN N
effective JJ N
health NN N
promotion NN N
and CC N
practice NN N
. . N

-DOCSTART- -24803366- O O

Virtual JJ i
reality NN i
job NN i
interview NN i
training NN i
in IN N
adults NNS p
with IN p
autism NN p
spectrum NN p
disorder NN p
. . p

The DT N
feasibility NN N
and CC N
efficacy NN N
of IN N
virtual JJ i
reality NN i
job NN i
interview NN i
training NN i
( ( i
VR-JIT NNP i
) ) i
was VBD N
assessed VBN N
in IN N
a DT N
single-blinded JJ N
randomized NN N
controlled VBD N
trial NN N
. . N

Adults NNS p
with IN p
autism NN p
spectrum NN p
disorder NN p
were VBD p
randomized VBN p
to TO p
VR-JIT NNP i
( ( p
n JJ p
= NNP p
16 CD p
) ) p
or CC p
treatment-as-usual JJ i
( ( i
TAU NNP i
) ) i
( ( p
n JJ p
= NNP p
10 CD p
) ) p
groups NNS p
. . p

VR-JIT NNP i
consisted VBD i
of IN i
simulated JJ i
job NN i
interviews NNS i
with IN i
a DT i
virtual JJ i
character NN i
and CC i
didactic JJ i
training NN i
. . i

Participants NNS N
attended VBD N
90 CD N
% NN N
of IN N
laboratory-based JJ N
training NN N
sessions NNS N
, , N
found VBD N
VR-JIT NNP i
easy JJ o
to TO o
use VB o
and CC N
enjoyable JJ o
, , N
and CC N
they PRP N
felt VBD N
prepared VBN o
for IN o
future JJ o
interviews NNS o
. . o

VR-JIT JJ i
participants NNS p
had VBD N
greater JJR o
improvement NN o
during IN o
live JJ o
standardized JJ o
job NN o
interview NN o
role-play NN o
performances NNS o
than IN N
TAU NNP i
participants NNS p
( ( N
p JJ N
= NNP N
0.046 CD N
) ) N
. . N

A DT N
similar JJ N
pattern NN N
was VBD N
observed VBN N
for IN N
self-reported JJ o
self-confidence NN o
at IN N
a DT N
trend NN N
level NN N
( ( N
p JJ N
= NNP N
0.060 CD N
) ) N
. . N

VR-JIT JJ o
simulation NN o
performance NN o
scores NNS o
increased VBD N
over IN N
time NN N
( ( N
R NNP N
( ( N
2 CD N
) ) N
= FW N
0.83 CD N
) ) N
. . N

Results JJ N
indicate JJ N
preliminary JJ N
support NN N
for IN N
the DT N
feasibility NN o
and CC N
efficacy NN o
of IN N
VR-JIT NNP i
, , N
which WDT N
can MD N
be VB N
administered VBN N
using VBG N
computer NN N
software NN N
or CC N
via IN N
the DT N
internet NN N
. . N

-DOCSTART- -21914906- O O

The DT N
effect NN N
of IN N
visual JJ N
supports NNS N
on IN N
performance NN o
of IN N
the DT N
TGMD-2 NNP i
for IN N
children NNS p
with IN p
autism NN p
spectrum NN p
disorder NN p
. . p

The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
examine VB N
the DT N
effects NNS N
of IN N
visual JJ N
supports NNS N
on IN N
the DT N
performance NN N
of IN N
the DT N
Test NNP i
of IN i
Gross NNP i
Motor NNP i
Development NNP i
( ( i
TGMD-2 NNP i
) ) i
for IN N
children NNS p
with IN p
autism NN p
spectrum NN p
disorder NN p
( ( p
ASD NNP p
) ) p
. . p

Participants NNS p
( ( p
N NNP p
= NNP p
22 CD p
) ) p
performed VBD N
the DT N
TGMD-2 NNP i
under IN N
three CD N
different JJ N
protocols NNS N
( ( i
traditional JJ i
protocol NN i
, , i
picture NN i
task NN i
card NN i
protocol NN i
, , i
and CC i
picture NN i
activity NN i
schedule NN i
protocol NN i
) ) i
. . N

Gross NNP o
motor NN o
quotient NN o
scores NNS o
on IN N
the DT N
TGMD-2 NNP i
were VBD N
measured VBN N
and CC N
statistically RB N
analyzed VBN N
using VBG N
a DT N
within-subjects JJ N
repeated-measures NNS N
ANOVA NNP N
. . N

Results NNP N
indicated VBD N
statistically RB N
significant JJ N
differences NNS N
between IN N
protocols NNS N
, , N
while IN N
post NN N
hoc NN N
tests NNS N
indicated VBD N
that IN N
the DT N
picture NN N
task NN N
card NN N
condition NN N
produced VBD N
significantly RB N
higher JJR N
gross JJ o
motor NN o
quotient NN o
scores NNS o
than IN N
the DT N
traditional JJ N
protocol NN N
and CC N
the DT N
picture NN N
activity NN N
schedule NN N
. . N

The DT N
results NNS N
suggest VBP N
that IN N
more JJR N
accurate JJ N
gross JJ N
motor NN N
quotient NN N
scores NNS N
on IN N
the DT N
TGMD-2 NNP o
by IN N
children NNS p
with IN p
ASD NNP p
can MD N
be VB N
elicited VBN N
using VBG N
the DT N
picture NN N
task NN N
card NN N
protocol NN N
. . N

-DOCSTART- -12559222- O O

Intravenous JJ N
levosimendan NN i
treatment NN N
is VBZ N
cost-effective JJ N
compared VBN N
with IN N
dobutamine NN i
in IN N
severe JJ p
low-output JJ p
heart NN p
failure NN p
: : p
an DT N
analysis NN N
based VBN N
on IN N
the DT N
international JJ N
LIDO NNP N
trial NN N
. . N

BACKGROUND NNP N
Levosimendan NNP i
, , N
a DT N
novel JJ N
calcium NN N
sensitiser NN N
, , N
improves VBZ N
cardiac JJ N
performance NN N
and CC N
symptoms NNS N
without IN N
increasing VBG N
oxygen NN N
consumption NN N
, , N
and CC N
decreases VBZ N
the DT N
mortality NN N
of IN N
patients NNS p
with IN p
low-output JJ p
heart NN p
failure NN p
. . p

AIMS NNP N
To TO N
estimate VB N
the DT N
cost-effectiveness NN N
of IN N
intravenous JJ N
treatment NN N
with IN N
levosimendan NNS i
compared VBN N
with IN N
dobutamine NN i
in IN N
patients NNS N
with IN N
severe JJ N
low-output JJ N
heart NN N
failure NN N
. . N

METHODS NNP N
This DT N
economic JJ N
evaluation NN N
was VBD N
based VBN N
on IN N
a DT N
European JJ N
clinical JJ N
trial NN N
( ( N
LIDO NNP N
) ) N
, , N
in IN N
which WDT N
203 CD p
patients NNS p
with IN p
severe JJ p
heart NN p
failure NN p
randomly RB N
received VBD N
a DT N
24 CD N
h NN N
infusion NN N
with IN N
either DT N
levosimendan NN i
or CC i
dobutamine NN i
. . i

Survival NNP N
and CC N
resource VB N
utilisation NN N
data NNS N
were VBD N
collected VBN N
for IN N
6 CD N
months NNS N
; : N
survival NN N
was VBD N
extrapolated VBN N
assuming VBG N
a DT N
mean JJ N
additional JJ N
lifetime NN N
of IN N
3 CD N
years NNS N
based VBN N
on IN N
data NNS N
from IN N
the DT N
Cooperative NNP N
North NNP N
Scandinavian JJ N
Enalapril NNP N
Survival NNP N
Study NNP N
trial NN N
. . N

Costs NNS N
were VBD N
based VBN N
on IN N
study JJ N
drug NN N
usage NN N
and CC N
hospitalisation NN N
in IN N
the DT N
6-month JJ N
follow-up NN N
. . N

A DT N
sensitivity NN N
analysis NN N
on IN N
dosage NN o
of IN o
drug NN o
and CC o
duration NN o
of IN o
survival NN o
was VBD N
performed VBN N
. . N

RESULTS VB N
The DT N
mean JJ o
survival NN o
over IN o
6 CD o
months NNS o
was VBD N
157+/-52 JJ N
days NNS N
in IN N
the DT N
levosimendan NN i
group NN N
and CC N
139+/-64 JJ N
days NNS N
in IN N
the DT N
dobutamine NN i
group NN N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

When WRB N
extrapolated VBD N
up RB N
to TO N
3 CD N
years NNS N
, , N
the DT N
gain NN o
in IN o
life NN o
expectancy NN o
was VBD N
estimated VBN N
at IN N
0.35 CD N
years NNS N
( ( N
discounted VBN N
at IN N
3 CD N
% NN N
) ) N
. . N

Levosimendan NNP i
increased VBD N
the DT N
mean NN o
cost NN o
per IN o
patient NN o
by IN N
1108 CD N
, , N
which WDT N
was VBD N
entirely RB N
due JJ N
to TO N
the DT N
cost NN N
of IN N
the DT N
study NN N
drug NN N
. . N

The DT N
incremental JJ o
cost NN o
per IN o
life-year JJ o
saved NN N
( ( N
LYS NNP N
) ) N
was VBD N
3205 CD N
at IN N
the DT N
European NNP N
level NN N
; : N
in IN N
the DT N
individual JJ N
countries NNS N
the DT N
cost NN N
per IN N
LYS NNP N
ranged VBD N
between IN N
3091 CD N
and CC N
3331 CD N
. . N

The DT N
result NN N
was VBD N
robust JJ N
in IN N
the DT N
sensitivity NN N
analysis NN N
. . N

CONCLUSIONS NNP N
Although IN N
the DT N
patients NNS N
in IN N
the DT N
levosimendan NN N
group NN N
were VBD N
alive JJ N
for IN N
more JJR N
days NNS N
and CC N
thus RB N
at IN N
risk NN o
of IN o
hospitalisation NN o
for IN N
longer JJR N
, , N
there EX N
was VBD N
no DT N
increase NN N
in IN N
hospitalisation NN o
or CC o
hospitalisation NN o
costs NNS o
with IN N
levosimendan JJ i
treatment NN N
. . N

The DT N
cost NN N
per IN N
LYS NNP N
using VBG N
levosimendan JJ i
compares NNS N
favourably RB N
with IN N
other JJ N
cost-effectiveness JJ o
analyses NNS o
in IN N
cardiology NN N
. . N

-DOCSTART- -22921159- O O

Interventional NNP N
study NN N
to TO N
strengthen VB N
the DT N
health NN N
promoting VBG N
behaviours NNS N
of IN N
pregnant JJ p
women NNS p
to TO N
prevent VB N
anaemia NN N
in IN N
southern JJ p
India NNP p
. . p

OBJECTIVES NNP N
to TO N
determine VB N
the DT N
effectiveness NN N
of IN N
a DT N
health NN i
information NN i
package NN i
in IN N
terms NNS N
of IN N
empowering VBG N
the DT N
pregnant JJ p
women NNS p
to TO N
modify VB N
their PRP$ N
health-care JJ N
behaviour NN N
and CC N
take VB N
appropriate JJ N
action NN N
to TO N
combat VB N
anaemia NN N
in IN N
pregnancy NN N
. . N

DESIGN VB N
the DT N
study NN N
was VBD N
conceptualized VBN N
based VBN N
on IN N
Rosenstock NNP N
and CC N
Becker NNP N
's POS N
health NN N
belief NN N
model NN N
. . N

A DT N
quasi-experimental JJ N
pretest-posttest JJ N
control NN N
group NN N
design NN N
was VBD N
used VBN N
. . N

The DT N
sample NN N
consists VBZ N
of IN N
225 CD p
anaemic JJ p
pregnant JJ p
women NNS p
randomly RB N
allocated VBN N
in IN N
experimental JJ i
( ( N
n=75 JJ N
) ) N
, , N
control NN i
group NN i
A NNP i
( ( N
n=75 NN N
) ) N
and CC N
control NN i
group NN i
B NNP i
( ( N
n=75 NN N
) ) N
. . N

The DT N
health NN N
seeking VBG N
behaviour NN N
outcome NN N
measure NN N
included VBD N
knowledge NN N
regarding VBG N
anaemia NN N
, , N
food NN N
selection NN N
ability NN N
, , N
increase NN N
in IN N
haemoglobin JJ N
level NN N
and CC N
compliance NN N
to TO N
iron VB N
supplementation NN N
. . N

Intervention NN N
was VBD N
a DT N
validated JJ i
planned JJ i
educational JJ i
programme NN i
with IN i
visual JJ i
aids NNS i
and CC i
iron NN i
supplementation NN i
. . i

FINDINGS IN N
the DT N
results NNS N
show VBP N
the DT N
mean JJ o
gain NN o
of IN o
knowledge NN o
scores NNS o
of IN N
experimental JJ N
group NN N
was VBD N
comparatively RB N
higher JJR N
and CC N
control VB N
groups NNS N
A NNP N
and CC N
B NNP N
showed VBD N
that IN N
F NNP N
ratio NN N
was VBD N
( ( N
F NNP N
( ( N
2,190 CD N
) ) N
=11.910 NN N
, , N
p NN N
< NNP N
0.01 CD N
) ) N
indicating NN N
that IN N
the DT N
pregnant JJ p
women NNS p
learned VBD N
more RBR N
about IN N
anaemia NN N
prevention NN N
than IN N
others NNS N
. . N

With IN N
regard NN N
to TO N
food NN N
selection NN N
ability NN N
scores NNS N
of IN N
experimental JJ N
, , N
control NN N
groups NNS N
A NNP N
and CC N
B NNP N
the DT N
F NNP N
ratio NN N
was VBD N
also RB N
significant JJ N
( ( N
F NNP N
( ( N
2,190 CD N
) ) N
=20.92 NN N
, , N
p NN N
< NNP N
0.01 CD N
) ) N
. . N

Nearly RB N
61.2 CD N
% NN N
of IN N
the DT N
subjects NNS N
in IN N
experimental JJ N
group NN N
became VBD N
non-anaemic JJ o
after IN N
the DT N
intervention NN N
when WRB N
compared VBN N
to TO N
control VB N
group NN N
A NNP N
. . N

This DT N
indicated VBD N
that IN N
inspite NN N
of IN N
iron NN i
supplementation NN i
received VBN N
by IN N
the DT N
three CD N
groups NNS N
health NN N
education NN N
contributed VBD N
significantly RB N
in IN N
modifying VBG N
their PRP$ N
health NN N
seeking VBG N
behaviour NN N
and CC N
their PRP$ N
perception NN N
about IN N
significance NN N
of IN N
anaemia NN N
has VBZ N
a DT N
problem NN N
. . N

CONCLUSION NNP N
developing VBG N
countries NNS N
still RB N
face VBP N
the DT N
critical JJ N
problem NN N
of IN N
anaemia NN N
in IN N
pregnancy NN N
. . N

These DT N
are VBP N
the DT N
socio-cultural JJ N
priority NN N
problems NNS N
that WDT N
demand VBP N
immediate JJ N
attention NN N
by IN N
the DT N
policy NN N
makers NNS N
and CC N
health NN N
professionals NNS N
. . N

The DT N
national JJ N
anaemia NN N
control NN N
programme NN N
focuses VBZ N
on IN N
iron NN N
supplementation NN N
, , N
but CC N
nutritional JJ N
education NN N
and CC N
supervision NN N
of IN N
iron NN N
supplementation NN N
has VBZ N
failed VBN N
in IN N
different JJ N
regions NNS N
. . N

The DT N
study NN N
implies VBZ N
that IN N
economic JJ N
empowerment NN N
; : N
strengthening VBG N
health NN N
literacy NN N
through IN N
planned VBN N
educational JJ N
programs NNS N
will MD N
definitely RB N
improve VB N
the DT N
health NN N
behaviour NN N
of IN N
individual JJ N
and CC N
community NN N
at IN N
large JJ N
. . N

-DOCSTART- -10148879- O O

Comparison NNP o
of IN N
patient-controlled JJ i
and CC i
nurse-administered JJ i
analgesia NN i
using VBG N
intravenous JJ N
fentanyl NN N
during IN p
labor NN p
. . p

Preliminary JJ N
observations NNS N
have VBP N
shown VBN N
that IN N
fentanyl NN i
citrate NN i
, , N
a DT N
potent JJ N
narcotic JJ N
, , N
is VBZ N
helpful JJ N
during IN N
labor NN N
without IN N
undue JJ N
side NN N
effects NNS N
. . N

This DT N
randomized JJ N
prospective JJ N
investigation NN N
compared VBN N
the DT N
patient-controlled JJ i
administration NN i
of IN i
fentanyl NN i
with IN N
that DT N
of IN N
administration NN i
by IN i
nurses NNS i
on IN i
request NN i
. . i

Eighty NNP p
healthy JJ p
women NNS p
beginning VBG p
active JJ p
labor NN p
( ( p
cervical JJ p
dilation NN p
4 CD p
cm NN p
) ) p
at IN p
term NN p
were VBD p
assigned VBN p
to TO p
receive VB p
fentanyl NN i
intravenously RB i
by IN i
either CC i
patient-controlled JJ i
administration NN i
( ( i
n=37 JJ i
) ) i
or CC i
nurse JJ i
administration NN i
on IN i
demand NN i
( ( p
n=43 JJ p
) ) p
. . N

Pain NNP o
intensity NN o
measurements NNS o
during IN N
early JJ N
and CC N
late JJ N
labor NN N
revealed VBD N
the DT N
degree NN o
of IN o
analgesia NN o
to TO N
be VB N
the DT N
same JJ N
in IN N
both DT N
groups NNS N
. . N

The DT N
delay NN N
in IN N
setting VBG o
up RP o
the DT o
infusion NN o
system NN o
and CC N
the DT N
short JJ N
time NN o
between IN o
requesting VBG o
analgesia NN o
and CC o
vaginal JJ o
delivery NN o
were VBD N
limitations NNS N
with IN N
self-administration NN N
. . N

Maternal JJ o
oversedation NN o
and CC o
vomiting VBG o
did VBD N
not RB N
occur VB N
. . N

Neonatal NNP o
naloxone NN o
therapy NN o
was VBD N
used VBN N
infrequently RB N
, , N
umbilical JJ o
serum NN o
levels NNS o
of IN o
fentanyl NN o
were VBD N
the DT N
same JJ N
in IN N
both DT N
groups NNS N
, , N
and CC N
postnatal JJ o
neuroadaptive JJ o
testing NN o
revealed VBD N
comparable JJ N
results NNS N
in IN N
both DT N
groups NNS N
. . N

Despite IN N
the DT N
usefulness NN N
of IN N
fentanyl NN N
during IN N
labor NN N
, , N
administration NN i
by IN i
the DT i
patient NN i
had VBD N
no DT N
advantages NNS N
over IN N
administration NN i
by IN i
the DT i
nurses NNS i
in IN N
significantly RB N
reducing VBG N
drug NN o
use NN o
, , o
improving VBG o
pain NN o
relief NN o
, , o
or CC o
avoiding VBG o
drowsiness NN o
. . o

-DOCSTART- -15509083- O O

Sustained VBN N
oral JJ o
health NN o
improvement NN o
and CC N
use NN N
of IN N
toothbrushes NNS i
and CC i
dentifrice NN i
by IN N
previous JJ p
users NNS p
of IN p
traditional JJ p
materials NNS p
in IN p
a DT p
rural JJ p
population NN p
in IN p
Andhra NNP p
Pradesh NNP p
, , p
India NNP p
. . p

AIM NNP N
To TO N
follow-up NN N
, , N
one CD N
year NN N
later RB N
, , N
a DT N
double-blind NN N
, , N
randomised VBN N
study NN N
, , N
which WDT N
investigated VBD N
the DT N
effect NN o
of IN N
regular JJ i
brushing NN i
with IN i
dentifrices NNS i
on IN N
the DT N
oral JJ p
health NN p
of IN p
an DT p
economically RB p
disadvantaged JJ p
rural JJ p
population NN p
in IN p
Andhra NNP p
Pradesh NNP p
, , p
India NNP p
who WP p
were VBD p
primarily RB p
users NNS p
of IN p
traditional JJ p
materials NNS p
. . p

SUBJECTS NNP N
150 CD p
of IN p
the DT p
original JJ p
study NN p
population NN p
. . p

METHOD NNP N
Examination NNP N
to TO N
determine VB N
whether IN N
the DT N
improvements NNS o
in IN o
oral JJ o
health NN o
status NN o
and CC o
oral JJ o
health NN o
behaviour NN o
( ( N
use NN N
of IN N
toothbrush NN i
and CC i
dentifrice NN i
) ) i
, , N
being VBG N
unsupported JJ N
, , N
had VBD N
been VBN N
sustained VBN N
since IN N
completion NN N
of IN N
the DT N
original JJ N
study NN N
. . N

RESULTS NNP N
Data NNP N
analysis NN N
showed VBD N
sustained VBN N
, , N
statistically RB o
significant JJ o
improvements NNS o
in IN o
gingival JJ o
health NN o
as IN o
measured VBN o
by IN o
gingival NN o
bleeding NN o
and CC o
plaque NN o
indices NNS o
( ( o
GBI NNP o
and CC o
PI NNP o
) ) o
comparing VBG N
users NNS N
and CC N
non-users NNS N
of IN N
toothbrushes NNS N
and CC N
dentifrice NN N
in IN N
the DT N
original JJ N
study NN N
( ( N
PI NNP N
: : N
p NN N
= VBZ N
0.04 CD N
; : N
GBI NNP N
: : N
p NN N
= VBZ N
0.03 CD N
) ) N
and CC N
sustained VBN o
use NN o
of IN o
toothbrushes NNS o
and CC o
dentifrice NN o
by IN N
60 CD N
% NN N
of IN N
the DT N
subjects NNS N
at IN N
follow-up JJ N
one CD N
year NN N
later RB N
. . N

CONCLUSIONS VB N
This DT N
study NN N
shows VBZ N
a DT N
beneficial JJ o
effect NN o
on IN o
oral JJ o
hygiene NN o
indices NNS N
following VBG N
the DT N
introduction NN i
of IN i
toothbrushes NNS i
and CC i
dentifrices NNS i
to TO N
a DT N
community NN N
using VBG N
traditional JJ N
oral JJ N
hygiene NN N
materials NNS N
and CC N
sustainability NN N
of IN N
use NN N
of IN N
these DT N
materials NNS N
with IN N
motivation NN N
and CC N
support NN N
. . N

It PRP N
may MD N
therefore RB N
be VB N
concluded VBN N
that IN N
it PRP N
is VBZ N
feasible JJ N
to TO N
achieve VB N
significant JJ N
use NN N
of IN N
conventional JJ N
toothbrushes NNS N
and CC N
toothpastes NNS N
, , N
with IN N
consequent JJ N
major JJ N
and CC N
sustained JJ N
improvements NNS N
in IN N
plaque NN N
control NN N
and CC N
gingival JJ N
health NN N
in IN N
a DT N
disadvantaged JJ N
population NN N
hitherto NN N
often RB N
considered VBN N
as IN N
not RB N
amenable JJ N
to TO N
conventional JJ N
oral JJ N
hygiene NN N
for IN N
cultural JJ N
or CC N
economic JJ N
reasons NNS N
. . N

-DOCSTART- -3189201- O O

Educational JJ i
intervention NN i
for IN N
altering VBG N
water-sanitation NN N
behavior NN N
to TO N
reduce VB N
childhood NN p
diarrhea NN o
in IN p
urban JJ p
Bangladesh NNP p
: : p
impact NN N
on IN N
nutritional JJ N
status NN N
. . N

We PRP N
evaluated VBD N
whether IN N
an DT N
educational JJ i
intervention NN i
that WDT N
was VBD N
effective JJ N
in IN N
reducing VBG N
childhood NN p
diarrhea NN o
also RB N
improved VBD N
childhood JJ o
nutritional JJ o
status NN o
. . o

Fifty-one CD p
communities NNS p
of IN p
38 CD p
families NNS p
each DT p
were VBD N
randomized VBN N
to TO N
receive VB N
the DT N
intervention NN i
or CC i
no DT i
intervention NN i
. . i

During IN N
1 CD N
y NNS N
of IN N
follow-up JJ N
the DT N
rate NN o
of IN o
diarrhea NN o
( ( N
per IN N
100 CD N
wk NN N
) ) N
in IN N
children NNS p
less JJR p
than IN p
6 CD p
y NN p
in IN N
the DT N
intervention NN N
group NN N
was VBD N
5.89 CD N
episodes NNS N
whereas VBP N
that IN N
in IN N
the DT N
nonintervention NN N
group NN N
was VBD N
7.55 CD N
episodes NNS N
( ( N
protective JJ N
efficacy NN N
22 CD N
% NN N
; : N
p CC N
less JJR N
than IN N
0.0001 CD N
) ) N
. . N

During IN N
the DT N
same JJ N
follow-up JJ N
period NN N
children NNS N
in IN N
both DT N
groups NNS N
exhibited VBD N
comparable JJ N
patterns NNS N
of IN N
weight JJ o
gain NN o
; : o
1 CD N
y NN N
after IN N
the DT N
intervention NN N
the DT N
mean JJ o
weight NN o
for IN o
age NN o
of IN N
children NNS N
in IN N
both DT N
groups NNS N
was VBD N
76 CD N
% NN N
of IN N
the DT N
NCHS NNP N
standard NN N
. . N

No DT N
significant JJ N
differences NNS N
were VBD N
observed VBN N
in IN N
the DT N
proportion NN N
of IN N
each DT N
group NN N
that WDT N
experienced VBD N
a DT N
major JJ o
deterioration NN o
or CC o
improvement NN o
of IN o
nutritional JJ o
status NN o
. . o

We PRP N
conclude VBP N
that IN N
an DT N
intervention NN N
that WDT N
reduces VBZ N
rates NNS N
of IN N
childhood NN o
diarrhea NN o
may MD N
not RB N
necessarily RB N
also RB N
improve VB N
nutritional JJ o
status NN o
. . o

-DOCSTART- -14980919- O O

Pretreatment NN N
with IN N
thiopental NN i
for IN N
prevention NN N
of IN N
pain NN o
associated VBN o
with IN o
propofol JJ o
injection NN o
. . o

UNLABELLED NNP N
Propofol NNP i
causes VBZ N
pain NN o
on IN o
IV NNP o
injection NN o
in IN N
28 CD N
% NN N
-90 CD N
% NN N
of IN N
patients NNS N
. . N

A DT N
number NN N
of IN N
techniques NNS N
have VBP N
been VBN N
tried VBN N
to TO N
minimize VB N
propofol-induced JJ N
pain NN N
, , N
with IN N
variable JJ N
results NNS N
. . N

We PRP N
compared VBN N
the DT N
efficacy NN N
of IN N
pretreatment NN N
with IN N
thiopental JJ i
0.25 CD N
mg/kg NN N
and CC N
0.5 CD N
mg/kg NN N
and CC N
lidocaine NN i
40 CD N
mg NN N
after IN N
venous JJ N
occlusion NN N
for IN N
prevention NN N
of IN N
propofol-induced JJ o
pain NN o
. . o

One-hundred-twenty-four JJ p
adult NN p
patients NNS p
, , p
ASA NNP p
physical JJ p
status NN p
I-II NNP p
, , p
undergoing VBG p
elective JJ p
surgery NN p
were VBD N
randomly RB N
assigned VBN N
into IN N
4 CD N
groups NNS N
of IN N
31 CD N
each DT N
. . N

Group NNP N
I PRP N
received VBD N
normal JJ i
saline NN i
, , N
group NN N
II NNP N
received VBD N
lidocaine JJ i
2 CD N
% NN N
( ( N
40 CD N
mg NN N
) ) N
, , N
and CC N
groups NNS N
III NNP N
and CC N
IV NNP N
received VBD N
thiopental JJ i
0.25 CD N
mg/kg NN N
and CC N
0.5 CD N
mg/kg NN N
, , N
respectively RB N
. . N

All DT N
pretreatment JJ N
drugs NNS N
were VBD N
made VBN N
in IN N
2 CD N
mL NNS N
and CC N
were VBD N
accompanied VBN N
by IN N
manual JJ i
venous JJ i
occlusion NN i
for IN N
1 CD N
min NN N
. . N

Propofol NNP i
was VBD N
administered VBN N
after IN N
release NN N
of IN N
venous JJ N
occlusion NN N
. . N

Pain NN o
was VBD N
assessed VBN N
with IN N
a DT N
four-point JJ N
scale NN N
: : N
0 CD N
= IN N
no DT N
pain NN N
, , N
1 CD N
= NN N
mild NN N
pain NN N
, , N
2 CD N
= NN N
moderate JJ N
pain NN N
, , N
and CC N
3 CD N
= NN N
severe JJ N
pain NN N
at IN N
the DT N
time NN N
of IN N
propofol JJ N
injection NN N
. . N

Twenty-four CD N
patients NNS N
( ( N
77 CD N
% NN N
) ) N
complained VBD N
of IN N
pain NN o
in IN N
the DT N
group NN N
pretreated VBD N
with IN N
normal JJ N
saline NN N
as IN N
compared VBN N
with IN N
12 CD N
( ( N
39 CD N
% NN N
) ) N
, , N
10 CD N
( ( N
32 CD N
% NN N
) ) N
, , N
and CC N
1 CD N
( ( N
3 CD N
% NN N
) ) N
in IN N
the DT N
groups NNS N
pretreated VBD N
with IN N
lidocaine JJ i
40 CD N
mg NN N
, , N
thiopental JJ i
0.25 CD N
mg/kg NN N
, , N
and CC N
thiopental JJ i
0.5 CD N
mg/kg NN N
, , N
respectively RB N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

Thiopental JJ i
0.5 CD N
mg/kg NN N
was VBD N
the DT N
most RBS N
effective JJ o
treatment NN N
. . N

We PRP N
therefore VBP N
suggest JJ N
routine JJ N
pretreatment NN N
with IN N
thiopental JJ i
0.5 CD N
mg/kg NNS N
along IN N
with IN N
venous JJ N
occlusion NN N
for IN N
1 CD N
min NN N
for IN N
prevention NN N
of IN N
pain NN o
associated VBN N
with IN N
propofol JJ N
injection NN N
. . N

IMPLICATIONS NNP N
Pain NNP o
associated VBD N
with IN N
IV NNP N
injection NN N
of IN N
propofol NN N
is VBZ N
seen VBN N
in IN N
28 CD N
% NN N
-90 CD N
% NN N
patients NNS N
. . N

Pretreatment NN N
with IN N
thiopental JJ i
0.25 CD N
mg/kg NN N
and CC N
0.5 CD N
mg/kg NN N
after IN N
manual JJ N
venous JJ N
occlusion NN N
for IN N
1 CD N
min NNS N
effectively RB N
attenuated VBD N
pain NN o
associated VBN N
with IN N
propofol JJ N
injection NN N
. . N

Thiopental JJ i
0.5 CD N
mg/kg NN N
was VBD N
the DT N
most RBS N
effective JJ N
in IN N
prevention NN N
of IN N
propofol NN o
pain NN o
and CC N
can MD N
be VB N
used VBN N
routinely RB N
. . N

-DOCSTART- -17947724- O O

Comparison NNP N
of IN N
menopausal NN N
symptoms NNS N
during IN N
the DT N
first JJ N
year NN N
of IN N
adjuvant JJ N
therapy NN N
with IN N
either DT N
exemestane NN i
or CC i
tamoxifen NN i
in IN N
early JJ p
breast NN p
cancer NN p
: : p
report NN N
of IN N
a DT N
Tamoxifen NNP N
Exemestane NNP N
Adjuvant NNP N
Multicenter NNP N
trial NN N
substudy NN N
. . N

PURPOSE NNP N
Hormonal NNP N
breast NN N
cancer NN N
treatment NN N
increases NNS N
menopausal VBP o
symptoms NNS o
in IN N
women NNS p
. . p

This DT N
study NN N
investigated VBD N
differences NNS N
between IN N
the DT N
symptoms NNS N
associated VBN N
with IN N
either DT N
adjuvant JJ i
tamoxifen NN i
or CC i
exemestane NN i
. . i

PATIENTS NNP N
AND CC N
METHODS NNP N
Ten NNP N
common JJ N
symptoms NNS N
were VBD N
assessed VBN N
by IN N
self-report JJ N
questionnaire NN N
administered VBD N
to TO N
1,614 CD p
consecutive JJ p
patients NNS p
at IN N
baseline NN N
and CC N
every DT N
3 CD N
months NNS N
during IN N
the DT N
first JJ N
year NN N
of IN N
a DT N
double-blind NN N
, , N
randomized VBN N
trial NN N
of IN N
postmenopausal JJ p
women NNS p
with IN p
early JJ p
hormone NN p
receptor-positive JJ p
breast NN p
cancer NN p
. . p

Symptoms NNS N
were VBD N
categorized VBN N
as IN N
none NN N
, , N
mild NN N
, , N
moderate JJ N
, , N
or CC N
severe RB N
. . N

A DT N
hot JJ o
flash NN o
score NN o
was VBD N
calculated VBN N
at IN N
each DT N
time NN N
point NN N
. . N

Symptoms NNS N
were VBD N
analyzed VBN N
by IN N
repeated-measures NNS N
analysis NN N
of IN N
variance NN N
. . N

Each DT N
time NN N
period NN N
was VBD N
tested VBN N
repeatedly RB N
against IN N
the DT N
baseline NN N
; : N
an DT N
overall JJ N
P NNP N
value NN N
was VBD N
assigned VBN N
for IN N
each DT N
reported VBN N
symptom NN N
. . N

RESULTS NNP N
Compliance NNP N
was VBD N
excellent JJ N
, , N
with IN N
7,286 CD N
questionnaires NNS N
analyzed VBN N
. . N

Baseline NNP o
symptom JJ o
prevalence NN N
ranged VBD N
from IN N
2 CD N
% NN N
( ( N
vaginal JJ N
bleeding NN N
) ) N
to TO N
60 CD N
% NN N
to TO N
70 CD N
% NN N
( ( o
bone/muscle NN o
aches NNS o
and CC o
low JJ o
energy NN o
) ) o
. . N

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
vaginal JJ o
bleeding NN o
, , o
mood NN o
alteration NN o
, , o
or CC o
low JJ o
energy NN o
. . o

Patients NNS p
receiving VBG p
tamoxifen NN p
had VBD N
significantly RB N
more RBR N
vaginal JJ o
discharge NN o
( ( N
P NNP N
< NNP N
.0001 NNP N
) ) N
. . N

Exemestane NN N
patients NNS N
reported VBD N
more RBR N
bone/muscle NN o
aches NNS o
( ( N
P NNP N
< NNP N
.0001 NNP N
) ) N
, , N
vaginal JJ o
dryness NN o
( ( N
P NNP N
= NNP N
.0004 NNP N
) ) N
, , N
and CC N
difficulty NN o
sleeping NN o
( ( N
P NNP N
= NNP N
.03 NNP N
) ) N
. . N

In IN N
both DT N
groups NNS N
, , N
the DT N
hot JJ o
flash NN o
score NN o
peaked VBD N
at IN N
3 CD N
months NNS N
and CC N
decreased JJ N
thereafter NN N
. . N

At IN N
12 CD N
months NNS N
, , N
patients NNS N
receiving VBG N
tamoxifen NN N
had VBD N
a DT N
significantly RB N
higher JJR N
mean JJ o
hot JJ o
flash NN o
score NN o
( ( N
P NNP N
= NNP N
.03 NNP N
) ) N
, , N
with IN N
daily JJ N
hot JJ o
flashes NNS o
increasing VBG N
from IN N
baseline NN N
by IN N
33 CD N
% NN N
compared VBN N
with IN N
a DT N
7 CD N
% NN N
increase NN N
from IN N
baseline NN N
with IN N
exemestane NN N
. . N

CONCLUSION NNP N
At IN N
12 CD N
months NNS N
, , N
exemestane NN N
was VBD N
associated VBN N
with IN N
fewer JJR N
hot JJ o
flashes NNS o
and CC N
less JJR N
vaginal JJ o
discharge NN o
than IN N
tamoxifen NN N
, , N
but CC N
with IN N
more JJR N
vaginal JJ o
dryness NN o
, , o
bone/muscle NN o
aches NNS o
, , o
and CC o
difficulty NN o
sleeping NN o
. . o

Symptoms NNS N
were VBD N
common JJ N
in IN N
both DT N
groups NNS N
. . N

-DOCSTART- -21097567- O O

A DT N
pilot NN N
study NN N
of IN N
the DT N
Tele-Airway NNP i
Management NNP i
System NNP i
in IN N
a DT N
hospital NN p
emergency NN p
department NN p
. . p

We PRP N
developed VBD N
a DT N
telemedicine NN N
system NN N
for IN N
remote JJ N
guidance NN N
of IN N
emergency NN N
airway NN N
management NN N
called VBD N
the DT N
Tele-Airway NNP i
Management NNP i
System NNP i
( ( N
TAMS NNP N
) ) N
. . N

In IN N
a DT N
pilot NN N
study NN N
we PRP N
examined VBD N
the DT N
usefulness NN N
of IN N
the DT N
TAMS NNP i
for IN N
intubations NNS N
of IN N
actual JJ N
patients NNS p
in IN p
a DT p
hospital NN p
emergency NN p
department NN p
. . p

Twenty-five JJ p
patients NNS p
were VBD p
allocated VBN p
randomly RB p
either DT p
to TO p
a DT p
TAMS NNP i
group NN i
or CC p
to TO p
an DT p
on-scene JJ i
directed NN i
( ( i
OSD NNP i
) ) i
group NN i
. . i

A DT N
total NN N
of IN N
12 CD p
were VBD p
intubated VBN p
using VBG N
the DT N
TAMS NNP i
. . i

The DT N
mean JJ o
time NN o
to TO o
intubation NN o
( ( i
TAMS NNP i
62 CD N
s NN N
vs. FW N
OSD NNP i
56 CD N
s NN N
) ) N
and CC N
the DT N
success NN o
rate NN o
was VBD N
not RB N
different JJ N
between IN N
the DT N
two CD N
groups NNS N
( ( N
P NNP N
> NNP N
0.05 CD N
) ) N
. . N

There EX N
were VBD N
two CD N
oesophageal JJ o
intubations NNS o
in IN N
the DT N
TAMS NNP i
group NN N
and CC N
four CD N
in IN N
the DT N
OSD NNP i
group NN N
, , N
but CC N
this DT N
was VBD N
not RB N
significantly RB N
different JJ N
( ( N
P NNP N
= NNP N
0.36 CD N
) ) N
. . N

There EX N
were VBD N
no DT N
mechanical JJ o
or CC o
technical JJ o
errors NNS o
such JJ o
as IN o
disconnection NN o
during IN N
use NN N
of IN N
the DT N
TAMS NNP i
. . i

The DT N
pilot NN N
study NN N
demonstrated VBD N
the DT N
feasibility NN o
of IN N
the DT N
TAMS NNP N
as IN N
an DT N
alternative NN N
to TO N
OSD NNP i
. . i

However RB N
, , N
a DT N
larger JJR N
study NN N
will MD N
be VB N
required VBN N
to TO N
determine VB N
non-superiority NN N
or CC N
equivalence NN N
. . N

-DOCSTART- -24626433- O O

The DT N
effect NN N
of IN N
lowering VBG N
LDL NNP N
cholesterol NN N
on IN N
vascular JJ N
access NN N
patency NN N
: : N
post NN N
hoc NN N
analysis NN N
of IN N
the DT N
Study NNP N
of IN N
Heart NNP N
and CC N
Renal NNP N
Protection NNP N
. . N

BACKGROUND NNP N
AND NNP N
OBJECTIVES NNP N
Reducing NNP N
LDL NNP N
cholesterol NN N
( ( N
LDL-C NNP N
) ) N
with IN N
statin-based JJ i
therapy NN i
reduces VBZ N
the DT N
risk NN N
of IN N
major JJ N
atherosclerotic JJ N
events NNS N
among IN N
patients NNS p
with IN p
CKD NNP p
, , p
including VBG p
dialysis NN p
patients NNS p
, , N
but CC N
the DT N
effect NN N
of IN N
lowering VBG N
LDL-C NNP N
on IN N
vascular JJ N
access NN N
patency NN N
is VBZ N
unclear JJ N
. . N

DESIGN NNP N
, , N
SETTING NNP N
, , N
PARTICIPANTS NNP N
, , N
& CC N
MEASUREMENTS NNP N
The DT N
Study NNP N
of IN N
Heart NNP N
and CC N
Renal NNP N
Protection NNP N
( ( N
SHARP NNP N
) ) N
randomized VBD N
patients NNS p
with IN p
CKD NNP p
to TO p
20 CD i
mg NN i
simvastatin NN i
plus CC i
10 CD i
mg NNS i
ezetimibe JJ i
daily JJ i
versus NN i
matching VBG i
placebo NN i
. . i

This DT N
study NN N
aimed VBD N
to TO N
explore VB N
the DT N
effects NNS N
of IN N
treatment NN N
on IN N
vascular JJ N
access NN N
occlusive JJ N
events NNS N
, , N
defined VBN N
as IN N
any DT o
access NN o
revision NN o
procedure NN o
, , o
access NN o
thrombosis NN o
, , o
removal NN o
of IN o
an DT o
old JJ o
dialysis NN o
access NN o
, , o
or CC o
formation NN o
of IN o
new JJ o
permanent JJ o
dialysis NN o
access NN o
. . o

RESULTS NNP N
Among IN N
2353 CD p
SHARP NNP p
participants NNS p
who WP p
had VBD p
functioning VBG p
vascular JJ p
access NN p
at IN N
randomization NN N
, , N
allocation NN N
to TO N
simvastatin VB N
plus JJ N
ezetimibe NN N
resulted VBD N
in IN N
a DT N
13 CD N
% NN N
proportional JJ N
reduction NN o
in IN o
vascular JJ o
access NN o
occlusive JJ o
events NNS o
( ( N
355 CD N
[ RB N
29.7 CD N
% NN N
] NN N
for IN N
simvastatin/ezetimibe JJ i
versus NN N
388 CD N
[ JJ N
33.5 CD N
% NN N
] NN N
for IN N
placebo NN i
; : i
risk NN N
ratio VBP N
[ NNP N
RR NNP N
] NNP N
, , N
0.87 CD N
; : N
95 CD N
% NN N
confidence NN N
interval NN N
[ VBD N
95 CD N
% NN N
CI NNP N
] NNP N
, , N
0.75 CD N
to TO N
1.00 CD N
; : N
P=0.05 NNP N
) ) N
. . N

There EX N
was VBD N
no DT N
evidence NN N
that IN N
the DT N
effects NNS N
of IN N
treatment NN N
differed VBN N
for IN N
any DT N
of IN N
the DT N
separate JJ N
components NNS N
of IN N
this DT N
outcome NN N
. . N

To TO N
test VB N
the DT N
hypothesis NN N
raised VBN N
by IN N
SHARP NNP N
, , N
comparable JJ N
analyses NNS N
were VBD N
performed VBN N
using VBG N
the DT N
AURORA NNP N
( ( N
A NNP N
Study NNP N
to TO N
Evaluate VB N
the DT N
Use NNP N
of IN N
Rosuvastatin NNP N
in IN N
Subjects NNP N
on IN N
Regular JJ N
Hemodialysis NN N
: : N
An DT N
Assessment NN N
of IN N
Survival NNP N
and CC N
Cardiovascular NNP N
Events NNP N
) ) N
trial NN N
cohort NN N
. . N

AURORA NNP N
did VBD N
not RB N
provide VB N
independent JJ N
confirmation NN N
( ( N
vascular JJ N
access NN N
occlusive JJ N
events NNS N
: : N
352 CD N
[ $ N
28.9 CD N
% NN N
] NN N
for IN N
rosuvastatin NN N
versus NN N
337 CD N
[ JJ N
27.6 CD N
% NN N
] NN N
for IN N
placebo NN N
; : N
RR NNP N
, , N
1.06 CD N
, , N
95 CD N
% NN N
CI NNP N
, , N
0.91 CD N
to TO N
1.23 CD N
; : N
P=0.44 NNP N
) ) N
. . N

After IN N
combining VBG N
the DT N
two CD N
trials NNS N
, , N
the DT N
overall JJ N
effect NN N
of IN N
reducing VBG N
LDL-C NNP o
with IN N
a DT N
statin-based JJ N
regimen NN N
on IN N
vascular JJ N
access NN N
occlusive JJ N
events NNS N
was VBD N
not RB N
statistically RB N
significant JJ N
( ( N
707 CD N
[ RB N
29.3 CD N
% NN N
] NN N
with IN N
any DT N
LDL-C-lowering JJ N
therapy NN N
versus NN N
725 CD N
[ JJ N
30.5 CD N
% NN N
] NN N
with IN N
placebo NN N
; : N
RR NNP N
, , N
0.95 CD N
, , N
95 CD N
% NN N
CI NNP N
, , N
0.85 CD N
to TO N
1.05 CD N
; : N
P=0.29 NNP N
) ) N
. . N

CONCLUSIONS NNP N
Exploratory NNP N
analyses VBZ N
from IN N
SHARP NNP N
suggest VBP N
that IN N
lowering VBG N
LDL-C JJ N
with IN N
statin-based JJ i
therapy NN i
may MD N
improve VB N
vascular JJ N
access NN N
patency NN N
, , N
but CC N
there EX N
was VBD N
no DT N
evidence NN N
of IN N
benefit NN N
in IN N
AURORA NNP N
. . N

Taken NNP N
together RB N
, , N
the DT N
available JJ N
evidence NN N
suggests VBZ N
that IN N
any DT N
benefits NNS N
of IN N
lowering VBG N
LDL-C NNP N
on IN N
vascular JJ N
access NN N
patency NN N
are VBP N
likely JJ N
to TO N
be VB N
modest JJ N
. . N

-DOCSTART- -8877260- O O

Baseline NNP N
characteristics NNS N
of IN N
participants NNS p
in IN p
the DT p
Appropriate NNP p
Blood NNP p
Pressure NNP p
Control NNP p
in IN p
Diabetes NNP p
trial NN p
. . p

The DT N
ABCD NNP N
( ( N
Appropriate NNP N
Blood NNP N
Pressure NNP N
Control NNP N
in IN N
Diabetes NNP N
) ) N
trial NN N
is VBZ N
a DT N
large JJ N
, , N
prospective JJ N
, , N
randomized JJ N
clinical JJ N
trial NN N
designed VBN N
to TO N
compare VB N
the DT N
effects NNS N
of IN N
intensive JJ i
with IN N
moderate JJ i
blood NN i
pressure NN i
control NN i
on IN N
the DT N
prevention NN N
and CC N
progression NN N
of IN N
diabetic JJ N
nephropathy NN N
, , N
retinopathy NN N
, , N
cardiovascular JJ N
disease NN N
, , N
and CC N
neuropathy JJ N
in IN N
non-insulin-dependent JJ N
diabetes NNS N
( ( N
NIDDM NNP N
) ) N
. . N

The DT N
secondary JJ N
objective NN N
is VBZ N
to TO N
determine VB N
equivalency NN N
of IN N
the DT N
effects NNS N
of IN N
a DT N
calcium NN i
channel NN i
blocker NN i
( ( i
nisoldipine JJ i
) ) i
and CC N
of IN N
an DT N
angiotensin-converting JJ i
enzyme NN i
inhibitor NN i
( ( i
enalapril NN i
) ) i
as IN N
a DT N
first-line JJ N
antihypertensive JJ N
agent NN N
in IN N
the DT N
prevention NN N
and/or POS N
progression NN N
of IN N
these DT N
diabetic JJ N
vascular NN N
complications NNS N
. . N

The DT N
study NN N
consists VBZ N
of IN N
two CD p
study NN p
populations NNS p
: : p
a DT p
hypertensive JJ p
one NN p
( ( o
diastolic JJ o
blood NN o
pressure NN o
of IN p
> NN p
or CC p
= $ p
90.0 CD p
mm NN p
Hg NNP p
at IN p
the DT p
time NN p
of IN p
randomization NN p
) ) p
and CC p
a DT p
normotensive JJ p
one NN p
( ( o
diastolic JJ o
blood NN o
pressure NN o
of IN p
80.0-89.0 JJ p
mm NN p
Hg NNP p
at IN p
the DT p
time NN p
of IN p
randomization NN p
) ) p
. . p

A DT N
total NN N
of IN N
950 CD p
men NNS p
and CC p
women NNS p
aged VBN p
40-74 JJ p
years NNS p
were VBD N
randomized VBN N
and CC N
are VBP N
being VBG N
followed VBN N
for IN N
5 CD N
years NNS N
at IN N
a DT N
single JJ N
center NN N
. . N

There EX p
were VBD p
470 CD p
randomized JJ p
participants NNS p
in IN p
the DT p
hypertensive JJ p
population NN p
and CC p
480 CD p
randomized JJ p
participants NNS p
in IN p
the DT p
normotensive JJ p
population NN p
. . p

This DT N
report NN N
summarizes VBZ N
the DT N
demographic JJ o
, , o
biochemical JJ o
, , N
and CC N
clinical JJ o
characteristics NNS o
of IN N
the DT N
randomized JJ p
patients NNS p
at IN N
the DT N
time NN N
of IN N
entry NN N
into IN N
the DT N
trial NN N
and CC N
evaluates VBZ N
the DT N
balance NN N
between IN N
the DT N
treatment NN N
groups NNS N
within IN N
each DT N
population NN N
. . N

-DOCSTART- -22214113- O O

Pilot NNP N
study NN N
of IN N
the DT N
effectiveness NN N
of IN N
weighted JJ i
vests NNS i
. . i

OBJECTIVE NN N
In IN N
this DT N
pilot NN N
study NN N
, , N
we PRP N
determined VBD N
the DT N
effectiveness NN N
of IN N
a DT N
weighted JJ i
vest NN i
on IN N
attention NN N
to TO N
task VB N
for IN N
second-grade JJ p
general JJ p
education NN p
students NNS p
with IN p
difficulty NN p
attending VBG p
. . p

METHOD NNP N
We PRP N
used VBD N
an DT N
intervention NN i
and CC N
a DT N
control NN i
group NN N
and CC N
an DT N
ABA NNP N
design NN N
to TO N
compare VB N
participants NNS N
' POS N
percentage NN N
of IN N
time NN N
on IN N
task NN N
with IN i
and CC i
without IN i
a DT i
vest NN i
. . i

Ten CD p
participants NNS p
from IN p
nine CD p
elementary JJ p
schools NNS p
in IN p
a DT p
suburban JJ p
Texas NNP p
school NN p
district NN p
were VBD p
randomly RB p
assigned VBN p
to TO N
an DT N
intervention NN i
or CC N
a DT N
control NN i
group NN N
. . N

Control NNP N
group NN N
participants NNS N
wore VBD N
a DT N
nonweighted JJ i
vest NN i
. . i

Participants NNS N
, , N
classroom NN N
teachers NNS N
, , N
and CC N
research NN N
assistants NNS N
who WP N
coded VBD N
the DT N
data NNS N
were VBD N
blind RB N
as IN N
to TO N
the DT N
group NN N
to TO N
which WDT N
the DT N
participants NNS N
were VBD N
assigned VBN N
. . N

RESULTS VB N
A NNP N
repeated JJ N
measures NNS N
analysis NN N
of IN N
variance NN N
indicated VBD N
no DT N
significant JJ N
differences NNS N
between IN N
groups NNS N
or CC N
between IN N
baseline NN N
, , N
intervention NN N
, , N
and CC N
withdrawal NN N
conditions NNS N
. . N

CONCLUSION NNP N
Our PRP$ N
results NNS N
indicated VBD N
that IN N
the DT N
weighted JJ i
vests NNS i
were VBD N
not RB N
effective JJ N
in IN N
increasing VBG N
time NN o
on IN o
task NN o
. . o

These DT N
results NNS N
should MD N
be VB N
generalized VBN N
cautiously RB N
owing VBG N
to TO N
the DT N
small JJ N
sample NN N
size NN N
and CC N
participant JJ N
selection NN N
process NN N
. . N

-DOCSTART- -12618690- O O

Optimal JJ N
therapy NN N
for IN N
advanced JJ N
chronic JJ N
venous JJ N
insufficiency NN N
. . N

INTRODUCTION NNP N
While IN N
definitive JJ N
therapy NN N
awaits NNS N
level VBP N
I PRP N
evidence NN N
, , N
controversy NN N
persists NNS N
regarding VBG N
the DT N
optimal JJ N
operation NN N
for IN N
treatment NN N
of IN N
advanced JJ p
chronic JJ p
venous JJ p
insufficiency NN p
( ( p
CVI NNP p
) ) p
. . N

We PRP N
propose VBP N
a DT N
pragmatic JJ N
approach NN N
to TO N
the DT N
correction NN N
or CC N
amelioration NN N
of IN N
venous JJ N
hypertension NN N
resulting VBG N
from IN N
hydrodynamic JJ N
and CC N
hydrostatic JJ N
venous JJ N
reflux NN N
. . N

We PRP N
evaluated VBD N
a DT N
strategy NN N
of IN N
balloon NN N
dissection NN N
, , N
subfascial JJ N
endoscopic NN N
perforating VBG N
vein NN N
surgery NN N
( ( N
SEPS NNP N
) ) N
with IN N
routine JJ N
posterior JJ N
deep JJ N
compartment NN N
fasciotomy NN N
, , N
including VBG N
ligation NN N
and CC N
stripping NN N
of IN N
the DT N
superficial JJ N
system NN N
, , N
for IN N
use NN N
when WRB N
reflux NN N
is VBZ N
documented VBN N
at IN N
duplex JJ N
ultrasound NN N
( ( N
US NNP N
) ) N
scanning NN N
. . N

METHODS NNP N
This DT N
is VBZ N
a DT N
cooperative JJ N
, , N
multicenter NN N
, , N
retrospective JJ N
review NN N
of IN N
832 CD p
patients NNS p
stratified VBN p
by IN p
CEAP NNP p
classification NN p
. . p

The DT N
series NN N
consisted VBD N
of IN N
300 CD p
patients NNS p
with IN p
C4 NNP p
CVI NNP p
, , p
119 CD p
patients NNS p
with IN p
C5 NNP p
CVI NNP p
, , p
and CC p
413 CD p
patients NNS p
with IN p
C6 NNP p
CVI NNP p
. . p

A NNP N
subset NN N
of IN N
92 CD p
patients NNS p
with IN p
C4 NNP p
disease NN p
were VBD N
prospectively RB N
randomized VBN N
, , N
and CC N
ambulatory RB N
venous JJ N
pressure NN N
( ( N
AVP NNP N
) ) N
was VBD N
determined VBN N
preoperatively RB N
and CC N
postoperatively RB N
. . N

All DT N
patients NNS N
underwent JJ N
duplex JJ i
US NNP i
scanning VBG i
to TO N
document VB N
reflux NN N
in IN N
the DT N
deep JJ N
, , N
superficial JJ N
, , N
and CC N
perforating VBG N
venous JJ N
systems NNS N
. . N

Efficacy NNP o
, , o
safety NN o
, , o
and CC o
durability NN o
were VBD N
evaluated VBN N
over IN N
follow-up NN N
of IN N
1 CD N
to TO N
9 CD N
years NNS N
( ( N
mean NN N
, , N
31/2 CD N
years NNS N
) ) N
. . N

Uniformity NN N
was VBD N
attempted VBN N
by IN N
adoption NN N
of IN N
the DT N
senior JJ N
author NN N
's POS N
protocol NN N
and CC N
technique NN N
through IN N
on-site JJ N
preceptorship NN N
in IN N
each DT N
surgeon NN N
's POS N
operative JJ N
theater NN N
. . N

RESULTS VB N
This DT N
technique NN N
interrupted VBD N
3 CD N
to TO N
14 CD N
( ( N
mean NN N
, , N
7 CD N
) ) N
incompetent NN N
perforating VBG N
veins NNS N
per IN N
patient NN N
. . N

Of IN N
the DT N
832 CD N
patients NNS N
undergoing JJ N
SEPS NNP i
, , N
460 CD N
( ( N
55 CD N
% NN N
) ) N
underwent NN N
saphenous JJ i
vein NN i
ligation NN i
and CC i
stripping NN i
at IN N
the DT N
same JJ N
operation NN N
. . N

In IN N
92 CD N
% NN N
ulcers NNS o
healed VBD o
or CC o
were VBD o
significantly RB o
improved VBN o
within IN N
4 CD N
to TO N
14 CD N
weeks NNS N
. . N

In IN N
64 CD N
( ( N
8 CD N
% NN N
) ) N
patients NNS N
, , N
ulcers NNS o
failed VBD o
to TO o
heal VB o
or CC N
there EX N
was VBD N
no DT N
benefit NN N
from IN N
the DT N
operation NN o
. . o

Thirty-two JJ N
patients NNS N
( ( N
4 CD N
% NN N
) ) N
experienced VBD N
recurrent JJ o
ulceration NN o
or CC o
skin JJ o
deterioration NN o
at IN N
6 CD N
months-2 JJ N
years NNS N
( ( N
mean NN N
, , N
15 CD N
mo NN N
) ) N
. . N

Repeat NNP N
SEPS NNP N
was VBD N
successful JJ N
in IN N
25 CD N
of IN N
these DT N
96 CD N
patients NNS N
, , N
and CC N
deep JJ N
valve NN N
repair NN N
was VBD N
successful JJ N
in IN N
4 CD N
patients NNS N
. . N

In IN N
the DT N
92 CD p
randomized VBD p
patients NNS p
with IN p
C4 NNP p
disease NN p
, , N
41 CD N
refused VBD N
postoperative JJ N
AVP NNP N
, , N
leaving VBG N
51 CD N
compliant JJ N
patients NNS N
. . N

The DT N
SEPS NNP N
group NN N
( ( N
n JJ N
= NNP N
25 CD N
) ) N
had VBD N
significantly RB N
reduced VBN N
AVP NNP o
( ( N
P NNP N
< NNP N
.01 NNP N
) ) N
compared VBN N
with IN N
the DT N
control NN N
group NN N
( ( N
n JJ N
= NNP N
26 CD N
) ) N
. . N

Complications NNS N
in IN N
825 CD N
patients NNS N
were VBD N
less JJR N
than IN N
3 CD N
% NN N
and CC N
consisted VBD N
mostly RB N
of IN N
transient NN o
neurologic NN o
disorders NNS o
( ( N
eg NN N
, , N
paradysthesia NN o
) ) o
, , o
but CC o
deep RB o
venous JJ o
thrombosis NN o
occurred VBD N
in IN N
2 CD N
patients NNS N
, , N
with IN N
pulmonary JJ N
embolus NN N
in IN N
1 CD N
. . N

No DT N
operative JJ N
deaths NNS o
occurred VBD N
. . N

Follow-up NN N
for IN N
1 CD N
to TO N
9 CD N
years NNS N
( ( N
mean NN N
, , N
31/2 CD N
years NNS N
) ) N
demonstrated VBD N
durability NN o
. . o

CONCLUSION VB N
The DT N
efficacy NN N
, , N
safety NN N
, , N
and CC N
durability NN N
of IN N
this DT N
operative JJ N
protocol NN N
proved VBD N
beneficial JJ N
in IN N
our PRP$ N
clinical JJ N
experience NN N
with IN N
832 CD p
patients NNS p
during IN N
9 CD N
years NNS N
of IN N
follow-up NN N
. . N

The DT N
SEPS NNP N
subset NN N
of IN N
randomized JJ N
patients NNS N
with IN N
C4 NNP N
disease NN N
experienced VBD N
significant JJ N
decrease NN N
in IN N
AVP NNP N
, , N
objectively RB N
supporting VBG N
the DT N
effectiveness NN N
of IN N
reflux NN N
surgery NN N
in IN N
advanced JJ N
CVI NNP N
. . N

Until IN N
definitive JJ N
level NN N
I PRP N
evidence NN N
is VBZ N
available JJ N
, , N
this DT N
operative JJ N
technique NN N
is VBZ N
advocated VBN N
as IN N
optimal JJ N
therapy NN N
for IN N
CVI NNP N
. . N

-DOCSTART- -8238214- O O

Relaxing VBG i
retinotomy NN i
with IN i
silicone JJ i
oil NN i
or CC i
long-acting NN i
gas NN i
in IN N
eyes NNS p
with IN p
severe JJ p
proliferative JJ p
vitreoretinopathy NN p
. . p

Silicone NNP N
Study NNP N
Report NNP N
5 CD N
. . N

The DT N
Silicone NNP N
Study NNP N
Group NNP N
. . N

In IN N
the DT N
Silicone NNP N
Study NNP N
, , N
117 CD p
of IN p
404 CD p
eyes NNS p
( ( p
29 CD p
% NN p
) ) p
with IN p
severe JJ p
proliferative JJ p
vitreoretinopathy NN p
( ( p
> CD p
or CC p
= VB p
C-3 NNP p
, , p
full-thickness JJ p
retinal JJ p
folds NNS p
in IN p
three CD p
or CC p
more JJR p
quadrants NNS p
) ) p
enrolled VBD N
in IN N
the DT N
study NN N
were VBD N
treated VBN N
with IN N
vitrectomy NN i
, , N
underwent VBD N
a DT N
relaxing VBG i
retinotomy NN i
, , N
and CC N
were VBD N
randomly RB N
assigned VBN N
to TO N
treatment NN i
with IN i
long-acting JJ i
gas NN i
or CC i
silicone NN i
oil NN i
. . i

Forty-six JJ p
eyes NNS p
( ( N
20 CD N
% NN N
) ) N
had VBD N
undergone JJ N
no DT N
previous JJ N
vitrectomy NN N
( ( N
group NN N
1 CD N
) ) N
; : N
71 CD N
eyes NNS N
( ( N
42 CD N
% NN N
) ) N
had VBD N
undergone JJ N
previous JJ N
vitrectomy NN N
( ( N
group NN N
2 CD N
) ) N
with IN N
intraocular JJ N
gas NN N
tamponade NN N
( ( N
P NNP N
< NNP N
.001 NNP N
) ) N
. . N

Group NNP N
1 CD N
eyes NNS N
not RB N
undergoing VBG N
retinotomy NN N
had VBD N
better JJR o
anatomic JJ o
( ( o
six CD o
months NNS o
) ) o
and CC o
visual JJ o
( ( o
six CD o
and CC o
24 CD o
months NNS o
) ) o
outcomes NNS o
and CC o
less JJR o
hypotony NN o
( ( N
six CD N
months NNS N
) ) N
than IN N
eyes NNS N
that WDT N
did VBD N
regardless RB N
of IN N
tamponade NN N
( ( N
P NNP N
< NNP N
.05 NNP N
) ) N
. . N

For IN N
eyes NNS N
undergoing VBG N
retinotomy NN N
, , N
silicone NN N
oil NN N
decreased VBD o
the DT o
likelihood NN o
of IN o
hypotony NN o
( ( N
six CD N
months NNS N
, , N
P NNP N
< NNP N
.05 NNP N
) ) N
. . N

These DT N
differences NNS N
were VBD N
not RB N
found VBN N
in IN N
group NN N
2 CD N
eyes NNS N
. . N

We PRP N
conclude VBP N
that IN N
eyes NNS N
undergoing VBG N
a DT N
vitreous JJ N
operation NN N
for IN N
the DT N
first JJ N
time NN N
for IN N
the DT N
treatment NN N
of IN N
proliferative JJ o
vitreoretinopathy NN o
can MD N
in IN N
most JJS N
instances NNS N
be VB N
successfully RB N
treated VBN N
by IN N
conventional JJ N
techniques NNS N
without IN N
the DT N
need NN N
for IN N
relaxing VBG N
retinotomy NN N
. . N

Retinotomy NNP N
may MD N
be VB N
required VBN N
more RBR N
often RB N
in IN N
patients NNS N
undergoing VBG N
repeat NN N
vitreous JJ N
surgery NN N
for IN N
proliferative JJ N
vitreoretinopathy NN N
, , N
in IN N
which WDT N
case NN N
both DT N
silicone NN N
oil NN N
and CC N
long-acting NN N
perflouropropane NN i
gas NN N
appear VBP N
to TO N
be VB N
equally RB o
effective JJ o
. . o

-DOCSTART- -23084254- O O

The DT N
effects NNS N
of IN N
a DT N
six-week JJ N
supervised JJ N
multimodal NN i
exercise NN i
intervention NN i
during IN N
chemotherapy NN i
on IN N
cancer-related JJ o
fatigue NN o
. . o

PURPOSE NNP N
Cancer NNP o
related VBN o
fatigue NN o
( ( o
CRF NNP o
) ) o
is VBZ N
a DT N
common JJ N
problem NN N
for IN N
cancer NN p
patients NNS p
across IN p
diagnoses NNS p
during IN p
chemotherapy NN i
and CC N
is VBZ N
associated VBN N
with IN N
physical JJ N
inactivity NN N
, , N
lower JJR N
functional JJ N
level NN N
and CC N
lack NN N
of IN N
energy NN N
. . N

Few JJ N
RCT NNP N
exercise NN i
intervention NN i
studies NNS N
have VBP N
included VBN N
cancer NN p
patients NNS p
undergoing VBG p
chemotherapy NN p
. . p

The DT N
objective NN N
of IN N
this DT N
study NN N
is VBZ N
to TO N
evaluate VB N
whether IN N
a DT N
six-week JJ N
supervised JJ i
multimodal NN i
exercise NN i
intervention NN i
, , i
adjunct JJ i
to TO i
chemotherapy VB i
and CC i
standard VB i
care NN i
, , N
can MD N
reduce VB N
the DT N
patient NN N
's POS N
CRF NNP o
level NN o
. . o

METHODS NNP N
Data NNP N
is VBZ N
based VBN N
on IN N
analyses NNS N
of IN N
a DT N
prospective JJ N
randomised VBN N
controlled VBN N
trial NN N
'The NNP N
Body NNP N
& CC N
Cancer NNP N
Trial NNP N
' POS N
. . N

213 CD p
cancer NN p
patients NNS p
with IN p
different JJ p
diagnoses NNS p
were VBD N
randomised VBN N
into IN p
an DT N
intervention NN i
group NN i
or CC N
wait-list JJ i
control NN i
group NN i
. . i

The DT N
primary JJ N
outcome NN N
, , N
Fatigue NNP o
score NN o
( ( o
CRF NNP o
) ) o
, , N
was VBD N
evaluated VBN N
by IN N
the DT N
Functional NNP o
Assessment NNP o
of IN o
Cancer NNP o
Therapy-Anaemia NNP o
Questionnaire NNP o
( ( o
FACT-An- NNP o
) ) o
( ( o
FACT-G NNP o
score NN o
& CC o
FACT-An NNP o
Anemia NNP o
subscale NN o
) ) o
. . o

INTERVENTION NNP N
Supervised VBD i
exercise NN i
, , i
comprising VBG i
high-intensity NN i
cardiovascular NN i
and CC i
heavy JJ i
resistance NN i
training NN i
, , i
relaxation- JJ i
and CC i
body NN i
awareness JJ i
training NN i
and CC i
massage NN i
, , N
9 CD N
h JJ N
weekly JJ N
for IN N
6 CD N
weeks NNS N
. . N

RESULTS NNP N
CRF NNP o
was VBD N
significantly RB N
reduced VBN N
in IN N
the DT N
intervention NN N
group NN N
, , N
corresponding VBG N
to TO N
a DT N
Fatigue NNP o
score NN o
reduction NN o
of IN N
3.04 CD N
( ( N
effect NN N
size NN N
of IN N
0.44 CD N
, , N
95 CD N
% NN N
CI NNP N
0.17-0.72 NN N
) ) N
( ( N
P NNP N
= NNP N
.002 NNP N
) ) N
, , N
the DT N
FACT-An NNP o
score NN o
by IN N
5.40 CD N
( ( N
P NNP N
= NNP N
.015 NNP N
) ) N
, , N
the DT N
FACT-An NNP o
Toi NNP o
score NN N
by IN N
5.22 CD N
( ( N
P NNP N
= NNP N
.009 NNP N
) ) N
and CC N
the DT N
Anaemia-ANS JJ o
by IN N
3.76 CD N
( ( N
P NNP N
= NNP N
.002 NNP N
) ) N
. . N

There EX N
was VBD N
no DT N
statistically RB N
significant JJ N
effect NN N
on IN N
the DT N
General NNP o
Quality NNP o
of IN o
Life NNP o
score NN o
( ( N
FACT-G NNP N
) ) N
or CC N
on IN N
any DT N
of IN N
the DT N
individual JJ o
wellbeing NN o
scores NNS o
; : o
Physical NNP o
( ( N
P NNP N
= NNP N
.13 NNP N
) ) N
, , N
Emotional NNP o
( ( N
P NNP N
= NNP N
.87 NNP N
) ) N
, , N
Social NNP o
( ( N
P NNP N
= NNP N
.83 NNP N
) ) N
and CC N
Functional NNP o
( ( N
P NNP N
= NNP N
.26 NNP N
) ) N
. . N

CONCLUSION NNP N
In IN N
summary JJ N
, , N
this DT N
six-week JJ N
supervised JJ i
multimodal NN i
exercise NN i
intervention NN i
can MD N
lead VB N
to TO N
significant JJ N
reduction NN N
in IN N
self-reported JJ o
CRF NNP o
in IN p
cancer NN p
patients NNS p
undergoing VBG p
chemotherapy NN p
. . p

-DOCSTART- -19011453- O O

Comparison NNP N
between IN N
lithium NN i
and CC i
valproate NN i
in IN N
the DT N
treatment NN N
of IN N
acute NN p
mania NN p
. . p

-DOCSTART- -26746121- O O

Efficacy NN N
of IN N
Low-Dose NNP i
Buspirone NNP i
for IN N
Restricted NNP N
and CC N
Repetitive NNP N
Behavior NNP N
in IN N
Young NNP p
Children NNP p
with IN p
Autism NNP p
Spectrum NNP p
Disorder NNP p
: : p
A DT N
Randomized NNP N
Trial NNP N
. . N

OBJECTIVES NNP N
To TO N
determine VB N
safety NN N
and CC N
efficacy NN N
of IN N
the DT N
5HT1A CD i
serotonin NN i
partial JJ i
agonist NN i
buspirone NN i
on IN N
core NN N
autism NN N
and CC N
associated JJ N
features NNS N
in IN N
children NNS p
with IN p
autism NN p
spectrum NN p
disorder NN p
( ( p
ASD NNP p
) ) p
. . p

STUDY NNP N
DESIGN NNP N
Children NNP p
2-6 CD p
years NNS p
of IN p
age NN p
with IN p
ASD NNP p
( ( p
N NNP p
= NNP p
166 CD p
) ) p
were VBD N
randomized VBN N
to TO N
receive VB N
placebo NN i
or CC N
2.5 CD N
or CC N
5.0 CD N
mg NN N
of IN N
buspirone NN i
twice JJ N
daily RB N
. . N

The DT N
primary JJ N
objective NN N
was VBD N
to TO N
evaluate VB N
the DT N
effects NNS N
of IN N
24 CD N
weeks NNS N
of IN N
buspirone NN i
on IN N
the DT N
Autism NNP o
Diagnostic NNP o
Observation NNP o
Schedule NNP o
( ( o
ADOS NNP o
) ) o
Composite NNP o
Total NNP o
Score NNP o
. . o

Secondary JJ N
objectives NNS N
included VBD N
evaluating VBG N
the DT N
effects NNS N
of IN N
buspirone NN i
on IN N
social JJ o
competence NN o
, , o
repetitive JJ o
behaviors NNS o
, , o
language NN o
, , o
sensory JJ o
dysfunction NN o
, , o
and CC o
anxiety NN o
and CC o
to TO o
assess VB o
side JJ o
effects NNS o
. . o

Positron NNP o
emission NN o
tomography NN o
measures NNS o
of IN o
tryptophan NN o
metabolism NN o
and CC o
blood NN o
serotonin NN o
concentrations NNS o
were VBD N
assessed VBN N
as IN N
predictors NNS N
of IN N
buspirone NN i
efficacy NN N
. . N

RESULTS NNP N
There EX N
was VBD N
no DT N
difference NN N
in IN N
the DT N
ADOS NNP o
Composite NNP o
Total NNP o
Score NNP o
between IN N
baseline NN N
and CC N
24 CD N
weeks NNS N
among IN N
the DT N
3 CD N
treatment NN N
groups NNS N
( ( N
P NNP N
= NNP N
.400 NNP N
) ) N
; : N
however RB N
, , N
the DT N
ADOS NNP o
Restricted NNP o
and CC o
Repetitive NNP o
Behavior NNP o
score NN o
showed VBD N
a DT N
time-by-treatment JJ N
effect NN N
( ( N
P NNP N
= NNP N
.006 NNP N
) ) N
; : N
the DT N
2.5-mg JJ N
buspirone NN i
group NN N
showed VBD N
significant JJ N
improvement NN N
( ( N
P NNP N
= NNP N
.003 NNP N
) ) N
, , N
whereas JJ N
placebo NN i
and CC N
5.0-mg JJ N
buspirone NN i
groups NNS N
showed VBD N
no DT N
change NN N
. . N

Children NNP N
in IN N
the DT N
2.5-mg JJ N
buspirone NN i
group NN N
were VBD N
more RBR N
likely JJ N
to TO N
improve VB N
if IN N
they PRP N
had VBD N
fewer JJR N
foci NN N
of IN N
increased JJ N
brain NN N
tryptophan NN N
metabolism NN N
on IN N
positron NN N
emission NN N
tomography NN N
( ( N
P NNP N
= NNP N
.018 NNP N
) ) N
or CC N
if IN N
they PRP N
showed VBD N
normal JJ N
levels NNS N
of IN N
blood NN N
serotonin NN N
( ( N
P NNP N
= NNP N
.044 NNP N
) ) N
. . N

Adverse JJ N
events NNS N
did VBD N
not RB N
differ VB N
significantly RB N
among IN N
treatment NN N
groups NNS N
. . N

CONCLUSIONS NNP N
Treatment NNP N
with IN N
2.5 CD N
mg NNS N
of IN N
buspirone NN i
in IN N
young JJ p
children NNS p
with IN p
ASD NNP p
might MD N
be VB N
a DT N
useful JJ N
adjunct JJ N
therapy NN N
to TO N
target VB N
restrictive JJ N
and CC N
repetitive JJ N
behaviors NNS N
in IN N
conjunction NN N
with IN N
behavioral JJ N
interventions NNS N
. . N

TRIAL NNP N
REGISTRATION NNP N
ClinicalTrials.gov NNP N
: : N
NCT00873509 NN N
. . N

-DOCSTART- -17907108- O O

A DT N
double-blind NN N
, , N
randomised VBD N
trial NN N
of IN N
tesaglitazar JJ i
versus NN N
pioglitazone NN i
in IN N
patients NNS p
with IN p
type JJ p
2 CD p
diabetes NNS p
mellitus RB p
. . p

The DT N
efficacy NN N
and CC N
safety NN N
of IN N
tesaglitazar NN i
( ( N
0.5 CD N
and CC N
1 CD N
mg NN N
) ) N
and CC N
pioglitazone NN i
( ( N
15 CD N
, , N
30 CD N
and CC N
45 CD N
mg NN N
) ) N
were VBD N
compared VBN N
in IN N
a DT N
24-week JJ N
, , N
randomised JJ N
, , N
double-blind JJ N
study NN N
in IN N
1,707 CD p
patients NNS p
with IN p
type JJ p
2 CD p
diabetes NNS p
mellitus RB p
. . p

Tesaglitazar VB i
1 CD N
mg NN N
was VBD N
non-inferior JJ N
to TO N
pioglitazone VB i
45 CD N
mg NN N
for IN N
change NN N
from IN N
baseline NN N
in IN N
glycosylated JJ N
haemoglobin NN N
( ( N
HbA1C NNP N
) ) N
at IN N
24 CD N
weeks NNS N
( ( N
difference NN N
: : N
-0.056 JJ N
[ VBP N
95 CD N
% NN N
confidence NN N
intervals NNS N
-0.161 VBP N
, , N
0.049 CD N
] NN N
, , N
pNI NN N
< VBD N
0.001 CD N
for IN N
non-inferiority JJ N
hypothesis NN N
) ) N
. . N

Tesaglitazar $ i
1 CD N
mg NN N
improved VBN N
triglyceride NN o
( ( o
TG NNP o
) ) o
, , o
high-density JJ o
lipoprotein NN o
cholesterol NN o
( ( o
HDL-C NNP o
) ) o
and CC o
non-HDL-C JJ o
levels NNS o
compared VBN N
with IN N
all DT N
pioglitazone NN N
doses VBZ N
at IN N
24 CD N
weeks NNS N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
. . N

Low-density JJ o
lipoprotein NN o
cholesterol NN o
( ( o
LDL-C NNP o
) ) o
was VBD N
lower JJR N
with IN N
tesaglitazar NN i
for IN N
all DT N
pioglitazone NN i
comparisons NNS N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
, , N
except IN N
for IN N
tesaglitazar NN i
0.5 CD N
mg NN N
versus NN N
pioglitazone NN i
15 CD N
mg. NN N
Tesaglitazar NNP i
1 CD N
mg NN N
decreased VBD N
LDL NNP o
particle NN o
number NN o
, , N
when WRB N
compared VBN N
with IN N
all DT N
pioglitazone NN i
doses NNS N
( ( N
p JJ N
< NNP N
0.01 CD N
) ) N
. . N

Both DT N
agents NNS N
increased VBD N
body NN o
weight NN o
and CC o
peripheral JJ o
oedema NN o
in IN N
a DT N
dose-dependent JJ N
manner NN N
, , N
but CC N
only RB N
tesaglitazar NN i
increased VBD N
serum JJ o
creatinine NN o
. . o

In IN N
summary JJ N
, , N
tesaglitazar NN i
provided VBD N
similar JJ N
glycaemic JJ o
control NN o
to TO N
pioglitazone VB i
, , N
was VBD N
associated VBN N
with IN N
significant JJ N
improvement NN N
in IN N
lipid JJ o
and CC o
lipoprotein JJ o
variables NNS o
, , N
and CC N
increased VBD N
serum NN N
creatinine NN N
in IN N
a DT N
dose-dependent JJ N
manner NN N
. . N

-DOCSTART- -24345974- O O

Does VBZ N
an DT N
in-season JJ i
detraining NN i
period NN N
affect VBP N
the DT N
shoulder NN N
rotator NN N
cuff NN N
strength NN N
and CC N
balance NN N
of IN N
young JJ p
swimmers NNS p
? . N
Imbalance NN N
in IN N
shoulder NN N
rotator NN N
muscles NNS N
is VBZ N
a DT N
well-documented JJ N
problem NN N
in IN N
swimmers NNS p
, , N
and CC N
it PRP N
is VBZ N
important JJ N
to TO N
implement VB N
land-based JJ N
strength NN N
training NN N
programs NNS N
. . N

Meanwhile RB N
, , N
the DT N
effects NNS N
of IN N
a DT N
detraining JJ N
period NN N
on IN N
swimmers NNS N
' POS N
shoulder NN N
rotator NN N
muscles NNS N
are VBP N
unknown JJ N
. . N

The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
analyze VB N
the DT N
effects NNS N
of IN N
a DT N
strength NN i
training NN i
program NN i
and CC i
detraining VBG i
on IN N
the DT N
strength NN N
and CC N
balance NN N
of IN N
shoulder NN N
rotator NN N
cuff NN N
muscles NNS N
in IN N
young JJ p
swimmers NNS p
, , N
despite IN N
the DT N
continuity NN N
of IN N
usual JJ N
water NN N
training NN N
. . N

An DT p
experimental JJ p
group NN p
( ( p
n JJ p
= NNP p
20 CD p
) ) p
and CC p
a DT p
control NN p
group NN p
( ( p
n JJ p
= NNP p
20 CD p
) ) p
of IN p
young JJ p
male NN p
swimmers NNS p
with IN p
the DT p
same JJ p
characteristics NNS p
( ( p
age NN p
, , p
body NN p
mass NN p
, , p
height NN p
, , p
training NN p
volume NN p
, , p
and CC p
maturational JJ p
state NN p
) ) p
were VBD p
evaluated VBN p
. . p

In IN N
both DT N
groups NNS N
, , N
the DT N
peak NN o
torques NNS o
of IN o
shoulder NN o
internal JJ o
( ( o
IR NNP o
) ) o
and CC o
external JJ o
( ( o
ER NNP o
) ) o
rotators NNS o
were VBD N
assessed VBN N
during IN N
preseason NN N
, , N
midseason NN N
( ( N
16 CD N
weeks NNS N
) ) N
, , N
and CC N
postseason NN N
( ( N
32 CD N
weeks NNS N
) ) N
. . N

The DT N
experimental JJ N
group NN N
underwent VBD N
a DT N
strength NN i
training VBG i
regimen NNS i
from IN N
baseline NN N
to TO N
16 CD N
weeks NNS N
and CC N
a DT N
detraining JJ i
period NN N
from IN N
16 CD N
to TO N
32 CD N
weeks NNS N
. . N

Concentric JJ N
action NN N
at IN N
60??s-1 JJ N
and CC N
180??s-1 JJ N
was VBD N
measured VBN N
using VBG N
an DT N
isokinetic JJ N
dynamometer NN N
. . N

The DT N
ER/IR NNP o
strength NN o
ratios NNS o
were VBD o
obtained VBN N
. . N

At IN N
60??s-1 JJ N
, , N
there EX N
were VBD N
significant JJ o
increments NNS o
in IN o
IR NNP o
strength NN o
and CC o
the DT o
ER/IR NNP o
ratio NN o
in IN N
both DT N
shoulders NNS N
. . N

This DT N
trend NN N
was VBD N
the DT N
same JJ N
throughout IN N
the DT N
competitive JJ N
season NN N
. . N

The DT N
tendency NN N
was VBD N
the DT N
same JJ N
at IN N
180??s-1 JJ N
because IN N
training VBG N
effects NNS N
were VBD N
noted VBN N
primarily RB o
in IN o
IR NNP o
and CC o
ER/IR NNP o
ratios NNS o
. . o

Moreover RB N
, , N
the DT N
absence NN N
of IN N
land-based JJ N
strength NN N
training NN N
, , N
from IN N
16 CD N
to TO N
32 CD N
weeks NNS N
, , N
revealed VBD N
a DT o
reduction NN o
in IN o
the DT o
ER/IR NNP o
ratio NN o
values NNS o
in IN N
both DT N
shoulders NNS N
. . N

Our PRP$ N
findings NNS N
suggest VBP N
that IN N
young JJ N
swimmers NNS N
' POS N
coaches NNS N
should MD N
use VB i
dry-land JJ i
strength NN i
training NN i
protocols NNS i
, , i
and CC i
that IN i
it PRP N
is VBZ N
recommended VBN N
that IN N
these DT N
should MD N
be VB N
conducted VBN N
on IN N
a DT N
regular JJ N
basis NN N
( ( N
during IN N
the DT N
whole JJ N
season NN N
) ) N
. . N

-DOCSTART- -19135077- O O

Face NNP i
composite JJ i
effects NNS N
reveal VBP N
abnormal JJ N
face NN N
processing NN N
in IN N
Autism NNP p
spectrum NN p
disorders NNS p
. . p

Although IN N
it PRP N
has VBZ N
been VBN N
suggested VBN N
that IN N
individuals NNS p
with IN p
an DT p
Autism NNP p
spectrum NN p
disorder NN p
( ( p
ASD NNP p
) ) p
process NN N
faces VBZ N
less RBR N
holistically RB N
than IN N
typically RB N
developing VBG N
controls NNS N
, , N
there EX N
are VBP N
few JJ N
direct JJ N
investigations NNS N
of IN N
this DT N
hypothesis NN N
. . N

This DT N
question NN N
was VBD N
addressed VBN N
before IN N
using VBG N
the DT N
composite JJ N
paradigm NN N
( ( N
Teunisse NNP N
, , N
J. NNP N
P. NNP N
, , N
& CC N
de FW N
Gelder NNP N
, , N
B NNP N
. . N

( ( N
2003 CD N
) ) N
. . N

Face NN N
processing NN N
in IN N
adolescents NNS N
with IN N
autistic JJ N
disorder NN N
: : N
The DT N
inversion NN N
and CC N
composite JJ N
effects NNS N
. . N

Brain NNP N
Cognition NNP N
, , N
52 CD N
( ( N
3 CD N
) ) N
, , N
285-294. JJ N
) ) N
. . N

The DT N
results NNS N
had VBD N
revealed VBN N
that IN N
adolescents NNS p
with IN p
ASDs NNP p
were VBD N
less RBR N
sensitive JJ N
than IN N
controls NNS N
to TO N
the DT N
misalignment NN N
of IN N
face NN N
parts NNS N
and CC N
it PRP N
was VBD N
concluded VBN N
their PRP$ N
face NN N
processing NN N
was VBD N
less RBR N
holistic JJ N
. . N

However RB N
, , N
because IN N
of IN N
shortcomings NNS N
of IN N
the DT N
design NN N
, , N
it PRP N
was VBD N
not RB N
possible JJ N
to TO N
distinguish VB N
whether IN N
individuals NNS p
with IN p
Autism NNP p
processed VBD N
both DT N
aligned VBN N
and CC N
misaligned VBN N
composites NNS N
in IN N
a DT N
part-based JJ N
fashion NN N
, , N
or CC N
both DT N
in IN N
a DT N
holistic JJ N
fashion NN N
. . N

We PRP N
compared VBN N
adolescents NNS i
with IN i
ASDs NNP i
to TO p
controls VB i
matched VBN p
on IN p
sex NN p
, , p
age NN p
and CC p
IQ NNP p
on IN N
a DT N
more RBR N
complete JJ N
version NN N
of IN N
the DT N
composite JJ i
paradigm NN i
. . i

The DT o
results NNS o
indicate VBP o
that IN o
individuals NNS o
with IN o
ASDs NNP o
, , o
like IN o
controls NNS o
, , o
experience NN o
interference NN o
from IN o
facial JJ o
features NNS o
that IN o
they PRP o
are VBP o
told VBN o
to TO o
ignore VB o
. . o

However RB o
, , o
while IN o
such JJ o
interference NN o
is VBZ o
released VBN o
for IN o
controls NNS o
if IN o
parts NNS o
of IN o
face NN o
composites NNS o
are VBP o
misaligned VBN o
, , o
individuals NNS o
with IN o
ASDs NNP o
show VBP o
comparable JJ o
interference NN o
from IN o
irrelevant JJ o
parts NNS o
regardless RB o
of IN o
alignment NN o
. . o

Two CD o
different JJ o
interpretations NNS o
are VBP o
discussed VBN o
, , o
both DT o
compatible JJ o
with IN o
the DT o
idea NN o
that WDT o
perceptual JJ o
and CC o
or CC o
attentional JJ o
abnormalities NNS o
in IN o
ASDs NNP o
result NN o
in IN o
a DT o
diminished JJ o
level NN o
of IN o
expertise NN o
for IN o
faces VBZ o
. . o

-DOCSTART- -2112233- O O

[ JJ N
GISSI-2 NNP N
; : N
the DT N
beginning NN N
of IN N
the DT N
end NN N
or CC N
the DT N
end NN N
of IN N
the DT N
beginning NN N
for IN N
tissue NN i
plasminogen NN i
activator NN N
in IN N
acute JJ o
myocardial JJ o
infarct NN o
? . N
] NN N
. . N

-DOCSTART- -24237999- O O

Remission NN o
in IN o
rheumatoid JJ o
arthritis NN o
patients NNS p
treated VBN p
with IN p
etanercept JJ i
monotherapy NN i
: : i
clinical JJ N
practice NN N
and CC N
clinical JJ N
trial NN N
experience NN N
. . N

OBJECTIVES NNP N
To TO N
assess VB N
, , N
in IN N
a DT N
randomised JJ N
controlled VBN N
trial NN N
( ( N
RCT NNP N
) ) N
and CC N
in IN N
clinical JJ N
practice NN N
, , N
an DT N
association NN o
of IN o
time NN o
to TO o
remission NN o
and CC N
baseline JJ o
disease NN o
activity NN o
with IN N
both DT N
induction NN N
of IN N
remission NN N
and CC N
sustained JJ N
remission NN N
in IN N
etanercept-treated JJ i
patients NNS p
with IN p
rheumatoid JJ p
arthritis NN p
( ( p
RA NNP p
) ) p
. . p

METHODS NNP N
Data NNP p
from IN p
an DT p
RCT NNP p
( ( p
Trial NNP p
of IN p
Etanercept NNP i
and CC i
Methotrexate NNP i
with IN p
Radiographic NNP p
Patient NNP p
Outcomes NNP p
[ NNP p
TEMPO NNP p
] NNP p
; : p
n=682 CC p
) ) p
and CC p
an DT p
observational JJ p
registry NN p
( ( p
Rheumatoid NNP p
Arthritis NNP p
DMARD NNP p
Intervention NNP p
and CC p
Utilization NNP p
Study NNP p
[ NNP p
RADIUS NNP p
II NNP p
] NNP p
; : p
n=4341 CC p
) ) p
were VBD N
used VBN N
to TO N
evaluate VB N
disease NN o
activity NN o
( ( N
Clinical JJ N
Disease NNP N
Activity NNP N
Index NNP N
[ NNP N
CDAI NNP N
] NNP N
score NN N
) ) N
over IN N
time NN N
in IN N
patients NNS p
initiating VBG p
etanercept NN i
( ( i
monotherapy NN i
or CC i
with IN i
methotrexate NN i
) ) i
. . i

CDAI NNP o
remission NN o
( ( N
CDAI?2.8 NNP N
) ) N
and CC o
sustained VBN o
remission NN o
( ( o
?6 JJ N
months NNS N
) ) N
were VBD N
determined VBN N
through IN N
year NN N
3 CD N
by IN N
treatment NN N
group NN N
, , N
study NN N
, , N
time NN N
to TO N
remission NN N
, , N
and CC N
disease NN N
severity NN N
. . N

RESULTS JJ p
Patients NNS p
from IN p
TEMPO NNP p
and CC p
RADIUS NNP p
II NNP p
who WP p
received VBD i
etanercept JJ i
monotherapy NN i
showed VBD i
similar JJ o
CDAI NNP o
remission NN o
rates NNS o
( ( o
39 CD o
% NN N
and CC N
35 CD N
% NN N
, , N
respectively RB N
, , N
at IN N
3 CD N
years NNS N
) ) N
. . N

Among IN N
patients NNS N
who WP N
received VBD i
etanercept IN i
with IN i
methotrexate NN o
, , o
remission NN o
rates NNS o
were VBD o
54 CD N
% NN N
and CC N
36 CD N
% NN N
, , N
respectively RB o
. . o

Remission NN o
occurred VBD o
more RBR N
rapidly RB N
in IN N
TEMPO NNP N
than IN N
RADIUS NNP N
II NNP N
perhaps RB N
from IN N
differences NNS o
in IN o
compliance NN o
, , o
patient JJ o
populations NNS o
, , o
or CC o
sequence NN o
of IN o
combination NN o
therapy NN o
initiation NN o
. . o

Generally RB o
, , N
more JJR N
patients NNS p
with IN p
lower JJR o
baseline NN o
CDAI NNP o
scores VBZ o
achieved VBN o
remission NN o
than IN o
those DT N
with IN N
higher JJR N
scores NNS o
. . o

Continued VBN o
remission NN o
appeared VBD o
more RBR N
likely JJ N
in IN N
patients NNS N
achieving VBG N
remission NN N
earlier RBR N
in IN N
the DT N
course NN N
of IN N
their PRP$ N
therapy NN N
( ( N
0-6 JJ N
months NNS N
) ) N
. . N

CONCLUSIONS NNP o
Remission NNP o
by IN o
year NN N
3 CD N
in IN N
etanercept-treated JJ i
( ( i
with IN i
and CC i
without IN i
methotrexate NN i
) ) i
patients NNS i
with IN N
RA NNP N
occurred VBD N
in IN N
?35 CD N
% NN N
of IN N
patients NNS N
in IN N
both DT N
an DT N
RCT NNP N
( ( N
TEMPO NNP N
) ) N
and CC N
a DT N
clinical JJ N
practice NN N
setting NN N
( ( N
RADIUS NNP N
II NNP N
) ) N
, , N
and CC N
more RBR N
frequently RB N
in IN N
those DT N
with IN N
lower JJR N
baseline NN N
disease NN N
severity NN N
. . N

Patients NNS N
with IN N
lower JJR N
RA NNP N
disease NN N
activity NN N
were VBD N
more RBR N
likely JJ N
to TO N
reach VB N
remission NN o
. . o

Continued VBN o
remission NN o
may MD o
be VB o
more RBR N
likely JJ N
in IN N
patients NNS N
who WP N
achieved VBD N
remission NN N
earlier RBR N
. . N

-DOCSTART- -10634838- O O

Randomised VBN N
controlled VBD N
study NN N
of IN N
clinical JJ N
outcome NN N
following VBG N
trophic JJ i
feeding VBG i
. . i

AIMS NNP N
To TO N
determine VB N
the DT N
effect NN N
of IN N
trophic JJ i
feeding VBG i
on IN N
clinical JJ N
outcome NN N
in IN N
ill JJ p
preterm JJ p
infants NNS p
. . p

METHODS NNP N
A DT N
randomised VBN N
, , N
controlled VBN N
, , N
prospective JJ N
study NN N
of IN N
100 CD p
preterm JJ p
infants NNS p
, , p
weighing VBG p
less JJR p
than IN p
1750 CD p
g NN p
at IN p
birth NN p
and CC p
requiring VBG p
ventilatory JJ p
support NN p
and CC p
parenteral JJ p
nutrition NN p
, , N
was VBD N
performed VBN N
. . N

Group NNP N
TF NNP N
( ( N
48 CD N
infants NNS N
) ) N
received VBD N
trophic JJ i
feeding VBG i
from IN i
day NN i
3 CD i
( ( i
0.5-1 JJ i
ml/h NN i
) ) i
along IN i
with IN i
parenteral JJ i
nutrition NN i
until IN N
ventilatory JJ i
support NN i
finished VBD N
. . N

Group NNP N
C NNP N
( ( N
52 CD N
infants NNS N
) ) N
received VBD N
parenteral JJ i
nutrition NN i
alone RB i
. . i

Nutritive JJ i
milk NN i
feeding NN i
was VBD N
then RB N
introduced VBN N
to TO N
both DT N
groups NNS N
. . N

Clinical JJ N
outcomes NNS N
measured VBN N
included VBD N
total JJ o
energy NN o
intake NN o
and CC o
growth NN o
over IN o
the DT o
first JJ o
six CD o
postnatal JJ o
weeks NNS o
, , o
sepsis NN o
incidence NN o
, , o
liver NN o
function NN o
, , o
milk NN o
tolerance NN o
, , o
duration NN o
of IN o
respiratory JJ o
support NN o
, , o
duration NN o
of IN o
hospital NN o
stay NN o
and CC o
complication NN o
incidence NN o
. . o

RESULTS JJ N
Groups NNP N
were VBD N
well RB N
matched VBN N
for IN N
birthweight NN N
, , N
gestation NN N
and CC N
CRIB NNP N
scores NNS N
. . N

Infants NNS N
in IN N
group NN N
TF NNP N
had VBD N
significantly RB N
greater JJR N
energy NN o
intake NN o
, , N
mean JJ N
difference NN N
41.4 CD N
( ( N
95 CD N
% NN N
confidence NN N
interval NN N
9 CD N
, , N
73.7 CD N
) ) N
kcal/kg NN N
p=0.02 NN N
; : N
weight JJ o
gain NN o
, , N
130 CD N
( ( N
CI NNP N
1 CD N
, , N
250 CD N
) ) N
g NN N
p NN N
= VBZ N
0.02 CD N
; : N
head NN o
circumference NN o
gain NN o
, , N
mean JJ N
difference NN N
0.7 CD N
( ( N
CI NNP N
0.1 CD N
, , N
1.3 CD N
) ) N
cm NN N
, , N
p NN N
= VBD N
0.04 CD N
; : N
fewer JJR N
episodes NNS o
of IN o
culture NN o
confirmed VBN o
sepsis NN o
, , N
mean JJ N
difference NN N
-0.7 NNP N
( ( N
-1.3 NNP N
, , N
-0.2 NNP N
) ) N
episodes VBZ N
, , N
p VB N
= JJ N
0.04 CD N
; : N
less JJR N
parenteral JJ o
nutrition NN o
, , N
mean JJ N
difference NN N
-11.5 NNP N
( ( N
CI NNP N
-20 NNP N
, , N
-3 NNP N
) ) N
days NNS N
, , N
p VBP N
= JJ N
0 CD N
. . N

03 CD N
; : N
tolerated VBN o
full JJ o
milk NN o
feeds NNS o
( ( N
165 CD N
ml/kg/day NN N
) ) N
earlier RBR N
, , N
mean JJ N
difference NN N
-11.2 NNP N
( ( N
CI NNP N
-19 NNP N
, , N
-3 NNP N
) ) N
days NNS N
, , N
p VBP N
= JJ N
0.03 CD N
; : N
reduced VBN N
requirement NN o
for IN o
supplemental JJ o
oxygen NN o
, , N
mean JJ N
difference NN N
-22.4 NNP N
( ( N
CI-41.5 NNP N
, , N
-3.3 NNP N
) ) N
days NNS N
, , N
p VBP N
= JJ N
0.02 CD N
; : N
and CC N
were VBD N
discharged VBN o
home NN o
earlier RBR N
, , N
mean JJ N
difference NN N
-22.1 NNP N
( ( N
CI NNP N
-42.1 NNP N
, , N
-2.2 NNP N
) ) N
days NNS N
, , N
p VBP N
= JJ N
0.04 CD N
. . N

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
the DT N
relative JJ N
risk NN o
of IN o
any DT o
complication NN o
. . o

CONCLUSIONS NNP N
Trophic NNP i
feeding VBG i
improves NNS N
clinical JJ N
outcome NN N
in IN N
ill JJ p
preterm JJ p
infants NNS p
requiring VBG p
parenteral JJ i
nutrition NN i
. . i

-DOCSTART- -20730486- O O

Reversal NNP N
of IN N
skeletal JJ N
effects NNS o
of IN N
endocrine NN i
treatments NNS i
in IN N
the DT N
Intergroup NNP N
Exemestane NNP N
Study NNP N
. . N

The DT N
adjuvant JJ N
use NN N
of IN N
aromatase NN i
inhibitors NNS i
in IN N
breast NN N
cancer NN N
is VBZ N
associated VBN N
with IN N
adverse JJ N
effects NNS N
on IN N
bone NN N
health NN N
. . N

We PRP N
previously RB N
reported VBD N
a DT N
decline NN N
in IN N
bone JJ N
mineral JJ N
density NN N
( ( N
BMD NNP N
) ) N
following VBG N
the DT N
switch NN N
from IN N
tamoxifen NN i
to TO N
exemestane VB i
in IN N
the DT N
Intergroup NNP N
Exemestane NNP N
Study NNP N
( ( N
IES NNP N
) ) N
. . N

Here RB N
we PRP N
report VBP N
effects NNS N
of IN N
endocrine JJ i
treatment NN i
withdrawal NN N
on IN N
BMD NNP N
, , N
bone NN N
turnover NN N
markers NNS N
( ( N
BTM NNP N
) ) N
and CC N
fracture JJ N
rates NNS N
. . N

4,724 CD p
patients NNS p
took VBD p
part NN p
in IN p
IES NNP p
, , p
and CC p
206 CD p
patients NNS p
were VBD p
included VBN p
in IN p
a DT p
bone NN p
sub-study NN p
. . p

BMD NNP N
and CC N
BTM NNP N
were VBD N
assessed VBN N
pre-randomization NN N
, , N
during IN N
and CC N
after IN N
the DT N
end NN N
of IN N
treatment NN N
( ( N
EOT NNP N
) ) N
. . N

To TO N
evaluate VB N
treatment NN N
withdrawal NN N
effects NNS N
, , N
12- JJ N
and CC N
24-month JJ N
post NN N
EOT NNP N
BMD NNP N
results NNS N
are VBP N
available JJ N
for IN N
122 CD N
and CC N
126 CD N
patients NNS N
, , N
respectively RB N
. . N

Similar JJ N
patient NN N
numbers NNS N
had VBD N
BTM NNP N
measured VBD N
post NN N
EOT NNP N
. . N

Following VBG N
treatment NN N
withdrawal NN N
, , N
the DT N
differences NNS N
in IN N
BMD NNP N
observed VBD N
between IN N
the DT N
two CD N
endocrine NN N
strategies NNS N
were VBD N
partially RB N
reversed VBN N
. . N

At IN N
24 CD N
months NNS N
from IN N
EOT NNP N
, , N
spine JJ o
BMD NNP o
increased VBN o
by IN N
1.53 CD N
% NN N
( ( N
95 CD N
% NN N
CI NNP N
0.63-2.43 CD N
; : N
p CC N
= VB N
0.001 CD N
) ) N
after IN N
stopping VBG N
exemestane NN N
and CC N
fell VBD N
by IN N
1.93 CD N
% NN N
( ( N
95 CD N
% NN N
CI NNP N
-2.91 NNP N
to TO N
0.95 CD N
; : N
p NN N
= VBZ N
0.0002 CD N
) ) N
following VBG N
tamoxifen NN i
withdrawal NN N
. . N

A DT N
similar JJ N
pattern NN N
of IN N
changes NNS N
was VBD N
observed VBN N
at IN N
the DT N
hip NN N
. . N

At IN N
2 CD N
years NNS N
post RB N
EOT NNP N
, , N
BMD NNP o
changes NNS o
from IN o
baseline NN o
were VBD N
similar JJ N
with IN N
both DT N
treatment NN N
strategies NNS N
. . N

Corresponding VBG N
inverse JJ o
changes NNS o
in IN o
BTM NNP o
were VBD N
seen VBN N
, , N
with IN N
an DT N
increase NN N
following VBG N
tamoxifen JJ N
withdrawal NN N
and CC N
a DT N
reduction NN N
after IN N
exemestane NN N
. . N

A DT N
higher JJR N
number NN o
of IN o
fractures NNS o
occurred VBD o
during IN N
exemestane NN i
treatment NN N
, , N
but CC N
fracture NN o
rates NNS o
were VBD N
similar JJ N
after IN N
treatment NN N
withdrawal NN N
. . N

With IN N
the DT N
switch NN N
strategy NN N
used VBN N
in IN N
IES NNP N
, , N
the DT N
on IN N
treatment NN N
adverse JJ o
bone NN o
effects NNS o
of IN N
exemestane NN i
are VBP N
reversed VBN N
. . N

Ongoing VBG N
monitoring NN N
of IN N
BMD NNP N
is VBZ N
therefore RB N
not RB N
routinely RB N
required VBN N
. . N

-DOCSTART- -3673207- O O

Pre-exposure JJ N
studies NNS N
with IN N
purified JJ i
chick JJ i
embryo NN i
cell NN i
culture NN i
rabies VBZ i
vaccine NN i
and CC N
human JJ i
diploid NN i
cell NN i
vaccine NN i
: : i
serological JJ N
and CC N
clinical JJ p
responses NNS p
in IN p
man NN p
. . p

Clinical JJ N
reactions NNS N
and CC N
neutralizing VBG N
antibody NN N
responses NNS N
to TO N
six CD N
pre-exposure NN N
regimens NNS N
of IN N
purified JJ i
chick JJ i
embryo NN i
cell NN i
culture NN i
rabies VBZ i
vaccine NN i
( ( i
PCECV NNP i
) ) i
and CC N
human JJ i
diploid NN i
cell NN i
strain NN i
rabies NNS i
vaccine VBP i
( ( i
HDCSV NNP i
) ) i
were VBD N
studied VBN N
in IN N
177 CD p
volunteers NNS p
. . p

Antibody NN o
kinetics NNS o
, , o
height NN o
of IN o
the DT o
response NN o
and CC o
persistence NN o
of IN o
antibody NN o
over IN o
two CD o
years NNS o
were VBD N
virtually RB N
identical JJ N
after IN N
PCECV NNP i
and CC N
HDCSV NNP i
. . i

An DT N
antibody NN o
response NN o
was VBD N
detected VBN N
in IN N
all DT N
subjects NNS N
on IN N
day NN N
14 CD N
when WRB N
the DT N
highest JJS N
titres NNS N
were VBD N
found VBN N
after IN N
two CD N
intramuscular JJ N
( ( N
i.m JJ N
. . N

) ) N
1.0 CD N
ml JJ N
doses NNS N
of IN N
a DT N
schedule NN N
of IN N
immunization NN N
on IN N
days NNS N
0 CD N
, , N
7 CD N
and CC N
21 CD N
. . N

In IN N
comparison NN N
, , N
a DT N
schedule NN N
of IN N
immunization NN N
on IN N
days NNS N
0 CD N
, , N
28 CD N
and CC N
56 CD N
ultimately RB N
evoked VBD N
the DT N
highest JJS N
titres NNS o
21 CD o
days NNS o
after IN o
the DT o
final JJ o
injection NN o
, , N
but CC N
antibody NN N
persisted VBD N
equally RB N
well RB N
over IN N
two CD N
years NNS N
with IN N
either DT N
schedule NN N
. . N

Neutralizing VBG o
antibody NN o
titres NNS o
were VBD N
lower JJR N
after IN N
intradermal JJ N
( ( N
i.d JJ N
. . N

) ) N
vaccination NN N
with IN N
0.1 CD N
ml NNS N
compared VBN N
to TO N
1.0 CD N
ml NN N
i.m NN N
. . N

on IN N
days NNS N
0 CD N
, , N
7 CD N
and CC N
21 CD N
, , N
but CC N
when WRB N
given VBN N
on IN N
days NNS N
0 CD N
, , N
28 CD N
and CC N
56 CD N
the DT N
responses NNS N
were VBD N
comparable JJ N
. . N

Three CD N
subjects NNS N
with IN N
a DT N
personal JJ N
or CC N
family NN N
history NN N
of IN N
atopy NN N
developed VBN N
urticarial JJ o
lesions NNS o
after IN N
PCECV NNP i
. . i

Both DT N
vaccines NNS N
were VBD N
otherwise RB N
well RB N
tolerated VBN N
. . N

-DOCSTART- -939970- O O

Radiotherapy NNP i
and CC N
CCNU NNP i
in IN N
the DT N
treatment NN N
of IN N
high-grade JJ N
supratentorial JJ N
astrocytomas NN N
. . N

Forty-one CD p
consecutive JJ p
patients NNS p
with IN p
supratentorial JJ p
primary JJ p
brain NN p
tumors NNS p
( ( p
38 CD p
Grade NNP p
III NNP p
and CC p
IV NNP p
astrocytomas RB p
, , p
one CD p
giant-cell NN p
astrocytoma NN p
, , p
and CC p
two CD p
cases NNS p
with IN p
insufficient JJ p
tissue NN p
for IN p
diagnosis NN p
) ) p
were VBD N
randomly RB N
allocated VBN N
within IN p
2 CD p
weeks NNS p
of IN p
surgery NN p
to TO N
one CD N
of IN N
three CD N
therapeutic JJ N
groups NNS N
. . N

Group NNP N
1 CD N
( ( N
15 CD N
patients NNS N
) ) N
received VBD N
radiation NN i
therapy NN i
totaling VBG N
4000 CD N
to TO N
4500 CD N
rads NNS N
in IN N
4 CD N
to TO N
5 CD N
weeks NNS N
. . N

Group NNP N
2 CD N
( ( N
13 CD N
patients NNS N
) ) N
received VBD N
1- JJ i
( ( i
2-chloroethyl JJ i
) ) i
-3-cyclohexyl-1-nitrosourea FW i
CCNU NNP i
) ) i
130 CD N
mg/sq JJ N
m NNS N
orally RB N
every DT N
6 CD N
weeks NNS N
. . N

Group NNP N
3 CD N
( ( N
13 CD N
patients NNS N
) ) N
received VBD N
radiation NN i
therapy NN i
plus CC i
CCNU NNP i
as IN N
for IN N
Groups NNP N
1 CD N
and CC N
2 CD N
. . N

When WRB N
the DT N
disease NN N
progressed VBD N
, , N
patients NNS N
in IN N
Groups NNP N
1 CD N
and CC N
2 CD N
were VBD N
crossed VBN N
over IN N
to TO N
receive VB N
CCNU NNP i
and CC N
irradiation NN N
respectively RB N
. . N

The DT N
median JJ o
survival NN o
time NN o
in IN N
these DT N
groups NNS N
was VBD N
188 CD N
, , N
259 CD N
, , N
and CC N
252 CD N
days NNS N
, , N
and CC N
the DT N
mean JJ N
survival NN o
263 CD N
, , N
262 CD N
, , N
and CC N
329 CD N
days NNS N
. . N

The DT N
median JJ o
time NN o
from IN o
diagnosis NN o
to TO o
crossover VB o
( ( o
Groups NNP o
1 CD o
and CC o
2 CD o
) ) o
or CC o
to TO o
progression NN o
( ( N
Group NNP N
3 CD N
) ) N
was VBD N
163 CD N
, , N
99 CD N
, , N
and CC N
220 CD N
days NNS N
, , N
and CC N
the DT N
mean JJ N
time NN N
was VBD N
172 CD N
, , N
108 CD N
, , N
and CC N
231 CD N
days NNS N
. . N

There EX N
was VBD N
no DT N
statistically RB N
significant JJ N
difference NN N
between IN N
the DT N
means NNS o
or CC o
medians NNS o
in IN N
any DT N
of IN N
these DT N
situations NNS N
. . N

-DOCSTART- -6667628- O O

Comparison NNP N
of IN N
the DT N
hypotensive JJ N
effects NNS N
of IN N
bendrofluazide NN i
, , i
bumetanide NN i
and CC i
xipamide NNP i
. . i

A NNP N
randomized JJ N
, , N
triple JJ N
crossover NN N
study NN N
was VBD N
carried VBN N
out RP N
in IN N
24 CD p
elderly JJ p
patients NNS p
requiring VBG p
chronic JJ i
diuretic JJ i
therapy NN i
to TO N
assess VB N
the DT N
different JJ N
hypotensive JJ N
effects NNS N
of IN N
a DT N
fixed JJ N
daily JJ i
dose NN i
of IN i
5 CD i
mg NNS i
bendrofluazide RB i
, , i
1 CD i
mg NN i
bumetanide NN i
and CC i
40 CD i
mg NN i
xipamide NN i
. . i

Each DT N
treatment NN N
was VBD N
given VBN N
for IN N
3 CD N
months NNS N
. . N

The DT N
results NNS N
showed VBD N
that IN N
no DT N
significant JJ N
weight NN o
change NN o
took VBD N
place NN N
during IN N
the DT N
study NN N
period NN N
. . N

There EX N
was VBD N
, , N
however RB N
, , N
a DT N
significant JJ N
( ( N
p NN N
less JJR N
than IN N
0.001 CD N
) ) N
decrease NN N
compared VBN N
to TO N
baseline VB o
values NNS o
both DT o
in IN o
systolic NN o
and CC o
diastolic JJ o
blood NN o
pressure NN o
during IN N
the DT N
xipamide JJ N
period NN N
and CC N
a DT N
decrease NN N
in IN N
diastolic JJ o
blood NN o
pressure NN o
( ( N
p NN N
less JJR N
than IN N
0.05 CD N
) ) N
when WRB N
taking VBG N
bumetanide NN i
. . i

Only RB N
minor JJ o
side-effects NNS o
were VBD N
reported VBN N
. . N

-DOCSTART- -24457421- O O

Improved VBN N
frontoparietal JJ o
white JJ o
matter NN o
integrity NN o
in IN N
overweight JJ p
children NNS p
is VBZ N
associated VBN N
with IN N
attendance NN N
at IN N
an DT N
after-school JJ i
exercise NN i
program NN i
. . i

Aerobic NNP N
fitness NN N
is VBZ N
associated VBN N
with IN N
white JJ o
matter NN o
integrity NN o
( ( o
WMI NNP o
) ) o
in IN N
adults NNS N
as IN N
measured VBN N
by IN N
diffusion NN o
tensor NN o
imaging NN o
( ( o
DTI NNP o
) ) o
. . N

This DT N
study NN N
examined VBD N
the DT N
effect NN N
of IN N
an DT N
8-month JJ N
exercise NN i
intervention NN i
on IN N
WMI NNP o
in IN N
children NNS p
. . p

Participants NNS N
were VBD N
18 CD p
sedentary JJ p
, , p
overweight JJ p
( ( p
BMI?85th NNP p
percentile NN p
) ) p
8- CD p
to TO p
11-year-old JJ p
children NNS p
( ( p
94 CD p
% NN p
Black NNP p
) ) p
, , p
randomly RB N
assigned VBN N
to TO N
either DT N
an DT N
aerobic JJ N
exercise NN N
( ( N
n=10 JJ N
) ) N
or CC N
sedentary JJ N
attention NN N
control NN N
group NN N
( ( N
n=8 RB N
) ) N
. . N

Each DT N
group NN N
was VBD N
offered VBN N
an DT N
instructor-led JJ i
after-school JJ i
program NN i
every DT i
school NN N
day NN N
for IN N
approximately RB N
8 CD N
months NNS N
. . N

Before IN N
and CC N
after IN N
the DT N
program NN N
, , N
all DT N
subjects NNS N
participated VBN N
in IN N
DTI NNP o
scans NNS o
. . o

Tractography NN i
was VBD i
conducted VBN N
to TO N
isolate VB N
the DT N
superior JJ N
longitudinal JJ N
fasciculus NN N
and CC N
investigate VB N
whether IN N
the DT N
exercise NN N
intervention NN N
affected VBD o
WMI NNP o
in IN o
this DT N
region NN N
. . N

There EX N
was VBD N
no DT N
group NN N
by IN N
time NN o
interaction NN o
for IN o
WMI NNP o
in IN o
the DT N
superior JJ N
longitudinal JJ N
fasciculus NN N
. . N

There EX N
was VBD N
a DT N
group NN o
by IN o
time NN o
by IN o
attendance NN o
interaction NN o
, , o
however RB N
, , N
such JJ N
that IN N
higher JJR o
attendance NN o
at IN o
the DT i
exercise NN i
intervention NN i
, , i
but CC N
not RB N
the DT i
control NN i
intervention NN i
, , i
was VBD N
associated VBN N
with IN o
increased JJ o
WMI NNP o
. . o

Heart NNP o
rate NN o
and CC o
the DT o
total JJ o
dose NN o
of IN o
exercise NN o
correlated VBN o
with IN o
WMI NNP o
changes NNS o
in IN o
the DT N
exercise NN N
group NN N
. . N

In IN N
the DT N
overall JJ N
sample NN N
, , N
increased VBD o
WMI NNP o
was VBD o
associated VBN N
with IN o
improved JJ o
scores NNS o
on IN o
a DT o
measure NN o
of IN o
attention NN o
and CC o
improved VBN o
teacher JJ o
ratings NNS o
of IN o
executive NN o
function NN o
. . o

This DT N
study NN N
indicates VBZ N
that IN N
participating VBG N
in IN N
an DT N
exercise NN i
intervention NN o
improves VBZ o
WMI NNP o
in IN o
children NNS N
as IN N
compared VBN N
to TO N
a DT N
sedentary JJ N
after-school JJ N
program NN N
. . N

-DOCSTART- -5575706- O O

Triamcinolone CD i
acetonide NN i
in IN N
the DT N
treatment NN N
of IN N
bursitis NN p
and CC p
other JJ p
foot NN p
disorders NNS p
. . p

-DOCSTART- -10682031- O O

[ JJ N
Administration NNP N
of IN N
tobramycin JJ i
aerosols NNS i
in IN N
patients NNS p
with IN p
nosocomial JJ p
pneumonia NN p
: : p
a DT N
preliminary JJ N
study NN N
] NNP N
. . N

OBJECTIVE CC N
The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
assess VB N
renal JJ o
and CC o
respiratory JJ o
tolerance NN o
of IN N
aerosolized JJ N
tobramycin NN i
in IN N
intubated JJ p
and CC p
mechanically RB p
ventilated JJ p
patients NNS p
with IN p
nosocomial JJ p
pneumonia NN p
. . p

PATIENTS NNP N
AND CC N
METHODS NNP N
This DT N
was VBD N
a DT N
multicenter NN N
, , N
randomized VBN N
, , N
double-blind JJ N
, , N
placebo NN N
controlled VBD N
study NN N
. . N

Thirty-eight NNP p
mechanically RB p
ventilated VBD p
patients NNS p
with IN p
documented JJ p
nosocomial JJ p
pneumonia NN p
were VBD p
included VBN p
. . p

Patients NNS N
treated VBD N
with IN N
intravenous JJ i
betalactam NNS i
and CC i
tobramycin NNS i
were VBD i
randomly RB i
allocated VBN i
to TO i
receive VB i
aerosolized VBN i
tobramycin NN i
( ( i
6 CD i
mg/kg/day NN i
, , i
n JJ i
= NNP i
21 CD i
) ) i
or CC i
placebo NN i
( ( i
n JJ i
= NNP i
17 CD i
) ) i
. . i

The DT i
aerosol NN i
was VBD i
administered VBN i
via IN i
a DT i
pneumatic JJ i
nebulizer NN i
once RB i
a DT i
day NN i
for IN i
5 CD i
days NNS i
. . i

RESULTS NNP N
Respiratory NNP o
tolerance NN o
was VBD o
good JJ o
in IN p
all DT p
but CC p
two CD p
patients NNS p
. . p

No DT o
acute JJ o
renal JJ o
failure NN o
occurred VBD N
. . N

By IN N
day NN N
10 CD N
, , N
7 CD N
patients NNS N
in IN N
the DT N
tobramycin NN N
group NN N
( ( N
35 CD N
% NN N
) ) N
had VBD N
been VBN N
extubated VBN o
versus NN N
3 CD N
in IN N
the DT N
placebo NN N
group NN N
( ( N
18.5 CD N
% NN N
, , N
p NN N
= NNP N
0.18 CD N
) ) N
. . N

By IN N
day NN N
28 CD N
, , N
6 CD N
patients NNS N
had VBD N
died VBN o
( ( N
2 CD N
in IN N
the DT N
tobramycin NN N
group NN N
and CC N
4 CD N
in IN N
the DT N
placebo NN N
group NN N
, , N
p VBP N
= RB N
0.23 CD N
) ) N
. . N

CONCLUSION NNP N
Aerosolized NNP N
tobramycin NN N
was VBD N
well RB N
tolerated VBN N
in IN N
ventilated JJ p
patients NNS p
with IN p
documented JJ p
nosocomial JJ p
pneumonia NN p
. . p

-DOCSTART- -7881454- O O

Analysis NN N
of IN N
multiple-dose JJ N
bioequivalence NN N
studies NNS N
. . N

In IN N
multiple-dose JJ i
bioequivalence NN i
studies NNS i
, , N
it PRP N
is VBZ N
possible JJ N
at IN N
steady JJ N
state NN N
to TO N
take VB N
repeated JJ N
measurements NNS N
of IN N
pharmacokinetic JJ o
variables NNS o
, , N
such JJ N
as IN N
area NN o
under IN o
the DT o
curve NN o
( ( o
AUC NNP o
) ) o
and CC N
the DT N
maximum JJ o
concentration NN o
( ( o
CMAX NNP o
) ) o
of IN N
the DT N
blood NN N
concentration-time NN N
profile NN N
, , N
within IN N
each DT N
period NN N
of IN N
a DT N
crossover NN N
design NN N
. . N

We PRP N
develop VBP N
a DT N
bivariate NN o
random NN o
effects NNS o
model NN o
for IN N
such JJ N
a DT N
situation NN N
in IN N
a DT N
2 CD N
x NN N
2 CD N
crossover NN N
design NN N
using VBG N
the DT N
natural JJ o
log NN o
scale NN o
for IN o
AUC NNP o
and CC o
CMAX NNP o
that WDT N
assumes VBZ N
no DT N
differential JJ N
carryover NN N
effects NNS N
and CC N
includes VBZ N
components NNS N
for IN N
inter- JJ N
and CC N
intrasubject JJ N
variability NN N
with IN N
respect NN N
to TO N
both DT N
formulations NNS N
. . N

We PRP N
derive VBP N
the DT N
uniformly JJ N
minimum JJ N
variance NN N
unbiased JJ N
estimators NNS N
, , N
which WDT N
also RB N
happen VBP N
to TO N
be VB N
restricted VBN N
maximum JJ N
likelihood NN N
estimators NNS N
, , N
and CC N
we PRP N
provide VBP N
a DT N
sample NN N
size NN N
formula NN N
. . N

-DOCSTART- -3236940- O O

Lack NN N
of IN N
antihistamine NN N
properties NNS N
of IN N
single JJ N
dose JJ N
cinnarizine NN i
in IN N
man NN p
. . p

A DT N
simple JJ N
way NN N
to TO N
study VB N
a DT N
histamine JJ N
antagonist NN N
in IN N
man NN p
is VBZ N
to TO N
observe VB N
the DT N
effect NN N
it PRP N
has VBZ N
on IN N
the DT N
magnitude NN N
of IN N
the DT N
skin JJ N
reaction NN N
to TO N
intradermal JJ N
histamine NN i
. . i

The DT N
aim NN N
of IN N
the DT N
present JJ N
study NN N
was VBD N
to TO N
evaluate VB N
the DT N
antihistamine JJ N
activity NN N
of IN N
single JJ N
oral JJ N
doses NNS N
of IN N
75 CD N
mg NNS N
cinnarizine VBP i
using VBG i
75 CD N
mg JJ N
diphenhydramine NN i
as IN i
control NN i
, , N
both DT N
being VBG N
compared VBN N
to TO N
placebo VB i
. . i

The DT N
study NN N
was VBD N
performed VBN N
with IN N
two CD p
groups NNS p
of IN p
5 CD p
healthy JJ p
subjects NNS p
, , p
each DT p
group NN p
receiving VBG p
one CD p
of IN p
the DT p
active JJ p
treatments NNS p
or CC p
placebo NN i
randomly RB p
under IN p
blind JJ p
conditions NNS p
. . p

All DT N
subjects NNS N
received VBN N
intradermal JJ N
injections NNS N
on IN N
the DT N
forearm NN N
of IN N
a DT N
0.05 CD N
ml NN N
saline JJ i
solution NN i
containing VBG N
5 CD N
micrograms NNS N
of IN N
histamine NN i
before IN N
and CC N
at IN N
different JJ N
times NNS N
after IN N
drug NN N
intake NN N
. . N

The DT N
histamine-induced JJ N
wheal JJ N
area NN N
was VBD N
measured VBN N
and CC N
, , N
after IN N
drug NN N
administration NN N
, , N
the DT N
percent NN N
decrease NN N
of IN N
the DT N
wheal JJ o
area NN o
was VBD N
calculated VBN N
. . N

Results NNS N
showed VBD N
that IN N
diphenhydramine NN o
produced VBD o
a DT o
significant JJ o
inhibition NN o
of IN o
the DT o
histamine-induced JJ o
wheal NN o
size NN o
at IN N
1.5 CD N
h NN N
which WDT N
lasted VBD N
up RB N
to TO N
4 CD N
h NNS N
after IN N
drug NN N
administration NN N
, , N
reaching VBG N
maximum JJ N
inhibition NN N
at IN N
2.5 CD N
h. NN N
After IN N
cinnarizine NN i
treatment NN N
no DT o
significant JJ o
decrease NN o
of IN o
the DT o
histamine-induced JJ o
wheal JJ o
area NN o
was VBD o
observed VBN o
at IN o
any DT o
time NN o
. . o

-DOCSTART- -23349254- O O

Influence NN N
of IN N
Aloe NNP i
arborescens NNS i
Mill NNP i
. . i

extract NN i
on IN N
selected VBN N
parameters NNS o
of IN N
pro-oxidant-antioxidant JJ o
equilibrium NN o
and CC N
cytokine JJ o
synthesis NN o
in IN N
rowers NNS p
. . p

This DT N
investigation NN N
examined VBD N
the DT N
effect NN N
of IN N
supplementation NN i
with IN i
Biostimine NNP i
, , i
extract NN i
from IN i
Aloe NNP i
arborescens NNS i
Mill NNP i
. . i

leaves NNS i
, , N
on IN N
the DT N
levels NNS N
of IN N
pro-oxidant-antioxidant JJ o
equilibrium NN o
markers NNS o
and CC N
anti- JJ N
and CC N
proinflammatory JJ o
cytokines NNS o
in IN N
rowers NNS p
subjected VBN p
to TO p
exhaustive VB p
exercise NN p
. . p

This DT N
double-blind NN N
study NN p
included VBD p
18 CD p
members NNS p
of IN p
the DT p
Polish JJ p
Rowing NNP p
Team NNP p
. . p

Subjects NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
the DT N
supplemented VBN N
group NN N
( ( N
n JJ N
= NNP N
9 CD N
) ) N
, , N
which WDT N
received VBD N
one CD N
ampoule NN N
of IN N
Biostimine NNP i
once RB N
daily RB N
for IN N
4 CD N
weeks NNS N
, , N
or CC N
to TO N
the DT N
placebo NN i
group NN N
( ( N
n JJ N
= NNP N
9 CD N
) ) N
. . N

Subjects NNS N
performed VBD N
a DT N
2,000-meter-maximum JJ N
test NN N
on IN N
a DT N
rowing NN N
ergometer NN N
at IN N
the DT N
beginning NN N
and CC N
end NN N
of IN N
the DT N
preparatory NN N
camp NN N
. . N

Blood NN N
samples NNS N
were VBD N
obtained VBN N
from IN N
the DT N
antecubital JJ N
vein NN N
before IN N
each DT N
exercise NN N
test NN N
, , N
1 CD N
min NN N
after IN N
completing VBG N
the DT N
test NN N
and CC N
after IN N
a DT N
24-hr JJ N
recovery NN N
period NN N
. . N

Superoxide NNP o
dismutase NN o
and CC o
glutathione NN o
peroxidase NN o
activity NN o
as RB N
well RB N
as IN N
the DT o
concentration NN o
of IN o
thiobarbituric JJ o
acid NN o
reactive JJ o
substances NNS o
( ( o
TBARS NNP o
) ) o
were VBD N
assessed VBN N
in IN N
erythrocytes NNS N
. . N

In IN N
addition NN N
, , N
total JJ o
antioxidant JJ o
capacity NN o
( ( o
TAC NNP o
) ) o
and CC o
creatine JJ o
kinase NN o
activity NN o
were VBD N
measured VBN N
in IN N
plasma NN N
samples NNS N
, , N
and CC N
cytokine NN o
( ( o
IL-6 NNP o
, , o
IL-10 NNP o
) ) o
concentrations NNS o
were VBD N
determined VBN N
in IN N
the DT N
serum NN N
. . N

Before IN N
and CC N
after IN N
Biostimine NNP i
supplementation NN i
, , N
exercise VBP N
significantly RB N
increased VBN N
the DT N
values NNS o
of IN o
SOD NNP o
, , o
IL-6 NNP o
, , o
IL-10 NNP o
, , o
and CC o
TBARS NNP o
in IN N
both DT N
groups NNS N
. . N

However RB N
, , N
postexercise NN N
and CC N
recovery NN N
levels NNS N
of IN N
TBARS NNP o
were VBD N
significantly RB N
lower JJR N
in IN N
athletes NNS N
receiving VBG N
Biostimine NNP i
than IN N
in IN N
controls NNS N
. . N

After IN N
supplementation NN N
, , N
TAC NNP o
was VBD N
the DT N
only JJ N
variable NN N
with IN N
the DT N
level NN N
being VBG N
significantly RB N
higher RBR N
in IN N
the DT N
supplemented JJ N
group NN N
than IN N
in IN N
the DT N
placebo NN i
group NN N
. . N

Consequently RB N
, , N
we PRP N
can MD N
conclude VB N
that DT N
Biostimine NNP i
supplementation NN i
reduces VBZ N
the DT N
postexercise NN N
level NN N
of IN N
TBARS NNP o
by IN N
increasing VBG N
the DT N
antioxidant JJ o
activity NN o
of IN o
plasma NN o
but CC N
has VBZ N
no DT N
effect NN N
on IN N
inflammatory NN o
markers NNS o
. . o

-DOCSTART- -21320312- O O

Enhancing VBG N
implementation NN N
of IN N
tobacco NN i
use NN i
prevention NN i
and CC i
cessation NN i
counselling VBG i
guideline NN i
among IN p
dental JJ p
providers NNS p
: : p
a DT N
cluster NN N
randomised VBN N
controlled VBN N
trial NN N
. . N

BACKGROUND NNP N
Tobacco NNP N
use NN N
adversely RB N
affects VBZ N
oral JJ N
health NN N
. . N

Tobacco NNP i
use NN i
prevention NN i
and CC i
cessation NN i
( ( i
TUPAC NNP i
) ) i
counselling VBG i
guidelines NNS i
recommend VBP N
that IN N
healthcare NN p
providers NNS p
ask VBP N
about IN N
each DT N
patient NN p
's POS p
tobacco NN N
use NN N
, , N
assess IN N
the DT N
patient NN N
's POS N
readiness NN N
and CC N
willingness NN N
to TO N
stop VB N
, , N
document NN N
tobacco NN p
use NN p
habits NNS p
, , N
advise VBP N
the DT N
patient NN N
to TO N
stop VB N
, , N
assist NN N
and CC N
help NN N
in IN N
quitting NN N
, , N
and CC N
arrange JJ N
monitoring NN N
of IN N
progress NN N
at IN N
follow-up JJ N
appointments NNS N
. . N

Adherence NN N
to TO N
such JJ N
guidelines NNS N
, , N
especially RB N
among IN N
dental JJ p
providers NNS p
, , N
is VBZ N
poor JJ N
. . N

To TO N
improve VB N
guideline NN N
implementation NN N
, , N
it PRP N
is VBZ N
essential JJ N
to TO N
understand VB N
factors NNS N
influencing VBG N
it PRP N
and CC N
find VB N
effective JJ N
ways NNS N
to TO N
influence VB N
those DT N
factors NNS N
. . N

The DT N
aim NN N
of IN N
the DT N
present JJ N
study NN N
protocol NN N
is VBZ N
to TO N
introduce VB N
a DT N
theory-based JJ i
approach NN i
to TO i
diagnose VB i
implementation NN i
difficulties NNS i
of IN i
TUPAC NNP i
counselling VBG i
guidelines NNS i
among IN i
dental JJ i
providers NNS i
. . i

METHODS NNP N
Theories NNPS o
of IN o
behaviour NN o
change NN o
have VBP N
been VBN N
used VBN N
to TO N
identify VB N
key JJ N
theoretical JJ N
domains NNS N
relevant VBP N
to TO N
the DT N
behaviours NN N
of IN N
healthcare JJ p
providers NNS p
involved VBN N
in IN N
implementing VBG N
clinical JJ N
guidelines NNS N
. . N

These DT N
theoretical JJ N
domains NNS N
will MD N
inform VB N
the DT N
development NN N
of IN N
a DT N
questionnaire NN o
aimed VBN N
at IN N
assessing VBG N
the DT N
implementation NN N
of IN N
the DT N
TUPAC NNP i
counselling VBG i
guidelines NNS i
among IN N
Finnish JJ p
municipal JJ p
dental JJ p
providers NNS p
. . p

Specific JJ N
items NNS N
will MD N
be VB N
drawn VBN N
from IN N
the DT N
guidelines NNS N
and CC N
the DT N
literature NN N
on IN N
TUPAC NNP i
studies NNS N
. . N

After IN N
identifying VBG N
potential JJ N
implementation NN N
difficulties NNS N
, , N
we PRP N
will MD N
design VB N
two CD N
interventions NNS N
using VBG N
theories NNS i
of IN i
behaviour JJ i
change NN i
to TO N
link VB N
them PRP N
with IN N
relevant JJ N
behaviour NN N
change NN N
techniques NNS N
aiming VBG N
to TO N
improve VB N
guideline NN i
adherence NN i
. . i

For IN N
assessing VBG N
the DT N
implementation NN N
of IN N
TUPAC NNP i
guidelines NNS i
, , N
the DT N
electronic JJ o
dental NN o
record NN o
audit NN o
and CC N
self-reported JJ o
questionnaires NNS o
will MD N
be VB N
used VBN N
. . N

DISCUSSION NNP N
To TO N
improve VB N
guideline NN N
adherence NN N
, , N
the DT N
theoretical-domains NNS N
approach NN N
could MD N
provide VB N
a DT N
comprehensive JJ N
basis NN N
for IN N
assessing VBG N
implementation NN N
difficulties NNS N
, , N
as RB N
well RB N
as IN N
designing VBG N
and CC N
evaluating VBG N
interventions NNS N
. . N

After IN N
having VBG N
identified VBN N
implementation NN N
difficulties NNS N
, , N
we PRP N
will MD N
design VB N
and CC N
test VB N
two CD N
interventions NNS N
to TO N
enhance VB N
TUPAC NNP i
guideline JJ i
adherence NN N
. . N

Using VBG N
the DT N
cluster NN N
randomised VBD N
controlled JJ N
design NN N
, , N
we PRP N
aim VBP N
to TO N
provide VB N
further JJ N
evidence NN N
on IN N
intervention NN N
effects NNS N
, , N
as RB N
well RB N
as IN N
on IN N
the DT N
validity NN N
and CC N
feasibility NN N
of IN N
the DT N
theoretical-domain JJ N
approach NN N
. . N

The DT N
empirical JJ N
data NNS N
collected VBN N
within IN N
this DT N
trial NN N
will MD N
be VB N
useful JJ N
in IN N
testing VBG N
whether IN N
this DT N
theoretical-domain JJ i
approach NN i
can MD N
improve VB N
our PRP$ N
understanding NN N
of IN N
the DT N
implementation NN N
of IN N
TUPAC NNP i
guidelines NNS i
among IN N
dental JJ p
providers NNS p
. . p

TRIAL NNP N
REGISTRATION NNP N
Current NNP N
Controlled NNP N
Trials NNP N
ISRCTN15427433 NNP N
. . N

-DOCSTART- -23212807- O O

Risperidone CD i
dosing NN p
in IN p
children NNS p
and CC p
adolescents NNS p
with IN p
autistic JJ p
disorder NN p
: : p
a DT N
double-blind NN N
, , N
placebo-controlled JJ N
study NN N
. . N

Efficacy NNP o
and CC N
safety NN o
of IN N
2 CD N
risperidone NN i
doses NNS N
were VBD N
evaluated VBN N
in IN N
children NNS p
and CC p
adolescents NNS p
with IN p
autism NN p
. . p

Patients NNS p
( ( p
N NNP p
= NNP p
96 CD p
; : p
5-17 CD p
years NNS p
) ) p
, , p
received VBD i
risperidone NN i
( ( i
low-dose JJ i
: : i
0.125 CD i
mg/day NN i
[ VBD i
20 CD i
to TO i
< VB i
45 CD i
kg NN i
] NN i
, , i
0.175 CD i
mg/day NN i
[ NNP i
> VBZ i
45 CD i
kg NN i
] NN i
or CC i
high-dose NN i
: : i
1.25 CD i
mg/day NN i
[ VBD i
20 CD i
to TO i
< VB i
45 CD i
kg NN i
] NN i
, , i
1.75 CD i
mg/day NN i
[ NNP i
> VBZ i
45 CD i
kg NN i
] NN i
) ) i
or CC i
placebo NN i
. . N

Mean JJ N
baseline NN N
( ( N
range VB N
27-29 JJ N
) ) N
to TO N
endpoint VB N
change NN o
in IN o
Aberrant NNP o
Behavior NNP o
Checklist-Irritability NNP o
( ( o
primary JJ o
endpoint NN o
) ) N
was VBD N
significantly RB N
greater JJR N
in IN N
the DT N
high-dose- NN N
( ( N
-12.4 JJ N
[ $ N
6.5 CD N
] NNP N
; : N
p VBZ N
< $ N
0.001 CD N
) ) N
, , N
but CC N
not RB N
low-dose JJ N
( ( N
-7.4 JJ N
[ $ N
8.1 CD N
] NNP N
; : N
p VBZ N
= $ N
0.164 CD N
) ) N
group NN N
, , N
versus NN N
placebo NN N
( ( N
-3.5 JJ N
[ $ N
10.7 CD N
] NN N
) ) N
. . N

Clinical JJ o
Global NNP o
Impressions-Severity NN o
and CC o
Children NNP o
's POS o
Yale-Brown JJ o
Obsessive NNP o
Compulsive NNP o
Scale NNP o
scores VBZ o
improved VBN o
significantly RB N
only RB p
in IN p
the DT p
high-dose JJ p
group NN p
, , p
consistent JJ p
with IN N
ABC-I JJ N
results NNS N
. . N

Somnolence NNP o
, , o
sedation NN o
and CC o
increased VBD o
appetite RB o
occurred VBN o
more RBR N
frequently RB N
in IN p
high-versus JJ p
low-dose JJ p
groups NNS p
. . p

Overall JJ p
, , o
increased VBD o
appetite RB o
occurred VBD o
most JJS N
frequently RB N
. . N

-DOCSTART- -23811316- O O

Arm-cranking JJ i
exercise NN i
reduced VBN N
oxidative JJ o
damage NN o
in IN N
adults NNS p
with IN p
chronic JJ p
spinal JJ p
cord NN p
injury NN p
. . p

OBJECTIVE UH N
To TO N
assess VB N
the DT N
effect NN N
of IN N
a DT N
12-week JJ N
arm-cranking JJ i
exercise NN i
program NN i
on IN N
reducing VBG N
oxidative JJ o
damage NN o
in IN N
untrained JJ p
adults NNS p
with IN p
chronic JJ p
spinal JJ p
cord NN p
injury NN p
( ( p
SCI NNP p
) ) p
. . p

DESIGN NNP N
Randomized NNP N
controlled VBD N
trial NN N
. . N

SETTING CC N
Community-based JJ N
supervised JJ N
intervention NN N
. . N

PARTICIPANTS NNP N
Male NNP p
adults NNS p
with IN p
complete JJ p
SCI NNP p
at IN p
or CC p
below IN p
the DT p
fifth JJ p
thoracic NN p
level NN p
( ( p
T5 NNP p
) ) p
( ( p
N=17 NNP p
) ) p
volunteered VBD p
for IN p
this DT p
study NN p
. . p

Participants NNS N
were VBD N
randomly RB N
allocated VBN N
to TO N
the DT N
intervention NN p
( ( p
n=9 JJ p
) ) p
or CC p
control NN i
( ( p
n=8 JJ p
) ) p
group NN p
using VBG N
a DT N
concealed JJ N
method NN N
. . N

INTERVENTION VB N
A DT N
12-week JJ i
arm-cranking JJ i
exercise NN i
program NN i
, , N
3 CD N
sessions/wk NN N
, , N
consisting VBG i
of IN i
warming-up JJ i
( ( i
10-15min JJ i
) ) i
followed VBN i
by IN i
a DT i
main JJ i
part NN i
in IN i
arm-crank JJ i
( ( N
20-30min JJ N
[ NN N
increasing VBG N
2min CD N
and CC N
30s CD N
every DT N
3wk CD N
] NN N
) ) N
at IN N
a DT N
moderate JJ N
work NN N
intensity NN N
of IN N
50 CD N
% NN N
to TO N
65 CD N
% NN N
of IN N
the DT N
heart NN N
rate NN N
reserve NN N
( ( N
starting VBG N
at IN N
50 CD N
% NN N
and CC N
increasing VBG N
5 CD N
% NN N
every DT N
3 CD N
weeks NNS N
) ) N
and CC N
by IN N
a DT N
cooling-down JJ i
period NN N
( ( N
5-10min JJ N
) ) N
. . N

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
Plasmatic NNP o
levels NNS o
of IN o
total JJ o
antioxidant JJ o
status NN o
as RB N
well RB N
as IN N
erythrocyte NN o
glutathione NN o
peroxidase NN o
activity NN o
were VBD N
measured VBN N
. . N

Lipid NNP o
and CC o
protein JJ o
oxidation NN o
were VBD N
determined VBN N
as IN N
malondialdehyde NN o
and CC o
carbonyl NN o
group NN o
levels NNS o
, , N
respectively RB N
. . N

Furthermore NNP N
, , N
physical JJ o
fitness NN o
and CC o
body NN o
composition NN o
were VBD N
assessed VBN N
. . N

RESULTS VB N
When WRB N
compared VBN N
with IN N
baseline NN N
results NNS N
, , N
maximum JJ o
oxygen NN o
consumption NN o
was VBD N
significantly RB N
increased VBN N
( ( N
P=.031 NNP N
) ) N
, , N
suggesting VBG N
an DT N
improvement NN N
in IN N
physical JJ o
fitness NN o
in IN N
the DT N
intervention NN N
group NN N
. . N

Regarding VBG N
the DT N
antioxidant NN N
defense NN N
system NN N
, , N
it PRP N
was VBD N
found VBN N
that IN N
both DT N
total JJ o
antioxidant NN o
status NN o
( ( N
P=.014 NNP N
) ) N
and CC N
erythrocyte $ o
glutathione NN o
peroxidase NN o
activity NN o
( ( N
P=.027 NNP N
) ) N
were VBD N
significantly RB N
increased VBN N
at IN N
the DT N
end NN N
of IN N
the DT N
training NN N
program NN N
. . N

As IN N
a DT N
consequence NN N
, , N
plasmatic JJ o
levels NNS o
of IN o
malondialdehyde NN o
( ( N
P=.008 NNP N
) ) N
and CC N
carbonyl JJ N
groups NNS N
( ( N
P=.022 NNP N
) ) N
were VBD N
significantly RB N
reduced VBN N
. . N

CONCLUSION VB N
A DT N
12-week JJ N
arm-cranking JJ i
exercise NN i
program NN i
improved VBD N
the DT N
antioxidant NN o
defense NN o
system NN o
in IN p
adults NNS p
with IN p
chronic JJ p
SCI NNP p
, , N
which WDT N
may MD N
finally RB N
attenuate VB N
both DT N
lipid JJ o
and CC o
protein JJ o
oxidation NN o
in IN N
this DT N
population NN N
. . N

-DOCSTART- -1699814- O O

A DT N
stable JJ i
prostacyclin NN i
analogue NN i
( ( i
iloprost NN i
) ) i
in IN N
the DT N
treatment NN N
of IN N
ischaemic JJ p
ulcers NNS p
of IN p
the DT p
lower JJR p
limb NN p
. . p

A DT N
Scandinavian-Polish JJ p
placebo NN i
controlled VBN p
, , p
randomised VBN p
multicenter NN p
study NN p
. . p

The DT N
clinical JJ o
efficacy NN o
of IN N
the DT N
prostacyclin NN i
analogue NN i
iloprost NN i
was VBD N
studied VBN N
during IN N
a DT N
2 CD N
week NN N
treatment NN N
and CC N
6 CD N
month NN N
follow-up JJ N
period NN N
in IN N
103 CD p
patients NNS p
with IN p
ischaemic JJ p
ulcers NNS p
who WP p
were VBD p
randomised VBN p
to TO p
receive VB p
active JJ i
treatment NN i
or CC i
placebo NN i
. . i

Responders NNS N
were VBD N
defined VBN N
as IN N
those DT N
patients NNS N
who WP N
achieved VBD N
healing NN N
of IN N
at IN N
least JJS N
one CD N
third NN N
of IN N
the DT N
ulcer JJ N
area NN N
during IN N
the DT N
study NN N
period NN N
. . N

The DT N
overall JJ N
responder NN o
rate NN o
was VBD N
41.3 CD N
% NN N
, , N
compared VBN N
with IN N
25 CD N
% NN N
for IN N
the DT N
control NN N
group NN N
( ( N
P NNP N
= NNP N
0.086 CD N
) ) N
. . N

Side JJ N
effects NNS N
including VBG N
flushing NN o
and CC o
headache NN o
, , N
were VBD N
common JJ N
. . N

The DT N
study NN N
population NN N
had VBD N
a DT N
mortality NN o
of IN N
23 CD N
% NN N
during IN N
the DT N
6 CD N
month NN N
period NN N
, , N
the DT N
amputation NN o
rate NN o
was VBD N
43.5 CD N
% NN N
for IN N
iloprost NN i
and CC N
50 CD N
% NN N
for IN N
placebo NN i
treated VBN N
patients NNS N
. . N

In IN N
this DT N
severely RB N
diseased JJ N
population NN N
of IN N
patients NNS N
a DT N
treatment NN N
period NN N
limited VBD N
to TO N
2 CD N
weeks NNS N
did VBD N
not RB N
sufficiently RB N
improve VB N
ulcer NN o
healing NN o
. . o

-DOCSTART- -22045826- O O

Single NNP i
negative JJ i
colposcopy NN i
: : i
is VBZ N
it PRP N
enough RB N
to TO N
rule VB N
out IN N
high-grade JJ N
disease NN N
? . N
It PRP N
has VBZ N
been VBN N
proposed VBN N
that IN N
women NNS p
who WP p
have VBP p
a DT p
negative JJ p
colposcopic NN p
examination NN p
or CC p
who WP p
have VBP p
no DT p
cervical JJ p
intraepithelial JJ p
neoplasia NN p
( ( p
CIN NNP p
) ) p
on IN p
colposcopic NN i
biopsy NN i
can MD N
be VB N
safely RB N
returned VBN N
to TO N
routine VB N
screening VBG N
with IN N
the DT N
next JJ N
visit NN N
being VBG N
three CD N
or CC N
five CD N
years NNS N
later RB N
. . N

We PRP N
present JJ N
data NNS N
regarding VBG N
551 CD p
women NNS p
who WP p
had VBD p
colposcopy NN i
in IN p
Wales NNP p
for IN p
a DT p
low-grade JJ p
cytological JJ p
abnormality NN p
and CC p
who WP p
were VBD p
followed VBN p
through IN p
Cervical NNP p
Screening NNP p
Wales NNP p
for IN p
subsequent JJ p
CIN NNP p
. . p

Of IN N
436 CD N
women NNS N
declared VBD N
CIN NNP o
free JJ o
initially RB N
, , N
26 CD N
( ( N
6.0 CD N
% NN N
) ) N
had VBD N
high-grade JJ o
CIN NNP o
diagnosed VBD N
on IN N
follow-up NN N
. . N

We PRP N
suggest VBP N
that IN N
additional JJ N
screening NN N
at IN N
an DT N
interval NN N
of IN N
less JJR N
than IN N
three CD N
years NNS N
should MD N
be VB N
offered VBN N
to TO N
women NNS p
with IN p
a DT p
negative JJ p
colposcopy NN p
or CC p
a DT p
biopsy NN p
without IN p
CIN NNP p
. . p

-DOCSTART- -24006504- O O

Intravesical JJ i
seeding NN i
of IN i
upper JJ i
urinary JJ i
tract NN i
urothelial JJ i
carcinoma NN i
cells NNS i
during IN N
nephroureterectomy NN i
: : i
an DT N
exploratory JJ N
analysis NN N
from IN N
the DT N
THPMG NNP N
trial NN N
. . N

OBJECTIVE CC N
The DT N
Pirarubicin NNP N
Monotherapy NNP N
Study NNP N
Group NNP N
trial NN N
was VBD N
a DT N
randomized JJ N
Phase NNP N
II NNP N
study NN N
that WDT N
evaluated VBD N
the DT N
efficacy NN N
of IN N
intravesical JJ N
instillation NN N
of IN N
pirarubicin NN i
in IN N
the DT N
prevention NN N
of IN N
bladder NN N
recurrence NN N
after IN N
nephroureterectomy NN p
for IN p
upper JJ p
urinary JJ p
tract NN p
urothelial JJ p
carcinoma NN p
. . p

This DT N
study NN N
conducted VBD N
further JJ N
analysis NN N
of IN N
the DT N
Pirarubicin NNP N
Monotherapy NNP N
Study NNP N
Group NNP N
cohort NN N
, , N
focusing VBG N
on IN N
intravesical JJ i
seeding NN i
of IN i
cancer NN i
cells NNS i
. . i

METHODS NNP N
Using VBG N
the DT N
data NN p
from IN p
the DT p
Pirarubicin NNP p
Monotherapy NNP p
Study NNP p
Group NNP p
trial NN p
, , N
bladder VB o
recurrence-free JJ o
survival NN o
rates NNS o
and CC o
factors NNS o
associated VBN o
with IN o
bladder NN o
recurrence NN o
in IN N
the DT N
control NN N
group NN N
were VBD N
analyzed VBN N
. . N

RESULTS NNP N
Of IN N
36 CD p
patients NNS p
in IN p
the DT p
control NN i
group NN p
, , p
14 CD p
with IN p
positive JJ o
urine JJ o
cytology NN o
had VBD N
more RBR N
frequent JJ N
recurrence NN o
when WRB N
compared VBN N
with IN N
the DT N
22 CD p
patients NNS p
with IN p
negative JJ p
cytology NN p
( ( p
P NNP p
= NNP p
0.004 CD p
) ) p
. . p

Based VBN N
on IN N
the DT N
multivariate NN N
analysis NN N
in IN N
the DT N
control NN N
group NN N
, , N
voided VBD N
urine JJ N
cytology NN N
was VBD N
an DT N
independent JJ N
predictive JJ N
factor NN N
of IN N
bladder NN N
recurrence NN N
( ( N
hazard JJ N
ratio NN N
, , N
5.54 CD N
; : N
95 CD N
% NN N
confidence NN N
interval JJ N
1.12-27.5 JJ N
; : N
P NNP N
= NNP N
0.036 CD N
) ) N
. . N

Of IN N
72 CD p
patients NNS p
in IN p
the DT p
Pirarubicin NNP p
Monotherapy NNP p
Study NNP p
Group NNP p
trial NN p
, , N
31 CD N
had VBD N
positive JJ N
urine JJ o
cytology NN o
. . o

Among IN p
the DT p
31 CD p
patients NNS p
, , p
17 CD p
patients NNS p
who WP p
received VBD p
pirarubicin JJ i
instillation NN i
had VBD N
fewer JJR N
recurrences NNS o
when WRB N
compared VBN N
with IN N
14 CD p
patients NNS p
who WP p
received VBD p
control NN i
treatment NN p
( ( N
P NNP N
= NNP N
0.0001 CD N
) ) N
. . N

On IN N
multivariate NN N
analysis NN N
, , N
pirarubicin JJ i
instillation NN i
was VBD N
an DT N
independent JJ N
predictor NN N
of IN N
better JJR N
recurrence-free JJ o
survival NN o
rates NNS o
in IN N
the DT N
patients NNS N
with IN N
positive JJ N
urine JJ N
cytology NN N
( ( N
hazard JJ N
ratio NN N
, , N
0.02 CD N
; : N
95 CD N
% NN N
confidence NN N
interval NN N
, , N
0.00-0.53 JJ N
; : N
P NNP N
= NNP N
0.018 CD N
) ) N
. . N

Of IN N
21 CD N
patients NNS N
with IN N
bladder NN N
recurrence NN N
, , N
17 CD N
had VBD N
recurrent JJ o
tumor NN o
around IN o
cystotomy NN o
or CC o
in IN o
the DT o
bladder NN o
neck NN o
compromised VBN N
by IN N
the DT N
urethral JJ N
catheter NN N
, , N
supporting VBG N
the DT N
notion NN N
that IN N
tumor NN N
cells NNS N
seeded VBN N
in IN N
the DT N
injured JJ N
urothelium NN N
. . N

CONCLUSIONS NNP N
Intravesical NNP i
instillation NN i
of IN i
pirarubicin NN i
immediately RB N
after IN N
nephroureterectomy NN i
significantly RB N
reduced VBD N
the DT N
bladder NN o
recurrence NN o
rate NN o
in IN N
patients NNS N
with IN N
positive JJ N
voided JJ N
urine JJ N
cytology NN N
. . N

The DT N
results NNS N
suggest VBP N
that IN N
intravesical JJ N
seeding NN N
of IN N
upper JJ N
urinary JJ N
tract NN N
urothelial JJ N
carcinoma NN N
occurs VBZ N
during IN N
nephroureterectomy NN N
. . N

-DOCSTART- -16907931- O O

Atorvastatin NNP i
and CC i
quinapril JJ i
inhibit NN N
blood NN N
coagulation NN N
in IN N
patients NNS p
with IN p
coronary JJ p
artery NN p
disease NN p
following VBG N
28 CD N
days NNS N
of IN N
therapy NN N
. . N

BACKGROUND IN N
We PRP N
evaluated VBD N
the DT N
antithrombotic JJ N
effects NNS N
of IN N
statins NNS i
and CC N
angiotensin-converting JJ i
enzyme NN i
inhibitor NN i
( ( i
ACEI NNP i
) ) i
drugs NNS i
in IN N
patients NNS p
with IN p
coronary JJ p
artery NN p
disease NN p
( ( p
CAD NNP p
) ) p
. . p

METHODS NNP N
AND CC N
RESULTS NNP N
Blood NNP N
coagulation NN N
at IN N
the DT N
site NN N
of IN N
microvascular JJ N
injury NN N
was VBD N
assessed VBN N
in IN N
26 CD p
males NNS p
with IN p
CAD NNP p
before IN p
and CC p
after IN p
treatment NN p
with IN p
quinapril NN i
( ( p
10 CD p
mg RB p
day-1 NN p
; : p
n=13 CC p
) ) p
or CC p
atorvastatin NN i
( ( p
40 CD p
mg RB p
day-1 NN p
; : p
n=13 CC p
) ) p
for IN p
4 CD p
weeks NNS p
and CC p
an DT p
additional JJ p
4 CD p
weeks NNS p
of IN p
combined JJ p
therapy NN p
( ( N
quinapril+atorvastatin NN N
) ) N
. . N

Rates NNS o
of IN o
prothrombin NN o
and CC o
factor NN o
V NNP o
activation NN o
( ( o
FVa NNP o
) ) o
, , o
fibrinogen NN o
( ( o
Fbg NNP o
) ) o
cleavage NN o
and CC o
FVa NNP o
inactivation NN o
showed VBD N
that IN N
both DT N
quinapril NNS N
and CC N
atorvastatin NN N
decreased VBD N
the DT N
rates NNS N
of IN N
: : N
formation NN o
of IN o
thrombin JJ o
B-chain NNP o
( ( N
by IN N
30.6 CD N
% NN N
, , N
P=0.007 NNP N
; : N
and CC N
by IN N
34.3 CD N
% NN N
, , N
P=0.003 NNP N
) ) N
, , N
formation NN o
of IN o
thrombin-antithrombin NN o
complexes NNS o
( ( N
by IN N
30.4 CD N
% NN N
, , N
P=0.0002 NNP N
; : N
and CC N
by IN N
40 CD N
% NN N
, , N
P=0.001 NNP N
) ) N
, , N
FV NNP o
activation NN o
( ( N
by IN N
19.1 CD N
% NN N
, , N
P=0.03 NNP N
; : N
and CC N
by IN N
21.8 CD N
% NN N
, , N
P=0.005 NNP N
) ) N
and CC N
Fbg NNP o
depletion NN o
( ( N
by IN N
29.2 CD N
% NN N
, , N
P=0.004 NNP N
; : N
and CC N
by IN N
32.7 CD N
% NN N
, , N
P=0.001 NNP N
) ) N
. . N

Atorvastatin NNP N
alone RB N
accelerated VBD N
FVa NNP o
inactivation NN o
( ( N
P=0.005 NNP N
) ) N
. . N

A DT N
further JJ N
4 CD N
weeks NNS N
of IN N
combined JJ N
therapy NN N
enhanced VBD N
most RBS N
anticoagulant JJ o
effects NNS o
only RB N
when WRB N
atorvastatin NN N
was VBD N
added VBN N
to TO N
quinapril VB N
. . N

CONCLUSIONS NNP N
In IN N
CAD NNP p
patients NNS p
, , N
atorvastatin NN N
and CC N
quinapril NN N
slowed VBD N
blood NN N
clotting NN N
at IN N
the DT N
site NN N
of IN N
microvascular JJ N
injury NN N
after IN N
28 CD N
days NNS N
of IN N
therapy NN N
. . N

Addition NN N
of IN N
atorvastatin NN i
to TO N
quinapril VB i
, , N
but CC N
not RB N
quinapril VB i
to TO N
the DT N
statin NN i
, , N
enhanced VBD N
the DT N
anticoagulant JJ N
effects NNS N
. . N

Our PRP$ N
findings NNS N
might MD N
help VB N
explain VB N
the DT N
reduced JJ N
risk NN N
of IN N
myocardial JJ N
infarction NN N
or CC N
stroke NN N
in IN N
patients NNS N
treated VBN N
with IN N
statins NNS i
and/or VBP N
ACEIs NNP N
and CC N
the DT N
lack NN N
of IN N
clinical JJ N
benefits NNS N
from IN N
ACEI NNP N
added VBD N
to TO N
prior VB N
statin JJ N
therapy NN N
in IN N
patients NNS N
at IN N
cardiovascular JJ N
risk NN N
. . N

-DOCSTART- -19544653- O O

[ NN N
Clinilal NNP N
study NN N
of IN N
medical JJ i
ozone NN i
therapy NN i
in IN N
chronic JJ p
hepatitis NN p
B NNP p
of IN p
20 CD p
patients NNS p
] JJ p
. . N

OBJECTIVE NN N
To TO N
study VB N
the DT N
effect NN N
of IN N
medical JJ i
ozone NN i
in IN N
the DT N
treatment NN N
of IN N
chronic JJ p
hepatitis NN p
B NNP p
. . p

METHODS NNP N
42 CD p
patients NNS p
with IN p
chronic JJ p
hepatitis NN p
B NNP p
were VBD N
divided VBN N
randomly RB N
into IN N
two CD N
groups NNS N
. . N

22 CD N
patients NNS N
treated VBN N
with IN N
basic JJ i
therapy NN i
were VBD N
as IN N
a DT N
control NN N
group NN N
. . N

20 CD N
patients NNS N
treated VBN N
with IN N
basic JJ i
therapy NN i
plus CC i
ozone NN i
therapy NN i
were VBD N
taken VBN N
as IN N
a DT N
treatment NN N
group NN N
. . N

Index NN o
of IN o
biochemistry NN o
and CC N
virology NN o
were VBD N
studied VBN N
at IN N
initial JJ N
and CC N
post-treatment JJ N
8 CD N
weeks NNS N
. . N

RESULTS NNP N
After IN N
the DT N
treatment NN N
, , N
liver JJ N
function NN N
of IN N
the DT N
treatment NN N
group NN N
and CC N
the DT N
control NN N
group NN N
had VBD N
more RBR N
significant JJ N
improvement NN N
. . N

The DT N
treatment NN N
group NN N
complete JJ o
effective JJ o
and CC N
partial JJ o
effective JJ o
were VBD N
10 CD N
% NN N
and CC N
35 CD N
% NN N
difference NN N
. . N

The DT N
control NN N
group NN N
complete JJ N
effective JJ N
and CC N
partial JJ N
effective JJ N
were VBD N
4.6 CD N
% NN N
and CC N
13.6 CD N
% NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

CONCLUSION NNP N
Treatment NNP N
of IN N
medical JJ N
ozone NN N
on IN N
patients NNS p
with IN p
chronic JJ p
hepatitis NN p
B NNP p
is VBZ N
effective JJ o
. . o

-DOCSTART- -3532353- O O

Treatment NN o
of IN o
gastrointestinal JJ o
cancer NN o
: : o
the DT N
Southeastern NNP p
Cancer NNP p
Study NNP p
Group NNP p
experience NN p
, , p
1979 CD p
to TO p
1983 CD p
. . p

The DT N
treatment NN N
of IN N
gastrointestinal JJ o
cancer NN o
was VBD N
studied VBN N
in IN N
20 CD N
phase NN N
I PRP N
, , N
II NNP N
, , N
and CC N
III NNP N
clinical JJ N
trials NNS N
from IN p
1979 CD p
to TO p
1983 CD p
at IN p
30 CD p
member NN p
institutions NNS p
of IN p
the DT p
Southeastern NNP p
Cancer NNP p
Study NNP p
Group NNP p
( ( p
SECSG NNP p
) ) p
. . p

These DT N
studies NNS N
used VBD N
both DT N
new JJ i
and CC i
commercially RB i
available JJ i
drugs NNS i
, , N
as RB N
well RB N
as IN N
surgery NN i
and/or NN i
radiation NN i
therapy NN i
in IN N
1,087 CD p
patients NNS p
. . p

No DT N
significant JJ N
benefit NN N
was VBD N
seen VBN N
from IN N
18 CD i
agents NNS i
, , N
and CC N
one CD N
agent NN N
is VBZ N
still RB N
under IN N
evaluation NN N
. . N

Unfortunately RB N
, , N
no DT N
recommendations NNS N
can MD N
be VB N
drawn VBN N
from IN N
these DT N
studies NNS N
that WDT N
would MD N
alter VB N
presently RB N
accepted VBN N
methods NNS N
of IN N
management NN N
. . N

Adenocarcinoma NNP N
of IN N
the DT N
gastrointestinal JJ N
tract NN N
remains VBZ N
a DT N
major JJ N
challenge NN N
to TO N
tumor VB N
biologists NNS N
and CC N
clinical JJ N
oncologists NNS N
because IN N
it PRP N
is VBZ N
generally RB N
resistant JJ N
to TO N
chemotherapy VB i
and CC N
radiation NN i
therapy NN i
, , N
yet RB N
common JJ N
enough RB N
to TO N
represent VB N
a DT N
vital JJ N
public JJ N
health NN N
concern NN N
in IN N
America NNP p
. . p

-DOCSTART- -15101027- O O

The DT N
reversibility NN N
of IN N
increased JJ N
airways NNS N
resistance NN N
in IN N
chronic JJ p
heart NN p
failure NN p
measured VBN N
by IN N
impulse JJ N
oscillometry NN N
. . N

BACKGROUND NNP N
Patients NNPS p
with IN p
chronic JJ p
heart NN p
failure NN p
complain NN N
of IN N
breathlessness NN N
and CC N
fatigue NN N
on IN N
exercise NN N
. . N

Airways NNS N
resistance NN N
is VBZ N
increased VBN N
and CC N
lung JJ N
compliance NN N
is VBZ N
reduced VBN N
in IN N
chronic JJ p
heart NN p
failure NN p
patients NNS p
. . p

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
determine VB N
whether IN N
the DT N
pulmonary JJ N
abnormalities NNS N
are VBP N
reversible JJ N
and CC N
whether IN N
any DT N
improvements NNS N
lead VBP N
to TO N
changes NNS N
to TO N
exercise VB N
capacity NN N
or CC N
symptoms NNS N
. . N

METHODS NNP N
Twelve NNP p
patients NNS p
with IN p
stable JJ p
chronic JJ p
heart NN p
failure NN p
and CC p
10 CD p
matched VBD p
controls NNS p
underwent JJ N
repeated VBD N
assessment NN N
of IN N
airways NNS N
resistance NN N
using VBG N
impulse JJ N
oscillometry NN i
and CC i
peak NN i
exercise NN i
testing VBG i
with IN i
metabolic NNP i
gas NN i
exchange NN i
after IN N
receiving VBG N
nebulized JJ i
saline NN i
as IN i
placebo NN i
or CC N
combined VBN i
salbutamol NNS i
and CC i
ipratropium NN i
bromide NN i
in IN N
a DT N
double-blind JJ N
crossover NN N
randomized VBN N
fashion NN N
. . N

RESULTS JJ N
Patients NNS N
had VBD N
lower JJR N
peak NN o
oxygen NN o
consumption NN o
and CC N
a DT N
steeper JJ N
slope NN N
relating VBG N
ventilation NN N
to TO N
carbon VB N
dioxide NN N
production NN N
than IN N
controls NNS N
. . N

Bronchodilators NNS N
reduced VBD N
peripheral JJ N
airways NNS N
resistance NN N
in IN N
patients NNS N
( ( N
0.53 CD N
versus NN N
0.38 CD N
, , N
P NNP N
< NNP N
.02 NNP N
) ) N
and CC N
controls NNS N
( ( N
0.21 CD N
versus NN N
0.19 CD N
, , N
P NNP N
< NNP N
.005 NNP N
) ) N
and CC N
increased JJ N
measures NNS N
of IN N
compliance NN N
in IN N
both DT N
groups NNS N
. . N

There EX N
was VBD N
no DT N
effect NN N
on IN N
the DT N
peak NN o
oxygen NN o
consumption NN o
, , o
exercise NN o
time NN o
, , o
ventilation NN o
to TO o
carbon VB o
dioxide NN o
slope NN o
, , o
or CC o
anaerobic JJ o
threshold NN o
. . o

There EX N
was VBD N
an DT N
increase NN N
in IN N
peak JJ o
tidal JJ o
volume NN o
( ( o
VT NNP o
) ) o
in IN N
both DT N
groups NNS N
but CC N
this DT N
did VBD N
not RB N
lead VB N
to TO N
an DT N
increase NN N
in IN N
peak JJ o
ventilation NN o
. . o

The DT N
slope NN N
relating VBG N
symptoms NNS N
to TO N
ventilation NN o
( ( N
ie JJ N
, , N
Borg/VE NNP N
) ) N
was VBD N
significantly RB N
reduced VBN N
in IN N
the DT N
patients NNS N
after IN N
bronchodilators NNS N
( ( N
17 CD N
% NN N
+/-8 JJ N
% NN N
, , N
P NNP N
< NNP N
.05 NNP N
) ) N
. . N

The DT N
relationship NN N
between IN N
the DT N
improvement NN N
in IN N
VT NNP N
and CC N
reduction NN N
in IN N
gradient NN N
of IN N
the DT N
Borg/VE NNP o
slope NN o
was VBD N
significant JJ N
( ( N
r=.40 NN N
, , N
P NNP N
< NNP N
.05 NNP N
) ) N
. . N

CONCLUSIONS NNP N
Nebulized NNP N
bronchodilators NNS N
improve VBP N
airways NNS o
resistance NN o
, , o
lung NN o
reactance NN o
, , o
and CC o
peak JJ o
tidal JJ o
volume NN o
during IN N
exercise NN N
in IN N
chronic JJ N
heart NN N
failure NN N
but CC N
do VBP N
not RB N
increase VB N
peak NN N
exercise NN N
capacity NN N
. . N

They PRP N
do VBP N
, , N
however RB N
, , N
reduce VB N
the DT N
symptom NN o
of IN o
breathlessness NN o
. . o

-DOCSTART- -22079469- O O

Evaluation NN N
of IN N
oral JJ N
beclomethasone NN i
dipropionate NN i
for IN N
prevention NN N
of IN N
acute JJ N
graft-versus-host JJ N
disease NN N
. . N

Results NNS N
from IN N
two CD N
randomized JJ N
trials NNS N
have VBP N
shown VBN N
that IN N
oral JJ i
beclomethasone NN i
dipropionate NN i
( ( i
BDP NNP i
) ) i
is VBZ N
effective JJ N
for IN N
treatment NN N
of IN N
acute JJ N
gastrointestinal JJ N
graft-versus-host NN N
disease NN N
. . N

Here RB N
, , N
we PRP N
report VBP N
results NNS N
of IN N
a DT N
double-blind NN N
, , N
randomized VBN N
placebo-controlled JJ N
phase NN N
II NNP N
study NN N
designed VBN N
to TO N
test VB N
the DT N
hypothesis NN N
that WDT N
acute VBZ N
graft-versus-host JJ N
disease NN N
could MD N
be VB N
prevented VBN N
by IN N
administration NN N
of IN N
oral JJ i
BDP NNP i
, , N
beginning VBG N
before IN N
hematopoietic JJ N
cell NN N
transplantation NN N
and CC N
continuing VBG N
until IN N
day NN N
75 CD N
after IN N
hematopoietic JJ N
cell NN N
transplantation NN N
after IN N
myeloablative JJ N
conditioning NN N
. . N

Study NNP i
drug NN i
( ( i
BDP NNP i
or CC i
placebo NN i
) ) i
was VBD N
administered VBN N
as IN N
1-mg JJ N
immediate-release JJ N
formulation NN N
plus IN N
1-mg JJ N
delayed-release JJ N
formulation NN N
orally RB N
four CD N
times NNS N
daily RB N
. . N

According VBG N
to TO N
the DT N
primary JJ N
endpoint NN N
, , N
systemic JJ o
glucocorticoid NN o
treatment NN o
for IN o
graft-versus-host JJ o
disease NN o
was VBD N
given VBN N
to TO p
60 CD p
of IN p
the DT p
92 CD p
participants NNS p
( ( p
65 CD p
% NN p
) ) p
in IN p
the DT p
BDP NNP i
arm NN p
, , p
versus NN p
31 CD p
of IN p
46 CD p
participants NNS p
( ( p
67 CD p
% NN p
) ) p
in IN p
the DT p
placebo NN i
arm NN p
. . N

The DT N
secondary JJ o
efficacy NN o
endpoints NNS o
showed VBD N
no DT o
statistically RB o
significant JJ o
differences NNS o
between IN N
the DT N
two CD N
arms NNS N
. . N

The DT N
proportion NN o
of IN o
participants NNS o
who WP o
took VBD o
at IN o
least JJS o
90 CD o
% NN o
of IN o
the DT o
prescribed JJ o
study JJ o
drug NN o
during IN N
the DT N
first JJ N
4 CD N
weeks NNS N
after IN N
hematopoietic JJ o
cell NN o
transplantation NN o
was VBD N
54 CD N
% NN N
overall JJ N
. . N

Lower JJR N
severity NN o
of IN o
mucositis NN o
strongly RB N
correlated VBN N
with IN N
higher JJR N
adherence NN o
to TO N
the DT N
schedule NN N
of IN N
study JJ N
drug NN N
administration NN N
. . N

Inconsistent JJ N
adherence NN o
related VBN N
to TO N
mucositis VB N
during IN N
recovery NN N
after IN N
myeloablative JJ i
conditioning NN i
may MD N
have VB N
obscured VBN N
a DT N
beneficial JJ N
therapeutic JJ N
effect NN N
in IN N
the DT N
current JJ N
study NN N
. . N

-DOCSTART- -24716586- O O

Application NN N
of IN N
the DT N
Itch NNP N
Severity NNP N
Score NNP N
in IN N
patients NNS p
with IN p
moderate-to-severe JJ p
plaque JJ p
psoriasis NN p
: : p
Clinically NNP N
important JJ N
difference NN N
and CC N
responder NN N
analyses NNS N
. . N

The DT N
Itch NNP N
Severity NNP N
Score NNP N
( ( N
ISS NNP N
) ) N
, , N
a DT N
0-10 JJ N
numeric JJ N
rating NN N
scale NN N
, , N
was VBD N
used VBN N
to TO N
assess VB N
pruritus NN N
due JJ N
to TO N
psoriasis VB N
in IN N
a DT N
Phase NNP N
2 CD N
b NN N
trial NN N
of IN N
tofacitinib NN N
, , N
a DT N
novel JJ N
oral JJ N
Janus NNP N
kinase NN N
inhibitor NN p
. . p

197 CD p
patients NNS p
with IN p
moderate-to-severe JJ p
plaque NN p
psoriasis NN p
were VBD p
randomized VBN p
to TO p
tofacitinib VB i
2 CD i
, , i
5 CD i
or CC i
15 CD i
mg JJ i
twice RB i
daily RB i
, , i
or CC i
placebo NN i
. . i

The DT i
ISS NNP N
was VBD N
recorded VBN N
daily RB N
from IN N
baseline NN N
to TO N
week NN N
2 CD N
and CC N
at IN N
study NN N
visits NNS N
. . N

Following VBG N
good JJ N
and CC N
recommended VBD N
research NN N
practice NN N
, , N
we PRP N
performed VBD N
analyses NNS N
to TO N
examine VB N
the DT N
clinically RB N
important JJ N
differences NNS N
( ( N
CID NNP N
) ) N
( ( N
between-group JJ N
difference NN N
or CC N
within-group JJ N
difference NN N
) ) N
and CC N
clinically RB N
important JJ N
responders NNS N
( ( N
CIR NNP N
) ) N
( ( N
within-patient JJ N
change NN N
) ) N
for IN N
the DT N
ISS NNP N
. . N

The DT N
CID NNP N
and CC N
CIR NNP N
were VBD N
defined VBN N
using VBG o
Patient NNP o
Global NNP o
Assessment NNP o
of IN o
psoriasis NN o
as IN o
an DT N
anchor NN N
and CC N
were VBD N
estimated VBN N
with IN N
a DT N
longitudinal JJ N
model NN N
. . N

A DT N
CID NNP N
on IN N
the DT N
ISS NNP N
was VBD N
1.64 CD N
and CC N
, , N
by IN N
day NN N
10 CD N
, , N
the DT N
mean JJ N
changes NNS N
from IN N
baseline NN o
in IN o
ISS NNP o
values NNS o
for IN o
the DT N
tofacitinib NN i
doses NNS i
( ( N
placebo-adjusted JJ N
) ) N
exceeded VBD N
CID NNP N
. . N

A NNP N
CIR NNP N
on IN N
the DT N
ISS NNP N
was VBD N
a DT N
30 CD N
% NN N
improvement NN N
from IN N
baseline NN N
and CC N
, , N
at IN N
week NN N
12 CD N
, , N
87.2 CD N
% NN N
to TO N
100 CD N
% NN N
of IN N
patients NNS N
receiving VBG i
tofacitinib NN i
reached VBD i
?30 CD N
% NN N
improvement NN N
versus IN N
29.4 CD N
% NN N
of IN N
patients NNS N
receiving VBG i
placebo NN i
( ( i
p JJ i
< NNP i
0.0001 CD N
) ) N
. . N

Overall UH N
, , N
the DT N
CID NNP N
and CC N
CIR NNP N
analyses NNS N
play VBP N
vital JJ N
roles NNS N
in IN N
the DT N
interpretation NN N
of IN N
the DT N
treatment NN N
effects NNS N
measured VBN N
by IN N
ISS NNP N
. . N

-DOCSTART- -7814306- O O

Vigorous JJ i
, , i
aerobic JJ i
exercise NN i
versus NN i
general JJ i
motor NN i
training NN i
activities NNS i
: : i
effects NNS N
on IN N
maladaptive JJ o
and CC o
stereotypic JJ o
behaviors NNS o
of IN N
adults NNS p
with IN p
both DT p
autism NN p
and CC p
mental JJ p
retardation NN p
. . p

Examined VBD N
the DT N
effects NNS N
of IN N
antecedent JJ i
exercise NN i
conditions NNS i
on IN N
maladaptive NN o
and CC o
stereotypic NN o
behaviors NNS o
in IN N
6 CD p
adults NNS p
with IN p
both DT p
autism NN p
and CC p
moderate VB p
to TO p
profound VB p
mental JJ p
retardation NN p
. . p

The DT N
behaviors NNS N
were VBD N
observed VBN N
in IN N
a DT N
controlled JJ N
environment NN N
before IN N
and CC N
after IN N
2 CD N
exercise NN i
and CC N
1 CD N
non-exercise JJ i
conditions NNS i
. . i

From IN N
the DT N
original JJ N
group NN N
of IN N
6 CD p
participants NNS p
, , N
2 CD N
were VBD N
selected VBN N
subsequently RB N
to TO N
participate VB N
in IN N
aerobic JJ i
exercise NN i
immediately RB N
before IN N
performing VBG N
a DT N
community-integrated JJ N
vocational JJ N
task NN N
. . N

Only RB N
antecedent JJ i
aerobic JJ i
exercise NN i
significantly RB N
reduced VBD N
maladaptive JJ o
and CC o
stereotypic JJ o
behaviors NNS o
in IN N
the DT N
controlled JJ N
setting NN N
. . N

Neither CC N
of IN N
the DT N
less RBR N
vigorous JJ N
antecedent JJ N
conditions NNS N
did VBD N
. . N

When WRB N
aerobic JJ i
exercise NN i
preceded VBD N
the DT N
vocational JJ N
task NN N
, , N
similar JJ N
reductions NNS N
were VBD N
observed VBN N
. . N

There EX N
were VBD N
individual JJ N
differences NNS N
in IN N
response NN N
to TO N
antecedent JJ i
exercise NN i
. . i

Use NN N
of IN N
antecedent NN i
aerobic JJ i
exercise NN i
to TO N
reduce VB N
maladaptive JJ o
and CC o
stereotypic JJ o
behaviors NNS o
of IN N
adults NNS p
with IN p
both DT p
autism NN p
and CC p
mental JJ p
retardation NN p
is VBZ N
supported VBN N
. . N

-DOCSTART- -25594611- O O

Exploring VBG N
the DT N
role NN N
of IN N
tanezumab NN i
as IN N
a DT N
novel JJ N
treatment NN N
for IN N
the DT N
relief NN N
of IN N
neuropathic JJ p
pain NN p
. . p

OBJECTIVE NNP N
Evaluate NNP N
efficacy NN N
and CC N
safety NN N
of IN N
tanezumab NN i
, , N
a DT N
humanized JJ N
monoclonal JJ N
antibody NN N
against IN N
nerve NN N
growth NN N
factor NN N
, , N
in IN N
neuropathic JJ p
pain NN p
. . p

DESIGN NNP N
Two CD N
randomized VBD N
controlled VBN N
trials NNS N
. . N

SUBJECTS NNP N
Patients NNPS p
with IN p
pain NN p
due JJ p
to TO p
diabetic JJ p
peripheral JJ p
neuropathy NN p
( ( p
DPN NNP p
) ) p
or CC p
postherpetic JJ p
neuralgia NN p
( ( p
PHN NNP p
) ) p
. . p

METHODS NNP N
In IN N
the DT N
DPN NNP N
study NN N
, , N
patients NNS N
received VBD N
subcutaneous JJ N
tanezumab NNS i
20 CD i
mg NN i
or CC i
placebo NN i
on IN N
Day NNP N
1 CD N
and CC N
Week NNP N
8 CD N
. . N

Evaluations NNS N
included VBD N
change NN N
from IN N
baseline NN N
in IN N
average JJ N
DPN NNP N
pain NN N
( ( N
primary JJ N
endpoint NN N
) ) N
, , N
Patient NNP N
's POS N
Global NNP N
Assessment NNP N
of IN N
DPN NNP N
, , N
and CC N
safety NN N
( ( N
including VBG N
neuropathy JJ N
assessments NNS N
) ) N
. . N

Due NNP N
to TO N
a DT N
partial JJ N
clinical JJ N
hold NN N
limiting VBG N
enrollment NN N
and CC N
treatment NN N
duration NN N
, , N
the DT N
prespecified JJ N
landmark NN N
analysis NN N
was VBD N
modified VBN N
post NN N
hoc NN N
from IN N
Week JJ N
16 CD N
to TO N
Week VB N
8 CD N
. . N

In IN N
the DT N
PHN NNP N
study NN N
, , N
patients NNS N
received VBD N
intravenous JJ N
tanezumab NNS i
50 CD N
?g/kg NNS N
, , N
tanezumab EX i
200 CD N
?g/kg NN N
, , N
or CC N
placebo NN i
on IN i
Day NNP N
1 CD N
. . N

Evaluations NNS N
included VBD N
change NN N
from IN N
baseline NN N
in IN N
average JJ o
daily JJ o
pain NN o
( ( o
primary JJ o
endpoint NN o
) ) o
, , o
Brief JJ o
Pain NNP o
Inventory-short NNP o
form NN o
, , o
Patient NNP o
's POS o
Global NNP o
Assessment NNP o
of IN o
pain NN o
from IN o
PHN NNP o
, , o
and CC o
safety NN o
. . o

RESULTS JJ o
Mean NNP o
DPN NNP o
pain VBP o
reduction NN o
from IN o
baseline NN N
to TO N
Week VB N
8 CD N
was VBD N
greater JJR N
with IN i
tanezumab NN i
vs NN i
placebo NN i
( ( i
P NNP N
= NNP N
0.009 CD N
) ) N
; : N
differences NNS N
in IN N
Patient NNP o
's POS o
Global NNP o
Assessment NNP o
of IN o
DPN NNP o
were VBD o
not RB N
significant JJ N
( ( N
P NNP N
> NNP N
0.05 CD N
) ) N
. . N

Neither CC i
tanezumab NN i
dose NN i
resulted VBD N
in IN N
significant JJ N
differences NNS N
vs VBP N
placebo NN i
in IN i
efficacy NN o
in IN o
PHN NNP N
( ( N
P NNP N
> NNP N
0.05 CD N
) ) N
, , N
although IN N
tanezumab JJ N
200 CD N
?g/kg NN N
provided VBD N
some DT N
benefit NN o
. . o

Neuropathy JJ o
assessments NNS o
showed VBD o
no DT N
meaningful JJ N
changes NNS N
. . N

CONCLUSIONS NNP i
Tanezumab NNP i
provided VBD i
effective JJ o
pain NN o
reduction NN o
in IN o
DPN NNP N
. . N

In IN N
PHN NNP N
, , N
only RB N
the DT N
highest JJS i
tanezumab NN i
dose NN i
reduced VBD o
pain NN o
; : o
treatment NN o
differences NNS N
were VBD N
not RB N
significant JJ N
. . N

No DT N
new JJ N
safety NN N
concerns NNS N
were VBD N
observed VBN N
despite IN p
preexisting VBG p
neuropathy JJ p
. . p

-DOCSTART- -19910815- O O

In-season JJ N
effect NN N
of IN N
short-term JJ i
sprint NN i
and CC i
power NN i
training NN i
programs NNS i
on IN N
elite JJ p
junior JJ p
soccer NN p
players NNS p
. . p

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
examine VB N
the DT N
effects NNS N
of IN N
2 CD N
in-season JJ N
short-term JJ i
sprint NN i
and CC i
power NN i
training NN i
protocols NNS i
on IN N
vertical JJ N
countermovement NN N
jump NN N
height NN N
( ( N
with IN N
or CC N
without IN N
arms NNS N
) ) N
, , N
sprint NN N
( ( N
Sprint-15m NNP N
) ) N
speed NN N
, , N
and CC N
agility NN N
( ( N
Agility-15m NNP N
) ) N
speed NN N
in IN N
male JJ p
elite JJ p
junior JJ p
soccer NN p
players NNS p
. . p

Twenty NNP p
highly RB p
trained VBD p
soccer NN p
players NNS p
( ( p
age NN p
18.3 CD p
+/- JJ p
0.6 CD p
years NNS p
, , p
height VBD p
177 CD p
+/- JJ p
4 CD p
cm NN p
, , p
body NN p
mass VBD p
71.4 CD p
+/- JJ p
6.9 CD p
kg NN p
, , p
sum NN p
skinfolds NNS p
48.1 CD p
+/- JJ p
11.4 CD p
mm NN p
) ) p
, , p
members NNS p
of IN p
a DT p
professional JJ p
soccer NN p
academy NN p
, , N
were VBD N
randomly RB N
allocated VBN N
to TO N
either VB N
a DT N
CONTRAST NNP N
( ( N
n JJ N
= NNP N
10 CD N
) ) N
or CC N
SPRINT NNP N
( ( N
n JJ N
= NNP N
10 CD N
) ) N
group NN N
. . N

The DT i
training NN i
intervention NN i
consisted VBD N
of IN N
6 CD i
supervised JJ i
training NN i
sessions NNS i
over IN N
7 CD N
weeks NNS N
, , N
targeting VBG N
the DT N
improvement NN N
of IN N
the DT N
players NNS N
' POS N
speed NN o
and CC o
power NN o
. . o

CONTRAST NNP N
protocol NN N
consisted VBD N
of IN N
alternating VBG N
heavy-light JJ N
resistance NN N
( ( N
15-50 CD N
% NN N
body NN N
mass NN N
) ) N
with IN N
soccer-specific JJ N
drills NNS N
( ( N
small-sided JJ N
games NNS N
or CC N
technical JJ N
skills NNS N
) ) N
. . N

SPRINT NNP i
training NN i
protocol NN i
used VBN N
line NN N
30-m JJ N
sprints NNS N
( ( N
2-4 JJ N
sets NNS N
of IN N
4 CD N
x JJ N
30 CD N
m NN N
with IN N
180 CD N
and CC N
90 CD N
seconds NNS N
of IN N
recovery NN N
, , N
respectively RB N
) ) N
. . N

At IN N
baseline JJ N
no DT N
difference NN N
between IN N
physical JJ o
test NN o
performance NN o
was VBD N
evident JJ N
between IN N
the DT N
2 CD N
groups NNS N
( ( N
p JJ N
> NNP N
0.05 CD N
) ) N
. . N

No DT N
time NN N
x VBZ N
training VBG N
group NN N
effect NN N
was VBD N
found VBN N
for IN N
any DT N
of IN N
the DT N
vertical JJ o
jump NN o
and CC o
Agility-15m JJ o
variables NNS o
( ( o
p JJ o
> NNP N
0.05 CD N
) ) N
. . N

A DT N
time NN N
x JJ N
training VBG N
group NN N
effect NN N
was VBD N
found VBN N
for IN N
Sprint-15m JJ N
performance NN N
with IN N
the DT N
CONTRAST NNP N
group NN N
showing VBG N
significantly RB N
better JJR N
scores NNS N
than IN N
the DT N
SPRINT NNP N
group NN N
( ( N
7.23 CD N
+/- JJ N
0.18 CD N
vs. FW N
7.09 CD N
+/- JJ N
0.20 CD N
m.s NN N
, , N
p NN N
< NNP N
0.01 CD N
) ) N
. . N

In IN N
light NN N
of IN N
these DT N
findings NNS N
CONTRAST NNP i
training NN i
should MD N
be VB N
preferred VBN N
to TO N
line NN N
sprint NN N
training NN N
in IN N
the DT N
short JJ N
term NN N
in IN N
young JJ p
elite JJ p
soccer NN p
players NNS p
when WRB N
the DT N
aim NN N
is VBZ N
to TO N
improve VB N
soccer-specific JJ o
sprint NN o
performance NN o
( ( o
15 CD o
m NN o
) ) o
during IN N
the DT N
competitive JJ N
season NN N
. . N

-DOCSTART- -10592853- O O

A DT N
comparative JJ N
study NN N
of IN N
the DT N
safety NN N
and CC N
efficacy NN N
of IN N
FemCap NNP i
, , i
a DT i
new JJ i
vaginal JJ i
barrier NN i
contraceptive NN i
, , N
and CC N
the DT N
Ortho NNP i
All-Flex NNP i
diaphragm NN i
. . i

The DT N
FemCap NNP N
Investigators NNP N
' POS N
Group NNP N
. . N

The DT N
FemCap NNP i
is VBZ N
a DT N
new JJ N
silicone NN N
rubber NN N
barrier RBR N
contraceptive JJ N
shaped VBN N
like IN N
a DT N
sailor NN N
's POS N
hat NN N
, , N
with IN N
a DT N
dome NN N
that WDT N
covers VBZ N
the DT N
cervix NN N
, , N
a DT N
rim NN N
that WDT N
fits VBZ N
into IN N
the DT N
fornices NNS N
, , N
and CC N
a DT N
brim NN N
that WDT N
conforms VBZ N
to TO N
the DT N
vaginal JJ N
walls NNS N
around IN N
the DT N
cervix NN N
. . N

It PRP N
was VBD N
designed VBN N
to TO N
result VB N
in IN N
fewer JJR N
dislodgments NNS N
and CC N
less JJR N
pressure NN N
on IN N
the DT N
urethra NN N
than IN N
the DT N
cervical JJ N
cap NN N
and CC N
diaphragm NN N
, , N
respectively RB N
, , N
and CC N
to TO N
require VB N
less JJR N
clinician JJ N
time NN N
for IN N
fitting VBG N
. . N

This DT N
was VBD N
a DT N
phase NN N
II/III NNP N
, , N
multicenter NN N
, , N
randomized VBN N
, , N
open-label JJ N
, , N
parallel JJ N
group NN N
study NN N
of IN N
841 CD p
women NNS p
at IN p
risk NN p
for IN p
pregnancy NN p
. . p

A DT N
subset NN p
of IN p
42 CD p
women NNS p
at IN p
one CD p
site NN p
underwent JJ p
colposcopy NN p
. . p

Women NNS N
were VBD N
randomized VBN N
to TO N
use VB N
the DT N
FemCap NNP i
or CC i
Ortho NNP i
All-Flex NNP i
contraceptive NN i
diaphragm NN i
, , i
both DT i
with IN i
2 CD i
% NN i
nonoxynol-9 JJ i
spermicide NN i
, , N
for IN N
28 CD N
weeks NNS N
. . N

The DT N
objectives NNS N
were VBD N
to TO N
compare VB N
the DT N
two CD N
devices NNS N
with IN N
regard NN N
to TO N
their PRP$ N
safety NN N
and CC N
acceptability NN N
and CC N
to TO N
determine VB N
whether IN N
the DT N
probability NN o
of IN o
pregnancy NN o
among IN N
FemCap NNP i
users NNS N
was VBD N
no DT N
worse JJR N
than IN N
that DT N
of IN N
the DT N
diaphragm NN i
( ( N
meaning VBG N
not RB N
more RBR N
than IN N
6 CD N
percentage NN N
points NNS N
higher JJR N
) ) N
. . N

The DT N
6-month JJ o
Kaplan-Meier NNP o
cumulative NN o
unadjusted VBD N
typical JJ N
use NN N
pregnancy NN N
probabilities NNS N
were VBD N
13.5 CD N
% NN N
among IN N
FemCap NNP i
users NNS N
and CC N
7.9 CD N
% NN N
among IN N
diaphragm JJ i
users NNS N
. . N

The DT N
adjusted JJ o
risk NN o
of IN o
pregnancy NN o
among IN N
FemCap NNP i
users NNS N
was VBD N
1.96 CD N
times NNS N
that WDT N
among IN N
diaphragm JJ i
users NNS N
, , N
with IN N
an DT N
upper JJ N
95 CD N
% NN N
confidence NN N
limit NN N
of IN N
3.01 CD N
. . N

Clinical JJ o
equivalence NN o
( ( o
noninferiority NN o
) ) o
of IN N
the DT N
FemCap NNP i
compared VBN N
with IN N
the DT N
diaphragm NN N
, , N
as IN N
defined VBN N
in IN N
this DT N
study NN N
, , N
would MD N
mean VB N
that IN N
the DT N
true JJ o
risk NN o
of IN o
pregnancy NN o
among IN N
FemCap NNP i
users NNS N
was VBD N
no DT N
more JJR N
than IN N
1.73 CD N
times NNS N
the DT N
pregnancy NN o
risk NN o
of IN N
diaphragm NN i
users NNS N
. . N

Because IN N
the DT N
observed JJ N
upper JJ N
95 CD N
% NN N
confidence NN N
limit NN N
( ( N
and CC N
even RB N
the DT N
point NN N
estimate NN N
) ) N
exceeded VBD N
1.73 CD N
, , N
the DT N
probability NN o
of IN o
pregnancy NN o
among IN o
FemCap NNP o
users NNS N
, , N
compared VBN N
with IN N
that DT N
among IN N
diaphragm JJ i
users NNS N
, , N
did VBD N
not RB N
meet VB N
the DT N
definition NN N
of IN N
clinical JJ o
equivalence NN o
used VBN N
in IN N
this DT N
study NN N
. . N

The DT N
FemCap NNP i
was VBD N
believed VBN N
to TO N
be VB N
safe JJ o
and CC N
was VBD N
associated VBN N
with IN N
significantly RB N
fewer JJR N
urinary JJ o
tract NN o
infections NNS o
. . o

More JJR N
women NNS p
reported VBD N
problems NNS N
with IN N
the DT N
FemCap NNP i
with IN N
regard NN N
to TO N
insertion NN o
, , o
dislodgement NN o
, , o
and CC o
especially RB o
removal JJ o
, , N
although IN N
their PRP$ N
general JJ N
assessments NNS N
were VBD N
positive JJ N
. . N

The DT N
two CD N
devices NNS N
were VBD N
comparable JJ N
with IN N
regard NN N
to TO N
safety NN o
and CC o
acceptability NN o
, , N
but CC N
a DT N
6-point JJ N
difference NN N
in IN N
the DT N
true JJ N
6-month JJ o
pregnancy NN o
probabilities NNS o
of IN N
the DT N
two CD N
devices NNS N
could MD N
not RB N
be VB N
ruled VBN N
out RP N
. . N

Further JJ N
studies NNS N
are VBP N
needed VBN N
to TO N
determine VB N
whether IN N
design NN N
modifications NNS N
can MD N
simplify VB N
insertion NN N
and CC N
removal NN N
. . N

-DOCSTART- -12824973- O O

A DT N
randomized JJ N
clinical JJ N
trial NN N
of IN N
treatment NN N
of IN N
clomiphene JJ N
citrate-resistant JJ N
anovulation NN N
with IN N
the DT N
use NN N
of IN N
oral JJ N
contraceptive NN N
pill NN N
suppression NN N
and CC N
repeat NN N
clomiphene NN N
citrate NN N
treatment NN N
. . N

OBJECTIVE CC N
The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
evaluate VB N
the DT N
effectiveness NN o
and CC N
endocrine JJ o
response NN o
of IN N
oral JJ i
contraceptive JJ i
ovarian JJ N
suppression NN N
followed VBN N
by IN N
clomiphene NN i
citrate NN i
in IN N
patients NNS p
who WP p
previously RB p
were VBD p
clomiphene JJ p
citrate NN p
resistant NN p
. . p

STUDY NNP N
DESIGN NNP N
Forty-eight NNP p
patients NNS p
from IN p
a DT p
private JJ p
tertiary JJ p
infertility NN p
clinic NN p
were VBD N
assigned VBN N
randomly RB N
prospectively RB i
to TO i
either DT i
group NN i
1 CD i
( ( i
oral JJ i
contraceptive/clomiphene NN i
citrate NN i
) ) i
, , i
which WDT i
received VBD i
continuous JJ i
oral JJ i
contraceptives NNS i
followed VBN i
by IN i
clomiphene NN i
citrate NN i
, , i
or CC i
to TO i
group NN i
2 CD i
( ( i
control NN i
) ) i
received VBD i
no DT i
treatment NN i
in IN i
the DT i
cycle NN i
before IN i
clomiphene JJ i
citrate NN i
treatment NN i
. . i

On IN i
day NN i
3 CD i
, , i
17 CD o
beta-estradiol NN o
, , o
follicle-stimulating JJ o
hormone NN o
, , o
luteinizing VBG o
hormone NN o
, , o
and CC o
androgens NNS o
were VBD i
assayed VBN i
before IN i
and CC i
after IN i
treatment NN i
. . i

Follicle NNP o
growth NN o
, , o
ovulation NN o
, , o
and CC o
pregnancy NN o
were VBD N
evaluated VBN N
. . N

The DT N
Student NN o
t JJ o
test NN o
and CC o
analysis NN o
of IN o
variance NN o
were VBD N
used VBN N
for IN N
statistical JJ N
significance NN N
. . N

RESULTS VB N
The DT N
oral JJ N
contraceptive/clomiphene NN N
citrate NN N
group NN N
had VBD N
a DT N
significantly RB N
higher JJR N
percentage NN o
of IN N
patients NNS N
who WP N
ovulated VBD o
and CC N
of IN N
ovulatory JJ o
cycles NNS o
and CC o
pregnancies NNS o
. . o

Significantly RB N
lower JJR N
levels NNS N
of IN N
17 CD o
beta-estradiol NN o
, , o
luteinizing VBG o
hormone NN o
, , o
and CC o
androgen NN o
levels NNS o
were VBD N
seen VBN N
in IN N
the DT N
oral JJ N
contraceptive/clomiphene NN N
citrate NN N
group NN N
, , N
with IN N
no DT N
significant JJ N
changes NNS N
in IN N
group NN N
2 CD N
. . N

CONCLUSION NNP N
Suppression NNP N
of IN N
the DT N
ovary JJ N
with IN N
oral JJ N
contraceptives NNS N
results NNS N
in IN N
excellent JJ N
rates NNS N
of IN N
ovulation NN N
and CC N
pregnancy NN N
in IN N
patients NNS p
who WP p
previously RB p
were VBD p
resistant JJ p
to TO p
clomiphene VB i
citrate NN i
. . i

The DT N
decreases NNS N
in IN N
ovarian JJ N
androgens NNS N
, , N
luteinizing VBG N
hormone NN N
, , N
and CC N
17 CD N
beta-estradiol NN N
may MD N
be VB N
responsible JJ N
for IN N
the DT N
improved JJ N
response NN N
. . N

-DOCSTART- -12739123- O O

The DT N
utility NN N
of IN N
laparoscopy NN N
in IN N
the DT N
diagnosis NN N
of IN N
acute JJ p
appendicitis NN p
in IN p
women NNS p
of IN p
reproductive JJ p
age NN p
. . p

AIM NNP N
To TO N
see VB N
whether IN N
laparoscopy NN i
improves VBZ N
the DT N
accuracy NN N
of IN N
a DT N
clinical JJ N
diagnosis NN N
of IN N
acute JJ p
appendicitis NN p
in IN p
women NNS p
of IN p
reproductive JJ p
age NN p
, , N
and CC N
to TO N
determine VB N
what WP N
the DT N
long-term JJ N
sequelae NN N
are VBP N
of IN N
not RB N
removing VBG N
an DT N
appendix NN N
deemed VBN N
at IN N
laparoscopy NN N
to TO N
be VB N
normal JJ N
. . N

METHOD NNP N
The DT N
initial JJ N
part NN N
of IN N
the DT N
study NN N
was VBD N
undertaken VBN N
during IN N
1991-1992 JJ p
. . p

Female JJ p
patients NNS p
between IN p
16 CD p
and CC p
45 CD p
years NNS p
were VBD N
eligible JJ N
for IN N
inclusion NN N
once RB N
a DT N
clinical JJ N
decision NN N
had VBD N
been VBN N
made VBN N
to TO N
perform VB N
an DT N
appendicectomy NN N
for IN N
suspected JJ p
acute JJ p
appendicitis NN p
. . p

Following VBG N
consent NN N
, , N
patients NNS N
were VBD N
randomized VBN N
into IN N
two CD N
groups NNS N
. . N

One CD N
group NN N
had VBD N
open JJ i
appendicectomy NN i
, , N
as IN N
planned VBN N
. . N

The DT N
other JJ N
group NN N
had VBD N
laparoscopy VBN i
, , i
followed VBN i
by IN i
open JJ i
appendicectomy NN i
only RB N
if IN N
the DT N
appendix NN N
was VBD N
seen VBN N
to TO N
be VB N
inflamed VBN N
or CC N
was VBD N
not RB N
visualized VBN N
. . N

The DT N
end NN N
points NNS N
for IN N
the DT N
study NN N
were VBD N
the DT N
clinical JJ N
outcomes NNS N
of IN N
all DT N
patients NNS N
, , N
and CC N
the DT N
results NNS N
of IN N
histology NN o
, , N
where WRB N
appropriate NN N
. . N

An DT N
attempt NN N
was VBD N
made VBN N
to TO N
contact VB N
all DT N
patients NNS N
at IN N
10 CD N
years NNS N
to TO N
determine VB N
whether IN N
they PRP N
had VBD N
had VBN N
a DT N
subsequent JJ N
appendicectomy NN N
, , N
or CC N
had VBD N
been VBN N
diagnosed VBN N
with IN N
another DT N
abdominal JJ N
condition NN N
that WDT N
might MD N
be VB N
relevant JJ N
to TO N
the DT N
initial JJ N
presentation NN N
in IN N
1991-1992 JJ N
. . N

RESULTS NNP N
Laparoscopic NNP N
assessment NN N
was VBD N
correct JJ N
in IN N
all DT N
cases NNS N
in IN N
which WDT N
the DT N
appendix NN N
was VBD N
visualized VBN N
. . N

Diagnostic JJ o
accuracy NN o
was VBD N
improved VBN N
from IN N
75 CD N
% NN N
to TO N
97 CD N
% NN N
. . N

Laparoscopy NNP N
was VBD N
associated VBN N
with IN N
no DT o
added JJ o
complications NNS o
, , o
no DT o
increase NN o
in IN o
hospital JJ o
stay NN o
in IN N
patients NNS N
who WP N
went VBD N
on IN N
to TO N
appendicectomy VB N
, , N
and CC N
a DT N
reduction NN o
in IN o
hospital NN o
stay NN o
for IN N
those DT N
who WP N
underwent JJ N
laparoscopy NN N
alone RB N
. . N

No UH N
patients NNS N
developed VBD N
a DT N
problem NN N
over IN N
the DT N
10-year JJ N
follow-up JJ N
period NN N
from IN N
having VBG N
a DT N
normal-looking JJ N
appendix NN N
not RB N
removed VBN N
at IN N
laparoscopy NN N
. . N

CONCLUSION NNP N
Laparoscopic NNP N
assessment NN N
of IN N
the DT N
appendix NN N
is VBZ N
reliable JJ N
, , N
and CC N
to TO N
leave VB N
a DT N
normal-looking JJ N
appendix NN N
at IN N
laparoscopy NN N
does VBZ N
not RB N
appear VB N
to TO N
cause VB N
any DT N
long-term JJ N
problems NNS N
. . N

-DOCSTART- -14752429- O O

Left NNP i
internal JJ i
thoracic NN i
artery-radial JJ i
artery NN i
composite JJ i
grafts NNS i
as IN N
the DT N
technique NN N
of IN N
choice NN N
for IN N
myocardial JJ p
revascularization NN p
in IN p
elderly JJ p
patients NNS p
: : p
a DT N
prospective JJ N
randomized VBN N
evaluation NN N
. . N

OBJECTIVES IN N
The DT N
technique NN N
of IN N
choice NN N
for IN N
myocardial JJ N
revascularization NN N
in IN N
elderly JJ p
patients NNS p
remains VBZ N
a DT N
debated JJ N
issue NN N
. . N

We PRP N
evaluated VBD N
the DT N
potential JJ N
advantages NNS N
of IN N
the DT N
use NN N
of IN N
left JJ i
internal JJ i
thoracic NN i
artery-radial JJ i
artery NN i
composite JJ i
grafts NNS i
compared VBN N
with IN N
conventional JJ i
coronary JJ i
artery NN i
bypass NN i
grafts NNS i
in IN N
elderly JJ p
patients NNS p
. . p

METHODS NNP N
We PRP N
prospectively RB N
enrolled VBD N
160 CD p
patients NNS p
aged VBD p
more JJR p
than IN p
70 CD p
years NNS p
scheduled VBN p
to TO p
undergo VB p
isolated JJ i
myocardial JJ i
revascularization NN i
. . i

Patients NNS N
were VBD N
assigned VBN N
at IN N
random NN N
to TO N
group NN N
1 CD N
, , N
80 CD p
patients NNS p
undergoing JJ p
total JJ i
arterial JJ i
revascularization NN i
( ( i
left VBN i
internal JJ i
thoracic NN i
artery NN i
on IN i
left JJ i
anterior JJ i
descending VBG i
coronary JJ i
artery NN i
plus CC i
radial JJ i
artery NN i
) ) i
, , N
or CC N
group NN N
2 CD N
, , N
80 CD p
patients NNS p
undergoing JJ p
standard JJ i
coronary JJ i
artery NN i
bypass NN i
graft NN i
surgery NN i
( ( i
left VBN i
internal JJ i
thoracic NN i
artery NN i
on IN i
left JJ i
anterior JJ i
descending VBG i
coronary JJ i
artery NN i
plus CC i
saphenous JJ i
veins NNS i
) ) i
. . i

The DT N
radial JJ N
artery NN N
was VBD N
used VBN N
in IN N
all DT N
cases NNS N
as IN N
a DT N
composite JJ i
Y-graft NN i
. . i

RESULTS NNP N
Preoperative JJ p
characteristics NNS p
and CC p
risk NN p
factors NNS p
( ( p
EuroSCORE NNP p
: : p
group NN p
1 CD p
= $ p
7.9 CD p
vs NN p
group NN p
2 CD p
= $ p
8.1 CD p
) ) p
, , p
number NN o
of IN o
grafted JJ o
coronary JJ o
vessels NNS o
( ( p
group NN p
1 CD p
= $ p
2.4 CD p
vs NN p
group NN p
2 CD p
= $ p
2.5 CD p
) ) p
, , p
aortic JJ o
crossclamping NN o
time NN o
( ( p
group NN p
1 CD p
= $ p
37 CD p
+/- JJ p
7 CD p
minutes NNS p
vs JJ p
group NN p
2 CD p
= $ p
38 CD p
+/- JJ p
7 CD p
minutes NNS p
) ) p
, , p
ventilation NN o
time NN o
( ( p
group NN p
1 CD p
= $ p
22 CD p
+/- JJ p
12 CD p
hours NNS p
vs JJ p
group NN p
2 CD p
= $ p
23 CD p
+/- JJ p
11 CD p
hours NNS p
) ) p
, , p
intensive JJ o
care NN o
unit NN o
stay NN o
( ( p
group NN p
1 CD p
= $ p
39 CD p
+/- JJ p
10 CD p
hours NNS p
vs JJ p
group NN p
2 CD p
= $ p
40 CD p
+/- JJ p
9 CD p
hours NNS p
) ) p
, , p
and CC p
hospital JJ o
mortality NN o
( ( p
group NN p
1 CD p
= RB p
3.8 CD p
% NN p
vs NN p
group NN p
2 CD p
= RB p
5 CD p
% NN p
) ) p
were VBD p
comparable JJ p
between IN p
the DT p
groups NNS p
. . p

Comparison NNP N
between IN N
the DT N
2 CD N
groups NNS N
in IN N
terms NNS N
of IN N
early JJ o
postoperative JJ o
complications NNS o
showed VBD N
a DT N
higher JJR N
incidence NN N
of IN N
cerebrovascular JJ o
accidents NNS o
in IN N
group NN N
2 CD N
( ( N
group NN N
1 CD N
= $ N
0 CD N
patients NNS N
vs JJ N
group NN N
2 CD N
= $ N
4 CD N
patients NNS N
, , N
5 CD N
% NN N
) ) N
. . N

At IN N
a DT N
mean JJ N
follow-up NN N
of IN N
16 CD N
+/- JJ N
3 CD N
months NNS N
, , N
patients NNS N
in IN N
group NN N
1 CD N
showed VBD N
superior JJ N
clinical JJ N
results NNS N
with IN N
a DT N
lower JJR N
incidence NN N
of IN N
graft NN o
occlusion NN o
( ( N
group NN N
1 CD N
= $ N
2 CD N
vs NN N
group NN N
2 CD N
= $ N
11 CD N
; : N
P NNP N
=.06 NNP N
) ) N
and CC N
angina JJ o
recurrence NN o
( ( N
group NN N
1 CD N
= $ N
2 CD N
patients NNS N
vs JJ N
group NN N
2 CD N
= $ N
12 CD N
patients NNS N
; : N
P NNP N
=.03 NNP N
) ) N
. . N

Multivariate NNP N
analysis NN N
identified VBD N
saphenous JJ N
vein NNS N
grafts NNS N
as IN N
independent JJ N
predictors NNS N
for IN N
graft NN o
occlusion NN o
and CC o
angina JJ o
recurrence NN o
. . o

CONCLUSIONS NNP N
Left NNP N
internal JJ N
thoracic NN N
artery-radial JJ N
artery NN N
composite JJ N
grafts NNS N
proved VBD N
to TO N
be VB N
a DT N
safe JJ N
procedure NN N
in IN N
elderly JJ p
patients NNS p
. . p

It PRP N
improved VBD N
the DT N
clinical JJ N
outcome NN N
, , N
providing VBG N
a DT N
significantly RB N
higher JJR N
graft NN N
patency NN N
rate NN N
and CC N
a DT N
lower JJR N
incidence NN N
of IN N
late JJ N
cardiac JJ N
events NNS N
. . N

-DOCSTART- -22834767- O O

Direct JJ i
renin NN i
inhibition NN i
improves VBZ N
parasympathetic JJ N
function NN N
in IN N
diabetes NNS p
. . p

AIM VB N
The DT N
renin-angiotensin-aldosterone NN N
system NN N
( ( N
RAAS NNP N
) ) N
and CC N
autonomic JJ N
nervous JJ N
system NN N
regulate VB N
the DT N
cardiovascular JJ N
system NN N
. . N

Blockade NN N
of IN N
the DT N
RAAS NNP N
may MD N
slow VB N
the DT N
progression NN N
of IN N
end-organ JJ N
damage NN N
. . N

Direct JJ i
renin NN i
inhibition NN i
offers VBZ N
a DT N
means NN N
for IN N
blocking VBG N
the DT N
RAAS NNP N
. . N

The DT N
objective NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
examine VB N
the DT N
effect NN N
of IN N
direct JJ i
renin NN i
inhibition NN i
on IN N
cardiovascular JJ N
autonomic JJ N
function NN N
. . N

METHODS NNP N
In IN N
this DT N
double-blind NN N
, , N
placebo-controlled JJ i
trial NN N
, , N
60 CD p
individuals NNS p
with IN p
diabetes NNS p
were VBD N
randomly RB N
assigned VBN N
to TO N
300 CD N
mg NN N
of IN N
aliskiren NN i
or CC i
placebo NN i
once RB N
daily JJ N
for IN N
6 CD N
weeks NNS N
. . N

The DT N
primary JJ N
end NN N
point NN N
was VBD N
a DT N
change NN o
in IN o
tests NNS o
of IN o
cardiovascular JJ o
autonomic JJ o
function NN o
. . o

Autonomic NNP o
function NN o
was VBD N
assessed VBN N
by IN N
power NN N
spectral JJ N
analysis NN N
and CC N
RR-variation NNP N
during IN N
deep JJ N
breathing NN N
[ JJ N
i.e NN N
. . N

mean VB N
circular JJ N
resultant NN N
( ( N
MCR NNP N
) ) N
, , N
expiration/inspiration NN N
( ( N
E/I NNP N
) ) N
ratio NN N
] NN N
. . N

The DT N
MCR NNP N
and CC N
E/I NNP N
ratio NN N
assess NN N
parasympathetic JJ N
function NN N
. . N

Secondary JJ N
measures NNS N
included VBD N
change NN o
in IN o
biochemical JJ o
parameters NNS o
[ VBP o
e.g NN o
. . o

plasma JJ o
renin NN o
activity NN o
, , o
leptin NN o
and CC o
interleukin-6 JJ o
] NN o
. . o

Change NN o
in IN o
cardiovascular JJ o
autonomic JJ o
function NN o
and CC o
blood NN o
analytes NNS o
were VBD N
analysed VBN N
by IN N
a DT N
mixed JJ N
effects NNS N
model NN N
for IN N
repeated JJ N
measures NNS N
. . N

RESULTS NNP N
Baseline NNP N
characteristics NNS N
were VBD N
similar JJ N
between IN N
treatment NN N
groups NNS N
. . N

In IN N
response NN N
to TO N
aliskiren NNS i
compared VBN N
with IN N
placebo NN i
, , N
blood NN o
pressure NN o
was VBD N
reduced VBN N
as RB N
well RB N
as IN N
plasma JJ N
renin NN N
activity NN N
[ VBP N
from IN N
2.4 CD N
? . N
3.8 CD N
( ( N
mean VB N
? . N
standard JJ N
deviation NN N
) ) N
to TO N
0.5 CD N
? . N
0.4 CD N
?g/l/h NN N
, , N
p NN N
< VBD N
0.001 CD N
] NN N
. . N

There EX N
was VBD N
a DT N
significant JJ N
interaction NN i
( ( i
aliskiren VB i
? . i
visit NN i
) ) N
for IN N
MCR NNP N
( ( N
p JJ N
= NNP N
0.003 CD N
) ) N
and CC N
E/I NNP N
ratio NN N
( ( N
p JJ N
= NNP N
0.003 CD N
) ) N
indicating VBG N
improvement NN N
in IN N
MCR NNP N
and CC N
E/I NNP N
ratio NN N
for IN N
those DT N
on IN i
aliskiren NNS i
. . i

MCR NNP i
means VBZ N
, , N
baseline VB N
vs. IN N
follow-up JJ N
, , N
were VBD N
41.8 CD N
? . N
19.7 CD N
vs. IN N
50.8 CD N
? . N
26.1 CD N
( ( i
aliskiren NN i
) ) i
and CC i
38.2 CD i
? . N
23.6 CD N
vs. IN N
37.5 CD N
? . N
24.1 CD N
( ( N
placebo NN i
) ) N
. . N

CONCLUSIONS NNP N
Parasympathetic NNP N
function NN N
( ( N
i.e JJ N
. . N

MCR NNP N
and CC N
E/I NNP N
ratio NN N
) ) N
was VBD N
enhanced VBN N
by IN N
downregulation NN N
of IN N
the DT N
RAAS NNP N
. . N

-DOCSTART- -25162407- O O

Use NNP N
of IN N
Transcutaneous NNP i
Electrical NNP i
Nerve NNP i
Stimulation NNP i
Device NNP i
in IN N
Early NNP o
Osteoarthritis NNP o
of IN o
the DT o
Knee NNP o
. . o

Some DT N
have VBP N
proposed VBN N
the DT N
use NN N
of IN N
transcutaneous JJ i
electrical JJ i
nerve NN i
stimulation NN i
( ( i
TENS NNP i
) ) i
as IN N
an DT N
adjunct NN N
to TO N
the DT N
current JJ N
standard NN N
of IN N
care NN N
in IN N
treatment NN o
of IN o
osteoarthritis NN o
knee NN o
pain NN o
. . o

The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
evaluate VB N
the DT N
effects NNS N
of IN N
TENS NNP i
on IN N
the DT N
following JJ N
issues NNS N
in IN N
patients NNS p
who WP p
have VBP p
early-stage JJ o
osteoarthritis NN o
of IN o
the DT o
knee NN o
: : o
( ( o
1 CD o
) ) o
pain NN o
reduction NN o
; : o
( ( o
2 CD o
) ) o
subjective NN o
and CC o
( ( o
3 CD o
) ) o
objective JJ o
functional JJ o
improvements NNS o
; : o
( ( o
4 CD o
) ) o
quality-of-life NN o
( ( o
QOL NNP o
) ) o
measure NN o
improvements NNS o
; : o
and CC o
( ( o
5 CD o
) ) o
isokinetic JJ o
strength NN o
. . o

A DT N
prospective JJ N
, , N
randomized VBN N
, , N
and CC N
single-blinded JJ N
trial NN N
was VBD N
performed VBN N
on IN N
23 CD p
patients NNS p
who WP N
were VBD N
randomized VBN N
to TO N
either DT N
novel JJ i
TENS NNP i
device NN i
or CC i
standard NN i
of IN i
care NN i
. . i

Metrics NNS N
analyzed VBD N
included JJ N
stair-climb JJ o
test NN o
; : o
timed-up-and-go JJ o
test NN o
( ( o
TUGT NNP o
) ) o
; : o
2-minute JJ o
walk NN o
test NN o
; : o
20 CD o
times NNS o
, , o
single JJ o
leg NN o
6-inch JJ o
step NN o
test NN o
; : o
five-repetition JJ o
chair-rise JJ o
test NN o
; : o
active JJ o
and CC o
passive JJ o
range-of-motion NN o
( ( o
ROM NNP o
) ) o
score NN o
; : o
short JJ o
form NN o
health NN o
survey-36 JJ o
scores NNS o
( ( o
SF-36 NNP o
) ) o
score NN o
; : o
Knee NNP o
Society NNP o
Score NNP o
( ( o
KSS NNP o
) ) o
; : o
lower JJR o
extremity NN o
functional JJ o
scale NN o
( ( o
LEFS NNP o
) ) o
; : o
visual JJ o
analog NN o
scale NN o
( ( o
VAS NNP o
) ) o
; : o
and CC o
isokinetic JJ o
quadriceps NNS o
and CC o
hamstring VBG o
strength NN o
. . o

In IN N
objective JJ N
functional JJ N
scores NNS N
, , N
TENS NNP N
had VBD N
significant JJ N
improvements NNS N
in IN N
TUGT NNP o
and CC o
objective JJ o
KSS NNP o
when WRB N
compared VBN N
with IN N
the DT N
matching VBG N
cohort NN N
. . N

Subjective JJ o
functional JJ o
and CC o
QOL NNP o
outcomes VBZ o
patients NNS N
had VBD N
a DT N
significant JJ N
improvement NN N
of IN N
their PRP$ N
LEFS NNP o
and CC o
SF-36 NNP o
physical JJ o
component NN o
with IN N
the DT N
use NN N
of IN N
TENS NNP N
brace NN N
. . N

The DT N
TENS NNP N
device NN N
significantly RB N
improved VBD N
the DT N
quadriceps NNS o
strength NN o
when WRB N
compared VBN N
with IN N
standard JJ N
therapy NN N
. . N

In IN N
evaluation NN N
for IN N
improvement NN N
within IN N
the DT N
TENS NNP N
cohort NN N
, , N
patients NNS N
had VBD N
a DT N
significant JJ N
improvement NN N
at IN N
3-month JJ N
follow-up NN N
in IN N
the DT N
TUG NNP o
test NN o
, , o
timed VBD o
stair-climb JJ o
test NN o
, , o
20-times JJ o
single JJ o
leg NN o
, , o
KSS NNP o
, , o
LEFS NNP o
, , o
and CC o
SF-36 NNP o
physical JJ o
component NN o
compared VBN N
to TO N
their PRP$ N
initial JJ N
visit NN N
. . N

In IN N
addition NN N
, , N
within IN N
the DT N
TENS NNP N
cohort NN N
, , N
patients NNS N
had VBD N
a DT N
significant JJ N
reduction NN o
in IN o
pain NN o
via IN o
VAS NNP o
at IN N
their PRP$ N
3-month JJ N
follow-up NN N
. . N

In IN N
conclusion NN N
, , N
the DT N
use NN N
of IN N
TENS NNP N
for IN N
3 CD N
months NNS N
has VBZ N
shown VBN N
encouraging JJ N
results NNS N
to TO N
improve VB o
pain NN o
, , o
function NN o
, , o
and CC o
QOL NNP o
in IN N
patients NNS p
with IN p
painful JJ p
osteoarthritic JJ p
knees NNS p
, , N
and CC N
could MD N
positively RB N
contribute VB N
as IN N
an DT N
adjunct NN N
to TO N
current JJ N
nonoperative JJ N
treatment NN N
of IN N
knee NN N
arthritis NN N
. . N

However RB N
, , N
given VBN N
our PRP$ N
small JJ N
sample NN N
size NN N
, , N
larger JJR N
randomized VBN N
studies NNS N
are VBP N
needed VBN N
to TO N
further JJ N
evaluate VB N
these DT N
outcomes NNS N
. . N

-DOCSTART- -6384285- O O

Double-blind NNP N
efficacy NN N
study NN p
of IN p
selenium NN i
sulfide NN i
in IN p
tinea NN p
versicolor NN p
. . p

Selenium NNP i
sulfide NN i
( ( i
2.5 CD i
% NN i
) ) i
lotion NN i
applied VBN N
daily RB N
for IN N
10 CD N
minutes NNS N
for IN N
7 CD N
consecutive JJ N
days NNS N
was VBD N
found VBN N
to TO N
be VB N
an DT N
effective JJ N
therapeutic JJ N
agent NN N
, , N
significantly RB N
superior JJ N
to TO N
the DT N
vehicle NN N
, , N
in IN N
a DT N
double-blind NN N
study NN N
in IN N
the DT N
treatment NN N
of IN N
tinea NN p
versicolor NN p
. . p

Mild NNP o
transitory JJ o
contact NN o
dermatitis NN o
of IN N
the DT N
primary JJ N
irritant JJ N
type NN N
occurred VBD N
in IN N
all PDT N
the DT N
treatment NN p
groups NNS p
and CC N
was VBD N
apparently RB N
due JJ N
to TO N
the DT N
detergent NN N
base NN N
. . N

-DOCSTART- -8610775- O O

Efficacy NN o
of IN N
outpatient JJ N
induction NN N
with IN N
low-dose JJ N
intravaginal JJ N
prostaglandin NN i
E2 NNP i
: : i
a DT N
randomized JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ i
trial NN N
. . N

OBJECTIVE VB N
Our PRP$ N
purpose NN N
was VBD N
to TO N
determine VB N
whether IN N
a DT N
protocol NN N
for IN N
outpatient JJ p
induction NN N
is VBZ N
safe JJ o
and CC N
effective JJ o
for IN N
initiating VBG N
labor NN N
. . N

STUDY NNP N
DESIGN NNP N
A NNP N
randomized JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ i
trial NN N
was VBD N
performed VBN N
with IN N
100 CD p
low-risk JJ p
patients NNS p
having VBG p
well-dated JJ p
pregnancies NNS p
. . p

Women NNS p
with IN p
a DT p
Bishop NNP p
score NN p
< NN p
or CC p
= VB p
6 CD p
at IN p
38 CD p
to TO p
40 CD p
weeks NNS p
' POS p
gestation NN p
were VBD N
administered VBN N
either RB N
2 CD N
mg NN N
of IN N
intravaginal JJ i
prostaglandin NN i
E2 NNP i
gel NN i
or CC i
placebo NN i
for IN N
5 CD N
consecutive JJ N
days NNS N
as IN N
outpatients NNS N
while IN N
undergoing VBG N
fetal JJ N
monitoring NN N
. . N

RESULTS VB N
The DT N
median JJ N
interval NN o
from IN o
randomization NN o
to TO o
delivery NN o
was VBD N
4 CD N
days NNS N
in IN N
the DT N
prostaglandin NN i
E2 NNP i
group NN N
( ( N
range VBP N
0 CD N
to TO N
28 CD N
days NNS N
) ) N
versus VBP N
10 CD N
days NNS N
in IN N
the DT N
placebo NN i
group NN N
( ( N
range VBP N
0 CD N
to TO N
26 CD N
days NNS N
, , N
p VBP N
= RB N
0.002 CD N
) ) N
. . N

Twenty-seven CD N
of IN N
50 CD p
patients NNS p
( ( N
54 CD N
% NN N
) ) N
in IN N
the DT N
prostaglandin NN i
E2 NNP i
group NN N
were VBD N
admitted VBN o
for IN o
labor NN o
during IN o
the DT o
dosing VBG o
interval NN o
compared VBN N
with IN N
10 CD N
placebo-treated JJ N
patients NNS N
( ( N
20 CD N
% NN N
, , N
p NN N
= NNP N
0.001 CD N
) ) N
. . N

The DT N
mean JJ o
gestational JJ o
age NN o
at IN o
delivery NN o
was VBD N
significantly RB N
reduced VBN N
in IN N
the DT N
treatment NN N
group NN N
( ( N
39.9 CD N
+/- JJ N
1.0 CD N
weeks NNS N
vs RB N
40.5 CD N
+/- JJ N
0.99 CD N
weeks NNS N
, , N
p VBP N
= RB N
0.003 CD N
) ) N
as IN N
was VBD N
the DT N
incidence NN o
of IN o
postdates NNS o
pregnancy NN o
( ( N
40 CD N
% NN N
vs JJ N
66 CD N
% NN N
, , N
p NN N
= NNP N
0.016 CD N
) ) N
. . N

Hyperstimulation NN o
was VBD N
observed VBN N
in IN N
one CD N
prostaglandin NN i
E2-treated JJ i
patient NN N
, , N
but CC N
no DT N
intervention NN N
was VBD N
required VBN N
. . N

CONCLUSIONS JJ N
Outpatient NNP N
low-dose JJ N
prostaglandin NN i
E2 NNP i
gel NN i
administration NN N
is VBZ N
effective JJ o
for IN N
initiating VBG o
labor NN o
in IN N
patients NNS p
with IN p
an DT p
unfavorable JJ p
cervix NN p
and CC N
appears VBZ N
safe JJ N
if IN N
performed VBN N
with IN N
adequate JJ N
monitoring NN N
. . N

-DOCSTART- -3304622- O O

Dexamethasone NNP i
therapy NN i
and CC N
cortisol JJ N
excretion NN N
in IN N
severe JJ p
pediatric JJ p
head NN p
injury NN p
. . p

Glucocorticoids NNS i
are VBP N
used VBN N
in IN N
an DT N
attempt NN N
to TO N
reduce VB N
brain NN N
edema NN N
secondary JJ N
to TO N
head VB N
injury NN N
. . N

Nevertheless RB N
, , N
their PRP$ N
usefulness JJ N
remains NNS N
uncertain JJ N
and CC N
contradictory NN N
. . N

In IN N
a DT N
randomized JJ N
study NN N
of IN N
24 CD p
children NNS p
with IN p
severe JJ p
head NN p
injury NN p
, , p
urinary JJ p
free JJ p
cortisol NN p
was VBD N
measured VBN N
by IN N
radioimmunoassay NN i
. . i

Twelve CD p
patients NNS p
( ( N
group NN N
1 CD N
) ) N
received VBD N
dexamethasone NN i
and CC N
12 CD p
( ( p
group NN p
2 CD p
) ) p
did VBD N
not RB N
. . N

All DT N
patients NNS N
were VBD N
treated VBN N
with IN N
a DT N
standardized JJ N
regimen NN N
. . N

In IN N
group NN N
1 CD N
there EX N
was VBD N
complete JJ N
suppression NN o
of IN o
endogenous JJ o
cortisol NN o
production NN o
. . o

In IN N
group NN N
2 CD N
free JJ N
cortisol NN N
was VBD N
up RB N
to TO N
20-fold CD N
higher JJR N
than IN N
under IN N
basal JJ N
conditions NNS N
and CC N
reached VBN N
maximum JJ N
values NNS N
on IN N
days NNS N
1-3 RB N
. . N

Since IN N
the DT N
excretion NN o
of IN o
cortisol NN o
in IN o
urine JJ o
reflects VBZ N
the DT N
production NN N
rate NN N
closely RB N
and CC N
is VBZ N
not RB N
influenced VBN N
by IN N
liver NN N
function NN N
and CC N
barbiturates NNS N
, , N
the DT N
results NNS N
in IN N
group NN N
2 CD N
show NN N
that IN N
the DT N
endogenous JJ N
production NN N
of IN N
steroids NNS N
is VBZ N
an DT N
adequate JJ N
reaction NN N
to TO N
severe VB N
head JJ N
injury NN N
. . N

Exogenous JJ N
glucocorticoids NNS i
are VBP N
thus RB N
unlikely JJ N
to TO N
have VB N
any DT N
more JJR N
beneficial JJ N
effects NNS N
than IN N
endogenous JJ N
cortisol NN i
. . i

-DOCSTART- -23875574- O O

Components NNS N
of IN N
working VBG N
memory NN N
and CC N
visual JJ N
selective JJ N
attention NN N
. . N

Load NNP N
theory NN N
( ( N
Lavie NNP N
, , N
N. NNP N
, , N
Hirst NNP N
, , N
A. NNP N
, , N
De NNP N
Fockert NNP N
, , N
J. NNP N
W. NNP N
, , N
& CC N
Viding NNP N
, , N
E. NNP N
[ NNP N
2004 CD N
] NNP N
. . N

Load NNP N
theory NN N
of IN N
selective JJ N
attention NN N
and CC N
cognitive JJ N
control NN N
. . N

Journal NNP N
of IN N
Experimental NNP N
Psychology NNP N
: : N
General NNP N
, , N
133 CD N
, , N
339-354 JJ N
. . N

) ) N
proposes VBZ N
that IN N
control NN o
of IN o
attention NN o
depends VBZ N
on IN N
the DT N
amount NN o
and CC o
type NN o
of IN o
load NN o
that WDT N
is VBZ N
imposed VBN N
by IN N
current JJ N
processing NN N
. . N

Specifically RB N
, , N
perceptual JJ N
load NN N
should MD N
lead VB N
to TO N
efficient JJ N
distractor NN N
rejection NN N
, , N
whereas IN N
working VBG N
memory NN N
load NN N
( ( N
dual-task JJ N
coordination NN N
) ) N
should MD N
hinder VB N
distractor NN o
rejection NN o
. . o

Studies NNPS N
support VBP N
load NN N
theory NN N
's POS N
prediction NN N
that IN N
working VBG N
memory NN N
load NN N
will MD N
lead VB N
to TO N
larger JJR N
distractor NN o
effects NNS o
; : o
however RB N
, , N
these DT N
studies NNS N
used VBD N
secondary JJ N
tasks NNS N
that WDT N
required VBD N
only RB N
verbal JJ N
working VBG N
memory NN N
and CC N
the DT N
central JJ N
executive NN N
. . N

The DT N
present JJ N
study NN N
examined VBD N
which WDT N
other JJ N
working VBG N
memory NN N
components NNS N
( ( N
visual JJ N
, , N
spatial JJ N
, , N
and CC N
phonological JJ N
) ) N
influence NN N
visual JJ o
selective JJ o
attention NN o
. . o

Subjects NNS p
completed VBD p
an DT p
attentional JJ o
capture NN o
task NN o
alone RB i
( ( i
single-task JJ i
) ) i
or CC i
while IN i
engaged VBN i
in IN i
a DT i
working JJ i
memory NN i
task NN i
( ( i
dual-task JJ i
) ) i
. . i

Results CC N
showed VBD N
that IN N
along IN N
with IN N
the DT N
central JJ N
executive NN N
, , N
visual JJ N
and CC N
spatial JJ N
working VBG N
memory NN N
influenced VBD N
selective JJ o
attention NN o
, , N
but CC N
phonological JJ N
working VBG N
memory NN N
did VBD N
not RB N
. . N

Specifically RB N
, , N
attentional JJ o
capture NN o
was VBD N
larger JJR N
when WRB N
visual JJ N
or CC N
spatial JJ N
working VBG N
memory NN N
was VBD N
loaded VBN N
, , N
but CC N
phonological JJ N
working VBG N
memory NN N
load NN N
did VBD N
not RB N
affect VB N
attentional JJ o
capture NN o
. . o

The DT N
results NNS N
are VBP N
consistent JJ N
with IN N
load NN N
theory NN N
and CC N
suggest VBP N
specific JJ N
components NNS N
of IN N
working VBG N
memory NN N
influence NN N
visual JJ o
selective JJ o
attention NN o
. . o

-DOCSTART- -16343383- O O

Combined VBN i
typhoid JJ i
fever NN i
and CC i
hepatitis VB i
A DT i
vaccine NN i
: : i
comparison NN N
of IN N
immunogenicity NN o
and CC o
safety NN o
to TO N
concomitant VB N
monovalent JJ N
vaccine NN N
over IN N
3 CD N
years NNS N
. . N

BACKGROUND IN N
The DT N
safety NN o
and CC o
immunogenicity NN o
of IN N
Viatim NNP i
, , N
a DT N
combined JJ i
hepatitis NN i
A NNP i
( ( i
HA NNP i
) ) i
and CC i
typhoid JJ i
fever NN i
( ( i
Vi NNP i
) ) i
vaccine NN i
, , N
were VBD N
compared VBN N
with IN N
the DT N
monovalent JJ i
component NN i
vaccines VBZ i
up IN N
to TO N
and CC N
1 CD N
month NN N
after IN N
a DT N
booster NN N
dose NN N
at IN N
3 CD N
years NNS N
. . N

METHODS NNP N
Healthy NNP p
, , p
adult NN p
volunteers NNS p
were VBD N
randomized VBN N
to TO N
receive VB N
Viatim NNP i
( ( p
group NN p
A NNP p
, , p
n JJ p
= NNP p
179 CD p
) ) p
or CC N
separate JJ i
HA NNP i
and CC i
Vi NNP i
vaccines NNS i
( ( p
group NN p
B NNP p
, , p
n JJ p
= NNP p
181 CD p
) ) p
; : p
subgroups NNS N
were VBD N
boosted VBN N
after IN N
3 CD N
years NNS N
with IN N
Viatim NNP i
( ( p
groups NNS p
C NNP p
and CC p
D NNP p
, , p
n JJ p
= NN p
56 CD p
and CC p
46 CD p
, , p
respectively RB p
) ) p
. . p

Local JJ N
and CC N
systemic JJ N
reactions NNS N
were VBD N
recorded VBN N
for IN N
28 CD N
days NNS N
postvaccination NN N
. . N

Seroconversion NN o
and CC o
seroprotection NN o
rates NNS o
and CC o
geometric JJ o
mean NN o
antibody NN o
concentrations NNS o
were VBD N
measured VBN N
at IN N
14 CD N
and CC N
28 CD N
days NNS N
, , N
1 CD N
, , N
2 CD N
, , N
and CC N
3 CD N
years NNS N
postvaccination NN N
, , N
and CC N
28 CD N
days NNS N
after IN N
the DT N
booster NN N
dose NN N
. . N

RESULTS NNP N
Local NNP o
and CC o
systemic JJ o
safety NN o
profiles NNS o
were VBD N
equivalent JJ N
between IN N
the DT N
two CD N
groups NNS N
. . N

Immediate NNP o
local JJ o
reactions NNS o
were VBD N
infrequent JJ N
( ( N
1 CD N
in IN N
group NN N
A NNP N
and CC N
2 CD N
in IN N
group NN N
B NNP N
) ) N
. . N

Local JJ o
reactions NNS o
, , o
consisting VBG o
mostly RB o
of IN o
mild NN o
or CC o
moderate JJ o
pain NN o
, , N
were VBD N
least JJS N
frequent JJ N
with IN N
monovalent JJ N
HA NNP N
. . N

Antibody NNP o
concentrations NNS o
to TO N
both DT N
antigens NNS N
were VBD N
similar JJ N
in IN N
groups NNS N
A NNP N
and CC N
B NNP N
, , N
in IN N
which WDT N
HA NNP o
seroprotection NN o
rates NNS o
( ( N
> CD N
or CC N
= VB N
20 CD N
mIU/mL NN N
) ) N
were VBD N
respectively RB N
, , N
98.7 CD N
% NN N
and CC N
100 CD N
% NN N
at IN N
day NN N
28 CD N
, , N
and CC N
99.1 CD N
% NN N
and CC N
99.0 CD N
% NN N
after IN N
3 CD N
years NNS N
, , N
achieving VBG N
100 CD N
% NN N
after IN N
the DT N
booster NN N
. . N

Vi NNP o
seroprotection NN o
rates NNS o
( ( N
> CD N
or CC N
= VB N
1 CD N
microg/mL NN N
) ) N
of IN N
85.2 CD N
% NN N
and CC N
84.9 CD N
% NN N
after IN N
28 CD N
days NNS N
fell VBD N
to TO N
32.1 CD N
% NN N
and CC N
35.6 CD N
% NN N
after IN N
3 CD N
years NNS N
, , N
increasing VBG N
to TO N
67.3 CD N
% NN N
and CC N
69.8 CD N
% NN N
after IN N
the DT N
booster NN N
dose NN N
. . N

CONCLUSIONS VB N
The DT N
combined JJ i
HA/Vi NNP i
vaccine NN i
, , i
Viatim NNP i
, , N
had VBD N
equivalent JJ N
tolerability NN o
and CC o
safety NN o
and CC o
was VBD o
as IN o
rapidly RB o
immunogenic JJ o
as IN N
its PRP$ N
component NN N
monovalent NN N
vaccines NNS N
when WRB N
given VBN N
concurrently RB N
. . N

A DT N
booster NN N
dose NN N
after IN N
3 CD N
years NNS N
significantly RB N
increased VBD N
antibody NN o
levels NNS o
with IN N
some DT N
evidence NN N
of IN N
relative JJ N
hyporesponsiveness NN o
of IN o
the DT o
typhoid JJ o
response NN o
. . o

-DOCSTART- -8837189- O O

Inhibition NN N
of IN N
epidural JJ o
morphine-induced JJ o
pruritus NN o
by IN N
intravenous JJ N
droperidol NN i
. . i

The DT N
effect NN N
of IN N
increasing VBG N
the DT N
doses NNS N
of IN N
morphine NN i
and CC N
of IN N
droperidol NN i
. . i

BACKGROUND NNP N
AND CC N
OBJECTIVES NNP N
Because IN N
the DT N
mechanism NN N
of IN N
inhibition NN N
of IN N
epidural JJ N
morphine-induced JJ N
pruritus NN N
by IN N
droperidol NN N
is VBZ N
not RB N
clear JJ N
, , N
this DT N
study NN N
was VBD N
undertaken VBN N
to TO N
determine VB N
the DT N
effects NNS N
of IN N
larger JJR N
doses NNS N
of IN N
droperidol NN i
or CC i
morphine NN i
, , N
or CC N
both DT N
. . N

METHODS VB N
A DT N
double-blind NN N
study NN N
was VBD N
performed VBN N
in IN N
210 CD p
ASA NNP p
I PRP p
or CC p
II NNP p
patients NNS p
undergoing VBG p
cesarean JJ p
delivery NN p
, , p
who WP p
were VBD p
randomly RB p
assigned VBN p
to TO p
six CD p
groups NNS p
. . p

All DT N
patients NNS N
received VBD N
epidural JJ i
anesthesia NN i
with IN i
0.5 CD i
% NN i
bupivacaine NN i
containing VBG i
1:200,000 CD i
epinephrine NN i
, , i
to TO i
which WDT i
2 CD i
mg NN i
( ( N
groups NNS N
1 CD N
, , N
2 CD N
, , N
and CC N
3 CD N
) ) N
or CC N
4 CD N
mg NN N
( ( N
groups NNS N
4 CD N
, , N
5 CD N
, , N
and CC N
6 CD N
) ) N
morphine NN i
sulfate NN i
was VBD N
added VBN N
. . N

Just RB N
after IN N
delivery NN N
, , N
2.5 CD N
mg NN N
droperidol NN i
was VBD N
given VBN N
intravenously RB N
to TO N
groups NNS N
2 CD N
and CC N
5 CD N
, , N
and CC N
5 CD N
mg NN N
was VBD N
given VBN N
to TO N
groups NNS N
3 CD N
and CC N
6 CD N
. . N

During IN N
the DT N
postoperative JJ N
period NN N
, , N
the DT N
patients NNS N
were VBD N
assessed VBN N
for IN N
the DT N
occurrence NN o
and CC o
severity NN o
of IN o
pruritus NN o
( ( N
classified VBN N
as IN N
absent NN N
, , N
mild NN N
, , N
moderate JJ N
, , N
or CC N
severe RB N
) ) N
or CC N
other JJ o
untoward JJ o
symptoms NNS o
. . o

The DT N
groups NNS N
were VBD N
compared VBN N
for IN N
the DT N
incidence NN o
of IN o
pruritus NN o
by IN N
the DT N
Mann-Whitney NNP N
nonparametric JJ N
test NN N
. . N

RESULTS VB N
The DT N
incidence NN o
of IN o
pruritus NN o
was VBD N
significantly RB N
reduced VBN N
only RB N
when WRB N
the DT N
control NN N
group NN N
. . N

( ( N
no DT N
droperidol NN i
) ) i
was VBD N
compared VBN N
with IN N
the DT N
group NN N
that WDT N
received VBD N
2.5 CD N
mg NN N
droperidol NN i
, , N
both DT N
when WRB N
2 CD N
mg NN N
and CC N
when WRB N
4 CD N
mg NN N
morphine NN i
was VBD N
used VBN N
. . N

A DT N
5-mg JJ N
dose NN N
of IN N
droperidol NN N
had VBD N
no DT N
inhibitory JJ o
effect NN o
. . o

There EX N
was VBD N
no DT N
difference NN N
in IN N
the DT N
incidence NN o
of IN o
pruritus NN o
between IN N
use NN N
of IN N
2 CD N
mg NNS N
and CC N
4 CD N
mg NN N
morphine NN i
. . i

Other JJ N
untoward JJ o
effects NNS o
of IN N
morphine NN i
either DT N
could MD N
not RB N
be VB N
observed VBN N
or CC N
occurred VBN N
with IN N
an DT N
incidence NN N
unaffected VBN N
by IN N
either DT N
dose NN N
of IN N
droperidol NN i
. . i

CONCLUSION NNP N
Pruritus NNP o
caused VBN N
by IN N
epidural JJ N
use NN N
of IN N
2 CD N
or CC N
4 CD N
mg NN N
of IN N
morphine NN i
is VBZ N
inhibited VBN N
by IN N
the DT N
intravenous JJ N
use NN N
of IN N
2.5 CD N
mg NNS N
droperidol RB i
but CC N
not RB N
by IN N
a DT N
larger JJR N
dose NN N
. . N

-DOCSTART- -6882809- O O

Handwarming VBG N
and CC N
relaxation NN N
in IN N
temperature NN N
feedback NN N
: : N
positive JJ N
placebo NN i
effects NNS N
. . N

Sixteen JJ p
males NNS p
and CC p
females NNS p
were VBD N
randomly RB N
assigned VBN N
to TO N
either DT N
temperature NN i
feedback NN i
groups NNS i
warm-relax JJ i
( ( i
WR NNP i
) ) i
or CC i
cool-relax JJ i
( ( i
CR NNP i
) ) i
to TO N
determine VB N
how WRB N
successful JJ N
hand-warming NN N
and CC N
-cooling VBG N
alters NNS N
the DT N
subjective JJ N
report NN N
of IN N
relaxation NN N
. . N

After IN N
eight CD N
1/2-hour JJ N
sessions NNS N
the DT N
WR NNP N
and CC N
CR NNP N
demonstrated VBD N
a DT N
significant JJ N
difference NN N
in IN N
temperature NN o
change NN o
, , N
but CC N
there EX N
were VBD N
no DT N
significant JJ N
main JJ N
effects NNS N
in IN N
reported VBN N
subjective JJ o
relaxation NN o
. . o

The DT N
reported JJ N
feelings NNS N
of IN N
relaxation NN o
were VBD N
negatively RB N
correlated VBN N
to TO N
the DT N
directionality NN N
of IN N
temperature NN N
change NN N
and CC N
were VBD N
primarily RB N
attributed VBN N
to TO N
nonspecific JJ N
expectancies NNS N
. . N

-DOCSTART- -15167457- O O

Gender NNP N
difference NN N
in IN N
the DT N
response NN N
to TO N
an DT N
angiotensin-converting JJ i
enzyme NN i
inhibitor NN i
and CC i
a DT i
diuretic JJ i
in IN N
hypertensive JJ p
patients NNS p
of IN p
African JJ p
descent NN p
. . p

BACKGROUND IN N
The DT N
efficacy NN N
of IN N
angiotensin-converting JJ i
enzyme NN i
( ( i
ACE NNP i
) ) i
inhibitors NNS i
in IN N
decreasing VBG o
blood NN o
pressure NN o
in IN N
African JJ p
patients NNS p
is VBZ N
controversial JJ N
. . N

OBJECTIVE IN N
We PRP N
examined VBD N
the DT N
ambulatory JJ o
blood NN o
pressure NN o
( ( o
ABP NNP o
) ) o
response NN o
to TO N
a DT N
diuretic JJ i
and CC i
an DT i
ACE NNP i
inhibitor NN i
in IN N
hypertensive JJ N
patients NNS p
of IN p
East JJ p
African JJ p
descent NN p
and CC N
evaluated VBD N
the DT N
individual JJ N
characteristics NNS o
that WDT N
determined VBD N
treatment NN o
efficacy NN o
. . o

DESIGN VB N
A DT N
single-blind JJ N
randomized JJ N
AB/BA NNP N
crossover NN N
design NN N
. . N

SETTING NN N
Hypertensive JJ p
families NNS p
of IN p
East JJ p
African JJ p
descent NN p
from IN p
the DT p
general JJ p
population NN p
in IN p
the DT p
Seychelles NNP p
. . p

PARTICIPANTS NNP N
Fifty-two NNP p
( ( p
29 CD p
men NNS p
and CC p
23 CD p
women NNS p
) ) p
out IN p
of IN p
62 CD p
eligible JJ p
hypertensive JJ p
patients NNS p
were VBD p
included.Main JJ p
outcome JJ N
measures NNS N
ABP NNP o
response NN o
to TO N
20 CD N
mg NNS N
lisinopril NN i
( ( i
LIS NNP i
) ) i
daily RB N
and CC N
25 CD N
mg NNS N
hydrochlorothiazide RB i
( ( i
HCT NNP i
) ) i
daily RB N
given VBN N
for IN N
a DT N
4-week JJ N
period NN N
. . N

Results VB N
The DT N
daytime JJ o
systolic/diastolic JJ o
ABP NNP o
response NN o
to TO N
HCT NNP N
was VBD N
4.9 CD N
[ JJ N
95 CD N
% NN N
confidence NN N
interval NN N
( ( N
CI NNP N
) ) N
1.2-8.6 CD N
] JJ N
/3.6 NNP N
( ( N
1.0-6.2 JJ N
) ) N
mmHg NN N
for IN N
men NNS N
and CC N
12.9 CD N
( ( N
9.2-16.6 CD N
) ) N
/6.3 NN N
( ( N
3.7-8.8 JJ N
) ) N
mmHg NN N
for IN N
women NNS N
. . N

With IN N
LIS NNP N
the DT N
response NN o
was VBD N
18.8 CD N
( ( N
15.0-22.5 CD N
) ) N
/14.6 NN N
( ( N
12.0-17.1 JJ N
) ) N
mmHg NN N
for IN N
men NNS N
and CC N
12.4 CD N
( ( N
8.7-16.2 CD N
) ) N
/7.7 NN N
( ( N
5.1-10.2 JJ N
) ) N
mmHg NN N
for IN N
women NNS N
. . N

The DT N
night-time JJ o
systolic/diastolic JJ o
response NN o
to TO N
HCT NNP i
was VBD N
5.0 CD N
( ( N
0.6-9.4 CD N
) ) N
/2.7 NN N
[ NNP N
( ( N
-0.4 NNP N
) ) N
-5.7 VBP N
] JJ N
mmHg NN N
for IN N
men NNS N
and CC N
11.5 CD N
( ( N
7.1-16.0 CD N
) ) N
/5.7 NN N
( ( N
2.6-8.8 JJ N
) ) N
mmHg NN N
for IN N
women NNS N
, , N
and CC N
to TO N
LIS NNP i
was VBD N
18.7 CD N
( ( N
14.2-22.1 JJ N
) ) N
/15.4 NN N
( ( N
12.4-18.5 JJ N
) ) N
mmHg NN N
for IN N
men NNS N
and CC N
3.5 CD N
[ NN N
( ( N
-1.0 NNP N
) ) N
-7.9 VBP N
] JJ N
/2.3 NNP N
[ NNP N
( ( N
-0.8 NNP N
) ) N
-5.4 VBP N
] JJ N
mmHg NN N
for IN N
women NNS N
. . N

Linear JJ N
regression NN N
analyses NNS N
showed VBD N
that IN N
gender NN o
is VBZ o
an DT o
independent JJ o
predictor NN o
of IN o
the DT o
ABP NNP o
responses NNS o
to TO N
HCT NNP i
and CC N
to TO N
LIS NNP i
. . i

CONCLUSIONS NNP N
Hypertensive NNP N
patients NNS N
of IN N
African JJ N
descent NN N
responded VBD o
better JJR o
to TO N
LIS NNP i
than IN N
to TO N
HCT NNP i
. . i

Men NNP o
responded VBD o
better RBR o
to TO N
LIS NNP N
than IN N
to TO N
HCT NNP i
and CC N
women NNS o
responded VBD o
similarly RB o
to TO N
both DT N
drugs NNS N
. . N

-DOCSTART- -10172265- O O

Protocol NN N
for IN N
the DT N
Multicenter NNP N
Acute NNP N
Stroke NNP N
Trial NNP N
-- : N
thrombolysis NN N
study NN N
. . N

The DT N
rationale NN N
for IN N
the DT N
Multicenter NNP N
Acute NNP N
Stroke NNP N
Trial NNP N
( ( N
MAST NNP N
) ) N
is VBZ N
presented VBN N
in IN N
a DT N
companion NN N
article NN N
appearing VBG N
in IN N
this DT N
issue NN N
. . N

Acute NNP N
ischaemic JJ N
stroke NN N
is VBZ N
the DT N
third JJ N
major JJ N
cause NN N
of IN N
death NN o
in IN N
developed JJ N
countries NNS N
, , N
and CC N
a DT N
major JJ N
cause NN N
of IN N
disability NN o
. . o

Despite IN N
a DT N
very RB N
poor JJ N
prognosis NN N
, , N
no DT N
treatment NN N
has VBZ N
demonstrated VBN N
an DT N
efficacy NN N
in IN N
lowering VBG N
the DT N
mortality NN o
and CC o
disability NN o
resulting VBG N
from IN N
stroke NN N
events NNS N
. . N

Thrombolysis NN i
has VBZ N
been VBN N
proven VBN N
to TO N
reduce VB N
mortality NN o
in IN o
myocardial JJ o
infarction NN o
, , N
and CC N
it PRP N
has VBZ N
been VBN N
shown VBN N
able JJ N
to TO N
induce VB N
recanalisation NN o
when WRB N
administered VBN N
to TO N
acute VB p
stroke NN p
patients NNS p
. . p

A DT N
recent JJ N
meta NN N
analysis NN N
of IN N
small-sized JJ N
studies NNS N
suggests VBZ N
that IN N
thrombolysis NN i
could MD N
offer VB N
some DT N
benefit NN N
to TO N
stroke VB p
patients NNS p
, , N
by IN N
reducing VBG N
the DT N
mortality NN o
and CC o
severe JJ o
invalidity NN o
by IN N
56 CD N
% NN N
; : N
these DT N
results NNS N
need VBP N
to TO N
be VB N
confirmed VBN N
in IN N
adequately RB N
designed VBN N
and CC N
sized VBN N
studies NNS N
. . N

-DOCSTART- -12116339- O O

Monitoring VBG N
tumour NN N
cells NNS N
in IN N
the DT N
peripheral JJ N
blood NN N
of IN N
small JJ p
cell NN p
lung NN p
cancer NN p
patients NNS p
. . p

BACKGROUND NNP N
Flow NNP i
cytometry NN i
was VBD N
used VBN N
to TO N
enumerate VB N
tumour JJ N
cells NNS N
in IN N
longitudinal JJ N
studies NNS N
of IN N
peripheral JJ N
blood NN N
from IN N
small JJ p
cell NN p
lung NN p
cancer NN p
( ( p
SCLC NNP p
) ) p
patients NNS p
, , N
together RB N
with IN N
magnetic JJ N
bead NN N
selection NN N
to TO N
isolate VB N
and CC N
identify VB N
these DT N
cells NNS N
. . N

As IN N
part NN N
of IN N
a DT N
trial NN N
, , N
11 CD p
patients NNS p
received VBD p
either RB p
standard JJ p
( ( p
four CD p
weekly RB p
) ) p
chemotherapy NN i
with IN i
ifosfamide NN i
, , i
carboplatin NN i
, , i
and CC i
etoposide RB i
( ( i
ICE NNP i
) ) i
or CC i
accelerated VBN i
( ( i
two CD i
weekly RB i
) ) i
ICE NNP i
with IN i
filgrastim NN i
( ( i
granulocyte JJ i
colony-stimulating NN i
factor NN i
[ IN i
G-CSF NNP i
] NNP i
) ) i
and CC i
autologous JJ i
stem NN i
cell NN i
support NN i
. . i

METHODS NNP N
Fresh NNP N
venous JJ N
blood NN N
was VBD N
taken VBN N
throughout IN N
treatment NN N
and CC N
follow-up NN N
. . N

Aliquots NNS N
were VBD N
stained VBN N
with IN N
a DT N
tumour-specific JJ N
antibody NN N
against IN N
epithelial JJ N
tissue NN N
( ( N
Ber NNP N
EP4 NNP N
) ) N
, , N
verified VBD N
as IN N
a DT N
good JJ N
marker NN N
of IN N
SCLC NNP N
cells NNS N
by IN N
immunohistochemistry NN N
. . N

Matched NNP N
samples NNS N
labelled VBD N
with IN N
Ber NNP N
EP4 NNP N
were VBD N
separated VBN N
magnetically RB N
by IN N
adding VBG N
a DT N
secondary JJ N
bead-antibody NN N
conjugate NN N
for IN N
confirmation NN N
of IN N
tumour NN N
cell NN N
identity NN N
. . N

RESULTS NNP N
Circulating NNP o
tumour JJ o
cells NNS o
were VBD N
detected VBN N
and CC N
monitored VBN N
throughout IN N
treatment NN N
periods NNS N
. . N

An DT N
initial JJ o
rise NN o
in IN o
circulating VBG o
cells NNS o
after IN o
the DT o
first JJ o
cycle NN o
was VBD N
followed VBN N
by IN N
a DT N
fall NN N
in IN N
both DT N
treatment NN N
arms NNS N
to TO N
baseline NN N
levels NNS N
set VBN N
by IN N
normal JJ N
controls NNS N
. . N

This DT N
was VBD N
achieved VBN N
by IN N
week NN N
12 CD N
in IN N
the DT N
accelerated JJ N
treatment NN N
arm NN N
and CC N
by IN N
week NN N
24 CD N
in IN N
the DT N
standard JJ N
arm NN N
. . N

CONCLUSIONS NNP N
Flow NNP N
cytometry NN N
and CC N
magnetic JJ N
bead NN N
isolation NN N
can MD N
be VB N
used VBN N
to TO N
identify VB N
changes NNS N
in IN N
numbers NNS N
of IN N
circulating VBG N
tumour JJ N
cells NNS N
in IN N
patients NNS N
undergoing JJ N
chemotherapy NN i
for IN N
SCLC NNP N
and CC N
thereafter RB N
during IN N
follow-up JJ N
periods NNS N
. . N

Absence NN N
of IN N
tumour JJ N
cells NNS N
may MD N
indicate VB N
a DT N
more RBR N
favourable JJ N
patient NN N
group NN N
who WP N
would MD N
benefit VB N
from IN N
a DT N
more RBR N
intense JJ N
course NN N
of IN N
treatment NN N
. . N

-DOCSTART- -2711711- O O

[ JJ N
Dose-reduced NNP N
antihypertensive JJ i
agents NNS i
-- : i
use NN i
in IN N
complex JJ N
nonmedicamentous JJ i
therapy NN N
of IN N
hypertension NN N
] NNP N
. . N

In IN N
order NN N
to TO N
estimate VB N
the DT N
influence NN N
of IN N
a DT N
non-medicamentous JJ i
therapy NN i
( ( i
CNT NNP i
) ) i
on IN N
the DT N
consumption NN N
of IN N
medicaments NNS N
and CC N
coronary JJ N
risk NN N
in IN N
high JJ N
blood NN N
pressure NN N
73 CD p
hypertensives NNS p
of IN p
a DT p
medicamentously RB p
stabilized VBN p
CNT-group NNP p
were VBD N
examined VBN N
in IN N
comparison NN N
to TO N
a DT N
group NN p
of IN p
the DT p
same JJ p
size NN p
of IN p
patients NNS p
with IN p
hypertension NN p
who WP p
were VBD p
managed VBN p
exclusively RB p
medicamentously RB p
for IN N
behaviour NN N
of IN N
blood NN N
pressure NN N
, , N
need NN N
of IN N
antihypertensive JJ i
drugs NNS i
and CC N
changes NNS N
of IN N
hypertension-associated JJ N
risk NN N
factors NNS N
. . N

After IN N
an DT N
exactly RB N
controlled VBN N
6-month JJ N
treatment NN N
hypertensives NNS p
with IN N
additionally RB N
recommended VBN N
far-reaching NN N
CNT NNP N
showed VBD N
an DT N
economization NN N
of IN N
medicaments NNS N
by IN N
scarcely RB N
the DT N
half NN N
in IN N
comparison NN N
to TO N
the DT N
reference NN N
group NN N
. . N

By IN N
means NNS N
of IN N
suitable JJ N
control NN N
methods VBZ N
a DT N
causal JJ N
non-medicamentously RB i
conditioned JJ N
decrease NN N
of IN N
blood NN o
pressure NN o
could MD N
be VB N
excluded VBN N
. . N

A DT N
different JJ N
need NN N
of IN N
antihypertensive JJ i
drugs NNS i
was VBD N
simulated VBN N
by IN N
the DT N
exacter JJ N
intake NN N
of IN N
medicaments NNS N
in IN N
the DT N
index-patients NNS N
. . N

Notwithstanding VBG N
the DT N
metabolic JJ N
effects NNS N
of IN N
the DT N
additional JJ N
therapy NN N
have VBP N
induced VBN N
a DT N
positive JJ N
change NN N
of IN N
atherogenic JJ o
lipids NNS o
. . o

The DT N
examinations NNS N
indicate VBP N
in IN N
general JJ N
the DT N
difficulty NN N
of IN N
the DT N
judgement NN N
of IN N
efficacy NN N
of IN N
non-medicamentous JJ i
therapeutic JJ i
measures NNS N
in IN N
connection NN N
with IN N
a DT N
rational JJ N
dose-reduced JJ N
long-term JJ N
therapy NN N
with IN N
antihypertensive JJ N
drugs NNS N
. . N

-DOCSTART- -11877686- O O

Benefits NNS o
, , o
morbidity NN o
, , o
and CC o
mortality NN o
associated VBN N
with IN N
long-term JJ N
administration NN N
of IN N
oral JJ i
anticoagulant JJ i
therapy NN i
to TO N
patients NNS p
with IN p
peripheral JJ p
arterial JJ p
bypass NN p
procedures NNS p
: : p
a DT N
prospective JJ N
randomized NN N
study NN N
. . N

BACKGROUND NNP N
The DT N
benefits NNS N
of IN N
the DT N
long-term JJ N
administration NN N
of IN N
oral JJ i
anticoagulant JJ i
therapy NN i
remain VBP N
unclear JJ N
in IN N
patients NNS p
with IN p
lower JJR p
extremity NN p
arterial JJ p
bypass NN p
surgery NN p
. . p

We PRP N
studied VBD N
the DT N
effect NN N
of IN N
warfarin NN i
plus CC i
aspirin JJ i
therapy NN i
( ( i
WASA NNP i
) ) i
versus NN i
aspirin JJ i
therapy NN i
alone RB i
( ( i
ASA NNP i
) ) i
on IN N
patient NN o
mortality NN o
, , o
morbidity NN o
and CC o
bypass NN o
patency NN o
rates NNS o
in IN N
a DT N
randomized JJ N
clinical JJ N
trial NN N
. . N

METHODS NNP N
In IN N
a DT N
multicenter NN N
, , N
prospective JJ N
, , N
nonmasked JJ N
clinical JJ N
trial NN N
, , N
831 CD p
patients NNS p
who WP p
underwent JJ p
peripheral JJ p
arterial JJ p
bypass NN p
surgery NN p
were VBD N
compared VBN N
in IN N
a DT N
long-term JJ p
treatment NN p
program NN p
of IN p
WASA NNP i
( ( N
target VB N
international JJ N
normalized JJ N
ratio NN N
of IN N
1.4 CD N
to TO N
2.8 CD N
; : N
325 CD N
mg/day NN N
) ) N
with IN N
ASA NNP i
( ( N
325 CD N
mg/day NN N
) ) N
. . N

The DT N
primary JJ N
end NN N
point NN N
was VBD N
bypass JJ o
patency NN o
, , o
and CC o
mortality NN o
and CC o
morbidity NN o
were VBD N
the DT N
secondary JJ N
endpoints NNS N
. . N

RESULTS VB N
There EX N
were VBD N
133 CD N
deaths NNS o
in IN N
the DT N
WASA NNP i
group NN N
( ( N
31.8 CD N
% NN N
) ) N
and CC N
95 CD N
deaths NNS o
in IN N
the DT N
ASA NNP i
group NN N
( ( N
23.0 CD N
% NN N
; : N
risk NN N
ratio NN N
, , N
1.41 CD N
; : N
95 CD N
% NN N
confidence NN N
interval NN N
, , N
1.09 CD N
to TO N
1.84 CD N
; : N
P NNP N
=.0001 NNP N
) ) N
. . N

Major JJ o
hemorrhagic JJ o
events NNS o
occurred VBD N
more RBR N
frequently RB N
in IN N
the DT N
WASA NNP i
group NN N
( ( N
WASA NNP N
, , N
n JJ N
= VBP N
35 CD N
; : N
ASA NNP i
, , N
n JJ N
= VBP N
15 CD N
; : N
P NNP N
=.02 NNP N
) ) N
. . N

In IN N
the DT N
prosthetic JJ N
bypass NN N
group NN N
, , N
there EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
patency NN o
rate NN o
in IN N
the DT N
8-mm JJ N
bypass NN N
subgroup NN N
, , N
but CC N
there RB N
was VBD N
a DT N
significant JJ N
difference NN N
in IN N
patency NN o
rate NN o
in IN N
the DT N
6-mm JJ N
bypass NN N
subgroup NN N
( ( N
femoral-popliteal JJ N
; : N
71.4 CD N
% NN N
in IN N
the DT N
WASA NNP i
group NN N
versus VBD N
57.9 CD N
% NN N
in IN N
the DT N
ASA NNP i
group NN N
; : N
P NNP N
=.02 NNP N
) ) N
. . N

In IN N
the DT N
vein JJ N
bypass NN N
group NN N
, , N
patency NN o
rate NN o
was VBD N
unaffected VBN N
( ( N
75.3 CD N
% NN N
in IN N
the DT N
WASA NNP i
group NN N
versus VBD N
74.9 CD N
% NN N
in IN N
the DT N
ASA NNP N
group NN N
) ) N
. . N

CONCLUSION VB N
The DT N
long-term JJ N
administration NN N
of IN N
warfarin JJ i
therapy NN i
when WRB N
combined VBN N
with IN N
aspirin JJ N
therapy NN N
has VBZ N
only RB N
a DT N
few JJ N
selected VBN N
indications NNS N
for IN N
improvement NN N
of IN N
bypass NN o
patency NN o
and CC N
is VBZ N
associated VBN N
with IN N
an DT N
increased VBN N
risk NN o
of IN o
morbidity NN o
and CC o
mortality NN o
. . o

-DOCSTART- -3030386- O O

Antihypertensive JJ o
effect NN o
of IN N
single JJ N
doses NNS N
of IN N
enalapril NN i
in IN N
hypertensive JJ p
patients NNS p
treated VBN p
with IN p
bendrofluazide NN i
. . i

This DT N
study NN N
was VBD N
designed VBN N
to TO N
investigate VB N
the DT N
validity NN N
of IN N
the DT N
then RB N
current JJ N
recommendations NNS N
for IN N
initiation NN N
of IN N
therapy NN N
with IN N
enalapril NN i
in IN N
hypertensive JJ p
patients NNS p
on IN p
treatment NN p
with IN p
a DT p
diuretic JJ p
. . p

Enalapril NNP i
in IN N
single JJ N
doses NNS N
of IN N
10 CD N
and CC N
20 CD N
mg NN N
was VBD N
given VBN N
to TO N
13 CD p
hypertensive JJ p
patients NNS p
on IN p
treatment NN p
with IN p
bendrofluazide JJ i
5 CD p
mg JJ p
daily RB p
in IN N
a DT N
randomised JJ N
, , N
crossover NN N
, , N
placebo NN i
controlled VBD N
study NN N
. . N

The DT o
mean JJ o
maximal JJ o
reduction NN o
in IN o
blood NN o
pressure NN o
was VBD N
similar JJ N
with IN N
both DT N
doses NNS N
( ( N
35/20 CD N
mmHg NN N
supine NN N
, , N
38/20 CD N
mmHg NN N
standing NN N
) ) N
, , N
occurred VBD N
on IN N
average NN N
within IN N
6 CD N
h NN N
of IN N
tablet NN N
ingestion NN N
, , N
and CC N
was VBD N
not RB N
accompanied VBN N
by IN N
any DT N
significant JJ N
change NN N
in IN N
heart NN o
rate NN o
. . o

Three CD N
patients NNS N
experienced VBD N
symptomatic JJ o
hypotension NN o
. . o

In IN N
one CD N
patient NN N
this DT N
was VBD N
incapacitating VBG o
after IN N
10 CD N
mg NN N
and CC N
precluded JJ N
exposure NN N
to TO N
20 CD N
mg NN N
. . N

This DT N
study NN N
shows VBZ N
that IN N
in IN N
hypertensive JJ p
patients NNS p
receiving VBG p
treatment NN p
with IN p
diuretics NNS p
, , N
the DT N
addition NN N
of IN N
enalapril NN N
should MD N
be VB N
undertaken VBN N
with IN N
caution NN N
. . N

An DT N
optimal JJ N
starting VBG N
dose NN N
of IN N
enalapril NN N
in IN N
such JJ N
patients NNS N
remains VBZ N
to TO N
be VB N
confirmed VBN N
. . N

-DOCSTART- -11476129- O O

Clomipramine NNP i
versus NN i
haloperidol NN i
in IN N
the DT N
treatment NN N
of IN N
autistic JJ p
disorder NN p
: : p
a DT N
double-blind NN N
, , N
placebo-controlled JJ i
, , N
crossover NN N
study NN N
. . N

Clomipramine NNP i
, , i
haloperidol NN i
, , i
and CC i
placebo NN i
were VBD N
compared VBN N
with IN N
baseline NN N
in IN N
the DT N
treatment NN N
of IN N
autism NN p
, , N
and CC N
overall JJ o
outcome NN o
, , o
specific JJ o
symptoms NNS o
, , o
and CC o
side JJ o
effects NNS o
were VBD N
examined VBN N
. . N

It PRP N
was VBD N
hypothesized VBN N
that IN N
clomipramine NN i
would MD N
be VB N
better RB N
tolerated VBN N
than IN N
haloperidol NN i
and CC N
prove VB N
superior JJ N
on IN N
a DT N
measure NN N
of IN N
stereotypy NN N
. . N

Individuals NNS p
with IN p
a DT p
DSM-IV JJ p
diagnosis NN p
of IN p
autistic JJ p
disorder NN p
( ( p
mean JJ p
age NN p
, , p
16.3 CD p
years NNS p
; : p
range NN p
, , p
10-36 JJ p
years NNS p
) ) p
were VBD p
randomly RB p
assigned VBN p
, , p
by IN p
using VBG p
a DT p
Latin NNP p
square NN p
design NN p
, , p
to TO p
the DT p
following JJ p
7-week JJ p
trials NNS p
: : p
placebo NN i
, , i
clomipramine NN i
( ( p
mean JJ p
daily RB p
dose RB p
, , p
128.4 CD p
mg NN p
; : p
range NN p
, , p
100-150 JJ p
mg NN p
) ) p
, , p
or CC p
haloperidol NN i
( ( p
mean JJ p
daily RB p
dose RB p
, , p
1.3 CD p
mg NN p
; : p
range NN p
, , p
1-1.5 JJ p
mg NN p
) ) p
. . p

Data NNP p
on IN p
36 CD p
subjects NNS p
were VBD p
analyzed VBN p
and CC N
taken VBN N
together RB N
; : N
the DT N
results NNS N
favored VBD N
haloperidol NN i
. . i

In IN N
those DT N
patients NNS N
who WP N
were VBD N
able JJ N
to TO N
complete VB N
a DT N
full JJ N
therapeutic JJ N
trial NN N
, , N
clomipramine NN i
proved VBD N
comparable JJ N
to TO N
haloperidol VB i
in IN N
terms NNS N
of IN N
improvement NN o
compared VBN N
with IN N
baseline NN N
. . N

However RB N
, , N
significantly RB N
fewer JJR N
individuals NNS N
receiving VBG N
clomipramine NN i
versus NN N
haloperidol NN i
were VBD N
able JJ N
to TO N
complete VB N
the DT N
trial NN N
( ( N
37.5 CD N
% NN N
vs. FW N
69.7 CD N
% NN N
, , N
respectively RB N
) ) N
for IN N
reasons NNS N
related VBN N
to TO N
both DT N
side NN o
effects NNS o
and CC o
efficacy NN o
or CC o
behavior NN o
problems NNS o
. . o

In IN N
the DT N
intent-to-treat JJ N
sample NN N
, , N
which WDT N
is VBZ N
perhaps RB N
more RBR N
clinically RB N
relevant JJ N
, , N
only RB N
haloperidol VBZ i
proved VBN N
superior JJ N
to TO N
baseline VB N
on IN N
a DT N
global JJ N
measure NN N
of IN N
autistic JJ o
symptom NN o
severity NN o
, , N
as RB N
well RB N
as IN N
specific JJ N
measures NNS N
for IN N
irritability NN o
and CC o
hyperactivity NN o
. . o

Clomipramine NNP i
did VBD N
not RB N
seem VB N
more RBR N
effective JJ N
on IN N
a DT N
measure NN N
of IN N
stereotypy NN N
, , N
nor CC N
was VBD N
it PRP N
better RBR N
tolerated VBN N
. . N

-DOCSTART- -24350695- O O

A DT N
randomized VBN N
controlled JJ N
trial NN N
of IN N
nonlinear JJ i
frequency NN i
compression NN i
versus IN i
conventional JJ i
processing NN i
in IN i
hearing VBG i
aids NNS i
: : i
speech NN N
and CC N
language NN N
of IN N
children NNS p
at IN p
three CD p
years NNS p
of IN p
age NN p
. . p

OBJECTIVE UH N
To TO N
determine VB N
the DT N
effect NN N
of IN N
nonlinear JJ i
frequency NN i
compression NN i
( ( i
NLFC NNP i
) ) i
on IN N
children NNS p
's POS p
development NN p
of IN p
speech NN p
and CC p
language NN p
at IN p
three CD p
years NNS p
of IN p
age NN p
. . p

DESIGN VB N
A DT N
randomized NN N
controlled VBD N
trial NN N
was VBD N
conducted VBN N
as IN N
part NN N
of IN N
the DT N
population-based JJ p
longitudinal JJ N
study NN N
on IN N
outcomes NNS N
of IN N
children NNS p
with IN p
hearing VBG p
impairment NN p
( ( p
LOCHI NNP p
) ) p
. . p

Participants NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
fitting VBG N
with IN N
NLFC NNP i
( ( i
Phonak NNP i
Naida NNP i
V NNP i
SP NNP i
or CC i
UP NNP i
) ) i
or CC N
with IN N
conventional JJ i
processing NN i
in IN i
hearing VBG i
aids NNS i
, , N
prescribed VBN N
by IN N
using VBG N
either CC N
the DT N
NAL NNP i
or CC N
the DT N
DSL NNP i
formula NN N
. . N

Standardized JJ N
tests NNS N
of IN N
speech NN o
production NN o
, , o
receptive JJ o
and CC o
expressive JJ o
language NN o
were VBD N
administered VBN N
, , N
and CC N
parent NN N
ratings NNS N
were VBD N
collected VBN N
. . N

All DT N
assessments NNS N
were VBD N
double-blinded JJ N
. . N

STUDY NNP N
SAMPLE NNP N
Participants NNP p
were VBD p
44 CD p
of IN p
the DT p
450 CD p
children NNS p
in IN p
the DT p
LOCHI NNP p
cohort NN p
. . p

RESULTS NNP N
Compared VBD N
to TO N
children NNS p
using VBG N
conventional JJ i
processing NN i
, , N
receptive JJ o
and CC o
expressive JJ o
language NN o
was VBD N
higher JJR N
but CC N
receptive JJ o
vocabulary NN o
and CC o
consonant JJ o
articulation NN o
scores NNS o
were VBD N
lower JJR N
for IN N
children NNS N
who WP N
use VBP N
NLFC NNP i
. . i

There EX N
was VBD N
increased VBN N
substitution NN o
of IN o
affricates NNS o
by IN o
fricatives NNS o
for IN N
children NNS N
using VBG N
NLFC NNP i
, , N
compared VBN N
to TO N
children NNS N
using VBG N
conventional JJ i
amplification NN i
. . i

After IN N
allowing VBG N
for IN N
the DT N
effect NN N
of IN N
multiple JJ N
demographic JJ N
variables NNS N
, , N
the DT N
difference NN N
in IN N
global JJ o
language NN o
scores NNS o
between IN N
groups NNS N
was VBD N
not RB N
significant JJ N
( ( N
effect NN N
: : N
0.8 CD N
[ $ N
95 CD N
% NN N
confidence NN N
interval NN N
: : N
- : N
6.7 CD N
, , N
8.3 CD N
] NN N
) ) N
. . N

CONCLUSIONS NNP N
There EX N
is VBZ N
insufficient JJ N
evidence NN N
to TO N
indicate VB N
a DT N
difference NN N
in IN N
language NN o
ability NN o
between IN N
children NNS p
using VBG p
NLFC NNP i
and CC p
those DT p
using VBG p
conventional JJ i
amplification NN i
. . i

-DOCSTART- -12044624- O O

A DT N
single JJ N
infusion NN N
of IN N
intravenous JJ N
ketamine NN i
improves VBZ N
pain VBP N
relief NN N
in IN N
patients NNS p
with IN p
critical JJ p
limb NN p
ischaemia NN p
: : p
results NNS N
of IN N
a DT N
double JJ N
blind NN N
randomised VBD N
controlled VBN N
trial NN N
. . N

We PRP N
report VBP N
the DT N
first JJ N
double JJ N
blind NN N
randomised VBD N
controlled JJ N
trial NN N
of IN N
regular JJ N
opioids NNS i
and CC N
an DT N
infusion NN N
of IN N
low JJ N
dose NN N
( ( N
0.6 CD N
mg/kg NN N
) ) N
intravenous JJ N
ketamine NN i
compared VBN N
with IN N
opioids NNS i
and CC N
placebo NN i
in IN N
patients NNS p
with IN p
allodynia NN p
, , p
hyperalgesia NN p
and CC p
hyperpathia NN p
secondary JJ p
to TO p
critical JJ p
limb NN p
ischaemia NN p
. . p

Thirty-five JJ p
patients NNS p
completed VBD p
the DT p
study NN p
, , p
18 CD p
received VBD N
regular JJ N
opioids NNS i
plus CC i
ketamine NN i
, , N
while IN N
17 CD p
received VBD N
regular JJ i
opioids NNS i
plus CC i
placebo NN i
. . i

Using VBG N
the DT N
Brief NNP o
Pain NNP o
Inventory NNP o
, , o
the DT o
% NN o
pain NN o
relief NN o
that IN N
the DT N
patients NNS N
in IN N
the DT N
ketamine NN N
group NN N
attributed VBD N
to TO N
their PRP$ N
medication NN N
improved VBN N
significantly RB N
from IN N
50 CD N
% NN N
immediately RB N
pre-infusion NN N
to TO N
65 CD N
% NN N
24 CD N
h JJ N
post-infusion NN N
and CC N
69 CD N
% NN N
5 CD N
days NNS N
post VBN N
infusion NN N
. . N

Over IN N
the DT N
same JJ N
period NN N
, , N
the DT N
pain NN o
relief NN o
achieved VBN o
by IN N
the DT N
placebo NN N
group NN N
rose VBD N
from IN N
58 CD N
% NN N
pre-infusion NN N
to TO N
56 CD N
% NN N
24 CD N
h NN N
post NN N
infusion NN N
and CC N
then RB N
50 CD N
% NN N
relief NN N
5 CD N
days NNS N
later RB N
. . N

This DT N
was VBD N
statistically RB o
significant JJ o
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
using VBG N
both DT N
the DT N
t-test NN o
and CC o
the DT o
Wilcoxon NNP o
Rank NNP o
Sum NNP o
test NN o
. . o

The DT N
ketamine NN N
group NN N
also RB N
showed VBD N
a DT N
statistically RB N
significant JJ N
difference NN N
24 CD N
h NN N
post NN N
infusion NN N
of IN N
the DT N
effect NN N
of IN N
pain NN o
on IN N
their PRP$ N
general JJ N
activity NN N
( ( N
P=0.03 NNP N
) ) N
and CC N
on IN N
their PRP$ N
enjoyment NN N
of IN N
life NN N
( ( N
P=0.004 NNP N
) ) N
. . N

This DT N
study NN N
shows VBZ N
that IN N
combining VBG N
a DT N
single JJ N
infusion NN N
of IN N
low JJ N
dose JJ N
ketamine NN N
with IN N
regular JJ N
opioid JJ i
analgesia NN i
can MD N
result VB N
in IN N
a DT N
significant JJ N
improvement NN N
in IN N
pain NN o
relief NN o
for IN N
this DT N
patient NN N
group NN N
. . N

-DOCSTART- -10781855- O O

Immunogenicity NN o
and CC N
reactogenicity NN o
of IN N
a DT N
group NN N
C NNP N
meningococcal JJ N
conjugate NN N
vaccine NN N
compared VBN N
with IN N
a DT N
group NN N
A+C NNP N
meningococcal JJ N
polysaccharide NN N
vaccine NN N
in IN N
adolescents NNS p
in IN N
a DT N
randomised JJ N
observer-blind NN N
controlled VBN N
trial NN N
. . N

This DT N
study NN N
evaluated VBD N
the DT N
immunogenicity NN o
and CC N
reactogenicity NN o
of IN N
a DT N
group NN i
C NNP i
meningococcal JJ i
conjugate NN i
vaccine NN i
( ( i
MenC NNP i
) ) i
compared VBN i
with IN i
a DT i
group NN i
A+C NNP i
meningococcal JJ i
polysaccharide NN i
vaccine NN i
( ( i
MenPS NNP i
) ) i
in IN N
healthy JJ p
adolescents NNS p
. . p

Subjects NNS N
were VBD N
randomised VBN N
to TO N
receive VB N
one CD N
dose NN N
of IN N
either DT N
MenC NNP i
( ( N
n=92 NN N
) ) N
or CC N
MenPS NNP i
( ( N
n=90 NN N
) ) N
. . N

Group NNP N
C NNP N
meningococcal JJ o
IgG NNP o
antibody NN o
concentrations NNS o
and CC o
bactericidal JJ o
titres NNS o
were VBD N
higher JJR N
in IN N
the DT N
MenC NNP N
group NN N
than IN N
the DT N
MenPS NNP N
group NN N
at IN N
1 CD N
month NN N
( ( N
22.8 CD N
U/ml NNP N
vs NN N
4.0 CD N
U/ml NNP N
, , N
p NN N
< VBD N
0.001 CD N
, , N
and CC N
87 CD N
vs NN N
20 CD N
, , N
p NN N
< VBD N
0.001 CD N
, , N
respectively RB N
) ) N
and CC N
12 CD N
months NNS N
( ( N
6.1 CD N
U/ml NNP N
vs NN N
3.0 CD N
U/ml NNP N
, , N
p NN N
< VBD N
0.001 CD N
, , N
and CC N
81.3 CD N
vs NN N
20.2 CD N
, , N
p NN N
< VBD N
0.001 CD N
, , N
respectively RB N
) ) N
. . N

No DT N
differences NNS N
in IN N
post NN o
immunisation NN o
reaction NN o
rates NNS o
were VBD N
noted VBN N
between IN N
the DT N
two CD N
vaccinated VBD N
groups NNS N
. . N

This DT N
study NN N
demonstrated VBD N
the DT N
safety NN N
and CC N
enhanced JJ N
immunogenicity NN o
of IN N
the DT N
candidate NN N
meningococcal JJ N
conjugate NN N
vaccine NN N
as IN N
compared VBN N
with IN N
the DT N
licensed JJ N
polysaccharide NN N
vaccine NN N
in IN N
adolescents NNS p
. . p

-DOCSTART- -20946200- O O

Randomized VBN N
comparative JJ N
study NN N
of IN N
group NN i
versus FW i
individual JJ i
cognitive JJ i
behavioural JJ i
therapy NN i
for IN N
obsessive JJ p
compulsive JJ p
disorder NN p
. . p

OBJECTIVE CC N
The DT N
primary JJ N
aim NN N
of IN N
the DT N
study NN N
was VBD N
to TO N
compare VB N
the DT N
effectiveness NN N
of IN N
group NN i
and CC i
individual JJ i
cognitive JJ i
behaviour NN i
therapy NN i
( ( i
CBT NNP i
) ) i
for IN N
obsessive JJ p
compulsive JJ p
disorder NN p
( ( p
OCD NNP p
) ) p
. . p

METHOD NNP N
One CD p
hundred CD p
and CC p
ten VB p
out-patients NNS p
with IN p
OCD NNP p
were VBD N
randomly RB N
assigned VBN N
to TO N
15 CD N
sessions NNS N
of IN N
either DT N
group NN i
CBT NNP i
or CC i
individual JJ i
CBT NNP i
. . i

Outcome NNP N
measures NNS N
were VBD N
administered VBN N
before IN N
and CC N
after IN N
treatment NN N
, , N
as RB N
well RB N
as IN N
at IN N
6- JJ N
and CC N
12-month JJ N
follow-ups NNS N
. . N

The DT N
study NN N
was VBD N
supplemented VBN N
by IN N
a DT N
meta-analysis NN N
of IN N
accomplished JJ N
comparative JJ N
studies NNS N
of IN N
group NN i
vs. FW i
individual JJ i
CBT NNP i
for IN N
OCD NNP N
. . N

RESULTS NNP N
Large NNP N
and CC N
stable JJ N
pre-post JJ N
effect NN o
sizes NNS o
were VBD N
found VBN N
for IN N
both DT N
treatment NN N
conditions NNS N
in IN N
the DT N
study NN N
( ( N
d JJ N
= NNP N
1.06-1.24 NN N
on IN N
the DT N
Yale-Brown JJ o
Obsessive NNP o
Compulsive NNP o
Scale NNP o
) ) o
. . N

There EX N
were VBD N
no DT N
significant JJ N
between-group JJ N
differences NNS N
in IN N
outcome NN N
at IN N
any DT N
data NNS N
point NN N
( ( N
ds= JJ N
-0.13 NN N
to TO N
0.15 CD N
) ) N
. . N

The DT N
meta-analysis NN N
of IN N
four CD N
accomplished JJ N
comparative NN N
studies NNS N
( ( N
including VBG N
the DT N
present JJ N
one NN N
) ) N
found VBD N
a DT N
between-group JJ N
mean JJ N
effect NN N
size NN N
of IN N
( ( N
d= JJ N
0.15 CD N
favouring VBG N
individual JJ N
over IN N
group NN N
CBT NNP i
at IN N
posttreatment NN N
( ( N
95 CD N
% NN N
confidence NN N
interval NN N
, , N
-0.12 NNP N
, , N
0.42 CD N
) ) N
. . N

CONCLUSION VB N
The DT N
results NNS N
of IN N
this DT N
study NN N
suggest VBP N
that IN N
OCD NNP N
can MD N
be VB N
treated VBN N
effectively RB o
with IN N
a DT N
group NN i
format NN i
of IN i
CBT NNP i
, , N
thus RB N
sparing VBG N
some DT N
therapist JJ N
resources NNS N
, , N
although IN N
the DT N
four CD N
accomplished VBD N
comparative JJ N
studies NNS N
do VBP N
not RB N
rule VB N
out IN N
the DT N
possibility NN N
of IN N
a DT N
small JJ N
superiority NN N
of IN N
individually RB N
conducted VBN N
CBT NNP i
. . i

-DOCSTART- -18322606- O O

[ JJ N
Effects NNS N
of IN N
Kang NNP i
Gang NNP i
Qian NNP i
Granule NNP i
( ( i
KGQG NNP i
) ) i
on IN N
clinical JJ o
and CC o
pathological JJ o
features NNS o
in IN N
chronic JJ p
hepatitis NN p
B NNP p
patients NNS p
] NNP p
. . N

OBJECTIVE NNP N
To TO N
explore VB N
the DT N
efficacy NN N
of IN N
KGQG NNP i
and CC N
its PRP$ N
therapeutic JJ N
mechanisms NNS N
in IN N
chronic JJ p
hepatitis NN p
B NNP p
patients NNS p
with IN p
liver JJ p
fibrosis NN p
. . p

METHODS NNP N
57 CD p
chronic NN p
hepatitis NN p
B NNP p
patients NNS p
with IN p
liver JJ p
fibrosis NN p
were VBD N
randomly RB N
divided VBN N
into IN N
two CD N
groups NNS N
: : N
45 CD N
cases NNS N
in IN N
KGQG NNP i
group NN N
were VBD N
treated VBN N
by IN N
KGQG NNP i
and CC i
routine JJ i
medications NNS i
; : i
12 CD N
cases NNS N
in IN N
control NN N
group NN N
were VBD N
treated VBN N
by IN N
routine JJ N
medications NNS N
only RB N
. . N

Serum NNP o
liver NN o
function NN o
test NN o
results NNS o
, , o
PCIII NNP o
, , o
CIV NNP o
, , o
HA NNP o
and CC o
liver RB o
biopsy JJ o
results NNS o
of IN N
these DT N
57 CD N
patients NNS N
were VBD N
simultaneously RB N
collected VBN N
and CC N
analyzed VBN N
before IN N
and CC N
after IN N
this DT N
intervention NN N
. . N

RESULTS NNP N
KGQG NNP i
group NN N
showed VBD N
better JJR N
efficacy NN o
over IN N
control NN N
group NN N
in IN N
liver NN o
function NN o
recovery NN o
, , N
decrease NN N
of IN N
serum NN o
PCIII NNP o
, , o
CIV NNP o
, , o
HA NNP o
levels NNS o
and CC o
liver NN o
pathologic NN o
grades NNS o
( ( N
P NNP N
0.05 CD N
or CC N
0.01 CD N
) ) N
. . N

CONCLUSION VB N
The DT N
KGQG NNP i
could MD N
effectively RB N
ameliorate VB N
liver NN N
function NN N
and CC N
facilitate VB N
the DT N
inhibition NN N
and CC N
degradation NN N
of IN N
liver JJ p
fibrosis NN p
in IN p
chronic JJ p
hepatitis NN p
B NNP p
patients NNS p
, , N
which WDT N
may MD N
be VB N
developed VBN N
as IN N
a DT N
novel JJ N
therapeusis NN N
to TO N
treat VB N
this DT N
hard-to-cure JJ N
disease NN N
. . N

-DOCSTART- -20965956- O O

Complement JJ N
activation NN N
on IN N
the DT N
surface NN N
of IN N
cell-derived JJ N
microparticles NNS N
during IN N
cardiac JJ p
surgery NN p
with IN p
cardiopulmonary JJ i
bypass NN i
- : N
is VBZ N
retransfusion NN N
of IN N
pericardial JJ N
blood NN N
harmful NN N
? . N
OBJECTIVES UH N
To TO N
investigate VB N
whether IN N
cell-derived JJ N
microparticles NNS N
play VBP N
a DT N
role NN N
in IN N
complement JJ o
activation NN o
in IN N
pericardial JJ N
blood NN N
of IN N
patients NNS p
undergoing VBG p
cardiac JJ i
surgery NN i
with IN i
cardiopulmonary JJ i
bypass NN i
( ( i
CPB NNP i
) ) i
and CC i
whether IN N
microparticles NNS N
in IN N
pericardial JJ N
blood NN N
contribute NN N
to TO N
systemic VB o
complement JJ o
activation NN o
upon IN N
retransfusion NN N
. . N

METHODS NNP N
Pericardial NNP p
blood NN p
of IN p
13 CD p
patients NNS p
was VBD N
retransfused VBN N
in IN N
9 CD N
and CC N
discarded VBD N
in IN N
4 CD N
cases NNS N
. . N

Microparticles NNS N
were VBD N
isolated VBN N
from IN N
systemic JJ N
blood NN i
collected VBN i
before IN i
anesthesia NN i
( ( N
T1 NNP N
) ) N
and CC N
at IN N
the DT N
end NN N
of IN N
CPB NNP i
( ( N
T2 NNP N
) ) N
, , N
and CC N
from IN N
pericardial JJ N
blood NN N
. . N

The DT N
microparticles NNS N
were VBD N
analyzed VBN N
by IN N
flow JJ N
cytometry NN N
for IN N
bound NN N
complement NN N
components NNS N
C1q NNP N
, , N
C4 NNP N
and CC N
C3 NNP N
, , N
and CC N
bound VB N
complement NN N
activator NN N
molecules VBZ N
C-reactive JJ N
protein NN N
( ( N
CRP NNP N
) ) N
, , N
serum JJ N
amyloid JJ N
P-component NN N
( ( N
SAP NNP N
) ) N
, , N
immunoglobulin NN N
( ( N
Ig NNP N
) ) N
M NNP N
and CC N
IgG NNP N
. . N

Fluid-phase NNP N
complement JJ N
activation NN N
products NNS N
( ( N
C4b/c NNP N
, , N
C3b/c NNP N
) ) N
and CC N
activator JJ N
molecules NNS N
were VBD N
determined VBN N
by IN N
ELISA NNP i
. . i

RESULTS NNP N
Compared VBD N
with IN N
systemic JJ N
T1 NNP N
blood NN N
, , N
pericardial JJ N
blood NN N
contained VBD N
increased JJ N
C4b/c NNP o
and CC o
C3b/c NNP o
, , N
and CC N
increased VBD N
levels NNS o
of IN o
microparticles NNS o
with IN N
bound JJ N
complement NN N
components NNS N
. . N

In IN N
systemic JJ N
T1 NNP N
samples NNS N
, , N
microparticle-bound JJ N
CRP NNP N
, , N
whereas NN N
in IN N
pericardial JJ N
blood NN N
, , N
microparticle-bound JJ N
SAP NNP N
and CC N
IgM NNP N
were VBD N
associated VBN N
with IN N
complement JJ N
activation NN N
. . N

At IN N
the DT N
end NN N
of IN N
CPB NNP i
, , N
increased VBD N
C3b/c NNP o
( ( o
but CC o
not RB o
C4b/c NNP o
) ) o
was VBD N
present JJ N
in IN N
systemic JJ N
T2 NNP N
blood NN N
compared VBN N
with IN N
T1 NNP N
, , N
while IN N
concentrations NNS N
of IN N
microparticles NNS N
binding VBG N
complement JJ N
components NNS N
and CC N
of IN N
those DT N
binding VBG N
complement JJ N
activator NN N
molecules NNS N
were VBD N
similar JJ N
. . N

Concentrations NNS o
of IN o
fluid-phase JJ o
complement NN o
activation NN o
products NNS o
and CC o
microparticles NNS o
were VBD N
similar JJ N
in IN N
patients NNS N
whether IN N
or CC N
not RB N
retransfused VBN N
with IN N
pericardial JJ N
blood NN N
. . N

CONCLUSIONS NNP N
In IN N
pericardial JJ N
blood NN N
of IN N
patients NNS p
undergoing VBG p
cardiac JJ p
surgery NN p
with IN p
CPB NNP i
, , N
microparticles VBZ N
contribute VBP N
to TO N
activation NN o
of IN o
the DT o
complement NN o
system NN o
via IN N
bound NN N
SAP NNP N
and CC N
IgM NNP N
. . N

Retransfusion NN N
of IN N
pericardial JJ N
blood NN N
, , N
however RB N
, , N
does VBZ N
not RB N
contribute VB N
to TO N
systemic VB o
complement JJ o
activation NN o
. . o

-DOCSTART- -20413513- O O

The DT N
11-beta-hydroxysteroid JJ N
dehydrogenase NN N
type NN N
1 CD N
inhibitor NN N
INCB13739 NNP i
improves VBZ N
hyperglycemia NN o
in IN p
patients NNS p
with IN p
type JJ p
2 CD p
diabetes NNS p
inadequately RB p
controlled VBN p
by IN p
metformin NN p
monotherapy NN p
. . p

OBJECTIVE CC N
11-Beta-hydroxysteroid JJ N
dehydrogenase NN N
type NN N
1 CD N
( ( N
11betaHSD1 CD N
) ) N
converts NNS N
inactive JJ N
cortisone NN N
into IN N
active JJ N
cortisol NN N
, , N
thereby RB N
amplifying VBG N
intracellular JJ N
glucocorticoid JJ N
action NN N
. . N

The DT N
efficacy NN o
and CC o
safety NN o
of IN N
the DT N
11betaHSD1 CD N
inhibitor NN N
INCB13739 NNP N
were VBD N
assessed VBN N
when WRB N
added VBN N
to TO N
ongoing VBG N
metformin NN N
monotherapy NN N
in IN N
patients NNS p
with IN p
type JJ p
2 CD p
diabetes NNS p
exhibiting VBG p
inadequate JJ p
glycemic NNS p
control NN p
( ( p
A1C NNP p
7-11 CD p
% NN p
) ) p
. . p

RESEARCH NNP N
DESIGN NNP N
AND NNP N
METHODS NNP N
This DT N
double-blind JJ N
placebo-controlled JJ i
paralleled VBN N
study NN N
randomized VBD N
302 CD p
patients NNS p
with IN p
type JJ p
2 CD p
diabetes NNS p
( ( p
mean JJ p
A1C NNP p
8.3 CD p
% NN p
) ) p
on IN p
metformin NN i
monotherapy NN i
( ( p
mean JJ p
1.5 CD p
g/day NN p
) ) p
to TO N
receive VB N
one CD N
of IN N
five CD N
INCB13739 NNP i
doses NNS i
or CC i
placebo NN i
once RB N
daily JJ N
for IN N
12 CD N
weeks NNS N
. . N

The DT N
primary JJ N
end NN N
point NN N
was VBD N
the DT N
change NN o
in IN o
A1C NNP o
at IN o
study JJ o
end NN o
. . o

Other JJ N
end NN N
points NNS N
included VBD N
changes NNS o
in IN o
fasting VBG o
glucose NN o
, , o
lipids NNS o
, , o
weight NN o
, , o
adverse JJ o
events NNS o
, , o
and CC o
safety NN o
. . o

RESULTS NNP N
After IN N
12 CD N
weeks NNS N
, , N
200 CD N
mg NN N
of IN N
INCB13739 NNP N
resulted VBD N
in IN N
significant JJ N
reductions NNS N
in IN N
A1C NNP o
( ( N
-0.6 NNP N
% NN N
) ) N
, , N
fasting VBG o
plasma NN o
glucose NN o
( ( N
-24 NNP N
mg/dl NN N
) ) N
, , N
and CC N
homeostasis NN o
model NN o
assessment-insulin JJ o
resistance NN o
( ( N
HOMA-IR NNP N
) ) N
( ( N
-24 CD N
% NN N
) ) N
compared VBN N
with IN N
placebo NN N
. . N

Total JJ o
cholesterol NN o
, , o
LDL NNP o
cholesterol NN o
, , o
and CC o
triglycerides NNS o
were VBD N
all DT N
significantly RB N
decreased VBN N
in IN N
hyperlipidemic JJ N
patients NNS N
. . N

Body NNP o
weight VBD o
decreased JJ N
relative NN N
to TO N
placebo VB N
after IN N
INCB13739 NNP N
therapy NN N
. . N

A DT N
reversible JJ N
dose-dependent JJ N
elevation NN N
in IN N
adrenocorticotrophic JJ o
hormone NN o
, , N
generally RB N
within IN N
the DT N
normal JJ N
reference NN N
range NN N
, , N
was VBD N
observed VBN N
. . N

Basal NNP o
cortisol JJ o
homeostasis NN o
, , o
testosterone NN o
in IN o
men NNS o
, , o
and CC o
free JJ o
androgen NN o
index NN o
in IN o
women NNS o
were VBD N
unchanged JJ N
by IN N
INCB13739 NNP N
. . N

Adverse JJ N
events NNS N
were VBD N
similar JJ N
across IN N
all DT N
treatment NN N
groups NNS N
. . N

CONCLUSIONS NNP N
INCB13739 NNP N
added VBD N
to TO N
ongoing VBG N
metformin NN N
therapy NN N
was VBD N
efficacious JJ o
and CC N
well RB N
tolerated VBN o
in IN N
patients NNS p
with IN p
type JJ p
2 CD p
diabetes NNS p
who WP p
had VBD p
inadequate JJ p
glycemic NNS p
control NN p
with IN p
metformin NN p
alone RB p
. . p

11BetaHSD1 CD N
inhibition NN N
offers NNS N
a DT N
new JJ N
potential JJ N
approach NN N
to TO N
control VB N
glucose JJ o
and CC o
cardiovascular JJ o
risk NN o
factors NNS o
in IN N
type NN p
2 CD p
diabetes NNS p
. . p

-DOCSTART- -15523393- O O

A DT N
randomized JJ N
multicenter NN N
trial NN N
comparing VBG N
resection NN i
and CC i
radiochemotherapy NN i
for IN N
resectable JJ p
locally RB p
invasive JJ p
pancreatic JJ p
cancer NN p
. . p

BACKGROUND NNP N
Though IN N
the DT N
outcome NN N
of IN N
resection NN N
for IN N
locally RB N
invasive JJ N
pancreatic JJ N
cancer NN N
is VBZ N
still RB N
poor JJ N
, , N
it PRP N
has VBZ N
gradually RB N
improved VBN N
in IN N
Japan NNP p
, , N
and CC N
the DT N
5-year JJ o
survival NN o
is VBZ N
now RB N
about RB N
10 CD N
% NN N
. . N

However RB N
, , N
the DT N
advantage NN N
of IN N
resection NN i
over IN N
radiochemotherapy NN i
has VBZ N
not RB N
yet RB N
been VBN N
confirmed VBN N
by IN N
a DT N
randomized JJ N
trial NN N
. . N

We PRP N
conducted VBD N
this DT N
study NN N
to TO N
compare VB N
surgical JJ i
resection NN i
alone RB N
versus JJ N
radiochemotherapy NN i
without IN N
resection NN N
for IN N
locally RB N
invasive JJ N
pancreatic JJ N
cancer NN N
using VBG N
a DT N
multicenter NN N
randomized VBN N
design NN N
. . N

METHODS NNP N
Patients NNPS p
with IN p
pancreatic JJ p
cancer NN p
who WP p
met VBD p
our PRP$ p
preoperative JJ p
criteria NNS p
for IN p
inclusion NN p
( ( p
pancreatic JJ p
cancer NN p
invading VBG p
the DT p
pancreatic JJ p
capsule NN p
without IN p
involvement NN p
of IN p
the DT p
superior JJ p
mesenteric JJ p
artery NN p
or CC p
the DT p
common JJ p
hepatic JJ p
artery NN p
, , p
or CC p
without IN p
distant JJ p
metastasis NN p
) ) p
underwent JJ p
laparotomy NN p
. . p

Patients NNS N
with IN N
operative JJ N
findings NNS N
consistent NN N
with IN N
our PRP$ N
criteria NNS N
were VBD N
randomized VBN N
into IN N
a DT N
radical JJ i
resection NN i
group NN i
and CC i
a DT i
radiochemotherapy NN i
group NN i
( ( N
200 CD N
mg/m NN N
( ( N
2 CD N
) ) N
/day NN N
of IN N
intravenous JJ i
5-fluorouracil CD i
and CC i
5040 CD i
cGy NN i
of IN i
radiotherapy NN i
) ) i
without IN N
resection NN N
. . N

The DT N
2 CD N
groups NNS N
were VBD N
compared VBN N
for IN N
mean JJ o
survival NN o
, , o
hazard NN o
ratio NN o
, , o
1-year JJ o
survival NN o
, , o
quality NN o
of IN o
life NN o
scores NNS o
, , o
and CC o
hematologic NN o
and CC o
blood NN o
chemical NN o
data NNS o
. . o

RESULTS NNP N
Twenty NNP p
patients NNS p
were VBD p
assigned VBN p
to TO p
the DT p
resection NN p
group NN p
and CC p
22 CD p
to TO p
the DT p
radiochemotherapy NN i
group NN p
. . p

There EX N
was VBD N
1 CD N
operative JJ o
death NN o
. . o

The DT N
surgical JJ N
resection NN N
group NN N
had VBD N
better JJR N
results NNS N
than IN N
the DT N
radiochemotherapy NN N
group NN N
as IN N
measured VBN N
by IN N
1-year JJ o
survival NN o
( ( N
62 CD N
% NN N
vs JJ N
32 CD N
% NN N
, , N
P=.05 NNP N
) ) N
, , N
mean JJ o
survival NN o
time NN o
( ( N
> JJ N
17 CD N
vs JJ N
11 CD N
months NNS N
, , N
P NNP N
< NNP N
.03 NNP N
) ) N
, , N
and CC N
hazard RB o
ratio NN o
( ( N
0.46 CD N
, , N
P=.04 NNP N
) ) N
. . N

There EX N
were VBD N
no DT N
differences NNS N
in IN N
the DT N
quality NN o
of IN o
life NN o
score NN o
or CC N
laboratory NN o
data NNS o
apart RB N
from IN N
increased VBN N
diarrhea NN o
after IN N
surgical JJ N
resection NN N
. . N

CONCLUSIONS NNP N
Locally NNP p
invasive JJ p
pancreatic JJ p
cancer NN p
without IN p
distant JJ p
metastases NNS p
and CC N
major JJ N
arterial JJ N
invasion NN N
appears VBZ N
to TO N
be VB N
best RB N
treated VBN N
by IN N
surgical JJ N
resection NN N
. . N

-DOCSTART- -10759619- O O

Pharmacokinetic JJ N
interaction NN N
between IN N
proton NN i
pump NN i
inhibitors NNS i
and CC i
roxithromycin NN i
in IN N
volunteers NNS p
. . p

BACKGROUND NNP N
Triple NNP N
therapy NN N
including VBG N
two CD N
antibiotics NNS N
and CC N
a DT N
proton NN N
pump NN N
inhibitor NN N
is VBZ N
a DT N
rational JJ N
approach NN N
to TO N
the DT N
treatment NN N
of IN N
Helicobacter NNP N
pylori NN N
induced VBD N
peptic JJ N
ulcer JJ N
disease NN N
. . N

The DT N
interaction NN N
of IN N
antimicrobial JJ N
therapy NN N
and CC N
acid JJ N
suppression NN N
is VBZ N
not RB N
yet RB N
well RB N
elucidated VBN N
. . N

AIMS NNP N
To TO N
investigate VB N
the DT N
effects NNS N
of IN N
proton NN i
pump NN i
inhibitors NNS i
on IN N
roxithromycin NN i
levels NNS N
in IN N
plasma NN N
and CC N
gastric JJ N
tissue NN N
under IN N
steady-state JJ p
conditions NNS p
in IN p
volunteers NNS p
. . p

METHODS NNP N
In IN N
two CD N
crossover NN N
studies NNS N
omeprazole VBP i
20 CD i
mg NN i
b.d. NN i
, , N
lansoprazole JJ i
30 CD i
mg NN i
b.d. NN i
, , N
roxithromycin VBZ i
300 CD i
mg NN i
b.d. NN i
, , N
and CC i
the DT i
combination NN i
of IN i
roxithromycin NN i
with IN i
either DT i
omeprazole NN i
or CC i
lansoprazole NN i
were VBD N
administered VBN N
to TO N
12 CD p
healthy JJ p
volunteers NNS p
over IN p
6 CD p
days NNS p
. . p

Blood NNP o
plasma NN o
levels NNS o
of IN N
the DT N
drugs NNS N
were VBD N
measured VBN N
. . N

In IN N
addition NN N
, , N
roxithromycin JJ o
concentrations NNS o
were VBD N
also RB N
determined VBN N
in IN N
gastric JJ N
juice NN N
and CC N
gastric JJ N
tissue NN N
obtained VBN N
during IN N
endoscopy NN N
. . N

RESULTS VB N
The DT N
proton NN i
pump NN i
inhibitors NNS i
and CC i
roxithromycin NN i
did VBD N
not RB N
alter VB N
the DT N
blood NN o
plasma NN o
pharmacokinetics NNS o
of IN N
each DT N
other JJ N
. . N

When WRB N
compared VBN N
to TO N
roxithromycin VB i
administered JJ N
alone RB N
, , N
its PRP$ N
combination NN N
with IN N
a DT N
proton NN i
pump NN i
inhibitor NN i
significantly RB N
increased VBD N
the DT N
roxithromycin NN o
concentrations NNS o
in IN o
gastric JJ o
juice NN o
( ( N
3.0-5.0 JJ N
microg/mL NN N
vs. IN N
0.3-0.4 NNP N
microg/mL NN N
) ) N
and CC N
gastric JJ o
tissue NN o
( ( N
antrum NN N
: : N
3.8-4.0 JJ N
vs. FW N
2.8 CD N
microg/g NN N
, , N
fundus NN N
: : N
5.9-7.4 JJ N
vs. IN N
4.2-4.4 JJ N
microg/g NN N
) ) N
. . N

CONCLUSIONS NNP N
Proton NNP i
pump NN i
inhibitors NNS i
and CC N
roxithromycin VB i
do VBP N
not RB N
alter VB N
the DT N
systemic JJ N
bioavailability NN N
of IN N
each DT N
other JJ N
. . N

However RB N
, , N
proton VBP i
pump NN i
inhibitors NNS i
increase VBP N
the DT N
local JJ N
concentration NN o
of IN o
roxithromycin NN o
in IN N
the DT N
stomach NN N
which WDT N
may MD N
contribute VB N
to TO N
the DT N
clinically RB N
proven JJ N
synergic JJ N
beneficial JJ N
action NN N
in IN N
eradication NN N
therapy NN N
of IN N
H. NNP N
pylori NN N
. . N

-DOCSTART- -22588803- O O

Ambient JJ i
temperature NN i
and CC i
biomarkers NNS i
of IN N
heart NN N
failure NN N
: : N
a DT N
repeated JJ N
measures NNS N
analysis NN N
. . N

BACKGROUND NNP N
Extreme NNP N
temperatures NNS N
have VBP N
been VBN N
associated VBN N
with IN N
hospitalization NN N
and CC N
death NN N
among IN p
individuals NNS p
with IN p
heart NN p
failure NN p
, , N
but CC N
few JJ N
studies NNS N
have VBP N
explored VBN N
the DT N
underlying JJ N
mechanisms NN N
. . N

OBJECTIVES IN N
We PRP N
hypothesized VBD N
that IN N
outdoor JJ N
temperature NN N
in IN N
the DT N
Boston NNP p
, , p
Massachusetts NNP p
, , N
area NN N
( ( N
1- JJ N
to TO N
4-day JJ N
moving NN N
averages NNS N
) ) N
would MD N
be VB N
associated VBN N
with IN N
higher JJR o
levels NNS o
of IN o
biomarkers NNS o
of IN o
inflammation NN o
and CC N
myocyte JJ o
injury NN o
in IN N
a DT N
repeated-measures JJ N
study NN N
of IN N
individuals NNS p
with IN p
stable JJ p
heart NN p
failure NN p
. . p

METHODS NNP N
We PRP N
analyzed VBD N
data NNS N
from IN N
a DT N
completed VBN N
clinical JJ N
trial NN N
that WDT N
randomized VBD N
100 CD p
patients NNS p
to TO N
12 CD i
weeks NNS i
of IN i
tai NN i
chi NN i
classes NNS i
or CC i
to TO i
time-matched JJ i
education NN i
control NN i
. . i

B-type NNP o
natriuretic JJ o
peptide NN o
( ( o
BNP NNP o
) ) o
, , o
C-reactive JJ o
protein NN o
( ( o
CRP NNP o
) ) o
, , o
and CC o
tumor NN o
necrosis NN o
factor NN o
( ( o
TNF NNP o
) ) o
were VBD N
measured VBN N
at IN N
baseline NN N
, , N
6 CD N
weeks NNS N
, , N
and CC N
12 CD N
weeks NNS N
. . N

Endothelin-1 NNP o
was VBD N
measured VBN N
at IN N
baseline NN N
and CC N
12 CD N
weeks NNS N
. . N

We PRP N
used VBD N
fixed VBN N
effects NNS N
models NNS N
to TO N
evaluate VB N
associations NNS N
with IN N
measures NNS N
of IN N
temperature NN N
that WDT N
were VBD N
adjusted VBN N
for IN N
time-varying JJ N
covariates NNS N
. . N

RESULTS NNP N
Higher NNP N
apparent JJ N
temperature NN N
was VBD N
associated VBN N
with IN N
higher JJR N
levels NNS N
of IN N
BNP NNP o
beginning VBG N
with IN N
2-day JJ N
moving VBG N
averages NNS N
and CC N
reached VBD N
statistical JJ N
significance NN N
for IN N
3- JJ N
and CC N
4-day JJ N
moving NN N
averages NNS N
. . N

CRP NNP o
results NNS N
followed VBD N
a DT N
similar JJ N
pattern NN N
but CC N
were VBD N
delayed VBN N
by IN N
1 CD N
day NN N
. . N

A DT N
5?C CD N
change NN N
in IN N
3- JJ N
and CC N
4-day JJ N
moving NN N
averages NNS N
of IN N
apparent JJ o
temperature NN o
was VBD N
associated VBN N
with IN N
11.3 CD N
% NN N
[ JJ N
95 CD N
% NN N
confidence NN N
interval NN N
( ( N
CI NNP N
) ) N
: : N
1.1 CD N
, , N
22.5 CD N
; : N
p NN N
= VBZ N
0.03 CD N
) ) N
and CC N
11.4 CD N
% NN N
( ( N
95 CD N
% NN N
CI NNP N
: : N
1.2 CD N
, , N
22.5 CD N
; : N
p NN N
= VBZ N
0.03 CD N
) ) N
higher JJR o
BNP NNP o
. . o

A DT N
5?C CD N
change NN N
in IN N
the DT N
4-day JJ N
moving JJ N
average NN N
of IN N
apparent JJ o
temperature NN o
was VBD o
associated VBN N
with IN N
21.6 CD N
% NN N
( ( N
95 CD N
% NN N
CI NNP N
: : N
2.5 CD N
, , N
44.2 CD N
; : N
p NN N
= VBZ N
0.03 CD N
) ) N
higher JJR N
CRP NNP o
. . o

No DT N
clear JJ N
associations NNS N
with IN o
TNF NNP o
or CC o
endothelin-1 JJ o
were VBD o
observed VBN N
. . N

CONCLUSIONS NNP N
Among IN p
patients NNS p
undergoing VBG p
treatment NN p
for IN p
heart NN p
failure NN p
, , p
we PRP N
observed VBD N
positive JJ N
associations NNS N
between IN o
temperature NN o
and CC o
both DT o
BNP NNP o
and CC o
CRP-predictors NNS o
of IN o
heart NN o
failure NN o
prognosis NN o
and CC o
severity NN o
. . o

-DOCSTART- -23518801- O O

Effect NN N
of IN N
phenylephrine NN i
on IN N
the DT N
haemodynamic JJ o
state NN o
and CC o
cerebral JJ o
oxygen NN o
saturation NN o
during IN N
anaesthesia NN N
in IN N
the DT N
upright JJ N
position NN N
. . N

BACKGROUND IN N
The DT N
upright JJ N
sitting NN N
or CC N
beachchair NN N
position NN N
is VBZ N
associated VBN N
with IN N
hypotension NN o
, , o
risk NN o
of IN o
cerebral JJ o
hypoperfusion NN o
, , o
and CC o
cerebral JJ o
injury NN o
. . o

We PRP N
hypothesized VBD N
that IN N
by IN N
increasing VBG N
arterial JJ N
pressure NN N
with IN N
phenylephrine JJ i
administration NN N
, , N
cerebral JJ o
perfusion NN o
, , N
and CC N
postoperative JJ o
recovery NN o
would MD N
be VB N
improved VBN N
. . N

METHODS NNP N
Thirty-four JJ p
patients NNS p
undergoing VBG p
elective JJ p
shoulder NN p
surgery NN p
were VBD p
randomized VBN p
to TO N
receive VB N
either DT N
saline NN i
or CC i
phenylephrine NN i
infusion NN i
( ( i
PE NNP i
) ) i
5 CD N
min NN N
before IN N
being VBG N
placed VBN N
in IN N
the DT N
upright JJ N
position NN N
. . N

Simultaneous JJ N
measurements NNS N
of IN N
mean JJ o
arterial JJ o
pressure NN o
, , o
cerebral JJ o
oxygen NN o
saturation NN o
, , o
middle JJ o
cerebral JJ o
artery NN o
velocity NN o
, , o
and CC o
cardiac JJ o
function NN o
using VBG o
transthoracic JJ o
echocardiography NN o
were VBD N
made VBN N
. . N

Postoperative JJ N
neurocognitive JJ o
function NN o
was VBD N
assessed VBN N
. . N

RESULTS NNP N
At IN N
the DT N
commencement NN N
of IN N
PE NNP N
, , N
mean NN o
( ( o
SD NNP o
) ) o
cerebral JJ o
oxygen NN o
saturation NN o
significantly RB N
decreased VBN N
from IN N
77 CD N
( ( N
10 CD N
) ) N
to TO N
67 CD N
( ( N
13 CD N
) ) N
% NN N
( ( N
P=0.02 NNP N
) ) N
, , N
and CC N
further RB N
to TO N
59 CD N
( ( N
11 CD N
) ) N
% NN N
on IN N
upright JJ N
positioning NN N
. . N

The DT N
level NN o
of IN o
cerebral JJ o
saturation NN o
upright NN o
was VBD N
not RB N
significantly RB N
different JJ N
to TO N
patients NNS N
receiving VBG N
saline NN N
( ( N
P=0.07 NNP N
) ) N
, , N
with IN N
values NNS N
remaining VBG N
at IN N
room-air JJ N
levels NNS N
. . N

Middle NNP o
cerebral JJ o
artery RB o
blood NN o
velocity NN o
increased VBN N
by IN N
20 CD N
% NN N
( ( N
P=0.04 NNP N
) ) N
. . N

Phenylephrine NNP N
prevented VBD N
hypotension NN o
in IN N
the DT N
upright JJ N
position NN N
primarily RB N
by IN N
maintaining VBG N
preload NN N
and CC N
increasing VBG N
systemic JJ o
vascular NN o
resistance NN o
( ( N
P=0.01 NNP N
) ) N
, , N
and CC N
was VBD N
associated VBN N
with IN N
a DT N
decrease NN N
in IN N
cardiac JJ o
output NN o
. . o

No DT N
postoperative JJ o
neurocognitive JJ o
dysfunction NN o
was VBD N
identified VBN N
. . N

CONCLUSIONS NNP N
Despite IN N
maintaining VBG N
arterial JJ N
pressure NN N
with IN N
phenylephrine NN i
, , N
cerebral JJ o
desaturation NN o
occurred VBD N
with IN N
upright JJ N
positioning VBG N
. . N

Cerebral NNP o
oxygen IN o
saturation NN o
can MD N
provide VB N
a DT N
valuable JJ N
endpoint NN N
when WRB N
evaluating VBG N
the DT N
effect NN N
of IN N
vasopressor NN N
therapy NN N
on IN N
cerebral JJ N
perfusion NN N
. . N

-DOCSTART- -25086152- O O

Assessing VBG N
the DT N
benefit NN o
of IN N
a DT N
personalized JJ i
EHR-generated JJ i
informed JJ i
consent NN i
in IN p
a DT p
dental JJ p
school NN p
setting VBG p
. . p

Informed VBN N
consents NNS N
are VBP N
routinely RB N
used VBN N
as IN N
an DT N
important JJ N
source NN N
of IN N
information NN N
to TO N
help VB N
patients NNS p
make VB N
appropriate JJ N
clinical JJ N
decisions NNS N
. . N

However RB N
, , N
current JJ N
standard JJ N
consent NN N
forms NNS N
may MD N
not RB N
accomplish VB N
their PRP$ N
intended VBN N
purpose NN N
due JJ N
to TO N
the DT N
variety NN N
of IN N
patient JJ N
literacy NN N
and CC N
experiences NNS N
and CC N
, , N
in IN N
the DT N
dental JJ N
school NN N
setting NN N
, , N
the DT N
developing VBG N
competence NN N
of IN N
students NNS N
. . N

The DT N
purpose NN N
of IN N
this DT N
pilot NN N
study NN N
was VBD N
to TO N
test VB N
the DT N
efficacy NN o
of IN N
a DT N
personalized VBN N
informed JJ N
consent NN N
generated VBD N
through IN N
an DT N
electronic JJ N
health NN N
record NN N
( ( N
EHR NNP N
) ) N
at IN N
one CD N
dental JJ N
school NN N
and CC N
its PRP$ N
role NN N
in IN N
patient JJ N
decision NN N
making NN N
. . N

In IN N
the DT N
study NN N
, , N
a DT N
set NN N
of IN N
informed JJ N
consents NNS N
, , N
or CC N
SmartConsents NNS i
, , N
were VBD N
developed VBN N
for IN N
specific JJ N
diagnoses NNS N
and CC N
procedures NNS N
, , N
enhanced VBN N
with IN N
graphics NNS N
, , N
and CC N
delivered VBD N
through IN N
the DT N
school NN N
's POS N
EHR NNP N
. . N

Fifty NNP p
patients NNS p
were VBD p
recruited VBN p
in IN p
the DT p
school NN p
's POS p
Urgent NNP p
Care NNP p
Clinic NNP p
and CC N
divided VBN N
evenly RB N
into IN N
two CD N
groups NNS N
: : N
one CD N
( ( N
control NN N
) ) N
receiving VBG N
the DT N
standard JJ i
consent NN i
, , N
with IN N
the DT N
second JJ N
receiving VBG N
a DT N
SmartConsent NNP i
. . i

Following VBG N
treatment NN N
, , N
patients NNS N
were VBD N
assessed VBN N
based VBN N
on IN N
demographics NNS o
, , o
decisional JJ o
conflict NN o
, , o
satisfaction NN o
, , o
health NN o
literacy NN o
, , o
and CC o
knowledge NN o
. . o

Overall JJ N
, , N
there EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
main JJ o
effects NNS o
between IN N
SmartConsent NNP N
and CC N
standard NN N
informed VBD N
consents NNS N
for IN N
decisional JJ o
conflict NN o
and CC o
satisfaction NN o
, , N
although IN N
significant JJ N
differences NNS N
were VBD N
identified VBN N
during IN N
secondary JJ N
analysis NN N
of IN N
satisfaction NN o
, , o
gender NN o
, , o
and CC o
ethnicity NN o
. . o

The DT N
study NN N
also RB N
demonstrated VBD N
the DT N
potential NN N
for IN N
consents NNS N
to TO N
aid VB N
the DT N
student NN N
provider NN N
in IN N
better JJR o
communicating NN o
with IN o
patients NNS o
. . o

-DOCSTART- -9497116- O O

The DT N
importance NN N
of IN N
the DT N
dual-switch JJ i
valve NN i
for IN N
the DT N
treatment NN N
of IN N
adult NN p
normotensive JJ p
or CC p
hypertensive JJ p
hydrocephalus NN p
. . p

Since IN N
the DT N
beginning NN N
of IN N
1995 CD N
the DT N
new JJ p
hydrostatic JJ i
dual-switch NN i
valve NN i
( ( i
DSV NNP i
) ) i
was VBD p
implanted VBN p
in IN p
35 CD p
adult NN p
patients NNS p
with IN p
hydrocephalus NN p
of IN p
different JJ p
etiology NN p
. . p

26 CD p
patients NNS p
suffered VBD p
from IN p
normotensive JJ p
hydrocephalus NN p
( ( p
10 CD p
idiopathic NN p
and CC p
16 CD p
symptomatic JJ p
) ) p
, , p
and CC p
9 CD p
patients NNS p
from IN p
hypertensive JJ p
hydrocephalus NN p
of IN p
various JJ p
origin NN p
. . p

The DT N
first JJ N
21 CD N
cases NNS N
of IN N
this DT N
cohort NN N
were VBD N
compared VBN N
in IN N
a DT N
randomized JJ N
study NN N
with IN N
a DT N
comparable JJ N
group NN N
of IN N
21 CD N
hydrocephalic JJ N
patients NNS N
who WP N
received VBD N
a DT N
conventional JJ i
differential-pressure NN i
( ( i
DP- NNP i
) ) i
valve NN i
. . i

The DT N
clinical JJ N
status NN N
and CC N
CT NNP N
were VBD N
assessed VBN N
prior RB N
to TO N
shunting VBG N
, , N
14 CD N
days NNS N
and CC N
3 CD N
and CC N
6 CD N
months NNS N
after IN N
the DT N
operation NN N
. . N

The DT N
reduction NN N
of IN N
ventricular JJ o
size NN o
was VBD N
evaluated VBN N
by IN N
the DT N
measurement NN N
of IN N
the DT N
Evans NNP N
Index NNP N
. . N

The DT N
CT NNP N
follow-up NN N
in IN N
the DT N
DSV NNP i
group NN N
was VBD N
characterized VBN N
by IN N
an DT N
only JJ N
minimal NN N
( ( N
14 CD N
) ) N
or CC N
only RB N
slight JJ N
( ( N
16 CD N
) ) N
reduction NN N
of IN N
ventricular JJ N
size NN N
in IN N
the DT N
vast JJ N
majority NN N
of IN N
cases NNS N
. . N

A DT N
comparison NN N
of IN N
21 CD p
patients NNS p
with IN N
a DT N
DSV NNP i
and CC N
the DT N
patients NNS N
with IN N
DP NNP i
valves NNS i
, , N
evaluated VBN N
by IN N
measuring VBG N
the DT N
reduction NN N
of IN N
the DT N
Evans NNP o
Index NNP o
, , N
revealed VBD N
a DT N
distinctly RB N
higher JJR N
percentage NN N
of IN N
significant JJ N
regressions NNS N
in IN N
the DT N
DP NNP i
valve NN i
collective NN N
, , N
without IN N
doubt NN N
due JJ N
to TO N
chronic JJ N
overdrainage NN N
. . N

The DT N
overall JJ N
clinical JJ N
result NN N
of IN N
our PRP$ N
35 CD p
patients NNS p
with IN N
a DT N
DSV NNP i
was VBD N
excellent JJ N
and CC N
good JJ N
in IN N
31 CD N
patients NNS N
, , N
but CC N
the DT N
outcome NN N
seems VBZ N
to TO N
be VB N
more RBR N
dependent JJ N
on IN N
the DT N
preshunt NN o
damage NN o
of IN o
the DT o
brain NN o
than IN N
on IN N
hydrocephalic JJ o
aspects NNS o
. . o

A DT N
neglegible JJ N
incidence NN N
of IN N
subdural JJ o
effusions NNS o
in IN N
the DT N
DSV NNP i
group NN N
compared VBN N
to TO N
11 CD N
cases NNS N
in IN N
the DT N
DP NNP i
valve FW i
collective JJ N
reflects VBZ N
the DT N
ability NN N
of IN N
the DT N
DSV NNP i
to TO N
prevent VB N
overdrainage NN o
. . o

The DT N
capability NN N
of IN N
the DT N
DSV NNP i
to TO N
maintain VB N
the DT N
IVP NNP o
within IN N
physiological JJ N
limits NNS N
after IN N
shunting VBG N
, , N
especially RB N
in IN N
the DT N
upright JJ N
position NN N
, , N
is VBZ N
documented VBN N
by IN N
a DT N
comparison NN N
with IN N
possible JJ o
unphysiological JJ o
IVP NNP o
variations NNS o
in IN N
other JJ N
valve NN N
constructions NNS N
, , N
which WDT N
depend VBP N
on IN N
the DT N
level NN o
of IN o
implantation NN o
, , o
subcutaneous JJ o
pressure NN o
or CC o
CSF NNP o
flow VBP o
through IN o
the DT o
valve NN o
. . o

-DOCSTART- -24610180- O O

Do VB N
physicians NNS p
' POS p
implicit JJ N
views NNS N
of IN N
African JJ N
Americans NNPS N
affect VBP N
clinical JJ N
decision NN N
making NN N
? . N
BACKGROUND NNP N
Total NNP i
knee FW i
replacement NN i
( ( i
TKR NNP i
) ) i
is VBZ N
a DT N
cost-effective JJ N
treatment NN N
option NN N
for IN N
severe JJ N
osteoarthritis NN N
( ( N
OA NNP N
) ) N
. . N

While IN N
prevalence NN N
of IN N
OA NNP p
is VBZ p
higher JJR p
among IN p
blacks NNS p
than IN p
whites NNS p
, , N
TKR NNP i
rates NNS N
are VBP N
lower JJR N
among IN N
blacks NNS N
. . N

Physicians NNPS N
' POS N
implicit JJ N
preferences NNS N
might MD N
explain VB N
racial JJ N
differences NNS N
in IN N
TKR NNP i
recommendation NN N
. . N

The DT N
objective NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
evaluate VB N
whether IN N
the DT N
magnitude NN N
of IN N
implicit JJ N
racial JJ N
bias NN N
predicts VBZ N
physician JJ N
recommendation NN N
of IN N
TKR NNP N
for IN N
black JJ N
and CC N
white JJ N
patients NNS N
with IN N
OA NNP N
and CC N
to TO N
assess VB N
the DT N
effectiveness NN N
of IN N
a DT N
web-based JJ N
instrument NN N
as IN N
an DT N
intervention NN N
to TO N
decrease VB N
the DT N
effect NN N
of IN N
implicit JJ N
racial JJ N
bias NN N
on IN N
physician JJ N
recommendation NN N
of IN N
TKR NNP i
. . i

METHODS NNP N
In IN N
this DT N
web-based JJ i
study NN i
, , N
543 CD p
family NN p
and CC p
internal JJ p
medicine NN p
physicians NNS p
were VBD N
given VBN N
a DT N
scenario NN i
describing VBG i
either CC i
a DT i
black JJ i
or CC i
white JJ i
patient NN i
with IN i
severe JJ i
OA NNP i
refractory NN i
to TO i
medical JJ i
treatment NN i
. . i

Questionnaires VBZ i
evaluating VBG i
the DT i
likelihood NN i
of IN i
recommending VBG i
TKR NNP i
, , i
perceived VBD i
medical JJ i
cooperativeness NN i
, , i
and CC i
measures NNS i
of IN i
implicit JJ i
racial JJ i
bias NN i
were VBD i
administered VBN i
. . i

The DT N
main JJ N
outcome NN N
measures NNS N
included VBD N
TKR NNP i
recommendation NN N
, , N
implicit JJ N
racial JJ N
preference NN N
, , N
and CC N
medical JJ N
cooperativeness NN N
stereotypes NNS N
measured VBN N
with IN N
implicit JJ N
association NN N
tests NNS N
. . N

RESULTS NNP N
Subjects NNPS N
displayed VBD N
a DT N
strong JJ N
implicit JJ N
preference NN N
for IN N
whites NNS N
over IN N
blacks NNS N
( ( N
P NNP N
< NNP N
.0001 NNP N
) ) N
and CC N
associated VBN N
medically RB o
cooperative JJ o
with IN N
whites NNS N
over IN N
blacks NNS N
( ( N
P NNP N
< NNP N
.0001 NNP N
) ) N
. . N

Physicians NNPS N
reported VBD N
significantly RB N
greater JJR N
liking VBG o
for IN N
whites NNS N
over IN N
blacks NNS N
( ( N
P NNP N
< NNP N
.0001 NNP N
) ) N
and CC N
reported VBD N
believing VBG N
whites NNS N
were VBD N
more RBR N
medically RB o
cooperative JJ o
than IN N
blacks NNS N
( ( N
P NNP N
< NNP N
.0001 NNP N
) ) N
. . N

Participants NNS N
reported VBD N
providing VBG N
similar JJ N
care NN o
for IN N
white JJ N
and CC N
black JJ N
patients NNS N
( ( N
P NNP N
= NNP N
.10 NNP N
) ) N
but CC N
agreed VBD N
that IN N
subconscious JJ N
biases NNS N
could MD N
influence VB N
their PRP$ N
treatment NN N
decisions NNS N
( ( N
P NNP N
< NNP N
.0001 NNP N
) ) N
. . N

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
the DT N
rate NN o
of IN o
recommendation NN o
for IN o
TKR NNP o
when WRB N
the DT N
patient NN N
was VBD N
black JJ N
( ( N
47 CD N
% NN N
) ) N
versus NN N
white JJ N
( ( N
38 CD N
% NN N
) ) N
( ( N
P NNP N
= NNP N
.439 NNP N
) ) N
, , N
and CC N
neither DT N
implicit JJ N
nor CC N
explicit JJ N
racial JJ N
biases NNS N
predicted VBD N
differential JJ N
treatment NN N
recommendations NNS N
by IN N
race NN N
( ( N
all DT N
P NNP N
> NNP N
.06 NNP N
) ) N
. . N

Although IN N
participants NNS N
were VBD N
more RBR N
likely JJ N
to TO N
recommend VB o
TKR NNP o
when WRB N
completing VBG N
the DT N
implicit JJ N
association NN N
test NN N
before IN N
the DT N
decision NN N
, , N
patient JJ N
race NN N
was VBD N
not RB N
significant JJ N
in IN N
the DT N
association NN N
( ( N
P NNP N
= NNP N
.960 NNP N
) ) N
. . N

CONCLUSIONS NNP N
Physicians NNPS p
possessed VBD N
explicit NN N
and CC N
implicit JJ N
racial JJ N
biases NNS N
, , N
but CC N
those DT N
biases NNS N
did VBD N
not RB N
predict VB N
treatment NN N
recommendations NNS N
. . N

Clinicians NNPS p
' POS p
biases NNS N
about IN N
the DT N
medical JJ N
cooperativeness NN N
of IN N
blacks NNS N
versus VBP N
whites NNS N
, , N
however RB N
, , N
may MD N
have VB N
influenced VBN N
treatment NN N
decisions NNS N
. . N

-DOCSTART- -15889546- O O

Automatic JJ p
detection NN p
of IN p
red JJ p
lesions NNS p
in IN p
digital JJ p
color NN p
fundus NN p
photographs NN p
. . p

The DT N
robust JJ N
detection NN i
of IN i
red JJ o
lesions NNS o
in IN i
digital JJ i
color NN i
fundus NN i
photographs NN i
is VBZ N
a DT N
critical JJ N
step NN N
in IN N
the DT N
development NN N
of IN N
automated JJ N
screening VBG N
systems NNS N
for IN N
diabetic JJ p
retinopathy NN p
. . p

In IN N
this DT N
paper NN N
, , N
a DT N
novel NN i
red JJ i
lesion NN i
detection NN i
method NN i
is VBZ N
presented VBN N
based VBN N
on IN N
a DT N
hybrid JJ N
approach NN N
, , N
combining VBG N
prior JJ N
works NNS N
by IN N
Spencer NNP N
et CC N
al NN N
. . N

( ( N
1996 CD N
) ) N
and CC N
Frame NNP N
et NNP N
al NN N
. . N

( ( N
1998 CD N
) ) N
with IN N
two CD N
important JJ N
new JJ N
contributions NNS N
. . N

The DT N
first JJ N
contribution NN N
is VBZ N
a DT N
new JJ N
red JJ i
lesion NN i
candidate NN i
detection NN i
system NN i
based VBN N
on IN N
pixel JJ N
classification NN N
. . N

Using VBG N
this DT N
technique NN N
, , N
vasculature NN o
and CC o
red JJ o
lesions NNS o
are VBP N
separated VBN N
from IN N
the DT N
background NN N
of IN N
the DT N
image NN N
. . N

After IN N
removal NN N
of IN N
the DT N
connected JJ N
vasculature NN N
the DT N
remaining VBG N
objects NNS N
are VBP N
considered VBN N
possible JJ N
red JJ N
lesions NNS N
. . N

Second NNP N
, , N
an DT N
extensive JJ N
number NN N
of IN N
new JJ N
features NNS N
are VBP N
added VBN N
to TO N
those DT N
proposed VBN N
by IN N
Spencer-Frame NNP N
. . N

The DT N
detected JJ N
candidate NN N
objects NNS N
are VBP N
classified VBN N
using VBG N
all DT N
features NNS N
and CC N
a DT N
k-nearest JJ N
neighbor NN N
classifier NN N
. . N

An DT N
extensive JJ N
evaluation NN N
was VBD N
performed VBN N
on IN N
a DT N
test NN N
set NN N
composed VBN N
of IN N
images NNS N
representative NN N
of IN N
those DT N
normally RB N
found VBN N
in IN N
a DT N
screening NN N
set NN N
. . N

When WRB N
determining VBG N
whether IN N
an DT N
image NN N
contains VBZ N
red JJ o
lesions NNS o
the DT N
system NN N
achieves VBZ N
a DT N
sensitivity NN o
of IN N
100 CD N
% NN N
at IN N
a DT N
specificity NN N
of IN N
87 CD N
% NN N
. . N

The DT N
method NN N
is VBZ N
compared VBN N
with IN N
several JJ N
different JJ N
automatic JJ N
systems NNS N
and CC N
is VBZ N
shown VBN N
to TO N
outperform VB N
them PRP N
all DT N
. . N

Performance NNP o
is VBZ N
close RB N
to TO N
that DT N
of IN N
a DT N
human JJ N
expert NN N
examining VBG N
the DT N
images NNS N
for IN N
the DT N
presence NN N
of IN N
red JJ N
lesions NNS N
. . N

-DOCSTART- -16037751- O O

Determinants NNS N
of IN N
the DT N
effect NN N
of IN N
estrogen NN i
on IN N
the DT N
progression NN N
of IN N
subclinical JJ o
atherosclerosis NN o
: : o
Estrogen NN i
in IN N
the DT N
Prevention NNP N
of IN N
Atherosclerosis NNP N
Trial NNP N
. . N

OBJECTIVE NN N
To TO N
determine VB N
the DT N
extent NN N
to TO N
which WDT N
the DT N
estrogen-induced JJ N
changes NNS N
in IN N
lipids NNS N
and CC N
markers NNS N
of IN N
carbohydrate NN N
metabolism NN N
explain VBP N
the DT N
beneficial JJ N
effect NN N
of IN N
estrogen NN i
therapy NN i
on IN N
the DT N
progression NN o
of IN o
carotid JJ o
artery JJ o
intima-media JJ o
thickness NN o
( ( o
IMT NNP o
) ) o
in IN N
postmenopausal JJ p
women NNS p
. . p

DESIGN VB N
A DT N
randomized JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ i
, , N
single-center JJ N
trial NN N
enrolling VBG N
222 CD p
postmenopausal JJ p
women NNS p
45 CD p
years NNS p
and CC p
older JJR p
without IN p
cardiovascular JJ p
disease NN p
and CC p
with IN p
low-density JJ p
lipoprotein NN p
( ( p
LDL NNP p
) ) p
cholesterol NN p
levels NNS p
of IN p
3.37 CD p
mmol/L NN p
or CC p
greater JJR p
( ( p
> CD p
or CC p
= VB p
130 CD p
mg/dL NN p
) ) p
. . p

Intervention NN N
was VBD N
unopposed JJ i
micronized JJ i
17beta-estradiol JJ i
versus NN i
placebo NN i
. . i

Measurements NNS N
were VBD N
made VBN N
using VBG N
high-resolution JJ N
B-mode NNP i
ultrasonography NN i
to TO N
measure VB N
carotid JJ o
artery NN o
IMT NNP o
at IN N
baseline NN N
and CC N
every DT N
6 CD N
months NNS N
on-trial JJ N
. . N

RESULTS NNP N
Progression NNP N
of IN N
carotid NN o
IMT NNP o
was VBD N
inversely RB N
related VBN N
to TO N
on-trial JJ N
high-density NN o
lipoprotein NN o
( ( o
HDL NNP o
) ) o
cholesterol NN o
( ( N
P NNP N
= NNP N
0.04 CD N
) ) N
and CC N
was VBD N
directly RB N
related VBN N
to TO N
on-trial JJ N
LDL-cholesterol NNP N
( ( N
P NNP N
= NNP N
0.005 CD N
) ) N
. . N

Compared VBN N
with IN N
placebo NN i
, , N
women NNS N
randomized VBD N
to TO N
estradiol VB i
showed VBD N
a DT N
higher JJR N
mean JJ N
on-trial JJ N
HDL-cholesterol NNP o
level NN o
and CC N
a DT N
lower JJR N
mean JJ N
on-trial JJ N
LDL-cholesterol NNP o
level NN o
. . o

In IN N
contrast NN N
, , N
fasting VBG o
glucose NN o
, , o
insulin NN o
, , o
and CC o
hemoglobin NN o
A1C NNP o
were VBD N
lowered VBN N
and CC N
insulin JJ N
sensitivity NN N
increased VBN N
with IN N
estradiol JJ i
therapy NN N
, , N
but CC N
the DT N
changes NNS N
were VBD N
not RB N
related VBN N
to TO N
carotid VB N
IMT NNP N
progression NN N
. . N

On-trial JJ N
HDL-cholesterol NNP o
and CC o
LDL-cholesterol NNP o
were VBD N
significant JJ N
independent JJ N
determinants NNS N
of IN N
carotid NN o
IMT NNP o
progression NN N
, , N
jointly RB N
explaining VBG N
30 CD N
% NN N
of IN N
the DT N
treatment NN N
effect NN N
of IN N
unopposed JJ i
estrogen NN i
on IN N
the DT N
progression NN N
of IN N
carotid NN o
IMT NNP o
. . o

CONCLUSION NNP N
Unopposed VBD i
17beta-estradiol JJ i
reduced JJ N
carotid NN o
IMT NNP o
progression NN N
in IN N
postmenopausal JJ p
women NNS p
in IN N
part NN N
by IN N
increasing VBG N
HDL-cholesterol NNP o
and CC N
decreasing VBG N
LDL-cholesterol NNP o
. . o

Although IN N
women NNS p
randomized VBN N
to TO N
estradiol VB i
showed JJ N
improvement NN N
in IN N
all PDT N
the DT N
markers NNS N
of IN N
carbohydrate NN N
metabolism NN N
, , N
these DT N
factors NNS N
did VBD N
not RB N
play VB N
a DT N
significant JJ N
role NN N
in IN N
carotid JJ o
IMT NNP o
progression NN N
. . N

-DOCSTART- -24324379- O O

Using VBG N
the DT N
virtual JJ i
reality-cognitive JJ i
rehabilitation NN i
approach NN N
to TO N
improve VB N
contextual JJ o
processing NN o
in IN o
children NNS p
with IN p
autism NN p
. . p

BACKGROUND NNP N
This DT N
pilot NN N
study NN N
investigated VBD N
the DT N
efficacy NN N
of IN N
a DT N
novel JJ i
virtual JJ i
reality-cognitive JJ i
rehabilitation NN i
( ( i
VR-CR NNP i
) ) i
intervention NN i
to TO N
improve VB N
contextual JJ o
processing NN o
of IN N
objects NNS N
in IN N
children NNS p
with IN p
autism NN p
. . p

Previous JJ N
research NN N
supports VBZ N
that IN N
children NNS p
with IN p
autism NN p
show NN N
deficits NNS N
in IN N
contextual JJ o
processing NN o
, , N
as RB N
well RB N
as IN N
deficits NNS N
in IN N
its PRP$ N
elementary JJ N
components NNS N
: : N
abstraction NN o
and CC o
cognitive JJ o
flexibility NN o
. . o

METHODS NNP N
Four CD p
children NNS p
with IN p
autism NN p
participated VBN N
in IN N
a DT N
multiple-baseline JJ N
, , N
single-subject JJ N
study NN N
. . N

The DT N
children NNS p
were VBD N
taught JJ N
how WRB N
to TO N
see VB N
objects NNS N
in IN N
context NN N
by IN N
reinforcing VBG N
attention NN N
to TO N
pivotal JJ N
contextual JJ N
information NN N
. . N

RESULTS NNP N
All NNP N
children NNS p
demonstrated VBD N
statistically RB N
significant JJ N
improvements NNS N
in IN N
contextual JJ o
processing NN o
and CC o
cognitive JJ o
flexibility NN o
. . o

Mixed JJ N
results NNS N
were VBD N
found VBN N
on IN N
the DT N
control NN N
test NN N
and CC N
changes NNS N
in IN N
context-related JJ o
behaviours NNS o
. . o

CONCLUSIONS NNP N
Larger-scale JJ N
studies NNS N
are VBP N
warranted VBN N
to TO N
determine VB N
the DT N
effectiveness NN N
and CC N
usability NN N
in IN N
comprehensive JJ N
educational JJ N
programs NNS N
. . N

-DOCSTART- -8127293- O O

National NNP N
Surgical NNP N
Adjuvant NNP N
Breast NNP N
and CC N
Bowel NNP N
Project NNP N
's POS N
Breast NNP N
Cancer NNP N
Prevention NNP N
Trial NNP N
. . N

The DT N
Breast NNP N
Cancer NNP N
Prevention NNP N
Trial NNP N
is VBZ N
the DT N
largest JJS N
breast NN N
cancer NN N
prevention NN N
study NN N
ever RB N
undertaken RB N
. . N

Administered VBN N
by IN N
the DT N
National NNP N
Surgical NNP N
Adjuvant NNP N
Breast NNP N
and CC N
Bowel NNP N
Project NNP N
, , N
it PRP N
is VBZ N
the DT N
first JJ N
trial NN N
seeking VBG N
to TO N
demonstrate VB N
whether IN N
a DT N
drug NN N
, , N
tamoxifen NN i
, , N
can MD N
prevent VB p
breast NN p
cancer NN p
in IN p
high-risk JJ p
women NNS p
. . p

The DT N
objectives NNS N
of IN N
this DT N
trial NN N
are VBP N
to TO N
determine VB N
whether IN N
tamoxifen NN i
is VBZ N
effective JJ N
in IN N
1 CD N
) ) N
reducing VBG o
the DT o
incidence NN o
of IN o
invasive JJ o
breast NN o
cancer NN o
, , o
2 CD o
) ) o
reducing VBG o
breast NN o
cancer NN o
mortality NN o
, , o
3 CD o
) ) o
reducing VBG o
deaths NNS o
from IN o
cardiovascular JJ o
disease NN o
, , o
and CC o
4 CD o
) ) o
reducing VBG o
bone NN o
fractures NNS o
. . o

In IN N
addition NN N
, , N
the DT N
study NN N
will MD N
evaluate VB N
side NN o
effects NNS o
, , o
toxicity NN o
, , o
and CC o
the DT o
quality NN o
of IN o
life NN o
of IN N
all DT N
study NN N
participants NNS N
. . N

-DOCSTART- -5341828- O O

Long-term JJ N
heparin NN i
treatment NN i
in IN N
ischaemic JJ p
heart NN p
disease NN p
. . p

Effects NNS N
on IN N
clinical JJ N
condition NN N
and CC N
plasma JJ N
lipids NNS N
. . N

-DOCSTART- -21632816- O O

Effect NN N
of IN N
intensive JJ i
insulin NN i
therapy NN i
on IN N
the DT N
somatotropic NN N
axis NN N
of IN N
critically RB p
ill JJ p
children NNS p
. . p

CONTEXT NNP N
Intensive NNP i
insulin NN i
therapy NN i
( ( i
IIT NNP i
) ) i
improved VBD N
outcome NN N
in IN N
the DT N
adult NN N
and CC N
pediatric JJ N
intensive JJ N
care NN N
unit NN N
( ( N
PICU NNP N
) ) N
compared VBN N
with IN N
conventional JJ i
insulin NN i
therapy NN i
( ( i
CIT NNP i
) ) i
. . i

IIT NNP N
did VBD N
not RB N
increase VB N
the DT N
anabolic JJ N
hormone NN N
IGF-I NNP N
in IN N
critically RB N
ill JJ N
adults NNS N
, , N
but CC N
feeding VBG N
in IN N
critically RB N
ill JJ N
children NNS N
and CC N
pediatric JJ N
hormonal JJ N
responses NNS N
may MD N
differ VB N
. . N

Twenty-five JJ p
percent NN p
of IN p
the DT p
children NNS p
with IN p
IIT NNP i
experienced VBD p
hypoglycemia NN p
, , N
which WDT N
may MD N
have VB N
evoked VBN N
counterregulatory JJ N
responses NNS N
. . N

OBJECTIVE IN N
We PRP N
hypothesized VBD N
that IN N
IIT NNP i
reactivates VBZ N
the DT N
somatotropic NN N
axis NN N
and CC N
anabolism NN o
in IN N
PICU NNP N
patients NNS N
. . N

DESIGN NNP N
This DT N
was VBD N
a DT N
preplanned JJ N
subanalysis NN N
of IN N
a DT N
randomized VBN N
controlled VBN N
trial NN N
on IN N
IIT NNP i
. . i

PATIENTS NNP N
We PRP p
studied VBD p
369 CD p
patients NNS p
who WP p
stayed VBD p
in IN p
PICU NNP p
for IN p
at IN p
least JJS p
3 CD p
d NN p
( ( p
study VB p
1 CD p
) ) p
and CC p
126 CD p
patients NNS p
in IN p
a DT p
nested JJ p
case-control NN p
study NN p
( ( p
study VB p
2 CD p
) ) p
. . p

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
Circulating NNP o
insulin NN o
, , o
C-peptide NNP o
, , o
GH NNP o
, , o
IGF-I NNP o
, , o
bioavailable JJ o
IGF-I JJ o
, , o
IGF-binding JJ o
protein NN o
( ( o
IGFBP NNP o
) ) o
-1 NN o
, , o
IGFBP-3 NNP o
, , o
and CC o
acid-labile JJ o
subunit NN o
were VBD N
analyzed VBN N
upon IN N
admission NN N
and CC N
d NN N
3 CD N
. . N

In IN N
the DT N
nested JJ N
case-control NN N
study NN N
, , N
the DT N
somatotropic NN N
axis NN N
, , N
cortisol NN o
, , N
and CC N
glucagon NN o
were VBD N
analyzed VBN N
before IN N
and CC N
after IN N
hypoglycemia NN N
. . N

RESULTS VB N
On IN N
d JJ N
3 CD N
, , N
C-peptide NNP o
was VBD N
more JJR N
than IN N
10-fold JJ N
lower JJR N
( ( N
P NNP N
< NNP N
0.0001 CD N
) ) N
in IN N
the DT N
IIT NNP i
group NN N
than IN N
in IN N
the DT N
CIT NNP i
group NN N
. . N

IIT NNP i
increased VBD N
circulating VBG o
GH NNP o
( ( N
P NNP N
= NNP N
0.04 CD N
) ) N
and CC N
lowered VBN N
bioavailable JJ o
IGF-I NNP o
( ( N
P NNP N
= NNP N
0.002 CD N
) ) N
. . N

IIT NNP i
also RB N
decreased VBD N
IGFBP-3 NNP o
( ( N
P NNP N
= NNP N
0.0005 CD N
) ) N
and CC N
acid-labile JJ o
subunit NN o
( ( N
P NNP N
= NNP N
0.007 CD N
) ) N
, , N
while IN N
increasing VBG N
IGFBP-1 NNP o
( ( N
P NNP N
= NNP N
0.04 CD N
) ) N
and CC N
the DT N
urea/creatinine JJ o
ratio NN o
, , N
a DT N
marker NN N
of IN N
catabolism NN N
( ( N
P NNP N
= NNP N
0.03 CD N
) ) N
. . N

In IN N
the DT N
nested JJ N
case-control NN N
study NN N
, , N
IGFBP-1 NNP o
was VBD N
increased VBN N
after IN N
hypoglycemia NN N
, , N
whereas IN N
the DT N
somatotropic NN N
axis NN N
and CC N
the DT N
counterregulatory NN N
hormones NNS N
cortisol NN o
and CC o
glucagon NN o
did VBD N
not RB N
change NN N
. . N

CONCLUSIONS NNP N
Despite IN N
improved JJ N
PICU NNP N
outcome NN N
, , N
IIT NNP i
did VBD N
not RB N
counteract VB N
the DT N
catabolic JJ o
state NN o
of IN o
critical JJ o
illness NN o
. . o

Suppression NN N
of IN N
portal JJ N
insulin NN N
may MD N
have VB N
resulted VBN N
in IN N
lower JJR N
bioavailable JJ N
IGF-I NNP N
. . N

-DOCSTART- -7946102- O O

Aerosolized NNP i
pentamidine NN i
as IN N
primary JJ N
prophylaxis NN N
for IN N
Pneumocystis NNP o
carinii NN o
pneumonia NN o
: : o
efficacy NN N
, , N
mortality NN N
and CC N
morbidity NN N
. . N

OBJECTIVE NNP N
Primary NNP N
prophylaxis NN N
against IN N
Pneumocystis NNP N
carinii NN N
pneumonia NN N
( ( N
PCP NNP N
) ) N
for IN N
patients NNS p
with IN p
HIV NNP p
infection NN p
has VBZ N
been VBN N
recommended VBN N
by IN N
the DT N
Centers NNPS N
for IN N
Disease NNP N
Control NNP N
and CC N
Prevention NNP N
. . N

We PRP N
evaluated VBD N
alternatives NNS N
to TO N
routine VB N
primary JJ N
PCP NNP N
prophylaxis NN N
with IN N
aerosolized JJ i
pentamidine NN i
. . i

METHODS NNP N
A NNP p
total NN p
of IN p
121 CD p
HIV-infected JJ p
patients NNS p
with IN p
CD4+ NNP p
cell NN p
counts VBZ p
< CD p
or CC p
= VB p
200 CD p
x JJ p
10 CD p
( ( p
6 CD p
) ) p
/l NN p
or CC p
an DT p
AIDS JJ p
diagnosis NN p
were VBD N
enrolled VBN N
in IN N
a DT N
controlled JJ N
study NN N
of IN N
aerosolized JJ i
pentamidine NN i
as IN N
primary JJ N
PCP NNP N
prophylaxis NN N
. . N

Patients NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
treatment NN N
( ( N
n JJ N
= NNP N
61 CD N
) ) N
with IN N
aerosolized JJ i
pentamidine NN i
once RB N
every DT N
month NN N
or CC N
to TO N
no DT i
treatment NN i
( ( N
n JJ N
= NNP N
60 CD N
) ) N
. . N

Patients NNS N
were VBD N
evaluated VBN N
for IN N
PCP NNP o
, , o
mortality NN o
, , o
morbidity NN o
and CC o
progression NN o
of IN o
HIV NNP o
disease NN o
. . o

Morbidity NNP N
was VBD N
estimated VBN N
from IN N
the DT N
number NN N
of IN N
days NNS N
patients NNS N
were VBD N
unable JJ N
to TO N
work VB N
due JJ N
to TO N
illness VB N
, , N
number NN N
of IN N
days NNS N
hospitalized VBN N
and CC N
AIDS NNP N
events NNS N
. . N

RESULTS NNP N
Baseline NNP N
characteristics NNS N
were VBD N
similar JJ N
in IN N
the DT N
treatment NN N
and CC N
control NN N
groups NNS N
and CC N
mean JJ N
CD4+ NNP o
cell NN o
counts NNS o
were VBD N
116 CD N
and CC N
107 CD N
x NNS N
10 CD N
( ( N
6 CD N
) ) N
/l NN N
, , N
respectively RB N
. . N

Eight CD N
incidents NNS N
of IN N
PCP NNP N
and CC N
19 CD N
deaths NNS o
were VBD N
observed VBN N
in IN N
the DT N
treatment NN N
group NN N
during IN N
a DT N
median JJ N
follow-up NN N
of IN N
16.4 CD N
months NNS N
( ( N
range NN N
, , N
2.3-32.4 JJ N
months NNS N
) ) N
. . N

Nineteen JJ N
incidents NNS N
of IN N
PCP NNP N
and CC N
13 CD N
deaths NNS o
, , N
of IN N
which WDT N
one NN N
was VBD N
related VBN N
to TO N
an DT N
acute JJ N
episode NN N
of IN N
PCP NNP N
, , N
were VBD N
noted VBN N
in IN N
the DT N
control NN N
group NN N
. . N

Median JJ o
follow-up NN o
of IN N
controls NNS N
was VBD N
18.5 CD N
months NNS N
( ( N
range NN N
, , N
3.1-32.9 JJ N
months NNS N
) ) N
. . N

Patients NNS N
in IN N
the DT N
treatment NN N
group NN N
were VBD N
unable JJ N
to TO N
work VB N
19 CD N
% NN N
of IN N
the DT N
observation NN o
time NN o
and CC N
were VBD N
hospitalized VBN N
for IN N
4.3 CD N
% NN N
of IN N
that DT N
time NN N
. . N

Corresponding JJ N
figures NNS N
were VBD N
20 CD N
and CC N
3.0 CD N
% NN N
, , N
respectively RB N
, , N
in IN N
the DT N
control NN N
group NN N
. . N

CONCLUSIONS NNP N
Aerosolized NNP i
pentamidine NN i
had VBD N
significant JJ N
prophylactic JJ o
efficacy NN o
, , N
but CC N
we PRP N
could MD N
not RB N
detect VB N
any DT N
major JJ N
effect NN N
on IN N
mortality NN o
and CC o
morbidity NN o
. . o

The DT N
overall JJ N
mortality NN o
and CC N
morbidity NN o
were VBD N
not RB N
markedly RB N
influenced VBN N
by IN N
PCP NNP N
. . N

Clinical JJ N
check-ups NNS N
and CC N
treatment NN N
of IN N
acute JJ N
PCP NNP N
could MD N
be VB N
a DT N
justifiable JJ o
alternative JJ N
to TO N
drug NN N
prophylaxis NN N
with IN N
aerosolized JJ i
pentamidine NN i
in IN N
selected VBN N
patients NNS p
. . p

-DOCSTART- -15818697- O O

Evidence NN N
of IN N
radiographic JJ o
benefit NN o
of IN N
treatment NN N
with IN N
infliximab JJ i
plus JJ i
methotrexate NN i
in IN N
rheumatoid JJ p
arthritis NN p
patients NNS p
who WP p
had VBD p
no DT p
clinical JJ p
improvement NN p
: : p
a DT N
detailed JJ N
subanalysis NN N
of IN N
data NNS N
from IN N
the DT N
anti-tumor JJ N
necrosis NN N
factor NN N
trial NN N
in IN N
rheumatoid JJ N
arthritis NN N
with IN N
concomitant JJ N
therapy NN N
study NN N
. . N

OBJECTIVE NNP N
To TO N
assess VB o
the DT o
relationship NN o
between IN N
inflammation NN N
and CC N
joint JJ N
destruction NN N
in IN N
rheumatoid JJ p
arthritis NN p
( ( p
RA NNP p
) ) p
patients NNS p
who WP p
have VBP p
not RB p
responded VBN p
clinically RB p
to TO p
treatment NN p
. . p

METHODS NNP N
Changes NNP N
from IN N
baseline NN N
to TO N
week NN N
54 CD N
in IN N
clinical JJ o
variables NNS o
and CC o
measures NNS o
of IN o
radiographic JJ o
progression NN o
were VBD N
compared VBN N
between IN N
patients NNS N
who WP N
received VBD N
infliximab NN i
( ( N
3 CD N
mg/kg NN N
or CC N
10 CD N
mg/kg NN N
every DT N
4 CD N
or CC N
8 CD N
weeks NNS N
) ) N
plus CC N
methotrexate NN i
( ( i
MTX NNP i
) ) i
and CC N
those DT N
who WP N
received VBD N
MTX NNP i
plus CC i
placebo NN i
in IN N
the DT N
Anti-Tumor NNP N
Necrosis NNP N
Factor NNP N
Trial NNP N
in IN N
RA NNP N
with IN N
Concomitant NNP N
Therapy NNP N
trial NN N
. . N

RESULTS NN N
At IN N
week NN N
54 CD N
, , N
patients NNS p
who WP N
did VBD N
not RB N
show VB N
20 CD N
% NN N
improvement NN o
by IN o
American NNP o
College NNP o
of IN o
Rheumatology NNP o
criteria NNS o
( ( N
ACR20 NNP N
nonresponders NNS N
) ) N
while IN N
receiving VBG N
infliximab JJ i
plus CC i
MTX NNP i
exhibited VBD N
mild JJ N
but CC N
statistically RB N
significant JJ N
improvement NN N
in IN N
clinical JJ N
variables NNS N
, , N
including VBG N
the DT N
28-joint JJ o
Disease NNP o
Activity NNP o
Score NNP o
( ( o
DAS28 NNP o
) ) o
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
tender NN o
joint NN o
count NN o
( ( N
P NNP N
= NNP N
0.014 CD N
) ) N
, , N
swollen JJ o
joint NN o
count NN o
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
and CC N
C-reactive JJ o
protein NN o
( ( o
CRP NNP o
) ) o
level NN o
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

Whereas IN N
the DT N
clinical JJ N
and CC N
CRP NNP N
changes NNS N
among IN N
ACR20 NNP N
nonresponders NNS N
to TO N
infliximab VB i
plus JJ i
MTX NNP i
were VBD N
small JJ N
and CC N
much JJ N
lower JJR N
than IN N
among IN N
ACR20 NNP N
responders NNS N
to TO N
this DT N
treatment NN N
, , N
radiographic JJ o
progression NN o
among IN N
ACR20 NNP N
nonresponders NNS N
to TO N
infliximab VB i
plus JJ i
MTX NNP i
was VBD N
significantly RB N
inhibited VBN N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
compared VBN N
with IN N
ACR20 NNP N
nonresponders NNS N
to TO N
MTX NNP N
plus CC N
placebo NN N
. . N

Radiographic JJ N
progression NN N
was VBD N
much RB N
greater JJR N
in IN N
patients NNS N
receiving VBG N
MTX NNP i
plus CC i
placebo NN i
than IN N
in IN N
patients NNS N
receiving VBG N
infliximab JJ N
plus CC N
MTX NNP N
, , N
irrespective NN N
of IN N
ACR NNP o
response NN o
status NN o
( ( o
mean JJ o
change NN o
in IN o
modified JJ o
Sharp/van NNP o
der NN o
Heijde NNP o
score VBD o
6.0 CD N
in IN N
ACR20 NNP N
responders NNS N
and CC N
7.2 CD N
in IN N
ACR20 NNP N
nonresponders NNS N
in IN N
the DT N
MTX NNP i
plus CC N
placebo-treated JJ N
group NN N
, , N
versus VBZ N
0.1 CD N
in IN N
ACR20 NNP N
responders NNS N
and CC N
1.2 CD N
in IN N
ACR20 NNP N
nonresponders NNS N
in IN N
the DT N
infliximab JJ i
plus CC i
MTX-treated JJ i
group NN N
) ) N
. . N

Furthermore UH N
, , N
among IN N
patients NNS N
who WP N
were VBD N
ACR20 NNP N
nonresponders NNS N
through IN N
week NN N
54 CD N
, , N
patients NNS N
who WP N
were VBD N
DAS NNP N
nonresponders NNS N
at IN N
weeks NNS N
30 CD N
and CC N
54 CD N
, , N
and CC N
patients NNS N
without IN N
any DT N
improvement NN N
in IN N
individual JJ N
clinical JJ N
variables NNS N
, , N
those DT N
receiving VBG N
infliximab JJ i
plus CC i
MTX NNP i
still RB N
demonstrated VBD N
inhibition NN N
of IN N
structural JJ N
damage NN N
that WDT N
was VBD N
statistically RB N
significant JJ N
compared VBN N
with IN N
inhibition NN N
in IN N
patients NNS N
who WP N
received VBD N
MTX NNP i
plus CC i
placebo NN i
( ( N
P NNP N
< VBZ N
0.05 CD N
to TO N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

CONCLUSION NNP N
Even RB N
in IN N
patients NNS p
without IN N
clinical JJ o
improvement NN o
, , N
treatment NN N
with IN N
infliximab JJ i
plus CC i
MTX NNP i
provided VBD N
significant JJ N
benefit NN N
with IN N
regard NN N
to TO N
the DT N
destructive JJ N
process NN N
, , N
suggesting VBG N
that IN N
in IN N
such JJ N
patients NNS N
these DT N
2 CD N
measures NNS N
of IN N
disease NN N
are VBP N
dissociated VBN N
. . N

-DOCSTART- -21309696- O O

Safety NN N
and CC N
efficacy NN N
of IN N
donepezil NN i
in IN N
children NNS p
and CC p
adolescents NNS p
with IN p
autism NN p
: : p
neuropsychological JJ N
measures NNS N
. . N

OBJECTIVE NNP N
There EX N
has VBZ N
been VBN N
recent JJ N
interest NN N
in IN N
the DT N
use NN N
of IN N
cognitive JJ i
enhancing VBG i
drugs NNS i
, , N
such JJ N
as IN N
cholinesterase NN i
inhibitors NNS i
, , N
as IN N
a DT N
possible JJ N
treatment NN N
for IN N
executive NN o
functioning NN o
( ( N
EF NNP N
) ) N
deficits NNS N
in IN N
autism NN p
spectrum NN p
disorder NN p
( ( p
ASD NNP p
) ) p
. . p

The DT N
goal NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
assess VB N
the DT N
tolerability NN o
, , o
safety NN o
, , o
and CC o
efficacy NN o
of IN N
donepezil NN N
on IN N
EF NNP N
in IN N
a DT N
sample NN p
of IN p
children NNS p
and CC p
adolescents NNS p
with IN p
ASD NNP p
. . p

METHOD NNP N
Thirty-four JJ p
children NNS p
and CC p
adolescents NNS p
with IN p
ASD NNP p
( ( p
age NN p
range NN p
8-17 CD p
years NNS p
; : p
IQ NNP p
> NNP p
75 CD p
) ) p
were VBD p
enrolled VBN p
in IN N
a DT N
10-week JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ i
trial NN N
of IN N
donepezil NN i
( ( i
doses NNS i
of IN i
5 CD i
and CC i
10 CD i
mg NN i
) ) i
, , i
followed VBN i
by IN i
a DT i
10-week JJ i
open JJ i
label NN i
trial NN i
for IN i
placebo NN i
nonresponders NNS i
. . i

RESULTS VB N
The DT N
effect NN N
of IN N
donepezil NN i
treatment NN i
on IN N
EF NNP N
was VBD N
examined VBN N
. . N

Despite IN N
improvement NN N
on IN N
a DT N
number NN N
of IN N
EF NNP o
measures NNS o
, , o
no DT N
statistically RB N
significant JJ N
between-group JJ N
differences NNS N
were VBD N
found VBN N
( ( N
with IN N
gains NNS N
observed VBN N
for IN N
both DT N
the DT N
placebo NN N
and CC N
donepezil NN N
groups NNS N
) ) N
. . N

CONCLUSIONS VB N
The DT N
results NNS N
suggest VBP N
that IN N
short-term JJ N
treatment NN N
with IN N
donepezil NN N
may MD N
have VB N
limited VBN N
impact NN N
on IN N
cognitive JJ N
functioning NN N
in IN N
ASD NNP N
. . N

Future NNP N
controlled VBD N
trials NNS N
may MD N
need VB N
to TO N
consider VB N
a DT N
longer RBR N
treatment NN N
period NN N
to TO N
detect VB N
significant JJ N
gains NNS N
on IN N
EF NNP N
measures NNS N
. . N

-DOCSTART- -9076457- O O

Long-term JJ N
follow-up NN N
of IN N
cytostatic JJ i
intravesical JJ i
instillation NN i
in IN N
patients NNS p
with IN p
superficial JJ p
bladder NN p
carcinoma NN p
. . p

Is VBZ N
short-term JJ N
, , N
intensive JJ N
instillation NN N
better RBR N
than IN N
maintenance NN N
therapy NN N
? . N
OBJECTIVES NNP N
Comparisons NNPS N
of IN N
two CD N
3-year JJ N
protocols NNS N
, , N
one CD N
20-week JJ N
protocol NN N
of IN N
mitomycin NN i
C NNP i
instillation NN i
and CC N
one CD N
3-year JJ N
protocol NN N
of IN N
doxorubicin JJ i
instillation NN i
for IN N
the DT N
prevention NN N
of IN N
recurrent NN o
tumors NNS o
and CC N
progression NN o
in IN N
patients NNS p
whose WP$ p
superficial JJ p
bladder NN p
tumors NNS p
had VBD p
been VBN p
removed VBN p
by IN p
transurethral JJ p
resection NN p
. . p

METHODS NNP N
A NNP N
prospective JJ N
, , N
randomized JJ N
parallel NN N
group NN N
multicenter RBR N
trial NN N
was VBD N
conducted VBN N
. . N

419 CD p
patients NNS p
were VBD p
evaluated VBN p
after IN p
a DT p
median JJ p
follow-up NN p
of IN p
57 CD p
months NNS p
. . p

Cox NNP N
proportional JJ N
hazards NNS N
analysis NN N
was VBD N
performed VBN N
. . N

RESULTS NNP N
An DT N
overall JJ o
recurrence NN o
rate NN o
of IN N
22.7 CD N
% NN N
and CC N
an DT N
overall JJ o
progression NN o
rate NN o
of IN N
9.8 CD N
% NN N
was VBD N
found VBN N
. . N

For IN N
time NN N
to TO N
progression VB N
a DT N
significant JJ N
overall JJ o
treatment NN o
effect NN o
was VBD N
detected VBN N
dependent NN N
on IN N
the DT N
recurrence NN N
status NN N
before IN N
entry NN N
into IN N
the DT N
study NN N
( ( N
p JJ N
= NNP N
0.0059 CD N
) ) N
. . N

Pairwise VB N
comparisons NNS N
showed VBD N
the DT N
mitomycin NN N
protocol NN N
with IN N
short-term JJ N
intensive JJ N
( ( N
weekly JJ N
) ) N
combined VBN N
with IN N
long-term JJ N
maintenance NN N
instillation NN N
to TO N
have VB N
a DT N
highly RB N
beneficial JJ o
effect NN o
compared VBN N
to TO N
long-term JJ N
maintenance NN N
instillation NN N
only RB N
especially RB N
for IN N
patients NNS N
entering VBG N
the DT N
study NN N
with IN N
recurrent JJ N
tumors NNS N
( ( N
RR NNP N
= NNP N
0.06 CD N
, , N
95 CD N
% NN N
CI NNP N
: : N
[ NN N
0.008 CD N
, , N
0.506 CD N
] NN N
. . N

CONCLUSION NNP N
These DT N
results NNS N
show VBP N
that IN N
intensive JJ o
therapeutic JJ o
instillation NN o
may MD N
have VB N
an DT N
advantage NN N
over IN N
less JJR N
intensive JJ N
, , N
prophylactic JJ N
regimens NNS N
. . N

-DOCSTART- -21425723- O O

Tramadol NNP i
suppository NN i
versus NN N
placebo NN i
for IN N
the DT N
relief NN N
of IN N
perineal NN o
pain NN o
after IN p
perineorrhaphy NN p
: : p
a DT N
randomized NN N
controlled VBN N
trial NN N
in IN N
Thailand NNP p
. . p

OBJECTIVE NNP N
This DT N
randomized JJ N
double-blinded JJ N
control NN N
trial NN N
was VBD N
conducted VBN N
to TO N
compare VB N
the DT N
effectiveness NN o
of IN N
tramodol NN i
and CC N
placebo NN i
rectal JJ N
suppository NN N
for IN N
the DT N
management NN N
of IN N
postpartum NN o
perineal NN o
pain NN o
after IN p
perineorrhaphy NN p
. . p

MATERIAL NNP N
AND CC N
METHOD NNP N
One NNP p
hundred VBD p
women NNS p
who WP p
gave VBD p
birth NN p
vaginally RB p
with IN p
episiotomy NN p
and CC p
a DT p
second- JJ p
or CC p
third-degree JJ p
tear NN p
, , N
were VBD N
randomly RB N
assign VBN N
to TO N
receive VB N
two CD N
tablets NNS N
oftramadol VBP i
50 CD i
mg NNS i
or CC i
two CD i
tablets NNS i
ofplacebo RB i
, , N
the DT N
pill NN N
were VBD N
physically RB N
similar JJ N
to TO N
the DT N
real JJ N
drug NN N
. . N

Pain VB o
ratings NNS o
were VBD N
recorded VBN N
immediately RB N
after IN N
perineorrhaphy NN N
, , N
30 CD N
minutes NNS N
, , N
and CC N
1 CD N
, , N
2 CD N
, , N
6 CD N
, , N
12 CD N
and CC N
24 CD N
hours NNS N
after IN N
first JJ N
dose NN N
on IN N
a DT N
10-cm JJ N
visual JJ o
analogue NN o
scale NN o
. . o

Side JJ o
effects NNS o
and CC o
overall JJ o
opinion NN o
were VBD N
assessed VBN N
. . N

RESULTS NNP N
Tramadol NNP i
and CC N
placebo NN i
had VBD N
no DT N
statistical JJ N
significances NNS N
in IN N
analgesic JJ o
properties NNS o
, , N
assessed VBN N
by IN N
the DT N
means NNS N
of IN N
pain NN o
rating NN o
at IN N
the DT N
different JJ N
time NN N
intervals NNS N
. . N

There EX N
were VBD N
no DT o
serious JJ o
adverse JJ o
events NNS o
reported VBN N
. . N

CONCLUSION NNP N
No NNP N
differences NNS N
were VBD N
found VBN N
in IN N
between IN N
Tramadol NNP N
and CC N
placebo NN N
in IN N
relief NN N
perineal NN N
pain NN N
after IN N
perineorrhaphy NN N
-DOCSTART- -11064610- O O

Comparison NNP N
of IN N
alfentanil NN i
, , i
fentanyl NN i
and CC N
sufentanil NN i
for IN N
total JJ N
intravenous JJ N
anaesthesia NN N
with IN N
propofol NN i
in IN N
patients NNS p
undergoing VBG p
coronary JJ p
artery NN p
bypass NN p
surgery NN p
. . p

We PRP N
have VBP N
studied VBN N
the DT N
pharmacokinetics NNS o
and CC o
pharmacodynamics NNS o
of IN N
alfentanil NN i
, , i
fentanyl NN i
and CC N
sufentanil VB i
together RB N
with IN N
propofol NN i
in IN N
patients NNS p
undergoing VBG p
coronary JJ p
artery NN p
bypass NN p
graft NN p
surgery NN p
( ( p
CABG NNP p
) ) p
. . p

Sixty JJ p
patients NNS p
( ( p
age NN p
40-73 CD p
yr NN p
, , p
56 CD p
male NN p
) ) p
were VBD p
assigned VBN p
randomly RB p
to TO p
receive VB p
alfentanil NN i
, , i
fentanyl NN i
or CC i
sufentanil NN i
and CC i
propofol NN i
. . i

Plasma NNP o
concentrations NNS o
of IN N
these DT N
drugs NNS N
and CC N
times NNS o
for IN o
the DT o
plasma NN o
concentration NN o
to TO o
decrease VB o
by IN o
50 CD o
% NN o
( ( N
t50 NN N
) ) N
and CC N
80 CD N
% NN N
( ( N
t80 NN N
) ) N
after IN N
cessation NN N
of IN N
the DT N
infusion NN N
were VBD N
determined VBN N
. . N

Times NNS o
were VBD N
recorded VBN N
to TO N
awakening VBG N
and CC N
tracheal JJ N
extubation NN N
. . N

Total JJ o
dose NN o
and CC o
plasma JJ o
concentrations NNS o
of IN N
propofol NN N
were VBD N
similar JJ N
in IN N
all DT N
groups NNS N
. . N

Mean NNP o
total JJ o
doses NNS o
of IN N
alfentanil NN i
, , i
fentanyl NN i
and CC i
sufentanil NN i
were VBD N
443 CD N
, , N
45 CD N
and CC N
4.4 CD N
micrograms NNS N
kg-1 JJ N
, , N
respectively RB N
. . N

Time NN o
to TO o
awakening VBG o
did VBD N
not RB N
differ VB N
significantly RB N
. . N

In IN N
patients NNS N
receiving VBG N
fentanyl NN i
, , N
the DT N
trachea NN o
was VBD N
extubated VBN o
on IN N
average JJ N
2 CD N
h NN N
later RB N
than IN N
in IN N
those DT N
receiving VBG N
sufentanil NN i
and CC N
3 CD N
h NN N
later RB N
than IN N
in IN N
those DT N
receiving VBG N
alfentanil NN i
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

The DT N
t80 NN o
of IN N
fentanyl NN i
was VBD N
longer JJR N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
than IN N
that DT N
of IN N
alfentanil NN i
or CC N
sufentanil NN i
, , N
and CC N
there RB N
was VBD N
a DT N
linear JJ N
correlation NN N
between IN N
the DT N
t80 NN o
of IN N
the DT N
opioid NN N
and CC N
the DT N
time NN o
to TO o
tracheal VB o
extubation NN o
( ( N
r JJ N
= VBZ N
0.51 CD N
; : N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

However RB N
, , N
the DT N
t50 NN o
values NNS o
for IN N
these DT N
opioids NNS N
were VBD N
similar JJ N
and CC N
did VBD N
not RB N
correlate VB N
with IN N
recovery NN o
time NN o
. . o

In IN N
conclusion NN N
, , N
patients NNS p
undergoing VBG p
CABG NNP p
and CC N
who WP N
were VBD N
anaesthetized VBN N
with IN N
fentanyl NN i
and CC N
propofol NN i
needed VBN N
mechanical JJ o
ventilatory NN o
support NN o
for IN N
a DT N
significantly RB N
longer JJR N
time NN N
than IN N
those DT N
receiving VBG N
alfentanil NN i
or CC N
sufentanil NN i
and CC N
propofol NN i
. . i

On IN N
the DT N
basis NN N
of IN N
the DT N
interindividual JJ N
variation NN N
observed VBD N
, , N
the DT N
time NN o
to TO o
tracheal VB o
extubation NN o
was VBD N
most RBS N
predictable JJ N
in IN N
patients NNS N
receiving VBG N
alfentanil NN i
and CC N
most RBS N
variable JJ N
in IN N
patients NNS N
receiving VBG N
fentanyl NN i
, , N
a DT N
finding NN N
which WDT N
may MD N
be VB N
important JJ N
if IN N
the DT N
patients NNS N
are VBP N
transferred VBN N
to TO N
a DT N
step-down JJ N
unit NN N
on IN N
the DT N
evening NN N
of IN N
the DT N
operation NN N
. . N

-DOCSTART- -15673801- O O

Etanercept NNP i
plus CC i
standard JJ i
therapy NN i
for IN N
Wegener NNP p
's POS p
granulomatosis NN p
. . p

BACKGROUND IN N
The DT N
majority NN N
of IN N
patients NNS p
with IN p
Wegener NNP p
's POS p
granulomatosis NN p
have VBP p
disease NN p
flares NNS p
after IN p
conventional JJ p
medications NNS p
are VBP p
tapered VBN p
. . p

There EX N
is VBZ N
no DT N
consistently RB N
safe JJ N
, , N
effective JJ N
treatment NN N
for IN N
the DT N
maintenance NN N
of IN N
remission NN N
. . N

METHODS NNP N
We PRP N
conducted VBD N
a DT N
randomized VBN N
, , N
placebo-controlled JJ i
trial NN N
at IN N
eight CD N
centers NNS N
to TO N
evaluate VB N
etanercept NN i
for IN N
the DT N
maintenance NN N
of IN N
remission NN N
in IN p
180 CD p
patients NNS p
with IN p
Wegener NNP p
's POS p
granulomatosis NN p
. . p

The DT N
primary JJ N
outcome NN N
was VBD N
sustained VBN o
remission NN o
, , N
defined VBD N
as IN N
a DT N
Birmingham NNP N
Vasculitis NNP N
Activity NNP N
Score NNP N
for IN N
Wegener NNP N
's POS N
Granulomatosis NNP N
of IN N
0 CD N
for IN N
at IN N
least JJS N
six CD N
months NNS N
( ( N
scores NNS N
can MD N
range VB N
from IN N
0 CD N
to TO N
67 CD N
, , N
with IN N
higher JJR N
scores NNS N
indicating VBG N
more RBR N
active JJ N
disease NN N
) ) N
. . N

In IN N
addition NN N
to TO N
etanercept VB i
or CC N
placebo VB i
, , N
patients NNS N
received VBD N
standard JJ i
therapy NN i
( ( i
glucocorticoids JJ i
plus CC i
cyclophosphamide JJ i
or CC i
methotrexate NN i
) ) i
. . i

After IN N
remission NN N
, , N
standard JJ i
medications NNS i
were VBD N
tapered VBN N
according VBG N
to TO N
the DT N
protocol NN N
. . N

RESULTS VB N
The DT N
mean JJ N
follow-up NN N
for IN N
the DT N
overall JJ N
cohort NN N
was VBD N
27 CD N
months NNS N
. . N

Of IN p
the DT p
174 CD p
patients NNS p
who WP p
could MD p
be VB p
evaluated VBN p
, , p
126 CD p
( ( p
72.4 CD p
percent NN p
) ) p
had VBD p
a DT p
sustained VBN o
remission NN o
, , p
but CC p
only RB p
86 CD p
( ( p
49.4 CD p
percent NN p
) ) p
remained VBD p
in IN p
remission NN o
for IN p
the DT p
remainder NN p
of IN p
the DT p
trial NN p
. . p

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
between IN N
the DT N
etanercept NN i
and CC N
control NN N
groups NNS N
in IN N
the DT N
rates NNS o
of IN o
sustained JJ o
remission NN o
( ( N
69.7 CD N
percent NN N
vs. FW N
75.3 CD N
percent NN N
, , N
P=0.39 NNP N
) ) N
, , N
sustained VBD N
periods NNS N
of IN N
low-level JJ o
disease NN o
activity NN o
( ( N
86.5 CD N
percent NN N
vs. FW N
90.6 CD N
percent NN N
, , N
P=0.32 NNP N
) ) N
, , N
or CC N
the DT N
time NN N
required VBN N
to TO N
achieve VB N
those DT N
measures NNS N
. . N

Disease NNP o
flares NNS o
were VBD N
common JJ N
in IN N
both DT N
groups NNS N
, , N
with IN N
118 CD N
flares NNS N
in IN N
the DT N
etanercept NN i
group NN N
( ( N
23 CD N
severe RB N
and CC N
95 CD N
limited VBN N
) ) N
and CC N
134 CD N
in IN N
the DT N
control NN i
group NN i
( ( N
25 CD N
severe RB N
and CC N
109 CD N
limited JJ N
) ) N
. . N

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
between IN N
the DT N
etanercept NN i
and CC N
control NN N
groups NNS N
in IN N
the DT N
relative JJ o
risk NN o
of IN o
disease NN o
flares NNS o
per IN N
100 CD N
person-years NNS N
of IN N
follow-up NN N
( ( N
0.89 CD N
, , N
P=0.54 NNP N
) ) N
. . N

During IN N
the DT N
study NN N
, , N
56.2 CD N
percent NN N
of IN N
patients NNS N
in IN N
the DT N
etanercept NN i
group NN N
and CC N
57.1 CD N
percent NN N
of IN N
those DT N
in IN N
the DT N
control NN N
group NN N
had VBD N
at IN N
least JJS N
one CD N
severe JJ o
or CC o
life-threatening JJ o
adverse JJ o
event NN o
or CC o
died VBN o
( ( N
P=0.90 NNP N
) ) N
. . N

Solid JJ o
cancers NNS o
developed VBD N
in IN N
six CD N
patients NNS N
in IN N
the DT N
etanercept NN i
group NN N
, , N
as IN N
compared VBN N
with IN N
none NN N
in IN N
the DT N
control NN N
group NN N
( ( N
P=0.01 NNP N
) ) N
. . N

CONCLUSIONS NNP N
Etanercept NNP i
is VBZ N
not RB N
effective JJ N
for IN N
the DT N
maintenance NN o
of IN o
remission NN o
in IN p
patients NNS p
with IN p
Wegener NNP p
's POS p
granulomatosis NN p
. . p

Durable JJ o
remissions NNS o
were VBD N
achieved VBN N
in IN N
only RB N
a DT N
minority NN N
of IN N
the DT N
patients NNS N
, , N
and CC N
there RB N
was VBD N
a DT N
high JJ N
rate NN N
of IN N
treatment-related JJ N
complications NNS N
. . N

-DOCSTART- -10555930- O O

The DT N
effect NN N
of IN N
Cys NNP i
LT1 NNP i
receptor NN i
blockade NN i
on IN N
airway NN p
responses NNS p
to TO p
allergen VB p
. . p

STUDY NNP N
OBJECTIVE NNP N
To TO N
evaluate VB N
the DT N
effect NN N
of IN N
a DT N
potent JJ N
experimental JJ N
leukotriene NN i
receptor NN i
antagonist NN i
, , i
MK-571 NNP i
, , N
on IN N
airway NN p
responses NNS p
to TO p
inhaled VB p
allergen NN p
. . p

DESIGN NNP N
Randomized NNP N
, , N
double-blind NN N
, , N
placebo-controlled JJ i
, , N
crossover JJ N
trial NN N
. . N

SETTING NNP N
Clinical NNP N
research NN N
center NN N
. . N

SUBJECTS NNP N
Eight NNP p
male NN p
volunteers NNS p
with IN p
allergic JJ p
asthma NN p
. . p

INTERVENTIONS NNP N
An DT N
intravenous JJ N
loading NN N
dose NN N
was VBD N
followed VBN N
by IN N
an DT N
8-hour JJ i
infusion NN i
of IN i
MK-571 NNP i
or CC i
placebo NN i
, , N
with IN N
a DT N
7- JJ N
to TO N
14-day JJ N
washout NN N
between IN N
treatments NNS N
. . N

Allergen NNP N
challenge NN N
was VBD N
performed VBN N
after IN N
the DT N
loading NN N
dose NN N
and CC N
a DT N
histamine NN i
challenge NN N
was VBD N
performed VBN N
before IN N
and CC N
24 CD N
hours NNS N
after IN N
allergen NN N
. . N

MEASUREMENTS NNP N
AND CC N
MAIN NNP N
RESULTS NNP N
Forced NNP o
expiratory JJ o
volume NN o
in IN N
1 CD N
second NN N
was VBD N
measured VBN N
serially RB N
. . N

MK-571 NNP i
provided VBD N
about IN N
50 CD N
% NN N
protection NN N
during IN N
maximum JJ N
early JJ N
and CC N
late JJ N
responses NNS N
compared VBN N
with IN N
placebo NN i
( ( N
p=0.005 NN N
) ) N
, , N
but CC N
airway RB o
obstruction NN o
persisted VBD N
8-24 CD N
hours NNS N
after IN N
allergen NN N
on IN N
both DT N
treatment NN N
days NNS N
. . N

Airway NNP o
responsiveness NN o
to TO o
histamine VB o
was VBD N
not RB N
significantly RB N
attenuated VBN N
at IN N
24 CD N
hours NNS N
. . N

CONCLUSION NNP N
Blocking NNP N
Cys NNP N
LT1 NNP N
receptors NNS N
for IN N
8 CD N
hours NNS N
attenuated VBD N
the DT N
early JJ N
and CC N
late JJ N
responses NNS N
but CC N
did VBD N
not RB N
interrupt VB N
the DT N
cascade NN N
of IN N
events NNS N
leading VBG N
to TO N
subsequent JJ N
allergen-induced JJ N
airway NN N
obstruction NN N
and CC N
hyperreactivity NN N
. . N

-DOCSTART- -1623694- O O

Differential JJ o
effects NNS o
of IN N
two CD N
dihydropyridine JJ i
calcium NN i
antagonists NNS i
in IN N
humans NNS N
. . N

We PRP N
studied VBD N
the DT N
effects NNS N
after IN N
single JJ N
doses NNS N
of IN N
niguldipine NN i
( ( N
0.3 CD N
, , N
0.6 CD N
, , N
and CC N
0.9 CD N
mg NN N
intravenously RB N
; : N
8 CD N
and CC N
16 CD N
mg NNS N
orally RB N
) ) N
and CC N
nifedipine JJ i
( ( N
2 CD N
mg NN N
intravenously RB N
; : N
20 CD N
mg NNS N
orally RB N
) ) N
in IN N
healthy JJ p
male NN p
volunteers NNS p
in IN N
randomized JJ N
placebo-controlled JJ i
experiments NNS N
. . N

Total JJ o
peripheral JJ o
resistance NN o
( ( o
TPR NNP o
) ) o
, , o
heart NN o
rate-corrected JJ o
electromechanical JJ o
systole NN o
( ( o
QS2c NNP o
) ) o
, , N
and CC N
preejection NN o
period NN o
( ( o
PEPc NNP o
) ) o
were VBD N
assessed VBN N
noninvasively RB N
. . N

Both DT N
drugs NNS N
induced VBD N
a DT N
similar JJ N
pronounced NN N
decreased VBD N
in IN N
TRP NNP o
, , N
indicating VBG N
peripheral JJ N
vasodilation NN N
, , N
followed VBN N
by IN N
increasing VBG N
heart NN o
rate NN o
and CC N
cardiac JJ o
output NN o
, , N
a DT N
decrease NN N
in IN N
diastolic JJ N
blood NN N
pressure NN N
, , N
and CC N
a DT N
shortening NN N
of IN N
the DT N
PEPc NNP N
. . N

QS2c NNP o
was VBD N
unchanged JJ N
after IN N
niguldipine NN N
. . N

The DT N
prolongation NN o
of IN o
QS2c NNP o
after IN N
oral JJ N
nifedipine NN i
is VBZ N
suggestive JJ N
of IN N
a DT N
negative JJ o
inotropic NN o
effect NN o
. . o

We PRP N
conclude VBP N
that IN N
the DT N
vasodilatory JJ o
effects NNS o
of IN N
dihydropyridines NNS i
may MD N
( ( N
as IN N
for IN N
nifedipine NN i
) ) i
or CC N
may MD N
not RB N
( ( N
as IN N
for IN N
niguldipine NN i
) ) i
be VB N
associated VBN N
with IN N
changes NNS N
that WDT N
are VBP N
suggestive JJ N
of IN N
negative JJ o
inotropic NN o
effects NNS o
, , N
and CC N
that IN N
this DT N
difference NN N
is VBZ N
detectable JJ N
by IN N
noninvasive JJ N
methods NNS N
in IN N
healthy JJ p
subjects NNS p
. . p

-DOCSTART- -10643677- O O

The DT N
effect NN N
of IN N
body NN N
weight JJ N
changes NNS N
and CC N
endurance NN N
training NN N
on IN N
24h CD o
substrate JJ o
oxidation NN o
. . o

OBJECTIVE UH N
To TO N
investigate VB N
the DT N
effect NN N
of IN N
exercise NN i
training NN i
and CC i
dietary JJ i
macronutrient NN i
composition NN i
on IN N
24 CD o
h NN o
substrate JJ o
oxidation NN o
in IN N
male NN p
, , p
obese JJ p
subjects NNS p
. . p

DESIGN VB N
A DT N
16 CD N
month NN N
exercise NN i
intervention NN i
study NN N
was VBD N
executed VBN N
, , N
including VBG N
a DT N
weight JJ N
loss NN N
period NN N
with IN N
a DT N
very RB i
low JJ i
energy NN i
diet NN i
( ( i
VLED NNP i
) ) i
for IN N
2 CD N
months NNS N
at IN N
the DT N
start NN N
of IN N
the DT N
study NN N
. . N

SUBJECTS NNP N
Twelve NNP p
male NN p
, , p
obese JJ p
subjects NNS p
( ( p
age NN p
36.3+/-5.1 CD p
y NN p
; : p
body NN p
weight VBD p
94.6+/-13.9 CD p
kg NN p
; : p
body NN p
mass NN p
index NN p
, , p
BMI NNP p
30.8+/-3.0 NNP p
kg/m2 NN p
) ) p
and CC p
in IN p
an DT p
additional JJ p
study NN p
15 CD p
lean JJ p
, , p
well-trained JJ p
subjects NNS p
( ( p
age NN p
36.2+/-7.2 CD p
y NN p
; : p
body NN p
weight VBD p
72.2+/-5.9 JJ p
kg NN p
; : p
BMI NNP p
22.3+/-1.7 CD p
kg/m2 NN p
) ) p
participated VBD p
. . p

MEASUREMENTS NNP N
Substrate NNP o
oxidation NN o
was VBD N
measured VBN N
during IN N
a DT N
standardized JJ N
36 CD N
h NN N
stay NN N
in IN N
the DT N
respiration NN N
chamber NN N
at IN N
the DT N
start NN N
of IN N
the DT N
study NN N
( ( N
0 CD N
months NNS N
) ) N
, , N
and CC N
at IN N
4 CD N
, , N
10 CD N
and CC N
16 CD N
months NNS N
. . N

In IN N
the DT N
respiration NN N
chamber NN N
subjects NNS p
were VBD p
randomly RB p
assigned VBN p
to TO N
a DT N
high-fat NN i
( ( i
Hi.F NNP i
) ) i
diet NN i
( ( i
60 CD i
% NN i
of IN i
energy NN i
( ( i
En NNP i
% NN i
) ) i
fat NN i
) ) i
or CC i
a DT i
reduced-fat JJ i
( ( i
Red.F NNP i
) ) i
diet NN i
( ( i
30 CD i
En NNP i
% NN i
fat NN i
) ) i
. . i

The DT N
well-trained JJ N
group NN N
was VBD N
measured VBN N
once RB N
in IN N
the DT N
respiration NN N
chamber NN N
for IN N
36 CD N
h NN N
according VBG N
to TO N
the DT N
same JJ N
protocol NN N
. . N

RESULTS NNP N
At IN N
any DT N
time NN N
point NN N
, , N
independent JJ N
of IN N
the DT N
diet NN N
consumed VBD N
, , N
the DT N
24 CD o
h NN o
carbohydrate NN o
( ( o
CHO NNP o
) ) o
balances NNS o
in IN N
the DT N
chamber NN N
were VBD N
mostly RB N
negative JJ N
( ( N
means NNS N
ranging VBG N
from IN N
+31 NN N
to TO N
-98 VB N
g/d NN N
) ) N
and CC N
the DT N
fat JJ o
balances NNS o
mostly RB N
positive JJ N
( ( N
means NNS N
ranging VBG N
from IN N
-26 NN N
to TO N
+38 VB N
g/d NN N
) ) N
for IN N
the DT N
obese NN N
a DT N
well RB N
as IN N
for IN N
the DT N
lean JJ N
, , N
well-trained JJ N
group NN N
. . N

For IN N
both DT N
diets NNS N
an DT N
increased JJ N
shortage NN o
of IN o
70 CD o
g NN o
of IN o
CHO NNP o
was VBD N
found VBN N
at IN N
16 CD N
months NNS N
compared VBN N
with IN N
4 CD N
months NNS N
, , N
and CC N
an DT N
increase NN N
in IN N
fat JJ o
balance NN o
of IN N
33 CD N
g NN N
during IN N
the DT N
same JJ N
time NN N
period NN N
in IN N
the DT N
obese JJ N
subjects NNS N
, , N
indicating VBG N
that IN N
CHO NNP o
oxidation NN o
had VBD N
increased VBN N
with IN N
12 CD N
months NNS N
endurance RB N
training VBG N
. . N

In IN N
the DT N
well-trained JJ N
group NN N
the DT N
24h CD o
CHO NNP o
balance NN o
was VBD N
even RB N
more RBR N
negative JJ N
for IN N
both DT N
types NNS N
of IN N
diet NN N
( ( N
-103 UH N
to TO N
-185 VB N
g/d NN N
for IN N
the DT N
Red.F NNP N
and CC N
Hi.F NNP N
diet NN N
, , N
respectively RB N
) ) N
under IN N
similar JJ N
conditions NNS N
compared VBN N
with IN N
the DT N
trained JJ N
obese JJ N
group NN N
. . N

CONCLUSION NNP N
The DT N
changes NNS N
in IN N
24 CD o
h NN o
substrate JJ o
utilization NN o
in IN N
the DT N
obese JJ N
, , N
as RB N
well RB N
as IN N
in IN N
the DT N
well-trained JJ N
group NN N
, , N
suggest VBP N
that IN N
endurance NN N
training NN N
increased VBD N
the DT N
reliance NN N
on IN N
carbohydrate NN o
oxidation NN o
and CC N
therefore RB N
did VBD N
not RB N
increase VB N
24 CD o
fat JJ o
oxidation NN o
. . o

-DOCSTART- -9895371- O O

Total JJ i
parenteral JJ i
nutrition NN i
with IN i
glutamine JJ i
dipeptide NN i
shortened VBD N
hospital JJ o
stays NNS o
and CC N
improved VBN N
immune JJ o
status NN o
and CC o
nitrogen NN o
economy NN o
after IN p
major JJ p
abdominal JJ p
surgery NN p
. . p

-DOCSTART- -8507025- O O

Metabolic JJ N
responses NNS N
to TO N
oral JJ i
surgery NN i
under IN N
local JJ i
anesthesia NN i
and CC N
sedation NN N
with IN N
intravenous JJ N
midazolam NNS i
: : i
the DT N
effects NNS N
of IN N
two CD N
different JJ N
local JJ i
anesthetics NNS i
. . i

The DT N
effects NNS N
of IN N
epinephrine-free JJ i
and CC i
epinephrine-containing JJ i
local JJ i
anesthetic JJ i
solutions NNS N
on IN N
plasma NN o
potassium NN o
and CC o
blood NN o
glucose JJ o
concentrations NNS o
were VBD N
investigated VBN N
in IN N
20 CD p
patients NNS p
undergoing JJ p
oral JJ p
surgery NN p
with IN p
intravenous JJ p
midazolam NNS i
sedation NN p
. . p

Ten CD N
patients NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
4.4 CD i
mL NN i
of IN i
2 CD i
% NN i
lidocaine NN i
with IN i
1:80,000 CD i
epinephrine NN i
as IN i
a DT i
local JJ i
anesthetic NN i
and CC i
10 CD i
were VBD i
given VBN i
4.4 CD i
mL NN i
of IN i
3 CD i
% NN i
prilocaine NN i
with IN i
0.03 CD i
IU/mL NNP i
felypressin NN i
. . i

There EX N
were VBD N
significant JJ N
changes NNS N
from IN N
baseline NN N
potassium NN o
and CC o
glucose JJ o
concentrations NNS o
both DT N
within IN N
and CC N
between IN N
treatments NNS N
in IN N
the DT N
early JJ N
postinjection NN N
period NN N
. . N

The DT N
epinephrine-containing JJ N
local JJ N
anesthetic NN N
significantly RB N
reduced VBD N
the DT N
plasma NN o
potassium NN o
concentration NN o
10 CD o
min NN o
after IN o
injection NN o
, , N
by IN N
0.16 CD N
+/- JJ N
0.20 CD N
mmol/L NN N
( ( N
mean JJ N
+/- NNP N
SD NNP N
) ) N
, , N
and CC N
increased VBD N
the DT N
blood NN o
glucose JJ o
concentration NN o
at IN N
10 CD N
, , N
20 CD N
, , N
and CC N
30 CD N
min NN N
( ( N
by IN N
0.46 CD N
+/- JJ N
0.37 CD N
, , N
0.63 CD N
+/- JJ N
0.45 CD N
, , N
and CC N
0.56 CD N
+/- JJ N
0.28 CD N
mmol/L NN N
, , N
respectively RB N
) ) N
. . N

Conversely RB N
, , N
plasma JJ o
potassium NN o
increased VBD N
and CC N
blood NN o
glucose NN o
decreased VBD N
10 CD N
, , N
20 CD N
, , N
and CC N
30 CD N
min NN N
following VBG N
the DT N
administration NN N
of IN N
the DT N
epinephrine-free JJ i
solution NN i
. . i

At IN N
30 CD o
min NN o
potassium NN o
was VBD N
increased VBN N
by IN N
0.24 CD N
+/- JJ N
0.16 CD N
mmol/L NN N
, , N
and CC N
glucose NN o
was VBD N
decreased VBN N
by IN N
0.23 CD N
+/- JJ N
0.16 CD N
mmol/L NN N
. . N

It PRP N
is VBZ N
concluded VBN N
that IN N
epinephrine-free JJ i
and CC N
epinephrine-containing JJ i
local JJ i
anesthetics NNS i
differ VBP N
in IN N
their PRP$ N
metabolic JJ N
effects NNS N
during IN N
oral JJ N
surgery NN N
with IN N
midazolam JJ i
sedation NN i
. . i

-DOCSTART- -26315981- O O

Extended-Release JJ N
Guanfacine NNP i
for IN N
Hyperactivity NNP N
in IN N
Children NNP p
With IN p
Autism NNP p
Spectrum NNP p
Disorder NNP p
. . p

OBJECTIVE NNP N
Hyperactivity NNP N
, , N
impulsiveness NN N
, , N
and CC N
distractibility NN N
are VBP N
common JJ N
problems NNS N
in IN N
children NNS p
with IN p
autism NN p
spectrum NN p
disorder NN p
( ( p
ASD NNP p
) ) p
. . p

Extended-release JJ N
guanfacine NN N
is VBZ N
approved VBN N
for IN N
children NNS p
with IN p
attention NN p
deficit NN p
hyperactivity NN p
disorder NN p
but CC N
not RB N
well RB N
studied VBN N
in IN N
ASD NNP N
. . N

METHOD NNP N
In IN N
a DT N
multisite NN N
, , N
randomized VBD N
clinical JJ N
trial NN N
, , N
extended-release JJ N
guanfacine NN i
was VBD N
compared VBN N
with IN N
placebo NN i
in IN N
children NNS p
with IN p
ASD NNP p
accompanied VBN N
by IN N
hyperactivity NN N
, , N
impulsiveness NN N
, , N
and CC N
distractibility NN N
. . N

RESULTS NNP N
Sixty-two JJ p
subjects NNS p
( ( p
boys NNS p
, , p
N=53 NNP p
; : p
girls NNS p
, , p
N=9 NNP p
; : p
mean JJ p
age=8.5 CD p
years NNS p
[ JJ p
SD=2.25 NNP p
] NN p
) ) p
were VBD N
randomly RB N
assigned VBN N
to TO N
guanfacine VB i
( ( N
N=30 NNP N
) ) N
or CC N
placebo NN i
( ( N
N=32 NNP N
) ) N
for IN N
8 CD N
weeks NNS N
. . N

The DT N
guanfacine NN N
group NN N
showed VBD N
a DT N
43.6 CD N
% NN N
decline NN N
in IN N
scores NNS o
on IN o
the DT o
Aberrant NNP o
Behavior NNP o
Checklist-hyperactivity NNP o
subscale NN o
( ( N
least JJS N
squares NNS N
mean VBP N
from IN N
34.2 CD N
to TO N
19.3 CD N
) ) N
compared VBN N
with IN N
a DT N
13.2 CD N
% NN N
decrease NN N
in IN N
the DT N
placebo NN N
group NN N
( ( N
least JJS N
squares NNS N
mean VBP N
from IN N
34.2 CD N
to TO N
29.7 CD N
; : N
effect NN N
size=1.67 NN N
) ) N
. . N

The DT N
rate NN N
of IN N
positive JJ N
response NN N
( ( N
much JJ N
improved VBN N
or CC N
very RB N
much JJ N
improved VBN N
on IN N
the DT N
Clinical JJ o
Global NNP o
Impression-Improvement NNP o
scale NN o
) ) o
was VBD N
50 CD N
% NN N
( ( N
15 CD N
of IN N
30 CD N
) ) N
for IN N
guanfacine NN N
compared VBN N
with IN N
9.4 CD N
% NN N
( ( N
3 CD N
of IN N
32 CD N
) ) N
for IN N
placebo NN i
. . i

A DT N
brief JJ N
cognitive JJ o
battery NN o
tapping VBG o
working VBG o
memory NN o
and CC o
motor NN o
planning NN o
showed VBD N
no DT N
group NN N
differences VBZ N
before IN N
or CC N
after IN N
8 CD N
weeks NNS N
of IN N
treatment NN N
. . N

The DT N
modal NN N
dose NN N
of IN N
guanfacine NN i
at IN N
week NN N
8 CD N
was VBD N
3 CD N
mg/day NN N
( ( N
range NN N
: : N
1-4 JJ N
mg/day NN N
) ) N
, , N
and CC N
the DT N
modal NN N
dose NN N
was VBD N
3 CD N
mg/day NN N
( ( N
range NN N
: : N
2-4 JJ N
mg/day NN N
) ) N
for IN N
placebo NN N
. . N

Four CD N
guanfacine-treated JJ i
subjects NNS N
( ( N
13.3 CD N
% NN N
) ) N
and CC N
four CD N
placebo NN N
subjects NNS N
( ( N
12.5 CD N
% NN N
) ) N
exited VBD N
the DT N
study NN N
before IN N
week NN N
8 CD N
. . N

The DT N
most RBS N
common JJ N
adverse JJ o
events NNS o
included VBD o
drowsiness NN o
, , o
fatigue NN o
, , o
and CC o
decreased VBD o
appetite RB o
. . o

There EX N
were VBD N
no DT N
significant JJ N
changes NNS N
on IN N
ECG NNP o
in IN N
either DT N
group NN N
. . N

For IN N
subjects NNS N
in IN N
the DT N
guanfacine NN N
group NN N
, , N
blood NN o
pressure NN o
declined VBD N
in IN N
the DT N
first JJ N
4 CD N
weeks NNS N
, , N
with IN N
return NN N
nearly RB N
to TO N
baseline VB N
by IN N
endpoint NN N
( ( N
week NN N
8 CD N
) ) N
. . N

Pulse JJ o
rate NN o
showed VBD N
a DT N
similar JJ N
pattern NN N
but CC N
remained VBD N
lower JJR N
than IN N
baseline NN N
at IN N
endpoint NN N
. . N

CONCLUSIONS NNP N
Extended-release NNP N
guanfacine NN N
appears VBZ N
to TO N
be VB N
safe JJ N
and CC N
effective JJ N
for IN N
reducing VBG N
hyperactivity NN o
, , o
impulsiveness NN o
, , o
and CC o
distractibility NN o
in IN N
children NNS p
with IN p
ASD NNP p
. . p

-DOCSTART- -15909709- O O

Uterine JJ N
incision NN N
closure NN N
at IN N
caesarean JJ N
section NN N
: : N
a DT N
randomised JJ N
comparative NN N
study NN N
of IN N
intraperitoneal JJ i
closure NN i
and CC i
closure NN i
after IN i
temporary JJ i
exteriorisation NN i
. . i

BACKGROUND IN N
The DT N
safety NN N
of IN N
the DT N
technique NN i
of IN i
uterine JJ i
exteriorization NN i
at IN i
caesarean JJ i
section NN i
though IN N
popular JJ N
among IN N
obstetricians NNS N
, , N
remains VBZ N
controversial JJ N
. . N

OBJECTIVE NN N
To TO N
evaluate VB N
the DT N
influence NN N
of IN N
exteriorization NN N
of IN N
uterus NN N
during IN N
uterine JJ N
repair NN N
on IN N
caesarean JJ N
morbidity NN N
. . N

METHODS NNP N
A NNP N
randomized VBD N
comparative JJ N
study NN N
of IN N
136 CD p
women NNS p
undergoing VBG p
primary JJ p
caesarean JJ p
delivery NN p
at IN p
Havana NNP p
Specialist NNP p
Hospital NNP p
Lagos NNP p
Nigeria NNP p
. . p

Data NNP N
on IN N
operation NN N
time NN N
, , N
estimated VBN N
blood NN N
loss NN N
, , N
postoperative JJ N
morbidities NNS N
were VBD N
collected VBN N
and CC N
analysed VBN N
with IN N
comparison NN N
between IN N
the DT N
two CD N
groups NNS N
using VBG N
chi JJ N
square NN N
, , N
Fischer NNP N
's POS N
exact JJ N
test NN N
and CC N
t-test NN N
as IN N
appropriate JJ N
. . N

RESULTS VB N
The DT N
mean JJ o
operative JJ o
time NN o
, , o
estimated VBN o
blood NN o
loss NN o
, , o
transfusion NN o
rate NN o
and CC o
postoperative JJ o
anemia NN o
rate NN o
were VBD N
significantly RB N
less RBR N
in IN N
the DT N
exteriorized JJ N
group NN N
than IN N
the DT N
intraperitoneal JJ N
group NN N
( ( N
p JJ N
= NN N
0.000 CD N
, , N
0.009,0.048 CD N
0.038 CD N
and CC N
0.028 CD N
respectively RB N
) ) N
, , N
but CC N
not RB N
in IN N
other JJ N
outcome JJ N
measures NNS N
. . N

CONCLUSION NNP N
With IN N
shorter JJR N
operative JJ N
time NN N
, , N
less JJR N
blood NN N
loss NN N
and CC N
similar JJ N
morbidity NN N
profile NN N
exteriorization NN N
of IN N
uterus NN N
during IN N
caesarean JJ N
section NN N
seems VBZ N
to TO N
be VB N
preferred VBN N
except IN N
where WRB N
it PRP N
is VBZ N
not RB N
possible JJ N
because IN N
of IN N
adhesions NNS N
and CC N
surgeons NNS N
inexperience NN N
. . N

-DOCSTART- -23940214- O O

EULAR NNP p
Sjogren NNP p
's POS p
Syndrome NNP p
Disease NNP p
Activity NNP p
Index NNP p
( ( p
ESSDAI NNP p
) ) p
is VBZ p
sensitive JJ p
to TO p
show VB p
efficacy NN o
of IN p
rituximab NN i
treatment NN i
in IN p
a DT p
randomised JJ p
controlled VBN p
trial NN p
. . p

-DOCSTART- -1359322- O O

Amphotericin NNP i
versus NN N
pentamidine NN i
in IN N
antimony-unresponsive JJ p
kala-azar NN p
. . p

We PRP N
compared VBN N
the DT N
efficacy NN N
of IN N
amphotericin NN i
B NNP i
and CC N
pentamidine JJ i
isethionate NN i
in IN N
a DT N
prospective JJ N
randomised VBN N
trial NN N
in IN N
120 CD p
uncomplicated JJ p
and CC p
parasitologically RB p
confirmed VBN p
cases NNS p
of IN p
antimony-unresponsive JJ p
kala-azar NN p
. . p

Doses NNS N
were VBD N
twenty JJ N
intramuscular JJ N
injections NNS N
of IN N
pentamidine NN i
4 CD N
mg/kg NN N
on IN N
alternate JJ N
days NNS N
or CC N
fourteen JJ N
definitive JJ N
doses NNS N
of IN N
amphotericin JJ i
0.5 CD N
mg/kg NN N
infused VBN N
in IN N
5 CD N
% NN N
dextrose NN N
on IN N
alternate JJ N
days NNS N
. . N

48 CD N
( ( N
80 CD N
% NN N
) ) N
patients NNS N
given VBN N
pentamidine VBP i
showed VBN N
initial JJ o
cure NN o
and CC N
46 CD N
( ( N
77 CD N
% NN N
) ) N
showed VBD N
definitive JJ o
cure NN o
compared VBN N
with IN N
60 CD N
( ( N
100 CD N
% NN N
) ) N
and CC N
59 CD N
( ( N
98 CD N
% NN N
) ) N
cases NNS N
, , N
respectively RB N
, , N
on IN N
amphotericin NN i
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
. . N

Amphotericin NNP i
also RB N
brought VBD N
about RB N
quicker JJR N
abatement NN o
of IN o
fever NN o
and CC N
more JJR N
complete JJ o
spleen JJ o
regression NN o
. . o

-DOCSTART- -7893582- O O

Angiotensin NNP N
converting VBG N
enzyme JJ N
inhibition NN N
does VBZ N
not RB N
affect VB N
the DT N
response NN N
to TO N
exogenous JJ N
angiotensin NN N
II NNP N
in IN N
the DT N
human JJ p
forearm NN p
. . p

Suppression NN N
of IN N
endogenous JJ N
levels NNS N
of IN N
angiotensin NN N
II NNP N
by IN N
angiotensin NN N
converting VBG N
enzyme JJ N
inhibition NN N
, , N
may MD N
result VB N
in IN N
up-regulation NN N
of IN N
vascular JJ N
AT1 NNP N
receptors NNS N
. . N

We PRP N
have VBP N
evaluated VBN N
the DT N
effects NNS N
of IN N
orally RB N
administered VBN N
enalapril NN i
on IN N
angiotensin NN N
II NNP N
induced VBD N
vasoconstriction NN N
in IN N
the DT N
human JJ p
forearm NN p
. . p

Subjects VBZ p
received VBN N
in IN N
random JJ N
order NN N
, , N
enalapril NN i
( ( N
20 CD N
mg NN N
) ) N
or CC i
matched VBN i
placebo JJ i
daily JJ N
for IN N
2 CD N
weeks NNS N
. . N

Forearm NNP o
blood NN o
flow NN o
response NN N
to TO N
increasing VBG N
doses NNS N
of IN N
angiotensin NN N
II NNP N
was VBD N
measured VBN N
using VBG N
venous JJ N
occlusion NN N
plethysmography NN N
at IN N
the DT N
beginning NN N
of IN N
the DT N
study NN N
and CC N
at IN N
the DT N
end NN N
of IN N
each DT N
2 CD N
week NN N
treatment NN N
period NN N
. . N

Treatment NN N
with IN N
enalapril NN N
significantly RB N
reduced VBN N
plasma NN o
angiotensin NN o
II NNP o
levels NNS o
and CC o
supine VB o
blood NN o
pressure NN o
compared VBN N
with IN N
placebo NN N
. . N

The DT N
percentage NN N
reductions NNS o
in IN o
forearm NN o
blood NN o
flow NN o
in IN N
the DT N
infused JJ N
arm NN N
, , N
in IN N
response NN N
to TO N
the DT N
maximum JJ N
dose NN N
of IN N
angiotensin NN N
II NNP N
( ( N
50,000 CD N
fmol RB N
min-1 NN N
) ) N
were VBD N
48.1 CD N
+/- JJ N
3.6 CD N
% NN N
at IN N
baseline NN N
, , N
57.5 CD N
+/- JJ N
3.6 CD N
% NN N
on IN N
placebo NN N
and CC N
54.5 CD N
+/- JJ N
4.2 CD N
% NN N
on IN N
enalapril NN N
. . N

The DT N
differences NNS N
were VBD N
not RB N
significantly RB N
different JJ N
. . N

This DT N
demonstrates VBZ N
that IN N
suppression NN N
of IN N
plasma NN N
angiotensin NN N
II NNP N
for IN N
a DT N
14 CD N
day NN N
period NN N
does VBZ N
not RB N
enhance VB N
the DT N
response NN N
to TO N
exogenous JJ N
intra-arterial JJ N
angiotensin NN N
II NNP N
in IN N
the DT N
human JJ p
forearm NN p
of IN p
healthy JJ p
salt NN p
replete JJ p
subjects NNS p
. . p

-DOCSTART- -10636373- O O

Treatment NN N
of IN N
hypertension NN p
with IN N
ascorbic JJ i
acid NN i
. . i

In IN N
a DT N
randomised JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ i
study NN N
we PRP N
showed VBD N
that IN N
treatment NN N
of IN N
hypertensive JJ p
patients NNS p
with IN N
ascorbic JJ i
acid NN i
lowers NNS N
blood VBD o
pressure NN o
. . o

Further JJ N
studies NNS N
of IN N
ascorbic JJ i
acid NN i
to TO N
treat VB N
hypertension NN o
, , N
with IN N
clinical JJ o
endpoints NNS o
, , N
are VBP N
warranted VBN N
. . N

-DOCSTART- -8436638- O O

Metronidazole NNP i
in IN N
periodontitis NN i
( ( N
IV NNP N
) ) N
. . N

The DT N
effect NN N
of IN N
patient NN N
compliance NN N
on IN N
treatment NN N
parameters NNS N
. . N

Patient NNP N
compliance NN N
with IN N
the DT N
unsupervised JJ N
usage NN N
of IN N
prescription NN N
medication NN N
can MD N
be VB N
poor JJ N
. . N

In IN N
the DT N
treatment NN N
of IN N
periodontal JJ p
infections NNS p
with IN p
systemic JJ p
antimicrobial JJ p
agents NNS p
, , N
in IN N
situations NNS N
where WRB N
the DT N
efficacy NN N
of IN N
the DT N
antimicrobial JJ N
agent NN N
is VBZ N
being VBG N
evaluated VBN N
, , N
non-compliance NN N
could MD N
underestimate VB N
the DT N
true JJ N
efficacy NN N
of IN N
the DT N
agent NN N
. . N

Metronidazole NNP i
is VBZ N
an DT N
agent NN N
with IN N
reported JJ N
success NN N
in IN N
the DT N
treatment NN N
of IN N
anaerobic JJ N
periodontal JJ N
infections NNS N
. . N

Metronidazole NNP i
is VBZ N
particularly RB N
effective JJ N
in IN N
vitro NN N
against IN N
spirochetes NNS N
, , N
and CC N
this DT N
efficacy NN N
was VBD N
investigated VBN N
as IN N
a DT N
means NN N
of IN N
measuring VBG N
patient JJ N
compliance NN N
with IN N
metronidazole JJ i
usage NN N
. . N

Patients NNS p
who WP p
had VBD p
high JJ p
proportions NNS p
of IN p
spirochetes NNS p
, , p
i.e. FW p
, , N
> FW p
20 CD p
% NN p
, , p
in IN p
plaques NNS p
removed VBN p
from IN p
diseased JJ p
periodontal NN p
sites NNS p
, , N
were VBD N
given VBN N
metronidazole NNS i
( ( N
500 CD N
mg RB N
bid NN N
) ) N
under IN N
supervision NN N
. . N

In IN N
all DT N
individuals NNS N
who WP N
received VBD N
the DT N
metronidazole NN i
, , N
there EX N
was VBD N
a DT N
significant JJ o
and CC o
rapid JJ o
decline NN o
and/or NN o
disappearance NN o
of IN o
spirochetes NNS o
from IN o
the DT o
plaque NN o
during IN N
the DT N
time NN N
interval NN N
that IN N
metronidazole NN i
was VBD N
detectable JJ N
in IN N
the DT N
saliva NN N
. . N

This DT N
observed JJ N
decline NN N
in IN N
spirochetes NNS N
was VBD N
then RB N
used VBN N
to TO N
determine VB N
which WDT N
patients NNS N
had VBD N
been VBN N
compliant VBN N
in IN N
a DT N
double-blind JJ N
clinical JJ N
trial NN N
involving VBG N
the DT N
unsupervised JJ N
usage NN N
of IN N
metronidazole NN i
. . i

Only RB N
10 CD N
of IN N
18 CD p
patients NNS p
( ( N
56 CD N
% NN N
) ) N
were VBD N
considered VBN N
compliant NN N
in IN N
their PRP$ N
usage NN N
of IN N
metronidazole NN i
. . i

These DT N
10 CD N
patients NNS N
experienced VBD N
a DT N
significantly RB o
greater JJR o
benefit NN o
from IN o
the DT o
metronidazole NN o
than IN N
did VBD N
the DT N
8 CD N
patients NNS N
who WP N
were VBD N
considered VBN N
noncompliant JJ N
, , N
i.e. FW N
, , N
a DT N
reduction NN o
of IN o
surgical JJ o
needs NNS o
of IN N
8.3 CD N
teeth NNS N
per IN N
compliant NN N
patient NN N
versus IN N
3.6 CD N
teeth NNS N
per IN N
non-compliant JJ N
patient NN N
. . N

A DT N
test NN N
for IN N
the DT N
hydrolysis NN N
of IN N
the DT N
synthetic JJ N
peptide NN N
( ( N
BANA NNP N
) ) N
was VBD N
also RB N
able JJ N
to TO N
identify VB N
most RBS N
non-compliant JJ N
patients NNS N
. . N

Clinical JJ N
trials NNS N
involving VBG N
the DT N
unsupervised JJ N
usage NN N
of IN N
systemic JJ N
medication NN N
need NN N
to TO N
take VB N
into IN N
account NN N
patient JJ N
non-compliance NN N
. . N

-DOCSTART- -15180835- O O

Prospective JJ N
randomized VBN N
evaluation NN N
of IN N
diode-laser NN N
and CC N
cryotherapy NN N
in IN N
prethreshold JJ o
retinopathy NN o
of IN p
prematurity NN p
. . p

PURPOSE NNP N
To TO N
study VB N
the DT N
efficacy NN N
of IN N
indirect JJ N
diode NN N
laser NN N
photocoagulation NN N
and CC N
cryotherapy NN N
in IN N
prethreshold JJ o
retinopathy NN o
of IN o
prematurity NN o
( ( o
ROP NNP o
) ) o
. . N

METHODS NNP N
Thirty-six JJ p
eyes NNS p
of IN p
18 CD p
premature NN p
infants NNS p
less RBR p
than IN p
34 CD p
weeks NNS p
gestational JJ p
age NN p
and/or NN p
less JJR p
than IN p
1600 CD p
g JJ p
birth NN p
weight NN p
with IN p
prethreshold JJ p
ROP NNP p
were VBD N
prospectively RB N
randomized VBN N
to TO N
treatment NN N
with IN N
either DT N
indirect JJ i
laser NN i
photocoagulation NN i
or CC i
cryotherapy NN i
. . i

Prethreshold NNP N
ROP NNP N
was VBD N
defined VBN N
as IN N
any DT N
stage NN N
of IN N
ROP NNP N
in IN N
zone NN N
I PRP N
with IN N
plus JJ N
disease NN N
; : N
or CC N
stage VB N
3 CD N
with IN N
three CD N
or CC N
more JJR N
contiguous JJ N
clock NN N
hours NNS N
or CC N
five CD N
or CC N
more JJR N
total JJ N
clock NN N
hours NNS N
of IN N
involvement NN N
of IN N
retina NN N
in IN N
zone NN N
II NNP N
with IN N
plus JJ N
disease NN N
but CC N
less JJR N
than IN N
threshold JJ N
disease NN N
. . N

Regression NN o
of IN o
the DT o
ROP NNP o
was VBD N
assessed VBN N
for IN N
a DT N
minimum JJ N
period NN N
of IN N
6 CD N
months NNS N
. . N

RESULTS NNP N
Regression NNP o
of IN o
ROP NNP o
occurred VBD N
in IN N
all DT N
36 CD p
eyes NNS p
( ( N
100 CD N
% NN N
) ) N
in IN N
both DT N
groups NNS N
. . N

CONCLUSIONS NNP N
Excellent JJ N
results NNS N
are VBP N
achieved VBN N
if IN N
ROP NNP o
is VBZ N
treated VBN N
at IN N
the DT N
prethreshold JJ N
stage NN N
with IN N
both DT N
indirect JJ N
laser NN N
photocoagulation NN N
and CC N
cryotherapy NN N
. . N

Although IN N
laser NN N
has VBZ N
definite VBN N
advantages NNS N
, , N
cryotherapy NN N
can MD N
be VB N
considered VBN N
as IN N
an DT N
alternative JJ N
modality NN N
of IN N
treatment NN N
in IN N
developing VBG N
countries NNS N
due JJ N
to TO N
economic JJ N
reasons NNS N
. . N

-DOCSTART- -15238023- O O

Why WRB N
distinctive JJ i
information NN i
reduces NNS N
false JJ o
memories NNS o
: : o
evidence NN N
for IN N
both DT N
impoverished JJ p
relational-encoding NN p
and CC p
distinctiveness NN p
heuristic JJ p
accounts NNS p
. . p

Two CD N
accounts NNS N
explain VBP N
why WRB N
studying VBG i
pictures NNS i
reduces VBZ N
false JJ o
memories NNS o
within IN N
the DT N
Deese-Roediger-McDermott NNP N
paradigm NN N
( ( N
J. NNP N
Deese NNP N
, , N
1959 CD N
; : N
H. NNP N
L. NNP N
Roediger NNP N
& CC N
K. NNP N
B. NNP N
McDermott NNP N
, , N
1995 CD N
) ) N
. . N

The DT N
impoverished JJ N
relational-encoding JJ N
account NN N
suggests VBZ N
that IN N
studying VBG o
pictures NNS o
interferes VBZ N
with IN N
the DT N
encoding NN N
of IN N
relational JJ N
information NN N
, , N
which WDT N
is VBZ N
the DT N
primary JJ N
basis NN N
for IN N
false JJ N
memories NNS N
in IN N
this DT N
paradigm NN N
. . N

Alternatively RB N
, , N
the DT N
distinctiveness NN N
heuristic JJ N
assumes NNS N
that WDT N
critical JJ o
lures NNS o
are VBP N
actively RB N
withheld VBN N
by IN N
the DT N
use NN N
of IN N
a DT N
retrieval NN i
strategy NN i
. . i

When WRB N
participants NNS p
were VBD p
given VBN p
inclusion NN i
recall NN i
instructions NNS i
to TO i
report VB i
studied JJ i
items NNS i
as RB i
well RB i
as IN i
related JJ i
items NNS i
, , N
they PRP N
still RB N
reported VBD o
critical JJ o
lures NNS o
less RBR N
often RB N
after IN N
picture NN N
encoding VBG N
than IN N
they PRP N
did VBD N
after IN N
word NN N
encoding NN N
. . N

As IN N
the DT N
impoverished JJ N
relational-encoding JJ N
account NN N
suggests VBZ N
, , N
critical JJ o
lures NNS o
appear VBP N
less RBR N
likely JJ N
to TO N
come VB N
to TO N
mind VB N
after IN N
picture NN i
encoding VBG i
than IN N
they PRP N
do VBP N
after IN N
word NN i
encoding NN i
. . i

However RB N
, , N
the DT N
results NNS N
from IN N
a DT N
postrecall NN o
recognition NN o
test NN i
provide NN N
evidence NN N
in IN N
favor NN N
of IN N
the DT N
distinctiveness NN N
heuristic NN N
. . N

-DOCSTART- -1584317- O O

Calcium NN i
acetate NN i
versus NN N
calcium NN i
carbonate NN i
as IN N
phosphate NN N
binders NNS N
in IN N
hemodialysis NN p
patients NNS p
. . p

We PRP N
conducted VBD N
a DT N
randomized VBN N
unblinded JJ N
parallel RB N
clinical JJ N
trial NN N
to TO N
compare VB N
the DT N
effectiveness NN o
, , o
side NN o
effects NNS o
and CC o
tolerance NN o
between IN o
calcium NN o
acetate NN o
( ( o
CA NNP o
) ) o
and CC o
calcium NN o
carbonate NN o
( ( o
CC NNP o
) ) o
in IN N
80 CD p
stable JJ p
chronic JJ p
hemodialysis NN p
patients NNS p
selected VBN p
on IN p
the DT p
basis NN p
of IN p
their PRP$ p
acceptable JJ p
control NN p
of IN p
serum NN p
phosphorus NN p
( ( p
P NNP p
) ) p
levels NNS p
with IN p
aluminum NN p
hydroxide NN p
( ( p
AH NNP p
) ) p
. . p

All DT N
patients NNS p
were VBD p
dialyzed VBN p
against IN p
the DT p
same JJ p
calcium NN i
dialyzate NN i
( ( N
1.62 CD N
mmol/l NN N
) ) N
. . N

The DT N
serum JJ N
analytical JJ N
tests NNS N
included VBD N
: : N
calcium NN o
corrected VBD o
to TO o
total JJ o
protein NN o
, , o
P NNP o
, , o
PTH NNP o
( ( o
intact JJ o
molecule NN o
) ) o
and CC o
bicarbonate NN o
. . o

The DT N
study NN N
was VBD N
divided VBN N
into IN N
the DT N
following JJ N
periods NNS N
: : N
P0 NN N
: : N
baseline NN N
measurements NNS N
; : N
P1 NNP N
: : N
washout NN N
( ( N
withdrawal NN N
of IN N
AH NNP N
for IN N
15 CD N
days NNS N
) ) N
; : N
P2 NNP N
: : N
random NN N
allocation NN N
to TO N
CA NNP i
and CC N
CC NNP i
treatment NN N
at IN N
doses NNS N
equivalent JJ N
to TO N
75 CD N
mEq NN N
of IN N
elemental JJ N
calcium NN N
, , N
stratified VBD N
according VBG N
to TO N
previous JJ N
doses NNS N
of IN N
AH NNP N
( ( N
2 CD N
months NNS N
) ) N
; : N
P3 NNP N
: : N
adjustment NN N
of IN N
doses NNS N
until IN N
control NN N
P NNP N
( ( N
2 CD N
months NNS N
) ) N
. . N

CA NNP o
was VBD o
poorly RB o
tolerated VBN o
in IN N
7 CD N
patients NNS N
and CC N
CC NNP N
in IN N
2 CD N
( ( N
NS NNP N
) ) N
. . N

The DT N
changes NNS o
in IN o
serum NN o
P NNP o
levels NNS o
between IN N
P0 NNP N
and CC N
P2 NNP N
periods NNS N
were VBD N
lower JJR N
in IN N
the DT N
CA NNP N
group NN N
( ( N
1.73 CD N
+/- JJ N
0.25 CD N
vs. FW N
1.80 CD N
+/- JJ N
0.50 CD N
mmol/l NN N
; : N
p CC N
= VB N
0.26 CD N
) ) N
than IN N
in IN N
the DT N
CC NNP N
group NN N
( ( N
1.77 CD N
+/- JJ N
0.35 CD N
vs. FW N
1.93 CD N
+/- JJ N
0.48 CD N
mmol/l NN N
; : N
p CC N
= $ N
0.03 CD N
, , N
paired VBD N
t JJ N
test NN N
) ) N
. . N

Serum NNP o
calcium NN o
was VBD N
hardly RB N
modified VBN N
by IN N
CA NNP N
( ( N
2.42 CD N
+/- JJ N
0.20 CD N
vs. FW N
2.47 CD N
+/- JJ N
0.17 CD N
mmol/l NN N
; : N
NS NNP N
) ) N
while IN N
in IN N
the DT N
CC NNP N
group NN N
, , N
it PRP N
rose VBD N
significantly RB N
( ( N
2.40 CD N
+/- JJ N
0.12 CD N
vs. FW N
2.55 CD N
+/- JJ N
0.22 CD N
mmol/l NN N
; : N
p CC N
= VB N
0.0004 CD N
) ) N
. . N

There EX N
were VBD N
no DT N
differences NNS N
in IN N
the DT N
control NN N
of IN N
PTH NNP N
or CC N
bicarbonate NN N
. . N

( ( N
ABSTRACT NNP N
TRUNCATED NNP N
AT NNP N
250 CD N
WORDS NNP N
) ) N
-DOCSTART- -9230829- O O

Mortality NN o
in IN N
patients NNS p
with IN p
small JJ p
choroidal NNS p
melanoma NN p
. . p

COMS NNP N
report NN N
no DT N
. . N

4 CD N
. . N

The DT N
Collaborative JJ N
Ocular NNP N
Melanoma NNP N
Study NNP N
Group NNP N
. . N

OBJECTIVE NNP N
To TO N
describe VB N
the DT N
clinical JJ N
characteristics NNS N
and CC N
survival JJ N
experience NN N
of IN N
a DT N
prospectively RB N
followed VBN N
up RP N
group NN N
of IN N
patients NNS p
with IN p
small JJ p
choroidal NNS p
melanoma NN p
. . p

METHODS NNP N
The DT N
Collaborative NNP N
Ocular NNP N
Melanoma NNP N
Study NNP N
( ( N
COMS NNP N
) ) N
is VBZ N
a DT N
set NN N
of IN N
clinical JJ N
trials NNS N
designed VBN N
to TO N
compare VB N
the DT N
role NN N
of IN N
radiotherapy NN i
and CC N
enucleation NN i
in IN N
the DT N
treatment NN N
of IN N
medium NN N
and CC N
large-size JJ N
choroidal NN N
melanoma NN N
. . N

From IN p
December NNP p
1986 CD p
to TO p
August NNP p
1989 CD p
, , p
patients NNS p
with IN p
small JJ p
choroidal NN p
melanoma NN p
, , p
not RB p
large JJ p
enough RB p
to TO p
be VB p
eligible JJ p
for IN p
the DT p
COMS NNP p
clinical JJ p
trials NNS p
, , N
were VBD N
offered VBN N
participation NN N
in IN N
a DT N
nonrandomized JJ N
prospective JJ N
follow-up NN N
study NN N
. . N

Small NNP N
choroidal JJ N
melanomas NN N
were VBD N
defined VBN N
as IN N
1.0 CD N
to TO N
3.0 CD N
mm NNS N
in IN N
apical JJ N
height NN N
and CC N
at IN N
least JJS N
5.0 CD N
mm NN N
in IN N
basal NN N
diameter NN N
. . N

A DT p
total NN p
of IN p
204 CD p
patients NNS p
were VBD p
enrolled VBN p
in IN p
the DT p
study NN p
. . p

Patients NNS N
were VBD N
followed VBN N
up RP N
annually RB N
through IN N
August NNP N
1989 CD N
. . N

Two CD N
additional JJ N
assessments NNS N
of IN N
treatment NN N
status NN N
and CC N
mortality NN o
were VBD N
conducted VBN N
in IN N
1993-1994 JJ N
and CC N
1995-1996 JJ N
. . N

The DT N
median JJ o
length NN o
of IN N
follow-up NN N
was VBD N
92 CD N
months NNS N
. . N

Eight NNP N
percent NN N
of IN N
patients NNS N
were VBD N
treated VBN N
at IN N
the DT N
time NN N
of IN N
study NN N
enrollment NN N
and CC N
an DT N
additional JJ N
33 CD N
% NN N
were VBD N
treated VBN N
during IN N
follow-up JJ N
. . N

RESULTS JJ N
Twenty-seven JJ N
patients NNS N
have VBP N
died VBN o
; : o
6 CD N
deaths NNS o
were VBD N
reported VBN N
by IN N
the DT N
clinical JJ N
center NN N
as IN N
due JJ N
to TO N
metastatic JJ o
melanoma NN o
. . o

The DT N
Kaplan-Meier NNP N
estimate NN N
of IN N
5-year JJ N
all-cause JJ N
mortality NN o
was VBD N
6.0 CD N
% NN N
( ( N
95 CD N
% NN N
confidence NN N
interval NN N
, , N
2.7 CD N
% NN N
-9.3 NNP N
% NN N
) ) N
and CC N
8-year JJ N
all-cause NN N
mortality NN o
was VBD N
14.9 CD N
% NN N
( ( N
95 CD N
% NN N
confidence NN N
interval NN N
, , N
9.6 CD N
% NN N
-20.2 NNP N
% NN N
) ) N
. . N

CONCLUSIONS NNP N
Otherwise NNP p
healthy JJ p
patients NNS p
, , p
average JJ p
age NN p
of IN p
60 CD p
years NNS p
, , p
without IN p
a DT p
previous JJ p
diagnosis NN p
of IN p
malignant JJ p
disease NN p
who WP p
have VBP p
small JJ p
choroidal JJ o
lesions NNS o
judged VBD p
to TO p
be VB p
melanoma VBN p
have VBP N
a DT N
low JJ N
risk NN N
of IN N
dying VBG N
within IN N
5 CD N
years NNS N
. . N

-DOCSTART- -19103729- O O

Effect NN N
of IN N
recombinant JJ i
adenovirus-p53 NN i
combined VBN i
with IN i
radiotherapy NN i
on IN N
long-term JJ o
prognosis NN o
of IN o
advanced JJ o
nasopharyngeal JJ o
carcinoma NN o
. . o

PURPOSE NNP N
To TO N
centrally RB N
assess VB N
the DT N
safety NN o
, , o
efficacy NN o
, , o
and CC o
6-year JJ o
follow-up NN o
of IN N
recombinant JJ i
adenovirus-p53 JJ i
( ( i
rAd-p53 NN i
) ) i
combined VBN i
with IN i
radiotherapy NN i
( ( i
RT NNP i
) ) i
for IN N
patients NNS p
with IN p
nasopharyngeal JJ p
carcinoma NN p
( ( p
NPC NNP p
) ) p
. . p

PATIENTS NNP N
AND CC N
METHODS NNP N
A NNP N
randomized VBD N
controlled VBN N
clinical JJ N
study NN N
on IN N
rAd-p53 NN i
combined VBN i
with IN i
RT NNP i
in IN N
42 CD p
patients NNS p
with IN p
NPC NNP p
was VBD p
compared VBN p
with IN p
a DT p
control NN p
group NN p
of IN p
40 CD p
patients NNS p
with IN p
NPC NNP p
treated VBD p
with IN p
RT NNP i
alone RB i
. . i

In IN N
the DT N
group NN N
receiving VBG N
rAd-p53 NN i
combined VBN i
with IN i
RT NNP i
, , i
rAd-p53 NN i
was VBD N
intratumorally RB N
injected VBN N
once RB N
a DT N
week NN N
for IN N
8 CD N
weeks NNS N
. . N

Concurrent NNP N
RT NNP N
( ( N
70 CD N
Gy NNP N
in IN N
35 CD N
fractions NNS N
) ) N
was VBD N
given VBN N
to TO N
the DT N
nasopharyngeal JJ N
tumor NN N
and CC N
neck NN N
lymph NN N
node NN N
. . N

Patients NNS N
and CC N
tumors NNS N
were VBD N
monitored VBN N
for IN N
adverse JJ o
events NNS o
and CC o
responses NNS o
. . o

RESULTS NNP N
rAd-p53-specific JJ o
p53 NN o
mRNA NN o
was VBD N
detected VBN N
in IN N
postinjection NN N
of IN N
rAd-p53 JJ N
biopsies NNS N
from IN N
16 CD N
( ( N
94.1 CD N
% NN N
) ) N
of IN N
17 CD N
patients NNS N
. . N

Upregulation NN N
of IN N
p21/WAF1 NN o
and CC o
Bax NNP o
and CC N
downregulation NN N
of IN N
vascular JJ o
endothelial JJ o
growth NN o
factor NN o
were VBD N
observed VBN N
in IN N
postinjection NN N
tumor NN N
biopsy NN N
. . N

Complete JJ o
response NN o
rate NN o
in IN N
the DT N
group NN N
receiving VBG N
rAd-p53 NN i
combined VBN i
with IN i
RT NNP i
was VBD N
observed VBN N
at IN N
2.73 CD N
times NNS N
that WDT N
of IN N
the DT N
group NN N
receiving VBG N
RT NNP i
alone RB i
( ( N
66.7 CD N
% NN N
v JJ N
24.4 CD N
% NN N
) ) N
. . N

Six-year JJ N
follow-up JJ N
data NN N
showed VBD N
that IN N
rAd-p53 JJ i
significantly RB N
increased VBD N
the DT N
5-year JJ o
locoregional JJ o
tumor NN o
control NN o
rate NN o
by IN N
25.3 CD N
% NN N
for IN N
patients NNS p
with IN p
NPC NNP p
treated VBD N
with IN N
irradiation NN N
( ( N
P NNP N
= NNP N
.002 NNP N
) ) N
. . N

The DT N
5-year JJ o
overall JJ o
survival NN o
rate NN o
and CC o
5-year JJ o
disease-free JJ o
survival NN o
rate NN o
of IN N
the DT N
group NN N
receiving VBG N
rAd-p53 NN i
combined VBN i
with IN i
RT NNP i
were VBD N
7.5 CD N
% NN N
( ( N
P NNP N
= NNP N
.34 NNP N
) ) N
and CC N
11.7 CD N
% NN N
( ( N
P NNP N
= NNP N
.21 NNP N
) ) N
higher JJR N
than IN N
those DT N
of IN N
the DT N
group NN N
receiving VBG N
RT NNP i
alone RB i
. . i

No DT N
dose-limiting JJ o
toxicity NN o
or CC o
adverse JJ o
events NNS o
appeared VBD N
, , N
except IN N
for IN N
transient NN o
fever NN o
after IN N
rAd-p53 JJ i
administration NN N
. . N

CONCLUSION NNP N
In IN N
patients NNS p
with IN p
NPC NNP p
, , N
rAd-p53 NN i
was VBD N
safe JJ o
and CC o
biologically RB o
active JJ o
. . o

Our PRP$ N
results NNS N
indicated VBD N
that IN N
rAd-p53 JJ i
improves NNS N
radiotherapeutic JJ o
tumor NN o
control NN o
and CC o
survival JJ o
rate NN o
in IN N
patients NNS p
with IN p
NPC NNP p
. . p

-DOCSTART- -1819001- O O

Response NN p
of IN p
patients NNS p
to TO p
enalapril VB i
, , i
felodipine NN i
and CC i
their PRP$ i
combination NN i
. . i

-DOCSTART- -18278302- O O

Microtensile NNP N
bond NN N
strength NN N
of IN N
a DT N
repair NN N
composite JJ N
to TO N
leucite-reinforced JJ N
feldspathic JJ N
ceramic NN N
. . N

The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
evaluate VB N
the DT N
microtensile NN N
bond NN N
strength NN N
of IN N
a DT N
repair NN N
composite JJ N
resin NN N
to TO N
a DT N
leucite-reinforced JJ N
feldspathic JJ N
ceramic NN N
( ( N
Omega NNP N
900 CD N
, , N
VITA NNP N
) ) N
submitted VBD N
to TO N
two CD N
surface NN N
conditionings NNS N
methods NNS N
: : N
1 CD N
) ) N
etching VBG i
with IN i
hydrofluoric JJ i
acid NN i
+ NNP i
silane NN i
application NN i
or CC i
2 CD i
) ) i
tribochemical NN i
silica NN i
coating NN i
. . i

The DT N
null JJ N
hypothesis NN N
is VBZ N
that IN N
both DT N
surface NN N
treatments NNS N
can MD N
generate VB N
similar JJ N
bond NN o
strengths NNS o
. . N

Ten CD p
ceramic JJ p
blocks NNS p
( ( p
6x6x6 CD p
mm NN p
) ) p
were VBD p
fabricated VBN p
and CC p
randomly RB p
assigned VBN p
to TO p
2 CD p
groups NNS p
( ( p
n=5 NN p
) ) p
, , p
according VBG p
to TO p
the DT p
conditioning NN p
method NN p
: : p
G1- JJ p
10 CD p
% NN p
hydrofluoric JJ i
acid NN i
application NN p
for IN p
2 CD p
min NN p
plus CC p
rinsing NN p
and CC p
drying NN p
, , p
followed VBN p
by IN p
silane NN i
application NN p
for IN p
30 CD p
s NNS p
; : p
G2- NNP p
airborne JJ N
particle NN N
abrasion NN N
with IN N
30 CD N
microm NNS N
silica JJ N
oxide IN N
particles NNS N
( ( N
CoJet-Sand NNP N
) ) N
for IN N
20 CD N
s NNS N
using VBG N
a DT N
chairside JJ N
air-abrasion NN N
device NN N
( ( N
CoJet NNP N
System NNP N
) ) N
, , N
followed VBN N
by IN N
silane NN N
application NN N
for IN N
5 CD N
min NN N
. . N

Single NNP N
Bond NNP N
adhesive JJ N
system NN N
was VBD N
applied VBN N
to TO N
the DT N
surfaces NNS N
and CC N
light NN N
cured VBN N
( ( N
40 CD N
s NN N
) ) N
. . N

Z-250 JJ N
composite JJ N
resin NN N
was VBD N
placed VBN N
incrementally RB N
on IN N
the DT N
treated JJ N
ceramic JJ N
surface NN N
to TO N
build VB N
a DT N
6x6x6 CD N
mm NN N
block NN N
. . N

Bar NNP N
specimens VBZ N
with IN N
an DT N
adhesive JJ N
area NN N
of IN N
approximately RB N
1 CD N
+/- JJ N
0.1 CD N
mm NN N
( ( N
2 CD N
) ) N
were VBD N
obtained VBN N
from IN N
the DT N
composite-ceramic JJ N
blocks NNS N
( ( N
6 CD N
per IN N
block NN N
and CC N
30 CD N
per IN N
group NN N
) ) N
for IN N
microtensile NN o
testing VBG o
. . o

No DT N
statistically RB N
significant JJ N
difference NN N
was VBD N
observed VBN N
between IN N
G1 NNP N
( ( N
10.19 CD N
+/- JJ N
3.1 CD N
MPa NNP N
) ) N
and CC N
G2 NNP N
( ( N
10.17 CD N
+/- JJ N
3.1 CD N
MPa NNP N
) ) N
( ( N
p=0.982 NN N
) ) N
( ( N
Student NNP N
's POS N
t JJ N
test NN N
; : N
? . N
= $ N
0.05 CD N
) ) N
. . N

The DT N
null JJ N
hypothesis NN N
was VBD N
, , N
therefore RB N
, , N
accepted VBD N
. . N

In IN N
conclusion NN N
, , N
both DT N
surface VBP N
conditioning VBG N
methods NNS N
provided VBD N
similar JJ o
microtensile NN o
bond NN o
strengths NNS o
between IN N
the DT N
repair NN N
composite JJ N
resin NN N
and CC N
the DT N
ceramic NN N
. . N

Further JJ N
studies NNS N
using VBG N
long-term JJ N
aging NN N
procedures NNS N
should MD N
be VB N
conducted VBN N
. . N

-DOCSTART- -18824288- O O

Safety NN o
of IN N
ferumoxytol NN i
in IN N
patients NNS p
with IN p
anemia NN p
and CC p
CKD NNP p
. . p

BACKGROUND NNP N
Iron NNP N
deficiency NN N
anemia NN N
is VBZ N
a DT N
common JJ N
complication NN N
in IN N
patients NNS p
with IN p
chronic JJ p
kidney NN p
disease NN p
( ( p
CKD NNP p
) ) p
. . p

Currently NNP N
available JJ N
intravenous JJ N
( ( N
IV NNP N
) ) N
iron NN i
replacement NN i
therapies NNS i
have VBP N
either DT N
inconvenient JJ N
regimens NNS N
of IN N
administration NN N
or CC N
adverse JJ N
event NN N
profiles NNS N
that WDT N
limit VBP N
their PRP$ N
utility NN N
in IN N
the DT N
outpatient NN p
setting NN N
. . N

Ferumoxytol NNP i
is VBZ N
a DT N
novel NN N
, , N
semisynthetic JJ N
, , N
carbohydrate-coated JJ N
, , N
superparamagnetic JJ N
iron NN N
oxide NN N
nanoparticle NN N
that WDT N
is VBZ N
administered VBN N
IV NNP N
as IN N
an DT N
injection NN N
. . N

The DT N
main JJ N
objective NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
assess VB N
the DT N
safety NN o
of IN N
ferumoxytol NN i
for IN N
the DT N
treatment NN N
of IN N
patients NNS p
with IN p
CKD NNP p
stages VBZ p
1 CD p
to TO p
5 CD p
and CC p
5D CD p
. . p

STUDY NNP N
DESIGN NNP N
Phase NNP N
3 CD N
, , N
randomized VBN N
, , N
double-blind JJ N
, , N
placebo-controlled JJ i
, , N
crossover NN N
, , N
multicenter NN N
study NN N
of IN N
a DT N
single JJ N
510-mg JJ N
dose NN N
of IN N
ferumoxytol JJ i
versus NN i
saline NN i
as IN i
placebo NN i
. . i

SETTING NNP N
& CC N
PARTICIPANTS NNP N
750 CD p
patients NNS p
with IN p
CKD NNP p
stages VBZ p
1 CD p
to TO p
5 CD p
and CC p
5D CD p
. . p

INTERVENTION NNP N
An DT N
IV NNP i
injection NN i
of IN N
either CC N
17 CD N
mL NN N
of IN N
ferumoxytol NN i
or CC i
saline NN i
placebo NN i
over IN N
17 CD N
seconds NNS N
on IN N
day NN N
0 CD N
and CC N
the DT N
alternate NN N
agent NN N
on IN N
day NN N
7 CD N
. . N

OUTCOMES NNP N
& CC N
MEASUREMENTS NNP N
Descriptive NNP N
comparison NN N
of IN N
adverse JJ o
events NNS o
, , o
laboratory NN o
tests NNS o
, , o
and CC o
vital JJ o
signs NNS o
. . o

RESULTS NNP N
Of IN N
750 CD p
randomly NNS p
assigned VBD p
patients NNS p
with IN p
CKD NNP p
, , p
60 CD p
% NN p
were VBD p
not RB p
on IN p
dialysis NN i
therapy NN i
. . i

713 CD p
patients NNS p
received VBD p
ferumoxytol JJ i
, , p
and CC p
711 CD p
received VBD p
placebo NN i
. . i

There EX N
were VBD N
420 CD p
adverse JJ o
events NNS o
reported VBD p
; : p
242 CD p
in IN p
152 CD p
patients NNS p
( ( p
21.3 CD p
% NN p
) ) p
with IN p
ferumoxytol NN p
and CC p
178 CD p
in IN p
119 CD p
patients NNS p
( ( p
16.7 CD p
% NN p
) ) p
with IN p
placebo NN i
. . i

The DT N
incidence NN o
of IN o
related JJ o
adverse JJ o
events NNS o
was VBD N
5.2 CD N
% NN N
with IN N
ferumoxytol NN i
and CC N
4.5 CD N
% NN N
with IN N
placebo NN i
. . i

The DT N
most RBS N
common JJ N
related JJ N
adverse JJ o
events NNS o
after IN N
each DT N
treatment NN N
included VBD N
symptoms NNS o
related VBN N
to TO N
the DT N
injection/infusion NN o
site NN o
, , o
dizziness NN o
, , o
pruritus NN o
, , o
headache NN o
, , o
fatigue NN o
, , o
and CC o
nausea NN o
. . o

Serious JJ o
adverse JJ o
events NNS o
occurred VBD N
in IN N
21 CD N
patients NNS N
( ( N
2.9 CD N
% NN N
) ) N
after IN N
ferumoxytol NN i
and CC N
13 CD N
patients NNS N
( ( N
1.8 CD N
% NN N
) ) N
after IN N
placebo NN i
. . i

Serious JJ o
related JJ o
adverse JJ o
events NNS o
were VBD N
observed VBN N
in IN N
1 CD N
patient NN N
( ( N
0.1 CD N
% NN N
) ) N
after IN N
each DT N
treatment NN N
. . N

There EX N
was VBD N
no DT N
meaningful JJ N
decrease NN N
in IN N
blood NN o
pressure NN o
after IN N
administration NN N
of IN N
ferumoxytol NN i
or CC i
placebo NN i
. . i

LIMITATIONS NNP N
Follow-up NNP N
was VBD N
7 CD N
days NNS N
after IN N
each DT N
study NN N
treatment NN N
. . N

CONCLUSIONS NNP N
Ferumoxytol NNP i
is VBZ N
well RB N
tolerated VBN o
and CC N
has VBZ N
a DT N
safety NN o
profile NN o
similar JJ N
to TO N
placebo VB i
in IN N
anemic JJ p
patients NNS p
with IN p
CKD NNP p
stages VBZ p
1 CD p
to TO p
5 CD p
and CC p
5D CD p
. . p

-DOCSTART- -7923712- O O

[ JJ N
Effect NNP N
of IN N
acupuncture NN i
on IN N
T-lymphocyte NNP o
and CC o
its PRP$ o
subsets NNS o
from IN N
the DT N
peripheral JJ N
blood NN N
of IN N
patients NNS p
with IN p
malignant JJ p
neoplasm NN p
] NN p
. . N

Effect NN N
of IN N
acupuncture NN i
on IN N
the DT N
T-lymphocyte NNP o
and CC N
its PRP$ N
subsets NNS o
from IN N
the DT N
peripheral JJ N
blood NN N
of IN N
patients NNS p
with IN p
malignant JJ p
neoplasm NN p
has VBZ N
been VBN N
researched VBN N
in IN N
this DT N
study NN N
. . N

51 CD p
patients NNS p
were VBD N
divided VBN N
into IN N
two CD N
groups NNS N
: : N
one CD N
in IN N
acupuncture NN i
treatment NN i
and CC N
the DT N
other JJ N
without IN N
any DT N
treatment NN N
. . N

48 CD p
healthy JJ p
adults NNS p
were VBD p
also RB p
studied VBN p
as IN p
normal JJ p
control NN p
group NN p
. . p

The DT N
results NNS N
showed VBD N
that IN N
the DT N
percentages NNS o
of IN o
OKT3+ NNP o
, , o
OKT4+ NNP o
, , o
OKT8+ NNP o
cells NNS o
in IN o
the DT o
peripheral JJ o
blood NN o
of IN N
the DT N
51 CD N
patients NNS N
were VBD N
lower JJR N
than IN N
those DT N
of IN N
the DT N
normal JJ N
adults NNS N
respectively RB N
. . N

After IN N
the DT N
acupuncture NN i
treatment NN N
, , N
the DT N
percentages NNS o
of IN o
OKT3+ NNP o
, , o
OKT4+ NNP o
, , o
OKT8+ NNP o
cells NNS o
were VBD N
obviously RB N
higher JJR N
than IN N
those DT N
before IN N
acupuncture NN i
; : i
the DT N
control NN N
group NN N
of IN N
patients NNS N
showed VBD N
no DT N
significant JJ N
variation NN N
. . N

This DT N
result NN N
revealed VBD N
that IN N
acupuncture NN i
seemed VBD N
to TO N
have VB N
more JJR N
affect NN N
on IN N
OKT4+ NNP o
cells NNS o
than IN N
on IN N
OKT8+ NNP o
cells NNS o
. . o

From IN N
our PRP$ N
study NN N
we PRP N
believe VBP N
that IN N
acupuncture NN i
can MD N
be VB N
used VBN N
as IN N
one CD N
of IN N
the DT N
many JJ N
treatments NNS N
for IN N
patients NNS p
with IN p
cancer NN p
. . p

-DOCSTART- -10734271- O O

Computer-assisted JJ i
instruction NN i
: : i
an DT N
effective JJ N
instructional JJ N
method NN N
for IN N
HIV NNP o
prevention NN o
education NN N
? . N
PURPOSE NNP N
To TO N
compare VB N
the DT N
effectiveness NN N
of IN N
a DT N
computer-assisted JJ i
instruction NN i
( ( i
CAI NNP i
) ) i
-based VBD i
intervention NN i
to TO N
a DT N
more RBR N
traditional JJ i
lecture-based JJ i
intervention NN i
for IN N
influencing VBG N
psychosocial JJ N
correlates NNS N
of IN N
human JJ p
immunodeficiency NN p
virus NN p
( ( p
HIV NNP p
) ) p
preventive JJ N
behaviors NNS N
. . N

METHODS NNP N
Students NNPS p
enrolled VBD p
in IN p
a DT p
Human NNP p
Sexuality NNP p
course NN p
( ( p
N NNP p
= NNP p
152 CD p
) ) p
were VBD N
randomly RB N
assigned VBN N
to TO N
one CD N
of IN N
three CD N
groups NNS N
: : N
CAI NNP i
, , i
Lecture NNP i
, , i
or CC i
No DT i
Intervention NNP i
group NN i
. . i

Participants NNS N
in IN N
the DT N
CAI NNP N
group NN N
reviewed VBD N
a DT N
1-hour JJ N
long JJ N
CAI NNP i
program NN i
, , N
participants NNS N
in IN N
the DT N
Lecture NNP N
group NN N
were VBD N
presented VBN N
with IN N
a DT N
1-hour JJ N
long JJ N
lecture NN N
, , N
and CC N
participants NNS N
in IN N
the DT N
No NNP N
Intervention NNP N
group NN N
received VBD N
no DT N
intervention NN N
. . N

After IN N
completing VBG N
the DT N
respective JJ N
interventions NNS N
, , N
all DT N
participants NNS N
completed VBD N
the DT N
HIV NNP o
questionnaire NN o
, , N
which WDT N
measured VBD N
selected VBN N
Social NNP o
Cognitive NNP o
Theory NNP o
constructs NNS N
associated VBN N
with IN N
HIV NNP o
preventive JJ o
behaviors NNS o
. . o

MANCOVA NNP N
, , N
ANCOVA NNP N
and CC N
Post NNP N
Hoc NNP N
analyses NNS N
were VBD N
utilized JJ N
to TO N
test VB N
for IN N
significant JJ N
differences NNS N
among IN N
the DT N
three CD N
groups NNS N
. . N

RESULTS VB N
The DT N
analyses NNS N
disclosed VBD N
that IN N
, , N
compared VBN N
to TO N
participants NNS N
in IN N
the DT N
Lecture NNP N
group NN N
, , N
participants NNS N
in IN N
the DT N
CAI NNP N
group NN N
scored VBD N
significantly RB N
higher JJR N
on IN N
the DT N
scales NNS o
measuring VBG o
autoimmune JJ o
deficiency NN o
syndrome NN o
( ( o
AIDS NNP o
) ) o
knowledge NN o
, , o
self-evaluative JJ o
outcome NN o
motivation NN o
, , o
and CC o
intention NN o
to TO o
practice NN o
HIV NNP o
preventive JJ o
behaviors NNS o
with IN N
current JJ N
partner NN N
. . N

In IN N
addition NN N
, , N
compared VBN N
to TO N
the DT N
No NNP N
Intervention NNP N
group NN N
, , N
the DT N
CAI NNP N
group NN N
scored VBD N
significantly RB N
higher JJR N
on IN N
the DT N
scales NNS o
measuring VBG o
physical JJ o
outcome NN o
motivation NN o
and CC o
social JJ o
outcome NN o
motivation NN o
. . o

CONCLUSIONS NNP N
CAI-based JJ N
programs NNS N
can MD N
be VB N
effective JJ N
for IN N
delivering VBG N
instruction NN N
on IN N
HIV NNP o
prevention NN o
. . o

However RB N
, , N
because IN N
of IN N
certain JJ N
limitations NNS N
, , N
this DT N
type NN N
of IN N
program NN N
is VBZ N
best RB N
utilized VBN N
as IN N
part NN N
of IN N
a DT N
more RBR N
comprehensive JJ N
intervention NN N
that WDT N
uses VBZ N
several JJ N
different JJ N
delivery NN N
systems NNS N
. . N

-DOCSTART- -9547958- O O

Simulating VBG N
a DT N
memory NN N
impairment NN N
: : N
can MD N
amnesics VB p
implicitly RB N
outperform JJ N
simulators NNS N
? . N
OBJECTIVES IN N
The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
examine VB N
the DT N
effectiveness NN o
of IN N
a DT N
variety NN N
of IN N
tests NNS N
in IN N
differentiating VBG N
simulating VBG o
test NN o
performances NNS o
from IN N
genuine JJ N
memory-impaired JJ o
and CC N
normal JJ N
( ( N
control NN N
) ) N
test NN N
performances NNS N
. . N

DESIGN VB N
A DT i
simulation NN i
design NN i
was VBD N
implemented VBN N
, , N
based VBN N
on IN N
an DT N
analogue NN N
design NN N
in IN N
which WDT N
normal JJ N
participants NNS N
were VBD N
given VBN N
experimental JJ N
instructions NNS N
to TO N
feign VB N
a DT N
mental JJ N
impairment NN N
and CC N
are VBP N
compared VBN N
to TO N
( ( N
a DT N
) ) N
other JJ N
normal JJ N
participants NNS N
with IN N
instructions NNS N
to TO N
perform VB N
honestly RB N
, , N
and CC N
( ( N
b NN N
) ) N
a DT N
comparison NN N
group NN N
, , N
for IN N
example NN N
, , N
acquired VBD p
brain-injured JJ p
persons NNS p
, , N
with IN N
similar JJ N
instructions NNS N
. . N

METHOD NNP N
Forty NNP p
individuals NNS p
comprised VBD p
the DT p
simulating NN p
and CC p
control NN p
group NN p
and CC N
all DT N
participants NNS N
were VBD N
randomly RB i
assigned VBN i
to TO i
the DT i
simulating NN i
and CC i
control NN i
groups NNS i
. . i

Twenty CD p
memory-impaired JJ p
patients NNS p
, , p
all DT p
of IN p
whom WP p
had VBD p
been VBN p
diagnosed VBN p
as IN p
suffering VBG p
from IN p
a DT p
memory NN p
impairment NN p
following VBG p
acquired VBD p
brain NN p
damage NN p
, , p
participated VBD p
as IN p
the DT p
memory-impaired JJ p
control NN p
group NN p
. . p

The DT i
simulation NN i
group NN i
was VBD i
directed VBN i
to TO i
imitate VB i
a DT i
person NN i
with IN i
a DT i
memory NN i
impairment NN i
. . i

The DT N
primary JJ o
outcome JJ o
measure NN o
involved VBN N
identifying VBG o
those DT o
tests NNS o
, , o
if IN o
any DT o
, , o
where WRB o
simulators NNS o
were VBD o
significantly RB o
different JJ o
from IN o
normal JJ o
and CC o
memory-impaired JJ o
participants NNS o
. . o

RESULTS VB N
On IN N
5 CD N
of IN N
the DT N
15 CD N
tasks NNS N
administered VBN N
, , N
simulators NNS o
performed VBD o
significantly RB o
differently RB o
from IN o
normal JJ o
and CC o
memory-impaired JJ o
participants NNS o
. . o

Of IN N
these DT N
5 CD N
tasks NNS N
, , N
the DT N
coin-in-the-hand NN N
, , N
when WRB N
administered VBN N
in IN N
conjunction NN N
with IN N
the DT N
autobiographical JJ N
interview NN N
, , N
identified VBD N
95 CD N
per IN N
cent NN N
of IN N
the DT N
simulators NNS N
without IN N
misclassifying VBG N
any DT N
of IN N
the DT N
memory-impaired JJ N
or CC N
normal JJ N
participants NNS N
. . N

CONCLUSION VB N
It PRP N
is VBZ N
suggested VBN N
that IN N
these DT N
two CD N
tests NNS N
, , N
when WRB N
administered VBN N
jointly RB N
, , N
might MD N
be VB N
of IN N
use NN N
in IN N
clinical JJ N
settings NNS N
to TO N
assist VB N
in IN N
the DT N
detection NN N
of IN N
malingerers NNS N
. . N

-DOCSTART- -11162323- O O

Counselor NNP N
and CC N
stimulus VB N
control NN N
enhancements NNS N
of IN N
a DT N
stage-matched JJ o
expert NN o
system NN o
intervention NN o
for IN o
smokers NNS o
in IN N
a DT N
managed VBN N
care NN N
setting VBG N
. . N

BACKGROUND NNP N
Previous NNP N
research NN N
has VBZ N
demonstrated VBN N
the DT N
efficacy NN o
of IN N
an DT N
interactive JJ i
expert NN i
system NN i
intervention NN i
for IN N
smoking VBG N
cessation NN N
for IN N
a DT N
general JJ p
population NN p
. . p

The DT N
intervention NN N
provides VBZ N
individualized JJ N
feedback NN N
that WDT N
guides VBZ N
participants NNS N
through IN N
the DT N
stages NNS N
of IN N
change NN N
for IN N
cessation NN N
. . N

Enhancing VBG N
the DT N
expert NN N
system NN N
by IN N
adding VBG N
proactive JJ N
telephone NN N
counseling NN N
or CC N
a DT N
stimulus NN N
control NN N
computer NN N
designed VBN N
to TO N
produce VB N
nicotine JJ N
fading NN N
could MD N
produce VB N
preventive JJ N
programs NNS N
with IN N
greater JJR N
population NN N
impacts NNS N
. . N

METHODS NNP N
Four CD N
interventions NNS N
were VBD N
compared VBN N
: : N
( ( N
a DT N
) ) N
the DT i
interactive JJ i
expert NN i
system NN i
intervention NN i
; : i
( ( N
b NN N
) ) N
the DT N
expert NN i
system NN i
intervention NN i
plus CC i
counselor NN i
calls VBZ i
; : i
( ( N
c NN N
) ) N
the DT i
expert NN i
system NN i
intervention NN i
plus CC i
the DT i
stimulus NN i
control NN i
computer NN i
; : i
and CC N
( ( N
d NN N
) ) N
an DT N
assessment NN i
only RB i
condition NN i
. . i

A DT N
4 CD N
( ( N
intervention NN N
) ) N
x VBZ N
4 CD N
( ( N
occasions NNS N
) ) N
( ( N
0,6,12 CD N
, , N
and CC N
18 CD N
months NNS N
) ) N
design NN N
was VBD N
used VBN N
. . N

Smokers NNS p
were VBD N
contacted VBN N
at IN N
home NN N
via IN N
telephone NN N
or CC N
mail NN N
. . N

The DT N
initial JJ p
subject JJ p
pool NN p
was VBD p
the DT p
24,178 JJ p
members NNS p
of IN p
a DT p
managed VBN p
care NN p
company NN p
. . p

Screening NN N
was VBD N
completed VBN N
for IN N
19,236 CD p
members NNS p
( ( p
79.6 CD p
% NN p
) ) p
, , p
of IN p
whom WP p
4,653 CD p
were VBD p
smokers NNS p
; : p
85.3 CD p
% NN p
of IN p
the DT p
smokers NNS p
were VBD p
enrolled VBN p
. . p

RESULTS NNP N
Thirty-eight JJ p
percent NN p
were VBD p
in IN p
the DT p
precontemplation NN p
stage NN p
, , p
45 CD p
% NN p
in IN p
the DT p
contemplation NN p
stage NN p
, , p
and CC p
only RB p
17 CD p
% NN p
in IN p
the DT p
preparation NN p
stage NN p
. . p

At IN N
18 CD N
months NNS N
, , N
the DT N
expert NN N
system NN N
resulted VBD N
in IN N
23.2 CD N
% NN N
point NN N
prevalence NN o
abstinence NN o
, , N
which WDT N
was VBD N
33 CD N
% NN N
greater JJR N
than IN N
that DT N
of IN N
assessment NN N
only RB N
. . N

The DT N
counselor NN N
enhancement NN N
produced VBD N
increased JJ N
cessation NN o
at IN N
12 CD N
months NNS N
but CC N
not RB N
at IN N
18 CD N
months NNS N
. . N

The DT N
stimulus NN N
control NN N
computer NN N
produced VBD N
no DT N
improvement NN o
, , N
resulting VBG N
in IN N
20 CD N
% NN N
worse JJR N
cessation NN o
rates NNS o
than IN N
the DT N
assessment NN N
only RB N
condition NN N
. . N

CONCLUSIONS VB N
The DT N
enhanced JJ N
conditions NNS N
failed VBD N
to TO N
outperform VB o
the DT N
expert NN o
system NN o
alone RB N
. . N

The DT N
study NN N
also RB N
demonstrated VBD N
the DT N
ability NN N
of IN N
the DT N
interactive JJ i
expert NN i
system NN i
to TO N
produce VB N
significantly RB N
greater JJR N
cessation NN o
in IN N
a DT N
population NN p
of IN p
smokers NNS p
than IN N
assessment JJ N
alone RB N
. . N

-DOCSTART- -24988118- O O

High-dose JJ N
vitamin NN i
D3 NNP i
supplementation NN i
in IN N
children NNS p
and CC p
young JJ p
adults NNS p
with IN p
HIV NNP o
: : o
a DT N
randomized JJ N
, , N
placebo-controlled JJ i
trial NN i
. . i

BACKGROUND NNP N
Suboptimal NNP N
vitamin NNP N
D NNP N
status NN N
is VBZ N
prevalent JJ N
in IN N
HIV-infected JJ p
patients NNS p
and CC N
associated VBN N
with IN N
increased JJ N
risk NN o
of IN o
disease NN o
severity NN o
and CC o
morbidity NN o
. . o

We PRP N
aimed VBD N
to TO N
determine VB N
12-month JJ N
safety NN o
and CC o
efficacy NN o
of IN N
daily JJ N
7000 CD i
IU NNP i
vitamin FW i
D3 NNP i
( ( N
vitD3 NN N
) ) N
versus NN N
placebo NN i
to TO N
sustain VB N
increased JJ o
serum NN o
25-hydroxyvitamin JJ o
D NNP o
( ( o
25 CD o
( ( o
OH NNP o
) ) o
D NNP o
) ) o
and CC o
improve VB o
immune NN o
status NN o
in IN N
HIV-infected JJ p
subjects NNS p
. . p

METHODS NNP N
This DT N
was VBD N
a DT N
double-blind JJ N
trial NN N
of IN N
perinatally RB p
acquired VBN p
HIV NNP p
( ( p
PHIV NNP p
) ) p
-infected VBD p
subjects NNS p
or CC p
behaviorally RB p
acquired VBN p
HIV NNP p
( ( p
BHIV NNP p
) ) p
-infected VBD p
subjects NNS p
( ( p
5.0-24.9 CD p
years NNS p
) ) p
. . p

Safety NNP o
, , o
25 CD o
( ( o
OH NNP o
) ) o
D-related NNP o
parameters NNS o
and CC o
immune JJ o
status NN o
were VBD N
assessed VBN N
at IN N
baseline NN N
, , N
3 CD N
, , N
6 CD N
and CC N
12 CD N
months NNS N
. . N

RESULTS NNP N
Fifty-eight JJ p
subjects NNS p
enrolled VBN p
( ( p
67 CD p
% NN p
male NN p
, , p
85 CD p
% NN p
African JJ p
American NNP p
and CC p
64 CD p
% NN p
BHIV NNP p
) ) p
and CC p
50 CD p
completed VBN p
with IN p
no DT p
safety NN o
concerns NNS o
. . o

In IN N
unadjusted JJ N
analyses NNS N
, , N
there EX N
were VBD N
no DT N
differences NNS N
between IN N
randomization NN N
groups NNS N
at IN N
baseline NN N
; : N
at IN N
3 CD N
, , N
6 CD N
and CC N
12 CD N
months NNS N
, , N
25 CD N
( ( N
OH NNP N
) ) N
D NNP N
was VBD N
higher RBR N
with IN N
supplementation NN N
than IN N
baseline NN N
and CC N
higher JJR N
than IN N
with IN N
placebo NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

In IN N
adjusted JJ N
mixed JJ N
models NNS N
, , N
in IN N
the DT N
supplementation NN N
group NN N
, , N
the DT N
fixed JJ N
effect NN N
of IN N
25 CD o
( ( o
OH NNP o
) ) o
D NNP o
was VBD N
higher JJR N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

Percentage NN o
of IN o
naive JJ o
T-helper NNP o
cells NNS o
( ( o
Th NNP o
naive CD o
% NN o
) ) o
were VBD N
significantly RB N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
and CC N
T-helper NNP o
cells NNS o
( ( o
CD4 NNP o
% NN o
) ) o
marginally RB N
( ( N
P NNP N
< NNP N
0.10 CD N
) ) N
increased VBN N
with IN N
supplementation NN N
in IN N
those DT N
taking VBG N
highly RB N
active JJ N
antiretroviral JJ N
therapy NN N
( ( N
HAART NNP N
) ) N
, , N
and CC N
RNA NNP o
viral JJ o
load NN o
was VBD N
reduced VBN N
( ( N
P NNP N
? . N
0.05 CD N
) ) N
. . N

In IN N
exploratory JJ N
linear JJ N
models NNS N
, , N
change NN N
in IN N
25 CD o
( ( o
OH NNP o
) ) o
D NNP o
predicted VBD o
RNA NNP o
viral JJ o
load NN o
at IN o
3 CD N
and CC N
12 CD N
months NNS N
and CC o
CD4 NNP o
% NN o
at IN o
3 CD N
months NNS N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

CONCLUSIONS NNP N
Daily JJ N
7000 CD N
IU NNP N
vitD3 NN N
for IN N
12 CD N
months NNS N
was VBD N
safe JJ N
in IN N
HIV-infected JJ N
subjects NNS N
and CC N
effective JJ N
in IN N
increasing VBG o
25 CD o
( ( o
OH NNP o
) ) o
D. NNP o
Supplementation NNP N
improved VBD N
some DT o
clinically RB o
important JJ o
HIV NNP o
immune NN o
markers NNS o
in IN o
subjects NNS N
on IN N
HAART NNP N
. . N

Adjunct NNP N
therapy NN N
with IN N
high-dose JJ N
, , N
daily JJ i
vitD3 NN i
for IN i
HIV-infected JJ N
subjects NNS N
and CC N
for IN N
those DT N
on/off JJ N
HAART NNP N
requires VBZ N
further JJ N
investigation NN N
. . N

-DOCSTART- -19968048- O O

The DT N
efficacy NN N
of IN N
melatonin NN i
for IN N
sleep JJ N
problems NNS N
in IN N
children NNS N
with IN N
autism NN N
, , N
fragile JJ N
X NNP N
syndrome NN N
, , N
or CC N
autism NN N
and CC N
fragile JJ N
X NNP N
syndrome NN N
. . N

STUDY NNP N
OBJECTIVE NNP N
To TO N
determine VB N
the DT N
efficacy NN N
of IN N
melatonin NN i
on IN p
sleep NN p
problems NNS p
in IN p
children NNS p
with IN N
autistic JJ N
spectrum NN N
disorder NN N
( ( N
ASD NNP N
) ) N
and CC N
fragile JJ N
X NNP N
syndrome NN N
( ( N
FXS NNP N
) ) N
. . N

METHODS VB N
A DT N
4-week JJ N
, , N
randomized VBN N
, , N
double JJ N
blind NN N
, , N
placebo-controlled JJ N
, , N
crossover JJ N
design NN N
was VBD N
conducted VBN N
following VBG N
a DT N
1-week JJ N
baseline NN N
period NN N
. . N

Either CC N
melatonin NN i
, , N
3 CD N
mg NN N
, , N
or CC N
placebo NN i
was VBD N
given VBN N
to TO N
participants NNS p
for IN p
2 CD p
weeks NNS p
and CC N
then RB N
alternated VBD N
for IN N
another DT N
2 CD N
weeks NNS N
. . N

Sleep JJ o
variables NNS o
, , N
including VBG N
sleep JJ o
duration NN o
, , o
sleep-onset JJ o
time NN o
, , o
sleep-onset JJ o
latency NN o
time NN o
, , o
and CC o
the DT o
number NN o
of IN o
night NN o
awakenings NNS o
, , N
were VBD N
recorded VBN N
using VBG N
an DT N
Actiwatch NN N
and CC N
from IN N
sleep JJ N
diaries NNS N
completed VBN N
by IN N
parents NNS N
. . N

All DT p
participants NNS p
had VBD N
been VBN N
thoroughly RB N
assessed VBN N
for IN N
ASD NNP N
and CC N
also RB N
had VBD N
DNA NNP N
testing VBG N
for IN N
the DT N
diagnosis NN N
of IN N
FXS NNP N
. . N

RESULTS NNP N
Data NNP N
were VBD N
successfully RB N
obtained VBN N
from IN N
the DT N
12 CD p
of IN p
18 CD p
subjects NNS p
who WP p
completed VBD p
the DT p
study NN p
( ( p
11 CD p
males NNS p
, , p
age NN p
range NN p
2 CD p
to TO p
15.25 CD p
years NNS p
, , p
mean JJ p
5.47 CD p
, , p
SD NNP p
3.6 CD p
) ) p
. . p

Five CD p
participants NNS p
met VBD N
diagnostic JJ N
criteria NNS N
for IN N
ASD NNP N
, , N
3 CD N
for IN N
FXS NNP N
alone RB N
, , N
3 CD N
for IN N
FXS NNP N
and CC N
ASD NNP N
, , N
and CC N
1 CD N
for IN N
fragile JJ N
X NNP N
premutation NN N
. . N

Eight CD p
out IN p
of IN p
12 CD p
had VBD p
melatonin VBN i
first RB p
. . N

The DT N
conclusions NNS N
from IN N
a DT N
nonparametric JJ N
repeated-measures NNS N
technique NN N
indicate VBP N
that IN N
mean JJ o
night NN o
sleep NN o
duration NN o
was VBD N
longer RBR N
on IN N
melatonin NN i
than IN N
placebo NN i
by IN N
21 CD N
minutes NNS N
( ( N
p JJ N
= NNP N
.02 NNP N
) ) N
, , N
mean JJ o
sleep-onset JJ o
latency NN o
was VBD N
shorter JJR N
by IN N
28 CD N
minutes NNS N
( ( N
p JJ N
= NNP N
.0001 NNP N
) ) N
, , N
and CC N
mean VB o
sleep-onset JJ o
time NN o
was VBD N
earlier RB N
by IN N
42 CD N
minutes NNS N
( ( N
p JJ N
= NNP N
.02 NNP N
) ) N
. . N

CONCLUSION VB N
The DT N
results NNS N
of IN N
this DT N
study NN N
support VBD N
the DT N
efficacy NN N
and CC N
tolerability NN N
of IN N
melatonin NN i
treatment NN N
for IN N
sleep JJ N
problems NNS N
in IN N
children NNS N
with IN N
ASD NNP N
and CC N
FXS NNP N
. . N

-DOCSTART- -8463520- O O

Treatment NN N
of IN N
vasculogenic JJ p
sexual JJ p
dysfunction NN p
with IN N
pentoxifylline NN i
. . i

OBJECTIVE UH N
To TO N
evaluate VB N
the DT N
use NN N
of IN N
pentoxifylline NN i
to TO N
treat VB N
impotence NN N
in IN N
men NNS p
with IN p
mild NN p
to TO p
moderate VB p
penile IN p
vascular JJ p
insufficiency NN p
. . p

DESIGN NNP N
Double-blind NNP N
randomized VBD N
clinical JJ N
trial NN N
. . N

SETTING NN N
Sexual JJ p
Dysfunction NNP p
Clinic NNP p
at IN p
VA NNP p
Medical NNP p
Center NNP p
, , p
Sepulveda NNP p
, , p
CA NNP p
. . p

PARTICIPANTS NNP N
Convenience NNP p
sample NN p
of IN p
couples NNS p
. . p

INTERVENTION NNP N
Twelve NNP N
weeks NNS N
of IN N
treatment NN N
with IN N
placebo NN i
or CC i
400 CD i
mg JJ i
tid NN i
of IN i
pentoxifylline NN i
. . i

MEASUREMENTS NNP N
( ( N
1 CD N
) ) N
Report NN o
of IN o
patient JJ o
verified VBN o
by IN o
partner NN o
as IN o
to TO o
number NN o
of IN o
coital JJ o
episodes NNS o
per IN o
month NN o
; : o
( ( N
2 CD N
) ) N
penile-brachial JJ o
pressure NN o
index NN o
determinations NNS o
. . o

RESULTS NNP N
Pentoxifylline NNP i
therapy VBZ i
regularly RB N
increased VBN N
the DT N
PBPI NNP o
in IN N
impotent JJ p
men NNS p
in IN N
comparison NN N
with IN N
the DT N
placebo NN N
, , N
frequently RB N
into IN N
the DT N
normal JJ N
range NN N
. . N

Pentoxifylline NNP N
therapy NN N
was VBD N
particularly RB N
useful JJ N
in IN N
restoring VBG o
the DT o
PBPI NNP o
in IN N
men NNS p
with IN p
the DT p
pelvic JJ p
steal JJ p
syndrome NN p
; : p
six CD N
of IN N
seven CD N
such JJ N
subjects NNS N
improved VBN N
into IN N
the DT N
normal JJ N
range NN N
. . N

During IN N
the DT N
pentoxifylline JJ N
treatment NN N
period NN N
, , N
in IN N
contrast NN N
with IN N
the DT N
control NN N
period NN N
, , N
nine CD N
men NNS N
were VBD N
able JJ N
to TO N
reestablish VB o
coital JJ o
function NN o
and CC N
three CD N
had VBD N
no DT N
improvement NN N
. . N

Six NNP N
couples NNS N
did VBD N
not RB N
attempt VB o
intercourse JJ o
despite IN N
a DT N
professed JJ N
interest NN N
in IN N
sexual JJ o
activity NN o
; : o
however RB N
five CD N
out IN N
of IN N
the DT N
six CD N
men NNS N
experienced VBD N
erections NNS o
during IN o
episodes NNS o
of IN o
fantasy NN o
or CC o
attempts NNS o
at IN o
masturbation NN o
during IN N
treatment NN N
. . N

There EX N
were VBD N
no DT N
complications NNS o
of IN N
therapy NN N
. . N

CONCLUSIONS NNP N
These DT N
promising VBG N
preliminary JJ N
results NNS N
suggest VBP N
a DT N
well RB N
tolerated JJ N
alternative JJ N
therapy NN N
for IN N
erectile JJ p
dysfunction NN p
in IN p
patients NNS p
with IN p
mild JJ p
to TO p
moderate VB p
penile IN p
vascular JJ p
disease NN p
. . p

-DOCSTART- -9892252- O O

A DT N
placebo-controlled JJ i
trial NN N
of IN N
D-cycloserine NNP i
added VBD N
to TO N
conventional JJ N
neuroleptics NNS N
in IN N
patients NNS p
with IN p
schizophrenia NN p
. . p

BACKGROUND NNP N
In IN N
a DT N
preliminary JJ N
dose-finding NN N
study NN N
, , N
D-cycloserine NNP i
, , N
a DT N
partial JJ N
agonist NN N
at IN N
the DT N
glycine NN N
modulatory NN N
site NN N
of IN N
the DT N
glutamatergic JJ N
N-methyl-D-aspartate NNP N
( ( N
NMDA NNP N
) ) N
receptor NN N
, , N
improved VBN N
negative JJ N
symptoms NNS N
and CC N
cognitive JJ N
function NN N
when WRB N
added VBD N
to TO N
conventional JJ N
neuroleptics NNS N
at IN N
a DT N
dose NN N
of IN N
50 CD N
mg/d NN N
. . N

METHODS NNP N
Forty-seven JJ p
patients NNS p
with IN p
schizophrenia JJ p
meeting NN p
criteria NNS p
for IN p
deficit NN p
syndrome NN p
were VBD N
randomized VBN N
to TO N
D-cycloserine NNP i
, , N
50 CD N
mg/d NN N
( ( N
n=23 JJ N
) ) N
or CC N
placebo NN i
( ( N
n=24 JJ N
) ) N
added VBD N
to TO N
their PRP$ N
conventional JJ N
neuroleptic JJ N
for IN N
an DT N
8-week JJ N
, , N
double-blind JJ N
trial NN N
. . N

Clinical JJ N
assessments NNS N
were VBD N
performed VBN N
at IN N
baseline NN N
and CC N
at IN N
weeks NNS N
1 CD N
, , N
2 CD N
, , N
4 CD N
, , N
6 CD N
, , N
and CC N
8 CD N
. . N

Serum NNP o
concentrations NNS o
of IN o
D-cycloserine NNP o
, , o
relevant JJ o
amino NN o
acids NNS o
, , o
and CC o
homovanillic JJ o
acid NN o
were VBD N
assayed VBN N
at IN N
baseline NN N
and CC N
at IN N
weeks NNS N
4 CD N
and CC N
8 CD N
. . N

A DT N
cognitive JJ o
battery NN o
was VBD N
performed VBN N
at IN N
baseline NN N
and CC N
at IN N
week NN N
8 CD N
. . N

RESULTS VB N
Thirty-nine JJ p
patients NNS p
completed VBD N
the DT N
8-week JJ N
trial NN N
. . N

Seven NNP N
dropouts NNS N
occurred VBD N
in IN N
the DT N
D-cycloserine NNP i
group NN N
and CC N
1 CD N
in IN N
the DT N
placebo NN i
group NN N
. . N

The DT N
mean JJ o
reduction NN o
in IN o
negative JJ o
symptoms NNS o
with IN N
D-cycloserine NNP i
( ( N
23 CD N
% NN N
) ) N
was VBD N
significantly RB N
greater JJR N
than IN N
with IN N
placebo NN i
( ( N
7 CD N
% NN N
) ) N
as IN N
calculated VBN N
by IN N
slopes NNS N
representing VBG N
Scale NNP N
for IN N
the DT N
Assessment NNP N
of IN N
Negative NNP N
Symptoms NNP N
( ( N
SANS NNP N
) ) N
total JJ N
scores NNS N
. . N

Improvement NNP N
of IN N
negative JJ N
symptoms NNS N
was VBD N
predicted VBN N
by IN N
low JJ N
neuroleptic JJ N
dose NN N
and CC N
low JJ N
baseline NN N
SANS NNP N
total JJ N
score NN N
. . N

No DT N
differences NNS N
were VBD N
found VBN N
in IN N
performance NN o
on IN o
any DT o
cognitive JJ o
test NN o
between IN N
groups NNS N
or CC N
in IN N
changes NNS N
in IN N
any DT N
other JJ N
clinical JJ N
measure NN N
. . N

Clinical JJ N
response NN N
did VBD N
not RB N
correlate VB N
significantly RB N
with IN N
serum NN N
amino NN N
acid JJ N
concentrations NNS N
at IN N
baseline NN N
or CC N
with IN N
concentrations NNS N
of IN N
D-cycloserine NNP i
at IN N
weeks NNS N
4 CD N
and CC N
8 CD N
. . N

CONCLUSION NNP N
These DT N
results NNS N
support VBD N
the DT N
hypothesis NN N
that WDT N
agents VBZ N
acting VBG N
at IN N
the DT N
glycine NN N
modulatory NN N
site NN N
of IN N
the DT N
NMDA NNP N
receptor NN N
improve VBP N
primary JJ N
negative JJ N
symptoms NNS N
. . N

-DOCSTART- -1289508- O O

Left NNP i
ventricular JJ i
mass NN i
regression NN i
in IN N
elderly JJ p
hypertensives NNS p
. . p

It PRP N
is VBZ N
now RB N
recognized VBN N
that IN N
left VBD N
ventricular JJ N
hypertrophy NN N
( ( N
LVH NNP N
) ) N
, , N
often RB N
associated VBN N
with IN N
hypertension NN N
, , N
is VBZ N
itself PRP N
a DT N
risk NN N
factor NN N
for IN N
coronary JJ N
disease NN N
in IN N
the DT N
elderly JJ N
. . N

Although IN N
many JJ N
agents NNS N
are VBP N
capable JJ N
of IN N
controlling VBG N
blood NN N
pressure NN N
, , N
the DT N
ability NN N
of IN N
these DT N
agents NNS N
to TO N
induce VB N
regression NN N
of IN N
left JJ N
ventricular NN N
( ( N
LV NNP N
) ) N
mass NN N
, , N
and CC N
the DT N
effect NN N
of IN N
regression NN N
on IN N
diastolic JJ N
relaxation NN N
and CC N
contractile NN N
indices NNS N
in IN N
the DT N
elderly JJ N
are VBP N
less RBR N
well RB N
known VBN N
. . N

Our PRP$ N
study NN N
compared VBN N
the DT N
ability NN N
of IN N
the DT N
calcium NN i
blocker NN i
, , i
verapamil NN i
, , i
and CC i
the DT i
beta-blocker NN i
, , i
atenolol NN i
, , N
to TO N
both DT N
control VB N
blood NN o
pressure NN o
( ( o
BP NNP o
) ) o
and CC N
to TO N
induce VB N
regression NN o
of IN o
LV NNP o
mass NN o
in IN N
older JJR N
hypertensives NNS N
. . N

In IN N
addition NN N
, , N
the DT N
influence NN N
of IN N
regression NN N
on IN N
resting VBG N
diastolic JJ N
filling NN N
and CC N
on IN N
cardiac JJ N
output NN N
and CC N
ejection NN N
fraction NN N
during IN N
rest NN N
and CC N
mild VB N
upright JJ N
bicycle NN N
exercise NN N
were VBD N
determined VBN N
. . N

Forty-two JJ p
hypertensives NNS p
60 CD p
years NNS p
of IN p
age NN p
or CC p
above NN p
, , p
without IN p
evidence NN p
of IN p
ischemic JJ p
disease NN p
underwent JJ N
2-D JJ i
echocardiographic JJ i
evaluation NN i
of IN N
LV NNP N
mass NN N
and CC N
gated VBD N
blood NN N
pool NN N
scan JJ N
determination NN N
of IN N
early JJ N
diastolic JJ N
filling NN N
, , N
cardiac JJ N
output NN N
and CC N
ejection NN N
fraction NN N
. . N

They PRP N
were VBD N
then RB N
randomized VBN N
to TO N
receive VB N
verapamil NN i
or CC N
atenolol NN i
during IN N
a DT N
four-week JJ N
titration NN N
period NN N
so RB N
as IN N
to TO N
achieve VB N
a DT N
BP NNP o
of IN N
less JJR N
than IN N
160/90 CD N
mm JJ N
Hg NNP N
. . N

If IN N
BP NNP o
was VBD N
not RB N
controlled VBN N
with IN N
either DT N
agent NN N
, , N
chlorthalidone NN N
was VBD N
added VBN N
. . N

Individuals NNS N
whose WP$ N
BP NNP o
was VBD N
controlled VBN N
continued VBN N
on IN N
the DT N
protocol NN N
for IN N
six CD N
months NNS N
. . N

At IN N
that DT N
time NN N
, , N
the DT N
echocardiographic JJ N
and CC N
gated VBD N
blood NN N
pool NN N
studies NNS N
were VBD N
repeated VBN N
both DT N
on IN N
and CC N
after IN N
subsequent JJ N
withdrawal NN N
of IN N
the DT N
study NN N
medications NNS N
. . N

Twenty-one CD N
patients NNS N
were VBD N
randomized VBN N
to TO N
receive VB N
verapamil NN i
and CC N
21 CD N
patients NNS N
to TO N
receive VB N
atenolol NN i
. . i

Blood NNP N
pressure NN N
control NN N
was VBD N
achieved VBN N
with IN N
verapamil NN N
alone RB N
in IN N
18 CD N
patients NNS N
, , N
but CC N
with IN N
atenolol JJ N
alone RB N
in IN N
only RB N
8 CD N
patients NNS N
( ( N
p JJ N
< NNP N
0.01 CD N
) ) N
. . N

( ( N
ABSTRACT NNP N
TRUNCATED NNP N
AT NNP N
250 CD N
WORDS NNP N
) ) N
-DOCSTART- -25912590- O O

Peritonsillar JJ N
infiltration NN N
with IN N
levobupivacaine NN i
for IN N
posttonsillectomy NN p
pain NN o
relief NN o
: : o
does VBZ N
concentration NN N
have VB N
any DT N
effect NN N
? . N
A DT N
double-blind JJ N
randomized NN N
controlled VBD N
clinical JJ N
study NN N
. . N

OBJECTIVE NNP N
Post-tonsillectomy JJ p
pain NN p
is VBZ N
believed VBN N
to TO N
be VB N
mediated VBN N
by IN N
noxious JJ N
stimulation NN N
of IN N
C-fiber NNP N
afferents NNS N
located VBN N
in IN N
the DT N
peritonsillary JJ N
space NN N
, , N
and CC N
local JJ N
anesthetic JJ N
infiltration NN N
to TO N
this DT N
area NN N
may MD N
decrease VB N
pain NN N
by IN N
blocking VBG N
the DT N
sensory JJ N
pathways NNS N
and CC N
thus RB N
preventing VBG N
the DT N
nociceptive JJ N
impulses NNS N
. . N

We PRP N
aimed VBD N
to TO N
compare VB N
the DT N
effects NNS N
of IN N
different JJ N
concentrations NNS N
of IN N
preincisional JJ N
peritonsillar JJ i
levobupivacaine NN i
( ( N
0.25 CD N
% NN N
and CC N
0.5 CD N
% NN N
) ) N
infiltration NN N
on IN N
postoperative JJ o
pain NN o
and CC o
bleeding NN o
in IN N
a DT N
placebo-controlled JJ i
design NN N
. . N

PATIENTS NNP N
AND CC N
METHODS NNP N
After IN N
obtaining VBG N
Institutional NNP N
Ethics NNP N
Committee NNP N
approval NN N
, , N
72 CD p
ASA NNP p
I-II JJ p
patients NNS p
between IN p
3 CD p
and CC p
12 CD p
years NNS p
of IN p
age NN p
, , p
scheduled VBN p
to TO p
undergo VB p
tonsillectomy NN p
were VBD p
enrolled VBN p
and CC N
randomly RB N
assigned VBN N
to TO N
one CD N
of IN N
the DT N
three CD N
groups NNS N
using VBG N
the DT N
sealed VBN N
envelope NN N
technique NN N
, , N
as IN N
Group NNP N
I PRP N
( ( i
Control NNP i
group NN i
) ) i
, , N
Group NNP N
II NNP N
, , N
and CC N
Group NNP N
III NNP N
receiving VBG N
preincisional JJ i
bilateral JJ i
peritonsillar JJ i
infiltration NN i
with IN i
saline NN i
, , i
0.25 CD i
% NN i
levobupivacaine NN i
and CC i
0.5 CD i
% NN i
levobupivacaine NN i
, , N
respectively RB N
( ( N
3 CD N
mL NN N
to TO N
each DT N
tonsil NN N
) ) N
. . N

Pain NNP o
, , o
fever NN o
, , o
dysphagia NN o
; : o
nausea-vomiting JJ o
and CC o
hemorrhage NN o
were VBD N
evaluated VBN N
at IN N
postoperative JJ N
0 CD N
, , N
30 CD N
, , N
and CC N
60 CD N
minutes NNS N
and CC N
2 CD N
, , N
6 CD N
, , N
12 CD N
, , N
and CC N
24 CD N
hours NNS N
. . N

Oral NNP i
paracetamol NN i
was VBD N
administered VBN N
at IN N
a DT N
dose NN N
of IN N
15 CD N
mg/kg NN N
when WRB N
FLACC NNP N
score NN N
was VBD N
> JJ N
4 CD N
. . N

The DT N
number NN o
of IN o
paracetamol JJ o
administrations NNS o
within IN N
the DT N
first JJ N
24 CD N
hours NNS N
were VBD N
recorded VBN N
. . N

RESULTS VB N
The DT N
patients NNS N
in IN N
Groups NNP N
I PRP N
, , N
II NNP N
and CC N
III NNP N
defined VBD N
pain NN o
( ( N
FLACC NNP N
> NNP N
4 CD N
) ) N
at IN N
a DT N
rate NN N
of IN N
87 CD N
% NN N
, , N
60.9 CD N
% NN N
, , N
and CC N
54.2 CD N
% NN N
within IN N
the DT N
postoperative JJ N
first JJ N
24 CD N
hours NNS N
, , N
respectively RB N
. . N

The DT N
total JJ N
number NN N
of IN N
additional JJ o
analgesic JJ o
requirements NNS o
was VBD N
significantly RB N
low JJ N
in IN N
Group NNP N
II NNP N
and CC N
III NNP N
when WRB N
compared VBN N
with IN N
Group NNP N
I PRP N
. . N

There EX N
was VBD N
no DT N
difference NN N
between IN N
groups NNS N
in IN N
terms NNS N
of IN N
fever NN o
, , o
dysphagia NN o
, , o
nausea-vomiting JJ o
, , o
hemorrhage NN o
. . o

CONCLUSIONS NNP N
Both NNP N
concentrations NNS N
( ( N
0.50 CD N
% NN N
and CC N
0.25 CD N
% NN N
) ) N
of IN N
levobupivacaine NN i
were VBD N
found VBN N
to TO N
be VB N
equally RB N
safe JJ o
and CC o
effective JJ o
during IN N
preincisional JJ N
peritonsillar JJ N
infiltration NN N
in IN N
children NNS p
. . p

NCT NNP N
number NN N
: : N
02322346 CD N
. . N

-DOCSTART- -12830748- O O

Clinic JJ N
visit NN N
and CC N
waiting NN N
: : N
patient JJ o
education NN o
and CC o
satisfaction NN o
. . o

Patients NNS i
who WP i
were VBD i
taught VBN i
about IN i
their PRP$ i
health NN i
problems NNS i
while IN i
waiting VBG i
in IN i
the DT i
clinic NN i
( ( p
n JJ p
= NNP p
104 CD p
) ) p
were VBD N
significantly RB N
more RBR N
satisfied JJ o
with IN o
the DT o
education NN o
received VBD N
during IN N
that DT N
visit NN N
than IN N
the DT N
control NN i
group NN i
( ( p
n JJ p
= NNP p
101 CD p
) ) p
. . p

The DT N
longer JJR N
patients NNS N
waited VBD N
in IN N
the DT N
clinic NN N
to TO N
see VB N
their PRP$ N
providers NNS N
, , N
the DT N
less JJR N
satisfied JJ o
they PRP N
were VBD N
with IN N
the DT N
clinic JJ N
visit NN N
. . N

-DOCSTART- -3602327- O O

The DT N
effects NNS N
of IN N
amantadine NN i
vs. FW i
trihexyphenidyl NN i
on IN N
memory NN o
in IN N
elderly JJ p
normal JJ p
volunteers NNS p
. . p

-DOCSTART- -7856515- O O

Acute JJ N
exposure NN p
to TO p
acid VB p
fog NN p
: : p
influence NN N
of IN N
breathing VBG N
pattern NN N
on IN N
effective JJ o
dose NN o
. . o

Concern JJ N
about IN N
the DT N
possible JJ N
adverse JJ o
health NN o
effects NNS o
of IN N
acid NN N
fog NN N
has VBZ N
been VBN N
fed VBN N
by IN N
two CD N
observations NNS N
: : N
air NN N
pollution NN N
disasters NNS N
earlier RBR N
in IN N
this DT N
century NN N
were VBD N
typically RB N
associated VBN N
with IN N
fog NN N
, , N
and CC N
current JJ N
samples NNS N
of IN N
fog JJ N
water NN N
can MD N
be VB N
strongly RB N
acid JJ N
. . N

To TO N
study VB N
the DT N
acute JJ N
effects NNS N
of IN N
acid JJ N
fog NN N
on IN N
the DT N
lung NN N
, , N
the DT N
authors NNS N
generated VBD N
a DT N
monodisperse JJ i
10 CD i
microM NN i
MMAD NNP i
aerosol NN i
of IN i
H2SO4 NNP i
with IN N
a DT N
pH NN N
of IN N
2.0 CD N
and CC N
a DT N
nominal JJ i
concentration NN i
of IN N
500 CD N
micrograms/m3 NNS N
. . N

They PRP N
exposed VBD N
seven CD p
healthy JJ p
young JJ p
men NNS p
on IN N
alternate NN N
days NNS N
to TO N
acid VB i
or CC i
control VB i
equiosmolar JJ i
NaCl NNP i
aerosol NN i
during IN N
40 CD N
min NNS N
of IN N
resting VBG N
ventilation NN N
and CC N
20 CD N
min NN N
of IN N
exercise NN N
; : N
the DT N
latter NN N
was VBD N
sufficiently RB N
intense JJ N
to TO N
induce VB N
oronasal RP o
breathing VBG o
. . N

Exposure NN N
was VBD N
by IN N
means NNS N
of IN N
a DT N
head NN N
dome NN N
, , N
a DT N
head-only JJ N
exposure NN N
device NN N
that WDT N
permitted VBD N
continuous JJ N
measurement NN N
( ( N
unfettered JJ N
breathing NN N
) ) N
of IN N
Vr NNP N
, , N
f NN N
, , N
VE NNP N
, , N
and CC N
the DT N
onset NN N
and CC N
persistence NN N
of IN N
oronasal NN o
breathing NN o
. . o

In IN N
this DT N
article NN N
the DT N
authors NNS N
compare VBP N
the DT N
relative JJ N
importance NN N
of IN N
parameters NNS N
contributing VBG N
to TO N
the DT N
between-subject JJ N
variability NN N
in IN N
estimated VBN N
hydrogen NN N
ion NN N
dose NN N
to TO N
the DT N
lower JJR o
airways NNS o
( ( N
H+LAW NNP N
) ) N
, , N
based VBN N
on IN N
analysis NN N
of IN N
variance NN N
. . N

Physiologic NNP N
parameters NNS N
accounted VBD N
for IN N
70 CD N
% NN N
of IN N
the DT N
variability NN N
, , N
of IN N
which WDT N
34 CD N
% NN N
was VBD N
due JJ N
to TO N
differences NNS N
in IN N
duration NN o
of IN o
oronasal NN o
breathing NN o
( ( o
tON NN o
) ) o
and CC N
36 CD N
% NN N
to TO N
differences NNS N
in IN N
ventilation NN o
rate NN o
during IN o
oronasal NN o
breathing NN o
( ( o
VE NNP o
( ( o
ON NNP o
) ) o
) ) o
; : o
inhaled VBN o
hydrogen NN o
ion NN o
concentration NN o
[ NNP o
H+ NNP o
] NNP o
, , N
the DT N
environmental JJ N
parameter NN N
, , N
contributed VBD N
only RB N
30 CD N
% NN N
. . N

Minute JJ N
ventilation NN N
at IN N
the DT N
time NN N
of IN N
transition NN N
from IN N
nasal NN N
to TO N
oronasal VB N
breathing VBG N
varied JJ N
significantly RB N
among IN N
subjects NNS N
even RB N
if IN N
normalized VBN N
to TO N
FVC NNP N
, , N
an DT N
index NN N
of IN N
lung NN N
size NN N
. . N

-DOCSTART- -9474450- O O

Influence NN N
of IN N
special-effect JJ i
contact NN i
lenses NNS i
( ( i
Crazy NNP i
Lenses NNP i
) ) i
on IN N
visual JJ o
function NN o
. . o

PURPOSE NNP N
Special-effect JJ i
contact NN i
lenses NNS i
( ( N
opaque NN N
, , N
tinted VBD N
soft JJ N
contact NN N
lenses VBZ N
that IN N
incorporate JJ N
decorative JJ N
images NNS N
such JJ N
as IN N
cateyes NNS N
, , N
stars NNS N
, , N
or CC N
hearts NNS N
to TO N
alter VB N
eye NN N
color NN N
and CC N
structure NN N
) ) N
have VBP N
become VBN N
increasingly RB N
popular JJ N
. . N

The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
investigate VB N
whether IN N
such JJ N
lenses NNS N
impair VBP N
visual JJ o
function NN o
. . o

METHODS NNP N
A DT i
clear JJ i
soft JJ i
contact NN i
lens NNS i
and CC i
a DT i
special-effect JJ i
soft JJ i
contact NN i
lens NNS i
( ( i
Crazy NNP i
lens VBZ i
, , i
) ) i
were VBD N
fit JJ N
in IN N
changing VBG N
sequence NN N
in IN N
nine CD p
healthy JJ p
subjects NNS p
. . p

The DT N
parameters NNS N
studied VBD N
included VBN N
: : N
visual JJ o
acuity NN o
, , o
contrast NN o
sensitivity NN o
( ( o
with IN o
and CC o
without IN o
glare NN o
) ) o
, , o
visual JJ o
field NN o
, , o
and CC o
mesopic NN o
vision NN o
( ( o
with IN o
and CC o
without IN o
glare NN o
) ) o
. . o

RESULTS VB N
The DT N
following JJ N
parameters NNS N
displayed VBD N
a DT N
statistically RB N
significant JJ N
difference NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

Visual JJ o
acuity NN o
was VBD N
decreased VBN N
to TO N
0.9 CD N
+/- JJ N
0.23 CD N
in IN N
the DT N
Crazy NNP N
lens VBZ N
group NN N
as IN N
compared VBN N
with IN N
1.2 CD N
+/- JJ N
0.13 CD N
in IN N
the DT N
clear JJ i
lens NNS i
group NN N
. . N

Goldmann NNP o
visual JJ o
field NN o
displayed VBD N
a DT N
significant JJ N
constriction NN o
of IN o
the DT o
isopters NNS o
: : o
III/4 NNP N
, , N
I/4 NNP N
, , N
and CC N
I/3 NNP N
. . N

Mesopic NNP o
vision NN o
without IN o
glare NN o
was VBD N
reduced VBN N
from IN N
1:2.5 CD N
to TO N
1:7.4 CD N
. . N

Contrast NNP o
sensitivity NN o
was VBD N
significantly RB N
reduced VBN N
in IN N
a DT N
photopic JJ N
condition NN N
with IN N
and CC N
without IN N
glare NN N
and CC N
in IN N
a DT N
scotopic JJ N
condition NN N
without IN N
glare NN N
. . N

Furthermore RB N
, , N
the DT N
special-effect JJ i
lenses NNS i
were VBD N
associated VBN N
with IN N
a DT N
decrease NN N
in IN N
lens NNS o
wearing VBG o
comfort NN o
. . o

CONCLUSIONS NNP N
Special-effect JJ i
contact NN i
lenses NNS i
were VBD N
associated VBN N
with IN N
a DT N
reduction NN N
of IN N
many JJ N
visual JJ o
functions NNS o
, , N
including VBG N
visual JJ o
acuity NN o
and CC o
contrast NN o
sensitivity NN o
. . o

For IN N
some DT N
wearers NNS p
this DT N
may MD N
interfere VB N
with IN N
activities NNS N
where WRB N
excellent JJ N
vision NN N
is VBZ N
crucial JJ N
, , N
such JJ N
as IN N
driving VBG N
a DT N
car NN N
. . N

-DOCSTART- -1444609- O O

[ NN i
Mitoxantrone NNP i
( ( i
MTX NNP i
) ) i
versus NN i
mitomycin NN i
C NNP i
( ( i
MMC NNP i
) ) i
in IN N
the DT N
ablative JJ N
treatment NN N
of IN p
Ta NNP p
, , p
T1 NNP p
superficial JJ p
bladder NN p
tumors NNS p
. . p

Phase NNP N
III NNP N
, , N
randomized VBD N
prospective JJ N
study NN N
] NNP N
. . N

A NNP N
prospective JJ N
randomized NN N
study NN N
was VBD N
conducted VBN N
to TO N
determine VB N
the DT N
ablation NN o
capacity NN o
of IN N
mitoxantrone NN i
in IN N
Ta-T1 NNP N
superficial JJ N
bladder NN N
tumors NNS N
versus VBP N
mitomycin JJ i
C NNP i
, , N
a DT N
drug NN N
whose WP$ N
intravesical JJ N
ablation NN N
properties NNS N
are VBP N
well-known JJ N
. . N

Fifty-seven JJ p
patients NNS p
comprised VBD N
the DT N
study NN N
. . N

The DT N
tumor NN N
was VBD N
not RB N
completely RB N
resected VBN N
when WRB N
the DT N
patient NN N
underwent JJ N
TUR NNP N
. . N

This DT N
residual JJ N
tumor NN N
was VBD N
used VBN N
as IN N
control NN N
. . N

The DT N
patients NNS N
were VBD N
treated VBN N
with IN N
either DT N
20 CD N
mg NN N
Mitoxantrone NNP i
or CC N
40 CD N
mg NNS N
mitomycin JJ i
C NNP i
weekly NN N
for IN N
8 CD N
weeks NNS N
and CC N
two CD N
other JJ N
instillations NNS N
every DT N
15 CD N
days NNS N
in IN N
50 CD N
ml NNS N
saline JJ N
solution NN N
. . N

Response NNP o
to TO o
therapy NN o
was VBD N
evaluated VBN N
between IN N
the DT N
4th CD N
and CC N
8th CD N
week NN N
and CC N
classified VBD N
as IN N
complete JJ o
response NN o
( ( o
CR NNP o
) ) o
, , N
defined VBD N
as IN N
no DT N
gross JJ o
and CC o
microscopic JJ o
evidence NN o
of IN o
residual JJ o
tumor NN o
, , N
or CC N
no DT o
response NN o
( ( o
NR NNP o
) ) o
or CC o
therapeutic JJ o
failure NN o
. . o

CR NNP N
was VBD N
observed VBN N
in IN N
77.7 CD N
% NN N
of IN N
the DT N
patients NNS N
treated VBN N
with IN N
mitomycin JJ i
C NNP i
and CC N
in IN N
50 CD N
% NN N
in IN N
those DT N
that WDT N
had VBD N
been VBN N
treated VBN N
with IN N
Mitoxantrone NNP i
. . i

Treatment NNP N
was VBD N
discontinued VBN N
because IN N
of IN N
side NN o
effects NNS o
in IN N
15 CD N
% NN N
of IN N
the DT N
patients NNS N
treated VBN N
with IN N
mitomycin JJ i
C NNP i
and CC N
in IN N
63.4 CD N
% NN N
of IN N
those DT N
who WP N
received VBD N
Mitoxantrone NNP i
. . i

We PRP N
can MD N
conclude VB N
from IN N
the DT N
results NNS N
of IN N
the DT N
present JJ N
study NN N
that IN N
Mitoxantrone NNP i
is VBZ N
a DT N
useful JJ N
agent NN N
for IN N
ablation NN N
therapy NN N
of IN N
superficial JJ p
bladder NN p
tumors NNS p
, , N
although IN N
the DT N
high JJ N
incidence NN N
of IN N
severe JJ N
side NN o
effects NNS o
warrants NNS N
its PRP$ N
limited JJ N
use NN N
and CC N
at IN N
high JJ N
dilutions NNS N
. . N

-DOCSTART- -24161568- O O

A DT N
prospective JJ N
randomized VBN i
trial NN N
comparing VBG N
hypofractionation NN N
with IN N
conventional JJ N
fractionation NN N
radiotherapy NN N
for IN N
T1-2 NNP p
glottic JJ p
squamous JJ p
cell NN p
carcinomas NNS p
: : p
results NNS N
of IN N
a DT N
Korean JJ N
Radiation NNP N
Oncology NNP N
Group NNP N
( ( N
KROG-0201 NNP N
) ) N
study NN N
. . N

BACKGROUND NNP N
AND CC N
PURPOSE NNP N
To TO N
prospectively RB N
investigate VB N
the DT N
effect NN o
of IN o
radiotherapy NN o
fraction NN o
size NN o
on IN N
clinical JJ o
outcomes NNS o
in IN N
early JJ p
glottic JJ p
carcinoma NN p
METHODS NNP N
AND NNP N
MATERIALS NNP N
Patients NNS p
with IN p
T1-2 NNP p
glottic JJ p
carcinoma NN p
were VBD p
eligible JJ p
for IN N
the DT N
protocol NN N
. . N

Although IN N
282 CD p
patients NNS p
were VBD p
required VBN p
, , p
the DT p
study NN p
was VBD p
closed VBN p
prematurely RB p
due JJ p
to TO p
poor JJ p
accrual JJ p
with IN p
only RB p
156 CD p
patients NNS p
. . p

Of IN N
these DT N
, , N
82 CD N
patients NNS N
were VBD N
allocated VBN N
to TO N
conventional JJ i
fractionation NN i
( ( i
CONV NNP i
) ) i
arm NN i
( ( i
66 CD i
Gy/33 NNP i
fractions NNS i
for IN i
T1 NNP i
and CC i
70 CD i
Gy/35 NNP i
fractions NNS i
for IN i
T2 NNP i
) ) i
, , i
with IN i
74 CD i
patients NNS i
to TO i
hypofractionation NN i
( ( i
HYPO NNP i
) ) i
arm NN i
( ( i
63 CD i
Gy/28 NNP i
fractions NNS i
for IN i
T1 NNP i
and CC i
67.5 CD i
Gy/30 NNP i
fractions NNS i
for IN i
T2 NNP i
) ) i
. . i

The DT N
primary JJ N
objective NN N
was VBD N
local JJ o
progression-free JJ o
survival NN o
( ( o
LPFS NNP o
) ) o
. . o

RESULTS VBN N
With IN N
a DT N
median JJ N
follow-up NN N
of IN N
67 CD N
months NNS N
( ( N
range NN N
, , N
2-122 JJ N
months NNS N
) ) N
, , N
the DT N
5-year JJ N
LPFS NNP o
was VBD N
77.8 CD N
% NN N
for IN N
CONV NNP N
arm NN N
and CC N
88.5 CD N
% NN N
for IN N
HYPO NNP N
arm NN N
( ( N
HR NNP N
1.55 CD N
, , N
p=0.213 NN N
) ) N
. . N

No DT N
significant JJ N
difference NN N
was VBD N
observed VBN N
in IN N
the DT N
toxicity NN o
profile NN o
between IN N
the DT N
two CD N
arms NNS N
. . N

In IN N
a DT N
subgroup JJ N
exploratory NN N
analysis NN N
for IN N
T1a NNP N
disease NN N
, , N
the DT N
5-year JJ N
LPFS NNP o
trended VBD N
positively RB N
in IN N
HYPO NNP N
arm NN N
( ( N
76.7 CD N
% NN N
vs. FW N
93.0 CD N
% NN N
, , N
HR NNP N
3.65 CD N
, , N
p=0.056 NN N
) ) N
. . N

CONCLUSIONS VB N
Given NNP N
that IN N
HYPO NNP N
is VBZ N
at IN N
least JJS N
not RB N
inferior JJ N
to TO N
CONV NNP N
with IN N
a DT N
similar JJ N
toxicity NN N
profile NN N
, , N
the DT N
hypofractionation NN N
scheme NN N
used VBN N
in IN N
this DT N
study NN N
can MD N
be VB N
offered VBN N
to TO N
patients NNS p
with IN p
T1-2 NNP p
glottic JJ p
carcinoma NN p
with IN N
potential JJ N
advantages NNS N
in IN N
terms NNS N
of IN N
local JJ N
control NN N
and CC N
a DT N
shortened JJ N
overall JJ N
treatment NN N
time NN N
. . N

-DOCSTART- -22588377- O O

The DT N
Coping NNP N
Cat NNP N
program NN N
for IN N
children NNS p
with IN p
anxiety NN p
and CC p
autism NN p
spectrum NN p
disorder NN p
: : p
a DT N
pilot NN N
randomized VBN N
controlled VBN N
trial NN N
. . N

The DT N
purpose NN N
of IN N
this DT N
pilot NN N
study NN N
was VBD N
to TO N
evaluate VB N
whether IN N
a DT N
modified JJ i
version NN i
of IN i
the DT i
Coping NNP i
Cat NNP i
program NN i
could MD N
be VB N
effective JJ N
in IN N
reducing VBG N
anxiety NN o
in IN N
children NNS p
with IN p
autism NN p
spectrum NN p
disorder NN p
( ( p
ASD NNP p
) ) p
. . p

Twenty-two JJ p
children NNS p
( ( p
ages VBZ p
8-14 NN p
; : p
IQ NNP p
? . p
70 CD p
) ) p
with IN p
ASD NNP p
and CC p
clinically RB p
significant JJ p
anxiety NN p
were VBD p
randomly RB N
assigned VBN i
to TO i
16 CD i
sessions NNS i
of IN i
the DT i
Coping NNP i
Cat NNP i
program NN i
( ( i
cognitive-behavioral JJ i
therapy NN i
; : i
CBT NNP i
) ) i
or CC i
a DT N
16-week JJ i
waitlist NN i
. . i

Children NNP i
in IN N
the DT N
CBT NNP N
condition NN N
evidenced VBD N
significantly RB N
larger JJR N
reductions NNS o
in IN o
anxiety NN o
than IN o
those DT N
in IN N
the DT N
waitlist NN N
. . N

Treatment NN N
gains NNS N
were VBD N
largely RB N
maintained VBN N
at IN N
two-month JJ N
follow-up NN N
. . N

Results NNP N
provide VBP N
preliminary JJ N
evidence NN N
that IN N
a DT N
modified JJ N
version NN N
of IN N
the DT N
Coping NNP i
Cat NNP i
program NN i
may MD i
be VB N
a DT N
feasible JJ N
and CC N
effective JJ N
program NN N
for IN N
reducing VBG N
clinically RB N
significant JJ N
levels NNS o
of IN o
anxiety NN o
in IN o
children NNS p
with IN p
high-functioning JJ p
ASD NNP p
. . N

-DOCSTART- -21552085- O O

The DT N
effects NNS N
of IN N
aerobic JJ i
exercise NN i
on IN N
academic JJ N
engagement NN N
in IN N
young JJ p
children NNS p
with IN p
autism NN p
spectrum NN p
disorder NN p
. . p

PURPOSE NNP N
To TO N
determine VB N
whether IN N
participation NN N
in IN N
aerobic JJ i
exercise NN i
before IN N
classroom NN N
activities NNS N
improves VBZ N
academic JJ N
engagement NN N
and CC N
reduces NNS N
stereotypic VBP N
behaviors NNS N
in IN N
young JJ p
children NNS p
with IN p
autism NN p
spectrum NN p
disorder NN p
. . p

METHODS NNP N
This DT N
study NN N
employed VBD N
a DT N
within-subjects NNS N
crossover NN N
design NN N
, , N
using VBG N
a DT N
treatment NN N
condition NN N
( ( i
aerobic JJ i
exercise NN i
) ) i
and CC N
a DT N
control NN i
condition NN i
, , N
across IN N
4 CD N
classrooms NNS N
. . N

The DT i
treatment NN i
condition NN i
included VBD i
15 CD i
minutes NNS i
of IN i
running/jogging VBG i
followed VBN i
by IN i
a DT i
classroom NN i
task NN i
. . i

The DT i
control NN i
condition NN i
included VBD i
a DT i
classroom NN i
task NN i
not RB i
preceded VBN i
by IN i
exercise NN i
. . i

The DT N
number NN o
of IN o
stereotypic JJ o
behaviors NNS o
, , o
percentage NN o
of IN o
on-task JJ o
behavior NN o
, , o
and CC o
correct/incorrect JJ o
responses NNS o
were VBD i
measured VBN i
. . i

The DT i
Wilcoxon NNP o
signed VBD o
rank JJ o
test NN o
was VBD o
used VBN o
to TO o
compare VB o
differences NNS o
between IN o
conditions NNS o
. . o

RESULTS NNP N
Statistically NNP N
significant JJ N
improvements NNS N
were VBD N
found VBN N
in IN N
correct JJ N
responding VBG N
following VBG N
exercise NN N
( ( N
P NNP N
< NNP N
.05 NNP N
) ) N
. . N

No DT N
significant JJ N
differences NNS N
were VBD N
found VBN N
for IN N
on-task JJ o
behavior NN o
or CC N
stereotypic NN o
behaviors NNS o
. . o

CONCLUSIONS NNP N
Consistent NNP N
with IN N
findings NNS N
in IN N
older JJR N
children NNS N
, , N
these DT N
results NNS N
indicate VBP N
that IN N
aerobic JJ i
exercise NN i
prior RB N
to TO N
classroom VB N
activities NNS N
may MD N
improve VB N
academic JJ N
responding NN N
in IN N
young JJ p
children NNS p
with IN p
autism NN p
spectrum NN p
disorder NN p
. . p

-DOCSTART- -24915929- O O

Quantifying VBG N
narrative JJ o
ability NN o
in IN N
autism NN p
spectrum NN p
disorder NN p
: : p
a DT N
computational JJ N
linguistic JJ N
analysis NN N
of IN N
narrative JJ N
coherence NN N
. . N

Autism NNP p
is VBZ N
a DT N
neurodevelopmental JJ N
disorder NN N
characterized VBN N
by IN N
serious JJ N
difficulties NNS N
with IN N
the DT N
social JJ N
use NN N
of IN N
language NN N
, , N
along IN N
with IN N
impaired JJ N
social JJ N
functioning NN N
and CC N
ritualistic/repetitive JJ N
behaviors NNS N
( ( N
American NNP N
Psychiatric NNP N
Association NNP N
in IN N
Diagnostic NNP N
and CC N
statistical JJ N
manual NN N
of IN N
mental JJ N
disorders NNS N
: : N
DSM-5 NNP N
, , N
5th CD N
edn NN N
. . N

American NNP N
Psychiatric NNP N
Association NNP N
, , N
Arlington NNP N
, , N
2013 CD N
) ) N
. . N

While IN N
substantial JJ N
heterogeneity NN N
exists VBZ N
in IN N
symptom JJ N
expression NN N
, , N
impairments NNS N
in IN N
language NN N
discourse NN N
skills NNS N
, , N
including VBG N
narrative JJ N
( ( N
or CC N
storytelling VBG N
) ) N
, , N
are VBP N
universally RB N
observed VBN N
in IN N
autism NN N
( ( N
Tager-Flusberg NNP N
et RB N
al RB N
. . N

in IN N
Handbook NNP N
on IN N
autism NN N
and CC N
pervasive JJ N
developmental NN N
disorders NNS N
, , N
3rd CD N
edn NN N
. . N

Wiley NNP N
, , N
New NNP N
York NNP N
, , N
pp JJ N
335-364 CD N
, , N
2005 CD N
) ) N
. . N

This DT N
study NN N
applied VBD N
a DT N
computational JJ i
linguistic JJ i
tool NN i
, , i
Latent NNP i
Semantic NNP i
Analysis NNP i
( ( i
LSA NNP i
) ) i
, , N
to TO N
objectively RB N
characterize VB N
narrative JJ N
performance NN N
in IN N
high-functioning JJ p
individuals NNS p
with IN p
autism NN p
and CC p
typically-developing NN p
controls NNS p
, , N
across IN N
two CD N
different JJ N
narrative JJ N
contexts NN N
that WDT N
differ VBP N
in IN N
the DT N
interpersonal JJ N
and CC N
cognitive JJ N
demands NNS N
placed VBN N
on IN N
the DT N
narrator NN N
. . N

Results NNS N
indicated VBD N
that IN N
high-functioning JJ p
individuals NNS p
with IN p
autism NN p
produced VBN N
narratives NNS o
comparable JJ N
in IN N
semantic JJ N
content NN N
to TO N
those DT N
produced VBN N
by IN N
controls NNS N
when WRB N
narrating VBG N
from IN N
a DT N
picture NN N
book NN N
, , N
but CC N
produced VBD N
narratives NNS o
diminished VBN N
in IN N
semantic JJ N
quality NN N
in IN N
a DT N
more RBR N
demanding JJ N
narrative JJ N
recall NN N
task NN N
. . N

This DT N
pattern NN N
is VBZ N
similar JJ N
to TO N
that DT N
detected VBN N
from IN N
analyses NNS N
of IN N
hand-coded JJ N
picture NN N
book NN N
narratives NNS N
in IN N
prior JJ N
research NN N
, , N
and CC N
extends VBZ N
findings NNS N
to TO N
an DT N
additional JJ N
narrative JJ N
context NN N
that WDT N
proves VBZ N
particularly RB N
challenging VBG N
for IN N
individuals NNS p
with IN p
autism NN p
. . p

Results NNS N
are VBP N
discussed VBN N
in IN N
terms NNS N
of IN N
the DT N
utility NN N
of IN N
LSA NNP N
as IN N
a DT N
quantitative JJ N
, , N
objective JJ N
, , N
and CC N
efficient JJ N
measure NN N
of IN N
narrative JJ o
ability NN o
. . o

-DOCSTART- -16840576- O O

Resistance NNP i
training NN i
increases NNS N
basal VBP N
limb JJ N
blood NN N
flow NN N
and CC N
vascular JJ N
conductance NN N
in IN N
aging VBG p
humans NNS p
. . p

Age-related JJ N
reductions NNS N
in IN N
basal NN N
limb NN N
blood NN N
flow NN N
and CC N
vascular JJ N
conductance NN N
are VBP N
associated VBN N
with IN N
the DT N
metabolic JJ N
syndrome NN N
, , N
functional JJ N
impairments NNS N
, , N
and CC N
osteoporosis NN N
. . N

We PRP N
tested VBD N
the DT N
hypothesis NN N
that IN N
a DT N
strength NN i
training NN i
program NN i
would MD N
increase VB N
basal JJ o
femoral JJ o
blood NN o
flow NN o
in IN N
aging VBG p
adults NNS p
. . p

Twenty-six JJ p
sedentary JJ p
but CC p
healthy JJ p
middle-aged JJ p
and CC p
older JJR p
subjects NNS p
were VBD N
randomly RB i
assigned VBN i
to TO i
either CC i
a DT i
whole JJ i
body NN i
strength NN i
training VBG i
intervention NN i
group NN i
( ( i
52 CD i
+/- JJ i
2 CD i
yr NN i
, , i
3 CD i
men NNS i
, , i
10 CD i
women NNS i
) ) i
who WP i
underwent VBD i
three CD i
supervised VBN i
resistance NN i
training NN i
sessions NNS i
per IN i
week NN i
for IN i
13 CD i
wk NN i
or CC i
a DT i
control NN i
group NN i
( ( i
53 CD i
+/- JJ i
2 CD i
yr NN i
, , i
4 CD i
men NNS i
, , i
9 CD i
women NNS i
) ) i
who WP i
participated VBD i
in IN i
a DT i
supervised JJ i
stretching NN i
program NN i
. . i

At IN p
baseline NN p
, , p
there EX p
were VBD p
no DT p
significant JJ p
differences NNS p
in IN p
blood NN o
pressure NN o
, , o
cardiac JJ o
output NN o
, , o
basal JJ o
femoral JJ o
blood NN o
flow NN o
( ( o
via IN o
Doppler NNP o
ultrasound NN o
) ) o
, , o
vascular JJ o
conductance NN o
, , o
and CC o
vascular JJ o
resistance NN o
between IN p
the DT p
two CD p
groups NNS p
. . p

The DT N
strength NN i
training VBG i
group NN i
increased VBD N
maximal JJ o
strength NN o
in IN N
all PDT N
the DT N
major JJ N
muscle NN N
groups NNS N
tested VBD N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

Whole JJ o
body NN o
lean JJ o
body NN o
mass NN o
increased VBD N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
with IN N
strength NN N
training NN N
, , N
but CC N
leg VBZ o
fat-free JJ o
mass NN o
did VBD N
not RB N
. . N

Basal NNP o
femoral JJ o
blood NN o
flow NN o
and CC o
vascular JJ o
conductance NN o
increased VBN N
by IN N
55-60 CD N
% NN N
after IN N
strength NN i
training NN i
( ( N
both DT N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

No DT N
such JJ N
changes NNS N
were VBD N
observed VBN N
in IN N
the DT N
control NN N
group NN N
. . N

In IN N
both DT N
groups NNS N
, , N
there EX N
were VBD N
no DT N
significant JJ N
changes NNS N
in IN N
brachial JJ o
blood NN o
pressure NN o
, , o
plasma JJ o
endothelin-1 NN o
and CC o
angiotensin NN o
II NNP o
concentrations NNS o
, , o
femoral JJ o
artery NN o
wall NN o
thickness NN o
, , o
cardiac JJ o
output NN o
, , o
and CC o
systemic JJ o
vascular JJ o
resistance NN o
. . o

Our PRP$ N
results NNS N
indicate VBP N
that IN N
short-term JJ i
strength NN i
training NN i
increases NNS N
basal VBP N
femoral JJ N
blood NN N
flow NN N
and CC N
vascular JJ N
conductance NN N
in IN N
healthy JJ p
middle-aged JJ p
and CC p
older JJR p
adults NNS p
. . p

-DOCSTART- -23768813- O O

Targeting VBG N
alpha-7 JJ i
nicotinic JJ i
neurotransmission NN i
in IN N
schizophrenia NN p
: : p
a DT N
novel JJ N
agonist NN N
strategy NN N
. . N

Alpha7 NNP i
nicotinic JJ i
acetylcholine NN i
receptor NN i
( ( i
?7 NNP i
nAChR RB i
) ) i
agonists NNS i
may MD N
be VB N
valuable JJ N
treatments NNS N
for IN N
negative JJ N
symptoms NNS N
and CC N
cognitive JJ N
impairment NN N
in IN p
schizophrenia NN p
. . p

Unfortunately RB N
, , N
chronic JJ N
exposure NN N
to TO N
an DT N
agonist NN N
may MD N
reduce VB N
the DT N
receptor NN N
's POS N
sensitivity NN N
. . N

Therefore RB N
, , N
we PRP N
combined VBD i
CDP-choline NNP i
, , i
a DT N
dietary JJ N
source NN N
of IN N
the DT N
direct JJ N
agonist NN N
choline NN N
, , N
with IN i
galantamine NN i
, , i
a DT i
positive JJ i
allosteric JJ i
modulator NN i
( ( i
PAM NNP i
) ) i
of IN i
nicotinic JJ i
acetylcholine NN i
receptors NNS i
, , i
to TO N
improve VB N
the DT N
efficiency NN N
of IN N
transducing VBG N
the DT N
choline JJ N
signal NN N
and CC N
, , N
possibly RB N
, , N
preserve VB N
the DT N
receptor NN N
in IN N
a DT N
sensitive JJ N
state NN N
. . N

We PRP N
conducted VBD N
a DT N
single-site JJ N
, , N
double-blind JJ N
randomized JJ N
clinical JJ N
trial NN N
comparing VBG i
galantamine/CDP-choline NN i
to TO i
placebos VB i
in IN p
schizophrenia NN p
patients NNS p
with IN p
negative JJ p
symptoms NNS p
who WP p
were VBD p
receiving VBG p
second JJ p
generation NN p
antipsychotics NNS p
. . p

Forty-three JJ p
subjects NNS p
received VBN i
galantamine JJ i
and CC i
CDP-choline JJ i
or CC N
matching JJ i
placebos NNS i
for IN N
16weeks CD N
. . N

The DT N
primary JJ N
outcome NN N
measure NN N
was VBD N
the DT o
5-item JJ o
Marder NNP o
negative-symptoms JJ o
factor NN o
of IN o
the DT o
Positive NNP o
and CC o
Negative NNP o
Syndrome NNP o
Scale NNP o
( ( o
PANSS NNP o
) ) o
. . o

Cognition NN o
and CC o
functioning NN o
were VBD N
also RB N
assessed VBN N
. . N

Trial JJ N
completion NN N
was VBD N
high JJ N
; : N
79 CD N
% NN N
. . N

There EX N
was VBD N
no DT N
significant JJ N
treatment NN N
effect NN N
on IN o
negative JJ o
symptoms NNS o
, , o
other JJ o
PANSS NNP o
symptom NN o
factors NNS o
, , o
or CC o
the DT o
MATRICS NNP o
Cognitive NNP o
Consensus NNP o
Battery NNP o
. . o

There EX N
were VBD N
significant JJ N
treatment NN N
effects NNS N
in IN o
overall JJ o
functioning NN o
and CC o
a DT o
test NN o
of IN o
free JJ o
verbal JJ o
recall NN o
. . o

Three CD N
subjects NNS N
discontinued VBN N
treatment NN N
in IN N
the DT N
active JJ N
treatment NN N
group NN N
for IN N
gastro-intestinal JJ N
adverse JJ N
events NNS N
( ( N
AE NNP N
) ) N
. . N

The DT N
most RBS N
common JJ N
AE NNP N
for IN i
galantamine/CDP-choline NN i
was VBD o
abdominal JJ o
pain NN o
; : o
for IN i
placebo NN i
it PRP N
was VBD o
headache NN o
and CC o
sweating NN o
. . o

Although IN N
there EX N
was VBD N
no DT N
significant JJ N
treatment NN N
effect NN N
on IN N
negative JJ N
symptoms NNS N
, , N
the DT N
direction NN N
of IN N
effect NN N
mirrored VBD N
the DT N
effects NNS N
on IN N
a DT N
cognitive JJ N
measure NN N
and CC N
overall JJ N
functioning NN N
. . N

Further NNP N
study NN N
of IN i
?7 NNP i
nAChR JJ i
agonist/PAMs NN i
is VBZ i
warranted VBN N
in IN N
larger JJR N
studies NNS N
that WDT N
will MD N
have VB N
greater JJR N
power NN N
. . N

-DOCSTART- -12056851- O O

Clinical JJ N
evaluation NN N
of IN N
the DT N
WOMAC NNP N
3.0 CD N
OA NNP N
Index NNP N
in IN N
numeric JJ N
rating NN N
scale NN N
format NN N
using VBG N
a DT N
computerized JJ i
touch NN i
screen NN i
version NN i
. . i

BACKGROUND IN N
The DT N
Western NNP N
Ontario NNP N
and CC N
McMaster NNP N
Universities NNP N
( ( N
WOMAC NNP N
) ) N
Osteoarthritis NNP N
Index NNP N
is VBZ N
a DT N
previously RB N
described VBN N
self-administered JJ N
questionnaire NN N
covering VBG N
three CD N
domains NNS N
: : N
pain NN o
, , o
stiffness NN o
and CC o
function NN o
. . o

It PRP N
has VBZ N
been VBN N
validated VBN N
in IN N
patients NNS N
with IN N
osteoarthritis NN p
( ( p
OA NNP p
) ) p
of IN p
the DT p
hip NN p
or CC p
knee NN p
in IN N
a DT N
paper-based JJ N
format NN N
. . N

AIM NNP N
To TO N
validate VB N
the DT N
WOMAC NNP N
3.0 CD N
using VBG N
a DT N
numerical JJ N
rating NN N
scale NN N
in IN N
a DT N
computerized JJ N
touch NN N
screen NN N
format NN N
allowing VBG N
immediate JJ N
evaluation NN N
of IN N
the DT N
questionnaire NN N
. . N

In IN N
the DT N
computed JJ N
version NN N
cartoons NNS N
, , N
written VBN N
and CC N
audio JJ N
instruments NNS N
were VBD N
included VBN N
in IN N
order NN N
facilitate NN N
application NN N
. . N

METHODS NNP N
Fifty NNP p
patients NNS p
, , p
demographically RB p
balanced VBN p
, , p
with IN p
radiographically RB p
proven JJ p
primary JJ p
hip NN p
or CC p
knee NN p
OA NNP p
completed VBD p
the DT p
classical JJ i
paper NN i
and CC i
the DT i
new JJ i
computerized JJ i
WOMAC NNP i
version NN i
. . i

Subjects NNS N
were VBD N
randomized VBN N
either RB N
to TO N
paper NN N
format NN N
or CC N
computerized JJ N
format NN N
first RB N
to TO N
balance VB N
possible JJ N
order NN N
effects NNS N
. . N

RESULTS VB N
The DT N
intra-class JJ N
correlation NN N
coefficients NNS N
for IN N
pain NN o
, , o
stiffness NN o
and CC o
function NN o
values NNS o
were VBD N
0.915 CD N
, , N
0.745 CD N
and CC N
0.940 CD N
, , N
respectively RB N
. . N

The DT N
Spearman NNP N
correlation NN N
coefficients NNS N
for IN N
pain NN o
, , o
stiffness NN o
and CC o
function NN o
were VBD N
0.88 CD N
, , N
0.77 CD N
and CC N
0.87 CD N
, , N
respectively RB N
. . N

CONCLUSION NNP N
These DT N
data NNS N
indicate VBP N
that IN N
the DT N
computerized JJ N
WOMAC NNP N
OA NNP N
index NN N
3.0 CD N
is VBZ N
comparable JJ N
to TO N
the DT N
paper NN N
WOMAC NNP N
in IN N
all DT N
three CD N
dimensions NNS N
. . N

The DT i
computerized JJ i
version NN i
would MD N
allow VB N
physicians NNS N
to TO N
get VB N
an DT N
immediate JJ N
result NN N
and CC N
if IN N
present JJ N
a DT N
direct JJ N
comparison NN N
with IN N
a DT N
previous JJ N
exam NN N
. . N

-DOCSTART- -7941489- O O

Promoting VBG N
health NN N
in IN p
schools NNS p
through IN N
a DT N
board NN i
game NN i
. . i

Primary JJ N
prevention NN N
and CC N
health NN N
promotion NN N
have VBP N
become VBN N
salient JJ N
topics NNS N
in IN N
Canadian JJ N
society NN N
and CC N
in IN N
nursing NN N
during IN N
the DT N
past JJ N
two CD N
decades NNS N
. . N

The DT N
noncommunicable JJ N
chronic NN N
diseases NNS N
, , N
such JJ N
as IN N
heart NN N
disease NN N
and CC N
cancer NN N
, , N
have VBP N
been VBN N
linked VBN N
to TO N
specific JJ N
lifestyle JJ o
behaviors NNS o
or CC N
habits NNS N
, , N
which WDT N
often RB N
develop VBP N
early JJ N
in IN N
life NN N
. . N

The DT N
success NN N
of IN N
public JJ N
health NN N
efforts NNS N
to TO N
improve VB N
the DT N
health NN N
status NN N
of IN N
all DT N
Canadians NNPS N
depends VBZ N
substantially RB N
on IN N
the DT N
success NN N
of IN N
educational JJ N
programs NNS N
directed VBD N
toward IN N
children NNS p
. . p

Effective JJ N
teaching NN N
strategies NNS N
that WDT N
seek VBP N
to TO N
promote VB N
health NN N
and CC N
wellness NN N
in IN p
children NNS p
need VBP N
to TO N
be VB N
developed VBN N
and CC N
empirically RB N
evaluated VBN N
. . N

Educational JJ N
games NNS N
may MD N
provide VB N
an DT N
efficient JJ N
vehicle NN N
for IN N
carrying VBG N
out RP N
developmentally RB N
specific JJ N
nursing NN N
interventions NNS N
in IN p
school NN p
settings NNS p
. . p

This DT N
article NN N
begins VBZ N
with IN N
a DT N
brief JJ N
overview NN N
of IN N
the DT N
historical JJ N
origins NNS N
of IN N
games NNS N
, , N
along IN N
with IN N
their PRP$ N
advantages NNS N
and CC N
disadvantages NNS N
as IN N
educational JJ N
strategies NNS N
. . N

The DT N
results NNS N
of IN N
a DT N
pretest-posttest JJ N
control NN N
group NN N
design NN N
study NN N
that WDT N
evaluated VBD N
the DT N
effectiveness NN i
of IN i
a DT i
board NN i
game NN i
as IN i
a DT i
primary JJ i
prevention NN i
teaching VBG i
strategy NN i
with IN N
23 CD p
sixth NNS p
grade JJ p
children NNS p
in IN p
Winnipeg NNP p
, , p
Manitoba NNP p
are VBP N
presented VBN N
. . N

The DT N
experimental JJ N
group NN N
had VBD N
significant JJ N
gains NNS N
in IN N
knowledge NN o
related VBN o
to TO o
anatomy VB o
and CC o
physiology VB o
, , o
diet JJ o
, , o
and CC o
lifestyle JJ o
risk NN o
factors NNS o
associated VBN o
with IN o
the DT o
development NN o
of IN o
heart NN o
disease NN o
and CC o
cancer NN o
. . o

-DOCSTART- -6350097- O O

Recurrent NNP N
ulcer NN N
after IN N
successful JJ N
treatment NN N
with IN N
cimetidine NN i
or CC N
antacid NN i
. . i

This DT N
study NN N
was VBD N
designed VBN N
to TO N
compare VB N
the DT N
rates NNS N
of IN N
duodenal JJ N
ulcer NN N
healing NN N
and CC N
recurrence NN N
after IN N
treatment NN N
with IN N
cimetidine NN i
or CC i
antacid NN i
. . i

Patients NNS p
with IN p
endoscopically RB p
documented VBN p
duodenal JJ p
ulcer NN p
received VBD N
cimetidine NN i
, , N
1200 CD N
mg NN N
daily RB N
, , N
or CC i
Mylanta NNP i
II NNP i
, , N
7 CD N
oz JJ N
daily RB N
, , N
in IN N
a DT N
randomized JJ N
, , N
double-blind JJ N
trial NN N
. . N

For IN N
the DT N
69 CD p
patients NNS p
in IN p
each DT p
group NN p
who WP N
completed VBD N
the DT N
healing VBG N
phase NN N
of IN N
the DT N
trial NN N
, , N
endoscopic JJ N
ulcer NN N
healing NN N
was VBD N
almost RB N
identical JJ N
. . N

At IN N
2 CD N
, , N
4 CD N
, , N
and CC N
6 CD N
wk NN N
, , N
the DT N
cumulative JJ N
percent NN N
healed VBD N
on IN N
antacid NN i
was VBD N
33 CD N
% NN N
, , N
64 CD N
% NN N
, , N
and CC N
80 CD N
% NN N
, , N
and CC N
on IN N
cimetidine NN i
it PRP N
was VBD N
25 CD N
% NN N
, , N
62 CD N
% NN N
, , N
and CC N
86 CD N
% NN N
. . N

The DT N
114 CD p
patients NNS p
with IN p
healed JJ p
ulcer NN p
were VBD N
observed VBN N
on IN N
no DT N
therapy NN N
and CC N
underwent JJ N
additional JJ N
endoscopy NN N
to TO N
detect VB N
recurrences NNS N
when WRB N
symptomatic JJ N
or CC N
at IN N
3 CD N
, , N
6 CD N
, , N
and CC N
12 CD N
mo NN N
. . N

There EX N
was VBD N
no DT N
difference NN N
in IN N
the DT N
frequency NN o
of IN o
recurrences NNS o
between IN N
treatments NNS N
. . N

At IN N
3 CD N
and CC N
6 CD N
mo NN N
, , N
the DT N
cumulative JJ o
percentages NNS o
of IN o
patients NNS o
with IN o
recurrence NN o
were VBD N
29 CD N
% NN N
and CC N
56 CD N
% NN N
after IN N
antacid JJ i
therapy NN i
and CC N
36 CD N
% NN N
and CC N
55 CD N
% NN N
after IN N
cimetidine JJ i
therapy NN i
. . i

Some DT N
patient JJ N
variables NNS N
were VBD N
associated VBN N
with IN N
delayed JJ o
ulcer NN o
healing NN o
or CC o
ulcer JJ o
recurrence NN o
. . o

These DT N
included VBD N
sex NN N
, , N
pain NN N
frequency NN N
, , N
smoking NN N
, , N
disease NN N
duration NN N
, , N
and CC N
acid JJ N
secretion NN N
. . N

-DOCSTART- -7726441- O O

The DT N
antiemetic JJ o
efficacy NN o
of IN N
prophylactic JJ i
granisetron NN i
in IN N
gynecologic JJ p
surgery NN p
. . p

Postoperative NNP o
nausea NN o
and CC o
vomiting NN o
are VBP N
common JJ N
after IN N
recovery NN p
from IN p
anesthesia NN p
. . p

We PRP N
examined VBD N
the DT N
prophylactic JJ N
effect NN N
of IN N
granisetron NN i
on IN N
postoperative JJ o
nausea NN o
and CC o
vomiting NN o
in IN N
120 CD p
female JJ p
patients NNS p
( ( p
ASA NNP p
physical JJ p
status NN p
I PRP p
) ) p
undergoing VBG p
gynecologic JJ p
surgery NN p
. . p

They PRP N
were VBD N
randomly RB N
allocated VBN N
to TO N
one CD N
of IN N
three CD N
groups NNS N
( ( N
n JJ N
= VBP N
40 CD N
for IN N
each DT N
) ) N
: : N
saline NN i
( ( N
as IN N
a DT N
control NN N
) ) N
, , N
granisetron $ i
20 CD N
micrograms/kg NN N
, , N
and CC N
granisetron $ i
40 CD N
micrograms/kg NN N
. . N

Saline NNP i
or CC N
granisetron NN i
was VBD N
given VBN N
intravenously RB N
( ( N
IV NNP N
) ) N
over IN N
5 CD N
min NNS N
approximately RB N
30 CD N
min NN N
before IN N
the DT N
end NN N
of IN N
anesthesia NN N
. . N

Nausea NN o
, , o
vomiting NN o
, , o
and CC o
safety NN o
assessments NNS o
were VBD N
performed VBN N
during IN N
the DT N
24-h JJ N
recovery NN N
period NN N
. . N

For IN N
the DT N
24-h JJ N
period NN N
after IN N
surgery NN N
, , N
the DT N
number NN o
of IN o
emesis-free JJ o
patients NNS o
was VBD N
significantly RB N
larger JJR N
in IN N
the DT N
granisetron NN N
groups NNS N
than IN N
in IN N
the DT N
control NN N
group NN N
( ( N
83 CD N
% NN N
, , N
78 CD N
% NN N
, , N
and CC N
20 CD N
% NN N
of IN N
patients NNS N
receiving VBG N
granisetron NN N
20 CD N
micrograms/kg NN N
and CC N
40 CD N
micrograms/kg NN N
, , N
and CC N
saline NN N
, , N
respectively RB N
) ) N
. . N

Granisetron NNP i
at IN N
both DT N
doses NNS N
also RB N
was VBD N
superior JJ N
to TO N
the DT N
control NN N
for IN N
the DT N
prevention NN N
of IN N
nausea NN o
over IN N
the DT N
24-h JJ N
study NN N
period NN N
( ( o
nausea JJ o
visual JJ o
analog NN o
scales NNS o
at IN N
24-h JJ N
postsurgery NN N
: : N
49 CD N
mm NN N
, , N
17 CD N
mm NN N
, , N
and CC N
18 CD N
mm NN N
in IN N
the DT N
control NN N
, , N
granisetron VBP i
20 CD N
micrograms/kg NN N
, , N
and CC N
granisetron $ i
40 CD N
micrograms/kg NN N
groups NNS N
, , N
respectively RB N
) ) N
. . N

Fewer JJR N
patients NNS N
received VBD N
rescue JJ o
antiemetics NNS o
in IN N
the DT N
granisetron NN i
groups NNS N
than IN N
in IN N
the DT N
control NN N
group NN N
( ( N
10 CD N
% NN N
, , N
10 CD N
% NN N
, , N
and CC N
43 CD N
% NN N
of IN N
patients NNS N
in IN N
granisetron NN N
20 CD N
micrograms/kg NN N
and CC N
40 CD N
micrograms/kg NN N
, , N
and CC N
the DT N
control NN N
groups NNS N
, , N
respectively RB N
) ) N
. . N

The DT N
adverse JJ o
events NNS o
in IN N
the DT N
granisetron NN N
groups NNS N
were VBD N
similar JJ N
to TO N
those DT N
in IN N
the DT N
control NN N
group NN N
. . N

The DT N
administration NN N
of IN N
granisetron NN N
had VBD N
no DT N
significant JJ N
effect NN N
on IN N
vital JJ o
signs NNS o
or CC o
clinical JJ o
laboratory NN o
test NN o
profiles NNS o
. . o

Granisetron NNP i
given VBN N
at IN N
20 CD N
or CC N
40 CD N
micrograms/kg JJ N
i.v NN N
. . N

during IN N
anesthesia JJ N
appears VBZ N
to TO N
be VB N
a DT N
simple JJ o
, , o
effective JJ o
, , o
and CC o
safe JJ o
method NN o
for IN N
preventing VBG N
postoperative JJ o
nausea NN o
and CC o
vomiting NN o
. . o

-DOCSTART- -25778837- O O

Examining VBG N
the DT N
Relationship NNP N
Between NNP N
Parental NNP N
Anxiety NNP N
and CC N
Treatment NNP N
Response NNP N
in IN N
Children NNP p
and CC p
Adolescents NNP p
with IN p
Autism NNP p
Spectrum NNP p
Disorder NNP p
and CC p
Anxiety NNP p
. . p

In IN N
response NN N
to TO N
the DT N
high JJ N
co-occurrence NN N
of IN N
anxiety NN N
symptoms NNS N
in IN N
youth NN p
with IN p
autism NN p
spectrum NN p
disorder NN p
( ( p
ASD NNP p
) ) p
, , N
several JJ N
interventions NNS N
have VBP N
been VBN N
developed VBN N
for IN N
this DT N
population NN N
. . N

In IN N
spite NN N
of IN N
promising JJ N
findings NNS N
, , N
some DT N
youth NN p
with IN p
ASD NNP p
respond NN N
only RB N
minimally RB N
to TO N
such JJ N
interventions NNS N
. . N

To TO N
understand VB N
potential JJ N
factors NNS N
that WDT N
may MD N
impact VB N
treatment NN N
response NN N
, , N
the DT N
current JJ N
study NN N
explores VBZ N
the DT N
role NN N
of IN N
parental JJ N
anxiety NN N
in IN N
youth NN N
treatment NN N
outcome NN N
. . N

Thirty-one CD p
youth NN p
with IN p
ASD NNP p
, , p
ages VBZ p
7-18 CD p
, , p
and CC p
their PRP$ p
parents NNS p
participated VBN N
in IN N
the DT N
study NN N
. . N

Parents NNS i
completed VBD i
the DT i
State/Trait NNP o
Anxiety NNP o
Inventory NNP o
pre- JJ i
and CC i
post-treatment JJ i
. . i

Contrary NNP N
to TO N
previous JJ N
research NN N
, , N
there EX N
was VBD N
no DT N
correlation NN N
between IN N
parental JJ o
anxiety NN o
and CC o
youth NN o
anxiety NN o
at IN N
baseline NN N
or CC N
post-treatment NN N
. . N

However RB N
, , N
parental JJ o
trait NN o
anxiety NN o
significantly RB N
decreased VBN N
from IN N
pre- JJ N
to TO N
post-treatment NN N
for IN N
parents NNS N
of IN N
treatment NN N
responders NNS N
. . N

The DT N
findings NNS N
are VBP N
consistent JJ N
with IN N
previous JJ N
research NN N
and CC N
suggest VB N
a DT N
youth-to-parent JJ N
influence NN N
. . N

-DOCSTART- -11253439- O O

Sun NNP i
protection NN i
behaviors NNS i
and CC N
stages NNS N
of IN N
change NN N
for IN N
the DT N
primary JJ N
prevention NN N
of IN N
skin JJ p
cancers NNS p
among IN p
beachgoers NNS p
in IN p
southeastern JJ p
New NNP p
England NNP p
. . p

Sun NNP N
exposure NN N
is VBZ N
the DT N
most RBS N
important JJ N
avoidable JJ N
cause NN N
of IN N
skin NN N
cancers NNS N
. . N

We PRP N
report VBP N
characteristics NNS N
of IN N
a DT N
representative JJ p
sample NN p
( ( p
N NNP p
= NNP p
2,324 CD p
) ) p
of IN p
beachgoers NNS p
in IN p
Southeastern NNP p
New NNP p
England NNP p
during IN p
the DT p
summer NN p
of IN p
1995 CD p
. . p

This DT N
sample NN N
was VBD N
not RB N
employing VBG N
adequate JJ N
sun NN i
protection NN i
behaviors NNS i
( ( N
83 CD N
% NN N
did VBD N
not RB N
often RB N
avoid VBZ i
the DT i
sun NN i
during IN i
midday NN i
and CC N
only RB N
45 CD N
% NN N
often RB N
used VBD N
sunscreen JJ i
) ) i
. . N

Important JJ N
demographic JJ N
and CC N
skin JJ N
cancer NN N
risk NN N
factor NN N
differences NNS N
in IN N
sun JJ N
protective JJ N
behaviors NNS N
and CC N
stages NNS N
of IN N
change NN N
for IN N
sun NN N
protection NN N
were VBD N
found VBN N
, , N
especially RB N
differences NNS N
based VBN N
on IN N
age NN N
, , N
gender NN N
, , N
and CC N
degree NN N
of IN N
sun NN N
sensitivity NN N
. . N

Consistent JJ N
with IN N
previous JJ N
research NN N
, , N
increased VBD N
age NN N
, , N
female JJ N
gender NN N
, , N
and CC N
greater JJR N
sun NN N
sensitivity NN N
were VBD N
each DT N
independently RB N
associated VBN N
with IN N
more RBR N
sun JJ o
protective JJ o
behaviors NNS o
. . o

These DT N
findings NNS N
underscore VBP N
the DT N
need NN N
for IN N
interventions NNS N
targeting VBG N
high-risk JJ N
populations NNS N
, , N
such JJ N
as IN N
those DT N
receiving VBG N
high-intensity NN N
sun NN N
exposures NNS N
at IN N
the DT N
beach NN N
. . N

-DOCSTART- -14649341- O O

Intraperitoneal NNP N
application NN N
of IN N
bupivacaine NN i
plus CC N
morphine NN i
for IN N
pain NN o
relief NN o
after IN N
laparoscopic JJ p
cholecystectomy NN p
. . p

BACKGROUND NNP N
AND NNP N
OBJECTIVE NNP N
Intraperitoneal NNP N
administration NN N
of IN N
a DT N
local JJ N
anaesthetic NN N
in IN N
combination NN N
with IN N
an DT N
opioid NN i
, , N
for IN N
the DT N
relief NN N
of IN N
postoperative JJ o
pain NN o
, , N
has VBZ N
already RB N
been VBN N
reported VBN N
except IN N
after IN N
laparoscopic JJ p
cholecystectomy NN p
. . p

This DT N
study NN N
was VBD N
aimed VBN N
at IN N
assessing VBG N
the DT N
analgesic JJ N
effect NN N
of IN N
the DT N
intraperitoneal JJ N
administration NN N
of IN N
bupivacaine NN i
and CC i
morphine NN i
in IN N
patients NNS p
undergoing VBG p
laparoscopic JJ p
cholecystectomy NN p
. . p

METHODS NNP N
At IN N
the DT N
end NN N
of IN N
laparoscopic JJ N
cholecystectomy NN N
, , N
in IN N
a DT N
double-blind NN N
, , N
randomized JJ N
manner NN N
, , N
one CD N
of IN N
the DT N
following JJ N
injections NNS N
was VBD N
given VBN N
intraperitoneally RB N
. . N

There EX N
were VBD N
30 CD p
patients NNS p
in IN p
each DT p
group NN p
: : p
Group NNP N
1 CD N
, , N
physiological JJ i
saline NN i
30 CD N
mL NN N
; : N
Group NNP N
2 CD N
, , N
bupivacaine VBP i
0.25 CD N
% NN N
30 CD N
mL NN N
; : N
Group NNP N
3 CD N
, , N
bupivacaine VBP i
0.25 CD N
% NN N
30 CD N
mL NN N
plus CC i
morphine JJ i
2 CD N
mg NN N
. . N

In IN N
addition NN N
, , N
Group NNP N
2 CD N
received VBD N
2 CD N
mg NNS N
intravenous JJ N
( ( N
i.v JJ N
. . N

) ) N
morphine NN i
in IN N
2 CD N
mL NNS N
saline NN i
, , N
and CC N
Groups NNP N
1 CD N
and CC N
3 CD N
, , N
2 CD N
mL NN N
saline NN i
intravenously RB N
. . N

Patients NNS N
' POS N
postoperative JJ o
pain NN o
was VBD N
evaluated VBN N
using VBG N
a DT N
visual JJ o
analogue NN o
scale NN o
and CC N
a DT N
verbal JJ o
rating NN o
score NN o
. . o

The DT N
postoperative JJ N
analgesic JJ N
requirement NN N
was VBD N
assessed VBN N
by IN N
the DT N
total JJ N
dose NN N
of IN N
metamizol NN o
administered VBN N
by IN N
an DT N
i.v NN N
. . N

patient-controlled JJ o
analgesia NN o
( ( o
PCA NNP o
) ) o
device NN N
. . N

Pain NNP o
, , o
vital JJ o
signs NNS o
, , o
supplemental JJ o
analgesic JJ o
consumption NN o
and CC o
side-effects NNS o
were VBD N
recorded VBN N
for IN N
all DT N
patients NNS N
for IN N
24 CD N
h. JJ N
RESULTS NNP N
There EX N
were VBD N
no DT N
differences NNS N
between IN N
the DT N
three CD N
groups NNS N
regarding VBG N
pain NN o
scores NNS o
( ( N
at IN N
rest NN N
and CC N
coughing VBG N
) ) N
during IN N
the DT N
study NN N
except IN N
in IN N
the DT N
first JJ N
2 CD N
h NN N
, , N
when WRB N
scores NNS N
were VBD N
lower JJR N
for IN N
patients NNS N
receiving VBG N
intraperitoneal JJ N
bupivacaine NN i
plus CC N
i.v NN N
. . N

morphine NN i
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

Supplemental JJ o
consumption NN o
of IN o
metamizol NN o
was VBD N
significantly RB N
lower JJR N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
in IN N
Group NNP N
3 CD N
than IN N
in IN N
Group NNP N
1 CD N
during IN N
the DT N
first JJ N
6 CD N
h NN N
after IN N
surgery NN N
. . N

However RB N
, , N
the DT N
cumulative JJ o
doses NNS o
of IN N
metamizol NN N
were VBD N
also RB N
lower JJR N
in IN N
Group NNP N
2 CD N
than IN N
in IN N
Groups NNP N
1 CD N
and CC N
3 CD N
over IN N
the DT N
entire JJ N
study NN N
( ( N
2025 CD N
+/- NN N
1044 CD N
mg NN N
vs. FW N
4925 CD N
+/- JJ N
1238 CD N
and CC N
4125 CD N
+/- JJ N
1276mg CD N
; : N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

CONCLUSIONS NNP N
In IN N
patients NNS p
undergoing VBG p
laparoscopic JJ p
cholecystectomy NN p
, , N
the DT N
intraperitoneal JJ N
administration NN N
of IN N
morphine JJ i
plus CC N
bupivacaine JJ i
0.25 CD N
% NN N
reduced VBD N
the DT N
analgesic JJ o
requirements NNS o
during IN N
the DT N
first JJ N
6 CD N
postoperative JJ N
hours NNS N
compared VBN N
with IN N
the DT N
control NN N
group NN N
. . N

However RB N
, , N
the DT N
combination NN N
of IN N
intraperitoneal JJ N
bupivacaine JJ i
0.25 CD N
% NN N
and CC N
i.v NN N
. . N

morphine NN i
was VBD N
more RBR N
effective JJ N
for IN N
treatment NN N
of IN N
pain NN o
after IN N
laparoscopic JJ p
cholecystectomy NN p
. . p

-DOCSTART- -25806587- O O

The DT N
Impact NNP N
of IN N
Partial NNP i
Vascular NNP i
Occlusion NNP i
on IN N
Oxidative NNP N
Stress NNP N
Markers NNP N
during IN N
Resistance NNP i
Exercise NNP i
. . i

This DT N
study NN N
sought VBD N
to TO N
examine VB N
the DT N
effects NNS N
of IN N
partial JJ i
vascular JJ i
occlusion NN i
( ( i
PVO NNP i
) ) i
on IN N
oxidative JJ N
stress NN N
markers NNS N
in IN N
response NN N
to TO N
resistance VB i
exercise NN i
and CC N
at IN N
rest NN N
in IN N
young JJ p
resistance-trained JJ p
males NNS p
. . p

12 CD p
resistance-trained JJ p
males NNS p
performed VBD p
6 CD p
conditions NNS p
in IN p
random NN p
counterbalanced VBN p
order NN p
: : p
rest NN i
( ( i
R NNP i
) ) i
, , i
low-intensity NN i
( ( i
LIRE NNP i
: : i
30 CD p
% NN p
1RM CD p
) ) p
and CC p
moderate-intensity NN i
( ( i
MIRE NNP i
: : i
70 CD p
% NN p
1RM CD p
) ) p
resistance NN i
exercise NN i
with IN i
or CC i
without IN i
PVO NNP i
. . i

Blood NN o
samples NNS o
were VBD N
obtained VBN N
before IN N
and CC N
immediately RB N
after IN N
each DT N
condition NN N
and CC N
plasma NN o
protein NN o
carbonyls NN o
( ( o
PC NN o
) ) o
, , o
glutathione NN o
ratio NN o
, , o
oxygen RB o
radical JJ o
absorbance NN o
capacity NN o
( ( o
ORAC NNP o
) ) o
, , o
and CC o
xanthine JJ o
oxidase NN o
( ( o
XO NNP o
) ) o
were VBD N
evaluated VBN N
. . N

The DT N
addition NN N
of IN N
PVO NNP i
resulted VBD N
in IN N
significantly RB N
greater JJR N
plasma JJ o
PC NN o
and CC o
glutathione NN o
ratio NN o
in IN N
the DT N
rest NN N
condition NN N
. . N

During IN N
LIRE NNP i
the DT N
addition NN N
of IN N
PVO NNP i
significantly RB N
attenuated VBD N
plasma JJ N
PC NN N
. . N

The DT N
MIRE NNP N
condition NN N
, , N
independent JJ N
of IN N
PVO NNP i
, , N
resulted VBD N
in IN N
significantly RB N
higher JJR o
PC NN o
concentration NN o
and CC o
glutathione NN o
ratio NN o
compared VBN N
to TO N
the DT N
rest NN N
and CC N
LIRE NNP N
conditions NNS N
. . N

The DT N
addition NN i
of IN N
PVO NNP i
during IN i
MIRE NNP i
resulted VBD N
in IN N
a DT N
significant JJ N
increase NN N
in IN N
PC NNP o
. . o

Thus RB N
, , N
this DT N
study NN N
revealed VBD N
that IN N
PVO NNP i
increased VBD N
oxidative JJ o
stress NN o
at IN N
rest NN N
and CC N
enhanced VBD N
the DT N
oxidative JJ N
stress NN N
response NN N
to TO N
MIRE NNP i
, , N
but CC N
when WRB N
combined VBN N
with IN N
LIRE NNP i
oxidative JJ N
stress NN N
was VBD N
attenuated VBN N
. . N

These DT N
findings NNS N
suggest VBP N
that IN N
the DT N
utilization NN N
of IN N
PVO NNP i
during IN N
LIRE NNP i
may MD N
alter VB N
ROS-induced NNP N
accumulation NN N
in IN N
the DT N
blood NN N
which WDT N
may MD N
influence VB N
cellular JJ N
signaling NN N
. . N

-DOCSTART- -11450818- O O

Children NNP p
's POS p
attitudes NNS o
and CC o
behavioral JJ o
intentions NNS o
toward IN p
a DT p
peer NN p
with IN p
autistic JJ o
behaviors NNS o
: : o
does VBZ N
a DT N
brief JJ N
educational JJ i
intervention NN i
have VBP N
an DT N
effect NN N
? . N
This DT N
study NN N
examined VBD N
children NNS p
's POS p
ratings NNS p
of IN p
attitudes NNS o
and CC o
behavioral JJ o
intentions NNS o
toward IN p
a DT p
peer NN p
presented VBN p
with IN p
or CC p
without IN p
autistic JJ o
behaviors NNS o
. . o

The DT N
impact NN N
of IN N
information NN N
about IN N
autism NN N
on IN N
these DT N
ratings NNS N
was VBD N
investigated VBN N
as RB N
well RB N
as IN N
age NN N
and CC N
gender NN N
effects NNS N
. . N

Third- CD p
and CC p
sixth-grade JJ p
children NNS p
( ( p
N NNP p
= NNP p
233 CD p
) ) p
were VBD N
randomly RB N
assigned VBN N
to TO N
view VB i
a DT i
video NN i
of IN i
the DT i
same JJ i
boy NN i
in IN i
one CD i
of IN i
three CD i
conditions NNS i
: : i
No DT i
Autism NNP i
, , i
Autism NNP i
, , i
or CC i
Autism/Information NNP i
. . i

Children NNP N
at IN N
both DT N
grade NN N
levels NNS N
showed VBD N
less RBR o
positive JJ o
attitudes NNS o
toward IN N
the DT N
child NN N
in IN N
the DT N
two CD N
autism NN N
conditions NNS N
. . N

In IN N
rating NN N
their PRP$ N
own JJ N
behavioral JJ o
intentions NNS o
, , N
children NNS N
showed VBD N
no DT N
differences NNS N
between IN N
conditions NNS N
. . N

However RB N
, , N
in IN N
attributing VBG N
intentions NNS N
to TO N
their PRP$ N
classmates NNS N
, , N
older JJR N
children NNS N
and CC N
girls NNS N
gave VBD N
lower JJR o
ratings NNS o
to TO N
the DT N
child NN N
in IN N
the DT N
autism NN N
conditions NNS N
. . N

Information NN N
about IN N
autism NN N
did VBD N
not RB N
affect JJ N
ratings NNS N
of IN N
either DT N
attitudes NNS o
or CC o
behavioral JJ o
intentions NNS o
as IN N
ascribed NN N
to TO N
self VB N
or CC N
others NNS N
. . N

-DOCSTART- -17118092- O O

The DT N
effects NNS o
of IN N
chewing VBG i
versus NN i
caffeine NN i
on IN N
alertness NN N
, , N
cognitive JJ N
performance NN N
and CC N
cardiac JJ N
autonomic JJ N
activity NN N
during IN N
sleep JJ p
deprivation NN p
. . p

Chewing NNP i
has VBZ N
been VBN N
shown VBN N
to TO N
alleviate VB N
feelings NNS N
of IN N
sleepiness NN N
and CC N
improve VB N
cognitive JJ N
performance NN N
during IN N
the DT N
day NN N
. . N

This DT N
study NN N
investigated VBD N
the DT N
effect NN o
of IN N
chewing VBG i
on IN N
alertness NN N
and CC N
cognitive JJ N
performance NN N
across IN N
one CD N
night NN N
without IN N
sleep NN N
as RB N
well RB N
as IN N
the DT N
possible JJ N
mediating JJ N
role NN N
of IN N
cardiac JJ N
autonomic JJ N
activity NN N
. . N

Fourteen NNP p
adults NNS p
participated VBD p
in IN N
a DT N
randomized JJ N
, , N
counterbalanced VBD N
protocol NN N
employing VBG N
a DT N
chewing NN i
, , i
placebo NN i
and CC i
caffeine JJ i
condition NN N
. . N

Participants NNS N
completed VBD N
tasks NNS N
assessing VBG N
psychomotor NN o
vigilance NN o
, , o
tracking VBG o
, , o
grammatical JJ o
reasoning NN o
, , o
alertness NN o
and CC o
sleepiness JJ o
each DT N
hour NN N
across IN N
the DT N
night NN N
. . N

All DT N
participants NNS N
received VBD N
either CC N
placebo NN i
or CC i
caffeine NN i
( ( N
200 CD N
mg NN N
) ) N
, , N
while IN N
the DT N
chewing VBG i
condition NN N
also RB N
chewed VBD i
on IN i
a DT i
tasteless NN i
and CC i
odorless JJ i
substance NN i
for IN N
15 CD N
min NNS N
each DT N
hour NN N
. . N

Heart NNP o
rate NN o
( ( o
HR NNP o
) ) o
, , o
root JJ o
mean JJ o
square NN o
of IN o
the DT o
successive JJ o
differences NNS o
in IN o
R-R NNP o
intervals NNS o
on IN o
the DT o
ECG NNP o
( ( o
RMSSD NNP o
) ) o
, , o
and CC o
preejection NN o
period NN o
( ( o
PEP NNP o
) ) o
were VBD N
simultaneously RB N
recorded VBN N
. . N

Alertness NNP o
and CC o
cognitive JJ o
performance NN o
amongst VBD N
the DT N
chewing VBG N
condition NN N
did VBD N
not RB o
differ VB o
or CC o
were VBD o
in IN o
fact NN o
worse NN o
when WRB N
compared VBN N
with IN N
placebo NN i
. . i

Similarly RB N
, , N
measures NNS N
of IN N
HR NNP o
and CC o
RMSSD NNP o
remained VBD N
the DT N
same JJ o
between IN N
these DT N
two CD N
conditions NNS N
; : N
however RB N
, , N
PEP NNP o
was VBD N
reduced VBN N
in IN N
the DT N
later JJ N
part NN N
of IN N
the DT N
night NN N
in IN N
the DT N
chewing VBG i
condition NN N
compared VBN N
with IN N
a DT N
relative JJ N
increase NN N
for IN N
placebo NN i
. . i

Caffeine NNP i
led VBD N
to TO N
improved VBN o
speed NN o
and CC o
accuracy NN o
on IN o
cognitive JJ o
tasks NNS o
and CC o
increased VBD o
alertness NN o
when WRB N
compared VBN N
with IN N
chewing VBG i
. . i

Relative JJ o
increases NNS o
in IN o
RMSSD NNP o
and CC N
reductions NNS o
in IN o
HR NNP o
were VBD N
demonstrated VBN N
following VBG N
caffeine NN N
; : N
however RB N
, , N
no DT o
change NN o
in IN o
PEP NNP o
was VBD N
seen VBN N
. . N

Strong JJ N
associations NNS N
between IN N
cardiac JJ N
parasympathetic JJ N
activity NN N
and CC N
complex JJ N
cognitive NN N
tasks NNS N
, , N
as RB N
well RB N
as IN N
between IN N
subjective JJ N
alertness NN o
and CC N
simpler NN o
cognitive JJ o
tasks NNS o
, , N
suggest VBP N
a DT N
differential JJ N
process NN N
mediating VBG N
complex JJ N
versus NN N
simple JJ N
cognitive JJ N
performance NN N
during IN N
sleep JJ N
deprivation NN N
. . N

-DOCSTART- -21044518- O O

[ JJ N
Effects NNS N
of IN N
computer-assisted JJ i
practice NN i
on IN N
reading NN o
and CC o
spelling NN o
in IN N
children NNS p
with IN p
learning VBG p
disabilities NNS p
] NNP p
. . N

The DT N
main JJ N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
analyze VB N
the DT N
effects NNS N
of IN N
computer-assisted JJ i
practice NN i
on IN i
reading NN i
and CC i
spelling NN i
in IN i
children NNS p
with IN p
learning VBG p
disabilities NNS p
( ( p
LD NNP p
) ) p
. . p

We PRP N
compared VBN N
three CD N
practice NN N
conditions NNS N
, , N
one CD N
with IN N
reading NN i
and CC N
two CD N
with IN N
spelling NN i
, , N
in IN N
order NN N
to TO N
test VB N
whether IN N
computer-based JJ i
reading NN i
and CC i
spelling NN i
practice NN i
has VBZ N
an DT N
influence NN N
on IN N
the DT N
development NN N
of IN N
reading NN N
and CC N
spelling VBG N
ability NN N
in IN N
children NNS p
with IN p
LD NNP p
. . p

A NNP N
sample NN N
was VBD N
selected VBN N
of IN N
85 CD p
children NNS p
with IN p
LD NNP p
, , p
with IN p
age NN p
range NN p
between IN p
8 CD p
years NNS p
and CC p
10 CD p
years NNS p
( ( p
age NN p
, , p
M=111.02 NNP p
, , p
SD=9.6 NNP p
) ) p
, , p
whose WP$ p
spelling VBG p
performance NN p
was VBD p
two CD p
years NNS p
below IN p
grade JJ p
level NN p
. . p

The DT N
participants NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
one CD N
of IN N
four CD N
groups NNS N
: : N
1 CD i
) ) i
Copy NNPS i
the DT i
target NN i
word NN i
from IN i
the DT i
computer NN i
screen NN i
( ( i
n=22 NN i
) ) i
, , i
2 CD i
) ) i
Memorize VB i
the DT i
target NN i
word NN i
and CC i
write VB i
it PRP i
from IN i
memory NN i
( ( i
n=21 JJ i
) ) i
, , i
3 CD i
) ) i
Word NNP i
reading NN i
( ( i
n=21 JJ i
) ) i
, , i
and CC i
4 CD i
) ) i
the DT i
untrained JJ i
control NN i
group NN i
( ( N
n=21 RB N
) ) N
. . N

We PRP N
administered VBD N
measures NNS N
of IN N
pseudoword NN o
reading NN o
, , o
phonological JJ o
awareness NN o
, , o
phonological JJ o
word NN o
decoding NN o
and CC o
orthographical JJ o
word NN o
decoding VBG o
tasks NNS o
. . o

We PRP N
examined VBD N
the DT N
learning NN o
effects NNS o
and CC o
transfer NN o
effects NNS o
on IN o
words NNS o
classified VBN o
as IN o
a DT o
function NN o
of IN o
length NN o
, , o
consistency NN o
, , o
and CC o
complexity NN o
of IN o
syllable JJ o
structure NN o
. . o

Overall JJ N
, , N
the DT N
results NNS N
showed VBD N
that IN N
reading VBG N
training VBG N
did VBD N
not RB N
improve VB N
spelling NN N
; : N
however RB N
, , N
the DT N
children NNS N
who WP N
participated VBD N
in IN N
the DT N
copy NN N
training NN N
condition NN N
improved VBD N
their PRP$ N
spelling NN N
skills NNS N
. . N

-DOCSTART- -10360656- O O

A DT N
randomized JJ N
phase NN N
II NNP N
trial NN N
of IN N
5-fluorouracil JJ i
, , N
with IN N
or CC N
without IN N
human JJ i
interferon-beta NN i
, , N
for IN N
advanced JJ p
colorectal JJ p
cancer NN p
. . p

This DT N
study NN N
compared VBN N
the DT N
efficacy NN o
and CC o
safety NN o
of IN N
5-fluorouracil JJ i
( ( i
5-FU JJ i
) ) i
monotherapy NN i
to TO N
that DT N
of IN N
5-FU JJ i
combined VBN i
with IN i
natural JJ i
human JJ i
interferon-beta NN i
( ( i
IFN-beta NNP i
) ) i
in IN N
patients NNS p
with IN p
unresectable JJ p
, , p
advanced JJ p
colorectal JJ p
carcinoma NN p
. . p

Forty-nine JJ p
chemotherapy-naive JJ p
patients NNS p
were VBD p
randomized VBN p
to TO N
5-FU JJ N
alone RB N
or CC N
to TO N
the DT N
combination NN N
. . N

All DT N
patients NNS N
received VBD N
750 CD N
mg NNS N
m NN N
( ( N
-2 JJ N
) ) N
day NN N
( ( N
-1 JJ N
) ) N
5-FU NN N
for IN N
5 CD N
days NNS N
by IN N
continuous JJ N
intravenous JJ N
( ( N
i.v JJ N
. . N

) ) N
infusion NN N
, , N
followed VBD N
after IN N
day NN N
15 CD N
by IN N
a DT N
weekly JJ N
i.v NN N
. . N

bolus NN N
of IN N
750 CD N
mg NNS N
m NN N
( ( N
-2 NNP N
) ) N
. . N

IFN-beta NNP i
was VBD N
injected VBN N
intramuscularly RB N
three CD N
times NNS N
weekly RB N
at IN N
9 CD N
M NNP N
IU NNP N
. . N

Treatment NNP N
continued VBD N
for IN N
52 CD N
weeks NNS N
, , N
or CC N
until IN N
disease JJ o
progression NN o
or CC N
intolerable JJ o
toxicity NN o
. . o

Clinical JJ N
endpoints NNS N
were VBD N
tumor JJ o
response NN o
, , o
time NN o
to TO o
progression NN o
, , o
survival NN o
and CC o
toxicity NN o
. . o

The DT N
addition NN N
of IN N
IFN-3 NNP i
to TO i
5-FU CD i
significantly RB N
improved VBN o
response NN o
rate NN o
( ( N
33.3 CD N
% NN N
vs JJ N
4.5 CD N
% NN N
for IN N
evaluable JJ N
patients NNS N
; : N
P NNP N
= NNP N
0.021 CD N
) ) N
, , N
time NN o
to TO o
progression NN o
( ( N
median JJ N
7.2 CD N
vs JJ N
4.2 CD N
months NNS N
; : N
P NNP N
= NNP N
0.0435 CD N
) ) N
, , N
and CC N
survival JJ o
time NN o
( ( N
median JJ N
15.9 CD N
vs JJ N
7.2 CD N
months NNS N
; : N
P NNP N
= NNP N
0.038 CD N
) ) N
without IN N
significantly RB N
increasing VBG N
toxicity NN o
compared VBN N
to TO N
5-FU JJ N
alone RB N
. . N

Cumulative JJ o
5-FU JJ o
dose NN o
was VBD N
higher JJR N
with IN N
combined JJ N
therapy NN N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
: : N
more JJR N
patients NNS N
receiving VBG N
monotherapy JJ N
discontinued VBN N
treatment NN N
because IN N
of IN N
disease NN o
progression NN o
. . o

Fever NNP o
was VBD N
more RBR N
frequent JJ N
with IN N
combined JJ N
therapy NN N
( ( N
P NNP N
= NNP N
0.008 CD N
) ) N
; : N
there EX N
were VBD N
no DT N
other JJ N
differences NNS N
in IN N
toxicity NN o
. . o

The DT N
only JJ N
grade NN o
IV NNP o
toxicity NN o
observed VBD N
was VBD N
neutropenia JJ N
( ( N
two CD N
patients NNS N
per IN N
group NN N
) ) N
. . N

A DT N
randomized JJ N
phase NN N
III NNP N
trial NN N
has VBZ N
been VBN N
initiated VBN N
to TO N
confirm VB N
the DT N
synergy NN N
between IN N
5-FU JJ i
and CC N
IFN-beta NNP i
. . i

-DOCSTART- -19368937- O O

[ NNS N
Randomized NNP N
clinical JJ N
trial NN N
between IN N
nutritional JJ i
counselling NN i
and CC N
commercial JJ N
hypocaloric NN i
diet NN i
in IN N
weight JJ N
loss NN N
in IN N
obese JJ p
patients NNS p
with IN p
chronic JJ p
arthropathy JJ p
] NN p
. . N

BACKGROUND NNP N
AND CC N
OBJECTIVE NNP N
The DT N
aim NN N
of IN N
our PRP$ N
work NN N
was VBD N
to TO N
evaluate VB N
in IN N
obese JJ p
patients NNS p
with IN p
an DT p
indication NN p
of IN p
replacement NN p
surgery NN p
for IN p
degenerative JJ p
osteoarthritis NN p
, , N
the DT N
utility NN N
of IN N
a DT N
hypocaloric JJ N
diet NN N
with IN N
Optisource NNP i
vs FW N
nutritional JJ N
counseling NN N
. . N

MATERIAL NNP N
AND NNP N
METHOD NNP N
Thirty NNP p
six CD p
patients NNS p
were VBD p
randomized VBN p
in IN N
both DT N
branches NNS N
: : N
diet JJ i
I PRP i
with IN i
lunch NN i
and CC i
dinner NN i
substituted VBN i
by IN i
two CD i
Optisource NNP i
( ( N
1109,3 CD N
kcal/day NN N
, , N
166,4g CD N
of IN N
carbohydrates NNS N
( ( N
60 CD N
% NN N
) ) N
, , N
63g CD N
of IN N
proteins NNS N
( ( N
23 CD N
% NN N
) ) N
, , N
21,3g CD N
of IN N
lipids NNS N
17 CD N
% NN N
) ) N
and CC N
diet JJ N
II NNP i
with IN i
nutritional JJ i
counselling VBG i
with IN i
a DT i
decrease NN i
of IN i
500 CD i
cal/day NN i
from IN i
the DT i
previous JJ i
dietary JJ i
intake NN i
. . i

Before IN N
and CC N
3 CD N
months NNS N
after IN N
treatment NN N
, , N
a DT N
nutritional JJ N
and CC N
biochemical JJ N
study NN N
was VBD N
performed VBN N
. . N

RESULTS NNP N
Nineteen JJ N
patients NNS N
were VBD N
randomized VBN N
in IN N
group NN N
I PRP N
and CC N
17 CD N
patients NNS N
in IN N
group NN N
II NNP N
. . N

19 CD N
patients NNS N
finished VBD N
the DT N
study NN N
in IN N
group NN N
I PRP N
and CC N
14 CD N
in IN N
group NN N
II NNP N
. . N

Weight NNP o
loss NN o
was VBD N
higher RBR N
in IN N
group NN N
I PRP N
than IN N
II NNP N
( ( N
7,7 CD N
[ RB N
4,7 CD N
] JJ N
vs NN N
3,92 CD N
[ NN N
3,32 CD N
] NNP N
kg NN N
; : N
P=.05 NNP N
) ) N
, , N
with IN N
a DT N
significant JJ N
decrease NN N
of IN N
HOMA NNP o
and CC o
diastolic JJ o
blood NN o
pressure NN o
in IN N
group NN N
I. NNP N
Decreases NNP N
of IN N
body NN o
mass NN o
index NN o
( ( N
-2,9 NNP N
[ VBZ N
1,8 CD N
] NN N
vs NN N
-1,4 NNP N
[ VBZ N
0,9 CD N
] NN N
; : N
P=.05 NNP N
) ) N
, , N
fat JJ o
mass NN o
( ( N
-3,8 JJ N
[ $ N
3,4 CD N
] NNP N
vs NN N
-2,3 NNP N
[ VBZ N
1,7 CD N
] NN N
kg NN N
; : N
P=.0,05 NNP N
) ) N
and CC N
HOMA NNP o
( ( N
-2,0 NNP N
[ VBZ N
2,2 CD N
] NN N
vs NN N
-0,4 NNP N
[ VBZ N
1,82 CD N
] NN N
; : N
P=.05 NNP N
) ) N
were VBD N
higher JJR N
in IN N
group NN N
I PRP N
than IN N
II NNP N
. . N

CONCLUSIONS NNP N
Obese JJ p
patients NNS p
with IN p
chronic JJ p
osteoarthritis NN p
treated VBN N
with IN N
a DT N
mixed JJ N
diet NN N
supplemented VBN N
with IN N
a DT N
commercial JJ i
hypocaloric NN i
formula NN i
improved VBD N
weight NN o
, , o
fat JJ o
mass NN o
and CC o
HOMA NNP o
in IN N
a DT N
better JJR N
way NN N
than IN N
patients NNS N
treated VBN N
with IN N
a DT N
dietary JJ i
counselling NN i
alone RB N
. . N

-DOCSTART- -24694748- O O

Cobedding NN i
of IN i
twin JJ i
premature NN i
infants NNS i
: : i
calming VBG N
effects NNS o
on IN N
pain NN o
responses NNS o
. . o

BACKGROUND IN N
The DT N
purpose NN N
of IN N
this DT N
trial NN N
was VBD N
to TO N
determine VB N
whether IN N
cobedding VBG i
of IN i
preterm NN i
twins NNS i
has VBZ N
analgesic JJ o
effects NNS o
during IN N
heel NN N
lancing VBG N
or CC N
not RB N
. . N

METHODS NNP N
One CD p
hundred VBD p
premature NN p
twins NNS p
( ( p
50 CD p
sets NNS p
) ) p
born VBP p
between IN p
26 CD p
weeks NNS p
' POS p
and CC p
34 CD p
weeks NNS p
' POS p
gestation NN p
undergoing VBG p
heel NN p
blood NN p
sampling VBG p
were VBD N
randomly RB N
assigned VBN N
into IN N
two CD N
groups NNS N
: : N
the DT N
cobedding VBG i
group NN i
( ( i
receiving VBG i
care NN i
in IN i
the DT i
same JJ i
incubator NN i
) ) i
and CC N
the DT N
standard JJ i
care NN i
group NN i
( ( i
receiving VBG i
care NN i
in IN i
separate JJ i
incubators NNS i
) ) i
. . i

Pain NN o
was VBD o
assessed VBN o
using VBG o
the DT o
premature NN o
infant NN o
pain NN o
profile IN o
score NN o
. . o

Duration NN o
of IN o
crying NN o
was VBD N
measured VBN N
after IN N
heel NN N
blood NN N
sampling NN N
, , N
and CC N
salivary JJ o
cortisol NN o
was VBD N
measured VBN N
prior RB N
to TO N
and CC N
after IN N
heel NN N
blood NN N
sampling VBG N
. . N

RESULTS JJ N
Infants NNS N
in IN N
the DT N
standard NN i
care NN i
group NN N
cried VBD o
for IN o
a DT o
longer JJR o
time NN o
during IN N
heel NN N
lancing VBG N
than IN N
those DT N
in IN N
the DT N
cobedding NN i
group NN N
( ( N
42.6 CD N
? . N
19.8 CD N
seconds NNS N
vs. FW N
36.4 CD N
? . N
21.7 CD N
seconds NNS N
, , N
p NN N
= NNP N
0.03 CD N
) ) N
. . N

The DT o
mean JJ o
premature NN o
infant NN o
pain NN o
profile IN o
score NN o
after IN o
heel NN N
lancing NN N
was VBD o
significantly RB o
higher JJR o
in IN o
the DT i
standard NN i
care NN i
group NN i
( ( N
9.8 CD N
? . N
2.6 CD N
vs. IN N
8.06 CD N
? . N
2.8 CD N
, , N
p NN N
= NNP N
0.002 CD N
) ) N
. . N

The DT N
mean JJ o
salivary JJ o
cortisol NN o
after IN o
heel NN N
lancing NN N
was VBD N
also RB N
significantly RB o
higher RBR o
in IN o
the DT N
standard NN i
care NN i
group NN i
( ( N
24.3 CD N
? . N
7.4 CD N
nmol/L JJ N
vs. FW N
20.8 CD N
? . N
7.4 CD N
nmol/L NN N
, , N
p NN N
= NNP N
0.02 CD N
) ) N
. . N

No DT o
significant JJ o
adverse JJ o
effects NNS o
were VBD o
seen VBN N
with IN i
cobedding VBG i
. . i

CONCLUSION NNP i
Cobedding NNP i
is VBZ i
a DT i
comforting JJ N
measure NN p
for IN p
twin JJ p
premature NN p
infants NNS p
during IN p
heel NN N
lancing NN N
, , N
which WDT N
can MD N
be VB N
performed VBN N
without IN N
any DT N
significant JJ o
adverse JJ o
effects NNS o
. . o

-DOCSTART- -24437202- O O

[ JJ N
Rehabilitation NNP N
of IN N
the DT N
patients NNS p
presenting VBG p
with IN p
combined JJ p
pathology NN p
: : p
dyscirculatory NN p
encephalopathy NN p
and CC p
climacteric JJ p
syndrome NN p
] NN p
. . p

The DT N
present JJ N
paper NN N
reports VBZ N
the DT N
data NNS N
on IN N
rehabilitation NN p
of IN p
women NNS p
presenting VBG p
with IN p
combined JJ p
pathology NN p
: : p
dyscirculatory NN p
encephalopathy NN p
and CC p
climacteric JJ p
syndrome NN p
. . p

It PRP N
is VBZ N
shown VBN N
that IN N
the DT N
introduction NN N
of IN N
ozonotherapy NN i
and CC i
klimadynon NN i
, , N
a DT N
herbal JJ N
medicine NN N
possessed VBN N
of IN N
the DT N
estrogen-like JJ N
action NN N
, , N
into IN N
combined VBN N
rehabilitative JJ N
treatment NN N
ensures VBZ N
the DT N
significant JJ N
improvement NN N
of IN N
the DT N
parameters NNS N
of IN N
interest NN N
, , N
such JJ N
as IN N
climacteric NN o
symptoms NNS o
, , o
short-term JJ o
memory NN o
, , o
lipid JJ o
profile NN o
, , o
endothelial JJ o
function NN o
, , o
cerebral JJ o
circulation NN o
, , o
and CC o
quality NN o
of IN o
life NN o
. . o

-DOCSTART- -2990708- O O

Intensive JJ i
induction NN i
chemotherapy NN i
for IN N
small JJ N
cell NN N
anaplastic JJ N
carcinoma NN N
of IN N
the DT N
lung NN N
. . N

The DT N
role NN N
of IN N
intensive JJ i
induction NN i
chemotherapy NN i
in IN N
small JJ N
cell NN N
cancer NN N
of IN N
the DT N
lung NN N
remains VBZ N
unclear JJ N
. . N

Twenty-eight JJ p
newly RB p
diagnosed VBN p
patients NNS p
with IN p
small JJ p
cell NN p
lung NN p
cancer NN p
were VBD N
randomized VBN N
to TO N
receive VB N
either DT N
high-dose JJ i
or CC i
standard-dose JJ i
cyclophosphamide NN i
, , i
vincristine NN i
, , i
and CC i
semustine NN i
in IN N
a DT N
trial NN N
where WRB N
the DT N
dose NN N
of IN N
induction NN N
chemotherapy NN N
was VBD N
the DT N
sole JJ N
treatment NN N
variable JJ N
. . N

Complete JJ o
responses NNS o
( ( o
CR NNP o
) ) o
were VBD N
achieved VBN N
in IN N
57 CD N
% NN N
of IN N
patients NNS N
receiving VBG N
high-dose JJ N
therapy NN N
as IN N
compared VBN N
to TO N
21 CD N
% NN N
of IN N
patients NNS N
receiving VBG N
standard-dose JJ N
therapy NN N
( ( N
P NNP N
less JJR N
than IN N
0.05 CD N
) ) N
. . N

There EX N
was VBD N
a DT N
higher JJR N
rate NN N
of IN N
severe JJ o
toxicity NN o
in IN N
the DT N
high-dose JJ N
group NN N
( ( N
P NNP N
less JJR N
than IN N
0.01 CD N
) ) N
. . N

The DT N
overall JJ o
median JJ o
survival NN o
was VBD N
not RB N
improved VBN N
( ( N
36 CD N
weeks NNS N
for IN N
the DT N
high-dose JJ N
group NN N
vs VBD N
43 CD N
weeks NNS N
for IN N
the DT N
standard-dose JJ N
group NN N
) ) N
; : N
however RB N
, , N
the DT N
median JJ o
survival NN o
in IN N
patients NNS N
achieving VBG N
CR NNP N
was VBD N
prolonged VBN N
( ( N
92 CD N
weeks NNS N
for IN N
the DT N
high-dose JJ N
group NN N
vs VBD N
50 CD N
weeks NNS N
for IN N
the DT N
standard-dose JJ N
group NN N
) ) N
. . N

These DT N
effects NNS N
were VBD N
most RBS N
pronounced VBN N
in IN N
patients NNS p
with IN p
extensive JJ p
disease NN p
; : p
a DT N
CR NNP o
after IN N
induction NN N
was VBD N
achieved VBN N
in IN N
five CD N
of IN N
nine CD N
patients NNS N
treated VBN N
with IN N
high JJ N
doses NNS N
but CC N
not RB N
in IN N
any DT N
of IN N
those DT N
treated VBN N
with IN N
standard JJ N
doses NNS N
( ( N
P NNP N
less JJR N
than IN N
0.05 CD N
) ) N
. . N

A NNP N
small JJ N
group NN N
of IN N
patients NNS N
appear VBP N
to TO N
benefit VB N
by IN N
achieving VBG N
a DT N
long-term JJ N
remission NN N
with IN N
intensive JJ N
induction NN N
chemotherapy NN N
, , N
but CC N
this DT N
effect NN N
may MD N
be VB N
offset VBN N
by IN N
increased JJ N
morbidity NN N
. . N

-DOCSTART- -4716523- O O

Truncal JJ o
vagotomy NN o
and CC o
drainage NN o
for IN N
duodenal JJ o
ulcer NN o
. . o

-DOCSTART- -25629971- O O

The DT p
effect NN p
of IN p
power NN p
asymmetries NNS p
on IN p
cooperation NN o
and CC o
punishment NN o
in IN o
a DT o
prisoner NN o
's POS o
dilemma JJ o
game NN o
. . o

Recent JJ N
work NN N
has VBZ N
suggested VBN N
that IN N
punishment NN i
is VBZ N
detrimental JJ N
because IN N
punishment NN N
provokes NNS N
retaliation NN N
, , N
not RB N
cooperation NN N
, , N
resulting VBG N
in IN N
lower JJR N
overall JJ N
payoffs NNS N
. . N

These DT N
findings NNS N
may MD N
stem VB N
from IN N
the DT N
unrealistic JJ N
assumption NN N
that IN N
all DT N
players NNS N
are VBP N
equal JJ N
: : N
in IN N
reality NN N
individuals NNS N
are VBP N
expected VBN N
to TO N
vary VB N
in IN N
the DT N
power NN N
with IN N
which WDT N
they PRP N
can MD N
punish VB N
defectors NNS N
. . N

Here RB N
, , N
we PRP N
allowed VBD N
strong JJ p
players NNS p
to TO p
interact VB p
with IN p
weak JJ p
players NNS p
in IN p
an DT p
iterated JJ i
prisoner NN i
's POS i
dilemma JJ i
game NN i
with IN i
punishment NN i
. . i

Defecting VBG N
players NNS N
were VBD N
most RBS N
likely JJ N
to TO N
switch VB N
to TO N
cooperation VB N
if IN N
the DT N
partner NN N
cooperated VBD N
: : N
adding VBG N
punishment NN i
yielded VBN N
no DT N
additional JJ N
benefit NN N
and CC N
, , N
under IN N
some DT N
circumstances NNS N
, , N
increased VBD N
the DT N
chance NN N
that IN N
the DT N
partner NN N
would MD N
both VB N
defect JJ N
and CC N
retaliate VB N
against IN N
the DT N
punisher NN N
. . N

Our PRP$ N
findings NNS N
show VBP N
that IN N
, , N
in IN N
a DT N
two-player JJ i
game NN i
, , N
cooperation NN o
begets NNS N
cooperation NN N
and CC N
that DT N
punishment NN N
does VBZ N
not RB N
seem VB N
to TO N
yield VB N
any DT N
additional JJ N
benefits NNS N
. . N

Further JJ N
work NN N
should MD N
explore VB N
whether IN N
strong JJ N
punishers NNS N
might MD N
prevail VB N
in IN N
multi-player JJ N
games NNS N
. . N

-DOCSTART- -15312096- O O

Evaluation NN N
of IN N
additional JJ N
amine NN i
fluoride/stannous JJ i
fluoride-containing JJ i
mouthrinse NN i
during IN N
supportive JJ N
therapy NN N
in IN N
patients NNS p
with IN p
generalized JJ p
aggressive JJ p
periodontitis NN p
. . p

A DT N
randomized JJ N
, , N
crossover RB N
, , N
double-blind NN N
, , N
controlled VBN N
trial NN N
. . N

OBJECTIVES CC N
The DT N
objective NN N
of IN N
the DT N
present JJ N
randomized NN N
controlled VBD N
trial NN N
was VBD N
to TO N
evaluate VB N
the DT N
efficacy NN N
of IN N
a DT N
mouthrinse NN i
containing VBG i
a DT i
combination NN i
of IN i
AmF/SnF2 NNP i
in IN N
controlling VBG N
supragingival JJ N
plaque NN N
accumulation NN N
and CC N
gingival JJ N
inflammation NN N
during IN N
a DT N
12-week JJ N
period NN N
in IN N
patients NNS p
affected VBN p
by IN p
generalized JJ p
aggressive JJ p
periodontitis NN p
( ( p
GAP NNP p
) ) p
. . p

METHODS NNP N
Eighteen NNP p
subjects NNS p
, , p
six CD p
males NNS p
and CC p
12 CD p
females NNS p
, , p
mean JJ p
age NN p
: : p
32.2 CD p
years NNS p
, , p
were VBD p
evaluated VBN p
. . p

One-half NN N
of IN N
the DT N
patients NNS N
was VBD N
either RB N
prescribed VBN N
an DT N
AmF/SnF2-containing JJ i
mouthrinse NN i
( ( N
test JJS N
mouthrinse NN N
) ) N
or CC N
a DT N
control NN i
mouthrinse NN i
in IN N
addition NN N
to TO N
mechanical JJ i
plaque NN i
control NN i
for IN N
12 CD N
weeks NNS N
. . N

After IN N
a DT N
2-week JJ N
wash-out JJ N
period NN N
, , N
the DT N
patients NNS N
received VBD N
the DT N
alternative JJ N
mouthrinse NN i
. . i

Before IN N
and CC N
after IN N
treatment NN N
plaque NN o
index NN o
( ( o
PlI NNP o
) ) o
, , o
gingival JJ o
index NN o
( ( o
GI NNP o
) ) o
, , o
angulated VBD o
bleeding VBG o
index NN o
( ( o
AngBI NNP o
) ) o
, , o
tooth EX o
stain NN o
( ( o
GMSI NNP o
) ) o
, , o
and CC o
tongue NN o
stain NN o
were VBD N
recorded VBN N
. . N

RESULTS JJ N
Test NNP i
mouthrinse NN i
resulted VBD N
in IN N
a DT N
statistically RB N
significant JJ N
decrease NN N
in IN N
PlI NNP o
( ( N
p JJ N
= NNP N
0.029 CD N
) ) N
and CC N
GI NNP N
( ( N
p JJ N
= NNP N
0.017 CD N
) ) N
. . N

After IN N
treatment NN N
, , N
PlI NNP o
was VBD N
significantly RB N
lower JJR N
in IN N
test NN N
compared VBN N
to TO N
control VB N
mouthrinse NN N
( ( N
p JJ N
= NNP N
0.027 CD N
) ) N
. . N

GMSI NNP o
significantly RB N
increased VBD N
post-treatment NN N
for IN N
both DT N
mouthrinse NN i
regimens VBZ i
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
, , N
a DT N
significantly RB N
higher JJR N
score NN N
being VBG N
observed VBN N
for IN N
the DT N
test NN N
compared VBN N
to TO N
control VB i
mouthrinse NN i
( ( N
p JJ N
= NNP N
0.002 CD N
) ) N
. . N

CONCLUSIONS VB N
The DT N
12-week JJ N
use NN N
of IN N
a DT N
AmF/SnF2-containing JJ i
mouthrinse NN i
as IN N
an DT N
adjunct NN N
to TO N
conventional JJ N
mechanical JJ N
oral JJ N
hygiene NN N
procedures NNS N
in IN N
GAP NNP p
patients NNS p
was VBD N
effective JJ N
in IN N
controlling VBG N
the DT N
amount NN N
of IN N
supragingival JJ N
plaque NN N
deposits NNS N
. . N

-DOCSTART- -12358871- O O

Multifaceted VBN i
support NN i
to TO N
improve VB N
clinical JJ N
decision NN N
making NN N
in IN N
diabetes NNS N
care NN N
: : N
a DT N
randomized NN N
controlled VBN N
trial NN N
in IN N
general JJ N
practice NN N
. . N

AIMS NNP N
To TO N
evaluate VB N
the DT N
effectiveness NN N
of IN N
a DT N
multifaceted VBN i
intervention NN i
to TO N
improve VB N
the DT N
clinical JJ N
decision NN N
making NN N
of IN N
general JJ p
practitioners NNS p
( ( p
GPs NNP p
) ) p
for IN p
patients NNS p
with IN p
diabetes NNS p
. . p

To TO N
identify VB N
practice NN N
characteristics NNS N
which WDT N
predict VBP N
success NN N
. . N

METHODS NNP N
Cluster NNP p
randomized VBD p
controlled VBN p
trial NN p
with IN p
124 CD p
practices NNS p
and CC p
185 CD p
GPs NNP p
in IN p
The DT p
Netherlands NNP p
. . p

The DT i
intervention NN i
group NN i
received VBD i
feedback JJ i
reports NNS i
and CC i
support NN i
from IN i
a DT i
facilitator NN i
; : i
the DT i
control NN i
group NN i
received VBD i
no DT i
special JJ i
attention NN i
. . i

Outcome JJ i
measures NNS i
were VBD i
the DT i
compliance NN o
rates NNS o
with IN o
evidence-based JJ o
recommendations NNS o
pertaining VBG o
to TO o
discussion NN o
of IN o
body NN o
weight NN o
control NN o
, , o
discussion NN o
of IN o
problems NNS o
with IN o
medication NN o
, , o
blood NN o
pressure NN o
measurement NN o
, , o
foot NN o
examination NN o
, , o
eye NN o
examination NN o
, , o
initiating VBG o
anti-diabetic JJ o
medication NN o
or CC o
increasing VBG o
the DT o
dosage NN o
in IN o
cases NNS o
of IN o
uncontrolled JJ o
blood NN o
glucose NN o
, , o
and CC o
scheduling VBG o
a DT o
follow-up JJ o
appointment NN o
. . o

RESULTS VB N
The DT N
GPs NNP N
reported VBD N
on IN N
their PRP$ N
clinical JJ N
decision NN N
making NN N
in IN N
1410 CD p
consultations NNS p
with IN p
Type NNP p
2 CD p
diabetic JJ p
patients NNS p
at IN p
baseline NN p
and CC p
1449 CD p
consultations NNS p
after IN N
the DT N
intervention NN N
period NN N
. . N

The DT N
intervention NN N
resulted VBD N
in IN N
statistically RB N
significant JJ N
improvement NN N
for IN N
two CD N
of IN N
the DT N
seven CD N
outcome JJ N
measures NNS N
: : N
foot NN o
examination NN o
( ( N
odds NNS N
ratio VBP N
1.68 CD N
; : N
95 CD N
% NN N
confidence NN N
interval JJ N
1.19-2.39 JJ N
) ) N
and CC N
eye NN N
examination NN o
( ( N
1.52 CD N
; : N
1.07-2.16 JJ N
) ) N
. . N

Discussion NN o
of IN o
problems NNS o
with IN o
medication NN o
showed VBD N
a DT N
near JJ N
significant JJ N
trend NN N
towards NNS N
increased VBD N
benefit NN N
for IN N
the DT N
intervention NN N
group NN N
( ( N
1.52 CD N
; : N
0.99-2.32 JJ N
) ) N
. . N

Practice NNP o
characteristics NNS o
were VBD N
not RB N
found VBN N
to TO N
be VB N
related VBN N
to TO N
the DT N
success NN N
of IN N
the DT N
intervention NN N
. . N

CONCLUSIONS NNP N
Feedback NNP N
reports NNS N
with IN N
support NN N
from IN N
facilitators NNS N
appear VBP N
to TO N
increase VB N
rates NNS N
of IN N
foot NN o
examination NN o
and CC o
eye NN o
examination NN o
in IN N
general JJ N
practice NN N
. . N

Alternative JJ N
interventions NNS N
should MD N
be VB N
explored VBN N
to TO N
improve VB N
the DT N
pursuit NN N
of IN N
metabolic JJ N
control NN N
by IN N
GPs NNP N
. . N

-DOCSTART- -9349928- O O

A DT N
drug NN N
interaction NN N
study NN N
between IN N
ticlopidine NN i
and CC N
cyclosporin NN i
in IN N
heart NN p
transplant NN p
recipients NNS p
. . p

OBJECTIVES NNP N
Previous NNP N
uncontrolled JJ N
studies NNS N
have VBP N
suggested VBN N
an DT N
interaction NN N
between IN N
ticlopidine NN i
, , N
a DT N
major JJ N
antiplatelet NN N
agent NN N
, , N
and CC N
cyclosporin NN i
in IN N
heart- JJ N
and CC N
kidney-transplant JJ N
recipients NNS N
. . N

The DT N
aims NNS N
of IN N
this DT N
study NN N
were VBD N
to TO N
examine VB N
in IN N
a DT N
randomised JJ N
, , N
double-blind JJ N
fashion NN N
, , N
the DT N
possible JJ N
interaction NN N
between IN N
cyclosporin NN i
A NNP i
and CC i
ticlopidine NN i
( ( N
250 CD N
mg NNS N
per IN N
day NN N
) ) N
and CC N
the DT N
tolerability NN N
of IN N
this DT N
combination NN N
in IN N
heart-transplant JJ p
recipients NNS p
. . p

METHODS NNP N
Twenty NNP p
heart-transplant JJ p
recipients NNS p
were VBD p
randomised VBN p
into IN p
either CC p
a DT p
treated JJ p
or CC p
a DT p
placebo NN i
group NN p
. . p

Blood NN N
samples NNS N
were VBD N
drawn VBN N
for IN N
time-course JJ N
evaluation NN N
of IN N
cyclosporin NN N
blood NN N
levels NNS N
over IN N
a DT N
period NN N
of IN N
12 CD N
h NNS N
, , N
following VBG N
the DT N
morning NN N
intake NN N
of IN N
cyclosporin NN i
and CC N
, , N
for IN N
platelet NN N
aggregation NN N
studies NNS N
, , N
before IN N
and CC N
after IN N
14 CD N
days NNS N
of IN N
ticlopidine JJ i
administration NN N
. . N

Twenty CD N
four-hour JJ N
urine JJ N
samples NNS N
were VBD N
collected VBN N
for IN N
6-beta-hydroxycortisol JJ N
measurements NNS N
, , N
before IN N
and CC N
after IN N
14 CD N
days NNS N
of IN N
ticlopidine NN N
. . N

RESULTS NNP N
Although IN N
given VBN N
at IN N
half PDT N
the DT N
recommended JJ N
daily JJ N
dosage NN N
, , N
ticlopidine NN N
significantly RB N
reduced VBN N
platelet NN o
aggregation NN o
. . o

Pharmacokinetic JJ N
parameters NNS N
indicate VBP N
that IN N
the DT N
bioavailability NN o
of IN o
cyclosporin NN o
A NNP o
was VBD N
not RB N
significantly RB N
modified VBN N
by IN N
ticlopidine NN i
. . i

However RB N
, , N
one CD p
patient NN p
in IN p
the DT p
ticlopidine NN p
group NN p
was VBD p
withdrawn VBN p
because IN p
of IN p
a DT p
major JJ p
fall NN o
in IN o
cyclosporin JJ o
blood NN o
level NN o
within IN p
3 CD p
days NNS p
of IN p
treatment NN p
. . p

Urinary JJ o
excretion NN o
of IN o
6-beta-hydroxycortisol NNP o
was VBD N
augmented VBN N
after IN N
treatment NN N
in IN N
the DT N
ticlopidine NN i
group NN N
compared VBN N
with IN N
the DT N
placebo NN i
group NN N
, , N
suggesting VBG N
that IN N
induction NN N
of IN N
drug NN N
metabolism NN N
might MD N
have VB N
occurred VBN N
. . N

Data NNP N
also RB N
show VBP N
quite RB N
a DT N
large JJ N
intra-individual JJ N
variability NN N
in IN N
cyclosporin JJ o
bioavailability NN o
in IN N
the DT N
placebo NN i
group NN N
, , N
suggesting VBG N
that IN N
poor JJ N
absorption NN N
of IN N
the DT N
drug NN N
formulation NN N
and/or IN N
poor JJ N
compliance NN N
might MD N
have VB N
contributed VBN N
to TO N
the DT N
decreased VBN N
cyclosporin NN o
blood NN o
levels NNS o
in IN N
the DT N
patient JJ N
withdrawn NN N
from IN N
this DT N
study NN N
and CC N
in IN N
previous JJ N
uncontrolled JJ N
studies NNS N
. . N

CONCLUSION NNP N
Cyclosporin NNP o
bioavailability NN o
was VBD N
not RB N
clearly RB N
modified VBN N
by IN N
a DT N
half JJ N
dosage NN N
of IN N
ticlopidine NN i
in IN N
this DT N
study NN N
. . N

We PRP N
, , N
however RB N
, , N
recommend VBP N
closely RB N
monitoring JJ N
cyclosporin NNS N
blood NN N
levels NNS N
when WRB N
prescribing VBG N
ticlopidine NN i
. . i

Further JJ N
studies NNS N
will MD N
be VB N
needed VBN N
with IN N
new JJ N
formulations NNS N
of IN N
cyclosporin NN i
or CC N
when WRB N
using VBG N
the DT N
full JJ N
dosage NN N
of IN N
ticlopidine NN i
. . i

-DOCSTART- -25078976- O O

Pharmacokinetics NNS N
of IN N
pregabalin JJ i
controlled-release NN N
in IN N
healthy JJ p
volunteers NNS p
: : p
effect NN N
of IN N
food NN N
in IN N
five CD N
single-dose JJ N
, , N
randomized VBN N
, , N
clinical JJ N
pharmacology NN N
studies NNS N
. . N

BACKGROUND IN N
The DT N
pharmacokinetic JJ N
properties NNS N
of IN N
the DT N
immediate-release NN N
( ( N
IR NNP N
) ) N
and CC N
the DT N
recently RB N
developed VBN N
controlled-release NN N
( ( N
CR NNP N
) ) N
formulation NN N
of IN N
pregabalin NN i
are VBP N
dose JJ N
proportional JJ N
. . N

Pregabalin NNP i
IR NNP i
can MD N
be VB N
taken VBN N
with IN N
or CC N
without IN N
food NN N
. . N

OBJECTIVES CC N
This DT N
analysis NN N
characterizes VBZ N
the DT N
effect NN N
of IN N
food NN N
on IN N
pregabalin NN i
CR NNP i
. . i

The DT N
objectives NNS N
of IN N
this DT N
analysis NN N
were VBD N
: : N
( ( N
1 CD N
) ) N
to TO N
evaluate VB N
the DT N
effect NN o
of IN o
administration NN o
time NN o
and CC o
fat NN o
or CC o
caloric JJ o
content NN o
of IN N
an DT N
accompanying VBG N
meal NN N
on IN N
the DT N
pharmacokinetic JJ N
properties NNS N
of IN N
a DT N
single JJ N
dose NN N
of IN N
pregabalin NN i
CR NNP i
( ( N
330 CD N
mg NN N
) ) N
relative NN N
to TO N
a DT N
single JJ i
dose NN i
of IN i
pregabalin NN i
IR NNP i
( ( N
300 CD N
mg NN N
) ) N
; : N
( ( N
2 CD N
) ) N
to TO N
evaluate VB N
the DT o
pharmacokinetic JJ o
properties NNS o
of IN o
a DT N
single JJ N
dose NN N
of IN N
pregabalin NN i
CR NNP i
administered VBD i
fasted JJ N
relative NN N
to TO N
a DT N
single JJ N
dose NN N
of IN N
pregabalin NN i
CR NNP i
administered VBD i
immediately RB N
after IN N
food NN N
; : N
and CC N
( ( N
3 CD N
) ) N
to TO N
determine VB N
the DT o
safety NN o
and CC o
tolerability NN o
of IN o
single-dose JJ N
administration NN N
of IN N
pregabalin JJ i
CR NNP i
and CC i
IR NNP i
with IN i
and CC N
without IN N
food NN N
. . N

METHODS NNP N
The DT N
effect NN N
of IN N
food NN N
on IN N
the DT o
pharmacokinetic JJ o
properties NNS o
of IN o
pregabalin NN o
CR NNP o
was VBD o
determined VBN N
in IN N
five CD N
phase NN N
I PRP N
, , N
open-label JJ N
, , N
single-dose JJ N
, , N
crossover JJ N
studies NNS p
( ( p
24-28 JJ p
participants/study NN p
) ) p
. . p

Caloric NNP N
and CC N
fat JJ N
content NN N
of IN N
meals NNS N
were VBD N
varied VBN N
and CC N
treatments NNS N
were VBD N
administered VBN N
in IN N
the DT N
morning NN N
, , N
at IN N
midday NN N
, , N
or CC N
in IN N
the DT N
evening NN o
. . o

Blood NN o
samples NNS o
were VBD o
collected VBN N
up RB N
to TO N
48 CD N
h JJ N
post-dose JJ o
. . o

Pharmacokinetic JJ o
parameters NNS o
were VBD o
estimated VBN N
from IN o
plasma JJ o
concentration-time JJ o
data NNS o
using VBG o
standard JJ N
noncompartmental JJ N
methods NNS N
. . N

Adverse JJ N
events NNS N
were VBD N
monitored VBN N
throughout IN N
all DT N
studies NNS N
. . N

RESULTS VB p
One CD p
hundred CD p
and CC p
twenty-eight JJ p
healthy JJ p
participants NNS p
( ( p
19-54 CD p
years NNS p
of IN p
age NN p
) ) p
received VBD i
pregabalin NN o
. . o

Peak NNP o
plasma JJ o
concentrations NNS o
( ( o
C NNP o
max NN o
) ) o
were VBD o
lower JJR N
for IN N
CR NNP N
than IN N
the DT N
respective JJ N
pregabalin NN i
IR NNP i
doses VBZ N
, , N
and CC N
time NN N
to TO N
C NNP N
max NN N
occurred VBD N
later RB N
. . N

When WRB N
pregabalin NN i
CR NNP i
was VBD N
administered VBN N
with IN N
food NN N
at IN N
midday NN N
or CC N
in IN N
the DT N
evening NN o
, , o
total JJ o
exposures NNS o
[ VBP o
area NN o
under IN N
the DT N
plasma JJ N
concentration-time JJ N
curve NN N
from IN N
time NN N
zero CD N
extrapolated VBN N
to TO N
infinite VB N
time NN N
( ( N
AUC? NNP N
) ) N
] WDT N
were VBD N
equivalent JJ N
for IN N
pregabalin NN N
CR NNP N
and CC N
IR NNP N
formulations NNS N
regardless RB N
of IN N
fat NN N
or CC N
caloric JJ N
content NN N
. . N

When WRB N
pregabalin NN i
CR NNP i
was VBD i
administered VBN N
with IN N
an DT N
800-1,000 JJ N
calorie NN N
medium-fat JJ N
breakfast NN o
, , o
AUC? NNP o
was VBD N
equivalent JJ N
for IN N
pregabalin NN N
CR NNP N
and CC N
IR NNP N
. . o

Bioequivalence NNP o
criteria NNS o
for IN N
comparison NN N
of IN N
pregabalin NN N
CR NNP N
after IN N
a DT N
low- JJ N
or CC N
medium-calorie JJ N
breakfast NN N
relative NN N
to TO i
pregabalin VB i
IR NNP i
were VBD i
not RB N
met VBN N
; : N
however RB N
, , N
bioavailability NN i
of IN i
the DT i
pregabalin NN i
CR NNP i
vs. IN i
IR NNP i
formulation NN N
was VBD N
relatively RB N
high JJ N
( ( N
75-86 CD N
% NN N
) ) N
. . i

When WRB i
pregabalin NN i
CR NNP i
was VBD i
administered VBN i
fasted VBN N
, , N
the DT o
AUC? NNP o
was VBD N
70-78 JJ N
% NN N
of IN N
the DT N
AUC? NNP N
of IN N
pregabalin NN N
CR NNP N
administered VBD N
with IN N
food NN N
and CC N
bioequivalence NN N
criteria NNS N
were VBD N
not RB N
met VBN N
. . N

Additionally RB N
, , N
the DT o
AUC? NNP o
of IN o
the DT o
pregabalin NN N
CR NNP N
formulation NN N
administered VBD N
fasted VBN N
was VBD N
62-69 JJ N
% NN N
of IN N
that DT N
of IN i
pregabalin NN i
IR NNP i
administered VBD N
fasted VBN N
and CC N
bioequivalence NN N
criteria NNS N
were VBD N
not RB N
met VBN N
. . N

Single-dose JJ i
pregabalin NN i
CR NNP i
and CC i
IR NNP o
were VBD o
well RB o
tolerated VBN o
in IN o
all DT N
studies NNS N
, , N
with IN N
no DT o
serious JJ o
or CC o
severe JJ o
adverse JJ o
events NNS o
reported VBN o
. . N

CONCLUSION NNP N
Time NNP N
of IN N
day NN N
of IN N
administration NN N
and CC N
the DT N
fat NN N
and CC N
caloric JJ N
content NN N
of IN N
the DT N
accompanying VBG N
meal NN N
had VBD o
minimal JJ o
overall JJ o
effect NN o
on IN o
the DT N
pharmacokinetic JJ N
properties NNS N
and CC N
bioavailability NN N
of IN N
the DT i
pregabalin NN i
CR NNP N
formulation NN N
. . N

-DOCSTART- -15053783- O O

Metoprolol NNP i
CR/XL NNP i
improves VBZ N
systolic JJ o
and CC o
diastolic JJ o
left VBD o
ventricular JJ o
function NN o
in IN N
patients NNS p
with IN p
chronic JJ p
heart NN p
failure NN p
. . p

AIMS NNP N
To TO N
investigate VB N
whether IN N
metoprolol NN i
controlled VBN i
release/extended VBD i
release NN i
( ( i
CR/XL NNP i
) ) i
once RB N
daily RB N
would MD N
improve VB N
diastolic NN o
and CC o
systolic JJ o
left VBD o
ventricular JJ o
function NN o
in IN N
patients NNS p
with IN p
chronic JJ p
heart NN p
failure NN p
and CC p
decreased JJ p
ejection NN p
fraction NN p
. . p

METHODS NNP N
In IN N
an DT N
echocardiographic JJ N
substudy NN N
to TO N
the DT N
Metoprolol NNP i
CR/XL NNP i
Randomized NNP N
Intervention NNP N
Trial NNP N
in IN N
Heart NNP N
Failure NNP N
( ( N
MERIT-HF NNP N
) ) N
, , N
66 CD p
patients NNS p
were VBD p
examined VBN p
three CD N
times NNS N
during IN N
a DT N
12-month JJ N
period NN N
blinded VBD N
to TO N
treatment NN N
group NN N
, , N
assessing VBG N
left VBD o
ventricular JJ o
dimensions NNS o
and CC o
ejection NN o
fraction NN o
, , o
and CC o
Doppler NNP o
mitral JJ o
inflow NN o
parameters NNS o
, , N
all DT N
measured VBN N
in IN N
a DT N
core NN N
laboratory NN N
. . N

RESULTS NNP N
In IN N
the DT N
metoprolol NN i
CR/XL NNP i
group NN N
left VBD o
ventricular JJ o
ejection NN o
fraction NN o
increased VBD N
from IN N
0.26 CD N
to TO N
0.31 CD N
( ( N
P NNP N
= NNP N
0.009 CD N
) ) N
after IN N
a DT N
mean JJ N
observation NN N
period NN N
of IN N
10.6 CD N
months NNS N
, , N
and CC N
deceleration NN N
time NN o
of IN o
the DT o
early JJ o
mitral JJ o
filling NN o
wave NN o
( ( N
E NNP N
) ) N
increased VBD N
from IN N
189 CD N
to TO N
246 CD N
ms NN N
( ( N
P NNP N
= NNP N
0.0012 CD N
) ) N
, , N
time NN o
velocity JJ o
integral JJ o
of IN o
E-wave NNP o
increased VBD N
from IN N
8.7 CD N
to TO N
11.2 CD N
cm NN N
( ( N
P NNP N
= NNP N
0.018 CD N
) ) N
, , N
and CC N
the DT N
duration NN o
of IN o
the DT o
late JJ o
mitral JJ o
filling NN o
wave NN o
( ( N
A NNP N
) ) N
increased VBD N
from IN N
122 CD N
to TO N
145 CD N
ms NN N
( ( N
P NNP N
= NNP N
0.014 CD N
) ) N
. . N

No DT N
significant JJ N
changes NNS N
were VBD N
seen VBN N
in IN N
the DT N
placebo NN i
group NN N
regarding VBG N
any DT N
of IN N
these DT N
variables NNS N
. . N

CONCLUSION NNP N
Metoprolol NNP i
CR/XL NNP i
once RB N
daily RB N
in IN N
addition NN N
to TO N
standard VB N
therapy NN N
improved VBN N
both DT N
diastolic JJ o
and CC o
systolic JJ o
function NN o
in IN N
patients NNS p
with IN p
chronic JJ p
heart NN p
failure NN p
and CC p
decreased JJ p
ejection NN p
fraction NN p
. . p

-DOCSTART- -17076630- O O

A DT N
comparative JJ N
analysis NN N
of IN N
the DT N
effects NNS N
of IN N
the DT N
fixed JJ N
combination NN i
of IN i
timolol NN i
and CC i
dorzolamide VB i
versus NN N
latanoprost NN i
plus CC i
timolol NN i
on IN N
ocular JJ o
hemodynamics NNS o
and CC o
visual JJ o
function NN o
in IN N
patients NNS p
with IN p
primary JJ p
open-angle JJ p
glaucoma NN p
. . p

AIMS IN N
The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
assess VB N
the DT N
effects NNS N
of IN N
fixed JJ N
combination NN N
of IN N
timolol NN i
and CC i
dorzolamide NN i
and CC i
latanoprost NN i
plus CC i
timolol NN i
on IN N
retinal JJ o
, , o
choroidal JJ o
, , o
and CC o
retrobulbar NN o
hemodynamics NNS o
and CC N
visual JJ o
function NN o
in IN N
primary JJ p
open-angle JJ p
glaucoma NN p
( ( p
OAG NNP p
) ) p
subjects VBZ p
. . p

METHODS NNP N
Sixteen NNP p
( ( p
16 CD p
) ) p
OAG NN p
patients NNS p
( ( p
age NN p
, , p
63.5 CD p
+/- JJ p
10.8 CD p
years NNS p
; : p
9 CD p
male NN p
) ) p
were VBD N
evaluated VBN N
in IN N
a DT N
randomized JJ N
, , N
crossover RB N
, , N
double-blind JJ N
study NN N
design NN N
after IN N
4 CD N
weeks NNS N
of IN N
treatment NN N
of IN N
latanoprost NN i
with IN i
timolol NN i
and CC N
fixed JJ N
combination NN N
of IN N
timolol NN i
and CC i
dorzolamide NN i
. . i

After IN N
randomization NN N
, , N
9 CD p
right JJ p
eyes NNS p
and CC p
7 CD p
left JJ p
eyes NNS p
were VBD N
included VBN N
in IN N
the DT N
hemodynamic JJ N
portion NN N
of IN N
the DT N
study NN N
. . N

Measurements NNS N
included VBD N
: : N
adverse JJ o
events NNS o
check NN o
, , o
visual JJ o
acuity NN o
, , o
contrast NN o
sensitivity NN o
, , o
blood NN o
pressure NN o
, , o
heart NN o
rate NN o
, , o
intraocular JJ o
pressure NN o
( ( o
IOP NNP o
) ) o
, , o
and CC o
fundus JJ o
examination NN o
. . o

Ocular JJ o
blood NN o
flow NN o
was VBD N
assessed VBN N
using VBG N
confocal JJ N
scanning VBG N
laser NN N
Doppler NNP N
flowmetry NN N
, , N
color NN N
Doppler NNP N
imaging NN N
, , N
and CC N
scanning VBG N
laser NN N
ophthalmoscopy NN N
. . N

RESULTS NNP N
Both NNP N
therapies NNS N
were VBD N
effective JJ N
at IN N
lowering VBG N
IOP NNP o
, , N
whereas IN N
there EX N
was VBD N
no DT N
statistically RB N
significant JJ N
difference NN N
between IN N
latanoprost NN i
plus CC i
timolol NN i
and CC N
the DT N
fixed JJ N
combination NN i
of IN i
timolol NN i
and CC i
dorzolamide NN i
( ( N
13.9 CD N
% NN N
and CC N
12.2 CD N
% NN N
reduction NN N
, , N
respectively RB N
; : N
P NNP N
= NNP N
0.5533 CD N
) ) N
. . N

Fixed VBN N
combination NN i
of IN i
timolol NN i
and CC i
dorzolamide VB i
significantly RB N
increased JJ N
central JJ o
retinal JJ o
artery NN o
end NN o
diastolic NN o
blood NN o
flow NN o
velocity NN o
( ( N
P NNP N
= NNP N
0.0168 CD N
) ) N
and CC N
lowered VBD N
resistance NN o
to TO o
flow VB o
( ( N
P NNP N
= NNP N
0.0279 CD N
) ) N
. . N

Temporal JJ o
posterior JJ o
ciliary JJ o
artery NN o
peak NN o
systolic NN o
and CC o
end VB o
diastolic JJ o
velocities NNS o
were VBD N
significantly RB N
increased VBN N
with IN N
the DT N
fixed JJ N
combination NN i
of IN i
timolol NN i
and CC i
dorzolamide NN i
( ( N
P NNP N
= NNP N
0.0125 CD N
and CC N
0.0238 CD N
, , N
respectively RB N
) ) N
. . N

Latanoprost NNP i
plus CC i
timolol NN i
had VBD N
no DT N
significant JJ N
effects NNS N
on IN N
ocular JJ o
blood NN o
flow NN o
during IN N
4 CD N
weeks NNS N
of IN N
treatment NN N
. . N

There EX N
were VBD N
no DT N
statistically RB N
significant JJ N
differences NNS N
in IN N
adverse JJ o
events NNS o
, , o
blood NN o
pressure NN o
, , o
heart NN o
rate NN o
, , o
visual JJ o
acuity NN o
, , o
contrast NN o
sensitivity NN o
scanning VBG o
laser NN o
ophthalmoscopy NN o
, , o
or CC o
Heidelberg NNP o
Retinal NNP o
Flowmeter NNP o
for IN N
any DT N
treatment NN N
period NN N
. . N

CONCLUSIONS NNP N
Fixed NNP N
combination NN i
of IN i
timolol NN i
and CC i
dorzolamide JJ i
therapy NN N
might MD N
increase VB N
blood NN o
flow NN o
in IN N
OAG NNP p
patients NNS p
while IN N
attaining VBG N
a DT N
similar JJ N
IOP NNP o
reduction NN N
compared VBN N
to TO N
latanoprost VB i
plus JJ i
timolol NN i
. . i

Visual JJ o
function NN o
, , N
however RB N
, , N
was VBD N
not RB N
different JJ N
in IN N
this DT N
short-term JJ N
comparison NN N
between IN N
the DT N
two CD N
treatments NNS N
. . N

-DOCSTART- -19508318- O O

One-year JJ N
follow-up NN N
of IN N
the DT N
outcome NN N
of IN N
a DT N
randomized VBN N
controlled JJ N
trial NN N
of IN N
a DT N
home-based JJ i
intervention NN i
programme NN i
for IN N
children NNS p
with IN p
autism NN p
and CC p
developmental JJ p
delay NN p
and CC N
their PRP$ N
families NNS N
. . N

INTRODUCTION NNP N
There EX N
is VBZ N
debate NN N
about IN N
the DT N
type NN N
and CC N
intensity NN N
of IN N
early JJ i
childhood NN i
intervention NN i
that WDT N
is VBZ N
most RBS N
helpful JJ N
for IN N
children NNS p
with IN p
developmental JJ p
problems NNS p
. . p

The DT N
aim NN N
of IN N
the DT N
study NN N
was VBD N
to TO N
determine VB N
whether IN N
a DT N
home-based JJ N
programme NN N
provided VBD N
over IN N
12 CD N
months NNS N
resulted VBN N
in IN N
sustained JJ o
improvement NN o
in IN o
development NN o
and CC o
behaviour $ o
12 CD N
months NNS N
after IN N
the DT N
intervention NN N
ceased VBD N
. . N

The DT N
characteristics NNS N
of IN N
the DT N
children NNS N
and CC N
families NNS N
who WP N
benefited VBD N
most RBS N
from IN N
the DT N
intervention NN N
were VBD N
also RB N
studied VBN N
. . N

METHOD NNP N
Randomized NNP N
controlled VBD N
trial NN N
. . N

Participants VBZ p
A DT p
total NN p
of IN p
59 CD p
children NNS p
, , p
aged VBN p
3-5 CD p
years NNS p
, , p
attending VBG p
two CD p
early JJ p
childhood NN p
intervention NN p
centres NNS p
in IN p
Melbourne NNP p
, , p
Australia NNP p
. . p

Intervention NNP i
Half NNP i
of IN i
the DT i
subjects NNS i
received VBD i
an DT i
additional JJ i
home-based JJ i
programme NN i
consisting NN i
of IN i
40 CD i
weekly JJ i
visits NNS i
. . i

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
Bayley NNP o
Scales NNP o
of IN o
Infant NNP o
Development NNP o
and CC o
Wechsler NNP o
Preschool NNP o
and CC o
Primary NNP o
Scale NNP o
of IN o
Intelligence NNP o
Revised VBD o
, , o
Preschool NNP o
Behaviour NNP o
Checklist NNP o
, , o
Bayley NNP o
Behaviour NNP o
Rating NNP o
Scale NNP o
and CC o
Behaviour NNP o
Screening NNP o
Questionnaire NNP o
. . o

All DT N
tests NNS N
administered VBD N
pre-intervention NN N
, , N
following VBG N
the DT N
intervention NN N
and CC N
12 CD N
months NNS N
later RB N
. . N

Secondary JJ N
outcome NN o
measures NNS o
Family NNP o
stress NN o
, , o
support NN o
and CC o
empowerment NN o
. . o

RESULTS NNP N
Fifty-four JJ p
children NNS p
completed VBD N
the DT N
assessments NNS N
12 CD N
months NNS N
after IN N
conclusion NN N
of IN N
the DT N
intervention NN N
. . N

Compared VBN N
with IN N
the DT N
control NN N
group NN N
, , N
improvement NN o
in IN o
aspects NNS o
of IN o
cognitive JJ o
development NN o
in IN N
the DT N
children NNS N
who WP N
received VBD N
the DT N
extra JJ N
intervention NN N
was VBD N
sustained VBN N
1 CD N
year NN N
later RB N
( ( N
P= NNP N
0.007 CD N
) ) N
while IN N
significant JJ N
behavioural JJ o
differences NNS o
post VBN N
intervention NN N
were VBD N
not RB N
. . N

Analyses NNS N
of IN N
the DT N
data NNS N
by IN N
the DT N
Reliable NNP o
Change NNP o
Index NNP o
indicated VBD N
improvement NN N
of IN N
clinical JJ N
significance NN N
occurred VBD N
in IN N
non-verbal JJ o
areas NNS o
. . o

In IN N
contrast NN N
to TO N
the DT N
control NN N
group NN N
who WP N
deteriorated VBD N
, , N
language NN o
skills NNS o
in IN N
the DT N
intervention NN N
group NN N
remained VBD N
stable JJ N
. . N

Improvements NNS N
were VBD N
significantly RB N
associated VBN N
with IN N
higher JJR N
stress NN o
in IN N
the DT N
families NNS N
. . N

CONCLUSION NNP N
Improvements NNPS o
following VBG N
the DT N
provision NN N
of IN N
a DT N
home-based JJ N
programme NN N
to TO N
preschool VB N
children NNS N
with IN N
developmental JJ N
disabilities NNS N
were VBD N
sustained VBN N
1 CD N
year NN N
later RB N
. . N

Children NNP N
from IN N
highly RB N
stressed JJ o
families NNS N
appeared VBD N
to TO N
benefit VB N
most JJS N
, , N
reinforcing VBG N
the DT N
importance NN N
of IN N
involving VBG N
families NNS N
in IN N
early JJ N
childhood NN N
intervention NN N
programmes NNS N
. . N

-DOCSTART- -10719133- O O

Blood NNP o
pressure NN o
biofeedback NN i
treatment NN i
of IN N
white-coat JJ N
hypertension NN N
. . N

OBJECTIVE CC N
The DT N
objective NN N
of IN N
the DT N
study NN N
was VBD N
to TO N
compare VB N
blood NN o
pressure NN o
( ( o
BP NNP o
) ) o
biofeedback NN i
treatment NN i
( ( i
BF NNP i
) ) i
effects NNS N
between IN N
white-coat JJ N
hypertension NN N
and CC N
essential JJ N
hypertension NN N
. . N

METHODS NNP N
Fifteen NNP p
white-coat JJ p
hypertensive JJ p
out-patients NNS p
and CC p
23 CD p
essential JJ p
hypertensive JJ p
out-patients NNS p
were VBD N
randomly RB N
assigned VBN N
to TO N
groups NNS N
A NNP N
or CC N
B NNP N
. . N

Subjects NNS N
in IN N
group NN N
A NNP N
underwent NN N
BF NNP i
once RB N
a DT N
week NN N
for IN N
a DT N
total NN N
of IN N
four CD N
sessions NNS N
. . N

Those DT N
in IN N
group NN i
B NNP i
visited VBD i
the DT i
clinic NN i
only RB i
to TO N
measure VB N
BP NNP o
and CC N
later RB N
underwent VBD N
the DT N
same JJ N
BF NNP i
. . i

RESULTS NNP N
In IN N
group NN N
A NNP N
, , N
BPs NNP o
of IN o
white-coat JJ o
hypertensives NNS o
and CC o
essential JJ o
hypertensives NNS o
were VBD N
significantly RB N
reduced VBN N
by IN N
22/11 CD N
and CC N
14/8 CD N
mmHg NN N
, , N
respectively RB N
. . N

In IN N
group NN N
B NNP N
, , N
they PRP N
were VBD N
unchanged JJ N
during IN N
the DT N
same JJ N
period NN N
but CC N
later RB N
suppressed VBN N
by IN N
BF NNP i
. . i

Under IN N
BF NNP i
, , N
pulse NN o
and CC o
respiratory NN o
rates NNS o
were VBD N
significantly RB N
higher JJR N
, , N
and CC N
elevation NN o
of IN o
diastolic JJ o
BP NNP o
due JJ o
to TO o
mental JJ o
stress NN o
testing NN o
was VBD N
better RBR N
suppressed VBN N
in IN N
white-coat NN N
hypertensives NNS N
than IN N
in IN N
essential JJ N
hypertensives NNS N
. . N

CONCLUSION VB N
This DT N
treatment NN N
was VBD N
effective JJ N
in IN N
both DT N
types NNS N
of IN N
hypertension NN N
, , N
and CC N
pressor NN N
response NN N
to TO N
stress VB o
seems VBZ N
to TO N
be VB N
important JJ N
in IN N
the DT N
differentiated JJ N
BF NNP i
effect NN N
. . N

-DOCSTART- -25348594- O O

The DT N
effect NN N
of IN N
endoscopic NN i
fundoplication NN i
and CC i
proton NN i
pump NN i
inhibitors NNS i
on IN N
baseline NN o
impedance NN o
and CC o
heartburn NN N
severity NN o
in IN N
GERD NNP p
patients NNS p
. . p

BACKGROUND NNP N
Antireflux NNP N
therapy NN N
may MD N
lead VB N
to TO N
recovery NN N
of IN N
impaired JJ N
mucosal NN N
integrity NN N
in IN N
gastro-esophageal JJ p
reflux NN p
disease NN p
( ( p
GERD NNP p
) ) p
patients NNS p
as IN N
reflected VBN N
by IN N
an DT N
increase NN o
in IN o
baseline JJ o
impedance NN o
. . o

The DT N
study NN N
objective NN N
was VBD N
to TO N
evaluate VB N
the DT N
effect NN N
of IN N
endoscopic NN i
fundoplication NN i
and CC i
proton NN i
pump NN i
inhibitor NN i
( ( i
PPI NNP i
) ) i
PPI NNP i
therapy NN i
on IN N
baseline NN o
impedance NN o
and CC o
heartburn NN o
severity NN o
in IN N
GERD NNP p
patients NNS p
. . p

METHODS NNP N
Forty-seven JJ p
GERD NNP p
patients NNS p
randomized VBD p
to TO p
endoscopic VB i
fundoplication NN i
( ( p
n JJ p
= NNP p
32 CD p
) ) p
or CC p
PPI NNP i
therapy NN i
( ( i
n JJ p
= NNP p
15 CD p
) ) p
, , p
and CC p
29 CD p
healthy JJ p
controls NNS p
were VBD p
included VBN p
. . p

Before IN p
randomization NN N
and CC N
6 CD N
months NNS N
after IN N
treatment NN o
, , o
baseline NN o
impedance NN o
was VBD o
obtained VBN i
during IN i
24-h JJ i
pH-impedance NN i
monitoring NN o
. . o

Heartburn NNP o
severity NN o
was VBD o
evaluated VBN o
using VBG o
the DT o
GERD-HRQL NNP o
questionnaire NN o
. . o

KEY NNP o
RESULTS NNP N
Before IN N
treatment NN o
, , o
baseline NN o
impedance NN o
in IN o
GERD NNP o
patients NNS p
was VBD p
lower JJR N
than IN N
in IN p
healthy JJ p
controls NNS p
( ( p
p VB p
< RB p
0.001 CD N
) ) N
. . N

Antireflux NNP N
therapy NN N
increased VBD o
baseline JJ o
impedance NN o
( ( o
from IN o
1498 CD N
[ JJ N
IQR NNP N
951-2472 CD N
] NN N
to TO N
2393 CD N
[ NNP N
IQR NNP N
1353-3027 JJ N
] NN N
? . N
, , N
p VBZ N
= NNP N
0.001 CD N
) ) N
, , N
however RB N
it PRP N
only RB N
led VBD N
to TO o
a DT o
partial JJ o
recovery NN o
when WRB N
compared VBN N
to TO N
healthy JJ N
controls NNS N
( ( N
2393 CD N
[ NNP N
IQR NNP N
1353-3027 JJ N
] NNP N
vs NN N
2983 CD N
[ NNP N
2335-3810 JJ N
] NN N
? . N
, , N
p VBZ N
< NNP N
0.01 CD N
) ) N
. . N

The DT N
effect NN N
of IN N
both DT N
treatment NN N
options NNS N
was VBD N
not RB N
significantly RB N
different JJ N
( ( N
p JJ N
= NNP N
0.13 CD N
) ) N
despite IN N
the DT N
increased JJ N
number NN o
of IN o
non-acid JJ o
reflux NN o
events NNS o
in IN i
the DT i
PPI NNP i
group NN i
. . N

No DT o
correlation NN o
was VBD N
found VBN N
between IN o
baseline NN o
impedance NN o
and CC o
GERD NNP o
symptoms NNS o
before IN N
or CC N
after IN N
treatment NN N
. . N

CONCLUSIONS NNP N
& CC N
INFERENCES NNP N
Reduction NNP N
in IN N
acid NN N
reflux NN N
by IN N
endoscopic JJ i
fundoplication NN i
or CC i
PPI NNP i
therapy VBP i
leads VBZ N
to TO N
an DT N
increase NN N
in IN N
baseline JJ o
impedance NN o
in IN o
GERD NNP o
patients NNS p
, , p
likely RB N
to TO N
reflect VB N
recovery NN N
of IN N
mucosal NN N
integrity NN N
. . N

The DT N
impact NN N
of IN N
non-acid JJ N
reflux NN N
events NNS N
on IN N
esophageal NN N
mucosal NN N
integrity NN N
may MD N
be VB N
limited VBN N
as IN N
no DT N
difference NN N
in IN N
the DT N
increase NN N
in IN N
baseline JJ o
impedance NN o
was VBD o
observed VBN N
after IN N
both DT N
treatment NN N
options NNS N
. . N

The DT N
lack NN N
of IN N
association NN N
between IN o
impedance NN o
baseline NN o
and CC o
heartburn NN o
severity NN o
indicates VBZ o
that IN N
other JJ N
factors NNS N
may MD N
contribute VB N
to TO N
heartburn VB N
perception NN N
in IN N
GERD NNP N
. . N

-DOCSTART- -7964960- O O

Randomized VBN N
double-blind NN N
, , N
placebo-controlled JJ i
evaluation NN N
of IN N
oral JJ i
ondansetron NN i
in IN N
the DT N
prevention NN N
of IN N
nausea NN p
and CC p
vomiting NN p
associated VBN p
with IN p
fractionated JJ p
total-body JJ p
irradiation NN p
. . p

PURPOSE NNP N
To TO N
evaluate VB N
oral JJ i
ondansetron NN i
in IN N
the DT N
prevention NN N
of IN N
total-body JJ p
irradiation NN p
( ( p
TBI NNP p
) ) p
-induced VBD p
nausea NN p
and CC p
vomiting NN p
. . p

METHODS NNP N
Twenty NNP p
patients NNS p
who WP p
received VBD p
4 CD p
days NNS p
of IN p
TBI NNP p
as IN p
part NN p
of IN p
their PRP$ p
preparative JJ p
regimen NNS p
before IN p
bone NN p
marrow NN p
transplantation NN p
were VBD N
randomized VBN N
to TO N
receive VB N
either DT N
8-mg JJ N
oral JJ i
doses NNS i
of IN i
ondansetron NN i
or CC i
placebo NN i
. . i

Administration NNP N
of IN N
drug NN N
was VBD N
double-blinded JJ N
. . N

Initial JJ N
rescue NN N
therapy NN N
consisted VBD N
of IN N
intravenous JJ N
( ( N
i.v JJ N
. . N

) ) N
ondansetron VBD i
0.15 CD N
mg/kg NNS N
following VBG N
two CD N
or CC N
more JJR N
emetic JJ N
episodes NNS N
between IN N
successive JJ N
fractions NNS N
of IN N
TBI NNP N
or CC N
five CD N
total JJ N
emetic JJ N
episodes NNS N
during IN N
the DT N
4 CD N
days NNS N
of IN N
therapy NN N
. . N

If IN N
, , N
after IN N
receipt NN N
of IN N
i.v NN N
. . N

ondansetron NN i
, , N
patients NNS N
had VBD N
two CD N
or CC N
more JJR N
emetic JJ N
episodes NNS N
between IN N
fractions NNS N
of IN N
TBI NNP N
or CC N
five CD N
total JJ N
emetic JJ N
episodes NNS N
, , N
additional JJ N
antiemetics NNS N
were VBD N
administered VBN N
. . N

RESULTS JJ N
Patients NNPS N
who WP N
received VBD N
oral JJ N
ondansetron NN i
had VBD N
significantly RB N
fewer JJR N
emetic JJ o
episodes NNS o
compared VBN N
with IN N
those DT N
who WP N
received VBD N
placebo NN i
( ( N
P NNP N
= NNP N
.005 NNP N
) ) N
over IN N
the DT N
entire JJ N
4-day JJ N
study NN N
period NN N
. . N

Oral NNP N
ondansetron NN i
was VBD N
also RB N
significantly RB N
superior JJ N
to TO N
placebo VB i
with IN N
respect NN N
to TO N
the DT N
time NN o
of IN o
onset NN o
of IN o
emesis NN o
or CC o
rescue NN o
( ( N
P NNP N
= NNP N
.003 NNP N
) ) N
. . N

Six NNP N
of IN N
10 CD N
patients NNS N
treated VBN N
with IN N
oral JJ N
ondansetron NN i
completed VBD N
the DT N
study NN N
without IN N
additional JJ N
antiemetic JJ i
therapy NN i
, , N
while IN N
none NN N
of IN N
10 CD N
patients NNS N
who WP N
received VBD N
placebo RB i
completed VBN N
the DT N
study NN N
without IN N
rescue NN o
antiemetic JJ o
therapy NN o
. . o

Six NNP N
placebo NN i
patients NNS N
who WP N
received VBD N
initial JJ i
rescue NN i
therapy NN i
with IN N
i.v NN N
. . N

ondansetron NN i
required VBN N
no DT N
additional JJ o
antiemetics NNS o
. . o

No DT N
relationships NNS N
were VBD N
apparent JJ N
between IN N
peak JJ o
ondansetron NN o
concentration NN o
( ( o
Cmax NNP o
) ) o
or CC o
area NN o
under IN o
the DT o
concentration NN o
versus NN o
time NN o
curve NN o
( ( o
AUC NNP o
) ) o
and CC o
number NN o
of IN o
emetic JJ o
episodes NNS o
. . o

CONCLUSION NNP N
Oral NNP i
ondansetron NN i
is VBZ N
an DT N
effective JJ N
therapy NN N
for IN N
the DT N
prevention NN N
of IN N
emesis NN N
induced VBN N
by IN N
TBI NNP N
. . N

-DOCSTART- -21639806- O O

Exemestane NN i
for IN N
breast-cancer JJ p
prevention NN p
in IN p
postmenopausal JJ p
women NNS p
. . p

BACKGROUND NNP N
Tamoxifen NNP N
and CC N
raloxifene NN N
have VBP N
limited VBN N
patient JJ N
acceptance NN N
for IN N
primary JJ N
prevention NN N
of IN N
breast NN N
cancer NN N
. . N

Aromatase NNP N
inhibitors NNS N
prevent VBP N
more JJR N
contralateral JJ N
breast NN N
cancers NNS N
and CC N
cause NN N
fewer JJR N
side NN N
effects NNS N
than IN N
tamoxifen NN N
in IN N
patients NNS p
with IN p
early-stage JJ p
breast NN p
cancer NN p
. . p

METHODS NNP N
In IN N
a DT N
randomized JJ N
, , N
placebo-controlled JJ i
, , N
double-blind JJ N
trial NN N
of IN N
exemestane NN i
designed VBN N
to TO N
detect VB N
a DT N
65 CD N
% NN N
relative JJ N
reduction NN N
in IN N
invasive JJ N
breast NN N
cancer NN N
, , N
eligible JJ p
postmenopausal NN p
women NNS p
35 CD p
years NNS p
of IN p
age NN p
or CC p
older JJR p
had VBD p
at IN p
least JJS p
one CD p
of IN p
the DT p
following JJ p
risk NN p
factors NNS p
: : p
60 CD p
years NNS p
of IN p
age NN p
or CC p
older JJR p
; : p
Gail NNP p
5-year JJ p
risk NN p
score NN p
greater JJR p
than IN p
1.66 CD p
% NN p
( ( p
chances NNS p
in IN p
100 CD p
of IN p
invasive JJ p
breast NN p
cancer NN p
developing VBG p
within IN p
5 CD p
years NNS p
) ) p
; : p
prior JJ p
atypical JJ p
ductal NN p
or CC p
lobular JJ p
hyperplasia NN p
or CC p
lobular JJ p
carcinoma NN p
in IN p
situ NN p
; : p
or CC p
ductal JJ p
carcinoma NN p
in IN p
situ NN p
with IN p
mastectomy NN p
. . p

Toxic NNP o
effects NNS o
and CC o
health-related JJ o
and CC o
menopause-specific JJ o
qualities NNS o
of IN o
life NN o
were VBD N
measured VBN N
. . N

RESULTS VB N
A DT N
total NN p
of IN p
4560 CD p
women NNS p
for IN p
whom WP p
the DT p
median JJ p
age NN p
was VBD p
62.5 CD p
years NNS p
and CC p
the DT p
median JJ o
Gail NNP o
risk NN o
score NN o
was VBD p
2.3 CD p
% NN p
were VBD N
randomly RB N
assigned VBN N
to TO N
either DT N
exemestane NN i
or CC i
placebo NN i
. . i

At IN N
a DT N
median JJ N
follow-up NN N
of IN N
35 CD N
months NNS N
, , N
11 CD N
invasive JJ N
breast NN N
cancers NNS N
were VBD N
detected VBN N
in IN N
those DT N
given VBN N
exemestane NN i
and CC N
in IN N
32 CD N
of IN N
those DT N
given VBN N
placebo NNS i
, , N
with IN N
a DT N
65 CD N
% NN N
relative JJ N
reduction NN o
in IN o
the DT o
annual JJ o
incidence NN o
of IN o
invasive JJ o
breast NN o
cancer NN o
( ( N
0.19 CD N
% NN N
vs. FW N
0.55 CD N
% NN N
; : N
hazard CC N
ratio NN N
, , N
0.35 CD N
; : N
95 CD N
% NN N
confidence NN N
interval NN N
[ NNP N
CI NNP N
] NNP N
, , N
0.18 CD N
to TO N
0.70 CD N
; : N
P=0.002 NNP N
) ) N
. . N

The DT N
annual JJ o
incidence NN o
of IN o
invasive JJ o
plus CC o
noninvasive JJ o
( ( o
ductal JJ o
carcinoma NN o
in IN o
situ NN o
) ) o
breast NN o
cancers NNS o
was VBD N
0.35 CD N
% NN N
on IN N
exemestane NN N
and CC N
0.77 CD N
% NN N
on IN N
placebo NN i
( ( N
hazard JJ N
ratio NN N
, , N
0.47 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
0.27 CD N
to TO N
0.79 CD N
; : N
P=0.004 NNP N
) ) N
. . N

Adverse JJ o
events NNS o
occurred VBD N
in IN N
88 CD N
% NN N
of IN N
the DT N
exemestane NN N
group NN N
and CC N
85 CD N
% NN N
of IN N
the DT N
placebo NN N
group NN N
( ( N
P=0.003 NNP N
) ) N
, , N
with IN N
no DT N
significant JJ N
differences NNS N
between IN N
the DT N
two CD N
groups NNS N
in IN N
terms NNS N
of IN N
skeletal JJ o
fractures NNS o
, , o
cardiovascular JJ o
events NNS o
, , o
other JJ o
cancers NNS o
, , o
or CC o
treatment-related JJ o
deaths NNS o
. . o

Minimal JJ N
quality-of-life JJ o
differences NNS N
were VBD N
observed VBN N
. . N

CONCLUSIONS NNP N
Exemestane NNP i
significantly RB N
reduced VBD N
invasive JJ p
breast NN p
cancers NNS p
in IN p
postmenopausal JJ p
women NNS p
who WP p
were VBD p
at IN p
moderately RB p
increased VBN p
risk NN p
for IN p
breast NN p
cancer NN p
. . p

During IN N
a DT N
median JJ N
follow-up JJ N
period NN N
of IN N
3 CD N
years NNS N
, , N
exemestane NN N
was VBD N
associated VBN N
with IN N
no DT N
serious JJ N
toxic NN N
effects NNS N
and CC N
only RB N
minimal JJ N
changes NNS N
in IN N
health-related JJ N
quality NN N
of IN N
life NN N
. . N

( ( N
Funded VBN N
by IN N
Pfizer NNP N
and CC N
others NNS N
; : N
NCIC NNP N
CTG NNP N
MAP.3 NNP N
ClinicalTrials.gov NNP N
number NN N
, , N
NCT00083174 NNP N
. . N

) ) N
. . N

-DOCSTART- -23386127- O O

Plasma NNP N
Epstein-Barr NNP N
virus NN N
DNA NNP N
predicts VBZ N
outcome VBN N
in IN N
advanced JJ p
Hodgkin NNP p
lymphoma NN p
: : p
correlative JJ N
analysis NN N
from IN N
a DT N
large JJ p
North JJ p
American JJ p
cooperative NN p
group NN p
trial NN p
. . p

Epstein-Barr JJ N
virus NN N
( ( N
EBV NNP N
) ) N
is VBZ N
associated VBN N
with IN N
Hodgkin NNP N
lymphoma NN N
( ( N
HL NNP N
) ) N
and CC N
can MD N
be VB N
detected VBN N
by IN N
in IN N
situ JJ N
hybridization NN N
( ( N
ISH NNP N
) ) N
of IN N
viral JJ N
nucleic JJ N
acid NN N
( ( N
EBER NNP N
) ) N
in IN N
tumor NN N
cells NNS N
. . N

We PRP N
sought VBD N
to TO N
determine VB N
whether IN N
plasma JJ N
EBV-DNA NNP N
could MD N
serve VB N
as IN N
a DT N
surrogate NN N
for IN N
EBER-ISH NNP o
and CC N
to TO N
explore VB N
its PRP$ N
prognostic JJ N
utility NN N
in IN N
HL NNP N
. . N

Specimens NNS p
from IN p
the DT p
Cancer NNP p
Cooperative NNP p
Intergroup NNP p
Trial NNP p
E2496 NNP p
were VBD N
used VBN N
to TO N
compare VB i
pretreatment JJ i
plasma JJ i
EBV-DNA JJ i
quantification NN i
with IN i
EBV NNP i
tumor NN o
status NN o
by IN i
EBER-ISH NNP o
. . o

A NNP N
cutoff NN N
of IN N
> $ N
60 CD N
viral JJ N
copies/100 NN N
?L NNP N
plasma NN N
yielded VBD N
96 CD N
% NN N
concordance NN N
with IN o
EBER-ISH NNP o
. . o

Pretreatment NNP N
and CC N
month NN N
6 CD N
plasma NN p
specimens NNS p
were VBD N
designated VBN N
EBV NNP N
( ( N
- : N
) ) N
or CC N
EBV NNP N
( ( N
+ NNP N
) ) N
by IN N
this DT N
cutoff NN N
. . N

Patients NNS N
with IN N
pretreatment JJ N
EBV NNP N
( ( N
+ NNP N
) ) N
plasma NN N
( ( N
n JJ N
= NNP N
54 CD N
) ) N
had VBD o
inferior JJ o
failure-free JJ o
survival NN o
( ( o
FFS NNP o
) ) o
compared VBN N
with IN N
those DT N
with IN N
pretreatment JJ N
EBV NNP N
( ( N
- : N
) ) N
plasma NN N
( ( N
n JJ N
= NNP N
274 CD N
) ) N
, , N
log-rank JJ N
P NNP N
= NNP N
.009 NNP N
. . N

By IN N
contrast NN N
, , N
no DT N
difference NN N
in IN o
FFS NNP o
was VBD N
observed VBN N
when WRB N
patients NNS N
were VBD N
stratified VBN N
by IN o
EBER-ISH NNP o
. . o

Pretreatment NNP N
plasma NN N
EBV NNP N
positivity NN N
was VBD N
an DT N
independent JJ N
predictor NN N
of IN N
treatment NN N
failure NN N
on IN N
multivariate NN N
analyses NNS N
. . N

At IN N
month NN N
6 CD N
, , N
plasma NN o
EBV NNP o
( ( o
+ NNP o
) ) o
patients NNS N
( ( N
n JJ N
= NNP N
7 CD N
) ) N
had VBD o
inferior JJ o
FFS NNP o
compared VBN N
with IN o
plasma NN o
EBV NNP o
( ( o
- : o
) ) o
patients NNS N
( ( N
n JJ N
= NNP N
125 CD N
) ) N
, , N
log-rank JJ N
P NNP N
= NNP N
.007 NNP N
. . N

These DT N
results NNS N
confirm VBP N
that IN N
plasma JJ N
EBV-DNA NNP N
is VBZ N
highly RB N
concordant JJ N
with IN o
EBER-ISH NNP o
in IN N
HL NNP N
and CC N
suggest VBP N
that IN N
it PRP N
may MD N
have VB N
prognostic JJ N
utility NN N
both DT N
at IN N
baseline NN N
and CC N
after IN N
therapy NN N
. . N

This DT N
trial NN N
was VBD N
registered VBN N
at IN N
www.clinicaltrials.gov NN N
as IN N
# # N
NCT00003389 NNP N
. . N

-DOCSTART- -24268858- O O

Low-fluence JJ i
photodynamic JJ i
therapy NN i
versus NN N
ranibizumab NN i
for IN N
chronic JJ p
central JJ p
serous JJ p
chorioretinopathy NN p
: : p
one-year JJ N
results NNS N
of IN N
a DT N
randomized JJ N
trial NN N
. . N

PURPOSE NNP N
To TO N
compare VB N
the DT N
efficacy NN o
and CC N
safety NN o
between IN N
low-fluence JJ N
photodynamic JJ N
therapy NN N
( ( N
PDT NNP N
) ) N
and CC N
the DT N
intravitreal JJ N
ranibizumab NN N
in IN N
the DT N
treatment NN N
of IN N
chronic JJ N
central JJ N
serous JJ N
chorioretinopathy NN N
( ( N
CSC NNP N
) ) N
. . N

DESIGN NNP N
Prospective NNP N
, , N
randomized VBD N
, , N
single-center JJ N
, , N
parallel-arm JJ N
, , N
controlled JJ N
trial NN N
. . N

PARTICIPANTS CC N
Thirty-four JJ p
eyes NNS p
of IN p
32 CD p
patients NNS p
with IN p
chronic JJ p
CSC NNP p
with IN p
> NNP p
6 CD p
months NNS p
' POS p
duration NN p
of IN p
symptoms NNS p
or CC p
recurrent JJ p
CSC NNP p
were VBD p
randomly RB p
placed VBN p
into IN p
the DT p
low-fluence JJ p
PDT NNP p
group NN p
( ( p
n JJ p
= NNP p
18 CD p
) ) p
or CC p
the DT p
ranibizumab NN p
group NN p
( ( p
n JJ p
= NNP p
16 CD p
) ) p
. . p

INTERVENTION NNP N
The DT N
patients NNS N
underwent VBP N
a DT N
single JJ N
session NN N
of IN N
low-fluence NN i
PDT NNP i
or CC i
3 CD i
consecutive JJ i
monthly JJ i
injections NNS i
of IN i
ranibizumab NN i
. . i

Rescue NNP i
treatment NN i
was VBD N
available JJ N
from IN N
month NN N
3 CD N
if IN N
the DT N
subretinal JJ N
fluid NN N
( ( N
SRF NNP N
) ) N
persisted VBD N
or CC N
recurred VBN N
after IN N
primary JJ N
treatment NN N
; : N
low-fluence JJ N
PDT NNP N
was VBD N
given VBN N
to TO N
the DT N
ranibizumab NN N
group NN N
and CC N
intravitreal NN N
ranibizumab NN N
to TO N
the DT N
low-fluence NN N
PDT NNP N
group NN N
. . N

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
The DT N
primary JJ N
outcome NN N
was VBD N
the DT N
proportion NN o
of IN o
eyes NNS o
with IN o
complete JJ o
resolution NN o
of IN o
SRF NNP o
without IN N
rescue NN N
treatment NN N
. . N

Secondary JJ N
outcomes NNS N
included VBD N
the DT N
mean NN o
changes NNS o
in IN o
logarithm NN o
of IN o
the DT o
minimum JJ o
angle NN o
of IN o
resolution NN o
best-corrected JJ o
visual JJ o
acuity NN o
( ( o
BCVA NNP o
) ) o
, , o
central JJ o
retinal JJ o
thickness NN o
( ( o
CRT NNP o
) ) o
, , N
and CC N
angiographic JJ o
findings NNS o
from IN N
baseline NN N
to TO N
12 CD N
months NNS N
. . N

RESULTS NNP N
At IN N
month NN N
12 CD N
, , N
16 CD p
eyes NNS p
( ( N
88.9 CD N
% NN N
) ) N
of IN N
the DT N
low-fluence JJ N
PDT NNP N
group NN N
maintained VBD N
complete JJ N
resolution NN o
of IN o
SRF NNP o
without IN o
rescue NN o
treatment NN o
versus IN N
2 CD p
eyes NNS p
( ( N
12.5 CD N
% NN N
) ) N
in IN N
the DT N
ranibizumab NN N
group NN N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

Two CD N
eyes NNS N
( ( N
11.1 CD N
% NN N
) ) N
in IN N
the DT N
low-fluence NN N
PDT NNP N
group NN N
and CC N
11 CD N
eyes NNS N
( ( N
68.8 CD N
% NN N
) ) N
in IN N
the DT N
ranibizumab NN N
group NN N
met VBD N
the DT N
criteria NNS N
for IN N
rescue NN N
treatment NN N
( ( N
P NNP N
= NNP N
0.001 CD N
) ) N
. . N

In IN N
the DT N
low-fluence NN N
PDT NNP N
group NN N
, , N
the DT N
mean JJ o
decrease NN o
in IN o
CRT NNP o
from IN N
baseline NN N
was VBD N
significantly RB N
greater JJR N
than IN N
that DT N
in IN N
the DT N
ranibizumab NN N
group NN N
until IN N
month NN N
6 CD N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
, , N
but CC N
the DT N
differences NNS N
became VBD N
insignificant JJ N
thereafter NN N
. . N

The DT N
improvement NN o
in IN o
BCVA NNP o
from IN N
baseline NN N
was VBD N
superior JJ N
in IN N
the DT N
low-fluence NN N
PDT NNP N
group NN N
to TO N
that DT N
in IN N
the DT N
ranibizumab NN N
group NN N
, , N
but CC N
the DT N
differences NNS N
were VBD N
not RB N
statistically RB N
significant JJ N
except IN N
at IN N
month NN N
3 CD N
( ( N
P NNP N
= NNP N
0.025 CD N
) ) N
. . N

On IN N
indocyanine NN N
green JJ N
angiography NN N
, , N
a DT N
significantly RB N
greater JJR N
proportion NN N
of IN N
the DT N
low-fluence JJ N
PDT NNP N
group NN N
( ( N
16 CD N
eyes NNS N
; : N
88.9 CD N
% NN N
) ) N
showed VBD N
a DT N
marked JJ N
reduction NN N
in IN N
choroidal JJ o
hyperpermeability NN o
after IN N
primary JJ N
treatment NN N
than IN N
that DT N
of IN N
the DT N
ranibizumab NN N
group NN N
( ( N
0 CD N
eyes NNS N
; : N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

No DT N
serious JJ o
adverse JJ o
events NNS o
related VBN N
to TO N
the DT N
drugs NNS N
or CC N
procedures NNS N
were VBD N
observed VBN N
. . N

CONCLUSIONS VB N
This DT N
study NN N
represents VBZ N
the DT N
overall JJ N
superiority NN N
of IN N
low-fluence NN N
PDT NNP N
compared VBN N
with IN N
intravitreal JJ N
ranibizumab NN N
in IN N
the DT N
treatment NN N
of IN N
chronic JJ N
CSC NNP N
. . N

-DOCSTART- -11867842- O O

Effect NN N
of IN N
delayed JJ i
cord NN i
clamping VBG i
on IN N
iron NN o
stores NNS o
in IN N
infants NNS p
born VBN p
to TO p
anemic JJ p
mothers NNS p
: : p
a DT N
randomized NN N
controlled VBN N
trial NN N
. . N

OBJECTIVE UH N
To TO N
study VB N
the DT N
effects NNS N
of IN N
cord NN N
clamping VBG N
on IN N
iron NN N
stores NNS N
of IN N
infants NNS p
born VBN p
to TO p
anemic VB p
mothers NNS p
at IN p
3 CD p
months NNS p
of IN p
age NN p
. . p

DESIGN NNP N
Randomized NNP N
controlled VBD N
trial NN N
. . N

SETTING NN N
Teaching NNP p
hospital NN p
. . p

METHODS NNP N
Infants NNPS p
born VBN p
to TO p
mothers NNS p
with IN p
hemoglobin NN p
( ( p
Hb NNP p
) ) p
< VBD p
100 CD p
g/L NNS p
were VBD N
randomized VBN N
at IN N
delivery NN N
to TO N
either DT N
immediate JJ i
cord NN i
clamping NN i
( ( N
early JJ N
group NN N
) ) N
or CC N
cord NN i
clamping VBG i
delayed VBN i
till JJ i
descent NN i
of IN i
placenta NN i
into IN i
vagina NN i
( ( N
delayed VBN N
group NN N
) ) N
. . N

The DT N
outcome NN N
measures NNS N
were VBD N
infant NN o
's POS o
hemoglobin NN o
and CC o
serum NN o
ferritin VBP o
3 CD o
months NNS o
after IN o
delivery NN o
. . o

RESULTS CC N
There EX N
were VBD N
102 CD p
neonates NNS p
randomized VBN N
to TO N
early JJ N
( ( N
n JJ N
= NNP N
43 CD N
) ) N
or CC N
delayed VBN N
cord NN N
clamping NN N
( ( N
n JJ N
= NNP N
59 CD N
) ) N
. . N

The DT N
groups NNS N
were VBD N
comparable JJ N
for IN N
maternal JJ N
age NN N
, , N
parity NN N
, , N
weight NN N
and CC N
supplemental JJ N
iron NN N
intake NN N
, , N
infant JJ N
s NN N
birth NN N
weight NN N
, , N
gestation NN N
and CC N
sex NN N
. . N

The DT N
mean JJ o
infant NN o
ferritin NN o
and CC o
Hb NNP o
at IN o
3 CD o
months NNS o
were VBD N
significantly RB N
higher JJR N
in IN N
the DT N
delayed JJ i
clamping NN i
group NN N
( ( N
118.4 CD N
microg/L NN N
and CC N
99 CD N
g/L NN N
) ) N
than IN N
in IN N
the DT N
early JJ i
clamping NN i
group NN N
( ( N
73 CD N
microg/L NN N
and CC N
88 CD N
g/L NN N
) ) N
. . N

The DT N
mean JJ N
decrease NN N
in IN N
Hb NNP o
( ( N
g/L NN N
) ) N
at IN N
3 CD N
months NNS N
adjusted VBN N
for IN N
co-variates NNS N
was VBD N
significantly RB N
less RBR N
in IN N
the DT N
delayed JJ i
clamping NN i
group NN N
compared VBN N
to TO N
the DT N
early JJ i
clamping NN i
group NN N
( ( N
-1.09 NNP N
, , N
95 CD N
% NN N
CI-1.58 NNP N
to TO N
-0.62 VB N
, , N
p VB N
> NNP N
0.001 CD N
) ) N
. . N

The DT N
odds NNS N
for IN N
anemia NN o
( ( N
< JJ N
100 CD N
g/L NN N
) ) N
at IN N
3 CD N
months NNS N
was VBD N
7.7 CD N
( ( N
95 CD N
% NN N
CI NNP N
1.84-34.9 CD N
) ) N
times NNS N
higher RBR N
in IN N
the DT N
early JJ N
compared VBN N
to TO N
the DT N
delayed JJ i
clamping NN i
group NN N
. . N

CONCLUSION NNP N
Iron NNP o
stores NNS o
and CC o
Hb NNP o
in IN N
infancy NN N
can MD N
be VB N
improved VBN N
in IN N
neonates NNS p
born VBN p
to TO p
anemic VB p
mothers NNS p
by IN N
delaying VBG i
cord NN i
clamping NN i
at IN N
birth NN N
. . N

-DOCSTART- -1457432- O O

Leukocyte-depleted JJ i
reperfusion NN i
of IN p
transplanted JJ p
human JJ p
hearts NNS p
: : p
a DT N
randomized JJ N
, , N
double-blind JJ N
clinical JJ N
trial NN N
. . N

Standard NNP N
methods NNS N
of IN N
myocardial JJ N
preservation NN N
for IN N
heart NN N
transplantation NN N
have VBP N
generally RB N
provided VBN N
good JJ N
results NNS o
. . o

Preservation NNP N
times VBZ N
beyond IN N
3 CD N
hours NNS N
, , N
however RB N
, , N
have VBP N
been VBN N
associated VBN N
with IN N
decreased JJ N
survival NN o
. . o

Leukocyte-mediated JJ N
reperfusion NN N
injury NN N
is VBZ N
partly RB N
responsible JJ N
for IN N
decreased JJ N
graft NN o
function NN o
after IN N
prolonged JJ N
graft NN N
ischemia NN N
. . N

Leukocyte-depleted JJ i
reperfusion NN i
has VBZ N
been VBN N
shown VBN N
experimentally RB N
to TO N
improve VB N
cardiac JJ o
function NN o
after IN N
cold JJ N
ischemic JJ N
arrest NN N
. . N

To TO N
determine VB N
the DT N
efficacy NN o
and CC o
safety NN o
of IN N
leukocyte-depleted JJ i
reperfusion NN i
, , N
20 CD p
patients NNS p
were VBD p
enrolled VBN p
in IN p
a DT p
randomized JJ p
, , p
double-blind JJ p
clinical JJ p
trial NN p
to TO p
be VB p
treated VBN p
with IN p
either DT p
warm JJ i
whole NN i
blood NN i
reperfusion NN i
( ( p
group NN p
I PRP p
; : p
n CC p
= VB p
9 CD p
) ) p
or CC i
warm JJ i
leukocyte-depleted JJ i
blood NN i
reperfusion NN i
( ( p
group NN p
II NNP p
; : p
n CC p
= VB p
11 CD p
) ) p
. . p

Reperfusion NN i
with IN i
leukocyte-depleted JJ i
blood NN i
or CC i
whole JJ i
blood NN i
was VBD N
carried VBN N
out IN N
for IN N
10 CD N
minutes NNS N
, , N
with IN N
enriched JJ N
cardioplegic JJ N
solution NN N
added VBD N
for IN N
the DT N
first JJ N
3 CD N
minutes NNS N
of IN N
reperfusion NN N
. . N

The DT N
mean JJ o
donor NN o
and CC o
recipient JJ o
age NN o
and CC o
the DT o
ischemic JJ o
time NN o
( ( N
142 CD N
versus NN N
153 CD N
minutes NNS N
) ) N
were VBD N
not RB N
significantly RB N
different JJ N
between IN N
the DT N
two CD N
groups NNS N
. . N

Coronary NNP o
sinus VBD o
release NN o
of IN o
creatinine JJ o
phosphokinase-MB JJ o
5 CD o
minutes NNS o
after IN o
reperfusion NN o
was VBD N
significantly RB N
less RBR N
in IN N
group NN N
II NNP N
( ( N
1.65 CD N
EU/min NNP N
) ) N
than IN N
in IN N
group NN N
I PRP N
( ( N
3.83 CD N
units/min NN N
; : N
p CC N
= VB N
0.05 CD N
) ) N
. . N

Thromboxane NNP o
B2 NNP o
release NN o
was VBD N
also RB N
significantly RB N
less JJR N
( ( N
p JJ N
= NNP N
0.05 CD N
) ) N
in IN N
group NN N
II NNP N
( ( N
33.6 CD N
pg/min NN N
) ) N
than IN N
in IN N
group NN N
I PRP N
( ( N
67.0 CD N
pg/min NN N
) ) N
. . N

All DT N
hearts NNS o
functioned VBD o
adequately RB N
in IN N
both DT N
groups NNS N
. . N

The DT N
duration NN o
of IN o
inotropic JJ o
support NN o
was VBD N
shorter JJR N
in IN N
group NN N
II NNP N
than IN N
in IN N
group NN N
I PRP N
, , N
but CC N
the DT N
difference NN N
was VBD N
not RB N
statistically RB N
significant JJ N
. . N

Postoperative JJ o
hemodynamics NNS o
, , o
rejection NN o
episodes NNS o
, , o
and CC o
infectious JJ o
complications NNS o
were VBD N
also RB N
not RB N
significantly RB N
different JJ N
between IN N
groups NNS N
in IN N
a DT N
mean JJ N
follow-up NN N
of IN N
9 CD N
months NNS N
. . N

Mean NNP o
ejection NN o
fraction NN o
1 CD o
month NN o
after IN o
operation NN o
was VBD N
65 CD N
% NN N
in IN N
both DT N
groups NNS N
. . N

One CD N
early JJ N
death NN o
occurred VBD N
at IN N
66 CD N
days NNS N
secondary JJ N
to TO N
infection NN N
; : N
two CD N
late JJ N
deaths NNS o
occurred VBD N
in IN N
group NN N
II NNP N
, , N
both DT N
from IN N
rejection NN N
. . N

Leukocyte-depleted JJ i
reperfusion NN i
is VBZ N
safe JJ o
and CC N
easily RB N
applied VBN N
in IN N
the DT N
operating NN N
room NN N
. . N

Furthermore CD N
, , N
leukocyte-depleted JJ N
reperfusion NN N
decreases VBZ N
biochemical JJ o
evidence NN o
of IN N
reperfusion NN N
injury NN N
. . N

Although IN N
not RB N
influencing VBG N
postoperative JJ N
cardiac JJ o
function NN o
when WRB N
the DT N
ischemic JJ N
time NN N
is VBZ N
short JJ N
, , N
less JJR N
than IN N
3 CD N
hours NNS N
, , N
leukocyte-depleted JJ N
reperfusion NN N
may MD N
prevent VB N
significant JJ N
reperfusion NN o
injury NN o
and CC N
improve VB N
posttransplantation NN o
graft NN o
function NN o
when WRB N
ischemic JJ o
times NNS o
are VBP N
long JJ N
. . N

Safe JJ N
extension NN N
of IN N
the DT N
ischemic JJ N
time NN N
would MD N
expand VB N
the DT N
donor NN N
pool NN N
and CC N
allow VB N
for IN N
better JJR N
crossmatching NN N
. . N

-DOCSTART- -19324944- O O

Acute JJ N
effects NNS N
of IN N
decaffeinated JJ i
coffee NN i
and CC N
the DT N
major JJ N
coffee NN N
components NNS N
chlorogenic JJ i
acid NN N
and CC N
trigonelline NN i
on IN N
glucose JJ o
tolerance NN o
. . o

OBJECTIVE NNP N
Coffee NNP i
consumption NN N
has VBZ N
been VBN N
associated VBN N
with IN N
lower JJR N
risk NN N
of IN N
type NN p
2 CD p
diabetes NNS p
. . p

We PRP N
evaluated VBD N
the DT N
acute JJ N
effects NNS N
of IN N
decaffeinated JJ i
coffee NN i
and CC N
the DT N
major JJ N
coffee NN N
components NNS N
chlorogenic JJ N
acid NN N
and CC N
trigonelline NN N
on IN N
glucose JJ N
tolerance NN N
. . N

RESEARCH NNP N
DESIGN NNP N
AND NNP N
METHODS NNP N
We PRP N
conducted VBD N
a DT N
randomized VBN N
crossover NN N
trial NN N
of IN N
the DT N
effects NNS N
of IN N
12 CD N
g NN N
decaffeinated VBD i
coffee NN i
, , N
1 CD N
g NN N
chlorogenic JJ i
acid NN i
, , N
500 CD N
mg NN N
trigonelline NN i
, , i
and CC i
placebo NN i
( ( N
1 CD N
g NN N
mannitol NN i
) ) i
on IN N
glucose NN N
and CC N
insulin NN N
concentrations NNS N
during IN N
a DT N
2-h JJ N
oral JJ N
glucose NN N
tolerance NN N
test NN N
( ( N
OGTT NNP N
) ) N
in IN N
15 CD p
overweight JJ p
men NNS p
. . p

RESULTS NNP N
Chlorogenic NNP N
acid NN N
and CC N
trigonelline NN N
ingestion NN N
significantly RB N
reduced VBN N
glucose NN o
( ( N
-0.7 JJ N
mmol/l NN N
, , N
P NNP N
= NNP N
0.007 CD N
, , N
and CC N
-0.5 NNP N
mmol/l NN N
, , N
P NNP N
= NNP N
0.024 CD N
, , N
respectively RB N
) ) N
and CC N
insulin NN o
( ( N
-73 JJ N
pmol/l NN N
, , N
P NNP N
= NNP N
0.038 CD N
, , N
and CC N
-117 NNP N
pmol/l NN N
, , N
P NNP N
= NNP N
0.007 CD N
) ) N
concentrations NNS N
15 CD N
min NN N
following VBG N
an DT N
OGTT NNP N
compared VBN N
with IN N
placebo NN N
. . N

None NN N
of IN N
the DT N
treatments NNS N
affected VBD N
insulin NN o
or CC o
glucose JJ o
area NN o
under IN o
the DT o
curve NN o
values NNS o
during IN N
the DT N
OGTT NNP N
compared VBN N
with IN N
placebo NN i
. . i

CONCLUSIONS NNP N
Chlorogenic NNP N
acid NN N
and CC N
trigonelline NN N
reduced VBD N
early JJ N
glucose NN o
and CC o
insulin NN o
responses NNS o
during IN N
an DT N
OGTT NNP N
. . N

-DOCSTART- -1326339- O O

The DT N
use NN N
of IN N
adrenocorticotrophic JJ i
hormone NN i
( ( i
4-9 JJ i
) ) i
analog NN i
ORG NNP i
2766 CD i
in IN N
autistic JJ p
children NNS p
: : p
effects NNS N
on IN N
the DT N
organization NN N
of IN N
behavior NN N
. . N

In IN N
a DT N
double-blind JJ N
placebo-controlled JJ N
crossover NN N
trial NN N
, , N
14 CD p
autistic JJ p
children NNS p
were VBD N
treated VBN N
with IN N
the DT N
neuropeptide NN i
ORG NNP i
2766 CD i
, , N
a DT N
synthetic JJ N
analog NN N
of IN N
adrenocorticotrophic JJ N
hormone NN N
( ( N
ACTH NNP N
) ) N
( ( N
4-9 JJ N
) ) N
. . N

ORG JJ i
2766 CD i
treatment NN i
( ( N
20 CD N
mg NNS N
per IN N
day NN N
during IN N
4 CD N
weeks NNS N
) ) N
was VBD N
associated VBN N
with IN N
an DT N
increased JJ N
amount NN N
and CC N
an DT N
improved JJ N
quality NN N
of IN N
the DT N
social JJ N
interaction NN N
of IN N
the DT N
autistic JJ p
children NNS p
with IN N
a DT N
familiar JJ N
experimenter NN N
. . N

These DT N
changes NNS N
in IN N
interaction NN N
were VBD N
clinically RB N
relevant JJ N
. . N

Following VBG N
treatment NN N
with IN N
ORG NNP i
2766 CD i
gaze NN o
and CC o
smile JJ o
behaviors NNS o
of IN N
child NN N
and CC N
experimenter NN N
showed VBD N
stronger JJR o
temporal JJ o
contingencies NNS o
. . o

Further NNP N
, , N
after IN N
ORG NNP i
2766 CD i
, , N
stereotypies NNS N
were VBD N
temporally RB N
disconnected VBN N
from IN N
verbal JJ o
initiatives NNS o
. . o

The DT N
data NN N
supported VBD N
the DT N
notion NN N
of IN N
a DT N
stimulating JJ N
effect NN N
of IN N
ORG NNP i
2766 CD i
on IN N
social JJ N
interaction NN N
. . N

The DT N
implications NNS N
of IN N
these DT N
findings NNS N
for IN N
the DT N
endogenous JJ N
opioid JJ N
theory NN N
of IN N
autism NN N
are VBP N
discussed VBN N
. . N

-DOCSTART- -15084616- O O

Phase NNP N
III NNP N
trial NN N
of IN N
gemcitabine NN i
plus CC i
tipifarnib NN i
compared VBN N
with IN N
gemcitabine JJ i
plus CC i
placebo NN i
in IN N
advanced JJ N
pancreatic JJ N
cancer NN N
. . N

PURPOSE NNP N
To TO N
determine VB N
whether IN N
addition NN N
of IN N
the DT N
farnesyltransferase NN N
inhibitor NN N
tipifarnib NN i
( ( N
Zarnestra NNP N
, , N
R115777 NNP N
; : N
Johnson NNP N
and CC N
Johnson NNP N
Pharmaceutical NNP N
Research NNP N
and CC N
Development NNP N
, , N
Beerse NNP N
, , N
Belgium NNP N
) ) N
to TO N
standard VB N
gemcitabine NN N
therapy NN N
improves VBZ N
overall JJ o
survival NN o
in IN N
advanced JJ N
pancreatic JJ N
cancer NN N
. . N

PATIENTS NNP N
AND CC N
METHODS NNP N
This DT N
randomized VBN N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
study NN N
compared VBN N
gemcitabine JJ i
+ NNP i
tipifarnib NN i
versus NN N
gemcitabine NN i
+ NNP i
placebo NN i
in IN N
patients NNS p
with IN p
advanced JJ p
pancreatic JJ p
adenocarcinoma NN p
previously RB p
untreated VBN p
with IN p
systemic JJ p
therapy NN p
. . p

Tipifarnib NNP i
was VBD i
given VBN i
at IN i
200 CD i
mg NNS i
bid VBD i
orally RB i
continuously RB i
; : i
gemcitabine NN i
was VBD i
given VBN i
at IN i
1,000 CD i
mg/m NN i
( ( i
2 CD i
) ) i
intravenously RB i
weekly JJ i
x NN i
7 CD i
for IN i
8 CD i
weeks NNS i
, , i
then RB i
weekly JJ i
x NN i
3 CD i
every DT i
4 CD i
weeks NNS i
. . i

The DT N
primary JJ N
end NN N
point NN N
was VBD N
overall JJ o
survival NN o
; : o
secondary JJ N
end NN N
points NNS N
included VBD N
6-month JJ o
and CC o
1-year JJ o
survival NN o
rates NNS o
, , o
progression-free JJ o
survival NN o
, , o
response NN o
rate NN o
, , o
safety NN o
, , o
and CC o
quality NN o
of IN o
life NN o
. . o

RESULTS NNP N
Six NNP p
hundred VBD p
eighty-eight JJ p
patients NNS p
were VBD p
enrolled VBN p
. . p

Baseline JJ N
characteristics NNS N
were VBD N
well RB N
balanced VBN N
between IN N
the DT N
two CD N
treatment NN N
arms NNS N
. . N

No DT N
statistically RB N
significant JJ N
differences NNS N
in IN N
survival JJ o
parameters NNS o
were VBD N
observed VBN N
. . N

The DT N
median JJ o
overall JJ o
survival NN o
for IN N
the DT N
experimental JJ N
arm NN N
was VBD N
193 CD N
v JJ N
182 CD N
days NNS N
for IN N
the DT N
control NN N
arm NN N
( ( N
P NNP N
=.75 NNP N
) ) N
; : N
6-month JJ o
and CC o
1-year JJ o
survival NN o
rates NNS o
were VBD N
53 CD N
% NN N
and CC N
27 CD N
% NN N
v JJ N
49 CD N
% NN N
and CC N
24 CD N
% NN N
for IN N
the DT N
control NN N
arm NN N
, , N
respectively RB N
; : N
median JJ o
progression-free JJ o
survival NN o
was VBD N
112 CD N
v JJ N
109 CD N
days NNS N
for IN N
the DT N
control NN N
arm NN N
. . N

Ten CD N
drug-related JJ o
deaths NNS o
were VBD N
reported VBN N
for IN N
the DT N
experimental JJ N
arm NN N
and CC N
seven CD N
for IN N
the DT N
control NN N
arm NN N
. . N

Neutropenia NNP o
and CC o
thrombocytopenia NN o
grade NN o
> NN o
or CC o
= $ o
3 CD o
were VBD N
observed VBN N
in IN N
40 CD N
% NN N
and CC N
15 CD N
% NN N
in IN N
the DT N
experimental JJ N
arm NN N
versus NN N
30 CD N
% NN N
and CC N
12 CD N
% NN N
in IN N
the DT N
control NN N
arm NN N
. . N

Incidences NNS N
of IN N
nonhematologic JJ o
adverse JJ o
events NNS o
were VBD N
similar JJ N
in IN N
two CD N
groups NNS N
. . N

CONCLUSION NNP N
The DT N
combination NN N
of IN N
gemcitabine NN i
and CC i
tipifarnib NN i
has VBZ N
an DT N
acceptable JJ N
toxicity NN N
profile NN N
but CC N
does VBZ N
not RB N
prolong VB N
overall JJ o
survival NN o
in IN N
advanced JJ N
pancreatic JJ N
cancer NN N
compared VBN N
with IN N
single-agent JJ N
gemcitabine NN N
. . N

-DOCSTART- -3962622- O O

The DT N
effect NN N
of IN N
polyvinylpyrrolidone-iodine NN i
as IN N
an DT N
disinfectant NN o
in IN N
eye NN p
surgery NN p
. . p

105 CD p
patients NNS p
admitted VBN p
for IN p
cataract NN p
surgery NN p
were VBD N
treated VBN N
pre-operatively RB N
with IN N
polyvinylpyrrolidone-iodine JJ i
( ( i
PVP-I NNP i
) ) i
as IN N
a DT N
disinfectant NN N
, , N
and CC N
consecutive JJ N
bacterial JJ N
cultures NNS N
were VBD N
obtained VBN N
before IN N
initiating VBG N
surgery NN N
and CC N
at IN N
the DT N
end NN N
of IN N
the DT N
operation NN N
. . N

A DT N
control NN p
group NN p
( ( p
n JJ p
= NNP p
99 CD p
) ) p
only RB N
had VBD N
a DT N
standard JJ o
disinfection NN o
procedure NN i
of IN N
the DT N
eye NN N
( ( N
including VBG N
instillation NN N
of IN N
Terramycin NNP i
cum NN i
polymyxin NN i
B NNP i
cream NN i
in IN N
the DT N
conjunctival NN N
sac VBD N
the DT N
evening NN N
before IN N
surgery NN N
) ) N
. . N

The DT N
cultures NNS N
obtained VBN N
from IN N
the DT N
conjunctival NN N
sac NN N
of IN N
the DT N
control NN N
group NN N
principally RB N
showed VBD N
growth NN N
of IN N
Staph NNP N
. . N

albus NN N
and CC N
Staph NNP N
. . N

aureus NN N
, , N
and CC N
to TO N
a DT N
minor JJ N
degree NN N
diphtheroids NNS N
( ( N
Corynebacterium NNP N
species NNS N
) ) N
. . N

Proteus NNP N
mirabilis NN N
, , N
Escherichia NNP N
coli NN N
and CC N
micrococci NN N
. . N

There EX N
was VBD N
a DT N
significant JJ o
quantitative JJ o
diminished VBN o
growth NN o
( ( N
P NNP N
less JJR N
than IN N
0.05 CD N
) ) N
of IN N
bacteria NN N
in IN N
the DT N
group NN N
of IN N
patients NNS N
treated VBN N
with IN N
PVP-I NNP i
compared VBN N
to TO N
the DT N
control NN N
group NN N
. . N

Concerning VBG N
the DT N
growth NN N
of IN N
Staph NNP N
. . N

albus NN N
, , N
this DT N
was VBD N
reduced VBN N
to TO N
almost RB N
one CD N
third JJ N
and CC N
other JJ N
bacteria NNS N
were VBD N
almost RB N
eliminated VBN N
in IN N
the DT N
group NN N
receiving VBG N
PVP-I NNP i
. . i

As IN N
we PRP N
disclosed VBD N
no DT N
toxic NN o
or CC o
allergic JJ o
reaction NN o
post-operatively RB o
which WDT N
could MD N
be VB N
related VBN N
to TO N
the DT N
use NN N
of IN N
PVP-I NNP i
as IN N
a DT N
disinfectant NN N
, , N
this DT N
agent NN N
seems VBZ N
to TO N
constitute VB N
an DT N
effective JJ o
pre-operative JJ o
antimicrobial JJ o
treatment NN o
, , N
taking VBG N
into IN N
consideration NN N
the DT N
broad JJ N
antimicrobial JJ N
spectrum NN N
of IN N
PVP-I NNP i
shown VBN N
by IN N
other JJ N
authors NNS N
. . N

-DOCSTART- -8179165- O O

[ NN N
No DT N
better JJR N
vigilance NN o
after IN N
general JJ N
anesthesia NN N
with IN N
propofol NN i
in IN i
colonic JJ N
surgery NN N
. . N

A DT N
comparison NN N
of IN N
three CD N
procedures NNS N
for IN N
general JJ i
anesthesia NN i
( ( i
propofol NN i
, , i
halothane NN i
and CC i
midazolam/fentanyl NN i
) ) i
in IN i
combination NN i
with IN i
catheter JJ i
epidural JJ i
anesthesia NN i
] NN i
. . i

Early JJ o
mental NN o
and CC N
psychomotor NN o
recovery NN o
was VBD N
studied VBN p
in IN p
67 CD p
patients NNS p
undergoing JJ p
colorectal JJ p
surgery NN p
under IN p
continuous JJ i
epidural JJ i
anaesthesia NN i
and CC i
light JJ i
general JJ i
anaesthesia NN i
using VBG i
propofol NN i
, , i
halothane NN i
, , i
and CC i
midazolam/fentanyl NN i
. . i

The DT N
study NN N
was VBD N
approved VBN N
by IN N
the DT N
local JJ N
ethics NNS N
committee NN N
. . N

All DT N
patients NNS N
received VBD N
epidural JJ i
anaesthesia NN i
with IN N
0.25 CD N
% NN N
bupivacaine NN i
and CC N
were VBD N
then RB N
randomly RB N
allocated VBN N
to TO N
one CD N
of IN N
three CD N
groups NNS N
. . N

In IN N
group NN N
I PRP N
( ( i
halothane NN i
) ) i
, , i
light JJ i
general JJ i
anaesthesia NN i
was VBD N
induced VBN N
with IN N
thiopental JJ i
3-5 JJ i
mg/kg NN i
and CC i
maintained VBD i
with IN i
halothane NN i
. . i

The DT N
propofol NN i
group NN N
( ( N
II NNP N
) ) N
received VBD N
2 CD N
mg/kg NN N
for IN N
induction NN N
and CC N
a DT N
mean JJ N
continuous JJ N
infusion NN N
of IN N
1.7 CD N
mg/kg.h NN N
. . N

In IN N
group NN N
III NNP N
( ( N
Mi/Fe NNP N
) ) N
, , N
midazolam FW i
and CC i
fentanyl NNS i
were VBD N
used VBN N
for IN N
induction NN N
and CC N
maintenance NN N
. . N

All DT N
patients NNS N
were VBD N
intubated VBN i
, , N
received VBD N
non-depolarising JJ i
muscle NN i
relaxants NNS i
, , N
and CC N
were VBD N
manually RB i
ventilated VBN i
with IN i
nitrous JJ i
oxide-oxygen NN i
( ( N
2:1.2 CD N
) ) N
. . N

For IN N
postoperative JJ N
analgesia NN N
, , N
0.05 CD N
mg/kg NN N
morphine NN i
was VBD N
administrated VBN N
epidurally RB i
30 CD N
min NN N
before IN N
the DT N
end NN N
of IN N
the DT N
operation NN N
; : N
30 CD N
, , N
60 CD N
, , N
90 CD N
, , N
and CC N
120 CD N
min NN N
after IN N
arriving VBG N
in IN N
the DT N
recovery NN N
room NN N
, , N
vigilance NN N
was VBD N
assessed VBN N
using VBG N
a DT N
modified VBN N
Steward NNP N
score NN N
, , N
the DT N
Trieger NNP N
test NN N
, , N
the DT N
ability NN N
to TO N
recall VB N
a DT N
column NN N
of IN N
numbers NNS N
( ( N
KAI NNP N
test NN N
) ) N
, , N
and CC N
symbol NN N
counting NN N
( ( N
CI NNP N
test NN N
) ) N
. . N

Heart NNP o
rate NN o
, , o
blood NN o
pressure NN o
, , o
arterial JJ o
oxygen NN o
saturation NN o
, , o
and CC o
blood NN o
gases NNS o
were VBD N
recorded VBN N
. . N

RESULTS NNP N
. . N

The DT N
three CD N
groups NNS N
were VBD N
comparable JJ N
with IN N
regard NN N
to TO N
age NN N
, , N
sex NN N
, , N
ASA NNP N
classification NN N
, , N
and CC N
duration NN N
of IN N
anaesthesia NN N
and CC N
operation NN N
( ( N
Table JJ N
3 CD N
) ) N
. . N

There EX N
was VBD N
no DT N
difference NN N
between IN N
the DT N
groups NNS N
in IN N
performance NN N
of IN N
the DT N
recovery NN o
tests NNS o
( ( N
Figs NNP N
. . N

2-5 CD N
) ) N
, , N
blood NN o
pressure NN o
, , o
heart NN o
rate NN o
, , o
arterial JJ o
blood NN o
gas NN o
analysis NN o
( ( o
Fig NNP o
. . o

6 CD o
) ) o
, , o
or CC o
oxygen NN o
saturation NN o
. . o

Comparing VBG N
pre- JJ N
and CC N
postoperative JJ N
values NNS N
, , N
we PRP N
found VBD N
severe JJ N
psychomotor NN o
and CC o
mental JJ o
impairment NN o
in IN N
all DT N
groups NNS N
. . N

pCO2 NN o
was VBD N
slightly RB N
elevated VBN N
in IN N
all DT N
groups NNS N
, , N
but CC N
only RB N
3 CD N
patients NNS N
in IN N
the DT N
propofol NN N
group NN N
and CC N
6 CD N
in IN N
the DT N
midazolam/fentanyl NN i
group NN N
developed VBD N
hypercapnia RB o
above IN N
50 CD N
mm NN N
Hg NNP N
. . N

Patients NNS N
receiving VBG N
propofol NN i
or CC N
midazolam/fentanyl NN i
had VBD N
significantly RB N
less RBR N
postoperative JJ o
nausea NN o
and CC o
vomiting NN o
than IN N
those DT N
receiving VBG N
halothane NN i
( ( N
Table JJ N
5 CD N
) ) N
. . N

CONCLUSION NNP N
. . N

It PRP N
is VBZ N
concluded VBN N
that IN N
propofol NN i
offers VBZ N
no DT N
advantage NN N
over IN N
halothane NN i
or CC N
midazolam/fentanyl NN i
where WRB N
early RB N
postoperative JJ o
recovery NN o
is VBZ N
concerned VBN N
. . N

Intraoperatively RB N
, , N
all DT N
three CD N
techniques NNS N
provided VBD N
good JJ N
anaesthesia NN N
. . N

Propofol NNP i
and CC N
midazolam/fentanyl NN i
caused VBD N
less RBR N
postoperative JJ o
nausea NN o
and CC o
vomiting NN o
than IN N
halothane NN i
anaesthesia NN N
. . N

-DOCSTART- -7733183- O O

Dose-related JJ N
difference NN N
in IN N
progression NN N
rates NNS N
of IN N
cytomegalovirus NN p
retinopathy NN p
during IN N
foscarnet JJ i
maintenance NN i
therapy NN i
. . i

AIDS NNP N
Clinical JJ N
Trials NNP N
Group NNP N
Protocol NNP N
915 CD N
Team NNP N
. . N

PURPOSE VB N
A DT N
previous JJ N
dose-ranging NN N
study NN N
of IN N
foscarnet JJ i
maintenance NN i
therapy NN i
for IN N
cytomegalovirus NN N
retinopathy NN N
showed VBD N
a DT N
positive JJ N
relationship NN N
between IN N
dose NN N
and CC N
survival NN N
but CC N
could MD N
not RB N
confirm VB N
a DT N
relationship NN N
between IN N
dose NN N
and CC N
time NN N
to TO N
first JJ N
progression NN N
. . N

This DT N
retrospective JJ N
analysis NN N
of IN N
data NNS N
from IN N
that DT N
study NN N
was VBD N
undertaken VBN N
to TO N
determine VB N
whether IN N
there EX N
was VBD N
a DT N
relationship NN N
between IN N
dose NN N
and CC N
progression NN N
rates NNS N
, , N
which WDT N
reflects VBZ N
the DT N
amount NN N
of IN N
retina NN N
destroyed VBN N
when WRB N
progression NN N
occurs VBZ N
. . N

METHODS JJ N
Patients NNPS p
were VBD N
randomly RB N
given VBN N
one CD N
of IN N
two CD i
foscarnet JJ i
maintenance NN i
therapy NN i
doses NNS i
( ( N
90 CD N
mg/kg NN N
of IN N
body NN N
weight/day JJ N
[ NNP i
FOS-90 NNP i
group NN N
] VBD N
or CC N
120 CD i
mg/kg NN i
of IN i
body NN i
weight/day JJ i
[ NNP i
FOS-120 NNP i
group NN N
] NNP N
after IN N
induction NN N
therapy NN N
. . N

Using VBG N
baseline NN N
and CC N
follow-up JJ N
photographs NN N
and CC N
pre-established JJ N
definitions NNS N
and CC N
methodology NN N
in IN N
a DT N
masked JJ N
analysis NN N
, , N
posterior JJ N
progression NN N
rates NNS N
and CC N
foveal JJ N
proximity NN N
rates NNS N
for IN N
individual JJ N
lesions NNS N
, , N
selected VBN N
by IN N
prospectively RB N
defined VBN N
criteria NNS N
, , N
were VBD N
calculated VBN N
in IN N
each DT N
patient NN N
. . N

Rates NNS N
were VBD N
compared VBN N
between IN N
groups NNS N
. . N

RESULTS VB N
The DT N
following JJ N
median JJ o
rates NNS o
were VBD N
greater JJR N
for IN N
the DT N
FOS-90 NNP i
group NN N
( ( N
N NNP N
= NNP N
8 CD N
) ) N
than IN N
for IN N
the DT N
FOS-120 NNP N
group NN N
( ( N
N NNP N
= NNP N
10 CD N
) ) N
: : N
greatest JJS o
maximum JJ o
rate NN o
at IN o
which WDT o
lesions NNS o
enlarged VBD N
in IN N
a DT N
posterior JJ N
direction NN N
( ( N
43.5 CD N
vs RB N
12.5 CD N
microns/day NN N
; : N
P NNP N
= NNP N
.002 NNP N
) ) N
; : N
posterior JJ o
progression NN o
rate NN o
for IN o
lesions NNS o
closest VBP o
to TO o
the DT o
fovea NN o
( ( N
42.8 CD N
vs RB N
5.5 CD N
microns/day NN N
; : N
P NNP N
= NNP N
.010 NNP N
) ) N
; : N
and CC N
maximum JJ o
foveal JJ o
proximity NN o
rate NN o
for IN o
either DT o
eye NN o
( ( N
32.3 CD N
vs RB N
3.4 CD N
microns/day NN N
; : N
P NNP N
= NNP N
.031 NNP N
) ) N
. . N

CONCLUSION NNP N
Patients NNPS p
receiving VBG p
higher JJR p
doses NNS p
of IN p
foscarnet NN i
have VBP N
slower VBN N
rates NNS N
of IN N
progression NN N
and CC N
therefore RB N
less JJR N
retinal JJ N
tissue NN N
damage NN N
during IN N
maintenance NN N
therapy NN N
. . N

A DT N
foscarnet JJ i
maintenance NN N
therapy NN N
dose NN N
of IN N
120 CD N
mg/kg NN N
of IN N
body NN N
weight/day JJ N
instead RB N
of IN N
90 CD N
mg/kg NN N
of IN N
body NN N
weight/day NN N
may MD N
help VB N
to TO N
preserve VB N
vision NN N
in IN N
patients NNS p
with IN p
cytomegalovirus NN p
retinopathy NN p
. . p

-DOCSTART- -17722826- O O

[ JJ N
Observation NNP N
on IN N
therapeutic JJ N
effect NN N
of IN N
acupuncture NN i
on IN N
early JJ p
peripheral JJ p
facial JJ p
paralysis NN p
] NN p
. . N

OBJECTIVE UH N
To TO N
observe VB N
therapeutic JJ N
effects NNS N
of IN N
acupuncture NN i
at IN N
different JJ N
opportunities NNS N
on IN N
peripheral JJ p
facial JJ p
paralysis NN p
. . p

METHODS NNP N
Fifty-two JJ p
cases NNS p
were VBD N
randomly RB N
divided VBN N
into IN N
a DT N
treatment NN N
group NN N
( ( N
n=28 CC N
) ) N
and CC N
a DT N
control NN N
group NN N
( ( N
n=24 RB N
) ) N
. . N

The DT N
treatment NN N
group NN N
at IN N
the DT N
acute JJ N
stage NN N
( ( N
1-10 JJ N
days NNS N
) ) N
were VBD N
treated VBN N
with IN N
acupuncture NN i
at IN i
Dicang NNP i
( ( i
ST NNP i
4 CD i
) ) i
, , i
Jiache NNP i
( ( i
ST NNP i
6 CD i
) ) i
, , i
Yangbai NNP i
( ( i
GB NNP i
14 CD i
) ) i
, , i
etc. FW i
, , N
with IN i
less JJR i
than IN i
4 CD i
points NNS i
selected VBN i
on IN i
the DT i
face NN i
and CC i
with IN i
shallow JJ i
puncture NN i
, , i
and CC i
10 CD i
days NNS i
later RB i
electroacupuncture VBP i
were VBD i
added VBN i
at IN i
acupoints NNS i
selected VBN i
routinely RB i
; : i
the DT i
control NN i
group NN i
were VBD i
treated VBN i
with IN i
the DT i
same JJ i
methods NNS i
as IN i
the DT i
treatment NN i
group NN i
but CC i
acupuncture NN i
was VBD i
not RB i
given VBN i
at IN i
the DT i
acute JJ i
stage NN i
. . i

RESULTS VB N
The DT N
cured JJ o
rate NN o
of IN N
78.6 CD N
% NN N
in IN N
the DT N
treatment NN N
group NN N
was VBD N
significantly RB N
higher JJR N
than IN N
50.0 CD N
% NN N
in IN N
the DT N
control NN N
group NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

CONCLUSION NNP N
Early JJ N
acupuncture NN i
is VBZ N
a DT N
key NN N
for IN N
achieving VBG N
the DT N
best JJS N
therapeutic JJ N
effect NN N
on IN N
facial JJ p
paralysis NN p
. . p

-DOCSTART- -9935005- O O

The DT N
influence NN N
of IN N
ventricular JJ N
fibrillation NN N
duration NN N
on IN N
defibrillation NN o
efficacy NN o
using VBG N
biphasic JJ N
waveforms NNS N
in IN N
humans NNS N
. . N

OBJECTIVES IN N
The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
prospectively RB N
investigate VB N
the DT N
influence NN N
of IN N
ventricular JJ N
fibrillation NN N
( ( N
VF NNP N
) ) N
durations NNS N
of IN N
5 CD N
, , N
10 CD N
and CC N
20 CD N
s NN N
on IN N
the DT N
defibrillation NN o
threshold NN o
( ( o
DFT NNP o
) ) o
during IN N
implantable JJ N
cardioverter-defibrillator NN N
( ( N
ICD NNP N
) ) N
implantation NN N
. . N

BACKGROUND NNP N
Although IN N
the DT N
DFT NNP o
using VBG o
monophasic JJ o
waveforms NNS o
has VBZ N
been VBN N
shown VBN N
to TO N
increase VB N
with IN N
VF NNP N
duration NN N
in IN N
humans NNS N
, , N
the DT N
effect NN N
of IN N
VF NNP N
duration NN N
on IN N
defibrillation NN N
efficacy NN N
using VBG N
biphasic JJ N
waveforms NNS N
in IN N
humans NNS N
is VBZ N
not RB N
known VBN N
. . N

METHODS NNP N
Thirty NNP p
patients NNS p
undergoing VBG p
primary JJ p
ICD NNP p
implantation NN p
or CC p
pulse JJ p
generator NN p
replacement NN p
were VBD N
randomly RB N
assigned VBN N
to TO N
have VB N
the DT N
DFT NNP i
determined VBD i
using VBG i
biphasic JJ i
shocks NNS i
at IN N
two CD N
durations NNS N
of IN N
VF NNP i
each DT N
( ( N
5 CD N
and CC N
10 CD N
s NN N
, , N
10 CD N
and CC N
20 CD N
s NN N
or CC N
5 CD N
and CC N
20 CD N
s NN N
) ) N
. . N

RESULTS NNP N
There EX N
was VBD N
no DT N
statistically RB N
significant JJ N
difference NN N
in IN N
the DT N
mean JJ o
DFT NNP o
comparing VBG N
VF NNP N
durations NNS N
of IN N
5 CD N
s NNS N
( ( N
9.5+/-6.0 CD N
J NNP N
) ) N
and CC N
10 CD N
s NN N
( ( N
10.8+/-7.0 JJ N
J NNP N
) ) N
( ( N
p=0.4 NN N
) ) N
. . N

The DT N
mean JJ o
DFT NNP o
significantly RB N
increased VBD N
from IN N
10.9+/-6.1 JJ N
J NNP N
at IN N
10 CD N
s NN N
of IN N
VF NNP N
to TO N
12.6+/-5.6 JJ N
J NNP N
( ( N
p=0.03 NN N
) ) N
at IN N
20 CD N
s NN N
of IN N
VF NNP N
, , N
and CC N
from IN N
7.0+/-3.5 JJ N
J NNP N
at IN N
5 CD N
s NN N
of IN N
VF NNP N
to TO N
10.5+/-6.3 JJ N
J NNP N
( ( N
p=0.04 NN N
) ) N
at IN N
20 CD N
s NN N
of IN N
VF NNP N
. . N

An DT N
increase NN N
in IN N
the DT N
DFT NNP o
was VBD N
observed VBN N
in IN N
14 CD p
patients NNS p
as IN N
VF NNP N
duration NN N
increased VBD N
. . N

There EX N
were VBD N
no DT N
clinical JJ N
characteristics NNS N
that WDT N
differentiated VBD N
patients NNS N
with IN N
and CC N
without IN N
an DT N
increase NN N
in IN N
the DT N
DFT NNP o
. . o

CONCLUSIONS NNP N
Defibrillation NNP o
efficacy NN o
decreases VBZ N
with IN N
increasing VBG N
VF NNP N
duration NN N
using VBG N
biphasic JJ N
waveforms NNS N
in IN N
humans NNS N
. . N

Ventricular JJ N
fibrillation NN N
durations NNS N
greater JJR N
than IN N
10 CD N
s NN N
may MD N
negatively RB N
affect VB N
the DT N
effectiveness NN o
of IN o
ICD NNP o
therapy NN o
. . o

-DOCSTART- -21484517- O O

The DT N
effects NNS N
of IN N
face NN i
expertise NN i
training NN i
on IN N
the DT o
behavioral JJ o
performance NN o
and CC N
brain NN o
activity NN o
of IN N
adults NNS p
with IN p
high JJ p
functioning VBG p
autism NN p
spectrum NN p
disorders NNS p
. . p

The DT N
effect NN N
of IN N
expertise NN i
training NN i
with IN i
faces VBZ i
was VBD N
studied VBN N
in IN N
adults NNS p
with IN p
ASD NNP p
who WP p
showed VBD p
initial JJ p
impairment NN p
in IN p
face NN p
recognition NN p
. . p

Participants NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
a DT N
computerized JJ i
training NN i
program NN i
involving VBG i
either CC i
faces VBZ i
or CC i
houses NNS i
. . i

Pre- JJ N
and CC N
post-testing NN N
included VBD N
standardized JJ N
and CC N
experimental JJ N
measures NNS N
of IN N
behavior NN o
and CC o
event-related JJ o
brain NN o
potentials NNS o
( ( o
ERPs NNP o
) ) o
, , N
as RB N
well RB N
as IN N
interviews NNS o
after IN N
training NN N
. . N

After IN N
training NN N
, , N
all DT N
participants NNS N
met VBD N
behavioral JJ o
criteria NNS o
for IN N
expertise NN N
with IN N
the DT N
specific JJ N
stimuli NN N
on IN N
which WDT N
they PRP N
received VBD N
training NN N
. . N

Scores NNS o
on IN o
standardized JJ o
measures NNS o
improved VBN N
after IN N
training VBG N
for IN N
both DT N
groups NNS N
, , N
but CC N
only RB N
the DT N
face NN N
training NN N
group NN N
showed VBD N
an DT N
increased JJ N
face NN o
inversion NN o
effect NN o
behaviorally RB o
and CC o
electrophysiological JJ o
changes NNS o
to TO o
faces VBZ o
in IN N
the DT N
P100 NNP N
component NN N
. . N

These DT N
findings NNS N
suggest VBP N
that IN N
individuals NNS p
with IN p
ASD NNP p
can MD N
gain VB N
expertise NN N
in IN N
face NN o
processing NN o
through IN N
training NN i
. . i

-DOCSTART- -6342928- O O

Caries NNS o
preventive JJ o
effects NNS o
of IN N
toothpastes NNS N
containing VBG N
monofluorophosphate NN i
and CC N
trimetaphosphate NN i
: : i
a DT N
3-year JJ N
clinical JJ N
trial NN N
. . N

The DT N
caries-preventive JJ o
effects NNS o
of IN N
two CD N
toothpastes NNS N
were VBD N
tested VBN N
in IN N
a DT N
3-year JJ N
clinical JJ N
trial NN N
involving VBG N
1319 CD p
children NNS p
aged VBN p
11-13 CD p
years NNS p
. . p

The DT N
test NN N
toothpastes NNS N
were VBD N
: : N
1 CD N
) ) N
a DT i
low JJ i
abrasion NN i
paste NN i
containing VBG i
0.8 CD i
% NN i
sodium NN i
monofluorophosphate NN i
( ( i
MFP NNP i
) ) i
, , N
and CC N
2 CD N
) ) N
a DT i
paste NN i
containing VBG i
3 CD i
% NN i
sodium NN i
trimetaphosphate NN i
( ( i
TMP NNP i
) ) i
. . i

The DT N
control NN N
toothpaste NN N
was VBD N
a DT N
conventional JJ i
, , i
moderately RB i
abrasive JJ i
paste NN i
containing VBG i
0.8 CD i
% NN i
sodium NN i
monofluorophosphate NN i
. . i

The DT N
children NNS p
were VBD N
examined VBN N
clinically RB N
and CC N
radiologically RB N
each DT N
year NN N
. . N

Toothpaste NN N
was VBD N
supplied VBN N
to TO N
the DT N
children NNS N
's POS N
homes NNS N
, , N
and CC N
its PRP$ N
use NN N
was VBD N
unsupervised JJ N
. . N

Caries NNS o
increments NNS o
after IN N
3 CD N
years NNS N
, , N
in IN N
terms NNS N
of IN N
DMF NNP N
teeth NNS N
and CC N
DMF NNP N
surfaces NNS N
, , N
showed VBD N
no DT N
significant JJ N
differences NNS N
between IN N
the DT p
MFP NNP i
test NN i
group NN p
( ( p
444 CD p
children NNS p
) ) p
and CC p
the DT p
MFP NNP i
control NN i
group NN p
( ( p
450 CD p
children NNS p
) ) p
. . N

However RB N
, , N
the DT N
TMP NNP i
test NN p
group NN p
( ( p
425 CD p
children NNS p
) ) p
had VBD N
significantly RB N
higher JJR N
caries NNS o
increments NNS o
than IN N
the DT N
MFP NNP i
control NN i
group NN N
. . N

All DT N
three CD p
groups NNS p
of IN p
children NNS p
showed VBD N
some DT N
improvement NN N
in IN N
oral JJ o
hygiene NN o
and CC o
in IN o
gingival JJ o
health NN o
, , N
but CC N
there EX N
were VBD N
no DT N
significant JJ N
differences NNS N
between IN N
the DT N
groups NNS N
. . N

-DOCSTART- -4154124- O O

Bites NNS N
by IN N
the DT N
saw-scaled JJ N
or CC N
carpet NN N
viper NN N
( ( N
Echis NNP N
carinatus NN N
) ) N
: : N
trial NN N
of IN N
two CD N
specific JJ N
antivenoms NNS N
. . N

Echis NNP N
carinatus NN N
is VBZ N
the DT N
most RBS N
important JJ N
cause NN N
of IN N
morbidity NN N
and CC N
mortality NN N
from IN N
snake JJ N
bite NN N
in IN N
Nigeria NNP N
and CC N
in IN N
many JJ N
other JJ N
parts NNS N
of IN N
the DT N
world NN N
. . N

Forty-six JJ p
patients NNS p
with IN p
systemic JJ p
poisoning NN p
by IN p
this DT p
snake NN p
were VBD N
given VBN N
echis JJ i
antivenom NN i
made VBD i
either CC i
by IN i
the DT i
South JJ i
African NNP i
Institute NNP i
for IN i
Medical NNP i
Research NNP i
( ( i
S.A.I.M.R NNP i
. . i

) ) i
or CC N
by IN N
Behringwerke NNP N
( ( i
North NNP i
and CC i
West NNP i
African NNP i
polyvalent NN i
antivenom NN i
) ) i
. . N

A DT N
simple JJ o
test NN o
of IN o
blood NN o
coagulability NN o
was VBD N
used VBN N
to TO N
assess VB N
whether IN N
an DT N
adequate JJ N
neutralizing NN N
dose NN N
of IN N
antivenom NN N
had VBD N
been VBN N
given VBN N
. . N

An DT N
average NN N
of IN N
15.2 CD N
ml NN N
S.A.I.M.R NNP i
. . i

antivenom RB i
restored VBD N
normal JJ o
coagulability NN o
permanently RB N
in IN N
all DT N
23 CD p
patients NNS p
in IN p
one CD p
group NN p
, , N
but CC N
in IN N
the DT N
other JJ N
group NN N
receiving VBG N
an DT N
average JJ N
dose NN N
of IN N
37.9 CD N
ml NNS N
Behringwerke NNP i
antivenom VBP i
normal JJ o
clotting NN o
resulted VBD N
in IN N
only RB N
18 CD N
out IN N
of IN N
23 CD N
patients NNS N
. . N

Local JJ o
tissue NN o
swelling NN o
was VBD N
similar JJ N
in IN N
both DT N
groups NNS N
, , N
but CC N
local JJ o
necrosis NN o
occurred VBD N
in IN N
three CD N
patients NNS N
treated VBN N
with IN N
Behringwerke NNP i
antivenom NN i
and CC N
in IN N
none NN N
given VBN N
S.A.I.M.R NNP N
. . N

antivenom NN N
. . N

-DOCSTART- -18467912- O O

Effect NN N
of IN N
esomeprazole JJ i
triple JJ i
therapy NN i
on IN N
eradication NN o
rates NNS o
of IN o
Helicobacter NNP o
pylori NN o
, , o
gastric JJ o
ulcer NN o
healing NN o
and CC o
prevention NN o
of IN o
relapse NN o
in IN N
gastric JJ p
ulcer JJ p
patients NNS p
. . p

OBJECTIVES NNP N
To TO N
compare VB N
esomeprazole-based JJ i
triple JJ N
therapy NN N
with IN N
esomeprazole JJ N
alone NN N
for IN N
the DT N
eradication NN o
of IN o
Helicobacter NNP o
pylori FW o
( ( o
H. NNP o
pylori NN o
) ) o
, , o
healing VBG o
of IN o
ulcer NN o
and CC o
prevention NN o
of IN o
relapse NN o
in IN N
H. NNP N
pylori-related JJ N
gastric JJ N
ulcer NN N
( ( N
GU NNP N
) ) N
diseases VBZ N
. . N

METHODS NNP N
In IN N
this DT N
double-blind NN N
study NN N
, , N
401 CD p
H. NNP p
pylori-positive JJ p
patients NNS p
with IN p
more JJR p
than IN p
or CC p
equal JJ p
to TO p
two CD p
GUs NNP p
were VBD N
randomized VBN N
to TO N
: : N
esomeprazole NN i
( ( N
20 CD N
mg NN N
) ) N
twice RB N
daily RB N
( ( N
bid NN N
) ) N
and CC N
amoxicillin NN i
( ( N
1000 CD N
mg NN N
) ) N
bid NN N
and CC N
clarithromycin NN i
( ( N
500 CD N
mg NN N
) ) N
bid NN N
( ( N
EAC NNP N
) ) N
for IN N
1 CD N
week NN N
, , N
followed VBN N
by IN N
placebo NN i
for IN N
3 CD N
weeks NNS N
( ( N
EAC NNP N
and CC N
placebo NN N
) ) N
; : N
EAC NNP N
for IN N
1 CD N
week NN N
, , N
followed VBN N
by IN N
esomeprazole NN i
( ( N
20 CD N
mg NN N
) ) N
once RB N
daily JJ N
( ( N
E20 NNP N
) ) N
for IN N
3 CD N
weeks NNS N
( ( N
EAC NNP N
and CC N
E20 NNP N
) ) N
; : N
or CC N
esomeprazole VB i
( ( N
20 CD N
mg NN N
) ) N
bid NN N
and CC N
placebo NN i
antimicrobials NNS i
for IN N
1 CD N
week NN N
, , N
followed VBN N
by IN N
E20 NNP N
for IN N
3 CD N
weeks NNS N
( ( N
E20 NNP N
bid NN N
and CC N
E20 NNP N
) ) N
. . N

Patients NNS p
with IN p
unhealed JJ p
GUs NNP p
at IN p
4 CD p
weeks NNS p
received VBD N
E20 NNP N
for IN N
an DT N
additional JJ N
4 CD N
weeks NNS N
. . N

Healed VBN p
patients NNS p
were VBD N
followed VBN N
up RP N
for IN N
12 CD N
months NNS N
. . N

RESULTS NNP N
Eradication NNP o
rates NNS o
at IN N
4 CD N
weeks NNS N
or CC N
8 CD N
weeks NNS N
were VBD N
82 CD N
% NN N
for IN N
EAC NNP N
and CC N
E20 NNP N
, , N
77 CD N
% NN N
for IN N
EAC NNP N
and CC N
placebo NN N
and CC N
9.5 CD N
% NN N
for IN N
E20 NNP N
bid NN N
and CC N
E20 NNP N
( ( N
intention-to-treat JJ N
analysis NN N
) ) N
. . N

Significantly RB N
more RBR N
patients NNS N
receiving VBG N
EAC NNP N
than IN N
those DT N
receiving JJ N
esomeprazole JJ N
alone RB N
remained VBD o
free JJ o
of IN o
GUs NNP o
during IN N
follow-up JJ N
[ NNP N
EAC NNP N
and CC N
E20 NNP N
, , N
90 CD N
% NN N
; : N
EAC NNP N
and CC N
placebo NN N
, , N
87 CD N
% NN N
; : N
P=0.0005 NNP N
for IN N
combined VBN N
group NN N
vs. FW N
esomeprazole FW N
alone RB N
[ JJ N
E20 NNP N
bid NN N
and CC N
E20 NNP N
( ( N
74 CD N
% NN N
) ) N
] NN N
. . N

All DT N
treatments NNS N
were VBD N
well RB N
tolerated VBN o
. . o

CONCLUSION NNP N
Esomeprazole-based JJ i
triple JJ N
therapy NN N
is VBZ N
effective JJ o
for IN N
the DT N
eradication NN o
of IN o
H. NNP o
pylori NN o
, , o
healing NN o
of IN o
GU NNP o
and CC o
prevention NN o
of IN o
relapse NN o
. . o

Esomeprazole NNP N
monotherapy NN N
for IN N
3 CD N
weeks NNS N
after IN N
triple JJ N
therapy NN N
may MD N
be VB N
beneficial JJ o
in IN N
terms NNS N
of IN N
healing NN N
. . N

-DOCSTART- -2192405- O O

[ IN N
The DT N
equipotency NN N
of IN N
ropivacaine NN i
, , i
bupivacaine NN i
and CC N
etidocaine NN i
] NN i
. . N

Ropivacaine NNP i
, , N
congenerate NN N
to TO N
bupivacaine VB N
and CC N
mepivacaine VB N
has VBZ N
been VBN N
widely RB N
studied VBN N
in IN N
laboratory NN N
animals NNS N
, , N
but CC N
there RB N
have VBP N
been VBN N
few JJ N
investigations NNS N
of IN N
its PRP$ N
efficacy NN N
in IN N
human JJ N
epidural JJ N
anesthesia NN N
and CC N
peripheral JJ N
nerve NN N
blocks NNS N
. . N

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
compare VB N
the DT N
three CD N
long-acting JJ N
local JJ N
anesthetics NNS N
( ( i
bupivacaine VB i
0.75 CD N
% NN N
, , N
ropivacaine VB i
1 CD N
% NN N
and CC N
etidocaine VB i
1 CD N
% NN N
) ) N
and CC N
to TO N
try VB N
, , N
with IN N
reference NN N
to TO N
previous JJ N
studies NNS N
, , N
to TO N
make VB N
some DT N
statement NN N
about IN N
the DT N
equipotency NN N
of IN N
ropivacaine JJ i
relative NN N
to TO N
bupivacaine VB i
and CC N
etidocaine VB i
. . i

METHODS NNP N
. . N

In IN N
a DT N
double JJ N
blind NN N
randomized VBN N
study NN N
, , N
epidural JJ N
anesthesia NN N
was VBD N
carried VBN N
out IN N
with IN N
20 CD N
ml NNS N
bupivacaine VBP i
0.75 CD N
% NN N
( ( N
n JJ N
= NNP N
24 CD N
) ) N
and CC N
ropivacaine VB i
1 CD N
% NN N
( ( N
n JJ N
= NNP N
21 CD N
) ) N
. . N

Following VBG N
this DT N
study NN N
epidural JJ N
anesthesia NN N
was VBD N
carried VBN N
out IN N
with IN N
20 CD N
ml NNS N
etidocaine VBP i
1 CD N
% NN N
( ( N
n JJ N
= NNP N
20 CD N
) ) N
in IN N
an DT N
open JJ N
study NN N
. . N

Patients NNS p
with IN p
ASA NNP p
I PRP p
or CC p
II NNP p
were VBD p
enrolled VBN p
in IN p
the DT p
study NN p
. . p

All DT p
patients NNS p
were VBD p
scheduled VBN p
for IN p
varicose JJ p
vein NN p
stripping VBG p
. . p

Male NNP p
and CC p
female JJ p
patients NNS p
aged VBN p
18-70 JJ p
years NNS p
and CC p
weighing VBG p
50-100 JJ p
kg NNS p
were VBD p
included VBN p
in IN p
the DT p
study NN p
. . p

Patients NNS N
were VBD N
all DT N
placed VBN N
in IN N
a DT N
sitting JJ N
position NN N
, , N
after IN N
which WDT N
the DT N
epidural JJ N
space NN N
was VBD N
identified VBN N
by IN N
the DT N
loss NN N
of IN N
resistance NN N
technique NN N
and CC N
a DT N
midline NN N
approach NN N
, , N
at IN N
the DT N
L-3/4 JJ N
interspace NN N
. . N

Injections NNS i
of IN i
3 CD i
ml NN i
of IN i
the DT i
local JJ i
anesthetic NN i
were VBD N
given VBN N
, , N
followed VBN i
by IN i
the DT i
remainder NN i
of IN i
the DT i
local JJ i
anesthetic NN i
at IN i
10 CD i
ml/min NN i
1 CD i
min NN i
later RB i
. . i

Following VBG N
injection NN N
patients NNS N
were VBD N
immediately RB N
positioned VBN N
supine NN N
. . N

Analgesia NNP N
was VBD N
determined VBN N
by IN N
the DT N
pin-prick JJ o
method NN o
and CC N
motor NN N
blockade NN N
was VBD N
assessed VBN N
according VBG N
to TO N
the DT N
Bromage NNP o
scale NN o
. . o

Heart NNP o
rate NN o
and CC o
blood NN o
pressure NN o
were VBD N
monitored VBN N
until IN N
3 CD N
h NNS N
after IN N
injection NN N
. . N

RESULTS NNP N
. . N

The DT N
latency NN o
of IN o
analgesia NN o
for IN N
the DT N
first JJ N
blocked VBN N
segment NN N
( ( N
T NNP N
12 CD N
for IN N
bupivacaine NN N
and CC N
ropivacaine NN N
and CC N
L-1 NNP N
for IN N
etidocaine NN N
) ) N
was VBD N
6.0 CD N
min NN N
for IN N
bupivacaine NN i
0.75 CD N
, , N
5.5 CD N
min NN N
for IN N
ropivacaine JJ i
1 CD N
% NN N
, , N
and CC N
5.2 CD N
min NN N
for IN N
etidocaine JJ i
1 CD N
% NN N
, , N
and CC N
the DT N
highest JJS N
thoracic JJ N
dermatome NN N
( ( N
T NNP N
5 CD N
for IN N
bupivacaine NN i
, , N
T NNP N
4 CD N
for IN N
ropivacaine NN i
and CC N
T NNP N
7 CD N
for IN N
etidocaine NN i
) ) i
was VBD N
reached VBN N
after IN N
24 CD N
+/- JJ N
10 CD N
, , N
26 CD N
+/- JJ N
9 CD N
, , N
and CC N
30 CD N
+/- JJ N
18 CD N
min NN N
for IN N
bupivacaine NN i
, , i
ropivacaine NN i
, , N
and CC N
etidocaine NN i
, , N
respectively RB N
. . N

The DT N
duration NN o
of IN o
sensory JJ o
anesthesia NN o
at IN N
the DT N
T NNP N
10 CD N
dermatomal JJ N
level NN N
was VBD N
257 CD N
+/- JJ N
102 CD N
, , N
278 CD N
+/- JJ N
67 CD N
, , N
and CC N
191 CD N
+/- JJ N
86 CD N
min NN N
for IN N
bupivacaine NN i
, , i
ropivacaine NN i
, , N
and CC N
etidocaine NN i
, , N
respectively RB N
. . N

The DT N
two-segment JJ o
regression NN o
time NN o
was VBD N
199 CD N
+/- JJ N
80 CD N
min NN N
for IN N
bupivacaine NN i
, , N
201 CD N
+/- JJ N
52 CD N
min NN N
for IN N
ropivacaine NN i
, , N
and CC N
174 CD N
+/- JJ N
81 CD N
min NN N
for IN N
etidocaine NN i
. . i

The DT N
total JJ o
duration NN o
of IN o
sensory JJ o
block NN o
was VBD N
340 CD N
+/- JJ N
103 CD N
min NN N
for IN N
bupivacaine NN i
, , N
428 CD N
+/- JJ N
65 CD N
min NN N
for IN N
ropivacaine NN i
and CC N
223 CD N
+/- JJ N
62 CD N
min NN N
for IN N
etidocaine NN i
, , N
respectively RB N
. . N

In IN N
the DT N
ropivacaine NN i
and CC N
bupivacaine NN i
groups NNS N
sensory JJ N
anesthesia NN N
was VBD N
considered VBN N
adequate NN N
for IN N
surgery NN N
in IN N
all DT N
cases NNS N
but CC N
one CD N
in IN N
each DT N
group NN N
; : N
in IN N
the DT N
etidocaine NN i
group NN N
, , N
however RB N
60 CD N
% NN N
of IN N
the DT N
patients NNS N
showed VBD N
inadequate JJ o
analgesia NN o
and CC N
all PDT N
these DT N
patients NNS N
( ( N
12/20 CD N
) ) N
required VBN N
additional JJ N
analgesics NNS N
. . N

Bupivacaine NNP i
achieved VBD N
an DT N
average NN N
of IN N
motor NN N
block NN N
2.1 CD N
, , N
ropivacaine NN i
2.3 CD N
, , N
and CC N
etidocaine VB i
2.4 CD N
. . N

CONCLUSION NNP N
. . N

The DT N
results NNS N
of IN N
this DT N
study NN N
indicate VBP N
that IN N
ropivacaine NN i
is VBZ N
an DT N
effective JJ N
local JJ N
anesthetic JJ N
agent NN N
. . N

Its PRP$ N
potency NN N
is VBZ N
about RB N
equal JJ N
to TO N
that DT N
of IN N
bupivacaine NN i
and CC N
much RB N
higher JJR N
than IN N
that DT N
of IN N
etidocaine NN i
... : i
-DOCSTART- -27348905- O O

[ JJ p
Diabetic NNP p
constipation NN p
treated VBD N
with IN N
acupoint NN i
embedding VBG i
therapy NN i
and CC i
forlax NN i
: : i
a DT N
randomized NN N
controlled VBN N
trial NN N
] NN N
. . N

OBJECTIVE UH N
To TO N
compare VB N
the DT N
difference NN N
among IN N
the DT N
combined JJ N
method NN N
of IN N
oral JJ i
administration NN i
of IN i
forlaxand NN i
acupoint NN i
embedding VBG i
therapy NN i
, , N
the DT N
simple JJ i
acupoint NN i
embedding VBG i
therapy NN i
and CC N
the DT N
simple JJ i
oral JJ i
administration NN i
of IN i
for-lax JJ i
in IN N
the DT N
clinical JJ N
efficacy NN N
on IN N
diabetic JJ p
constipation NN p
. . p

METHODS NNP N
One CD p
hundred CD p
and CC p
fifty JJ p
patients NNS p
were VBD p
randomized VBN p
intoa RB p
comprehensive JJ p
group NN p
, , N
an DT N
acupoint NN i
embedding VBG i
group NN i
and CC i
a DT i
forlax JJ i
group NN i
, , N
50 CD N
cases NNS N
in IN N
each DT N
one CD N
. . N

In IN N
the DT N
acupointembedding VBG i
group NN i
, , N
the DT N
embedding VBG i
therapy NN i
was VBD N
applied VBN N
to TO N
bilateral JJ i
Tianshu NNP i
( ( i
ST NNP i
25 CD i
) ) i
, , i
Daheng NNP i
( ( i
SP NNP i
15 CD i
) ) i
, , i
Shangjuxu NNP i
( ( i
ST NNP i
37 CD i
) ) i
and CC i
Dachangshu NNP i
( ( N
BL NNP N
25 CD N
) ) N
, , N
once RB N
a DT N
week NN N
. . N

In IN N
the DT N
forlax NN i
group NN i
, , i
forlax NN i
( ( i
polyethylene JJ i
glycol NN i
) ) i
was VBD N
prescribedfor JJ N
oral JJ N
administration NN N
, , N
once RB N
a DT N
day NN N
, , N
10 CD N
g NN N
each DT N
time NN N
. . N

In IN N
the DT N
comprehensive JJ i
group NN i
, , N
the DT N
acupoint NN i
embedding VBG i
therapyand NN i
forlax NNS i
were VBD i
combined VBN i
and CC N
the DT N
methods NNS N
were VBD N
the DT N
same JJ N
as IN N
the DT N
first JJ N
two CD N
groups NNS N
. . N

The DT N
treatment NN N
for IN N
4 CD N
weeks NNS N
wasas VBP N
one CD N
session NN N
, , N
and CC N
2 CD N
sessions NNS N
were VBD N
required VBN N
in IN N
the DT N
three CD N
groups NNS N
. . N

Separately RB N
, , N
in IN N
4 CD N
weeks NNS N
, , N
8 CD N
weeks NNS N
of IN N
treatment NN N
and2 JJ N
months NNS N
after IN N
treatment NN N
, , N
the DT N
constipation NN N
symptom NN N
scores NNS N
were VBD N
compared VBN N
among IN N
the DT N
three CD N
groups NNS N
. . N

At IN N
the DT N
end NN N
of2 NN N
sessions NNS N
of IN N
treatment NN N
, , N
the DT N
clinical JJ o
efficacy NN o
and CC o
adverse JJ o
reactions NNS o
were VBD N
compared VBN N
among IN N
the DT N
three CD N
groups NNS N
. . N

In2 NNP N
months NNS N
after IN N
treatment NN N
, , N
the DT N
recurrence NN N
rate NN N
was VBD N
compared VBN N
among IN N
the DT N
three CD N
groups NNS N
. . N

RESULTS VB N
The DT N
total JJ o
effectiverate NN o
was VBD N
98 CD N
. . N

0 CD N
% NN N
( ( N
49/50 CD N
) ) N
in IN N
the DT N
comprehensive JJ N
group NN N
, , N
better JJR N
than IN N
86 CD N
. . N

0 CD N
% NN N
( ( N
43/50 CD N
) ) N
in IN N
the DT N
acupoint NN N
embeddinggroup NN N
and CC N
78 CD N
. . N

0 CD N
% NN N
( ( N
11/50 CD N
) ) N
in IN N
the DT N
forlax NN N
group NN N
( ( N
both DT N
P NNP N
< VBD N
0 CD N
. . N

01 CD N
) ) N
. . N

In IN N
the DT N
4 CD N
weeks NNS N
and CC N
8 CD N
weeks NNS N
of IN N
treatment NN N
, , N
the DT N
con-stipation NN o
symptom NN o
scores NNS o
were VBD N
reduced VBN N
significantly RB N
as IN N
compared VBN N
with IN N
those DT N
before IN N
treatment NN N
in IN N
the DT N
three CD N
groups NNS N
( ( N
all DT N
P NNP N
< NNP N
0 CD N
. . N

05 CD N
) ) N
. . N

The DT N
results NNS N
in IN N
the DT N
comprehensive JJ N
group NN N
were VBD N
lower JJR N
than IN N
those DT N
in IN N
the DT N
other JJ N
two CD N
groups NNS N
( ( N
all DT N
P NNP N
< NNP N
0 CD N
. . N

05 CD N
) ) N
. . N

In IN N
the DT N
4 CD N
weeks NNS N
of IN N
treatment NN N
, , N
the DT N
scores NNS N
were VBD N
not RB N
different JJ N
significantly RB N
between IN N
the DT N
acupoint NN N
embedding VBG N
group NN N
and CC N
the DT N
forlax NN N
group NN N
( ( N
P NNP N
> NNP N
0.05 CD N
) ) N
. . N

In IN N
8 CD N
weeks NNS N
of IN N
treatment NN N
and CC N
2 CD N
months NNS N
after IN N
treatment NN N
, , N
the DT N
scores NNS N
in IN N
the DT N
acupoint NN N
embedding VBG N
group NN N
were VBD N
better JJR N
tan NN N
those DT N
in IN N
the DT N
forlax NN N
group NN N
( ( N
all DT N
p VBP N
< $ N
0.05 CD N
) ) N
. . N

There EX N
were VBD N
2 CD N
cases NNS N
of IN N
drug NN N
adverse JJ N
reaction NN N
in IN N
the DT N
comprehensive JJ N
group NN N
, , N
6 CD N
cases NNS N
in IN N
the DT N
forlax NN N
group NN N
and CC N
0 CD N
case NN N
in IN N
the DT N
acupoint NN N
embedding VBG N
group NN N
. . N

The DT N
recurrence NN o
rate NN o
was VBD N
8.1 CD N
% NN N
( ( N
4/49 CD N
) ) N
in IN N
the DT N
comprehensive JJ N
group NN N
, , N
lower JJR N
than IN N
32.6 CD N
% NN N
( ( N
14/43 CD N
) ) N
in IN N
the DT N
acupoint NN N
embedding VBG N
group NN N
and CC N
59.0 CD N
% NN N
( ( N
23/39 CD N
) ) N
in IN N
the DT N
forlax NN N
group NN N
( ( N
both DT N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

CONCLUSION VB N
the DT N
combined JJ i
therapy NN i
of IN i
acupoint NN i
embedding NN i
and CC i
forlax JJ i
achieves VBZ N
the DT N
better JJR N
clinical JJ N
efficacy NN N
on IN N
diabetic JJ p
constipation NN p
and CC N
constipation NN o
symptom NN o
scores VBZ o
as IN N
compared VBN N
with IN N
the DT N
simple JJ i
acupoint NN i
embedding VBG i
therapy NN i
and CC N
the DT N
oral JJ i
administration NN i
of IN i
forlax JJ i
the DT N
short-term JJ N
efficacy NN N
of IN N
the DT N
simple JJ N
acupoint NN N
embedding VBG N
therapy NN N
is VBZ N
not RB N
different JJ N
significantly RB N
from IN N
the DT N
simple JJ N
forlax JJ N
medication NN N
, , N
but CC N
the DT N
long-term JJ N
efficacy NN N
and CC N
safety NN N
are VBP N
better JJR N
than IN N
those DT N
of IN N
simple JJ N
forlax JJ N
medicaiton NN N
. . N

-DOCSTART- -20452382- O O

Response NN o
to TO o
familiar JJ o
faces VBZ o
, , i
newly RB i
familiar JJ i
faces VBZ i
, , N
and CC N
novel JJ i
faces VBZ i
as IN N
assessed VBN N
by IN N
ERPs NNP N
is VBZ N
intact JJ N
in IN N
adults NNS p
with IN p
autism NN p
spectrum NN p
disorders NNS p
. . p

Individuals NNS p
with IN p
autism NN p
spectrum NN p
disorders NNS p
( ( p
ASD NNP p
) ) p
have VBP N
pervasive JJ N
impairments NNS N
in IN N
social JJ N
functioning NN N
, , N
which WDT N
may MD N
include VB N
problems NNS N
with IN N
processing NN N
and CC N
remembering NN N
faces VBZ N
. . N

In IN N
this DT N
study NN N
, , N
we PRP N
examined VBD N
whether IN N
posterior JJ N
ERP NNP N
components NNS N
associated VBN N
with IN N
identity NN N
processing NN N
( ( N
P2 NNP N
, , N
N250 NNP N
and CC N
face-N400 NN N
) ) N
and CC N
components NNS N
associated VBN N
with IN N
early-stage JJ N
face NN N
processing NN N
( ( N
P1 NNP N
and CC N
N170 NNP N
) ) N
are VBP N
atypical JJ N
in IN N
ASD NNP N
. . N

We PRP N
collected VBD N
ERP NNP o
responses NNS o
to TO o
a DT o
familiar JJ o
repeated VBN o
face NN o
( ( o
Familiar NNP o
) ) o
, , N
an DT N
unfamiliar JJ o
repeated JJ o
face NN o
( ( o
Other JJ o
) ) o
and CC o
novel JJ o
faces VBZ o
( ( o
Novels NNP o
) ) o
in IN N
29 CD p
high-functioning JJ p
adults NNS p
with IN p
ASD NNP p
and CC p
matched VBD p
controls NNS p
. . p

For IN N
both DT N
groups NNS N
, , N
the DT N
P2 NNP N
and CC N
N250 NNP N
were VBD N
sensitive JJ N
to TO N
repetition NN N
( ( N
Other JJ N
vs. FW N
Novels NNP N
) ) N
and CC N
personal JJ N
familiarity NN N
( ( N
Familiar NNP N
vs. IN N
Other JJ N
) ) N
, , N
and CC N
the DT N
face-N400 NN N
was VBD N
sensitive JJ N
to TO N
repetition NN N
. . N

Adults NNS p
with IN p
ASD NNP p
did VBD N
not RB N
show VB N
significantly RB N
atypical JJ N
processing NN o
of IN o
facial JJ o
familiarity NN o
and CC o
repetition NN o
in IN N
an DT N
ERP NNP N
paradigm NN N
, , N
despite IN N
showing VBG N
significantly RB N
poorer JJR N
performance NN N
than IN N
controls NNS N
on IN N
a DT N
behavioral JJ N
test NN N
of IN N
face NN o
memory NN o
. . o

This DT N
study NN N
found VBD N
no DT N
evidence NN N
that IN N
early-stage JJ N
facial JJ N
identity NN N
processing NN N
is VBZ N
a DT N
primary JJ N
contributor NN N
to TO N
the DT N
face NN N
recognition NN N
deficit NN N
in IN N
high-functioning JJ N
ASD NNP N
. . N

-DOCSTART- -21206549- O O

The DT N
nightly RB N
use NN N
of IN N
sodium NN i
oxybate NN i
is VBZ N
associated VBN N
with IN N
a DT N
reduction NN N
in IN N
nocturnal JJ o
sleep JJ o
disruption NN o
: : o
a DT N
double-blind NN N
, , N
placebo-controlled JJ i
study NN N
in IN N
patients NNS p
with IN p
narcolepsy JJ p
. . p

OBJECTIVE VB N
To TO N
further RB N
explore VB N
the DT N
effects NNS N
of IN N
sodium NN i
oxybate NN i
( ( i
SXB NNP i
) ) i
administration NN N
on IN N
nocturnal JJ o
sleep NN o
in IN N
narcolepsy JJ p
patients NNS p
during IN N
a DT N
double-blind JJ N
, , N
placebo-controlled JJ N
, , N
parallel JJ N
group NN N
study VBD N
conducted VBN N
with IN N
228 CD p
adult NN p
patients NNS p
with IN p
narcolepsy/cataplexy NNS p
in IN p
the DT p
United NNP p
States NNPS p
, , p
Canada NNP p
, , p
and CC p
Europe NNP p
. . p

METHOD NNP N
Patients NNPS N
were VBD N
withdrawn VBN i
from IN i
antidepressants NNS i
and CC i
sedative/hypnotics NNS i
, , N
and CC N
then RB N
randomized VBN N
to TO N
receive VB N
4.5 CD N
, , N
6 CD N
, , N
or CC N
9 CD N
g JJ N
SXB NNP N
or CC N
placebo VB i
nightly RB N
for IN N
8 CD N
weeks NNS N
. . N

Patients NNS N
receiving VBG p
6 CD p
and CC p
9 CD p
g/night NN p
doses NNS p
were VBD N
titrated VBN N
to TO N
their PRP$ N
final JJ N
dose NN N
in IN N
weekly JJ N
1.5 CD N
g NN N
increments NNS N
, , N
while IN N
patients NNS N
receiving VBG N
placebo NN i
were VBD N
randomized VBN N
to TO N
undergo VB N
a DT N
similar JJ N
mock NN N
dose NN N
titration NN N
. . N

The DT N
use NN N
of IN N
stimulant JJ N
therapy NN N
continued VBD N
unchanged JJ N
. . N

Changes NNS o
in IN o
sleep JJ o
architecture NN o
were VBD o
measured VBN o
using VBG o
centrally RB o
scored VBN o
nocturnal JJ o
polysomnograms NNS o
. . o

Daily JJ N
diaries NNS N
were VBD N
used VBN N
to TO N
record VB N
changes NNS o
in IN o
narcolepsy NN o
symptoms NNS o
and CC o
adverse JJ o
events NNS o
. . o

RESULTS NNP N
Following VBG N
8 CD N
weeks NNS N
of IN N
SXB NNP N
treatment NN N
, , N
study NN N
patients NNS N
demonstrated VBD N
significant JJ N
dose-related JJ N
increases NNS N
in IN N
the DT N
duration NN o
of IN o
stage NN o
3 CD o
and CC o
4 CD o
sleep NN o
, , N
reaching VBG N
a DT N
median JJ N
increase NN N
of IN N
52.5 CD N
minutes NNS N
in IN N
patients NNS N
receiving VBG N
9 CD N
g NN N
nightly RB N
. . N

Compared VBN N
to TO N
placebo-treated JJ N
patients NNS N
, , N
delta JJ o
power NN o
was VBD N
significantly RB N
increased VBN N
in IN N
all DT N
dose JJ N
groups NNS N
. . N

Stage NN o
1 CD o
sleep NN o
and CC o
the DT o
frequency NN o
of IN o
nocturnal JJ o
awakenings NNS o
were VBD N
each DT N
significantly RB N
decreased VBN N
at IN N
the DT N
6 CD N
and CC N
9 CD N
g/night NN N
doses NNS N
. . N

The DT N
changes NNS o
in IN o
nocturnal JJ o
sleep NN o
coincided VBD N
with IN N
significant JJ N
decreases NNS N
in IN N
the DT N
severity NN o
and CC o
frequency NN o
of IN o
narcolepsy NN o
symptoms NNS o
. . o

CONCLUSIONS VB N
The DT N
nightly JJ N
administration NN N
of IN N
SXB NNP N
to TO N
narcolepsy VB N
patients NNS N
significantly RB N
impacts VBZ N
measures NNS N
of IN N
slow JJ o
wave NN o
sleep NN o
, , o
wake VBP o
after IN o
sleep JJ o
onset NN o
, , o
awakenings NNS o
, , o
total JJ o
sleep JJ o
time NN o
, , o
and CC o
stage NN o
1 CD o
sleep NN o
in IN N
a DT N
dose-related JJ N
manner NN N
. . N

The DT N
frequency NN o
and CC o
severity NN o
of IN o
narcolepsy NN o
symptoms NNS o
decreased VBN N
with IN N
treatment NN N
. . N

-DOCSTART- -3544187- O O

Treatment NN N
of IN N
duodenal JJ p
ulcer NN p
with IN N
low-dose JJ i
antacids NNS i
. . i

The DT N
aim NN N
of IN N
the DT N
present JJ N
investigation NN N
was VBD N
to TO N
compare VB N
the DT N
efficacy NN N
of IN N
a DT N
low-dose JJ i
antacid NN i
( ( i
Maalox NNP i
70 CD i
, , N
280 CD N
mmol/day NN N
) ) N
with IN N
that DT N
of IN N
the DT N
H2-receptor NNP i
antagonist NN i
cimetidine NN i
( ( i
Tagamet NNP i
, , N
200 CD N
mg NN N
three CD N
times NNS N
daily RB N
and CC N
400 CD N
mg/day NN N
) ) N
after IN N
14 CD N
and CC N
28 CD N
days NNS N
in IN N
the DT N
treatment NN N
of IN N
duodenal JJ p
ulcer NN p
. . p

The DT N
prospective JJ N
multicentre NN N
study NN N
included VBD N
171 CD p
patients NNS p
with IN p
endoscopically RB p
confirmed VBN p
duodenal JJ p
ulcers NNS p
. . p

The DT N
patients NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
the DT N
treatment NN N
groups NNS N
with IN N
antacid JJ i
containing VBG i
Mg NNP i
and CC i
Al NNP i
hydroxide NN i
( ( i
M NNP i
) ) i
( ( i
4 CD i
X RB N
70 CD N
mmol/day NN N
; : N
n CC N
= VB N
86 CD N
) ) N
or CC N
to TO N
the DT N
group NN N
receiving VBG N
cimetidine NN i
( ( N
T NNP N
) ) N
( ( N
1000 CD N
mg/day NN N
; : N
n CC N
= VB N
85 CD N
) ) N
. . N

The DT N
two CD p
treatment NN p
groups NNS p
were VBD N
matched VBN N
for IN N
age NN N
, , N
sex NN N
, , N
drinking NN N
and CC N
smoking NN N
habits NNS N
, , N
and CC N
drug NN N
use NN N
. . N

Endoscopic JJ N
examinations NNS N
were VBD N
carried VBN N
out RP N
before IN N
the DT N
start NN N
of IN N
treatment NN N
and CC N
14 CD N
days NNS N
later RB N
. . N

If IN N
the DT N
ulcer NN N
was VBD N
still RB N
present JJ N
at IN N
this DT N
time NN N
, , N
the DT N
second JJ N
endoscopic NN N
examination NN N
was VBD N
done VBN N
after IN N
a DT N
further JJ N
14 CD N
days NNS N
. . N

Endoscopically RB N
, , N
the DT N
ulcer NN N
had VBD N
healed VBN o
at IN N
14 CD N
days NNS N
in IN N
38.8 CD N
% NN N
( ( N
M NNP N
) ) N
and CC N
in IN N
34.9 CD N
% NN N
( ( N
T NNP N
) ) N
and CC N
at IN N
28 CD N
days NNS N
in IN N
80.0 CD N
% NN N
( ( N
M NNP N
) ) N
and CC N
74.7 CD N
% NN N
( ( N
T NNP N
) ) N
, , N
respectively RB N
. . N

The DT N
healing VBG o
rate NN o
did VBD N
not RB N
differ VB N
significantly RB N
between IN N
the DT N
two CD N
treatment NN N
groups NNS N
. . N

Complaints NNS o
, , N
measured VBN N
as IN N
percentage NN N
of IN N
days NNS N
per IN N
week NN N
with IN N
upper JJ o
abdominal JJ o
pain NN o
, , N
were VBD N
significantly RB N
reduced VBN N
in IN N
both DT N
groups NNS N
. . N

No DT N
significant JJ N
differences NNS N
were VBD N
found VBN N
between IN N
the DT N
two CD N
treatment NN N
groups NNS N
with IN N
regard NN N
to TO N
pain VB o
relief NN o
or CC o
side NN o
effects NNS o
. . o

Treatment NN N
had VBD N
to TO N
be VB N
abandoned VBN N
in IN N
one CD N
patient NN N
receiving VBG N
antacid NN N
because IN N
of IN N
diarrhoea NN N
and CC N
in IN N
one CD N
patient NN N
receiving VBG N
cimetidine NN N
because IN N
of IN N
the DT N
absence NN N
of IN N
any DT N
response NN N
. . N

( ( N
ABSTRACT NNP N
TRUNCATED NNP N
AT NNP N
250 CD N
WORDS NNP N
) ) N
-DOCSTART- -11413274- O O

Gabapentin NNP N
but CC N
not RB N
vigabatrin JJ N
is VBZ N
effective JJ N
in IN N
the DT N
treatment NN N
of IN N
acquired VBN p
nystagmus NN p
in IN p
multiple JJ p
sclerosis NN p
: : p
How NNP N
valid JJ N
is VBZ N
the DT N
GABAergic NNP N
hypothesis NN N
? . N
Acquired NNP N
nystagmus NN N
occurs VBZ N
frequently RB N
in IN N
patients NNS p
with IN p
multiple JJ p
sclerosis NN p
and CC N
is VBZ N
often RB N
the DT N
cause NN N
of IN N
illusory JJ N
motion NN N
of IN N
the DT N
environment NN N
( ( N
oscillopsia NN N
) ) N
, , N
and CC N
blurring NN N
of IN N
vision NN N
. . N

Based VBN N
primarily RB N
on IN N
the DT N
beneficial JJ N
effect NN N
of IN N
gabapentin NN N
on IN N
acquired VBN N
pendular JJ N
nystagmus NN N
( ( N
APN NNP N
) ) N
, , N
a DT N
GABAergic NNP N
mechanism NN N
in IN N
controlling VBG N
nystagmus NN N
has VBZ N
been VBN N
hypothesised VBN N
. . N

If IN N
increasing VBG N
GABA NNP N
concentrations NNS N
in IN N
the DT N
CNS NNP N
are VBP N
critical JJ N
for IN N
the DT N
treatment NN N
of IN N
nystagmus NN N
, , N
then RB N
a DT N
selective JJ N
GABAergic NNP N
drug NN N
should MD N
be VB N
highly RB N
successful JJ N
. . N

However RB N
, , N
as IN N
gabapentin NN N
is VBZ N
not RB N
a DT N
selective JJ N
GABAergic NNP N
agent NN N
, , N
vigabatrin NN N
, , N
a DT N
pure JJ N
GABAergic NNP N
medication NN N
, , N
and CC N
gabapentin NN N
, , N
were VBD N
compared VBN N
in IN N
a DT N
single JJ N
blind NN N
cross NN N
over IN N
trial NN N
in IN N
eight CD p
patients NNS p
with IN p
definite JJ p
multiple JJ p
sclerosis NN p
. . p

Patients NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
begin VB N
with IN N
gabapentin NN i
( ( i
1200 CD i
mg FW i
daily RB i
) ) i
or CC i
vigabatrin NN i
( ( i
2000 CD i
mg FW i
daily RB i
) ) i
. . N

Neuro-ophthalmological JJ N
and CC N
electro-oculographic JJ N
( ( N
EOG NNP N
) ) N
evaluations NNS N
were VBD N
performed VBN N
four CD N
and CC N
three CD N
times NNS N
, , N
respectively RB N
. . N

Treatment NNP N
efficacy NN o
was VBD N
based VBN N
on IN N
improving VBG N
visual JJ o
acuity NN o
and CC N
EOG NNP o
indices NNS o
( ( o
amplitude NN o
or CC o
frequency NN o
of IN o
nystagmus NN o
, , o
or CC o
both DT o
) ) o
by IN N
at IN N
least JJS N
50 CD N
% NN N
of IN N
pretreatment NN N
values NNS N
. . N

Three CD p
out IN p
of IN p
eight CD p
patients NNS p
dropped VBD p
out RP p
due JJ p
to TO p
adverse JJ o
effects NNS o
. . o

In IN N
the DT N
remaining VBG N
five CD N
patients NNS N
gabapentin NN N
improved VBN N
symptomatic JJ o
pendular NN o
or CC o
gaze NN o
evoked VBN o
jerk NN o
nystagmus NN o
in IN N
four CD N
. . N

Three CD p
patients NNS p
decided VBD p
to TO p
continue VB p
gabapentin JJ p
therapy NN p
. . p

Importantly RB N
, , N
vigabatrin FW N
proved VBD N
useful JJ N
in IN N
only RB N
one CD N
out IN N
of IN N
five CD N
patients NNS N
, , N
suggesting VBG N
that IN N
gabapentin NN N
effectiveness NN N
may MD N
be VB N
related VBN N
to TO N
additional JJ N
non-GABAergic JJ N
mechanisms NN N
of IN N
action NN N
. . N

Interaction NN N
with IN N
cerebral JJ N
glutamate NN N
transmission NN N
by IN N
inhibition NN N
of IN N
NMDA NNP N
receptor NN N
might MD N
be VB N
an DT N
alternative JJ N
hypothesis NN N
for IN N
the DT N
therapeutic JJ N
action NN N
of IN N
gabapentin NN N
. . N

-DOCSTART- -21859193- O O

Ameliorating VBG o
intrusive JJ o
memories NNS o
of IN o
distressing VBG o
experiences NNS o
using VBG N
computerized JJ i
reappraisal NN i
training NN i
. . i

The DT N
types NNS N
of IN N
appraisals NNS N
that WDT N
follow VBP p
traumatic JJ p
experiences NNS p
have VBP N
been VBN N
linked VBN N
to TO N
the DT N
emergence NN N
of IN N
posttraumatic JJ N
stress NN N
disorder NN N
( ( N
PTSD NNP N
) ) N
. . N

Could MD N
changing VBG N
reappraisals NNS N
following VBG N
a DT N
stressful JJ N
event NN N
reduce VB N
the DT N
emergence NN N
of IN N
PTSD NNP N
symptoms NNS N
? . N
The DT N
present JJ N
proof-of-principle JJ N
study NN N
examined VBD N
whether IN N
a DT N
nonexplicit NN i
, , i
systematic JJ i
computerized VBD i
training NN i
in IN N
reappraisal JJ N
style NN N
following VBG p
a DT p
stressful JJ p
event NN p
( ( p
a DT p
highly RB p
distressing JJ p
film NN p
) ) p
could MD N
reduce VB N
intrusive JJ N
memories NNS N
of IN N
the DT N
film NN N
, , N
and CC N
symptoms NNS N
associated VBN N
with IN N
posttraumatic JJ N
distress NN N
over IN N
the DT N
subsequent JJ N
week NN N
. . N

Participants NNS p
were VBD N
trained VBN i
to TO i
adopt VB i
a DT i
generally RB i
positive JJ i
or CC i
negative JJ i
poststressor NN i
appraisal NN i
style NN i
using VBG i
a DT i
series NN i
of IN i
scripted JJ i
vignettes NNS i
after IN i
having VBG i
been VBN i
exposed VBN i
to TO i
highly RB i
distressing VBG i
film NN i
clips NNS i
. . i

The DT N
training NN N
targeted VBD N
self-efficacy JJ N
beliefs NNS N
and CC N
reappraisals NNS N
of IN N
secondary JJ N
emotions NNS N
( ( N
emotions NNS N
in IN N
response NN N
to TO N
the DT N
emotional JJ N
reactions NNS N
elicited VBN N
by IN N
the DT N
film NN N
) ) N
. . N

Successful JJ N
appraisal JJ N
induction NN N
was VBD N
verified VBN N
using VBG N
novel JJ N
vignettes NNS N
and CC N
via IN N
change NN N
scores NNS N
on IN N
the DT N
post NN N
traumatic JJ N
cognitions NNS N
inventory NN N
. . N

Compared VBN N
with IN N
those DT N
trained JJ N
negatively RB N
, , N
those DT N
trained VBN N
positively RB N
reported VBN N
in IN N
a DT N
diary JJ N
fewer JJR N
intrusive JJ o
memories NNS o
of IN N
the DT N
film NN N
during IN N
the DT N
subsequent JJ N
week NN N
, , N
and CC N
lower JJR N
scores NNS N
on IN N
the DT N
Impact NNP o
of IN o
Event NNP o
Scale NNP o
( ( N
a DT N
widely RB N
used JJ N
measure NN N
of IN N
posttraumatic JJ N
stress NN N
symptoms NNS N
) ) N
. . N

Results JJ N
support NN N
the DT N
use NN N
of IN N
computerized JJ i
, , i
nonexplicit JJ i
, , i
reappraisal JJ i
training NN i
after IN p
a DT p
stressful JJ p
event NN p
has VBZ N
occurred VBN N
and CC N
provide VB N
a DT N
platform NN N
for IN N
future JJ N
translational JJ N
studies NNS N
with IN N
clinical JJ N
populations NNS N
that WDT N
have VBP N
experienced VBN N
significant JJ N
real-world JJ N
stress NN N
or CC N
trauma NN N
. . N

-DOCSTART- -20637249- O O

Double-blind NNP N
, , N
placebo-controlled JJ N
trial NN N
of IN N
risperidone NN i
plus CC i
topiramate NN i
in IN N
children NNS p
with IN p
autistic JJ p
disorder NN p
. . p

BACKGROUND NNP N
Autism NNP N
is VBZ N
a DT N
complex JJ N
neurodevelopmental JJ N
disorder NN N
that WDT N
forms VBZ N
part NN N
of IN N
a DT N
spectrum NN N
of IN N
related JJ N
disorders NNS N
referred VBD N
to TO N
as IN N
Autism NNP N
Spectrum NNP N
Disorders NNP N
. . N

The DT N
present JJ N
study NN N
assessed VBD N
the DT N
effects NNS N
of IN N
topiramate NN i
plus CC i
risperidone NN i
in IN N
the DT N
treatment NN N
of IN N
autistic JJ p
disorder NN p
. . p

METHOD NNP N
Forty NNP p
children NNS p
between IN p
the DT p
ages NNS p
of IN p
4 CD p
and CC p
12 CD p
years NNS p
with IN p
a DT p
DSM NNP p
IV NNP p
clinical JJ p
diagnosis NN p
of IN p
autism NN p
who WP p
were VBD p
outpatients NNS p
from IN p
a DT p
specialty NN p
clinic NN p
for IN p
children NNS p
were VBD p
recruited VBN p
. . p

The DT N
children NNS p
presented VBN N
with IN N
a DT N
chief JJ N
complaint NN N
of IN N
severely RB p
disruptive JJ p
symptoms NNS p
related VBN p
to TO p
autistic JJ p
disorder NN p
. . p

Patients NNS N
were VBD N
randomly RB N
allocated VBN N
to TO N
topiramate+risperidone VB i
( ( i
Group NNP i
A NNP i
) ) i
or CC i
placebo+risperidone NN i
( ( i
Group NNP i
B NNP i
) ) i
for IN N
an DT N
8-week JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
study NN N
. . N

The DT N
dose NN N
of IN N
risperidone NN i
was VBD N
titrated VBN N
up RB N
to TO N
2 CD N
mg/day NN N
for IN N
children NNS N
between IN N
10 CD N
and CC N
40 CD N
kg NN N
and CC N
3 CD N
mg/day NN N
for IN N
children NNS N
weighting VBG N
above IN N
40 CD N
kg NN N
. . N

The DT N
dose NN N
of IN N
topiramate NN i
was VBD N
titrated VBN N
up RB N
to TO N
200 CD N
mg/day NN N
depending VBG N
on IN N
weight NN N
( ( N
100 CD N
mg/day NN N
for IN N
< $ N
30 CD N
kg NN N
and CC N
200 CD N
mg/day NN N
for IN N
> $ N
30 CD N
kg NN N
) ) N
. . N

Patients NNS N
were VBD N
assessed VBN N
at IN N
baseline NN N
and CC N
after IN N
2 CD N
, , N
4 CD N
, , N
6 CD N
and CC N
8 CD N
weeks NNS N
after IN N
starting VBG N
medication NN N
. . N

Measure NN N
of IN N
outcome NN N
was VBD N
the DT N
Aberrant NNP o
Behavior NNP o
Checklist-Community NNP o
( ( o
ABC-C NNP o
) ) o
Rating VBG o
Scale NNP o
. . o

RESULTS NNP N
Difference NNP N
between IN N
the DT N
two CD N
protocols NNS N
was VBD N
significant JJ N
as IN N
the DT N
group NN N
that WDT N
received VBD N
topiramate NN i
had VBD N
a DT N
greater JJR N
reduction NN o
in IN o
ABC-C NNP o
subscale NN o
scores NNS o
for IN o
irritability NN o
, , o
stereotypic JJ o
behavior NN o
and CC o
hyperactivity/noncompliance NN o
. . o

CONCLUSION VB N
The DT N
results NNS N
suggest VBP N
that IN N
the DT N
combination NN N
of IN N
topiramate NN i
with IN N
risperidone NN N
may MD N
be VB N
superior JJ N
to TO N
risperidone VB N
monotherapy NN N
for IN N
children NNS p
with IN p
autistic JJ p
disorder NN p
. . p

However RB N
the DT N
results NNS N
need VBP N
to TO N
be VB N
further RB N
confirmed VBN N
by IN N
a DT N
larger JJR N
randomized VBN N
controlled VBN N
trial NN N
. . N

-DOCSTART- -2576261- O O

Effect NN N
of IN N
two CD N
monophasic JJ i
oral JJ i
contraceptives NNS i
containing VBG i
gestodene NN i
or CC i
desogestrel NN i
on IN N
serum NN N
lipoprotein NN N
lipid JJ N
levels NNS N
. . N

Forty-nine NNP p
healthy JJ p
women NNS p
aged VBN p
20-35 JJ p
years NNS p
who WP p
had VBD p
not RB p
been VBN p
pregnant JJ p
or CC p
using VBG p
an DT p
oral JJ i
contraceptive NN i
( ( i
OC NNP i
) ) i
for IN p
the DT p
previous JJ p
3 CD p
months NNS p
were VBD N
randomized VBN N
into IN N
two CD N
groups NNS N
, , N
one CD N
group NN N
taking VBG N
an DT N
OC NNP i
containing VBG N
75 CD N
micrograms NNS N
gestodene NN i
( ( i
GTD NNP i
) ) i
and CC N
30 CD N
micrograms NNS N
ethinyl VBP i
estradiol NN i
( ( i
EE NNP i
) ) i
, , N
and CC N
the DT N
other JJ N
group NN N
using VBG N
an DT N
OC NNP i
with IN N
150 CD N
micrograms NNS N
desogestrel NN i
( ( i
DSG NNP i
) ) i
and CC N
30 CD N
micrograms NNS N
EE NNP i
. . i

Fasting VBG o
blood NN o
samples NNS o
were VBD N
taken VBN N
before RB N
treatment NN N
, , N
and CC N
after IN N
cycles NNS N
3 CD N
and CC N
6 CD N
, , N
between IN N
the DT N
18th CD N
and CC N
the DT N
22nd CD N
day NN N
of IN N
the DT N
cycle NN N
. . N

Blood NNP o
lipoprotein JJ o
lipid JJ o
levels NNS o
were VBD N
measured VBN N
. . N

Serum NNP o
total JJ o
cholesterol NN o
did VBD o
not RB o
change VB o
significantly RB N
in IN N
both DT N
groups NNS N
. . N

However RB N
, , N
in IN N
the DT N
first JJ N
three CD N
cycles NNS N
, , N
serum JJ o
triglyceride NN o
increased VBN o
by IN N
46 CD N
% NN N
and CC N
40 CD N
% NN N
and CC N
HDL-cholesterol NNP o
by IN o
14 CD o
% NN o
and CC N
8 CD o
% NN o
in IN o
the DT o
GTD NNP o
and CC o
DSG NNP o
groups NNS N
, , N
respectively RB N
. . N

The DT N
serum NN o
LDL NNP o
level NN o
decreased VBN o
by IN N
6.2 CD N
% NN N
and CC N
11.8 CD N
% NN N
, , N
respectively RB N
. . N

Between VB N
the DT N
third JJ N
and CC N
sixth JJ N
cycle NN N
, , N
no DT o
further JJ o
significant JJ o
changes NNS o
were VBD N
observed VBN N
, , N
nor CC N
did VBD N
these DT N
changes NNS N
differ VBP N
significantly RB N
between IN N
the DT N
two CD N
groups NNS N
. . N

In IN N
conclusion NN N
, , N
both DT N
OC NNP i
preparations NNS N
exerted VBD N
small JJ o
and CC o
probably RB o
favorable JJ o
effects NNS o
on IN o
serum NN o
lipoprotein NN o
lipid JJ o
levels NNS o
. . o

-DOCSTART- -24730708- O O

Effect NN N
of IN N
propranolol NN i
on IN N
facial JJ N
scanning NN N
in IN N
autism NN p
spectrum NN p
disorder NN p
: : p
a DT N
preliminary JJ N
investigation NN N
. . N

BACKGROUND NNP N
Autism NNP p
spectrum NN p
disorder NN p
( ( p
ASD NNP p
) ) p
is VBZ N
a DT N
neurodevelopmental JJ N
disorder NN N
characterized VBN N
by IN N
social JJ N
communication NN N
impairments NNS N
and CC N
restricted VBN N
, , N
repetitive JJ N
behaviors NNS N
. . N

Whereas NNP N
current JJ N
pharmacological JJ N
interventions NNS N
for IN N
ASD NNP N
focus VBP N
primarily RB N
on IN N
psychiatric JJ N
symptoms NNS N
, , N
including VBG N
agitation NN N
and CC N
obsessive JJ N
behaviors NNS N
, , N
few JJ N
agents NNS N
target VB N
core NN N
symptomatology NN N
. . N

It PRP N
has VBZ N
been VBN N
previously RB N
hypothesized VBN N
that IN N
abnormalities NNS N
in IN N
facial JJ N
scanning NN N
, , N
such JJ N
as IN N
reduced JJ N
eye NN N
contact NN N
or CC N
increased VBN N
mouth JJ N
fixation NN N
, , N
contribute NN N
to TO N
social JJ N
communication NN N
deficits NNS N
in IN N
ASD NNP N
. . N

In IN N
addition NN N
, , N
previous JJ N
reports NNS N
have VBP N
suggested VBN N
elevated JJ N
stress NN N
and CC N
anxiety NN N
in IN N
ASD NNP N
, , N
symptoms NNS N
that WDT N
are VBP N
believed VBN N
to TO N
impact VB N
facial JJ N
scanning NN N
patterns NNS N
. . N

OBJECTIVES IN N
The DT N
present JJ N
pilot NN N
study NN N
sought VBD N
to TO N
explore VB N
the DT N
effects NNS N
of IN N
pharmacological JJ N
intervention NN N
via IN N
propranolol NN i
, , N
a DT N
nonselective JJ N
?-adrenergic JJ N
antagonist NN N
and CC N
known VBN N
anxiolytic JJ N
, , N
on IN N
facial JJ N
scanning NN N
in IN N
ASD NNP N
. . N

Specifically RB N
, , N
we PRP N
wished VBD N
to TO N
determine VB N
whether IN N
there EX N
is VBZ N
an DT N
increase NN N
in IN N
eye NN N
contact NN N
and CC N
a DT N
decrease NN N
in IN N
mouth JJ N
fixation NN N
with IN N
administration NN N
of IN N
propranolol NN N
. . N

METHOD NNP p
A NNP p
sample NN p
of IN p
14 CD p
participants NNS p
with IN p
ASD NNP p
and CC p
14 CD p
matched VBD p
controls NNS p
participated VBN N
in IN N
two CD N
study NN N
sessions NNS N
in IN N
which WDT i
propranolol NN i
and CC i
placebo NN i
were VBD i
administered VBN i
in IN i
a DT i
counterbalanced JJ i
, , i
double-blinded JJ i
manner NN i
. . i

At IN N
each DT N
session NN N
, , N
ocular JJ o
fixation NN o
data NNS o
were VBD N
collected VBN N
during IN i
presentation NN i
of IN i
video JJ i
stimuli NNS i
of IN i
16 CD i
human JJ i
faces VBZ i
. . i

Fixation NNP N
time NN N
on IN N
the DT N
eye NN N
, , N
nose JJ N
, , N
and CC N
mouth JJ N
regions NNS N
of IN N
the DT N
face NN N
stimuli NN N
was VBD N
analyzed VBN N
. . N

RESULTS VB N
The DT N
baseline JJ N
fixation NN N
patterns NNS N
for IN N
the DT p
ASD NNP p
and CC p
control NN p
groups NNS p
did VBD N
not RB N
significantly RB N
differ VBP N
; : N
however RB N
, , N
administration NN N
of IN N
propranolol NN N
was VBD N
associated VBN N
with IN N
a DT N
significant JJ N
reduction NN N
in IN o
mouth NN o
fixation NN o
for IN N
the DT p
ASD NNP p
group NN p
. . p

Additionally RB N
, , N
mouth JJ o
fixation NN o
was VBD N
positively RB N
related VBN N
to TO N
nonverbal JJ N
communication NN N
impairment NN N
in IN N
the DT N
ASD NNP N
group NN N
. . N

CONCLUSIONS NNP N
Although IN N
eye NN N
fixation NN N
in IN N
ASD NNP N
appears VBZ N
typical JJ N
in IN N
the DT N
present JJ N
study NN N
, , N
the DT N
effect NN N
of IN N
propranolol NN N
in IN N
reducing VBG N
mouth JJ N
fixation NN N
suggests VBZ N
an DT N
important JJ N
focus NN N
for IN N
further JJ N
research NN N
. . N

Future JJ N
studies NNS N
are VBP N
needed VBN N
to TO N
better RBR N
characterize VB N
the DT N
relationship NN N
between IN N
stress NN N
and CC N
anxiety NN N
and CC N
facial JJ N
scanning NN N
in IN N
ASD NNP N
, , N
as RB N
well RB N
as IN N
the DT N
effects NNS N
of IN N
pharmacological JJ N
intervention NN N
. . N

-DOCSTART- -26122384- O O

Risk NN N
of IN N
anterior JJ p
cruciate NN p
ligament NN p
fatigue NN p
failure NN p
is VBZ p
increased VBN N
by IN N
limited JJ N
internal JJ N
femoral JJ N
rotation NN N
during IN N
in IN N
vitro NN N
repeated VBN N
pivot JJ N
landings NNS N
. . N

BACKGROUND VB N
A DT N
reduced JJ N
range NN N
of IN N
hip NN N
internal JJ N
rotation NN N
is VBZ N
associated VBN N
with IN N
increased JJ N
peak NN N
anterior JJ N
cruciate NN N
ligament NN N
( ( N
ACL NNP N
) ) N
strain NN N
and CC N
risk NN N
for IN N
injury NN N
. . N

It PRP N
is VBZ N
unknown JJ N
, , N
however RB N
, , N
whether IN N
limiting VBG N
the DT N
available JJ N
range NN N
of IN N
internal JJ N
femoral JJ N
rotation NN N
increases VBZ N
the DT N
susceptibility NN N
of IN N
the DT N
ACL NNP N
to TO N
fatigue VB N
failure NN N
. . N

HYPOTHESIS NNP N
Risk NNP N
of IN N
ACL NNP N
failure NN N
is VBZ N
significantly RB N
greater JJR N
in IN N
female JJ p
knee NN p
specimens NNS p
with IN N
a DT N
limited JJ N
range NN N
of IN N
internal JJ N
femoral JJ N
rotation NN N
, , N
smaller JJR N
femoral-ACL JJ N
attachment NN N
angle NN N
, , N
and CC N
smaller JJR N
tibial JJ N
eminence NN N
volume NN N
during IN N
repeated VBN N
in IN N
vitro NN N
simulated VBD N
single-leg JJ N
pivot JJ N
landings NNS N
. . N

STUDY NNP N
DESIGN NNP N
Controlled NNP N
laboratory NN N
study NN N
. . N

METHODS VB N
A DT i
custom-built JJ i
testing NN i
apparatus NN i
was VBD N
used VBN N
to TO N
simulate VB N
repeated VBN i
single-leg JJ i
pivot NN i
landings NNS i
with IN i
a DT i
4?-body JJ i
weight NN i
impulsive JJ i
load NN i
that WDT i
induces VBZ i
knee JJR i
compression NN i
, , i
knee NN i
flexion NN i
, , i
and CC i
internal JJ i
tibial JJ i
torque NN i
in IN p
32 CD p
paired JJ p
human JJ p
knee NN p
specimens NNS p
from IN p
8 CD p
male NN p
and CC p
8 CD p
female JJ p
donors NNS p
. . p

These DT N
test NN N
loads NNS N
were VBD N
applied VBN N
to TO N
each DT N
pair NN N
of IN N
specimens NNS N
, , N
in IN N
one CD N
knee NN N
with IN N
limited JJ N
internal JJ N
femoral JJ N
rotation NN N
and CC N
in IN N
the DT N
contralateral JJ N
knee NN N
with IN N
femoral JJ N
rotation NN N
resisted VBN N
by IN N
2 CD N
springs NNS N
to TO N
simulate VB N
the DT N
active JJ N
hip NN N
rotator NN N
muscles NNS N
' POS N
resistance NN N
to TO N
stretch VB N
. . N

The DT N
landings NNS N
were VBD N
repeated VBN N
until IN N
ACL NNP N
failure NN N
occurred VBD N
or CC N
until IN N
a DT N
minimum NN N
of IN N
100 CD N
trials NNS N
were VBD N
executed VBN N
. . N

The DT N
angle NN N
at IN N
which WDT N
the DT N
ACL NNP N
originates VBZ N
from IN N
the DT N
femur NN N
and CC N
the DT N
tibial JJ N
eminence NN N
volume NN N
were VBD N
measured VBN N
on IN N
magnetic JJ N
resonance NN N
images NNS N
. . N

RESULTS VB N
The DT N
final JJ N
Cox NNP N
regression NN N
model NN N
( ( N
P NNP N
= NNP N
.024 NNP N
) ) N
revealed VBD N
that IN N
range NN N
of IN o
internal JJ o
femoral JJ o
rotation NN o
and CC o
sex NN o
of IN o
donor NN o
were VBD N
significant JJ N
factors NNS N
in IN N
determining VBG N
risk NN N
of IN o
ACL NNP o
fatigue JJ o
failure NN o
. . o

The DT N
specimens NNS N
with IN N
limited JJ N
range NN N
of IN N
internal JJ N
femoral JJ N
rotation NN N
had VBD N
a DT N
failure NN o
risk NN o
17.1 CD N
times NNS N
higher JJR N
than IN N
did VBD N
the DT N
specimens NNS N
with IN N
free JJ N
rotation NN N
( ( N
P NNP N
= NNP N
.016 NNP N
) ) N
. . N

The DT N
female JJ N
knee NN N
specimens NNS N
had VBD N
a DT N
risk NN o
of IN o
ACL NNP o
failure NN o
26.9 CD N
times NNS N
higher JJR N
than IN N
the DT N
male NN N
specimens NNS N
( ( N
P NNP N
= NNP N
.055 NNP N
) ) N
. . N

CONCLUSION NNP N
Limiting VBG N
the DT N
range NN N
of IN N
internal JJ N
femoral JJ N
rotation NN N
during IN N
repetitive JJ N
pivot JJ N
landings NNS N
increases VBZ N
the DT o
risk NN o
of IN o
an DT o
ACL NNP o
fatigue NN o
failure NN N
in IN N
comparison NN N
with IN N
free JJ N
rotation NN N
in IN N
a DT N
cadaveric JJ N
model NN N
. . N

CLINICAL JJ N
RELEVANCE NNP N
Screening NNP N
for IN i
restricted VBN i
internal JJ i
rotation NN i
at IN i
the DT i
hip NN i
in IN N
ACL NNP N
injury NN N
prevention NN N
programs NNS N
as RB N
well RB N
as IN N
in IN N
individuals NNS N
with IN N
ACL NNP N
injuries NNS N
and/or VBP N
reconstructions NNS N
is VBZ N
warranted VBN N
. . N

-DOCSTART- -12651635- O O

Single-dose JJ N
tranexamic JJ i
acid NN i
reduces NNS N
postoperative VBP o
bleeding NN o
after IN N
coronary JJ i
surgery NN i
in IN N
patients NNS p
treated VBN p
with IN p
aspirin NN i
until IN p
surgery NN p
. . p

UNLABELLED NNP N
Tranexamic NNP i
acid NN i
reduces NNS N
postoperative VBP N
bleeding NN N
after IN N
coronary JJ i
artery NN i
bypass NN i
grafting VBG i
. . i

We PRP N
evaluated VBD N
the DT N
effects NNS o
of IN N
a DT N
single JJ N
dose NN N
of IN N
tranexamic JJ i
acid NN i
given VBN N
immediately RB N
before IN N
cardiopulmonary JJ i
bypass NN i
( ( i
CPB NNP i
) ) i
in IN p
patients NNS p
treated VBN p
with IN p
aspirin NN i
until IN p
the DT p
day NN p
before IN p
surgery NN p
. . p

The DT N
study NN N
was VBD N
a DT N
prospective JJ N
, , N
randomized VBN N
, , N
double-blinded JJ N
, , N
placebo-controlled JJ i
, , N
parallel-group JJ N
trial NN N
. . N

Eighty JJ p
patients NNS p
were VBD p
included VBN p
and CC p
divided VBN p
into IN p
two CD p
groups NNS p
: : p
one CD p
group NN p
received VBD p
tranexamic JJ i
acid NN i
30 CD i
mg/kg NN i
, , i
and CC i
one CD i
group NN i
received VBD i
placebo NN i
( ( i
0.9 CD i
% NN i
NaCl NNP i
) ) i
as IN i
a DT i
bolus JJ i
injection NN i
before IN i
CPB NNP i
. . i

Postoperative NNP o
blood NN o
loss NN o
was VBD N
recorded VBN N
for IN N
16 CD N
h. JJ N
Transfusions NNS o
of IN o
blood NN o
products NNS o
were VBD N
recorded VBN N
for IN N
the DT N
whole JJ N
hospital NN N
stay NN N
. . N

Transfusions NNS N
of IN N
packed JJ N
red JJ N
cells NNS N
were VBD N
given VBN N
when WRB N
the DT N
hematocrit NN o
value NN o
was VBD N
less JJR N
than IN N
20 CD N
% NN N
during IN N
CPB NNP N
and CC N
less JJR N
than IN N
25 CD N
% NN N
after IN N
surgery NN N
. . N

The DT p
patients NNS p
in IN p
the DT p
tranexamic JJ i
acid NN i
group NN p
had VBD N
significantly RB N
less RBR N
postoperative JJ o
bleeding NN o
compared VBN N
with IN N
the DT p
patients NNS p
in IN p
the DT p
placebo NN i
group NN p
( ( N
mean JJ N
[ NNP N
SD NNP N
] NNP N
) ) N
( ( N
475 CD N
[ RB N
274 CD N
] JJ N
mL NN N
versus NN N
713 CD N
[ NN N
243 CD N
] NNP N
mL NN N
; : N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

An DT N
effective JJ N
inhibition NN o
of IN o
fibrinolysis NN o
was VBD N
found VBN N
in IN N
patients NNS p
receiving VBG p
tranexamic JJ i
acid NN i
. . i

Tranexamic NNP i
acid NN i
reduces NNS N
postoperative VBP o
bleeding NN o
in IN N
coronary JJ i
artery NN i
bypass NN i
grafting VBG i
patients NNS N
treated VBN N
with IN N
aspirin NN N
until IN N
the DT N
day NN N
before IN N
surgery NN N
. . N

IMPLICATIONS NNP N
Continuation NNP N
of IN N
aspirin JJ i
medication NN N
until IN N
the DT N
day NN N
before IN N
coronary JJ i
artery NN i
bypass NN i
grafting NN i
may MD N
increase VB N
postoperative JJ o
bleeding NN o
. . o

The DT N
administration NN N
of IN N
a DT N
single JJ N
dose NN N
of IN N
tranexamic JJ i
acid NN i
( ( N
30 CD N
mg/kg NN N
) ) N
immediately RB N
before IN N
cardiopulmonary JJ N
bypass NN N
significantly RB N
reduced VBD N
postoperative JJ o
bleeding NN o
and CC N
inhibited JJ N
fibrinolysis NN o
in IN N
these DT N
patients NNS N
. . N

-DOCSTART- -7028532- O O

A DT N
controlled VBN N
trial NN N
with IN N
diclofensine NN i
, , N
a DT N
new JJ N
psychoactive JJ N
drug NN N
, , N
in IN N
the DT N
treatment NN N
of IN N
depression NN N
. . N

Diclofensine NNP i
inhibits VBZ N
the DT N
uptake NN N
of IN N
serotonin NN N
, , N
noradrenaline NN N
and CC N
dopamine NN N
. . N

In IN N
a DT N
controlled JJ N
study NN N
, , N
out-patients NNS p
suffering VBG p
from IN p
moderate JJ p
to TO p
severe JJ p
depression NN p
were VBD N
treated VBN N
with IN N
the DT N
objective NN N
of IN N
assessing VBG N
the DT N
new JJ N
drug NN N
's POS N
therapeutically RB N
effective JJ N
dose NN N
range NN N
. . N

Maprotiline NNP i
was VBD N
used VBN N
as IN N
a DT N
reference NN N
drug NN N
: : N
fourteen JJ p
patients NNS p
were VBD p
assigned VBN p
to TO p
receive VB p
diclofensine NN i
and CC p
thirteen NN p
to TO p
receive VB p
maprotiline NN i
in IN p
a DT p
double-blind JJ p
design NN p
. . p

Depending VBG N
on IN N
tolerance NN N
and CC N
efficacy NN N
, , N
they PRP N
were VBD N
treated VBN N
for IN N
periods NNS N
ranging VBG N
from IN N
5 CD N
to TO N
150 CD N
days NNS N
. . N

Doses NNS N
were VBD N
titrated VBN N
to TO N
the DT N
optimum NN N
. . N

Findings NNS N
suggest VBP N
that IN N
a DT N
50 CD N
mg JJ N
daily JJ N
dose NN N
of IN N
diclofensine NN i
would MD N
be VB N
sufficient JJ N
for IN N
the DT N
majority NN N
of IN N
the DT N
patients NNS N
. . N

The DT N
dosage NN N
can MD N
be VB N
safely RB N
increased VBN N
up RP N
to TO N
150 CD N
mg NNS N
daily RB N
but CC N
this DT N
offers VBZ N
few JJ N
therapeutic JJ N
advantages NNS N
. . N

While IN N
the DT N
efficacy NN o
index NN o
of IN N
the DT N
two CD N
drugs NNS N
was VBD N
similar JJ N
( ( N
approximately RB N
60 CD N
% NN N
) ) N
, , N
they PRP N
differed VBD N
greatly RB N
in IN N
their PRP$ N
profile NN o
of IN o
side-effects NNS o
. . o

No DT o
signs NNS o
of IN o
abrupt JJ o
dissipation NN o
of IN o
the DT o
achieved JJ o
clinical JJ o
effects NNS o
were VBD N
observed VBN N
during IN N
continued JJ N
treatment NN N
, , N
and CC N
no DT o
withdrawal NN o
reactions NNS o
were VBD N
observed VBN N
when WRB N
the DT N
treatment NN N
was VBD N
stopped VBN N
. . N

The DT N
new JJ N
drug NN N
may MD N
be VB N
more RBR N
effective JJ o
in IN N
treating VBG N
patients NNS p
in IN p
whom WP p
a DT p
psycho-energizing NN p
and CC p
mood NN p
alleviating VBG p
effect NN p
is VBZ p
desired VBN p
. . p

-DOCSTART- -16393600- O O

Pilot NNP N
study NN N
of IN N
imiquimod JJ i
5 CD i
% NN i
cream NN i
as IN N
adjunctive JJ i
therapy NN i
to TO N
curettage VB i
and CC N
electrodesiccation NN i
for IN N
nodular JJ p
basal NN p
cell NN p
carcinoma NN p
. . p

BACKGROUND NNP N
Curettage NNP i
and CC i
electrodesiccation NN i
( ( i
C NNP i
& CC i
D NNP i
) ) i
is VBZ N
a DT N
widely RB N
used VBN N
method NN N
to TO N
treat VB N
nodular JJ p
basal NN p
cell NN p
carcinoma NN p
( ( p
BCC NNP p
) ) p
. . p

However RB N
, , N
residual JJ N
tumor NN N
is VBZ N
present JJ N
immediately RB N
after IN N
the DT N
procedure NN N
in IN N
approximately RB N
20 CD N
to TO N
40 CD N
% NN N
of IN N
cases NNS N
. . N

Imiquimod NNP N
, , N
a DT N
topical JJ N
immune NN N
response NN N
modifier NN N
that WDT N
targets VBZ N
Toll-like NNP N
receptor NN N
7 CD N
, , N
is VBZ N
currently RB N
approved VBN N
for IN N
superficial JJ N
BCC NNP N
. . N

OBJECTIVE NNP N
In IN N
a DT N
double-blind JJ N
, , N
vehicle-controlled JJ N
study NN N
, , N
the DT N
administration NN N
of IN N
imiquimod NN i
after IN N
C NNP N
& CC N
D NNP N
was VBD N
investigated VBN N
to TO N
determine VB N
if IN N
the DT N
combination NN N
regimen NNS N
would MD N
reduce VB N
the DT N
frequency NN N
of IN N
residual JJ N
tumor NN N
compared VBN N
with IN N
C NNP i
& CC i
D NNP i
alone RB N
in IN N
patients NNS p
with IN p
nodular JJ p
BCC NNP p
. . p

METHODS NNP N
Twenty NNP p
patients NNS p
received VBD N
three CD N
cycles NNS N
of IN N
C NNP i
& CC i
D NNP i
followed VBN N
by IN N
imiquimod JJ i
5 CD i
% NN i
or CC i
vehicle NN i
cream NN i
once RB i
daily JJ i
for IN N
1 CD N
month NN N
as IN N
adjunctive JJ i
therapy NN i
. . i

The DT N
primary JJ N
end NN N
point NN N
was VBD N
the DT N
frequency NN N
of IN N
residual JJ N
tumor NN N
. . N

The DT N
secondary JJ N
end NN N
points NNS N
included VBD N
the DT N
time NN N
to TO N
heal VB N
and CC N
cosmetic JJ N
appearance NN N
. . N

RESULTS NNP N
Twenty NNP p
patients NNS p
were VBD N
randomized VBN N
to TO N
the DT N
imiquimod NN i
( ( p
n JJ p
= NNP p
10 CD p
) ) p
or CC N
vehicle NN i
( ( p
n JJ p
= NNP p
10 CD p
) ) p
treatment NN N
group NN N
. . N

At IN N
8 CD N
weeks NNS N
, , N
the DT N
proportion NN o
of IN o
patients NNS o
with IN o
residual JJ o
tumor NN o
was VBD N
substantially RB N
decreased VBN N
with IN N
imiquimod JJ i
therapy NN N
( ( N
10 CD N
% NN N
) ) N
compared VBN N
with IN N
vehicle NN i
( ( N
40 CD N
% NN N
) ) N
. . N

Wounds VBZ N
in IN N
the DT N
vehicle NN N
group NN N
healed VBD o
more RBR N
quickly RB N
than IN N
those DT N
in IN N
the DT N
imiquimod NN N
group NN N
, , N
although IN N
by IN N
8 CD N
weeks NNS N
, , N
all DT N
excision NN N
sites NNS N
were VBD N
healed VBN N
. . N

The DT N
majority NN N
of IN N
scars NNS N
in IN N
the DT N
control NN N
group NN N
were VBD N
atrophic JJ N
and CC N
hypopigmented VBD N
, , N
whereas IN N
most JJS N
scars NNS N
in IN N
the DT N
imiquimod NN i
group NN N
were VBD N
flat JJ N
and CC N
slightly RB N
pink VBP N
. . N

CONCLUSION NNP N
Imiquimod NNP i
5 CD N
% NN N
cream NN N
once RB N
daily JJ N
for IN N
1 CD N
month NN N
as IN N
adjunctive JJ N
therapy NN N
after IN N
C NNP i
& CC i
D NNP i
substantially RB N
reduced VBD N
the DT N
frequency NN N
of IN N
residual JJ N
tumor NN N
and CC N
improved VBD N
the DT N
cosmetic JJ N
appearance NN N
compared VBN N
with IN N
C NNP i
& CC i
D NNP i
alone RB N
. . N

These DT N
preliminary JJ N
results NNS N
suggest VBP N
that IN N
further JJ N
studies NNS N
to TO N
investigate VB N
imiquimod JJ i
adjunctive JJ i
therapy NN i
are VBP N
warranted VBN N
. . N

-DOCSTART- -25519880- O O

Sustaining VBG N
control NN o
of IN o
schistosomiasis NN o
mansoni NN o
in IN N
moderate JJ p
endemicity NN p
areas NNS p
in IN p
western JJ p
C?te NNP p
d'Ivoire NN p
: : p
a DT N
SCORE NNP N
study NN N
protocol NN N
. . N

BACKGROUND NNP N
Schistosomiasis NNP N
is VBZ N
a DT N
parasitic JJ N
disease NN N
that WDT N
occurs VBZ N
in IN N
the DT p
tropics NNS p
and CC p
subtropics NNS p
. . p

The DT N
mainstay NN N
of IN N
control NN N
is VBZ N
preventive JJ N
chemotherapy NN N
with IN i
praziquantel NN i
. . i

In IN N
Africa NNP N
, , N
an DT N
estimated VBN N
230 CD N
million CD N
people NNS N
require VBP N
preventive JJ N
chemotherapy NN N
. . N

In IN N
western JJ N
C?te NNP N
d'Ivoire NN N
, , N
infections NNS N
with IN N
Schistosoma NNP N
mansoni NNS N
are VBP N
widespread JJ N
. . N

To TO N
provide VB N
an DT N
evidence-base NN N
for IN N
programme NN N
decisions NNS N
about IN N
preventive JJ N
chemotherapy NN N
to TO N
sustain VB o
control NN o
of IN o
schistosomiasis NN o
, , o
a DT N
5-year JJ N
multi-country NN N
study NN N
with IN N
different JJ N
treatment NN N
arms NNS N
has VBZ N
been VBN N
designed VBN N
by IN N
the DT i
Schistosomiasis NNP i
Consortium NNP i
for IN i
Operational NNP i
Research NNP i
and CC i
Evaluation NNP i
( ( i
SCORE NNP i
) ) i
and CC i
is VBZ N
currently RB N
being VBG N
implemented VBN N
in IN N
various JJ N
African JJ N
settings NNS N
, , N
including VBG N
C?te NNP N
d'Ivoire NN N
. . N

METHODS/DESIGN NNP N
We PRP N
report VBP N
the DT N
study NN N
protocol NN N
, , N
including VBG N
ethics NNS N
statement NN N
and CC N
insight NN N
from IN N
a DT N
large-scale JJ N
eligibility NN N
survey NN N
carried VBD N
out RP N
in IN N
four CD p
provinces NNS p
in IN p
western JJ p
C?te NNP p
d'Ivoire NN p
. . p

The DT p
study NN N
protocol NN N
has VBZ N
been VBN N
approved VBN N
by IN N
the DT N
ethics NNS N
committees NNS N
of IN N
Basel NNP N
and CC N
C?te NNP N
d'Ivoire NN p
. . p

A DT p
total NN p
of IN p
12,110 CD p
children NNS p
, , p
aged VBN p
13-14 CD p
years NNS p
, , p
from IN p
264 CD p
villages NNS p
were VBD p
screened VBN p
for IN p
S. NNP p
mansoni NNP p
using VBG p
duplicate JJ p
Kato-Katz NNP p
thick NN p
smears NNS p
from IN p
single JJ p
stool NN p
samples NNS p
. . p

Among IN p
the DT p
schools NNS p
with IN p
a DT p
S. NNP p
mansoni NN p
prevalence NN p
of IN p
10-24 JJ p
% NN p
, , p
75 CD p
schools NNS p
were VBD p
selected VBN p
and CC p
randomly RB p
assigned VBN p
to TO p
one CD p
of IN p
three CD p
treatment NN p
arms NNS p
. . p

In IN p
each DT p
school NN p
, , p
three CD p
stool NN p
samples NNS p
are VBP p
being VBG p
collected VBN p
from IN p
100 CD p
children NNS p
aged VBN p
9-12 CD p
years NNS p
annually RB p
and CC p
one CD p
stool NN p
sample NN p
from IN p
100 CD p
first-year JJ p
students NNS p
at IN p
baseline NN p
and CC p
in IN p
the DT p
final JJ p
year NN p
and CC p
subjected VBN p
to TO p
duplicate VB p
Kato-Katz NNP p
thick JJ p
smears NNS p
. . p

Cost NN p
and CC N
coverage NN N
data NNS N
for IN N
the DT N
different JJ N
intervention NN N
arms NNS N
, , N
along IN N
with IN N
environmental JJ N
, , N
political JJ N
and CC N
other JJ N
characteristics NNS N
that WDT N
might MD N
impact VB N
on IN N
the DT N
infection NN N
prevalence NN N
and CC N
intensity NN N
will MD N
be VB N
recorded VBN N
in IN N
each DT N
study NN N
year NN N
, , N
using VBG N
a DT N
pretested JJ N
village NN N
inventory NN N
form NN N
. . N

DISCUSSION VB N
The DT N
study NN N
will MD N
document VB N
changes NNS o
in IN o
S. NNP o
mansoni NNP o
infection NN o
prevalence NN o
and CC o
intensity NN o
according VBG o
to TO N
different JJ N
treatment NN N
schemes NNS N
. . N

Moreover RB o
, , o
factors NNS o
that WDT o
determine VBP o
the DT o
effectiveness NN o
of IN o
preventive JJ o
chemotherapy NN o
will MD o
be VB N
identified VBN N
. . N

These DT N
factors NNS N
will MD N
help VB N
to TO N
develop VB N
reasonable JJ N
measures NNS N
of IN N
force NN N
of IN N
transmission NN N
that WDT N
can MD N
be VB N
used VBN N
to TO N
make VB N
decisions NNS N
about IN N
the DT N
most RBS N
cost-effective JJ N
means NNS N
of IN o
lowering VBG o
prevalence NN o
, , o
intensity NN o
and CC o
transmission NN o
in IN o
a DT o
given VBN N
setting NN N
. . N

The DT N
gathered JJ N
information NN N
and CC N
results NNS N
will MD N
inform VB N
how WRB N
to TO N
effectively RB N
sustain VB o
control NN o
of IN o
schistosomiasis NN o
at IN o
a DT o
low JJ N
level NN N
in IN N
different JJ N
social-ecological JJ N
contexts NN N
. . N

TRIAL NNP N
REGISTRATION NNP N
ISRCTN99401114 NNP N
( ( N
date NN N
assigned VBN N
: : N
12 CD N
November NNP N
2014 CD N
) ) N
. . N

-DOCSTART- -12614193- O O

ACE NNP i
inhibitors NNS i
or CC i
AT-1 JJ i
antagonists NNS i
- : N
which WDT N
is VBZ N
OPTIMAAL NNP N
after IN N
acute JJ N
myocardial JJ N
infarction NN N
? . N
OPTIMAAL NNP N
( ( N
Optimal NNP N
Trial NNP N
in IN N
Myocardial NNP N
Infarction NNP N
with IN N
the DT N
Angiotensin NNP N
II NNP N
Antagonist NNP N
Losartan NNP N
) ) N
is VBZ N
the DT N
first JJ N
major JJ N
study NN N
to TO N
compare VB N
an DT N
angiotensin NN i
II NNP i
Type NNP i
1 CD i
antagonist NN i
losartan NN i
( ( N
Cozaar NNP N
trade NN N
mark NN N
, , N
Merck NNP N
) ) N
with IN N
an DT N
ACE NNP N
inhibitor NN N
captonpril NN i
( ( N
Capoten NNP N
trade NN N
mark NN N
, , N
Elan NNP N
) ) N
after IN p
myocardial JJ p
infarction NN p
in IN p
patients NNS p
with IN p
left JJ p
ventricular JJ p
dysfunction NN p
. . p

Patients NNS p
were VBD N
assigned VBN N
to TO N
a DT N
target NN N
dose NN N
of IN N
losartan JJ i
50 CD N
mg/day NN N
and CC N
captopril NN i
50 CD N
mg NN N
t.i.d. NN N
, , N
as IN N
tolerated VBN N
. . N

The DT N
primary JJ N
end NN N
point NN N
was VBD N
all-cause JJ o
mortality NN o
and CC N
there EX N
were VBD N
499 CD N
( ( N
18 CD N
% NN N
) ) N
and CC N
447 CD N
( ( N
16 CD N
% NN N
) ) N
deaths NNS o
in IN N
the DT N
losartan NN i
and CC i
captopril NN i
group NN N
, , N
respectively RB N
( ( N
p JJ N
= NNP N
0.07 CD N
) ) N
. . N

However RB N
, , N
there EX N
were VBD N
significantly RB N
more JJR N
cardiovascular JJ o
deaths NNS o
with IN N
losartan NN N
( ( N
420 CD N
, , N
15 CD N
% NN N
) ) N
than IN N
with IN N
captopril NN i
( ( N
363 CD N
, , N
13 CD N
% NN N
; : N
p CC N
= VB N
0.03 CD N
) ) N
. . N

Losartan NNP i
was VBD N
better RBR N
tolerated VBN o
than IN N
captopril NN i
with IN N
fewer JJR N
patients NNS o
discontinuing VBG o
medication NN o
( ( N
17 CD N
versus RB N
23 CD N
% NN N
for IN N
losartan NN i
and CC N
captopril NN i
, , N
respectively RB N
) ) N
. . N

In IN N
conclusion NN N
, , N
if IN N
tolerated VBN N
, , N
captopril NN i
should MD N
remain VB N
the DT N
preferred JJ N
treatment NN N
for IN N
patients NNS p
after IN N
complicated VBN N
acute JJ o
myocardial JJ o
infarction NN o
. . o

-DOCSTART- -23782653- O O

Home-based JJ i
reach-to-grasp JJ i
training NN i
for IN p
people NNS p
after IN p
stroke NN p
: : p
study NN p
protocol NN p
for IN N
a DT N
feasibility NN N
randomized VBN N
controlled VBN N
trial NN N
. . N

BACKGROUND VB N
This DT N
feasibility NN N
study NN N
is VBZ N
intended VBN N
to TO N
assess VB N
the DT N
acceptability NN N
of IN N
home-based JJ i
task-specific JJ i
reach-to-grasp NN i
( ( i
RTG NNP i
) ) i
training NN N
for IN N
people NNS p
with IN p
stroke NN p
, , N
and CC N
to TO N
gather VB N
data NNS N
to TO N
inform VB N
recruitment NN N
, , N
retention NN N
, , N
and CC N
sample JJ N
size NN N
for IN N
a DT N
definitive JJ N
randomized NN N
controlled VBD N
trial NN N
. . N

METHODS/DESIGN NNP N
This DT N
is VBZ N
to TO N
be VB N
a DT N
randomized JJ N
controlled JJ N
feasibility NN N
trial NN N
recruiting VBG N
50 CD p
individuals NNS p
with IN p
upper-limb JJ p
motor NN p
impairment NN p
after IN p
stroke NN p
. . p

Participants NNS p
will MD p
be VB p
recruited VBN p
after IN p
discharge NN p
from IN p
hospital NN p
and CC p
up RB p
to TO p
12 CD p
months NNS p
post-stroke RB p
from IN p
hospital NN p
stroke NN p
services NNS p
and CC p
community NN p
therapy-provider NN p
services NNS p
. . p

Participants NNS p
will MD N
be VB N
assessed VBN N
at IN N
baseline NN N
, , N
and CC N
then RB N
electronically RB N
randomized VBN N
and CC N
allocated VBN N
to TO N
group NN N
by IN N
minimization NN N
, , N
based VBN N
on IN N
the DT N
time NN N
post-stroke JJ N
and CC N
extent NN N
of IN N
upper-limb JJ N
impairment NN N
. . N

The DT N
intervention NN N
group NN N
will MD N
receive VB N
14 CD i
training NN i
sessions NNS i
, , N
each DT N
1 CD N
hour NN N
long RB N
, , N
with IN N
a DT N
physiotherapist NN N
over IN N
6 CD N
weeks NNS N
and CC N
will MD N
be VB N
encouraged VBN N
to TO N
practice NN N
independently RB N
for IN N
1 CD N
hour/day NN N
to TO N
give VB N
a DT N
total NN N
of IN N
56 CD N
hours NNS N
of IN N
training NN N
time NN N
per IN N
participant NN N
. . N

Participants NNS p
allocated VBD N
to TO N
the DT N
control NN N
group NN N
will MD N
receive VB N
arm NN i
therapy NN i
in IN N
accordance NN N
with IN N
usual JJ N
care NN N
. . N

Participants NNS p
will MD N
be VB N
measured VBN N
at IN N
7 CD N
weeks NNS N
post-randomization NN N
, , N
and CC N
followed-up NN N
at IN N
3 CD N
and CC N
6 CD N
months NNS N
post-randomization NN N
. . N

Primary JJ N
outcome NN N
measures NNS N
for IN N
assessment NN o
of IN o
arm NN o
function NN o
are VBP N
the DT o
Action NNP o
Research NNP o
Arm NNP o
Test NNP o
( ( o
ARAT NNP o
) ) o
and CC o
Wolf NNP o
Motor NNP o
Function NNP o
Test NNP o
( ( o
WMFT NNP o
) ) o
. . o

Secondary JJ N
measures NNS N
are VBP N
the DT N
Motor NNP o
Activity NNP o
Log NNP o
, , o
Stroke NNP o
Impact NNP o
Scale NNP o
, , o
Carer NNP o
Strain NNP o
Index NNP o
, , o
and CC o
health NN o
and CC o
social JJ o
care NN o
resource NN o
use NN o
. . o

All DT N
assessments NNS N
will MD N
be VB N
conducted VBN N
by IN N
a DT N
trained JJ N
assessor NN N
blinded VBD N
to TO N
treatment NN N
allocation NN N
. . N

Recruitment NNP o
, , o
adherence NN o
, , o
withdrawals NNS o
, , o
adverse JJ o
events NNS o
( ( o
AEs NNP o
) ) o
, , o
and CC o
completeness NN o
of IN o
data NNS o
will MD N
be VB N
recorded VBN N
and CC N
reported VBN N
. . N

DISCUSSION NNP N
This DT N
study NN N
will MD N
determine VB N
the DT N
acceptability NN o
of IN N
the DT N
intervention NN N
, , N
the DT N
characteristics NNS N
of IN N
the DT N
population NN N
recruited VBD N
, , N
recruitment NN N
and CC N
retention NN N
rates NNS N
, , N
descriptive JJ N
statistics NNS N
of IN N
outcomes NNS N
, , N
and CC N
incidence NN N
of IN N
AEs NNP N
. . N

It PRP N
will MD N
provide VB N
the DT N
information NN N
needed VBN N
for IN N
planning VBG N
a DT N
definitive JJ N
trial NN N
to TO N
test VB N
home-based JJ N
RTG NNP N
training NN N
. . N

TRIAL NNP N
REGISTRATION NNP N
ISRCTN NNP N
ISRCTN56716589 NNP N
. . N

-DOCSTART- -12713767- O O

Effects NNS N
of IN N
ezetimibe NN i
, , N
a DT N
new JJ N
cholesterol NN N
absorption NN N
inhibitor NN N
, , N
on IN N
plasma JJ o
lipids NNS o
in IN N
patients NNS p
with IN p
primary JJ p
hypercholesterolemia NN p
. . p

AIMS VB N
This DT N
randomized VBN N
, , N
double-blind JJ N
, , N
placebo-controlled JJ i
, , N
parallel-group JJ N
study NN N
evaluated VBD N
the DT N
safety NN N
and CC N
efficacy NN N
of IN N
ezetimibe $ i
10 CD N
mg/day NN N
in IN N
patients NNS p
with IN p
primary JJ p
hypercholesterolemia NN p
. . p

METHODS NNP N
AND CC N
RESULTS NNP N
Following NNP N
dietary JJ N
stabilization NN N
, , N
a DT N
2-12-week JJ N
washout NN N
period NN N
, , N
and CC N
a DT N
4-week JJ N
, , N
single-blind JJ N
, , N
placebo JJ i
lead-in JJ N
period NN N
, , N
827 CD p
patients NNS p
with IN p
baseline JJ p
low-density NN p
lipoprotein NN p
cholesterol NN p
( ( p
LDL-C NNP p
) ) p
> NN p
or CC p
=3.36 VB p
mmol/l NN p
( ( p
130 CD p
mg/dl NN p
) ) p
to TO p
< VB p
or CC p
=6.47 VB p
mmol/l NN p
( ( p
250 CD p
mg/dl NN p
) ) p
and CC p
triglycerides VBZ p
< NN p
or CC p
=3.95 VB p
mmol/l NN p
( ( p
350 CD p
mg/dl NN p
) ) p
were VBD N
randomized VBN N
3:1 CD N
to TO N
receive VB N
ezetimibe NN i
10 CD i
mg NN i
or CC i
placebo NN i
orally RB N
once RB N
daily JJ N
in IN N
the DT N
morning NN N
for IN N
12 CD N
weeks NNS N
. . N

The DT N
primary JJ N
efficacy NN N
endpoint NN N
was VBD N
percentage NN o
reduction NN o
in IN o
direct JJ o
plasma NN o
LDL-C. NNP o
Ezetimibe NNP N
reduced VBD N
direct JJ o
LDL-C NNP o
by IN N
a DT N
mean NN N
of IN N
17.7 CD N
% NN N
from IN N
baseline NN N
to TO N
endpoint VB N
, , N
compared VBN N
with IN N
an DT N
increase NN N
of IN N
0.8 CD N
% NN N
with IN N
placebo NN N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

Response NN N
to TO N
ezetimibe VB i
was VBD N
generally RB N
consistent JJ N
across IN N
all DT N
subgroups NNS N
analyzed VBN N
. . N

Ezetimibe NNP i
also RB N
significantly RB N
improved VBN N
levels NNS o
of IN o
plasma NN o
total JJ o
cholesterol NN o
, , o
apolipoprotein NN o
B NNP o
, , o
high-density NN o
lipoprotein NN o
( ( o
2 CD o
) ) o
-cholesterol NN o
and CC o
lipoprotein NN o
( ( o
a DT o
) ) o
, , o
and CC o
elicited VBD o
a DT o
trend NN o
toward IN o
lower JJR o
triglyceride NN o
levels NNS o
. . o

Ezetimibe NNP i
did VBD N
not RB N
alter VB N
the DT o
serum NN o
concentrations NNS o
of IN o
lipid-soluble JJ o
vitamins NNS o
or CC o
significantly RB o
affect JJ o
baseline NN o
or CC o
stimulated VBN o
cortisol JJ o
production NN o
. . o

Ezetimibe NNP i
was VBD N
well RB o
tolerated VBN o
, , N
with IN N
a DT N
safety NN o
profile NN o
similar JJ N
to TO N
that DT N
of IN N
placebo NN N
. . N

CONCLUSIONS NNP N
Ezetimibe NNP i
, , N
which WDT N
significantly RB N
reduces VBZ N
LDL-C NNP o
and CC N
favorably RB N
affects VBZ N
other JJ N
lipid JJ o
variables NNS o
, , N
may MD N
provide VB N
a DT N
well RB o
tolerated VBN o
and CC N
effective JJ N
new JJ N
option NN N
for IN N
lipid JJ N
management NN N
in IN N
the DT N
future NN N
. . N

-DOCSTART- -24330473- O O

Short- JJ o
and CC o
long-term JJ o
effects NNS o
of IN N
tactile JJ i
massage NN i
on IN N
salivary JJ o
cortisol NN o
concentrations NNS o
in IN N
Parkinson NNP p
's POS p
disease NN p
: : p
a DT N
randomised JJ N
controlled VBN N
pilot NN N
study NN N
. . N

BACKGROUND NNP N
Parkinson NNP N
's POS N
disease NN N
( ( N
PD NNP N
) ) N
is VBZ N
a DT N
chronic JJ N
neurodegenerative JJ N
disorder NN N
with IN N
limited JJ N
knowledge NN N
about IN N
the DT N
normal JJ N
function NN N
and CC N
effects NNS N
of IN N
non-pharmacological JJ i
therapies NNS i
on IN N
the DT N
hypothalamic-pituitary-adrenal JJ o
( ( o
HPA NNP o
) ) o
axis NN o
. . o

The DT N
aim NN N
of IN N
the DT N
study NN N
was VBD N
to TO N
analyse VB N
the DT N
basal NN o
diurnal JJ o
and CC o
total JJ o
secretion NN o
of IN o
salivary JJ o
cortisol NN o
in IN N
short- JJ N
and CC N
long-term JJ N
aspects NNS N
of IN N
tactile JJ i
massage NN i
( ( i
TM NNP i
) ) i
. . i

METHODS NNP N
DESIGN NNP N
Prospective NNP N
, , N
Controlled NNP N
and CC N
Randomised VBD N
Multicentre NNP N
Trial NNP N
. . N

SETTING NN N
AND JJ N
INTERVENTIONS NNP N
Forty-five NNP p
women NNS p
and CC p
men NNS p
, , p
aged VBN p
50-79 CD p
years NNS p
, , p
were VBD p
recruited VBN p
. . p

Twenty-nine NN p
of IN p
them PRP p
were VBD p
blindly RB p
randomised VBN p
to TO p
tactile VB i
massage NN i
( ( i
TM NNP i
) ) i
and CC p
16 CD p
of IN p
them PRP p
to TO p
the DT p
control NN i
group NN p
, , p
rest NN i
to TO i
music NN i
( ( i
RTM NNP i
) ) i
. . i

Ten CD N
interventions NNS N
were VBD N
given VBN N
during IN N
8 CD N
weeks NNS N
followed VBN N
by IN N
a DT N
26 CD N
weeks NNS N
of IN N
follow JJ N
up RB N
. . N

Salivary JJ o
cortisol NN o
was VBD N
collected VBN N
at IN N
8 CD N
am VBP N
, , N
1 CD N
pm NN N
, , N
8 CD N
pm NN N
, , N
and CC N
8 CD N
am VBP N
the DT N
next JJ N
day NN N
, , N
on IN N
five CD N
occasions NNS N
. . N

With IN N
the DT N
first JJ N
and CC N
eighth JJ N
interventions NNS N
, , N
it PRP N
was VBD N
collected VBN N
immediately RB N
before IN N
and CC N
after IN N
intervention NN N
. . N

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
The DT N
primary JJ N
aim NN N
was VBD N
to TO N
assess VB o
and CC o
compare VB o
cortisol JJ o
concentrations NNS o
before IN N
and CC N
immediately RB N
after IN N
intervention NN N
and CC N
also RB N
during IN N
the DT N
follow-up JJ N
period NN N
. . N

The DT N
secondary JJ N
aim NN N
was VBD N
to TO N
assess VB N
the DT N
impact NN o
of IN o
age NN o
, , o
gender NN o
, , o
body NN o
mass NN o
index NN o
( ( o
BMI NNP o
) ) o
, , o
duration NN o
and CC o
severity NN o
of IN o
PD NNP o
, , o
effects NNS o
of IN o
interventional JJ o
time-point NN o
of IN o
the DT o
day NN o
, , o
and CC o
levodopa JJ o
doses NNS o
on IN o
cortisol JJ o
concentration NN o
. . o

RESULTS VB N
The DT N
median JJ o
cortisol NN o
concentrations NNS o
for IN N
all DT N
participants NNS N
were VBD N
16.0 CD N
, , N
5.8 CD N
, , N
2.8 CD N
, , N
and CC N
14.0 CD N
nmol/L NN N
at IN N
baseline NN N
, , N
later RB N
reproduced VBD N
four CD N
times NNS N
without IN N
significant JJ N
differences NNS N
. . N

Cortisol NNP o
concentrations NNS o
decreased VBD N
significantly RB N
after IN N
TM NNP i
intervention NN N
but CC N
no DT N
change NN N
in IN N
diurnal JJ N
salivary JJ N
cortisol NN N
pattern NN N
was VBD N
found VBN N
. . N

The DT N
findings NNS N
of IN N
reduced JJ N
salivary JJ o
cortisol NN o
concentrations NNS o
immediately RB N
after IN N
the DT N
interventions NNS N
are VBP N
in IN N
agreement NN N
with IN N
previous JJ N
studies NNS N
. . N

However RB N
, , N
there EX N
was VBD N
no DT N
significant JJ N
difference NN N
between IN N
the DT N
TM NNP i
and CC N
control NN N
groups NNS N
. . N

There EX N
were VBD N
no DT N
significant JJ N
correlations NNS N
between IN N
cortisol JJ o
concentrations NNS o
and CC N
age NN o
, , o
gender NN o
, , o
BMI NNP o
, , o
time-point NN o
for IN o
intervention NN o
, , o
time NN o
interval NN o
between IN o
anti-parkinson JJ o
pharmacy NN o
intake NN o
and CC o
sampling NN o
, , o
levodopa NN o
doses NNS o
, , o
duration NN o
, , o
or CC o
severity NN o
of IN o
PD NNP o
. . o

CONCLUSIONS NNP N
Diurnal NNP o
salivary JJ o
cortisol NN o
rhythm NN o
was VBD N
normal JJ N
. . N

Salivary JJ o
cortisol NN o
concentrations NNS o
were VBD N
significantly RB N
reduced VBN N
after IN N
the DT N
TM NNP i
intervention NN N
and CC N
after IN N
RTM NNP i
, , N
but CC N
there EX N
were VBD N
no DT N
significant JJ N
differences NNS N
between IN N
the DT N
groups NNS N
and CC N
no DT N
sustained JJ N
long-term JJ N
effect NN N
. . N

No CC N
associations NNS N
were VBD N
seen VBN N
between IN N
salivary JJ o
cortisol NN o
concentration NN o
and CC N
clinical JJ N
and/or NN N
pharmacological JJ N
characteristics NNS N
. . N

TRIAL NNP N
REGISTRATION NNP N
ClinicalTrial.gov NNP N
, , N
NCT01734876 NNP N
and CC N
FoU NNP N
Sweden NNP N
108881 CD N
. . N

-DOCSTART- -23292082- O O

HOXB13 NNP i
G84E NNP i
mutation NN i
in IN N
Finland NNP p
: : p
population-based JJ N
analysis NN N
of IN N
prostate NN p
, , p
breast NN p
, , p
and CC p
colorectal JJ p
cancer NN p
risk NN p
. . p

BACKGROUND VB N
A DT N
recently RB N
identified VBN N
germline NN N
mutation NN N
G84E NNP i
in IN i
HOXB13 NNP i
was VBD N
shown VBN N
to TO N
increase VB N
the DT N
risk NN N
of IN N
prostate NN N
cancer NN N
. . N

In IN N
a DT N
family-based JJ N
analysis NN N
by IN N
The DT N
International NNP N
Consortium NNP N
for IN N
Prostate NNP N
Cancer NNP N
Genetics NNP N
( ( N
ICPCG NNP N
) ) N
, , N
the DT N
G84E NNP i
mutation NN i
was VBD N
most RBS N
prevalent JJ N
in IN N
families NNS N
from IN N
the DT N
Nordic NNP N
countries NNS N
of IN N
Finland NNP N
( ( N
22.4 CD N
% NN N
) ) N
and CC N
Sweden NNP N
( ( N
8.2 CD N
% NN N
) ) N
. . N

METHODS NNP N
To TO N
further VB N
investigate VB N
the DT N
importance NN N
of IN N
G84E NNP N
in IN N
the DT N
Finns NNP p
, , N
we PRP N
determined VBD N
its PRP$ N
frequency NN N
in IN N
more JJR p
than IN p
4,000 CD p
prostate JJ p
cancer NN p
cases NNS p
and CC p
5,000 CD p
controls NNS p
. . p

In IN p
addition NN p
, , p
986 CD p
breast NN p
cancer NN p
and CC p
442 CD p
colorectal JJ p
cancer NN p
( ( p
CRC NNP p
) ) p
cases NNS p
were VBD p
studied VBN p
. . p

Genotyping VBG i
was VBD N
conducted VBN N
using VBG N
TaqMan NNP N
, , N
MassARRAY NNP N
iPLEX NN N
, , N
and CC N
sequencing VBG N
. . N

Statistical JJ N
analyses NNS N
were VBD N
conducted VBN N
using VBG N
Fisher NNP N
exact JJ N
test NN N
, , N
and CC N
overall JJ o
survival NN o
was VBD N
analyzed VBN N
using VBG N
Cox NNP N
modeling NN N
. . N

RESULTS VB N
The DT N
frequency NN o
of IN o
the DT o
G84E NNP o
mutation NN o
was VBD N
significantly RB N
higher JJR N
among IN N
patients NNS N
with IN N
prostate JJ N
cancer NN N
and CC N
highest JJS N
among IN N
patients NNS N
with IN N
a DT N
family NN N
history NN N
of IN N
the DT N
disease NN N
, , N
hereditary JJ N
prostate NN N
cancer NN N
[ VBZ N
8.4 CD N
% NN N
vs. FW N
1.0 CD N
% NN N
in IN N
controls NNS N
; : N
OR CC N
8.8 CD N
; : N
95 CD N
% NN N
confidence NN N
interval NN N
( ( N
CI NNP N
) ) N
, , N
4.9-15.7 JJ N
] NN N
. . N

The DT N
mutation NN o
contributed VBD N
significantly RB N
to TO N
younger JJR N
age NN N
( ( N
?55 CD N
years NNS N
) ) N
at IN N
onset NN N
and CC N
high JJ N
prostate-specific JJ N
antigen NN N
( ( N
PSA NNP N
; : N
?20 NNP N
ng/mL NN N
) ) N
at IN N
diagnosis NN N
. . N

An DT N
association NN N
with IN N
increased JJ o
prostate NN o
cancer NN o
risk NN o
in IN o
patients NNS N
with IN N
prior JJ N
benign NN N
prostate NN N
hyperplasia NN N
( ( N
BPH NNP N
) ) N
diagnosis NN N
was VBD N
also RB N
revealed VBN N
. . N

No DT N
statistically RB N
significant JJ N
evidence NN N
for IN N
a DT N
contribution NN o
in IN o
CRC NNP o
risk NN o
was VBD o
detected VBN N
, , N
but CC N
a DT N
suggestive JJ N
role NN N
for IN N
the DT N
mutation NN N
was VBD N
observed VBN N
in IN N
familial JJ N
BRCA1/2-negative JJ N
breast NN N
cancer NN N
. . N

CONCLUSIONS NNP N
These DT N
findings NNS N
confirm VBP N
an DT N
increased JJ o
cancer NN o
risk NN o
associated VBN o
with IN N
the DT N
G84E NNP N
mutation NN N
in IN N
the DT N
Finnish JJ p
population NN p
, , p
particularly RB p
for IN N
early-onset JJ N
prostate NN N
cancer NN N
and CC N
cases NNS p
with IN p
substantially RB N
elevated VBN N
PSA NNP N
. . N

IMPACT NNP N
This DT N
study NN N
confirms VBZ N
the DT N
overall JJ N
importance NN N
of IN N
the DT N
HOXB13 NNP o
G84E NNP o
mutation NN o
in IN o
prostate NN p
cancer NN p
susceptibility NN p
. . N

-DOCSTART- -3535021- O O

An DT N
international JJ N
multi-clinic JJ N
study NN N
comparing VBG N
the DT N
therapeutic JJ N
efficacy NN N
of IN N
colloidal JJ i
bismuth NN i
subcitrate NN i
coated VBD i
tablets NNS i
with IN N
chewing VBG i
tablets NNS i
in IN N
the DT N
treatment NN N
of IN N
duodenal JJ p
ulceration NN p
. . p

The DT N
results NNS N
of IN N
a DT N
randomized JJ N
, , N
single-blind JJ N
, , N
multi-clinic JJ p
study NN p
comparing VBG p
the DT p
therapeutic JJ o
efficacy NN o
and CC o
degree NN o
of IN o
oral JJ o
staining NN o
of IN p
new JJ p
colloidal JJ i
bismuth NN i
subcitrate NN i
( ( i
CBS NNP i
) ) i
coated VBD i
tablets NNS i
over IN p
4 CD p
weeks NNS p
of IN p
treatment NN p
in IN p
patients NNS p
suffering VBG p
from IN p
duodenal JJ p
ulceration NN p
are VBP N
reported VBN N
. . N

The DT N
data NNS N
were VBD N
collected VBN N
from IN N
9 CD p
clinics NNS p
in IN p
the DT p
Netherlands NNP p
, , p
Belgium NNP p
, , p
Ireland NNP p
, , p
the DT p
United NNP p
Kingdom NNP p
, , p
and CC p
Italy NNP p
. . p

The DT N
results NNS N
from IN N
94 CD p
patients NNS p
treated VBN p
with IN p
CBS NNP i
coated VBD i
tablets NNS i
and CC p
95 CD p
patients NNS p
treated VBN p
with IN p
CBS NNP i
chewing VBG i
tablets NNS i
were VBD N
statistically RB N
evaluated VBN N
. . N

Healing VBG o
rates NNS o
after IN N
4 CD N
weeks NNS N
of IN N
therapy NN N
appeared VBD N
to TO N
be VB N
76 CD N
% NN N
for IN N
CBS NNP i
coated VBD i
tablets NNS i
and CC N
72 CD N
% NN N
for IN N
CBS NNP i
chewing VBG i
tablets NNS i
, , N
so IN N
no DT N
statistically RB N
significant JJ N
difference NN N
in IN N
therapeutic JJ N
efficacy NN N
was VBD N
seen VBN N
. . N

A DT o
highly RB o
significant JJ o
degree NN o
of IN o
discolouration NN o
of IN o
all DT o
parts NNS o
of IN o
the DT o
oral JJ o
cavity NN o
was VBD N
observed VBN N
in IN N
patients NNS N
treated VBN N
with IN N
CBS NNP i
chewing VBG i
tablets NNS i
, , N
whereas IN N
only RB N
a DT N
few JJ N
patients NNS N
treated VBN N
with IN N
CBS NNP i
coated VBD i
tablets NNS i
experienced VBD N
a DT N
slight JJ o
staining NN o
of IN o
the DT o
tongue NN o
. . o

Blood NNP o
bismuth JJ o
concentrations NNS o
during IN N
the DT N
study NN N
had VBD N
a DT N
range NN N
of IN N
less JJR N
than IN N
or CC N
equal JJ N
to TO N
3 CD N
to TO N
33 CD N
micrograms/l NN N
. . N

The DT N
new JJ N
CBS NNP i
coated VBD i
tablet NN i
form NN N
has VBZ N
an DT N
excellent JJ o
patient NN o
compliance NN o
as IN N
compared VBN N
to TO N
the DT N
chewing VBG i
tablets NNS i
. . i

-DOCSTART- -9512152- O O

Primary JJ N
glaucoma NN N
triple JJ N
procedure NN N
in IN N
patients NNS p
with IN p
primary JJ p
open-angle JJ p
glaucoma NN p
: : p
the DT N
effect NN o
of IN N
mitomycin NN i
C NNP i
in IN N
patients NNS N
with IN N
and CC N
without IN N
prognostic JJ N
factors NNS N
for IN N
filtration NN N
failure NN N
. . N

PURPOSE NNP N
To TO N
investigate VB N
the DT N
effect NN o
of IN N
adjunctive JJ i
mitomycin NN i
C NNP i
on IN N
primary JJ p
glaucoma NN p
triple JJ p
procedure NN p
in IN p
patients NNS p
with IN p
primary JJ p
open-angle JJ p
glaucoma NN p
with IN p
and CC p
without IN p
one CD p
or CC p
more JJR p
of IN p
the DT p
prognostic JJ p
factors NNS p
for IN p
filtration NN p
failure NN p
of IN p
primary JJ p
glaucoma NN p
triple JJ p
procedure NN p
. . p

Those DT N
factors NNS N
include VBP N
being VBG N
of IN N
African-American JJ p
race NN p
, , N
having VBG N
a DT N
preoperative JJ N
intraocular JJ N
pressure NN N
of IN N
20 CD N
mm NNS N
Hg NNP N
or CC N
more JJR N
on IN N
maximum NN N
tolerated JJ N
medications NNS N
, , N
and CC N
being VBG N
on IN N
two CD N
or CC N
more JJR N
medications NNS N
preoperatively RB N
. . N

METHODS NNP N
Study NNP N
patients NNS N
consisted VBD N
of IN N
197 CD p
consecutive JJ p
patients NNS p
with IN p
primary JJ p
open-angle JJ p
glaucoma NN p
who WP N
were VBD N
randomly RB i
assigned VBN i
to TO i
receive VB i
either DT i
no DT i
adjunctive JJ i
mitomycin NN i
C NNP i
( ( i
101 CD i
eyes NNS i
of IN i
101 CD i
patients NNS i
) ) i
or CC i
to TO i
receive VB i
adjunctive JJ i
subconjunctival NN i
mitomycin NN i
C NNP i
( ( i
96 CD i
eyes NNS i
of IN i
96 CD i
patients NNS i
) ) i
during IN i
the DT i
primary JJ i
glaucoma NN i
triple JJ i
procedure NN i
. . i

Kaplan-Meier NNP o
survival JJ o
analysis NN o
comparisons NNS o
were VBD N
made VBN N
between IN N
respective JJ N
subgroups NNS N
with IN N
and CC N
without IN N
prognostic JJ N
indicators NNS N
for IN N
filtration NN N
failures NNS N
using VBG N
a DT N
relatively RB N
stringent JJ N
set NN N
of IN N
criteria NNS N
for IN N
filtration NN N
success NN N
of IN N
primary JJ N
glaucoma NN N
triple JJ N
procedure NN N
. . N

RESULTS NNP N
There EX N
was VBD N
no DT N
statistically RB N
significant JJ N
( ( N
P NNP N
= NNP N
.117 NNP N
) ) N
difference NN N
in IN N
filtration NN o
success NN o
of IN N
primary JJ N
glaucoma NN N
triple JJ N
procedure NN N
between IN N
the DT N
control NN i
and CC N
mitomycin NN i
C NNP i
groups NNS N
. . N

Adjunctive NNP i
mitomycin NN i
C NNP i
significantly RB N
( ( N
P NNP N
< NNP N
.05 NNP N
) ) N
improved VBD N
the DT N
filtration NN o
outcome NN N
of IN N
the DT N
primary JJ N
glaucoma NN N
triple JJ N
procedure NN N
in IN N
the DT N
subgroups NNS N
with IN N
each DT N
of IN N
the DT N
three CD N
prognostic JJ N
factors NNS N
for IN N
filtration NN N
failure NN N
of IN N
primary JJ N
glaucoma NN N
triple JJ N
procedure NN N
. . N

On IN N
the DT N
other JJ N
hand NN N
, , N
in IN N
the DT N
subgroups NNS N
without IN N
the DT N
prognostic JJ N
factors NNS N
, , N
adjunctive JJ i
mitomycin NN i
C NNP i
did VBD N
not RB N
significantly RB N
( ( N
P NNP N
> NNP N
.05 NNP N
) ) N
change VBP N
the DT N
filtration NN o
outcome NN o
of IN N
the DT N
primary JJ N
glaucoma NN N
triple JJ N
procedure NN N
. . N

CONCLUSION NNP N
These DT N
findings NNS N
establish VB N
the DT N
basis NN N
for IN N
selective JJ N
use NN N
of IN N
mitomycin NN i
C NNP i
in IN N
patients NNS p
with IN p
primary JJ p
open-angle JJ p
glaucoma NN p
undergoing VBG p
primary JJ p
glaucoma NN p
triple JJ p
procedure NN p
. . p

-DOCSTART- -21987240- O O

Oral JJ N
bioavailability NN N
of IN N
moxifloxacin NN i
after IN p
Roux-en-Y NNP i
gastric JJ i
bypass NN i
surgery NN i
. . i

OBJECTIVES CC N
Roux-en-Y JJ i
gastric JJ i
bypass NN i
surgery NN i
is VBZ N
the DT N
most RBS N
commonly RB N
performed JJ N
procedure NN N
for IN N
the DT N
treatment NN N
of IN N
morbid NN N
obesity NN N
. . N

This DT N
anatomical JJ N
alteration NN N
may MD N
affect VB N
the DT N
absorption NN N
and CC N
consequently RB N
the DT N
bioavailability NN N
of IN N
oral JJ N
drugs NNS N
. . N

This DT N
study NN N
aims VBZ N
to TO N
investigate VB N
the DT N
oral JJ o
bioavailability NN o
of IN N
moxifloxacin NN i
in IN N
12 CD p
healthy JJ p
volunteers NNS p
who WP p
underwent VBP p
gastric JJ i
bypass NN i
surgery NN i
. . i

PATIENTS NNP N
AND CC N
METHODS NNP N
In IN N
this DT N
randomized VBN N
crossover NN N
study NN N
, , N
each DT N
subject NN N
received VBD N
two CD N
single JJ N
standard NN N
doses NNS N
of IN N
400 CD i
mg NN i
of IN i
moxifloxacin NN i
orally RB i
or CC i
intravenously RB i
administered VBN N
on IN N
two CD N
occasions NNS N
separated VBN N
by IN N
a DT N
washout JJ N
period NN N
of IN N
1 CD N
week NN N
. . N

Serial JJ N
venous JJ N
blood NN N
samples NNS N
were VBD N
drawn VBN N
up RB N
to TO N
72 CD N
h NN N
after IN N
dosing VBG N
and CC N
moxifloxacin JJ o
plasma NN o
levels NNS o
were VBD N
measured VBN N
by IN N
a DT N
validated JJ N
HPLC NNP N
method NN N
with IN N
fluorescence NN N
detection NN N
. . N

[ CC N
clinicaltrials.gov JJ N
database NN N
( ( N
identifier NN N
: : N
NCT01130922 NNP N
) ) N
. . N

] JJ N
RESULTS NNP N
After IN N
oral JJ N
dosing NN N
, , N
moxifloxacin FW o
plasma NN o
concentrations NNS o
reached VBD N
a DT N
maximum JJ N
( ( N
C NNP N
( ( N
max NN N
) ) N
) ) N
of IN N
3.38 CD N
? . N
1.41 CD N
mg/L NN N
after IN N
1.75 CD N
h NN N
( ( N
0.75-4.00 JJ N
) ) N
. . N

After IN N
intravenous JJ N
dosing NN N
, , N
C NNP N
( ( o
max NN o
) ) o
and CC o
T NNP o
( ( o
max NN o
) ) o
were VBD N
4.53 CD N
? . N
1.43 CD N
mg/L NN N
and CC N
1.03 CD N
h NN N
( ( N
0.75-2.50 JJ N
) ) N
, , N
respectively RB N
. . N

The DT o
mean JJ o
areas NNS o
under IN o
the DT o
plasma JJ o
concentration NN o
time NN o
curve NN o
extrapolated VBD o
to TO N
infinity NN N
( ( N
AUC NNP N
( ( N
? . N
) ) N
) ) N
were VBD N
46.2 CD N
? . N
1.4 CD N
mg NN N
? . N
h/L NN N
after IN N
oral JJ N
dosing NN N
and CC N
52.3 CD N
? . N
1.3 CD N
mg NN N
? . N
h/L NN N
after IN N
intravenous JJ N
dosing NN N
, , N
resulting VBG N
in IN N
a DT N
mean JJ o
oral JJ o
bioavailability NN o
of IN N
88.32 CD N
% NN N
[ JJ N
90 CD N
% NN N
confidence NN N
interval NN N
( ( N
CI NNP N
) ) N
85.64 CD N
% NN N
-91.08 CD N
% NN N
] NN N
. . N

CONCLUSIONS VB N
This DT N
study NN N
confirms VBZ N
that IN N
exposure NN N
to TO N
moxifloxacin VB i
is VBZ N
equivalent JJ N
for IN N
oral JJ N
and CC N
intravenous JJ N
administration NN N
of IN N
400 CD N
mg NN N
dosages NNS N
in IN p
healthy JJ p
volunteers NNS p
who WP p
underwent VBP p
gastric JJ p
bypass NN p
surgery NN p
. . p

But CC N
these DT N
exposures NNS N
were VBD N
more JJR N
than IN N
50 CD N
% NN N
higher JJR N
than IN N
those DT N
described VBN N
for IN N
subjects NNS N
without IN N
gastric JJ N
bypass NN N
. . N

This DT N
may MD N
suggest VB N
a DT N
higher JJR N
enterohepatic JJ N
recirculation NN N
of IN N
moxifloxacin NN i
after IN p
gastric JJ p
bypass NN p
. . p

-DOCSTART- -18802150- O O

Results NNS N
of IN N
the DT N
EICESS-92 NNP N
Study NNP N
: : N
two CD N
randomized JJ N
trials NNS N
of IN N
Ewing NNP N
's POS N
sarcoma NN N
treatment NN i
-- : i
cyclophosphamide NN i
compared VBN N
with IN N
ifosfamide NN i
in IN N
standard-risk JJ p
patients NNS p
and CC N
assessment NN N
of IN N
benefit NN N
of IN N
etoposide NN i
added VBD N
to TO N
standard VB N
treatment NN N
in IN N
high-risk JJ p
patients NNS p
. . p

PURPOSE VB N
The DT N
European NNP N
Intergroup NNP N
Cooperative NNP N
Ewing NNP N
's POS N
Sarcoma NNP N
Study NNP N
investigated VBD N
whether IN N
cyclophosphamide NN i
has VBZ N
a DT N
similar JJ N
efficacy NN N
as IN N
ifosfamide NN i
in IN N
standard-risk JJ p
( ( p
SR NNP p
) ) p
patients NNS p
and CC N
whether IN N
the DT N
addition NN N
of IN N
etoposide JJ i
improves NNS N
survival VBP o
in IN N
high-risk NN p
( ( p
HR NNP p
) ) p
patients NNS p
. . p

PATIENTS NNP N
AND CC N
METHODS NNP N
SR NNP p
patients NNS p
( ( p
localized JJ p
tumors NNS p
, , p
volume NN p
< VBD p
100 CD p
mL NN p
) ) p
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
four CD N
courses NNS N
of IN N
vincristine NN i
, , i
dactinomycin NN i
, , i
ifosfamide NN i
, , i
and CC i
doxorubicin NN i
( ( i
VAIA NNP i
) ) i
induction NN i
therapy NN i
followed VBN N
by IN N
10 CD N
courses NNS N
of IN N
either DT N
VAIA NNP i
or CC i
vincristine NN i
, , i
dactinomycin NN i
, , i
cyclophosphamide NN i
, , i
and CC i
doxorubicin NN i
( ( i
VACA NNP i
; : i
cyclophosphamide NN i
replacing VBG i
ifosfamide NN i
) ) i
. . N

HR $ p
patients NNS p
( ( p
volume NN p
> NNP p
or=100 VBZ p
mL NN p
or CC p
metastases NNS p
) ) p
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
14 CD N
courses NNS N
of IN N
either DT N
VAIA NNP i
or CC N
VAIA NNP i
plus CC i
etoposide NN i
( ( i
EVAIA NNP i
) ) i
. . N

Outcome JJ N
measures NNS N
were VBD N
event-free JJ o
survival NN o
( ( o
EFS NNP o
; : o
defined VBD N
as IN N
the DT N
time NN N
to TO N
first JJ N
recurrence NN N
, , N
progression NN N
, , N
second JJ N
malignancy NN N
, , N
or CC N
death NN N
) ) N
and CC N
overall JJ o
survival NN o
( ( o
OS NNP o
) ) o
. . o

RESULTS VB N
A DT N
total NN p
of IN p
647 CD p
patients NNS p
were VBD p
randomly RB p
assigned VBN p
: : p
79 CD p
SR NNP p
patients NNS p
were VBD p
assigned VBN p
to TO p
VAIA NNP i
, , p
76 CD p
SR NN p
patients NNS p
were VBD p
assigned VBN p
to TO p
VACA NNP i
, , p
240 CD p
HR NNP p
were VBD p
assigned VBN p
to TO p
VAIA NNP i
, , p
and CC p
252 CD p
HR NNP p
patients NNS p
were VBD p
assigned VBN p
to TO p
EVAIA NNP i
. . i

The DT N
median JJ N
follow-up NN N
was VBD N
8.5 CD N
years NNS N
. . N

In IN N
the DT N
SR NNP p
group NN p
, , N
the DT N
hazard NN o
ratios NNS o
( ( N
VACA NNP N
v NNP N
VAIA NNP N
) ) N
for IN N
EFS NNP N
and CC N
OS NNP N
were VBD N
0.91 CD N
( ( N
95 CD N
% NN N
CI NNP N
, , N
0.55 CD N
to TO N
1.53 CD N
) ) N
and CC N
1.08 CD N
( ( N
95 CD N
% NN N
CI NNP N
, , N
0.58 CD N
to TO N
2.03 CD N
) ) N
, , N
respectively RB N
. . N

There EX N
was VBD N
a DT N
higher JJR N
incidence NN N
of IN N
hematologic JJ o
toxicities NNS o
in IN N
the DT N
VACA NNP N
arm NN N
. . N

In IN N
the DT N
HR NNP p
group NN p
, , N
the DT N
EFS NNP o
and CC o
OS NNP o
hazard NN o
ratios NNS o
( ( N
EVAIA NNP N
v NNP N
VAIA NNP N
) ) N
indicated VBD N
a DT N
17 CD N
% NN N
reduction NN N
in IN N
the DT N
risk NN N
of IN N
an DT N
event NN N
( ( N
95 CD N
% NN N
CI NNP N
, , N
-35 NNP N
% NN N
to TO N
5 CD N
% NN N
; : N
P NNP N
= NNP N
.12 NNP N
) ) N
and CC N
15 CD N
% NN N
reduction NN N
in IN N
dying VBG N
( ( N
95 CD N
% NN N
CI NNP N
, , N
-34 NNP N
% NN N
to TO N
10 CD N
% NN N
) ) N
, , N
respectively RB N
. . N

The DT N
effect NN N
seemed VBD N
greater JJR N
among IN N
patients NNS N
without IN N
metastases NNS N
( ( N
hazard NN N
ratio NN N
= VBZ N
0.79 CD N
; : N
P NNP N
= NNP N
.16 NNP N
) ) N
than IN N
among IN N
those DT N
with IN N
metastases NNS N
( ( N
hazard NN N
ratio NN N
= VBZ N
0.96 CD N
; : N
P NNP N
= NNP N
.84 NNP N
) ) N
. . N

CONCLUSION NNP N
Cyclophosphamide NNP N
seemed VBD N
to TO N
have VB N
a DT N
similar JJ N
effect NN N
on IN N
EFS NNP o
and CC o
OS NNP o
as IN N
ifosfamide NN N
in IN N
SR NNP p
patients NNS p
but CC N
was VBD N
associated VBN N
with IN N
increased JJ N
toxicity NN o
. . o

In IN N
HR NNP p
patients NNS p
, , N
the DT N
addition NN N
of IN N
etoposide NN N
seemed VBD N
to TO N
be VB N
beneficial JJ N
. . N

-DOCSTART- -11881749- O O

Comparison NNP N
of IN N
comfort NN o
and CC o
local JJ o
complications NNS o
after IN N
cardiac JJ i
catheterization NN i
. . i

The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
compare VB N
the DT N
effects NNS N
of IN N
4 CD N
hours NNS N
of IN N
bed NN i
rest NN i
versus NN N
6 CD N
hours NNS N
of IN N
bed NN i
rest NN i
on IN N
patients NNS N
' POS N
safety NN o
, , o
comfort NN o
, , o
and CC o
satisfaction NN o
levels NNS o
. . o

Using VBG N
a DT N
quasi-experimental JJ N
design NN N
, , N
the DT N
authors NNS N
studied VBD N
118 CD p
left-heart JJ i
catheterization NN i
patients NNS p
who WP p
were VBD p
randomly RB p
assigned VBN p
to TO p
4 CD p
hours NNS p
or CC p
6 CD p
hours NNS p
of IN p
bed NN p
rest NN p
. . p

Among IN N
the DT N
study NN N
participants NNS N
, , N
only RB N
1 CD N
in IN N
the DT N
6-hour JJ N
group NN N
had VBD N
significant JJ o
bleeding NN o
. . o

There EX N
were VBD N
no DT N
complications NNS o
in IN N
the DT N
4-hour JJ N
group NN N
. . N

There EX N
were VBD N
no DT N
statistically RB N
significant JJ N
differences NNS N
between IN N
the DT N
two CD N
groups NNS N
on IN N
any DT N
of IN N
the DT N
other JJ N
study NN N
variables NNS N
. . N

Given VBN N
the DT N
lack NN N
of IN N
significant JJ N
complications NNS N
for IN N
the DT N
4-hour JJ N
group NN N
and CC N
similar JJ N
comfort NN o
levels NNS o
for IN N
both DT N
study NN N
groups NNS N
, , N
these DT N
findings NNS N
suggest VBP N
the DT N
feasibility NN N
of IN N
reducing VBG N
the DT N
standard JJ N
period NN N
of IN N
postcatheterization NN N
bed VBN N
rest NN N
from IN N
6 CD N
hours NNS N
to TO N
4 CD N
hours NNS N
, , N
thereby RB N
possibly RB N
lowering VBG N
the DT N
cost NN o
of IN o
the DT o
outpatient JJ o
procedure NN o
. . o

-DOCSTART- -21664059- O O

The DT N
benefits NNS N
of IN N
including VBG N
clinical JJ N
factors NNS N
in IN N
rectal JJ N
normal JJ N
tissue NN N
complication NN i
probability NN i
modeling NN i
after IN p
radiotherapy NN p
for IN p
prostate NN p
cancer NN p
. . p

PURPOSE NNP N
To TO N
study VB N
the DT N
impact NN N
of IN N
clinical JJ N
predisposing VBG N
factors NNS N
on IN N
rectal JJ N
normal JJ N
tissue NN N
complication NN N
probability NN N
modeling VBG N
using VBG N
the DT N
updated JJ N
results NNS N
of IN N
the DT N
Dutch JJ N
prostate NN N
dose-escalation NN N
trial NN N
. . N

METHODS NNP N
AND CC N
MATERIALS NNP N
Toxicity NNP N
data NN N
of IN N
512 CD p
patients NNS p
( ( p
conformally RB p
treated VBN p
to TO p
68 CD p
Gy NNP p
[ NNP p
n VBD p
= $ p
284 CD p
] NNP p
and CC p
78 CD p
Gy NNP p
[ NNP p
n VBD p
= $ p
228 CD p
] NN p
) ) p
with IN p
complete JJ p
follow-up NN p
at IN p
3 CD p
years NNS p
after IN p
radiotherapy NN i
were VBD p
studied VBN p
. . p

Scored JJ N
end NN N
points NNS N
were VBD N
rectal JJ N
bleeding NN N
, , N
high JJ N
stool NN N
frequency NN N
, , N
and CC N
fecal JJ N
incontinence NN N
. . N

Two CD i
traditional JJ i
dose-based JJ i
models NNS i
( ( i
Lyman-Kutcher-Burman NNP i
( ( i
LKB NNP i
) ) i
and CC i
Relative JJ i
Seriality NNP i
( ( i
RS NNP i
) ) i
and CC i
a DT i
logistic JJ i
model NN i
were VBD N
fitted VBN N
using VBG N
a DT N
maximum JJ N
likelihood NN N
approach NN N
. . N

Furthermore RB N
, , N
these DT N
model FW N
fits NNS N
were VBD N
improved VBN N
by IN N
including VBG N
the DT N
most RBS N
significant JJ N
clinical JJ N
factors NNS N
. . N

The DT N
area NN N
under IN N
the DT N
receiver NN N
operating VBG N
characteristic JJ N
curve NN N
( ( N
AUC NNP N
) ) N
was VBD N
used VBN N
to TO N
compare VB N
the DT N
discriminating VBG N
ability NN N
of IN N
all DT N
fits NNS N
. . N

RESULTS NNP N
Including NNP N
clinical JJ N
factors NNS N
significantly RB N
increased VBD N
the DT N
predictive JJ N
power NN N
of IN N
the DT N
models NNS N
for IN N
all DT N
end NN N
points NNS N
. . N

In IN N
the DT N
optimal JJ N
LKB NNP N
, , N
RS NNP N
, , N
and CC N
logistic JJ N
models NNS N
for IN N
rectal JJ N
bleeding NN N
and CC N
fecal JJ N
incontinence NN N
, , N
the DT N
first JJ N
significant JJ N
( ( N
p JJ N
= NNP N
0.011-0.013 NN N
) ) N
clinical JJ N
factor NN N
was VBD N
previous JJ N
abdominal JJ N
surgery NN N
. . N

As IN N
second JJ N
significant JJ N
( ( N
p JJ N
= NNP N
0.012-0.016 NN N
) ) N
factor NN N
, , N
cardiac JJ N
history NN N
was VBD N
included VBN N
in IN N
all DT N
three CD N
rectal JJ N
bleeding VBG N
fits NNS N
, , N
whereas IN N
including VBG N
diabetes NNS N
was VBD N
significant JJ N
( ( N
p JJ N
= NNP N
0.039-0.048 NN N
) ) N
in IN N
fecal JJ N
incontinence NN N
modeling NN N
but CC N
only RB N
in IN N
the DT N
LKB NNP N
and CC N
logistic JJ N
models NNS N
. . N

High JJ o
stool NN o
frequency NN o
fits VBZ N
only RB N
benefitted VBN N
significantly RB N
( ( N
p JJ N
= NNP N
0.003-0.006 NN N
) ) N
from IN N
the DT N
inclusion NN N
of IN N
the DT N
baseline NN N
toxicity NN N
score NN N
. . N

For IN N
all DT N
models NNS N
rectal VBP N
bleeding VBG N
fits NNS N
had VBD N
the DT N
highest JJS N
AUC NNP N
( ( N
0.77 CD N
) ) N
where WRB N
it PRP N
was VBD N
0.63 CD N
and CC N
0.68 CD N
for IN N
high JJ N
stool NN N
frequency NN N
and CC N
fecal JJ N
incontinence NN N
, , N
respectively RB N
. . N

LKB NNP N
and CC N
logistic JJ N
model NN N
fits NNS N
resulted VBN N
in IN N
similar JJ N
values NNS N
for IN N
the DT N
volume NN N
parameter NN N
. . N

The DT N
steepness NN N
parameter NN N
was VBD N
somewhat RB N
higher JJR N
in IN N
the DT N
logistic JJ N
model NN N
, , N
also RB N
resulting VBG N
in IN N
a DT N
slightly RB N
lower JJR N
D NNP N
( ( N
50 CD N
) ) N
. . N

Anal NNP N
wall NN N
DVHs NNP N
were VBD N
used VBN N
for IN N
fecal JJ N
incontinence NN N
, , N
whereas IN N
anorectal JJ N
wall NN N
dose NN N
best RBS N
described VBD N
the DT N
other JJ N
two CD N
endpoints NNS N
. . N

CONCLUSIONS NNP N
Comparable JJ N
prediction NN N
models NNS N
were VBD N
obtained VBN N
with IN N
LKB NNP N
, , N
RS NNP N
, , N
and CC N
logistic JJ N
NTCP NNP N
models NNS N
. . N

Including VBG N
clinical JJ N
factors NNS N
improved VBD N
the DT N
predictive JJ N
power NN N
of IN N
all DT N
models NNS N
significantly RB N
. . N

-DOCSTART- -12973849- O O

Outcome NN o
of IN N
children NNS p
with IN p
centrally RB p
reviewed VBN p
low-grade JJ p
gliomas NN p
treated VBN p
with IN p
chemotherapy NN i
with IN i
or CC i
without IN i
radiotherapy NN i
on IN N
Children NNP N
's POS N
Cancer NNP N
Group NNP N
high-grade VBD N
glioma NN N
study NN N
CCG-945 NNP N
. . N

BACKGROUND NNP N
The DT N
objectives NNS N
of IN N
the DT N
current JJ N
study NN N
were VBD N
to TO N
determine VB N
the DT N
outcome NN o
of IN N
children NNS p
who WP p
were VBD p
treated VBN p
with IN p
chemotherapy NN i
and CC i
radiotherapy NN i
on IN p
the DT p
Children NNP p
's POS p
Cancer NNP p
Group NNP p
( ( p
CCG NNP p
) ) p
high-grade NN p
glioma NN p
protocol NN p
( ( p
CCG-945 NNP p
) ) p
who WP p
were VBD p
diagnosed VBN p
with IN p
low-grade JJ p
gliomas NN p
on IN p
post NN p
hoc JJ p
central JJ p
pathologic NN p
review NN p
and CC N
to TO N
identify VB N
clinical JJ o
and CC o
biologic JJ o
features NNS o
associated VBN N
with IN N
prognosis NN N
. . N

METHODS NNP N
Between NNP p
1985 CD p
and CC p
1991 CD p
, , p
250 CD p
children NNS p
with IN p
institutionally RB p
classified VBN p
high-grade JJ p
gliomas NNS p
were VBD p
enrolled VBN p
on IN p
CCG-945 NNP p
. . p

Patients NNS p
older JJR p
than IN p
24 CD p
months NNS p
with IN p
intracranial JJ p
lesions NNS p
were VBD N
assigned VBN N
randomly RB N
to TO N
receive VB N
either DT N
lomustine NN i
, , i
vincristine NN i
, , i
and CC i
prednisone NN i
( ( i
control VB i
regimen NNS i
) ) i
or CC i
the DT i
8-drugs-in-1-day JJ i
regimen NNS i
( ( i
experimental JJ i
regimen NNS i
) ) i
; : i
younger JJR p
patients NNS p
and CC p
those DT p
with IN p
primary JJ p
spinal JJ p
cord NN p
tumors NNS p
were VBD N
assigned VBN N
nonrandomly RB N
to TO N
the DT N
experimental JJ N
regimen NNS N
. . N

Central NNP N
independent JJ N
review NN N
by IN N
5 CD N
neuropathologists NNS N
led VBD N
to TO N
a DT N
reclassification NN N
of IN N
low-grade JJ p
glioma NN p
in IN p
70 CD p
patients NNS p
, , p
who WP p
were VBD p
the DT p
focus NN p
of IN p
the DT p
current JJ p
study NN p
. . p

RESULTS VB N
The DT N
study NN N
involved VBD N
42 CD p
males NNS p
and CC p
28 CD p
females NNS p
( ( p
median JJ p
age NN p
, , p
7.7 CD p
years NNS p
) ) p
with IN p
a DT p
median JJ p
follow-up NN p
of IN p
10.4 CD p
years NNS p
. . p

At IN N
5 CD N
years NNS N
, , N
the DT N
progression-free JJ o
survival NN o
( ( o
PFS NNP o
) ) o
rate NN o
was VBD N
63 CD N
% NN N
+/- JJ N
6 CD N
% NN N
, , N
and CC N
the DT N
overall JJ o
survival NN o
( ( o
OS NNP o
) ) o
rate NN o
was VBD N
79 CD N
% NN N
+/- JJ N
5 CD N
% NN N
, , N
compared VBN N
with IN N
a DT N
PFS NNP o
rate NN o
of IN N
19 CD N
% NN N
+/- JJ N
3 CD N
% NN N
( ( N
P NNP N
< NNP N
0.0001 CD N
) ) N
and CC N
an DT N
OS NNP o
rate NN o
of IN N
22 CD N
% NN N
+/- JJ N
3 CD N
% NN N
( ( N
P NNP N
< NNP N
0.0001 CD N
) ) N
in IN N
the DT N
remainder NN N
of IN N
the DT N
cohort NN N
. . N

Significantly RB N
poorer JJR N
5-year JJ o
PFS NNP o
was VBD N
seen VBN N
in IN N
children NNS N
younger JJR N
than IN N
24 CD N
months NNS N
, , N
those DT N
with IN N
fibrillary JJ N
astrocytoma NN N
, , N
and CC N
those DT N
with IN N
posterior JJ N
fossa NN N
tumors NNS N
. . N

Patients NNS N
demonstrated VBD N
a DT N
modest JJ N
improvement NN N
in IN N
PFS NNP o
but CC N
no DT N
improvement NN N
in IN N
OS NNP o
compared VBN N
with IN N
children NNS N
with IN N
low-grade JJ N
gliomas NNS N
who WP N
were VBD N
treated VBN N
with IN N
contemporary JJ N
chemotherapy-alone NN N
approaches NNS N
. . N

CONCLUSIONS VB N
The DT N
current JJ N
report NN N
calls VBZ N
attention NN N
to TO N
the DT N
importance NN N
of IN N
central JJ N
pathologic JJ N
review NN N
in IN N
large JJ N
multiinstitutional JJ N
trials NNS N
of IN N
children NNS N
with IN N
gliomas NN N
and CC N
suggests VBZ N
that IN N
aggressive JJ N
front-line NN N
combined VBN N
chemoradiotherapy NN N
does VBZ N
not RB N
confer VB N
a DT N
survival JJ o
advantage NN o
in IN N
this DT N
highly RB N
selected VBN N
population NN N
of IN N
patients NNS N
. . N

-DOCSTART- -2146389- O O

Direct JJ i
trocar NN i
insertion NN i
vs. FW i
Verres NNP i
needle FW i
use NN i
for IN N
laparoscopic JJ p
sterilization NN p
. . p

A DT N
randomized JJ p
, , p
prospective JJ p
trial NN p
was VBD p
designed VBN p
to TO p
compare VB p
direct JJ i
trocar NN i
insertion NN i
with IN i
prior JJ i
peritoneal JJ i
insufflation NN i
with IN i
a DT i
Verres NNP i
needle NN i
for IN i
laparoscopic NN i
tubal JJ i
sterilization NN i
. . i

Direct JJ i
trocar NN i
insertion NN i
resulted VBD N
in IN N
fewer JJR N
instrument NN o
insertions NNS o
( ( N
21.8 CD N
% NN N
vs. FW N
7.8 CD N
% NN N
) ) N
and CC N
use NN N
of IN N
smaller JJR o
volumes NNS o
of IN o
CO2 NNP o
( ( N
2.67 CD N
vs. FW N
2.32 CD N
L NNP N
) ) N
. . N

Direct JJ i
trocar NN i
use NN N
resulted VBD N
in IN N
a DT N
decrease NN N
in IN N
operating NN o
time NN o
from IN N
9 CD N
minutes NNS N
, , N
40 CD N
seconds NNS N
in IN N
the DT N
needle JJ p
group NN p
to TO N
7 CD N
minutes NNS N
, , N
30 CD N
seconds NNS N
in IN N
the DT N
trocar NN p
group NN p
. . p

Minor NNP o
omental JJ o
injuries NNS o
occurred VBD N
in IN N
a DT N
small JJ N
percentage NN N
of IN N
each DT N
group NN N
, , N
while IN N
serious JJ N
complications NNS N
occurred VBD N
once RB N
in IN N
each DT N
group NN N
. . N

-DOCSTART- -26214440- O O

Radiofrequency NNP i
thermocoagulation NN i
combined VBN i
with IN i
pulsed JJ i
radiofrequency NN i
helps VBZ N
relieve VB N
postoperative JJ N
complications NNS N
of IN N
trigeminal JJ N
neuralgia NN N
. . N

Trigeminal NNP N
neuralgia NN N
is VBZ N
a DT N
sudden JJ N
, , N
severe JJ N
condition NN N
characterized VBN N
by IN N
stabbing VBG N
and CC N
recurrent JJ N
pain NN N
. . N

Radiofrequency NNP i
thermocoagulation NN i
( ( i
RFT NNP i
) ) i
and CC i
pulsed JJ i
radiofrequency NN i
( ( i
PRF NNP i
) ) i
are VBP N
common JJ N
surgical JJ N
interventions NNS N
used VBN N
to TO N
treat VB N
trigeminal JJ N
neuralgia NN N
. . N

This DT N
study NN N
aimed VBD N
to TO N
investigate VB N
the DT N
therapeutic JJ N
effects NNS N
and CC N
associated JJ N
complications NNS N
of IN N
a DT N
combination NN N
of IN N
RFT NNP N
and CC N
PRF NNP N
in IN N
the DT N
treatment NN N
of IN N
trigeminal JJ N
neuralgia NN N
. . N

Computed VBN i
tomography-guided JJ i
percutaneous JJ i
RFT NNP i
of IN N
the DT N
Gasserian JJ N
ganglion NN N
was VBD N
performed VBN N
on IN N
80 CD p
patients NNS p
with IN p
trigeminal JJ p
neuralgia NNS p
. . p

Patients NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
either DT N
group NN N
A NNP i
( ( i
RFT NNP i
at IN i
70?C CD i
) ) i
or CC i
group NN i
B NNP i
( ( i
RFT NNP i
at IN i
75?C CD i
) ) i
. . i

Patients NNS N
in IN N
each DT N
group NN N
were VBD N
divided VBN N
into IN N
2 CD N
subgroups NNS N
, , N
receiving VBG i
percutaneous JJ i
RFT NNP i
( ( i
240 CD i
s NN i
) ) i
with IN i
or CC i
without IN i
PRF NNP i
( ( i
42?C CD i
, , i
2 CD i
Hz NNP i
, , i
240 CD i
s NN i
) ) i
. . i

Six CD i
months NNS N
later RB o
, , o
pain NN o
relief NN o
and CC o
complication NN o
status NN o
were VBD o
evaluated VBN N
. . N

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
visual JJ o
analogue NN o
scores NNS o
among IN o
groups NNS N
with IN N
RFT NNP N
at IN N
70? CD N
or CC N
75?C CD N
, , N
with IN N
or CC N
without IN N
PRF NNP N
. . N

Data NNP N
showed VBD N
that IN N
facial JJ o
numbness NN o
and CC o
postoperative JJ o
masticatory NN o
muscle NN o
weakness NN o
recovered VBD o
more RBR N
rapidly RB N
in IN N
patients NNS N
receiving VBG N
combined VBN N
RFT NNP N
and CC N
PRF NNP N
treatment NN o
. . o

Decreased VBN o
corneal NN o
reflex NN o
was VBD o
relieved VBN N
to TO N
a DT N
significantly RB N
greater JJR N
extent NN N
in IN N
groups NNS N
receiving VBG N
PRF NNP N
than IN N
those DT N
without IN N
. . N

Thus NNP N
, , N
compared VBN N
to TO N
the DT N
use NN N
of IN N
RFT NNP N
at IN N
75?C CD N
alone RB N
, , N
the DT N
combination NN N
of IN N
PRF NNP N
and CC N
RFT NNP N
helped VBD N
eliminate VB N
postoperative JJ N
complications NNS N
, , N
such JJ N
as IN N
facial JJ N
numbness NN N
, , N
masticatory JJ N
muscle NN N
weakness NN N
, , N
and CC N
decreased VBD N
corneal NN N
reflex NN N
, , N
indicating VBG N
that IN N
it PRP N
could MD N
be VB N
useful JJ N
for IN N
surgically RB N
treating VBG N
trigeminal JJ N
neuralgia NN N
. . N

-DOCSTART- -4404700- O O

Auditory NNP o
signal JJ o
detection NN o
in IN N
paranoid NN p
and CC p
nonparanoid JJ p
schizophrenics NNS p
. . p

-DOCSTART- -20440639- O O

Randomized VBN N
controlled JJ N
trial NN N
of IN N
the DT N
focus NN N
parent NN N
training NN N
for IN N
toddlers NNS p
with IN p
autism NN p
: : p
1-year JJ N
outcome NN N
. . N

This DT N
randomized VBD N
controlled JJ N
trial NN N
compared VBN N
results NNS N
obtained VBD N
after IN N
12 CD N
months NNS N
of IN i
nonintensive JJ i
parent NN i
training VBG i
plus CC i
care-as-usual JJ i
and CC i
care-as-usual JJ i
alone NN i
. . i

The DT i
training NN i
focused VBD i
on IN i
stimulating VBG i
joint JJ i
attention NN i
and CC i
language NN i
skills NNS i
and CC i
was VBD i
based VBN i
on IN i
the DT i
intervention NN i
described VBN i
by IN i
Drew NNP i
et CC i
al NN i
. . i

( ( N
Eur NNP N
Child NNP N
Adolesc NNP N
Psychiatr NNP N
11:266-272 CD N
, , N
2002 CD N
) ) N
. . N

Seventy-five JJ p
toddlers NNS p
with IN p
autism NN p
spectrum NN p
disorder NN p
( ( p
65 CD p
autism NN p
, , p
10 CD p
PDD-NOS NN p
, , p
mean JJ p
age NN p
= VBD p
34.4 CD p
months NNS p
, , p
SD NNP p
= NNP p
6.2 CD p
) ) p
were VBD p
enrolled VBN N
. . N

Analyses NNS N
were VBD N
conducted VBN N
on IN N
a DT N
final JJ N
sample NN N
of IN p
67 CD p
children NNS p
( ( p
lost VBN p
to TO N
follow-up JJ N
= NNP N
8 CD N
) ) N
. . N

No DT N
significant JJ N
intervention NN o
effects NNS o
were VBD N
found VBN N
for IN N
any DT N
of IN N
the DT o
primary JJ o
( ( o
language NN o
) ) o
, , o
secondary JJ o
( ( o
global JJ o
clinical JJ o
improvement NN o
) ) o
, , o
or CC o
mediating NN o
( ( o
child JJ o
engagement NN o
, , o
early JJ o
precursors NNS o
of IN o
social JJ o
communication NN o
, , o
or CC o
parental JJ o
skills NNS o
) ) o
outcome VBP o
variables NNS o
, , o
suggesting VBG o
that IN N
the DT N
'Focus NNP N
parent NN N
training VBG N
' '' N
was VBD N
not RB N
of IN N
additional JJ N
value NN N
to TO N
the DT N
more JJR N
general JJ N
care-as-usual JJ N
. . N

-DOCSTART- -15798610- O O

Comparison NNP N
of IN N
intravenous JJ N
and CC N
intra-arterial JJ N
urokinase JJ N
thrombolysis NN N
for IN N
acute JJ p
ischaemic JJ p
stroke NN p
. . p

Intravenous JJ i
fibrinolysis NN i
( ( i
IVF NNP i
) ) i
with IN i
rt-PA NN i
( ( i
alteplase NN i
) ) i
provides VBZ N
significant JJ N
benefits NNS N
in IN N
acute JJ N
ischaemic JJ N
stroke NN N
when WRB N
it PRP N
is VBZ N
given VBN N
within IN N
the DT N
first JJ N
three CD N
hours NNS N
following VBG N
stroke NN N
onset VBN N
. . N

Intra-arterial JJ i
fibrinolysis NN i
( ( i
IAF NNP i
) ) i
with IN i
pro-urokinase NN i
in IN N
PROACT NNP N
II NNP N
study NN N
provides VBZ N
quite RB N
the DT N
same JJ N
benefit NN N
in IN N
the DT N
first JJ N
6 CD N
hours NNS N
. . N

IVF NNP i
and CC N
IAF NNP i
have VBP N
never RB N
been VBN N
compared VBN N
. . N

To TO N
compare VB N
the DT N
efficacy NN o
and CC o
safety NN o
of IN N
IVF NNP i
and CC N
IAF NNP i
with IN N
urokinase JJ N
given VBN N
within IN p
the DT p
first JJ p
6 CD p
hours NNS p
of IN p
acute JJ p
ischaemic JJ p
stroke NN p
. . p

Patients NNS p
fulfilling VBG p
the DT p
selection NN p
criteria NNS p
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
urokinase JJ i
900,000 CD N
units NNS N
via IN N
intravenous JJ N
or CC N
intra-arterial JJ N
routes NNS N
. . N

This DT N
randomised VBD N
monocentre NN N
study NN N
was VBD N
done VBN N
between IN N
December NNP N
1995 CD N
and CC N
August NNP N
1997 CD N
. . N

The DT N
primary JJ N
outcome NN N
was VBD N
defined VBN N
as IN N
the DT N
number NN o
of IN o
patients NNS o
with IN o
a DT o
modified JJ o
Rankin NNP o
score NN o
of IN o
2 CD o
or CC o
less JJR o
. . o

Secondary JJ N
outcomes NNS N
included VBD N
mortality NN o
, , o
frequency NN o
of IN o
symptomatic JJ o
intracranial JJ o
haemorrhage NN o
( ( o
SIH NNP o
) ) o
, , o
neurological JJ o
and CC o
functional JJ o
scores NNS o
. . o

Fourteen CD p
patients NNS p
were VBD p
given VBN p
IVF NNP i
and CC p
13 CD p
IAF NNP i
. . i

The DT N
study NN N
was VBD N
terminated VBN N
by IN N
the DT N
National NNP N
Health NNP N
Authorities NNP N
when WRB N
27 CD p
patients NNS p
had VBD p
been VBN p
included VBN p
because IN p
of IN p
the DT p
mortality NN p
rate NN p
. . p

Seven CD N
patients NNS N
( ( N
26 CD N
% NN N
) ) N
died VBD N
, , N
4 CD N
in IN N
the DT N
IV NNP N
group NN N
( ( N
oedematous JJ N
infarct NN N
in IN N
3 CD N
and CC N
recurrence NN N
in IN N
1 CD N
) ) N
, , N
3 CD N
in IN N
the DT N
IA NNP N
group NN N
( ( N
SIH NNP N
in IN N
2 CD N
, , N
and CC N
oedematous JJ N
infarct NN N
in IN N
1 CD N
) ) N
. . N

Patients NNS N
given VBN N
IVF NNP i
were VBD N
treated VBN N
significantly RB N
earlier RBR N
( ( N
4:16 CD N
h NN N
vs NN N
5:24 CD N
h NN N
; : N
p=.007 NN N
) ) N
. . N

Although IN N
IA NNP N
patients NNS N
showed VBD N
greater JJR N
and CC N
earlier RBR N
improvement NN N
there EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
primary JJ N
and CC N
secondary JJ N
outcomes NNS N
. . N

Because IN N
of IN N
premature NN N
termination NN N
, , N
the DT N
trial NN N
was VBD N
too RB N
small JJ N
to TO N
provide VB N
any DT N
reliable JJ N
and CC N
conclusive JJ N
results NNS N
. . N

Intra-arterial JJ N
fibrinolysis NN N
began VBD N
significantly RB N
later RBR N
than IN N
IV NNP N
fibrinolysis NN N
but CC N
it PRP N
gave VBD N
non-significantly RB N
better JJ N
results NNS N
in IN N
this DT N
prematurely RB N
terminated VBN N
study NN N
. . N

-DOCSTART- -17767200- O O

Comparison NNP N
of IN N
the DT N
therapeutic JJ N
efficacy NN N
of IN N
phonophoresis NN i
and CC N
iontophoresis NN i
using VBG N
dexamethasone NN i
sodium NN i
phosphate NN i
in IN N
the DT N
management NN N
of IN N
patients NNS p
with IN p
knee JJ p
osteoarthritis NN p
. . p

BACKGROUND NNP N
AND NNP N
OBJECTIVE NNP N
Many NNP N
treatment NN N
options NNS N
, , N
including VBG N
non-pharmacological JJ N
and CC N
pharmacological JJ N
measures NNS N
, , N
have VBP N
been VBN N
recommended VBN N
in IN N
the DT N
management NN N
of IN N
osteoarthritis NN N
( ( N
OA NNP N
) ) N
. . N

Among IN N
the DT N
non-pharmacological JJ N
approach NN N
is VBZ N
physiotherapy NN N
, , N
which WDT N
involves VBZ N
the DT N
use NN N
of IN N
physical JJ N
modalities NNS N
like IN N
, , N
heat NN N
therapy NN N
, , N
exercise NN N
therapy NN N
, , N
electrical JJ N
stimulation NN N
, , N
therapeutic JJ N
ultrasound NN N
, , N
iontophoresis NN N
, , N
and CC N
phonophoresis NN N
. . N

This DT N
study NN N
was VBD N
therefore RB N
designed VBN N
to TO N
compare VB N
the DT N
effectiveness NN N
of IN N
0.4 CD N
% NN N
Dexamethasone NNP i
sodium NN i
phosphate NN i
( ( i
DEX-P NNP i
) ) i
phonophoresis NN i
( ( i
PH NNP i
) ) i
with IN N
0.4 CD i
% NN i
DEX-P JJ i
iontophoresis NN i
( ( i
ION NNP i
) ) i
therapy NN i
in IN N
the DT N
management NN N
of IN N
patients NNS p
with IN p
knee JJ p
joint JJ p
OA NNP p
. . p

METHODS NNP N
Fifty NNP p
patients NNS p
( ( p
19 CD p
males NNS p
and CC p
31 CD p
females NNS p
) ) p
with IN p
a DT p
mean JJ p
age NN p
of IN p
53.6 CD p
+/- JJ p
8.9 CD p
years NNS p
were VBD N
randomly RB N
assigned VBN N
to TO N
PH NNP i
or CC N
ION NNP i
groups NNS N
with IN N
25 CD N
patients NNS N
in IN N
each DT N
group NN N
. . N

Ultrasound NNP N
waves VBZ N
of IN N
1 CD N
MHz NNP N
frequency NN N
was VBD N
applied VBN N
for IN N
5 CD N
minutes NNS N
to TO N
the DT N
target NN N
knee NN N
, , N
so RB N
also RB N
was VBD N
the DT N
direct JJ N
current JJ N
for IN N
10 CD N
minutes NNS N
for IN N
10 CD N
sessions NNS N
treatment NN N
period NN N
. . N

Western JJ o
Ontario NNP o
and CC o
McMaster NNP o
University NNP o
Osteoarthritis NNP o
Index NNP o
( ( o
WOMAC NNP o
) ) o
scores VBZ o
, , o
20 CD o
meters NNS o
ambulatory JJ o
time NN o
, , N
and CC N
knee VB o
range NN o
of IN o
motion NN o
( ( o
ROM NNP o
) ) o
were VBD N
evaluated VBN N
before IN N
and CC N
after IN N
therapy NN N
as IN N
the DT N
outcome NN N
measures NNS N
. . N

RESULTS NNP N
At IN N
the DT N
end NN N
of IN N
two CD N
weeks NNS N
, , N
significant JJ N
improvement NN N
in IN N
total JJ N
WOMAC NNP o
scores NNS o
was VBD N
observed VBN N
in IN N
15 CD N
( ( N
60 CD N
% NN N
) ) N
and CC N
16 CD N
( ( N
64 CD N
% NN N
) ) N
patients NNS N
in IN N
the DT N
PH NNP N
and CC N
ION NNP N
groups NNS N
respectively RB N
, , N
indicating VBG N
no DT N
significant JJ N
difference NN N
in IN N
the DT N
improvement NN N
rate NN N
. . N

Twenty NNP N
( ( N
20 CD N
) ) N
metres NNS N
ambulatory JJ o
time NN o
and CC o
knee NN o
range NN o
of IN o
motion NN o
also RB N
improved VBN N
significantly RB N
in IN N
both DT N
groups NNS N
, , N
yet RB N
these DT N
variables NNS N
showed VBD N
no DT N
significant JJ N
difference NN N
between IN N
the DT N
two CD N
groups NNS N
. . N

CONCLUSION NNP N
Both NNP N
therapeutic JJ N
modalities NNS N
were VBD N
found VBN N
to TO N
be VB N
effective JJ N
and CC N
generally RB N
well RB N
tolerated VBN N
after IN N
10 CD N
treatment NN N
sessions NNS N
. . N

DEX-P JJ i
phonophoresis NN i
was VBD N
not RB N
superior JJ N
to TO N
DEX-P JJ i
iontophoresis NN i
in IN N
the DT N
treatment NN N
of IN N
patients NNS p
with IN p
OA NNP p
of IN p
the DT p
knee NN p
. . p

-DOCSTART- -8888660- O O

Effect NN o
of IN N
hydrochlorothiazide NN i
therapy NN i
on IN N
cardiac JJ o
arrhythmias NN o
in IN p
African-American JJ p
men NNS p
with IN p
systemic JJ p
hypertension NN p
and CC p
moderate VB p
to TO p
severe VB p
left JJ p
ventricular JJ p
hypertrophy NN p
. . p

The DT N
effect NN N
of IN N
hydrochlorothiazide NN i
therapy NN i
on IN N
ventricular JJ o
arrhythmias NN o
was VBD N
studied VBN N
in IN N
45 CD p
hypertensive JJ p
African-American JJ p
men NNS p
with IN p
moderate JJ p
to TO p
severe VB p
left VBN p
ventricular JJ p
( ( p
LV NNP p
) ) p
hypertrophy NN p
. . p

After IN N
medication NN N
washout NN N
, , N
patients NNS i
were VBD i
treated VBN i
with IN i
placebo NN i
followed VBN i
by IN i
hydrochlorothiazide NN i
. . i

Clinical NNP o
, , o
biochemical JJ o
, , o
and CC o
48-hour JJ o
ambulatory NN o
electrocardiographic JJ o
data NN o
was VBD N
collected VBN N
after IN N
each DT N
treatment NN N
phase NN N
. . N

Signal-averaged JJ o
electrocardiograms NNS o
were VBD N
recorded VBN N
in IN N
a DT N
subgroup NN p
of IN p
24 CD p
patients NNS p
. . p

Average JJ o
LV NNP o
posterior NN o
wall NN o
thickness NN o
was VBD N
15 CD N
+/- JJ N
1.1 CD N
mm NN N
, , N
septum VBD N
16 CD N
+/- JJ N
2 CD N
mm NN N
, , N
LV NNP N
mass VBD N
420 CD N
+/- JJ N
90 CD N
g NN N
, , N
and CC N
LV NNP N
mass NNP N
index NN N
212 CD N
= NN N
51 CD N
g/m2 NN N
. . N

Systolic NNP o
blood NN o
pressure NN o
( ( o
BP NNP o
) ) o
was VBD N
168 CD N
+/- JJ N
18 CD N
mm NN N
Hg NNP N
after IN N
the DT N
placebo NN N
phase NN N
and CC N
146 CD N
+/- JJ N
15 CD N
mm NN N
Hg NNP N
after IN N
hydrochlorothiazide NN N
; : N
diastolic JJ N
BP NNP N
was VBD N
103 CD N
+/- JJ N
6 CD N
mm NN N
Hg NNP N
and CC N
89 CD N
+/- JJ N
9 CD N
mm NN N
Hg NNP N
, , N
respectively RB N
. . N

Serum NNP o
potassium NN o
decreased VBD N
significantly RB N
from IN N
4.2 CD N
+/- JJ N
0.4 CD N
mmol/L NN N
to TO N
3.7 CD N
+/- JJ N
0.6 CD N
mmol/L NN N
after IN N
hydrochlorothiazide JJ i
therapy NN i
. . i

The DT N
average JJ N
hourly JJ N
incidence NN N
of IN N
ventricular JJ o
premature NN o
contractions NNS o
was VBD N
22 CD N
with IN N
placebo NN i
and CC N
25 CD N
with IN N
hydrochlorothiazide NN i
. . i

There EX N
were VBD N
3 CD N
and CC N
1 CD N
couplets NNS N
and CC N
0.2 CD N
and CC N
0.2 CD N
runs NNS N
of IN N
ventricular JJ o
tachycardia NN o
per IN N
patient NN N
per IN N
hour NN N
, , N
respectively RB N
. . N

Variables NNS N
of IN N
signal-averaged JJ o
electrocardiography NN o
did VBD N
not RB N
differ VB N
between IN N
the DT N
2 CD N
treatments NNS N
. . N

Thus RB N
, , N
in IN N
hypertensive JJ p
African-American JJ p
men NNS p
with IN p
moderate JJ p
to TO p
severe VB p
LV NNP p
hypertrophy NN p
, , N
hydrochlorothiazide NN i
does VBZ N
not RB N
worsen VB N
ventricular JJ o
arrhythmias NNS o
or CC N
signal-averaged JJ o
electrocardiographic JJ o
variables NNS o
. . o

-DOCSTART- -3001523- O O

Treatment NN N
of IN N
varicella-zoster JJ N
virus NN N
infection NN N
in IN N
severely RB p
immunocompromised JJ p
patients NNS p
. . p

A DT N
randomized JJ N
comparison NN N
of IN N
acyclovir NN i
and CC i
vidarabine NN i
. . i

In IN N
a DT N
prospective JJ N
, , N
randomized JJ N
trial NN N
, , N
we PRP N
compared VBN N
intravenous JJ i
acyclovir NNS i
and CC i
vidarabine NN i
in IN N
the DT N
treatment NN N
of IN N
varicella-zoster JJ p
virus NN p
infection NN p
in IN p
severely RB p
immunocompromised JJ p
patients NNS p
who WP p
presented VBD p
within IN p
72 CD p
hours NNS p
of IN p
onset NN p
of IN p
the DT p
infection NN p
. . p

Eleven JJ p
patients NNS p
were VBD p
treated VBN p
in IN p
each DT p
group NN p
. . p

Cutaneous JJ o
dissemination NN o
of IN o
infection NN o
occurred VBD N
in IN N
none NN N
of IN N
the DT N
10 CD N
acyclovir NN i
recipients NNS N
and CC N
in IN N
5 CD N
of IN N
the DT N
10 CD N
vidarabine NN i
recipients NNS N
who WP N
had VBD N
presented VBN N
with IN N
localized JJ N
dermatomal JJ N
disease NN N
( ( N
P NNP N
= NNP N
0.016 CD N
) ) N
. . N

As IN N
compared VBN N
with IN N
vidarabine NN N
, , N
acyclovir JJ N
treatment NN N
shortened VBD N
the DT N
median JJ o
periods NNS o
during IN o
which WDT o
cultures NNS o
were VBD o
positive JJ o
for IN o
the DT o
virus NN o
( ( N
four CD N
vs. FW N
seven CD N
days NNS N
, , N
P NNP N
= NNP N
0.004 CD N
) ) N
and CC N
new JJ o
lesions NNS o
formed VBN N
( ( N
three CD N
vs. IN N
six CD N
days NNS N
, , N
P NNP N
= NNP N
0.03 CD N
) ) N
. . N

Acyclovir NNP i
also RB N
shortened VBD N
the DT N
median JJ N
interval NN o
until IN o
the DT o
first JJ o
decrease NN o
in IN o
pain NN o
( ( N
4 CD N
vs. FW N
7 CD N
days NNS N
, , N
P NNP N
= NNP N
0.005 CD N
) ) N
, , N
the DT N
pustulation NN o
of IN o
all DT o
lesions NNS o
( ( N
4 CD N
vs. FW N
7 CD N
days NNS N
, , N
P NNP N
= NNP N
0.0004 CD N
) ) N
, , N
the DT N
crusting NN o
of IN o
all DT o
lesions NNS o
( ( N
7 CD N
vs. FW N
17 CD N
days NNS N
, , N
P NNP N
= NNP N
0.0003 CD N
) ) N
, , N
and CC N
the DT N
complete JJ o
healing NN o
of IN o
lesions NNS o
( ( N
17 CD N
vs. FW N
28 CD N
days NNS N
, , N
P NNP N
= NNP N
0.003 CD N
) ) N
. . N

In IN N
addition NN N
, , N
acyclovir NN i
reduced VBD N
the DT N
incidence NN N
of IN N
fever NN o
( ( N
two CD N
vs. FW N
eight CD N
patients NNS N
, , N
P NNP N
= NNP N
0.015 CD N
) ) N
. . N

We PRP N
conclude VBP N
that DT N
acyclovir NN i
is VBZ N
better JJR N
than IN N
vidarabine NN i
for IN N
the DT N
treatment NN N
of IN N
varicella-zoster JJ N
infection NN N
in IN N
immunocompromised JJ p
patients NNS p
. . p

-DOCSTART- -8297739- O O

Granulocyte-macrophage JJ i
colony-stimulating JJ i
factor NN i
( ( i
GM-CSF NNP i
) ) i
allows VBZ N
acceleration NN N
and CC N
dose JJ N
intensity NN N
increase NN N
of IN N
CEF NNP i
chemotherapy NN i
: : i
a DT N
randomised JJ N
study NN N
in IN N
patients NNS p
with IN p
advanced JJ p
breast NN p
cancer NN p
. . p

A DT N
randomised JJ N
study NN N
was VBD N
conducted VBN N
in IN N
62 CD p
patients NNS p
with IN p
advanced JJ p
breast NN p
cancer NN p
to TO N
assess VB N
whether IN N
granulocyte-macrophage JJ N
colony-stimulating JJ N
factor NN N
( ( i
GM-CSF NNP i
) ) i
would MD N
yield VB N
an DT N
increase NN N
in IN N
the DT N
dose JJ N
intensity NN N
of IN N
a DT N
standard-dose JJ i
CEF NNP i
regimen NNS i
through IN N
an DT N
acceleration NN N
of IN N
chemotherapy JJ i
administration NN N
. . N

Patients NNS N
received VBD N
CEF NNP i
( ( i
cyclophosphamide VB i
600 CD i
mg JJ i
m-2 NN i
, , i
epidoxorubicin VBZ i
60 CD i
mg NN i
m-2 NN i
and CC i
fluorouracil NN i
600 CD i
mg JJ i
m-2 NN i
) ) i
i.v NN N
. . N

on IN N
day NN N
1 CD N
or CC N
the DT N
same JJ N
chemotherapy NN i
, , N
plus CC N
GM-CSF NNP i
10 CD N
micrograms NNS N
kg-1 JJ N
s.c. NNS N
starting VBG N
from IN N
day NN N
4 CD N
, , N
repeated VBN N
as RB N
soon RB N
as IN N
haematopoietic JJ N
recovery NN N
from IN N
nadir NN N
occurred VBD N
. . N

Patients NNS N
in IN N
the DT N
CEF NNP i
+ NNP i
GM-CSF NNP i
group NN N
received VBD N
chemotherapy NN N
at IN N
a DT N
median JJ N
interval NN N
of IN N
16 CD N
days NNS N
compared VBN N
with IN N
20 CD N
days NNS N
in IN N
the DT N
control NN N
group NN N
. . N

This DT N
led VBD N
to TO N
a DT N
significant JJ N
increase NN N
( ( N
P NNP N
= NNP N
0.02 CD N
) ) N
in IN N
the DT N
dose JJ N
intensity NN N
actually RB N
administered VBN N
in IN N
the DT N
third JJ N
, , N
fourth JJ N
and CC N
sixth JJ N
cycles NNS N
: : N
+28 CD N
% NN N
, , N
+25 CD N
% NN N
, , N
+20 CD N
% NN N
respectively RB N
. . N

Non-haematological JJ o
toxicity NN o
was VBD N
mild JJ N
. . N

GM-CSF NNP i
had VBD N
to TO N
be VB N
reduced VBN N
or CC N
suspended VBN N
in IN N
50 CD N
% NN N
of IN N
patients NNS N
because IN N
of IN N
toxicity NN o
. . o

Haematological JJ o
toxicity NN o
, , N
mainly RB N
cumulative JJ o
anaemia NN o
and CC o
thrombocytopenia NN o
, , N
was VBD N
manageable JJ N
. . N

An DT N
increase NN N
in IN N
response NN o
rate NN o
for IN N
patients NNS N
with IN N
measurable JJ o
disease NN o
, , N
of IN N
borderline JJ N
statistical JJ N
significance NN N
( ( N
P NNP N
= NNP N
0.088 CD N
, , N
P NNP N
for IN N
trend NN N
= NNP N
0.018 CD N
) ) N
, , N
from IN N
42 CD N
% NN N
in IN N
the DT N
CEF NNP i
group NN N
to TO N
69 CD N
% NN N
in IN N
the DT N
CEF NNP i
+ NNP i
GM-CSF NNP i
group NN N
, , N
was VBD N
observed VBN N
. . N

This DT N
randomised JJ N
trial NN N
indicates VBZ N
that IN N
GM-CSF NNP i
is VBZ N
useful JJ N
for IN N
chemotherapy NN N
acceleration NN N
. . N

Accelerated NNP N
CEF NNP i
+ NNP i
GM-CSF NNP i
is VBZ N
a DT N
moderately RB N
dose-intensive JJ N
regimen NNS N
that WDT N
can MD N
be VB N
administered VBN N
in IN N
an DT N
outpatient NN N
clinic NN N
and CC N
is VBZ N
associated VBN N
with IN N
a DT N
high JJ N
objective JJ N
response NN N
. . N

-DOCSTART- -20508979- O O

Effects NNS N
of IN N
cognitive JJ i
behavioral JJ i
therapy NN i
on IN N
daily JJ o
living NN o
skills NNS o
in IN p
children NNS p
with IN p
high-functioning JJ p
autism NN p
and CC p
concurrent JJ p
anxiety NN p
disorders NNS p
. . p

CBT NNP i
is VBZ N
a DT N
promising JJ N
treatment NN N
for IN N
children NNS p
with IN p
autism NN p
spectrum NN p
disorders NNS p
( ( p
ASD NNP p
) ) p
and CC N
focuses VBZ N
, , N
in IN N
part NN N
, , N
on IN N
children NNS N
's POS N
independence NN o
and CC o
self-help JJ o
skills NNS o
. . o

In IN N
a DT N
trial NN N
of IN N
CBT NNP i
for IN N
anxiety NN N
in IN N
ASD NNP N
( ( N
Wood NNP N
et RB N
al RB N
. . N

in IN N
J NNP N
Child NNP N
Psychol NNP N
Psychiatry NNP N
50:224-234 CD N
, , N
2009 CD N
) ) N
, , N
children NNS N
's POS N
daily JJ N
living NN N
skills NNS N
and CC N
related JJ N
parental JJ o
intrusiveness NN o
were VBD N
assessed VBN N
. . N

Forty NNP p
children NNS p
with IN p
ASD NNP p
( ( p
7-11 CD p
years NNS p
) ) p
and CC p
their PRP$ p
primary JJ p
caregiver NN p
were VBD N
randomly RB i
assigned VBN i
to TO i
an DT i
immediate JJ i
treatment NN i
( ( i
IT NNP i
; : i
n JJ i
= NNP i
17 CD i
) ) i
or CC i
3-month JJ i
waitlist NN i
( ( i
WL NNP i
; : i
n CC i
= VB i
23 CD i
) ) i
condition NN i
. . i

In IN N
comparison NN N
to TO N
WL NNP N
, , N
IT NNP N
parents VBZ N
reported VBN N
increases NNS N
in IN N
children NNS N
's POS N
total NN o
and CC o
personal JJ o
daily JJ o
living NN o
skills NNS o
, , N
and CC N
reduced JJ N
involvement NN o
in IN o
their PRP$ o
children NNS o
's POS o
private JJ o
daily JJ o
routines NNS o
. . o

Reductions NNS N
correlated VBD N
with IN N
reduced JJ N
anxiety NN N
severity NN o
. . o

These DT N
results NNS N
provide VBP N
preliminary JJ N
evidence NN N
that IN N
CBT NNP N
may MD N
yield VB N
increased JJ N
independence NN o
and CC o
daily JJ o
living NN o
skills NNS o
among IN N
children NNS p
with IN p
ASD NNP p
. . p

-DOCSTART- -17003665- O O

Atomoxetine NNP i
for IN N
hyperactivity NN p
in IN p
autism NN p
spectrum NN p
disorders NNS p
: : p
placebo-controlled JJ N
crossover NN N
pilot NN N
trial NN N
. . N

OBJECTIVE UH N
To TO N
explore VB N
placebo-controlled JJ N
efficacy NN N
and CC N
safety NN N
of IN N
atomoxetine NN i
( ( i
ATX NNP i
) ) i
for IN N
attention-deficit/hyperactivity NN p
disorder NN p
( ( p
ADHD NNP p
) ) p
symptoms NNS p
in IN p
children NNS p
with IN p
autism NN p
spectrum NN p
disorders NNS p
( ( p
ASD NNP p
) ) p
. . p

METHOD NNP N
Children NNP p
ages VBZ p
5 CD p
to TO p
15 CD p
with IN p
ASD NNP p
and CC p
prominent JJ p
ADHD NNP p
symptoms NNS p
were VBD N
randomly RB N
assigned VBN N
to TO N
order NN N
in IN N
a DT N
crossover NN N
of IN N
clinically RB i
titrated VBN i
ATX NNP i
and CC i
placebo NN i
, , i
6 CD i
weeks NNS i
each DT i
, , i
separated VBN i
by IN i
1-week JJ i
washout NN i
. . i

Slopes NNP N
for IN N
each DT N
condition NN N
were VBD N
compared VBN N
by IN N
paired JJ N
t JJ N
test NN N
. . N

RESULTS NNP N
In IN p
2004-2005 JJ p
, , p
12 CD p
boys NNS p
and CC p
4 CD p
girls NNS p
( ( p
7 CD p
with IN p
autistic JJ p
disorder NN p
, , p
1 CD p
Asperger NNP p
's POS p
, , p
8 CD p
pervasive JJ p
developmental NN p
disorder NN p
not RB p
otherwise RB p
specified VBN p
) ) p
all DT N
completed VBN N
at IN N
least JJS N
3 CD N
weeks NNS N
of IN N
each DT N
condition NN N
. . N

On IN N
the DT N
primary JJ N
outcome NN N
, , N
the DT N
Hyperactivity NNP o
subscale NN o
of IN o
the DT o
Aberrant NNP o
Behavior NNP o
Checklist NNP o
, , o
ATX NNP o
was VBD N
superior JJ N
to TO N
placebo VB N
( ( N
p JJ N
=.043 NN N
, , N
effect NN N
size NN N
d NN N
= NNP N
0.90 CD N
) ) N
. . N

It PRP N
was VBD N
also RB N
superior JJ N
on IN N
a DT N
0 CD N
to TO N
3 CD N
rating NN N
of IN N
nine CD N
DSM-IV NNP o
ADHD NNP o
hyperactive/impulsive NN o
symptoms NNS o
( ( N
p JJ N
=.005 NN N
, , N
d NN N
= NNP N
1.27 CD N
) ) N
, , N
but CC N
missed VBD N
significance NN N
on IN N
nine CD N
inattentive JJ N
symptoms NNS N
( ( N
p JJ N
=.053 NN N
, , N
d= VB N
0.89 CD N
) ) N
. . N

Nine JJ N
subjects NNS N
responded VBD N
to TO N
ATX NNP N
, , N
four CD N
to TO N
placebo VB i
( ( N
25 CD N
% NN N
improvement NN N
on IN N
the DT N
Hyperactivity NNP o
subscale NN o
plus CC o
Clinical JJ o
Global NNP o
Impressions-Improvement NN o
of IN N
1-2 JJ N
. . N

One CD N
was VBD N
rehospitalized VBN o
for IN N
recurrent JJ N
violence NN N
on IN N
ATX NNP N
. . N

Adverse JJ o
events NNS o
were VBD N
otherwise RB N
tolerable JJ N
, , N
with IN N
no DT N
tendency NN N
to TO N
stereotypy VB N
. . N

CONCLUSIONS NNP N
ATX NNP N
appears VBZ N
safe JJ N
and CC N
effective JJ N
for IN N
treating VBG N
hyperactivity NN p
in IN p
some DT p
children NNS p
with IN p
autism NN p
spectrum NN p
disorders NNS p
. . p

The DT N
effect NN N
appears VBZ N
as RB N
large JJ N
as IN N
in IN N
a DT N
multisite JJ N
methylphenidate NN i
trial NN N
in IN N
the DT N
same JJ N
population NN N
, , N
with IN N
fewer JJR N
intolerable JJ N
side NN N
effects NNS N
. . N

Further NNP N
study NN N
in IN N
autism NN N
spectrum NN N
disorders NNS N
is VBZ N
indicated VBN N
. . N

-DOCSTART- -25496415- O O

Increased VBN N
dietary JJ i
?-linolenic JJ i
acid NN i
has VBZ o
sex-specific JJ o
effects NNS o
upon IN N
eicosapentaenoic JJ N
acid NN N
status NN N
in IN p
humans NNS p
: : p
re-examination NN N
of IN N
data NNS N
from IN N
a DT N
randomised VBN N
, , N
placebo-controlled JJ N
, , N
parallel JJ N
study NN N
. . N

BACKGROUND NNP N
There EX N
is VBZ N
a DT N
metabolic JJ N
pathway NN N
by IN N
which WDT p
mammals NNS p
can MD N
convert VB N
the DT N
omega-3 JJ i
( ( i
n-3 JJ i
) ) i
essential JJ i
fatty JJ i
acid JJ i
?-linolenic JJ i
acid NN i
( ( i
ALA NNP i
) ) i
into IN i
longer-chain JJ i
n-3 JJ i
polyunsaturated VBN i
fatty JJ i
acids NNS i
( ( i
LC NNP N
n-3 JJ N
PUFA NNP N
) ) N
including VBG i
eicosapentaenoic JJ i
acid NN i
( ( i
EPA NNP N
) ) N
and CC i
docosahexaenoic JJ i
acid NN i
( ( i
DHA NNP N
) ) N
. . N

As RB N
far RB N
as IN N
we PRP N
know VBP N
there EX N
are VBP N
currently RB N
no DT N
studies NNS N
that WDT N
have VBP N
specifically RB N
examined VBN N
sex NN N
differences NNS N
in IN N
the DT N
LC NNP N
n-3 JJ N
PUFA NNP N
response NN N
to TO N
increased VBN N
dietary JJ N
ALA NNP N
intake NN N
in IN N
humans NNS N
, , N
although IN N
acute JJ N
studies NNS N
with IN N
isotope-labelled JJ N
ALA NNP N
identified VBD N
that IN p
women NNS p
have VBP p
a DT N
significantly RB N
greater JJR N
capacity NN N
to TO N
synthesise VB o
EPA NNP o
and CC o
DHA NNP o
from IN o
ALA NNP N
compared VBN N
to TO N
men NNS p
. . p

FINDINGS NNP N
Available NNP N
data NNS N
from IN N
a DT N
placebo-controlled JJ N
, , N
randomised VBN N
study NN N
were VBD N
re-examined JJ N
to TO N
identify VB N
whether IN N
there EX N
are VBP N
sex NN N
differences NNS N
in IN N
the DT N
LC NNP N
n-3 JJ N
PUFA NNP N
response NN N
to TO N
increased VBN i
dietary JJ i
ALA NNP i
intake NN i
in IN i
humans NNS N
. . N

There EX N
was VBD N
a DT N
significant JJ N
difference NN N
between IN N
sexes NNS N
in IN N
the DT N
response NN N
to TO N
increased VBN o
dietary JJ o
ALA NNP o
, , o
with IN N
women NNS N
having VBG N
a DT N
significantly RB N
greater JJR N
increase NN N
in IN N
the DT o
EPA NNP o
content NN o
of IN o
plasma JJ o
phospholipids NNS o
( ( o
mean JJ N
+2.0 NNP N
% NN N
of IN N
total JJ N
fatty JJ N
acids NNS N
) ) N
after IN N
six CD N
months NNS N
of IN N
an DT N
ALA-rich JJ i
diet NN i
compared VBN i
to TO N
men NNS N
( ( N
mean VB N
+0.7 CD N
% NN N
, , N
P NNP N
= NNP N
0.039 CD N
) ) N
. . N

Age NNP N
and CC N
BMI NNP N
were VBD N
identified VBN N
as IN N
predictors NNS N
of IN N
response NN N
to TO N
dietary JJ N
ALA NNP N
among IN N
women NNS N
. . N

CONCLUSIONS NNP p
Women NNP p
show VBP N
a DT N
greater JJR N
increase NN o
in IN o
circulating VBG o
EPA NNP o
than IN o
men NNS N
during IN N
increased VBN N
dietary JJ N
ALA NNP N
consumption NN N
. . N

Further RBR N
understanding NN N
of IN N
individual JJ N
variation NN N
in IN N
the DT N
response NN i
to TO i
dietary JJ i
ALA NNP i
could MD i
inform VB N
nutrition NN N
advice NN N
, , N
with IN N
recommendations NNS N
being VBG N
specifically RB N
tailored VBN N
according VBG N
to TO N
habitual JJ N
diet NN N
, , N
sex NN N
, , N
age NN N
and CC N
BMI NNP N
. . N

-DOCSTART- -8623957- O O

Recovery NN N
profile NN N
after IN N
desflurane NN i
with IN i
or CC i
without IN i
ondansetron NNS i
compared VBN i
with IN i
propofol NN i
in IN N
patients NNS p
undergoing JJ p
outpatient JJ p
gynecological JJ i
laparoscopy NN i
. . i

We PRP N
studied VBD N
the DT N
effect NN N
of IN N
combining VBG N
prophylactic JJ i
ondansetron NN i
( ( N
4 CD N
mg NN N
intravenously RB N
[ NNP N
IV NNP N
] NNP N
) ) N
to TO i
desflurane-based JJ i
anesthesia NN i
in IN N
90 CD p
ASA NNP p
grade NN p
I PRP p
or CC p
11 CD p
women NNS p
undergoing VBG p
outpatient JJ p
gynecological JJ i
laparoscopy NN i
. . i

Recovery NN N
after IN N
anesthesia NN N
, , N
with IN N
special JJ N
focus NN N
on IN N
postoperative JJ N
nausea NN N
and CC N
vomiting NN N
( ( N
PONV NNP N
) ) N
, , N
was VBD N
assessed VBN N
. . N

Control NNP N
groups NNS N
received VBD N
a DT N
similar JJ N
desflurane NN i
anesthetic NN i
( ( i
placebo NN i
) ) i
or CC i
a DT i
propofol-infusion-based JJ i
( ( i
active JJ i
control NN i
) ) i
anesthetic NN i
. . i

The DT N
study NN N
design NN N
was VBD N
randomized VBN N
, , N
controlled VBN N
, , N
and CC N
double-blind NN N
( ( N
regarding VBG N
ondansetron NN i
) ) i
and CC N
single-blind JJ N
( ( N
regarding VBG N
the DT N
anesthetic JJ N
technique NN N
) ) N
. . N

Early JJ N
recovery NN N
( ( N
eye NN N
opening NN N
, , N
orientation NN N
, , N
following VBG N
commands NNS N
, , N
sitting VBG N
) ) N
was VBD N
similar JJ N
in IN N
the DT N
three CD N
groups NNS N
. . N

However RB N
, , N
overall JJ N
home NN o
readiness NN o
( ( N
toleration NN N
of IN N
oral JJ N
fluids NNS N
, , N
walking VBG N
, , N
pain NN N
tolerable JJ N
by IN N
oral JJ N
analgesics NNS N
, , N
no DT N
or CC N
only RB N
mild JJ N
nausea NN N
) ) N
was VBD N
achieved VBN N
faster RBR N
in IN N
the DT N
desflurane NN N
group NN N
receiving VBG N
ondansetron NN i
( ( N
109 CD N
[ RB N
21-937 JJ N
] NNP N
min NN N
, , N
P NNP N
< NNP N
0.01 CD N
) ) N
and CC N
in IN N
the DT N
propofol NN N
group NN N
( ( N
110 CD N
[ RB N
33-642 JJ N
] NNP N
min NN N
, , N
P NNP N
< NNP N
0.001 CD N
) ) N
when WRB N
compared VBN N
to TO N
the DT N
desflurane NN i
only RB N
group NN N
( ( N
372 CD N
[ RB N
45-723 JJ N
] NNP N
min NN N
) ) N
( ( N
median JJ N
[ NNP N
range NN N
] NN N
) ) N
. . N

The DT N
total JJ N
incidence NN N
of IN N
PONV NNP o
in IN N
the DT N
desflurane-only JJ i
group NN N
was VBD N
80 CD N
% NN N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
, , N
compared VBN N
to TO N
40 CD N
% NN N
and CC N
20 CD N
% NN N
in IN N
the DT N
desflurane NN i
group NN N
receiving VBG N
ondansetron NN N
and CC N
the DT N
propofol NN i
group NN N
, , N
respectively RB N
. . N

The DT N
postoperative JJ o
antiemetic JJ o
requirements NNS o
were VBD N
consistently RB N
and CC N
significantly RB N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
higher JJR N
in IN N
the DT N
desflurane-only JJ i
group NN N
compared VBN N
to TO N
the DT N
other JJ N
two CD N
groups NNS N
. . N

Postoperative JJ o
sedation NN o
, , o
analgesic JJ o
requirements NNS o
, , o
and CC o
psychomotor NN o
recovery NN o
( ( N
assessed VBN N
by IN N
the DT N
Maddox NNP N
Wing NNP N
and CC N
the DT N
Digit NNP N
Symbol NNP N
Substitution NNP N
Tests NNP N
) ) N
were VBD N
similar JJ N
in IN N
the DT N
three CD N
groups NNS N
. . N

Our PRP$ N
results NNS N
suggest VBP N
that IN N
in IN N
order NN N
to TO N
achieve VB N
a DT N
propofol-like JJ o
recovery NN o
profile NN o
in IN N
patients NNS N
with IN N
a DT N
high JJ N
likelihood NN N
of IN N
PONV NNP N
, , N
desflurane NN i
should MD N
be VB N
combined VBN N
with IN N
a DT N
potent JJ N
antiemetic JJ N
( ( N
e.g. JJ N
, , N
ondansetron NN N
) ) N
. . N

-DOCSTART- -15304616- O O

IV NNP i
amantadine NN i
improves VBZ N
chorea NNS p
in IN p
Huntington NNP p
's POS p
disease NN p
: : p
an DT N
acute NN N
randomized NN N
, , N
controlled VBN N
study NN N
. . N

-DOCSTART- -10741095- O O

Comparison NNP N
of IN N
different JJ N
long-term JJ N
asthma NN N
treatments NNS N
in IN N
subjects NNS p
with IN p
mild-to-moderate JJ p
asthma NN p
. . p

In IN N
order NN N
to TO N
compare VB N
the DT N
efficacy NN N
of IN N
different JJ N
asthma NN N
treatment NN N
in IN N
subjects NNS p
with IN p
mild-to-moderate JJ p
asthma NN p
, , p
three CD p
groups NNS p
of IN p
11 CD p
patients NNS p
were VBD N
treated VBN N
with IN N
nedocromil JJ i
sodium NN i
( ( i
NS NNP i
) ) i
, , i
beclomethasone JJ i
dipropionate NN i
( ( i
BDP NNP i
) ) i
and CC i
beclomethasone NN i
dipropionate NN i
plus CC i
salmeterol NN i
( ( i
BDP NNP i
+ NNP i
S NNP i
) ) i
in IN N
an DT N
open JJ N
, , N
randomized VBN N
study NN N
. . N

Symptom NNP N
score NN N
, , N
peak JJ N
expiratory NN N
flow NN N
( ( N
PEF NNP N
) ) N
maximal JJ N
amplitude NN N
, , N
forced VBD N
expiratory JJ N
volume NN N
in IN N
one CD N
second NN N
( ( N
FEV1 NNP N
) ) N
, , N
and CC N
methacholine JJ N
reactivity NN N
were VBD N
measured VBN N
at IN N
the DT N
baseline NN N
and CC N
at IN N
intervals NNS N
of IN N
3 CD N
months NNS N
up RB N
to TO N
12 CD N
months NNS N
. . N

After IN N
3 CD N
months NNS N
, , N
symptoms NNS N
reduced VBD N
significantly RB N
in IN N
all DT N
treatment NN N
groups NNS N
, , N
while IN N
PEF NNP N
variability NN N
improved VBN N
in IN N
BDP NNP N
and CC N
BDP NNP N
+ NNP N
S NNP N
groups NNS N
; : N
FEV1 NNP N
and CC N
bronchial JJ N
responsiveness NN N
to TO N
methacholine VB N
were VBD N
significantly RB N
improved VBN N
in IN N
comparison NN N
with IN N
baseline JJ N
value NN N
in IN N
the DT N
BDP NNP N
+ NNP N
S NNP N
group NN N
only RB N
. . N

No DT o
significant JJ o
difference NN o
was VBD o
observed VBN o
after IN o
6 CD o
and CC o
12 CD o
months NNS o
of IN o
treatment NN o
in IN o
PEF NNP o
variability NN o
, , o
FEV1 NNP o
or CC o
bronchial JJ o
hyperreactivity NN o
in IN o
the DT o
NS NNP o
group NN o
compared VBN o
with IN o
baseline NN o
values NNS o
, , o
while IN o
a DT o
significant JJ o
difference NN o
was VBD o
observed VBN o
in IN o
symptom NN o
score NN o
. . o

BDP NNP o
group NN o
showed VBD o
a DT o
significant JJ o
improvement NN o
in IN o
FEV1 NNP o
and CC o
bronchial JJ o
reactivity NN o
to TO o
methacholine VB o
after IN o
6 CD o
and CC o
12 CD o
months NNS o
of IN o
treatment NN o
. . o

In IN o
the DT o
BDP NNP o
+ NNP o
S NNP o
group NN o
, , o
the DT o
improvement NN o
in IN o
symptoms NNS o
and CC o
pulmonary JJ o
function NN o
persisted VBN o
until IN o
the DT o
end NN o
of IN o
the DT o
study NN o
. . o

In IN N
conclusion NN N
, , N
the DT o
combination NN o
of IN o
beclomethasone NN o
dipropionate NN o
and CC o
salmeterol NN o
improved VBD o
pulmonary JJ o
function NN o
and CC o
bronchial JJ o
reactivity NN o
earlier RBR o
than IN o
beclomethasone CD o
dipropionate NN o
alone RB o
, , o
while IN o
nedocromil JJ o
sodium NN o
improved VBD o
symptoms NNS o
but CC o
not RB o
pulmonary JJ o
function NN o
. . o

Assuming VBG N
that IN N
bronchial JJ o
reactivity NN o
could MD N
be VB N
an DT N
indirect JJ N
measurement NN N
of IN N
airway JJ N
inflammation NN N
, , N
overtreatment NN o
of IN o
asthma NN o
in IN o
relationship NN o
with IN o
the DT o
classification NN o
of IN o
asthma JJ o
severity NN o
of IN o
the DT o
International NNP o
Guidelines NNP o
could MD o
improve VB o
both DT o
airway JJ o
inflammation NN o
and CC o
the DT o
prognosis NN o
of IN o
airway JJ o
obstruction NN o
. . o

-DOCSTART- -12575712- O O

The DT N
results NNS N
of IN N
a DT N
randomized VBN N
study NN N
on IN N
the DT N
use NN N
of IN N
long-acting JJ N
octreotide NN i
in IN N
hepatocellular JJ p
carcinoma NN p
. . p

-DOCSTART- -17426180- O O

Low JJ N
efficacy NN N
of IN N
mebendazole NN i
against IN N
hookworm NN o
in IN p
Vietnam NNP p
: : p
two CD N
randomized VBD N
controlled VBN N
trials NNS N
. . N

Vietnam NNP p
is VBZ N
participating VBG N
in IN N
a DT N
global JJ N
de-worming NN N
effort NN N
that WDT N
aims VBZ N
to TO N
treat VB N
650 CD N
million CD N
school NN N
children NNS N
regularly RB N
by IN N
2010 CD N
. . N

The DT N
treatment NN N
used VBN N
in IN N
Vietnam NNP N
is VBZ N
single JJ N
dose JJ N
oral JJ N
mebendazole NN i
( ( i
Phardazone NNP i
) ) i
500 CD N
mg. NN N
We PRP N
tested VBD N
the DT N
efficacy NN N
of IN N
single JJ N
dose JJ N
mebendazole NN i
500 CD N
mg NN N
in IN N
the DT N
therapy NN N
of IN N
hookworm NN p
infection NN p
in IN N
a DT N
randomized JJ N
double-blind JJ N
placebo-controlled JJ i
trial NN p
among IN p
271 CD p
Vietnamese JJ p
schoolchildren NNS p
. . p

The DT N
treatment NN N
efficacy NN N
of IN N
single JJ N
dose JJ N
mebendazole NN i
in IN N
children NNS N
did VBD N
not RB N
differ VB N
significantly RB N
from IN N
placebo NN i
, , N
with IN N
a DT N
reduction NN N
in IN N
mean NN o
eggs NNS o
per IN o
gram NN o
of IN o
feces NNS o
relative VBP N
to TO N
placebo VB i
of IN N
31 CD N
% NN N
( ( N
95 CD N
% NN N
CI NNP N
-9 NNP N
to TO N
56 CD N
% NN N
, , N
P NNP N
= NNP N
0.1 CD N
) ) N
. . N

In IN N
light NN N
of IN N
these DT N
findings NNS N
we PRP N
then RB N
carried VBD N
out RP N
a DT N
similar JJ N
randomized VBN N
trial NN N
comparing VBG N
triple JJ N
dose JJ N
mebendazole NN i
, , N
single JJ N
dose NN N
albendazole NN i
, , N
and CC N
triple RB N
dose JJ N
albendazole NN i
against IN N
placebo NN i
in IN N
209 CD p
adults NNS p
in IN p
the DT p
same JJ p
area NN p
. . p

The DT N
estimated JJ N
reduction NN o
in IN o
mean JJ o
post-treatment JJ o
eggs NNS o
per IN o
gram NN o
of IN o
feces NNS o
relative VBP N
to TO N
placebo VB i
was VBD N
63 CD N
% NN N
( ( N
95 CD N
% NN N
CI NNP N
30-81 CD N
% NN N
) ) N
for IN N
triple JJ N
mebendazole NN i
, , N
75 CD N
% NN N
( ( N
47-88 CD N
% NN N
) ) N
for IN N
single JJ N
albendazole NN i
, , N
and CC N
88 CD N
% NN N
( ( N
58-97 CD N
% NN N
) ) N
for IN N
triple JJ N
albendazole NN i
. . i

Our PRP$ N
results NNS N
suggest VBP N
that IN N
single JJ N
dose JJ N
oral JJ N
mebendazole NN N
has VBZ N
low JJ o
efficacy NN o
against IN o
hookworm NN o
infection NN o
in IN N
Vietnam NNP N
, , N
and CC N
that IN N
it PRP N
should MD N
be VB N
replaced VBN N
by IN N
albendazole NN i
. . i

These DT N
findings NNS N
are VBP N
of IN N
major JJ N
public JJ N
health NN N
relevance NN N
given VBN N
the DT N
opportunity NN N
costs NNS N
of IN N
treating VBG N
entire JJ N
populations NNS N
with IN N
ineffective JJ N
therapies NNS N
. . N

We PRP N
recommend VBP N
that DT N
efficacy NN N
of IN N
anti-helminth JJ i
therapies NNS i
is VBZ N
pilot JJ N
tested VBN N
before IN N
implementation NN N
of IN N
national JJ N
gut NN N
worm NN N
control NN N
programs NNS N
. . N

-DOCSTART- -17909199- O O

Phase NNP N
II NNP N
study NN N
of IN N
efficacy NN o
and CC o
safety NN o
of IN N
bevacizumab NN i
in IN i
combination NN i
with IN i
chemotherapy NN i
or CC N
erlotinib NN i
compared VBN N
with IN N
chemotherapy NN i
alone RB i
for IN N
treatment NN p
of IN p
recurrent NN p
or CC p
refractory NN p
non JJ p
small-cell JJ p
lung NN p
cancer NN p
. . p

PURPOSE NNP N
Bevacizumab NNP i
, , N
a DT N
humanized JJ N
anti-vascular JJ N
endothelial JJ N
growth NN N
factor NN N
monoclonal JJ N
antibody NN N
, , N
and CC N
erlotinib RB i
, , N
a DT N
reversible JJ N
, , N
orally RB N
available JJ N
epidermal JJ N
growth NN N
factor NN N
receptor NN N
tyrosine NN N
kinase NN N
inhibitor NN N
, , N
have VBP N
demonstrated VBN N
evidence NN N
of IN N
a DT N
survival JJ N
benefit NN N
in IN N
the DT N
treatment NN N
of IN N
non-small-cell JJ N
lung NN N
cancer NN N
( ( N
NSCLC NNP N
) ) N
. . N

A DT N
single-arm JJ N
phase NN N
I PRP N
and CC N
II NNP N
study NN N
of IN N
bevacizumab NN i
plus CC i
erlotinib NN i
demonstrated VBD N
encouraging JJ N
efficacy NN N
, , N
with IN N
a DT N
favorable JJ N
safety NN N
profile NN N
. . N

PATIENTS NNP N
AND CC N
METHODS NNP N
A NNP N
multicenter NN N
, , N
randomized VBN N
phase NN N
II NNP N
trial NN N
evaluated VBD N
the DT N
safety NN N
of IN N
combining VBG i
bevacizumab NN i
with IN i
either DT i
chemotherapy NN i
( ( i
docetaxel NN i
or CC i
pemetrexed NN i
) ) i
or CC i
erlotinib JJ i
and CC N
preliminarily RB N
assessed VBN N
these DT N
combinations NNS N
versus VBP N
chemotherapy NN i
alone RB N
, , N
as IN N
measured VBN N
by IN N
progression-free JJ o
survival NN o
( ( o
PFS NNP o
) ) o
. . o

All DT p
patients NNS p
had VBD p
histologically RB p
confirmed VBN p
nonsquamous JJ p
NSCLC NNP p
that WDT p
had VBD p
progressed VBN p
during IN p
or CC p
after IN p
one CD p
platinum-based JJ p
regimen NNS p
. . p

RESULTS NNP N
One CD p
hundred VBD p
twenty NN p
patients NNS p
were VBD N
randomly RB N
assigned VBN N
and CC N
treated VBN N
. . N

No DT N
unexpected JJ N
adverse JJ o
events NNS o
were VBD N
noted VBN N
. . N

Fewer JJR N
patients NNS N
( ( N
13 CD N
% NN N
) ) N
in IN N
the DT N
bevacizumab-erlotinib JJ i
arm NN N
discontinued VBN N
treatment NN N
as IN N
a DT N
result NN o
of IN o
adverse JJ o
events NNS o
than IN N
in IN N
the DT N
chemotherapy NN i
alone RB N
( ( N
24 CD N
% NN N
) ) N
or CC N
bevacizumab-chemotherapy NN i
( ( N
28 CD N
% NN N
) ) N
arms NNS N
. . N

The DT N
incidence NN N
of IN N
grade NN o
5 CD o
hemorrhage NN o
in IN N
patients NNS N
receiving VBG N
bevacizumab NN i
was VBD N
5.1 CD N
% NN N
. . N

Although IN N
not RB N
statistically RB N
significant JJ N
, , N
relative JJ N
to TO N
chemotherapy VB N
alone RB N
, , N
the DT N
risk NN o
of IN o
disease NN o
progression NN o
or CC o
death NN o
was VBD N
0.66 CD N
( ( N
95 CD N
% NN N
CI NNP N
, , N
0.38 CD N
to TO N
1.16 CD N
) ) N
among IN N
patients NNS N
treated VBN N
with IN N
bevacizumab-chemotherapy NN i
and CC N
0.72 CD N
( ( N
95 CD N
% NN N
CI NNP N
, , N
0.42 CD N
to TO N
1.23 CD N
) ) N
among IN N
patients NNS N
treated VBN N
with IN N
bevacizumab-erlotinib JJ i
. . i

One-year JJ o
survival NN o
rate NN o
was VBD N
57.4 CD N
% NN N
for IN N
bevacizumab-erlotinib NN i
and CC N
53.8 CD N
% NN N
for IN N
bevacizumab-chemotherapy NN i
compared VBN N
with IN N
33.1 CD N
% NN N
for IN N
chemotherapy NN i
alone RB N
. . N

CONCLUSION NNP N
Results NNP N
for IN N
PFS NNP o
and CC o
overall JJ o
survival NN o
favor NN N
combination NN N
of IN N
bevacizumab NN i
with IN N
either DT N
chemotherapy NN i
or CC N
erlotinib NN N
over IN N
chemotherapy NN i
alone RB N
in IN N
the DT N
second-line JJ N
setting NN N
. . N

No DT N
unexpected JJ N
safety NN o
signals NNS o
were VBD N
noted VBN N
. . N

The DT N
rate NN o
of IN o
fatal JJ o
pulmonary JJ o
hemorrhage NN o
was VBD N
consistent JJ N
with IN N
previous JJ N
bevacizumab NN i
trials NNS N
. . N

The DT N
toxicity NN o
profile NN o
of IN N
the DT N
bevacizumab-erlotinib JJ i
combination NN i
is VBZ N
favorable JJ N
compared VBN N
with IN N
either DT N
chemotherapy-containing JJ i
group NN N
. . N

-DOCSTART- -20206437- O O

A DT N
prospective JJ N
multicenter NN N
randomized VBD N
comparative JJ N
study NN N
between IN N
the DT N
U- NNP i
and CC i
H-type NNP i
methods NNS i
of IN i
the DT i
TVT NNP i
SECUR NNP i
procedure NN i
for IN N
the DT N
treatment NN N
of IN N
female JJ p
stress NN p
urinary JJ p
incontinence NN p
: : p
1-year JJ N
follow-up NN N
. . N

BACKGROUND NNP N
No NNP N
studies NNS N
have VBP N
been VBN N
published VBN N
comparing VBG N
the DT N
U- JJ i
and CC i
H-type JJ i
methods NNS i
of IN i
the DT i
TVT NNP i
SECUR NNP i
( ( i
TVT-S NNP i
) ) i
procedure NN i
. . i

OBJECTIVE CC N
Our PRP$ N
aim NN N
was VBD N
to TO N
compare VB N
the DT N
efficacy NN N
and CC N
safety NN N
of IN N
the DT N
two CD i
types NNS i
of IN i
TVT-S NNP i
for IN N
female JJ p
stress NN p
urinary JJ p
incontinence NN p
( ( p
SUI NNP p
) ) p
. . p

DESIGN NNP N
, , N
SETTING NNP N
, , N
AND NNP N
PARTICIPANTS NNP N
Women NNP p
with IN p
urodynamic JJ p
SUI NNP p
were VBD p
enrolled VBN p
in IN N
this DT N
12-mo JJ N
multicenter NN N
randomized VBN N
study NN N
. . N

INTERVENTION NNP N
Subjects NNPS p
were VBD N
randomly RB N
allocated VBN N
to TO N
either VB N
the DT N
U- JJ i
or CC i
H-type JJ i
method NN i
of IN i
TVT-S. JJ i
MEASUREMENTS NNP N
Pre- NNP N
and CC N
postoperative JJ N
evaluations NNS N
included VBD N
a DT N
standing VBG o
stress NN o
test NN o
, , N
the DT N
Sandvik NNP o
questionnaire NN o
, , N
the DT N
Incontinence NNP o
Quality NNP o
of IN o
Life NNP o
( ( o
I-QOL NNP o
) ) o
questionnaire NN o
, , N
and CC N
the DT N
International NNP o
Consultation NNP o
on IN o
Incontinence NNP o
Questionnaire-Female NNP o
Lower NNP o
Urinary NNP o
Tract NNP o
Symptoms NNP o
( ( o
ICIQ-FLUTS NNP o
) ) o
. . o

Patients NNS N
' POS N
satisfaction NN o
and CC N
complications NNS o
were VBD N
evaluated VBN N
. . N

Objective NNP N
and CC N
subjective JJ N
cures NNS N
were VBD N
defined VBN N
as IN N
no DT N
leakage NN N
on IN N
the DT N
stress JJ o
test NN o
and CC N
responses NNS N
on IN N
the DT N
Sandvik NNP o
questionnaire NN o
, , N
respectively RB N
. . N

We PRP N
compared VBN N
the DT N
surgical JJ o
outcomes NNS o
between IN N
the DT N
two CD N
methods NNS N
. . N

RESULTS NNP N
AND NNP N
LIMITATIONS NNP N
Of IN p
285 CD p
women NNS p
, , p
144 CD p
had VBD p
the DT p
U-type JJ p
method NN p
and CC p
141 CD p
had VBD p
the DT p
H-type JJ p
method NN p
. . p

Objective JJ o
cure NN o
rates NNS o
were VBD N
87.5 CD N
% NN N
for IN N
the DT N
U-type JJ N
method NN N
and CC N
80.1 CD N
% NN N
for IN N
the DT N
H-type NNP N
method NN N
( ( N
p=0.091 NN N
) ) N
. . N

Subjective JJ o
cure NN o
rates NNS o
were VBD N
77.1 CD N
% NN N
for IN N
the DT N
U-type JJ N
method NN N
and CC N
75.7 CD N
% NN N
for IN N
the DT N
H-type NNP N
method NN N
( ( N
p=0.786 NN N
) ) N
. . N

Improvement NN N
in IN N
I-QOL NNP o
and CC o
domain NN o
scores NNS o
of IN o
the DT o
ICIQ-FLUTS NNP o
( ( o
filling VBG o
and CC o
incontinence NN o
sum NN o
, , o
QOL NNP o
score NN o
) ) o
, , N
and CC N
patients NNS o
' POS o
satisfaction NN o
favored VBD N
the DT N
U-type JJ N
method NN N
. . N

There EX N
were VBD N
three CD N
cases NNS N
of IN N
intraoperative JJ o
vaginal JJ o
wall NN o
perforation NN o
, , N
one CD N
case NN N
of IN N
increased VBN o
bleeding NN o
, , N
and CC N
three CD N
cases NNS N
of IN N
temporary JJ o
postoperative JJ o
retention NN o
. . o

A DT N
power NN N
calculation NN N
was VBD N
not RB N
performed VBN N
, , N
and CC N
some DT N
baseline NN N
characteristics NNS N
were VBD N
not RB N
balanced VBN N
between IN N
the DT N
two CD N
methods NNS N
. . N

CONCLUSIONS NNP N
Both NNP N
methods NNS i
of IN i
TVT-S NNP i
provided VBD N
comparable JJ N
cure NN o
rates NNS o
for IN N
female JJ p
SUI NNP p
. . p

However RB N
, , N
QOL NNP o
and CC N
treatment NN o
satisfaction NN o
favored VBD N
the DT N
U-type JJ i
method NN i
. . i

TRIAL NNP N
REGISTRATION NNP N
The DT N
protocol NN N
of IN N
this DT N
study NN N
was VBD N
not RB N
registered VBN N
. . N

-DOCSTART- -9205762- O O

Comparison NNP N
of IN N
the DT N
efficacy NN o
and CC o
safety NN o
of IN N
ebrotidine NN N
in IN N
the DT N
treatment NN N
of IN N
duodenal JJ N
ulcer NN N
. . N

A DT N
multicentre NN N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
phase NN N
II NNP N
study NN N
. . N

Ebrotidine NNP N
( ( N
N- NNP N
[ NNP N
( ( N
E NNP N
) ) N
- : N
[ JJ N
[ JJ N
2- JJ N
[ NN N
[ NNP N
[ NNP N
2- JJ N
[ NNP N
( ( N
diaminomethylene NN N
) ) N
amino NN N
] JJ N
-4 NNP N
-thiazoly NNP N
] NNP N
methyl NN N
] NNP N
thio NN N
] NNP N
ethyl VBZ N
] NNP N
amino NN N
] NNP N
methylene NN N
] NNP N
-4-bromo-benzenesulfon NNP N
amide RB N
, , N
CAS NNP N
100981-43-9 CD N
, , N
FI-3542 NNP N
) ) N
is VBZ N
a DT N
new JJ N
H2-receptor NNP N
antagonist NN N
characterized VBN N
by IN N
its PRP$ N
high JJ N
receptor NN N
affinity NN N
and CC N
gastroprotective JJ N
effect NN N
. . N

This DT N
Phase NNP N
II NNP N
study NN N
has VBZ N
been VBN N
undertaken VBN N
to TO N
establish VB N
the DT N
efficacy NN o
and CC o
safety NN o
of IN N
ebrotidine NN i
, , N
administered VBN N
in IN N
four CD N
dosages NNS N
as IN N
a DT N
single JJ N
evening NN N
dose JJ N
versus NN N
placebo NN i
in IN N
the DT N
treatment NN N
of IN N
duodenal JJ N
ulcer NN N
. . N

A DT N
total NN N
of IN N
110 CD p
duodenal JJ p
ulcer NN p
patients NNS p
were VBD N
studied VBN N
in IN N
a DT N
randomized JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
, , N
multicentre JJ N
clinical JJ N
trial NN N
. . N

The DT i
patients NNS i
were VBD i
assigned VBN i
to TO i
5 CD i
groups NNS i
: : i
placebo NN i
, , i
200 CD i
mg NN i
, , i
400 CD i
mg NN i
, , i
600 CD i
mg NN i
and CC i
800 CD i
mg NN i
of IN i
ebrotidine JJ i
once IN i
daily JJ i
. . i

Controls NNS i
were VBD i
performed VBN i
at IN i
baseline NN i
and CC i
every DT i
two CD i
weeks NNS i
at IN i
four CD i
follow-up JJ i
visits NNS i
unless IN i
ulcer NN i
healed VBN i
before RB i
. . i

Endoscopic NNP N
examination NN N
was VBD N
the DT N
main JJ N
parameter NN N
for IN N
the DT N
assessment NN N
of IN N
treatment NN o
efficacy NN o
and CC o
ulcer JJ o
healing VBG o
rate NN o
. . o

Vital NNP o
signs NNS o
and CC o
blood/ JJ o
urine JJ o
analysis NN o
were VBD i
used VBN i
to TO i
establish VB i
safety NN i
. . i

The DT N
three CD N
groups NNS N
treated VBD N
with IN N
higher JJR N
dosages NNS N
( ( N
400 CD N
to TO N
800 CD N
mg NN N
of IN N
ebrotidine JJ N
daily NN N
) ) N
showed VBD N
an DT N
endoscopic NN o
ulcer JJ o
healing VBG o
rate NN o
of IN N
90-95 CD N
% NN N
, , N
significantly RB N
higher JJR N
than IN N
55 CD N
% NN N
achieved VBN N
with IN N
placebo NN N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
, , N
whilst VBP N
the DT N
differences NNS N
between IN N
these DT N
three CD N
dosages NNS N
of IN N
ebrotidine NN N
were VBD N
not RB N
statistically RB N
significant JJ N
. . N

Healing VBG o
rate NN o
in IN N
the DT N
group NN N
treated VBD N
with IN N
200 CD N
mg NNS N
of IN N
ebrotidine JJ N
daily NN N
was VBD N
not RB N
significantly RB N
different JJ N
from IN N
that DT N
in IN N
the DT N
placebo NN N
group NN N
. . N

The DT N
development NN o
of IN o
symptoms NNS o
, , o
number NN o
of IN o
episodes NNS o
of IN o
ulcer-related JJ o
pain NN o
, , o
total JJ o
ulcerated JJ o
surface NN o
area NN o
or CC o
subjective JJ o
ratings NNS o
by IN o
the DT o
patients NNS o
and CC o
investigators NNS o
also RB N
differed VBD N
significantly RB N
between IN N
ebrotidine NN N
( ( N
400 CD N
, , N
600 CD N
and CC N
800 CD N
mg NNS N
daily RB N
) ) N
and CC N
placebo NN N
, , N
and CC N
again RB N
, , N
no DT N
marked JJ N
differences NNS N
were VBD N
found VBN N
between IN N
these DT N
three CD N
doses NNS N
of IN N
ebrotidine NN N
. . N

As RB N
far RB N
as IN N
tolerance NN o
is VBZ N
concerned VBN N
, , N
no DT N
clinically RB N
or CC N
statistically RB N
significant JJ N
changes NNS N
were VBD N
observed VBN N
in IN N
vital JJ N
signs NNS N
and CC N
analytical JJ N
parameters NNS N
. . N

The DT N
incidence NN N
of IN N
side NN o
effects NNS o
was VBD N
less JJR N
than IN N
that DT N
presented VBN N
by IN N
the DT N
placebo NN N
group NN N
, , N
possibly RB N
due JJ N
to TO N
a DT N
greater JJR N
consumption NN N
of IN N
antacids NNS N
in IN N
this DT N
group NN N
. . N

Results NNS N
showed VBD N
that IN N
a DT N
daily JJ N
dose NN N
of IN N
400 CD N
mg NNS N
ebrotidine NN N
is VBZ N
effective JJ N
and CC N
safe JJ N
in IN N
the DT N
treatment NN N
of IN N
duodenal JJ N
ulcers NNS N
. . N

-DOCSTART- -8986845- O O

Pedantic JJ i
speaking NN i
style NN N
differentiates VBZ N
Asperger NNP N
syndrome NN N
from IN N
high-functioning JJ N
autism NN N
. . N

Asperger NNP N
syndrome NN N
( ( N
AS IN N
) ) N
is VBZ N
a DT N
pervasive JJ N
developmental NN N
disorder NN N
recently RB N
introduced VBD N
as IN N
a DT N
new JJ N
diagnostic JJ N
category NN N
in IN N
the DT N
ICD-10 NNP N
and CC N
the DT N
DSM-IV NNP N
. . N

Along IN N
with IN N
motor NN N
clumsiness NN N
, , N
pedantic JJ i
speech NN i
has VBZ N
been VBN N
proposed VBN N
as IN N
a DT N
clinical JJ N
feature NN N
of IN N
AS NNP N
. . N

However RB N
, , N
few JJ N
attempts NNS N
have VBP N
been VBN N
made VBN N
to TO N
define VB N
and CC N
measure VB N
this DT N
symptom NN N
. . N

We PRP N
studied VBD N
17 CD p
patients NNS p
with IN p
AS NNP p
( ( p
ICD-10 NNP p
; : p
14 CD p
male NN p
, , p
3 CD p
female NN p
; : p
mean JJ p
age NN p
16.4 CD p
years NNS p
, , p
mean JJ p
full-scale JJ p
IQ NNP p
97 CD p
) ) p
and CC N
compared VBN p
them PRP p
with IN p
a DT p
control NN p
group NN p
of IN p
13 CD p
patients NNS p
with IN p
normal-intelligence JJ p
autism NN p
or CC p
high-functioning JJ p
autism NN p
( ( p
HFA NNP p
) ) p
( ( p
ICD-10/DSM-III-R NNP p
; : p
12 CD p
male NN p
, , p
1 CD p
female NN p
; : p
mean JJ p
age NN p
15.5 CD p
years NNS p
, , p
mean JJ p
full-scale JJ p
IQ NNP p
81.2 CD p
) ) p
. . p

An DT N
operational JJ N
definition NN N
of IN N
pedantic JJ N
speech NN N
was VBD N
formulated VBN N
and CC N
a DT N
rating NN N
scale NN N
devised VBD N
. . N

13 CD p
( ( p
76 CD p
% NN p
) ) p
of IN p
the DT p
AS NNP p
patients NNS p
were VBD N
rated VBN N
as IN N
pedantic JJ o
compared VBN N
to TO N
4 CD p
( ( p
31 CD p
% NN p
) ) p
of IN p
the DT p
HFA NNP p
group NN p
( ( N
chi JJ N
2 CD N
= JJ N
6.3 CD N
; : N
p NN N
= NNP N
.01 NNP N
) ) N
. . N

Results VB N
suggest JJS N
that IN N
pedantic JJ i
speech NN i
is VBZ N
common JJ N
in IN N
AS NNP N
and CC N
may MD N
help VB N
differentiate VB o
AS IN o
from IN o
high-functioning JJ o
autism NN o
. . o

-DOCSTART- -21432860- O O

Calcium NNP i
channel NN i
blocker NN i
inhibition NN i
of IN i
AGE NNP i
and CC i
RAGE NNP i
axis VBP N
limits NNS N
renal JJ o
injury NN o
in IN N
nondiabetic JJ p
patients NNS p
with IN p
stage NN p
I PRP p
or CC p
II NNP p
chronic JJ p
kidney NN p
disease NN p
. . p

BACKGROUND NNP N
There EX N
is VBZ N
a DT N
growing VBG N
body NN N
of IN N
evidence NN N
that IN N
advanced VBD N
glycation JJ N
end NN N
products NNS N
( ( N
AGE NNP N
) ) N
and CC N
their PRP$ N
receptor NN N
( ( N
RAGE NNP N
) ) N
system NN N
are VBP N
implicated VBN N
in IN N
chronic JJ N
kidney NN N
disease NN N
( ( N
CKD NNP N
) ) N
. . N

We PRP N
have VBP N
previously RB N
found VBN N
that IN N
a DT N
long-acting JJ N
calcium NN i
channel NN i
blocker NN i
, , i
azelnidipine NN i
, , i
but CC i
not RB i
amlodipine VB i
, , N
improves VBZ N
renal JJ o
injury NN o
in IN N
CKD NNP N
patients NNS N
. . N

However RB N
, , N
little JJ N
is VBZ N
known VBN N
about IN N
the DT N
effect NN N
of IN N
azelnidipine NN i
on IN N
the DT N
AGE-RAGE NNP o
axis NN o
in IN N
humans NNS N
. . N

In IN N
this DT N
study NN N
, , N
we PRP N
examined VBD N
whether IN N
azelnidipine JJ i
addition NN N
could MD N
have VB N
renoprotective JJ o
properties NNS o
in IN N
hypertensive JJ N
CKD NNP N
patients NNS N
by IN N
reducing VBG N
serum NN o
levels NNS o
of IN o
AGE NNP o
and CC o
soluble JJ o
form NN o
of IN o
RAGE NNP o
( ( o
sRAGE NN o
) ) o
. . o

Thirty NNP p
nondiabetic JJ p
stage NN p
I PRP p
or CC p
II NNP p
CKD NNP p
patients NNS p
who WP p
had VBD p
already RB p
been VBN p
treated VBN p
with IN p
angiotensin NN p
II NNP p
receptor NN p
blockers NNS p
were VBD N
enrolled VBN N
in IN N
this DT N
study NN N
. . N

HYPOTHESIS NNP N
We PRP N
hypothesized VBD N
that IN N
azelnidipine NN i
treatment NN N
could MD N
limit VB N
renal JJ N
injury NN N
partly RB N
by IN N
blocking VBG N
the DT N
AGE-RAGE NNP o
axis NN o
. . o

METHODS JJ N
Patients NNPS p
were VBD N
randomly RB N
divided VBN N
into IN N
2 CD p
groups NNS p
; : p
one CD N
group NN N
was VBD N
treated VBN N
with IN N
16 CD N
mg NNS N
azelnidipine NN i
and CC N
the DT N
other JJ N
with IN N
5 CD N
mg NNS N
amlodipine JJ i
once RB N
daily JJ N
. . N

They PRP N
were VBD N
followed VBN N
up RP N
for IN N
6 CD N
months NNS N
. . N

RESULTS NNP N
Proteinuria NNP o
was VBD N
positively RB N
correlated VBN N
with IN N
circulating VBG o
AGE NNP o
and CC o
sRAGE NN o
levels NNS o
in IN N
our PRP$ N
subjects NNS N
. . N

Both DT N
drugs NNS N
exhibited VBN N
comparable JJ N
and CC N
significant JJ N
blood NN o
pressure NN o
( ( o
BP NNP o
) ) o
-lowering VBG o
effects NNS o
. . o

Although IN N
neither DT N
of IN N
them PRP N
affected VBD N
glucose NN o
, , o
glycated VBD o
hemoglobin NN o
, , o
lipid JJ o
levels NNS o
, , o
and CC o
estimated VBD o
glomerular JJ o
filtration NN o
rate NN o
, , o
treatment NN o
with IN o
azelnidipine NN o
, , N
but CC N
not RB N
amlodipine VB i
, , N
decreased VBN N
circulating NN o
AGE NNP o
, , o
sRAGE NN o
, , o
proteinuria NN o
, , o
and CC o
urinary JJ o
levels NNS o
of IN o
liver-type JJ o
fatty JJ o
acid NN o
binding VBG o
protein NN o
, , N
a DT N
marker NN N
of IN N
tubular JJ N
injury NN N
, , N
in IN N
a DT N
BP-lowering-independent JJ N
manner NN N
. . N

CONCLUSIONS NNP N
Our PRP$ N
present JJ N
results NNS N
suggest VBP N
that IN N
azelnidipine NN i
may MD N
exert VB N
renoprotective JJ o
properties NNS o
in IN N
nondiabetic JJ p
hypertensive JJ p
CKD NNP p
patients NNS p
via IN N
its PRP$ N
unique JJ N
inhibitory JJ N
effects NNS N
on IN N
the DT N
AGE-RAGE NNP N
axis NN N
. . N

-DOCSTART- -10757250- O O

Antisaccade NNP N
and CC N
smooth JJ N
pursuit NN N
eye NN N
movements NNS N
in IN N
healthy JJ p
subjects NNS p
receiving VBG p
sertraline NN i
and CC p
lorazepam NN i
. . i

Patients NNS p
suffering VBG p
from IN p
some DT p
psychiatric JJ p
and CC p
neurological JJ p
disorders NNS p
demonstrate VBP N
abnormally RB N
high JJ N
levels NNS N
of IN N
saccadic JJ N
distractibility NN N
when WRB N
carrying VBG N
out RP N
the DT N
antisaccade NN N
task NN N
. . N

This DT N
has VBZ N
been VBN N
particularly RB N
thoroughly RB N
demonstrated VBN N
in IN N
patients NNS p
with IN p
schizophrenia NN p
. . p

A DT N
large JJ N
body NN N
of IN N
evidence NN N
has VBZ N
been VBN N
accumulated VBN N
from IN N
studies NNS N
of IN N
patients NNS N
which WDT N
suggests VBZ N
that IN N
such JJ N
eye NN N
movement NN N
abnormalities NNS N
may MD N
arise VB N
from IN N
frontal JJ N
lobe NN N
dysfunction NN N
. . N

The DT N
psychopharmacology NN N
of IN N
saccadic JJ N
distractibility NN N
is VBZ N
less RBR N
well RB N
understood JJ N
, , N
but CC N
is VBZ N
relevant JJ N
both DT N
to TO N
interpreting VBG N
patient JJ N
studies NNS N
and CC N
to TO N
establishing VBG N
the DT N
neurological JJ N
basis NN N
of IN N
their PRP$ N
findings NNS N
. . N

Twenty NNP p
healthy JJ p
subjects NNS p
received VBD N
lorazepam JJ i
0.5 CD i
mg NN i
, , i
1 CD i
mg NN i
and CC i
2 CD i
mg NN i
, , i
sertraline VBP i
50 CD i
mg NN i
and CC i
placebo NN i
in IN N
a DT N
balanced JJ N
, , N
repeated VBD N
measures NNS N
study VB N
design NN N
. . N

Antisaccade NNP N
, , N
no-saccade JJ N
, , N
visually RB N
guided VBN N
saccade NN N
and CC N
smooth JJ N
pursuit NN N
tasks NNS N
were VBD N
carried VBN N
out IN N
and CC N
the DT N
effects NNS N
of IN N
practice NN N
and CC N
drugs NNS N
measured VBN N
. . N

Lorazepam NNP o
increased VBD o
direction NN o
errors NNS o
in IN o
the DT o
antisaccade NN o
and CC o
no-saccade JJ o
tasks NNS o
in IN o
a DT o
dose-dependent JJ o
manner NN o
. . o

Sertraline NNP o
had VBD o
no DT o
effect NN o
on IN o
these DT o
measures NNS o
. . o

Correlation NN o
showed VBD o
a DT o
statistically RB o
significant JJ o
, , o
but CC o
rather RB o
weak JJ o
, , o
association NN o
between IN o
direction NN o
errors NNS o
and CC o
smooth JJ o
pursuit NN o
measures NNS o
. . o

Practice NNP o
was VBD o
shown VBN o
to TO o
have VB o
a DT o
powerful JJ o
effect NN o
on IN o
antisaccade JJ o
direction NN o
errors NNS o
. . o

This DT N
study NN N
supports VBZ N
our PRP$ N
previous JJ N
work NN N
by IN N
confirming VBG N
that IN N
lorazepam NN o
reliably RB o
worsens VBZ o
saccadic JJ o
distractibility NN o
, , o
in IN o
contrast NN o
to TO o
other JJ o
psychotropic NN o
drugs NNS o
such JJ o
as IN o
sertraline NN o
and CC o
chlorpromazine NN o
. . o

Our PRP$ N
results NNS o
also RB o
suggest VBP o
that IN o
other JJ o
studies NNS o
in IN o
this DT o
field NN o
, , o
particularly RB o
those DT o
using VBG o
parallel JJ o
groups NNS o
design NN o
, , o
should MD o
take VB o
account NN o
of IN o
practice NN o
effects NNS o
. . o

-DOCSTART- -14650863- O O

Future NNP N
therapeutic JJ N
directions NNS N
for IN N
factor NN N
Xa NNP N
inhibition NN N
in IN N
the DT N
prophylaxis NN N
and CC N
treatment NN N
of IN N
thrombotic JJ p
disorders NNS p
. . p

The DT N
targeted JJ N
mechanism NN N
of IN N
factor NN N
Xa NNP N
inhibition NN N
has VBZ N
been VBN N
studied VBN N
extensively RB N
, , N
initially RB N
as IN N
prophylaxis NN N
for IN N
venous JJ p
thromboembolism NN p
( ( p
VTE NNP p
) ) p
in IN p
the DT p
orthopedic JJ p
surgical JJ p
setting NN p
. . p

Future NNP N
therapeutic JJ N
directions NNS N
for IN N
selective JJ N
factor NN N
Xa NNP N
inhibition NN N
in IN N
the DT N
management NN N
of IN N
other JJ N
thrombotic JJ N
diseases NNS N
are VBP N
discussed VBN N
. . N

Thromboembolic JJ N
diseases NNS N
can MD N
occur VB N
in IN N
the DT N
venous JJ N
or CC N
arterial JJ N
sides NNS N
of IN N
the DT N
circulatory NN N
system NN N
. . N

Factor NNP N
Xa NNP N
inhibition NN N
is VBZ N
a DT N
targeted JJ N
approach NN N
to TO N
anticoagulation VB N
that IN N
resulted VBD N
from IN N
significant JJ N
advances NNS N
in IN N
our PRP$ N
understanding NN N
of IN N
the DT N
coagulation NN N
cascade NN N
. . N

The DT N
factor NN i
Xa NNP i
inhibitor NN i
fondaparinux NN i
has VBZ N
been VBN N
studied VBN N
extensively RB N
in IN N
the DT N
orthopedic JJ N
surgical JJ N
setting NN N
for IN N
the DT N
prophylaxis NN N
of IN N
VTE NNP N
. . N

Current NNP N
investigations NNS N
that WDT N
are VBP N
under IN N
way NN N
or CC N
completed VBN N
evaluate VBP N
the DT N
efficacy NN o
and CC o
safety NN o
of IN N
fondaparinux NN N
for IN N
the DT N
management NN N
of IN N
various JJ N
thrombotic JJ N
diseases NNS N
. . N

The DT N
future NN N
development NN N
of IN N
fondaparinux NN N
resides NNS N
primarily RB N
in IN N
three CD N
therapeutic JJ N
areas NNS N
: : N
prevention NN N
of IN N
VTE NNP N
, , N
treatment NN N
of IN N
VTE NNP N
, , N
and CC N
treatment NN N
of IN N
acute JJ o
coronary JJ o
syndromes NNS o
. . o

For IN N
the DT N
prevention NN N
of IN N
VTE NNP N
, , N
fondaparinux NN i
has VBZ N
been VBN N
studied VBN N
as IN N
extended JJ N
prophylaxis NN N
following VBG N
hip NN N
fracture NN N
surgery NN N
( ( N
PENTHIFRA NNP N
Plus NNP N
) ) N
, , N
for IN N
use NN N
in IN N
high-risk JJ N
abdominal JJ N
surgical JJ N
patients NNS N
( ( N
PEGASUS NNP N
and CC N
APOLLO NNP N
) ) N
, , N
and CC N
for IN N
use NN N
in IN N
medical JJ N
patients NNS N
( ( N
ARTEMIS NNP N
) ) N
. . N

Studies NNPS N
evaluating VBG N
fondaparinux NN i
for IN N
the DT N
treatment NN N
of IN N
VTE NNP N
are VBP N
part NN N
of IN N
the DT N
large JJ N
MATISSE NNP N
clinical JJ N
program NN N
( ( N
MATISSE NNP N
DVT NNP N
and CC N
MATISSE NNP N
PE NNP N
) ) N
. . N

Fondaparinux NNP i
was VBD N
investigated VBN N
in IN N
phase NN N
2 CD N
studies NNS N
for IN N
the DT N
treatment NN N
of IN N
acute JJ p
coronary JJ p
syndromes NNS p
, , N
including VBG N
acute JJ o
ST-segment JJ o
myocardial JJ o
infarction NN o
( ( o
PENTALYSE NNP o
) ) o
and CC o
unstable JJ o
angina NN o
( ( o
PENTUA NNP o
) ) o
. . o

Encouraging VBG N
data NNS N
from IN N
these DT N
trials NNS N
are VBP N
the DT N
basis NN N
for IN N
phase NN N
3 CD N
programs NNS N
in IN N
this DT N
area NN N
( ( N
MICHELANGELO NNP N
) ) N
. . N

The DT N
orthopedic JJ N
prophylactic JJ N
and CC N
nonorthopedic JJ N
clinical JJ N
programs NNS N
for IN N
fondaparinux NN N
in IN N
the DT N
management NN N
of IN N
thrombosis NN N
support NN N
the DT N
concept NN N
that WDT N
targeted VBD o
inhibition NN o
of IN o
coagulation NN o
is VBZ N
an DT N
effective JJ o
advance NN o
in IN o
antithrombotic JJ o
therapy NN o
. . o

-DOCSTART- -7272152- O O

Single NNP N
and CC N
combined VBN N
effects NNS N
of IN N
atropine NN i
and CC i
metoclopramide NN i
on IN N
the DT N
lower JJR p
oesophageal JJ p
sphincter NN p
pressure NN p
. . p

The DT N
effects NNS N
of IN N
atropine NN i
and CC i
metoclopramide NN i
on IN N
the DT N
lower JJR o
oesophageal JJ o
sphincter NN o
pressure NN o
( ( o
LOSP NNP o
) ) o
were VBD N
studied VBN N
in IN N
12 CD p
healthy JJ p
volunteers NNS p
using VBG p
oesophageal JJ p
pressure NN p
transducers NNS p
. . p

Atropine NNP i
decreased VBD N
LOSP NNP o
significantly RB N
at IN N
5 CD N
min NN N
after IN N
i.v NN N
. . N

injection NN N
( ( N
P NNP N
less JJR N
than IN N
0.005 CD N
) ) N
and CC N
this DT N
change NN N
was VBD N
sustained VBN N
for IN N
60 CD N
min NN N
. . N

Metoclopramide NNP i
increased VBD N
LOSP NNP o
significantly RB N
at IN N
3 CD N
min NN N
after IN N
administration NN N
i.v NN N
. . N

( ( N
P NNP N
less JJR N
than IN N
0.05 CD N
) ) N
and CC N
this DT N
change NN N
was VBD N
sustained VBN N
for IN N
40 CD N
min NNS N
. . N

Following VBG N
consecutive JJ N
administration NN N
of IN N
the DT N
drugs NNS N
the DT N
effects NNS N
of IN N
atropine NN i
predominated VBN N
. . N

-DOCSTART- -1742482- O O

Recombinant JJ N
human JJ N
granulocyte-macrophage NN i
colony-stimulating NN i
factor NN i
ameliorates VBZ N
zidovudine-induced JJ N
neutropenia NN N
in IN N
patients NNS p
with IN p
acquired JJ p
immunodeficiency NN p
syndrome NN p
( ( p
AIDS NNP p
) ) p
/AIDS-related VBD p
complex JJ p
. . p

To TO N
evaluate VB N
the DT N
effect NN o
of IN N
recombinant JJ N
granulocyte-macrophage JJ N
colony-stimulating JJ N
factor NN N
( ( i
GM-CSF NNP i
) ) i
on IN N
patients NNS p
with IN p
acquired JJ p
immunodeficiency NN p
syndrome NN p
( ( p
AIDS NNP p
) ) p
or CC p
AIDS-related JJ p
complex NN p
( ( p
ARC NNP p
) ) p
who WP p
were VBD p
intolerant JJ p
to TO p
zidovudine VB p
because IN p
of IN p
neutropenia NN p
, , N
we PRP N
performed VBD N
a DT N
randomized VBN N
, , N
open-label JJ N
study NN N
in IN N
which WDT N
patients NNS N
were VBD N
assigned VBN N
to TO N
one CD N
of IN N
two CD N
groups NNS N
. . N

Zidovudine NNP i
was VBD i
discontinued VBN i
in IN i
group NN i
A NNP i
patients NNS i
before IN i
instituting VBG i
GM-CSF NNP i
treatment NN i
and CC i
was VBD i
restarted VBN i
in IN i
a DT i
graduated JJ i
fashion NN i
over IN i
4 CD i
weeks NNS i
. . i

Group NNP i
B NNP i
patients NNS i
continued VBD i
on IN i
full-dose JJ i
( ( i
1,200 CD i
mg/d NN i
) ) i
zidovudine NN i
therapy NN i
while IN i
beginning VBG i
GM-CSF NNP i
therapy NN i
. . i

A DT p
total NN p
of IN p
17 CD p
patients NNS p
were VBD p
entered VBN p
, , N
eight CD N
in IN N
group NN N
A NNP N
and CC N
nine CD N
in IN N
group NN N
B NNP N
. . N

Five CD p
of IN p
eight CD p
patients NNS p
in IN p
group NN p
A NNP p
and CC p
seven CD p
of IN p
nine CD p
in IN p
group NN p
B NNP p
had VBD p
a DT p
history NN p
of IN p
Pneumocystis NNP p
carinii NN p
pneumonia NN p
( ( p
PCP NNP p
) ) p
. . p

All DT p
were VBD p
homosexual JJ p
males NNS p
, , p
except IN p
one CD p
female NN p
in IN p
group NN p
A NNP p
who WP p
was VBD p
the DT p
sex NN p
partner NN p
of IN p
a DT p
bisexual JJ p
male NN p
with IN p
AIDS NNP p
. . p

All DT p
patients NNS p
had VBD p
neutropenia VBN o
( ( N
absolute JJ N
neutrophil NN N
count NN N
[ NNP N
ANC NNP N
] VBZ N
less JJR N
than IN N
1,000/microL CD N
) ) N
while IN N
taking VBG N
full-dose JJ N
zidovudine NN N
. . N

The DT N
mean JJ N
CD4 NNP N
( ( N
+/- JJ N
SD NNP N
) ) N
lymphocyte VBD N
level NN N
was VBD N
37 CD N
( ( N
+/- JJ N
29 CD N
) ) N
/microL NN N
and CC N
39 CD N
( ( N
+/- JJ N
44 CD N
) ) N
/microL NN N
in IN N
groups NNS N
A NNP N
and CC N
B NNP N
, , N
respectively RB N
. . N

After IN N
randomization NN N
, , N
patients NNS N
were VBD N
begun VBN N
on IN N
subcutaneous JJ N
GM-CSF NNP N
at IN N
a DT N
dose NN N
of IN N
1.0 CD N
microgram/kg/d NNS N
. . N

Patients NNS N
in IN N
group NN N
A NNP N
received VBD N
2 CD N
weeks NNS N
of IN N
daily JJ N
GM-CSF NNP N
, , N
at IN N
which WDT N
time NN N
zidovudine NN N
was VBD N
restarted VBN N
if IN N
the DT N
ANC NNP N
was VBD N
greater JJR N
than IN N
1,000/microL CD N
; : N
if IN N
the DT N
ANC NNP N
was VBD N
less JJR N
than IN N
1,000/microL CD N
, , N
the DT N
dose NN N
of IN N
GM-CSF NNP N
was VBD N
increased VBN N
to TO N
3.0 CD N
micrograms/kg NN N
, , N
and CC N
at IN N
2-week JJ N
intervals NNS N
either CC N
zidovudine NN N
was VBD N
restarted VBN N
or CC N
the DT N
dose NN N
of IN N
GM-CSF NNP N
was VBD N
increased VBN N
to TO N
5 CD N
micrograms/kg NNS N
and CC N
then RB N
10 CD N
micrograms/kg NNS N
, , N
to TO N
maintain VB N
the DT N
ANC NNP N
greater JJR N
than IN N
1,000/microL CD N
. . N

Group NNP N
B NNP N
patients NNS N
received VBD N
full-dose JJ N
zidovudine NN N
concurrently RB N
with IN N
GM-CSF NNP N
administration NN N
. . N

The DT N
dose NN N
of IN N
GM-CSF NNP N
was VBD N
increased VBN N
every DT N
2 CD N
weeks NNS N
if IN N
necessary JJ N
to TO N
keep VB N
the DT N
ANC NNP o
greater JJR N
than IN N
1,000/microL CD N
while IN N
maintaining VBG N
full-dose JJ N
zidovudine NN N
therapy NN N
. . N

Patients NNS N
in IN N
each DT N
group NN N
showed VBD N
an DT N
increase NN N
in IN N
total JJ o
white JJ o
blood NN o
cell NN o
( ( o
WBC NNP o
) ) o
count NN o
. . o

Neutrophils NNP o
and CC o
eosinophils NNS o
were VBD N
responsible JJ N
for IN N
the DT N
majority NN N
of IN N
this DT N
increase NN N
. . N

Patients NNS N
in IN N
group NN N
A NNP N
had VBD N
a DT N
more RBR N
rapid JJ N
increase NN o
in IN o
WBC NNP o
than IN N
those DT N
in IN N
group NN N
B NNP N
; : N
however RB N
, , N
by IN N
week NN N
8 CD N
, , N
the DT N
WBC NNP o
in IN N
each DT N
group NN N
was VBD N
essentially RB N
equal JJ N
. . N

Viral JJ o
replication NN o
as IN N
measured VBN N
by IN N
human JJ o
immunodeficiency NN o
virus NN o
( ( o
HIV NNP o
) ) o
p24 NN o
antigen NN o
( ( o
Ag NNP o
) ) o
was VBD N
decreased VBN N
in IN N
four CD N
patients NNS N
in IN N
each DT N
group NN N
, , N
increased VBN N
in IN N
one CD N
patient NN N
in IN N
each DT N
group NN N
, , N
and CC N
remained VBD N
unchanged JJ N
in IN N
the DT N
remainder NN N
. . N

The DT N
ability NN o
to TO o
culture NN o
virus NN o
from IN N
peripheral JJ N
blood NN N
mononuclear NN N
cells NNS N
was VBD N
not RB N
changed VBN N
by IN N
the DT N
regimen NNS N
. . N

The DT N
major JJ N
toxicities NNS N
of IN N
the DT N
regimen NNS N
were VBD N
fever RB N
and CC N
malaise VB N
. . N

( ( N
ABSTRACT NNP N
TRUNCATED NNP N
AT NNP N
400 CD N
WORDS NNP N
) ) N
-DOCSTART- -8582461- O O

Chronopharmacology NN N
of IN N
enalapril NN i
in IN N
hypertensive JJ p
patients NNS p
. . p

The DT N
pharmacokinetics NNS N
and CC N
pharmacodynamics NNS N
of IN N
enalapril NN i
, , N
an DT N
angiotensin NN N
converting VBG N
enzyme JJ N
inhibitor NN N
, , N
are VBP N
reported VBN N
to TO N
vary VB N
with IN N
the DT N
time NN N
of IN N
administration NN N
. . N

The DT N
present JJ N
study NN N
was VBD N
undertaken VBN N
to TO N
examine VB N
whether IN N
the DT N
effect NN N
of IN N
enalapril NN i
on IN N
plasma NN o
bradykinin NN o
( ( o
BK NNP o
) ) o
, , o
substance NN o
P NNP o
and CC o
prostaglandin VB o
E2 NNP o
( ( o
PGE2 NNP o
) ) o
, , N
which WDT N
are VBP N
likely JJ N
to TO N
be VB N
involved VBN N
in IN N
the DT N
mechanism NN N
of IN N
enalapril-induced JJ N
cough NN N
, , N
might MD N
also RB N
be VB N
affected VBN N
by IN N
its PRP$ N
time NN N
of IN N
administration NN N
. . N

Enalapril NNP i
5 CD N
mg NN N
or CC N
placebo NN i
was VBD N
given VBN N
orally RB N
at IN N
10:00 CD N
h NN N
( ( N
day NN N
trial NN N
) ) N
or CC N
22:00 CD N
h NN N
( ( N
night NN N
trial NN N
) ) N
to TO N
12 CD p
patients NNS p
with IN p
essential JJ p
hypertension NN p
. . p

Serum NNP o
concentrations NNS o
of IN o
total JJ o
drug NN o
( ( o
enalapril JJ o
+ NNP o
enalaprilat NN o
, , o
its PRP$ o
active JJ o
metabolite NN o
) ) o
during IN N
the DT N
day NN N
and CC N
night NN N
trials NNS N
did VBD N
not RB N
differ VB N
significantly RB N
at IN N
any DT N
time NN N
. . N

However RB N
, , N
serum JJ o
enalaprilat NN o
tended VBD N
to TO N
be VB N
higher JJR N
and CC N
its PRP$ N
maximum JJ N
concentration NN N
greater JJR N
in IN N
the DT N
day NN N
trial NN N
than IN N
in IN N
the DT N
night NN N
trial NN N
. . N

Blood NNP o
pressure NN o
24 CD o
h NN o
after IN N
administration NN N
of IN N
enalapril NN i
was VBD N
reduced VBN N
at IN N
22:00 CD N
h NN N
, , N
but CC N
not RB N
at IN N
10:00 CD N
h. NN N
Plasma NNP o
BK NNP o
tended VBD N
to TO N
increase VB N
following VBG N
enalapril JJ i
administration NN N
at IN N
10:00 CD N
h NN N
, , N
but CC N
not RB N
at IN N
22:00 CD N
h. NN N
Remarkable JJ N
increases NNS N
in IN N
plasma NN o
BK NNP o
were VBD N
observed VBN N
in IN N
two CD N
patients NNS N
in IN N
the DT N
day NN N
trial NN N
and CC N
one CD N
of IN N
them PRP N
also RB N
complained VBD N
of IN N
cough NN N
. . N

However RB N
, , N
no DT N
such JJ N
increase NN N
in IN N
plasma JJ o
BK NNP o
or CC N
subsequent JJ N
adverse JJ o
effect NN o
were VBD N
recorded VBN N
in IN N
the DT N
night NN N
trial NN N
. . N

Plasma NNP o
substance NN o
P NNP o
and CC o
PGE2 NNP o
did VBD N
not RB N
change VB N
significantly RB N
following VBG N
enalapril JJ i
administration NN N
either RB N
in IN N
the DT N
day NN N
or CC N
night NN N
trial NN N
. . N

The DT N
results NNS N
suggest VBP N
that IN N
the DT N
response NN N
of IN N
BK NNP N
to TO N
enalapril VB i
is VBZ N
affected VBN N
by IN N
the DT N
time NN N
of IN N
administration NN N
. . N

In IN N
patients NNS N
who WP N
complain VBP N
of IN N
cough NN o
during IN N
treatment NN N
with IN N
enalapril NN i
during IN N
the DT N
daytime NN N
, , N
this DT N
adverse JJ N
effect NN N
might MD N
be VB N
diminished VBN N
or CC N
eliminated VBN N
by IN N
a DT N
switch NN N
to TO N
night-time JJ N
administration NN N
. . N

-DOCSTART- -10607234- O O

Quantitative JJ N
monitoring NN N
of IN N
serum NN o
hepatitis NN o
B NNP o
virus NN o
DNA NNP o
and CC N
blood NN o
lymphocyte JJ o
subsets NNS o
during IN N
combined JJ i
prednisolone NN i
and CC i
interferon-alpha JJ i
therapy NN i
in IN N
patients NNS p
with IN p
chronic JJ p
hepatitis NN p
B NNP p
. . p

Several JJ N
investigators NNS N
have VBP N
reported VBN N
a DT N
significantly RB N
reduced VBN N
CD4/CD8 NNP o
ratio NN o
, , N
as IN N
defined VBN N
by IN N
monoclonal JJ N
antibodies NNS N
, , N
in IN N
the DT N
peripheral JJ N
blood NN N
of IN N
Caucasian JJ p
patients NNS p
with IN N
chronic JJ p
active JJ p
hepatitis NN p
B NNP p
( ( p
CAHB NNP p
) ) p
. . N

In IN N
Asian JJ p
patients NNS p
with IN N
chronic JJ N
hepatitis NN N
B NNP N
, , N
quantitative JJ N
analyses NNS N
of IN N
subpopulations NNS N
of IN N
peripheral JJ N
blood NN N
lymphocytes NNS N
have VBP N
not RB N
been VBN N
able JJ N
to TO N
confirm VB N
these DT N
findings NNS N
. . N

In IN N
this DT N
work NN N
, , N
we PRP N
analysed VBD N
the DT N
frequency NN N
of IN N
peripheral JJ N
blood NN N
lymphocyte NN N
subsets NNS N
in IN N
10 CD p
Chinese JJ p
patients NNS p
with IN p
histologically RB p
proven VBN p
CAHB NNP p
and CC p
seven CD p
healthy JJ p
Chinese JJ p
individuals NNS p
. . p

Four CD N
of IN N
the DT N
10 CD N
CAHB NNP N
patients NNS N
received VBD N
combined JJ i
prednisolone/interferon-alpha2b JJ i
( ( i
IFN-alpha2b NNP i
) ) i
therapy NN i
. . i

Peripheral NNP o
blood NN o
samples NNS o
were VBD N
consecutively RB N
collected VBN N
for IN N
analysis NN N
of IN N
lymphocyte JJ N
subpopulations NNS N
using VBG N
an DT N
indirect JJ N
immunofluorescence NN N
( ( N
IF NNP N
) ) N
method NN N
, , N
and CC N
hepatitis NN N
B NNP N
virus NN N
( ( N
HBV NNP N
) ) N
DNA NN N
was VBD N
quantified VBN N
by IN N
a DT N
chemiluminescent NN N
, , N
molecular-hybridization NN N
assay NN N
. . N

Peripheral NNP o
blood NN o
mononuclear NN o
cells NNS o
from IN N
seven CD N
Chinese JJ N
control NN N
individuals NNS N
comprised VBD N
63 CD N
+/- JJ N
3 CD N
% NN N
CD3+ NNP N
cells NNS N
, , N
of IN N
which WDT N
41 CD N
+/- JJ N
4 CD N
% NN N
were VBD N
of IN N
CD4+ NNP N
and CC N
23 CD N
+/- JJ N
2 CD N
% NN N
of IN N
CD8+ NNP N
subsets NNS N
. . N

The DT N
mean JJ o
CD4/CD8 NNP o
ratio NN o
in IN N
the DT N
healthy JJ N
controls NNS N
was VBD N
1.9 CD N
( ( N
95 CD N
% NN N
confidence NN N
interval JJ N
= NNP N
1.1-2.7 NN N
) ) N
. . N

The DT N
CD4/CD8 NNP o
ratios NNS o
were VBD N
significantly RB N
reduced VBN N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
in IN N
the DT N
10 CD N
patients NNS N
with IN N
chronic JJ N
hepatitis NN N
B NNP N
, , N
compared VBN N
with IN N
those DT N
of IN N
the DT N
controls NNS N
, , N
owing VBG N
to TO N
a DT N
significant JJ N
increase NN N
in IN N
the DT N
number NN o
of IN o
CD8+ NNP o
cells NNS o
( ( N
P NNP N
< NNP N
0.005 CD N
) ) N
. . N

During IN N
the DT N
treatment NN N
with IN N
prednisolone NN i
, , N
a DT N
significant JJ N
increase NN N
in IN N
the DT N
CD4/CD8 NNP o
ratio NN o
was VBD N
observed VBN N
in IN N
all DT N
treated JJ N
patients NNS N
. . N

This DT N
increase NN N
was VBD N
mainly RB N
caused VBN N
by IN N
a DT N
decrease NN N
in IN N
the DT N
number NN o
of IN o
CD8+ NNP o
cells NNS o
and CC N
was VBD N
accompanied VBN N
by IN N
an DT N
increase NN o
in IN o
serum JJ o
HBV NNP o
DNA NNP o
levels NNS o
, , N
which WDT N
peaked VBD N
during IN N
the DT N
latter JJ N
part NN N
of IN N
the DT N
prednisolone NN N
cycle NN N
. . N

During IN N
the DT N
treatment NN N
with IN N
IFN-alpha2b NNP i
, , N
a DT N
second JJ N
increase NN N
in IN N
the DT N
CD4/CD8 NNP o
ratio NN o
was VBD N
observed VBN N
, , N
which WDT N
was VBD N
caused VBN N
by IN N
an DT N
increase NN N
in IN N
CD4+ NNP o
cells NNS o
. . o

A DT N
marked JJ N
decrease NN N
in IN N
viral JJ o
load NN o
was VBD N
observed VBN N
, , N
during IN N
treatment NN N
with IN N
IFN-alpha2b NNP i
, , N
in IN N
patients NNS N
with IN N
HBV NNP N
DNA NNP N
levels NNS N
below IN N
10 CD N
000 CD N
pg JJ N
ml-1 NN N
. . N

Our PRP$ N
data NNS N
indicate VBP N
that IN N
the DT N
CD4/CD8 NNP o
ratios NNS o
in IN N
Chinese JJ p
CAHB NNP p
patients NNS p
do VBP N
not RB N
differ VB N
from IN N
those DT N
of IN N
Caucasian JJ p
patients NNS p
with IN p
CAHB NNP p
, , N
when WRB N
analysed VBN N
using VBG N
similar JJ N
methods NNS N
for IN N
the DT N
enumeration NN N
of IN N
lymphocyte JJ N
subsets NNS N
. . N

Profound NNP N
effects NNS N
on IN N
cellular JJ o
distribution NN o
and CC o
viral JJ o
replication NN o
were VBD N
noted VBN N
during IN N
the DT N
combined JJ N
prednisolone/IFN-alpha2b JJ N
therapy NN N
. . N

Additional JJ N
studies NNS N
of IN N
the DT N
modulatory JJ o
effect NN o
of IN N
the DT N
combined JJ N
therapy NN N
on IN N
the DT N
distribution NN N
of IN N
lymphocyte JJ N
subsets NNS N
and CC N
cytokine NN N
profiles NNS N
in IN N
relation NN N
to TO N
the DT N
therapeutic JJ N
outcome NN N
of IN N
HBV NNP N
infection NN N
are VBP N
warranted VBN N
. . N

-DOCSTART- -20689977- O O

Cost-effectiveness NN o
of IN N
cognitive-behavioral JJ i
group NN i
therapy NN i
for IN N
dysfunctional JJ N
fear NN N
of IN N
progression NN N
in IN N
cancer NN p
patients NNS p
. . p

Anxiety NNP o
and CC o
fear NN o
are VBP N
often RB N
associated VBN N
with IN N
chronic JJ N
conditions NNS N
such JJ N
as IN N
cancer NN N
. . N

This DT N
paper NN N
targets VBZ N
the DT N
cost-effectiveness JJ o
analysis NN o
of IN N
a DT N
cognitive-behavioral JJ i
group NN i
therapy NN i
( ( i
CBT NNP i
) ) i
in IN N
comparison NN N
to TO N
a DT N
client-centered JJ i
, , i
supportive-experiential JJ i
group NN i
therapy NN i
( ( i
SET NNP i
) ) i
in IN N
cancer NN p
patients NNS p
with IN p
dysfunctional JJ p
fear NN p
of IN p
progression NN p
. . p

An DT N
incremental JJ N
cost-effectiveness JJ o
analysis NN o
was VBD N
performed VBN N
using VBG N
data NNS N
from IN N
a DT N
randomized VBN N
controlled VBN N
trial NN N
among IN N
cancer NN p
patients NNS p
receiving VBG p
inpatient JJ p
rehabilitation NN p
. . p

The DT N
means NNPS o
, , o
95 CD o
% NN o
confidence NN o
intervals NNS o
[ VBP o
95 CD o
% NN o
CI NNP o
] NNP o
, , o
incremental JJ o
cost-effectiveness JJ o
graphic NN o
and CC o
acceptability NN o
curve NN o
were VBD N
obtained VBN N
from IN N
1,000 CD N
bootstrap NN N
replications NNS N
. . N

A DT p
total NN p
of IN p
174 CD p
patients NNS p
were VBD p
included VBN p
in IN p
the DT p
economic JJ p
evaluation NN p
. . p

The DT N
estimated JJ o
means VBZ o
[ JJ N
95 CD N
% NN N
CI NNP N
] NNP N
of IN o
direct JJ o
costs NNS o
and CC o
reduction NN o
of IN o
fear NN o
of IN o
progression NN o
were VBD N
< JJ N
euro JJ N
> NN N
9,045.03 CD N
[ JJ N
6,359.07 CD N
; : N
12,091.87 CD N
] NN N
and CC N
1.41 CD N
[ JJ N
0.93 CD N
; : N
1.92 CD N
] NN N
for IN N
patients NNS N
in IN N
the DT N
SET NNP N
and CC N
< NNP N
euro VBP N
> $ N
6,682.78 CD N
[ JJ N
4,998.09 CD N
; : N
8,440.95 CD N
] NN N
and CC N
1.44 CD N
[ JJ N
1.02 CD N
; : N
1.09 CD N
] NN N
for IN N
patients NNS N
in IN N
the DT N
CBT NNP i
. . i

The DT N
incremental JJ o
cost-effectiveness JJ o
ratio NN o
[ VBD N
95 CD N
% NN N
CI NNP N
] NNP N
amounts NNS N
to TO N
minus NNS N
< NNP N
euro VBP N
> $ N
78,741.66 CD N
[ NNP N
-154,987.20 NNP N
; : N
110,486.32 CD N
] NN N
for IN N
an DT N
additional JJ N
unit NN N
of IN N
effect NN N
. . N

Given VBN N
the DT N
acceptability NN o
curve NN o
, , N
there EX N
is VBZ N
a DT N
92.4 CD N
% NN N
chance NN N
that IN N
the DT N
CBT NNP i
, , N
compared VBN N
with IN N
the DT N
SET NNP i
, , N
is VBZ N
cost-effective JJ o
without IN N
the DT N
need NN N
of IN N
additional JJ N
costs NNS N
to TO N
payers NNS N
. . N

Our PRP$ N
main JJ N
result NN N
is VBZ N
the DT N
superior JJ N
cost-effectiveness NN o
of IN N
the DT N
cognitive-behavioral JJ i
intervention NN i
program NN N
in IN N
comparison NN N
to TO N
the DT N
non-directive JJ N
encounter NN N
group NN N
for IN N
our PRP$ N
sample NN N
of IN N
cancer NN p
patients NNS p
with IN p
high JJ p
levels NNS p
of IN p
anxiety NN o
. . o

-DOCSTART- -25122429- O O

Safety NN o
and CC o
effectiveness NN o
of IN N
bevacizumab-containing JJ i
treatment NN N
for IN N
non-small-cell JJ N
lung NN N
cancer NN N
: : N
final JJ N
results NNS N
of IN N
the DT N
ARIES NNP N
observational JJ N
cohort NN N
study NN N
. . N

INTRODUCTION NNP N
Bevacizumab NNP i
, , N
a DT N
recombinant JJ N
humanized JJ N
monoclonal JJ N
antibody NN N
against IN N
vascular JJ N
endothelial JJ N
growth NN N
factor NN N
, , N
was VBD N
approved VBN N
by IN N
the DT N
US NNP N
Food NNP N
and CC N
Drug NNP N
Administration NNP N
for IN N
the DT N
treatment NN N
of IN N
advanced JJ N
non-small-cell JJ N
lung NN N
cancer NN N
( ( N
NSCLC NNP N
) ) N
in IN N
combination NN N
with IN N
carboplatin NN i
and CC N
paclitaxel NN i
. . i

ARIES NNP N
( ( N
Avastin NNP N
Regimens NNP N
: : N
Investigation NN N
of IN N
Effectiveness NNP N
and CC N
Safety NNP N
) ) N
, , N
a DT N
prospective JJ N
observational JJ N
cohort NN N
study NN N
, , N
evaluated VBN N
outcomes NNS N
in IN N
a DT N
large JJ N
, , N
community-based JJ N
population NN N
of IN N
patients NNS p
with IN p
first-line JJ p
NSCLC NNP p
. . p

METHODS NNP N
From IN N
2006 CD N
to TO N
2009 CD N
, , N
ARIES NNP p
enrolled VBD p
patients NNS p
with IN p
locally RB p
advanced JJ p
or CC p
metastatic JJ p
NSCLC NNP p
who WP p
were VBD p
eligible JJ p
for IN p
bevacizumab NN i
, , p
excluding VBG p
those DT p
with IN p
predominantly RB p
squamous JJ p
histology NN p
. . p

Patients NNS p
were VBD p
required VBN p
to TO p
provide VB p
informed JJ p
consent NN p
and CC p
to TO p
have VB p
initiated VBN p
bevacizumab NN i
with IN i
chemotherapy NN i
within IN p
4 CD p
months NNS p
before IN p
enrollment NN p
. . N

There EX N
were VBD N
no DT N
protocol-defined JJ N
treatments NNS N
or CC N
assessments NNS N
. . N

The DT N
dosing NN N
of IN N
bevacizumab NN i
and CC i
chemotherapy NN i
, , N
and CC N
the DT N
choice NN N
of IN N
chemotherapy NN N
regimen NNS N
, , N
was VBD N
at IN N
the DT N
discretion NN N
of IN N
the DT N
treating NN N
physician NN N
. . N

RESULTS NNP N
ARIES NNP N
enrolled VBD N
1967 CD p
patients NNS p
with IN p
first-line JJ p
NSCLC NNP p
. . p

At IN N
study NN N
closure NN N
, , N
median JJ o
follow-up NN o
was VBD N
12.5 CD N
months NNS N
( ( N
range NN N
, , N
0.2-65.5 JJ N
) ) N
. . N

Median JJ p
age NN p
was VBD p
65 CD p
years NNS p
( ( p
range NN p
, , p
31-93 JJ p
) ) p
, , p
and CC p
252 CD p
patients NNS p
( ( p
12.8 CD p
% NN p
) ) p
identified VBN p
as IN p
never RB p
smokers NNS p
. . p

Median JJ o
progression-free JJ o
survival NN o
was VBD N
6.6 CD N
months NNS N
( ( N
95 CD N
% NN N
confidence NN N
interval NN N
, , N
6.3-6.9 JJ N
) ) N
, , N
and CC N
median JJ o
overall JJ o
survival NN o
was VBD N
13.0 CD N
months NNS N
( ( N
95 CD N
% NN N
confidence NN N
interval NN N
, , N
12.2-13.8 JJ N
) ) N
with IN N
first-line JJ N
bevacizumab NN i
plus CC i
chemotherapy NN i
. . i

Incidences NNS o
of IN o
bevacizumab-associated JJ o
adverse JJ o
events NNS o
( ( N
19.7 CD N
% NN N
overall JJ N
) ) N
were VBD N
consistent JJ N
with IN N
those DT N
in IN N
randomized VBN N
controlled JJ N
trials NNS N
of IN N
bevacizumab NN i
in IN N
NSCLC NNP N
. . N

CONCLUSION NNP N
Results NNP N
from IN N
ARIES NNP N
demonstrate VBP N
similar JJ N
outcomes NNS N
to TO N
randomized VB N
controlled JJ N
trials NNS N
of IN N
bevacizumab NN i
when WRB N
added VBD N
to TO N
standard VB N
chemotherapy NN N
in IN N
a DT N
real-world JJ p
patient NN p
population NN p
with IN p
advanced JJ p
NSCLC NNP p
. . p

-DOCSTART- -25694364- O O

Computer-Assisted JJ i
Face NNP i
Processing NNP i
Instruction NNP i
Improves VBZ N
Emotion NNP o
Recognition NNP o
, , o
Mentalizing NNP o
, , o
and CC o
Social NNP o
Skills NNP o
in IN N
Students NNP p
with IN p
ASD NNP p
. . p

This DT N
study NN N
examined VBD N
the DT N
extent NN N
to TO N
which WDT N
a DT N
computer-based JJ i
social JJ i
skills NNS i
intervention NN i
called VBN i
FaceSay NNP i
was VBD N
associated VBN N
with IN N
improvements NNS N
in IN N
affect JJ o
recognition NN o
, , o
mentalizing NN o
, , o
and CC o
social JJ o
skills NNS o
of IN N
school-aged JJ p
children NNS p
with IN p
Autism NNP p
Spectrum NNP p
Disorder NNP p
( ( p
ASD NNP p
) ) p
. . p

FaceSay NNP i
offers VBZ N
students NNS p
simulated JJ N
practice NN N
with IN N
eye NN o
gaze NN o
, , o
joint JJ o
attention NN o
, , o
and CC o
facial JJ o
recognition NN o
skills NNS o
. . o

This DT N
randomized VBD N
control NN N
trial NN N
included VBD N
school-aged JJ p
children NNS p
meeting VBG p
educational JJ p
criteria NNS p
for IN p
autism NN p
( ( p
N NNP p
= NNP p
31 CD p
) ) p
. . p

Results NNP N
demonstrated VBD N
that IN N
participants NNS N
who WP N
received VBD N
the DT N
intervention NN N
improved VBD N
their PRP$ N
affect JJ o
recognition NN o
and CC o
mentalizing NN o
skills NNS o
, , o
as RB o
well RB o
as IN o
their PRP$ o
social JJ o
skills NNS o
. . o

These DT N
findings NNS N
suggest VBP N
that IN N
, , N
by IN N
targeting VBG N
face-processing JJ N
skills NNS N
, , N
computer-based JJ N
interventions NNS N
may MD N
produce VB N
changes NNS N
in IN N
broader JJR o
cognitive NN o
and CC o
social-skills NNS o
domains NNS o
in IN N
a DT N
cost- JJ o
and CC o
time-efficient JJ o
manner NN o
. . o

-DOCSTART- -21950736- O O

Polymorphisms NNP p
of IN p
ADORA2A NNP p
modulate NNP p
psychomotor NN p
vigilance NN p
and CC p
the DT p
effects NNS p
of IN p
caffeine NN p
on IN p
neurobehavioural JJ o
performance NN o
and CC o
sleep JJ o
EEG NNP o
after IN p
sleep JJ p
deprivation NN p
. . p

BACKGROUND NNP N
AND CC N
PURPOSE NNP N
Prolonged NNP N
wakefulness NN N
impairs NNS N
sustained VBD N
vigilant JJ o
attention NN o
, , N
measured VBN N
with IN N
the DT N
psychomotor NN o
vigilance NN o
task NN o
( ( o
PVT NNP o
) ) o
, , N
and CC N
induces VBZ N
a DT N
compensatory JJ N
increase NN N
in IN N
sleep JJ N
intensity NN N
in IN N
recovery NN N
sleep NN N
, , N
quantified VBN N
by IN N
slow-wave JJ o
activity NN o
( ( o
SWA NNP o
) ) o
in IN N
the DT N
sleep JJ o
electroencephalogram NN o
( ( o
EEG NNP o
) ) o
. . N

These DT N
effects NNS N
of IN N
sleep JJ N
deprivation NN N
are VBP N
counteracted VBN N
by IN N
the DT N
adenosine NN N
receptor NN N
antagonist JJ N
caffeine NN N
, , N
implying VBG N
involvement NN N
of IN N
the DT N
adenosine NN N
neuromodulator/receptor NN N
system NN N
. . N

To TO N
examine VB N
a DT N
role NN N
for IN N
adenosine NN N
A NNP N
( ( N
2A CD N
) ) N
receptors NNS N
, , N
we PRP N
investigated VBD N
whether IN N
variation NN N
of IN N
the DT N
A NNP N
( ( N
2A CD N
) ) N
receptor NN N
gene NN N
( ( N
ADORA2A NNP N
) ) N
modified VBD N
effects NNS N
of IN N
caffeine NN i
on IN N
PVT NNP o
and CC N
SWA NNP o
after IN N
sleep JJ i
deprivation NN i
. . i

EXPERIMENTAL NNP N
APPROACH NNP N
A NNP p
haplotype JJ p
analysis NN p
of IN p
eight CD p
single-nucleotide JJ p
polymorphisms NNS p
of IN p
ADORA2A NNP p
was VBD p
performed VBN p
in IN p
82 CD p
volunteers NNS p
. . p

In IN p
45 CD p
young JJ p
men NNS p
carrying VBG p
five CD p
different JJ p
allele NN p
combinations NNS p
, , p
we PRP p
investigated VBD p
the DT p
effects NNS p
of IN p
prolonged JJ i
waking NN i
and CC i
2 CD i
? . i
200 CD i
mg JJ i
caffeine NN i
or CC i
2 CD i
? . i
100 CD i
mg NN i
modafinil NN i
on IN i
psychomotor NN i
vigilance NN i
, , i
sleepiness NN i
, , i
and CC i
the DT i
waking NN i
and CC o
sleep JJ o
EEG NNP o
. . o

KEY NNP N
RESULTS NNP N
Throughout NNP N
extended VBD N
wakefulness NN N
, , N
the DT N
carriers NNS N
of IN N
haplotype NN N
HT4 NNP N
performed VBD N
faster RBR N
on IN N
the DT o
PVT NNP o
than IN o
carriers NNS N
of IN N
non-HT4 JJ N
haplotype NN N
alleles NNS N
. . N

In IN N
haplotype JJ N
HT4 NNP N
, , N
caffeine NN N
failed VBD N
to TO N
counteract VB N
the DT N
waking-induced JJ N
impairment NN N
of IN N
PVT NNP o
performance NN o
and CC o
the DT N
rebound NN N
of IN N
SWA NNP o
in IN o
recovery NN N
sleep NN N
. . N

However RB i
, , i
caffeine NN i
was VBD i
effective JJ N
in IN N
non-HT4 JJ N
allele NN N
carriers NNS N
, , N
and CC N
modafinil NN N
reduced VBD N
the DT N
consequences NNS N
of IN N
prolonged JJ N
waking NN N
, , N
independently RB N
of IN N
ADORA2A NNP N
haplotype NN N
. . N

CONCLUSIONS NNP N
AND CC N
IMPLICATIONS NNP N
Common NNP N
genetic JJ N
variation NN N
of IN N
ADORA2A NNP N
is VBZ N
an DT N
important JJ N
determinant NN N
of IN N
psychomotor NN o
vigilance NN o
in IN o
rested JJ N
and CC N
sleep-deprived JJ N
state NN N
. . N

It PRP N
also RB N
modulates VBZ N
individual JJ N
responses NNS N
to TO N
caffeine VB i
after IN i
sleep JJ N
deprivation NN N
. . N

These DT N
findings NNS N
demonstrate VBP N
a DT N
role NN N
for IN N
adenosine NN N
A NNP N
( ( N
2A CD N
) ) N
receptors NNS N
in IN N
the DT N
effects NNS N
of IN N
prolonged JJ o
wakefulness NN o
on IN o
vigilant JJ o
attention NN o
and CC o
the DT o
sleep JJ o
EEG NNP o
. . o

-DOCSTART- -16719652- O O

Tradeoffs NNS N
and CC N
theory NN N
: : N
the DT N
double-mediation NN i
model NN i
. . i

Most JJS N
theories NNS N
of IN N
decision NN N
making VBG N
suggest VBP N
that IN N
, , N
when WRB N
options NNS N
imply VBP N
tradeoffs NNS N
between IN N
their PRP$ N
attributes NNS N
, , N
conflict NN N
increases NNS N
as IN N
tradeoff NN N
size NN N
increases NNS N
, , N
because IN N
greater JJR N
sacrifices NNS N
are VBP N
to TO N
be VB N
incurred VBN N
in IN N
choosing VBG N
one CD N
option NN N
instead RB N
of IN N
another DT N
. . N

An DT N
alternative JJ N
view NN N
is VBZ N
that IN N
conflict NN N
decreases NNS N
as IN N
tradeoff NN N
size NN N
increases NNS N
, , N
because IN N
stronger JJR N
arguments NNS N
can MD N
be VB N
made VBN N
for IN N
any DT N
decision NN N
. . N

The DT N
authors NNS N
propose VBP N
a DT N
unified JJ N
model NN N
, , N
the DT N
double-mediation NN i
model NN i
, , i
which WDT i
combines VBZ i
the DT i
mediating JJ i
effects NNS i
of IN i
sacrifice NN i
and CC i
argumentation NN i
. . i

Our PRP$ N
model NN N
generally RB N
predicts VBZ N
an DT N
inverse JJ N
U-shaped JJ N
relation NN p
between IN p
tradeoff NN p
size NN p
and CC p
conflict NN p
. . p

Results VB N
support NN N
this DT N
prediction NN N
. . N

Also RB o
, , o
when WRB o
the DT o
decision NN o
situation NN o
increases VBZ o
the DT o
mediating VBG o
effect NN o
of IN o
sacrifice NN o
relative NN o
to TO o
that DT o
of IN o
argumentation NN o
, , o
the DT o
relation NN o
between IN o
tradeoff NN o
size NN o
and CC o
conflict NN o
changes NNS o
in IN o
an DT o
upward JJ o
direction NN o
; : o
conversely RB o
, , o
when WRB o
the DT o
decision NN o
situation NN o
increases VBZ o
the DT o
mediating VBG o
effect NN o
of IN o
argumentation NN o
relative NN o
to TO o
that DT o
of IN o
sacrifice NN o
, , o
the DT o
relation NN o
changes NNS o
in IN o
a DT o
downward JJ o
direction NN o
. . o

Results VB N
support NN N
these DT N
predictions NNS N
as RB N
well RB N
. . N

Commonalities NNS N
and CC N
differences NNS N
between IN N
our PRP$ N
model NN N
and CC N
other JJ N
formulations NNS N
are VBP N
discussed VBN N
. . N

-DOCSTART- -17664467- O O

Clinical JJ N
benefit NN N
with IN N
docetaxel JJ i
plus CC i
fluorouracil JJ i
and CC i
cisplatin NNS i
compared VBN N
with IN N
cisplatin NN i
and CC i
fluorouracil NN i
in IN N
a DT N
phase NN N
III NNP N
trial NN N
of IN N
advanced JJ p
gastric NN p
or CC p
gastroesophageal NN p
cancer NN p
adenocarcinoma NN p
: : p
the DT N
V-325 NNP N
Study NNP N
Group NNP N
. . N

PURPOSE NNP N
For IN p
patients NNS p
with IN p
advanced JJ p
gastric NN p
or CC p
gastroesophageal NN p
cancer NN p
( ( p
AGGEC NNP p
) ) p
providing VBG N
clinical JJ N
benefit NN N
with IN N
improved JJ N
palliation NN N
is VBZ N
highly RB N
desirable JJ N
. . N

However RB N
, , N
a DT N
prospective JJ N
evaluation NN N
of IN N
clinical JJ N
benefit NN N
in IN N
AGGEC NNP N
patients NNS N
has VBZ N
never RB N
before RB N
been VBN N
reported VBN N
in IN N
a DT N
phase NN N
III NNP N
setting NN N
. . N

PATIENTS NNP N
AND CC N
METHODS NNP N
In IN p
a DT p
multinational JJ p
trial NN p
( ( p
V325 NNP p
) ) p
, , p
445 CD p
patients NNS p
were VBD p
randomly RB p
assigned VBN p
and CC p
treated VBN p
with IN N
either DT N
docetaxel JJ i
plus CC i
cisplatin JJ i
and CC i
fluorouracil NN i
( ( i
DCF NNP i
) ) i
or CC N
cisplatin NN i
and CC i
fluorouracil NN i
( ( i
CF NNP i
) ) i
. . i

Clinical JJ N
benefit NN N
was VBD N
prospectively RB N
evaluated VBN N
in IN N
this DT N
trial NN N
as IN N
a DT N
secondary JJ N
end NN N
point NN N
. . N

The DT N
primary JJ N
measure NN N
for IN N
clinical JJ N
benefit NN N
analysis NN N
was VBD N
time NN o
to TO o
definitive VB o
worsening NN o
by IN N
one CD N
or CC N
more JJR N
categories NNS N
of IN N
Karnofsky NNP o
performance NN o
status NN o
( ( N
KPS NNP N
) ) N
. . N

Secondary JJ N
clinical JJ N
benefit NN N
end NN N
points NNS N
included VBD N
time NN o
to TO o
5 CD o
% NN o
definitive JJ o
weight NN o
loss NN o
, , o
time NN o
to TO o
definitive JJ o
worsening NN o
of IN o
appetite NN o
by IN o
one CD o
grade NN o
, , o
pain-free JJ o
survival NN o
( ( o
defined VBN o
as IN o
time NN o
to TO o
first JJ o
appearance NN o
of IN o
pain NN o
) ) o
, , o
and CC o
time NN o
to TO o
first JJ o
cancer NN o
pain-related JJ o
opioid JJ o
intake NN o
. . o

Clinical JJ N
benefit NN N
assessments NNS N
were VBD N
recorded VBN N
at IN N
each DT N
clinic JJ N
visit NN N
. . N

RESULTS NNP N
Clinical JJ N
benefit NN N
assessments NNS N
were VBD N
performed VBN N
in IN N
more JJR N
than IN N
75 CD N
% NN N
of IN N
patients NNS N
throughout IN N
V325 NNP N
. . N

DCF NNP N
significantly RB N
prolonged VBD N
time NN o
to TO o
definitive JJ o
worsening NN o
of IN o
KPS NNP o
compared VBN N
with IN N
CF NNP i
( ( N
median JJ N
, , N
6.1 CD N
v NN N
4.8 CD N
months NNS N
; : N
hazard RB N
ratio NN N
, , N
1.38 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
1.08 CD N
to TO N
1.76 CD N
; : N
log-rank JJ N
P NNP N
= NNP N
.009 NNP N
) ) N
. . N

Although IN N
time NN o
to TO o
definitive JJ o
weight NN o
loss NN o
and CC o
time NN o
to TO o
definitive JJ o
worsening NN o
of IN o
appetite NN o
favored VBN N
DCF NNP i
, , N
the DT N
results NNS N
were VBD N
not RB N
statistically RB N
significant JJ N
. . N

Pain-free JJ o
survival NN o
and CC o
time NN o
to TO o
first JJ o
cancer NN o
pain-related JJ o
opioid JJ o
intake NN o
were VBD N
comparable JJ N
. . N

CONCLUSION NN N
To TO N
our PRP$ N
knowledge NN N
, , N
V325 NNP N
is VBZ N
the DT N
first JJ N
phase NN N
III NNP N
trial NN N
to TO N
report VB N
clinical JJ N
benefit NN N
in IN N
AGGEC NNP N
patients NNS N
. . N

Clinical JJ N
benefit NN N
was VBD N
assessed VBN N
beyond IN N
protocol-specific JJ i
chemotherapy NN i
. . i

The DT N
addition NN N
of IN N
D NNP i
to TO N
CF NNP i
not RB N
only RB N
significantly RB N
improved VBN N
clinical JJ N
benefit NN N
but CC N
also RB N
improved JJ N
quality NN o
of IN o
life NN o
, , o
time NN o
to TO o
progression NN o
, , o
and CC o
overall JJ o
survival NN o
compared VBN N
with IN N
CF NNP i
. . i

-DOCSTART- -8872499- O O

Relationship NN N
of IN N
the DT N
dose NN N
of IN N
intravenous JJ N
gammaglobulin NN i
to TO N
the DT N
prevention NN N
of IN N
infections NNS N
in IN N
adults NNS p
with IN p
common JJ p
variable JJ p
immunodeficiency NN p
. . p

The DT N
objective NN N
was VBD N
to TO N
assess VB N
clinical JJ N
efficacy NN N
of IN N
3 CD N
dosages NNS N
of IN N
intravenous JJ i
gammaglobulins NNS i
to TO N
prevent VB N
infectious JJ N
episodes NNS N
in IN N
adult NN N
common JJ N
variable JJ N
immunodeficiency NN N
. . N

We PRP N
designed VBD N
a DT N
randomized VBN N
, , N
double JJ N
blind NN N
, , N
dose-assessing JJ N
study NN N
. . N

The DT p
setting NN p
was VBD p
at IN p
University NNP p
Hospital NNP p
, , p
Out-patient NNP p
Clinic NNP p
. . p

Our PRP$ N
patients NNS p
were VBD p
twenty-one JJ p
adult NN p
patients NNS p
with IN p
common JJ p
variable JJ p
immunodeficiency NN p
. . p

The DT N
measurements NNS N
were VBD N
comparative JJ N
study NN N
of IN N
the DT N
number NN o
and CC o
severity NN o
of IN o
infections NNS o
using VBG N
3 CD N
various JJ N
dosages NNS N
of IN N
intravenous JJ N
gammaglobulins NNS i
, , N
each DT N
given VBN N
monthly RB N
for IN N
M NNP N
least JJS N
6 CD N
months NNS N
. . N

Results NNS N
indicated VBD N
four CD N
hundred CD N
and CC N
eighty-four JJ N
infectious JJ o
episodes NNS o
occurred VBD N
while IN N
giving VBG N
305 CD i
infusions NNS i
of IN i
IVIG NNP i
200 CD i
mg/kg NN i
; : i
205 CD N
infectious JJ N
episodes NNS N
while IN N
giving VBG N
170 CD i
infusions NNS i
of IN i
400 CD i
mg/kg NNS i
and CC N
436 CD N
infectious JJ N
episodes NNS N
while IN N
giving VBG N
247 CD i
infusions NNS i
of IN i
600 CD i
mg/kg NN i
. . i

The DT N
morbidity NN o
scores NNS o
( ( o
infection/infusion NN o
) ) o
were VBD N
1.59 CD N
, , N
1.21 CD N
and CC N
1.77 CD N
respectively RB N
( ( N
p JJ N
- : N
N/S NN N
) ) N
. . N

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
the DT N
severity NN o
of IN o
infections NNS o
on IN N
the DT N
above JJ N
3 CD N
dosages NNS N
, , N
and CC N
no DT N
difference NN N
in IN N
the DT N
duration NN o
of IN o
infection-free JJ o
intervals NNS o
. . o

The DT N
conclusions NNS N
resulted VBD N
in IN N
no DT N
significant JJ N
differences NNS N
in IN N
morbidity NN o
in IN N
adult NN N
patients NNS N
with IN N
common JJ N
variable JJ N
immunodeficiency NN N
treated VBN N
in IN N
cross-over JJ N
pattern NN N
with IN N
IVIG NNP N
200 CD N
mg/kg NN N
, , N
400 CD N
mg/kg NN N
and CC N
600 CD N
mg/kg NN N
. . N

Thus NNP N
, , N
high JJ N
dosages NNS N
of IN N
IVIG NNP N
are VBP N
not RB N
conferring VBG N
better JJR N
protection NN N
against IN N
infections NNS N
in IN N
such JJ N
patients NNS N
. . N

-DOCSTART- -10599355- O O

Enalapril NNP i
( ( N
10 CD N
mg/day NN N
) ) N
in IN N
systemic JJ N
sclerosis NN N
. . N

One CD N
year NN N
, , N
double JJ N
blind NN N
, , N
randomised VBN N
study NN N
( ( N
ESS-1 NNP N
) ) N
: : N
echocardiographic JJ N
substudy NN N
-- : N
three CD N
months NNS N
follow-up RB N
. . N

The DT N
ESS-1 JJ N
study NN N
was VBD N
designed VBN N
to TO N
evaluate VB N
the DT N
long-term JJ N
effects NNS N
of IN N
the DT N
angiotensin NN N
converting VBG N
enzyme JJ N
inhibitor NN N
( ( N
ACEI NNP N
) ) N
enalapril NN i
( ( N
10 CD N
mg NNS N
per IN N
day NN N
) ) N
on IN N
the DT N
cardio-pulmonary JJ N
system NN N
in IN N
patients NNS p
with IN p
scleroderma NN p
( ( p
SSc NNP p
) ) p
. . p

We PRP N
estimated VBD N
changes NNS N
in IN N
heart NN o
diameters NNS o
, , o
systolic JJ o
and CC o
diastolic JJ o
left VBD o
ventricle NN o
function NN o
and CC o
mean JJ o
values NNS o
of IN o
pulmonary JJ o
artery NN o
pressure NN o
after IN N
3 CD N
months NNS N
treatment NN N
. . N

The DT N
study NN N
group NN N
comprise VBD N
41 CD p
patients NNS p
with IN p
SSc NNP p
. . p

18 CD N
patients NNS N
received VBN N
placebo NNS i
and CC N
23 CD N
ones NNS N
were VBD N
given VBN N
enalapril NNS i
. . i

After IN N
3 CD N
months NNS N
of IN N
treatment NN N
we PRP N
did VBD N
not RB N
observe VB N
statistically RB N
significant JJ N
differences NNS N
in IN N
heart NN o
diameters NNS o
and CC o
left VBD o
ventricle NN o
systolic JJ o
function NN o
parameters NNS o
between IN N
treated VBN N
group NN N
and CC N
placebo NN N
. . N

Enalapril NNP i
therapy NN N
did VBD N
not RB N
affect VB N
left JJ o
ventricle NN o
diastolic JJ o
function NN o
, , N
nevertheless RB N
differences NNS N
in IN N
MVA NNP o
were VBD N
almost RB N
of IN N
statistical JJ N
significance NN N
. . N

Echocardiographic JJ N
signs NNS o
of IN N
pulmonary JJ o
hypertension NN o
were VBD N
found VBN N
in IN N
4 CD N
patients NNS N
. . N

-DOCSTART- -10476617- O O

Trial NN N
of IN N
prophylactic JJ N
administration NN N
of IN N
TXA2 NNP i
synthetase NN i
inhibitor NN i
, , i
ozagrel JJ i
hydrochloride NN i
, , N
for IN N
preeclampsia NN o
. . o

OBJECTIVE NNP N
In IN N
an DT N
attempt NN N
to TO N
investigate VB N
the DT N
prophylactic JJ N
effect NN N
of IN N
a DT N
thromboxane NN i
A2 NNP i
( ( i
TXA2 NNP i
) ) i
synthetase NN i
inhibitor NN i
on IN N
pregnant JJ p
women NNS p
with IN p
a DT p
high JJ p
risk NN p
of IN p
preeclampsia NN p
, , N
the DT N
following VBG N
clinical JJ N
study NN N
was VBD N
undertaken VBN N
. . N

METHODS NNP N
Forty NNP p
pregnant JJ p
women NNS p
were VBD N
randomly RB N
allocated VBN N
to TO N
control VB N
or CC N
treatment NN N
groups NNS N
. . N

Ozagrel NNP i
Hydrochloride NNP i
( ( N
400 CD N
mg/day NN N
, , N
orally RB N
) ) N
and CC i
placebo NN i
were VBD N
started VBN N
at IN N
20 CD N
weeks NNS N
of IN N
gestation NN N
and CC N
continued VBD N
until IN N
delivery NN N
. . N

RESULTS NNP N
Seventeen NNP N
of IN N
20 CD N
( ( N
85 CD N
% NN N
) ) N
women NNS N
in IN N
the DT N
control NN N
group NN N
developed VBD N
preeclampsia NN o
, , N
whereas IN N
9 CD N
of IN N
20 CD N
( ( N
45 CD N
% NN N
) ) N
in IN N
the DT N
treatment NN N
group NN N
developed VBD N
preeclampsia NN o
. . o

Ozagrel NNP N
Hydrochloride NNP N
significantly RB N
( ( N
p JJ N
< NNP N
0.01 CD N
) ) N
reduced VBD N
the DT N
occurrence NN o
of IN o
preeclampsia NN o
, , N
and CC N
the DT N
incidence NN N
of IN N
both DT N
hypertension NN o
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
and CC N
proteinuria NN o
( ( N
p JJ N
< NNP N
0.01 CD N
) ) N
was VBD N
significantly RB N
less RBR N
in IN N
the DT N
treatment NN N
group NN N
compared VBN N
with IN N
the DT N
control NN N
group NN N
. . N

One CD N
month NN N
after IN N
administration NN N
, , N
the DT N
mean JJ o
plasma NN o
concentration NN o
of IN o
TXB2 NNP o
, , o
a DT o
metabolite NN o
of IN o
TXA2 NNP o
, , N
was VBD N
significantly RB N
decreased VBN N
( ( N
p JJ N
< NNP N
0.01 CD N
) ) N
to TO N
62.4 CD N
+/- JJ N
13.6 CD N
% NN N
, , N
whereas IN N
that DT N
of IN N
6-keto JJ o
prostaglandin NN o
F1 NNP o
alpha NN o
, , o
a DT o
metabolite NN o
of IN o
PGI2 NNP o
, , N
was VBD N
significantly RB N
increased VBN N
( ( N
p JJ N
< NNP N
0.01 CD N
) ) N
to TO N
206.7 CD N
+/- JJ N
52.8 CD N
% NN N
. . N

There EX N
were VBD N
no DT N
maternal JJ o
or CC o
fetal JJ o
side NN o
effects NNS o
observed VBN o
. . o

CONCLUSIONS VB N
It PRP N
seems VBZ N
likely JJ N
that IN N
Ozagrel NNP i
Hydrochloride NNP i
could MD N
be VB N
used VBN N
for IN N
the DT N
prevention NN o
of IN o
preeclampsia NN o
in IN p
high-risk JJ p
pregnant JJ p
women NNS p
. . p

-DOCSTART- -21616612- O O

Effectiveness NN N
of IN N
a DT N
short-term JJ N
treatment NN N
with IN N
progesterone NN i
injections NNS N
on IN N
synchrony NN N
of IN N
lambing NN N
and CC N
fertility NN N
in IN N
tropical JJ p
hair NN p
sheep NN p
. . p

The DT N
efficacy NN N
of IN N
using VBG N
a DT N
low JJ N
cost NN N
system NN N
for IN N
delivering VBG N
progesterone NN i
as IN N
part NN N
of IN N
an DT N
estrous JJ N
synchronization NN N
protocol NN N
in IN N
sheep NN p
was VBD N
evaluated VBN N
. . N

In IN N
experiment JJ N
1 CD N
, , N
Barbados NNP p
Black NNP p
Belly NNP p
ewes FW p
( ( p
n=34 NN p
) ) p
and CC p
ewe JJ p
lambs NN p
( ( p
n=35 JJ p
; : p
37.5?0.9 CD p
kg NN p
) ) p
were VBD i
assigned VBN i
to TO i
be VB i
untreated JJ i
, , i
control NN i
animals NNS i
( ( i
C NNP i
) ) i
, , i
or CC i
to TO i
receive VB i
PGF NNP i
( ( i
2? CD i
) ) i
on IN i
d0 NN i
( ( i
PG NNP i
) ) i
, , i
or CC i
receive VB i
two CD i
injections NNS i
of IN i
progesterone NN i
( ( i
200mg CD i
, , i
i.m NN i
. . i

each DT i
) ) i
on IN i
D NNP i
-5 NNP i
and CC i
on IN i
D NNP i
-2.5 NNP i
, , i
prior RB i
to TO i
PGF NNP i
( ( i
2? CD i
) ) i
, , i
on IN i
D NNP i
0 CD i
( ( i
2PPG CD i
) ) i
. . i

Treatment NN i
with IN N
2PPG CD N
increased VBD N
the DT N
proportion NN o
of IN o
animals NNS o
lambing VBG o
to TO o
the DT N
first JJ N
service NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
, , N
an DT N
effect NN N
that WDT N
was VBD N
greater JJR N
in IN N
ewe NN p
lambs NNS p
than IN p
ewes NN p
( ( p
treatment NN p
? . N
parity NN N
; : N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

The DT N
interval NN N
from IN N
ram JJ N
introduction NN o
to TO o
lambing NN o
and CC o
the DT o
mean JJ o
lambing NN o
day NN o
was VBD N
less JJR N
( ( N
P=0.04 NNP N
) ) N
in IN N
the DT N
2PPG-treated JJ N
animals NNS N
compared VBN N
to TO N
control VB N
animals NNS p
. . p

In IN p
Experiment JJ p
2 CD p
, , p
lactating VBG p
ewes NN p
from IN p
experiment JJ p
1 CD p
( ( p
n=61 NN p
) ) p
60-85 JJ p
days NNS p
postpartum NN p
were VBD p
assigned VBN N
within IN N
parity NN N
and CC N
number NN N
of IN N
lambs NNS N
reared VBN N
to TO N
remain VB N
nursing NN N
( ( N
S NNP N
; : N
n=29 CC N
) ) N
or CC N
weaned VBN N
( ( N
W NNP N
; : N
n=32 CC N
) ) N
3 CD N
weeks NNS N
prior RB N
to TO N
treatment NN N
with IN N
the DT N
2PPG CD N
protocol NN N
. . N

There EX N
was VBD N
no DT N
effect NN N
of IN N
treatment NN N
on IN N
the DT N
proportion NN o
of IN o
animals NNS o
lambing VBG o
to TO o
the DT o
first JJ o
service NN o
or CC o
overall JJ o
, , o
interval NN o
from IN N
ram JJ N
introduction NN N
to TO N
lambing NN N
and CC N
lambing VBG N
interval NN N
. . N

An DT N
8-month JJ o
lambing NN o
interval NN o
was VBD o
observed VBN p
in IN p
ewes NN p
in IN p
which WDT N
estrus NN N
was VBD N
synchronized VBN N
regardless RB N
of IN N
physiological JJ N
state NN N
. . N

In IN N
conclusion NN N
, , N
the DT N
two-progesterone JJ N
injection NN N
synchronization NN N
protocol NN N
may MD N
be VB N
used VBN N
as IN N
a DT N
practical JJ N
low JJ N
cost NN N
and CC N
efficient JJ N
method NN N
of IN N
synchronizing VBG N
estrus NN N
to TO N
reduce VB N
the DT N
lambing NN N
interval NN N
and CC N
maximize VB N
productivity NN p
in IN p
tropical JJ p
breeds NNS p
of IN p
sheep NN p
. . p

-DOCSTART- -26204331- O O

A DT N
Double-Blind JJ N
Placebo-Controlled JJ i
Study NNP N
of IN N
the DT N
Effects NNS N
of IN N
Olprinone NNP i
, , N
a DT N
Specific JJ i
Phosphodiesterase NNP i
III NNP i
Inhibitor NNP i
, , N
for IN N
Preventing VBG N
Postoperative NNP N
Atrial NNP N
Fibrillation NNP N
in IN N
Patients NNP p
Undergoing NNP p
Pulmonary NNP p
Resection NNP p
for IN p
Lung NNP p
Cancer NNP p
. . p

BACKGROUND NNP N
We PRP N
previously RB N
reported VBD N
that IN N
patients NNS N
with IN N
elevated JJ p
preoperative JJ p
B-type NNP p
natriuretic JJ p
peptide NN p
( ( p
BNP NNP p
) ) p
levels NNS p
have VBP N
an DT N
increased VBN N
risk NN N
for IN N
postoperative JJ N
atrial JJ N
fibrillation NN N
following VBG N
lung NN N
cancer NN N
surgery NN N
. . N

The DT N
present JJ N
study NN N
evaluated VBD N
whether IN N
the DT N
specific JJ i
phosphodiesterase NN i
III NNP i
inhibitor NN i
olprinone NN i
can MD N
reduce VB N
the DT N
incidence NN N
of IN N
postoperative JJ N
atrial JJ N
fibrillation NN N
in IN N
patients NNS N
with IN N
elevated JJ N
BNP NNP N
levels NNS N
undergoing VBG N
pulmonary JJ N
resection NN N
for IN N
lung NN N
cancer NN N
. . N

METHODS NNP N
A NNP N
prospective JJ N
randomized NN N
study NN N
was VBD N
conducted VBN N
with IN N
40 CD p
patients NNS p
who WP p
had VBD p
elevated VBN p
preoperative JJ p
BNP NNP p
levels NNS p
( ( p
? . p
30 CD p
pg/mL NN p
) ) p
and CC p
underwent JJ p
scheduled VBN p
lung NN p
cancer NN p
surgery NN p
. . p

All DT p
patients NNS p
were VBD p
in IN p
sinus JJ p
rhythm NN p
at IN p
surgery NN i
. . i

Low-dose JJ i
olprinone NN i
or CC i
placebo NN i
was VBD i
continuously RB N
infused VBN N
for IN N
24 CD N
h NN N
and CC N
started VBD N
just RB N
before RB N
anesthesia JJ N
induction NN N
. . N

The DT N
primary JJ N
end NN N
point NN N
was VBD N
the DT o
incidence NN o
of IN o
postoperative JJ o
atrial JJ o
fibrillation NN o
. . o

The DT N
secondary JJ N
end NN N
points NNS N
were VBD o
perioperative JJ o
hemodynamics NNS o
and CC o
levels NNS o
of IN o
BNP NNP o
, , o
WBC NNP o
counts VBZ o
, , o
and CC o
C-reactive JJ o
protein NN o
. . o

RESULTS VB N
The DT o
incidence NN o
of IN o
postoperative JJ o
atrial JJ o
fibrillation NN o
was VBD o
significantly RB N
lower JJR N
in IN N
the DT i
olprinone NN i
group NN i
than IN N
in IN N
the DT N
placebo NN N
group NN N
( ( N
10 CD N
% NN N
vs JJ N
60 CD N
% NN N
, , N
P NNP N
< NNP N
.001 NNP N
) ) N
. . N

Patients NNS N
in IN N
the DT i
olprinone NN i
group NN i
showed VBD N
significantly RB o
lower JJR o
BNP NNP o
, , o
WBC NNP o
counts VBZ o
, , o
and CC o
C-reactive JJ o
protein NN o
levels NNS o
after IN o
surgery NN N
. . N

CONCLUSIONS NNP N
Continuous NNP N
infusion NN N
of IN N
olprinone NN N
during IN N
lung NN N
cancer NN N
surgery NN N
was VBD o
safe JJ o
and CC o
reduced VBD N
the DT o
incidence NN o
of IN o
postoperative JJ o
atrial JJ o
fibrillation NN o
following VBG o
pulmonary JJ N
resection NN N
in IN N
patients NNS N
with IN N
elevated JJ N
preoperative JJ N
BNP NNP N
levels NNS N
. . N

TRIAL NNP N
REGISTRY NNP N
Japan NNP N
Primary NNP N
Registries NNP N
Network NNP N
; : N
No NNP N
. . N

: : N
JPRN-UMIN2404 JJ N
; : N
URL NNP N
: : N
http NN N
: : N
//www.umin.ac.jp/ctr/ NN N
. . N

-DOCSTART- -17698601- O O

Predictors NNS N
of IN N
incident NN o
depression NN o
after IN p
hip NN p
fracture NN p
surgery NN p
. . p

OBJECTIVE NNP N
Depression NNP N
after IN N
hip NN i
fracture NN i
surgery NN i
is VBZ N
prevalent JJ N
and CC N
associated VBN N
with IN N
increased JJ N
mortality NN N
rates NNS N
and CC N
impaired JJ N
functional JJ N
recovery NN N
. . N

The DT N
incidence NN N
of IN N
new-onset JJ N
depressive NN N
symptoms NNS N
in IN N
patients NNS N
initially RB N
not RB N
depressed VBN N
after IN N
hip NN i
fracture NN i
surgery NN i
and CC N
their PRP$ N
relationship NN N
with IN N
functional JJ N
recovery NN N
is VBZ N
unknown JJ N
. . N

METHODS VB N
A DT N
cohort NN N
of IN N
139 CD p
nondepressed JJ p
elderly JJ p
patients NNS p
( ( p
> JJ p
60 CD p
years NNS p
) ) p
hospitalized VBD p
for IN p
hip NN i
fracture NN i
surgery NN i
were VBD N
followed VBN N
up RP N
for IN N
six CD N
months NNS N
. . N

Clinically NNP N
significant JJ N
depressive NN N
symptoms NNS N
were VBD N
defined VBN N
as IN N
a DT N
score NN N
of IN N
7 CD N
or CC N
more JJR N
on IN N
the DT N
15-item JJ o
Geriatric NNP o
Depression NNP o
Scale NNP o
. . o

RESULTS VB N
The DT N
authors NNS N
found VBD N
a DT N
cumulative JJ o
incidence NN o
rate NN o
of IN N
20.5 CD N
% NN N
adjusted VBN N
for IN N
dropouts NNS N
. . N

Multiple JJ N
Cox-regression JJ N
analyses NNS N
yielded VBD N
the DT N
presence NN N
of IN N
subthreshold JJ N
symptoms NNS N
of IN N
depression NN o
, , o
anxiety NN o
, , o
pain NN o
, , o
and CC o
cognitive JJ o
impairment NN o
at IN o
baseline NN o
, , o
the DT o
premorbid NN o
level NN o
of IN o
mobility NN o
, , o
and CC o
a DT o
history NN o
of IN o
( ( o
treated VBN o
) ) o
depression NN o
as IN o
risk NN o
factors NNS o
for IN o
incident JJ o
depression NN o
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
. . N

A DT N
forward NN N
, , N
conditional JJ N
procedure NN N
identified VBN N
postoperative JJ o
pain NN o
( ( N
hazard JJ N
ratio NN N
[ NNP N
HR NNP N
] NNP N
= NNP N
1.32 CD N
, , N
95 CD N
% NN N
confidence NN N
interval NN N
[ NNP N
CI NNP N
] NN N
: : N
1.14-1.53 JJ N
, , N
Wald NNP N
chi NN N
( ( N
2 CD N
) ) N
= NN N
13.57 CD N
, , N
df NN N
= VBD N
1 CD N
, , N
p NN N
< NNP N
0.001 CD N
) ) N
and CC N
baseline JJ o
anxiety NN o
( ( N
HR NNP N
= NNP N
1.25 CD N
, , N
95 CD N
% NN N
CI NNP N
: : N
1.08-1.44 JJ N
, , N
Wald NNP N
chi NN N
( ( N
2 CD N
) ) N
= NN N
8.86 CD N
, , N
df NN N
= VBD N
1 CD N
, , N
p NN N
= NNP N
0.003 CD N
) ) N
as IN N
the DT N
strongest JJS N
independent JJ N
risk NN N
factors NNS N
. . N

Incident NNP o
depression NN o
was VBD N
associated VBN N
with IN N
a DT N
less RBR N
favorable JJ N
outcome NN N
at IN N
3 CD N
months NNS N
follow-up RB N
. . N

CONCLUSION VB N
This DT N
exploratory NN N
study NN N
identified VBD N
two CD N
treatable JJ N
baseline NN N
characteristics NNS N
that WDT N
predicted VBD N
incident JJ o
depression NN o
in IN N
nondepressed JJ p
patients NNS p
after IN p
hip-fracture JJ p
surgery NN p
. . p

-DOCSTART- -8619354- O O

Iobitridol NNP i
300 CD i
compared VBN N
to TO N
iopromide VB i
300 CD i
-- : i
a DT i
double-blind JJ N
randomized JJ N
phase-III NN N
study NN N
of IN N
clinical JJ N
tolerance NN N
in IN N
total JJ p
body NN p
CT. NNP p
UNLABELLED NNP N
PURPOSE NNP N
, , N
MATERIAL NNP N
AND NNP N
METHODS NNP N
: : N
The DT N
clinical JJ N
safety NN N
of IN N
iobitriodol JJ i
300 CD i
mg NN i
I/ml NNP i
and CC i
iopromide RB i
300 CD i
mg NNS i
I/ml NNP i
were VBD N
compared VBN N
in IN N
a DT N
randomized JJ N
double JJ N
blind IN N
phase-III JJ N
study NN N
conducted VBD N
on IN N
60 CD p
patients NNS p
undergoing JJ p
abdominal JJ p
CT NNP p
for IN p
a DT p
variety NN p
of IN p
indications NNS p
. . p

Each DT N
examination NN N
was VBD N
rated VBN N
as IN N
diagnostic JJ N
or CC N
nondiagnostic JJ N
and CC N
the DT N
image NN N
quality NN N
was VBD N
noted VBN N
. . N

Nature NN N
, , N
onset NN o
, , N
intensity NN N
as RB N
well RB N
as IN N
outcome NN N
of IN N
each DT N
adverse JJ o
reaction NN o
were VBD N
recorded VBN N
. . N

RESULTS NNP N
There EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
imaging VBG o
quality NN o
and CC o
side NN o
effects NNS o
between IN N
the DT N
contrast NN N
media NNS N
. . N

In IN N
this DT N
study NN N
, , N
both DT N
iobitridol NNS i
and CC N
iopromide NN i
provided VBD N
excellent JJ o
image NN o
quality NN o
and CC N
a DT N
low JJ o
rate NN o
of IN o
side NN o
effects NNS o
. . o

CONCLUSION NNP N
Iobitridol NNP i
is VBZ N
a DT N
safe JJ o
and CC o
effective JJ o
nonionic JJ o
contrast NN o
agent NN o
for IN N
contrast-enhanced JJ N
body NN N
CT NNP N
. . N

-DOCSTART- -11156811- O O

Sertraline NNP i
treatment NN N
of IN N
generalized VBN o
social JJ o
phobia NN o
: : o
a DT N
20-week JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
study NN N
. . N

OBJECTIVE CC N
The DT N
authors NNS N
evaluated VBD N
the DT N
efficacy NN o
, , o
safety NN o
, , o
and CC o
tolerability NN o
of IN o
sertraline NN o
, , N
a DT N
selective JJ N
serotonin NN N
reuptake NN N
inhibitor NN N
, , N
in IN N
the DT N
treatment NN N
of IN N
generalized VBN o
social JJ o
phobia NN o
. . o

METHOD NNP N
Adult NNP p
outpatients NNS p
with IN p
generalized JJ p
social JJ p
phobia NN p
( ( p
N=204 NNP p
) ) p
from IN p
10 CD p
Canadian JJ p
centers NNS p
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
sertraline NN i
or CC i
placebo NN i
in IN N
a DT N
2:1 CD N
ratio NN N
for IN N
a DT N
20-week JJ N
double-blind NN N
study NN N
following VBG N
a DT N
1-week JJ N
, , N
single-blind JJ N
, , N
placebo JJ N
run-in NN N
. . N

The DT N
initial JJ N
dose NN N
of IN N
sertraline NN i
was VBD N
50 CD N
mg/day NN N
with IN N
increases NNS N
of IN N
50 CD N
mg/day JJ N
every DT N
3 CD N
weeks NNS N
permitted VBN N
after IN N
the DT N
fourth JJ N
week NN N
of IN N
treatment NN N
( ( N
dosing VBG N
was VBD N
flexible JJ N
up RB N
to TO N
a DT N
maximum NN N
of IN N
200 CD N
mg/day NN N
) ) N
. . N

Primary JJ N
efficacy NN o
assessments NNS o
were VBD N
the DT N
percentage NN N
of IN N
patients NNS N
rated VBN N
much JJ N
or CC N
very RB N
much JJ N
improved VBN N
on IN N
the DT N
Clinical NNP o
Global NNP o
Impression NNP o
( ( o
CGI NNP o
) ) o
improvement NN o
item NN o
and CC o
the DT o
mean JJ o
changes NNS o
from IN o
baseline NN o
to TO o
study VB o
endpoint NN o
in IN o
total JJ o
score NN o
on IN o
the DT o
social JJ o
phobia JJ o
subscale NN o
of IN o
the DT o
Marks NNP o
Fear NNP o
Questionnaire NNP o
and CC o
total JJ o
score NN o
on IN o
the DT o
Brief NNP o
Social NNP o
Phobia NNP o
Scale NNP o
. . o

RESULTS NNP N
In IN N
intent-to-treat JJ N
endpoint NN N
analyses NNS N
of IN N
203 CD N
of IN N
the DT N
patients NNS N
, , N
significantly RB N
more JJR N
of IN N
the DT N
134 CD p
patients NNS p
given VBN p
sertraline JJ i
( ( N
N=71 NNP N
[ RB N
53 CD N
% NN N
] NN N
) ) N
than IN N
of IN N
the DT N
69 CD p
patients NNS p
receiving VBG p
placebo NN i
( ( N
N=20 NNP N
[ RB N
29 CD N
% NN N
] NN N
) ) N
were VBD N
considered VBN N
responders NNS N
according VBG N
to TO N
their PRP$ N
CGI NNP o
improvement NN o
scores NNS o
at IN N
the DT N
end NN N
of IN N
treatment NN N
. . N

The DT N
mean JJ N
reductions NNS N
in IN N
the DT N
social JJ o
phobia JJ o
subscale NN o
of IN o
the DT o
Marks NNP o
Fear NNP o
Questionnaire NNP o
and CC N
in IN N
the DT N
total JJ o
score NN o
on IN o
the DT o
Brief NNP o
Social NNP o
Phobia NNP o
Scale NNP o
were VBD N
32.6 CD N
% NN N
and CC N
34.3 CD N
% NN N
in IN N
the DT N
sertraline NN i
group NN N
and CC N
10.8 CD N
% NN N
and CC N
18.6 CD N
% NN N
in IN N
the DT N
placebo NN i
group NN N
, , N
respectively RB N
. . N

Analysis NN N
of IN N
covariance NN N
showed VBD N
superiority NN N
of IN N
sertraline NN i
over IN N
placebo NN i
on IN N
all DT N
primary JJ N
and CC N
secondary JJ N
efficacy NN o
measures NNS o
. . o

Sertraline NNP i
was VBD N
well RB N
tolerated VBN N
: : N
103 CD N
( ( N
76 CD N
% NN N
) ) N
of IN N
the DT N
135 CD N
sertraline-treated JJ i
patients NNS N
and CC N
54 CD N
( ( N
78 CD N
% NN N
) ) N
of IN N
the DT N
69 CD N
placebo-treated JJ i
patients NNS N
completed VBD N
the DT N
study NN N
. . N

CONCLUSIONS NNP N
Sertraline NNP i
is VBZ N
an DT N
effective JJ N
treatment NN N
for IN N
patients NNS N
with IN N
generalized JJ o
social JJ o
phobia NN o
. . o

-DOCSTART- -8964113- O O

Modulation NN i
of IN i
oxidant JJ i
stress NN i
in IN i
vivo NN i
in IN N
chronic JJ p
cigarette NN p
smokers NNS p
. . p

BACKGROUND NNP N
Free JJ N
radical-induced JJ N
oxidative JJ N
damage NN N
is VBZ N
thought VBN N
to TO N
be VB N
involved VBN N
in IN N
the DT N
pathogenesis NN N
of IN N
diseases NNS N
associated VBN N
with IN N
cigarette NN N
smoking NN N
. . N

We PRP N
examined VBD N
the DT N
production NN N
of IN N
8-epi-prostaglandin JJ i
( ( i
PG NNP i
) ) i
F2 NNP i
alpha NN i
, , i
a DT i
stable JJ i
product NN i
of IN i
lipid JJ i
peroxidation NN i
in IN i
vivo NN i
, , N
and CC N
its PRP$ N
modulation NN i
by IN i
aspirin NN i
and CC i
antioxidant JJ i
vitamins NNS i
in IN N
chronic JJ p
cigarette NN p
smokers NNS p
. . p

METHODS NNP N
AND CC N
RESULTS NNP N
We PRP N
performed VBD N
the DT N
following JJ N
studies NNS N
: : N
( ( N
1 CD N
) ) N
a DT p
cross-sectional JJ p
comparison NN p
of IN p
smokers NNS p
and CC p
control NN p
subjects NNS p
, , N
( ( N
2 CD N
) ) N
an DT N
examination NN N
of IN N
the DT N
dose-response JJ N
relationship NN N
, , N
( ( N
3 CD N
) ) N
an DT N
exploration NN N
of IN N
the DT N
effect NN N
of IN N
smoking VBG i
cessation NN i
( ( i
3 CD i
weeks NNS i
) ) i
and CC i
nicotine JJ i
patch NN i
supplementation NN i
, , N
( ( N
4 CD N
) ) N
the DT N
effect NN N
of IN N
aspirin NN i
consumption NN i
, , N
and CC N
( ( N
5 CD N
) ) N
the DT N
effects NNS N
of IN N
5 CD N
days NNS N
' POS N
dosing VBG N
with IN N
vitamin NN i
E NNP i
( ( N
100 CD N
and CC N
800 CD N
U NNP N
) ) N
, , N
vitamin FW i
C NNP i
( ( i
2 CD i
g NN i
) ) i
, , N
and CC N
their PRP$ N
combination NN N
. . N

8-epi-PGF2 JJ o
alpha JJ o
excretion NN o
( ( N
in IN N
pmol/mmol NN N
, , N
mean JJ N
+/- JJ N
SEM NNP N
) ) N
was VBD N
176.5+/-30.6 JJ N
in IN N
heavy JJ p
smokers NNS p
, , N
92.7+/-4.8 CD N
( ( N
P NNP N
< NNP N
.05 NNP N
) ) N
in IN N
moderate JJ p
smokers NNS p
, , N
and CC N
54.1+/-2.7 JJ N
( ( N
P NNP N
< NNP N
.005 NNP N
) ) N
in IN N
nonsmokers NNS p
. . p

Urinary JJ o
levels NNS o
fell VBD o
from IN N
145.5+/-24.9 CD N
to TO N
114.6+/-27.1 CD N
( ( N
week NN N
2 CD N
, , N
P NNP N
< NNP N
.05 NNP N
) ) N
and CC N
112.6+/-24.9 JJ N
( ( N
week NN N
3 CD N
, , N
P NNP N
< NNP N
.05 NNP N
) ) N
on IN N
cessation NN N
of IN N
smoking NN N
. . N

Aspirin NNP i
treatment NN i
failed VBD N
to TO N
suppress VB N
urinary JJ o
levels NNS o
of IN o
8-epi-PGF2 JJ o
alpha NN o
despite IN N
a DT N
significant JJ N
reduction NN N
in IN N
urinary JJ o
11-dehydro-TxB2 JJ o
production NN o
and CC N
suppression NN o
of IN o
8-epi-PGF2 JJ o
alpha NN o
and CC o
TxB2 NNP o
in IN o
serum NN o
. . o

Vitamin NNP i
C NNP i
( ( N
pre NN N
, , N
194.6+/-40.9 JJ N
; : N
post NN N
, , N
137.2+/-34.1 JJ N
; : N
P NNP N
< NNP N
.05 NNP N
) ) N
and CC N
a DT N
combination NN i
of IN i
vitamin JJ i
C NNP i
and CC i
E NNP i
( ( N
pre NN N
, , N
171.0+/-39.8 JJ N
; : N
post NN N
, , N
133.5+/-29.6 JJ N
P NNP N
< NNP N
.05 NNP N
) ) N
suppressed VBD N
urinary JJ o
8-epi-PGF2 JJ o
alpha NN o
, , N
whereas IN N
vitamin JJ i
E NNP i
alone RB N
had VBD N
no DT N
effect NN N
. . N

CONCLUSIONS NNP N
Urinary NNP o
8-epi-PGF2 JJ o
alpha NN o
may MD N
represent VB N
a DT N
noninvasive JJ N
, , N
quantitative JJ N
index NN N
of IN N
oxidant JJ N
stress NN N
in IN N
vivo NN N
. . N

Elevated JJ o
levels NNS o
of IN o
8-epi-PGF2 JJ o
alpha NN o
in IN o
smokers NNS o
may MD N
be VB N
modulated VBN N
by IN N
quitting VBG i
cigarettes NNS i
and CC i
switching VBG i
to TO i
nicotine VB i
patches NNS i
or CC N
by IN N
antioxidant JJ i
vitamin NN i
therapy NN i
. . i

-DOCSTART- -24559178- O O

Dentists NNS N
United NNP N
to TO N
Extinguish VB N
Tobacco NNP N
( ( N
DUET NNP N
) ) N
: : N
a DT N
study NN N
protocol NN N
for IN N
a DT N
cluster NN N
randomized VBN N
, , N
controlled VBN N
trial NN N
for IN N
enhancing VBG N
implementation NN N
of IN N
clinical JJ i
practice NN i
guidelines NNS i
for IN N
treating VBG N
tobacco NN p
dependence NN p
in IN p
dental JJ p
care NN p
settings NNS p
. . p

BACKGROUND NNP N
Although IN N
dental JJ N
care NN N
settings NNS N
provide VBP N
an DT N
exceptional JJ N
opportunity NN N
to TO N
reach VB N
smokers NNS p
and CC N
provide VB N
brief JJ N
cessation NN N
advice NN N
and CC N
treatment NN N
to TO N
reduce VB N
oral JJ N
and CC N
other JJ N
tobacco-related JJ N
health NN N
conditions NNS N
, , N
dental JJ N
care NN N
providers NNS N
demonstrate VBP N
limited JJ N
adherence NN N
to TO N
evidence-based JJ N
guidelines NNS N
for IN N
treatment NN N
of IN N
tobacco NN p
use NN p
and CC p
dependence NN p
. . p

METHODS/DESIGN NNP N
Guided VBN N
by IN N
a DT N
multi-level NN N
, , N
conceptual JJ N
framework NN N
that WDT N
emphasizes VBZ N
changes NNS N
in IN N
provider NN N
beliefs NNS N
and CC N
organizational JJ N
characteristics NNS N
as IN N
drivers NNS N
of IN N
improvement NN N
in IN N
tobacco NN N
treatment NN N
delivery NN N
, , N
the DT N
current JJ N
protocol NN N
will MD N
use VB N
a DT N
cluster NN N
, , N
randomized VBN N
design NN N
and CC N
multiple JJ N
data NNS N
sources NNS N
( ( N
patient JJ N
exit NN N
interviews NNS N
, , N
provider NN N
surveys NNS N
, , N
site NN N
observations NNS N
, , N
chart JJ N
audits NN N
, , N
and CC N
semi-structured JJ N
provider NN N
interviews NNS N
) ) N
to TO N
study VB N
the DT N
process NN N
of IN N
implementing VBG N
clinical JJ N
practice NN N
guidelines NNS N
for IN N
treating VBG N
tobacco NN N
dependence NN N
in IN N
18 CD p
public JJ p
dental NN p
care NN p
clinics NNS p
in IN p
New NNP p
York NNP p
City NNP p
. . p

The DT N
specific JJ N
aims NNS N
of IN N
this DT N
comparative-effectiveness JJ o
research NN N
trial NN N
are VBP N
to TO N
: : N
compare VB N
the DT N
effectiveness NN N
of IN N
three CD N
promising VBG N
strategies NNS N
for IN N
implementation NN N
of IN N
tobacco NN i
use NN i
treatment NN i
guidelines-staff JJ i
training NN i
and CC i
current JJ i
best JJS i
practices NNS i
( ( i
CBP NNP i
) ) i
, , i
CBP NNP i
+ NNP i
provider NN i
performance NN i
feedback NN i
( ( i
PF NNP i
) ) i
, , i
and CC i
CBP NNP i
+ NNP i
PF NNP i
+ NNP i
provider NN i
reimbursement NN i
for IN i
delivery NN i
of IN i
tobacco NN i
cessation NN i
treatment NN i
( ( i
pay-for-performance NN i
, , i
or CC i
P4P NNP i
) ) i
; : i
examine JJ i
potential JJ N
theory-driven JJ N
mechanisms NNS N
hypothesized VBN N
to TO N
explain VB N
the DT N
comparative JJ N
effectiveness NN N
of IN N
three CD N
strategies NNS N
for IN N
implementation NN N
; : N
and CC N
identify VB N
baseline JJ N
organizational JJ N
factors NNS N
that WDT N
influence VBP N
the DT N
implementation NN N
of IN N
evidence-based JJ N
tobacco NN N
use NN N
treatment NN N
practices NNS N
in IN N
dental JJ N
clinics NNS N
. . N

The DT N
primary JJ N
outcome NN o
is VBZ o
change VBN o
in IN o
providers NNS o
' POS o
tobacco NN o
treatment NN o
practices NNS o
and CC o
the DT N
secondary JJ N
outcomes NNS N
are VBP N
cost VBN o
per IN o
quit NN o
, , o
use NN o
of IN o
tobacco NN o
cessation NN o
treatments NNS o
, , o
quit NN o
attempts NNS o
, , o
and CC o
smoking VBG o
abstinence NN o
. . o

DISCUSSION NNP N
We PRP N
hypothesize VBP N
that IN N
the DT N
value NN N
of IN N
these DT N
promising JJ N
implementation NN N
strategies NNS N
is VBZ N
additive JJ N
and CC N
that IN N
incorporating VBG N
all DT N
three CD N
strategies NNS N
( ( N
CBP NNP N
, , N
PF NNP N
, , N
and CC N
P4P NNP N
) ) N
will MD N
be VB N
superior JJ N
to TO N
CBP VB i
alone RB i
and CC i
CBP NNP i
+ NNP i
PF NNP i
in IN i
improving VBG N
delivery NN N
of IN N
cessation NN N
assistance NN N
to TO N
smokers NNS N
. . N

The DT N
findings NNS N
will MD N
improve VB N
knowledge NN N
pertinent NN N
to TO N
the DT N
implementation NN N
, , N
dissemination NN N
, , N
and CC N
sustained VBD N
utilization NN N
of IN N
evidence-based JJ N
tobacco NN N
use NN N
treatment NN N
in IN N
dental JJ N
practices NNS N
. . N

TRIAL NNP N
REGISTRATION NNP N
NCT01615237 NNP N
. . N

-DOCSTART- -25919773- O O

The DT N
impact NN N
of IN N
amalgam JJ i
dental JJ i
fillings NNS i
on IN N
the DT N
frequency NN o
of IN o
Helicobacter NNP o
pylori POS o
infection NN o
and CC o
H. NNP o
pylori JJ o
eradication NN o
rates NNS o
in IN N
patients NNS p
treated VBN p
with IN p
concomitant NN i
, , i
quadruple NN i
, , i
and CC i
levofloxacin-based JJ i
therapies NNS i
. . i

BACKGROUND NNP N
AND NNP N
AIM NNP N
Mercury NNP N
exposure NN N
is VBZ N
encountered VBN N
most RBS N
commonly RB N
in IN N
individuals NNS p
with IN p
amalgam JJ i
fillings NNS i
. . i

The DT N
toxic NN N
, , N
bactericidal NN N
, , N
and CC N
immunosuppressive JJ N
effects NNS N
of IN N
mercury NN N
are VBP N
well RB N
known VBN N
. . N

Furthermore NN N
, , N
multiple JJ N
antibiotic JJ N
resistance NN N
can MD N
be VB N
transferred VBN N
, , N
together RB N
with IN N
mercury NN N
resistance NN N
. . N

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
investigate VB N
the DT N
frequency NN o
of IN o
Helicobacter NNP o
pylori FW o
infection NN o
in IN N
dyspeptic JJ p
patients NNS p
with IN p
amalgam JJ p
fillings NNS p
and CC p
the DT p
effect NN p
of IN p
the DT p
amalgam JJ p
fillings NNS p
on IN p
H. NNP o
pylori JJ o
eradication NN o
rates NNS o
in IN p
these DT p
patients NNS p
. . p

PATIENTS NNP N
AND CC N
METHODS NNP N
Four NNP p
hundred VBD p
and CC p
seventy-five JJ p
patients NNS p
who WP p
presented VBD p
with IN p
dyspeptic JJ p
complaints NNS p
and CC p
underwent JJ p
upper JJ p
gastrointestinal JJ p
endoscopy NN p
and CC p
gastric JJ p
biopsy NN p
were VBD p
included VBN p
in IN N
this DT N
study NN N
. . N

One CD N
hundred CD N
and CC N
sixty-nine JJ N
( ( N
35.6 CD N
% NN N
) ) N
patients NNS N
were VBD N
negative JJ N
and CC N
306 CD N
( ( N
64.4 CD N
% NN N
) ) N
patients NNS N
were VBD N
positive JJ N
for IN N
H. NNP N
pylori NN N
. . N

All DT N
of IN N
the DT N
participants NNS N
underwent JJ N
dental JJ N
examinations NNS N
in IN N
a DT N
blinded JJ N
manner NN N
. . N

The DT N
participants NNS N
were VBD N
divided VBN N
into IN N
two CD N
groups NNS N
on IN N
the DT N
basis NN N
of IN N
the DT N
presence NN N
of IN N
amalgam JJ N
fillings NNS N
. . N

The DT N
H. NNP N
pylori-positive JJ N
patients NNS N
were VBD N
divided VBN N
randomly RB N
into IN N
three CD N
subgroups NNS N
: : N
patients NNS N
who WP N
received VBD N
concomitant JJ i
therapy NN i
( ( i
CT NNP i
) ) i
( ( i
rabeprazole-amoxicillin-clarithromycin-metronidazole JJ i
for IN N
14 CD N
days NNS N
; : N
n=122 CC N
) ) N
; : N
patients NNS N
who WP N
received VBD N
quadruple JJ i
therapy NN i
( ( i
QT NNP i
) ) i
( ( i
rabeprazole-tetracycline-metronidazole-colloidal JJ i
bismuth NN i
subcitrate NN i
for IN N
10 CD N
days NNS N
; : N
n=97 CC N
) ) N
; : N
and CC N
patients NNS N
who WP N
received VBD N
levofloxacin-based JJ i
therapy NN i
( ( i
LT NNP i
) ) i
( ( i
rabeprazole-amoxicillin-levofloxacin JJ i
for IN N
10 CD N
days NNS N
; : N
n=87 CC N
) ) N
. . N

Eradication NNP o
success NN o
was VBD N
detected VBN N
by IN N
a DT N
urea JJ N
breath NN N
test NN N
6 CD N
weeks NNS N
after IN N
the DT N
end NN N
of IN N
treatment NN N
. . N

RESULTS VB N
The DT N
frequency NN o
of IN N
H. NNP o
pylori FW o
infection NN o
was VBD N
significantly RB N
lower JJR N
in IN N
the DT N
filling NN i
group NN p
compared VBN N
with IN N
the DT N
nonfilling VBG p
group NN p
( ( N
53.7 CD N
and CC N
78.8 CD N
% NN N
, , N
respectively RB N
; : N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

The DT N
eradication NN o
rates NNS o
in IN N
the DT N
CT NNP i
, , i
QT NNP i
, , i
and CC i
LT NNP i
groups NNS N
were VBD N
65.5 CD N
, , N
67.0 CD N
, , N
and CC N
58.6 CD N
% NN N
, , N
respectively RB N
, , N
in IN N
the DT N
intention-to-treat NN N
( ( N
ITT NNP N
) ) N
analysis NN N
and CC N
69.6 CD N
, , N
70.7 CD N
, , N
and CC N
62.2 CD N
% NN N
, , N
respectively RB N
, , N
in IN N
the DT N
per-protocol NN N
( ( N
PP NNP N
) ) N
analysis NN N
. . N

In IN N
all DT N
of IN N
the DT N
H. NNP p
pylori-positive JJ p
patients NNS p
and CC N
separately RB N
in IN N
the DT N
CT NNP i
and CC N
LT NNP i
groups NNS N
, , N
the DT N
eradication NN o
rates NNS o
were VBD N
significantly RB N
lower JJR N
in IN N
the DT N
filling NN i
group NN N
compared VBN N
with IN N
the DT N
nonfilling VBG i
group NN N
. . N

However RB N
, , N
in IN N
the DT N
QT NNP i
group NN N
, , N
there EX N
was VBD N
no DT N
significant JJ N
difference NN N
between IN N
the DT N
patients NNS N
with IN N
and CC N
without IN N
fillings NNS N
( ( N
P=0.001 NNP N
, , N
0.003 CD N
, , N
0.012 CD N
, , N
0.14 CD N
, , N
respectively RB N
) ) N
. . N

Logistic JJ N
regression NN N
analysis NN N
showed VBD N
that IN N
the DT N
absence NN N
of IN N
amalgam NN N
filling VBG N
exerts NNS N
independent JJ N
effects NNS N
on IN N
the DT N
increased JJ N
frequency NN o
of IN o
H. NNP o
pylori FW o
infection NN o
and CC N
increased JJ o
rate NN o
of IN o
H. NNP o
pylori FW o
eradication NN o
. . o

CONCLUSION NNP N
This DT N
is VBZ N
the DT N
first JJ N
study NN N
to TO N
show VB N
a DT N
lower JJR N
frequency NN o
of IN o
H. NNP o
pylori FW o
colonization NN o
in IN N
patients NNS p
with IN p
amalgam JJ i
fillings NNS i
than IN N
without IN N
and CC N
that IN N
H. NNP o
pylori FW o
eradication NN o
rates NNS o
are VBP N
lower JJR N
in IN N
patients NNS p
with IN p
amalgam JJ i
fillings NNS i
compared VBN N
to TO N
those DT N
without IN N
. . N

-DOCSTART- -1697487- O O

Trials NNS o
and CC N
tribulations NNS o
in IN N
speech NN i
therapy NN i
. . i

-DOCSTART- -23241003- O O

Is VBZ N
chronic JJ i
sildenafil NN i
therapy NN i
safe JJ N
and CC N
clinically RB N
beneficial JJ N
in IN N
patients NNS p
with IN p
systolic JJ p
heart NN p
failure NN p
? . N
Sildenafil NNP i
is VBZ N
a DT N
selective JJ N
phosphodiesterase-5 JJ N
inhibitor NN N
and CC N
causes VBZ N
vasodilatation NN N
, , N
particularly RB N
in IN N
pulmonary JJ N
circulation NN N
. . N

Since IN N
left JJ p
heart NN p
failure NN p
may MD N
be VB N
associated VBN N
with IN N
pulmonary JJ N
hypertension NN N
out IN N
of IN N
proportion NN N
to TO N
left VB N
heart NN N
disease NN N
, , N
sildenafil NN i
may MD N
have VB N
beneficial JJ N
effect NN N
in IN N
such JJ N
patients NNS N
. . N

The DT N
present JJ N
investigation NN N
was VBD N
designed VBN N
as IN N
a DT N
12-week JJ N
, , N
single-center JJ N
, , N
randomized VBN N
, , N
double-blind JJ N
, , N
placebo-controlled JJ i
study NN N
evaluating VBG N
the DT N
effects NNS N
of IN N
sildenafil NN i
on IN N
mean JJ o
blood NN o
pressure NN o
( ( N
primary JJ N
endpoint NN N
) ) N
in IN N
patients NNS p
with IN p
left JJ p
systolic JJ p
heart NN p
failure NN p
. . p

Secondary JJ N
endpoints NNS N
included VBD N
exercise NN o
capacity NN o
assessed VBN N
by IN N
6-minute JJ o
walk NN o
test NN o
. . o

A DT N
total NN N
of IN N
106 CD p
patients NNS p
were VBD p
randomized VBN p
1:1 CD p
to TO p
sildenafil VB i
( ( p
n=53 NN p
) ) p
or CC p
placebo NN i
( ( p
n=53 JJ p
) ) p
. . p

Patients NNS p
received VBD p
sildenafil JJ i
25 CD p
mg NN p
twice RB p
a DT p
day NN p
or CC p
matching VBG p
placebo NN i
for IN p
the DT p
first JJ p
2 CD p
weeks NNS p
and CC p
50 CD p
mg NN p
3 CD p
times NNS p
a DT p
week NN p
for IN p
the DT p
remainder NN p
of IN p
the DT p
trial NN p
. . p

The DT N
placebo-corrected JJ N
effect NN N
on IN N
mean JJ o
blood NN o
pressure NN o
was VBD N
1.16 CD N
mm NN N
Hg NNP N
( ( N
95 CD N
% NN N
confidence NN N
interval NN N
, , N
-1.6 VBP N
to TO N
5.1 CD N
, , N
P NNP N
> NNP N
.05 NNP N
) ) N
, , N
demonstrating VBG N
that IN N
sildenafil NN N
did VBD N
not RB N
decrease VB N
mean JJ o
blood NN o
pressure NN o
. . o

Compared VBN N
with IN N
placebo NN N
, , N
sildenafil NN i
increased VBD N
the DT N
6-minute JJ o
walk NN o
test NN o
by IN N
a DT N
nonsignificant JJ N
treatment NN N
effect NN N
of IN N
14 CD N
m NN N
( ( N
P=.67 NNP N
) ) N
. . N

Adverse JJ o
effects NNS o
occurred VBD N
in IN N
a DT N
comparable JJ N
proportion NN N
of IN N
patients NNS N
taking VBG N
sildenafil JJ i
and CC N
placebo NN N
, , N
and CC N
none NN N
of IN N
the DT N
patients NNS N
needed VBN N
to TO N
discontinue VB N
therapy NN N
. . N

Sildenafil NNP N
is VBZ N
well RB N
tolerated VBN o
in IN N
left JJ p
heart NN p
failure NN p
patients NNS p
and CC N
does VBZ N
not RB N
decrease VB N
blood NN o
pressure NN o
. . o

It PRP N
can MD N
be VB N
safely RB N
added VBN N
to TO N
standard VB N
heart NN N
failure NN N
therapy NN N
. . N

-DOCSTART- -26398887- O O

Effect NN N
of IN N
Ezetimibe NNP i
on IN N
LDL-C NNP o
Lowering NNP o
and CC N
Atherogenic NNP o
Lipoprotein NNP o
Profiles NNP o
in IN N
Type NNP p
2 CD p
Diabetic NNP p
Patients NNPS p
Poorly NNP p
Controlled VBN p
by IN p
Statins NNP p
. . p

BACKGROUND NNP N
There EX N
exists VBZ N
a DT N
subpopulation NN N
of IN N
T2DM NNP N
in IN N
whom WP N
first-line JJ N
doses NNS N
of IN N
statin NN N
are VBP N
insufficient JJ N
for IN N
optimally RB N
reducing VBG N
LDL-C NNP o
, , N
representing VBG N
a DT N
major JJ N
risk NN N
of IN N
CVD NNP N
. . N

The DT N
RESEARCH NNP N
study NN N
focuses VBZ N
on IN N
LDL-C NNP o
reduction NN N
in IN N
this DT N
population NN N
along IN N
with IN N
modifications NNS N
of IN N
the DT N
lipid JJ N
profiles NNS N
leading VBG N
to TO N
residual JJ N
risks NNS N
. . N

METHODS NNP N
Lipid NNP o
changes NNS o
were VBD N
assessed VBN N
in IN N
a DT N
randomized JJ N
, , N
multicenter NN N
, , N
12-week JJ N
, , N
open-label JJ N
study NN N
comparing VBG N
a DT N
high-potency NN i
statin NN i
( ( i
10mg CD i
of IN i
atorvastatin NN i
or CC i
1mg CD i
of IN i
pitavastatin NN i
) ) i
plus CC i
ezetimibe JJ i
( ( N
EAT JJ N
: : N
n JJ N
= NNP N
53 CD N
) ) N
with IN N
a DT N
double JJ N
dose NN N
of IN N
statin NN i
( ( N
20mg CD N
of IN N
atorvastatin NN i
or CC N
2mg CD N
of IN N
pitavastatin NN i
) ) i
( ( N
DST NNP N
: : N
n JJ N
= NNP N
56 CD N
) ) N
in IN N
DM NNP p
subjects NNS p
who WP p
had VBD p
failed VBN p
to TO p
achieve VB p
the DT p
optimal JJ p
LDL-C NNP p
targets NNS p
. . p

Lipid JJ o
variables NNS o
were VBD N
compared VBN N
with IN N
a DT N
primary JJ N
focus NN N
on IN N
LDL-C NNP o
and CC N
with IN N
secondary JJ N
focuses NNS N
on IN N
the DT N
percentage NN N
of IN N
patients NNS N
who WP N
reached VBD N
the DT N
LDL-C NNP o
targets NNS N
and CC N
changes NNS N
in IN N
the DT N
levels NNS o
of IN o
RLP-C NNP o
( ( N
remnant VBP N
like IN N
particle NN N
cholesterol NN N
) ) N
and CC N
sd-LDL-C JJ o
, , N
two CD N
characteristic JJ N
atherogenic JJ N
risks NNS N
of IN N
DM NNP N
. . N

RESULTS VB N
The DT N
reduction NN o
of IN o
LDL-C NNP o
( ( N
% NN N
) ) N
, , N
the DT N
primary JJ N
endpoint NN N
, , N
differed VBD N
significantly RB N
between IN N
the DT N
two CD N
groups NNS N
( ( N
-24.6 NN N
in IN N
EAT NNP N
vs. FW N
-10.9 NNP N
in IN N
DST NNP N
) ) N
. . N

In IN N
the DT N
analyses NNS N
of IN N
the DT N
secondary JJ N
endpoints NNS N
, , N
EAT NNP N
treatment NN N
brought VBD N
about RB N
significantly RB N
larger JJR N
reductions NNS N
in IN N
sd-LDL-C NN o
( ( N
-20.5 JJ N
vs. FW N
-3.7 NN N
) ) N
and CC N
RLP-C NNP o
( ( N
-19.7 NNP N
vs. IN N
+5.5 NNP N
) ) N
. . N

In IN N
total JJ N
, , N
89.4 CD N
% NN N
of IN N
the DT N
patients NNS N
receiving VBG N
EAT NNP N
reached VBD N
the DT N
optimized JJ N
treatment NN N
goal NN N
compared VBN N
to TO N
51.0 CD N
% NN N
of IN N
the DT N
patients NNS N
receiving VBG N
DST NNP i
. . i

The DT N
changes NNS N
in IN N
TC NNP o
( ( N
-16.3 NNP N
vs. IN N
-6.3 NNP N
) ) N
and CC N
non-HDL-C JJ o
( ( N
-20.7 JJ N
vs. FW N
-8.3 NN N
) ) N
differed VBD N
significantly RB N
between IN N
the DT N
two CD N
groups NNS N
. . N

CONCLUSION NNP N
Ezetimibe NNP i
added VBD N
to TO N
high-potency NN N
statin NN i
( ( N
10 CD N
mg NN N
of IN N
atorvastatin NN i
or CC N
1 CD N
mg NN N
of IN N
pitavastatin NN i
) ) i
was VBD N
more RBR N
effective JJ N
than IN N
the DT N
intensified-dose JJ N
statin NN i
( ( N
20 CD N
mg NN N
of IN N
atorvastatin NN i
or CC N
2 CD N
mg NN N
of IN N
pitavastatin NN i
) ) i
treatment NN N
not RB N
only RB N
in IN N
helping VBG N
T2DM NNP N
patients NNS N
attain VBP N
more JJR N
LDL-C JJ o
reduction NN o
, , N
but CC N
also RB N
in IN N
improving VBG N
their PRP$ N
atherogenic JJ o
lipid JJ o
profiles NNS o
, , N
including VBG N
their PRP$ N
levels NNS N
of IN N
sd-LDL-C JJ o
and CC o
RLP-C. JJ o
We PRP N
thus RB N
recommend VBP N
the DT N
addition NN N
of IN N
ezetimibe NN N
to TO N
high-potency NN N
statin NN N
as IN N
a DT N
first JJ N
line NN N
strategy NN N
for IN N
T2DM NNP p
patients NNS p
with IN p
insufficient JJ p
statin NN p
response NN p
. . p

TRIAL NNP N
REGISTRATION NNP N
The DT N
UMIN NNP N
Clinical NNP N
Trials NNP N
Registry NNP N
UMIN000002593 NNP N
. . N

-DOCSTART- -19779611- O O

Cost-effectiveness NN o
of IN N
a DT N
telephone-delivered JJ i
intervention NN i
for IN i
physical JJ i
activity NN i
and CC i
diet NN i
. . i

BACKGROUND NNP N
Given NNP N
escalating VBG N
rates NNS N
of IN N
chronic JJ N
disease NN N
, , N
broad-reach NN N
and CC N
cost-effective JJ N
interventions NNS N
to TO N
increase VB N
physical JJ N
activity NN N
and CC N
improve VB N
dietary JJ N
intake NN N
are VBP N
needed VBN N
. . N

The DT N
cost-effectiveness NN o
of IN N
a DT N
Telephone NNP i
Counselling NNP i
intervention NN i
to TO i
improve VB i
physical JJ i
activity NN i
and CC i
diet NN i
, , N
targeting VBG N
adults NNS p
with IN p
established VBN p
chronic JJ p
diseases NNS p
in IN p
a DT p
low JJ p
socio-economic JJ p
area NN p
of IN p
a DT p
major JJ p
Australian JJ p
city NN p
was VBD N
examined VBN N
. . N

METHODOLOGY/PRINCIPAL NNP N
FINDINGS NNP N
A NNP N
cost-effectiveness NN N
modelling NN N
study NN N
using VBG N
data NNS N
collected VBN N
between IN N
February NNP p
2005 CD p
and CC p
November NNP p
2007 CD p
from IN N
a DT N
cluster-randomised JJ N
trial NN N
that WDT N
compared VBN N
Telephone NNP i
Counselling NNP i
with IN i
a DT i
Usual NNP i
Care NNP i
( ( i
brief JJ i
intervention NN i
) ) i
alternative NN N
. . N

Economic JJ o
outcomes NNS o
were VBD N
assessed VBN N
using VBG N
a DT N
state-transition NN N
Markov NNP N
model NN N
, , N
which WDT N
predicted VBD N
the DT N
progress NN N
of IN N
participants NNS N
through IN N
five CD N
health NN N
states NNS N
relating VBG N
to TO N
physical JJ N
activity NN N
and CC N
dietary JJ N
improvement NN N
, , N
for IN N
ten CD N
years NNS N
after IN N
recruitment NN N
. . N

The DT N
costs NNS o
and CC o
health NN o
benefits NNS o
of IN N
Telephone NNP o
Counselling NNP o
, , i
Usual NNP i
Care NNP i
and CC i
an DT i
existing VBG i
practice NN i
( ( i
Real NNP i
Control NNP i
) ) i
group NN N
were VBD N
compared VBN N
. . N

Telephone CD i
Counselling VBG i
compared VBN N
to TO N
Usual NNP i
Care NNP i
was VBD N
not RB N
cost-effective JJ o
( ( N
$ $ N
78,489 CD N
per IN N
quality NN N
adjusted VBN N
life NN N
year NN N
gained VBN N
) ) N
. . N

However RB N
, , N
the DT N
Usual NNP i
Care NNP i
group NN N
did VBD N
not RB N
represent VB N
existing VBG N
practice NN N
and CC N
is VBZ N
not RB N
a DT N
useful JJ N
comparator NN N
for IN N
decision NN N
making NN N
. . N

Comparing VBG N
Telephone CD i
Counselling VBG i
outcomes NNS N
to TO N
existing VBG i
practice NN i
( ( i
Real NNP i
Control NNP i
) ) i
, , N
the DT N
intervention NN N
was VBD N
found VBN N
to TO N
be VB N
cost-effective JJ o
( ( N
$ $ N
29,375 CD N
per IN N
quality NN N
adjusted VBN N
life NN N
year NN N
gained VBN N
) ) N
. . N

Usual JJ i
Care NNP i
( ( i
brief JJ i
intervention NN i
) ) i
compared VBN N
to TO N
existing VBG i
practice NN i
( ( i
Real NNP i
Control NNP i
) ) i
was VBD N
also RB N
cost-effective JJ o
( ( N
$ $ N
12,153 CD N
per IN N
quality NN N
adjusted VBN N
life NN N
year NN N
gained VBN N
) ) N
. . N

CONCLUSIONS/SIGNIFICANCE VB N
This DT N
modelling NN N
study NN N
shows VBZ N
that IN N
a DT N
decision NN N
to TO N
adopt VB N
a DT N
Telephone CD i
Counselling VBG i
program NN N
over IN N
existing VBG i
practice NN i
( ( i
Real NNP i
Control NNP i
) ) i
is VBZ N
likely JJ N
to TO N
be VB N
cost-effective JJ o
. . o

Choosing VBG N
the DT N
'Usual JJ i
Care NNP i
' POS i
brief NN i
intervention NN i
over IN N
existing VBG i
practice NN i
( ( i
Real NNP i
Control NNP i
) ) i
shows VBZ N
a DT N
lower JJR N
cost NN N
per IN N
quality NN N
adjusted VBN N
life NN N
year NN N
, , N
but CC N
the DT N
lack NN N
of IN N
supporting VBG N
evidence NN N
for IN N
efficacy NN N
or CC N
sustainability NN N
is VBZ N
an DT N
important JJ N
consideration NN N
for IN N
decision NN N
makers NNS N
. . N

The DT N
economics NNS N
of IN N
behavioural JJ N
approaches NNS N
to TO N
improving VBG N
health NN N
must MD N
be VB N
made VBN N
explicit JJ N
if IN N
decision NN N
makers NNS N
are VBP N
to TO N
be VB N
convinced VBN N
that IN N
allocating VBG N
resources NNS N
toward IN N
such JJ N
programs NNS N
is VBZ N
worthwhile JJ N
. . N

TRIAL NNP N
REGISTRATION NNP N
This DT N
paper NN N
uses VBZ N
data NNS N
collected VBN N
in IN N
a DT N
previous JJ N
clinical JJ N
trial NN N
registered VBD N
at IN N
the DT N
Australian JJ N
Clinical NNP N
Trials NNP N
Registry NNP N
, , N
Australian JJ N
New NNP N
Zealand NNP N
Clinical NNP N
Trials NNP N
Registry NNP N
: : N
Anzcrt.org.au NNP N
ACTRN012607000195459 NNP N
. . N

-DOCSTART- -24488157- O O

A DT N
parent-mediated JJ i
intervention NN i
that WDT N
targets VBZ N
responsive JJ N
parental JJ N
behaviors NNS N
increases VBZ N
attachment JJ o
behaviors NNS o
in IN N
children NNS p
with IN p
ASD NNP p
: : p
results NNS N
from IN N
a DT N
randomized JJ N
clinical JJ N
trial NN N
. . N

The DT N
current JJ N
study NN N
is VBZ N
a DT N
randomized JJ N
clinical JJ N
trial NN N
evaluating VBG N
the DT N
efficacy NN N
of IN N
Focused JJ i
Playtime NNP i
Intervention NNP i
( ( i
FPI NNP i
) ) i
in IN N
a DT N
sample NN N
of IN N
70 CD p
children NNS p
with IN p
Autism NNP p
Spectrum NNP p
Disorder NNP p
. . p

This DT N
parent-mediated JJ N
intervention NN N
has VBZ N
previously RB N
been VBN N
shown VBN N
to TO N
significantly RB N
increase VB N
responsive JJ N
parental JJ N
communication NN N
( ( N
Siller NNP N
et RB N
al RB N
. . N

in IN N
J NNP N
Autism NNP N
Dev NNP N
Disord NNP N
43:540-555 CD N
, , N
2013a CD N
) ) N
. . N

The DT N
current JJ N
analyses NNS N
focus VBP N
on IN N
children NNS N
's POS N
attachment NN o
related VBN o
outcomes NNS o
. . o

Results NNS N
revealed VBD N
that IN N
children NNS N
who WP N
were VBD N
randomly RB N
assigned VBN N
to TO N
FPI NNP i
showed VBD N
bigger JJR N
increases NNS N
in IN N
attachment-related JJ o
behaviors NNS o
, , N
compared VBN N
to TO N
children NNS N
assigned VBN N
to TO N
the DT N
control NN N
condition NN N
. . N

Significant JJ N
treatment NN N
effects NNS N
of IN N
FPI NNP i
were VBD N
found VBN N
for IN N
both DT N
an DT N
observational JJ N
measure NN N
of IN N
attachment-related JJ o
behaviors NNS o
elicited VBD N
during IN N
a DT N
brief JJ N
separation-reunion JJ N
episode NN N
and CC N
a DT N
questionnaire JJ N
measure NN N
evaluating VBG N
parental JJ o
perceptions NNS o
of IN o
child JJ o
attachment NN o
. . o

The DT N
theoretical JJ N
and CC N
clinical JJ N
implications NNS N
of IN N
these DT N
findings NNS N
are VBP N
discussed VBN N
. . N

-DOCSTART- -10683506- O O

Effect NN N
of IN N
sensory JJ i
stimulation NN i
( ( i
acupuncture NN i
) ) i
on IN N
sympathetic JJ N
and CC N
parasympathetic JJ N
activities NNS N
in IN N
healthy JJ p
subjects NNS p
. . p

UNLABELLED NN N
It PRP N
has VBZ N
been VBN N
postulated VBN N
that IN N
sensory JJ i
stimulation NN i
( ( i
acupuncture NN i
) ) i
affects VBZ N
the DT N
cardiovascular JJ N
system NN N
via IN N
the DT N
autonomic JJ N
nervous JJ N
system NN N
. . N

Previously RB N
, , N
skin JJ o
temperature NN o
, , o
thermography NN o
, , o
plethysmography NN o
and CC o
blood NN o
pressure NN o
changes NNS N
have VBP N
been VBN N
used VBN N
in IN N
evaluation NN N
of IN N
sympathetic JJ N
nerve NN N
activity NN N
following VBG N
acupuncture NN N
. . N

By IN N
using VBG N
power NN N
spectral JJ N
analysis NN N
, , N
the DT N
low JJ N
frequency NN N
and CC N
high JJ N
frequency NN N
components NNS N
of IN N
heart NN N
rate NN N
variability NN N
can MD N
be VB N
calculated VBN N
reflecting VBG N
the DT N
sympathetic JJ N
and CC N
parasympathetic JJ N
activity NN N
. . N

The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
investigate VB N
to TO N
what WP N
extent JJ N
acupuncture NN N
applied VBN N
into IN N
the DT N
thenar JJ N
muscle NN N
and CC N
into IN N
the DT N
cavum JJ N
concha NN N
of IN N
the DT N
ear NN N
induced VBD N
changes NNS N
in IN N
the DT N
sympathetic JJ N
and/or NN N
parasympathetic JJ N
nervous JJ N
system NN N
in IN N
healthy JJ p
subjects NNS p
. . p

MATERIALS NNP N
AND CC N
METHODS NNP N
Twelve NNP p
healthy JJ p
volunteers NNS p
, , p
six CD p
men NNS p
and CC p
six CD p
women NNS p
, , p
mean JJ p
age NN p
34.4 CD p
( ( p
range VB p
23-48 CD p
) ) p
participated VBD N
in IN N
three CD N
balanced NNS N
, , N
randomly RB N
distributed VBN N
sessions NNS N
. . N

At IN N
an DT N
individual JJ N
initial JJ N
visit NN N
the DT N
12 CD N
volunteers NNS N
were VBD N
introduced VBN N
to TO N
the DT N
needle JJ i
sensation NN i
by IN N
having VBG N
a DT N
needle JJ N
inserted VBN N
into IN N
the DT N
point NN N
LI NNP N
11 CD N
. . N

The DT N
needle JJ N
sensation NN N
was VBD N
evoked VBN N
and CC N
the DT N
subject NN N
was VBD N
trained VBN N
to TO N
identify VB N
the DT N
characteristic JJ N
needle JJ N
sensation NN N
. . N

The DT N
introduction NN N
was VBD N
followed VBN N
by IN N
three CD N
test NN N
sessions NNS N
. . N

SESSION VB N
A DT N
A NNP N
short JJ i
acupuncture NN i
needle NN i
, , N
( ( N
Seirin NNP N
no DT N
3 CD N
, , N
& CC N
emptyv NN N
; : N
0.20x15 CD N
mm NN N
) ) N
was VBD N
inserted VBN N
perpendicular JJ N
into IN N
the DT N
earpoint NN N
, , N
Lu NNP N
1 CD N
, , N
in IN N
the DT N
left JJ N
inferior JJ N
hemi-conchae NN N
. . N

SESSION NNP N
B NNP N
An DT N
acupuncture NN i
needle NN i
( ( N
Hwato NNP N
, , N
& CC N
emptyv NN N
; : N
0.30x30 CD N
mm NN N
) ) N
was VBD N
inserted VBN N
perpendicular JJ N
into IN N
the DT N
Hegu NNP N
point NN N
( ( N
LI NNP N
4 CD N
) ) N
in IN N
the DT N
middle NN N
of IN N
the DT N
right JJ N
dorsal NN N
thenar JJ N
muscle NN N
. . N

SESSION NNP N
C NNP N
An DT N
acupuncture NN i
needle NN i
( ( N
Hwato NNP N
, , N
& CC N
emptyv NN N
; : N
0.30x30 CD N
mm NN N
) ) N
was VBD N
inserted VBN N
perpendicular JJ N
superficially RB N
into IN N
the DT N
skin NN N
overlying VBG N
the DT N
Hegu NNP N
point NN N
on IN N
the DT N
left JJ N
hand NN N
. . N

Results NNP N
. . N

Stimulation NNP N
of IN N
the DT N
ear NN N
induced VBD N
a DT N
significant JJ N
increase NN N
in IN N
the DT N
parasympathetic JJ o
activity NN o
during IN N
the DT N
stimulation NN N
period NN N
of IN N
25 CD N
min NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
and CC N
during IN N
the DT N
post-stimulation JJ N
period NN N
of IN N
60 CD N
min NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

No DT N
significant JJ N
changes NNS N
were VBD N
observed VBN N
in IN N
either CC N
the DT N
sympathetic JJ o
activity NN o
, , o
blood NN o
pressure NN o
or CC o
heart NN o
rate NN o
. . o

Stimulation NN N
of IN N
the DT N
thenar NN N
muscle NN N
resulted VBD N
in IN N
a DT N
significant JJ N
increase NN N
in IN N
the DT N
sympathetic JJ o
and CC o
the DT o
parasympathetic JJ o
activity NN o
during IN N
the DT N
stimulation NN N
period NN N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
and CC N
during IN N
the DT N
post-stimulation JJ N
period NN N
( ( N
P NNP N
< NNP N
0.01 CD N
and CC N
P NNP N
< NNP N
0.001 CD N
, , N
respectively RB N
) ) N
. . N

A DT N
significant JJ N
decrease NN N
in IN N
the DT N
heart NN o
rate NN o
frequency NN o
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
at IN N
the DT N
end NN N
of IN N
the DT N
post-stimulation JJ N
period NN N
was VBD N
also RB N
demonstrated VBN N
. . N

The DT N
superficial JJ N
needle JJ N
insertion NN N
into IN N
the DT N
skin NN N
overlaying VBG N
the DT N
right JJ N
thenar NN N
muscle NN N
caused VBD N
a DT N
pronounced JJ N
balanced JJ N
increase NN N
in IN N
both CC N
the DT N
sympathetic JJ o
and CC o
parasympathetic JJ o
activity NN o
during IN N
the DT N
post NN N
stimulation NN N
period NN N
of IN N
60 CD N
min NN N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
while IN N
no DT N
changes NNS N
were VBD N
observed VBN N
during IN N
the DT N
stimulation NN N
period NN N
. . N

CONCLUSION VB N
It PRP N
is VBZ N
indicated VBN N
that IN N
sensory JJ i
stimulation NN i
( ( i
acupunctura NN i
) ) i
in IN N
healthy JJ p
persons NNS p
is VBZ N
associated VBN N
with IN N
changed JJ N
activity NN N
in IN N
the DT N
sympathetic JJ o
and CC o
parasympathetic JJ o
nervous JJ o
system NN o
depending VBG N
on IN N
site NN N
of IN N
stimulation NN N
and CC N
period NN N
of IN N
observation NN N
. . N

-DOCSTART- -393286- O O

A DT N
comparative JJ N
study NN N
of IN N
methyldopa NN i
and CC N
labetalol NN i
in IN N
the DT N
treatment NN N
of IN N
hypertension NN o
. . o

1 CD N
Twenty CD p
patients NNS p
with IN p
essential JJ p
hypertension NN p
completed VBD N
a DT N
double-blind JJ N
, , N
dose-tritrated JJ N
, , N
cross-over JJ N
comparison NN N
of IN N
methyldopa NN i
and CC i
labetalol NN i
. . i

2 CD N
Average JJ o
lying VBG o
BPs NNP o
( ( o
systolic/diastolic JJ o
) ) o
were VBD N
reduced VBN N
by IN N
28/15 CD N
mmHg NNS N
with IN N
methyldopa NN i
and CC N
by IN N
23/15 CD N
mmHg NNS N
with IN N
labetalol NN i
. . i

3 CD N
Average JJ o
standing VBG o
BPs NNP o
( ( o
systolic/diastolic JJ o
) ) o
were VBD N
reduced VBN N
by IN N
29/14 CD N
mmHg NNS N
with IN N
methyldopa NN i
and CC N
by IN N
29/15 CD N
mmHg NNS N
with IN N
labetalol NN i
. . i

4 CD N
Both DT N
lying NN o
and CC o
standing VBG o
heart NN o
rates NNS o
were VBD N
reduced VBN N
with IN N
labetalol NN i
. . i

5 CD N
It PRP N
is VBZ N
concluded VBN N
that IN N
the DT N
antihypertensive JJ o
properties NNS o
of IN N
labetalol NN i
and CC N
methyldopa NN i
are VBP N
similar JJ N
but CC N
that IN N
larger JJR N
patient NN N
populations NNS N
are VBP N
needed VBN N
to TO N
study VB N
the DT N
relative JJ N
incidence NN N
of IN N
subjective JJ N
adverse JJ N
effects NNS N
. . N

-DOCSTART- -1741218- O O

Acute NNP i
prolactin NN i
and CC i
oxytocin JJ i
responses NNS N
and CC N
milk NN o
yield NN o
to TO N
infant VB N
suckling NN N
and CC N
artificial JJ o
methods NNS o
of IN o
expression NN o
in IN N
lactating VBG p
women NNS p
. . p

Breast-feeding NN N
is VBZ N
today NN N
the DT N
major JJ N
form NN N
of IN N
infant JJ N
nutrition NN N
in IN N
the DT N
immediate JJ N
postpartum NN N
period NN N
. . N

Despite IN N
this DT N
, , N
recent JJ N
trends NNS N
in IN N
modern JJ N
life-styles NNS N
have VBP N
raised VBN N
obstacles NNS N
to TO N
successful JJ N
lactation NN N
. . N

These DT N
include VBP N
infant NN N
illness NN N
and CC N
maternal JJ N
responsibilities NNS N
outside IN N
the DT N
home NN N
, , N
both DT N
requiring VBG N
separation NN N
from IN N
the DT N
mother NN N
. . N

While IN N
the DT N
hormonal JJ N
dynamics NNS N
of IN N
infant JJ N
suckling NN N
are VBP N
understood JJ N
, , N
little JJ N
is VBZ N
known VBN N
about IN N
the DT N
effects NNS N
of IN N
artificial JJ N
methods NNS N
of IN N
milk NN o
expression NN o
. . o

A DT N
variety NN N
of IN N
breast NN N
pumps NNS N
exist VBP N
in IN N
the DT N
current JJ N
US NNP N
market NN N
which WDT N
vary VBP N
considerably RB N
in IN N
price NN N
and CC N
effectiveness NN N
. . N

To TO N
understand VB N
better JJR N
the DT N
ability NN N
of IN N
these DT N
pumps NNS N
to TO N
assist VB N
women NNS N
in IN N
the DT N
maintenance NN N
of IN N
lactation NN N
, , N
the DT N
current JJ N
study NN N
was VBD N
undertaken VBN N
to TO N
evaluate VB N
their PRP$ N
effects NNS N
on IN N
milk NN o
yield NN o
and CC o
prolactin NN o
and CC o
oxytocin NN o
release NN o
when WRB N
compared VBN N
to TO N
natural JJ N
infant NN N
suckling NN N
. . N

Twenty-three JJ p
women NNS p
who WP p
were VBD p
exclusively RB p
breast-feeding VBG p
their PRP$ p
infants NNS p
were VBD p
randomly RB p
assigned VBN p
to TO N
serially RB N
use VB N
several JJ N
pumping VBG N
methods NNS N
, , N
as RB N
well RB N
as IN N
infant NN N
suckling NN N
, , N
with IN N
blood NN N
being VBG N
taken VBN N
at IN N
10-minute JJ N
intervals NNS N
to TO N
determine VB N
the DT N
hormonal JJ N
responses NNS N
. . N

The DT N
results NNS N
reveal VBP N
variability NN N
in IN N
the DT N
prolactin NN o
responses VBZ o
to TO N
the DT N
artificial JJ N
pumping NN N
methods NNS N
, , N
with IN N
the DT N
greatest JJS N
responses NNS N
found VBN N
with IN N
an DT N
electric JJ N
pulsatile NN N
pump NN N
; : N
these DT N
responses NNS N
compare VBP N
favorably RB N
with IN N
those DT N
of IN N
natural JJ N
infant NN N
suckling NN N
. . N

Other JJ N
methods NNS N
were VBD N
less RBR N
successful JJ N
in IN N
causing VBG N
prolactin JJ o
elevations NNS o
. . o

No DT N
differences NNS N
were VBD N
seen VBN N
among IN N
the DT N
methods NNS N
in IN N
the DT N
oxytocin JJ o
response NN o
. . o

The DT N
results NNS N
of IN N
this DT N
study NN N
demonstrate VB N
striking JJ N
differences NNS N
in IN N
the DT N
ability NN N
of IN N
breast-pumping JJ N
methods NNS N
to TO N
produce VB N
an DT N
acute NN o
and CC o
sustained VBD o
prolactin NNS o
rise NN o
in IN N
breast-feeding JJ p
mothers NNS p
. . p

The DT N
large JJ N
discrepancies NNS N
found VBD N
suggest VBP N
the DT N
need NN N
for IN N
further JJ N
studies NNS N
in IN N
to TO N
enable JJ N
women NNS N
and CC N
health NN N
care NN N
providers NNS N
to TO N
choose VB N
the DT N
most RBS N
appropriate JJ N
method NN N
for IN N
milk NN N
expression NN N
. . N

( ( N
ABSTRACT NNP N
TRUNCATED NNP N
AT NNP N
250 CD N
WORDS NNP N
) ) N
-DOCSTART- -11300174- O O

Effectiveness NN o
of IN N
the DT N
school NN i
dental JJ i
screening VBG i
programme NN i
in IN N
stimulating VBG o
dental JJ o
attendance NN o
for IN N
children NNS p
in IN p
need NN p
of IN p
treatment NN p
in IN p
Northern NNP p
Ireland NNP p
. . p

UNLABELLED IN N
The DT N
school NN i
dental JJ i
screening NN i
programme NN i
has VBZ N
been VBN N
in IN N
existence NN N
from IN N
the DT N
beginning NN N
of IN N
the DT N
20th JJ N
century NN N
yet RB N
its PRP$ N
value NN N
in IN N
encouraging JJ N
attendance NN N
among IN N
children NNS p
with IN p
a DT p
dental JJ p
health NN p
need NN p
is VBZ N
not RB N
fully RB N
established VBN N
. . N

OBJECTIVE NNP N
To TO N
evaluate VB N
the DT N
effectiveness NN N
of IN N
school NN i
dental JJ i
screening NN i
in IN N
promoting VBG N
dental JJ o
attendance NN o
among IN N
children NNS p
with IN p
a DT p
treatment NN p
need NN p
and CC N
to TO N
examine VB N
the DT N
relative JJ N
importance NN N
of IN N
screening NN N
, , N
social JJ N
class NN N
and CC N
other JJ N
factors NNS N
in IN N
dental JJ o
attendance NN o
. . o

METHODS NNP N
Sixty-four JJ p
participating NN p
schools NNS p
were VBD N
assigned VBN N
to TO N
study VB N
and CC N
control VB N
groups NNS N
using VBG N
a DT N
stratified JJ N
, , N
blocked JJ N
randomisation NN N
technique NN N
. . N

The DT N
study NN N
group NN N
children NNS N
received VBD N
the DT N
standard JJ i
school NN i
dental JJ i
screening NN i
and CC N
the DT N
dental JJ o
attendance NN o
of IN N
those DT N
with IN N
a DT N
positive JJ N
screening NN o
result NN o
was VBD N
assessed VBN N
after IN N
2 CD N
months NNS N
by IN N
means NNS N
of IN N
a DT N
questionnaire NN N
issued VBN N
to TO N
the DT N
children NNS N
's POS N
parents NNS N
. . N

The DT N
control NN N
group NN i
children NNS i
were VBD i
not RB i
, , i
at IN i
this DT i
stage NN i
, , i
screened VBD i
, , N
yet CC N
their PRP$ N
parents NNS N
received VBD N
the DT N
same JJ i
questionnaire NN i
assessing VBG i
dental JJ o
attendance NN o
over IN i
the DT i
2-month JJ i
period NN i
. . i

However RB N
, , N
only RB N
questionnaires VBZ N
from IN N
control NN i
group NN N
children NNS N
who WP N
had VBD N
a DT N
positive JJ N
result NN N
at IN N
a DT N
subsequent JJ N
screening NN N
were VBD N
retained VBN N
for IN N
analysis NN N
. . N

RESULTS VB N
A DT p
total NN p
of IN p
2,321 CD p
children NNS p
were VBD p
screened VBN p
, , p
with IN p
980 CD p
having VBG p
a DT p
positive JJ p
result NN p
. . p

The DT N
mean JJ N
dmft NN N
of IN N
those DT N
screening VBG N
positive JJ N
was VBD N
4.85 CD N
. . N

In IN N
all DT N
, , N
664 CD p
completed VBN p
questionnaires NNS p
were VBD N
returned VBN N
, , N
giving VBG N
a DT N
response NN N
rate NN N
of IN N
67.8 CD N
% NN N
. . N

Dental JJ o
attendance NN o
was VBD N
reported VBN N
among IN N
45.5 CD N
% NN N
of IN N
the DT N
study NN N
group NN N
( ( N
n=352 NN N
) ) N
in IN N
the DT N
2 CD N
months NNS N
following VBG N
screening NN N
. . N

In IN N
the DT N
same JJ N
period NN N
, , N
27.6 CD N
% NN N
of IN N
the DT N
control NN N
group NN N
( ( N
n=312 RB N
) ) N
claimed VBD N
attendance NN N
. . N

The DT N
effect NN N
was VBD N
found VBN N
to TO N
be VB N
significant JJ N
among IN N
the DT N
high JJ N
employed VBN N
group NN N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
and CC N
the DT N
unemployed JJ N
group NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

CONCLUSION NNP N
School NNP N
dental JJ N
screening NN N
was VBD N
capable JJ N
of IN N
stimulating VBG N
dental JJ o
attendance NN o
. . o

The DT N
strong JJ N
effect NN N
among IN N
the DT N
lowest JJS N
socio-economic JJ N
group NN N
shows VBZ N
that IN N
school NN N
dental JJ N
screening NN N
may MD N
be VB N
used VBN N
to TO N
decrease VB N
dental JJ o
health NN o
inequalities NNS o
. . o

-DOCSTART- -21830957- O O

Rivaroxaban NNP i
versus NN i
warfarin NN i
in IN N
nonvalvular JJ p
atrial JJ p
fibrillation NN p
. . p

BACKGROUND IN N
The DT N
use NN N
of IN N
warfarin NN i
reduces VBZ N
the DT N
rate NN o
of IN o
ischemic JJ o
stroke NN o
in IN N
patients NNS p
with IN p
atrial JJ p
fibrillation NN p
but CC N
requires VBZ N
frequent JJ N
monitoring NN N
and CC N
dose JJ N
adjustment NN N
. . N

Rivaroxaban NNP i
, , N
an DT N
oral JJ N
factor NN N
Xa NNP N
inhibitor NN N
, , N
may MD N
provide VB N
more JJR N
consistent JJ N
and CC N
predictable JJ N
anticoagulation NN N
than IN N
warfarin NN i
. . i

METHODS NNP N
In IN N
a DT N
double-blind JJ p
trial NN p
, , p
we PRP p
randomly VBP p
assigned VBD p
14,264 CD p
patients NNS p
with IN p
nonvalvular JJ p
atrial JJ p
fibrillation NN p
who WP p
were VBD p
at IN p
increased VBN p
risk NN p
for IN p
stroke NN p
to TO N
receive VB N
either DT N
rivaroxaban NN i
( ( N
at IN N
a DT N
daily JJ N
dose NN N
of IN N
20 CD N
mg NN N
) ) N
or CC N
dose-adjusted JJ N
warfarin NN i
. . i

The DT N
per-protocol JJ N
, , N
as-treated JJ N
primary JJ N
analysis NN N
was VBD N
designed VBN N
to TO N
determine VB N
whether IN N
rivaroxaban NN i
was VBD N
noninferior JJ N
to TO N
warfarin VB i
for IN N
the DT N
primary JJ N
end NN N
point NN N
of IN N
stroke NN o
or CC o
systemic JJ o
embolism NN o
. . o

RESULTS NNP N
In IN N
the DT N
primary JJ N
analysis NN N
, , N
the DT N
primary JJ N
end NN N
point NN N
occurred VBD N
in IN N
188 CD N
patients NNS N
in IN N
the DT N
rivaroxaban NN i
group NN N
( ( N
1.7 CD N
% NN N
per IN N
year NN N
) ) N
and CC N
in IN N
241 CD N
in IN N
the DT N
warfarin NN i
group NN N
( ( N
2.2 CD N
% NN N
per IN N
year NN N
) ) N
( ( N
hazard JJ N
ratio NN N
in IN N
the DT N
rivaroxaban NN i
group NN N
, , N
0.79 CD N
; : N
95 CD N
% NN N
confidence NN N
interval NN N
[ NNP N
CI NNP N
] NNP N
, , N
0.66 CD N
to TO N
0.96 CD N
; : N
P NNP N
< VBZ N
0.001 CD N
for IN N
noninferiority NN N
) ) N
. . N

In IN N
the DT N
intention-to-treat JJ N
analysis NN N
, , N
the DT N
primary JJ N
end NN N
point NN N
occurred VBD N
in IN N
269 CD N
patients NNS N
in IN N
the DT N
rivaroxaban NN i
group NN N
( ( N
2.1 CD N
% NN N
per IN N
year NN N
) ) N
and CC N
in IN N
306 CD N
patients NNS N
in IN N
the DT N
warfarin NN i
group NN N
( ( N
2.4 CD N
% NN N
per IN N
year NN N
) ) N
( ( N
hazard JJ N
ratio NN N
, , N
0.88 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
0.74 CD N
to TO N
1.03 CD N
; : N
P NNP N
< VBZ N
0.001 CD N
for IN N
noninferiority NN N
; : N
P=0.12 NNP N
for IN N
superiority NN N
) ) N
. . N

Major JJ o
and CC o
nonmajor JJ o
clinically RB o
relevant JJ o
bleeding NN o
occurred VBD N
in IN N
1475 CD N
patients NNS N
in IN N
the DT N
rivaroxaban NN i
group NN N
( ( N
14.9 CD N
% NN N
per IN N
year NN N
) ) N
and CC N
in IN N
1449 CD N
in IN N
the DT N
warfarin NN i
group NN N
( ( N
14.5 CD N
% NN N
per IN N
year NN N
) ) N
( ( N
hazard JJ N
ratio NN N
, , N
1.03 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
0.96 CD N
to TO N
1.11 CD N
; : N
P=0.44 NNP N
) ) N
, , N
with IN N
significant JJ N
reductions NNS N
in IN N
intracranial JJ o
hemorrhage NN o
( ( N
0.5 CD N
% NN N
vs. FW N
0.7 CD N
% NN N
, , N
P=0.02 NNP N
) ) N
and CC N
fatal JJ o
bleeding NN o
( ( N
0.2 CD N
% NN N
vs. FW N
0.5 CD N
% NN N
, , N
P=0.003 NNP N
) ) N
in IN N
the DT N
rivaroxaban NN i
group NN N
. . N

CONCLUSIONS NNP N
In IN N
patients NNS N
with IN N
atrial JJ N
fibrillation NN N
, , N
rivaroxaban NN i
was VBD N
noninferior JJ N
to TO N
warfarin VB N
for IN N
the DT N
prevention NN N
of IN N
stroke NN N
or CC N
systemic JJ N
embolism NN N
. . N

There EX N
was VBD N
no DT N
significant JJ N
between-group JJ N
difference NN N
in IN N
the DT N
risk NN N
of IN N
major JJ o
bleeding NN o
, , N
although IN N
intracranial JJ o
and CC o
fatal JJ o
bleeding NN o
occurred VBD N
less RBR N
frequently RB N
in IN N
the DT N
rivaroxaban NN i
group NN N
. . N

( ( N
Funded VBN N
by IN N
Johnson NNP N
& CC N
Johnson NNP N
and CC N
Bayer NNP N
; : N
ROCKET NNP N
AF NNP N
ClinicalTrials.gov NNP N
number NN N
, , N
NCT00403767 NNP N
. . N

) ) N
. . N

-DOCSTART- -19207781- O O

Esophageal JJ N
damage NN N
during IN N
radiofrequency NN i
ablation NN i
of IN N
atrial JJ N
fibrillation NN N
: : N
impact NN N
of IN N
energy NN N
settings NNS N
, , N
lesion NN N
sets NNS N
, , N
and CC N
esophageal JJ N
visualization NN N
. . N

INTRODUCTION NNP N
Atrioesophageal NNP N
fistula NN N
is VBZ N
an DT N
uncommon JJ N
but CC N
often RB N
lethal JJ N
complication NN N
of IN N
atrial JJ p
fibrillation NN p
( ( p
AF NNP p
) ) p
ablation NN p
. . p

The DT N
purpose NN N
of IN N
our PRP$ N
study NN N
was VBD N
to TO N
prospectively RB N
investigate VB N
the DT N
incidence NN N
of IN N
esophageal JJ o
ulcerations NNS o
( ( o
ESUL NNP o
) ) o
as RB N
well RB N
as IN N
the DT N
impact NN N
of IN N
energy NN N
settings NNS N
, , N
radiofrequency NN N
lesion NN N
sets NNS N
, , N
and CC N
direct JJ N
visualization NN N
of IN N
the DT N
esophagus NN N
on IN N
esophageal NN N
wall JJ N
injury NN N
. . N

METHODS NNP N
AND CC N
RESULTS NNP N
One CD p
hundred VBD p
seventy-five JJ p
patients NNS p
, , p
57.1 CD p
% NN p
paroxysmal JJ p
AF NNP p
, , p
78.5 CD p
% NN p
male NN p
, , p
underwent JJ p
AF NNP i
ablation NN i
and CC i
esophagoscopy $ i
24 CD i
hours NNS i
thereafter RB i
. . i

We PRP N
performed VBD N
a DT N
2:1:1-randomization JJ N
as IN N
follows VBZ N
: : N
CONTROL NNP N
GROUP NNP N
Ablation NNP i
without IN i
visualization NN i
of IN i
the DT i
esophagus NN i
using VBG N
25 CD N
Watt NNP N
( ( N
W NNP N
) ) N
power NN N
limit NN N
on IN N
the DT N
posterior NN N
wall NN N
, , N
n JJ N
= NN N
70 CD N
. . N

Visualization NN i
and CC i
15 CD i
W NNP i
maximum NN i
: : i
Ablation NN i
guided VBN i
by IN i
barium NN i
visualization NN i
of IN N
the DT N
esophageal JJ N
course NN N
using VBG N
a DT N
limit NN N
of IN N
15 CD N
W NNP N
, , N
n JJ N
= NN N
35 CD N
. . N

Visualization NN i
and CC i
25 CD i
W NNP i
short JJ i
burns NNS i
: : i
Ablation NN i
guided VBN i
by IN i
barium NN i
visualization NN i
using VBG i
25 CD i
W NNP i
and CC i
short JJ i
burns NNS i
( ( N
max NN N
. . N

5 CD N
sec NN N
) ) N
, , N
n JJ N
= NN N
35 CD N
. . N

Patients NNS N
performed VBN N
under IN N
general JJ N
anesthesia NN N
( ( N
n JJ N
= NNP N
35 CD N
) ) N
were VBD N
separated VBN N
as IN N
a DT N
nasogastric JJ N
tube NN N
for IN N
visualization NN N
of IN N
the DT N
esophagus NN N
was VBD N
used VBN N
. . N

In IN N
total JJ N
, , N
we PRP N
found VBD N
2.9 CD N
% NN N
of IN N
patients NNS N
( ( N
5/175 CD N
) ) N
presenting NN N
ESUL NNP o
. . o

Parameters NNS N
discriminating VBG N
the DT N
development NN N
of IN N
ESUL NNP o
in IN N
a DT N
specific JJ N
patient NN N
were VBD N
type NN N
of IN N
AF NNP o
, , o
maximum JJ o
energy NN o
delivered VBN o
, , o
usage NN o
of IN o
a DT o
nasogastric JJ o
tube NN o
, , o
and CC o
additional JJ o
left NN o
atrial JJ o
lines NNS o
. . o

Visualization NN N
of IN N
the DT N
esophageal JJ N
course NN N
by IN N
barium NN N
contrast NN N
was VBD N
not RB N
able JJ N
to TO N
prevent VB N
ESUL NNP o
. . o

CONCLUSION NNP N
ESUL NNP N
is VBZ N
a DT N
rare JJ N
finding NN N
when WRB N
using VBG N
a DT N
reasonable JJ N
energy NN N
maximum NN N
of IN N
25 CD N
W NNP N
with IN N
open-irrigated JJ N
tip NN N
catheters NNS N
at IN N
the DT N
posterior JJ N
wall NN N
. . N

Lower NNP N
energy NN N
settings NNS N
may MD N
increase VB N
safety NN N
without IN N
losing VBG N
efficacy NN N
. . N

Additional JJ N
linear JJ N
radiofrequency NN N
lesions NNS N
increase VBP N
the DT N
risk NN N
of IN N
ESUL NNP N
development NN N
. . N

-DOCSTART- -22640463- O O

Impact NN N
on IN N
learning NN o
of IN N
an DT N
e-learning JJ i
module NN i
on IN N
leukaemia NN N
: : N
a DT N
randomised JJ N
controlled VBN N
trial NN N
. . N

BACKGROUND NNP N
e-learning JJ i
resources NNS N
may MD N
be VB N
beneficial JJ N
for IN N
complex JJ N
or CC N
conceptually RB N
difficult JJ N
topics NNS N
. . N

Leukaemia NNP N
is VBZ N
one CD N
such JJ N
topic NN N
, , N
yet RB N
there EX N
are VBP N
no DT N
reports NNS N
on IN N
the DT N
efficacy NN N
of IN N
e-learning NN N
for IN N
leukaemia NN N
. . N

This DT N
study NN N
compared VBN N
the DT N
learning VBG N
impact NN N
on IN p
senior JJ p
medical JJ p
students NNS p
of IN N
a DT N
purpose-built JJ N
e-learning JJ i
module NN i
on IN N
leukaemia NN N
, , N
compared VBN N
with IN N
existing VBG i
online JJ i
resources NNS i
. . i

METHODS VB N
A DT N
randomised JJ N
controlled JJ N
trial NN N
was VBD N
performed VBN N
utilising JJ N
volunteer NN p
senior JJ p
medical JJ p
students NNS p
. . p

Participants NNS N
were VBD N
randomly RB N
allocated VBN N
to TO N
Study NNP N
and CC N
Control NNP N
groups NNS N
. . N

Following VBG N
a DT N
pre-test JJ N
on IN N
leukaemia NN N
administered VBN N
to TO N
both DT N
groups NNS N
, , N
the DT N
Study NNP N
group NN N
was VBD N
provided VBN N
with IN N
access NN N
to TO N
the DT N
new JJ i
e-learning JJ i
module NN i
, , N
while IN N
the DT N
Control NNP N
group NN N
was VBD N
directed VBN i
to TO i
existing VBG i
online JJ i
resources NNS i
. . i

A DT N
post-test JJ o
and CC o
an DT o
evaluation NN o
questionnaire NN o
were VBD N
administered VBN N
to TO N
both DT N
groups NNS N
at IN N
the DT N
end NN N
of IN N
the DT N
trial NN N
period NN N
. . N

RESULTS NNP N
Study NNP N
and CC N
Control NNP N
groups NNS N
were VBD N
equivalent JJ N
in IN N
gender NN N
distribution NN N
, , N
mean JJ N
academic JJ N
ability NN N
, , N
pre-test JJ N
performance NN N
and CC N
time NN N
studying VBG N
leukaemia NN N
during IN N
the DT N
trial NN N
. . N

The DT N
Study NNP N
group NN N
performed VBD N
significantly RB N
better RBR N
than IN N
the DT N
Control NNP N
group NN N
in IN N
the DT N
post-test NN o
, , N
in IN N
which WDT N
the DT N
group NN N
to TO N
which WDT N
the DT N
students NNS N
had VBD N
been VBN N
allocated VBN N
was VBD N
the DT N
only JJ N
significant JJ N
predictor NN N
of IN N
performance NN N
. . N

The DT N
Study NNP N
group NN N
's POS N
evaluation NN N
of IN N
the DT N
module NN N
was VBD N
overwhelmingly RB N
positive JJ N
. . N

CONCLUSIONS VB N
A DT N
targeted JJ N
e-learning JJ i
module NN i
on IN N
leukaemia NN N
had VBD N
a DT N
significant JJ N
effect NN N
on IN N
learning VBG o
in IN N
this DT N
cohort NN N
, , N
compared VBN N
with IN N
existing VBG N
online JJ N
resources NNS N
. . N

We PRP N
believe VBP N
that IN N
the DT N
interactivity NN N
, , N
dialogic JJ N
feedback NN N
and CC N
integration NN N
with IN N
the DT N
curriculum NN N
offered VBN N
by IN N
the DT N
e-learning JJ i
module NN i
contributed VBD N
to TO N
its PRP$ N
impact NN N
. . N

This DT N
has VBZ N
implications NNS N
for IN N
e-learning JJ i
design NN N
in IN N
medicine NN N
and CC N
other JJ N
disciplines NNS N
. . N

-DOCSTART- -9084194- O O

Doxymycine-cyanoacrylate NNP i
treatment NN N
of IN N
recurrent NN N
aphthous JJ N
ulcers NNS N
. . N

OBJECTIVE VB N
This DT N
study NN N
addressed VBD N
the DT N
efficacy NN N
of IN N
singularly RB N
applied VBN N
topical JJ N
doxymycine NN i
in IN N
the DT N
pain NN o
relief NN o
treatment NN N
of IN N
recurrent NN N
aphthous JJ N
stomatitis NN N
. . N

STUDY NNP N
DESIGN NNP N
Thirty-one CD p
patients NNS p
with IN p
recurrent JJ p
aphthous JJ p
lesions NNS p
were VBD N
examined VBN N
and CC N
divided VBN N
randomly RB N
in IN N
two CD N
groups NNS N
. . N

Experimental JJ i
group NN i
( ( i
n JJ i
= NNP i
15 CD i
) ) i
received VBD i
a DT i
topical JJ i
application NN i
of IN i
doxymycine NN i
and CC i
controls NNS i
( ( i
n JJ i
= NNP i
16 CD i
) ) i
received VBD i
calcii JJ i
gluconase NN i
in IN i
the DT i
same JJ i
manner NN i
. . i

Medications NNS i
were VBD i
covered VBN i
by IN i
isobutyl JJ i
cyanoacrylate NN i
( ( i
Iso-Dent JJ i
) ) i
. . i

Application NN N
was VBD N
made VBN N
only RB N
once RB N
during IN N
the DT N
recurrent NN N
aphthous JJ N
ulcer JJ N
episode NN N
. . N

RESULTS JJ N
Patients NNS p
recorded VBD p
their PRP$ p
pain NN o
level NN o
on IN p
a DT p
visual JJ p
analog NN p
scale NN p
for IN p
10 CD p
days NNS p
during IN p
healing VBG p
. . p

Pain VB o
decreased VBD N
more RBR N
rapidly RB N
in IN N
the DT N
experimental JJ N
group NN N
, , N
and CC N
a DT N
statistically RB N
significant JJ N
difference NN N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
in IN N
the DT N
pain NN o
intensity NN o
was VBD N
found VBN N
from IN N
the DT N
second JJ N
to TO N
the DT N
seventh JJ N
day NN N
after IN N
application NN N
of IN N
doxymycine NN i
. . i

CONCLUSIONS NNP N
In IN N
recurrent NN N
aphthous JJ N
ulcers NNS N
, , N
singular JJ N
treatment NN N
of IN N
topical JJ N
doxymycine-cyanoacrylate JJ i
relieves VBZ N
the DT N
pain NN o
intensity NN o
remarkably RB N
for IN N
6 CD N
days NNS N
after IN N
a DT N
1 CD N
day NN N
latency NN N
period NN N
. . N

Topical JJ N
doxymycine NN i
treatment NN N
further JJ N
exerts VBZ N
potential JJ N
to TO N
directly RB N
prevent VB N
tissue NN N
destruction NN N
and CC N
to TO N
indirectly RB N
suppress VB N
host NN N
inflammatory JJ N
reaction NN N
. . N

-DOCSTART- -2181434- O O

Using VBG N
a DT N
population-based JJ p
cancer NN p
registry NN p
for IN N
recruitment NN N
in IN N
a DT N
pilot NN N
cancer NN N
control NN N
study NN N
. . N

Cancer NNP N
control NN N
investigations NNS N
in IN N
the DT N
United NNP p
States NNPS p
rarely RB N
use VBP N
population-based JJ p
registries NNS p
as IN N
a DT N
resource NN N
for IN N
recruitment NN N
. . N

A DT N
placebo-controlled JJ i
, , N
double-blind JJ N
, , N
randomized JJ N
toxicity NN N
trial NN N
of IN N
tamoxifen NN i
was VBD N
conducted VBN N
among IN N
postmenopausal JJ p
women NNS p
with IN p
node JJ p
negative JJ p
breast NN p
cancer NN p
. . p

To TO N
achieve VB N
the DT N
accrual JJ N
goal NN N
of IN N
140 CD p
subjects NNS p
in IN p
this DT p
single JJ p
institution NN p
study NN p
, , p
the DT p
Wisconsin NNP o
Cancer NNP o
Reporting NNP o
System NNP o
( ( o
WCRS NNP o
) ) o
, , p
a DT p
population-based JJ p
cancer NN p
registry NN p
, , p
was VBD p
used VBN p
. . p

Registry VB N
information NN N
from IN N
the DT N
last JJ N
9 CD N
years NNS N
was VBD N
used VBN N
to TO N
identify VB N
3,585 CD p
women NNS p
who WP p
met VBD p
the DT p
study NN p
criteria NNS p
with IN p
respect NN p
to TO p
age NN p
, , p
stage NN p
, , p
and CC p
previous JJ p
therapy NN p
. . p

The DT N
vital JJ N
status NN N
of IN N
identified JJ N
women NNS p
was VBD N
confirmed VBN N
using VBG N
Wisconsin NNP N
state NN N
death NN N
records NNS N
. . N

For IN N
identified JJ N
cases NNS N
, , N
rosters NNS N
were VBD N
prepared JJ N
and CC N
sent VBD N
to TO N
the DT N
physician NN N
with IN N
a DT N
cover NN N
letter NN N
and CC N
study NN N
description NN N
. . N

The DT N
physicians NNS N
were VBD N
asked VBN N
to TO N
update VB N
the DT N
list NN N
and CC N
, , N
if IN N
appropriate JJ N
, , N
to TO N
sign VB N
letters NNS N
to TO N
potentially RB N
eligible JJ p
and CC p
interested JJ p
women NNS p
. . p

Thirty-eight JJ N
percent NN N
of IN N
women NNS N
receiving VBG N
a DT N
letter NN N
and CC N
study NN N
information NN N
from IN N
their PRP$ N
physicians NNS N
contacted VBN N
the DT N
study NN N
office NN N
about IN N
participation NN N
. . N

Eighteen JJ N
months NNS N
from IN N
its PRP$ N
initiation NN N
, , N
140 CD p
women NNS p
were VBD p
entered VBN p
on IN p
study NN p
. . p

This DT N
successful JJ N
use NN N
of IN N
a DT N
population-based JJ o
cancer NN o
registry NN o
illustrates VBZ N
an DT N
efficient JJ o
recruitment NN o
method NN o
which WDT N
could MD N
be VB N
modified VBN N
for IN N
other JJ N
cancer NN N
control/chemoprevention NN N
trials NNS N
. . N

-DOCSTART- -16293958- O O

Efficacy NN o
of IN N
nebulized JJ i
flunisolide NN i
combined VBN i
with IN i
salbutamol NN i
and CC i
ipratropium NN i
bromide NN i
in IN N
stable JJ p
patients NNS p
with IN p
moderate-to-severe JJ p
chronic JJ p
obstructive JJ p
pulmonary JJ p
disease NN p
. . p

BACKGROUND IN N
The DT N
efficacy NN o
of IN N
nebulized JJ N
corticosteroids NNS i
in IN N
the DT N
prevention NN N
of IN N
exacerbation NN N
of IN N
chronic JJ p
obstructive JJ p
pulmonary JJ p
disease NN p
( ( p
COPD NNP p
) ) p
has VBZ N
been VBN N
poorly RB N
studied VBN N
. . N

OBJECTIVE UH N
To TO N
evaluate VB N
the DT N
efficacy NN o
and CC N
tolerability NN o
of IN N
nebulized JJ i
flunisolide NN i
( ( N
1 CD N
mg NN N
) ) N
+ VBZ i
salbutamol/ipratropium JJ i
bromide NN i
( ( N
1,875/375 CD N
microg NN N
) ) N
b.i.d NN N
. . N

in IN N
comparison NN N
with IN N
placebo NN i
+ NNP i
salbutamol/ipratropium NN i
bromide NN i
. . i

METHODS NNP N
This DT N
was VBD N
a DT N
randomized JJ N
, , N
parallel-group JJ N
, , N
double-blind JJ N
study NN N
on IN N
114 CD p
patients NNS p
with IN p
COPD NNP p
of IN p
moderate-to-severe JJ p
degree NN p
. . p

The DT N
main JJ N
outcome NN N
was VBD N
the DT N
frequency NN o
of IN o
severe JJ o
exacerbations NNS o
over IN N
a DT N
6-month JJ N
period NN N
. . N

Before IN N
and CC N
after IN N
treatment NN N
, , N
respiratory NN o
symptoms NNS o
, , o
forced VBD o
expiratory JJ o
volume NN o
in IN o
1 CD o
s NN o
( ( o
FEV NNP o
( ( o
1 CD o
) ) o
) ) o
, , o
shuttle JJ o
walking VBG o
test NN o
distance NN o
and CC o
St. NNP o
George NNP o
's POS o
Respiratory NNP o
Questionnaire NNP o
scores NNS o
were VBD N
evaluated VBN N
. . N

RESULTS VB N
The DT N
total JJ o
number NN o
of IN o
exacerbations NNS o
was VBD N
slightly RB N
lower JJR N
in IN N
the DT N
flunisolide NN i
group NN N
compared VBN N
to TO N
the DT N
placebo NN i
group NN N
( ( N
19 CD N
vs. FW N
34 CD N
, , N
p NN N
= NNP N
0.054 CD N
) ) N
; : N
the DT N
number NN o
of IN o
patients NNS o
experiencing VBG o
at IN o
least JJS o
one CD o
exacerbation NN o
during IN o
the DT o
study NN o
was VBD N
also RB N
decreased VBN N
( ( N
16 CD N
vs. FW N
26 CD N
, , N
p NN N
= NNP N
0.059 CD N
) ) N
. . N

In IN N
particular JJ N
, , N
type JJ o
3 CD o
Anthonisens NNP o
's POS o
exacerbations NNS o
were VBD N
significantly RB N
reduced VBN N
by IN N
flunisolide NN i
( ( N
p JJ N
= NNP N
0.044 CD N
) ) N
. . N

In IN N
the DT N
placebo NN i
group NN N
, , N
scores NNS N
were VBD N
higher JJR N
than IN N
in IN N
the DT N
flunisolide JJ i
group NN N
but CC N
nonsignificant NN N
for IN N
dyspnea NN o
, , o
cough NN o
, , o
sputum NN o
amount NN o
and CC o
purulence NN o
. . o

FEV NNP o
( ( o
1 CD o
) ) o
was VBD N
significantly RB N
increased VBN N
compared VBN N
to TO N
baseline VB N
in IN N
both DT N
groups NNS N
, , N
and CC N
the DT N
area NN o
under IN o
the DT o
FEV NNP o
( ( o
1 CD o
) ) o
-time NN o
curve NN o
during IN o
the DT o
6-month JJ o
period NN o
was VBD N
significantly RB N
greater JJR N
in IN N
the DT N
flunisolide NN i
group NN N
( ( N
5.2 CD N
+/- JJ N
10.6 CD N
vs. FW N
2.1 CD N
+/- JJ N
5.0 CD N
, , N
flunisolide RB i
vs. FW N
placebo NN i
, , N
respectively RB N
; : N
p VB N
= $ N
0.047 CD N
) ) N
. . N

For IN N
shuttle JJ o
walking VBG o
test NN o
distance NN o
and CC o
scores NNS o
of IN o
the DT o
St. NNP o
George NNP o
's POS o
Respiratory NNP o
Questionnaire NNP o
, , N
no DT N
significant JJ N
difference NN N
between IN N
the DT N
baseline NN N
evaluation NN N
and CC N
the DT N
end NN N
of IN N
the DT N
study NN N
was VBD N
observed VBN N
in IN N
both DT N
groups NNS N
. . N

CONCLUSIONS NNP N
Nebulized NNP i
flunisolide NN i
is VBZ N
a DT N
good JJ N
alternative NN N
to TO N
other JJ N
inhaled JJ N
corticosteroids NNS N
when WRB N
added VBN N
to TO N
nebulized JJ i
salbutamol/ipratropium NN i
bromide NN i
in IN N
the DT N
long-term JJ N
treatment NN N
of IN N
moderate-to-severe JJ p
COPD NNP p
patients NNS p
. . p

-DOCSTART- -22007005- O O

Use NNP i
of IN i
an DT i
Internet NNP i
portal NN i
to TO N
improve VB N
community-based JJ p
pediatric JJ p
ADHD NNP p
care NN p
: : p
a DT N
cluster NN N
randomized VBN N
trial NN N
. . N

OBJECTIVE NN N
To TO N
determine VB N
the DT N
effectiveness NN N
of IN N
a DT N
quality NN i
improvement NN i
program NN i
to TO N
improve VB N
pediatricians NNS p
' POS p
adherence NN N
to TO N
existing VBG N
, , N
evidence-based JJ N
, , N
attention-deficit/hyperactivity JJ N
disorder NN N
( ( N
ADHD NNP N
) ) N
practice NN N
guidelines NNS N
. . N

METHODS NNP N
Forty-nine JJ p
community-based JJ p
pediatricians NNS p
at IN p
8 CD p
practices NNS p
participated VBN p
in IN p
a DT p
cluster-randomized JJ p
trial NN p
. . p

Practices NNS N
were VBD N
matched VBN N
according VBG N
to TO N
the DT N
numbers NNS p
of IN p
pediatricians NNS p
and CC p
the DT p
proportions NNS p
of IN p
patients NNS p
receiving VBG p
Medicaid NNP p
. . p

The DT N
medical JJ N
charts NNS N
for IN N
a DT N
random JJ N
sample NN N
of IN N
patients NNS N
with IN N
ADHD NNP N
for IN N
each DT N
of IN N
the DT N
participating VBG N
pediatricians NNS N
were VBD N
examined VBN N
at IN N
baseline NN N
and CC N
6 CD N
months NNS N
. . N

All DT N
practices NNS N
participated VBN N
in IN N
4 CD N
sessions NNS N
of IN N
training NN i
, , i
including VBG i
didactic JJ i
lectures NNS i
and CC i
office NN i
flow NN i
modification NN i
workshops NNS i
. . i

Practices NNS N
were VBD N
then RB N
given VBN N
access NN N
to TO N
an DT N
ADHD NNP i
Internet NNP i
portal NN i
that WDT N
allowed VBD N
parents NNS N
, , N
teachers NNS N
, , N
and CC N
pediatricians NNS N
to TO N
input VB N
information NN N
( ( N
eg NN N
, , N
rating NN N
scales NNS N
) ) N
about IN N
patients NNS N
, , N
after IN N
which WDT N
information NN N
was VBD N
scored VBN N
, , N
interpreted VBN N
, , N
and CC N
formatted VBN N
in IN N
a DT N
report NN N
style NN N
that WDT N
was VBD N
helpful JJ N
for IN N
assessment NN N
and CC N
treatment NN N
of IN N
patients NNS N
with IN N
ADHD NNP N
. . N

Physicians NNPS N
evaluated VBD N
their PRP$ N
practice NN o
behaviors NNS o
quarterly RB N
and CC N
addressed VBD N
underperforming JJ o
areas NNS o
. . o

RESULTS NNP N
Pediatricians NNPS N
in IN N
the DT N
intervention NN N
group NN N
, , N
compared VBN N
with IN N
those DT N
in IN N
the DT N
control NN i
group NN N
, , N
demonstrated VBD N
significantly RB N
higher JJR N
rates NNS N
of IN N
many JJ N
American JJ N
Academy NNP N
of IN N
Pediatrics-recommended NNP N
ADHD NNP N
care NN N
practices NNS N
, , N
including VBG N
collection NN o
of IN o
parent NN o
( ( N
Cohen NNP N
's POS N
d NN N
= VBZ N
0.69 CD N
) ) N
and CC N
teacher $ o
( ( N
d JJ N
= NNP N
0.68 CD N
) ) N
rating NN o
scales NNS o
for IN N
assessment NN N
of IN N
children NNS N
with IN N
ADHD NNP N
, , N
use NN N
of IN N
Diagnostic NNP N
and CC N
Statistical NNP o
Manual NNP o
of IN o
Mental NNP o
Disorders NNP o
, , N
Fourth NNP N
Edition NNP N
, , N
criteria NNS N
( ( N
d VB N
= RB N
0.85 CD N
) ) N
, , N
and CC N
use NN N
of IN N
teacher NN o
rating NN o
scales NNS o
to TO N
monitor VB N
treatment NN N
responses NNS N
( ( N
d VB N
= RB N
1.01 CD N
) ) N
. . N

CONCLUSION VB N
A DT i
quality NN i
improvement NN i
intervention NN i
that WDT N
can MD N
be VB N
widely RB N
disseminated VBN N
by IN N
using VBG N
Internet-based JJ i
information NN i
technology NN i
significantly RB N
improved VBD N
the DT N
quality NN N
of IN N
ADHD NNP N
care NN N
in IN N
community-based JJ p
pediatric JJ p
settings NNS p
. . p

-DOCSTART- -12504399- O O

Sulfadoxine/pyrimethamine NNP i
alone RB i
or CC i
with IN i
amodiaquine JJ i
or CC i
artesunate NN i
for IN N
treatment NN N
of IN N
uncomplicated JJ o
malaria NNS o
: : o
a DT N
longitudinal JJ N
randomised JJ N
trial NN N
. . N

BACKGROUND NNP N
New NNP N
antimalarial JJ N
treatments NNS N
are VBP N
urgently RB N
needed VBN N
in IN N
sub-Saharan JJ p
Africa NNP p
. . p

Improved NNP N
therapies NNS N
should MD N
decrease VB N
failure NN o
rates NNS o
in IN N
the DT N
short JJ N
term NN N
, , N
but CC N
their PRP$ N
effect NN N
on IN N
incidence NN N
of IN N
subsequent JJ N
episodes NNS N
of IN N
malaria NN N
is VBZ N
little JJ N
studied JJ N
. . N

We PRP N
aimed VBD N
to TO N
compare VB N
the DT N
short-term JJ N
and CC N
long-term JJ N
effectiveness NN N
of IN N
three CD N
antimalarial JJ N
regimens NNS N
in IN N
children NNS p
from IN p
Kampala NNP p
, , p
Uganda NNP p
. . p

METHODS NNP N
We PRP N
randomly RB N
allocated VBD N
healthy JJ p
children NNS p
aged VBD p
6 CD p
months NNS p
to TO p
5 CD p
years NNS p
to TO N
receive VB N
25 CD i
mg/kg JJ i
sulfadoxine NN i
and CC i
1.25 CD i
mg/kg NN i
pyrimethamine NN i
plus CC i
either DT i
placebo NN i
, , i
25 CD i
mg/kg NN i
amodiaquine NN i
, , i
or CC i
12 CD i
mg/kg JJ i
artesunate NN i
. . i

Participants NNS N
were VBD N
followed VBN N
up RP N
for IN N
1 CD N
year NN N
and CC N
received VBD N
the DT N
same JJ N
preassigned JJ N
treatment NN N
for IN N
every DT N
new JJ N
episode NN N
of IN N
uncomplicated JJ N
malaria NNS N
diagnosed VBN N
during IN N
follow-up JJ N
. . N

Recrudescent NNP N
and CC N
new JJ N
infections NNS N
were VBD N
distinguished VBN N
by IN N
comparison NN N
of IN N
polymorphisms NNS N
in IN N
merozoite JJ N
surface NN N
protein NN N
2 CD N
( ( N
MSP2 NNP N
) ) N
. . N

Our PRP$ N
primary JJ N
endpoint NN N
was VBD N
the DT N
total JJ o
number NN o
of IN o
treatments NNS o
for IN o
malaria NNS o
per IN N
time NN N
at IN N
risk NN N
. . N

Analyses NNS N
were VBD N
done VBN N
per IN N
protocol NN N
. . N

FINDINGS $ N
183 CD N
( ( N
61 CD N
% NN N
) ) N
of IN N
316 CD p
participants NNS p
were VBD N
diagnosed VBN N
with IN N
at IN N
least JJS N
one CD N
episode NN N
of IN N
uncomplicated JJ N
malaria NN N
. . N

A DT N
total NN N
of IN N
577 CD N
episodes NNS N
of IN N
uncomplicated JJ N
Plasmodium NNP N
falciparum NN N
malaria NNS N
were VBD N
treated VBN N
with IN N
study NN N
drugs NNS N
; : N
all DT N
regimens NNS N
were VBD N
safe JJ o
and CC N
well RB N
tolerated VBN o
. . o

Clinical JJ o
treatment NN o
failure NN o
after IN N
14 CD N
days NNS N
was VBD N
significantly RB N
more RBR N
frequent JJ N
in IN N
the DT N
sulfadoxine/pyrimethamine NN N
group NN N
( ( N
38 CD N
of IN N
215 CD N
, , N
18 CD N
% NN N
) ) N
compared VBN N
with IN N
either CC N
the DT N
sulfadoxine/pyrimethamine NN N
plus CC N
amodiaquine JJ N
group NN N
( ( N
two CD N
of IN N
164 CD N
, , N
1 CD N
% NN N
; : N
p CC N
< VB N
0.0001 CD N
) ) N
or CC N
sulfadoxine/pyrimethamine JJ N
plus CC N
artesunate JJ N
group NN N
( ( N
one CD N
of IN N
198 CD N
, , N
1 CD N
% NN N
; : N
p CC N
< VB N
0.0001 CD N
) ) N
. . N

After IN N
28 CD N
and CC N
42 CD N
days NNS N
, , N
patients NNS N
in IN N
the DT N
sulfadoxine/pyrimethamine NN N
plus CC N
amodiaquine JJ N
group NN N
were VBD N
significantly RB N
less RBR N
likely JJ N
to TO N
develop VB N
malaria NNS o
than IN N
were VBD N
those DT N
in IN N
the DT N
other JJ N
groups NNS N
. . N

Overall NNP N
, , N
sulfadoxine/pyrimethamine NN N
plus CC N
amodiaquine NN N
reduced VBD N
the DT N
rate NN o
of IN o
subsequent JJ o
treatments NNS o
for IN o
malaria NN o
by IN N
54 CD N
% NN N
( ( N
95 CD N
% NN N
CI NNP N
36-66 CD N
, , N
p VBZ N
< NNP N
0.0001 CD N
) ) N
compared VBN N
with IN N
sulfadoxine/ JJ N
pyrimethamine NN N
alone RB N
and CC N
by IN N
37 CD N
% NN N
( ( N
12-54 JJ N
, , N
p=0.007 NN N
) ) N
compared VBN N
with IN N
sulfadoxine/pyrimethamine JJ N
plus JJ N
artesunate NN N
. . N

INTERPRETATION NNP N
Sulfadoxine/pyrimethamine NNP N
plus CC N
amodiaquine NN N
could MD N
be VB N
used VBN N
as IN N
an DT N
inexpensive JJ N
regimen NNS N
to TO N
decrease VB o
the DT o
rate NN o
of IN o
subsequent JJ o
episodes NNS o
of IN o
malaria NN o
. . o

-DOCSTART- -24092940- O O

18F-FDG JJ i
PET/CT NNP i
for IN N
early JJ N
prediction NN N
of IN N
response NN N
to TO N
neoadjuvant JJ i
lapatinib NN i
, , i
trastuzumab NN i
, , i
and CC i
their PRP$ i
combination NN i
in IN N
HER2-positive JJ p
breast NN p
cancer NN p
: : p
results NNS N
from IN N
Neo-ALTTO NNP N
. . N

UNLABELLED NNP N
Molecular NNP N
imaging VBG N
receives NNS N
increased VBD N
attention NN N
for IN N
selecting VBG N
patients NNS p
who WP p
will MD p
benefit VB p
from IN p
targeted JJ p
anticancer NN p
therapies NNS p
. . p

Neo-ALTTO NNP i
( ( i
Neoadjuvant NNP i
Lapatinib NNP i
and/or VBZ i
Trastuzumab NNP i
Treatment NNP N
Optimisation NNP N
) ) N
enrolled VBD N
455 CD p
women NNS p
with IN p
invasive JJ p
human JJ p
epidermal JJ p
growth NN p
factor NN p
receptor NN p
2 CD p
( ( p
HER2 NNP p
) ) p
-positive VBP p
breast NN p
cancer NN p
and CC N
compared VBN N
rates NNS N
of IN N
pathologic JJ N
complete JJ N
response NN N
( ( N
pCR NN N
) ) N
to TO N
neoadjuvant JJ i
lapatinib NN i
, , i
trastuzumab NN i
, , i
and CC i
their PRP$ i
combination NN i
. . i

Each DT N
anti-HER2 JJ i
therapy NN i
was VBD N
given VBN N
alone RB N
for IN N
6 CD N
wk NN N
, , N
followed VBN N
by IN N
12 CD N
wk NN N
of IN N
the DT N
same JJ N
therapy NN N
plus CC N
weekly JJ N
paclitaxel NN i
. . i

The DT N
early JJ N
metabolic JJ o
effects NNS o
of IN N
the DT N
anti-HER2 JJ i
therapies NNS i
on IN N
the DT N
primary JJ N
tumors NNS N
and CC N
their PRP$ N
predictive JJ N
values NNS N
for IN N
pCR NN N
were VBD N
assessed VBN p
in IN p
a DT p
subset NN p
of IN p
patients NNS p
. . p

METHODS NNP N
Eighty-six JJ p
patients NNS p
underwent JJ p
( ( i
18 CD i
) ) i
F-FDG CD i
PET/CT NNP i
at IN N
baseline NN N
and CC N
weeks NNS N
2 CD N
and CC N
6 CD N
of IN N
anti-HER2 JJ i
treatment NN i
. . i

An DT N
imaging VBG N
core NN N
laboratory NN N
provided VBD N
central JJ N
validation NN N
, , N
and CC N
2 CD N
independent JJ N
reviewers NNS N
, , N
masked VBD N
to TO N
assigned VB N
treatment NN N
arm NN N
and CC N
clinical JJ N
outcomes NNS N
, , N
performed VBN N
consensus NN N
( ( N
18 CD N
) ) N
F-FDG NNP N
PET/CT NNP N
readings NNS N
. . N

Maximum NNP N
standardized VBD o
uptake JJ o
value NN o
( ( o
SUVmax NNP o
) ) o
reductions NNS o
from IN o
baseline NN o
were VBD N
used VBN N
to TO N
measure VB N
metabolic JJ N
response NN N
. . N

RESULTS NNP N
Seventy-seven NNP N
of IN N
the DT N
86 CD N
enrolled VBD N
patients NNS N
presented VBD N
an DT N
evaluable JJ N
baseline NN N
( ( N
18 CD N
) ) N
F-FDG NNP N
PET/CT NNP N
scan JJ N
; : N
of IN N
these DT N
, , N
68 CD N
and CC N
66 CD N
were VBD N
evaluable JJ N
at IN N
weeks NNS N
2 CD N
and CC N
6 CD N
, , N
respectively RB N
. . N

Metabolic JJ o
responses NNS o
in IN N
the DT N
primary JJ N
tumors NNS N
were VBD N
evident JJ N
after IN N
2 CD N
wk NN N
of IN N
targeted JJ N
therapy NN N
and CC N
correlated VBN N
highly RB N
with IN N
metabolic JJ N
responses NNS N
at IN N
week NN N
6 CD N
( ( N
R NNP N
( ( N
2 CD N
) ) N
= FW N
0.81 CD N
) ) N
. . N

pCRs NN N
were VBD N
associated VBN N
with IN N
greater JJR N
SUVmax NNP N
reductions NNS N
at IN N
both DT N
time NN N
points NNS N
. . N

Mean NNP N
SUVmax NNP N
reductions NNS N
for IN N
pCR NN N
and CC N
non-pCR JJ N
, , N
respectively RB N
, , N
were VBD N
54.3 CD N
% NN N
versus IN N
32.8 CD N
% NN N
at IN N
week NN N
2 CD N
( ( N
P NNP N
= NNP N
0.02 CD N
) ) N
and CC N
61.5 CD N
% NN N
versus IN N
34.1 CD N
% NN N
at IN N
week NN N
6 CD N
( ( N
P NNP N
= NNP N
0.02 CD N
) ) N
. . N

( ( o
18 CD o
) ) o
F-FDG NNP o
PET/CT NNP o
metabolic JJ o
response NN o
rates NNS o
at IN N
weeks NNS N
2 CD N
and CC N
6 CD N
were VBD N
71.6 CD N
% NN N
and CC N
60 CD N
% NN N
, , N
respectively RB N
using VBG N
European JJ N
Organization NNP N
for IN N
Research NNP N
and CC N
Treatment NNP N
of IN N
Cancer NNP N
criteria NNS N
; : N
pCR VBN N
rates NNS N
were VBD N
twice RB N
as RB N
high JJ N
for IN N
( ( N
18 CD N
) ) N
F-FDG NNP N
PET/CT NNP N
responders NNS N
than IN N
nonresponders NNS N
( ( N
week NN N
2 CD N
: : N
42 CD N
% NN N
vs. FW N
21 CD N
% NN N
, , N
P NNP N
= NNP N
0.12 CD N
; : N
week NN N
6 CD N
: : N
44 CD N
% NN N
vs. FW N
19 CD N
% NN N
, , N
P NNP N
= NNP N
0.05 CD N
) ) N
. . N

CONCLUSION NNP N
Early NNP N
metabolic JJ N
assessment NN N
using VBG N
( ( N
18 CD N
) ) N
F-FDG CD N
PET/CT NNP N
can MD N
identify VB N
patients NNS N
with IN N
an DT N
increased VBN N
likelihood NN N
of IN N
pCR NN N
after IN N
neoadjuvant JJ i
trastuzumab NN i
, , i
lapatinib NN i
, , i
or CC i
their PRP$ i
combination NN i
when WRB N
given VBN N
with IN N
chemotherapy NN i
. . i

-DOCSTART- -16107454- O O

NHS NNP i
Direct NNP N
and CC N
older JJR p
people NNS p
. . p

-DOCSTART- -3076138- O O

Comparative JJ N
effects NNS N
of IN N
pinacidil NN i
and CC i
nifedipine NN i
in IN N
the DT N
treatment NN N
of IN N
arterial JJ p
hypertension NN p
. . p

-DOCSTART- -3279698- O O

BCG NNP i
( ( i
RIVM NNP i
) ) i
versus NN N
mitomycin JJ i
intravesical JJ i
therapy NN i
in IN N
superficial JJ p
bladder NN p
cancer NN p
. . p

First JJ N
results NNS N
of IN N
randomized JJ N
prospective JJ N
trial NN N
. . N

This DT N
study NN N
presents VBZ N
the DT N
preliminary JJ N
results NNS N
of IN N
a DT N
randomized JJ N
prospective JJ N
two-arm NN N
study NN N
in IN N
which WDT N
bacillus JJ i
Calmette-Gu?rin NNP i
( ( i
BCG NNP i
) ) i
RIVM NNP i
, , i
a DT i
Dutch JJ i
BCG NNP i
preparation NN N
, , N
is VBZ N
compared VBN N
with IN i
mitomycin JJ i
C NNP i
( ( N
MMC NNP N
) ) N
in IN p
patients NNS p
with IN p
primary JJ p
or CC p
recurrent JJ p
superficial JJ p
bladder NN p
tumors NNS p
, , p
including VBG p
carcinoma NN p
in IN p
situ NN p
( ( p
CIS NNP p
) ) p
. . p

Therapeutic JJ N
regimens NNS N
were VBD N
as IN N
follows VBZ N
: : N
after IN N
complete JJ N
transurethral JJ N
resection NN N
of IN N
all DT N
visible JJ N
tumors NNS N
, , N
BCG NNP i
RIVM NNP i
( ( N
1 CD N
x RB N
10 CD N
( ( N
9 CD N
) ) N
bacilli NN N
in IN N
50 CD N
mL NNS N
saline NN N
) ) N
was VBD N
instilled VBN N
once RB N
a DT N
week NN N
for IN N
six CD N
consecutive JJ N
weeks NNS N
, , N
and CC i
mitomycin VB i
C NNP i
( ( N
30 CD N
mg NN N
in IN N
50 CD N
mL NNS N
saline NN N
) ) N
was VBD N
administered VBN N
once RB N
a DT N
week NN N
for IN N
one CD N
month NN N
( ( N
weeks NNS N
1 CD N
to TO N
4 CD N
) ) N
and CC N
thereafter RB N
once RB N
a DT N
month NN N
for IN N
a DT N
total NN N
of IN N
six CD N
months NNS N
. . N

Reported VBN o
are VBP o
the DT o
incidence NN o
of IN o
side NN o
effects NNS o
in IN p
165 CD p
patients NNS p
and CC p
the DT o
recurrence NN o
rate NN o
of IN o
tumors NNS o
in IN p
308 CD p
patients NNS p
after IN p
a DT p
follow-up JJ p
period NN p
of IN p
twelve JJ p
months NNS p
. . p

Drug-induced NNP o
, , o
or CC o
chemical NN o
cystitis NN o
was VBD N
observed VBN N
in IN N
13 CD N
( ( N
16.7 CD N
% NN N
) ) N
of IN N
78 CD N
BCG-treated JJ N
patients NNS N
and CC N
in IN N
12 CD N
( ( N
13.8 CD N
% NN N
) ) N
of IN N
87 CD N
MMC-treated JJ N
patients NNS N
. . N

In IN N
the DT N
same JJ N
groups NNS o
bacterial JJ o
cystitis NN o
occurred VBD N
in IN N
17 CD N
( ( N
21.8 CD N
% NN N
) ) N
patients NNS N
and CC N
in IN N
16 CD N
( ( N
18.4 CD N
% NN N
) ) N
patients NNS N
, , N
respectively RB N
. . N

In IN N
the DT N
BCG-treated JJ N
group NN N
( ( N
N NNP N
= NNP N
148 CD N
) ) N
, , N
44 CD N
( ( N
29.8 CD N
% NN N
) ) N
had VBD o
recurrent JJ o
tumors NNS o
, , o
while IN N
in IN N
the DT N
MMC-treated JJ N
group NN N
( ( N
N NNP N
= NNP N
160 CD N
) ) N
, , N
40 CD N
( ( N
25.0 CD N
% NN N
) ) N
had VBD N
a DT N
recurrence NN o
. . o

The DT o
recurrence NN o
rate NN o
for IN i
BCG-treated JJ i
patients NNS N
was VBD N
0.33 CD N
; : N
the DT N
recurrence NN N
rate NN N
for IN i
MMC-treated JJ i
patients NNS N
was VBD N
0.29 CD N
( ( N
P NNP N
= NNP N
0.560 CD N
, , N
not RB N
significant JJ N
) ) N
. . N

These DT N
preliminary JJ N
data NNS N
demonstrated VBD N
no DT N
statistically RB N
significant JJ N
difference NN N
between IN N
the DT N
two CD N
arms NNS N
with IN N
regard NN N
to TO o
toxicity NN o
and CC o
recurrence NN o
of IN o
tumors NNS o
. . o

-DOCSTART- -23531317- O O

A DT N
randomized JJ N
cross-over NN N
study NN N
of IN N
inhalation NN N
of IN N
diesel NN N
exhaust NN N
, , N
hematological JJ N
indices NNS N
, , N
and CC N
endothelial JJ N
markers NNS N
in IN N
humans NNS N
. . N

BACKGROUND NNP N
Exposure NNP N
to TO N
traffic-related JJ N
air NN N
pollution NN N
( ( N
TRAP NNP N
) ) N
is VBZ N
considered VBN N
a DT N
trigger NN N
for IN N
acute JJ N
cardiovascular JJ N
events NNS N
. . N

Diesel NNP N
Exhaust NNP N
( ( N
DE NNP N
) ) N
is VBZ N
a DT N
major JJ N
contributor NN N
to TO N
TRAP NNP N
in IN N
the DT N
world NN N
. . N

We PRP N
evaluated VBD N
the DT N
effect NN N
of IN N
DE NNP N
inhalation NN N
on IN N
circulating VBG N
blood NN N
cell NN N
populations NNS N
, , N
hematological JJ N
indices NNS N
, , N
and CC N
systemic JJ N
inflammatory NN N
cytokines NNS N
in IN N
humans NNS N
using VBG N
a DT N
specialized JJ N
facility NN N
. . N

METHODS NNP N
In IN N
a DT N
randomized JJ N
double-blind NN N
crossover NN N
study NN N
balanced VBD N
to TO N
order NN N
, , N
17 CD p
metabolic JJ p
syndrome NN p
( ( p
MetS NNP p
) ) p
and CC p
15 CD p
healthy JJ p
subjects NNS p
inhaled VBN i
filtered JJ i
air NN i
( ( i
FA NNP i
) ) i
or CC i
DE NNP i
exposure NN i
in IN p
two-hour JJ p
sessions NNS p
on IN p
different JJ p
days NNS p
with IN p
a DT p
minimum JJ p
2-week JJ p
washout NN p
period NN p
. . p

We PRP N
collected VBD N
blood NN N
pre-exposure NN N
, , N
7 CD N
, , N
and CC N
22 CD N
hours NNS N
after IN N
exposure NN N
initiation NN N
and CC N
measured VBD N
the DT N
complete JJ N
blood NN o
count NN o
and CC o
differential JJ o
. . o

We PRP N
performed VBD N
multiplex JJ N
cytokine NN N
assay NN N
to TO N
measure VB N
the DT N
changes NNS N
in IN N
the DT N
systemic JJ N
inflammatory NN N
cytokines NNS N
, , N
and CC N
endothelial JJ N
adhesion NN N
molecules NNS N
( ( N
n=15 NN N
) ) N
. . N

A DT N
paired JJ N
analysis NN N
compared VBN N
the DT N
effect NN N
of IN N
DE NNP N
and CC N
FA NNP N
exposures NNS N
for IN N
the DT N
change NN N
from IN N
pre-exposure NN N
to TO N
the DT N
subsequent JJ N
time NN N
points NNS N
. . N

RESULTS VB N
A DT N
significant JJ N
increase NN o
in IN o
the DT o
hematocrit NN o
was VBD N
noted VBN N
7 CD N
hrs NNS N
after IN N
DE NNP N
[ FW N
1.4 CD N
% NN N
( ( N
95 CD N
% NN N
CI NNP N
: : N
0.9 CD N
to TO N
1.9 CD N
% NN N
) ) N
] NN N
compared VBN N
to TO N
FA NNP N
exposure NN N
[ VBZ N
0.5 CD N
% NN N
( ( N
95 CD N
% NN N
CI NNP N
: : N
-0.09 NN N
to TO N
1.0 CD N
% NN N
) ) N
; : N
p=0.008 NN N
. . N

The DT N
hemoglobin NN o
levels NNS o
increased VBD o
non-significantly RB N
at IN N
7 CD N
hrs JJ N
post NN N
DE NNP N
[ NNP N
0.3 CD N
gm/dL NN N
( ( N
95 CD N
% NN N
CI NNP N
: : N
0.2 CD N
to TO N
0.5 CD N
gm/dL NN N
) ) N
] VBZ N
versus JJ N
FA NNP N
exposure NN N
[ VBZ N
0.2 CD N
gm/dL NN N
( ( N
95 CD N
% NN N
CI NNP N
: : N
0 CD N
to TO N
0.3 CD N
gm/dL NN N
) ) N
] NN N
; : N
p=0.06 NN N
. . N

Furthermore RB N
, , N
the DT N
platelet NN o
count NN o
increased VBD o
22 CD N
hrs NN N
after IN N
DE NNP N
exposure NN N
in IN N
healthy JJ N
, , N
but CC N
not RB N
in IN N
MetS NNP N
subjects NNS N
[ FW N
DE NNP N
: : N
16.6 CD N
( ( N
95 CD N
% NN N
CI NNP N
: : N
10.2 CD N
to TO N
23 CD N
) ) N
thousand CD N
platelets/mL JJ N
versus NN N
[ NN N
FA NNP N
: : N
3.4 CD N
( ( N
95 CD N
% NN N
CI NNP N
: : N
-9.5 NN N
to TO N
16.3 CD N
) ) N
thousand CD N
platelets/mL NN N
) ) N
] NN N
; : N
p=0.04 NN N
. . N

No DT N
DE NNP o
effect NN o
was VBD N
observed VBN N
for IN N
WBC NNP o
, , o
neutrophils RB o
, , o
lymphocytes VBZ o
or CC N
erythrocytes VBZ o
. . o

Using VBG N
the DT N
multiplex JJ N
assay NN N
, , N
small JJ N
borderline NN N
significant JJ N
increases NNS o
in IN o
matrix JJ o
metalloproteinase-9 NN o
, , o
interleukins NNS o
( ( o
IL NNP o
) ) o
-1 NNP o
beta NN o
, , o
6 CD o
and CC o
10 CD o
occurred VBD N
7 CD N
hrs NN N
post NN N
exposure NN N
initiation NN N
, , N
whereas IN N
E-selectin NNP o
, , o
intercellular JJ o
adhesion NN o
molecule-1 NN o
, , N
and CC N
vascular JJ o
cell NN o
adhesion NN o
molecule NN o
-1 NNP o
, , N
and CC N
myeloperoxidase VB o
22 CD o
hrs NN N
post NN N
exposure NN N
. . N

CONCLUSIONS NNP N
Our PRP$ N
results NNS N
suggest VBP N
that IN N
short-term JJ N
DE NNP N
exposure NN N
results NNS N
in IN N
hemoconcentration NN o
and CC o
thrombocytosis NN o
, , N
which WDT N
are VBP N
important JJ N
determinants NNS N
of IN N
acute JJ N
cardiovascular JJ N
events NNS N
. . N

Multiplex NNP N
assay VBP N
showed VBD N
a DT N
non-significant JJ N
increase NN N
in IN N
IL-1? NNP N
and CC N
IL-6 NNP N
immediately RB N
post NN N
exposure NN N
followed VBN N
by IN N
myeloperoxidase NN N
and CC N
endothelial JJ N
activation NN N
molecules NNS N
. . N

Further NNP N
specific JJ N
assays NNS N
in IN N
a DT N
larger JJR N
population NN N
will MD N
improve VB N
our PRP$ N
understanding NN N
of IN N
the DT N
systemic JJ N
inflammatory JJ N
mechanisms NNS N
following VBG N
acute NN N
exposure NN N
to TO N
TRAP NNP N
. . N

-DOCSTART- -19470936- O O

MDM2 NNP N
and CC N
Ki-67 NNP N
predict NN N
for IN N
distant JJ o
metastasis NN o
and CC o
mortality NN o
in IN N
men NNS p
treated VBN p
with IN p
radiotherapy NN i
and CC p
androgen NN i
deprivation NN i
for IN p
prostate JJ p
cancer NN p
: : p
RTOG NNP N
92-02 CD N
. . N

PURPOSE NNP N
MDM2 NNP N
regulates VBZ N
p53 NN N
, , N
which WDT N
controls VBZ N
cell NN N
cycle NN N
arrest NN N
and CC N
apoptosis NN N
. . N

Both DT N
proteins NNS N
, , N
along IN N
with IN N
Ki-67 NNP N
, , N
which WDT N
is VBZ N
an DT N
established VBN N
strong JJ N
determinant NN N
of IN N
metastasis NN N
, , N
have VBP N
shown VBN N
promise NN N
in IN N
predicting VBG N
the DT N
outcome NN N
of IN N
men NNS N
treated VBN N
with IN N
radiation NN i
therapy NN i
( ( i
RT NNP i
) ) i
with IN i
or CC i
without IN i
short-term JJ i
androgen NN i
deprivation NN i
( ( i
STAD NNP i
) ) i
. . i

This DT N
report NN N
compares VBZ N
the DT N
utility NN N
of IN N
abnormal JJ N
expression NN N
of IN N
these DT N
biomarkers NNS N
in IN N
estimating VBG N
progression NN N
in IN N
a DT N
cohort NN N
of IN N
men NNS N
treated VBN N
on IN N
RTOG NNP N
92-02 CD N
. . N

PATIENTS NNPS N
AND CC N
METHODS NNP N
Adequate NNP N
tissue NN N
for IN N
immunohistochemistry NN N
was VBD N
available JJ N
for IN N
p53 NN N
, , N
Ki-67 NNP N
, , N
and CC N
MDM2 NNP N
analyses NNS N
in IN N
478 CD p
patient JJ p
cases NNS p
. . p

The DT N
percentage NN N
of IN N
tumor NN o
nuclei NN o
staining VBG o
positive JJ o
( ( N
PSP NNP N
) ) N
was VBD N
quantified VBN N
manually RB N
or CC N
by IN N
image NN N
analysis NN N
, , N
and CC N
the DT N
per-sample JJ o
mean JJ o
intensity NN o
score NN o
( ( o
MIS NNP o
) ) o
was VBD N
quantified VBN N
by IN N
image NN N
analysis NN N
. . N

Cox NNP N
regression NN N
models NNS N
were VBD N
used VBN N
to TO N
estimate VB N
overall JJ o
mortality NN o
( ( o
OM NNP o
) ) o
, , N
and CC N
Fine NNP N
and CC N
Gray NNP N
's POS N
regressions NNS N
were VBD N
applied VBN N
to TO N
the DT N
end NN N
points NNS N
of IN N
distant JJ o
metastasis NN o
( ( o
DM NNP o
) ) o
and CC o
cause-specific JJ o
mortality NN o
( ( o
CSM NNP o
) ) o
. . o

Results NNS N
In IN N
multivariate JJ N
analyses NNS N
that WDT N
adjusted VBD N
for IN N
all DT N
markers NNS N
and CC N
treatment NN N
covariates NNS N
, , N
MDM2 NNP o
overexpression NN o
was VBD N
significantly RB N
related VBN N
to TO N
DM NNP o
( ( N
P NNP N
= NNP N
.02 NNP N
) ) N
and CC N
OM NNP N
( ( N
P NNP N
= NNP N
.003 NNP N
) ) N
, , N
and CC N
Ki-67 NNP o
overexpression NN o
was VBD N
significantly RB N
related VBN N
to TO N
DM NNP o
( ( N
P NNP N
< NNP N
.0001 NNP N
) ) N
, , N
CSM NNP o
( ( N
P NNP N
= NNP N
.0007 NNP N
) ) N
, , N
and CC N
OM NNP o
( ( N
P NNP N
= NNP N
.01 NNP N
) ) N
. . N

P53 NNP o
overexpression NN o
was VBD N
significantly RB N
related VBN N
to TO N
OM NNP o
( ( N
P NNP N
= NNP N
.02 NNP N
) ) N
. . N

When WRB N
considered VBN N
in IN N
combination NN N
, , N
the DT N
overexpression NN o
of IN o
both DT o
Ki-67 NNP o
and CC o
MDM2 NNP o
at IN N
high JJ N
levels NNS N
was VBD N
associated VBN N
with IN N
significantly RB o
increased VBN o
failure NN o
rates NNS o
for IN N
all DT N
end NN N
points NNS N
( ( N
P NNP N
< NNP N
.001 NNP N
for IN N
DM NNP N
, , N
CSM NNP N
, , N
and CC N
OM NNP N
) ) N
. . N

CONCLUSION NNP N
Combined VBD N
MDM2 NNP o
and CC o
Ki-67 NNP o
expression NN o
levels NNS o
were VBD N
independently RB N
related VBN N
to TO N
distant JJ o
metastasis NN o
and CC o
mortality NN o
and CC N
, , N
if IN N
validated VBN N
, , N
could MD N
be VB N
considered VBN N
for IN N
risk NN N
stratification NN N
of IN N
patients NNS p
with IN p
prostate JJ p
cancer NN p
in IN N
clinical JJ N
trials NNS N
. . N

-DOCSTART- -2165088- O O

Low-dose JJ N
clonidine NN i
administration NN N
in IN N
the DT N
treatment NN N
of IN N
mild NN p
or CC p
moderate JJ p
essential JJ p
hypertension NN p
: : p
results NNS N
from IN N
a DT N
double-blind JJ N
placebo-controlled JJ i
study NN N
( ( N
Clobass NNP N
) ) N
. . N

The DT N
Clobass NNP N
Study NNP N
Group NNP N
. . N

Five CD p
hundred JJ p
and CC p
fifty-nine JJ p
hypertensive JJ p
outpatients NNS p
with IN p
diastolic JJ p
blood NN p
pressure NN p
between IN p
95 CD p
and CC p
110 CD p
mmHg NN p
participated VBN N
in IN N
this DT N
double-blind NN N
, , N
placebo-controlled JJ i
, , N
multicenter NN N
study NN N
. . N

Eligible JJ N
subjects NNS p
were VBD N
randomly RB N
allocated VBN N
to TO N
receive VB N
either DT N
clonidine NN i
( ( N
75 CD N
micrograms NNS N
twice RB N
daily RB N
) ) N
or CC N
a DT N
placebo NN i
. . i

After IN N
4 CD N
weeks NNS N
, , N
'responders NNS N
' POS N
to TO N
treatment NN N
( ( o
diastolic JJ o
blood NN o
pressure NN o
reduced VBD N
to TO N
less JJR N
than IN N
or CC N
equal JJ N
to TO N
90 CD N
mmHg NNS N
or CC N
by IN N
greater JJR N
than IN N
or CC N
equal JJ N
to TO N
10 CD N
mmHg NNS N
) ) N
were VBD N
kept VBN N
on IN N
monotherapy NN i
and CC N
checked VBN N
at IN N
4-weekly JJ N
intervals NNS N
for IN N
another DT N
3 CD N
months NNS N
. . N

Non-responders NNS N
were VBD N
given VBN N
15 CD N
mg JJ N
chlorthalidone NN i
and CC N
were VBD N
also RB N
checked VBN N
for IN N
a DT N
further JJ N
3 CD N
months NNS N
. . N

At IN N
the DT N
end NN N
of IN N
the DT N
first JJ N
month NN N
, , N
54.2 CD N
% NN N
of IN N
the DT N
subjects NNS N
were VBD N
responders NNS N
to TO N
clonidine VB i
and CC N
41.5 CD N
% NN N
were VBD N
responders NNS N
to TO N
the DT N
placebo NN i
( ( N
P NNP N
less JJR N
than IN N
0.05 CD N
for IN N
both DT N
groups NNS N
) ) N
. . N

Of IN N
the DT N
remaining VBG N
patients NNS N
, , N
69.0 CD N
% NN N
became VBD N
responders NNS N
to TO N
clonidine VB i
plus CC N
chlorthalidone VB i
, , N
whereas IN N
only RB N
34.7 CD N
% NN N
were VBD N
responders NNS N
to TO N
placebo VB i
plus CC N
chlorthalidone NN i
( ( N
P NNP N
less JJR N
than IN N
0.01 CD N
for IN N
both DT N
groups NNS N
) ) N
. . N

Withdrawals NNS N
from IN N
the DT N
study NN N
because IN N
of IN N
excessive JJ o
diastolic JJ o
blood NN o
pressure NN o
levels NNS o
were VBD N
about RB N
eight CD N
times NNS N
less RBR N
frequent JJ N
among IN N
the DT N
subjects NNS N
treated VBN N
with IN N
clonidine NN i
, , N
either CC N
alone RB N
or CC N
with IN N
chlorthalidone NN i
. . i

Dry NNP o
mouth NN o
was VBD N
twice RB N
as RB N
frequent JJ N
in IN N
the DT N
clonidine-treated JJ i
patients NNS N
, , N
but CC N
there EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
the DT N
incidence NN N
of IN N
all DT N
side NN o
effects NNS o
or CC N
the DT N
number NN o
of IN o
withdrawals NNS o
from IN N
the DT N
study NN N
because IN N
of IN N
side NN N
effects NNS N
between IN N
the DT N
two CD N
groups NNS N
. . N

We PRP N
conclude VBP N
that IN N
low-dose JJ N
clonidine NN i
is VBZ N
effective JJ N
in IN N
the DT N
treatment NN N
of IN N
mild NN N
or CC N
moderate JJ N
hypertension NN N
. . N

Clonidine-related JJ i
side NN N
effects NNS N
are VBP N
still RB N
evident JJ N
, , N
but CC N
the DT N
overall JJ N
tolerance NN N
profile NN N
for IN N
this DT N
reduced JJ N
dosage NN N
of IN N
the DT N
drug NN N
appears VBZ N
to TO N
be VB N
favorable JJ N
. . N

-DOCSTART- -9109702- O O

Comparative JJ N
efficacy NN o
and CC o
safety NN o
of IN N
twice JJ N
daily JJ N
fluticasone NN i
propionate NN i
powder NN i
versus NN N
placebo NN i
in IN N
the DT N
treatment NN N
of IN N
moderate JJ p
asthma NN p
. . p

BACKGROUND NNP N
Fluticasone NNP i
propionate NN i
, , N
an DT N
inhaled JJ N
corticosteroid NN N
with IN N
negligible JJ N
systemic JJ N
bioavailability NN N
via IN N
the DT N
oral JJ N
route NN N
, , N
is VBZ N
efficacious JJ N
in IN N
the DT N
treatment NN N
of IN N
asthma NN p
when WRB N
administered VBN N
via IN N
metered-dose JJ N
inhaler NN N
. . N

OBJECTIVE UH N
To TO N
evaluate VB N
the DT N
efficacy NN o
and CC o
safety NN o
of IN N
inhaled JJ i
fluticasone NN i
propionate NN i
powder NN i
in IN N
patients NNS p
with IN p
moderate JJ p
asthma NNS p
previously RB p
treated VBN p
with IN p
an DT p
inhaled JJ p
corticosteroid NN p
. . p

METHODS NNP N
This DT N
was VBD N
a DT N
randomized JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
, , N
parallel-group JJ N
, , N
multicenter NN N
study NN N
of IN N
342 CD p
adolescent NN p
and CC p
adult NN p
patients NNS p
with IN p
moderate JJ p
asthma NNS p
[ RB o
forced VBD o
expiratory JJ o
volume NN o
in IN o
1 CD o
second JJ o
( ( o
FEV1 NNP o
) ) o
between IN p
50 CD p
% NN p
and CC p
80 CD p
% NN p
of IN p
predicted JJ p
] NNP p
treated VBD p
previously RB p
by IN p
beclomethasone NN i
dipropionate NN i
or CC p
triamcinolone NN i
acetonide RB i
. . i

Patients NNS N
received VBD N
fluticasone JJ i
propionate NN i
powder NN i
50 CD N
micrograms NNS N
, , N
100 CD N
micrograms NNS N
, , N
250 CD N
micrograms NNS N
, , N
or CC N
placebo NN i
via IN N
a DT N
breath-actuated JJ N
inhalation NN N
device NN N
, , N
the DT N
Diskhaler NNP N
, , N
twice RB N
daily RB N
for IN N
12 CD N
weeks NNS N
. . N

RESULTS JJ N
Patients NNPS N
in IN N
the DT N
fluticasone NN N
propionate NN N
groups NNS N
experienced VBD N
a DT N
mean JJ o
increase NN o
from IN o
baseline NN o
to TO o
endpoint VB o
in IN o
FEV1 NNP o
ranging VBG N
from IN N
0.43 CD N
L NNP N
to TO N
0.47 CD N
L. NNP N
Patients NNPS N
in IN N
the DT N
placebo NN N
group NN N
experienced VBD N
a DT N
mean JJ N
decrease NN N
from IN N
baseline NN N
of IN N
0.22 CD N
L NNP N
( ( N
P NNP N
< NNP N
.001 NNP N
) ) N
. . N

The DT N
probability NN N
of IN N
patients NNS N
remaining VBG o
in IN o
the DT o
study NN o
over IN o
time NN o
without IN N
developing VBG N
signs NNS o
of IN N
exacerbating VBG o
asthma NN o
was VBD N
significantly RB N
greater JJR N
in IN N
the DT N
fluticasone NN N
propionate NN N
groups NNS N
than IN N
in IN N
the DT N
placebo NN N
group NN N
( ( N
P NNP N
= NNP N
.001 NNP N
) ) N
. . N

Asthma NNP o
symptom NN o
scores NNS o
, , o
supplemental JJ o
rescue NN o
albuterol NN o
use NN o
, , o
and CC o
number NN o
of IN o
nighttime JJ o
awakenings NNS o
due JJ o
to TO o
asthma VB o
requiring VBG N
treatment NN N
also RB N
improved VBN N
significantly RB N
with IN N
all DT N
fluticasone NN N
propionate NN N
treatment NN N
regimens NNS N
compared VBN N
with IN N
placebo NN N
( ( N
P NNP N
< NNP N
.001 NNP N
) ) N
. . N

There EX N
were VBD N
no DT N
statistically RB N
significant JJ N
differences NNS N
at IN N
endpoint NN N
among IN N
the DT N
three CD N
fluticasone NN N
propionate NN N
groups NNS N
. . N

No DT N
serious JJ o
drug-related JJ o
adverse JJ o
events NNS o
occurred VBD N
. . N

CONCLUSIONS NNP N
Fluticasone NNP N
propionate NN N
powder NN N
( ( N
50 CD N
, , N
100 CD N
, , N
and CC N
250 CD N
micrograms NNS N
) ) N
was VBD N
well-tolerated JJ o
and CC o
significantly RB o
improved VBN o
lung NN o
function NN o
in IN N
patients NNS p
with IN p
moderate JJ p
asthma NNS p
. . p

-DOCSTART- -6650773- O O

Bovine NNP i
carotid NN i
artery NN i
heterografts NNS i
versus VBP i
polytetrafluoroethylene JJ i
grafts NNS i
. . i

A DT N
prospective JJ N
, , N
randomized VBN N
study NN N
. . N

A DT N
prospective JJ N
, , N
randomized JJ N
comparison NN N
of IN N
BCAH NNP i
and CC i
PTFE NNP i
vascular JJ i
access NN i
grafts NNS i
resulted VBD N
in IN N
no DT N
statistically RB N
significant JJ N
difference NN N
when WRB N
analyzed VBN N
for IN N
survival JJ o
rates NNS o
of IN o
complications NNS o
, , o
types NNS o
of IN o
complications NNS o
, , o
reasons NNS o
for IN o
failure NN o
, , o
and CC o
clot NN o
salvageability NN o
. . o

The DT N
results NNS N
in IN N
diabetic JJ p
patients NNS p
were VBD N
similar JJ N
to TO N
those DT N
in IN N
nondiabetic JJ p
patients NNS p
. . p

The DT N
majority NN N
of IN N
retrospective JJ N
studies NNS N
and CC N
subjective JJ N
experiences NNS N
favor VBP N
PTFE NNP i
grafts NNS i
over IN N
BCAHs NNP i
. . N

The DT N
explanation NN N
may MD N
be VB N
part NN N
that IN N
BCAH NNP i
preceded VBD N
PTFE NNP i
grafts NNS i
into IN N
clinical JJ N
use NN N
, , N
and CC N
inexperience NN N
in IN N
the DT N
operating NN N
room NN N
and CC N
in IN N
the DT N
dialysis NN N
unit NN N
had VBD N
an DT N
effect NN N
on IN N
BCAH NNP N
results NNS N
. . N

A DT N
review NN N
of IN N
impressions NNS N
of IN N
the DT N
graft NN N
materials NNS N
indicated VBD N
a DT N
decided JJ N
preference NN N
for IN N
PTFE NNP i
grafts NNS i
. . i

-DOCSTART- -21238531- O O

Clinical JJ N
evaluation NN N
of IN N
Er NNP i
, , i
Cr NNP i
: : i
YSGG NN i
and CC i
GaAlAs NNP i
laser NN i
therapy NN i
for IN N
treating VBG N
dentine JJ o
hypersensitivity NN o
: : o
A DT N
randomized NN N
controlled VBD N
clinical JJ N
trial NN N
. . N

OBJECTIVE CC N
The DT N
advent NN N
of IN N
dental JJ N
lasers NNS N
has VBZ N
raised VBN N
another DT N
possible JJ N
treatment NN N
option NN N
for IN N
dentine NN o
hypersensitivity NN o
( ( o
DH NNP o
) ) o
and CC N
has VBZ N
become VBN N
a DT N
research NN N
interest NN N
in IN N
the DT N
last JJ N
decades NNS N
. . N

The DT N
aim NN N
of IN N
this DT N
randomized VBN N
, , N
controlled VBN N
, , N
double-blind NN N
, , N
split NN N
mouth NN N
, , N
clinical JJ N
study NN N
was VBD N
to TO N
evaluate VB o
and CC o
compare VB o
the DT N
desensitizing JJ N
effects NNS N
of IN N
erbium NN i
, , i
chromium-doped JJ i
: : i
yttrium NN i
, , i
scandium NN i
, , i
gallium NN i
and CC i
garnet NN i
( ( i
Er NNP i
, , i
Cr NNP i
: : i
YSGG NN i
) ) i
to TO i
galium-aluminium-arsenide JJ i
( ( i
GaAlAs NNP i
) ) i
laser NN i
on IN N
DH NNP N
. . N

METHODS NNP N
Fifty-one CD p
patients NNS p
participated VBN p
in IN p
this DT p
study NN p
for IN p
a DT p
total NN p
of IN p
174 CD p
teeth NNS p
. . p

DH NNP o
was VBD o
assessed VBN o
for IN N
all DT N
groups NNS N
with IN N
a DT N
visual JJ o
analog NN o
scale NN o
. . o

For IN N
each DT N
patient NN N
, , N
the DT N
teeth NNS N
were VBD N
randomized VBN N
to TO N
three CD N
groups NNS N
. . N

In IN N
the DT N
diode NN N
laser NN N
group NN N
, , N
sensitive JJ N
teeth NNS N
were VBD N
irradiated VBN i
with IN i
the DT i
GaAlAs NNP i
laser NN i
at IN i
8.5J/cm CD i
( ( i
2 CD i
) ) i
energy NN i
density NN i
. . i

In IN N
the DT N
Er NNP i
, , i
Cr NNP i
: : i
YSGG NNP i
laser NN i
group NN N
, , N
sensitive JJ N
teeth NNS N
were VBD N
irradiated VBN i
with IN i
Er NNP i
, , i
Cr NNP i
: : i
YSGG PRP$ i
laser NN i
in IN N
the DT N
hard JJ N
tissue NN N
mode NN N
using VBG N
a DT N
none-contact JJ N
probe NN N
at IN N
an DT N
energy NN N
level NN N
of IN N
0.25W CD N
and CC N
repetition NN N
rate NN N
of IN N
20Hz CD N
, , N
0 CD N
% NN N
water NN N
and CC N
10 CD N
% NN N
air NN N
. . N

In IN N
the DT N
control NN N
group NN N
no DT i
treatment NN i
was VBD N
performed VBN N
. . N

Treatment JJ N
time NN N
was VBD N
60s CD N
for IN N
GaAlAs NNP i
laser NN i
and CC N
30s CD N
for IN N
Er NNP i
, , i
Cr NNP i
: : i
YSGG NNP i
laser NN i
. . i

RESULTS VB N
When WRB N
compared VBN N
with IN N
the DT N
control NN N
group NN N
and CC N
baseline NN N
data NNS N
, , N
in IN N
both DT N
laser NN N
groups NNS N
, , N
laser JJR i
irradiation NN i
provided VBD N
a DT N
desensitizing JJ o
effect NN o
immediately RB N
after IN N
treatment NN N
and CC N
this DT N
effect NN N
was VBD N
maintained VBN N
throughout IN N
the DT N
study NN N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
. . N

No DT N
significant JJ N
differences NNS N
between IN N
Er NNP i
, , i
Cr NNP i
: : i
YSGG NN i
and CC N
GaAlAs NNP i
laser NN i
groups NNS N
were VBD N
found VBN N
at IN N
any DT N
follow-up JJ N
examination NN N
( ( N
p JJ N
> NNP N
0.05 CD N
) ) N
. . N

CONCLUSION NNP N
Based VBD N
on IN N
these DT N
findings NNS N
, , N
it PRP N
may MD N
be VB N
concluded VBN N
that IN N
both DT N
Er NNP i
, , i
Cr NNP i
: : i
YSGG NN i
and CC i
GaAlAs NNP i
lasers NNS i
were VBD N
effective JJ o
in IN N
the DT N
treatment NN N
of IN N
DH NNP N
following VBG N
a DT N
single JJ N
application NN N
. . N

-DOCSTART- -18812446- O O

Endobronchial JJ N
ultrasonography-guided JJ N
transbronchial JJ i
needle JJ i
aspiration NN i
increases VBZ N
the DT N
diagnostic JJ o
yield NN o
of IN N
peripheral JJ p
pulmonary JJ p
lesions NNS p
: : p
a DT N
randomized JJ N
trial NN N
. . N

BACKGROUND VB N
The DT N
diagnostic JJ o
yield NN o
of IN N
endobronchial JJ i
ultrasonography NN i
( ( i
EBUS NNP i
) ) i
-guided VBD i
transbronchial JJ i
needle JJ i
aspiration NN i
( ( i
TBNA NNP i
) ) i
for IN N
peripheral JJ N
pulmonary JJ N
lesions NNS N
( ( N
PPLs NNP N
) ) N
has VBZ N
not RB N
been VBN N
evaluated VBN N
. . N

The DT N
diagnostic JJ N
impact NN N
of IN N
TBNA NNP N
when WRB N
the DT N
EBUS NNP N
probe NN N
is VBZ N
adjacent JJ N
to TO N
lesions NNS N
remains VBZ N
to TO N
be VB N
determined VBN N
. . N

DESIGN VB N
A DT N
prospective JJ N
, , N
randomized JJ N
trial NN N
. . N

METHODS NNP N
Two CD p
hundred VBD p
two CD p
patients NNS p
with IN p
PPLs NNP p
and CC p
positive JJ p
EBUS NNP p
findings NNS p
were VBD p
enrolled VBN p
. . p

They PRP N
were VBD N
randomly RB N
classified VBN N
into IN N
two CD N
groups NNS N
. . N

In IN N
the DT N
EBUS NNP N
conventional JJ N
diagnostic JJ N
procedures NNS N
( ( N
CDPs NNP N
) ) N
group NN N
( ( N
103 CD N
patients NNS N
) ) N
, , N
both DT N
transbronchial JJ i
biopsy NN i
( ( N
TBB NNP N
) ) N
and CC N
bronchial JJ N
washing NN N
( ( N
BW NNP N
) ) N
were VBD N
performed VBN N
. . N

In IN N
the DT N
EBUS-TBNA JJ N
plus CC N
CDPs NNP N
group NN N
( ( N
99 CD N
patients NNS N
) ) N
, , N
TBNA NNP N
, , N
TBB NNP N
, , N
and CC N
BW NNP N
were VBD N
performed VBN N
. . N

The DT N
diagnostic JJ o
yield NN o
in IN N
each DT N
group NN N
was VBD N
compared VBN N
. . N

RESULTS VB N
A DT p
total NN p
of IN p
182 CD p
patients NNS p
( ( p
94 CD p
in IN p
the DT p
EBUS NNP p
CDPs NNP p
group NN p
and CC p
88 CD p
in IN p
the DT p
EBUS-TBNA JJ p
plus CC p
CDPs NNP p
group NN p
) ) p
were VBD p
analyzed VBN p
. . p

The DT N
yield NN o
in IN o
the DT o
EBUS-TBNA JJ o
plus CC N
CDPs NNP N
group NN N
( ( N
78.4 CD N
% NN N
) ) N
was VBD N
significantly RB N
higher JJR N
than IN N
the DT N
EBUS NNP N
CDPs NNP N
group NN N
( ( N
60.6 CD N
% NN N
, , N
p NN N
= NNP N
0.015 CD N
) ) N
. . N

Cases NNS N
in IN N
which WDT N
the DT N
EBUS NNP N
probe NN N
was VBD N
located VBN N
within IN N
the DT N
lesions NNS N
had VBD N
a DT N
significantly RB N
higher RBR o
diagnostic JJ o
yield NN o
( ( N
78.3 CD N
% NN N
) ) N
than IN N
when WRB N
the DT N
EBUS NNP N
probe NN N
was VBD N
adjacent JJ N
to TO N
them PRP N
( ( N
47.2 CD N
% NN N
, , N
p NN N
< NNP N
0.001 CD N
) ) N
. . N

Concerning VBG N
the DT N
three CD N
different JJ N
techniques NNS N
, , N
TBNA NNP N
showed VBD N
the DT N
highest JJS o
diagnostic JJ o
yield NN o
( ( N
62.5 CD N
% NN N
) ) N
in IN N
comparison NN N
to TO N
TBB NNP N
( ( N
48.9 CD N
% NN N
) ) N
and CC N
to TO N
BW NNP N
( ( N
19.8 CD N
% NN N
) ) N
. . N

The DT N
diagnostic JJ o
yield NN o
of IN o
TBNA NNP o
remained VBD N
unchanged JJ N
even RB N
when WRB N
the DT N
EBUS NNP N
probe NN N
was VBD N
adjacent JJ N
to TO N
the DT N
lesions NNS N
( ( N
p JJ N
= NNP N
0.89 CD N
) ) N
. . N

No DT N
additional JJ N
adverse JJ o
effects NNS o
were VBD N
observed VBN N
in IN N
the DT N
EBUS-TBNA JJ N
plus CC N
CDPs NNP N
group NN N
. . N

CONCLUSIONS NNP N
Applying NNP N
TBNA NNP N
to TO N
EBUS-guided NNP N
CDPs NNP N
further RBR N
increased VBD N
the DT N
diagnostic JJ o
yield NN o
of IN N
PPLs NNP N
without IN N
additional JJ N
risk NN N
. . N

The DT N
diagnostic JJ o
advantage NN o
of IN N
TBNA NNP N
became VBD N
more RBR N
obvious JJ N
if IN N
the DT N
EBUS NNP N
probe NN N
was VBD N
adjacent JJ N
to TO N
the DT N
lesions NNS N
. . N

TRIAL NNP N
REGISTRATION NNP N
Clinicaltrials.gov NNP N
Identifier NNP N
: : N
NCT00626587 NN N
. . N

-DOCSTART- -19763803- O O

Azelnidipine NNP i
and CC N
amlodipine VB i
anti-coronary JJ N
atherosclerosis NN N
trial NN N
in IN N
hypertensive JJ p
patients NNS p
undergoing VBG p
coronary JJ p
intervention NN p
by IN p
serial JJ p
volumetric JJ p
intravascular NN p
ultrasound NN p
analysis NN p
in IN p
Juntendo NNP p
university NN p
( ( p
ALPS-J NNP p
) ) p
. . N

PURPOSE NNP N
Many JJ N
trials NNS N
have VBP N
shown VBN N
that IN N
calcium NN N
channel NN N
blockers NNS N
( ( N
CCBs NNP N
) ) N
can MD N
reduce VB N
the DT N
cardiovascular NN o
( ( o
CV NNP o
) ) o
events NNS o
in IN N
patients NNS p
with IN p
coronary JJ p
artery NN p
disease NN p
( ( p
CAD NNP p
) ) p
. . p

The DT N
mechanisms NN N
of IN N
this DT N
effect NN N
could MD N
be VB N
associated VBN N
with IN N
plaque JJ N
regression NN N
due JJ N
to TO N
the DT N
anti-atherosclerotic JJ N
properties NNS N
of IN N
CCBs NNP N
. . N

The DT N
goal NN N
of IN N
this DT N
study NN N
is VBZ N
to TO N
determine VB N
the DT N
effects NNS N
of IN N
CCB NNP N
on IN N
volumetric JJ N
quantitative JJ N
changes NNS N
of IN N
coronary JJ N
plaques NNS N
accessed VBN N
by IN N
intravascular JJ N
ultrasound NN N
( ( N
IVUS NNP N
) ) N
. . N

To TO N
confirm VB N
this DT N
hypothesis NN N
, , N
a DT N
multicenter NN N
randomized VBN N
trial NN N
of IN N
CCBs NNP N
treatment NN N
with IN N
azelnidipine NN i
or CC N
amlodipine NN i
will MD N
be VB N
conducted VBN N
in IN N
hypertensive JJ p
CAD NNP p
patients NNS p
undergoing VBG p
elective JJ p
percutaneous JJ p
coronary JJ p
intervention NN p
( ( p
PCI NNP p
) ) p
. . p

METHODS NNP N
AND CC N
RESULTS NNP N
Patients NNPS p
who WP p
have VBP p
hypertension NN p
and CC p
are VBP p
scheduled VBN p
for IN p
PCI NNP p
will MD p
be VB p
enrolled VBN p
. . p

Subjects NNS N
will MD N
be VB N
randomized VBN N
to TO N
azelnidipine VB i
or CC N
amlodipine VB i
and CC N
observed VB N
for IN N
48 CD N
weeks NNS N
. . N

The DT N
primary JJ N
endpoint NN N
will MD N
be VB N
the DT N
percent NN o
change NN o
of IN o
coronary JJ o
plaque NN o
volume NN o
. . o

The DT N
secondary JJ N
endpoint NN N
will MD N
include VB N
inflammatory JJ o
markers NNS o
, , o
antioxidant JJ o
activity NN o
, , o
and CC o
incidence NN o
of IN o
composite JJ o
cardiovascular JJ o
events NNS o
. . o

CONCLUSIONS NNP N
In IN N
this DT N
study NN N
, , N
we PRP N
will MD N
investigate VB N
the DT N
improvement NN N
of IN N
coronary JJ o
plaque NN o
with IN N
IVUS NNP N
by IN N
treatment NN N
with IN N
two CD N
dihydropyridine NN N
CCBs NNP N
in IN N
hypertensive JJ p
patients NNS p
undergoing VBG p
elective JJ p
PCI NNP p
. . p

This DT N
result NN N
will MD N
lead VB N
to TO N
the DT N
discovery NN N
of IN N
more RBR N
effective JJ N
drug NN N
therapy NN N
for IN N
inhibition NN N
of IN N
coronary JJ o
events NNS o
. . o

-DOCSTART- -9529556- O O

Pruritus NN N
in IN N
HIV-1 NNP N
disease NN N
: : N
therapy NN N
with IN N
drugs NNS N
which WDT N
may MD N
modulate VB N
the DT N
pattern NN N
of IN N
immune JJ o
dysregulation NN o
. . o

BACKGROUND NNP N
Pruritus NNP p
in IN p
HIV-1+ NNP p
patients NNS p
is VBZ N
common JJ N
and CC N
increases VBZ N
with IN N
disease NN N
progression NN N
. . N

The DT N
causes NNS N
of IN N
pruritus NN N
are VBP N
numerous JJ N
including VBG N
xerosis NN N
, , N
drug NN N
and CC N
photoeruptions NNS N
, , N
follicular JJ N
and CC N
papular JJ N
eruptions NNS N
as RB N
well RB N
as IN N
infestations NNS N
and CC N
infections NNS N
by IN N
a DT N
wide JJ N
range NN N
of IN N
organisms NNS N
. . N

One CD N
other JJ N
possible JJ N
factor NN N
contributing VBG N
to TO N
pruritus VB N
is VBZ N
the DT N
pattern NN N
of IN N
immune JJ N
dysregulation NN N
. . N

With IN N
advancing VBG N
HIV-1 JJ N
disease NN N
there EX N
is VBZ N
Th1 NNP N
to TO N
Th2 NNP N
cytokine NN N
switching VBG N
. . N

METHODS NNP N
After IN N
some DT N
positive JJ N
results NNS N
with IN N
prostaglandin JJ N
inhibitors NNS N
, , N
we PRP N
undertook VBP N
a DT N
study NN N
in IN N
which WDT N
we PRP N
randomly VBP N
placed VBN N
patients NNS p
on IN p
four CD p
different JJ p
forms NNS p
of IN p
therapy NN p
for IN p
their PRP$ p
pruritus NN p
. . p

The DT N
therapies NNS N
included VBD N
hydroxyzine NN i
with IN i
or CC i
without IN i
doxepin NN i
at IN i
night NN i
, , i
pentoxifylline NN i
, , i
indomethacin NN i
and CC i
topical JJ i
moisturization NN i
with IN i
medium-strength JJ i
topical JJ i
steroids NNS i
. . i

All DT N
patients NNS N
were VBD N
evaluated VBN N
for IN N
both DT N
subjective JJ o
relief NN o
as RB N
well RB N
as IN N
side NN o
effects NNS o
. . o

RESULTS NNP N
Patients NNPS N
placed VBD N
on IN N
indomethacin NN N
obtained VBN N
relief NN o
more RBR N
consistently RB N
and CC N
more RBR N
completely RB N
. . N

Patients NNS p
on IN p
pentoxifylline NN p
had VBD N
the DT N
fewest JJS N
side NN o
effects NNS o
of IN N
all DT N
oral JJ N
therapies NNS N
. . N

Patients NNS N
on IN N
antihistamines NNS N
with IN N
or CC N
without IN N
doxepin NN N
had VBD N
the DT N
highest JJS N
incidence NN o
of IN o
side NN o
effects NNS o
, , N
although IN N
more JJR N
of IN N
these DT N
patients NNS N
reported VBD N
a DT N
greater JJR N
degree NN o
of IN o
relief NN o
than IN N
patients NNS N
on IN N
pentoxifylline NN N
. . N

All DT N
patients NNS N
on IN N
oral JJ N
therapy NN N
overall NN N
had VBD N
greater JJR o
relief NN o
than IN N
patients NNS N
using VBG N
topical JJ N
steroids NNS N
. . N

CONCLUSION VB N
The DT N
systemic JJ N
therapies NNS N
which WDT N
may MD N
modulate VB N
the DT N
pattern NN N
of IN N
immune JJ o
dysregulation NN o
seen VBN N
in IN N
HIV-1 NNP N
disease NN N
may MD N
be VB N
beneficial JJ o
in IN N
the DT N
pruritus NN N
seen VBN N
in IN N
late-stage JJ N
patients NNS N
. . N

-DOCSTART- -12792318- O O

A DT N
randomized JJ N
trial NN N
of IN N
the DT N
canalith NN i
repositioning NN i
procedure NN i
. . i

OBJECTIVE UH N
To TO N
compare VB N
the DT N
effectiveness NN o
and CC o
complications NNS o
of IN o
our PRP$ o
adaptation NN o
of IN o
the DT o
canalith NN o
repositioning NN o
procedure NN o
( ( o
CRP NNP o
) ) o
with IN N
the DT N
expectation NN N
treatment NN N
for IN N
benign JJ N
paroxysmal JJ N
positional JJ N
vertigo NN N
. . N

STUDY NNP N
DESIGN NNP N
A NNP N
randomized NN N
, , N
controlled VBN N
trial NN N
in IN N
the DT N
setting NN N
of IN N
a DT N
neurotological JJ N
clinic NN N
in IN N
Thailand NNP N
. . N

METHODS NNP N
Fifty-eight JJ p
patients NNS p
with IN p
posterior JJ p
benign NN p
paroxysmal JJ p
positional JJ p
vertigo NN p
were VBD N
randomly RB N
assigned VBN N
to TO N
treatment NN N
and CC N
control NN N
groups NNS N
using VBG N
a DT N
block NN N
of IN N
four CD N
. . N

The DT N
treatment NN N
group NN N
was VBD N
treated VBN N
with IN N
the DT N
modified JJ i
CRP NNP i
technique NN i
until IN N
the DT N
nystagmus NN N
disappeared VBD N
. . N

A DT N
mastoid JJ N
oscillator NN N
was VBD N
not RB N
used VBN N
, , N
nor CC N
were VBD N
any DT N
instructions NNS N
given VBN N
for IN N
patients NNS N
after IN N
the DT N
maneuver NN N
. . N

Both DT N
groups NNS N
recorded VBD N
the DT N
daily JJ o
grading NN o
of IN o
symptoms NNS o
and CC o
the DT o
amount NN o
of IN o
anti-vertiginous JJ o
drugs NNS o
( ( o
cinnarizine NN o
) ) o
taken VBN o
. . o

Objective JJ o
and CC o
subjective JJ o
assessments NNS o
were VBD N
made VBN N
weekly RB N
until IN N
the DT N
nystagmus NN o
disappeared VBD N
or CC N
until IN N
4 CD N
weeks NNS N
had VBD N
passed VBN N
since IN N
treatment NN N
began VBD N
. . N

RESULTS VB N
The DT N
rates NNS o
of IN o
effectiveness NN o
of IN o
CRP NNP o
treatment NN o
and CC N
the DT N
control NN N
treatment NN N
for IN N
benign JJ N
paroxysmal JJ N
positional JJ N
vertigo NN N
were VBD N
75.9 CD N
% NN N
and CC N
48.2 CD N
% NN N
, , N
respectively RB N
. . N

There EX N
was VBD N
a DT N
significant JJ N
difference NN N
in IN N
the DT N
treatment NN N
outcomes NNS N
of IN N
the DT N
CRP NNP i
and CC N
control NN N
groups NNS N
( ( N
P NNP N
=.03 NNP N
) ) N
. . N

The DT N
CRP NNP i
group NN N
used VBD o
significantly RB o
fewer JJR o
drugs NNS o
than IN N
the DT N
control NN N
group NN N
( ( N
P NNP N
=.001 NNP N
) ) N
. . N

Complications NNS o
in IN N
the DT N
CRP NNP i
group NN N
, , N
such JJ N
as IN N
lateral JJ o
canalithiasis NN o
and CC o
fainting NN o
, , N
were VBD N
observed VBN N
in IN N
13.8 CD N
% NN N
of IN N
the DT N
patients NNS N
. . N

CONCLUSIONS VB N
The DT N
CRP NNP i
was VBD N
more RBR N
effective JJ N
than IN N
the DT N
expectation NN N
treatment NN N
for IN N
benign JJ N
paroxysmal JJ N
positional JJ N
vertigo NN N
insofar NN N
as IN N
it PRP N
provided VBD N
faster RBR N
recovery NN o
and CC N
required VBD N
less JJR N
dependence NN o
on IN o
medication NN o
. . o

Complications NNS o
of IN N
CRP NNP i
were VBD N
limited VBN N
to TO N
13.8 CD N
% NN N
of IN N
patients NNS N
. . N

-DOCSTART- -21672315- O O

A DT N
randomized VBN N
crossover NN N
study NN N
comparing VBG N
patient JJ N
preference NN N
for IN N
tamsulosin NN i
and CC i
silodosin NN i
in IN N
patients NNS p
with IN p
lower JJR p
urinary JJ p
tract NN p
symptoms NNS p
associated VBN p
with IN p
benign JJ p
prostatic JJ p
hyperplasia NN p
. . p

Patient JJ p
preference NN p
for IN p
benign JJ p
prostatic JJ p
hyperplasia NN p
( ( p
BPH NNP p
) ) p
treatment NN p
with IN p
the DT p
? . i
( ( i
1 CD i
) ) i
-blockers NNS i
, , i
tamsulosin NN i
or CC i
silodosin NN i
, , i
was VBD N
compared VBN N
using VBG N
patient-reported JJ N
outcomes NNS N
. . N

Japanese JJ p
patients NNS p
with IN p
lower JJR p
urinary JJ p
tract NN p
symptoms NNS p
associated VBN p
with IN p
BPH NNP p
were VBD N
randomly RB N
allocated VBN N
to TO N
either VB N
the DT i
T-S NNP i
group NN i
( ( i
tamsulosin $ i
0.2 CD i
mg NN i
orally RB i
once RB i
daily JJ i
for IN i
4 CD i
weeks NNS i
then RB i
silodosin VBD i
4 CD i
mg NNS i
orally RB i
twice RB i
daily RB i
for IN i
4 CD i
weeks NNS i
) ) i
or CC i
the DT i
S-T JJ i
group NN i
( ( i
silodosin $ i
4 CD i
mg NN i
orally RB i
twice JJ i
daily RB i
for IN i
4 CD i
weeks NNS i
then RB i
tamsulosin VBD i
0.2 CD i
mg NNS i
orally RB i
once RB i
daily JJ i
for IN i
4 CD i
weeks NNS i
) ) i
. . i

The DT N
primary JJ N
endpoint NN N
was VBD N
the DT o
preferred JJ o
drug NN o
for IN o
treatment NN o
continuation NN o
at IN o
8 CD o
weeks NNS o
, , o
determined VBN o
by IN o
a DT o
patient-reported JJ o
questionnaire NN o
. . o

In IN N
total JJ N
, , N
102 CD p
patients NNS p
( ( p
mean JJ p
age NN p
70.3 CD p
years NNS p
) ) p
were VBD p
enrolled VBN p
and CC p
84 CD p
( ( p
n JJ p
= $ p
42 CD p
per IN p
group NN p
) ) p
completed VBD p
the DT p
study NN p
. . p

A DT N
significant JJ N
difference NN N
was VBD N
observed VBN N
between IN N
the DT N
proportion NN N
of IN N
patients NNS N
who WP N
preferred VBD i
tamsulosin NN i
( ( N
59/84 CD N
patients NNS N
; : N
70.2 CD N
% NN N
) ) N
and CC N
those DT N
who WP N
preferred VBD i
silodosin NN i
( ( N
18/84 CD N
patients NNS N
; : N
21.4 CD N
% NN N
) ) N
. . N

A DT N
major JJ N
reason NN N
for IN N
preference NN N
of IN N
either DT N
drug NN N
was VBD N
'good VBN o
efficacy NN o
' '' o
. . o

Incidence NN o
of IN o
adverse JJ o
effects NNS o
was VBD N
significantly RB N
lower JJR N
with IN i
tamsulosin NN i
( ( N
3/91 CD N
patients NNS N
; : N
3.3 CD N
% NN N
) ) N
than IN N
with IN i
silodosin NN i
( ( N
25/88 CD N
patients NNS N
; : N
28.4 CD N
% NN N
) ) N
. . N

These DT N
findings NNS N
indicate VBP N
that IN i
tamsulosin NN i
is VBZ N
very RB N
effective JJ N
for IN N
BPH NNP N
, , N
has VBZ N
few JJ N
adverse JJ N
effects NNS N
and CC N
that IN p
patients NNS p
want VBP N
to TO N
continue VB N
to TO N
use VB N
it PRP N
. . N

-DOCSTART- -11778352- O O

Physical JJ i
activity NN i
in IN N
first-degree JJ p
relatives NNS p
of IN p
breast NN p
cancer NN p
patients NNS p
. . p

This DT N
study NN N
sought VBD N
to TO N
evaluate VB N
physical JJ i
activity NN i
in IN N
women NNS p
at IN p
moderate JJ p
risk NN p
for IN p
breast NN p
cancer NN p
, , N
the DT N
correlates NNS N
of IN N
engaging VBG N
in IN N
regular JJ N
physical JJ i
activity NN i
, , N
and CC N
whether IN N
physical JJ i
activity NN i
relates VBZ N
to TO N
psychological JJ o
well-being NN o
. . o

The DT N
results NNS N
revealed VBD N
that IN N
55 CD p
% NN p
of IN p
women NNS p
were VBD p
regularly RB p
active JJ p
. . p

Logistic JJ N
regression NN N
models NNS N
indicated VBD N
that IN N
positive JJ N
affect NN N
was VBD N
associated VBN N
with IN N
increased JJ N
and CC N
negative JJ N
affect NN N
was VBD N
associated VBN N
with IN N
decreased JJ N
overall JJ N
and CC N
leisure NN o
activity NN o
. . o

Older JJR N
, , N
married VBN N
, , N
and CC N
employed JJ N
women NNS N
were VBD N
more RBR N
likely JJ N
to TO N
engage VB N
in IN N
household/occupational JJ o
activity NN o
, , N
whereas JJ N
women NNS N
who WP N
perceived VBD N
their PRP$ N
risk NN N
for IN N
breast NN N
cancer NN N
as IN N
high JJ N
were VBD N
less RBR N
likely JJ N
. . N

More RBR N
educated JJ N
women NNS N
and CC N
those DT N
with IN N
higher JJR N
perceived VBN N
risk NN N
were VBD N
more RBR N
likely JJ N
to TO N
engage VB N
in IN N
leisure NN o
activity NN o
, , N
and CC N
married JJ N
women NNS N
were VBD N
less RBR N
likely JJ N
. . N

These DT N
results NNS N
suggest VBP N
a DT N
need NN N
to TO N
increase VB i
activity NN i
levels NNS i
in IN N
women NNS p
at IN p
moderate JJ p
risk NN p
for IN p
breast NN p
cancer NN p
, , N
provide VBP N
variables NNS N
upon IN N
which WDT N
interventions NNS N
can MD N
be VB N
tailored VBN N
to TO N
promote VB N
activity NN N
, , N
and CC N
point NN N
to TO N
psychological JJ N
benefits NNS N
of IN N
activity NN N
in IN N
this DT N
population NN N
. . N

-DOCSTART- -21222024- O O

The DT N
dud JJ N
effect NN N
: : N
adding VBG p
highly RB p
dissimilar JJ p
fillers NNS p
increases VBZ p
confidence NN p
in IN N
lineup JJ p
identifications NNS p
. . p

Recent JJ N
research NN N
in IN N
decision-making NN N
has VBZ N
demonstrated VBN N
the DT N
dud-alternative JJ N
effect NN N
-- : N
the DT N
tendency NN N
to TO N
become VB N
more RBR N
confident JJ N
that IN N
a DT N
chosen NN N
response NN N
option NN N
is VBZ N
correct JJ N
if IN N
it PRP N
is VBZ N
surrounded VBN N
by IN N
implausible JJ N
response NN N
options NNS N
( ( N
Windschitl NNP N
& CC N
Chambers NNP N
, , N
J NNP N
Exp NNP N
Psychol NNP N
30:198-215 CD N
, , N
2004 CD N
) ) N
. . N

This DT N
finding NN N
may MD N
be VB N
applicable JJ N
to TO N
a DT N
lineup NN N
task NN N
: : N
The DT N
presence NN N
of IN N
duds NN N
( ( N
i.e. FW N
, , N
highly RB N
dissimilar JJ N
fillers NNS N
) ) N
may MD N
increase VB N
a DT N
witness NN o
's POS o
confidence NN o
that IN N
an DT N
identified VBN p
( ( p
non-dud JJ p
) ) p
lineup NN p
member NN p
is VBZ N
the DT N
criminal JJ N
. . N

Four CD p
studies NNS p
( ( p
N NNP p
= NNP N
665 CD N
) ) N
demonstrate NN N
that IN N
the DT N
mere JJ N
presence NN N
of IN N
highly RB N
dissimilar JJ N
fillers NNS N
inflates VBZ N
witnesses NNS o
' POS o
confidence NN o
in IN N
a DT N
mistaken JJ N
identification NN N
( ( N
Studies NNP N
1-4 CD N
) ) N
, , N
provides VBZ N
evidence NN N
that IN N
this DT N
confidence NN o
inflation NN o
is VBZ N
due JJ N
to TO N
the DT N
duds NN N
inflating VBG N
the DT N
perceived JJ N
similarity NN N
of IN N
the DT N
other JJ N
lineup NN N
members NNS N
to TO N
the DT N
criminal NN N
( ( N
Studies NNPS N
2 CD N
, , N
3 CD N
) ) N
, , N
and CC N
delineates VBZ N
some DT N
conditions NNS N
under IN N
which WDT N
the DT N
effect NN N
holds VBZ N
( ( N
Studies NNPS N
3 CD N
, , N
4 CD N
) ) N
. . N

The DT N
addition NN N
of IN N
highly RB N
dissimilar JJ i
lineup NN i
members NNS i
, , N
far RB N
from IN N
being VBG N
inert JJ N
, , N
as IN N
is VBZ N
often RB N
implicitly RB N
assumed VBN N
, , N
can MD N
bias VB N
witnesses NNS p
' POS p
confidence NN N
reports NNS N
. . N

-DOCSTART- -12564611- O O

Utilization NN N
of IN N
health NN i
care NN i
services NNS i
by IN N
patients NNS p
with IN p
chronic JJ p
obstructive JJ p
pulmonary JJ p
disease NN p
. . p

In IN N
order NN N
to TO N
identify VB N
healthcare NN o
resource NN o
use NN o
patterns NNS o
associated VBN N
with IN N
chronic JJ p
obstructive JJ p
pulmonary JJ p
disease NN p
( ( p
COPD NNP p
) ) p
, , N
resource JJ N
utilization NN N
( ( N
RU NNP N
) ) N
data NNS N
collection NN N
was VBD N
integrated VBN N
into IN N
a DT N
randomized JJ N
, , N
double-blind JJ N
placebo-controlled JJ i
study NN N
of IN N
Viozan NNP N
( ( N
sibenadet JJ N
HCl NNP N
) ) N
. . N

This DT N
study NN N
enrolled VBD N
patients NNS p
with IN p
symptomatic JJ p
, , p
smoking-related JJ p
COPD NNP p
, , N
randomized VBN N
to TO N
receive VB N
sibenadet NN i
or CC i
placebo NN i
for IN N
a DT N
52-week JJ N
treatment NN N
period NN N
. . N

A DT N
questionnaire NN o
establishing VBG o
typical JJ o
pre-trial JJ o
, , o
COPD-related JJ o
RU NNP o
was VBD N
completed VBN N
by IN N
each DT N
patient NN N
. . N

Subsequent JJ N
data NNS N
were VBD N
collected VBN N
by IN N
means NNS N
of IN N
an DT N
Interactive JJ o
Voice NNP o
Response NNP o
System NNP o
( ( o
IVRS NNP o
) ) o
at IN N
30-day JJ N
intervals NNS N
( ( N
14 CD N
time NN N
points NNS N
) ) N
during IN N
the DT N
study NN N
and CC N
in IN N
the DT N
follow-up JJ N
period NN N
. . N

The DT N
IVRS NNP N
system NN N
facilitated VBD N
data NNS N
collection NN N
and CC N
minimized VBD N
inconvenience NN N
to TO N
the DT N
patient NN N
. . N

Compliance NN N
with IN N
the DT N
requirement NN N
to TO N
record VB N
details NNS N
of IN N
the DT N
healthcare NN N
services NNS N
during IN N
the DT N
year-long JJ N
study NN N
was VBD N
high JJ N
. . N

No DT N
overall JJ N
trend NN N
for IN N
lower JJR N
RU NNP o
was VBD N
associated VBN N
with IN N
sibenadet JJ N
therapy NN N
, , N
which WDT N
correlates VBZ N
with IN N
the DT N
lack NN N
of IN N
sustained JJ N
clinical JJ N
effect NN N
seen VBN N
in IN N
studies NNS N
conducted VBN N
concurrently RB N
. . N

These DT N
data NNS N
do VBP N
, , N
however RB N
, , N
provide VBP N
valuable JJ N
information NN N
on IN N
RU NNP N
associated VBN N
with IN N
COPD NNP N
and CC N
insights NNS N
into IN N
adjustments NNS N
associated VBN N
with IN N
changes NNS N
in IN N
disease NN N
course NN N
. . N

Physicians NNPS N
were VBD N
seen VBN N
to TO N
be VB N
the DT N
most RBS N
common JJ N
source NN N
of IN N
care NN N
for IN N
patients NNS N
with IN N
COPD NNP N
and CC N
more JJR N
of IN N
the DT N
patients NNS p
with IN p
severe JJ p
COPD NNP p
( ( p
stage NN p
III NNP p
) ) p
than IN p
mild NN p
( ( p
stage NN p
I PRP p
) ) p
were VBD N
seen VBN N
to TO N
utilize VB N
the DT N
most RBS N
expensive JJ N
resources NNS N
( ( N
e.g NN N
. . N

inpatient JJ o
hospital NN o
care NN o
) ) o
. . N

For IN N
those DT N
patients NNS N
who WP N
experienced VBD N
an DT N
exacerbation NN N
during IN N
the DT N
trial NN N
( ( N
irrespective JJ N
of IN N
treatment NN N
group NN N
) ) N
, , N
resource NN o
use NN o
was VBD N
increased VBN N
during IN N
the DT N
periods NNS N
when WRB N
an DT N
exacerbation NN N
was VBD N
reported VBN N
when WRB N
compared VBN N
with IN N
the DT N
periods NNS N
before IN N
or CC N
after IN N
an DT N
exacerbation NN N
. . N

The DT N
proportion NN o
of IN o
cases NNS o
attending VBG o
the DT o
physician NN o
doubled VBD o
and CC o
with IN o
a DT o
trip NN o
to TO o
the DT o
Emergency NNP o
Room NNP o
( ( o
ER NNP o
) ) o
increased VBD N
approximately RB N
ninefold JJ N
during IN N
the DT N
reporting NN N
period NN N
in IN N
which WDT N
the DT N
exacerbation NN N
occurred VBD N
compared VBN N
with IN N
the DT N
previous JJ N
month NN N
. . N

This DT N
study NN N
has VBZ N
shown VBN N
that IN N
use NN N
of IN N
an DT N
IVRS NNP N
, , N
even RB N
in IN N
elderly JJ p
patients NNS p
, , N
is VBZ N
an DT N
effective JJ N
means NNS N
of IN N
gathering VBG N
RU NNP N
data NNS N
over IN N
long JJ N
periods NNS N
. . N

The DT N
study NN N
findings NNS N
suggest VBP N
that IN N
the DT N
advent NN N
of IN N
effective JJ N
therapeutic JJ N
interventions NNS N
, , N
particularly RB N
any DT N
with IN N
the DT N
ability NN N
to TO N
minimize VB N
exacerbations NNS N
and CC N
limit NN N
disease NN N
progression NN N
, , N
could MD N
impact VB N
on IN N
the DT N
health NN N
care NN N
services NNS N
used VBN N
and CC N
potentially RB N
reduce VB N
associated JJ N
costs NNS N
. . N

-DOCSTART- -19958945- O O

A DT N
prospective JJ N
, , N
randomized JJ N
trial NN N
of IN N
nerve NN N
monitoring NN N
of IN N
the DT N
external JJ N
branch NN N
of IN N
the DT N
superior JJ N
laryngeal NN N
nerve NN N
during IN N
thyroidectomy NN i
under IN N
local/regional JJ i
anesthesia NN i
and CC i
IV NNP i
sedation NN i
. . i

BACKGROUND IN N
The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
assess VB N
the DT N
impact NN N
of IN N
the DT N
neuromonitoring NN N
of IN N
the DT N
external JJ N
branch NN N
of IN N
the DT N
superior JJ N
laryngeal NN N
nerve NN N
( ( N
EBSLN NNP N
) ) N
on IN N
the DT N
voice NN o
quality NN o
after IN N
mini-incision NN i
thyroidectomy NN i
under IN N
local/regional JJ i
anesthesia NN i
and CC i
intravenous JJ i
sedation NN i
. . i

METHODS NNP N
Patients NNPS p
undergoing VBG p
mini-incision JJ i
thyroidectomy NN i
under IN i
local JJ i
anesthesia NN i
were VBD N
prospectively RB N
randomized VBN N
for IN N
either DT N
nerve JJ i
monitoring NN i
of IN i
the DT i
EBSLN NNP i
( ( N
group NN N
1 CD N
) ) N
or CC i
no DT i
nerve NN i
monitoring NN i
( ( N
group NN N
2 CD N
) ) N
. . N

Voice NNP o
and CC o
swallowing VBG o
assessment NN N
were VBD N
obtained VBN N
by IN N
using VBG N
the DT N
Voice NNP o
Handicap NNP o
Index-10 NNP o
( ( o
VHI-10 NNP o
) ) o
and CC o
the DT o
Reflux NNP o
Symptom NNP o
Index NNP o
questionnaires NNS o
( ( o
RSI NNP o
) ) o
before IN N
surgery NN N
and CC N
at IN N
3 CD N
weeks NNS N
and CC N
3 CD N
months NNS N
after IN N
surgery NN N
. . N

RESULTS NNP N
Recruitment NNP p
led VBD p
to TO p
22 CD p
patients NNS p
in IN p
group NN p
1 CD p
and CC p
25 CD p
patients NNS p
in IN p
group NN p
2 CD p
. . p

The DT N
rate NN o
of IN o
visualized JJ o
EBSLN NNP o
was VBD N
higher RBR N
in IN N
group NN N
1 CD N
( ( N
66 CD N
% NN N
vs JJ N
21 CD N
% NN N
; : N
P NNP N
= NNP N
.003 NNP N
) ) N
. . N

Contrary JJ N
to TO N
group NN N
1 CD N
, , N
in IN N
group NN N
2 CD N
, , N
the DT N
median JJ o
total JJ o
VHI-10 NNP o
score NN o
was VBD N
significantly RB N
higher JJR N
3 CD N
months NNS N
after IN N
surgery NN N
( ( N
P NNP N
= NNP N
.034 NNP N
) ) N
compared VBN N
with IN N
preoperatively RB N
, , N
indicating VBG N
a DT N
subjective JJ N
voice NN N
handicap NN N
. . N

In IN N
both DT N
groups NNS N
, , N
there EX N
was VBD N
no DT N
difference NN N
in IN N
median JJ o
total NN o
RSI NNP o
score NN o
before IN N
surgery NN N
or CC N
at IN N
3 CD N
weeks NNS N
and CC N
3 CD N
months NNS N
after IN N
surgery NN N
. . N

CONCLUSION NNP N
Nerve NNP N
monitoring NN N
aids NNS N
in IN N
the DT N
visualization NN N
of IN N
the DT N
EBSLN NNP o
during IN N
mini-incision JJ i
thyroidectomy NN i
under IN N
local/regional JJ i
anesthesia NN i
and CC N
leads VBZ N
to TO N
an DT N
improvement NN N
in IN N
patient-assessed JJ N
voice NN o
quality NN o
after IN N
surgery NN N
but CC N
does VBZ N
not RB N
impact VB N
swallowing VBG o
. . o

-DOCSTART- -23134960- O O

[ JJ N
Effects NNS N
of IN N
transcutaneous JJ i
electrical JJ i
stimulation NN i
of IN i
auricular JJ i
Shenmen NNP i
point NN i
on IN N
postoperative JJ N
nausea NN N
and CC N
vomiting NN N
and CC N
patient-controlled JJ N
epidural JJ N
analgesia NN N
in IN N
cesarean JJ p
section NN p
] NNP p
. . N

OBJECTIVE NNP N
To TO N
investigate VB N
the DT N
effects NNS N
of IN N
transcutaneous JJ N
electrical JJ N
stimulation NN N
of IN N
auricular JJ N
Shenmen NNP N
point NN N
on IN N
postoperative JJ N
nausea NN N
and CC N
vomiting NN N
and CC N
patient-controlled JJ N
epidural JJ N
analgesia NN N
in IN N
cesarean JJ N
section NN N
. . N

METHODS NNP N
After IN N
IRB NNP N
approval NN N
and CC N
informed JJ N
consent NN N
, , N
one CD p
hundred CD p
and CC p
eighty VB p
singleton NN p
primiparas IN p
undergoing VBG p
elective JJ p
cesarean JJ p
section NN p
, , p
in IN p
Qingdao NNP p
Municipal NNP p
Hospital NNP p
, , p
and CC p
Qingdao NNP p
Hiser NNP p
Medical NNP p
Center NNP p
, , p
from IN p
November NNP p
2011 CD p
to TO p
March NNP p
2012 CD p
, , p
were VBD p
randomly RB p
assigned VBN p
to TO N
three CD N
groups NNS N
: : N
transcutaneous JJ i
electrical JJ i
stimulation NN i
of IN i
auricular JJ i
Shenmen NNP i
point NN i
group NN i
( ( N
group NN N
A NNP N
, , N
n JJ N
= NNP N
60 CD N
) ) N
, , N
transcutaneous JJ i
electrical JJ i
stimulation NN i
of IN i
auricular JJ i
Eye NNP i
point NN i
group NN i
( ( N
group NN N
B NNP N
, , N
n JJ N
= NNP N
60 CD N
) ) N
and CC N
control NN i
group NN i
( ( N
group NN N
C NNP N
, , N
n JJ N
= NNP N
60 CD N
) ) N
. . N

Women NNP N
of IN N
group NN N
A NNP N
received VBD N
transcutaneous JJ i
electrical JJ i
stimulation NN i
of IN N
auricular JJ N
Shenmen NNP N
point NN N
( ( N
frequency NN N
1.5 CD N
HZ NNP N
) ) N
at IN N
the DT N
time NN N
of IN N
preoperation NN N
, , N
4 CD N
, , N
10 CD N
and CC N
22 CD N
hours NNS N
of IN N
postoperation NN N
for IN N
30 CD N
minutes NNS N
. . N

The DT N
strength NN N
was VBD N
controlled VBN N
by IN N
themselves PRP N
. . N

Women NNP N
of IN N
group NN N
B NNP N
received VBD N
stimulation NN N
of IN N
auricular JJ N
Eye NNP N
point NN N
as IN N
group NN N
A NNP N
. . N

Women NNP N
of IN N
group NN N
C NNP N
received VBD N
pressurization NN i
and CC i
connected VBN i
line NN i
were VBD i
the DT i
same JJ i
with IN i
group NN i
A NNP i
, , i
but CC i
without IN i
electrical JJ i
stimulation NN i
. . i

The DT N
following JJ N
indexes NNS N
was VBD N
observed VBN N
: : N
the DT N
incidence NN N
of IN N
postoperative JJ N
nausea NN N
and CC N
vomiting NN N
( ( N
PONV NNP N
) ) N
for IN N
48 CD N
hours NNS N
; : N
the DT N
rate NN N
of IN N
metoclopramide NN N
; : N
the DT o
visual JJ o
analogue NN o
scale NN o
( ( o
VAS NNP o
) ) o
score NN o
of IN o
rest NN o
pain NN o
, , o
uterine JJ o
contration NN o
pain NN o
and CC o
dynamic JJ o
pain NN o
at IN o
the DT o
time NN o
of IN o
postoperation NN o
for IN o
6 CD o
, , o
12 CD o
, , o
24 CD o
and CC o
48 CD o
hours NNS o
( ( o
T NNP o
( ( o
1 CD o
) ) o
-T NN o
( ( o
4 CD o
) ) o
) ) o
; : o
the DT o
total JJ o
number NN o
and CC o
effective JJ o
compressions NNS o
number NN o
of IN o
patient-controlled JJ o
epidural JJ o
analgesia NN o
( ( o
PCEA NNP o
) ) o
; : o
the DT o
dose NN o
of IN o
analgesia JJ o
mixture NN o
; : o
the DT o
anal JJ o
exhaust JJ o
time NN o
; : o
the DT o
volume NN o
of IN o
postoperative JJ o
bleeding NN o
for IN o
6 CD o
hours NNS o
of IN o
postoperation NN o
and CC o
the DT o
other JJ o
side NN o
effects NNS o
. . o

RESULTS NNP N
Compared NNP N
with IN N
group NN N
B NNP N
and CC N
group NN N
C NNP N
, , N
the DT N
incidence NN o
of IN o
PONV NNP o
, , o
the DT o
rate NN o
of IN o
metoclopramide NN o
, , o
the DT o
VAS NNP o
score NN o
at IN N
the DT N
time NN N
T NNP N
( ( N
1 CD N
) ) N
-T NN N
( ( N
4 CD N
) ) N
, , N
the DT N
total JJ o
number NN o
and CC o
effective JJ o
compressions NNS o
number NN o
of IN o
PCEA NNP o
, , o
the DT o
ratio NN o
of IN o
the DT o
total JJ o
number NN o
with IN o
effective JJ o
compressions NNS o
number NN o
and CC o
the DT o
dose NN o
of IN o
analgesia JJ o
mixture NN o
were VBD N
decreased VBN N
in IN N
group NN N
A NNP N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
, , N
but CC N
no DT N
difference NN N
compared VBN N
group NN N
B NNP N
with IN N
group NN N
C NNP N
( ( N
P NNP N
> NNP N
0.05 CD N
) ) N
. . N

The DT N
anal JJ o
exhaust NN o
time NN o
and CC o
the DT o
volume NN o
of IN o
postoperative JJ o
bleeding NN o
for IN N
6 CD N
hours NNS N
of IN N
postoperation NN N
were VBD N
no DT N
difference NN N
in IN N
the DT N
three CD N
groups NNS N
( ( N
P NNP N
> NNP N
0.05 CD N
) ) N
. . N

No UH N
other JJ N
side NN o
effects NNS o
were VBD N
observed VBN N
. . N

CONCLUSION NNP N
Transcutaneous NNP N
electrical JJ N
stimulation NN N
of IN N
auricular JJ N
Shenmen NNS N
point NN N
can MD N
reduce VB N
the DT N
incidence NN o
of IN o
PONV NNP o
and CC o
improves VBZ o
analgesia JJ o
effect NN o
of IN o
PCEA NNP o
in IN o
postoperation NN o
of IN o
cesarean JJ o
section NN o
. . o

-DOCSTART- -9203648- O O

Safety NN o
and CC o
pharmacokinetics NNS o
of IN N
hyperimmune JJ i
anti-human JJ i
immunodeficiency NN i
virus NN i
( ( i
HIV NNP i
) ) i
immunoglobulin NN i
administered VBN N
to TO N
HIV-infected NNP p
pregnant JJ p
women NNS p
and CC p
their PRP$ p
newborns NNS p
. . p

Pediatric NNP N
AIDS NNP N
Clinical NNP N
Trials NNP N
Group NNP N
Protocol NNP N
185 CD N
Pharmacokinetic NNP N
Study NNP N
Group NNP N
. . N

The DT N
pharmacokinetics NNS o
and CC o
safety NN o
of IN N
hyperimmune JJ i
anti-human JJ i
immunodeficiency NN i
virus NN i
( ( i
HIV NNP i
) ) i
intravenous JJ i
immunoglobulin NN i
( ( i
HIVIG NNP i
) ) i
were VBD N
evaluated VBN N
in IN N
the DT N
first JJ p
28 CD p
maternal-infant JJ p
pairs NNS p
enrolled VBN p
in IN p
a DT p
randomized JJ p
, , p
intravenous JJ p
immunoglobulin NN p
( ( p
IVIG NNP p
) ) p
-controlled VBD p
trial NN p
of IN p
HIVIG NNP p
maternal-infant JJ p
HIV NNP p
transmission NN p
prophylaxis NN p
. . p

Using VBG N
200 CD N
mg/kg NN N
, , N
mean JJ N
half-life NN N
and CC N
volume NN N
of IN N
distribution NN N
( ( N
Vd NNP N
) ) N
in IN N
women NNS N
were VBD N
15 CD N
days NNS N
and CC N
72 CD N
mL/kg NN N
, , N
respectively RB N
, , N
after IN N
one CD N
and CC N
32 CD N
days NNS N
and CC N
154 CD N
mL/kg NN N
after IN N
three CD N
monthly JJ N
infusions NNS N
, , N
with IN N
stable JJ N
4 CD N
mL/kg/day JJ N
clearance NN N
. . N

Transplacental JJ N
passage NN N
occurred VBD N
. . N

Newborn JJ N
single-dose JJ N
half-life NN N
, , N
Vd NNP N
, , N
and CC N
clearance NN N
were VBD N
30 CD N
days NNS N
, , N
143 CD N
mL/kg NN N
, , N
and CC N
4 CD N
mL/kg/day NN N
, , N
respectively RB N
. . N

HIVIG NNP o
rapidly RB o
cleared VBD o
maternal JJ o
serum NN o
immune JJ o
complex-dissociated JJ o
p24 NN o
antigen NN o
, , o
and CC o
plasma VB o
HIV-1 NNP o
RNA NNP o
levels NNS o
were VBD N
stable JJ N
. . N

Mild NNP N
to TO N
moderate VB N
adverse JJ o
clinical JJ o
effects NNS o
occurred VBD N
in IN N
2 CD N
of IN N
103 CD N
maternal JJ N
and CC N
2 CD N
of IN N
25 CD N
infant JJ N
infusions NNS N
. . N

No DT N
adverse JJ o
hematologic NN o
, , o
blood NN o
chemistry NN o
, , o
or CC o
immunologic JJ o
effects NNS o
were VBD N
seen VBN N
. . N

HIVIG NNP i
is VBZ N
well-tolerated JJ o
in IN N
HIV-infected NNP p
pregnant JJ p
women NNS p
and CC p
their PRP$ p
newborns NNS p
, , N
clears NNS N
antigenemia VBP N
, , N
crosses VBZ N
the DT N
placenta NN N
, , N
and CC N
exhibits VBZ N
pharmacokinetics NNS o
similar JJ N
to TO N
those DT N
of IN N
other JJ N
immunoglobulin JJ N
preparations NNS N
. . N

-DOCSTART- -15324531- O O

Oxaprozin NNP i
versus NN N
diclofenac NN i
in IN N
NSAID-refractory NNP N
periarthritis NN N
pain NN N
of IN N
the DT N
shoulder NN N
. . N

OBJECTIVE UH N
To TO N
evaluate VB N
the DT N
efficacy NN N
and CC N
safety NN N
of IN N
oxaprozin NN i
in IN N
comparison NN N
with IN N
diclofenac NN i
in IN N
patients NNS p
with IN p
periarthritis NN p
pain NN p
of IN p
the DT p
shoulder NN p
previously RB p
unsuccessfully RB p
treated VBN p
with IN p
nonsteroidal JJ p
anti-inflammatory JJ p
drugs NNS p
other JJ p
than IN p
diclofenac NNS p
and CC p
oxaprozin NN p
. . p

METHODS NNP N
In IN N
this DT N
open JJ N
, , N
multicentre NN N
, , N
randomised VBN N
, , N
controlled VBN N
study NN N
, , N
eligible JJ p
patients NNS p
with IN p
periarthritis NN p
of IN p
the DT p
shoulder NN p
were VBD N
randomised VBN N
to TO N
receive VB i
either RB i
oxaprozin JJ i
1200 CD i
mg NN i
once RB i
daily JJ i
( ( i
n JJ i
= NNP i
49 CD i
) ) i
or CC i
diclofenac $ i
50 CD i
mg NN i
three CD i
times NNS i
daily RB i
( ( i
n JJ i
= NNP i
47 CD i
) ) i
. . i

The DT N
treatment NN N
period NN N
was VBD N
15 CD N
+/- JJ N
1 CD N
days NNS N
. . N

The DT N
study NN N
was VBD N
planned VBN N
on IN N
a DT N
hypothesis NN N
of IN N
equivalence NN N
between IN N
the DT N
two CD N
study NN N
drugs NNS N
. . N

The DT N
primary JJ N
study NN N
endpoint NN N
was VBD N
the DT N
change NN o
from IN o
baseline NN o
at IN o
day NN o
15 CD o
in IN o
the DT o
patient-assessed JJ o
shoulder NN o
pain NN o
score NN o
. . o

Secondary JJ N
efficacy NN N
variables NNS N
included VBD N
investigator-assessed JJ o
shoulder NN o
function NN o
, , o
patient-assessed JJ o
quality NN o
of IN o
life NN o
on IN o
the DT o
Short-Form-36 NNP o
( ( o
SF-36 NNP o
) ) o
Acute NNP o
Health NNP o
Survey NNP o
and CC o
both DT o
patients NNS o
' POS o
and CC o
investigators NNS o
' POS o
overall JJ o
assessment NN o
of IN o
efficacy NN o
. . o

RESULTS NNP N
At IN N
day NN N
15 CD N
, , N
the DT N
mean NN N
changes NNS N
in IN N
shoulder NN o
pain NN o
score NN o
from IN N
baseline NN N
in IN N
the DT N
oxaprozin NN i
and CC N
diclofenac NN i
groups NNS N
were VBD N
-5.85 JJ N
+/- JJ N
SD NNP N
4.62 CD N
and CC N
-5.54 JJ N
+/- JJ N
SD NNP N
4.41 CD N
, , N
respectively RB N
. . N

The DT N
difference NN o
between IN N
the DT N
two CD N
groups NNS N
was VBD N
not RB N
statistically RB N
significant JJ N
, , N
confirming VBG N
the DT N
hypothesis NN N
of IN N
the DT N
study NN N
that IN N
oxaprozin NN i
is VBZ N
as RB N
effective JJ N
as IN N
diclofenac NN i
. . i

Investigator-assessed JJ o
shoulder NN o
function NN o
improved VBN N
in IN N
both DT N
groups NNS N
but CC N
more JJR N
so RB N
in IN N
the DT N
oxaprozin NN N
group NN N
( ( N
p JJ N
= RB N
0.028 CD N
at IN N
day NN N
15 CD N
) ) N
. . N

Quality NN o
of IN o
life NN o
as IN o
measured VBN o
by IN o
SF-36 NNP o
total JJ o
score NN o
was VBD N
also RB N
improved VBN N
in IN N
both DT N
treatment NN N
groups NNS N
, , N
with IN N
a DT N
trend NN N
toward IN N
greater JJR N
improvement NN N
in IN N
the DT N
oxaprozin NN i
group NN N
. . N

Furthermore RB N
, , N
a DT N
significantly RB N
more RBR N
favourable JJ N
effect NN o
on IN N
the DT N
SF-36 NNP o
'mental NNP o
health NN o
' '' o
item NN o
was VBD N
observed VBN N
in IN N
oxaprozin NN N
compared VBN N
with IN N
diclofenac-treated JJ N
patients NNS N
at IN N
day NN N
15 CD N
( ( N
p NN N
= RB N
0.0202 CD N
) ) N
. . N

As IN N
assessed VBN N
by IN N
investigators NNS N
, , N
the DT N
overall JJ N
efficacy NN N
of IN N
oxaprozin NN i
was VBD N
superior JJ N
to TO N
that DT N
for IN N
diclofenac NN i
at IN N
visit NN N
3 CD N
( ( N
8 CD N
+/- JJ N
1 CD N
days NNS N
) ) N
( ( N
p JJ N
= NNP N
0.0067 CD N
) ) N
. . N

Patients NNS p
also RB p
assessed VBD p
the DT p
overall JJ p
efficacy NN o
of IN p
oxaprozin NN i
as IN p
superior JJ p
to TO p
that DT p
of IN p
diclofenac NN i
at IN N
visits NNS N
3 CD N
( ( N
8 CD N
+/- JJ N
1 CD N
days NNS N
) ) N
( ( N
p JJ N
= NNP N
0.0235 CD N
) ) N
and CC N
4 CD N
( ( N
15 CD N
+/- JJ N
1 CD N
days NNS N
) ) N
( ( N
p JJ N
= NNP N
0.0272 CD N
) ) N
. . N

Only RB N
six CD N
adverse JJ o
events NNS o
, , N
all DT N
of IN N
which WDT N
were VBD N
mild NNS N
or CC N
moderate VB N
in IN N
intensity NN N
and CC N
occurred VBD N
in IN N
four CD N
diclofenac NN i
recipients NNS N
, , N
were VBD N
observed VBN N
in IN N
the DT N
study NN N
. . N

CONCLUSIONS NNP N
As IN N
expected VBN N
, , N
once-daily JJ N
oxaprozin NN i
proved VBD N
to TO N
be VB N
as RB N
effective JJ N
as IN N
diclofenac NN i
three CD N
times NNS N
daily RB N
in IN N
reducing VBG N
the DT N
primary JJ N
efficacy NN N
variable NN N
of IN N
patient-assessed JJ o
shoulder NN o
pain NN o
score NN o
in IN N
patients NNS p
with IN p
periarthritis NN p
of IN p
the DT p
shoulder NN p
refractory NN p
to TO N
previous JJ N
treatments NNS N
with IN N
other JJ N
NSAIDs NNP N
. . N

Oxaprozin NNP i
was VBD N
shown VBN N
to TO N
be VB N
superior JJ N
to TO N
diclofenac VB i
in IN N
improving VBG N
shoulder NN o
function NN o
and CC N
was VBD N
considered VBN N
by IN N
investigators NNS N
and CC N
patients NNS N
to TO N
have VB N
greater JJR N
overall JJ N
efficacy NN N
than IN N
diclofenac NN i
. . i

In IN N
addition NN N
, , N
oxaprozin NN i
showed VBD N
a DT N
trend NN N
toward IN N
superior JJ N
results NNS N
in IN N
improving VBG N
patients NNS N
' POS N
quality NN o
of IN o
life NN o
compared VBN N
with IN N
diclofenac NN i
. . i

A DT N
trend NN N
towards VBZ N
better JJR N
tolerability NN o
results NNS o
for IN N
oxaprozin JJ i
compared VBN N
with IN N
diclofenac NN i
was VBD N
also RB N
noted VBN N
. . N

-DOCSTART- -9099447- O O

Partial-area JJ p
method NN p
in IN p
bioequivalence NN p
assessment NN N
: : N
naproxen NN i
. . i

Regulatory NNP N
authorities NNS N
require VBP N
demonstration NN N
of IN N
bioequivalence NN p
through IN N
comparisons NNS N
of IN N
different JJ N
pharmacokinetic JJ N
parameters NNS N
, , N
the DT N
area NN o
under IN o
the DT o
plasma JJ o
concentration-time JJ o
curve NN o
( ( o
AUC NNP o
) ) o
, , o
the DT o
maximum JJ o
plasma JJ o
concentration NN o
( ( o
Cmax NNP o
) ) o
, , N
and CC N
the DT o
time NN o
to TO o
reach VB o
peak JJ o
concentration NN o
( ( o
Tmax NNP o
) ) o
. . o

The DT N
applicability NN N
and CC N
validity NN N
of IN N
regulatory JJ N
requirements NNS N
have VBP N
been VBN N
widely RB N
criticized VBN N
on IN N
statistical JJ N
and CC N
clinical JJ N
relevance NN N
grounds NNS N
. . N

For IN N
most JJS N
noncomplicated JJ N
absorption NN N
models NNS N
, , N
the DT N
AUC NNP o
correlates VBZ N
well RB N
with IN N
the DT N
extent NN N
of IN N
absorption NN N
. . N

However RB N
, , N
in IN N
nonlinear JJ N
models NNS N
of IN N
absorption NN N
, , N
in IN N
mechanisms NN N
involving VBG N
recycling NN N
of IN N
drugs NNS N
, , N
and CC N
for IN N
drugs NNS N
with IN N
long JJ N
half-life NN N
, , N
the DT N
use NN N
of IN N
total JJ N
AUC NNP o
( ( N
from IN N
zero CD N
to TO N
infinity NN N
) ) N
can MD N
give VB N
erroneous JJ N
and CC N
clinically RB N
irrelevant JJ N
results NNS N
since IN N
the DT N
area NN N
is VBZ N
mostly RB N
determined VBN N
by IN N
elimination NN N
phase NN N
or CC N
by IN N
recycling VBG N
. . N

The DT N
calculation NN N
of IN N
total JJ N
AUC NNP o
also RB N
involves VBZ N
prolonged JJ N
sampling NN N
, , N
adding VBG N
to TO N
the DT N
cost NN N
and CC N
risks NNS N
associated VBN N
with IN N
bioequivalence NN N
studies NNS N
. . N

The DT N
use NN N
of IN N
Cmax NNP o
or CC o
Tmax NNP o
as IN N
a DT N
measure NN N
of IN N
rate NN N
of IN N
absorption NN N
, , N
to TO N
correlate VB N
with IN N
clinical JJ N
relevance NN N
, , N
is VBZ N
widely RB N
criticized VBN N
on IN N
logical JJ N
, , N
technical JJ N
, , N
and CC N
statistical JJ N
grounds NNS N
. . N

For IN N
drugs NNS N
used VBN N
on IN N
a DT N
multiple-dose JJ N
basis NN N
, , N
Cmax NNP o
and CC N
Tmax NNP o
evaluations NNS N
become VBP N
redundant JJ N
since IN N
the DT N
average JJ N
plateau NN o
concentration NN o
is VBZ N
not RB N
affected VBN N
by IN N
these DT N
parameters NNS N
. . N

To TO N
resolve VB N
the DT N
drawbacks NNS N
in IN N
the DT N
traditional JJ N
methodology NN N
of IN N
bioequivalence NN N
evaluation NN N
, , N
the DT N
use NN N
of IN N
partial JJ N
areas NNS N
in IN N
lieu NN N
of IN N
total JJ N
AUC NNP o
, , o
Tmax NNP o
, , o
and CC o
Cmax NNP o
is VBZ N
suggested VBN N
. . N

This DT N
study NN N
investigates VBZ N
the DT N
logic NN N
and CC N
robustness NN N
of IN N
the DT N
partial-area JJ p
method NN p
in IN p
establishing VBG p
bioequivalence NN p
. . p

We PRP N
conclude VBP N
that IN N
the DT N
5h CD o
AUC NNP o
is VBZ N
a DT N
more RBR N
relevant JJ N
parameter NN N
to TO N
establish VB N
naproxen NNS i
bioequivalence NN N
than IN N
AUCinf NNP o
. . o

We PRP N
recommend VBP N
against IN N
using VBG N
symmetrical JJ N
confidence NN N
intervals NNS N
and CC N
report NN N
excellent JJ N
agreement NN N
among IN N
several JJ N
methods NNS N
of IN N
calculating VBG N
confidence NN o
intervals NNS o
, , o
probability NN o
values NNS o
, , o
and CC o
nonparametric JJ o
tests NNS o
. . o

We PRP N
suggest VBP N
that IN N
a DT N
single-point JJ o
short-term JJ o
AUC NNP o
is VBZ N
a DT N
better JJR N
indicator NN N
of IN N
the DT N
bioequivalence NN N
of IN N
generic JJ N
products NNS N
than IN N
the DT N
total JJ N
AUC NNP o
, , o
Cmax NNP o
, , o
and CC o
Tmax NNP o
as IN N
required VBN N
currently RB N
by IN N
the DT N
regulatory JJ N
authorities NNS N
. . N

-DOCSTART- -17367324- O O

p16 NN o
( ( o
INK4a NNP o
) ) o
Expression NN o
does VBZ N
not RB N
predict VB N
the DT N
outcome NN N
of IN N
cervical JJ N
intraepithelial JJ N
neoplasia NN N
grade VBD N
2 CD N
. . N

Spontaneous JJ N
regression NN N
of IN N
cervical JJ N
intraepithelial JJ N
neoplasia NN N
grade VBD N
2 CD N
( ( N
CIN2 NNP N
) ) N
lesions NNS N
has VBZ N
been VBN N
recognized VBN N
since IN N
1955 CD N
, , N
but CC N
predictors NNS N
of IN N
this DT N
are VBP N
poorly RB N
understood JJ N
. . N

Among IN N
the DT N
predictive JJ N
markers NNS N
studied VBN N
, , N
p16 FW i
( ( i
INK4a NNP i
) ) i
has VBZ N
been VBN N
suggested VBN N
to TO N
be VB N
of IN N
some DT N
value NN N
in IN N
monitoring VBG N
the DT N
diagnosis NN N
of IN N
CIN2 NNP N
. . N

In IN N
this DT N
clinical JJ N
trial NN N
, , N
90 CD p
Brazilian JJ p
women NNS p
, , p
diagnosed VBD p
to TO p
CIN2 NNP p
and CC p
high-risk JJ p
human JJ p
papillomavirus NN p
infection NN p
, , p
were VBD p
randomized VBN p
into IN p
two CD p
groups NNS p
of IN p
equal JJ p
size NN p
: : p
45 CD p
women NNS p
whose WP$ p
lesions NNS i
were VBD i
excised VBN i
and CC p
45 CD p
women NNS p
subjected VBN p
to TO p
prospective JJ i
follow-up NN i
at IN p
3-month JJ p
intervals NNS p
at IN p
least JJS p
for IN p
1 CD p
year NN p
( ( p
mean JJ p
6.8 CD p
months NNS p
) ) p
. . p

p16 NN o
( ( o
INK4a NNP o
) ) o
expression NN o
was VBD N
analyzed VBN N
in IN N
paraffin-embedded JJ N
sections NNS N
using VBG N
immunohistochemical JJ i
staining NN i
. . i

Among IN N
the DT N
45 CD p
women NNS p
in IN N
the DT N
follow-up JJ N
group NN N
, , N
42 CD N
% NN N
experienced VBD N
spontaneous JJ N
regression NN N
, , N
11 CD N
% NN N
showed VBD N
persistence NN N
, , N
22 CD N
% NN N
progressed VBN N
to TO N
CIN3 NNP N
, , N
and CC N
20 CD N
% NN N
had VBD N
partial JJ N
regression NN N
to TO N
CIN1 NNP N
or CC N
ASCUS NNP N
( ( N
atypical JJ N
squamous JJ N
cell NN N
undetermined JJ N
signifiance NN N
) ) N
. . N

p16 NN o
( ( o
INK4a NNP o
) ) o
expression NN o
was VBD N
detected VBN N
in IN N
68.9 CD N
% NN N
of IN N
the DT N
patients NNS N
. . N

In IN N
univariate JJ o
survival NN o
( ( o
Cox NNP o
) ) o
analysis NN o
, , N
no DT N
significant JJ N
difference NN N
in IN N
regression NN N
was VBD N
obtained VBN N
between IN N
p16 NN i
( ( i
INK4a NNP i
) ) i
-negative NN i
and CC i
-positive JJ i
CIN2 NNP N
lesions NNS N
( ( N
adjusted VBN N
HR NNP N
= NNP N
1.1 CD N
; : N
95 CD N
% NN N
CI NNP N
0.6-2.0 NN N
) ) N
. . N

In IN N
conclusion NN N
, , N
p16 NN o
( ( o
INK4a NNP o
) ) o
expression NN o
could MD N
be VB N
useful JJ N
in IN N
the DT N
diagnosis NN o
of IN o
CIN2 NNP o
. . o

However RB N
, , N
it PRP N
failed VBD N
to TO N
predict VB N
the DT N
outcome NN N
of IN N
CIN2 NNP o
. . o

Because IN N
of IN N
its PRP$ N
high JJ N
spontaneous JJ N
regression NN N
rate NN N
, , N
follow-up NN N
could MD N
be VB N
considered VBN N
as IN N
a DT N
management NN N
option NN N
of IN N
CIN2 NNP N
in IN N
young JJ N
and CC N
compliant JJ N
women NNS N
. . N

-DOCSTART- -11545671- O O

A DT N
randomized JJ N
effectiveness NN o
trial NN N
of IN N
collaborative JJ i
care NN i
for IN N
patients NNS p
with IN p
panic JJ p
disorder NN p
in IN p
primary JJ p
care NN p
. . p

BACKGROUND NNP N
Effectiveness NNP o
studies NNS N
have VBP N
tested VBN N
interventions NNS N
to TO N
improve VB N
quality NN o
of IN o
care NN o
for IN N
depression NN N
in IN N
primary JJ N
care NN N
, , N
but CC N
none NN N
, , N
to TO N
our PRP$ N
knowledge NN N
, , N
have VBP N
been VBN N
completed VBN N
for IN N
panic JJ N
disorder NN N
( ( N
PD NNP N
) ) N
in IN N
this DT N
setting NN N
. . N

This DT N
study NN N
sought VBD N
to TO N
test VB N
the DT N
clinical JJ o
effectiveness NN o
of IN N
PD NNP i
pharmacotherapy NN i
embedded VBD i
in IN i
a DT i
disease NN i
management NN i
framework NN i
of IN i
collaborative JJ i
care NN i
( ( i
CC NNP i
) ) i
. . i

METHODS NNP N
One CD p
hundred VBD p
fifteen JJ p
patients NNS p
with IN p
PD NNP p
from IN p
3 CD p
primary JJ p
care NN p
clinics NNS p
were VBD N
randomized VBN N
to TO N
CC NNP i
or CC N
usual JJ i
care NN i
( ( i
UC NNP i
) ) i
. . i

Patients NNS N
in IN N
CC NNP N
( ( N
n JJ N
= NNP N
57 CD N
) ) N
received VBD N
educational JJ i
videotapes NNS i
and CC i
pamphlets NNS i
; : i
pharmacotherapy NN i
with IN i
the DT i
selective JJ i
serotonin NN i
reuptake NN i
inhibitor NN i
paroxetine NN i
; : i
2 CD i
psychiatrist NN i
visits NNS i
and CC i
2 CD i
telephone NN i
calls NNS i
in IN N
the DT N
first JJ N
8 CD N
weeks NNS N
; : N
and CC N
up RB N
to TO N
5 CD N
telephone NN i
calls NNS i
between IN N
3 CD N
and CC N
12 CD N
months NNS N
' POS N
follow-up NN N
. . N

Usual NNP N
care NN N
patients NNS N
( ( N
n JJ N
= NNP N
58 CD N
) ) N
were VBD N
treated VBN N
by IN N
their PRP$ N
primary JJ N
care NN N
physician NN N
. . N

Telephone CD N
assessments NNS N
of IN N
panic NN o
, , o
anxiety NN o
sensitivity NN o
, , o
depression NN o
, , o
and CC o
disability NN o
variables NNS o
were VBD N
performed VBN N
at IN N
3 CD N
, , N
6 CD N
, , N
9 CD N
, , N
and CC N
12 CD N
months NNS N
' POS N
follow-up NN N
. . N

Adequacy NNP o
of IN o
pharmacotherapy NN o
was VBD N
assessed VBN N
with IN N
an DT N
algorithm NN o
based VBN N
on IN N
a DT N
review NN N
of IN N
efficacy NN N
studies NNS N
. . N

RESULTS JJ N
Patients NNPS N
in IN N
CC NNP N
were VBD N
more RBR N
likely JJ N
to TO N
receive VB N
adequate NN o
( ( o
type NN o
, , o
dose NN o
, , o
duration NN o
) ) o
medication NN o
and CC N
more RBR N
likely JJ N
to TO N
adhere VB o
to TO o
this DT o
medication NN o
at IN N
3 CD N
and CC N
6 CD N
months NNS N
. . N

Random NNP N
regression NN N
analyses NNS N
showed VBD N
that IN N
CC NNP N
patients NNS N
improved VBD o
significantly RB N
more RBR N
over IN N
time NN N
compared VBN N
with IN N
UC NNP N
patients NNS N
on IN N
anxiety NN o
, , o
depression NN o
, , o
and CC o
disability NN o
measures NNS o
, , N
with IN N
the DT N
greatest JJS N
effects NNS o
at IN N
3 CD N
and CC N
6 CD N
months NNS N
. . N

CONCLUSIONS NNP N
Compared NNP N
with IN N
UC NNP N
, , N
CC NNP N
interventions NNS N
significantly RB N
improved VBN N
both DT N
quality NN o
of IN o
care NN o
and CC o
clinical JJ o
and CC o
functional JJ o
outcomes NNS o
in IN N
primary JJ p
care NN p
PD NNP p
patients NNS p
. . p

Clinical JJ N
differences NNS N
were VBD N
greatest JJS N
in IN N
the DT N
first JJ N
6 CD N
months NNS N
, , N
corresponding VBG N
to TO N
the DT N
greater JJR N
quality NN o
of IN o
care NN o
and CC N
the DT N
greater JJR N
intensity NN o
of IN N
intervention NN N
. . N

-DOCSTART- -19570717- O O

Effects NNS N
of IN N
tonabersat NN i
on IN N
migraine NN p
with IN p
aura NN p
: : p
a DT N
randomised JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
crossover NN N
study NN N
. . N

BACKGROUND NNP N
Migraine NNP N
with IN N
aura NN N
is VBZ N
thought VBN N
likely RB N
to TO N
be VB N
caused VBN N
by IN N
cortical JJ N
spreading VBG N
depression NN N
( ( N
CSD NNP N
) ) N
. . N

Tonabersat NNP i
inhibits VBZ N
CSD NNP N
, , N
and CC N
we PRP N
therefore RB N
investigated VBD N
whether IN N
tonabersat NN N
has VBZ N
a DT N
preventive JJ N
effect NN N
in IN N
migraine NN N
with IN N
aura NN N
. . N

METHODS NNP N
In IN N
this DT N
randomised JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
crossover NN N
trial NN N
, , N
40 CD i
mg NN i
tonabersat NN i
once IN i
daily JJ i
was VBD i
compared VBN i
with IN i
matched JJ i
placebo NN i
in IN N
patients NNS p
who WP p
had VBD p
at IN p
least JJS p
one CD p
aura NN p
attack NN p
per IN p
month NN p
during IN p
the DT p
past JJ p
3 CD p
months NNS p
. . p

Randomisation NN N
was VBD N
by IN N
computer-generated JJ N
list NN N
. . N

Patients NNS N
kept VBD N
a DT N
detailed JJ N
diary NN N
to TO N
enable VB N
objective JJ N
diagnosis NN N
of IN N
each DT N
attack NN N
as IN N
migraine NN N
with IN N
aura NN N
, , N
migraine NN N
without IN N
aura NN N
, , N
or CC N
other JJ N
type NN N
of IN N
headache NN N
. . N

Primary JJ N
endpoints NNS N
were VBD N
a DT N
reduction NN o
in IN o
aura NN o
attacks NNS o
with IN o
or CC o
without IN o
headache NN o
and CC o
a DT o
reduction NN o
in IN o
migraine JJ o
headache NN o
days NNS o
with IN o
or CC o
without IN o
an DT o
aura NN o
. . o

Analysis NN N
was VBD N
per IN N
protocol NN N
. . N

This DT N
trial NN N
is VBZ N
registered VBN N
, , N
number NN N
NCT00332007 NNP N
. . N

FINDINGS NNP N
39 CD p
patients NNS p
were VBD p
included VBN p
in IN p
the DT p
study NN p
, , p
of IN p
whom WP p
31 CD p
were VBD p
included VBN p
in IN p
the DT p
statistical JJ p
analysis NN p
of IN p
efficacy NN p
. . p

Median JJ o
( ( o
IQR NNP o
) ) o
attacks NNS o
of IN o
aura NN o
were VBD N
reduced VBN N
from IN N
3.2 CD N
( ( N
1.0-5.0 JJ N
) ) N
per IN N
12 CD N
weeks NNS N
on IN N
placebo NN i
to TO N
1.0 CD N
( ( N
0-3.0 CD N
) ) N
on IN N
tonabersat NN N
( ( N
p=0.01 NN N
) ) N
, , N
whereas VBP N
the DT N
other JJ N
primary JJ N
outcome JJ N
measure NN N
, , N
median JJ o
migraine NN o
headache NN o
days NNS o
with IN o
or CC o
without IN o
aura NN o
, , N
was VBD N
not RB N
significantly RB N
different JJ N
between IN N
placebo NN i
and CC N
tonabersat NN i
groups NNS N
( ( N
3.0 CD N
days NNS N
in IN N
each DT N
group NN N
; : N
p=0.09 NN N
) ) N
. . N

Tonabersat NNP N
was VBD N
well RB N
tolerated VBN o
but CC N
overall JJ N
had VBD N
more RBR N
side-effects NNS N
than IN N
placebo NN N
. . N

INTERPRETATION NNP N
Tonabersat NNP i
showed VBD N
a DT N
preventive JJ N
effect NN N
on IN N
attacks NNS N
of IN N
migraine NN N
aura NN N
but CC N
no DT N
efficacy NN N
on IN N
non-aura JJ N
attacks NNS N
, , N
in IN N
keeping VBG N
with IN N
its PRP$ N
known JJ N
inhibitory JJ N
effect NN N
on IN N
CSD NNP N
. . N

The DT N
results NNS N
support VBD N
the DT N
theory NN N
that IN N
auras NNS N
are VBP N
caused VBN N
by IN N
CSD NNP N
and CC N
that IN N
this DT N
phenomenon NN N
is VBZ N
not RB N
involved VBN N
in IN N
attacks NNS N
without IN N
aura NN N
. . N

FUNDING NN N
Minster NNP N
Pharmaceuticals NNP N
; : N
Lundbeck NNP N
Foundation NNP N
. . N

-DOCSTART- -23532629- O O

Erythropoietin NNP N
treatment NN N
in IN N
chemotherapy-induced JJ N
anemia NN N
in IN N
previously RB p
untreated VBN p
advanced JJ p
esophagogastric JJ p
cancer NN p
patients NNS p
. . p

BACKGROUND NNP N
The DT N
impact NN N
of IN N
erythropoiesis-stimulating JJ N
agents NNS N
in IN N
chemotherapy-induced JJ N
anemia NN N
has VBZ N
been VBN N
a DT N
constant JJ N
topic NN N
of IN N
debate NN N
over IN N
recent JJ N
years NNS N
. . N

We PRP N
prospectively RB N
assessed VBD N
the DT N
efficacy NN N
of IN N
epoetin NN N
beta NN N
( ( N
Epo-b NNP N
) ) N
in IN N
improving VBG N
hemoglobin NN o
( ( o
Hb NNP o
) ) o
levels NNS o
and CC N
outcome NN N
in IN N
patients NNS p
within IN p
an DT p
open JJ p
label NN p
, , p
randomized VBD p
clinical JJ p
phase NN p
II NNP p
trial NN p
with IN p
advanced JJ p
or CC p
metastatic JJ p
gastric/esophagogastric JJ p
cancer NN p
. . p

METHODS NNP N
Previously RB p
untreated VBD p
patients NNS p
were VBD p
randomized VBN p
to TO N
receive VB N
3-weekly JJ N
cycles NNS N
of IN N
capecitabine NN i
( ( N
1000 CD N
mg/m NN N
( ( N
2 CD N
) ) N
bid NN N
) ) N
for IN N
14 CD N
days NNS N
plus CC N
on IN N
day NN N
1 CD N
either CC N
irinotecan JJ i
250 CD N
mg/m NN N
( ( N
2 CD N
) ) N
or CC N
cisplatin $ i
80 CD N
mg/m NN N
( ( N
2 CD N
) ) N
. . N

Epo-b NNP i
( ( N
30000 CD N
IU NNP N
once RB N
weekly RB N
) ) N
was VBD N
initiated VBN N
in IN N
patients NNS N
with IN N
Hb NNP N
< NNP N
11 CD N
g/dl NN N
and CC N
continued VBD N
until IN N
Hb NNP N
?12 NNP N
g/dl NN N
was VBD N
reached VBN N
. . N

If IN N
after IN N
4 CD N
weeks NNS N
the DT o
Hb NNP o
increase NN o
was VBD N
< JJ N
0.5 CD N
g/dl NN N
, , N
Epo-b NNP N
was VBD N
increased VBN N
to TO N
30000 CD N
IU NNP N
, , N
twice RB N
weekly RB N
. . N

RESULTS NNP N
Of IN N
118 CD p
patients NNS p
enrolled VBD p
, , p
32 CD N
received VBD N
Epo-b NNP N
treatment NN N
; : N
of IN N
these DT N
, , N
65 CD N
% NN N
achieved VBD N
an DT N
increase NN N
in IN N
Hb NNP o
levels NNS o
of IN o
at IN N
least JJS N
2 CD N
g/dl NN N
, , N
with IN N
74 CD N
% NN N
achieving VBG N
the DT N
target NN N
Hb NNP N
of IN N
?12 NNP N
g/dl NN N
. . N

Within IN N
the DT N
study NN N
population NN N
, , N
patients NNS N
receiving VBG N
Epo-b NNP N
showed VBD N
better JJR o
overall JJ o
survival NN o
( ( o
median JJ o
14.5 CD N
vs. FW N
8.0 CD N
months NNS N
, , N
P NNP N
= NNP N
0.056 CD N
) ) N
as RB N
well RB N
as IN N
a DT N
significantly RB N
improved VBN o
disease NN o
control NN o
rate NN o
( ( o
78 CD o
vs. FW N
55 CD N
% NN N
, , N
P NNP N
= NNP N
0.025 CD N
) ) N
. . N

Patients NNS N
in IN N
the DT N
irinotecan JJ N
group NN N
profited VBD N
significantly RB N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
in IN N
terms NNS o
of IN o
progression-free JJ o
survival NN o
and CC o
overall JJ o
survival NN o
under IN o
Epo-b NNP N
treatment NN N
( ( N
median JJ N
6.5 CD N
vs JJ N
4.1 CD N
months NNS N
and CC N
median JJ N
15.4 CD N
vs JJ N
8.4 CD N
months NNS N
, , N
respectively RB N
) ) N
. . N

CONCLUSIONS NNP N
Epo-b NNP N
was VBD N
effective JJ N
in IN N
raising VBG o
Hb NNP o
levels NNS o
in IN o
patients NNS p
with IN p
advanced JJ p
esophagogastric JJ p
cancer NN p
. . p

Patients NNS p
receiving VBG N
Epo-b NNP N
had VBD N
a DT N
significantly RB N
increased VBN o
response NN o
to TO o
chemotherapy VB o
and CC o
a DT N
clear JJ N
trend NN N
to TO N
improved VBN o
survival NN o
. . o

-DOCSTART- -25311217- O O

Intense JJ p
androgen-deprivation NN i
therapy NN i
with IN i
abiraterone NN i
acetate NN i
plus CC i
leuprolide JJ i
acetate NN i
in IN p
patients NNS p
with IN p
localized JJ p
high-risk JJ p
prostate NN p
cancer NN p
: : p
results NNS p
of IN p
a DT p
randomized JJ p
phase NN p
II NNP p
neoadjuvant NN p
study NN p
. . p

PURPOSE NNP N
Cure NNP N
rates NNS N
for IN N
localized JJ N
high-risk JJ N
prostate NN N
cancers NNS N
( ( N
PCa NNP N
) ) N
and CC N
some DT N
intermediate-risk JJ N
PCa NNP N
are VBP N
frequently RB N
suboptimal JJ N
with IN N
local JJ N
therapy NN N
. . N

Outcomes CC N
are VBP N
improved VBN N
by IN N
concomitant JJ N
androgen-deprivation NN N
therapy NN N
( ( N
ADT NNP N
) ) N
with IN N
radiation NN N
therapy NN N
, , N
but CC N
not RB N
by IN N
concomitant JJ N
ADT NNP N
with IN N
surgery NN N
. . N

Luteinizing VBG N
hormone-releasing JJ N
hormone NN N
agonist NN N
( ( N
LHRHa NNP N
; : N
leuprolide JJ N
acetate NN N
) ) N
does VBZ N
not RB N
reduce VB N
serum NN o
androgens NNS o
as RB N
effectively RB N
as IN N
abiraterone NN N
acetate NN N
( ( N
AA NNP N
) ) N
, , N
a DT N
prodrug NN N
of IN N
abiraterone NN N
, , N
a DT N
CYP17 NNP N
inhibitor NN N
that IN N
lowers VBZ N
serum VBP N
testosterone NN N
( ( N
< JJ N
1 CD N
ng/dL NN N
) ) N
and CC N
improves VBZ N
survival NN N
in IN N
metastatic JJ N
PCa NNP N
. . N

The DT N
possibility NN N
that IN N
greater JJR N
androgen NN N
suppression NN N
in IN N
patients NNS N
with IN N
localized JJ N
high-risk JJ N
PCa NNP N
will MD N
result VB N
in IN N
improved JJ N
clinical JJ N
outcomes NNS N
makes VBZ N
paramount VBP N
the DT N
reassessment NN N
of IN N
neoadjuvant JJ N
ADT NNP N
with IN N
more RBR N
robust JJ N
androgen NN N
suppression NN N
. . N

PATIENTS NNP p
AND CC p
METHODS NNP p
A NNP p
neoadjuvant JJ p
randomized VBN p
phase NN p
II NNP p
trial NN p
of IN p
LHRHa NNP i
with IN i
AA NNP i
was VBD p
conducted VBN p
in IN p
patients NNS p
with IN p
localized JJ p
high-risk JJ p
PCa NNP p
( ( p
N NNP p
= NNP p
58 CD p
) ) p
. . p

For IN p
the DT p
first JJ p
12 CD p
weeks NNS p
, , p
patients NNS p
were VBD p
randomly RB p
assigned VBN p
to TO p
LHRHa NNP i
versus NN i
LHRHa NNP i
plus CC i
AA NNP i
. . i

After IN p
a DT p
research NN p
prostate NN p
biopsy NN p
, , p
all DT p
patients NNS p
received VBD p
12 CD p
additional JJ p
weeks NNS p
of IN p
LHRHa NNP i
plus CC i
AA NNP i
followed VBN i
by IN i
prostatectomy NN i
. . i

RESULTS VB N
The DT N
levels NNS o
of IN o
intraprostatic JJ o
androgens NNS o
from IN N
12-week JJ N
prostate NN N
biopsies NNS N
, , N
including VBG N
the DT N
primary JJ o
end NN o
point NN o
( ( o
dihydrotestosterone/testosterone NN o
) ) o
, , N
were VBD N
significantly RB N
lower JJR N
( ( N
dehydroepiandrosterone NN N
, , N
? . N
( ( N
4 CD N
) ) N
-androstene-3,17-dione NN N
, , N
dihydrotestosterone NN N
, , N
all DT N
P NNP N
< NNP N
.001 NNP N
; : N
testosterone NN N
, , N
P NNP N
< NNP N
.05 NNP N
) ) N
with IN N
LHRHa NNP N
plus CC N
AA NNP N
compared VBN N
with IN N
LHRHa NNP N
alone RB N
. . N

Prostatectomy NNP N
pathologic JJ N
staging NN N
demonstrated VBD N
a DT N
low JJ o
incidence NN o
of IN o
complete JJ o
responses NNS o
and CC N
minimal JJ o
residual JJ o
disease NN o
, , o
with IN N
residual JJ N
T3- NNP N
or CC N
lymph JJ N
node-positive JJ N
disease NN N
in IN N
the DT N
majority NN N
. . N

CONCLUSION NNP i
LHRHa NNP i
plus CC i
AA NNP i
treatment NN N
suppresses NNS o
tissue VBP o
androgens VBZ o
more RBR N
effectively RB N
than IN i
LHRHa NNP i
alone RB i
. . i

Intensive JJ N
intratumoral JJ o
androgen NN o
suppression NN o
with IN i
LHRHa NNP i
plus CC i
AA NNP i
before IN N
prostatectomy NN N
for IN N
localized JJ N
high-risk JJ N
PCa NNP N
may MD N
reduce VB N
tumor NN N
burden NN N
. . N

-DOCSTART- -6734073- O O

Short-term JJ N
studies NNS N
on IN N
the DT N
use NN N
of IN N
glycerol NN i
as IN N
an DT N
osmotic JJ N
agent NN N
in IN N
continuous JJ p
ambulatory JJ p
peritoneal JJ p
dialysis NN p
( ( p
CAPD NNP p
) ) p
. . p

The DT N
use NN N
of IN N
glycerol NN i
as IN N
an DT N
osmotic JJ N
agent NN N
in IN N
two CD N
different JJ N
concentrations NNS N
( ( N
92 CD N
mmol/l NN N
and CC N
272 CD N
mmol/l NN N
) ) N
in IN N
peritoneal JJ N
dialysis NN N
fluid NN N
was VBD N
investigated VBN N
over IN N
3 CD N
days NNS N
in IN p
six CD p
patients NNS p
on IN p
continuous JJ p
ambulatory JJ p
peritoneal JJ p
dialysis NN p
and CC N
compared VBN N
with IN N
two CD N
concentrations NNS N
of IN N
glucose NN i
( ( N
76 CD N
mmol/l NN N
and CC N
215 CD N
mmol/l NN N
) ) N
in IN N
the DT N
same JJ N
patients NNS N
. . N

The DT N
calorific JJ o
value NN o
of IN N
the DT N
absorbed JJ N
osmotic JJ N
agent NN N
was VBD N
lower JJR N
, , N
by IN N
19 CD N
% NN N
with IN N
isotonic JJ N
and CC N
22 CD N
% NN N
with IN N
hypertonic JJ N
solutions NNS N
, , N
when WRB N
glycerol NN i
was VBD N
used VBN N
in IN N
place NN N
of IN N
glucose NN i
. . i

However RB N
, , N
glycerol NN N
provided VBD N
significantly RB N
lower JJR N
total JJ o
ultrafiltration NN o
than IN N
glucose NN N
at IN N
each DT N
concentration NN N
, , N
despite IN N
a DT N
higher JJR N
initial JJ N
osmotic JJ N
pressure NN N
of IN N
the DT N
glycerol-based JJ N
solutions NNS N
. . N

Thus RB N
, , N
the DT N
higher JJR N
concentration NN N
of IN N
glycerol NN N
required VBN N
to TO N
provide VB N
equal JJ o
ultrafiltration NN o
may MD N
offset VB N
any DT N
calorific JJ N
advantage NN N
. . N

Equilibration NN o
of IN o
creatinine NN o
and CC o
urea NN o
was VBD N
slower JJR N
and CC N
creatinine JJ o
clearance NN o
lower RBR N
with IN N
glycerol NN i
. . i

Solutions NNS N
containing VBG N
glycerol NN i
were VBD N
initially RB N
less JJR N
acid JJ N
( ( N
pH JJ N
6.5 CD N
) ) N
than IN N
those DT N
containing VBG N
glucose NN N
( ( N
pH JJ N
5.1 CD N
) ) N
. . N

Blood NNP o
glycerol NN o
levels NNS o
, , N
which WDT N
were VBD N
in IN N
the DT N
physiological JJ N
range NN N
with IN N
glucose NN N
as IN N
the DT N
osmotic JJ N
agent NN N
, , N
reached VBD N
a DT N
peak JJ N
80-fold JJ N
greater JJR N
at IN N
4.3 CD N
+/- JJ N
0.8 CD N
mmol/l NN N
during IN N
dialysis NN N
with IN N
fluid NN N
containing VBG N
glycerol NN i
at IN N
272 CD N
mmol/l NN N
and CC N
eightfold VB N
higher JJR N
at IN N
0.42 CD N
+/- JJ N
0.09 CD N
mmol/l NN N
with IN N
glycerol NN i
at IN N
92 CD N
mmol/l NN N
. . N

There EX N
was VBD N
no DT N
evidence NN N
of IN N
haemolysis NN o
or CC N
other JJ N
toxic JJ o
effect NN o
despite IN N
these DT N
levels NNS N
. . N

The DT N
rise NN N
in IN N
blood NN o
glucose NN o
and CC o
insulin NN o
noted VBD N
during IN N
the DT N
use NN N
of IN N
glucose-based JJ N
solutions NNS N
was VBD N
not RB N
found VBN N
with IN N
glycerol NN i
. . i

Circulating NNP o
levels NNS o
of IN o
lactate NN o
, , o
pyruvate NN o
, , o
alanine NN o
, , o
non-esterified JJ o
fatty JJ o
acids NNS o
and CC o
the DT o
ketone NN o
bodies NNS o
were VBD N
similar JJ N
with IN N
the DT N
two CD N
agents NNS N
. . N

Although IN N
these DT N
short-term JJ N
studies NNS N
have VBP N
shown VBN N
no DT N
conclusive JJ N
advantage NN N
of IN N
glycerol NN i
over IN N
glucose JJ i
, , N
long-term JJ N
effects NNS N
of IN N
glycerol NN i
, , N
particularly RB N
on IN N
circulating VBG o
lipid JJ o
levels NNS o
, , N
will MD N
determine VB N
its PRP$ N
future JJ N
role NN N
as IN N
an DT N
osmotic JJ N
agent NN N
in IN N
continuous JJ N
ambulatory JJ p
peritoneal JJ p
dialysis NN p
. . p

-DOCSTART- -22572567- O O

Roles NNS o
of IN o
adapalene NN o
in IN N
the DT N
treatment NN N
of IN N
pityriasis NN p
versicolor NN p
. . p

BACKGROUND NNP N
Ketoconazole NNP i
is VBZ N
a DT N
typical JJ N
treatment NN N
available JJ N
for IN N
pityriasis NN p
versicolor NN p
; : p
tretinoin CC i
cream NN i
is VBZ N
effective JJ N
, , N
too RB N
. . N

Adapalene NNP i
gel NN i
is VBZ N
a DT N
tretinoin JJ N
derivative NN N
and CC N
has VBZ N
a DT N
lower JJR N
incidence NN N
of IN N
irritation NN o
compared VBN N
with IN N
other JJ N
topical JJ N
retinoid NN N
products NNS N
. . N

However RB N
, , N
there EX N
are VBP N
no DT N
reports NNS N
on IN N
adapalene NN i
gel NN i
for IN N
the DT N
treatment NN N
of IN N
pityriasis NN p
versicolor NN p
. . p

OBJECTIVE UH N
To TO N
study VB N
the DT N
effect NN N
of IN N
adapalene NN i
gel NN i
comparing VBG N
the DT N
treatment NN N
with IN N
adapalene JJ i
gel NNS i
and CC i
2 CD i
% NN i
ketoconazole JJ i
cream NN i
in IN N
pityriasis NN p
versicolor NN p
. . p

METHODS NNP N
Eighty NNP p
patients NNS p
suffering VBG p
from IN p
pityriasis NN p
versicolor NN p
were VBD N
randomly RB N
divided VBN N
into IN N
two CD N
groups NNS N
; : N
one CD N
group NN N
were VBD N
treated VBN N
with IN N
2 CD i
% NN i
ketoconazole JJ i
cream NN i
topically RB N
twice JJ N
daily RB N
for IN N
2 CD N
weeks NNS N
, , N
adapalene JJ i
gel NN i
was VBD N
used VBN N
for IN N
the DT N
other JJ N
group NN N
in IN N
a DT N
similar JJ N
fashion NN N
. . N

RESULTS CC N
There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
efficacy NN o
between IN N
the DT N
two CD N
groups NNS N
. . N

No DT N
major JJ N
side NN o
effects NNS o
were VBD N
noted VBN N
in IN N
any DT N
of IN N
the DT N
groups NNS N
either CC N
. . N

CONCLUSION NNP N
Adapalene NNP i
was VBD N
the DT N
favorable JJ N
option NN N
in IN N
the DT N
treatment NN N
of IN N
pityriasis NN p
versicolor NN p
. . p

The DT N
probable JJ N
therapeutic JJ N
mechanism NN N
of IN N
adapalene NN i
is VBZ N
also RB N
discussed VBN N
. . N

-DOCSTART- -20228284- O O

The DT N
unconscious JJ N
thought NN N
effect NN N
in IN N
clinical JJ N
decision NN N
making NN N
: : N
an DT N
example NN N
in IN N
diagnosis NN N
. . N

The DT N
unconscious JJ N
thought NN N
effect NN N
refers NNS N
to TO N
improved JJ N
judgments NNS N
and CC N
decisions NNS N
after IN N
a DT N
period NN N
of IN N
distraction NN N
. . N

The DT N
authors NNS N
studied VBD N
the DT N
unconscious JJ N
thought NN N
effect NN N
in IN N
a DT N
complex JJ N
and CC N
error-prone JJ N
part NN N
of IN N
clinical JJ N
decision NN N
making NN N
: : N
diagnosis NN N
. . N

Their PRP$ N
aim NN N
was VBD N
to TO N
test VB N
whether IN N
conscious JJ N
versus FW N
unconscious JJ N
processing NN N
influenced JJ N
diagnosis NN N
of IN N
psychiatric JJ N
cases NNS N
. . N

They PRP N
used VBD N
case NN N
descriptions NNS N
from IN N
the DT N
DSM-IV NNP N
casebook NN N
. . N

Half NN p
of IN p
the DT p
participants NNS p
were VBD p
randomly RB p
assigned VBN p
to TO p
the DT p
conscious-processing-condition NN i
( ( p
i.e. FW p
, , N
consciously RB p
thinking VBG p
about IN p
the DT p
information NN p
they PRP p
read VBP p
in IN p
the DT p
case NN p
description NN p
) ) p
, , p
the DT p
other JJ p
half NN p
to TO p
the DT p
unconscious-processing JJ i
condition NN i
( ( p
i.e. FW p
, , N
performing VBG p
an DT p
unrelated JJ p
distracter NN p
task NN p
) ) p
. . p

The DT N
main JJ N
dependent JJ N
measure NN N
was VBD N
the DT N
total JJ o
number NN o
of IN o
correct JJ o
classifications NNS o
. . o

Compared VBN N
to TO N
conscious JJ N
processing NN N
, , N
unconscious JJ N
processing VBG N
significantly RB N
increased VBN N
the DT N
number NN o
of IN o
correct JJ o
classifications NNS o
. . o

The DT N
results NNS N
show VBP N
the DT N
potential JJ N
merits NNS N
of IN N
unconscious JJ N
processing NN N
in IN N
diagnostic JJ o
decision NN o
making NN o
. . N

-DOCSTART- -8311760- O O

Does NNP N
wavelength VB N
matter NN N
when WRB N
photocoagulating VBG N
eyes NNS N
with IN N
macular JJ N
degeneration NN N
or CC N
diabetic JJ N
retinopathy NN N
? . N
-DOCSTART- -25963425- O O

The DT N
SOFT JJ N
trial NN N
: : N
a DT N
Phase NNP N
III NNP N
study NN N
of IN N
the DT N
dihydropyrimidine NN i
dehydrogenase NN i
inhibitory JJ i
fluoropyrimidine JJ i
S-1 NNP i
and CC i
oxaliplatin NN i
( ( i
SOX NNP i
) ) i
plus CC i
bevacizumab JJ i
as IN N
first-line JJ N
chemotherapy NN N
for IN N
metastatic JJ p
colorectal JJ p
cancer NN p
. . p

A DT N
combination NN N
of IN N
oxaliplatin NN i
, , i
leucovorin NN i
and CC i
5-fluorouracil JJ i
( ( i
FOLFOX NNP i
) ) i
plus CC i
bevacizumab NN i
has VBZ N
been VBN N
widely RB N
used VBN N
for IN N
the DT N
first-line JJ N
chemotherapy NN N
of IN N
metastatic JJ p
colorectal NN p
cancer NN p
( ( p
mCRC NN p
) ) p
. . p

S-1 NNP i
is VBZ i
an DT i
oral JJ i
fluoropyrimidine NN i
preparation NN i
that IN i
combines VBZ i
tegafur NN i
, , i
a DT i
prodrug NN i
of IN i
5-fluorouracil JJ i
, , N
with IN N
two CD N
modulators NNS N
. . N

Several JJ N
studies NNS N
of IN N
combination NN N
chemotherapy NN i
with IN N
oxaliplatin JJ i
plus CC i
S-1 JJ i
( ( i
SOX NNP i
) ) i
conducted VBD N
in IN N
Asia NNP N
have VBP N
reported VBN N
promising JJ N
efficacy NN N
and CC N
safety NN N
in IN N
patients NNS p
with IN p
mCRC NN p
, , N
suggesting VBG N
the DT N
potential JJ N
to TO N
replace VB N
mFOLFOX6 NN i
. . i

The DT N
SOFT JJ N
trial NN N
( ( N
JapicCTI-090699 NNP N
) ) N
was VBD N
a DT N
randomized JJ N
Phase NNP N
III NNP N
trial NN N
designed VBN N
to TO N
evaluate VB o
the DT o
noninferiority NN o
of IN o
SOX NNP o
plus CC o
bevacizumab NN o
to TO o
mFOLFOX6 VB o
plus JJ o
bevacizumab NN o
in IN N
patients NNS p
with IN p
mCRC NN o
. . o

This DT N
review NN N
summarizes VBZ N
the DT N
drug NN N
concept NN N
of IN N
S-1 NNP N
and CC N
the DT N
results NNS N
of IN N
clinical JJ N
trials NNS N
of IN N
S-1 NNP i
and CC i
SOX NNP i
in IN N
CRC NNP N
and CC N
presents VBZ N
an DT N
overview NN N
of IN N
the DT N
SOFT NNP N
trial NN N
. . N

-DOCSTART- -20830241- O O

Anti-angiogenic JJ o
effects NNS o
of IN N
epigallocatechin-3-gallate NN i
in IN N
human JJ N
skin NN N
. . N

Epigallocatechin-3-gallate NNP i
( ( i
EGCG NNP i
) ) i
is VBZ N
the DT N
main JJ N
polyphenol JJ N
component NN N
of IN N
green JJ N
tea NN N
. . N

This DT N
compound NN N
exhibits VBZ N
antioxidant JJ o
, , o
immunomodulatory JJ o
, , o
photoprotective JJ o
, , o
anti-angiogenic JJ o
, , o
and CC o
anti-inflammatory JJ o
properties NNS o
. . o

We PRP N
conducted VBD N
a DT N
small JJ N
randomized NN N
, , N
double JJ N
blind NN N
, , N
split VBD N
face NN N
trial NN N
using VBG N
a DT N
cream NN i
containing VBG i
2.5 CD i
% NN i
w/w NN i
of IN i
EGCG NNP i
. . i

Four CD p
healthy JJ p
volunteers NNS p
with IN p
significant JJ p
erythema NN p
and CC p
telangiectasia NN p
on IN p
the DT p
face NN p
applied VBD N
EGCG NNP i
cream NN i
to TO N
one CD N
side NN N
of IN N
the DT N
face NN N
, , N
and CC N
vehicle NN i
control NN i
cream NN i
to TO N
the DT N
other JJ N
, , N
twice JJ N
daily RB N
for IN N
six CD N
weeks NNS N
. . N

After IN N
six CD N
weeks NNS N
, , N
biopsies NNS o
were VBD N
taken VBN N
from IN N
EGCG NNP i
and CC N
vehicle NN i
treated VBN i
sites NNS N
. . N

Immunohistochemistry NN o
was VBD N
used VBN N
to TO N
measure VB N
VEGF NNP o
and CC o
HIF-1 NNP o
?. NNP o
HIF-1 NNP o
? . o
expression NN o
was VBD o
decreased VBN N
in IN N
EGCG NNP i
treated VBD i
sites NNS N
, , N
such JJ N
that IN N
28.4 CD N
% NN N
of IN N
the DT N
epidermis NN N
showed VBD o
positive JJ o
staining NN o
in IN o
vehicle NN N
treated VBD N
vs. FW N
13.8 CD N
% NN N
in IN N
EGCG NNP i
treated VBD i
sites NNS N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
. . N

A DT N
similar JJ N
decrease NN N
in IN N
VEGF NNP o
expression NN o
was VBD o
found VBN N
( ( N
6.7 CD N
% NN N
in IN N
EGCG NNP i
vs. FW i
11.0 CD N
% NN N
in IN N
in IN N
vehicle-treated JJ i
skin NN i
( ( N
p JJ N
< NNP i
0.005 CD i
) ) i
. . i

EGCG NNP i
topical JJ i
treatments NNS N
influence VB o
HIF-1 NNP o
? . o
induction NN o
and CC o
VEGF NNP o
expression NN o
and CC o
may MD N
serve VB N
as IN N
a DT N
potential JJ N
agent NN N
in IN N
the DT N
prevention NN o
of IN o
telangiectasias NN o
. . o

-DOCSTART- -19278832- O O

Stability NN N
, , N
tipping VBG N
and CC N
relapse NN N
of IN N
bone-borne JJ N
versus NN N
tooth-borne JJ N
surgically RB i
assisted VBN i
rapid JJ i
maxillary JJ i
expansion NN i
; : i
a DT N
prospective JJ N
randomized VBN N
patient JJ N
trial NN N
. . N

This DT N
study NN N
evaluated VBD N
stability NN N
, , N
tipping VBG N
and CC N
relapse NN N
after IN N
surgically RB i
assisted VBN i
rapid JJ i
maxillary JJ i
expansion NN i
( ( i
SARME NNP i
) ) i
, , N
comparing VBG N
bone-borne JJ i
and CC i
tooth-borne JJ i
devices NNS i
, , N
in IN N
skeletally RB p
matured VBN p
non-syndromal JJ p
patients NNS p
with IN p
transverse JJ p
maxillary JJ p
hypoplasia NN p
. . p

The DT N
study NN N
is VBZ N
a DT N
randomized JJ N
, , N
open-label JJ N
, , N
clinical JJ N
trial NN N
. . N

Patients NNS N
were VBD N
randomized VBN N
to TO N
bone-borne JJ N
( ( N
n=25 JJ N
) ) N
and CC N
tooth-borne JJ N
( ( N
n=21 JJ N
) ) N
groups NNS N
. . N

The DT N
surgical JJ N
technique NN N
for IN N
corticotomy NN N
was VBD N
the DT N
same JJ N
in IN N
both DT N
groups NNS N
. . N

Expansion NN N
was VBD N
performed VBN N
using VBG N
a DT N
bone-borne JJ N
or CC N
tooth-borne JJ N
device NN N
. . N

Dental NNP N
study NN N
casts NNS N
, , N
lateral JJ N
and CC N
postero-anterior JJ N
cephalograms NNS N
were VBD N
taken VBN N
before RB N
treatment NN N
, , N
after IN N
the DT N
distraction NN N
phase NN N
and CC N
at IN N
12-month JJ N
follow VBP N
up RP N
. . N

Stability NNP o
, , o
segmental JJ o
maxillary JJ o
tipping NN o
and CC o
relapse NN o
were VBD N
studied VBN N
. . N

23 CD p
bone-borne JJ p
and CC p
19 CD p
tooth-borne JJ p
patients NNS p
were VBD p
analyzed VBN p
. . p

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
between IN N
the DT N
two CD N
groups NNS N
. . N

Widening NNP o
was VBD N
comparable JJ N
at IN N
canine NN N
, , N
premolar JJ N
and CC N
molar JJ N
level NN N
. . N

Relapse NNP o
was VBD N
not RB N
significant JJ N
and CC N
at IN N
follow VB N
up RP N
the DT N
significant JJ N
increase NN N
in IN N
distance NN N
was VBD N
sustained VBN N
. . N

A DT N
significant JJ N
increase NN N
in IN N
palatal JJ o
width NN o
, , o
at IN o
premolar JJ o
and CC o
molar JJ o
level NN o
, , N
occurred VBN N
in IN N
both DT N
groups NNS N
. . N

The DT N
maxilla NN N
moves VBZ N
slightly RB N
downward JJ N
in IN N
SARME NNP N
. . N

Segmental NNP o
maxillary JJ o
tipping NN o
occurred VBD N
in IN N
both DT N
groups NNS N
and CC N
did VBD N
not RB N
affect VB N
relapse NN o
. . o

There EX N
is VBZ N
no DT N
significant JJ N
difference NN N
between IN N
the DT N
two CD N
groups NNS N
. . N

In IN N
SARME NNP i
, , N
the DT N
widening NN N
achieved VBN N
at IN N
dental JJ N
level NN N
is VBZ N
stable JJ N
after IN N
12 CD N
months NNS N
. . N

Over-correction NN N
is VBZ N
not RB N
necessary JJ N
. . N

Tipping NN N
of IN N
the DT N
maxillary JJ N
segments NNS N
and CC N
increases NNS N
in IN N
the DT N
retention NN o
period NN o
are VBP N
equal JJ N
in IN N
both DT N
groups NNS N
. . N

-DOCSTART- -417361- O O

Effects NNS N
of IN N
piracetam NN i
on IN N
regional JJ N
cerebral JJ o
blood NN o
flow NN o
and CC o
mental JJ o
functions NNS o
in IN N
patients NNS p
with IN p
organic JJ p
dementia NN p
. . p

The DT N
effects NNS N
of IN N
piracetam NN i
( ( N
Nootropil NNP N
, , N
UCB6215 NNP N
) ) N
on IN N
mental JJ o
functions NNS o
and CC o
on IN o
regional JJ o
cerebral JJ o
blood NN o
flow NN o
( ( o
rCBF NN o
) ) o
were VBD N
investigated VBN N
in IN N
eight CD p
patients NNS p
in IN p
the DT p
presenile JJ p
age NN p
who WP p
displayed VBD p
symptoms NNS p
of IN p
moderate JJ p
dementia NN p
. . p

The DT N
double-blind JJ N
crossover NN N
design NN N
included VBD N
nine CD N
measurement NN N
occasions NNS N
, , N
each DT N
involving VBG N
rCBF NN o
measurement NN o
by IN N
the DT N
133-Xe JJ i
inhalation NN i
method NN i
, , N
ratings NNS N
of IN N
symptoms NNS N
of IN N
dementia NN N
, , N
personality NN N
changes NNS N
, , N
and CC N
side NN N
effects NNS N
, , N
and CC N
a DT N
psychometric JJ N
investigation NN N
. . N

Three CD N
investigations NNS N
were VBD N
included VBN N
in IN N
each DT N
of IN N
three CD N
treatment NN N
periods NNS N
. . N

The DT N
first JJ N
investigation NN N
in IN N
a DT N
period NN N
was VBD N
made VBN N
without IN N
medication NN N
. . N

Then RB N
either DT N
placebo NN i
or CC i
piracetam VB i
4.8 CD N
g/day NN N
or CC N
9.6 CD N
g/day NN N
was VBD N
given VBN N
during IN N
four CD N
weeks NNS N
with IN N
measurements NNS N
after IN N
2 CD N
weekks NN N
and CC N
4 CD N
weeks NNS N
. . N

There EX N
were VBD N
intervals NNS N
of IN N
4 CD N
weeks NNS N
without IN N
medication NN N
between IN N
the DT N
treatment NN N
periods NNS N
. . N

Piracetam NNP i
had VBD N
no DT N
significant JJ N
effect NN N
on IN N
either CC N
mental JJ o
functions NNS o
or CC o
rCBF NN o
. . o

-DOCSTART- -8858230- O O

Prospective JJ N
comparison NN N
of IN N
nasal JJ i
versus IN i
oral JJ i
insertion NN i
of IN i
a DT i
thin JJ i
video NN i
endoscope NN i
in IN N
healthy JJ p
volunteers NNS p
. . p

BACKGROUND NNP N
AND NNP N
STUDY NNP N
AIMS NNP N
Attempts NNP N
have VBP N
been VBN N
made VBN N
to TO N
improve VB N
patient NN N
's POS N
tolerance NN N
of IN N
upper JJ i
gastrointestinal JJ i
endoscopy NN i
and CC N
to TO N
decrease VB N
the DT N
need NN N
for IN N
sedation NN N
, , N
using VBG N
thinner NN N
endoscopes NNS N
and CC N
a DT N
nasal JJ N
introduction NN N
route NN N
. . N

We PRP N
prospectively RB N
compared VBN N
the DT N
oral JJ i
and CC i
nasal JJ i
routes NNS i
in IN N
volunteers NNS N
, , N
using VBG N
a DT N
thin JJ i
prototype NN i
video NN i
endoscope NN i
. . i

METHODS NNP N
Ten NNP p
healthy JJ p
volunteers NNS p
underwent JJ p
two CD i
upper JJ i
gastrointestinal JJ i
endoscopies NNS i
in IN p
a DT p
random JJ p
order NN p
on IN p
two CD p
different JJ p
days NNS p
, , p
with IN p
the DT p
procedure NN p
being VBG p
carried VBN p
out RP p
by IN p
a DT p
single JJ p
experienced JJ p
endoscopist NN p
. . p

Parameters NNS N
assessed VBD N
were VBD N
the DT N
tolerance NN o
of IN o
scope NN o
insertion NN o
and CC o
the DT o
assessment NN o
of IN o
the DT o
entire JJ o
procedure NN o
( ( N
0-10 JJ N
scale NN N
) ) N
, , N
the DT N
method NN o
of IN o
insertion NN o
preferred VBN o
by IN o
the DT o
volunteers NNS o
, , o
the DT o
completeness NN o
of IN o
the DT o
examination NN o
( ( N
assessed VBN N
by IN N
an DT N
independent JJ N
endoscopist NN N
) ) N
, , N
and CC N
the DT N
time NN o
required VBN o
for IN o
the DT o
procedure NN o
. . o

RESULTS NNP N
In IN N
one CD N
patient NN N
, , N
nasal JJ o
insertion NN o
failed VBD N
, , N
and CC N
she PRP N
was VBD N
excluded VBN N
from IN N
further JJ N
analysis NN N
. . N

The DT N
insertion NN o
of IN o
the DT o
scope NN o
was VBD N
easier JJR N
via IN N
the DT N
oral JJ N
route NN N
, , N
as IN N
reflected VBN N
in IN N
a DT N
shorter JJR N
examination NN o
time NN o
( ( N
mean JJ N
165 CD N
vs. FW N
210 CD N
seconds NNS N
, , N
p NN N
= NNP N
0.017 CD N
) ) N
and CC N
patients NNS o
' POS o
tolerance NN o
for IN o
the DT o
scope NN o
insertion NN o
( ( N
mean JJ N
score NN N
: : N
8 CD N
for IN N
oral JJ N
vs. FW N
4 CD N
for IN N
nasal JJ N
route NN N
; : N
p CC N
= VB N
0.03 CD N
) ) N
. . N

On IN N
the DT N
other JJ N
hand NN N
, , N
gagging VBG o
occurred VBD N
more RBR N
frequently RB N
during IN N
oral JJ i
endoscopy NN i
( ( N
6/9 CD N
vs NN N
1/9 CD N
, , N
p NN N
= NNP N
0.05 CD N
) ) N
. . N

Three CD N
of IN N
the DT N
volunteers NNS N
in IN N
each DT N
case NN N
preferred VBD o
the DT N
oral JJ N
or CC N
the DT N
nasal JJ N
route NN N
, , N
and CC N
three CD N
were VBD N
not RB N
decided VBN N
, , N
in IN N
case NN N
of IN N
a DT N
repeated JJ N
endoscopy NN N
. . N

Similarly RB N
, , N
the DT N
overall JJ o
tolerance NN o
for IN o
the DT o
procedure NN o
did VBD N
not RB N
between IN N
the DT N
two CD N
groups NNS N
. . N

CONCLUSION NNP N
Thin-diameter NNP i
gastroscopes NNS i
seem VBP N
to TO N
improve VB N
patient NN o
's POS o
tolerance NN o
. . o

In IN N
this DT N
small JJ N
study NN N
in IN N
volunteers NNS N
, , N
nasal JJ N
introduction NN N
showed VBD N
no DT N
overall JJ N
benefit NN N
over IN N
oral JJ N
introduction NN N
. . N

Modifications NNS N
of IN N
the DT N
scope NN N
to TO N
achieve VB N
better JJR N
nasal NN N
passage NN N
are VBP N
necessary JJ N
. . N

-DOCSTART- -18681363- O O

[ JJ o
Intra-uterine JJ o
insemination NN o
with IN i
controlled JJ i
ovarian JJ o
hyperstimulation NN o
compared VBN i
to TO i
an DT i
expectant JJ o
management NN o
in IN N
couples NNS p
with IN p
unexplained JJ p
subfertility NN o
and CC p
an DT p
intermediate JJ p
prognosis NN p
: : p
a DT N
randomised JJ N
study NN N
] NNP N
. . N

OBJECTIVE NNP N
Intrauterine NNP o
insemination NN o
( ( o
IUI NNP o
) ) o
with IN i
controlled JJ o
ovarian JJ o
hyperstimulation NN o
( ( o
COH NNP o
) ) o
is VBZ N
commonly RB N
used VBN N
as IN N
treatment NN N
of IN N
first JJ N
choice NN N
in IN N
couples NNS p
with IN p
unexplained JJ o
subfertility NN o
. . o

This DT N
treatment NN N
should MD N
only RB N
be VB N
applied VBN N
when WRB N
there EX N
is VBZ N
a DT N
realistic JJ N
increase NN o
in IN o
chance NN o
of IN o
pregnancy NN o
, , N
particularly RB N
because IN N
it PRP N
carries VBZ N
the DT N
increased VBN N
risk NN N
of IN N
multiple JJ N
pregnancies NNS N
. . N

We PRP N
evaluated VBD N
the DT N
effectiveness NN N
of IN N
IUI NNP o
with IN i
COH NNP o
relative VBP N
to TO N
expectant VB o
management NN o
in IN N
couples NNS p
with IN p
unexplained JJ o
subfertility NN o
and CC N
an DT N
intermediate JJ N
prognosis NN N
of IN N
a DT N
spontaneous JJ o
ongoing JJ o
pregnancy NN o
. . o

DESIGN NNP N
Multicentre NNP N
randomised VBD N
clinical JJ N
study NN N
. . N

METHOD NNP N
253 CD p
couples NNS p
with IN p
unexplained JJ o
subfertility NN o
and CC p
a DT p
probability NN p
of IN p
a DT p
spontaneous JJ o
ongoing JJ o
pregnancy NN o
of IN p
30 CD p
% NN p
to TO p
40 CD p
% NN p
within IN p
12 CD p
months NNS p
, , N
were VBD N
randomly RB N
assigned VBN N
to TO N
IUI NNP o
with IN i
COH NNP o
for IN N
6 CD N
months NNS N
or CC N
expectant JJ i
management NN i
for IN N
6 CD N
months NNS N
. . N

The DT N
primary JJ N
endpoint NN N
of IN N
our PRP$ N
study NN N
was VBD N
ongoing JJ o
pregnancy NN o
within IN o
6 CD o
months NNS o
. . o

Analysis NN N
was VBD N
carried VBN N
out RP N
according VBG N
to TO N
the DT N
intention NN N
to TO N
treat VB N
principle NN N
. . N

This DT N
study NN N
was VBD N
registered VBN N
with IN N
the DT N
Dutch JJ N
Trial NNP N
Register NNP N
and CC N
has VBZ N
the DT N
International NNP N
Standard NNP N
Randomised VBD N
Clinical JJ N
Trial NNP N
number NN N
ISRCTN72675518 NNP N
. . N

RESULTS NNP N
Of IN N
the DT N
253 CD N
couples NNS N
included VBD N
, , N
127 CD N
couples NNS N
were VBD N
allocated VBN N
to TO N
IUI NNP o
with IN i
COH NNP o
and CC N
126 CD N
to TO N
expectant VB o
management NN o
. . o

In IN N
the DT N
intervention NN N
group NN N
, , N
42 CD N
women NNS N
( ( N
33 CD N
% NN N
) ) N
conceived VBD N
, , N
of IN N
which WDT N
29 CD N
pregnancies NNS N
were VBD N
ongoing VBG N
( ( N
23 CD N
% NN N
) ) N
. . N

In IN N
the DT N
expectant JJ N
management NN N
group NN N
, , N
40 CD N
women NNS N
( ( N
32 CD N
% NN N
) ) N
conceived VBD o
, , N
of IN N
which WDT N
34 CD N
pregnancies NNS N
were VBD N
ongoing VBG o
( ( N
27 CD N
% NN N
) ) N
( ( N
relative JJ N
risk NN N
: : N
0.85 CD N
; : N
95 CD N
% NN N
CI NNP N
: : N
0.63-1.1 NN N
) ) N
. . N

In IN N
the DT N
expectant JJ i
management NN i
group NN N
one CD N
twin NN o
pregnancy NN o
occurred VBD N
and CC N
in IN N
the DT N
intervention NN N
group NN N
one CD N
woman NN N
conceived VBD N
twins NNS o
and CC o
one CD o
a DT o
triplet NN o
. . o

CONCLUSION VB N
A DT N
substantial JJ N
beneficial JJ N
effect NN N
of IN N
IUI NNP o
with IN o
COH NNP o
in IN N
couples NNS N
with IN N
unexplained JJ o
subfertility NN o
and CC N
an DT N
intermediate JJ N
prognosis NN N
can MD N
be VB N
excluded VBN N
. . N

Expectant JJ o
management NN o
for IN N
a DT N
period NN N
of IN N
6 CD N
months NNS N
therefore RB N
appears VBZ N
justified JJ N
in IN N
these DT N
couples NNS N
. . N

-DOCSTART- -8655293- O O

Pentoxifylline NNP i
therapy NN N
in IN N
HIV NNP p
seropositive JJ p
subjects NNS p
with IN p
elevated JJ p
TNF NNP p
. . p

Tumor NNP N
necrosis IN N
factor-alpha JJ N
( ( N
TNF-alpha NNP N
) ) N
is VBZ N
thought VBN N
to TO N
induce VB N
cachexia NN N
in IN N
subjects NNS N
infected VBN N
with IN N
human JJ N
immunodeficiency NN N
virus NN N
( ( N
HIV NNP N
) ) N
, , N
and CC N
it PRP N
has VBZ N
been VBN N
suggested VBN N
that IN N
HIV-seropositive JJ p
patients NNS p
would MD N
benefit VB N
from IN N
treatment NN N
with IN N
pentoxifylline NN i
, , N
a DT N
known VBN N
suppressor NN N
of IN N
TNF-alpha NNP N
production NN N
. . N

The DT N
purpose NN N
of IN N
the DT N
present JJ N
study NN N
was VBD N
to TO N
examine VB N
how WRB N
pentoxifylline NN i
at IN i
a DT i
dose NN i
of IN i
800 CD i
mg JJ i
thrice JJ i
daily RB i
would MD N
influence VB N
the DT N
cellular JJ o
immune NN o
system NN o
in IN N
HIV-seropositive JJ N
persons NNS p
with IN p
elevated JJ p
TNF-alpha NNP p
. . p

Six NNP p
HIV-seropositive JJ p
subjects NNS p
with IN p
elevated JJ p
amounts NNS p
of IN p
TNF-alpha NNP p
in IN p
plasma NN p
at IN p
least JJS p
at IN p
two CD p
occasions NNS p
were VBD N
included VBN N
in IN N
an DT N
open JJ N
, , N
controlled VBN N
, , N
randomized VBN N
, , N
cross-over JJ N
study NN N
consisting VBG N
of IN N
a DT N
6 CD i
week NN i
treatment NN i
period NN i
and CC i
a DT i
6 CD i
week NN i
control NN i
period NN i
. . i

Blood NN N
samples NNS N
were VBD N
collected VBN N
before RB N
and CC N
at IN N
the DT N
end NN N
of IN N
each DT N
period NN N
. . N

Pentoxifylline NNP N
treatment NN N
did VBD N
not RB N
influence VB N
the DT N
concentration NN o
of IN o
plasma-TNF-alpha NN o
, , o
subpopulations NNS o
of IN o
blood NN o
mononuclear NN o
cells NNS o
, , o
the DT o
proliferative JJ o
responses NNS o
nor CC o
the DT o
natural JJ o
killer NN o
( ( o
NK NNP o
) ) o
, , o
and CC o
lymphokine NN o
activated VBN o
killer NN o
( ( o
LAK NNP o
) ) o
cell NN o
activities NNS o
. . o

Furthermore RB N
, , N
pentoxifylline JJ N
treatment NN N
did VBD N
not RB N
influence VB N
the DT N
weight NN o
, , o
temperature NN o
, , o
well RB o
being VBG o
, , o
or CC o
tiredness NN o
of IN o
the DT o
subjects NNS o
. . o

However RB N
, , N
the DT N
patients NNS N
frequently RB N
reported VBD N
gastrointestinal JJ o
side NN o
effects NNS o
. . o

In IN N
vitro NN N
, , N
however RB N
, , N
pentoxifylline NN N
at IN N
suprapharmacological JJ N
concentrations NNS N
inhibited VBD N
the DT N
blood NN o
mononuclear NN o
cell NN o
( ( o
BMNC NNP o
) ) o
proliferative NN o
responses NNS o
, , o
NK NNP o
, , N
and CC N
LAK NNP o
cell NN o
activities NNS o
. . o

-DOCSTART- -14669937- O O

Effect NN N
of IN N
a DT N
carbohydrate-protein JJ i
supplement NN i
on IN N
endurance NN o
performance NN o
during IN N
exercise NN N
of IN N
varying VBG N
intensity NN N
. . N

Increasing VBG N
the DT N
plasma NN N
glucose NN N
and CC N
insulin NN N
concentrations NNS N
during IN N
prolonged JJ N
variable JJ N
intensity NN N
exercise NN N
by IN N
supplementing VBG N
with IN N
carbohydrate NN N
has VBZ N
been VBN N
found VBN N
to TO N
spare VB N
muscle NN N
glycogen NN N
and CC N
increase VB N
aerobic JJ o
endurance NN o
. . o

Furthermore RB N
, , N
the DT N
addition NN N
of IN N
protein NN i
to TO i
a DT i
carbohydrate NN i
supplement NN i
will MD N
enhance VB N
the DT N
insulin NN N
response NN N
of IN N
a DT N
carbohydrate JJ N
supplement NN N
. . N

The DT N
purpose NN N
of IN N
the DT N
present JJ N
study NN N
was VBD N
to TO N
compare VB N
the DT N
effects NNS N
of IN N
a DT N
carbohydrate NN i
and CC N
a DT N
carbohydrate-protein JJ i
supplement NN i
on IN N
aerobic JJ o
endurance NN o
performance NN o
. . o

Nine NNP p
trained JJ p
cyclists NNS p
exercised VBD N
on IN N
3 CD N
separate JJ N
occasions NNS N
at IN N
intensities NNS N
that WDT N
varied VBD N
between IN N
45 CD N
% NN N
and CC N
75 CD N
% NN N
VO2max NNP N
for IN N
3 CD N
h NN N
and CC N
then RB N
at IN N
85 CD N
% NN N
VO2max NNP N
until IN N
fatigued VBN N
. . N

Supplements NNS i
( ( i
200 CD i
ml NN i
) ) i
were VBD i
provided VBN i
every DT i
20 CD i
min NN i
and CC i
consisted VBN i
of IN i
placebo NN i
, , i
a DT i
7.75 CD i
% NN i
carbohydrate JJ i
solution NN i
, , i
and CC i
a DT i
7.75 CD i
% NN i
carbohydrate/1.94 NN i
% NN i
protein JJ i
solution NN i
. . i

Treatments NNS N
were VBD N
administered VBN N
using VBG N
a DT N
double-blind JJ N
randomized JJ N
design NN N
. . N

Carbohydrate NNP N
supplementation NN N
significantly RB N
increased VBD N
time NN o
to TO o
exhaustion NN o
( ( N
carbohydrate JJ N
19.7 CD N
+/- JJ N
4.6 CD N
min NN N
vs. FW N
placebo NN N
12.7 CD N
+/- JJ N
3.1 CD N
min NN N
) ) N
, , N
while IN N
the DT N
addition NN N
of IN N
protein NN N
enhanced VBD N
the DT N
effect NN N
of IN N
the DT N
carbohydrate NN N
supplement NN N
( ( N
carbohydrate-protein JJ N
26.9 CD N
+/- JJ N
4.5 CD N
min NN N
, , N
p NN N
< NNP N
.05 NNP N
) ) N
. . N

Blood NNP o
glucose NN o
and CC o
plasma JJ o
insulin NN o
levels NNS o
were VBD N
elevated VBN N
above IN N
placebo NN N
during IN N
carbohydrate NN i
and CC N
carbohydrate-protein JJ i
supplementation NN i
, , N
but CC N
no DT N
differences NNS N
were VBD N
found VBN N
between IN N
the DT N
carbohydrate NN N
and CC N
carbohydrate-protein JJ i
treatments NNS N
. . N

In IN N
summary JJ N
, , N
we PRP N
found VBD N
that IN N
the DT N
addition NN N
of IN N
protein NN N
to TO N
a DT N
carbohydrate NN i
supplement NN i
enhanced VBD N
aerobic JJ o
endurance NN o
performance NN o
above IN N
that DT N
which WDT N
occurred VBD N
with IN N
carbohydrate NN N
alone RB N
, , N
but CC N
the DT N
reason NN N
for IN N
this DT N
improvement NN N
in IN N
performance NN N
was VBD N
not RB N
evident JJ N
. . N

-DOCSTART- -24635110- O O

Prophylactic JJ i
training NN i
for IN N
the DT N
prevention NN N
of IN N
radiotherapy-induced JJ N
trismus NN N
- : N
a DT N
randomised JJ N
study NN N
. . N

BACKGROUND NNP N
Radiotherapy-induced JJ N
trismus NN N
( ( N
RTIT NNP N
) ) N
is VBZ N
a DT N
debilitating VBG N
condition NN N
without IN N
any DT N
proven JJ N
effective JJ N
treatment NN N
. . N

This DT N
study NN N
investigates VBZ N
the DT N
effectiveness NN o
of IN N
prophylactic JJ i
training NN i
to TO N
prevent VB N
RTIT NNP N
during IN N
and CC N
up RB N
to TO N
12 CD N
months NNS N
after IN N
completed VBN p
RT NNP p
in IN p
patients NNS p
with IN p
head NN p
and CC p
neck NN p
cancer NN p
( ( p
HNC NNP p
) ) p
, , N
also RB N
investigating VBG N
the DT N
incidence NN N
of IN N
RTIT NNP N
. . N

METHODS NNP N
Sixty-six JJ p
consecutive JJ p
patients NNS p
from IN p
two CD p
RT NNP p
clinics NNS p
in IN p
Sweden NNP p
were VBD N
randomised VBN N
into IN N
one CD N
of IN N
two CD N
groups NNS N
: : N
training NN i
with IN i
TheraBite NNP i
( ( i
? . i
) ) i
Jaw NNPS i
Motion NNP i
Rehabilitation NNP i
System NNP i
( ( i
? . i
) ) i
or CC i
a DT i
control NN i
group NN o
. . o

Maximum NNP o
interincisal JJ o
openings NNS o
( ( o
MIO NNP o
) ) o
were VBD o
recorded VBN o
at IN N
baseline NN N
and CC N
once RB N
a DT N
week NN N
during IN N
treatment NN N
, , N
three CD N
, , N
six CD N
and CC N
12 CD N
months NNS N
after IN N
completed VBN N
RT NNP N
. . N

Training NNP N
frequency NN N
was VBD N
recorded VBN N
by IN N
patients NNS N
in IN N
a DT N
log NN N
book NN N
. . N

RESULTS CC N
There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
MIO NNP o
between IN o
the DT N
intervention NN N
and CC N
control NN N
groups NNS N
at IN N
any DT N
of IN N
the DT N
measurement NN N
points NNS N
. . N

Patients NNS N
in IN N
both DT N
groups NNS N
maintained VBD N
their PRP$ N
normal JJ N
variation NN N
in IN N
MIO NNP o
at IN o
12 CD N
months NNS N
after IN N
completed VBN N
RT NNP N
. . N

A NNP N
small JJ N
group NN N
of IN N
patients NNS N
in IN N
the DT N
control NN N
group NN N
had VBD N
a DT N
17 CD N
% NN N
mean JJ N
decrease NN N
in IN N
MIO NNP o
by IN o
week NN N
6 CD N
compared VBN N
to TO N
baseline VB N
and CC N
improved VB N
their PRP$ o
MIO NNP o
by IN o
using VBG N
the DT N
training NN N
programme NN N
. . N

There EX N
was VBD N
a DT N
significant JJ N
mean JJ N
difference NN N
in IN N
MIO NNP o
from IN o
baseline NN N
to TO N
week NN N
6 CD N
( ( N
3 CD N
mm NN N
, , N
p NN N
= NNP N
0.018 CD N
) ) N
, , N
and CC N
month NN N
6 CD N
( ( N
2.7 CD N
mm NN N
, , N
p NN N
= NNP N
0.040 CD N
) ) N
, , N
for IN N
patients NNS N
receiving VBG N
3D CD N
conformal JJ N
radiotherapy NN N
. . N

There EX N
was VBD N
a DT N
significant JJ N
difference NN N
in IN N
MIO NNP o
between IN o
patients NNS N
treated VBN N
with IN N
RT NNP N
and CC N
concurrent JJ N
chemotherapy NN N
compared VBN N
to TO N
patients NNS N
with IN N
RT NNP N
only RB N
at IN N
12 CD N
months NNS N
( ( N
p JJ N
= NNP N
0.033 CD N
) ) N
. . N

CONCLUSIONS JJ p
Patients NNS p
with IN p
HNC NNP p
undergoing VBG p
high JJ p
dose NN p
RT NNP p
do VBP N
not RB N
need VB N
to TO N
be VB N
burdened VBN N
with IN N
an DT N
intense JJ N
prophylactic JJ N
training NN N
programme NN N
during IN N
RT NNP N
and CC N
up RB N
to TO N
12 CD N
months NNS N
after IN N
completed VBN N
RT NNP N
. . N

MIO NNP o
measurements NNS o
during IN N
RT NNP N
and CC N
up RB N
to TO N
12 CD N
months NNS N
after IN N
completed VBN N
RT NNP N
are VBP N
recommended VBN N
to TO N
identify VB N
a DT N
small JJ N
risk NN N
group NN N
who WP N
are VBP N
an DT N
exception NN N
and CC N
may MD N
need VB i
a DT i
training NN i
programme NN i
. . i

-DOCSTART- -15267097- O O

Herpesvirus-like JJ N
particles NNS N
in IN N
the DT N
skin NN N
of IN N
a DT N
saltwater NN p
crocodile NN p
( ( p
Crocodylus NNP p
porosus NN p
) ) p
. . p

-DOCSTART- -19562475- O O

Brief JJ N
report NN N
: : N
effects NNS N
of IN N
cognitive JJ i
behavioral JJ i
therapy NN i
on IN N
parent-reported JJ o
autism NN o
symptoms NNS o
in IN p
school-age JJ p
children NNS p
with IN p
high-functioning JJ p
autism NN p
. . p

This DT N
pilot NN N
study NN N
tested VBD N
the DT N
effect NN N
of IN N
cognitive JJ i
behavioral JJ i
therapy NN i
( ( i
CBT NNP i
) ) i
on IN N
parent-reported JJ p
autism NN p
symptoms NNS p
. . p

Nineteen JJ p
children NNS p
with IN p
autism NN p
spectrum NN p
disorders NNS p
and CC p
an DT p
anxiety NN p
disorder NN p
( ( p
7-11 CD p
years NNS p
old JJ p
) ) p
were VBD p
randomly RB p
assigned VBN p
to TO N
16 CD N
sessions NNS N
of IN N
CBT NNP i
or CC N
a DT N
waitlist JJ i
condition NN i
. . i

The DT N
CBT NNP i
program NN N
emphasized VBN N
in IN N
vivo NN N
exposure NN N
supported VBN N
by IN N
parent NN N
training NN N
and CC N
school NN N
consultation NN N
to TO N
promote VB N
social JJ N
communication NN N
and CC N
emotion NN N
regulation NN N
skills NNS N
. . N

Parents NNS N
completed VBD N
a DT N
standardized JJ o
autism NN o
symptom JJ o
checklist NN o
at IN N
baseline NN N
and CC N
posttreatment/postwaitlist NN N
and CC N
3-month JJ N
follow-up JJ N
assessments NNS N
. . N

CBT NNP i
outperformed VBD N
the DT N
waitlist JJ N
condition NN N
at IN N
posttreatment/postwaitlist NN N
on IN N
total JJ o
parent-reported JJ o
autism NN o
symptoms NNS o
( ( N
Cohen NNP N
's POS N
d JJ N
effect NN N
size NN N
= NNP N
.77 NNP N
) ) N
. . N

Treatment NN N
gains NNS N
were VBD N
maintained VBN N
at IN N
3-month JJ N
follow-up NN N
. . N

Further JJ N
investigation NN N
of IN N
this DT N
intervention NN N
modality NN N
with IN N
larger JJR N
samples NNS N
and CC N
broader JJR N
outcome NN N
measures NNS N
appears VBZ N
to TO N
be VB N
indicated VBN N
. . N

-DOCSTART- -19675193- O O

Sustained JJ N
benefit NN N
of IN N
continuous JJ N
glucose JJ N
monitoring NN N
on IN N
A1C NNP N
, , N
glucose JJ N
profiles NNS N
, , N
and CC N
hypoglycemia NN N
in IN N
adults NNS p
with IN p
type JJ p
1 CD p
diabetes NNS p
. . p

OBJECTIVE NNP N
To TO N
evaluate VB N
long-term JJ N
effects NNS N
of IN N
continuous JJ i
glucose JJ i
monitoring NN i
( ( i
CGM NNP i
) ) i
in IN N
intensively RB p
treated VBN p
adults NNS p
with IN p
type JJ p
1 CD p
diabetes NNS p
. . p

RESEARCH NNP N
DESIGN NNP N
AND NNP N
METHODS NNP N
We PRP N
studied VBD N
83 CD p
of IN p
86 CD p
individuals NNS p
> JJ p
or=25 CD p
years NNS p
of IN p
age NN p
with IN p
type JJ p
1 CD p
diabetes NNS p
who WP p
used VBD p
CGM NNP p
as IN p
part NN p
of IN p
a DT p
6-month JJ p
randomized JJ p
clinical JJ p
trial NN p
in IN p
a DT p
subsequent JJ p
6-month JJ p
extension NN p
study NN p
. . p

RESULTS NNP N
After IN N
12 CD N
months NNS N
, , N
median JJ N
CGM NNP N
use NN N
was VBD N
6.8 CD N
days NNS N
per IN N
week NN N
. . N

Mean JJ o
change NN o
in IN o
A1C NNP o
level NN o
from IN N
baseline NN N
to TO N
12 CD N
months NNS N
was VBD N
-0.4 JJ N
+/- JJ N
0.6 CD N
% NN N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
in IN N
subjects NNS N
with IN N
baseline NN N
A1C NNP N
> NNP N
or=7.0 MD N
% NN N
. . N

A1C NNP o
remained VBD N
stable JJ N
at IN N
6.4 CD N
% NN N
in IN N
those DT N
with IN N
baseline JJ N
A1C NNP N
< NNP N
7.0 CD N
% NN N
. . N

The DT N
incidence NN o
rate NN o
of IN o
severe JJ o
hypoglycemia NN o
was VBD N
21.8 CD N
and CC N
7.1 CD N
events NNS N
per IN N
100 CD N
person-years NNS N
in IN N
the DT N
first JJ N
and CC N
last JJ N
6 CD N
months NNS N
, , N
respectively RB N
. . N

Time NNP o
per IN o
day NN o
with IN o
glucose JJ o
levels NNS o
in IN N
the DT N
range NN N
of IN N
71-180 JJ N
mg/dl NN N
increased VBN N
significantly RB N
( ( N
P NNP N
= NNP N
0.02 CD N
) ) N
from IN N
baseline NN N
to TO N
12 CD N
months NNS N
. . N

CONCLUSIONS NNP N
In IN N
intensively RB p
treated VBN p
adults NNS p
with IN p
type JJ p
1 CD p
diabetes NNS p
, , N
CGM NNP N
use NN N
and CC N
benefit NN N
can MD N
be VB N
sustained VBN N
for IN N
12 CD N
months NNS N
. . N

-DOCSTART- -19958431- O O

Different NNP N
therapeutic JJ N
modalities NNS N
for IN N
treatment NN N
of IN N
melasma NN o
. . o

BACKGROUND NNP N
Chemical NNP i
peels NNS i
and CC N
topical JJ i
depigmenting NN i
agents NNS i
have VBP N
become VBN N
a DT N
popular JJ N
modality NN N
in IN N
the DT N
treatment NN N
of IN N
melasma NN o
. . o

AIMS NNP N
To TO N
compare VB N
the DT N
clinical JJ o
efficacy NN o
of IN N
trichloroacetic JJ i
acid NN i
peel VB i
20 CD i
% NN i
vs NN i
. . N

Jessner NNP i
's POS i
solution NN i
peel NN i
vs. IN i
the DT i
topical JJ i
mixture NN i
of IN i
hydroquinone NN i
2 CD i
% NN i
and CC i
kojic NN i
acid NN i
. . i

PATIENTS NNP N
AND CC N
METHODS NNP N
Forty NNP p
five CD p
patients NNS p
with IN p
melasma NNS p
were VBD p
randomly RB p
assigned VBN p
into IN p
three CD p
groups NNS p
of IN p
fifteen JJ p
patients NNS p
each DT p
. . p

Group NNP N
A NNP N
received VBD N
Jessner NNP i
's POS i
solution NN i
peel NN i
, , N
group NN N
B NNP N
received VBD N
trichloroacetic JJ i
acid NN i
peel VB i
20 CD i
% NN i
, , N
and CC N
group NN N
C NNP N
received VBD N
topical JJ i
hydroquinone NN i
2 CD i
% NN i
and CC i
kojic NN i
acid NN i
. . i

All DT N
patients NNS N
were VBD N
seen VBN N
in IN N
follow-up JJ N
period NN N
after IN N
16 CD N
weeks NNS N
; : N
clinical JJ N
evaluation NN N
using VBG N
Melasma NNP o
Area NNP o
and CC o
Severity NNP o
Index NNP o
( ( o
MASI NNP o
) ) o
score NN o
and CC o
photography NN o
were VBD N
recorded VBN N
before IN N
and CC N
after IN N
treatment NN N
and CC N
after IN N
16 CD N
weeks NNS N
. . N

RESULTS NNP N
There EX N
was VBD N
a DT N
decrease NN N
in IN N
MASI NNP o
score NN o
in IN N
all DT N
three CD N
groups NNS N
after IN N
treatment NN N
and CC N
after IN N
follow-up JJ N
period NN N
but CC N
after IN N
treatment NN N
MASI NNP o
score NN o
was VBD N
statistically RB N
significantly RB N
lower JJR N
in IN N
group NN N
A NNP N
than IN N
group NN N
C NNP N
( ( N
P NNP N
= NNP N
0.01 CD N
) ) N
, , N
and CC N
it PRP N
was VBD N
also RB N
statistically RB N
significantly RB N
lower JJR N
in IN N
group NN N
B NNP N
than IN N
group NN N
C NNP N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
but CC N
there EX N
was VBD N
no DT N
statistically RB N
significant JJ N
difference NN N
between IN N
groups NNS N
A NNP N
and CC N
B NNP N
. . N

After IN N
the DT N
follow-up JJ N
period NN N
, , N
MASI NNP o
score NN o
was VBD N
statistically RB N
significantly RB N
lower JJR N
in IN N
group NN N
A NNP N
than IN N
group NN N
C NNP N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
statistically RB N
significantly RB N
lower JJR N
in IN N
group NN N
B NNP N
than IN N
group NN N
C NNP N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
and CC N
statistically RB N
significantly RB N
lower JJR N
in IN N
group NN N
B NNP N
than IN N
group NN N
A NNP N
( ( N
P NNP N
= NNP N
0.035 CD N
) ) N
. . N

The DT N
statistical JJ N
analysis NN N
was VBD N
done VBN N
through IN N
one-way JJ N
anova NN N
followed VBN N
by IN N
least JJS N
significant JJ N
difference NN N
( ( N
LSD NNP N
) ) N
. . N

CONCLUSION NNP N
Trichloroacetic NNP i
acid VBD i
20 CD i
% NN i
showed VBD N
better JJR N
results NNS N
than IN N
Jessner NNP i
's POS i
solution NN i
as IN N
peeling NN N
agent NN N
and CC N
hydroquinone VB i
2 CD i
% NN i
with IN i
kojic JJ i
acid NN i
as IN N
a DT N
topical JJ N
agent NN N
in IN N
the DT N
treatment NN o
of IN o
melasma NN o
. . o

-DOCSTART- -21975231- O O

Design NN N
and CC N
implementation NN N
of IN N
the DT N
TRACIA NNP N
: : N
intracoronary JJ N
autologous JJ N
transplant NN N
of IN N
bone NN N
marrow-derived JJ N
stem NN N
cells NNS N
for IN N
acute JJ p
ST NNP p
elevation NN p
myocardial JJ p
infarction NN p
. . p

OBJECTIVE UH N
To TO N
describe VB N
the DT N
design NN N
of IN N
a DT N
protocol NN N
of IN N
intracoronary JJ i
autologous JJ i
transplant NN i
of IN i
bone NN i
marrow-derived JJ i
stem NN i
cells NNS i
for IN N
acute JJ p
ST-elevation NNP p
myocardial JJ p
infarction NN p
( ( p
STEMI NNP p
) ) p
and CC N
to TO N
report VB N
the DT N
safety NN N
of IN N
the DT N
procedure NN N
in IN N
the DT N
first JJ N
patients NNS N
included VBN N
. . N

METHODS NNP N
The DT N
TRACIA NNP N
study NN N
was VBD N
implemented VBN N
following VBG N
predetermined JJ N
inclusion NN N
and CC N
exclusion NN N
criteria NNS N
. . N

The DT N
protocol NN N
includes VBZ N
procedures NNS N
such JJ N
as IN N
randomization NN i
, , i
bone NN i
marrow NN i
retrieval NN i
, , i
stem NN i
cells NNS i
processing NN i
, , i
intracoronary JJ i
infusion NN i
of IN i
stem NN i
cells NNS i
in IN i
the DT i
infarct-related JJ i
artery NN i
, , i
preand- JJ i
post NN i
MRI NNP i
, , i
pre-and-post JJ i
SPECT NNP i
with IN i
radioisotope NN i
ventriculography NN i
, , i
and CC i
clinical JJ i
follow-up NN i
at IN i
6 CD i
months NNS i
. . i

RESULTS NNP N
Eight VBD p
patients NNS p
with IN p
a DT p
diagnosis NN p
of IN p
acute JJ o
STEMI NNP o
and CC o
duration NN o
of IN o
symptoms NNS o
of IN p
? . p
24 CD p
hours NNS p
that WDT p
were VBD p
perfused VBN p
successfully RB p
through IN p
primary JJ p
percutaneous JJ p
coronary JJ p
intervention NN p
( ( p
PPCI NNP p
) ) p
with IN p
a DT p
LVEF NNP p
of IN p
? . p
45 CD p
% NN p
were VBD N
assigned VBN N
randomly RB N
to TO N
two CD N
groups NNS N
( ( N
n JJ N
= RB N
4 CD N
each DT N
) ) N
. . N

One CD N
group NN N
treated VBD N
with IN N
stem NN i
cells NNS i
and CC N
the DT N
other JJ N
corresponded VBD N
to TO N
the DT N
control NN i
group NN i
. . i

Neither CC N
death NN o
, , o
re-infarction NN o
, , o
no DT o
need NN o
for IN o
revascularization NN o
or CC o
thrombosis NN o
of IN o
the DT o
stent NN o
were VBD N
observed VBN N
at IN N
follow-up NN N
. . N

CONCLUSIONS VB N
The DT N
initial JJ N
experience NN N
at IN N
the DT p
Instituto NNP p
Nacional NNP p
de FW p
Cardiolog?a NNP p
Ignacio NNP p
Ch?vez NNP p
in IN p
the DT N
treatment NN N
of IN N
acute JJ p
STEMI NNP p
by IN p
means NNS N
of IN N
autologous JJ N
transplantation NN N
of IN N
bone NN i
marrow-derived JJ i
stem NN i
cells NNS i
is VBZ i
encouraging VBG N
. . N

Implementation NN N
was VBD N
possible JJ N
in IN N
the DT N
first JJ N
eight CD N
patients NNS N
with IN N
no DT N
complications NNS N
. . N

-DOCSTART- -25256627- O O

Working VBG N
memory NN N
and CC N
cognitive JJ N
flexibility-training NN N
for IN N
children NNS p
with IN p
an DT p
autism NN p
spectrum NN p
disorder NN p
: : p
a DT N
randomized NN N
controlled VBN N
trial NN N
. . N

BACKGROUND NNP N
People NNPS p
with IN p
autism NN p
spectrum NN p
disorders NNS p
( ( p
ASDs NNP p
) ) p
experience NN N
executive NN N
function NN N
( ( N
EF NNP N
) ) N
deficits NNS N
. . N

There EX N
is VBZ N
an DT N
urgent JJ N
need NN N
for IN N
effective JJ N
interventions NNS N
, , N
but CC N
in IN N
spite NN N
of IN N
the DT N
increasing VBG N
research NN N
focus NN N
on IN N
computerized JJ N
cognitive JJ N
training NN N
, , N
this DT N
has VBZ N
not RB N
been VBN N
studied VBN N
in IN N
ASD NNP N
. . N

Hence NNP N
, , N
we PRP N
investigated VBD N
two CD N
EF NNP i
training NN i
conditions NNS i
in IN N
children NNS p
with IN p
ASD NNP p
. . p

METHODS NNP N
In IN N
a DT N
randomized NN N
controlled VBN N
trial NN N
, , N
children NNS p
with IN p
ASD NNP p
( ( p
n JJ p
= NN p
121 CD p
, , p
8-12 CD p
years NNS p
, , p
IQ NNP p
> NNP p
80 CD p
) ) p
were VBD N
randomly RB N
assigned VBN N
to TO N
an DT i
adaptive JJ i
working JJ i
memory NN i
( ( i
WM NNP i
) ) i
training NN i
, , i
an DT i
adaptive JJ i
cognitive JJ i
flexibility-training NN i
, , i
or CC i
a DT i
non-adaptive JJ i
control NN i
training NN i
( ( i
mock-training JJ i
) ) i
. . i

Braingame NNP i
Brian NNP i
, , i
a DT i
computerized JJ i
EF-training NN i
with IN i
game-elements NNS i
, , N
was VBD N
used VBN N
. . N

Outcome JJ N
measures NNS N
( ( N
pretraining VBG N
, , N
post-training NN N
, , N
and CC N
6-week-follow-up JJ N
) ) N
were VBD N
near-transfer JJ o
to TO o
trained JJ o
EFs NNP o
, , o
far-transfer NN o
to TO o
other JJ o
EFs NNP o
( ( o
sustained VBN o
attention NN o
and CC o
inhibition NN o
) ) o
, , o
and CC o
parent NN o
's POS o
ratings NNS o
of IN o
daily JJ o
life NN o
EFs NNP o
, , o
social JJ o
behavior NN o
, , o
attention NN o
deficit NN o
hyperactivity NN o
disorder NN o
( ( o
ADHD NNP o
) ) o
-behavior NN o
, , o
and CC o
quality NN o
of IN o
life NN o
. . o

RESULTS NNP N
Attrition-rate NNP o
was VBD N
26 CD N
% NN N
. . N

Children NNP N
in IN N
all DT N
conditions NNS N
who WP N
completed VBD N
the DT N
training NN N
improved VBN N
in IN N
WM NNP o
, , o
cognitive JJ o
flexibility NN o
, , o
attention NN o
, , o
and CC o
on IN o
parent NN o
's POS o
ratings NNS o
, , o
but CC o
not RB o
in IN o
inhibition NN o
. . o

There EX N
were VBD N
no DT N
significant JJ N
differential JJ N
intervention NN N
effects NNS N
, , N
although IN N
children NNS N
in IN N
the DT N
WM NNP N
condition NN N
showed VBD N
a DT N
trend NN N
toward IN N
improvement NN N
on IN N
near-transfer JJ o
WM NNP o
and CC o
ADHD-behavior NNP o
, , N
and CC N
children NNS N
in IN N
the DT N
cognitive JJ N
flexibility NN N
condition NN N
showed VBD N
a DT N
trend NN N
toward IN N
improvement NN N
on IN N
near-transfer JJ o
flexibility NN o
. . o

CONCLUSION NNP N
Although IN N
children NNS N
in IN N
the DT N
WM NNP N
condition NN N
tended VBD N
to TO N
improve VB N
more RBR N
in IN N
WM NNP o
and CC o
ADHD-behavior NNP o
, , N
the DT N
lack NN N
of IN N
differential JJ N
improvement NN N
on IN N
most JJS N
outcome JJ N
measures NNS N
, , N
the DT N
absence NN N
of IN N
a DT N
clear JJ N
effect NN N
of IN N
the DT N
adaptive JJ N
training NN N
compared VBN N
to TO N
the DT N
mock-training NN N
, , N
and CC N
the DT N
high JJ N
attrition NN N
rate NN N
suggest VBP N
that IN N
the DT N
training NN N
in IN N
its PRP$ N
present JJ N
form NN N
is VBZ N
probably RB N
not RB N
suitable JJ N
for IN N
children NNS p
with IN p
ASD NNP p
. . p

-DOCSTART- -20488452- O O

Learning VBG N
about IN N
the DT N
equal JJ N
sign NN N
: : N
does VBZ N
comparing VBG N
with IN N
inequality NN N
symbols NNS N
help VB N
? . N
This DT i
study NN i
investigated VBD i
whether IN i
instruction NN i
that WDT i
involves VBZ i
comparing VBG i
the DT i
equal JJ i
sign NN i
with IN i
other JJ i
relational JJ i
symbols NNS i
is VBZ i
more RBR i
effective JJ i
at IN i
imparting VBG i
a DT i
relational JJ o
interpretation NN o
of IN o
the DT o
equal JJ o
sign NN o
than IN i
instruction NN i
about IN i
the DT i
equal JJ i
sign NN i
alone RB i
. . i

Third- JJ i
and CC i
fourth-grade JJ i
students NNS i
in IN i
a DT i
comparing NN i
symbols NNS i
group NN i
learned VBD i
about IN i
the DT i
greater JJR i
than IN i
, , i
less JJR i
than IN i
, , i
and CC i
equal JJ i
signs NNS i
and CC i
had VBD i
the DT i
opportunity NN i
to TO i
compare VB i
the DT i
inequality NN i
symbols VBZ i
with IN i
the DT i
equal JJ i
sign NN i
. . i

Students NNS i
in IN i
an DT i
equal JJ i
sign NN i
group NN i
learned VBD i
about IN i
the DT i
equal JJ i
sign NN i
only RB i
. . i

A NNP i
third JJ i
group NN i
of IN i
students NNS i
served VBD i
as IN i
a DT i
control NN i
group NN i
. . i

Three CD N
aspects NNS N
of IN N
students NNS N
' POS N
knowledge NN N
were VBD N
assessed VBN N
before IN N
and CC N
after IN N
the DT N
lesson NN N
: : N
( ( N
a DT N
) ) N
conceptual JJ o
understanding NN o
of IN o
the DT o
equal JJ o
sign NN o
, , N
( ( N
b NN N
) ) N
equation NN o
encoding NN o
, , N
and CC N
( ( N
c NN N
) ) N
problem NN o
solving VBG o
. . o

Students NNS N
in IN N
the DT N
comparing NN N
symbols NNS N
group NN N
showed VBD N
greater JJR N
gains NNS N
in IN N
conceptual JJ o
understanding NN o
from IN N
pretest NN N
to TO N
posttest VB N
than IN N
students NNS N
in IN N
the DT N
other JJ N
two CD N
groups NNS N
, , N
and CC N
students NNS N
in IN N
the DT N
comparing NN N
symbols NNS N
group NN N
also RB N
scored VBD N
higher JJR N
on IN N
a DT N
posttest NN o
that WDT o
assessed VBD o
knowledge NN o
about IN o
inequality NN o
symbols NNS o
and CC o
inequality NN o
problem NN o
solving VBG o
. . o

Thus RB N
, , N
they PRP N
learned VBD N
about IN N
three CD N
symbols NNS N
in IN N
the DT N
same JJ N
amount NN N
of IN N
time NN N
as IN N
other JJ N
students NNS N
learned VBD N
about IN N
the DT N
equal JJ N
sign NN N
alone RB N
or CC N
not RB N
at IN N
all DT N
. . N

Therefore NNP N
, , N
an DT N
instructional JJ N
approach NN N
involving VBG N
comparison NN N
can MD N
be VB N
an DT N
effective JJ N
tool NN N
for IN N
learning VBG N
about IN N
concepts NNS N
in IN N
mathematics NNS N
. . N

-DOCSTART- -19696287- O O

Depiction NN o
of IN o
hypervascular JJ o
hepatocellular JJ o
carcinoma NN o
with IN N
64-MDCT JJ o
: : o
comparison NN N
of IN N
moderate- JJ i
and CC i
high-concentration JJ i
contrast NN i
material NN i
with IN i
and CC i
without IN i
saline JJ i
flush NN i
. . i

OBJECTIVE CC N
The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
evaluate VB N
prospectively RB N
the DT N
depiction NN o
of IN o
hypervascular JJ o
hepatocellular JJ o
carcinoma NN o
on IN N
64-MDCT JJ N
scans NNS N
obtained VBN N
with IN N
contrast NN i
agents NNS i
of IN N
varying VBG N
iodine JJ i
concentrations NNS i
administered VBN N
with IN N
and CC N
without IN N
saline JJ i
flush NN i
. . i

SUBJECTS NNP N
AND CC N
METHODS NNP N
The DT p
study NN p
included VBD p
149 CD p
patients NNS p
, , p
among IN p
whom WP p
36 CD p
patients NNS p
with IN p
hypervascular JJ p
hepatocellular JJ p
carcinoma NN p
were VBD p
identified VBN p
. . p

Patients NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
one CD N
of IN N
three CD N
protocols NNS N
: : N
A DT N
, , N
contrast JJ i
material NN i
of IN i
300 CD i
mg NNS i
I/mL NNP i
; : i
B NNP i
, , i
370 CD i
mg NN i
I/mL NNP i
; : i
C NNP i
, , i
370 CD i
mg NN i
I/mL NNP i
plus CC i
saline JJ i
flush NN i
. . i

In IN N
all DT N
protocols NNS N
, , N
the DT N
same JJ i
iodine NN i
load NN i
per IN i
kilogram NN i
of IN i
body NN i
weight NN i
( ( N
516 CD N
mg/kg NN N
) ) N
was VBD N
administered VBN N
for IN N
the DT N
same JJ N
injection NN N
duration NN N
( ( N
30 CD N
seconds NNS N
) ) N
. . N

Enhancement JJ o
values NNS o
in IN o
the DT o
aorta NN o
, , o
liver NN o
, , o
and CC o
portal JJ o
vein NN o
and CC o
tumor-liver JJ o
contrast NN o
were VBD N
measured VBN N
at IN N
multiphase NN N
CT NNP N
. . N

RESULTS NNP N
Aortic JJ o
enhancement NN o
was VBD N
significantly RB N
different JJ N
between IN N
protocols NNS N
A NNP N
and CC N
B NNP N
( ( N
p JJ N
= NN N
0.04 CD N
, , N
p NN N
< NNP N
0.0001 CD N
) ) N
and CC N
protocols VBZ N
B NNP N
and CC N
C NNP N
( ( N
p JJ N
= NN N
0.02 CD N
, , N
p NN N
< NNP N
0.001 CD N
) ) N
in IN N
the DT N
first JJ N
and CC N
second JJ N
phases NNS N
. . N

Portal NNP o
venous JJ o
enhancement NN o
was VBD N
significantly RB N
different JJ N
between IN N
protocols NNS N
B NNP N
and CC N
C NNP N
( ( N
p JJ N
= NNP N
0.02 CD N
) ) N
in IN N
the DT N
first JJ N
phase NN N
and CC N
between IN N
protocols NNS N
B NNP N
and CC N
C NNP N
and CC N
protocols VBZ N
A DT N
and CC N
C NNP N
( ( N
p JJ N
< NN N
0.01 CD N
, , N
p NN N
= NNP N
0.02 CD N
) ) N
in IN N
the DT N
second JJ N
phase NN N
. . N

Tumor-liver JJ o
contrast NN o
was VBD N
significantly RB N
different JJ N
between IN N
protocols NNS N
A NNP N
and CC N
B NNP N
( ( N
p JJ N
= NN N
0.03 CD N
, , N
p NN N
= NNP N
0.02 CD N
) ) N
and CC N
protocols VBZ N
B NNP N
and CC N
C NNP N
( ( N
p JJ N
= NN N
0.03 CD N
, , N
p NN N
= NNP N
0.04 CD N
) ) N
in IN N
the DT N
first JJ N
and CC N
second JJ N
phases NNS N
but CC N
not RB N
between IN N
protocols NNS N
A NNP N
and CC N
C. NNP N
There EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
hepatic JJ o
enhancement NN o
among IN N
the DT N
three CD N
protocols NNS N
. . N

CONCLUSION NNP N
Use NNP N
of IN N
moderate JJ N
concentration NN N
was VBD N
more RBR N
effective JJ N
than IN N
use NN N
of IN N
a DT N
high JJ N
concentration NN N
of IN N
contrast NN N
material NN N
for IN N
depiction NN N
of IN N
hepatocellular JJ N
carcinoma NN N
. . N

Adding VBG N
a DT N
saline NN N
flush NN N
to TO N
the DT N
high-concentration NN i
protocol NN i
eliminated VBD N
the DT N
difference NN N
in IN N
depiction NN o
of IN o
hepatocellular JJ o
carcinoma NN o
between IN N
the DT N
moderate- JJ N
and CC N
high-concentration NN N
protocols NNS N
. . N

-DOCSTART- -15196300- O O

The DT N
prophylactic JJ o
effect NN o
of IN N
valproate NN i
on IN N
glyceryltrinitrate NN o
induced VBN o
migraine NN o
. . o

In IN N
this DT N
study NN N
the DT N
human JJ N
glyceryltrinitrate NN N
( ( N
GTN NNP N
) ) N
model NN N
of IN N
migraine NN N
was VBD N
for IN N
the DT N
first JJ N
time NN N
used VBN N
to TO N
test VB N
the DT N
effect NN N
of IN N
a DT N
prophylactic JJ i
drug NN i
. . i

We PRP N
chose VBD N
to TO N
test VB N
valproate NN i
due JJ N
to TO N
its PRP$ N
well RB N
documented JJ N
effect NN N
as IN N
a DT N
migraine JJ i
prophylactic JJ i
drug NN i
. . i

Efficacy NN o
of IN N
this DT N
compound NN N
would MD N
support VB N
the DT N
usefulness NN N
of IN N
the DT N
model NN N
in IN N
prophylactic JJ N
antimigraine JJ N
drug NN N
development NN N
. . N

Twelve CD p
patients NNS p
with IN p
migraine NN p
without IN p
aura NN p
were VBD p
included VBN p
in IN p
a DT p
randomized JJ p
double JJ p
blind NN p
crossover NN p
study NN p
. . p

Valproate VB i
1000 CD N
mg NN N
or CC i
placebo NN i
was VBD N
given VBN N
daily RB N
, , N
each DT N
for IN N
a DT N
minimum NN N
of IN N
13 CD N
days NNS N
. . N

On IN N
the DT N
last JJ N
treatment NN N
day NN N
of IN N
each DT N
arm NN N
a DT N
20 CD N
min NN N
intravenous JJ N
infusion NN N
of IN N
GTN NNP i
( ( N
0.25 CD N
microg/kg/min NN N
) ) N
was VBD N
given VBN N
. . N

Headache NNP o
was VBD N
registered VBN N
for IN N
12 CD N
h NN N
after IN N
the DT N
infusion NN N
and CC N
headache NN o
intensity NN o
was VBD N
scored VBN N
on IN N
a DT N
scale NN N
from IN N
0 CD N
to TO N
10 CD N
. . N

Fulfillment NN N
of IN N
IHS NNP N
criteria NNS N
was VBD N
recorded VBN N
for IN N
24 CD N
h. PDT N
The DT N
middle JJ o
cerebral JJ o
arteries NNS o
were VBD N
evaluated VBN N
by IN N
transcranial JJ o
Doppler NNP o
and CC N
the DT N
diameter NN o
of IN o
the DT o
superficial JJ o
temporal JJ o
and CC o
radial JJ o
arteries NNS o
were VBD N
measured VBN N
with IN N
high JJ o
frequency NN o
ultrasound NN o
. . o

GTN NNP o
evoked VBD o
migraine JJ o
fulfilling NN o
IHS NNP o
criteria NNS o
1.1 CD N
in IN N
6 CD N
patients NNS N
after IN N
placebo NN i
and CC N
in IN N
2 CD N
patients NNS N
after IN N
valproate NN i
( ( N
P NNP N
= NNP N
0.125 CD N
) ) N
. . N

Including VBG N
additionally RB N
3 CD N
patients NNS N
on IN N
placebo NN i
and CC N
1 CD N
patient NN N
on IN N
valproate NN i
who WP N
felt VBD N
they PRP N
had VBD N
suffered VBN N
a DT N
migraine JJ o
attack NN o
, , N
but CC N
who WP N
had VBD N
as IN N
associated VBN o
symptoms NNS o
only RB N
photophobia VBP o
or CC N
phonophobia VBP o
, , N
a DT N
significant JJ N
reduction NN N
in IN N
the DT N
number NN o
of IN o
patients NNS o
with IN o
induced JJ o
migraine NN o
after IN N
valproate NN i
was VBD N
seen VBN N
( ( N
P NNP N
= NNP N
0.031 CD N
) ) N
. . N

Median JJ o
peak NN o
headache NN o
intensity NN o
was VBD N
1 CD N
( ( N
range VB N
0-9 NN N
) ) N
after IN N
valproate NN i
compared VBN N
to TO N
4.5 CD N
( ( N
range VB N
0-8 NN N
) ) N
after IN N
placebo NN i
( ( N
P NNP N
= NNP N
0.120 CD N
) ) N
. . N

Pretreatment NN N
with IN N
valproate NN i
as IN N
compared VBN N
to TO N
placebo VB i
reduced VBN N
the DT N
velocity NN o
in IN N
both DT N
middle JJ o
cerebral NN o
arteries NNS o
after IN N
GTN NNP N
( ( N
left VBN N
P NNP N
= NNP N
0.021 CD N
, , N
right JJ N
P NNP N
= NNP N
0.031 CD N
) ) N
. . N

No DT N
effect NN N
of IN N
valproate NN i
was VBD N
seen VBN N
in IN N
the DT N
diameter NN o
of IN o
the DT o
superficial JJ o
temporal JJ o
artery NN o
( ( N
P NNP N
= NNP N
0.781 CD N
) ) N
or CC N
the DT N
radial JJ o
artery NN o
( ( N
P NNP N
= NNP N
0.367 CD N
) ) N
before IN N
or CC N
after IN N
GTN NNP N
. . N

The DT N
study NN N
indicates VBZ N
that IN N
a DT N
prophylactic JJ N
effect NN N
of IN N
valproate NN i
may MD N
be VB N
demonstrated VBN N
using VBG N
the DT N
GTN NNP o
human JJ o
migraine NN o
model NN i
. . i

Although IN N
, , N
all DT N
headache NN o
parameters NNS o
were VBD N
reduced VBN N
after IN N
valproate NN i
compared VBN N
to TO N
placebo VB i
, , N
only RB N
one CD N
parameter NN N
was VBD N
statistically RB N
significantly RB N
reduced VBN N
probably RB N
because IN N
of IN N
the DT N
small JJ N
number NN N
of IN N
patients NNS N
. . N

The DT N
size NN N
of IN N
the DT N
effect NN N
was VBD N
similar JJ N
to TO N
that DT N
of IN N
valproate NN N
in IN N
clinical JJ N
trials NNS N
. . N

The DT i
GTN NNP i
model NN i
may MD N
therefore RB N
be VB N
a DT N
valid JJ N
tool NN N
for IN N
testing VBG N
new JJ N
prophylactic JJ N
antimigraine NN N
drugs NNS N
. . N

-DOCSTART- -9676408- O O

A DT N
prospective JJ N
randomized VBN N
study NN N
of IN N
transurethral JJ i
resection NN i
of IN i
the DT i
prostate NN i
and CC i
transurethral JJ i
vaporization NN i
of IN i
the DT i
prostate NN i
as IN N
a DT N
therapeutic JJ N
alternative NN N
in IN N
the DT N
management NN N
of IN N
men NNS p
with IN p
BPH NNP p
. . p

OBJECTIVE CC N
The DT N
common JJ N
goals NNS N
of IN N
new JJ N
surgical JJ N
treatment NN N
for IN N
benign JJ o
prostatic JJ o
hyperplasia NN o
( ( p
BPH NNP p
) ) p
are VBP N
to TO N
improve VB N
subjective NN N
and CC N
objective JJ N
symptoms NNS N
, , N
to TO N
decrease VB N
the DT N
risk NN N
of IN N
postoperative JJ o
complications NNS o
and CC N
short JJ N
hospitalization NN N
. . N

Transurethral JJ i
electrovaporization NN i
of IN i
the DT i
prostate NN i
( ( i
TUVP NNP i
) ) i
is VBZ N
a DT N
new JJ N
, , N
minimally RB N
invasive JJ N
and CC N
a DT N
promising JJ N
alternative NN N
to TO N
standard VB i
transurethral JJ i
resection NN i
of IN i
the DT i
prostate NN i
( ( i
TURP NNP i
) ) i
in IN N
the DT N
treatment NN N
of IN N
BPH NNP N
. . N

The DT N
aim NN N
of IN N
this DT N
study NN N
is VBZ N
to TO N
compare VB N
the DT N
efficacy NN o
and CC o
safety NN o
of IN N
these DT N
two CD N
treatment NN N
alternatives NNS N
. . N

METHODS NNP N
A NNP N
prospective JJ N
randomized VBN N
trial NN N
of IN N
60 CD p
patients NNS p
with IN p
symptomatic JJ p
BPH NNP p
was VBD p
performed VBN p
. . p

Preoperative JJ o
and CC o
postoperative JJ o
International NNP o
Prostate NNP o
Symptom NNP o
Score NNP o
( ( o
IPSS NNP o
) ) o
, , o
maximum JJ o
flow NN o
rates NNS o
( ( o
Qmax NNP o
) ) o
and CC o
complications NNS o
were VBD N
recorded VBN N
in IN N
each DT N
patient NN N
. . N

The DT N
volume NN N
of IN N
the DT N
prostate NN N
was VBD N
measured VBN N
preoperatively RB N
and CC N
postoperatively RB N
using VBG N
transrectal JJ o
ultrasound NN o
. . o

RESULTS NNP N
Of IN N
the DT N
30 CD N
patients NNS N
who WP N
underwent JJ N
TURP NNP N
, , N
mean JJ N
hospital NN N
stay NN N
was VBD N
4.5 CD N
days NNS N
. . N

The DT N
Foley NNP o
catheter NN o
was VBD N
removed VBN N
on IN N
postoperative JJ N
day NN N
4 CD N
following VBG N
surgery NN N
. . N

IPSS NNP o
decreased VBD N
from IN N
21.6 CD N
to TO N
5.2 CD N
, , N
Qmax NNP N
increased VBD N
from IN N
9.2 CD N
to TO N
19.2 CD N
ml/s NNS N
at IN N
3 CD N
months NNS N
. . N

Mean NNP o
prostatic JJ o
volume NN o
at IN N
3 CD N
months NNS N
decreased VBN N
from IN N
51.7 CD N
to TO N
26.2 CD N
g NN N
, , N
a DT N
49.3 CD N
% NN N
reduction NN N
. . N

Of IN N
30 CD N
patients NNS N
undergoing JJ N
TUVP NNP N
, , N
mean JJ N
hospital NN N
stay NN N
was VBD N
2.5 CD N
days NNS N
and CC N
the DT N
catheter NN N
was VBD N
removed VBN N
within IN N
2 CD N
days NNS N
following VBG N
surgery NN N
. . N

Postoperative NNP o
urinary JJ o
retention NN o
did VBD N
not RB N
occur VB N
in IN N
any DT N
patient NN N
. . N

IPSS NNP o
decreased VBD N
from IN N
19.4 CD N
to TO N
4.1 CD N
and CC N
Qmax NNP N
increased VBD N
from IN N
7.9 CD N
to TO N
17.7 CD N
ml/s NNS N
at IN N
3 CD N
months NNS N
. . N

Mean NNP o
prostatic JJ o
volume NN o
decreased VBD N
from IN N
48.9 CD N
to TO N
27.8 CD N
g NN N
, , N
a DT N
43.1 CD N
% NN N
reduction NN N
at IN N
3 CD N
months NNS N
. . N

In IN N
the DT N
TUVP NNP N
group NN N
, , N
none NN N
of IN N
the DT N
patients NNS N
required VBN N
blood NN o
transfusions NNS o
or CC N
developed JJ N
clinical JJ o
transurethral JJ o
resection NN o
syndrome NN o
. . o

There EX N
were VBD N
no DT o
major JJ o
complications NNS o
. . o

Sphincteric JJ o
incontinence NN o
, , o
urethral JJ o
strictures NNS o
or CC o
bladder NN o
neck NN o
contractures NNS o
were VBD N
not RB N
recorded VBN N
. . N

At IN N
3 CD N
months NNS N
postoperatively RB N
, , N
13 CD N
patients NNS N
in IN N
the DT N
TURP NNP N
group NN N
and CC N
7 CD N
patients NNS N
in IN N
the DT N
TUVP NNP N
group NN N
had VBD N
retrograde VBN o
ejaculation NN o
. . o

CONCLUSION NNP N
Our PRP$ N
initial JJ N
experience NN N
of IN N
TUVP NNP N
suggests VBZ N
advantages NNS N
over IN N
conventional JJ N
TURP NNP N
through IN N
reduced VBN o
blood NN o
loss NN o
and CC N
shorter JJR o
hospital NN o
stay NN o
. . o

It PRP N
appears VBZ N
to TO N
be VB N
an DT N
effective JJ N
treatment NN N
for IN N
BPH NNP N
; : N
however RB N
, , N
long-term JJ N
results NNS N
should MD N
be VB N
evaluated VBN N
. . N

-DOCSTART- -24767206- O O

[ IN N
The DT N
effects NNS N
of IN N
tirofiban NN i
on IN N
acute JJ N
non-ST JJ N
segment NN N
elevation NN N
myocardial JJ o
infarction NN o
patients NNS p
not RB p
receiving VBG p
early JJ p
reperfusion NN p
intervention NN p
] NNP p
. . N

OBJECTIVE NNP N
To TO N
study VB N
the DT N
efficacy NN o
and CC o
safety NN o
of IN N
tirofiban NN i
in IN N
patients NNS p
with IN p
acute JJ p
non-ST- JJ p
segment NN p
elevation NN p
myocardial JJ p
infarction NN p
( ( p
NSTEMI NNP p
) ) p
without IN p
early JJ p
reperfusion NN p
intervention NN p
. . p

METHODS NNP N
A NNP N
total NN p
of IN p
151 CD p
NSTEMI NNP p
patients NNS p
without IN p
early JJ p
reperfusion NN p
intervention NN p
were VBD N
enrolled VBN N
in IN N
the DT N
study NN N
and CC N
randomized VBN N
to TO N
the DT N
tirofiban NN i
group NN N
( ( N
n JJ N
= NNP N
76 CD N
) ) N
and CC N
the DT N
control NN i
group NN i
( ( i
n JJ i
= NNP N
75 CD N
) ) N
. . N

Coronary JJ i
angiography NN i
was VBD N
performed VBN N
at IN N
day NN N
3 CD N
and CC N
day NN N
7 CD N
, , N
while IN N
percutaneous JJ N
coronary JJ N
intervention NN i
( ( N
PCI NNP N
) ) N
was VBD N
performed VBN N
when WRB N
necessary JJ N
. . N

Parameters NNS N
including VBG N
thrombolysis NN o
in IN o
myocardial JJ o
infarction NN o
( ( o
TIMI NNP o
) ) o
flow NN o
, , o
bleeding VBG o
complications NNS o
and CC o
clinic JJ o
events NNS o
within IN N
30 CD N
days NNS N
were VBD N
compared VBN N
between IN N
the DT N
two CD N
groups NNS N
. . N

RESULTS NNP N
Before IN N
PCI NNP N
, , N
no DT N
increase NN N
in IN N
the DT N
percentage NN o
of IN o
patient NN o
with IN o
TIMI NNP o
flow VBP o
better JJR N
than IN N
TIMI-2 NNP N
was VBD N
observed VBN N
by IN N
the DT N
treatment NN N
of IN N
tirofiban NN i
( ( N
69.3 CD N
% NN N
vs JJ N
78.9 CD N
% NN N
, , N
P NNP N
= NNP N
0.10 CD N
) ) N
. . N

While IN N
after IN N
PCI NNP N
, , N
significant JJ N
increase NN N
in IN N
the DT N
percentage NN o
of IN o
patient NN o
with IN o
TIMI NNP o
flow VBP o
better JJR N
than IN N
TIMI-2 NNP N
was VBD N
manifested VBN N
in IN N
the DT N
tirofiban NN i
group NN N
( ( N
96.0 CD N
% NN N
vs JJ N
100.0 CD N
% NN N
, , N
P NNP N
= NNP N
0.04 CD N
) ) N
. . N

Tirofiban NNP N
treatment NN N
also RB N
significantly RB N
decreased VBD o
the DT o
rate NN o
of IN o
poor JJ o
myocardial JJ o
perfusion NN o
after IN N
PCI NNP N
( ( N
19.7 CD N
% NN N
vs JJ N
34.7 CD N
% NN N
, , N
P NNP N
= NNP N
0.04 CD N
) ) N
. . N

There EX N
were VBD N
0 CD N
and CC N
4 CD N
major JJ o
adverse JJ o
cardiovascular NN o
events NNS o
( ( o
MACE NNP o
) ) o
within IN N
30 CD N
days NNS N
observed VBN N
in IN N
the DT N
tirofiban NN i
group NN N
and CC N
the DT N
control NN N
group NN N
( ( N
0.0 CD N
% NN N
vs JJ N
5.3 CD N
% NN N
, , N
P NNP N
= NNP N
0.05 CD N
) ) N
. . N

No DT N
difference NN N
between IN N
the DT N
two CD N
groups NNS N
was VBD N
found VBN N
in IN N
the DT N
bleeding NN o
complications NNS o
within IN N
30 CD N
days NNS N
including VBG N
the DT N
mild JJ o
hemorrhage NN o
( ( N
5 CD N
vs RB N
4 CD N
cases NNS N
, , N
P NNP N
= NNP N
0.75 CD N
) ) N
, , N
severe JJ o
hemorrhage NN o
( ( N
2 CD N
vs RB N
1 CD N
cases NNS N
, , N
P NNP N
= NNP N
0.56 CD N
) ) N
or CC N
severe JJ o
thrombocytopenia NN o
( ( N
2 CD N
vs RB N
0 CD N
cases NNS N
, , N
P NNP N
= NNP N
0.49 CD N
) ) N
. . N

CONCLUSIONS NNP N
Tirofiban NNP N
treatment NN N
does VBZ N
not RB N
increase VB N
the DT N
bleeding JJ o
complications NNS o
in IN N
NSTEMI NNP p
patients NNS p
without IN p
early JJ p
PCI NNP p
. . p

Tirofiban NN N
can MD N
improve VB N
the DT N
TIMI NNP N
flow NN N
and CC N
the DT N
myocardial JJ N
perfusion NN N
after IN N
PCI NNP N
with IN N
less JJR N
MACE NNP N
within IN N
30 CD N
days NNS N
. . N

-DOCSTART- -3653128- O O

Deleterious JJ N
effects NNS N
of IN N
low-dose JJ i
oestrogen NN i
therapy NN i
on IN N
coronary JJ N
status NN N
in IN N
patients NNS p
with IN p
prostatic JJ p
cancer NN p
. . p

The DT N
effects NNS N
of IN N
oestrogen NN i
therapy NN i
and CC N
of IN N
orchidectomy NN i
on IN N
coronary JJ N
status NN N
, , N
as IN N
reflected VBN N
by IN N
exercise NN N
ECG-testing NN N
before IN N
and CC N
after IN N
one CD N
year NN N
of IN N
treatment NN N
, , N
were VBD N
assessed VBN N
in IN N
a DT N
randomized JJ N
study NN N
of IN N
patients NNS p
( ( p
N NNP p
= NNP p
100 CD p
) ) p
with IN p
prostatic JJ p
cancer NN p
. . p

Oestrogen NNP i
was VBD N
given VBN N
as IN N
polyestradiol NN i
phosphate NN i
80 CD N
mg NN N
i.m NN N
. . N

per IN N
month NN N
in IN N
combination NN N
with IN N
150 CD i
micrograms NNS i
ethinylestradiol JJ i
p.o NN N
. . N

per IN N
day NN N
. . N

There EX N
were VBD N
no DT N
significant JJ N
inter-group JJ N
differences NNS N
in IN N
conventional JJ N
risk NN N
factors NNS N
or CC N
in IN N
pre-treatment JJ N
exercise NN N
test NN N
results NNS N
. . N

Twelve NNP N
months NNS N
after IN N
the DT N
start NN N
of IN N
therapy NN N
the DT N
oestrogen NN N
group NN N
showed VBD N
a DT N
significantly RB N
greater JJR N
depression NN N
of IN N
the DT N
ST-segment NNP N
during IN N
maximal JJ N
exercise NN N
in IN N
leads NNS N
CH2 NNP N
( ( N
P NNP N
less JJR N
than IN N
0.0005 CD N
) ) N
and CC N
CH5 NNP N
( ( N
P NNP N
less JJR N
than IN N
0.01 CD N
) ) N
compared VBN N
with IN N
the DT N
pre-treatment JJ N
depression NN N
. . N

Twenty-five JJ N
per IN N
cent NN N
( ( N
N NNP N
= NNP N
13 CD N
) ) N
of IN N
the DT N
patients NNS N
in IN N
the DT N
oestrogen NN N
group NN N
suffered VBD N
cardiovascular JJ o
complications NNS o
during IN N
the DT N
year NN N
of IN N
therapy NN N
, , N
whereas JJ N
no DT N
such JJ N
complications NNS N
were VBD N
observed VBN N
in IN N
the DT N
orchidectomy NN N
group NN N
. . N

However RB N
, , N
even RB N
the DT N
patients NNS N
in IN N
the DT N
oestrogen NN N
group NN N
who WP N
had VBD N
not RB N
suffered VBN N
cardiovascular JJ o
complications NNS o
had VBD N
significantly RB N
greater JJR N
depressions NNS o
of IN o
the DT o
ST-segment NNP o
during IN N
exercise NN N
both DT N
in IN N
lead NN N
CH2 NNP N
( ( N
P NNP N
less JJR N
than IN N
0.0005 CD N
) ) N
and CC N
in IN N
CH5 NNP N
( ( N
P NNP N
less JJR N
than IN N
0.05 CD N
) ) N
. . N

There EX N
was VBD N
no DT N
significant JJ N
change NN N
in IN N
the DT N
ST-segment JJ o
level NN o
in IN N
the DT N
orchidectomy NN N
group NN N
twelve VBD N
months NNS N
after IN N
surgery NN N
. . N

In IN N
summary JJ N
, , N
we PRP N
found VBD N
evidence NN N
of IN N
an DT N
induction NN N
of IN N
myocardial JJ o
ischaemia NN o
during IN N
treatment NN N
with IN N
exogenous JJ i
oestrogens NNS i
at IN N
low JJ N
dosage NN N
in IN N
patients NNS p
with IN p
prostatic JJ p
cancer NN p
. . p

This DT N
deleterious JJ N
effect NN N
of IN N
oestrogen NN i
on IN N
the DT N
coronary JJ N
status NN N
argues NNS N
against IN N
oestrogen NN N
therapy NN N
, , N
since IN N
oestrogen NN i
has VBZ N
not RB N
been VBN N
shown VBN N
to TO N
be VB N
more RBR N
beneficial JJ N
than IN N
orchidectomy NN N
against IN N
prostatic JJ N
carcinoma NN N
. . N

-DOCSTART- -8681312- O O

A DT N
phase NN N
I PRP N
study VBP N
of IN N
recombinant JJ i
human JJ i
ciliary JJ i
neurotrophic JJ i
factor NN i
( ( i
rHCNTF NN i
) ) i
in IN N
patients NNS p
with IN p
amyotrophic JJ p
lateral JJ p
sclerosis NN p
. . p

The DT N
ALS NNP N
CNTF NNP N
Treatment NNP N
Study NNP N
( ( N
ACTS NNP N
) ) N
Phase NNP N
I-II NNP N
Study NNP N
Group NNP N
. . N

Fifty-seven CD p
patients NNS p
with IN p
amyotrophic JJ p
lateral JJ p
sclerosis NN p
( ( p
ALS NNP p
) ) p
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
0.5 CD N
, , N
1 CD N
, , N
3 CD N
, , N
7 CD N
, , N
10 CD N
, , N
or CC N
30 CD N
micrograms/kg NN N
recombinant JJ i
human JJ i
ciliary JJ i
neurotrophic JJ i
factor NN i
( ( i
rHCNTF NN i
) ) i
or CC N
placebo VB i
subcutaneously RB N
3 CD N
times NNS N
a DT N
week NN N
for IN N
2 CD N
weeks NNS N
. . N

Dose-limiting JJ o
toxicity NN o
, , o
consisting VBG o
of IN o
febrile JJ o
reactions NNS o
in IN o
some DT o
patients NNS o
, , o
fatigue NN o
, , o
and CC o
nonproductive JJ o
cough NN o
, , N
was VBD N
observed VBN N
at IN N
a DT N
dose JJ N
level NN N
of IN N
30 CD N
micrograms/kg NNS N
. . N

Dose-related JJ o
changes NNS o
in IN o
parameters NNS o
of IN o
the DT o
acute-phase JJ o
response NN o
were VBD N
noted VBN N
, , N
consistent JJ N
with IN N
the DT N
relationship NN N
of IN N
CNTF NNP i
and CC N
its PRP$ N
receptor NN N
system NN N
to TO N
the DT N
cytokine NN N
interleukin-6 NN N
( ( N
IL-6 NNP N
) ) N
and CC N
its PRP$ N
receptor NN N
. . N

No DT N
adverse JJ o
neurologic JJ o
consequences NNS o
of IN o
rHCNTF JJ o
administration NN o
were VBD N
observed VBN N
. . N

Antibodies NNS o
to TO o
rHCNTF VB o
were VBD N
observed VBN N
in IN N
sera NN N
of IN N
most JJS N
patients NNS N
tested VBN N
after IN N
2 CD N
weeks NNS N
of IN N
continuous JJ N
treatment NN N
and CC N
4 CD N
weeks NNS N
' POS N
withdrawal NN N
period NN N
. . N

rHCNTF NN i
was VBD N
safe JJ o
and CC o
tolerated VBD o
within IN N
acceptable JJ N
limits NNS N
when WRB N
administered VBN N
to TO N
patients NNS p
with IN p
ALS NNP p
in IN N
this DT N
study NN N
at IN N
doses NNS N
of IN N
up IN N
to TO N
30 CD N
micrograms/kg NN N
3 CD N
times NNS N
a DT N
week NN N
for IN N
2 CD N
weeks NNS N
. . N

Further JJ N
studies NNS N
to TO N
explore VB N
the DT N
efficacy NN N
of IN N
rHCNTF NN i
in IN N
the DT N
treatment NN N
of IN N
human JJ N
motor NN N
neuron NN N
diseases NNS N
are VBP N
justified VBN N
. . N

-DOCSTART- -25053766- O O

Effects NNS N
of IN N
a DT N
music NN i
therapy NN i
group NN i
intervention NN i
on IN N
enhancing VBG N
social JJ o
skills NNS o
in IN N
children NNS p
with IN p
autism NN p
. . p

BACKGROUND NNP N
Research NNP N
indicates VBZ N
that IN N
music NN i
therapy NN i
can MD N
improve VB N
social JJ N
behaviors NNS N
and CC N
joint JJ N
attention NN N
in IN N
children NNS p
with IN p
Autism NNP p
Spectrum NNP p
Disorder NNP p
( ( p
ASD NNP p
) ) p
; : p
however RB N
, , N
more JJR N
research NN N
on IN N
the DT N
use NN N
of IN N
music NN N
therapy NN N
interventions NNS N
for IN N
social JJ o
skills NNS o
is VBZ N
needed VBN N
to TO N
determine VB N
the DT N
impact NN N
of IN N
group NN N
music NN N
therapy NN N
. . N

OBJECTIVE UH N
To TO N
examine VB N
the DT N
effects NNS N
of IN N
a DT N
music NN i
therapy NN i
group NN N
intervention NN N
on IN N
eye NN o
gaze NN o
, , o
joint JJ o
attention NN o
, , o
and CC o
communication NN o
in IN N
children NNS p
with IN p
ASD NNP p
. . p

METHOD NNP N
Seventeen NNP p
children NNS p
, , p
ages VBZ p
6 CD p
to TO p
9 CD p
, , p
with IN p
a DT p
diagnosis NN p
of IN p
ASD NNP p
were VBD p
randomly RB p
assigned VBN p
to TO p
the DT p
music NN i
therapy NN i
group NN i
( ( i
MTG NNP i
) ) i
or CC p
the DT p
no-music JJ i
social JJ i
skills NNS i
group NN i
( ( i
SSG NNP i
) ) i
. . i

Children NNP N
participated VBD N
in IN N
ten JJ N
50-minute JJ N
group NN N
sessions NNS N
over IN N
a DT N
period NN N
of IN N
5 CD N
weeks NNS N
. . N

All DT N
group NN N
sessions NNS N
were VBD N
designed VBN N
to TO N
target VB N
social JJ N
skills NNS N
. . N

The DT N
Social NNP o
Responsiveness NNP o
Scale NNP o
( ( o
SRS NNP o
) ) o
, , o
the DT o
Autism NNP o
Treatment NNP o
Evaluation NNP o
Checklist NNP o
( ( o
ATEC NNP o
) ) o
, , o
and CC o
video JJ o
analysis NN o
of IN o
sessions NNS o
were VBD N
used VBN N
to TO N
evaluate VB N
changes NNS N
in IN N
social JJ N
behavior NN N
. . N

RESULTS CC N
There EX N
were VBD N
significant JJ N
between-group JJ N
differences NNS N
for IN N
joint JJ o
attention NN o
with IN o
peers NNS o
and CC o
eye NN o
gaze NN o
towards NNS o
persons NNS o
, , N
with IN N
participants NNS N
in IN N
the DT N
MTG NNP N
demonstrating NN N
greater JJR N
gains NNS N
. . N

There EX N
were VBD N
no DT N
significant JJ N
between-group NN N
differences NNS N
for IN N
initiation NN o
of IN o
communication NN o
, , o
response NN o
to TO o
communication NN o
, , o
or CC o
social JJ o
withdraw/behaviors NNS o
. . o

There EX N
was VBD N
a DT N
significant JJ N
interaction NN N
between IN N
time NN N
and CC N
group NN N
for IN N
SRS NNP o
scores NNS o
, , N
with IN N
improvements NNS N
for IN N
the DT N
MTG NNP N
but CC N
not RB N
the DT N
SSG NNP N
. . N

Scores NNS o
on IN o
the DT o
ATEC NNP o
did VBD N
not RB N
differ VB N
over IN N
time NN N
between IN N
the DT N
MTG NNP i
and CC N
SSG NNP N
. . N

CONCLUSIONS NNP N
The DT N
results NNS N
of IN N
this DT N
study NN N
support VB N
further JJ N
research NN N
on IN N
the DT N
use NN N
of IN N
music NN N
therapy NN N
group NN N
interventions NNS N
for IN N
social JJ o
skills NNS o
in IN N
children NNS p
with IN p
ASD NNP p
. . p

Statistical JJ N
results NNS N
demonstrate VBP N
initial JJ N
support NN N
for IN N
the DT N
use NN N
of IN N
music NN N
therapy NN N
social JJ N
groups NNS N
to TO N
develop VB N
joint JJ o
attention NN o
. . o

-DOCSTART- -9002920- O O

Chlorhexidine NNP i
swabbing VBG N
applications NNS N
under IN N
various JJ N
conditions NNS N
of IN N
use NN N
in IN N
preventive JJ N
oral JJ N
care NN N
for IN N
persons NNS p
with IN p
disabilities NNS p
. . p

A DT N
sample NN N
of IN N
44 CD p
adults NNS p
with IN p
severe JJ p
disabilities NNS p
completed VBD N
a DT N
randomized JJ N
single-blind JJ N
cross-over NN N
study NN N
testing VBG N
chlorhexidine NN i
swabbing VBG N
under IN N
various JJ N
conditions NNS N
: : N
with/without NN N
prior RB N
dental JJ N
prophylaxis NN N
, , N
reduced VBD N
frequency NN N
of IN N
application NN N
( ( N
2 CD N
vs. NN N
5 CD N
times NNS N
per IN N
week NN N
) ) N
, , N
and CC N
prolonged VBN N
use NN N
( ( N
42 CD N
weeks NNS N
) ) N
. . N

All DT N
subjects NNS N
received VBN N
therapeutic JJ N
doses NNS N
of IN N
10 CD i
mL NNS i
0.12 CD i
% NN i
chlorhexidine NN i
gluconate NN i
( ( N
Peridex NNP N
, , N
Procter NNP N
& CC N
Gamble NNP N
) ) N
and CC N
10 CD i
mL NNS i
0.05 CD i
% NN i
NaF NNP i
applied VBN i
with IN i
a DT i
Toothette NNP i
( ( N
Sage NNP N
Products NNPS N
) ) N
. . N

Clinical JJ o
effectiveness NN o
of IN N
chlorhexidine NN i
swabbing NN N
compared VBN N
with IN N
placebo NN i
was VBD N
previously RB N
reported VBN N
. . N

In IN N
the DT N
present JJ N
study NN N
, , N
while IN N
initial JJ N
benefits NNS N
were VBD N
observed VBN N
to TO N
be VB N
independent JJ N
of IN N
dental JJ N
prophylaxis NN N
, , N
significant JJ N
reductions NNS N
in IN N
periodontal JJ o
scores NNS o
were VBD N
sustained VBN N
by IN N
a DT N
combination NN N
of IN N
dental JJ N
prophylaxis NN N
and CC N
swabbing VBG N
protocol NN N
, , N
at IN N
reduced JJ N
frequency NN N
of IN N
application NN N
and CC N
over IN N
prolonged JJ N
time NN N
. . N

High JJ N
levels NNS N
of IN N
acceptance NN o
and CC o
compliance NN o
by IN N
subjects/caregivers NNS N
were VBD N
maintained VBN N
. . N

Subjects/caregivers NNS N
reported VBD N
improvements NNS o
in IN o
dental JJ o
health NN o
as RB o
well RB o
as IN o
in IN o
attitude NN o
, , o
quality NN o
of IN o
life NN o
, , o
and CC o
smile NN o
. . o

Chlorhexidine VB i
swabbing VBG N
at IN N
maintenance NN N
frequency NN N
, , N
combined VBN N
with IN N
periodic JJ N
dental JJ N
prophylaxis NN N
, , N
may MD N
offer VB N
an DT N
effective JJ N
and CC N
pragmatic JJ N
long-term JJ o
preventive JJ o
regimen NNS o
for IN N
persons NNS N
with IN N
disabilities NNS N
. . N

-DOCSTART- -11932900- O O

Detection NN o
of IN N
recurrent NN o
or CC o
persistent JJ o
nasopharyngeal NN o
carcinomas NN o
after IN p
radiotherapy NN i
with IN i
technetium-99m JJ i
methoxyisobutylisonitrile NN i
single JJ i
photon NN i
emission NN i
computed VBD i
tomography NN i
and CC i
computed VBD i
tomography NN i
: : i
comparison NN N
with IN N
18-fluoro-2-deoxyglucose JJ i
positron NN i
emission NN i
tomography NN i
. . i

BACKGROUND IN N
The DT N
diagnostic JJ N
accuracy NN N
of IN N
technetium-99m JJ i
methoxyisobutylisonitrile NN i
( ( i
Tc-MIBI NNP i
) ) i
single JJ i
photon NN i
emission NN i
computed VBN i
tomography NN i
( ( i
SPECT NNP i
) ) i
and CC i
computed VBN i
tomography NN i
( ( i
CT NNP i
) ) i
of IN N
the DT N
head NN N
and CC N
neck NN N
for IN N
differentiating VBG N
recurrent NN N
or CC N
residual JJ p
nasopharyngeal NN p
carcinomas NN p
( ( p
NPC NNP p
) ) p
from IN N
benign JJ N
lesions NNS N
after IN N
radiotherapy NN i
was VBD N
compared VBN N
with IN N
positron NN i
emission NN i
tomography NN i
( ( i
PET NNP i
) ) i
with IN i
18-fluoro-2-deoxyglucose JJ i
( ( i
FDG NNP i
) ) i
. . i

METHODS NNP N
Thirty NNP p
six CD p
NPC NNP p
patients NNS p
underwent JJ p
head NN p
and CC p
neck NN p
CT NNP i
, , i
Tc-MIBI NNP i
SPECT NNP i
, , i
and CC i
FDG-PET NNP i
four CD p
months NNS p
after IN p
radiotherapy NN p
to TO N
differentiate VB N
recurrent NN N
or CC N
residual JJ N
NPC NNP N
from IN N
benign JJ N
lesions NNS N
. . N

Histopathologic NNP N
examinations NNS N
of IN N
nasopharyngeal JJ N
biopsies NNS N
were VBD N
performed VBN N
for IN N
all DT N
36 CD p
patients NNS p
. . p

No DT p
patients NNS p
had VBD p
multiple JJ p
foci NN p
of IN p
NPC NNP p
. . p

RESULTS NNP N
Based VBD N
on IN N
biopsy NN N
results NNS N
, , N
the DT N
sensitivity NN o
, , o
specificity NN o
, , o
and CC o
accuracy NN o
of IN o
CT NNP o
for IN N
differentiating VBG N
recurrent NN o
or CC N
residual JJ N
NPC NNP N
from IN N
benign JJ N
lesions NNS N
were VBD N
73 CD N
% NN N
, , N
88 CD N
% NN N
, , N
and CC N
83 CD N
% NN N
, , N
respectively RB N
. . N

The DT N
sensitivity NN o
, , o
specificity NN o
, , o
and CC o
accuracy NN o
of IN o
Tc-MIBI NNP o
SPECT NNP o
were VBD N
73 CD N
% NN N
, , N
96 CD N
% NN N
, , N
and CC N
89 CD N
% NN N
, , N
respectively RB N
. . N

The DT N
sensitivity NN o
, , o
specificity NN o
, , o
and CC o
accuracy NN o
of IN o
FDG-PET NNP o
were VBD N
100 CD N
% NN N
, , N
96 CD N
% NN N
, , N
and CC N
97 CD N
% NN N
, , N
respectively RB N
. . N

Combination NNP N
CT NNP N
and CC N
Tc-MIBI NNP N
SPECT NNP N
for IN N
28 CD N
NPC NNP N
patients NNS N
with IN N
congruent JJ N
results NNS N
showed VBD N
the DT N
same JJ N
sensitivity NN o
, , o
specificity NN o
, , o
and CC o
accuracy NN o
of IN N
100 CD N
% NN N
, , N
96 CD N
% NN N
, , N
and CC N
96 CD N
% NN N
, , N
respectively RB N
, , N
as IN N
FDG-PET NNP i
for IN N
differentiating VBG N
recurrent NN N
or CC N
residual JJ N
NPC NNP N
from IN N
benign JJ N
lesions NNS N
. . N

In IN N
eight CD N
patients NNS N
with IN N
incongruent JJ N
results NNS N
between IN N
CT NNP N
and CC N
Tc-MIBI NNP N
SPECT NNP N
, , N
FDG-PET NNP N
correctly RB N
differentiated VBD N
two CD N
benign JJ N
lesions NNS N
and CC N
six CD N
recurrent NN N
or CC N
residual JJ N
NPCs NNP N
. . N

CONCLUSIONS NNP N
In IN N
detecting VBG N
recurrent NN o
or CC o
residual JJ o
NPC NNP o
, , N
FDG-PET NNP i
is VBZ N
the DT N
best JJS N
tool NN N
. . N

However RB N
, , N
combined VBN N
use NN N
of IN N
CT NNP i
and CC i
Tc-MIBI NNP i
SPECT NNP i
can MD N
result VB N
in IN N
the DT N
same JJ N
accuracy NN o
as IN N
FDG-PET NNP i
. . i

-DOCSTART- -24676906- O O

Decreased VBN N
glutathione NN N
and CC N
elevated VBD N
hair JJ N
mercury NN N
levels NNS N
are VBP N
associated VBN N
with IN N
nutritional JJ p
deficiency-based JJ p
autism NN p
in IN p
Oman NNP p
. . p

Genetic NNP N
, , N
nutrition NN N
, , N
and CC N
environmental JJ N
factors NNS N
have VBP N
each DT N
been VBN N
implicated VBN N
as IN N
sources NNS N
of IN N
risk NN N
for IN N
autism NN N
. . N

Oxidative JJ N
stress NN N
, , N
including VBG N
low JJ N
plasma NN N
levels NNS N
of IN N
the DT N
antioxidant JJ i
glutathione NN i
, , N
has VBZ N
been VBN N
reported VBN N
by IN N
numerous JJ N
autism NN N
studies NNS N
, , N
which WDT N
can MD N
disrupt VB N
methylation-dependent JJ N
epigenetic JJ N
regulation NN N
of IN N
gene NN N
expression NN N
with IN N
neurodevelopmental JJ N
consequences NNS N
. . N

We PRP N
investigated VBD i
the DT i
status NN o
of IN i
redox NN i
and CC i
methylation NN i
metabolites NNS i
, , i
as RB i
well RB i
as IN i
the DT i
level NN i
of IN i
protein JJ i
homocysteinylation NN i
and CC i
hair JJ i
mercury NN i
levels NNS i
, , p
in IN p
autistic JJ p
and CC p
neurotypical JJ p
control NN p
Omani NNP p
children NNS p
, , p
who WP p
were VBD p
previously RB p
shown VBN p
to TO p
exhibit VB p
significant JJ p
nutritional JJ p
deficiencies NNS p
in IN p
serum NN p
folate NN i
and CC p
vitamin NN i
B?? NNP i
. . i

The DT i
serum JJ o
level NN o
of IN o
glutathione NN o
in IN o
autistic JJ o
subjects NNS o
was VBD o
significantly RB N
below IN N
control NN N
levels NNS N
, , N
while IN o
levels NNS o
of IN o
homocysteine NN o
and CC o
S-adenosylhomocysteine NNP o
were VBD o
elevated VBN N
, , N
indicative JJ o
of IN o
oxidative JJ o
stress NN o
and CC o
decreased JJ o
methionine NN o
synthase NN o
activity NN o
. . o

Autistic JJ o
males NNS p
had VBD p
lower JJR o
glutathione NN o
and CC o
higher JJR o
homocysteine NN o
levels NNS o
than IN o
females NNS p
, , p
while IN o
homocysteinylation NN o
of IN o
serum NN o
proteins NNS o
was VBD o
increased VBN N
in IN N
autistic JJ N
males NNS N
but CC N
not RB N
females NNS o
. . o

Mercury NN o
levels NNS o
were VBD o
markedly RB N
elevated VBN N
in IN N
the DT N
hair NN N
of IN p
autistic JJ p
subjects NNS p
vs. FW p
control NN p
subjects NNS p
, , p
consistent NN p
with IN N
the DT N
importance NN N
of IN N
glutathione NN N
for IN N
its PRP$ N
elimination NN N
. . N

Thus RB N
, , p
autism NN p
in IN p
Oman NNP p
is VBZ p
associated VBN N
with IN N
decreased JJ N
antioxidant JJ N
resources NNS N
and CC N
decreased JJ N
methylation NN N
capacity NN N
, , N
in IN N
conjunction NN N
with IN N
elevated JJ i
hair NN i
levels NNS i
of IN i
mercury NN i
. . i

-DOCSTART- -8487324- O O

Recombinant JJ i
human JJ i
erythropoietin NN i
therapy NN i
for IN N
anemic JJ p
cancer NN p
patients NNS p
on IN p
combination NN p
chemotherapy NN p
. . p

BACKGROUND NNP N
Patients NNPS p
with IN p
advanced JJ p
cancer NN p
frequently RB p
experience VBZ p
clinically RB o
significant JJ o
anemia NN o
, , N
which WDT N
is VBZ N
often RB N
exacerbated VBN N
by IN N
myelosuppressive JJ N
chemotherapy NN N
. . N

Consistent JJ N
with IN N
the DT N
anemia NN N
of IN N
chronic JJ N
disease NN N
, , N
studies NNS N
have VBP N
documented VBN N
serum JJ N
erythropoietin NN N
levels NNS N
that WDT N
are VBP N
inappropriately RB N
low JJ N
for IN N
the DT N
degree NN N
of IN N
anemia NN N
in IN N
cancer NN p
patients NNS p
. . p

Myelosuppressive JJ N
chemotherapy NN N
impairs NNS N
erythropoiesis NN N
, , N
which WDT N
may MD N
not RB N
fully RB N
recover VB N
between IN N
treatment NN N
cycles NNS N
. . N

Recombinant NNP i
human JJ i
erythropoietin NN i
( ( i
rHuEPO NN i
) ) i
has VBZ N
been VBN N
used VBN N
safely RB N
and CC N
effectively RB N
to TO N
treat VB N
anemia NN N
in IN N
AIDS NNP N
patients NNS N
receiving VBG N
zidovudine NN N
( ( N
AZT NNP N
) ) N
and CC N
in IN N
patients NNS N
with IN N
chronic JJ N
renal JJ N
failure NN N
. . N

PURPOSE VB N
This DT N
study NN N
was VBD N
designed VBN N
to TO N
evaluate VB N
the DT N
clinical JJ N
role NN N
of IN N
rHuEPO NN N
in IN N
reducing VBG N
symptomatic JJ o
anemia NN o
in IN N
patients NNS p
with IN p
advanced JJ p
cancer NN p
who WP p
were VBD p
receiving VBG p
myelosuppressive JJ p
chemotherapy NN p
( ( p
excluding VBG p
cisplatin NN p
) ) p
. . p

METHODS NNP N
We PRP N
studied VBD N
153 CD p
anemic JJ p
cancer NN p
patients NNS p
receiving VBG p
cyclic JJ i
combination NN i
chemotherapy NN i
in IN N
a DT N
prospective JJ N
multicenter NN N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
trial NN N
. . N

The DT N
patients NNS p
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
either DT N
rHuEPO NN i
( ( N
150 CD N
U/kg NNP N
) ) N
or CC N
placebo NN i
subcutaneously RB N
three CD N
times NNS N
a DT N
week NN N
for IN N
a DT N
maximum NN N
of IN N
12 CD N
weeks NNS N
or CC N
until IN N
the DT N
hematocrit JJ o
level NN o
increased VBD N
to TO N
38 CD N
% NN N
-40 JJ N
% NN N
. . N

If IN N
the DT N
hematocrit NN o
reached VBD N
this DT N
target NN N
level NN N
before IN N
12 CD N
weeks NNS N
, , N
the DT N
rHuEPO NN i
dose NN N
could MD N
be VB N
reduced VBN N
to TO N
maintain VB N
the DT N
hematocrit NN N
at IN N
that DT N
level NN N
for IN N
the DT N
duration NN N
of IN N
the DT N
study NN N
. . N

Response NNP N
to TO N
rHuEPO VB i
therapy NN N
was VBD N
assessed VBN N
by IN N
measuring VBG N
changes NNS o
in IN o
hematocrit NN o
level NN o
, , o
transfusion NN o
requirements NNS o
, , o
and CC o
quality NN o
of IN o
life NN o
. . o

Quality-of-life JJ o
assessment NN N
was VBD N
based VBN N
on IN N
patients NNS N
' POS N
responses NNS N
to TO N
questionnaires NNS N
before IN N
and CC N
after IN N
the DT N
courses NNS N
of IN N
therapy NN N
. . N

RESULTS VB N
The DT N
increase NN o
in IN o
hematocrit NN o
in IN N
the DT N
rHuEPO-treated JJ i
group NN p
compared VBN N
with IN N
hematocrit NN o
in IN N
the DT N
placebo-treated JJ i
group NN p
was VBD N
statistically RB N
significant JJ N
( ( N
P NNP N
= NNP N
.0001 NNP N
) ) N
as IN N
measured VBN N
by IN N
percentage NN N
point NN N
of IN N
change NN N
from IN N
baseline NN N
to TO N
final JJ N
evaluation NN N
, , N
by IN N
an DT N
increase NN N
in IN N
hematocrit JJ o
level NN N
of IN N
six CD N
percentage NN N
points NNS N
or CC N
more JJR N
unrelated JJ N
to TO N
transfusion NN N
, , N
and CC N
by IN N
a DT N
rise NN N
in IN N
hematocrit NN o
level NN o
to TO N
38 CD N
% NN N
or CC N
more JJR N
unrelated JJ N
to TO N
transfusion NN N
. . N

There EX N
was VBD N
a DT N
trend NN N
toward IN N
the DT N
reduction NN N
in IN N
mean JJ o
units NNS o
of IN o
blood NN o
transfused VBN o
per IN o
patient NN o
during IN N
months NNS N
2 CD N
and CC N
3 CD N
of IN N
therapy NN N
combined VBN N
in IN N
rHuEPO-treated JJ i
patients NNS p
compared VBN N
with IN N
placebo-treated JJ p
patients NNS p
( ( N
0.91 CD N
U NNP N
versus NN N
1.65 CD N
U NNP N
; : N
P NNP N
= NNP N
.056 NNP N
) ) N
. . N

In IN N
addition NN N
, , N
rHuEPO-treated JJ i
patients NNS p
experienced VBD N
a DT N
statistically RB N
significant JJ N
improvement NN N
in IN N
energy NN o
level NN o
and CC o
ability NN o
to TO o
perform VB o
daily JJ o
activities NNS o
( ( N
P NNP N
< NNP N
or CC N
= NNP N
.05 NNP N
) ) N
. . N

The DT N
two CD N
treatment NN N
groups NNS N
showed VBD N
no DT N
statistically RB N
significant JJ N
differences NNS N
in IN N
toxic JJ o
effects NNS o
except IN N
for IN N
increased JJ N
incidence NN N
of IN N
diaphoresis NN o
( ( N
P NNP N
< NNP N
.05 NNP N
) ) N
and CC N
diarrhea NN o
( ( N
P NNP N
= NNP N
.05 NNP N
) ) N
in IN N
the DT N
rHuEPO-treated JJ p
group NN p
. . p

CONCLUSIONS NNP N
We PRP N
conclude VBP N
that DT N
rHuEPO NN i
is VBZ N
safe JJ N
and CC N
effective JJ N
for IN N
reversing VBG N
anemia RB o
related VBN N
to TO N
advanced JJ N
cancer NN N
or CC N
to TO N
chemotherapy VB N
for IN N
cancer NN N
. . N

-DOCSTART- -11443835- O O

Risk NN N
factors NNS N
for IN N
malnutrition NN N
in IN N
patients NNS p
undergoing JJ p
gastroenterological JJ i
and CC i
hernia JJ i
surgery NN i
: : i
an DT p
analysis NN p
of IN p
374 CD p
patients NNS p
. . p

OBJECTIVE IN N
The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
assess VB N
the DT N
nutritional JJ N
status NN N
of IN N
374 CD p
surgical JJ p
patients NNS p
with IN p
gastrointestinal JJ p
disease NN p
and CC p
hernias NN p
of IN p
the DT p
abdominal JJ p
wall NN p
; : p
to TO N
identify VB N
risk NN N
factors NNS N
associated VBN N
with IN N
a DT N
poorer JJR N
nutritional JJ N
status NN N
in IN N
this DT N
group NN N
of IN N
patients NNS N
and CC N
to TO N
assess VB N
awareness NN N
of IN N
the DT N
patient NN N
's POS N
nutritional JJ N
status NN N
by IN N
medical JJ N
teams NNS N
. . N

SUMMARY NNP N
BACKGROUND NNP N
DATA NNP N
Malnutrition NNP N
is VBZ N
prevalent JJ N
among IN N
surgical JJ p
patients NNS p
and CC N
is VBZ N
associated VBN N
with IN N
higher JJR N
surgical JJ N
complication NN N
rates NNS N
and CC N
mortality NN N
. . N

The DT N
major JJ N
causes NNS N
of IN N
poor JJ N
nutritional JJ N
status NN N
are VBP N
related VBN N
to TO N
the DT N
underlying JJ N
disease NN N
, , N
socio-economic JJ N
factors NNS N
, , N
age NN N
, , N
and CC N
length NN N
of IN N
hospitalization NN N
. . N

Despite IN N
its PRP$ N
high JJ N
prevalence NN N
, , N
medical JJ N
teams NNS N
often RB N
overlook VBP N
malnutrition NN N
, , N
and CC N
screening NN N
of IN N
these DT N
patients NNS N
is VBZ N
not RB N
routine JJ N
. . N

It PRP N
is VBZ N
of IN N
utmost JJ N
importance NN N
to TO N
identify VB N
patients NNS N
at IN N
risk NN N
for IN N
malnutrition NN N
in IN N
order NN N
to TO N
prevent VB N
related JJ N
complications NNS N
. . N

METHODS NNP N
The DT N
374 CD p
patients NNS p
evaluated VBN p
in IN p
this DT p
study NN p
were VBD N
a DT N
subgroup NN N
of IN N
a DT N
larger JJR N
multicenter NN N
, , N
cross-sectional JJ N
, , N
randomized VBN N
study NN N
that WDT N
was VBD N
carried VBN N
out RP N
in IN N
1996 CD N
. . N

Nutritional JJ i
status NN i
was VBD N
assessed VBN N
by IN N
using VBG N
Subjective NNP i
Global NNP i
Assessment NNP i
. . i

RESULTS NNP N
Malnutrition NNP o
was VBD N
present JJ N
in IN N
55 CD N
% NN N
of IN N
the DT N
patients NNS N
, , N
with IN N
19 CD N
% NN N
of IN N
the DT N
patients NNS N
severely RB N
malnourished VBN N
. . N

The DT N
presence NN N
of IN N
cancer NN N
, , N
infection NN N
, , N
age NN N
over IN N
60 CD N
years NNS N
, , N
upper JJ N
gastrointestinal JJ N
disease NN N
, , N
and CC N
longer JJR N
length NN N
of IN N
hospital NN N
stay NN N
all DT N
negatively RB N
influenced VBN N
nutritional JJ o
status NN o
. . o

Despite IN N
the DT N
high JJ N
prevalence NN N
of IN N
malnutrition NN o
, , N
the DT N
medical JJ N
teams NNS N
only RB N
assessed VBD N
the DT N
nutritional JJ o
status NN N
of IN N
a DT N
few JJ N
patients NNS N
. . N

CONCLUSION NNP N
Malnutrition NNP o
was VBD N
highly RB N
prevalent JJ N
in IN N
this DT N
setting NN N
of IN N
patients NNS N
. . N

Therefore NNP N
, , N
patients NNS N
with IN N
the DT N
risk NN N
factors NNS N
above IN N
presented VBN N
should MD N
routinely RB N
undergo VB N
nutritional JJ N
screening NN N
and/or JJ N
assessment NN N
in IN N
order NN N
to TO N
be VB N
able JJ N
to TO N
early JJ N
diagnose NN N
or CC N
prevent NN N
malnutrition NN N
and CC N
its PRP$ N
correlated JJ N
morbidity NN N
and CC N
mortality NN N
. . N

-DOCSTART- -19852790- O O

Safety NN o
and CC o
efficacy NN o
of IN N
oral JJ N
DMSA NNP i
therapy NN i
for IN N
children NNS p
with IN p
autism NN p
spectrum NN p
disorders NNS p
: : p
part NN N
B NNP N
- : N
behavioral JJ N
results NNS N
. . N

BACKGROUND NNP N
This DT N
study NN N
investigated VBD N
the DT N
effects NNS N
of IN N
oral JJ i
dimercapto NN i
succinic JJ i
acid NN i
( ( i
DMSA NNP i
) ) i
therapy NN i
on IN N
the DT N
behavioural JJ N
symptoms NNS N
of IN N
children NNS p
with IN p
autism NN p
spectrum NN p
disorders NNS p
( ( p
ASD NNP p
) ) p
ages VBZ p
3-8 JJ p
years NNS p
. . p

METHODS NNP N
Phase NNP p
1 CD p
involved VBD p
65 CD p
children NNS p
with IN p
ASD NNP p
who WP p
received VBD p
one CD p
round NN p
of IN p
DMSA NNP p
( ( p
3 CD p
days NNS p
) ) p
. . p

Participants NNS p
who WP p
had VBD p
high JJ p
urinary JJ p
excretion NN p
of IN p
toxic JJ p
metals NNS p
were VBD p
selected VBN p
to TO p
continue VB p
on IN p
to TO p
phase VB p
2 CD p
. . p

In IN N
phase NN p
2 CD p
, , p
49 CD p
participants NNS p
were VBD p
randomly RB p
assigned VBN p
in IN p
a DT p
double-blind JJ p
design NN p
to TO p
receive VB p
an DT p
additional JJ p
6 CD i
rounds NNS i
of IN i
either DT i
DMSA NNP i
or CC i
placebo NN i
. . i

RESULTS VB N
The DT N
groups NNS N
receiving VBG N
one CD N
round NN N
and CC N
seven CD N
rounds NNS N
of IN N
DMSA NNP i
had VBD N
significant JJ N
improvements NNS N
on IN N
all PDT N
the DT N
assessment JJ N
measures NNS N
. . N

For IN N
the DT N
seven CD N
round NN N
group NN N
, , N
the DT N
degree NN N
of IN N
improvement NN o
on IN N
the DT N
assessment NN o
measures NNS o
could MD N
be VB N
partially RB N
explained VBN N
by IN N
a DT N
regression NN N
analysis NN N
based VBN N
on IN N
excretion NN o
of IN o
toxic JJ o
metals NNS o
and CC o
changes NNS o
in IN o
glutathione NN o
( ( N
adjusted VBN N
R2 NNP N
of IN N
0.28-0.75 NNP N
, , N
p NN N
< VBD N
0.02 CD N
in IN N
all DT N
cases NNS N
) ) N
. . N

One CD N
round NN N
of IN N
DMSA NNP N
had VBD N
nearly RB N
the DT N
same JJ N
benefit NN N
as IN N
seven CD N
rounds NNS N
. . N

The DT N
assessment JJ N
measures NNS N
correlated VBN N
reasonably RB N
with IN N
one CD N
another DT N
at IN N
the DT N
beginning NN N
of IN N
the DT N
study NN N
( ( N
r JJ N
= NNP N
0.60-0.87 NN N
) ) N
and CC N
even RB N
better JJR N
at IN N
the DT N
end NN N
of IN N
the DT N
study NN N
( ( N
r JJ N
= NNP N
0.63-0.94 NN N
) ) N
. . N

CONCLUSION NNP N
Overall NNP N
, , N
both DT N
one CD N
and CC N
seven CD N
rounds NNS N
of IN N
DMSA NNP i
therapy NN N
seems VBZ N
to TO N
be VB N
reasonably RB N
safe JJ o
in IN N
children NNS p
with IN p
ASD NNP p
who WP p
have VBP p
high JJ p
urinary JJ p
excretion NN p
of IN p
toxic JJ p
metals NNS p
, , N
and CC N
possibly RB N
helpful JJ N
in IN N
reducing VBG N
some DT N
of IN N
the DT N
symptoms NNS N
of IN N
autism NN N
in IN N
those DT N
children NNS N
. . N

-DOCSTART- -10992833- O O

Onset/offset NNP o
characteristics NNS o
and CC o
intubating VBG o
conditions NNS o
of IN N
rapacuronium NN N
: : N
a DT N
comparison NN N
with IN N
rocuronium NN N
. . N

We PRP N
compared VBN N
onset PRP o
and CC o
offset VB o
of IN o
action NN o
and CC o
tracheal JJ o
intubating NN o
conditions NNS o
after IN N
rapacuronium NN i
and CC i
rocuronium NN i
in IN N
60 CD p
patients NNS p
in IN N
a DT N
randomized JJ N
, , N
assessor-blinded JJ N
study NN N
. . N

Following VBG N
induction NN N
of IN N
anaesthesia NN i
with IN i
propofol JJ i
2.5 CD i
mg JJ i
kg-1 NN i
, , i
either CC i
rapacuronium NN i
1.5 CD i
mg NN i
kg-1 NN i
( ( i
n JJ i
= NNP i
30 CD i
) ) i
or CC i
rocuronium $ i
0.6 CD i
mg JJ i
kg-1 NN i
( ( i
n JJ i
= NNP i
30 CD i
) ) i
was VBD i
administered VBN i
to TO i
facilitate VB i
tracheal JJ i
intubation NN i
. . i

Anaesthesia NNP i
was VBD i
maintained VBN i
with IN i
either CC i
a DT i
propofol JJ i
infusion NN i
( ( i
100 CD i
micrograms NNS i
kg-1 JJ i
min-1 JJ i
) ) i
or CC i
sevoflurane NN i
( ( i
1 CD i
% NN i
end-tidal JJ i
) ) i
with IN i
66 CD i
% NN i
nitrous JJ i
oxide NN i
( ( i
N2O NNP i
) ) i
, , i
n JJ i
= VBP i
15 CD i
in IN i
each DT i
subgroup NN i
. . i

Neuromuscular JJ o
monitoring NN o
was VBD i
performed VBN i
using VBG i
an DT i
electromyographic JJ i
( ( i
EMG NNP i
) ) i
device NN i
( ( i
Datex NNP i
Relaxograph NNP i
) ) i
. . i

The DT N
lag NN o
times NNS o
( ( N
mean JJ N
42 CD N
( ( N
SD NNP N
11 CD N
) ) N
s NN N
and CC N
44 CD N
( ( N
16 CD N
) ) N
s NN N
) ) N
, , N
maximum JJ o
block NN o
( ( N
99 CD N
( ( N
2 CD N
) ) N
% NN N
and CC N
98 CD N
( ( N
3 CD N
) ) N
% NN N
) ) N
and CC N
intubating JJ o
conditions NNS o
at IN o
60 CD o
s NN o
( ( N
good-to-excellent JJ N
in IN N
86 CD N
% NN N
and CC N
84 CD N
% NN N
of IN N
patients NNS N
) ) N
were VBD N
similar JJ N
for IN N
rapacuronium NN N
and CC N
rocuronium NN N
, , N
respectively RB N
. . N

The DT N
onset JJ o
time NN o
of IN N
rapacuronium NN N
was VBD N
shorter JJR N
than IN N
rocuronium NN N
( ( N
87 CD N
( ( N
20 CD N
) ) N
vs NN N
141 CD N
( ( N
65 CD N
) ) N
s NN N
, , N
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
and CC N
the DT N
degree NN o
of IN o
block NN o
at IN o
60 CD o
s NN o
was VBD N
greater JJR N
( ( N
69 CD N
( ( N
26 CD N
) ) N
vs NN N
50 CD N
( ( N
27 CD N
) ) N
% NN N
, , N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

Twenty-five JJ N
per IN N
cent NN N
recovery NN o
was VBD N
shorter JJR N
with IN N
rapacuronium NN N
than IN N
rocuronium NN N
during IN N
propofol NN N
( ( N
15.0 CD N
( ( N
3.2 CD N
) ) N
vs NN N
39.1 CD N
( ( N
14.2 CD N
) ) N
min NN N
, , N
P NNP N
< NNP N
0.001 CD N
) ) N
and CC N
sevoflurane NN N
( ( N
15.1 CD N
( ( N
4.2 CD N
) ) N
vs NN N
47.8 CD N
( ( N
19.0 CD N
) ) N
min NN N
, , N
P NNP N
< NNP N
0.001 CD N
) ) N
anaesthesia NN N
. . N

We PRP N
conclude VBP N
that IN N
rapacuronium NN N
1.5 CD N
mg NN N
kg-1 NN N
had VBD N
a DT N
more RBR N
rapid JJ N
onset NN o
, , N
similar JJ N
intubating NN o
conditions NNS o
, , N
and CC N
shorter JJR N
recovery NN o
times NNS o
than IN N
rocuronium NN N
0.6 CD N
mg JJ N
kg-1 NN N
. . N

-DOCSTART- -24752311- O O

Association NNP N
of IN N
PAX4 NNP N
genetic JJ N
variants NNS N
with IN N
oral JJ i
antidiabetic JJ i
drugs NNS i
efficacy NN N
in IN N
Chinese NNP p
type NN p
2 CD p
diabetes VBZ p
patients NNS p
. . p

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
investigate VB N
the DT N
association NN N
of IN N
PAX4 NNP i
variants NNS i
with IN N
therapeutic JJ N
effect NN N
of IN N
oral JJ i
antidiabetic JJ i
drugs NNS i
in IN N
Chinese NNP p
type NN p
2 CD p
diabtes NNS p
mellitus FW p
( ( p
T2DM NNP p
) ) p
patients NNS p
. . p

A DT p
total NN p
of IN p
209 CD p
newly RB p
diagnosed VBN p
T2DM NNP p
patients NNS p
were VBD N
randomly RB N
assigned VBN N
to TO N
treatment NN N
with IN N
repaglinide NN i
or CC i
rosiglitazone NN i
for IN N
48 CD N
weeks NNS N
, , N
and CC N
the DT N
therapeutic JJ N
effects NNS N
were VBD N
compared VBN N
. . N

In IN N
the DT N
rosiglitazone NN N
cohort NN N
, , N
rs6467136 VB N
GA+AA NNP N
carriers NNS N
showed VBD N
greater JJR N
decrease NN N
in IN N
2-h JJ o
glucose NN o
levels NNS o
( ( N
P=0.0063 NNP N
) ) N
and CC N
higher JJR N
cumulative JJ N
attainment NN N
rates NNS o
of IN o
target NN o
2-h JJ o
glucose NN o
levels NNS o
( ( N
Plog NNP N
rank=0.0093 NN N
) ) N
than IN N
GG NNP N
homozygotes NNS N
. . N

In IN N
the DT N
subgroup NN N
with IN N
defective JJ N
?-cell JJ N
function NN N
, , N
rs6467136 VB N
GA+AA NNP N
carriers NNS N
exhibited VBD N
greater JJR N
decrements NNS N
of IN o
2-h JJ o
glucose JJ o
level NN o
and CC N
improvement NN N
of IN o
homeostasis NN o
model NN o
assessment NN o
of IN o
insulin NN o
resistance NN o
( ( N
P=0.0143 NNP N
) ) N
. . N

Moreover RB N
, , N
GA+AA NNP N
carriers NNS N
were VBD N
more RBR N
likely JJ N
to TO N
attain VB N
the DT o
target NN o
fasting NN o
and CC o
2-h JJ o
glucose JJ o
level NN o
( ( N
Plog NNP N
rank=0.0091 NN N
and CC N
0.007 CD N
, , N
respectively RB N
) ) N
. . N

However RB N
, , N
these DT N
single-nucleotide JJ N
polymorphisms NN N
showed VBD N
no DT N
effect NN N
on IN o
repaglinide NN o
efficacy NN o
. . o

In IN N
conclusion NN N
, , N
PAX4 NNP N
variant NN N
rs6467136 NN N
was VBD N
associated VBN N
with IN N
the DT N
therapeutic JJ N
effect NN N
of IN i
rosiglitazone NN i
in IN p
Chinese JJ p
T2DM NNP p
patients NNS p
. . p

-DOCSTART- -6839001- O O

Human NNP N
platelet NN N
response NN N
to TO N
three CD N
salicylate NN i
dosage NN N
forms NNS N
. . N

Acetylsalicylic NNP i
acid NN i
( ( N
ASA NNP N
) ) N
inhibition NN N
of IN N
platelet NN N
aggregation NN N
as IN N
evaluated VBN N
by IN N
collagen-induced JJ N
14C-serotonin JJ N
release NN N
, , N
has VBZ N
been VBN N
measured VBN N
in IN N
12 CD p
healthy JJ p
male JJ p
subjects NNS p
. . p

Each DT N
subject NN N
received VBD N
a DT N
single JJ N
oral JJ N
dose NN N
( ( N
650 CD N
mg NN N
) ) N
of IN N
enteric-coated JJ i
ASA NNP i
( ( N
ecASA NN N
) ) N
and CC N
compressed VBN i
ASA NNP i
tablets NNS i
( ( i
cASA NN i
) ) i
, , N
or CC N
ecASA NN i
and CC N
sodium NN i
salicylate NN i
( ( N
578 CD N
mg NN N
) ) N
separated VBN N
by IN N
a DT N
minimum NN N
of IN N
5 CD N
weeks NNS N
. . N

The DT N
platelet NN N
response NN N
was VBD N
related VBN N
to TO N
plasma VB N
ASA NNP N
and CC N
salicyclic JJ N
acid NN N
determined VBN N
by IN N
high-pressure NN N
liquid NN N
chromatography NN N
. . N

Both DT N
ecASA JJ i
and CC N
cASA JJ i
inhibited VBN N
14C-serotonin JJ N
release NN N
; : N
no DT N
significant JJ N
difference NN o
was VBD N
observed VBN N
in IN N
the DT N
maximum JJ o
effect NN o
between IN N
these DT N
two CD N
products NNS N
( ( N
p NN N
less JJR N
than IN N
0.05 CD N
) ) N
. . N

No DT N
relationship NN N
was VBD N
found VBN N
between IN N
the DT N
maximum JJ N
observed JJ N
plasma NN o
ASA NNP o
level NN o
and CC o
the DT o
maximum JJ o
effect NN o
. . o

Further NNP N
, , N
no DT N
correlation NN N
was VBD N
found VBN N
between IN N
the DT N
maximum JJ N
inhibition NN N
of IN N
14C-serotonin JJ N
release NN N
in IN N
vivo NN N
and CC N
the DT N
release NN N
predicted VBD N
from IN N
in IN N
vitro JJ N
experiments NNS N
wherein VBP N
the DT N
effect NN N
was VBD N
measured VBN N
after IN N
incubating VBG N
plasma NN N
containing VBG N
specified VBN N
ASA NNP i
concentrations NNS N
. . N

-DOCSTART- -16030275- O O

Administrative JJ N
Data NNP N
Feedback NNP N
for IN N
Effective NNP o
Cardiac NNP o
Treatment NNP o
: : o
AFFECT NNP N
, , N
a DT N
cluster NN N
randomized VBN N
trial NN N
. . N

CONTEXT NNP N
Hospital NNP N
report NN N
cards NNS N
are VBP N
increasingly RB N
being VBG N
implemented VBN N
for IN N
quality NN N
improvement NN N
despite IN N
lack NN N
of IN N
strong JJ N
evidence NN N
to TO N
support VB N
their PRP$ N
use NN N
. . N

OBJECTIVE NN N
To TO N
determine VB N
whether IN N
hospital JJ i
report NN i
cards NNS i
constructed VBN i
using VBG i
linked VBN i
hospital NN i
and CC i
prescription NN i
administrative JJ i
databases NNS i
are VBP N
effective JJ N
for IN N
improving VBG N
quality NN o
of IN o
care NN o
for IN N
acute JJ p
myocardial JJ o
infarction NN p
( ( N
AMI NNP N
) ) N
. . N

DESIGN VB N
The DT N
Administrative NNP i
Data NNP i
Feedback NNP i
for IN i
Effective NNP i
Cardiac NNP i
Treatment NNP i
( ( N
AFFECT NNP N
) ) N
study NN N
, , N
a DT N
cluster NN N
randomized VBN N
trial NN N
. . N

SETTING NN N
AND CC N
PATIENTS NNP N
Patients NNPS p
with IN p
AMI NNP p
who WP p
were VBD p
admitted VBN p
to TO p
76 CD p
acute NN p
care NN p
hospitals NNS p
in IN p
Quebec NNP p
that WDT p
treated VBD p
at IN p
least JJS p
30 CD p
AMI NNP p
patients NNS p
per IN p
year NN p
between IN p
April NNP p
1 CD p
, , p
1999 CD p
, , p
and CC p
March NNP p
31 CD p
, , p
2003 CD p
. . p

INTERVENTION NN N
Hospitals NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
rapid JJ i
( ( p
immediate JJ p
; : p
n CC p
= $ p
38 CD p
hospitals NNS p
and CC p
2533 CD p
patients NNS p
) ) p
or CC p
delayed VBN i
( ( p
14 CD p
months NNS p
; : p
n CC p
= $ p
38 CD p
hospitals NNS p
and CC p
3142 CD p
patients NNS p
) ) p
confidential JJ i
feedback NN i
on IN i
quality NN i
indicators NNS i
constructed VBD i
using VBG i
administrative JJ i
data NNS i
. . i

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
Quality NNP N
indicators NNS N
pertaining VBG N
to TO N
processes NNS N
of IN N
care NN N
and CC N
outcomes NNS N
of IN N
patients NNS N
admitted VBN N
between IN N
4 CD N
and CC N
10 CD N
months NNS N
after IN N
randomization NN N
. . N

The DT N
primary JJ N
indicator NN N
was VBD N
the DT N
proportion NN N
of IN N
elderly JJ N
survivors NNS N
of IN N
AMI NNP N
at IN N
each DT N
study NN N
hospital NN N
who WP N
filled VBD N
a DT N
prescription NN N
for IN N
a DT N
beta-blocker NN N
within IN N
30 CD N
days NNS N
after IN N
discharge NN N
. . N

RESULTS VB N
At IN N
follow-up JJ N
, , N
adjusted JJ N
prescription NN N
rates NNS N
within IN N
30 CD N
days NNS N
after IN N
discharge NN N
were VBD N
similar JJ N
in IN N
the DT N
early JJ N
vs NN N
late JJ N
groups NNS N
( ( N
for IN N
beta-blockers NNS N
, , N
odds NNS N
ratio VBP N
[ CD N
OR NNP N
] NNP N
, , N
1.06 CD N
; : N
95 CD N
% NN N
confidence NN N
interval NN N
[ NNP N
CI NNP N
] NNP N
, , N
0.82-1.37 NNP N
; : N
for IN N
angiotensin-converting JJ N
enzyme NN N
inhibitors NNS N
, , N
OR NNP N
, , N
1.17 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
0.90-1.52 NNP N
; : N
for IN N
lipid-lowering NN N
drugs NNS N
, , N
OR NNP N
, , N
1.14 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
0.86-1.50 NNP N
; : N
and CC N
for IN N
aspirin NN N
, , N
OR NNP N
, , N
1.05 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
0.84-1.33 NN N
) ) N
. . N

In IN N
addition NN N
, , N
adjusted VBN o
mortality NN o
was VBD N
similar JJ N
in IN N
both DT N
groups NNS N
, , N
as IN N
were VBD N
length NN o
of IN o
in-hospital JJ o
stay NN o
, , o
physician JJ o
visits NNS o
after IN o
discharge NN o
, , o
waiting VBG o
times NNS o
for IN o
invasive JJ o
cardiac NN o
procedures NNS o
, , o
and CC o
readmissions NNS o
for IN o
cardiac JJ o
complications NNS o
. . o

CONCLUSIONS NNP N
Feedback NNP N
based VBN N
on IN N
one-time JJ N
, , N
confidential JJ N
report NN N
cards NNS N
constructed VBN N
using VBG N
administrative JJ N
data NNS N
is VBZ N
not RB N
an DT N
effective JJ N
strategy NN N
for IN N
quality NN o
improvement NN o
regarding VBG N
care NN N
of IN N
patients NNS p
with IN p
AMI NNP p
. . p

A NNP N
need NN N
exists VBZ N
for IN N
further JJ N
studies NNS N
to TO N
rigorously VB N
evaluate VB N
the DT N
effectiveness NN o
of IN N
more RBR N
intensive JJ N
report NN i
card NN i
interventions NNS i
. . i

-DOCSTART- -15838684- O O

Loss NNP N
of IN N
tooth JJ N
substance NN N
during IN N
root NN i
planing VBG i
with IN N
various JJ N
periodontal JJ N
instruments NNS N
: : N
an DT N
in IN N
vitro NN N
study NN N
. . N

Ultrasonic JJ i
and CC i
power-driven JJ i
instrumentation NN i
is VBZ N
gaining VBG N
in IN N
significance NN N
as IN N
an DT N
acceptable JJ N
alternative NN N
to TO N
manual JJ N
periodontal JJ N
root NN N
treatment NN N
. . N

Some DT N
question NN N
whether IN N
they PRP N
do VBP N
not RB N
remove VB N
too RB N
much JJ N
tooth DT N
substance NN N
. . N

Various JJ i
ultrasonic JJ i
scalers NNS i
, , i
hand NN i
instruments NNS i
and CC i
two CD i
power-driven JJ i
systems NNS i
were VBD N
compared VBN N
by IN N
assessing VBG N
the DT N
loss NN o
of IN o
tooth JJ o
substance NN o
due JJ N
to TO N
root VB N
instrumentation NN N
. . N

Quantitative JJ N
analysis NN N
of IN N
this DT N
effect NN N
of IN N
the DT N
instruments NNS N
used VBN N
was VBD N
performed VBN N
on IN N
20 CD p
freshly RB p
extracted VBN p
, , p
non-periodontally RB p
involved VBN p
, , p
large JJ p
human JJ p
molars NNS p
. . p

In IN N
the DT N
first JJ N
study NN N
, , N
40 CD p
specimens NNS p
were VBD N
randomly RB N
assigned VBN N
to TO N
four CD N
groups NNS N
of IN N
treatment NN N
: : N
combined VBN N
use NN N
of IN N
ultrasonic JJ i
scaler NN i
and CC i
Periopolisher NNP i
diamond-coated JJ i
inserts NNS i
( ( i
US-POL NNP i
) ) i
, , i
hand NN i
instruments NNS i
( ( i
MANUAL NNP i
) ) i
, , i
Perioplaner-Periopolisher NNP i
system NN i
( ( i
PPL-POL NNP i
) ) i
and CC i
Periokit NNP i
ultrasonic-designed JJ i
scalers NNS i
( ( i
PERIOKIT NNP i
) ) i
. . i

The DT N
second JJ N
study NN N
involved VBN N
two CD N
treatment NN N
groups NNS N
, , N
ultrasonic JJ i
scaler NN i
alone RB i
and CC i
hand NN i
instruments NNS i
, , N
each DT N
allocated VBN N
with IN N
20 CD N
teeth NNS N
( ( N
small JJ N
root NN N
fragments NNS N
) ) N
. . N

An DT N
unpaired JJ N
two-tailed JJ N
t NN N
test NN N
was VBD N
carried VBN N
out RP N
for IN N
both DT N
studies NNS N
to TO N
compare VB N
the DT N
average JJ N
weight JJ o
loss NN o
of IN o
root JJ o
substance NN o
with IN N
the DT N
modes NNS N
of IN N
instrumentation NN N
. . N

The DT N
level NN N
of IN N
significance NN N
was VBD N
set VBN N
at IN N
p JJ N
< NNP N
or=0.05 NN N
. . N

The DT N
overall JJ N
results NNS N
of IN N
the DT N
first JJ N
and CC N
second JJ N
experimental JJ N
trials NNS N
did VBD N
not RB N
reveal VB N
obvious JJ N
differences NNS N
in IN N
weight JJ o
loss NN o
between IN N
the DT N
manual JJ N
, , N
ultrasonic JJ N
or CC N
power-driven JJ N
root NN N
treatments NNS N
. . N

Based VBN N
on IN N
the DT N
results NNS N
of IN N
these DT N
two CD N
comparative NN N
studies NNS N
, , N
the DT N
power-driven JJ N
inserts NNS N
or CC N
the DT N
various JJ N
ultrasonic JJ N
scalers NNS N
tested VBD N
did VBD N
not RB N
remove VB o
more RBR o
tooth JJ o
substance NN o
than IN N
conventional JJ N
hand NN N
instruments NNS N
. . N

They PRP N
may MD N
thus RB N
be VB N
a DT N
useful JJ N
alternative NN N
for IN N
the DT N
debridement NN N
of IN N
root NN N
surfaces NNS N
. . N

-DOCSTART- -23504941- O O

Bizzy NNP N
Break NNP N
! . N
The DT N
effect NN N
of IN N
a DT N
classroom-based JJ i
activity NN i
break NN i
on IN N
in-school JJ o
physical JJ o
activity NN o
levels NNS o
of IN N
primary JJ p
school NN p
children NNS p
. . p

The DT N
school NN N
has VBZ N
been VBN N
identified VBN N
as IN N
a DT N
key JJ N
setting NN N
to TO N
promote VB N
physical JJ N
activity NN N
. . N

The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
evaluate VB N
the DT N
effect NN N
of IN N
a DT N
classroom-based JJ i
activity NN i
break NN i
on IN N
in-school JJ o
step NN o
counts NNS o
of IN N
primary JJ p
school NN p
children NNS p
. . p

Data NNP p
for IN p
90 CD p
children NNS p
( ( p
49 CD p
boys NNS p
, , p
41 CD p
girls NNS p
, , p
9.3 CD p
? . p
1.4 CD p
years NNS p
) ) p
from IN p
three CD p
Irish JJ p
primary NN p
schools NNS p
is VBZ N
presented VBN N
. . N

In IN p
each DT p
school NN p
one CD p
class NN p
was VBD p
randomly RB p
assigned VBN p
as IN p
the DT i
intervention NN i
group NN p
and CC p
another DT p
as IN i
controls NNS i
. . i

Children NNP o
's POS o
step NN o
counts NNS o
were VBD N
measured VBN N
for IN N
five CD N
consecutive JJ N
days NNS N
during IN N
school NN N
hours NNS N
at IN N
baseline NN N
and CC N
follow-up NN N
. . N

Teachers NNS N
of IN N
the DT N
intervention NN N
classes VBZ N
led VBD N
a DT N
10 CD i
min NN i
activity NN i
break NN i
in IN N
the DT N
classroom NN N
each DT N
day NN N
( ( N
Bizzy NNP N
Break NNP N
! . N
) ) N
. . N

Mean JJ o
daily JJ o
in-school JJ o
steps NNS o
for IN N
the DT N
intervention NN N
at IN N
baseline NN N
and CC N
follow-up NN N
were VBD N
5351 CD N
and CC N
5054 CD N
. . N

Corresponding VBG N
values NNS N
for IN N
the DT N
control NN N
group NN N
were VBD N
5469 CD N
and CC N
4246 CD N
. . N

There EX N
was VBD N
a DT N
significant JJ N
difference NN N
in IN N
the DT o
change NN o
in IN o
daily JJ o
steps NNS o
from IN N
baseline NN N
to TO N
follow-up NN N
between IN N
groups NNS N
( ( N
p JJ N
< NNP N
.05 NNP N
) ) N
. . N

There EX N
was VBD N
no DT N
evidence NN N
that IN N
girls NNS N
and CC N
boys NNS N
responded VBD N
differently RB N
to TO N
the DT N
intervention NN N
( ( N
p JJ N
> NNP N
.05 NNP N
) ) N
. . N

Children NNP N
participating VBG N
in IN N
a DT N
daily JJ N
10 CD N
min JJ i
classroom-based JJ i
activity NN i
break VB i
undertake JJ N
more JJR o
physical JJ o
activity NN o
during IN o
school NN o
hours NNS o
than IN N
controls NNS N
. . N

-DOCSTART- -23444169- O O

Comparative NNP N
in IN N
vitro JJ N
dissolution NN N
and CC N
in IN N
vivo JJ N
bioavailability NN N
of IN N
diflunisal/naproxen JJ N
fixed-dose JJ N
combination NN N
tablets NNS N
and CC N
concomitant JJ N
administration NN N
of IN N
diflunisal NN N
and CC N
naproxen NN N
in IN N
healthy JJ p
adult NN p
subjects NNS p
. . p

A DT N
simple JJ N
validated JJ N
high-performance NN N
liquid NN N
chromatography NN N
( ( N
HPLC NNP N
) ) N
assay NN N
was VBD N
developed VBN N
for IN N
determination NN N
of IN N
diflunisal NN N
and CC N
naproxen NN N
in IN N
human JJ N
plasma NN N
samples NNS N
. . N

This DT N
is VBZ N
to TO N
compare VB N
the DT N
bioavailability NN o
of IN o
diflunisal-naproxen JJ o
fixed-dose JJ o
combination NN o
( ( o
FDC NNP o
) ) o
with IN N
their PRP$ N
separate JJ N
dosage NN N
forms NNS N
. . N

The DT N
in IN N
vitro JJ N
dissolution NN N
study NN N
was VBD N
adopted VBN N
to TO N
compare VB N
the DT N
dissolution NN o
behavior NN o
of IN o
FDC NNP o
with IN N
respect NN N
to TO N
separate VB N
marketed VBN N
tablets NNS N
. . N

In IN N
vivo NN N
study NN N
was VBD N
conducted VBN N
according VBG N
to TO N
a DT N
single-center NN N
, , N
randomized VBN N
, , N
single-dose JJ N
, , N
laboratory-blinded JJ N
, , N
2 CD N
Way NNP N
, , N
Cross-Over NNP N
Study NNP N
with IN N
a DT N
washout JJ N
period NN N
of IN N
10 CD N
days NNS N
. . N

Under IN p
fasting VBG p
conditions NNS p
, , p
24 CD p
healthy JJ p
Egyptian JJ p
male NN p
volunteers NNS p
were VBD N
randomly RB i
allocated VBN i
to TO i
receive VB i
a DT i
single JJ i
oral JJ i
dose NN i
of IN i
either DT i
one CD i
FDC NNP i
tablet NN i
or CC i
co-administration NN i
of IN i
two CD i
separate JJ i
diflunisal NN i
and CC i
naproxen RB i
marketed VBN i
tablets NNS i
. . i

Plasma NNP i
samples NNS i
were VBD i
obtained VBN i
over IN i
a DT i
72-h JJ i
interval NN i
and CC i
analyzed VBN i
for IN i
diflunisal NN o
and CC o
naproxen NN o
by IN i
reversed JJ i
phase NN i
liquid NN i
chromatography NN i
with IN i
UV NNP i
detection NN i
. . i

The DT N
pharmacokinetic JJ N
parameters NNS N
Cmax NNP o
, , o
AUC0-t NNP o
, , o
AUC0-? NNP o
, , o
tmax NN o
, , o
and CC o
t1/2 NNS o
were VBD o
determined VBN o
from IN N
plasma JJ N
concentration-time JJ N
profiles NNS N
. . N

The DT N
90 CD N
% NN N
confidence NN N
intervals NNS N
for IN N
the DT N
ratio NN N
of IN N
log NN N
transformed VBN N
values NNS N
of IN N
Cmax NNP o
, , o
AUC0-t NNP o
, , o
and CC o
AUCt-? NNP o
of IN o
the DT N
2 CD N
treatments NNS N
were VBD N
within IN N
the DT N
acceptable JJ N
range NN N
( ( N
0.8-1.25 JJ N
) ) N
for IN N
bioequivalence NN N
. . N

From IN N
pharmacokinetic JJ N
and CC N
in IN N
vitro JJ N
studies NNS N
perspectives NNS N
, , N
1 CD N
FDC NNP N
tablet NN N
demonstrated VBD N
similar JJ N
relative JJ N
bioavailability NN N
with IN N
the DT N
2 CD N
individual JJ N
-reference NN N
tablets NNS N
. . N

-DOCSTART- -21719717- O O

Pharmacodynamic JJ N
effects NNS N
on IN N
biochemical JJ o
markers NNS o
of IN o
bone NN o
turnover NN o
and CC o
pharmacokinetics NNS o
of IN N
the DT N
cathepsin NN i
K NNP i
inhibitor NN i
, , i
ONO-5334 NNP i
, , N
in IN N
an DT N
ascending VBG N
multiple-dose NN N
, , N
phase NN N
1 CD N
study NN N
. . N

Selective JJ N
inhibitors NNS N
of IN N
cathepsin NN N
K NNP N
, , N
which WDT N
has VBZ N
a DT N
major JJ N
role NN N
in IN N
the DT N
degradation NN N
of IN N
bone NN N
collagen NN N
, , N
are VBP N
potential JJ N
new JJ N
treatments NNS N
for IN N
osteoporosis NN N
. . N

The DT N
pharmacokinetics NNS o
and CC o
the DT o
pharmacodynamic JJ o
effects NNS o
on IN o
biochemical JJ o
markers NNS o
of IN o
bone NN o
turnover NN o
of IN N
the DT N
new JJ N
cathepsin NN i
K NNP i
inhibitor NN i
, , i
ONO-5334 NNP i
, , N
were VBD N
investigated VBN N
in IN N
a DT N
multiple JJ N
ascending NN N
dose NN N
, , N
phase NN N
1 CD N
study NN N
. . N

A DT p
total NN p
of IN p
120 CD p
healthy JJ p
postmenopausal NN p
women NNS p
were VBD p
enrolled VBN p
, , p
and CC p
doses NNS i
of IN i
10 CD i
to TO i
600 CD i
mg NNS i
once RB i
daily JJ i
and CC i
50 CD i
and CC i
300 CD i
mg NN i
twice RB i
daily RB i
were VBD i
evaluated VBN i
in IN i
15- JJ i
and CC i
28-day JJ i
multiple-dosing JJ i
cohorts NNS i
. . i

Plasma NNP N
ONO-5334 NNP N
concentration NN N
reached VBD N
steady JJ N
state NN N
within IN N
2 CD N
days NNS N
. . N

Twenty-four CD N
hours NNS N
after IN N
the DT N
last JJ N
dose NN N
in IN N
the DT N
15-day JJ N
multiple-dose JJ N
cohort NN N
, , N
100 CD N
, , N
300 CD N
, , N
and CC N
600 CD N
mg NN N
once RB N
daily RB N
reduced VBN N
urinary JJ o
C-terminal JJ o
telopeptide NN o
of IN o
type NN o
I PRP o
collagen VBP o
by IN N
a DT N
mean NN N
( ( N
? . N
standard JJ N
deviation NN N
) ) N
44.9 CD N
% NN N
? . N
13.6 CD N
% NN N
, , N
84.5 CD N
% NN N
? . N
4.4 CD N
% NN N
, , N
and CC N
92.5 CD N
% NN N
? . N
1.3 CD N
% NN N
, , N
respectively RB N
. . N

The DT N
28-day JJ N
cohort NN N
showed VBD N
similar JJ N
effects NNS N
. . N

There EX N
were VBD N
far RB N
smaller JJR N
effects NNS o
on IN o
bone-specific JJ o
alkaline JJ o
phosphatase NN o
( ( o
B-ALP NNP o
) ) o
, , o
tartrate-resistant JJ o
acid NN o
phosphatase NN o
5b CD o
( ( o
TRAP5b NNP o
) ) o
, , o
or CC o
osteocalcin NN o
( ( o
OC NNP o
) ) o
( ( o
measured VBN o
after IN N
28 CD N
days NNS N
) ) i
. . i

ONO-5334 NN i
was VBD i
well RB N
tolerated VBN N
up RP N
to TO N
600 CD N
mg/d NNS N
and CC N
for IN N
up RB N
to TO N
28 CD N
days NNS N
of IN N
multiple JJ N
dosing NN N
. . N

Multiple JJ N
dosing VBG N
with IN N
ONO-5334 NNP i
100 CD i
mg NN N
resulted VBD N
in IN N
considerable JJ N
suppression NN o
of IN o
bone NN o
resorption NN o
markers NNS o
with IN o
no DT N
appreciable JJ N
effects NNS o
on IN o
bone NN o
formation NN o
markers NNS o
( ( o
B-ALP NNP o
, , o
OC NNP o
) ) o
or CC o
osteoclast JJ o
number NN o
( ( o
TRAP5b NNP o
) ) o
. . o

-DOCSTART- -9751554- O O

Braced NNP N
for IN N
impact NN N
: : N
reducing VBG N
military JJ p
paratroopers NNS p
' POS p
ankle NN N
sprains NNS N
using VBG N
outside-the-boot JJ i
braces NNS i
. . i

BACKGROUND NNP N
Ankle NNP N
injuries VBZ N
account NN N
for IN N
30 CD N
to TO N
60 CD N
% NN N
of IN N
all DT N
parachuting VBG N
injuries NNS N
. . N

This DT N
study NN N
was VBD N
designed VBN N
to TO N
determine VB N
if IN N
outside-the-boot JJ N
ankle NN N
braces NNS N
could MD N
reduce VB N
ankle JJ N
sprains NNS N
during IN N
Army NNP p
paratrooper IN p
training NN p
. . p

METHODS NNP N
The DT N
randomized JJ N
trial NN N
involved VBD N
777 CD p
volunteers NNS p
from IN p
the DT p
U.S. NNP p
Army NNP p
Airborne NNP p
School NNP p
, , p
Fort NNP p
Benning NNP p
, , p
Ga. NNP p
Of IN N
this DT N
group NN N
, , N
745 CD p
completed VBD p
all DT p
study NN p
requirements NNS p
( ( p
369 CD p
brace-wearers NNS i
and CC p
376 CD p
non-brace-wearers NNS i
) ) i
. . p

Each DT N
volunteer NN N
made VBD N
five CD N
parachute NN N
jumps NNS N
, , N
for IN N
a DT N
total NN N
of IN N
3,674 CD N
jumps NNS N
. . N

RESULTS VB N
The DT N
incidence NN o
of IN o
inversion NN o
ankle NN o
sprains NNS o
was VBD N
1.9 CD N
% NN N
in IN N
non-brace-wearers NNS N
and CC N
0.3 CD N
% NN N
in IN N
brace-wearers NNS N
( ( N
risk NN N
ratio NN N
, , N
6.9 CD N
; : N
p NN N
= VBZ N
0.04 CD N
) ) N
. . N

Other JJ N
injuries NNS N
appeared VBD N
unaffected JJ N
by IN N
the DT N
brace NN N
. . N

Overall NNP N
, , N
5.3 CD N
% NN N
of IN N
the DT N
non-brace JJ N
group NN N
and CC N
4.6 CD N
% NN N
of IN N
the DT N
brace NN N
group NN N
experienced VBD N
at IN N
least JJS N
one CD N
injury NN N
. . N

The DT N
risk NN o
ratio NN o
for IN o
injured JJ o
individuals NNS o
was VBD N
1.2:1 CD N
( ( N
non-brace NN N
to TO N
brace VB N
groups NNS N
; : N
p CC N
= VB N
0.65 CD N
) ) N
. . N

CONCLUSION NNP N
Inversion NNP o
ankle NN o
sprains NNS o
during IN p
parachute JJ p
training NN p
can MD N
be VB N
significantly RB N
reduced VBN N
by IN N
using VBG N
an DT N
outside-the-boot JJ N
ankle NN N
brace NN N
, , N
with IN N
no DT N
increase NN N
in IN N
risk NN N
for IN N
other JJ N
injuries NNS N
. . N

-DOCSTART- -18818024- O O

Influence NN N
of IN N
phase-related JJ N
variability NN N
in IN N
premenstrual JJ o
symptomatology NN o
, , o
mood NN o
, , o
smoking VBG o
withdrawal NN o
, , o
and CC o
smoking VBG o
behavior NN o
during IN o
ad NN o
libitum NN o
smoking NN o
, , o
on IN o
smoking VBG o
cessation NN o
outcome NN o
. . o

Emerging VBG N
evidence NN N
suggests VBZ N
that IN N
women NNS N
have VBP N
a DT N
more RBR N
difficult JJ N
time NN N
quitting VBG o
smoking VBG o
than IN N
men-possibly RB N
due JJ N
, , N
in IN N
part NN N
, , N
to TO N
sex VB N
hormones NNS N
. . N

The DT N
present JJ N
study NN N
characterized VBD N
mood NN o
, , o
premenstrual JJ o
symptomatology NN o
, , o
and CC o
smoking VBG o
withdrawal NN o
, , o
as RB o
well RB o
as IN o
smoking VBG o
behavior NN o
, , N
in IN N
the DT N
follicular NN N
and CC N
luteal JJ N
phases NNS N
during IN N
ad NN i
libitum NN i
smoking NN i
in IN N
25 CD p
women NNS p
intending VBG p
to TO p
quit VB p
. . p

We PRP N
also RB N
investigated VBD N
the DT N
possible JJ N
influence NN N
of IN N
phase-related JJ N
variability NN N
in IN N
these DT N
measures NNS N
on IN N
likelihood NN o
of IN o
study NN o
adherence NN o
and CC o
smoking NN o
cessation NN o
. . o

We PRP N
found VBD N
that IN N
premenstrual JJ o
symptomatology NN o
, , N
as RB N
well RB N
as IN N
some DT N
measures NNS o
of IN o
mood NN o
and CC o
smoking NN o
withdrawal NN o
, , N
were VBD N
significantly RB N
higher JJR N
during IN N
the DT N
luteal NN N
phase NN N
than IN N
in IN N
the DT N
follicular JJ N
phase NN N
. . N

Cigarettes/day NNP o
did VBD N
not RB N
vary JJ N
by IN N
menstrual JJ N
cycle NN N
phase NN N
. . N

Phase-related JJ o
variability NN o
in IN N
premenstrual JJ N
symptomatology NN N
[ NNP N
F NNP N
( ( N
3 CD N
, , N
20 CD N
) ) N
=2.82 NN N
, , N
p=0.0650 NN N
) ) N
] NN N
and CC N
urge NN o
to TO o
smoke VB o
[ NNP N
F NNP N
( ( N
2 CD N
, , N
21 CD N
) ) N
=4.85 NN N
, , N
p=0.0186 NN N
) ) N
] NN N
were VBD N
associated VBN N
with IN N
relapse NN N
. . N

These DT N
data NNS N
support NN N
the DT N
inference NN N
that WDT N
sex NN N
hormones NNS N
influence NN N
smoking VBG o
cessation NN o
outcome NN o
. . o

This DT N
knowledge NN N
may MD N
contribute VB N
to TO N
the DT N
development NN N
of IN N
more JJR N
rational JJ N
and CC N
effective JJ N
smoking NN N
cessation NN N
interventions NNS N
for IN N
women NNS N
. . N

-DOCSTART- -8791949- O O

Prospective JJ N
evaluation NN N
of IN N
the DT N
macrolide NN i
antibiotic JJ i
dirithromycin NN i
for IN N
the DT N
treatment NN N
of IN N
Helicobacter NNP p
pylori NN p
. . p

BACKGROUND NNP N
Macrolide NNP i
antibiotics NNS i
are VBP N
active JJ N
in IN N
vitro NN N
and CC N
in IN N
vivo NN N
against IN N
Helicobacter NNP p
pylori NN p
. . p

We PRP N
assessed VBD N
a DT N
newer JJR N
macrolide NN i
, , i
dirithromycin NN i
, , N
for IN N
the DT N
treatment NN N
of IN N
H. NNP N
pylori FW N
in IN N
two CD N
separate JJ N
studies NNS N
. . N

METHODS NNP N
Volunteers NNPS p
with IN p
H. NNP p
pylori FW p
infection NN p
( ( p
by IN p
13C-urea JJ p
breath NN p
test NN p
) ) p
were VBD N
randomly RB N
assigned VBN N
to TO N
2-week JJ N
treatment NN N
regimens NNS N
. . N

Study NNP N
1 CD N
: : N
dirithromycin NN i
500 CD i
mg NN i
q.d.s. NN i
, , N
dirithromycin VBZ i
500 CD i
mg NN i
q.d.s NN i
. . i

plus CC i
omeprazole JJ i
40 CD i
mg JJ i
q.d.s. NN i
, , N
or CC i
dirithromycin VB i
500 CD i
mg NN i
q.d.s NN i
. . i

plus CC i
metronidazole JJ i
500 CD i
mg NN i
t.d.s NN i
. . i

Study CC N
2 CD N
: : N
dirithromycin NN i
500 CD i
mg NN i
q.d.s NN i
. . i

plus CC i
omeprazole JJ i
20 CD i
mg NN i
b.d. NN i
, , N
dirithromycin NN i
1000 CD i
mg NN i
q.d.s NN i
. . i

plus CC i
omeprazole JJ i
20 CD i
mg NN i
b.d. NN i
, , N
or CC i
amoxycillin RB i
500 CD i
mg NN i
q.d.s NN i
. . i

plus CC i
omepirazole JJ i
20 CD i
mg NN i
b.d NN i
. . i

Four CD N
weeks NNS N
after IN N
the DT N
completion NN N
of IN N
therapy NN N
a DT N
repeat NN N
13C-urea JJ N
breath NN N
test NN N
was VBD N
done VBN N
to TO N
assess VB N
for IN N
cure NN N
. . N

RESULTS NNP N
No NNP N
patient NN N
taking VBG N
dirithromycin JJ i
alone RB p
( ( p
n JJ p
= NNP p
6 CD p
) ) p
or CC N
in IN N
combination NN N
with IN N
omeprazole JJ i
( ( N
n JJ N
= NNP N
26 CD N
) ) N
achieved VBD N
cure NN o
of IN o
their PRP$ o
infection NN o
. . o

Eradication NN o
of IN o
H. NNP o
pylori NN o
was VBD N
seen VBN N
in IN N
one CD N
of IN N
seven CD N
patients NNS N
taking VBG N
dirithromycin JJ i
plus CC N
metronidazole JJ i
. . i

Five CD N
of IN N
10 CD N
patients NNS N
taking VBG N
omeprazole-amoxycillin JJ i
dual JJ N
therapy NN N
had VBD N
their PRP$ N
H. NNP o
pylori NN o
infection NN o
cured VBD o
( ( N
P NNP N
= VBZ N
0.0007 CD N
vs. NN N
patients NNS N
taking VBG N
dirithromycin JJ i
plus CC N
omeprazole JJ i
) ) i
. . N

Eleven NNP N
( ( N
47 CD N
% NN N
) ) N
of IN N
32 CD N
patients NNS N
taking VBG N
dirithromycin JJ i
alone RB N
or CC N
combined VBN N
with IN N
omeprazole JJ i
reported VBD o
side-effects NNS o
, , N
but CC N
only RB N
two CD N
( ( N
6 CD N
% NN N
) ) N
stopped VBD N
therapy NN N
prematurely RB N
as IN N
a DT N
result NN N
of IN N
side-effects NNS o
. . o

CONCLUSION NNP N
No NNP N
subject JJ N
taking VBG N
dirithromycin NN i
alone RB N
or CC N
in IN N
combination NN N
with IN N
omeprazole NN i
had VBD N
their PRP$ N
H. NNP N
pylori NN N
infection NN N
cured VBD o
. . o

Dirithromycin NNP i
, , N
in IN N
the DT N
regimen NNS N
used VBN N
, , N
shows VBZ N
little JJ N
promise NN N
in IN N
the DT N
treatment NN N
of IN N
patients NNS p
with IN p
H. NNP p
pylori JJ p
infection NN p
. . p

